<SEC-DOCUMENT>0001144204-11-062631.txt : 20130115
<SEC-HEADER>0001144204-11-062631.hdr.sgml : 20130115

<ACCEPTANCE-DATETIME>20111109172637

<PRIVATE-TO-PUBLIC>

ACCESSION NUMBER:		0001144204-11-062631

CONFORMED SUBMISSION TYPE:	S-1/A

PUBLIC DOCUMENT COUNT:		56

FILED AS OF DATE:		20111109

DATE AS OF CHANGE:		20111130


FILER:


	COMPANY DATA:	

		COMPANY CONFORMED NAME:			NOVELOS THERAPEUTICS, INC.

		CENTRAL INDEX KEY:			0001279704

		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]

		IRS NUMBER:				043321804

		STATE OF INCORPORATION:			DE

		FISCAL YEAR END:			1231



	FILING VALUES:

		FORM TYPE:		S-1/A

		SEC ACT:		1933 Act

		SEC FILE NUMBER:	333-175284

		FILM NUMBER:		111192626



	BUSINESS ADDRESS:	

		STREET 1:		ONE GATEWAY CENTER, SUITE 504

		CITY:			NEWTON

		STATE:			MA

		ZIP:			02458

		BUSINESS PHONE:		617-244-1616



	MAIL ADDRESS:	

		STREET 1:		ONE GATEWAY CENTER, SUITE 504

		CITY:			NEWTON

		STATE:			MA

		ZIP:			02458



	FORMER COMPANY:	

		FORMER CONFORMED NAME:	COMMON HORIZONS INC

		DATE OF NAME CHANGE:	20040211



</SEC-HEADER>

<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>v236909_s1a.htm
<DESCRIPTION>FORM S-1 AMENDMENT
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">As filed with the Securities and Exchange Commission on&#160;November 9, 2011</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Registration No. 333-175284</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED STATES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington, D.C. 20549</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<hr style="COLOR: black" align="center" noshade size="1" width="15%">
</div>

<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amendment No.&#160;3 to</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FORM S-1</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<hr style="COLOR: black" align="center" noshade size="1" width="15%">
</div>

<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOVELOS THERAPEUTICS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Exact name of registrant as specified in its charter)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Delaware</font></div>
</td>
<td valign="bottom" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2834</font></div>
</td>
<td valign="bottom" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">04-3321804</font></div>
</td>
</tr><tr>
<td valign="bottom" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">(State or other jurisdiction</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">of incorporation or organization)</font></div>
</td>
<td valign="bottom" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">(Primary Standard Industrial</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Classification Code Number)</font></div>
</td>
<td valign="bottom" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">(I.R.S. Employer</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Identification Number)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">One Gateway Center</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Suite 504</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Newton, Massachusetts 02458</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(617) 244-1616</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Harry S. Palmin</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President and Chief Executive Officer</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Novelos Therapeutics, Inc.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">One Gateway Center, Suite 504</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Newton, Massachusetts 02458</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(617) 244-1616</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Copies to:</font><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Paul Bork, Esq.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Foley Hoag LLP</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">155 Seaport Boulevard</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Boston, Massachusetts 02210</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(617) 832-1000</font></div>
</td>
<td align="left" valign="bottom" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Harvey Kesner, Esq.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Sichenzia Ross Friedman Ference LLP</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">61 Broadway</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">New York, New York 10006</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(212) 930-9700</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage2"><!--EFPlaceholder--></a>&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<hr style="COLOR: black" align="center" noshade size="1" width="15%">
</div>

<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Approximate date of commencement of proposed sale to the public:</font> As soon as practicable after this Registration Statement is declared effective.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. <font style="DISPLAY: inline; FONT-FAMILY: wingdings"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Check one):</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="61%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Large accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font></font></div>
</td>
<td align="left" valign="bottom" width="39%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font></font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="61%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font></font></div>
</td>
<td align="left" valign="bottom" width="39%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Smaller reporting company <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Do not check if a smaller reporting company)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<hr style="COLOR: black" align="center" noshade size="1" width="15%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CALCULATION OF REGISTRATION FEE</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title of Each Class of</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Securities to be</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Registered</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proposed Maximum</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Aggregate Offering</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Price (1)</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amount of</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Registration Fee</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common Stock, par value $0.00001 per share&#160;&#160;(2)</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,000,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td valign="bottom" width="9%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,719.00</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common Stock issuable upon exercise of warrants (2)</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,000,000</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,719.00</font></font> </div>
</div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common Stock, par value $0.00001 per share (2) (3)&#160;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,250,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="9%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">257.85</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common Stock issuable upon exercise of warrants (2) (3)</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,250,000</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">257.85</font></font> </div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td valign="bottom" width="9%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,953.70</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1)</font> </div>
</td>
<td align="left" valign="top" width="89%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act.</font> </div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2)</font> </div>
</td>
<td align="left" valign="top" width="89%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pursuant to Rule 416, the securities being registered hereunder include such indeterminate number of additional shares of common stock as may be issued after the date hereof as a result of stock splits, stock dividends or similar transactions.</font> </div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3)</font> </div>
</td>
<td align="left" valign="top" width="89%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consists of additional proceeds which may be received pursuant to the exercise of a 45-day option granted by the registrant to the underwriters to cover over-allotments, if any.</font> </div>
</td>
</tr><tr>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">*</font> </div>
</td>
<td align="left" valign="top" width="89%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Of the total amount of the registration fee, $2,002.73 has been previously paid.</font> </div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.</font> </div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="red" style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage3"><!--EFPlaceholder--></a><font color="red" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="37%" style="BORDER-TOP: black 2px solid; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="red" style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PRELIMINARY PROSPECTUS</font></div>
</td>
<td align="right" valign="bottom" width="59%" style="BORDER-TOP: black 2px solid; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font color="red" style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SUBJECT TO COMPLETION, DATED NOVEMBER 9, 2011</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="logo1.jpg"></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Novelos Therapeutics, Inc.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Units, each consisting of one share of common stock and a warrant to purchase one share of common stock</font> </font></div>

<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font> </div>

<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This is a firm commitment public offering of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">units, each unit consisting of one share of our common stock and a warrant to purchase one share of our common stock at an exercise price equal to 100% of the unit price.&#160;&#160;The warrants will be exercisable immediately after the closing of this offering until the close of business on the fifth anniversary of the date of issuance. The units will not be certificated and the common stock and warrants will be immediately separable and transferable upon issuance.&#160;&#160;We anticipate that the public offering price of the units will be between $5.00 and $7.00 per unit.</font></font></font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our common stock is quoted on the OTC Bulletin Board under the symbol &#8220;NVLT.OB&#8221;. We&#160;have applied&#160;for listing of our common stock on The NASDAQ Capital Market under the symbol &#8220;NVLT&#8221;. No assurance can be given that our application will be approved. In connection with the effectiveness of the registration statement of which this prospectus is a part, we anticipate that we will effect a reverse stock split within a range of 1:2 to 1:10 (the &#8220;Offering Reverse Split&#8221;). The proposal for the Offering Reverse Split has been approved by our stockholders and our board of directors is authorized to determine the time and ratio at which the reverse split will be effected by filing the appropriate amendment to our certificate of incorporation. <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have estimated that the Offering Reverse Split will be on a 1-for-10 basis. </font>On November 8, 2011, the last reported sale price for our common stock was $9.40 per share<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">, after giving effect to an estimated 1-for-10 Offering Reverse Split</font>.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investing in the offered securities involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page 7 of this prospectus for a discussion of information that you should consider before investing in our securities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNIDENTIFIED_TABLE_3"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<div>&#160;</div>
</div>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Per&#160;Unit</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Public offering price</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Underwriting discounts and commissions (1)</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds, before expenses, to us</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(1)</font>&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">See &#8220;Underwriting&#8221; for a description of compensation payable to the underwriter.</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We have granted a 45-day option to Rodman &amp; Renshaw, LLC, the underwriter, to purchase up to an additional&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; units from us solely to cover over-allotments, if any. The&#160;units issuable upon exercise of the underwriter option are identical to those offered by this prospectus and the underlying shares have been registered under the registration statement of which this prospectus forms a part.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The underwriter expects to deliver the&#160;secutities to purchasers in the offering on or about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2011.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Rodman &amp; Renshaw, LLC</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The date of this prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2011.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage4"><!--EFPlaceholder--></a>Cancer-Targeting, Broad Spectrum, Multi-Product Technology Platform</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="pg4a.jpg"></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Time-Lapse Photography Illustrating Tumor Regression in Mouse After a Single Dose of <font style="DISPLAY: inline; FONT-WEIGHT: bold">HOT</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="pg4b.jpg"></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">LIGHT</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Compared to FDG as a Cancer PET Imaging Agent in Mouse Xenograft Model</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Same mouse: first imaged with FDG, then with LIGHT 24 hours later)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="pg4c.jpg"></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">T = Cancerous Tumor, B = Bladder, I = Inflammation site, H = Heart</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">The images provided above are for illustrative purposes only and may not be indicative of all results.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font style="FONT-SIZE: 12pt; FONT-FAMILY: times new roman">The above illustrations do not refer to products approved by the FDA. </font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font style="FONT-SIZE: 12pt; FONT-FAMILY: times new roman">Novelos has not received any revenue from the sale of its products.</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOVELOS THERAPEUTICS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="FIS_TABLE_OF_CONTENTS"><!--EFPlaceholder--></a>TABLE OF CONTENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="white">
<td align="left" valign="bottom" width="92%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PROSPECTUS SUMMARY</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">RISK FACTORS</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FORWARD-LOOKING STATEMENTS</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">USE OF PROCEEDS</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CAPITALIZATION</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DILUTION</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">22</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">22</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BUSINESS</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">LITIGATION</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PROPERTIES</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">MANAGEMENT</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">45</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">47</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">UNDERWRITING</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">48</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DESCRIPTION OF SECURITIES</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">52</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">54</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">WHERE YOU CAN FIND MORE INFORMATION</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">54</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">LEGAL MATTERS</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">54</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EXPERTS</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">54</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">GLOSSARY OF SCIENTIFIC TERMS</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">55</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="92%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FINANCIAL STATEMENTS (POST-ACQUISITION)</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-1</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FINANCIAL STATEMENTS (PRE-ACQUISITION)</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-26</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="92%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</font></div>
</td>
<td valign="bottom" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-60</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No dealer, salesperson or other person has been authorized to give any information or to make any representations other than those contained in this prospectus in connection with the offer contained in this prospectus and, if given or made, such information or representations must not be relied upon as having been authorized by us.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Neither the delivery of this prospectus nor any sale made hereunder shall under any circumstances create an implication that there has been no change in our affairs since the date hereof. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy securities other than those specifically offered hereby or of any securities offered hereby in any jurisdiction where, or to any person to whom, it is unlawful to make such offer or solicitation. The information contained in this prospectus speaks only as of the date of this prospectus unless the information specifically indicates that another date applies.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This prospectus has been prepared based on information provided by us and by other sources that we believe are reliable. This prospectus summarizes certain documents and other information in a manner we believe to be accurate, but we refer you to the actual documents, if any, for a more complete understanding of what we discuss in this prospectus. In making a decision to invest in the common stock, you must rely on your own examination of us and the terms of the offering and securities offered in this prospectus, including the merits and risks involved.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are not making any representation to you regarding the legality of an investment in the securities offered in this prospectus under any legal investment or similar laws or regulations. You should not consider any information in this prospectus to be legal, business, tax or other advice. You should consult your own attorney, business advisor and tax advisor for legal, business and tax advice regarding an investment in our common stock.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage6"><!--EFPlaceholder--></a><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">You may only rely on the information contained in this prospectus or that we have referred you to. We have not authorized anyone to provide you with different information. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities other than the securities offered by this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities in any circumstances in which such offer or solicitation is unlawful or in any state or to any person within any state to whom such offer would be unlawful under the laws or securities regulations of such state. Neither the delivery of this prospectus nor any sale made in connection with this prospectus shall, under any circumstances, create any implication that there has been no change in our affairs since the date of this prospectus or that the information contained by reference to this prospectus is correct as of any time after its date.</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PROSPECTUS SUMMARY</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before investing in our securities, you should carefully read this entire prospectus, including our financial statements and the related notes and the information set forth under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; in each case included elsewhere in this prospectus.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">References in this prospectus to &#8220;Cellectar&#8221; relate to the activities and financial information of Cellectar, Inc. prior to the Acquisition, references to &#8220;Novelos&#8221; relate to the activities and financial information of Novelos Therapeutics, Inc. prior to the Acquisition and references to &#8220;we&#8221; &#8220;us&#8221; or &#8220;the Company&#8221; relate to the activities and obligations of the combined company following the Acquisition.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Please refer to the Glossary of Scientific Terms on page&#160;55 of this prospectus for definitions of certain technical and scientific terms used throughout this prospectus.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 446pt; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Overview</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Our Business</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On April 8, 2011, Novelos Therapeutics, Inc. (&#8220;we, the &#8220;Company&#8221;, &#8220;Novelos&#8221;) completed a business combination with Cellectar, Inc. (&#8220;Cellectar&#8221;), a privately held Wisconsin corporation that designed and developed products to detect, treat and monitor a wide variety of human cancers (the &#8220;Acquisition&#8221;). Following the Acquisition, we are developing novel drugs for the treatment and diagnosis of cancer based on our cancer-targeting technology platform: CLR1401(&#8220;COLD&#8221;), <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">131</font> I-CLR1404 (&#8220;HOT&#8221;, iodine-131 radiolabeled compound) and <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">124</font> I-CLR1404 (&#8220;LIGHT&#8221;, labeled with a shorter-lived radioisotope, iodine-124). </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A radiolabeled compound is a radioactive compound containing radioisotopes as a part of its structure.&#160;&#160;A radioisotope (also referred to as radioactive isotopes or radionuclides) is a variant of a particular chemical element (e.g. iodine) that has an unstable nucleus and can undergo radioactive decay, during which ionizing radiation (e.g. gamma rays or subatomic particles) is emitted. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We believe our compounds are selectively taken up and retained in a wide variety of cancer cells (including cancer stem cells) versus normal cells. We believe our therapeutic compounds directly kill cancer cells while minimizing harm to normal cells, offering the potential for a paradigm shift in cancer therapy by providing efficacy against all three major drivers of mortality in cancer: primary tumors, metastases and cancer stem cell-based relapse. More specifically, we believe our technology enables targeted delivery to cancer cells of apoptosis-inducing Akt inhibition or, when a radioactive molecule is attached, of ionizing radiation sufficient to kill cancer cells. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Apoptosis is a tightly regulated form of cell death by which organisms can eliminate damaged or aberrant cells.&#160; Apoptosis is often&#160;absent<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;</font>in cancer cells, contributing to their uncontrolled growth. Akt is a molecule that can regulate cell growth and survival and is present at high levels in many cancer types. </font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">When radiolabeled with iodine-124 for PET imaging, we believe our agent can provide an accurate and quantitative diagnosis of cancer, including metastases, and we also believe our agent can objectively predict and measure therapeutic success. Together, we believe this platform is capable of yielding multiple, distinct oncology product opportunities in a broad spectrum of cancers that would enable us to &#8220;find, treat and follow&#8221; cancer anywhere in the body in a novel, effective and highly selective way.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COLD is a cancer-targeted chemotherapy that in pre-clinical has experiments has been observed to inhibit the phosphatidylinosotol 3-kinase (PI3K)/Akt survival pathway, which is overexpressed in many types of cancer. As a result, in such pre-clinical experiments COLD has been observed to selectively inhibit Akt activity, induce apoptosis through caspase activation and inhibit cell proliferation in cancer cells versus normal cells. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Caspases are molecules that can stimulate apoptosis. </font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COLD also exhibits significant <font style="DISPLAY: inline; FONT-STYLE: italic">in vivo</font> efficacy in mouse xenograft tumor models, including non-small cell lung cancer and triple-negative breast cancers, producing long-lasting tumor growth suppression and significantly increased survival. We believe COLD has the potential to be best-in-class versus other Akt inhibitors in development due to a) cancer cell/cancer stem cell targeting, resulting in cancer-selective inhibition of Akt and cell proliferation or b) suitability for intravenous administration that we believe offers the prospect of greater systemic exposure and hence Akt inhibition in cancer cells, which we believe would result in superior efficacy. We expect to submit an Investigational New Drug (&#8220;IND&#8221;) application to the United States Food and Drug Administration (&#8220;FDA&#8221;) in late 2012.</font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">HOT (iodine-131 radiolabeled compound) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that we believe has first-in-class potential. HOT is comprised of a small quantity of COLD (too little for significant Akt inhibition), acting as a cancer-targeted delivery and retention vehicle, and incorporating a cytotoxic (cell-killing) dose of radiotherapy (in the form of iodine-131, a radioisotope that is already in common use to treat thyroid and other cancer types). It is this &#8220;intracellular radiation&#8221; mechanism of cancer cell killing, coupled with selective delivery to a wide range of malignant tumor types, that we believe&#160;imbues HOT with broad-spectrum anti-cancer activity. In 2009, we filed an IND with the FDA to study HOT in humans. In early 2010, we successfully completed a Phase 1a dosimetry trial in humans demonstrating initial safety and establishing dosing parameters for a Phase 1b dose-escalation trial. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Radiation dosimetry measures how much radiation is absorbed by tumors and body organs in order to optimize delivery of radiation therapy. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Phase 1b dose-escalation trial is aimed at determining the Maximum Tolerated Dose, and we expect it to begin in the fourth quarter of 2011. In parallel, we expect to initiate Phase 2 efficacy trials in solid tumors in 2012 as soon as a minimal efficacious dose is established. We may determine such an effective dose upon seeing a tumor response in the Phase 1b trial or calculating it from parallel imaging trials in patients (see LIGHT below). Preclinical experiments <font style="DISPLAY: inline; FONT-STYLE: italic">in vitro</font> (in cell culture) and <font style="DISPLAY: inline; FONT-STYLE: italic">in vivo</font> (in animals) have demonstrated selective killing of cancer cells along with a benign safety profile. HOT&#8217;s anti-tumor/survival-prolonging activities have been demonstrated in over a dozen different xenograft models (human tumor cells implanted into animals) including breast, prostate, lung, glioma (brain), pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. In all but two models, a single administration of HOT was sufficient to demonstrate efficacy. In view of HOT&#8217;s selective uptake and retention in a wide range of solid tumors, its single-agent efficacy in xenograft models and its non-specific mechanism of cancer-killing (radiation), we expect to first develop HOT as a monotherapy, initially for solid tumors.</font> </div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LIGHT (labeled with a shorter-lived radioisotope, iodine-124) is a small-molecule imaging agent that we believe has first-in-class potential in detecting and quantifying cancerous tumors and metastases. LIGHT is comprised of a small quantity of COLD (too little for Akt inhibition), acting as a cancer-targeted delivery and retention vehicle, and incorporating iodine-124, a recently discovered positron emission tomography (PET) imaging isotope. PET imaging used in conjunction with CT scanning has now become the imaging method of choice in oncology. In studies to date, LIGHT selectively illuminated malignant tumors in 52 of 54 animal models of cancer, reflecting broad-spectrum, cancer-selective uptake and retention. We expect investigator-sponsored Phase 1/2 trials of LIGHT as a PET imaging agent to begin in the fourth quarter of 2011. The trials will initially include brain metastases, lung and breast cancers. These human trials, if successful, will serve two important purposes:</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 13pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To provide proof-of-concept for LIGHT itself as a PET imaging agent with the potential to supplant the current &#8220;gold standard&#8221; agent, 18-fluoro-deoxyglucose (FDG), due to what we believe to be LIGHT&#8217;s superior cancer-specificity and more favorable logistics of clinical use; and</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 13pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To accelerate clinical development of HOT by predicting efficacy and enabling estimation of efficacious doses of HOT for Phase 2 trials.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Our core technology platform is based upon the research conducted by Cellectar&#8217;s founder and our Chief Scientific Officer, Dr. Jamey Weichert, commencing in 1994 at the University of Michigan (<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8220;</font>U. Mich.<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8221;</font>) where alkyphospholipid analogs were initially designed, synthesized, radiolabeled, and evaluated. Since 1998, Dr. Weichert has continued his research at the University of Wisconsin (&#8220;U. Wisc.&#8221;) and founded Cellectar in 2002 to further develop and commercialize the technology. Cellectar obtained exclusive rights to the related technology patents in North America owned by U. Mich. in 2003, and continued development of the platform while obtaining ownership of numerous additional patents and patent applications in North America, Europe and Japan (lasting until 2025, 2028 and 2030, without extensions) prior to the Acquisition. The license granted by U. Mich. to Cellectar (&#8220;the U.Mich license&#8221;) gives us the exclusive right to develop, manufacture, market and sublicense our HOT and LIGHT compounds, and provides, among other things, that we pay a royalty equal to 3% of net sales of any licensed products sold by us or our sublicensees, with a reduction in such royalties in the case of certain incoming or outgoing sublicense arrangements. The license also requires us to make payments to U. Mich., ranging from $50,000 to $200,000, upon the achievement of certain key regulatory and commercial milestones, for an aggregate of up to $400,000 in milestone payments. The license expires upon the expiration of the last covered Michigan patent (currently 2016 without extensions).&#160; <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">U. Mich. may terminate the agreement if we cease operations, if we fail to make any required payments under the agreement, or if we otherwise materially breach the agreement, subject to the applicable notice and cure periods. </font>If the U. Mich. license expires or terminates for any reason, it will not impact the ownership of the additional patents that we have independently obtained<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">, however the early termination of the U. Mich. license would result in the loss of our rights to use the covered patents.</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Key Risks and Uncertainties</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are subject to numerous risks and uncertainties, including the following:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 13pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We will require additional capital in order to continue our operations, and may have difficulty raising additional capital.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 13pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are a development stage company with a history of losses and can provide no assurance of our future operating results;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 13pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We and our Chief Executive Officer are defendants in a securities fraud class action lawsuit. We are also defending counterclaims in another lawsuit that we initiated, and if we are not successful in defending claims against us, the resulting liability could be substantial;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 13pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At present, our success depends solely on the successful commercialization of Cellectar compounds;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 13pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The integration of Novelos and Cellectar may be costly and difficult;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 13pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have a history of recurring losses and an accumulated deficit which, among other factors, raise substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 13pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The failure to complete development of our therapeutic technology, to obtain government approvals, including required FDA approvals, or to comply with ongoing governmental regulations could prevent, delay or limit introduction or sale of proposed products and result in failure to achieve revenues or maintain our ongoing business;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 13pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 13pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We may be required to suspend or discontinue clinical trials due to unexpected side effects or other safety risks that could preclude approval of our product candidates;</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 13pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have limited in-house research and manufacturing capacity and will rely, to some extent, on research and manufacturing facilities at various universities, hospitals, contract research organizations and contract manufacturers for a portion of our research, development, and manufacturing. In the event we exceed our in-house capacity or lose access to those facilities, our ability to gain FDA approval and commercialization of our drug delivery technology and products could be delayed or impaired; and</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 13pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are exposed to product, clinical and preclinical liability risks that could create a substantial financial burden should we be sued.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For a more detailed description of the material risks and uncertainties we face, please see &#8220;Risk Factors&#8221; beginning on page 7 of this prospectus.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Reverse Stock Split</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">At a special meeting of our stockholders held on June 30, 2011, our stockholders approved a proposal to amend our Amended and Restated Certificate of Incorporation, or Charter, to effect a reverse split of our common stock within a range of 1:2 to 1:10 (&#8220;the Offering Reverse Split&#8221;) in order to satisfy requirements for the listing of our common stock on The NASDAQ Capital Market. The exact ratio will be set within such range in the discretion of our board of directors without further approval or authorization of our stockholders, with our board of directors having the ultimate discretion as to whether or not to proceed with the Offering Reverse Split.&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If the Offering Reverse Split is effected, it will occur in connection with the effectiveness of the registration statement of which this prospectus is a part.<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>We have estimated that the Offering Reverse Split will be on a 1-for-10 basis for the purpose of calculating an estimated number and price range of the units offered.&#160;&#160;As noted throughout this prospectus, certain share and per share amounts have been adjusted to give effect to an estimated Offering Reverse Split without regard to settlement of fractional shares.</font></font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recent Changes in Capital</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Immediately prior to the Acquisition, we completed a 1-for-153 reverse split of our common stock (the &#8220;April Reverse Split&#8221;). We then issued to the former shareholders of Cellectar&#160;1,700,159 shares of our common stock as consideration for the Acquisition<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">, giving effect to an estimated 1-for-10 Offering Reverse Split</font>. The shares issued to Cellectar shareholders in the Acquisition constituted approximately 85% of our outstanding common stock after giving effect to the Acquisition. Upon the closing of the Acquisition, we completed the private placement of 684,653 shares of our common stock and warrants to purchase an additional 684,653 shares of our common stock, both <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">giving effect to an estimated 1-for-10 Offering Reverse Split,</font>&#160;for gross proceeds of approximately $5,135,000. As a result of the Acquisition, we are implementing a revised business plan focused on the development of the Cellectar compounds. Development of our other compounds (NOV-002 and NOV-205) has been suspended.</font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Company Information</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our headquarters and manufacturing operation, which is compliant with current Good Manufacturing Practices (cGMP), is located at 3301 Agriculture Drive, Madison, WI 53716. Our principal executive offices are located at One Gateway Center, Suite 504, Newton, MA 02458. Our telephone number is (617) 244-1616 and our web address is www.novelos.com. The information included or referred to on, or accessible through, our website does not constitute part of, and is not incorporated by reference into, this prospectus.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="3" valign="middle" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="fis_the_offering"><!--efplaceholder--></a><a name="fis_unidentified_table_4"><!--efplaceholder--></a>The Offering</font></div>
</td>
</tr><tr>
<td colspan="3" valign="middle" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Proposed Reverse Split</font> </div>
</td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" valign="top" width="53%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In connection with this offering, we anticipate that we will effect the Offering Reverse Split within a range of 1:2 to 1:10 in order to satisfy the minimum price requirement for our common stock to be listed on The NASDAQ Capital Market. The proposal for the Offering Reverse Split has been approved by our stockholders and our board of directors is authorized to determine the time and ratio at which the reverse split will be effected by filing the appropriate amendment to our certificate of incorporation. <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We estimate that the Offering Reverse Split will be on a 1-for-10 basis.</font></font> </div>
</td>
</tr><tr>
<td align="left" valign="top" width="45%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="53%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr>
<td align="left" valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Securities offered by us:</font></font> </div>
</td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" valign="top" width="53%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Up to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;units (up to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;units if the underwriter exercises its over-allotment option). <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Each unit will consist of one share of our common stock and a warrant to purchase one share of our common stock.</font></font> </div>
</td>
</tr><tr>
<td valign="top" width="45%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="53%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Description of Warrants:</font> </font></div>
</td>
<td valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="top" width="53%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The warrants will be exercisable on or after the applicable closing date of this offering until the close of business on the&#160;fifth anniversary of the date of issuance at an exercise price equal to 100% of the unit price.</font> </font></div>
</td>
</tr><tr>
<td valign="top" width="45%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="53%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Common Stock to be outstanding after this offering:</font></font> </div>
</td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" valign="top" width="53%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;shares, <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">giving effect to an estimated 1-for-10 Offering Reverse Split</font>. (1)</font> </div>
</td>
</tr><tr>
<td valign="top" width="45%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="top" width="53%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Use of Proceeds:</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="53%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We expect to use the net proceeds received from this offering to fund our research and development activities, including furthering development of LIGHT, HOT and COLD and for general corporate purposes, including capital expenditures, working capital, and, potentially, acquisition activities. For a more complete description of our anticipated use of proceeds from this offering, see &#8220;Use of Proceeds.&#8221;</font></div>
</td>
</tr><tr>
<td valign="top" width="45%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="53%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Risk Factors:</font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" valign="top" width="53%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">See &#8220;Risk Factors&#8221; beginning on page 7 and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding whether to purchase our securities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">OTC Bulletin Board symbol for our Common Stock:</font></div>
</td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" valign="top" width="53%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NVLT.OB</font></div>
</td>
</tr><tr>
<td valign="top" width="45%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="53%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Proposed NASDAQ Capital Market listing symbol for our common stock:</font> </div>
</td>
<td valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="53%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We&#160;have applied&#160;for listing of our common stock on The NASDAQ Capital Market under the symbol &#8220;NVLT&#8221;. No assurance can be given that our application will be approved.</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="eolPage9"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1)</font> </div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The number of shares of our common stock to be outstanding after this offering is based on&#160;2,682,615&#160;shares of common stock outstanding as of November 4, 2011 and excludes, as of that date:</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">shares issuable upon the exercise of warrants sold in this offering;</font></font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">an aggregate of 370,263 shares of common stock issuable upon the exercise of outstanding stock options issued to employees, directors and consultants, including under our 2006 Stock Incentive Plan;</font></font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">an aggregate of 340,611 additional shares of common stock reserved for future issuance under our 2006 Stock Incentive Plan;</font></font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">an aggregate of 703,946 additional shares of common stock reserved for issuance under outstanding warrant agreements entered into in connection with the private placement of our securities completed on April 8, 2011 expiring on March 31, 2016 at an exercise price of $7.50 per share; and</font></font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">an aggregate of 28,785 additional shares of common stock reserved for issuance under various outstanding warrant agreements, with expiration dates between May 7, 2012 and December 31, 2016, at exercise prices ranging from $7.50 to $1,912.50.</font></font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The above figures give effect to an estimated 1-for-10 Offering Reverse Split without regard to settlement of fractional shares. </font>Unless we specifically state otherwise, the share information in this prospectus is as of November 4, 2011 and reflects or assumes no exercise of outstanding options or warrants to purchase shares of our common stock.</font> </div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Since the former stockholders of Cellectar retained the majority voting interest in the combined business following the Acquisition, the Acquisition has been accounted for as a reverse acquisition whereby Cellectar, Inc. is treated as the acquirer for accounting and financial reporting purposes. As such, the historical financial information presented in this prospectus represents the historical financial information of Cellectar<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">, except for the capital structure which represents the historical amounts of Cellectar retroactively adjusted to reflect the legal capital structure of Novelos by applying the exchange ratio established in the Acquisition.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Summary Historical Financial Information</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes our financial data. We have derived the following summary of our statements of operations data for the nine months ended September 30, 2011 and 2010 and the summary of our balance sheet data as of September 30, 2011 from our unaudited consolidated financial statements appearing elsewhere in this prospectus. We have derived the following summary of our statements of operations data for the fiscal years ended December 31, 2010 and 2009 and the summary of our balance sheet data as of&#160;December 31, 2010 and 2009&#160;from our audited financial statements appearing elsewhere in this prospectus. The following summary of our financial data set forth below should be read together with our financial statements and the related notes to those statements, as well as the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; appearing elsewhere in this prospectus.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months&#160;Ended</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Year&#160;Ended</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December&#160;31,</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Statement of Operations Data:</font> </div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development costs</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,445,429</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,616,834</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,984,207</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,351,983</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative costs</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,827,510</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,014,094</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,156,549</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,824,302</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Merger costs</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">746,207</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">52,925</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total costs and expenses</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,019,146</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,630,928</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,193,681</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,176,285</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other expense</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(450,356</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(467,495</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(366,582</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(43,588</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,469,502</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,098,423</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,560,263</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,219,873</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic and diluted net loss attributable to common stockholders per common share</font> </font></div>
</td>
<td align="right" valign="bottom" width="1%"> &#160; </td>
<td align="left" valign="bottom" width="1%"> &#160; </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.25</font> </font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"> &#160; </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"> &#160; </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.32</font> </font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"> &#160; </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"> &#160; </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.36</font> </font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"> &#160; </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"> &#160; </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.49</font> </font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: right">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center"> &#160;&#160; <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font></font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December&#160;31,</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> &#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-WEIGHT: bold">2011</font></font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> &#160; <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> &#160; <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance Sheet Data:</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%"> &#160; </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%"> &#160; </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%"> &#160; </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Current assets</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> $ </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,108,688</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%"> &#160; </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> $ </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,279,781</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> $ </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,704,212</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Working capital</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,586,871</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%"> &#160; </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">374,964</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">795,891</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total assets</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,994,975</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%"> &#160; </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,802,142</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,824,706</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Long term debt, including current portion</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">450,000</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%"> &#160; </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,846,728</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">866,532</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total stockholders&#8217; equity</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,897,099</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%"> &#160; </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">133,762</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,126,893</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage11"><!--EFPlaceholder--></a><a name="FIS_FINANCIAL_DATA_2"><!--EFPlaceholder--></a>Summary Pro Forma Financial Information</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes certain pro forma statement of operations and balance sheet data to give effect for the Acquisition and the private placement of our securities that occurred immediately following the Acquisition as though it occurred at the beginning of the periods presented for the purpose of statement of operations data. We have derived the following summary pro forma financial information from the unaudited pro forma financial statement data appearing elsewhere in this prospectus and the below information should be read together with the unaudited pro forma information.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></font></td>
<td align="left" valign="top"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months&#160;</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Ended</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font> </div>
</td>
<td align="left" valign="top"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Year&#160;Ended</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December&#160;31,</font> </div>
</td>
<td align="left" valign="top"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pro Forma Statement of Operations Data:</font> </div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development costs</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> $ </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,982,884</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> $ </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,982,191</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative costs</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,406,619</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,618,501</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total costs and expenses</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,389,503</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,600,692</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other income</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">98,984</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,895,726</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,290,519</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,704,966</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss attributable to common stockholders</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,290,519</font></font> </div>
</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,704,966</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic and diluted net loss attributable to common stockholders per common share</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.20</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.06</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic and diluted net loss attributable to common stockholders per common share giving effect to an estimated 1-for-10 Offering Reverse Split</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1.97</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.64</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">RISK FACTORS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Investing in our securities involves a high degree of risk. Before you invest in our securities, you should be aware that our business faces numerous financial and market risks, including those described below, as well as general economic and business risks. The following discussion provides information concerning the material risks and uncertainties that we have identified and believe may adversely affect our business, financial condition and results of operations. Before you decide whether to invest in our securities, you should carefully consider these risks and uncertainties, together with all of the other information included in this prospectus.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Risks Related to Our Business and Industry</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We will require additional capital in order to continue our operations, and may have difficulty raising additional capital.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We expect that we will continue to generate significant operating losses for the foreseeable future. At September 30, 2011, our consolidated cash balance was approximately $1,591,000. We believe our cash on hand, together with the net proceeds from this offering (without exercise of the underwriters over-allotment option), would be adequate to fund operations through the end of 2012<font style="DISPLAY: inline; FONT-STYLE: italic">.</font> During that time, we anticipate that we will incur approximately $14,000,000 in costs, subject to the availability of funds. Of this amount, approximately $10,400,000 is estimated for research and development activities and $3,600,000 is estimated for general and administrative costs. The research and development costs consist of approximately $2,300,000 for the development of HOT (including approximately $1,500,000 in Phase 1b trial costs), $1,100,000 for the development of LIGHT, $3,200,000 for the development of COLD (principally activities preceding an IND) and $3,800,000 for our general, unallocated research and development costs including salaries, overhead, patent and other costs that are not specific to a certain development project. In addition to these estimated costs, we may incur up to $800,000 in clinical development costs during 2013, if necessary, to complete the Phase 1b dose-escalation trial in HOT. We have expended and expect to continue to expend substantial funds on the research, development and clinical and pre-clinical testing of our drug compounds. We will require additional funds to conduct research and development, establish and conduct clinical and pre-clinical trials, establish commercial-scale manufacturing arrangements and provide for the marketing and distribution of our products. Our ability to execute our operating plan beyond that time depends on our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. Although we have not entered into negotiations for a financing or strategic transaction (other than the offering contemplated in this prospectus), we plan to actively pursue financing alternatives. However, there can be no assurance that we will obtain the necessary funding or that it will be available on a timely basis or upon terms acceptable to us. If we obtain capital by issuing debt or preferred stock, the holders of such securities would likely obtain rights that are superior to those of holders of our common stock.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our capital requirements and our ability to meet them depend on many factors, including:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the number of potential products and technologies in development;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">continued progress and cost of our research and development programs;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">progress with pre-clinical studies and clinical trials;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the time and costs involved in obtaining regulatory clearance;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">costs of developing sales, marketing and distribution channels and our ability to sell our drugs;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">costs involved in establishing manufacturing capabilities for clinical trial and commercial quantities of our drugs;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">competing technological and market developments;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">market acceptance of our products;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">costs for recruiting and retaining management, employees and consultants;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">costs for educating physicians regarding the application and use of our products;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">whether or not we obtain listing on a national exchange and, if not, our prospects for obtaining such listing;</font></font> </div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">uncertainty and economic instability resulting from terrorist acts and other acts of violence or war; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the condition of capital markets and the economy generally, both in the U.S. and globally.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We may consume available resources more rapidly than currently anticipated, resulting in the need for additional funding sooner than expected. We may seek to raise any necessary additional funds through the issuance of warrants, equity or debt financings or executing collaborative arrangements with corporate partners or other sources, which may be dilutive to existing stockholders or have a material effect on our current or future business prospects. In addition, in the event that additional funds are obtained through arrangements with collaborative partners or other sources, we may have to relinquish economic and/or proprietary rights to some of our technologies or products under development that we would otherwise seek to develop or commercialize by ourselves. If we cannot secure adequate financing when needed, we may be required to delay, scale back or eliminate one or more of our research and development programs or to enter into license or other arrangements with third parties to commercialize products or technologies that we would otherwise seek to develop ourselves and commercialize ourselves. In such event, our business, prospects, financial condition, and results of operations may be adversely affected.</font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage13"><!--EFPlaceholder--></a>We are a development stage company with a history of losses and can provide no assurance of our future operating results.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We are a development stage company and have incurred net losses and negative cash flows since inception. We currently have no product revenues, and may not succeed in developing or commercializing any products which will generate product or licensing revenues. We do not expect to have any marketable products on the market for several years. Our primary activity to date has been research and development. In addition, development of our product candidates requires a process of pre-clinical and clinical testing, during which our product candidates could fail. We may not be able to enter into agreements with one or more companies experienced in the manufacturing and marketing of therapeutic drugs and, to the extent that we are unable to do so, we will not be able to market our product candidates. Eventual profitability will depend on our success in developing, manufacturing, and marketing our product candidates. Cellectar has experienced net losses and negative cash flows from operating activities since inception and we expect such losses and negative cash flows to continue in the foreseeable future. As of December 31, 2009 and 2010, Cellectar had working capital of $795,891 and $374,964, respectively, and stockholders&#8217; equity of $4,126,893 and $133,762, respectively. As of September 30, 2011, we had working capital of $1,586,871 and stockholders&#8217; equity of $5,897,099. For the period from Cellectar&#8217;s inception in November 2002 through September 30, 2011, the years ended December 31, 2009 and 2010, and for the nine months ended September 30, 2011, we incurred net losses of $(29,514,506), $(6,219,873), $(4,560,263), and $(5,469,502), respectively. We may never achieve profitability.</font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><br>
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We and our Chief Executive Officer are defendants in a securities fraud class action lawsuit. We are also defending counterclaims in another lawsuit that we initiated. If we are not successful in defending claims against us, the resulting liability could be substantial.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A putative class action complaint was filed on March 5, 2010 in the U.S. District Court for the District of Massachusetts by an alleged shareholder on behalf of himself and all others who purchased or otherwise acquired our common stock in the period between December 14, 2009 and February 24, 2010, against us and our President and Chief Executive Officer, Harry S. Palmin. The complaint claimed, among other things, that the defendants violated Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder in connection with alleged misleading disclosures related to the progress of the Phase 3 trial of NOV-002 in advanced non-small cell lung cancer. On June 23, 2011, the case was dismissed without prejudice. On August 5, 2011, the plaintiffs filed a second amended complaint realleging that the defendants violated Section 10(b) of the Exchange Act and Rule 10b-5 in connection with alleged misleading disclosures related to the Phase 3 clinical trial for NOV-002 in non-small cell lung cancer. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On September 9, 2011, the defendants filed a motion to dismiss the second amended complaint. The plaintiff<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#8217;</font>s opposition to the motion&#160;was filed on&#160;October 14, 2011 and the defendants filed a reply brief on November 4, 2011. </font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In addition, on June 28, 2010, we received a letter from counsel to ZAO BAM and ZAO BAM Research Laboratories (Russian companies, collectively referred to as &#8220;BAM&#8221;) alleging that we modified the chemical composition of NOV-002 without prior notice to or approval from BAM, constituting a material breach of a technology and assignment agreement we had entered into with BAM on June 20, 2000 (the &#8220;June 2000 Agreement&#8221;). On September 24, 2010, we filed a complaint in Suffolk Superior Court seeking a declaratory judgment by the court that the June 2000 Agreement has been replaced by a subsequent agreement between the parties dated April 1, 2005 (the &#8220;April 2005 Agreement&#8221;), that Novelos&#8217; obligations to BAM are governed solely by the April 2005 Agreement and that the obligations of the June 2000 Agreement have been performed and fully satisfied. BAM answered the complaint, denying the material allegations, and stating its affirmative defenses and certain counterclaims. In June 2011, BAM filed an amended counterclaim alleging additional claims related to Novelos&#8217; acquisition of Cellectar. On June 15, 2011 we filed our response to their amended counterclaim. On August 5, 2011, we filed a motion for judgment on the pleadings as to our declaratory judgment count and all counts of BAM&#8217;s amended counterclaim. The motion&#160;was opposed by BAM and a hearing on the motion&#160;was held&#160;on September 27, 2011. <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On October 17, 2011, the court ruled on our <font style="DISPLAY: inline; FONT-SIZE: 10pt">behalf for each of our declaratory judgment claims and dismissed all counts of BAM&#8217;s counterclaim. Judgment in favor of the Company was entered on October 20, 2011 and BAM has until November 21, 2011 to appeal or otherwise seek post-judgment relief.</font></font></font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">While we intend to vigorously defend ourselves in these actions, the uncertainties of litigation and the uncertainties related to insurance coverage and collection as well as the actual value of claims make it difficult to accurately predict the financial effect these claims may ultimately have on us. We may not be successful in defending such claims, and the resulting liability could be substantial and may not be covered by insurance. At the time the class action complaint was filed, we carried a total of $10 million in directors and officers liability insurance coverage, consisting of $5 million in primary coverage (including costs to defend) and $5 million in excess liability coverage. The BAM dispute is not covered by insurance. In addition, the lawsuits divert management&#8217;s attention and resources, whether or not the claims are ultimately successful, and this could adversely affect our business. As a result, there can be no assurance as to the long-term effect litigation will have on our business, prospects, financial condition or results of operations.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At present, our success depends solely on the successful commercialization of Cellectar compounds.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prior to the Acquisition, Novelos had for over ten years been developing oxidized glutathione-based compounds for the treatment of cancer, including NOV-002, an injectable small-molecule compound based on a proprietary formulation of oxidized glutathione that Novelos had been developing for use in combination with standard-of-care chemotherapies for the treatment of solid tumors, and NOV-205, a hepatoprotective agent with immunomodulating and anti-inflammatory properties.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Following the Acquisition, development of NOV-002 and NOV-205 has been suspended and we are now focused on the development of novel drugs for the treatment and diagnosis of cancer based on the cancer-targeting technologies of Cellectar: CLR1401 (&#8220;COLD&#8221;), <font style="DISPLAY: inline; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">131</font></font></font> I-CLR1404 (&#8220;HOT&#8221;, a radiolabeled compound) and <font style="DISPLAY: inline; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">124</font></font></font> I-CLR1404 (&#8220;LIGHT&#8221;, labeled with a shorter-lived radioisotope, iodine-124). As a result the successful commercialization of HOT, COLD and LIGHT is crucial for our success. Our proposed products and their potential applications are in an early stage of clinical and manufacturing/process development and face a variety of risks and uncertainties. Principally, these risks include the following:</font> </div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="eolPage14"><!--EFPlaceholder--></a><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">future clinical trial results may show that the cancer-targeting technologies of Cellectar are not well tolerated by recipients at its effective doses or are not efficacious;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">future clinical trial results may be inconsistent with Cellectar&#8217;s previous preliminary testing results and data from Cellectar&#8217;s earlier studies may be inconsistent with clinical data;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">even if the cancer-targeting technologies of Cellectar are shown to be safe and effective for their intended purposes, we may face significant or unforeseen difficulties in obtaining or manufacturing sufficient quantities at reasonable prices or at all;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">our ability to complete the development and commercialization of the cancer-targeting technologies of Cellectar for our intended use is substantially dependent upon our ability to obtain and maintain experienced and committed partners to assist us with obtaining clinical and regulatory approvals for, and the manufacturing, marketing and distribution of, our products;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">even if the cancer-targeting technologies of Cellectar are successfully developed, commercially produced and receive all necessary regulatory approvals, there is no guarantee that there will be market acceptance of our products; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">our competitors may develop therapeutics or other treatments which are superior or less costly than our own with the result that our product candidates, even if they are successfully developed, manufactured and approved, may not generate sufficient revenues to offset the development and manufacturing costs of our product candidates.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If we are unsuccessful in dealing with any of these risks, or if we are unable to successfully commercialize the cancer-targeting technologies of Cellectar for some other reason, our business, prospects, financial condition, and results of operations may be adversely affected.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The integration of Novelos and Cellectar may be costly and difficult.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The successful integration of independent businesses or assets can be a complex, costly and time-consuming process. The difficulties of integrating Novelos and Cellectar include, among others:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">consolidating research and development operations;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">preserving important research and development, manufacturing and supply, and other relationships;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">minimizing the diversion of management&#8217;s attention from ongoing business concerns;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">coordinating geographically separate organizations; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">optimizing the functioning of a newly constituted Board of Directors.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We may not accomplish the integration of Novelos and Cellectar smoothly or successfully. The diversion of the attention of our management from current operations to integration efforts and any difficulties encountered in combining operations could prevent the combined company from realizing the full benefits anticipated to result from the Acquisition and may adversely affect the combined business. Additionally, the costs associated with the integration of Novelos and Cellectar may be significant. To the extent that we incur integration costs that are not anticipated, these unexpected costs could adversely impact our liquidity and force us to seek additional funding sooner than would otherwise be necessary. To date, there have been no notable difficulties encountered during integration.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have a history of recurring losses and an accumulated deficit which, among other factors, raise substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Our financial statements as of December 31, 2010 included elsewhere in this prospectus were prepared under the assumption that we will continue as a going concern. The independent registered public accounting firm that audited our 2010 financial statements, in their report, included an explanatory paragraph referring to our recurring losses&#160;since inception&#160;and expressing substantial doubt in our ability to continue as a going concern. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our ability to continue as a going concern depends on our ability to obtain additional equity or debt financing, attain further operating efficiencies, reduce expenditures, and, ultimately, to generate revenue.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage15"><!--EFPlaceholder--></a>The failure to complete development of our therapeutic technology, to obtain government approvals, including required FDA approvals, or to comply with ongoing governmental regulations could prevent, delay or limit introduction or sale of proposed products and result in failure to achieve revenues or maintain our ongoing business.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our research and development activities and the manufacture and marketing of our intended products are subject to extensive regulation for safety, efficacy and quality by numerous government authorities in the U.S. and abroad. Before receiving clearance to market our proposed products by the FDA, we will have to demonstrate that our products are safe and effective for the patient population for the diseases that are to be treated. Clinical trials, manufacturing and marketing of drugs are subject to the rigorous testing and approval process of the FDA and equivalent foreign regulatory authorities. The Federal Food, Drug and Cosmetic Act and other federal, state and foreign statutes and regulations govern and influence the testing, manufacturing, labeling, advertising, distribution and promotion of drugs and medical devices. As a result, clinical trials and regulatory approval can take many years to accomplish and require the expenditure of substantial financial, managerial and other resources.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In order to be commercially viable, we must successfully research, develop, obtain regulatory approval for, manufacture, introduce, market and distribute our technologies. This includes meeting a number of critical developmental milestones including:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">demonstrating benefit from delivery of each specific drug for specific medical indications;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">demonstrating through pre-clinical and clinical trials that each drug is safe and effective; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">demonstrating that we have established viable Good Manufacturing Practices capable of potential scale-up.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The timeframe necessary to achieve these developmental milestones may be long and uncertain, and we may not successfully complete these milestones for any of our intended products in development.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition to the risks previously discussed, our technology is subject to developmental risks that include the following:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">uncertainties arising from the rapidly growing scientific aspects of drug therapies and potential treatments;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">uncertainties arising as a result of the broad array of alternative potential treatments related to cancer and other diseases; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">anticipated expense and time believed to be associated with the development and regulatory approval of treatments for cancer and other diseases.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In order to conduct the clinical trials that are necessary to obtain approval by the FDA to market a product, it is necessary to receive clearance from the FDA to conduct such clinical trials. The FDA can halt clinical trials at any time for safety reasons or because we or our clinical investigators do not follow the FDA&#8217;s requirements for conducting clinical trials. If we are unable to receive clearance to conduct clinical trials for a product, or the trials are halted by the FDA, we will not be able to achieve any revenue from such product in the U.S. as it is illegal to sell any drug for use in humans in the U.S. without FDA approval.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Even if we do ultimately receive FDA approval for any of our products, these products will be subject to extensive ongoing regulation, including regulations governing manufacturing, labeling, packaging, testing, dispensing, prescription and procurement quotas, record keeping, reporting, handling, shipment and disposal of any such drug. Failure to obtain and maintain required registrations or to comply with any applicable regulations could further delay or preclude development and commercialization of our drugs and subject us to enforcement action.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In order to receive regulatory approval for the commercialization of our product candidates, we must conduct, at our own expense, extensive clinical trials to demonstrate safety and efficacy of these product candidates. Clinical testing is expensive, it can take many years to complete and its outcome is uncertain. Failure can occur at any time during the clinical trial process. For example, we incurred costs of over $35 million in clinical trial expenses over a period of 4 years in connection with the Phase 3 trial of NOV-002 for non-small cell lung cancer, and NOV-002 did not ultimately demonstrate efficacy for that indication.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We may experience delays in clinical testing of our product candidates. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a trial, in reaching agreement on acceptable clinical trial terms with prospective sites, in obtaining institutional review board approval to conduct a trial at a prospective site, in recruiting patients to participate in a trial or in obtaining sufficient supplies of clinical trial materials. Many factors affect patient enrollment, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, competing clinical trials and new drugs approved for the conditions we are investigating. Prescribing physicians will also have to decide to use our product candidates over existing drugs that have established safety and efficacy profiles. Any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and delay our ability to generate revenue.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition, the results of preclinical studies and early clinical trials of our product candidates do not necessarily predict the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through initial clinical testing. The data collected from clinical trials of our product candidates may not be sufficient to support the submission of a new drug application or to obtain regulatory approval in the United States or elsewhere. Because of the uncertainties associated with drug development and regulatory approval, we cannot determine if or when we will have an approved product for commercialization or achieve sales or profits.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our clinical trials may not demonstrate sufficient levels of efficacy necessary to obtain the requisite regulatory approvals for our drugs, and our proposed drugs may not be approved for marketing. As discussed elsewhere in this prospectus, we suffered significant setbacks in the development of NOV-002 and NOV-205, as some of the promising results of earlier trials were not demonstrated in later stage trials. As a result, following the Acquisition, development of these compounds has been suspended.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We may be required to suspend or discontinue clinical trials due to unexpected side effects or other safety risks that could preclude approval of our product candidates.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our clinical trials may be suspended at any time for a number of reasons. For example, we may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to the clinical trial patients. In addition, regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements or that they present an unacceptable safety risk to the clinical trial patients.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Administering any product candidates to humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials of our product candidates and could result in the FDA or other regulatory authorities denying further development or approval of our product candidates for any or all targeted indications. Ultimately, some or all of our product candidates may prove to be unsafe for human use. Moreover, we could be subject to significant liability if any volunteer or patient suffers, or appears to suffer, adverse health effects as a result of participating in our clinical trials.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have limited in-house research and manufacturing capacity and will rely, to some extent, on research and manufacturing facilities at various universities, hospitals, contract research organizations and contract manufacturers for a portion of our research, development, and manufacturing. In the event we exceed our in-house capacity or lose access to those facilities, our ability to gain FDA approval and commercialization of our drug delivery technology and products could be delayed or impaired.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We remain in the research and development and clinical and pre-clinical trial phase of product commercialization and have limited experience in establishing, supervising and conducting commercial manufacturing. Accordingly, if our products are approved for commercial sale, we will need to establish the capability, or engage a contract manufacturer that has the capability, to commercially manufacture our products in accordance with FDA and other regulatory requirements. There can be no assurance that we would be able to successfully establish any such capability, or indentify a suitable manufacturing partner on acceptable terms.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At the present time, we have limited research, development or manufacturing capabilities within our facilities. Our manufacturing facility in Madison, WI has adequate capacity to supply drug product for Phase 2 studies of HOT, but we will need to expand for larger Phase 3 studies. We are exploring scaling up production capacity of COLD, via contract manufacturers or at our facility, to support an IND filing and clinical trials. LIGHT is currently manufactured by our collaborator, the University of Wisconsin at Madison in small quantities, at no cost to us, for use in investigator-sponsored clinical trials pursuant to a materials transfer agreement expiring in June 2013, but which may be terminated at any time by either party. We rely and expect to continue to rely, to some extent, on contracting with third parties to use their facilities to conduct research, development and manufacturing. The limited facilities of our own in which to conduct research, development and manufacturing may delay or impair our ability to gain FDA approval and commercialization of our drug delivery technology and products.</font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We may rely on third-party contract research organizations, service providers and suppliers to support development and clinical testing of our products. This may expose us to the risks of not being able to directly oversee the production and quality of the manufacturing process. Furthermore, these contractors, whether foreign or domestic, may experience regulatory compliance difficulties, mechanical shutdowns, employee strikes or other unforeseeable acts that may delay production. Failure of any of these contractors to provide the required services in a timely manner or on commercially reasonable terms could materially delay the development and approval of our products, increase our expenses and materially harm our business, prospects, financial condition and results of operations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We believe that we have a good working relationship with our contractors. However, should the situation change, we may be required to relocate these activities on short notice, and we do not currently have access to alternate facilities to which we could relocate our research, development and/or manufacturing activities. The cost and time to establish or locate an alternate research, development and/or manufacturing facility to develop our technology would be substantial and would delay obtaining FDA approval and commercializing our products.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are exposed to product, clinical and preclinical liability risks that could create a substantial financial burden should we be sued.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our business exposes us to potential product liability and other liability risks that are inherent in the testing, manufacturing and marketing of pharmaceutical products. In addition, the use, in our clinical trials, of pharmaceutical products that we or our current or potential collaborators may develop and then subsequently sell may cause us to bear a portion of or all product liability risks. While we carry an insurance policy covering up to $5,000,000 per occurrence and $5,000,000 in the aggregate of liability incurred in connection with such claims should they arise, there can be no assurance that our insurance will be adequate to cover all situations. Moreover, there can be no assurance that such insurance, or additional insurance, if required, will be available in the future or, if available, will be available on commercially reasonable terms. Furthermore, our current and potential partners with whom we have collaborative agreements or our future licensees may not be willing to indemnify us against these types of liabilities and may not themselves be sufficiently insured or have a net worth sufficient to satisfy any product liability claims. A successful product liability claim or series of claims brought against us could have a material adverse effect on our business, prospects, financial condition and results of operations.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Acceptance of our products in the marketplace is uncertain and failure to achieve market acceptance will prevent or delay our ability to generate revenues.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our future financial performance will depend, at least in part, on the introduction and customer acceptance of our proposed products. Even if approved for marketing by the necessary regulatory authorities, our products may not achieve market acceptance. The degree of market acceptance will depend on a number of factors including:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">receiving regulatory clearance of marketing claims for the uses that we are developing;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">establishing and demonstrating the advantages, safety and efficacy of our technologies;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">pricing and reimbursement policies of government and third-party payers such as insurance companies, health maintenance organizations and other health plan administrators;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">our ability to attract corporate partners, including pharmaceutical companies, to assist in commercializing our intended products; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">our ability to market our products.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Physicians, patients, payers or the medical community in general may be unwilling to accept, use or recommend any of our products. If we are unable to obtain regulatory approval or commercialize and market our proposed products as planned, we may not achieve any market acceptance or generate revenue.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We may face litigation from third parties who claim that our products infringe on their intellectual property rights, particularly because there is often substantial uncertainty about the validity and breadth of medical patents.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We may be exposed to future litigation by third parties based on claims that our technologies, products or activities infringe on the intellectual property rights of others or that we have misappropriated the trade secrets of others. This risk is exacerbated by the fact that the validity and breadth of claims covered in medical technology patents and the breadth and scope of trade-secret protection involve complex legal and factual questions for which important legal principles are unresolved. Any litigation or claims against us, whether or not valid, could result in substantial costs, could place a significant strain on our financial and managerial resources and could harm our reputation. The U. Mich license does require and license agreements that we may enter into in the future would likely require that we pay the costs associated with defending this type of litigation. In addition, intellectual property litigation or claims could force us to do one or more of the following:</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">cease selling, incorporating or using any of our technologies and/or products that incorporate the challenged intellectual property, which would adversely affect our ability to generate revenue;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">obtain a license from the holder of the infringed intellectual property right, which license may be costly or may not be available on reasonable terms, if at all; or</font></font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">redesign our products, which would be costly and time-consuming.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If we are unable to protect or enforce our rights to intellectual property adequately or to secure rights to third-party patents, we may lose valuable rights, experience reduced market share, assuming any, or incur costly litigation to protect our intellectual property rights.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our ability to obtain licenses to patents, maintain trade secret protection and operate without infringing the proprietary rights of others will be important to commercializing any products under development. Therefore, any disruption in access to the technology could substantially delay the development of our technology.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The patent positions of biotechnology and pharmaceutical companies, such as ours, that involve licensing agreements, are frequently uncertain and involve complex legal and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued or in subsequent legal proceedings. Consequently, our patent applications and any issued and licensed patents may not provide protection against competitive technologies or may be held invalid if challenged or circumvented. To the extent we license patents from third parties, as in the case of the U. Mich. license, the early termination of any such license agreement would result in the loss of our rights to use the covered patents which could severely delay, inhibit or eliminate our ability to develop and commercialize compounds based on the licensed patents. Our competitors may also independently develop products similar to ours or design around or otherwise circumvent patents issued or licensed to us. In addition, the laws of some foreign countries may not protect our proprietary rights to the same extent as U.S. law.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We also rely on trade secrets, technical know-how and continuing technological innovation to develop and maintain our competitive position. Although we generally require our employees, consultants, advisors and collaborators to execute appropriate confidentiality and assignment-of-inventions agreements, our competitors may independently develop substantially equivalent proprietary information and techniques, reverse engineer our information and techniques, or otherwise gain access to our proprietary technology. We may be unable to meaningfully protect our rights in trade secrets, technical know-how and other non-patented technology.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We may have to resort to litigation to protect our rights for certain intellectual property, or to determine their scope, validity or enforceability. Enforcing or defending our rights is expensive, could cause diversion of our resources and may not prove successful. Any failure to enforce or protect our rights could cause us to lose the ability to exclude others from using our technology to develop or sell competing products.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Confidentiality agreements with employees and others may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We operate in the highly technical field of research and development of small molecule drugs, and rely in part on trade secret protection in order to protect our proprietary trade secrets and unpatented know-how. However, trade secrets are difficult to protect, and we cannot be certain that our competitors will not develop the same or similar technologies on their own. We have taken steps, including entering into confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors, to protect our trade secrets and unpatented know-how. These agreements generally require that the other party keep confidential and not disclose to third parties all confidential information developed by the party or made known to the party by us during the course of the party&#8217;s relationship with us. We also typically obtain agreements from these parties which provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us. Enforcing a claim that a party has illegally obtained and is using our trade secrets or know-how is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets or know-how. The failure to obtain or maintain trade secret protection could adversely affect our competitive position.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that we or these employees have used or disclosed trade secrets or other proprietary information of their former employers, either inadvertently or otherwise. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The use of hazardous materials, including radioactive materials, in our research and development imposes certain compliance costs on us and may subject us to liability for claims arising from the use or misuse of these materials.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our research and development, manufacturing and administration of our drugs involves the controlled use of hazardous materials, including chemicals and radioactive materials, such as radioactive isotopes. We are subject to federal, state and local laws and regulations governing the storage, use and disposal of these materials and some waste products and are required to maintain both a manufacturer&#8217;s license and a radioactive materials license with State of Wisconsin agencies. We believe that our safety procedures for the storage, use and disposal of these materials comply with the standards prescribed by federal, state and local regulations. However, we cannot completely eliminate the risk of accidental contamination or injury from these materials. If there were to be an accident, we could be held liable for any damages that result, which could exceed our financial resources. We currently maintain insurance coverage, with limits of up to $2,500,000 depending on the nature&#160;of the claim,&#160;for damages resulting from the hazardous materials we use; however, future claims may exceed the amount of our coverage. Also, we do not have insurance coverage for pollution cleanup and removal. Currently the costs of complying with federal, state and local regulations are not significant, and consist primarily of waste disposal expenses and permitting fees. However, they could become expensive, and current or future environmental regulations may impair our research, development, production and commercialization efforts. If we are unable to maintain the required licenses and permits for any reason, it will negatively impact our research and development activities.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Due to our limited marketing, sales and distribution experience, we may be unsuccessful in our efforts to sell our proposed products, enter into relationships with third parties or develop a direct sales organization.</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We have not established marketing, sales or distribution capabilities for our proposed products. Until such time as our proposed products are further along in the development process, we will not devote any meaningful time and resources to this effort. At the appropriate time, we intend to develop our own sales and marketing capabilities or enter into agreements with third parties to sell our products.</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have limited experience in developing, training or managing a sales force. If we choose to establish a direct sales force, we may incur substantial additional expenses in developing, training and managing such an organization. We may be unable to build a sales force on a cost-effective basis or at all. Any such direct marketing and sales efforts may prove to be unsuccessful. In addition, we will compete with many other companies that currently have extensive marketing and sales operations. Our marketing and sales efforts may be unable to compete against these other companies. We may be unable to establish a sufficient sales and marketing organization on a timely basis, if at all.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">If we choose to enter into agreements with third parties to sell our proposed products, we may be unable to establish or maintain third-party relationships on a commercially reasonable basis, if at all. In addition, these third parties may have similar or more established relationships with our competitors.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We may be unable to engage qualified distributors. Even if engaged, these distributors may:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">fail to adequately market our products;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">fail to satisfy financial or contractual obligations to us;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">offer, design, manufacture or promote competing products; or</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">cease operations with little or no notice.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If we fail to develop sales, marketing and distribution channels, we would experience delays in product sales and incur increased costs, which would have a material adverse effect on our business, prospects, financial condition, and results of operation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage20"><!--EFPlaceholder--></a>If we are unable to convince physicians of the benefits of our intended products, we may incur delays or additional expense in our attempt to establish market acceptance.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Achieving use of our products in the target market of cancer diagnosis and treatment may require physicians to be informed regarding these products and their intended benefits. The time and cost of such an educational process may be substantial. Inability to successfully carry out this physician education process may adversely affect market acceptance of our proposed products. We may be unable to timely educate physicians regarding our intended proposed products in sufficient numbers to achieve our marketing plans or to achieve product acceptance. Any delay in physician education may materially delay or reduce demand for our proposed products. In addition, we may expend significant funds towards physician education before any acceptance or demand for our proposed products is created, if at all.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The market for our proposed products is rapidly changing and competitive, and new therapeutics, new drugs and new treatments that may be developed by others could impair our ability to maintain and grow our business and remain competitive.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The pharmaceutical and biotechnology industries are subject to rapid and substantial technological change. Developments by others may render our technologies and intended products noncompetitive or obsolete, or we may be unable to keep pace with technological developments or other market factors. Technological competition from pharmaceutical and biotechnology companies, universities, governmental entities and others diversifying into the field is intense and is expected to increase. Most of these entities have significantly greater research and development capabilities and budgets than we do, as well as substantially more marketing, manufacturing, financial and managerial resources. These entities represent significant competition for us. Acquisitions of, or investments in, competing pharmaceutical or biotechnology companies by large corporations could increase our competitors&#8217; financial, marketing, manufacturing and other resources.</font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We operate with limited day-to-day business management, serve as a vehicle to hold certain technology for possible future exploration, and have been and will continue to be engaged in the development of new drugs and therapeutic technologies. As a result, our resources are limited and we may experience management, operational or technical challenges inherent in such activities and novel technologies. Competitors have developed or are in the process of developing technologies that are, or in the future may be, the basis for competition. Some of these technologies may accomplish therapeutic effects similar to those of our technology, but through different means. Our competitors may develop drugs and drug delivery technologies that are more effective than our intended products and, therefore, present a serious competitive threat to us.</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For example, Perifosine, an alkylphospholipid that is being developed by Keryx Biopharmaceuticals, which has licensed it in North America from &#198;terna Zentaris Inc., is a possible future competitor to COLD. We do not know of any current or potential direct competitors for HOT and LIGHT. Marketed drugs Zevalin (Spectrum Pharmaceuticals) and Bexxar (Glaxo Smith Kline) provide examples of targeted radiotherapeutics specifically for lymphoma indication. FDG is the current standard for PET imaging for cancer and may be an alternative diagnostic imaging agent to LIGHT.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The potential widespread acceptance of therapies that are alternatives to ours may limit market acceptance of our products even if they are commercialized. Many of our targeted diseases and conditions can also be treated by other medication or drug delivery technologies. These treatments may be widely accepted in medical communities and have a longer history of use. The established use of these competitive drugs may limit the potential for our technologies and products to receive widespread acceptance if commercialized.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If users of our products are unable to obtain adequate reimbursement from third-party payers, or if additional healthcare reform measures are adopted, it could hinder or prevent our product candidates&#8217; commercial success.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The continuing efforts of government and insurance companies, health maintenance organizations and other payers of healthcare costs to contain or reduce costs of healthcare may adversely affect our ability to generate future revenues and achieve profitability, including by limiting the future revenues and profitability of our potential customers, suppliers and collaborative partners. For example, in certain foreign markets, pricing or profitability of prescription pharmaceuticals is subject to government control. The U.S. government and other governments have shown significant interest in pursuing healthcare reform. Any government-adopted reform measures could adversely affect the pricing of healthcare products and services in the U.S. or internationally and the amount of reimbursement available from governmental agencies or other third-party payers. The continuing efforts of the U.S. and foreign governments, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce healthcare costs may adversely affect our ability to set prices for our products, should we be successful in commercializing them, and this would negatively affect our ability to generate revenues and achieve and maintain profitability.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">New laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, that relate to healthcare availability, methods of delivery or payment for healthcare products and services, or sales, marketing or pricing of healthcare products and services, also may limit our potential revenue and may require us to revise our research and development programs. The pricing and reimbursement environment may change in the future and become more challenging for several reasons, including policies advanced by the current or future executive administrations in the U.S., new healthcare legislation or fiscal challenges faced by government health administration authorities. Specifically, in both the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. In the U.S., changes in federal healthcare policy were passed into law in 2010 and are being considered by Congress again this year. Some of these proposed reforms could result in reduced reimbursement rates for our product candidates, which would adversely affect our business strategy, operations and financial results.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage21"><!--EFPlaceholder--></a>Our ability to commercialize our products will depend in part on the extent to which appropriate reimbursement levels for the cost of our products and related treatment are obtained by governmental authorities, private health insurers and other organizations, such as health maintenance organizations (HMOs). Third-party payers are increasingly challenging the prices charged for medical drugs and services. Also, the trend toward managed healthcare in the U.S. and the concurrent growth of organizations such as HMOs that could control or significantly influence the purchase of healthcare services and drugs, as well as legislative proposals to reform healthcare or change government insurance programs, may all result in lower prices for or rejection of our drugs. The cost containment measures that healthcare payers and providers are instituting and the effect of any healthcare reform could materially harm our ability to operate profitably.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We depend on key personnel who may terminate their employment with us at any time, and our success will depend on our ability to hire additional qualified personnel.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our success will depend to a significant degree on the continued services of our chief executive officer, Harry Palmin, Cellectar founder and our chief scientific officer, Jamey Weichert and our senior vice president of research and development, Christopher Pazoles. There can be no assurance that these individuals will continue to provide services to us. In addition, our success may depend on our ability to attract and retain other highly skilled personnel. We may be unable to recruit such personnel on a timely basis, if at all. Our management and other employees may voluntarily terminate their employment with us at any time. The loss of services of key personnel, or the inability to attract and retain additional qualified personnel, could result in delays in development or approval of our products, loss of sales and diversion of management resources. To date, we have not experienced difficulties attracting and retaining highly qualified personnel, but there can be no assurance we will be successful in doing so in the future.</font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Risks Related to our Common Stock</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our stock price has experienced price fluctuations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There can be no assurance that the market price for our common stock will remain at its current level and a decrease in the market price could result in substantial losses for investors. The market price of our common stock may be significantly affected by one or more of the following factors:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">announcements or press releases relating to the biopharmaceutical sector or to our own business or prospects;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">regulatory, legislative, or other developments affecting us or the healthcare industry generally;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">sales by holders of restricted securities pursuant to effective registration statements or exemptions from registration; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">market conditions specific to biopharmaceutical companies, the healthcare industry and the stock market generally.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Our four largest stockholders beneficially&#160;own approximately 52% of our outstanding common stock, which limits the influence of other shareholders.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">As of November 4, 2011, 52% of our outstanding common stock is&#160;beneficially owned&#160;by our four largest shareholders, all of whom are former shareholders of Cellectar. The interests of these stockholders may differ from those of other stockholders. These stockholders will likely continue to have the ability to significantly affect the outcome of all corporate actions requiring stockholder approval, including the following actions:</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the election of directors;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the amendment of charter documents; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the approval of certain mergers and other significant corporate transactions, including a sale of substantially all of our assets.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There may be a limited public market for our securities; we presently fail to qualify for listing on any national securities exchanges.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Our common stock currently does not meet all of the requirements for initial listing on a registered stock exchange. Specifically, the bid price of our common stock is less than the minimum bid price required to obtain a listing, which is why we have undertaken to effect an Offering Reverse Split in connection with this offering. Trading in our common stock continues to be conducted on the electronic bulletin board in the over-the-counter market. As a result, an investor may find it difficult to dispose of or to obtain accurate quotations as to the market value of our common stock, and our common stock may be less attractive for margin loans, for investment by financial institutions, as consideration in future capital raising transactions or other purposes. In connection with this offering, we have applied for listing of our common stock on The NASDAQ Capital Market under the symbol &#8220;NVLT&#8221;. No assurance can be given that our application will be approved.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our common stock has historically been a &#8220;penny stock&#8221; under SEC rules. It may be more difficult to resell shares of common stock classified as &#8220;penny stock&#8221;.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our common stock has historically been a &#8220;penny stock&#8221; under applicable SEC rules (generally defined as non-exchange traded stock with a per share price below $5.00). These rules impose additional sales practice requirements on broker-dealers that recommend the purchase or sale of penny stocks to persons other than those who qualify as &#8220;established customers&#8221; or &#8220;accredited investors.&#8221; For example, broker-dealers must determine the appropriateness for non-qualifying persons of investments in penny stocks. Broker-dealers must also provide, prior to a transaction in a penny stock not otherwise exempt from the rules, a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, disclose the compensation of the broker-dealer and its salesperson in the transaction, furnish monthly account statements showing the market value of each penny stock held in the customer&#8217;s account, provide a special written determination that the penny stock is a suitable investment for the purchaser, and receive the purchaser&#8217;s written agreement to the transaction.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Legal remedies available to an investor in "penny stocks" may include the following:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160; &#160;&#160;</font></div>
</td>
<td style="TEXT-ALIGN: left">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">if a "penny stock" is sold to the investor in violation of the requirements listed above, or other federal or states securities laws, the investor may be able to cancel the purchase and receive a refund of the investment.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160; &#160;&#160;</font></div>
</td>
<td style="TEXT-ALIGN: left">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">if a &#8220;penny stock&#8221; is sold to the investor in a fraudulent manner, the investor may be able to sue the persons and firms that committed the fraud for damages.&#160; </font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">However, investors who have signed arbitration agreements may have to pursue their claims through arbitration.</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These requirements may have the effect of reducing the level of trading activity, if any, in the secondary market for a security that becomes subject to the penny stock rules. The additional burdens imposed upon broker-dealers by such requirements may discourage broker-dealers from effecting transactions in our securities, which could severely limit the market price and liquidity of our securities. These requirements may restrict the ability of broker-dealers to sell our common stock and may affect your ability to resell our common stock.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Many brokerage firms will discourage or refrain from recommending investments in penny stocks. Most institutional investors will not invest in penny stocks. In addition, many individual investors will not invest in penny stocks due, among other reasons, to the increased financial risk generally associated with these investments.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For these reasons, penny stocks may have a limited market and, consequently, limited liquidity. We have applied for a listing of our common stock on the NASDAQ Capital Market in connection with this offering. Upon obtaining such listing, our common stock would cease to be a penny stock. However, we can give no assurance at what time, if ever, our common stock will not be classified as a &#8220;penny stock&#8221; in the future.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If we fail to maintain effective internal controls over financial reporting, the price of our common stock may be adversely affected.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our internal control over financial reporting may have weaknesses and conditions that could require correction or remediation, the disclosure of which may have an adverse impact on the price of our common stock. We are required to establish and maintain appropriate internal controls over financial reporting. Failure to establish those controls, or any failure of those controls once established, could adversely affect our public disclosures regarding our business, prospects, financial condition or results of operations. In addition, management&#8217;s assessment of internal controls over financial reporting may identify weaknesses and conditions that need to be addressed in our internal controls over financial reporting or other matters that may raise concerns for investors. Any actual or perceived weaknesses and conditions that need to be addressed in our internal control over financial reporting or disclosure of management&#8217;s assessment of our internal controls over financial reporting may have an adverse impact on the price of our common stock.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>During the year ended December 31, 2005, a material weakness existed in Novelos&#8217; internal controls over financial reporting with respect to the identification of and accounting for the beneficial conversion feature of a preferred stock financing transaction. This material weakness was remediated during 2006. As a result of this material weakness, we were required to restate our financial statements as of and for the quarter ended September 30, 2005 and as of and for the year ended December 31, 2005.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are required to comply with certain provisions of Section 404 of the Sarbanes-Oxley Act of 2002 and if we fail to comply in a timely manner, our business could be harmed and our stock price could decline.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Rules adopted by the SEC pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 require an annual assessment of internal controls over financial reporting, and for certain issuers an attestation of this assessment by the issuer&#8217;s independent registered public accounting firm. The standards that must be met for management to assess the internal controls over financial reporting as effective are evolving and complex, and require significant documentation, testing, and possible remediation to meet the detailed standards. We expect to incur significant expenses and to devote resources to Section 404 compliance on an ongoing basis. It is difficult for us to predict how long it will take or costly it will be to complete the assessment of the effectiveness of our internal control over financial reporting for each year and to remediate any deficiencies in our internal control over financial reporting. As a result, we may not be able to complete the assessment and remediation process on a timely basis. In addition, although attestation requirements by our independent registered public accounting firm are not presently applicable to us we could become subject to these requirements in the future and we may encounter problems or delays in completing the implementation of any resulting changes to internal controls over financial reporting. In the event that our Chief Executive Officer or Chief Financial Officer determine that our internal control over financial reporting is not effective as defined under Section 404, we cannot predict how regulators will react or how the market prices of our shares will be affected; however, we believe that there is a risk that investor confidence and share value may be negatively affected.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage23"><!--EFPlaceholder--></a>Our common stock could be further diluted as the result of the issuance of additional shares of common stock, convertible securities, warrants or options.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In the past, we have issued common stock, convertible securities (such as convertible preferred stock and notes) and warrants in order to raise money. We have also issued options and warrants as compensation for services and incentive compensation for our employees and directors. We have shares of common stock reserved for issuance upon the exercise of certain of these securities and may increase the shares reserved for these purposes in the future. Our issuance of additional common stock, convertible securities, options and warrants could affect the rights of our stockholders, could reduce the market price of our common stock or could result in adjustments to exercise prices of outstanding warrants (resulting in these securities becoming exercisable for, as the case may be, a greater number of shares of our common stock), or could obligate us to issue additional shares of common stock to certain of our stockholders. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">If the offering price of the securities in this offering is below $7.50 per unit, it will result in a reduction to the exercise price of warrants to purchase 7,772 shares of common stock pursuant to the terms of the warrants, giving effect to an estimated 1-for-10 Offering Reverse Split.</font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Shares eligible for future sale may adversely affect the market.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">From time to time, certain of our stockholders may be eligible to sell all or some of their shares of common stock by means of ordinary brokerage transactions in the open market pursuant to Rule 144 promulgated under the Securities Act, subject to certain limitations. In general, pursuant to amended Rule 144, non-affiliate stockholders may sell freely after six months subject only to the current public information requirement. Affiliates may sell after six months subject to the Rule 144 volume, manner of sale (for equity securities), current public information and notice requirements. Giving effect to an estimated 1-for-10 Offering Reverse Split, of the approximately 2.7 million shares of our common stock outstanding as of November 4, 2011, approximately 130,000 shares are freely tradable without restriction as of that date. On October 8, 2011, 2,384,812 shares that had been issued in unregistered transactions, after giving effect to an estimated 1-for-10 Offering Reverse Split, became tradable pursuant to Rule 144. Any substantial sales of our common stock pursuant to Rule 144 may have a material adverse effect on the market price of our common stock.</font> </div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">17</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Provisions of our charter, bylaws, and Delaware law may make an acquisition of us or a change in our management more difficult.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certain provisions of our amended restated certificate of incorporation and bylaws could discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock or warrants, thereby depressing the market price of our common stock. Stockholders who wish to participate in these transactions may not have the opportunity to do so.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Furthermore, these provisions could prevent or frustrate attempts by our stockholders to replace or remove our management. These provisions:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="T1"><!--EFPlaceholder--></a><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#8226;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">provide for the division of our board into three classes as nearly equal in size as possible with staggered three-year terms and further limit the removal of directors and the filling of vacancies;</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="T2"><!--EFPlaceholder--></a><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#8226;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">authorize our board of directors to issue without stockholder approval blank check preferred stock that, if issued, could operate as a &#8220;poison pill&#8221; to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that is not approved by our board of directors;</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="T3"><!--EFPlaceholder--></a><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#8226;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent;</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="T4"><!--EFPlaceholder--></a><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#8226;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at stockholder meetings;</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="T5"><!--EFPlaceholder--></a><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#8226;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">limit who may call stockholder meetings; and</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 25.95pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="T6"><!--EFPlaceholder--></a><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#8226;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">require the approval of the holders of 75% of the outstanding shares of our capital stock entitled to vote in order to amend certain provisions of our restated certificate of incorporation and restated bylaws.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a prescribed period of time.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have not paid dividends in the past and do not expect to pay dividends for the foreseeable future. Any return on investment may be limited to the value of our common stock.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No cash dividends have been paid on Novelos common stock. We do not expect to pay cash dividends in the near future. Payment of dividends would depend upon our profitability at the time, cash available for those dividends, and other factors as our board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on an investor&#8217;s investment will only occur if our stock price appreciates.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Risks Related to this Offering</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our management team will have immediate and broad discretion over the use of the net proceeds from this offering and we may use the net proceeds in ways with which you disagree.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There is no minimum offering amount required as a condition to closing this offering and therefore net proceeds from this offering will be immediately available to our management to use at their discretion. We currently intend to use the net proceeds from this offering to fund our research and development activities, for general corporate purposes, and possibly for acquisitions of other companies, products or technologies, though no such acquisitions are currently contemplated. See &#8220;Use of Proceeds.&#8221; We have not allocated specific amounts of the net proceeds from this offering for any of the foregoing purposes. Accordingly, our management will have significant discretion and flexibility in applying the net proceeds of this offering. You will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return for us or our stockholders. The failure of our management to use such funds effectively could have a material adverse effect on our business, prospects, financial condition, and results of operation.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">You will experience immediate and substantial dilution as a result of this offering and may experience additional dilution</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">in the future.</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">You will incur immediate and substantial dilution as a result of this offering. After giving effect to the sale by us of up to&#160;$15,000,000&#160;in units offered in this offering at an assumed public offering price of $6.00&#160;per unit, and after deducting the underwriter&#8217;s discounts and commissions and estimated offering expenses payable by us, investors in this offering can expect an immediate dilution of $2.54&#160;per share, or 42%, at the assumed public offering price. In addition, in the past, we issued options and warrants to acquire shares of common stock. To the extent these options are ultimately exercised, you will sustain future dilution. We may also acquire or license other technologies or finance strategic alliances by issuing equity, which may result in additional dilution to our stockholders.</font> </div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="FIS_FORWARD_LOOK"><!--EFPlaceholder--></a>FORWARD-LOOKING STATEMENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This prospectus, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Exchange Act. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In some cases, you can identify forward-looking statements by terminology, such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;may,&#8221; &#8220;should&#8221;, &#8220;could&#8221; or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this prospectus.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">You should read this prospectus and the documents that we reference herein and therein and have filed as exhibits to the registration statement, of which this prospectus is part, completely and with the understanding that our actual future results may be materially different from what we expect. You should assume that the information appearing in this prospectus is accurate as of the date on the front cover of this prospectus or such prospectus supplement only. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of the information presented in this prospectus and any accompanying prospectus supplement, and particularly our forward-looking statements, by these cautionary statements.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">USE OF PROCEEDS<a name="V227496_S1_HTM_USEOFPROCEEDS_075211"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Based on an assumed public offering price of $6.00 per unit, we estimate that the net proceeds to us from the sale of the&#160;securities that we are offering, assuming gross proceeds of $15.0 million, will be approximately $13.7 million, after deducting underwriting discounts and commissions and estimated offering expenses, <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">however if the underwriter&#8217;s over-allotment is exercised in full, we estimate that the net proceeds would be approximately $15.8 million.</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We expect to use any proceeds received from this offering as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">to fund our research and development activities, including the further development of our LIGHT, HOT and COLD compounds in a wide range of cancers; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">for general corporate purposes, such as general and administrative expenses, capital expenditures, working capital, prosecution and maintenance of our intellectual property, and the potential investment in technologies or products that complement our business.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We believe that our cash on hand, together with the net proceeds from this offering (assuming $15 million of units are sold in this offering, no exercise of the underwriters over-allotment option and no exercise of the warrants being issued pursuant to the offering) would be adequate to fund operations through the end of 2012. We estimate that our&#160;costs through the end of 2012 will be&#160;approximately $14 million. This amount consists of approximately $2.3 million for HOT development, approximately $1.1 million for LIGHT development, approximately $3.2 million for COLD development, approximately $3.8&#160;million for general, fixed and overhead research and development expenses that are not allocated to specific projects, and approximately $3.6 million in general and administrative costs.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The above estimates contemplate the conduct of the following clinical trials: the initiation of HOT Phase 1b dose-escalation trial in the fourth quarter of 2011, the initiation of two HOT Phase 2a proof-of-concept trials in second half of 2012, the initiation of investigator sponsored LIGHT Phase 1/2 imaging trials in multiple solid tumors (such as brain metastasis, lung and breast cancers) starting in the fourth quarter of 2011, and the initiation of COLD Phase 1 trial in late 2012. We anticipate that the planned trials will generate initial proof-of-concept data for LIGHT in the first quarter of 2012 and initial proof-of concept data for HOT in late 2012. The HOT Phase 1b dose-escalation trial may not be completed until late-2013.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have no current understandings, commitments or agreements with respect to any acquisition of or investment in any technologies or products.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pending the application of the net proceeds as described above or otherwise, we may invest the proceeds in short-term, investment-grade, interest-bearing securities or guaranteed obligations of the U.S. government or other securities.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">19</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="FIS_CAPITALIZATION"><!--EFPlaceholder--></a>CAPITALIZATION<a name="V227496_S1_HTM_CAPITALIZATION_075213"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The following table sets forth our cash and cash equivalents and capitalization, each as of September 30, 2011:</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">on an actual basis<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">,&#160;giving effect to an estimated 1-for-10 Offering Reverse Split</font>; and</font></font> </div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">on a pro forma as adjusted basis to give effect to the issuance of the&#160;securities offered hereby.</font></font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">You should consider this table in conjunction with our financial statements and the notes to those financial statements and the pro forma financial information included elsewhere in this prospectus.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="85%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="71%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="5" valign="bottom" width="27%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">As&#160;of&#160;September 30,&#160;2011</font> </div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> &#160; </td>
</tr><tr>
<td align="left" valign="bottom" width="71%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Actual</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> &#160; </td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pro&#160;Forma&#160;As</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjusted&#160;(1)</font> </div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> &#160; </td>
</tr><tr>
<td align="left" valign="bottom" width="71%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> &#160; </td>
<td align="left" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> &#160; </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="71%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash and cash equivalents</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,590,755</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> $ </td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 15,290,755 </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="71%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="71%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Wisconsin Department of Commerce Loan</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">450,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%"> &#160; </td>
<td align="left" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">450,000</font> </div>
</div>
</td>
<td align="left" valign="bottom" width="1%"> &#160; </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="71%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Capital lease obligations</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,862</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> &#160; </td>
<td align="left" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,862</font></font> </div>
</div>
</div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> &#160; </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="71%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total debt obligations</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">456,862</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%"> &#160; </td>
<td align="left" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">456,862</font></font> </div>
</div>
</div>
</td>
<td align="left" valign="bottom" width="1%"> &#160; </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="71%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="71%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stockholders&#8217; equity (deficit):</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="71%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common stock, par value $0.00001 per share: 150,000,000 shares authorized; 2,682,615 issued as of September 30, 2011</font> </div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"> &#160; </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"> 52 </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"> &#160; </td>
</tr><tr bgcolor="white">
<td valign="bottom" width="71%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Additional paid in capital</font> </div>
</td>
<td align="right" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,411,578</font> </div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"> &#160; </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"> 49,111,553 </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"> &#160; </td>
</tr><tr bgcolor="white">
<td valign="bottom" width="71%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deficit accumulated during the development stage</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(29,514,506</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">)</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> &#160; </td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"> (29,514,506 </div>
</td>
<td valign="middle" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> ) </td>
</tr><tr bgcolor="white">
<td valign="bottom" width="71%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total stockholders&#8217; equity</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,897,099</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"> &#160; </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"> 19,597,099 </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"> &#160; </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="71%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="71%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total capitalization</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,353,961</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,053,961</font> </div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> &#160; </td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>&#160;</div>

<div>
<hr style="COLOR: black" align="center" noshade size="1" width="15%">
</div>

<div>&#160;</div>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(1)</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Assumes that $15,000,000 of&#160;units&#160;are&#160;sold in this offering at an assumed offering price of $6.00 per&#160;unit and that the net proceeds thereof are approximately $13,700,000 after deducting underwriting discounts and commissions and our estimated offering expenses.</font></font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><a name="eolPage26"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="FIS_MARKET"><!--EFPlaceholder--></a>MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><br>
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Market Information (Pro forma for Offering Reverse Split)</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our common stock has been quoted on the OTC Bulletin Board under the symbol &#8220;NVLT&#8221; since June 14, 2005. The following table provides, for the periods indicated, the range of high and low bid prices for our common stock. These over-the-counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission, and may not represent actual transactions.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fiscal Year 2009</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">High</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Low</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">First Quarter</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">917.40</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">458.70</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Second Quarter</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,437.30</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">504.50</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Third Quarter</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,498.40</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">871.50</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fourth Quarter</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,434.20</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">993.80</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fiscal Year 2010</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">High</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Low</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">First Quarter</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,663.60</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">261.60</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Second Quarter</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">426.60</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">146.70</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Third Quarter</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">230.80</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">61.70</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fourth Quarter</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">91.70</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">28.20</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fiscal Year 2011</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">High</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Low</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">First Quarter</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">81.00</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15.20</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Second Quarter</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38.20</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9.50</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Third Quarter </font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15.50</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11.30</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fourth Quarter (through November 4, 2011)</font> </font></div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13.90</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.32</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The above share prices have been adjusted to&#160;give effect to&#160;the April Reverse Split,&#160;and an estimated 1-for-10 Offering Reverse Split anticipated to be effected <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">in connection with the effectiveness of the registration statement of which this prospectus is a part.</font></font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On November 4, 2011 there were 293 holders of record of our common stock. This number does not include stockholders for whom shares were held in a &#8220;nominee&#8221; or &#8220;street&#8221; name.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have not declared or paid any cash dividends on our common stock and do not anticipate declaring or paying any cash dividends in the foreseeable future. We currently expect to retain future earnings, if any, for the development of our business.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our transfer agent and registrar is American Stock Transfer and Trust Company, 59 Maiden Lane, New York, NY 10038.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Equity compensation plans</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The following table provides information as of December 31, 2010, giving effect to the April Reverse Split, regarding shares authorized for issuance under our equity compensation plans, including individual compensation arrangements. <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The information in the following table also gives effect to an estimated 1-for-10 Offering Reverse Split.</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have two equity compensation plans approved by our stockholders: the 2000 Stock Option and Incentive Plan and the 2006 Stock Incentive Plan. During 2004 and 2005, we also issued options to our directors and consultants that were not approved by our stockholders. These options are exercisable within a ten-year period from the date of the grant and vest at various intervals with all options being fully vested within three years of the date of grant. The option price per share is not less than the fair market value of our common stock on the date of grant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Equity compensation plan information (Pro forma for Offering Reverse Split)</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Plan&#160;category</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number&#160;of&#160;shares&#160;to</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">be&#160;issued&#160;upon</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">exercise&#160;of&#160;outstanding</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">options,&#160;warrants&#160;and</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">rights&#160;(#)</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted-average</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">exercise&#160;price&#160;of</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">outstanding&#160;options,</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">warrants&#160;and&#160;rights</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">($)</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number&#160;of&#160;shares</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">remaining&#160;available&#160;for</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">future&#160;issuance&#160;under</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">equity&#160;compensation&#160;plans</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(excluding&#160;shares&#160;reflected</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">in&#160;column&#160;(a))&#160;(#)</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(a)</font> </div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(b)</font> </div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(c)</font> </div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Equity compensation plans approved by stockholders</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,865</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,009.80</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,555</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Equity compensation plans not approved by stockholders</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,056</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,009.80</font></font> </div>
</div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,921</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,009.80</font></font> </div>
</div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,555</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">21</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="FIS_DILUTION"><!--EFPlaceholder--></a>DILUTION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Our pro forma net tangible book value as of September 30, 2011 was $4,221,637 or $1.57 per share of common stock, based upon 2,682,615 shares outstanding as of that date, giving effect to an estimated 1-for-10 Offering Reverse Split. Net&#160;tangible book value per share is determined by dividing such number of outstanding shares of common stock into our net tangible book value, which is our total tangible assets less total liabilities. After giving effect to the sale of the&#160;securities in this offering at the assumed public offering price of $6.00 per unit, excluding exercise of the underwriter's over-allotment, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us, our pro forma as adjusted net tangible book value at September 30, 2011 would have been approximately $17.9 million, or $3.46 per share. This represents an immediate increase in net tangible book value of approximately $1.89 per share to our existing stockholders, and an immediate dilution of $2.54 per share to investors purchasing securities in the offering.<a name="fis_unidentified_table_10"><!--efplaceholder--></a></font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The following table illustrates the per share dilution to investors purchasing securities in the offering:</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Assumed public offering price per unit</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> &#160; </td>
<td align="right" valign="bottom" width="9%"> &#160; </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> 6.00 </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pro forma net tangible book value per share as of September 30, 2011</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> $ </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> 1.57 </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Increase per share attributable to sale of securities to investors</font> </div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> $ </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> 1.89 </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pro forma as adjusted net tangible book value per share after the offering</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"> &#160; </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.46</font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dilution per share to investors</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> &#160; </td>
<td align="right" valign="bottom" width="9%"> &#160; </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.54</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> The foregoing illustration does not reflect potential dilution from the exercise of outstanding options or warrants to purchase shares of our common stock. The foregoing illustration also does not reflect the dilution that would result from the exercise of the warrants sold in the offering .</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="FIS_MANAGEMENTS_DISCUSSION"><!--EFPlaceholder--></a>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OPERATIONS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">The following discussion and analysis should be read together with our financial statements and the related notes appearing elsewhere in this prospectus. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. See &#8220;Forward-Looking Statements&#8221; for a discussion of the uncertainties, risks and assumptions associated with these statements. Actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under &#8220;Risk Factors&#8221; and elsewhere in this prospectus.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-STYLE: italic"> The references throughout this discussion to share and per share numbers do not give effect to an estimated Offering Reverse Split. </font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Acquisition</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On April 8, 2011, we entered into a business combination with Cellectar (the &#8220;Acquisition&#8221;). Immediately prior to the Acquisition, we completed a 1-for-153 reverse split of our common stock (the &#8220;April Reverse Split&#8221;). We then issued 17,001,596 shares of our common stock to the former shareholders of Cellectar as consideration for the Acquisition, constituting approximately 85% of our outstanding common stock after giving effect to the Acquisition. Upon the closing of the Acquisition, we completed the private placement of 6,846,537 shares of our common stock and warrants to purchase an additional 6,846,537 shares of our common stock (in each case after giving effect to the April Reverse Split but not an estimated Offering Reverse Split). As a result of the Acquisition, we are implementing a revised business plan focused on the development of the Cellectar compounds. We conduct our operations from Cellectar&#8217;s headquarters in Madison, WI and our executive offices are in Newton, MA. Further development of our other compounds (NOV-002 and NOV-205) has been suspended. The following discussion for activity prior to April 8, 2011 corresponds to the results of operations of Cellectar prior to Acquisition.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 8, 2011, immediately prior to the Acquisition, Cellectar paid approximately $627,000 in full settlement of a note payable to a bank. The payment was made in order to avoid an event of default that would have occurred as a result of the change of control that occurred at the time of the Acquisition. On April 8, 2011, the holders of Cellectar convertible notes converted outstanding principal of $2,720,985 and unpaid interest thereon into a total of 4,181,535 shares of common stock.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Overview</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. We currently have three cancer-targeted compounds, which we believe are selectively taken up and retained in cancer cells (including cancer stem cells) versus normal cells. Thus, we believe our therapeutic compounds directly kill cancer cells while minimizing harm to normal cells offering the potential for a paradigm shift in cancer therapy &#8211; efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. LIGHT is a small-molecule cancer imaging agent. We believe LIGHT has first-in-class potential and we expect it to enter Phase 1/2 clinical trials in the fourth quarter of this year. HOT is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. We believe HOT also has first-in-class potential, and we expect it to enter a Phase 1b dose escalation trial in the fourth quarter of this year and Phase 2 trials in 2012 as a monotherapy for solid tumors with significant unmet medical need. COLD, a cancer-targeted chemotherapy that we expect to submit an Investigational New Drug (&#8220;IND&#8221;) application to the FDA late in 2012, works primarily through Akt inhibition. Together, we believe our compounds are able to &#8220;find, treat and follow&#8221; cancer anywhere in the body in a novel, effective and highly selective way.</font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">22</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prior to the Acquisition, for more than ten years, Novelos had been developing oxidized glutathione-based compounds for the treatment of cancer, including NOV-002, an injectable small-molecule compound based on a proprietary formulation of oxidized glutathione that we had been developing for use in combination with standard of care chemotherapies for the treatment of solid tumors. From 2005 through 2010 Novelos raised approximately $67 million in capital for the development of our compounds. From November 2006 through January 2010, Novelos conducted a Phase 3 trial of NOV-002 plus first-line chemotherapy in advanced non-small cell lung cancer which, when completed in February 2010, did not meet its primary and secondary efficacy endpoints. Following the completion of the Phase 3 trial during 2010, Novelos continued clinical development of NOV-002 in breast cancer and NOV-205 in hepatitis C, although further development of those compounds has now been suspended. We also explored strategic alternatives which resulted in the completion of the Acquisition in April 2011.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Results of Operations</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Executive summary</font>. In March 2010, Cellectar completed a Phase 1a dosimetry trial of HOT in humans (the &#8220;Phase 1a Trial&#8221;), demonstrating initial safety and establishing dosing parameters for a Phase 1b dose-escalation trial. Following the completion of the Phase 1a Trial and as a result of limited funding, Cellectar suspended research and manufacturing activities, terminated certain non-key personnel and implemented salary reductions in an effort to contain costs while Cellectar concentrated on its fund raising efforts. The decreases in research and development costs for the nine months ended September 30, 2011 compared to the nine months ended September 30, 2010 and the decrease in operating costs in the year ended December 31, 2010 compared to the year ended December 31, 2009 are primarily attributable to the cost reduction efforts implemented in 2010. The decreases in general and administrative expense for the nine-month period ended September 30, 2011 were offset by increases in professional fees associated with Cellectar becoming a public company. Following the Acquisition, we are resuming development activities in preparation for planned clinical trials in HOT and LIGHT scheduled to begin in the fourth quarter of 2011.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Research and</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">development expense.</font> Research and development expense consists of costs incurred in identifying, developing and testing and manufacturing product candidates, which primarily include salaries and related expenses for personnel, costs of our research and manufacturing facility, cost of manufacturing materials, fees paid to professional service providers for independent monitoring and analysis of our clinical trials, and costs to secure intellectual property. The Company analyzes its research and development expenses based on four categories as follows: clinical projects, preclinical projects, chemistry and manufacturing costs, and general fixed and overhead costs that are not allocated to the functional project costs, including personnel costs, manufacturing facility costs, related overhead costs and patent costs.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">General and administrative expense.</font> General and administrative expense consists primarily of salaries and other related costs for personnel in executive, finance and administrative functions. Other costs include insurance, costs for public and investor relations, directors&#8217; fees and professional fees for legal and accounting services.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Nine Months Ended September 30, 2011 and 2010</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Research and Development.</font> &#160;&#160;Research and development expense for the nine months ended September 30, 2011 was approximately $2,445,000 (comprised of approximately $37,000 in clinical project costs, $141,000 of preclinical project costs, $95,000 of manufacturing and related costs and $2,172,000 in general unallocated research and development costs) compared to approximately $2,617,000 (comprised of $200,000 in clinical project costs, $453,000 of preclinical project costs, $88,000 of manufacturing and related costs and $1,876,000 in general unallocated research and development costs) for the same period in 2010.&#160;&#160;The approximately $172,000, or 7%, decrease in research and development occurred in several categories.&#160;&#160;The $163,000 decrease in clinical projects in the nine months ended September 30, 2011 versus the comparable period in 2010 was related to the completion of the Phase 1a trial in March 2010.&#160;&#160;The $312,000 decrease in preclinical projects, for the nine months ended September 30, 2011 versus the same period in 2010 was primarily related to a $267,000 decrease in subcontracted preclinical research as those activities had increased in the first half of 2010 in preparation for future clinical trials.&#160;&#160;These decreases were partially offset by an increase of approximately $296,000 in general unallocated research and development costs primarily due to a $116,000 increase in stock-based compensation as a result of stock options granted in May 2011 following the Acquisition, as well as increases in consulting, maintenance and permitting costs as we prepared to resume manufacturing and research activities following the Acquisition.</font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="eolpage30"><!--EFPlaceholder--></a><font style="DISPLAY: inline; FONT-STYLE: italic">General and Administrative.</font> &#160;&#160;General and administrative expense for the nine months ended September 30, 2011 was approximately $1,828,000 compared to approximately $1,014,000 in the same period of 2010.&#160;&#160;The $814,000 or 80% increase in general and administrative costs were primarily related to the following items: Salary and related increased approximately $293,000 resulting from the from the addition of employees in connection with the Acquisition and the removal of salary reductions that had been in place in order to conserve cash; stock-based compensation increased by $209,000 associated with stock option grants made in May 2011; the cost of subcontracted services increased by approximately $196,000 as a result of increased investor relations activities, directors&#8217; fees and costs associated with public company reporting.&#160;&#160;Insurance costs increased approximately $39,000, rent increased approximately $34,000 associated with the addition of the Massachusetts location following the Acquisition and travel costs increased approximately $23,000 due to an increase in travel between our Massachusetts and Wisconsin offices.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"> <br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23</font> </div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Merger Costs. </font>Merger costs during the nine months ended September 30, 2011 consisted of $450,000 in investment banking fees, approximately $286,000 in legal fees and approximately $10,000 in insurance costs.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Grant income.&#160;&#160;</font> Qualifying therapeutic discovery projects, among others, include those designed to treat or prevent diseases or conditions by conducting pre-clinical or clinical activities for the purpose of securing FDA approval of a product.&#160;&#160;We received payments of approximately $44,000 in the first nine months of 2011 under a cash grant from the U.S. Internal Revenue Service as a qualifying therapeutic discovery project credit pursuant to Patient Protection and Affordable Care Act. The payments have been recorded as a component of other income.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Loss on</font> <font style="DISPLAY: inline; FONT-STYLE: italic">Derivative Warrants.</font>&#160;&#160;We recorded a loss on derivative warrants of approximately $67,000 in the nine months ended September 30, 2011. This amount represents the change in fair value, during the respective period, of outstanding warrants which contain &#8220;down-round&#8221; anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise prices of the warrants.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Interest expense, net</font>.&#160;&#160;Interest expense, net for the nine months ended September 30, 2011 and 2010 consists approximately of the following:</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNIDENTIFIED_TABLE_12"><!--EFPlaceholder--></a><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="72%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="6" valign="bottom" width="26%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended September 30,</font> </div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="bottom" width="72%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="bottom" width="72%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest expense, convertible notes</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(159,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(223,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Beneficial conversion feature, convertible notes</font> </div>
</td>
<td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(258,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(214,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest expense, bank note</font> </div>
</td>
<td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(43,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest expense, other</font> </div>
</td>
<td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(9,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="72%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest income</font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,000</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,000</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td valign="bottom" width="72%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(428,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(468,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Since the convertible notes were converted based on revised conversion terms that resulted in the issuance of an additional 343,963 shares of common stock than would have been issued if the convertible notes had been converted in accordance with their original terms, the value of these additional shares of approximately $258,000 was recorded as a component of interest expense in the second quarter of 2011.&#160;&#160;Since the convertible notes were convertible into common stock at the date of issuance at a price per share which is less than the estimated fair value of our common stock at that date, the estimated intrinsic value of the beneficial conversion feature of approximately $214,000 was recorded as a component of interest expense on the date of issuance in the first three months of 2010. The decrease in interest expense on the convertible notes and bank note was a result of the settlement of those obligations in connection with the Acquisition.&#160;&#160;The increase in other interest expense is principally a result of the issuance of notes payable to the Wisconsin Department of Commerce in September 2010. The reduction of interest income was a result of a decrease in average cash balances and interest rates.</font> </div></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Years Ended December 31, 2010 and 2009</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="eolpage30"><!--EFPlaceholder--></a><font style="DISPLAY: inline; FONT-STYLE: italic">Research and Development.</font> Research and development expense for the year ended December 31, 2010 was approximately $2,984,000, (comprised of $200,000 in clinical project costs, $458,000 of preclinical project costs, $76,000 of chemistry and manufacturing and related costs and $2,250,000 in general unallocated research and development costs) compared to approximately $4,352,000 (comprised of $468,000 in clinical project costs, $267,000 of preclinical project costs, $437,000 of chemistry and manufacturing and related costs and $3,180,000 in general unallocated research and development costs) for the year ended December 31, 2009. The approximately $1,368,000, or 31%, decrease in research and development expense occurred in several categories. The approximately $268,000 decrease in clinical project costs is primarily related to an approximately&#160;$237,000 decrease in clinical trial costs associated with the Phase 1a Trial in 2010 compared to 2009 as a result of the completion of the trial in March 2010. Preclinical project costs increased by approximately $191,000 related to an approximately&#160;$340,000 increase in subcontracted preclinical research activities in preparation for future clinical trials offset by an approximately&#160;$150,000 decrease in lab supplies as a result of the cost reduction efforts described above. General unallocated research and development costs decreased by approximately $930,000 primarily related to an approximately&#160;$715,000 decrease in salary and overhead costs and an approximately&#160;$117,000 decrease in patent costs in 2010 compared to 2009 as a result of the cost reduction efforts described above. Chemistry and manufacturing costs decreased by approximately $361,000 due to the completion of the Phase 1a trial in early 2010 and as a result of the cost reduction efforts described above.<a name="fis_unidentified_table_12"><!--efplaceholder--></a><a name="fis_liquidity"><!--efplaceholder--></a><a name="eolpage31"><!--efplaceholder--></a><a name="v227496_s1_htm_v189973_s1a_htm_eolpage25"><!--efplaceholder--></a><a name="eolpage32"><!--efplaceholder--></a><a name="fis_business"><!--efplaceholder--></a><a name="eolpage34"><!--efplaceholder--></a><a name="eolpage35"><!--efplaceholder--></a><a name="eolpage37"><!--efplaceholder--></a><a name="eolpage38"><!--efplaceholder--></a><a name="fis_competition"><!--efplaceholder--></a><a name="eolpage39"><!--efplaceholder--></a><a name="eolpage40"><!--efplaceholder--></a><a name="fis_employees"><!--efplaceholder--></a><a name="eolpage41"><!--efplaceholder--></a><a name="eolpage42"><!--efplaceholder--></a><a name="eolpage43"><!--efplaceholder--></a><a name="fis_properties"><!--efplaceholder--></a><a name="fis_management"><!--efplaceholder--></a><a name="fis_name_and_title"><!--efplaceholder--></a><a name="eolpage45"><!--efplaceholder--></a><a name="eolpage46"><!--efplaceholder--></a><a name="eolpage47"><!--efplaceholder--></a><a name="eolpage48"><!--efplaceholder--></a><a name="v227496_s1_htm_v189973_s1a_htm_eolpage36"><!--efplaceholder--></a><a name="fis_executive_compensation"><!--efplaceholder--></a><a name="fis_compensation_table"><!--efplaceholder--></a><a name="eolpage49"><!--efplaceholder--></a><a name="fis_unidentified_table_13"><!--efplaceholder--></a><a name="eolpage50"><!--efplaceholder--></a><a name="fis_name_and_title_2"><!--efplaceholder--></a><a name="eolpage51"><!--efplaceholder--></a><a name="fis_director_compensation"><!--efplaceholder--></a><a name="fis_stockholders"><!--efplaceholder--></a><a name="fis_beneficial_owners"><!--efplaceholder--></a><a name="fis_certain_transactions"><!--efplaceholder--></a><a name="eolpage53"><!--efplaceholder--></a><a name="v227496_s1_htm_v189973_s1a_htm_v183722_s"><!--efplaceholder--></a><a name="fis_distribution_plan"><!--efplaceholder--></a><a name="fis_underwriting"><!--efplaceholder--></a><a name="fis_unidentified_table_14"><!--efplaceholder--></a><a name="eolpage54"><!--efplaceholder--></a><a name="eolpage55"><!--efplaceholder--></a><a name="eolpage56"><!--efplaceholder--></a><a name="eolpage57"><!--efplaceholder--></a><a name="fis_securities_description"><!--efplaceholder--></a><a name="v227496_s1_htm_eolpage55"><!--efplaceholder--></a><a name="eolpage58"><!--efplaceholder--></a><a name="v227496_s1_htm_v189973_s1a_htm_eolpage47"><!--efplaceholder--></a><a name="eolpage59"><!--efplaceholder--></a><a name="fis_more_information"><!--efplaceholder--></a><a name="fis_legal_matters"><!--efplaceholder--></a><a name="fis_experts"><!--efplaceholder--></a><a name="eolpage60"><!--efplaceholder--></a><a name="fis_financial_statements"><!--efplaceholder--></a><a name="eolpage61"><!--efplaceholder--></a><a name="fis_unidentified_table_11"><!--efplaceholder--></a><a name="fis_unidentified_table_15"><!--efplaceholder--></a><a name="eolpage99"><!--efplaceholder--></a><a name="eolpage173"><!--efplaceholder--></a><a name="v189973_ex23_2_htm"><!--efplaceholder--></a><a name="fis_exhibit_23"><!--efplaceholder--></a><a name="fis_notes_to_financial_statement"><!--efplaceholder--></a><a name="eolpage67"><!--efplaceholder--></a><a name="fis_unidentified_table_16"><!--efplaceholder--></a><a name="fis_unidentified_table_17"><!--efplaceholder--></a><a name="eolpage68"><!--efplaceholder--></a><a name="eolpage69"><!--efplaceholder--></a><a name="fis_unidentified_table_18"><!--efplaceholder--></a><a name="sl4676344-128484"><!--efplaceholder--></a><a name="sl4676335-128484"><!--efplaceholder--></a><a name="sl4676339-128484"><!--efplaceholder--></a><a name="eolpage71"><!--efplaceholder--></a><a name="fis_unidentified_table_19"><!--efplaceholder--></a><a name="fis_unidentified_table_20"><!--efplaceholder--></a><a name="fis_unidentified_table_21"><!--efplaceholder--></a><a name="eolpage73"><!--efplaceholder--></a><a name="fis_unidentified_table_22"><!--efplaceholder--></a><a name="fis_unidentified_table_23"><!--efplaceholder--></a><a name="fis_options"><!--efplaceholder--></a><a name="eolpage76"><!--efplaceholder--></a><a name="fis_unidentified_table_24"><!--efplaceholder--></a><a name="eolpage78"><!--efplaceholder--></a><a name="fis_unidentified_table_27"><!--efplaceholder--></a><a name="eolpage79"><!--efplaceholder--></a><a name="fis_auditors_opinion"><!--efplaceholder--></a><a name="eolpage85"><!--efplaceholder--></a><a name="fis_unidentified_table_30"><!--efplaceholder--></a><a name="fis_unidentified_table_31"><!--efplaceholder--></a><a name="eolpage86"><!--efplaceholder--></a><a name="fis_unidentified_table_32"><!--efplaceholder--></a><a name="eolpage87"><!--efplaceholder--></a><a name="fis_unidentified_table_33"><!--efplaceholder--></a><a name="eolpage88"><!--efplaceholder--></a><a name="eolpage89"><!--efplaceholder--></a><a name="fis_unidentified_table_35"><!--efplaceholder--></a><a name="fis_unidentified_table_36"><!--efplaceholder--></a><a name="eolpage91"><!--efplaceholder--></a><a name="fis_unidentified_table_37"><!--efplaceholder--></a><a name="fis_unidentified_table_38"><!--efplaceholder--></a><a name="eolpage94"><!--efplaceholder--></a><a name="fis_part_ii"><!--efplaceholder--></a><a name="fis_offering_expense"><!--efplaceholder--></a><a name="fis_unidentified_table_25"><!--efplaceholder--></a><a name="fis_unidentified_table_39"><!--efplaceholder--></a><a name="fis_indemnification"><!--efplaceholder--></a><a name="fis_indemnification_2"><!--efplaceholder--></a><a name="eolpage95"><!--efplaceholder--></a><a name="fis_sale_of_unregistered_securities"><!--efplaceholder--></a><a name="eolpage96"><!--efplaceholder--></a><a name="eolpage97"><!--efplaceholder--></a><a name="eolpage98"><!--efplaceholder--></a><a name="fis_exhibits"><!--efplaceholder--></a><a name="fis_unidentified_table_40"><!--efplaceholder--></a><a name="fis_unidentified_table_41"><!--efplaceholder--></a><a name="fis_unidentified_table_42"><!--efplaceholder--></a><a name="fis_undertakings"><!--efplaceholder--></a><a name="eolpage102"><!--efplaceholder--></a><a name="fis_signatures"><!--efplaceholder--></a><a name="fis_power_of_attorney"><!--efplaceholder--></a><a name="v227496_s1_htm_eolpage99"><!--efplaceholder--></a><a name="eolpage103"><!--efplaceholder--></a><a name="fis_exhibit_index"><!--efplaceholder--></a><a name="fis_unidentified_table_26"><!--efplaceholder--></a><a name="fis_unidentified_table_43"><!--efplaceholder--></a><a name="eolpage104"><!--efplaceholder--></a><a name="fis_unidentified_table_44"><!--efplaceholder--></a><a name="eolpage105"><!--efplaceholder--></a><a name="fis_unidentified_table_45"><!--efplaceholder--></a><a name="eolpage106"><!--efplaceholder--></a><a name="v227496_ex3_3_htm"><!--efplaceholder--></a><a name="fis_exhibit_3"><!--efplaceholder--></a><a name="fis_experts_consent"><!--efplaceholder--></a></font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">General and Administrative.&#160; </font>&#160;General and administrative expense for the year ended December 31, 2010 was approximately $1,157,000 compared to approximately $1,824,000 in the year ended December 31, 2009.&#160; The approximately $667,000, or 37%, decrease is primarily due to a decrease of approximately $688,000 in salary and overhead costs and a decrease in consulting of approximately $83,000 as a result of cost reduction efforts.&#160; This decrease was offset by an increase in legal and other professional fees of approximately $277,000 associated with fund raising efforts and the Acquisition.</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Merger Costs</font>.&#160;&#160;Merger costs during the twelve months ended December 31, 2010 consisted of approximately $53,000 in legal fees.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Grant income.&#160; </font>Qualifying therapeutic discovery projects, among others, include those designed to treat or prevent diseases or conditions by conducting pre-clinical or clinical activities for the purpose of securing FDA approval of a product.&#160; We received a cash grant during 2010 of approximately $200,000 from the U.S. Internal Revenue Service as a qualifying therapeutic discovery project credit pursuant to Patient Protection and Affordable Care Act. This grant has been recorded as a component of other income.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Interest expense, net</font>.&#160; Interest expense, net for the years ended December 31, 2010 and 2009 consists approximately of the following:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNIDENTIFIED_TABLE_12"><!--EFPlaceholder--></a><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Year ended December 31,</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2009</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest expense, convertible notes</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(305,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Beneficial conversion feature, convertible notes</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(214,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest expense, bank note</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(55,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(68,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest expense, other</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(7,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest income</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">15,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">24,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(566,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(44,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since the convertible notes were convertible into common stock at the date of issuance at a price per share which is less than the estimated fair value of our common stock at that date, the estimated intrinsic value of the beneficial conversion feature of approximately $214,000 was recorded as a component of interest expense on the date of issuance. In addition, we recorded approximately $305,000 in interest expense on the convertible notes based on the stated interest rate. The increase in other interest expense is principally a result of the issuance of notes payable to the Wisconsin Department of Commerce in September 2010. The approximately $9,000, or 37% decrease in interest income is attributable to the lower average cash and cash equivalents balance during the year end December 31, 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liquidity and Capital Resources</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We have financed our operations since inception primarily through the sale of equity securities and securities convertible into equity securities. To date, Cellectar and Novelos have raised capital aggregating approximately $105 million.&#160;&#160;Novelos has raised capital aggregating approximately $78 million, including proceeds from the April 2011 private placement.&#160;&#160;Since its inception, Cellectar raised capital aggregating approximately $27 million.&#160;&#160;As of September 30, 2011, we had approximately $1,591,000 in cash and cash equivalents.</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">During the nine months ended September 30, 2011, approximately $4,435,000 in cash was used in operations.&#160;&#160;During this period we reported a net loss of approximately $5,470,000.&#160;&#160;However, this loss included the following non-cash items: an approximately $67,000 loss on derivative warrants, approximately $6,000 loss on the disposal of fixed assets, approximately $656,000 in stock-based compensation, approximately $440,000 in depreciation and amortization expense and approximately $258,000 of interest expense attributed to the estimated intrinsic value of the beneficial conversion feature associated with convertible notes. After adjustment for these non-cash items, we used approximately $331,000 in cash for the payment of accounts payable and accrued liabilities resulting from the payment of vendor liabilities that had accumulated leading up to the Acquisition and private placement.&#160;&#160;The Company utilized approximately $225,000 in cash for the prepayment of certain items, including an annual renewal of its directors and officers&#8217; insurance and general business insurance.&#160;&#160;Other changes in working capital provided cash of $6,000.&#160;&#160;We incurred $159,000 of accrued interest associated with notes payable that were converted to common stock on April 8, 2011.</font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">During the nine months ended September 30, 2011, we purchased approximately $112,000 in fixed assets.&#160;&#160;As described above, on April 8, 2011, we completed the Acquisition.&#160;&#160;In connection with the Acquisition, we acquired cash of approximately $906,000.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">During the nine months ended September 30, 2011, we repaid $676,000 in long-term obligations, including the payment, immediately prior to the Acquisition, of approximately $627,000 in full settlement of a Cellectar note payable to a bank. In connection with that repayment, restrictions were released on $500,000 of cash equivalents.&#160;&#160;On April 8, 2011, the holders of Cellectar convertible notes converted outstanding principal of $2,720,985 and unpaid interest thereon into a total of 4,181,535 shares of common stock.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Upon the closing of the Acquisition, we completed the private placement of our common stock and warrants for net proceeds of $4,866,000.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred issuance costs increased by approximately $131,000 due to costs incurred in advance of a proposed underwritten offering of our securities.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25</font> </div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</div>

<div>&#160;</div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The financial statements included elsewhere in this prospectus have been prepared on a basis that assumes that we will continue as a going concern and that contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business.&#160;&#160;We have incurred losses since inception in devoting substantially all of our efforts toward research and development and have an accumulated deficit of $29,514,506 at September 30, 2011.&#160;&#160;During the nine months ended September 30, 2011, we generated a net loss of $5,469,502 and we expect that we will continue to generate operating losses for the foreseeable future. At September 30, 2011, our cash balance was approximately $1,591,000.&#160;&#160;We believe our cash on hand is adequate to fund operations until the end of 2011.&#160;&#160;Our ability to execute our operating plan beyond that time depends on our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise.&#160;&#160;We estimate that our costs through the end of 2012 will be approximately $14,000,000.&#160;&#160;This amount consists of approximately $2,300,000 for HOT development, approximately $1,100,000 for LIGHT development, approximately $3,200,000 for COLD development, approximately $3,800,000 for general, fixed and overhead research and development expenses that are not allocated to specific projects, and approximately $3,600,000 for general and administrative costs.&#160;&#160;On July 1, 2011, we filed with the SEC a Registration Statement on Form S-1 for an underwritten public offering of our securities with proceeds of up to $15,000,000, excluding the underwriter&#8217;s over-allotment. There can be no assurance that the registration statement will become effective or that any securities will be sold pursuant to it. We plan to actively pursue this and other financing alternatives; however we have not entered into negotiations for any such alternative transaction. There can be no assurance that we will obtain the necessary funding.&#160;&#160;Other than the uncertainties regarding our ability to obtain additional funding, there are currently no known trends, demands, commitments, events or uncertainties that are likely to materially affect our liquidity.</font> </div></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage31"><!--EFPlaceholder--></a>Critical Accounting Policies</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States, or GAAP, requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, as well as the reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates. We review these estimates and assumptions periodically and reflect the effects of revisions in the period that they are determined to be necessary.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="V227496_S1_HTM_V189973_S1A_HTM_EOLPAGE25"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We believe that the following accounting policies reflect our more significant judgments and estimates used in the preparation of our financial statements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Accrued Liabilities.</font> As part of the process of preparing financial statements, we are required to estimate accrued liabilities. This process involves identifying services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for such service as of each balance sheet date in our financial statements. Examples of estimated expenses for which we accrue include: contract service fees such as amounts paid to clinical research organizations and investigators in conjunction with clinical trials; fees paid to vendors in conjunction with the manufacturing of clinical materials; and professional service fees, such as for lawyers and accountants. In connection with such service fees, our estimates are most affected by our understanding of the status and timing of services provided relative to the actual levels of services incurred by such service providers. The majority of our service providers invoice us monthly in arrears for services performed. In the event that we do not identify certain costs that have begun to be incurred, or we over- or underestimate the level of services performed or the costs of such services, our reported expenses for such period would be too high or too low. The date on which certain services commence, the level of services performed on or before a given date and the cost of such services are often determined based on subjective judgments. We make these judgments based on the facts and circumstances known to us in accordance with GAAP.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Stock-based Compensation</font> . We account for stock-based compensation by measuring the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award, <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">using the Black-Scholes option-pricing model</font>. That cost is recognized over the period during which an employee is required to provide service in exchange for the award, the requisite service period (usually the vesting period). We account for transactions in which services are received from non-employees in exchange for equity instruments based on the fair value of such services received or of the equity instruments issued, <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">using the Black-Scholes option-pricing model</font>.&#160;whichever is more reliably measured. <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The measurement of stock-based compensation for non-employees is subject to periodic adjustments as the options vest, and the expense is recognized over the period during which a non-employee is required to provide services for the award (usually the vesting period).</font></font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounting for equity instruments granted or sold by us under accounting guidance requires fair-value estimates of the equity instrument granted or sold. If our estimates of the fair value of these equity instruments are too high or too low, our expenses may be over- or understated. For equity instruments granted or sold in exchange for the receipt of goods or services, we estimate the fair value of the equity instruments based on consideration of factors that we deem to be relevant at that time.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The following table sets forth information regarding all options to purchase common stock granted since the Acquisition. The exercise prices of the following grants are equal to the closing price of our common </font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">stock on the date of grant:</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td nowrap valign="bottom" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Date of Grant</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Number of Options</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Granted</font></font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Price</font></font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Fair value of</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Underlying Stock</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">on Grant Date</font></font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Fair Value of</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Instrument on</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Grant Date</font></font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Compensation</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Expense</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Recognized</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">through September 30,</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr>
<td valign="bottom" width="25%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="25%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 25, 2011</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100,000</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.00</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.00</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.79</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,000</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td valign="bottom" width="25%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 18, 2011</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,581,100</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.40</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.40</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.17</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">177,778</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="25%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 18, 2011</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">670,200</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.40</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.40</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.18</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">72,467</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td valign="bottom" width="25%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 18, 2011</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">750,000</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.40</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.40</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.15</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">158,751</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="25%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 18, 2011</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">405,100</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.40</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.40</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.14</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">47,799</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td valign="bottom" width="25%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 18, 2011</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">150,000</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.40</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.40</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.30</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">119,481</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="25%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 23, 2011</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,000</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.88</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.88</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.57</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,690</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td valign="bottom" width="25%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 25, 2011</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">20,000</font></font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.65</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.65</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.34</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">12,709</font></font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="25%" style="PADDING-BOTTOM: 2px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> October 6, 2011 </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> 70,000 </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> &#160; </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> $ </td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"> 1.05 </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> &#160; </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> $ </td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"> 1.05 </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> &#160; </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> $ </td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"> 0.85 </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> &#160; </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> - </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> &#160; </td>
</tr><tr bgcolor="white">
<td valign="bottom" width="25%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,766,400</font></font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">597,675</font></font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"> &#160;&#160; </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">There were no option grants during 2010 or in 2011 prior to the Acquisition. <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The estimated public offering price is between $5.00 per unit and $7.00 per unit, which gives effect to an estimated 1-for-10 &#160;Offering Reverse Split.&#160;&#160;If the above option issuances are adjusted to give effect to an estimated 1-for-10 Offering Reverse Split, the mid-point of the offering price range, $6.00, is approximately 43% lower than the lowest exercise price of the above option issuances, $10.50, and approximately 29% lower than the lowest grant-date fair value for the above option issuances, $8.50.&#160;&#160;We believe that the drop in market price since the dates of the above option grants is a result of general market conditions which have created downward pressure on our stock price. On October 8, 2011, the shares that were sold in the private placement completed in connection with the Acquisition became saleable under Rule 144. This caused increased selling activity and resulted in additional price volatility.</font></font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Off-Balance Sheet Arrangements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">As of December 31, 2010 and September 30, 2011, we had no off-balance sheet arrangements.</font> </div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">26</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage32"><!--EFPlaceholder--></a><a name="FIS_BUSINESS"><!--EFPlaceholder--></a>BUSINESS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Business of Novelos</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Novelos Therapeutics, Inc. (&#8220;Novelos&#8221; or the &#8220;Company&#8221;) is a pharmaceutical company developing compounds for the treatment of cancer.&#160; On April 8, 2011, Novelos entered into a business combination with Cellectar, Inc. (&#8220;Cellectar&#8221;), a privately held Wisconsin corporation that designed and developed products to detect, treat and monitor a wide variety of human cancers, and Cell Acquisition Corp. (the &#8220;Merger Subsidiary&#8221;), a wholly owned subsidiary of Novelos, pursuant to which Cellectar was merged into the Merger Subsidiary (the &#8220;Acquisition&#8221;).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We are developing novel drugs for the treatment and diagnosis of cancer based on our cancer-targeting technology: COLD, HOT (iodine-131 radiolabeled compound) and LIGHT (labeled with a shorter-lived radioisotope, iodine-124).&#160; We believe our compounds are selectively taken up and retained in a wide variety of cancer cells (including cancer stem cells) versus normal cells.&#160; We believe our therapeutic compounds directly kill cancer cells while minimizing harm to normal cells, offering the potential for a paradigm shift in cancer therapy by providing efficacy against all three major drivers of mortality in cancer: primary tumors, metastases and cancer stem cell-based relapse.&#160; More specifically, we believe our technology enables targeted delivery to cancer cells of apoptosis-inducing Akt inhibition or, when a radioactive molecule is attached, of ionizing radiation sufficient to kill cancer cells.&#160; When radiolabeled with iodine-124 for PET imaging, we believe our agent can provide an accurate and quantitative diagnosis of cancer, including metastases, and can also objectively measure therapeutic success.&#160; Together, we believe this platform is capable of yielding multiple, distinct oncology product opportunities in a broad spectrum of cancers which enable us to &#8220;find, treat and follow&#8221; cancer anywhere in the body in a novel, effective and highly selective way.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Market Overview</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our target market is broad and represents the market for the treatment and diagnosis of cancer. According to Drug Discovery News (April 2009), Datamonitor (July 3, 2006) and PharmaLive (October 8, 2009), the global market for cancer pharmaceuticals reached an estimated $66 billion in 2007, nearly doubling from $35 billion in 2005 and is expected to grow to $80 billion by 2012.&#160; Furthermore, the US National Cancer Institute (January 12, 2011) estimates that the overall cost of treating cancer in the US will increase to $158 billion by 2020 from $125 billion in 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Technology Overview</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our compounds are alkylphospholipids (&#8220;APLs&#8221;) that interact with lipid rafts, which are specialized microdomains within cell membranes. Importantly, the core chemical structure shared across all three products provides selective targeting of cancer cells in preference to normal cells (due to enrichment of lipid rafts in the former).&#160; COLD was deliberately designed to contain iodine (in the form of the stable, non-radioactive isotope, <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">127</font> I), thus enabling additional, distinct products differing only with respect to the form of iodine they contain &#8211; HOT contains short-lived radioactive <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">131</font> I and LIGHT contains the even more short-lived radioactive <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">124</font> I. As a result, three cancer-targeted product profiles have been generated from a single chemical structure that is the foundation of our technology platform &#8211; a chemotherapeutic (COLD), a molecular radiotherapeutic (HOT) and a diagnostic/imaging agent (LIGHT).</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our core technology platform is based upon the research conducted by Cellectar&#8217;s founder and our Chief Scientific Officer, Dr. Jamey Weichert beginning in 1994 at U. Mich. where alkyphospholipid analogs were initially designed, synthesized, radiolabeled, and evaluated. Since 1998, Dr. Weichert has continued his research at U. Wisc. and subsequently founded Cellectar in 2002 to further develop and commercialize the technology. Cellectar obtained exclusive rights to the related technology patents owned by U. Mich. in 2003 and continued development of the platform while obtaining ownership of numerous additional patents and patent applications (lasting until 2025, 2028 and 2030 without extensions) prior to the Acquisition.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COLD is a cancer-targeted chemotherapy that, in pre-clinical experiments, has been observed to inhibit the phosphatidylinosotol 3-kinase (PI3K)/Akt survival pathway, which is overexpressed in many types of cancer.&#160; As a result, in such pre-clinical experiments COLD has been observed to selectively inhibit Akt activity, induce apoptosis through caspase activation and inhibit cell proliferation in cancer cells versus normal cells.&#160; COLD also exhibits significant <font style="DISPLAY: inline; FONT-STYLE: italic">in vivo</font> efficacy in mouse xenograft tumor models, including non-small cell lung cancer and triple-negative breast cancers, producing long-lasting tumor growth suppression and significantly increased survival.&#160; We believe COLD has the potential to be best-in-class versus other Akt inhibitors in development due to a) cancer cell/cancer stem cell targeting, resulting in cancer-selective inhibition of Akt and cell proliferation or b) suitability for intravenous administration which offers the prospect of greater systemic exposure and hence Akt inhibition in cancer cells that we believe results in superior efficacy.&#160; We expect to submit an Investigational New Drug (&#8220;IND&#8221;) application to the FDA in late 2012.</font> </div>
<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">27</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">HOT (iodine-131 radiolabeled compound) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that we believe has first-in-class potential.&#160; HOT is comprised of a small quantity of COLD (too little for significant Akt inhibition), acting as a cancer-targeted delivery and retention vehicle, and incorporating a cytotoxic dose of radiotherapy (in the form of iodine-131, a radioisotope that is already in common use to treat thyroid and other cancer types).&#160; It is this &#8220;intracellular radiation&#8221; mechanism of cancer cell killing, coupled with selective delivery to a wide range of malignant tumor types, that we believe imbues HOT with broad-spectrum anti-cancer activity.&#160; In 2009, we opened an IND with the FDA to study HOT in humans.&#160; In early 2010, we successfully completed a Phase 1a dosimetry trial in humans demonstrating initial safety and establishing dosing parameters for a Phase 1b dose-escalation trial.&#160; The Phase 1b dose-escalation trial is aimed at determining the Maximum Tolerated Dose, and we expect it to begin in the fourth quarter of 2011.&#160; In parallel, we expect to initiate Phase 2 efficacy trials in solid tumors in 2012 as soon as a minimal efficacious dose is established.&#160; We may determine such an effective dose upon seeing a response in the Phase 1b trial or calculating it from imaging trials in patients (see LIGHT below).&#160; Preclinical experiments <font style="DISPLAY: inline; FONT-STYLE: italic">in vitro</font> (in cell culture) and <font style="DISPLAY: inline; FONT-STYLE: italic">in vivo</font> (in animals) have demonstrated selective killing of cancer cells along with a benign safety profile.&#160; HOT&#8217;s anti-tumor/survival-prolonging activities have been demonstrated in over a dozen different xenograft models (human tumor cells implanted into animals) including breast, prostate, lung, glioma (brain), pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers.&#160; In all but two models, a single administration of HOT was sufficient to demonstrate efficacy.&#160; In view of HOT&#8217;s selective uptake and retention in a wide range of solid tumors, its single-agent efficacy in xenograft models and its non-specific mechanism of cancer-killing (radiation), we expect to first develop HOT as a monotherapy, initially for solid tumors.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">LIGHT (labeled with a shorter-lived radioisotope, iodine-124) is a small-molecule imaging agent that we believe has first-in-class potential in detecting and quantifying cancerous tumors and metastases.&#160; LIGHT is comprised of a small quantity of COLD (too little for Akt inhibition), acting as a cancer-targeted delivery and retention vehicle, and incorporating <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">124</font> I, a new positron emission tomography (PET) imaging isotope.&#160; PET imaging used in conjunction with CT scanning has now become the imaging method of choice in oncology.&#160; In studies to date, LIGHT selectively illuminated malignant tumors in 52 of 54 animal models of cancer, demonstrating evidence of broad-spectrum, cancer-selective uptake and retention.&#160; PET imaging studies with LIGHT in cancer patients are being conducted at the University of Wisconsin under an investigator-sponsored IND. The investigator-sponsored IND for LIGHT was submitted on March 28, 2003 and was approved by the FDA on April 25, 2003. The IND is held by Dr. Anne Traynor at the University of Wisconsin, who both initiates and conducts the investigation and under whose immediate direction the investigational drug is administered.&#160; Novelos provides funding for the studies and the data is shared with Novelos while the study progresses and at the conclusion of the study. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We expect additional investigator-sponsored Phase 1/2 trials of LIGHT as a PET imaging agent to begin in the fourth quarter of 2011, and that the trials will initially include brain metastases, lung and breast cancers.&#160; These human trials, if successful, will serve two important purposes.&#160; First, to provide proof-of-concept for LIGHT itself as a PET imaging agent with the potential to supplant the current &#8220;gold standard&#8221; agent, 18-fluoro-deoxyglucose (FDG), due to what we believe to be LIGHT&#8217;s superior cancer-specificity and more favorable logistics of clinical use.&#160; Second, to accelerate clinical development of HOT by predicting efficacy and enabling estimation of efficacious doses of HOT for Phase 2 trials.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Products in Development</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">COLD</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COLD is a cancer-targeted chemotherapy that, in pre-clinical experiments, has been observed to inhibit the phosphatidylinosotol 3-kinase (PI3K)/Akt survival pathway, which is overexpressed in many types of cancer.&#160; We believe COLD has the potential to be best-in-class versus other Akt inhibitors in development.&#160; We believe that&#160;&#160;COLD has important advantages over competitor agents including:</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 27pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8226;&#160;</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Selective uptake and retention by cancer cells/cancer stem cells compared to normal cells/stem cells.&#160; This results in significantly greater potency of COLD as an inhibitor of cell proliferation in cancer cells vs. normal cells (greater than a 10-fold difference), or</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 27pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8226;&#160;</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Suitability for intravenous administration, avoiding dose-limiting gastrointestinal toxicity seen with orally administered Akt-inhibiting APCs and potentially enabling greater systemic drug exposure and, hence, Akt-inhibition in cancer cells, resulting in superior efficacy.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We expect to submit an IND application to the FDA in late 2012.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chemically, COLD is 18-(p-[<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">127</font> I] iodophenyl) octadecyl phosphocholine, an alkyl phosphocholine (APC) subtype within the alkyl-phospholipid (APL) class of anti-tumor agents that includes perifosine, miltefosine and eldefosine.&#160; The iodine atom in its structure is the stable, non-radioactive (&#8220;cold&#8221;) isotope, <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">127 </font>I.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">COLD exhibits significant <font style="DISPLAY: inline; FONT-STYLE: italic">in vivo</font> efficacy in mouse xenograft tumor models, including non-small cell lung cancer and triple-negative breast cancers. In these models, human cancer cells are transplanted to and grow/metastasize in immunosuppressed animals.&#160; Tumor-bearing mice treated therapeutically (i.e., after primary tumors were established) with COLD i.v. (100-times the mass dose&#160;&#160;used as a carrier in the radiotherapy agent, HOT) once a week for 5 weeks, showed almost complete suppression of tumor growth compared to saline-treated control animals. Tumor growth suppression by COLD was maintained long after the end of the treatment period.&#160; Importantly, survival in COLD-treated groups at experiment termination (100-200 days post tumor-cell injection) was 90% or more compared to 20% or less in control groups.&#160; Additionally, in a side-by-side comparison, COLD was much more effective in suppressing tumor growth and increasing survival in the lung cancer model than a standard dosing regimen of erlotinib (Tarceva, a marketed epidermal growth factor receptor kinase inhibitor).</font></div>
<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The <font style="DISPLAY: inline; FONT-STYLE: italic">in vivo</font> efficacy of COLD is believed to be at least in part the result of selective inhibition of the apoptosis-suppressing PI3K/Akt signaling pathway in cancer cells.&#160; This pathway, which is activated by growth factors such as PDGF (platelet-derived growth factor), EGF (epidermal growth factor), and insulin, is overactive in many human cancers and contributes to cell growth, proliferation, survival and resistance to radiation and chemotherapeutics.&#160; COLD selectively inhibits Akt activation in human cancer cells compared to normal proliferating cells (e.g., human fibroblasts).&#160; At the same concentrations, COLD induces apoptosis through caspase activation&#160;and suppresses proliferation in a wide range of human cancer cell lines including prostate carcinoma, ovarian carcinoma, triple-negative breast carcinomas, pancreatic adenocarcinoma and non-small cell lung cancer. At these concentrations, COLD does not inhibit proliferation of normal cells.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="eolpage34"><!--EFPlaceholder--></a>Other cancer targeting APCs have also been reported to be active in xenograft models and to selectively inhibit tumor cell proliferation via a mechanism that involves induction of apoptosis&#160;through caspase activation subsequent to inhibition of Akt activation and signaling.&#160;However, APCs are generally dose-limited <font style="DISPLAY: inline; FONT-STYLE: italic">in vivo</font> (including in man) by side effects stemming from the necessity for their oral administration (due to their hemolytic properties), thus limiting Akt inhibition and anti-tumor efficacy.&#160; In contrast, data to date support the contention that COLD can be safely administered intravenously at doses that we believe will result in greater drug exposure compared to other APCs and, thus, in greater Akt inhibition and improved efficacy.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Non-APC Akt inhibitors in development are not cancer-targeting and thus have the potential for an unfavorable therapeutic index (due to non-selective inhibition of Akt, and hence proliferation) in normal vs. cancer cells.&#160; In contrast, selective uptake and retention of COLD results in more than 10-fold more potent inhibition of Akt activity and cell proliferation in cancer cells vs. normal cells.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The development path for COLD includes evaluation in a standard battery of IND-enabling pre-clinical tests and scaled-up manufacture.&#160; &#160;In parallel, we intend to test COLD in mouse xenograft tumor models in combination with standard chemotherapeutic agents to demonstrate synergies as have been reported for perifosine.&#160; These additional pre-clinical data will enable estimation of COLD plasma levels associated with <font style="DISPLAY: inline; FONT-STYLE: italic">in vivo</font> efficacy, establish a starting dose for the initial Phase 1 clinical trial and facilitate selection of target indications.&#160; We expect to file an IND with the FDA for COLD in late 2012.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">HOT (</font> iodine-131 radiolabeled compound <font style="DISPLAY: inline; FONT-WEIGHT: bold">)</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">HOT is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that we believe has first-in-class potential.&#160; HOT is comprised of a small quantity of COLD (too little for Akt inhibition), acting as a cancer-targeted delivery and retention vehicle and incorporating a cytotoxic dose of radiotherapy (in the form of iodine-131, a radioisotope that is already in common use to treat thyroid and other cancer types).&#160; It is this &#8220;intracellular radiation&#8221; mechanism of cancer cell killing, coupled with delivery to a wide range of malignant tumor types, that imbues HOT with broad-spectrum anti-cancer activity.&#160; In 2009, we opened an IND with the FDA to study HOT in humans.&#160; In early 2010, we successfully completed a Phase 1a dosimetry trial in humans demonstrating initial safety and establishing dosing parameters for a Phase 1b dose-escalation trial.&#160; The Phase 1b dose-escalation trial is aimed at determining the Maximum Tolerated Dose, and we expect it to begin in the fourth quarter of 2011.&#160; In parallel, we expect to initiate Phase 2 efficacy trials in solid tumors in 2012 as soon as a minimal efficacious dose is established.&#160; We may determine such an effective dose upon seeing a tumor response in the Phase 1b trial or calculating it from imaging trials in patients (see LIGHT below).&#160; HOT&#8217;s anti-tumor/survival-prolonging activity has been demonstrated in multiple animal xenograft models (human tumor cells implanted into mice).&#160; &#160;In all but two models, a single administration of HOT was sufficient for efficacy.&#160; In view of HOT&#8217;s selective uptake and retention in a wide range of solid tumors, its single-agent efficacy in xenograft models and its non-specific mechanism of cancer-killing (radiation), we expect to first develop HOT as a monotherapy, initially for solid tumors.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chemically, HOT is 18-(p-[ <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">131</font> I]iodophenyl) octadecyl phosphocholine, identical to COLD except that the iodine in its structure is the radioactive (&#8220;hot&#8221;) isotope, <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">131</font> I, which has a radiation half-life of eight days.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Single intravenous doses of HOT administered therapeutically in animals (i.e., after primary tumors were established) have been observed to result in significant anti-tumor and/or survival benefit compared to control animals in mouse xenograft tumor models including ovarian, pancreatic, non-small cell lung, triple-negative breast, prostate, glioma, colorectal and kidney cancers.&#160;Survival benefit generally reflected the degree of tumor growth suppression.&#160; Efficacy was also seen in a xenograft model employing human uterine sarcoma cells which over-express efflux pumps known to underlie resistance to many standard chemotherapeutic drugs. The broad <font style="DISPLAY: inline; FONT-STYLE: italic">in vivo</font> efficacy profile of HOT across many tumor types is reflected in the fact that selective tumor localization of LIGHT (which uses the same cancer-targeting drug delivery and retention vehicle as HOT) has been demonstrated in over 50 xenograft, spontaneous and transgenic cancer models.&#160; HOT was also tested in combination with a standard efficacious dose of gemcitabine in a pancreatic cancer xenograft model.&#160; Single doses of HOT or gemcitabine given alone were equally efficacious while the combination therapy was significantly more efficacious than either treatment alone (additive).&#160; In each xenograft study, the dose of HOT was ~100 &#181;Ci, which is at least 50% less than the maximum tolerated dose in mice.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Extensive, IND-enabling, Good Laboratory Practices (GLP) <font style="DISPLAY: inline; FONT-STYLE: italic">in vivo</font> and <font style="DISPLAY: inline; FONT-STYLE: italic">in vitro</font> pre-clinical pharmacokinetic/distribution, toxicology and drug safety studies were successfully completed using non-pharmacological concentrations/doses of COLD consistent with its role as a delivery/retention vehicle in HOT.&#160; Tissue distribution studies supported prediction of acceptable human organ exposures and body clearance for HOT.&#160; Importantly, and in sharp distinction from biological products labeled with <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">131</font> I, the small molecule HOT showed very minimal variation in excretion kinetics and tissue distribution between individuals within species or across a 500-fold variation in dose.&#160; Single- and repeated-dose animal toxicology studies indicated very high margins of safety (80-200x) over the anticipated maximum human therapy dose of HOT.</font></div>
<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">29</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In February 2010 we completed a Phase 1a dosimetry trial with a single intravenous doses of 10 mCi HOT in eight patients with relapsed or refractory advanced solid tumors.&#160; Single doses of HOT were well tolerated.&#160; The reported adverse events were all considered minimal, manageable and either not dose limiting or not related to HOT. There were no serious adverse events reported.&#160; Analysis of total body imaging and blood and urine samples collected over 42 days following injection indicated that doses of HOT expected to be therapeutically effective can be administered without harming vital organs.&#160; Two subjects (one with colorectal cancer metastasized to lung and another with prostate cancer) had tumors that were imaged with 3D nuclear scanning (SPECT/CT) on day 6 after administration of HOT.&#160; Uptake of HOT into tumor tissue (but not adjacent normal tissue or bone marrow) was clearly demonstrated in both subjects.&#160; Echoing animal studies, pharmacokinetic analyses demonstrated a prolonged halflife of radioactivity in the plasma after HOT administration (approximately 200 hours) and that there was no significant variation in excretion or radiation dosimetry between subjects.&#160; The trial established an initial dose of 12.5 mCi / m <font style="DISPLAY: inline; FONT-SIZE: 10pt">2</font> (for example, 20 mCi dose for a patient with 1.6m <font style="DISPLAY: inline; FONT-SIZE: 10pt">2</font> body surface area) for the Phase 1b escalating dose trial that is expected to begin in the fourth quarter of 2011.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The primary objective of this Phase 1b dose-escalation trial in patients with a range of advanced solid tumors is to define the Maximum Tolerated Dose (MTD) of HOT.&#160; In addition to determining the MTD, the Phase 1b trial will evaluate overall tumor response (using standard RESIST I criteria) and safety.&#160; Concurrently, separate studies will generate quantitative imaging data in cancer patients using LIGHT (see below).&#160; These imaging trials with LIGHT will predict efficacy and enable calculation of a minimal efficacious dose of HOT for Phase 2 trials, expected to begin in 2012, with an initial focus on solid tumors with significant unmet medical need.&#160; &#160;Based on its broad-spectrum mechanism of action and wide-ranging single agent activity in animal cancer models, HOT&#160;is anticipated to&#160;be used as monotherapy through proof-of-concept clinical trials, with subsequent exploration of combination with chemotherapeutic agents (a number of which are known to be radiosensitizers and thus with potential to enhance the efficacy of HOT).</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tumor treatment with radioactive isotopes has been used as a fundamental cancer therapeutic for decades.&#160; The goals of targeted cancer therapy &#8212; selective delivery of effective doses of isotopes that destroy tumor tissue, sparing of surrounding normal tissue, non-accumulation in vital organs such as the liver and kidneys &#8212; remain goals of novel therapies as well.&#160; We believe our isotope delivery technology is poised to achieve these goals.&#160; Because, to date, HOT has been shown to reliably and near-universally accumulate in cancer cells and because the therapeutic properties of the iodine-<font style="DISPLAY: inline; FONT-SIZE: 10pt">131</font>&#160;are well known, we believe the risk of non-efficacy in human clinical trials is less than that of other cancer therapies at this stage of development, although no assurance can be given.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other targeted radiotherapies include the marketed drugs Zevalin&#174; (<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">90</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font>Y, Spectrum Pharmaceuticals) and Bexxar&#174; (<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">131</font> I, GSK).&#160; In both cases, tumor-targeting is monoclonal antibody-based and limited to non-Hodgkins lymphoma, which is a type of cancer involving cells of the immune system.&#160; Thus, these agents are not appropriate comparators for HOT because of their limited therapeutic utility (only one type of tumor) and because their target indication is often well-managed by other drugs (unlike HOT which has potential to treat tumor types for which the current standard of care is associated with very poor outcomes). Notably, both Zevalin&#174; and Bexxar&#174; were approved on the basis of objective response rates (shrinking of tumors) without data to support improvement in survival, suggesting that regulatory approval of radiopharmaceuticals can be based on relatively shorter and smaller pivotal clinical trials than is often the case in oncology.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In conclusion, we believe that HOT is not subject to the full extent of development risk typically associated with early-stage cancer therapeutics for the following reasons:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">HOT is selectively taken up by and retained in cancer vs. normal cells and its delivery vehicle (COLD) is intended to be given to patients in sub-pharmacological doses, resulting in an improved safety profile compared to standard chemotherapy.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">HOT does not rely on inhibition or enhancement of a specific pathway; it works by exposing cancer cells to sustained lethal radiation from within.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">To date, HOT (as demonstrated with LIGHT studies) has shown near-universal cancer-specific retention in more than 50 </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic">in vivo</font><font style="DISPLAY: inline; FONT-SIZE: 10pt"> tumor models, making the molecule potentially effective in numerous cancer types (broad-spectrum) as compared to type-specific therapies.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We believe we have completed all preclinical safety, pharmacology and toxicology studies required for an NDA including both single-dose and multi-dose studies.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">HOT is a small molecule that is easily characterized and synthesized and is therefore not subject to scale-up and manufacturing risks typically associated with large molecules such as monoclonal antibodies.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">HOT exploits a new cancer-selective delivery and retention mechanism, but is paired with a proven and effective radioisotope ( </font><font style="DISPLAY: inline; FONT-SIZE: 10pt"><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">131</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt"> I) for therapy.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">LIGHT (</font> labeled with a shorter-lived radioisotope, iodine-124 <font style="DISPLAY: inline; FONT-WEIGHT: bold">)</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LIGHT is a small-molecule imaging agent that we believe has first-in-class potential in detecting and quantifying cancerous tumors and metastases.&#160; LIGHT is comprised of a small quantity of COLD (too little for Akt inhibition), acting as a cancer-targeted delivery and retention vehicle, and incorporating <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">124</font> I, a new positron emission tomography (PET) imaging isotope.&#160; PET imaging used in conjunction with CT scanning has now become the imaging method of choice in oncology.&#160; In studies to date, LIGHT selectively illuminated malignant tumors in 52 of 54 animal models of cancer, demonstrating evidence of broad-spectrum, cancer-selective uptake and retention.&#160; We expect investigator-sponsored Phase 1/2 trials of LIGHT as a PET imaging agent to begin in the fourth quarter of 2011, and that the trials will initially include brain metastases, lung and breast cancers.&#160; These human trials, if successful, will serve two important purposes.&#160; First, they will provide proof-of-concept for LIGHT itself as a PET imaging agent with the potential to supplant the current &#8220;gold standard&#8221; agent, 18-fluoro-deoxyglucose (FDG), due to what we believe to be LIGHT&#8217;s superior cancer-specificity and more favorable logistics of clinical use.&#160; Second, they will accelerate clinical development of HOT by predicting efficacy and enabling estimation of efficacious doses of HOT for Phase 2 trials.</font></div>
<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">30</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chemically, LIGHT is 18-(p-[ <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">124</font> I]iodophenyl) octadecyl phosphocholine, identical to COLD except that the iodine is the radioactive&#160;&#160;isotope, <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">124</font> I, which has a radiation half-life of 4 days.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Studies demonstrating the utility of LIGHT for imaging primary tumors and metastases as well as cancer stem cells are described above (Technology Overview).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FDG is the current gold standard for PET imaging.&#160; According to Bio-Tech Systems (November 2010), sales of FDG in the US in 2009 were approximately $300 million and projected to grow to approximately $900 million in 2017.&#160; FDG accumulates in any tissue having increased glucose metabolism compared to surrounding tissue.&#160; As a result and in contrast to LIGHT, FDG is not selective for malignant tumors.&#160; FDG localizes in certain normal tissue such as heart, kidney and brain tissues that also have high glucose metabolism.&#160; FDG is also known to localize in inflammatory sites. Other major limitations to the use of FDG are found in pelvic imaging due to the high renal (kidney) clearance of the compound.&#160; These characteristics of FDG, therefore, decrease its diagnostic specificity for certain malignancies.&#160; FDG is no longer covered by patent and is typically manufactured onsite at PET imaging medical facilities because of its limited (110 minute) half life.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We compared LIGHT and FDG side by side (24 hours apart) in the same tumor-bearing mouse that was also treated with carageenan to induce inflammation.&#160; As expected, FDG demonstrated significant uptake into the inflammatory lesion and organs such as heart and bladder compared to the malignant tumors which were poorly imaged.&#160; LIGHT, on the other hand, showed no uptake into the inflammatory lesion and organs, yet clear and demonstrable uptake into the tumors.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Additionally, the radioisotopic half-life of only 110 minutes for fluorine-18 labeled agents, such as FDG, severely limits their delivery range relative to the point of manufacture</font>.&#160; <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">124</font><font style="DISPLAY: inline; FONT-SIZE: 10pt"> I has a four-day half-life that permits worldwide distribution of LIGHT from one manufacturing location.&#160; Additionally, the longer half-life affords a longer imaging window of up to seven days following injection.</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We expect to begin investigator sponsored Phase 1/2 trials of LIGHT aimed at demonstrating and quantifying selective uptake and retention in human solid tumors in the fourth quarter of 2011.&#160; We expect initial indications to include brain metastases, lung and breast cancers, with extension to other cancer types to follow.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Technology</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">COLD, HOT and LIGHT are alkylphospholipids (&#8220;APLs&#8221;) that interact with specialized microdomains within cell membranes (called &#8220;lipid rafts&#8221;) and, as a result, whose molecular targets are located at cellular membranes.&#160; Importantly, the core chemical structure shared across all three products provides selective targeting of cancer cells in preference to normal cells (due to enrichment of lipid rafts in the former).&#160; COLD was deliberately designed to contain iodine (in the form of the stable, non-radioactive isotope, <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">127</font> I), thus enabling additional, distinct products differing only with respect to the form of iodine they contain &#8211; HOT contains short-lived radioactive <font style="DISPLAY: inline; FONT-SIZE: 10pt"><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">131 </font></font>I and LIGHT contains even more short-lived <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">124 </font>I. As a result, three cancer-targeted product profiles have been generated from a single chemical structure &#8212; a chemo-therapeutic agent (COLD), a molecular radiotherapeutic agent (HOT) and a diagnostic/imaging agent (LIGHT).</font></div>
<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="eolPage37"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Using a fluorescent-labeled analog of COLD (CLR1501 or &#8220;GLOW1&#8221;), selective uptake and retention has been demonstrated in cancer cells <font style="DISPLAY: inline; FONT-STYLE: italic">in vitro</font> .&#160; Twenty-four hours after treatment, a variety of human tumor cell types (melanoma, colorectal, uterine, pancreatic, ovarian, glioblastoma) show six to ten-fold more staining with GLOW1 relative to&#160;&#160;normal cells (e.g., skin fibroblasts) do not.&#160; Significantly, uptake/retention was also seen in cancer stem cells which are known to be relatively resistant to both chemotherapy and radiation and may therefore contribute to eventual relapse of disease following conventional chemotherapy.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Malignant tumor targeting, including targeting of cancer stem cells, has also been demonstrated <font style="DISPLAY: inline; FONT-STYLE: italic">in vivo</font> . For example, mice without intact immune systems, and inoculated with Panc-1 (pancreatic carcinoma), were injected with CLR1502 (&#8220;GLOW2&#8221;, a fluorescent-labeled analog of COLD that is active in the near-infrared range) 24 and 96 hours prior to imaging.&#160; &#160;<font style="DISPLAY: inline; FONT-STYLE: italic">In vivo</font> optical imaging showed pronounced accumulation of GLOW2 in tumors versus non-target organs and tissues.&#160; Similarly, PET imaging of tumor-bearing animals (colon, glioma, triple negative breast and pancreatic tumor xenograft models) administered the imaging agent LIGHT clearly shows selective uptake and retention by both primary tumors and metastases, including cancer stem cells.&#160; Furthermore, PET/CT analysis following co-injection of HOT (for therapy) and LIGHT (for imaging) revealed time-dependent tumor shrinkage and disappearance (over 9 days) in a cancer xenograft model.&#160; Finally, we believe that the capability of our technology in targeting cancer stem cells <font style="DISPLAY: inline; FONT-STYLE: italic">in vivo</font> was demonstrated by treating tumor-bearing mice with GLOW1 and then removing the tumor and isolating cancer stem cells, which continued to display GLOW1 labeling even after three weeks in cell culture.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The basis for selective tumor targeting of our compounds lies in differences between the plasma membranes of cancer cells as compared to those of most normal cells.&#160; Specifically, cancer cell membranes are highly enriched in &#8220;lipid rafts&#8221;.&#160; Lipid rafts are specialized regions of the membrane phospholipid bilayer that contain high concentrations of cholesterol and sphingolipids and serve to organize cell surface and intracellular signaling molecules (e.g. growth factor and cytokine receptors, the phophatidylinosotol 3-kinase (P13K)/Akt survival pathway). Lipid rafts are central to the activity of our compounds in two ways:</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Lipid rafts are portals of entry for APLs such as COLD, HOT and LIGHT.&#160; The marked selectivity of our compounds for cancer cells versus non-cancer cells is due to the fact that cancer cells have far more lipid rafts. In addition to accumulating in lipid rafts, COLD, HOT and LIGHT are transported into the cytoplasm, where they distribute to organelle membranes (mitochondria, ER, lysosomes) but not the nucleus.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Lipid rafts also regulate signaling-based cell functions including apoptosis and cell proliferation, and COLD disrupts this regulation. For example, one key signaling pathway that is regulated by interactions with lipid rafts and phospholipids is the phosphatidylinosotol 3-kinase (PI3K)/Akt pathway.&#160; Akt (a serine/threonine protein kinase) is activated in lipid raft regions via phosphorylation by PI-dependent kinases and goes on to phosphorylate anti-apoptotic proteins (e.g., Bcl-xL and FLIP) resulting in their inactivation and, thus, promotion of tumor cell survival.&#160; COLD pharmacologically inhibits the activation of Akt.&#160; In cancer cells, Akt inhibition is associated with induction of apoptosis and decreased cell proliferation/survival.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The pivotal role played by lipid rafts is underscored by the fact that disruption of lipid raft architecture suppresses uptake of GLOW1 and radiolabeled COLD into cancer cells.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Legacy Products</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOV-002, our legacy compound, is a small-molecule immunomodulating and anti-cancer compound based on a proprietary formulation of oxidized glutathione.&#160; NOV-002 has been administered to approximately 1,000 cancer patients in clinical trials and was in Phase 2 development for solid tumors in combination with chemotherapy.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">From November 2006 through January 2010, we conducted a Phase 3 trial of NOV-002 plus first-line chemotherapy in advanced non-small cell lung cancer (&#8220;NSCLC&#8221;) following three Phase 2 trials (two conducted in Russia and one conducted by us in the U.S.) that had demonstrated clinical activity and safety.&#160; The Phase 3 trial enrolled 903 patients, 452 of whom received NOV-002.&#160; In February 2010, we announced that the primary endpoint of improvement in overall survival compared to first-line chemotherapy alone was not met in this pivotal Phase 3 trial.&#160; Following evaluation of the detailed trial data, we announced in March 2010 that the secondary endpoints also were not met in the trial and that adding NOV-002 to paclitaxel and carboplatin chemotherapy was not statistically or meaningfully different in terms of efficacy-related endpoints or recovery from chemotherapy toxicity versus chemotherapy alone. However, NOV-002 was safe and did not add to the overall toxicity of chemotherapy.&#160; Based on the results from the Phase 3 trial, we have discontinued development of NOV-002 for NSCLC in combination with first-line paclitaxel and carboplatin chemotherapy.&#160; The aggregate costs incurred in connection with our development of NOV-002, including administrative overhead, were approximately $70 million.</font></div>
<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">32</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage38"><!--EFPlaceholder--></a>Novelos had also been developing NOV-205, a second oxidized glutathione-based compound. NOV-205 had been administered to approximately 200 hepatitis patients in clinical trials and was in Phase 2 development for chronic hepatitis C non-responders.&#160; An IND for NOV-205 as a monotherapy for chronic hepatitis C was accepted by the FDA in 2006.&#160; A U.S. Phase 1b clinical trial with NOV-205 in patients who previously failed treatment with pegylated interferon plus ribavirin was completed in December 2007.&#160; Based on favorable safety results of that trial, in March 2010 Novelos initiated a multi-center U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.&#160; Safety was established in twenty patients receiving either 30mg or 60mg of NOV-205 daily for 49 days; however, no viral load reduction was observed.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Further development of NOV-002 and NOV-205 has been suspended.&#160; At this time, we expect to devote our resources to the development and commercialization of the Cellectar compounds, and we do not expect to conduct any further development of the oxidized glutathione compounds. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The IND for NOV-205 was withdrawn on July 5, 2011.&#160;&#160;We anticipate that the IND for NOV-002 will be placed on inactive status.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Manufacturing</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We manufacture HOT and COLD at our current Good Manufacturing Practices (cGMP)-compliant radiopharmaceutical manufacturing facility in Madison, WI.&#160; This facility, consisting of approximately 19,500 square feet, contains offices, laboratories, a radiopharmaceutical research lab, a cGMP radiopharmaceutical manufacturing suite and a cGMP analytical laboratory for product release.&#160; Our manufacturing facility holds a State of Wisconsin Department of Health Services Radioactive Materials License which authorizes the use and possession of radioactive material for both manufacturing and distribution activities. This license establishes a possession limit of 9 Curies of iodine-131. The facility also holds a State of Wisconsin DHS Radioactive Materials License which authorizes the use and possession of radioactive materials by Cellectar for research and development. The research and development license permits the use and possession of iodine-125, iodine-131 and iodine-124 in quantities sufficient to support in-house HOT manufacturing and other research needs. To date, small quantities of LIGHT have been manufactured by our collaborator, the University of Wisconsin in Madison, at no cost to the Company, in connection with investigator-sponsored clinical trials, pursuant to a materials transfer agreement expiring in June 2013. The materials transfer agreement contains standard provisions for the protection of data and intellectual property and may be terminated by either party at any time before expiration. We are in the process of negotiating a fee-based arrangement with the University of Wisconsin covering the manufacture of LIGHT in the future. If the University was unable to manufacture LIGHT for any reason, we could manufacture it at our Madison facility, without material additional investment. We are exploring scaling up production capacity of COLD, via contract manufacturers or at our facility, to support an IND filing and clinical trials, but we have not yet entered into any agreements for the manufacture of COLD.&#160; The drug substance is identical for all three products with the exception of the different iodine isotope used in each.&#160; The base molecule is a dry powder produced via a six-step synthetic scheme.&#160; The release specifications for drug substance have been established and validated.&#160; The impurity levels at small scale are very low suggesting that larger scale production should be feasible.&#160; We have also demonstrated 24-month stability for the drug substance in desiccated and refrigerated form.&#160; We believe our laboratories are well equipped with the appropriate equipment for manufacturing pilot and small-scale batches to cGMP.&#160; We believe we have adequate capacity for any Phase 2 trials of HOT and the potential for larger scale build-out for larger Phase 3 trials.&#160; All investigational drug substance and product intended for human use during clinical studies will be manufactured according to ICH guidelines, FDA requirements (CFR part 211) and cGMP.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Sales and Marketing</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">COLD, HOT and LIGHT have not been partnered to date.&#160; We plan to pursue and evaluate all available options to develop, launch and commercialize our compounds.&#160; These options presently include, but are not limited to, entering into a partnering arrangement with a pharmaceutical company or various pharmaceutical companies with strong development and commercial expertise and infrastructure in the U.S, Europe and/or Japan.&#160; While we currently do not plan to build our own sales force or utilize a contract sales organization for launch and commercialization of our compounds, we may reconsider.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_COMPETITION"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Competition</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">COLD</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We believe COLD has the potential to be best-in-class versus other Akt inhibitors in development.&#160; We believe COLD has important advantages over competitor agents including:</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 27pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8226;&#160;</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Selective uptake and retention by cancer cells/cancer stem cells compared to normal cells/stem cells.&#160; This results in significantly greater potency of COLD as an inhibitor of cell proliferation in cancer cells vs. normal cells (&gt;10-fold difference), or</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 27pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8226;&#160;</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Suitability for intravenous administration, avoiding dose-limiting gastrointestinal toxicity seen with orally administered Akt-inhibiting APCs and potentially enabling greater systemic drug exposure and, hence, Akt-inhibition in cancer cells, resulting in superior efficacy.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perifosine, an alkylphospholipid that is being being developed by Keryx Biopharmaceuticals, which has licensed it in North America from &#198;terna Zentaris Inc., is a possible future competitor to COLD.</font></div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">33</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">HOT</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">HOT&#8217;s &#8220;intracellular radiation&#8221; mechanism of cancer cell killing, coupled with delivery to a wide range of malignant tumor types, imbues HOT with broad-spectrum anti-cancer activity.&#160; Other targeted radiotherapies include the marketed drugs Zevalin&#174; (manufactured by Spectrum Pharmaceuticals) and Bexxar&#174; (manufactured by GlaxoSmithKline).&#160; In both cases, tumor-targeting is monoclonal antibody-based and limited to non-Hodgkins lymphoma, which is a type of cancer involving cells of the immune system.&#160; Thus, these agents are not appropriate comparators for HOT because of their limited therapeutic utility (only one type of tumor) and because their target indication is often well-managed by other drugs (unlike HOT which has potential to treat tumor types for which the current standard of care is associated with very poor outcomes). Notably, both Zevalin&#174; and Bexxar&#174; were approved on the basis of objective response rates (shrinking of tumors) without data to support improvement in survival, suggesting that regulatory approval of radiopharmaceuticals can be based on relatively shorter and smaller pivotal clinical trials than is often the case in oncology.&#160; We do not believe Zevalin or Bexxar would be competing products of HOT in any material respect.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">LIGHT</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FDG is the current gold standard for cancer PET imaging.&#160; According to Bio-Tech Systems (November 2010), sales of FDG in the US in 2009 were approximately $300 million and projected to grow to approximately $880 million in 2017.&#160; FDG accumulates in any tissue having increased glucose metabolism compared to surrounding tissue.&#160; As a result, and in contrast to LIGHT, FDG is not selective for malignant tumors.&#160; FDG localizes in certain normal tissue such as heart, kidney and brain tissues that also have high glucose metabolism.&#160; FDG is also known to localize in inflammatory sites.&#160; Other major limitations to the use of FDG are found in pelvic imaging due to the high renal (kidney) clearance of the compound.&#160; We believe these characteristics of FDG, therefore, decrease its diagnostic specificity for certain malignancies. FDG is no longer covered by patent and is typically manufactured onsite at PET imaging medical facilities because of its limited (110 minute) half-life.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We compared LIGHT and FDG side by side (24 hours apart) in the same tumor-bearing mouse that was also treated with carageenan to induce inflammation.&#160; As expected, FDG demonstrated significant uptake into the inflammatory lesion and organs such as heart and bladder compared to the malignant tumors which were poorly imaged.&#160; LIGHT, on the other hand, showed no uptake into the inflammatory lesion and organs, yet clear and demonstrable uptake into the tumors.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additionally, the radioisotopic half-life of only 110 minutes for fluorine-18 labeled agents, such as FDG, severely limits their delivery range relative to the point of manufacture. <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">124</font> I has a four-day half-life that permits worldwide distribution of LIGHT from one manufacturing location.&#160; Additionally, the longer half-life affords a longer imaging window of up to seven days following injection.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Intellectual Property</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have established a broad U.S. and international intellectual property rights portfolio around our cancer-targeting alkylphospholipid technology platform including COLD, HOT and LIGHT.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Our proprietary rights include patents and patent applications that are either owned by us or exclusively licensed to us by the U. Mich. (the <font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#8220;</font>U. Mich. patents<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#8221;</font>). HOT and LIGHT are covered by the U. Mich. patents that provide compound (composition of matter) coverage in the US and Canada and expire in 2016.&#160; Our patents and applications cover methods of use, composition and method of manufacture related to COLD, HOT and LIGHT.&#160; Many of these patents and applications are filed in key commercial markets worldwide.&#160; These will generally expire between 2025 and 2030 unless extended.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In particular, HOT is covered by two additional series of our patents and applications aside from the U. Mich. patents.&#160; The first is directed to a method of use for cancer therapy and has also been filed in Europe and Japan, in addition to the U.S.&#160; These will be expected to expire in 2025.&#160; Secondly, an application directed to cancer stem cell therapy is pending in the U.S., is expected to be filed/nationalized in foreign countries in 2011 and is expected to expire in 2030. Some of these resulting patents may be extendable on a country-by-country basis.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COLD is covered by a series of pending applications directed to methods of using COLD for cancer therapy and&#160;is expected to&#160;be filed/nationalized in foreign countries by 2012.&#160; These patents, once issued, would expire in 2030.&#160; Some of these resultant patents may be extendable on a country-by-country basis.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Separate from any patent protection and following product approval by regulatory authorities, data exclusivity may be available for HOT and COLD for up to 10 years on a country-by-country basis (e.g., up to 5 years in the U.S.).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">The early termination of the U. Mich. license would result in the loss of our rights to use the covered patents which could severely delay, inhibit or eliminate our ability to develop and commercialize compounds based on the licensed patents.</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">34</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LIGHT is covered by the U. Mich. patents as well as two of our U.S. patents, one of which is directed to its use for virtual colonoscopy (expiring 2025) and one of which is directed to its use for <font style="DISPLAY: inline; FONT-STYLE: italic">in vitro</font> diagnostics (expiring 2025).&#160; LIGHT is also covered by pending U.S. and European patent applications directed to its use for <font style="DISPLAY: inline; FONT-STYLE: italic">in vivo</font> diagnostics and once issued should expire in 2025.&#160; Lastly, the use of LIGHT for diagnostics purposes with cancer stem cells is pending in the U.S. and will be filed/nationalized in foreign countries in 2011.&#160; These patents are expected to expire in 2030.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition to the above noted patents/applications directed to HOT, COLD and LIGHT, we own other patents/applications directed to different forms of alkylphospholipids and methods of manufacturing of alkylphospholipids.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We also own all intellectual property rights worldwide (excluding Russia and the other states of the former Soviet Union, the &#8220;Russian Territory&#8221;) related to our clinical-stage pipeline compound, NOV-002, and other pre-clinical compounds based on oxidized glutathione.&#160; Issued composition of matter patents cover proprietary formulations of oxidized glutathione that do not expire until 2019, and these patents include methods of manufacture for oxidized glutathione formulated with various metals.&#160; In our dispute with BAM, one of the remedies BAM is seeking is the revocation of our rights in these compounds.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Licenses / Collaborations</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In September 2003, Cellectar entered into the U. Mich license which granted Cellectar exclusive rights to the development, manufacture and marketing of products under several composition of matter patents in North America which expire at varying dates in 2016.&#160; The U. Mich. license expires upon the expiration of the last covered patent.&#160; We are responsible for an annual license fee of $10,000 and are required to pay costs associated with the maintenance of the patents covered by the U. Mich. license.&#160; Additionally, we are required to make milestone payments of $50,000 upon the filing of a New Drug Application (NDA) for a licensed product intended for use in a therapeutic or diagnostic application (such milestone fees may be deferred and paid within twelve months of the first commercial sale of such product) and make certain milestone payments within a year following the first commercial sale of any licensed products.&#160; The sales milestones range from $100,000 to $200,000, dependent upon whether the drug is for use in a therapeutic or diagnostic application, provided that if sales in the first 12 months are less than the amount of the milestone, then we are required to pay 50% of all sales until the milestone is satisfied. </font>The milestone payments may total up to $400,000. <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The U. Mich. license provides that we pay a royalty equal to 3% of net sales of any licensed products sold by us or our sublicensees for such licensed products, provided however if the sublicense fee payable to us is between 4%-5% of net sales then the royalties payable to U. Mich. shall be equal to 50% of the sublicense fee.&#160; Furthermore, the U. Mich. license provides for a reduction in the royalties owed by up to 50% if we are required to pay royalties to any third parties related to the sale of the licensed products.&#160; If we receive any revenue in consideration for rights to the licensed technology that is not based on net sales, excluding any funded research and development, we are required to pay U.Mich. 10% of amounts received. During 2003, pursuant to the U. Mich. license, Cellectar paid approximately $54,000 of back patent costs and issued 20,348 shares of common stock, giving effect to an estimated 1-for-10 Offering Reverse Split, to U. Mich. as partial consideration for the rights described above. U. Mich. may terminate the agreement if we cease operations, if we fail to make any required payment under the agreement, or if we otherwise materially breach the agreement, subject to applicable notice and cure periods.&#160; To date, we have made all payments as they have become due, there have been no defaults under the U. Mich. license, nor have we ever been notified of a default by U. Mich. We may terminate the agreement with six months notice to U. Mich. and the return of licensed product and related data.&#160; The U. Mich. license contained milestones that required certain development activities to be completed by specified dates. All such development milestones have been either completed or removed by subsequent amendment to the agreement.&#160; U. Mich. has provided no warranties as to validity or otherwise with respect to the licensed technology.</font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employees</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">As of November 4, 2011 we had 16 full time employees. We believe our relationships with our employees are good.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Regulation</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The production, distribution, and marketing of products employing our technology, and our development activities, are subject to extensive governmental regulation in the United States and in other countries.&#160; In the United States, we are subject to the Federal Food, Drug, and Cosmetic Act, as amended, and the regulations of the FDA, as well as to other federal, state, and local statutes and regulations.&#160; These laws, and similar laws outside the United States, govern the clinical and preclinical testing, manufacture, safety, effectiveness, approval, labeling, distribution, sale, import, export, storage, record-keeping, reporting, advertising, and promotion of drugs.&#160; Product development and approval within this regulatory framework, if successful, will take many years and involve the expenditure of substantial resources.&#160; Violations of regulatory requirements at any stage may result in various adverse consequences, including the FDA&#8217;s and other health authorities&#8217; delay in approving or refusal to approve a product.&#160; Violations of regulatory requirements also may result in enforcement actions.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following paragraphs provide further information on certain legal and regulatory issues with a particular potential to affect our operations or future marketing of products employing its technology.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research, Development, and Product Approval Process</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The research, development, and approval process in the United States and elsewhere is intensive and rigorous and generally takes many years to complete.&#160; The typical process required by the FDA before a therapeutic drug may be marketed in the United States includes:</font></div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">35</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 63pt; TEXT-ALIGN: right">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160; </font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">preclinical laboratory and animal tests performed under the FDA&#8217;s Good Laboratory Practices regulations, referred to herein as GLP;</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 63pt; TEXT-ALIGN: right">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160; </font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">submission to the FDA of an IND, which must become effective before human clinical trials may commence;</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 63pt; TEXT-ALIGN: right">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160; </font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">human clinical studies performed under the FDA&#8217;s Good Clinical Practices regulations, to evaluate the drug&#8217;s safety and effectiveness for its intended uses;</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 63pt; TEXT-ALIGN: right">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage41"><!--EFPlaceholder--></a><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160; </font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">FDA review of whether the facility in which the drug is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued quality; and</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 63pt; TEXT-ALIGN: right">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160; </font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">submission of a marketing application to the FDA, and approval of the application by the FDA.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Preclinical Testing</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During preclinical testing, studies are performed with respect to the chemical and physical properties of candidate formulations. These studies are subject to GLP requirements. Biological testing is typically done in animal models to demonstrate the activity of the compound against the targeted disease or condition and to assess the apparent effects of the new product candidate on various organ systems, as well as its relative therapeutic effectiveness and safety. An IND must be submitted to the FDA and become effective before studies in humans may commence.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Clinical Trials</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Clinical trial programs in humans generally follow a three-phase process.&#160; Typically, Phase 1 studies are conducted in small numbers of healthy volunteers or, on occasion, in patients afflicted with the target disease.&#160; Phase 1 studies are conducted to determine the metabolic and pharmacological action of the product candidate in humans and the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness.&#160; In Phase 2, studies are generally conducted in larger groups of patients having the target disease or condition in order to validate clinical endpoints, and to obtain preliminary data on the effectiveness of the product candidate and optimal dosing. This phase also helps determine further the safety profile of the product candidate.&#160; In Phase 3, large-scale clinical trials are generally conducted in patients having the target disease or condition to provide sufficient data for the statistical proof of effectiveness and safety of the product candidate as required by United States regulatory agencies.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the case of products for certain serious or life-threatening diseases, the initial human testing may be done in patients with the disease rather than in healthy volunteers. Because these patients are already afflicted with the target disease or condition, it is possible that such studies will also provide results traditionally obtained in Phase 2 studies. These studies are often referred to as &#8220;Phase 1/2&#8221; studies. However, even if patients participate in initial human testing and a Phase 1/2 study carried out, the sponsor is still responsible for obtaining all the data usually obtained in both Phase 1 and Phase 2 studies.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Before proceeding with a study, sponsors may seek a written agreement from the FDA regarding the design, size, and conduct of a clinical trial. This is known as a Special Protocol Assessment (&#8220;SPA&#8221;). Among other things, SPAs can cover clinical studies for pivotal trials whose data will form the primary basis to establish a product&#8217;s efficacy. SPAs help establish upfront agreement with the FDA about the adequacy of a clinical trial design to support a regulatory approval, but the agreement is not binding if new circumstances arise. There is no guarantee that a study will ultimately be adequate to support an approval even if the study is subject to an SPA.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">United States law requires that studies conducted to support approval for product marketing be &#8220;adequate and well controlled.&#8221; In general, this means that either a placebo or a product already approved for the treatment of the disease or condition under study must be used as a reference control. Studies must also be conducted in compliance with good clinical practice requirements, and informed consent must be obtained from all study subjects.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The clinical trial process for a new compound can take ten years or more to complete. The FDA may prevent clinical trials from beginning or may place clinical trials on hold at any point in this process if, among other reasons, it concludes that study subjects are being exposed to an unacceptable health risk. Trials may also be prevented from beginning or may be terminated by institutional review boards, who must review and approve all research involving human subjects. Side effects or adverse events that are reported during clinical trials can delay, impede, or prevent marketing authorization. Similarly, adverse events that are reported after marketing authorization can result in additional limitations being placed on a product&#8217;s use and, potentially, withdrawal of the product from the market.</font></div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">36</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><a name="eolPage42"><!--EFPlaceholder--></a>Submission of NDA</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Following the completion of clinical trials, the data are analyzed to determine whether the trials successfully demonstrated safety and effectiveness and whether a product approval application may be submitted. In the United States, if the product is regulated as a drug, an NDA must be submitted and approved before commercial marketing may begin. The NDA must include a substantial amount of data and other information concerning the safety and effectiveness of the compound from laboratory, animal, and human clinical testing, as well as data and information on manufacturing, product quality and stability, and proposed product labeling.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each domestic and foreign manufacturing establishment, including any contract manufacturers we may decide to use, must be listed in the NDA and must be registered with the FDA.&#160; The application generally will not be approved until the FDA conducts a manufacturing inspection, approves the applicable manufacturing process and determines that the facility is in compliance with cGMP requirements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under the Prescription Drug User Fee Act, as amended, the FDA receives fees for reviewing an NDA and supplements thereto, as well as annual fees for commercial manufacturing establishments and for approved products. These fees can be significant. For fiscal year 2011, the NDA review fee alone is $1,542,000, although certain limited deferral, waivers, and reductions may be available.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each NDA submitted for FDA approval is usually reviewed for administrative completeness and reviewability within 45 to 60 days following submission of the application. If deemed complete, the FDA will &#8220;file&#8221; the NDA, thereby triggering substantive review of the application. The FDA can refuse to file any NDA that it deems incomplete or not properly reviewable. The FDA has established performance goals for the review of NDAs&#8212; six months for priority applications and 10 months for standard applications. However, the FDA is not legally required to complete its review within these periods and these performance goals may change over time.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Moreover, the outcome of the review, even if generally favorable, typically is not an actual approval but an &#8220;action letter&#8221; that describes additional work that must be done before the application can be approved. The FDA&#8217;s review of an application may involve review and recommendations by an independent FDA advisory committee. Even if the FDA approves a product, it may limit the approved therapeutic uses for the product as described in the product labeling, require that warning statements be included in the product labeling, require that additional studies be conducted following approval as a condition of the approval, impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Post NDA Regulation</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Significant legal and regulatory requirements also apply after FDA approval to market under an NDA. These include, among other things, requirements related to adverse event and other reporting, product advertising and promotion and ongoing adherence to cGMPs, as well as the need to submit appropriate new or supplemental applications and obtain FDA approval for certain changes to the approved product labeling, or manufacturing process. The FDA also enforces the requirements of the Prescription Drug Marketing Act which, among other things, imposes various requirements in connection with the distribution of product samples to physicians.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The regulatory framework applicable to the production, distribution, marketing, and/or sale, of our product pipleline may change significantly from the current descriptions provided herein in the time that it may take for any of our products to reach a point at which an NDA is approved.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Overall research, development, and approval times depend on a number of factors, including the period of review at FDA, the number of questions posed by the FDA during review, how long it takes to respond to the FDA&#8217;s questions, the severity or life-threatening nature of the disease in question, the availability of alternative treatments, the availability of clinical investigators and eligible patients, the rate of enrollment of patients in clinical trials, and the risks and benefits demonstrated in the clinical trials.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other United States Regulatory Requirements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the United States, the research, manufacturing, distribution, sale, and promotion of drug and biological products are potentially subject to regulation by various federal, state, and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services (formerly the Heath Care Financing Administration), other divisions of the United States Department of Health and Human Services (e.g., the Office of Inspector General), the United States Department of Justice and individual United States Attorney offices within the Department of Justice, and state and local governments. For example, sales, marketing, and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the False Claims Act, the privacy provision of the Health Insurance Portability and Accountability Act, and similar state laws, each as amended. Pricing and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Health Care Act of 1992, each as amended. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially subject to federal and state consumer protection, unfair competition, and other laws.</font></div>
<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">37</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage43"><!--EFPlaceholder--></a>Moreover, we are now, and may become subject to, additional federal, state, and local laws, regulations, and policies relating to safe working conditions, laboratory practices, the experimental use of animals, and/or the use, storage, handling, transportation, and disposal of human tissue, waste, and hazardous substances, including radioactive and toxic materials and infectious disease agents used in conjunction with our research work.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Foreign Regulatory Requirements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We and any future collaborative partners may be subject to widely varying foreign regulations, which may be quite different from those of the FDA, governing clinical trials, manufacture, product registration and approval, and pharmaceutical sales. Whether or not FDA approval has been obtained, we or any future collaboration partners must obtain a separate approval for a product by the comparable regulatory authorities of foreign countries prior to the commencement of product marketing in these countries. In certain countries, regulatory authorities also establish pricing and reimbursement criteria. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. In addition, under current United States law, there are restrictions on the export of products not approved by the FDA, depending on the country involved and the status of the product in that country.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Reimbursement and Pricing Controls</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In many of the markets where we or any future collaborative partners would commercialize a product following regulatory approval, the prices of pharmaceutical products are subject to direct price controls (by law) and to drug reimbursement programs with varying price control mechanisms. Public and private health care payors control costs and influence drug pricing through a variety of mechanisms, including through negotiating discounts with the manufacturers and through the use of tiered formularies and other mechanisms that provide preferential access to certain drugs over others within a therapeutic class. Payors also set other criteria to govern the uses of a drug that will be deemed medically appropriate and therefore reimbursed or otherwise covered. In particular, many public and private health care payors limit reimbursement and coverage to the uses of a drug that are either approved by the FDA or that are supported by other appropriate evidence (for example, published medical literature) and appear in a recognized drug compendium. Drug compendia are publications that summarize the available medical evidence for particular drug products and identify which uses of a drug are supported or not supported by the available evidence, whether or not such uses have been approved by the FDA. For example, in the case of Medicare coverage for physician-administered oncology drugs, the Omnibus Budget Reconciliation Act of 1993, with certain exceptions, prohibits Medicare carriers from refusing to cover unapproved uses of an FDA-approved drug if the unapproved use is supported by one or more citations in the American Hospital Formulary Service Drug Information the American Medical Association Drug Evaluations, or the United States Pharmacopoeia Drug Information. Another commonly cited compendium, for example under Medicaid, is the DRUGDEX Information System.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During 2009 and 2010, there have been positive developments regarding medical reimbursement for therapeutic radiopharmaceuticals in the United States.&#160; The Centers for Medicare and Medicaid Services have proposed that the reimbursement for radiopharmaceuticals shift from a cost-to-charge ratio (&#8220;CCR&#8221;) to an average selling price (&#8220;ASP&#8221;) plus 4% model.&#160; There has been support expressed for this proposal by government agencies, key industry members and the industry consortium, The Council on Radionuclides and Radiopharmaceuticals.&#160; The historical CCR model resulted in a reimbursement rate that was lower than the cost to purchase the drugs, thus creating a disincentive for hospitals to prescribe radiopharmaceuticals.&#160; The current ASP proposal is a solution to this reimbursement problem.&#160; Furthermore, there are proposals pending, which, if adopted, would decrease the physician reimbursement for chemotherapy and conventional radiation therapy.&#160; The proposed reduction in physician reimbursement for chemotherapy could likely result in the movement of a large volume of cancer care from the physician&#8217;s office to the hospital environment.&#160; The proposed reduction in physician reimbursement for radiation therapy would result in a gap in revenue for radiation oncologists.&#160; Both proposed reductions favor an increase in opportunities to prescribe therapeutic radiopharmaceuticals.&#160; In fact, Zevalin&#174; had an 84% increase in 2010 revenues versus 2009, according to Spectrum&#8217;s Form 10-K for the year ended December 31, 2010.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LITIGATION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A putative federal securities class action complaint was filed on March 5, 2010 in the United States District Court for the District of Massachusetts by an alleged shareholder of Novelos, on behalf of himself and all others who purchased or otherwise acquired our common stock in the period between December 14, 2009 and February 24, 2010, against Novelos and our President and Chief Executive Officer, Harry S. Palmin.&#160; On October 1, 2010, the court appointed lead plaintiffs (Boris Urman and Ramona McDonald) and appointed lead plaintiffs&#8217; counsel.&#160; On October 22, 2010, an amended complaint was filed.&#160; The amended complaint claims, among other things, that the defendants violated Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder in connection with alleged misleading disclosures related to the progress of the Phase 3 clinical trial of NOV-002 for non-small cell lung cancer.&#160; On December 6, 2010, we filed a motion to dismiss the complaint with prejudice.&#160; On January 20, 2011, the plaintiffs filed their opposition to our motion and on March 3, 2011, we filed our response to their opposition. On June 23, 2011, the motion to dismiss was granted and the case was dismissed without prejudice.&#160; &#160;On August 5, 2011, the plaintiffs filed a second amended complaint realleging that the defendants violated Section 10(b) of the Exchange Act and Rule 10b-5 in connection with alleged misleading disclosures related to the Phase 3 clinical trial for NOV-002 in non-small cell lung cancer. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On September 9, 2011, the defendants filed a motion to dismiss the second amended complaint. The plaintiff<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#8217;</font>s opposition to the motion&#160;was filed on&#160;October 14, 2011 <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and the defendants filed a reply brief on November 4, 2011</font>. </font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Company and Mr. Palmin believe the allegations are without merit and intend to vigorously defend against them.</font> </div>
<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">38</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On June 28, 2010, we received a letter from counsel to ZAO BAM and ZAO BAM Research Laboratories (Russian companies, collectively referred to as &#8220;BAM&#8221;) alleging that we modified the chemical composition of NOV-002 without prior notice to or approval from BAM, constituting a material breach of a technology and assignment agreement we had entered into with BAM on June 20, 2000 (the &#8220;June 2000 Agreement&#8221;).&#160; The letter references our amendment, submitted to the FDA on August 30, 2005, to our investigational new drug application dated August 1999 as the basis for BAM&#8217;s claims and demands the transfer of all intellectual property rights concerning NOV-002 to BAM.&#160; Mark Balazovsky, a director of Novelos from June 1996 until November 2006 and a shareholder of Novelos through at least June 25, 2010, is, to our knowledge, still the general director and principal shareholder of ZAO BAM.&#160; On September 24, 2010, we filed a complaint in Suffolk Superior Court seeking a declaratory judgment by the court that the June 2000 Agreement has been replaced by a subsequent agreement between the parties dated April 1, 2005 (the &#8220;April 2005 Agreement&#8221;), that Novelos&#8217; obligations to BAM are governed solely by the April 2005 Agreement and that the obligations of the June 2000 agreement have been performed and fully satisfied.&#160; On November 29, 2010, BAM answered the complaint, denying the material allegations, and stating its affirmative defenses and certain counterclaims. On January 14, 2011, we responded to the counterclaims, denying BAM&#8217;s material allegations and stating our affirmative defenses.&#160; On June 9, 2011, BAM filed an amended counterclaim alleging additional claims related to Novelos&#8217; acquisition of Cellectar.&#160; In that amended counterclaim, BAM alleges that the acquisition evidences Novelos&#8217; abandonment of the technology assigned to it by BAM constituting a breach of the June 2000 Agreement or, if that agreement is determined to no longer be in effect, a breach of the April 2005 Agreement and/or a breach of the implied duty of good faith and fair dealing with respect to the April 2005 Agreement.&#160; &#160;On June 15, 2011 we filed our response to their amended counterclaim.&#160; On August 5, 2011, we filed a motion for judgment on the pleadings as to our declaratory judgment count and all counts of BAM&#8217;s amended counterclaim.&#160; The motion&#160;was opposed by BAM and a hearing on the motion&#160;was&#160;held&#160;on September 27, 2011. <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On October 17, 2011, the court ruled on our <font style="DISPLAY: inline; FONT-SIZE: 10pt">behalf for each of our declaratory judgment claims and dismissed all counts of BAM&#8217;s counterclaim. Judgment in favor of the Company was entered on October 20, 2011 and BAM has until November 21, 2011 to appeal or otherwise seek post-judgment relief.</font></font></font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="FIS_PROPERTIES"><!--EFPlaceholder--></a>PROPERTIES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We lease our executive office in Newton, Massachusetts.&#160; Our office consists of approximately 2,000 square feet and is rented for approximately $5,300 per month.&#160; This lease may be terminated by either party with one month notice.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We lease office, laboratory and manufacturing space in Madison, WI.&#160; The space consists of approximately 19,500 square feet and is rented for approximately $12,600 per month and expires on September 14, 2012.&#160; The lease may be renewed for two-year periods through 2024 with an increase of 3% in annual rent.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We believe that our present facilities are adequate to meet our current needs.&#160; If new or additional space is required, we believe that adequate facilities are available at competitive prices.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_MANAGEMENT"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">MANAGEMENT</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">As of November 4, 2011, our directors and executive officers are:</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><a name="FIS_NAME_AND_TITLE"><!--EFPlaceholder--></a><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Age</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Position</font></div>
</td>
</tr><tr>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="58%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stephen A. Hill, B.M. B.Ch., M.A., F.R.C.S. (3)</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">53</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chairman of the Board (term expiring at 2012 annual meeting or upon his successor being duly elected and qualified)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Harry S. Palmin</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">41</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">President, Chief Executive Officer and Director (term as Director expiring at 2013 annual meeting or upon his successor being duly elected and qualified)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Kimberly A. Hawkins</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vice President of Clinical Development</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Christopher J. Pazoles, Ph.D.</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">61</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Senior Vice President of Research and Development</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Joanne M. Protano</font> </div>
</td>
<td valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">43</font> </div>
</td>
<td valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vice President, Chief Financial Officer and Treasurer</font> </div>
</td>
</tr><tr>
<td align="left" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Jamey P. Weichert, Ph.D.</font> </div>
</td>
<td valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">55</font> </div>
</td>
<td valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Scientific Officer and Director (term as Director expiring at 2013 annual meeting or upon his successor being duly elected and qualified)</font> </div>
</td>
</tr><tr>
<td align="left" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas Rockwell Mackie, Ph.D. (2)</font> </div>
</td>
<td valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">57</font> </div>
</td>
<td valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director (term expiring at 2011 annual meeting or upon his successor being duly elected and qualified)</font> </div>
</td>
</tr><tr>
<td align="left" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">James S. Manuso, Ph.D. (2)(3)</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">62</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director (term expiring at 2011 annual meeting or upon his successor being duly elected and qualified)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">John Neis (1)(2)</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">56</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director (term expiring at 2012 annual meeting or upon his successor being duly elected and qualified)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">John E. Niederhuber, M.D. (1)(3)</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">73</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director (term expiring at 2011 annual meeting or upon his successor being duly elected and qualified)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Howard M. Schneider (1)</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">67</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director (term expiring at 2013 annual meeting or upon his successor being duly elected and qualified)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Michael F. Tweedle, Ph.D. (2)</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">60</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director (term expiring at 2012 annual meeting or upon his successor being duly elected and qualified)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font></div>

<div>
<hr style="COLOR: black" align="center" noshade size="1" width="20%">
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 54pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(1)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Member of the audit committee.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 54pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(2)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Member of the compensation committee</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 54pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(3)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Member of the nominating and corporate governance committee</font></font></div>
</td>
</tr></table>
</div>

<div>&#160;<a name="eolPage45"><!--EFPlaceholder--></a></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">39</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our executive officers are appointed by, and serve at the discretion of, our board of directors.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Stephen A. Hill</font>.&#160; Dr. Hill was elected the chairman of the board of directors of Novelos in September 2007. Dr. Hill has been the President and CEO of 21CB since March 2011.&#160; 21CB is a nonprofit initiative of UPMC designed to provide the United States government with a domestic solution for its biodefense and infectious disease biologics portfolio.&#160; Dr. Hill served as the President and Chief Executive Officer of Solvay Pharmaceuticals, Inc. since April 2008 until its acquisition by Abbott Laboratories in 2010.&#160; Prior to joining Solvay, Dr. Hill had served as ArQule's President and Chief Executive Officer since April 1999.&#160; Prior to his tenure at ArQule, Dr. Hill was the Head of Global Drug Development at F. Hoffmann-La Roche Ltd. from 1997 to 1999.&#160; Dr. Hill joined Roche in 1989 as Medical Adviser to Roche Products in the United Kingdom.&#160; He held several senior positions at Roche, including Medical Director where he was responsible for clinical trials of compounds across a broad range of therapeutic areas, including CNS, HIV, cardiovascular, metabolic and oncology products.&#160; Subsequently, he served as Head of International Drug Regulatory Affairs at Roche headquarters in Basel, Switzerland, where he led the regulatory submissions for seven major new chemical entities.&#160; Dr. Hill also was a member of Roche's Portfolio Management, Research, Development and Pharmaceutical Division Executive Boards.&#160; Prior to Roche, Dr. Hill served seven years with the National Health Service in the United Kingdom in General and Orthopedic Surgery.&#160; Dr. Hill is a Fellow of the Royal College of Surgeons of England and holds his scientific and medical degrees from St. Catherine's College at Oxford University. Dr. Hill&#8217;s extensive experience in a broad range of senior management positions with companies in the life sciences sector make him a highly qualified member of our board of directors.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Harry S. Palmin</font>.&#160; &#160;Mr. Palmin has served as our president and a director since 1998 and our chief executive officer since January 2005.&#160; From 1998 to September 2005, he served as our acting chief financial officer.&#160; From 1996 to 1998, he was a vice president at Lehman Brothers and from 1993 to 1996, he was an associate at Morgan Stanley &amp; Co.&#160; Mr. Palmin earned a B.A. in economics and business and a M.A. in international economics and finance from the International Business School at Brandeis University.&#160; He has also studied at the London School of Economics and the Copenhagen Business School.&#160; Mr. Palmin&#8217;s experience managing the funding and development of our product candidates for 13 years and his knowledge of capital markets are strong qualifications to serve on our board of directors.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Kimberly A. Hawkins.&#160; </font>Ms. Hawkins has served as our vice president of clinical development since November 2010 and served as our director of clinical development since May 2006. She has worked for 17 years in the biopharmaceutical industry managing and overseeing clinical operations for multiple global Phase 1, 2 and 3 clinical studies. From 2001 to 2006, Ms. Hawkins was a senior manager in clinical development at Antigenics, Inc., a cancer biotechnology company where she managed multiple Phase 1 and 2 studies.&#160; From 1994 to 2001 she was employed by Genzyme Corporation, Center for Clinical Research Practice where she held the positions of clinical research associate, trainer of good clinical practice and study coordinator.&#160; From 1993 to 1994 she held the position of clinical research coordinator at Boston Medical Center. Ms. Hawkins has a B.S. degree in Human Physiology from Boston University and a Masters Degree in Public Health from Boston University School of Public Health.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Christopher J. Pazoles</font>.&#160; Dr. Pazoles has served as our vice president of research and development since July 2005.&#160; He has 30 years of biopharmaceutical research and development and senior management experience.&#160; From May 2004 to June 2005, he held a senior research and development position at the Abbott Bioresearch Center, a division of Abbott Laboratories.&#160; From October 2002 to January 2004, he served as chief operating officer and head of research and development at ALS Therapy Development Foundation.&#160; From 1994 to October 2002, Dr. Pazoles served as vice president of research for Phytera, Inc.&#160; From 1981 to 1994, he served as a researcher and senior manager with Pfizer.&#160; Dr. Pazoles holds a Ph.D. in microbiology from the University of Notre Dame.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Joanne M. Protano</font>.&#160; Ms. Protano was appointed our vice president, chief financial and accounting officer, and treasurer in December 2007.&#160; She has 20 years of finance and senior management experience. She previously held the position of Senior Director of Finance and Controller of the Company from June 2006 to December 2007.&#160; From 1996 to 2006, she held various management and senior management positions with Ascential Software, Inc. and predecessor companies including Assistant Controller, Reporting for Ascential Software, Vice President and Chief Financial Officer for the Ascential Software Division of Informix Software, Inc. and Corporate Controller of Ardent Software, Inc.&#160; Prior to her tenure in the technology industry, from 1990 to 1996 she was employed by Deloitte and Touche LLP as an audit manager, serving technology and healthcare clients.&#160; Ms. Protano received a B.S. in business administration from Bryant College.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Jamey P. Weichert.&#160; </font>Dr. Weichert was the primary founder of Cellectar serving as Cellectar&#8217;s Chairman and Chief Scientific Officer since 2002.&#160; He was appointed as the Chief Scientific Officer and a director of Novelos at the time of the Acquisition.&#160; Dr. Weichert is an Associate Professor of the Departments of Radiology, Medical Physics, Pharmaceutics and member of the Comprehensive Cancer Center at the University of Wisconsin, Madison.&#160; He has a bachelors degree in chemistry from the University of Minnesota and a doctorate in medicinal chemistry from U. Mich..&#160; His research interests include the design, synthesis and evaluation of biomimetic CT and MRI imaging agents and diapeutic radiopharmaceuticals.&#160; He has been involved in molecularly targeted imaging agent development his entire professional career and has developed or co-developed several imaging agents nearing clinical trial status. Dr. Weichert serves or has served on the editorial boards of numerous scientific journals and has authored more than 40 peer reviewed publications and 150 abstracts.&#160; He also has 20 issued or pending patents related to drug delivery, imaging and contrast agent development.&#160; Dr. Weichert&#8217;s experience founding and managing the development of Cellectar&#8217;s product candidates and his knowledge of radiation technology are strong qualifications to serve on our board of directors.</font></div>
<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">40</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Thomas Rockwell Mackie.&#160; </font>&#160;Dr. Mackie became a director of the Company at the time of the Acquisition. He served as a director of Cellectar since December 2006.&#160; In 1997, he co-founded TomoTherapy Incorporated, a maker of advanced radiation therapy solutions for the treatment of cancer and other diseases and served as Chairman of its board of directors from 1999 until its Acquisition by Accuray Incorporated in June 2011. Dr. Mackie also served as President of TomoTherapy Inc. from 1997 until 1999 and as Treasurer from 1997 until 2000. Since 1987, Dr. Mackie has been a professor in the departments of Medical Physics and Human Oncology at the University of Wisconsin, where he established the TomoTherapy research program. Dr. Mackie also co-founded Geometrics Corporation (now merged with ADAC Corp.), which developed a radiotherapy treatment planning system. Dr. Mackie currently serves as a director of Shine Medical Technologies and Bioionix Inc. and served on the management committee of Wisconsin Investment Partners from 2006 to 2009.&#160; &#160;Dr. Mackie has a B.Sc. in Physics from the University of Saskatchewan and a Ph.D. in Physics from the University of Alberta in Edmonton. Dr. Mackie&#8217;s qualifications to serve on our board of directors include his extensive senior management experience with radiation technology companies.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">James S. Manuso</font>.&#160; Dr. Manuso has served as one of our directors since August 2007.&#160; Since January 2005, Dr. Manuso has served as Chairman and Chief Executive Officer of SuperGen, Inc. (now renamed Astex Pharmaceuticals, Inc.), served as President&#160;of SuperGen from January 2005&#160;through July 2011 and has served as a director of SuperGen since February 2001.&#160; Dr. Manuso is co-founder and former president and chief executive officer of Galenica Pharmaceuticals, Inc.&#160; Dr. Manuso co-founded and was general partner of PrimeTech Partners, a biotechnology venture management partnership, from 1998 to 2002, and Managing General Partner of The Channel Group LLC, an international life sciences corporate advisory firm.&#160; He was also president of Manuso, Alexander &amp; Associates, Inc., management consultants and financial advisors to pharmaceutical and biotechnology companies.&#160; Dr. Manuso was a vice president and Director of Health Care Planning and Development for The Equitable Companies (now Group Axa), where he also served as Acting Medical Director. He currently serves on the board of directors of the Biotechnology Industry Organization (BIO) and its Health Section Governing Board and serves on the board of privately-held KineMed, Inc.&#160; He previously served on the boards of Merrion Pharmaceuticals Ltd. (Dublin, Ireland)&#160;&#160;&#160;Inflazyme Pharmaceuticals, Inc. (Vancouver, Canada), Symbiontics, Inc., (ZyStor, Inc., sold to BioMarin), Quark Biotech, Inc., Galenica Pharmaceuticals, Inc., Supratek Pharma, Inc., and EuroGen, Ltd. (London, UK).&#160; Dr. Manuso earned a B.A. in economics and chemistry from New York University, a Ph.D. in experimental psychophysiology from the Graduate Faculty of The New School University, a certificate in health systems management from Harvard Business School, and an executive M.B.A. from Columbia Business School.&#160; Dr. Manuso&#8217;s experience founding, leading and serving as a director for pharmaceutical companies makes him a highly qualified member of our board of directors.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">John Neis.&#160; </font>Mr. Neis became a director of our Company at the time of the Acquisition. He served as director of Cellectar since February 2008.&#160; Mr. Neis has been Managing Director of Venture Investors LLC since 1986 and heads the firm&#8217;s Healthcare practice. He has over 23 years in the venture capital industry and serves on the Board of Directors of companies from formation through initial public offering or sale.&#160; Mr. Neis also currently serves on the boards of directors of Virent Energy Systems, Deltanoid Pharmaceuticals, Inviragen, Inc. and Mithridion, Inc. He is a former member of the Boards of Directors of several firms including TomoTherapy, Third Wave Technologies (acquired by Hologic) and NimbleGen Systems (acquired by Roche).&#160; Mr. Neis was appointed to the Board of the Wisconsin Technology Council and he also serves on the advisory boards for the Weinert Applied Ventures Program, the University of Wisconsin, Madison Business School and Tandem Press.&#160; Mr. Neis has a B.S. in Finance from the University of Utah, and a M.S. in Marketing and Finance from the University of Wisconsin, Madison. He is a Chartered Financial Analyst. Mr. Neis&#8217; extensive experience leading emerging companies make him a highly qualified member of our board of directors.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><a name="eolPage47"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">John E. Niederhuber.&#160; </font>&#160;&#160;Dr. Niederhuber became a director of our Company at the time of the Acquisition.&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">From August 2010 to the present, Dr. Niederhuber has served as executive vice president of Inova Health System and chief executive officer of the Inova Translational Medicine Institute. Since July 2011, he has been an adjunct Professor of Oncology at the Johns Hopkins University School of Medicine and Deputy Director of The Johns Hopkins Clinical Research Network. Since August 2010, Dr. Niederhuber has served as a Director on the Emergent Biosolutions Board.</font> Dr. Niederhuber&#160;&#160;served as Director of the National Cancer Institute (NCI) from 2005 to 2010. He has also served as NCI's Chief Operating Officer and Deputy Director for Translational and Clinical Sciences. Dr. Niederhuber served as Chair of the National Cancer Advisory Board (NCAB) from 2002 to 2004. In addition to his management and advisory roles, Dr. Niederhuber has remained involved in research, through his laboratory on the National Institutes of Health (NIH) campus. Under his leadership, the Tumor and Stem Cell Biology Section, which is a part of the Cell and Cancer Biology Branch of NCI's Center for Cancer Research, is studying tissue stem cells as the cell-of-origin for cancer.&#160; Dr. Niederhuber also holds a clinical appointment on the NIH Clinical Center Medical Staff.&#160; As a surgeon, Dr. Niederhuber's clinical emphasis is on gastrointestinal cancer, hepatobiliary (liver, bile duct, and gall bladder) cancer, and breast cancer. He is recognized for his pioneering work in hepatic artery infusion chemotherapy and was the first to demonstrate the feasibility of totally implantable vascular access devices. Dr. Niederhuber is a graduate of Bethany College in West Virginia and the Ohio State University School of Medicine. He was an NIH Academic Trainee in Surgery at the University of Michigan from 1969 to 1970 and was a Visiting Fellow in the Division of Immunology at The Karolinska Institute in Stockholm, Sweden from 1970 to 1971. He completed his training in surgery at the University of Michigan in 1973 and was a member of the faculty of the University of Michigan from 1973 to 1987, being promoted to Professor of Microbiology/Immunology and Professor of Surgery in 1980. During 1986 and 1987, he was Visiting Professor in the Department of Molecular Biology and Genetics at The Johns Hopkins University School of Medicine in Baltimore, MD.&#160; Dr. Niederhuber&#8217;s qualifications to serve on our board of directors include his extensive experience with cancer research.</font> </div>
<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">41</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Howard M. Schneider</font>.&#160; Mr. Schneider has served as one of our directors since February 2005.&#160; Mr. Schneider is currently retired.&#160; From January to December 2003, he served as chief executive officer of Metrosoft, Inc., and had been an advisor to such company from July to December 2002.&#160; From May 2000 to May 2001, he served as president of Wofex Brokerage, Inc. and from 1965 to 1999, he served as an executive at Bankers Trust Company holding a variety of positions in the commercial banking and investment banking businesses.&#160; Mr. Schneider received a B.A. in economics from Harvard College and a M.B.A. from New York University.&#160; Mr. Schneider&#8217;s extensive senior management experience in the financial sector makes him a highly qualified member of our board of directors.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Michael F. Tweedle.&#160; &#160;</font> Dr. Tweedle became a director of Novelos at the time of the Acquisition.&#160;Since May 2009 he has served as&#160;Professor and Stefanie Spielman Chair in Cancer Imaging in Radiology and the James Comprehensive Cancer Center of Ohio State University, Director of the Wright Center Molecular Imaging (MI) Agents Laboratory of Ohio State University, and since May 2010, has had an adjunct appointment in the Chemistry Department of Ohio State University. Prior to joining Ohio State University, his academic appointments included Adjunct Associate Professor at University of Pennsylvania and the Science Advisory Board of New York University. Dr. Tweedle was the President of Bracco Research USA Inc. from 1995 to 2009 where he was the lead scientist and chief executive for creation of new molecular imaging pharmaceuticals. His industrial experience in drug discovery research also includes appointments at the Diagnostics Drug Discovery Division at Bristol-Myers Squibb, New England Nuclear, NEN/DuPont Pharmaceuticals, and The Squibb Institute for Medical Research.&#160; He has invented and led translational development of diagnostic imaging pharmaceuticals for nuclear medicine, one of the first Gd-based MRI agents (ProHance TM ), X ray, Optical and US agents, and a radiotheranostic. In 2005 he won the Harry Fisher Medal.&#160; Dr. Tweedle holds a B.A from Knox College, B.A. (1973), a Ph.D. from Rice University (1978) and was a Stanford University NRS Fellow.&#160; Dr. Tweedle&#8217;s qualifications to serve on our board of directors include his extensive experience with radiation and cancer research and drug discovery.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Code of Ethics</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The board of directors has adopted a Code of Ethics applicable to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. A copy of the Code of Ethics is available at our website www.novelos.com.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;<!--EFPlaceholder--></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Compensation of Directors and Executive Officers (Pro forma for Offering Reverse Split)</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Summary Compensation:</font> The following table sets forth certain information about the compensation we paid or accrued with respect to our principal executive officer and our two most highly compensated executive officers (other than our chief executive officer) who served as executive officers during the year ended December 31, 2010 and whose annual compensation exceeded $100,000 for that year. <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The share and per share information set forth in the notes to the following table give effect to an estimated 1-for-10 Offering Reverse Split.</font></font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other annual compensation in the form of perquisites and other personal benefits has been omitted as the aggregate amount of those perquisites and other personal benefits was less than $10,000 for each person listed.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_COMPENSATION_TABLE"><!--EFPlaceholder--></a><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="42%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name and Principal Position</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Year</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Salary</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">($)</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Bonus</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">($)</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(4)</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Option</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Awards ($)</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(5)</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Total ($)</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="42%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="42%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Harry S. Palmin (1)</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">270,000</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">0</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">0</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">270,000</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="42%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">President, Chief Executive Officer</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">270,000</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">40,500</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">131,650</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">442,150</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="42%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="42%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Christopher J. Pazoles (2)</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td valign="top" width="1%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">235,000</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">39,167</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">0</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">274,167</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="42%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vice President of Research and Development</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">235,000</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">35,250</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">105,320</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">375,570</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="42%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="42%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Elias B. Nyberg (3)</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">225,000</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">37,500</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">0</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">262,500</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="42%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vice President of Regulatory, Quality and Compliance</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">225,000</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">33,750</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">78,990</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">337,740</font></font></td>
<td nowrap valign="top" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 22.2pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(1)</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">There has been no increase to Mr. Palmin&#8217;s annual salary for 2011. On May 18, 2011, Mr. Palmin was granted an option to purchase 134,040 shares of common stock at an exercise price of $14.00 per share, which option will vest with respect to: 67,020 such shares in equal quarterly installments over a four-year period; 16,755 such shares upon the closing of one or more financings with total gross proceeds of at least $10 million before December 31, 2011; 16,755 such shares upon the closing of one or more financings with total gross proceeds of at least $20 million before December 31, 2012; 16,755 such shares upon the availability of proof of concept data in man for LIGHT by December 31, 2011; and 16,755 such shares upon the initiation of a Phase 2a clinical trial for HOT by August 31, 2012.</font></font> </div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 22.2pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(2)</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">On May 18, 2011, Dr. Pazoles&#8217; annual salary was increased to $250,000 and he was granted an option to purchase 20,000 shares of common stock at an exercise price of $14.00 per share, which option will vest in equal quarterly installments over a three-year period.</font></font> </div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 22.2pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(3)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">On March 10, 2011, the Company terminated Dr. Nyberg&#8217;s employment. In connection with that termination, which was without cause, Dr. Nyberg received a payment of approximately $83,000 pursuant to the terms of the executive retention agreement between him and the Company dated May 14, 2010.</font></font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">42</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 22.2pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(4)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Bonus amounts for 2009 were paid in 2010.&#160; Bonus amounts for Dr. Pazoles and Dr. Nyberg in 2010 represent retention bonuses paid as of October 1, 2010 pursuant to their respective retention agreements dated May 14, 2010.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 22.2pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(5)</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">The fair value of each stock award was estimated on the grant date using the Black-Scholes option-pricing model. See Note 7 to the pre-acquisiton financial statements for a description of the assumptions used in estimating the fair value of stock options. There were no option grants during 2010.</font></font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment Agreements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On January 31, 2006, we entered into an employment agreement with Harry Palmin effective January 1, 2006, whereby he agreed to serve as our president and chief executive officer for an initial term of two years at an annual salary of $225,000.&#160; The agreement is automatically renewed for successive one-year terms unless notice of termination is provided by either party at least 90 days prior to the end of such term.&#160; The agreement was renewed for an additional one-year term on January 1, 2011 in accordance with its terms.&#160; On December 17, 2007, the Board of Directors approved an increase in Mr. Palmin&#8217;s annual salary to $270,000 effective January 1, 2008.&#160; He is eligible to receive an annual cash bonus at the discretion of the compensation committee and he is entitled to participate in our employee fringe benefit plans or programs generally available to our senior executives.&#160; The agreement provides that in the event that we terminate Mr. Palmin without cause (as defined below)&#160;or he resigns for good reason (as defined below), we will (i) pay Mr. Palmin his pro rata share of the average of his annual bonus paid during the two fiscal years preceding his termination; (ii) pay Mr. Palmin his base salary for 11 months after the date of termination; (iii) continue to provide him benefits for 11 months after the date of termination; and (iv) fifty percent of his unvested stock options will vest.&#160; The agreement provides for the vesting of unvested options upon a Change of Control, defined as the sale of all or substantially all of the assets or issued and outstanding capital stock of the Company, (ii) merger or consolidation involving the Company in which stockholders of the Company immediately before such merger or consolidation do not own immediately after such merger or consolidation capital stock or other equity interests of the surviving corporation or entity representing more than fifty percent (50%) in voting power of capital stock or other equity interests of such surviving corporation or entity outstanding immediately after such merger or consolidation, or (iii) a change, without the approval of the board of directors, in the composition of the board of directors such that directors who were serving as of the date of the agreement cease to constitute a majority of the board of directors. The agreement also contains a non-compete provision, which prohibits Mr. Palmin from competing with us for one year after termination of his employment with us.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Cause&#8221; means (i) gross neglect of duties for which employed; (ii) committing fraud, misappropriation or embezzlement in the performance of duties as our employee; (iii) conviction or guilty or nolo plea of a felony or misdemeanor involving moral turpitude; or (iv) willfully engaging in conduct materially injurious to us or violating a covenant contained in the employment agreement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Good Reason&#8221; means (i) the failure of our board of directors to elect Mr. Palmin to the offices of president and chief executive officer; (ii) the failure by our stockholders to continue to elect Mr. Palmin to our board of directors; (iii) our failure to pay Mr. Palmin the compensation provided for in the employment agreement, except for across-the-board cuts applicable to all of our officers on an equal percentage basis, provided that such reduction is approved by our board of directors; (iv) relocation of Mr. Palmin&#8217;s principal place of employment to a location beyond 50 miles of Newton, Massachusetts; (v) a reduction of base salary or material reduction in other benefits or any material change by us to Mr. Palmin&#8217;s function, duties, authority, or responsibilities, which change would cause Mr. Palmin&#8217;s position with us to become one of lesser responsibility, importance, or scope; and (vi) our material breach of any of the other provisions of the employment agreement.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 1, 2011, the employment agreement between the Company and Harry Palmin dated January 31, 2006 was amended to remove the obligation of the Company to continue to pay Mr. Palmin&#8217;s salary and benefits for a period of 11 months following termination by the Company without Cause or termination by Mr. Palmin with Good Reason.&#160; The Company may elect that the obligation of Mr. Palmin not to compete with the Company survive for a period of one year from his termination, provided however that Mr. Palmin would continue to receive his base salary during that one-year noncompetition period.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We have entered into retention agreements with each of our four vice presidents.&#160; The agreements provide for the lump-sum payment of six months&#8217; base salary and benefits to each such officer following a termination without cause or a resignation with good reason occurring on or before November 14, 2011.&#160; Certain of the agreements provide that if the executives were employed by us as of October 1, 2010, they would receive a payment of two months&#8217; base salary as a retention bonus on that date. The retention bonus was paid in October 2010 and will be deducted from the severance amounts that may become payable upon a subsequent involuntary termination.&#160; The total remaining amount that may become payable to our Named Executive Officers pursuant to the retention agreements is approximately $87,000 to Christopher Pazoles.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">43</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding Equity Awards at Fiscal Year-End (Pro forma for Offering Reverse Split)</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The following table sets forth certain information regarding stock options held as of December 31, 2010 by the executive officers named in the summary compensation table and gives effect to the April Reverse Split.&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The information in the following table gives effect to an estimated 1-for-10 Offering Reverse Split. </font>There were no option grants during 2010.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="29%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="15" valign="bottom" width="70%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Individual Grants</font></font></div>
</td>
</tr><tr>
<td valign="bottom" width="29%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Name</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Year</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">of Grant</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Number of</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">securities</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">underlying</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">unexercised</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">options</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(#</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">exercisable)</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Number of</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">securities</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">underlying</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">unexercised</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">options</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(#</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">unexercisable)</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise or</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">base price</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">($/share)</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Expiration</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">date</font></font></div>
</td>
</tr><tr>
<td valign="bottom" width="29%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="29%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Harry S. Palmin</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2009</font></font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1)</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">54</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">109</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1,147.50</font></font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12/8/2019</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="29%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2008</font></font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2)</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">174</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">87</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">657.90</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12/15/2018</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="29%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2007</font></font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2)</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">130</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">688.50</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12/17/2017</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="29%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2006</font></font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2)</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">98</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,392.30</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12/11/2016</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="29%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2005</font></font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3)</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">163</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15.30</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1/31/2015</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="29%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2005</font></font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3)</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">98</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15.30</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3/31/2015</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="29%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2004</font></font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4)</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">215</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15.30</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4/1/2014</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="29%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2003</font></font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5)</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,071.00</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8/1/2013</font> </div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="29%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="29%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Christopher J. Pazoles</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2009</font></font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1)</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">43</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">87</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1,147.50</font></font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12/8/2019</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="29%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2008</font></font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2)</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">87</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">43</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">657.90</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12/15/2018</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="29%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2007</font></font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2)</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">81</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">688.50</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12/17/2017</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="29%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2006</font></font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2)</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">65</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,392.30</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12/11/2016</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="29%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2005</font></font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6)</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">65</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15.30</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4/8/2015</font> </div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="29%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="29%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Elias B. Nyberg</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2009</font></font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1)</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">33</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">65</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1,147.50</font></font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12/8/2019</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="29%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2008</font></font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2)</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">43</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">22</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">657.90</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12/15/2018</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="29%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2008</font></font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7)</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">65</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">887.40</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4/1/2018</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(1)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">These shares vest quarterly in increments of one-twelfth over three years from the date of grant.&#160; The exercise price equals the closing price on the date of grant.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(2)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">These shares vest annually in increments of one-third over three years from the date of grant.&#160; The exercise price equals the closing price on the date of grant.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(3)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">These shares initially vested over a two-year period.&#160; Pursuant to their terms, the shares fully vested upon the completion of a non-bridge loan financing, which occurred in the second quarter of 2005.&#160; The exercise price equals the fair market value of our common stock on the date of grant as determined by our board of directors.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(4)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">These shares initially vested one-third upon grant and one-third annually over the following two years. Pursuant to their terms, one additional year of vesting occurred upon the completion of a non-bridge loan financing, which occurred in the second quarter of 2005.&#160; The exercise price equals the fair market value of our common stock on the date of grant as determined by our board of directors.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(5)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">These shares vest annually in increments of one-third over three years from the date of grant. The exercise price equals the fair market value of our common stock on the date of grant as determined by our board of directors.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(6)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">These shares vested in increments of one-fourth every six months over two years from the date of grant. The exercise price equals the fair market value of our common stock on the date of grant as determined by our board of directors.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(7)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">These shares were fully vested upon grant. The exercise price equals the closing price on the date of grant.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage50"><!--EFPlaceholder--></a>Options granted pursuant to the 2006 Stock Incentive Plan will become fully vested upon a termination event within one year following a change in control, as defined.&#160; A termination event is defined as either termination of employment other than for cause or constructive termination resulting from a significant reduction in either the nature or scope of duties and responsibilities, a reduction in compensation or a required relocation.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director Compensation (Pro forma for Offering Reverse Split)</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Summary Compensation:&#160;&#160;</font> The following table sets forth certain information about the compensation we paid or accrued with respect to our directors who served during the year ended December 31, 2010. <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The share and per share information set forth in the notes to the following table give effect to an estimated 1-for-10 Offering Reverse Split.</font></font> </div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">44</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><a name="FIS_NAME_AND_TITLE_2"><!--EFPlaceholder--></a><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="57%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Name and Principal Position</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Year</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Director</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Fees</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">($) (3)</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Total ($)</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="57%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="57%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stephen A. Hill, Chairman (1)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">39,500</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">39,500</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="57%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Michael J. Doyle, Director (1)(2)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">33,250</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">33,250</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="57%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Sim Fass, Director (1)(2)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="57%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">James S. Manuso, Director (1)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="57%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">David B. McWilliams, Director (1)(2)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="57%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Howard M. Schneider, Director (1)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(1)</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">As of December 31, 2010, outstanding options to purchase common stock held by directors were as follows:&#160;&#160;Dr. Hill 228; Mr. Doyle 228; Dr. Fass 228; Dr. Manuso 196; Mr. McWilliams 264; Mr. Schneider 163.</font></font> </div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(2)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">In connection with the Acquisition, Mr. Doyle, Dr. Fass and Mr. McWilliams resigned from the board of directors.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(3)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Director fees include all fees earned for director services including quarterly fees, meeting fees and committee chairman fees.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(4)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">There were no option grants during 2010.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">During 2010, we paid our non-employee directors a cash fee of $5,000 per quarter.&#160; The non-employee directors also received a fee of $1,500 for any board or committee meeting attended and $750 for each telephonic board or committee meeting in which the director participated.&#160; We also paid our chairman an additional annual fee in the amount of $15,000, our non-employee director who serves as the chair of the audit committee an additional annual fee of $10,000 and our non-employee directors who served as the chairman of the compensation and the nominating and corporate governance committees an additional annual fee of $5,000.&#160; We reimbursed directors for reasonable out-of-pocket expenses incurred in attending board and committee meetings and undertaking certain matters on our behalf.&#160; Directors who are our employees do not receive separate fees for their services as directors.&#160; There has been no change to cash fees payable to non-employee directors for 2011.&#160; On May 18, 2011 options to purchase 15,000 shares of common stock at $14.00 per share, vesting quarterly over two years were granted to our chairman Stephen Hill.&#160; On that same date, options purchase 10,000 shares of common stock at $14.00 per share, vesting quarterly over two years were granted to each of the six non-employee directors other than the chairman.</font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><a name="eolPage51"><!--EFPlaceholder--></a><a name="FIS_DIRECTOR_COMPENSATION"><!--EFPlaceholder--></a><a name="FIS_STOCKHOLDERS"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITY OWNERSHIP OF CERTAIN</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BENEFICIAL OWNERS AND MANAGEMENT</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">At the close of business on November 4, 2011, there were 2,682,615 shares of our common stock outstanding, giving effect to an estimated 1-for-10 Offering Reverse Split.&#160; The following table provides information regarding beneficial ownership of our common stock as of November 4, 2011, giving effect to an estimated 1-for-10 Offering Reverse Split:</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 35.4pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each person known by us to be the beneficial owner of more than five percent of our common stock;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 35.4pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Each of our directors;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 35.4pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Each executive officer named in the summary compensation table; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 35.4pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">All of our current directors and executive officers as a group.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The address of each executive officer and director is c/o Novelos Therapeutics, Inc., One Gateway Center, Suite 504, Newton, Massachusetts 02458.&#160; The persons named in this table have sole voting and investment power with respect to the shares listed, except as otherwise indicated.&#160; The inclusion of shares listed as beneficially owned does not constitute an admission of beneficial ownership.&#160; Shares included in the &#8220;Right to Acquire&#8221; column consist of shares that may be purchased through the exercise of options or warrants that are exercisable within 60 days of November 4, 2011.</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">45</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="47%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="14" valign="bottom" width="50%" style="BORDER-BOTTOM: #000000 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 13.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares Beneficially Owned (Pro forma for Offering Reverse Split)</font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr>
<td align="left" valign="bottom" width="47%" style="BORDER-BOTTOM: #000000 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name and Address of Beneficial Owner</font> </div>
</td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: #000000 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding</font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: #000000 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Right to Acquire</font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: #000000 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: #000000 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Percentage</font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr>
<td align="left" valign="bottom" width="47%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" colspan="2" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" colspan="2" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" colspan="2" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" colspan="2" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Venture Investors LLC (1) (2)</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">University Technology Park</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">505 S. Rosa Road; Suite 201</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Madison, WI&#160;&#160;53719</font> </div>
</td>
<td align="right" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">453,430</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">200,000</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">653,430</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">22.7</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="47%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Jamey P. Weichert (3)</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">c/o Novelos Therapeutics, Inc.</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3301 Agriculture Drive</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Madison, WI&#160;&#160;53716</font> </div>
</td>
<td align="right" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">470,673</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,266</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">472,939</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17.6</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="47%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Greenway Properties Inc. (2)(4)</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">725 Heartland Trail, Suite 102</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Madison, WI&#160;&#160;53707</font> </div>
</td>
<td align="right" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">133,740</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100,000</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">233,740</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8.4</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="47%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Continuum Investment Limited Partnership (5)</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">P.O. Box 620557</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Middleton, WI&#160;&#160;53562</font> </div>
</td>
<td align="right" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">180,852</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">180,852</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6.7</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="47%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Harry S. Palmin (6)</font> </div>
</td>
<td align="right" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">419</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,457</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,876</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">*</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Christopher J. Pazoles</font> </div>
</td>
<td align="right" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,763</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,763</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">*</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stephen A. Hill</font> </div>
</td>
<td align="right" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,978</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,978</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">*</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas Rockwell Mackie</font> </div>
</td>
<td align="right" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,612</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,500</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,112</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">*</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">James S. Manuso</font> </div>
</td>
<td align="right" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,695</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,695</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">*</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">John Neis (1) (7)</font> </div>
</td>
<td align="right" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">453,430</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">202,500</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">655,930</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">22.7</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">John E. Niederhuber</font> </div>
</td>
<td align="right" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,500</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,500</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">*</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Howard M. Schneider</font> </div>
</td>
<td align="right" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">65</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,662</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,727</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">*</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Michael F. Tweedle</font> </div>
</td>
<td align="right" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,500</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,500</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">*</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="47%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">All directors and officers as a group (12 persons)</font> </div>
</td>
<td align="right" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">936,199</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">240,342</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,176,541</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">40.3</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<hr style="COLOR: black" align="center" noshade size="1" width="20%">
</div>

<div>&#160;</div>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(1)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Ownership consists of shares of common stock held by Venture Investors Early Stage Fund IV Limited Partnership and Advantage Capital Wisconsin Partners I, Limited Partnership.&#160; VIESF IV GP LLC is the general partner of Venture Investors Early Stage Fund IV Limited Partnership and Venture Investors LLC is the submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of VIESF IV GP LLC and Venture Investors LLC are made collectively by six managers, including Mr. Neis.&#160; Each such manager and Mr. Neis disclaim such beneficial ownership except to the extent of his pecuniary interest therein.&#160; The address of Mr. Neis is c/o Venture Investors LLC, 505 South Rosa Road, #201, Madison, Wisconsin 53719.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(2)</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Shares in the &#8220;Right to Acquire&#8221; column consist of warrants to purchase common stock at a price of $7.50, expiring on March 31, 2016</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">.</font></font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(3)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Dr. Weichert serves as a director and our Chief Scientific Officer following the Acquisition. The shares beneficially owned by him have been included in the total of directors and officers as a group.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4)</font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Jeffrey Straubel is the President and principal owner of Greenway Properties, Inc. and has sole dispositive and voting power over shares held by Greenway Properties, Inc.</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(5)</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Ownership includes shares of common stock held by Cellectar Investor I, LLC.&#160; Continuum Investment Limited Partnership is the manager of Cellectar Investor I, LLC. Bruce Neviaser is the president of Continuum Investment Limited Partnership and has sole dispositive and voting power over shares held by Continuum Investment Limited Partnership and Cellectar Investor I, LLC.</font></font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6)</font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Ownership of H. Palmin includes shares owned by his wife, Deanna Palmin.</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7)</font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares in the &#8220;Right to Acquire&#8221; column consist of warrants to purchase 200,000 shares of common stock at a price of $7.50, expiring on March 31, 2016, held by Venture Investors Early Stage Fund IV Limited Partnership and options to purchase&#160;2,500 shares of common stock at $14.00 per share, held by Mr. Neis.</font> </div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">46</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage52"><!--EFPlaceholder--></a><a name="FIS_CERTAIN_TRANSACTIONS"><!--EFPlaceholder--></a>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We do not have a written policy for the review, approval or ratification of transactions with related parties or conflicted transactions.&#160; When such transactions arise they are referred to the Audit Committee for consideration or for referral to the Board of Directors for its consideration.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">One of our directors, John Neis, is a managing director of Venture Investors LLC which beneficially owns approximately 23% of our common stock.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Jamey Weichert, our Chief Scientific Officer, director, shareholder and principal founder of Cellectar is a faculty member at the University of Wisconsin-Madison (U. Wisc.).&#160; Cellectar paid $16,082 to the U. Wisc. during 2009 for research related activities.&#160; No payments were made to UW during the year ended December 31 2010. During the nine months ended September 30, 2011, we made contributions totaling $125,000 to the UW Foundation for use towards research activities associated with the development of our compounds.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are obligated to ZAO BAM, a Russian company engaged in the pharmaceutical business, under a royalty and technology transfer agreement. Mark Balazovsky, a director until November 2006, is the majority shareholder of ZAO BAM. Pursuant to the royalty and technology transfer agreement between Novelos and ZAO BAM, we are required to make royalty payments of 1.2% of net sales of oxidized glutathione-based products. We are also required to pay ZAO BAM $2 million for each new oxidized glutathione-based drug within eighteen months following FDA approval of such drug.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If a royalty is not being paid to ZAO BAM on net sales of oxidized glutathione products, then we are required to pay ZAO BAM 3% of all license revenues. If license revenues exceed our cumulative expenditures including, but not limited to, preclinical and clinical studies, testing, FDA and other regulatory agency submission and approval costs, general and administrative costs, and patent expenses, then we would be required to pay ZAO BAM an additional 9% of the amount by which license revenues exceed our cumulative expenditures. During 2008, we paid ZAO BAM $15,000, which was 3% of the upfront license payment received under the collaboration agreement with Lee&#8217;s Pharm, described in Note 5 to the financial statements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On June 28, 2010, we received a letter from counsel to ZAO BAM and ZAO BAM Research Laboratories (collectively, &#8220;BAM&#8221;) alleging that we modified the chemical composition of NOV-002 without prior notice to or approval from BAM, constituting a material breach of a technology and assignment agreement we had entered into with BAM on June 20, 2000 (the &#8220;June 2000 Agreement&#8221;).&#160; The letter references our amendment, submitted to the FDA on August 30, 2005, to our investigational new drug application dated August 1999 as the basis for BAM&#8217;s claims and demands the transfer of all intellectual property rights concerning NOV-002 to BAM.&#160; Mark Balazovsky, a director of Novelos from June 1996 until November 2006 and a shareholder of Novelos through at least June 25, 2010, is, to our knowledge, still the general director and principal shareholder of ZAO BAM.&#160; On September 24, 2010, we filed a complaint in Suffolk Superior Court seeking a declaratory judgment by the court that the June 2000 Agreement has been replaced by a subsequent agreement between the parties dated April 1, 2005 (the &#8220;April 2005 Agreement&#8221;), that the Company&#8217;s obligations to BAM are governed solely by the April 2005 Agreement and that the obligations of the June 2000 agreement have been performed and fully satisfied.&#160; &#160;On November 29, 2010, BAM answered our complaint, denying the material allegations and stating its affirmative defenses and certain counterclaims. On January 14, 2011, we responded to the counterclaims, denying BAM&#8217;s material allegations and stating our affirmative defenses. On June 9, 2011, BAM filed an amended counterclaim alleging additional claims related to Novelos&#8217; acquisition of Cellectar.&#160; In that amended counterclaim, BAM alleges that the acquisition evidences Novelos&#8217; abandonment of the technology assigned to it by BAM constituting a breach of the June 2000 Agreement or, if that agreement is determined to no longer be in effect, a breach of the April 2005 Agreement and/or a breach of the implied duty of good faith and fair dealing with respect to the April 2005 Agreement.&#160; On June 15, 2011 we filed our response to their amended counterclaim.&#160; On August 5, 2011, we filed a motion for judgment on the pleadings as to our declaratory judgment count and all counts of BAM&#8217;s amended counterclaim.&#160; The motion was opposed by BAM and a hearing on the motion&#160;was held&#160;on September 27, 2011. <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On October 17, 2011, the court ruled on our <font style="DISPLAY: inline; FONT-SIZE: 10pt">behalf for each of our declaratory judgment claims and dismissed all counts of BAM&#8217;s counterclaim. Judgment in favor of the Company was entered on October 20, 2011 and BAM has until November 21, 2011 to appeal or otherwise seek post-judgment relief.</font></font></font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As a result of the assignment to Novelos of the exclusive worldwide intellectual property and marketing rights of oxidized glutathione (excluding the Russian Territory), Novelos is obligated to the Oxford Group, Ltd., or its assignees, for future royalties. Simyon Palmin, a founder of Novelos, a director until August 15, 2008 and the father of our president and chief executive officer, is president of Oxford Group, Ltd. Mr. Palmin was also an employee of Novelos until September 2008 and performed consulting services to the Company through December 2009. Pursuant to the agreement, as revised May 26, 2005, Novelos is required to pay Oxford Group, Ltd., or its assignees, a royalty in the amount of 0.8% of our net sales of oxidized glutathione-based products.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director Independence</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each member of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee and seven of our nine directors meet the independence requirements of the Nasdaq Stock Market for membership on the committees on which he serves.&#160; The board of directors considered the information included in transactions with related parties as outlined above along with other information the board considered relevant, when considering the independence of each director. Harry S. Palmin and Jamey P. Weichert are not independent directors.</font></div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">47</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage53"><!--EFPlaceholder--></a><a name="V227496_S1_HTM_V189973_S1A_HTM_V183722_S"><!--EFPlaceholder--></a><a name="FIS_DISTRIBUTION_PLAN"><!--EFPlaceholder--></a><a name="FIS_UNDERWRITING"><!--EFPlaceholder--></a>UNDERWRITING</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Rodman &amp; Renshaw, LLC is acting as the sole managing underwriter of this offering. Under the terms and subject to the conditions contained in an underwriting agreement dated the date of this prospectus, Rodman &amp; Renshaw, LLC, or the underwriter, has agreed to purchase, and we have agreed to sell to them, all units offered by this prospectus.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Nature of Underwriting Commitment</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The underwriting agreement provides that the underwriter&#160;is committed to purchase all&#160;units offered in this offering, other than those covered by the over-allotment option described below, if the underwriter purchases any of these securities. The underwriting agreement provides that the obligations of the underwriter to purchase the&#160;securities offered hereby&#160;is conditional and may be terminated at&#160;its discretion based on its assessment of the state of the financial markets. The obligations of the underwriter may also be terminated upon the occurrence of other events specified in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriters obligations are subject to various other customary conditions, representations and warranties contained in the underwriting agreement, such as receipt by the underwriter of officers&#8217; certificates and legal opinions of our counsel.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pricing of Securities</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The underwriter has advised us that&#160;it proposes to offer the&#160;securities directly to the public at the public offering price set forth on the cover page of this prospectus, and to certain dealers that are members of the Financial Industry Regulatory Authority (FINRA), at such price less a concession not in excess of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per unit. The underwriter may allow, and the selected dealers may reallow, a concession not in excess of $&#160;&#160;&#160;per&#160;unit to certain brokers and dealers. After this offering, the offering price and concessions and discounts to brokers and dealers and other selling terms may from time to time be changed by the underwriter. These prices should not be considered an indication of the actual value of our shares of common stock and are subject to change as a result of market conditions and other factors. No variation in those terms will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Our common stock is quoted on the OTC Bulletin Board under the symbol &#8220;NVLT.OB.&#8221; On&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2011, the closing market price of our common stock as quoted on OTC Bulletin Board was&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. The public offering price for the&#160;securities was determined by negotiation between us and the underwriter. The principal factors considered in determining the public offering price of the securities included:</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the information in this prospectus and otherwise available to the underwriters;</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the history and the prospects for the industry in which we will compete;</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">our current financial condition and the prospects for our future cash flows and earnings;</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the general condition of the economy and the securities markets at the time of this offering;</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the recent market prices of, and the demand for, publicly-traded securities of generally comparable companies; and</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the public demand for our securities in this offering</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We cannot be sure that the public offering price will correspond to the price at which our shares of common stock will trade in the public market following this offering or that an active trading market for our shares of common stock will develop and continue after this offering.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNIDENTIFIED_TABLE_14"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commissions and Discounts</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The following table summarizes the compensation to be paid to the underwriter by us and the proceeds, before expenses, payable to us, assuming a $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;offering price. The information assumes either no exercise or full exercise by the underwriter of the over-allotment option.</font></div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">48</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; &#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Total</font></font> </div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr>
<td valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" nowrap valign="bottom" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Per</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">Unit</font></font> </div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" nowrap valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Without</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Over-Allotment</font> </div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" nowrap valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">With</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Over-Allotment</font> </div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Public offering price</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Underwriting discount (5%) (1)</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-accountable expense allowance (1%) (2)</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds, before expenses, to us (3)</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<hr style="COLOR: black" align="center" noshade size="1" width="20%">
</div>

<div>&#160;</div>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(1)</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Underwriting discount is $&#160;&#160;&#160;&#160;&#160;per&#160;unit (5% of the price of the&#160;securities sold in the offering).</font></font> </div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2)</font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The expense allowance of 1% is not payable with respect to the&#160;units sold upon exercise of the underwriter&#8217;s over-allotment option.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>Includes $50,000 which was previously paid to the underwriter as an advance.</font> </div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(3)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We estimate that the total expenses of this offering, excluding the underwriter&#8217;s discount and the non-accountable expense allowance are approximately $&#160;&#160;&#160;&#160;&#160;&#160;.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage54"><!--EFPlaceholder--></a>Over-allotment Option</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We have granted the underwriter an option, exercisable for 45 days after the closing date of this offering, to purchase up to 15% of the securities sold in the offering (&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; additional units) solely to cover over-allotments, if any, at the same price as the initial&#160;units offered. If the underwriter fully exercises the over-allotment option, the total public offering price, underwriting discount and expenses and net proceeds (before expenses) to us will be $&#160;&#160;&#160;, $&#160;&#160;&#160;&#160;, and $&#160;&#160;&#160;&#160;&#160;respectively.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Lock-ups</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All of our directors and executive officers and our significant stockholders will enter into lock-up agreements that prevent them from selling any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, subject to certain exceptions, for a period of not less than six months from the date of this prospectus without the prior written consent of the underwriter. The underwriter may in its sole discretion and at any time without notice release some or all of the shares subject to lock-up agreements prior to the expiration of the lock-up period. When determining whether or not to release shares from the lock-up agreements, the underwriter will consider, among other factors, the stockholder&#8217;s reasons for requesting the release, the number of shares for which the release is being requested and market conditions at the time.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Right of First Refusal</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have granted to the underwriter a right of first refusal to purchase for its account or to sell for our account, or any subsidiary or successor, any securities of the Company or any such subsidiary or successor which we or any subsidiary or successor may seek to sell in public or private equity and public debt offerings whether with or without or through an underwriter, placement agent or broker-dealer.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We may, however, in lieu of granting a right of first refusal, designate the underwriter as lead underwriter or co-manager of any underwriting group or co-placement agent of any proposed financing, and the underwriter shall be entitled to receive as its compensation 50% of the compensation payable to the underwriting or placement agent group when serving as co-manager or co-placement agent and 33% of&#160;&#160;the compensation payable to the underwriting or placement agent group when serving as co-manager or co-placement agent with respect to a proposed financing in which there are three co-managing or lead underwriters or co-placement agents.</font></div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">49</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage55"><!--EFPlaceholder--></a>Other Terms</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The underwriting agreement provides that we will be responsible for and pay all expenses related to the offering including, among other things, the $16,000 cost associated with the use of i-Deal&#8217;s book building, prospectus tracking and compliance software for the offering and up to $20,000 of the underwriter&#8217;s actual accountable &#8220;road show&#8221; expenses for the offering.</font> </div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In connection with this offering, the underwriter or certain of the securities dealers may distribute prospectuses electronically. No forms of prospectus other than printed prospectuses and electronically distributed prospectuses that are printable in Adobe PDF format will be used in connection with this offering.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The underwriter previously acted as placement agent for the private placement which closed simultaneously with the Acquisition. For such services, the underwriter was paid a cash fee of $200,000 and we issued to the underwriter warrants to purchase 19,293 shares of our common stock<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">, giving effect to an estimated 1-for-10 Offering Reverse Split</font>. The cash fee was used to acquire 26,666 shares of our common stock and a warrant to purchase 26,666 shares of our common stock upon the same terms as other purchasers in the private placement<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">, giving effect to an estimated 1-for-10 Offering Reverse Split</font>. These shares and warrants are subject to a 360-day lock-up pursuant to Rule 5110(g)(1) of FINRA.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with the offering we are applying to have our common stock approved for listing on the NASDAQ Capital Market under the symbol &#8220;NVLT&#8221;.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The underwriter has informed us that it does not expect to confirm sales of&#160;securities offered by this prospectus to accounts over which they exercise discretionary authority without obtaining the specific approval of the account holder.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stabilization</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Until the distribution of the shares offered by this prospectus is completed, rules of the SEC may limit the ability of the underwriter to bid for and to purchase our securities. As an exception to these rules, the underwriter may engage in transactions effected in accordance with Regulation M under the Securities Exchange Act of 1934 that are intended to stabilize, maintain or otherwise affect the price of our common stock. The underwriter may engage in over-allotment sales, syndicate covering transactions, stabilizing transactions and penalty bids in accordance with Regulation M.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Stabilizing transactions permit bids or purchases for the purpose of pegging, fixing or maintaining the price of the common stock, so long as stabilizing bids do not exceed a specified maximum.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;</font></font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Over-allotment involves sales by the underwriter of securities in excess of the number of&#160;units the underwriter is obligated to purchase, which creates a short position. The short position may be either a covered short position or a naked short position. In a covered short position, the number of&#160;units over-allotted by the underwriter is not greater than the number of&#160;units that it&#160;may purchase in the over-allotment option. In a naked short position, the number of&#160;units involved is greater than the number of&#160;units in the over-allotment option. The underwriter may close out any covered short position by either exercising&#160;its over-allotment option or purchasing shares in the open market.</font></font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Covering transactions involve the purchase of securities in the open market after the distribution has been completed in order to cover short positions. In determining the source of securities to close out the short position, the underwriter will consider, among other things, the price of securities available for purchase in the open market as compared to the price at which&#160;it may purchase securities through the over-allotment option. If the underwriter sells more shares of common stock than could be covered by the over-allotment option, creating a naked short position, the position can only be closed out by buying securities in the open market. A naked short position is more likely to be created if the underwriter&#160;is concerned that there could be downward pressure on the price of the securities in the open market after pricing that could adversely affect investors who purchase in this offering.</font></font></div></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Penalty bids permit the underwriter to reclaim a selling concession from a selected dealer when the shares of common stock originally sold by the selected dealer are purchased in a stabilizing or syndicate covering transaction.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These stabilizing transactions, covering transactions and penalty bids may have the effect of raising or maintaining the market price of our securities or preventing or retarding a decline in the market price of our securities. As a result, the price of our securities may be higher than the price that might otherwise exist in the open market.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the prices of our securities. These transactions may occur on the over the counter market or on any other trading market. If any of these transactions are commenced, they may be discontinued without notice at any time.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Foreign Regulatory Restrictions on Purchase of the Securities</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">We have not taken any action to permit a public offering of our securities outside the United States or to permit the possession or distribution of this prospectus outside the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about and observe any restrictions relating to this offering of shares and the distribution of the prospectus outside the United States.</font> </div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">50</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In addition to the public offering of the securities in the United States, the underwriters may, subject to the applicable foreign laws, also offer the securities to certain institutions or accredited persons in the following countries:</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><a name="eolPage56"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Australia</font> . If this document is issued or distributed in Australia it is issued or distributed to &#8220;wholesale clients&#8221; only, not to &#8220;retail clients&#8221;. For the purposes of this paragraph, the terms &#8220;wholesale client&#8221; and &#8220;retail client&#8221; have the meanings given in section 761 of the Australian Corporations Act 2001 (Cth). This document is not a disclosure document under the Australian Corporations Act, has not been lodged with the Australian Securities &amp; Investments Commission and does not purport to include the information required of a disclosure document under the Australian Corporations Act. Accordingly, (i) the offer of securities under this document is only made to persons to whom it is lawful to offer such securities under one or more exemptions set out in the Australian Corporations Act, (ii) this document is only made available in Australia to those persons referred to in clause (i) above, and (iii) the offeree must be sent a notice stating in substance that, by accepting this offer, the offeree represents that the offeree is such a person as referred to in clause (i) above, and, unless permitted under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within 12 months after its transfer to the offeree under this document.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">China</font> . THIS PROSPECTUS HAS NOT BEEN AND WILL NOT BE CIRCULATED OR DISTRIBUTED IN THE PRC, AND ADSs MAY NOT BE OFFERED OR SOLD, AND WILL NOT BE OFFERED OR SOLD TO ANY PERSON FOR RE-OFFERING OR RESALE, DIRECTLY OR INDIRECTLY, TO ANY RESIDENT OF THE PRC EXCEPT PURSUANT TO APPLICABLE LAWS AND REGULATIONS OF THE PRC</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">DIFC</font> . DIFC and UAE have different requirements and, as a result, a generic legend for each is provided below</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">UAE</font> . The offering has not been approved or licensed by the Central Bank of the United Arab Emirates (the &#8220;UAE&#8221;), Securities and Commodities Authority of the UAE and/or any other relevant licensing authority in the UAE including any licensing authority incorporated under the laws and regulations of any of the free zones established and operating in the territory of the UAE, in particular the Dubai Financial Services Authority (the &#8220;DFSA&#8221;), a regulatory authority of the Dubai International Financial Centre (the &#8220;DIFC&#8221;).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The offering does not constitute a public offer of securities in the UAE, DIFC and/or any other free zone in accordance with the Commercial Companies Law, Federal Law No.8 of 1984 (as amended), DFSA Offered Securities Rules and NASDAQ Dubai Listing Rules, accordingly, or otherwise. The securities offered hereby may not be offered to the public in the UAE and/or any of the free zones, including, in particular, the DIFC.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The securities offered hereby may be offered and issued only to a limited number of investors in the UAE or any of its free zones (including, in particular, the DIFC) who qualify as sophisticated investors under the relevant laws and regulations of the UAE or the free zone concerned, including, in particular, the DIFC.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company represents and warrants that the securities offered hereby will not be offered, sold, transferred or delivered to the public in the UAE or any of its free zones, including, in particular, the DIFC.&#8221;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Dubai</font> . The issuer is not licensed by the Dubai Financial Services Authority (&#8220;DFSA&#8221;) to provide financial services in the Dubai International Financial Centre (&#8220;DIFC&#8221;). The offering has not been approved or licensed by the Central Bank of the United Arab Emirates (the &#8220;UAE&#8221;), Securities and Commodities Authority of the UAE and/or any other relevant licensing authority in the UAE including any licensing authority incorporated under the laws and regulations of any of the free zones established and operating in the territory of the UAE, in particular the DFSA, a regulatory of the DIFC.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The offering does not constitute a public offer of securities in the UAE, DIFC and/or any other free zone in accordance with the Commercial Companies Law, Federal Law No.8 of 1984 (as amended), DFSA Offered Securities Rules and NASDAQ Dubai Listing Rules, accordingly, or otherwise. The securities offered hereby may not be offered to the public in the UAE and/or any of the free zones, including, in particular, the DIFC.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The securities offered hereby may be offered and issued only to a limited number of investors in the UAE or any of its free zones (including, in particular, the DIFC) who qualify as sophisticated investors under the relevant laws and regulations of the UAE or the free zone concerned, including, in particular, the DIFC.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company represents and warrants that the securities offered hereby will not be offered, sold, transferred or delivered to the public in the UAE or any of its free zones, including, in particular, the DIFC.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Israel</font> . The securities offered by this prospectus have not been approved or disapproved by the Israeli Securities Authority (the ISA), nor have such securities been registered for sale in Israel. The securities may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with the offering or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the common stock being offered. Any resale, directly or indirectly, to the public of the securities offered by this prospectus is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities laws and regulations.</font> </div>
<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">51</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage57"><!--EFPlaceholder--></a><font style="DISPLAY: inline; FONT-STYLE: italic">Pakistan</font> . The investors / subscribers in Pakistan will be responsible for ensuring their eligibility to invest under the applicable laws of Pakistan and to obtain any regulatory consents if required for such purpose.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Saudi Arabia</font> . NO OFFERING OF SECURITIES IS BEING MADE IN THE KINGDOM OF SAUDI ARABIA, AND NO AGREEMENT RELATING TO THE SALE OF THE SECURITIES WILL BE CONCLUDED IN SAUDI ARABIA. THIS DOCUMENT IS PROVIDED AT THE REQUEST OF THE RECIPIENT AND IS BEING FORWARDED TO THE ADDRESS SPECIFIED BY THE RECIPIENT. NEITHER THE AGENT NOR THE OFFERING HAVE BEEN LICENSED BY THE SAUDI&#8217;S SECURITIES AND EXCHANGE COMMISSION OR ARE OTHERWISE REGULATED BY THE LAWS OF THE KINGDOM OF SAUDI ARABIA.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">THEREFORE, NO SERVICES RELATING TO THE OFFERING, INCLUDING THE RECEIPT OF APPLICATIONS AND/OR THE ALLOTMENT OF THE SECURITIES, MAY BE RENDERED WITHIN THE KINGDOM BY THE AGENT OR PERSONS REPRESENTING THE OFFERING.</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">UK</font> . The content of this prospectus has not been issued or approved by an authorised person within the meaning of the United Kingdom Financial Services and Markets Act 2000 (&#8220;FSMA&#8221;). Reliance on this prospectus for the purpose of engaging in any investment activity may expose an Investor to a significant risk of losing all of the property or other assets invested. This prospectus does not constitute a Prospectus within the meaning of the FSMA and is issued in reliance upon one or more of the exemptions from the need to issue such a prospectus contained in section 86 of the FSMA.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indemnification</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The underwriting agreement provides for indemnification between us and the underwriter against specified liabilities, including liabilities under the Securities Act, and for contribution by us and the underwriter to payments that may be required to be made with respect to those liabilities. We have been advised that, in the opinion of the SEC, indemnification for liabilities under the Securities Act is against public policy as expressed in the Securities Act, and is therefore, unenforceable.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="FIS_SECURITIES_DESCRIPTION"><!--EFPlaceholder--></a>DESCRIPTION OF SECURITIES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under our amended and restated certificate of incorporation, our authorized capital stock consists of 150,000,000 shares of common stock, $0.00001 par value per share, and 7,000 shares of preferred stock, $0.00001 par value per share.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our amended and restated certificate of incorporation authorizes us to issue shares of our preferred stock from time to time in one or more series without stockholder approval.&#160; No shares of preferred stock are outstanding,</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All outstanding shares of our common stock are duly authorized, validly issued, fully-paid and non-assessable.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Common Stock</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Voting.</font> Holders of our common stock are entitled to one vote per share held of record on all matters to be voted upon by our stockholders. Our common stock does not have cumulative voting rights. Persons who hold a majority of the outstanding common stock entitled to vote on the election of directors can elect all of the directors who are eligible for election.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Dividends.</font> Subject to preferences that may be applicable to the holders of any outstanding shares of our preferred stock, the holders of our common stock are entitled to receive such lawful dividends as may be declared by our board of directors.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Liquidation and Dissolution.</font> In the event of our liquidation, dissolution or winding up, and subject to the rights of the holders of any outstanding shares of our preferred stock, the holders of shares of our common stock will be entitled to receive pro rata all of our remaining assets available for distribution to our stockholders.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Other Rights and Restrictions.</font> Our amended and restated certificate of incorporation prohibits us from granting preemptive rights to any of our stockholders. All outstanding shares are fully paid and nonassessable.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="V227496_S1_HTM_EOLPAGE55"><!--EFPlaceholder--></a>Anti-Takeover Effect of Certain Charter and By-Law Provisions</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Provisions of our charter and our by-laws could make it more difficult to acquire us by means of a merger, tender offer, proxy contest, open market purchases, removal of incumbent directors and otherwise. These provisions, which are summarized below, are expected to discourage types of coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of us to first negotiate with us. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging takeover or acquisition proposals because negotiation of these proposals could result in an improvement of their terms.</font></div>

<div>&#160;<a name="eolPage58"><!--EFPlaceholder--></a></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">52</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

&#160;

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Authorized but Unissued Stock</font> . We have shares of common stock and preferred stock available for future issuance, in some cases, without stockholder approval. We may issue these additional shares for a variety of corporate purposes, including public offerings to raise additional capital, corporate acquisitions, stock dividends on our capital stock or equity compensation plans.&#160; The existence of unissued and unreserved common stock and preferred stock may enable our board of directors to issue shares to persons friendly to current management or to issue preferred stock with terms that could render more difficult or discourage a third-party attempt to obtain control of us, thereby protecting the continuity of our management. In addition, if we issue preferred stock, the issuance could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Amendments to by-laws</font> . Our certificate of incorporation and by-laws authorize the Board to amend, repeal, alter or rescind the by-laws at any time without stockholder approval.&#160; Allowing the Board to amend our by-laws without stockholder approval enhances Board control over our by-laws.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Classification of Board; removal of directors; vacancies.&#160; </font>Our certificate of incorporation provide for the&#160; division of the Board into three classes as nearly equal in size as possible with staggered three-year terms;&#160; that directors may be removed only for cause by the affirmative vote of the holders of two-thirds of our shares of capital stock entitled to vote; and&#160; that any vacancy on the Board, however occurring, including a vacancy resulting from an enlargement of the board, may be filled only by the vote of a majority of the directors then in office.&#160; The limitations on the removal of directors and the filling of vacancies could have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from acquiring, control of us. Our certificate of incorporation requires the affirmative vote of the holders of at least 75% of our shares of capital stock issued and outstanding and entitled to vote to amend or repeal any of these provisions.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="V227496_S1_HTM_V189973_S1A_HTM_EOLPAGE47"><!--EFPlaceholder--></a><font style="DISPLAY: inline; FONT-STYLE: italic">Notice Periods for Stockholder Meetings</font> . Our by-laws provide that for business to be brought by a stockholder before an annual meeting of stockholders, the stockholder must give&#160;written notice to the corporation not less than 90 nor more than 120 days prior to the one year anniversary of the date of the annual meeting of stockholders of the previous year; provided, however, that in the event that the annual meeting of stockholders is called for a date that is not within 30 days before or after such anniversary date, notice by the stockholder must be received not later than the close of business on the tenth day following the day on which the corporation's notice of the date of the&#160;meeting is first given or made to the stockholders or disclosed to the general public, whichever occurs first.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Stockholder action; special meetings</font> .&#160; Our certificate of incorporation provides that stockholder action may not be taken by written action in lieu of a meeting and provides special meetings of the stockholders may only be called by our president or by our Board. These provisions could have the effect of delaying until the next stockholders' meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities. These provisions may also discourage another person or entity from making a tender offer for our common stock, because that person or entity, even if it acquired a majority of our outstanding voting securities, would be able to take action as a stockholder only at a duly called stockholders' meeting, and not by written consent. Our certificate of incorporation requires the affirmative vote of the holders of at least 75% of our shares of capital stock issued and outstanding and entitled to vote to amend or repeal the provisions relating to prohibition on action by written consent and the calling of a special meeting of stockholders.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Nominations</font> .&#160; Our by-laws provide that nominations for election of directors may be made only by (i) the Board or a committee appointed by the Board; or (ii) a stockholder entitled to vote on director election, if the stockholder provides notice to the Secretary of the Corporation presented not less than 90 days nor more than 120 days prior to the anniversary of the last annual meeting (subject to the limited exceptions set forth in the bylaws). These provisions may deter takeovers by requiring that any stockholder wishing to conduct a proxy contest have its position solidified well in advance of the meeting at which directors are to be elected and by providing the incumbent Board with sufficient notice to allow them to put an election strategy in place.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">53</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">DISCLOSURE OF COMMISSION POSITION ON</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our charter contains provisions to indemnify our directors and officers to the maximum extent permitted by Delaware law. We believe that indemnification under our charter covers at least negligence on the part of an indemnified person. Our charter permits us to advance expenses incurred by an indemnified person in connection with the defense of any action or proceeding arising out of the person&#8217;s status or service as our director, officer, employee or other agent upon an undertaking by the person to repay those advances if it is ultimately determined that the person is not entitled to indemnification.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the&#160;registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WHERE YOU CAN FIND MORE INFORMATION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are a reporting company and file annual, quarterly and special reports, and other information with the Securities and Exchange Commission. Copies of the reports and other information may be read and copied at the SEC&#8217;s Public Reference Room at 100 F Street NE, Washington, D.C. 20549. You can request copies of such documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a web site at http://www.sec.gov that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This prospectus is part of a registration statement on Form S-1 that we filed with the SEC. Certain information in the registration statement has been omitted from this prospectus in accordance with the rules and regulations of the SEC. We have also filed exhibits and schedules with the registration statement that are excluded from this prospectus. For further information you may:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">read a copy of the registration statement, including the exhibits and schedules, without charge at the SEC&#8217;s Public Reference Room; or</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">obtain a copy from the SEC upon payment of the fees prescribed by the SEC.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="FIS_LEGAL_MATTERS"><!--EFPlaceholder--></a>LEGAL MATTERS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The validity of the securities being offered by this prospectus is being passed upon for us by Foley Hoag LLP, Boston, Massachusetts.&#160; &#160;Sichenzia Ross Friedman Ference LLP, New York, New York, is acting as counsel to the underwriter in this offering.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXPERTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The audited financial statements of Novelos Therapeutics, Inc. included in this prospectus and elsewhere in the registration statement have been so included in reliance upon the report of Grant Thornton LLP, independent registered public accountants, upon the authority of said firm as experts in accounting and auditing in giving said report.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The audited financial statements of Novelos Therapeutics, Inc. (Pre-Acquisition) included in this prospectus and elsewhere in the registration statement have been so included in reliance upon the report of Stowe &amp; Degon LLC, independent registered public accountants, upon the authority of said firm as experts in accounting and auditing in giving said report.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">54</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">GLOSSARY OF SCIENTIFIC TERMS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Akt - </font>Akt (also known as Akt/PKB)&#160;is an important cell signaling enzyme (a serine/threonine protein kinase) that plays a key role in multiple cellular processes such as glucose metabolism, cell proliferation,&#160;apoptosis, transcription and cell migration.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Apoptosis - </font>A highly regulated, normal cell process leading to programmed cell death by which organisms can eliminate damaged or aberrant cells.&#160; Apoptosis is often abnormally suppressed in cancer cells, contributing to their uncontrolled proliferation.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Caspases - </font>Caspases are a family of enzymes (cysteine-aspartic proteases&#160;or&#160;cysteine-dependent&#160;aspartate-directed proteases)&#160; that play essential roles in&#160;apoptosis&#160;(programmed cell death),&#160;necrosis, and&#160;inflammation.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Cytotoxic - </font>Cytotoxicity is the quality of being toxic to cells (i.e. cell-killing).&#160; Many cancer chemotherapeutic drugs are cytotoxic to cancer cells (and, to some extent, normal cells) thus resulting in unwanted side-effects e.g. nausea/vomiting, hair loss, suppression of the immune system.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Dosimetry - </font>Radiation&#160;dosimetry&#160;is the calculation of absorbed dose and optimization of dose delivery in&#160;radiation therapy.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Lipid Rafts - </font>Specialized regions of the membrane phospholipid bilayer that contain high concentrations of cholesterol and sphingolipids and serve to organize cell surface and intracellular signaling molecules (e.g. growth factor and cytokine receptors, the phophatidylinosotol 3-kinase (P13K)/Akt survival pathway).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Radiolabeled - </font>Refers to a molecule containing a radioisotope as a part of its structure.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Radioisotop</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">e - </font>Also referred to as radioactive isotopes or radionuclides.&#160; These are variants of atoms of particular chemical elements (e.g. iodine) with an unstable nucleus that can undergo radioactive decay during which ionizing radiation (e.g. gamma rays, subatomic particles) is emitted.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Uptake &#8211; </font>An act of taking in or absorbing, especially into a living organism, tissue or cell.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Xenograft - </font>Tissue, organs or cells from an individual of one species transplanted into or grafted onto an individual of another species.</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">55</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="eolPage60"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FINANCIAL STATEMENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">INDEX TO FINANCIAL STATEMENTS FOR NOVELOS THERAPEUTICS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a Development Stage Company)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Page</font></font> </div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Report of Independent Registered Public Accounting Firm</font> </div>
</td>
<td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-2</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance Sheets at September 30, 2011, December 31, 2010 and 2009</font> </div>
</td>
<td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-3</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Statements of Operations for the Nine Months Ended September 30, 2011 and 2010, the Years Ended December 31, 2010 and 2009, and the Cumulative Development-Stage Period from November 7, 2002 (date of inception) to December 31, 2010</font> </div>
</td>
<td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-4</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Statements of Stockholders&#8217; Equity&#160;for the Nine Months Ended September 30, 2011 and&#160; Cumulative Development-Stage Period from November 7, 2002 (date of inception) to December 31, 2010</font> </div>
</td>
<td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-5</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Statements of Cash Flows for the Nine Months Ended September 30, 2011 and 2010, the Years Ended December 31, 2010 and 2009, and the Cumulative Development-Stage Period from November 7, 2002 (date of inception) to December 31, 2010</font> </div>
</td>
<td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-6</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Notes to Financial Statements</font> </div>
</td>
<td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-7</font> </div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-1</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage61"><!--EFPlaceholder--></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Board of Directors and Stockholders</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Novelos Therapeutics, Inc.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have audited the accompanying balance sheets of Novelos Therapeutics, Inc. (a Development Stage Company) (a Delaware corporation) (the &#8220;Company&#8221;) as of December 31, 2010 and 2009, and the related statements of operations, stockholders&#8217; equity (deficiency), and cash flows for each of the two years in the period ended December 31, 2010 and the period from November 7, 2002 (date of inception) through December 31, 2010.<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>These financial statements are the responsibility of the Company&#8217;s management.<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>Our responsibility is to express an opinion on these financial statements based on our audits.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>The Company is not required to have, nor were we engaged to perform an audit of its internal control over financial reporting.<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>Accordingly, we express no such opinion.<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>We believe that our audits provide a reasonable basis for our opinion.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Novelos Therapeutics, Inc. as of December 31, 2010 and 2009, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2010 and the period from November 7, 2002 (date of inception) through December 31, 2010, in conformity with accounting principles generally accepted in the United States of America.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.&#160; As discussed in Note 1 to the financial statements, the Company has incurred losses since its inception and, as of December 31, 2010, had an accumulated deficit of $24,045,004.&#160; These conditions, along with other matters as set forth in Note 1, raise substantial doubt about the Company&#8217;s ability to continue as a going concern.&#160; Management&#8217;s plans in regard to these matters are also described in Note 1.&#160; The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/ GRANT THORNTON LLP</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chicago, Illinois</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">June 14, 2011</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOVELOS THERAPEUTICS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a Development Stage Company)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BALANCE SHEETS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated September&#160;30,</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font> </div>
</td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31,</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font> </div>
</td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December&#160;31,</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font> </div>
</td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(unaudited)</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(audited)</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(audited)</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ASSETS</font> </div>
</td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CURRENT ASSETS:</font> </div>
</td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash and cash equivalents</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,590,755</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">673,739</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">980,125</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Restricted cash</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">55,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">555,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">555,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Prepaid expenses and other current assets</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">303,633</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">51,042</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">69,626</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred issuance costs</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">159,300</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99,461</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total current assets</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,108,688</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,279,781</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,704,212</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FIXED ASSETS, NET</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,183,603</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,510,489</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,088,951</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">INTANGIBLE ASSETS</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19,671</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EXCESS PURCHASE PRICE OVER NET ASSETS ACQUIRED</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,675,462</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">OTHER ASSETS</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27,222</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,872</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,872</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TOTAL ASSETS</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,994,975</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,802,142</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,824,706</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="fis_unidentified_table_15"><!--efplaceholder--></a>&#160;LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CURRENT LIABILITIES:</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts payable and accrued liabilities</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">441,653</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">392,881</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">715,588</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued interest</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">305,049</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Derivative liability</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">77,967</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Notes payable, current portion</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">204,802</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">190,789</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Capital lease obligations, current portion</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,197</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,085</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,944</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total current liabilities</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">521,817</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">904,817</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">908,321</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">LONG-TERM LIABILITIES:</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Convertible debt (Note 7)</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,720,985</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Notes payable, net of current portion</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">450,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">920,941</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">675,743</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred rent</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">121,394</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">115,311</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">105,338</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Capital lease obligations, net of current portion</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,665</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,326</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,411</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total long-term liabilities</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">576,059</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,763,563</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">789,492</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COMMITMENTS AND CONTINGENCIES</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">STOCKHOLDERS&#8217; EQUITY:</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Preferred stock, $0.00001 par value; 7,000 shares authorized; none issued none outstanding as of September 30, 2011, December 31, 2010 and December 31, 2009</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common stock, $0.00001 par value; 150,000,000 shares authorized; 26,826,157 shares issued and outstanding at September 30, 2011, 12,820,102 shares issued and outstanding at December 31, 2010 and&#160;December 31, 2009</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">268</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">128</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">128</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Additional paid-in capital</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,411,337</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24,178,638</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23,611,506</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deficit accumulated during the development stage</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(29,514,506</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(24,045,004</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(19,484,741</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total stockholders&#8217; equity</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,897,099</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">133,762</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,126,893</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,994,975</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,802,142</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,824,706</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">The accompanying notes are an integral part of these financial statements.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOVELOS THERAPEUTICS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a Development Stage Company)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">STATEMENTS OF OPERATIONS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 6.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 6.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 6.5pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Year Ended</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 6.5pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;December 31,</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.5pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cumulative Development- Stage Period from November 7, 2002 (date of inception) through December 31, 2010</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.6pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(unaudited)</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.6pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(unaudited)</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.6pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(audited)</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.6pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(audited)</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.6pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(audited)</font> </div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COSTS AND EXPENSES:</font> </div>
</td>
<td align="right" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,445,429</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,616,834</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,984,207</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,351,983</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,205,959</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,827,510</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,014,094</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,156,549</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,824,302</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,970,179</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Merger costs</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">746,207</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">52,925</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">52,925</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total costs and expenses</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,019,146</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,630,928</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,193,681</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,176,285</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24,229,063</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">LOSS FROM OPERATIONS</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,019,146</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,630,928</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,193,681</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,176,285</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(24,229,063</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">OTHER INCOME (EXPENSE):</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Grant income</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">44,479</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">200,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">200,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Loss on derivative liability</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(66,820</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest expense, net</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(428,015</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(467,495</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(566,156</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(43,588</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(17,102</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other income</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(426</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,161</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total other income (expense)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(450,356</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(467,495</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(366,582</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(43,588</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">184,059</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NET LOSS</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,469,502</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,098,423</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,560,263</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,219,873</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(24,045,004</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.25</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.32</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.36</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.49</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2.53</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21,847,984</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,820,102</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,820,102</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,820,102</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,513,115</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">The accompanying notes are an integral part of these financial statements</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-4</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOVELOS THERAPEUTICS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a Development Stage Company)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;<font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></font> </td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Common&#160;Stock</font></font> </div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Additional</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Paid-in</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Capital</font></font> </div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Deficit</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Accumulated</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">During&#160;the</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Development</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Stage</font></font> </div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Total</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Stockholders&#8217;</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Equity</font></font> </div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Shares</font></font> </div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Par</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Amount</font></font> </div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">BALANCE AT NOVEMBER 7, 2002</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;$</font> </div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;$</font> </div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;$</font> </div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;$</font> </div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Issuance of common stock for cash</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">6,440,123</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">64</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">590,205</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">590,269</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Issuance of common stock in exchange for professional services</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">101,220</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">9,107</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">9,108</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net loss</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">BALANCE AT DECEMBER 31, 2002</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">6,541,343</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">65</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">599,312</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">599,377</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Issuance of common stock for cash, net of issuance costs</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">37,958</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">4,937</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">4,937</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Issuance of common stock in exchange for licensed technology</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">203,483</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">80,410</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">80,412</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net loss</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(295,790)</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(295,790</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">BALANCE AT DECEMBER 31, 2003</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">6,782,784</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">67</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">684,659</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(295,790</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)&#160;</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">388,936</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net loss</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(342,761</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)&#160;</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(342,761</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)&#160;</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">BALANCE AT DECEMBER 31, 2004</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">6,782,784</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">67</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">684,659</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(638,551</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)&#160;</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">46,175</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Issuance of common stock for cash, net of issuance costs</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">610,664</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">6</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">835,862</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">835,868</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net loss</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(481,837</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)&#160;</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(481,837</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)&#160;</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">BALANCE AT DECEMBER 31, 2005</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">7,393,448</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">73</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,520,521</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(1,120,388</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)&#160;</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">400,206</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Issuance of common stock for cash, net of issuance costs</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,202,179</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">22</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">7,097,050</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">7,097,072</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Common stock repurchased</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(43,819</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(31,667</font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(31,667</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Stock-based compensation</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">43,994</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">43,994</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net loss</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(963,440</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(963,440</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">BALANCE AT DECEMBER 31, 2006</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">9,551,808</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">95</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">8,629,898</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(2,083,828</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">6,546,165</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Issuance of common stock for cash, net of issuance costs</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">60,250</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">249,999</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">250,000</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Exercise of warrant to purchase common stock</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">75,045</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">249,999</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">250,000</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Stock-based compensation</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">570,392</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">570,392</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net loss</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(5,090,325</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(5,090,325</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">BALANCE AT DECEMBER 31, 2007</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">9,687,103</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">97</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">9,700,288</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(7,174,153</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,526,232</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Issuance of common stock for cash, net of issuance costs</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">3,132,999</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">31</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">12,931,531</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">12,931,562</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Stock-based compensation</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">477,488</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">477,488</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net loss</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(6,090,715</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(6,090,715</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">BALANCE AT DECEMBER 31, 2008</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">12,820,102</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">128</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">23,109,307</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(13,264,868</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)&#160;</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">9,844,567</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Stock-based compensation</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">502,199</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">502,199</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net loss</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(6,219,873</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(6,219,873</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">BALANCE AT DECEMBER 31, 2009</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">12,820,102</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">128</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">23,611,506</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(19,484,741</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">4,126,893</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Stock-based compensation</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">353,340</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">353,340</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Intrinsic value of beneficial conversion feature associated with convertible debt issued in exchange for cash</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">213,792</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">213,792</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net loss</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(4,560,263</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(4,560,263</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">BALANCE AT DECEMBER 31, 2010</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">12,820,102</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">128</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">24,178,638</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(24,045,004</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">133,762</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Issuance of common stock upon conversion of convertible notes</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">4,181,535</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">42</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">3,184,665</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">3,184,707</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Issuance of common stock in a business combination</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,959,871</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">30</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,219,873</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,219,903</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Cash paid in lieu of fractional shares in a business combination</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(41</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(145</font> </div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(145</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Issuance of common stock and warrants, net of issuance costs</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">6,846,537</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">68</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">4,866,338</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">4,866,406</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Intrinsic value of beneficial conversion feature associated with the conversion of convertible debt</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">257,973</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">257,973</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Issuance of common stock upon the cashless exercise of warrants</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">18,153</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">48,339</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">48,339</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Stock-based compensation</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">655,656</font> </font></div>
</div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">655,656</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net loss</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(5,469,502</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(5,469,502</font></font> </font></font></div>
</div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">BALANCE AT SEPTEMBER 30, 2011 (CONSOLIDATED) (unaudited)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">26,826,157</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></font> </div>
</td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">268</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></font> </div>
</td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">35,411,337</font></font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></font> </div>
</td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(29,514,506</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font></font> </div>
</td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">5,897,099</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </font> </td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">The accompanying notes are an integral part of these financial statements</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-5</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOVELOS THERAPEUTICS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a Development Stage Company)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">STATEMENTS OF CASH FLOWS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ffffff">
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Nine Months Ended</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">September 30,</font> </div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Year Ended</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">December 31,</font> </div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.7pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Cumulative Development-Stage Period from November 7, 2002 through December 31, 2010</font> </div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ffffff">
<td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Consolidated</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2011</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(unaudited)</font> </div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2010</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(unaudited)</font> </div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2010</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(audited)</font> </div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2009</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(audited)</font> </div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.7pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(audited)</font> </div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Net loss</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(5,469,502</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(4,098,423</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(4,560,263</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(6,219,873</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(24,045,004</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Adjustments to reconcile net loss to cash used in operating activities:</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Depreciation and amortization</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">439,587</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">435,917</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">580,114</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">576,745</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,831,197</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Stock-based compensation</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">655,656</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">331,186</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">353,340</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">502,199</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,947,413</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Intrinsic value of beneficial conversion feature associated with convertible debt</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">257,973</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">213,792</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">213,792</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">213,792</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Issuance of stock for technology and services</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">89,520</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Impairment of intangible assets</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">19,671</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">19,671</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">19,671</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Loss on disposal of fixed assets</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">6,009</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,607</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">30,468</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Loss on derivative warrants</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">66,820</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Changes in:</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Prepaid expenses and other current assets</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(224,548 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">20,614</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">18,584</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">23,152</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(62,914 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Accounts payable and accrued liabilities</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(331,357 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(419,634 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(322,707 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">278,131</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">392,881</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Accrued interest</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">158,672</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">222,748</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">305,049</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">305,049</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Deferred rent</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">6,083</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">4,765</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">9,973</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">62,789</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">115,311</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Cash used in operating activities</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(4,434,607 </font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(3,269,364 </font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(3,382,447 </font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(4,775,250 </font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(19,162,616 </font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">CASH FLOWS FROM INVESTING ACTIVITIES:</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Cash acquired in a business combination</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">905,649</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Purchases of fixed assets</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(112,195 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(1,652 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(143,347 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(5,368,181 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Proceeds from sale of fixed assets</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">7,000</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Purchases of short-term certificates of deposit</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(5,500,730 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Proceeds from short-term certificates of deposit</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">5,500,730</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Change in restricted cash</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">500,000</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(555,000 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;&#160;&#160;Payment for intangible assets</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(19,671 </font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Cash provided by (used in) investing activities</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,293,454</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(1,652</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(143,347 </font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(5,935,852 </font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">CASH FLOWS FROM FINANCING ACTIVITIES:</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Proceeds from issuance of convertible notes</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,720,985</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,720,985</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,720,985</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Proceeds from long-term obligations</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">450,000</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,677,945</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Payments on long-term obligations</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(675,743 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(141,794 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(190,789 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(177,807 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(552,201 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Payments on capital lease obligations</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(1,549 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(1,446 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(1,944 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(619 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(2,563 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Proceeds from issuance of common stock, net of issuance costs</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">4,866,406</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">21,709,708</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;&#160;&#160;Proceeds from exercise of warrant</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">250,000</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Repurchase of common stock</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(31,667 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Cash paid in lieu of fractional shares in a business combination</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(145 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Change in deferred issuance costs</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(130,800 </font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">99,461</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">99,461</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(99,461 </font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Cash provided by (used in) financing activities</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">4,058,169</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">2,677,206</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">3,077,713</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(277,887 </font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">25,772,207</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">INCREASE (DECREASE) IN CASH AND EQUIVALENTS</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">917,016</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(592,158 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(306,386 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(5,196,484 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">673,739</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">CASH AND EQUIVALENTS AT BEGINNING OF PERIOD</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">673,739</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">980,125</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">980,125</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">6,176,609</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">CASH AND EQUIVALENTS AT END OF PERIOD</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,590,755</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">387,967</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">673,739</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">980,125</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">673,739</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Interest paid</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">13,716</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">42,888</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">55,454</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">68,436</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">194,973</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Fair value of derivative warrants reclassified to additional paid-in capital upon cashless exercise</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">48,339</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Issuance of common stock upon conversion of notes payable and accrued interest</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">3,184,707</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Fair value of assets acquired in exchange for securities in a business combination</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">78,407</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Fair value of liabilities assumed in exchange for securities in a business combination</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">(439,615</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">)</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">Excess of purchase price over net assets acquired in a business combination</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">1,675,462</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">The accompanying notes are an integral part of these financial statements.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-6</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage99"><!--EFPlaceholder--></a><a name="eolPage173"><!--EFPlaceholder--></a><a name="V189973_EX23_2_HTM"><!--EFPlaceholder--></a><a name="FIS_EXHIBIT_23"><!--EFPlaceholder--></a>NOVELOS THERAPEUTICS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a Development Stage Company)<a name="FIS_NOTES_TO_FINANCIAL_STATEMENT"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO FINANCIAL STATEMENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(ALL INFORMATION AS OF AND FOR THE NINE MONTHS ENDED</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SEPTEMBER 30, 2011 AND 2010 IS UNAUDITED)</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Novelos Therapeutics, Inc. (&#8220;Novelos&#8221; or the &#8220;Company&#8221;) is a pharmaceutical company developing compounds for the treatment of cancer. On April 8, 2011, Novelos completed a business combination with Cellectar, Inc. (&#8220;Cellectar&#8221;), a privately held Wisconsin corporation that designed and developed products to detect, treat and monitor a wide variety of human cancers, and Cell Acquisition Corp. (the &#8220;Merger Subsidiary&#8221;), a Wisconsin corporation and a wholly owned subsidiary of Novelos. Pursuant to the transaction Cellectar was merged into the Merger Subsidiary (the &#8220;Acquisition&#8221;, see Note 4). References in these financial statements and notes to &#8220;Cellectar&#8221; relate to the activities and financial information of Cellectar prior to the Acquisition, references to &#8220;Novelos&#8221; relate to the activities and financial information of Novelos prior to the Acquisition and references to &#8220;the Company&#8221; or &#8220;we&#8221; or &#8220;us&#8221; or &#8220;our&#8221; relate to the activities and obligations of the combined Company following the Acquisition.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Immediately prior to the Acquisition, Novelos completed a 1-for-153 reverse split of its common stock (the &#8220;Reverse Split&#8221;).&#160; Novelos then issued to the shareholders of Cellectar at that date 17,001,596 shares of its common stock as consideration for the Acquisition, representing a ratio of 0.8435 shares of Novelos common stock in exchange for one share of Cellectar common stock (the &#8220;Exchange Ratio&#8221;) as set forth in the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) dated April 8, 2011.&#160; The shares issued to Cellectar shareholders in the Acquisition constituted approximately 85% of Novelos&#8217; outstanding common stock after giving effect to the Acquisition.&#160; Upon the closing of the Acquisition, the Company completed the private placement of 6,846,537 shares of its common stock and warrants to purchase an additional 6,846,537 shares of its common stock for gross proceeds of approximately $5,135,000.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounting principles generally accepted in the United States require that a company whose security holders retain the majority voting interest in the combined business be treated as the acquirer for financial reporting purposes.&#160; Accordingly, the Acquisition will be accounted for as a reverse acquisition whereby Cellectar, Inc. will be treated as the acquirer for accounting and financial reporting purposes. The financial statements presented herein as of and for the twelve months ended December 31, 2010 and 2009 represent the historical financial information of Cellectar, except for the capital structure which represents the historical amounts of Cellectar, retroactively adjusted to reflect the legal capital structure of Novelos by applying the Exchange Ratio. On April, 8, 2011, Cellectar was merged into the Merger Subsidiary a wholly owned subsidiary of Novelos; as such, the financial statements presented herein as of and for the nine months ended September 30, 2011 include the historical results of Cellectar from January 1, 2011 through April 8, 2011, except for the capital structure which represents the historical amounts of Cellectar, retroactively adjusted to reflect the legal capital structure of Novelos by applying the Exchange Ratio, and include the consolidated results of the combined company from April 9, 2011 through September 30, 2011.&#160; All per-share amounts and outstanding shares, including all common stock equivalents, and stock options, have been retroactively restated in these financial statements and notes for all periods presented to reflect the capital structure of Novelos by applying the Exchange Ratio.&#160;&#160;The cumulative capital activity from the date of inception (November 7, 2002) up to the closing of the Acquisition, as presented in the accompanying statement of stockholders&#8217; equity, equals 17,001,596 shares of common stock, which represents the equity interests the legal parent (Novelos) issued to effect the Acquisition. The number of authorized shares of common stock disclosed on the balance sheet (150,000,000) represents the number of authorized shares of Novelos common stock following the Acquisition.&#160; Additionally, on the accompanying balance sheets as of December 31, 2010 and 2009 and statements of stockholders&#8217; equity for the period from inception (November 7, 2002) to December 31, 2010 the aggregate par value of the issued common stock was reduced to reflect the $0.00001 par value of Novelos common stock associated with the shares of Cellectar common stock adjusted for the Exchange Ratio and the difference was reclassified to additional paid-in capital.</font></font> </div></div>

<div>&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As a result of the Acquisition, the Company has implemented a revised business plan focused on the development of the Cellectar compounds.&#160; Development of Novelos&#8217; other compounds (NOV-002 and NOV-205) has been suspended.&#160; The Company is conducting its operations from Cellectar&#8217;s headquarters in Madison, WI and the Company&#8217;s executive offices are in Newton, MA.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company is subject to a number of risks similar to those of other small pharmaceutical companies. Principal among these risks are dependence on key individuals, competition from substitute products and larger companies, the successful development and marketing of its products in a highly regulated environment and the need to obtain additional financing necessary to fund future operations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The accompanying financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Cellectar has incurred losses since inception in devoting substantially all of its efforts toward research and development and has an accumulated deficit of $24,045,004 at December 31, 2010. During the year ended December 31, 2010, Cellectar generated a net loss of $4,560,263 and the Company expects that it will continue to generate operating losses for the foreseeable future.&#160; The Company believes that its cash on hand following the Acquisition, plus the proceeds from the private placement completed in connection with the Acquisition, is adequate to fund operations until the end of 2011.&#160; The Company&#8217;s ability to execute its operating plan beyond that time depends on its ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise.&#160; The Company plans to continue to actively pursue financing alternatives, but there can be no assurance that it will obtain the necessary funding.&#160; The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font> </div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-7</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The accompanying financial statements reflect the application of certain accounting policies, as described in this note and elsewhere in the accompanying notes to the financial statements.&#160; The unaudited financial statements as of and for the nine months ended September 30, 2011 are presented on a consolidated basis to reflect the Acquisition described in Note 4.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The accompanying consolidated unaudited September 30, 2011 balance sheet, the statements of operations and cash flows for the nine months ended September 30, 2011 and 2010, and the statements of stockholders&#8217; equity for the nine months ended September 30, 2011 and the related interim information contained within the notes to the financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, the unaudited interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position at September 30, 2011 and results of its operations and its cash flows for the nine months ended September 30, 2011 and 2010 and the period from November 7, 2002 (inception) to September 30, 2011. The results for the nine months ended September 30, 2011 are not necessarily indicative of future results.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Development Stage Company</font> &#8212; Cellectar has been in the development stage since its inception.&#160; The primary activities since inception have been organizational activities, research and development and raising capital.&#160; No significant revenues have been generated from planned principal operations.&#160; As of September 30, 2011 and December 31, 2010 and 2009 the Company continues to be in the development stage.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The summary unaudited condensed statement of operations for the cumulative development-stage period from November 7, 2002 (date of inception) through September 30, 2011 is as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COSTS AND EXPENSES:</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19,651,388</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,797,688</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Merger costs</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">799,133</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total costs and expenses</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">29,248,209</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">LOSS FROM OPERATIONS</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(29,248,209</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">OTHER EXPENSE, NET</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(266,297</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NET LOSS</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(29,514,506</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2.80</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,549,244</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr></table>
</div>

&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The summary unaudited condensed statement of cash flow for the cumulative development-stage period from November 7, 2002 (date of inception) through September 30, 2011 is as follows:</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(29,514,506</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustments to reconcile net loss to cash used in operating activities</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,558,106</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Changes in working capital</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">359,177</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash used in operating activities</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(23,597,223</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH FLOWS FROM INVESTING ACTIVITIES:</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash acquired in a business combination</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">905,649</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Purchases of fixed assets, net of $7,000 proceeds from sale of fixed assets</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,473,376</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Change in restricted cash</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(55,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;Payment for intangible assets</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(19,671</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash used in investing activities</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,642,398</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH FLOWS FROM FINANCING ACTIVITIES:</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from issuance of common stock and warrants, net of issuance costs, repurchase of common stock, and cash paid in lieu of fractional shares in a business combination</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">26,794,302</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Change in deferred issuance costs</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(130,800</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from issuance of long-term obligations</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,398,930</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Payments on long-term obligations</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,232,056</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash provided by financing activities</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">29,830,376</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">INCREASE IN CASH AND EQUIVALENTS</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,590,755</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH AND EQUIVALENTS AT BEGINNING OF PERIOD</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH AND EQUIVALENTS AT END OF PERIOD</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,590,755</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest paid</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">208,689</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair value of derivative warrants reclassified to additional paid-in capital upon cashless exercise</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">48,339</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Issuance of common stock upon the conversion of notes payable and accrued interest</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,184,707</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair value of assets acquired in exchange for securities in a business combination</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">78,407</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair value of liabilities assumed in exchange for securities in a business combination</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(439,615</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Excess of purchase price over net assets acquired in a business combination</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,675,462</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr></table>
</div>

<div align="center">&#160;</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-8</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage68"><!--EFPlaceholder--></a><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Use of Estimates</font> &#8212; The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenue and expenses and disclosure of contingent assets and liabilities. On an on-going basis, management evaluates its estimates including those related to unbilled vendor amounts and share-based compensation. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from those estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Cash and Cash Equivalents</font> &#8212; All short-term investments purchased with original maturities of three months or less are considered to be cash equivalents.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Restricted Cash</font> &#8212; Restricted cash at September 30, 2011 consists of a certificate of deposit required under the Company&#8217;s lease agreement (see Note 14).&#160; Restricted cash at December 31, 2010 and December 31, 2009 consists of a certificate of deposit required for collateral for a promissory note with a bank (see Note 8) and a certificate of deposit required under the Company&#8217;s lease agreement (see Note 14).</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Fixed Assets</font> &#8212; Property and equipment are stated at cost. Depreciation on property and equipment is provided using the straight-line method over the estimated useful lives of the assets (5 years).&#160; Due to the significant value of leasehold improvements purchased during the initial 3-year lease term and the economic penalty for not extending the building lease, leasehold improvements are depreciated over 17 years (their estimated useful life) which represents the full term of the lease, including all extensions (Note 14).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Intangible Assets</font> &#8212; Intangible assets at September 30, 2011 consist of the excess of purchase price over net assets acquired in connection with the Acquisition and will be allocated to intangibles, which could potentially include the fair value of the compounds developed prior to the Acquisition by Novelos, with the remainder allocated to goodwill once the Company completes the final allocation of purchase price (Note 4).&#160; Intangible assets at December 31, 2009 consisted of costs incurred to obtain trademarks.&#160; These costs were capitalized when the expense was incurred and at which time the assets were deemed to have an indefinite life.&#160; During 2010, following a reduction in staff and suspension of research and manufacturing activities in order to reduce operating costs, it was determined that the trademarks had been impaired and the carrying value was reduced to zero.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Impairment of Long</font> - <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Lived Assets</font> &#8212; Whenever events or circumstances change, an assessment is made as to whether there has been an impairment in the value of long-lived assets by determining whether projected undiscounted cash flows generated by the applicable asset exceed its net book value as of the assessment date.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Stock-Based Compensation</font> &#8212; Employee stock-based compensation is accounted for in accordance with the guidance of Financial Accounting Standards Board Accounting Standards Codification (&#8220;FASB ASC&#8221;) Topic 718, <font style="DISPLAY: inline; FONT-STYLE: italic">Compensation &#8211; Stock Compensation</font> which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values.&#160; Non-employee stock-based compensation is accounted for in accordance with the guidance of FASB ASC Topic 505, <font style="DISPLAY: inline; FONT-STYLE: italic">Equity.&#160; </font>As such, the Company recognizes expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed by such non-employees.</font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-9</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Research and Development</font> &#8212; Research and development costs are expensed as incurred.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Income Taxes</font> &#8212; Income taxes are accounted for using the liability method of accounting.&#160; Under this method, deferred tax assets and liabilities are determined based on temporary differences between the financial statement and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; Valuation allowances are established when it is more likely than not that some portion of the deferred tax assets will not be realized.&#160; Management has provided a full valuation allowance against the Company&#8217;s gross deferred tax asset.&#160; Tax positions taken or expected to be taken in the course of preparing tax returns are required to be evaluated to determine whether the tax positions are &#8220;more likely than not&#8221; of being sustained by the applicable tax authority.&#160; Tax positions deemed not to meet a more-likely-than-not threshold would be recorded as tax expense in the current year.&#160; There were no uncertain tax positions that require accrual or disclosure to the financial statements as of September 30, 2011, December 31, 2010 and 2009.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Comprehensive Loss</font> &#8212; There were no components of comprehensive loss other than net loss in all of the periods presented.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Grant Income</font> &#8212; Cellectar received a cash grant of $44,000 and $200,000 for the nine-month period ended September 30, 2011 and the year ended December 31, 2010, respectively, from the U.S. Internal Revenue Service as a qualifying therapeutic discovery project credit pursuant to the Patient Protection and Affordable Care Act.&#160; This grant has been recorded as a component of other income.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Fair Value of Financial Instruments</font> &#8212; The guidance under FASB ASC Topic 825, <font style="DISPLAY: inline; FONT-STYLE: italic">Financial Instruments</font> , requires disclosure of the fair value of certain financial instruments. Financial instruments in the accompanying financial statements consist of cash equivalents, accounts payable, convertible debt and long-term obligations.&#160; The carrying amount of cash equivalents, investments and accounts payable&#160;approximate&#160;their&#160;fair value due to their short-term nature.&#160; The estimated fair value of the convertible debt, determined on an as-converted basis including conversion of accumulated unpaid interest, was approximately $0 and $3,264,000 at September 30, 2011 and December 31, 2010, respectively.&#160; The carrying value of long-term obligations, including the current portion, approximates fair value because the fixed interest rate approximates current market rate of interest available in the market.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Derivative Instruments</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>&#8211; The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks.&#160; However, certain warrants to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the Financial Accounting Standards Board Accounting Standards Codification (&#8220;FASB ASC&#8221;),<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>are classified as liabilities.&#160; In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments because the agreements contain &#8220;down-round&#8221; provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The number of shares issuable under such warrants was 77,729 at September 30, 2011. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock.&#160; Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of gain or loss on derivatives in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At September 30, 2011, these warrants represented the only outstanding derivative instruments issued or held by the Company.&#160; There were no outstanding derivative instruments at December 31, 2010 or 2009.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Concentration of Credit Risk</font> &#8212; Financial instruments that subject the Company to credit risk consist of cash and equivalents on deposit with financial institutions, which may exceed federally insured limits.&#160; Excess cash is invested on an overnight basis in an investment account that is fully collateralized principally by government-backed obligations.&#160; Cash and equivalent balances are maintained with a stable and well-capitalized financial institution.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">New Accounting Pronouncements</font> &#8212;&#160;In January 2010, the FASB issued ASU No.&#160;2010-06, <font style="DISPLAY: inline; FONT-STYLE: italic">Improving Disclosures about Fair Value Measurements</font> , which requires additional disclosures about the amounts of and reasons for significant transfers in and out of Level&#160;1 and Level&#160;2 fair value measurements. This standard also clarifies existing disclosure requirements related to the level of disaggregation of fair value measurements for each class of assets and liabilities and disclosures about inputs and valuation techniques used to measure fair value for both recurring and non-recurring Level&#160;2 and Level&#160;3 measurements. Since this new accounting standard only required additional disclosure, the adoption of the standard in the first quarter of 2010 did not impact the accompanying financial statements. Additionally, effective for interim and annual periods beginning after December&#160;15, 2010, this standard will require additional disclosure and require an entity to present disaggregated information about activity in Level&#160;3 fair value measurements on a gross basis, rather than one net amount.&#160; The adoption of this accounting standard did not impact the accompanying financial statements.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In December 2010, the FASB issued ASU No. 2010-29, <font style="DISPLAY: inline; FONT-STYLE: italic">Disclosures of Supplementary Pro Forma Information for Business Combinations</font>, which, if comparative financial statements are presented, requires the supplemental pro forma disclosure of revenue and earnings to be presented as if the business combination had occurred at the beginning of the comparable prior annual reporting period only.&#160; This standard also expands the supplemental pro forma disclosures required under FASB ASC Topic 850, <font style="DISPLAY: inline; FONT-STYLE: italic">Business Combinations</font> , to include a description of the nature and amount of material nonrecurring pro forma adjustments directly attributable to the business combination in the reported pro forma revenue and earnings.&#160; This standard is effective for the Company for any business combinations completed after January 1, 2011.&#160; The Company adopted the provisions of this standard during the first quarter of 2011.</font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-10</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In May 2011, the FASB issued ASU No. 2011-04, <font style="DISPLAY: inline; FONT-STYLE: italic">Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) and International Financial Reporting Standards (&#8220;IFRSs&#8221;).</font> &#160;This standard updates accounting guidance to clarify the measurement of fair value to align the guidance and improve the comparability surrounding fair value measurement within GAAP and IFRSs.&#160; The standard also updates requirements for measuring fair value and expands the required disclosures.&#160; The standard does not require additional fair value measurements and was not intended to establish valuation standards or affect valuation practices outside of financial reporting.&#160; This standard will become effective for the Company on January 1, 2012.&#160; The Company does not expect that the adoption of this standard will have a material impact when applied prospectively on the Company&#8217;s financial statements or required disclosures.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In June 2011, the FASB issued ASU No. 2011-05, <font style="DISPLAY: inline; FONT-STYLE: italic">Presentation of Comprehensive Income.</font>&#160;This standard eliminates the current option to report other comprehensive income and its components in the statement of changes in equity. The standard is intended to enhance comparability between entities that report under US&#160;GAAP and those that report under IFRS, and to provide a more consistent method of presenting non-owner transactions that affect an entity's equity. Under the ASU, an entity can elect to present items of net income and other comprehensive income in one continuous statement, referred to as the statement of comprehensive income, or in two separate, but consecutive, statements. Each component of net income and each component of other comprehensive income, together with totals for comprehensive income and its two parts, net income and other comprehensive income, would need to be displayed under either alternative. The statement(s) would need to be presented with equal prominence as the other primary financial statements. The ASU does not change items that constitute net income and other comprehensive income, when an item of other comprehensive income must be reclassified to net income or the earnings-per-share computation (which will continue to be based on net income). The new US&#160;GAAP requirements are effective for public entities as of the beginning of a fiscal year that begins after December&#160;15, 2011 and interim and annual periods thereafter. Early adoption is permitted, but full retrospective application is required under the accounting standard. The Company does not expect that the adoption of this standard will have a material impact on our results of operations, cash flows, and financial position.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In September 2011, the FASB issued ASU No. 2011-08, <font style="DISPLAY: inline; FONT-STYLE: italic">Intangibles &#8211; Goodwill and Other (Topic 350) Testing Goodwill for Impairment.</font>&#160;&#160;This standard simplifies how an entity tests goodwill for impairment and allows an entity to first assess qualitative factors in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test.&#160;&#160;This standard is effective for entities as of the beginning of a fiscal year that begins after December 15, 2011 and interim and annual periods thereafter.&#160;&#160;Early adoption is permitted.&#160;&#160;The Company does not expect the adoption of this standard will have a material impact on our results of operations, cash flows, and financial position.</font> </div></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Reclassifications</font> &#8212; Certain prior-period amounts have been reclassified to conform to the current-period presentation.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="FIS_UNIDENTIFIED_TABLE_18"><!--EFPlaceholder--></a>3.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FAIR VALUES OF ASSETS AND LIABILITIES</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In accordance with Fair Value Measurements and Disclosures Topic of the FASB ASC, the Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level 1: Input prices quoted in an active market for identical financial assets or liabilities.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable or supported by an active market.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Assets and liabilities measured at fair value on a recurring basis are summarized below:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="14" valign="bottom" width="58%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">September 30, 2011</font></font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level 1</font></font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level 2</font></font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level 3</font></font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Fair Value</font></font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr>
<td valign="bottom" width="40%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liabilities:</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 4px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">77,967</font></font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">77,967</font></font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="14" valign="bottom" width="58%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">December 31, 2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level 1</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level 2</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level 3</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Fair Value</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 4px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Assumptions used are generally consistent with those disclosed for stock-based compensation (see Note 11).</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-11</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ACQUISITION</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Merger Agreement</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 8, 2011, Novelos acquired Cellectar through a merger with and into the Merger Subsidiary, pursuant to the merger Agreement entered into on that date.&#160; As a result of the Acquisition, the Merger Subsidiary, which has been renamed Cellectar, Inc., owns all assets of and operates the business previously owned and operated by Cellectar.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the Acquisition, the former stockholders of Cellectar received an aggregate number of shares of Novelos common stock constituting approximately 85% of the outstanding shares of Novelos common stock, after giving effect to the Acquisition but before giving effect to the concurrent private placement of Novelos securities described below.&#160; Prior to the Acquisition, Novelos amended and restated its certificate of incorporation and in connection therewith, among other things, effected a 1-for-153 reverse split of its common stock (the &#8220;Reverse Split&#8221;) resulting in&#160;2,959,871 shares of Novelos common stock outstanding. Novelos then issued 17,001,596 shares of Novelos common stock to the stockholders of Cellectar upon the effective date of the Acquisition.&#160; Warrants and options to purchase Novelos common stock that were outstanding prior to the Acquisition remained outstanding following the Acquisition. These consist of warrants to purchase a total of 315,164 shares of Novelos common stock with prices ranging from $16.07 to $191.25 and options to purchase a total of 49,159 shares of Novelos common stock with prices ranging from $1.53 to $1,072.53.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XMS Capital Partners, the financial advisor to Cellectar in connection with the Acquisition, received a cash fee of $200,000 upon the completion of the Acquisition in consideration of their services.&#160; Rodman &amp; Renshaw, LLC (&#8220;Rodman&#8221;), financial advisor to Novelos in connection with the Acquisition, received a cash fee of $250,000 upon the completion of the Acquisition in consideration of their services.&#160; These amounts were recorded as merger costs and expensed as incurred on the date of the Acquisition.&#160; In addition to the investment banking fees, the Company also incurred an additional $296,207 of merger-related legal and other costs during the nine months ended September 30, 2011 which were included as a component of expense in the respective period.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Acquisition was completed principally to leverage synergies between Novelos&#8217; strategic focus and experience in developing and funding the development of cancer drugs and Cellectar&#8217;s portfolio of cancer-targeted compounds.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Purchase Accounting</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Acquisition was accounted for using the purchase method of accounting as a reverse acquisition.&#160; In a reverse acquisition, the post-acquisition net assets of the surviving combined company includes the historical cost basis of the net assets of the accounting acquirer (Cellectar) plus the fair value of the net assets of the accounting acquiree (Novelos).&#160; Further, under the purchase method, the purchase price is allocated to the assets acquired and liabilities assumed based on their estimated fair values and the excess of the purchase price over the estimated fair value of the identifiable net assets is presented as excess purchase price over net assets acquired.&#160; The cost of acquisition and related purchase-price allocation is based on preliminary evaluation of the fair value of assets and liabilities assumed from Novelos and may change when the final valuation of certain intangible assets is determined.&#160; The evaluation is preliminary principally due to the pending evaluation of the Company&#8217;s intangible assets.&#160; The excess of purchase price over net assets acquired will be allocated to intangibles and goodwill once the Company completes the final allocation of purchase price.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The fair value of the consideration transferred in the Acquisition was $2,219,903 and was calculated as the number of shares of common stock that Cellectar would have had to issue (adjusted for the Exchange Ratio) in order for Novelos shareholders to obtain a 15% equity interest in the combined Company post-acquisition, multiplied by the estimated fair value of the Company<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#8217;</font>s common stock on the acquisition date.&#160; The estimated fair value of the Company&#8217;s common stock was based on the offering price of the common stock sold in the private placement which was both completed concurrently with and conditioned upon the closing of the Acquisition.&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This price was determined to be the best indication of fair value on that date since the price was based on an arm&#8217;s length negotiation with a group consisting of both new and existing investors that had been advised of the pending Acquisition and assumed similar liquidity risk as those investors holding the majority of shares being valued as purchase consideration.</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes the Company&#8217;s preliminary estimated fair values of the assets acquired and the liabilities assumed at the date of acquisition.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="85%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consideration - issuance of securities</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,219,903</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="85%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="85%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Prepaid expenses and other assets</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">71,892</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="85%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fixed assets</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,515</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="85%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(380,130</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="85%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Derivative liability</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(59,485</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="85%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Excess of purchase price over net assets acquired</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,675,462</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="85%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="85%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total purchase price &#8211; net of cash acquired of $905,649</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,314,254</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-12</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The excess of purchase price over net assets acquired will be allocated to intangibles, which could potentially include the fair value of the compounds developed prior to the Acquisition by Novelos, with the remainder allocated to goodwill once the Company completes the final allocation of purchase price.&#160; The estimated fair values of assets acquired and liabilities assumed are provisional and are based on the information that was available as of the acquisition date to estimate the fair value of assets acquired and liabilities assumed.&#160; The Company believes that the information provides a reasonable basis for estimating the fair values of assets acquired and liabilities assumed, but the Company is waiting for additional information necessary to finalize those fair values.&#160; Therefore, the provisional measurements of fair value reflected are subject to change and such changes may be significant.&#160; The Company expects to finalize the valuation and complete the purchase price allocation as soon as practicable but no later than one year from the acquisition date.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FIXED ASSETS</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fixed assets consisted of the following at December 31:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Office and laboratory equipment</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,984,375</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,982,723</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Leasehold improvements</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,317,597</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,317,597</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total fixed assets</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,301,972</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,300,320</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Less accumulated depreciation and amortization</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,791,483</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,211,369</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fixed assets, net</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,510,489</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">4,088,951</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">During the nine months ended&#160;September 30, 2011, the change to net fixed assets consisted of an increase of approximately $440,000 related to accumulated depreciation and amortization, purchases of equipment totaling approximately $112,000, equipment disposals of approximately $6,000, and approximately $7,000 related to the fair value of fixed assets acquired as a result of the Acquisition (see Note 4).</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LICENSE AGREEMENTS</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">2003 License Agreement with the University of Michigan</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In September 2003, Cellectar entered into an exclusive license agreement (the &#8220;U. Mich. Agreement&#8221;) with the Regents of the University of Michigan, (&#8220;U. Mich.&#8221;) for the development, manufacture and marketing of products under several composition of matter patents in North America which expire at varying dates in 2016.&#160; The U. Mich. Agreement expires upon the expiration of the last covered patent.&#160; The Company is responsible for an annual license fee of $10,000 and is required to pay costs associated with the maintenance of the patents covered by the U. Mich. Agreement.&#160; Additionally, the Company is required to make milestone payments of $50,000 upon the filing of a New Drug Application (&#8220;NDA&#8221;) for a licensed product intended for use in a therapeutic or diagnostic application (such milestone fees may be deferred and paid within 12 months of the first commercial sale of such products) and make certain milestone payments within a year following the first commercial sale of any licensed products.&#160; The sales milestones range from $100,000 to $200,000, dependent upon whether the drug is for use in a therapeutic or diagnostic application, provided that if sales in the first 12 months are less than the amount of the milestone, then we are required to pay 50% of all sales until the milestone is satisfied.&#160;The milestone payments may&#160;total up to $400,000. The U. Mich. Agreement provides that the Company pay a royalty equal to 3% of net sales of any licensed products sold by the Company or its sublicensees for such licensed products, provided however if the sublicense fee payable to the Company is between 4%-5% of net sales, then the royalties payable to U. Mich. shall be equal to 50% of the sublicense fee.&#160; Furthermore, the U. Mich. Agreement provides for a reduction in the royalties owed by up to 50% if the Company is required to pay royalties to any third parties related to the sale of the licensed products.&#160; If we receive any revenue in consideration for rights to the licensed technology that is not based on net sales, excluding any funded research and development, we are required to pay U. Mich. 10% of amounts received.&#160; U. Mich. may terminate the agreement if the Company ceases operations, if the Company fails to make any required payment under the agreement, or if the Company otherwise materially breaches the agreement, subject to the applicable notice and cure periods.&#160; To date, the Company has made all payments as they have become due, there have been no defaults under the U. Mich. Agreement, nor has the Company been notified of a default by U. Mich. The Company may terminate the agreement with six months notice to U. Mich. and the return of licensed product and related data.&#160; The U. Mich. Agreement contained milestones that required certain development activities to be completed by specified dates. All such development milestones have either been completed or have been removed by subsequent amendment to the agreement.&#160; U. Mich. has provided no warranties as to validity or otherwise with respect to the licensed technology.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cellectar paid approximately $600,&#160;$300 and $5,000 to U. Michigan for the reimbursement of patent maintenance fees during the nine months ended September 30, 2011 and the years ended December 31, 2010 and 2009, respectively.&#160; As of September 30, 2011 and December 31, 2010, all annual license fees have been paid in a timely manner.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In connection with the Michigan Agreement, during 2003 Cellectar paid approximately $54,000 of back patent costs and issued 203,483 shares of common stock to U. Michigan as partial consideration for the rights described above.&#160; The estimated fair-market value of the issuance was $80,412 and was recorded as a license cost and is included as a component of stockholders equity in the accompanying balance sheets.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-13</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">License Agreement with Wisconsin Alumni Research Foundation</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In January 2006, Cellectar entered into a license agreement (the &#8220;WARF Agreement&#8221;) with the Wisconsin Alumni Research Foundation (&#8220;WARF&#8221;) under which Cellectar received a license, with a right to grant sublicenses, to develop, manufacture, and market products with respect to certain patents.&#160; The WARF Agreement required an initial license fee of $8,800 and provided that Cellectar pay royalties equal to 0.3% of sales of any licensed products.&#160; Cellectar was also required to reimburse WARF for patent filing fees and related costs.&#160; During the years ended December 31, 2010 and 2009, there were no costs related to the patents under the WARF Agreement.&#160;&#160;During 2010, the WARF Agreement was terminated.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Novelos License Agreements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During 2007, Novelos entered into a Collaboration Agreement with Lee&#8217;s Pharmaceutical (HK) Ltd. (&#8220;Lee&#8217;s Pharm&#8221;) whereby Lee&#8217;s Pharm obtained an exclusive license to develop, manufacture and commercialize NOV-002 and NOV-205 in China, Hong Kong, Taiwan and Macau (the &#8220;Chinese Territory&#8221;). Under the terms of the agreement the Company is entitled to receive up to $1,700,000 in future milestone payments upon the completion of development and marketing milestones by Lee&#8217;s Pharm and to receive royalty payments of between 12-25% of net sales of NOV-205 and NOV-002, as applicable, in the Chinese Territory and receive royalty payments of 12-15% of net sales of NOV-205 in the Chinese Territory. The agreement expires upon the expiration of the last patent covering any of the licensed products, or twelve years from the date of the first commercial sale in China, whichever occurs later.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During 2009, Novelos entered into a collaboration agreement (the &#8220;Collaboration Agreement&#8221;) with Mundipharma International Corporation Limited (&#8220;Mundipharma&#8221;) to develop, manufacture and commercialize, on an exclusive basis, Licensed Products (as defined in the Collaboration Agreement), including NOV-002, in Europe (other than the Russian Territory), Asia (other than the Chinese Territory) and Australia (collectively referred to as the &#8220;Mundipharma Territory&#8221;).&#160; Mundipharma is an independent associated company of Purdue Pharma, L.P. (&#8220;Purdue&#8221;).&#160; The Collaboration Agreement provides for Mundipharma to pay the Company royalties and fixed milestone payments based on sales and commercial launches in the licensed territories.&#160; For countries in which patents are held, the Collaboration Agreement expires on a country-by-country basis within the Mundipharma Territory on the earlier of (1) expiration of the last applicable Novelos patent within the country or (2) the determination that any patents within the country are invalid, obvious or otherwise unenforceable.&#160; For countries in which no patents are held, the Collaboration Agreement expires the earlier of 15 years from its effective date or upon generic product competition in the country resulting in a 20% drop in Mundipharma&#8217;s market share.&#160; The Company may terminate the Collaboration Agreement upon breach or default by Mundipharma.&#160; Mundipharma may terminate the Collaboration Agreement upon breach or default, filing of voluntary or involuntary bankruptcy by Novelos, the termination of certain agreements with companies associated with the originators of the licensed technology, or 30-day notice for no reason.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has suspended development of the products covered by the collaboration agreements described above. The Company does not anticipate that the collaboration agreements will have a material effect on its results of operations, cash flows, and financial position following the Acquisition.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CONVERTIBLE DEBT</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On January 25, 2010, Cellectar issued nine convertible promissory notes (&#8220;Convertible Notes&#8221;) in an aggregate principal amount of $2,720,985.&#160; The Convertible Notes provided for interest of 12% compounded annually with a maturity date of the earlier of (i) the date on which Cellectar&#8217;s cash reserves fall below $250,000 or (ii) January 20, 2011.&#160; Upon an event of default, as defined, the interest rate increased by 10% to 22%.&#160; The outstanding principal balance, together with any unpaid interest, was convertible immediately, by the lender, into common stock of the Company at $0.82987 per share (giving effect to the Exchange Ratio).&#160; Furthermore, the Convertible Notes were subject to an automatic conversion feature equal to 70% of the per share price of a qualified financing, should the Company complete a qualified financing transaction which raises at least $20,000,000 in proceeds to the Company.&#160; Since the Convertible Notes were convertible into common stock at date of issuance at a per share price which was less than the estimated fair value of the Company&#8217;s common stock at that date, the Convertible Notes contained a beneficial conversion feature (&#8220;BCF&#8221;).&#160; The estimated intrinsic value of the BCF of $213,792 was determined as the difference between the conversion price and the estimated fair value of Cellectar common stock on the date of issuance, multiplied by the 3,278,786 shares of common stock into which the Convertible Notes were convertible at issuance. This amount was recorded as a component of interest expense on the date of issuance.&#160; The estimated per-share fair value of Cellectar common stock was determined by management based on a number of factors including an independent valuation, which was determined to be the best indication of the fair value as of the issuance date of the Convertible Notes.&#160; Since the conversion price was subject to adjustment in the event of a qualified transaction, as defined, the Convertible Notes also contain a contingent beneficial conversion feature (&#8220;CBCF&#8221;).&#160; This contingency did not materialize; therefore no intrinsic value was allocated to the CBCF.&#160; As of December 31, 2010 and 2009, principal of $2,720,985 and $0 was outstanding, respectively, on the Convertible Notes.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of December 31, 2010, the Convertible Notes are classified as a long-term obligation on the accompanying balance sheets as a result of the conversion of the short-term obligation through the issuance of equity securities in connection with the Acquisition.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-14</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On January 20, 2011, the Convertible Notes matured but remained unpaid.&#160; Following the maturity and default of the Convertible Notes, the holders of the Convertible Notes agreed that all of the outstanding notes would be automatically converted simultaneous with the completion of an acquisition and financing (the &#8220;Conversion Time&#8221;), if completed.&#160; The amount of shares issued upon such conversion would be dependent on the amount of investment made by the note holders at the Conversion Time and were negotiated based on outstanding principal and projected accrued interest based on an assumed closing date for the acquisition and financing.&#160; Since the number of shares to be issued upon conversion could not be determined until the Conversion Time the Convertible Notes contained a CBCF.&#160; On April 1, 2011, Cellectar&#8217;s Board of Directors voted to accept the note holders consent to convert the Convertible Notes into 4,181,535 shares of common stock immediately prior to the Acquisition.&#160; On April 8, 2011, immediately prior to the Acquisition, the principal and unpaid interest on the Convertible Notes was converted into the agreed total of 4,181,535 shares of common stock.&#160; Upon conversion of the Convertible Notes, the Company reclassified the aggregate outstanding principal and interest totaling $3,184,706 to a component of additional paid-in capital.&#160; The revised conversion terms resulted in the issuance of an additional 343,963 shares of common stock over the 3,837,572 shares of common stock that would have been issued if the unpaid principal and accrued interest on the Convertible Notes had been converted on that date in accordance with their original terms at the stated conversion price.&#160; On the date of conversion, the Company determined that the value of these additional shares was $257,973, based on the $0.75 per share offering price of the common stock sold in the private placement completed concurrently with the Acquisition, which is the best indication of fair value on the date of conversion.&#160; Since the conversion was not completed until April 8, 2011, the value of the additional shares of $257,973 was recorded as a component of interest expense during the second quarter of 2011.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.&#160; LONG-TERM NOTES PAYABLE</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On January 11, 2008, Cellectar entered into a loan agreement with a bank to borrow up to $1,200,000.&#160; The borrowing, evidenced by a note (the &#8220;Bank Note&#8221;), bore interest at a rate of 7.01% per annum, could be prepaid without penalty and was payable in 48 monthly principal and interest payments of $20,520 with a balloon payment of any remaining unpaid principal and interest on March 28, 2012.&#160; In the event of default of payment, Cellectar would be required to pay a late charge equal to 5% of the delinquent payment and the interest rate on the unpaid principal would be increased by 3%.&#160; The Bank Note was collateralized by substantially all assets of Cellectar and a deposit account in the amount of $500,000.&#160; The cash collateral is classified as restricted cash in the accompanying balance sheet.&#160; As of December 31, 2010 and 2009, $470,941 and $675,743 are classified as a long-term note payable in the accompanying balance sheet, respectively.&#160; On April 8, 2011, immediately prior to the Acquisition, Cellectar paid approximately $627,000 in full settlement of the Bank Note. The payment was made in order to avoid an event of default that would have occurred as a result of the change of control that occurred at the time of the Acquisition.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On September 15, 2010, Cellectar entered into certain loan agreements with the Wisconsin Department of Commerce (&#8220;WDOC Notes&#8221;) to borrow a total of $450,000.&#160; The WDOC Notes bear interest at 2% per annum beginning on the date of disbursement and allow for the deferral of interest and principal payments until April 30, 2015.&#160; In the event of default of payment, interest on the delinquent payment is payable at a rate equal to 12% per annum.&#160; Monthly payments of $20,665 for principal and interest shall commence on May 1, 2015 and continue for 23 equal installments with the final installment of any remaining unpaid principal and interest due on April 1, 2017.&#160; As of December 31, 2010, $450,000 is classified as a long-term note payable in the accompanying balance sheet.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Long-term notes payable consists of the following as of December 31:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNIDENTIFIED_TABLE_19"><!--EFPlaceholder--></a><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2009</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bank Note, 7.01% interest</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">675,743</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">866,532</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Wisconsin Department of Commerce,&#160; 2% interest</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">450,000</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,125,743</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">866,532</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Less current portion</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(204,802</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(190,789</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Long-term note payable, net of current portion</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">920,941</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">675,743</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of December 31, 2010, long-term notes payable matures as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table cellpadding="0" cellspacing="0" width="70%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="85%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Years ended December 31,</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="85%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="fis_unidentified_table_20"><!--efplaceholder--></a>2011</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">204,802</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="85%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2012</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">470,941</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="85%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2013</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="85%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2014</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="85%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2015</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">119,957</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="85%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thereafter</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">330,043</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="85%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,125,743</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-15</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">During the nine-months ended September 30, 2011, payments of $675,743 were made in connection with the Bank Note including a payment of approximately $627,000 in full settlement of the Bank Note made immediately prior to the Acquisition in order to avoid an event of default that would have occurred as a result of the change in control that occurred at the time of the Acquisition.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">As of September 30, 2011, the outstanding principal on the WDOC Notes of $450,000 is classified as long-term debt outstanding in the accompanying balance sheet.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LINE OF CREDIT</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In 2009, Cellectar had a $100,000 line of credit with a bank.&#160; Borrowings under the line of credit bore interest at LIBOR plus 3.25% with a 4.5% minimum rate.&#160; The line of credit expired on January 10, 2010 and was not renewed.&#160; There were no amounts outstanding under the line as of December 31, 2009.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10. STOCKHOLDERS&#8217; EQUITY</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On January 1, 2008, Cellectar converted from a Wisconsin limited liability company to a Wisconsin corporation (the &#8220;Conversion&#8221;). Each issued and outstanding unit of equity in the limited liability company immediately prior to the Conversion was converted into one issued and outstanding share of Cellectar common stock and each unexercised unit option outstanding immediately prior to the Conversion was converted into an option to acquire the same number of shares of the corporation&#8217;s common stock.&#160; For the purpose of presentation in these financial statements, all amounts and disclosures related to equity issuances prior to the Acquisition have been retroactively restated by applying the Exchange Ratio in order to reflect the capital structure of Novelos and therefore the issuance of Novelos common stock, rather than member units in the limited liability company or common stock of Cellectar, as applicable.</font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">From inception until December 31, 2010, Cellectar issued 12,559,218 shares of common stock for net proceeds of approximately $21,710,000.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">April 2011 Private Placement</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Concurrently with and conditioned upon the execution of the Merger Agreement, the Company entered into a Securities Purchase Agreement with certain accredited investors under which the Company sold an aggregate of 6,846,537 units, each unit consisting of one share of its common stock and a warrant to purchase one share of its common stock, at a price of $0.75 per unit, for gross proceeds of approximately $5,135,000 (the &#8220;April Private Placement&#8221;).&#160; The warrants have an exercise price of $0.75 and expire on March 31, 2016.&#160; The warrant exercise price and/or the common stock issuable pursuant to such warrant will be subject to adjustment only for stock dividends, stock splits or similar capital reorganizations so that the rights of the warrant holders after such event will be equivalent to the rights of warrant holders prior to such event.&#160; The relative fair value of the warrants issued to the investors was $2,124,286 at issuance and has been included as a component of stockholders&#8217; equity.&#160; The Company uses the Black-Scholes option pricing model to value warrants and applies assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants. Assumptions used are generally consistent with those disclosed for stock-based compensation (see Note 11).</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Securities Purchase Agreement included a requirement that the Company file with the SEC no later than October 5, 2011 (the "Filing Deadline"), a registration statement covering the resale of the shares of common stock, and the shares of common stock underlying the warrants, issued pursuant to the Securities Purchase Agreement that are not otherwise saleable under an available exemption from registration requirements.&#160; The Company is also required to use commercially reasonable efforts to have the registration statement declared effective by December 4, 2011 (the "Effectiveness Deadline"), and to keep the registration statement continuously effective under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), until the earlier of the date when all the registrable securities covered by the registration statement have been sold or the second anniversary of the closing.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In the event the Company fails to file the registration statement within the timeframe specified by the Securities Purchase Agreement, or if it fails to obtain effectiveness of this registration on or prior to the December 4, 2011 (if there is no review by the SEC) or by January 3, 2012 (if there is review by the SEC) with respect to the maximum number of shares permitted to be registered by the SEC, the Company will be required to pay to the purchasers liquidated damages equal to 1.5% per month (pro-rated on a daily basis for any period of less than a full month) of the aggregate purchase price of the units purchased until the registration statement is filed or declared effective, as applicable, not to exceed 5% of the aggregate purchase price.&#160; The Company will be allowed to suspend the use of the registration statement for not more than 30 consecutive days, on not more than two occasions, in any 12-month period.&#160; The Company has also granted piggy-back registration rights with respect to any shares of common stock that it is required to exclude from the registration statement as a condition of its effectiveness, and has also agreed to file further registration statements with respect to any such shares six months after the effective date of the initial registration statement. </font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On November 3, 2011, a majority of purchasers in the April Private Placement, which majority constituted the requisite holders, as defined by the applicable securities purchase agreement, consented to extend the Filing Deadline to the 180<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> day following the final prospectus of a public offering of securities contemplated by the Company and to extend the Effectiveness Deadline to the 240<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> day following the final prospectus of the public offering.&#160;&#160;As of September 30, 2011, and through the date of this filing, the Company has not concluded that it is probable that damages will become due; therefore, no accrual for damages has been recorded.&#160;&#160;The Company will use its reasonable best efforts to register the shares as may be permitted by the SEC until such time as all of these shares either have been registered or may be sold without restriction in reliance on Rule 144 under the Securities Act.</font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-16</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company paid to Rodman, the placement agent for the financing, a cash fee equal to $200,000 and issued warrants to purchase 192,931 shares of its common stock (having an exercise price of $0.75 and which expire March 31, 2016) in consideration for their advisory services with respect to the financing pursuant to the placement agency agreement between Rodman and the Company.&#160; Rodman is entitled to registration rights with respect to the shares of common stock issuable upon exercise of these warrants.&#160; The cash fee was recorded as a reduction of gross proceeds received.&#160; The estimated fair value of the warrants issued to the placement agent was $112,096 and was recorded as a component of stockholders&#8217; equity.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Common Stock Warrants</font> &#160;&#8212; The following table summarizes information with regard to outstanding warrants to purchase common stock as of September 30, 2011.&#160; There were no outstanding common stock purchase warrants as of December 31, 2010 and 2009.&#160; The Company issued warrants to purchase 7,039,468 shares of common stock in connection with the April Private Placement.&#160; In addition, outstanding warrants to purchase 315,164 shares of common stock, originally issued in connection with Novelos equity and debt financings from 2007 through 2010, remained outstanding subsequent to the Acquisition (Note 4).</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 36pt" align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="50%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Offering</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Number&#160;of&#160;Shares</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Issuable&#160;Upon</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise&#160;of</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Outstanding</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Warrants</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Price</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Expiration&#160;Date</font></font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 8, 2011 Private Placement</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,039,468</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.75</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">March 31, 2016</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series B Preferred Stock &#8211; placement agents</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,392</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">191.25</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 2, 2012</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series C Exchange</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,169</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">191.25</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 2, 2012</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series E Preferred Stock</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">60,330</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.45</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" nowrap valign="bottom" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31, 2015</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">August 2009 Private Placement</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31,194</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100.98</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31, 2015</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 2010 Direct Offering (1)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">77,729</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.75</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 27, 2015</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Preferred Incentive Warrants</font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">105,040</font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16.065</font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="20%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 27, 2015</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">7,327,322</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="20%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)&#160; The exercise price of these warrants was adjusted to $0.75 per share in connection with the private placement completed on April 8, 2011.&#160; This warrant has been accounted for as a derivative instrument as described in Note 2.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On May 4, 2011, 18,153 shares of common stock were issued in connection with the cashless exercise of warrants to purchase 27,310 shares of common stock at $0.75 per share.&#160; The Company reclassified $48,339 from the derivative liability to additional paid-in capital upon the exercise of the warrants.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following shares were reserved for future issuance upon exercise of stock options and warrants or conversion of debt:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNIDENTIFIED_TABLE_21"><!--EFPlaceholder--></a><br>
</div>

<div style="MARGIN-LEFT: 36pt; TEXT-ALIGN: left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: left;">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">December&#160;31,</font></font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr>
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(unaudited)</font></font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2009</font></font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,327,322</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock options</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,632,638</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">769,189</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">991,736</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Convertible notes</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,646,370</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total number of shares reserved for future issuance</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">10,959,960</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">4,415,559</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">991,736</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11.&#160; STOCK-BASED COMPENSATION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cellectar&#8217;s stock-based compensation plans prior to the Acquisition are summarized below:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">2006 Unit Option Plan.&#160; </font>The 2006 Unit Option Plan (the &#8220;2006 Cellectar Plan&#8221;), as amended and restated, provided Cellectar the ability to grant to employees, directors, consultants, and other non-employees units of interest in Cellectar.&#160; The maximum aggregate number of shares that were subject to grant under the 2006 Cellectar Plan was 1,012,200.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-17</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cellectar granted 631,360 unit options under the 2006 Cellectar Plan and no additional grants will be made thereunder.&#160; In connection with the Conversion described in Note 10, each issued and outstanding unexercised unit option outstanding immediately prior to the Conversion was converted into an option to acquire the same number of shares of Cellectar&#8217;s common stock.&#160; A total of 606,889 and 691,248 options to purchase shares of Cellectar&#8217;s common stock were outstanding under the 2006 Cellectar Plan as of December 31, 2010 and 2009, respectively.&#160; These options generally vested annually over four years and expire on the eighth anniversary of the grant date.&#160; No options were granted under the 2006 Cellectar Plan during 2010 or 2009.&#160; There have been no exercises of options issued under the 2006 Cellectar Plan.&#160; On March 17, 2011, in contemplation of the Acquisition, Cellectar terminated the remaining options outstanding under the 2006 Cellectar Plan as of that date.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">2008 Stock Incentive Plan</font>.&#160; The 2008 Stock Incentive Plan (the &#8220;2008 Plan&#8221;) provided Cellectar the ability to grant to employees, directors, consultants and other non-employees of Cellectar options to purchase common stock.&#160; The maximum aggregate number of shares that were subject to grant under the 2008 Plan was 823,930.&#160; Cellectar granted a total of 382,223 options under the 2008 Plan.&#160; A total of 162,300 and 300,488 options to purchase shares of Cellectar&#8217;s common stock were outstanding as of December 31, 2010 and 2009, respectively.&#160; These options generally vested annually over four years and expire on the tenth anniversary of the grant date.&#160; &#160;During 2009, 90,929 options were granted under the 2008 Plan.&#160; During 2010, no options were granted under the 2008 Plan. No options have been exercised.&#160; On March 17, 2011, in contemplation of the Acquisition, Cellectar terminated the remaining options outstanding under the 2008 Plan as of that date.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of December 31, 2010, an aggregate of 1,066,941 shares were available for grant under the 2006 Cellectar Plan and 2008 Plan.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cellectar&#8217;s Board of Directors determined exercise prices and vesting periods on the date of grant, subject to the provisions of the 2006 Cellectar Plan and 2008 Plan.&#160; Options have been granted at or above the estimated fair-market value of the common stock at the grant date. Options granted pursuant to the 2006 Cellectar Plan and 2008 Plan generally would have become fully vested in the event of a business combination whereby the options are not assumed or replaced by the surviving company, as defined.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with the Acquisition, the Company assumed options to purchase 49,159 shares of common stock at exercise prices ranging from $1.53 to $1,072.53.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">2006 Novelos Stock Option Plan.</font>&#160; Following the Acquisition, option grants to directors and employees will be made under the Novelos Therapeutics 2006 Stock Incentive Plan (the &#8220;Plan&#8221;).&#160; On May 18, 2011, the Board of Directors of the Company approved certain amendments to the Plan to, among other things, increase the aggregate number of shares of the Company&#8217;s common stock reserved for issuance under the Plan (including any shares that have already been issued thereunder), to 7,000,000 and remove the 750,000 share annual individual limitation on grants under the Plan.&#160; On June 30, 2011, the Company&#8217;s stockholders ratified those amendments.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A total of 7,000,000 shares of common stock are reserved for issuance under the Plan for grants of incentive or nonqualified stock options, rights to purchase restricted and unrestricted shares of common stock, stock appreciation rights and performance share grants.&#160; A committee of the board of directors determines exercise prices, vesting periods and any performance requirements on the date of grant, subject to the provisions of the Plan.&#160; Options are granted at or above the fair market value of the common stock at the grant date and expire on the tenth anniversary of the grant date.&#160; Vesting periods are generally between one and four years.&#160; Options granted pursuant to the Plan generally will become fully vested upon a termination event occurring within one year following a change in control, as defined.&#160; A termination event is defined as either termination of employment or services other than for cause or constructive termination of employees or consultants resulting from a significant reduction in either the nature or scope of duties and responsibilities, a reduction in compensation or a required relocation.&#160; As of September 30, 2011, there are an aggregate of 3,476,112 shares available for grant under the Plan.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounting for Stock-Based Compensation</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employee stock-based compensation is accounted for in accordance with the guidance of FASB ASC Topic 718, <font style="DISPLAY: inline; FONT-STYLE: italic">Compensation &#8211; Stock Compensation</font> which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values.&#160; Non-employee stock-based compensation is accounted for in accordance with the guidance of FASB ASC Topic 505, <font style="DISPLAY: inline; FONT-STYLE: italic">Equity</font>. As such, the Company recognizes expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed by such non-employees.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-18</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and stock-based compensation recorded in connection with stock options granted to non-employee consultants:</font></div>

<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 4.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nine Months Ended</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 4.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 4.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(unaudited)</font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 4.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Year Ended</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 4.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31,</font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cumulative Development- Stage Period from November 7, 2002 through December 31,</font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr>
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Employee and director stock option grants:</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" colspan="2" valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" colspan="2" valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" colspan="2" valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" colspan="2" valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" colspan="2" valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">121,393</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">52,492</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">61,791</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">87,598</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">298,386</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">349,781</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">278,694</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">291,549</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">414,401</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,577,303</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">471,174</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">331,186</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">353,340</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">501,999</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,875,689</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-employee consultant stock option grants:</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">46,851</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">200</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">71,724</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">137,631</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">184,482</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">200</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">71,724</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total stock-based compensation</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">655,656</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">331,186</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">353,340</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">502,199</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,947,413</font> </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On July 14, 2010, the expiration date of vested options held by a former employee was extended until July 8, 2015.&#160; The extension constituted a modification to the terms of the award and additional stock-based compensation was measured as the excess of the fair value of the modified award over the fair value of the original award immediately before the modification.&#160; Accordingly, incremental stock-based compensation expense of approximately&#160;$20,000 was recorded in connection with the modification.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Company granted 3,496,400 stock options to employees and non-employees during the nine months ended September 30, 2011 under the Plan.&#160; The Company issued options to purchase a total of 200,000 shares of common stock to non-employees outside of any formalized plan, but 100,000 were forfeited as a result of the cancellation and replacement as described below.&#160; Exercise prices for all grants made in the during the nine months ended September 30, 2011 were equal to the market value of the Company&#8217;s common stock on the date of grant.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On May 18, 2011, the Company cancelled 100,000 options originally granted on April 25, 2011 with an exercise price of $3.00 per share and issued 100,000 replacement stock option awards with an exercise price of $1.40.&#160; The cancellation and replacement constituted a modification to the terms of the award and additional stock-based compensation was measured as the excess of the fair value of the modified award over the fair value of the original award immediately before the modification.&#160; Accordingly, incremental stock-based compensation expense of $4,494 was recorded in connection with the modification.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="FIS_UNIDENTIFIED_TABLE_23"><!--EFPlaceholder--></a>Assumptions Used In Determining Fair Value</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Valuation and amortization method</font>. The fair value of each stock award is estimated on the grant date using the Black-Scholes option-pricing model.&#160; The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period.</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The estimated fair value of the non-employee options is amortized to expense over the period during which a non-employee is required to provide services for the award (usually the vesting period).</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Volatility.</font> Cellectar estimated volatility based on a review of volatility estimates of publicly held drug development companies in a similar stage of development. Subsequent to the Acquisition, the Company estimates volatility based on an average of (1) the Company&#8217;s historical volatility since its common stock has been publicly traded and (2) review of volatility estimates of publicly held drug development companies with similar market capitalizations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Risk-free interest rate</font>. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Expected term</font> . The expected term of stock options granted is based on an estimate of when options will be exercised in the future. The Company applied the simplified method of estimating the expected term of the options, as described in the SEC&#8217;s Staff Accounting Bulletins 107 and 110, as the Company has had a significant change in its business operations as result of the Acquisition and the historical experience is not indicative of the expected behavior in the future. The expected term, calculated under the simplified method, is applied to groups of stock options that have similar contractual terms. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. The Company applied the simplified method to non-employees who have a truncation of term based on termination of service and utilizes the contractual life of the stock options granted for those non-employee grants which do not have a truncation of service.</font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-19</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Forfeitures.</font> &#160; Stock-based compensation expense is recorded only for those awards that are expected to vest.&#160; FASB ASC Topic 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&#160; The term &#8220;forfeitures&#8221; is distinct from &#8220;cancellations&#8221; or &#8220;expirations&#8221; and represents only the unvested portion of the surrendered option.&#160; An annual forfeiture rate of 0% was applied to all unvested options as of December 31, 2010 as Cellectar had experienced very few forfeitures through 2009 and there was insufficient history to develop an accurate estimate of future forfeitures.&#160; An annual forfeiture rate of 0% was applied to all unvested options as of September 30, 2011 as the historical experience of forfeitures is not representative of expected future forfeiture rates as a result of the significant changes in the business operations as a result of the Acquisition.&#160; This analysis will be re-evaluated semi-annually and the forfeiture rate will be adjusted as necessary.&#160; Ultimately, the actual expense recognized over the vesting period will be for only those shares that vest.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes weighted-average values and assumptions used for options granted to employees, directors and consultants in the periods indicated:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="TEXT-ALIGN: center" align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: center;">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Nine Months</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Ended&#160;September</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">30,&#160;2011</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(unaudited)</font></font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Year&#160;Ended</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">December&#160;31,</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2009</font></font> </div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Volatility</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">110 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">85 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk-free interest rate</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.84% &#8211; 3.17 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td nowrap valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.72%-1.91 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected life (years)</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.5 &#8211; 6.25</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6.25</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dividend</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0 </font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted-average exercise price</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.45</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.76</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted-average grant-date fair value</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.22</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.55</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">There were no stock options granted in the nine months ended September 30, 2010 or the year ended December 31, 2010.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Stock Option Activity</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A summary of stock option activity under stock option plans is as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_OPTIONS"><!--EFPlaceholder--></a><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="95%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number&#160;of</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Issuable&#160;Upon</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercise&#160;of</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options</font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercise&#160;Price</font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Remaining</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Contracted</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Term&#160;in</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Years</font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Aggregate</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Intrinsic</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Value</font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding at November 7, 2002</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">922,654</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.52</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Forfeited</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(12,653</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.04</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding at January 1, 2009</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">910,001</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.86</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">90,929</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.76</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; &#160; Forfeited</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(9,194</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.72</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding at December 31, 2009</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">991,736</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.68</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Canceled</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(222,547</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.63</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding at December 31, 2010</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">769,189</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.69</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; &#160; Canceled</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(769,189</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.69</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="52%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options acquired in connection with a business combination</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,159</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100.52</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td valign="bottom" width="52%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,696,400</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.45</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="52%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Canceled</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(12,921</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">112.21</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td valign="bottom" width="52%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 446pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Forfeited</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(100,000</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.00</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding at September 30, 2011 (unaudited)</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,632,638</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.35</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vested, December 31, 2010</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">743,450</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.69</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.07</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unvested, December 31, 2010</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25,739</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.62</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.08</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></font> </div>
</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercisable at December 31, 2010</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">743,450</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.69</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.07</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vested, September 30, 2011 (unaudited)</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">332,685</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.47</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9.25</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unvested, September 30, 2011 (unaudited)</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,299,953</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.53</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9.63</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></font> </div>
</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercisable at September 30, 2011 (unaudited)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">332,685</font> </font></font></div>
</div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.47</font> </font></div>
</div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9.25</font> </font></div>
</div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-20</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The aggregate intrinsic value of options outstanding is calculated based on the positive difference between the estimated per share fair value of Cellectar&#8217;s common stock at the end of the respective period and the exercise price of the underlying options.&#160;As of December 31, 2010, the estimated fair-market value of Cellectar&#8217;s common stock at the end of the periods shown was less than the exercise price of the underlying options, as such, the aggregate intrinsic value is $0.&#160; As of September 30, 2011, the fair value of the Company&#8217;s common stock was less than the exercise price of the underlying options, as such, the aggregate intrinsic value was $0.&#160; There have been no option exercises to date. Shares of common stock issued upon the exercise of options are from authorized but unissued shares.</font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The weighted-average grant-date fair value of options granted during the year ended December 31, 2009 and for the period November 2, 2002 to December 31, 2009 was $0.55 and $1.90, respectively.&#160; There were no options granted during the year ended December 31, 2010.&#160; The total fair value of shares vested during December 31, 2010 and 2009 and for the period November 2, 2007 (date of inception) to December 31, 2010 was $199,600, $185,600 and $2,050,000, respectively.&#160; &#160;The weighted-average grant-date fair value of vested and unvested options outstanding at December 31, 2010 and 2009 was $2.01 and $1.91 and $1.85 and $1.88, respectively.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">As of December 31, 2010, there was approximately $58,000 and $0 of total unrecognized compensation cost related to unvested stock-based compensation arrangements related to employees and non-employees, respectively.&#160; Of the total unrecognized amount as of December 31, 2010, all was recognized in the nine months ended September 30, 2011.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 4, 2011, in contemplation of the Acquisition and in accordance with terms of the applicable option agreements, Cellectar accelerated the vesting on all outstanding and unvested options at that date and notified all option holders that any unexercised options as of March 17, 2011 would then be terminated.&#160; On March 17, 2011, Cellectar terminated all outstanding options.&#160; The remaining unamortized compensation expense of $58,000 was recorded related to the acceleration of outstanding options in the quarter ended March 31, 2011.&#160; No additional compensation expense was recorded related to the acceleration of unvested shares as the acceleration did not represent a modification to the original terms of the options.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">As of September 30, 2011, there was $2,728,294 of total unrecognized compensation cost related to unvested stock-based compensation arrangements.&#160; Of this total amount, the Company expects to recognize $281,357, $1,125,400, $858,452, $387,397 and $75,688 during 2011, 2012, 2013, 2014 and 2015, respectively.&#160; The Company expects 3,299,953 in unvested options to vest in the future.&#160; The weighted-average grant-date fair value of vested and unvested options outstanding at September 30, 2011 was $1.44 and $1.17, respectively.</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On October 6, 2011, the Company granted 70,000 options with an exercise price of $1.05, which was equal to the closing price of the Company&#8217;s common stock on the date of grant, to a non-employee in exchange for certain consulting services.&#160;&#160;The grant-date fair value using the Black-Scholes option pricing model was $0.85 per share, or $59,500.</font> </div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12. &#160;INCOME TAXES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Deferred tax assets consisted of the following at December 31:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2009</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred tax assets</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Federal net operating loss</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,116,804</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,754,001</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Federal research and development tax credit carryforwards</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">390,600</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">273,788</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Wisconsin net operating loss credit carryforwards</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">814,492</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">589,548</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Wisconsin research and development tax credit carryforwards</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">220,738</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">171,552</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation expense</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">552,859</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">415,060</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Charitable contribution carryforwards</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,725</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,725</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued liabilities</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">25,327</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">75,711</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total deferred tax assets</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,170,545</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,329,385</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred tax liabilities</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Depreciable and intangible assets</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(434,056</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(475,524</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total deferred tax liabilities</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(434,056</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(475,524</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net deferred tax assets</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,736,489</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,853,861</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Less valuation allowance</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(7,736,489</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(5,853,861</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total deferred tax assets</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-21</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of December 31, 2010, Cellectar had federal and state net operating loss carryforwards (&#8220;NOLs&#8221;) of approximately $15,684,000 and $15,633,000 respectively, which expire beginning in 2030 and 2025, respectively.&#160; In addition, Cellectar has federal and state research and development and investment tax credits of approximately $391,000 and $335,000, respectively.&#160; The amount of NOLs which may be utilized annually in future periods will be limited pursuant to Section 382 of the Internal Revenue Code as a result of substantial changes in the Company&#8217;s ownership that have occurred or that may occur in the future.&#160; The Company has not quantified the amount of such limitations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Because of the limited operating history, continuing losses and uncertainty associated with the utilization of the NOLs in the future, management has provided a full allowance against the gross deferred tax asset.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cellectar did not have unrecognized tax benefits or accrued interest and penalties at any time during the years ended December 31, 2010 and 2009, and does not anticipate having unrecognized tax benefits over the next twelve months.&#160; The Company is subject to audit by the IRS for tax periods commencing January 1, 2007.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For the nine-month period ended September 30, 2011, the federal and state NOLs increased by approximately $5,470,000 as a result of the loss recorded.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13. &#160; NET LOSS PER SHARE</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss, as adjusted, by the sum of the weighted average number of shares of common stock and the dilutive potential common stock equivalents then outstanding.&#160; Potential common stock equivalents consist of stock options and convertible debt.&#160; Since there is a net loss attributable to common stockholders for the nine months ended September 30, 2011 and 2010 and the years ended December 31, 2010 and 2009, the inclusion of common stock equivalents in the computation for those periods would be antidilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following potentially dilutive securities have been excluded from the computation of diluted net loss per share since their inclusion would be antidilutive:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Nine Months&#160;Ended&#160;September&#160;30,</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(unaudited)</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Twelve&#160;Months&#160;Ended</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">December&#160;31,</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Cumulative</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Development-</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Stage&#160;Period&#160;</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">from&#160;</font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">November</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">7,&#160;2002</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(inception)</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">through</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">December&#160;31,</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Consolidated</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2009</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Convertible debt</font> </div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,547,198</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,646,370</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,646,370</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font> </div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">7,327,322</font></font> </div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font> </div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font> </div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font> </div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font> </div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock options</font> </div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,632,638</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">775,853</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">769,189</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">991,736</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">769,189</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14.&#160; COMMITMENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Property Lease</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On September 5, 2007, Cellectar entered into a 36-month lease for office and manufacturing space, commencing September 15, 2007.&#160; The lease provides for the option to extend the lease under its current terms for seven additional two-year terms.&#160; Rent is $8,050 per month for the first year and then escalates by 3% per year for the duration of the term including any lease extension terms.&#160; The lease also requires the payment of monthly rent of $1,140 for approximately 3,400 square feet of expansion space.&#160; The monthly rent for the expansion space is fixed until such time as the expansion space is occupied at which time the rent would increase to the current per square foot rate in effect under the original lease terms.&#160; The Company is responsible for certain building-related costs such as property taxes, insurance, and repairs and maintenance.&#160; Rent expense is recognized on a straight-line basis and accordingly the difference between the recorded rent expense and the actual cash payments has been recorded as deferred rent as of each balance sheet dates.&#160; Due to the significant value of leasehold improvements purchased during the initial 3-year lease term and the economic penalty for not extending the building lease, straight-line rent expense and the associated deferred rent has been calculated over 17 years, which represents the full term of the lease, including all extensions.</font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-22</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company is required to remove certain alterations, additions and improvements upon termination of the lease that altered a portion of the rentable space.&#160; In no event shall the cost of such removal, at commercially reasonable rates, paid by the Company exceed $55,000 (&#8220;Capped Amount&#8221;) and any amount in excess of the Capped Amount shall be the obligation of the landlord.&#160; The Company is required to maintain a certificate of deposit equal to the Capped Amount during the term of the lease, which amount is shown as restricted cash in the accompanying balance sheets.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective June 1, 2010, Cellectar entered into a seven-month extension of its office space and effective December 13, 2010 amended the extension to increase the lease extension an additional five-months, expiring May 31, 2011.&#160; In connection with the extension, the monthly rent was adjusted to fifty percent of the rent due immediately prior to the extension and the Company could terminate the lease at the end of a month with 10-day written notice.&#160; The option was retained, prior to May 31, 2011, to further extend the lease through September 14, 2012, in accordance with the original lease terms provided that it pay the unpaid rent for June 1, 2010 through March 31, 2011, based on the original terms of the lease, plus interest at 10% per annum.&#160; As of December 31, 2010, $45,000 was accrued in the accompanying balance sheet for the unpaid rent and accrued interest.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 15, 2011, the Company extended its building lease for the Madison, WI headquarters through September 14, 2012 according to the terms in the original lease and paid all unpaid rent and related accrued interest.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Future minimum lease payments under this non-cancelable lease are approximately $196,000 and $124,000 during 2011 and 2012.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As a result of the Acquisition, the Company assumed the lease agreement for Novelos&#8217; office space in Newton, MA, which has a term that is month-to-month and requires monthly rental payments of $5,300.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Rent expense was $143,000 and $117,000 for the nine months ended September 30, 2011 and 2010, respectively, $159,000 and $180,000 for the years ended December 31, 2010 and 2009, respectively and $945,000 from inception to December 31, 2010.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Capital Lease</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certain equipment is leased under a capital lease.&#160; The lease agreement requires monthly principal and interest payments of $217 and expires on September 3, 2014.&#160; The outstanding obligation is being amortized using a 7% interest rate based on comparable borrowing rates.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table provides the estimated future minimum rental payments under all capital leases together with the present value of the net minimum lease payments as of December 31, 2010:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left">
<table cellpadding="0" cellspacing="0" width="85%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Minimum</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">lease</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">payments</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Less&#160;interest</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Present&#160;value</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">of&#160;net</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">minimum</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">lease</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">payments</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="55%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,608</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">523</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,085</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="55%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2012</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,608</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">373</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,235</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="55%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2013</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,608</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">211</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;2,397</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="55%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2014</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,739</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">45</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,694</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">9,563</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,152</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">8,411</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The equipment recorded under capitalized leases is included in fixed assets as of December 31:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNIDENTIFIED_TABLE_27"><!--EFPlaceholder--></a><br>
</div>

<div style="MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table cellpadding="0" cellspacing="0" width="70%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2009</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Office equipment</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,973</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,973</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Less accumulated amortization</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(2,928</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(732</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">8,045</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">10,241</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Retention Agreements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Following the Acquisition, the Company has retention agreements with each of its four vice presidents, three of such agreements were executed by Novelos during 2010.&#160; The agreements provide for the lump-sum payment of six months&#8217; base salary and benefits to each such officer following a termination without cause or a resignation with good reason occurring on or before November 14, 2011.&#160; Certain of the agreements provide that if the executives were employed with Novelos as of October 1, 2010, they would receive a payment of two months&#8217; base salary as a retention bonus on that date. The retention bonus of $68,000 was paid in October 2010 and will be deducted from the severance amounts that may become payable upon a subsequent involuntary termination.&#160; The total remaining amount that may become payable to the Company&#8217;s executive officers pursuant to the retention agreements is approximately $350,000.</font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-23</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On May 18, 2011, the Company&#8217;s board of directors approved the entry into a retention agreement with each of 5 individuals that were employees of Cellectar at the time of the Acquisition.&#160; The agreements provide for the lump-sum payment of six months&#8217; base salary and benefits following a termination without cause or a resignation with good reason occurring on or before November 18, 2011.&#160; The agreements expire November 18, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">LITIGATION</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Following the Acquisition, the Company is party to certain legal matters that existed with Novelos prior to the Acquisition. The following summarizes the status of those matters.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Class Action</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A putative federal securities class action complaint was filed on March 5, 2010 in the United States District Court for the District of Massachusetts by an alleged shareholder of Novelos, on behalf of himself and all others who purchased or otherwise acquired Novelos common stock in the period between December 14, 2009 and February 24, 2010, against Novelos and its President and Chief Executive Officer, Harry S. Palmin.&#160; On October 1, 2010, the court appointed lead plaintiffs (Boris Urman and Ramona McDonald) and appointed lead plaintiffs&#8217; counsel.&#160; On October 22, 2010, an amended complaint was filed.&#160; The amended complaint claims, among other things, that Novelos violated Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder in connection with alleged misleading disclosures related to the progress of the Phase 3 clinical trial of NOV-002 for non-small cell lung cancer.&#160; On December 6, 2010, the defendants filed a motion to dismiss the complaint with prejudice.&#160; On January 20, 2011, the plaintiffs filed their opposition to our motion and on March 3, 2011, the defendants filed their response to the opposition. On June 23, 2011, the motion to dismiss was granted and the case was dismissed without prejudice.&#160; Because the dismissal was without prejudice, the plaintiffs could&#160;reinstitute the&#160;proceeding by filing&#160;an amended complaint.&#160; On August 5, 2011, the plaintiffs filed a second amended complaint realleging that the defendants violated Section 10(b) of the Exchange Act and Rule 10b-5 in connection with alleged misleading disclosures related to the Phase 3 clinical trial for NOV-002 in non-small cell lung cancer. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On September 9, 2011, the defendants filed a motion to dismiss the second amended complaint. The plaintiff<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#8217;</font>s opposition to the motion&#160;was filed on&#160;October 14, 2011 and the defendants filed a reply brief on November 4, 2011. </font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Company and Mr. Palmin believe the allegations are without merit and intend to vigorously defend against them.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">BAM Dispute</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On June 28, 2010, Novelos received a letter from counsel to ZAO BAM and ZAO BAM Research Laboratories (Russian companies, collectively referred to as &#8220;BAM&#8221;) alleging that it modified the chemical composition of NOV-002 without prior notice to or approval from BAM, constituting a material breach of a technology and assignment agreement Novelos had entered into with BAM on June 20, 2000 (the &#8220;June 2000 Agreement&#8221;).&#160; The letter references the amendment, submitted to the FDA on August 30, 2005, to Novelos&#8217; investigational new drug application dated August 1999 as the basis for BAM&#8217;s claims and demands the transfer of all intellectual property rights concerning NOV-002 to BAM.&#160; Mark Balazovsky, a director of Novelos from June 1996 until November 2006 and a shareholder of Novelos through at least June 25, 2010, is, to our knowledge, still the general director and principal shareholder of ZAO BAM.&#160; On September 24, 2010, Novelos filed a complaint in Suffolk Superior Court seeking a declaratory judgment by the court that the June 2000 Agreement has been replaced by a subsequent agreement between the parties dated April 1, 2005 (the &#8220;April 2005 Agreement&#8221;), that Novelos&#8217; obligations to BAM are governed solely by the April 2005 Agreement and that the obligations of the June 2000 agreement have been performed and fully satisfied.&#160; On November 29, 2010, BAM answered the complaint, denying the material allegations, and stating its affirmative defenses and certain counterclaims. On January 14, 2011, Novelos responded to the counterclaims, denying BAM&#8217;s material allegations and stating its affirmative defenses.&#160; On June 9, 2011, BAM filed an amended counterclaim alleging additional claims related to Novelos&#8217; acquisition of Cellectar.&#160; In that amended counterclaim, BAM alleges that the acquisition evidences Novelos&#8217; abandonment of the technology assigned to it by BAM constituting a breach of the June 2000 Agreement or, if that agreement is determined to no longer be in effect, a breach of the April 2005 Agreement and/or a breach of the implied duty of good faith and fair dealing with respect to the April 2005 Agreement.&#160; On June 15, 2011 the Company filed its response to their amended counterclaim.&#160; On August 5, 2011, the Company filed a motion for judgment on the pleadings as to its declaratory judgment count and all counts of BAM&#8217;s amended counterclaim.&#160; The motion&#160;was opposed by BAM and a hearing on the motion&#160;was held&#160;on September 27, 2011. <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On October 17, 2011, the court ruled on the Company&#8217;s <font style="DISPLAY: inline; FONT-SIZE: 10pt">behalf for each of its declaratory judgment claims and dismissed all counts of BAM&#8217;s counterclaim. Judgment in favor of the Company was entered on October 20, 2011 and BAM has until November 21, 2011 to appeal or otherwise seek post-judgment relief.</font></font></font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We do not anticipate that these litigation contingencies will have a material impact on the Company&#8217;s future financial position, results of operations or cash flows.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16.&#160; EMPLOYEE RETIREMENT PLAN</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 1, 2009, Cellectar adopted a Safe Harbor defined contribution plan under Section 401(k) of the Internal Revenue Code which covered eligible employees who meet minimum age requirements and allowed participants to contribute a portion of their annual compensation on a pre-tax basis.&#160; Cellectar contributed 3% of each participant&#8217;s compensation.&#160; Contributions made for the years ended December 31, 2010 and 2009 were $23,000 and $56,000, respectively.&#160; Cellectar paid administrative expenses for the plan of $3,300 and $2,800 for the years ended December 31, 2010 and 2009, respectively.&#160; The plan was canceled effective August 30, 2010.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-24</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Following the Acquisition, the Company has a defined contribution plan under Section 401(k) of the Internal Revenue Code which allows eligible employees who meet minimum age requirements to contribute a portion of their annual compensation on a pre-tax basis.&#160; The Company has not made any matching contributions under this plan.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">17.&#160; RELATED PARTY TRANSACTIONS</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Jamey Weichert, the Company&#8217;s Chief Scientific Officer, director, shareholder and principal founder is a faculty member at the University of Wisconsin-Madison (&#8220;UW&#8221;).&#160; Cellectar paid $16,082 to the UW during 2009 for research related activities.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cellectar made contributions of $25,000 to the UW Foundation, a not-for-profit, tax-exempt Wisconsin corporation, which serves as the official fundraising and gift-receiving organization for the UW and other donor-designated units of the UW System during the year ended December 31, 2009.&#160; During the nine months ended September 30, 2011, the Company made contributions totaling $125,000 to the UW Foundation for use towards research activities associated with the development of the Company&#8217;s compounds.&#160; No payments were made to UW during the nine months ended September 30, 2010 or the year ended December 31, 2010.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18.&#160; (UNAUDITED) SUPPLEMENTAL PRO FORMA INFORMATION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The table below summarizes&#160;net loss for the periods shown as though the Acquisition occurred as of January 1, 2010:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">For&#160;the&#160;Nine&#160;Months&#160;Ended&#160;September&#160;30,</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For&#160;the&#160;Twelve</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Months&#160;Ended</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December&#160;31,</font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="bottom" width="64%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font> </div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font> </div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(5,290,519</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font> </div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(783,007</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font> </div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font> </div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,704,966</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The pro forma&#160;net loss&#160;has been adjusted for the following:</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font>1)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font></font> </div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Elimination of $165,000, $266,000, and $361,000 of interest expense for the nine months ended September 30, 2011 and 2010 and the twelve months ended December 31, 2010, respectively; such amounts relate to interest accrued on the Convertible Notes which were converted immediately prior to the Acquisition (see Note 7) and the Bank Note which was paid in full settlement of the note immediately prior to the Acquisition (see Note 8).</font> </div>
</td>
</tr></table>
</div>
</div>

<div>
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 9pt">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font>2)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font></font> </div>
</div>
</td>
<td align="left">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Recognition of a additional BCF of $463,000 in the nine months ended September 30, 2010 and the year ended December 31, 2010 and the elimination of BCF of $258,000 in the nine months ended September 30, 2011 in connection with the conversion of the Convertible Notes, which is assumed to have occurred on January 1, 2010 for the purpose of pro forma presentation (see Note 7).</font> </div>
</div>
</td>
</tr></table>
</div>

<div>
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 9pt">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font>3)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font></font> </div>
</div>
</td>
<td align="left">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Elimination of Acquisition costs incurred during the nine months ended September 30, 2011 and the twelve months ended December 31, 2010, which are assumed to have been incurred prior to January 1, 2010 for the purpose of presentation in the pro forma statements of operations.</font> </div>
</div>
</td>
</tr></table>
</div>

<div>
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 9pt">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font>4)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font></font> </div>
</div>
</td>
<td align="left">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Elimination of $450,000 of investment banking fees incurred upon the consummation of the Acquisition on April 8, 2011 from the nine months ended September 30, 2011.</font> </div>
</div>
</td>
</tr></table>
</div>

<div>
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 9pt">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font>5)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font></font></div>
</div>
</td>
<td align="left">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Elimination of dividends and deemed dividends on Novelos&#8217; preferred convertible stock, which is assumed to have been exchanged for common stock at January 1, 2010 in order to reflect the post-acquisition capital structure for the purpose of pro forma presentation.</font></div>
</div>
</td>
</tr></table>
</div>

<div>
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 9pt">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font>6)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font></div>
</div>
</td>
<td align="left">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">Elimination of Novelos historical revenue related to the amortization of deferred revenue that was determined to have no fair value in purchase accounting.</div>
</div>
</td>
</tr></table>
</div>

<div>
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font>7)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font></font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Elimination of liquidated damages accrued in 2010 related to Novelos<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#8217;</font> convertible preferred stock. The liquidated damages are assumed not to have accrued as the preferred stock&#160;is assumed to&#160;have been exchanged for common stock at January 1, 2010 in order to reflect the post-acquisition capital structure for the purpose of pro forma presentation.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>
</div>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">19.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PROPOSED REVERSE STOCK SPLIT</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On June 30, 2011, the Company held a special meeting of stockholders.&#160; At the meeting, the stockholders approved, among other things, separate amendments to the certificate of incorporation that would effect a reverse split of the Company&#8217;s common stock within a range of 1:2 to 1:10, and authorized the Company&#8217;s board of directors to determine the ratio at which the reverse split will be effected by filing the appropriate amendment to the certificate of incorporation.&#160; The purpose of the proposed reverse split is to increase the price per share of the Company&#8217;s common stock in order to exceed the minimum price per share required to secure a listing on a national securities exchange. <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On July 1, 2011, the Company filed with the SEC&#160;a Registration Statement on Form S-1 for an underwritten public offering of its common stock with proceeds of up to $15,000,000, excluding the underwriters over-allotment. The Company has applied for listing on the NASDAQ Capital Market under the symbol "NVLT" in connection with the proposed underwritten offering.</font></font><br></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-25</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FINANCIAL STATEMENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FINANCIAL STATEMENTS FOR NOVELOS THERAPEUTICS, INC. (PRE-ACQUISITION)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Table of Contents</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="92%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Page</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="92%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Report of Independent Registered Public Accounting Firm</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-27</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance Sheets at December 31, 2010 and 2009</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-28</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Statements of Operations for the Years Ended December 31, 2010 and 2009</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-29</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Statements of Redeemable Preferred Stock and Stockholders&#8217; Equity (Deficiency) for the Years Ended December 31, 2010 and 2009</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-30</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Statements of Cash Flows for the Years Ended December 31, 2010 and 2009</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-31</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Notes to Financial Statements</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-32</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="92%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance Sheet at March 31, 2011</font></font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-48&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Statements of Operations for the Three Months Ended March 31, 2011 and 2010</font></font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-49</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Statements of Cash Flows for the Three Months Ended March 31, 2011 and 2010</font></font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-50&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Notes to Interim Financial Statements</font></font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-51</font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-26</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To the Stockholders and Board of Directors</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Novelos Therapeutics, Inc.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Newton, Massachusetts</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have audited the accompanying balance sheets of Novelos Therapeutics, Inc. as of December 31, 2010 and 2009 and the related statements of operations, redeemable preferred stock and stockholders&#8217; equity (deficiency), and cash flows for the years then ended.&#160; These financial statements are the responsibility of the Company&#8217;s management.&#160; Our responsibility is to express an opinion on these financial statements based on our audits.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Novelos Therapeutics, Inc. as of December 31, 2010 and 2009 and the results of its operations, changes in redeemable preferred stock and stockholders&#8217; equity (deficiency), and cash flows for the years then ended in conformity with accounting principles generally accepted in the United States.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has generated insignificant revenues and has incurred continuing losses in the development of its products. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in this regard are described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/ Stowe &amp; Degon LLC</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Westborough, Massachusetts</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">April 11, 2011</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-27</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOVELOS THERAPEUTICS, INC. (PRE-ACQUISITION)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BALANCE SHEETS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December&#160;31,</font></div>
</td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December&#160;31,</font></div>
</td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2009</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ASSETS</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CURRENT ASSETS:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash and equivalents</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,372,951</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,769,529</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Prepaid expenses and other current assets</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">63,526</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">102,923</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total current assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,436,477</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,872,452</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FIXED ASSETS, NET</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,755</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">44,097</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DEPOSITS</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">15,350</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">15,350</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TOTAL ASSETS</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,460,582</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">8,931,899</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIENCY</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CURRENT LIABILITIES:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts payable and accrued liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">565,723</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,299,217</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued compensation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">245,711</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued dividends</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,902,963</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Derivative liability (see Note 2)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">288,250</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,486,594</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred revenue &#8211; current</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">33,333</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">33,333</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total current liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">887,306</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">16,967,818</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DEFERRED REVENUE &#8211; NONCURRENT</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">366,667</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">400,000</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COMMITMENTS AND CONTINGENCIES</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">REDEEMABLE PREFERRED STOCK:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series E convertible preferred stock, $0.00001 par value; 735 shares designated, 0 and 548.26078125 shares issued and outstanding at December 31, 2010 and 2009, respectively (see Note 6)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">18,459,619</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">STOCKHOLDERS&#8217; EQUITY (DEFICIENCY):</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Preferred Stock, $0.00001 par value; 7,000 shares authorized: Series C 8% cumulative convertible preferred stock; 272 shares designated; 0 and 204 issued and outstanding at December 31, 2010 and 2009, respectively</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common stock, $0.00001 par value; 150,000,000 shares authorized; 2,959,914 and 455,281 shares issued and outstanding at December 31, 2010 and&#160;2009, respectively</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Additional paid-in capital</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">75,183,275</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,176,545</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accumulated deficit</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(73,976,696</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(76,072,088</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total stockholders&#8217; equity (deficiency)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,206,609</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(26,895,538</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TOTAL LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIENCY)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,460,582</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">8,931,899</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">See report of independent registered public accounting firm and notes to financial statements.</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-28</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOVELOS THERAPEUTICS, INC. (PRE-ACQUISITION)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">STATEMENTS OF OPERATIONS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Year&#160;Ended&#160;December&#160;31,</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2009</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">REVENUES</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">33,334</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">33,334</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COSTS AND EXPENSES:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,997,984</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,080,242</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,486,032</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,182,253</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total costs and expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">5,484,016</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">10,262,495</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">LOSS FROM OPERATIONS</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(5,450,682</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(10,229,161</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">OTHER INCOME (EXPENSE):</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest income</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,421</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,013</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Grant income</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">244,479</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">62,980</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gain (loss) on derivative warrants (see Note 2)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,118,174</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(12,114,371</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liquidated damages (see Note 6)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(819,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Miscellaneous</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">6,233</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total other income (expense)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">7,546,074</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(12,044,145</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NET INCOME (LOSS)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,095,392</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(22,273,306</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PREFERRED STOCK DIVIDENDS</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,207,827</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,296,289</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PREFERRED STOCK DEEMED DIVIDENDS</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(12,541,201</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(714,031</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(12,653,636</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(26,283,626</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(15.36</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(80.57</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">823,933</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">326,209</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">See report of independent registered public accounting firm and notes to financial statements.</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-29</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOVELOS THERAPEUTICS, INC. (PRE-ACQUISITION)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold"><font style="FONT-WEIGHT: normal"><font style="FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold">STATEMENTS OF REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIENCY</font>)</font></font></font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="37%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;<font style="FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">REDEEMABLE</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">PREFERRED&#160;STOCK</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Series&#160;D&#160;and&#160;E</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Convertible</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Preferred&#160;Stock</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Common&#160;Stock</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Series&#160;C&#160;Cumulative</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Convertible</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Preferred&#160;Stock</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Additional</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Paid-in</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Capital</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Accumulated</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Deficit</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Total</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Stockholders&#8217;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Equity</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(Deficiency)</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="37%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Shares</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Amount</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Shares</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Par</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Amount</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Shares</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Par</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Amount</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="5%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="5%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="5%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">BALANCE&#160;AT JANUARY 1, 2009</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">413.5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">13,904,100</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">287,423</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">272</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">40,204,549</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(59,693,153</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(19,488,601</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Reclassification of warrants to derivative liability (see Note 2)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(6,893,316</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">5,894,371</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(998,945</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Conversion of Series C convertible preferred stock and accumulated dividends into common stock</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">10,058</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(68</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">184,246</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">184,246</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Conversion of Series E convertible preferred stock and accumulated dividends into common stock</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(97.18209375</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(3,213,056</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">51,889</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">3,514,313</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">3,514,314</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Cashless exercise of warrants</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">3,162</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">1,000,962</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">1,000,962</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Issuance of common stock in exchange for warrants</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">13,623</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">1,625,760</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">1,625,760</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Issuance of common stock and warrants in a private placement, net of issuance costs of $61,116</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">89,126</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">8,938,883</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">8,938,884</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Compensation expense associated with options issued to employees</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">437,066</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">437,066</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Compensation expense associated with options issued to non-employees</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">427,271</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">427,271</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Issuance of Series E redeemable convertible preferred stock and warrants, net of issuance costs of $795,469</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">200</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">6,297,323</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">2,907,208</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">2,907,208</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Issuance of Series E redeemable convertible preferred stock in payment of accumulated dividends</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">31.942875</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">1,597,144</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Adjustment to record the carrying value of Series E redeemable convertible preferred stock at fair value on the date of sale</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(125,892</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">125,892</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">125,892</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Fair value of the extension of expiration date of warrants</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">839,923</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">839,923</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Accretion of deemed dividend associated with the extension of expiration date of warrants</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(839,923</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(839,923</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Dividends accrued on preferred stock</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(3,296,289</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(3,296,289</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(22,273,306</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(22,273,306</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">BALANCE AT DECEMBER 31, 2009</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">548.26078125</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">18,459,619</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">455,281</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">204</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">49,176,545</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(76,072,088</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(26,895,538</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Exercise of stock options</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">5,991</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">158,567</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">158,567</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Conversion of Series E convertible preferred stock and accumulated dividends into common stock</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(139.99673625</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(4,689,593</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">76,770</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">5,324,517</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">5,324,518</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Cashless exercise of warrants</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">53,478</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">2,584,396</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">2,584,397</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Compensation expense associated with options issued to employees</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">586,321</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">586,321</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Compensation expense (benefit) associated with options issued to non-employees</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(249,023</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(249,023</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Issuance of common stock and warrants in a public offering (net of issuance costs of $250,862)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">140,056</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">744,910</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">744,911</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Fair value of warrants issued to preferred shareholders</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">586,050</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">586,050</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Accretion of deemed dividend associated with the issuance of warrants to preferred stockholders</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(586,050</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(586,050</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Exchange of preferred stock and dividends for common stock</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(408.264045</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(13,770,026</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">2,228,338</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">22</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(204</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">19,064,869</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">19,064,891</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Fair value of incremental shares issued to preferred stockholders in connection with exchange of preferred stock for common stock</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">11,955,151</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">11,955,151</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Accretion of deemed dividend associated with the incremental shares of common stock issued in connection with the exchange of preferred stock</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(11,955,151</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(11,955,151</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Dividends accrued on preferred stock</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(2,207,827</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(2,207,827</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">Net income</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">2,095,392</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">2,095,392</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="37%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">BALANCE AT DECEMBER 31, 2010</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">$&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-RIGHT: black 2px solid; PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">2,959,914</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">30</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">75,183,275</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">(73,976,696</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">1,206,609</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 6pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">See report of independent registered public accounting firm and notes to financial statements.</font></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-30</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOVELOS THERAPEUTICS, INC. (PRE-ACQUISITION)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">STATEMENTS OF CASH FLOWS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Year&#160;Ended&#160;December&#160;31,</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2009</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH FLOWS FROM OPERATING ACTIVITIES:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income (loss)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,095,392</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(22,273,306</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustments to reconcile net income (loss) to cash used in operating activities:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Depreciation and amortization</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,342</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32,354</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">337,298</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">864,337</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Gain) loss on derivative warrants</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(8,118,174</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,114,371</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-cash settlement of liquidated damages</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">819,000</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Changes in:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Prepaid expenses and other current assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39,397</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">26,862</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts payable and accrued liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,733,494</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,354,695</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued compensation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(245,711</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,072</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred revenue</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(33,333</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(33,333</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash used in operating activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(7,804,283</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(10,618,338</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH FLOWS FROM INVESTING ACTIVITIES:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Purchases of fixed assets</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(18,000</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash used in investing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(18,000</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH FLOWS FROM FINANCING ACTIVITIES:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from issuance of common stock, net</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,249,138</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,938,884</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from issuance of Series E convertible preferred stock and warrants, net</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,204,531</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from exercise of stock options</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">158,567</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash provided by financing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,407,705</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">18,143,415</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">INCREASE (DECREASE) IN CASH AND EQUIVALENTS</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(6,396,578</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,507,077</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH AND EQUIVALENTS AT BEGINNING OF YEAR</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">8,769,529</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,262,452</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH AND EQUIVALENTS AT END OF YEAR</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,372,951</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">8,769,529</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dividends accumulated on shares of Series E preferred stock exchanged for or converted into shares of common stock</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">5,110,790</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,898,402</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dividends accumulated on shares of Series C preferred stock converted into shares of common stock</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">184,246</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair value of derivative warrants upon adoption of new accounting principle</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">998,945</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair value of common stock issued in exchange for tender of derivative warrants</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,625,760</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair value of derivative warrants upon cashless exercise</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,584,397</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,000,962</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exchange of Series D for Series E preferred stock</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">13,904,100</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Relative fair value of warrants issued to stockholders</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">504,227</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">4,835,727</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">See report of independent registered public accounting firm and notes to financial statements.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-31</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOVELOS THERAPEUTICS, INC. (PRE-ACQUISITION)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO FINANCIAL STATEMENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Novelos Therapeutics, Inc. (&#8220;Novelos&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company developing compounds for the treatment of cancer.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 8, 2011, the Company entered into a business combination with Cellectar, Inc. (&#8220;Cellectar&#8221;), a privately held Wisconsin corporation that designed and developed products to detect, treat and monitor a wide variety of human cancers (the &#8220;Acquisition&#8221;, see Note 12). Immediately prior to the Acquisition, the Company completed a 1-for-153 reverse split of its common stock (the &#8220;Reverse Split&#8221;). The Company then issued 17,001,596 shares of its common stock to the former shareholders of Cellectar as consideration for the Acquisition, constituting approximately 85% of Novelos&#8217; outstanding common stock after giving effect to the Acquisition. Upon the closing of the Acquisition, the Company completed the private placement of 6,846,537 shares of its common stock and warrants to purchase an additional 6,846,537 shares of its common stock (in each case after giving effect to the Reverse Split) for gross proceeds of approximately $5,135,000. As a result of the Acquisition, the Company is implementing a revised business plan focused on the development of the Cellectar compounds. Development of Novelos&#8217; other compounds (NOV-002 and NOV-205) has been suspended. The Company will conduct its operations from Cellectar&#8217;s headquarters in Madison, WI and the Company&#8217;s executive offices will remain in Newton, MA.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Reverse Split reduced the number of outstanding shares of Common Stock from 452,866,983 shares to 2,959,914 (2,959,871 after the cash settlement of fractional shares). On the accompanying balance sheet, the aggregate par value of the issued common stock was reduced by reclassifying the par value amount of the eliminated shares of common stock to additional paid-in capital. All per share amounts and outstanding shares, including all common stock equivalents, stock options and warrants, have been retroactively restated in these financial statements and notes for all periods presented to reflect the Reverse Split. Additionally, the number of authorized shares of common stock disclosed on the balance sheet has been reduced to 150,000,000 from 750,000,000 to reflect the reduction in authorized shares of common stock that became effective concurrent with the Reverse Split.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounting principles generally accepted in the United States require that a company whose security holders retain the majority voting interest in the combined business be treated as the acquirer for financial reporting purposes.&#160; Accordingly, the Acquisition will be accounted for as a reverse acquisition whereby Cellectar, Inc. will be treated as the acquirer for accounting and financial reporting purposes. The financial statements presented herein represent the historical financial information of Novelos, prior to the acquisition.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company is subject to a number of risks similar to those of other small biopharmaceutical companies. Principal among these risks are dependence on key individuals, competition from substitute products and larger companies, the successful development and marketing of its products in a highly regulated environment and the need to obtain additional financing necessary to fund future operations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On February 24, 2010, the Company announced that its Phase 3 clinical trial for NOV-002 in non-small cell lung cancer (the &#8220;Phase 3 Trial&#8221;) did not meet its primary endpoint of a statistically significant increase in median overall survival. Following evaluation of the detailed trial data, on March 18, 2010, the Company announced that the secondary endpoints had also not been met in the Phase 3 Trial and that it had discontinued development of NOV-002 for NSCLC in combination with first-line paclitaxel and carboplatin chemotherapy.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has generated insignificant revenues and has incurred operating losses since inception in devoting substantially all of its efforts toward research and development. The Company expects that it will continue to generate operating losses for the foreseeable future. The Company believes that its cash on hand at December 31, 2010, plus the proceeds from the private placement completed in connection with the Acquisition, is adequate to fund operations into the fourth quarter of 2011. The Company&#8217;s ability to execute its operating plan beyond the fourth quarter of 2011 depends on its ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. The Company plans to continue to actively pursue financing alternatives, but there can be no assurance that it will obtain the necessary funding.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The accompanying financial statements reflect the application of certain accounting policies, as described in this note and elsewhere in the accompanying notes to the financial statements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Use of Estimates</font> &#8212; The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the Company&#8217;s management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenue and expenses and disclosure of contingent assets and liabilities. On an on-going basis, the Company&#8217;s management evaluates its estimates including those related to unbilled research and development costs, valuation of derivatives and share-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from those estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-32</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Cash Equivalents</font> &#8212; The Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Fixed Assets</font> &#8212; Property and equipment are stated at cost. Depreciation on property and equipment is provided using the straight-line method over the estimated useful lives of the assets, which range from three to five years. Leasehold improvements are depreciated over the lesser of the estimated useful lives of the assets or the remaining lease term.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Impairment of Long</font>-<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Lived Assets</font> &#8212; Whenever events or circumstances change, the Company assesses whether there has been an impairment in the value of long-lived assets by determining whether projected undiscounted cash flows generated by the applicable asset exceed its net book value as of the assessment date.&#160; There were no impairments of the Company&#8217;s assets at the end of each period presented.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Stock-Based Compensation</font> &#8212; The Company accounts for employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718, <font style="DISPLAY: inline; FONT-STYLE: italic">Compensation &#8211; Stock Compensation</font> which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values.&#160; The Company accounts for non-employee stock-based compensation in accordance with the guidance of FASB ASC Topic 505, <font style="DISPLAY: inline; FONT-STYLE: italic">Equity</font> which requires that companies recognize compensation expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered by such non-employees.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Revenue Recognition</font> &#8212; Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred, and there is reasonable assurance of collection.&#160; Upfront payments received in connection with technology license or collaboration agreements are recognized over the estimated term of the related agreement.&#160; The Company has not yet received milestone or royalty payments in connection with license or collaboration agreements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Research and Development</font> &#8212; Research and development costs are expensed as incurred.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Income Taxes</font> &#8212; The Company uses the liability method of accounting for income taxes.&#160; Under this method, deferred tax assets and liabilities are determined based on temporary differences between the financial statement and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; Valuation allowances are established when it is more likely than not that some portion of the deferred tax assets will not be realized.&#160; Tax positions taken or expected to be taken in the course of preparing the Company&#8217;s tax returns are required to be evaluated to determine whether the tax positions are &#8220;more likely than not&#8221; of being sustained by the applicable tax authority.&#160; Tax positions deemed not to meet a more-likely-than-not threshold would be recorded as tax expense in the current year.&#160; There were no uncertain tax positions that require accrual or disclosure to the financial statements as of December 31, 2010 and 2009.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Comprehensive Income (Loss)</font> &#8212; The Company had no components of comprehensive income other than net income (loss) in all of the periods presented.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Fair Value of Financial Instruments</font> &#8212; The guidance under FASB ASC Topic 825, <font style="DISPLAY: inline; FONT-STYLE: italic">Financial Instruments</font> , requires disclosure of the fair value of certain financial instruments. The Company&#8217;s financial instruments consist of cash equivalents, accounts payable, accrued expenses and redeemable preferred stock. The estimated fair value of the redeemable preferred stock, determined on an as-converted basis including conversion of accumulated unpaid dividends, was $114,780,000 at December 31, 2009. The estimated fair value of the remaining financial instruments approximates their carrying value due to their short-term nature.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Concentration of Credit Risk</font> &#8212; Financial instruments that subject the Company to credit risk consist of cash and equivalents on deposit with financial institutions. The Company&#8217;s excess cash is on deposit in an overnight investment account that is fully collateralized by government-backed obligations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Derivative Instruments</font> &#8212; The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks; however, starting January 1, 2009, certain warrants to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the FASB ASC, are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments as the agreements contain &#8220;down-round&#8221; provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The number of such warrants was 91,524 at January 1, 2009, 48,489 at December 31, 2009 and 138,611 at December 31, 2010. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock. Such financial instruments are initially recorded at fair value, or relative fair value when issued with other instruments, with subsequent changes in fair value recorded as a component of gain or loss on derivatives in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At December 31, 2010 and 2009, these warrants represent the only outstanding derivative instruments issued or held by the Company. As a result of the significant decline in the Company&#8217;s stock price following the announcement of the results of the Phase 3 Trial, the Company recorded a gain of approximately $8,118,000 during the year ended December 31, 2010 in connection with the revaluation of the derivative liability balance at December 31, 2010.</font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-33</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">New Accounting Pronouncements</font> &#8212;&#160; In September 2009, the Financial Accounting Standards Board (&#8220;FASB&#8221;) amended the accounting standards related to revenue recognition for arrangements with multiple deliverables and arrangements that include software elements (&#8220;new accounting principles&#8221;). The new accounting principles permit prospective or retrospective adoption, and the Company elected prospective adoption at the beginning of the first quarter of 2010. The adoption of the standard in 2010 had no impact on the Company&#8217;s financial statements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In January 2010, the FASB issued ASU No.&#160;2010-06, <font style="DISPLAY: inline; FONT-STYLE: italic">Improving Disclosures about Fair Value Measurements</font>, which requires additional disclosures about the amounts of and reasons for significant transfers in and out of Level&#160;1 and Level&#160;2 fair value measurements. This standard also clarifies existing disclosure requirements related to the level of disaggregation of fair value measurements for each class of assets and liabilities and disclosures about inputs and valuation techniques used to measure fair value for both recurring and non-recurring Level&#160;2 and Level&#160;3 measurements. Since this new accounting standard only required additional disclosure, the adoption of the standard in the first quarter of 2010 did not impact the Company&#8217;s financial statements. Additionally, effective for interim and annual periods beginning after December&#160;15, 2010, this standard will require additional disclosure and require an entity to present disaggregated information about activity in Level&#160;3 fair value measurements on a gross basis, rather than one net amount.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Adoption of New Accounting Principle</font> &#8212; Effective January 1, 2009, the Company adopted the guidance of FASB ASC 815-40-15, <font style="DISPLAY: inline; FONT-STYLE: italic">Derivatives and Hedging</font> , which establishes a framework for determining whether certain freestanding and embedded instruments are indexed to a company&#8217;s own stock for purposes of evaluation of the accounting for such instruments under existing accounting literature. As a result of this adoption, certain warrants that were previously determined to be indexed to the Company&#8217;s common stock upon issuance were determined not to be indexed to the Company&#8217;s common stock because they include &#8220;down-round&#8221; anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The fair value of the warrants at the dates of issuance totaling $6,893,000 was initially recorded as a component of additional paid-in capital. Upon adoption of this guidance on January 1, 2009, the Company recorded a derivative liability of $999,000, a decrease to the opening balance of additional paid-in capital of approximately $6,893,000 and recorded a decrease to accumulated deficit totaling approximately $5,894,000, representing the decrease in the fair value of the warrants from the date of issuance to December 31, 2008. The increase in fair value of the warrants of approximately $12,114,000 during the year ended December 31, 2009 and the decrease in fair value of the warrants of $8,118,000 during the year ended December 31, 2010 have been included as a component of other income (expense) in the accompanying statement of operations. Certain of the warrants that had been recorded as a derivative liability were exchanged or exercised for shares of the Company&#8217;s common stock during the years ended December 31, 2010 and 2009. See Note 6 for a description of those transactions. The fair value of the warrants of $288,000 and $10,487,000 at December 31, 2010 and 2009 is included as a current liability in the accompanying balance sheet as of that date.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Reclassifications </font>&#8212; Certain prior year amounts have been reclassified to conform to the current year presentation.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160; FIXED ASSETS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fixed assets consisted of the following at December 31:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="MARGIN-LEFT: 36pt" align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2009</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Office and computer equipment</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">61,907</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">73,261</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Computer software</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">43,896</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">43,896</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Leasehold improvements</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,095</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,095</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total fixed assets</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">109,898</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">121,252</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Less accumulated depreciation and amortization</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(101,143</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(77,155</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fixed assets, net</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,755</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">44,097</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.&#160; FAIR VALUES OF ASSETS AND LIABILITIES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In accordance with Fair Value Measurements and Disclosures Topic of the FASB ASC, the Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Level 1: Input prices quoted in an active market for identical financial assets or liabilities.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data.</font></font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-34</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Level 3: Input prices that are significant to the fair value of the financial assets or liabilities which are not observable or supported by an active market.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Assets and liabilities measured at fair value on a recurring basis are summarized below:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 18pt" align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="14" valign="bottom" width="46%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">December&#160;31,&#160;2010</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level&#160;1</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level&#160;2</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level&#160;3</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Fair&#160;Value</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liabilities:</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">288,250</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">288,250</font></font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 18pt" align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="14" valign="bottom" width="46%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">December&#160;31,&#160;2009</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level&#160;1</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level&#160;2</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level&#160;3</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Fair&#160;Value</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liabilities:</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">10,487,000</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">10,487,000</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company uses valuation methods and assumptions that consider among others the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Assumptions used are generally consistent with those disclosed for stock-based compensation (see Note 7).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">5.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">COLLABORATION AGREEMENTS</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">2007 Collaboration Agreement with Lee&#8217;s Pharmaceutical (HK) Ltd.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In December 2007 the Company entered into a Collaboration Agreement with Lee&#8217;s Pharmaceutical (HK) Ltd. (&#8220;Lee&#8217;s Pharm&#8221;). Pursuant to this agreement, Lee&#8217;s Pharm obtained an exclusive license to develop, manufacture and commercialize NOV-002 and NOV-205 in China, Hong Kong, Taiwan and Macau (the &#8220;Chinese Territory&#8221;). The Company has suspended further development of NOV-205; however, this suspension may not impact the development strategy of Lee&#8217;s Pharm.&#160; Under the terms of the agreement the Company received a license fee of $500,000 in March 2008 and is entitled to receive up to $1,700,000 in future milestone payments upon the completion of development and marketing milestones by Lee&#8217;s Pharm. This initial $500,000 payment received is being amortized over the estimated term of this agreement, 15 years. Accordingly, $33,000 of license revenue was recognized in each of the years ended December 31, 2010 and 2009.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Lee&#8217;s Pharm agreement provides that the Company receive royalty payments of 20-25% of net sales of NOV-002 in the Chinese Territory and receive royalty payments of 12-15% of net sales of NOV-205 in the Chinese Territory. Lee&#8217;s Pharm is obligated to reimburse the Company for the manufacturing cost of pharmaceutical products provided to Lee&#8217;s Pharm in connection with the agreement. Lee&#8217;s Pharm has committed to spend a minimum amount on development in the first four years of the agreement. The agreement expires upon the expiration of the last patent covering any of the licensed products, or twelve years from the date of the first commercial sale in China, whichever occurs later.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">2009 Collaboration Agreement with Mundipharma</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On February 11, 2009, Novelos entered into a collaboration agreement (the &#8220;Collaboration Agreement&#8221;) with Mundipharma International Corporation Limited (&#8220;Mundipharma&#8221;) to develop, manufacture and commercialize, on an exclusive basis, Licensed Products (as defined in the Collaboration Agreement), which includes the Company&#8217;s lead compound, NOV-002, in Europe (other than the Russian Territory), Asia (other than the Chinese Territory) and Australia (collectively referred to as the &#8220;Mundipharma Territory&#8221;).&#160; Mundipharma is an independent associated company of Purdue Pharma, L.P. (&#8220;Purdue&#8221;).&#160; The Collaboration Agreement provides for Mundipharma to pay the Company royalties and fixed milestone payments based on sales and commercial launches in the licensed territories.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For countries in which patents are held, the Collaboration Agreement expires on a country-by-country basis within the Mundipharma Territory on the earlier of (1) expiration of the last applicable Novelos patent within the country or (2) the determination that any patents within the country are invalid, obvious or otherwise unenforceable.&#160; For countries in which no patents are held, the Collaboration Agreement expires the earlier of 15 years from its effective date or upon generic product competition in the country resulting in a 20% drop in Mundipharma&#8217;s market share.&#160; Novelos may terminate the Collaboration Agreement upon breach or default by Mundipharma.&#160; Mundipharma may terminate the Collaboration Agreement upon breach or default, filing of voluntary or involuntary bankruptcy by Novelos, the termination of certain agreements with companies associated with the originators of the licensed technology, or 30-day notice for no reason.&#160; If any regulatory approval within the Mundipharma Territory is suspended as a result of issues related to the safety of the Licensed Products, then Mundipharma&#8217;s obligations under the Collaboration Agreement will be suspended until the regulatory approval is reinstated.&#160; If that reinstatement does not occur within 12 months of the suspension, then Mundipharma may terminate the Collaboration Agreement.</font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-35</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Concurrently with the execution of the Collaboration Agreement, Novelos completed a private placement of Series E preferred stock and common stock purchase warrants to Purdue.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company expects that the negative results of its Phase 3 Trial will adversely affect development and commercialization of NOV-002 under the collaboration agreements with Lee&#8217;s Pharm and Mundipharma.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6. STOCKHOLDERS&#8217; DEFICIENCY</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Exchange of Outstanding Preferred Stock for Common Stock</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On November 30, 2010, the Company entered into an Exchange Agreement with each of the holders of its Series E convertible preferred stock (the &#8220;Series E Preferred Stock&#8221;) and Series C convertible preferred stock (the &#8220;Series C Preferred Stock&#8221;) pursuant to which each such holder exchanged all of the holder&#8217;s shares of Series E Preferred Stock or Series C Preferred Stock, as applicable, and all rights, preferences and privileges associated therewith (including but not limited to any accrued but unpaid dividends thereon) and any rights of the holder to liquidated damages under agreements to register the Company&#8217;s capital stock, for an aggregate of 2,228,338 shares of common stock, representing 75.3% of the Company&#8217;s common stock outstanding effective immediately following the exchange.&#160; As a result of the exchange, all of the liquidation preference applicable to the preferred stock, approximately $27,337,000 as of November 30, 2010, was eliminated.&#160; Furthermore, future dividends totaling $2,327,000 annually were eliminated, special voting rights applicable to the preferred stock are no longer applicable, and the former holders of Series E Preferred Stock have released any rights to require the registration of shares of the Company&#8217;s common stock for resale under the Securities Act.&#160; The effective price per share at which the common stock was issued in connection with the exchange (based on the aggregate liquidation preference of all of the preferred stock divided by the total number of shares of common stock issued in exchange for such preferred stock) was approximately $12.27.&#160; The market price of the Company&#8217;s common stock as of the last trading day immediately preceding the exchange was $6.12.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The exchange was accounted for as a recapitalization and the carrying value of the Series E Preferred Stock of $13,770,000, accumulated dividends totaling $4,476,000 and estimated liquidated damages of $819,000 for failure to timely file a resale registration statement (see &#8220;Registration Rights&#8221; below) were reclassified to additional paid-in-capital as of the date of the exchange.&#160; If the preferred stock had been converted according to its terms, the holders would have received a total of 274,882 shares of common stock.&#160; At the date of issuance the fair market value totaling $11,955,151 of the additional 1,953,456 shares issued in the exchange has been recorded as a deemed dividend to preferred stockholders in the year ended December 31, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Issuance of</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Series C Preferred</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Stock</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During 2007, the Company issued 272 shares of Series C Preferred Stock in exchange for all 3,264 shares of Series A preferred stock, originally issued in 2005.&#160;The Series C Preferred Stock was initially convertible at $153.00 per share into 21,333 shares of common stock.&#160; In connection with the sale of Series D preferred stock in 2008, the conversion price of the Series C Preferred Stock was reduced to $99.45 per share, according to its terms.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Terms of the Series C Preferred Stock</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Series C Preferred Stock had an annual dividend rate of 8% until October 1, 2008 and 20% thereafter.&#160; The dividends were payable quarterly.&#160; Such dividends were to be paid only after all outstanding dividends on the Series D Preferred Stock (with respect to the current fiscal year and all prior fiscal years) had been paid to the holders of the Series D Preferred Stock.&#160; No dividends were paid on Series C Preferred Stock during 2009 and 2010.&#160; The conversion price was subject to adjustment for stock dividends, stock splits or similar capital reorganizations and upon the occurrence of certain dilutive issuances of securities.&#160; The Series C Preferred Stock did not have voting rights and was redeemable only at the option of the Company upon 30 days&#8217; notice at a 20% premium plus any accrued but unpaid dividends.&#160; In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company&#8217;s affairs, the Series C Preferred Stock would have been treated as senior to Novelos common stock.&#160; After all required payments were made to holders of Series E Preferred Stock, the holders of Series C Preferred Stock would have been entitled to receive first, $12,000 per share and all accrued and unpaid dividends.&#160; If, upon any winding up of the Company&#8217;s affairs, the Company&#8217;s remaining assets available to pay the holders of Series C Preferred Stock were not sufficient to permit the payment in full, then all of the Company&#8217;s assets would have been distributed to the holders of Series C Preferred Stock (and any remaining holders of Series E Preferred Stock as may be required) on a pro rata basis.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Conversions of Series C Preferred Stock</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the year ended December 31, 2009, 68 shares of the Company&#8217;s Series C Preferred Stock, having an aggregate stated value of $816,000, and accumulated dividends thereon of $184,000 were converted into shares of the Company&#8217;s common stock, leaving 204 shares of Series C Preferred Stock outstanding which were convertible into 24,615 shares of common stock as of December 31, 2009.&#160; During 2010, all shares of Series C Preferred Stock were exchanged for shares of common stock (see &#8220;Exchange of Outstanding Preferred Stock for Common Stock&#8221; above).</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-36</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Series E Preferred Stock Private Placement</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Sale of Series E Preferred Stock to Purdue</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Concurrently with the execution of the Collaboration Agreement on February 11, 2009, Novelos sold to Purdue 200 shares of a newly created series of the Company&#8217;s preferred stock, designated &#8220;Series E Convertible Preferred Stock,&#8221; par value $0.00001 per share (the &#8220;Series E Preferred Stock&#8221;), and a warrant (the &#8220;Series E Warrant&#8221;) to purchase 60,330 shares of Novelos common stock for an aggregate purchase price of $10,000,000 (the &#8220;Series E Financing&#8221;).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Series E Warrant is exercisable for an aggregate of 60,330 shares of Novelos common stock at an exercise price of $99.45 per share. The warrant expires on December 31, 2015. The warrant exercise price and/or the common stock issuable pursuant to such warrant are subject to adjustment for stock dividends, stock splits or similar capital reorganizations so that the rights of the warrant holder after such event will be equivalent to the rights of the warrant holder prior to such event.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Exchange of Series D Preferred Stock for Series E Preferred Stock</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company also entered into an exchange agreement with the holders (the &#8220;Series D Investors&#8221;) of the Company&#8217;s Series D preferred stock, issued during 2008, under which all 413.5 outstanding shares of Series D preferred stock and accumulated but unpaid dividends thereon totaling $1,597,144 were exchanged for 445.442875 shares of Series E Preferred Stock. The rights and preferences of the Series E Preferred Stock were substantially the same as the Series D preferred stock. In addition, the Series D Investors waived liquidated damages through the date of the exchange as a result of the Company&#8217;s failure to file a registration statement covering the shares of common stock underlying the Series D preferred stock and warrants not otherwise registered. In connection with the execution of this exchange agreement, warrants held by the Series D Investors to purchase a total of 77,551 shares of the Company&#8217;s common stock were amended to extend the expiration of the warrants to December 31, 2015 (from April 11, 2013) and to remove a forced exercise provision.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Terms of Series E Preferred Stock</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The shares of Series E Preferred Stock had a stated value of $50,000 per share and were convertible into shares of common stock at any time after issuance at the option of the holder at $99.45 per share of common. If there was an effective registration statement covering the shares of common stock underlying the Series E Preferred Stock and the VWAP, as defined in the Series E Certificate of Designations, of Novelos common stock exceeded $306.00 for 20 consecutive trading days, then the outstanding shares of Series E Preferred Stock would automatically convert into common stock at the conversion price then in effect. The conversion price was subject to adjustment for stock dividends, stock splits or similar capital reorganizations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Series E Preferred Stock has an annual dividend rate of 9%, payable semi-annually on June 30 and December 31. Such dividends were payable in cash, in shares of Series E Preferred Stock or in registered shares of Novelos common stock at the Company&#8217;s option, subject to certain conditions. The Company has not paid any cash dividends on Series E Preferred Stock.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The terms of the Series E Preferred Stock provided that for as long as any shares of Series E Preferred Stock remained outstanding, Novelos was prohibited without the prior consent of holders of a majority of the outstanding shares of Series E preferred stock (including in such majority the Xmark Funds and Purdue) from (i) paying dividends to its common stockholders, (ii) amending its certificate of incorporation or by-laws, (iii) issuing any equity security or any security convertible into or exercisable for any equity security at a price of $99.45 or less or with rights senior to the Series E Preferred Stock (except for certain exempted issuances), (iv) increasing the number of shares of Series E Preferred Stock or issuing any additional shares of Series E Preferred Stock, (v) selling or otherwise granting rights with respect to all or substantially all of its assets (or in the case of licensing, any material intellectual property) or the Company's business and/or entering into a merger or consolidation with another company unless Novelos would be the surviving corporation, the Series E Preferred Stock would remain outstanding, there would be no changes to the rights and preferences of the Series E Preferred Stock and there would not be created any new class of capital stock senior to the Series E Preferred Stock, (vi) redeeming or repurchasing any capital stock other than the Series E Preferred Stock, (vii) incurring any new debt for borrowed money in excess of $500,000 and (viii) changing the number of the Company&#8217;s directors. As of December 31, 2010, no shares of Series E preferred stock remained outstanding, and accordingly, none of these restrictions applied. See &#8220;Exchange of Outstanding Preferred Stock for Common Stock&#8221; above.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Advisor Fees</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ferghana Partners, Inc. (&#8220;Ferghana&#8221;), a New York consulting firm, received a cash fee for their services in connection with the negotiation and execution of the Collaboration Agreement equal to $700,000 (or seven percent (7%) of the gross proceeds to the Company resulting from the sale of Series E Preferred Stock and common stock purchase warrants to Purdue in connection with the Collaboration Agreement).&#160; Novelos is also obligated to pay Ferghana six percent (6%) of all payments to Novelos by Mundipharma under the Collaboration Agreement other than royalties on net sales.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-37</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Accounting Treatment of Series E Financing</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The terms of the Series E Preferred Stock contained provisions that required redemption in circumstances that were beyond the Company&#8217;s control, such as the acquisition of more than 50% of our outstanding stock by any person or entity. Therefore, the shares were recorded as redeemable preferred stock outside of permanent equity in the balance sheet as of December 31, 2009. The gross proceeds of $10,000,000 received in conjunction with the Series E Financing were allocated on a relative fair value basis between the Series E Preferred Stock and the warrants. The relative fair value of the warrants issued to investors of $2,907,000 (determined using the Black-Scholes option pricing model, estimated volatility of 80%, a risk-free interest rate of 2.17% and a term equal to the term of the warrant) was recorded as additional paid-in capital while the relative fair value of the Series E Preferred Stock of $7,093,000 was recorded as temporary equity. The carrying value of the Series E Preferred Stock was immediately adjusted to its fair value of $7,385,000 based on the fair value of the as-converted common stock. The difference of $292,000 represents a beneficial conversion feature and was recorded as a deemed dividend to preferred stockholders. Issuance costs related to the Series E Financing of $795,000 were netted against temporary equity. The Series E Preferred Stock that was issued in payment of dividends was initially recorded in temporary equity at the value of the dividends that had accrued totaling $1,597,000. This amount was then adjusted to the fair value of $1,179,000 based on the fair value of the as-converted common stock. The difference of $418,000 was recorded as an offset to the deemed dividends recorded. The Series E Preferred Stock that was issued in exchange for outstanding shares of Series D preferred stock was recorded at $13,904,000, the carrying value of the shares of Series D preferred stock as of the date of the exchange.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As a result of the modification to the warrants to extend their expiration by approximately 32 months that occurred in connection with the exchange of all outstanding shares of Series D preferred stock for shares of Series E Preferred Stock, in the year ended December 31, 2009, a deemed dividend of $840,000 was recorded.&#160; This amount represented the incremental fair value of the warrants immediately before and after modification using the Black-Scholes option pricing model, volatility of 80%, discount rates of 1.54% and 2.17% and the remaining warrant term.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Conversions of Series E Preferred Stock</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the year ended December 31, 2009, 97.18209375 shares of the Company&#8217;s Series E Preferred Stock, having an aggregate stated value of $4,859,000 and accumulated dividends thereon of $301,000, were converted into 51,889 shares of common stock.&#160; The associated carrying value of the converted shares totaling approximately $3,213,000 was reclassified to permanent equity from temporary equity.&#160; During the year ended December 31, 2010, 140 shares of the Company&#8217;s Series E Preferred Stock, having an aggregate stated value of $7,000,000, and accumulated dividends thereon totaling $635,000, were converted into 76,770 shares of common stock.&#160; The associated carrying value of the converted shares totaling approximately $4,690,000 was reclassified to permanent equity from temporary equity.&#160; In November 2010, all outstanding shares of Series E Preferred Stock were exchanged for shares of common stock. See &#8220;Exchange of Preferred Stock&#8221; below.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">August 2009 Common Stock Private Placement</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Securities Purchase Agreement</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On August 25, 2009, the Company entered into the August 2009 Purchase Agreement with Purdue to sell 89,126 shares of its common stock, $0.00001 par value and warrants to purchase 31,194 shares of its common stock at an exercise price of $100.98 per share, expiring December 31, 2015, for an aggregate purchase price of $9,000,000 (the &#8220;August 2009 Private Placement&#8221;). Concurrent with the execution and delivery of the August 2009 Purchase Agreement, the Company sold Purdue 34,660 shares of its common stock and a warrant to purchase 12,131 shares of its common stock at $100.98 per share for approximately $3,500,000 (the &#8220;Initial Closing&#8221;). On November 10, 2009, the Company completed the final closing under the August 2009 Purchase Agreement and sold Purdue 54,466 shares of Novelos common stock and warrants to purchase 19,063 shares of Novelos common stock for gross proceeds of $5,500,000. Issuance costs associated with the transactions totaled $61,000 and such amount was recorded as a reduction of additional paid-in capital.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the August 2009 Purchase Agreement,&#160;Purdue acquired a right of first refusal (the &#8220;Right of First Refusal&#8221;) with respect to bona fide offers for the license or other acquisition of NOV-002 Rights (as defined in the August 2009 Purchase Agreement) in the U.S. (the &#8220;U.S. License&#8221;) received from third parties and approved by the Company&#8217;s board of directors.&#160; Under the Right of First Refusal, Novelos will be required to communicate to Purdue the terms of any such third-party offers received and Purdue will have 30 days to enter into a definitive agreement with Novelos on substantially similar terms that provide no lesser economic benefit to Novelos as provided in the third-party offer.&#160; The Right of First Refusal terminates upon business combinations, as defined in the August 2009 Purchase Agreement. Novelos has separately entered into letter agreements with Mundipharma and its independent associated company providing for a conditional exclusive right to negotiate for, and a conditional right of first refusal with respect to, NOV-002 Rights for Latin America, Mexico and Canada.</font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-38</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the August 2009 Purchase Agreement, Purdue has the right to either designate one member to Novelos&#8217; Board or designate an observer to attend all meetings of the Board and committees thereof and to have access to all information made available to members of the Board.&#160; This right lasts until the later of such time as Purdue or its independent associated companies no longer hold at least one-half of the common stock purchased pursuant to the August 2009 Purchase Agreement and no longer hold at least one-half of the Series E Preferred Stock issued to them on February 11, 2009.&#160; The right to designate a Board observer had previously been granted in connection with the financing that occurred on February 11, 2009 and Purdue appointed such an observer in February 2009.&#160; Purdue also has the right to participate in future equity financings in proportion to their pro rata ownership of common stock.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Common Stock Purchase Warrant</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The common stock purchase warrants have an exercise price of $100.98 per share and expire on December 31, 2015.&#160; The warrant exercise price and/or the number of shares of common stock issuable pursuant to such warrant will be subject to adjustment for stock dividends, stock splits or similar capital reorganizations so that the rights of the warrant holders after such event will be equivalent to the rights of warrant holders prior to such event.&#160; The relative fair value of the warrants issued to Purdue totaled $1,929,000 and was recorded as a component of additional paid-in capital.&#160; The fair value of the warrants was determined based on the market value of the Company&#8217;s common stock on the dates of issuance using the Black-Scholes method of valuation, estimated volatility of 90%, risk-free interest rates ranging from 2.02% to 2.7% and a term equal to the term of the warrant.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Registration Rights</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As part of the August 2009 Private Placement, the Company entered into a registration rights agreement with Purdue (the &#8220;Purdue Registration Agreement&#8221;).&#160; The Purdue Registration Agreement required the Company to have filed with the SEC no later than May 17, 2010, a registration statement covering the resale of all the shares of common stock issued pursuant to the August 2009 purchase agreement and all shares of common stock issuable upon exercise of the warrants issued pursuant to the August 2009 purchase agreement.&#160; The registration rights agreement provided for liquidated damages equal to 1.5% per month (pro-rated on a daily basis for any period of less than a full month) of the aggregate purchase price of the common stock until the delinquent registration statement is filed.&#160; The Company did not file the registration statement and accrued $819,000 as a component of other income (expense) during the year ended December 31, 2010, representing management&#8217;s best estimate of the probable total liquidated damages that may be settled. In connection with the exchange of their shares of Series E Preferred Stock for common stock on November 30, 2010, Purdue released the Company from any requirement to register shares of its common stock for resale and forfeited any rights to receive liquidated damages pursuant to any registration agreements. The accrued liquidated damages were settled in connection with the exchange and, accordingly, the amount that had been accrued was reclassified to additional paid-in capital.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">July 2010 Registered Offering</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 27, 2010, pursuant to securities purchase agreements entered into with institutional investors on July 21, 2010, the Company completed the sale, in an offering registered under the Securities Act of 1933, as amended, of an aggregate of 140,056 shares of its common stock and five-year warrants to purchase up to an aggregate of 150,040 shares of its common stock at an exercise price of $10.71 per share, for gross proceeds of $1,500,000 and net proceeds of $1,249,000 after deducting transaction costs.&#160; The warrant exercise price is subject to adjustment in certain circumstances and therefore, the relative fair value of the warrants at the date of issuance, $504,000, has been bifurcated from the proceeds and recorded as a derivative liability.&#160; The Company uses valuation methods and assumptions that consider among others the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. The assumptions used to value these warrants at the time of issuance are generally consistent with those disclosed for stock-based compensation (see Note 7).</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since the securities in this financing were issued at a price less than $100.98 per share, the Company obtained the consent of its preferred stockholders pursuant to a consent and waiver dated July 6, 2010, as amended on July 21, 2010. In connection with obtaining this consent, the Company issued five-year warrants (the &#8220;Incentive Warrants&#8221;) to its preferred stockholders for the purchase of up to an aggregate of 150,039 shares of common stock at an exercise price of $16.065 per share. No adjustments to the conversion price of the preferred stock or warrants held by preferred stockholders were made in connection with the financing. The fair value of the Incentive Warrants at date of issuance, $586,000, is reflected as a deemed dividend to the preferred stockholders on the statement of operations. The Company used valuation methods and assumptions that consider among others the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value of the Incentive Warrants. The assumptions used to value these warrants are generally consistent with those disclosed for stock-based compensation (see Note 7).</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The financing resulted in adjustments to certain warrants pursuant to their terms.&#160; Warrants issued in 2005 that were exercisable for 1,591 shares at an exercise price of $99.45 per share as of immediately prior to the transaction became exercisable for 14,776 shares at an exercise price of $10.71 per share, and warrants issued in 2006 that were exercisable for 29,787 shares at an exercise price of $263.16 per share as of immediately prior to the transaction became exercisable for 33,569 shares at an exercise price of $234.09 per share.&#160; The 2005 warrants expired unexercised on August 9, 2010, and the 2006 warrants will expire in March 2011.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-39</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Common Stock Warrants</font> &#160; &#8212; The following table summarizes information with regard to outstanding warrants as of December 31, 2010, issued in connection with equity and debt financings since 2005.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="50%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Offering</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Outstanding</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(as&#160;adjusted)</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Price</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(as&#160;adjusted)</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Expiration&#160;Date</font></font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2006 Issuance of Common Stock</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">33,569</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">234.09</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">March 7, 2011</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series B Preferred Stock &#8211; placement agents</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,392</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">191.25</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 2, 2012</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series C Exchange</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,169</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">191.25</font></font></div>
</div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 2, 2012</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series E Preferred Stock</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">60,330</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.45</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31, 2015</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">August 2009 Private Placement</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31,194</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100.98</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31, 2015</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 2010 Direct Offering (1)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">105,039</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.71</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 27, 2015</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Preferred Incentive Warrants</font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">105,040</font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16.065</font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="20%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 27, 2015</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="20%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">348,733</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="20%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)&#160; The exercise price of these warrants was adjusted in connection with the private placement completed on April 8, 2011.&#160; See Note 12.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the year ended December 31, 2010, warrants to purchase 14,776 shares of common stock at $10.71 and 5,941 shares of common stock at $99.45 expired unexercised.&#160; On March 7, 2011, warrants to purchase 33,569 shares of common stock at $234.09 expired unexercised.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the year ended December 31, 2010, 53,478 shares of the Company&#8217;s common stock were issued upon the cashless exercise of warrants to purchase 89,752 shares of the Company&#8217;s common stock.&#160; The Company reclassified $2,584,000 from derivative liability to additional paid-in capital upon the exercise of warrants.&#160; The following is a summary of the exercises:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 27pt" align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="64%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Original&#160;private&#160;placement&#160;</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Shares&#160;of</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Common&#160;Stock</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Issued</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Warrants</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercised</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Price</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2005 Bridge Financing</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,059</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,614</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">95.625</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2005 Issuance of Common Stock &#8211; placement agents</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,481</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,074</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.45</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2006 Issuance of Common Stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,395</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,480</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">263.16</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series B Preferred Stock &#8211; purchasers</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">29,709</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,019</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.45</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series B Preferred Stock &#8211; placement agents</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">229</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">490</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">191.25</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series D Preferred Stock</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,292</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">28,531</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.45</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series C Exchange</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">313</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">544</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">191.25</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">53,478</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">89,752</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the year ended December 31, 2009, a total of 3,162 shares of the Company&#8217;s common stock were issued upon the cashless exercise of warrants to purchase 6,975 shares of common stock. The Company reclassified a total of $1,001,000 from derivative liability to additional paid-in capital upon the exercise of warrants.&#160; The following is a summary of the exercises:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="MARGIN-LEFT: 27pt" align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="64%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Original&#160;private&#160;placement</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Shares&#160;of</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Common&#160;Stock</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Issued</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Warrants</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercised</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Price</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2005 Bridge Financing</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,429</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,091</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">95.625</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2005 Common Stock</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,310</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,172</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.45</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series A Preferred Stock</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">250</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">396</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.45</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2006 Issuance of Common Stock</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">173</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,316</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">263.16</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,162</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">6,975</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-40</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On August 21, 2009, the Company entered into exchange agreements with certain accredited investors who held warrants, issued in the 2006 private placement, to purchase 45,409 shares of its common stock. Pursuant to the exchange agreements, an aggregate of 13,623 shares of the Company&#8217;s common stock with a fair value of $1,626,000 were issued in exchange for these warrants. The holders agreed not to transfer or dispose of the shares of common stock before February 18, 2010. The warrants had been recorded as a derivative liability on the Company&#8217;s balance sheet at their estimated fair value of $1,109,000 at the date of exchange. The difference of $517,000 between the estimated fair value of the warrants at the date of exchange and the common stock issued to settle the derivative liability has been included as a component of the loss on derivative warrants for the year ended December 31, 2009. Following the exchange, warrants expiring on March 7, 2011 to purchase a total of 35,504 shares of common stock at $278.46 per share remained outstanding. Following the final closing of the August 2009 Private Placement, described above, the number of these outstanding warrants was increased to 37,584 and the exercise price was reduced to $263.16, as a result of anti-dilution provisions in the warrants.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Authorized and Reserved Shares</font> &#8212; On October 18, 2010 the Company&#8217;s stockholders approved an amendment to the certificate of incorporation to increase the total number of authorized shares of the Company&#8217;s common stock from 225,000,000 to 750,000,000. On April 8, 2011, the Company completed the Reverse Split described in Note 12, and amended the certificate of incorporation to decrease the total number of authorized shares to 150,000,000 from 750,000,000.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following shares were reserved for future issuance upon exercise of stock options or warrants or conversion of preferred stock as of the dates indicated:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="MARGIN-LEFT: 27pt" align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="6" valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">December 31,</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2009</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2000 Stock Option Plan</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">291</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">366</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2006 Stock Incentive Plan</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38,366</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">43,856</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options issued outside of formalized plans</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,569</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,037</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">348,733</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">232,164</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Preferred stock</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">329,451</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total shares reserved for future issuance</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">397,959</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">621,874</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.&#160; STOCK-BASED COMPENSATION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s stock-based compensation plans are summarized below:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">2000 Stock Option Plan.&#160; </font>As of December 31, 2010, there are options to purchase 291 shares of the Company&#8217;s common stock outstanding under a stock option plan established in August 2000 (the &#8220;2000 Plan&#8221;).&#160; There will be no further grants made under the 2000 Plan. Options generally vested annually over three years and expire on the tenth anniversary of the grant date.&#160; No options were granted or exercised under the 2000 Plan during 2009.&#160; During 2010, options to purchase 65 shares of common stock under the 2000 Plan were exercised and options to purchase 9 shares of common stock were canceled.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">2006 Stock Incentive Plan</font>. On May 1, 2006, the Company&#8217;s board of directors adopted, and on July 21, 2006 the Company&#8217;s stockholders approved, the 2006 Stock Incentive Plan (the &#8220;2006 Plan&#8221;). A total of 65,359 shares of common stock are reserved for issuance under the 2006 Plan for grants of incentive or nonqualified stock options, rights to purchase restricted and unrestricted shares of common stock, stock appreciation rights and performance share grants. A committee of the board of directors determines exercise prices, vesting periods and any performance requirements on the date of grant, subject to the provisions of the 2006 Plan. Options are granted at or above the fair market value of the common stock at the grant date and expire on the tenth anniversary of the grant date. Vesting periods are generally two to three years. In the year ended December 31, 2009, stock options for the purchase of 12,679 shares of common stock were granted under the 2006 Plan. During the year ended December 31, 2010, options to purchase 1,438 shares of common stock were exercised and options to purchase 3,921 shares of common stock were canceled. As of December 31, 2010 and December 31, 2009, 25,555 and 21,503 shares remain available for grant under the 2006 Plan. Options granted pursuant to the 2006 Plan generally will become fully vested upon a termination event occurring within one year following a change in control, as defined. A termination event is defined as either termination of employment or services other than for cause or constructive termination of employees or consultants resulting from a significant reduction in either the nature or scope of duties and responsibilities, a reduction in compensation or a required relocation.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Other Stock Option Activity.</font> &#160; During 2005 and 2004, the Company issued options to purchase a total of 17,345 shares of common stock to employees, directors and consultants outside of any formalized plan.&#160; These options are exercisable within a ten-year period from the date of grant, and vest at various intervals with all options being fully vested within two to three years of the grant date.&#160; The options are not transferable except by will or domestic relations order.&#160; The option price per share is not less than the fair market value of the shares on the date of the grant.&#160; During the year ended December 31, 2010, options to purchase 4,488 shares of common stock were exercised and options to purchase 980 shares of common stock were canceled.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-41</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounting for Stock-Based Compensation</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company accounts for employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718, <font style="DISPLAY: inline; FONT-STYLE: italic">Compensation &#8211; Stock Compensation</font> which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values.&#160; The Company accounts for non-employee stock-based compensation in accordance with the guidance of FASB ASC Topic 505, <font style="DISPLAY: inline; FONT-STYLE: italic">Equity</font> which requires that companies recognize compensation expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered by such non-employees.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and stock-based compensation recorded in connection with stock options and restricted stock awards granted to non-employee consultants:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 45pt" align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="6" valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Year&#160;Ended</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">December&#160;31,</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2009</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Employee and director stock option grants:</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">230,101</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">148,030</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">356,220</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">289,036</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">586,321</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">437,066</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-employee consultant stock option grants and restricted stock awards:</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(220,969</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">328,614</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(28,054</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">98,657</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(249,023</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">427,271</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total stock-based compensation</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">337,298</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">864,337</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On December 31, 2009, the expiration of options held by a former employee was extended until January 31, 2010 and incremental stock-based compensation expense for non-employees of $15,000 was recorded in connection with the one-month extension.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In January 2009, the Company modified the terms of options to purchase 261 shares of common stock held by two employees to vest all unvested options and to extend the expiration dates of the options.&#160; The modification was made in connection with the termination of the two employees to reduce costs.&#160; During the year ended December 31, 2009, incremental stock-based compensation expense of $8,000 was recorded in connection with the modification of the option terms.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Determining Fair Value</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Valuation and amortization method</font>. The fair value of each stock award is estimated on the grant date using the Black-Scholes option-pricing model.&#160; The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Volatility.</font> The Company estimates volatility based on an average of (1) the Company&#8217;s historical volatility since its common stock has been publicly traded and (2) review of volatility estimates of publicly held drug development companies with similar market capitalizations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Risk-free interest rate</font>. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Expected term</font>. The expected term of stock options granted is based on the Company&#8217;s estimate of when options will be exercised in the future as there have been limited stock option exercises to date.&#160; The expected term is generally applied to one group as a whole as the Company does not expect substantially different exercise or post-vesting termination behavior within its population of option holders.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Forfeitures.</font> &#160; The Company records stock-based compensation expense only for those awards that are expected to vest.&#160; FASB ASC Topic 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&#160; The term &#8220;forfeitures&#8221; is distinct from &#8220;cancellations&#8221; or &#8220;expirations&#8221; and represents only the unvested portion of the surrendered option.&#160; The Company has applied an annual forfeiture rate of 0% to all unvested options as of December 31, 2010 as the Company has experienced very few forfeitures to date and believes that there is insufficient history to develop an accurate estimate of future forfeitures.&#160;&#160;This analysis will be re-evaluated semi-annually and the forfeiture rate will be adjusted as necessary.&#160;&#160;Ultimately, the actual expense recognized over the vesting period will be for only those shares that vest.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-42</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes weighted average values and assumptions used for options granted to employees, directors and consultants in the periods indicated:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="MARGIN-LEFT: 18pt" align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Year&#160;Ended</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">December&#160;31,&#160;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2009</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Volatility</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">90</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted-average volatility</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">90</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk-free interest rate</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.12</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected life (years)</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dividend</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted-average exercise price</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.75</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted-average grant-date fair value</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.53</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There were no stock option grants during the year ended December 31, 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock Option Activity</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A summary of stock option activity under the 2000 Plan, the 2006 Plan and outside of any formalized plan is as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 18pt; TEXT-ALIGN: left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: left;">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Options</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Outstanding</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Weighted</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Average</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise&#160;Price</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Weighted</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Average</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Remaining</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Contracted</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Term&#160;in</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Years</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Aggregate</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Intrinsic</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Value</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding at January 1, 2009</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">47,580</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">91.80</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7.9</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">989,718</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options granted</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">12,679</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$&#160;</font></div>
</td>
<td align="right" valign="top" width="9%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">114.75</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding at December 31, 2009</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">60,259</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">96.39</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7.5</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17,650,255</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options exercised</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,991</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">26.01</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;663,600</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options canceled</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(5,042</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">139.23</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0&#160;</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding at December 31, 2010</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">49,226</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">100.98</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">6.9</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">24,842</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercisable at December 31, 2010</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">39,270</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">100.98</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">6.4</font></font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">24,842</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The aggregate intrinsic value of options outstanding is calculated based on the positive difference between the closing market price of the Company&#8217;s common stock at the end of the respective period and the exercise price of the underlying options.&#160;&#160;During the year ended December 31, 2010, the total intrinsic value of options exercised was $663,000 and the total amount of cash received from exercise of these options was $158,600.&#160;&#160;Shares of common stock issued upon the exercise of options are from authorized but unissued shares.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of December 31, 2010, there was approximately $647,000 of total unrecognized compensation cost related to unvested stock-based compensation arrangements.&#160;&#160;Of this total amount, 70% and 30% are expected to be recognized during 2011 and 2012, respectively.&#160;&#160;The Company expects 9,956 in unvested options to vest in the future.&#160;&#160;The weighted-average grant-date fair value of vested and unvested options outstanding at December 31, 2010 was $62.73 and $68.85, respectively.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8. &#160;INCOME TAXES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s deferred tax assets consisted of the following at December 31:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="MARGIN-LEFT: 18pt" align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2009</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net operating loss carryforwards</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,872,000</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,543,000</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,180,000</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,906,000</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tax credits</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,711,000</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,563,000</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Capital loss carryforward</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">340,000</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">340,000</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">365,000</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">650,000</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gross deferred tax asset</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">29,468,000</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27,002,000</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Valuation allowance</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(29,468,000</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(27,002,000</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net deferred tax asset</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-43</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of December 31, 2010, the Company had federal and state net operating loss carryforwards of approximately $33,180,000 and $25,812,000 respectively, which expire through 2030.&#160;&#160;In addition, the Company has federal and state research and development and investment tax credits of approximately $1,382,000 and $449,000, respectively, which expire through 2030.&#160;&#160;The amount of net operating loss carryforwards which may be utilized annually in future periods may be limited pursuant to Section 382 of the Internal Revenue Code as a result of substantial changes in the Company&#8217;s ownership that have occurred or that may occur in the future.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The capital loss carryforward relates to the loss recorded in prior years for Novelos&#8217; investment in an unrelated company.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Because of the Company&#8217;s limited operating history, continuing losses and uncertainty associated with the utilization of the net operating loss carryforwards in the future, management has provided a 100% allowance against the Company&#8217;s gross deferred tax asset.&#160;&#160;In 2010, the difference between the Company&#8217;s total statutory tax rate of approximately 40% and its effective tax rate of 0% is due to the nontaxable gain of $8,118,000 on derivative warrants, an increase in the valuation allowance of $2,466,000 and nondeductible liquidated damages accrued of $819,000.&#160;&#160;In 2009, the difference between the Company&#8217;s total statutory tax rate of approximately 40% and its effective tax rate of 0% is due equally to the increase in valuation allowance and the reduction in tax loss resulting from the nondeductible loss on derivative warrants.&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company did not have any unrecognized tax benefits or accrued interest and penalties at any time during the years ended December 31, 2010 and 2009, and does not anticipate having any unrecognized tax benefits over the next twelve months.&#160;&#160;The Company is subject to audit by the IRS for tax periods commencing January 1, 2007.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9. &#160;&#160;NET INCOME (LOSS) PER SHARE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net loss attributable to common stockholders, as adjusted, by the sum of the weighted average number of shares of common stock and the dilutive potential common stock equivalents then outstanding. Potential common stock equivalents consist of stock options, warrants and convertible preferred stock and accumulated dividends.&#160;&#160;Since the Company has a net loss attributable to common stockholders for the years ended December 31, 2010 and 2009, the inclusion of common stock equivalents in the computation for those periods would be antidilutive. Accordingly, basic and diluted net loss per share is the same for the periods presented.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following potentially dilutive securities have been excluded from the computation of diluted net income (loss) per share since their inclusion would be antidilutive:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Year Ended</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">December 31,</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2009</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock options</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">50,074</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">60,260</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">356,925</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">232,164</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Conversion of preferred stock</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,042,108</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">329,451</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;(1)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1) Includes shares of common stock that may become issuable upon conversion of preferred stock dividends accumulated at the respective date.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10. COMMITMENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Property Lease</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective September 1, 2010, the Company entered into a six-month extension to its lease for office space, at a rate of $5,275 per month, expiring February 28, 2011. Rent expense was $65,000 and $87,000 for the years ended December 31, 2010 and 2009, respectively. Future minimum lease payments under this non-cancelable lease are approximately $10,600 during 2011.&#160;&#160;After February 28, 2011, the lease may be canceled with 30-day notice by either party.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Royalty Arrangements</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company is obligated to a Russian company, ZAO BAM, under a royalty and technology transfer agreement. Mark Balazovsky, a director of the Company until November 2006, is the majority shareholder of ZAO BAM. Pursuant to the royalty and technology transfer agreement between the Company and ZAO BAM, the Company is required to make royalty payments of 1.2% of net sales of oxidized glutathione-based products. The Company is also required to pay ZAO BAM $2 million for each new oxidized glutathione-based drug within eighteen months following FDA approval of such drug.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-44</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If a royalty is not being paid to ZAO BAM on net sales of oxidized glutathione products, then the Company is required to pay ZAO BAM 3% of all license revenues. If license revenues exceed the Company&#8217;s cumulative expenditures including, but not limited to, preclinical and clinical studies, testing, FDA and other regulatory agency submission and approval costs, general and administrative costs, and patent expenses, then the Company would be required to pay ZAO BAM an additional 9% of the amount by which license revenues exceed the Company&#8217;s cumulative expenditures.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As a result of the assignment to Novelos of the exclusive worldwide intellectual property and marketing rights of oxidized glutathione (excluding the Russian Territory), Novelos is obligated to the Oxford Group, Ltd., or its assignees, for future royalties.&#160;&#160;Simyon Palmin, a founder of Novelos, a director until August 12, 2008 and the father of the Company&#8217;s president and chief executive officer, is president of Oxford Group, Ltd.&#160;&#160;Mr. Palmin was also an employee of the Company until September 2008 and performed consulting services through December 2009.&#160;&#160;Pursuant to the agreement, as revised May 26, 2005, Novelos is required to pay Oxford Group, Ltd., or its assignees, a royalty in the amount of 0.8% of the Company&#8217;s net sales of oxidized glutathione-based products.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Employment Agreements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company entered into an employment agreement with Harry Palmin effective January 1, 2006, whereby he agreed to serve as the Company&#8217;s president and chief executive officer for an initial term of two years.&#160;&#160;The agreement is automatically renewed for successive one-year terms unless notice of termination is provided by either party at least 90 days prior to the end of such term.&#160;&#160;The agreement was renewed most recently for an additional one-year term on January 1, 2011 in accordance with its terms.&#160;&#160;The agreement provides for an initial salary of $225,000 in 2006, participation in standard benefit programs and an annual cash bonus at the discretion of the compensation committee.&#160;&#160;The agreement further provides that upon resignation for good reason or termination without cause, both as defined in the agreement, Mr.&#160;Palmin will receive his pro rata share of the average of his annual bonus paid during the two fiscal years preceding his termination, his base salary and benefits for 11 months after the date of termination and fifty percent of his unvested stock options will vest.&#160;&#160;The agreement also contains a non-compete provision, which prohibits Mr.&#160;Palmin from competing with the Company for one year after termination of his employment with the Company.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Retention Agreements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On May 14, 2010, the Company entered into retention agreements with each of its four vice-presidents.&#160;&#160;The agreements provide for the lump-sum payment of six months&#8217; base salary and benefits to each such officer following a termination without cause or a resignation with good reason occurring on or before November 14, 2011.&#160;&#160;The agreements further provide that if the executives remain employed with the Company as of October 1, 2010, they will receive a payment of two months&#8217; base salary as a retention bonus on that date. The retention bonus, an aggregate of $140,000, was paid in October 2010 and will be deducted from the severance amounts that may become payable upon a subsequent involuntary termination.&#160;&#160;Elias Nyberg&#8217;s employment was terminated on March 10, 2011, without cause, and he received a payment of approximately $83,000 pursuant to the executive retention agreement. The agreements expire November 14, 2011.&#160;&#160;The total remaining amount that may become payable to the Company&#8217;s Named Executive Officers pursuant to the retention agreements is approximately $86,000 to Christopher Pazoles. Concurrently with the execution of the retention agreements, the employment agreement between the Company and Christopher Pazoles dated July 15, 2005 was terminated.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On May 14, 2010, the Company also entered into retention agreements with each of its three non-executive employees. The agreements provide for the lump-sum payment of six months&#8217; base salary and benefits to each employee following a termination without cause or a resignation with good reason occurring on or before November 14, 2011.&#160;&#160;The agreements expire November 14, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">11.&#160;&#160;LITIGATION</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A purported class action complaint was filed on March 5, 2010 in the United States District Court for the District of Massachusetts by an alleged shareholder of the Company, on behalf of himself and all others who purchased or otherwise acquired the Company&#8217;s common stock in the period between December 14, 2009 and February 24, 2010, against the Company and its President and Chief Executive Officer, Harry S. Palmin.&#160;&#160;On October 1, 2010, the court appointed lead plaintiffs (Boris Urman and Ramona McDonald) and appointed lead plaintiffs&#8217; counsel.&#160;&#160;On October 22, an amended complaint was filed.&#160;&#160;The amended complaint claims that the Company violated Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder in connection with alleged disclosures related to the Phase 3 clinical trial of NOV-002 for non-small cell lung cancer.&#160;&#160;On December 6, 2010, the Company filed a motion to dismiss the complaint with prejudice.&#160;&#160;On January 20, 2011, the plaintiffs filed their opposition to our motion and on March 3, 2011, we filed our response to their opposition. Our motion to dismiss remains pending. The Company believes the allegations are without merit and intends to defend vigorously against the allegations.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-45</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 28, 2010, the Company received a letter from counsel to ZAO BAM and ZAO BAM Research Laboratories (collectively, &#8220;BAM&#8221;) alleging that the Company modified the chemical composition of NOV-002 without prior notice to or approval from BAM, constituting a material breach of a technology and assignment agreement the Company had entered into with BAM on June 20, 2000 (the &#8220;June 2000 Agreement&#8221;).&#160;&#160;The letter references the Company&#8217;s amendment, submitted to the FDA on August 30, 2005, to its investigational new drug application dated August 1999 as the basis for BAM&#8217;s claims and demands the transfer of all intellectual property rights concerning NOV-002 to BAM.&#160;&#160;Mark Balazovsky, a director of Novelos from June 1996 until November 2006 and a shareholder of Novelos through at least June 25, 2010, is, to the Company&#8217;s knowledge, still the general director and principal shareholder of ZAO BAM.&#160;&#160;The Company believes the allegations are without merit and intends to defend vigorously against any proceedings that BAM may initiate as to these allegations. On September 24, 2010, the Company filed a complaint in Suffolk Superior Court seeking a declaratory judgment by the court that the June 2000 Agreement has been replaced by a subsequent agreement between the parties dated April 1, 2005 (the &#8220;April 2005 Agreement&#8221;), that Novelos&#8217; obligations to BAM are governed solely by the April 2005 Agreement and that the obligations of the June 2000 agreement have been performed and fully satisfied.&#160;&#160;On November 29, 2010, BAM answered the complaint, denying the material allegations, and stating its affirmative defenses and certain counterclaims. On January 14, 2011, the Company responded to the counterclaims, denying BAM&#8217;s material allegations and stating our affirmative defenses.&#160;&#160;The Company believes the counterclaims are without merit and intends to vigorously defend against them.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SUBSEQUENT EVENTS</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Merger Agreement</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 8, 2011, the Company entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with Cellectar, Inc. (&#8220;Cellectar&#8221;) and Cell Acquisition Corp. (the &#8220;Merger Subsidiary&#8221;), a wholly owned subsidiary of Novelos, pursuant to which Cellectar was merged into the Merger Subsidiary (the &#8220;Acquisition&#8221;).&#160;&#160;As a result of the Acquisition, the Merger Subsidiary, which has been renamed Cellectar, Inc., owns all assets and operates the business previously owned and operated by Cellectar. Prior to the Acquisition, Cellectar was in the business of developing drugs for the treatment and diagnosis of cancer.&#160;&#160;The Company will continue to develop Cellectar&#8217;s compounds following the Acquisition.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As consideration for the Acquisition, the former stockholders of Cellectar&#160;&#160;received aggregate consideration consisting of a number of shares of Novelos common stock constituting, after giving effect to the Acquisition but before giving effect to the concurrent private placement of our securities described below, approximately 85% of the outstanding shares of Novelos common stock.&#160;&#160;Prior to the Acquisition, the Company amended and restated its certificate of incorporation and in connection therewith, among other things, effected a 1-for-153 reverse split of its common stock (the &#8220;Reverse Split&#8221;).&#160;&#160;Immediately following the effectiveness of the Reverse Split, there were approximately 2,959,871 shares of our common stock outstanding, and the Company issued 17,001,596 shares of our common stock to the former stockholders of Cellectar upon the effectiveness of the Acquisition.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Rodman &amp; Renshaw, LLC (&#8220;Rodman&#8221;), financial advisor to Novelos in connection with the Acquisition, received a cash fee of $250,000 upon the completion of the Acquisition in consideration of their services.&#160;&#160;XMS Capital Partners, the financial advisor to Cellectar in connection with the Acquisition, received a cash fee of $200,000 upon the completion of the Acquisition in consideration of their services.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Securities Purchase Agreement</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Concurrently with the execution of the Merger Agreement, the Company entered into a Securities Purchase Agreement with certain accredited investors under which the Company sold an aggregate of 6,846,537 units, each unit consisting of one share of its common stock and a warrant to purchase one share of its common stock, at a price of $0.75 per unit, for gross proceeds of approximately $5,135,000.&#160;&#160;The warrants have an exercise price of $0.75 and expire on March 31, 2016.&#160;&#160;The warrant exercise price and/or the common stock issuable pursuant to such warrant will be subject to adjustment for stock dividends, stock splits or similar capital reorganizations so that the rights of the warrant holders after such event will be equivalent to the rights of warrant holders prior to such event.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Securities Purchase Agreement includes a requirement that the Company file with the Securities and Exchange Commission (&#8220;SEC&#8221;) no later than October 5, 2011, a registration statement covering the resale of the shares of common stock, and the shares of common stock underlying the warrants, issued pursuant to the Securities Purchase Agreement.&#160;&#160;The Company is also required to use our commercially reasonable efforts to have the registration statement declared effective by December 4, 2011, and to keep the registration statement continuously effective under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) until the earlier of the date when all the registrable securities covered by the registration statement have been sold or the second anniversary of the closing.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the event the Company fails to file the registration statement within the timeframe specified by the Securities Purchase Agreement, or if it fails to obtain effectiveness of this registration on or prior to the December 4, 2011 (if there is no review by the SEC) or by January 3, 2012 (if there is review by the SEC) with respect to the maximum number of shares permitted to be registered by the SEC, the Company will be required to pay to the purchasers liquidated damages equal to 1.5% per month (pro-rated on a daily basis for any period of less than a full month) of the aggregate purchase price of the units purchased until the registration statement is filed or declared effective, as applicable.&#160;&#160;The Company will be allowed to suspend the use of the registration statement for not more than 30 consecutive days, on not more than two occasions, in any 12 month period.&#160;&#160;The Company has also granted piggy-back registration rights with respect to any shares of common stock that it is required to exclude from the registration statement as a condition of its effectiveness, and has also agreed to file further registration statements with respect to any such shares six months after the effective date of the initial registration statement.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-46</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company paid to Rodman, the placement agent for the financing, a cash fee equal to $200,000 and warrants to purchase 192,931 shares of its common stock in consideration for their advisory services with respect to the financing pursuant to the placement agency agreement between Rodman and the Company.&#160;&#160;Rodman is entitled to registration rights with respect to the shares of common stock issuable upon exercise of these warrants.&#160;&#160;The warrants have the same terms as those issued to the investors in the private placement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Changes in Directors and Executive Officers</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective April 8, 2011, prior to the completion of the Acquisition, Michael J. Doyle, Sim Fass and David B. McWilliams resigned from the Company&#8217;s board of directors and their respective committee appointments.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective April 8, 2011, as a condition to the completion of the Acquisition, Jamey P. Weichert, Thomas Rockwell Mackie, John Neis, John E. Niederhuber and Michael F. Tweedle were appointed to the Company&#8217;s board of directors.&#160;&#160;Committee assignments have not yet been determined.&#160;&#160;Jamey P. Weichert, Thomas Rockwell Mackie and John Neis, previously served on the board of directors of Cellectar.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Amendment of Certificate of Incorporation</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective April 7, 2011 the Company&#8217;s certificate of incorporation was amended to eliminate the Certificate to Set Forth Designations, Voting Powers, Preferences, Restrictions and Relative Rights of Series C 8% Cumulative Convertible Preferred Stock.&#160;&#160;There had not been any shares of Series C preferred stock outstanding since December 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective April 7, 2011 the Company&#8217;s certificate of incorporation was amended to eliminate the Certificate of Designations, Preferences and Rights of Series E Convertible Preferred Stock.&#160;&#160;There had not been any shares of Series E preferred stock outstanding since December 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prior to the closing of the Acquisition on April 8, 2011, the Company amended and restated its certificate of incorporation in order (a) to effect the reverse split; (b) to reduce the number of shares of our authorized common stock from 750,000,000 to 150,000,000; (c) to eliminate the right of the stockholders to act by written consent; and (d) to classify the board of directors into three classes.&#160;&#160;Class I directors will stand for re-election at the Company&#8217;s next annual meeting of stockholders, Class II directors will stand for re-election at the 2012 annual meeting of stockholders, and Class III directors will stand for re-election at the 2013 annual meeting of stockholders.&#160;&#160;Thomas Rockwell Mackie, James S. Manuso and John Niederhuber serve as Class I directors, Stephen A. Hill, Michael F. Tweedle and John Neis serve as Class II directors, and Harry S. Palmin, Jamey P. Weichert and Howard M. Schneider serve as Class III directors.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-47</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOVELOS THERAPEUTICS, INC. (PRE-ACQUISITION)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BALANCE SHEET</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">March&#160;31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(unaudited)</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ASSETS</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CURRENT ASSETS:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash and equivalents</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,030,942</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Prepaid expenses and other current assets</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">28,042</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred transaction costs</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">28,500</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total current assets</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,087,484</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FIXED ASSETS, NET</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,515</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DEPOSITS</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">15,350</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TOTAL ASSETS</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,109,349</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CURRENT LIABILITIES:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts payable and accrued liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">250,008</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Derivative liability (see Note 2)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">162,760</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred revenue &#8211; current</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">33,333</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total current liabilities</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">446,101</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DEFERRED REVENUE &#8211; NONCURRENT</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">358,333</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COMMITMENTS AND CONTINGENCIES</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">STOCKHOLDERS&#8217; EQUITY:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common stock, $0.00001 par value; 150,000,000 shares authorized;&#160;&#160;2,959,871 shares issued and outstanding at March 31, 2011</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Additional paid-in capital</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">75,291,653</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accumulated deficit</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(74,986,768</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total stockholders&#8217; equity</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">304,915</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">TOTAL LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,109,349</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">See notes to financial statements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Share totals give retroactive effect to the 1-for-153 reverse split of our common stock completed</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">&#160;on April 8, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-48</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>NOVELOS THERAPEUTICS, INC. (PRE-ACQUISITION)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">STATEMENTS OF OPERATIONS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Unaudited)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Three&#160;Months&#160;Ended&#160;March&#160;31,</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">REVENUE</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">8,333</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">8,333</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COSTS AND EXPENSES:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">532,686</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,910,889</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">611,877</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">644,763</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total costs and expenses</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,144,563</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,555,652</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">LOSS FROM OPERATIONS</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,136,230</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(2,547,319</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">OTHER INCOME:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest income</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">668</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gain on derivative warrants (see Note 2)</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">125,490</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">7,897,441</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total other income</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">126,158</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">7,897,441</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NET INCOME (LOSS)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(1,010,072</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,350,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PREFERRED STOCK DIVIDENDS</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(656,635</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(1,010,072</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4,693,487</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BASIC NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(0.34</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">8.99</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SHARES USED IN COMPUTING BASIC NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,959,871</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">522,350</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DILUTED NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(0.34</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.41</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SHARES USED IN COMPUTING DILUTED NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,959,871</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">881,861</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">See notes to financial statements.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Share totals and share-based calculations give retroactive effect to the 1-for-153 reverse split of our common stock completed on April 8, 2011.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-49</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOVELOS THERAPEUTICS, INC. (PRE-ACQUISITION)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">STATEMENTS OF CASH FLOWS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Unaudited)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Three&#160;Months&#160;Ended&#160;March&#160;31,</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH FLOWS FROM OPERATING ACTIVITIES:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income (loss)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(1,010,072</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,350,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustments to reconcile net income (loss) to cash used in operating activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Depreciation and amortization</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,240</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27,290</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">108,378</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(97,479</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gain on derivative warrants</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(125,490</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,897,441</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Changes in:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Prepaid expenses and other current assets</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,483</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(47,574</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts payable and accrued liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(315,715</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(403,760</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued compensation</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(238,022</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred revenue</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(8,333</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(8,333</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash used in operating activities</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,313,509</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(3,315,197</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH FLOWS FROM FINANCING ACTIVITIES:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred financing costs</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(28,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from exercise of stock options</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">157,400</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash provided by financing activities</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(28,500</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">157,400</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DECREASE IN CASH AND EQUIVALENTS</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,342,009</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,157,797</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH AND EQUIVALENTS AT BEGINNING OF PERIOD</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,372,951</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">8,769,529</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">CASH AND EQUIVALENTS AT END OF PERIOD</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,030,942</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">5,611,732</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dividends accumulated on shares of Series E preferred stock exchanged or converted into shares of common stock</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">634,925</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fair value of derivative warrants reclassified to additional paid-in capital upon cashless exercise</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,584,397</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Carrying value of redeemable preferred stock converted into common stock</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">4,689,593</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">See notes to financial statements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-50</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOVELOS THERAPEUTICS, INC. (PRE-ACQUISITION)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOTES TO FINANCIAL STATEMENTS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Unaudited)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.&#160;</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NATURE OF BUSINESS, BASIS OF PRESENTATION</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Novelos Therapeutics, Inc. (&#8220;Novelos&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company developing compounds for the treatment of cancer.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On April 8, 2011, the Company entered into a business combination with Cellectar, Inc. (&#8220;Cellectar&#8221;), a privately held Wisconsin corporation that designed and developed products to detect, treat and monitor a wide variety of human cancers (the &#8220;Acquisition&#8221;, see Note 10).&#160;&#160;Immediately prior to the Acquisition, the Company completed a 1-for-153 reverse split of its common stock (the &#8220;Reverse Split&#8221;). The Company then issued to the former shareholders of Cellectar 17,001,596 shares of its common stock as consideration for the Acquisition, which shares constituted approximately 85% of Novelos&#8217; outstanding common stock after giving effect to the Acquisition.&#160;&#160;Upon the closing of the Acquisition, the Company completed the private placement of 6,846,537 shares of its common stock and warrants to purchase an additional 6,846,537 shares of its common stock (in each case after giving effect to the Reverse Split) for gross proceeds of approximately $5,135,000.&#160;&#160;As a result of the Acquisition, the Company is implementing a revised business plan focused on the development of the Cellectar compounds.&#160;&#160;Development of Novelos&#8217; other compounds (NOV-002 and NOV-205) has been suspended<font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Reverse Split reduced the number of outstanding shares of Common Stock from 452,866,983 shares to&#160;2,959,871 shares. On the Company's balance sheet, the aggregate par value of the issued common stock was reduced by reclassifying the par value amount of the eliminated shares of common stock to additional paid-in capital. All per share amounts and outstanding shares, including all common stock equivalents, stock options and warrants, have been retroactively restated in these financial statements and notes for all periods presented to reflect the Reverse Split. Additionally, the number of authorized shares of common stock disclosed on the balance sheet has been reduced to 150,000,000 from 750,000,000 to reflect the reduction in authorized shares of common stock that became effective concurrent with the Reverse Split.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounting principles generally accepted in the United States require that a company whose security holders retain the majority voting interest in the combined business be treated as the acquirer for financial reporting purposes.&#160; Accordingly, the Acquisition will be accounted for as a reverse acquisition whereby Cellectar, Inc. will be treated as the acquirer for accounting and financial reporting purposes. The financial statements presented herein represent the historical financial information of Novelos, prior to the Acquisition.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Company is subject to a number of risks similar to those of other small biopharmaceutical companies. Principal among these risks are dependence on key individuals, competition from substitute products and larger companies, the successful development and marketing of its products in a highly regulated environment and the need to obtain additional financing necessary to fund future operations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On February 24, 2010, the Company announced that its Phase 3 clinical trial for NOV-002 in non-small cell lung cancer (&#8220;NSCLC&#8221;) (the &#8220;Phase 3 Trial&#8221;) did not meet its primary endpoint of a statistically significant increase in median overall survival. Following evaluation of the detailed trial data, on March 18, 2010, the Company announced that the secondary endpoints had also not been met in the Phase 3 Trial and that it had discontinued development of NOV-002 for NSCLC in combination with first-line paclitaxel and carboplatin chemotherapy.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">These financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has generated insignificant revenues and has incurred operating losses since inception in devoting substantially all of its efforts toward research and development. The Company expects that it will continue to generate operating losses for the foreseeable future.&#160;&#160;The Company believes that its cash on hand at March 31, 2011, plus the proceeds from the private placement completed in connection with the Acquisition, is adequate to fund operations into the fourth quarter of 2011.&#160;&#160;The Company&#8217;s ability to execute its operating plan beyond that time depends on its ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise.&#160;&#160;The Company plans to continue to actively pursue financing alternatives, but there can be no assurance that it will obtain the necessary funding.</font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-51</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for the fair presentation of these financial statements have been included. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Interim results are not necessarily indicative of results to be expected for other quarterly periods or for the entire year ending December 31, 2011. These unaudited financial statements should be read in conjunction with the audited financial statements and related notes thereto included in the Company&#8217;s latest annual report for the year ended December 31, 2010 on Form 10-K, which was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on April 14, 2011.&#160;The report from the Company&#8217;s independent registered public accounting firm dated April 11, 2011 and included with its annual report on Form 10-K indicated that factors exist that raised substantial doubt about the Company&#8217;s ability to continue as a going concern.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Comprehensive Income (Loss) </font>&#8211; The Company had no components of comprehensive income (loss) other than the net income (loss) in all periods presented.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Derivative Instruments </font>&#8211; The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks.&#160;&#160;However, certain warrants to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the Financial Accounting Standards Board Accounting Standards Codification (&#8220;FASB ASC&#8221;),<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>are classified as liabilities.&#160;&#160;In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments because the agreements contain &#8220;down-round&#8221; provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants.&#160;&#160;The number of shares issuable under such warrants was 105,042 at March 31, 2011.&#160;&#160;The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock.&#160;&#160;Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of gain or loss on derivatives in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity.&#160;&#160;At March 31, 2011, these warrants represented the only outstanding derivative instruments issued or held by the Company.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">2.</font></font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FAIR VALUES OF ASSETS AND LIABILITIES </font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In accordance with Fair Value Measurements and Disclosures Topic of the FASB ASC, the Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level 1: Input prices quoted in an active market for identical financial assets or liabilities.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable or supported by an active market.</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-52</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Assets and liabilities measured at fair value on a recurring basis are summarized below:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="96%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="14" nowrap valign="bottom" width="46%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">March&#160;31,&#160;2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level&#160;1</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level&#160;2</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Level&#160;3</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Fair&#160;Value</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">162,760</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">162,760</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Company uses valuation methods and assumptions that consider among others the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Assumptions used are generally consistent with those disclosed for stock-based compensation (see Note 5).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.&#160;</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COLLABORATION AGREEMENTS</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In December 2007 the Company entered into a Collaboration Agreement with Lee&#8217;s Pharmaceutical (HK) Ltd. (&#8220;Lee&#8217;s Pharm&#8221;). Pursuant to this agreement, Lee&#8217;s Pharm obtained an exclusive license to develop, manufacture and commercialize NOV-002 and NOV-205 in China, Hong Kong, Taiwan and Macau (the &#8220;Chinese Territory&#8221;). The Company has suspended further development of NOV-205; however, this suspension may not impact the development strategy of Lee&#8217;s Pharm.&#160;&#160;Under the terms of the agreement the Company received a license fee of $500,000 in March 2008 and is entitled to receive up to $1,700,000 in future milestone payments upon the completion of development and marketing milestones by Lee&#8217;s Pharm. This initial $500,000 payment received is being amortized over the estimated term of this agreement, 15 years. Accordingly, $8,333 of license revenue was recognized in each of the three-month periods ended March 31, 2011 and 2010.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Lee&#8217;s Pharm agreement provides that the Company receive royalty payments of 20-25% of net sales of NOV-002 in the Chinese Territory and receive royalty payments of 12-15% of net sales of NOV-205 in the Chinese Territory. Lee&#8217;s Pharm is obligated to reimburse the Company for the manufacturing cost of pharmaceutical products provided to Lee&#8217;s Pharm in connection with the agreement. Lee&#8217;s Pharm has committed to spend a minimum amount on development in the first four years of the agreement. The agreement expires upon the expiration of the last patent covering any of the licensed products, or twelve years from the date of the first commercial sale in China, whichever occurs later.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On February 11, 2009, Novelos entered into a collaboration agreement (the &#8220;Collaboration Agreement&#8221;) with Mundipharma International Corporation Limited (&#8220;Mundipharma&#8221;) to develop, manufacture and commercialize, on an exclusive basis, Licensed Products (as defined in the Collaboration Agreement), which includes the Company&#8217;s compound, NOV-002, in Europe (other than the Russian Territory), Asia (other than the Chinese Territory) and Australia (collectively referred to as the &#8220;Mundipharma Territory&#8221;).&#160; Mundipharma is an independent associated company of Purdue Pharma, L.P. (&#8220;Purdue&#8221;).&#160;&#160;The Collaboration Agreement provides for Mundipharma to pay the Company royalties and fixed milestone payments based on sales and commercial launches in the licensed territories.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For countries in which patents are held, the Collaboration Agreement expires on a country-by-country basis within the Mundipharma Territory on the earlier of (1) expiration of the last applicable Novelos patent within the country or (2) the determination that any patents within the country are invalid, obvious or otherwise unenforceable.&#160;&#160;For countries in which no patents are held, the Collaboration Agreement expires the earlier of 15 years from its effective date or upon generic product competition in the country resulting in a 20% drop in Mundipharma&#8217;s market share.&#160;&#160;Novelos may terminate the Collaboration Agreement upon breach or default by Mundipharma.&#160; Mundipharma may terminate the Collaboration Agreement upon breach or default, filing of voluntary or involuntary bankruptcy by Novelos, the termination of certain agreements with companies associated with the originators of the licensed technology, or 30-day notice for no reason.&#160;&#160;If any regulatory approval within the Mundipharma Territory is suspended as a result of issues related to the safety of the Licensed Products, then Mundipharma&#8217;s obligations under the Collaboration Agreement will be suspended until the regulatory approval is reinstated.&#160;&#160;If that reinstatement does not occur within 12 months of the suspension, then Mundipharma may terminate the Collaboration Agreement.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Concurrently with the execution of the Collaboration Agreement, Novelos completed a private placement of Series E preferred stock and common stock purchase warrants to Purdue.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-53</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Company expects that the negative results of its Phase 3 Trial will adversely affect development and commercialization of NOV-002 under the collaboration agreements with Lee&#8217;s Pharm and Mundipharma.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">STOCKHOLDERS&#8217; EQUITY</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Common Stock Warrants</font> &#160;&#160;&#8212; The following table summarizes information with regard to outstanding warrants as of March 31, 2011, issued in connection with equity and debt financings since 2005.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="96%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="58%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Offering</font></font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Number&#160;of&#160;Shares</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Issuable&#160;Upon</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise&#160;of</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Outstanding</font></font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Warrants</font></font> </div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Price</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="18%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Expiration&#160;Date</font></font></div>
</td>
</tr><tr>
<td valign="bottom" width="58%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="18%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series B Preferred Stock &#8211; placement agents</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,392</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td valign="top" width="9%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">191.25</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="18%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 2, 2012</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series C Exchange</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,169</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td valign="top" width="9%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">191.25</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="18%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 2, 2012</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Series E Preferred Stock</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">60,331</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td valign="top" width="9%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.45</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="18%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31, 2015</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">August 2009 Private Placement</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31,194</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td valign="top" width="9%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">100.98</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="18%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31, 2015</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 2010 Direct Offering (1)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">105,042</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td valign="top" width="9%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.71</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="18%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 27, 2015</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="58%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Preferred Incentive Warrants</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="9%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">105,042</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td valign="top" width="9%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16.065</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="18%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 27, 2015</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="58%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="18%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="58%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">315,170</font></font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="9%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="18%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1)&#160;&#160;The exercise price of these warrants was adjusted to $0.75 per share in connection with the private placement completed on April 8, 2011.&#160;&#160;See Note 10.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On March 7, 2011, warrants to purchase 33,569 shares of common stock at $234.09 per share expired unexercised.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On May 3, 2011, 18,153 shares of common stock were issued in connection with the cashless exercise of warrants to purchase 27,311 shares of common stock at $0.75 per share.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.&#160;</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">STOCK-BASED COMPENSATION</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The following table summarizes amounts charged (credited) to expense for stock-based compensation related to employee and director stock option grants and stock-based compensation recorded in connection with stock options granted to non-employee consultants:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Three&#160;Months&#160;Ended</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">March&#160;31,</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Employee and director stock option grants:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,298</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">57,113</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">59,682</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">82,928</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">108,980</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">140,041</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-employee consultant stock option grants:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(545 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(210,825 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(57 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(26,695 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(602 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(237,520 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total stock-based compensation</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">108,378</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(97,479</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-54</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">There were no stock option grants during the three months ended March 31, 2011 or 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Number&#160;of</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Shares</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Issuable&#160;Upon</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise&#160;of</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Outstanding</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Options</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Weighted</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Average</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise&#160;Price</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Weighted</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Average</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Remaining</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Contracted</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Term&#160;in</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Years</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Aggregate</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Intrinsic</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Value</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding at December 31, 2010</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">49,227</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">100.61</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">6.9</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">24,842</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding at March 31, 2011</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">49,227</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">100.61</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">6.6</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">12,421</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercisable at March 31, 2011</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">40,348</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">101.03</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">6.2</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">12,421</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The aggregate intrinsic value of options outstanding is calculated based on the positive difference between the closing market price of the Company&#8217;s common stock at the end of the respective period and the exercise price of the underlying options.&#160;&#160;There were no options exercised during the three months ended March 31, 2011. Shares of common stock issued upon the exercise of options are from authorized but unissued shares.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">As of March 31, 2011, there was approximately $538,000 of total unrecognized compensation cost related to unvested stock-based compensation arrangements.&#160;&#160;Of this total amount, 64% and 36% are expected to be recognized during 2011 and 2012, respectively.&#160;&#160;The Company expects 8,879 in unvested options to vest in the future.&#160;&#160;The weighted-average grant-date fair value of vested and unvested options outstanding at March 31, 2011 was $62.75 and $68.07, respectively.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6.&#160;</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NET INCOME (LOSS) PER SHARE</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic net income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income attributable to common stockholders by the sum of weighted average number of shares of common stock and the dilutive potential common stock equivalents then outstanding. Potential common stock equivalents consist of stock options, warrants and convertible preferred stock and accumulated dividends.&#160;&#160;Since the Company has a net loss for the three months ended March 31, 2011, the inclusion of common stock equivalents in the computation would be antidilutive. Accordingly, basic and diluted net loss per share are the same for the three months ended March 31, 20011.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The following table sets forth the shares and net income used in the diluted earnings per share computation for the three months ended March 31, 2010:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Numerator:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income available to common stockholders used in basic earnings per share calculation</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,693,487</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Derivative gain recorded on dilutive warrants</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,340,515</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dividends on convertible preferred stock</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">656,635</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income available to common stockholders used in diluted earnings per share calculation</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,009,607</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Denominator:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted average shares of common stock used in the computation of basic earnings per share</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">522,350</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dilutive effect of stock options</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">26,430</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dilutive effect of warrants to purchase common stock</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">79,646</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dilutive effect of convertible preferred stock</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">253,435</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares used in computation of diluted earnings per share</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">881,861</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-55</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The following potentially dilutive securities have been excluded from the computation of diluted net income (loss) per share since their inclusion would be antidilutive:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Three&#160;Months&#160;Ended</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">March&#160;31,</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock options</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">49,227</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,970</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">315,170</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">43,349</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7.&#160;</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">INCOME TAXES</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Company accounts for income taxes in accordance with the Income Taxes Topic of the FASB ASC. Under this guidance, deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax basis of assets and liabilities, and net operating loss carryforwards, using the enacted tax rates. Deferred income tax expense or benefit is based on changes in the asset or liability from period to period. The Company did not record a provision or benefit for federal, state or foreign income taxes for the three months ended March 31, 2011 or 2010 because the Company has experienced losses on a tax basis since inception. The net income reported for the three months ended March 31, 2010 was a result of the gain recorded on the revaluation of derivative warrant liability during that period, which is a nontaxable item. The Company has not recorded deferred tax assets as their realization is uncertain.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8.&#160;</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">LITIGATION</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A purported class action complaint was filed on March 5, 2010 in the United States District Court for the District of Massachusetts by an alleged shareholder of the Company, on behalf of himself and all others who purchased or otherwise acquired the Company&#8217;s common stock in the period between December 14, 2009 and February 24, 2010, against the Company and its President and Chief Executive Officer, Harry S. Palmin.&#160;&#160;On October 1, 2010, the court appointed lead plaintiffs (Boris Urman and Ramona McDonald) and appointed lead plaintiffs&#8217; counsel.&#160;&#160;On October 22, 2010, an amended complaint was filed.&#160;&#160;The amended complaint claims that the Company violated Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder in connection with alleged disclosures related to the Phase 3 clinical trial of NOV-002 for non-small cell lung cancer.&#160;&#160;On December 6, 2010, the Company filed a motion to dismiss the complaint with prejudice.&#160;&#160;On January 20, 2011, the plaintiffs filed their opposition to our motion and on March 3, 2011, the Company filed its response to their opposition. The motion to dismiss remains pending. The Company believes the allegations are without merit and intends to defend vigorously against the allegations.</font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-56</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On June 28, 2010, the Company received a letter from counsel to ZAO BAM and ZAO BAM Research Laboratories (Russian companies, collectively referred to as &#8220;BAM&#8221;) alleging that the Company modified the chemical composition of NOV-002 without prior notice to or approval from BAM, constituting a material breach of a technology and assignment agreement the Company had entered into with BAM on June 20, 2000 (the &#8220;June 2000 Agreement&#8221;).&#160;&#160;The letter references the Company&#8217;s amendment, submitted to the FDA on August 30, 2005, to its investigational new drug application dated August 1999 as the basis for BAM&#8217;s claims and demands the transfer of all intellectual property rights concerning NOV-002 to BAM.&#160;&#160;Mark Balazovsky, a director of Novelos from June 1996 until November 2006 and a shareholder of Novelos through at least June 25, 2010, is, to the Company&#8217;s knowledge, still the general director and principal shareholder of ZAO BAM.&#160;&#160;The Company believes the allegations are without merit and intends to defend vigorously against any proceedings that BAM may initiate as to these allegations. On September 24, 2010, the Company filed a complaint in Suffolk Superior Court seeking a declaratory judgment by the court that the June 2000 Agreement has been replaced by a subsequent agreement between the parties dated April 1, 2005 (the &#8220;April 2005 Agreement&#8221;), that Novelos&#8217; obligations to BAM are governed solely by the April 2005 Agreement and that the obligations of the June 2000 agreement have been performed and fully satisfied.&#160;&#160;On November 29, 2010, BAM answered the complaint, denying the material allegations, and stating its affirmative defenses and certain counterclaims. On January 14, 2011, the Company responded to the counterclaims, denying BAM&#8217;s material allegations and stating its affirmative defenses.&#160;&#160;The Company believes the counterclaims are without merit and intends to vigorously defend against them.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COMMITMENTS</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Retention Agreements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Company has entered into retention agreements with each of its three vice presidents.&#160;&#160;The agreements provide for the lump-sum payment of six months&#8217; base salary and benefits to each such officer following a termination without cause or a resignation with good reason occurring on or before November 14, 2011.&#160;&#160;Certain of the agreements provide that if the executives were employed with the Company as of October 1, 2010, they would receive a payment of two months&#8217; base salary as a retention bonus on that date. The retention bonus was paid in October 2010 and will be deducted from the severance amounts that may become payable upon a subsequent involuntary termination.&#160;&#160;The total remaining amount that may become payable to the Company&#8217;s Named Executive Officers pursuant to the retention agreements is approximately $86,000 to Christopher Pazoles.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">During the three months ended March 31, 2011, pursuant to retention agreements, the Company paid a total of approximately $218,000 in severance payments to employees terminated during that period, including $83,000 to Elias Nyberg, the Company&#8217;s former vice president of regulatory, quality and compliance.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SUBSEQUENT EVENTS</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Merger Agreement</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On April 8, 2011, the Company entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with Cellectar, Inc. (&#8220;Cellectar&#8221;) and Cell Acquisition Corp. (the &#8220;Merger Subsidiary&#8221;), a wholly-owned subsidiary of Novelos, pursuant to which Cellectar was merged into the Merger Subsidiary (the &#8220;Acquisition&#8221;).&#160;&#160;As a result of the Acquisition, the Merger Subsidiary, which has been renamed Cellectar, Inc., owns all assets of and operates the business previously owned and operated by Cellectar. Prior to the Acquisition, Cellectar was in the business of developing drugs for the treatment and diagnosis of cancer.&#160;&#160;The Company will continue to develop Cellectar&#8217;s compounds following the Acquisition.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">As consideration for the Acquisition, the former stockholders of Cellectar received aggregate consideration consisting of a number of shares of Novelos common stock constituting, after giving effect to the Acquisition but before giving effect to the concurrent private placement of the Company&#8217;s securities described below, approximately 85% of the outstanding shares of Novelos common stock.&#160;&#160;Prior to the Acquisition, the Company amended and restated its certificate of incorporation and in connection therewith, among other things, effected a 1-for-153 reverse split of its common stock (the &#8220;Reverse Split&#8221;).&#160;&#160;Immediately following the effectiveness of the Reverse Split, there were 2,959,871 shares of common stock outstanding, and the Company issued 17,001,596 shares of its common stock to the former stockholders of Cellectar upon the effectiveness of the Acquisition.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Rodman &amp; Renshaw, LLC (&#8220;Rodman&#8221;), financial advisor to Novelos in connection with the Acquisition, received a cash fee of $250,000 upon the completion of the Acquisition in consideration for their services.&#160;&#160;XMS Capital Partners, the financial advisor to Cellectar in connection with the Acquisition, received a cash fee of $200,000 upon the completion of the Acquisition in consideration for their services.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounting principles generally accepted in the United States require that a company whose security holders retain the majority voting interest in the combined business be treated as the acquirer for financial reporting purposes.&#160; Accordingly, the Acquisition will be accounted for as a reverse acquisition whereby Cellectar, Inc. will be treated as the accounting acquirer.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-57</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Securities Purchase Agreement</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Concurrently with the execution of the Merger Agreement, the Company entered into a Securities Purchase Agreement with certain accredited investors under which the Company sold an aggregate of 6,846,537 units, each unit consisting of one share of its common stock and a warrant to purchase one share of its common stock, at a price of $0.75 per unit, for gross proceeds of approximately $5,135,000.&#160;&#160;The warrants have an exercise price of $0.75 and expire on March 31, 2016.&#160;&#160;The warrant exercise price and/or the common stock issuable pursuant to such warrant will be subject to adjustment for stock dividends, stock splits or similar capital reorganizations so that the rights of the warrant holders after such event will be equivalent to the rights of warrant holders prior to such event.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Securities Purchase Agreement includes a requirement that the Company file with the SEC no later than October 5, 2011, a registration statement covering the resale of the shares of common stock, and the shares of common stock underlying the warrants, issued pursuant to the Securities Purchase Agreement.&#160;&#160;The Company is also required to use commercially reasonable efforts to have the registration statement declared effective by December 4, 2011, and to keep the registration statement continuously effective under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), until the earlier of the date when all the registrable securities covered by the registration statement have been sold or the second anniversary of the closing.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In the event the Company fails to file the registration statement within the timeframe specified by the Securities Purchase Agreement, or if it fails to obtain effectiveness of this registration on or prior to the December 4, 2011 (if there is no review by the SEC) or by January 3, 2012 (if there is review by the SEC) with respect to the maximum number of shares permitted to be registered by the SEC, the Company will be required to pay to the purchasers liquidated damages equal to 1.5% per month (pro-rated on a daily basis for any period of less than a full month) of the aggregate purchase price of the units purchased until the registration statement is filed or declared effective, as applicable.&#160;&#160;The Company will be allowed to suspend the use of the registration statement for not more than 30 consecutive days, on not more than two occasions, in any 12 month period.&#160;&#160;The Company has also granted piggy-back registration rights with respect to any shares of common stock that it is required to exclude from the registration statement as a condition of its effectiveness, and has also agreed to file further registration statements with respect to any such shares six months after the effective date of the initial registration statement.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Company paid to Rodman, the placement agent for the financing, a cash fee equal to $200,000 and warrants to purchase 192,931 shares of its common stock in consideration for their advisory services with respect to the financing pursuant to the placement agency agreement between Rodman and the Company.&#160;&#160;Rodman is entitled to registration rights with respect to the shares of common stock issuable upon exercise of these warrants.&#160;&#160;The warrants have the same terms as those issued to the investors in the private placement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">As a result of the financing, warrants to purchase 105,042 shares of common stock at $10.71 per share, giving effect to the Reverse Split, became exercisable for $0.75 per share according to their terms. On May 3, 2011, 18,153 shares of common stock were issued in connection with the cashless exercise 27,311 of these warrants.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Changes in Directors and Executive Officers</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Effective April 8, 2011, prior to the completion of the Acquisition, Michael J. Doyle, Sim Fass and David B. McWilliams resigned from the Company&#8217;s board of directors and their respective committee appointments.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Effective April 8, 2011, as a condition to the completion of the Acquisition, Jamey P. Weichert, Thomas Rockwell Mackie, John Neis, John E. Niederhuber and Michael F. Tweedle were appointed to the Company&#8217;s board of directors.&#160;&#160;Jamey P. Weichert, Thomas Rockwell Mackie and John Neis previously served on the board of directors of Cellectar.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On April 25, 2011, the Company&#8217;s board of directors appointed the following individuals to serve on the following committees of the board of directors.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-58</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Howard M. Schneider, John Neis and John E. Niederhuber were appointed to the audit committee of the board of directors.&#160;&#160;Mr. Schneider was appointed as the chairman of that committee, a position that he held prior to the Acquisition.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Thomas Rockwell Mackie, James S. Manuso, John Neis and Michael F. Tweedle were appointed to the compensation committee of the board of directors. Dr. Mackie was appointed as the chairman of that committee.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stephen A. Hill, John E. Niederhuber and James S. Manuso were appointed to the nominating and corporate governance committee of the board of directors.&#160;&#160;Dr. Hill was appointed as the chairman of that committee.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Amendment of Certificate of Incorporation</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Effective April 7, 2011 the Company&#8217;s certificate of incorporation was amended to eliminate the Certificate to Set Forth Designations, Voting Powers, Preferences, Restrictions and Relative Rights of Series C 8% Cumulative Convertible Preferred Stock.&#160;&#160;There had not been any shares of Series C preferred stock outstanding since December 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Effective April 7, 2011 the Company&#8217;s certificate of incorporation was amended to eliminate the Certificate of Designations, Preferences and Rights of Series E Convertible Preferred Stock.&#160;&#160;There had not been any shares of Series E preferred stock outstanding since December 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Prior to the closing of the Acquisition on April 8, 2011, the Company amended and restated its certificate of incorporation in order to (a) effect the reverse split; (b) reduce the number of shares of authorized common stock from 750,000,000 to 150,000,000; (c) eliminate the right of the stockholders to act by written consent; and (d) classify the board of directors into three classes.&#160;&#160;Class I directors will stand for re-election at the Company&#8217;s next annual meeting of stockholders, Class II directors will stand for re-election at the 2012 annual meeting of stockholders, and Class III directors will stand for re-election at the 2013 annual meeting of stockholders.&#160;&#160;Thomas Rockwell Mackie, James S. Manuso and John Niederhuber serve as Class I directors, Stephen A. Hill, Michael F. Tweedle and John Neis serve as Class II directors, and Harry S. Palmin, Jamey P. Weichert and Howard M. Schneider serve as Class III directors.</font><a name="eolpage19"><!--efplaceholder--></a></font></div>
<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-59</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font></div>
</div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage85"><!--EFPlaceholder--></a><a name="FIS_UNIDENTIFIED_TABLE_30"><!--EFPlaceholder--></a>NOVELOS THERAPUETICS, INC. (a Development Stage Company)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Table of Contents</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Page</font></font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unaudited Pro Forma Condensed Combined Statement of Operations for the Nine Months Ended September 30, 2011</font></div>
</td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-61</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unaudited Pro Forma Condensed Combined Statement of Operations for the Twelve Months Ended December 31, 2010</font></div>
</td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-62</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Notes to Unaudited Pro Forma Condensed Combined Financial Statements</font></div>
</td>
<td align="right" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">F-63</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 8, 2011, Novelos completed the acquisition of Cellectar, Inc. (&#8220;Cellectar&#8221;) pursuant to an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) between Novelos, Cellectar and Cell Acquisition Corp., a wholly owned subsidiary of Novelos (the &#8220;Merger Subsidiary&#8221;). As a result, Cellectar was merged into the Merger Subsidiary (the &#8220;Acquisition&#8221;) and the Merger Subsidiary, which has been renamed Cellectar, Inc., owns all assets and operates the business previously owned and operated by Cellectar.&#160;&#160;References in these unaudited pro forma combined financial statements and notes to &#8220;Cellectar&#8221; relate to the activities and financial information of Cellectar prior to the Acquisition,&#160;references to &#8220;Novelos&#8221; relate to the activities and financial information of Novelos prior to the Acquisition and references to &#8220;the Company&#8221; or &#8220;we&#8221; or &#8220;us&#8221; or &#8220;our&#8221; relate to the activities of the combined Company following the Acquisition.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The following unaudited pro forma condensed combined financial statements combine the historical financial statements of Novelos and Cellectar after giving effect to the Acquisition.&#160;&#160;The unaudited pro forma condensed combined financial statements are provided for informational purposes only and are subject to a number of uncertainties and assumptions and do not purport to represent what the combined companies&#8217; actual performance or financial position would have been if Novelos and Cellectar had been operating as combined entities for the periods presented and does not purport to indicate the financial position or results of operations as of any future date or for any future period.&#160;&#160;These unaudited condensed combined financial statements should be read in conjunction with the historical financial statements, including the notes thereto, of Novelos included in our Form 10-K for the year ended December 31, 2010, our Form 10-Q for the nine-month period ended September 30, 2011 and in the historical financial statements included elsewhere in this prospectus.</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The unaudited pro forma condensed combined statement of operations for the nine-month period ended September 30, 2011 and the twelve-month period ended December 31, 2010 give effect to the Acquisition as if it had occurred January 1, 2010.&#160;&#160;</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The pro forma adjustments are based on available information, preliminary estimates and certain assumptions that the Company believes are reasonable and are described in the accompanying notes to the unaudited pro forma condensed combined financial statements.&#160;&#160;The unaudited pro forma condensed combined financial statements assume that the Acquisition will be accounted for using the purchase method of accounting in accordance with <font style="DISPLAY: inline; FONT-STYLE: italic">ASC Topic 805 &#8211; Business Combinations</font>.&#160;&#160;The total purchase price has been preliminarily allocated based on available information and the preliminary estimates and assumptions that management believes are reasonable.&#160;&#160; The evaluation is prelimary principally as a result of the pending evaluation of the Company&#8217;s intangible assets.&#160;&#160;The allocation of the purchase price has not been finalized and the actual adjustments may change when the final valuation of certain intangible assets is determined.&#160;&#160;Accordingly, there can be no assurance that the final allocation of purchase price will not materially differ from the preliminary allocations reflected in the unaudited pro forma condensed combined financial statements.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-60</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="FIS_UNIDENTIFIED_TABLE_32"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOVELOS THERAPEUTICS, INC.</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(a Development Stage Company)</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">for the Nine Months Ended September 30, 2011</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="6" valign="bottom" width="27%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 6.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Historical</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom" width="12%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" colspan="2" valign="bottom" width="12%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Novelos (Pre-</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Acquisition)</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Combined Company as Reported</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pro forma Adjustments</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 2.6pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pro forma Combined</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">REVENUE</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,333</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(8,333</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font> </div>
</td>
<td align="left" valign="bottom" width="3%"> &#160;(a) </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COSTS AND EXPENSES:</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">537,455</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,445,429</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,982,884</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">862,546</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,573,717</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,029,644</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;(b)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,406,619</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total costs and expenses</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,400,001</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,019,146</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,029,644</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,389,503</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">LOSS FROM OPERATIONS</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,391,668</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,019,146</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,021,311</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,389,503</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">OTHER INCOME (EXPENSE):</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Grant income</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">44,479</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">44,479</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gain (loss) on derivative instruments</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">125,490</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(66,820</font> </div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">58,670</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest income (expense), net</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">691</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(428,015</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">423,159</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(c)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,165</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total other income (expense)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">126,181</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(450,356</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">423,159</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">98,984</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,265,487</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></font> </div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,469,502</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="2%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,444,470</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,290,519</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,265,487</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,469,502</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,444,470</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,290,519</font> </div>
</td>
<td align="left" valign="middle" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.43</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.25</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="10%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.20</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,959,871</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21,847,984</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">26,818,045</font> </div>
</td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="40%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PRO FORMA NET LOSS PER SHARE GIVING EFFECT TO AN ESTIMATED 1-FOR-10 OFFERING REVERSE SPLIT (SEE NOTE 4):</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PRO FORMA BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</font> </div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="11%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="11%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="2%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="10%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1.97</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PRO FORMA SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="3%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,681,804</font> </div>
</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">See accompanying notes to the unaudited pro forma condensed combined financial statements.</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-61</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="FIS_UNIDENTIFIED_TABLE_33"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOVELOS THERAPEUTICS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a Development Stage Company)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">for the Twelve Months Ended December 31, 2010</font><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Historical</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" nowrap valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; &#160; &#160; </font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" nowrap valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Novelos</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cellectar</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pro&#160;forma</font></font></font></font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustments</font></font></font></font></font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pro&#160;forma<br>
Combined</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">REVENUE</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">33,334</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(33,334</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)(a) &#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COSTS AND EXPENSES:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; 2,997,984 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; 2,984,207 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; &#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,982,191 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,486,032 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,209,474 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(77,005</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)(b)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,618,501</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total costs and expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; 5,484,016</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; 4,193,681</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; (77,005</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160; &#160; &#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,600,692</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div>LOSS FROM OPERATIONS</div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">(5,450,682</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left">)</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">(4,193,681</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left">)</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">43,671 &#160; </td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">(9,600,692</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left">)</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">&#160; </td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">OTHER INCOME (EXPENSE):</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Grant income</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; 244,479 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; 200,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; &#8212; </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">444,479 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gain on derivative instruments</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; 8,118,174 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; &#8212; </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; &#8212; </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,118,174 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liquidated damages</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; (819,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; &#8212; </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">819,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;(d)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; &#8212; </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest income (expense), net</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; 2,421 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; (566,156</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; (102,766</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)(e)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(666,501</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other income</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; &#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; (426</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; &#8212;</font></font></font></font></font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(426</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total other income (expense)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; 7,546,074</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; (366,582</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; 716,234</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,895,726</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="52%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income (loss)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,095,392</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,560,263</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">) </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">759,905</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,704,966</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Preferred stock dividend</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; (2,207,827</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; &#8212; </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,207,827 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(f)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212; </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Preferred stock deemed dividend</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(12,541,201</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,541,201</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(f)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; &#8212; </font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(12,653,636</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,560,263</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,508,933 </font></font></font></font></font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,704,966</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(15.36</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.36</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.06</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; 823,933</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; 12,820,102</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">26,808,004</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PRO FORMA NET LOSS PER SHARE GIVING EFFECT TO AN ESTIMATED 1-FOR-10 OFFERING REVERSE SPLIT (NOTE 4):</font> </div>
</td>
<td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="8%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="2%">&#160;</td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="9%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PRO FORMA BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE (NOTE 4)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="8%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.64</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font> </div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 1.6pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PRO FORMA SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE (NOTE 4)</font> </div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="8%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="2%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,680,800</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">See accompanying notes to the unaudited pro forma condensed combined financial statements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-62</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOVELOS THERAPEUTICS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a Development Stage Company)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1. BASIS OF PRESENTATION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The unaudited pro forma condensed combined statement of operations for the nine-month period ended September 30, 2011 has been prepared based on the unaudited consolidated statement of operations of the Company for the nine-month period ended September 30, 2011 as reported on Form 10-Q as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on November 7, 2011 and the historical information of Novelos for the period&#160;from January 1, 2011 through April 8, 2011&#160;giving effect to the Acquisition as if it had occurred January 1, 2010.&#160;&#160;The unaudited pro forma condensed combined statements of operations for the twelve-month period ended December 31, 2010 has been prepared based on the historical information of Novelos and Cellectar giving effect to the Acquisition as if it had occurred January 1, 2010.&#160;&#160;</font> </div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In accordance with the rules and regulations of the SEC, unaudited statements may omit or condense information and disclosures normally required for a complete set of financial statements prepared in accordance with generally accepted accounting principles.&#160;&#160;Management believes that the notes to the unaudited pro forma financial statements as presented contain disclosures adequate to make the information presented useful and not misleading.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The pro forma adjustments are based on available information, preliminary estimates and certain assumptions that the Company believes are reasonable and are described in the accompanying notes to the unaudited pro forma condensed combined financial statements, which should be read in conjunction with these unaudited pro forma condensed combined financial statements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As consideration for the Acquisition, the stockholders of Cellectar received aggregate consideration consisting of a number of shares of Novelos common stock constituting approximately 85% of the outstanding shares of Novelos common stock, after giving effect to the Acquisition but before giving effect to the concurrent private placement of our securities.&#160;&#160;Since the former shareholders of Cellectar retained the majority voting interest in the combined business, the Acquisition (see Note 2) will be accounted for as a reverse acquisition whereby Cellectar will be treated as the acquirer for accounting and financial reporting purposes.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The unaudited pro forma condensed combined financial statements assume that the Acquisition will be accounted for using the purchase method of accounting in accordance with <font style="DISPLAY: inline; FONT-STYLE: italic">ASC Topic 805 &#8211; Business Combinations</font>.&#160;&#160;The total purchase price has been preliminarily allocated based on available information and the preliminary estimates and assumptions that management believes are reasonable.&#160;&#160;The allocation of the purchase price has not been finalized and the actual adjustments may change when the final valuation of certain intangible assets is determined.&#160;&#160;The evaluation is preliminary principally as a result of the pending evaluation of the Company&#8217;s intangible assets. Accordingly, there can be no assurance that the final allocation of purchase price will not materially differ from the preliminary allocations reflected in the unaudited pro forma combined financial statements.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2. ACQUISITION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Conversion of Convertible Notes and Payment of Long-Term Debt</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 8, 2011, immediately prior to the Acquisition, Cellectar paid the note payable to a bank in full settlement of the note.&#160;&#160;The payment was made in order to avoid an event of default that would have occurred as a result of the change of control that occurred at the time of the Acquisition.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Following the maturity and default of the Convertible Notes, the holders of the Convertible Notes agreed that all of the outstanding notes would be automatically converted simultaneous with the completion of an acquisition and financing (the &#8220;Conversion Time&#8221;), if completed. The amount of shares issued upon such conversion would be dependent on the amount of investment made by the note holders at the Conversion Time and were negotiated based on outstanding principal and projected accrued interest based on an assumed closing date for the acquisition and financing.&#160;&#160;On April 1, 2011, Cellectar&#8217;s Board of Directors voted to accept the note holders consent to convert the Convertible Notes into 4,181,535 shares of common stock immediately prior to the Acquisition. On April 8, 2011, immediately prior to the Acquisition, the principal and unpaid interest on the Convertible Notes was converted into the agreed total of 4,181,535 shares of common stock. The revised conversion terms resulted in the issuance of an additional 343,963 shares of common stock over the 3,837,572 shares of common stock that would have been issued if the unpaid principal and accrued interest on the Convertible Notes had been converted on that date in accordance with their original terms at the stated conversion price.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Merger Agreement</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 8, 2011, Novelos completed the acquisition of Cellectar, Inc. (&#8220;Cellectar&#8221;) pursuant to an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) between Novelos, Cellectar and Cell Acquisition Corp., a wholly owned subsidiary of Novelos (the &#8220;Merger Subsidiary&#8221;).&#160;&#160;As a result, Cellectar was merged into the Merger Subsidiary (the &#8220;Acquisition&#8221;) and the Merger Subsidiary, which has been renamed Cellectar, Inc., owns all assets and operates the business previously owned and operated by Cellectar.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-63</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;<a name="eolPage89"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As consideration for the Acquisition, the stockholders of Cellectar received aggregate consideration consisting of a number of shares of Novelos common stock constituting, after giving effect to the Acquisition but before giving effect to the concurrent private placement of Novelos securities described below, approximately 85% of the outstanding shares of Novelos common stock.&#160;&#160;Prior to the Acquisition, Novelos amended and restated its certificate of incorporation and in connection therewith, among other things, effected a 1-for-153 reverse split of its common stock (the &#8220;Reverse Split&#8221;), which has been retroactively reflected in the accompanying pro forma financial statements.&#160;&#160;Immediately prior to the Acquisition, there were&#160;2,959,871 shares of Novelos common stock outstanding. Novelos then issued 17,001,596 shares of Novelos common stock to the former stockholders of Cellectar upon the effective date of the Acquisition.&#160;&#160;Warrants and options to purchase Novelos common stock that were outstanding prior to the Acquisition remained outstanding following the Acquisition. These consist of warrants to purchase a total of 315,164 shares of Novelos common stock with prices ranging from $16.07 to $191.25 and options to purchase a total of 49,159 shares of Novelos common stock with prices ranging from $1.53 to $1,072.53.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XMS Capital Partners, the financial advisor to Cellectar in connection with the Acquisition, received a cash fee of $200,000 upon the completion of the Acquisition in consideration of their services.&#160;&#160;Rodman &amp; Renshaw, LLC (&#8220;Rodman&#8221;), financial advisor to Novelos in connection with the Acquisition, received a cash fee of $250,000 upon the completion of the Acquisition in consideration of their services.&#160;&#160;These amounts were recorded to general and administrative expense as of the date of the Acquisition.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Securities Purchase Agreement</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Concurrently with the execution of the Merger Agreement, Novelos entered into a Securities Purchase Agreement with certain accredited investors under which it sold an aggregate of 6,846,537 units, each unit consisting of one share of its common stock and a warrant to purchase one share of its common stock, at a price of $0.75 per unit, for gross proceeds of approximately $5,135,000.&#160;&#160;The warrants have an exercise price of $0.75 and expire on March 31, 2016.&#160;&#160;The warrant exercise price and/or the common stock issuable pursuant to such warrant will be subject to adjustment for stock dividends, stock splits or similar capital reorganizations so that the rights of the warrant holders after such event will be equivalent to the rights of warrant holders prior to such event.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Rodman, the placement agent for the financing, was paid a cash fee equal to $200,000 and issued warrants to purchase 192,931 shares of the Company&#8217;s common stock (having an exercise price of $0.75 and which expire March 31, 2016) in consideration for their advisory services with respect to the financing pursuant to the placement agency agreement between Rodman and Novelos.&#160;&#160;Rodman is entitled to registration rights with respect to the shares of common stock issuable upon exercise of these warrants.&#160;&#160;These amounts were recorded as a reduction of gross proceeds received.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Purchase Accounting</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Acquisition will be accounted for using the purchase method of accounting as a reverse acquisition.&#160;&#160;In a reverse acquisition, the post-acquisition net assets of the surviving combined company includes the historical cost basis of the net assets of the accounting acquirer, Cellectar, plus the fair value of the net assets of the accounting acquiree, Novelos.&#160;&#160;Further, under the purchase method, the purchase price is allocated to the assets acquired and liabilities assumed based on their estimated fair values and the excess of the purchase price over the estimated fair value of the identifiable net assets is presented as excess purchase price over net assets acquired.&#160;&#160;The cost of acquisition and related purchase price allocation is based on preliminary evaluation of the fair value of assets and liabilities assumed of Novelos and may change when the final valuation of certain intangible assets is determined.&#160;&#160;The preliminary evaluation principally relates to the evaluation of the Company&#8217;s intangible assets.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The fair value of the consideration transferred in the Acquisition was $2,219,903 and was calculated as the number of shares of common stock that Cellectar would have had to issue (adjusted for the Exchange Ratio) in order for Novelos shareholders to obtain a 15% equity interest in the combined Company post-acquisition, multiplied by the estimated fair value of the Company<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#8217;</font>s common stock on the acquisition date.&#160;&#160;The estimated fair value of the Company&#8217;s common stock was based on the offering price of the common stock sold in the private placement which was both completed concurrently with and conditioned upon the closing of the Acquisition.&#160; This price was determined to be the best indication of fair value on that date since the price was based on an arm's length negotiation with a group consisting of both new and existing investors that were aware of the pending Acquisition and assumed similar liquidity risk as those investors holding the majority of shares being valued as purchase consideration.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes the Company&#8217;s preliminary estimated fair values of the assets acquired and the liabilities assumed at the date of acquisition.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 18pt" align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consideration - issuance of securities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,219,903</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Prepaid expenses and other assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">71,892</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fixed assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,515</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(380,130 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Derivative liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(59,485 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Excess of purchase price over net assets acquired</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,675,462</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total purchase price &#8211; net of cash acquired of $905,649</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,314,254</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-64</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The excess of purchase price over net assets acquired will be allocated to intangibles, which could potentially include the fair value of the compounds developed prior to the Acquisition by Novelos, with the remainder allocated to goodwill once the Company completes the final allocation of purchase price.&#160;&#160;The estimated fair values of assets acquired and liabilities assumed are provisional and are based on the information that was available as of the acquisition date to estimate the fair value of assets acquired and liabilities assumed.&#160;&#160;The Company believes that the information provides a reasonable basis for estimating the fair values of assets acquired and liabilities assumed, but the Company is waiting for additional information necessary to finalize those fair values.&#160;&#160;Therefore, the provisional measurements of fair value reflected are subject to change and such changes may be significant.&#160;&#160;The Company expects to finalize the valuation and complete the purchase price allocation as soon as practicable but no later than one year from the acquisition date<a name="FIS_UNIDENTIFIED_TABLE_34"><!--EFPlaceholder--></a><a name="eolPage90"><!--EFPlaceholder--></a>.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNIDENTIFIED_TABLE_35"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3. PRO FORMA ADJUSTMENTS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNIDENTIFIED_TABLE_36"><!--EFPlaceholder--></a><a name="eolPage91"><!--EFPlaceholder--></a><a name="FIS_UNIDENTIFIED_TABLE_37"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Statement of operations adjustments</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Represents the elimination of Novelos historical revenue related to the amortization of an advance payment made to Novelos in connection with a collaboration agreement.&#160; The payment was recorded as deferred revenue and recognized as revenue on a straight-line basis over the life of the collaboration agreement.&#160; As a result of the Acquisition, the Company determined as part of the purchase price allocation that the estimated fair value of the deferred revenue was $0.&#160; As such, for purposes of the pro forma presentation the historical revenue associated with deferred revenue has been eliminated.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Represents the adjustment to reflect transaction-related costs in connection with the Acquisition.&#160; For purposes of the pro forma unaudited statement of operations presentation for the nine and twelve month period ended September 30, 2011 and December 31, 2010, the Company gives effect to the Acquisition as if it had&#160;occurred on January 1, 2010.&#160; As such, the Company eliminated transaction-related costs that were incurred prior to the consummation of the Acquisition and therefore excluded for pro forma presentation.&#160; Additionally, the Company paid $450,000 related to investment banking fees as described in Note 2 on April 8, 2011.&#160; For purposes of the pro forma presentation, these investment banking fees were eliminated from the nine month period ended September 30, 2011.&#160; See adjustments as follows:</font> </div></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For the Nine<br>
Months<br>
Ended</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 30,<br>
2011</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" nowrap valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">For the<br>
Twelve<br>
Months<br>
Ended</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December<br>
31, 2010</font> </div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustment to eliminate transaction related costs that were incurred prior to the consummation of the Acquisition.</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(579,644</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(77,005</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustment to eliminate the merger costs as a result of the consummation of the Acquisition (as described in Note 2)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(450,000</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total adjustment to merger costs</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,029,644</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(77,005</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="eolPage92"><!--EFPlaceholder--></a>&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Represents the adjustment to eliminate interest expense associated with the convertible notes and the bank note for the nine-month period ended September 30, 2011 and to eliminate interest expense associated with a beneficial conversion feature that was recorded as a result of the conversion of convertible notes immediately prior to the Acquisition.&#160; For purposes of the pro forma unaudited statement of operations for the nine months ended September 30, 2011 presentation, the conversion of the notes would have occurred immediately before the Acquisition, or January 1, 2010 and therefore the associated interest expense has been excluded from the pro forma presentation.&#160; A detail of the components of the adjustment is presented below:</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustment to eliminate interest expense associated with the convertible notes</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">158,680</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustment to eliminate interest expense associated with the bank note</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,506</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustment to reflect the impact of the beneficial shares that were issued&#160;&#160;on the date of the conversion of the convertible notes in connection with the acquisition</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">257,973</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total adjustment to interest income (expense), net</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">423,159</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-65</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(d)</font></div>
</td>
<td align="left">Represents the adjustment to eliminate the estimated liquidated damages recorded for failure to file a registration statement for the resale of common stock issuable upon exercise of shares of Novelos&#8217; convertible preferred stock.&#160;&#160;For pro forma presentation, the preferred stock is assumed to have been exchanged for common stock at January 1, 2010 in order to reflect the post-acquisition capital structure and liquidated damages are therefore assumed not to have accrued.</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(e)</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Represents the adjustment to eliminate the interest expense for the year ended December 31, 2010 associated with the convertible notes and the bank note, net of an adjustment to reflect the additional interest expense associated with beneficial shares that were issued on the assumed date of conversion (January 1, 2010) in connection with the Acquisition associated with the outstanding principal balance of $2,720,985 on convertible notes.&#160; For the purpose of pro forma presentation, the fair value of the beneficial shares was calculated assuming the notes were converted on the date of issuance (January 2010); at which time no interest would have accrued or converted resulting in a higher fair value for the pro forma presentation in the statement of operations. The Company determined the interest expense for pro forma purposes of $677,062 as the difference between the conversion price and the estimated fair value of Novelos common stock as of the Acquisition date, or $0.75 per share, multiplied by the beneficial shares assumed converted of 902,749 less the amount of interest expense already included in the statement of operations of $213,793.</font></div></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="MARGIN-LEFT: 45pt" align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustment to eliminate interest expense associated with the convertible notes</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">305,049</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustment to eliminate interest expense associated with the bank note</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">55,454</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustment to eliminate interest expense associated with a beneficial conversion feature resulting from the conversion of convertible notes on April 8, 2011.</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">213,793</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustment to reflect interest expense related to beneficial shares that were issued&#160;&#160;on the date of the conversion of the convertible notes, for pro forma purposes, in connection with the acquisition as if it occurred on January 1, 2010</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(677,062</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total adjustment to interest income (expense), net</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(102,766</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(f)</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Represents the elimination of the accruing dividends and deemed dividends on Novelos&#8217; convertible preferred stock, which is assumed to have been exchanged for common stock at January 1, 2010 in order to reflect the post-acquisition capital structure for the purpose of presentation in the pro forma statements of operations.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4. PRO FORMA NET LOSS PER SHARE ADJUSTED FOR AN ESTIMATED OFFERING REVERSE SPLIT</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">At a special meeting of the Company&#8217;s stockholders held on June 30, 2011, the stockholders approved a proposal to amend the Company&#8217;s Amended and Restated Certificate of Incorporation to effect a reverse split of its common stock within a range of 1:2 to 1:10 (the &#8220;Offering Reverse Split&#8221;) in order to satisfy requirements for the listing of Novelos common stock on The NASDAQ Capital Market.&#160;&#160;The exact ratio will be set within such range in the discretion of the Company&#8217;s board of directors without further approval or authorization of the stockholders, with the board of directors having the ultimate discretion as to whether or not to proceed with the Offering Reverse Split.&#160;&#160;The Company has estimated that the Offering Reverse Split will be on a 1-for-10 basis.</font> </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Giving effect to an estimated 1-for-10 Offering Reverse Split, the pro forma basic and diluted net loss attributable to common stockholders per share would be $1.97 and $0.64 for the nine months ended September 30, 2011 and the twelve months ended December 31, 2010, respectively.</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F-66</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In Humans, <font style="DISPLAY: inline; FONT-WEIGHT: bold">HOT</font> Targets Cancerous Tumors - Not Normal Tissue or Bone Marrow</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(SPECT/CT imaging of HOT in Phase 1a trial patients; Bright areas = HOT uptake)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="pg118a.jpg"></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our Therapeutic Compounds (<font style="DISPLAY: inline; FONT-WEIGHT: bold">HOT</font> and <font style="DISPLAY: inline; FONT-WEIGHT: bold">COLD</font>) Selectively Target Cancer Stem Cells</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Fluorescence photomicrographs; Green = uptake of fluorescent-labeled COLD)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="pg118b.jpg"></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cGMP Radiopharmaceutical Manufacturing Facility at Our Headquarters in Madison, WI</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="pg118c.jpg"></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: bold"><font style="FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">The images provided above are for illustrative purposes only and may not be indicative of all results.</font></font></font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="3">The above illustrations do not refer to products approved by the FDA.</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="3">Novelos has not received any revenue from the sale of its products.</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">&#160;</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<hr style="COLOR: black" align="left" noshade size="3" width="100%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="logo2.jpg"></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Novelos Therapeutics, Inc.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Units, each consisting of one share of common stock and a warrant to purchase one share of common stock</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div>
<hr style="COLOR: black" align="center" noshade size="1" width="20%">
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PROSPECTUS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div>
<hr style="COLOR: black" align="center" noshade size="1" width="20%">
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Rodman &amp; Renshaw, LLC</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="3" width="100%">
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="FIS_PART_II"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PART II</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">INFORMATION NOT REQUIRED IN PROSPECTUS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="FIS_OFFERING_EXPENSE"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Item 13. Other Expenses of Issuance and Distribution</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The following table provides information regarding the various actual and anticipated expenses (other than&#160;underwriting fees and expenses) payable by us in connection with the issuance and distribution of the securities being registered hereby.&#160;&#160;All amounts shown are estimates except the Securities and Exchange Commission registration fee.</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNIDENTIFIED_TABLE_25"><!--EFPlaceholder--></a><a name="FIS_UNIDENTIFIED_TABLE_39"><!--EFPlaceholder--></a><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nature of Expense</font> </div>
</td>
<td align="left" valign="top"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td colspan="2" nowrap valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amount</font> </div>
</td>
<td align="left" valign="top"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SEC registration fee</font> </div>
</td>
<td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font> </div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,954</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounting fees and expenses</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">80,000</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Legal fees and expenses</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">150,000</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Transfer agent&#8217;s fees and expenses</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,000</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Printing and related fees</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25,000</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Miscellaneous</font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#160;10,000</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font> </div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$&#160;</font></font> </div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">278,954</font></font> </div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="FIS_INDEMNIFICATION"><!--EFPlaceholder--></a><a name="FIS_INDEMNIFICATION_2"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Item 14. Indemnification of Directors and Officers</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section 102(b)(7) of the Delaware General Corporation Law allows us to adopt a charter provision eliminating or limiting the personal liability of directors to us or our stockholders for breach of fiduciary duty as directors, but the provision may not eliminate or limit the liability of directors for (a) any breach of the director's duty of loyalty to us or our stockholders, (b) any acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (c) unlawful payments of dividends or unlawful stock repurchases or redemptions under Section 174 of the Delaware General Corporation Law or (d) any transaction from which the director derived an improper personal benefit. Article Seventh of our charter provides that none of our directors shall be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, subject to the limitations imposed by Section 102(b)(7). Article Seventh also provides that no amendment to or repeal of Article Seventh shall apply to or have any effect on the liability or the alleged liability of any director with respect to any acts or omissions of such director occurring prior to such amendment or repeal. A principal effect of Article Seventh is to eliminate or limit the potential liability of our directors for monetary damages arising from breaches of their duty of care, unless the breach involves one of the four exceptions described in (a) through (d) above.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Section 145 of the Delaware General Corporation Law provides, in general, that a corporation incorporated under the laws of the State of Delaware, such as us, may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than a derivative action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person's conduct was unlawful. In the case of a derivative action, a Delaware corporation may indemnify any such person against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification will be made in respect of any claim, issue or matter as to which such person will have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery of the State of Delaware or any other court in which such action was brought determines such person is fairly and reasonably entitled to indemnity for such expenses.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Article Eighth of our amended and restated certificate of incorporation and Section 5.1 of our bylaws provide that we will indemnify our directors, officers, employees and agents to the extent and in the manner permitted by the provisions of the Delaware General Corporation Law, as amended from time to time, subject to any permissible expansion or limitation of such indemnification, as may be set forth in any shareholders&#8217; or directors&#8217; resolution or by contract.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">II-1</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The effect of these provisions would be to permit indemnification by us for, among other liabilities, liabilities arising out of the Securities Act of 1933.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="FIS_SALE_OF_UNREGISTERED_SECURITIES"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Item 15. Recent Sales of Unregistered Securities</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In the last three years we have sold the following securities in reliance on, unless otherwise indicated, the exemption under Section 4(2) of the Securities Act of 1933, as amended, as transactions not involving any public offering.&#160;&#160;All share and per share amounts have been adjusted to give effect to the 1-for-153 reverse stock split that occurred immediately prior to the Acquisition but have not been adjusted to give effect to an estimated Offering Reverse Split.</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2011</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">From July 1, 2011 through present</font>:</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> None. </div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">From April 1, 2011 through June 30, 2011</font>:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 8, 2011, we issued an aggregate of 17,001,596 shares of our common stock as merger consideration to the former shareholders of Cellectar.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Concurrently with the Acquisition, on April 8, 2011, we entered into a Securities Purchase Agreement with certain accredited investors under which we sold an aggregate of 6,846,537 units, each unit consisting of one share of our common stock and a warrant to purchase one share of our common stock, at a price of $0.75 per unit for gross proceeds of $5,134,903.&#160;&#160;The warrants have an exercise price of $0.75 and expire on March 31, 2016.&#160;&#160;We also issued a warrant to purchase 192,931 shares of our common stock for $0.75, expiring March 31, 2016, to the placement agent in the financing.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On May 3, 2011, we issued 18,153 shares of our common stock in connection with the cashless exercise of warrants to purchase 27,310 shares of common stock at $0.75 per share.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">From January 1, 2011 through March 31, 2011:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2010</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">From October 1, 2010 through December 31, 2010:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On November 30, 2010, we issued 2,228,338 shares of common stock in exchange for all outstanding shares of Series E preferred stock and all outstanding shares of Series C preferred stock.&#160;&#160;The issuance was made pursuant to an exchange agreement between the Company and all holders of its preferred stock.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">From July 1, 2010 through September 30, 2010:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 27, 2010, we issued five-year warrants (the &#8220;Incentive Warrants&#8221;) to our preferred stockholders for the purchase of up to an aggregate of 105,042 shares of common stock at an exercise price of $16.07 per share pursuant to a consent and waiver dated July 6, 2010, as amended on July 21, 2010.&#160;&#160;The Incentive Warrants were issued in connection with an offering registered under the Securities Act of 1933, as amended, of an aggregate of 140,056 shares of its common stock and five-year warrants to purchase up to an aggregate of 105,042 shares of its common stock, for gross proceeds of $1,500,000.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">From April 1, 2010 through June 30, 2010:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">From January 1, 2010 through March 31, 2010:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 76,769 shares of our common stock upon conversion of approximately 140 shares of our Series E preferred stock, having an aggregate stated value of approximately $7,000,000, and accumulated undeclared dividends thereon.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">II-2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 47,000 shares of our common stock upon the cashless exercise of warrants to purchase 77,551 shares of common stock.&#160;&#160;The warrants had an expiration date of December 31, 2015 and an exercise price of $99.45 per share.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 1,480 shares of our common stock upon the cashless exercise of warrants to purchase 2,075 shares of common stock.&#160;&#160;The warrants had an expiration date of August 9, 2010 and an exercise price of $99.45 per share.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 229 shares of our common stock upon the cashless exercise of warrants to purchase 490 shares of common stock.&#160;&#160;The warrants had an expiration date of May 2, 2012 and an exercise price of $191.25 per share.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 2,395 shares of our common stock upon the cashless exercise of warrants to purchase 6,480 shares of common stock. The warrants had an expiration date of March 7, 2011 and an exercise price of $263.16 per share.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 313 shares of our common stock upon the cashless exercise of warrants to purchase 544 shares of common stock.&#160;&#160;The warrants had an expiration date of May 2, 2012 and an exercise price of $191.25 per share.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 2,058 shares of our common stock upon the cashless exercise of warrants to purchase 2,614 shares of common stock. The warrants had an expiration date of April 1, 2010 and an exercise price of $95.62 per share.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2009</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">From October 1, 2009 through December 31, 2009:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 31,384 shares of our common stock upon conversion of approximately 58 shares of our Series E preferred stock, having an aggregate stated value of approximately $2,907,000, and accumulated undeclared dividends thereon.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 4,330 shares of our common stock upon conversion of 28 shares of our Series C preferred stock having an aggregate stated value of $336,000, and accumulated undeclared dividends thereon.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 172 shares of our common stock upon the cashless exercise of warrants to purchase an aggregate of 1,316 shares of common stock.&#160;&#160;The warrants had an expiration date of March 7, 2011 and an exercise price of $263.16 per share.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 793 shares of our common stock upon the cashless exercise of warrants to purchase an aggregate of 1,320 shares of common stock.&#160;&#160;The warrants had an expiration date of August 9, 2010 and an exercise price of $0.65 per share.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 218,648 shares of our common stock upon the cashless exercise of warrants to purchase an aggregate of 320,000 shares of common stock.&#160;&#160;The warrants had an expiration date of April 1, 2010 and an exercise price of $99.45 per share.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 249 shares of our common stock upon the cashless exercise of warrants to purchase an aggregate of 396 shares of common stock.&#160;&#160;The warrants had an expiration date of October 3, 2010 and an exercise price of $99.45 per share.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We sold 54,466 shares of our common stock and warrants to purchase 19,063 shares of common stock at an exercise price of $100.98 per share for gross proceeds of approximately $5,500,000.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">From July 1, 2009 through September 30, 2009:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We sold 34,660 shares of our common stock and warrants to purchase 12,131 shares of common stock at an exercise price of $100.98 per share for gross proceeds of approximately $3,500,000.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 13,622 shares of our common stock in exchange for outstanding warrants to purchase 45,409 shares of common stock at an exercise price of $278.46 per share.&#160;&#160;These warrants had been issued in a March 2006 financing.&#160;&#160;The issuance was made pursuant to an exchange agreement with each warrant holder and was exempt from registration under Section 3(a)(9) of the Securities Act.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">II-3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 747 shares of our common stock upon conversion of approximately 39 shares of our Series E preferred stock, having an aggregate stated value of approximately $1,952,000, and accumulated undeclared dividends thereon.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 747 shares of our common stock upon conversion of 5 shares of our Series C preferred stock, having an aggregate stated value of $60,000, and accumulated dividends thereon.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 476 shares of our common stock upon the cashless exercise of warrants to purchase an aggregate of 1,715 shares of common stock.&#160;&#160;The warrants had an expiration date of August 9, 2010 and an exercise price of $99.45 per share.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">From April 1, 2009 through June 30, 2009:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 39 shares of our common stock upon the cashless exercise of warrants to purchase an aggregate of 136 shares of common stock.&#160;&#160;The warrants had an expiration date of August 9, 2010 and an exercise price of $99.45 per share.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We issued 4,979 shares of our common stock upon conversion of 35 shares of our Series C preferred stock, having an aggregate stated value of $420,000, and accumulated dividends thereon.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">From January 1, 2009 through March 31, 2009:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We sold 200 shares of our Series E preferred stock and warrants to purchase 60,331 shares of our common stock at an exercise price of $99.45 per share for gross proceeds of approximately $10,000,000 and paying approximately $800,000 in fees and expenses.&#160;&#160;In addition, 413.5 shares of our Series D preferred stock and accumulated undeclared dividends thereon were exchanged for 445.442875 shares of our Series E preferred stock.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2008</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">From July 1, 2008 through September 30, 2008:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In August 2008, we sold 30,165 shares of our common stock to two related accredited investors at $99.45 per share, for gross proceeds of approximately $3,000,000.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">II-4</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Item 16. Exhibits and Financial Statement Schedules</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="FIS_UNIDENTIFIED_TABLE_40"><!--EFPlaceholder--></a></font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="5" valign="top" width="42%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Incorporated by Reference</font></font></div>
</td>
</tr><tr>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exhibit<br>
No.</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="33%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Description</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Filed&#160;with<br>
this<br>
Form S-1</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Form</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Filing&#160;Date</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exhibit<br>
No.</font></font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.1</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Underwriting Agreement</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">X</font> </font></div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#160; </font></td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Agreement and Plan of Merger by and among Novelos Therapeutics, Inc., Cell Acquisition Corp. and Cellectar, Inc. dated April 8, 2011&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 11, 2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Second Amended and Restated Certificate of Incorporation&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 11, 2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.2</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amended and Restated By-laws&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 1, 2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Novelos Therapeutics, Inc.</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;S-1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;July 1, 2011</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;3.3</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.1</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Legal Opinion of Foley Hoag LLP*</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="10%" style="TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.1&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="33%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of common stock certificate</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">X</font> </font></div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr>
<td valign="top" width="10%" style="TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="33%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="12%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr>
<td valign="top" width="10%" style="TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.2&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="33%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of&#160; Warrant</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">X</font> </font></div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Employment Agreement with Harry S. Palmin dated January 31, 2006&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">February 6, 2006</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.2</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Second Amendment to Employment Agreement between the Company and Harry Palmin</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 1, 2011</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.3</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2000 Stock Option and Incentive Plan</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SB-2</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 16, 2005</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.2</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.4</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of 2004 non-plan non-qualified stock option&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SB-2</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 16, 2005</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.3</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.5</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of non-plan non-qualified stock option used from February to May 2005&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SB-2</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 16, 2005</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.4</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.6</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of non-plan non-qualified stock option used after May 2005&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SB-2</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 16, 2005</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.5</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.7</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consideration and new technology agreement dated April 1, 2005 with ZAO BAM&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10-QSB</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">August 15, 2005</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.2</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.8</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of common stock purchase warrant dated March 2006&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">March 3, 2006</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.3</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.9</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2006 Stock Incentive Plan, as amended&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 23,2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.10</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Incentive Stock Option under Novelos Therapeutics, Inc.&#8217;s 2006 Stock Incentive Plan&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 15, 2006</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.11</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Non-Statutory Stock Option under Novelos Therapeutics, Inc.&#8217;s 2006 Stock Incentive Plan&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 15, 2006</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.2</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.12</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Non-Statutory Director Stock Option under Novelos Therapeutics, Inc.&#8217;s 2006 Stock Incentive Plan&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 15, 2006</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.3</font></div>
</td>
</tr></table>
</div>

<a name="FIS_UNIDENTIFIED_TABLE_41"><!--EFPlaceholder--></a></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">II-5</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.13</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Common Stock Purchase Warrant dated May 2, 2007 issued pursuant to the Agreement to Exchange and Consent dated May 2, 2007&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10-QSB</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 8, 2007</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.2</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.14</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Collaboration Agreement dated February 11, 2009**&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">March 30, 2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.39</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.15</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common Stock Purchase Warrant dated February 11, 2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">February 18, 2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.2</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.16</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Warrant Exchange Agreement dated August 21, 2009&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">August 26, 2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.5</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.17</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Securities Purchase Agreement dated August 25, 2009&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">S-1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 15, 2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.41</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.18</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common Stock Purchase Warrant dated August 25, 2009&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">S-1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 15, 2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.43</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.19</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Letter Agreement with LP Clover Limited dated August 25, 2009&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">S-1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 15, 2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.44</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.20</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Letter Agreement with Mundipharma International Corporation Limited dated August 25, 2009&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">S-1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 15, 2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.45</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.21</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consent and Amendment Agreement dated January 21, 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">S-1/A</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">January 26, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.47</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.22</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Executive Retention Agreement dated May 14, 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10-Q</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 17, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.3</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.23</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Placement Agent Agreement Between the Company and Rodman and Renshaw LLC</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">S-1A</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 25, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.50</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.24</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Written Consent and Waiver of Holders of Series C Convertible Preferred Stock and Series E Convertible Preferred Stock dated July 6, 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">S-1A</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 7, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.52</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.25&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Common Stock Purchase Warrant to be issued pursuant to the Consent and Waiver of Holders of Series C Convertible Preferred Stock and Series E Convertible Preferred Stock dated July 6, 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">S-1A</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 7, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.53</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.26</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Securities Purchase Agreement dated July 21, 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 22, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.27</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amendment to Consent and Waiver of Holders of Series C Convertible Preferred Stock and Series E Convertible Preferred Stock dated July 21, 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 22, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.2</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.28</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exchange Agreement dated November 30, 2010 between the Company and the holders of Series C Convertible Preferred Stock and Series E Convertible Preferred Stock&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 30, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="FIS_UNIDENTIFIED_TABLE_42"><!--EFPlaceholder--></a></font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">II-6</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.29</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Common Stock Purchase Warrant dated April 8, 2011&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 11, 2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.3</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.30</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Securities Purchase Agreement dated April 8, 2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 11, 2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.31</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Placement Agency Agreement dated April 1, 2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 11, 2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.32</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">License Agreement between Cellectar, LLC and the Regents of the University of Michigan dated September 14, 2003, as amended through June 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;S-1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;July 1, 2011</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;10.31</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.33</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Lease Agreement between Cellectar, LLC and McAllen Properties LLC, as amended and extended to date&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;S-1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;July 1, 2011</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;10.32</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.34</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Loan Agreement between the Wisconsin Department of Commerce and Cellectar, Inc. dated September 15, 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;S-1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;July 1, 2011</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;10.33</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.35</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General Business Security Agreement dated September 15, 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;S-1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;July 1, 2011</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;10.34</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23.1</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" nowrap valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consent of Foley Hoag LLP (included in Exhibit 5.1)*</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23.2</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consent of Grant Thornton LLP</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">X</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23.3</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consent of Stowe &amp; Degon LLC</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">X</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24.1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="33%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Powers of Attorney (included on signature page)</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;S-1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;July 1, 2011</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;24.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="33%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="10%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="33%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interactive Data Files</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="top" width="12%" style="TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">X&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"> *&#160; To be filed by amendment. </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">** Portions of this exhibit have been omitted pursuant to a confidential treatment order.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNDERTAKINGS"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Item 17. Undertakings.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned registrant hereby undertakes:</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 76.5pt">
<div> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.</font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90pt">
<div> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="a.1.i"><!--EFPlaceholder--></a>i.</font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90pt">
<div> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="a.1.ii"><!--EFPlaceholder--></a>ii.</font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement.</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 90pt">
<div> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="a.1.iii"><!--EFPlaceholder--></a>iii.</font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 76.5pt">
<div> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.</font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 76.5pt">
<div> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="a.3"><!--EFPlaceholder--></a>3.</font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 76.5pt">
<div> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="a.4"><!--EFPlaceholder--></a><a name="a.5"><!--EFPlaceholder--></a>4.</font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to the offering shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.</font> </div>
</td>
</tr></table>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">II-7</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 76.5pt">
<div> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="a.5.i"><!--EFPlaceholder--></a><a name="a.5.ii"><!--EFPlaceholder--></a><a name="a.6"><!--EFPlaceholder--></a>5.</font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 112.5pt">
<div> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="a.6.i"><!--EFPlaceholder--></a>i.</font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 112.5pt">
<div> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="a.6.ii"><!--EFPlaceholder--></a>ii.</font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 112.5pt">
<div> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="a.6.iii"><!--EFPlaceholder--></a>iii.</font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 112.5pt">
<div> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="a.6.iv"><!--EFPlaceholder--></a>iv.</font> </div>
</td>
<td>
<div align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</font> </div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</font> </div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font color="#ff00ff">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">II-8</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Newton, Commonwealth of Massachusetts, on November 9, 2011.</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOVELOS THERAPEUTICS, INC.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ Harry S. Palmin</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="42%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Harry S. Palmin</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="42%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">President and Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_POWER_OF_ATTORNEY"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES AND POWER OF ATTORNEY</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Signature</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="56%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date</font> </div>
</td>
</tr><tr>
<td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ Harry S. Palmin</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer and Director</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="20%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 9, 2011</font> </div>
</td>
</tr><tr>
<td align="left" valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Harry S. Palmin</font> </div>
</td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;( <font style="DISPLAY: inline; FONT-STYLE: italic">principal</font> <font style="DISPLAY: inline; FONT-STYLE: italic">executive officer</font> )</font> </div>
</td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ Joanne M. Protano</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Financial Officer</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="20%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 9, 2011</font></font> </font></font></div>
</div>
</div>
</div>
</td>
</tr><tr>
<td align="left" valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Joanne M. Protano</font> </div>
</td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;( <font style="DISPLAY: inline; FONT-STYLE: italic">principal financial officer and principal accounting officer)</font></font> </div>
</td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ *</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chairman of the Board of Directors</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="20%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 9, 2011</font></font> </font></font></div>
</div>
</div>
</div>
</td>
</tr><tr>
<td align="left" valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stephen A. Hill</font> </div>
</td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ *</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="20%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 9, 2011</font></font> </font></font></div>
</div>
</div>
</div>
</td>
</tr><tr>
<td align="left" valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">T. Rockwell Mackie</font> </div>
</td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ *</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="20%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 9, 2011</font></font> </font></font></div>
</div>
</div>
</div>
</td>
</tr><tr>
<td align="left" valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">James S. Manuso</font> </div>
</td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ *</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="20%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 9, 2011</font></font> </font></font></div>
</div>
</div>
</div>
</td>
</tr><tr>
<td align="left" valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">John Neis</font> </div>
</td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ *</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="20%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 9, 2011</font></font> </font></font></div>
</div>
</div>
</div>
</td>
</tr><tr>
<td align="left" valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">John E. Niederhuber</font> </div>
</td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ *</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="20%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 9, 2011</font></font> </font></font></div>
</div>
</div>
</div>
</td>
</tr><tr>
<td align="left" valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Howard M. Schneider</font> </div>
</td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ *</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font> </div>
</td>
<td align="left" valign="top" width="56%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;</font> </div>
</td>
<td valign="top" width="20%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 9, 2011</font></font> </font></font></div>
</div>
</div>
</div>
</td>
</tr><tr>
<td align="left" valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Michael F. Tweedle</font> </div>
</td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ *</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Director</font> </div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td valign="top" width="20%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 9, 2011</font></font> </font></font></div>
</div>
</div>
</div>
</td>
</tr><tr>
<td align="left" valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Jamey P. Weichert</font> </div>
</td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="56%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="2%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="V227496_S1_HTM_EOLPAGE99"><!--EFPlaceholder--></a>&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">*/s/ Harry S. Palmin</font> as attorney-in-fact.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="eolPage103"><!--EFPlaceholder--></a>&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_EXHIBIT_INDEX"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT INDEX</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>
</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="5" valign="top" width="37%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Incorporated by Reference</font></div>
</td>
</tr><tr>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit<br>
No.</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="38%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Description</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Filed&#160;with<br>
this<br>
Form S-1</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Filing&#160;Date</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit<br>
No.</font></div>
</td>
</tr><tr>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="10%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; 1.1&#160; </font></div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;Form of Underwriting Agreement</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">X</font> </font></div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="15%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Agreement and Plan of Merger by and among Novelos Therapeutics, Inc., Cell Acquisition Corp. and Cellectar, Inc. dated April 8, 2011&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 11, 2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Second Amended and Restated Certificate of Incorporation&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 11, 2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.2</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amended and Restated By-laws&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 1, 2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.3</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Novelos Therapeutics, Inc.</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;S-1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;July 1, 2011</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;3.3</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.1</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Legal Opinion of Foley Hoag LLP*</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="12%">&#160;</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="15%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="38%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="12%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="15%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr>
<td valign="top" width="10%" style="TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.1&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="38%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of common stock certificate</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">X</font> </font></div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="15%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr>
<td valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="38%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="12%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="15%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
</tr><tr>
<td valign="top" width="10%" style="TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.2&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="38%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Warrant</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">X</font> </font></div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="15%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Employment Agreement with Harry S. Palmin dated January 31, 2006&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">February 6, 2006</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.2</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Second Amendment to Employment Agreement between the Company and Harry Palmin</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 1, 2011</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.3</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2000 Stock Option and Incentive Plan</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SB-2</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 16, 2005</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.2</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.4</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of 2004 non-plan non-qualified stock option&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SB-2</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 16, 2005</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.3</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.5</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of non-plan non-qualified stock option used from February to May 2005&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SB-2</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 16, 2005</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.4</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.6</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of non-plan non-qualified stock option used after May 2005&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SB-2</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 16, 2005</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.5</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.7</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consideration and new technology agreement dated April 1, 2005 with ZAO BAM&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10-QSB</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">August 15, 2005</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.2</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.8</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of common stock purchase warrant dated March 2006&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">March 3, 2006</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.3</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.9</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2006 Stock Incentive Plan, as amended&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 23,2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.10</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Incentive Stock Option under Novelos Therapeutics, Inc.&#8217;s 2006 Stock Incentive Plan&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 15, 2006</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.11</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Non-Statutory Stock Option under Novelos Therapeutics, Inc.&#8217;s 2006 Stock Incentive Plan&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 15, 2006</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.2</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><a name="eolPage104"><!--EFPlaceholder--></a><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font></font></font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>

<div>&#160;</div>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.13</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Common Stock Purchase Warrant dated May 2, 2007 issued pursuant to the Agreement to Exchange and Consent dated May 2, 2007&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10-QSB</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 8, 2007</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.2</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.14</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Collaboration Agreement dated February 11, 2009**&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">March 30, 2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.39</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.15</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common Stock Purchase Warrant dated February 11, 2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">February 18, 2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.2</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.16</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Warrant Exchange Agreement dated August 21, 2009&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">August 26, 2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.5</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.17</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Securities Purchase Agreement dated August 25, 2009&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">S-1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 15, 2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.41</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.18</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common Stock Purchase Warrant dated August 25, 2009&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">S-1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 15, 2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.43</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.19</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Letter Agreement with LP Clover Limited dated August 25, 2009&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">S-1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 15, 2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.44</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.20</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Letter Agreement with Mundipharma International Corporation Limited dated August 25, 2009&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">S-1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">September 15, 2009</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.45</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.21</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consent and Amendment Agreement dated January 21, 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">S-1/A</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">January 26, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.47</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.22</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Executive Retention Agreement dated May 14, 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10-Q</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">May 17, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.3</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.23</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Placement Agent Agreement Between the Company and Rodman and Renshaw LLC</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">S-1A</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 25, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.50</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.24</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Written Consent and Waiver of Holders of Series C Convertible Preferred Stock and Series E Convertible Preferred Stock dated July 6, 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">S-1A</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 7, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.52</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.25&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Common Stock Purchase Warrant to be issued pursuant to the Consent and Waiver of Holders of Series C Convertible Preferred Stock and Series E Convertible Preferred Stock dated July 6, 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">S-1A</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 7, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.53</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.26</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Securities Purchase Agreement dated July 21, 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 22, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.27</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amendment to Consent and Waiver of Holders of Series C Convertible Preferred Stock and Series E Convertible Preferred Stock dated July 21, 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">July 22, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.2</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.28</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exchange Agreement dated November 30, 2010 between the Company and the holders of Series C Convertible Preferred Stock and Series E Convertible Preferred Stock&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 30, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><a name="eolPage105"><!--EFPlaceholder--></a>&#160;</font></font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
</div>

<div>&#160;</div>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.29</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Common Stock Purchase Warrant dated April 8, 2011&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 11, 2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.3</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.30</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Securities Purchase Agreement dated April 8, 2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 11, 2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.31</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Placement Agency Agreement dated April 1, 2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8-K</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">April 11, 2011</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.32</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">License Agreement between Cellectar, LLC and the Regents of the University of Michigan dated September 14, 2003, as amended through June 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;S-1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;July 1, 2011</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;10.31</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.33</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Lease Agreement between Cellectar, LLC and McAllen Properties LLC, as amended and extended to date&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;S-1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;July 1, 2011</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;10.32</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.34</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Loan Agreement between the Wisconsin Department of Commerce and Cellectar, Inc. dated September 15, 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;S-1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;July 1, 2011</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;10.33</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.35</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General Business Security Agreement dated September 15, 2010&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;S-1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;July 1, 2011</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;10.34</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23.1</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consent of Foley Hoag LLP (included in Exhibit 5.1)*</font> </div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="15%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
<td align="left" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font> </td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23.2</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consent of Grant Thornton LLP</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">X</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23.3</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consent of Stowe &amp; Degon LLC</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;X</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24.1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Powers of Attorney (included on signature page)</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;S-1</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;July 1, 2011</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;24.1</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="10%" style="TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td align="left" valign="top" width="38%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interactive Data Files</font> </td>
<td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> </td>
<td valign="top" width="12%" style="TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">X</font> </td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">*&#160; To be filed by amendment.</font> </div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">** Portions of this exhibit have been omitted pursuant to a confidential treatment order.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,0$4`P$1``(1`0,1`?_$`.````("`04!`0``````
M``````D*``@&`0(%!PL#!`$``@("`P$`````````````!P@`!@4)`@,$`1``
M``8!`P(#`@4-"0T)`0```0(#!`4&!P`1"!()(3$3%!5!(A87"E%A<8&QP3(S
MM3=W&#CP<H*R<R1T-AF1H5)BPB-3LS0U=;9X0D.$)6755D>W*!$``0($!`(&
M`P@.!@D%`0```0(#`!$$!2$2!@<Q05%A<2(3"($R%)&Q0G*R,S05H<%28H(C
M0[,U=18V%S?1DJ+2<W3P8R14)54F5G:#DT2$&"?_V@`,`P$``A$#$0`_`&?)
MOC#W8'$K*NX?N)8WCHE=\[<1T>KQWC7*S*/46.=LS.X&5`5E&Z)@()_#J$-]
MM%!G4.V\DI<L;Q.$_P#:#_1"]5FB]]4N.OTVJJ0,2)"32F8YRPA9RU=Y7N;5
M.7D8U_F9M[,UF;!$1\L?&=6:LIPE<FWD"\>Q9UHOH72!XR,!@(8XIF^*8=],
ME0[0;;UM.A_V=0<4VE11XBB4YA,3QZ(3BO\`,/N_15*VEW'NA12"&D!)*3(D
M33T\8,-VF^]#)9PM!>/G+NP0[;),](&^;')7L;"OQ5J6<[B%+FVK5-"/839#
MDW8KATD=@84A`%`+U"C='9L6*F^O-+H6J@;3^-:Q4I/WZ>)*?NARX\(/NQ?F
M-?U#7C2^O76Q<7E2IZF02E1/Y)R0`!)]17`GNG&1AE@/+RV^L/[ATND.<.'1
M$'Q\_+P\-?)RX\(^$3X\(%+F[CWW19Z^9`L^%.<6-JA29*7?R-!QS/859R"\
M)%BB46$`]M(N5CN%`5()1<F0-L!]Q*.VVB39[[MY3T3%+=[0\Y5I`#CJ7CWN
MDA.'N3@%ZETKO14W.KKM-ZAI6K>MQ2F&%L8I3+NH*RDCJF1Z8%5PYR?WH^7.
M3LT8]_6,IF*6>!+8[HN1;+8<:UJ;3;7!F\?-%(&%C(]DT/)+=,>=451532(D
M8AAWZP#12U=:MHM*VFDK11/5-57-!QI"7%`9"`05$G#CUP"-OKYY@]?WNOM3
M=U;I&K<\IJH=6V@I2ZE2DE"$I1-1FDS$QA(SQAF_%D)>:YCRF062[>TOU_B*
M]'L+C=&,0G7VEGGT$2D?S+>$1.JE&)/5@$X(E,($WV`=+?7/TE16NN4+9:I2
MONH)S91R&;G#K62EN5):Z>GN[XJKDAJ3KH3D#B^:@CE..A>3G-O!7%5H@CD&
M>6D+8_;G<Q5&KA$I"R.D0`>ARZ1]5-&)8J&#8%G!B`8?P0-L.O&5`=L9>!43
M_?,="].%6X_)A&@8P$-8+H/MIR@.Q3B6.B@1()@\=MQV^J.OF<1)1VQBOO98
MHL$@UC,K8SLF/TESE(I88>10M,2@8VP`9PQ(V8R22!`W$QB^J/U"ZF<1)08V
MC7NGY+J\5=*'8HNTU>;;@YC9F(<D<M'!!_"((E^.BX2-\51(X%43,&Q@`=<@
M0>$2,MU]B1-2)$U(D34B1-2)$U(D34B1-2)$U(D==9;A,AV/&UR@\37&-Q]D
MB3A'+6FW68@RV:+K<V<2"UDWT`==L65;H[#U(BH3JW\]>VW/4;%<V]<&B]1)
M5-:`K*5#H"N7;&)OM-=*RTOTUDJ$TMU6@AIU2<Z4*Z2GF.J%YNXC=^ZEPDP,
MAFB=YMX\MK)W=H&DEAJ=@>&J\DFK/MI-PG(ED91[/-^EM[M$#$%+<1.`@/AH
M\:`M^W.M;X;*BUNT[@94YF6^I8[A2")"7'-AC"C;LW'>W;C3*+\_J&FJ67*@
M,Y6J8-J&9*UA696;[DB4N8QCI#LI\\^7')GF+,TK.>:[#D"J(XCM4ZE`R#&`
M8QZ4LQE8)%J^(E$1,>)544G:A0\=MC>6L]O)H;2VF])M5MEI4,U)J4)*A.9!
M2J?$GHBM^6W<K6^KMP'*#4=Q?JJ/V)Q61<I9DE$B)`8B9ALW2N0^<34B1-2)
M$U(D34B1-2)$U(D34B1-2)$U(D34B1\SA\0X_P"*;[@Z^CU@.4Q'4]\TL_>G
MWC"SO%[@-C3GIVR7E,LI&\!D:NY^Y*26+LC)M4SR-8FS9-GOYB^."9EWM7EC
MD*1XUW\0`%";*$`186^:ZN&B-PQ64Q+E`JCIDNM3P4GPP9CH4.1]!PA,]&[5
MVG<[9<T+X2U>F[C6JIWY8I5XI[JC*9;5P4.1[PQA6#..$<J\8\M6+%.5()_4
M+[2I$NYDSK)).4DUC*Q-DKTDGZ9G<7(%("[5RD("'A^"<H@#3V6]VO4]I;NE
M"L.T#B,>T^LA0Y$<"#"0:CTY>M&7QVRW9M;%RIW.L3EP6DX3!P*5#WX;&[-?
M=L3S9'0?%GDI9$$<PQ+1&/QI?)5<J)<FQ+-$B:$%,.UU-C7IBD3XIAV]X)%W
M#=8#`95MWMJC8G%:DT^@JM2R2ZVD?-DXYD@?`//[D]4/1Y>M^OKYMO1&L7@+
MND!--4+/SP'!IPD_.`>JKX0PXB&/O`?W?4TO0(.'&''XQIL`?;$!URCX1+W8
M$7VRB%#.'=$V*`;\W+!OL`!OO6(PP[_;,(_;T4]QOT/IV?\`RE/OPOFQX`U!
MK,C_`+A7\DP74?[FA5PQ`QAA#@.J%A.\K@5U2LTU_.$:1=6O97CDXN744,HJ
MFPN%<;)I>@4QQ,"*$E"@14A=P#U$E-@UUKX\)?;CX#)?,@CW(#3KA'.-0$`W
M$?+8=_L!KZ./"<?<.?"&T>TQAN7Q9Q7BK!.N9`DAEB65O:$2Y75%K$PBJ)6$
M(5LS4'TV:LDT;^U*B4`]3U2"/D&N;86$36)+QF(ZLQ4!/`B7#G!!YG)V.*Y(
M*Q%@O]*@I9`B9UXV8M$)&OT"K%`Z1E6CQZBNF50@@)1$H;AXAK*,6FZ5+0J*
M:F?<IS\)*%%/N@$1AJW4M@M]0:2OK:5BJ`F4+=0E0GPF"1QCB?GJPZ`[?.OC
M@?K?+:M_^Y:[OJ"^\?8ZK_VE_P!$>,:TTC.7UG0G_P!9O^]'.P.1*!:GAHZL
M7BHV.0(@9R=C!V2'EGA&Y#%*=P9LP>+K%1(8X`)A+T@(AKS5-MN-&WXU8P\T
MS.4UH4D3Z)D`1[Z#4%CNCOL]MK*:HJ`F>5MQ"U2Z9)).$<K/6:NU9F61LT]#
M5V.,L1N5_.2;*)9F<*`84VX.7RR"(K*`41`N_4(`.P:Z::CJZQPM4;:W7N.5
M*2HRZ9`$RCU5USH+8T*BXO-,4W#.XH(3/D)J($XP[YZ\.AYY7QQY_P#S:M_6
M_P#4M>X6&^'#V.IG_AK_`*(PYUII$8_6=#+_`!F_[T9]&2T9-,&LK#2+&6C'
MR8+,I&,=H/F+Q(3"7U6SML=5!=/J*(=13"&X:QKK+[#BF7D*0ZGB%`@@]!!Q
M'IC/L5=-5LIJ:5Q+C"Q-*DD*"AT@C`^B.D,U\IN/''1DF^S9F*B8Z*L0QFS*
MPSS-"7>=/2/\RADSJRCOP.'XM(?,-9BTZ:O]^PM5(\ZGFI*3E!^-++]F*OJ3
M7VC](@_M!<*6G<E/(I8\0]B`<WV(J(?O!<"4E0!?*\ZW8"80]_+XRR*C7@3#
MS7&:4K0,0;@`[]?7T[>.K.C:_6*R4I8:+GW/C-YNS+FG.*`KS"[9)D5U-4&3
M^4-,\&^W/EE+KBY.&.2F!N0\2,UA/+%'R2Q3(4SD*Q/,GS]EU!N`/XL%"2+(
M1#_2I%U5KQIZ]V!SP[O2O,*/#,D@'L5P/H,$73FM-,:M:\;3M;3U20,0A8*T
M_&1ZP]R.\-P$?,/JZPN.'1%IF)RYP!WZ1)X<"8GP_P#OC'GY-M.CAY?\-<J_
MR;G'XS<*YYMOY:L2_P"9-_FGH"W]'<_;MGO+\QMT_+59T8O,)CHQD\_;$#^R
MJ%X\I'\RG?U>[[Z(>'TET;*XV@(_:^KJ1QF9X\(I]G'GUQ#XYOQA<L9TI<)9
M@`.FHQSQ2R6U0P]72D6NU]*2E"K*"40*4R91,(;`&^K59]#ZIOJ/'MU&\JF/
MPU#*C^LJ0@<ZFW:V_P!).FFO%R9%8.+:#XK@[4(F03PBO)^\1PH:IH/)B=RS
M7H9T)?9['/X,RC%5\Z9O)<TFXK8(HH`7Q$Y^DH!XZSB=J]5K.1GV5Q\#%"7V
MRL>B?'L,55SS#;=L(2[5&XM4ZSW5KHWPD@\YY<!UF+IX2Y-8#Y'0ZDWA#+%*
MR0R0*0SLE;FFKJ08=9>HI9"*,9.28F$/]*D753O&G;W8'/#O%,ZP2<"I)D>P
M\#Z#!&TSK?2VL6B[IVM8J9"92E0SIG]TCU@>T1WMK"C$3$6R-HCMX[@```[[
M^7[@U!T1Q)D09C+SBG^6.?O#G",RYK>2.0>/8>S-#@F[K;*6^4$^T4,'45)U
M%5]*3=M51+X]*A2F^MJT6S1.J+JT*BBHWE4RN"U#*CW52$H'5^W9V]TT\JDN
M]TIDUB#(MI5G6.@%*)X]48)5>Z/P*M\FWAV')"CQ<@[.";=&U#*5%-4YC`0A
M2N[''QK,!.80`-U`W'7NJ=NM9TR"[[$XXTD8EN2Y?U28QENWRVON50*9NZ--
MNJX>*%-#W5@#[,7B:6.OR$,%C83L,]KYFIGI9UK)LG$,+,B?J'=>\TECL_9B
M)AU&/U](!XB.J>NFJ&W_`&=Q"TU$Y92DYI]$I3@FM7"A?I/;V7F5466?B!:2
MB73FG*77.-_O^$]S?*'WQ%>X?8_>/OOW@T]S^P=/7[=[S]7V+V/T_C>KU]&W
MCOKC[-4^+[-D7[1GRY9'-/HR\?1*<<O;J7V7VSQ&_9LF;/F&3+]UFX2ZYRCE
M3_BS_O3_`'!UP3ZP[8[GOF5_%/O&!*]E4/\`^*EA\?'D#R*\_P!*4[HE[M#_
M`*N`Y"BIOS0@%^7(2VW!YFXUGYXQFG<Q[<-$Y[8M%-'V&L9RI3%XOC&_&0*&
MZI@]=2HV,Q!(=W6IA4@`/4(F:*F!5/\`[13=6W&X5;H2Y3FI=D>(#S<\)?=I
M')0^R,.B/7O3M!;]T+-F8"&=34Z26'92S=+3A^Y5+`_!./"<(,9&QWDSC[E"
M;H5\AYF@Y+QW/^B\:F.LSD8J3CG`*,92+>HB05FJPIE7:.D3"10@E.0VVGJM
MU?:=1VI-=1J2]05",.8RD8I(^P08U;7:TWC2MY=MEQ;<I[K3.92#-)"DGB#]
MD*'$2(AR3L^=V6.Y/P,3QWS[.-(_D-78\C6M6-^LBU;Y@AF*0$*N01*DBG=V
M2!`]I;@(B\*`K)AU=904+=K:U_3-2J^V5LJL;BIK2`?Q)/3Q[G0?@\#A&PCR
M^;ZM:NI&M(:I="=2M)"6G%$#VE($@#P'BC^WQ&,Q!^_/[N@4#[L-<<8$9VR_
MSW]T/_K=G_\`E:+T5-QIBT:=_5"?E0OFQ_Z?UG_Y$OY)B\/+OD?6^)G';)^>
MK.B5ZVHL"=>(A_5]$]ALT@JG&UJ!24V$2#)S+I),Y@`1(EUGV'IU3-+V!_4U
M^IK*P9%Y<E&4\J!BI7H2#!/W!UC2Z#TC6ZGJP%"G;[B9R\1Q4DH1/E-1$^H$
MP$SBYGNQ=VGM_9YIF2W,:]Y$8HMTK;(I-DV0:=2:PR%AHPQC1$I!3:'8&>0?
M5X]7IE$X[FU=]W=!T^C+TRU;@KZM?9!23CWTB2L>O`RZX&'EYW3K=QK!5IO;
MB5WJEJ#.0`FTX2IL@=",43ZH!LHFJDH=)PD=!=(YTET%"B51%9,PD424*/B4
MZ:A1*(#X@(:#^((2H25(SZI0P@*B.\)+Z.KICOSB[A.1Y#9XQUBEB13V6?FT
M7%A<ID$_L%5B3%?V%X<`$-BECTC$*.X!UJ%#?<0U]`!,CPCD#(S@L',+NWH<
M1N?^'^/=439+<?L9UN(IN<8AHDBHHS?VOW<2+>1[CTS+MW&.8(C98R)3`"X.
M%2'\0*(,!I#:3]HM!5%[=S(NCI*J?K2@$2ET+((GR$C"A;D;_O:-W9H]/4I"
M].4J4MUB<)E;N)(/(M)*3+F<PB[7-[MA\8N95%RED:*H5>+R#OE(:OJ1F%JX
MD%'ZTI$Q**]1`Q0?A%KQ4DV;I-5!]+_9U>KS`-5#1VX%\TI<&*%Y<[.R[E=9
M4$D`9B%8RF"DDGCQ@C;E[/Z4W`LU;=*%H#4U4P'&7TJ7WE)0"C">4A8`23+@
M0>4(6P;5OBS*D:EDN@,[`G0;P@VON.I]-5LE)IU^7]FLM6D?0,DY0%P1NLCU
MD$#%,(&#3QOI;N=E<?MJPVZ\U-M:`"!F3W5`&<^,XU>L*<LM]2S=FE*]FJ).
MM*)3FR+[R"09B<BDGE'H/<+.*'!*FP]0Y-\3L.U.G*9*H#9:*M,$YEUG:U:L
M)6C]U$K%?2;U!-1%VU*FN4"]1%41#?PTA6KM0ZNJ'G=.ZD?4XW3ND%)2D=Y,
MQ/``X@S'48VN[=:0VYIZ.FUIHRB0T[54TTK2M:B$KEF1WE$3!$CA/"+.9[XY
M84Y.TQ#'F=Z%%9%IS:99V)"!F%'J35*98HN6[-^4T>Z9K^L@D[4`/C[;&'P'
M5>LM^NFGJOV^SNEFK4@HS``F7$C$$1<]3Z3L&L:)-LU&S[12(6%A)4I,E2(!
MFD@\R.,+$8O[/O'+-'<IY`U.HM9$>(7'Q6K(6J";2+LQ7N4I^#3D7F+(Z?%4
M9`8R!5$7+TQ#F51(8B`G`3;Z8^X;IWFR[>4+U0EL:JK<Q2HH&#23(.Y92FKE
MR)QA*[)L5I_4>\%TH*%;W["6M:`Y)1)+JT!7LZ5SG@K-F/$)`'."#=S#FU3.
MUMQXQ]QMXO0</7,BS]?>1N.8<@G?1N*Z.V<JE>6Q=L^.Z4>O7$@Y42CTEC"4
MZ_J*&W*GTC1=N-%U>Y=]?U!J%2EVYM04X0)%U>'<F)`"7K2Y2'."OO-N50;*
MZ8IM'Z.0$7AULAH3S"G:F9N'-,E:E$Y9]9QE%5NS#P*C\\1S[N!<MRNLQ7>[
M3\B.+6N03J3S<C>)?.&DE>Y%J_,HV?.GLH15!@B=,6[9)$QRDW.40M&\&M?J
M1T:&TD12T++8\4M]TS(!"`1B)#%1XF<HHGEWVK:U4TO<W76>MJGGE>`A[O)4
M4GO.K!];O3"`>Z)$RX0SDYKT"\BE()Y"Q#J#5;BT5AW,:S7BE&O3T`U/'JHF
M:&;]/AT"3IV^#2XBJJD.A\.N!T8YLQS3'.?&'05;+<NG-(MADTIP*"A.61PE
MEE*7HA.OO&<7G7;ZS[BSEMQ&DI'#D?DF6DF;UG35E(^/K.0X9-.45.T:D.=L
M,':8Y0ZBC%4AFOK(J`4@`;8&TVDU(C7MDJ]+ZH2FK73H!!6`5*;.`QZ4F0F,
M9$1KYW_T,YM+J:CUKH5;E#1U2U=UM1`:>20HA.)[JP<V4B0D1(P?WM;<\V?/
M#CVC:YI!C%9;H#U&I94A68]+=25!J5:-M$:@(`*45:&A3+%(&X(KD53`=BAH
M%[FZ'.B=0FF8S*MCZ<[*CQ`YH/24G"?,2,-7L?N@WN9I5-359$W^DDW4)&$S
M+NN`="QB>04"(J9](E_8*B?T[X\_)MIU:=@?WY5_DW/E-Q1?-M_+5C]9-_FG
MH"U]'<_;MGOT&W3\LUG1C\P?[EL_YU/R50O'E(_F4[^KW??1#Q&DNC97"IW>
ME[M5WJ%UL'$+C+9G%8=U](6&9<DPBP%G`DW2!O:<?5IT!#&CCM6ZY?>#I,06
M]0WHD$O2<19W9W:NAK:).JM2(S@XL-$=TIY+/3,\!PEC"*>8K?6ZTMS>T%I!
MWP6FI)J7T'OJ69YFDD>JE(D%D&9,Q,2B^7:4[9N.L`XAJ.=LMU=C=.2>48IG
M=9.?MK8)E[18V?;H2$;7XD)$SHB4L5LH19Z],'M)W)Q+U`4@`-%W0W$K[S=G
MK):7"Q8*9S($-G*%J3@5*(D93P`X2@H[#[.6?3^GZ;5&HF$U.J:QKQ9O#-X*
M5R(2D*F,Q$E*4<9GJ@U[^*C91DXCI)@QD(]VB9N[8OFB#MFY0.'2=%=LN11!
M5(Y?`2F*(#]30@;??:6'&UJ2X,002#/M$,>]0450RIA]IM;*A(I*04RZ)$$0
MHMWD^(3C@IDG'?-[AZ]E,,MK-9_<-T94=56,CJ[>3%5E8>99-4C"T3A[2D@L
MDY8G(9J+A$!`NR@E!JMHM5,ZVHG]'ZN2BK4TWF;4X)J6C@4$\9I)$E<9'JA!
M_,'H%>U]ZH]?Z"4[1,/.D+2V2$M/`9@4]"5@&:3,33@,8,IVF>XLGSPPW)-K
MFBQB\Z8M-'QF0V#$"H,K"Q?)J%B+Q$--B^S-)4[<Z;E$O45NZ((`/2<@:$.Z
M.@3HF[)71A2K+4DEHGX)'K-D\Y3P/,0PVPN[BMS=/K8NN0:EHB`\$X>(@^JZ
M$\ID95`<#CP,5)[[?-F^85BL0<8<8VMWCR5SL=>1R#D&/5,WDJ]CI&:95Y5I
M'.R`"C(TFZ=+'<JD,50&S82E$.L1"T;+:,H[V:S45P:\=%$F337)3F4JF>F6
M$ATGJBC>9[<*Y6-JAT5:GS2FXC,^\#)26LX2$@B1`5)14009"6$YP5/C#PIX
MO\=<=UR$Q=C>G/SK1<>_D;_*1<?8K1=9!TV3<.+-)V203>NWB\LHJ*H"10$P
M*8`*&VVAGJ/5VHKW<7%U[[J$I60&DDH2V`2,@2)##G/&<&O1&VVB--62G:M=
M'2O.+:0M3ZTI=6ZH@$N%:LW'B)8`2E'>]RPEAW(42[@KQBV@6J*?(&;.F4U4
MX1\FHB<.DQ.I5D*J8"'AN4P"&L-2WJ[T3@=I*E]M8Z%J]Z<HM%QTEI>ZTZJ6
MXV^C=96)$%I'#M`"AZ#"V/=>[?MXXN<?,DY(X89!O]%X]S"#9OGWCC&V.3<T
MMK`.9!`J=DJS=XY<.(N&0D%B%D6*9@)Z)^L!],JA!8':S7%NU)?*>W:MIZ=V
M[MA7L]2I("YA).54A(J('=/'E">;Y[47+1&G:F\:!JJMC2KQ2*RB"U*:2,PD
MM,S\WF("DXRP,Y3B_P#TE_L+.GI#I_4CZ>C;XO1\D]MMO\'I_O:I4Q_&G@,O
MUOZ/6@I^(K_\P>+,YOV?^UQZ8,Z?\6?]Z?[@Z$*?6';#'/?,K^*?>,"6[*O[
M%*WUN0/(K_\`4IW1,W:_>[_Z5-^:3`+\N9__`)L/UC6?GC!:AW'^\.AE('C!
MX,YX0(KNI=L.J\Z*`:W4I",K7)"D1B_R-LJA"-6=QCD2G7-2;:NDD8ZK5P<!
M]A='ZC,UAV_%&.`%?;#<FJT17^SU>9VPNJ[Z.)03\-$\.T<QUPON^>RU%N5:
MS<;6E#6KJ='XM6`#R1CX;AE_44<0<.!A$J8B,CX.R0ZB95M8L<Y2QK9O353Z
MG$18JO98-WUD6072,FL@X;KI`=)4@B50@@8HF*8!%W&7K=?[6E]LHJ*"I1,?
M"2H*'`CLXQK%?I[MIR[J8>#M+=:5V1!FE:%H.!',$$3!':(=M[27=6@>8M38
M8=R])L83DM48HA5Q6,BS995AF"9$ALT&03`3W\DGL,BS*`&ZMUDP%,1Z$SW5
MVOJ-(UBKM;$E>GWE82Q\$G'*?O?N5=&!C9)L+OE2Z]H4:>OZTMZM9;`F2`*E
M*9#.G_6`>NGGQ$=F=LS\^'=$_P"MR?\`^5HK6,W&5.SZ<'1:$_*C*[(?O!K.
M?_<*_DF*A_21KC,1'%G#=/8KG0BK?F<CJ;*0QR@Z+6:S*O8ULL`#TG1*^>`K
ML._QTBB'EJT^7BF9>U34ONI!=12D)^]FM()]P2BC><&N>:T;;Z!LD,NUTU]>
M5I<@>F4Y]L`9[./*P.+7-.E*3DC[)C[,94<2WGUE.AFV^4,@U&K3:_48$R#$
M60B("H/X*"ZH>0CH[;O:6_:72#RF1FN%*2ZV>?<!S)_"3/TRA6-@-='0^X5*
MZ^K+:JV5.\#P"7%#*L]:%`'LS=,$*[E_'_YA^3]H4BV96U,R@17(-5%),2M$
M#R;DY9^*0$``@"PF0.8"!OTI+$^`=(*Z?#7,S.88]L;9$<!C/-/'TX"+D]MR
M'JW&'C/R"YZY,12090E;G(FG@Y*4BSJ*@$TUWA&(J`4?6L]H%LP1$@[G%(P>
M6VLUIZT/WV\4]IIA^.?=2GL!.)]`QBM:SU+1Z-TS6ZBKS^)I65*EA-2P.Z@3
MPFI4A"B.4\C6;,.1+WE*YNCO+1D6TSEMGG!SB<?;YMZL\.B4QA$WH-2*%13#
M?8J9"@&P`&MD-IM35HMK%NIR`PPVE*1U)$OL\^N--%[N]7?;U4WJN5GK*AY3
MBCCB5**C+J$\.J/13[;EHEKEP.XI6.=74<RKW"]/0=N%A$RJPQC+W2DJ<QA$
M3"H@R*._PAK7WN'2-4>MKE3,_-IJE'^MWO?,;;-F*U^OVKLE54G,\:%(GU))
M2./.0$+.?2!.%'S59CA^6%(B_1I&:W7NG(23)#H;0>3&+9/T9-8J28)HI7",
M1ZQ.(_&>-U!'Q/XLCL-K15SM2],5BQ[92)FU,XEL\NO(?<!$)GYI]ME6'4(U
MM;D?\.N*CXH`P0^`)GA@'!WNT'F8M%]':YF^WQ5OX6W:4,9Y#!(9"PZ=TMN*
MD0J<I[I56WJ',<?=[M0L@@F78"IJK[!X:K7F!T<&WFM8T*)-KDT^!]U\!?I]
M4^B+OY2MQ<Z7MO+BOO34]2S]UUL'^V/PI0?7FAR+:\6^.M^RNDT&7MC=JUK.
M-JTD0%GMKR7;'2<'28!DUW`SI1S-.TU%"!Y()*&'8`$=`?2-@.I+\Q;B<M/,
MK<5P"&D#,XHGE@)=L-/N5K!O0VD*F]`9Z\R:80,2M]TY6D@<Y*.;L!C'N"/'
M!UQCXZU:EV1W[XRC:',EDG,UG4-ZSNQY2N[@9FTNW#HX`LNDQ<K@S0ZA'I0;
ME`/#7?K:_MZBOKE0P,MM:`:81R2RW@GW>)[8\>U6CG=%Z19H*U7B7RH4JHJG
M#B5/N]Y4SQ(3ZHGPE"5W>GO\I?NXUG\'[I51G1E:K0H-NH8PI,HV!JD2LN5(
M@B)2`XEI!RL;8`ZA/N/CIRMF*!NCV^HU)$@Z%N+Z5%2U<#V`>Y&NCS$W=^Z;
MMW-+I);8<0RCJ2AM&'NDGTPQSP6Y<9DQWP]XYTRJ=OSD?=*_`XMKC2.MU:D<
M9)0%E2,@=PI-Q*<A;&C\K*276,J7UDDU/C?&#?2\ZUTM:+AJRX5=3?*%E]=2
MHE"TN9D<)),DD3`Z(;;;#</4=GV^M-NHM+W6II6J-*4O(4SD<Q)S)FL&1)YB
M<6O_`%[.0@_A=M7E7YAX>]L3?W?&Z?!JJJT38N'U_;B#U._W8O?\5M5_"T?>
M3^$Q_?@;O="<\J^>W'^#Q)3.W_R#IEC@LBPMU:SMMD,=+1I&T?&R\<]:IEA[
M0]>`NZ3DPV^*!-B^(^6B'MH-,Z%ORKM67NB>IUL*04H#DYD@@F:0,)0'MZG]
M;[IZ:I[';M+7.FJ6JH/9W%,D`9%I(`2LF9S<^B,%[%7$7F!Q:S]EMSFS#]JQ
MYCV\8L;LR/IEPP,P<VB$LK!S%E319OG`B\]W.G8`82^!!$-]>S>W5FE=46BE
M^IZIM^M9?X)!F$%)!X@<Y1X_+'H+76BM45CNH:!^EMM31%.9<@"I+B5)$@HX
M^MC+F>F+6?2)?V"HG].^//R;:=5G8']^5?Y-SY3<7GS;?RU8_63?YIZ`M?1W
M/V[9[]!MT_+-9T8_,'^Y;/\`G4_)5"\>4C^93OZO=]]$.VV:4-!UNP31"]9X
M>$EI0I/\,T>P<.RE_A"CMI-:5H/U+;)X+<2GW2!&QZYU"Z2VU%6WZ[3#BQVI
M22/>CS)(J3=9:Y-Q4S:G*CU[DO/L6^L#EP85%')[?D5LI('5,<3>`E?'#8=P
M`/#RUL>?8%LTFMFF[J*:@(1+D4-R^U&F.E?5?=9MO5TU&KN`+D^?B.S5\HQZ
M=C9L@S;MF;=,J3=LW2;-TTR@5-)%!,J:29"EV`I"$(```>``&M;3BE.N**O6
M4<Q/228W1,M-T[3;"!^+2@)3U`"0^P(_5J1WP*WO35-A;.W#R#!\@FJ:M,:Q
M;H\YRE,9N_A+5$'362$0$2*"BLHGN'CTG$/AT3=GJI5+N#0E'%96@_A(5]N1
M]$`KS(4;=7M'<LZ9J:4RXGJ*7$X^X2.PPL+V$\@3-0[AE*@&;EP6'R/1+]5Y
MUDD802<D9PI['%*KI[@0WL4E$E,4P@(@!A`/,=,MOK;VJG0CU0Y+Q*9YLHZI
MJ"5>Z#"7>5RY/T.ZU-3M%7@U#+S:P#@H>&5`GXJD@CT],%D^D0</\A9.K>+N
M3N/(21LS7%4+-4S(L/$ME7LC'5B5D$I>+M!&3=-1=PPCG_K).S%`?135(<0Z
M0,("C8'5UOM574V&X.!HU!2MM1,DY@)%./,B1'3C!U\VN@KK=J>BUE:VU.LT
MC99?2D$J2DJ*D.88Y02I*CRP)PF87RP1W.^<''.#CJKC7.UC+5(=(J,56;4B
MTN,-&H$W`K1DVL"3TS5JF.X%2*<"$#P``#PT?KOMIHK4:_;Z^B1[4Y,E39RD
M]9RRF3TG&%/TSO'N-I!@4EHN3Z:1&"6UD.(2!P`2L&0ZA(=$76JWTA/GY"*H
MC/?,Y<TB&)ZR<M0CQ)UB`/Q@*K7)2+!,Y@\A`H@'U!U3:K8+0[R"*7VMISD0
MYFEZ%3^S!&H?-9NI3+"JMVDJ&Y\%4Z$X=$T9?=@AN'^_O@_D%"S&#>9N'5Z#
M4\EPTA2;%<JI(*3U.3C;"S6C'HSD<[(2>B&HIN-P<M_:_0-L<0*!>K0^O&Q5
M\L+J;WI.J2^_3J#B6U#*N:2")$=TG#@2)\(+-A\TFGM4TCFF=PZ`L6^L0IIQ
MQI14@(6"%%:3WAVIF0<>4'>^9[CU^IK\R?O\GZLOS,_)3Y2_*PO1\V7N;H]Y
M_+'KVV]U?']KWW^'S\-`_P"MK_\`M;]<9/\`J7VK/ER?E9\,G;RAGOV>T?\`
MPX_9OQO^AOJ[)XGB_P#QY3GXO'ASX\N,6Q4\$U!_Q#_<'593ZX[8OSQDPLGA
ME5[Q@2G93,4_"E<2&`P?K!<B=Q`=]A'*$V8`^V4P#]@=$S=H$:NQ_P!RIOS0
M@%^7'^6X_659^=,%NT,H/4;1#X0\_P!WG]O4$HXD$XCUH"!W;^U3"\Q:H\S-
MA]@QA>2U/B%!3*FFDU:97A8](QTJQ-K?%(G.-DP$(YX8!$##Z*@]!@$AGVIW
M0?TA5BTW4ES3[RI3YLD\5)^]/PAZ1"R[][&4VO:%>I+`@(U8PV<P&`J4)$\J
MN7B`>H>?JF$D8N4R)A3([:3CG-@QYD[&EG]1)<@+Q-DJMKK[P2*)G*8"+-W+
M1TD)%"&#I.&Y1`2CXN:\U:K_`&PM94U%#4-<.*5(4.7HC6\R]==-W9+S)=I;
MO2NX<4K0M)Y\P01SZP8<G[`F4+1FR@\P,MW91HK;LA<B&=FLBS%#V5JXF'U%
MAQ?.DFW48J`.5B"H)0^*!C#ML&P:47?>W4]GN%JM=+A2L4&1`XD)"\`>N-A7
ME2NU=?[3?[U<5!=;4W1+BR!*:U-3)EUQ8+OB\=9+/G!2WR=;C59.V85G8O+<
M6U:I&6=N(B%2=Q]O003(`G4Z*U)+N1*&^_LP#L(@&J]LOJ!JPZU:;J3EI*M!
M95U*404?VP!Z8MOF9TB[J?;5ZKI4E59;7!4`#B4`%#GN(45?@P@XFLJF=)=!
M4Z*R1RK(.$3"51)5(04162.`@8ATE"@8HAX@(:>M3:5,EMT`@`X=(/&-6R%*
M9<"TS"TD'L(,.?0+:0[K';9PA?:X*$ER`Q'.1=%M>YR>TJRC`T97K<=R<P@H
M4DK!+,YH!-YB0P`'COK7QN;I=S2NK*FA"94KBO%:Z,CA)D/BF:?1&W+8_6Z=
M<[?4ER=5FN;"/9W\<?$;``4>C.G*KTQ53OJ9A@L#8(X^=O#&SLJ#-C!0MUR(
M5HH"9UH>",X:5MF_(0>H36*R^UR:I##\8R!#"'B&BQY>M*^/5/:HJTS2T/":
MG]T9%:AV"2?287SS<Z[]GI:3;ZA4<[DJBH,^0F&DGM,U^@0L/6*S-W6R5^GU
MF/<2UEMDW&5R`BV:9E7+Z6F'B3!BV23(`F,91PN7X/`-Q'P#345=4Q0TCMPK
M%96FDDG'D!.$8H:2HKZUJAI4E3[JTI2.DJ(`'I)E'IO\:\4DP;Q^PSA\HD$^
M.,;5"I.C)B!DSR$1#-&\B=,P"(&(H_*H8!^$!WUK:U#<_KB^5=T_WBH6L=BE
M&7V(W/:*L/[,Z1MU@D`:2C:0H??!(S?VIQCG+?CE5>5_'G)F"K:FB#6ZU]PA
M$2*B)5E("T,P]LK4^U`VPE<14NBDIX"`F)U%WV'7?I2_5&E[]37FE)DRL9A]
MTDX*2>T81XMP](4FNM(5FG*L)\1]H^&HB>1U.+:AV*EZ)QYWE*LV6^#7*2*G
MO9%Z_E?C]DA5M,11U%$2NEX5V=E.0RQ^C=2)L4495+JZ1`[=<#;#I_ZREM&N
M-*J1,+M]73]T]!4)I/:#(]HC4M;JV][;:V14C,S=[;5]Y/#%"I+2>D*$T\.!
MG#E6.LJ5+N=<K,.W&FJ*2O&SB;3H#+LRFL0QHZQ<DLD0IODG6GI3%!)PZQ)!
M`Y<K%#J!-^L4!\-MU`N=JJMN=.55'6#)J&Y.J:1THI6SWEC_`!C(#[V<;`[+
M?J+?#7-!7T'?T98Z=%2X".ZNO='<;((Q]G&8]$X-3L/A]</'[>A!AZ89F1Y0
MA#WU<,S.,.X#D2TNF:R-:S/"UC(-;?"D)6[Q9."85RRM4E/P3+,IF(,8X;[@
M"Q1VV$-//LC>6;CH)BD2H>-1K4VM/.145`]A21&K3S,Z>JK)NI65JTGV:O#;
M[:I2$LB4*'60M)GVB&JNSUE.&RIV\^/+F->IN7])K+C'%C;E.4RT?-4^1=1X
MMW!`^,F96-]G7)OYIJE'2P[N6MZV:^KPZDI0^X'4=:5@'WYB'B\O-[I[SM/;
M$LJS.TB%4Z^D*;4>(ZTE)'2()KH:X?Z3@V1-242*NT+D4ID;D[F;!E;KC9[4
M<'T^EK6W(B4DHITY/N"[U]\WJ,>5J+8QX>JH(O'2WK^HFJX(D*8?A:L5;830
M6"DO%2N515N+R-R_)(P\3L*L!U8Q1+1K)-YUM<=+4;(716UAHN5`.'CN&?@2
MZ4H[QZ#A`O\`Z1+^P5$_IWQY^3;3HG;`_ORK_)N?*;@+>;;^6K'ZR;_-/0%O
MZ.Y^W;/?H-NGY9K.C%Y@_P!RV?\`.I^2J%W\I!'\2G?U>[[Z(=YDV"$K&R$6
MZ#=M),7;!P'GN@\;J-U0V\/--0=)DTXIEU+J?62H$=H,XV25=.BKI7:1SYMU
MM2#V*!!]^/,OSICZQ\8.5&0J/-M'#*9Q%F-\HV`Y!2%TQA+2$U`2C;?8#-I2
M*(@ND8-RB4X;#K8U9*ZGU/I%FM:,VJBE"?2I&5?N&<:9]1VNLT7K>HMKZ2FI
MH:Y02#S"%]P_A)RJ'48]*'%U[A\GXXH>1:^Z1>PEYJ%>M<8Z;G!1)5K.1360
M3Z3%W#<GM'2(>8&`0'QUKNNE$];KD_;WAE=8>4@^@D1N$T[=J>^6*CN](K-3
MU5,AP'XR1/[.';&>!Y!KQ1FQ@)0'COJ92C<==O/)D.Y<IIRN49RHX^A&@G`%
M7:CN:;S,F9-/?J,FVB8=8QQ#\'<-_/18V4MKE=KZG?`/@TZ%K4>0[I2F?I4(
M7GS/7IBU[5U-&LRJ*Y]II`Z9*\19]"4'W1`*?H[O'Z<O'*ZT9^79*DI^%J7+
M0Z<@HD(MG5ROC48QC'HJ"'29RS@BNG!P`=R`9/\`P@T<?,'?Z>DTXU8DJ_VV
MJ="B/O&SFF>U4A[L+'Y2M+U=QUTYJ3+_`,.M].L%4L"XZDH2D'I`*E'T0RAR
M2YJ-L`<O.*/'RV1U?+CGDM&WR%D[+)BL#^'MK`T6UI[$GJ+EC#1,\]?&:."K
M)F'K5(("`;@*X:=T@J_:8N5^I%.?6-O+:DH'!2#,K)EC-($Q+HAQ=:[CMZ3U
MW9=*W!MDV6\(=0MQ1Q0L$)0,>[D63E5,<X_!F/M-<!LX2LA8+7@"MPUCDU#K
MOIVC.)"E/73E3;K<N48!RSCG+@=@^.H@8WU]=UHW1US9FA3TE>X:=/!*Y+$N
MB:@3Z)QUW_8?:W4=2NMK;8VW6+XEI2FQ/IRH(3/KE%*;5]'8X1S1%0KUGS+3
MU3[BFJSM$=+@D(CN``G-0[HIBA]01WV^'5PI=_=8,$!]NF=(Z4J$_P"J0(&E
M=Y1=OJD'V2JKJ>9Y*2H#JDH&`R]PWL@WOA[C2=SIC#(XY9Q55Q;+7)E,Q"4%
M<:K&/7J#!&5,BS<.XZ<BT'+I,JZB8H*)@;K%/I`1T8MOMZZ35=Q;L=TIQ37!
MTD)*3-"C(F6.(,IRG"\;L^6V[;?VMS4EIJ!6V%E2<\QE>;"B$A2@)I*<Q`F)
M2G,B,3_6*R]_8>?-S[SE?DS^M+\U?M_M+KK^;WW/\N?DIZV^_N?Y0>'I;]'1
M\3\'PUV_LW:OXR^US;]I]A\3)(>OFR9OC9<8QW[57S_\Z_4V9SV'ZY\//F/S
M?A^+D^)GPR\.J#N9X[J^=5J)<J[A+M\<L%;](Q<O"P5BMM(<L:U"/7**S)*:
M61CTG;^2*UZ_6223`@',!>HP!OH'6+;BR?6#3MXOEN30H6%$(7,JEC+&0$^$
M,_JK?'4U3::B@TWI>\"Y.-K2%O-D);S`IS`)22HB<QB!AQ@?/;"Y9\NN$6.K
M+AS+/!GDID.FS%REKS7YRI4F3;3D'+60R2UC;R#&59IH2$>^>(@NF9-4JB9S
MG`2B`[ZO>Y6G-(ZNKVKQ:+S0LU(;#:DK5@0GU>!F".'1`MV9UWK[;6VO6"^Z
M>NE70O.^*T6T*"DJ5@N<TE)!D"9D&<,O\:\[..1.-R9$<XKR3AQ0\]+P8T[*
MT+[AM8!%`V$)/V`3&_\`+GPN=D3[_&],WU-+K?;0+'<30BH8J4!`5G:.9&)X
M3Z8<S1^IU:ML_P!:FCJJ#\<I!;J$Y7.Z!B!]R2<#U&+!AY:Q$6L<,>,:"(>7
MEOKBKA(C`Q"0#+F87T[PO:89<E(>8Y(\?H5NQS]7XY1U;ZNR3(@VRY"Q[<YN
MI!(@D23O3%$O^96'_;B`"1QZP(;1ZVEW4<TV^C3][639G#E0LXEDGI^\ZO@\
M1A"D^8+8A.K&'=8Z3:"=0MI*GVAPJ$I'%(X!T`?AC#C(Q@_T;-J\C\`<E(Z0
M:N&,A'YS8,G[%X@HV>,WK6F1J+EJ[;K%(J@X;JD$AR&`#%,`@(;Z]WF(=9>O
M]O=8(4T:,R4.!&?B(\?D[;=9TQ>671E4FXH!!P((:D01R(E*4,>/&C=^U<,7
MC=!VS>(+-7;5RF19NY:N$S).&ZZ*A3)K(K)'$IBF`0$HB`Z7M"U-K#B"0M)F
M".((X$=D-\^RBH953NI"F5I*5`X@I(D01SF,)0GEW*>QADBHV^QYBX:P![SC
MV??/IN9P^Q53):Z0Z=&5>/@JJ;I5-.>K1E3&%!J0WM38/\V`'*!1TVNW&]MN
MJ:5JT:P<#5:T`$/GU5@8#.>2ATG`QKXWC\L]VMM>[?\`0+2ZJU.J*E4Z<7&2
M<3E&&=OHEWDC"1PECG8ISU:.*W(#*>`\X0EGQY4\F5*3MB2=QA96OI0]TQK&
MO99T*B,JV;`FK)50CLIA#Q.=JF7Q$2Z[-[[11ZFLM-?K4ZT]5,NI1W%)5-#I
M`Y'DJ7NF/%Y9M4U^B=4UFGK\T^Q;JNG6O*XA2<KU.DKG(@2*D9P3U"!OYZ;\
MD^Y'RYREE+&6)<AWU2^VM="G-HNOR2D7"TF*,$54VCB:=)(1$<U2B&R:BAU5
MB%]50X^8Z(E@?T]MWI.DHKA4LL^"V"OO)FMQ0FHD`DXG#AR@1:J;UANWKJMO
M5LH:NH54OGPTI0HA+0.5M,Y``!('$@3G#)W:F[,[7BM+Q7(+D4K$67.:30QZ
MC48\Q7]<Q>9XB=)R\5=G`R,W;C(GZ2.$P!%F4P@GU'$3@N^Z.[R]3M*L.GPI
MJS9N\M6"G9<ND(ZN?9#A[&^7=&C7V]5ZO*7=0`3:9&*&)\U'@MSHE@CK,X8+
MT"(;.)J1(4X^D"\$I5Y;Z1RWQ-6'LL\NDA#8RRE#03%5R[<V9<Y6-$LOLS0A
MCF/*IC[M7/T^*A$!,;<VFCV(US3LTSVEKPZ$,MI4ZTM1P"1BM'8#CZ3"'^:C
M:Y]VZ4VMK"R5FJ6EBH2A,SXOY-<A]V.Z3TI3TP=KMQ\2H_AGQ0QQB84&_P`L
MG+$+;DR12*'J2-[L2:;R63,IMU'0AR&38H@(B`)MPV\]!'<353FK=3U-T)/L
M@/AM#H;3@#^%BKTPS>SF@V]OM#TEH(`N3H\:I/2ZL#N]B!)([#TQ>T-4J"J(
MH)W">`N..?.'PHUG<DK-[K"SB6QED-!J#EU6)I=,J;EJ^;E,FI(UV832*F[;
M`<H_%*H00.0-[UH+75PT+=O;:<>+0N"3S1,@I/(@\E#D?0<#`FW<VKM6Z-A]
M@J5)8N[$S3ORF4*/%*@,5-JD)B>![PQ$+.\?7W<-[*N5;''W'!]GRAQ_M4DF
M-L;U%!Y/4^?*P$R+2VU.?CF[WY*V$K14"G3?()$7+LFJ`B0IBL7?_P!@]Y+4
MVJFJD4U_:2<JED)6)_`4DD33T2)Z1"9:5=W5\NM_<%;0/56G'EY7$HS+9<`X
M+;6D'(L#F0)^J01(P>K'?>TX'7:+07F[M<,;SPH)F>56Z4"U(RS5R(;J,TC1
M49)-GITS`(`9,VQO/0(K]HM8T3_AMM,U"29!2'4$$=)F1*&IM'F.VXN;.:J<
MJJ)\`30ZRN<^:04A041U1S<WSIRAR2;.*'P+P]=YF5FP/'N>1>7:C*43#..&
MRX&35L*#.PHLI[(,FT)N9LQ9(>FHH`>H<"^`]3.C[?I]8K=95+*6V\?9FEA;
MSA'!)*9I0#S).$2JW2OFLT*M.U]NJ5O.G(:ZI;+5,RDB2G`%=YQ0^"D"1BPF
M*\2P7!/C)<%H.-NF9K;$-+/E;(TE&-BR62<TY(D$ADK%(H(',;UY6:=)@BQ:
M]0D;HE32+X%U@;I=7]9ZB;+A:I:112TTDF3;#8,@#T`#%1YF9BX:?T_2[6:*
M?6P'[A<&PNI?4D3>JGCBHCC,DX)&,AA`).Z)R>RYSHXULL+T'@KRYJ<\WR16
M+D,K:<>.!C/8H-I,H.6H!'E<+BZ7/(DZ/#I`"COHU[86*TZ*U(;K<+Q;G&#3
M+;DES&:BD@F?+"%GWKUEJ#<W2C5@M>G+PP^FK2[G<;[I"4.)([HG,E0]R*"]
MKZ.Y&\%N1TEF;(?#KDQ;8-[CR>IR4=5<<RP22;Z5?1+I!T?W@V01,U(6/,4V
MQNK<P#MYZOFY]5IS6]@:M%MNE`T\AY*R5N"4@"#P[8$FS0U5M9JT:BNMANC]
M(:=QK*VTK-->61Q3+B/LPV'Q2YFRW)^PVV"?\9L^8()589A+DE\PUHD#&SQG
MKT[,8Z&5*<PN'S8I?44+\!!`=*UJ/2K>GF67TW"CJ_$404LJS%.!Q/1#XZ'W
M&?UK5U%(JT7&VEA`5FJ4Y4KF994]?/LBGG=.[2E<YQM$LJ8TD8RC\B8")".3
MD7Z9BUS(4.R(JHR@;,9N7U6DFW4-T-)#X_I$-T*%%/82W7;'=6HT2LVRXI+^
MGW#B/A-J/%2>KI'N0.M[]A:7<9OZ^LA2QJQ">>#;Z0,$*/)8X)7P/`B*1\`N
M9.<^W17$N)?<`POE2J4&KOG!<8YBBJQ)7"M040[7%0U<DY*`1D$'L"FZ,HLS
M<HG]1ND<4U$P*!!"W:ZTC8M>N_M/HBLIG*MQ(+S"EA"BKD0%2[TL".9'&!EM
M9N-J?:&F&A]SK=7-VIM9+#Z6RL-I)Q2HIF%-DS4DI,TCE*"QS?=JX#Q4,O*1
MF<F]R=I(>HA6Z54;O/6=ZIMX-FL0E74U/:#&$`Z3F(`"/B.A8SMEK1Q82[2>
M$T52SK<;"1CQGFX>B#W6;^;7TU(JIIZ\U*TI^;99>4X3*>610!/EQ@+/(/#O
M-OO59HISU'&ECXS\0,?+NB528RJQ5BYN6*_43),VX*NH9"2E;%*,D2)-$?33
M:M41`#*B)E!T8[!>M'[/V=Y"GT5^IWT]\-$$)D.ZC-P2D'$DF9/+A"X:IL.X
MWF-U&Q4(HG;5HBGP:74`I,B>\YEP*W"!@`)`2&;$PQOQ3XLXKX?8<KN&,2QA
MFD'#$.YE)=YZ:DY:K`Z`HR=BGG9"E%R_?*%\`_`12`J9``I0#2_ZGU-<]671
M=VN:IO+P`'JH2."4CD/?XF'!T'H6S;?6!JP69/XI&*UD#,XL^LM1'$GD.`&`
M@-?>=X=9WYA\C.&%+PS#2;1%NSOAK!DP6[LE:QP1&3KLBC-S,FUZ3MG2)&9C
MM44S`NNJ4"I^/B!;VAU=8])V*[U%W6,RO#R-<5.X*!2!PYXDX`<87KS%Z`U-
MK[5E@H-.LJF&WL[_``;9[Z#-:@9B0!(EB3@(L1CWF3R:X=0\;C#N!8:NULB*
MXDG%0O+'","\O]*MT4T*"+%Y>:U$I*62K3HH%+ZZQT/15-\8=CB(#7KAI33V
MK7E7'0]4TT^Y-2J1]0;6A1Q(;4>ZI/&71%EL^XNL]N:=%BW2MU344K,DMW"E
M27FUMC`%U*>\%``3.$^>,6-:=UOM^.FY%S\DJLQ6,0#'C9&"NC.51./_`'"K
M!2M>T%7`?`2@`COJNKVWUHA?ABA6>@A;9';//PB[)WUVK7E"KNTATB>0M/!7
M8?Q9$^J<4XY<\H+1W`,37+B9P@Q9>[XEEILWJM\SY<JK,T;#^/JBM(-5YE\A
M*61G'O++*.VC8R2*3-(YB=?5MOTZMNE].T^B+BUJ?5U4PRNE)4W3H6%O.+`(
M2)))"0"9F9@;:^U[5[JVA_0FV]#553=64H?K'&U-4[384%*D5@%1.64P,)\#
M'?']E-B?^SL_41]\']7V+Y2?.3[)_/?G>]J][_+7V3KZO8O>/\V]FZM_=W^;
MWZO'6)_BC=/XA_MMEPS9?"_U,I9)\)RQGTQ:?X$67^$7\-LX]H^>]HD?I7'Q
M)<<GP<OW,%?T,(/T34B1\%/PT_WP?Y6N0_ICH?XM_'^U'U+Y?W=?#'8CU?3&
MTWX1?W?5U]^"8XN>LCMC:;\87[?W-=:?6_!^W':KEZ?>@6';8_.%W`/^K2;_
M`.7V&BWN;]`L'ZJ3\J%M\OGT_5__`)"Y\F"J#\'V?OAH3B&1YQL^'^$/WM=7
MPAVGWHY'B.R**\E?ZYP7]`G_`,A2.KO8/T>Y\=/RDP#]>?IVG^*]\A<=K<7/
MS:,/Y$G\0-8_4WTQ7^G3%MVV_0C?Q4Q94OG_``2ZK?P$Q?\`\JKLC?K['.)J
M1(P2^?[B)_QN!_*[361MWTC\%7O&*]J+Z*?\1'OB,Z#R#['WM8T^L.TQ8$^J
M.R-0\M?$>J(^QM-YA]D/\K7U7JQ\/+M^U'`V3_<4I_(J:]-#]+'QA]J,9>/H
M#D"F=_G!2_XH;^.&B:W\PKXD+K4_I9'^.KWA!5ZQ_5^+_HQ/X@Z&M;])7VGW
MX8:S?HQN.93^#]\'W]>%/KGLCWM>KZ1'Z`^^/W]<^7HCT#[9C74C['P<_BC?
M9#[NN"^`[8\U7\P8U-Y%_A?<'7T?.>B/3^3]`^U'6F6OZCR_]'-_JC:REL^E
MH^,(J6KOT:[_`*=$#RP;^<#_`,6K]T-$*\?0O1`-T=]-7\<P5-/\6A_)I??T
M**GUU=OVX9>G^B-=B?>C]0?#]D=<X])C8;S-^\^^.N0X>F.K\KZ![YCBYG_=
M4E_1C_<UV4WTI/:(\UQ^AO?X?],![G?S@G_XF;_7Z+2?HGX,*14_I\?XRH+)
K0/ZI17\BG_$)H3WSY]7;_3#3:7_12/3&9_!_"_RM>3\C^#]J+!\/\&/_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>pg4a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg4a.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X1N417AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````<````<@$R``(````4````CH=I``0````!````I````-``"OR````G
M$``*_(```"<0061O8F4@4&AO=&]S:&]P($-3,R!7:6YD;W=S`#(P,3$Z,#@Z
M,3$@,34Z,S0Z,30``````Z`!``,````!__\``*`"``0````!```">*`#``0`
M```!```!>0`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$``!I>````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"``!(`$@``/_M``Q!9&]B
M95]#30`"_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`7P"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]0ON])HAI>]YVL8.[CKS^;[6[G*KFVY-
M%3;+7'WO#-E?M8V=?TM^RVWMZ;'ULK]2WTJ]GZ16KZC:T;7;+&'=6[F#&WW-
M_.8YKMCT#)=DOQ[*7M=2][2T7T^\#SVMV9'_`&W_`-;O_P`(DISQU?`],V.Q
M,US!N`]2M[IVG:[8VU[G?RO^+_3?S5&1Z,W]4P&/K8>G7[K6AS`*!.N\P[]S
M:UGNW_Z7]_U?3&W&S&D#]LOI9KNK?6T$$G\Q^9ONV-_X3U$G49;G%XZ\&OV[
M6PVK;S+G.KW;-SFI*8U]<Z;:&.IQ<PU6:-MI8_8>/HNH?MLKU_G6?HEI8KLB
MW%JR:7.`M8UXHR`)`<-WI^I5[FN_E_K"SG5=5#_T/6!:TM`#6TL<006A[HI;
M9OW-]1VSV?X-:QON?I141X66^UO^9_/?V=E?_&)*8GJ6)6T')L;CO)+2RQP!
MEL;OZWTF?YZ;]K],B?M54'^4%E]:J--F-+B][Q:ZQ_$DFCM^:UK1L8L2[#R;
M+GVUYEE(>9+6"#&W8UCK/4]S6?3K3XPL6P9,YC,QH:/7CJW3"8&543_6";]K
M]+_[E5?YX7(-PLG:]MN8^]KRTQ8'$-VN;9[&^M^>YGO0GX.4T!MO5[&RWA[M
MI=J?>[=>W^JW9_TT?;6?>?`?B]K^U^EGC*J_S@F_:_2_^Y57^>%QK^GY5M98
M[J-KF/(<Q[9G;M?46ML]9S7L?ZKO_`_]&G^P9L@_M&[=I)UD@'=M=^E_Z34O
M;5]Y\!^+V/[7Z7_W*J_SPC59F+=4^ZFUEE=<A[VD$`@;SNC^25Q>/B955K7V
M9MMS1/Z-T@&1MU_2.;]+])]%='T%K;,7)8\;FNMVN![@U4A"4*%K\><SEPT-
MK;S3E7C=/V:L_1;`-D>+M\UU?\7LL6=9?FLN-?V*[))L<P'U'-:UH^A9:]SO
M0?ZW\Y^@K_1?S/\`.UHN=TNS(=2ZU]KSC;O0NI<UM@+MONL99^CL>WT_YS=_
MUE5F]*IK!CJ6;4\EFY]SG#=LV?3<65;W/8S8[W)C.D;EY+O4V]&<-C"]IL+!
MN='MJ_/=OW>RS;O_`,+Z7KU_9_M(W=1OW,:WHUS76%VP-<&&&G;ZCW,VLJ9[
MF?SEGK?\%_.^G)G3>GL(`ZMD^F&!C:QD@`:[C9N9M?O=_7_/_P"*]-'IV,=T
M=8RB'.:Z!>"0&C;L9L;NV._/_E_]<]1*2X.1U"^X5NQ;\)NQSG/M>+6[FE@:
MSW!S]C]]G^%H?^C_`.VM"NZP6>C>`'D$L>WZ+@/I<_S;_P#@_P#P2S])Z>2[
MI1>VQM>9U!QN.ZQS7"O6=Q+3<RMC6._X/_!_]/0P,&S&8T76NN+-_IA[B\M#
MW;X-C@UUFW^;K=M]E7Z-)3__T/54SG-:)<0!XG3E`_:&!_W)J_SV_P!ZA=D]
M+OJ=3?;1;4\0^M[F.:1X.:[VN25;7^L.391T?(LQ[37:W9M<P^X2]C3']DK-
MZ/A9/4>G59=W5<RNRPO!9796&C:]];8WTO=]%G[R'U#ZN=!NFS!R:<2WD-W-
M=7_F[M]7_6K/3_X)0P?JO]7JR+.H9-.9;R6;FMJ_S=WJ6_\`7;/3?_H4>C2(
MYB7,V<8]K@X=,WHXN*^/AX.+C_P/^J.E_P`W[7B6]:ZC'BVRGM_Z#)C]6L@_
M][G4Q_URC_WD6A1D]*QZFTX]N/34P0RNMS&M:/!K&^UJG]OP/^Y-7^>W^]!M
MB,1_OO/9W2[>GWU&S/RL_P!5CP!E.K<&;35[JO1IH]S]WNW("T^NVU6V8KZG
MML9MM&YI!$@T]VK#MPK;'N<,RZIKBXAM<""YV_G]UGT%-#Y0T\X'N'Z-J#X'
M7A<OUCI+CU"W(R<!N<S*MVTY!R&5&;89C8;67O;^FIV>G2QGZ*S_`*[=Z>Q=
MA8H>6OS[:-^TOK]9K9#8%1]Y:_:W9_UQ!SWLS:Z:K;6L?C9=65ZF/9CEC_1<
M7UPW+OKLKWM=[V[/T=WZ.O[33].;%FGBEQ0WJNO_`''"LA,1-@CQM-T/!MP<
M`4V4_9I=N;C;_4V:-8\[Q^C:^^QCKWU4?H6>I_I/46A!6<?LU]MMSLY^.+'3
M]G;?6P``-:[W56W;M_[[7L1:<.HL86Y=V0QM@L)]0.#BS9MJ>6#;Z5;J_P";
M3)2,I&1WD23]4$@DFQ9[-Q:_0V&S#RZPYU9=86[VQN;-50W,W!S=S5S9Z8=L
M?;,HN+=A<^PND$C=+?8WW,_1_P#J1=!T3*IQL>QEA<7.L]NUCG2&UT-+OT;7
M;5'/Y67!0G=]"L/JSD@`?MWJACQLH_\`>13'U<O'_>UU(_&RG_WE5_\`:F&"
M`2\$_1!K>"?ZHV>Y/^T<;PM_[:L_\@HJ+:O&?TA_C-`=#>)'[9SS!@S95S_[
M#K/Z;D9E/UGMP'YEV1CU-<!ZS@9]E5ONV-8S<USU<ZIT_P"KG4BZW*QW"^).
M2RE[;-!'N>*_TNW]RWU&+'9]5\(7;795AQ?S6C&>+._MES'4;OY?H_\`6D0U
M.8.02QG"(R`F)2/O<%QH^F49?H_X[V>]D@;A)X$\PI+'Z?C="Z=[L7&<RV(-
MQIL-A!Y;ZKF;]O\`P?\`-JZ[J>(T$N]0!HDDU6:`?V$*+;CD%#B,0>PEQ#_&
M]#__T>F97UJNKU6Y5+,;TPYC7MGTV!IL;_@CNVM=[O=_-U?Z3]*JK>IYF\SU
M&@>Z7UN8Z6B-K=OZJ-C/SO4L^G[+/T:V\=@?BTM(WM-3`YI$@@L;HX*56#AN
MM96:*VAQC^;:#&O\E.<X$$U0U-='#KZMF[+*[,W%]8B*W;+`-S7?I7M9]F_2
MLV?2_P"$]3](B.ZCD.%E].=0VAH87O<7/AI;M:[;]F;4S>]ES][&?O\`_<=;
M.9@X>*\,9@&UC@2',8PC0?0VUU/<W^U_@_4_PGI47!HQL*RRNJOI;ZR^=Y?4
MUC6EKC#MQIV;=OZ6O_"?I:_T?\_Z+A"1%UIYLWL2_=#D6=1ZA0359U#';<"`
M0ZMTM#B==OV?V_N?\%_-V;[$3'ZAGWM]*G-Q[+K"&T$L=$@M<YSAZ#-_J5_R
M_P#"5?\`7-O+Z;@4O8T45G<"27,83X?N_P`I";CXK'![*JV/'#FL:#_G-'\I
M-8I5$F)`L>34R@X,H#SN>'7;W>+OU?<=`S_J4!6<WFK^O?\`EQU64D-D9-Q_
M=C_T6AF5TOR0;*&V'=!>X,=[:ZG7N^E[MOOJ_P#!?^#54TU0*OL;!)K83MJD
M&VP/+/4_.M]*E]=?I_0_J6(MCZ<OJMN'1E7^I4)R!4&FNE^T5MIN<[W-MR&5
M^W_B_P#!I9U%G3^GY&;]LO>,-CLH5^QNY];89[RQ^W_1_0?_`,6H\L3./I`,
MH2XAQ&H\<?[BZ/HD.*!''$5I'U1EM(<2/TL=S&DXE;@-I]C:A(`W.\&_I-V[
M_P`#>KU-F-AXP]4MHJ%CFB!I(^G_`#8_>:_^P@U],<['K->7>YIK:^NMOI_G
M--C:V/=M9_A7MWN?^>B='SJ<O":^BRPOJ+J\BNX;;JK=SC9CY-8#=EC'*2($
M0`!5"A]%DB"2>&M?ZHW_`+K%G4Z0]_KWT-K:#!8+=T_2]V^O;M:Q;/3QN='B
M]PGXC%5;<_Q/WJST^03&AW.CXQBI3V^J014O+_NHMGJW2,1U3+,NVT5L,?HJ
MPZ"XM]_T+;&NW,9L]-96/T/I.4]C,;(S3N:6[F[```:_>_<W>VQOKL_X:MBU
M?VK:2-EA<TQ!EC2X'O579M=9_P"!_P#!>HA6_6/`H(&1U.BASIAMMC*W>T['
M_H[-K_8]NSW*KCS0RSE'%EA.4/GC`B<HML2P0@.+E\ER^67%PQ_Q?_0FYG8O
MH5$@[MS7"`(`AI0NH=/QK,`'*L>RAY8][F-'M@^I+W.W-;4US?>]#^W5YV*;
MJ<AF506OV6UN:]A(!:Z'U_NI\CJ]&"*QE9M6*U\BH7/KKW!L;MGJ[=^S<U34
M=ANU@<?$?2:_1'4'_&<AW3.@"QX&7EO+-WZ-H:0=OLW-]GZ-OL_1;W556?3J
M]3]`MEG36XO27!KK"*JW@>L&AYG=+G^G#/<YWYC4-G7:;6@X^8S)W3'HNK?]
M$AKI>W]&S:Y[&^]Z9W4S?1;6ZT.#FO;[7->PN#2\LWL:US;&M_,M94H3GQQR
MC#/+`93MC^6:^@8&7MR('Z5>D'_&?__2O?6&OJ#KL/<WJ+\+T*_1'3=QAVS]
M8]?T/?Z_\WZ7K_HOYOTO^U:M_5#[=4+:;W9;:G1Z(SY9:ZYI<;W8==Q^U>BW
M']#U?\'ZO\U_VH6]C2,:B)_FF?\`4M396-1F8[\?*K%U-FCV.F#'N;JTAS7-
M=]%S59.>\(Q<$?[]>MSSDTX:^J=KK7;MCW.@P8+M"EOMDC>[30^X\KS3K)I?
MU[J8ZOU#)PFC)`Q@YMKFEA<=[V>QWZ"O'_FF,_G/4K]-;GU"-N_J+?M%^5BQ
MC^C9<'M8;7"QV2S'99[-S;?T;_2^G[%$84#J-/Q_N_\`=MG+R?MX?>]P2TB>
M'^_XO7$N,;G3\3*:#Y<I`<:)HTX36DX?UMZE;TGI#^H4L9;9198&LLG8=]F+
M4=VQS'?G_O+AG?XR^KM^ET[%'SN/Y+EV/U\Q,G,^K=^+B4OOR++';*:VESG;
M;<-[MK&_NM;N7F;?JU]:6N:X=(RSMX!I>1^3<A(S%<+:C&)`)`)J.YK]"+U/
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M;'.`<XN(#JL&W9OL+G^USUY+D_5;ZYY&\9&!D6CEH):0UWC7KY?F+U#'LOHP
M'NI.RYN1569;N&K.FTW,<W^KO]R:.*AQ``WT3(DXY`RL\.OKEDC?N8_WG3LQ
M&/GWEH+MP`#=#N]0;'.;N_G/<N?ZS]7NI7=2MR<&G!R*+VMW#)+F6-+65T>F
MYX#_`%6[:M]5O_I+]+VPP<:USWNW@EQT9;8T::?18]K&JK;B58V4!=9:<6Z2
M#ON.Q\TUUUNN99M;6_=8[]+_`)Z;RYCRN2>7#CA"60_K)#]+BZR70P9Y&A,2
MH'A$N+[(N%T#I65TW$R?M7HLMO:W]#CR:VBJLTM?O=M]6^[_``UFW_1JGU_Z
MO=6R^IG/P:L;+;:RMCF9)(-?I"QL4NA[?2N];U?^.789F+31@W[`XRV9>]SS
MX>UUKG[5Y%]>.L=1Q_K7F8V/F9=%5?H0RBUP`W4U/=Z=6]K/SMW\M68\SDCD
M.73C._;5CCCG[A!D+X>+;_!>W^KW0\["HR#F4X^+9=8',KQ!NB/5W.LLL#F/
M:[UWU54>G^@H_P`)_HM1V-Z3+["7.<ZMPEP`'T-O#&L_,K8Q>5=0ZIF5]'P,
MAF=F-RG"T6V-OO;7>[U/T+J=[][&55%WK,=Z/J^STUI_XN^K=1S>K9U.7D6W
MULZ?:]K+++'@.]2EN[;=99[O<Y5\D<>;/]XG",LVWN4../\`5XEV3'DC&5S/
M#\QCL'__T^WQC^K4:_X)G_4M4YTY[J&,3]FH_P"*9_U+423';E.<P[J#BW=M
M<1)DP3RF>QE@++`'L?&YKM0>/S3\$\G7A/)GLDJSW8?8>H86)[)RVT`PZRTN
MN<R?I/>ZIC7V,9_ZL1*Z;'XYR"^MU4!U;JG%X=K'=K5I-R:``-X^]5;F8#6V
M64-8VZP$.+1!=+@]V_;]-V[]Y,]5C6QV;LL6#@D?TQ9B0;OP(<C-YJ_KW_EQ
MUCY.`WU'/HQ6W&R7OW7/K!L)/NT?_5^C7[_4?[ZO\+L9W-7]>_\`+CJJYP8Q
MSSPT%QCF`-RGC\K5E?%&NL8_]%JWU#%Q6,Q0T/;9NK%KB6FPMLCU;+'>ILW_
M`,M#=;U&VJVJZK"V/KL9(R"=VYNU@V;6;=\[7_ID4=2Z?8`"^0^(:YA(GG;]
M%S=S4F9?37\;![2^'5Q#6C<YQ]FWZ*''&])1U\6<\OF$0)X,MQZ\$_-SJNBX
MME[_`+7C8PIL#M]C<NRRUSOHM]3U#[_6:/?[_P!#_P`*FRNE"V]X^RXF1C`@
M4E^78QX9MKK?NK]U+'O;4RMGI_Z)GJ>HM#[?TJ0V622`/T?B=O[GYOYR=V;T
MMK0XED%@L$5_FNG:[Z'MW;?SD../[T?M"?N^>_YG/_B38-MZ@RIC&588],;!
M7]H)&QK:FU?I7,#F[?T_^#M_F:O],BTFRS`<+GM9<_,`?Z+76M+PW!?LHVN:
M]ON9_/.^A7ZB.*Z2`16R"`1[&]]?!7.GM`#@P!HW/T`@:MQ?!&8-#S8A*(C,
M`&R!O_?B]%5P[^L[\JD]C+&.KL:'L<(<UPD$'LYI6<+\@\:`DR1N[\GZ2JUY
MG7?4:R[&J+"8LN9:X;06_3;0=_YWLV>M_P`(HZ9QS,-Q>C>R\3&Q\/)=0P5>
MHT;FL$-]OYVUOMW>Y>,_76EUWU\S6-#GF*';6`N<0W'I=%;&^Y[UZ_8^^ZMU
M3OHO&L3X1WE<YU3ZB]*ZIU2WJMUN71F7;`7X]C:]NQ@H::_T3WMW5-]_O2`H
M4%IYB)R\9)/IX;.^[YEDUUMZ;Z%=]MC:1=>UOM+=HLJP6O=M>YOHOV;=]?T_
M^#8MC_%A'[<ZA_Z;;?\`SY0NH=_BOZ%)>[)ZAO<-CGFZO<6D;/2<?L_\WL_,
M5_HWU/Z7]7_M%V#9>]]E-E;O7>QTAVU_^#JJ=[?1]G]M("E9.8A*)%DDBMG_
MU.R!8,-DW^A&,TEQV^P;1^L'Z-G\C^<V?]=0*G,+A8.J"RH/!B6P8#_8+#;M
M>Q_Y_P#.,_1*U6-N+6+:P6MI:+)=26[0T`R3=[JO^@J[_P!C^D?4KQO3+W3+
ML7;NAWJ?X;Z>S?O3FA[<_P!P_P"*QK>ZOTS=U>NSTPXV2VAOJ?1/NVO]C:O=
M_-?Z1*#766V=8,AT>JX4!WM'NJ=/LW_I*['^WU/^MIB>@[#->'LGN<2-T?\`
M'?3VHF0>E1^LUXVW<[^=.+&^#ZWT[OYS9N]5)7!/]P_XK"M_HW`W]6%C6>Y]
M+F5MEL.M'N;+FM],_29_@F+0@#MW50_LV'S71MVCU?=C1MAFS?\`I_H;/2V?
M];5LBWO6Z9U]U7_I=)!QS_</^*TLWFK^O?\`EQUFY]KJV,BT4[B=Q+=X(&V1
MMV6_O+>&%BWL!R[CCO;9:6`/KDAWI[]W\\W\QBA9TOH@CU<X=]N]]/\`:V[Z
MT>(<)&Q;&/$1DA.41*(`N)K]SAVG#)#_`)CRS[+&.-;\AA?6=8J9$#;K]#<Y
MGZ1OO<B-O8/3<^^IVAL+35!<PNV-W#T/T?OJL_X1=%^S/J[_`-S:_P#.Q_\`
MTDG_`&9]7O\`N<R>_OH_]))E5^E_TO\`OFV<D2`#C%]3'V87I4O\@\TRUQ)C
M)I.UN]P%$0T0USG#T-_O?[DSLAH8QGVFK=^>X4_2)+=-OH-]/]Q=+^S/J[_W
M-K_S\?\`]))_V9]7O^YK/\_'_P#225'][_I?]^GW(79Q[?[`?XW]&]3CX%CK
M*7;KA>6N@/`+8$`;#+6;O<UZT,;9Z5F_=LE^[9NW1MQ?H>C^FW?\7[U;KZ7T
M0@^EG:3[MCZ8F/SME?[J1IQ<6QK,>YUS7A[G._G"'?J[=OZ!GM]@:G\0X0.K
M1S8SQ9)@`1-4!5_-']R..'_-<WJ1Z+Z]GVWU:[A#;+*A:WAKGM/J4#9]"W\S
M_@ZT%[>@7UAH;?8^NMNUC&6-MV;RS=Z6RMME;;+7L^CZ;/["VA:8]I?':&6?
M^02-ON,E^Z/]'9,?]MH->].KE6#HC&GU3:T!C;S8\6.)#I8Q^[8][]K\]_Z"
MQOZ/U/YGTZ4PKZ3:*Z0<I];GFMIBP-8Z6MVOL]-MM/NL8SU/_17JK7%IG0V?
MYEG/^8F]4Z27_P"99_Y!)5GQ<ZK)Z1C?I&L?6ZMK:76%CRZ"'W?I=N]V[]!8
M^VVQO_5JS5EXV9B778SB^L->TDM<PSLW_1L:QWT7L5CU3V+_`"]EG_D%"^W]
M%;N+Y]-W++/W3XL25]"__]G_[2">4&AO=&]S:&]P(#,N,``X0DE-!`0`````
M``<<`@```@```#A"24T$)0``````$.CQ7/,OP1BAHGMGK<5DU;HX0DE-!"\`
M`````$I`=P$`2````$@``````````````-`"``!``@`````````````8`P``
M9`(````!P`,``+`$```!``\G`0!<`'``9P`T`&$`+@!J`#A"24T#[0``````
M$`!(`````0`!`$@````!``$X0DE-!"8```````X`````````````/X```#A"
M24T$#0``````!````!XX0DE-!!D```````0````>.$))30/S```````)````
M```````!`#A"24T$"@```````0``.$))32<0```````*``$``````````CA"
M24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@``````
M`0`R`````0!:````!@```````0`U`````0`M````!@```````3A"24T#^```
M````<```_____________________________P/H`````/______________
M______________\#Z`````#_____________________________`^@`````
M_____________________________P/H```X0DE-!`@``````!`````!```"
M0````D``````.$))300>```````$`````#A"24T$&@`````#/0````8`````
M`````````7D```)X````!`!P`&<`-`!A`````0``````````````````````
M```!``````````````)X```!>0`````````````````````!````````````
M`````````````!`````!````````;G5L;`````(````&8F]U;F1S3V)J8P``
M``$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`
M`````````$)T;VUL;VYG```!>0````!29VAT;&]N9P```G@````&<VQI8V5S
M5FQ,<P````%/8FIC`````0``````!7-L:6-E````$@````=S;&EC94E$;&]N
M9P`````````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L
M:6-E3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N=6T````*15-L
M:6-E5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````````4F-T,0``
M``0`````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N
M9P```7D`````4F=H=&QO;F<```)X`````W5R;%1%6%0````!````````;G5L
M;%1%6%0````!````````37-G951%6%0````!```````&86QT5&%G5$585```
M``$```````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585```
M``$```````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D
M969A=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````
M!V1E9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4
M>7!E`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E
M=&QO;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T
M<V5T;&]N9P``````.$))300H```````,`````3_P````````.$))3001````
M```!`0`X0DE-!!0```````0````!.$))300,`````!IZ`````0```*````!?
M```!X```LB```!I>`!@``?_8_^``$$I&248``0(``$@`2```_^T`#$%D;V)E
M7T--``+_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,
M#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!?`*`#`2(``A$!`Q$!_]T`!``*
M_\0!/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0``
M```````!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!
M46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%
MPJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V
M-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3
M!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%
M539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G
M=X>7I[?'_]H`#`,!``(1`Q$`/P#U"^[TFB&E[WG:Q@[N.O/YOM;N<JN;;DT5
M-LM<?>\,V5^UC9U_2W[+;>WIL?6ROU+?2KV?I%:OJ-K1M=LL8=U;N8,;?<W\
MYCFNV/0,EV2_'LI>UU+WM+1?3[P//:W9D?\`;?\`UN__``B2G/'5\#TS8[$S
M7,&X#U*WNG:=KMC;7N=_*_XO]-_-49'HS?U3`8^MAZ=?NM:',`H$Z[S#OW-K
M6>[?_I?W_5],;<;,:0/VR^EFNZM];002?S'YF^[8W_A/42=1EN<7CKP:_;M;
M#:MO,N<ZO=LW.:DIC7USIMH8ZG%S#59HVVEC]AX^BZA^VRO7^=9^B6EBNR+<
M6K)I<X"UC7BC(`D!PW>GZE7N:[^7^L+.=5U4/_0]8%K2T`-;2QQ!!:'NBEMF
M_<WU';/9_@UK&^Y^E%1'A9;[6_YG\]_9V5_\8DIB>I8E;0<FQN.\DM++'`&6
MQN_K?29_GIOVOTR)^U50?Y067UJHTV8TN+WO%KK'\22:.WYK6M&QBQ+L/)LN
M?;7F64AYDM8(,;=C6.L]3W-9].M/C"Q;!DSF,S&AH]>.K=,)@951/]8)OVOT
MO_N55_GA<@W"R=KVVYC[VO+3%@<0W:YMGL;ZWY[F>]"?@Y30&V]7L;+>'NVE
MVI][MU[?ZK=G_31]M9]Y\!^+VO[7Z6>,JK_.";]K]+_[E5?YX7&OZ?E6UECN
MHVN8\AS'MF=NU]1:VSUG->Q_JN_\#_T:?[!FR#^T;MVDG62`=VUWZ7_I-2]M
M7WGP'XO8_M?I?_<JK_/"-5F8MU3[J;665UR'O:00"!O.Z/Y)7%X^)E56M?9F
MVW-$_HW2`9&W7](YOTOTGT5T?06MLQ<ECQN:ZW:X'N#52$)0H6OQYS.7#0VM
MO-.5>-T_9JS]%L`V1XNWS75_Q>RQ9UE^:RXU_8KLDFQS`?4<UK6CZ%EKW.]!
M_K?SGZ"O]%_,_P`[6BYW2[,AU+K7VO.-N]"ZES6V`NV^ZQEGZ.Q[?3_G-W_6
M56;TJFL&.I9M3R6;GW.<-VS9]-Q95O<]C-CO<F,Z1N7DN]3;T9PV,+VFPL&Y
MT>VK\]V_=[+-N_\`POI>O7]G^TC=U&_<QK>C7-=87;`UP88:=OJ/<S:RIGN9
M_.6>M_P7\[Z<F=-Z>P@#JV3Z88&-K&2`!KN-FYFU^]W]?\__`(KTT>G8QW1U
MC*(<YKH%X)`:-NQFQN[8[\_^7_USU$I+@Y'4+[A6[%OPF['.<^UXM;N:6!K/
M<'/V/WV?X6A_Z/\`[:T*[K!9Z-X`>02Q[?HN`^ES_-O_`.#_`/!+/TGIY+NE
M%[;&UYG4'&X[K'-<*]9W$M-S*V-8[_@_\'_T]#`P;,9C1=:ZXLW^F'N+RT/=
MO@V.#76;?YNMVWV5?HTE/__0]53.<UHEQ`'B=.4#]H8'_<FK_/;_`'J%V3TN
M^IU-]M%M3Q#ZWN8YI'@YKO:Y)5M?ZPY-E'1\BS'M-=K=FUS#[A+V-,?V2LWH
M^%D]1Z=5EW=5S*[+"\%E=E8:-KWUMC?2]WT6?O(?4/JYT&Z;,')IQ+>0W<UU
M?^;NWU?]:L]/_@E#!^J_U>K(LZADTYEO)9N:VK_-W>I;_P!=L]-_^A1Z-(CF
M)<S9QCVN#ATS>CBXKX^'@XN/_`_ZHZ7_`#?M>);UKJ,>+;*>W_H,F/U:R#_W
MN=3'_7*/_>1:%&3TK'J;3CVX]-3!#*ZW,:UH\&L;[6J?V_`_[DU?Y[?[T&V(
MQ'^^\]G=+MZ??4;,_*S_`%6/`&4ZMP9M-7NJ]&FCW/W>[<@+3Z[;5;9BOJ>V
MQFVT;FD$2#3W:L.W"ML>YPS+JFN+B&UP(+G;^?W6?04T/E#3S@>X?HVH/@=>
M%R_6.DN/4+<C)P&YS,JW;3D'(949MAF-AM9>]OZ:G9Z=+&?HK/\`KMWI[%V%
MBAY:_/MHW[2^OUFMD-@5'WEK]K=G_7$'/>S-KIJMM:Q^-EU97J8]F.6/]%Q?
M7#<N^NRO>UWO;L_1W?HZ_M-/TYL6:>*7%#>JZ_\`<<*R$Q$V"/&TW0\&W!P!
M393]FEVYN-O]39HUCSO'Z-K[[&.O?51^A9ZG^D]1:$%9Q^S7VVW.SGXXL=/V
M=M];```UKO=5;=NW_OM>Q%IPZBQA;EW9#&V"PGU`X.+-FVIY8-OI5NK_`)M,
ME(RD9'>1)/U02"2;%GLW%K]#8;,/+K#G5EUA;O;&YLU5#<S<'-W-7-GIAVQ]
MLRBXMV%S["Z02-TM]C?<S]'_`.I%T'1,JG&Q[&6%Q<ZSV[6.=(;70TN_1M=M
M4<_E9<%"=WT*P^K.2`!^W>J&/&RC_P!Y%,?5R\?][74C\;*?_>57_P!J88(!
M+P3]$&MX)_JC9[D_[1QO"W_MJS_R"BHMJ\9_2'^,T!T-XD?MG/,&#-E7/_L.
ML_IN1F4_6>W`?F79&/4UP'K.!GV56^[8UC-S7/5SJG3_`*N=2+K<K'<+XDY+
M*7MLT$>YXK_2[?W+?48L=GU7PA=M=E6'%_-:,9XL[^V7,=1N_E^C_P!:1#4Y
M@Y!+&<(C("8E(^]P7&CZ91E^C_CO9[V2!N$G@3S"DL?I^-T+IWNQ<9S+8@W&
MFPV$'EOJN9OV_P#!_P`VKKNIXC02[U`&B2359H!_80HMN.04.(Q!["7$/\;T
M/__1Z9E?6JZO5;E4LQO3#F->V?38&FQO^".[:UWN]W\W5_I/TJJMZGF;S/4:
M![I?6YCI:(VMV_JHV,_.]2SZ?LL_1K;QV!^+2TC>TU,#FD2""QNC@I58.&ZU
ME9HK:'&/YMH,:_R4YS@035#4UT<.OJV;LLKLS<7UB(K=LL`W-=^E>UGV;]*S
M9]+_`(3U/TB([J.0X67TYU#:&AA>]Q<^&ENUKMOV9M3-[V7/WL9^_P#]QULY
MF#AXKPQF`;6.!(<QC"-!]#;74]S?[7^#]3_">E1<&C&PK+*ZJ^EOK+YWE]36
M-:6N,.W&G9MV_I:_\)^EK_1_S_HN$)$76GFS>Q+]T.19U'J%!-5G4,=MP(!#
MJW2T.)UV_9_;^Y_P7\W9OL1,?J&?>WTJ<W'LNL(;02QT2"USG.'H,W^I7_+_
M`,)5_P!<V\OIN!2]C116=P))<QA/A^[_`"D)N/BL<'LJK8\<.:QH/^<T?RDU
MBE428D"QY-3*#@R@/.YX==O=XN_5]QT#/^I0%9S>:OZ]_P"7'5920V1DW']V
M/_1:&972_)!LH;8=T%[@QWMKJ=>[Z7NV^^K_`,%_X-5335`J^QL$FMA.VJ0;
M;`\L]3\ZWTJ7UU^G]#^I8BV/IR^JVX=&5?ZE0G(%0::Z7[16VFYSO<VW(97[
M?^+_`,&EG46=/Z?D9OVR]XPV.RA7[&[GUMAGO+'[?]']!_\`Q:CRQ,X^D`RA
M+B'$:CQQ_N+H^B0XH$<<16D?5&6TAQ(_2QW,:3B5N`VGV-J$@#<[P;^DW;O_
M``-ZO4V8V'C#U2VBH6.:(&DCZ?\`-C]YK_["#7TQSL>LUY=[FFMKZZV^G^<T
MV-K8]VUG^%>W>Y_YZ)T?.IR\)KZ++"^HNKR*[AMNJMW.-F/DU@-V6,<I(@1`
M`%4*'T62())X:U_JC?\`NL6=3I#W^O?0VMH,%@MW3]+W;Z]NUK%L]/&YT>+W
M"?B,55MS_$_>K/3Y!,:'<Z/C&*E/;ZI!%2\O^ZBV>K=(Q'5,LR[;16PQ^BK#
MH+BWW_0ML:[<QFSTUE8_0^DY3V,QLC-.YI;N;L``!K][]S=[;&^NS_AJV+5_
M:MI(V6%S3$&6-+@>]5=FUUG_`('_`,%ZB%;]8\"@@9'4Z*'.F&VV,K=[3L?^
MCLVO]CV[/<JN/-#+.4<66$Y0^>,")RBVQ+!"`XN7R7+Y9<7#'_%_]";F=B^A
M42#NW-<(`@"&E"ZAT_&LP`<JQ[*'ECWN8T>V#ZDO<[<UM37-][T/[=7G8INI
MR&95!:_9;6YKV$@%KH?7^ZGR.KT8(K&5FU8K7R*A<^NO<&QNV>KMW[-S5-1V
M&[6!Q\1])K]$=0?\9R'=,Z`+'@9>6\LW?HVAI!V^S<WV?HV^S]%O=559].KU
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MPWNVL;^ZUNY>9M^K7UI:YKATC+.W@&EY'Y-R$C,5PMJ,8D`D`FH[FOT(O4]*
M^MV5U+#ZKDNP\?&?AU?:B:/48;GAMGMR;&V>K8W]&S\_U%G/^NG5'X[?M/3L
M?T,EI@7/RBQ[>'#:Z]U=C?Y*?H'1.L8O3^MUY.#D469>-Z>.RVMP+["+OT56
M[^<>@V=+Z\[I-.`>DYTU["2:3M;#7-?MG=^<Y1Y)9/3PQXK/JT^6*9SE`0&.
MZ,O5PR,>&/[SK_5;ZT9/6>K?L[(Q68];:7V`U6Y`(V`;&MWY#F;/["G]9?K.
M.@=5^Q4X3;?6K9D/M-]U;G.?["ZSTW_I'^S9ZC_>J/U(Z-U3$Z\W+OP;\;&?
MCVM;;8TBL[@/2V6?1]WYJE]=_J]U?JG6CEX-7JU444UDAS9WG?[-N[<WW*7]
M"^'6^RO</N4<DA'A_?G\W^,@N_QAY5#MMO2MCB)&[)R-1_VXO1NBN)K>03!L
M<X!SBX@.JP;=F^PN?[7/7DN3]5OKGD;QD8&1:.6@EI#7>->OE^8O4,>R^C`>
MZD[+FY%59ENX:LZ;3<QS?ZN_W)HXJ'$`#?1,B3CD#*SPZ^N62-^YC_>=.S$8
M^?>6@NW``-T.[U!L<YN[^<]RY_K/U>ZE=U*W)P:<'(HO:W<,DN98TM971Z;G
M@/\`5;MJWU6_^DOTO;#!QK7/>[>"7'1EMC1II]%CVL:JMN)5C90%UEIQ;I(.
M^X['S3776ZYEFUM;]UCOTO\`GIO+F/*Y)Y<..$)9#^LD/TN+K)=#!GD:$Q*@
M>$2XOLBX70.E973<3)^U>BRV]K?T./)K:*JS2U^]VWU;[O\`#6;?]&J?7_J]
MU;+ZF<_!JQLMMK*V.9DD@U^D+&Q2Z'M]*[UO5_XY=AF8M-&#?L#C+9E[W//A
M[76N?M7D7UXZQU''^M>9C8^9ET55^A#*+7`#=34]WIU;VL_.W?RU9CS.2.0Y
M=.,[]M6...?N$&0OAXMO\%[?ZO=#SL*C(.93CXMEU@<RO$&Z(]7<ZRRP.8]K
MO7?551Z?Z"C_``G^BU'8WI,OL)<YSJW"7``?0V\,:S\RMC%Y5U#JF97T?`R&
M9V8W*<+1;8V^]M=[O4_0NIWOWL9547>LQWH^K[/36G_B[ZMU'-ZMG4Y>1;?6
MSI]KVLLLL>`[U*6[MMUEGN]SE7R1QYL_WB<(RS;>Y0XX_P!7B79,>2,97,\/
MS&.P?__3[?&/ZM1K_@F?]2U3G3GNH8Q/V:C_`(IG_4M1),=N4YS#NH.+=VUQ
M$F3!/*9[&6`LL`>Q\;FNU!X_-/P3R=>$\F>R2K/=A]AZAA8GLG+;0##K+2ZY
MS)^D][JF-?8QG_JQ$KIL?CG(+ZW50'5NJ<7AVL=VM6DW)H``WC[U5N9@-;99
M0UC;K`0XM$%TN#W;]OTW;OWDSU6-;'9NRQ8."1_3%F)!N_`AR,WFK^O?^7'6
M/DX#?4<^C%;<;)>_=<^L&PD^[1_]7Z-?O]1_OJ_PNQG<U?U[_P`N.JKG!C'/
M/#07&.8`W*>/RM65\4:ZQC_T6K?4,7%8S%#0]MFZL6N):;"VR/5LL=ZFS?\`
MRT-UO4;:K:KJL+8^NQDC()W;F[6#9M9MWSM?^F11U+I]@`+Y#XAKF$B>=OT7
M-W-29E]-?QL'M+X=7$-:-SG'V;?HH<<;TE'7Q9SR^81`G@RW'KP3\W.JZ+BV
M7O\`M>-C"FP.WV-R[++7.^BWU/4/O]9H]_O_`$/_``J;*Z4+;WC[+B9&,"!2
M7Y=C'AFVNM^ZOW4L>]M3*V>G_HF>IZBT/M_2I#99)(`_1^)V_N?F_G)W9O2V
MM#B606"P17^:Z=KOH>W=M_.0XX_O1^T)^[Y[_F<_^)-@VWJ#*F,95ACTQL%?
MV@D;&MJ;5^E<P.;M_3_X.W^9J_TR+2;+,!PN>UES\P!_HM=:TO#<%^RC:YKV
M^YG\\[Z%?J(XKI(!%;((!'L;WU\%<Z>T`.#`&C<_0"!JW%\$9@T/-B$HB,P`
M;(&_]^+T57#OZSORJ3V,L8ZNQH>QPAS7"00>SFE9POR#QH"3)&[OR?I*K7F=
M=]1K+L:HL)BRYEKAM!;]-M!W_G>S9ZW_``BCIG',PW%Z-[+Q,;'P\EU#!5ZC
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M[(%@PV3?Z$8S27';[!M'ZP?HV?R/YS9_UU`J<PN%@ZH+*@\&);!@/]@L-NU[
M'_G_`,XS]$K58VXM8MK!:VEHLEU);M#0#)-WNJ_Z"KO_`&/Z1]2O&],O=,NQ
M=NZ'>I_AOI[-^].:'MS_`'#_`(K&M[J_3-W5Z[/3#C9+:&^I]$^[:_V-J]W\
MU_I$H-=9;9U@R'1ZKA0'>T>ZIT^S?^DKL?[?4_ZVF)Z#L,UX>R>YQ(W1_P`=
M]/:B9!Z5'ZS7C;=SOYTXL;X/K?3N_G-F[U4E<$_W#_BL*W^C<#?U86-9[GTN
M96V6PZT>YLN:WTS])G^"8M"`.W=5#^S8?-=&W:/5]V-&V&;-_P"G^AL]+9_U
MM6R+>];IG7W5?^ETD''/]P_XK2S>:OZ]_P"7'6;GVNK8R+13N)W$MW@@;9&W
M9;^\MX86+>P'+N..]MEI8`^N2'>GOW?SS?S&*%G2^B"/5SAWV[WT_P!K;OK1
MXAPD;%L8\1&2$Y1$H@"XFOW.':<,D/\`F/+/LL8XUOR&%]9UBID0-NOT-SF?
MI&^]R(V]@]-S[ZG:&PM-4%S"[8W</0_1^^JS_A%T7[,^KO\`W-K_`,['_P#2
M2?\`9GU>_P"YS)[^^C_TDF57Z7_2_P"^;9R1(`.,7U,?9A>E2_R#S3+7$F,F
MD[6[W`41#1#7.</0W^]_N3.R&AC&?::MWY[A3](DMTV^@WT_W%TO[,^KO_<V
MO_/Q_P#TDG_9GU>_[FL_S\?_`-))4?WO^E_WZ?<A=G'M_L!_C?T;U./@6.LI
M=NN%Y:Z`\`M@0!L,M9N]S7K0QMGI6;]VR7[MF[=&W%^AZ/Z;=_Q?O5NOI?1"
M#Z6=I/NV/IB8_.V5_NI&G%Q;&LQ[G7->'N<[^<(=^KMV_H&>WV!J?Q#A`ZM'
M-C/%DF`!$U0%7\T?W(XX?\US>I'HOKV?;?5KN$-LLJ%K>&N>T^I0-GT+?S/^
M#K07MZ!?6&AM]CZZV[6,98VW9O+-WI;*VV5MLM>SZ/IL_L+:%ICVE\=H99_Y
M!(V^XR7[H_T=DQ_VV@U[TZN58.B,:?5-K0&-O-CQ8XD.EC'[MCWOVOSW_H+&
M_H_4_F?3I3"OI-HKI!RGUN>:VF+`UCI:W:^STVVT^ZQC/4_]%>JM<6F=#9_F
M6<_YB;U3I)?_`)EG_D$E6?%SJLGI&-^D:Q];JVMI=86/+H(?=^EV[W;OT%C[
M;;&_]6K-67C9F)==C.+ZPU[22US#.S?]&QK'?1>Q6/5/8O\`+V6?^04+[?T5
MNXOGTW<LL_=/BQ)7T+__V3A"24T$(0``````50````$!````#P!!`&0`;P!B
M`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`
M=`!O`',`:`!O`'``(`!#`%,`,P````$`.$))300&```````'``0````!`0#_
MX0Z7:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G
M:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\>#IX
M;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B
M92!835`@0V]R92`T+C$M8S`S-B`T-BXR-S8W,C`L($UO;B!&96(@,3D@,C`P
M-R`R,CHT,#HP."`@("`@("`@(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P
M.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&%P/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN
M;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W`O,2XP+R(@>&UL;G,Z>&%P34T](FAT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G1I9F8](FAT
M='`Z+R]N<RYA9&]B92YC;VTO=&EF9B\Q+C`O(B!X;6QN<SIE>&EF/2)H='1P
M.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(@>&%P.D-R96%T941A=&4](C(P
M,3$M,#@M,3%4,34Z,CDZ,#$K,#4Z,S`B('AA<#I-;V1I9GE$871E/2(R,#$Q
M+3`X+3$Q5#$U.C,T.C$T*S`U.C,P(B!X87`Z365T861A=&%$871E/2(R,#$Q
M+3`X+3$Q5#$U.C,T.C$T*S`U.C,P(B!X87`Z0W)E871O<E1O;VP](D%D;V)E
M(%!H;W1O<VAO<"!#4S,@5VEN9&]W<R(@9&,Z9F]R;6%T/2)I;6%G92]J<&5G
M(B!P:&]T;W-H;W`Z0V]L;W)-;V1E/2(S(B!P:&]T;W-H;W`Z2&ES=&]R>3TB
M(B!X87!-33I);G-T86YC94E$/2)U=6ED.C(X,C-#,C,V,#%#-$4P,3%!0S@R
M13%$0D0V13-!0D4P(B!T:69F.D]R:65N=&%T:6]N/2(Q(B!T:69F.EA297-O
M;'5T:6]N/2(W,C`P,#`O,3`P,#`B('1I9F8Z65)E<V]L=71I;VX](C<R,#`P
M,"\Q,#`P,"(@=&EF9CI297-O;'5T:6]N56YI=#TB,B(@=&EF9CI.871I=F5$
M:6=E<W0](C(U-BPR-3<L,C4X+#(U.2PR-C(L,C<T+#(W-RPR.#0L-3,P+#4S
M,2PR.#(L,C@S+#(Y-BPS,#$L,S$X+#,Q.2PU,CDL-3,R+#,P-BPR-S`L,C<Q
M+#(W,BPS,#4L,S$U+#,S-#,R.SE!-T(T,#1#-C)#,T0V1#<T,S9%03(X1C@R
M-S@P-#4S(B!E>&EF.E!I>&5L6$1I;65N<VEO;CTB-C,R(B!E>&EF.E!I>&5L
M641I;65N<VEO;CTB,S<W(B!E>&EF.D-O;&]R4W!A8V4](BTQ(B!E>&EF.DYA
M=&EV941I9V5S=#TB,S8X-C0L-#`Y-C`L-#`Y-C$L,S<Q,C$L,S<Q,C(L-#`Y
M-C(L-#`Y-C,L,S<U,3`L-#`Y-C0L,S8X-C<L,S8X-C@L,S,T,S0L,S,T,S<L
M,S0X-3`L,S0X-3(L,S0X-34L,S0X-38L,S<S-S<L,S<S-S@L,S<S-SDL,S<S
M.#`L,S<S.#$L,S<S.#(L,S<S.#,L,S<S.#0L,S<S.#4L,S<S.#8L,S<S.38L
M-#$T.#,L-#$T.#0L-#$T.#8L-#$T.#<L-#$T.#@L-#$T.3(L-#$T.3,L-#$T
M.34L-#$W,C@L-#$W,CDL-#$W,S`L-#$Y.#4L-#$Y.#8L-#$Y.#<L-#$Y.#@L
M-#$Y.#DL-#$Y.3`L-#$Y.3$L-#$Y.3(L-#$Y.3,L-#$Y.30L-#$Y.34L-#$Y
M.38L-#(P,38L,"PR+#0L-2PV+#<L."PY+#$P+#$Q+#$R+#$S+#$T+#$U+#$V
M+#$W+#$X+#(P+#(R+#(S+#(T+#(U+#(V+#(W+#(X+#,P.S$R044W.4(U03!&
M,D8T,4(V-S)",S,R.3(V,D8Q1$$Y(B\^(#PO<F1F.E)$1CX@/"]X.GAM<&UE
M=&$^("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@/#]X<&%C:V5T(&5N9#TB=R(_
M/O_N``Y!9&]B90!D``````'_VP"$``8$!`0%!`8%!08)!@4&"0L(!@8("PP*
M"@L*"@P0#`P,#`P,$`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!!P<'
M#0P-&!`0&!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#/_``!$(`7D">`,!$0`"$0$#$0'_W0`$`$__Q`&B
M````!P$!`0$!```````````$!0,"!@$`!P@)"@L!``("`P$!`0$!````````
M``$``@,$!08'"`D*"Q```@$#`P($`@8'`P0"!@)S`0(#$00`!2$2,4%1!A-A
M(G&!%#*1H0<5L4(CP5+1X3,68O`D<H+Q)4,T4Y*BLF-SPC5$)Y.CLS875&1T
MP]+B"":#"0H8&82414:DM%;352@:\N/SQ-3D]&5UA96EM<75Y?5F=H:6IK;&
MUN;V-T=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@I.4E9:7F)F:FYR=GI^2HZ
M2EIJ>HJ:JKK*VNKZ$0`"`@$"`P4%!`4&!`@#`VT!``(1`P0A$C%!!5$382(&
M<8&1,J&Q\!3!T>$C0A528G+Q,R0T0X(6DE,EHF.RP@=STC7B1(,75),("0H8
M&28V11HG9'15-_*CL\,H*=/C\X24I+3$U.3T976%E:6UQ=7E]4969G:&EJ:V
MQM;F]D=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*
M6FIZBIJJNLK:ZOK_V@`,`P$``A$#$0`_`/5.*NQ5V*NQ5V*NQ5V*I-J7G+RK
MILI@O-5MH[D;?55D$D]?:%.4I_X#%4+_`(T6=N.G:)JM^#]EQ:_54/\`LKUK
M7%7+JWGBXKZ'E^VM1V:]OP&^E;>&X'_)3%7+%^8DI^.ZTBT![+!<W)'TF:V_
MXCBK1T7SM(?WGF6*,>%OI\:_\G99L57+Y<\R'[?FN]_V%M8+_P`2MWQ5=_AC
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M_P`Q)J>G9Z39`_[\N+BZ8?,+#;C_`(?%6SI_GV5?CUK3[<^$.GRM_P`-)=-_
MQ'%5H\O^;6-9?-,P]H;.T7_B:2XJO_PWKQ^WYKU'WXPZ<O\`V*G%6_\`#&L#
M=?-6J5[533B/N^J8JM;RYYB'V/-=]_L[?3V_5;+BJT:)YT0_N_,RO[3V$3?\
MFGAQ5MK?\PXO[N_TFZ`[/:7%N3_LEN)A_P`)BKCJ7GR!1ZVAV5WXFTOV5OH2
M>WC7_DKBKCYPN("!J/E[5;3Q=(8[Q!_TAR7#_P#)/%5:S\]^4+J80)JL$-R3
M06MT3:S5\/2G$<G_``N*IZ""`0:@]#BKL5=BKL5=BKL5?__0]4XJ[%78J[%4
MIUGS3HND2);W,QDOYARM].MD:>ZD'BD,8:3C_P`6$>FO[3XJE_UKSUJG^\MK
M;^7[5NDUZ?K=X1X^A"RP1G_6N9O\J+%6_P#`MC=?%KE]>ZVQIRCNIC';U'_+
MM;B&W(_XR1OBJ=:=I&DZ9%Z.FV4%E%WCMXDB7[D`Q5%XJ[%78J[%78J[%78J
M[%78J[%78J[%4DU#R3Y4OYOK$^F0I=UK]<MP;:XK[3P&.7_A\50I\N>9+#XM
M%UZ65!6EEJR"\C^0G4Q72_ZTDL_^IBK1\WWFF;>9M+DTZ(==3MB;RQ^;R(JS
M0#_*G@CC7_?N*LAM;JUN[>.YM9DN+>4<HIHF#HRGNK*2",55<5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BJG<W-O:P27%S*D%O$I>6:1@B*HZEF:@`Q5CH\XW&I'CY8TR754/34
M9C]4L/"JS.K23C_*MH)D_P`O%6_\/^:-0WUC77MXVZV6D1BV3Y-<2>M<-_K1
M-;?ZN*HBR\C^5+2?ZRFFQ3W=:_7+OE=7%?'UK@RR_P##XJA+_P#,_P#+S3M8
M_0M[Y@L;?4E<1/;O*H].1OLI(WV(W/9'96Q5E&*NQ5V*NQ5V*J5U=VMI;R7-
MU,EO;Q#E+-*P1%'BS-0#%57%78J[%78JI07=K<&46\R3&"0Q3"-@W"10"4:G
MV7`(^$XJMO+&RO8#!>V\5S`WVHID61#\U8$8JQA?*OE%-4FT[1;N71=5@CCN
MIK;3+AH0D4K,L<C6IYVI5VC<#E!^SBJ(*>?=+W22U\Q6R]4<?4;RE>S+SM96
M_P!A:K_E8JBM,\XZ1>WBZ=.)=,U9JE=-OT]&9J=3$:F*X4?S6\DJXJGF*NQ5
MV*O_T?5.*NQ5V*L3;5=7\T320>7YS8:#&QBN->"AI9V4T=+!7#)Q4CBUY(KQ
M\OA@CE_O453K1?+NCZ+$Z:?;A))CRN;ERTD\S_SS3.6EE;_*=VQ5,L58M^8O
MF?4=`T2V_121R:SJ]];:3I?K@F%)[M^/JRA2&9(8Q)*5!^/APQ5!:?H7YE:3
MK.GS/YB'F+2YW,>L6MY;V]JT*E"5GM&MD4_"X56@F]7DC?WG)<5:'YKZ8+VS
M6;1]4@TG4+Y=+L]<FAC2UDN7D,48X&3ZTL<D@X1S/;K&W^K\6*J$?YR:$]UQ
M&EZFNF)JC:)<:RT,8M(KT7'U948^KZI1YN*B6.)XUYIZC(W)5515U^:>DP:C
M=01:9J-WIEA>+IVH:W;P*]I!=%E1D(YBXD$3LJ320P21Q-]IOA;BJMO/S7T6
MUN+ISI^H2Z'871L;_P`Q1Q(;&&=7].0,3(+AHX9/W<TT<#PQ/RY/\+\54=I'
MG^RU?S/J&@6.FW[_`**F>UU#4S'&MG%.D:R"/F9/49G1U*\(V_R^'PXJ@=;\
M\:GI_P"9VB>6$T^:32[[3KR\NKQ%C(5H)(55N32*PCB#MZW[MGY2P>GR^/BJ
M[3?S4T^[U+2;6?1M4TZTUZ1HM&U*\ACCAN)%C:4+P$K7$)DCC=XOK$$7/%4-
M#^<VAS6MS>1:3JC6D=T=.LYA#%_IE^L[6YM;5?5Y/)R1FYLJ0K&KLTOP/Q55
MH/S=\OF/7!?V.H:;>>7_`*HM_87$*M.TU^S+;0P"%Y5N))F7BGIMP;FOQ_;X
M*H/S%^;$UEY9\R31:+?:?YDT?3)-2M]+OXX29(:%5N%:&9XI(8I*?656;U8_
MY/B3DJC(/S.K;:?!'H6J:CK4MA%J&H:?:1VYDM8I*JK3%YTA#3,DAAACEDF=
M5^QBJH_YKZ%,MA^A;*_UZ:_M#J)M["%?4@M`YC,DPG>'@_JI)$(!RG:2.1%C
M^#%5;\I?,FH^9OR^TO7-0E]>ZO3<,TO`1U1+J5(_@4*%(C5!TQ5E^*NQ5C5[
MY/-K<2:CY7G72-1<EY[?B6L+ICN?K%N"`KM_RT0>G/\`S^JO[O%49Y>\R+JC
M7%G=6[:?K5CQ%_ITC!B@>O"2)P`)K>2C>E,H_P`AUCE1XT53G%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78JD_F#S''I7H6T%NU_K%Z673]-B(5Y"M.3NQVB@CJ/5F;X4^%5YRO'&ZJ!M
M/)[WL\>H>:IUU:^0AX;(`C3[9AT]&!O[UU_Y:+CG+_OOT%_=XJR;%78JA]1^
MM_H^Z^IT^M^C)]7KT]3B>'_#8J\Y_+6+R>_Y$V/Z46!M(ETUW\RF?H;CB3J!
MN"?B]7UO5]3E\?+%4GU[7&U&>*S\JW^O2:;8:-:7-K8Z0+>R6T2>-W@GOKO4
MG5W:2%%X6_'X$C=YE=I,50_E+6O-_G>]\JVEYY@O-,@U#RFNJ:BVG"&*2:[^
MLI$)`[QR>EU+-Z:_Y/V,57^4/,?FKSC_`(6T'4-;N=/6;2K^^O\`4++TH+J]
MFLK\6,:ARC+&%3]_.(E7D[)_NO%5.[\P>;+WS#:^4K75M2U^WT[3YKFYU/07
MT^SNKF=;Z2U"S/<NJ?Z(L8CG%M_>7#<Y51/W>*K]/U;SSY@O?)VAW^MW.E->
M?IV/4[FPDLFN9TTV6%+8O)"+FWBN!RI<K%^WZJ?!R^%5%?G)K=_K7Y<>9M.E
MTC6-&CLDC==1G%JD-SZ=U''P4I+.Y$E?4^*./X?Y?LXJH>>M4UR*]URSTG6/
M,%[)Y;T^(L^G_4;6WM)UMS.9;^YNBGUN65>$KQQ1>G'%\/I\WQ54TG7_`#9Y
MCU[0Y9=7N[>VC\H:?YBN=/L!%&+N^DE<LCEXW80R!>#Q)PY?#\7PXJA=/U?S
M2EA^7'F5O-=U=3>;]1M1JVF-Z'U4I<6TL[16Z",20I;LJQ-\?Q_[M^/%4!HG
MG'\Q;_2]-\XH-366^OXUEAN+G2H=$^K27GU=K58GE6Z21(_@CD;_`$I[I?B7
M@WIXJA[*^\P>7K/6;32;W4;F;7_/-UI4TL;VOUB.-8GF8VS7`BMX[FYX+#ZD
MS<?]]IZG'%4UD\T>?--2\T&6YO;"WN]0T:RM=0U.;3[G4[&/4II([@M]6>9.
M)$2_4Y;E/[R5O[STUQ5/_)&ESZ7^<GF>REU6XU<1Z+I9BFO&1YXT:>Z/I.Z*
MG/XN3JSCGPD5<5>I8JA-5TC2]6LVLM3M8[NU?<Q2J&`(Z,*_99?V77XE_9Q5
MCDHUSRD#,LD^M>64WFBDY3:A9)_.C[O>0)^TC\KM%^)'N/[O%64VEW:WEK#=
MVLJ3VTZ+)#-&0R.C"JLK#8J1BJKBK__2]4XJ[%6-^=6ENX].\OPR-%^G+DV]
MU*A*NMI%&TUP$8;JTJ1_5^7[/K<L59!;V\%M!';V\:PP0JL<,2`*B(HHJJ!L
M%4"@&*JF*NQ5CGGWRI-YET-+:TN19:K8W4&HZ3>.O-([NTD$D1=`1RC>ACD'
M^^W;%4GMK3\U]8U?2SK1L-`TG3IA<WPTNZFNIK]T4A8?WD,"P6I8\Y5/JR/Q
M5/A^UBK!Q^3OG2YN-)FOX;"XU;2]7MM2O/,=Q?7ES<7L4%T)2L5O)'Z5C^ZV
MX(SQ_!Z2?`WJ*JRF3\M]=;R3=:&LUO\`6YO,AUI'+/Z?U<ZR-0XD\:^IZ(X\
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M(!9V\'FBW'&]T-O5E9=C+8NP%W`WBIC_`'R?RS0Q-BJ-\YZW<Z%Y7U'5K6-)
MKBTBYQ1RU"%B0HY<=Z;]L0B1H6PL^>?S`!(X:1L?Y+K_`)KR_P`#S=?_`"@/
MYK7^.OS`_P!]Z1_P%U_S7CX'FO\`*`_FN_QU^8'^^](_X"Z_YKQ\#S7^4!_-
M=_CK\P/]]Z1_P%U_S7CX'FO\H#^:[_'7Y@?[[TC_`("Z_P":\?`\U_E`?S7?
MXZ_,#_?>D?\``77_`#7CX'FO\H#^:[_'7Y@?[[TC_@+K_FO'P/-?Y0'\UW^.
MOS`_WWI'_`77_->/@>:_R@/YKO\`'7Y@?[[TC_@+K_FO'P/-?Y0'\UW^.OS`
M_P!]Z1_P%U_S7CX'FO\`*`_FN_QU^8'^^](_X"Z_YKQ\#S7^4!_-=_CK\P/]
M]Z1_P%U_S7CX'FO\H#^:[_'7Y@?[[TC_`("Z_P":\?`\U_E`?S7?XZ_,#_?>
MD?\``77_`#7CX'FO\H#^:[_'7Y@?[[TC_@+K_FO'P/-?Y0'\UW^.OS`_WWI'
M_`77_->/@>:_R@/YKO\`'7Y@?[[TC_@+K_FO'P/-?Y0'\UW^.OS`_P!]Z1_P
M%U_S7CX'FO\`*`_FN_QU^8'^^](_X"Z_YKQ\#S7^4!_-=_CK\P/]]Z1_P%U_
MS7CX'FO\H#^:[_'7Y@?[[TC_`("Z_P":\?`\U_E`?S7?XZ_,#_?>D?\``77_
M`#7CX'FO\H#^:[_'7Y@?[[TC_@+K_FO'P/-?Y0'\UW^.OS`_WWI'_`77_->/
M@>:_R@/YKO\`'7Y@?[[TC_@+K_FO'P/-?Y0'\UW^.OS`_P!]Z1_P%U_S7CX'
MFO\`*`_FJNG^?O.'Z:TJUU"'3FM+^[6UD-N)UD7G'(X9>;%>L>1GBX1;;AU8
MR2JGI65.8[%6+^2(1?17/FFX^.\UIB;=FZQ6$;L+6%/!2G[^3^:::3_)Q5E&
M*NQ5V*NQ5B.H?E+^7&HZM)JMYH-M->32B>XKS$4LJFHDE@#""5Z_MR1LV*HS
M6?R\\EZUJ:ZGJ>E17-XL:PNY+JLD2'DD<R(RQSHI/PI,LBXJBM(\H>6M'EMI
M=,T^*UDL[4V%JT=?W=J9/5,*U/V/4^+%4'>?ESY*O-+L]+GTJ/ZGI[R2V*QM
M)%)"\S%I3%+&RRIZA9O4XO\`'^UBJV]_+7R+>:=8:=+H\*6NE*R:<L!>W>!7
M^VL<D+1R*LG^[!S_`'G[?+%4?8^4O+6GG3#8Z=#;?H>*6#3!$O`01S\?55`-
MOWG!>?\`-BJ+UC1],UG2[G2M4MTN]/O(S%<VTFZNC=0:4.*L?F_*G\OIYHI9
M]&BF>*&*V(D>5UEB@7C$MPC.4N?379&N!*V*IMIWE70=,DBETZT2UGM[*/3+
M>9*EH[2$EHHAR+?"C,66N*O.="_)G48O,VE:GJL>CQ_HF[:_;4-.@EBNKV?@
MZ*7B8_5[-7:7UKE+;EZ\JK]C%6;)^6OD5-<_3BZ/"-1$YNP]7],7)ZW`@Y>@
M)_\`B[T_5_RL57W'Y=>2;@ZOZ^DPR#7I(YM51BY2::+[$O#EQCE7KZL823E\
M7+%6[/\`+SR5::/?:/%I,+:?JAY:C'-RF:X8`!6EEE+RR,E!P9G_`'?[''%5
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MQ*;F()',>D3L6HLG^0WQ8JB-1UK1]-@CN-1O[>R@E(6*6XE2)&8[@*SD`DXJ
MEM_YUT"Q\SZ5Y;GG4:CK$,UQ:#D@7A!P&]6#5D,G[KBK<^$G\N*J'DKS]H?F
MK2+"\MYHK>]OX/K(TIYHVN4CY%>3(#RX_#]KCBJ;G6-$EU!](-];2:CQY2:?
MZL9GX4K4Q5Y\:?Y.*K8M7T&.9K&*]M4F@C>1[5)8PR1QMQ=B@-51&^%VI\+8
MJZS\Q^7KZUEN[+5+2ZM+<TGN(9XI(XS_`);JQ5?]EBK<.OZ%.EU)!J5K+'8M
MPO72:-A"P[2D-^[/^OBJ+:YMEGC@:5%GE#-%$6`=U2G(JO5@M1RQ54Q5V*NQ
M5V*L9\^S?6-,C\NP&M]Y@?ZG&@ZK;[&[F/\`D10<M_\`?KQ1_P"[%Q53_-/_
M`,E]K7_&`?\`$UPCFQG])]S#'^VWS.9SSC6*I)YIUF^T^"RM=-2-]6U:Y6SL
M?6J8D8JTDDT@4AF2**-WX`_&W%<C(MF.(-D\HJ5N/,VDRS3ZI?KJ^D);/-)*
MEL(KJ.=""$CA@Y>LDB\N(_O$9?V^6.X2>&7(<)0\GG_3+>WOY+^SN[.;3X[>
M:6U=8I)7CNY?1A*"&212S2`J8RWJ8\:?!)JCS56\[V$;WD%Q9W<%_:S6\"6#
M)&T\[W:LT`B".R?&J.6YNGI<&:3CCQ(\([<J:_QO;<TM1IMZ=8>26+]$E8EF
M`A"L\ID:06_HTDCXR^MQ9GX?;QXD^%UL5_.6#S]I<S:?%8VEY?76I0RW$5K!
M&GJ1K;RB"83<W18S'(2I^+C\#<?V.3QKX)WL@4O\_7NL:;Y=O-6TS4!9R6$+
MR>D;=)Q/(:+$E7(X5<\?A_FQF2`N$`R`(YMI?:WHL,<>IR3Z_?78Y1QVMM!;
M)"(U!DYR,Z1`<F^#U).;?L+]K&R/-:$N7I"BGYAZ-.UFMG;W5U];LQJ)*(BK
M!:^H8GDG9W58_3*OR^U]G]WSQXPGP#O??PM?\K$T>-K=KRUO+&TNX9KNTO;B
M-1%);6\?J/-\+LZ#CPXQR(LK^I'\&/&%\`]**R__`#!@M=+U*X?3;NWO+.Q;
M4;:TN1$&GAY>FK#A(W'C(R"6-RDJ\OLX#-8X;(WZ\+4?G7ZM(!J4=P+I!864
M^FQ01LXO[U&EHC+(_+X%^)*\8TXMR;XN+Q+X5\O/_2Q14?GBRD0Q+8W9U47<
ME@-)`B,YFBC65SR$GH>DD3H[2&7BO+C]OX</$CP3W[5?$F/E_7[36[6:Z@BF
MMX[>XDM9DN4$;B2&@E%`6^PQ*5_F5OV<(-L)P,33$_*WY@WUSY9U;5]517G@
MNN.F6T8"&6*[17L8]NK/S^)_Y>3?LY",]K;\F$"0`^/^_7>7OS#N/\-VUUJL
M$NH:@EH-0U:2QCC6*VMY6=H2P=TY,8%]3TX_4EX?'QQ$]MT3P>JAL.4>)/;C
MSII\=Q(MM:W5_:V[0K>WUJBO#`;@*T8(++)(>$B/)Z,<GIH_Q9+B:QB/4TE^
MD>=Y)M3N(+NVF-G<:S-I6FWJ(@@#1+Q5&)822%Y(IOWBQLB?99L`DSEAVV_F
M\280^<;)]4@L9;.ZM8[MYHK.[G1$CE>W5G?X.?KHO"-V1Y(D5^/^KAXF!Q&K
M0]C^86DW26L[6EW;6=]9SWUG=SHBI)%:H)):*'9UHAY*S*J/^PV(FDX2.HY\
M*GI_GB$F"T:WO-0N$@M)M0N8H8D,0O@&A9[=9#+3BR^H84E2+]I_M8!),L/7
M8<_]BO;\P=-^M1P16%].DU[/IEO<1QQE);NWY<HXZR!F4^F_[WCZ2\?WCIAX
MU\$US'+B3C0-;M]:TX7T$4D`$LUO+#,%YI+;R-%(IX%T-'4_$K,N$&VN<.$T
MF.%@II_RD'EO_MJQ?\F)LJS?2YFA_O/@]BS%=R[%6,>0Y1:V$_EN<\;[09#;
M%#L7M6):TF7Q22&BU_W]',G[&*LGQ5Y)^;.I6\/Y@>6+#4;[6;?1Y]/U*6:#
M0FOO5>:*2V$;.E@&E945Y/B9>"\L54/R[\QWXD\RZQY;;6?,7DNWM8CI<>IR
M.US+J<;R+<16SWA6=8`HB67ZQ\,<O/A^UBJ86WYW0VNH:I9Z];V`.G:3-K32
M:-J"ZD!';NL;V\H].`QW!:1/3_W7)_-BJ$U'S9YX;SUY;M]<TTZ-9SZ7K%XU
MM9WS3)-P@A98IB(H>%S;5ZA98_WG**3[6*IAY?\`S"UO4--T?3?*NB_I*[31
M+'5=0?4]09/2CO(R;>!KCT9I+BZE$<C-(\<:?MR/\?'%5UK^;FIZW?:-8>6-
M!%W=:OIT^HN;ZY^JQVIM+D6L\4Y2*X8E)JQ`QAN3_P"1\>*I3=_F'YEU?S/Y
M,FT+3W%Y=)KMEJFA7%UZ-O%=V#P12&XE1)!(D#A_2=(79_47BB<VXJI_!^9^
MJW7EJ'4+?18H=16_NM,U1+R]2"PLIK)WCEDENRA9HF9`(>$'.3G]E,52NT_.
MV\O=)A?3]&M[_6)=>/EL0VU^LEDT_P!5:Z6XCNQ%\=OP`Y_N?43X_A9EXLJJ
M:S^;OF;3/\1.?+$4MOY1CM9M?E6_I\,]LEQ*EH#!^^DA#M_>>@CJJ_'R?@JJ
M:V'YC:_^EM0TO5/+C0WT>E'6M+M;.Y6YDN(!)Z7H2<DA2&Y#E-@\D/Q_WOPX
MJE5M^=L=IJEW9>8;:PB6VTJZUAGTC45U)HDLN)E@N$].#TYJ/^[IR21N6*IF
M_P"8WF+2=-N-9\V>7/T9HT>GRZDEU:W0NVC](`BVN5:.`1W$@8>GZ;2Q,_)?
M4^'EBJ`TG\YO5U&*PU*UTX3WMG<WFGIIFIQ:@0]I$9WM[H)''Z,GIAF61/6A
M;BZ\_L\U4W'YC7$^G^39K335>Z\XVSSV\,D_!()%T]KU4=Q&W)6*^D7X?#]O
MC^QBK$/(WYA:BVA^1M2\UF7ZU>Z=J]]->PW;&%H+..*1Y;BW6*-))"K?NT_X
M]^/P.WJ?"JRS1//7G"]AL]1NO*<B:-JEI)>6$EK=+<72!8O6ACNH62)(GN4^
M&/TYIE27]W)_/BJ21?FYJ$^K1^7]0L["TO-5L+VXM?T=J:7MQ:2VL'JF*\B6
M*+T7X_9>-Y$]1.'^5BJ7:+^;>J:=Y?\`*FDB&UOM7NO+MCJDEQJ^HBQ:]DEC
MXF&U>2.47%V60M)S>-5YIR;X_A5>P64\EQ9P7$D+VTDT:2/;R<2\;,H)1N)9
M>2UXMQ9EQ5CVD2C5O..H:K">5CI<'Z)@E'V9+@R"6[*GNL3)!#7_`'ZDR?L8
MJR?%7__4]4XJ[%6F564JP#*PH0=P0<58C'9ZMY0)&G02:GY6J2-.B^.[L`=R
M+93_`+T6H[6_]]!]FW]:/A!&JR+2-:TK6+07FF74=U;DE2R'=6'5'4_$CK^U
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MP&;ZU.AH./`S>CQ6O]YZ?^2V*L:\IC3-('E;4?/>GRS:6_E#3['3IKJSENXX
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M<+`105Z-=ST9+9?\D\IW_P!U0R8JJ>7_`"[-97$^JZI<"^U^\4)<W04K%%$I
MJMM;(2WI0(=^OJ2O^\E9FX\%4#^:G_DOM;_XP#_B:X1S8S^D^YAC_;;YG,YY
MQK%6+^=H;N;]'O8VUX=2T^;ZY8WEM`EQ"C\6B>.9&EA+)+&[*P5N7[2MD9-V
M(C>ZHL>OX/,>J6-_^DK?5&O[Q(8HHX+18[&**&42F,P_6C))]8(X7$C2<_3^
M!.*Y$V6T&((KAKW^K_<H:ST*ZBOY+N31[R)9[O3[J6TLM.A@A5-.]1EA0?62
M3SE=)#(_Q?#_`,"*9&8JK'*7\7\[X(R[M-2;4I]7M=,U(:H=234;8S6D;0A$
MM/J8@D5;A7/[MI&]167B[?9P^;$$55BJX>?GQ=R%U+2M6OI[6_N=,N]2U..&
M:WG?4M-AGMPLTOJJ;>(7*F+T#\$:L[\T_O&P$)C(#8$`?T9?L330(3HU^;F/
M1=5D1;&"PA06=M%Q$4DDTTA$<JQUGEDYE41>/'"-NC"9XA5QY\7-%^9+RXUK
M3XK$Z+JT,(NK:XN*VT3>I';3+,8O[\4]0HHY82;1C'";N*6^9H=0UC5X[]-&
MO2@M7M?0OK"*Z2%F<M]8@0W*1B;?@WJ*WPJG^R!W++&1$58_TW[$+I>DOIVB
MZC8RZ-J]VMWI5OI*K%;0Q,(K:!XVXEIV'*62627_`"?\K`!092E9!N/U<27&
MUU_S`)H=7T[5)=/BTO\`1UC*FG);,L[2H[R/!+.2_P`-O"'^)8W^-$5<&YYL
MKC'D1?%Q?5^Q%/H5Z^GZ@JZ%-:7UY]75%L],AAMEBMYUG9&I<&=_K#)23][Q
M5>/!/YC7DCC%C?;^M^Q,X+>[774U6?2]5D/Z2GU26(6L0Y-):BT@0$W!H((P
MV_[7+]G#U8$CAJX\N'GY\7<ETAU72KVVU*UTO5OTC]9U">:Y;3UN8G&HR*WI
M-#'<"16C6.(1S<^'[OX_MX.3/:0HF-;?Q?S?@F>A3ZY:>23I-SI.JIK-U#<F
M[O!;PNHNKMG=Y*"9>7%Y/\G[.$73"8!G=QX?^)2R3R],'E^K:=JT,8TR.QLH
MC:1%8KJ*V:T6\;_2!S98'98T_9Y,W+!3/C\X_5?/_.X>2E<^5D:YE%OH-T+.
MYCM8YGN=,M[BZB6UA2"EM(\_IJLL<:_WD;^FW)EY8\/DHR>?^R_8F]F=>L=1
MG^H6.IVNCW%[^D9(([.(7/+BH-N)?K'`6[&-:_N_4X?NO\K#NP/"1N1=<//]
MBG8V5S;V?E^U?3-78:*]S<2R+:Q*TUS<QR+ZH_?GAP>>20?:Q'1)())N/J_'
M<DMMY7U2);<G3;J*XM+*\LX[J#38UFEDNX?1%U<2M=,\DR@LS+7AR9LCPLSD
M'?U'\7^Q^E-M:TRXU"!;>'2]6MH8='?1K9?JL3<%F:,2R?[T#[4,(B"Y(AA"
M5=8_5Q\_V.N[/5;G7;:^;3+_`-"RNDNK&X^HQ+?P1)3_`$-)TN54VK4HP=&^
M!F3_`"\>J@@"K&_GZ?ZW+ZE;2+6ZT\^7^>E:K-^@TNW;_18AZUU>?:F_WH/'
MCSE^'XO[S[6(VI$C=[Q]5=?YOP9+Y)L6L/+-G9/%/'+#ZGK&YC6*1Y'D:223
M@KR`!W=B/CR41LU93<K3W)-2FG_*0>6_^VK%_P`F)LJS?2YFA_O/@]BS%=R[
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MEH.H#47N;C21JDE[))&`UW=:Q)'+/,>)XQ4DC^"-5;X.*<O@^)5*=0_)N:0V
M\]MJ-K-<6NL:GK$=MJ5E];LG_2C%BDD'JQDRV]?W$XD^'X_@^/%571?R?GT^
M[BNKC61=2IY@7S&Y6U2%2_U`V30(B/Q2/?G'_(J^FWJ-^\Q5,=:_+,:E9^>;
M;](>E_C1(T+>ER^K>G:):UIS'JU]/G^Q_+BJWS=^5R>8[N]F?4Y+07NA2:"1
M$@++SG6;UJEOB7X.#PT^-&;X\529/R4DO+Q)M:O[(6?Z,OM'ETO2-/73[?T+
M]$5Y$_>S.LU8U;D2R?95(T^TZJ8S?EIY@UJPETKS;YD;4=(^H3:=%:V5N;(R
M^LH7ZS=$RS+-<1!08N*1PI)RD]/%531/RXUF*]236M6M;FUAM9K18-.T^.P:
MX,Z>FTUT_.8O($KQ2'T8N;<^/[.*H7R[^5GF#3[_`,JR:EYB2^T_R>LL&EVD
M5F(&DADM6M4-Q)ZTG*:.-E^-%C3_`(KY/R559H7Y.O:66A:?JNJ)?V.@VVJ:
M=#%';F%IK+4HXXPDK>K)^]B5&Y.HXR<OL)Q^)5>/RO\`--SHT?E[4O-TQT*S
ML9]/LEL8#:W4BRP&VB>\F$KI.;>-JJL<4"22\99,50NF_DWJ$.H:->76IV$,
M>BP7=K!9:7IBV,$BW=J;9I9/WTK&;[#_`&O3^%D]/X^>*MZO^6MY9>5[#3GU
M_3_T)IVD6^EWT&N6"7=D/JR<!>1*TT(MYF!^/F\L;?N_Y/B53'R[9ZG=^7--
M\N:!-=6?EK3[6&TD\Q7(*7MW%$@3_0T8!H^:C_>R15X_\>L;_#-&JSC3M.L=
M-L8+"PA6WL[9!'!"@HJJ.W]N*HC%7__5]4XJ[%78J[%4DU7RAI-_=G4(C+IV
MK4`_2=B_HSD#H)-C'<*/Y+B.5/\`)Q5""7SYI=!+#;^8K5:#U8"+*]I[QR$V
MLK>XFM?^,>*KX_/_`)<1UBU.271+AMO2U2)K45\%F?\`T>3_`)Y3/BK((9X)
MXEF@D66)Q5)$(92/$$;'%5^*NQ5V*NQ5V*NQ5V*NQ5V*I=YBT#3?,.B7FBZF
MC26%_&8KA$8HQ4D'9AN.F*HJ]M%N[&>T,LL"SQM%ZT#F.5`PX\HW&Z.O56Q5
M!>6O+>E^7-'BTK3%<6\;/(\DSM+-++*YDEEED<EI)9)&9W=L57ZMYD\OZ0`=
M4U&WLR=U2:5$=O\`50GDQ_U1BJ5_XOO+WX=!T2\OP:<;NZ4Z?:T/?G<`3L/>
M&VEQ5:?+OF+5=_,&K&*V/VM+TGG;1D?RR71/UJ7_`)Y-:JW[4>*I[INEZ;I=
MHEGIUK%9VL=2L,*!%J>IH.K']IOVL516*L5_-3_R7VM_\8!_Q-<(YL9_2?<P
MQ_MM\SF<\XUBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BJFG_`"D'EO\`[:L7_)B;*LWTN9H?[SX/8LQ7<NQ5V*H;4=,T
M[4[.2RU&VBN[27^\@F170TZ;-7IVQ5(1Y:U[2M_+NK,;=?LZ7JG.[@`_ECGY
M"ZB_V4EPB_LQ8JN_Q;J-B>.O:'=V@%:W=D#J-MMW_<K]94?\9+5,53+2?,_E
MW5SQTS4K>ZD'VH8Y%,B_ZT=>:'_67%4SQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*M,RJI9B%514L30`8JD%SY]\K13&WM[S](WBUK::<CWLH([,MN).'_/3ABJE
M^DO.NI[:?ID6C6YI_I>J.)IZ'NMI;,5_Y&7<?_&/%52T\EV)N8[[6;B;7-0B
M(>*:]*F&)Q^U!;(%MXF':3T_6_XM;%60XJ[%78J__];U3BKL5=BKL5=BKL56
MO&DB,DBAT8496%01X$'%4AF\@>4FF,]O8#3[@]9].>2Q<GQ+6S1<O]EBJG_A
M76K=::=YFOXP.D=VMO>)][QK.?\`D?BK9@_,."@2[TJ_4=?4@N+1C_LEEN5_
MX3%7-JOGJ':3R_:7'B;74"3]"S6\/_$L5;7S+KR#]_Y5U`>\,UA(/QN4/X8J
MM/G*X4_O/+>L)_SQ@?\`Y-S/BKO\;*.NA:P#_P`P;']3'%7?XU)^SH&L-X?Z
M(%_XDZXJN7S;J#_W?EC5V\.2V<?_`"<N5Q5IO,'FQS2#RM,OO<WEI&/^23W!
MQ5S77YA3`>GIVEV=>\MW/<$?[%+>$?\`)3%7'2O/-Q3ZQK]M:+^TMC8@-]#W
M,MPO_)+%6O\`!%M.2=3U75-2#?:26[>WC/SCLQ;1D>S+BJ8Z5Y8\NZ02VF:;
M;6<A%&EBB19&_P!9P.;?[)L53/%78J[%78JQ7\U/_)?:W_Q@'_$UPCFQG])]
MS#'^VWS.9SSC6*NQ5V*NQ5V*NQ5V*NQ5V*M>YV`W)/2F*L.E_-[\O8Y7C_2C
M2&-BA>*VN9$)4T/%TC*N/\I3DXXIR%B,B/ZLG(_+9.Y;_P`KB_+W_JXR_P#2
M)=?]4LEX&3^;/_22_4OY6?<[_E<7Y>_]7"7_`*1+O_JECX&3^9/_`$DOU+^5
MGW,HTG5M-U?3H=1TVX6ZLK@5BF3H:&A!!H593LRM\2Y5;3*)B:*,Q8NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*J:?\`*0>6_P#MJQ?\F)LJS?2YFA_O/@]BS%=R[%78
MJ[%78J[%4NU7RYH&K@?I33K:](V5YXD=E_U6(Y+_`+$XJEG^!;&#C^B]2U/2
MPOV4@NY)8Q\HKKZQ$/\`8QXJV-(\[6Y)MO,,-TO9;^Q5F_X.VDM1_P`D\5<M
MQ^8<(/J66E7H'>.YN+8G_8M!<#_DIBK0U_S<AI/Y6D?Q-M>VL@_Y+-;XJN;S
M7J2?WOEC5E/?B+*3_B%TV*K?\:L/M>7]87Q_T56_XC(V*N_QLO;0]8)\/J;#
M]9&*N_QG.W]WY=UA_P#GA$G_`"<F3%5Y\SZVX_<>5=2;_C+)81C\;HG_`(7%
M5JZQYWE/[KRY!".QNM05:?,0PW&*N"?F).WQ2Z18*?Y4N;TC[VLQ^&*M?X:\
MQW`(O_,]UQ/6.Q@MK5?^"=+B8?1+BK:_E]Y7=E>^MY-5D7]K4YYKT5\>$[O$
MO^Q1<53ZVM;:UA6"UA2"!-DBB4(@'LJ@#%57%78J[%78J[%7_]?U3BKL5=BK
ML5=BKL5=BKL5=BKL5=BKST?GGY(;=(]0D2I"NME,5:AI4&G3;#PEUV3M?2PD
M8RR0$H_4X_GGY*_WSJ7_`$A3?TP\)8_RUH_]5@U_RO7R1WBU'_I"F_ICPE?Y
M9TG^J06_\KX\C#K'J/\`TA3?TP<)3_+&D_U2#1_/KR)W34?^D*;^F/"4_P`K
MZ7_5(K3^?WD$=5U'_I"F_ICPE/\`*VE_U2+1_P"<@?R_'4:A_P!(4W],>$I_
ME33?ZI%:?^<A/R\'4Z@/^C*;^F/"4_RGIOY\5I_YR(_+D=6O_P#I"F_IC13_
M`"EI_P"?%H_\Y%?EN.KW_P#TA3_TQHI_E'3_`,^+1_YR-_+0=9+_`/Z0I_Z8
MT4_G\'\^*W_H9#\LA_NV^_Z0I_Z8T5_/8/Y\6O\`H9+\L?\`?U]_TA3_`/-.
M-%/Y[#_.B[_H9/\`+#_?U]_TA3_\TXT5_.X?YT4D\Z?GQ^7NN^6;[1K">Z^N
MWZK#;"6UFC0N7!`+LO%>G?$#=/YG',$1D":*8/\`;;YG,YT;6*NQ5V*NQ5V*
MNQ5V*NQ5V*O(/S9\WZA<ZE<>4[0FUT^!(VU6=322X]9`ZP*1]B'B?WI^U)]C
M[/VMKV5V>-1(F7]W#^'^?+^;_5<[38@!Q'G_``L,N=,U"PAA:YLYK2"5:VYE
MB>)&4#]CD%!%/Y<[#'.!VB8^G^&/\+DD+KC3-4MK>*YN;.X@MI_[B>6)TC?_
M`%68!6^C#'+$F@02/-:4GMKM+CZL\,B7-0OH,C"3DW0<".537;;")@B[V5-=
M"USS!Y$U#Z[)9W$>E7CC](Z?/&\0DW"^O!S`"SI^U^S*OPO^RV<YVMHL<XRS
M8S'BC_>1!^K^E_7_`-TQR8N,4>?\+Z`/AG-NJ=BKL5=BKL5=BKL5=BKL5=BK
ML54T_P"4@\M_]M6+_DQ-E6;Z7,T/]Y\'L68KN78J\M;_`)R2_*]79?K%ZW$E
M:BRG(-#3;X<-./+5X@:,A;O^AD_RP_W]??\`2%/_`,TXTQ_.X?YT6_\`H9'\
ML?\`?U]_TA3_`/-.-%?SV'^=%O\`Z&/_`"S/^[;[_I"G_IC11^?P?SXMC_G(
MW\M3_NR__P"D*?\`IC11^?P?SXMC_G(K\MST>_\`^D*?^F/"4?RCI_Y\5P_Y
MR'_+H]&O_P#I"F_IC11_*6G_`)\5P_YR#_+P]/TA_P!(4W],>$K_`"GIOY\6
MQ_SD!^7YZ#4/^D*;^F/"4?RKIO\`5(KA^?OD(]%U'_I"F_ICPEC_`"MI?]4B
MV/SZ\B'HFH_](4W],>$H_E?2?ZI%</SW\CG_`'7J/_2%-_3'A*_RQI/]4@W_
M`,KU\D_[ZU+_`*0IOZ8>$H_EG2?ZI!O_`)7GY*_WSJ7_`$A3?TQX2C^6M'_J
ML$5I7YP^4=3U2TTV!+V.XOI?1MVFM98T,A4L`7(HM0IP$$-V#M+3YI<..<9R
M_FQ9Q@<YV*NQ5V*NQ5V*NQ5V*NQ5_]#U3BKL5=BKL5=BKL5=BKL5=BKL5=BK
MY.TS_CG0?ZI_XD<R(\GR3M3_`!K)_P`,DFF@:,-=\T:3HKW,MI!?RS+--`(S
M(!%;2S`+ZJR+NT:U^'!,T'/[`T6/49C'(+CP<7\WN>EG\@='/_2_U/[K/_LG
MROC+V'^AS1_S3_IY+3_SC]HIZZ]J?W6?_9/@XRG_`$/:3^:?]-):?^<>M#/7
M7M4_Z<_^R?'C*?\`0_I/YI_TTEI_YQVT`]==U3_IS_[)\>,LOY!TO\T_Z:2T
M_P#..7ET]==U3_IT_P"R?'C*?Y#TO\T_Z8K#_P`XV^6SUUS5/OM/^R?'C*?Y
M$TW\T_Z8K3_SC3Y8/77-5^^T_P"R?'B++^1M/W'_`$Q6G_G&3RJ>NMZK]]I_
MV3X\13_)&G[C_IEI_P"<8?*9ZZWJO_!6G_9/CQ%/\DX.[[5O_0KWE$]=:U7_
M`(*U_P"R?!Q)_DO!W?:M/_.+?D\_]+K5?^"M?^R?'B3_`"9@[OM:_P"A6?)W
M_5ZU7_@K7_LGQXBG^3</=]J4>;/^<=_*GE[R_=ZY;ZGJ-Q<Z<%G@BF:W],NK
M`#GPA1B-^S80=V4=%CQW*(WHLB?[;?,YFNG:Q5V*NQ5V*NQ5V*NQ5V*NQ5X[
M?W6E6GYZM<:OQ_1T-UILMUS%5$8A7XF7>J*P^+_5S?=E1E+39HP^L_3_`*1V
MFG^B*?:C_B6QO4N?.>NP7GEZ?7+:X^H-<1WIN85E+&>`(9##!'$?C7]UR7X.
M.9F/PI1K!`QRC%*/'PG'X<J^B?T\<^+^LY&_5'ZP?,MK'YUO?-6I+=^7M3MY
MET13=1SQ3W#S*UF]I$KMP])/M<43@N58?"EX4<4>'+`CQ?3PRA#A_>^++^DD
MWO:EYO\`+6KC\VHO,YCB.A-J>FN+P7$##CR@2O`/ZGVA_)DM)J8?E#BW\3@R
M>GAE_2\N%$AZK0OYERZU:^4_/4?F:^$]KJ-_"?*MI+=1W,G/ZX6]2!%>1H8_
MJYXM]C[2IQS7ZCPSAB<0X3#%+QY</A_P#TR_GS\1EOO;T0]3FH="[%78J[%7
M8J[%78J[%78J[%78JII_RD'EO_MJQ?\`)B;*LWTN9H?[SX/8LQ7<NQ5XNW_.
M+/DPNS+K&JJ&8L%#VII4UIO!AMPIZ#%(DD;GS;_Z%9\G?]7K5?\`@K7_`+)\
M>(L?Y,P]WVMC_G%OR>/^EUJO_!6O_9/CQ(_DS!W?:V/^<7O*(_Z76J_\%:_]
MD^/$C^2L'=]JX?\`.,/E,?\`2[U7_@K3_LGP\11_).#N^U</^<9?*HZ:WJOW
MVG_9/CQ%![(T_<?],N'_`#C3Y8'37-5^^T_[)\>(H_D;3=Q_TQ7C_G&[RV.F
MN:I]]I_V3X\98_R)IOYI_P!,5P_YQR\O#IKNJ?\`3I_V3X\91_(6E_FG_327
M#_G'?0!TUW5/^G/_`+)\>,L?Y`TO\T_Z:2\?\X]Z&.FO:I_TY_\`9/CQE'^A
M_2?S3_II+A_SC]HPZ:]J?W6?_9/CQE'^AW1_S3_II-C\@M''_2_U/[K/_LGP
M\91_H<T?\T_Z>3R6*-XGN('D,QMKFYMQ*P4,RP7#Q*6"A5Y%4%>*Y;$V'@NU
M,$<.IG"'TPEZ4W\K?\IEY;_[:4?_`":DP9.3L/9C_'!_4F^E<H?278J[%78J
M[%78J[%78J[%7__1]4XJ[%78J[%78J[%78J[%78J[%78J^3M,_XYT'^J?^)'
M,B/)\D[4_P`:R?\`#),F_+S_`,F/Y<_XS77_`%`SY')R=S[*?XR?^%G_`'47
MT7E+Z$[%78J[%78J[%78J[%78J[%78J[%6*_FI_Y+[6_^,`_XFN$<V,_I/N8
M8_VV^9S.><:Q5V*NQ5V*NQ5V*NQ5V*NQ5B7G[R%;>9[19[=EM==M%(L;TCX6
M'4P34W:%_P#@HV^-/\J[!GGAF)P/J'^R_HR;\.;@_JO&6T7S)!(\4V@:BD\;
M%)5CM994Y`T/&1%*.O\`*RYU4.WM.8@RXHR_F\,I.?Q1[PT-*UT;C0M3K_S`
MS_\`-.2_ES3=\O\`227BCWQ^;7Z)UP?]*+4_^D&?_FG'^7--WR_TDEXH]\?F
M]"_+;\M9$FB\Q>8K?T[A#STK2Y!O!X3SC_?Y_P!UI_NC_C)]GG>T>T):F7=C
MC]$?]_/\>EQ<^?\`AC_G%ZGFO<-V*NQ5V*NQ5V*NQ5V*NQ5V*NQ533_E(/+?
M_;5B_P"3$V59OI<S0_WGP>Q9BNY=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5?*[_[VZC_VT+__`*C)<OAR?+.W/\<R?UOT!,_*W_*9>6_^VE'_`,FI,<G)
MRO9C_'!_4F^E<H?278J[%78J[%78J[%78J[%7__2]4XJ[%78J[%78J[%5.XN
M(+:WEN)W$<$*-)+(VRJB"K,?8`8JQ>/\V?RSD021^9M.=#T=;A&!^D'%KEE@
M#1E$'^L%W_*U?RW_`.IDL/\`D>G]<:1X^/\`G1_TT7?\K5_+?_J9+#_D>G]<
M5\?'_.C_`*:+O^5J_EO_`-3)I_\`R/3^N*^/C_G1_P!-%\\:40VF6[#<,E0?
M8DD',B/)\I[3(.IR$?SY)WY1U;3=)\\:!J&IW,=G8PS7'JW,S!8UYV<Z+R8[
M#DQ"Y')R=Q[+2$=2;->@_?%[7_RM?\M?^IET_P#Y'I_7*:>^\;'_`#H_Z:+O
M^5K_`):_]3-I_P#R/3^N*?&A_.C_`*8-?\K8_+3_`*F;3O\`I(3^N-+XT/YT
M?],%6T_,_P#+N\O;>PM?,=A/>W;B.UMDG0R2.=@J*#5CBRC.,N1!9/BR=BKL
M5=BKL5=BKL5=BK%?S4_\E]K?_&`?\37".;&?TGW,,?[;?,YG/.-8J[%78J[%
M78J[%78J[%78J[%75/CBKPC\SOSH\Z^6_/5[HFFM;"QM_1],2PAW_>1([5:O
MBV43R$&G9:?2PG`$\WNR,2BDG<@$_2,O=<WBAV*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*J:?\I!Y;_P"VK%_R8FRK-]+F:'^\^#V+,5W+L5=BKL5=BKL5=BKL5=BK
ML5:=U1&=C15!+$]@.N*L33\V_P`L7!*>:--8`T-+B,T(Z@[]<6$LD1L2!\6_
M^5L?EI_U,VG?])"?UQI'C0_G1_TP;_Y6O^6O_4RZ?_R/3^N-+XT/YT?]-%W_
M`"M?\M?^IET__D>G]<:1XV/^='_31?/T<\5Q->7$+B2">]O989%W#(]W*R,/
M9E(89?#D^8=MD'5Y"/YWZ$?HM_9:?YET&^OIDMK.WU")Y[B0\41?3D')F/05
M(&.3DY/LU(1U@)->B;W/_E:OY;_]3)I__(]/ZY0^C>/C_G1_TT7?\K6_+;_J
M9-/_`.1Z?UQI?'Q_SH_Z:+O^5J_EO_U,EA_R/3^N&E\?'_.C_IHMI^:?Y<R3
MPP)YCL&GN'$5O%ZZ<G=C0*@K\3$]A@91R1ER(E_5+*<6;L5=BKL5=BK_`/_3
M]4XJ[%78J[%78J[%78JP[S)^57E/6I9+N.)]*U.3=K_3R(6=O&6,AH)_^>L;
M-_E802'"U?9V#4"LL1+^E_'_`*?ZGFVO?EMYWT7E)'"-=L5_X^+$%+E1XO:.
MQY?]&\LC?\4Y8,G>\AKO9&0WP2XO]KR?5_I_^*8K#>0SM(L4A,D1XS1-59(V
M_EDC8!XV]G5<L!MY34:7)AEPY(F$OZ2XLWB<+2`IMOBS"F21TP,@I,S>)Q9@
M*,7UB[O186,,U]J#;BSM4::6GBRK_=K_`)<A1/\`*R)D`['1]G9M0?W<;'\[
M^#_3,^\N?D;YFU$K/Y@NUT:U.YL[8K<7A'@TI#6\/^P6X_UURLS>LT?LSCCO
ME/&?YL?3#_BGJWE?R#Y3\L*3I%@D=RPXRWTI,US(/\J:0M)3_(Y</Y5R#T>+
M##&.&`$(_P!%D.+:[%78J[%78J[%78J[%6*_FI_Y+[6_^,`_XFN$<V,_I/N8
M8_VV^9S.><:Q5(M0U2]'F_1](MG"P2VUW>Z@M`2T<7"*$5.Z_O9:_#_)D2=V
MV,1P$GR0^N^;;?2M3N%<7$ZV-M;O+90)&WJRW]SZ%NJEB']6J/\`!\*</\K$
MRI,,=C\?PJ5UYP#+/82PW.E:JE[9V7I_N)F'UP\XY5;D\31M&DOJ?M1\'_R<
M'$D8NOU"C_L4'J'G>^O&T6/2+*>VMM:U&&"RU.41-'-;(6DN&6,LTD8DAC;T
M6D3XT^/X<3+N91Q`79^D?2J>>_,K:;JVC:<-5;1H+M;JXO;Q(%N'$4"*$4*R
M2A>4L@J_#]G&4J1AQV":XE'0/-.IK;:A=N]SKVD>K;1Z-J!MX[-YVE4F8DL(
M8OJT9X_Z4ZHOVE^/$23/&-A])_B_B_']53UCSKJ>HZ=8VV@6\T&I7VJ-I<[Q
MO:2M";=/6G])W9K>3E"/W<GQ1K^W\?PX#*^2QQ`$\7(1XNJ=>1=:U36M"_2%
M_`81)/*MFS&.LENCE(W/IDCDW'X_L_%]A?3XY*)L->:`C*@R+)-36*OD[\]`
M?^5KZG7_`)=?^3$>8F7ZG=Z/^Z#ZPCVC2O\`*OZLRW2L=UR>Z_Q?Y>M4N9H;
M5X;^YGAA<HLK6ZPF-9*?:0<V^'(GF&V`'`3_`%4KMOS)GCTBPUS6-*%CI&IV
M\T]I)%/Z\P:&%I^$D?",+ZT<;^B5=O\`BSCRP<>UEF<&YB#9"MJ'GO5-(M9I
M=:T=;>4V,NHV,4%SZWJ+`4$L$C&-/3F02HWP^I&WQ?%\.)E7-$<(ER/7A6)Y
ME\W0^9;B&_TZ!+:WT=KYK&"Z5V,@G95/J21Q)R8*$?DZQQ_$_P`6-FU\./#L
M?XN%*]3_`#$N[O3=7LX&MH;^T@M+N*\TR[^MQ<);R.!XV?A'QD%=Z<E96P&;
M..``@]/Z0\F:>8M:FTV2SM;.U%WJ.I7#6]E`\GI1U1&ED>23BY5(XT8_"C,W
MV<F33CPA>YY!B6I>8-?U;7-$T=(FTYXM1GM]:BM[QHRS06PN4].58B7@>)UE
MI^[9V_<R<?MY`DDTWQA&,2>>WIV3OS5YU@T34;734^JB\NHGN>=]<_5($B1@
MGV^$K-([FBJJ?LLS-DI2IKQXN(7]WJ2Z+\Q-0U%8CH6C+>,VG'4IO7NA`J".
M:2!X@RQR>HW.)O2=?@?[7PX..^3/P`/J/7A0LOYA:K%=7^IQV8N=&72M+OK.
MT]4)-SU"9D%?W9')B>+?'Q7TE_WXW`<:1@&POU<4O]BFUWYUOM,BU&+5M-2'
M5+.WM[BVM()S*ERUU,;=(XY#&A!$X1'^#]OEAXJYL!B!JCLB?*TEX-9\S6<]
MS-<1VE["MN)Y#*8Q+:QRNB,:?`)';@,,>91DJHGR_2GZ?\I!Y;_[:L7_`"8F
MR&;Z6[0_WGP>Q9BNY=BKL5=BKL5=BKL5=BKL5=BKL58AYJ_*KR;YCD>ZN+4V
M6IOUU.Q(@G)_XLH#'-_SW23"#3C:C28LPK)$2>4^8OR<\ZZ+RFL./F"Q7>L`
M$%XH_P`J!CZ<O_/*56;]F#)C)WO,:SV8ZX9?YD_^+_XIAL4X,TENW*.ZA-)[
M:56BFC/@\3A9$_V2Y8#;RNITF3":R1,$2K-XG"XA"JN+`JBDCIA8%4#-XG%B
M0M%QRNDLX5DN;Z05CLK9&FG8>(C0,W'_`"V^#_*P&0#EZ3L[-J36.)E_2_@_
MTS-=!_*7S?JG&759ET"S;?TEX7-\P^@M;0??<_ZBY6<G<]=H?9&`WSRXO]KQ
M_3_I_J>E^6?R]\J^76$]A9^I?TH^I73&>Z;Q_>O4HI_DBX1_Y&5DO6:?2XL,
M>''&,(_T61X'(=BKL5=BKL5?_]3U3BKL5=BKL5=BKL5=BKL5=BJ0^9?(WE;S
M(H.K6*27*"D-]&3#<Q_ZD\960#_)Y</YEQ:LV&&6/#,"<>Z3S+7_`,FO,NG\
MIM"NEUFU&XM+HK!>`>"S*!;S'_C(EO\`\9,L&3O>6UOLGCGOA/AG^9+U8_\`
MBH_[)@5PTEK>&QOX);"_`J;.[0PRD#J5#?#(O^7$SI_E98)`O):SLS4:8_O(
MD#^?]4/],J:1I^KZ],8-`L)=4=3QDFAHMM&?^++EZ0J1_(K/)_Q7@,P',T/8
M6IU&X'AP_GY/3_L?JD]&\O\`Y$O(5G\TZB7'4Z9IQ:*+Y27)XSR?\\A;?[+*
MS,EZ_1>SFGP[S_?2_I?1_I/^*>G:+H&B:'9"RT>QAL+4;^G`@0$_S,1N[?Y3
M?%D'?@`"AR3#%+L5=BKL5=BKL5=BKL5=BKL58K^:G_DOM;_XP#_B:X1S8S^D
M^YAC_;;YG,YYQK%6.:EY;UN7S(^N:9JT5G(]FED89[3ZR`B2-*2I]6*G-F^+
M;]E<B0;MNCD'#PD=>]*=8\I:U+J=I+%>&6ZOK^UN[Z_6`+%`NF6K^BIC+FJ2
MW)Y<.7[;+R_;P&)9QR"CMT_W9_XE,$\CB6^CU#4;TW5XUR]W?%(_320_57M(
M8XUY,8H[>.1V7XI&9VY,V'A8^+M0'XOB6Z1Y+OK2ZT1[S5?KEIY?BD@TZV6W
M$50\0A225N;\Y4BJE55$_P`A<`CR\EEE!!H?4G,>CA?,SZZ9B7-DMC#!2@11
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M^>?./Y`^:KOSE&VFWCWNE7[<GU*\E,DMJJ`?#,6/.7BNT++]O[+<,QY8C;M,
M6MB(;C</=O+NB1Z)I$&G)=7%Z81\=W=R-+-(Y^TQ9B:#^5!\*9>!0=;.?$;Y
M(#6K#4G\T:'J%K;&XM;:*^M[M@\:&+ZTL01Z.074>FW()R;`1NR@1PD>Y)_+
M/Y=+'Y>TRQ\PW-Q>K:6;P#3)6C,$#W$1BFX/&JO)\#.D1>1_25O@P1AMNV9,
M_J)CMO\`4CIOR_MKNVGAU/5+W46>T;3[:68PAH('96?AZ<:AY7]./G+('9E7
M'@8C-7(`;\2+\P>3+'7+N6XN+J>%;FR;3KJ&+T^,D1?U4)YJQ5HY?B%/A?[,
MBLF$QMC#*8CX\2$G_+ZUNY+B:_U.[NI[FVCLY'XP1(L4-PMR@CCCC5$_>)\7
M\W+_`%<'`R&8CD$YUW1(M66W?UY;.\LYOK-E>P<?4BDXE&V<.CHZ.R.CKQ9<
MD1;7"?#\4#8>3;&UN[6^>YGN;^"YGO9KJ4IRGFN(?J[%PJJJJD058DC"*G'`
M(LCE)%=$1K'ET7]]!J-M>S:;J5O&]NMU`L3\X9"&:-XYDD1AS4.AIR1L)"(Y
M*%586V/E6SM)S.+FXGF:P&FR23N)':/U'E,C,17U"\C?Y''X53`(J<A/SXDM
M?\NM-:**!;VY2V6QL].EA'I$2)I\HEMY&)3DLBM4-P^%N7V<'`S\<]W4R_TR
M_7-`N-9\[:->36ABL-%]2X:],BTGDD"F*`1`\Z0RKZS,_P`/)$X82+*PGPP(
MO>2*\MV6I0ZMYBO;VV-JFH7D<EHA=)&:.*VCAYGTRW'DT=0K?%B!S8Y"*`'0
M)VG_`"D'EO\`[:L7_)B;(9OI;]#_`'GP>Q9BNY=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL527S)Y,\L>985CUK3X[IH_P"YN-TGB_XQS(5EC_V#XL,F.,QPR`E'
MND\N\P?D?K=ERF\N7RZE`-QI]^1'<`>$=R@]-_99HE_RI\F,A>:UOLQBR;XC
MX4OYOU8_^*BP&[CNM/O!8:K:S:;?'[-M=IZ;/3KZ3;Q3#_*A>3+1(%Y#6]DZ
MC3?7'T_SX^J'X_K*VEVVHZQ<M:Z)93:K<*>,@M@#%&?"6=BL$7^J\G/_`",3
M,!GHNQ-3J=XQX8?SY^F/_%2>B:!^2.H7'&;S-J/H1G<Z9IC$'Y27;A9#[^A'
M!_QD;*CD+UVA]E]/BWR?OI>?IQ_Z3_BGIF@^6=`T"U-KHUA#90G>3TEHSG^:
M1S5Y&_RI&9L@])&(B*`X0F>+)V*NQ5V*NQ5V*NQ5_]7U3BKL5=BKL5=BKL5=
MBKL5=BKL5=BJ"U;1-&UBU^J:M8P7]K4-Z-S&DJ<AT/%P17%!1-O;V]M`D%O$
MD,$8"QQ1J%15'0*HH`,4JF*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5BOYJ?^2^U
MO_C`/^)KA'-C/Z3[F&/]MOF<SGG&L5=BKL5=BKL5=BKL5=BJUT#HR&H#`J2"
M5-"*;$;CYC%+SF#RCH/D'7TO_+=GJ-]J&LI);_H>*19(G"4D:62:>GH^G_,\
MC<N7'*^$1.SE'+++&I$`1_B3S_%/G3_J2;G_`*3[+_FK#Q'N:_#A_.^R2&N=
M;_,V>YMI[+RREI:6K,]]:7-[;M+=*PXB.!D#K&R$^IR=EY?8QN7<D0QCG+[/
MI1/^*?.G_4DW/_2?9?\`-6/$>Y'AP_G?9)4L_.&JC4+2TUGRW=Z3'?2>A;7A
ME@NHO6(+*DGH,6BY4^%V'#EA$N\(.(42)"3*,DTNQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*J:?\I!Y;_P"VK%_R8FRK-]+F:'^\^#U>ZUC2;.417=[;V\I'(1RRHC4/
M>C$',5W*C_B3R[_U=;/_`)'Q?\U8J[_$GEW_`*NMG_TD1?\`-6*N_P`2>7?^
MKK9_\CXO^:L5=_B3R[_U=;/_`*2(O^:L5=_B3R[_`-76S_Y'Q?\`-6*N_P`2
M>7?^KK9_\CXO^:L5=_B3R[_U=;/_`*2(O^:L5=_B3R[_`-76S_Z2(O\`FK%7
M?XD\N_\`5UL_^DB+_FK%7?XD\N_]76S_`.DB+_FK%7?XD\N_]76S_P"DB+_F
MK%7?XD\N_P#5UL_^1\7_`#5BKO\`$GET_P#2TM/^1\7_`#5BKO\`$GEW_JZV
M?_(^+_FK%4)JE]Y)U6S>RU.YTV^M)/MV]Q)!+&:>*N2,5I4L]7\HV-M':V5[
MI]M:Q#C%!#+#&BCP55(48JK_`.)?+O\`U=;/_I(B_P":L5=_B3R[_P!76S_Y
M'Q?\U8J[_$GEW_JZV?\`TD1?\U8J[_$OEW_JZV?_`$D1?\U8J[_$GEW_`*NM
MG_R/B_YJQ5W^)/+O_5UL_P#D?%_S5BKO\2>7?^KK9_\`(^+_`)JQ5W^)/+O_
M`%=;/_I(B_YJQ5P\R>7B0!JEH2>@]>+_`)JQ5__6[;IOYD:SJ5C;WUGY:D:V
MNT]6W+WENC%#]DE3]FN&G%GK,<9<)NT3_C?S'O\`\ZRQ`ZGZ];XTQ_/8_/Y-
M?XX\Q[?\ZTU#T/UZWQI'Y_%Y_)</.WF2M/\`#+`CK_IUOMX_=C2?SV/S6_XY
M\QTK_AEJ?\QUOC2/S^+S^3?^-_,A-!Y9:O4#Z];XTG\]C\_D[_''F,`G_#+4
M%?\`C^M_\]\:7\_C\_D[_&_F.H'^&6WZ?Z=;XTOY_'Y_)W^-_,E:'RRVW7_3
MK?;Q^[&E_/8_/Y-#SQYCH#_AE@#_`,OUOC2/S^+S^3?^-O,M:?X9:M*T^O6V
M-)_/8_-K_'/F.A/^&6('_+];XTC\_B\_DW_C;S)4#_#+;]/].M]\:3^>Q^?R
M=_CCS'4C_#+;=?\`3K?;&E_/8_/Y.'GCS&0#_AE@#T/UZW_SVQI?SV/S^3CY
MW\R`T/EEJ]:?7K?&E_/8_/Y.'GCS&02/++4'_+];XTC\_C\_DX^=_,@_Z9EM
M^G^G6^_^WC23KL?G\G?XX\QU-/+3;=?].M\:7\_B\_D[_&_F/8GRRP!Z'Z];
MXTOY['Y_)W^./,=:?X9:HZCZ];XTOY_'Y_)W^./,G'E_AEJ?\QUOC2_GL=7O
M\G?XX\QU`_PRU3T_TZWW_P!O&E_/X_/Y.'G?S&02/++$#K_IUOC2_GL?G\FE
M\_:I%=V,5_H#VUO>W,-H+A;J"7B\[<%)1?B*\MFQIGCU4)FAU17YJ?\`DOM;
M_P",`_XFN(YM\_I/N88_VV^9S.><:Q5V*NQ5V*NQ53GGBM[>6XE/&*%&DD:E
M:*@+,:?(8I`LTPQOS$U!%@>31OAORJ:>J7`+!W4NHN:H!&OIJS,T7K<>/#XL
MKXW71[6TY,Q<OW0OZ?KX3P^C_._G<*Y?/NK/<-8)I$?Z0A599F:Y(MC$Y*IZ
M;B,R%V974J\2\./VFY8\;"7;&G&(9/74I<'#7KCP_5UX?XHJ7_*S)A:-JAT=
MQI4999!ZRF[#(WIN1%Q](JLHX_WW)E_>?Y&/B>3=_*.#QABL\4OXZ_=^J/'_
M`%OI_HJK^?\`5H98[2;1T%Y=\C:<+DM"!&.4@G<QJRE%/P^FDGJ?Y./&TP[8
MT\H2F.*L=;5ZI\?T\&_^Z^EI/S`U.626"'1E-Q94%\KW/%&++S46[",\^2?%
M^]6+BWP?Y6/'Y)GVOIXQA*Y5E\OHX?3Z]_YW\SB6?\K*N/JT6H#1W;3;LHMF
M!,HN2TQ"PF6,KZ:)(Q7EQE=HOM?%CQMO\I8/%ECLWCXN*5>C]W]?#_%_L?4J
M'S[JRW`L&TB+](.AFC<7)-J(5(5BSF,2^H'95X"+XN7+GCQ^32.V=.<1R>K:
M7!P5Z_YW?P<*Q?S&OFCGN$T<BWL2T>H@W`]7G$.4OU=0G&157XE,C0^I]GX,
M>-L/:F`2A&Y?O1&4=OHX_IX_^.MM^8E\B02R:-6._*IIX2X!<.X+(+FJ`1J4
M#,S1&;A]CXL>-$>U<!,Q<OW0OE]?#Z?1_G?SN%<//VJM<-8)I$?Z0B032NUR
M1;&)R50HXC,ID9E=>#1+PX\N;8\;`]L:<8AD]7JEP<%>OT_5UX?XHJ1_,N<6
MTFHG1W&F6Y9+D&9?K0>-N$A2,+Z;(D@*[S*SK\?^3CQMW\I8/%&*S<P)<=?N
M_7'CA_2^G^BFVB^:KR\U)-/U"Q2SEN$>2U>*8S*?2H7CDJD?%PK<JKR1OB_V
M4A).CU^+4<7!Q>C^=_-_G,DR3F.Q5V*NQ5V*NQ5V*J:?\I!Y;_[:L7_)B;*L
MWTN9H?[SX)UJ5AIUUY[\P-=VD%P5M]/59)HDD*@K.:`L#U_ES'BV=H2((]RL
M-%T(L*Z795WXCZO$>5?]CO7_`(?"X'B2OG^/Q_IEQT30=Z:79'^;]Q#\.U/Y
M/\_L8LO$/?\`;^/QZ5GZ%T&@_P!QED`*<6]"$5I_L?\`KG%AXA[_`+?Q_P`=
M2+S#K_D#R[<I#JNF)&[^DJF'2Y)XN4K\8T$D4#IZC-LL?+GR_P!;%OAQGE\N
M)7TF]\E:M.+2TTZ%;AH&NC#<:>;>40B7TN3)-$C*#)4*&^W_`'B_#BURX@.>
MW]9.AH>B$5_15D3O1?J\1!KX_!O7_A\5\0_C\?\`22TZ'H9)(TNS()^(_5XC
M2HIUX?Y_9Q8G(>_[?Q^/2VNA:'4`Z79BFZ_Z/$"=J?R?]<_9Q2,A[_M_'X]+
M3:'H@;_CE6084Y)]7B'$#_8[4_X3%?$E^/Q_TBT-$T&@!TRRX4^U]7B\:T^S
M_G]K%`R'OV_'X_V2YM$T+?\`W%V7+>B?5X36O^PWK_P^+(Y#W_C\?Z99^A=!
M-?\`<;9$$GD?J\1I7_8_]=8L?$/?]OX_X\@O,6C>65T'46N=(MY+<6\I>*WA
MB$TB^F01&0NSD;*?]CBV0R'B&_V_C\>E&C1="!_XY=E44JOH1#C3_8]O^$Q:
M_$EW_;^/^.KAHGE_B/\`<99<:"C_`%>$=#6GV?\`KG[6*1D/?^/Q_P`4T=$T
M*O\`QR[+EV3ZO%N":_R_Y_:Q0<DOQ^/Q]2%L(?*5_=ZC:6MA9RRZ;*L%_P#Z
M+'2.62-90@8IQ>L;HQXXLN*0&YVEY_C_`(^C'T+1!0G2[(;GC_H\7Q;4W^#_
M`#^SB@Y#W_;^/QZ6ET/1`P)TJR[5_P!'B'&@ZUX?]<_9Q0,AOG]OX_XZU/H^
M@06[ROI=H(HEYEQ;1EB$J:!0A)]E7%/B'O\`M_'_`!U3M=*T&YMX;F+2;0)-
M&LB(]HB,$?XAR1D#(?%6')<4>)('S]_X_'J5CH6A%"?T79%#6K_5XC2N]/L_
M]=8I\0]_X_'^F6G1="K_`,<NRKOQ'H1'E4?ZF_\`QMA1XDN_[?Q_QY<-$T'J
M-,LB=N7[B'X=J=>'^?V<#(9#W_;^/QZ4H\UZ-H:>5]89-.LT*V-P8Y%@B5JK
M"U*47:G_``F)98LAXQOU'X_'TO\`_]?H_EW6=,T+\L-.UC5)O0TVRL4DNIJ,
MQ4$TV102Q)/V1]O)AT.7&992!UD4YUKS7H6C:1;ZSJ-SZ=C=M"EFRAY'F:ZH
M(@J*"[%Z_P`OV?M?9Q8QQ2E*AS_'X_I)L876M:?Y>YHNU/#_`#^SA::_'X_'
M\*[TR`*FB"G%JD$D?J_XTP,J_'X_$%CJ4Y.]%XBK`F@"C<GIV'Q?Y/V\45OY
M_C\?[)+=,\P:-J5S':6-SZ[SV2:E&RAZ&UF<I&]2!_>,K<5^TZ_O,61QD`WR
MM-&C8FNQ._$5)!^>V_\`QOBQ(_'X_$G)&U21N#]H\CMM38T_S^SBH'XO\?CT
MM-&:J*T'534@F@^7_7.*D?C\?B+A&X;H`PIR6I``KUZ;?\:XH`_'X_$6VC^$
MBHX$?:KO6M:?Y_Z^*:V\OQ^/]DM:*2NX',UXK4D&OT;U_P"'PHK\?C\27,`B
MLS,%0`M*[-0**;FI[?Y7^QP,@/Q^/Q_"Q:Q_,7RK?7EI!!+<"WOI?0TW4I+:
MXBLKF4`@)%=.BQ.S4/IFO&3[$7/&V<L$AW;>?J_SF5+&XWH`=N0J0`!]&W_&
MF+`#\?C\1::%N('['9JFM:UIT_S^UA8D;>7X_'^R0@U&U_3(T?E74VMFO!``
MQ'H"01\F-./Q.=E_W9\3_LX&8@:M>+F-[R:R59"\<:S22E7]+C(Q4!92.#O\
M!Y(&Y?9Y\?AQ08[?M_'_`!Y7$3\P#UZI\1WVIX?Y_8Q0!^/Q^/X5&ZO;2TGM
M8+B58I[Z;ZO;1$M5Y1&TA5:`TXQH[,W^ZU7%D(D_[[\?CA6V,\=[;">)9$AY
ML@]9'A?E&Y0_`X#!:K5/\C]XOPMBP,:_'X_XZBA&Y%0!RI]FII3[O\_M8LJ^
M?X_'^R4PE5-&!7?DW(FE?\_]EA85^/Q^)+PC=Z<NJCD=P13?;_KK[.!F!^/Q
M^/X6/ZAJ-G?MISVDGJK;:_96TS?%Q]6&=5<(2/C"-\!9?A5^4?[.`N5I8D91
M^.C*/S4_\E]K?_&`?\37`.;N)_2?<PQ_MM\SF<\XUBKL5=BKL5=BKN"/\#@,
MC_"RG<$'8@CWQ2P?RQY&T*_T.QN+PW,TC*3;AIW`MF$A"FWI3@R*."LW/X?@
M^RS97&`IA/3XHRE4(?O/[ST_WG]9+[?ROIYT32]5,UTM]<7JV^HWJS,)Y8);
MA[=8RWV0L3&)D"JO#X^/'U'P<(I,M'@(\/@AP1]4(U_'7^^3&]\B^6X=8TJP
M2&3]%W?UDW&EF5S;.T40=7*$UKS^)_BXO)^\9>>$P%I&&'$<G#'Q(UZZ]7\W
M_<^E3TGR?I$UZKW#7-P\&LM903RSR,\,`(41HP(XB2O&1OM2?MMFG[<U,]/I
M9Y('AE`2]7^9+@_V?"[#LSLS3Y./&<<*GC$^"OJX<D..7^9CX_ZOU(SS7Y$\
ML:1?+':SW4373QQWK&X?G.TK,W%F%&=DB5N/\B,J_8SG_9_M?6ZO2SRSX.(2
MX,/IX?%E&$IY./\`H_3]/"YN3LC1B7"<<>##CE/_`(3ZHQQ\'];)_.XN)5\S
M>0O)^EW=II,4<KVIL[R^CMWF?TXVB:%(C$BE53TVE8Q!1\#_`&,A[+=MZG7#
M-/,8\.*(X(PCP\,Y<2<G9.GCGQF,`<F:8ADE_JF/_*<7^9]<OYJ16_E;33:W
M,][<72ZE927UN^J"8^NJPKZL:*:<.'HMR:/A\<B\V^+.QR<0H#ZC&?\`RLX>
M*'^^=;C[.TIPY(QQP.,3Q9.'_:^.6.>3_IG'^CQ)_)^7?E2"X:R@:YEMYB+B
MX1YWI=1M%'1YJ<0_JR-)ZI''U.'!_@7CG*>RO:VJUV69S$<$(?1"/#'Q>/A_
MK?1_2<_MCLK38<>&<(1X_5&,_P";X<CZ?YOHCX?"@+;R/H$NNZA92BXDM+."
MUET^)IY*6KRF4%H*&J,HC7@QY<$^#[#9VO`+=%^7Q`&0A"\M^)Z?[S^LEU_Y
M7T^VBUQUFNAJ5E<VHBU$3,)WM;HPTAD(^%D0F8(."\?MK\7+D#$)&BP&$8<$
M/#WEP5_'_.3*7R)Y;7S%%I:PR#29+.6XFTWUI#;RRI-$G.12:L3RY2?%^\D_
M>/\`%AX!:?!A?B<,?$CZ8SKU1C2-\IZ#96VI:I>(\T_U:X:PL6N9&E:**-(S
M*%)_GEK5F^/BB_%AB$1T^/$/1&,./U3X?XF4Y-+L5=BKL5=BKL5=BJFG_*0>
M6_\`MJQ?\F)LJS?2YFA_O/@R&Y'_`#O/F$C<_5].^#Q^&?,>+/M'ZA[D:`>7
M4[UJVWP[;]/\_P"7).OK\?C\?S6R&]Q3I]GXMO\`/_KO`R/X_I?C\>I;1NHK
M4T^';X?O_P`_YL+#?\?C\?Q,8\XPSWGF#R=I*J[0/J3:E<2!:KZ>G0/(@)I0
M5N)(>/+`Y&(T)&^G#_IBP[SEI,^I3^>=:,5RU[;+8Z%H:1O+'QN**WUA0A7F
MT=Q>_"W[/!O\K`6W%*N$?UI2_'^:@]5C\P7_`)JU.SFO/1UX:K':Z(O^FM=V
MUI$8REQ%%"4MC;RKSFN9G^!^3QO]A8\+.'"(_P!&O5]/X_'I5M3A=M.OO,U\
M]WSUK7KBSM9YKJXMK2RT]',`9Q""4AN%M>+LJHS^LB+-%]O%B);T/X8_T?7)
M+]/U%%$.GWMU-8Z#=^97:EL;J"&.QT_3T>5E,S-/#:W%U+%S;GZ7%^7P\\#,
MB]Q]7#_1^J1_W7"F4E[J.@Z99:_IT-W-HR>8IDT*P9I.4]I>6C6\**LIY^C-
M?#U+=7'[N*3G]GCA8F/$>$\^$<4_\[_B?^//2/*^D7NDZ/#;W\[WFIORGU&9
MC4/<3/SD*`_9B5CPB3]F-%_9Q<24K-CE_-_'X_S4V8&C"IIO5]MO;;_/^7%B
M?Q^/Q_16T:M:&H)^';XON_S_`)<*/Q^/Q_50NMM.FCWSPW0L91!(4O9./"W8
M(:2-[)]K_F[`V1YCK^/Q_P!)(H`[;G:E&V^+PZ_Y_P`V+77X_'X_G+A6@-#6
M@_=[;;]=_P#/^;X<60_'X_'^E:XEF"U-#^WMMOT_S_XCBQ(_'X_'^:\CT&SN
M-6U"QEO%NH]/O[O7O,NJ1(SP^K`CBRLX92G%F1HOC].OQ</AQ<TRX;KF!&$>
M7]:7X_TJCY>L-4TJ#RIJ:Q:A=ZC#H>IZQJ,(EED=H3&OU2P"R%U'`S#TDXLW
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M_%_$]@(.^Y-:U;;X=O;_`#_ER3@5^/Q^/YJ\!MNHI2A^'XMO\_\`KK`S'X_'
MX_TR3>;>7^%=:-#O87%5V^']RW^?_$L66+ZQ[X_C\?YS_]"5RV3ZM^7_`)(T
M#TC+#JUU9QWJ!2R_5;8/=R\Z=%8P(OQ?:Y9-TTI5ED>HXF.V=CY@\P6?DV*[
MLY?2TR>"QM+>5&4&33(6GO+F2HV66:VM[*!F^TGK<?[W`SXHCBWY_P"^1.F7
MR00:)J^G)?7'FFQM[O4/.5TZ7`?X;.4R6EP''`NUX8DM+=!^[2+E'\/VEC*7
M,'Z?\GR_TW^E5+K0/,.A6>D_H1;N7S)9>6+R[U*[)EFFEN95ACB3XB59HI&G
ME@AI\#1+\.+(91(FSMQ#T_S?Z2AK<>E+I>N2^4%NIM#C\OSVVK7K_62ES?7$
ML2V[.9?CDN;=/7FN9%^.-6XR?R*HC(DCB._%MR;U'RE8'2O-=UIMI+_HRZ;H
M'E9(O64(56,_6XP"*E9[UY%E_9X-Q^'EBF.;<6?YTI?C_-7:Q:Z[J/FS5K6>
MYX:Z^K1P:*QAO);NTLHFC,5S`T<D5HMNZ!Y;F4_WC-)%)ZC<8\*B<1'^C7JW
MBK7MG_N%OO-%]'<M=:[KEQ;QW-Q-=0P6.FF8PJ62#XT@ECM463@$]3UU5I8T
MQ8QR;@`_3'R]:76UW%&OU"\>>RT*_P#,RGTK2*ZM(4L=/L$GFECCD9YX;:>X
M:/U'Y<./)_AY8&R4K-CZN'^C_$4?)<W^@V]IY@T>SN'TEO,4L7E[3"73U8+V
MQ-N@5)35()K]/7C5A^[B;U>/Q8L!4C1._".*?]67_$LRU73?,&@?EGJ$%A//
M>>81;O+<W48+S/<3R!KJ>%=VJBM(UO&OV>$?'"TQE&4]^7\W\?C^+Z6$ZO:V
MLHU"V\BF[CT;4+.UT>ZU"/ZP4DO;R^B7U4:7XGN+>T^L/<W`_G17;DOPANC.
MJ,SN+E_FU]/X_P`UG7F[RJ]O^7&O:)Y;@E%Q<VTYAB]1Y)KAY`/5_>2%F:6=
M`R_:^)FPM./+<P9%#Q^==+U:.TTWRQIDFIRQQ^H\$UN]O#IWU:%C`)?6B"+<
M"98X8H%^/[3?#PY8J84;D6&V-Y':66DZOHBWUQY@T^PO+[S?>.EQS>4V;_Z+
M<+(.)G:_,?U:!5_<1Q-QXQ_:#<3T)J-C@Y=__$KW\I1Z8DRW5O=WHT;RD)M2
M#R3N+[49BQC65>7[TP^@_IQ_[J]1?\G%?'OKSG_I8I?=Z='Z6KV6IQWMYYFM
M-&TS1/+;J+@/+?QV_K2312+\)>&ZN%:65V_=QIRY<>>*8SY$$</%*4O^)_'U
M,AFL=:UCS)]4NWNQ#>Z^D=P\;21!K31-.'J%63CQ2ZOG/V"OJ_LX6!F(QO;Z
M?+^,_P#$I:0MO`MA-;FTT#4-=U.>V%W];:RBBL^%O#;M!!227ZU();F&%I$A
M=O\`?C\5P,A*S=^H`?S?Q_10.C$I!H%_JUK,T^DZ;Y@U?2H)8IU;UENBMI;1
MHY=E:"%&*1.S-&K*N+*4N='F8Q1,MBMIIM[I?F..]O=<M-)LK7RI9I]8+R3R
M6@:6>W:/;ZS]?9O5F=N=O'&G+C%B@3WN-<SQ\OQ]*)U+1-7O]"U^^U`W-SKD
MNH:;HVESJTJK#-;BW@FNX46B@F=[J7UN/V4_DY8HCE`(`/IHR_XXS'\S+O5-
M/L]'U33;>:[NK+58^%I&&;U?7AFMU#A/]U^K)&9#]G]K"7'PD$D$\Q^/Q_I6
M'Z-!YLLYIM)$MS-<Z3J-S;6%Y-S*3ZGJ*U^M-_-;6-N;BXI]CE(D:_&F!R92
MB=^\>K^C&/\`Q3/[O3+/2M.\N:9:`BVM-4TV.(L:L])QR=SW=V+.[?S-\7Q8
MEAII7E!_')D_YJ?^2^UO_C`/^)K@'-V\_I/N88_VV^9S.><:Q5V*NQ5V*NQ5
MP-"#X8JD_E3]WI3V_:TO+R!3[)=2<?\`A2,C%LR<_@/N271XA/J]OIDQ8VNG
M3ZG<)"#1&FBO4,+,!]KTEGJJ_9Y_%^RN`<VR1VOOX?\`<IU<_O/-NGH>EO8W
M<WTR20Q#\.62ZM8^D^\(:TAYW>MZ?S]/GJ=O()/Y5N(H'8^Q7A(V:;V@RC'H
M<I._I_V4JX7;]B`_FL<O]3C/)+^KBC/_`'7T(-WN]<UNVN[DKP35[Q2IV/I1
M0DPJ/\I0RH_^IE?8_9XT>'#B_FPE&?\`PV7[V?\`OX_Z5GES^+AS5WX\O^9_
M<_['BA./]:2[S[?R176BZM'\4MGITZ.IW!=(FG-1WXM;\O\`6S0^S>A_+0U'
M^UZL_P"DP_\`63B<V&7Q,D8?ZMA,+_FRR#_??1_5E)0UZUBM/R^D@B+22WL(
M>6X=BTDDUPO.29F/[3$_[%?A^QG9:D;1C_.G'_8^O_>NJ[-E62<^F/%/;^O^
MYA#_`$V3B_S4VUN>:*Y\MB"5D-H8=.N$6G&1)'DB*O\`ZH@]1<Y/V:[/.#6:
MK^;XO#'_`#_WG^YD[#79Q+0P!W.0\?\`5\&/#_LY9/\`8JNC_O->UV8]IK:V
M`[TBMED_XE.V=J.9>=E](2.WC$OE?3IY&:2[UV_LI;Z=S4LWKJ_'_)2..'TH
MT'V5R/1L/U'^B"G=]\'FG2)?]_V][;G_`))3#_DVV2/-K'TGX+88Q:^;)8H&
M98=0M'N[F&I*>O%+'$)5'[+21MQ>GV_35OM8.JG>/N*=9)K=BJ`UK4FTZP,\
M<7UBX>2*WMH.7$/-.XCC#-0\5Y-5VI]G`2SA&REEWYEN-%4+KXMVDG<+8FR8
M)ZI",\@*W#J(_2"_;:7C)R7C\?P8.*N;(8^+Z5NG^;AJ.L0VME&LEE.U8[@\
M@YC6T2Y=N/8A[BWC_P!DV(E93+%0L_C=DF2:78JII_RD'EO_`+:L7_)B;*LW
MTN9H?[SX,BN/^4Z\PCHWH:<0_A\,_P!W^MF/%GVC]0]R,%/Y=@2&2@'*@_S_
M`-3"Z\?C\?CA1ATJ_P!OW!(/V/L_#]%?\_M?:QMR?RN3N^[T_C_CS7Z(U'_?
M)Y#[3?">5/F=_P#C;]K&T?E,G=]WX_XICT_Y4Z+/-)/+9WA,SL[HNH7B@.QJ
MQ"K<!0/Y>/\`JX+;?!RU].WN@I?\JAT6H_T:]Y]I/TE?;#P_WH\,;"^#F[OL
M@V/RCT/C06=[P&QC_2-]\5.G_'Q_USC87P<O\W[(-'\H=$K7ZK>DG[)_2-]\
M(_Z2,;"^#F[O]C!2;\EO+KWL=X]I>FXAC>)7.HWA^&0J7I6?E\15?VOB7[6-
MA(Q9JJOLAZEEQ^2GER>YAN9K.^D$)Y06[:C>,D<G3U0#/7U%!XJ_+'9?#S5]
M/V09-IOEBXTZTBLK6%UBA!"/)(TK4)+$&25GD;KU9O\`(^QAMK.ERD[C?X(D
MZ3?D$BW(7NGPBI\>NW_&N-H_*Y/YOW?C_B4//;3V[JDR\78%D.WPCZ/\UQ:L
MF.4#4N?X_']%+]=1GT74%6S^O,8)`;$[?63P/[K;^?\`YO\`M8K#GW?C\?[I
M'P0R3NJ1)S)`*QT'PBE>YW_XW_:Q1"!D:`O\?C^NBAI.HUIZ1YTWD^$UIVZ_
M]=?9QMO_`"F3NW_G?C\?PJ4^AWD\$D3V[>C*K1O&&"DAA0D,I#+M^TOQ+^SC
M:/RN3^;]S'5_*'1`:?5;WEMP<ZE??#3I7_2/^N<%AL&'-W?9!H_E%H9K2TO1
M3[0_2-]\7O\`[T8V%\'+W?9#U*=S^37E^YA,,]G?-$_0?I&])0@U#"MQ3DK;
MK_P6-A1BS#^'[(++3\D_+]MZA%O?RW4M#<WLNI7C2S4%`'<3KRXK\*;8[,CB
MS':OL@K_`/*H=#(J;.]*'8Q_I*^_[*/#&PP\'+_-^R"CI7Y+:!IFH07UO;WT
MEW:&NGR7&H74J6R[?NXE:6BQGBO-#S7X57XEQV9RQ9CM7/\`J_C_`(EEGZ(O
MZ$B`@?M+\(Y5^G_KG]G#;1^4R=WW?C_B5WZ)OZ"L!-?LCX?AVIX_Y_:^UC:?
MRN3N^[\?CB8[YO5E\L:XC;2+8W(=MMSZ+[?Y_:Q:\8(R`=>(?C\?4__1Z'Y8
M\O:7K'DGR]]?69O1M%]-H;B>WIRZ\O0>,MT_:Y<?V,F'0Y9F.25?SO)'G\O/
M*^_[J]H-F4ZC??%3?_?^-(\:7XC!9_RKWRP:5CO3_*/TC??#M7_?^-,/&E^(
MP7C\NO*YV$=[7J6&HW_Q5\/W_P!W_#8TS\:7XC']2!OO*GDJSOM/M+A;X7.I
MRO#8PB_U!BSQQ-*Y)$_PJL:,>3?ZN*!EF;.W^EA^I'+^77EFO]W>\A^W^D+_
M`&[4_O\`&E&:7XC']33?EWY8XT$-Z$%04_2%]0T_Y[_?C2#GE^(P<OY=>6>8
M_=7I8[`_I"^JNU?]_P"-*,TOQ&'ZD!JWD+R'8M#JM^MW&;<BWAN&O[]CRNW2
M-42DQ;E+)P1:?:_;QID,TSL/]S!2M?(?D'5=2NC'%?7$^C7`MI4>^OC'#<M&
MLA:,M-O((IE7U%;]K@V-+XTP!R]7]&*:G\N?*X!/I7E:5]3](7_R_P!_XTCQ
MI>7^EC^I:WY>>6=V,-[05JIU&_WI_P`]_OQICX\O+_2P_4N_Y5QY7Z>C>DCO
M^D+[X>_^_P#&F?C2_$8-/^7?EDFABO?#?4;[XC2O^_\`%CXTOQ&'ZFU_+SRP
MU*Q7I_E3](W_`,)/A^__`,_VL4C/+\1@T?RZ\L[`17O+[7,:A?\`<T_W_C2#
MGE^(Q_4Y/R\\L4($-[0=8_TC?[TV[3XTHSR_$8-O^77ED"GI7OLQU"^^$+_S
MW[?]<XTDYI?B,/U)?K/E?R1HEB;_`%`7\5L)88"4OM0=GDN)%BB4*L]3RD=1
M_JXIADF30K_2P_4B[3R-Y6N4E9+;4D$<SP%);W48SRC8KR4/..2-3]T_V9%^
M+&E.:7E\H(2Y\J^2;:XFM&%_)=PVK7TEO!>ZC+*T`8I5468EB[@I&GVY&Q0,
MDSW?UJA^I'1?E]Y6DA2807P5D#>FVH7ZD`_S`S[>X_FQI?&EY?Z6/ZFO^5=>
M6%_W5>@T-'_2%\*`?\]_OQICX\OQ&'ZER_EWY6(/[J]H-BOZ1OOBIO\`[_QI
MD,TOQ&"*U6VBM8M`MH0PAAU734B5V+LJK,``78L['W9FY?M?%B6W2&\H/XY,
MD_-3_P`E]K?_`!@'_$UR(YNYG])]S#'^VWS.9SSC6*NQ5V*NQ5V*I1YGU#4=
M-TE]2LHUF^I$S7-NQ"^I"$8,%8_9*L4D_P!5&7!(TV8X@FBA+E-5T'RLUS;E
M;R]M3)?ZBC403\BTURB'<)NW[K_45>7[6#<!D*E+_8I5Y7L=337VN99&N566
MY2\E``C26YMK:YDX@?93U_@3_5P1&[/(1P_CS1.ICS)>ZW-J.A&)?T6?T<\,
MW&EQR9)[D@T)CX`11Q'XOB]7X/LXF[V8QX0*EU]2D_UV;R/?:[ZI@OM1$>J2
MA0#Z<4?`K`M#VMH_3=J_;:1LKRXHY(5(6-I?Z4\7^]9QEPY`!T]"%A;5[C4H
M8-/01W.FW=WJ5QZG'A*]Y/-'';GNG*V65^?[+>EE9U,?$C#^*?'*/_)+Z_\`
M=-L\!A$F0VJ'^EG'CC)3N8M<GUBXMM0G4"TU&&WLFA`'JQ:DY+,_=>%FKP\*
M?;>7[7PX<6`0,J_CGXDOZTZC_O6)R`@?U?\`<?\`'D:#J5YY2TOR_<(;74=0
M5;&1S0F&&!`TLQ#5K)Z2T1?]^NF.'/'*#7\,Y8C_`%\?U,90X)WTKC_TS=HF
MN2^8X8=3HS0R6NH7(3^[B_T2YB<CK\+W"^I_K/DX8A&1(&\R)S_TO!_O42F#
M#W7&/^FXE,7.O1Z9JVO1.(;76HUN+*,4]6WE?T;:U/(?:,L7[R0?[K?X>66;
M\T5&Q'^;^)+I;/5VM++0+("WO+&>XU%9I`I416UU)]50*?M?6':.NZ\8>?Q<
MN.-'D@$69'^K]GJ1V@G6;[6Y'U@(D^B)Z"+$05EENP)&FVH0%@]*)5I]OUOM
M?#A%WNQG0&W\3O+0OY]9U"YNN3BU$MC',V]2M[.Y7_8Q?5_^%QCS7)5"OZW^
MQ#)\DTN(;P.*H;4=-M]1M'M+I&,;E6JC,CJR,'1T9:,CHRAE88D6RC*C82JY
M\J:%2)+B2<74\K<;M[AQ<S/)$59/4ZL#"GV%^RJ<DX_:R/"&8R21UEY?TVSN
MS=VT3+,PE`)9F'[YD9Z`_P#&&,?ZJ<<-,3,D4F%#2O;"P<01UVQ533_E(/+?
M_;5B_P"3$V59OI<S0_WGP9#=?\IQYAKNH@TZH[_9G_SKF/%EVE]0]R,`^-:T
MKOQ/$[`?Y_[').`.?X_'_$LU'096]*[%*`U?6;/2HK=[DG_2KB*T@4<1669N
M*BK%5]^O^K\7PY"<Q'GU/"Y.ETL\QD(_P0EEE_4QI0GG[1Y)M(2&.65-9NKB
MSM9%X%0UMRY,_P`554\/A'V_YD7*OS$=OZ9X?]*YQ[&R@9"3$?EX0RS^K_*U
MP\.W]+^K_-DZ^_,'0K"[UZ"]]2!/+T5O+>3D`J_UI:QK&`>3.3\%"%^+&6IC
M$R!_@K_9+B[%S9(8I0J7YHSCCC_-\'Z^/^C_`!(;2_S%@N=2M;#4-(U#1YM0
M5FTUKV-%2<JO(Q@H[<)>._IOQR,-2"0")1XOIXFW4=ARACE/'DQ9QB_OO",O
MW7]/U1CQ0_IQ0MI^:+W.L_H<>6=6COE6.2:-XX/W<4C<1(])3\%<B-7<N'AE
M;?E]GA##XOCX##>,=Y^N</5P1]'U)MHWG:UU2_M;-+&Z@>Z2[=7E50JFRG^K
MR*U&/Q%CR7_)RV&<2(%'K_L#PN#JNR9882F90EP'']-_\B,?BPER9'E[JG8J
MQ[S%_O7'7[/I_$*;GXC_`)_Y.2BZ?M'ZQ[F.>8OJXT#43<W#V=N+:7E=Q*QD
MA3@274#?DOV@/]EA<2`]0_'X_$D]T(#]))M\7$\FIUJ/'_/EB6_0_P!ZR?(.
M\0&KZS9Z4EJUR36\N8K.!1Q%99C1=V*CH&;K_J\G^'(3F(U?4\+7DR"-7U/"
ME-MY]T6YN]'MH5E<ZY)=Q64@"%/]"KZA>C57E3X!3G_.J96-1$D#^??^P:HZ
MJ),0/\IQ</\`F(W4O,UEI^OZ3HLT<AN-7%PT$J\?306L8D?F20=U.U!DI91&
M0C_.O_8LYYA&<8GG._\`8L;;\W-,X&_CTC4IO+JR^B=>CA4VWV^'J*O+UFBY
M?#Z@CRC\X.=2X/Y[C?GX\^&7!_/_`(626/F>QO/,6HZ'%'(+C388)Y9CQ]-E
MN063@0:[<=ZC+XY09&/\UR8YA*9A_-K_`&3&KK\W;"#RY;^8TT74;C29DD>6
MXC2$B'TYC!26L@H69:KQY?#E!U@X!.I<+C'7@0$^&1C^WA3"+\P"8[5KC0M1
MM'O/K/HQ3)$&/U6#ZQVD/]ZO)(O\M?BXY,:CE<9;W_L1Q-@U?*XR%\7^QCQ,
MBTC4H]3TJSU*)'BBO88[A(Y``ZK*H8!J$BN^70EQ1![W(QSXHB7\Y%Y-F\X\
M[@?X?U^HV^J7?$4.Q,;_`.?^5D^CS_\`E?\`/_WS_]+JOY?T_P`#Z(:?!]43
MDM.I'>O\?V,F'G]1]<NZS^/Q]+(B#R`('+?@>-.-!7?PI_PGVL6NM_QZ?Q_L
M?J6`=:`5V#_#]K:NW^?^7BQ_'X_'])B?Y@M$&T&/45D'E>6\8ZWZ4<KCBL#M
M;QS"$&0P2W'#U-N,O%$?X6Q<C#U(Y_P?C\<3&+#RYI5_K-BYTJ^A\N:7IVH:
MO'IUXDH4O>3K%'"J`\A$T-O++':.>2^LJ/&OV<6?$0#N..1C'B_'^EXO\UC/
MZ-UZ'3]/L=<B,D,>A6HTC3;FTO[EI+JY]1Y_J_U=XE2[@9HH%:=N4$:IQ:-?
M4?%N$AN1_./%_#^(_P#2*<:UY6UJ]L-=.H"[O=6MH]%\O:3>,LJ<9U6)KF^1
M5+*LL;W+L9^3>EZ3?']K`PC,1(Z?7/\`XXB=2T1[#5=?]&"\M/*LFK:78ZSZ
M*W!:2UAM6GNIR5)E99YYH(;J:/XO35V9OM841-@7]7#+_CL?]]P_YR'DT/3=
M1UK3K8:=+%Y(U#S!!)IEO+!.(A]6L',KI&PY10W=V8ECY+&DWI/,O'E@9&1`
MN_5P_P"Z/_$JNE^7;^1-!UJWL9AYBUO7;W5I;B5908K6-;AHH#6BQ1SHEM"Z
MM_?<\6/'N1>PC&/];_BOXDI\N1ZW;PP:RH>XUK3=.OKW7FAL;Y+J6X>!E^J7
MDL\GI/)]99#!'!"_#T?W?I1?$RRGPG:O3_#_`*;Z_P#CW^:F=]Y6LO+]MY=T
M>ZM/5>:Q%QJ6IWT=_?1W5Y`BQK;-!`X]29?4D:%)'2.)?L([_8+$3XK-_P!7
M^'AC_6_A_I)?Y=FTXKHEIYOM;N6UTW07FDTXPW,@:ZU*Z=X;5XDY/ZL=M`%M
MHY?L?:^TF!G(59C4?5_N1^/]TC[;3?-UK>Z+Y7E,Z:GYC\OV]M?W'(R/916<
M\AN9&-2?6%M<K;1R?MS\'Y?#A82X#<ND9>G_`#A^),Q\]6\=K9Z#8S12Q>5Q
M=I#KCP)*X%K';R>A'(8JR_5Y)UB29O\`=G^[/@Y8M6$[D_Q_C\?TF)V&@3ZO
MJ=CID-I>6GDR\UB[U2TLZ3P@65K9)`!0\9((+R\F>2.$^GSCY<57E@;)3X1?
M.5#^EZI2_'^Y95YK\N"^O?*7EFWAFM])6YDN+MK?U8D2TL;=EC@>53R5)))8
MD^WRXJRX6O'*N*1^JN?X_$&"6]FTWF'2DT[3/J%W%KZ02VR6]^UU9V5H7`22
M[D86\-M/%"H6".-X^,_VW^)\#?,CA-_S?]-+^K^.!UK:6EY_A>>>QOI_-$.H
M2ZMYJN&@N:QO80RW)M92P$;+ZZ0):0)\/!%EC^U\2FB.+EPU6/\`SOQZD'JT
M&HIY=2QU"P>;5[+04N+6.ZMKZ[FNKR_22YF>U2%XX8IH)G]-YI&>5>'["+\:
MRC1E8/.7^Q_'^G36YT![G4]8C>WFDUNZE\O:&;STIC-]4*127ESSH%X3?OD:
M0?:]+C\.%J$A0_F^J?#_`+E%6D+7EY:.;:[_`.5@_IPW.IW;1W""ST^WNFYK
MZA'H_4VL56&&)&99VE^RTG)E";Y_S.'\?YW%_I?H7Z%Y=NF?R5J<MI<)J^I:
MA?:OJERXE#PVS1S3?53R^&*)C-!'Z/'[7^5A83F/4/X8CA_X]^/I>KA>Q`KO
MP/&G&@KOX?\`&OVL7&K\?C\1^I*M?`]31Z"A&L:=R-*5K.#_`)_S?:Q+DZ/^
M]'X_A_'^Z3[\U/\`R7VM_P#&`?\`$UR(YNYG])]S#'^VWS.9SSC6*NQ5V*NQ
M5V*I/YO)_P`,ZC&OVKB,6R_.X=8?^9F"7)LQ?4%_FR00^6-6*[_Z++$GSD4Q
MK^+8RY+C^H*&@@6.H:EI,RLD_K->6[,/AEMW2./DK>,;KZ<B_:7X/V77`.Y,
M]P"UIEP+-O,9;I:W<ES_`+&2UBF_7RQ'59"^'W?I0%PZV'Y=6]HZM+<W6G):
M6\*"K//-;G;V5?B=V_8C1LA.8C`D]`W8<1RYA$;<4_XOI^KA370-"EM8=7U&
M5P\DB:>[\=PK1-+ZE#X>G+G%=HZLX.U-)$GZ_$X_^ML\#N<QCEQ9>'Z<?#CA
M?U<.GC&/^R^ICVI3R0^9=0U)T=[73[RS>5(QR8QVMJQG<+^TT0NUDXK\?!&X
M\N.=CQ5FH\C'T_YOU_[J+@1QB6DL#U1G+C_JY1'P?\SBQY(_U_ZR;^:X#;7_
M`)2O4'.-E5G"[\JV[NY'O\$=,XOV:UWC?F!S\/5'/_F9)?\`5MV?AB,HQ/I\
M7#+!Q?S9RCPP_P!E+A5=-9-2\P:A=P`M8"VCT\7%*+)*DDK2^GW98_4"%_L\
M^2K]C.[B1+<<GG<D3`<,MI`_3_-2^!+FY_+_`$[TH6GFM5LV>",`NXLKA/55
M`:5;C"W%?VOLX.B3M,_'_9(^&[M[CS-97MNXDMM1TN1H9!M4131R*=]Q59\/
M5B142.Z2_29$&H^8;V1@D27*1,YV`2VM8RQ/R+OB.J)<@/QS7>6/4DL[N],;
MQ1:A>2WELD@XOZ,@41LR_L\POJ<3\7Q?%\6&*Y.==P1FKB];2;U;`5OF@E6U
M%0O[UD(0U/2C8EC&K%\F&W7E#S'"LOZ*N)H[A))/JEQ)=.]$33Q"K$.Y'.XN
MF,C<E^%D1OAR'"7(&6/7\>I;_A?S*^GR0UG$7"\EM[9KCTV$S0)!;ARDLG5S
M+<.OK.GJ*K?:;CCPE?$C?R77WE76?6>,6\]]:++<26H-X582FSBMH9F=G#@/
M(;F:7BW)?]]_LXF)49![OAYMWWEOS/\`478B2]O[B>;UG]=A^ZBA$=L`AEBC
M6.61/6F^TZNW]VV)!49(WW!>/+GFWTXYUN)%U2/X8[AYR458=-]%"4!*-Z]Z
MWJ2?"WV>;8:*../P_P"/?\2G'DS2M4L+6Y^OM*/5=#%#,X=EX1A7D-))P&E?
M=OWGQ<>?P<N.&(899`G9/D_Y2#RW_P!M6+_DQ-D,WTMVA_O/@R.8`^>O,-/M
M^AIW&O3[,_\`GOF.&SM#ZAWTC5"UV'PU^/K7Z/\`/_6PN``/Q^/Q_$S(=!D'
MI'8JH7=C9WBQK=P1W"Q2+-$LJAPLD9JCKR!HRG[+9$Q!YMF/-.%F),>(<)X?
MYDOJC_5DP;SSY,34-4\K6EC9O!ID%[<2WSV)^K^D)(R2_*/B4+R=67[68FHP
M<1B`/39^EZ/LCM4XL>>4Y"666.$<?C?O>/@E]/#/ZN&#'+[\M=96Y\XVFEPS
M212'2KG2I;V5I?K$EI622(RR$L=_@^+[/P_LYCRTLKF!_0X>+^+A=MA[>Q&.
MFED,01^8QYHXH\'@QS>B$_#A_ID\NYO,/G'7/+R-H-WHUGHUXNHW]U?>FM9(
ME(6&`*S&579MW^'X<ND9991])@('B/$Z[%'!H,.8^+CU$]1C\#%##Q?3/_*9
M>(?N^'^:G%CI>HI^:6J:F]NXT^;2[>"*Y(^!I%E8LH/B!EL8'QB>G"'7YM1C
M/9N/&"/$CFG/@_BX.#ZF406%C;LK06\4+(GIJ415(2O+B*#[/+XN.9`B!R#I
MYYIR^HREOQ;G^)7R36[%4@U\`WD6WQ\/AZ_S'Z/\_BR0=3K_`*Q[DCUA;DZ3
M?"RBBFNS"XCBN-X6?B>*ORH.!;[7_-&%Q(@7_NOQ^/\`2IOH@'U]*#X>+<>M
M>F_^?_`X"WZ(?O!^/Q^.%DF1=TH75C9W8C6Z@CG$,BS1"50_"1#5'7D#1U_9
M;(F(/-C*(/,,#\Z:;=:5YE\IZEHVB37=AI;W[W-KIT<8*FYC50W$F-:NY9FS
M$SP,9P,1M'B^G^DX&I@83A*,;C#C^C^DI:E!J_FCS/Y:OSH][IEI`FJVUX;I
M45XA/:JD;G@[CB[-1-_M+@F)9)Q-&(]?^Y1,2RS@>&41ZQ*_Z46.SVWY@6OE
M*Q\J6.FZO9Z[I*M;VFH:=+`FG7"U`26:5SRX\-_3HC\LI(R"`@!(2C_-^AH(
MRB`Q@3$X?Q0KPY)Y%^7]SJOGK6+O6?KL-N;&PC@N[6YEMUFF2,K,"T3*7XL/
MVLM&G,LA,KY1;AI3++(ROZ8\B@HO*WF!?R"GT'ZA+^ERDBI94'JFMZ7'?^3X
ML@,4ORW#7J_X\UC!/\IP5ZO^/O4%L;6:WB%S;I(XA,1]1%8A)%`D3<'X7I\:
M_M9L.$=7:<((W"*5550J@*JBBJ-@`.PPLV\*O._.P'^'O,%!\7U.[Y=:4])_
M\_\`B.3=$!^]_P`__?/_T^J^0"W^"]"_WY]43B:?=[?Y_%DP\_J#^]EWVR';
MXJ#X=^8H?PK_`)_S8M7X_'X_K+*[+4;?L;'P[_Y_\+A8_C\?C_8H#5?+ND:M
M-%+J$!FFA%`PDFC`!-3_`'3IR_SX8&Z&24>7X_'_`$BEQ\A>4*U^HMQVI_I%
MW6O_`"-_S_UL:7\Q/O\`]BVOD'RG0J+%N1KTN+NG7_C+C21J)]_V.?R#Y0K4
M6#<14'_2+NOT5E_S_:QI3J)]_P!GX_'U.3R#Y2#?[PM7]BEQ=^'?][_G_JXT
MHU$^_P"S\?C^BYO(/E.M/J+<MN9-Q=T.W_&7?_/CC2G43[_L_'X^EH>0O*-0
M38-Q-/\`CXNZDU[_`+W_`#_9QI`U,^_[/Q^/I7'R#Y3I3ZBW,#;_`$B[H-^W
M[W_/_6QIE^8GW_9^/Q_26_X"\HBI%BP7?E2XNP?^3O\`G^UC3'\S/O\`L_'X
M^I9%^6WDJ*YN+E-/87%WQ]1_K%WOP7BH-9=@!V_V6-,_S$^__8_C\?T5*/\`
M++R3%=2W*Z>[7$M!)))<7;%4&_IQDRU6.OQ>FOP\OCQIB=3/O^S\?C^BBH_(
M/E`4;Z@P&W'_`$B[K]-)?\_V<:2-1/O^S\?CZ6F\@>4J<38MR.YK<75.O_&7
MK_G]K&D'43[_`+/Q^/Z3E\@^3Z$_4&X=Q]8NZUK_`,9?\_VL:4:B??\`[%M_
M(/E/B5^HM4UXCZQ=TI],O^?[6-).HGW_`.Q_'X^IH>0O*1(_T%J+U'UB[\.W
M[W_/_5QI`U$^_P"S\?C^BN'D+RB!_O"_$D<?](N^OO27&D_F)]_^Q_'X^E8/
M(/E.@7ZBU12O^D7=*?\`(W&F/YB??]BX>0O*/'_>%_3\/K%W6M>W[W_/_6QI
ME^8GW_['\?C^DJ6?DWRW9W45U;6ACNHF]2%_6N6`8="0\C*?]E_LL:8'/,BK
M^S\?CZD\4BC4'PU//8^';_/_`%OAQ8!*M?/QZ(.WZ8T[AL:T]<?Y_P#-N)<G
M1_WH_'1/_P`U/_)?:W_Q@'_$UR(YNZG])]S#'^VWS.9SSC6*NQ5V*NQ5V*I!
MYVNX[70#(X9V-U:>E#&.4DC+<QR<$'=N",?]CD9G9D)QA<I'AC$'BDDWF+SK
MINH:1=:?:6MY)J;<&DL/2'JQHLB.'<\O2X.%/I\)']1N2JOPMD3,$-$=;@C$
M9#./AR/#&7]+_=>G^)S>?/+\GF!M79IAHD-H;:/4_2;T!-++SF#C^]7AZ<47
M+T^'J\TY?#CQBVSQ\?%X7%'Q3ZN#X>G^C_2^KZ4)<>;K!_\`$4;VUW!=:S$L
M>E6KPTEGI:>DS+1BB\&WD]1T:-/B;'BYL8:[`8\0G$QQ?WA_F^K_`'W\/"JW
MGG/2I[?21;V]U+=:5/#+J5L(?BMX_2:&59*D<F]*1I(UB]3U%7DOVL3(+^=P
MQJ7'$#+_`'4OYV_^Q]7\[A3G3?S*\K6'EZ>*;ZS<07O*&VO8X6]&0"(1Q!6-
M&/JD$1?!^\;[/VESS[MKV>UFIUN/+C,!#!''&,YR_P!3EQ_34I/0Q[:TAGDC
MQ5DE*>2>/^9_JG]#T_UO2QB7S4&74[5;.Y75+V::YM;-T7D1):QVZRE@QC6-
M&]7G\?+X47CR=<[C/(F0H<N.?^?P\$/]VZO3=HZ:.FGE\2/"3CT_^S.?)Z/K
M_P`E#^'^)-O.OYA:'JXTE-*@NUM=&NC^DK^2(1Q6T?HO$ZN"WJ\TJCOQC^!/
MB;.']FNP-9HI9)Y."LT.'AC+BGQ\7U?S?3'C_B=O+MG12RXP9C<^)C_VS^9_
MRLG&,8K-#\[Z)IL=Q!-%=1VLUW-+HS^B3]:CG?U0D2@\A)R=^*RB/E$OJ?9Y
M<?08R`%='FY:S%DE(\<3*'JS?T?YTOZ7^;Q>I;HGG>RL-&%D+.[EUF$W$KZ8
MD:^HBR322Q,[%A%Z;\U5661N3<U5?@;$3V8Y-;@X1D,X^'+T\7]+^+T_5Z4'
MI?FW0K,:#,6F;3-+LIK>^U7TF%ND\JPAE-?WGPR(ZR-Z?&-_@;]K`)#9NEJ<
M9R''Q1\2=2C"_P`1^E%6GF[1UM=6LKVWO(9=6N;E[&W,/[VXBGC5:QCEQ5D%
M6D65H_37[6$2#5^=PD&8G$QQ5Q_T?^DOX>%D?E#5EU'0;4L&CO+6-+:_MW%'
MCGC1>0(Z484=&7X65LE$V&P9(S'%`\4)?3).LDKL5=BKL5=BKL5=BJFG_*0>
M6_\`MJQ?\F)LJS?2YFA_O/@R*Y:GGCS%793!IU6[_9GV]_EF/%GVB?4/<C!(
M>8K2N_`5.]?Z_P##9)P.+?\`'X_XID7Z?L*'[7P_:V&WXY"G<?G\?FU_B'3P
M`27`/0T']>V-(_E#'YM_IZQKQ^/D.HH*C\>V-)_/8_-K_$6G4Y?'3QH.OAUQ
MI'\H8_-O]/V%0/CJ>@IU\*;]^V-)_/X_-K_$.G[[N>/4T']<:1_*&/S=_B#3
MZ`U8`]"0/ZXTG\_C\VSK]@#Q/,$=10;>/?MWQI?S^/S:'F'3R*_'3QH.OAUQ
MI'\H8_-LZ_8`T^.O84%3^/?&D_G\?FE.JZA!=SJ\1_=JO%B=B-ST_P`_BR0#
MK]5GCDE8Y)'YF:T/EW4A>H\MH;67U8H&_>R1^F0P2O[9&R_\#BU0D>(?9^/Q
M_-3G3+R.WO!+*?A`HX!K3:G3_/CB0STV80G93G_$&G\0WQT/L/ZY&G9?G\?F
MT?,%@&X_'RZTH/ZXTC\_C\W#S#IY!(YD#J:#Z._?&E_E#'YMGS!IXI]O?[.P
MW_'&DG7X_-H>8-/)(^.H^UL-OGOVQI`U^/S=_B#3^/(\P#WH/Z]L:3^?Q\]W
M?X@L*\?CY>''?]>-(_E#'YM_X@T_B6^,@=Z#^O?&D_G\?FU_B'3Z@?'O]G8;
M_+?OC2/Y0Q^;8U^P-=VVZ[#;\<:3^?Q^;"O.DPD\M:ZX-$>SNBAJ:FL3]?\`
M/X<DZR,[R`].+]/X_JO_U.J_E^H_P1HF_P`'U1.1KN#DP\_J!^\E_6+(RIJ-
MQRWX?$=Z^/\`G\6+"E,+UH1_E[G;;M_G_DX6%+^(HM6^#;B>1!V\:?YK^S@9
M5\OQ^/Z*TJW,[CGM5:FE.O3%%;^;E4<3\7P;U-36N*@;>3;J>0W'+?@*D@U_
MS_V7[6*D?C\?B7\2?6.D6$EI%(Z$O(H+D._4^&^1)=M@TF,P!(W([Y*QT/32
M`/3;;I\;_P!<;;/R6+N^V3AHFFUKZ9K_`*[_`*JXVOY+%W?:7?H33:<?3:G^
MN_\`7&U_)8N[[9._0FFU!],[?Y;T_7C:_DL7=]I=^A-.H1Z;;]?C?^N-K^2Q
M]WVR=^@]--/W;;=/C?\`KC:_DL7=]LFQHNG`DB,BO^6_X;XVG\EC[OM+1T/3
M2H'IF@_RW_KC:/R6+N^V38T330:^F:_Z[4^ZN-K^2Q]WVE+=:T^VMH4,*E0[
M$2,68]O<G""X>LT\8`</WI8%^(5(_P`CXCOM3?\`S_R<DX("X*=]QR_;'(T%
M/U?\:X&5*?$<1\7P;4-36O\`G_P.%A7R7A6VW'J4^S7:GR_S_F^U@95\U@4<
M31O@WY&I)J?"O^;?M86-+U7IN*[\/B.^W?`R`2GS`O[S1J&I_3&G<A4FG[\#
M;$N3HQ^]'XZ)]^:G_DOM;_XP#_B:Y$<W<S^D^YAC_;;YG,YYQK%78J[%78J[
M%4K\P:(NKV20B8VUQ!*L]K<!0X2105^)"1S1D=D9:K\+?"RX)"V&7%')`PD+
MC-CJ>0[]+F2[BUI/TG,JI=*;<-`(DKZ7"(2"1&0LYYO*_J<_L_9RNA=7NX4^
MQ<)PQB1/@C(F.3^?+_*>KAX/YOT_2M_Y5FWU5M,.KRG2)"6E4Q+];+.W-P)Z
M\%1I3S_N>2_W>'PVS^3\'C#+7JC_``W^[],>#_<?TE[_`)?ZE++'=3ZR#>VO
M(692V"PD..,AGC]1FD9U_D>+T_M+CP>;3#LC3QA*`$JR?TO5#A^G@V_W3E_+
M[4(I)9X=:I<7M/K[/;AD!4<5-NO,>D53X?WC3<OMMCP>:9]DZ>481(E6+^E]
M?\4O$_SOYO"L_P"5:2?5XK`:Q(NFVI1K,+$OUE6B(:$22EBDB1L`=HD:7CQ9
ML>#S;/Y-P>++)1O)Q<4;]'[SZ^'^+_9>EN7R)?I(=3FUJ-+V"-HPQM^-H+?[
M;\T,OJ<N2J_J>LO#CQX<<>#S:AV/I_"..I;RX^._WG%]/=P_[%*M.T+R_J<L
MVFZ;YPM;\:@'EU&"$PR7#<A29K?A)^Y1DHOQI-Z7VN6`1!ZM\NR,0E"9C*/@
MU&/\V7!]'B?B/$FS?EW>2>B)=9;C8L'TYD@4-S4%%:YJY$P],LC+&(.7+G]K
MCAX/-KCV5IXF>Q_>^D^KZ-^/]W_G?SN)M?(&I).]]'K"_I&95BG#6U;;TD),
M82+U!(KH6=N;3-SY_9^SCP>;"78^G.(8ZE429<7%Z_5]73A_A_FK#^6;?57T
MW],2G2IN37"F)?K19VYR!)@>"(\A+_W+,GV%;'PV[^3L'BC+7JC7IO\`=^@<
M$?Z7T_TE1OR_U*:2.ZGUD-=VE?J;);!8OC'%S.GJ$R%UV_=O%P^TN/`U0[(T
M\82@!*LG]+U0X?5'@V_W7U)]Y>T(Z3!/ZMQ]:N[N02W,_'TUJJA$1$JW%$5>
M[,W[39*(IS,&"&*`A#Z8_CB3;)-KL5=BKL5=BKL5=BJFG_*0>6_^VK%_R8FR
MK-]+F:'^\^#(KD?\[UYAINWU?3AP\?AG^_Y9CQ9]HCU#W(L=?M5!KR:H/&H_
MS_UOV<DZ_P#'X_'J7&O<TI]DU'Q;>/\`G_+]K`D_C\?C^:LWZCKM5:@<?Z?\
M:_M86/X_'X]*\=AR^$4H]0*T/3_/[.!G^/Q^/2LHW7]JG]WMTKU_S_UOLX6'
MX_'X_I+QT(Y54UY/4&E?U_\`&_[.!E^/Q^/5_"M:O*I-"#\(J#RV_P`_^(X4
M%M*@['<_:%1\.WC_`)_RX$AH]OB^$4XOL*T[?Y_8_:PH/X_'XX7+RK7]JE/3
MVZ5Z_P"?^M]G%1^/Q^/YRX]&'*JFO)]C0GM[_P#&W[.!)_'X_'$MWK7O4\5J
M#R_S_P"&PH0NM/<)I%\]M=I9SB&0I>2E?3MV"&DCU!'%._\`P'VL#9'GW_C\
M?[GZD4!T^*BBG%J@<J?Y_P"P_:PM?X_'X]*X<O\`94`,>PH*]?\`/[/VL#(?
M@?C\?Q+6`W'+X>[[=:]/\_\`6Q8G\?C\?SFUY5/\V]$J#RK_`)_[/]G%(_'X
M_'%_"YO]:M2>1J/AV_S_`.(XH+2_:'Q4`IQ:H'+;Q_SXX5#?Q4_RMJIL.._O
MX?\`"_M8$_C\?CTK0-@.7P_S[>/3_/\`UL+&OQ^/Q_$J$.06ION.&Q!!_P`_
M]E^S@9'\?C\<2F1U^*H->35!X[?Y_P"MA1^/Q^/4O%:"K4I]DU'Q;?Y_\1^U
M@3^/Q^/Z*4>;:_X5UH]_J%S5-OA_<M_G_DXEGB^L>^/X_'TO_]7J_P"7[T\E
M:$*?$+-`$['Z/\^63#H-1+]Y+WED7J+\6]0:\FK6E1X_Y\OLXM?$/Q^/^DE/
MU!05-*?9->NU/\_^!Q8\7X_'X_A5!)\5?VMN2UIQI^JG_"8LN+\?C\14S(O2
MOP;4:OTT_P`_];%CQ#\?C\?4N63?I\>]$K6H)_S_`-;[6*1)S2+OO537DU:T
MK_7_`(?%3+\?C\293IIK80'K\`]\B7>Z;^[C[D3@;V)76@>;I==ENX[^$:>^
MI6=RL#-.&^IP0E982%(3D9CZR<?A?_=W-?@S81U&$8ZX3Q<$X_P_WDI>F?\`
MI?3_`+AA1MA>AZ.GFW1M9\UZSK][I6I07]W%;745T\,&G16DI1%]'DL)^%>4
MOJCX^6;+/F_+SAAA".2!A#BCP\4LTL@_G_5_5X6`%B[1ZZ>/.7GW6-+U?4[E
M],T.TL38VUG</:K.UU$9'NV,#+SW^%/BX+E1R?EM/"<(QX\LI\<IQX^#PS_=
M>M-64CL]<UQ&TC2FU.XNH-+\Z?HF*]:0^I<6B0LXCF=:>MP+<&Y?:XYE3P8S
MQ3X8Q.32^+P_S,G%]4?YJ+/^R9?^;R236OEJR6XGMXK[7;2VN6MI7@=HI%D#
M+SC*L*YKNR2`<DJ!X,4I1XAQ=S*?3WI*=!OK7S7K'D33=5O)--U/11>Q-<W,
MTLEG<"X]+DDU?6567XN'/XF7,GQXRQ1U$HQXX9>#TQC'Q8</%]/T(K>F?^7]
M"N-,NM5GFNGG&H7*S11N[N(U2)(Z#G]GFR%V5/@^+-3J,XF(@"N"/^^XF8%)
MUF,R2?S$P6*$_M<C1?';I_9D@Z[M$T`DJRCD=_\`6W^SM3_/_@,+K!+?\?C\
M<+?J+0;T`IQ:M*T'^?\`JXIXOQ^/Q%;ZF_3XJ"J5I0#]7_&N+'B_'X_$6Q(O
M"E?@_GKWK6G^?^OBGB%>7X_'^R6^I7M\6]%K6M?UU_X;%'%^/Q^)+UD%#O4$
MGD>5:;4_S_F^SBD2_'X_'\*4^8'J^BCM^F-.XFO6DX_S_P"%Q+DZ27[P?CHG
MOYJ?^2^UO_C`/^)KD1S=S/Z3[F&/]MOF<SGG&L5=BKL5=BKL50&H:WINGS)%
M=R&(R#DK\&*4K3=@"!F)J-=BPD"9X>+R/"[;L_L34ZR$I88C)P'A,>*,<G^;
M"1]3QO\`./SQJMFTUUY8NYK8&:""[NXT*%O24R@QN1O%RXJS?9?['V<UD-5"
M6KD82$A/''_8EZ>?9F6'94(YH2A+#J,GIF/X,L/J>H?E_K/F'6?*=CJ.OV0L
M=0G6I0;>HG[$W#_=7J=?3_YJS>1)(W>'S1C&1$389'DFIV*NQ5+O,7_*.ZK_
M`,P5S_R9;`>3.'U#WOFO_G'(`_F0GM97-/\`@0,QL/U.VUW]W\7U+F4Z9V*N
MQ5\X_FUYV_,OR]^8D%S-+]5L[-C)H\,7(VLT!V8R`T]5V'P3!OL?L<?A;,;)
M*0D[;38L<L?^Z>T^0O/6D><M#34K$^G.E$OK(FKP2TZ'Q1O]UO\`M?ZW++X2
ML.OS83CE19+DFEV*NQ5V*NQ5V*NQ533_`)2#RW_VU8O^3$V59OI<S0_WGP9%
M<G_G>O,(^R?J^G?'X?#/_GMF/%GVC]0]R,[G8[5JNWQ;?Y_\:87`_'X_']5=
MOX$UZ"B_#M_G_P!=XI/X_H_C\>I(IO-$$L[V6B02:S?1GC*;8H+>-AU$]TU8
MDI_OM?4G_P"*<U?:7;6ET0O+*I?ZG'U99?YG_%.5I]#ER\A0_G_C\?SEZ^6]
M;U`>KK&K2VS#>"RTEFMX86[$RM6:Y=?^+>,+_M6V>=]H>WFHG/\`<1&*`_G_
M`+R<_P"M_#'_`#?].[[#V5BB/5ZUCOYKT@'ZW%^G;)>EW:*L5\B]?WEOM%/_
M`*\#12?R6^;[LKVYP9:CJ!X$_P"?]6'_`(J'^R_K.%J>QR-\9_S4PTK6M+U6
M%Y=/G$RQ$K<04X2HW\LT3<9(7_F5U1E_8SM\>2,XB42)1/\`%'U1=/.$H&I`
MQ_H_C\?S46Q/+N22:&@^';_/_KK+&L_C\?C_`$S:5]Q0BIHOQ;?Y_P#76!1^
M/Z7X_'J:)Z&AH:43;;WW_#_A\5_'X_']=R]:5-:?WFWCT_S_`.(X5'XE^/Q_
MFMMT8T(&]4VW]]O\_P"3`D_C\?C^BUO6E34UHVWP_=_G_+BQ_'X_']5!Z\I?
M1-07ZFU_6"0&Q%`;FL9_=56I'/IM_P`3Q;(\^[\?C_I)%@]#0T/&B;?#]_\`
MG_/BUW^/Q^/YR\5V%36@_>;;[]/\_P#9?#BR'X_'X_TJUCU-#3>J;;[]?\_^
M(XL3^/Q^/]*V*U(J:FM'V^'[O\_Y,4C\?C\?T7-\B*$U'P_%M_G_`-=85/X_
M'X_TS2GXAL36E%V^';W_`,_YOBP*/Q^/Q_24;^_LM/LWN[ZY2UMHN/J74S*B
M;G8<F[G]D?:;$E(!.PY_C\?[I*(]3U[6*#0[/ZG9'KJ>I1LBG?[4%I5)I?'G
M.UNG\OJIG)=K>V6ETUQQ_P"$9?Z']W'^MD_XCB=KINR9SWGZ(_S?XE;_``+9
MR?Z3<ZC?S:OU35A<-'+'7]F*./C;QQ_\4^CZ;?[L5\X+)[9Z^6;Q!(1B/\EP
M_NO\[^*7];BXG=#L_"(\/#_Q7^F4I+GS/HY_W(6WZ9T\5Y7UA&$N@/\`BZTZ
M2>[VK<OY+5<[3LKVWT^>HYQ^7R?SO\C_`*;^#_/_`-,ZG4]CR&^/U#^:FFEZ
MMINJ6WUG3KA;N'EP8QE28G`W1U-&C<?[[<<OYOCSM8R$@"#8+J)1,31!O_<_
MC\>I`^;:_P"%=:%346%Q5]OB_<O_`)_\2PE<7UCWQ_'X_P`Y_];JOD"O^"=$
M%33ZHGQ>'\?\_AR8>>U']Y+WED1K7H=J[;?%M[?Y_P`N+#\?C\?U5/>O<UIM
MM\.W^?\`UUA8?C\?C_9+Q785.U*/MO\`?_G_`#X&7X_'X_K+#6M:'M\&VV_7
M_/\`XCA8_C\?C_8KEK0BIIO\>VV_3_/_`(C@2'/RKT/?X=M_N_S_`),5E^/Q
M^/Z+*]-_XY]O_J#(EW^F_NX^Y$X&]V*L/U7\J/)FIZC/>W-O.HO)!-?V<5Q-
M%:W,B[AYX$81NVWQ;?%^UFQQ=JYX1$01Z?HEPQXX?U)L#`%%>8/R[\M:W>0W
ML\<]G?P1?5TN[">2TE,/^^F:$KRC\%/V<KT_:&7$#$5*)/%PY(C)'B_G>I)@
M"HW7Y8>3KC0K'0UM9+:PTZ?ZU:BVFEAE$]&!D,JL)&<\VJS-DH]IYAD.2^*4
MQPRX@)>G^;PHX!5*,GY4>59=,_1TTE_-!]9CO4>6^N7E2:)616CD9RZ;.=E/
MVLD.U<HEQ#@!X>#Z(</#_5I>`)IY9\D^7_+CW$NFPR&ZN^/UF\N9I+F>0)]E
M3+*SOQ6NRY1J=;DS4)':/TQB!"'^EBD1`3[,5D[%4F\R5]&';]IOB\-LD'6]
MH_2$C6O+N*?+XMO\_P#KK).K'/\`'X_'\Y>"W6AWI\.WP[>_^?\`-@9?C\?C
M^LIBM`*FFWQ[;[]/\_\`986'X_'X_K+Q7C6AZ?8V\>O^?_$<#+\?C\?[%9O0
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MQ<>../++^C*4?X4PS,=.[%78JQS\P-=MM%\IZC=W,%Q-!)!+`S6T?J>F9(V5
M7D%5XQ\C1G_9R,S0;L,.*0#YN_(S7;;1O/T$T\%Q<M<02VT$-I'ZLK22\>/P
MU7X=CR:OPYC8C1=KJX<4'UGF6Z1O%78JD'G;R7I'F_0I=*U)>)W>TNE%9():
M;.O_`!NO[:Y&400VXLIA*P^4TO\`S7^7'FR_M;&\6#4;7G:SO"5EB=6&QH:J
M>JNO+XHW_P`K,6S$NZX8Y8@D;/KKRZ+@>7]+%S(TUS]3MS/*YY,TAB4LS$]2
M6S+')T<ZXC28X6#L5=BKL5=BKL54T_Y2#RW_`-M6+_DQ-E6;Z7,T/]Y\&0W7
M_*<>8:[J(-.)7_8S[^W^MF.&?:7U#W(L#XATKOQ-*<:?JI_PF2==U_'X_P")
M8_YHM(IM4TE-1:1M!N9&L[ZT1FBB>XFHUL\W"C21,R-#Z+-Z3R2QLRYSOM1D
MU./1RGIY<$H>J?#]7A?Q</\`-X7:]EC&<E2&_P#"F6LW,FC_`*"M=-CBM[2X
MOX[.2!8P%$+12M2,+Q5/B1>V>-:>`S>)*9,I1QG)Q7_'Q1^K^=]3TY-4AFU;
M58/,&JZ?)<AE6P^NV*O;E0K!F4\)`:2HG[OU5?\`><V^'X'^&P8,<L,)@?Y3
MPY^K_=1_@XO7P?P_YRV;0J>=KR&#R;'-:)<3^:$17F63TEBE^J&Z=N'!ZKQ1
M^/Q9:>S8DYR)<(TO\-<7%'Q/"CZKC_.1Q\OZ2OY[L-,&GG41;D:Z"EOI-U`Y
M@N?K,S<(4$R4;T^;<Y%;E'Z:NSIF;[,9]7^:ABP3,!.7K_BQ^'_'*4/I^EIU
M<<?`3,6(L*U3\T=3\DV\^D><;3Z]Y@5"=&NK./T[?5E%%YFFUI)$2/K*-\"_
MWD/+EPSW7#AGEF(0'%*3RHTXF;CM'^/^C^/X7F[?F_\`FF[%SK%M#4EA#'8P
M-&E?V5+@N5'BWQ-G41]FHT.*<N+^B`Y'Y?'W-?\`*W/S3)).NQ5/4_4+:I_#
MOWR7^AK'_/E\HK^7Q]WVM?\`*VOS2I3].PT_Y@+;KX],?]#6/^?+Y17\MC[O
MM>L_E=^:4'FJ`Z5JHCM?--M&6=%'&*YB7;UX*G:G^[8_M0_\8\YS6Z*>GGPR
M_P`V7\^/X^J+C9\'#N.7^Y_'\YZ!0;_#0`_$M*5I_G_L<Q'%_'X_'I07F+T%
MT'4#<7#64`MY>5Y$I+P+Z9)D4+OR3[0`_P!?`V0'J&WX_'_%(T`D]!RVY-2O
M*OZZ_P##X6NOQ^/Q)"ZMJ^E:-I4^JZI.EIIMJGJ3RR=%%:?-BQ^%0HY2?W>+
M.$.+8!X7J7Y_><[B_FFTBQL+332U+..]AFDNC&.CRF.:-49O]]J/W:_!R;.A
MT_L[DG`2E+PR?X*XO],YPTD!SW/DAA^>OYC@$"+1Z'J/JMQ_V4=NV7?Z&9?Z
MH/\`2_\`'D_E<?FV?SV_,@T_=:/MT_T6XV^7^D8_Z&9?ZH/]+_QY3IL?FR7R
MO^?%U=VS:;J&D_6O.$\@BTFRL59;>_+UI\<C-]7]+K<>J[?!^\3E]C--K^S\
MFFE4O5$_3/\`G?\`'FN>DWL'T_Q?C^)F'E+2M1MO,2_XPD@U/7+R$WNF72*1
M!;%2%N+2U1R0HAK$ZS!5FN%D=I/L9Y;[>PU`A"<92\`^C)C_`(?$_AE+^M_2
M_FNW[(GC((B*(_TR=7EVZ^<[BVFO7MK+]#--(/4XI&5G*F85^%&5?]V9P&/'
M>F$A'BGXW#R^KT?1_P`==N3O\&):WKUUI_D[6)-%O;O4+21YI[6[MIOKDMI$
MD<?&)YF<R+ZS\Y5Y,[QQ/P_DS;:;2QR:F`RQACD.&,X3CX,<T^*7KC#AX?1'
MAA_2GZFLRH&F4Z9YAU:Y_,'4M$D*+IMKIMI?PQF,K.'NI)D9'?D5HGH?R?M9
MJ\VDQQTD,HOQ)9<F+GZ/W482].W^V,Q(\5+/,6GV<_FO2$LH_J^K%C=7]]#5
M)#8V]*PR\2/56>4QQ*DO/X/5=/BCSKO8*.HEED1*0T^,>J'\$\L_I_XKTNM[
M6E`8]P#*7THCS;3_``KK/P_";&YXK3I6%O\`/_*SU)YK%]<?ZT?Q^/J?_]?J
MOY?T_P`#Z(:?#]43DGC3O7_/CDP\_J/KE[S^/Q]*G^8'GW2?)FE"[O`;G4+@
MM'I6G)02S2@=/^*XT^U+)]F+_7;CEN'#/+,0@.*4DX\)F?\`??S'SY<?F)^8
M]U<2W,OF2[MI)V+M;V?I1VZ5Z)&K(S<%_P`IN3?:;XLZ[%[.81$<9D9_Q<)X
M8_<YPQ0'0*?^._S"H!_BK4J#H.4/_5++/]#NF[Y_Z;_CJ^'#^;%W^.OS"K7_
M`!5J=>YYPU_Y-8_Z'=-_3_TW_'5\.'/A#TC\J?S?FFN(O+?FV<27,S<=*U9P
MJ"X9CM!<$!52X_WU+_NY?@_O/M\]VIV7+32L>K%+Z9?[V?X]3C9\``XHC;^*
M/X_$7LCJ0U#]KXN+4`XT[>U/^$_9S4N(1^/Q^(*L=U=K15ED54VX@D5V["OX
M?[/%LCEF-@9;?C\?Z9LWE[4'UI:-2BAB2-MJ[[_\;8TGQI]\OQ^/\YI;N]J%
M]>2HX_%R)!WVIO\`]=8H&:?+BE^/Q_G-F]N^)?UI>-*<>1KUZUKX_P#-&*?&
MGSN7S_'X]+1N[W=?K$E3R^+D0!XUW_ZXQ1XL_P"<?Q^/\U=]<O:D^M*.->0J
M:G;Y[?YMBR\:??+\?C_?-?7+VH_?2_%2@Y';;OO_`)_:QICXT^^7X_'^^;2[
MO311/)4<26Y$U\*;_P#7>*1EG_.E^/Q_G-&]NZ!O6EXD4"<C7KUK7_/[.-(\
M:?.Y?/\`'X]+A=WM"OUB2I!//D:`5WKO_P!<_9Q3XL_YQ_'X_P`U;///*I]5
MW=5)JC[U(ZGKM_QIBQG.4AN3^/Q_FJ8'Q"HK_)L/AVKT_P`_Y\6%;_CT_C_C
MS84[@?:VY-0'E4=/>O\`PV*:_'\[\?[)8`**>/P&G%*`TJ>OO_QMA8_C\?CU
M+P#X_'2OJ>`K2E?P_P"%P,J^??\`C\?PK*#B3QHHKR2@%:?+P_X3"Q_'X_'I
M7A=]QO4\30?#05_S_E^U@95^/YOX_P"/)3KX^/1]J$:QIW)J`<JS`_Y_S?:Q
M+DZ/^]'X_A_'^Z3[\U/_`"7VM_\`&`?\37(CF[F?TGW,,?[;?,YG/.-8J[%7
M8J[%78JDFN>2O*>O7$=SK.EP7]Q$GI1R2ABP2I;CL1M4G`8@\VR&64>1I$:1
MY9T#1H$M]+L(K2&-VECC0&BNX`9EY$\>0&],@<420:%Q^G^BV#591&4>*7#D
MKQ(_ZIP?3Q_SN%`:KJ_F`>8!I.DQ6K$6HNG>Z+C]LI0%/H[9B9L^7Q?#QB/T
M\?KOO>D[-[+T'Y#\UJI9Q^__`"\8Z?P_]3\3_*?YW\37/\PO]]:7_P`'/_3&
M]7W8O]FO!V#_`#M=_I<#N?YA?[ZTO_@Y_P"F-ZONQ?[->#L'^=KO]+@=S_,+
M_?6E_P#!S_TQO5]V+_9KP=@_SM=_I<#3'\P&5D>#2F1@596:8@@[$$$;@XWJ
M^[%_LEX.P?YVN_TN!CGEG\O]4\LZC>ZAH^F:3!=7S$LY>=O20]8X:C]W&3OQ
M'_$55<C&.J'(8O\`9-V3)V',`&>NV_HX&2<_S"_WUI?_``<_],E>K[L7^S:>
M#L'^=KO]+@=S_,+_`'UI?_!S_P!,;U?=B_V:\'8/\[7?Z7`[G^87^^M+_P"#
MG_IC>K[L7^S7@[!_G:[_`$N!WJ?F'_OK2_\`@Y_Z8WJ^[%_LEX.P?YVN_P!+
M@2:7R=J,LCRR^7?+<DDC%Y':`EF9C4L24W).1K5=V+_9-G%V'_/U_P`L*<*W
MY@JH58=*"@44!I@`!T'3)7J^[%_LVO@[!_G:[_2X&^?YA?[ZTO\`X.?^F-ZO
MNQ?[->#L'^=KO]+@=S_,+_?6E_\`!S_TQO5]V+_9KP=@_P`[7?Z7`[G^87^^
MM+_X.?\`IC>K[L7^S7@[!_G:[_2X'<_S"_WUI?\`P<_],;U?=B_V:\'8/\[7
M?Z7`[G^87^^M+_X.?^F-ZONQ?[->#L'^=KO]+@=S_,+_`'UI?_!S_P!,;U?=
MB_V:\'8/\[7?Z7`[R]JVMS^=])TW58[9);74+656MBY4^K!/U+Y"&?(92AD$
M;CP_1_2;M7V;H\>'%J-++-*&>67'_A'!Q?N?^%O0YO\`E.O,-/M^AIU#V^S/
MEH>>[0^H>Y&BF]/L[\A0U^C_`#_UL+@!"ZQI=OJNEW.G7!*Q7,91)%!Y1M]I
M)!_E1N%D7_+7E]G(S@)`QEO&7IDSC,Q((Z?2A-#DBU[2K.75(@=4TNX*748)
M`COK:L;L`I'PM7G'7_=4BYX+VKHYZ#4Y,(^GE_7PS]4?Q_.>RPY!D@))E%H^
MG1F<K&2UR'65W=W;C(2S*K,Q*)R:O!.*YK9:B9K?Z?(?P_[K_.;:8IYHT::+
MS#Y$33;*5].T>\F,YB5G2"`V4MO'R))-.3HO[7PYM=%J`<.H,Y#CS0CPW_E)
M^+#++_<M<AN$SJ-7\UO,?BT[R\#%'3</J$\?[QA[VUN_"O[+W+\OL9W?L+V7
MX>&6ID/5E]&/_A4?J_T\_P#<.F[7U'+&/?)Y)YGTO2KKSYY_\QZ[%)J5MY<7
M3K>STX2O"&^MQQA$+CD\4".TDCK'QYNV>O\`8TI`",*ADRSE'Q:XN''C@)\,
M7'P`>&$KTW2/)E\^K>81I=Y!HVDZ=#>2:+),1ZMQ--Z(6*XIZAM`3R]2GJ9O
MLF7-#AQ\43DR3,/$KZ81CQ^K']/BLP!S3+2O)_E'78=.UJVL9;&ROK75EGTP
MSO*L=UI\'J1R12FDC1MR^)'_`&OARG+J\V(R@2)2C+%Z^'^#-+AX91^GB2(@
M[L:\@Z;H5W:^8-0UFR;4(M(T[ZY#;+,]ORD]9$W>/>E&S-U^3)$PC`\'B3X.
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M`+K?2/)>CVOEFTUC2I]4O/,D$=U/>QW+P&VCN)C#&L$:@K)(G'D_J_ZN,LN?
M(<AA(8XX3P\/#Q<?!'CEQR_XE:`JT%YY\FZ=Y=T6T,3&6^&JZG83W)8TDCLW
M18CPKQ5J-\7'+-%K)9IF_I\/'/A_X9?$LHT$UL/+'D>:W\EZ7>:;<_I/S/"L
MBZW;7DD4MK<FX:**:**A2L;*K?LY@:WQ,T,UF/AX3_=RA_1XOK^J,F40-O-Z
MY>V.K3^5M/N@_P!<\QZ5'!>1S@<?K%Q$G&=13;_2XS+$?^,B_P`F>?=I:&.K
MT\L,O\I'_2S_`()?YLG!PYO"S<0[_P#8L@L+G3M4L8-1MU66"\A5XW*BIC<5
M"M7Y_$N?/^;'/#,XY>F6.7#+^M%ZT$$6B([:WBC,<<2)&VY15`!/N!E9F2;)
M2QJTT/4[;\P=6\Q3^@FE7>G6MG&WJ'U5:UDFD9W4H$5&$W^_/V,V634PEI(8
M1Q>)#)/)R]/[V,(=_P#M?\U@(GB)7^55:\6Z\Q3J1+K+JUF&4U2QB!%JI\/4
M#/<E?YI_\G/9O9_LS\EI(XS]9_>9?^&3_P"(^AY?M#/XF7RCZ8JWFZO^%=;_
M`)_J%SS--C^Y;_/_`(CFZ</%]8]X?__0ZKY`)_P7H9K\?U1.+>%/?_/CDP\]
MJ/[V7?;S#SCH%CKWYYW-GJ#2"QM-'BNYTB^&1H[>.>9XHN7V#*RK_P`2S?\`
M8^8XL>240./BQXX_T?$<_2@<'QDD^@Z1Y.\X:WH]K8Z5=Z'%))<'4A',US!)
M!;PF?C!+*.8N65>++]CXN>=!GRYM/"1E*.7Z>#;@EQSEP>N,?\FW@`E&:#H/
MDOS=`+S3])ET==/U/3K6[@^M27"7-IJ$_H[LX#1SK2OP'CE>?/GTYJ4ADXX9
M)1]/!P3Q1XO\Z"0`4J\L^6-&O_S7_P`.7,3/I(O[NW,(=E;TX!*4','E^PN^
M7ZG4SAI/$'U\$)?Z;A0`.*D!YRTORQJ'Y<7OF71=/ETF6RNS875F]PUU&_.!
MIHI8W<*ZNA3XE_V68VIGDB)XLA&42PSRQEP\'T?CTI`&Q'>^EK$UTVU)Z&",
MR5!J3Z:FN_\`FO[6<,'1RZ_C\?[U$+3D*T_R/A.W?_/_`(+"H_'X_'\YS5Y=
MN1^V:'>OT[U_X;%3^/Q^.):.-%J*I446A)J?\_\`98H'V+S6I-1ZE/MTVITZ
M_P"?\N!E]_X_'^Q6'C0[43?DM"#4>'^?PX6.WP_'X_HJG<5I4?8^$[;5^C_-
ML#)8?M&@%3]OX3OM7_/_`(+"Q+:\2JU%5VXCB217_/\`V6*15?C\?\4YJU!V
M]2F[4-*5IU_S_EQ4_;^/Q_L6EX\6V^#NM#6H[_Y_9P(%?!<_T<A7@>)`%/U4
M_P"%PI/X_'XX5JTY&@'^6.)WVK_G_P`%BH_'X_'\Y=\-!457]@<2:5'?_/XL
M"?Q^/QZEH)K7;U"/B:A((/\`G_LL+'[_`,?C^DN''AT_=]UH:UZ5_P`_]7%.
MU>7X_'^Q6[U'3F!\+4(``^G:G_"XH^_\?C^BN6E&H!2IYCB=]J_Y_P`OVL4A
M*M?^WHGA^F-.X"A%/WX.`N5H_P"]'XZ)_P#FI_Y+[6_^,`_XFN1'-W4_I/N>
M.?FEY]F\E:-!J<5DE\UQ="V,3N8P`49^50&_DS*R3X1;H\&+C-6\P_Z&>U#_
M`*EZ#_I)?_FC*?S/DY7Y$=[?_0SVH?\`4O0?])+_`/-&/YGR7\B.]K_H9[4/
M^I>@_P"DE_\`FC'\SY+^1'>W_P!#/:A_U+T'_22__-&/YGR7\B.]W_0SVH?]
M2]!_TDO_`,T8_F?)?R([W?\`0SVH?]2]!_TDO_S1C^9\E_(CO3OR3^?=[YD\
MTZ?H<FBQ6J7SLC3K.[E>*,]0I05^SDH9[-4UY=((Q)MGQ/'\P)&_ETFOW391
M_P`B_P#DE_OG?G_C!'_0]_TX>1/_`,Y1WZNR_P"'8#Q)'^]+]O\`89?X_DZ?
M^3QWMK_SE#J!7E_AZ`#H/])?_FC'Q_)'\GCO;_Z&@O\`_J7X/^DB3_FC!X_D
MOY`?SG?]#07_`/U+\'_21)_S1C^8\E_D\?SG?]#0:A_U+T'_`$DR?\T8_F/)
M?Y/'\Y:W_.46H*?^4=@/_1R__-&'Q_)/\GCO:_Z&EO\`_J78/^DE_P#FC'Q_
M)?Y/'>]L\J:T^N^6M,UEX1;MJ%ND[0J2P0M^R&(%<OB;%NOR0X9$=R;86M)_
M-GF6S\L^7[O7+R*2:VLPADBAX\SS=8Q3D0.K8)2H6V8\9G(1#S7_`*&=\F_]
M6K4?N@_ZJ95XP<O^3Y]X=_T,[Y-_ZM6H_=!_U4Q\8+_)\^\._P"AG?)O_5JU
M'[H/^JF/C!?Y/GWAW_0SODW_`*M6H_=!_P!5,?&"_P`GS[P[_H9WR;_U:M1^
MZ#_JICXP7^3Y]X=_T,[Y-_ZM6H_=!_U4Q\8+_)\^\,O\@?FCH?G>:\BTVVN+
M=K%$>7ZP$%1(2!3@S>&2ADXBX^;3RQ\T=I?_`)-BT_YB[#_DQ/F`?[^?]6#U
MW_.JTW_#M3^AZ%=$CSQYAK]CT-.J1UKQGZ9=%YGM'F.ZD8&;D-_BWX"IH:^/
M^?\`K9)U]F_Q^/QZEQ8T:A_U_B.WR_S_`.%P)O\`'X_'^:DUWY9T2ZNI;R:*
M59[CB99(;JZ@YE%"`NL,B*6"A5Y<>7V<QL^AP93>2$,DOYTXQG_NFW'JLD!4
M9$1:_P`':%7CPN>8^T/K]_T[_P"[LI_DG2?ZEB_Y5P_4W?GLW\XVL_PAH/7C
M=<?'Z_?5K_R/Q_DG2?ZEB_Y5P_4P_/YOYQ333=/M-.M4M+*/THE+NB<W?DTC
M%V9F<LSL[&O)RW/]O,V$(PB(Q'#&/TQ#3+)*1LFY?C\?[IXA^97^*?)GGO4_
M,ML(Y=$\Q^C#,TL8N+8ND21_5KJ*0%?B,?.%S_JK\6=!V/FPD>#D])E+CQ9+
MX/77#P\7\/\`OG8:;*#&A]46,?\`*QO-7Z:;56FA9VMOJ#6+01_4S9C_`(]O
MJU/3]+OQ_F^+.I_D[%P<%'ZN/BO]YXG\_P`3ZN)OXRJC\S?,R:K::A$MG"EA
M!-:V>G16R)91Q7`I,!`-CZG[;,69LC_)N+@,3Q'C(E*?%^\E*'T^O^BO&70?
MF3K-O=2SV^GZ3"MQ;&SN;:.PB6"6(N)/WD0^%VY*/B;&79T"`#+(:EQQEQRX
MHR^GZEXRI6B>:OS(\UV5C$L9&GF!IWBC6"SL+6&42A%2,!0\I4^G$/CD^VWP
M+FH[6S8=/AE@CZLF7Z]^*7]?)+_<L,F7A%G_`#7T\S\G9@3Q));<U%?#_/\`
MULY)T]I=YF-H?+NIB]65[,VLWJI`Q]5H_3/()7]JGV:_M?Y.!M@3Q#_8H\%J
M]?B%.0).P_S_`.;<+79_'X_'\+Q#_G(+0-435;#S4D1ET6&S%A>3J2S6[^LT
MBO*O[,3<^/,?"C?;^UFZ[#UL,&4\>PR#AXOYO]9SM)(&/#U8EIGYC^:M.TV&
MQM9H#]6B>"QO9+>*2[MHI*\D@N&!DC4\C3^7]G.LR=G8IR,B#ZO5*/$?#R?T
MIP^F3F"9#>C?F-YBTFQM;.%+.Y&GEFTRXO+:.XGM&<\B8)'W7XOB^+E\6.;L
M_'DD2>*/']?!+@CD_KQ43(;L/S&UZUT];":WL-2A6>:Z5M1M([M_6N&Y2MRD
M_G;K@GV?CE+B!G`T(_NY>'Z8?2HF573_`,Q?.KQZ=H6AVEI/JX22UT22.TB:
M\A$A9F,<SU]%(^;,TOV8ES`[2Q:?#&4YF=Y/\GQG][/^K_NDB="SRB^A_+UE
M<Z;Y<TK3[F023V5I;V\LJLQY2Q1JKM4[T+"N<0Z?).R3T)_'X_TJ#D\E>49)
MGD?1K1IY&+R'TP*EC5F--JFM3_S5E9PXR;,8_P"EBD9\G\X_Z8M?X%\E<331
M;3AW/#>O:G\/^&P?E\?\V/\`I8LO'G7U2K^M):WD7R8=FT2S-:A5].H(]Z]?
MI_V6/@8_YL?]+%C^8R?SI?Z:2?H0J\4H%4`%02``!3;P_P`_V<M8`I1YM;_G
M5-9W/'ZC<\=S7^Y;K_G_`*N++$?7'WA__]'J_P"7ZJ?)&B=>/U1.7C7?I_G_
M`*V3#H-0!XDO>\__`#?\M^:-'\R1?F-Y>E=S:P1Q7\42\I8(X.8$ZJ0?6A*R
M.MQ&R\E3X_B3EFU[,UF/&98\HXL66N/^CP_3)R=-EKT]?X7GMS^8WF:[N--N
M[:>"Q73)#<Z?'I\$5O`LL@^*7TXQP=I%^%N7[/PYV./08>$_Y091O*<O$XH?
MP^K^:Y1D56[_`#)\QSFU$,5EI\=M=QZAZ%C:I;QRW41Y)+.%_O"I[5XXP[.Q
MB[XI\4?#]<N/AA+^&'\U>,JK_F?Y@.J6VJQ6>F6VHVT[7*W-O91Q2/)(C(_J
M,OQ2*PD8L&_:^+(CLS'P&!.249#AX93,O]*O&6H6\W?F?<IY5M([:RTFW8S:
MB]E;);VEJ)EXM*Z1\?5NI$^&%&;_`(%,U':6?%I1*$+R9LD>"4IR.3P\?X_@
M_P`YC/+PBR^EH[=88H85)/I(L<1)ZJJA03]W_-6<DZJ0W\_Q^/\`=+U1:FE?
M\O<_A_G_`,+B@#\?C\?YKF1?AZ\?V-S7Z:?Y_P`N*D#\?C\?PM!/B_R]N6^U
M/H_A_L<4`;^?X_'^Y7%4X'KZ?SWK_G_GRQ30KR_'X_X\M*;]^?[.^U/I_P`_
MY\45\_Q^/]TN"KO2O']O<^':N_\`G_+BRI:R+45K3]C<^'?_`#_X7%B0%RI_
MP?[=2:4^C^'^PQ9`?C\?C^:TR+Q'7T^V^]:_Y_\`76*"!\&U0U_XL_9WVI^K
M_/XOBQ4#Y_C\?[IIE7B:5XU^/<U^BO\`G_/BI`K\?C\>II4'(5K_`)&Y\._^
M?_"XJ!^/Q^/\U?QZ]>7[>YI3VI_G_+BFOQ^/Q_-4^"4'7AVWWK[_`.?^KA8T
M/A^/Q_N5X4U[^I3;?:GZO\_YL#(#Y_C\?\>6!$XFE>'[6YK7VK_G_-A8T/A^
M/Q_NEZH-NM:_!N:=._\`G_K?#@9`)3Y@4!]'(KR_3&G<J_\`&<=/\_\`A<2Y
M&D'[T?CHGOYJ?^2^UO\`XP#_`(FN1'-W,_I/N?.__.1\)F\I6*#K^D01_P`B
M9,MU<JC\72Z67#*_)\XS6$L3$5#$;D=QF#'("[*.4%#LCH:,"/"N3!ML!MJN
M*NQ5V*NQ5F?Y-?\`DSM`_P",S_\`)E\MP_4&C4_W9?2;_P#*>R_]L@_\GC@_
MY%_\DO\`?NU/_&"/^A[_`*</C&;^]?\`UC^O"XX3/3+2.:V/-1\345B:``;M
M0^(7*<LZ+CYLA!V1EQIFG"8QP%WC6.-I+AOLI79CMU5C]G*HY959^33#-.K(
MWW]/\Y?8Z3I]QJ8LXB&@+<9+F0THM0"ZKL?HR.3/*,.+K_-89=1*./B/U?S$
M-=6EDD\MO`%9!(_I3LQJRKL!V'Q99"9(!+;CR2(!/=]*6W=N\1`84)`8#V.7
MPE8<F$K0N29OL[\KO_)<^7/^8&+^.9L/I#H-1_>2][*,DTL&_.U2?RNUP#^6
M$_=<1G*\OTN3I/[P/D/,5WB*CMXPJLX+D[E%._'O3*S(M9D;5'LHI&`CK&Q!
M(1^M.V#C(YHXR.:%>!U)'ADP;;`;4L*78J]R_P"<6_\`CI^8?^8>W_Y.-E^#
MJZ[M#D'K^E_^38M/^8NP_P"3$^8A_OY_U8/0_P#.JTW_``[4_H>AW`'^.O,-
M-W^KZ<`OC\,_W_ZN71>9[1^H=](L<=Z-5=^;<JTJ/\_]?).O_'X_'K7$CN:?
MR'E]K:G7_/\`DP)/X_'X_F+>G?XMN2\J<:?JI_PF%'X_'X]"X%*#XJ)MQ?E2
MI!Z>W_&GVL#+;OV_'X_H_4M_XG2@2NU*UZ?Y_P`^+'[_`,?C_9KAQH?BJAKR
M;E4BOZ_^9F%.WX_'_2:%U/3M/U.QN-/U&!+JRND,<MO(>22HPI0_P;^;[/Q8
M%XJ-@[_P[_C\>EY:?^<<M`Y$0^8-2BB!VA/U9_33LO-XBS<>G)_B_FS:0[9U
M40`)\O*+EC6'NBU_T+GH@W/F74N!I1N-H*GO_NK;_C3)?RWJOY_^QC^I?SGE
M&OQ^/Z+0_P"<<M'/P_XCU/U/Y>%I7K_QA\/^:L?Y;U7\_P#V,?U+^</\V-_'
M\?CB>B^5/*6A^5=#32=(CX6JDO<7+L&FFF;[4DKT^-W_`.!X_8X(O'-7*1D2
M2;D7'R9#,DD_\=_H_CZTW[C^;?@O*O*OT;_\;X&O\?C\>I#:R]PNDWS6MU':
M7(AD*7<S#TX'"'C(Y((XJ>II_D8&R//O_'X_W")'&BU:BBG%N5*D?J_XTPM?
MX_'X]#I(HYHGAFC219$X36[T*%#4,&4@BE.JG_6P,A]OX_']'ZGD&I?\XZZ:
M]_-+I&O2Z;ICL6AL3;I<K#7K&DC.K<*_85OLKFTT_;&HQ0$(D<(_G#B<L:S;
M<7_2O\?CU(8?\XXSFH_Q4_/]E191&OR_>?\``_S9?_H@U7?#_2I&K'\W_9?L
M<?\`G'*7MYL8@?;(LHMO^2N/^B#5=\/]*OYP=W^R9Q^7GY9:-Y-6:=)S?ZO=
MFDVJRA8W,0W6&-1R6&)?VN)^)_M_L\=9J=3DS3XYFY?CZ6C+G,S_`#8_P[_C
M_CK,C]`?;DE:4`/RVI_PF8[3^/Q^/0M^&@^+X/YZ]ZUI_G_KX6.WP_'X_P!D
MO)Z].=#Q2M:@_1O7_A_M8&9^W\?C^DL/'?XJJ:\FY5I4?Y_Z_P!G"Q_'X_'J
M7`C:K`?R'E]K:G7^/^PP,OQS_'X]*4>;?^46UK^;ZA<\EK]FD+?Y_P"1BRQ?
M6/>/Q^/I?__2ZM^7[T\E:$*#G]30*M=C7V_SY9,.@U!_>'OMD7J+O0@@UYGE
M6E=OQ_X;[.+7Q?C\?B3SR[_(S\M+FZFN?J5Q;&=S)Z-M>3PPAFW;A&K<44MV
M7X>7PYDX]7F@.&,YQC_-$FX:R0[EG_*@ORVJ!Z%]R%.:G4;D4IU_:_X+^7)_
MRAJ/]4G_`*8LOS<_Z*S_`)4)^6M:^C?\>@;](7/7_@L?Y0U'^J3_`-,6/YV7
M]%E^@>5-"T#0FT/1K=K*U<2<C'*WKL\OVI3*:NTW\KG_`"?Y<Q)$DV=RUG*9
M2L_4DK:SYA\HJ4UYI-<\MK4#S!"O*\M5.P^OP1C]\G_+W;)\7^[X4_O,#,\,
M_IVE_-_XC_B?XF466M:5>-#]4O(+@SP_6;;T9E?U(">'JJ5/Q1\O@Y_S?N\6
MHV.8K\?C_<NU6VEN[5HH)VM;I2LD4R,?@D3=2R_M)7X73^7X<KS8S*-`\)_A
MDY.CU4<.42E&.6'TY,<OYDOJX/\`4Y_S,G^3DHZ+JS7L30W$?H7]J52\MPQ^
M%NSH>\+_`&HV_9_ULA@S<8(/IG'ZX_C^"7\+9K](,)C*!X]/E]6#+_._G0G_
M`#,V+Z<L/X?KCZ9)A)<1H2'9$DI]AG`VK7H?O_X;+W!,OG^/Q_LE$7MFP/&>
M-DWY,)%8@GMU_P"N\6/$/Q^/^DD/JNJRP>C;62"?5+NHLXN19`M*--*1_NI.
M_P#OQOW68^?*8U&.^27T_P#%R_H1=KV=I(Y;RY3P:;#_`'DQ]63^9@Q?SLV;
M_8QXIR],5:PMS9VJ6[3/<2+O//*Y+,[;LW^3\1V`^Q_=Y;BQ\$0+XOZ4G$UF
MJ&;*9B,<8_U.'TXX1'#&/_%3^J4D2LB\1O113BW*A)']/^$R;CB0_'X_Z1::
M3<;#G3=:[4K7_/\`X+"IE\_Q^/\`9.61:'?X.[5J:D]/\_M8$"0^'X_'])MY
M/ERWXCE6M?UU_P"'Q29?C\?B32R"IW_USR.VU-O\_P#)Q0)?C\?C^%=ZBT%3
M1=N)Y4K0=_\`/X<4\0_'X_Z16>IOT',4JM:``?JI_P`+BCB^?X_']%<'7AU^
M#^:N]:UI_G_KXIXA7E^/Q_LEOJ;C8<M^*UJ"#^NO_#XL>+\?C\27+(*'?:IY
MGD=MJ?Y_S?9Q9"7X_'X_A2KS`]7T4=OTQIW$UK7]^/\`/_A<2Y.D/[T?CHGO
MYJ?^2^UO_C`/^)KD1S=S/Z3[GSG_`,Y+.R>3[!E)!&I+N/\`C#)EVI%Q=/HA
M<C[GSU;WO)N,M*MMR\?GFMEC[G,GBK<)A%(145J-_A(!'AT(R@AQI!!W*P<P
MIC4?Y0V/X9;`GO;\9-<U);2!_LDJ?#)F9#,Y"%KZ?(-U/)>QPC*$C,"I>@_8
M5IU'?)<3/B9E^3I0?F9H*\*-ZSBN^U(7R["/6&K4`\!?1S_\I[+_`-L@_P#)
MXX_\B_\`DE_OW;'_`(P1_P!#W_3A\8R_WK_ZQ_7A<</9/RUT30;SR9%]>LDF
MFEFD)E(^(#EQ7?MTSD^U]3EAJ/0:`B\/V[K,^/5>B7#$16^:/R[%K8RSZ/,T
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MN;WN7_.+?_'3\P_\P]O_`,G&R_!U==VAR#U_2_\`R;%I_P`Q=A_R8GS$/]_/
M^K!Z'_G5:;_AVI_0]#N3_P`[SYB'0&WT[X_#X9\N#S/:/U#W(P,>5:&OQ?#M
M\6WM^/\`PN%P+W_'X_'I7%B*]36E?L_#M_G_`-=XIO\`'X_'^<LY;`5(I2C;
M;[>_^?\`-A87^/Q^/YR\,>M#V^#:@WZ[_P"?\WPX&=_C\?C^<I\OAI4TW^/;
MQZ?Y_P#$<6%_C\?C_-7\CUH=N7P;?%\Z?C3_`&&+._Q^/Q_,:9OB.Y-3N?A^
M';V_S_V6%!+:MTW(H10_#\6W^?\`UU@4'\?C\?YS1?<&AKM\&VWRK^'_``^%
M;_'X_'\YI6VIR-*?;V\>G^?_`!'`@'\?C\?YJYF-"=ZT;X-M_?;_`#_DQ9$_
MC\?C^:MY;D5)J35MOAV]O\_Y<+&_Q^/Q_-0?F`!]#U!7M7OE^KR`V*FC7`],
M_NP5!(+_`&?A_P")X&R)W&]?C\?])(P,:@T-3Q^';X?O_P`_YL6N_P`?C\?S
MERGX0.1I0?'MOOTW_P`_YOAQ2/Q^/Q_I6F8UK0UH?@VWWZ_Y_P#$<*"?Q^/Q
M_FN!^T*FAK5S3;[OQ_X3`D'\?C\?S6W8U[BA-!\/Q;?Y_P#76*D_C\?C_.:1
MCR'7>FVWP[?Y_P#&WQ8J#O\`C\?CU-\CQ`J:"E'VWWZ;_P"?\^%;V_'X_'J6
MAC6M#_J;4Z]?\_\`B.*+_'X_'^:O)^$BI(/+X]MM^FW^?\N!D3^/Q^/YJPL:
MUH=J[;?%MWI_G_+A8W^/Q^/YJ]6/N:T_E^'X?\_^N\#('\?C\?YR3^;3_P`Z
MIK(J=K"XHVV_[EO\_P#B6++$?7'WQ_'X_P`Y_]/JOD#_`)0C1!7X?JB5;P]J
M?Y\LF'GM1_>2]Y9$2W+?KO05!Y;?Y_ZW[.+#=3^+>G7:NX^';_/_`(C]K"PW
M7C]D<J**<7J!7[^G_&O[6++\?C\>G^):>?([?%M\%1L*_P"?_$OLX$;MK7B1
MR^'>KU![]/\`/_6Q4-L7Y5W#"M%J/BK_`%_X?]G"F5_C\?\`27\+RZP_)K4=
M*_,T^=M'UR.WBED<76CBU6*$6TO]Y"K1R<1_OSGZ?Q3_`!M\61IROS-PX"/\
MZ_Q^/2J_GKYV\P>5=#TIM%F,#W]R\4URBQM*(XXN7[OU`4#5/A\/^MEN/&92
MH-_9FD&?)PGU<(XOZSPAO.DM](YU;4[^<S*%DDN))V=0I)6A!X\5)^POP8-3
MHY;3@/WD/YWTY(_ZG/\`WO\`-D]CH\>/%$XIP/@3_H\7A9/]6A_2_G_SX>E"
M7ATJ&7T[EX2Q`=&<@\D855@6Z@Y9@RPR1X@*_G1_BA+^*$OZ3#4:7P9\,@/(
M_P`,X?PSC_6:MDT6X=O3-L%C4R2R`)1$'5C3!GS0QQNN(_3"'\4Y_P`W\?2G
M3:49I4.$`>J<_P"''#^*4OQZE5_,&GQ%%LKN2".$$1?5WF1]]R28J'XLAIM+
M5RD.+)/Z]O\`I7#^A#_9?4SU<X90,<(_N<?T1X?]-EG_`+9/_8_2RKR)^:WF
M^'S3H^GQ:E>7MA>7MO;7,%^WJIZ<KB,E&EK.C`-\/%N/\V7Y,!$;JG1Z[LR(
MQ2F(\'#ZOYKZ@7D#M]K:JU`XT[^W_&O[68KS`_'X_'#_`!+3]D#E\/9ZCQZ?
MY_ZWV<4'\?C\?SFUY5.WQ4-$J-Q7_/\`UL4BW/7B?BJ"3R:H-*_Y_P"R_9Q4
M\OQ^/^*_A<O+D-_]7<?%M_G_`,1^UB@<_P`?C\<+8+;TZ[<EJ!QV_P`_]7]K
M%EO^/Q_TBL`-`*T7:CU`KOT]O^-<+!>.5.GQ4_N_:O\`G_Q+[.!EO^/Q^/J6
M4/$_%537DU0:5^7^;?LX6/X_'X]2]>7<[U/$5'Q;?Y_\1P,A:4Z_7U-&WK_N
M8T[D*C;]^/\`/_A<2Y.C_O1^/X4__-3_`,E]K?\`Q@'_`!-<B.;NI_2?<^=/
M^<E(VD\H6"K2OZ27J0!_<R>.7:DU%T^C-2/N?-K1NKE*?$#0@;_JS#MV=J\-
MW-``&4E:[5V.0E`282QB2(-S;3@!CQ?M7*Q`Q:1CE%4MX%60,7!0=*;U]LC*
M6S&<]J1EY"T=J7@6C!2:]:@]:97CE9W:L4KE18_S:M:FOCF;3L:9G^39)_,[
M0*FO[Y_^3+Y;A^H-&H_NR^DG_P"4]E_[9!_Y/'!_R+_Y)?[]VI_XP1_T/?\`
M3A\92#]\_P#K']>2<</8/)4DL'E^QBAC9><=6=J\:EB:[>-<Y/M&(EED2\3V
MM&,LTB>C,+1W:(PL`31N1)VI3?X>M",U,HT;=%,`2MY/J%M:+!,L;F*XAD8>
ML:LS+4@<OY32N=5CG*Q>XD'ML625BQ<9121[?ZYQX1L[M7XJBIXUH!7QIF6)
M</,N=Q\',H9XUE>4[CU%:G+8\A2@H!EH-4W1D125SBDE?YM\O<E]E?E=_P"2
MY\N?\P,7\<S8?2'0:C^\E[V49)I89^<5P]M^6^LSH:.B1<36E"9D&4YX\4""
MW:>`E,`OD">0R2ESU8U)S%`H.^B*%*MJZ;QN!1NA\#@DQF#S#,O+^O&PTRZ-
MPE8[<KU8&1J_R@T6FP^+-7J=,)S%'ZG3:S1C)D%'ZO\`2H&[_,&_DO#<6UM%
M`IH/3W8;=STRR/9L!'A)MNAV1`0X9$R*C+Y@BUI_0OXA&\FR&*BIRI1:@@TR
MR&F.(7$ML-(<`N!V_I)!>6DMK.\,@(932AV.9D)B0L.=CF)"P]J_YQ;_`..G
MYA_YA[?_`).-F3@ZN#VAR#U_2_\`R;%I_P`Q=A_R8GS$/]_/^K!Z'_G5:;_A
MVI_0]#N03YX\Q'JHM].JO^QGW_MRX/,]HCU#W(@21<@/52N]&Y)\-!\_^N<+
M@<)3W2[=GLGX11-+ZE&:9:U6BGMD2[718XF!L=6/26OY@O?7XT>'1&T];F01
M"]6X,HV7D#P'#C7[-,Q,AU'%Z>#A_I<3'-AS<1X!AX/Z0EQ-_4_S:Y<_0\M\
MJ$<N-U6AZ]LK_P`*_P!K_P!FU^%J>[!_LG?4OS:I3T/+=/#C=?TQ_P`*_P!K
M_P!FO@ZGNP?*3OJGYMU!]#RW4=#QNMJ?1C_A7^U_[-?"U/=@_P!DENFZE^9N
MH:CJFGP6OE]9M+DCBN2R7(5C(GJ*4I6HI_-E6//J9RE$>'Z/ZSEY^S=9BQPR
M$:?AS@RC]?\`!+A]29?4_P`VMOW'EO;I\-U_3+;U7^U_[-Q/!U/\W!_LG?4_
MS;J3Z'ENIZGC=]_HQ_PK_:_]FO@ZGNP?*3OJ7YM4IZ'ENG6G&Z_IC>J_VO\`
MV:^#J>[!\I*MK:?FE]:A-U!Y>^KAU]8QK=>IZ=1RX5%.7'[.2@=18XO#X?\`
M.9X\6HXAQ##P]>$2XF8?4K/<>A'0]?@7^F9EN=X,.X?)A/FM4CTS5C)<M8PK
M%/\`Z;&*M;J%/[Q0I#50?$%7_B63=-.-9#M_$KA'K3OM5MCRK_7_`(;]K"X]
M'\?C_I)\Y?F%^8OGC3_.>NV=GK-Q;6=M=21V]NIN0%6HX\>"&/X?L_:S'E(V
M]/BPPX!M'EW,8N/S7_,"(2&7S1>PNK.%#&=#M]@#DGANO+]G[6`2DR\+&.@^
M2D/SB\[EF_YV6Y5#0+RGFW-/M;1G#ZE&/%W13.'S_P#F/>6L,T/FN>)2H:HG
MEDW`W4UC7B:^&-R\U.+'W1^2=3^8/S+.AQWT7FB\+35#2PNY*@$@FC$U^RW+
MX/AP0F3LG+@C$74=V):O^8OYHV%OZJ^<KV0!@HC+*"2>XVRUH\./</D@;'\U
M/S@O)1Z/F/4W3DJR2Q@R\.7<A$)Z=L4^''N"91^>_P`W)%JGF^_DC(8@QQ3L
M#Q_YX@=\4>''N'R1\?Y@_F662SB\Q:A>W`"EKI$NU9%+GXS$(^BT]/\`XC\6
M*^''N#U7\B/,?F;6X]?36M1FU![.6W6(SAP1R$W*BRA6'+@NW^3_`#9(.!KX
M``4&>>;5/^%=9/'X38W-%VV_<M_G_E877XAZQ_6B_P#_U.K?E_\`\H/HAI\(
MLTJFV_O7K_G\.3#S^H_O)>\_C\?YK(B#RH:DFM&^'X=O;_/^7XL6!_']'\?]
M(K`"=MP12I^'XMO\_P#KO%C^/Q^/]DN'[)XD@\:)\/PUZ=?X_:_;Q2/Q^/Q_
M36T-:5-=OWFVXKT_S_XABC\?C\?[%L=">)XBM8]M]^O^?_$<5#GY`T-:GE1O
MA^'[O\U_8Q67X_'X_H.6O+H13J/A^+;_`#_ZZQ4?C\?C_3/'/^<EEY:/Y>KL
M#=SD+MM^X'^?_$LSNSQ>7X%Z/V9%Z@_U'@OIKF]X7O.$/4+K\G[F'\L;3S%-
M>A[R18;G]'%`&MK:Z=DBD9^18QRE5/V/A^+^5LY[5ZD8,QRQ'I^G./\`5>'^
M*'^WX_\`I9'T?S6&EU@S9?RQ'\[PLG^V1]4\?]3_`'/U)1J?Y>WT/E;R[/I7
MJW]YK\UVC:?#"QD+V3!:BA+.OVF"\?A^UEN@R#-,Y\E?2/!W].'%D_Z>S_RD
MO^2;9GU,82G@^F.+A\2?^J3_`.(A_!_ID%+^5_F:+R3)YLEMG6SCNFM6@]-S
M(JQAA).YIQ6%9%]+E_OS-IX\./@\G$&IQG)X=[UQ?\=2KR;&!YQT`CK^D[*G
M_20GCD=;']T7&[9C_@L_ZK['4&M`344^/;XO`;_Q_P!GG//F@_'X_']-H_9!
MH>/:/;;?K_G_`,0Q0?Q^/Q_I7`&I%36A_>;;"OM_G_+\.*_C\?C^JYP:'8@`
MFJ_#\7CT_P`_Y,*3^/Q^/Z+@#R'4U.WV?A^'_/\`Z[P(Z_CT_C\>I<`W05!%
M*M\/Q;>_^?\`-BFOQ_._'_22P=`>)IM1-MJGKO\`Y_S8L?Q^/Q_67`&E*FM*
M^IMTKT_S_P"(8LOQ?X_'^:L[$\2`*U3X=_N_S_DPL?Q^/Q_57@'W))-#\/P[
M?Y_\:_%@9#\?T?Q^/4E7F"O/1NHIK&G5.WQ?OAX?Y_S?%B7)T?\`>C\?PI[^
M:G_DOM;_`.,`_P")KD1S=S/Z3[GSE_SDP?\`G3K#_MI+_P`F9,OU')U&B^H^
MY\Y174T5>!I7O_3,$Q!YNQ,`>:K+?R3,K2@$J`!]'SR(Q@<F,<0CR4F,!W'4
M[Y(6R%N5N)K&Q&`CO01?-'6^IW2`AG#)3B5;PZ4`.52PQ+1/!$H>6".0EHB%
M/7AX_+)B1'-MC(C8LL_)N%A^9N@GL)I.O_&%QF1A/J##42]!?1[_`/*>R_\`
M;(/_`">./_(O_DE_OW;'_C!'_0]_TX?&4O\`?/\`ZQ_7DG'#U[2(+F.PT^WA
MG546"-C0M]I@&"M04[YRVH(,Y$]Y>-U7"9SD1OQ%DFG!%D,;$+Z88,XJH*DD
M?:"G_9'-=E%CWNISQ)%WS><:D]M/?7DD5SZ9:5N!*L:!=@.G7.BQ1(B`>YZO
M!$QC$'?9`QRV=GZ<T`K(OQ32FK<FY;-3;CLWV:9<8&=@G9OEC,[!.W\*%DFM
M^7JN>/J;K%Z8!8A@?B/($`U^T,LC&M@W1A6P2?5([=9:P'DA)(VH`&`:G4]*
MYEPY.="^$6^O_P`KO_)<^7/^8&+^.9\/I#HM1_>2][*,DTL%_.__`,E;KG^K
M!_U$1Y7D^ER=)_>!\C+%(_V5)^68=N[)`5#:7"J'*4!Z;C!QA'&%6"=4+QW"
M\@XX[DBG@<$AW,91/,*4L'%OA:H.XKM_9DA)D"U%$Q<*S!!7=B:`>^)*F5>:
M8ZL=->1$LY'G^']],:TKX@$`Y3AXJ]31@XZ]6SUS_G%U2NJ^81X6]O\`\G&S
M.P=7'[0Y!Z]I?_DV+3_F+L/^3$^8A_OY_P!6#T/_`#JM-_P[4_H>AW'$^>?,
M2FE3;Z?U%10I.#7+HO-=H'U#OIXUYZTH:;K5ZUCI&FV.G6LOHVL":%#<&5C;
M)-!QF:-_CNIA<6Z\5_T:2./U/M_$IQ9+`LG_`$WX^E]):$P%F?V1S^%3L1\(
MV(\<!;]#]!]Z_1O^/[_F+E_A@<U,,5=BKL58;<>1-976M2U/3/,<^G?I.199
MH$MXI!5$"+N]3L!FOEHI\<I1F8<?]$._AVQB\&&/)ACE\$<,9<<X_4>+^%#Z
M*?,NG>?H]%U#6Y=5M)-->\I)%%%1Q,(Q]@=A[Y7A.2&HX)2XX\''R'\[A;-5
M^7RZ$YH8HX9C,,7IE.?IX./^)G6;1YQV*NQ5V*L)\R?6&M-56TMXKJZ*3".U
MG6L<S\3QC>I`X,?M?\%DW13(\0_UOQ^/\Y?5*#H5VXCB32O^?^SPN/8_`_'_
M`!Y\E?FK&K_F%YAYAE3Z],[2+$[@@$)N1,M?B/\`*OQ9C$T7JL5F`]S![G3)
MGF=6N)YY"`8N:[L:4%>3FG3")>2F-]532_*]QJD#Q6D\3:LK'CICNJ2R*%+U
MBY;2-0?84\LL:R*2>"=HV4\V6*H+@$BHKOTQ0^PHI=.O_)%EHHG2%;S3HRNL
M6!4/%,65TD0J`/1Y#B\7[461X=[978I\P76A_6?S";0!<JT9U'ZI]8EY)&!Z
ME':A^)(_M4_R,DQ2W5[JSMM8N?\`#]S,FGAN,$JLT3.JBG(@']K>F*I>MW=J
M.*SR*-]@[`;]>A[XJVM[>J:K<2J2*$B1AMX=<5?1'_.*$A?3_,QE8NWUBT"L
MU7_W7*<D'7]H547L7FYA_A;6]QS-A<\FH=ZPM_G_`)6%UV(^L>\?C\?4_P#_
MU>J>0`?\%Z'N.7U1.+^`'O\`Y\<F'GM1_>2]Y_'X^ED5!\5%``KS7C2M/;_/
MC]K%K_'X_'I4Z=*@$?L"G3:O^?\`P>%A^/Q^/Z2H`:]N1IR:E>5?UU_X?`SK
M\?C\24S3K0<-J+3OTK_G_JX6/W?C\?[%<H->HY[T>E*#IU_S_EQ2/M_'X_V+
MG`WVHHKR6E*T_I_PF*G\?C\<#E'Q"H!_E^'[.U?\_P#@L5`_'X_'\3QK_G)I
MQ'HWE]CU^MS\FIUK`/\`/_*S+T,JR?`O0^S<N'4$_P!!XMY6M['5/,FFZ??7
M4=G97-Q''=7,K!$2(M\9+':O&O'_`"LVV74<,2>X/;9,Y$3PCBE_#%[7??F%
M^66M?F7?Z9J*/;Z->6GZ)2^>XI9Q"!)%BE:-@%''E^Z_WT[\_M?9YW#CR9A'
M*?HQRX\,/XLDO]6G_P!.O],T3ADTN'@B;S?5F_G1_P!HC+_IM_RK6>1_-GEO
M3/+NE^7+W7HFFU5-3TZ:[@D#SZ=)ZACCGAD4\DAND$3%?VO3]16^UCJ(G3Y3
MDB/W$C&<X_S)_P`_^I_JG\R7J93!U1Y?OL?"<?\`T$P_U&?^VX_\G_I/YK%V
MOK-OR6U'R^OF"R34M%UN:>2U:ZXFZM1%Z8%J!7UU>0\U4?#^UFY$_P!\)5M*
M+C>)6<3(/JAP\OIE_28'Y+N%?SGY?7K74[+;K_Q\)EFLR7B*.U\MZ68_HOLL
M`4'PU4D<5I6E?\_]GFC?-P/Q^/Q-I@:]N=-WIL16G7\/^%Q4C\?C\?PM*%XL
M>/P"M5I3H>O^?V?LXJ/Q^/QPKG6GARWXFE.-/U4_X3%3^/Q^.%:H^+H/\H<>
MNU?\_P#@\4`?C\?C^)=04&P*FG%:5I4?Q_X;`R_'X_'J6`&O;F0*O2M0?UU_
MX;"Q_'X_'J7@#A7C\'=*=ZTK_G_J8$CEY?C\?[%90BG3EOQ:E*4_53_A,*/Q
M^/QZ5ZC9M@!4\AQI6@K_`)_R_:Q2!^/Q^/XDJU\?O-%\/TQIW$4I3]^/\_\`
M*^U@+E:/^]'XZ)_^:G_DOM;_`.,`_P")KD1S=U/Z3[GSE_SDP:>3K"O_`%<E
M_P"3,F7ZCDZC0_4?<^;.2^(S#=G37(>(Q33N0\1BBF^0\1BM-\AXX%I<)S0#
MEL.@KTP<*.%FOY.2HWYFZ#X^L]/^1+Y9A%2#CZB)$"^CW_Y3Z7_MD'_D]A_Y
M%_\`)+_?NW/_`!@C_H>_Z</C*7^]?_6/Z\DX[+X/-XBMUC$JT$<:4^(;(!UH
MI\*9K,G9XE*W49.S!*7$U_C>Y52L=SQ5E*L`&J:U[T]\'\FQZH'9,.92U-9L
M$8..99C68;@,/;YG,G\N7+_*D]0L;6[05X(S`JH4.H:C*_+EN1UI2F'P/-D-
M+YJ$NJV\@0E7,B+Q5C2@%:[`DY9'%3.."NNR&U*^2\E$BQB,[\@``*GP`V&3
MA'A%-N.'"*M]@_E=_P"2Y\N?\P,7\<SX?2'1ZC^\E[V49)I89^<%LUU^7.KV
MZJS%Q".*`L=IT.P&4YS4"6[!+AF"\&L/([-8NTD<\0^$*44BON:K3.=R:N8E
ML+^##+VC(3H>I`ZQHFDV:FU59Y)TW?A!(Y#>'/[/W9?@.>>].3ILF:?J(H)5
M-Y;>XM#/:+*[K]N!XY`Z^XJOQ#,D3E$U(.9'/*,JD$G.F:K'\#6<]#_Q6_X;
M9D5;E"0/5PTK4#2EK-\O3>OZL-),P%RZ5JD;5^JW"KTKZ3@T^[!5L3,%[5_S
MC3!<IK'F%YH7A#6]N%YJ5K1V\0,OP!P-=](>K:7_`.38M/\`F+L/^3$^8I_O
MY_U8/1_\ZK3?\.U/Z'H-ZP3SMYC9S2);?3V8CKLDYVIET7F>T?J'N>=^8[NT
MF\TFXL]87RU(3#(VI6BW\UU=H8T91+;\%L@.-$K.+F3C]KAA:\<9</+BY]W_
M`$F]MTBSL[JS_?Q+*8Y2R\Q6C<5W%<B7,T'T'^LKZ*JJ+X*`H^MS;#;K0X'.
M3+%78J[%78JPZ=E'YMVY8@#]!ON?^8H9KI?XV/\`A7^_=]`?ZUG_`*&1_P!,
MF7B6,F@8$GH*C-A;HN$KL*'8J[%6`><_JGZ)UKZ]ZGU/T;CU?0_O?3XMRX5V
MY?RU_:_R,FZ&=^*?ZWI_'X_TJ(WJ?YMN?6E/\_#_`&&%QOQ^/Q_5?%OYP!?^
M5I>::#_I82_/ME9>EQ_2/<Q#;%DOAEE@ECFA<QS1,'BD4T964U5@?$'%6=6&
ML^6;"2VUZUM[>[U;4[J%;C3I4/&R*$&Z9%^P4NF8?5SQ_<KZB_L+BK,]*\Q^
M9M'\K36^GGG!9R2BQDDXGTEF;D">(6JI7X<I&>)EPN2=-,0XF-ZIJVF7$-[>
MZB8X-;T>UI9R=9[M[JW^K`,?VV@GYS%O]]O_`)*Y<XSS,``4'0=,5=BKL5?1
M?_.)]?T9YFIT]>TY=>GIR>&2#KNT.0^+V'S;3_"NL]>'U&YX]:_W+=?\_P#5
MPNMQ?6/ZP_'X_P`U_];J_P"7X7_`^A[?#]43EMO7VR8=!G`\27O9&5W&PY?L
M44T'S_S_`-;%A2P*-Z`5_;^$[_+_`#_X7%C2[BE%J/@VXCB2:^]/\V_9Q30^
M'X_'^Y6D?&=AZG<TVI_G_GRQ16_FVH3B=O@[BAK7%0!7DYA\0V'(5X'B:`=O
M\_\`@L4D?C\?C^<Y56IH!3]OX3O\O\_^%Q0!^/Q^/\UC7G[\O]"\[:5#IVJF
M:(02&6RN;<\98I&7B30AE=6'VE9?B_8R49$&PY&GU,L,N*'W/';+_G'>Z-W?
MG0]=2804AMKZ[MV11+4B41^DS\VC^SZO\_+@O+,>>HEJ#P_Y&)]?^W2_F?\`
M"X_Q_P`[Z7L!VO+1XXRR#_"LHXH0_P"4?#+_`"L_]NR_Y*'\,/7_`!12F;_G
M&'\P%!:/4=,E'B9+A2=_>$YL1JSW.N';T:LQDL3_`)QE_,82"E]IB,-U83S[
M$';<0;?\:XG56*(3_+\0=A*T;?\`_./6OO?V0U35K.RDNZQ37D,<TT+3C[`(
M80E))1_L&;_6S`Q:F6`^'_DI?W7^U_[3_P!4O]([.?;`U6*66$?WV+U9\?\`
MJF/_`)2<?]7_`"\/X?[WZ>)G/DS_`)QT\O\`E_5;35M0U.XU6\LY$FMHO3%O
M`LJ'DK,@:21^+"H7U%_V2YE3S2EL7F=5VMERQ,=A&3TS6+^\T^R:[M=/DU-X
MV4W-M;T];T37F\2-03.O7T596E_W5\7PM2ZV$03W+M*U;2=8TZ+4-,G2ZL)"
M0KH#R#J:,CJ:,DB'X71U5E^S]K%$X5L0C%'Q=!ZE/A-#2G^?_-V*`/FYE7B:
M`<:_&.)K]%?\_P";%2!7X_'X]305>0J!_D?"=MN_^?\`PN*`/Q^/Q_FKN/7I
MR_;JIH?E_G_JXLJ6<4XC;X.PH:U]_P#/_5Q84/@O`^7J4V--J?J_S_FQ9U\_
MQ^/^/+`J<30?!OR'$@_17_/^;%A0_'X_'\2\`;;"O['PG;;O_G_PN+(!*?,`
M'/1Z#XOTQIW(T(_W>.F)<G2#]Z/QT3S\U/\`R7VM_P#&`?\`$UR(YNXG])]S
M!-1T[3K]?2O[6&[B5^:QSQK*H;<5`<$5WS-(MYV,B.2`_P`)>5/^K+8?](L/
M_-.#A'<R\27>4`--_+\Z[^@OT7I_Z4^K_7/JYM(O[DOPY<N'&O+]FO+]K!4;
MIG<^'BLTK:=H7DG4;&WOK32+![:Z7G`YM(E++X@,@.$1B>B)2F#1)1!\I^4A
M_P!*;3_'_>:'I_P./".YCXDN\M_X2\J5I^A;"HZ_Z-#_`,TX\`[E\27>4-=:
M%Y)M9+2.;2+`/?2^A:@6D3<I.#2=DV'"-FY8\,>YD)3-[G9&VWEOR[:SI<6N
ME6=O<1FL<T5O$CJ:4^%E4$8>$,3.1ZI</_)A-X?HH?\`)_,'_D7_`,DO]^]2
M?^,$?]#W_3A,O\.>7/\`JTV-?^8:'_FG,Z@\MXDN\N_PWY<_ZM-C_P!(T/\`
MS3C07CEWEW^&_+G_`%:+'_I%A_YIQH+XDN\N_P`-^7/^K38_](T/_-.-!?$E
MWEA^H7,MSJVJ6'E;RGI-^FB<$OY;M(X?5G=/4^K6P6)OWBI3D\A5.3<<@>>P
M;P*`,I2]282ZEY$MKZRTZ_T6&TOKPP1E&T]7ABN+E:QP27"1F#U&/P[/AL,>
M&9!(.W]92L_,/Y7WFHQZ?!96OJRR7$,<SZ>$@,MF"TZ"9HQ'5%4O]K[.(,5,
M,@%W_LOYR,LOS#\E?49Y+>9[>SLXXWC4VLT*R13/Z<)M4X#UEDD^"/TE^+$3
M"#@G?O\`QZETGYD>4X[6WG>:</<SS6D5F+:<W7UBV`:6%H`ID6105V*_M8>,
M(\"5JOF3S-?V-_INCZ-9I>:WJHDDA2X=HH(8(0#)+,RAGH"P544<F;$GH%QX
MP023Z8J*^=IM,L$/FJS:PU1Y9HX;2Q$E[]8C@4.]S"L8,OH!/B?U57A^UCQU
MS3X5GTFQ_I4N\P?FC]1:Y;2K>/4+6+3+;4()N;*)9K^Y6"UA``Z.I,C?M8#-
ME#3WSVWK_2_4GVF>==%U+4WTRUDFDN8FDC:803"V:6#:9$G*^FS1M_E81(-<
ML1`LI[R;Q.2:G<F\3BKN3>)Q5HDGJ:XJQK2__)L6G_,78?\`)B?-8?[^?]6#
MVO\`SJM-_P`.U/Z'H=Q_RG?F"F[^AIW%3T/PS_?\LNB\SVC]0[Z8+JT$VI>;
MM1_1.L0>5YK"XBCU&_\`KDCW%S6&.04L92EH8V1O26>42._%OY<+0*$1?J!O
M_-_S_J_XI[#I4US'9CT+<W`:4@E7447BOQ$M3ED9.?H/H/O5]#9F6^++P/UR
M;X20>A%.F!SDRQ5V*NQ5V*I'KODGROKUU'=:M8K=3Q)Z2.7D6B5+4^!E'4YB
MY]'BRFYCB/Q=CH^UM3IHF.*7!$GBY1^K_.#"_,GE;RGY7\P>5KVPMX].5]0*
MW,[2OQX"%C\1D8J!7-?GTN'!DA*(X/5W_P#%._T/:.JUF#/"9.7]UZ(\(^KC
MC_,BSK_%WE7_`*O-C_TDQ?\`-6;+\WB_GP_TT7G?Y,U/^IY/])/]2Z+S3Y9E
ME2*+5K.261@J(MQ$69B:``!MR<(U.(FA*/\`I@QEV=J(BSCR`#^A)-,O<-@_
MF1KA;756L[B*UN0DQCNIVI'"_$\9'J&`53]H_P"QR;H<E>(?ZV_X_'\U=\-%
MJ1QVXMR(K3Q_S^#"XVWX_'_2+XM_."O_`"M/S344/Z0EK^&5O28_I'N8?BS1
MMI:6]UP)D^KJC*+IR"P6-F"^J`-Z*3\2X0`3NF`LT4=IUE8IKBK%?1RQ02@Q
M2&.0"4*1N!0\?'XLCE,8@D'DWX\(E*@7LV@V6B7M]^A;*Z-Y&T3_`%F9#Q5N
M*5/7;;-%+).,N)W0HPJ7+^:\B\[6T<5]"4?U*)Z7J#>H0GC^&V;C!F\0673Z
MK3^%+;Z6.,K*Q5@5([$$'[CESB`WR:Q2[%7T7_SB?Q_1OF7D:'ZQ:<=R*GTY
M<D'7=H54?B]C\V_\HMK>PY_4+GFM>E(6_P`_\G"Z[%]8[['X_'TO_]?JWY?L
MW^"M#&W/ZHG%:]1[CIDP\_J"?$EWVR'GUH:KOS/(FGRQ:[6<SM4BG[&YWV[_
M`.?_``N+'B5`[U[<]N8J:`#]7T?9_9Q96?Q^/Q_"IE_?X-J&IK7_`#_SY8L>
M+Y+E=Z]O4["II3%()^+3/UH:KOR/(GKX5_S;]K"IE^/Q^/YSE<\A6G^1\1W^
M?^?_``N*B2%U6WN;NU:VAN#:M(0+B52>8B_;"&OP,P^'G^Q^QE6;&9QH'A_X
MER]'J8X<HG*(RF'TPD?1XO\`!.?\^$)>J4/\WZ56VB@MK>&W@18K6(*D**2`
M`O;;)P@(B@*`<?-J)Y9F<SQ2F>*4Y?5*7X_TO\*N7??IZE/LU-*?+I_G_-A8
MV?C^/Q_QY9SV._P;\C4UK[5_S;]K"QXOE^/Q_NE.]M;:^M9+2[198)UX\"S4
M(/0UZU!^RWVN60R8Q.)C+<%R-/J9X<@R0/#.'JA^/XHR^GU?5],O2IZ?%=6U
MJD%Q<?6I8JJT[55B@V7E0GXPM`[C[38,43&-$\1_G)UF>&3*9PCX49?Y/B],
M)?Q\']#B^F/\'T(I7^$5/P;<3R(-1XT_S7]G)N.#^/Q^/YK&?,&@/;75QYCT
M2YCTK6E0R:AS#-9WL<2UI>1)OS51\%Q%^_B_XM_NL6V.2ZB=_P`?P_\`$_3_
M`)S&_P`IOSGM//FHZUI\EH--N+$K+:VS.S2/;,`K,2W$LR2_:^%/@DCY+RQ!
M;=1I_#`[B]*=VIVY?L#D:&O^?^R_:Q<4G\?C\?SFE<\C2E/V_B.VW;_/_A<5
M$EW/85/P_L'D:FGC3_-?V<4\2P.U>W/]H5-`/\_^;<+'B/Q7!_@_XK\:FM?\
M_P#/E@3>WDMYM4=.>_$5)!!^?^;?M84<1_'X_'\2Y7V:E.-3S/([;=L"1)*O
M,#$OHH-*?IC3N.Y)/[\8ERM(?WH_'1/OS4_\E]K?_&`?\37(CF[F?TGW,,?[
M;?,YG/.-8JP3S%Y?\Q2-JVN:9;AM<AO$.DQ%T7U;1;46KIR)HH<RS2T;]I$R
ML@\W)A..P/TUZOGQ*)\H:BC'3Q9&69&TZ+2]:+IPL[2T2+U>%6]5)O42<\8X
M_P!_ZJ\WX?9>%/BCG?\`.XH_SFXO)MU(UE>7FF)-=$ZGJ>HH[(W.ZG+"TM6)
M-&C596^'^YY)\6/"IRC<`_S8_P#%20H\EZM8VD<-M9>H@TW3[&^92KR3MZQE
MO'"M)&)6BXQQHDLGI^FSHO)/@QX2GQ03SZD_\2F'E3RYK5OJ5I+?6QM[6VN-
M3O(X_P!R%1KCTX+=5CA/II6`32,(QP5I/YL8@L<F0$;?T6=98XS'!_Y,-O\`
MME#_`)/Y@?\`(O\`Y)?[]ZP_\8(_Z'O^G#(\SWDW8J[%7#KX>^*O+-2T;SF=
M8U9]+LM5L-*UF=9]2MK>33O5>1`$9[>X-PLEOZRHO+X.?^KE1!MS8RA0LQ)C
M_6_4A9O*WF.;S4FO3:'J$PAOEU"V@E>PDD0I%Z:0^LUU7THV_>(H1?B^WRP<
M)NZ2,D>'AL<N'^+_`(E=:^4]5BL-+L9_+NIS6^FV%_9&DVGHTDNIU$US7ZP>
M+\6:B_%_K8\/DIR"R>(;F/\`._@^#4_E[SE?>65T35-+U"\6V>T;33_N,C@A
M%D.,8:$7),WJC^_Y2_%_NOT\:-4HG`2L$=?YW\7P1/E[0M;TC5-/U'_#%W)+
M8Q78]*$Z;;QM/>LG.4*EP>/&*-85Y<WX_:DP@$=$3F)`CB'3^=_#\$;YD3SE
MJ.J6&LZ3H>H:5J]A'+;I.7TVYBD@GH71XGN$Z,H9&Y83?.F./@`()$@?ZWZD
MFU?REYAO[?3"VBZG<:A8)<1R7FHR:=>"87;!I&]-KE%C9&'[GB?3C7X.#KD3
M$ELCDB+WC1_F\4?T*G^%-7%R9%\NZBD!NM-N/02335`ATJ,K%`.-P%56E;UF
M(3[7P\,>'R1X@[Q_%_._C^"8>2?+?F"Q\WOJVH:==0&XBEBFN0MC;I(7;GZM
MXEM/()YMN"/'!']KFV&(-VQRY(F%`_[K_8\3TO+7#=BKL5=BK&M+_P#)L6G_
M`#%V'_)B?-8?[^?]6#VO_.JTW_#M3^AZ%='_`)WCS$.BF#3JM_L9]O[,NB\S
MVC]0]SSC\P%LOTO?2VT\<^NH(S;Z6WE]+XS.0O&/ZXT#5]3_`'X9>,?^PPEI
MPRY`_P"[_P![^.)[KH'^\;D]3)N-C0\5VJ-LB7.T'T'^LOT;_C^_YBY?X8'.
M3#%78J[%78J[%4)J.D:5J<:1ZC9PWB1GDB3QK(%-*5`8'*\F*$_J`E_6;\&I
MRX23CE+&3_,/"@/\$^3O^K)8_P#2/%_S3E7Y/#_,A_I0Y/\`*VK_`-5R_P"G
MDQCS[Y8T33[+2;S3=)@@DAU>P,TMM;J'6-I@IKZ:\N/)EY?\-F-J=%'TG'&-
MB<?I`^EV79O:^2\@S9)F,L.2,>.4I_O)1]#T'-D\ZP/S;P?3M766U:]C,<];
M&,E6N`5(,8*U:K_8JO\`J_:R;H<A_>G>O5^/Q_FJX9@:]]JK4#C3^G_"_M87
M&O\`'X_$7Q9^<%/^5I>::;_[D)=_NRMZ3'](]S#\6:8:/&[O>4!*+9SM)3LH
M7:O^SX8JI6CM"XG0T=3XTV_MR,X"0HMF+(82$@SW\L_-5WIU_?)!'&YN;:4S
M<P24`%!0_3F'GP7NYN'*)$7SOB8UK>I:G);1B:XY)&%2.,`;*&)`Z9;AR&P+
MY"FC4Z6$8DU]1,O]/]227U_>7]W)=WDK3W,IJ\C=3V_#,HR)YN%BQQA$1B.&
M(0^!F[%7T9_SB<2-,\S4_P"6BTJ:TI^[EWR0==V@=H_%[#YM/_.J:R.7PBQN
M>+;;TA;_`#_R<+K<1]<?ZT7_T.J>0`/\$:)O\'U1.3>!/:G^?+)AY[4?WDNZ
MS^/Q]3(]^521RWX#E7E4?C7_`(?[.+#\?UOQ_LE/QH1_EBOV=J?Y_P#`86'X
M_'X_HKQ2B_%1!3B]:5I^JG_"8&7Q_'X_TBTUY'ISVK'7H.O3_/\`FPHZ^?X_
M'^R<./$CE\!K5ZUWKT_S^U]K%1]GX_'^R;?=JDCEOQ6M>5?UU_X?`I_'X_'&
MY3\1HU:_;/+[.WC_`!_V&%1^/Q^/YK34^'X@%'V&K2M!_G_J8J?Q^/QPN%>0
M.W/:J5I0`]?:G_"8J/M_'X_HMGCP(Y?N_P">O>M:?V?[/`G:O+\?C_9+36O;
MGOQ2M>0/ZZ_\/A8_C\?CU+]MZ,"#]MN5>-13K_GR^Q@9?C\?C^BM-*CX@!MP
M-?M;4_S_`)?L84?C\?C^BN2H.U.>W):TXT[^U/\`A,"1^/Q^.!4MK9KAQ&CA
M5`+>I4_LFI%!^K_98VV8L1R'A'X_'_'F.7GFSR38ZK<1W=VL>HVK-!(XLYW;
ML6'J+$:@_M?%\68<^T,4203N/Z,FN<\<)&)EN/Z,_P#B5I_,'R05(.J/\1)/
M^BW9I7_GE]^0_E/#WG_2R8'-B_G_`.QR?\2U_P`K#\C+1FU9@%[FUNQVIN?2
MQ/:>#O\`]C)ECE"<@(R,I?S8PR2E_N5P_,/R/N?TH^]-OJEWM3P_=?=C_*>'
MO/\`I9(\;%_._P!CD_XE://_`)'H!^E7H*4(M+NNW_/+'^4\/>?]+)CXN+^?
M_L<G_$JD/G[R5+(D::FQD<A%7ZI=T))V_P!U9*/:.$D`'G_1DSADQR(`EN?3
M],_^)99+H<Z6SS&93&%+D_%6A%>X&9EN9/0RC$DE`J?$BN_`<OM;?Y_ZWV<+
MB#\?C\<7TI3K_P#>:-0U/Z8T[D*UI^_'^?\`D_9Q+DZ/^]'XZ?C_`'*?_FI_
MY+[6_P#C`/\`B:Y$<W=3^D^YAC_;;YG,YYQK%78JDFH:QJC:LVDZ-:P3W4$*
M7%[<7<CQ01+*6$2?NUD=Y9.#MTXHGQ-]I5R)/<V1B*LK5\VV-O#"NK1R6%]P
M5[VV"O.ML'<QJTTT2E(XI'7]U))PY+\7P_%CQ=Z?#/3<*=OYIDN/,C:/';*8
MUN+B`S\S7C:6\4DC\:?[_N$@_P"";'BWI3CJ-LAR34[%6.H!_P`K#-30?HH5
M/_/?,#_D7_R2_P!^]8?^,$?]#W_3AC>B><?-MQYJFL-0DMH'BEN3)Y>EMW@N
M#:1!C%/9W3,8KMGHO-?@7_5S+$C;ST\4>&Q_IOZ7]*/\*G9?G/:+H=MJ.IZ;
M+%<7PN;NUM(W@4_H^W;B)RTLJ*S-3B(U_>2R<O3CX?%CXFRG2GBH'E_NDTO_
M`,UM%MIV6"POKZVC^H"6[MTC**=34/;J%=UD>0J5K&J\L)R!B-,3U`Y_[!-M
M*\Y6-_HNJZK):SV<>C2W4%]!-P+A[->4G$QLZ-MX-]K");6URQ$$#^=_ODGT
M/5_/<]E8>9M2N=.BT&[B-W>:;Z;I+:V9C,J2+<<F,TJIQ:1#&J_RX`3S;)QA
M9B+XO]U)`W7YQ:;<^7M:N]+@DAU"RLDO-/2X,4BS+<2"&!BL,C\&]5EYP2<)
M<'B;,AI2)`'E;;?FA)IESJ*ZM$+F.+4$TG3U@]*`-<06JRW9DFG>.)1ZK<8E
M+?Y"X\=+^7NJ[N+[?2SVPN_KEE;W?HR6_KQK)Z$P"R)R%>+A2PY#V;+`XQ%&
MD1BQ>?>;_P`P[S0O/6F:96*/0EA6;6YW6KKZHF:,(U?A/&W8Y7*=%RL6`2@3
M_%_"@_+7YH:RV@ZAK&OV0;_<@UI8VEN8;?TT2$3,)I;B2-.2<_3._P#>?#QP
M1F:LLLFG'$!$]$9-^;,'UVWE@TV=M#&C-KE[=L(Q(D)JL2JGJ#=I%,?^4_'A
M^[_>8?$8C3;<_5Q<"::G^9.D:<TZ36=V\MO%8220Q*C/SU-BL,"KSWF`!=U_
ME^SRPF;".`G[?]@AI?S6T:#5XM+N[*YMKGUH+:]5WMZVT]T?W4;H)#)(:<3*
MT"R)#S^-L?$%LORY(L%&^9=;UT^8M/\`*^@R06M_=V\M[=ZA<QF=8+:)A&.$
M09/4DDD;B.3<5PR)N@QQPCPF4N2`O_/MUY7LH+7S0D5[K4GUB5!I[1PI):6Y
M_OV%P\:1R,/A]!7=FD_N\!G7-D,(F;C]/])+=<_,K4FN;O\`0#0O:FVTE;!I
M8R6:\U>:J<MQLEJ"WI_S8#/N9PP#^+^E_L/^/,ETP4_-FU%:TN[`5_YX3Y@'
M^_G_`%8/4_\`.JTW_#M3^AZ!?K.?.7F;T"/7^J6'I*WV>?IS\2W^3RZY=%YK
MM`>H>YY<]CYIN=$0RV^O1W]A:PVFDJ[SK,^O3NTMU=R%7X-9Q%402R_Z+Z+2
M1PKBP%"5;43O_1Q_S?QZGO>EV0GM!ZDDB-%*6Y1.8PQXK6H4[K@+EZ'Z#[U?
M0T"+?*"2/KDQ^(ECN0>IP.:F6*NQ5V*NQ5V*NQ5V*NQ5V*L%\V`+IVKL]XUB
MHCG)OD%6MQQ/[T`$-5/M;?\`$LFZ*8_>'KZE81GQ-=OBV^+[_P#/^;%Q^'\?
MC\?SGQ7^<'_DT_-/_;0EV^[(/18_I'N8?BS3S2T,'EW5;H?WMZ\&F6PVWYN)
MYNO8+%$M?^+,53O6_P`L[^RU*;2])OH-9U2Q5/K^E1`QWB2F-7=889*?6D3E
M]J#F_P#-'BJ=>3]#2TM$MKV-X=5UB'ZO*C?`T,4]RL,1=2/AD/[SX6_8XX"$
M@T;#'[#RM?:O<)=ZM*-'T%KH6L5S(I+S/ZGI^E:1?;N91^VR_NX_]V.N1A`1
MY-F7-*?-C_F+2?T/K^HZ5ZHF^HW$EOZH_:]-BM3[_P`W^5DVI+L5=BKZ-_YQ
M-4MIOF:A(I<6FPIO^[EVWR477]H"Q%[%YM0_X5UH[_[P7-%VV_<M_G_Q+"Z[
M$/6/?'\?C_.?_]'JWY?D_P""-#-#M9I\'8_Q_P`_AR8>?U!_>2]Y_'X_S61$
MFI%6-:U;;X:CV_S_`)?BQ:_Q^/Q_56<MQN12E#M\6W^?_7>%C?X_'X_SEP8[
M&AWI\`I\-.G7\*_[/`R!_'X_'\]:3VY&FWQ[;[]/\_\`B.+'\?C\?[%L,:$T
M-=_W>V^_7_/_`(CBD'\?C\?YKG)J14FO*K&GP^/3\?\`A,5)_'X_'\URL>7<
M4_U?BV_S_P"NL5!_'X_'^<XL:@T.]/AV^';_`#_XVPJ3^/Q^/YS2GH*F@XT<
M4WWZ;_Y_S8$#\?C\?TEQ8\2:'I3T]J=>O^?_`!#%E?\`TC^/Q_FK2>HJ:&M7
MVVKVV_'_`(3"QO\`'X_'\U=4]=Q2NWP_%M_G_P`:_%@97^/YWX_'J6ECR[FM
M-MOAV_S_`.NL47^/Q^/\Y<E:`5(`I1Q3XJ?/\/\`A\4C\?C\?TD9I$BQWHD<
ME56-JH!6@'L`3_QM@+E:+^\'N*>V3J[7++6AEVJ"/]UIV.1=TB<52CS;H/Z?
M\NWND>KZ!NT"B8KR"E7#@\:BNZYCZK!XN,PNN)SNS=9^6SQRUQ<'\/PX6+RW
M/G?0==T&WU'68=1LM2NC:R0+:I`0!$S!N8+'MF&3FQ3@)2XXS/#]/"[B./1Z
MG#EECQRQ3PP\3B\0Y/XOYK/\VCS+L50^H?[P7&U?W;;?1[80TZC^[E[BQ4$[
MBI-2:MM\.W^?_&OQ9)T(/X_'X_SDI\P&KZ,-]M8T[<T^+]\/#_/^;XL2Y.C/
M[T?C^%/OS4_\E]K?_&`?\37(CF[F?TGW,,?[;?,YG/.-8J[%4COM"U7]*W&I
M:1J*6,E]%'#>I-;BX4F'D(Y8OCCX2*KE?C]2-OA^'(D-HF*HCDE4OY<VDFH>
MO)<"YAF%L+QKR(7%S)]54+03,W`+,!^]Y0OQ^+TN'+X1P,_'-)EHOE8:;J<F
MH277UB61+A:<.-'N[MKF5_M-V]**G\L6$1IA/)8K\<N%/\DU.Q5C;(DGG^2-
MQR1])XNI[AIJ$?=F!_R+_P"27^^>L/\`Q@C_`*'O^G"%TO\`+31K">&0WU_>
M0V4$]MI5M<SAX[.*Y7A((**K<N!XJTC/Q7,P0#S4LY/0;\_Z2B/RLT46>FVZ
MWU\DFF6S6,5TC0B5[1GYB!SZ7$!"/@DC5)E_WYCP!/Y@V=AOO_G)A_@+0_K1
MN"T[,VIPZPR%U*F>VB$4*'X:^C&HJ%^UR_;P\`8^,:^'"CM)\M:9IFD3Z5&'
MGM+J2XENO7(9I&NV9I>14+UY<?\`5PB-!C+(2;2;3?RRT&S*)<7-[J=M;V\M
ME86E]-ZD5K;SH8Y$A553K&?3YOS=4R(@&<M1(]P=:?EGHD%@+&2[O+FW6:UE
M19GBV2R?G##1(T!3D!ZC-^]DX_%)CP!3J#=[=?\`9.N_RSTFXL9+--0OH(KB
M6ZFO%22)EG-Z_J2^K')&\1(.T4@3U8U_;QX`HU!!NA_TBR;3K"UT[3[;3[12
MEK9Q)!`A)8A(U"J"3N=AD@*:I2)-E$X6+%M:_+CRYK5_<7NH^M+)<W%G<2Q\
MEX?Z`KK%'3C_`'3>H_J+^U_,N1,`6^&>410\_P#9(6[_`"J\O7,4*&YNXGB>
M^=IHWCYO^DFY7`8M&P7_`"&0)(J_#RP<`2-1(=W3_8+KO\KM!N8;BW-S=Q6U
MUIMOI$T,;QA3#:$&%Q5"1(I%33]V_P"TF/`%&HD.[GQ*]O\`EUHT=V+R:ZO+
MRZ^OV^IRS7$B,TD]K$8H0_%%'IH&+*B\>+?Y/PX\`0<YJMN7"KOY%TD^8Y-=
M2>XBEGE2YN;1&002SQ)P5VJAE^R!R195C?C\28>'>T>,>'A5/,/D^SUF]M=1
M6]O-+U.T1X8KZPD6*4PRD%XFY*ZLA(Y#X>2M]G$QM$,IB*H$?TDON?RP\N/;
MZ?#:27.GMI\,MM'/;NAEDAG?U)5D:5):L\G[SU5XR*WV&7!P!D-1+>][1(_+
M_0OT@+XM.THOX-3X%U*F:U@^KPJ?AJ8XT^)17ES^+EAX`CQI57EPMZ7_`.38
MM/\`F+L/^3$^:X_W\_ZL'K_^=5IO^':G]#T*Z?CYW\QD*6=;;3V6G79)]A6E
M*^.71>:[0/J'N8QJGYA7/UN.VT*P:YG2-WO;&X@N5N1*I`6W,42DVY<$LMU/
M_HG\DC_%A<>.(=30_'X_HO3]+O$M[1>4<C"20@+&A?A\(/Q<:\?GD2[#0_0?
M>KZ&X=;Y@"/],F%&!!V('0X'-3+%78J[%78J[%78J[%78J[%6$^91.]IJJVE
MK'=W)281V<P!CG<J>,;U*CBW??\`RLFZ*9'B'^M^/Q_G+ZI0;54TXK2M*_Y_
M[/%Q['X_'_23XJ_.'_R:?FGO_N0EW^[(/1X_I'N8?BR9)YM4Z=;:%H\1%;.R
MBOICUK<Z@!<,?]C%]7C_`-ABJ-_-+59K_P`]2ZY'6&74+>RU"-XS0JT]M')R
M4KN.+E@O^KBK)?+WF:?_``5?Z_=2N;G2VL;**Y;C)+(YD>5@S.&9J\>[<L5/
M)B_DZ^UK6//6EZC?2S:C)I;_`%^5I2TG&"P4W+"G1(_W?^KR;%6+7=Y/>W<]
M[<'E/=2//,?%Y&+-^)Q52Q5V*OHW_G$TK^C?,U14FXM*;5H?3ER0=?VARB]C
M\VD'RMK8_:^H7-6IUK"WZ_\`AL+KL7UCWC\?CZG_TNJ^0`?\%:'X_5$H_A]/
M^?')AY_4#]Y+WED/$U/PD`5Y+0"M!_G_`*N+72SB=OA)K]D4&VW^?_$L6%+P
MIJ!ORVJ]*\J_KK_PW[6+.OQ^/Q)81WXGCM\%/?K_`)_ZN%A7DN53T_:W^.G0
M5_S_`.(XI`:=>IXD`5Y+0"M/\_\`8XJ1^/Q^(MJIY;@FOV=A\.W^?_$L5`_'
MX_'\3F4UI0U_::@/*H_S_P!;%2/Q^/Q):HZ'B2II1*`TJ>OO_P`;8H`7E3O_
M`#4KZGM6E/\`/_5Q9$?C\?C^%3(V)XD**U6E*T_S_P!CBQK\?C\15.)J-C7]
MDT'P[?Y_\2P,J6E37H:[<C0?%M_G_P`2PHIM!L#Q)!IQ6@-*_P"?^RQ2!^/Q
M^)([1V$=\'<%N,;EF52Q(]@*L<!<O1#]X/<GMDX=KE@"`9?V@5/]VG8Y!W2)
MQ5V*L9\Z>7M:U672+K2)K>*\TJZ-RHNPYC:L;)0^G\7?,+5X)SX3"N*!XO4[
M?LK6X<(R1RB<H9H>'^[X>+ZN+^-+M*\W:U9>9[C1/-ESIL`6S2[@N(&:%"6D
M*<"9VW.U=LIQ:J<<IAF,!Z>+T^G_`';EZGLS#DTPS:6.:7[PXY0G63^'BXOW
M09+#YD\NSRK%#JMG+*YHD:3Q,Q/@`&J<S1J,9-"4?],'3RT&HB+./(!_4E^I
M%:A7ZC<4-#Z;;].V7AU^H_NY>XL35=C\)`!/(4'Q;?Y_ZOVLDZ`!*M?!#Z*:
M;?IC3J"G3]^,2Y.C'[T?C^%/_P`U/_)?:W_Q@'_$UR(YNZG])]S#'^VWS.9S
MSC6*NQ5V*NQ5V*NQ5V*L5U2:^T_S@-133KF]MFL!;UMDY4?U2V]2!T&:S-*4
M-1QB,IQ\/A]']9[;L[%AU79/Y<YL.FRQU7C?X1+@_=^%X?\`ND1_BZZ_ZE_4
M_P#D4O\`S5EGYV7^IY?DXG^AC%_RF:+_`)62_P")=_BZZ_ZE_4_^12_\U8_G
M9?ZGE^2_Z&,7_*9HO^5DO^)=_BZZ_P"I?U/_`)%+_P`U8_G9?ZGE^2_Z&,7_
M`"F:+_E9+_B7?XNNO^I?U/\`Y%+_`,U8_G9?ZGE^2_Z&,7_*9HO^5DO^)=_B
MZZ_ZE_4_^12_\U8_G9?ZGE^2_P"AC%_RF:+_`)62_P")=_BZZ_ZE_4_^12_\
MU8_G9?ZGE^2_Z&,7_*9HO^5DO^)=_BZZ_P"I?U/_`)%+_P`U8_G9?ZGE^2_Z
M&,7_`"F:+_E9+_B7?XNNO^I?U/\`Y%+_`,U8_G9?ZGE^2_Z&,7_*9HO^5DO^
M)=_BZZ_ZE_4_^12_\U8_G9?ZGE^2_P"AC%_RF:+_`)62_P")=_BZZ_ZE_4_^
M12_\U8_G9?ZGE^2_Z&,7_*9HO^5DO^)=_BZZ_P"I?U/_`)%+_P`U8_G9?ZGE
M^2_Z&,7_`"F:+_E9+_B7?XNNO^I?U/\`Y%+_`,U8_G9?ZGE^2_Z&,7_*9HO^
M5DO^)=_BZZ_ZE_4_^12_\U8_G9?ZGE^2_P"AC%_RF:+_`)62_P")=_BZZ_ZE
M_4_^12_\U8_G9?ZGE^2_Z&,7_*9HO^5DO^)=_BZZ_P"I?U/_`)%+_P`U8_G9
M?ZGE^2_Z&,7_`"F:+_E9+_B7?XNNO^I?U/\`Y%+_`,U8_G9?ZGE^2_Z&,7_*
M9HO^5DO^)=_BZZ_ZE_4_^12_\U8_G9?ZGE^2_P"AC%_RF:+_`)62_P")0WEN
M2\N_S$T_49K"XL8)KZSCC%RO$DQP3@TI491C,I9)S,90!$?K=CKH8<.CT^GA
MEQ:F>/)GG/P)<<8QR5PO1KY6?SIYD0.4#6VG@.H!924G`85[K[_#F3%Y+M'Z
MAW4QS1_R\6)G.L7;7MP%1;*YB>Z2:%X^1>=9Y9I9H99N2^K'%)'!\'QQOA<:
M67?T[/4_+X`LW'<2&IZ5/$;Y$NQT'T'WK]&_X_O^8N7^&!SDPQ5V*NQ5V*NQ
M5V*NQ5V*NQ5@'G/ZG^B=:-\TJV@AN/5>`5E6/B2Q2NW*GV?^"^SDPZ&=^*?Z
MVR)IO_E&G(\20:_U_P"&_9PN,^+/S@_\FEYIIT_2$M/PRMZ3'](]P8@144\<
M6;V"R\DZ3YNTNQ\\:E<21:3:6,%IJVGVP_TN2YLE%ORCV94MI(T5WGXMZ?&1
M./+%6':S<:_Y\\PQ0Z/I3K:6D:V6D6$*'A;6<.T:RSL!]E?BEGG?_@5Q5OS;
MJ5AI^@6'DS2KE+R&RF>]UB_A-8;B_D`3C"3]J&VC'IK)]F5V=\54ORQUBTTK
MS?!)?*7TZ[@N;#4(P_IEK>[A:&0!NS?%R3_*Q5+/-OEV3R[YAO-):03QV[_Z
M/<#I+"V\;_[)3\7^5BJ3XJN2.21UCC4N[D*BJ*DL30``=R<5?27_`#B]INHZ
M=;>:+6_MI;2X6>T+P3QLC\3'+3X6HV2#KNT.4?B]8\V@?X5UG;X?J-SQ%#7>
M%NO^?Q876XOKC_6#_]/K'Y?\?\#Z)_+]43D*;DBO?_/CDPZ'/]<O>61'[0Z<
MM^!XTXT_5_QKBU_C\?CTK-JFE/\`+VZ[5V_S_P`K%C^/Q^/Z2^BT7:J;<5XU
M(K^O_C?%EM^/Q_TDM/VCN.>U6IM3Y_Y_RXL>OG^/Q_L7#CQ.WP;U6F]?'_/_
M`%<4BO@Y_M"M.6_$\:4I_3_A,5/X_'XX7*!4TI_ECB=]J[#_`#_FQ4?C\?C^
M<YN/P[57]D<:TJ._^?Q8J?Q^/QQ.7[7;F:5:E003^/\`QMB@?;^/Q_2;/'@=
MO@_EIO6M*_Y_ZN*=J\OQ^/\`8K3UZCGOQ:E``/U4_P"%Q1^/Q^/2OHN]``/V
MQQ(KMV_S_P`K%E^/Q^/Z2U@*BM*;<!QZ;5_S_P""Q0?Q^/Q_.;4&O;D:<C2M
M0?UU_P"&Q2/Q^/QQ(S2'5+L/0\%1SQ52S5\0!N?NP%RM%_>#W%.[)PSW+`$`
MR]P0?[M.QR+N$3BKL5=BJ6ZCY;\OZG.)]1TVVNYE7@LD\22,%!)`JP.V^4Y-
M/CF;E&,C_2#EX-?GPCAQSGCC_0D8I!YG_+;0K_1I;?2=/LK'4.4<D%PL*IO&
MX?CR0<E#\>!8?\"V8V?L_'*-1$82_G<+L=#V]GQ9.+)+)EA4AP2F?XH\/^Q9
M1>D_H^8N*'TFY`'OQWWI_#,\/.Y_[N7N+&%'3I7?@>)VH._^?P_:R;H@E/F&
MG/1Z=?TQIW(TI7]^/\_\K[6`N3I/[T?CHGGYJ?\`DOM;_P",`_XFN`<W<3^D
M^YAC_;;YG,YYQK%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%5-/\`E(/+?_;5B_Y,395F^ES-#_>?!D5Q_P`IWY@X_;]#
M3N(/3[,_^>_PYCQ9]H_4.^D8"N]#\&_,U-?HK_G_`#9)U_X_'X_K)UI<5Q)9
MCT;DVZK*2:*K\UXC8\Q7(2=QH#Z/BOL+&Z1KNE[*@>YD<`QQ`4:A'&JGDO\`
ME8'-L+YUOH[FWB6\G992W-UBB95`7;DW$<-\5M4GAO(X9)!?2L44L%2.)F)`
MZ!0N_P`L5MJVAO9;>.1KZ5&=065XXE8$C>J\33Y8K:G`+Z2ZN(3>3JL7'@[0
MQ*K5&_%N/Q_\:XK;KQ;^$P!+R=_4E5'X0Q/136I:BC@/\O%;5VMKM5+?7Y6H
M*T"0U/L/@Q6T/IPO[BV#RWD\<@)5A)#%&21W"E6^'Z<5MH_7QJ/U<W=P8R@(
MD$,7`,*DUDXTZ4''CBMJEY]=M8?66ZFGX,I,211N67D.0XJ%;==OM?#BML9\
MQ27/U+4Y+*6.VN?3E:.:Y-(XG*GBSUJ`JM]O_FC)NBR5XA[N+U?C\?Z54JM!
M7[&W`U-:]ZT_S7]C"X_W?C\?[E\@_FYHD;_F-YCN#-+62^D:15@)"$T_:Y`,
M*>&8WB&Z>EQCTCW,2?RQJ3PH]I!/<R48S(L+#@%[UJ>7?'QAU-,^%#_6]=TJ
MXCC%Q<V5Q:DF)%=XGC+_`&N(!''E^U_-E@((L,5?4O-WFK4[<VVH:O>75J=C
M!),YC.U/B6O%NG[6%4%9:?)=A^$L49CIM*X2M:_9K\L/#;7/*(\PU=V<MG,J
M.\<C4#@Q.)%Z^(VQ(I./()#95U?6-1U>[%W?R>I,$6-2`%`1.@`&!F@<59;Y
M.T9+NTN)[BU,D+.(UG:SFNU3TP"[*T,L3(R\QR!^U\&*O=?^<=Q&)/,U$],-
M)9-'\$D7-6CF*.RM),P]2,HWV_\`)R477=H54?B],\VU_P`+:W_.+"YYBIH/
MW+5_S_X'"Z[%]8[['X_'^:__U.J^0"_^"]"W^/ZI'Q\/Z?Y_%DP\_J"?%EWV
MR&O6A/']OK^%?\_YL6N_Q^/Q_.6<CM4FG['7P[_Y_P#"X6%_C\?C_-5`6KU^
M/]OK2G?I_P`:_P"PP,[/Q_'X_P!RIEO<\.W6M?\`/_/EA87\OQ^/^/+E+UZ_
MO.W6E/\`/_/E@9`GXN8]:$\-^76OT5_S_GQ03^/Q^/YS2DU%3_J?:_'_`#_X
M7"H/X_'X_P`UMBU>OQ?M]:?13_/^7%2?Q^/Q_-6@]*D\*BG6M?>G^?\`+B@'
MY?C\?[E>2^^_[RGT4_5_G_-@96?C^/Q_QY83L:$\-^76M?:O^?\`/A8W^/Q^
M/YR^K5%3O_NOK3Z?[?\`B.!G?X_'X_S5I+5.YK^WU\.W^?\`PN%B2VK?"*D\
M-N/6M?>G^?\`+@2#^/Q^/YJ.TB3A?!W#,RHY*J"Q/R`ZG`7+T7]Z.^BGMDX=
MKEJ$?O>C"A^PG;(NZ1.*NQ5V*NQ5V*H>_P"7U&XX_:]-J=/#WQ#3G_NY5W%B
M:G9J$\?V^OAV_P`_];X<FZ`%*M?)YZ+4[?IC3N'7_?XZ_P"?_"XER=&?WH_'
M1/\`\U/_`"7VM_\`&`?\37(CF[J?TGW,,?[;?,YG/.-8J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78JII_RD'EO_MJQ?\`
M)B;*LWTN9H?[SX,ANO\`E./,5=E,&G`M_L9]O?\`U<QXL^T?J'N1@8\A4[[\
M1RKRJ/QK_P`/DG7WO^/Q_P`4V6.Y#5_G^+[.U/[/^$P))_'X_'\*SE0#XJ`4
MXMRI6G]/^$PL;_'X_$50,P/^4`*I6@`!KT[4_P"$^U@9W^/Q^(J=?A^U\'\U
M>]:T_P`_];"PO\?C\?Q,8\SZ]YQT[6-,M--M=-GM]6N#:6K74URL@D]"2=FD
M6-&4H?1*KQ^)\#?CC$@DDV/Q^/Y[KCS]I>G230:M-RO4GDMS!8175TW."VAG
MG`58RQX+-RYCX/2_R^>*/")W'+^M_F_C_2JMK^8WE&>VN+F.\E]"V2&9',%P
MK7$=PQC@>V!CY7"RR`QQF$/\7P8KX4A_;_-_G?S4VT?7+#5[9KFQ=_W4A@N(
M)DD@EADCH2DD4BJ\;*&#?$OV?C^)6Q83B8G\?C_B$:I%*<O@I3E7O6M/[/\`
M98L`?/\`'X_XI>S'??XR#1.5:@_KK_P^+(G\?C\26<NOQ5!)Y-RK2O\`7_AL
M+&_Q^/Q)3OK2UO[.>RNQSMKE&BD3F1S1UXL"PH>AX\O]C@9B5&_Q^/\`I%4#
M$'K\6W)>5.-/U4_X3"PO\?C\02#4/R\\@ZE=S7VH:%8W5S<MZD]U+&"\DAV)
M;WI_P.1X0Y(U4ZKBV0W_`"J[\MPVWEG3@_91$/O_`,_];'A"_G,O>T/RL_+-
MN1/EG3BO=_2!(_S_`.&PT%&KR?SOQ^/],YORK_+,4_YUC30=^/[H?$/\_P#F
MG&E.KR?SG+^5?Y9EO^47TT_SCT5^'Q^7_&N-*-7E[W'\JORQX_\`*,Z;Q[-Z
M(%3W'^?V<:4ZO)7U?C\?Z5W_`"JS\M>7_*+Z;S[IZ(^_[O\`FK&E_-Y>_P#'
MX_XIO_E57Y8\33RSIO'N_I`T/8?Y_:QI/YO)_._'X_TSE_+#\N%V7RUIZU%`
MJQBC#KO3[6__``6-,?SF7O3C0O+7ES0$G30].MM.6X96NEM@(P2JD*33^7D1
M_P`)C3&>:4^9O_>_C_CJCYM(_P`*:R.7PBQN>)KUI"W^?^3B6.(^N/\`6'X_
M'TO_U>J_E_Q_P/HF_P`'U1.35W!/:G\/VLF'G]17B2]Y_'X^ID1ZCIR-?3'(
MGE7]?_&_V<6O\<_Q_P`>6;;TI7]OXCMM3_/_`('"Q_'X_']%<.%%WHFW!N1!
M)'CX?\:8$[?#\?C^@M/VB-O4VJG(T`Z]/\_YL*.OG^/Q_LFQPXG?]WO5N1K6
MM:?Y_P"M@45\/Q^/]DYZ$CIS->`Y$@UZ?.O_``^*3^/Q^.)R\:FA'^6>1VVI
ML?\`/^3%`K\'\?CTN;A\-2..W!N1%:#O_G\&%37X/X_XZT!\0Z<Q3DO(@`#]
M7_&N!1]OX_']%L\.!W_=_P`U36M:T_LK_EXIVKR_'X_V31&_;GOP7D2"#T^=
M?^'PH^_\?C^FNJM#0@K^VW(FFU-O\_B^S@9;?@_C\>E:>-14@#;@>1WVIO\`
MY_Y.+$U^#^/QZ5R;'MS%.:\B*`=?E3_A,4C\?C\<"-T=PEV'`+HJ/3C4L3X`
M?\:XER]#_>#W%-[>ZXR7%89=Y:CX/\A<@[I52_1P2L4IH2#\!Z@T.*M+J,;1
M^HL4I2E>7`TH,5<=1C$7JF*4)3ERX'IUQ5M]0CC7D\4JKL*E-MS3%7/J$:<>
M44HY$*/@/4XJHWUY$UK+$ZR1F2-^)9:`T6N$-.H_NY?U2QP4\17?@.1^*HI_
MG_-]G).@'XW_`!_Q[Z4JU^GJ:-0U;],:=R%2:4G`V_S^'[.)<G1_WH_'1/OS
M4_\`)?:W_P`8!_Q-<B.;NI_2?<PQ_MM\SF<\XUBKL5=BKL58IK'FK4K?6KC3
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M_'P1^KN_C_I.'J>PLD<49XXRVT_YK/QRQ?3QG'+)@\.7%+#_`%O7_%]*I+YF
MT:.-G]5GXSM:A(XW=WFC%76-5!+\?VF7X<D=7C`N_P"+@Y'Z_P"BU8_9_5RD
M!PQC>*.IXISACACP9/[N>6<I<./C_AC/U_T49::C9WED+VVD$ELRLW,`@CC7
MD"#N"M-URV&6,X\0/I<#4Z'-@S'#DCP9;$>'^O\`1ZOIE&7\[Z4/%K^E2K8L
MDI(U%7:S^%OC$8Y/7;X:#^;(#4P/#O\`WGT?YKDY.Q=3`Y08_P"*&$<_JCZ)
M9I<&/KZ_5_,0]GYOT"[DC2"=V]56>%C%(%?TQ5E0E?B=1^P/BRN&NQ2(H\_*
M7XXG+U7LOKL$29PB."48Y/WF.4L?B>G'/)&,O1BG_JDO2A=.\[Z7=:<EY,DL
M3RRR11VZ1R2NW`DU7BOQ?`.3T^%/LY7B[1A*'$;%D^FI2<S7^R&IPZ@XH&$X
MPA#)/+/)CPXX^)7U<4_1^\]./B]63ZU\WFVR6\L626/]%7=K-=/=-R!'I$``
M#;O\/'CRY89:V(E'<>'*,I\7]5KQ>S.8X<H,9_F\&?%IXX8\/#+QOQQ<?'P<
M/J15UYHT>U2%II)!Z\7KJ@AD9UA_WY(H4M&GN^63UF.(%D[CB^F7T?SI?S7#
MT_L[J\QD("!\.?@\7BXXXYY_]1PSE+ARY/Z./B1MQJ%E;V+7\LH%FJ"0S#X@
M4/0BE:UKMETLL8QXB?2Z[!H<V7.,$8GQC+P_#^GU_P`7%Q?3P_Q(`>;="^K3
M7+S/%';R)%.LL4B.C2_8Y(1RHW\V4#6XN$FZX:XK!_B^EVA]F=;XD<8C&<LL
M9Y,7AY,>3'DAA_O>')&7!Q0_FMIYJT-K6ZNC.T<=FRI<+)&Z2*S_`&!P8!CS
M_9VPC68^$ROZ/JV/^Y8S]G-:,N/%P"4M0#/%P3ADQRCC_O/WL9>''P_XU/1?
M,0U35M1M8DXVUFL)C9D>.3E(#R5U>E.)'\N1T^J\3)*(^F'#_6]7\YM[6[".
MCTN')(_O<\LO%PRAEQ<.(Q\.6*>/ZN/B_G)WF8\Z[%78J[%5-/\`E(/+?_;5
MB_Y,395F^ES-#_>?!D<X!\\^83U/H:=\/C\,^8\6SM`>H>Y&A17J36M6VVV_
MS_XUR3@5^/Q^/YJXK[D4Z=/BV_S_`.NL"2/Q^/Q_G+./?>NU5V^'[_\`/^;%
MC7X_'X_G+P@V'(T%*/MOOT_S_P!EBSI9Q]C6GV-O'K_G_P`1Q85^/Q^/\U+]
M6T)-1O='NC.T?Z)NWO!LK<RT$D'`G;C_`'W*M&^S\.+9$T"/YWX_'^Q2Q/),
M::_<:O\`7'+33WLX@X+_`,?MK;VQ'(']@6O.O[?/C^SBR\3:O=_L?^DDKO\`
M\J[._P!-M;*:]+FTTZPT^%I(4D0/ITGJI+)&S<722O!X3^Q_NSGC3..8@D]Y
M/^R3ORAY4A\N:=+:K)"TEQ.;F62TMH[.$L5555(E+FBJH^*1Y)/YVX\5Q:\L
MN(A/545K0UI]C;I7_/\`ZYQ:P/Q^/Q_FKBHXL.1H:U?;;VV_S_EQ21^/Q^/Y
MJWCO7>N_P[?%]W^?\N**7A=SU->NZ_#M_G_UUBRK\?C\?YRGQ&VYH*4;;?[_
M`//^;%C7X_'X_G+PO0T-:#X-MM^O^?\`Q'%("UD7<<C3^?;QZ?Y_\1Q00VJ[
MGK7?X-OB^[_/^7%('X_'X_FN=1XDU)J=OAV_S_ZZQ4AI4'(;D4I0[?%MB@!L
MKM7>NWP;;;^_^?\`-BFOQ^/Q_.6A!TY&G\^WCT_S_P"(XL:7E=B=Z[_!MOOU
MV_S_`)<65?C\?C^:LX#?<[UJVVVW^?\`QKBQI>%&VY%*4-5^+;_/_KK%F!^/
MQ^/\Y)_-JT\JZT=Z_4+FJ[;?N6_S_P")8IQ#UCWA_];JOD!C_@K0]M_J:`)V
M(/MU_P":LF'G]0?WDO>61%MV^(D&O)J@\:C_`#_UL6NUG+IN10CB:CXMJ>'^
M?V<+&UX8@U_:VJE0.-/#PI_PG[6!D#^/Q^(K"PI3E\(I1ZCQK3_/_6PL;7*Q
MZT^*A'"O6IK7_/\`UL"06G;J.50>7)J@TK\AO_QM^SBI/X_'XDX.2PW(I]G<
M?%M3_/\`X'%0=_Q^/QPN+$-7N:56H'&@_P`_]7]K%2?Q^/Q%I6V4<B%%*/4"
MM#T_S^SA0#^/Q^(KBQW-/BI3T^U*UK_G_K?9P)O^S\?C^)86^$CE536K5K2O
M;;_-OV<+&_Q^/Q)4YDD$U!'05'Q5%.O^?\N!G:TN0Q\32HJ/AVI_G_P.+&VT
M;91RH!3BU0*T^?\`FO[6*0?Q^/Q%<D\L3AXV*24X\5-*"O\`G_Q+%(F8FQS_
M`!^/]DO2_O`&I<.`=VDY=^GT_P#&V--@U$_YQ=]>NT'P2LFY(0,*-O6IH-_?
M^?&E.HR=Y^?X_P"/-)>W(4QK*WIFH9`1113PI3_/CC2!J)_SC\VS>7!B$33-
MZ0'$"HHP\*$4_P":<:3^8G_./S6M?7;CB\C.#2L3&JCWH?\`-<:1^8R=Y7&]
MN70!YV900P=B#1ATZC_/[6-)_,3KZBLDO+F4#U)&<@'BC$-7M7IX>'VL:8G/
M,BB3_5_'XDM5MFW)!)Y&H^&HI_G_`#?9Q8`I5Y@:KZ*.PUC3J&OVOWP_S_X7
M$N3HS^]'X_A3[\U/_)?:W_Q@'_$UR(YNZG])]S#'^VWS.9SSC6*NQ5V*NQ5@
MGF.]DGO+RW5X+RUF'IB.]M+EC;.!Q8PM'$P85^+[7VLTNKR&4I#:<3_JD)_N
MOZG#%]+[!TD<>''D(R8,N/U\>DU.FA'6XY>N$=3#+FCP2_@^GZ4MN;:R1H_J
MUPUR&LXK.<W$-_%0QBG,")?WBE?]UOF/.$17">+T"$N*.6/T_P`7H^K^K)VV
MGU&:0/B0&&M1DU6/P,G9^;B\7U>%Q:B?[F?'_E\2(OH=)N%U"*.X>.*XMK2&
MUI;7?PO:;_$.%>#4[.S99DCCEQ`&A*,(Q]&3_)?YKBZ/+JL1PRE",YXLVIRY
MO\(TGJAK?YG[W^]C_P`+A!3"V<D$L[.+?41/;SVP6'4)D/U8DA99)5+D,6/V
M5^#(U$@GZ9\491].:?\`=_SI3;3++&<8`>+IO"S8<W%E[/T^3_"OX\&+!...
M,H</\<_WG]%%ZEJ]QJ-B&GG1;V*\AN[>W2VNA$JP_L-)Z7-BW\W'+<N<Y([G
MU"<9QCP9.'T?TN'B<'0=EX]+FJ$9'!/3Y=+ERRU&D\:4L_\`E(8/'\*$8?S>
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M'$=L7%RCD]7$/ZKT.NP^)'4''`^)KY89R\3/H_#Q2PSC.4(\.?BE_7_V*SR]
M>L+;0XM0?T;72G:X58[>Y:9G/(*C40QT'*O)6^+(Z7)MC$]HXO5].3C_`-SP
MMG;FD!R:J6`<>;6QCA]>?2QP1Q^GBR0_>^-Q2X>'@G#T+(9+F*RM[$77*SMI
M9R85COXO569BRO(T<8:L9/\`=@\6_FP1)$1&_3$RZ98\7'_.X8_P_P`UGEQX
MYYIY_#K-EAA_>&?9^;P)X(B$L>*.;-*'[V,?[Z7KA_-6KIFD3VFF6E[<2&.P
M@N8B\5O=!O4D<O$ZCTA]FOQ*<`PXY1C&1/HC,;1R?5(^B7TLSVAJL>7/EPPA
MQ:G+@R<.3-I.'PL,!CU&*?[_`/RG\$H_[%7U"7ZU/'>O,)KR2T6TO%:*_CCY
M(325?212_('XXG^')Y9<1$KN1AP3VS1_SO3'_8./H<?@PEA$3CP0SG4Z?AR=
MGY<O!,>K!/Q\N2.+@E_=Y\?JX4XOM8L/\.?HS3+J:UN8XDCBE%M=*H"4Y`'@
MSJ&`*U^)ES+R9X^#P0)C*OYF3]3S^C[+S_RA^9U./'FQ2G/).'CZ24O7?#+^
M\ACR2A+U</IA-(HX;?A><IN!NY[.<)Z5]+Q^K,>8+R1%W)!V;_B.80B/5O\`
M5*$N667]W_2E%Z:>7)>*H\7@8M3AXO$T.'C_`#41X<HXL.>./'&/\W^;_/DC
M=4EL;N]U2[BN722YFM+FS#VUT1SM`1QDI']EJ_LY=F,92G('ZI0G#T9/\E_.
M]+KNSL>;!AP8I0C*.''J=/J.'4:7^[UI^K!^^^N']+A3;RM</<Z[JE]/(IGO
M8X3Z4<4Z*@A!4CE,B<NHS)T<C++.1.\Q'I/^#^O&+I/:/!'#HL&&`EX>GGE]
M<\FGR2R>/Z_HTV3+P?3+^C'^<RK-F\2[%78J[%5-/^4@\M_]M6+_`),395F^
MES-#_>?!D4[4\]>813?ZOIQY>'PSYCAL[0/J'N1H;<_#0"O)=MZ#_/\`U?V<
M+K[7,W^36OV>GP[?Y_\`$OM8LB4'<ZII]J)/K-S%"88S-,SNHI&JEF9J_LA1
MRJW[/VL4`$]/^/(.Q\Z^4+\.;'5[*Z6+TQ(L4\3\#+((XZT/[<C*B?SO\&+8
M82'\)1/Z:TKZO<W/UR#T+.1H+NY]1.$,J,%:.1J_`ZLRJRM\2M\.+71NJW0Y
M\X^5%U-M);5K)-320POI[3Q+,9?Y"E:\_P#)^U_)BSX)5=&OQ^/Z/\*KK7F/
M0M%6.36+^WT])F*PO=2)$*J`2`6(Z5W_`)?M8L1&1.PO_>H/_'WDE+:.Z?7K
M!+:9G2.<W$7"5HP.:J2:,4YKR'^5\6+(8Y=Q5;SSEY3M+*UOKG5[*&QOJ_4I
MFN(O3DX_:,;UXOQ[T/\`KXHX)75'^JKV_F/09M.75(M1MGTYF$:ZB)4]`NT@
MC">I6G(R$1_Z_P`&*B,KJO4LUCS;Y7T:86^KZI::=-(O)+>ZFCB9Q4KR`8C;
MD"/^(XI$92!H+V\Q:&FDKK+W]NNDL`R:DTB"`*S!0?4^S]KX?^(XL0#=5NIV
MOG#RK=6-SJ%MJ]G)869`O+M9XC$A8;!WKQ4GL#_Q+%F82!JC_P`4OL_,OE^\
ML5U"TU"VN+!I4@6>*6-XUE=@BQ\@:<V9E54/Q/BP,2#1'P_'X_G(YKRWCN8;
M5Y52ZN%9H4)'.18Z<^(.[<>2\O\`6^+X<5%_\>0.L>9O+VC>E^E]0M=.$]1#
M'<S1Q%Z&A*\B-A^TW[/V<5$3+D+1'Z7TQ3<5NX0;:`74\G-*16[ABLK$'X8F
M"/\`']GX6X8J`>[\?C_2J,WF/08[>VN7O[=+>[3UK64R)QGC/`<XR#1E_>Q[
MK\/QI^TV*D'NY*,WF[RO;21+<:I:Q&>$7,"O*@K!Q+>JM31H^/Q<OL_M-BRC
M"7<?^)1]OJ5C<R206UQ'//$D4DPC=78)."T3$#<+*H)C)_O,6)!`_'X_'J50
M^P/'X?Y-O&E<6-KRQ%1^U0T?84WZ?Y_9_9Q96L+]?AH!7DNV]!_G_J_LX6-^
M2\-L/A)K3B-OAVK_`)_\%@96D_FUB?*VM"F_U"YJ^V]86_S_`,K%EB/K'O#_
M`/_7ZM^7Z,?).A]=[1*/MM_'_/X<F'G]0#XDO>4XU74M/TFPGU'4[A+*PMAR
MN+B9E5`#058^Y('_`!#XL6(@2:`_X\OMY([FWBN+=Q/;SJLD,J%64HZ\E92-
MB&4U'^3_`)6+`Q(/X]/X_'J2;5];UI=:30]"LX+K45M5O;NXO)FAMXX7=HXE
MK''+(\DSI)Q7BO%49I&^RN+=#'M9_P"DD%)YF\QS2V&FVFB)#K]U;R75[9WE
MP%M[2&*7T>9EB21YO6E_N`J*S)\4GI\>.*/"&Y)]*W3O.MW-JMCHUY8"UU22
M]N;#4D642)"T%I]<22%PBF6*>,IQY)&Z?9_9QM/@[$WT_3PJ^JZYYH/F>XT3
M0].L[EK6RAO9FO;E[<OZ\LL81/3BF7_='VF_F^'%'ACALWS\OQ^/2BM-\V:=
M<>5X_,=R'L[0JPGC<!Y(9DD,#P\8P3(XG4Q*(U;U/V/B;%B<1$J&_P"/Q_TD
MH/Y^\M"S%UZMSR%RUFUI]4N#>&XCC]5HS:>G]8JL7[W>/CZ7QMC:?!E?_2/X
M_'J3&YUW2[32(M8EE8Z?,(6@,:-([^N0(A'&JM*[R%AP3CS_`)EQ81QRNJ^Y
M*YOS&\IQ6T,K7-P6N/K"I"EI<O<*UF5^L(\"QF:-H>:F3G&OP_\`%>-MG@3Y
M?[+TIG>ZYI]MY>F\P!_6TV.U-XC1T(FC*\T*4Z^I50O^4WP8VUC&2:_'X_$4
MFB\\R1Z-IM[J=JEA=3ZB=+UB"690EC*D<CRDR$*&54C5U)"KZ<G/%N.$@D>7
MI1.D^=-.U;S$='LX;G_CGPZG'=20R1I+',[HH_>(H79.:<C^\Y?9Y(V+"6&0
M%GOKHIW/Y@^7].FN(-0F;UHIKB..WM(+BY<1V8C,SLJ1D@Q>LID^U'Q_;Q3'
M#(C8=W\W\?CU*<'YAZ&^NSZ5-(4`ELXK*^C226&47T*30F254]*#U6D].'U'
M_>MC:98)4#[^[^%"1_F?HT&I&UU']U;&T^MBY@2>:,#ZY/:R&7C'6&*(P+ZD
M\G!%9_Y/BQM/Y>5;#_-]**N/S"TJVUM=*NSQ1FU`R:@BR&"W33Q&S^LYC"*U
M)*N5;TX_@X.S2KC:#@D1M_O?XOQ_Q*LGYA^5/J4MZUQ/$D$L,$D$EK.ERSW(
M/U<+;M&)F$_$^BRIQ?\`U\6/@SOE_N62P-ZT$<RH_"94=$=>#*&6HJK496_R
M6_V?Q8L>$M"-]AO7;X]M_;_/_986'"?Q^/Q_$O"-QKQ-*?8V\>O^?_$<#*C7
MX_'X_FK/3?IO7?X]MON_S_EPL>$_C\?C^%>J/0[$4)J/A^+;_/\`ZZP,@"E/
MF!6#Z*2#3],:=MMM^_'AB7)T8_>C\?PI]^:G_DOM;_XP#_B:Y$<W<S^D^YAC
M_;;YG,YYQK%78JMD=8XVD8T5%+,?914X":%LX0,I"(YR/#_IDFB\XZ%-;?68
MI)7B+)'%2&3E*[UHL2TK(WPGEQ^SF)'78B+%U_5/J_J_SG?Y/9;6X\GAR$(S
MX93G^]Q\.''CKBR9Y\7#BCZH\'']?\*E=^=+&(Z=]762>.^F:%R$DY1\-G!0
M+R]0'_=?^RR,^T(CAJY<<N'KZ?\`CW]%NTWLGGF,WB&&*6FQC+'UX^#-XG]W
M+Q.+@\&4?\M]/\'U(V+S/I,M\+))G,AD:%)2CB%I4W:-9:<&<>%<N&LQF7"#
M_1_H<7\WC<#)[/:J&#QC&/#PQRRAQP\>&&?T9IX+\2..7\[A4;/SCHEW-#%!
M-*3<<Q"YBD"LT=2R*Q%"X`^SD(:_'(@`GU>4OQQ-VJ]EM9@A*4XP_=</B1\3
M'*<(Y/HR3AQ<4<7]-!Z=YQ.HBS:)1;^O>O:M',DI+(`Q7TV`"^H>/Q<OA3[.
M58M?XG#7IXI\'JXO]C_2=AK_`&5&E\42/B^%IHZB,L4L7HGZ>/Q8<4I^%ZO1
MP>O)]?TIA!YJT>>]6SCG<O)(88I2CB%Y5ZHDI'!F^G+XZW&9<(/7A_H<7\WC
M=5F]F]7CPG+*$>&,/%G#CAX^/#+Z<N3!?B0A_FK(?.&B37,=NDTG.64VZ.8Y
M!'ZRDCTRY''D>V1CKL9(`)W/#R/U_P`WB;<OLMK,>.62485"`SRCXF.67P)?
MY7PN+CX/YR(O]3DMM2TZU$B*MXTJLKAR["-.7P%?A%/VN>69<QC.,;^N_P#8
MC^%Q-%V?'+I\V6I$Z>./AX>#@CXL^#][Q>N7]'P_XOJ]*'L?-^BWUQ!!;S2%
MKKD+=VCD1'9-V4.P"\AX9#'KL<R`"?5].Q<K6>R^LTV.<\D85AX?%C')CGDA
M')]$Y8XRXN"7\Y%:GKECIIB6Y>0RS\O1@A1I9&"BK$*@)XKW.69M3''5W9Z1
M]4G#[/['S:OB.,0X,=<>3+.&'%#C^B/B9/XI_P`,4+<>;]%AMX+CUI)8IXC.
MAABDDI$IHSN%'P*IV/+*Y:[&`#9(D.+T@_3_`#G,P>R^LR9)8^&$)XI^#+Q<
MF/%Q9I>J&+'Q2_>SE'U1X&[SS=HMHX22:1W,"W0$4<DE87Z/\(/P_P`U?LXY
M-=CCS)^GCY&7H_G(TOLQK,XN,81'B2TW[R>/%_A$/\EZS]?\SA^IUWYNT6U$
M3/.\BRPBYK#&\@6%NDC\0>"?ZV,];CC5GF./T@R]'\Z2Z;V9UF8R`A&!AD.#
M][.&+CU$?JPXN,_O,G]5NZ\UZ-;3B&2X8T6-Y)41WBC67^[,DB@JG/MRPSUN
M.)HGN_JQXOIXI?PL=/[-ZO-#CC"/.<80G.&/-FE@_OO`Q3/'E\/^+@54\QZ;
M)JKZ4DDCWL;<9%5'*J>//XGIQ`(Z81JH&?`">+W-4^PM1'2C52$(X)#B@3.'
M'/U>'Z,7]Y+AE]2W4_,VEZ;/Z%U+)Z@3U9!%&\GIQUISD*@\%^>.;5PQFI$_
MSN1EPQ_I,NS_`&?U.KAQXXPX>+PX>).&'Q<O^IX?$/[R?]5;<>:]&@N?J[W#
M$CT_4F1':&,RT,8DD`X)SKM7!+6XXRHGN_J1XOIXI,\/LWJ\F/Q(PC_'PXY2
MA#/E\#^^\'#(^)D\/^+A2VY\U7\<]S$(XR(=5ATY:\J^G**ECO\`;\,QYZR0
M)%#;+'%_FR=MI_9S!.$)<4_WFARZ[^'^]PGTP^G^[_V7]),X/,NDSWPLXGD9
MVD:%)?2<0M(GVD62G`L,R(ZO'*7"+Y\/(\/%_6=1F[`U6+#XLA"N".64/$Q^
M/#%D^C)/!Q>)P233,ETKL5=BJFG_`"D'EO\`[:L7_)B;*LWTN9H?[SX,ANA_
MSO'F*NZB#3B5[_9GW]O];,>+/M+ZA[D+YIT_7[_0KJTT'4%TG6)0!9ZBT0D6
M(JP+54\J57DO_%?+GA<+&0)`R'%^/Q_53*UBN([2**XD$]S'&BW4XCX>K(%'
M-P@.W-OCX_[+%$AN:_'X_P"/,9\]^7[.X\M:_?069FU6;2[J"`QAVD8M;NBH
M$!HQ:M!\')\2SPRJ41_#Q#\?CZDOUS0-=A\I)%<WTFL7#W>CNJBSBB:-([Z!
MI/\`>=09!Q%69OY,6R,H\?*MI?I_'])B'F#RYY@L]!\QW^EV<TT&M:O>6^KZ
M<$;F0-2Y6M_$G5N"_N92OVX'1O\`=.+:)@D`UZ8C[O5'\?U$WU%X9=+\[>7#
MIEU=:WJFIZ@=,06,_I\IDC$$_P!:*>A&D3CU?5];]SPQ+&(]496/2/\`<_C_
M`#65^=8I+WR%YCLX8WN;V&PN+:11"_*2<6]3Z8(J_(M4<.6+1CVF#R%_C\?Y
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M[TV0^G`6X*;Z(^HH*F-_2"-(Z?%Z:_WOPMB6&"A*SR]7^Y4=?TC4K!M"O=3D
ME\P6.F:A)<WJQV48D1'MGCAE^K6X_>BVE;U:*C2_'ZR_W>+9`@V!Z;'I8YYB
M#ZA<:KYBTZPN4TAWT-9G^IS))=S6VHB:6X2W*"=Q#;D(9#%RF_9^&+%EC%4"
M1?J_V4?]\G>J^:-(E\R^7=<CBO6TFW34K>:0:?>EDEE2#T^4?H^IQ>AXR>GP
M;^[Y<L6,,?H(V_AZCS<FK6&F^:-4UO4[*ZGL]:MK0Z1?I87%P1!$C)+9M$L;
M36[^J3+PE1%D]7^9<6)B3$`$7&_Q_O?Z/TL;;RSKEIIFD6J:?-!%Y@%QI-_9
MJA)LK&34?KL"S4Y+&L%DUS!_+"\BQ8&X3%D_S?5_6EP\,D\\F^79SKNIV6HV
M3KIGE\2:7HQE1EC>&XNFO@T9-.2Q0BTBV^SZ>%KS3V%<Y?\`$_\`24O]DRC5
M/*=GJ,2VRN;:%+&YTT1QH"OI7:QJ:`G?@(1Q7]O[6+5"9!^(4O+'DRS\OR7<
M\$\ER;T1(?50%E2%I!"M5ZK'%(D"[?&L*_M<L5R9.(#;\?C_`$S(`K<ATY]>
M=-J5IUK]'_"86JM_/\?C_8MD#@QXT05JO&AJ._T?\)BRZ>7X_']%:4((V%=^
M)XTXT'?PI_PGVL6-?C\?B*]5ZT`KMS^'[6U?\_\`@\#(#\?C\?Q)-YM`_P`*
M:R:?";&YXBFXK"W^?^5BRQ#UQ_K1_'X^I__0ZQ^7X7_`^AGC\/U1.2^-.]?\
M^.3#H<_UR]Z<ZII6G:I8S:=J=K%>65RI26WF0&,J-Z,OL=_\C[6+`$@[<_\`
M<_C_`&*ZWMK>W@CM[>)(8(56-(D4!`BK1551V`&R_P"RQ8<_Q^/QZDFUGR[J
M4NL0ZYH=]%8:@;<65Q'<VQNH)H!(9(^2+)"XDC=G]-UD^/FZNN+=&0JB+'X_
M'])!_P"#M7MY+*^L=;9_,%K%+!=:C?0B>&[AN)?6:.2)'B,:QR?[S>E(OI+^
MY^-<5\0601M^/XOQQ(5O(.JI+:ZG:ZO&==BOI]0O+NYM.<,SS6WU,(L$<L?I
M10PA4B_>.R\?CYLV*?%%$5Z?YOQ1$WECS>NMG6+;6[*&_N+*.QO';3W>/_1Y
M994DB0W(](CUZ%7,G'C_`+'%3./(CJ>O[/\`I%7F\DA?)7^&-.OI;9E`Y7S@
MF29_5^L2F41-"W&X<OZJQ21_`[<&7%C&?JLC\?C_`(ICJ?E"T6D7%B+NSE%W
MJ"ZB8);%GMT<VRP%$`G%S'QX>I%*ETLK?[M9UQIM.?<&CRX?Q_Q/\3(+_P`G
M7ESY0L_+T6JR&YM1;^IJ$XD?ZTL)^*.?TY(IFCE^RW&=7;X>3M\7):XY!QW7
MX_'^F0/E7\M5T"03"]695_21])(/24'4C!RX@O(52)K;X:EF;EQ9N7Q,TF>4
M2'+N_P!C^/\`>HVX\BP7/E71?+%W<>MIVG"V6^!0K];BLTHL3$-6-&E6.1]V
MX\/3_:Q8^)4C+J;_`,W\?[%+KW\H?+MQ+):QQI%Y>FN;:]O-%*,R23VT4L3.
MK%^2>K')%R_D:!9,6R.<CWIMHOE?4].U>&_N=3%^!I\>FS>K!29Q;RR2V\I<
M/Q]3A,RS_!^^;]\OI_9Q:YS!%5U_TNRG9^1_1UN^U,7A9KU=05D]/H-2,!V/
M+XO3^K?\]>?[/'%EXEBOZOZ4+9?EX+71GT\7W-))=(FY>ET_1*V\?3E_N_ZK
M]K]GGQ^+CBLLMT:_G?[-"?\`*L]4B%Q#9:VEO!?V$NF7X:T$A,$MW<7#M$QD
M'I2JMVT*LPD1?Y&^'B&7C"]QY_='\?Z5=??E;'.DT4=_Z-I-)J2SQ^A5Q!J"
M0`+&Q>@EMWM8GYNKI]KDF%'C4.7XC^/\U%KY'U2[U*'5=9U6.[U-+FPD5K>U
M]"%8=.>658Q&9)&YRO.[R/S^']A,4>(.0&V_^R_'^^9B!6NPY;<FI7E4?C_Q
MMBU5^/Q^)+*+0?#\!I1*5Z]_?_C;%C^/Q^/4N`^7.E?4IVZ=?P_X3%E7X_'X
M_A647B?AHHKR6E*T_P`_]ABQK\?C\17JOL*[\3Q^SM_G_J_:Q9`?C\?C^)*?
M,('/1Z"A&L:=R-*5_?C_`#_X;`7(TG]X/QT3S\U/_)?:W_Q@'_$UP#F[B?TG
MW,,?[;?,YG/.-8J[%4-J,D<>GW+R$A/38$JK.1R''[*@L>O[(RO*0(&^YR]!
MCE//`1Y\<?JE''])XOKR<,(_YTF$7"V+Z#H]HDKM=Z2>7%K>]2*2H(=><<:R
M+UV89II\)Q0C?JQ?T<O#+_2QXGT?!+-'7:G*8Q&'7?S<^BGGP_ZG/P\N66')
M_2A)I&AM[;3Y+5@M]:WK7DL9MK[T6YKQ(Y%'D9@/VOVL01$1,?KC/Q/HR\'W
M<29QGER9HY1>#/IXZ2$O'T/CP\.7B<7AQR8\,82E_!ZN!2T^VT^UU"+FQDL8
M+A[F.5K>_,QJ2RKZ?$0JRD_W@R.*$(S'6$9<?TY>/_2_1_G-VNU&?-@E0X,^
M3%'3SAXW9_Y?^;.?C<7YF<9Q_P`C+Z?YR)TY[.UM-!@::1FTFYDGF(M;JC*Y
M8@)^ZZ_%WRS$8QCC%_W4C(^C)_Q+AZZ.7-EU<Q&`&NPPPX_\(TGHECX/[S]_
M]/H_AXE*Q>.%[*.68FVL=0DO(V6VN^;QR\JA@8J!@6R.,@&()],,AR?1D^F7
M^:W:R,L@RRA'][J=)#2SXL^C\/'EP\'#*/[_`(I0]/\`QUUIZ<<=AILUP3H^
MG78NX9%M+OZP_%RZ(P,?!:%OB<'&%`1@3^[QRX_HR>)_5^E.IXI2RZF$!^<U
M>#\KDC+4Z3\KCXH1QY,L/WWBR],/3CE'TJD;6BV%G;&:3G;:H=0<BUNJ&,N6
MXC]U]O?".'AB+/IR^+]&3_B6J8RG/DR",:RZ+\C'_"-)_>\$8<?]_P#W?I_K
M?T4RU35=-N]6TJ]2298[!IFD5K6YY-ZL?`<:1^.9.;-"62$A?HXOX)_Q1_JN
MG[.[-U&#2ZC#(8S+4QQ1A6HTO#'P<GB2XOWR7:>]G;6>@0/-(S:3-++.1:W5
M&$G*G#]UU^+]K,?$8QCC%G]U(\7HR?Q?YKMM='-FRZR8C`?GL>/'C_PC2>CP
MN#^\_?\`]#^'B1NK:O"^IVFJZ8[?6K:.2!H;FUNQ&R2;U#)&2K*1EV?.#,3A
M]408^N&3^+_-=?V9V7..FR:74@>%FG#-')@U&D\2&3%_0R9N&4)Q_P!*E>K2
M76H+&EQ?O.C6S0S(;:]AC25F)]5(XD"R44A0)/\`6S&SF62@9<7IX?HRPCQ?
MS^&$?5_G.Z[-ACTI,H8HXI#-'+CEX^AU&7)@A$?N,F;4992P^O\`><6'^=P(
MBTELX7=WEDJ^DIINUK=?WB@@MO$/@RR!B#S/]UX7T9/J_P!*XFJQY9Q`$8>G
M7SU_^,:3^ZG_``?W_P#>?['^DHVL\VF^F^FW`,TEE#9W7KVEX0C0B@DCI$>7
M7[#C(0D<=&!WX(XY<4,G\'\4?2WZG##5\4=1#T0U.758?!U.CXIPU'U8,W%G
M]'_#,<I*5_;6L]_<S+*;B._$1NGGMKY"K1J%<K%$JQN'ILK_`&,AEA$R)OBX
M^'BXH9?X?Z$/3+B;]%GR8\$(&/A2TWB>#'#J-!DXX99&>/CSZB<\V*6+B^O'
M_>)WI.J:78ZCJER7F,=])$\2K:W/)5CCX4:L>9N#-"$YG>ID?P9/X1_5><[3
M[.U.HP:?&!CXM-#)&=ZC2\,IY<GB>C]]_P`2A;[5&CU:ZU#29J&^ACAG%S:7
M9,9BJ%D3C&0VQ^PV59,U9#/&?K`C+CAD]/#_`!1]+FZ/LX3TN/!JH_XMDGEQ
M^!J=)^]\7Z\67BS1E#U?Y2'JX4NO+:TFU"XD]4W%O?/')<R36U\KJR@"3C%&
MJQ.'I5>7V,QYPB9DWQ"=<7%#+_G>B/I_XEV^EU&6&"$>'PLFFC/'ACBU&@G"
M<9D^%QY\TI9\?A\7#/@_O43<&RDFN'6:0++JL&HH#:W51'"*%3^Z^WELN$DF
MSOECE^C)],?\UP\`S1A`&,+AH<NAE_A&D_O<Y^O^_P#[O_9?T5EI'$/,45W#
M*;9&N3))+;P7L;3HQVCDA*>@M:_')RR,`/&$@>'U?PQRQX_Z,H5P?YS/4SD>
MSY8IQ\8C#X<(9LVARQTTX?Y;#J8Y/S4_]KQ</]%Z#F]?+78J[%5-/^4@\M_]
MM6+_`),395F^ES-#_>?!D5Q_RG?F#C]OT-.XUZ?9G_SW^',>+/M'ZAWTC!QW
MI]C?GL:_17_/^?"Z_P#'X_']9LTVKT_W7LWX_P"?_"8LC_TC^/Q_I%N]33[>
MW/K3WI3^'^PPL?Q^/Q_57@K0=?3VX]:UKWI_G_+\6!EM\/Q^/]RMJW*O^[:;
M'>E/U=/\^>%C]_X_'_'EP8<"`3Z6_,?%6O:E?P_X?`D57E^/Q_NUK$\AXC^[
MIRVV[_Y_\+A4_P!GX_'^E;2N].O^[-FIT[?V?['X<"C^W\?C_2N)H!N?3VX=
M:U]Z?Y_R85/V?C\?[AP,A?<UEIUWI3]73_/GBHN_/\?C_CS9(XM2OI[\NM:^
MU?\`/^?`NU>7X_'^Z6CD&&_Q?[KI6GTU_C_L\5Z_C\?CU+AU-/\`GI]KP[?Y
M_P#"8I_!_'X_TBVO0D_#4<#\5:^]/\_Y,+';X?C\?[E>&DK7E^]H.1WI3Z-O
M\_A^+`R_W7X_'^Y]2PD4)!/#]KKRK_G_`)\L6)KX?C\?\>;6O(T/[RGP4K2G
M:M?^-O\`9XI'/S_'X_W;FI0TZ"O/K^%?\_\`88J?Q^/Q_I6AQJM?L_L;-X=Z
M;_Y_#\.%1^/Q^/Z/I;/+?_?FW.M:4[TIM]W^PP)^_P#'X_W*T<:?\5_36M?\
M_P#KK"QV^'X_'_'EYK7_`(MH>!WI3MUV^_\`V?Q8&7W_`(_'^Z6?#0T^SOSV
M;\*_Y_S_``X6/X_'X_K+MJ"O3_=>S>'?_/\`X3`R_$?Q^/\`2I1YNK_A;6_Y
M_J%SSZT_N6K_`)C_`&.++%]8[['X_'^:_P#_T>J^0"W^"]#-?C^J)Q;L*>_3
M)AY_4?WLN^V0U&]-EWYBA%?EBU+/"O3]C8[;=_\`/_A<+%44.6VW<T#&A(-?
MEU^C[7[.!G]_X_'^Y4SOT!X5%!0UKA8'[%X613O42;\6((%/IP)%_%:Q%#2O
M'?D*$?=7_-?VL*G\?C\?TG+]H5_V&QV^?^?_``N*AS5Y=?B_;-#0U_S_`-E^
MSBI:%/AK7AM04)-:]_\`/_5Q0/L7DMN:_O*?:H:4_P`_^:?M8LM_BLVH:5X;
M\A0UJ/#_`#^']K%C]R_?;Q&R&AH-J[X&2TD\C3K^WL=]NV%!;6E`"#QVXK0U
M!/C3_-OV<"CE^/Q^/2TQ:HW_`'G=J&E*_P"?_76%2?FY-P0`>/=0#6OMBH^Q
M<P?I0\Q7C13L!X^'_&O[6*9?C\?C^DM6M33H/[S8[[=O\_\`A<4!<0>()!X'
M[&Q_'_/_`%<"5@+5Z_'^T:&A!_S_`-EA8[_%<*<._#PH:U_S_P`^6++IY+=]
MM_CI\)H0`!\_\U_:Q8KEZ-3I4\Q0[[=L"0E6O_;T3P_2^G<=B*?OQB7*T?\`
M>C\=$_\`S4_\E]K?_&`?\37(CF[J?TGW,,?[;?,YG/.-8J[%5"]O(K*SGO)B
M1%;QM*].M$%:#(9,@A$R/*(MR=)I9:C-###Z\LXXX_YYX4IM?,%SZMJ+YHHO
M5T]K^XA59"ZT-?A.Z\50T(^WRS%AJI6.*A>/Q)<W>:GL3'PY/!$Y\&KCHL62
M4L?AS_KQ^OCGD^F7]W&'U>I$:=YITG4;E+:UED,DL?K0EXWC61!U*,P`;CWR
MS%K,>0U$G<<7(^IQ-?[.ZK2XSDR1APPGX63@GCRRQ9/X?$C`^CC_`(4M\R^;
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MJ]/"K6?F:4:%+J=Y);7#"3T[9+%G82.:!(Z2`-ZC/VI]GXLGCU9\(SD8RW]/
MAWZOZ/J_B<;5^S\3K8Z;$,V(</B9I:R,(>%CCZLF;]UQ8_!AC_BXOK]",\M:
MO<ZIH=OJ%R%BEEYEU2H4<'9>Y/9<MTF<Y,0F>9<#V@[+QZ/6ST^.YPAP</%]
M<N.$9_P\/\]9:>;-(NI'2.252D3W"M)%(BR11_:>,L!S`]L$-;CD:%\N+Z3Z
MHQ_FMFI]FM7AB#(0/%DC@]&3'DEBS9?HQYN`_NY?UEMMYNTF\)CM9G]5H'N(
M&EBD1'5%JQ4D#EQ_:XX(:['/:)WX>(<0DRU'LQJL%2RQCPC+'!D\/)CR9,<\
MDO3QQB?1XG\''_148O..G0V5J][*SW,]L+HBVBE92E2&=10L%%/V_LY`:^`B
M.(^J4>/T"3D9/9743S9!AB(XL>;\M^_R8H3\3ZHXYRO@E.7%_D_JDB;7S9HM
MU(Z17#CA";D.\;HC1+]IT9@.87O3+(:W'(['IQ\C]/\`1<34^S6LPQ!E"/JR
M#!PQGCR3AGG]&/+&,OW?'_#Q(2\\Y6ITK4+BPY_6[*`7"PW,4D7)&("N`W$L
MA]LKR:^/!(Q^J$>+U@Q<[2^RN4:K#CS\/@ZC*<'B:?)CR\.2`XIX^*''P98_
MTDUN]7MK'3%U"^D,4'&,R,`6H9*`;"IZG,F>>,(<4MAM_LG2Z7LO)J=0<&$<
M>2Y\(VC_`'7%_O8I<?/&@*7#RS(8G"3!X)5]/E3BTE1\"-7X2V8_\HXN\_TO
M3+T_UG:CV0UQJHXY<<3/'PY<4O&X/KAB]7[S)#A]<8_2B+[S5H]C=/;7$[\X
MN/UATC=XXN?V?5=053E[Y9DUF.$J)Y?5L>&/]:7\+BZ/V;U>HQ#)",>&?%X4
M9SACRY_#^OP,4SQY>'^BA?,/G"STV"\2!S+?6T0DH$=X59]T$CK\*\Q]GXLJ
MU6NCC$@-YQ'<>#^CQ2<WL3V6S:N>.4QP:?-/@^O'CSSCC_O98<63U3\/^+T*
M\OFO2K9HXKF5UE].)[ADC=XH?6`*^JX!6/E7;EEDM;".TCO4>+8\,.+^?+^%
MQ<?LUJ<H,L<8\'%DABC.<(9M1X!_>>!BEZ\W!_%P*2>:8X;C5%OCPAL[J.UM
MA$K/)(TJ<@O$5Y,3_+D!K`#/BY0D(1K^+B;Y>SDLF/3G!ZIZC!DU&;Q)1ABP
MQPSX)2XY</!#^LONO,\2VEO?6X9K3ZTMK?+*KQR1<SQKQ:E"CE.7^3AGJP(B
M0^GCX)\7U18:?V>D<L\&2AF\"6ITWARAEQ9O#]?UPXN*.3%XG!_33JE-LS'G
M78J[%5-/^4@\M_\`;5B_Y,395F^ES-#_`'GP9#=?\IQYAKLI@TX$]#]F?;^S
M,>+/M+ZA[ENM:[I.AZ=/JNKW26=A;#E)<2,Q4!B%6M`2W)C0?"W/"X$8F1H<
M_P`?C^DC(+F"YMTN;>198)T65)5<E2CJ"K*?`@]?]CBIZ_C\?B+&]8\[66C:
MS=VNI?NM-L["VO3=1^I)*7N;MK18^$89C\07[(9EY8LHX[`KO_W(_']52O\`
M\QM,@T][^WCF:2W:[CNM.G@N(;H26=JUT8UB*5C;@%DY.O#TVYI\6+8,)NO=
M_5^K\?U6K'\P-/GL3=2Q7!$BVGI6%O;7,MX)+NW^L^FT80U^$,]1Q3A\4GQX
ML#B/PW]5^:&F_-/2I+E8[)'-O)IOZ2AU":*X]`<KL6IBD4(&#AN2MR^+U?@?
M%F,)Z\[[_P`?\>3!/S$\JR:C/9F>:$1/=QR7<\,\=L9+$-]9C2X9?3=XEC=V
M"M\2+BP.*7XE_.17EWSGHFNW4]G9_68KFUBBN7ANX)[5_1G++%)255Y+)P;B
M5Q08&//[V,+^9&J+J<OJ_HEK9-8.CC3$N9%U0@77U42I#\2$C^^X<5XQ<N+8
MVW'"/.^'B_H?SOQ_-3?R=Y_T[7E@M9HY;6_F%R4!BG6WD^J3F.003NH25D'!
MI%5OAY<L;:I8C$?T??\`SOQ_ODPO/,=[#YRTS0!IS_5M0CN6.I/(!&7BC$@C
MB0'E(:']X[JJ?ZS_`&5>&XDWO_-_'XDEWD[\P=,\PQVT+I+:ZA<QS2<'CG2&
M3T)#'*+::10D_I_#ZG!O^%Q3EQ<)/=[_`,?\>3*Z\YZ':ZU'I,YN5G>>*U2Y
M$$YM!<3J#%"]SP](2/R6GQ?M+'BH@2+_`-\E]I^9OE&YCDG6XGBACMWNQ-/;
MW$4<L,#B.0V[,G[YHY'1.$7Q<G7ARY8VIP2!\_?]/X_V*,\J>;(?,&HZO:Q0
M2VUOI<MK"OUB.6WN"\T0E8212A63B3\/[/'X\43AP@;\V+:7^9NKW+Z?/.-)
MGCU*YFM8]-L[F5M0A],RTDEA;DK(OH\IOL<5;U,;;IX`">=@?YK(?)?GS2_,
MMI;A%FM[Z>QAOYH98IHD*3`!FMWE4">)93Z?-6^+]K]G%IGCX2>Z^_\`'_'D
M5_B.[;SK'Y?:P:&T>SFNHM1DD%)GB>)"L:`EN"^M\4LGVW_=K\*\L5E#T\5]
M4AN_/?F2#1QYA@TRT.C+22LURZW%RDEPT,,5JBJU)WC$<B^I\+O,L,7[3XLX
MXXW5GB_W/I9!YC\T0:)?Z)926T\Z:O<O;+/$KL(O2A>8L_`-3[(VY?`O.3]A
ML6N,+B=]HI;9_F/H=V!>0M-]0-I];B#VMT)IT,T<:/;Q\/WL;F957BO)I/B7
M&T^%(?UO>U+^9.BB2W<>I!I];]=7>[CFAN+1[&W6Y*M"X#5975J?[L7BRXL_
M!-?M_GIWHFOV>M6S7-JEQ%Z;F-H;N*6WDJ5#"J2JI965E*N.2O\`9Q:9`CG]
MZ:`]:'PY_$=MJ?Y_\#BH/XO\?CTI-YM(_P`*:SO\/U&YXFIWI"W^?^3BRQ?7
M'^L'_]+JOY?\?\$:)_)]43D:[U]O\_\`6R8>?U%>)+NLH[S/=:]::%>7&@64
M>HZU&E=.LI9#''*Q('Q,2G;D15EY_89L40`,AQ&@BK![N2QMY+R)8+UXHVO8
M$<NL<A0<T5_VE5_AY?\`&N+7("S3SS\TKB9+K5XXYY88CY7G9#&[*P?Z_$O,
M4/PN`?M?L_LXERM.!M_6_1^/]ZD?FC6-<@N]2T#4IY?TOHOEK6>5V"R+=VY^
MKFTO%I\/J\`Z3?[[G23^?`RC`$V!]4H_\>BR?2K;R]I7F[0+3RQ<#T[ZVNFU
MNS@NI+B/T8XE:*=T:201N+@K'&_P^HLCKA:C*XGBY*.M>?\`S'!YSN=/M8(?
MJ%A>VEB;>0P*TXNUC8R"66YBF5OWO^CJEI*LK1\7Y?[K;9##$QLGU&^'ZOQ_
MID%J7YD^8;;_`!!%!<:>OZ!=46^E63T;Q9KV.W]5!R4+%8J[0WAC=_\`2?\`
M?<>-IC@CL=_5S_H^G_??PJFJ^?O,UFQTF"XM=1NOTE]1BUVUCC6$K]3%WZ?H
MS7,4'UA2?2(^M_9^PG+X<4#%$B^E=Y_JK['S[YBOTB>6_P!)T1K.Q6]O'N_W
MT-W2ZE@;TGBG*Q1*L'*3T7N7CEF1%Y<?C;7P0#R,MZ2V/SKYNL(ET^*]BNY;
MJ_UF4WKQQ$Q1V5UP6WX7-W;)T?U?[WE';\>$7^[,#8<4#N?IJ/?W.UCSKK^L
M::DCW=CI8CN]#C;2E;U+BX-Y-;3M+#.LO$Q'FR1<8Y4ECCF]23^5MB,40:HD
M^O\`2RC\PO,>H:-J8DTQ(&NAIEQ+'+.)'"N;VS@`H&6L=)B6_;Y+]I5^T2UX
M8"7S_P!Z4S\O:CJ\L_F#3-7N8+NYTB=(H;RWC>V$D<UJDZAX^<O%D+E.0?\`
MEQ:YB.Q'7\?C_B7G>F_F1K.F:7Y?BM;F&>VMX-&MK^"6+DS-?",/SN99XY!+
MPE]2,6UM<<?]V-]K@+<KP8DG_._V/X_XE7'G3SAIS3:;'>Q7<LNHZW*+R2.&
ML<=C=B-;?C<7=LO&C>J:2\HH./IQ_P"[<6/A0(L\JCW]WN9CK.JZ3?>0[+5/
M,DDEE!=QVL\]G93DFXDE`*VB/$:S+.Y'%8Y/WJ?;DX\\+5&!$R(\]_Q^/]TQ
M-+6S*6EAYCO_`*II":=JFHV,"ZC(5MIA<)Z4/UI)!Z\UC;L.%7;BSO\`L(K8
MMIGS,1U`_'];_I)/+)];GU3\N]3U"^G]:]MV6XTXGA"9CICR/+(H'.25I/\`
M?C<8_LJGQ<L6&U2%#R_TWX_Z1=Y1BTN?SA-=:%>R3VMLES#J][<7C2MJ-TT@
M_NX:T]*R*NOUB**-/B]"#E&KMBRR$\-&N+;_`#(L]^#B/]][4-36OO\`Y_ZN
M%P]OA^/Q_N5X!K3_`';385-*?JZ?Y\L#/[_Q^/\`CRP!.)I]C?D:FM3X5_S_
M`)L+#;X?C\?[I>M-NG(U]/<T.W^?_&WPX&0_L2K7Z>IHU/M?IC3N>Y-/WXZ5
M_P`_]CB7)T?]Z/QT3[\U/_)?:W_Q@'_$UR(YNZG])]S#'^VWS.9SSC6*NQ5*
M?-*+)Y<U")N7[V%D7@K.>3?9^%`S?:S&U@O#(=X=W[.2,>T,,A7HR"9XY1QQ
MX(_7Z\AC#Z&,MJ%I=R079,T1.DO821&UN6*S.!O58RI53[YK3EC,B7J_NO#^
MB?U_Z5[&.ARX(RQ#PY_X?#6QG^8TT>+!C_KY8SXYQ_HJMC>6-O<Z'*SSE=+L
MWM9@+2ZJS,JJ"O[OIMWR6/)&,L9]7[J'!]&3_B6G6:7-EQZJ(&,'6ZB&HQ_X
M3I?1"$I2X<G[[ZO5_#Q-Z_K#WK3QV4A%I>6YMITN+&YYQU)K(C+'5]C]A_AY
M8=3G,[$3Z9QX)<6.?I_I1]*.Q>RXZ<1EFC^^T^7Q\4L&LTOAY?\`:LN.>;AQ
M^K_*X_7*/I2Z\FN#?6;VTHFLM-B2*RM[NTO6`=%`,SJD8!DV^'?X<Q\DCQ1H
MW#&!P1G#+_I_I^IVNEQ8QARC)'P\^LR3R:G+IM3H8_NYS,OR^.>3+Q1P_P`_
MTQXY?4CX]4,=E=/'*ZZG<7AO&+V5S)"RBBK&>47)?@4?$OQ+EXS5$D']Y*?'
M_=SX/ZOTNLGV=Q9L<91B=+BT_P"5].KTV+/&7JE/-Z,_!/\`>3EZ)^B?\2&@
M@TN=I+N_NKV"_EN7N_\`0+:YCCC9E"`+SB))"_MY7&,#<IF<9F7'^ZA/AC_L
M',S9=3C$<6#'ILFGAACIO\-SZ;)ERPA+Q/7X>>,8^K^#U1],4;Y:O['2-"_1
M[W-V]P?4*R_5;EEC+UX\`8QL/M4_FY9=I,D<6+@N?%O_``3]/]7TNN[?T6;7
M:[QQ#!''Z/1^8TT)Y8PKB\7AS2]4OHXO]3X$HL$].Z%S=32/*;2XM9)/0OY'
MD:52%E8R1D+O^PGPKF+C%2N1-\$H?3EEQ<7\7JC_`+%WNMGQX_#Q1A&'CX=3
M"'C=GXL>*&"7KPQ\'+ZO^&Y.*4Y?S4='-9JNC@R3?[CK&>SE_P!$NOB>6,(&
M7]U]FO7+A*/HW/[N$H?1D_CCP_S76SQ9B=2:Q_X7JL.JA_A.D]./!E\649_O
MOK_FJ=DUI!Z/*68^EI+Z::6EU_>,Q/(?NOL;Y''PQK<_W7A?1D^K_2MVK&7+
MQ5''Z]?'7_XSI/[J$1'@_OO[S_8_TFQ+$D=AZ%S/!-9Z8]@)EM+JHE:E'7]W
M]G;_`%L;`$:,@88_#^C)]7^E0<<I2R\<,>2&HUL-9X<M3I/5@A?%CG^^^O\`
MV'])`QVZF'4/4=UEOK(6II!?R_O%<-S9Y(V8\J;T^S_+E(CM*^<X<'TY9=?J
M]478SSD3P\(B8:;4G4_WW9^']U*$H>%CQX,L81\/B_B^OZI33[7=4T[4="&G
M1-.DH,!YO:77']RRL>D9._';,[4YH9,7`.*_3_!D_A_S7F.QNSM1I=;^8D,4
MH?OO3'4Z7B_?QG&/^6_IH#5)+.\'F`)+,OZ8-L8>5I=?#Z%.7.D?>FU,HS&,
M_$HG][P5Z,G\'^:[3LZ&7`='<<9_(>/XE:G2>O\`,WP>'^^_A_BXN%J_N>;:
MI;V<S+8ZR5:Z::SNS+$0H5_3"Q\7Y`?#RX\<&6=\8B?1F^KBADXH_P!7TLM%
M@X1@R9HCQ^S^+P?"U6C\'/ZC/'XO%EX\?!+ZN#BXU*^91'J=GITS"QU2.-9#
M<6EX94:)`E%XQ\2'"]3]G(Y#M.,#Z,@'U0R<7I_S6[1@F6#+J(Q\?1SR&/@Z
MG1^#EAGG++ZN/+Q1ECXOIC]?\Y3O;:SEO9GB+207BPBX]>VOP8S$@1N*1JJ2
MAPNWJ?9R.2,3(D<I\/%Q0R^GA_HQ^K_.;=)GS0PQC*H9-.<OA>#G[/\`WOC3
MEDAQY<TYY,$L?%ZO"^M$WC6,J:HJJ94O;F*>*&>SO"O"*/AQ+*@>-_Y73EED
MS$B?7CD)<,H9/X1_5]+B:6.>$L!)X):?#DPSR8=5H^+Q,V3Q..,)Y?#S8_YV
M+)P(>2=$\O-I;R7,KW5Y%(L0@NW6W@1U9E1Y4YOQ"UR!D!BX#Q'BF/X<G[N'
M^</4Y,,,I:\:F(PP&'3Y(&?C:2$]7J9PE"$LF/!D\+%Q\?#_`+YZ/R#`,.AW
M%??.@M\EJMBWBAV*J:?\I!Y;_P"VK%_R8FRK-]+F:'^\^#(YP#YZ\PGJWU?3
M@%\?AG^_Y9CAL[0'J'N5+_3=-U*SELM0MXKRQGJ+B"=5EC(ZT96!5MQ_LL+@
MQ-&P?Q^/],B5CB1%C0"..,!8E6@%%%`!04``V_X3%3^/Z7X_XZQK7?)-OJ^I
M37[730O-!8V[1*H(06-\+Y6J2/ML/3/^^\649T*_'+A6:CY`L[^_N[J6]=4O
M+BXN&`05'UG3OT<4!)_87]Z-L68R4`/=_NN+\?S4IN/RMFGMD635P]P#:&>-
M[4-;3"TM3:KZMOZHY_#25%+\5E^/BZXI&:CR_P"*=:_E);6VEV^G0ZL_U6*R
MEL)V,$=61[[Z\C*$951D>L=%7A*GV53%EX^Y/Z?+A1^J?E_:W.D_4FF>X$5Q
MJMXD%1%Z[:I%<(8O4^+T^'UKX9>+_9^QBP&6C_I?]C7_`!*&_+[2/-J:YJ6L
M^8C-SEL[.PMUNA:QR@6S2NS<;1YHPO[T#U&?D[\_W<:\%Q3,QJAW_C\?YK(-
M`\JZ5HSW$Z1Q37-S>W-]]=,2)+6YF,OI\Z%J)RXCXL6N<[H=-O\`8_C_`#4+
MHWDR'33H?"Z>5M%%Z$1E`]07SEC6A^'TZ[?\%BGQ+O;ZJ_V*9WNC176LZ7JA
MF93I7UJB;$/]:C$9!/\`D\>7^7BB_21_._'X_G)#Y:\AW&D76GM=:N^H6ND)
M<KI-F88XN#79/J,[H2TU$/IQ?9^'^=_BQ93RW>WU?[+\?[)#:K^5ZZCYK&O2
M:H3Z=]:ZC'#)`DLL36I0B!+AFK';-Z?V(XT;F_Q._P!G&F8S5&O+??\`'X]*
M^X_+.QN-*TK3WOY432K.>TMKE%4.7FEAGCF^(E5,,ENAX$,O[+XL/%W)[_Q^
M/YJ=>6?+U]I5]J>HW^H_I/4=5DMY;@B%;9$%O&(E5(U+T6@Y?$W)?M8K*0-`
M"J4]`\GZ3HNC?H^%8GE*3I)J/I(LS_6)'D/(J.1IS_F^+CRQ1ER<1OH[0_*4
M.EW&ES+<-*VEZ0NCQQE0!*BM&WJFA.[>E]@?:Q4SN_,\7X_'J5=7\NB^U(:A
M'>-;SKI]YIRLJAO3^N&,^J#4?%'Z0X_S8H$@!7/?B2>_\B:A+J^EWFGZREI:
M:-;16^EV,]HMS'$\:\#.O*2,>NR?N_496:%?@3CS?DLXY!1!Z_Q7]2<^8/+[
M:K)ID\5U]5N-,N3<!>`D5D>&2WD0J2O&L<S<6K^Z;XOBQ81D!?FD-Y^6D4^D
MV.GPZK+;_4=+ATE+@)42+#/%-61`RDI)Z/IRPAUY1NWQXLXYJ/QXOQ^/Z2AI
M7Y30:=',$U/C++)>3!8+6".-6O;2.U8)"?4B]-!$'5'63U?V^7VL:92SD\_O
M_FE-_)/DR+RQ:WD"W:SB\E$K101"VM8.*!*06ZM(L?J?:EXMQD;[*KBUY<G%
M^.)DX"T%32E.)K]K:G^?_`XL/Q^/Q_12?S:!_A76C^U]0N:K_+2%O\_\G%EB
M'K'O'X_'TO\`_]/JOD!O^=*T(4'(6:`)V(/M_GRR8>?U!_>'WG\?CZF0\A\7
MQ5!KS;E4BHIU_P`^?V<6N_Q^/Q)9R&U30#=3RZ[4_P`_^`PL+_'X_'\*R:SL
MIW8W%M#,[1^C*LBJW[KER*?$#\'(<N/V4;`S$C^/Q_T@IW%GI]P2;B"*>L;0
M^I(JL3'(07B/(']V]!RC^S^WA8\5==OQ^/\`9+=-TG2--#C3=/MK%I!\<=M%
M'$'`Z<A&J\O\VP,C,GGS]_X_'J;N-,TJ:]COY;.WEO801%?.B//&#V24KS'4
M_9;X\5,S1%['S_'_`!]!:KY8T/5-.CTZ>VCBMXF1K<1+&I4)*DQ5:J0JR/&O
MJT'Q_8_RL5AD(-_I_'X]*)?1-"-@=,.FVATXGD^G^E&+=36I/I<>`/(]>/P8
MJ9F[O?W_`(_XZZ32-%F%F)K"UD2P*FQ9XHSZ)6E/2JI]*E/V/L8H$R.OV_C_
M`(ZZYT'0;E9EN-+LY_7D^L30R0Q.KS4IZK*RGE+Q_;/Q?M<L67'(&P=_?^/Q
MZF[C2='N)DN9[*VFGB'".YDCC>2-0W(*C%>07D.0`/Q?:Q8\9JKV]_X_X^B+
MBUL[E@US!%,_$JGJ!7+*2&H2PW!9%;_*9%_EQ3Q?B_Q^/2N"0K++(B*))B&N
M&%`20O$%C3<A?AJ?LK^[Q09?B_I_'_'4&=!\O22132:;9M+%&L,,[0Q<Q&A^
M&-6*U5%_97_=>+(9#7/;^M^/^.M76@Z!<B07.EV<YGE^L3QR0Q,'F&WJL&4U
MDX_M'XO\K%'B$<CO[_Q^/4K7FG:7?VWU:^M8+NT4\ECG1)45A4"BN"O0G_6Q
M1&5<C_G7^/\`CR@_E[R[]3BL_P!%67U2"4S6]IZ,1B60_P"[%3CQ#_Y:CX\6
M1R2YWO\`UOQ_QY'%(7F21U5Y(R65V(+1EEXDHU/AJIXU'[/[O"Q$OQ?X_'I0
M5GY?\NV-P+JRTRSM+A:A+F"&**0AOM#FJAM_VM\#(S)&YV]_X_XZC@QK6@YT
M%4K2@!_"G_"?:PL+_'X_$5P*\*5^`_M5WK6M/[/]G@3>WE^/Q_LEO,D@T^*A
MXKRJ"#^NO_#X6-_C\?B2Y6%&WJ"3R/*M*BG^?\WV<#('\?C\?PI7K[5?11V_
M3&G<36M:3@?Y_P`OV<2Y.C/[T?C^'\?[E/?S4V_+W7">BV_(_(.I)R(YNZG]
M)]SSA_-7EKFW^Y2VZG_=BYF<0[W0^#/N/R:_Q5Y:_P"KI;?\C%QXAWKX,^XN
M_P`5>6O^KI;?\C%QXAWKX,^XN'FKRV/^EI;?\C!CQCO7P9]Q^3?^+/+?_5UM
M_P#D8,>,=Z/`E_-/R=_BSRY_U=;?_D8,>,=Z^!+^:?D[_%GES_JZV_\`R,&/
M&.]?`E_-/R=_BSRY_P!76W_Y&#'C'>O@2_FGY._Q9Y<_ZNMO_P`C!CQCO7P)
M?S3\G?XL\N?]76W_`.1@QXQWKX$OYI^3O\6>7/\`JZV__(P8\8[U\"7\T_)W
M^+/+G_5UM_\`D8,>,=Z^!+^:?D[_`!9Y<_ZNMO\`\C!CQCO7P)?S3\G?XL\N
M?]76W_Y&#'C'>O@2_FGY._Q9Y<_ZNMO_`,C!CQCO7P)?S3\G?XL\N?\`5UM_
M^1@QXQWKX$OYI^3O\6>7/^KK;_\`(P8\8[U\"7\T_)W^+/+G_5UM_P#D8,>,
M=Z^!+^:?D[_%GES_`*NMO_R,&/&.]?`E_-/R=_BSRY_U=;?_`)&#'C'>O@2_
MFGY._P`6>7/^KK;_`/(P8\8[U\"7\T_)W^+/+G_5UM_^1@QXQWKX$OYI^3O\
M6>6_^KK;_P#(P8\8[U\"7\T_)K_%7EK_`*NEM_R,&/&.]/@S[B[_`!5Y:_ZN
MEM_R,7'B'>O@S[B[_%7EK_JZ6W_(Q<>(=Z^#/N*_3M;T>^\S>7(+*\BN9AJ<
M;F.)@S<5@FJ:#L,KRR!BY6CQR&2R#R9A<-3SSYA'3]QIU6\/AGRB*>T3ZA[D
M:)#RKQ.U?AV^+;V_S_DPNOXOQ^/Q_-7%SX$U_P!7X=O\_P#KK%D9?C\?C_.6
M<STW[?%MO]_^?\V+'B_'X_'\Y>)#L>)[?!MMOUW_`,_YL67$LYFE-^GV]O'I
M_G_Q'"PXEXD-*\3^U\.V_P!W^?\`)@9<7X_'X_FK6<\CL34]=OAV_P`_^NL4
M&6[:.?<4(W^'XMO?_/\`V6*1)Q<U!XG>GP;;??\`Y_SXKQ?C\?C^<TKGIOT^
MWMX]/\_^(XH$OQ^/Q_FKF<T8E3W^#;?WV_S_`),61E^/Q^/YJWF:TWW)^+;X
M?N_S_EQ8W^/Q^/YJ_FU>A%#_`)/Q;?Y_]=8LK_'X_'^<IAS4;'M\.VWW_P"?
M\^+'B_'X_'\Y>'-`*GH/CVWWZ=/\_P!KX<60/X_'X_S5K.=SQ/?X-O'K_G_Q
M'%B9-JY^(;]_CVV^[_/^3%(/X_'X_FN=SX$4)VV^+;_/_KK%3+\?C\?YS22'
MD/A)K3;;X=O?_/\`FQ42;+GB!OV^/;??W_S_`)L5O\?C\?SEHD.QXG_4V\>O
M^?\`Q'%'%^/Q^/\`-7ES0C?O\>VV_3;_`#_EQ97^/Q^/YJPR'?X3M6HV^+;_
M`#_XUQ8\7X_'X_FKP[>!-:?R_#M_G_UUBR$OQ^/Q_G)/YM<GRKK0W_W@N?BV
MW_<M_G_Q+%EB/K'OC^/Q_G/_U.K?E^I_P1H>^QM$^+P]O\_]CDP\_J!^\E[R
MR(AZ]ZBM!M\6WM_G_+BPH_C\?C^%3XMUZUIMM\.W^?\`UUBPH_C\?C^LO"ML
M*D`4HVV_WC_/]O%D!^/Q^/YRTJ]2:&NWP;;;]?\`/_B.+&C^/Q^/ZK:JU".6
MV]7VVWZ=/\_]7%(#G5ZUWKO\.V_W?Y_R8J0?Q^/Q_"Y5;EU)KUZ?#M_G_P!=
M8J`?Q^/Q_6<RM5=S04HVWQ;?+_/]K%2#^/Q^/XFE5Z@TWV^#;;?KO_G_`#8H
M`/X_'X_B7%&XD5VI]O;QZ=/\_P#5Q95^/Q^/\U85;<TWW^#;?[O\_P"3%C1_
M'X_'\*IQ;Q)KU.WP[?Y_]=8LJ*PJU1N12E#M\6W^?_76*""N17VVW-/AVV^_
M_/\`FQ2`?Q^/Q_$TRM0"NW\^WCTZ?Y_ZN*"/Q^/Q_FN57W--Z'X-M]_\_P#C
M7%0"VZOQ.Y-2:MMM]W^?\N*2#^/Q^/X5JJ_(=J=.GQ;?Y_\`76*`#^/Q^/ZR
M_B_7>NWP[?#M[_Y_S8LJ/X_'X_B4PK4`KMM1]M]^FX_S_:PL*7A7I6F]/L;>
M/7_/_B.!E1_'X_']59Q:A%30UJVVWW#_`#_9PL:/X_'X_A7JK^XH30;?%M_G
M_P`:_%@9`%*?,"L'T8_]KC3JC;;]^/\`/_F[$N3HQ^]'X_A>D9!W;L5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M>?70_P"=X\Q$[J(-.JO^QGW]O];)!U/:7,>Y&!6#"O7?BU*<:#^'_"X77U^/
MQ^(KBI^*@H1]K;[6U>G^?\^*:_'X_'\2SCL/AJ#3BM*TK_7_`(?"QK\?C\25
M`K<J?M4%7I6H)I]-?^&^S@9T?Q^/^DE/C\->/P]TIWK2O^?^IA85M^/Q^.%?
MQ8$`_:WH]*<:?JI_PF!E7X_'X@M*FK?#0`_$*4Y4%?\`/_@L*"/Q^/Q_$VJ]
M/AJ#]D4!XU%>G^?+[6!('X_'X_B:*L33;EM5Z5#5_K_P^*"/Q^/Q-I1M7C\%
M/L4]Z5_M_P!CA0!^/Q^/X5[*U2/VJ&CTI0#M[4_X3`R(_'X_$5G'J>-`">2T
MI6G^?^QPL:_'X_$5_$U%16I^$<1\.U>GX_\`#X&=?C\?C^):$8M0==JM2O*O
MAXU_X?"QK\?C\2;`'$'C5#2B4KU-*_Y_:^S@36WX_'XX6F1N5-N5*A^P%>G\
M/^%PH(W_`!^/QPN5:!SQHHKR6E":?T_X3%0/Q^/Q%MU/P[;DGCM]G:O^8_V6
M*D?C\?C^)I%;G0#?;D:5Y5%:`=Z_\-BH&_X_'_%-D50'C5#2B4K2IZ_3_P`/
M@6MOQ^/^*:"MR`_:Z\Z=JT_L_P"%PHH_C\?CZ5Q'PL>-%%:I2E:&E?:G_"8L
MJV_'X_XE:58&AZ[\32G&@_"G_"XHK\?C\17*IH:"A%.6WVMJ_P"?_!X$@?C\
M?C^))_-H_P"=4UD\?A-C<\5ITK"W^?\`E8LL0]<?>/Q^/J?_U>R:+Y*\]:1I
M-II<%SI4MO9QB%'DCN0[JO0MQ>G+Y8;<&>A$I$WS1OZ!_,'KZVCU['T[K;Y?
M'C;'\@._[&O\/_F#3^^T?W_=W6__``^'B1_)X[_L7?H'\P*_WNC\1]E>%U0?
M\/CQ,OR`[_L6GR_^8/7U]'Y?S>G=5I_P>-H_D\?SOL;&@?F`/]VZ/Q[KPNO^
M:\;7^3QWN.@?F">LVCU['T[K;Y?'C:_R>/YWV.&@?F"#M-H_^5^[NM_^'QM?
MY/'?]CCH'Y@'_=NCT'V1Z=UM_P`/C:_R>._[&O\`#_Y@]?6T?EW/IW53_P`/
MCQ+_`">/YWV-_H#\P.GJZ/Q/[/"Z^_[>#B7\@.]K_#_Y@T_O]'Y=F].ZV_X?
M#:/Y/'\[[&_T#^8'^_='_P`H>G=;_P##X.)/Y`=_V-'R_P#F!_O[1_\`)'IW
M6W_#X>)?Y/'?]C8T#\P1TFT>O<^G=;_/X\'$OY`?SOL<=`_,`[>KH_'LO"Z_
MYKQXE_D\=[AH'Y@[_OM'Y=F].ZV_X?#:_P`GC^=]CCH'Y@$4]71P#]H>G=;_
M`/#X+7^3QW_8X:!^8-:^MH^WV?W=UM_P^'B7^3QW_8[]`_F#_O[1Z]SZ=UO_
M`,/C:_D!W_8U_A_S_P#[]T?CV7A=?\UX\2_R?'O;_0'Y@T_OM'Y?S<+JM/\`
M@\;7\@/YS7^'OS`_W[H].X].Z%?^'QM'\GCO^QL:!^8(K^^T<G]D^G=;?+X\
M;3^0'?\`8IMY2\Y7EWIYO[G3$M;2\M[R;ZO'<>J_U=^85>;%1RI@);,6D$)"
M5L\P.8[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%7G]Q_RG?F"FS^AIW$GH/AG^[YY*+J>T?J'?2,''>FR[\QQ-
M33P_S^']K).OV_'X_P"D6R!05I_Q6.)V^?\`G_E?9P)/X_'X_G+>YZ<MN9H2
M#]W7_C;]G"C\?C\>I>.'$;?N]J+0DU)ZG_/XOV<"=OA^/Q_26;U[>I39J&E/
M\_\`FG[6%'WKAPXF@^#?FO$@DCP_S^']K%(JO+\?C^C_`!--3D*TK_NOX3MM
MW_S_`,K[.*"V@%3TK_NSX20=NV!(:/"BU'[O;BM"2"?&G^;?LX4&OA^/Q_2_
MA<M>74>K3[5-J5IUKX?\T_:P)'/S_'X_V+9X\&H*1[\EXD&H\*_YK^UBNU>7
MX_']%K]H=.7^ZS0@"GZO^-?VL*/Q^/QZ5P`^*E/^+/A.^W;?_/[7V<#+\?C\
M?TOI6?#05`*;<10DBOC3_-OV<+';\?C_`*2_A7CE7J/4H.34)!'SK_G]G[6!
ME]ZP\:'_`'WW6AK6O7_/_5PL37P7+7EU'/\`8:A`'AWV_P"-?VL"1S\_Q^/Z
M/\3FIO2@&_,<2*[=O\_\K[.%37X_'X^II>-5J`5_8'$FFW?_`#^+%`IL]]QZ
MAIS:A((/7Y_\;?LX$_?^/Q_2_A6CA3I^[K]FAK6O7_/_`%?M84;?!>:U[>I0
M\6H0`!_G_L?VL#+[_P`?C^BL^'>@`7?F.)%:#M_G\/[6%CLO%/AJ`1_NOX3M
MM7?_`#_ROLXIV_'X_'U)/YMK_A;6^G/ZA<\S0[UA;_/_`"OV<#/%]8[[#__6
M]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J^7/^<AO_)F3_\`;-M?^)RX6C-S^#S@]3_LOU8M7[7=_I'_
M`!'%/X^QR_L_[']6*!^IPZ+\E_7BH:/3Z#_Q+%?Q]K9[_P"S_ABI_6YNI^9_
MXCBI<O4?,?\`$<4AH?L_[#%`_4X=/H_XVQ1^/M;;HW^S_7BD_K<?VO\`9?JQ
M4_K;_:^G_C7%/X^QI>W^Q_5A0/U.7[(^2_\`$L"AH]#\C_Q+%!;/[7^RQ2?U
MN/VOI/\`Q'%?Q]CAU'S7_B.*APZ#Y+^O%1^IKL/E_P`;8JVW1ODWZ\5/ZW'J
>WS;]6%3^MOO](_XC@3^/L4I?[EO]4?JQ6/,?!__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>pg4b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg4b.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`N`)8`P$1``(1`0,1`?_$`-````$$`@,!`0``````
M```````("0H+!`<#!08"`0$!```'`0$!``````````````$$!08'"`D#`@H0
M```&`0,"`@0&#`L%!@4%``$"`P0%!@<`$0@2"2$3,11X"D$B%=:W.5%A(Y2U
M%C9V.+A9&G$RLS1TM'6V%W=Y@4*3E1F1H5(S)!CPL<%B)>%#4S5&$0`"`0,#
M`@0#!04'`P,%`0```0(1`P0A!08Q$D%1$P=A(C)Q@9$4"*&QP4(5\-%28B,S
M%N'Q)'*"":*RPC071/_:``P#`0`"$0,1`#\`C437O!G>;:3$LU1[@.:"HMI-
M^W2#U6A!LFBZ53(&Q::4H;%*'H``T!UG[PGWG_V@6:/O:B?,_0'"X]X+[S#M
MNNU<\_LS+-W**K=PB=K1!(JBL0R:J1P_$_Q(HF80'[0Z`\'C7O==T_#4`M5,
M2\P;OC2L.)1].+UVC57&%8A%)F3,522E31</16C+Y1D5"`=PMT>8L<.HXF'Q
MT!L+]X3[S_[0+-'WM1/F?H`_>$^\_P#M`LT?>U$^9^@/T/>$N]`8=@[@.:1'
M[`-:((^'B/@%.^QH#\_>$^]!Z/\`J!9IW';P]6HGP^C_`/QWPZ`!]X3[T`>G
MN!9I#^%M1/F=H!S+LU]Z[NH\A>Z'PKPMF;FGE:_8MR)F:-K]VILPA3BQ=BA5
M8>9<*QSX6-7:.P;J*MR"/EJ$-\7P$-`..>]+=U+N%<)^XE0,4<5^4^1,+XYE
MN*^/+K(5&JHU=2,<6N4R)EN)D9PYI>O2;SUQY'0;-$X>;Y?2W+L4!ZA$",U/
M]_/O`6N$E:U:><V4++7)UBXC)NOV"#QO,PDQ&NTS(NH^4BI*D.6$@R<I&$IT
ME4SD,`["&@/%XM[UG=`P=7UJIACEA9,35ER^5E'4!C>AXBI,.ZDER$35D'4?
M7,?1S5R].FF4HJG*8_24`WV``T!LO]X3[S_[0+-'WM1/F?H#6]N[V7=)OUII
M=WN_+VZVVY8X?*2>/K38:IC"6GZ/)*B45I"I2SVC+/:\^7`@`HLT.DH<H`4P
MB'AH#9'[PGWG_P!H%FC[VHGS/T!Y2[]]GNTY,J\K1\C<T\@WVF3I6I)NI7*L
MXPLU;ER,7S649%DX29HKR-?%9R3%%PD"J1O+72(<NQB@(`>I)[PAWFTB$32Y
M_P"94DTRE(FFFSH2::9"`!2$33)3@(0A"AL`````>C0'U^\)]Y_]H%FC[VHG
MS/T`?O"?>?\`V@6:/O:B?,_0`/O"?>?'P_Z@6:/'[#:B!_WA3]PT!)B]XJ[I
M?<$XE5[M<N^.?*3(>*7.:>&$1D'*:M=1K!C72ZKL:0JO8Y4)*OORE?K*22XB
M"())!Y@[$#0$9W]X3[S_`.T"S1][43YGZ`/WA/O/_M`LT?>U$^9^@#]X3[S_
M`.T"S1][43YGZ`/WA/O/_M`LT?>U$^9^@#]X3[S_`.T"S1][43YGZ`T[$=XS
MN0U_)\IFV"Y*/87,<X1T28RK%8PPK'Y$E`?I&0?F?7)IC=*PNE'Z)A(N<[@3
MK$$0.)@T!N+]X3[S_P"T"S1][43YGZ`/WA/O/_M`LT?>U$^9^@-]<5>_5W@+
MSR@XWTJU\\,PS56N&>\/5>R0[IO2`;2T!/Y#KL3,1CD4JDFKY#^.=J)'Z3%-
MTG'80'0%C=WY\\Y@XQ]IGE[G/`=]FL89;H,!C1W3[S7BL#S$$O+YLQK7I0[,
MLFRD&(B^@Y=TU/UHFV36-T])MC`!6+_O"?>?_:!9H^]J)\S]`'[PGWG_`-H%
MFC[VHGS/T`?O"?>?_:!9H^]J)\S]`'[PGWG_`-H%FC[VHGS/T`?O"?>?_:!9
MH^]J)\S]`=9-=_GO#62(DZ_8N=>5)^!FF+J+F82;AL<RL1+1KY$[=['R<:_I
M+AD_8NVZAB*)*D.F<@B`@(#H#P>*^]-W.L&0KRMX5Y56#$=?D7YI21A<:T#$
M%(C)"2.4$S/WS*MX]C6[QYY8=(**%,<"^`"`>&@-G_O"?>?_`&@6:/O:B?,_
M0!^\)]Y_]H%FC[VHGS/T`?O"?>?_`&@6:/O:B?,_0#A/:<[W?=<SKW+.#^'<
MM<VLL7;&>2.1^-*E>:A*MZ86,LE;EYYNVE(=^+2JMG0-7S<PD/Y:A#[#\4P#
ML.@)D'O17+?DCPM[;E8R_P`6LN6;"^27?*'&%,=6VJ$B3R3BK3-*RI(2D(H$
MQ&RC8&;Q]"M%3]*95.IN78P!U`(%>M^\)]Y_]H%FC[VHGS/T`?O"?>?_`&@6
M:/O:B?,_0!^\)]Y_]H%FC[VHGS/T`?O"?>?_`&@6:/O:B?,_0!^\)]Y_]H%F
MC[VHGS/T`?O"?>?_`&@6:/O:B?,_0!^\)]Y_]H%FC[VHGS/T`?O"?>?_`&@6
M:/O:B?,_0!^\)]Y_]H%FC[VHGS/T`?O"?>?_`&@6:/O:B?,_0"]^Y7WP.[#A
MOE,:D8TYOY;JE5_]NW"ZVA#1[:DBU"QY#X<X(OUUE0%>I*J^L6*YV1_(K[F$
MH+NS@0")])"@((_>$^\_^T"S1][43YGZ`/WA/O/_`+0+-'WM1/F?H`_>$^\_
M^T"S1][43YGZ`/WA/O/_`+0+-'WM1/F?H`_>$^\_^T"S1][43YGZ`/WA/O/_
M`+0+-'WM1/F?H`_>$^\_^T"S1][43YGZ`/WA/O/_`+0+-'WM1/F?H`_>$^\_
M^T"S1][43YGZ`U'?>\1W(,S6>I67+?)1[DVRU!R@%4L5_P`884N,Y6@]<!R4
ML'*6+&TD\CDR.S"L4B9BD!4>O;J\=`6#WO1G,SE'PT[<_&?*G%S-5QPID*U\
MDJ!4+'::6K'-I*7K,EA'+-@?0KKUR/>(`R<34(T<B4A"#YC<FP@&X"!`J_Z_
MO>5_:#Y[_P"8UWYO:`/^O[WE?V@^>_\`F-=^;V@#_K^]Y7]H/GO_`)C7?F]H
M`_Z_O>5_:#Y[_P"8UWYO:`/^O[WE?V@^>_\`F-=^;V@#_K^]Y7]H/GO_`)C7
M?F]H`_Z_O>5_:#Y[_P"8UWYO:`/^O[WE?V@^>_\`F-=^;V@.\K'?R[QS^RUY
MBY[@N>CMWDY$M'!!D*V('1</VZ*I1`U<,40,0XAX@(:`9YL?Y0SO]LRG]>7T
M!TV@#0!H`T`:`R&K@[1RW<I[=;=9-8H&`1*(IF`P`8`,01*.VP["`[?"&@%P
MFY]Y(<1"L/)8DXMS9!<W!VSE)KCIC^1G8M>Z*NG#]1A,.&IGP#%N77FQX*G5
M!H=,G3N4NP@))R%=761;E/75]"U:N.[`[(\7A*376%3JK`Y&S=KY<-78P"L(
MIN<&X',FD'2*AC&])AT`Z;V!OKD^WO\`Y_17X!G]`.Q>^>?6J8N]B_%WTJ9P
MT!$=T`:`-`&@#0!H#<.(L5,,I.+*A(Y-QQC!*O0Y91&0R1,.HAC..5'!$$H.
M(,Q:2#MQ+K@(F(7R?*``W543+\;0&_Y7A0V8I*NV7+OA9+,P;QR[<S3-#Y%X
MY4?L'KT[08QU4$GS->/,P.BX,N5-%-8Z11/]U)N`B`Q1*.P_:'X0\!`!#P'[
M0Z`_-`2_/>MOR5[-/^G_``?X.QWH"('H`T`:`-`&@,IBQ>2;UI&Q[5P^?OW*
M#)BR:(JN7;QXZ5*BV:M6R)3K.'+A8Y2)D(`F.<0``$1T!LN4P7FF#<+-9K$F
M38ETWD7$.X;2-"M31=O+M2I'<1:Z2T20R,B@18@G0'[J0#@(E#<-`:ZE(J3A
M'R\9,1S^*D6WE>L,)-FY8/4`713<(BLT=I(N$O-05*<O44.HA@$-P$!T`HKA
M3^F3Q*]IK`WTIU70%L1[R[]2%SL_-?$GZPF)-`4[N@#0!H`T!DMVCAVJ5%LD
MHLJ<0*1-(AU#F,/H*4A`$QC#MX`'CJ%?EE+^6,7)_!+JSVL8][)FK>/%SNMT
M45JV_@CC605;J&26(9-0O@8A@$IBC]@0$`$-?3[='%J46DTUT::(7[%[&NRL
M9$)0O1>J:HT<6H'D*5P[3.-5AK:[O,^5[MC^R?C=#,6L;5J0>VHJ4E9S&)SE
MA#=1J@XEV:3ET9%F9TV`X-0\1%0H:`]ODW$?#NO5FQR.,>6-MR+9V;9ZZK%8
MD^/5AI;::.WFZU'M(V1L+ZWOT(ET^B).2?@J#=5),L6")Q*HZ3Z`$9Z`=-[(
M7UN_;I]K'$?]Y&V@)\WOE7U2E1]L?#OT?9HT!5F:`-`&@#0!H`T`:`7IBS#W
M!6Y1\>SR)RLR!B2Q/8*E.3O5\*2-XKD?87\"]7O$7(DBI2(<DB(.QE02;/DW
M!S*-#";R5#B/E@);R_7,9U:ZO8C$=_E\G4=-E#KQUQG:6YQ]*/G;N)9NIEBY
MJKN6G%&00TNJNT*J#I4CDJ(*EV`X%`#5^@'..[S^F@/LI]OS]0OC=H!L?0!H
M`T`:`-`&@/=8UA*=8KK"Q%_M1Z33W(R"DW9D8Y>7<1R#.+>O4"-(UL`G>/I%
MXV3:H$$2)^<N45%$TP,<H"WE.*W#IU2T;;']P:B1\I^+L:Z>42=PWDY6QM[4
M\I:T^I`)O(I)2,=L`LC8T2=ZCUIM53IG5^*;0#=)PV.8.GIV,8.G??IV$0Z=
M_AVT!D,?YZS_`*4W_E2:`LL_?)OJI^(_M:XR_5ZS;H"M"T`:`-`&@#0"[8CC
MWQ"L:S]BQYM1E:<INVX1+ZYX?NK.-E6ZM-J$LY;KC'*/`AEX^VS$G&F775%!
M9*,%9(#>8F4X"1LAP%6J]TGX&DWAKDFJ1SLB4)>&<%+5E"PLU&R#@'7R!.%+
M*1:R*JID54E!.`*)F$ASD$IS`>+T!Z6F?EA4_P`Y8+\*-=`8=C_*&=_MF4_K
MR^@.FT`:`4+Q5P1(\F,_XQPA&&>IN<@VJ+@#.(\61731N]=)HKNR'D54F2?D
MD/Z5!$.H0\#"(%&@\HW#<]IX]E[CLF,\S=[-F4K5C5>K-*JBY*O;]O[B[N";
M)L_(^4XVS[_E3PMINN7J7HQ[NQ*+=6GX.E">M$>YL<7F:4;,3&2>2<PT)78Z
M0F(!#(&+V,@XG%V)%)*)BG:&(U3(H,GHB!%5DS'43';H`P:P?=Y=^HV=B.=#
MC6R6\16(3<%F3N9,W**<E&WI%=C=.KJE4N+'V[VI5^]M^1N.?+*>3.W;NJS_
M`*,(1GVQG.FLNZ*K14I7J0.^86`;+Q>Y+YHP1;*78*!*XYOD[!-ZS9EG#N5:
MP:3U4U?=*R3B/BAET9&&,BNF[(V03<%4ZRD(`](9_P!GNYF7M&-E9]MVLV6/
M"5R+5/GDM:+P5?BRR>18FWX&^9.)M=SU=NC/_2G6M8^#KXZ":-3Y10T`:`>`
M[`WUR?;W_P`_HK\`S^@'8O?//K5,7>Q?B[Z5,X:`B.Z`-`&@-L82PU>,_P"2
MJOBC',:25N%QE&4-"-%E5$&YGL@Z29MA=NDT%RLVOK"Y"G64`$D^K<Q@#QU0
MN2\DVCB.Q9/(]\E<AMN+;<YN$>Y]JU>GV?:75PWAV[\ZWN.P[([*S90G/_4E
MV1[8+NEKYT0[9E'L)<O<0T.Z7FV6S#*Z5`AYB6LL7`3=[FCH+PK0SUW`-)EM
MC\*\_L`D(8A$4W0D,H`@)P].L!['^K3VGY+R#&XULGY^]N&9)*T_1:CKYU?3
MX_C0S++],'N':VBYOV5=VRWM<<-Y$?\`R$[TH>'^BTIT_P`U$FOV,@KH*ME#
M)+$%-0HB`D-Z0$!$-A_[-;,FN+5'3R.'0@&@#0!H"7Y[UM^2O9I_T_X/\'8[
MT!$#T`:`-`&@#0&?%2DE!R<=-0S]W%R\0^:R<7)Q[A9F_CI%BN1RR?,G;<Z:
M[5VT<I%434(8IR'*!@$!`-`*8;\XN9#1U-/FW*+/*+RQS+JQ3[DF4KCYTS/O
M6JS)W-21QEA%Y*N6C@Z9W!]U3$-L)M`)_N%TMN09]S:KS9)JVV5ZVBV3N>L,
MD[EI9RT@XEC!0S5=^]56<JH1<+&MVJ!3&$$D$2$+L4H!H#>?"G],GB5[36!O
MI3JN@+8CWEWZD+G9^:^)/UA,2:`IW=`&@#0!H!?7;BQ!(Y8Y28U12I$1D2&K
ML\WGINH6"0>1L!--X[[JBVG'4>(/218N>D503V$Y0$NX`81U@_\`4%S7%X7[
M<9EV>3<Q<S)M>G;N07=-2FZ4BO.FE?"M?`V;_2_[<Y?,N;1W"5IW=LPNYS2:
MJI.+4&^NB>M&J.AV7<4Q(UI&=[/<HIO4X^!O]JLAT(.E(R;*O0$Q$ND4)>*A
MV4HW271BFRR@%0Z3*$$`'8VH^PG*9;_P[&VB_*_/.PL>WW3O*DYQG'NC)NKJ
M_"KH_,G_`-4OM?\`\)YE#>[&F!N-QU7^&<4E1*BIHJT0WXLS=-RIJ+MET2+`
M)DC+(J)E4*`;]1#'*4IP$/A`1UG!TK\O0U5,;4`&@#0#IO9"^MW[=/M8XC_O
M(VT!/F]\J^J4J/MCX=^C[-&@*LS0!H`T!^AMN&_B&X;A]K0.M-.IM.$PY>IZ
M/9S+*(VA'YSH-YMRL5&*];32!=1B+P`,F+\B)@,*!>I78P?%\0U;V1R?9<;*
M_(WLB$<Q=8>-/.GE\>ADW:O:#G>]X,-RV[#E+!G#N4].U^:3\_@:T=M5F3E=
MHX(*:[=0Z2I#`("11,PE,40,`&`0$/A`!U<"G;G%3M2[H-)U,<9./>Q,B>+D
M1[;]N3C)>33HS&U$\0T`:`-`.<=WG]-`?93[?GZA?&[0#8^@#0!H#E23%4Y2
M[@&X[;C\'@(CX?".P:'W;A*[-6X?6^ADN&*K9)-53I`JFX%*!MSAL'I$/L:\
MK5^U.<H:U1/9FU96#9A?O4[)]#!UZE.#0!H`T!E,?YZS_I3?^5)H"RS]\F^J
MGXC^UKC+]7K-N@*T+0!H`T`:`-`&@#0!H#TM,_+"I_G+!?A1KH##L?Y0SO\`
M;,I_7E]`=-H#8N+<190S=;4*'B&A6K)%R<,9"42K=/AGDW+?)<2V,[E))1JR
M25,A'QS8HG66/TI)EVZC!N&HI-NBZ@EM^Z`8.AY+F!FK)]EI\9(VS&T-!U*M
MR<TQ;/EJ(]=R3R3NLHT0=!Y;&4&#A#,RN@'K;BL(E^-L(2E_)NV+]JQ:59W)
M-/X)+4N78=MQLK$S\_(GVRQ<9=B3IW3NOLC'3S?_`%+(Y>UP4R+J,:R[5L1[
M`MW*,F1RDBLV4F3.&<:J5%=1)0JJW@HWW`/,V\/2&OJ_*W=4K5G_`'=56E*5
MTZT\^A+6MKS]OM8VX7\>=WTLE5MT;C-02<UW+Y7_`(9:Z5*VKWKWBO>:ED/#
M6>K@LE8K8SC9O$%XO";)RF[MD9"S!Y_',M(.SE,#E:.J=E;,#"J=14H$(7K$
M`#4AL4,RWB7,//N.[?QY**E1JJ?V]2ZO<3"V/)W>/)N*6HXW&MQP[>1#'[DW
MCW>]VK]IT=?EG'315C22T(@CVK6.-A8ZQR$'*,H"8=NV,3,.F3AO'2CM@V8/
M'J,>Z5(1)X9JUE6RBGEB8"E73$?XP;U<QR=#H`T`\!V!OKD^WO\`Y_17X!G]
M`.Q>^>?6J8N]B_%WTJ9PT!$=T`:`_0#<0`?A$`U!]#ZBDY)/I4DK>[O<?I=/
M)>1N9KN_)4>(Q&FUQ33HKU0%760KK?V3A]*,472Y#,6T?68",\Y<YP,85G*(
M$$I@ZM:\?J5SML__`)KD[5FSI=R)P[8ZINC<G^"3T-M_TE>WF3ROFE_<;N-<
MO[;C69QNN+^6*DEJVG6572-(U>NNA)VN$K!Y*AK/C"7LKPL+9F4XQD?5%'90
M,A-,%8YXZ,<A#)J*`10=U"'$X^!B["'CH'PG-XQ@\OPMZM8\WDX^59C%ZQJH
MJBTHO^IU(W7@<Y<:R+MC$5KU,*6.IM1K%)-**3UZ:]%Y%?1S0XQV[AIR/R%@
MNW`T?NJK((OX"72`5HZQ5"?03E*S.,Q,<Q5$G<:X*!AW'[J0WCKKOM^;'/Q8
M958OOBG\K4DGXJL=/B<).7\=S^*\AR=DS6Y>E-TDTXU3?5)_@)5%X81W]7:_
M!X`B`%\`,'B&^P[]6ITMD_?7/BG`6K0W642@/E"'EB(;=1-C!L;X?L:`Q#FZ
MS";8I=]O`H;%#8`#P#Q^QH#YT!+\]ZV_)7LT_P"G_!_@['>@(@>@,AKZKYZ7
MKOGBUZP\X&HI@N*?^]Y0J@*8'^QN&V@'6>U-V^:YW+>5E>XW0++,2#=U`2UI
MM=IJ[BG$2J4!$F;(*2DD:7BG;%NR.\>))>8H<H]1P`I#F$"C]1C5.3^B/44;
M3:5:$K6]]A3MXX'+/XRJZ=ORC\C.3MBY7R0YJ1)^-E4]EW0OS0M=C(MU&-'8
M&3)YC90Q2#_%-L&M+O='W"Y?9YU*QQ+=IV=HQYQC>M7.WM3TJDZ=SKTK%G3K
MV)]J>*Y7`<#(Y9Q?:,K>9VG.-R[&]+(G&55!IQ?95Q?<U)45$M.I#_Y[X0K?
M$?.EOP>MB)-M+1[./EXVXREYGIN/GXBRL&THPGJVSBV56A_DM1-<2(%%-0"@
M`E.'47PVGX7NU[?=@M9MYQ>0H_-3HZ):JO6M:FE'OIPO:^"\_P`C9]BC<CL\
MEWV^[P[I2[H)/6*A).-'KIY4&ZA\1$1\!$1W`/0'C\&KH,.-4='U/T`W`1W`
M-@WV$=A'^#PV';0'SH!37"G],GB5[36!OI3JN@+8CWEWZD+G9^:^)/UA,2:`
MIW=`&@#0'HX6R.X0BA&T=7GO4/F=<S7H>9.00$H[IGDVCD2AN'\7T#]C0%DY
MVYNWQ&<8N"''*\7^F8OC,]YBJ$'?K<]@<?U:,LT'#6)$)Z&A;&_CF3)PI)I0
M\PF*I0`A42&(00,8!UK'^HOBN)RM;8\B,KMC&?S6TZ*G1S==/E6M3=_])VX9
M.W8FXV5&<(IUJJKN=-%I]7P7F:H[OW&&%R!Q8N5DPE>['C#D=AC'EASC3`JK
M6&:5'(-*JCU@GE&F/K#\FH2"5B8P"YI6/,W.3RE6IR*&$J@[5SV2X7QWAKOY
M6Q.:GEM3DFW*+2CVMQD]/"E$2GZE,K?.0;-BY-Z"EC8V5*K<J7$G'1R@VVE^
M#;\"NXL=JLUPD5)6TV"9L<DJ(B9]-R;N3="`_P"Z"KQ94Q2A\!0V`/L:V!:2
M=(_2:5(Z$H`)@`P&'X!`FW4/V`#T^.^H$04`H'$"=72'_BV$?M[[`'PZ`^-`
M.F]D+ZW?MT^UCB/^\C;0$^;WRKZI2H^V/AWZ/LT:`JS-`&@#0"Y.W;PBN_<!
MY14OC_4I&.K40Y1=VK)-^G'9(^NX\QM`*-?QBM4W(*)JD;))G>(-&Q>DZB[U
MTBDF0YSE*,'2FNB/6S'NN)N+G!-52ZM5U7WD_P`Q][N/P8H=+2Q;+3F5\BQ`
MC'*6V/<WU[4U@FFS51%U;H)5M"I.8UD43E$I$A2%8A2E4^R&+<OC-G*Y-#?;
MS3O0K%K3Z*UU?BJTT>IO)L?.<_;/;R7$MOQ_RNWY5A=MWN]52>E8+M:=N;5?
M'3KJ0S^\EVT\>\'[_6+YQSRU$9NXXY$EIZEHS;$\H6QXWRS2$F?XVX_O368%
M1V5P_;NR2$4]*<Z#]KYO0("B.^2,.["=OMBU5-Z?#P-.>3[;E[?NDX9-IVNY
MU59*5:^-4WJ_Q&3]39;@:`-`&@'..[S^F@/LI]OS]0OC=H!L?0'9Q,@C&O$G
M+B*CIE%/KZH^4]>]35ZP`-SC'/8]V!B;>'2J'^W0&;,S;>7%,&U=@8(J>^Q8
M=.3*)PW$WW522E)%100#PWW#0="=O[N[V,L563$*O(KG-C'"&31RG28VU8_P
MG>F\?:;Q7,;7)1LM4,A6:#%?SZ6WLS>)6=1"AP([7;+#X%34W'PR56TW_*BY
M^-*V\APE"N1*G9*B=*5JJ/K5TJ*Q[KO8IP/G_"\Q;.-;#CUQ)M,`C'U3'U,5
MI==I4+<;/ZTX<5REO+I#,"(1<M;EC*,D7;]043+"@F90H[[T/:U.%^=VZZ6I
M=/']G]YEOG-W`_XUC;)'#G/?G!3GE1551:N#BM4GTKT5:E<I9ZS/4RQS]1M,
M4]@K-5IJ3KEBA))(4)"'G85ZO&RL8]0-\9)TQ?-5$U"CZ#%$-7(E6/<OI9K\
MTU6O5.AT6H$`T`:`RF/\]9_TIO\`RI-`66?ODWU4_$?VM<9?J]9MT!6A:`-`
M9\7%R,U(-(J(CWTK)/UTVK&.C&CA^_>.51Z4F[1FU35<.5U#>!2$*8PCZ`T`
MIN.X+<UYAB[DX?B!RAE(UBFNJ]D&6`LJN&3-)LF59RHZ=)U0R"!&Z1P,<QC`
M!2CN.P:`3/*0\I!R;R&FH]Y$2T>Y49R$9)MEF+]@[1-T+-7K1P1-=JX2-X&(
M<I3%'P$-`8[EHHU$H*BGN<`,`)JI*_%'X1%(YP+_``#H#%T`:`]+3/RPJ?YR
MP7X4:Z`P['^4,[_;,I_7E]`=-H!Y/L092CZAW$L38=M4227QGR_.7BMDX&KA
M:*L\/7,F2T4>+M%+LK$AI2NV6LV^'C7B:R`@"R*2B)_BJ;EBI.+4DJM,^H]W
M<NU5D2NO=SZ]`\6^2_-VJ0$"_?T6T\C+70:JO,).)">9TX)N185:3?3:Y!5<
MR6Q2HKIJ@`*IJ=2A^OQ"R.1\@>S\OP]MNVG/;[[TNJM8R:U5.E%YU-A^&^V%
MGD_LEN7,\7NQMQP]P[>RY**G>MVEWS[HIU48I]T6NK)=XUR3^7YIO(H`ULLS
M$1;U_+_):DK#0SEE)E)5F"PMRD1*X(DBF<_084D`^`0^,-T1L7K>1*Y%)J;\
M:T6NE?C\"UKF\[;#;<:<'*YLMC(E"%OU.R<U./==G3K]3:3T[M*M="/9[QS@
MVT9^@.+V-+U%RS7%,G;ZS4,BY*B14&-K+N^6VOUU>3<NE&B30KU%KTN4`6#X
MID`W`Q!,`R\KV18SX/,FXV90E7M2[&_Y:OK7R1X6MFV?<O;;*W+:TOSEO>7-
M6Z_Z\,5VVH]MNKK;<WW3ETC*B(JOO%-]XG8#M6/.USQ%ILPV;\26->@\W93L
MY6J\W<[@RJ$"QBZRU?*I&>J,XJ&:L%Y)1#U9LZ?(H@8BHMB')5OW&)OBNA&`
MT`:`>`[`WUR?;W_S^BOP#/Z`=B]\\^M4Q=[%^+OI4SAH"([H`T!M/##O%;7+
M6+E\UQ\\_P`/M\A4U?*S.KK`G8WN.T9^//<FD"<QTA)*KP!7`("4Y#>8(;'*
M.PA!JJ:K2OB1BDVE+Z2P<F./'&WC]2*U9.)BF-F?&S.L1%YYQ,RQZA=(R/<5
M6WPS1G6GTXRODY.652==,H\Y79U52"DH3RQ3*8H[Z:_J<NXN5FQQLB3C8M8Z
MFDO&7TU:^.IV0_\`CQLV7[?YZL66L^[GM3?;HH1BG\LO'K%Z^9XMA)FC[`Q6
M$Z[)?I8K-E$UC+%<I#TJF2$5R#ZLW4*/@8W1TE#X?#6G=N]B6X6,VVTW"]&4
MGTHK>B7W^9T)SL7\UM%RW13@Y2BU2E&M/#Q\^HR![P)3*G86N%\Q038%).(9
MHTB?<,TTU53,G*+U>/+)/C$*=0C!5B1)`/C%*"@AX;[CT5]AN28F[\=GAVI0
M[[335)N3=?M\O@<5?UO<'W'8^386^9./.,,F,N^484BJ=-?B_,\#R9[?N`>*
MO8?XTY[S?6JO6N:_*+-$#?,&*P5E7DKI8^.DC!3$Y(O+;')G&+:1*,-,1XBE
MY`+-'IVI3+G,H9$F>O`T3@H7+3O0[NVM%7Q(Z0FB^G8I'H&W,/4)T1#QZ@*'
M3T#X`&V_V1^UH>9B+^1YQ_5O,\C</+\T0%3;I#<3](`7<1W]&@.'0$OSWK;\
ME>S3_I_P?X.QWH"('H!QCMR=N>\]QB[YCJ-+O$91DL+X:E<P3KE>M3=XGYQL
MRL$%6F%>JU+K!PGIF0D)&=(*BJ13)M4B"90/C%`0)+WNMV,;?AV#[@MME(U]
M3[O5;#5\6VUE.1;N(LD>A26EQDI*GO"**-Y"(<N[BY8F<M]P.!V0%,`[`(6_
MRK._(;%>O0E2='^XRK[,;%8Y%S_"V_(A*YC>I'O2BFE62UUJG1:CEKQ>5L3J
MR(O'RBCLS\AW,4=1=VFHNZ-YSD%5U3B=<Q"&,`G,;Q\/'PUHEE[#@;UGY.3-
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M$`Z42;J'$P%`PCU"`B([:$#RIQ`QS&*7I*)A$I=Q-TE$?`NX^([!H!3'"G],
MGB5[36!OI3JN@+8CWEWZD+G9^:^)/UA,2:`IW=`&@,R.;(O9!BS</$(]!V\:
MMEG[D#BV8I+KII*/'`)@904&Q#B<_2`FZ2CMH!_+N==H1GP+S=Q/5QVUR#;>
M,&?WE`AZOG.Y3]2G83)UE=C79J=DJ7^*,5%(QU1EZW/M7D85SYRRZ1S[*#Y1
MM!]G4L*\FI0=<K>+XAD[]=2<5IA)_)W6+SY3>2B#1>-CH]XD84F,-'Q($3`Q
M>LIB](%$`*&^$?</.P;NY6=N5RE]_+VT7SQEI*/P37BC?+]/F#O:XQ>S;D(Q
MC&K<H_RT55-_XG7HOQ/.W^MXNO>-KS0KU\EMFL3"6A9)/U--^W;TNPU*2AKU
M"I/2]"XFG(&362/Z0$2D-MU%\/GC>^;5B93V.Q)6KF-<2A;3JE%KN<:]75DQ
MSCCNZ[OCQW*S!WL+,L3A>G*J?J)M1N*/147W4JR$[V?>Q-2N9\SS=O6=[_'8
MUX]\7+VWIAL@JRRL%8F2\&^;W2=?(*S!/Q99PCS%A]G#J1ZP05=(G+T@!CCF
MVW<]6W&Y2G<DZ>530O(L2Q<B>-)UE;FXM^?:Z5^\C5V=T%7O=F@:S-Q=DA:U
M9[)#0%C(R8BSG8AE*.F,?-IB@02J(2S-$CA,0,8H`IX>&OL\3P\W*N99V+AT
MBR36*7RS"S;I($/L<Q@$P)``','5MU#XB4`WT!TV@'3>R%];OVZ?:QQ'_>1M
MH"?-[Y5]4I4?;'P[]'V:-`59F@#0#FN9NVG?<,\"<"\Y9NS*/H+.JHO(R"1K
M3YI#Q$*XD741&-CVMTN1O(VE9PQ,X4:(H=!6ARG!01*.X#Q_NQ&+@D[7G+),
M@C(?BW'2V./QP4CRMS+NJ=C%U*Y9<P"`+$$3J6:Y5Z%2,03$()6X[CJ1SLNU
MC6Y=W^%M_!4+_P#;[:<G==Z[;%M3?9VQ355W/1/34E[3/+!\GDI:P3[H'4S3
MZQ*6*22KIRO8DRUC77<0U4.]\T#R,E!5]1LF].*9$/7?,$A1*4!U8/YN[/)[
MW)JU+H_B_P#H;9PVNS9XQ<VW%LJ-FBCZ2^:2NQ6MSSC754\*]2/=[P5Q9/.\
M<<B9[Q,P*;$V2+7C_.+DH.6I0KN2V!K%!V^L/VZ1$D(Z9DX6Q+2!6P"/F`W$
M2;`7I"\]J44JPDYQ=77_`+&MGN0U.%BQ=M3ADVTHRDU\KHO!O5Z:/XZ,BV\6
M^V7R"Y6XMLN7J<,%7:A'MK>A3WUG<*,T<@6:D,F<I/UB&<%#R6;IM'/`."RP
M^690!('B!A+63$`W6JF=%11%4ADU$CG34(<.DY#D,)3D,4?$IBF#80^`=`?&
M@#0#G'=Y_30'V4^WY^H7QNT`V/H#]#81\=]O'T?:`1T`O'/G`[(^%(/#ML:*
M/;S4<JT:L7-.Q5^OSCB!B6DLQK1I)TO821X0IX9&4L:2""X*B)MA$P!MXNHU
M\%5^18T\;+ZQXS<9KE=[*Q,I/YHD8V,=F*[3:'BL=T%@?%&-JJV4;B+XKXZL
M2[4(FD3I0;$$Q@(`)`:B;GDR5J5OHJ&P'M?L.VW<W'W7.3]11;BE&J3T?CU5
M#N:'.169L`S6`[*^)-5R0;RT!/OW3MS&S\&QGGC23JN0H5V_1<DE_P`3K"H`
M.6A@*Z31*FLF)NDY#4#&G.U8B^ZO:J_Q,O;KB2R7D3L0KZO<U)I:IIIQIT55
MXKQ*]+O#XGGL3\X<A-[.S,RL=TC*_=+*F<!3.O:'C,\789%1(Q$U$E9R1BC2
M!NHI3&%WUB'QM7GAWW?Q(R:2=33[DF#_`$_=[N.M-:T\JB*^.^%WV=\G0=";
MJRS!E(K%)(S,5!KSQXI-8WDM3K-$3I@7UIT)4D^HP=:A@*'B8->Y0CQF5L<3
MV(,E7K%MI!$+'C^U3=3F?5A,+<S^$D%V*RJ'6!5`26%'K*4P`<H&V,`&`0`#
M7^@,IC_/6?\`2F_\J30%EG[Y-]5/Q']K7&7ZO6;=`5H6@`-`20_=Z>`N),]Y
M9LG+SDU?9VDX'XPW>AP4)`T^/D)&YY4S1="OWU;K$2#)-0[2(KL1%J/I-0I3
M*B11%,O0!Q.'E.]"S;=ZY]$>O[BH[5M6=O\`E6]OVI1_.-^/1K7KJJ=/,M%)
M7D%BA2K235ZG+RT.,8YBGT&Y8G5?OXU5H=J[;.&3IX5TY26:&,505`$P@(]0
M[B.J;=WS!M*L]%6A?UCV?YMDYUO#[<6$[D4U6?[WJOVD`?WB#M&<88VJWSFY
MPKC;'0+-68^*O^=,*3"9G<#;J-9)]O6Y#*V+UDUWCE@\HM@=H)V6.6-T$9N2
M.TQ*!%.J<P\ZQN-IW\?Z%*G[O[RV^4\-WCB&0L3=O3=[Q<'5>6NGC_;XPHS^
M!A*`@(`/AT^C_MV`1U-KXEK2IW/MZ'QH?(:`]+3/RPJ?YRP7X4:Z`P['^4,[
M_;,I_7E]`=-H!<_;*L\?2>X'P^N$F[!BRK&?<=SJKHPE*"1HV>;.DAZC;`01
M53*`#Z0'T>.OF;:BW'ZJ:'S/L[?]15M^/V%K4I1\58%Q_D#`N.85+&5M?,Y3
MD+)6)/U"8L;N[S^2)95L#B029-W(1LK#IIKM^H1%DV$B1`$2G$V/N79-K*>1
MLUJ[&&^6K5J]"6G=K<HU7R:5'3PJ;8^S7&MPO9N!S"YC0R^+Y6X7=OO8ZFX6
MY6WCJ4ISC5IRJ^WPJU]@XC"7Z7-@F&M,?($F[::J(@$A((%\MQ9!8'2%S(M&
M:QBF1];#J,0I_C%+Z=]7/D[M'&V+\[&XIWE".JZ=Z237V=U4T8<R>*X<O<R]
MLF;:N8?'X;C.L(R7?"S&;2C&35/H^GY=-!)-:<-\W8ML^"\^QJ=BE+Y+65TY
M%)VX9-1GX9BRL<`6#*4BSJ&Z5XQ19$HE.85"&$"B`[:M[8-ZN[K@V[>X]L\B
M]D7JI*B2A1Q45X)>%:F6O<3BNW\3W9<KX7-0X[9P[$)1DE*<K-VMNZ[E$E)Z
MJK25"K[]X6@9*+[O7-&4>)G%K9,J2<E'._(,FFX0:(MH=8GF"4`76:+QXIJ#
MZ0$``=7[X)>"1JR])RB_K4FW]DFY1_\`I:&5]`&@'@.P-]<GV]_\_HK\`S^@
M'8O?//K5,7>Q?B[Z5,X:`B.Z`^B@01^.)BA\(E*!A_[!,70'8((1QSCYCQ4A
M0V$I/5A%18?B_<RB!A33,<1$`$P[!J#:2J^A%1E)J,:=S=%4GV4T3P'%CAO'
M-VFWXI<9<>4`K=8Y735%*"6E7O4F"A`Z%##)[&$1W`Q1^SKGO^I;<5N.?+(Q
ME<C:A'TFWXM5;/T'?HLX=#C_`+9K;KDX0E.<;]8Z2^>W!4;75::(\\HYGGCE
MR\A6SA58$2(K$(9=RX*F(>2(G`"=1A5'8H`4-@*&M4;4\7%PU:O78VK,EJY_
M2_MZ&Z$;.S8>*K&ZSMPQW-R[J)1;>O\`WUZBNK=V]Z[R-XZSU?R1$)`WE:*`
MS:1A=!-,74AZRHTEX]0R)D?6HU0"K=*1A4+T>``;PU->RGO9D</YI/'M9+6V
MSRHJ':WV4G\O8U6CCKHNM3GQ[V\NX-[C9^5P#D%B.3M^5ERM8]VD4[7:E10G
MUBVUIX>9'M]X?Q_.X]Q/VG,?2SY1Y%XDXHVS$45+"\))LWC&I7U1G%NO7&J8
M)+KNXEHD7K`"B<B(`8`,0==E]HW"YNF%#.DHJW<C%Q[>E&NIQW]T.'[?P?=9
M;+MURY.%N]<B^]U:UBDGHM:(C('CFY>G:39CN&X_^8'2(B(=/B0-Q+MX[>&P
M_#JK&,9+MDUY&"X1(@8I2+)K[D`PF2$1*`CON4!$`$=MOL:'R8^@)?GO6WY*
M]FG_`$_X/\'8[T!$#T`LSM[\F,E\0^9?'?/&*[3,5:P5#*E))*FB)!:/3LE+
ME+)&,;G3)P$U$T7U=M5>57:.VZ_4D8BG5L!BE,`C&+E)0C]3=$6#UWXGWSC;
ME7N!\M`OTI`5#D;R0L%SBJFA&=45D"OSL/65$["W>BJFDVBTEC$!)4B9UCNT
MU3"?H`2CASWMW.YMO"<F]8FX7TTM.M'_`-S>O]#'$OZW[I1LY$'.78_E=.V,
MDG*,NUKN<FM.M*=1&K#)"[!(QDE/-C7RQA>?=C'<J.1<*"0CM<I0`2%W'8H[
M;EV'T:T4VCD<X^M/(N2E+Z55]9/IW?V1V_RN#6LV<5=MI9MI4BJ42C15[5_;
M4\+EO#3+F+5%ZJK'FFY.NK-%20@MCKMY(D:_0D6R;-P!P,PDF+I$3HB42`<1
M$H"&_C>W"?=^/%-]A/D.1"SBRI!RDW2"3;I&KHJ^-:FM7ZC?:3:-^XG'9=YO
M6L?%R/4E!RHJW>WY7)TJXJBUZI_`9Q]Y]SC=\M=QJ-A;G;K@]Q[3^/6!/Q+I
MYWCT*S6Y69Q]&/\`(#B#@7CCY-8R;NXKO$WBR:955?)(0YS%3)MT!V3?MIY+
MMUO=]DOPR,"ZDU*/35)K]YP-Y5QC.X?O%[8]RC+\Q:G)1DOIE&,FE->:DDFO
M@R.`]^0_$D>>3V`?BG=E;[&`1'J**:9_B;E'??<?$/1\.JN6V=0<"@<P$$3$
M`P])C!TF$N_@(@`CL(AH!3'"G],GB5[36!OI3JN@+8CWEWZD+G9^:^)/UA,2
M:`IW=`&@#0$V'M@\<KIW7.U3PHP;8+7,GB>&?<9N19.:47^6WU0Q!.4>)OK!
MR*4BZ`2Q=??#*HM6W61,$Q313+T](!Y7YRMVN^/4J6VX']0N^C"OJ>'Q?@A[
M^6D4<46=/%-:NUDL[''<VE&1$C<"E4>)5^0:%>-4RO$2E2-%LE3J`0J12>7U
M=/H*`CHOS[E-NQSZW<5WM4+D=9=%%]3M+[4<`M8_MGC2NV(J&1@UG1U<KB?;
M5TI63IK6M3UDIE-*8D9(UBDD(R"E4755<.&`)*/CH/FAV3E82#U^>F"!A,`;
M&^P.K?R^4X>)RN]RJ65&&V6YKODNK=/'ST*C?]MK*X[/:\2R[F5&Q.[2?T):
MKIX:?8--]R+"]OXL]G#N#X_:.)MK6,N9WXOW*!F2>KQ\C<:"A9C(3RSPC-5-
M0Q6;:$BDWB"HG`40`-A3$-ML_:[W7XS[E84H[)?A^=QTE*RW6Y*,=/57^65*
M_`Y2^\'MQC\1W%;CLU^WE[==E)7E#_\`SWJ_-"7P3=%IX=2!^JXK`(E(A&2A
MW`%$IU57A`*&P[E5("11'KZ0`-A^*&LM&$3SJOD>'D^;Z1W%3IW$!]'@7T"'
MP^G0'#H!TWLA?6[]NGVL<1_WD;:`GS>^5?5*5'VQ\._1]FC0%69H`T`_#QUM
M5XY5]FOD#P_8V!_,V;C+R6QSGS&]*6=`(NJAEEF:@V1M&%5!18Z$5;XQF8K<
M@E2(K+"8"]9MQ'I;@II^8\CPPXFNNVWCS#4W'YS>/,@97LDM6,P44T8K%PT&
M>?K4,\4JL^"JIA*S37,5(RQNL3JH&\OI,4=8N]PMU>!;B[4NV71_'X/X>!O9
M^D+@N-N.Z7-TW!0N8[BG"J3E&=?E[*_S)ZK3K0<=6K;^O3?JC9K-6-A+UYW,
MWE>+518,0>RDH\."-5;KG3>.BP,4X(85!%4AG!1(80`!*%EWM^]/;W5.5+:D
MJ=8NM*_9X&S%KV]7_(Y9L5;LV)94H]NB=QT;_P!3S\]*:B<>9F/;9EWBU*XE
MA;HRF/Q?=2MCKM632>O/QSD'$&[20"2CBJ^II+K,4CE*N0#*(B82;`8^JYQG
MG6#CRC9W.ZL>S2O?=?RNOX&,/?/V$W[=>-SS>-V(WLBS.4Y0C!-)-UI5*O[2
M/CRKR[E[AEVV>#O$2ES[_'5CRC,YXY*93<5UX6.M?R39+0A0J54WTRS*G)!#
MIMX!^KT=9!.<A3>@1#69X.%RS#(M7(7;%Q5C*/1HYGY>)DX.3<PLRU.SEVG2
M49=:C!IC&.8QC")C&$3&,81$3&$=Q$1'<1$1'TZ^B6/S0!H!SCN\_IH#[*?;
M\_4+XW:`;'T`:`D5]E?.N:KQC7G%Q(>6X]JQS9^*P-J-3;H[-)15'M,OFW%-
M:+.TMPZ1>/JN=!E9'!UR,Q!N<G48R)S``A&/;7YVU'X'I:_W$O%Z?>]%^TDS
MW*LY-F(/%..LEY%87&,P-5HV+LMIJK5L26=,G42E-0T82&,<Q)>5;)3!2'?.
M2@IT&`5">:<":QMR7=?R]]SA)]K:5/!+^\Z`>R?"_P`SQ>Q:RK=I9[3DIR7S
MNJ7B^BT6B1T>*K->(9M)+.DI!C)L'97<>_?MR$KCB+!N!7D9,@W45=0\FQ/L
MIUG)]V1*<`#J`H#1\C>%CPBHOY:?L,K;5[;9V=FW,:MO\U&Y\L'],TO"*^/1
M?$8MY^\`[ARRH.4N8T;E!E<<CP]NO"05QV1X[L%IB*VY9K2)8\Y%E#&*S3=B
M8BBR"29D$Q\LPB`EU??']TQ\K&4%)N7@:5^^W`=TV+?[N?;Q+D<6#I<HM(O7
MX=%0;^XA93E^$?;\Y1\@H^FQ;/-.;\L8_P".V"+U.H*N9JBN:DS>W_)EI@8)
M[YD.NXB8P[9FFY<MU1;OGB1B;&)N%SSA*#I-4=*FO/Q71C.4[.S-HFI:QV*4
M?3<_/23Z9FIB3<JO)&4E9-RH\D)!\[6,=9R[>.UCJ*',(F,<PB.OD'4Z`RF/
M\]9_TIO_`"I-`66?ODWU4_$?VM<9?J]9MT!6A:`])3JA9;_:ZW2*;#/K';;=
M.Q-:K-?BT3.)*;GIQ\C&Q46P0+_YCIZ]<$3(`B`;F\1VT74$^'L(=O\`SU@.
MM2.+N2>-GU1?5WD7:,JVB!6D&$ZP;+5C$4,RJ:LF]KTA(1B#I.<(\2*!U0%)
MVS41/L<IBZH^\-*U*OTF2O;C)AB[C*XNU7N^,56E?F?;X_:/5WK)Q%W;YS"M
M)"5/5K,1!H)9%(HRS=XN+"1.HJ<-SMTT%OB`<VQS#Z-8JW"7=>2BW)*7_<Z+
M;'Q;%MX]FYDQ2N2M)]/F4Z527QUU7D<F2\&0F=>+^1*Y;[=`3#*`J-\8.[E)
MK-6KZ&QG=:O+PV0ZO;E$C%8OT&<8Z252\HH&6<LT#]/F`!M7KQV3])]K^52_
MN-7O?C88W+WJ2M3L-Z)2BTY4;:DO--5_`JK%L.2Z6;@PBK,0C*76OK:A-K!)
M.C-*Z#E_+)Q<=+.WHIG,VBUP735,H)1`B9MQ\`$=7O%U29J+?M>C>E:K7M;1
MLG+?%*UX9PEBK,%PG8MD]RM/VZ*C,?+IJMK3'Q=76\E.QN4%3[JQ4J'2HDH4
M@)"DX1$ISB8P%B>0E70'I:9^6%3_`#E@OPHUT!AV/\H9W^V93^O+Z`Z;0';0
M,O)U^;AYZ%?+1DQ"R;&6B9%N;I78R4<Z2>,7B)MAV4;ND2G+X#XAI5K5=4?4
M:N222;JM//4M#.U;SGM7<KP0PSU?Q;Q.3VT#4<56U$A$7,'*OZ/')1#ZQ)ME
M$U'31Q97J1WZR)`(U(Y<#T%`/1K+[@[AE[9[C96XW91_I\=K4>Y?3&4F^WXU
M<GIHZ/R-Z_;R5G`]HMGOXL5*S/*S[EQQ=)>JKW8D]4JQ@E%/K1#_`%CB[PS.
MOKUQ!%%=I%@HLX4:-3JJG.4A43J*)[=9W1E#@`F+\7;8`]``-Q\*>X;GQ.>/
ME1G&]=@Y6TW5R>KJM7J_N,,<OXMNE_?%O/<X7+]RE):5TJM>E&E6KU\Q)6<[
MM`X*D"Y^8M9^Q-L=N'ERLU5C2L"`NTB8F2%VR,Z,X4(@^%FLJ4JBI/N)1W_W
M`#5O<1Y1D7,ZU"-O_P`W$RH0G#^91FZ2DZOP2U,N;!M][E_!]RXCND,6Q"Y@
M7%9ON4G)N%)JE4OE;BNC6O3J557<\Y8O>8'*[)&47<6:+._MEPD'":H="II6
MQ6-W,R92D`1Z6C(RI&R(#XF*EUB`";6SMVY&Y/Y*=BT5/$TDR7WY$IT2I2'V
M^DO3K]_;4;MUY'@&@'@.P-]<GV]_\_HK\`S^@'8O?//K5,7>Q?B[Z5,X:`B.
MZ`^B%$YRD`2E$P@`"<P%*&_PF,.P`&@,HC81'J*J@8"&#<!5*7<P``F*4#;=
M6WV0\!U"7TL@^G6GQ)K'"_.T7R/X<\?DS)D)/46!_P`/K6;SP+Y\I"N@05?+
M'`=D4UFQ2*'`=A*40,7P-X<[?U-7OZ7O4MJA%OOB[J5.K:HOAXGZ#_T8\E_J
M_L[C<FLN%W)]%6I0^KLNV5V=C5.K2[EYC^F#*3QP!]!SQWS"5E8=M'Q3F9.S
M>),G3IRU`"@XCE55&2:B#@@)-E`\U540ZQZ=]<[-XW#+C>GB;MW/"3JDZUU_
M<EX&+/<_E/O6[.9MF7;O6-OOW+ER$$X]T(1F]5).O;*-&TJ=JTZFU;I:I;"[
MJ:+(N/+K;UK,.%'3\RKA$BKQ%0L8FR.0=_4P2.'483'`IO`-6OM.#ESW.UC[
M=!QRG>BTDOYNY..B\?)^#\2U..<;V_W%LXM[#BGN=J[;?;'27RM>I*5>DM'Y
M.FI#5]Y)Y&TS)-JX@8!I,A#S#O"V$W-@M[N$5;*LF$O?9^5EF4&#E!90%WS)
MDH=1<@[&2%0"CX[Z_0S[=0R[?"-LAFNM]85I/SJHZU\W4YM_J(GA?_U[><?`
M[_1M9/:ZRK%S22;CJUU6OQ(QQ(MZ<A#^7\50`,3XZ6X@8.H/`RA1`1#5ZF$S
M%<ME6B@)K!TG$A3@&Y1'I/OMOTB8`'P]&^@,?0$OSWK;\E>S3_I_P?X.QWH"
M('H#+CWJ\:^92#8PD<,';9Z@<!V$JS58BZ1@]/B51,!T(Q?;)2\4ZEG'.<F*
MQR>[<O%+*%9LJ,@_N&&R0^1(IHY6>!'7>O15(@'A7Z+H5$XYU\GP23@"D#H6
M,[,<AA,!]8#]^/GXW/`CK<R7^%$E_`Z??_'M;]?E-_<HJLL;(MR[O%KMDNO5
MJKIY*GQ0CW%W'FQY1BFRK&4CXHBSIPS9E55`Z[A-N*@J*@D<^PKI"7;XVW5N
M'2`ZY8<EYO'C&==V^=MR]-_-1:QFNE?L.M'.O>/9>#;C.&38NW[BBG)Q3[85
MZ+IT?PT\QWSBAQ;C,00[F=7ZW2DB@P,ZD'"QA1,B*)%G(ND52D%NY3?F'I%,
M?B]'^W6,<O<M]Y?);ENEN?\`Q^Q)2E):QHWTEUU?DSG7[]^^>X^Y.Y6]ML=M
MNW:E+TX)?,Z-]*>#CUKU_817_>P,0U)'*/';.L%),TY6RUN9QY.,P6;]7J]?
M7)*0[@J"0"Y."2$BH110>HOB4/2(AKI)^B;F]W=K&\<2MJ;P<64+EINKBH4I
M2+Z))45%XKH:-^]_'W<X+M_),Q1M[C8S)XZ35)WH7%WRDZZR4)Z*O1:+0A^*
MID3,`$5(L`@`]1`.`!N`#T_'*4=R^@?MZWU-4#BT`IKA3^F3Q*]IK`WTIU70
M%L1[R[]2%SL_-?$GZPF)-`4[N@#0!H":G[H;GZOMY?F#Q<L\RUCGTM58SD%C
M-N^>*-DGUNH,1.5^:9D31ZUWJ05R:.Y7;D(<ZB3<>DIA``UX93[<:5R7^W%5
M?X,N+BN3=L;[CVH)]EZ[&VVE5IR:I1>;\'T0ZQ;WDC8[;%+N'C=R24@:JS7<
MI"*#=ZNG6HWSBI?Q5P*HX'K+YH`</'?;<=<I_P!1&5=P-[N[Y9K^6O4JUHE3
MX?W'Z!/:^U;VCVUPXW%3,QX2E*+7<TFVV_%=/)BX^,'%XLI?6$W<V4;8%(B*
M3>DK$J"CIL@U6-N@+IP0#-R.@Z@-T&*(FV#Q\!UK#Q_>MTY7NT=KP&[V"O\`
M4NP[NVL5HW\[C73P56_(U[]]O?/\OQ:>W;#*_APR+K@[]OM3E-:42?ST\--$
M>@[V6+JYEGMA<GZ:=PUC'=8Q=,V*GE!!`@C,5Q`D@2.31$""#=5NW.B!A#XA
M3=0>)0UN%[4\JAL7N+QW;=EN6K3N7OR[MJ*5RY:O/MN]R2K2"Z.7_M-!H;;D
M[MB[IC9EN=Z&5@W[MV[72W.U!SMW'K]4I*KIX-UU94P&1$J7F`Y2`1`OQ>L>
MLP=/\78"^`E^WKI^_P#9B]#5>GRM^4W'\/'[#`UYD`T`Z;V0OK=^W3[6.(_[
MR-M`3YO?*OJE*C[8^'?H^S1H"K,T`:`=U[*66*;1^:,7BO)]@:U7&'*>DVCC
MG:+0^6(V95":NR*#C'%W<NU%$@9)T_(L9&/A6`Q13(F80$-'1:O1$U@VU>RH
M676DG^))SYCO6Y.1?)"D0\A\JU2*R%1(9B8BAWI7<E4*0V8OI3UP02,=\O)L
MU'9UDOBJF<`8AC%-XX7]QXJ]C7KV&DU;4N]R55HM>WR^%#IK^E:SE[7D8&R[
MP[4<:Y-SMN"49Q4J>F[CTDZ/SJT>>"_W$]5CIQ*1*N_B84(9$72BI$FK-)T'
MEHD`XF*DV]8,HL8O3N!CCX^.VM8+7,,W"W2&/=4GCI.M75=M.C^'P9U*S?;W
M8,S"RKN#;@MXN2C.Q=E%.#FH4E*C7E5-T'#^%6-'DPNXE[H*CJP$>PLR\_&!
MHU(B"#I`ZB4A$G;G%N+4Z._3TI)B(;`8.K6G?O-[B;UO._VMMP,N4-N]9I-7
M))53U5$UT?P-;O>'D;X]M$-OVIR4;F/<MW)VW3OO1TFG1)T[GIY>!&A]Z`QV
MP@^66.K;644FE66QA#UI".:MP;Q\<Y;OI5^`1I"&.B1J\4,LH8I-ME1,(AXZ
MZ1?H]Y?N?+?:>2S[OK6\#/G9C<;<I.7:NZ/=*LGV_AY'(SW]V7\MD;3ON1IN
M&;BR]2B4=83DDY42K+M\]?-D8?6U)KT&@#0#G'=Y_30'V4^WY^H7QNT`V/H`
MT!)2]U]K5>O_`#KN.,I!0S6PY!Q#/Q5<DC(F<-8U>#63N2CEV@4AP4;"XK2!
M3=6Q`$0$1]&O.ZF[;2ZT)O`]+\_8]>+E9]6%4NM.Y#LN2\O9%I69+5*QL@>-
M<LY1S$O&SA,J;3J@WKYJS!RBF8$'#ELU7*3=0BA3$$H#OT$VP?RN_P#E%/*A
M\]V-4H]:U\:=-#KO[+;#CY6TXVR9TTK#N.XI+2XK>FG?U[=>E?N..R7JS2:4
ME$Q;_P!3#($JW6=^KJ+%,8'Z*;EXB"HF$42^N.!$"`'Q2E``UA+>>:?DL.=V
M<U6U&5:M]4JT9OAM/M/MMC,6>H=F!&S6$Y).452J:>LJ^*:UJ+-X@\=#3I6I
M)"P$CHMC!6*&"04:^4A')S**YEUG*!TU$UNMRH!AZBFW.4-QVWUK#OGZIN1\
M3Y%CRP?DM0NQ<XNKC*#=/IZ=6ON,'?J&V[@F!M$ML>W2S,NZHJ:2BYWHS^65
M&]>Y5[JO70BX]\E6N8PG./'$RMOV3]YA^MW:[9"=1J:"+>4R)E>VO9UY*KIM
M4TD/6OQ:1C6VP`'EE;](``!KJQPSDW_,.+X7(W]658C)_!TUI\#A[[G<1APG
MFN;L&-W?T^%SNL=W7TII2C%_&-:,8-U<Y8`:`RF/\]9_TIO_`"I-`66?ODWU
M4_$?VM<9?J]9MT!6B%$H;]1>K<-@\1#8?L^'IT![+'>0;ABB]U')>/9Y[5KQ
M1+%$6RI6*..!7T-/P3U&0C'[<3%.03H.D"CTF`Q3!N4P"41#1=069G$7F9/9
MWQ-VXLMQM995Z^<H>+V;)+E7*4[SZ]7[6ZH]Z;XYB)%XW=/GI41)<6;I=,B!
MB+I+2)BH&*0PAJ@[_=5K#G<E]-%7\3*WM'A?G>5V)2A&<8WE*GQ2;JE\/V]&
M=W=V$C6Z4VKD5,)V&TGDG3J2DFH>K5F$8F=BLUK[1)R9\<Q04^(==03KF,CU
M?%`?'#F?F0@^ZUK-RU^"_P"YU+X5Q?-W;)GF[C/LQFT[4:ZMTI6GA1?O.KN[
M[_$_%,SA5O-(TA#*RD;79<BYB21(^5D7[=LHX0.R=,5)"+!,QUB(F4#KZ0(/
M3MKSV;D\K6X0Q*M6IM:4\>GX%(]RO:R>\<=W'*NP=W*L6I.$M4NVE4G7I)?Q
M^)%LOG;+FN+/>QX58>SRX@LEX/SAG3%,7#7^LL7:T#;H>8M*E<=0LDQ=IJ+Q
MMG9/R@1=N8RGE?%.FH8I>K6?,2[&[:C%?4DJG(3<L/*P\^YBY<>W(4Y57V,1
M]WR>3,-DGFCF3`V.X6-0Q5QOO4WA:JVB19INK[9F6.)F8BCIS$T8I"H0T=,N
M'9&S9LDB"H$(JN=8X$$DR2`R9H#TM,_+"I_G+!?A1KH##L?Y0SO]LRG]>7T!
MTV@,^+8/9218QL<V5>OW[MNR9M$"B95RZ=*%1003#X3JJ&``T<>[Y>E2*3E)
M12;DVJ)=6_!+XLLZ_=^^)-HX[\)JVULS0$I"WR9KH^9/4%"K-3K)G32`$%FR
M2J1S*$!0!`5$U""0P#N;8-%_>3F&VYO(\K&Q:SO0MJ#I+1.+T?377P-V,3$E
MPS@&S\6W!2M[SZ5Z_=AW5[%DW/4C%O\`Q*+2?1^(]/'5\M3NZTY)/O5HN8(L
MR226$5`<?*")R&\M#R")LC$6.'_C-N&_AN`Z^O9_G^Y9^]XFTYNC2DJUT2JZ
M:4\B8W/<+F_\8M[=A6U/+Q[JN-KK%1TIW:N55]G6FHG?D5D)M3Z_:T)4BRK2
MQ1$B9JS%J`-@!:/,C(MG!$2(I*%=MCJ$'^,4`,.^X^F^=ZVK-M>XTLK;THVI
M>G-T?:FYZ4[:>'F9$X)Q"WO&WSR9T_)8=F;O.M9>G&,I52;KH]?-T\"KY[DN
M`V^'\ZR5@K[59M2[^Y?RD2DN7[LR?)JE.Z:*CTD$P+-ETEDS"4HG`QA$-;6Q
MMRMV;:G3O=M5H<Z-RE:GGW[F(J;?+(N^DWUE!7)*K7@ZUTU&[-"1#0#P'8&^
MN3[>_P#G]%?@&?T`[%[YY]:IB[V+\7?2IG#0$1W0!H#[+U;]7QNDHEZA#X-Q
M\-Q^WI5K5=2*[:_-K'Q):7:$P%<*QQC6E9@B[1SDRR*VR,C')?*6;0HM&S&/
M/ZNL)1\R410%8`\>I,Q/`-<W_P!6_-\2YR^UA8\82R+-KME*JZ^*I3S.[?Z%
M-FO^WGL39W#?924=SRIY-N$DUV6Z=L7]_6NGD/,PC)Q3H%U&).'$8NWFD7KP
M0\P'9#$3'X@)^81$13.8/3\8H`&VWCK1[,4-TSY9%VVKLFDNU:=-/(V8W3,Q
M^3;Q#,E:MWK-S&=J*HDJ/^:M&^G@NIA7.[J6N&CX*5NDM)QT9YB;4JSLR@D%
M[U"91=(=S*MVBA`$"'$P"(`&P:NKV]VN_MG)[-[(Q.Z<KJ=>J23K3H0V;A5K
M9;V9E[9MN-BY>;;:G)1IKVN-8/I"4J]4B%KW0,66O'G*6U3,XLM(0=^1:SU4
ME=C';GC6;9"*5C$U?%,3QBK,-R@/@10H_#KMSQ;<+6X\<P[MI)=ME)JE*/R^
M)^>?WSXED\*]TMWV/*;=V.7.=7+NKWR<M)?S)5ZC=/4/AXCX>CQ'P_@^QJO&
M)`$PCZ1$?X1WT!^:`E^>];?DKV:?]/\`@_P=CO0$0/0'Z'I#X?'T:`F']HJL
MO8'@I%6RR.'+MQ,625C:E%&55,X"'4EGTL?U1$3)F.W*=-(2!U$3^Z&W.4!`
M!P![Z[ULNV8&/+<+BC>C5J/C+Q.I'_QV8/(<F>[/$:M;>VJ7)1^6+Z/7[:_W
M,<"BW]LK"CXR#EY#JOGC18$!5,`,S"<RS=WYR96O04I$?CE)_&+\/PZY@\ES
M>/<GWZ]FX=CNM-TFO\5?&M-/VG6O+V_8=ZQX6LQ6LJ5JS*-R2BOGTI2FOGI7
MQ%>4WG+FJO4JRT15*#L,F]$J[.3=M0*FU1("9$(]JFB*903622ZRF/N)A'<1
M\=2.P<`L;W=?'+&5D8>RYV3%SMP=:-4JT].JHJ4TI4UKY?\`I?\`;_(W:QSG
M"EEV;&/:N2E8C/\`W)).3;DUH]::)T2(,?=/Y'YXSYRBN37-KM-NG0WKJ'I-
M:8)+H0\/6WXEDF;ILBX.H<SN40<$.NIOXG#I#XI`#76[V=]K.)>UO%;>V<5M
M2C"[25R<W6Y.356W+RK5I>%3BM[\^X>_<PY;D;-N,%8V?;,B=O'LQ\$FU&<Y
M47?-QIW.BJV-FZRZ8)#0"FN%/Z9/$KVFL#?2G5=`6Q'O+OU(7.S\U\2?K"8D
MT!3NZ`-`&@'(NU":ZGYL8JC:1)2<2_FR3D0]>1;A=JY)'/H\Z`F!PW4270(F
M^.B83E,!@VV^$=2>X+OP+T/\I<G$,C+Q^38#P4G?_.6^JJNJ\"</?&K1S8S1
M\*FJR&K*)1B3M(0`?_QA4FJ:RB12$\@CA!$JO4NH==4JN_D(E`"FYU_J"W#C
MD\+^ANU"]F-KN3=&J/X)G>?V:EOEGCTY[X_4QK\>V$6J:-4=.M?P/;8UY-Y)
MPU99"3CW@R\>]<L4I=J\.82%;EW(51(P&.L8`((@'4`%`=A\-:C;+PF&5F+_
M`(Y*>-NRTBXKN4]:]KJU2K^TJ?/O9'A//MBACY<5BYF/:E*W<27G5U3HEKXC
M7_?D[EV=*_A21QE'TDD16LQ,OD-K:4G1%4V<+)1ZBQG1A(3J64DVJ:R21/XA
M52&$X_%*!M]_T]?IOEL6\V/=#FEQWN40M-6K?:E&VIZIU[GK#PT53EA[X\HV
M/VYAD>VW$*WLS(L2CDY?=1ZZ7+,;:35/#O[JOR(,0FW\/@#X/^[_`.6MY'*L
M%'R-,.FA\Z^0&@'3>R%];OVZ?:QQ'_>1MH"?-[Y5]4I4?;'P[]'V:-`59F@#
M0'=5X9$L["'A_,^5RS$8,7Y1/,5^40>(BR\M/Q\P_K/3L'PCX:C*-;4F^B/;
M'E*%Z$X:34U1_>3`H,]@_$F'-*.G3^=D&$?,STS).5G*_6BR;LBD!VLL=8#)
MI%*1%,@F.!"E(`E`I=8KY5>Q+6%>Q+D/4E/NJJTK5=.CI7I4Z#>P^R;WG;AB
M<JN7+D]MQIVK::33A-25&XU^:*?5Z:"EZ0@UF:&[:H$`'7E+,TO..8ZI'@LU
MW1%EF^[L4SJ+@78HJ&\1]'IUJD]DV^&Y/'[)2OW;CJJ](-/1/Q:?B=?(<LW"
MSM,,J]2&/#$24J=9Z:M>&E3=^*.:BE/HZ$>I!S2\]4V2QS3)006=RR6Q"C',
MV0*%0;`FF?I(510YQ-N(;;;!@_?OTL;QR+D:R]A=IV+UQM0N3<96G_-+_,I/
M5=#5_F^Z\`PX9F^<OSXO'M8[O3MQ27:UT<=6Y.7C2E/B1.>Z1S5;<K,FKM(E
M!\2,KTPZ34/(E5*LT/'F=,F\00%P*JH=LJX<*+GV`GF'`I-P`1UT6]E_:K&]
MI>$V./Q:>7<;N7::)W7]4J5?5:');]0ONWB^ZG+;>1M-N-K8\.Q&U:2I\U.L
MM$J5\>HU'K+1@`-`&@'..[S^F@/LI]OS]0OC=H!L?0!H!?G;&R9F+$?-#$%Z
MP?8Y6JW.)D7PJRT6LNB!(55@L1^VD/(42\Z-?&%-%5,P]*A3](^G7E>TM.A-
M8+2S;+?3U8^%?%>!(FD!?9FR"FT=B0II6W&6D!9_<&Q7CIZH\EEFJKEXJ":*
M`K*E`5.D"$#;K^'6&.1PL7/4C==)U=%Y^9UA]LKF]1Q\6S9M.-B[9@HWZ]%H
MY5A3_P#(V-89>.A):JJIKF%J#PSHH',8!3:^OG2;J*J@9='J,BF`[]7@'AOK
M63EO'K=RQERA"4KTG.:5:5:CI'[VJ'3SCG((9&UXUER7JJU&.KT;I37[1>[#
ME_2,.8QD0+(MTVR[<2OG952&.)7">XB=3K,D".^_QM]@V].M09>R7,N5<FA>
MCC2E"=V+HXO2-5I7QU,,>XO$]J>Z+EO*\NS:V['?<OF3IVIR2I5/HB#CSZS-
M$YTY-7R^PZWKK=VN1HI(^>+@KU=NJL8ZA%Q$WFD1*H5(#`(AN00#P`-=DO;_
M`&&]QOA^#LU^BNV;*37EIT^XX5_J"YAM7-O=+<=ZV77;?54(-:)J'RZ?#XB+
MM7F83#0&4Q_GK/\`I3?^5)H"RS]\F^JGXC^UKC+]7K-N@*T+0!H"S`[8$@PP
MYV+<#Y=CX^%EY.JX;OM+@;"^13<*H3EVS\TLQ85J?<3%1)(3IW!B#X>8T(/V
MM6]R14V^ZZ5?;_$S5[*V<BYR3'EAO_RO63<?)4=:ORII]YH^TY>M<G9)^*1"
M.C8>2=N%",&>R"J"JR7G'<IF#<^ZBH=0AZ`WV\-:9\VWS>]LR;ES&MTM5?B_
M[CO=[;\4V/+V#%W6XU++A:C6.C[GY-JE/P/.5F=GC7*!%P\06=,`<.V`*@(J
MD7%N[*FZ2`W051R@)S'+OL.Y?B^.P:EN$;IE[EF6KN1.MSOK]G30KONA@[=M
M_!\J>!;C&=Q-2C\>W77J.Q\.G<9R2Q)QKCKQ2*C;L@<8.8^-G_XS3;(KZW5Z
MDOIMU-0\]$/5#"JDNTM":#5PJH!A%J)?081'6ZVP93R+$4XTEV]3\_'OAL-S
M;>3W,^,>VW?FY)45$Z^'VK]Q69]PJ+<0W.WF&P=JF6<EY*9F=K*&#8QE)*_3
MDD;J`0#8P"[V'[>K@,(B.]`>EIGY85/\Y8+\*-=`8=C_`"AG?[9E/Z\OH#IM
M`/:]C/B%`\G.6L-(W-8C:G4`II605,FFKT.$F3EZHL";ALZ:&,FS1\LGG!Y8
M'<`/I``UCOW7Y1/B7"<O<L55SI]MNU_ZI*C_`&]7X&7/9?CEOD/-8+(M*ZL*
M"R(VZ-QN2BTXQE375]54LY\0L:]6*S&LJ>S8MJ]\G@V;QC%)%LF11!$J)^MN
MRZB=0E(!BD$NX`8?@US'S;^XPO3SMS3>5D7)2?WJM*K]QL+S2&=G;M<ENW<L
M]33<FND>D4FZ*B6FGD?60909&4K"31NLBJV7%47!%#$-T%$0$GB'EMS`/@!S
M;>CT:R1[1W)7.7XM^VI*XU+]FG0G>*X$L7;L^Y?E%VIQ24=.O[W]B--9!AJE
M9HNP1]CAFDA#1T,F[.BY1`[HG2V'[OY8F0`!("H%!,2F`3?&`!W#5_>YW(M[
MV;W,Q+FV.4[US'LQE#PE)^:\&O)49>O%KF[8,\>&!<<99<W;E'^6:DZ.,M'H
MU6KT^X@C]\*G8J=8\B9^B/WDDXK-K;$=KO67R>+)R]<.8M:+0:I?^F2:)-_+
M`O2(B(EW'81VUN)PC+W[-VY7-_LJS?<EVI>,>U:O5T=:KP^PU9]^>/\`MSL'
M(+6-PN[%9G==67:MS]2U"]5MQC*K27BTFTI552,`;8#&V]'4.W\&_AJ\Y:2:
M72I@%5HJ]:'SJ!$>`[`WUR?;W_S^BOP#/Z`=B]\\^M4Q=[%^+OI4SAH"([H`
MT`M_@'QQ:<DL]Q,!/I'-2*DT_'"X@&X$>LF#A))A"&-N&P3$BJ0APW`11(H`
M>.VI7-O?E<.[D2=%"W)Z_!-ES\/V:6_\GP=KA6EV_;32571SBFZ?9U)NN*HE
ME$1,5$LV<:BT9I-UDUP$6S=JDBDD1FBD`^41!)$I@)T[@4`#T[!KB9[YY\=S
MYSGYMZ[*JDZ-:M:]*'Z+8[;M^R\.P-LL2G'$Q\"U9C;2Z)Q4I46KU:K7J>FO
MS>4D6L\U4=JL7*#M)Z^*U.<C=1NL`J(HB8H^4]%?X"E.4?C!JQ-GR<;!G&^V
MYN2771U^SQ*YQ6]@8N1B7HP5VS*+C;<NJ<=&Z?RTZ.J$N.H-:%>K*.BN/40*
M`)+AN(I`H3S2E`3',)1,;<#".X%\-];;^S>Z<7MSE#?+4)0B]):N2?A37SZE
MR>ZW_+^3\4CB<%RH8V[R:4^[M[91[DI5TJGV_3VTU&O.[)BYE<^+"]T(R$)7
M%]KC):-=B'48T7*JI0TVW*X`/NB9B/$53AX%$R11#T:Z#<,WC"R<)8^)%>DZ
M=M/!4\?+[S@Q^J#A7(]BY"LOD-VW=R[-;4G%-5<I]U6Y:R^WI0BV#Z1_A'5^
M-4=#5)=#\U`!H"7Y[UM^2O9I_P!/^#_!V.]`1`]`>RQY2)G)-WJM"KJ/GSEN
MGHR`C2;#T@YD72;<%5!#T)($.*AQ^`I!UXY%Z.-8ED3_`-N$6V5/9MKRM[W2
MQM&&D\G(NQA'[6Z$[##5/98PQ52L90Z9F\+6X"+KT+ZLL4HLA:H)-9-^/08?
M5WKM-$QSF4`1`#^`;:YF?J)Y9'F6]NU9D_1Q:QHGH]-=5^!^@W]./M%'VI]M
ML?;+KIF7(.Y?MT=).3E*&M.Y_5%T35&J&S<SB_=Q<$U9+)KC$Q9T0]6*)7!4
MMNLIG9@/N^,1$2B*@_9$=:R\%497+MF\EZ5>CT_;HS8;VPCBV,S+N9GT7[Z=
M)/1>%%7Z:^74T77F<LX([?%DCI.3H.G"BKEPV3;."M"&.H0CA9<A2.E";%21
M`#'4$-BAOK:KVTX7B[MN5O+MVTI6[FFKT=$Z]?\`H>/OQSC$XAQ>]8P[-O\`
M-.#[(O3Y9*C7A6NNO48;[R>'5$'^-\YM8X$SR;1:EV5Z1,P&>J,S*N85VZ,`
M`45D"BJAU#X])DP^QKH9QSO6TV[<Y=TX/M?W:?P/SC>^F)!<ZR-XLVXV[692
M4HJK2GY=7TZ?<,4:KIA@-`*:X4_ID\2O::P-]*=5T!;$>\N_4A<[/S7Q)^L)
MB30%.[H`T`:`?\[&6,'$7>[YR2DH]15G4$&]+J2IVYSHGGGPEDY1V!RAUE"-
M(1H`"02CYBH`!@'?:F[O-PVZ\H.EQQT\V7_[983S>98<?IA&XI=W@FNCKTJB
M2]69H[VP-DW2B<>232=)D!J<ITFZS@IU$P59(;H`JJKZ2B910.K<QQ'<=<J/
M>/;;F5O^1GPJLF%V$9?XEWRIJO"I^AGCN-W^W>)N.):B^V,))4HG&NLD_+QK
MT,N69O8":CHI^JW1D9)-H_CWYGB+5%F1R44]W[DZJ;E@V,J03";<X%)MOMN`
MCECV1]OMMN;G:R]QDNV*4G'RE2NOE*G@8C]]/<K,V/@=Z]QBP[N=.$[?1TJJ
MU<:=4EU:^(A7N"8V#D+QXR)0K'$MU)*L5Q]8J>Z2!-R^9S4.V/+,';1^V33,
MY;NEAZ#@(J`H54Y=PUT&P;5BQCQAC4[>Q*J\:>9PHY1NFY;QNMW.W*3EFW)R
M<U6J575I?Y4^A"&.4Q#F(8HE,0PE,4P;&*8/`Q1`?$!*/AJ;+:/G0!H!TWLA
M?6[]NGVL<1_WD;:`GS>^5?5*5'VQ\._1]FC0%69H`T`L'A/BW_$7,T-(/S(H
MU^EKMYZ26=%5\A1Z`JEAVQC))J&*)G9/-WZ1_P#+VV\=]?%V?99EK1%8V+%6
M5N=F-R/?95R/='777X:DC-U969VSR$^4&DN@R1:>0NFT<LF"W2W(*B*31ZFA
M(`=DINB;J\L#*$$WQBB!AP5S#'OY.3*,9_+.;5-.CT.M/L#N>RX&UR_+6,JU
M.Q%1:^7TVDM522;:?G]7DZBK\"2C5]3IAPJ"AE&UDK!4$C&,90K5N1X1\DBD
MW,5`$4T]C+#U`H4NQ4MSF':T\'CL,#/LVLR'J7O44E+71>55I^)FODWN?FYF
MQ9SVE]L8XSMJ#[4JIUKKK^`D2W6_\5[+8V$(OZX8)>7:G,4I3J%(1\X*F(=9
MTWK9)1,FP#N;J#?J)\&MC=OVS;;%B,[-JVI-:NE77[=3CW[@\OYON>X78;Y>
MN)VI3C&"HX*$GXT5'W?YJT\*#`'/JB)UK+Z%I91(1;&_0R4RY!$@E:K3;=86
M\DJ3XH$375(9$ZA?28PB<0W,.JLDHJB_M^)AB47W5DJ-?"@A;42`:`-`.<=W
MG]-`?93[?GZA?&[0#8^@#0#RG`#'1L=0SO),DD`6"WQJ1HPIP(B,57#&.*"_
MK*Y!!-:0.(J"``8>DI``-_$)'<;WY?"N7*ZI?Q1D/VTV"UO_`">S9R).&.IJ
MK2JUH^BUJWTZ#R^`)(RUBL$HHZ5;C&5^;F4#*J+-RN7R\<LS1<@J8%E%3>L.
MMR;["KOL`!Z=8$WK(>7?E<DGW0;I]_[SL#[?8=K:,.UM[@I8<(Q^:55*.FNC
MUU-993M`I6UNV3,04XZ(BV2)43$1*H?R?6#*J&*8025\Q8WW,Y?@\?AUZ87%
M[>[[9#+[5^84TVWU>O2A*<M][WQ+E-SC6+D659].78G&7=TT7=T[J]#4$Y<H
MR:KTS4)R+37A+$T=1DB4@]!2IR"8HKG*@4/*(N(#OU)=`#Z>D!\=97XWQO%V
MZU'*=N'JKHZ:IFA/O;[W;QRQY''U?N0FZON4W3Q5-'3QKT(VN1JFM1;U:J@L
M<JAJ_-/HY)8NXE7:I+&,S<`(@`CYS4Q#?[=7:C3UQE#Y)ZS2U?FSQ6HD`T!E
M,?YZS_I3?^5)H"RS]\F^JGXC^UKC+]7K-N@*T+0!HNH)D?9X[FU8M?;1NO;+
MM%:$V2:ADF.N.,IGY)<R458<?VBS(3-J2E'Q7:!("?I\HU3!FJ!3$717`-NL
MNXT;>X=^)*TEJZ?L,N^RVYVMJY;#)N3HVI)_?%T?]O@+\J\%'VRQV>447!)K
M#14W()NU=B^:Y<+,RLTRF5(!OB@L8"?=#B(%'<@:P!S7CMG,V^[ZS4:5:?QZ
M4.P'LCSS<H7+6'CV[DL.26KJUJ]=74\M<1_%B69N!>D=^KOTPZXYRIY[55HF
MV<`84@^(MUF6,38IPZC%V#Q\=8^XEL6)ME^'IONGW5K73[#,GNEON=>X]<>-
M:E^7=9337XTKJN@IGC1S^P]V^V68^4&73SYXM7%-J0AJY7HE[+*W>VQ#EJ_I
MT,\3)_Z9LLYEE.DSPX(>II$$ROB40UM+Q:[-QBGT[#CO^HO+P]RM0NXL5&<)
M=*ZI>/VE=SF/)4[F7*V1<MVCRPL>2[I9;S-D0$YFZ,C9Y=W+N&[<RICJ"@V.
MZ\LG4(CTE#5Z&HQK;0'I:9^6%3_.6"_"C70&'8_RAG?[9E/Z\OH#IM`/^=D/
M*KC$EBMEB(U(L@I98]HZ%5LDX!>+<Q`-I=NW*L14A')$3D$I^GXN^^X:L;W#
MXU;Y3QB]@7$G."E<A7IW):>#,\_IXYEA\0Y_:6Y?+M.:X6;EQ?5;[I:SZKY5
MXZZHG,XUSO&0$E%RC:=:FJ\@#4Y@;*&<I`NX0(9N595`4P+Y1E.A0Q=B%/N4
M?AUH;R+BNY7F]MQ[;C?A/Y>ZJ5>CJTF^GC0Z,\K]NH<HV*>3B6?5SI6W.$]/
MGMIU36KZ]8JM6*<QK=PR[>AB84%3#%NI-P^4=BX<G63:%3$2-3MS@R.R(9<A
MA,<0Z@'8-]C"&;?:KV^>W[K@YUU0_,13[VFW1UTUHC"?-N.SX#QN&;NB4/S$
M;<8J*U[I1K5IZITT:5:/013RGY/,JF&8:<VCS21Y:(FJQ#+(2"C9-%8Z!HD[
MM[(%,JDL=HL4GDH$2!4>G<3%`0$:YNGMU=Y5[C?U:;4<;&R(S<JM.78_#2CK
M]J)W>[>V<-]L\'E;S;-K?'CRN6H7*QE*XTZ..CI2M9.OP29"3[I-O80>)XS'
MC1TB^7D[=$@HJEL8&J,<T=2;IL90YA,JH#I-$>LH`.QMC>G6TDXN,W\L8VZ+
MMIU:22K+XU.:^7<]:Z[[^J[.<WY.4YN4FO@VQA#7R2@:`>`[`WUR?;W_`,_H
MK\`S^@'8O?//K5,7>Q?B[Z5,X:`B.Z`-`/1=F&UQ<7EC+%6>(IJ.[+0XA\QW
M-Y:HA7YLX.P24#<1%(DN17H]!A3\?1JV>;*_<XKEVL2GYI6+DHUZ5[)4_:9?
M]@\K%P?>'8,C/TQ)9D82?@E*<5K_`):=7Y$M>&CF)XI56.D$C(BQ7$#G5**9
MA,@58B`>44?C@/\`%#;;<?@UQ3W^W&]R/*Q]UM78[G/(>G;X:ZZM:5\:'Z#L
MC<IW,FTKEG_1N.'IN"U<$J=W7Z=?-FLFES?OWDE!G;FD#*F:*'.+<RA#&0<`
M04#`3J3+L4OI`!.(_:U6['MQGS=G/MV7.PG71.OX4H7OD<:P,>U:W&W>5J<4
MZZJM'K7\?`Z*WND6\8\3;%2%PLJJEZBND8YRH=/6X5`?--T^4`=)0_\`EK-G
MLUP#*R]XF\V$K>+JV]:II-I?>]#'WN%S:?"-B_.J+NY5QQ5M1HVVVE5JJZ=1
M!7-^3CPX69\:RG41J]HBXMR=764LLA),U(U;H-\<HCN5(#!L4P"'I'70+@^+
M9PKWY:Q%1A&W2J\?BSD1^JK,W3?MN_KFXS3O7;R?;)ZQ5>B1#G/_`!C;^G?Q
M_AUDA=#1,^=1`:`E^>];?DKV:?\`3_@_P=CO0$0/0#@O:\)`'YGXP"P$353!
MG;SQ:1S))J*3)*M*G9$:J+%.FF\$H'\H1`?C>@-]26YV_6VS(L>$[4D7I[=W
MX8O.=KRKDE&-K-M2J_\`+)/3X^1,`B')%A;%0ZEQ*NF4I$U4$U5D#B#<"`F7
M8`6'I'J#T_9].N6W/^+/#W/)G+MC;=QT6M=?N/TH\0Y-A;SQRSD.YVW/17UI
M_P#MZ57EXGOI7KL#)1!H&ZT8FJUZO5U"/D&RC58>AYOX*$'R]A\=A\`UBCBG
M#[ZS[L)R=UIN6E7T\>G@3^+/^D95N[=4J9%R,GJG&J?5:Z&GVE?44$J2(`*B
MA6ZB*0I'132'XRH'.V`@$Z5S$-L&VX`'\&MO_92=VSOWH7X7%CT[>GC_`'&&
M?U<.YNG`+US#</SL(4A*OS)ZM:ZZ?'S$>]UVHMB\#[V>;CB-G1'M3M<"X<-5
M4O-4+.(1ZSF*ZR%!9LL`'2,H01(4Q-O$0'6\.);QL6/IXZ:[EK5'`7?\GD&Y
MN]/>*.5B33=6Z]LJ-]"&]J=++#0"FN%/Z9/$KVFL#?2G5=`6Q'O+OU(7.S\U
M\2?K"8DT!3NZ`-`&@)CO`+''^&_"K"_R<`E;7*(_&V:<(K%$RTQ9'*LL=N\3
M3-U$4*CY9$@.`B*:11#P#5F<YRKV%LLLJPGW0ZFPGZ:<#"W;W&M8.:XRCI2'
MB_QT'!*D1!&2C5$UP2,T4(*2P&,4J9]B`!!)N8IO..8`ZA'<!US#]PKNZRW7
M+S;D)^G*<92=/YDZQ_:?H$V^U9L<6L8.W)3VV&+&W1->&K?V'H<T)S!#UJ0=
ME<"J[CG:+=43B1-9.-?&(;8RN_F&3.M\`[@3I#;;8=9Y]HWN-G;<;-R8R7YB
M2=?LTU-9_<3$V?/PY;=:NVXJ'JOM;UJX5HJ>+_>=,@JK:WQ6UM.M(IEC$8!4
MYBJ"DE5Q:'21CHSI!0S=!FFX,9,I0$"`&MX]GJL6->O8OW'$SGN/CX&_W;&-
M%Q7SI_BR"=RAI#3&_(G-%&8'!1C6\BV>/9'*`@4[0))99L8@"4@@0452[>`>
M'P!JIEA&A]`&@'3>R%];OVZ?:QQ'_>1MH"?-[Y5]4I4?;'P[]'V:-`59F@#0
M#L_`-JS0QS;I$Z10=NK49N=4Q3;.$&\;'^6D=0NYBD1,J8=@_P#$(_9U([C!
MW,64%U9?_MQE6\;D=KU(1E62U?@."-Y1XDDJV54*8IDQ1,4PF3."1@V3\E3J
M*)B@3T!MX_#K%6]6;:4'&+]:#Z^%4=$.&3C9M92]>,=OS(RC)I_/:E-=O=;7
M1]O5:K46]Q3$)&%OD451`4FKRK.=U5"D4%%%VY*V,H/0*2'DN7!N@X>E82@8
M!#4G:M9DIPN75_I]Q<.X[GMUS%R,.,I2SL2TK/8J=U]4JIQ5?FN.E6G14KJQ
M*&2WZ+&^VDZGW4JUDE06=%,558G6\5%-0#)AL<!'83@7I#JW'62,"[D3MJW9
M6B\S3[G>1L&#D_E;L8J=[_<4J*2_RR6NJ^T0#W$6S)]AZI2;AP5:1:6Y#U,_
MQ?%)ZP>$=)I^`*`!B)IG$H^C8-7-Y5ZFLF?<A=O7;L:]DFJ?<QF/42EAH`T`
MYQW>?TT!]E/M^?J%\;M`-CZ`SXI`CJ3CVBH]*3I\T;*F_P#"FNX33.;X?04V
M@)#-8:HP[6,CF[51'U.,9M4$13+_`.G!FB0J/0FGL0=D@`=P`0'?^'5'WRU.
M[ASE#P7\49<]GLJQC<JQKEZ;@I9$$FNJ:>G[18_'5<5Y.Y$2,X`SBOG`6QUB
MK'``=,A$#"'E'!P82B*8@'Q?'XOV,+;GCWO62IYG5OB5]1QKF5E9$;ER=^3K
M6NBZ&FLNJ/1R'/II^9YB;GR3%*0I?$K=(A3+]`"'F]/I-_XA$=7?Q]=N!&R_
MK[D_NJ:^^]VWX6?O]S*M3I*Y8FJKJI.-%+[NIII<X%?-XYVY*19<P>6EZ5-R
M](*"4NP"<2%`=_A^'63;'^PCG5NF)/!SKV/<N>I-7'\SZL9EY8P3VNY]O\:]
M$IC@]8N452&ZB+-G46R715(;TF*8#B&X^.X:]442]]?W"=-#R#0&4Q_GK/\`
MI3?^5)H"RS]\F^JGXC^UKC+]7K-N@*T+0!H%U'0^TG;1K7+"*9^J>>6P5R:9
MJ.2'4!=DBR3"14,D0@@55-?R`*<IA`-@`?@U([A*,,.Y<DJM1K^XOSVYL1R>
M68]AM*,[B7[R4?0[`M#'OBK%7RTI1BD`D-L8RI1=@"YS`8H"":BB0=0>`*F`
M3!\4`VU(YUO60KN1;<Y^G3IW.G7R/T">S7#,1\<P;L+4.]0BTU%)UIYI:GB;
MA8%1EI)^LHJL#PB0`B*R:I4@4(D'3Y*FPG2.9,.HO@8=]P$!VU:O&LRY?G"4
M)23^#9F/FVQ8EGCUVQ-6G+T75-1KX^#-&\@I"(M?'K)U8(L$>_4JLE*QYEDT
MG!R/V#!P4#-T'7G)O"/4.M+IZ0-MX'_B@8=L.&MO%M.7U>FJUZ_><(OU08MO
M#S+MNS"-M*_*G:E'2OP2T(;"@"!A`V^Y=P'?[(&'X/\`=_@U?YIR?&@/2TS\
ML*G^<L%^%&N@,.Q_E#._VS*?UY?0'3@&X[>C0%@#VONT=Q1ENT9Q<R]9\LQ.
M*^3_`"ELMXLE-RDZL$BXQHZE%)&2C:AB+(!2JKPD'(#$P8%`Q#-')'BJQ!\Y
M0@(C&*3DDU5>1,X^2L:?=X>)VB=4Y`\<<@S&%<UU=U5;@R5!N=*2;KJQEC0<
M];&-L<=9VYUTYN"<)B91%U'@)#J$`JOEJE.!<;<PV3;5>EN'I)Y,EVJ,51.7
M@Z4\']6NO@=!?TP>ZW(LS&Q>)Y>:K]BU.=WUKC?=CQ@JQ]9M_/8I5=D(J5:?
M-0DS\>8:@8!KS:*L)GJ^183C[%6+(B0E12^3)^012E&+$A2D$Q)DD>Y(/4.Y
M2IIJ=0]0`759X]M&/M5KL<)QR)6XN=6FHMJNE%IU\3%7O5SSD?/L_OA=4MKN
M;[?_`"$-?]>U:;C.YUH[:G&2732G7J,L\N,"WO*_.AOQ=P2S=R)W,344UW;\
MRIX^%0LE7A[C;KK.+D*4[.+CB3/6NN<.M8Z9$BB*BA2C<=G;\?'5()]WB_%_
M:S`/)>=<OY1:]/D%^=[#4EV6Y4].U3^6W%:Q7P;8F;OU]OW@2MVCE\LX">-C
MY4XQ9@&GAE5BS.X?9QM3!F5/*T;.NTUA2>1K9J"[V-<)B9LQ%F9!`IDE1.,]
M*3E2O@BQYS<W5T2\$NB*\(=MQVWVW';?T[?!OZ/';7R?!^:`>`[`WUR?;W_S
M^BOP#/Z`=B]\\^M4Q=[%^+OI4SAH"([H`T!*?]U5X2X6Y;\I^2=ES=/E1@L*
M\=GCZ%JK*5?1,[(35VF4V(W-FNR,4%F5`80:JJJ2@+$,X>MQ.B<I3;2^5BPS
M+,K$W13C3\50J^Q[M>V3=L7=;';ZF-=4U55776NJ\/+H/H<C^/V0>)-S)7GD
MF6WXYMC7Y?Q?D*-'S*_=ZXX!%=M(L7+<YF(RK)NZ(#E`IA#?90OW(Y!UJW[F
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M6G;*WT[D^JFU1=.OD.'9"[1.$<E\(>4.$LO2S./Y"3''JRY`?VQ.1=N(_`DL
MS9NK#2(I\@T(FS$I',.!94#E77=M3K"D!"E2,.<]GV>&!_Y*E6[*-&O+X=.I
MS1]T?<"]S3'N7O4_\99"48T^JB;[HNK^7IY='YE5BNF9%=5(PE,9)4Z9A*(F
M(8R9A*(E'8!$@B'A]K5P?88.;JZOJ?JJYUBD`Q$B@GN`"FD1,1W_`/$)0#J$
M/MZ$#@T!+\]ZV_)7LT_Z?\'^#L=Z`B!Z`=L[&7%>&YE=T;BO@RR6M>G5R1M4
MW<K!)1TJ6&GGT+CBISMWD:]6WQV[LJ<W8&\(+5/=(_Q%#CML`Z^914E1]&J?
MB>^/?ECW%=AI.+3375-:JC^WK\"9/S1XDVKA5F1"MING$_2+`DK.XNN3E,I/
ME"/;."E7B94Q"F;%L-=7Z4W1"ATK)J)+%*!5.DN%.8>V.V;M*<Y159.M6M?W
M'1GV-_55N^'MLMIW2[-JW:C"-OY:422DU7775K4VO@[",BO5(_(,GY$C"WZO
M!.Q)DW9FKII)LW;N,DXE=($S`NF@[;"8JI=B%(`@?8=M["QO;_;MBC&%JU!7
M(6VFW]3KXMT7WFT>#[ZY',,2#Q9I1C<[:I5[;;Z5U^NGBM&^B-`7G%#K&DG'
M1,\]30F9FL-;DT:IG5%O\G2RCI=I&$<`!5&Z)2HB;S1\-M_$-M9"X7Q3%Q''
M-AVJ_+73I^%/XFO/OC[X7,E7-BV^[>N8UGY)3FTTFFZIZJLEYTH*SY*]IJR\
MO>U[EB/G+,:HY_7PS.7O!F/GK]JVAV]?K;@UH;)VTLFFX?LBWU=N8J*A%&K6
M+5<IJ&*)C+%#,%JRXTE-UE\#G)OF[7<[,O2MRDL>4W5::MNOAU15QG*8ASD.
M`E.0QBF*/I`Q1$#`.WP@(:F"W3YT`IKA3^F3Q*]IK`WTIU70%L1[R[]2%SL_
M-?$GZPF)-`4[N@#0`&@)GO;_`(7,)^`G'K(-YQ_/5BDV^!L=:H5QDX\PPUVB
M:-:'\`#^(?B5;U9RD$;Y8`8R*BH('%,#$^-JB[_AO<MNE@7%_P"/)ZTZ_B9$
M]M-]7&>3V-^MR4,C'3[?"K?1R?BET[:?>+EIM9EW\_%MF1T7B99"%5<N$TC`
MV;!(OTTDE'9S=(`D#H>D!-]SZA*([`.L9W?:79,B-Q9$.^5Q4?<JK\*^'@;A
MXGZS^00M3LVNVSCV9QBHI_[D).D]>U4:6M=1T?N#<=F5-88<;1K!VI).HV>-
M)N&@"L5!1(8YXNNJ5J0"(^658"."F`2I;D*41W':J8W`L#;,6S@V$_1M+2FG
MC_;0M_&]\[V]9%[<,B:4(7)3@VVJUC3L:\5I52\?(2?C*FQ=Q<.Z<P@9"<N<
MQ!)0-$BXQP<DP_MZCQ%>*5)'`F=-^R3;ME4UDU3MTT4C^L&4`$1*;(V!8_+6
M(P7^%+[-#4+E6ZW-\WJ_N-Z*BW<FZ+XMOK_`@1]R'']TQ;SEY+T+(D#)5JYU
M[)<BWG8>72\I\T=.&;%X3KZ3'16170<$4253,=)9(Y3IF$A@$9PM9M/HJ"(M
M"`:`=-[(7UN_;I]K'$?]Y&V@)\WOE7U2E1]L?#OT?9HT!5F:`-`/<\&\9Y3J
M_&8,HR-6>M<=7C(DA^(]O5:$<PSN=K)6S&6BEW1`43;.%5FH@#=<2"J5/K`!
M(("/E=MJ[!Q?4J&VY$\/)CE6O]R#7X"FXZ0;O9(Y%$R-RO712IG53$H(K++"
M04]P$I`3\W<I=@^+N`;:H%_88WM;DEVK73J9XV+W7O6L*>%&$H-+ZI276GP?
M0="X?TUU%5'*TE(LSH)-W#)K(@JF3K9#&-G4B5(Z*X`J55P=(HD,EN)R&``^
M,&^O%[5;CV0AT4O$K5WW+R\BSF[NWV;A&PG"4>G<J1K!=SI*G5NHWUDJ!EW]
MF2`(U7S;#-F49,O+]2.JI(.S`W:>3YRRI1'K+TF`3"/5]G<`N:Q9MXM/35=/
M$P'NV^YF^RCDYC4\BKDY-.K;\]>IYOO.]O>P8?XJ\=>3E5MWRQ4W$LO1LMT9
M58`?4^\23<SRM6`$3',K\E3,<@=$@*=2A1$BF_2KL'V42]]'WD9+424#0!H!
MSCN\_IH#[*?;\_4+XW:`;'T!O3C/@N^<E<\8OP?C5H=U<LA6R-A8DP-7CQ%@
M`J>LO)5XBP0<NA8Q3)!1=82$,($3'0$A#+^++QQ_RG8\59%CODVZ4.2+"SB1
M%A=,W'JR"8HOHU\U-T/XB5;&`Z"I!$#%';P$#`'E>@KEMP>J95=NORP,ZSG6
MI-7+5R,E1Z53%`\58Q_,VJQ.`9+&.%<7!0J8K(.15650+N&R8`H`%Z2CU;;%
M/U;#L.K'W#;+<I.ZTTDZ:_$W5X'[I2OQ_)W+BC&4)7'7K5+5=?PT-;923*7)
M-H9J-5$C,IM8IE`!)4IP3*FV>HBJ8$?66Q!3'RQ-X@!1V$-_":PMLCC7%"DG
M5I573]Q1.3<^_JV'=W.PXRN4E%5UHJ->?4T78:^2>G8$Y62B;Y%X@E&LXI!1
M1RY6`IFJ21D404.HX?D`H]``81,(B'IU=\(RMQ[&TXFIVZ-7<Z>3W5E-U:&)
M^25@<63.&1WSA-=$6MB<PB3=R"A5VR,`4D.1!4BOW1-0@LAZBCL(&$0VUZ(H
MMWZV:/T/,-`93'^>L_Z4W_E2:`LL_?)OJI^(_M:XR_5ZS;H"M"T`:`4SQ%R^
MVPAGNB7EZU,[C2/UH.73(;H5)%6%(8MRZ0/N`%69>>"H;^`@00^'4ME67?QY
MV5_-&A<G%=VM;+O./N%S56KB?W=&2]Z&\82T@9%J^,Y:3T2X*V,HAT*"Z1(5
MTRZS)FV$3MTS=`@)@ZO`0UJ%[E[)E6)7KD8?*Z^)^A?].'N-@<DXCA/#G&EN
M$6Z:/P3T9A9$BC(+1YP14*>28E,"2^Z29BHF%(YG`E^Z$.!B`/A_NZM[V^P>
M]1NW5JIT_8B^?>'DEC`VK(R^_56VE3[V(?YIR\E2^.]KFH5SY,@Q@Y)DUD43
M#Y)!?L5FA_)4$.H5$VZA@('HW,(ZW!XOB688\+DOI<-#@]^H/D61O>]--U2F
M_AX_$BN"._B/B(^(B/PZN8UL#0'I:9^6%3_.6"_"C70&'8_RAG?[9E/Z\OH#
MIM`3@NP+R;JW*_MQ9N[4ML(BYRC2I2RYKP.V<*I'<V)FFF$W/U>%36,91&P1
MJ"3V0C@3V!95)5,>DPDZXIN+JNJ/NVZ7$].OCJA:?%#N8VV)0QS@KDEC>K<G
M*=5;)"0N*)FX/W4+D7%\X,BC$,6#6],TG,M(5=%98B+EF\`P^KE!(RAD2E2#
MRG;M79J5]1HDW5JO;1:LKNSY^7M%Z[+!RIX5N[8N6YSB].V<:=K7^9NBIJO`
MD(-YRODRGSJR*>-')%:]4Q'$N*^1@@K"R+UU)(P3V)5L;1P(24*S=,T7@H@J
M@=JD<HJ^!C:H6!G86YQS,G`GZF)*2CW/Q</D:C\*I_<9*Y=;RL?;.-;+E3L8
M>YX^TW*2E*:DH79SNQDX](RFI+7JVQHGN(]VB$H%WY%4/#N.:_A_(,_8)7%>
M8>0<K8&4S-V>ATU)Q6H.&I2XHM&U28/8I,%50(=0Q3G$2!Y@%6"X68@6-=BJ
MW6W#[1L_F!D%$_N^-B9@*+F*D>3^1NAZ"Z!SE,MB1H#!)F8HG`R3UU-=0F`=
MC%VV\!U!'A=BHM*/D00!#81#[`[:B>8:`>`[`WUR?;W_`,_HK\`S^@'8O?//
MK5,7>Q?B[Z5,X:`B.Z`^P.)2B4-MA$!'<`$?B[^@?2`#OX_9T!)%]U^Y95KC
M9W'X*.N:K5"O9@KHX[=BX,FV;"$JZ&..*AOBE4%JE+&=]!O`Y&I@#81#3QH0
M?0E8S')FE8>R'R`X+\@J2&8>-U3RG=D:W%)R16.2<2K-9A^$/(T62,NF+6*.
MW$I@;G.1+8Y@(;H.HD>EYO;?N+%O)2LO\?Q,M;`L?%L6M_VC+5C>;*C\E$TX
MU6C3ZZ]#:.3F59_'-_-48TU4TV^)Z0J$*]#K<PT!-5UC+QY6RS-$&KMTQC7Q
M&[L&Y?!82@'@81UK]RS:UC[U<R\)2A<48KK6B2\NGB=/?9GF&3OW!L/;=VM1
MNR_,RN::=UQ2TKKYJJ3=%]QZ:Y9_X\<=7=,R9#4Z2MO)R,Q)4XR@LK)&*IU.
MI,)R/6DHZ[S"[@B9I&=:QKPZ":0;'1.F)?N0")QREQZ$+.%9S(+_`,EK72JU
M7X&E_N_O&Y;EOF9LF5?]/9WFW&TFE5QJZ47152U\:FC<V\RBX#[-W,[D9;I1
MU(Y`Y%3URQM'S+]T=1Q+S<I7`8O'S=7Q4.U2(_%N@5,?+*LZ*``!2B`7[C_[
M=?%FJV_*U;NQQ+$U+'C5JBI1U\7XE8H#MH'E@9B4PEZ?--YZH"J/AU#Z0`@F
M\?@](Z]BAMU=3GE7L2[(W+&1(Q@IE$%S&=JNS.#")AZA,IT@0"@(!L`?!H0.
MET!+\]ZV_)7LT_Z?\'^#L=Z`B!Z`<%[566O\#.X3Q8RIZ\:/"HY-9/?/(X]4
M,H=6.D6J+('0F*"'RBNL5OU;[?==AW`1#0%F5G_-N%+OF?,W$GDY*.8O$^37
ME/R_@/+JR9'SC"]HO]&A[`0ZRX^8HWITR^>J]0@/JY%%'"2O2DH"J/Q.$+BI
M-)I%8VG/S=JR(YVWM1R55:I23KIT::?P.TR#B")I],PI!XJOU0R-!4'!-A@W
M2-546>_+THA8'C*S6^*>"Y!L\AGUD*Y252(H94IRD*4XE`3:QKSK"RHWK>7A
M03M.VU)?:^OW&[/Z:^:X"VS+V'>X.&X7LVW-7/!=J24*>%?PK^!YA6'XZQ+?
M#6;N1>3VDTIB['1$G6)$%FSR:RC;H^74"O1\<U`52%K42^:+-I$PJ&155:$(
MH8"E-YE=XM'%N8-J5N7=)12E\)>7W&,??5YEK=LW$QL7T[5S*E/U%HO3:6DD
M].YO6M*ZG7QW-9O+\2>YQS"O[UNLU8XWG*3!Q;1\44ZU&2U:E(FMUN,6ZDTR
MH(.I0YU1*4IC&:'./QQ'5X=&S66ZDH**Z(J5UC@HLJH`;`HH=0`'?<.LPFV\
M1$?#?0ECCT`IKA3^F3Q*]IK`WTIU70%L1[R[]2%SL_-?$GZPF)-`4[N@#0!H
M"VH[>EXP1R/[*';YP]>H1K1JUD_%=8P/!V-DU;(,*3G*C5T`J]A`A>@$%K;+
M1RKCS!$!6<.C(JCTKF.$&DU1]"*;3JG1FHN#^`[#B;EAFB@9OJB18K%V&LB.
M,@EDDC.(-["K)Q1*].MGRP"DO'2IQ*NS7_\`XRF$1`Z9P#Z39.NYW+1JM*?C
MU_94=FY0'KM[Q9?X\(1-E>U.+(7JIF8IDLCJ/B&TI&.)X&2J`%<*E239)E!T
M&WK"!CJ$$_2(:\+O<[T4J]G;_$KEF[&&T6(J='^9DI*O\O8FJZZ*O[=!%'#^
MK-N/M*@>4-YC$'>3LPRT5BOCO!3!`3<J,9]RSCY2\OTRF26*S7;@!$!^*IZB
M7T[.@-KV=*_`MZ<W./S/YJ5?VD./WQ>.J[3NLP;N$K\;$3LCQJQ@I=99@7RU
M[7-MY*TH,)B5*!A`\@TKH,V!3[`(MFB)1WZ="6(H8]/24"@/5X]8CL(#X_%Z
M0](>'I^WH#YT`Z;V0OK=^W3[6.(_[R-M`3YO?*OJE*C[8^'?H^S1H"K,T!^A
MMOX^C_\`3_YZ`G?<&,V8WFNS[Q^-8<=(N\`TZS'PWR3AH$@GEH2;L:*H,,PP
M[8ACIJ.NDR1E]P];,JFH)3[D(`F3%CHQ*G)_A%>^.61L;(`+"XX:S"VA9;`^
M9*PHB\JF2*],+H?)KE6116<,F]NC$'R99)H84E0.0%2)@'5T_-*Z/H>W;WNF
MKUZ)TK\!PV4E6T9,<D*]4H`7"-!A*)'OE&S44C2$JI"MHEP^2`Q3NGA+$50N
MQ4P$$CG,)A#<`#S]"U6KZKXE>Q=RW'"L2A;MJ%OM_F2G7X:U/0U/BY$6_F)<
M,N7A)&H\<L(X7K&<)Z>407"):28U)FG"T5`79-B6)[:RJMTFX"HH"A2"/@<N
M_J]2AROW,AN]<IWM^"27X+0;-[P]U6G.V)A6URCH6DSG?(N4[ZZC2JJ>6O$P
M>1HZLUPP)D,5`R+7Y+4;("!1Z4VXE`0#8-$>5WZ"'@;TCMZ-QV_[=1)0_-`&
M@'..[S^F@/LI]OS]0OC=H!L?0#GO:%RE/84YL4/*-:611EZE%32Z0+%Z@792
M)6L5,-2^)>DSN)>+)]>X"3JZ@\0T!,%[OO%H\C"T'E/4&[A1`SB&H&09$4]T
M&3^S1,;=::[=*)&,"#-ZTGE"D.IX?^L03+_%V!&3B^Y=2=HI1H_)&L,!8HBH
M")Q79'TH1M9<H8FEI)6/<&<(%<M*Y9A:,IQR=0OE@J]9QJ@ME`,4#F)TFZ@,
M`:I^?9M7;;[UK6OEJB]^#[I';=SEZFJG;<577K]HD[D106M5:U.^Q+I*0_Q:
ML&0;$W7<I,GRZ*-8FRLT64DD8I&B9VI3"=5$NQ/C;^.X;_&-.4H0;ZZ>!,YF
M7?VN61M5VU)^K*3C*KHHOX=-*F\>-.-H?BPQH?)3+L>X>Y#R//)OL+XY522:
MNW5815!*5M;]-9-56(B%04\%B)@L"0$2;B"JQA3J3,?R_P#V)?8,!>\#4C$5
M0[C^2)#$=44HR5ZK51O.0*F1=->+B<E3T:5>SG@P222\AC)#Y+A9,X=0/5%S
M>`&`-1)>]]?W#).AY!H#*8_SUG_2F_\`*DT!99^^3?53\1_:UQE^KUFW0%:%
MH`T!(+[>78TRCS)XAY.YD)SS>N0V-EE)^FU]=1,QLHM*X<7$]7(Y84P1C99-
MNV4734.J)3"F"`D`Z@"$*.2HM&3F#8C>NIWHMVM:K[G3]HX#@U\^BV,,\DS/
MSN(->'3:+@=0J`G17$Y&RHE\Q1N"GQB#Z0`1'T[^...8;/C9F)*W**<VWK3H
M;J?I8]R]QXO>>U5N3MMJC[Z)+NZ4:8XMR%HI#0D%.1[83>?+('BR$*90[AM.
MLD5VQ#J`<Q&Q6S[=-%,?C*>DW2`>..>.;+;Q[ZM6XJBE_9FZ'N?[@SRN/SE=
M;<7'IW?#[!%%DXPI<JEV7'V;=.HII:),&4LZ8*K*24:1LN5!P=NQ:HKBNY7<
M+E1(0"B4%5"B.X!XYWVZ/Y6S"#5=#DQ[CY]W>][NW,=.,876NM:C.7>9[+V4
M.U)<L>2[BPL,@81S%'+N:A:XU8SMU5;0Q%0TQCJUN`;-$%YB,0*"J3I(A$G*
M8F`"E,F.]7,=7;?I3[:U_8,@Z'F>EIGY85/\Y8+\*-=`8=C_`"AG?[9E/Z\O
MH#IM`;[XP\C<J\3<[8TS_A:=<P&0L;6V"LT&X;AUIOE(F4:/SP[Y`2G!U'2Q
M6_J[A/8?,24,7X=`2*.^[C^0[?G,F@<B,%9@:0L;S8K$)R@<<55DYC\8\(M;
M-%5J5?-YQM(QR3"!C9JZN99&(11%-XW^3E!43`"@&H22E!VW],E1GU&4H24X
M.DXM-/R:U3'Q^+?(%VKV`^0_)DCAX^L>4+-4JU#.I#Y";KO;97I91TBP-*'G
M_5CO&K_J*=15FD^0-N/W=(R1TO''PL3&MJU!OM57][=?[RX]XY/O_(\FSF;I
M?[\BQ;4(2I_+%**7X4_`@8\H<M9[R-DF<5SE8WSV?.[4DEH9.2*XAV9I00="
M=-%JL=!=RL`@*BJPG7.;<3&^#7N6T21<IX.S)8/=2^-]TH+B4OT>RYDV>W9%
MCJ4BZM;NNXV<0%BK*/XTI0[9\Y@6-9GJRS!WZT*)6R:J(B()J!N!$?'TCH#\
MT`\!V!OKD^WO_G]%?@&?T`[%[YY]:IB[V+\7?2IG#0$1W0',5;I*4HIIFZ3`
M;J$H]8@'^Z)M]NG_`&;Z`]-7;A,U">B+75'2M=LT`\0DH29BEEV[V-DFJA56
MSYLH"A@*NF<OP@)!`1`0$!$-`2HO>!F5_P`.Y5X"]R.EY5:57+?-[AQA6XY-
MQ8"[QE;HJ\5C'-/0MEIL-0>,4V2E.N+J7*@(.2]:LDT="!`,`G`1BW&2DNJ=
M1[[LR9I5YF=OGDQRARLJFUL^/X>1@+S()EM"$:V=TVOMC)2D>,:,B1!JWKB:
M!@2:@B\0)X',9(051MW?..XN[P=R7^^U3\.FIG'VY]X-ZXG*WB*[*&+";DDD
MY=>NG]O/K0AO<H>Y/GWF!D*/QA`W%'&V-)*<A,9UM9M*#%NW%21EP@JXZN=R
M>KE=(Q3-DZ!19,JR#9-#?S3'`HF&LXF+;PK'H6?HHOV&,>3\CRN2[U=W3*T[
MY.E/B^OW]1\OWE?%&=N*W#OM:<38<+#:.-5!PA*RUYRI6&CF9QW<,S2<TQ]3
M1D+RV;KQ;EXC`H)N&(*+%]<06*JF!P)\69+>N24I570AM;1?P^O`.^VP"@<-
MA+Z0/L7?I-]KQT/@X%P9@0!;F<"?<>H%BI@4"_!L)!$1'0&+H"7Y[UM^2O9I
M_P!/^#_!V.]`1`]`9;!Z[C7C5^Q74:O63EN\9ND3&(LU=-5B+MW")RB`D516
M(!BC\`AH"77W0LL<F(3M_P#9?[E];R3`(N,E\=2<>\K51VZ;J.KK<<53EF+7
MK&^K"Z8'EHQ:J,%F3UTW.FI'*IMR;AZP0VA,6\F[:2C%_*AWGL(=P1AW*GB>
M")JKLJ39L"84MD9\F&%E))R*%REK+-OK##2AE8B5.P"0?>JF9KJ+E1(`&%,3
M&%RG*9N''.Q9XT_YEI]I=O#N8Y'$]\LYUB/=;GDP<T_).O\`#PU&%.[CW2+C
M3+_9^)F(#-FU@Q(O:*%/Y915C5W+5E-R)9QS`U1&%47ATGD>L\.GZZ118K4H
M@FD914@KC2MFV2WMUI6Y^#U\2^/>/W!?+]T>-826(NV;I_C_`.U#<69(3.W%
M;W5_#[B8<R:*G-WES#3LE+J.PD7:N&'M1N]HKC)P^(=RH@VL4K%F,8BYRJ@!
ME";!U@&K@^SH82ZD1H!$!`WAN`@(>`;>'H\/1H#\T`IKA3^F3Q*]IK`WTIU7
M0%L1[R[]2%SL_-?$GZPF)-`4[N@#0!H"<1VE>5]?O_9(Y%8[F[-\FR/"J[XV
MRS*-SN3@K7J*I*2-6FK6Q(0!=H-6S.58K*G2\062'IV$N@'_`'@+W5T>15&G
MF,[#XJRG,PF";^Y)G-_)L6[F]5"K10/HREW%4R9$G*CJ2?)$=**KI;E`YSH@
MN<QS#[MJLTAT?(F:*]C%C7;*G063TUNXH6IW#1=V5BXP%(NA0[FRAC<B#)#U
MA^E*,#+E>'`ID$DB-3$((*'#3P*E^7=[;YSC**<;NJ\7IU1&\J?='9<KN[1Q
MAX\OGS!:T%N-?4A*/53@YH.-H.&79.CU$#BX*D$\K!H+/%Q!,3@#<`."7W),
M!2WJV1'?>!N2B'*#NH<E[9'3:,Y!4NTN,7P;]!<7#,&5*>/(\S5FH7J)Y#!8
MQFX[>'6D;Q'QT(#+Y3`CU!NFIYB70(;&$2=6QAV'8H=9=MO3H#@T`Z;V0OK=
M^W3[6.(_[R-M`3YO?*OJE*C[8^'?H^S1H"K,T`:`DJ=A#/D??R9][9]NE4V2
M?+C%5PB\+&DG14H\.0-.8.+UBF.;`L(I-Y*QS46[AP-_^Z22*3;<I=#VMS4$
MZF[^&/=%R-CQM+<9V4Y&VJJ5Z[+'2Q5F6";SY\5WUG*_)TE:<?(S!_685U&R
M*1C+D:F*05$MS)%,8PB6CJ>GK17S1^H><KZ$/F'(W<-R/C>L0\,VJU(D;9&.
M/E)Y'Q,8I6I]HT:3;%CNH5L)BF`!0$JR3@"E(0`4Z1&1NV+DLA7(T["_'N,)
M\:_+W9+U):+[:?LT&X^Z1W);/`0O^%CG(YI'%ECIN)9"`QO6^AFJ_LS:C0+>
M;9)>4B@]<0R%I0<._P#UAMD5EP$VZA"EU//4L><HVVH2^I)#?_>NOLU&</>T
M-BA]"_(RD[PV=Y7DRI',+4ZEJS;E!ZB@4QP*HX4$@HJ^8(`!BB`AZ="1(WF@
M#0!H!SCN\_IH#[*?;\_4+XW:`;'T!N#!&25L492JMQ`YRL6CXC2:*3^,I"OC
M%0D-@V$1,@F/FE`/$1)MH"P8R7W`<=XYO>/,)YY@E,H</^9/`;B9?+C7X=9(
M;-#S*%$0J37)='6<%2,629S%.*4QTQ`H]!3>)R%`8$U&<942^H]@JOAO(&0,
M((XVCYB&<+\/7$M&UJVNPDV4;!>L3BS6'7<LDFZ19=@E")2""H$Z"DDO*.4G
MEDU(YD92<:>3+TX@K:R[EZ7^Y&.AX"!L7!_'G'+CU:,^1>1<CLFMORK<*34(
M-G#(L9JWU9W%-)>%MLV^Z9*#BK(M*-G?D%ZTBMDDC'$X[ICZ8=N5I-RZ,IV_
M[QE9UUV)T].W*GW(19A_.EG[C?<HJ"EM^3@/+S4#`0M5KI1;53%>,*:=27<P
MT%'J[_)]>@ZO&.U3*F`#N7`*+*")SB`31;OJV_-D8GNSYU:<B.>W(+)$:1!&
M+?W.4:QJ#7J%J@P1D':S%N@)E%!$&K%PDD8=]A.F.VP;!J)+W)*4JKH-OZ'P
M&@,IC_/6?]*;_P`J30%EG[Y-]5/Q']K7&7ZO6;=`5H6@#0%G;[K?-LK'VWX_
M%MTZ++`1F1FL!#L':H*M8J.S%#RTJ^:%;F'84PFJ]UI;[B1557I_C#O]0IW:
M]-?W$[9S;EI=B45#[-1*5$XFHX]Y'<LL67-B_;53$#.\2<BL9H5R1HW--H%H
MSX"K$Z#M)$LDB)1`0$2'Z@\"CM0=VM6WW+K'5&6_;7=8;?O%FWC*3NW)+M^V
MM77X"M8^HTO*\;AJB2[]W&C;$4`KPNVZ(@>3B&QSMH$I$%?NCYP'23S3"=0"
MF#?<1U:.!C6L?*;MKQKJ;8\VW#(S-F6+ZUOO[*S5*47XZ'FN$&.'4?D#D#GN
M9:JMFG'NF32;1?H^YNIN"4$D$W.'W%(JR4O'L4SD#XQP$1/N.L@6;<;EJ-R7
M5JNAI'ON98V[>KEC%:G"4I:RU_#H-0^\>NY&=X$</II>9D7/RRV96U]'NWKA
M;K<*6F[0X2:R*IA(*SOUT/NFW4()@`CL`:FBQKMR5V7=*E2$;H>9Z6F?EA4_
MSE@OPHUT!AV/\H9W^V93^O+Z`Z;0$G+ME\5^(O"+BR7N\=PEQ!76WGC;5/\`
M;WX;321S%S!D"F/D8F#ROD".<%13DZ;%W)4BD<P,?R%FS-9^L"Q"MDC@,5<N
M>6F;N<W(7(?)CD/:W%PR;D221=R+HJ96L9$1;!NFP@JM7(I/I:0]<@(U$C=J
MV2*4I2E$YMU#G,;[A#N;;:44FW]WD?<8]VFM7HOC)]$2U^8.'K+Q)]TOXBUQ
MA)(-IS-O(3'^6[:_8MPA95LAD9M>;5#QA7!/+>NG<9&-&319<#`8Z0&+_P"5
ML&K5V'E&#OMM.RUWW,C(MVTNDECW96I2?VN+Z>:+JW/C_P#3;M_'K<[\:QC2
MN52TG?IWQ5/"+=(^+\2$DY=.7JZCEXX7=N51W5<.5E%UU!```!455,90X@`;
M>(CX:N<M(>L[,W>-SOVP\O\`R`PMS]_Q@RJ^5C,O8RD$D)."9NY*/4BHW),"
MT=,WYXZPUAPHDLX*W+T2;%-1NL0^Z9B`+<]X1CN/>2*MASD94./V,>-7(*4L
MR=4RO`8NC&->B,KL+!5'-@0O4C6HAJPC&LK6K!!/(XTAZNB[D`6$KCK.@40`
MBX:`>`[`WUR?;W_S^BOP#/Z`=B]\\^M4Q=[%^+OI4SAH"([H#,16:E3$JR!S
MGW\%"*B38NP!Z-AW$!W'_;H"5!V!^WMQNL&-<@=S_F%0)O+6+,%99K..\2X3
M^1EYRK6VXL5JW-9#ROD*-9`L^L%$PW7K(S=FC@049N%_-5>`=NV.F(#('<8Y
MWY9[C?*C(W)C+\BL:1L+\(:AU1N)4Z[CG&4*NY0J-&KK4IC$;LXQDKYJQR["
MY>K+KG$3J".@),O9PL=8P][N;W1;]?+%8Z?6<J9I;XA>6>M2#]>8AX>1IM*B
MI:0AX)!7RW#MJWLKCK3(0!>D-Y:PF2)L$AG;A9P?0C<?SWLB-I+_`-7BONJ7
M!QO:9[OE9';56<7%G?FTNB@OXU1#-L36N,[)--*U*R$S6&TF^1@I=]'EC)&2
MBDW!R,'CR,\]P5BY<MP`QT_,-T".V^J@]&6^2)NSCWM.7.`+#6N&5YL54Y!<
M5;[7;-1H+#?(YM$62ATB>7@)5[2QCIRR(.S0-(2LK9NE(L'1U(E)@LL<B:1R
M%.$`?/O"N'^$=;O7&S,7%BEXCP?:\P5C(K/.>%<'SQ+!CJ)MM$M",8WO5<:,
M&Z$+68^RJO5VGJ30J)!,QZC()+$7ZP(YKMO')%$6K]1R;?P(9J9'<-_3UB<P
M>'\&@.MT!+\]ZV_)7LT_Z?\`!_@['>@(@>@-^<5*Q3+OR?XXTK([/Y1Q[<<\
MX?JU[8>L/6GKM-L&0J[$VAIZU&F)(-O68-VN3S$!!8F^Y!Z@#0#UWO'G-6N\
ME^3F%<.8690%-XL<8<!4JIX:Q?344HZJU*3LS4)*XD+$M3D;LYJ+(RCX1PF9
M%%5#Y(Z#$*83[@+,]SR!>M\O.9>8'DE,L*MB'A=;[+80CEF_J#C>S0KMJ639
M.$E"OU&K2)=KMB[E`JJ>YA$!$HB*I6K5:?L_MT^\:5SQFK'?/K'&5)VOT'".
M(<QQ&69[*2YE44&F0\BU^182SV=D5[NNWC2/E9:1?"JZ9K"X*1TW1,7H*<H@
M/J<N^7=2C-\]JCO+U_C7C><X%<]L5-.6';5RS-)_C=CFPI.)BW877>F4.XN6
M(A4>M5&IFDF*3Y1BW<,UTG!#N6*[=T8PJCX.+NV]KOC)@S$.,.?O;?S5)9QX
M(YLM;^EJQEG(8N0<"Y"43D7T/3K(Y<HLW\_79IM#OT63Y=N1P@O'*(K'7$Z2
MZ@#`(D,!0.)1`IO0;;P'TAX#\/B`Z`4QPI_3)XE>TU@;Z4ZKH"V(]Y=^I"YV
M?FOB3]83$F@*=W0!H`T!*I]V$P[%7B0[G=ESW"6>/X.O.WWEC&O([)31=K%0
M%>";>P=D8L6<I)B5DO=VM;KTF_CB)@L=LHB4ZI0(H4#@,(\:^6N3>*N4QF\-
MW:RQ5`DK$5I8:Q)N$_4K92#RR15F=CC$A7C$I-W#I%!59`OQ%?`!,F'2(C&3
MBZKJ6`?O"N2LY4S@SPKK_$NLVZ8RME6D(MF4WC.&K\R\A<:A4D96=<-GL`S&
M333?MIM%!HJBFU8J`X4,5,S@2D0'VKLUT?4C3>ZK#@=?NXT^8Y`9(_%#(;>G
MW8V"VEA(=1O?LT2Y",%*_(3#XP`RGS03I^[9@N;S'KQ#R"=2RA`$>;U=1F7G
MUQFSOQ3Y<9RQ-R&HEBH]^8Y&M\SY4XW5!"T04W8)&3B+C7)8/,96*O6%BX*X
M0>-E%4S=8E,)5"G(4!'"I.DVW08@!L'QMQ\=M_3L'IT!QZ`=-[(7UN_;I]K'
M$?\`>1MH"?-[Y5]4I4?;'P[]'V:-`59F@#0"RNWC5<YV_G)Q/CN-E8G+?FR/
MSYBZST*%KXG2>&EJC;XFS&?NW@?<8J%BVL6HX?O%Q*V:LTU%%1!,IM`.(^\5
M0?&?'?=NY'L>)JTC'%1L3>RY=7C9AJO7XSD#:2&LN28VCJ1:#8T;'0\G*%0=
MI>8?RY4KHA!*0I2@(IT=1[/W>#D*%@X$]R^?R)+%EYW#G'RS)2,Y/3;I)VO7
MY9<9J-/+2#A)\J)E5VZ[=-5,"J*^0"8CYITU`'W.]=FNUR?:NB(8&4\B3.0,
MEV*\R<X^GUY&=<R3%T_,X2\AF+PSEFP:-S+&.Q8LB[)IID,78I=_`1WT/.K?
M7J2K^3:N&._?PPXC7G%>1*#@7G9Q/QJCQM?<;;*9.N8URI$Q9T9*'&DW!1N=
MK4K#.G`Z\>E*KDCW!A<)F72.03B!$[R9C+(.&K[:L7Y5IT_0,A4B9>5^UU"T
M1Z\7.0<NQ4Z'#1ZT7*4P?`9-0O4DLD8JB9C$,4P@>%T`:`<X[O/Z:`^RGV_/
MU"^-V@&Q]`&@)5?=[AGTQVFNPCS<JC=U5[8QX^6#C%/R[>3,=T_0QVN5Q6A,
M@DU0;J,73N*G'`E,(](._),!^@#B(Q;BZKJ*O]W$Y-37*WE=`T3(!V1K)6,6
MVVJD9)O6149&!;8[FFT-*LHN7(LDL[:N&9DE$Q.9(IE"F$O2/Q?.=M3I5E5P
M-PNXLI3MI5:IX^/V#.O/WE]E9O>;_P`:L6-5WD1BJ;F7$Y>&BIY)XSDIEI&A
M8%8LZ;=NPC4_*CD4?60*!A.F?R0`O2;7U&/;%+R)*]?E.Y)M:MBR^P7A?--?
MPCW(.>T)`7!=KB[B1R'AZY<CD6.Q6N:^([%ZN5L]>;F?30*3A54^@QC=**GC
MN&P_1+$6UZ[=2#MP^?+JNGCQ95TZ=+J"JNX<+G,JLLLH81,=110PB(CX[Z`Q
MM`&@,IC_`#UG_2F_\J30%EG[Y-]5/Q']K7&7ZO6;=`5H6@#0$Q[L+<NWU+[:
M?<J@XJ?>5J\<7H7!'(2OV),JQB1U?K>5E3F?`=$QMT8P'RY71?2#?8-A`1#4
M4VG5=2#))51YI<1^:^-<XY:6I-AJ.6)CC$PF,TS43-$7K,^Y@G#>IL6D&5L"
MS9<TZG8$S1[LY2J=)2)&+U)BH:1SH0=KNDEW%^\)SGMV\8\XI.4[BC7QC\:G
MFZOCNOR63>`[<LTV8HRS*,D:Y,-2N6<@[?G=M&%:,\C720H@Y(JX2475W-N(
M='B(:M?'M0_,]%JS8?D6\V=OV[(OY$.^<[=*O75KKU_LSP'<I[@_%;`7''+-
M)Q+/N8&?R5DFP6+.\],1C2OO&$ZSDG,>A56K5F1-J[</))L59-!MYA1*EN8P
MG4/TWC:TMQ2Z4-3LEJ[?E<G1M-T=:Z?:1_O>),E)EX0]K"N$V5>90X[HV-9V
M5(R::\96;C8'0*@!MP\U9>9:B.W@`>.^P@.O0II#[T!Z6F?EA4_SE@OPHUT!
MAV/\H9W^V93^O+Z`Z<!V'?\`^/1H!8G)GFEDKDUCCB]B6Q()P./>*F&HG$M&
MK+"1=/H]ZZ9N7*LO>'A'21#-YZPMO5&ZR9!,BFFR)T;&.H)@$F1*"CIZW9HD
M,HN\<-VB)"!U'.JX5*B0I"AXB<3'\`^SKROW86+,[\Z=D(3;KTIVO7[NI.;?
M8>5G8^*G25S(MJOE\W7]I8J>\Z3+;&/8XX)XC?U]%K+6.VX!A4TO+38&KCRC
MX:EI"3Z&!$^E-9P9J=`Q`$.CK,(B(ZPI[?P=V?'_`$X^G=AM.1?G%:-N[=?=
M-^;;DG*3U;U,B;U<MRER.[.]WR>78M0UKWM7G+1^/;&+IY(KF=9P,7GZ`B`@
M("("`[@(>`@(>@0'X!#0'>SUIL]J<(O+/8YZQNV[<K1!U/2\A,.$&A#G5*U1
M7D'#A5-N554Q@(40*!C".VXCH#H=`/`=@;ZY/M[_`.?T5^`9_0#L7OGGUJF+
MO8OQ=]*F<-`1'=`<J8(B`^:*@#N'3T`00V\>K?J,'CZ-@T`M.A]P3E)BWC8;
MBCC;)LM1\2&OD_D19*OF59V5Q/V`*2=8$YPKHQXILQ=4)FLV.R(@Z3.N[**Q
MDG2J9@$8=*!S;BJ8A3&\?N8&$`W'QV`_B(Z`F1<>%86I>Z;917D3,"DR-RWR
MBW$5TS^L%79Q]68-UT"IKD\YXB$0'04?`"FW$!VUC/W"_,/*V2&-W>H]ZL-T
MT;BD^[[O,SG[*6<:=KDEW(C%VH\?OIMT:K)KMJGXZ:$-P$DA$-W)"[B'I(H.
MVX_#TD$/#639?4_M,&&4DU;F/T_*:"1>H`\PR:X``;A\?8I!-L&WP>.H`_5T
M3'Z"GDT5RIDV2ZUEC`F4QC&$A`.0>@!,(CL'PCOH#$60!(`,"Z"H&';9(XF,
M'AN(F*)0$`W\-`8^@)?GO6WY*]FG_3_@_P`'8[T!$#T!WM7L<Q3K+7;=7G9X
M^?JL[$V.#?I?^8RF(-^WDXUVG_\`>V>M2'#[9=`;5Y*\@KORISIDGD+DJ/IT
M9?LKV`]JMZ%!JT?2ZLXGW#1LWD91E7(H`8L7<PNV%V\.7XSEZLJL<1.H81`D
MP^[_`'1C;MB=_'D``%1=1/%B&QNR>*'41*16S0&0R@DDN1-39873U`2DV`3'
MZ0W#?<!ZV8.=Q02JWX$;?+<WAE]BW`L/CJ/4:W>%K,\&6'"T>JW65LCJ52!!
M$[]1,I)=%1)L=R@=,QBMT7`(B(&*(!!$+L>R7:U226OVB==QWWW'<1W$?AW'
MTZB>8HE+E?GI/CC+\3%+\^=X"F;A6+ZM07S2.>LV-IJ!;*$')0KYPT4DX7RO
MQOD163;+)IN1<F%4#[%Z0$[[&Z=]C=._I\>G?^'T>&^@%,<*?TR>)7M-8&^E
M.JZ`MB/>7?J0N=GYKXD_6$Q)H"G=T`:``T!)W;<UYG$GNV,#Q9KA'E-2Y!9>
MR0R>VB(:JM6N0EZ]FF!FLBT^6FF3(Z"TY'4=S7A,R<K$46AUS&**B1.@H$:J
MI0:]FME9K;0HF=6"Q0T(V)L)Q,O*R39@B7I*`F.(J.`#8`$1T!-^]Y'YJW'C
M-S@X2\<*E)/F^/,"\4<</LKU>A-V<?(/PDI"7;(`DN+156&+!0\$DZ:$3]6*
M4JWQC`!@$@$-C+TC2:KEPMNP)>;`\CROHZZP-BZY.)LU6LY9`\F1-"4.5F_^
M5(A\BFX2=DZ5"*&#8XF)U"!+KX%]RO&G>^Q36.UEW1\4P.0<L#1YFNX&YNHJ
MQZ&5Z?>554(:@S\DN[(W>O;(\G)A@R>IM')6\V1$!=ME3J*&T!#,OE/>4"\W
M6A2SM%>3H]KLE1D'"!%RMW$A6IEW"NU4"+$(L1%9=F8Q`.4I@*/Q@`?#0'CM
M`.F]D+ZW?MT^UCB/^\C;0$^;WRKZI2H^V/AWZ/LT:`JS-`&@)9'%;)6-.U1V
MXL)<BL5Q$VIR(YD1LV.7\X)L2,9.@4=T\O3&BXSQW<$D':M6K3V7J;!6RJH%
M3=2+AP9JHH"229=`1:;Z:[O;/+V#()9I2T6U^\M4M)SQ5Q?S<A/KFE'TPLX7
M#=TM(.79E3GW$1,?Q\=`2;>U'*EQCV&^]KE(';^/?6%MCG%$2L5H*L.\5LK=
M.,>,Y%P5%4/6%49X!:$$2@1<GF=8#L&@(L&@%?\`"G,$KB_-M/9'LC6OTRRV
MBNJ6U:3>"RBF_P`A.5WD5-+K@DJ9-U$F66*EZ"J%7.F?XIQV'W;IWKNZ&VNZ
M#R7BN67)&.RZTL2MNF'.+*)7;/95$D$0D)*O(OV44T("(=1_D&H_)L>8R@F4
MZVHE$=BAH1N]O=\OD-S:'F&@'..[S^F@/LI]OS]0OC=H!L?0!H"8KW-DJ'#=
MF;MHU'(3*X2=`@.(7'B=H[?'LY74WK'+=Q97>Q2EFFV4P#Q)O57;J6D8R07*
MB=VDNJT*0H@H`@/IPDE5K0::]WQSH;!'=AXNRXNU6D-<[BKCZ2;"=HF=^G:V
M;J,C6(O'2C9LS<+/ETR$7$Q"IG,!A^+N`B%6N@=PW%-]J7<?YZX(C82Q#:9G
M-\])H2EC>QL2DSC)\X/(YU9GC,1CTV[="44\@$1534-L!"[AOH0ZZLY>$/.7
MF5VC[%,V&AY&J$U0'CQ)C<\%V.=/,T_)$6Z,#27:I5=^W7;JE?1YQZ'!FG2)
M/C%,`AX@+:RM6.U'W,KNUE*K4H7@?G/+L2M.U>;PL=U9<+REW,\%67B<D8JD
M)'SZ.*AEC'<.H-4I4S"506QB&-L!&QRMC.TX;R/<\771H#.S4>P2-?E")]1F
MSA1BN9-&08*F*47$;)MNAPV5V`%$%2F^'0&OM`93'^>L_P"E-_Y4F@++/WR;
MZJ?B/[6N,OU>LVZ`K0M`>EJ=,MU\GHVJT>K6*Y6B:7!M#UJJ0DG8K!+.1WV;
MQD+#M7DD_7';^*DD8=`37^U9P1D^UQV[.Y3R6[MM/-A#"7+7C='X0I>+W=E8
ML>1-G<R(6=TA!1E"5072KUDM#F49*QJ4@LF^:"U,NZ:)-P,?0$=_@5W*<C\6
M)67Q>S!>9QCD5S#TM9>0DB-K%4ZLXM+%\";9\"(L72:`D(8Z:A"I)#UB00*(
M%"#MPN1<9_<3>!?N8N9;OVY^GVRU?P)T?<7R>RXL<"^$_*X!=$6QUC]G8W*K
M%S`-5K#*H2L!(1<:TL*CMF9U*2"ZHBW0;IG(IN)_0'C(6L"W&\I/1?\`4NW+
MY=E9.'?Q+MSU%.=8O7IVI:>6J97K\RN:%TYF9CF[K9_/JU,E+/+34?5&BY'0
M,?EY^NZD9625`B",E-G2=&#K,4"I%#H3V#<1J+48ND?I18_Q\227WX\8T')'
M9D[-G(SC]!3UCQKAJC/L$7*YJS99]2GO9:N5XS:#MWDBJ=![+W*KR!D7!C$2
M3ZR(@`>:F&H`AK"`@.PAL.@/24S\L*G^<L%^%&N@,.Q_E#._VS*?UY?0'3:`
M-`;$Q)7G-MR?CNKLE!2>V.]T^`9G*`"<'4S88^-;"3<Q2]95W)1#<0#?X=4C
MD.6\#CV?FJ/?Z6'>EV^?;;E*E?#Z:?>5KC4+5SD6!;O35NU++M)S:;[4Y+YJ
M+5T\D3EO?.LA2<-2>W;Q\4=*F(R@KM?YQ,3)@5S*0D'6*A'.E"%4$051"2?;
M&Z>D?,'8?@UCS@,92W:W*_17,38<6TVEIW9"5V4:><8]K;\?#X7-NW;/CM[+
MLJDLK>[TD_\`+8MN5/O]73["!+K+1C\-`&@#0#P'8&^N3[>_^?T5^`9_0#L7
MOGGUJF+O8OQ=]*F<-`1'=`?H;;AN.P;AN.V^P?".WAOMH#ZV)U"'7L7<0`PE
M'Q#Q\>D!$0W^QH#E!)$3;`Y(`;AL8Y%"AMU``CX`<0V`=_L^&@)>LBZ3J_NF
MV$&#AS&H'N_,++B3$[PH@#@@S<T05VQA(!R+%-&&(!Q`!`IOL:M?D.%++SMK
MO1C58^=&XUI]*ZO7RK]IESVMRHXVU\EC*7:[NU."_P#5)JB^_P`R(<+0>HP`
MX;"`=0@/G``'`HA_$$0#??J\-]M73)UDW\3$9C&3$-@W*81$0^*8!VZ?L^/A
MJ`.0K=8^PE*`]0](?')Z?#_[O#TZ`Y%6+I$@**HB4@AN!NH@@(`.P["!AW'?
MX/3H#$T!+\]ZV_)7LT_Z?\'^#L=Z`B!Z`-`?H`)A`I0$1$=@``W$1^T&@)7_
M`&P%1@?=NN^/+'321&:R!A&L&77$$SF\M>IJBW2`4>I1;>4`"EZQV\W<`+MN
M:#U37P)G$DX7U*E:5_"G4BCN@,"ZG4&P]9AV'T^D=%Y#+3_,3D^C=48^HDL`
M>/@'I'0'*(*@78>OH+N.VXB0-^G?_P"WQ$0T`I7A3^F3Q*]IK`WTIU70%L1[
MR[]2%SL_-?$GZPF)-`4[N@#0!H#=9>0N:U,")\6@R#.J8#)DT^8T<8G4;GKR
M.3%($E84MR!%$#.F\FI!)@W-T*%(8@>)1'QT!L[@+30OO.+AY356Q7:%GY-8
M1B%VQO+$BS=QDBN$<I*`J8J1B&0ZNH##L)?#0#^GO#/)JH0/>>Y[M[+!#9UB
MX'Q_@ZHO8PC90]>L!,:59VH1Z9RZ+Y;!49ETF\%+J4`X%V3'XP:`BJ"`CTB(
M[[B(!N(_!L'_`-=`=K#S$W6)2-GZ_+2<!-QCIO)1$S#/W47*QSUHJ59J^CI%
MDJB[9.VRY`.FHF<IR'*!@$!`!T!BNW;^7?NY"0=N9&2D7+A\_?OG*CIZ^>.E
M3N';QX[<G.NZ=.%E#'44.8QSF$1$1$=`88AM_P#'VQ#_`.F@'3.R%];OVZ?:
MQQ'_`'D;:`GS>^5?5*5'VQ\._1]FC0%69H`T!OYMR>S:VP6MQM_'=^YPZK8%
M+(E5'Z#61)'/5TNEVTAWKY%P\AXAZXV<JM&QTD#NP!<2^;\;0'FYK,=HLM)"
MD6%M$R[9!S%N8V:=,S#/1AHQ$S79L\(L5,QGS3H17.<ACJ)IE`1\`'0$B7`S
MYC1O=;.:\DA(ID>Y6YPXCIZL6Y!B8S@L2%6E_6615O\`UI!028JEW2$P"!3&
MZ2@*@Z`C`:`-`?NXCH#\T`:`<X[O/Z:`^RGV_/U"^-V@&Q]`&@'''7/^6LO&
M+'&!;Y4B6:2Q%#2=#J4RHY1"-FL:R:KF0;UZX-72+M=W\@/#)H-/5!;'!NF@
M<BJ2[1)084/5W4X=E/`1Y@[(<CBO-.,LEPCQ2)DJ5>ZY98]\B<PJL%HR40<I
MK)GV,?K0`NX&]/AOZ=1/(D!>\?5@CKD1Q_YLXI<W1ACGFEQUI5G<3J[^4(TE
M;[26Z,1:VK.4%X=:1:(&4;'3*ITBB("7H+TZ`C5*.%UE3+++*K+&$1.JJ<RB
MAQ'TB<YQ$QM_MB.@-D8CRE.X@O4#>X$B+A_!.S+I-W("9$Y%BE(Y*0-^E)55
M(O3U[#X>`@(>&@,[.>8K'GK)UBRE:R%3G+$$81RF1PNY(1*)BF<.S(51<1-\
M5FQ(&Q0*0!\"E`-@T!J/0&4Q_GK/^E-_Y4F@++/WR;ZJ?B/[6N,OU>LVZ`K0
MM`2WNR-G:K\6NVER\SCABI4^5Y;ERK*U"PVEROZADRMXMC\(SV0,>Q%&EU?+
M69M+S>:R^:+M&:J:DB9H*1P-\4-`,2]P#GWE?G+D"#E;C9YAW2J?7X1A7*ZN
MY>D8+V0T.V"X7F4CUW2Z2]ILDVHX$[@?%-H5)%,"IEV$!!48)PD&0I^6*OKC
M3RO.$`2\WUA,4_-$1``3W#Q'T`&@)R7O/UXE,>]MGM.\?Y%C26D]8\9P=NL8
MQ+YRO-(%@J573JHQ+,XHE;UEY-2I555C$$5'1"$*(`F.X$%_<1'<?'?T_!OX
MZ`EJ]FGF[4E.'$QP=SO+5R]82R)=;?0K]A*S,4R$D<8VR'1G'-N@I98I`B[;
M3[$U(O&OD!,Z9.%"*E\"&`0&(>Y;PH?<!>7&0\!$LS>\4DA(N]X@O3=9NL>X
MX?O#<TS0YJ33;[$96$L4<&TDWZ2@D^;J](=`D$0$64S\L*G^<L%^%&N@,.Q_
ME#._VS*?UY?0'3:`-`;-PNZ!CE[%CXRA$2L\CT9V950P$(D5M:(M<5#F$0`I
M2`GN(B(;!JD\CM*]QG<8-TB\.ZGXO6W..B\>O0JVP0=S?\*"ZO*M?_?$F/>^
M@KK2>>."4RFB@>*=8&OS1I*)"45'SIO::^Z=)'`/C%2;I/$Q3$1V-YAA#6+_
M`&GW[`Y!?W"]A*N/:Q\&W&7C-V\:,)-KPI)->/0NKD.'=Q=@L6Y-JFZY]8O^
M7_3M4_%+4A*:S,8_#0!H`T`\!V!OKD^WO_G]%?@&?T`[%[YY]:IB[V+\7?2I
MG#0$1W0!H`T!]IEZS@7J`N_PF,!`_P!IC>!=`2J^;[X:3[LMVE:@U32*.2LY
M9\MSHQ#HIF.6,G;*4ZAB^60YQZGI`$W4/B4`'?XNTGDVE._8;>BD_P"!=FPY
M-S%V+=?3ZWO0MU\JN6O[.A%;6;+HEZC[=`CL`E4(<!'['Q3&\0WU.%I]-#C\
MA82@<"")!WV,&Q@^*`"("(".VP#H#C,!B^!MP\`\-_@$/#_NT!\[C]D=`&@)
M?GO6WY*]FG_3_@_P=CO0$0/0!H`T!)_X0R2Y/=D>[JT8-P<.TN5G'1234\P/
M,;Q4FXQTT!R8G7UF*51FH0/`=P.(_P"Z(@";70C!',)C")A$P[CN(B(B/V_'
MQT(MMZR=6?.A`^BF,F<IBCL8A@,4?L&*.X#_`+!#0&6K(.UDQ156,9(1ZNCX
MO3U;E'?T>`[E#T>G;0"C>%/Z9/$KVFL#?2G5=`6Q'O+OU(7.S\U\2?K"8DT!
M3NZ`-`&@/W8=A'8=@V`1V\`W]&X^@-]`.9=FF'/,=USMZ1WD`N"_+/#)^@W6
M"9RM+A'.SCU%3/N"9$!-Z!]'CX:`VQ[P*^-(]Y7N!.!,F84\Y.60^3TB0H1U
M8KD>0HF(4H&4Z&P=8[;]>X#N(;Z`9TT`:`Y"(JJ;="9S=6X%$"F$#"&_@`@&
MPCX:`^3%$H[&#8?A#X0^T/VPT`Z7V0OK=^W3[6.(_P"\C;0$^;WRKZI2H^V/
MAWZ/LT:`JS-`&@#0`'I#^'0$F:RO96"]UBI3)1E')1UZ[E4FN@\;+JING!:Y
M02`9-9H#<S<Q4W!1^."NXFZA$N^^P$9G0!H`T`:`-`.<=WG]-`?93[?GZA?&
M[0#8^@#0!H`#P$!^P.@)4>37"?-'W=*G3<E947F0N`^;6AJU7$6[;S%,=7E@
M>.M3@#)`J^1*TD$O.,"IRIJ"`&+\;PT/56JQ[J^!%<T/(-`&@#0&4Q_GK/\`
MI3?^5)H"RS]\F^JGXC^UKC+]7K-N@*T+0'L*]D&\U*/DHFK6^R5V,F7#)U+1
M\),R$8SDW4:D]0CW+Y!FNBFZ<,49)P5$YP$R15U`*(=9MP/'Z`53Q3R+B*@W
M"9',T6Z=U&;A4&2SR+KC.SR[1=I)(/A0:1[V3B")(RB"8I*JD7(H38HAH!U;
MO\=T/C]W,\I<7I;C9`Y'KN/,!<?&&+5FF2(9E`RBL\6027=A'L(ZVW!J:);-
M&B)$EQ<$65V'S";AU"`P!H!6/$',6,\*9,;VO)L!8YN&$S)!12KG9#+L6*3]
ML]DP8-WZK=LJ\DF[7U<AE#@FF50QQ`P@4-`9G.;E5*<RN1USS:]@TZO$/V\)
M5J15R.U7ZM>H%-BT("HQCY^L8ZK^5+%-2*.UM^D[E0_0`$`H``F>F?EA4_SE
M@OPHUT!AV/\`*&=_MF4_KR^@.FT`:`V+B*R5RG94QK;+@P>RE3K-_IMAL\9&
MD14D)&O0MBCI*:8L2.%VR!GCJ.;*$2`ZB9!.8.HQ0\0IF]8=[<-GR\'&DHY5
M['N0@W514IP<4VU5I)O6B;^!4-IRX8&Z6,ZXFXV;L9Z=?E:>E:*NA(3]X#[O
M/$GNGL.,ZW'2A9KI4WA);(49,?XIU^EP[)U6+6A65(QM%+5>[6QRX=M'T(IY
MA5BI%`AP$#&,([8I]H_;S?.!7\K^J7,66)>LQC&-F4W2<:UD^Z$.M?C]A<F^
M\DQ]VVRWC)77F1RI792DDD^^';.E)/65(U\/XQI]9I++#0!H`T`\!V!OKD^W
MO_G]%?@&?T`[%[YY]:IB[V+\7?2IG#0$1W0!H`T`:`>WY5=Q3C[R![9?!#A?
M&5S*D;D3B!CFXQ[Z3?PM92H\YD&[9'7FI!['/4;6^F31#6G"5,JQV3==1X<2
MBF"8`8;:S\?D<^2X65A3Q_\`CMNS=5^$G)7'<E3TY02BXOMUK64?L9?FP[SQ
M;"X=NNT[K8OW-^RKEJ6/<BHN%M03KW-S4DW\(R&2-7*6&?HB(^D1_P#I_P!G
M^S0'YO\`!H`T`:`EZ>]9N4SP'9P9@!O-0[>]9<G,(!T"F[949),"COOU%,R-
MOX;;"'V]`1"]`&@#0#OG$WN"8LP=VM>Y)P5NU;ODK>N7$]@2R8EFZ^WB%:=7
MY3&UJ3D+6>ZN'DXPE&A'L(@F#3U1H]\U<@%4!,H`;3["*I77H-#'$!,/2(B7
MX!$``=OM@&X:@JTUZD9**DU!MQ^/4^-1/D-`&@%-<*?TR>)7M-8&^E.JZ`MB
M/>7?J0N=GYKXD_6$Q)H"G=T`:`-`&X[;;CM]CX-`+=[;_).E<0^=G%+DSDV-
MLTYC[!F:*EDBTQ%0;,'UG?1=?<BNLC!,Y64A(YS(CL'ED7=MTC"&QC@&@.O[
MB'(VI\N></*+DQ0XRP0M+S7F"UWRKQ5J2:-[(Q@9=T48QM-H1\E+L49(C5,O
MFD2=+IE-X%.(:`1EH`T!F(/W;<I2HKJ)`01,7H-TB`B(B([[#Z1'0&,HH94Y
ME#CN<XB8P_9,81,81^V(CH!TKLA?6[]NGVL<1_WD;:`GS>^5?5*5'VQ\._1]
MFC0%69H`T`:``T`Z]?\`G'B*Q]H7!W`>#@+ZVR_0.5%XS?;YYXUCD\?/JO8:
MP$/%LHATA95GZTZB^`3JD4BD$RICN"QS";<!J'0!H`T`:`-`.<=WG]-`?93[
M?GZA?&[0#8^@#0!H`T`\YV\NXYB7C!Q4YM\8,RTRXVJ'Y18I?TZMR-:CH652
MK5D243?0DD\0E)Z!5;-TGY!!15$RYP3,(>6<!VU`]U=2AVZUH,RF$!,.WH#P
M`=MA$`\`$0W'Q$/3J)X'SH`T`:`RF/\`/6?]*;_RI-`66?ODWU4_$?VM<9?J
M]9MT!6A:`-`&@#0!H`T`:`-`>EIGY85/\Y8+\*-=`8=C_*&=_MF4_KR^@'`.
M.':VY2\FL7U?,%6<81QQ2LEW.6QM@USG_/F+,%R7(C(\"LR:3=)P7$Y&L<(]
MO\I$R<HU8N'*)4XQ*1<IM#.@<B*0`(3OU"N>++S<,9Y%K4O3;_C^SSE,NM2G
MVBC";K-JK4DYAYZ"EF:OQVTA%R;-5%4@^@Y!].@-O<AN+>5^,*&!W&5&L`U3
MY'<>,=\H,:?(4\TG1<XJR@YL#2JNIH&H!\BSRJU:=>>P5W50`"B;^,&@/G.'
M%[*W'JH<=[QD=I!-H'E#AQOG7%*D/-MY9T[H+JV6:E).)QL@0IH64&<J;PHM
MCB8X)E*;?XVP`)VT`:`-`<B**KA9)N@F=9==0B***11.HJJJ8")IID*`F.<Y
MS```'B(CH"3-VB.VMS4XN=S3MA9PSC@+(]"H5MSRF65>S]'ND,OC25:6?(N,
MXFM94&:KD9'TVRW&9JKAW"LU'"JDE%*H.T_N:Q=`;X]\\^M4Q=[%^+OI4SAH
M"([H`T`J;C%PPY%\P%,N*X)Q^_M$)@;$%^SEEZVN#?)E0H>/L=UF5M$J\GK$
MY($>VEIAK#JMXE@!A=R3OXB1!(191,!+.@'H$.QARF3K6-)RRY[[?N.IO+F+
M\?9?HF-\J<WL(XSRC+4O*5;96JC.E*5=9N%D63B?BGZ?DE5$B9E=R@<=A'0#
M9?(GCGFOB=F"XX$Y"X^FL8Y8H;MLULE3F_5%E44W[)O)Q4I&R<8Y?0T]`S<4
M\1=L)!BX<,GK58BJ*ITS`80-)Z`-`&@#0$N;WK#^9=GK_3II/\E6=`1&=`.M
M%[,G-TU.^50B\+_XM?X6?XX!Q''/V*0YDCB/\6?QW_';_P!N'XR?C_T?B/\`
M_FODD4/Q@^3/N_J'3H!LRDU&9R!<ZC0ZZ1NI8+M9X&HP2;MP1HT4F;)*M(:,
M(Z=J;IM6YGKT@'4-X$+N(^`:`><LG8`YHPMSG<3PV7.!%^SS`R\A6EN.E(YS
M\?WN>']NBU%$7U*C<;S5J@IA>YH.4C(C%G\MX*X>6"8G^+H!EJU5:RT:SV*E
M7.!EZK;ZC.2M9M-9GX]U$SM>L4$^7C)F$F8MZFB\CI2*D6JB#A!4A5$E2&*8
M`$!#0'0Z`-`&@%-<*?TR>)7M-8&^E.JZ`MB/>7?J0N=GYKXD_6$Q)H"G=T`:
M`=%QYV>N:V3<8T7(%>@L3L[3EO'DCE["?'>S9QQ?6.4V;\3QC24?K9$Q1@":
ML;2_VVN/X^"?.8P$VQ'DTV9JJQR#M,"F,`UV8IB&,0Y3%.4PE,4P"4Q3%'8Q
M3%'80,`AXAH!\>S^[_<R*E;CXPFLW=O=CFKI@TV^!Y3G=@&MYE=REGC(R9K=
M?3HUMLM??-YV?C)EHLS0<&1]82<I'((E.41`9WRMBG(^#<D77$&7J9/X\R;C
MJPR%5NU*L[%2.G*[/1:PHNV#YLIN`^.QTE4S'1<(G(JD<Z9R'$#7^@#0!H`T
M`Z;V0OK=^W3[6.(_[R-M`3YO?*OJE*C[8^'?H^S1H"K,T`:`=?8=FKETMA"H
M9[G;3Q3H-4OF&XW/=3K.2^6V!\?Y2F<93D$YLE=G&>,+3<XVY*J66(:BI'H%
M:"H\$Q2I@8P[:`;1QW19_*&0*-C.J)M5K3D2XUFBUI%\Z38LE9^VS3*`ATWC
MU4!29M3R,@F"BIOBID$3#X!H!XZP]@3FC$VZPXMKN6>!N2<[5N6F*V[XZ8]Y
MQX`EL]N[;`*NF\S2XW&<K:H2;=72/=LU4%(H0*^]8(*0)"I\70#+-BKL_4+!
M.U.UPLI6[15YB3KUDKLXP<Q<U`ST*]7C9>&F(QZFB\CI2+D&RB#A!4A%452&
M(8`,`AH#IM`&@#0!H!SCN\_IH#[*?;\_4+XW:`;'T`:`>DQ/V'.:V;QHC/%]
M_P"$5NL628R)DJA1XGG)QK>7^4&8B"3;>++2&U^6LI9UO'B8SAEZL+EN9)0I
MR`)#;`-$W2E3%#OELQU-+0[F?IENG:5+.(&9C[!`.)BNS+J"?K0M@B5W45-P
MZKUF<S9XV54;N41*HF8Q#`(@//6OW?CF;4+L\Q+)YJ[?/^.;5S&QI,!*\[N/
M\)FAY/S31B^A:PWHMJL]??)V*9:R;8[5LN9$RY5TQ*(@<HB`S;D[&60<+Y#N
M>)\KT^>H&2<>6*3J=VI=G8*QD]6[%#.3M)&,DF:P`9-9!9,=C%$R:A!*<AC$
M,4P@>%T`:`-`93'^>L_Z4W_E2:`LL_?)OJI^(_M:XR_5ZS;H"N0QGA+,V:G4
MVRPWB/)V6GM9C!FK&TQG0K5?'5?AB^9U2TVWJT3*JQ48'DGW77!-+XH_&\!T
M!K59%5NJJ@NDH@N@H=%9%8ADU454S"11)5,X%.FHF<H@8H@`@(;#H!2=&X7<
MQ<H52+OF-.)O)?(=&FT7#B%N=&P1E*VU27;M'3AB[7B[%`560AWZ+5ZS614,
MDL<I%4CD$0,4P`!H&PURP5&;DZS:X*9K%CA7:C"9K]ABWL+-Q+Y$0!9E)Q4D
M@V?L':0C\9-5,AR_"&@.FT`:`-`&@/2TS\L*G^<L%^%&N@,.Q_E#._VS*?UY
M?0#C7&.Y0W'VU\4,Q=P_C_R8S]Q'19V&R\7*.RRW+XPHK\E<RRQ7R!+X\=3]
M9MD1.4^/M[&03FX.$5@!D)E4HN9!`P'%0#)[S>.L@8R[GO,&'RAD)AE2Z6C)
M:&7)"\Q]7+1BS##.55KN9:\@^HX/9(:9,0U<O31B]BQ<.!8NVRB7FJ`4%#`.
MV<_\H=N:EXJ[3D5RWXD\B<[9+6[0?#U]&7+$_*N!PC66=.5>9-2BJ^XJ$I@[
M)CAW,L9)!ZLM(`^2(NDY23!`HHB<X"M,@8VXIYKN7;]RK%8!>V'"G&+W?[DC
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M_K;*CXDR`M&N[/2<@R5:K;R,:2,+Y$M(J2:**ZRI&K,J("@.<]9Q1R.XV\X9
M?B/']N7/6+L.-&N4JMB^E<8'/!#N$=NW&M2RE"PM@;S%31Q[7W?(2IUJ,FF]
M7N+F9LEA,9XHE))E1<F*``:,[1W<5Y,<H^Y)VJ..^6IJJ2.*<*<A:";$5?AZ
ME'PJN.X^MX<7QV^@JW(M3"\3A+N6";SD^@N9?Y2LH'D1,1510#`;Y]\\^M4Q
M=[%^+OI4SAH"([H`T!(:[*')_/4NGR2XHN,E3K;CO4>W-W.,BQ^*(@K"#K$G
M?9SC+<2NK?;TX9FQ>7N?9-_N$>O-+/S1;?=)GY!#G`P$>70#VO?6$!SWPPV$
M-P[4G;F`VVVX#_[?80=A^P/2(?[-`.K6/%-GNN2.UT?).'<`93S+Q[['1\IY
MTE^9UI?5S!G'6B-<B9*:<<,P\EH-O7;7,9&;XRI%P@@9TAQ'.7LTH^C6QTO*
MZ0`#67*N>X_U?A=Q"Y\OAX,\R,I8-[G\3BC(-WXW<.2<;\)Y2Q%'XA89<L&`
M,A4"=P[A>KYB!,T>3HF_Q81%HSES-O.4/N8`-<\RN%N#>`6+>Z)R%9TFHW+'
M?*/(V'<'=K^3L%;C)R'88=Y(UV"YC7C+%#0FF:HM97%F!W4!2FLTR`CB/DYU
MP0JA#[E,!&'T`:`ES>]8?S+L]?Z=-)_DJSH"(V0YDSE.01*<ABG(8/24Q1`2
MB'VP$-`24<*6"?[=DHT[N'<"RI/Y,[C.7:#+V_A)QELE@<6'+<F]R#C]]0*I
MR^Y:/7BZSZEXF@ZB_,K5(!X)9BW+(HG*1NP0.J8!BCBP8Q^47'(YAW,?/F(3
M&'P#<QLAUX1'8-@#<1T`N7NR,+G+]Z/G5&8S;SSW(<ASSRXQH;6H@[/:'-U<
M99D&];;UP(T?7QL"DZ9$K7R/NWK/3T_&VT`_=RIIL,3N8]WKD)&5G@C6&&-Y
M3B;BZV<RN;+8V1,,X!Y*SF)*K_CE!8VXX1N*\RLL[9NR;>:784@%2`>DKI8U
M^Z,!3KE$0-:Y6A.$%9Y5=GC*N4:YQARMBCN`8%SK@3E7E?$G&Q'CSANVK6G,
M60^.U5Y'T3"MII]6+BN[8M>R$9(J6)C"0QY%2`,_;(-TG!2Z`TQ0^)6#^W(P
MX;<>N;W%E_R)S!GGN%Y;R9FZDT/':E]S&TX=\,Y&Z8/K4)4J^V;'M+RB98S*
MSL]PE&<<NW+9:S44$U%/5S`<P&O>XS387-/!R\YUPU8.VURZQIA_-F-5GO)+
MB-Q^3X0<DN/%)R6UL];JV*<Z\9(W'5!BIO'-WL39(D1*N',^_CY5@LD1\JBH
MH8`&/>%/Z9/$KVFL#?2G5=`6Q'O+OU(7.S\U\2?K"8DT!3NZ`-`2#NU??%<!
M]PKC"SYN8EY-S'*+(J?'ZF<'LO72X2<W$<>XK+%>6HG'O+BV"[=$#)YWQS5C
MVJ&D*_"M;1`Q+>-8*$21=]2:!0&4>0N-9_#.?<XX?M<Y&6>TXHS!DO&MELL*
M?S8:PS]%NDU5YF<B5.DOF1DM(Q:CA`VP;I*%';0#K'O$:#AUWE^7#9FBLX=N
M!XY(-F[9,ZKA=RKQ7P8FBB@DD!E%%U%3`4I2@)A,.P>.@'>N06-I6>[B<U?+
MSB[B];LI\;.SSPI7Y?YEYW3TA_@5Q=Y13&*<44O_`!?R_0VU/R"[SKE9DWFH
MN%B*@ZB9(LA./4U5FZGJG2`&H>25JXKXPQOVJ.?=SA^&7+9>)YMYOP_R3N^`
M.'7_`+><)YVP=4:]AF0GJ=-8;M.+L85F_P!HID)>9I*,M3>J1I#KKHIB"SAA
MYN@/"Y4X'82[;5=Y$PV7<(K\C@Y3=RG#_&OB/6H.`3L>5;IP9QI/TGDEE7(>
M`I%-L[>$NF<J#D:@TAC)Q1@=>=)2+9%4.I3<#WG.NL8IY'<9^;TWQ*8=N//^
M+,.I,,H5;'-$XPK\$>X'V\<9UG*</!SS*<IJ./*XYY!T^"C9QM5K<YF;'8C^
MNG2DDP1<F`-`1*=`.F]D+ZW?MT^UCB/^\C;0$^;WRKZI2H^V/AWZ/LT:`JS-
M`?::9U5$TDRB=14Y4TR!Z3'.8"E*'VS&';0$MMO>>.O<>[C&/NW'R.[7KWC%
M=;5AK&W%YCEJT9-S2'+'CE8<&\96$?CN[NJN[G*YA5/&\##TMJ]DJ^XJ"0+P
M[E=^H^%8P"`$<7AHW!IS6XIM2KI.2MN4F#&Y7*!NI!P".6:NF"Z)AV$R2H%Z
MBC\(#H!6'<PC;_-]Z?G'$XA0GWF4I'N-9Z8XV;T\'1K2M?UN0=C1JJ=<^3__
M`%@3X6(40;"E]U*X`HAL8-`/^\I*E76'<3[QO)"!K_`*A5FL9RX]X>=\V>;D
M0OE+%V&N03S%K67SUC["W&AAB+-##,>;,EW>J3B[QXX@'?XNL(UVJ7RE'0J:
M`U?E:J\(8/G1VI;!D2J<;+WA_N/\.+IA;D=E+%7'%/`F)YJX93RKF+C]2^4N
M-L+7*MU\N&[C29UI7Y0\RPBH0'1(E5^V;M2/!T!IO&7%S`_;O:\$>/'.+BB^
MS]F#-G-O.^=^1U(IV,G.0LQ5[BKQ2&_\?\;5R*KC%`EJF,87/+]>ME^GHYBN
MW3L=9K+<JQA0$HB!K'N0TN,S!P;GL\8FG.VYRXQYB?/-`:R?*CAY@@.%7(7!
M]1R7!VV)J6'<_P#%F-QUCN%=T.Z3T,*T),KFG9%E)1R[8CY1!14=`1L-`.<=
MWG]-`?93[?GZA?&[0#98G`4B)]!0$ISG$^P]9NL"!TB.XATEZ/#P#Q$=`<>@
M'MN)CA+A/VP^1W/*,Z&7(SE-DJ4[?G%:P@)$YS&-`_$9G=N8.7ZJH8HKL)^6
MI-DAJ-'RK4Z#R."=D!2/N<VP#*T;_P#V+#^FM?Y=/0#TWO"[=Z\[U/-=I&(.
MG4BZOF+6S!LQ257>N'RV$,5)-F[-%N4RZKM5P8I4R$`3F.(``;Z`>7Y(8ZEG
M_/?D-ENXT#B,XR;QS[;/;SK7*[D[ST=N[5A+BSRPNF*,75V6M=HPXPQ_E57/
M>>;4PBQA(:&<PT@FSDR.';A%0[;HT!I?D7/<-\063LF<W<AU;B)R4IN7<H\K
M\0<Q,@8;XHC@'`N=L3T:WXSQO)61O@FP4#'$4O=,65K*4T#.S,JY"F?R,6T5
M*4%F95=`:<OO!C%/;/I$_B?D1@5]R,O/)WNNUC"&,ZS!U).P9BN_`'B)=*_;
MLD6KC^^:(*3L):.5TEDBO0+%S&F17?-&#EN14"F4*(&Q^>E8Q?R*XJ<S[;Q6
M2[;W(O%>'9*M9*J]>Q;QI/P/YY]OW&4=D^.K,I"V7&C;'565SY0FS2Q,ZO97
M,K/V11N_\J23%-8>H`(H;'^>L_Z4W_E2:`LL_?)OJI^(_M:XR_5ZS;H",?QR
M0SYFCM)\?\4]MS.E;P_F?$'*'/62.=E-CN2E%XMY,M#6;9X\'C=G"0L]TOV-
MCV_$V-:K$3$:KZO(+IPLH(N#M@,8%B`)C[_5%KE/Y]1\_#3]0M\[F#BIQ%S5
MDR[T)!%K3\AY8R#@>GOL@Y0@FZ#&,3*VRK.MCV4ZHMFYW2\L=P=,IU3:`WIS
M2Y/\EL"=N/L@1>"^1&<\+QDUQ4Y"2LQ&XFRW?\<L):4:<O,IMVLE),Z?8(=N
M^D&[<H)D65*90A``H"`!MH#9.8HF"[B/&7LR<BN9T[EV8R_E;-O*#B/FK,6)
M,=NLL\F^0V),(.\=V#%+R/JK%LK)9/RQ"*7=U3VDLNF]=J@L@J]!V+8Q#@8'
M+SM9XJH/!3._*]?A!RGX%V_C5DS`L;'8^S]R2H689+D-B[+]QEZ9)NIZI1N-
M:!?<)WVLO&31<7*C)2$=E<KH()G60,)`-?W'M:<;J5RSY$79:5R3*=M['';P
M9]Q[%MD7L\1&9`O=$S)CV%@..N*G-S3KKR%;6^7Y26U&IO3ECNM5*$D-B(J%
M$R8&]9'M1<3H[BK3\D5/CUR\Y(XGL?%F&RC9>Y!Q0S-C;.-?QCR(D<;FMTUC
M3(G"FKT=2\47&%`O!#5Z<7FYQA,M4$57YER%(=),"+7H#TM,_+"I_G+!?A1K
MH!X&9]WW[S+R9EG2/;]S6*3F3?N$C"M1@W36=*J$'<+@)?$I@]`B&@%Y\=>%
M7O)G&;&$3AJE\$)*\8WJ%ND<AXOK.><$<8N0#7"V0YCU<TM=\-JY>;V]SCJ<
ME5V:*[HD>=-DY=)$<*H'7#S-`(RR9V.^^[F;(5RROE7A7R)O^2,A6*4MEVN=
MGE*;)SUDL4RZ4>24I)/5K>)U5W"Z@[`'21,H`0A2D*4H`>_SGV@^_P"\CD<,
M(9<X/Y@L*7'_``71>-^+2M87%<%\@XBQNXFW-1KKD8.>CQFG4<M8G8G?O?/?
M+^8`*JG`I=@-PP7`+WEZJ7+BSD&H\6L\5.Y\,<:GQ!Q\GJ]"8?CG-4QPO,VR
M;D:I--R2AF%[B9IQ>)5"01G49%-^Q>':N`4;CY>@,[DKP$]XVY246MXGNG`N
M>Q[AZK6]UD=AA[CUAOCKQYQB^R>_9GCGV3K%4<0J5./M%^6CU#-TI&1!RJR;
MG.BU\A(YR&`479\:^]:6V&M,=*<2[,A-Y(Q-9L(YGR-$8!XI0V6\]XYM&/WV
M,G4+G#*<;&-[UDI2.J3\Q&2\@^460>)(/>HSUN@NF`AFX]J#WAB\Q_&F/F.'
M&=F9N(-1:TKCU*5MKC6JS^/85AD"=RE'*L9^O6..EWTU&WFQNGS>0<K+/4#F
M(4BH$33*4!46<^+?O-?(/'^1\?W3@T]KY<X$CB<A+YBKCYQ7Q#EGD06+E6L^
MW3S;E#'#&MW.]-G,^Q1?O4%G9&\D]3*N[374`#`!R]FOLJ=U#CWW0^%6:,S<
M*\L4#%V/,SQL_=;G,J5(T5785*'F6ZLB_P#4K,[=>KIJN"`/0F<VY@V`=`.-
M^],=K#N$<U^XG0,K<6.+&1LT8YB>*^/*5(6ZJ'K18MO:XO(F6Y:1@SA+3\:[
M]<9QTXS6/]RZ.EP78PCU``$;']WO[SO[/S-?_%I'SNT`?N]_>=_9^9K_`.+2
M/G=H#>6`^S[W^.,UCN=KPYP=S#6YR_XDR=@ZTNG</BR?(_QMF&JO:7?X1-M/
M3\BW9.)>O2"J)':)2.VIC=:*A#@!@`T;^[W]YW]GYFO_`(M(^=V@'B(:D^]5
MP=:QU7&_"&#DE<38]I&+\>6VT\.>"UTR!6:=C>`9UFCL&E[N%+G+.NO7(E@D
M1NNNY55`Y1.(B<QA$!+N/^"/O,^/N2F1N6A.+N>+YFK,U?L=-S5+9>A<0Y9K
M68Z);D(YK8,?Y+HE]EIRFVJC/&L.R32BEV7JC$C%L#0B'JZ/0![/*'`/WB+E
MI3*5Q=SYQ#M.-N*:6::;D!I4<7<?./5/H>"7;9C-4^8N&.L=XG4J+U%LVK5P
MD7<G%L5BJS[DA#KF5<E24*!M3N?]KSNPYQJ'"KB)@3BCRGS1QPX!8$7Q/3<K
M7ZMUFA/\K9"N%B<6?(][AJ%+WAS-5"CLFJ,/7*['R)C/V\1`IF4'[KT@`TE^
M[W]YW]GYFO\`XM(^=V@/P?=\.\Z`"/\`T_,V>`;^"E($?]@!;A$1T!)2]XF[
M6/<(Y9M>V.GQUXL9&RJ?#?!ZIXYR>%</6@_$V\LDX$KRLRHR$^Q`9%L+4_5Y
M7F)#TCTG'0$;F/\`=_.]%&OV4BAV^,Q*K,';9ZBD\2H#YFHJU6(NFFZ9.K4J
MU=MCG3`#I*%,FH7<I@$!$-`/8VM7WL:]S3NR7C@U2;E8W[=DT>V"U<'N`MBF
MW;6,8H1<:V=2LQ0WCYPA'1C5)N@0YS%203*F4`(4``!FJL]A_O=T^Y5^_5_@
M-F9C9ZM9XFX0CWR,>K(,YZ$E6\U&NO4%[0HQ52;R#4A_).F9(P!TB42^&@'?
M;"P][1G9FPV]GQ"3IN2;.K).9;+^/N(W!JE9D%_->8$O+L,JP5*:WF*GI$%C
M^9(MGR3\#&$Q5BG^-H!&?''MY^\8\9$<PQ52X*W+(M.S^]B)G,V.N0V,\$\A
ML>Y$M5>D927KMXL-4RZ_MD>M>H.4FWB[>83!-^)G2H***$.8H@;4LW:R[['<
M2R3Q]Q]W",1Y@Q1AW$3._P`+4<L5SCSBRR!B"KV(A;,A383&>%)JCR3ZG$FX
M%I&0<8T`&-=2<`5ND@T*J!0-D]PCAWWZ.1/<D)S<X]<0.7E(/A-MC:A<6;Q8
MY"@(Y1AJ'ABO-JY7+3:4RVYY&ELV1)/Y2L$['G*X9&=3SMHH59`3`<#1'(O@
M[[QYR8QK(8>M?;^5QUC&R7"-R)D&F<>L`\8>/41E?(4,D_2A[IE4,1HU1U?)
MB'^571V:;]15DS7<**H()JF$^@$^<5>PQW?J-R@XW76U\#\R0M7J&>\/6BR3
M#I2F"VB8"`R'7968DW()6M17U=A'M%%3])3#TD'8!T!9!]\[CCFCEOVJ^6G'
MCCU2ELB9BR/`8Y9TNFMYBOP"TTX@\RXYM$JF26M,K"0+06L#!NE]W#I(#@ET
ME$3F*40*RNR^[@=Z^JE9F?\``W(+\'PKE2_%J[X=MADA;@D)_7"UK(TH9B!P
M5#H%8"`IL;IWZ1V`\K^[W]YW]GYFO_BTCYW:`<YQCQN]Z$Q+C>@8\JO#BU.Y
M'#M3>4#!>9+=A+C)=^16!:&^]<\RG89SY:V\ME&@03'Y1<?)Q&<D56&\\X1Q
MV@;``#9SOW?OO42#MT_?\!LYO7SUPL[>/';NF.7;MVY4,LX=.G"UP.LX<.%C
MB<YSB)CF$1$1$=`/1RK?WM"6G?QS4X<1C;))&T:W:Y;:\.>"7^+;!:&BV<+#
MR;#)#JC.K8VFHF*CT$&KT'7K+<B)/+.42%$`$382[>GO(V"LN9;S3!</<OWZ
MV\@XN<A.0<?G.L8?SG3<[Q%CFVUEEF>6*=E*8L\#<#JV1DB_2<.$?6VSI(#H
MJI[F`P&S\B]NGW@SFXRPSQMY8\9KSC'C#4,N'M-<5H7'G!D94N.3"UQ<=5K*
M[Q_C+#3FG2)*.UCF2;UU7XL2@\>E5>^6L_6445`VMW,^WCWE,[Y<XDUOC;Q4
MY?V'$/;PX]8:X^\=LR6I&LT'(=OL^+46<K8<\-:__B`]EL?OY^Y-4"PK8SH[
M]C"0L6"YP<D4``-:YUXL^\U<A<?Y'Q]=>#+RO)9O&--R$N^*./G%?#^5>1)H
MJ6:V!M_C;DW&[&MW&]MW%A9)2#QNNZ(VD7R95W::ZH`8`$(0WNU/>WG(QK*M
M>"MM:-W8*&3;S.3\$P4FF"2RB(^M1,QE%E),Q,9,1*"J1!,00,&Y1`1`<1[5
MGN_'=VX[]Q[A5G+,/$*5IV+<5\B,<W6^VI;*V#99*`K$'-H.Y644C(')DI,O
MBM6Y!-Y39LLL?T%((Z`EM^]%\2>2'-#MN5C$/%O$=GS1DEKRAQA<G52J8Q99
M-O5H:E94CY.;4^5Y&,;>ILWTTT2/TJ"?J<%V+MU"`%>K^[W]YW]GYFO_`(M(
M^=V@#]WO[SO[/S-?_%I'SNT`YW(\</>B)7&+K'3SAY;S3TCBHN"9;D`GA?C0
MCRMF<*$AR5P,72O)Q)$F9WM8/6TBQJIC2_KZ\:'JBKD[?=(0&[J+V(^]_C>[
MT[(E0X$YHC;90K57KI5Y%5+'SY-A8JM+LYR$>J,7UH<,GA&LDQ2.*2R9TE`+
MTG*)1$!`=WL$;[VC-RMEM,;Q%&B9%MJLNXF\OXTXE\'J!F=5[8#+'GI5EEFM
M4QA?8F>F#.5#+R+5^C("=0QRK%./5H!'7''M[^\8<9(;*M3J?`^T9'H&;9J(
MMF3\:\B,4X!Y$8^M=[KZLDO`9%=U?+SNV,6U_B%)EWT2R'E.UBN3D7,J00*`
M&TISM4]\[N)Y>P%7.XKBW-F*<98@KENJU7S37N/V-+;)XUJ#J2D[S&4B)Q[A
MF=I,C(0#>>-\FUYH@`,:X@NB@@1NP2$J0&Q^?/$;O[<A.YO*\^N/?#SEMCF3
MQD^I57XQ6V<D,>_XD5S'F*:XA4*M+6A$;:_B%+!?D2/IFQQQRNHY=[.OFJA5
MFQS%.!H#D=P3]XVY-XW4P[;.WXMCG%<G<F>2+?0>/&!.,G'FN9'R-'-'[*.O
M.2VN(TZHM>9Z+;RKKU,)!19HR.Y5.W12.<QA`02/N^'>=#Q_Z?F:_#["E('_
M`+@MVXZ`7OW*^R'W8,R<IC7;&G!_+UKJH<=>%U2"9CU:;ZJ-CQ[PXP10KK%!
MYUJ24]9KESK;^.<?%Z?6&A^@3$Z3F`08?W>_O+])/+[?F<.O8?-ZU*,!=_#;
MRQ+;Q$0].^^@./\`=[^\[^S\S7_Q:1\[M`;UN?:![_=^P/A/C39N#V8'>'>/
M5@RK:<6UEM"XKCEX>?S1(5R2R%)24XPGF\Y8W$LO4F!4OE!PY!FBAY;<$R&,
M40-&I>[Z=Z!%5-9/M^YK*HDH10@^91QV.0P&*.PVX0'8P?#H!ZN:3][3F[$Y
MO2G#J.C\G.2MA+EZ,X=<$FV76;QDQ;QK&789)/1UK:TG&+!HDD@](Z!T@5,G
MEG*)"B`"+L$]O[WD7`-VS?=X3ACD_):W)I'RN1M7Y!4K"_("B9R73L*EN92N
M3*?EB5M,/9+#$VI8\@RDSD+(-'2BADEB@HH!P/?WSMF=_KGK+X"P;S5P!DG&
MO'K&=UN+RF6BL<?\-GKW':!R%%UME/QE(Q?A5Y39$V/4U*3%^77XT`0:J^<Z
M12,NJN*P&TNYIP![UG)'E#@2W<?>)/+]SCG@WA#`?'?B]EJUFJ%,RM/%P#%,
M%3YXDXYE?7+BI72]Y&(ZFFY07%ZT9E8I+&!=`P%`UQGKBC[S'R*QYD7&]SX)
MN:O'9M=Q4AR#LV'N/7%;"^1.1+^%F$+&P<YNR!C)C6;5?2!9&R<DNW<.2M'D
MB0KEPDJN4IP`;?;>[Y]YQ)RW5-V^\V"5-=(Y@!6C[B!%"F';JMY2[[!\(@&@
M)TWO5/$_DORI[;_&7&?&[!F3,X7^K\FL?V2QU#&=6D;;.PE?C<'Y=@G\U(L(
ME-PLA&-9F6:M3K;"0%G"9=_C!H"(]QSX`\OZK@5#`G+7L!\J^1+&HY2D\MXU
MR;C..MG'/,3=Q/0L/#V3$V2[XPQ#D1]D/#$V>`:NT&8%CY:%=BX.Q?)@Y,4@
M"?N8O;V[U_-/D5D+D7D7MI\FJ[,W56!CH:F4[!5XCZ9CVB4JM1%'QWCNH,7+
M5RX;5NCT>NL(UJ*JBBZQ&WFK'.LHH<P#C4'QXY*W/BWQ&X]\LO=R.<O(2P<0
M,?7?'-+R%6LT9APBSG8.[91M.4GI96GU[!UC(BHE)V86_6#]144TMP,7J`I`
M/FOM>]13.77%7.F/NRUF_'/';AI1,DXEP-P[I>/LSQU4J..,TUVVUS,#U'+#
MU*2R*KFB_A='<@[NQS&D`E4&J_D&*AY1P/(7CC)S7BN)G++A[QH["/.#%]5Y
M7RF&;5:<OY3MN1,T9J3MV&LCEN]?;RDHCAW'U.?T%&.?R3%"-;Q3*0!T^%\Z
MDG@II-TP%!<H."W=XH/96XJ]OMUPGRW?LV67*-SG,G3&)*:IDR7H_%/&-QF[
MQ@?!F2[Y2U9^!=NI#->4K-:642W>K_)C)BR!8J2A@3`#S>#:3SRX^W.A\H<8
M>[W\K<><YL=XE9XS8WK%S_(&-^*-SL,;CQ?&[++^1>*-;Q$@><MSR)5*\EXE
MM;65=FY@IWKEIU+K)'`8A5[*7=U75564[<_+H5%E#JJ"7"=O(`G4,)S"!"1I
M2$`3#Z```#X`T!W56[*W=L96>N/'/;IY<I-VL]#N5U#X7MY")HH2#=14YSG8
M%(0I"%$1$P@`!XB(!H"T>[R'"KE/SHX_TS$/%7-KC"EB7OB+J]2TK/LDL>O:
M;$M0NT<K;J(M1K._R))-\A4>#9Q:#:2@?DL9)Q(*JNTVXL5P%L890M_'KB-3
MW>>K3>+W>\:8@5MV7[#/3@Y9N4A9V$*[MMX9-9NFX_I:UY)$R2CEC%&CZTQ6
M=,V[<B;,%!Z!`1?A3NWX+R1B/&7(_(MFHF#,-7'AA&<L;E#7E3*2>4<<-7F1
M:]CV1</H]WBV'KD[BV$G)XL?^,#9T520>BFX9M58Q0'H`;!)WA.W4+YQ&.>0
MAXN1C+;!4VS,)W$F<:^]H;VV+P;:F6#)C6;QI'K8QQU>%[,P+!VJP%C:U,BY
M#U-^MT*]`&[[#SWXFU7+JV$)W+*+.\LKO6L83+Q.G9`>XXK.4;FWC7-0Q?;\
MRL*HZQ!4,DV=.:9`Q@9.=:RKA5\U2*@*KIL14#V'(7ESQ]XL'QZUSC>UJI*Y
M:G92K8OKL73[U>[5D&T0\6,T^K=0JV/JS:;!.SQ8LHK)M$&QEUBE-Y93"4VP
M&KYWN0<,(#&^+,J'S($_6,UN[BQQ=&T3'V4LBY$MSS&[APSR:U:8AH5)L>6&
M3C%SYHHVM!'<*W/7'9?5Y$&RYBIB!UEO[G?!:D0-+M<MGZ&DJE>L7QN;XVVT
MJIY"R+58##,O+.Z_'Y7R/8Z!4;+#8GQXO/QSMB,O9UHADD[8/$U%"F9//(`\
M9']QVAVB_=Q3&,!%$K,OP&HS"VR5^R-'Y'BL4VA!_AE/*KN?E;)$XYD`B:A6
MEW:;9R,8,U)OV"*T@P:N&XH^8!G3G=4X08^F(ZCY1SW6H/(#**PXYR`A7Z?E
MJQ4?'R^<:[6Y[',Q=+XTQZ-=Q]1;N6T-"Q$S95XAFN98$E#I.$UTD@/6#SSP
MQ2T,I.<LY"I*:E6Y.VKC=2*QB.'RWE/(MDM=<HE8O:U*6QO!8X5NT[E"+@Y=
MS(RK2ML9N)81!$G1GW2#D$`.XFNXAP]A,=XUR<&7#6&O9@D[A"XVAZ+0,G9#
MR1:9?')W:63(MKA^C4NPY892.+W#%5&SH.H5!6NN2>1(E;+&*F8!*EQ[O^"'
M-PS#3<23U-F(2@<+,9\RJIR`N@Y3:\>K-6,EVRXP+:/D[=2L5VU6,C82+JZ#
ME5XV%ZX<O7ZD<BU%[&223<!6DOW!^'T%G#_V[RF96+?)I+[!XG>%)5+ZYQ_$
MY<M$<TE:UB*=S(UJJ^'H'+%@92#<6=:>3J$VX4<H)$;"JNB10#H*9W+N$>0L
MQ16!JAG%I+9(F\@W[$42U-1\F1M2?Y<Q@M8TKSB=ODR6I;'&A\GP2=1DG`U_
MY7^5UV;4SE%NHW,FH<!=>@#0!H`T`:`-`&@#0!H`T`:`-`&@#0!H`T`:`-`&
M@#0!H`T`:`-`&@#0!H`T`:`-`&@#0!H`T`:`-`&@#0!H`T`:`-`&@#0!H`T`
M:`-`&@#0!H`T`:`-`&@#0!H`T`:`-`&@.HGXY28@9N)16*W6E(B2CDG!@,8J
M"CYFLV(L8""!A*D94#"`"`^&@(R__2?YFW'C-2,66ECA"L7&B]L"B<!102R9
M8+-`6&W8HY,8LO47?$Y(,;1SAE4;MCC'JSSU55J=Y&OW)&)RK$*9UH!;G*SM
M]YNS2GW9OQ/>XW06YO8.XN8YQ`><FI9D+.>PQ$Y`96=2^G:UE^>(C#.+2W%@
MHU^4#J!Y@F(D(`!@$_VCM;YN-D_/=$&G0F6L*<A>8,QR=/?+=S;Y88YQ_3*K
M?,GUC+5UI=WX<8RDH:E9$O\`3;)#NR560:R[&.D!^2W,H9`[%9)T`I/N..,P
M17-;M.67"&/*OE"[UK*7+61+3[C9WU$A92%<<5;?%S:+6]M*O<$*K9?D]^<T
M<JZ9&:NE2F:JJ(D7%8@&L,4<(^8?&C*E0Y@TZGX6S#F:[/.;R^=<`KY7GJ!4
M*6CS$SSC?/$"7#.59#&L^66<XX>8P91-B4D(*,"RB[7DD"MU4$62P"=[+VKN
M8-,HE+:8TA\5+9VD<;9F*?D5A#DGFCBQ<L(9HSCR,S5R)F*Q.1T=5[G2.47#
MBESV8RI1-8LE<^4$E8UZIZL)9I0C$#=EL[:')RUY=[A=LLF1'LVKR@X<PU`H
M-EK6;[GC?$]LSH7B`IQALS?-W&*$KKFI.XU]8C'L<;-D=29HML=!LDT\UJ0P
M@=C9NV?R!F../<OQ4UD,6A;.7F&^+./\8.E[!-$BVTMA;BWC+#=H_'-\6IJ.
MXN,-<*F^58&;HOC*,U"*F(DH<Z90$B8[XQW'EO?LO\O>.\BIDJ`Q/W..<+F$
MK=2Y#93XP$S=B_,6"N,^.;!:,5<B<1E4DV\M2;_B@&Z::A58&:;HRC)9PBL5
M)4H"P\1\'>4G&*Z8?Y/XJP_A>T9,:L^8<!E_CU*\FLTSXJQO*?)&&,CQ%^CN
M369Z]D6R7?,,&[P7%-K@Y=1$3%382#E:/1;F:))O0/#9[[?/.O+T5G2-F&W&
MB2L?)SMMT7C=<IZD3]GQQ0,:9TQIGW-^7XZ*K=%=U"Q2<]C*<@LU$C"37K+6
M0]=AUGB\<3U\$4`-B6W@IRQD:YFCB!$P6&%N-V<^>8<R)'DJYR!/,<G5*D3O
M)VH<L+?C<V'$Z&Z2G,L1UYKCB"K\^6R(Q:$*JS>K$3=,A9.`/?5W@'FV,Q;Q
MAJ#IWC@DWB+NTYOYR7$[6;EC,5\2Y'S;RQR'",X9R:LI+O[XE`9MATW+59-!
ML1=-R0KLY$DSJ@/,Z`-`&@#0!H`T`:`-`&@#0!H`T`:`-`&@#0!H`T`:`-`&
M@#0!H`T`:`-`&@#0!H`T`:`-`&@#0!H`T`:`-`&@#0!H`T`:`-`&@#0!H`T`
6:`-`&@#0!H`T`:`-`&@#0!H`T!__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>pg4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg4c.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`OP&9`P$1``(1`0,1`?_$`.<```$!"0$`````````
M```````+`0,$!08'"`D*`@$!```'`0$!``````````````(#!`4&!P@!"0H0
M``$"!0$%`@8,"@0("0T!``$"`P`1!`4&!R$Q$@@)01-1@2(4.0IA<;'!,A46
MMG=X&9F1H2.UUA=7M^A9\-%"4F)R,R25)A@:@I)3DS0E5=66LM+3U#56AJ8G
M*$A828D1``$#`@0#!`<%!0,)!@<```$``@,1!"$2!08Q00=182(3<8&1L3(4
M"/"AP=%"X5+2,Q5R(PGQ8H*2HK)#)!93<],U%QC"8S1$)=6&_]H`#`,!``(1
M`Q$`/P#HBZ^G4MULZ6'*!B','H?B6!9=E-^UJQO3JJMVHC%TK;&FS7>P7^Y/
M5?F]GKK;6?&(J+4E*2EY*0F9/%N(J>VE.WAW<3VKCT_WS_J,_L(Y4_\`0.H7
MZ9QY5'QN/`??5`]<^ZC)('ZB.5/:9?\`L'4+]-(\?3*:\**'R7]B?H]<[ZC4
MSQ:#\J8$O^Q-0T_^3F*S%+1G[P_U5[Y$B??[YSU%SM_43RH^.S:C?I=#P?O#
M_5"G,MY"VM/O_8C_`'SGJ+_L)Y4/]#:C?I='G@_>_P!D*/Y:3]W_`&C^2/\`
M?.>HO^PGE0_T-J-^ET/!^]_LA/EI/W?]H_DHZD]<HZD%>%^;Z$<J!X023\2Z
MC&0\(GEXG+V)SCU]VR*@<['T*\:?MN[U,'RHLP_M?F$Q?KE'4?964*T,Y3RK
M=+XCU'3+\.7"<>"^C<*YC[%%-MB]@E\MT8![,W[$_;]<=ZDE1(HT0Y2T3_L*
ML>I!(\8RTC;[<0G48FXEQHI\6S=1N/@A!<<!XN:KVP>MP]2^_K2AG1[DZHTJ
M3Q!%38M55#P#:SDRC.?9%GOMSV=J,V?#T+9FT_IZWGN1X8V`.)IAF8/OSA5@
M_P"M8]3A@E/ZJ.2]1X`LCX@U>!$SNE\HS.+3%O2RFX28UIP_8MAZE](^]]*>
MW_DZ58'82,_\16NOWK?O4ML-2:5_1/E&<X5*3WC-DU+#9X5%/$E+F4)5P&6R
M<C[$7BWU6WNFDB7U9*_>M'[HZ3;LT"^#;J++`T^($@_?F)]BIQ?KD_4?I_A:
M'\ICN_8BRZCI(EVGBRT3BZ6]Q'R=7U46*3;=O+?%\8'^E^Q0H]<SZC!)`T)Y
M3]I_[&U&G\[9F+CY\;F^$&M.U43]*GD\!8/#QJZOO"C1ZY-U'"%J3H7RG=XC
MC#B/B;47C;0WPE2U#Y7S#<U`!1$B=@VQ1R%\9SG!I[@5<&Z1'=0_+VS6BZ;B
M?'44`QP(`3A/KEW4<41_]">5!(42$*^)M1@%D;^$_*V2I3$_;$>&8AN;-A_9
M_:J*'0;R>0Q5CJ/\X)KOKE/4=;<6P=">4]*VP4J*K-J)Y"Y%1:43EX`=(!DF
M<S`3N<SS`[#^S^U)=OW4-U_2W%GFD5IF'"E?:I>KUS7J.(44?J)Y4"H$`@6+
M4)2CY((,AF4S),3XI"YN8DGU45#+I\D,KK67*7Q\J]OJ*8/7-^HY(']1'*@4
MDA/$+%J%PA1$^$J^6<@N79OB9F]*@%B":')3T_L7H>N:]1XD);T%Y4UK5N0B
MP:AEPRG/R/ED%#=#-7M7KK-C1_=AGJ-?P64/(YZV5SZ<S?.-RR\O&8Z*\M5H
MQC6S6S3K3'(;MCUISJGOU!:<OR:BL];46UVMRZLHVJRE8J%K1WC*@3O[(B5,
MYI::'BE#=(X4I3,GA`$U&9,A*9/:3!>)L$1!$01$$1!$01$$2;'ZR3U5.HCR
MH=575O1OETYO]:-'M+K+IMHG=;1@>&7VFH+!07+(M/[7=KW64["Z)\I=N%Q=
M4\ZKB*EN.'L$H(M"OV\_6(_F&\R'_BRD_P"[((C[>?K$?S#>9#_Q92?]V01-
M'7FZP\Q/J&\R($]I&5TA,O:^+8(GYZ\76#"`O[1#F2X2>$?ZU4<YCV/B[=!%
MX'7EZPA,AU#>916S9+*J,;?9G;MT$48CKM]8'NEN.]1/F30I*%*2A.44:ID`
MD`GXO$H(O=LZ[O5ZJZI+-5U$N9EIHI42MG**%2TD#9Y)M\E#QQ)GD=$S,VA5
M1`ZQ;F-\7M93#+3CWU!5]M..L]U3<AM=>[D'4&YN:JN#B!;W+5J':+52MHXP
M'!5-.XO<G'5<.T%*D^"7;&$:YNFZTV8,:&T]ZZLZ0="MM;]T22_O)IQ)R(IA
MZ*$+*A_J@]0^[4RODKU%^=.D=H+`B[7:KR'53$ETQ>I&&S=46YAC`TU"PA]Y
M(:0I7$I,R2(P@=4;R&4L?%F\5!QQKPY%=2V_T+=,M3LF3PZ^;>=T+7N!R'*:
M>)N-P#4'E0>A5EI1U'^=[+K?F;V:=7+G%QFOLMDL];C]%377'WJ>^5]7<$,7
MJD<K:BW^<TWQ=;BMU@ML*%0Z`F:-\07G5*_M&>:^W))<`*9O6"*$8#G18ZWZ
M*=BNO_EK#673ED;W.;X<WA&#@WS235U`1P`->Y859GUH^I_BUQR%AGJ*<WCE
M/3UE;3X]5.YE9W$5S+-2^W2.UU.O'!YNMZD0TM83\%2E#LC8>@[@GUAC'/RM
M+F@X'A7V<_S7+/4?I7I&Q[Z2UE,@MVD@.+1[:D?C[EC[5]>/K`MON!'4.YE.
M#B/`/E30@R$AMX;8V!M_P1&9@%HH[BN=KIL#;A[;5Q=;AWA/:/4H9KKQ]8AU
MQ+8ZAO,A-1D/];*,;>P3-M`VGPD1[5HQ=P4EK<QHHQGKL]8AY00GJ&<RI49R
M_P!;*%L&043)2[<D'8@]L2W&2O@`IWJ8U]BPD3/=4=E/VKT.NIUC5+6A'4.Y
MC0ILR4T[F%&A])'#Q<31MO>3'%N`),C'F=XH'BCBJ62YM0\.C)-L[@[#VUX(
M/73ZQ\P$=0SF06DJ">]^5E,&^(F4@3;)SG[1]B&=]0TM\1X"F)HJ^>"VAN&6
MK9*RR"O$885[?R1]NIUC3WO=]1#F)>2T5!3C694A:\DR'EJM*`DK`)2%2)`.
MR)E):GPG#N*I2T"<0YV8\,>/WIVYUU^L:UQ!SJ'<QB"@)XTJS"C0M)4?)!0J
MV!1)&W9,2,0DR#BT^PJL=9!IH9&<.W]J]+ZZO6/0TIW[0WF,4E+8=(3F%&I7
M`>(A24_%@[Q)2@JFF8X1.<>@O/$&GH4#[4,87^8PT%:`_M6R3HT]8;J>:_\`
M5&Y)M&]8^=K7;4/3#/\`6NT6/-,)R+):>IL>2695JN]4Y;;I3MT#:GZ5QZF0
MI29B?#$2I4J;>:5/]]O_`)U^"+DU]<N]&%II]:?`_FEF\2_-:[A7G]RG1G&G
M;3WI,$0WQ3.S^GBB!TS1VJ[1Q911W%>PS(@[-A![>P^U$#I@6D8J9D8GJE\(
MF?#+8(IP*X!>Y(NPI@4%">W\4>D$8*KB;'D&!31([-OXH\."G-CC<:"J]</L
M_P!/P1Y51^0U5UB-8EM2TD;4B0'")'LD9^&+3J$,I(?&6CTE;3Z=WEE"]T$[
M'.<304I^:K!_'5W$FJ"$I"25'>)A7@`$ISBR.U'Y4ACR"YW9RHME7FR+K6'&
M]LVL;"S$YJ@FO90%1=MLX#[=.EH\7$F4P3MXO8V[3%/<WV2,O?P+3P5WVYMG
M/<LMFM:9<XXUXU]"R]Q/`[O:;=07Y^V/M4-2XTFG?J$J2R^X%>4A"D\7%/<(
MTUKFLP7,C[>)P+V@UI0T7T*Z4[*U/2VLO[ML$<3:8.+@<.?"GWK*#5;0C4C3
MW"L:U,R;%*BVXUEE(PNT5?`M3*^_;[UCO2IM*$<:#L`)WQ@&W-R6]_?S6%O)
M_?Q2D&M/%05);0FH]BVYN;<FGS70AMV"5PB#2YGB`=4X$YN/JX+"[(<'5?:2
MLN+Z$-H4E?`25)_*D\01()(E.-S:1K++65@ESYG'E3'[US3U&Z2ZINVPN-0M
M/EF-R5\9>#Q[F.Q6+U]QQJEJWV"%>02F:9F9F9@3EV1M"QOFOA$_B#2OGYO'
M:$^DZ@[39,AN`:5;4C[P#]RI)_'B@+<FE*)CR23Q2EVCV8OEK=Q2$.KA7AS6
MOK_9]Y!`^7-&TTYD]G/PK89HERXZ$ZKZ"YY>K949W6ZFZ?Z<W[/,JNM)=+50
M4MERVGO-,C'=/,?P1WSR\Y7:ZZUD5=7<VVNZHDF:S*<LQLA;7@,5'$4KB,,%
MRENW=>L[-W)9V6:)S]5NODXLA<0UY8^4.EX492,BK<QK3#FJJU$Y;.76NU(U
MPT#T^L^?8KJ5I;IU<L_Q/-+ED[.36/.W,;Q6UY9>[%=\?9M](BP,72@JG4T]
M2UWDWVD(,DJG%4=-A,CH\N%,.P]QPP]JQ:TZDZ[I>W;+>EY/%)I5_J,-GY;,
MWG-?<2>4QQJ[(6-<*O-:M'`.5':%<H..:O<F_,+J_<$910:S8!>+9^K^TJ2:
M"TW6Q4%JK+UD+%9;:MEM5<Y\5T;KC+Z"2%(X9[1'EOHL-UG,5`&89.1X'TU4
MC>7634-`ZN:?MR[$9M[R)KC*"2YA.84!S``>$<0:UKC@KIZJ].+3RPZ4Z/9S
M1:I4F!4=%@??Z^Y9EU+<+_1V[5&\7>T4EEPO'\=LX^,*BL%/<UK>40E##=.X
M5&:0%7"]VA<6;&SMEA;&X"M2?#P`&#>]8UM_KPW4]VZII-_;3SRMNF,@\@-+
MBS)(Y\DA?(T!@R`U'[P%,0K/U730U+L66XQ:;SFN%N6*JJ=1QDN34ANKUGQB
MUZ;6BVY2[6UKZ*)QXG+L7O5)5V]:$N+[FI`4$K04Q3_]*ZCF##)"*UQJ:8?Z
M/K5^N>NFVVV5W<P0W;S;.8UK0UA=+GJ,T8$F+&D$/.!'8JVRGI<9]\8YNJBR
M6PX^:.[ZD,:?61ZFR6\4>4T6F5J9K;W45&555%2TV/HKG&W&J!5<ADU;PX4;
M=D>S;2U.WB=+(^$M!(%"X\!_9X'ECBH-I]>-LZQ>1662Z\]\;'&HB`!>31M/
M-S$M_4`#EP5K^D@DIZI/3\)06PGFWT-!;.]$LYMNP=I&V<SMC&BTQG*>*Z!N
M`RZRW,&$3@./&M$MC05`B"(@B((B"(@B((B"))?];0]-'K;]$_+W^Z^S01<T
M\$1!$#V1/V((FDDB4S('8.P01/F7DM&9;"S.>TR[-VXP1,4XM:E;9!1)E(;`
MK;+<-P,>5431F-%-[1;'ZVK:99<X%ND)XN&?""=IE,$Q2W5U';0F25M0K_H^
MVWZW=LM&GXG#EP';Q6=VE5B-ML(H6E4S]0^%26[Y"PL`<9VE>X1I/<UV;V4D
M,RBO&OX4"^L_0C;%EM;9PM7!DEPYHXT;^)60V$7#$L;JG;MECUVN+K=+545-
M;:%+2Z)9J&T(67PIT`ME38F);8UK=/GN7_+Q1M$8H:UH:COI7[UT?HVB;4TI
MAOM2CDG;(VI:)'M`+NRA.'JHI!5.VEB^*RRAI*=FF4\$MT%0B86RXZ5)0EA)
M+2`V=QB>]EQ<6ALWAS6UK7$X]M:*2(-F6&N?U?36"$EA:X&0NP-"1B>[LP5E
M->*_!KOCM$BU6ZKI\D-35OW5UX-IIP%K0JG\U"%+FA")@SEMC:&PFOB<V(U]
M-2N2/JL&V-PZ))!80,ANBT^,&IX4K2@]ZP+N*)ON+G+RE[`/`3VS]B-U92SP
MDU(7RG?;?)O-KFS>6:5X5[Z8J#II=\D*("3,*F9#A(VA1DHA)&_9.41-9YAR
M\%YR-#0T6XSI^-U%SM=BPG*M,[*=.M5KSJKB]'G#N`V#(Z')LV5@*Z:EQ[4C
M++J_4WC#,`P+SMBY)^*V6:M2GEK*R$@HRK1((6$,FC$K'!W9B<IH"?TCA0A:
M&ZF3ZC:M==Z?</9<0NA)HYP+6>8RKHXP*3O(+BYCC2G;7#(-R@N-UU^H]$[Q
MAN,5?+HODTPN]YPI_!<9MMLQ5ZJT#HLC.=#-D8_3WBSW=W-D4BA5FX.N++RD
M'CXR(JM1AM)+X!C6MB,3:MI4`Y:UKQ!KSYJW6-[<G95AJ-[<2Q:O#?RY<<9`
M+E[<CF5&8%F-,N&%,.-`\F^B&'7+EYYFM-\CK-*M1KUJG4Z38#A.98<ZSEE7
MA>>Y.QG;^&4[-XK+/;ZNR/W')+12T-6E@+4M%2-I('%*L[>TN31^0/(RM(H:
M.RFF.%*GFK'U3U[7;'>&D:[I[[J.PL`Z2>$M<WS82:/-`XYLK22T4-2*"BOU
MK#H)H53:%X[<6](K=G]?RUZ87["48KBINEC=U0RRTZL8IIUFV>9)DN$4C&27
MNT8O>C7MTZ#4E]LO-=^.Z/!%QDTO3',;()03&P@M`^)P(!-0ZI`-?3S5FT'=
M6Z[S6)OF+N2V9>W4<D<LD8RQ6[HY)&L+9,K6OD;DY#+Q%4XM7(=RLV_*KQF%
M);[M28KHGEC6,Y[C];EU4_=3FVIE!I?==%,>:KW5.(HZJSY'FMPH*L(;2NH3
M:7"XGBXTI]?H^ENG\QLV6%AH["IJ0W+^KM)KZ,5+U?J5U#M'OTZRC^;EN8F/
M@ER!C*,,PN*Y6.``$;,M3B7&E*8VHUUY5.5?"L%SVNO%!F]SR[+K9S$9=:<E
MQG%]2,FJ,5R3!M2LGLUJMJV<5>;TZH\?Q6BMC+60.7=`J&4UX<;4UP2-KU#3
M+*WM7/$CGR%CW5#30$.HT&A(X<UGVS=Q[VUC5XS=&.&PCGMF.B<69GL?`'22
M-S-#\'D4#:U&;'!6/Z!C8;ZRG3X2%%4N8"T;TE"A_P!1Y#(*2K:%2`/CC$%T
M(EFR"+DA]<N]&'IG]:?`_FEFT4C?XO<%-C^(>KWI,)9W'Q1*?Q5]3V(%XG3W
MP1_C#W#$;.*%>4?!'C]V/7<55P_`$]1O\40.X*HB^)/8A50IO:7O,ZAIPJDE
M3B5'L`$^W?.44EZSSHRUO&BR#;E\W3+]CY#1KG`^I9!VV\T:;:GB6`HB1/#Y
M,Y;$@[.*8]@1KZ6QN!>9I,WE@X57:&B[DT=NA^(M$CVBOI]BJ7$5?&%WIUH0
MVIM#B=I;XIS.V9V>_*+?N*<PV[F@_II]RR[IGID&K:['+$T.C$S'>GQ`E;^M
M.=#GM6M,=(+5CU"JH\QKZBLO(--)D(+J4M-.OI5-;8*)E7#*7@CY_;@W_=[7
MW/J$=PYQ(;5@Q=XB>P!U13DOIKJFDZ9<Z&[RWMMVY<3PY=V5;2>='$<DUIY3
M,4TXM.)V]NHT]M%LIFZ>VT[8J:E=MHU,^<!$TE:@E&^?E"-6=/NIFNZOU$9=
MW4)@L&.+3AE#JGXB,K>7<?2M$[.VUI^D:]>,EN_FGW<C7-!).0-%*"KG<>/)
M<O61VZLL=FKK!<:)ZBNE(^XI^FJ62T\R4`I6M0,Y\*DD$?CCZ`VVH,U'4K.2
MW=_<M&-.%5L3=^FFQVU<9?\`L_1S6#5]4R[=RE]U(XWE$)([9R,S,1O:R_\`
M+O4OE]O!MF[=COF*?'S]*F#UGMZJ4++C84KRY$;I3[0H':!V;1%F@O;ME[Y;
M<V0.XJZZKL_1+_1_/9(P/>RM/L0KOXWS84.E^(45GQW2;$3J+:=/<PTQMVIU
M/<;M;:US&,W%8S>*F^V>B=12W_)&Z&X.TU/7OJ+K#)`3(B<;:TF]:U@D=A)E
M//M7S\ZC]*;:YURWN6R-,5K>-G%:$AS6O8*$NJ/CQIQX%3+,>>VGN%^U$SS!
M=%;%@>KVJ&,4F&W?4UO*[[?Z_%;(W:+?9[W1X+:KKQ6^R.W:@MS32GG`\MMD
MJ2@S,XN?]5IF<UU'GTG#N[*T6DM'Z.3MTFTVWJTGF:=9ZMY[``&T-N_S!F.<
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M3Z[9=B.0FH0Y4A[3>UXPW26Q>(X:L'O&;)?;%9J.WUDU<3E,P`9DSB4[<!=$
M16N88<<*`>Q0#H)96[K>6-[O_P`0QUN\?]NZ8N\;O'0N:7D@D/IAB*547G74
M4N>J-NOU%GFC=@OY7>L[NV#)3F>6VB@Q!G.F*9QZSU]!:JRD;RRUX_>Z87&W
M(JR5,5!(F4$B)L^N"ZM,TKG9A4BA(XTP(YT(55M+H3!MRY#K3RQ&YK1(7,8Y
MQ+:C,QQ<2RH.-.8KZ)-TE>+[4?I_%2BI1YM]#25&4U'Y<6O:J6R9]B,4CD\T
M9^];NGL&Z;&VU:<P&-?2#WE+8(]\^[$Y6--@B((B"(@B((B"(@B27_6T/31Z
MV_1/R]_NOLT$7-/!$01$$1!$01/6AQ.H2"!,I$SN$Y"9]B/#P4R+XPKF8:`+
MU3,I9:4XD(5QE?&E1X@-QV`[8L6OG_DQZ5M_IDZ-NMUD`+1'7T8K*:Q.U-1W
M].WP4Z$)XW'F52*0E7P$\)V*/L;XT]J>5KL[L<>"^B&QM0GOK06ML2&Y1B%=
M9MH5++***2>&F2*JI?`2"O@/'O,N)6V,59)"R4AP`)70\UK<W&F1PPN.<1@'
MCQHK>W-N[4M)<''*M]-.A![AH.$-J/%Y)2D$R([(R73V6]V_RF`5#:\.06DM
MX:?KNE6YOL[Q'YH;Q/,'O[E9?+[J/BFJ%2V$ONM)2ETS*UI`(*@2=AG+:-L9
MIMZ$0W0#?AK[%RKU=UNX;I3GW!=F+>:QFJ'EK<6#*0,ALV[I3GVDQM"M<5Q!
M-+YTKI1^HU3A$^(2`)\!V@^V.T1Z'9#F4+6EYRCBKA8WJMJ3A]JNU@Q;.,MQ
M^QWY#S=_LMDR*[VJU7UJI952U35XM]#6,4EQ;JZ59:=#J%<;7DGR9B*Z+4'Q
M`AI(:5;+O2+"YD;)=11OD;P+F@D4X4KV<E4]QU^UNO&,IPZZZKZC77#S24=$
MK$:_-,GK,930VY"&:&C787KHNUJI*1MM(;:[H(0$@)```B5-?F5Y+R0.''CW
M>A>/V_HT44!\N(4<7#PCPN)Q<.PDXU&)5-6?4#-<;IG:/',NR2TT-3<+;>JR
MDM5UN=%2N7FS/><6>[K9HZII'QK:*K\K3/\`^58<\I!!VQ(-]*YA9\)KAC3A
MS5PU#0=L23123-C?)D+22T$Y7`YFX\CP(YJ=6[6W5VR7&CNUBU,SBQW*W*O*
M[=7VG)+];:V@<R&L%POKE%54MP:J*1R\5R4NU:FU)-2XA*G>-0G$(N;KC5U>
MX]N)]O/M5#)M?;$@RMCA+,,"P?I%&U_LC!O[HP%`I-^M34E";NTWGF5LLW^\
MT.1WYEJ_79IB]9%;*EVMMU_N["*Q+5SO5#6/K>9JGPX^TXLJ0I),XC;<W(X%
MV)KQY]O>4;MO1&`-;%$6M9E:<HJ&D4+0>(;3`@4!46]K1JV[8KWC2]3]0%8_
MDE56UV1V09CD@M&05US?\YNM;>[;\9FANE7=:J3M4X\VM=0X`I941.(S=73F
MECG'(>*J6Z9I,+A+%%&)VTH0T`B@H*'C@.'9R6R_H$+*NLCT]09;.8"U$F7E
M**K'?R2I6]1B0IZ6;H(N2'UR[T8>F?UI\#^:6;12-_B]P4V/XAZO>DPEG<?%
M$I_%7U/8@7B\J2%"1GOGLCT&F(1-0VG=,RVGL]OP16,A;(`XDU,9=ZP:*IA/
M!O);-^GITN]5.I+?LRPG0K5/1^Q:C89:E9#5X+J/=,PQZZW#&T/TE)\>4%;;
ML+OMD52FMK$M%"ZI-2@^46N';'-WU%?4CLGZ:-!L-R[^M]1DT;4)O):^V9$_
M)-2K6O,L\+1F%2*.-:%7BPL)KZ;RK<MSB-SJ&M<*4X`X$E6<RGD;U<I^8F\\
MK^CBJ3FFU4L-7?[5<+;R[V?,,R8-]Q--<YE5IMPK<;M-9=EX\U;'UU#U.TIH
M(:4J8`C.6=8=@6'3F3JGO*:7;VRVQVKQ=:DZ"VB8VZ=&R)TKC*X1B5TC615(
MSO<T-J#51Z?I&N7L<D@C9X"1AFIA3F13FLR^57HI<\FK',9HOIOKARF\T^D>
MC^:YY9L;U%U+>THOUI&#8S7EQFMR==PO]EJ+)2M6M7`XI54DM%((,I@QSCU;
M^NSZ>]E=+=?WGT\WMLK6]ZZ=I\L]CIQU&*1UY.RA9;^7#(V1SI!4`1NS5Q'!
M10Z!N"_N86ZA&(81(&ET=:AH!\1S5QP'<LV>=OU<OFNY2L5N^7X(ZSS%Z;XP
MB[W.ISC`J-VWY-;\>I4N5355F^FM;5UMQMRJ.D94NIJ[557.C:;3QN*:3,"V
M?2]_B/\`TL_5%I]IM/<%Y+LGKA,]L46GZ@X&POYI"UK(['4FQ^6^21Y#(X+I
MMI,]Y#(FRDA;TV[H-C<Z2VPEOI&ZVPD-!`:V4<J'*X9^`RU%3P[%ITTDQ"]5
ME_MF/T%!4U%ZK[@Q;6J$,..$UKU7W2$I+8'&WPD;1VQT/U`@ET>>>UU=CX9(
M@:MI1U1@!1U,2[!=<="+35=)E-S+$#!`"YY<'5`9XG$TH*@`]R4$.F5T9,OM
MV!X?GG,'FM^L[;EOHJRWX587VJ7OF'U"J53W%SS=QTH<;("@E:9@QHG:?132
M]YZX=P;AL-6BHXG*(F92/\[,"1AV'F5C'U`_7!86,C]!V?Y+F.!&<D@XC]);
M*6D]U%MCYT^1'%=1-![I9M)Z=&$Y?AUF%9:JBU,IH:F]T]!3NE=)<EAE3E6X
M^@;5I*3NVQE75+H'M%FF-UW0X[FRN8690TM8T/(J:GPDU]?*BYY^GWZG[O3.
MH[+'<EQ)/97TC7.S4/E%[LH+/$*-Y.!KQJDV_F`>N=-GV<XYD%`[17C&;I<;
M'6A]"A6*?H:KS9P.J5M42DDDG:3MBQ]/+/\`I^G%\K@YP8"*\CFRD<E]HMU:
MU;ZULZ2;11YK7P#CCV?NDK5QD]*?/:^K6YP+8=="4S$@D*)2=NT*(CI"R>QM
MO#`WQ->!7N7R.ZD96:O<WUZ\Q7,3G4:*4P)[<5;:IR*M*)(J%E.T`<2I;"1X
M8R>72K:WF,;`2!3C2O"JTG_UIJD]MYS)2(W\`#@!6GX*DZNJ=<)>6>(SE(SD
M03V[9Q6PQ-:,@P6N=;FN-0+G2S2`N(X$<B#V'LH5"+K7%SXD(VN.N&7%O>"0
MH?"W23$UMNUO`G@![%1W=U+=UKX"73'P]LS6M=QKPR^'OXU7HH3PJ(/"%#BX
M1+A&S<`9[!$_RV`8FI"IH;-T%F;1LLA:>9I4?=10;SA2$ID%#:1.>P^$2(VQ
MZ&-K4%2;@21L;&7N<`QP%:8$TH_^T.`Y=R>I=FDGNT`JD9B>P@J.S;VSEXHE
MD$&E30*D'F>#QN\+2'?YY/ZG=XY4HF%1)\$^P1$UQ:TM'`J(NF+<HD>#VX?D
MMA_2/]*)T_?K;Z'?/FUQ4PBC%3R-<R(![G/=7B>//L2V*/?/NQ4*S)L$1!$0
M1$$1!$01$$22_P"MH>FCUM^B?E[_`'7V:"+FG@B((B"(@B((GAV;O8]Z(`O&
M$YAZ56^',K?N]*EHK!*TB;94#O&R:=OBBU:S*V"T\QP!`[15;5Z96C[_`'-#
M;-<1F(&!XBO#]BSMP3!JJOKJ>E;4&45B05U"E\`3P)XCQ3,I$=IC0&XMP0OS
M/8&BCJ``4_!?6KIYTNO(9X'MS-B<T'L'LKBL[](^57)=5:"\O6JXV%JAL5%4
M52W*UQS_`*T?86`FB0MGR&'IB04HC:8TONOJMINB^5;7#&LG%`3EH:?O$Y?%
MZ.:Z?;LW+%Y.![P`/Q5"<R6D!PRYT]LJ<2<Q;S"VVT5E(T\+A3OOO4Z95IJF
M^-I(J7#/A)V1>-A[R&K5GBD)#FG$$UIZ.SN6*;XV6V[TF.-[06^>TD4'85KA
MU2H&*9::=:&4-$`)4M*4H3-.T`J`2)D1T7MB22<"1A)/I7S;^J#0(=,N(X6A
MK(:<``T'#LX+$NM0&ZI]`((2XH`I((EV2(V2C;$53&VO&B^?E_&R*\DC90,#
MC2G!0LR-VR)BI02,1Q39GPG\,*!>''CBFA:Q.2U">^2B)^W(QX6M/$!>%K3Q
M`-$T..)F$N+2#O`4H3]N1VPRM)J0*KPL8>(!]29QK.]:C_PC_7'J96]@3)D]
MI_#'M2HN[DB9\)A4I0+;]T!_3)=/;Z?[1^8K]'B)9Q@BY(?7+O1AZ9_6GP/Y
MI9M%(W^+W!38_B'J]Z3"6=Q\42G\5?4]B!>(@B>(W_T]F+E#\`_[EW^\JB'X
M@NJKU3-UY_J":IN20X\>7R[E`6E*AQG*[&=A<XBDD[S.9&PF6R/D[_BYNF'0
M_;#8`UTKMT6H`<`6DY),"#@1Z<%E&A>8S4#Y6+OE7_A^-%I7UHUUS'2?FKYJ
M1BUP=M=6YS':U/HN-%5UEMKV2YGN0MO-,U=N+3S;;C;BDD)4F:3(S$?7;H[U
M)U3;72?2]LW&DZ->MNM,T\O;=6=I<LJQL3VMR2QO:0'`!O)IH1P5]V1OZZVY
M;W7S,,;\SS7.`:4P%,#17%Y=>I_K3H1KCI3K/57"^9^G37,[9ERL'O&?970V
M?)U6WO5-VJY5BD71-/15#BQWA%.Z2D$!.V,3^H7;^TNN'2+=?2:ZT?1-$N-Q
MV%Q9R7EKIEEYUIYSAGD@#(HO&RA#,LC0"0:X+*YNL;-2TA]LRUM@UU02&@.]
M1RU&//%9J\S'6)YJ.=/#*G)-==1QC.#W"Y5:++HGIBFOQK"?R3I-'3NVU-2_
M=<J=IRO_`*3=ZFN=09EO@'DA]&WTD?1_]&.Q[?<NS-KV]SU"D8]K]<U(-OM6
M>0`'""5\7E6+'<X[&&V:[_B&0^);DV/N[:^WMGLUV^M(VZG*74DQ<_#DTEIR
M_P"CE!YA8N\H7,;BVG>MN.:I9;:V*VCL%R9JW+/W?>*<[A?$GO4*0%+J$*2.
M-1$R9QJ7ZF3?=2-3-[MP>3)YC7BGA!R/#V@_`#4C&N!YX+ISH?U)T36+*[@N
M0R-UQ#)'_9#V.;4G+B:'$U763DGK1M=1X;36'3G36B;NS%M1145;44R%,,.L
M,"GI5=VZYP*#:1MV;2(UW9[JZ[6ED&QOTZ$C`N,<#AZ<K22<%K/2_HXV)JVN
M&[UB_P#.LGO)#`UX(J:_%YA]W!5YRF=;'G!YIKE>L57C>'MVH6MUNHO'Q:IR
ML365B13I#):44);0%D\.Z-'=6NL6_M%L&V>X[J"YOYLV411-B:UM,"6MS`FO
M/`E;IU7Z*.BFW+&+=-K,]DD.4_&\EV4U(KFPKZ%JAZF?*@-+7\CU^R"I165&
M=.K?NG=[&?CFO4!4.M-":6@>`>,$[S&)=)MU[BUBXM]/N!_RTLI\51PQ-.WC
MBN@MD[DV_-M6\MK,DQVL):0['@*`C`\5RAZA7`5V45U-1*6&ZBK=;:0T?*5-
M4DH"?[943+PQ](=!TA[;6W=(*YFM'M7Q]ZP:\-;WO>V%L:,,KA0<\3@!AWJV
MEWH:JTU+E!5M+8?8X"XTY,+1WJ`\D*G,S*5@QEFK6QMM4E@(H6D?[H/XK3$\
M$NFQ"QEJ'QC$>G'\5)''%*3(RD2.R*-K0#@K$^=TKR#P3F6Q,MJBJ7`-Y&S:
M.W:8F*630A3"25J#3>_@*U!3J%$!"25CB0D)1("?E;1X9Q*)`&8UHJOS/TBA
M<H-UMLD#C#A`XN)!/!)6Y("DI5-)&WLB8#08*@N35PQ!P7D"0`&X1X34U5,F
MQXBV(](_TH?3]^MOH=\^;7%7#\`4JX_EM]/YI;%'OGW8J%8TV"(@B((B"(@B
M((B"))?];0]-'K;]$_+W^Z^S01<T\$1!$01$$1!%[*A[GXI1"`O&BAJ54V*U
MSE->[<&W.`&K;)5M'#,@3,6_5(&SV$C7\`TK/>G^J2V&[K!\!I6X:#Z%M*LM
M_8I,<LSCBF!4-?DQ4M#RUM*0%<"P`"H\2CMCD^]L))]6?%_P\W;AQ7WWVQN:
MQM]M6<CG-^8\MM2!^*V5<G>:)N^-W##::H11U*'GJ]YUA7=/5"*AQ"VV%J,@
MX&@)GP2E','7'07V=^R^<PO%:4K44`HMKZ;JT6HV[3!\9%3@0H?GXRNS-T6&
MVBCKB_=B'57I;C0#M2S3M!-('0$\92AP>23LC(>B6EWXM#/*VD98<OBYDC\%
M0[JOXK/3A)=8-$@Y9N1Y!:*^8>^(NJ:-=,TVT&N%I0;04!2D`<2C/X1V?CCN
MS8D3F1-$P`P7R/\`K#W!#JMZUVDDEC>-06T]1I]RQ`62I2B3,DSG*7XHVJ<M
M?#\*^>CGN>XO?\1XKS'B\1!$01$$1!$01$$6W_H#^F2Z>WT_VC\Q7Z")9Q@B
MY(?7+O1AZ9_6GP/YI9M%(W^+W!38_B'J]Z3"6=Q\42G\5?4]B!>)VZ2$@@RV
M^\8C8`3BB?,$\*%*'%/B\8!E%?$YUH^.XG;FMG`BG(BN(Y<^]5D)C\K'!ZWF
M=%SJ+\NG3.U5SS7;4S"M8-1LTR#%:G!;#C&!JP^AQMBTUU9;;RJ[WBZW>J:K
ME5K+E(6DTC:>%/%Q%1.R.)?K*^G#=?U0:!I^S='N;.RTJRU&.];(]\C90Z/,
M,C0V*9M*.J#08\2KKI-^VROC<%SR#&6$89:&A^P6M'G"S?1S4[F%U*U,T-1J
M)1X3J1EF0YVY;-3:+'J#)+3>\KO-;>[M;DC&KC<:"HMM.[7!+#JE)<6D34(Z
M@V#I&M[7VC8:+KTD<VKV-K#!YC"XYO)8UHD)<UOB.4$T:!4X`*U:K()6R"(D
MAY)->=?0L65O.I=)2XL%"O(/$=DCLE[49@\FX<Z6;Q2O)+B>))Q)/I*M=O#'
M%$&Q@`&A/I50TMSN#S5)3.UC[C%*5^:LK7-M@NG\H6A+R2KM,2[^]NKBSCLI
MY'.M(:Y&$^%M>-!WK+=.O]1O_+L+J622QC/A83X6YN-!W\U7MJK*RG<0MBH=
M:<X`@*21/A)E(S!G.?;MC#KAK:'`<_93%;FT&6]T+RAHLCK9[G-!R85J16M0
M5D;BU/4MT-/55?>.<!"E*)/%*8GNEL,XUMJWE/:]L+0#7BN_-@6M[%I<%]J)
M<XU%2:U/W!=/_1AU9PNQT=]QUY5LH+VU;GZJF%4`AZL'G82.[*`2HL@DC;L,
M<(=:;"^M-VC5]0B%SIGR]`UP):UPQY$8FO,\ENOJ7HL6Z-L0V>@,<RL3<XC%
M3FQJYV#NP5/W+*OJ5Y?R\:C6G`=(M?-;:[1'2J_WNC5?=2+1A=?J#66!#=07
MUM_$%LJ6:U*:T+[M=7PU":0?E%,.@%)Q#8>\NI4EE=W_`$HV]'KNY[4$V^GO
MNF64<KJ'_CRA[*MP(B+HS(?")&$U6M-/LKSIMTJU:9EJVZU=\.5K99!"0W-0
MR`EM'%M:AE!F_>"N[F/30Z0VE?3*U7S;0_)\0NF(9I0Z>(R'G1I[10<RVI3C
MC.I.%UK+%O\`B>X6AO'Q7W5-/1UMLLWQ*BG0\35,K*%I5H7Z<OJ7^O#J5_B$
M;.V5OG0;F_W18S:D^TV9<79VOITF32K\YY9[B&=LGDQM?<0W%VV[,KHFL@>W
M.TC@C9.GPZIOEEZ+&&^U"X=*YT;GY`\M9(^GF$/IY9\36T-2T-YKF2S[D4Z:
M&49;>KU7=3S4*UU%=4-J<MPY&LK=32EJG99"`X-64!0*6P=PWQ]S]U_^_&[W
M%=7,W1+;UO,YX)C_`/4/2G9?"!2IT@5P'8%2[JZ5ZG?Z_=7-W2WG?)4QF:(Y
M,!ABP'AW<%0]5T].FB*2L<MW5`SZMK6:.I=I*-[D@RFC;JJE#*C3TZJIS5M2
M*<.O!*2LI4$`SD92BTV6F?75>7+(9NCFWX;;.WS)!U`TMY8S,`YP8-)!?E!)
MR@@NI0$56-CH5?:B\0VUR(I`:DB:(5'8?!P6K/4#2"BP&BLM>WD-#>5UES8H
MW&&2SYP@$@K6L-.*_(F<IR&V.INH>SH=GZ-%Y+XY)G.<,[34X-<>P=BQ?J'T
MT?LNS+V7<<\H%`6N!-?4QJW_`'6EY`'\>U+Y('>4GE/OS.'9!RB:7Y%J&[HU
MICD%\LEVS^NKBJZU.355LIZNG%WJ;<ELNEQ:9MD$@S*H^2?T3_4++NO9&\I.
MK>[+6XUVRW%>06GS-S&)8H8R1&RCLI!;W`TY=BPK5+&2'5H(6>&)T+21RJ0*
MGU\59'UB[E[TAY<>8[EEQC1[2G&-(+?D/*9@62Y1CV,6A5G36974W*ZTUSN%
MVIU..3NR54_<.;BGN@#,S,;!^@+?N^.I71>]W-OO5WZW>'<FHPP7#W^9)Y$,
MQ8QCB&M;E;3P4'PTJ5)W-:-L]19'&,L9BX#A49:GUFOM7/D@DI23OE';;L"K
M`O4>(MB/2/\`2A]/WZV^AWSYM<5</P!2KC^6WT_FEL4>^?=BH5C38(B"(@B(
M(B"(@B((DE_UM#TT>MOT3\O?[K[-!%S3P1$$1!$01$$1!%-++(72BG_RZ-WM
MQ37@S6KV]H5_VNX-U^U<<*2@K-RQUM76M6^B;=XD)*`/*.R83L(V[=N^-%:E
MI[+2X?(\`.)7U?V5N'4-:BM-,MG.+&M:.)6?VAET^0S-[R6JJ7:9RGM#M#9E
MTZBGBO"U(4VZ\)'O6T\/"4^SOC1&^-.M=PR?)O`($E3Z!]BN]]IV,UK81B4>
M,1CVTQ*I'-=0JW.KID%^S[CN58B@;IJ5+2FZ=MHI/"T$@MKVA6_PQ?\`:VDV
M>CVK;:T%&@=U?N5HW7>1R02PW``:WAZ:+7/JY05%>TI-&T?R3CCZ6YS46CO,
MQ_=CHO9SO`VO8ODC]3-A)<SR.MA7T+%MU/"XM)W@R(W2(WCQ&-E#@N$"QT9+
M'_$,"G<>KQ$$1!$01$$1!$01;?\`H#^F2Z>WT_VC\Q7Z")9Q@BY(?7+O1AZ9
M_6GP/YI9M%(W^+W!38_B'J]Z3"6=Q\42G\5?4]B!>(WP1/FC*9[$@R&SMVQ4
M7-P9K>&W'_#S?[1JI,DCF^$5Q3$+((5-22F9"@9*!4);"/*!,72\D%O#':6X
M:9RT5=AV=O[5ZZX='X@,5Y4>+A2D&0)D)]IE,B>XF44S;:6R+;J[`<VO#,#7
MV$_>%$V0R@YE`N"2U#_",4[WB1YD`HUQK3LJO01P"J*RLEUT)(V)$]W^'*+9
M=GPBBRK:\1?>&H.%.2N4RVEM=(EL`N\2>.<I2)$O8V",8NJ4=7A0K?=G`W/`
M!B[S&?[P63%774]NQ%+C;O=/=V9GV#.8]LRC6,;9+F^$&4EI<NZ=P:Q%H.P&
M31$!P';CP]"@]+^8C,=-:YB]8OD5?:JVG4J3M+5*8.^90H#RE)/X(N^J]-]%
MW(QUC?Q,<7QUJ1PX]_'UK6FT?J#GTFW\VZ=G8UQ%">7H+3[E.];.:34'7`,N
M9?D=9=NX0&F&G5DMAR82IPS\DK5_>D#%IV#TPT+8KIXM,A#)Y#@X4K6M>/+#
MO5CZD]:9MV:'.RV=D:YM*`4YCL:U6/T\Y@]4-&:?*L:QG+<CMN$9R*!C/L,H
MK[<J/%<SH;?=*.ZT5/D=EIWDT%S=H[C1,O4SCK:G&76PI"DD3CI+:9TR+<&E
M[FU*PL+O<.BO>^PNIX(I+FR=-$^"8VMP]IE@,L,DD<@C<T2,>6O#@5R#8=1I
MMA;CCO(8\TCI"3X:_%4.(.4Y7$$XX$\#A@K8ZD9J]DN:WV^VNHK6:"XOL/4[
M"JA:>X2FDIVU,)"7`"AE:"E)WD"9VQD^Z=RZUJ^OW.H^>\>:\'!YY-`Y'N6%
M=0-Y;DW#O&^UJPF<VTN)&N:,U*`,:*4J.8/(*CZ>[7=2E?YW7$!))X:]UH@>
M&?>^5[46`ZMKS&.,=S(,,?&>'^LL0;J6]Y\+>X>'C'^8!_\`&%X177"LK*5J
MHJ77$)K*920\^IWA`>3,E2UGL&^*/4M:N[[2S;7;G2%N8@FI_2?3VKR;4-?=
M&6:M(Z3TNS?B5VD=8?JH\Y7)UFW(MIMRH<PCV"X-E_)WI-?LLM..4V)Y'1UV
M6/N_%%2NM>JJ:Y/4J_BUEI):#C2A/B[08^,_T1_3/TXWWL??>J]0](U"/4CN
M2^\NMS=6_FL+G.#FLC?'X75/$'\%E^L:L1K-N&N_NQ`RM*'A2@]6/:L`O6C,
MJ3F?-7RK7Y5\M^0U];R=8%4WBXVRNH:YEV\UE[O=7=%NF@>>;IJEVM>6I31X
M2D$$"1$=`?X9VGR:-]/MYHQLKBRMK;=&IMB$Q=G>PSN+799`'@`4%75S<:JA
MW7<-N-3CR&H;#RQ&.4T](7,VCX"?:CZ$.XK'%ZB%%L1Z1_I0^G[];?0[Y\VN
M*N'X`I5Q_+;Z?S2V*/?/NQ4*QIL$1!$01$$1!$01$$22_P"MH>FCUM^B?E[_
M`'7V:"+FG@B((B"(@B((FP7M*<5.[!3JJ+I1MMH6M9>0?)[`#,G=V117THBM
MW/<0&@*_[5L+N_W!:P0-)K**T[%L$TRQ+OUT[G#*H3P.!+ZY(,RE)VD`!(EN
MC0&Z]9E?5C<F6N&&/M7V:Z(;)M;)UM=S-D\Z@^(U'LHL]',.J*G"UT-NI%>?
MXVRK)*Q^G6%T#U)Y@A]UIU8!2IYMU7A&S9&@3J7EZ]D>0YDKLO'$&HX=@XKN
MJ[B@M+;/#4.+:GL]'<L4,HKC5=Z^EA33=7W27"1-!=1M5+<)<0W1M6RM[473
M6P%V4-KB<:GBM#[ZNI9K>L>#G/`/HQJL>,PH%?YY4!2^,TJTB2O)`"9$`2V1
MMG;UQ+;"C*4[PN#^MNA1BTDN(@3/3F01[%AA<&RFLJ01(AU4QNWF<;5MWYHF
MN/,+YLZO`^/4)@\>,2&OI4&0.&>V?9[43:FO<K/4U[EXB)1(@B((B"(@B((M
MO_0'],ET]OI_M'YBOT$2SC!%R0^N7>C#TS^M/@?S2S:*1O\`%[@IL?Q#U>])
MA+.X^*)3^*OJ>Q`O$01$$1!$010Z4*6\0D$^63(`SE/?%=+_`"A_9"DV,#C<
MD_YWXJKK85TY,TD<0`V[-L_:BQ3NRGO6U-"?):.)`/B`5=6IIRIJZ4E)"5.(
M`41LF"-VX;Q&.7TS6L>XG&A6W]`AGN[RW=E-/,;_`+P5Z<QI'Z?'V"HS;+:N
MS8=A`\.XB,.T:Z$MQD!P!_%=,]7;6YMMCL)!-&_@L;5.+0F:0J0*ID?!!XM@
M)[-@C8P:#V+A2:[F9*#3`#\4(KEIW3,MNS:8&(UK55\6N4;E=S^W:I'>G@^A
M2P05$)F`=H(&V8]B+M:"@QXK"MRW3;FI:I$W\!/M>_%2_P")80P4:`O40J)-
MV`<:-CP,@KLX);1+VXB!Y'@E.?-15375M6MA=965%9W#":=D/U574"G0$@)0
MUYPHJ:;0```W)*9"6P1Z2WD*>RI^W>I1:>>*]UUPK+DMEVNK:RK=8912MBMJ
MGJQ;3+0\A+;[JE2:,]B1\&40D-'`#$UP_P`JB:#S4#'BC1!%L1Z1_I0^G[];
M?0[Y\VN*N'X`I5Q_+;Z?S2V*/?/NQ4*QIL$1!$01$$1!$01$$22_ZVAZ:/6W
MZ)^7O]U]F@BYIX(B"(@B((B"*)X)J(&_@20/9\<2LV`]*F70R2-'(@*^VCN)
MN7F[IJ2S^3IT!9/`>'8H3[)2,81O74_D-.+LP!<_*!7NJNMOIKV(=Q;GBF?$
MXQQM!KD)'$=RSVLMH+"&F6^[9GW86XL`%".+:`-A[)F.<[^^=<$NDQ%3P7V5
MT3;L>E"!D(#<!ZEDI;,RJ<?P_+,6MU\2FGJ+56&J2H'O;JEVEIP*:D49J:#)
M))$]LHP%^B?,Z]#<EO-N(X#&N/>?P6P=6NCY!##6@QIC[EBED-TH&+"ZRXXZ
MNN[Z=.A4RD*4=BAX)1N*/3A;W[)(S5IBQ^Y<[[WU=D%BY[7`R"3A7'GRXK&_
M,+E7M%FGJIH2\/*4D_"01VD;P08V'HPJ,#6BXFZD;CENR8)@:4QP/XK&3(66
M$5KO=!/"7%'BD`I4]LU1M2SI\I%VY5P=NB&/^KW+@``92J26F6Z*MM:8A8/*
MQK34)W$2DH@B((B"(@B((MO_`$!_3)=/;Z?[1^8K]!$LXP1<D/KEWHP],_K3
MX'\TLVBD;_%[@IL?Q#U>])A+.X^*)3^*OJ>Q`O$01$$1!$011%$A2GE%(G*8
M.T;-IV;3%7+(P,%3AE_!7338QYM2,%6EJI_.GVV>'B45)V=FWPSV",9U&=L;
M3(#X0%MS;6G_`#UTR!@J\D4'^57KLMD0U64-.4`K4ZTM(\G;M3,SG(?AC`=1
MOLT,D@/A#37V+J;9&W+9VIVUBX#YD3,JW_2'/A]ZR!U`M-(O%&V@VA"VVCQ$
M%.P[9;CMF3&&[4G>Z[+Y":%WW+J_KKMFT.S!:PM!G8W$8#EVUHL*7:)"7.[_
M`+)4J?:)@D=G@C<PF:`"3@OF5=:/"971L`+FDCUU4ON%O73\*FT^21Q$S&X^
M.<MNZ)S)XWFE5BFJ:%=1PO?`S$<,0/Q5&5H*2L$;=Y\8B]6I!I1:XOX[F('Y
MD4(XX@^Y2UOX`E[/NF)[N*L-0<6\%[B%$01,V_TE$W^Z7N":)]L0NR_I1$0+
MQ$$6Q'I'^E#Z?OUM]#OGS:XJX?@"E7'\MOI_-+8H]\^[%0K&FP1$$1!$01$$
M1!$01)+_`*VAZ:/6WZ)^7O\`=?9H(N:>"(@B((B"(@BF5.A=0\RB4U/.-LI'
M9('MV[HII?[F,O.#0"56VK)=5U2&V`JYSFM'MHMGW+EIBY7TH6BX4-&M5%WK
MB*P.<*T(X#PHX$E2EJ4H2$<T[^U5MQ/D<<0]?<GZ5^GK]M[=&JTH)X`W[P?P
M5U5V:I8N@M]<E-(552DET)<!409!3:UCX)2!&OC.S('AU0%UDVU=F-13%7+N
MF)X[CU@5<[BY55=PN?>-T+#+J0ZTTQ(&M=3Q3*'5&1&^46FUU&XENO+B`P<<
M>"N,>CPV=J^>3#.*^U8K9K0)?<:J&G6VVE[$I"@=J9[.`'C$C&RM#NW3N,<N
M#@/M[5RGU*T@071OHL2YX'M6/V9TEY*%L]UWC2&UKXE(XE)0!.:5)!"01[,;
M.T6*%I`::+BOK##JMM;&:.-Q9E)!^Q6+%U>4_5+7)0(<DX%!4QP^3MF/8C9]
MFWRHP#3`8+@#5KO4+J]E=,TU+S]N*DBII!2=AG.+J9@^+*K)E(-2G<25ZB"(
M@B((B"(@BV_]`?TR73V^G^T?F*_01+.,$7)#ZY=Z,/3/ZT^!_-+-HI&_Q>X*
M;'\0]7O282SN/BB4_BKZGL0+Q$$1!$01>%+")3GM\$OZQ$0:3P13BV-D.)6?
M@J(4?#([=WAA-\"RG1[8N+7<CBKDXXAA%>@J&Q4N'8)S"MLYG=&(ZI4LR_IJ
MM\]/88H]78^7#@KN6^N9;NK2R3^3*.[.SR9`$SF=Q,85>VSO)<P#`@KI#;>J
MV=INECJBK7`^PA5AEN2.U-N+(<41(B6_VI;3NBU:)8&V=7@MI]3=^,U&R-KG
MJXMI]L58M5"HM*60DJ)4H$=@)W$R$E1GS7YF@=@7)/\`2W.CDGH<Q>37[!22
MH4D@MN34>'A1N($AV[I?CBH@KG!'!8AJ#:5AYE4+=J8^4H<('E>P=H/9*,HL
M@<%J+<MH0YQ`5.-B20/!/W3%4_XBM>Y<OA[%ZB%>(@B((B"(@B((MB/2/]*'
MT_?K;Z'?/FUQ5P_`%*N/Y;?3^:6Q1[Y]V*A6--@B((B"(@B((B"(@B27_6T/
M31ZV_1/R]_NOLT$7-/!$01$$1!$015EB5,BKOUO:""05MDC>`4D3/CBW:_*;
M>Q>[_-6P^FUA%JN\;2SC;XB]IJ>T46W#2BS.W.SU3%(E3=70VM+K)9=+"BE*
M6>)2%)(/&B?;''6[[AS;YLKAF8^3+3LXFI_8OT,]([<6VT[?27-RRQQ!V?\`
M21PH!QKZ<%?:BJ[JT*+#*_';-57FZTM-YCD+REU=;1-/+_RJ^&:2X@S]F<8M
MJ3H].MGWCW5B:W,0.-.P+9[X2W#`J$U$Q.^8?D;&,WYIS+6*6VT=Q:J4L/4K
MOF=73*<6PA?P?R1VJ.X@16;>N+#4V,N8"&->`:??14VX/F([$!CA\`6)]524
MU2Y<DO)\W:<?7YG3CRPV>*:07')N$I'@WQGS7^3A%\0YGF!R7.VKZ3-J<WRT
MDC`/.!%0>`_-2[*\=?H[,"^@)-32DH*4CB6T$R*O*$Y"<7+2-;G\[RO%Q[58
M^I6PM-=MHFY:Q[\G(=W>%B#?<8H4-U*VVP5%:C/AV^.0WQN+2]4=*&,.:M.W
M!?-/>?3:S@9/<P>6`7$TIC[E8.NIBR[4)*@2TM(V`[9GLF-@VQG\;#Y0?7"B
MX\UB$VFJ/M3Q!/#@I;$2H401$$1!$01$$6W_`*`_IDNGM]/]H_,5^@B6<8(N
M2'UR[T8>F?UI\#^:6;12-_B]P4V/XAZO>DPEG<?%$I_%7U/8@7B((B")BE<*
M293E+9XY1Z!4T10JU\9&R7CGV^T(FM;E"\)53VZ0#8\"4^Y%%<3T%*+/-$(H
MS#D%6%*\:=3;J1\%6X&4Q+P^W%CN&><#RJMI:9=NLIF7#.7+M4^H[DX'P\2=
MY/#/;[4XMLE@V1F2M#Z%E=CK%PW56ZE4T_=K^/[%.G;NNI<0E4Y&:.#BGM5L
M"MW]F<41TYMLW!P)]%%D=_K\^KWK6D%K?37\`IFE"4,=T?*XD_"W;]GL[HBC
MDIR64MA8VS$?,BM52E=;5)6ITN"0*E2X#N]OB\$54-Q1V6BU]JNAD2&Y\T96
M\LO[50MU0%<:!_9$YRW]F[LC)K&>HX+2V[<L%>8"HA3G`I2>&<B>V6_;X/9B
MZ9<WB[5J9S\[BX"@*$.<1EPR\<_>CPMH*KQ/8@1$$1!$01$$6Q'I'^E#Z?OU
MM]#OGS:XJX?@"E7'\MOI_-+8H]\^[%0K&FP1$$1!$01$$1!$01)+_K:'IH];
M?HGY>_W7V:"+FG@B((B"(@B((KHZ6)9<RVVH>(2V2A/&J0X5$IVJ)F.$&+%N
MTCY`CN"WE]/,,3NHEJ^>F7,/>%LUQ&]*H"S3VVH_+.H\U/=+""M#H""'"#M0
M"H'Q1RIK-GYKR'XAKR0OO'M3<5E';Q:?;$&1L0)IV+(+!*Y&-Y6W47-P5-9;
M'*1;X=*ZAMZG6$<*J61XDE!,E;2)B-7;KLKB]L'VL50V0$`CC4?O?@MGV,QN
MSWK*/F`K,?J+39\W;J`M^[T[%O:8IBH+:;33EI*GE'B#;7"LS!C7_3F/5H+]
MUG-\$;S]V%%5SQ_.1R1G@VH]BU>Y2TX+^JAITI/<!3\T[`I"I*!)W3ENCJAC
M1\J,WQ47.FNRN@UWR&_I-?8H"Y7>IK6W&ZSB4TU3*81WDSP`)V!O;(3(VQ+T
M^%L<X?6KG%6W=FJ/U'3G6SOA`P6/EWMS7=/\2QQK4K@2=V\SXMDXV3I-SEG`
M7'^\])#;.:G/,L3<FIE4ESJVCY04I/E#<"#.6Z7;&X+"4R6X')?-O?%G\MN"
M4\JE4U%8L11!$01$$1!$01;?^@/Z9+I[?3_:/S%?H(EG&"+DA]<N]&'IG]:?
M`_FEFT4C?XO<%-C^(>KWI,)9W'Q1*?Q5]3V(%XB"(@B\._`5XO=$1,^)%"#X
M0_IVQ.Y*$\?4JNMR!P-*VS*$D[O![466Y<<Q'>L\T7@WT!5`EX)0`J4CM\?X
MXH#4X!9X^;RVQJ)8=FL2.PD1++:&O-7:TN27"G,A3ZG"?.4%2C(&?9*8`(BB
MNL&^I9;9BE\U5CM*$$B7$D2BUL_%;1'\EO\`94JO#Z6Z11`3/@4DS]L)]^*B
M`5F`':L,W)/\MILTW8W\5:.MJBL.*`22HJ21X`!V2]DQE=K'DH.Y<V;CO#=U
MIS5'._Y17M^\(O+/A"UX\97$+RE7"9[X](J**%1*%<8G*6V7XA_7$IPH:+U>
MXA1$$1!$01;$>D?Z4/I^_6WT.^?-KBKA^`*5<?RV^G\TMBCWS[L5"L:;!$01
M$$1!$01$$1!$DO\`K:'IH];?HGY>_P!U]F@BYIX(B"(@B((B"*N<,6ZU=4=T
M2AT)24*!D>)0$I;]YBRZZ&OMB)O$RG-;-Z77\UON"-]F2RX#A0CBLX\%>K&T
MTU2\I?$>!/>$GBGL(V[!N$:#W"+8CRXVM%'&M.Q?7[I)<:@V&.]O2]SWQAN8
M\>6"R,H+Y46T-7EJME44[P9#+DEEQLI2X2>+B)3-1&V->7-B'_``/S76]CJ+
M(+02-?D-%>ZAS^KSW$[EC5#:*FXW-JG%0FAIDI6SPLI*EOH09JF@"<@1.,2_
MI+=*OA<#+&V1]2X<Z\:]ZN,>M0BV>Z)U74.:G,]ZQ'N]4_47BHMZFWF+JI2*
M=U#S?F]0.$R0R4$DA(W>Q&T[$EEL)Y_[R$C"N(]/):'W!JMCJ.JNMK=@;?\`
M$NX&@XCC^"@KY9;E1TZ&'$<#C:I5.V>U8XD#MG-(,5D=W:!X+&-#ASQ5FU;3
M+M]H'1$U/$JP>54=Q[YXM+4EL()0`3OGM5*6^8C.-%?`\L+F@O*Y+W_IVNLF
MN<LTGE!SLN(H!W8+%G+6WF*YQ#JBI2Y%95O)!!$SX8W%8"$0`,`!7SHWY!>1
M:V\W+R[$\?2J0BM6$(@B((B"(@B((MO_`$!_3)=/;Z?[1^8K]!$LXP1<D/KE
MWHP],_K3X'\TLVBD;_%[@IL?Q#U>])A+.X^*)3^*OJ>Q`O$01$$01/V8]4FX
M!='1N!J$[*9E,AV[3L[8B![54VL#J"O&JJNED$IE_<V=D6>;%Q]*V;IK&-AC
MH!7*/<ID=P'A3_3W8I>:OMU,(H0ZE33!/Z1\(=">$':.P=OX8.P&8\%'H%]F
MDH145YJKJ6D6[4H.V4P=YE^(2W1:KNYC<WP\5M/2=/FN;QLA!#:JOWF4N4K(
M'""TCAV``GP;MIVF+"\D.KBMP7NGMFTP11FC\OH/M5(7.V5+S#ZE*`0A*BE,
MR#P@@^"2B1%QLYF"1H'Q%:FUO0[FVTV>28N+`.9)YCM)5K*MD$+0.$%*C/<)
M]DMP[8RZV.8@]RT/J\3&APH,.Y4?4HX*A:?\)/XP#%W9\`[:+6MV`+EU.%5Z
M6!PG8-W@B%I-53KPQ\$_XQ]P1%)Q]2\;S3Z8\(_#$%"O43!W&/$1!$01;$>D
M?Z4/I^_6WT.^?-KBKA^`*5<?RV^G\TMBCWS[L5"L:;!$01$$1!$01$$1!$DO
M^MH>FCUM^B?E[_=?9H(N:>"(@B((F@$[NR/0">"\J`F\"I3ELB,0RNX`J*AI
M7DKKZ76%V]9#3I[M2TM$%2AN1(!0!V@S,8UNR;Y:R=EH/#BM\_3_`+3N-Q[J
MB^4B=*&OJ:4PQ';1;'K!BQ;L3:BP]W;'"7%]VKNT*"3+B7+A!,_#'+NH:FV2
M^<PO&4\%]W=E[%MK;;$+,M+AC02.8%.:I'(+T+4LTC*T*+@X5H!VI!,I^#<-
MD7VQTR5\'G2,/E&AS<EK/?FZX](S6.G2!]P/TCC]]%7&C^3.V'+;-=%5*V&6
M5H<<4@R2^VGRUL.?X#H3PJ]@Q8-Y6$;[0ML@'R@-.'(\U>.G6K27\;1J)\MC
MHZFO;ZJJ0ZK7>AN>:W3(Z!#5`JMKG'NXIB>%`<7,<.P1=-O0.?HS;:XPD'(K
M#-Y.T[3==^<L9FOF+J$"O`^D!2$7-VI9XW'E.K7+X9,Q(2D)Q5FRM&G%X!]?
MY*\0:LZ>R#CB**W&1UE,FH6EWA[R?E@J`,^$$=DMTHR;2;>:)S'@'R?TGM':
MM`=1M5TZ**?.]@F%:\>-%A=F%0:F\UKAV>7.7;M/]4;NTJ*3Y-LI!H>:^6/4
M._;=;BE#""RO)4E%R6"(@B((B"(@B((MO_0'],ET]OI_M'YBOT$2SC!%R0^N
M7>C#TS^M/@?S2S:*1O\`%[@IL?Q#U>])A+.X^*);^WDKZ4^B``GAR7@QX(E/
M=$;8I'BK&DCN"BRN[$T(4HA*4DD@D`;20-Y'M1X]CXQ60$#O7D0,\I@A&>9O
M%HQ(]2\F8!,MVP^Q[<,CLN>AR=JF-C)=E<"*<5%4K!<.XDSEL'X=T2G/:#XB
M`%?[&U?+\+23W*I!3J92@N)X)I'#Q`@DG=+;VQ:G2M>YP8:XK-8[:6T8QUPQ
MT8RBF844Q:;[QLR_L2)\>[P[XIWYFD"G%7^*&*[M7.)'EM&)Y!3O'K.NXUG`
MVTMU?:EM!6?)X3L`F3($;AVQ375U%;Q'SG!@H:5-,<5?]E[>.K7F6P:9@'"N
M09J`$5)H.0XK(*^Z:93A]IM]WO=@N5JI+PTI^W.5U!44B:AILR6Y3K>0CO4)
M.PD1@EEK-I>RCRY6.J:8$'FNF[K;0T+2_GY&Y(*8..`X=M%;-FYA;Y2I:0$F
M6\?!VGB[-D7NZMGU#@TU(P[U@FF[HCDN3'<O:UN;"II4>U/;U<:15$&P4\91
M\,*$B%2DL&>T3B.RMKCYAI+'8'L4C>6K6<VDRQP2,=F9R->83.7?1*Z<RO,3
MHGR^62^4&,7;6_5;!]++7DETI*BOMEBK\XR*AQZENU?1TBVJJKHZ!ZO2XXVV
MI*U)20"#%)U,WY;=*>F>O=2]0MI;NRV_H]WJ$D$;FLDE9:0OF=&QS@6M<\,+
M07`@$U(7,NHQNN9Q#$0#(_*#2H%:XD85'K6Q5?2<TBU&U&RS0#ELZCVA&N/-
M/C]7G=KLF@%PT:U_TCN.>9/IK27JLRG"\0S[-L47@E7EI:QRK104[U6RQ7NH
M`0\$JXQS$?K)WKMG;-GU(ZI]+MQ;?Z0W++2276&:GH^I,M(+YT3;>ZN;.UN!
M=MMZSQF9[8W/A:271DBBPNXT7SKI\-M=PR7N9P$9CD9F+*U:'&K:X&G;1:4G
MP4\3:TJ;<0LH<:6.%QM:"4K0M!VI6A0D0=QCO)C74#QC&1@>1KPH>]8WG:>X
MIC/P3_C'W!$+^*F-8]PJT$IRM*@I1((!)D?'$;2*!'1O;BX$!/&?[7_!]^(9
M.2@!"?Q+7J((MB/2/]*'T_?K;Z'?/FUQ5P_`%*N/Y;?3^:6Q1[Y]V*A6--@B
M((B"(@B((B"(@B27_6T/31ZV_1/R]_NOLT$7-/!$01$$7M`G/Q?CB?`VI)[%
MX1A7L4<U3+=*6VFRXXL@)2.TG\!E.)$EX6DXT8%':6MU?R^5;-+G=RV%Z!Z.
MUM%2T%YKK95)I:U3*4U:675(#C@1Q%4D[$A1E/='.F_]TBZ+[6&1H>'$4JOL
M=])O0P[?MH=8NF%LLD;'XU_4T.[%E>[J*G#\0OV&N6VGK$7-2TM//-M^<,%L
MF3J5$\22.&6SL,:C@VS<WNH,U9Y(CI2G*HYA=M;BW5'H%N^U@<,Y;EIW+#>\
MNU]YNZZI+:&T*(+DC)"`TF7$9^P.S>8W-:$"Q$'(!<0[POKV[U=UV/A)4/1Y
M!4T[O^;+5W2*EP2$N\!`V%)GP\!EX8]OM,M7PMK\5,?2J32-[:GIS7-8?"*C
MV*F\LR&NK*EA3#BT*FDN3&TJ]B1.^+IIFF6C8<:5RK7^[MWZW=W+98"<YD%<
M.2FU'=+@U1MN/.+6C8./A4D)41,)\H)F2/!$B\TJW::\BLVT/=NJLL0+FO#L
M"A+T$5S*%/L3<2F;I'%WB@3Q)*I"7P"-W9'MO*(<D3>#</4K#N6U_K5G+.[X
MG@G[46*N>4GFE\J$@`)<0AT`3V)40!/V1&XM%N/,TL-JOF[U#LOD=S2Q4IB5
M0\7!80B"(@B((B"(@BV_]`?TR73V^G^T?F*_01+.,$7)#ZY=Z,/3/ZT^!_-+
M-HI&_P`7N"FQ_$/5[TF(TC2EM.+#?$$D`JXTI(V$_!)F8K;2;2VM=#?12/F<
M:M<US@`.\!IKCWA7>21K7M:30D=A3SR$HFXF2E[6R5@!7:-F[LB8^QN;<>>&
MM=IQ()&9H<6UJ0*G,#3#A7N4+WD/#0X!>0X@\/"ML%1DE(4E9)D"`0-T^+M[
M=D#+I\LGEVMK*RIYS&GM(`4.:3M!]?[5-$6&]/4%5>*>F<=HZ0H:J'F0E2*<
MNS*2X$**DA7"=LI3$HJ9=!U%[2[R7"$$?J#Q6E1X@:?ES5YM-'OX+";7+5KC
M44)'(@>GN[%+:>FF5)F5>0VXL3FI`4J4UB<TA2E2$XQ^X,T),<@+2TD45%MI
M\EZZ6.Y^/..*N!9+0AP)5PSG+:)$]GM;Q&,WUXYIHN@MJ;79.T.I]O:IW<;6
M7$)#:9J;'@&PI&[;+MBWVMV0XUYK*->VZ;B(1L'P"GL]:I\(73N%IP%*B!,2
M)[1*?#,=L7=LGF4/)JU[<F73+B&QH<DQ(=Z`MM'1RT!Q'F"Y]>7O3K-F&:W%
M[CGMBK[S05#K3;-QHK=<*:IJ+<X'EI2XFM2G@*-O$-DHP?<DC[A\=J31DDK6
M'MH7`8=E*K=6@UVMMZ\UC3`/F&6DSF_VA&XX^P)0,ZSW34T(UUY&-0JK&,"Q
M?"LJT<LMTS+#[ACMFHK8^AJU4"^^L;M0V&BMJM:021(CB3%XW=M;3=N:1#<Z
M<&-E@-:BGB!I6N)J?2M*]$.KFY=]ZX-JZY/<3073PP,D<79'C,06U``!&!`[
M`N97HH<H?1EU(N&-5VNVH2]3>:Q-0REG0S7^FH,`TUI;VPYPIIL'L*+G6X_K
M$\'P4H17W.I=?0.-=GIR(^-OU]=9/KOVM97#>GVE#2>C60@ZMH[GWE\8N9NY
MO+;-I@IB3#`QK3@V^E"W;OW;>MZ#=.<+=K=.!H)&'.<*?$*`LY&M#0F@>5B[
MU==*.F"UU#.9FCU1YF>9'23-J/(<.H[WISI=RD85E6!8BBDTRPBGM-LQ:^.:
MT8@:^V_$K=,Z)6VE2VXXIL)(0%JVO]%6^/JV/TS[2GVCM3:VM:`ZVNG17M_N
M.ZM[RY+K^[=(^XB&EW.1_FE[?Y\A<`'$@G*-4W^HD63X7OD#0,<K2[C0_NX_
MZRUP<EV-:#X]U:.0RW<MFI.HVJ>F?^U%RVU#67ZGZ<6O2S*C?WM2K.;O;_DI
M:\NS>D3;Z`(9+-3YZ5/%:@6T\(*NH.NNL=1=4^C+J-<]5-*TO2-UG:.N`VUA
M>R:A;^2+&7RW_,26UJ[._P`69GE4;04<:X8M:QODN8WQE[H0\',X936AJ*88
M#"AYK;GRZ:DT.8]33)]*,.Z5-GT;R/4G6/7'2BJYQM$QKS1ZR:,VC-;MF.(Y
M1S'X[>M5KEJ#I5CUPQVR7&INM;6IM=*ENE6\FD=8*VQ'%75':MSH7TI6F\=<
MZPSZYIFEZ'I.H-VUJG](=IFIR6L=M<V^B31:?'9ZA,R:5C+>*(W$A=((S,R0
M!Q4OY,"^#FVC&/DDE:96YL[,Q?\`W@+FEH)XDUYX'@#R2:@8W08CGN<8I9\@
MI,NL^+YCD^.6K+*"2:'*+;9+Y76R@R*B'>._YI?*6E34M^4KR'1M.^/L_MS6
M+G7-LZ?JU];/LKZ[LH)Y+=_QP/EB9(^%V`\43G&-V`Q:<`M2SQ>3*8ZU#7N:
M#VAKB`?72OK4BI4(">%S8LF8&_R9#M`(WQ<74)5VM!X<4YJ1(D#<%$?@)@WB
MO;OX0G+/]K_@^X8]?R5I9Q=Z4^B6IB((MB/2/]*'T_?K;Z'?/FUQ5P_`%*N/
MY;?3^:6Q1[Y]V*A6--@B((B"(@B((B"(@B27_6T/31ZV_1/R]_NOLT$7-/!$
M01$$413HXU&?9+=X9$@>,B/1.800`#F4V")L\HA<2,P-*=H%0LL>5W1*Y:S9
MW;\>LE,NMJ:IYA#*.\92I53Y*G4%"SM9;!W[XU;U+WC;[0TWYN4LP/`DX]G#
MM76OTD]*8^H>KWMSKF>#2;'Q>8P`U(KQS`CDNY7EBZ5JKMH%9G4XDM=]H[%4
M-.ON-=YWM:WY:@424V$A\<(*1/ACYG/CZE;UU.]W+I\;Q:_,.,;,:9`:`G`\
M1C@>:^E?_N#VMTZUBVVD3`;#(UAD<3GH`!7!P;]RYH><C0+.=#-7\FQC/;%<
ML??%6Y5VZG73N):?M3Z2MFJ8<6V&RT5'AWSCKCIWJ0=MN./42YNK,H'QD<,.
M/;B>'<LKU\Z5N%PUK1[HSV,C<P(+2.^A%>!PXX+!V[*:I;>M;*%+=>40Z>+A
M"&TJ.SR2#-7;&P+*1[Y*$`,*T?NJ:WM&'**N[U3U=6,U%#2II+:U1=V$K<J$
MJ6I3RRF4MI`(/C,7=T0)SFN6G#DL&NIXY+9@@C:TD`DX\^/-1=!2T-:RA)I5
M.5('$2`"04;>T'9LVQ2BY=;N+7?#R5WTO1K&_8))VU<!6G>%$7)5RJJ1-"ME
ME##)XVE!/"KR01PF4ID^S$;93(X/=50:U;W8B-O:0,R\CC51N.8_>LC<:IV*
M=PN+`2N;"UD)2.$%'"-HDD;XI+F2&W8Z9SQ1IP'-9#L[:&X]TPMTW1X6.NG-
MHX/S4![LH)]JQNUIQ"YV*^CSQHR>0&T!`(=`;,R5(5V[/:C;NQ+NVU;1G7#7
M@.;0`=M3ZU\]OJ8Z=ZYLC?/R6HQGYIX)P^'M/$`JQCC`;*02J9,B#*8W;QV;
MXRTP2M/B`RKFL!XDR2"A3A:0E1`,P/#$LTKAP4R1H8XM'!>8\4"((B"(@BV_
M]`?TR73V^G^T?F*_01+.,$7)#ZY=Z,/3/ZT^!_-+-HI&_P`7N"FQ_$/5[TF)
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ML<:CPJ`'RT^D[5OK<ZKP7O438C=W;\Z?:+?"VN77NZM!T6MPQP;)$V&\M)97
ML-0/,:?$UQP:0:;ETS9^G:E,(;`6T5PYN8`O:W#D:O(',8*VO2=Z8G3%U#Y+
M.8'"+YJ]B?-W@+&JHO%TUMK]+;]R[Y)I-7)P.PL.6ZTY-D=YJKJBWM4S::]:
MU5)M96\4O,+(431?7/\`5E]=_P!/?U&;(EVGM_4-C[AU#;F2/0FZU8;NM-=B
M??SY73VFGV[+?S,^:WC8(A?-:W-%.VK:9E8:+J6TVC2QY4_GUJQCFS1R`T!:
M6L+L<.1S"N!"Y*>J)RO<H_*QKX_B7)_S2TW,C@UP?N+MTIDXY4TE9IS5L/M"
MFL3V=T:&L1U*8J$*64UUK:9:06Y*1Q$$_6#H?OOZ@.IW3N'=GU$]/QT_W@\1
MY+<W37F[8YI)G&GO+KW2P#0?+7KWR^*H<1PU-NS;TVV-9;<!HACFJ3#P>PGN
MY-[`[Q-YU6%&+*:4WP*^%-/"=G]W;V[IQF&HVLQ<2TM^_P#);PZ<7)FB;4]G
M%5MYFVHJ65-\.^1,C+\!VQC;)'LE\O'`T6Z6:2U\;Y)71T-3Q_8K?Y"NGHWB
M^@3XB4!(`.[:29[A&5:>)'\*4'%:"WD;+3[@ODQEJ<A&(![ZT^ZJOSRH<Q60
M<MVMVF>L>-5;M-?,$S"R911=R4I0\FT5]/5FD>/&C\G4!M2%#:""(MFX-$N;
MR(S6Q8V9GB;4D8MQY`]BN_3C=^DG/I>XQ)):3AT1#0TBCQEQS.&&./<NVOG$
M]9AT0USY,,ET\T]Q3*+1JIJ/BMPQO(%5XM2[=9C6V]5+6OLJ;=:><65N$MF2
M?:[(PC4K[<6X;1NG3`,FP#L]0T"HKE(KV+)NG/1+3>G^^COF:^LI-`@>7Q-C
MDK.[X@/,:8V,X'D_BN$G)\Q=K//6FW'%=_5+?*G`$N(="IAU*TK)2XI0XIC:
M#VQF>G:4^"!C'EN4-H0,:]V(Q!YU53U#ZD0:J+J*S\PL<\TJ!0>QQQY]RI'(
M<HR/-[T[?<MR&^Y7D-P9H:>MOV2W:OOMXK&K;04MKMS=9=;G455?4MT%LH6:
M9D+6KNF&D-IDE(`J],TC2]`L&Z=HUM;V>F1N>YL,$;(HFF1[I'EL<;6L:7R.
M<]U`,SW.<:DDK1NDN??5MY:E[S2O+UE57@5]R3`<IQW-<-OUVQ3,,2O%LR+%
MLGQVX5-KOF/7ZTU3=;:[Q9[G2+:J[?<K=6,H=9>;4E;;B0H$$1;];L='W%I-
MUH&X+:*]T.]@?!<6\S&R0S0R-+)(I8W5:^-[26N:X$.!(*V9H^WH1X9FM.'O
M]2RNU-Z@7/EJ/B=XPK.^=#F>RO#LBHG;??\`&+UK;J#5V2]V]YLIJ+==[>J^
MBGN-OJ4&3C#P6TX-BDD1J/;/TT_3CM?6H-?VWL3:5EK=L\/AGBTJS;+$\<'Q
MO$56/!Q#VD.'(A4VYM!9';O\C*UA'+#W`>]:U+BP&W9(`2D$;#LF!X)3CIJV
MDS-J<2N9];L)(+FE&AN:@IP'W<%Z9IU*<;X%MK/#M"5;1+;,S`$ML3GN#!4F
MOH4;;=UM#GJ'GL;B?9@G%93N(5Y0`XE'P^3M)V[(]C=FJ0#12=4CEM6M\QKC
M4`X#_(H5M!3.9&V6XF7;[$1NJ<:'!64.<UID+'T/=BGDO9'B,(XGR$`"@/,\
M!WE0QW!D=E$<HQIBW#WIYW*]HV`A/$09S"9`SE+MG%8ZP#;"*_$]N6RS&/('
M'S&$?J>VF#3R-3Z%)EOX89Q`X.+B:5`%*^U;#NDBDHZHO3]!D?\`[M]#B"-Q
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M]0=_3+N:SGDM3+(^V_O)8L\7F_\`#(SM:_`7K6+#0=.K!$;QUVZ)CVD^7D\;
M0X!U!7`'&G-:4:FAK:)%&Y64=52-W"E%=0+J:=YA%=1*??I4UE&IU"4U-*:F
ME=;#B.)'>-J3.:2!WE%<6\[GM@>Q[HGY'AK@2Q]`[*ZA\+LKFNRFAHX&E"%C
M!!%*CBBF"R2$">U'X9D)_"3$]K6N=1W%1Q!S'?,CX8@2?8M[711?T_H^82SO
MYO:E5PM[KJVFFZM3'>UBU41;0$!"BI1;4N6V1GNCB/ZMI+]NVO\`EW$1.(/?
MAFPK]N"^J/T97=E?]$=S:A:-:S4H6NJ>=*.Q2L%H718<WI3@M9AMEI+'9KWC
ME#=Z>E/Y12#4,M/K8=?J"ZLJ`5)1F-NW9'2W2[0=$T;:]C8>2SSY["![L*US
M1-)]>-5\Q]]ZMN+<^I3ZLRY<Z6"Y>!P&#7D<`"*8+F8]9*Y>,`NNG[.J-';Z
M7Y<4U!34JTMU$BU;F*UEI*!)00>%MT@&4SQ&9G',/4.`[:ZL.,#LME-$!3D/
M%@?8OJ!]#>XM0W)M34M!U'Q16D)DC)XG,07CVDI/KRZZ-VZJ?I?-N\+A4A31
M=*PSY:DD@MJ&W9VQOC0[)LNEMN#B:#%2NIFM26NL/M17*#2BE5$[3]RAEYU4
MEI;<0F9*4G>F8,]QCV=N1KAS5NL+CS(8F.Q:6@J[N"69FOJW^$MN<%,ZH!Q?
M=`\2`">(2$QV#MC"];G=#$'`_P#$`71_3G;+=:F,+!4^47>RBO)I;H3DNK^6
M6K#<2M597W2ZW:BH064KJ*>G\Y>*2_4J1_DF$(G.?;&([@WO9;>TY]Y?R!L;
M6.=Q%20,`VI%2?2%EVI;2@LJYVFN;GW?@NQOIW]`/$[G9+=J!K#<*3XN9H4T
M=+2)%1Y_6W@LMK54J9#89%&VM9`D=H$XQ;:FTNI_4ZP?N33G,@T2Y:708G%A
MX$^!V/H)"Y>ZP?5_I/2J]M]M]/VM_P"I+:C+EU`1G''',[&G+*%3?42]7%Q[
M,,+N^::85EALU;9*6XUSS:6W@MZFIJ-UUC@0.()6X\D#9VF+EMC2^J/2B:75
M-Q/+]#:_*X'D7?"15C/95:TDZZ[.Z[W4>B[OB#-XSM_NWTP<ZN+<'85KQRT[
MPD]/7#3FX:5:CY-@]S:=:K+!=*JW.EUM32EKIBD*6D*.U))V;([+V?KS-Q:-
M'>--1(VOX4^Y<5]4-`9MS=$UC&*-:XJSZMYB\N86'*>*UZYV8U7F/%"B"(@B
M((MO_0'],ET]OI_M'YBOT$2SC!%R0^N7>C#TS^M/@?S2S:*1O\7N"FQ_$/5[
MTF$L[CXHE/XJ^J;6%I)R"R*6L)0;S;"LF0"4^>L<1*B0``.V*/47'^FW`:*N
M\B2G^J5-MHFS7,<3C1KGM%>S%=(OK-E\M%TYN^7I[';_`&J^6]GE$TOI7ZNQ
MW.FN+'G+:K@L-NOT+SS+3Z4D305%0[8X(_PTM#W#M3H=J^D:C$^W_J&Y)YLA
M!;4')E/+F%D.YF7-G,V2QF\364&/,96UX\P/O6D?3_F;U`P'1[)](J#*LL5B
ME_R:ERH88W?+FWACU^:I&J!W(KCC[3XMETO+-#2M,-NOMK4VA`"2G;/Z>:7)
MH>V=Q1[K?INGS=0;6Q-G#J3[>)][#:.>Z4VT-TYKIHH3(]SWQQ2-#W$YJJ][
M1ZC:CMK2C*:&_)=XB*D`FF!Q-.T`BJQSN]TK+U6NW&M?=>J75SXEJGO5MG[&
MW9X(QO6-7N]7O'W5V]SWN)Q*PG4=;OMPZQ\]<O=)FJ23S/)5ECE2IL)\KP'M
M[(P;4&N+L%OC8MX;=C0"JVK+IYM3!7$I2EIX0B93M(\)GLBQ06N>8DC&I6S=
M8W'<V-K4'`A6UNU>NK0Y,$!1V$JGPF>_<.R,GLX1":!<_P"Z[^ZU!GG&M02J
M=IG71L*S-,PA0F.'\9GM$7)[&.<!3`G%8!I>HW44SF`D.K@>PJL:*JK5(X5U
M+IV(E-U1FM,N)2@5$&?@[(I=1TVTM_%&`3Z%MS0]2UN>W\B>X>6D?O'^),K^
M\*IJ5Y;Q!)\!^"#O.^+;``&]PJH;JREL(70R/SF1V:I[_65'66C4ISB49\*C
MMD?:[=D2[R0>6ZG8LBVEIIDF:\]JKAM26D+\F9"$IG/=+MW18>*V>/\`E?2I
M95<50E*"HB?;M/OB*JVKG]"MNK/-S:^I6_OE"E'&>,<1D&QPR!7.023/8#XX
MS32,KWNC.+G,-/35:%W;I@9`Z7`.+J#TGAS6R_1+H]\[FHFA6?<UV5:35^DO
M+WIUAZLR?RW5155A]SSN@:?9;9IM/<3K:,Y/>Q7*J4EJN>I:6TK1M35*5)!T
MEI/U5_3L[K]MSZ=+?7H=9ZG[CU9EA':Z9DO([.1P<XNO[ED@MX`P,.:%LDET
M#Q@`JX6GIALK5-7UR*WU+,RUN'@-+O;@TN!I2M2:4[UK>SRU)M.17FWT:FW:
M2BK:BB86W-0?2RX4AQ*PD)EL\,COCI.\TG5K;4)K86[P&3/;\/)KB!R[%+WK
M;7EEJ$MJ&-'ERN90D?I-%0P:J"1^142?@CR=H[9[91(_IFJEV$+J_P!D_DL*
M)OC)&`UN4@UQ:KI:+Z-:C<P&J>%Z*Z6V'Y0ZCZA7FGQ[%+`:FDH?C"[515W3
M+E;6.LTU(TI*2>\6H($MI&^,1WEN_3=B;>OMS[E>ZWT/3H'S7#VQOD<R-@JX
MMCC:Y[R!^EC2X\@5+U#4)M.GC@?%C(X"OI-.PK;^YZN#U?5^2WRQ42WT)"7`
MG5_2(!12I*%-()S0)*D$[3,#9')5Y_B0_11#IT%M9:_J#]5J'RC^E:O5M1\/
ME_)5!H1BKF-O7DCS<NB\`.';7GRY'!6/Y`=',_Y>^L[R;Z):J6=&/ZCZ9\ZF
MB^*YE8FZ^ANB+3?:#.+3YW0IN-LJ*JWUO<E8'>,N+0>PQU_MK=>S]][;T[>F
MQ+B2ZVSJEI'<122130/\=:@Q3M9*T@BGB8VO8K7=AS26.%'AQ!'M2S>/?/NQ
M?584V"(@B((B"(@B((B"))?];0]-'K;]$_+W^Z^S01<T\$73CU+JKI85.M6D
M#G,VYSZ5>KB>3'DS9O+O+U6<N3FF0H&>7?`V[.W;%9\A_)DW)JA"4UJ7B$BI
M"N['!*/D]]*L/U>Q;#UMO2@=.F;+.^MS&(:RW6Q?YSK-V9#)\F1!D+ZF(MQR
M4S>*JSG7#H!NH_GOF_F/EH:^7Y>7^6VE,V->WO6^K26MZ';715Y86^;44*^7
M,XYJR-%J7F7^2E1S;E)U?U+%Z5@2=%A\KFKFYDB:SN%XWP4Z:4L>>J'Y6/G7
MO.#Z_P!_UX;M=T9\P=3_`)K3OZH[0_F&[=_\ML?*^;_JG_+&,0>7G%[5YD\S
MY<'P++K4[6&V(!J%/DJ/R>;3SOC=7+DQK6M,O*E5P><U2N5DZVY;_L8,ZU4^
M@!JO]3TZ]N8JYJ`I??/>=%WY((3;T64GA-$E\KK@S+SA1<G'Z)>CC^KT?3ZU
M;UU=H+NI)8/F3I`N!9TH,M/F3G\WCYI92(N_E#)1:GU%EK;WAFTQLPLCP\RE
M?73"G97'MQ51\I><W?"=4;3<:"JJ*2H9JZ5Q2F%K2XMH/-D\(2I,U<(BV=8M
M"@U?:<D<K06N:ZA/:`?Q7;GT.;H$/45E@_\`^FDIF9^DX\V_">^H*5P>EEKX
MG4KE9LKM_JWG$X;C-IJ3<JL%+**'XN4]4-\2B>)3#<@H>&-8?3SO?6]2Z:ZQ
MKVL4%UI,LENWLRQ9FM(J.%&A:]^K?IU8Z-U5%CIK"TWMR^3*SPU,CRZE!0<^
M07)!ZP!U#6=1\_RG2?%ZEA^WMNTM#5UC)4D):HJXO`<2%A*4K[F9V;91J_8%
MEJO4S>-UO&_#O(%6,!K0EKN-*$>Q=X],]%LNA'1JWUA[F_U>_86/;A5K2,_.
MG`CVKC8O^7(K;X2^\4MOD)<6@S6A84I141OE,QVCI&B'3;(`CPT7!N\NIXUK
M<\I>Z@<[ER./>KAL43CU%27-JK\X=4RV>-9EW393O*0?AI&X1CEZX>:\.Q:7
M%;>L[5\ME:WT;R7.A:[B>8[E<^P7MU;-%2]\X]P.H;+J4E)<`/\`DER`44J&
M^<8=J4)!SE@.4YJ%=,[)W+'+96NGND(I*WQ`T)Y4)!KCS74YT,.7^Q9EJN-0
MKG>:E-EI;?;6+O2TI:%=2H-Q2P[PTZD*5WC9^"93*)F.7]TZHW=74^PVM<LR
M1?,`DD``M(``IP*V!]4&Y)=$Z8%]E4S>0:$8'`'B1BE"/$K+;K%8K=:+13EF
MV6^@IZ6B0XA`=++324!;Q2D#OED37_A$Q]&-,TN#0]/ATFU`%O!&&MH*"@'8
M%\)KJ]EU.Y??W)+IY7%Q)Q-3WFI3Z_V^BNE!56^L;;725S"J-X*0A2%)J$]U
MPJ!21PDKB7J^DPZWID^GS@.8^)QQ`.(!IQ55I=Z_3KYE]$<LL9J#P(H0>/'D
MDICUCOE@JM!N=34.X4&)"T8KD%517VQW1JE*:>ZJK;=1-W`MNAI*%H8J9C9_
M:G&H.BL@T^[O]'?)F;$7!H)X`N)P78'6RTCWAT.T7=UDQOG,D`E<`,U14$.(
M%:BG,KFDKI"I6!L\EN8E*1X$S$NS;&ZX22RIXU/O7'^IAC;LMC^$-8/]D*$B
M:K>B"(@B((MO_0'],ET]OI_M'YBOT$2SC!%R0^N7>C#TS^M/@?S2S:*1O\7N
M"FQ_$/5[TF$L[CXHE/XJ^I\#(@B4P01,3$QM$QVB(X)&PS-E<QLC6FN5W`]Q
MI0T4+@7-(!+2>8XA1#M2X\2IPE2U`]XHJ)+BC.:U_P!Y<U$S,R)F(VSMCM&6
MD4;&Y)<X<*UX`!O&E!3#!4?R;J`>;)]WY*`?7Q201+A(((4H$`_"&P[E=L3/
MF))`3)XG$G$]ZGOA#[=MLXG*TG'GCB@/'A*0A.\'BVSV>./'R!\>3*!WA5%J
M?EHO)8`16M3Q^Y5K8'TJ<0A7DS`G_5MC&[]A:"X+;FR;YL\HBDHWE@KEW"C9
M>M[:@)J#84#[(3OV]IBQV\CQ)X6CC[,5O'7M%M[S2F29G`MC'"F.'/!6GN+P
M8)8X4G:9S.T=G9&26T9?XS@N<]6OYK>9]FYC/*!P)K7\E*:>1>0!N6H^_NBM
M<VH6,0LC$X>*>(_BJJI&4_WE;-HW;]ABU/F>>.(6QK'3FAP>V:0=WA_)/:U8
M'=3.X[_8G_7$#:N)H*8*JU1QB`#G%V'$_L4_M58RR.%$E$@3F>TC;*4IQ27+
M'&%U>866[8U;R8JL##)]N]3M-67.*24[9>'V?9BS>41@LV^<?>M\8#33E5>?
M)X5J)(4F4ALD9^'MB=!5LE%17;W0PY6X@*N-%===2.6;5O#=<-+G<78SG`[H
MFYV1S+</Q7.["'E(4TZ*S'LRM=WM+I4RI00^AMJLIE$.4[S+R4N)MF_.G.V.
MK&T+S86]!=NVWJ$?ES"VNKBSF(K7PSVTD<@%>+"YT<@\,K'L):=6[BNI&L;,
M<K7L?AA45H>(.%/81R(77_I=ZS;;N8SE:U7TVU:TRM6F7-"_@U538+DN-6*S
MZ@Z-YID:'Z,MIN.$9ZB].6!50VE<J:L3>Z$J'$IUOR4Q\W^GO^"7I.V?J2VA
MOS:.Y7ZMT*@UN-^KZ?<WL^DZY:61:\.?9:EI[[?YG(XMJZ!]A=`8-9)XG+,>
MES].W)K=N;^1D4<<E96>:8R64(S1O#FNP-*@%I'`$K2=D_6SYIK)>KO:'L=Y
M=*UVVU]52&H<Y5>5I!?#*N[[Y27-)E%*U*252.X&1G*/HE??1M])MO?36S-$
MW7(V.5S0X[XWI5P!(!-->XD8E3=R[RV[;7T\$&EQO$<KVAQN;IQ<`<'&LYQ(
MXJDU=<WFE3NQ+EPF)_\`XK\JOXI:13$2?_9S]*`%?Z#ND_\`]OO3_P#>K#'=
M0M':?_)[?#_YUS_XWNHM5&H6M%7DN36C,<:HA@636FLK;HU>\6KV[+<F+O6U
M:ZLUMOJ;(FA>MRF%N$-!G@2T#),@!'1FY+K1]P&.`V<,-I'"V+RQF>US&-#6
MAYE<]SS0"KG$N<:EQ)-5K[>6Y;/<TK9!96UKDX>7FXCABYSC^:Z:JW6[6%SU
M86T:EN:K:E#4-//'06;Y<IS[+$9B;6NXWI9H#E";L+Z:1<P%-^<<*@D3!($?
M)C9VW-K1?XH.Y+>>RM3:Q[$M9HXO*8(S*7-:YQ:`!4MXD"N"DVUSEV[*X?$)
M>TX5+<*UJ!2JTE]+/([YEO5?Y#L@R6[W2_WVX\X&B51<[W>[C5W>[W6K<SJV
M+?K[E=+@Z_6UU94.**EN.K6M1.TQ]1K>TALK:*&W8V.'RP0UH`:*UP`&`'<L
M(-P^ZA$KP`[-3#N![<4M5#WS[L5"M*;!$01$$1!$01$$1!$DO^MH>FCUM^B?
ME[_=?9H(N:>"+TI2ED%:E*,DIFHE1"4@!(F9[$@2'@CP-`P:``G%1SS]75"G
M34U3]0BA8324B7WW7DTE(EUVH%-3)<4H,4X?J'%A"9)XUJ,IDQ`+6.VS.8QC
M3([,[*`,SJ`9G4`JZ@`J<:`#D%&Y^6=H)-`5=O%L13?;#6U"&2\^PF326Q,@
MD3*E&1($OQQCVJ:E'9F(>(/>\CNPHNBME["9N7;]S<`,=)%$",37&O(+WI;D
MZ].<]MMXJ*9I]VWUB6UT]8PBIIE'O`4]ZTI:$J;DDS,YPW58-UW;?R,&$SA6
MIP`KZ*\U:>ANZ[?IEU4;/J;9/+:\MHT`GXN=2VB[[.D7SLZGZ@Z)ZC8M8JW!
MF:9%BJ:#XL\S^+JRG9<II-!JN=J2E37<&3:`@C8!./F+U"UG>?2ALVU]OQ!V
MAW+WNF`)+B7$EQ%6FO'#Q!?37JSLS9._=[Z3O][Y6Z6WY<D!H<\O(8:4S9:'
M&IJN:CJDV![#]8,EK[^I3PN;HK$U+3J9K?J5U2GFT/!9XVVU[`-THZ&^G#4+
MO5]#^7L0&9`7N#QE/$8X`\2?1@KE]2MSH.G;7MKQ@EAT`M$;&N`#_-R$G#-3
M+3@<WJ6BZZFGJZWO:+C45O%7`I9<6$D$\1,@$I,=GV[G_+".X%7]WV"^-^KW
M%E<[@DDLG^#-A6GYE7\Q9I]-OIV_.&VWWFZ9H)[Q*TGO0`#(RX0F>W?*-;:B
M,TTI8#0//IP*[$V;.\,T_1IWM,]Q"PLQ\(J!Q/+CWJM;M<48&A3%Q:[Q]]MI
MZBJ:-V;S:U%)+P#84I3:0#,2E+MB@M=*GOIQ6@;2I!KP[%GV\]RVW3.^M[2]
M<3>5:_\`NJ.&7GQIC4CE3O6\_H]\[UFTJU76Q<[\FT,9:U04GQQ<:ANCHZ-=
M"\J;54@J+:>_4X#Q$3F(YHZN[,U73]S6NZ=&:P/MI2YPQK2@-1@:XCAPYU71
M<^X=N=<.E[X]/)%Q'$0X2T:<,,,KG)3?THU*Q_/\"Q?,+%?K5?+=>;/25"+A
M;;A25=.Z_P!PDNM)<:=DIT*!FD#9'8>S-TZ=K&VK&\NKNW%_+;M+VEX#FN/$
M$<B.Q?&K=VB/V_KUYI]QEB9#.YOBJ,`:5Q'`\E5UYR*V6FU7*[5KKC-!:Z*J
MKZRK2V7&Z=BC:4\\XO@*B@H0DG:`=D9+KFIVNB:'/K%Q(TV[8R!E-34@TXT'
MWJR6-J=3G98Z?)'+=SD,8UCLSLSC08`<`3CQ]"37?6<N87377#72@M6.Y55U
M=JM3=,FHKDH\[?HK>LT":MZEMSCU'YS4-!M:VV._:#I2$E:)\0Y(Z(W&OZAN
M_5-2B#9;4.>6`N+&N.):TO#'!H)H"[*[+B<KJ4/T&WSH/_0WTMV6V-?:(==N
MG&1K14Y07'%^;*02*$`"A'8M@G0PZ??0\R^R675#234RQ<ZG,?9J6EO%\MVO
MEKH,<R?3FXL\*EU5FY:KN]4T5LI:*J:!9N[ZLD0AY/%2W$;H^.O^(3]2OU_:
M1J5QM3>6DW.PNEMP]T<+](D?/!>L/!LNN1AKI'/:?%;,%B2TTEM5RAM71MLO
M:)HY!=:@T`GS!0M/=$>'I.;N*Y;L_P!`ND([G>:NW#J)\SM!7.9=DCE;0L<@
MU"\Q15:[S6JJ*1E[_:3I>^:IGB4)7W37$$SX$SX1]<-N=1_K69MZP9;=,=IR
M6XLH`UYW>\%S1$W*XC^ANH7"A(S.I6E3Q6!36>W/-=6]G!S'_P"W[_\`O%0O
M3?YC,3P?6_2'EMO/*QR><PF":R<T.G&-7;.^8709K.M4*/$LZS'$,%KK=C5^
M<RBD;QRA%G"ZNGI2S4IIJ^I=<*G`J49#]473#6=P;`UOJG8[OWOMK<.A[2O9
MX[31M7-I8.N+2VN;MCYX1;N,[_-I&^3-&9(6,;1M*J3HM['%=1V3K>VFBEG:
M"Z2/,ZCB&T!KAAB!C0E3;JG\Q&-7;7;F-Y5\+Y2>3'0_#M$>:753%,3S?0O0
MMK3W5:XXUIKF>:X18K)D^8,Y'<6KM;ZZU]T_7MII&$5-;3M.@-A/!%%](73/
M5;+I[M?J_KN\]];@US7]H:?<7%KJVK&\T]D]]:VMU++!;&!AC>R3,R%QD<61
M/>PEU<RBU^\8Z[FL(K>VBBBN'@.CCRO(:YS0":FN''#$K4G'9RQY;?\`H#^F
M2Z>WT_VC\Q7Z")9Q@BY(?7+O1AZ9_6GP/YI9M%(W^+W!38_B'J]Z3"6=Q\42
MG\5?4]B!>(@B\*;2HS,Y^W$0<1@$0EM*2"-_X8G0@RNRGL0G*">Y1]!5&GJ4
M%*MBMNWPCVY]D4EW;U86N&(5[VOJS[>\`K055T$Y"CS$)XDD\(!!`.],MT6.
MWM`)"*<UT*[>,;]+$1.(8!]WH5M+J^U4U*U),U\1*B#LENW#=MC(&Q>4P=A7
M/FO:I'=W[BTX@]_Y*`;46UH4DR*3,=LI[X\)J%:8;JDC:']0]ZK*FJ$!ML]J
MISWG:`!X8LCVN#CW+:EG=\"$YKWD+0%*GL!D9D;9S\)BNM(0]E:8U4K7+@>5
MF[E*:6ZEETGBV!>V?@F?;$3)[3,PMIQ5ATG<3K20.)\(*J6GOZ6P"5CRMG8>
MR?OQ:76+@<`L[L=[Q"A)X_;L4747UK@V*EQ2W>UL_!'D5F?,P"N=[N^`V]21
MC]NQ4O<J]50DM*5Q!1!(.V8'X]D7^&U>&`MXA:MW!K@U"(PQG'-7W]P4KMMT
MK[94MO4-0Y3.M/)>8<05!3#B2%!31!\@DI$_#%SBO;ZUH8'O:YIPH3@L/L=0
MU32K@3VKG`MX$&A'WJ<7.OJ[FJHKZYU3]77/JJ:IX@!3KKLBM9D)`J)F?9BT
M&6X?*Y[R<22?2LJU*:XDA\UY_O'@$GO(Q5)/DE?""9`D"4_Q]L7"!LKV$BO)
M8%++<^;EQJ5%MS+:0D2(!!(`!4/\(D>5$MC'.N6L/$N'O59%9W#QYCOA&)]7
MK6XFX]0W3971KHNFVSA66IU+9YDF-9OENY46]6'JLC=57N,VYMI/_6)N`35H
M4"9MD)5,SE',>A?3]JY^JR_Z[-EA-I>:+%8",9O,`C91V:OAIF!(YXA37:AY
M-L^R<#3-7NXBBL'TC>+[4+I^*4)%?-MH:N4Y_"SBUR_%'5,DOF%K*4\MH9_J
MX*VQT^6%.&<_BEL<>^?=CQ6Y-@B((B"(@B((B"(@B27_`%M#TT>MOT3\O?[K
M[-!%S3P1$>CBBB$J`(XAQ`J$T[ICP3W@;(J+@>$J$>*0.*O3IAG53C+]33ME
M`;N*&V"'"@A(*P2$A>]4O!MC!-PZ9)>-9+&2'1.)]M/R72?1W?UKH4TVE764
MMNF-8*N`I0GVIWGEEI3D#3]KJ'GQ6%NIK%)8V)=<4M2DI)6GX`]@#V8O&@WL
M)A\NZY846)=0-L7<>[_ZC8,<6R'-@#A4K,3E;U@U/TFNM3>\>NE[H+30MJ0_
MYM4U3(K:;A`6AY#*N[0I:00E1GP;]L:5ZH;+VYNN7R(HV&2N!_4./.I-*\JB
MJ[P^F#>.Z-/L7OW9;NDT^`$,SMS#P\/B:!PX=BH'FMYE+YKW?6&ZHU7=66G1
M2%52M#KB>%2^-:G%$./J6IS;LF(O_3?8]OL^USPAK<[,H':*U6D?JBZX#J5J
M+-FVE8;>TN3)A0?I+*84[58=6DV<VS$:34*X6]VAP^Z52:"EO2O,E-NO%"5<
M*:5NI57MIX%?"+83[,;'=>`FC!4U[>*YGM-A16L`U*YD#:G]1(P/$\5);J\W
M8ZIMBVW%VYNT[+#K=53J!I$(X.+@<6#_`)1(&V))T]LI.8#*[$]N*JQN34]/
MU.*]M'N,-JT-::X4;@,?4I;=LSNMY73W"JJUH?HV!3,%I(XRTJ25`J/8L;]D
M3[;3Q`XM:*UXGT*@W9OS5-U:BW4;QY=2/RP>(J:=W<IQ@V7W+'KDUYO6NLT]
M95,FK6])"*8J=3)PR/'(SWB6R(->VO9:E9ATH:33GV<^:R3I'U5U[8NNMTJ[
MD+;"=X!#CA0GO`Y=ZZ%.2#K@ZS\IUNQW`\2KK3?*7%;A<ZBE=R2JNU7:GDUR
M2"GS-=P2PAFF4H\)"!,_ACG75>A^I6E_)N#3+DB)[L[8FO=EI3D!PX5I3C5=
MI:AO7Z;M]V4N@;@A%ON(>&6=E'5=Q+@#.P8@T.`IR6U=SUGFX9-I=GUCO5LH
MJ?4C*Z:X4U2JPVZC=L+:W62AGN@[7!:&ED25(;3L.^,8U#1>I<]N=*E8XZ;*
M]OB+C@*X^$MK56G;G3/Z;=)W):[@T.^+[VT87F-Q'C+,:G_F74X`X!<;/,KK
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M422I1),5\$$-K`RVMVM9;QL#6M:*-:UHHUH`P`````X!222XU.)*OQRFYQC&
MF/-1RT:DYM<%6C#-/>8'1K.,MNJ*2KN"[9C&)ZC8Y?K]<$4%`S45]:JBM5`Z
MX&6&W'G2GA0E2B`==]9=OZMNSI!NO:V@Q";7=3VWJ=I;1ES6"2>XLIX86%[R
MUC,TCVMS.(:VM7$`$JKT^6."_@GE-(F3,<3V`.!)]BGW.YJ-A^L'.7S9:LZ>
MW1=\P+4[F2UOU`PF].4-=:W+OB>8:E9+D&/7-=MN=/2W*WKKK3<&72Q4--O-
M%7"M*5`@6[H'MC6]D]#-F[-W+"+?<>D[6TJSNH@]D@CN+:Q@AFC#XRYCPR1C
MFYF.<UU*M)!!4>J31W.IW%Q":PR3O<T\*@N)!H<>"Q@C;2H%M_Z`_IDNGM]/
M]H_,5^@B6<8(N2'UR[T8>F?UI\#^:6;12-_B]P4V/XAZO>DPEG<?%$I_%7U/
M8@7B((H=Q2@J0)`D(FM`(Q1.RM<OA&)C"6',S`JGN'%L1(3QE2BM,R3M'NQ#
M(2[%V)4[3VM8_,T4=532H<<0T.%:DS2D[/#%.UK0X&F*R">ZN&PT:]P"EC7E
M+6H[5$;2=YVQ/D<2!58[E:Z5SW"KC3%/2VXK:DD#LV_T[8E@BF(4;6M#@1VJ
M;6]Y9<[EQ2E>4$I"NSP@>"<4TT(<:M%%F.BWQS99W$CO4SO#)8;3/8%2([-G
ML;=T10L=$PBN-57ZU.R0T8?[O+P5*+"1Q%(`E,[/#%0"21587<>6T%K0!7L3
MCO%[/*5LW;8F96]BI6O<SX311U.AUXIXG%%)(D"=@VR/@B2[(TT:!F5UMH[J
MY`SO<8^P_P"11]72K!*@2#MV@[>WWXC9-*QWA<0JF^THQQ"6$!LM>(X^Y0-.
MA85)PE4U;)F<AN$3#<RYJM<>"M(L[L\7./V]"J:KI1YD%I&Y"3V[Y)\7;%);
M$N)+\1F*V#JMC2P:64KD'N5&.A27#.8GNBYN>8V@1&@/&BUD898Y7&8EQKA7
MDHEI:TI04J((D1+P@Q1F1[9!(#XVFH/854-FF:W*UQ#5[*U*D29D``'9,!.X
M3W[(G6M]=V3B^TD=&YU:D&E:\53OBCD-7@$K8=TCR3U0^GY/LYMM#4CV`G.+
M6`/:`$11$D9C\1))]).*ES-:R)H:*"OYI;%'OGW8GJRIL$1!$01$$1!$01$$
M22YZVCZ:;6OZ)N7W]UUD@BYJH(B"(F8]))XE%[2ZX@A2'%H4D@I4E:DE)&X@
M@@@B(<K3@0%$Q[XWB2,EKQP(-"/00HTW:ZE7$;G<"J4N(UE252&X3[R<A$L0
M0M-6L:#Z`JY^K:K(09+FX<1VR//O*BVLFR-AI;#&07MEAT%+K+5UKVVG`=A"
MVT/A"P1X1$OY*SS9_*BS=N5M?<J^/=FZ88_)AU+4&1?NBXF`]@?12M554J67
M55#ZG"9EQ3SA63X2LJXB8G".,"@:*>@*RRSSSS&XF>]]P>+G$EQ]+CC]Z?JN
M=R6TEA5PKE,HVH955OEI)\*6RX4)\0CSRHAP:WV!377MZ]N1\TI9V%[B/950
MPJ'TI4E+SJ4K^&D.+"5?XP!DKQQ'E:.`"E>?,&Y0]V4\JFB\<:_[RO\`C'^N
M/:*6"0*`X5KZ^U-+CAWN+/MK4=VT=OA$"210XA>N>][@]Y)>.!)J1ZUZ#[Z2
M5)>="B)%0<6"0=X)!F1'F5I&4@95$)I6O,K7.$AXFIJ?2>*](JJIN9;J7VYB
M1X'G$S'@/"H3$0F.-PHYK2!W!3H[Z]B=FBFE:ZE*A[@?N*\=\[M_*N;9S\M6
MV>TSV]L3'DR4\SQ4X5QIZ*JF))?YA^,\^?M7@DJ,R23X29G\)@27&KB24))Q
M/%,CQ>(@B((B"+;_`-`?TR73V^G^T?F*_01+.,$7)#ZY=Z,/3/ZT^!_-+-HI
M&_Q>X*;'\0]7O282SN/BB4_BKZGL0+Q$$4,[\/Q")S/A7B='=$2I[G^4?2$_
M8<*!(`$D@[1,CVMD0O539D-X]JB''5%"AO!$MLS(>Q/=$MO%7*>0.910S#+]
M2^S34K+U14U+K;%/3T[:WGZA]U80TPPRTE3CSSJU!*4I!4HF0$XG4JK27!KG
M$\%4--B&:U;EUIZ+%<HJGK"%F^,4U@N]0]90W/O/C=IFC6NV<$C/OPB7;'H8
M">]0F:E".![C]AZU3C=2&G.+O)'PA<B#[8VQ.$+5&+WR'5:X546JO6\/*<4X
M!Y(*UJ6`/``HF42)8Z.H.%%61ZBZ>(O<>:@550*E)F`"2/Z$F`B-,W-6J2ZS
M3@$BE3ZEXXTB4U)$]VT;?:CW*[L*J#+&,2YM#WA1C-5PHDCR@@>44S/#-6PD
MCX,R9>W$MT;B5.@U@PN\IHJT85^P3Y5RF)+5M]E<SXXA$+ZU%5<9==#F!I(J
M#VKRBLX7$NRFD#Q'?^*'EG_25.-5J<W=]N2F"[H^XCNR#P*'B`[);-D0PQY7
M4K@2KS<;B?-$(W?#2GVP4JJ"5%)EX9[/:\$5LM`UOK6/RSB=V8+VCX"?:BC=
MQ4M>HA1;$>D?Z4/I^_6WT.^?-KBKA^`*5<?RV^G\TMBCWS[L5"L:;!$01$$1
M!$01$$3"9`G?($_@@B22_6O*Y5RZS.LM8M@TRGM)>7Q19*N(IGI98COV>&"+
MF\@B((B"(@B((M@/2DP'"=4^IAR&:;:DXI8<ZT_SOFPT-Q3,\-RFVTMYQS*,
M:OFH-CM]XL5\M-:V[1W*UW*B?6T\RZE3;C:BE0(,$5L.??%<9P3GIYT<(PNP
M6K%<.PWFRYC,5Q/%[#1M6ZQXWC./:P9C:+#8+-;V$I8H;59[71M4].R@!#3+
M:4@2$$6QG+N7G3F[]![E"U3Q'2K#U\Q&I74UU8T=J-1J"P6]G4+*,93I5;'\
M9P2NR5+2;C66%C(*Q+M/2N.%EM]7$D`DDD65_-UK9RP]%'5!'(;RX\DO)[S2
M\P>CN,X8SS9<V/.9I8[S!NY9K3DV)VK*LJPO1G3Z^7FUXAIWI]A:+XS;D/(8
M>KJIUIQ#Q[UI=55$6O3GJY@>0+FUY=-(=<=*-!L,Y/>?"WZBY#@_,#H1H)B6
M1V3EEU*TT-C:O&+:XX-;+C772S:89%2WM1L]5CU'4.^=`N52N%+;2G2+,3K@
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M%MXZ!]1YKUC>GP]P*<`Y@;&@I0"I4GK/>V20E*5$\(<G*79!$L:?+I?_`&0Y
M_P`Z_P#^A@BY8_7+EI/3#TRDH>5S3X(!MWE.)9O.7M2BD;_%[@ID7Q#U>\),
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M4Q_7'-&,4JL*R&\W;#[C?[2:Q18H@]4/(IK:Q3-A`$B?`I[R0:`\A^/<N1'J
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MVD>JPMQDMOHXU@`AWKT5X$_;FLJ<DYM]*N7#GARGI7<C'0YTFYM]&^4NEM^+
M\P-<QI;;M0>8[-*)FDLU#E>HECN[EKKZ>@9=J,@2A3EP%2]752PD.4C2T\,N
M4>&G>I,AJT>[[=RX^>J'I]C.FW/#K?9,)Y8M5.3K"[E?*;)\4Y>M9:1N@SC!
M;+D-$S<&45-`RMUFWVJZ/N.5-%2MK=;I:9Q#27'`CC,HFH]"KK+[J+`L;A[0
MBG/%5R;'B(@B((MB'2/V=4/I^3__`&WT.^?-KBKA^`*5<?RV^G\TMC#WS[IB
MH5C38(B"(@B((B"(@B((DE;ULIIMCK1ZU--)*$-Z3<O:4I((("=*["D`[`"9
M#:1LG!%S801$$1!$01$$6RSHT*2CJR].):U)0A/.?R\J4I:@E*4C4S'B2I1(
M``$$6RGGCZ`_6`U2YUN<#4W`.1_4/)L$U%YI.8'.\*R.BRS2AJBR#$LNU9RW
M(,;O=(W6:@4U4W2W6S7!E]M+K;;@0X`I*53`(I!E647G2CU?'D8RVB9IT93I
MIUA]8,GIK?5K0M+=ZP[2NRW-ABJ0TM14RFX6X(64S!&X[1!%DESO<E7,=S]<
MXU%UA>DCC6/\U^GVLF3Z4Z]WO3G&Z[3S-=4^67F"Q^UXR]E.E6NNB&8UB*N[
M4%-FF-.5;3J[;762YV^H"%\=.IMRI(KH=4W,>8O$^CU=M-.I^URI:>\_6HG-
MOIIF&C^BFF.&\N^*:XXWR]8_A%W&0734#'M`;&PQBUNK<GK^-OXSJ`^[Q):5
M)Q!9016KZ^O42Y\>7KG\I],M`>='F<T=TUM?*]RFW"V8+I9KIJ)A6'6^ON^A
M>(5UWJZ*P8QD5OM-/4W*N<6\^M#84ZZHJ423!%8?JT:PZHZ\]'7H1ZIZUZF9
MGJ]JCDQZB/RHS[47*[IFF;WL6K7O#[-9Q?,@OE97WFM^+K-;V*6F[]Q113,(
M0GR4@`BMWQM_[KSW?>-][]MAQ]UWB.]X/]C:7>=UQ=YW<]G%*4]DX(N?>"(@
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MI5P#ZFW6`ZAM"I23/AAF[$-O*3PY]O<KB=+7G'Z::>GSSJ<FG4OUEUYPH\RG
M,!IGJPQ?],<4O&;9E=&-/Z&FN0K*O*';1?J=-76Y!2!#OGB7'%I65#AVJCRH
M`Q1T,K2#3MYJIN<3JJ\E/+ORN\N_)#T@UZK5^F^E?,OC7-KJ-K!K)05%GRG/
MM2</K+?6XY;:>E?HJ2M9IVJZWLKJ5J9:953M=VA/E$'W,.2""4XTY=OXK8=C
MO5IZ(>I^O%IZC%]U/YZ>2;G.RNQ65GF*T\Y=J-TXGK+<;!1V=ZJM-UOK%KNM
M&O'\BN6.TJ3W;]&I38`?3M6J)<E'-H.*EO@E=@T?@N9/JY<]MCZD7/;JUS78
MM@]PT]Q;+V,;Q_&<=O-=3W&_"PX;9J?'[7<K[4TK;=*FZ7*EI$NN--E:&.(-
MA2@F<0932G?55=K$^/%XI@M;@6B0V]@[#_5%.6E5="CO$>'\1_JAE<E"CO$>
M'\1_JAE<E"CO$>'\1_JAE<E"M@O2<??;ZG/(.Y1D><HYLM#RR5))25_+BV2!
M$5<((:%274L8I&X^+GZ""EL*SO53]N8=K9>=++_>R3P@%-0ZE(">P!``B<K2
M:5PX*9P7B((B"(@B((B"(@B26O6T$I3UI];0D2'ZJ.7WM)W:66)(WDRV`01<
MUD$1!$01$$1!$]9>>IG6ZBG==8?96EQEYEQ;3K3B#Q(<;<04K0M)$P0008(I
MS\JLG_\`>._?Z8N'_K$$4J565:Z=-&NJJ5TB'EU"*53[JJ=%0XD)<?2P5%I+
MRTB14!Q$;S!%,K!DV28I7?&>+Y!>\;N7=J9^,+!=J^SUW<K^&UYW;JBF?[M<
MMJ>*1@BEU;6UMRJZBON-755]=5NJ>JJVMJ':JKJ7EF:W:BH?6X\\ZL[U*))@
MB\U-755KO?UE345;W`AOOJEYQ]WNVDA#:.\=4M?`VA("1.0`D((ARKJGF&*9
MVIJ'::E[SS6G<><6Q3=\H+=[AI2BVSWJQ-7"!Q':8(CSNJ\U\R\YJ/,^^\Y\
MT[YSS7SC@[OO_-^+NN^[OR>*7%+9.4$4/!$01$$1!$01$$75)ZG@`KJ]N(4`
MI"^5;6Q"T':E:#=]/9I6D[%)/@.R")5.\WI_^09_YI'_`)L$7-)ZT7RU5O-)
MR#Z>:?6G67EPT.<M_,5C&1+RWF:UJPS0O`JQ-'C65TIL]OR[-:ZAM57D-2JM
M[QJC2LNN-,N*`\F![E4M%3CV#WK@+^QGRP?_`-%^C^?_`/2#EV_2>)$A`.(*
MJ&ND:/#4CN!_-'V-&6_S%^C_`/>0<NWZ31+S-["O?,G['>P_FC[&C+?YB_1_
M^\@Y=OTFAF;V%/,G['>P_FC[&C+?YB_1_P#O(.7;])H9F]A3S)^QWL/YH^QH
MRW^8OT?_`+R#EV_2:&9O84\R?L=[#^:/L:,M_F+]'_[R#EV_2:&9O84\R?L=
M[#^:/L:,M_F+]'_[R#EV_2:&9O84\R?L=[#^:/L:,M_F+]'_`.\@Y=OTFAF;
MV%/,G['>P_FC[&C+?YB_1_\`O(.7;])H5;V%/,G['>P_FC[&?+?YB_2`^\AY
M=OTGBJP[D\V;L=["C[&?+?YB_2`^\AY=OTGAAW)YLW8[V%'V,^6_S%^D!]Y#
MR[?I/##N3S9NQWL*])Z-.7I^#U%>C^J>^?4@Y=I#_P"9X#N7HDGY!WL*#T:,
MN)F>HMT?P?`.I!R[2V?_`!/VP]Z>9/S#J^@IIZ-68*$E=13H_)'A'4@Y=OTG
M@:\_Q0R7',.]A7C[&?+?YB_2`^\AY=OTGAAW+SS9NQWL*/L:,M_F+]'_`.\@
MY=OTFBEJWL*>9/V.]A_-'V-&6_S%^C_]Y!R[?I-#,WL*>9/V.]A_-'V-&6_S
M%^C_`/>0<NWZ30S-["GF3]CO8?S1]C1EO\Q?H_\`WD'+M^DT,S>PIYD_8[V'
M\UF_TU^E#E.F?/\`\F&H53SW]++-:3"N9+2C)GL2TXY^="<US_)19LLM]:;%
MAV(6;(G[MDN1W1+99HZ.G07'WU)2-\3XZ9<%1SEQDJZM:)5T2$@>201Q*.S=
M,J)(V>`F)BDKU!$01$$1!$01$$1!%SZ=03E$]75U=YFLIS?J)YGR;6;FCKK#
MB%)EE!K'SJC13.V\?MU@I*3#5W'`!KG@IM]([CS;)IGC;F_.F>%SB7/B)%A3
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C/VA>4O#!_P!=N?GXI;J*:C[^L\P_S<E`[Q'')1%OM@B__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>pg118a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg118a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`O0(;`P$1``(1`0,1`?_$`/X```$#!`,!````````
M```````&!P@#!`4)`0(*"P$!``$%`0$!`0````````````8"`P0%!P$("0H0
M``$#`P($`P0#!@L-#!4-``$"`P01!08`!R$Q$@@3%`E!42(587$R@4(C%A<8
MD:&Q4C,D5=:7&0K!T6+2-)6V-U=W6)C8X7*"DM0E-;5&9G99\,)#@]-$5'2$
ME$5EA28V5L8GMSA(LE-CLW6EID=GURAHB!$``0,"`P0&!P4%!08%`0D``0`"
M`Q$$(1(%,4%1!F%QD2(3%/"!L='A,@>AP2,S%4)28K((\8+2-!9RDJ+B%PG"
M0[,D-5-S@Z/31(0E-C?_V@`,`P$``A$#$0`_`/?QHB-$1HB-$37;X[DQ=FME
MMWMWIS#LN'M9MAGNXLF(PTI]^6QA6*W7)'(C#""''WY*;;X:&T_$M2@D<3HB
M\Y.`]KN\W8ML3M3WB9%@>P>Q&YVU6R35JS[.-K\MS[=3<#N*WM[B+5C6V\*\
M=SWY0+9V];;8OM9A6Y^<JS._NW"]3H\&;:V'1=(,.+(7+(DMDW?!W/9S8<>R
MJY;R>,.WO<3U"]P<#;BVS;N<SW1I[>.WW9O;C:_",ADX';;=A^>19?<'W-7,
M1_Q9ALPYUELS,](==B(N"R):1N_WO$VHD[N8OC%NVRM]E[<,7[EMMH';Y;86
M*29^)8KV\;?W/;79+<"=C./1[MN=B>2[L[^1<:D6QB]O1<5N^(9*TQ:4293"
M)T@B?3)-Q.[?,>X?:?M>W,[DV84>S]]';A:[UN#BFWV.8#`S*Z[7=H&2]VV]
MNS=G:4_+C7/`[KG9P2/;6'G9=Y<3/N4:1(DMQBEHB6/J79QW69EW#=LO;MC^
MS^^5I[<,I[G^UB+)W`VHRC:6''WSN5HS-_>K=?$<VEW/='']P<,VLV^VHVIN
M9F0V[4D9/<)'0[+:BQ$0KP1:][#NGLV];+CW);K[K[LX]DU[[=NY:Z^JIN%M
M?E.<V[/,+R3>#=;#-ONVOLI@^9EJM.V^ZV%7I<^P8M:VV[7<,=L]GDW%Y^"S
M=W+E((MU?I5X7B6,;`9ED&V]^VX:VMW(W@R3,MNMG]GMTCO/MEV[V!O',1Q6
M7M18MQTW.[P+[D#F08W,R#)$6QX6.'DE\G1[>'8[8F2R)_KSOCW'V^_WZV6O
MLFW!OUGMFY$'$K/DL;>?M^@Q,DP:0[<D2]UHEMN6?QKK;K+;VXC"U6N6TU>G
M!+2$1U%#@21,KZO,:ZS?38[MX%CAKN-UN.VK%MAVQ$NX0$71=QRK'(2[7*G6
MIB5<H4"Y-/J8DO,-.NMQW%J2A9'22*!5F[=>Z+LUR:T(V88V)[.\;[MNXGMV
MV(B;4[$7+.NY#`-O+58,.[BLSW.WQ8;W>PO;&QVK=#<:-&L=D2U$L35KCQ;'
M%D33<'W/"9(F[OGJ*]X##>[$G&-[-FINY?XH=X<C.=@,KVBO-N:[!3L+G4?&
MMJ<XW8R?%D9-F#]HS^S>&AV5D-L5:KQ.N\>\VM+6/V^>A9$V6.]_V_URN&V^
M_P#E7<ED%HM^W?;%ZEM@789&T>TV>XAO3N9M+?\`MQO^%WW%7MF=X1M-OY<,
M1Q/,G9OSG%;]C]N>B8S=DR&;,TB]AHB1-C[_`+O+SW(L-R]C>5[+8W;UW8[J
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MV4OMTV_MV\+_`'!M[L8U;,/VFW)W%PFPS;1;=O;([!LN47RZY3BLZ2$7WS'B
MB*2*1N%=^W<K=+UM3C^[_<WMKL3=\?L-MC6:#.[;[CEUS[\-PK/WE[X=MV<8
MMAF+6S(SD%ENT'#MJ[!,?LV'EVZ6JY9FW=I%;'&1'=(F(VX]3'U!<ZPK>Z]R
M,CV7Q_-%8#8KN=NU0\7S?-^U/=&^=U>T6RL7!,IVVQ-F%DEM@6W%,ZO2)]NS
MRX1[].N5E3-MJU0%241B+T\X=:K_`&/%,;LV592_G&2VJR6VWW[,I-HM=@D9
M3=XD1IFX7]^QV1IFSVAVZR4*>5&BH3'9*^E`"0!HB4FB(T1&B(T1&B(T1&B(
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MXQGD+:RU;1_BGV[[>;F6DS[==;E`ODZV0YIB1^F`P[<B)-9CZE/>3N;MCA=A
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M6=P6X&/Y_<8G=QO%MSM\]A6'JP;`K!@VSPQ_:ZY6/$+),O&37Z1`B[I8KDO7
M<+E<YLNX.?A?P#9;C,D3S[B=V6W.V629MBU^PKN,N]PP&SV.]WB9@?:SW$[D
M8_<HN0/VF/#CX?DV";:9!8,YNL5=Z:,R%9Y,V5`0V^N0VVF.^6R+*=QV[V2;
M9=I^^F_.W6-R<ARS`.WW<K=K",4OMGN]OEW:_8QMW><OQVR7O'I#=OR"(]*G
M0F694%2&9R"5-=*7OA!%K?>W;G]E>V,'N4RSOFS[NP>SCM(S??`[#9^YM8(&
M\V0X[;MN\@C;M;&9!AF+8M^1+:^Q.9DW#O#?@7RPLV>]0I)0F5#4_-(FCW\]
M3#N"V(S.W6W>#"\&M>;=O&>Y<O=G"MD-PYN2;3[RXUG79QNKNGLW:7\XSO!<
M<R?`'K'G]CCJORI-M/R^!$9NR/,1I0B((GZ9[_NZ"W[R8_VMY)LIL.-^H>];
M6$[CWS&MUL]O&T%LVS?[=;GW+-Y5B<B1MG`SBY[@IQO'YMF5CLV!#;$QR%/\
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M_M?J^[FY#N-N`K&^UFX7S8G"[GO/@)W'M4_.+E!3G^S&S&3;I73(5;CL8`WL
MA?\`;F_WW%7[/!1:;_+O3L!^->D1W(SKD9@B7/Y_?>C\DZOS=.W/\8_XOO\`
M/O\`!_+KN!\DZ_R@^%^1?S/Y'O/_`#+\E7X?\8/"\I^,/X#R?D_VQHBW1:(C
M1$:(C1$ELVPS']P\5O.%Y4Q<9./W^,B)<V+3?K_B]Q<81(9DI3%OV+7.S7^V
MK\9A-5QI3*RFJ22E2@2*-2^Q7MO<0XVY9=T76G6W&GFG>Y'N3<:>:=06W6G6
MU[MJ0ZTZA12I*@0H$@BFB+J>Q'MK46RJP;FJ+/%DJ[C>Y!19/AI9JT3NT2V?
M"2$?#3X0!R`&B+M^8IVW=;KGR/<_Q)`CID.?G']R7B2$Q`H1$ON?E;ZWDQ0L
MAH*)#=3TTT1<*[$^VU?25V+<]90X'D%7<?W)**'PE2`^@JW;)2^$**>L?%TD
MBM-$7;\Q;MP)!-FW2)%:$]R7<H2*BAZ2=W*IJ#0TYC1%U5V)]MJPXE=AW-6E
MYTOOI5W&]R"DOOE"&R^^D[M$//EMI*2M55=*0*T`T1#?8GVVM(#;-CW/9;!)
M#;/<AW)--@GB2$-[MI0"3SX<=$7?\Q?MQ_<?=3_&4[EO_P!W=$7![%NW`@@V
M;=)0/,*[DNY123]:5;N$'CHB#V+=N!I6S;IFAJ*]R7<H:'WBN[AH?I''1%V3
MV+]N*%N.HLVZ2'7@TE]U/<CW)I=?2PA33"7W!NV%OI8:6I*`HD(22!0$Z(J2
M>Q'MK0B.VBP;F(;ACIAM([C.Y!#<-)0MHIB-IW9"(J2TZI)#82"E2AR)!(@=
MB/;6&V6A8-S$M1PP([2>XSN/2U'$517%\NV-V0AGRJC5KI`\,_9IHB[I[%>V
M]`6ENR;H-I<>=DN):[D.Y-I+DF00J1)<2WNVD.2'U`%;AJM9'$G1%R.Q?MP2
M\Y(39=T4R'FV&GI*>Y'N33(>:BFL9IY\;MAYUJ,3^#2HD(^]`T1=$]B?;:A*
M4HL6YS:4+>=0EON.[D4)0[(<\60Z@(W:`2X^\>M:AQ6LU-3QT1=OS%>V^K1^
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M:1&6M`#K3B"I!(H`-=B&?L[:-;,I[W=\U;2-82C;9.V:]C^PQ>"_D_;L@QM.
M%G%U=HILYQ@8^GR7DO!\#RWX/IZ>&B)E;5Z0&`6.SLV"S[^9S;;0QD2,O3$B
M]O/8:VM_*D81=MLSDD^:>TM5PNE[>VYOLRPO293KSK]GDKB.J6R0@$2C_BK[
M,,W.Y0[EMQ$Y^<1&!#+D]O'8*B](PX8F<!%@;DI[10EJ,,"/R+Q4I$GY+^T?
M%\K^"T192Z>F6;TBS(NO=9NM-&.-;4,8\IS83L-;=L+&Q%RO%XV58LS[':2T
M_;&-J[ID-P?L:&5(3`7.D=`H\X%$5/=/TQ&=\<GPG-=YNZ3<S=/+MMY7G,"R
M3.^WOL%R2\8H^+A"NZ4VF9<>T1YQ$5%WMD:8F.YXD9,R,R^&P\TA:2*_Q[TV
M)F);M9;OWB_=GNOC^]V>V]NTYINQ:-@>P>%GN3VUM-L08=WR-GM%3/D-R$66
M$)!Z@J4(4</ESR[/01.!BG9ANW@=E3CF$]^O</B6/HN>07I-EQ_:#L8M=M%X
MRS(+IEF477RL7M+0T;AD647N9<9KQ!7(F2G75DK6HDB4?YL'</\`\8SW1?P8
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ML7\SXL2+:[D,ARXF,VEI@7)9EA`DGQ=$5L]Z..V$G'+/B#^]N5.8O8,'OVVE
MFL1[;.P,0+?@.4Y7"SS(L6:;3VC)6Y;[OG=N8OCRW%+D?.FQ.2XF45.DB7NV
M'IB,;)NV]_9[NDW,VO?M/XS_`"Q_!>WOL%QMZ$O-F,.C9H\P[;>T1A8E9@SM
MW8?FCQ)=N"K/$6^IQ;*5:(L=>O2MLF1[RVWN)O\`W)[@7G?BSR+9,MF[MR[<
M^P&7GD2XV2"JUV.[IOCO:$I]Z^V*UK,:!<'0N=!C'PF'6V_AT1):!Z.FV-KO
M^697;MZLCAY-G1R89C?H_;'Z?3=TR)K-9T>ZYC#N$L=H/BFV93=HK<RX0VRB
M)*FI\PXVI\EPD2FW0]*FP[VQ[G$WA[DMP-S8]ZS*-N'>&\U[=>P.^FZ9U$Q2
MU8&UE4YR7VB+=D7A6#6.'97G%**9-IBMQ'DN1T^'HBH2O2?Q:=N1=MXIG</F
MTC=6^XU-PZ\[@.=MGI^?C-<L8N>*G!+C9Y4]/:`GK9GX*?DCSH2)#EF_:*G#
M%`:T1/E^8_=/D_R[\YC<SS_Y"_S?/G_Y'NSOYE^(7X]?C5Y#RWYM?R7Y9^+7
M_BS\G\K\@^5?MCR/S7_7#1%/71%K6]0OO@S#LMR#L]=LF'8UE&#;T=Q,?;W?
M"ZWQV[-7+;_9R-B-]OF6;AXQ\NE,1W+CAZXL>=*3+;>CFUL2OA2OI<211MLW
MK&8OC6]'>_8MZ,5MMAVAV,WAV9V5[9YV*3(0W`WXRS+E[[XIN,BX3,YRG%=M
MK)$L.XW;CEC<*9*N5IMK5IM+KTF47%MI)$Y>*^KCMEGN=N-;?;0;R;A;.?FL
MPNX*-N+@V+P\DN;N7JW[RCM]O>SDG'8=[#<#(L8S7%)4>=<7)/R*,8\B4]/9
MMC'GUD60M?K(=J%Z7M=;K78MX[CE>YF:[HX&[@UMQ;$[ME.%7G9G,\2P;<;Y
MNU:<]G6?/#8;OG%L>3$P29F%TF6Y]4N-%=CLO.-D6-8]6G#\8V=W!WBW;[=>
MX/$K-@F_G=CM/,8LV,XK<8<?"^UC<&[X??=S;MDU_P`WQG$83-TA0$EJRIGK
MR"?<F9L6U0+BB&M]1$N[7ZMO:%=LBWIM\>YY\C#-@]O;ON1N+NVYB+:L`M5G
MLF"8GN/+AR8<:[R-Q[).G8OFL!5J>N^/VVVY!+6N):I<V2@M:(F[/K8=GAQ!
MB_L0-SYV6/;EQ-K3M/;8VUERSIN^7';Z[;HVF8F\0=UY&U$R)>\+L4QZ!$C9
M,_>9\Z,[;8\%RYMKAI(ID[\=U6&['8KM!N'D,NX6G#MP).972;$N&"Y!)RF1
MC6%]N6[O<)=8$>U2+GCLS#LFC8[M>^\I-SC2#UL+@KCM2'T/L$6.[;^]';[N
M@A;BIP_"=VMO<CVYQ[`LPGXGO/A`PB_7+"-U\8N.5;7YW:HD:[WIE[&LQ@V:
M<VVV\]'N<*5`D1YL2*\WT$B9?83U)-MMP]A]M-Q]P;==;%FU]A]GF/YY9<8L
MDF7CUHW*[Q-O\!S?![;CTFX7-<R9C,5.?Q429+RBY%2%=0<*221(?&?6)[<<
MF:QFX-[3]U5EQS)\>V+W"8R[(ME56O&K7LSW&Y1^(>U6]]ZF')GI,+;R^9ZA
MVTK;2RY?VG([LSY8;8@SM$5QLYZI&*9*SG=GW7VBWGQ?*L6S'O"L6)7#%-J,
MBR#"MZ6^U#>;-<#R+%]FY,*X7?(<NW"@X?8X5PFQW8<*!*=^8.0'WHUNG*B$
M2JV_]5#8?<V[8;B.([=;[W7<?+M]<L[?)6V]NQ3";]D.%YI@N"8/NEEEVS&^
MXQN-?-NHF%V7;7<2V7EVY0KY/06G51$H5<4^2)$[F7=^6R^(=V=@[-'K3N)?
M=V+O9<0OUUE8YCEMN&.8A;<^<RAG$9U_9?O\/-9UEN#V(3$2[M9[-=;+8U>%
M\VF0/%14B8C!?55V3W@LV"7+"[#NSMP-R+CV\W[;:7O7L]=K-#W>VJWOWLPS
M9=.8;<1[?ED>0Y#@95F,*W2),]49ZUN7*#<E0)MLDQW))%B[1ZR':?-V^O.Y
M5^Q_?#;W'$8#MIN7MX=R-OK;ATC>W$MV\\5M?A4_:QVY96+6^9N?ENWO"^2;
M&F*R^U<75)M3B9^B*:?:WW3;3]WVUQW6VAN$V19H.59)@F26BZFS+O>)9OB,
MQ,/(<7O+^-WG),8F3(7C,O-R;7<KC;I<60T_&DO-.)62*,L_U5.V''LFW-M>
M<6_=_;S"=K;[W"XA=MZ\TVWF6S9V_P"=]KL"_P![WBP3$,GBW"?<KYDMFQG%
M[C<80\@U$N[4&3'A/OSXTB(T1,I.]9+9.^6'%LOVYQ_);E;,=W=N>)=P.%7*
M'CF0[F89MVUVH]Q/<M9,SQ"%MKG67XCD,N_1-BWFVHR+J_)9;8G1I,:-.:2T
M")Y]W_4Z[?-I\DR=ZXY//?P':RR[AW7<:^6K!KEDL:_NX?LGM;OHB'M]E-MR
M2':4.VS#=WK$]/7,ANQ.JYMH6_$0Q)?012V[<]_\6[F-K[=NKA^/9GB]GN%S
MO%H%ISBW6B)=$R;+,5$>EV^Z8O?LLPG++!.`2[#NUBN]UM,QI=69*U)<2@BC
M];?47V)O6_>]O;W9,>W>O^4]O]NRQ_<*]XU@"\ILL:]85A-EW!O6)PK!C5UN
MVZ!O<O&[\P;0_)QV-:<BF]4*TS9TQ/@$B:K'/5LV!RU%\L&-[6]Q5^WFLF?6
M7;X=N=APG"LBWDND^^[<W;=B+>X+&/;DW7;N-CL+`[#-E3W9V10Y%MDL"#*8
M9N#\6*^1.3:O4@V4N^;R,*;P/?VV)@97VY;?7C*<FVJF8A8+#N-W2PMN;IM9
MMY?86572S9E;,R%JW.@2+S#<M(-D2T^B6IMX,M/$2'W-]67MHVLO.4VF[8KO
MUD4?;]>;RMRK[A&U4K*++MWC.W?<!E';1E699*N%=A<GK'$W1Q*2TQ'ML:X7
MB;!4)4>$ZVW)\`BEQVZ=QN*]R6.9I>\>Q+<;;^\;;[CWS:G/\#W6QN+C&;8G
MF=CM&/9(85Q@VV[Y!9Y,2Z8KEUKN<21#G267(D]L**'DNM-D4@M$1HB-$1HB
M-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$6F++O6FV:P_ML
M[U^X&?M)N*]=>S'N3ROMLG;1LW#'4YINW>+'F3>(V+,\"DN24VIK$\J$2[36
MURUH<BQ[!<0Z`J.02*:69=_W:?@4G/['D6[V,M9SMCMCE&ZF7[?PI7F\GAV?
M#,!=W.R6P0JI9M%RSFUX2U\R=L;4HW1N"I,EQA$<^+HBPNVGJ1=F&Z#NRMIL
MV^F&VS,-^L,P/,L%P>^SC`R!*-R<:<RS$,9R!P(=LN/9I?;-'>=@VF7+:FW%
MME3D-M]KI6HB2^0^J;V1VJR8;D./[SV/<*UYIO\`[4=N,1[!0Y=EVS-]Y_G;
MN`WFYQY`@R5X%?X&-SY,*]Q42;?<68RS#<D=*NDB7D'U%>Q^Z1-R9UM[F-KY
M\3:6/;IF;/Q+P](2Q!O&6C`+-<,<#412L\MUYSU2;'#D6$7-F5>7$06E+E+0
MTHBRUP[^.S2UV;:[(9_<;MBQ9-YV'YFW5S^>>)$O-OAW\8G<+I<'667!BMHM
M67'Y1-F7?R$:%=P83[C<I):!$O-N>ZCMVW<W*SG9[;7=[#<QW,VW-U_''$+/
M<%O7.V(Q^_?BIDC\53C+42^1<7RLBTW5Z`Y*:M=T(ARE,R2&M$20C]]'9])W
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M-GO:!E^;6/`MXL7RK`,2Q.QY+>8<=_<RX[A;90-S;.C&FD`IAOO0I$F%%CS'
M&7[G+M\E,1+Q:6E)%E8GJ!]EDZP[C9/#[D=L9%AVID6>/FMR:O2U,159%D"L
M2QMZQ#RWBYI"R;+4*M-LD61-Q8N-T!AQUNR1X6B)#;A^J!V.;<[5Q]W)V_>)
MY!8;QMYNGN7B-FQ5<J[Y;F5@V9^;1MQF+)CO@,38MSQ2^V9VTW!JXB"+==E(
MB3%1W5A.B*7VU6Y6*[R[9X!NU@\Q<_#MR</Q[-\9F.LKCO/V3);7&NUO6\PX
M`MEX1I20M)^RH$:(E_HB-$1HBC)W(=I6TW=0WB$?=9&12(6&6_=RUV^!9+I&
MML6="WJV=S38_,6KJ'K;.>>4UAN=S7(*VELKC7!#+Q*PWX:B*)D7TANV"U87
MBV+6#(]X;-?,%QSM_M&&;DJR/#LCSFQY!V\,;WQK'N%*&9X#DN'9=F>X;/<7
MEXS`WZT76UWQ5V6LPF7$(6"*\SOTH-C-P<8LV+WK=/?X,6_:VS[7WJ8<BVXO
M"LZ9QG?:/W'XIE&<6/*=K+_A][N>-[IB4^S:$VQG$9%MGO6V59I$!N+'CD2%
MNOHM]L=XVO?V>G;B[]OX#?-P-Q]QL\Q^3>=IY]HSR][J2,.FY895@N.STS&<
M!F,3L,:<LUXPN#C&1XXU-E1K5<8<-;4=DBSNZGH^]NN[HN$;)MQ]]FK3-S#N
M7R:/96+QM7=X%AM/=O>;-E.].&XH[F.T>47+%H-WRZTN7*!?H$AC-;2NX2XT
M6]MP74Q4$1>?1Q[5,MOK%QW`R#>+<2Q6S:2\[.8YB.69-B#D;%L;R+:6V;,W
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MMH((411`MGI/[!62Z;>.63<GN#M&)[?Q^V)Y6VT'.L81@V;95VBX];<1V;SK
M-H[N!NY!.R*'BMGB0;DQ!N%OL]Q$1B0Y!\XPS(01.6KTZ=@E81$P`W#<7Y'#
M[>NV#MG:<_&2U_,#MWVE9]=]Q]KI*Y'XN^&<FEY!>WDW:4&PU+C!*&F8ZAUD
MB:;)O20[?LTA[D63+]S^XS)</SJ5O_>,<P:[;@8R_B>SV5=S>XDG<S=_*]LK
M>C`FI"IU]O<IR*S!R)[(;+%M$B7!;@B/<+BB41+[MW]-'8?MMSFV[D8EDNYF
M09A`W!SO<]Z9D<O;VUV>;EVXNT.W>R61O-XCMUMS@6(8_9AA&UUI3$MMG@VV
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M=]UM1%(38KMQF;`KQZRXYNOG66X5"LVXTC*[;G3.'2+MFNXN=9;BE_@9Q*<Q
M#$<.Q[%F<1LUEFVF!9K#;K78VH<\=,-+C(<410NQ'THL"R1_?(]RN>9_NKB6
MZF\O>7G^.[*LYH6]F\%M_=;?<SM<W*L?M[.*6+-K=N>WM9ECUN6MV\SK3:+A
M.G2[6PS*D+EK(G[VS]/7:O;Z1AURO>X>[V[%\PG=)C=6V7?<6=MNRW*GQ-E-
MR]A(N,W+&-NMLMO\'=QA6#[LWEV86K6S=+M='D2;A-E%`1HB16%>E7VV[=;7
M8+M9A.2;W8[#V[M_<)#QS-+=N2IG<A,KN-;M\/)KQ/S`67SDZYX?9;);;7CX
M6CRT6T6V/"ELS8P<:<(G1[8^RK'^T<0[)M)N!E*L+O65[L;D[L62^V+;:V#<
MO<W<>-MW;K;E'R;;7`MN\$P-C%+7@ZVVH.-V>SP)+DQV1)8?ENNR5$39[O>E
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MWKR8[LXED>)9UDN3YM9[EE5Y;RWN'S7N=R"^+N;>)16&[]/W/SZX'Q`QY=JW
M%N,VR@-A9(IH;:[/8GM5>=X;[C+MX=F[W[JR-X<R3=9C$MAG+)6!8!MRXU9&
MV8<54&S_`"#;BWJ#+BGW!)4\OQ.E:4((G5T1&B(T1&B(T1&B(T1&B(T1&B(T
M1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1:(MP/1/BYU=LSEGN$?M=EW`Q#O7C9
M=BZ-N&I-IOVYW<7FO=#?MA=T;B59@R\[<.V3&>[_`#.UMQ@4_/W'HD@NP3%;
M:T1*V!Z/=MA;ZY]N`YN3AMQP#-<SWCW6C1;QM[N!=MW<8W)WKVIRK;?(?D65
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M`\ZVZR/=R;:+'N#W#]W.^EYG6'$&6+S':[H]C-R=FVL>B27;^ME<O!W<[8N"
MI;J%MW1J!Y1;#"'O$;(F<@>D=N_:L=4O'^XW;C!,TOFX=IOFX2=N-ONY?#L-
MW!PBP;>Y#@N/67)KM;^]+\O\Z\8Y/RB9>8D=.>M8PI;WD9%G?CI#NB*978#V
M&'L=QQVP+W,;W+6K8WMAV31<1B'XJ/KB=M>&9-AL._2&_P`8L@ZW<J9R#S*X
MP7TPW4K2EQT+JDB;2W>F[D7C[BL7_>/'KC9[[A7J1[>X$F%MG,B7?'<;]0K=
M7"MX9CV3SIF>7*+D5YVQR6QW*&'(;%J8O%NE1@IJ*['=7((FYV)](R%LEW%X
MMNPG<7",OP?%MR).]T.W9!M_N)*W6C[H77;5S!;NQ:,K?WUD;26;$/F\V7<X
M;K>!JR.-#?\`E1N;D<+><(I'[D]@\7<;/=X<SD[B(MS6[G<MVG[_`,R`SBO5
M-M4'MFQ[",>?PYJ\-WZ.^^_F#.).K9N`0T;6J8:,/E!*R*!^WGHLY]M1@$S%
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MACN:WH9988:O4U#3++;>:I2TTTVD)2E(`2!0<-60"#7[RLSNENP5ZNE)9KU)
M/42)X]^O><>(Y]S^]A_]-M>/<0K]O&PUJ`<>`]RKO>I'ZB(-!WZ]YPY<NY_>
ML?J9L!JACB1C]ZO2Q1AM0`/4/<J7\9'ZB7^'MWG?XS^]?[]M59BL3(WA[$?Q
MD?J)?X>W>=_C/[U_OVTS%,C>'L52/ZD'J).BGY^W>?6A/_O/[UGVC_?J3JF1
MY:</O5R&(/.4`5IP"N?XQGU$_P##V[S_`/&>WL_?IJCQ7>E5D>4ZNP*BCU'/
M44#A'Y^W><?B-*]S^]E*#WC\==9.<$#%6+>',\U&&;@/<KA7J->HHJ@'?IWG
M"G.G<]O8/U,UU;DE#-]5M1IPFIE:!3H"OF?42]1(I"CWZ=YWT@]S^]?\W-JZ
MQG3X5J5M[;0@X!V5I'4/<KK^,4]0_P#P\N\W_&=WJ_?MK%\U_$[M*V/Z)%_]
M-G^ZU=3ZC'J'HX?GX]Y9]O'N<WH/ZN:GW:]\R3L+NU>?HT`VQL_W6H7ZBOJ'
MA*B._/O,'M_]YW>KW_\`#;54=S5P%3VJS<:3#%"7^&S_`'6^Y6W\8YZAR.??
MIWEFO_\`9S>KV?7FOTZRO%Z2M6+6$?\`EL[&^Y7;'J,^H>Z"1WX]Y5*?X3F]
M7N/^_7Z-8CYRUQJ7=JVT-C`8P[P8S4?NM]RY/J+>H<>??EWF?<[G-ZA_Z;'5
M'F:?M.[2O)=/AI^4S;^ZWW+C^,5]0W_#R[S?\9W>K]^VO?-'B>TJR-/A)IX3
M/]UON5-SU%/40Z2?S\^\U/+_`.)W>KVG_AKJIMUC2I/K*OW6@M#*M8P?W6JV
M_C%O41'_`,>W>8?_`/3N]?[]=9#)P1M/:M#+9"W.5S&DG^$>Y4#ZC7J)]9'Y
M^G>;2M*_G.[V?OUUZ9ND]JHCMF2/#<C<3^Z/<J:_4;]1-!K^?IWG4/#_`-YW
M>O\`Y;-"-5-GKQ[4N=+#02T#L'W+I_&0>HB/_CS[S3]?<]O5^_4:&0DU!/VJ
MU#9-$8#FBO2`@^I#ZB/^'GWF_P",]O5_,S;7F=W$_:KOE(VXEK:=07'\9%ZB
M'^'GWF_XSV]?[]M>YW<2GEX?W6]@]R/XR+U$/\//O-_QGMZ_W[:9W<2GEX?W
M6]@]RI.^I%ZB5$T[].\X<3R[G]Z_H_WZG5;'FN)]JP+ZW;W<@`V[`/N5#^,B
M]1,<?S]>\_\`QG]Z_P!^NKF?TQ]ZU_@$8IT-AO46]06Z;Y[+VRY]]7>+<;;<
M-VMN(,^WSNYG>B5"G0I6969B5#F17\T6Q)BR6%J0XVM*D+0HI4""1JX"J'-`
M']B^V-JM8Z-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$6G+
MUZ>ZK=KLS],O>S?/9&\KQW<*V7[;#$[9?F),J'-L\//-P;!B5UN5MEPB),:Y
MQ+?=7%QUH(*70#HB^:B?5Z]5/[/\8CW?'P^EL+3O=F(#M$(47*&=U5*E$<>/
M#1%6C^KGZJKBE#^,.[PR"2$G\MV9<O>#YTT%-9-M;.>ZKMBPG/?F(J=JST;U
M;/5+0D>)ZAW=XLG]?O=F!(X_3.UOH[*%C#G8TFG!>>(_B5RKU=?5(2X4?QA/
M=T>*>/Y;,O\`:/\`K[6KGCC:X4:!BF=_$JY_C;_5'_XPONZ_ALR[_5VK?ALX
M!>>(_B53=]6_U2>@]/J%]W=?9T[V9?7]*=73PV<`GB/XE8[^-S]4JM/XP_N\
MK6E/RWYA6ONIY[GID9P">(_B5W3ZN7JF]7P^H9W>%00M7Q[W9AX80D`K4NLZ
M@Z1RTR,X!/$?Q*S=S]47U=K!;L:OE[[Z>]6S6/-8$VZXA>;IO/F;-LR>W6Z2
MN'/G6J0NY.%3$28VII5&T@*'TUT\-G`)XC^)6':]7+U2NH]7J&]WE*<*[W9A
MSJ/?.YZ9&<`GB/XE77\;=ZI7_&%=WO\`#9F'^K=/#9P">(_B5Q_&W^J3_P`8
M7W>?PV9?_J[3PV<`GB/XE<_QN7JD-A:SZ@W=X[T-J50;X9:DBE.(#DX-$"OM
MY:>&S@$\1_$I<6/U(O69R*]PL9M7>9WI.WZYL2I,*VSM];U!>>9ANLQG_&4;
MN3!<ZY*'F@H`NM#@*:!D8Q(%$SOKM*1DKU:?54B3YUMG=_\`W?P[A;YC\&?%
M7O;EJC'F0UEF0PVMJ;X+J$K!)4#[-;6T;9O'>C83U!>^(_B5;.>KAZI71\/J
M%]WO4"H'IWLR^M1]4[6+>6S#<.,30V/#`#H3._B5AI/JV^JHV2XGU$.\+I%*
MTWNS'IX\.7GM8$T!C9F5V)SB_$X45E_&]>JE_P`8EW@?PWYA_J[6(LE93^-T
M]4[RG7_&'=WW5\K\7J_+=F%?$^=^#UU\]7J\+X?\[PT1:9]PP?Q_SHT/_EEE
M'L_[^3M6ZA9;0:>L^U)9D$A5`3Q'($ZMO(!Q69;;#UJK0\1[>/#[FJ%?>"6D
M#:NFO5A$$;<%R$D\@3]0TJ!M538WO%6@D=`5\PVLMD="C\1X=)_G:L2/:#M"
MV%A!+X_?:X#+P5ZS"6Z#1IPFO"B%&OZ&K?BL'S.`]:W[-/N)?RXGD]#2?N6=
MC60$!1014`T4DUXT)''Z=8+KYH)J10*86/*3G`/<QU2`=AW^I9]JQJ*0$(42
M:4"4*/#V"@!YZL2W\9I1S>U2$<JOAREL3S7;0$K)1\:N2B0U"=((^'J:4":@
M>\=0KK"=J$5<I>RIZ0ME#H3V`UC(--X->Q7"<9N864N,,L?":J>5T`#D:]=*
M<]4MES?+4K'.D2-^:-X]15N_BKR%A)?BN**`K\"\E:14G@>DGB*:N&YR=U^!
MZ58.DAQV.!ZE7AXC*EU0A44+J4I"G$!1(]R2:DT&O!>`.KF%%<CT#S)\(L=4
M]!W+)_DNN!XJ>A()YI4\@$?<*O;JYY\?OMIUA5.Y-B&+FN'J62@[:I'"9,8`
M;%/VHZAU:5`5'4$$])^O5EUVYQ)J"%M;?E:T$36M<VM..*ZOX'`;<Z429#RB
M2.DI76@KQ'#CRU0;L@;0%F1<H0.<2\X47*,&C!-2Z^@`GFE5!]TC5)NJ[7!9
MK>2X*=T56"F8HI+KB?&9X?9ZG`"KCPX5''1MXT?M-[5I[[0BP$O:X8;Q1)Y[
M'Y#:J.-.*%"4$(44E(YD'W:RF7C"*M(I51P\N1W9+\2&X*V79BE)/AJ'"H)3
MPU6V\#C0$$JT_EF"%I?^T!58N1`"0"`":\0`"0*<Z"O#62R=U:$%:&[TT`;'
M5ZEBW(@ZN`KRY`G]0C6<R1A;5Q`*T;[%X=0,=3J5H^R`@]/%51P`-:>WA4\M
M7FT)P6!=1"..N^JL>E7ZT_H'5="M>&N.P%'2KE0U^HZ\7N5W`KFBD\P17]<"
M/T*Z8*AT6;YL/L7#E5-@5!Y\`>.JF4#@5:DA:&$C;3BG3[>_[?VQ?]^7;#^S
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M22KJ0#T]22VM%0L?$E22L$4X'VZ9^@IXXX%9*X9!?[O`MUMO.0Y!>H-H8$:S
M0;K=Y4RWV6.D]7E;3"=6J-#BOK4I3J4)3U+X\ZZ]S]!5YIS-!XK%MIZE<P*<
M>/UC7F?H*I>[(*[5DDJ3054!3AQ(_GZ9^@JWXXX%4JA2C]).LKP'<0O?&'!5
M$!/6CQ$EQH%?4CJ(%'&U-J/1]A9Z%$#JX#3P#Q">,."K1Y,J`E_Y9,FVY<AH
M-OF).FQ0^A"PZ$/JC26END*0/C42HC@01PU1+`[PS0C8O6R@D"BZ3\=VLC0[
M1=,3W'S:_9<8<)R;CMZM,V+:VI\I+SEW:<ER(S:5,-'BDEQ2U<^7'5F#Q(OF
M-5?KAL5LE*A\(-45HR:<"V?L])/%2:DT/MULFW<0'>:2[U+Q*.1B-T&%,9P7
M;2]8Y5_D8ZVTS=(SET3-C&6"MRW(JZELN0'1S/3T5/#6/=S1S0Y&-(=4*N-X
M8ZJ;J3&+9*TH(!J>1!/Z/#6K\(J_XXX*OXA\E]@_[%>'_H_G_+Z]49?;17<P
M^RJ8'<4'\?LZ3[?QRRCA]5]G5^C6,#C7<M@!W4F(H(2NOO'ZFK,Q!(HLJV%`
M5PX:*4?<=>MV!7W.R@N.Y<(0731''_DY\="<NU51P^9(#<2LI$@O+<".E1IQ
M(J!SY??`#6//.UK5L[2PG;)X0:4IH5K=<'0VTM:N)HW\9Z1S-4UY`<=:F:Z;
M6M5.-+Y>N9G@N;W:>F].-:L+FNAE93Y=AQ(5XBB%$<:<4))4*#WBNL4W`.U=
M%TW13;M^7$)P;=A]GA+0J?)1<^HI4&D%;('+X%%?02`>=-8=S@RN]2NTL\<1
MO2ZCP[25I;A1F(H:2GI#+2G%N<^"U.)H>FG"AUI'2Y*UWJ=Z)I+;L/#Z845P
M+7+NDIQJ&U-)1T]2FV$!)`2*T-!6@_4UI)[H"4.X%27_`$6U\3I6BM&U],58
M77`+T\2I$.24.I^%2DA-1P'WY21]W6[LM3;7;@HG=<N29=F"S%CV3O\`+80Z
MAF*@"O4F44EWD#U?"HCHXZN7EZ'39OX0K^F\C>9M/,O;CF([/6E"C9&X14J6
M_(:9*25U"D<.()*?CK05/W-8\=QG?EXJJXY;;8-,H`J$E[UAT**"U\W#RENM
MH<;05I<"4\%444@`\??K)V[%';VV.(W)=VC:FR*@-R8\QU1>"'%)+H*_I2?B
MXG66SY1U+30VI$I.ZJRYVJL92EPK>\0*XCXN1!X^X\3JW-L"WT5L20$FY.V:
M'%*;CO.("EJZ$+)!))^U4FE#JQL4CM+0T&"1MRV:O:R'F6XZT\2"%+!^G@36
MO#W:Q/.VXP!`6/JG+\MR"`%@%[<Y+;VG5.P%+:*%$+:;4X$I1PXCBKB?HU=C
MU*U:/#+AB:K367*DL$+P6[7?=UIK+C:IC,I3#[+C1+E*+0INJ>OF`JGL]FME
M;20F1KV$5VK4W_+SVU[N-*K!3[*XSU$-'XO8"DFG,&@)(%=;;S`41O=$=P2;
M7;5HJ5-K`-?96GZ`UZ+BI42OM)N6.<&--/3I2>?BJ;0HE*NKD/M'GP]Y&ME;
MS]_#910G5M,NF1DY3M]-ZP2TK05$I4D<.8/N'+6P$A=UJ*R/GM\'`H2>*2?H
M.J=ZSF.J`[B%R^I*DI`-:$^P^X:]"MS;E;:J6.[Y3U)V.WM"D[_;%DB@_++M
M=[1_Y\6+W'5YC@74'3[%JY_R_6/:%]X/64M(C1$:(C1$:(C1$:(C1$:(C1$:
M(C1$:(C1$:(C1$:(C1$:(C1%YY?Y4D@N>C7OX@<SN)V]_P#MJPNOZ6KT#!)*
M&G8K4WY97S"(K(8C@D#J0!TD@<!T\13VZE%I;-'"JP\%82B5N)ZC4%1K[!QK
M[N6L204D<.DI@NJ$)37I%*T]I/ZI.L6?<FW8A2$$DD?%]9]W#A75EHJ1UHJB
M14\1[-9J]H5PL`$`<.'U^T_7JZVV\09CM6)."'^I=PD$5Y\.//A]?NU5Y%65
M2<0A5/;2O*O"M/=IY((J7EB2*<$DBG_(3IY(<%FQD9!LV*Z3#Z:E*J>SB:_S
M_=H+&NP*W.1E&(VH5"*N)/LI77OD3P]JQ:A=A%<21\7+D"!]7NU9((W%>U"Y
M+:T?:XUY4'N^K2A2H712000I(4D@A25I"DJ!'$*200I)','GJB3Y#U*MGSCK
M73C4?$>%>`-$D4Z1U)2`E72DT%1P'#6%0K-H5P!TBG&@Y`G@!^M3[DCV#2A7
ME0N6[G?/)MV1=UD_BZQ/D72+851HR8\*?(0M+TAMY+0>"E^*LTZJ?&>'$ZO6
M\8DDRG91*KJZTIYI1KRX>SZ]9WDV]"]J.A67DU^3]O[%3_[\UI_#/#_SJ++K
M_(H];C-*_*!G2^%!F>5>WCQOL\>ZFM,'CY=]![%NQ"^@V)*L?95]?\S7OA.D
MQ:1AQ65!"X`G!`94ZM5*4KQ^KV^PZJ,3F-K48(^-S_PV_,[`++0(@"S4)H*4
M]IYCAP&L&6=K?F^Q2C1--D#QXE*^G0G`LEL#[R`AHNN+^RE`)42*CI`IQ.M'
M>7;2216BZ[R_H<5Q,TN;4GH6R?9SLAS_`#G'8F1NP%6J#-CIDQ'7&D,B4PKV
M-$I))`YB@X:CC[H>(02:KO-GR@QFGB2)K&GUC[E99KV\SL&O"[-<5N1G&TDI
M)XH<`YJ2>GEP_1UYYIO$K27UAY3!P[$AHNT\:5*:5*<D`>("VI(/20:T*^73
M7[NLF6^@>P-%:CJ]Z6%F^9U6`8\4YC.%X_CK32G64RW"`$)`"E5`!%:D<R=:
M"]>*`@\5T'1M+NXR2TM%:5Q/N3C83;;6'72ZPRTI2%'P4-I)4E05^QD])/PG
MC[CJ+7;SFP*ZGI]M(VV(DR_*LO+QMM97X(*4E02REQ144IIS6CIH`#].L*/5
MX[240R!^;H'Q6NN-,CE^6@7>(B%;$*;FNH+@24T0`2!]1Z.1KK>B];(W/1Q'
M5\51'-;Z=:FQD:?%J78"HQZ:_<F-W#RF[O*?AVB$E22E3?C(40H)"^"J=/,@
M<=9-C>QONVLHX;=HPV=:AVK,DEB<X#\.H]J96UXS<[I*4[/6ZTL$K4'%$`E5
M3^#X&M"./+4B\5G%02]@.."=.SV]=MC^&93JEFHX*JA/$TI6AX#66R5N0=2U
M\6G3!WB4&4]?N66"Y-:B<]PXBJ1^A]KZ=6YY6`"NVJVL<-'-80<Q-$JL6BRK
MS=8D5\>*A;J6D*2*J*E'A44X)'OUHM4UNSTR)SKC/\IV`'=TD*;VNA78@$Q+
M,NW::T[%.JS=O+$ZRHF2%O-O>#XC90W5(2JB2#5(XGJU\\3?4:UBE\-QDK7@
M/\2VUO/92'$.IU?%=;+L[9V$W"-=9`Z/#6ACK82I9)21R(H..LZ'F2:_E;-`
MZC!ACA[UGEEI(SN@TZ0HF;C;*6/YR[XT(O-)\5+3Z&4)``4>E8I3ESUU#1=4
ME9EDF>#&*$T-33H6CU#3&/MY"T"M$PMZV1M\ITF(5,)`(*G$E/50'@F@4"/;
MJ=6VJ075/"+O70?>N?WND/I\H3>2ME'05-QBMY"20%I%0I7M'+V'66ZX#30G
M%8;-%M9(@R1OXN]-Q>=I[BT5,JMDBO0I?7':\2GA@FAX)XG5^VOFLDJ22*+3
M:SR:Q]H7L#*5''I3*WW"9-L+WB)!#2@'$+2L.ME0ZP%(Z*#@??K>07;G"K5Q
M/7^4W1/-,IQ]-R;QZ&4I=(2E/3U4K4&@/"@(K76YCE9(*#;1<^GLI;>N8#**
M[.A8M;2J#E[??_.U?<TQT+M_!:X-,P[N%.*H$$'CI6JQWM+<#M*=[M^-=_=B
MP/[LNUW]G-BU7%@_U'V+7W$3A%7#YF_S!?=\UG*/HT1&B(T1&B(T1&B(T1&B
M(T1&B(T1&B(T1&B(T1&B(T1&B(T1>?'^5!@J]'7?@#^Z)V^G]#>C#=95G^>.
MH^Q8UW^0>L>U?+]E'@X/:D@']"NMNM0L62`"3R&B+H'D\@%'ZAJS+#XSF]"O
M13"*O2KAI@/_`!!*^H^_@.!I_,UMX+)WAG*,:*Z;T`5X+,1X#[KO0I%`4D@G
MI`)X4`)H.H^[5ZRTW4*_*:+$_66>OK6:CXQ<9;B&8L&3)?<4E+;$=AYY]:E&
MB0AEM"EJJ?:*CZ=;9O+VH7,HD##LIL6MOM9::T(K12#PSM0WQR]I#MGVSR%Z
M,HI2)DIM-FMY4H"B77I:FU&A/&B3QU(K/DW4+DB%[#E.W!1PZTR.</)3V6_T
M[.X5]+CKUDQ2VJ/2"S-R%)<!`J05-,E)I7WZE-E].;@?LX]2PKWF-E#BLY"]
M-K?66XI,AK$$I(^(HO;BT!/`*^,->P'6V_Z873^^&G'H6*SFV-C0RNP)0L>F
M=NJ2&7;WA<-`^(CS,N4M-/\`Z1+`)YZR+7Z9W,3BYS3LX+Q_-44PRDJ^D>F=
MN+';!1F&&R%<U(?^9M`5]@"&BDCZ=9O_`$ZF'[)[%9_U%`#M389-Z>?<!:FE
MNVO'[-D;`!4/D%Z#[JDA7#IC2_#=*B.-!2FH[>?3JXH>Z>Q;`<QP<5&G)=B=
MQ\.<<;RG"K_8O#*@IR?!=0RHH-%=#R`X@\2/;[=12[Y)O;0Y8V&A"SK76XYF
M$@["D!+QMU+5/"6%I024]*^H<.!("31/TZC,_*VHB0$L=AT+/M]9CCG;)78:
MI#2[>ZPLGPU`E704D453G4)(KT\.>H_J>F7UH*Y#@I/#K++K`%8]84@D$<:`
M\*>W[NL2(R&T;XF#\?:JI#5]4#EK32_,K)7=OD>%.'T?3[JZW%G]ZJ]ZOO"3
MY/\`[$\7_1?/-7?_`,Q9?^!1DW#3U9YG0K2N991Q_P##T\Z@I-'5]-BFK?E2
M.0@I(2`5=1YTY4^CCJXV7*"5D0GO9=Q6=@QB33I-3PK])^Y[]6I;JD3NI2?3
M])\>1A(WI;6C'GI"T+*"6Z@JJCDFO'VZC5W>Y1AM*Z?I'+U7#!3#[?<!MTW-
M,<>N$3Q(2+BVIQI:/A?;00%-U/``D>[4?GN^Z37%=PY8T6W@CC<\=ZOWKT="
M29T?'H=OA"V6B!!CLM183:FH]`H?L810("M:"2[_`!"2NRO9;C31%'3-4**W
M>QC4>&_BUPB14-OR64A82#UK`4LJZU&O45:I\Z%$+S1C<DFFU0<0\UX206%M
MJ#8!3X=0@@<1U@`&E.>GG0LW2N7CF`IB/3BD3(1-DW1$EY*FX:7.CI555*FB
M5>SG]6L*]O*M'%3^'2!;QC#&B<N'"%KCIFJ05O)2#'*3T=25GJITFM>>HK<7
M@8^IV`K($_@GPSL."<>TO,2+8Y,DQUI>*"VGJH!U*!Z1RY\-1:\U^T-\#T^F
MY7*<$Q=[M]X-T?6J.ZL.$K0V%*`2T5*Z5=721[]3G3=7M)X6C#;Z;EI+^#/<
M9A^Z$A5)=F7X0I3+C:T<$A*"A*P$JX*)]M/;[=2:,VXC\PRE1]ZUL]D9(BS<
M5D%0XK<U#*"4*;2KK!3U5ZJ$>P4I37OG`HU>:52HHJ#\())4'`0HF@Z2.5![
M3].LIMYW1U*U'I1R##<L8ZE06E"#4A8)I[10C]4ZIDNJT/`K(@T@NG8:;"I/
M["6*//RB`VZWXBP]'<;1T5\4J/%`/WM-<@^H>N&VB+:XT/L*G5S'Y:R#=AHM
MU^.X['C8T')\=IIIN*M"@0FIH*H]@^^H-?&3=2NKF^`!.+OO4.LZU4%=Y;U(
M@SUP<;@..2@5U<">!+BP4](":D`?3KL.F2W,,3*D@4JM_%^6HM96G-)<,NR(
M:F_"=I(5T<2@<7`D<"#34XTG79VW$<+W'*7=*R[:-LL[(G_*XT*15Y"FH<>0
M]'4V>BG0I/3UJZ*FJB/:-==T?5J.&*S+W2+3'`)KXSLMV>[X*%^'7@VE0H"?
MM*KT^WGJ7^?S]X[USV\L61ZB^-@[@I3L4Y]C-F+?>\4FY1?X2'&RZ\PVMY"5
M)2E(HISJ/.H]FJXKSO467)IIN;;PZ8[4U'==VGX/<-L[GN%A!7$O%K+;DV,P
M4!N8TFOB&G`(6/?0\-2.TN\-JY/S)R^<Y-%HPR/'7VO,+0D@)<>"T%)ZDI2H
MCJ*AP4?N:W-K=C,%R;7^6#%"9`VB;-QE20>KATDBE.?+CJ0M?XC!T+E$EJ8)
M'#94K%K^T?NZN#8M-<?..M.WV^?V_MB_[\NUO]G-AU=C^;U'V+#NS2'^\W^8
M+[ONLU1A&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B+SZ_R
MGY)7Z/&^Z1S.X?;]^EO/AI.LBUKXPR[<?8L:[_(/J]J^7O."FG5H53XZ*Y&O
M*G\S6V_$X+3XJR"*D`<R>%>1]WW-7(H[B4T:U6?%(=1U*)6VBPF8XRVGJ"GU
MI10,N/J4HFB&66F$+=6\\HT2`#QU*-%Y?GOGN$@<*4V=/6M9J>H-MVL+"*FM
M5.?:SL&WISYF-<%V(8G8GFTR!<LI6BW.EAQ56UHMY2J004\1R*AQX5UUO2?I
MTR6(2$S9AB!W:5_W5%[CF2:(.'<I3I]ZGE@OIK8!;(Z7\WRRY9:^VKI>MMEC
MMV>U**CP\68ZM5R=`Z3\*$A*J\2-3S2N17R.`EC(Z@M!_JEG\/;\5-K;[8S;
M7`T-1,3PK'+&&T-MB0F`U)N)Z"/POGY8?DAQ5*5"@.'#CKH-AR+;P@-+33II
M[EJ;[F6Z?+^`UACR].WU%/*O&$S7@UX8?2D(-9"BMMOI*5`IK1#=2*5I74QL
MN3M-:0Z3,VF\4]RTLNJWCZDM:.WWK*7>SL6VV%WJBM.*6*I\0.I'4!7H0#U"
MGT:SWZ/IMIA&7'KI[E;C$MWB\D=2H,L"UVGQ5.)?\[TJC!N.M;A!^%25-):*
MD`JJ.)Y:J;<V$;<E&X*EVEOS$ATFWH]RL'8D=`2[(Z(I4BI"HZFSU4'#BA'`
M_7K%N]0M(FM+&QXE&:;(S$%Y/33W*Q2Q'F$LQI,9P@T\,E#2JUY]3M0`=7;>
M[T^05ER`]"K\C/\`Q*V#\>%*=;DQPD-@`K6E)05'X0670$J!"N)H:'5IMKIE
MV:.-!T4^]>9;@8>]9)ZW6ZZL^#(2Q*1)31;4UIF2R\GE13+[;B"`#[JZUU_R
MYI[Y6BW!>TC&M,#V!9MM>75JTM:!B>E-3EG;%L1E$9X9#@&/>;D^(MR=;(_R
M^X%2TD$(=BJ;27/=PK76(_D*PFB,A#LU.CW*^=4O*8@`>OWK5OW,^GRO%X5X
MR_9^7(R.T0(Z[C.Q>8D&]0HJ4J4^N#*#?[<#'+PNE2R.->&N6\[_`$^;%:.G
MM6.<^FPTI]@4KT+5W!PSY?3UK4+<K7)CO.)\%22"?@>0XVZW0D%#S:@A;3J2
M*%)`(U\Q7^BW,4CHYVEC@<0/BNE6=Y%<L#B0%B`TVP"IPJZQPIP">-`?97EJ
M*7.G,95Q+LWJ6SDC@$>:-Q+N"M7G02.BA%#7GS_1UY$?"^7%6**Y\17D^0_J
M*GMY?//KYZ]\4\/VJK*W?W%&3<!P'/\`.0.?XYY3_M[/_F:ACFD''A]RF]O2
M5N*P,5*>H<*DD?7R)X:QY-BV<-DUT[`"4MK+`7*?;0V@J4I:3T@`_"2./W-:
M:>=S1E&-5U[ES2VR/CJ3\P]-BDCB..IFR&K:$K2A!:\=U"4E822*@=22GGJ-
MWDK\5W'1M%M\.\[[%,W"H<6P76RLPVD_M>0R0M=`I2E)"E=710<]:<CQ&XJ0
M3L=8/'@XTX_!;X-MW6[CA5EF/(:4UY-OJ6L`*ZZCHH?H(U@S63&]\.-?4IKH
M#G7H`G):W*=GQ42^^1Q#5QQ=A#RE-M1_$2`$D`JZST\J``ZL>7'[Q4N9;6T?
M[1^Q0)MM^MDQQ-O?+#:O!;0>J@*ET`(X^PTUI7W-PUY8`*`D;UF61C9)5M-J
MLKEY9BZ*;2@.L+0V6T``I*@3SIQUX7^,PF<Y<NRGQ4@FN3)$&@`4!2@MUNDW
M26A;KY2P@)"8U#T]"0*I-02*TX:B.K3VD<,ASFN1W#@5%KXY7&0;1CV8J:VW
M>QD&\6F'=%!0BOE*2AU:EA"U<4D(XG@`>)U\Q:]S#=6=[6WRN;7::_<M'/S#
M=Q;(XSV^]+[--H,*Q6Q39TQI$N?Y18B,QTH+A*`5)"DE-:%1/+6]Y?\`J%>"
M[9:3,B$>&-37'UJBTUV>[QFC8T[,*_>5ILSK,IEKS1[QK7Y.+XRFTJ"5I*4!
MY2.))XE*=?4V@7T5[8"0/J3PHI7;113M!?453HXSCHR-EV]PD+=CI3\:RD$D
M@$C@D$>PZV4MS#'@7>Q8=YIT&W,[[$E+M"EM2U-A@(94I702ARO,#C[.8U[I
M^IQW,KH20&M-*C^U8[-/=E&4=U6,>TO2)3:6/PBUJ\-8"2>E5"KA3CS%-5W>
MH1PDM:00!O5QEN;>1KGC`E;#.V+!9]JE?C3,M;LMN'&\P&DM&@4Q3IZ*@$]5
M>.OF_P"HVM6=TYT;G@;=A'WE:[FG57VUN&P-:>NOW+8UD&;Q'=O3<8UM0RIY
ME1+:RX`V4D$E0"ZUJ-<5Y;L67.I-$U6C-N^*T.E?C.`DP^*U<99O'\NRTN2T
MIDK??;99CA%>BII\'&I%>?5KZC;RI:.TQMQ;ND<X-I3"GV!3F'3(#&*/=]BH
M[A;CM/VZ,EB.RTZXM"Y/`]9<('6%@*Z:\>.M78<N/DF\1^9KVG`#XCV+(CTZ
M**02!SJ@]"9F1?F\HC+B+Z$*9"E42*='P]'4FM?BXTU.M/LQ:_G.<*=2ORVH
MEVO<.JB9NVR9%MR-RWNJ4XT5_LA'&BA44H`GA74OL9+:9WAYSE&\4JHSJ.DP
MV[S<-<XO--M%NO[8\2N&3;&,,=*UMIG20:<"Z/8'#TG]+54]U#;S9&NJ.FBV
M.F6<4L?B&M<J0/<?@<VR;?3K/;FG$(=*S,;"J=3:F25-J'(I.MM9:C%2E0HS
MKNA6LSS5SQV+0;N)@?A(F2X[:FRRXIN2P@(Z4MJ4?$4.!5UI/TTUMK;49!)@
MUM/6H%K/*L=[:$%SP`,*4^W!0]RC'50'G%M^(6%*40I02"%<.H&@`%/9J8:?
M?.>P@@57S/S%RR+*=_>?A6E:>Y-O*84THTJ1]/T_5J10Y)&UKBN3ZFQUO,&M
MQ%=Z=+M]_M^[%_WY=KO[.;%JN/YO4?8L"\_(/^TW^8+[OVLU1A&B(T1&B(T1
M&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B+S_`'\IR2%^D!OF"0D?E$[?
MR2>5!O/AI_3IK.TYT;;MIE-&4./J6-=BL!`XCVKY>4U29$TU<`2A3B``*]0"
MJ@TYG4I8R&05C(*TY%-J4^*X/><KO$&S6&W3KO<KG)0U#@P6UNR'E*<""4)2
M"4--J/Q+/PH',C4UY=T&6ZF&6,FJTFJWUK#'A(W,%Z">T?LPQO:FVP\OSF!;
M[UN3(;:D->80F?;<49=0%>4AL%/@KN82>+B@2DC@=?1?*?)C8ZF:(MS4I4;5
MS#5]8SN`:^I%=BV"R4I9::<57H2`E+JPE*U)'PFO3R/OUW?2]`TNR@_'+6NR
MX`[SN4/N=0DE=DW.-.U5FEM*01#0"0VH)"@GPTIX`D#[*2*_1H]]G:8G*`J/
MTW=4K&(??1*;898;NCZ@*M-+2/+DD_$ZM!Z@@?=UK;C6HAC#0K96E@6PT`)Q
M5EF.Y&#8<B.UF&96RRO*4A"XL:>R'254"6G$I)=X'A4CV:U#=<O))Q'E(B.]
M9#[/*TN<WNI*/;R[17*1%1;\TL<DMNMU;5<DN/%1ITI4TI(HI1'LU9N[VX.R
MN"V%E:MI5.-=-W[,PM+D(W1:!$:"3;G8:8@*0GBP5M5%0*D\36NH/>:Q<0W#
MVNJ*%2F+3621M<-X20OV[MJN%OB,/1[BX^'5.J$M:'E]`"@"7&Z(/!7#AK27
MO,\+&?C2M:*\5L+/1VND(+:U'!(%[<?'@XWUP''`X0AP-42XVD<>HGX2/N:A
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M;G&P7%MJ(J0.M-#4D\%(/%*J^RG#7SGK]A/`22PAN9=`T^],C@)#W:)-%ESJ
M("#[33ARKSU%2QXV@K>M&?Y<5<_])_\`8E/N_/.6K=#]JRLII_=I]JC#GB"-
MP<YK[,SRCV']W)XU%93@IG8,.85V5/M*LHC:?@X<>!YGZM84OR^I3+38!),#
MP*>[![8#&E7-U/2EEGPV%$\%%M/4[1/(D@</=J/7'SKMG+MN`&/X*6FTUI6Y
M!<N,A`6I]=4*H.0XCV\>&H_>[UU_1MR>FUJ6S?+>5GX?.-BE`.0]_'6M;\H6
M^O;</:URW81KJC$]GK1,`/X2+`4E:3\/Q)2XKAR^WJW/\GK6]LO_`&=@)AAB
M`H4=T]\=R7\6YZ22E3*4$UYGPE&H]PH=8=5<_5.E:Q\SDR;3.8F!QQLA8)Z%
M%)*$G@*`\_IUKG6H+B>E;RRNR:'BG0P;)XEVGVV+,=0M3WA(%2`I%2!51'$\
M]8-[8R/@)CW>G%2>WE\5IKN4]L;P&S.(;?3,:ZW&T*+(`4I`Z0.*N)J0*ZX3
MS.;J.1T8)H:A:V\Q)'%.;=,ZO6$6:/!Q]*Y33);;64`=:."BI?2:GX0/T]0/
M_1\U_";AP/IZU&;NVPV)PL"L.<;NV2[Y+:K-<KQ:[4E+=Q6A!>?9#C*E.I;0
MKBE#'!51[]<\UO2Y](O,S,"`/3:M`UQ@N?#'05K3[CL`QZ$YYD3W573QG`Y;
MRR4.-+\<A1=%.05S]FOH3Z<:K>/T\/)[E/N4]L+K\,;\$LNVJ>K';=*M5PM3
M=SM<L-N>(4)4X@A+W40>*DCXQPY<-9G,G-#K5YRN.WI]RHO;LFM4[616;$;J
MF0N)#:2^EDK0/#`"7%*4D`II0<=8?+G-,CW%[G8GK]RR(-7@9`UCZ9@T5]*(
MVBVDA7')@Q(C,'Q)+:D=0X="RGJ`%.=3SU>UOFQ\,4KLV.7C\%@ZIJ<<L`,9
MQ::_8MDLB#9MO,?3#:$:&D,%D.)2D`]8'6E5?M'AKYX<+_F?4GACB1F^_K"B
M,<YU23(XU`XIG)N11KO#D6FW/!4-Q"FUNN$=!4LT'AH)Z0>JE::ED5F-.O&$
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M4U)[>8Q`=*X;SO%%-+FC`_:K11LN".DK33BE2AR'"@(/ZFI9:2&@X%?..NVX
M;-FIBEUV^?V_MB_[\NUO]G-AUM(_F]1]BC%T*P_WF_S!?=]UFJ+HT1&B(T1&
MB(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1>?_\`E.92/1^WW4LD)3N!
ML$K@GJ)Z=Y<.(%`1S.LW3HO&NVQ\:^Q8UX[+`7=2^;9LEL3G&\V3M6'%+:RX
M/,)?O-YE)<3;;+:U@*6\_-"/#ZBGB$<"5<-=JY;Y4\VP&E:KFVKZ\+,G'!;[
MNW[M:P;9"W-FQQC<\MF-MINV72$I7.E@(32/;@X'!;K>A0^%#9!<33Q"HZ[_
M`,M\G"V+'9=PW*):CJ`EA\0_M"O:IF6UA8;\%2`VO[;IY=;E*=:A0?%04.NR
M6ECY;PUS^>X\27+AM6,OKCX;4UTI2RR?PCOB>\=7!%*JY\ZZQ^8=8-G'M^45
M[%N+'21<EK]U0D#+S2U8I$?N5_N#=NLD9EQZ05KZG'8XXJZ*"I41R&N?_P"J
M_.#YA7K4N_1OX5K]WB[SKC+DS+%M+'5C]F=7X*LG=:!N<Q!44J5%`'X)LII0
ME1/57AK9V<YN(?$Z5BS6WE7^'2F%5#BYW>?>9#D^YS)5SNEQD-A,R8I4^:X\
MM8J27>KP_$62?A`I76:PT=562SQ!DXJ9^Q&QD.W+:RW+UUEK<0_&AERH0*%2
M5O)3TA(544!!Y'4:UC6_)DBNQ;.SL^A2?ON36Y"Q$;(#J!TGP44;Z0*(2E(!
MI\`'W=<:YCY]LK4O,CAGJ:]:G6D<NWMWD\,'(0*+*8!M]E&XUWC0K>THL2'!
MTN)6:I;!2DHI05KU:^;.??K#:V]D3`\!P<=^ZB[#RQR')'<9[T4C+<.%:J1^
MY?:7-PW%6KM\2IBXAD+"^K@0#\/5UD<Q[M<(Y<^LGZUJCH2\5!X]*Z/J/)5C
MY48"M%$MFU7*"0WX3S(^^=:6L=)I3BG[ZIX:^C].^HWF;MC2[@%S+5>4?*,)
M#<$K<:R>-8Y[!OY2U&_8FIR5]+B%N*"0E2:5)4:&I/"FOI+ESFFUEMFF8BN"
MY9K&D5D&&P?>G<RR9&C-0B%JF(?\-V)(:4DAV,*+4I3B:A10FM??KJMES)9^
M6(C(STP4'OM'+&N?38%4LUU6YX/AJHTI5`*\23R%/9PUT[0K_P`[8CJ4'O;+
M<5TR"V.7*I4CX#3X5H#J:I%!\*ATE"O:""#J+\Q:#YIS[BF#E19W_DP+8GY3
M[5J<[KNR,R%73<#:NU#SG0Y/R/$&:`/!/[)<<?0E:FE%2>)C@5_HM?/O,_*P
M>QV'[04UTC5O%N`RO[)6G2?:I<&7*:DM.1I#*E,O0WD%N3%<!(+4AHU+3R".
M*=<9UC2O)N-`I[9WH+0/VEB?#5Y/_G?1_HOGE?U-1++_`#46^\0?\%5&K.DA
M>X><)(J/QRR@T_\`#D\GW:A,YRBH72]+B8]P%`NULMYDK2TA`"B4!)]O%0'O
M^G6FGN'MWFF*Z-IFGL<\>&T#$5HI"&"U:;1#MC3I*T^&J2T".D%83XP(Y_&#
MQKJ,S7$QD^8[5V[0=.`C;5HRJ6N"H-OQ^(A-4A4=+B$CDGJY%/NX'5EP#_GQ
M4UA'EMF`67=N3[,N/)`ZD1U]:B3Q*O8?K&L"0!KR&C!;R*\CE@:UV+AQ6Y'"
M;K&W6[?(D:WS6GKE;+.&GHJ2%+,N*GJ'0.9>*11.J0UKJAPJ**^)IG,\+,?`
MK6FY10RN-\_PR,Y<04SK,ZIMYM[B_'#!Z5(=Y4*A^EK5W9R.HS`*4Z596<]!
M+&UW6%K9W:O4*5?#"ML=IQ+3:F_"2.`6A722/NZLVI+WC-B%L]0%G!'2U:UC
MAP2/V^?N4/*HDB6VIN,I:0D_K"%$II[N>MYY(3V[Q&*'>HY;:G?13.897Y3N
MJMD6WF;W"`\//EP(*0&UK/-)-$'C[`DC7'N8>6)+BX/=J2?3<II8/9<1YYJ.
M*D%9)8R&X-,T8=7*ZFSTK"%_%PJ3R]ONU&[ZVDT6P+'.H:>G!6[QEK2N456X
M_LWM$';_`!^Y1X9CLNY!"\E)8*@OJ;?:=2M2@?A/7R/"O#7RSSIK$YOW![RY
ME`N4\T7\=E<$QT:[*#4?VK5+W7[*IM^;Y/-<AQY'G522P\TV"AE"W5O)!X4`
M`UON2.;9X<MJV5PA)Q;7`\-Z]Y=YBDO'BV;([.?N]:U\6G/OR:7;Y>.E(2@!
MQ`^U1*^ISPP?UZ*A7T:[--H(UVT\SE#B=Y_L72;C3Y);+Q&'\2FWT"FAMQCC
M^>%4J%#`:N#*'VT+3\0;D#Q$(5]`Z]<9U^>^Y?N'QVTCHPUQ&!X**ZG)':6S
M*4$H;WCO)3W8W@<_!;RQ<9KBO$:D)4&U'@&QQ"1PKS&HQ?\`.;WVK1(3*\DU
MKCA3K"U[9_&MJ@]?2%(&X81==TX\>*B.\MOQ%/>"GJ+2DKI0D#B2=9V@ZU-"
MX3:?`8W..):*'VJ+7/-6GZ'+6K6OKC2GO"1N0;&/8%&D2;T)$:/'CK=BE:RT
MDGI(X*(`'/A[];[4+R:\U-D43G"I&S9]ZE6D<W6.OR`6N4CH_M*U][R7:USG
M$,L)6ZXE84T$N)=ZEA025DC[[7TGR?;MTS1R9:>.X@@[Z4]6"ZAID0AMW90!
M4U^Q8[#YLFSVQ<IYLI97'+:DJ`KQ;->OZ:<]6[J>6YOV>(]SFYMZI=-*)@T.
M.6J@?E5N:R?/;Q+;;06O'4"D_9Z@[3E[R-=*TV"%MB"UH!I596=_%.+B]B<A
MI9C)^%4B4&Q3VIK3IX^S6WT>[MX9"ZX`))WK7739)GY7XLZ5M2QR)(^18+AK
M))G*\LE20>+#RW`I2Q_1*0D_HZL:K<0S7&:"@%=R]MVSQU;&:-`*17?U/$/#
ML8QE#BA*<>\THA5"&TM*;2W_`)U)3K(M7N`!!-5%M7DNB\]]RU&1&G8[2E..
M*4LIJ"H\1PZ@=;QGEQ0Y1F7+;FY\!SPS`YC6F_'K3#[LI0+C:+@$@)?JT[_1
MFB00??4'6;"YLA%*4"A>K4N6YB*NQ46LKA"+/>0VA*&WBI;:4\`D%(J`/9\1
M.I59&H'11</YBMFMD>0,<4H.WS^W]L7P_P#SFVM_LZL.MW'\WJ/L7.+ICQ#C
M^\W^8+[O>LY1E&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B
M+1U_**-OKWNCZ66[F%8^XPS<;KN/L(0_(5TML18N\.(29K_MZE-16U*`XU(U
M(^5(FS:W$Q[<S:.P_NE:K6I3#I[Y`:$%OM"\H7;WMYA&!6&X;989`OL:5B2[
M;$RAV[V2XVQ=^F7+H4+I&FRF4)O%K<-2TXRI3'"G/7U[R;9PMC%(J8=/O7$=
M=?#,XF7%2LBP_))*N:D_L)*:*3T\$T30<137T'I]FR*-CG-PRA0N6[N'UC+C
MX8P`PV;E1EEU;:G.OH<0">K@GF*>X#V:VE\Z,0AT.#@"K5M#$^2KFU*;2^3Y
MK7AAP&0V.OC4GG7[712M"=<9YGN)YRYDCB6XA=)T:.,`8;%J_P"Z3<*=?[N,
M)1+6S%B-5D.QW%LEU*N*(ZR@I^#C\0Y\-0FQL\I`:,?6I!<W#&"K,%%"V266
MXK]F=9;,R.VN1;*GX)28B093"EFM5="@H4-3[-2ZVNC9V^5QIB2M#)%)>S>+
MM%*++8;(2W>[;+?Z75JN$5!62E2$]3J?P5/V-*A6E*5UJKKFR*V#BY^SJ6QB
MT9[V]QOXFY;2S>2[;6V8Z4$O(;:'%*2*(;2W3I(ZNDJ.N0<_<\6\5J9(Y`V2
MFW!3_E_E-TX'BQYNW[E+W9KMAN&>B%<9[*RVL-K'N<ZD!0'L)`5KX$^I'U=C
MADFB$Y\4.()PV]B^BN7.7+*VLH<L($C6`';[UL_VJ[=&MOUQYJ8#;:X_A%"^
MD&BU`*41SJ?A^FFOE_7N?':O;.C9*2\UKTKHUK91/`;,T%C=@Z>."5^]*H=Z
ML"K.ZPTM:FRRDJ2D=-:]52FE*ZP?IR\6NH.N'FA.]6KV*,C(1W>"@#/V5@.1
MY*6VG$OM-N*\4$&I(/2$U/0:?=UWW3.:IHKUICE(QZ/<M#J.GQW,>69H</3@
MM?>_N(S<>@S&8K2TR6$AQ7Q=9>36I(2*A-/H`U].\I\UZC=OBC,[C'A^[[ES
M/F'0=,@MG2MA:):;:N]Z8K9C>Z+D^0,[87N;Y>[6B.[,M8<<4HOM%)#T4J4>
M*FD5(',Z^G^7I9W7%N7N)@+QF'$+AFI1,=%*`,<IHIK8R]!\<H=4YUM&H4I*
MT@$*2.`X#J%>.OIWE>[MXFB-E`S@N2:O'/&*M)3PLJMCC20XKJ)'$*^T0>7`
M4YZF^>VN)G0D`Q@##K4$D9.;HO>:U2>N5JAK7UME2&4U4&P@]'64\"$TI0$U
MH.&N?Z_H5J^5S1$,AQW^];JVO3;97P.I+LKU]:U2=^';SM]<;EC5XQUMRT[H
MYE)G0K!:+?990M.?R;9!-SN]O<N49(MMOR*!;AX[25]*G6P>!IKYYYPY?MQ(
M:1@8]/O73.7[U\[!XKBY:?OQ-D^!T^7E4^<?+?M(_9OF/B^!]C^JNKV_8^C7
M&OTC'Y1_F:;]E%/_`##./[%%"/./[8F<_P##+*/]O)^N/W.Q=<TG"1M4L\$:
MBNW>#YPT:0>OZUI22FOT5YZC<WS.7;^58&25<^F#M_4GSMR6[K=&P0A06Z`3
M\)!!<":GA0B@UH9FN\0&A7?-$M[81#O,'61[U+%F((<"&A-*"*E/"E!P^CEP
M]FJ:'@J=8_":71XX;L?8K1N0E;;T8A)H>9`^^)//F::PY6NSDT*C]E>R&7)4
MTJGZ[?=Y;CM#E+2)*Q.QR?*3'G172OH2VV*ET(Y!0]AIQU0W?U*>Q8VX>=M0
MIVYSAUCS*QR\YP%]E^RY$R^Y<([*NM46:M-#XC8ZB@!LCB0!76HO?G4VT7:U
M:FL@VP^39?)=N*5,I;==4$E*E^8'B*(`K6A6.(]^K-J"'-K@%'KF\>Z>1AK0
M/=[2J][QF(J$F1:$=,R&$N)^'I%%``]0`%3\/#6]-\+6.@QS+`F$@>US`75V
MT%:=B5>%WJZN/0;?,:<*%O)`64+/$)`(*R.">OASIJ,ZEJ%N(9)JM+FM<=HW
M`E2[2YI!%0`UITK:EM1M@V,2:R*4R6I"TA056I'7Q`!K\-:<]?+'-_.;KNZ\
MN#0$^FX*B\N2!0FA[%+W9S)GK;+$0N+\="CX5'%=/A@`(H.JA/4#KD?,FE"Y
MB\<GOD#K]JYSS18NO+<W`Q-*=BN]\<>G95"E-6JSRI<^2H)>F*"5LQPM'757
M2#PKP'MXZBNG6ES9#QF-?E:X;`=Y]:YQH]T-)OFROD:US2<"X`XX;"?N6H?(
MNS+-+KEZ[QDT&<U9?$DNH5':=0KJ*26Q5215)/*G/7UCHO,<.G<L->'L\?)\
MI()V<-OV+Z%TGF!MSIX#2'&FX@^P+:]LGLX,1QZVS4ME*X]NAM):=0/&!0PC
MI"P14J``U\K\Z\QS:A?3`!V,AW?`+G_-%Y*Z4EH=2IW'W)29=8//W**MR.LK
M4Z`Z0PHH"2A=>2*5K342CO(=/;'-./$#W4H,:>H`^Q0Z_P!?ET^P:6DESB13
M?LZBIG;+VG'[!:+>XL-E8+*Y76$%:6S2@'4"I/(Z^F^0;[E^YM`9V,:XM_:P
MW=("^>N;=4U*\F+FME`K^Z[W)GN^A=LFXZS"LI22E#Y/0000I`-%!/L]U=:2
M[L8+35VR1N:\9MQ!W]!*[S]#M/G,/BW&:O\`%4>U:&I&%S7+H),A"_!#@*NI
MM?*IK0*32@]^NTLU5OEHF!P:!'Q"^J]/DS0O'!U/L2MNC%NBV61'!!J'&P`0
MH\4$<$BI]NLNT<)IVO!!%=H5AU?,-IQ4-'+7#M]TG]"/PCTE:TJZ>))42!6E
M3KK.G_Y`=2S:&NQ2C[;]KYNX&9PQ-AAVT0SYM]SIX#P3T@5I1-2/NZA>N:HZ
MR/<<`>M7&L92II5;3[3M5!Q21<]Q;L^B%:[7!!MK+O3526$]*EA3E!UT5P(X
MZOZ%J)O@,S@7==5>BCC+CB-BU`=T.Y?Y3,WN#=L=\Q`@O)B1U$]24)C$H/20
M2D=7.HYUU/K45:-JBNL11^(3@!ZE%R39S\-0.(^(`<`217V4`&KY>^N_L4(N
M^7HG5<""78[>/K3$;PV#Q;6A0Z069#:P10%(X5H1RK36VTMY)=7;4;5`M?TE
MEHQM/VZ_8HD9NRA\PG6:>)X:VW#3X:M_`./*I2BNII9NH1BN#\RVI#W&E,"K
M[8**$[][&'_]9MK/</\`=U8?=QUO&&KL%S"^MP+<X4Q;_,%]V76Q7/T:(C1$
M:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(M6WK'Q43>Q/.XZPGI7
MGNS_`-I/4!T[EXVJM#[>&NB_2JUCO.=K:WE^0LE^R-Q4<YKD\+1)9.!;_,%Y
M8L9Q*+B]VR*_-7C(KM-RB;$?D-7RZ+N,6SP[8VEJ#:;`TI"!;K8P05>$FH*C
M77Z+<K\L6-M`V61H(Z%\[7^H-NK@Q,S!XXI47&<PEI1!9Z@GJXJ_"=7'V4H%
MUU(;NXM6`LC:X9<!Z56#';22&@(JD-<KOX`6A70KQND453B.?"G,\=1BXU2*
M)KFR!U",*?VK:VFEW&:M6;MY]R2N27B);K'/N;P9$>WPI$EY::U`;:ZZ)J$I
M*S7AQ&N7:W=Q3S=P&E5.M/@?#&2XCY=RT49+<7<HR:]WDRP^NXW:9X2'%4\)
MA*OP0H.H`4YZQ+<PQ?,K,SY)!@4W5]CW".`W'"0ZAX*2^A2BMCB/$Z.`X.H%
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M-1K])U'3VLDE<UP>ZF!)]H"V3KF&-NPU43LW$Z;,*8Z')#;KQ/`I)0HDU2H=
M7!(_FZZ1I=P=.@#W`UIN6KG>V4U:J]NVX=7:7[A-ZT,!EQ:J=1*:))XBE/M'
MWZSK7F,0ZBUCRZI/IO7LQB>VC0:K4'W9/QF[W.C0EME0"F?#%0ZI')2B*=-$
MT]^OL7Z97QDDB>YU6EPIBN:<YMR1"$#O.83T;5H.OEWF8/OFYD(><C-VB\VO
MPI+=&F?*2'$^.DKJ"XI*">H'V:^\]#O[9EBP][.`#7#WKYWOX'L<]CMK@5O^
MV\GVS(\97-;;;<4^EER/,X=+WC1VG5+;4"JJ>K]/75N6=;:2*YJ#TXKG>LV9
MH0*56<CK?:=4V5=90>GJY\.5`:5H!KL&CS.DE%T3^$[=OP4`O;?+4$=Y*E;B
M78Z`FH*.=?YE"=2.XMX[DE^%*;U&'LF\7`C*$S&=X9!R#(,&R6>]=ER]OKM<
M+_CEO1+#=D%XN%KDVAV?-AAI2WI/DW_#"PM-$<*:XIS=I6:0EH%/3H4[T34F
M6K!XF8FFY,#^;IAWSGK^0P?*_EB_*1X'@+IX/XA>!\LIUT^7?.?VQX?VJ\:^
MS7&?T-V:E&_YFO\`PUX+H?ZK'2O>_)S;ME>O[%Y%\X_MC9L?8,SRBI_\-3]?
M(]P#E/IO7T';?GMZTI,22I4YL)2I7X)SD*^S4?E!SE=LTAY9"W`TH$X5CNJ;
M7=XKBR^0'V5*;K\*P'02@"IJ%4IK'D/X9'0II8W+!(T5!%5-J'=Q<X+3K:>A
MMQ#7PUH!^"XZP5T..[B\C2K:TV5'O1%8:\4T4*D^SB:^VFJ9_P`L+56+PZ?,
M",2LFY%E,O//M/-J/02UUJ!0H_1[>H>SZ=:'$S&G!3@N\.U:\C"H4BMC=[;O
MME=HT.2X;SC,I'E[U;E*JTIB2**Z$G@5LJ57EPUK;QCR_`'L*E&C7;*``BO6
MII9]LE8-U\6@Y[M\VAY,P)\RT*.&(XD?@BZINI:J305IK#N=2CCC`D+00*8F
MFSK*VSM#:\F0_M8]N/!-[M3V?9QDM^9MU[QNZ1K?)DH3YM,.0ME]L.4J5E/3
MT`<0?IUS/F[GB+1+:D+VDR`URN!V=1Z5@7[OT*V<^+'.,:='513.W![!XN'6
M!JXVJV3)$M"4>&RU$<4I:^D*Z?A!X=7/7"8OJCXURZ%Q^<TV\</WEI-!YH==
MW&5Q(`=OPZ]I26VRL>XLRW3L;F8W.CQXI7$\)MN0'4%@A+2E)Z>"""=0#7I&
MW&JBX80YH.[%8?,NKVWG*&1E*_O#WI<1<9S'`9\:0+3.E*D.>&S'\M(>>0X5
M`!02$%7221KS5+ADY:^HP:!V+R"_CN;`LC<'$UV&OL*WF=EW;-?LUQ1.19A9
M&U?..E]$.7$(<04A)3UL.A*JE)]HYZZ/R/81ZLYMC(X"-[3B2*8`G>OE'Z@P
MSVVJF[R.JUV]IX]2?ON@[6[1$L<9^W8Y#C(AQ&U*:3#\'\(V&JU``J:_H:CO
M,VCQZ/J#BPM(!W4*GGTSYM+BVVK0^G2H^[';)2<SN+EE<QV&XU\**^!\=11-
M*](Z5_=U!H-,=KM^^*.KJO.S'MI5=)YSU^"QLW3ND8'D5IF%:\-JD)NAV*V&
MRXA=+M&AO1KNB"X\TRGJ6E#J4*4.E`^RNHH#36^O?IDW2+4:@0`]QQ]6/[H7
MS(SGZ74M8-JW,6L-=]-M-M2M+]XGWK%;O.MTKSL5VWR76'D*;6@OH0HA(2#]
MHT&N=W6IOMY3;0`NRUV"OL79;6SCU6S;)*X-V;2![5';.[U><K?;@Q$2GTOE
M3?4^XZZI*JU2CPR*DJ(H-;WES7)/$`H<U?3>ND:68-`M3*7M%!7:/@E#B/;#
M><IL<A]^VS''4LK4I;$1Q:8Z""I1>*1\'Q>_75I)K^YM!<M@F=&W`NR.([:4
M':M$_P"KT5OJ`LF2-+3_`!"G#<Y0>WVVMG;:+F-.-)"4JD(0MQ!2I*:*"%GA
M7V:FO)>JR/E9:D'O.`],5V_EG5XM8@;<,<TGH(/WE0JQ?%;CE>2,P(R"^N5*
M(Z^A2DM(5_S2M*`*'MUWT7#;;3^]P4N6^#MTV@PS:_#FLARZ='M=M3#"Y3B$
M-(<>6`5K'6H@JI7Z=<?YBF;=3.+<:E:>Z+?'<"17!0:[U>Z&3G3TO#,)=7:,
M1M[!9B^4;#:I:1Q_"J30$G]/4BY&L7PW(G(-/#(5MKPRKMU%JA\?P%**G.HK
M(6MSJ`*UTH2JOWVNTV1`;0FBAFLWD0<07-KPJ/>K$W0^(022WUFO$\4U_0Y:
MS"<5JVW<>48MV<1[TT6[4EMZS2"E'AI`511X!1)%`">9U=AV^M1_73YJ2+)C
ME#MBA/D22BVMA0(_;!6`01\/3]H?174EL=@7$N=8,C\SJ88J^V%>3^7[8T=0
M_MR[6CG_`+^K#].I3:MQ"XKK-TPPNQ%,S?Y@ONR:V:YDC1$:(C1$:(C1$:(C
M1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1%K`]8,T[&\X_X>;0_^TC'==0^CC2[
MGZT`%3DF_P#2<HMSFYK>7YBX@"K/Y@O,%#;>E]3:4%11XQ'2#P`5S5SX<-?I
MAHY#;!N;#`+YF<0V]+W8,KM.Q)R]P)#22YX2@'"4I<Z3TK62>"".!)/N.M3>
M]TN)P%5M[5I+J@$@I&MQER)@4^D+#(^Q2M*FE2#7B*:@.M7`8!D-1C6BDUH"
M-HI@$UW=1/8Q?MNR6Y1O#,F3(8@+6S0NI:GRC'4DJ2:I6:)"?IX<=<KU&[/C
MUW54JLXI"SY32G!:-K?=(D>JVVEH>(JLN'J!<%.*$T!Z3[=7?.MRYZ]SCN5]
MMEF^45ZE83IS\E;SO@O.E:3U>72H(2CB`2**HKB>.H1S/JD&0D/;E#>(VJ3Z
M+:!D>5^#LVPX%/!VIXS?<\WBQZ.XZ9ELQZ:)[\!25/(#<9:7&0\E)-"KZ:5(
MU\I<_7OB:;<.:\9:#O5P&(WKLO*\#3>1>'B['`;=A7KBPZ]8W:[19+BB2NV"
M+;@%=2DI:;2A#?C!YXE"&`%<J^S7PUS+!K&HZD8FLE=`2>\&DBG7L78K1CVC
MO`CK52^;U+R"ZJBH+TFQ06FZ.1%AQ@J`0KJ#S94ARO.GMUBCD\11->YOXA&.
M"R'W+@\M;4T*Q-ZWHE6"($QE!NU/*3U+FK#+@ZZCK`6I'`)KK7S\NOG+8PQQ
MRNKL537R.^<.`Z11*G`\D5D5P;6P$3V)"DJ$I3H\-`6`>A/2I0)!]M>/W-6-
M6TYMM;AC!W@-@"JQ4^<<P_YIBSL'Q4N251W/$:;(4`A2?P0*0">*J`>\ZX;J
MFK7,&KMC8UQE#L0`:]BH=+&P=]S0.DK3+WJ[!_)HTV_*I#F*?6VRV&277E?:
M<'30*H@#B/IU]0_2[GV.&XBAFE:QP<T$.<`0>!!V'H6KU&PMM3@=*US7.8*8
M$%>5[N9C>;SV1#AN!F%%*''W/LMR'&*I5UFM/?P/MU^F7*VK2SZ5%<2`B)S1
M1Q^7MV+YSYDLQ#J`AV.+Z`;^H!;I.TFYFZ]O&(W,KZUH<D-LO`D];3;B(X*E
M5/B)X4'TZ['RM?>(X9#4]&*Y[KEB6%V<$=84BW74QI3;:4=3CM*@BJB30D!/
M.O'7>]%O0VV8UQH<?:N<7]EFJ]H)9QW)>,V-#L3Q&I"0L`%;:CQ!%*530$:F
MUM<N>WHHHA=6N7%@)?P"P>1VWRKC++H0I)0A25!-.?%0)((/'6AU:P;+WYNZ
MWIP5VT>WY:C-39O[$G/*Q/.]7PU\]T?;'+Y#X5*5Y]/&G*NN3>0A\3:/\_3U
M9-O5TJ8^-+EV?^139TKPJ9R2=PLYX<3F644'U7N?KX%F%(R#Q^]?55K.!<L!
MX_>E1B+Q:GPU?>]70L^Q/4@CC]!.M!..\Y=OT:Z`M`T;4I[C%0S.*$.!MP$A
MLBO4%]1*2D\Z@G6BGS&3#8I';0%TS)1MJG\VTSEH046F>AU4E@A*7'B`"*]`
M4FIY\=4*1;4\5MD+7+;<1\2"I2NI-%`!7U$G5,_Y06QTO_,CK2Y>;:\%!;<2
MLIY@4J*TK6FM-%_F">A=2E:7:2`.(^]64"4VQ(HXWU557J]@``%/TM9HVJ/Z
M1>"WN]M"MI'8]O5:<-N[5ER$//8C=@(URCR*=#,IQ:4,RVTJ-"AE/+Z-<)YR
M=-22@PS.]J[,=0;/;L:#CD'L7ISV:MUB4U;+M9(<"ZV&0&5P9!CH>:4VI`7T
M(6"14=5*'7S?K;GF*7,%%M7:1;N/%2XN\*T9#!,=>.VT-,]!4GR2`0E("E\A
M]?+7(&8W#N%5SFU!'B8U-"N^V^S>(P94J^QL7LCT*XK6Z#)A-DJ4"D@UH>(I
MKIO*FB6NI.#9*4].A?/_`-0M:N-.N2YHQ].D)OM^(46%$=<QS#[%"E1B%,O1
M[;%4\VXDJ'C`K;Z@@@<.-.&J>>N7XM/O?`MA4")KNVO0%F?33Z@2-(;<&C\Y
M^[^)83MVWTS.S7-JV7H-(/CH2T`"AMS@1\0X`<`>'(:A.G<Y3Z"[RYJ*;O0A
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MEFOG2R`@N/M72=8N6:=`,F7*![$F?XN_8J[7V-+M66WF)X:P^A#D1+8):'BU
M*Q[@/NZ[QRI]+X9+YMQ*`&Y@?3NJ$W_U%EN[5UL":D4^[]Y;#ML]A]E]F,*D
MVZ,+3>KA>VF6Y#UV;:*Y#'6%O>"%`J*PD$GERU]`\Q7MERORN[0[=WYPSD5_
MN[J<."Y_ID6HW6I9&M.5[Z[%H(]3G:/9#)IK[EJ$6R%IU9DB.XVTE='%]:"@
M$D5]WTZY)R5%2^,[=F>J^_OI+936&DL-R`V4M"U`[?XEM5A+D^[15(;L=FZG
MKK<;CT>*0TL*4W&6O@/&*:#WZ[M/;FYL#2M:+L?F&]"1N?;[QMTY!MUIFR+?
MC4)1:@14=+4=R,U\"3(37IJ:5!IQUQK5[6>*Z+&CN@K!GL8YWFY-.]]V"UW;
MO7&&Q<'4M2HZFZ=(4E8(ZB:`<^9/#74>2H9G,!>,,I6ON9H;.%QKN(4<9+DA
MU'4VVM8X\4T/O/#[AUT#P'<%P[5)6W-^2..Y8>4X8L93TI\-MA'46RH!9X#X
M$\_B%=9PJ!1;!MN2T'H4==P<N;N:C;8ZEEE*Z*4LU1PI0`CD>&K\.WHJJ7_@
M"CMA"8[+U)3;V$5'!*J#WBOL_0U)K`8M'2%Q#ZASM)('!8W890/<!L70@_\`
MKEVO/_XYL.I;%\_IP7SWJ9'A4WU;_,%]W?6<HHC1$:(C1$:(C1$:(C1$:(C1
M$:(C1$:(C1$:(C1$:(C1$:(C1%J^]84@=C6;5X`Y[M`*^[JW)QT?S==6^BO_
M`/H=I_\`9S?^D]0SG[_^LS?[<?\`.U>:''F6TF0.M)<\5?(D5;*>*1]-=?I+
M8_\`QP7S5>[T7"(F1=HR%=7EZ):2A(KTGD"D&H+H_5U&]5NP&%O!273J>&S_
M`&1[$WUXM*;-=*"29#<UM2VR!TALUXH4DT4%"O'V:YS>3^+FIL"DK/F:F/[@
M,81F^PFXF-J2OSD%+%QB@$'K5$?BSV2$IJNI*%)Y<]<ZU/\`,4XT_P#(/^R?
M8M"8:BL..>=(CH;4M'45I!\1'/X:]0"?:.>K`_\`CW*]9;E97"3(<@R5PU.H
MC>&I'FFTI9;"0*^(%O%/B'^A34ZX=SG+<LAD$-<E%.]'BM7QYICW\R<_M`W+
MO6U>[;5VML=J[1I\4VR7XP4S'+<@+==>DHXEQX(!(U\_W<,^HP26=Q7P7G'U
M&JZMH7E+5[9XR,[:T[%.7?\`[MIV76Z9BK=WO&'622XQ`9N]DD/!EU*02IIZ
M(R5/2%J4*`BB176B_P!(62EWZQ_%BI7=L3.X-EQ"&N/D4Y5IEP67DW:[-J)E
M.*2IUI#,3J<6#X1%3RK75,_*-GX>[8L:/66^.:XXJ1C_`,FRN<UCNX/G9DFX
M^&S'?C2UQ&IC;E*^'X1JA*2>/"M=<_YHT`:?:B:T'?+J'JHI%:7PN^[P%5+W
M8[M[M=GFHC8?EE\M\?QXP<A.S5S"PEPCJ\!Q\BB4#V'7S+S7?WUK*00=JSPM
MK^V^TF6V63`D_CQ*NEL:*0Y:I*$CQ.D]0""@>(X5*I]%=<_Y3LH-:YX:RYV$
M[U'-?E\I$7'@L3WQ=OUHW`V!R^]6\L0[]:XCER2VZA;1\5MI2?"2I*>H*4>?
MLUVWF/EBSY<U2WGLJ97.#G==5H^7-6$\,S?X_N7SE]]S/=SS(H=Q;3;)$&Y3
M;6EA;R2E2&I+C754&KBGE?9^O7Z-_3W5!J/)]G`,:AH^Q<SYQAIJL=V=C'U6
MZ_M@AJP7MJVVQF0TXW<9K(E2D/4ZXXE.&8VV5>TEM/L]XUWWE5ILW`G:N>:V
M[S@("DGCT=J]91%4TF4TD>*IQP`/+;#3=?C0BJ0E9%$_3SUU2SN[N2<.CKDI
M@N?WT7@P^'PJGI6E#$M^#&0H`](=2L`N-J/V5$IJF@/$\==2T"6Y>\-E^2A4
M#=_F'=12&R)U<E\\>L(<::13C]\4'E[B*_5K:\Q_Y1::T_SA32_.FO-=7BC_
M`,L_(<T_L?R?P^OG]FNN&>9[_P#^\I_P+H.[_P"Y^]>'W/2H;@YP0>/XY953
MV</GMP]OU:^#II&O%&[:KZ5MX+AUPV1H[H/$+O9)W@O-.A9ZT.)/1QH:<>?+
MAK1W+2TDG91=;T6Z#@U@.(H$\,E#UR;ASTJ`;DM@U"/L+`^-*E_>TIS.HY.]
MOBKK^F1AUOFWT5G$:?AK40M?B+6`VH+Z0#4$JZZT)IJWXK.*R7.#/FKV*3&W
MS$S\$[%DE:PV%+6ZZ%IJ1Q`2I7LKJU-<Q%N2IS#H6UTEI?,'M^4E/''=<`*'
M$J`]O`D</J^G6J$C(Y?$?@TA=6R__P`;E.U4V5!3]17[5.((_5UF1RLE^1<X
MN67%K<F1V#:\0E[8LBEV<MEF0ZR4K2H):"CU="A]\GV^W4;YAT.*\A(B`+B.
MK'M71-*UB%[6L+C7*-QX+T2>E=W>-.2G-K\YN:76EK7(LC]P>4%K;2E02TUX
MG'Q*@?#6M-?,G/\`RAJ-K&P0QMK)FV.&ZG2I/<VLNJV^2QHYXVU(;MZUZ(;?
MG>+S)ELB0IL-3]P0$JC-N)60L)`Z5$5"5*3QX^_7R]JT<F@W)9J+2Q[ME`78
MGJ7-KFRN-+<]M\,I)(P[V/J2LQ+=6UX?DPVTNC`6FY%=TLS[J%!MWS!651@_
M3H;4T0H=)-=9.C<RW-F[\(D>G4N><S<J1ZV?,AH,6^N'V5"<"\X"<ZEMBU0P
MIAT)+Z:)(!42H_$:`JZ5CX?9KH&GZPW6Y?&OC5U,O'`;-E%Q[6.79=&O?'L@
MT6H:/V@,=^%25`CO+N5A[?6[;\H1&M>1)0'R'%I15:17KJ*@^)0\/9748YDT
M.QEN,\%/9]ZG/)][>ZE<QVA!+"#MZ!QI]ZPFUF_^1;C[66_);\XN*42@P'TJ
M*$%#9(24JH/$2H(%:<ONZTL%@^V'X>7M'O77;OE_3[JT\-P'C4Z?;5<Y7W51
M8-VMUJ@SO%3&C^&\$+65%:!QH`"5$GW:RX(KQ\QH\@5W'9U8XJ-GD6&&!TSF
M-K3#'XJ0/;3NFG=:X7.W7:$Q)3%'C-F6KK;<0ZH):14T'44$D^ZFND\L\G/U
MV5T,9\28-!HXTVFE:ER^?>:9KO0-0\2WHV-SB#U;>E*N^;'F\YTFY6AN-;FF
MW00VPE26U44KJ%0H#F=;W6N0=5Y;#9I8F-87#Y7!WL)6*=?CUF#PV.)D`QKA
M]P3H2I;FWL0W"^.>"S&94]U.KZ06VQTD$\T@@?H:W6J<Z1:';F%KR+FF%!45
MIQH0L7E7EJ36KL36K0Z`'&II]A-5%F][M9=G>43\@MTR7#QJ,T&+:AM:RV\X
M$*25M-"BNCA]JE-<ODYFUS6[P-O34D]WO#%O30"F.Y?5/*O)FC0-;=W#:>&0
M#@:UV[*XK7'W887=\Q@MO,OJ^82IJ`X^L.%;"E.?A'UA1`/AUK[CKM_*#6VT
M;(9<)WD`;\>O9VKNEA!!)$#I6,#=M>[]A7G][N,U8QZ6UM#BL]2X-J")&13X
MK_2Y=IU>IUA3B3P;#BN/&@UWG39(/*B*0]^G!94DCXL7FBAFUE=Y@QEA$QV*
MVLDMI0LK4VG_`.:JG]9RK[=8-SH$%Y)G#023U?>L>\OY66E6;*)OLBO8N+A=
M?4\5@I%5%2@37APU.=)TJVMK0-9A-PZ.NJYG=:O/).^)YPH4EU3YH;6&DE21
M5?`T%.6LJ3PHQW\/4HU%:W+KDR.`R$\0?L32YG<KD&5LK><1XZE=-":)2H\.
M7*FM:)HY'Y65K7@IJV#+&"0-@3'2V9#J@`"M76>HUJ22?:=9T+2#0[UH=6AF
M+6N8`6M!KB!P2*SPNL!J.O@IIGJ4D$<$J`(X@\?M:E&G,[PJOFWGZZ:Z4M!.
M&U4]@>._^Q9'+\LNUW]G%BU*8CWO3@N+:A*R1E6\6^T+[OFLU1I&B(T1&B(T
M1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B+5KZR#B6NQ/.'%_91G^SI5
M[.`W+QSVZZC]')/"Y]M9.$<W_I.44YUC;)R_*QVS/'_.%Y>+;>T,SHSS*NEA
MY:^H*HHJ`7T\SRX:_0/2=6N)(A$YP\/J'M7SU>VD!K@>TI77M9<#+L52FT/J
M"FE))#B'U\4J2Y]H`'[FKNJ6<,D)<T',>DK.LGQL`;P"QSC!N["6IKD9$YII
M341]Q*64F@XI<6@#K6?83Q)USV?39FYO#!IVJ4VS[=Y!?[4RD^V7%-]EV=]#
MZ!>H@C"'(34N.,K*T*Z%5!0Z#4?KDD:Y_JEA<M>21@I;9W,+69&[\%IT[H-J
M%;;9M<'V+.EJSWB2[.9ES4.>%"F*XRXXC)/2>@G@.0U'+F6YBB\-I_#/0/:M
MQ9PLX;U$VX3V9D93#:GK@B.CQT)Z%Q(#+@X>+X2:!0`3R/`TU!]7LQ/;/$S:
M@K<Q]R:C21ZUFL*;>@6M%WENH95<KH%A]A*6DMQV5%EPI2B@"4MU^O7#]:TX
M0M>RV;0DX;]ZEVGWL\3VBO<HLY=)8O>28HQ;W^B#+OEJ@-JI5#Y5/#'FJ'JX
M/-J(I]%=8^F:+'/_`)IKCZR%FW6LW49_#>.P%>B:T6]^TXM:;<A]/AV^UPXK
M:VDI;2AMMA-5)"0`%TJ%*YGVZW5URO:/@K;M?4#]YWO6)!K=V9*EXKU!=;8J
M>IIN0M*9CMOE"3;I!0DN)0DE2F0X!U%)3R'LIKF/,.A5B\&-I\3-O).%.!70
M^5M7DDN)!*X$>'P'%*/<[OHQ[MTQNU7-<=]^^9$U*C0(;#AZV7(K:0_+E'F&
M62:UUP'F/Z;MU*8NEB<37BX>Q3C]3;Q2J[3_`%M4Y#DK=AO,>?)$0)=9E2F5
M!A;C:%$`.%/3X?PT'L/#7+=6^EE]RGJ8U;2V.CNQC4DN'8[!7'0V&M6Y%V"X
M=!+?8I/]Y/K,X:C;6[81C<%#=^O\)QJ:TTV],<:2ZPIQYZC:%J;;0$E9-*(2
MDG@*ZW>EZ3S+S/>1_K#@^T:X`@-#,3L%0!CP&]:K2-&T+2O&&1X!?7%[CNZ2
MO*5MK@=L[B-Z57665S[:[,<O-UDK*G([KJ)9EQHS1K^#"G``2.)!XZ^ZOI_"
M_2[>UTVW:6M:YHH:FG63BN6<]2V;YB+3\L;<:X+<%'L13>K=CD=3CIL\5EMN
M)'J&FWEH0VRI24THA".'W=?4_+UK-.1X@.U<3U2]=!41$"G&A]JD3BUF<L;:
MTMRVS/=3X$Y4>@5&"7?$`Z^:55YT]G#7;="L6QP,9EQKZ]J@&I:E<RO=5PIU
M!+1;K=O;D/+%7RVHJ=6>I2B1P))K4U.NKZ59QT&<=VG4HC),\2.<3N3:7"<Q
M!L]RN\IQEMFWQI$WQ'5]/2X0M*3TU`4`HUIK1<Z7EO:6M!@1Q6'IL,LUX<JU
MT?EJL/F*?-6:?E%^4=7P_P!6?+.OQN?[%U?![M?+?ZZ[-7./_D>C9E77/TMM
M/E/^5KM/S57DZW`DI.?YT`"%#,\IX\*<;[//'C7D=?(KHB#7=1=VL[P@4"PT
M*04+!_H@??K"GAS-4OTF_,,HQWI]L*O#;\5^TRE#PG@A4=1I5E1J%5)-0D@^
MS47O+;*"\;EW/E[5&O8QKSW32J4DZ&I13%Z?##9#K2S]^*=-:CC36IZ%T2T@
MM+K`4/8G;VZG*AK1$4Z%+56G$BE36AK3AQUA3?F%2.RTEL1#VC!2<MS[,EE0
M66UFG!2*>P5I[QQUB7'Y8ZPI;"S/'X0X5[%8R4-I44MH*":T41\//B>!UE6.
MP*':S:XGC57-J*@5*64E22>E1X@4KQ/"M-7KOY5LM'M<6CH">/;G-;E@F48W
MDEGD`7"VW-E]"PXXA*4=0*Q\/23UI''V:A^IZ9:Z@P&YIW`:5Z?45/HO&MGL
M$=0UVW[EZJ.SV5E6?2K!F$.Z/O1IL6-/2'R76T..-)4^V""O[#@-?HU\D?57
ME[2V2F2C33'8-WJ6'S%%!(P.FI5;&]U[#)5$QO-&D`7#$I\><Z4]8<D0BI/F
MVD$#B022`J@ISUP2:T8]E;;:5!KV)DEJ^.#Y@-RF'B>YN.'&HEYLD^,ZIV*'
MGE(?"&VU>&E1#@)%%)J$GZ1KW3F:G;77AQAP%*X+DK^7+O4[DP3-JS,M-W=)
MC^4=QFZ%ZEB>\JQ6V&H--H0F0VLL+)<2E9*@*!)Y:NZC-J8N@9,U.D_%=%TC
ME&+1(FSY0)&C#9OPX!=MJ[UA>/87$PB8JD*`^XU,5UI0ZIP50KI:<*>@@UUB
M^8N^GT]:W::;<P;>8]>8UTLI:?;HKQ''UIJVHD&KG$CX:\:>S4SL(7BU9.X=
MXM!6\;:^/8T_A4O.VBWSK.;9E-G<_P!;[HPT)3J%],92PHK"FZD$CIX"M-=#
MY(YACTG47R2&C2T#L=5?*_U3Y5N[C*;5I+Q(2:<*=2W#X;#;?M,"Z>&R>KH*
MW%.-$J+O-0X_93[>.NXZGS1HFM6&65S2\,/#;3UKA^EZ#JUM.6N#A6JA[W*L
MW3=?+;=M[COB.QXUP0YD3D`D(9MC8#JV2M-**<\.AKPXZ^0=4N;O5'F05+03
M[5VSZ>B+1Y6LN:`$IE\UA-8!9T1(,(Q8=N0J*A)`HA+(`2I7M4I0!)/OUD\K
M,DFU-C)-H=1?4^EFVOHPRTH6NI6G%:3>^7NJFX#B-U5:Y"/G=X<<A6EI)0'$
M!Q*VG)*0I2:)9K4D<>&OKC0=%_)GI@T@KHEC:G3K)U=[5YH[WD,VY7*3.N<E
MR9<)<F1(?DNN>(^XN0Z72@DD_`DJX:Z?96M*+27MU@5BRJ0^"I3:DMH2#QI7
MB./+AQUM6-+),IXK4WMU_P"QZ*%)Z:MAY00E*@24J%:4^$U]A.I+:;/45R:Y
MO,MT3TKGQ4QX;SH2GI2D@@TZB0*U'T4U@WJE&DQFZ`--JCIG=W7(=Z4D)02I
M-2!\">HTY5Y:LVEK5V*S]1N_*QFNX)&1GV8R#(>4A"$H)+BS\)4!\-.%1QU(
M&6E2%S_4.8QX;F5].U,3E=T5/GR7'*TZ%-`?53H(Y<"D#4BLK<AM2OG+FZ[%
MS,\]:4/;_P#V_-B_[\NUW]G%BUM8OG]1]BYA/^7ZQ[0ON]ZSEI$:(C1$:(C1
M$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(M0WKDY':L4]/#<.]7J4(5O
MC[B[)-.R%)4H(7)W4Q=AJH34@*<6!7V:G_TRNH[/G"WGE)#`R7IVQN"C/-['
M2:%*UGS9F?S!>6?$KC;;NF*6Y;#S5Q2M^U3&'4NQY8Z.HICO(JA:T??#@4G7
MW#R]>-NVCP#4=.'M7`-08Z,D/&-4[D-]#]L\K)</FF#^!>Z2>H(%$M*_6UIS
MUTZ"UEF8`X#8-ZTL4Q9)F)%*KHY.89;\-,(+D$T2X54XCV^X:RG:0P1'.T5(
MZUM&W^;*V,]:QM\\Q>X+:5V^,Y.M;S<N!.;4$RXZTI'P+43\:2.`/L&H%K.C
MQY'Y&XY3["I+IUS+F:ZHRAPW]*97?K;'&M[<$EPI\8&_L56ZMDA;C"@P$!YL
M"GC!+G/IKKC=WIDN7Y11=(L]2L_WCV%:0\XVKR':^XS[+D%M;5YEQIJ(]Y=9
M:F1^KH:*G4`MI?*4\4GCJ&:M:B&-S'BA(ZUO(;J&23.T]WJ3:W^.])D1+5&;
M=BQFHY2\&VE*\-03UE)3PH!TTUR&ZM8WZ@!(#EJ=RW\4[`VH.Y38[4NW&\9/
M?K9N=ET)V#A]@BMSK!"FLE)O]VB%?A/)C*'CF!&4`5J("5=8I76Q.DF./Q6-
M[BQ;ETLOR$=JVFI=CWRTKLSUR3:;A<GO$8"G`VHE)KX+4<_&(_()]Z=;O1[>
M`QDW0(!&&!*LQPW4($LE`WK!61@VY&+VYR$JY*F/%2'UHBN)-.BG7TM<5T*2
M0?=77-.;N7=29<^;M8P;=SJ`U`/'9M4ET'5XH[AXS$.R<#Q4`>^+:.[9M&Q;
M,L=\[<,<@27;9D-M@H+TZTHN2V@W<&0FJW($?I*GRD$`<-0A^FW3?SXL>U2@
MZY'^_P#8H`0`QL_>I-NMSZWW0E*_/,J\,K2X*(4%J`"*=0/'4>UW3YKJ<-O8
MVAG6"I1RIJ[)8R'N.W@IK^FUF.7X_P"H3VY[D.HNETQK\>_Q4S>;)#)MC>);
MC6:Z8'=VI;\J'-C2H)C9#UO1T(+C[;90E2"KJ'`/ZJ?IB.=/Z8^=.6N70]NN
M'09[RV=&2R1ES8`7L)C>US2U^:W`:X'NDUQV*[JVK0VNJVP8:PN>`ZHPHYV4
MUZJU7K&[M.Q7M*VAVUW/WRVUV=:V[SQY;5Q6=K;:B#8KGD-TDLVZ')ON)AQO
M&K3853I"'+A)ALQ%H;ZG"5J^%7Y8?]J#^MK^J7ZC?U!\O?T\\QZQHVN\I7;)
M'%^N2&._C@MF&21NGWD8\>[O/#:[P+:X\9LF5U7,:TN&I^H.A:+9:)<:PUDL
M<[13\,5;4X`O:<&MK2KA2G2M+-IAW3%D.2H[3,N\W%XO3KNX`W,*'ZE;$-2B
M/":9!HDGG37]@/+W+=S&SQ'L'A]!!*^0-;U")H<2Y+FVW13:%EN/UNKH.IU8
M"ED<UK4>:B3QUT[3-/>`U[6]SI]RAYOH)AE:[O(<ER'T*2X0A`=7(6>H4*$)
M*P#]"B*:E\UQ:Z?9^-.:-%!LKBM9=0R-:9!3*3Q^Y:_._P![BHFVV$V[;BP2
M&49YG#`GSFDNI6]CN.MLJ7'7*;02(\J<Z24)5172:TU\Z?4SF:VN(BRU>2[J
M(]JEW*&ER&82RM&5:,OQFF^#^S7#]C\;]E-?.>?_`&7E_5M/O_=KY8_4Y*_-
M_P#JOMHNQ^69P_8IZEKCW!;_`/6#G)K_`+LLH_V[G:Y8YV"E\%M1P.;[."P<
M==!6G(TY_5JPYP:,I%05O+-AS"0N^4]J4T"XKCK;4@])-!P70BI^JIUK9[-L
MP-3M4VT_7YK5P:U@(.&VGW)Y+%D:+A&8;F.)#S9#:'"NI*?LA!!'"FH[/IPB
M<:./8NM<LZ^^0@/H/7\$ND3/)],AAT,O-!)\2OX-P*%0.OW@:U$UH15P/V+L
M-AS/$R-MKX;33]K-Z]E/O3R83N):E?M2:^XP^?L^(/A-!4_$2".`UK7QND/A
MD4&VJE-EJ$+G^+48C8GG=G0Y[*`PY4+9*TK;`7[3PX$`'63#&813:M-JES'(
MX[.U5;8IINB%J!3PZZ_#SYDBO`C5J:=T@(RT69HUX#(`6@`=*6D-4(NPUAP!
M*9"`X.!JE25<03RZ=1G6;21]N98WEI8TX4VKIME<VY8,P&;K7LQ](JV62^;#
M62XI=\=<)Z6QU`I40E3(;"3\7PAM2"1[ZZ^(OJG<W\]T^``AIJ*_?L7.>>[B
M5HS1'`FG:ID]R.3OXQ;9#41:A$6T&7D^$"E;3@4E:.9`ZA[>.H3R=H4T\K6Y
MG/'53[UYRE9><M,T^!(Z_<M'5][_`([49CE&U+D_R]ODI=E0U+2IQQI*BA"F
M$UH`E:D^_AKO=AR*'L%ZX$.V4R\.FJF=IHUM:2>*UN<CHI]Z6.UG?C@5DDN1
M[K.>>1/>4AWH/5TAQ55]2Z*(%>!UK=8Y(;.PG%AXY:_>K-_I;M0E%#X<?0*^
MY/;G\#&=Q+4,_P!LYS9>ELJ>7`94`%N*"%I*D-J)2JH5][QUSS4.5_)8-J_U
M4^\K3SZ!X)PD)'^S\5'[!]I\\W,OC[>6O?)L8AN_MR:_X@;`00ISI\3PDJ3X
M8/MU28I?*MA#""UM%>@E?;1^"&9J"E:T4S&.X/`]FK1;\0M]_AO,6UA<=*`L
M.H>\/X`Y]JC9/UG6M;H5]?.=X3GL+16H;5:E^C0W\CW7`P(V4V)>V?U$J6OY
M!;YR$GRRFF'D("FT*=_8B#U)ZE)`Y:U\EAJ%@2Q]T_'<6`?>HE<<C:?#*9JU
M=B?EI_XENC[2L-LV2;86O.YJ42[_`)A"$JY3*A2E))/0@.=14D#_`#-=?Y%Y
M%AUBP<^XF\,TK\H/_B"^5^>M4N-%U;R]FS-CMV;^H[E'CO7L5BQ>SRG@EEIK
MP7E=74E/@]#*W%K(J?$*BGZ*:I'*#=#YEBACD,C7#-7+2F.S:5]!_177;RYM
MO$G;F[XZ-W4O`_WK[K/;I[RW2VVR2MNR8P[(MJ7`"IGS/4]YKPA\*22!0&O#
M7U5H=N&V3&$8D!?4UU/'=6X8ZC,PIMK[E#:1:8,-86%J>>Z>HNK/L''@FIXU
M]NI+"TPFH%5"=4ABA%/$KZ=:Q<Z\*0RXPGK^(`=:4U'+A[OU=;)E@V>D]2VN
M-**#ZSJPM+7PVM#CCO3=2;NVQ5V0M+13PZ?$XFO(^P\]9M1:QYMN[@N<R&2Y
M<)V#O%VSXI!WO.$.!46(ZI"%(*7%!75\52*@$#[WZ=:FYF?)L:NEZ,7:?;"9
MXJ:=2;&[R&/*^<E2`I@`BIH%.*`JH4KP).MW9-)RBFX*%\S\PM\-P:P9JG]K
MIZDS=]R,/A<9A9\NE5:=5`>03[/9J36UMG&9QHN!ZOS++&\M:P'-7'-\$WDJ
M4J0I2C^C6M0D`>[Z-;6/\,91O7.-2U-]R_%M*GC\$YW;VOQ-_MC!2E-Y=KCS
MK_NZL(]WTZNL;E=7K]A6CG_+]8_F"^[_`*S5I$:(C1$:(C1$:(C1$:(C1$:(
MC1$:(C1$:(C1$:(C1$:(C1$:(O/U_*>)R[9Z/^^$]M2DKB[D]O+H*>?P[U89
M4&GL(UO.7;GRFJQS\`[[6E8E[:B]MW6YQ!I]AJOG_P"RO=OF>UDJ#+AK=R3#
M'7([]VQ&7(<;6E!4E#TK'K@X28DU":J+-0E8&OHKEWG=]HP"IP"YEK/++,QP
MP6Z_;?NLV(W$M<*]6O<*T6=V4CQ9EDR=PV2Z6QU"4F0TZRZEU$AIM9*4N(/Q
MTX#7?]+^HUKX,>8][(/8N33\NW@G?E'=S&G:G2:W5VSDR%,?CSCR5.K\O&6Y
M)5':D2E4*&V''TH#P4@UX:EEMSY9W(RBE0K)T&^B&;&J5SZ)K*6Y]KD%Z.\`
MM$A*FW(CK*A^#67VG'`KJ1[J>[6<-3L[YA9A5PIVX*QFOK1XQ-`0K/Q0^XEI
MZ(6WE?;5&26TK`YH<6/BHKVZCMYRRRFS%2VRUDUVX)-Y-M[MQG4==LR>.R3U
M<%=14M+P]SJ@5-*%>8(.N;:[RTPW7AG9E'WJ4V>L.(K5("+VP=ON,3VK_+L?
MSZ6"CRL%]]<MH/-4*%.1TT;>2%"M'*@TXZB;N08Y)!)0;5(3KCH[8NJG7;NS
M[JA`M5C8C1$MAI*A%"#Y9M)3Y8(0`RPPH4%$)32FI/)R!'Y'Y=RP?]1NXE)&
M!C_G+VT;@A+:DSU/O3'@$HAQVTI+:&7>:0`D``GC36N/+UC8V;6/:,[6T*SH
MN8W3-$=<*+"7A3Z;@X_;PZ9"+BY^'!ZNI@*6E`0FA0IMY!^*NM)^DV&K/=;D
M`A@S?<LQFJ>4'CU^;!*B+<%H8#USLU6TH<8;E1TA/AL.I'C17(_V)39K7XP:
M=7#6GO.2=-!)RBH5P<RG<Y,UDFQ.Q>?W9-[N5DM?S)"OA:3)7';64@]0>80$
MH6`*U2>&N/<Q\BOU&XR6HQJI[HFNNM[<N!.Q+"V8OCV'(MPQ%\6Q^T/QYEN-
MD:,!-MF0GFY$.1%\L$>%(:?;2M*TFH4D'F-9VA_1NZEMWVVI1MDM)V.8]C@"
MU\;VEKV.!P+7-)#@=H)"UVH<YQ/<YTI[[3AQP6S7LT[U,IQ?/;MB&_619!G.
MW&Z\U<6_73+IR;I&Q>_7CPX+U[?%Q2I#.)W"+^`N$1HMQV6R'T-_`M#GPC_7
MA_VJ;/ZB?1_2_J!_2CI=KRS_`%!?3R%MSHS-,C\JZ^MK4NN!IS/!R_\`O62U
MGT^=^9[I\T$C\L^=GG+/U;L[76'Z=S#(9=%OG9)"\Y@PO[N<U_8(P>-S<:88
MXWO![<G.W_,8MVLZU7/:?,UN/81=W);<I-I=3':F3,>NLT)0A"8J'"N"^HK$
MJ(`>I3B':?6__:X_[AO+W]8WT:N=)Y]C9IG]2O*`;;<QZ<Z+RYD<U[H6:E;P
MN.9L4[F%EW#E:;.\#XBT1O@+N6_5GZ=7_*NKB6P<9>6KNKK>3-FI4`F)Q&%6
MUJQV.=E#6H=37!E_<3LAA\INVW+/;6JXN%3*8-J"KK*5,K01P(H(4H'@0!4'
M7Z,W'/>G,89(*"*IHN8VG+]Z^AQ40M^O4`M>!LS;!A>'9"<H\/Q&+IDT`6Z%
M;F%-T1/9@NK4J:\A\CH2HEO]<#KFO-WU/B?IIAA=WLX^RJENG\MW$CP)OE`6
MCG+]Q,DSW*[ME-^N+]YO-ZE)?GRI10IUU*%J*8]23X+`"J)0W1*4B@U\W<P\
MVONW&I71-*TH6HH$G/.S?`_8^/C]/V_^;?,*>']=/;RU!?,]/[6=2?*>CY:*
M&&?I2K<+.!4G_P`<<IJ0/^_<^GOU$'D@54NB`PQQQ2:2CIY$\??_`)@U8+J[
M5ELF$0I7:NZ5%"@L'BD]0K6G#CQY<->L:'N#>*NLNZ.!!Q66B7!QH!7B%%#U
M#F/B^@@^S6/=VE30A2O2]<?;T(=0^G2ES9<I=:'1,0Y,B*K1!42`:\QQ)YZT
MT]F*4&U3G3N:Y3("YQ)].E+EB4)JNNW.'J4M*J.*`71)J>D@)&M&+7\?+T+H
MUIS4\0AV;'TZ4OK1N)=K+)2Q)4H16P$GIZBHCW@]=*T^C5\6BV,>M&Y%2:E/
M3C^X<"ZH*4N)"E)``4:.J)'M)/V^/NUKW6PJ13>I-:WSH`UPP%$XT.[+3T]0
M4&5A"FE)551510))'#[*M8-_:!]NYG$+>6G,C_,,9FV^G%>A3TA.\6/MG:K_
M`+?WFY485(#]MCO.="TJ<2$*XJ6$E-!7@`:DZ^<.<^16Z@Z1X;5Q:ZGI12?4
M[9NHVX<X`BBVM;T;_-YPS/B1D_@1&06GU+"FU*4"2JO52@]FM-R/R+^G2M,[
M>&[X*0\NV#;6SJVB\H_=G>KC+WTOL]J3\`(B(>9-:(4ZOJ4@U518*1Q]FOHJ
MVTJS%F*-;]GN6+<Z_%9WOE7GO4![4CL2O[Y>;\2X20`NJZ+2.HA)))JD\2H:
MC^JZ/;2P.8QN/JX]2DNGWL%[1C:9W!3N[>>[J^;>9C8[4U*5+L[\IB+.CRG2
M64M$E`5TJ6$]1ZSQY:@\_)4=T<6C'H^"KO+6H)I@I_\`<?WBN6ZT1,,L#@A&
MX16I;[\%;8*@^$J4GQ6Z)*.E?NU#'<H1^?D@#1W7D;.'J6$W2\S0X;PM-NX>
M]>5S;S\,]]]I,CI3U+)H%*KU**5`FFISHO(]M;LFEE:.]'A@./4O3IWAC-13
MR[6(*L\N>/LW6X+0F5<(?B=:ST4%.`/5P!KRUPSGOE=[+AQMAO\`3<M'>6E:
MBF)JO7]LAOC8]K<+MF(HFH3&M=I0TW5Y);*``:U24CJKJ+\O\P<UZ2PPM8_A
MO_Q!?.W-/TLEU>_$P::UX?!:S_4U[OL?MVWM]N)NC/6N+,C08X<JN1)<AKZ.
M*7!\"5*X@<:ZZUR1'J.O79OM4:?&9)1M?W:5XG>NN_3WDG_3UB(7BCBZNRF[
MJ7B.N^03[C=+I<G6%K5.GRIZBH@_%(*_;S("%\*DZ^H;&S\)L31L4HUO576<
MS8P=Z3EVN(:;#TA;<=LH-5N.)`105JJI!(H*:WOE1P7/]9UYV./M]Z8'(]TH
MD4NM6\F8M"R"XW0L$CF`G[0(]O'GK+B9D8&\%SS5=8=,RA-:^G%-8N^7?('@
M\\GP4_?(0HH33WT4I1Y:QK]P;!4_O!;?0Q&8VRR8A8^[WFW6UI02GS$A`X])
M`0D\?A<!%5*X<P>6K^GV+;H#!;#F+F>WTZUH#1,S>LADS2L*7T-*4I264]00
MFIX<.H\=2&ULFL.`7SQJ_-#[HO.;`D^WK2-==4Y6M./NK_-)UN6QF-HX%02>
MX=.23M5K]Z?NZKWJ/W`H\=83K=N_]O\`V,_OR;6_V=V#5\;1Z_85CS_E^L?S
M!?>#UE+2(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1>>W^
M5$`GT<M^0*_VQ.WRH'M'Y:<,J/J.L[3O\VWJ/L6/=/>R$N82'8;.M?,PQJ<'
M;;(8=5T>`%(+2C3\$34'I-1TUX?7J3MEE9\CG#J)6E>3)^9WNO%9/'LT?Q:_
M6U+W3-L\>ZP[@Y`<`0V^MB0AU3"G%!:4I6$]-2#2NI18ZS(UK6F1^``^8K3O
ML6.>2&MQ/`*<+FY=^S,7R]-V>+NK@5PN#]T>Q!3HA9SM\A72EF#99D1M-P91
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M_A5=6E:U3@HL\AIUY<)332>FJ@M/`J)!HE83TDU^GCJ1>2TZX9YB-S&MX"@5
M/G[N,5D+S&-Q)HJPD7F*%M_M=)4`/$"!U4%>)(%>(.KC-';<MRLF.7K-/:GZ
MM_"L#-9GRXS\=[PRVNO%E/3U@BI*N7511//W:C^J<KZC('1P1,?&-AR@D]-:
M+.M-<C:ZF45"0R[%,2Z`S+=3T`43XJZ=*>20`=1;3.2+^*\DDNF-BC<W`@9:
MFNS8MS<<P`P@%M17[EF&F+P$)2%H73A5WJ6OAP]M336[=R7&\]YP*P1S`W]P
M=@72!B<NY/D.6MJO62OPV>I9YJZ^D(XU/'GKRV^GNGQ/#Y"RO4%D3<U73FY(
M'R-ZG$>Q*&Z?BCA4`R\EO5AL;3:.I2;C<H<98"/M?M;Q4ON4K]8UNI(=)T-@
M9,8WN.(J`:=`JM(]VIZB?%;)+AA\Q4<LR[P-JK&XJUX';[QN9?T=4=5OQRUO
M*M7F*40E=P\-XE*U$"G,ZC=]]1[#3V.CA#0\#`B@IT@JU%HU[).W-F)KOJI^
M=D?>K9>[G&,V]._OD79L*M.[=J;QGM\NL/*[9:LX@.-PG78N(^=<=5(MV5VF
M1%:?QJ2MLEYQ"H"TNE3+3G\W_P#W(/H;S;]`OK-!_P!RG^CR)MESYILSIN:M
M-C#W0:E!*0+F_?;L^>*=A+-6C!%>Y?LR2LE>OJCZ;ZM'K6BGZ>\X5DLW@"VD
M=2K"/ECS'>T_E'K8:B@7G\[N.V/='L0WUS/9FXXS$L#]B0W>+1W%9K<XMT9R
MW#;J](^2Y1A;BVHT"W3I"6%-2X#+3MSARVUMJHGPU+_07^GO^J3DW^J7Z5Z?
M]6?I[<RLTV[:([FT<^DMA>L:TW%I,T$T<QQS1O'=FB<R5I[Q`T6K\JS:!?/T
MZZ8T.;\K@,'L.QPZ]XW&H6M'=S=>1FT;';(F?<,A&,1[E%>R^Z)<;NV1.3+A
MYD*?;<4IUN%'1P:230#V:ZQJ%X^:#%[BZHWK#CMO"=FW43*1@4/)*5FIJN@)
MJ@<J?1QUH'`.^?'KQ60"1L68\5SRM?$76O57K56OSGIZN?/IX5]VJ<K>`V4]
M7!9./_"H\[BH8MV5Y>VMB.\J[Y3E$P2$J)<B!O([@@,T!YGHXUX\=1%U2:E3
MZ..,-`IM%4V(42KI]JS\'+AS%->%HI4+'GC=GHT8+E\*;HFOQ4HKA^C[Z<->
MQFC\PVA6A&\$$C!6X<6``%<!RX#^=J\]QD^?%7PYS=BRD!]Q)!2LU%:^[]#E
MK$DB8XT<,%N]/G<`,<:I21;I(96"TZH`<0$_#]VH`.L&XM8<N9@H_CBIC9ZB
M\`->>[PZ4I(N5@GIE,A:5'XGRHJ<3R%$I)Z2FGT:PS;O&*W,6NS1]V)U!ZO<
ME]:#%E(\>!.Z'>D.$N*#10M0Z@`!1)H3[M::03->X##%=6L-6@FAC\1P-6`G
MLQ3I6#-[Y:D^6E`24-!!\8]*B6ZD#H32E>&K3V2OP?BI':/TPN\<@>(-AS'W
MIY\)WW?Q:[Q+Y:I$AB9#%'6!1@NCJKQZ0FOPZULND6DU3)'4]9]ZDS.8W,:(
MQ*,G]U;`1ZF[C6(HLHMBU75R&8J9Q=65-U04A9224$IKS(U@-T:R:.[$.T^]
M;ZQYJ>UOA"49.'=]RU^9/OQ,O5PEW"9#3,??DN/E]QP]2E+57[T@4X\J4UEQ
MV,<;,C&T;UE:35C!>7WFVXN+`*UX+I8MZ8D<++\?H*E$E55?"3S'/D-8\^G0
MEN;)CUGWK/T?5+FRNV/;)1@!W#AU)5-[Q0&7&YK#7X=*TJ04J4#TI4%+I3A6
MH''GJP+4-V-4J?S+))\\@[![DL;MW*IR25%^82GTN18[<="EK(4EIL`!"0*5
MI3V\=8'Z%8&X-R8OQW&I-7;>JM%8CYDNC)D$HR`X8-]R0MTW@L;;SCGC/N$D
M%5>HD#JY\>1KK+?:M$?AAO=69<:],&-'B#$XX#W)VL#[R96#.P';0Y+2F-)8
M<:D)?6T4N>U(17H/21[1QU"=5Y8L[UY+X<QV[7>]7;?4K&7&YH7==/8MO>%>
MK'A,S`K2[DV0/Q[VW$$:=%CME3SC@6$DGX*`E'.E-:RWY+9(^LD0*O?JVFYL
MQRU"A)W8=Y5JWULC=EM+[GR],PN!^2LI53HITU-#\2-3#2^6(+$9O"I+7`X[
M.K8L>_YHAA;^%(&FG`+6I?-QK9:HI"9/C2#5I*$K*B%@="4#C\1K[]2NTCG\
MQ&'5R!W!<HUWF%L\IFE>#EQW!1RS/+[O>9"A(FJ8MJP"&D.!*U4'$+I182!J
M3^&[@N5Z[S'$0?#=M3>/W6%%0E;*@X:=(0%GF.`)'5SU=;:APS$8J%C6)YY*
MN?\`A`X"@]RL&[^^>!D*`'&@(3Q'+E3WZ\?8QOP<VH4GM>8Y8X?!$M&#H'N6
M&O-S\R@**R3TE)((34U-*]-*G]/699P.MW4B&5OIQ4*YEUBXOP62R9F]0'L2
M$<=6LGJ42`33Z!K=-:&XC:N;/>XDBN"K"*^6O%'V*<>7ZM-5N<7?,J`7-V'!
M6A)%1]?#]77E%:?&Q_><,4^&QD)B)O\`;`EE75X^[>U+JT@U\-2LYL%0>)XG
M53'$NQZ?85KI_P`OUM]H7W:]9RTB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$
M1HB-$1HB-$1HB-$7GN_E0Z@CT<M^5'D-P^WW_P!M&&ZR;.40SAY%1C[%8N6Y
MH2WJ]J^8-:Y/EYK:NNK#J2AY%:<"/AX_0>.I+%()148+6>7/%75U:0HDI"5J
M1U4)^RLBM#3F*ZPFF6*0D.PJ5<\)O0J%KR"ZVEV)+MUSG6Z[V\@QKE"F/0YB
M:*J@E]EQ*DJ:YB@(5R4"-9AU%K125I=PQV?8KL0CCKF%:IVF=Y&;Z$,[DXC:
M<J>0`E&567P\:S!NGP^,N;#:-NGOA%*J>9JHCB:\=6_U%CG#*TBIX_!8TUO'
M(<U!1.WB.Y4F(T(VW.](A1"JGXE[GQ&S'*R>##DF8JX622I7)/AJ9''D=;F&
M_,6-25@S6T$N&6B<^#N->+8\+CE>SKUN=0>L9EM1=GH*G%\_-H:MKUQL_2H\
M2DMM&GNX:EFE<S2VT7X>;YN*T%WH4$LV<@'#@GHQ/NUN5K;#./[]YI8&T*"A
M:=R,0-Y9C/<`HB;9^J0ML$E-0TI1YD:F%I]0]3<1;-<YK3OKP6NNN6H)(',%
M`3OIL3]V[O9W7;,<P=QMB<M:Z4_'<IL['Y1H!]IB=#8#:EGGUJX4U+=/^I%W
M9_F9GGH-%IO](,WO;_NGWI4N]\.\R%(`Q[8^67$U$B+GMA<!/V0OI5<$\$GW
MCV<=;O\`ZO:K6K'AL6X$XCH./W+#_P!*".9S@]M*_NGWK#R^]W?+J56W[+L@
M`U=7EN+E*:CFKR\Y;@'W*:M77U9NYF!MPX%H.&-%E_Z:;.,F8-(QV)&W3O8W
ME*5*D;@[&8P.7B0[PB\.IH>9CV^'*<J?H/LU@GZHGT<%Y_H\?_4;_NGWIG+[
MW<Y/.26\@[G;BXHJ43;MN,0E("PI9/A^=NPM[/4:\":`>RIX:C%S]3=4FJ&%
MS?[RR[?DTQ&KWM<.H^]-Q-W/;OZ_-V3:_<+<&X*ZE+O>Y-ZFIM+RSQ3+?CLI
MBVMMI-":%_ZJZB&J\ZZO<2-,DA(IQ4AM=!CB86B@QX)%9%NYE\6&;9DNYV&[
M8V8A2%8IM?`^97UPD$%EQRUI6M)H>GK>E)H>)4!QUH;C7W31N\0.+R-N;X+.
MATED4K9"00#78F*D;NX?C<QJZ8)BLR\Y3!FLSHF>;AW-R=<(USBN)D1KC;;'
M$>0U$E193:76G7''%-J2/;QU';FYM[N)T%PT/@>TM<UU'-<UP+7-<"*%KFDM
M(.!!(*VQ9'M8"T@X<1_8O5#L1N7ME_*%>R*X]L&_^0LXKZA/;;9YN8;?[CMH
MM%EC9S,D1KA;K7EUOM411$[&KTTQ%MN9VYJ.#!DF-<8_25L(;_G_`/JARWS3
M_P!J_P#J/_ZV?2^VFN_Z0^<[MD&K::S-)^FREP<6LK\CXBZ2;392[\2/Q;*4
MX!SNRZ9<P<]:*--OW`<PVS:QO.&<;*^O`/&XT<%Y$=U]K-P-C=R,WV?W7QJ7
MA^Y.W&02\6S/&9KL>0]:KS#\-2T(EQ'7HD^%+CO-R(LEE:F9,9UMU!*5C7[@
M<J<[\N<_<K6'.?*%U'?\K:I:LN;6XC/<EAD%6N`(!:1BU['`.8\.8X!S2%S*
M]MY8)7VD[#'<,=1P.T$)%L,I#3KQ6$K2D@<*FG,TX^\:WOCC@L#P3Q5OXY\E
M]K_I*O\`HOGU/$T\8+-\`\?V%'/<-2CGV;I*B4HS#*$I!-0D&^SR0D<@"HU^
MO46.U3IE,H2>\@M+:'C7WC^AIQX<>9U22=BO,A;)WCM"ZJ6RJO6V":4*U`$C
MV$\1KP'&@26%@C)W@*YCVAF<A!@R`F6M90F`^*NKHDGQ$UYH5RU<S;G?8M6!
MP5)^/+M_AA^+X"4K6A1*0%E0-%5505%>6J1CUJN*8MDRC"A79*E)XI)2:<P:
M'Z1]6J0P/P4@9=%L>8;5P7_#^U4D\0:C_-]VJO`">><-A68@7<H4E(6H<@>)
M]GZO$:U,]IB7*36',$C:,!.`IZ8I5Q,KFQUU3)6L$!/X99<"0*T"02:<]8IM
M\-BEMIS%(&D%W#TVI1HS2H2IZ-&><I1;WB!*U#EP%:@A/#5)@%"%ENYBD#2<
MVP>F]7#.8V=3H\1,M*>D\4@N*^H@^S6+Y$TV*JSYKFP.8_;[UGDY+C;J!U/R
M4`"G0L>'R]O0#2GTZH\J."D]OS@YD>5YQKZ;U?1+ICKJ5(%S:9"OO95%J-?B
M'3U<AJB6U!9@LN/FYTKPQI[Q].*R(NMB9Z:WME?/I\+[SW_9Y5UB>4=P65_J
M.<[3]OQ75J?C\EXK^:(2I*@>OB%4`J2%<#6@UYY4[PLZUUN5YKF^WXJ^\QC*
MO$4;LEU10:^(HJ!%0?OCJQ/;X`#>=RW,FLN=&*NQ&/IBD_.G6E*>EB[QDMI(
M(2H`D*'M&LRVTN*7$C=Z;EH+OFB6`FCB/7\5A6L@B1W"XNZN*`ZBI*'%@J-*
M#DK_`)!J]:V\3,',IZE'_P#65P?VSVGWKJO<D)2M@JE.LH!4@>*KIX<`HCJI
M6FMD^UCDH0-@HM)J?.MQXK6AY)R\3QZTAYV6N3%]2&0A*5]84?V1)!J%=7,+
M%.?.NO8[)C9`:;UH+KF&:Z@>W,<6]/O28E2I4MU3JGW5=5!\;BB:>[GRUG^"
MQO`J./$TP[QP*L5=2#2IK[?U=9<4(<P'<L29[K8%H.(5EYT#]=7Z^&KGEF[J
M+2OUJ5KZ"OIZUR$R)8):"BA)Z2"33JI7EQ]AU[X`&Q6GWLMQC7#TZ5<13:XO
M6J6E<N0V/@C^$&V"ZFH+3[@%>BO,\]546N<[*:.^:JM)EP<D@!L".UU*Z6&6
MPVA(^&@\1-%.<O;KRB!U318W1>G84\.P"E'?W8LDDG\LFUHJ3QHG.+%0?4-5
M1?/ZC[%JY_R_6/:%]WK6<M(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1
M$:(C1$:(C1%YY/Y4FI*/1JW]4KD-P^WS]/>K#!JB1Y8W,-M0K<OR%?+BC7#X
MPGJX5!`^FG.M*ZV%I=NIC@L.AX%+Y#K$JWM.(3^%0E(6NI-5!/Q</LZV=2['
MBO$E)2$AQ2@**40":GCPKRK3F=6)]R%4$O\`2`CH)'*H!(XGCQ'NKJQ6F*I.
MQ72FTE`0I(Z$B@"N0'NXZJ\T[I6#BLY9<ER'&W/%Q_(+Q97"**-LN<J(EQ'+
MPW4-/);=;X?94"-76ZC+$,HK194,+7LS.VU3GV_??.4)+%V&-95$Z0A"<DQJ
MSW1]!``5^VT)CRT\N?6#J_#K,K)`['#K7LMJTL.Q7ZMU\=DH`N6T>%R5?$5N
M6ZZY+8G5%5.HH:CK?B)-?9Q`UG_Z@EZ5A^5'0L8]N!MDXNK^U$^.4\$I@YY<
M#]H<EJ>MJE*0?I)X'5EU]=3'Q6O(!Z5>&EPO`<:5*LEYKM>T0ZWM1*\2H2/&
MSN:EOC4T(;M@4KERU9FN[P-P>>U>/TV.(59M*[#=#%X_&W[4XPRNGPKN=ZO]
MS'T$M#P0H?336/YR]_?5KRO4NRM[<L8;`L=NPC&&FS5/R'%+4)22>'4B=-:E
M2D+X\2>)%:ZS?U:8;2L_RK.A(R^9]FF0A:<@RB]76.\>H0Y$]_R**>Q$%I2(
MJ.8Y('+5#]0DEH75)"L31",@#>DKU]8-*)2M?B%(^&J_UQ`I4\-6WW9+#MV*
MQ1=5H"SU+4I7L`4XOI'TA-:5X:P_,NZ4Q3L;%[W;F=M>[>![Y[+Y*K$=S-MK
MTF^XK>O`:G142"P]#G6V[6Z2%1[M8;W;9+L2=$<'1(BO+1P)"A#?J!R'RE]5
M>2]2^GW/MFR_Y1U>V=!<P.PS,=0AS'#&.6-P;)%(WO1R-:\8A;33[NXL)H[R
MU<67$9JT]/3Q!V$;PO3]ZC%M[9?5O].]GU1]LKUBFSW<CV[6BWX9OU@V173'
M;(YE#T=^"S*P:[.I=>N5TOQ<>7,P"6ZLNW:$XJWA(6JD7\A?Z4?^L7]$/]3C
M_P"C/FNUU+F#Z(\S237O+VH0Q23>2;WG.D>0`R&`81ZG&*-@GR7+>Y(<_1]?
M_3N9]#',ENYD6J0`-F82!FZ.D[V'>*MVC#R3O3V?+N-H24N<JU/`*'&H-:'7
M[45'$+F:L:J\ES_[E4Y?[X-:WS$G_P"+3U+-_P`*CWN%)4,_SH<?_++*3R'M
MOL\^_6.8@2MHU^"P$*>^V5%ISH57B32A2!Q3QJ..K;V95M;"<MC(&TNWK*F7
M%E)Z74%EZE`XV.H/-GFA5.`*N6K>(Q6?+.U\;F[Z*V+2VT+*$I6RI('!5%M`
M$$+'WU01KRN_>M:KV/D=Q96A$EYF>T(RXC<>>UXK"6UD4Z!2O6FG/F#JO*#B
M`JVW&09339L5^%6"6T^ZOSEH4S!264(;;FL3)[?%8?0:);2X3P)XC2M"K@>)
M3E!PVJU=QZ6I;*818NBW6$R'46Q[QA&*^/A.I`/0L#B:5`KH2KH:?0K$*8>0
MMQLM.!32U-N)Z22A:#125$#FDC5HK.;L%%RTZ6P3S"C0'C2HXT!]_'2BO13-
M9OVJKYKVT_5_GZ4'!7'7+<IZE3\W[*']/^?JNBP_,CBN#/IP)2/\\NA_0)/#
M3)7&GV+PZP+;\/-TJJW<U%8^$T'WWW#3C7VZ%N45P5^UUWQ)@PG`JZ\^%\U4
MI_14Y_6?HU2,=H6W&I-/[7VJ];NBDH2D'@`!6O\`.&L1[3G-`-JVT/,0BB;'
M4X"FU51<W#R"J>\=5/T@-492-P5X:_X^%3@NJIQ4?B)!]QY_IZ]`/!>'4VN;
M\VY8Z1+*E$@52GF14@5I2I!H#K-H%%W7(KM*QDATN%)Y4!]OT_7KT+`NI<[P
M0=RILJHZCC]\/;HX8*W;24G::[^*4L9AR2E*6TJ4I1/2E()*N')(2"3PUX`*
M*1"<4HJSD1EEI+C\QAHA\(7'4@J>2$\%%0I4#7F4*B:5A9CL6.\Y;HJG$L14
M3?C`2[)3\-">?32O+50&%%H9)HB\TQQ5&1<''@I%$]*C4!ALH0@4IT_2?IU[
MB@G;7<L0XH(ZR30@5H>=:_<J=>M!)`6#>$9?4K/Q_$X$TZ??0<Q]?T:RF,R+
M1M=B>M%:C@:_=U6=AZE<:3F'6GA[>O[?^Q?]^3:_^SBQ:LMVK*G_`"_6/:%]
MX762M(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1%YY?Y4D
ME*O1KW\"J`'</M\XGV?^NG#*?IZ(OEI*C@.I4V4E('Q?$*U(-/:=$2FL<Y*"
M['=6$L*-/>H.$TK05JD$_H>S6R9=@-#:[`%@/^8]:<J1M'NNIQU)VFW&0!`-
MS#SF-OMQ#!\M&EID>=+OE$-N1YK*@5+'!U/*NO73^,.I4D;DCI>*9=:+';<C
MN>(9';,;N[D1JUWZ=`#-HG2+C%7<(,6/.\933LN7"0IYMH'Q5-I*NFFJ5XL`
MMQQQ/2H&E:\&W/Z71%1Z5>Y7^D<_I-$5XAP"G!S@.0;<KRI^MT1#CZ:<4N)H
M%$=3:QU=*>I03PXD(23]0.B++7W$\JQV-8;ED..W:QV[++6J^8M-N48,,Y#9
MFG51G;I:4A:WY,)N0@H*^@#J'"M#0B3O2KW*_P!(Y_2:(CI5[E?Z1S^DT1'2
MKW*_TCG])HB.E7N5_I'/Z31%R`4D*(50$$_`YR!K^MT15%K\040EPD&I_!KY
M4(_6_3HBI="O:E8^@H<_I=$59VZ.QHS\9F3(2S)=C.R(C;KHC27H@?$1Z3&0
MOP9#\-,IWP5K2I37BKZ2.I5;,S6D!Y`SBH!H*@&E0#M`=05`P-!78%Z.&Y83
MK+I4L)74GCU#I_0*R"1K%52R-%^3^P?Z@]Z/W>_SVBRO\"C=N&H?E`SKC_NR
MR?\`V[G:MT*S0]M-N\^U)1MQ"0:JIQ^G^=JAS7$X!9$5PU@(J%53*`4!7@"/
MTOHIJ@Q85WJ\V[!=E)P]:NO-IYDJJ.*>GX17^B]XU;\)RO>-'Q5-R825]2$+
M4H("5I)2$4]PIQ/O^G5P18;:+"ED>9"6T+54#L<J=4A3B.K@&UDE*B2./"HJ
M/9J@M>`!0*]:2Y929#1M%DXJ)K)2(JE,/*:4X7&WBV2Q4I*24+X@J'UZHZ=R
MV(N(1L(JLJW?I[,$1'7VGH(?ZW&'`%K<4#52'5^&'%,J/,=7+5-*X;UFMNHA
M05[M/3<LB]?[!<[A&<N]D;AP&VD-NL6!7E''.A("7%^(5I6HGZM>BNU6YY(W
MT$9[%U#6(W2YI;8G3<>MBJA+LZMS(``2`MEM`*"2#Q!/`Z]ZPK#L^4EI]RIS
M[%9TR$Q[1?(ES4I8"7'(ZX;0KP*BZ[T?9)Y>W5(-!TK#K+P64=V\O"`T5S;$
MKQ&DN(\*ZL(`0HD`*2"KXQ3CJH.(^4FG6KK;9LPSR_,DM=+7*MSP9?<8D+^P
MDQ%H=2"GA0J02%4`YZ\..*]-L(&F2/YPL2I"D4ZT%->512M/N:I5KQ;CA]OQ
M5XV`I*$]24E0"?B("17A\1]@U9+79JTP6WBDB\)N=X#Z8[4IX6-W"4T%,.VE
M*>?4[.:2DTX4`4X..J2TN=4@T]2K\>-@_#=4]%5;W.SR[:W^'EVT+J#1B0TZ
MFA!I0I6KCPUZ&&NQU.M4F[/$U746VP*A>.,F;;EE"BJ)Y!]*BKIY!P)4@$^^
MNLGU+&+I#UJQ9=QP0BF0Q=7K@`KH>0^VRT">54T4377NQ`"[YJU"QJY25L(8
M2VA'2KJ+JB2XI`Y(4H`55[SKPXJM@#:$8%=FIJVTI2EQ;2FSU-N-D@I4>!K2
MAH0=4XK+\=VRJM9,KK)^)2E'BHJ-5*4>)43[:G536D]2Q[B^8UN3-WO6L;YA
M7(5I]?\`F:O^$%I771S8;%5;EE(()IQ]U?8/H&J'18X+SS+CM*I//-K'!8)H
M*\#S]OLU6QC@<0KMU=02-&5P)ITJT!K7Z]7BM8T@DT5RC[`^[^J=#\JOL-""
M=E4\7;RI*M_]BP#4_EDVO_LXL6K300<?3!7YI&.90'&H]H7WA]9"U"-$1HB-
M$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$7G)_E6LV3;O15[A9<1S
MPGV]P^WGH7TH72N]F%U^%:5)-1]&F&]%\G9.X>4IK2:V:^^+'/\`RFKM8?XD
MHY<G/\I57]NM@*KU!,9A-0>8-$UH1PU16&NU_;\$\H3CQ3@6KN8W_LGF1:MV
M<VAMS(+MLE,)O<I^*_;WV($9V([$E+?C*86S:XZ:='`,II35;)8F;,WIZD\F
ML%/WNW6NMO79[KF=YN=E7.A7--EG2#(L[%QML$VRWSHEM5^U(4N%;U*9;<:2
MA26U$5U<\RSI7GDL%@?RB97_`-5Q_P#M*+_T/3S,?`KSR/24?E$RO_JN/_VE
M%_Z'IYF/@4\CTE2"VVVPWSW7QR'D&#.V"ZOW/+)^'6FQ&;9X=\N-UM6-C*;H
MY&C2_"1Y6':3U=:E`.*)2GB*:\\W$-JJ_3W'^U.58>U'NWR29%B1[+96F9CL
MMB/<IM_Q1N&/`QY_(I#[),D2)#+=J;+:UH0I/BKZ!Q!T\W"GZ>X?VIO[-AF^
M6Z&&G<&-DUMR&+BAN6*O6Z[WV#'?QFQX0Q!EJ1`1<S'MT"RI>O[*&6(ZP[+D
M.GX3ST\U"#C6J]\B2*#VI7WOM?[N\<MJ;K><0B1([D23/8C&YXN[<W8\1B%+
M<1\NCRWI?FEQ)R%I;Z.J@4>0T\W"O/TYWH5Q>NV?NIQF+-?R/'X5I=CQUO0X
MBY-DFR;L\W=K!97($1JWKDNQYB9^30P4R0R`A:E5^$Z>;@3]/=Z%)K.MENX;
M;RT7>ZY'$M47\6[=<KCD\(/VI4ZP?*LL?PZ5&D,4K/>-T9"DJC%UORZTNE02
MH:>;AV;T.GN]"HV*W"RM/`RX]?\`K&+[@1_S/W'7OF8]U53Y'I/:N!N)E8(/
MFX_#C_447_H>GF8^!3R/25V.X^6G[,UA!]Z(44$_0:MGAIYF/@4\CUKK^47+
M#Q5-84?>J%%)_P#JQIYF/@4\CTGM5%S/LI<-536S]!BQB/T%-D:I=/&\4-4\
MEUKE&>Y*D$&4R?JB1T__`"$`'5`=!OS+T67&O:LO^/F2>1KYEG_8SQ/ZG:_\
MX>GW:\K#_%\%<\!WW*VW"8L'X_YSU7.\!7XXY-4"QPB/]FYW(G(4D_H:H5"1
M_@8]^ZEY_K%!_?'HBY#&/U'^NEYY_N#"_?'KP[%4WY@JO@6#]U+Q_6&%^^35
M&"R>]Q'9\4>!8/W4O']887[Y-,$[W$=GQ7(8L'[J7?[MAA?ODTP3O<1V?%7T
M5BU>(?`NM[ZN@]758(8^"O'GDIX:M/\`#IC]BJ'B<1V?%7_@6CP1UW2X>%U\
M>NPPN537JID?53]/5D9*X5JM@W/D%:+J\QCW4*W2X#X1^P6&*?9]]U9(-!LW
MK)AKCL^U4/`Q_P!EUO%/_L"%^^33!7G9LII2E.GWJD8^/?NM>^?WV/0:?V3Z
MN"BP3FZ/3UJX#%BH*76\4^BP1_\`ELD_S-4'+OJLF+Q<N%*+LTQ9O$'@72\A
M?'E8(9]G'@O)`->=W>O9,^0Y:4]?WJJ]'M7P^8NUY]O1U8_!^CJITY-]6O#D
MW5]/4L89]]/3UJW+%F_=2[]/TV"'TT^FN2<M>C)TU0Y^A4BQ9?O;K=Z5^]L$
M/HK]!3DI]GZ6J_P]]:JT[QZ=TCL^*ZABR]0ZKK<O^>V"'T\_>K):UU4,FZM?
M4K9\QO+<M>'Q57P+!^ZEW^Y887[Y-6L%MQGIM'8?>CP+!^ZEX_K#"_?)I@O>
M_P`1V?%'@6#]U+Q_6&%^^33!._Q'9\4>!8/W4O']887[Y-,$[_$=GQ5NZQ8>
MO_96[\A_W`A^[_A+JXRF7>M/=9_&.ST]:LO`L'[J7C^L,+]\FK^"Q.]Q'9\4
M>!8/W4O']887[Y-,$[W$=GQ5'P,>_=2\_P!8H/[X]7%B':NZ&,?XTNEY_K#"
M_?&-4N5Z*M#172&+#T#_`%UN]./_`'`A>\_[Y=>?LJ\,U-WIZT[?;PS8QO\`
M[&%NY75:_P`LFUU$KLD-M)_\>;#6JTY`X10<?LFO+Z=>&BI.:F)&[=T]:^[O
MJXL5&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B+6CZO:.S]
MST^]_D=\TBTQ.WU=BA)NLJ[0W+@J/F1N#`V[>LL%$ZV-3,G;S/R9MK;TAB.N
M:&PXM*25"IF3-^)7)T*S<>-X1\`TDPW5Z]X7RL/D7H/]*/%W2]6@.A"0Z8VP
MG:`8RG:?&8PD=R(EICD_8#I*PGF=7:VE=CNWX+&`U#**EE>H_P"*G8NOR+T'
MO[JGJY?<V"[/:?<__DII6RX'M^"O`:E3:WL/^)'R+T'O[JGJY_P!=GO^4II6
MRX'M^"4U+BWL/O1\B]![^ZIZN?\``%V>_P"4II6RX'M^"4U+BWL/O1\B]![^
MZIZN?\`79[_E*:5LN![?@E-2XM[#[T?(O0>_NJ>KG_`%V>_Y2FE;+@>WX)34
MN+>P^]*RRV+T2^N)^+VZ7K*>+YASR/R783M3\3SGE1X_E/E_<C7S7DJ=?1\?
MA<_ATK8;QCU_!4TU7B.S_F65;L7HS>-;_"W2]:OS'@._*_#V$[8?&\MX3GC?
M+^GN1Z_`\#JZO#^'HK7A77E=/X?;\$IJO'[/^98*/8O0_P#)N^4W2]8OY?XC
M_C^6V$[3O)>+2-YGQ_"[D?+^+3P?$ZOB^Q7[W7M;#A]OP7E-4XCL_P"9*>18
MO1S\TYYK=+UM?.^&[XWF-A.V;S7A>6;\;Q/$[D?%\/RG1U5X>'2OPTUY73^`
M[?@O::KQ^S_F7==B]'?QY/B;I>MOYKPAYOKV$[9_,>#YB-_5'5W(^+X7F_!^
MU\/B='WW3I73^'V_!*:MQ^S_`)E8W:Q>C-Y=_P"<[H^M<(_D9/CFZ;"]KQ8^
M6^::\[XHF=R`1Y#SG1XO4?#\7IZOBII73]PQZ_@O0-4WD4ZC_B2`-B]!_P!N
MZGJYU^G8+L]]W#_XE/=KVMEP/;\%[34N+>P^]<?(O0>_NJ>KG_`%V>_Y2FE;
M+@>WX)34N+>P^]'R+T'O[JGJY_P!=GO^4II6RX'M^"4U+BWL/O1\B]![^ZIZ
MN?\``%V>_P"4II6RX'M^"4U+BWL/O1\B]![^ZIZN?\`79[_E*:5LN![?@E-2
MXM[#[T?(O0>_NJ>KG_`%V>_Y2FE;+@>WX)34N+>P^]9/Y%Z$GD_[:?JW='RS
EG^0/L^Z_!^>UK3\Y+I\7S'"E?L<>?#2MGP/;\$IJ/%O8?>O_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>pg118b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg118b.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`L`%E`P$1``(1`0,1`?_$`-4```$"!P$!````````
M```````&!P$#!`4("@L""0$!``(#`0$!``````````````0&`@,%`0<($```
M!@$#`P(#!`4%!PT*#P`!`@,$!08'`!$((1(),1-!(A11814*<8$R(Q:1H4(7
M&+'!4B6W*%CPT>$S)-66UC=G>!DY\8*B)C9F)T=W2&*R0S5UQ5:FME>G.&B(
MF!$``0,#`P$&!0(&`0(%!`,``0`"`Q$$!2$Q$D%187$B$P:!D<$R%*'1\+%"
M(Q4'4N$S\6+"0Q9R@I*BTB0T_]H`#`,!``(1`Q$`/P#[)<>\\Y*H7D9S/S'M
MM[L$CQ.YC<XLN^.<\-*3+A;'V+K/Q=H%3IO'3)D`V66.PAFF1LOXXR;595PB
M5-%W)SD.*AC'#H15OCGY.<L\E8PH&,..<;C=_FCD#7,R>3/-^6>33W(%HH&,
ML4\M^2^95>*^,:I2J1-PMGG;)<Z/5#B@D,K$Q=?@X(RX%>J.F[<Q$]E(\H/+
M+DL]XBXJXNX.P4SSGG+#G+R_9QD,K76[3&(,#/>*^=XGC0>S1LC2XR.M&1:1
MD++3*92@VQ$8][(,RMU#KM"I.U"$2-K_`)1>=URC..^1:9@GC%.8\Y.<Y\R<
M,,+U=U<\E1-XR+`8_<YR9MN2YK$@SFH2C8YK#;!LC+2<2:,G)&6B"B=JLS5.
MW36(EXAY1<XUS`N=I+)!^(=:S)BWG[:N#M:R#8;;>:%@ZY)5*KU6V6S(U;QH
M[?W#,^0;'1C3,A"KTZONW;^4E(E58CQBQ*Y6:$6/ETYUY-YM<;4,%R:];96^
MW^6[C7P56ROA!AE#'-9R=0:RIBOEUEZS56GY+,VR=C]RRPW7YN`F8]V\?I@L
M@JHB[6;N"%*19G>8;*5WKB?C_P`/8SIF4,GV_,'/7$]HG,78:E:U#Y$O.).,
ML#;>261HF)?7&[8ZJQ(U=WCJ(;R))":8-5V+I1$QSF4(BJ18IYSYVY"M7-[$
MMHR-QSY#<5:+P!X0\X_(-D^FYHL^'2IY1;L*G!89QF@DUP?F;*T8[9QQIJV*
MIHRZC147B:2K9)04A.4BS@L'D(R)CIEP;;Y.Q_3(6Q9HX>YTYA\K&3)]-@WP
MM2<"X-HESM;>K%<+*KK)FRODZ)A2+2(G`6:;@P`*H!VD6,>'/(%Y+<J7/AMC
MU]@[B13[=S7X=W#E"RB'MARU(K<7H*D'PT8;CE[V5FH9&B[P?+K=@PJ\3^!O
M8Z4*";F9523753(J2"\N65[MQ=X29"1D>(^&,M<H:WE>X6AYDN4RA?HEG5,:
M7E_1*S9\/\<<:+IYVR-!9D400E&KU>081E:8*@D[>/7:K=%8B4^"O*)R9Y8Q
MG!2K8#P]A=MDOE'A;ECE_*UENLWD!QC'$5+XZY<KV#:CE&!B&S&O7JTUG,=S
ME_K(>`>EB93Z-8B+AXU.@X<`1?0CQZ<GKARWXB8_Y`Y'@*G5K+/3F7:Y+FI+
MJ4/0IY'%&8+]BM"_T_\`B!9>;CZC?F-()-L6[U9=PU:/B)G66[/>.1?`/A=S
M0R9Q5H6;>5F:+C9+'B#R.X1YW^1?!)+7)N7L9CC*6`+AE*XL\/54':ZA(R`R
M=P_"F3T.Q*)4Q<U>7%$H]XB)%?,5^27)O$?#^*^$U-M6%&&6^(W$#CS8^15N
MY8)9\N<YF7DIF'$[#,TOA?'7]4T7*.()X@VG$W,O:9EV_P#P]Q/,6S>$>`FN
M<A%];L'>1U;,E]NCI]CL,<X:Q;X[>./-+++JW*2+;(6.KSR)8Y+NS+$E@:JI
MLXQN>DXQQHX>R1U$$W'U#I'8"I[@)%B/0O)]S-RZZQ['U/$?'"A1E?\`'?@#
MR`\N<E9)F<F/:M@J&S3/W*QML5058K)BSUJO#S"^/Y1^U*Y=L&[-VB9=RH=,
MJ3-P1.]CWG]RX3><)<T9NQ+@ZG\9.?\`DR(QWC"@5V9NKKDEAAADG%=XS#A:
MY93FW[A7'%Q-.U&B*?Q5$1;&+&IK/R"F_E4VBYS$2`P!Y+N7^3P\=&4KQAS`
M]7POY!LN9%Q]2Z!"3-^D<XQ^-HO'V<,P4'D*O-/54*1&5MWC;%T<ZDZ^=D\<
M%2F$W!9-!0WT"9$G\=>7O(]RY1\?L>M7'%7(>->1_):[\?Z_0<(R^5L@9(H-
M<KU/R?;X7+\SR*9,%>-&0@/&8Q.YFJU"%35BD)$"-Y2049..\BS$\1,W-9'X
MHV/D5.RTQ*K<K>3O*GD1`$EY!\_+%8XMN<;C7\.Q,0#Y=?Z&#;8>J,"=N@CV
MHE*H)BE`3FT1?4/1$:(C1$WN6\B0V(,4Y-RS8E"I5_%^/;ID2=5.;M(G#4FM
MR5EDU#F$2@4I&48<1'<-@T1<_2L^0'FMBK\O[<*)-<2.72%^YNVFT*UKFS.7
MFEAC22L7*[,9@KB5-VOKS+3%N[QZ/X9&D0C4NQX'OD!-`X'T1;",AY1;?Q"A
MO)1A>.H]2N&*?#7P6XU-4\@S\W9W%CRCR5N6)2.JO1++,*O5VRL2\6C6:#Y9
M,#28NW)C'5,8X;$5NS#Y;^=,7DS%>!<,X#XQNLIH^*5'R+\JK)EVX9/KN-L`
M2"K15=6K)_PPQF[!8&23R,7:(L#@@[<F=(KG>-D$%S"1(WB9YK>:F9<R>+-C
MFGC1QRQ=A7R.8@SKD0R,'DR_2V7,<0&`<?JV^=SA9%9J!BL>U;$]U<>T>&B5
M7,I))QRGO.9`BG[H2*R8`\]N9<M^0/C?QM+"<)\G8CY294R]CNM1O&;)^8<I
M93Q7!8VK,S9V60[AEUY1(;CGDF,>L(D%'["KN55HY)7<ZPF*!3D2'B//#SRL
MV.<0\IJ_Q8XQFXFYA\EZ7!3&/UN2LD&SIG.M6+)$U1JU=L;5]G#K4RON8@E8
MD`?N9)^[(]?(*$08(((^^L1?5'S?\L,S\4>$[0W'*::U'/G)//6%N(N)<A/F
MC=^SQG:<[6):'7R`HS=IJM5G==KL:^.R%4IDTGYT%3%.4@D,1?$:>P#Q$X$>
M0GB/BG%7*GRHXYYLS'(C$%$R%R"R;2<PYZX\<YG60(Z'F+CBN[S%QM]3Q6J:
M693I%7<C"*+?PH":YS-W+EL19`B;6U<@YG*<MY$;1,M;;E6$\C'G4X\^+G#-
M,)F#*.-F41CGCBE',I^^TB>Q[8X:?JL"5W&G<R(L%FC:1.02N_=2,<AB+/'*
M_FUYCP6,N5?.#`_%_CU.^,_A%GM[Q^M\CD7*%ZA>3N>6]'O%9QK?K_A*/C(1
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M89A;ZP$DK7*T\M*`KSA&8^X^8.!*82F1(($4BJ8SQ]X4L?\`._(V`^:M.R)@
MV`C,9M:%PLY6\C&3"J<;,[SJ:;8!D^0-QMEWO57B\GQ;HTDE5E8,9"2%H'TJ
MBRARG(18BTK\Q3G!CQY\GF0K[C_C%E.U\%*!QULN/\@\?%L^0V%LE7;DM925
M"H8OEZ[FVNU#)_XW$S#A-47;$"H2K,BBC<B9`344(LKJAY@^6.&N3V8\1\_^
M/^!L<4;%OC*EO)#9R8`O=]OE_P`0PE<GT:TZQ-DQU<8*MUFQWVR2:#DC-"%2
M3;-E_92!R](8[@I$O,$>23R+IX\C^9G+_ASA#'WC[NO%7)/+-K<<09>D[!F[
MCY3:E2#9*HM9S=5[XC6&=_M&5JD"9&1:BR]F-=KE!^*!2*`!%B!PC_,0Y+S]
MGC%4%EW'G&9'"O('"^?,RP#7`M[RK;<O<5F>$<;2V86U=Y9N[A2X*@'D+Q1(
M)T1JM7S$1;R"9DU>A=A(K43S0^7<WC*<>4\_`7C$G@E.E,[2VIH9<ORF5W=7
M6R`^BWV:U*W]$G%L\61]9;MT"1WUZTZY.Y--_N8Y#Z5<B^U1O%S@1UX\IKQQ
M2EIRC*8QGFEL=N\I+SD"WS:AD"VY2E\U+9:C[2RK+>#9Y$A\GRXRS%V6,]E)
M5%,IDCI@8IB*WSGC'J<6\H<IQ\Y&<A.*DU5^,6->'-KFL-.L5NG^2,!XA0E$
M<;1DP7)6,+ZRK&0*+_$,K^$6B!1C)9B65<E`YR_3@@1.G@+Q]X%XRW4MRPV2
MS5?\)XN8SXDTBOFDF<C$T/&F-+;D6^)RD,Z?QR\_*7B[7')#F2L$I*O7ZLF\
M:-U3@"@+&6(K-BCQT84P_'\#HBMS^0'D7X^:ED"NXC92\G!KHVN;R1C\,<6'
M(&2`:U]G^+W3\$?2RB2S'\.;E=3;PYD3`9,J9$VBOBPQY!QF(9+%&=,VXDS#
MA?.G*+/=8SG"(XGMMQE;+S'M=HL^>8>UUO(V,[;CB=A9XME*SCSFAB/XM",9
M^RYW(O\`4$5WPIXML+83N&*[LQR7F^_3>*N27([E@T>9*LU7L3VXYHY,8^>X
MSM]FO<@SIL0[FE*W5YF02A/9,U,R!\8AA413023(LIKQQGI&0>2V!>4%AEK,
MI<..=)S53<>5I!U&DIJ:^=24)G;K9*,E(M66<V=C"4)./8*IO$44&D@\*=)0
MRI3$(F,SSXY<(<CK'RSLV2I[(KA]R]XL5#B#<"1$Y$QI*)BJGR^3;&@IC=3\
M!7<1D],V7*+I\_._/(M'"K)J06X)%536(F=L/B<I&1BYLFLT<F>2N7,CY[X=
MS?"&Y9%G)+%=<=P6&+18%)VU(XZIU'Q?6L?4>8LI`0;/U6\6<CPC5-5P55</
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MW`RXKWR*Q'Q[C\,16.[!5IB'C,@-([#5>:TI-D]F7$`^BW+7(E`-(05D3!B0
MDA&S#PA`1,<ATR*XY:\<5>R/D_,EZJ/)#D?@:J<FR4@.4&+,+6&C5N!S*YQ_
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M%FN9["]8QJJQ"E%9T[7<$3ZAX]L$G-Q(9.E[>\JO#/`&1>.V*J8>58-H)[5,
MEXQI6')F?LRD?%,Y=>W1^.:>I&LG3)RQ303F'YO:,91,4B+'?'GB.JE)<\;5
M)GEIRHO\;PZI&1L9<8*[8'^&86O8KHM]PC/X#9(&CJ1A^KFNESI-%G0)%V.:
M4>RR9VI"G4,DN]3=$7T3X^82IO&K!&&^/.._Q`:+@_&%&Q34E9A5JXF74!0J
MW'5F,?33EDT8,W,R_;1I5W:J2"*:CA0YBID`0*!$\&B(T1&B)A.4O'ZO<KN.
M6:^--NL]NIM3SKC>TXNM%EH;J*8W"+KEQC%X:=/`.YR)G8EN_<1;I5$#+LW"
M8%4'Y!Z:(L4<K^+;C[EO`?!OC/,3^1H3$'`S)G'C)^-ZU79*M-"7N1XSUQ2M
MX^@<H'=U=\27KCI)07$DC'DC57+D-RJ)EW)HBQ!Y$?E^>-?)'(/*ZT6KD7RY
MJM`YE9-Q;F'-F":-?:'%XILE_P`6+11HV0D&DIC6:LTQ#R+>+$AXMY)+Q[=5
MP9=%(BZ#%1F19293\4>#LKW[GEDF5R'F""LW/SC93.*=]6KDK36C?%F(Z?6)
M2KJ1F'4G=+>GA7=F;2ZJ\B:3/+(F<[&222*`D$BMIO$!Q:<W3$5GE)+)$G`8
M3\?-D\;](QVI-P+*HM,+7&%0J]JMAS1=:96%#*,W541CE9!L^;M`;G$2M`4V
M.!$P''7P-X7X\7[C_DA#EES*RC/\6\,YAP%@2/R==\9R=6Q=C3+=-7HQH^GU
MV#Q3`-8::JD,X,9K(IF^J>K`F5^9RW0;(($3QT;PT\9:#B'QS8/B+AEMQC_Q
MI9;5SCB.,?RM-.?(>215L[]E8,M';4EJE*K1<[;WT@@$22($'*OS"9/<@D68
MG-3AEA'GQQ\MG&W/T;.N:19GD'.,)NHS2E:O%(N-6DD9BJ7FBV1%%R>#M5<D
MT"J-UA261.0QT5TE4%54CD6!^#?"[0,>9VQ+R,SOS-YW<W,B<?7LM*X$9\I\
MWLK51<5STQ`NJT[MT12ZO4ZG'2]S4AW0IJ2$B9T*IR$4.F*B:9B$5QPYX3N,
M6&&G"=E$W_-EE0X09WSYR4IX6J<I;LV4LPY_5DEIBUY=_#Z+&EEW-+/)F_`O
MPL(H[?VR>^9QL;N(FVFO`'Q8G[Y:B2>:>4RW%2\\A%^5%QX#!DB!)Q4L>:W<
MRA9'LG(PA::%_/27UE:IR2M;+/%BC/4R&`@)D(D!$Y64O"GQLR]C#G'BNVY*
MSF>&\@?)BE\E,\RK*=I",X9QC^;J,U6,2UAVK0UT66*6`TYNW!J[3>R(-EEB
ME>%[BB0B5V<_#SQ?Y$W?G!><FSV4Y!WSIP!BOC?=8N-G:]%Q>+<?8A,G(UC^
MJ#V*L+^&D'%I:-9AZ637EF3AZT('TY4#*(J$7GASXEL<<1.1JW*YSR.Y.\CL
MUN^-$/Q76L/(2U46QLH[&D!;HFVPS6JQE5Q[3R5(K!2$;M@:LU"LEB^ZX725
M?.%W2A$JN=/BZQ7S<R-AS/+;,O(/BUR9P-'6.NXZY$<8KRPH^0T*3;@'^(Z#
M80F8*R0ECJ,@H=10&Z[4%$5%E@(H":ZZ:A%CA+^`WB(\XON^/L7D7D5%Y$E.
M2U$YCV'F"^R#$VSE-<.36.%I$U5RA<[I:ZM+5RQ*Q;69>H(1JD06-;%=*K(H
MINU#N#D5"CX#>-;FL9JK=QS_`,KLFK\B>3O'+E1FFV9(N^/K+<\@W'C8DJ:L
M5">G`QBR*KCNPR"OU#V.313,T`I$(Q5@V331(19;V_Q?\<<D9SYJ9SR8YO-]
MD><_'>H\7,HTV:EXI"I57$-6@Y2&<P^.!BH./LL"^LSF5-(OG#B0>F)(HIJM
M@;]HE$B93C7X7L!X+89$CLF9LY/<OV=ZXTK\,XZ.Y,Y+8S\%0>*Z[`\4MB.G
M5RC5NB0;=-['B1-S,ND',R?VP%)PCWK`J1)/''A(Q_0L5Y4PS*\V>>^2<>W;
MC!=.'6-ZS>\T5YS7L`X(O$2K7Y&*QW5H.A0E4GK?&UU0(V/G+.QG7C"/2210
M]L";B19^_P!B_#G]AS_J_?8F?ZB?[,G]E+_;HS^)OZNOZM?ZK_Q'ZO\`"OP?
M^*?P7_=/U'T7L?7?O/9[?DT19:Z(C1$:(C1$:(D_:YF,K]:G)F8LL33HYA&.
MUG-JG7+!G#U\!2,FE*R#B4<-8XC9FL<IQ!90B9MNT1`!T1:K?'CCG"X&S)QD
MQ3S!IO(WB_Y"7V<(-:G^3.EY7N.:<&^0BSPDG(W&ZXTM]ID+BY;T]WR#Q]"R
MZ(8ZO-<BVL2D4Q:XJNHS;#HBK\3^3;DOAC'Z-RR5D3$MMO7D6YI<L)_CO:;%
M0^0-UQAQSXP<7;`XQ!9KC.T3'UAM]ZM-5F4*17C4^MPQ:ZBYEK8L[DI8@'65
MT19<4WRG<H<@T7!]-Q]B;%5RY#Y8\@%FXAP=JFZOFW$.$,DX;I.!)CD3<.4=
M*J-_;%RK6:]7:85K'O(QPK,IEL#9VT;OG29T'`$27A?)=SV;0,7<['3>*$W4
M:UY28/QNNEJO`99BY[DZM)9WC,/6K).((V1R+,L,&HXR(O*G<-YAY>2S+FM2
M!BGCVPH'.19V^4;)N4J[CKCC@7#M[F,2W'FURWQ?Q1?9AK*B3:XXKQ[9*SD#
M)V5K307[E-9K$Y$?8WQ5)P\"^.F<T?*2B+I(/>03$")EKEPQX5^.J<J/++%V
M2KEQG<X4IF9LBYFJB.5[GD*2YCXBQ_B6U6K(%:O]9ROD27=9(NM34:-[,ULA
M2N9Z/<,A(9<K9VML1,AQ&\NF9,TYBX^1^0Z]BMUC?D57LA6&STK&^'^45<O7
M#!G7<73^8ZHZS;F?*$%'XFRO'/X"LKP,VXB8RL$CK*Y;E8_B;,3K`18.\2<S
M\DBL<>9\I-`O/('*N*/&5RR\DK7";"R3JKO(V9?)ORMG+Y@.G/F2:KMR]_A7
M".(Y)I$QB#=1RFR6]J/3!5<@*$7VP\;/,/)_+N/RA-66^<;,P4.IK5>,ALA8
M*K&4\+W.K9#71E?ZQ\(9XXR9NL-OR?B6]X_,W8.6[E_()!,,9,I@8M11$5B+
MZA:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(M%WR5XX(7EER_Y:\UW'*_
M+G":\KTV`X=>1+@-R+L-OJ?C9E*S%-JA/ML@<?\`&5Z@4&YH/)JB:TQ)K%?$
M7<%$B1#2#PY6Y%F9DOF%SFQ_Y/<#XJ;<C\>91X1\`/&^VYZ<FL@"6Y0MQY%8
MS4H!J-:+QD.&K1&5?F,URJK5_8J77B/`JQ2N2/WQSNR(IHD53PD_,*9PS_GC
M"*>5,;\=_P"SOR-H6=K^A#X50Y`O\S\1(?$V-K%ENLN.35WOU6A\.6MG?ZE6
M5D"+5H&Z31X?N,8Q"`54BL.#_-;Y8\NR?C*.GQ8X3(!Y/F'(8<18]4N^;8F[
MU&OX@:*R['.V1)HB%DAH#&36OO&[]>'9LY64EVK8XH/&2SQ%!J1?93P^<W<W
M<]>,=^ROGNI8MKERH7)K.6!&4YA8+8AC+)4!B*=8P+?(U2C[M*3EDC(N9E%'
MC8J3EXN<PLA5_=^Y[*9%\?./'&BG^:RZ>0_E_P`^,T9EB\+8-Y49SXM\7<14
MC/ETPKC/CE0^.[-BWF,WSJ%-FZRP>Y-FG<E^)O'LVJZ9MR-C>^FJT%NDV(I^
M7/*/DWQT07#WQU85Y68!Y:97<\;)C/,[S[Y>MLL6;%=@PR:[6&L8>A$&/&5U
MD>VY'OUJ4C%(M.;&7^D!G&$>.5'3AP<I2),2?D%N7/G//@CO=YK%FX^1L!CW
MFQY`^6.,VTK9(I&#C^+,/9L75%PY:OB0\F]HUBR169!['DDDS%%@Z1*K[IP,
M82+'+CGY*>5_`KQA\),SK0559*>1/-O+CDCF_EWR?JW(?+_'_C8VLE^D7.*Z
MI:H#`R$ED-NIDV";,"12@+LHR/1266[%R%7%`BVR^!^;\D<C^*6(\U97/@-W
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M0FYR$<.[MFK):V:Y&:LF2UFE:9$GB1\_GJ;DV*;4C`R+Y-H<QU"H"0Y$]7*C
MBSC+E[BPN+<FN+?!IQ-OJ>2*#?\`'%E<TS)V*,I4*3+,T?)N-;<T2<*5^XU>
M1*)D%3HN&RZ*JK=R@NV661.18UT_QD8E4EK_`&ODEE;.?-B]Y`PS>N.ZMNY*
MV&F+!2\)Y0C2Q&3*+C2G8@H>)L?44V2(Y!!*?F6<26P2J;9%)9^*"1$2D5#6
M/&556%:MU;R#REY=9J+)\<[SQ6QU)9'R%247&%,1Y!KZ59L*U&C:)C:E5RQY
M0<Q3-FF-QMK&R6,Q6*11==AW17!%!_XJ..ZD#D2(KUOS7192Z17#^+JUQI-Y
MCX2TX;_L+P81/'EQB]U_#;B-03@':SQ^_93369C)1U).RKMC-UA0`BR!XT<2
M:WQRG\R9#=9'R/FO-'(.=J$[F',>4QHK.SVS^KVJH4JA0K:NXMI&-\=5N`J-
M<2.BV0CX9NJJHNJJX574.!BD666B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T
M1&B+X'VO\N_Q$LD_D.'CL^<X:-Q>R]DJ1RUE;@G0^13NO<1[U;YJ<:66=))4
M1.M+6=C79Z;8(.'4>SFFZ7<@D5$42(H%2(LM'/BAX[+<O\G<MV]IRS'I9OX[
MQ_&'-''%E8*VGQQR9BN%HSS'5?B)RHFJ1K4P2@JL],FW0CIMFS*N`+>SWB?O
M(F/Q?X.L'8PH&1L5$Y6<\[OC:T<=,C<4L946]\A$)>I<<\)Y0AG-=L-?P_66
M=,C(%>68UYR#",DK.VL;N,9H(IH&)[13:(LAJ%XM..F-<I\2LLU2;R<RFN$_
M$>5X=X%A5)ZNJUN!I,W$14#*WZ09A4R/WF57L/$)MU9!)RW8J$.<3,C&$HE(
MGRX.\,\3<`.,N/.*N$W=NE:!CI6V/&<[?I2/G+O89:[7&>O-BF[1,14/`1\C
M*/)NQ+_.DS0*5$J9.WY=Q(OF]F+\OYQ*RUE;.%WCLW\S\,XLY27!>_\`*+BI
M@WD`[Q[QMS];Y$Y5;',7NFM*Z[GTCW)4!-+IQTLR([[A`H)!L`$3X\A?#OQP
MS)8</W/%&1N0?"2\87P7_9:KMOX8Y!B<42\KQE*X3>M,'SR<Q5+E&K5&&D""
M[CEFR#:38O#BLFY]PI!(1>I[PZ<9)VR76U&O/()O,V_QY2/C/92+K)B%HF*;
MQ^G9:1FK+/UJS7>NV>UN,MV9_**F>SDJ^D@5`0*#<H!MHB3U]\-&()FO8-@<
M.\G^:G%@<'<:*SQ%:NL`9D@HB/R)@ZK1A(QC#9&I5XH5ZQW(V98/<75FX^'C
M9([A83"H()H%2(OH!Q4XP8?X8<>L6\8,"0+JN8GQ!7C5ZIQLA(N)>44*ZDGT
MY,R\S*N=E9";L-AE7<@]5`J9#NG*@D33)VD*19!Z(C1$:(C1$:(C1%J?_F]\
MZ9MP'P"X_P!IP5F'*&%[/*\NJU`RECQ1?;1CV=DH);$677ZT*_EJG*13YW%*
MOF""QFZBADC*HIG$O<0HAJE)`_CL6J4D!<[K_K)?(T;HGSVYF#__`&<S-O\`
M?ZW+;4<2=M?U_=13,&_<?U/[JH#R5>1,``!YZ\RMP#8?\YK,W_'+6DE]=S\S
M^ZT'U2:@FGB?W43>2CR)&VVYZ\R_3K_G-9F]?^&>G-XZGYG]UB'RMT<3\S^Z
MHS^2GR+%'8>>W,S81'J')O,_P^[^,M;VN)'7YG]U*:\D`Z_,J)?)9Y$_CSVY
MF?\`?<F\S?\`',=>$O\`X)1Q>=B?F?W7H?)9Y$P`!_MZ\RQ`1VZ<FLS??_YY
M_=KP%Y-*GYG]UCY_^1^9_=0'R6>1,>G]O;F8'WAR;S-M_P#C/2K]]?F?W7HY
MC6I^9_=1_P"LG\BO^GOS-_\`]-YF_P".6G-W\$_NO>;OXJIH^2GR([`']O;F
M6`B'^DWF?<?O_P#++6/.3?6GB?W6D.F!KJ1XG]U(5\D_D5`2=O/CF;N(C_[S
MF9]OAZ[7/6;'N-:_7]UN9(\UY#]3^ZJD_))Y%?;`3<]>9AA$!_9Y-YGWWW'_
M`,\PU@7NKH33Q/[J,^9PDH"0*]I_=4JGDG\BY`Z\].9_J'7^TYF<`]/M"Y[Z
MS;(7;'^:D-EY;']2O9?)9Y$B_P#O[<RS?IY-YF_XY:\)>>W]?W7C@]VQ(^)_
M=5@>27R)K$$"<]N90F'^B')O,W<`!U$?_++TVUI]1[75-:>)_=1^<K#5U>([
MS^ZMRWDF\BZ8@']OGF:/J'3DWF</38/A=.NI#)"[_P`2I,<Q>*_4J4'DI\BV
MX;\^>9P!OZ_VG,S]/_OGK/D?XK^ZVAYKK]?W6VM^4)Y>\H.0//#D'3LZ<DL\
MYG@(;B+.V&+@,JY=OV082/F$<R8CC4YIC%VN>E6#25292:R`.$R%6!%<Y.[M
M,(#I@CE%R9"28RTZ5-*U;T^:CV\4PO'2ESC$6D4)-*U;T)\5T.-3UTD:(C1$
M:(C1$:(C1%SP_P`RMRVY.X0\F<[!XHY(9_QW5H7".%)MO0,>Y?R)1ZFX=R?\
M7%E9`8BKV&-C"OG0H)F44,B85!3+W@<`V#YG[ON\@,NW'VT[H()[5PYAQ!:Z
MNE`"-=]=#WKY![ZO<H,ZS%VMP^VM+BT<#(UY!:^OE+0"-=]10]X7Q:<>4CEE
MD6EM`KW,+E+5+8S=(N)5BIR"RCV`R25!!XHD_"S)E<D*F;W!*(%,F3<1WVW#
MY)#C_>OMK,/9DK^[O,5("&/$L@\Q'E!:7GB2=!2H)7PVWQ/^Q/:/N&5N7R=_
M?X*5I$3Q/+7E2K0YI>2TDZ`BH)3))^4'G^E:'+0>7_)><:L6;@6<LQY`YH;M
M"M@1%=95ZV/;R(N#E`O:)Q*(AML0>H:ODEC?G&-D;D+Z"5[QR8Z6KJ[`-=6H
M'=6G:OIDF-R1PK)H\KDK:>60<XWS\G<M@&.W`[JT)W25LGD7YVR[89S^W/S&
MKBB[H&Y&C#D3F`S90"D'8Y6:5O(+=$`_I`(CMZ@(]==C'7F8M9#9>HZYA#:\
MG/(<#WN)U/:-EV<+?Y^PE.',LEWQ;SY/D(<.XO)U/=LJHGD+Y]QL:T!7G?RW
M?OQ;++M4AY&9C2[FZQR^TJL=:W=SDWN`.Q0`1`.F^VVHKLGD+F=Q:Z=EJ7<2
M>9T<-Z4.@6K_`"N4OKE_%\\5G7BX^H?*X;@4.GBJ:3\D_D;.V!)OS/Y='<+I
M$*DX3S_EHB*1!*(%`PH6G=50/41W#;X[ZD6A#9*ONYN`-2#,XD]>KELLGM;-
MSFOKC@TGR^N\D_`N_=**+YF^2Q!@QEK%SYY1-H=X8!.0G([,JS\$P[3"*16M
ML`/<W';81V`0ZAMMKFW7O*RDN7VN-_-?>-!`\]&UZ5+CM\*KD7O^P+">YELL
M/_D),A'H/.6L)Z5+C2GPK39+MYY'\[QE=*6%\A/."1O":I4S-I+..:PC2+[@
M"@*IK6U$GTI3#\H@<3C]FVJ_!)_MB[R).1BBBP%*\F7`]3CW$$GEW4HJO:2_
M[MO<J796*&#VS2O**[!EX]"*$GEW4IWI0M/)-S[95)606YT<C0>M#`"<6ZR_
MDYPJZ2/V%*8KI*TKJ;%`WJ8W3U'KKDS.O9\U^/'+DOQG?UB\E`!UTX\@/D/!
M<>9V3N/<!M89\O\`AO\`_=;?RM`.NG`N`KX#P33!Y"/([9Y$P-.:/+!)-0"G
M34:<C<I-T022[1,HFV:6DP[;A\PF'8-^HZNO^2CQ%J/7N[GF!J'2/<>ZI+OE
M3=7[_,-PME6>]NBYNX=)(YQ/>YSM?AOWI93'-SGC4:F2S2W/GE2]DG3HZ2<`
MAR6RRL\:DW`#*.$26X`2.("(EZCUV'7"L_=66S.:_P`79?E,M6C68EP:3V`D
MZ_\`BJ[CO>N<]P9HXFP-Y'8M%73DO#2>E'$[=NW5,<GY'/(PNYDEF7-'F'])
M(H+),_?Y'9?3(S."I1*X:`I;!,L(%*)1[0V$=?07SEL,44UU)^1&\<J/=YM"
M*.(*^FNNG,BACNKU_P"3$X%W&1WGTV=1U*=>U3(GR7<^HCV"R/.;EXZ<-S@8
MR2O(G+*I14W$>U4O\6F]PA-@`2F'J.M%\R_NP?QI9F,<-Q([;NU%/$+7D692
M]#FVDT\<;V[B5XT[O-H>\)[6?D9Y\V4L817F-R^3D7I_<3.EG/*<,15,4Q`I
M4&:EO3!P7Y0-[A1[?7IJC7$^1Q)D:+Z4V[=ZSR34UZO!-/!?.+FXRN&?,&Y&
M<VL=-#=2S$:[EX<:'I3HD;:N?_D":NF\8WYR\O&CAPNF11(.1F3E3&4$>S8%
MV]U,=L7IU#M^`B.NQB,S<RPNNI9IGQM:2#SD`^1W\:E6+!YR\G@??.N+B5L<
M9/\`W)0*=2`[1Q2BG.5WDCHWX;/S?/CE:9L\;-G;5@;DKEQVU436+[R:!P"X
M`)U5.[YB]#``:Y]E_L2'W`9<;9_DME8XM<\%P((T)%-J+B8S_:]K[H;-BL9^
M8)8GN:^3DYCFD:$C7IT.J?[BGSIYR9!YM<+F!^9/)M2L3/*?CO$7.L2/(G*4
ME"62&D,NTUA,0SV$=6Q9H]B9)@LHBX;*E42725,4Y1*(E'O>U\O>6THL\K-<
M7$CI0&$DT`)TJ>I[:Z45E]EYO(V-P+#-7%U=223`,<XOT!.G(UU[P12G:NME
MKZ\OO2-$1HBT[OSIP`/CEXX;_P"F?5O\C&:-:)_M'C]"HUR2&"G;]"N9T(F*
M/R[A^C4,=^ZAMXN'GI52#&,`]=MO43=H]/Y];``1WK<`%-(H)?F[=_B'QW^_
M;6)&NBU/CY]5[.J"@!L'S`'V[[".WP]?AKRA&^R\:QS=W>5>4T3JFVVWVZ]"
MCT^_U'7CGM:*KU\K(Q4D?-5!D"I!NH(=0'M`/41W^P?36`>7'0&BTB1TCO[=
M:*V'$H[`4-O41'^]^K4IH/53-4$$/0>GK\V^VW37C@=T*F>V<![R`)_CZ"/K
M^CUUYR:?*=%YR`\IT*K&[1PKN8S<_878W>)!``#X[;_'6F26-FC7#EV54::>
M-AXAXY]E5+.*RJX@0I_W6V^VX@4@"!1$>G0-Q]=;2VC`YXT<-%G1HBY/I4CY
MKVKW`&QA^(?W!UJ:`"L(:5J.Q41DA]2@(A_*.^MP>.NZD<@-"=5Z)[J0@<O<
M`@.X;"(#OZ?#KH2Q^A7AXO'&H5:D<K@.U4.PV_RFV$=]_AZAUUJ?_;^W4*,Y
MIB-6'14KHJB1^TQ1(`@/;T``.7T`VVMD9:YM10G^2DQD/:"-2MPS\E1_VC_)
M?_H367_+I@_4J/\`?Z*7%M\_HNF?K:MR-$1HB-$1HB-$1HBYG/YIFS?A'EFM
M47](DZ2EN-^#4G8+%2.4C81NX&.F*@;HK%VZ'#TU\L]\XK\S(P7@>YLD+:MI
M74]]-QW+XQ_L7#B]S%MD.;FR6[:M`KJ:['M'<M96GQD2E:T%6\RO%HLW2@R$
M<FBLY(]15`R)R-':H(('!PF82""@`(`(@`FU"S-S>?X<QO@$AD:.+M/(0="Y
MNI!&X7*]P7UZ[!%C[?U9)&CTWU#>!!K4M!+A2E1T\%%J\_A1Y--"B1P$NH5)
M!-ZV7>K'CE3*"1DBV$H&`Q0[=P'8"F(`;ZUSPC,P0S`EKH6CDYI#0'`"KB:]
M?!:YK=N<M[>X!<R2W8"2QP:WF`*N>>ORV3I,<7S2L`I8'E0>N8-I%('^H?`+
M5\P3<]JPR'T"ITE#@7O*/R@<A4P`-5&?W59MR/\`C+>^C9?F4T:VCF/IIPY@
M$`G7<@U5'O?>]DW+?XB'(1,RKYB.+0'-D(-.'J`$`GOXFJ:B:CEIR7!TS78K
M),2IE:N"N"-O>0:&!%5HU0.!>]5`Q>\2@`]P`(ZN%I<0V%H891("_4CB7:GJ
M7=AZ*^6-U#C<<8)1(UTNI'$NH3U+NP[!+".GW3!)R9[`&G&T<F?V2"90K$IT
MBE,8RP-@*C[8&V[OMZEV]1UP;G&PW4C1!/Z$\AZ!O(^%=:T5:NL1!>2,;;W8
MMI9=20&E_8./(U&G7XJV7#)UJM,,U8IM8FOQ95P3,5BT1,4QOE$@%^I*90A"
M`H`B4HB7TW#4S"^TL1A[E]TYT]S=$5J\D>.@T/BIOMOV5@L%>R73WW%U?.:3
M_<<ZG?6FE>S2JL,.=JZD"-DHXLF]C4$1=2,BU;I"HN0P&,"9^\B8-P$P=AS[
M&#;X!TUTKZ.>&U,SI/1MY2>+&.)H.RFIKV@+L9%D]M:&5\_H03$\8V.<:#H*
M"IKO4"B6LC8UF0`FK"E6;?2J"HZ!-L+!82*"4J:KE-94/4_:()]Q]QW'7!M<
M1%-1[9Z2\J\:D/'?0@?KIT5:M<+%<4D%SQD+M&U<)!W\2`1\=$GXM]$H&43K
MK%\%H=B064&I^]3(=<.U90J[4$"`0`ZE$R1#`3U^W74NHKIY$F5='_B6`\I0
M`#Y=O*>O@XU*Z^0MKV5PGS$D?^#C;YYZ`$TV'$UU[1R-3T2]'&=UB$?Q":?P
M,ZX^E2%*L1*J;Y)@5T(`"\BLJ@FBHH@EN;L3,=03`'7U'5;;[IP-Z_\`$Q[+
MB"($UGD'IEQ'1HK6A--2``%56>]?;-^_\/'1W5K"":W,K?3]0MZ,`)=Q=M5P
M`W*5L!@&:=-RW:Y7IA"UXBJB3=@)R$<)-0`O:@HFJ*;5F@;<0[0,8=@'[]<;
M(?[(LH91@<%823Y(`5?KQ+MJ@BI<>^@"KV6_VUC(IC[:]M8V6XR]`3)0\2^M
M*\A5Q(KN0`F;4N2-;D9:O59.%?5HLR*C68<5ULWDG!"#\ZC5VJ#CM3#?;O,!
M@,(`.^KS_@SD;>+(Y%\[,EZ0K&)7&,=G)HI\E]('MZ3+6D&4R[KF/,&`!T39
MW.C!I_4T4J>T=%;INT6QN^5F17>RB1Q%)B"CI)0$.PQ3$2%5=85!$A!W#L3(
MEUWV'4NTQ>'F@;8M#(7-U.AU^`%-3VFJF8_"8"6W&.`C@E;J[RD$_`-IJ>UU
M4USYL[?29)9NE-HN5ERKF!(6+LZ3KOW,0AR.$Q#<_P"SN7T'TU:X)X(;3\-_
MHN@8TM%>310__;JKK:36MI8FPE_'?"UA;4AS00>M*:_-7[(V1K;8FM7BW@2J
MK"HQI&:!G_SE4.3<5`.N5%,JIS`;8VPB`!T+TZC!]L>W,3B9+FZ@,(N+J0NJ
MP`_=TH:FGC\5S/:'M'`86:\OK8P-NKZ9SCPIL[L%30=E0GI\>=@4)S]X-))L
M@3.YYE<82&.HY<*$1!3-M'`XH)=Q0`QB=/G$X``^FK;'8,?*USWZ--:!K16G
M::;>%%?(<7&Z9CC)5K#71K021M4TK3PHNWKKMJQHT1&B+3P_.F@(^.;CAM_I
MGU;_`",9H^W6BX^T>/T*BW1HP>/T*YGX&[>@@`_R#_KZ@&O1<PCEJ%+.<AO1
M/X?W]_0.FMFJWALHU+EY`A3`8>[VQ*&X`)1-WC_@[[@!?TZ5`WW67,MT=JIZ
M3?O]`ZAUW#Y0_6(AL(ZUN?31:'RN)XC8J)E01Z%ZCZ=-O4/O';1K>?W;+QL)
MDU=HJ,ZJZQP+VF.._P`H=O7[=@[0VUN:QH"D1L9"*MH#_':I1VZI.@E$!^ST
M'^360D:5FV5KME[*T5$0]`'[_P"_ZZQ=*T;K%TS6FA2NAVS9`X&>'34$QB_*
M'[(`'S;B7T$0-\-<B]E?(TBW!#J+A9*XFE8?0J'`)V$B1\DD)E#(&)L4H^RD
M5,?D*``'MID+Z]`$=OO'53D?<025<'<NVJHCWWEJ>,;7`BOW&N_>2DQ,P[,"
MC[20$*(@4#%+LH`^H]QOVA`P>NNKCKV5QJXN/ZKM8N_N7NI([7LK4)NG;=,A
MS$$!`2FV$1Z?;MMO]H:LD+W/'(GHK=`^3AZ@.BMP'3(.P%']>P^NMI#CJ"I/
M"234D(,NGVCN7IT]=OM^[KKT-?5>MAD!J"J45P`P=GRAOU'U_0(?$-;/3J/,
MMXC)'GU*4\8R).I"TZ_4D`#)'#J(AT#8P?$!V^[7-N9G8]WK&OHG=<F\N_\`
M%'UB"87'7N[:+;[_`"7T.^A_)-R61>)=G=PFL@D.7<4S@.<\("&QO\+8.H?#
M72L+R"\CYPNKOIU&RZF,R%KD(O5MG`[U'4;+I=:Z"ZB-$1HB-$1HB-$1HBYF
M/YIV/CWOEOL*3M0J9G''#!I2J@416;@BK=#;D$`$#>Z!A+VCT'[=?,?>]U<P
M7D9A%6!E2#L>[M^2^-_['O+NUR$,D#>36,K0_:ZO0]=.Y:U%AJ13H$4K[47D
MHQ*=U("J]5!/L]T"MEE4.U$`.F!B[$*8"B.YAW]-</&YFLA&4<([=^C/+J>T
M#4[]I%57,/GP#Z>4(CLW?91H)/\`R`-2:>.M-DF&!Y>"D6Z\F=5W,)/#2+C<
MB*J[99`P@5`P]J@E34,`=.T0'[M=2Z;:Y"V?%;@1V3F%@%2!0]>FJZ]ZRQR=
MG)':\(\>YAC:*EO('=P':-M2GZR!DK*KZK-I.R/"1+%R0_M,"*)M7CEFJD5(
MAWJ!!555(4=C%`Q2@7[-Q$=?/?;?M;VI:9-UKBX_4N8W>9Y'(!XW#304/Q*^
M6^T/9OL>RS3[+#1NGO(W5=(1R:UX.H:X@4->PE8O1TD0[TK@KM,J8=Q>PKA0
MBA`4`_>)3BF'13O$3?:(Z^J75M(8.!:2_MXUV[0%]LOK-[;;TN#B^@_I!T&V
M@U3O4NT65!C+P+=^>0C9@3M21*J*#YOLN8P@=-7YA1$ISB8P?*`_R#JF9W$8
MR2YAR$D?IW$.ID!+3IVCK^J^?>XL)AY;J#*21>E<VXJ90XQNT[1U&@[50OW2
MT*_(B5HF@X24(*#8S)N=,Z8`4@^^=8BBAC*B7?J<1'[M28(6Y&T,CW$PN%"\
M..A[J$*9#",I:&25[W6[QJ_DX._^T`@)[91G1[/7XZ3F:$\:RZR*)%&U>569
MQ[HQ2"F!W!U5W!BG4]L##T^(@&P;:HMG<^X,3D9+:PR#'60<164!SVC?RT`V
M[5\SLKOW3ALM-;8S)QNL&O(#IVA[V#>C0*'3Q3,SD1-.W3=!FC'P<`P40;IL
M"ND@6(4RICD.J@)2_5E+V_O#B4`]!'J.KQ8WN.AA,DCGW&2?4EY::'P/]/=1
M?2<9?8V"W?+<.?<Y60$F0M-"3O0U\G=3PJJ]R[5:IF(@V0;R"J?MN)./;MD)
M%PU.7VQ*L[*0%^TXFV$-QZ;`/346,>J2)'.=;`U#'EQ8T]PJ5%@8)Y#ZKGR6
MH)+8GESHP=ZAM2*)/247)I.O>0E["T5.03D27*L997V4.\IBG(X*0@B5,0*!
M@#?[-=.UN;65E)8+=\>Q(IQ!VI3C4KK65Y8O@$<UM9RQ#2H(X@D[$<:G?M*J
M:_2<C6]R<8U&1G46C)5\Y--KJ*-8_P!HG<W4.<RQVI%5M_W1#;[B'4-87F=]
MM81C3<.B@E<_@!&W5Q/32AIVD;+3E/<GM'V]"V2\?%;3/D#&B%HY/+C]N@!(
M&Y(V5VG[A`H1=?BK17ZJ1^4YF@34:14TPS30`"^XY.F8K=;N4*(%`X;!L.VH
M>,PF0_)GO,9<7AM'>;TY*>FXG?B#YOW4#%>W\G^9=WN$N[Y]H?-Z4E/1>3J0
MT&KATJ004T)+G%_7O6\A,G<MRK%!(L@W!1`J9#]I#ME6I3&2.1+]D2F(`!TV
M'TU<SA+GT&26\(#G#7B:'OJ':?,%?0C[>O76<4MM;ADM#7TS37J"';_$'N5I
M7M#YH9XLDY!V"A50CU"@LEL!QW(L8JJQ@.)0V$.F^^I#,3;3\(N'$@^>M#7N
MK312(\);7'")["T@CF#0U[14`42*F[;<9E!!O.2TFZ;(@!6Z+D!32*4H;%`I
M03(`]H#T]1UV['$X>P>Y]A#$R1VY%"3\:E67'X+`8Z1TF-MX62.-26T))[2:
MG591^.=!9WY!^"A0$3'#F1QA4'N'M`"IYLI!C"(B&W0A==,/CB-3I4@=M2=%
MV!)#!1SM!4`4UWT7<5U-701HB-$6G?\`G3?^SEXX?],^K?Y&,T:T7'VCQ^A4
M:Z^P>/T*YG8F`.G74("J@!A<*A0(D83`/ZO4=OY->EVB]?*TBG571NV]W8.P
M=OB;M';;XCOM\-1990W909)'-.AW5.]<%``2;CV$(`@80`.XPE#8=_7;?].M
MT,?]<FI.RE6T(_[LNKCJ.Y6Q,Q1[NXHG'U`3#ML/V[`(AJ0=%,U"]>ZHD`"&
MP?#<HB`]>OKTUX&M<>JP,;''5>TWHE`W<0IC&`0[C!W&+O\`$![@Z_IUX80?
M!>&%G8I/U2NX"!M@#X>N_P"L=QUEZ3*:KWT8^Q7(KP3@4=NPP@&XE#Y?0-A^
MT!^W45T(!/51'6H!J`".Q7)G+*QB_ND7./4`'V3F[3==_4=@$!'6B6T$[>-!
M\5$N,<V\CX/:`1VA7!>P&?=WN`?Y@';<W4=Q#U`!Z=0WU&CL/QO^W0*'!BOQ
M1Q:6_(*S+'!3J8=Q$0W]!]`V]-]M3&<FE=",.8WC7RJWJ)#N)B[=NV_4>H?=
MJ2P^752XY6@<36JM^QCB.VX[;C^@-2-`%+T4Y-`5B]J6QE>@]N_40^(%#XB'
MV>NL'/XGS?:L'/##YJT5ZKKQQ&2(N4^BJ29P3`X#V=^VP=-OM_1J'D8X[JV$
M,HK"75(V_DH&5@AN[9L,M?2)!--_%;DWY,Z6<2_D5Y'JO%RG<(\++$0$TRID
M("9\XX8-W;)@`;]P?SZU8>SBLY7,@;2(M/4GJW351\#80X^9S+9M(7-.I))K
M5O:NDYJP*T(T1&B(T1&B(T1&B+FC_FJ9MA%>3VV]C0B\T.`<&BBJ#=P<Z382
M7+Y5%$A%+VE3E[0[@Z"/KKY/[NQ]Q>^Z(.;^-C^/L7`#G4T(!UTZKX?[[Q=S
MD?>5N))"S&"S)/F:`7@FE`=:ZZ]JUOHAE(WIZ*!F,:BHZ1:"J5DZ;F=_NOVD
M@6`Y`)W[F[DPW'KL(!MJI7=S;>W[?D'R.8PFA<T\17K2A^>RHV0NK3VM:AWK
M2NC833DP\17J10[=NR3$IV05B-758]]7W9%Q09F5."+KU$$`,=R!T3)N#&*;
MW"[%V'H.VNQ:@Y'&-R4<L=S"14C<#O%*4`VH=:KN60DR>*;EHYHKNW<*GJT=
MI!:013L*M[IBQL3])2S6`\?(1*9FB2$NL8&\B4JX`1(')#&0;*"0PB)C@)%-
MMM]2H)Y\;;<<7:A\,GF+HQJTG^JAU-.Y3[:YN<59F/#6HD@E/(OB%2VNI\IH
M2!W&JO#K'L=%Q$G99Q&O1#5%LBK"HI&5,^E5CG%(HLT&)Q*X1,8HF%0W:4`]
M.FHD'N*ZO+R/&61N)IG$^HZGDC`%?,7#2NU`"N?;^ZKV^R,.'QC[F>X<YPE<
M1Y(P!6A+Q5KN@`!4'$<M4G4$\9HPLVI(,$)9RE$OUQ^E(IWF(U?+B**J*X$*
M!C$`!`0]##K6R:/,P3PROEA:QY8TR-%330EHU!UK0KR*>+/VERVX?<6\4<QA
M:98QYG4U+0`0178_HE0KD=E/)[3E*8HF]U)$)9B=8#@EOV%]]4K85>SNV`=S
M;@`A]FN,SVU-CR?\??2.%"?3=2GP!-*]BX$?L^ZQ8)Q63E>`TGTI`/\`]=0*
M]@HE!.7QS+,?X<;(IIQL.X]D[^,8I^PBJD!C`H+U0S=99`3].\`'J7]&\&P]
MMQ65R<C.^MW,VO%[C4UZ<!5H/<N9B_:4..N3E9Y"Z[N&UX2/U-=*!K:@'K2O
M7=(E;\14!!5J@+U)<"JNW+DB\>T1!0X@<3.W9FR1E-B[]P")>T>@Z[D<5L"6
MS.$<H^T-(>3\&\B/"GBK&R.T:'"=PCD;]K6GU">P<6\C\"*]JLC5E<$+"W?4
M8&IY!,4^UZO+1,N=HH0=U`:$<JKMB)E.<`$>P3"&V^NG+/@G8YT.?Y_CT-0(
MY(ZZ:5+0"?FNO/=>VIL2;7W3Z@LRTU8V*2+D.G(L:''NU'5.!:9IU+.#EOKN
M(>6-@3WWXLHQJV1`@]GM"Y,S[4%SIJ&'L`0W$YA`0$.FJYB;&.T@'_Q^.5F,
MD/EY/<2:GIRJ1]%4\)CFV,0?[7BGCPDOV\I'..I(TYU(':O-?LL*E%RTNXE9
MGO7:C#JH,7:<:U%@9,Y"@1FT%0P]Q1$"B;8X[B&WIMYD<=D#?06D4,/%IY@O
M;S<';?<?'5>Y?%90Y"TLH(+?C$_U`7L+WAQ.I+W=-=?V6.C^%J4NNJ1B_DXU
MU[ZI2-7K,[M!P03]R9VQO=%4H=@[]AMS?9OZ:^F07N9M(V_DQQRL#1JT\2.Z
ME*+Z[:9'.8]K'7,$$\/$$N8[@6^+:#YA)QXQC(T-E%F;13Y0*NX(DX5]KJ(J
ME003<G*HH;?8I2[%_I#ZCKJQ3W-R.<;9'LZ@&@KV$DC3MU79M[RZNS6%DKV[
MT'E'@7.+13XZ]%:[):E).*C84GO.&T>=PL5XND5-5V98^Z0#N`*`B@3H4!V]
M?0-2L?C19W,E^>+9Y::!U0T`4H-2-=RIN*P[;.^ER9HVXEI5H)+6T'3I4]4C
M3R#TY4TSN%>Q$O8F01W*0O\`@@`_#73;!"UQ>&CFXU)[5W?0@#W/:T!SMR-*
M^*R^\=RZAO(+P2[C;C_;+XO=?0?^6ZCA\-OAK=&QH=HML4;6NTV7<:U*4U&B
M(T1:=GYU`PE\<G'`0#?_`#T*L'KMT_J7S1K3,`6Z_P`:%:)VAS0#_&A7,Y$V
MX^H;_9_L:B`4'<HH'$4&R4\$R8K'!>3.9-``'M!,Y2F$X!\H_,4^Y0'UZ:Y]
M_+/""VV%7G^2X>2GN8F\+05E2HE'$42-4)&F*94I=S&*&P!N&W:/=\QSF'TV
MUS+%EVZZ#K@:$]=_@N-CX[\W@ENQ3735-IV&,.^X?,._[0;]?N]=6-]&D@=%
M<72M`[_!3/;$O7;U^/KK5R!6DR<MU5@W_=D,!#'$PF'NV-ML'38`#IK`OH>Y
M:B\$TJ`?%`MS]@[H[E$=M^W8=_N$-A#;6(E`.A1LP:[1S:^*D*,`2%,PD43`
MY>[8W<`CN(@`@(_`=M;&W!<#2A6T7+B-*%58"F)>WT``V]/78.FM'F#N6ZB$
M/Y<E9W)3`<`*`]@=2B`#Z_'4Z(M+>_JNG"6%M1]W5"*QRCVB&_H'H._K\?L]
M=>N:*5"\DB:X$]56^X'V#K1Q:HG`J(J@(B/41]1$>G_=TXM3@>JI3D[MQ*(@
M(_?T]?CTUF'4WV4ELAKYME`B2J0@?XB(&`P?`0Z@.LW.#F\>BS=(Q[2SHG8J
M4=6+"U6+-2)(Y^BF(%,`E3]\"@(B8?E[`4V^(B'Z!U4,O=93'3-_#B=+`XCX
M?54+/7N:Q=TUUA"9K1Q\:?\`1;:7Y,QBU8^2WDXFR6.LU+PIL9"*&`-CC_7G
MA0>XI@$0.'3UU:,1/+/;AT[0V76H[/M5TP5S+=6C9+AH9,:U'9]O3HNE;KKK
MN(T1&B(T1&B(T1&B+F5_FG$TQ\N%M4%R0"FXU8(0<1J[@S5"1*=:[F0(<XE$
MB@)K%[A#U#H.OFOO=S_S(&M:>5"6O`Y.;M4@#7:B^1_[%DD%];QM8ZI:YPD:
M.1CI3D:#4:4\5\3<:8^A485]9[#!N8]TJW74CI:-FE$BIMD^Y$7+)ML1-<B2
MH`&YBJ;]H@`!N`Z^$>Z/<M]^;'B\=.V6-KARC?$*UWHYU:BO34=Z_,_O+W9D
MG7\>'Q-S'-`UPYQR0U)/8YU0X5Z4(WUZA-?-5-C=[H9U*S#U9B@T(1O+,CI(
M*N7C=%,C1)==8IA:J'3[MTR!L`B&W35LQ^8G]OX006448N'.)+'5\H=JXBFX
MKU/Q5XQN>N/;7MQEIC[>$7)>:QO+B&,>:O(`-"*[$[=5>&M3;),)!)A8WT(X
M<M%8MV4BQCS#MBH<H+-'2(-SB"*B(@H(?LB7H!A'IJ&_-7'Y$4MS;QS,8X.9
MTC:[H0:[C:OZ+GR^XKC\B)TUI%<1,D$C"11@=T+7`ZD;:T/<EK&QFU9=03V)
M5MD::,7!J=TF!%VZ(-3&%W'&5%)NV,8I1-^[`QP#8`#7"EO",NS(03-M+KU!
M4#5KC7[7#<CQHJW-?D9R+)6LXL;TW#*ANH<XNT:X`DD5TUIXK&6C-TVL@O(B
MX;RK*+(*:;0Q%G4@!2&$&Z@QYE4RKK(D^0`'<O;N(A\-?4,[,7V[;4,=%/,*
MEU>+*]2'BM*[_HOLWN:=\]J+)C'P74^KG:,9R_J(>`>-=^WOZIV',E<FPRDW
M4XXE:JSMMV2)#PS9=BDH/55P@1XBHDW.Z,H/[.Q2]0`!VWU5([;`W!BL<O(;
MG*LU9_<<'&FU2UPJ!37549EK[<G=;XW/2_EYV'_M_P!YP>:="6.%:4U[=*IN
MGBTLXEC1\HAW!["G:_9&*P633.4'!`<MR*(H+[G-N!P(!AW^WULT4=HRR9=6
MSPT.=K&\<MM*AQJ1M2E3LKA;QV++!EU:2!K7/\T;_/MI7D02#I2A/2J;FT.I
M60<$92LFX:':I$*5O)JJE;@/9^[4#;<A.\@!\!`!Z>NK!B8K6VB,UO$UX>3Y
MF#7O5JPEO9VL!N+*"-PD<:OC:.1UV/;3X*S1,A"Q)B$<2:+IP9Q[@H)&5^E,
M/;VH['.V3[1*IZF[NTP"'IMJ?=VE_>,_MPN9&!]Y&H'70'KX+I7]ED;T_P!J
M![+<-^XT)`ZZ`U.G<E8O]>=9TG(@Z1FE4_KFCV09K?ARXID!;V78&*<JR9T0
M$`W$2]`'TZ#R8?2:UCH@UUD#Q<UK@'BII4:@C77M7%@9:!K7P<3C@>#F,<`]
MM33DW6HH=>U)!@5P]9J(S+Q9LW:KJO&T?&)H-F;ATIN4[E1PAL3W0+L4ORB!
M0Z=.NNU.Z&*9OX3`YS@&N?(2X@=E#J1\58KJ2"WN1^#&'ND#6NEE)<\`;-`)
M^WJ=:D@%6EA:)*.?&6;.FI7)##[8248WD.P4C_(!S+"4JG<`!U$!^W4JYQ=I
M=PB.9K^'4L>65KO2FH4R[PMC=6P;<LEX$:F.1S*]M*:A)@IEK!)NY"09"9$R
MRIGSED`-D$CF$1`$R%(*!`$P[@4`VUU'!F/M&VUNX<@!Q#O,3]3IU7:<!B[)
MEG;2#D`.+7>9Q[=3KH%+D*XM[`O$%C*LTB]@**E`@(AOLFD=0``AE#[[@`=1
MUE#D8ZB.2@F.P&I/:0.P+"US$)?Z,C>,Y.P-2>T@;T'5),Z($,)3'`!#[MOY
MM]]=,.)V"[H=R%1L5F#X[NW_`*P3@D`=?\\OB_U]-_\`TWT?X?#6R.O+5;(Z
M\UW'M25+1HB-$6G9^=1_[.3CA_TT*M_D8S1K3-]O\=A6F;[1_'1<SC;J&P?$
M.[8.O;\?OU$\5%5X44*4A1[@#M*!0#8>A=]MM@]-0VAQ<N6QCR^E*E42CD`^
M4H]1V'X]O\@_'6]L514J6R`'5VA5`)S"8=AVV$>@;@!ON^P-2`!12`T4HJI%
M0X@(&`1``';J`AN(_=N.M,C1T6F9HH*:)80SE%,$RJCL4![C%V$?E$0`PAN(
MZXU\R1U>%:JNY&&60GTAJE>Y>PB2'[@P$5Z"`#N<-S=!WW+L(=VN3##>2/I+
M7A\%7X+?)OD_NZL^20,H[24.)2AO\V^X!T+L/PZ;!W?=JPV['AFHHK;:1.:T
M/-:]BL)U2F'H.VV_Q_O>NIW$TV72;$_>FZE&4``W]=@$?]6^O0U;&QGKHJ?O
M$YOD#8=^OIZ?KULH&CS;+=0-&NRJBD$"B?<.@#TW#?\`NZUG79:7%K_*S=2U
M52B8/AT]``>O\VL@"0LHV<6T*"B._3KKPA9%H(HH@X$FX;=H#]^^_P!H].FW
MW:&.NRP,`.NJE`N('`R8]H[^NX@'7;U`-MPUL#"10K9Z;2.+MEN6?DNUSK^0
M_D290@;APGL@`H7;T#.F%@[!`/3?;?6FS8&7+Z$['3XM4>PB;'=OX.)%#H?%
MJZ6&NHNRC1$:(C1$:(C1$:(N9'^:W:K./*M9"D7CB$/Q[P28Q%DS_7)@F-VW
M<H'(4PF(F80W)ZCOKYY[FFCBS43B)3*(M.)\I)KH>P]Z^5^[IXHO<47)L[I/
MQ7AO%U&DNV:1VKX0031$]8C4TG\LDS5!1=!1-9(&S43%V,HNB#A(R318P"4P
M$`WR[=P".^OCU\\.S$SY&1>L#J"VI/@::D="?@O@>1F/^;G>^.`S,(#@YM2?
M!W$U(KU[-*:)3QK^-018L(XX*2!4#NCL3EW%Z0HD]QSNCLH01#Y2J`?O*.W:
M'J&N-<P7$CGW$X+8:\>=?M)V:*Z=Y%*'JN#=VUZ^66\N1QM2[B)`3Y=-&CEI
MWTXT[4L&,U)`_)),B1+>:029Q[)DHQ^K1<MQ%;Y78KIG!4Q2#^TO\PB&WIKC
MW-A:^D;*5TQLJE[G!Q!#M*EM-M>C=%7[G'68MG6$SIW8]SC(Y_,@AVA);QI0
M5Z-T2PQK3[+>)R<IAEXE%1**5L,F"\C(L4!8+"HHHD@5D19-JJ#A4A2)$("0
M_'Y`,;7(]RYG%8&SM\V&R%KI6PLHQKCSTI7E0GO<=0N'[L]P87VW96ON%[)B
MR29MO'1C'.]30-<2[4MZEQ\PZ:K&1YCAO+2[M\B20;.8TXK@M"D0`4T4S'Z.
MB@<IEC@)0+N';N'IOKZE![E?;6;;=WIR,E:-)"1J1KQTT^=%]FM_>+K'',M9
M#%)%,T`"8G<C7B*&@K4BI*L4U?[']%*U=6Q&&L&.)'D?](1:52;IF`Z<0B`I
M`":ISDZF%0#%*'4?@/0QWMS%_DLRK;6F5_I=RHPD[O-=33N"ZN+]IX3\F+-L
MLPW,D>63E2,D[OU/3N;J4V,9-HS#\OL-UA!J015,Y3%,R/MGW`I4`.8H@4H=
M.H@'QWU:K^S=:P_W7-Y//])J#7X"GR5RR&/=86I,CF^K([3B:@U'@**XRL5'
MRH@Z.(F.+5SLH*10)W%$3II[]H"4=AZ;CU$0WU"L[RYM/[0`#>0Z_K0*+8Y"
M\M:6XH&\@#K3_HF[BZO%RZ;DQ0^C7*L*!?=,L9`#;_,<P`4Y^P/40[!#5FNL
MS=6+VL^Z,MKIOX=%;[_.W>->QH\\9;4D4K_,)U&+"2C8H(991"7C$VO^+3F?
MO$8ULN<=Q]]$`*L<Y-S&,!P`!V``V#55FN+2ZNG7D?."X<[S@,:7.\"?+\1_
M-4FXN[*^O#?1"2WNB\<PV-I>ZG8X^6A&FFOQ2>BJI%.I^-B9VR1L`QGI-M'K
MSSI$92$BFSP!]Q911H\;"@1,Q1'N.8NP;!Z]==2YRUPS'RWMC;2SRVT9=Z3"
M&ROIW.:>7@!J>JZ]WG;R'%S9#&64]Q<6D)>(6.].:1S2/Z7M=R)K2@T)[DA<
MQ8RB<?SR"-;N,1<HEX"_M.(5P=P9FHV6%$Y7)B&63*FL;8Z0@H?<@]1$>NK!
M[/\`<MS[CQYFR-G+8W+!JR5H:2#M0;U[=`K3[!]XW7NO$F?*6$^.OH]7,F`;
M4':@H#7MT`2$9VM>/:I,#I-WS4AQ6$/:]M4BP_*;]X`F(J80*`"8Y1';IKN2
MXJ*XE,S262N`UJ:"FNG9\%8KG"-O+DWC'OCN3U+JBGAT^'57Q];)V7KA*U%H
MM"Q0N#O5FC=BDG(+.A*4?=.N8#'6["%[0!,P#V_T=M0H,186F0_R5PY[KH#B
M"YQ+0#O0#:IUUZJ!:X+%V.4.9NGO=D>/$.<\EH;V!NS174DCXIN3-7(!WKI*
MI`4XD'WB&(.X>H#W`4=_Y]=\/9_[9!TZ&O\`)6GU8B:1EI/<01^E5F%X\?9+
MY`N")2!N?^V7Q>[AW$?_`%WT<>F^X;:SBY%U3M1;(>9D\PH%W%]3%.1HB-$6
MG9^=1_[.3CA_TT*M_D8S1K3-]O\`'85IF^T?QT7,]*H!>H$V'[QW_O:AD*"Y
MA<='$!2C")O4=P^W<=_U=->B@68`&P4-A_P2CMZ"(]?_`(NO=%ZO1`[CE`P=
M-_@;H(=-P'<-NNO":`D+%YHPD;T5<!")@(E#8/B`;?WMM]:"7/T4/SR:;H(X
MV,``82@.X".X]`$.NWP`=]/2KNAA-*D:KT=?M'8#F$-NOS&V]?3X]=]&-)^X
M+P1<NBD+"4X%$%A$1_:`-R[#ZAU_I:V-J!L%NC:6:<%1II"=38O<([CTV#KZ
M_'?6QSZ-UI1;W2!K:FE%5"@??M$IMQWZ;;[[>O0-]]:A(.A"U"<':B/IQ)L/
M;L.^VVP;[[^@@'7X:]YUZKPS5J%,,#?L$ACG*J`_!,3`'_A!_<UX.>X&GBO(
M^=>30*>*J8]*+5,/U:JY-O0Z:0'Z?9MW>NM4[KIC:Q!I[B5JNI;V(5A##W5^
MM%)?@R]PQ6:BATP'8#'(!#"'IUVVZ]/AK9`)N'*6@/96JVVAN.%9V@.\:JVF
M(0`W$/0/AZ_[.MX)JI0)7I(R'<`&('P#<W]T-M_Y]'!^]5K>U^X/P6X]^2S6
M`WD9Y*I%*`%#A38C@8`_Y\L*%V#KL`!OZ?=K*VCXOYUUH?HO;.(MD,CMR#_Z
M5TO=35TD:(C1$:(C1$:(C1%S8?S0R2+_`,I]SC1>MT5E..6$UCMEU$&YCH)%
MN9O<166.0#+>X`%*GN`'W^X-?&?]@NEASMO.V,N;Z8`(J16IW[!1?GW_`&F^
M6V]RVET(WF+TP.307"M3HX"I`IK7HM>_\79+LT2QB14&$4D5N[:K+$)NFHHF
M4$T]B]Z:H*B;N["B3?T';<=?-W65Q',3=N)NI:EKA7IX[Z=I^"^3FPN8KA[[
MM[C>7%2UX!.VO7<4IN059)8&KETA98HSV*?1#M%D"48(%*=J17_=:YXY5`I7
M9?HA$=NY,#&^(B&NK8DQ0NQEX&30RM+O./ZNGF!\I^:Z^/=-'"["Y#T;BVG8
M75?6O*E``X$\37N)HK_'VH`5,_=F:K,U`4!-ZF3VBJM"F3;E<+*'!%!C(>W^
M\$1$?:'<-NNX\BZPX+1;VW-L[37B36AWXTU+FUT[UQ;WV^>/X5KZC9F&I:34
MAW_$4!<]G2G4)<-+6X3,^L^)'[Z"2%DE!RJI9!FI*.3K'*()(>T<\@)%%$]_
M<*`%V$`W*&N*_$1DQ8GW='%/*U_J1@L<(VZ;FHX\J?%5J3!PR-BPOOJ&.XN6
MRF6%O!PB90:.U''E32G1-`Y=RE7?/'[B;5D$I%`RBK".<"\D'+DH`!&JB:12
MJD`"F,;8!`!VVU<(K>SS$#((X!%+$:-<\<6`5U(KH:J_6]K9Y^TBMH;81S1/
MXM=(.#&MZO%=""=-TTI%!5L+^0(5=)J]43?J!+MT?]TJ*D+[Q3HJ)D%50I3[
M!W=HB/[(_'5R(8S'16TG$RQ^4&,DT'C6@'=\U]#DC;'BH;1Q:Z2-O$&(D\!X
M@D`=R<9I5XA\P!=@^38NY58R3\7*1V[=%(%"[$363!8VVP=3?$1VZ^NJK/F+
MZ&Y,=RQSX(A5E#4D]I'T*I4^<R-O=.ANXW26\#*LH:DG74@TKX)*S*18.6&'
M(U17;$(1)1\X,L(B!>T153.4Y$DT.[]D1W'8.NNO8O-_9?G%SA,2:,;3?L(H
M23X$:KMX][LE8_Y!SW"9VH8VE*GH10DGN!&JIY&3A(Q!H$?%KKF%4JTN@W!+
MW7+3L!-T+!4Y5`.)"#W"!0-L'KMMJ5:6>1NWO==3,H&^0N.@/0/%1OMN%)L+
M#*7\DIO)V-+6_P!HNKQ!Z!X!'<`"1UHG.AKE!TXL;*UT#6R#4`Z@1\PT;(N6
M8+=P+M5SB4O>LB)?E$Q1'TWZ;;U2]P=_G/5M\A2SOV&G*)SB'=CAO0>!5(R/
MMS*^XV36>5/^.R;74$D+W%KB-G-H31ITKKVIK+I92S,W,V&'A(V/BW38JRL6
MFB1)NW9J`F59=1LFB`G4[R_M$`2DWWU;<+C39V<-A=S227;74:^I)+M:`$GX
MZG57WV[B#C\?;8J_N99;]A`;*2XN<X;`.<?C3JDQ3X:+NDPM%-58F);`10K9
M^Z.J94JJA!(HLF45D`,BF(=`^0P].G377S=[=X&U%U<-GFD_X,`VZ5J":GY=
MA79]Q92]]KV0OYFW%Q*UVK&`:@=I+3K\PFYG:BV@IV6AG[YC(),3"1&4CNXK
M1R01`#'(8H&,*A=_3KL(#ZZLMEEI+['0WUHQ[#+O&_5[:?\`*NP5OQON";)8
MZ#(6,<L1EWCD^]M.T'HJ"/2)&M2+$*HZ`KT/:60[161;F_;.DEW`)'&Q-MS`
M.P]0^`ZDW$GY4M'EK06T+=J_IMX*5</_`#;KTY"UC'1^8'J>SLIW!*"U/X^P
M140L[9B,C],HC(/$SBE(BY;F#VW#E/O53<`LDH7N,<"F-L(]-<_#VUU874[8
M'_V"26M=0MXG^EIH""-@-5R\#:W&(O;EK)#^-S!C8:%G%V[6&@+2WH-0$_7C
MO@'J7D#X,*D3]]N',7C"L1=/J0Q"9NHXF'T$2G)MU*.P@(:LC+ZW+FM+@'EU
M*>*N$>3M7/8TNXREU*'OT7;^UUEWD:(C1%IZ?G2"$4\<_'$#B`!_;.JP]?M_
MJ8S1J+=.+6`MWK]"H=Z]S(P6UK7Z%<SY9)$H`)/VON'<H_W=A_7J$Q[G#4%<
MYDLCMU2B00#?J/Z`ULY"M%($@)H=%),7;?Y1`#>NWV_<'WZS!KXK:#790*(%
M_8`=PVW'T'IZ=/B.O2"=T(KH=E$ZAS;?-ML.^QC;?^#\->-:T=%XUC6[!2S"
M</FW#81V^4>G^KIK,!NRRH%$%#`.QQ';UZAUUX6C=J\XM&P41.00V'T_1KSB
MX+VBJ$G14Q#;]&XA\-MOMU@Z-Q!':H\D!<*UJJT')3%*/N%(?N'81/V?(8`#
M8!^&VW7].M/I%N@!6CT7-.@*44-7SR:@>XY0;(=![_<34.;<0_9*4X[_`!US
M;S(,M-.+G/[*%<C(Y1M@/L<^7LH:?$T2I>5F%;M@1+W.EP`P"83")A`H]3B!
M?3IT`-]NNN3%E[V6;E]D?>N+;YO(32"32-AZ42`>MTFO>BW(!>H@)NA@Z[=2
MFV#<P!]^P?9JQQ3.E(?)0BG16RVG=*!+-J.Q6<2=1Z_S?[.I7)3O5[`H=H!_
M2#_5^O2J"0G8(.B':`B.^X"(=/37H<1LC9JNXTZK<*_)5@!?(_R7`!$?\R:R
M=!_]NF$?]7Z]2X345\?HIT/[_1=,S6];T:(C1$:(C1$:(C1%S8OS/]?;3'E7
MN`$4<H2:_'[`+9)R"K4K-%G[ET!R"Q54@63[B*"/>54H;@`=INNOC?\`L/(R
MV>8AJUKK=ML]U*.Y%_2A!H3V"E5^?/\`;68DQF>MG/:UUHRU>[B`[D7U\M*&
MAVT'&N^JUH32C"O7J1AX<R/T`(D8(&2*19`H%3,5?WW(@0GOJ=1`P&^;[=<-
M]G/D,#%?7E1<;[T._9V=NBKWX-UEO:]OD;UQ%T:N=4EI`KI1NIIVZ)06@)&4
M:M$ZLC((2J2(%=I&3;)H&54`3""BON=ARG3,7<NW<4=]_3?7*Q`M[*5[LN8G
M6Y/EU)=3M`I71<?!?AV-P\YM\#K(^9IJ2[3304K4*P/UXZ.J:C"1L4BWLK.1
M%G*5=!@V?,3IF+^\62>)IF.=N'7]@3"/3?[==.UBN9,QZUO;QG'21\HYR\M=
MKM5IV/C1=6TAN[CW!ZUM9P.PTD/..Y,CFOJ=@6UH#M4&G@KA3I2*4,2,8II-
M'3Y`Z)U90%6B0'[O>;]J``B)@4*0=U!$"EVVWW'4;,6-V`;NX)DC800&$./8
M===NSJHN?Q]]Q-Y>.,EK$X$",AQ[#4U.VE`!5(1E*KO+46/;(%16,Y41=JPH
M@X,LU%005$XIJK(`F9,1$3%*50@?TO75@GM(K?$&Y>2\<`6B4<:&G0:'0]M0
M>Q6FYLXK3`?F2_W&\`Y@F\M#38`AKM^VH*?ZR8%H$,Q<V2=>6F9*<B;HC6!D
M6"[I!!9(%"HB1P8#J"F.X&,!_D]-M?.\7_L/.W]PW%V++2`@\>4K'!KC7?R]
M>ZFO:%\IQ/\`M/W3DKQF%QL6/M7UX\IXY`UQ!W\O;T!%#VIL:V=FNJHPA(A>
M-KZ+HCD5Y!Z+R3-[6YQ(LLGVD3,=(H[IEZ!\=6K)LN8QZE[*),D]O$!K>$8[
MP#72IW)5VS#+R,>K?W#)LO(SAQC;PB'>T'4BI.J4TW+P<O"/948T4WC+VV9"
M(MRF.LF<5#)K;B90ABI``%`3%_:].NN3C[+)65ZRU9(#$X\B2=`>HZ4KW%<#
M%V.6L,G%8LF:8'@O-7&@/5NPH36M*[)J85BNBNPEFT@D"C9P=)1)15NX6(=<
MP@)!;JJ``']L=C@4/41#X;:M]]/&]C[*:)PY-K4`M!IUK357S)W+'QRXV:%W
M%[`:@.:-!OR`_4E.1<',8DTA&Z9X4KM$I2OF2D:9DH\!RH4XNBE1*"??W``&
M^8IM@Z;ZK.%BO'.GFD]<PFI8X/#@T`4INJC[>BR$K[F>3\@P.)+'"0/#0!3C
M4]/XZ)#2[NNQTHF"SYPY16*5N#EG&JH)E>%1`J+/Z5R"AU44R["<P]#@.W;U
MU8K&VR=Q:ES&-J#LYX)+>KN0VUII2O>K1C[?+W-F3'&&O::GF\$\.KN;3H:T
MH-^_1,W;%8I=XT2]]1JDY#W2"@T001,45!("H"V(0P@&P@("4HE$-MM77#_F
MMA=)P#C'VN+CITUK^R^B8%E_%;.F:P/DCWYN+OAYOW(3Q5O%LG<*LE*U!,7D
M?`H*I2,H]>,@-W@0RHI+Q:BP.2[#_M2@$'O#Y3?:%,RGNVRPF5-EF/[5W.X<
M8VM=V]'TX'M(J.Y?/<O[ZL/;^<-CGR(KZZ</3BC:[MI5KZ<3_P"85%.B9N;C
ME&2$@F1:.!Z9=7]W'F,0^R1=A`R8`4Q=QZ!MT#[1#5QM;@2RQN>V4PT%'/&F
MO9T7T*PNFW,\3W>H8J#5]*:ZZ$:%-Y$3"T4]*LJV*X34$/JFZG<45#`(;*`J
M&XI+)B/0P?;L/35BN[5EU;>E&XMEKHX:_"G56S(V4=_:>BQ_"1OVN%/E3J%]
M2_'#7J^KS*X9V6LVY!N=7EUQI.M6I!BD8[<YLSTLKE(KI58Z@G,F82I"4G4=
MAWWU\Y?DL@W/V^-RMB]W&5H$['$`@.'$D``;T+A7:H7R:?+Y7_Y3:8O-XY[F
MMG8&W$3R&D!PXDM``%#0NJ=JA=G37V%?>D:(C1%I^?G0")'\=''7W?V2\RJN
M8.NP@/\`4UF8.GW[".H-^7"-O#<N^A7-R3GMC9PZOU\*%<S@_:;<`^4-^G7?
MH'H/K\=1?,S0FJA;$$=B@)REZ"7?</4!^W</38`WUD&D.K5`TNU&ZI#^H:S:
MI<8(&JDB&W40Z!N("'P#[1ZAOK/N"V;KR':(F,&X]-^H=/U:]-=`O3LH=O>`
M"`;#]OPZ=.@;_P![7M>)39>2D[O41_D'^Z(;:])ILO5XVZ]>@?;L.VLJHO8$
M`>O=N`>NP#O_`'-8EU/%*KV)D@`O[1Q#[=B@7]'3KO\`?KRCCW)JJQK*.FGR
MMA[`W^_?8?4-P]`'[M:Y;>.5M)0#\%%FLX9Z^KK\`KR>;>'3[15,!A-N;8?0
M?CL)@$0]`]!U!%C;M^T:KG,QT$;JM;\PK:H*BFXB<3"/KU$=Q_2(ZD!H;I12
M@0-PJ(QQ*([CML/W?;MK<&UV4P1M[%3F5,(_<'W>H:V!@`688!LH"J<0V[NG
MIM]VO>#?BG!M:TU6XE^2H_[1_DO_`-":R_Y=,'ZD1[?/Z*5%M\_HNF?K:MR-
M$1HB-$1HB-$1HBYFOYI.@W.W>7:QN:S'OW;1OQPP2B_6:.10(B`GO!A`YCJ)
MMR*F3,/:(_,/IKYA[[]PX3#W,,64ECCF<VK`YH).H&FA)UW7QO\`V9[I]MX&
MZ@@S<T4=P]I,;7M!Y>%`2:$;;+7*@X`M==V9Q:(96(;-5DF+$7+\B[Q9X8ZB
M8@";Q8"JG[1[S^V'R!MT'KJHY'(G(06L>'F;,\U+Z-(8!ONT:=U=U1,ID'Y2
MVLFX.=MR7\G/I&6L``K2K0:=@Y'5+:K%@7\A68F8F&*;>8D`0<2)W+IO(Q#5
M(_58Z([-U"K&-MT^<-@V`-5W*-R%M;7=[9PR.D@CJ&!K7->3IH=_HJGFCD[.
MSO;^PMY#/;QU$?!KF2.(V:=P1V;)5Y4I&/:[(QTS7E)NRQD0FW?OSH.DA:,M
MG1`*=15RW3.Y4<I*;=IC%$FP&$!`=<WVEF_<63LI;')>A;7DM6MJTU-1H``3
M2G;2BY'L/W'[OS&-FL,NRWL[Z9Q8T.:034=`"0`#U`\"F+N=D@IYB_28.I)X
MU<@*[->4:MH]\P5!9,Q46?L+'W]HI>P1*8"F#T#5]PV,R&-N&27#8V2#1P8>
M;7"F[JC2IUZ+Z?[>Q&2Q-W&^Y9%'*-VQN+V/TW?4:5W'84UP/)%LO',8PQ"N
M52>PX7(F8SI=-4?WH.C))#WJ"40`!`=R@'KU'5I?%!(R2>\UC;J!T'92IV[5
M=#':SPS75Z"6@U:"=`1_QY':JHS2TTRG_I7,E))]C@"B072Z*/:H;?YD3_*J
M02B'KMZ=-;?PK&;&^NR*(N<VM:`D4[QM\%O_`,=CYL0;B*&(ES*@\02/B!H?
M!/;#-I*4FTG20E.V[6Z:J1-TP%%79`YCI$`HJBXW'8P=?MVU0[ZXM[2R+3I,
MTFA.NHUTK7;L7S7(S6UICN$Q_O`D@G4U&HH3V=BJ)6ORX-'T7'$61]PZH"N!
M'13,D4QV!4YT?=**6QMA$P;@&V^L;+)61GBN+L@TH::>8D=AIKUT6K'Y?'F>
M*[O3&0*4%1YW=@!H:]=$VD3492)=MY@R/XVVC5$UU8]+WC)+.Q,`B)TT@[E6
MJ1^HCZ"/PU:[O-6=_$ZR8?2FD'WD"H:-P*Z:^%5=;W/6&0@=8,<VWFE%`\@5
M#`-1KL2--DYCJM6NQ0[.=GF22JOO*E0E6I03<E312[FR3I)$")E^G[>T`$HF
M[0]=56++8C'7+\?CGN#!3DQPT[Z$U)KJ=Z*EVV<P&,R+\3CY2V`-\S'?;7J6
MN-2ZI-=]U;9BK7*JM3EE(D[3WQ823*?39*2+5$%T@%4AMDC)I*]"&[@#H(=H
M_;J3997!Y:X#K&<.+*M?%S##4=:5!.NE%/Q^8]M9N5LEA<^HX<F/@YB)U6NI
MM4&A^5$WSNJR\PX9R,)'I3\EU3(!TDD"BHNHHH*B$8I[2)@$YA[>H@`^@?'5
MFCS%A91/MLC*;>TW--:#L+^WM_FK5'G\=80OM,G-^+8]:$F@'0RBIKVZ?%1"
MMW=B#MO/MC5!LN@)7*I]X,QTMC;*@FW.B1R``40Z@)C;[:Q?D\'.62XU[;U[
M7#C_`.[\*D&GST7C\S[:GDBEQ3V9"5CO*!_?\14BH^8HE!`U;#W\,OFS.USK
MW(2[9V9B#R&7)&.S)I&,V0;.D@.JF#DY=@$X?,;;?8-0+_*>]7YAC[BRMV>V
M^30XLD','M+>[L"YV2S7^P)<_')<V%JSVD'M#N$HYBO]3F'L'0;+%AQ[WN*(
MK[E4*<Y%.X-C]X&$#`?<1'N`0^W7U0<&T,1JP;%?:HVQ-:'Q@%M`1V46;'CG
ME727/?@JQ*<H(_VQN,91,`%`YBFS;2`[##T`P=?TZB_BPON1.YO]SE7JH/X$
M$EXVY<T^IR![AWA=OK7;5C1HB-$6GE^=*';QS<<>NV_,ZKA^G_T,9HV_3L.H
MUR*L'C]"HEY_VQX_0KF@'*7U'</T:A@4&JY32=@J,3"/36=`%.#&@U&Z\[>O
M4>OWC_-]FO:K)`!\/MZ=?C^G[=*]5X305*]`GM]GZ-QV_4'H&O.2P]5O>O0$
M``_1]GIKSD25@9"3ILHF%/;Y`'?[1$?[FO=5FP25\Y%%+`AC%'J'KZB'Z/A\
M=>\@"LB\--"O/L&_HFV^W;?J/Z.FVO?4'4+SU6]A1],.PF$Y1].G7N'7OJ"B
M>LVM*%2NX$S"`%Z^G4?U_?KVA<*U6P>850*H_`-OU[_WM>A@ZI11(HH`=%-N
MOQ$?]G0@=B\=&UVX4H1$1$1'<?MWWUD`!LL@@`$0$0#H'KI4(H`&X@`>HCMH
MA-!5;C7Y*M,R?D?Y+@<-C?V)K&.WW#G/"/4=^H>FML3J[;:_1;8'AWV[:_1=
M,O6Y24:(C1$:(C1$:(C1%S%_S6MVMU<\M5@95>[OJR*G'/!3A:*3=F8,9?O/
M>""9=;<$7`D!,I!3/L&P^OKJA^Z,'A\C>MN<I8QW/]HL]0MYOC!WH-V[[A?,
MO>7MOV_ELG'<YK&PWA]$QB4L]1\0W-!NVM:AP6LDV;-I-V21N\J@D;WU'*KA
M!V,D[>F.H*H@0J2BA#'[]]SF.&P#\=M<F9UQ;6YAP<)<"*!I:6`:4UJ`:?!<
M6:>>RM76OMR$O''C1S3&&Z4'*H!\``:I2VM_0$)*%&FRZSE=VF*4P::(@5L@
M^.J0J"I%6PB@#(INOSC[A0+OZ=-<[#VON*2RG_S,#&QL=5@CK4LIK4.U)\!1
M<G!6_NJ:RG;[C@:R)CJQB$FKF4UKR'(NKIH.)VW5#,2,Z$(]9G0*[0,9=N\?
M(OWCIJY653$$5S"JH<H)MB"'M@41W#X@&MUG!C1D&3M/"7B"&%@!`_X]QZ%2
M<=;8S_)LN6N].0-#@QS&M(:/Z0`-^B;])L1R[3;*/G8`V9E6`5F?;V.0+N5/
MM%;M*BH4`[3["([^FK%).Z*#U"Q@+G4H#N.W;?M"L\DOHP&4Q1A\CJ?<?M[=
MM3W;*_NXZ3%BU<,'`.3$-_C,[`W>NU<`(@W3<`E\R103'<!#H)M_B'3G0W5N
M)7Q7+*`TX!PJ'#J1VKDP75FV5\5TSA4_VP\:.']1%=_YI8RJ$B:M1KM\R%:4
M;IE("JJ`)NEFO<?]X98Z8@8R`!L!MP-L/J/PX=G-;MRDT%K)QM'.TH:M![!V
M`JO8Z:V9F)H;.3A:.<=`26@]@%=`>P!5%?L+VKM3KM4#/73EJ8(]%4B@+&2$
M=A.5,#G]U(A^[M-OO]FWIK5E,3!EIFPR'A&Q_F(V/QWKVBFRTY?$6^=N60RG
MTX&/\[F[5\=-=M/!+&LY5E6L9*MG$6D))!HJG(.S&5%5LV$#G,*:7R@X4`W[
M)0$#;CT';TXV4]G6TUY#-'*[E$X%K=`"::>;H*:JNY;V#8W%_!-;W+N4+ZL;
M0`.([7=-->Q):DV9NWG9`J=?%S%]2))RAWQCIE6*ILY33`Q015,;8Y"%`P`;
MU,(===;/XDR6,+G7/IW-1K&&5-*:'M'::CP7?]S89\F/@>;OT[RHKZ88*\:4
M#CU':20J]66G%VJ\*PC;*W*!5I!%99-P=11RW."O?]&F@D0I%2E$""'<)BCO
MN(`.M(LL?',+ZZDMGO(#2`12CA2M2:U'93=1VXW&LD&2OI;-[S1A#7,I0BE2
MXDUIU':GBC,TV->G_P`,3,2BJH*?M"603.5<Y2)![9B'5()5B',&Q0-N4!$1
MU1;KV+C8LW_DK*9S&$U\FU?@=%\VN_\`6N(@]R#-6%P]K"ZH],@MJ3W'17J&
MR%`RN,YLJ5%A:G8X$Z1QF928.U<+%4-V(FC6943G<*B4O:<"@`]@AMOMOJ'>
M>VLC;>Z(.>0N+S%SC6-D?(-[0\U%!V*%?>TLO8^]+8RY6YR&)NFD^C'#7CQ^
MX2/)H&[4WUJL4;M*&G%`=3,@YGU$DRID0>*JQJ*.P]PG57,8J2A$2FV#<H&$
MNP[CK['@;86$)@L6-MFD_P!`YU^%-"?%?>?:]B,=";;'0MLV$G6,-D<[L''<
M$]::)JK3.PGTK5G74547!4R'?.FJZY&PKAW%,W;JJ[.'")""'S#VAW;[!MMJ
MW8FPO(YW39-P<P_:T@$^+F[`_JKS@\7DH[E]QEW!\>O!KVM+J="0-&G]:)M3
MJG$PB/Q'X]1_6(]1UW@UM%:J+,/QVJ&'R"<$NO\`[Y?%[X?\]]'UG&T<ELC'
MG7<=U*4M&B(T1:=OYT\=O'+QP$/],^K?Y&,T:TSBK1_'0K1.`YH![?H5S.N\
M?N_U?KU"XA0O3;WJ($'?KZ:5[$=(*>7=`@4/7?TW_GV_ET%2O`Y[MJ*87;IO
MZ=/Y-8]=5J=6I[5-`A?7?<!]`UX[34+47';JH]Y2#^P!MNO41`/3TV`?37@`
M=KU7H:7"JD=Y1'H3KOOT,(``?<`[^FMH`ZK>&<?^Y]M%>FI&G:W.)^PHG$%A
M.G[@E`.T!'Y1VVV'].H;W2#D"*NIY:&@KWKG3/E!>T`EU/+0TU[TX:L5556I
M0;/D5'1DR&$G:()E'^D8P"!1+MOT`1_3JN,O,JR:LL9]*IZ_R55BO\['<<GQ
M/$8<=1J?@FWDV:;=P=,IA,4G<)>W;M$?M]3>NWVZL]N\R1!Y:6GO5OMKE\C`
MYS:/.]=TGU2=1$`$1WZ_'H`:F,.E"NFPU;4J2`B'H.VLZ5W62]D*00^8=AW^
MT`Z=-8N)!T7AJK@@Q4=)*^R/>8G;LF(#WB`C_1Z"`^GIOK0^9D3AZFBT23"%
MX$U&CM5,=@\3-VG;+%'X`9,Q=_Y0#6QL\3A4.'S6;+B"058]I'B%+'=`=O\`
MY4.AMA`P$'XAT]3;?JUF/-K_`$K9H[4:A;B/Y*HYC^2#DN)AW$>$UE_FSG@_
M6^(4'S^BD0B@^?T73-UN6]&B(T1&B(T1&B(T1<NO\V9%M9CR_3C`PH?7*\9\
M$@S!RL1JD!_JKOOW.E3%13(8N^_=\=M5G.W4UG(R5O+T->7$<CTZ#54WW->S
M8][+GS?BBO(M!<=A_2-5KL(XV4LT'+RZMB9-'<>\3B8BOQB8.DG:S)N4SEPL
MHD<I4DTR@'S@4PF,(^O75(F]S1XS(0V3+:1\<C.;YGGB6AQHT`4U).E*KYU/
M[PBQ&5M\;#:3/AF9ZDLTAXEH<:-`%-23TKH$UJ]1G&Z+=P\AWB*"RG<DX]LR
M;17M^?O*L<OMJ;$*(B4!Z;:M<66LII'QP2L<\,^T&KODKK'F\=+(^*WGC<]K
M-J^;7_R[]R>":-!,JXU4:7V,=RPE:HKU&/CGA400.F1,YEW:I1.H[*4-]P#M
MZ#UZ@`TFP9?3Y.1LV/E9:#D6W#G--379HZ#N5`QT62N,M*)\5<,L14MNWO;0
MFI-&MW#>P;I"M6;Y-\NX.IVI^P)6IP(H(N#)E#V$$A5(!MC@;Y=PV`VV^VK%
M*ZW,38G$<@=0>GR5FGEM70MB)JX'6O3O-$NJ%))1LNHI,-R+M![B@5T!A<E4
M$.IC$3#W1'<`W#T'5;]Q6SKFS:VR>62=VU/%5/W5:27M@V.PD].8;D:MI5*:
M>N[:;?*1,0V7E8\YD!>%,P74>LR`(BX<&78MS@V:%$P`.^QA'H/3?7/L?;\V
M.MQ>WA$=P0>!Y#BX]`T.<"7=BY6*]KRXNU_/O'^E><3P/-O!Y.S0U[JDFFA"
M<JJ5:)KK]E;6::=F)V@FVB5V2,FT(7Y`*T0;K*`JB(KB8X&[1#<P]VWQJF8S
M-[E;5V&E<;677E('NC<#_P`B0*'3OZ;*E9[W#?YJUDP4KO\`'RM^Z5LCHG?_
M`%DAM':4TKX)(WR/')DA+LZM6E*\R;2CEU(Q45&K*R+7Z%$HJ%7CTQ%<$SNU
M3&+L.Q0';?;;5AP5R/:4<4F2NQ=3OC:UCY7`,=7:A<*5I_%5:?:]VWV3:P2Y
MN];=W,D(9'+*\"-S7:@M>10NH-=R4D&<7*UB)4?M$K(B6,?-2.Y58#%<(=X!
M[2)VYE/<;%.("&X!Z^NNI/=6^4N_QYOQ7.>TD,%"".VM*%=F>^LLSD1:S?A/
M?*PED0^T@;FM*.Z*=!Y'G:'<8N].I9]--FAB?6-).2=>^Z9]2*,Q)^_5$Q$C
MB!2[%*'Q$/76O(>U\=[BP<N`9$R"=WVN:QM&NZ'IUUK]5AE/9>,]V^VY_;+(
M(K65]>+XV,HQW0Z<32HJ3KW!*JQ\D(C(MH<BWJ!&3-=(WX>1ZLFHX]Y(?=(4
MR:0*)@)]AZ`/4?41UR,=_K2]]NXAK'7KI)6D<N(-*=34Z_HN!B/]/W_M/!M;
M+DG23,<.?!M!QZZDUWHJ0D@SL4<[?R-3,D=ND</K$RN'HMA((@55-L">RI^S
M80[A+L!1^[6YUM+C;F*WMKRO,ZM)#>0[">SN"DNL[K$W45M9Y`O#R"6DM;RK
MT+M:>%%C3>HJ2^I,\*=!W'B&YG30QRIJ=PB8!60$Y@05*40`2;``;?'7U#!7
MEIZ/HT<VXZ`_KTU'>OLWMR^L_2$+0YEQT:[4GMH::A-ZB@*JR*""G>NJ;H4.
MA0$1#8.X?4?M^S5AD<(XS,_[!NK1.\QQ&:4?VP-U&2CE6)Q3<ALL`=W:41,'
MSE`Q![MMC`;[0UY;SMG:'Q&K3\%Y;73;AH=%]A^"RM\=H#_U@O!+H/\`^\OB
M]\/^>^CZFL(Y+HQ_<NX_J0I2-$1HBT[OSIQ#'\<O'`"%$P_VSZL.P?\`L8S1
MK1.X-:"[;_H5'N'M8P%QH*_0KFB$:'Z=Z9N[81[=P]/7?IU]-<\S"NFRYCKI
MH/E((^*!3+]X?K_U]]><B=EKYE>0`@&#U'8=AZ!M_.&L@7+VKB%6%1]P_:FF
M<P!MZ%W'K]NW0`$-:9'>GJ\@'Q6J5PB%7D#3M56=@JD!@7;+)`*7>!E"F(4H
M&V$A_3J4P>GP'6ILH<:`@E:!<-<?*6DUZ*UK)E(`&*8ARB82]Q1,([AZ@(&`
M-2Q4>5WW*8PN_JT*I3=`Z:R&ZWQ_<O!53)F`"[]0]?A\>@AZ:R+`X5*V.C#]
M2JGZD0#H;;I\_:``)OM`>T-Q#6OTQV+1Z+NQ2S/-Q(&_=UVV'?H'3I\W4`UL
M;&X;[+)MOORT5(J<#F'KV]=_M#T].FMC01JI#6\6@*5ML/IW!^L`_O:R_19:
MJ`?:(#M]VO3W;KU*"+**AB@F(`8H]PCWF)L`=?Z/KMKG79#`>0W^*Y>0XQ`A
MX)!'BEG*6:,&-+'+D6.Z!/L*Y0`AQ((;?M'-L.X^@[#N&N-:8JZ%R;D&D=:T
M/[*NX_#WK;PWK"T0\J\75U^&R;4P-@^;=0_=N.PB4#?KVWZCJS`OVT!"N1=*
MX[-'\EN(?DJQ2'R/<EO;`P?YD]EW[A`?_7IA'?T_5J1%RZTIK]%)@#Q]Q'7;
MX+IEZWJ0C1$:(C1$:(C1$:(N93^:EE*$EY8[C$7:`,^-(<;\!A$S;`W9+0KD
MRE[+[Z1NXB:C9(P`8Y%.XIOL^(?./>-I[A?D;>\P5PUC8VGU(G_9*--.I!Z5
M%/%?)_?EC[HDS%KD/;MTV-D4;Q+!)7TYFFG6A(<.A%.]:X+&#9M9ADV=65..
MA'RI2_BQ#L?JWCI,IA:K'8E4!0C8R1>TZFQB[[A^T(!JJ7=_-+CGS06CI;V,
M&L9Y4`ZT<>O8%1;S(SRXF6XALG3Y"('^T>5&CKQ=34_\1]%09,GGK*0?5B%!
MBO&(E(Y2EXU1XK%OG*B(%%8Q'AE21R@%$P;%$"[@'PUN]JXVWF@BRUZZ5MRX
M4]-_$/8*[5;]P[SJI?LS&VUQ:19F_=*RY=O#(U@D8*_:.&KQ7J=4WT`!4XA:
M,?`T2D'3_P"J;R)">\Y0(9/VU$%'1>\H,S]#"0.X1VU8\I(77PN+;D;1K*%I
M.A(Z@?\`+I56G+2!^1;=VG/\&.,!T9V)'4#3S5[=$X,F^<M86#B%+5'R+"!^
MJ49D;M#%[EESG.03KG0274.;^AW`!@#;NVZ:KEK'#)?7%XRT?'-.X%U7:4`I
MH*FG>JI9P0RY.YOH[&2*YNG`N)=44`Z-#B`.U4#-9Q^$O5%DB.E5"=C14Q$C
MNT";`787!=P'W!'I\QA+_)K=<-B%Y&UIXQ#[F]"M]PV`9")L;BV%OWBI#"?#
M?3Y%7?&&99/"CFR)(U*/FE+$@FD<DDV$I@01*<4S).03!0J9_<$QB@':<2^N
MHGNKV5;>^&VDS[R6W9:FHX&H)/:*]V]=.Q0_>O\`KBV_V+%9ROR$UI':DD>D
M[<D@T+:TZ:$&HU5'6[]8I9](JM6+XJ3GZ@QDV:S*.%JX55]XA61#'3,8PJF]
M"%,<P!Z:WY/V[B[2WA]21G-E`2[F_D!I5U`::=IT4C,^UL-900_D20\V4!+P
MYX<T`"KM"!H->1HIL&_RIB2PH6\8LS9W(F64!:4=I+MY!!;JHW?D24%P054Q
M`0ZE,!]AUKO[?VG[RQSL.9O4AA%*1M(<QPZM)H-#^BCY6U]B>_L4[`?D!]O"
MT#C$TAT;F[.C)TT(Z5%-%2V^_P`[;YU1U)D)%QCA5NJ]C(P5#HK.#`4RRBQS
M@43E54)OVFW[3`&_7KK;B/;]AA<>V&U)EO&AP$DA%:=/"G=12L'[6Q?M_&-M
MK1SIKUH<&R2TJ&]`.RG=1+ZIOJ183.(6;3:-W+<RAV!'B^RBR:J9BG2["AN0
MY@Z;>O7;<-5S,0>X,3POK%SGPNIS+!L54,[;^Z,(8\AC7/DMW$%_!IH'`U'P
M\-%CE88!"M69T>,4`6C-^51JH"I5U$/F]T""8FY3E2$HI["'<(>NOJ-ADG93
M$,9<CC,^*CNE?XW7V7&Y7_,X2-EXWC<R0^<;!U13ZUT3PLKK)K,9)[&+O8]D
M]33_`!9!JW142^O32*FJ<I3`!D.X`[O<#N#<1]!';5'N,%9-N8H;P,DN6'^V
M:D'C73K0T[U\^N?;=C'/#;WOIR7,7_:))!XDZ;&A(V3:2LJG&RL=&BS6<-Q.
MW>.E@4.F1<CL`.8R`(%*"I"D..XCT,("'IJTV=FZXM9;OFQLI:0T=A;L#6M"
M3I]5=+&PDN;":^YM9.6D,;3[2W8&NHKM\4ZURQ50VKULWK\K[JKV,;R1EMD$
M'B!7*1%CG'VQ.U4(!C]H=P)G^`A\=5/">\/<4\!DR41;&R4QTK5I(--.H_4=
MZH7MWWY[GN;9TV5MR(63NC`J7-/$D=0'#]0>A3+2%8KK@#H.[&_;JLSG1*HL
MQ:.$"@F4`'O.BL@XW)UW#M-L'H`ZO5OE[]E'16S'!^M.9!U[*@@_,+Z3:9K)
MQ4E@LHW-DH2!(YIU[G-(_4#O3]<`V$:R\A'!0C&91DBEYF<7P,H#1RVW,&;Z
M/\I2J%'?H'KN`:LME/<34=-"Z,G_`,S3_)77'W%U.ULEQ`8J].37?R7;^UUU
MVD:(C1%IZ_G1C=GCHXXC_P#S.JP?_HQFC_6U$O!6,#O^A4&_;RB`[_H5S1%'
M`B`;B("&^^PCW#O]OIT#4!L;:5*Y38Q2E`J<"B/7NW#?T]0_6`ZRK36BV$TT
MHKHQ235$QE>SVR[=QC[`0OZ1]"^FM-Q(ZE&$A_0#JHT[W-;Q8*R';M2UAW\(
M0WL?*4ZH]A3F2V1+W#^T'>7?<1#UUP;^WO"WU1K05(KJJUD[;(N9ZH%:"I`.
MJ7@L&"I/9<$3526`$Q'VP'O`=OV0WW)T'U#UUP67ES#)5E6N&ZJ\=W=QR<XR
MYKVZ[G^75-W/5Q%J*Z2"J`)$,)TP`VQNG78!$G<(CTU:,9DW3'E,UQ>?DKGB
M<M).`^<.+Z:Z?#9-\9$P"8!V^41#YNGI_+KN@@[%69KCQYBM.T*3\@#L;8/U
M:]U6=7D5;52SE2*&X'#YO^]ZC\/TZS'([+:QSR:%JD#[8_'?]`]1_7\1UD.2
MVZKR).U02'(9,0V`2*`9,Y1';]HHAW`.P^@ZR-0.]>FH%57IMR@&^XFW#H'J
M`;[#OK2]YI4[J&^<G0"A7KV4P#Y@*(?$-MNOV?IU@'NWU6'J/K0$U4?KO:#V
MTT2D_P`$2#L(A]X!V]=>B&IYDU\5D;7D>3GN)[U0?NU#")CB7YA'M-N/KZ@'
M4=M2"Y]*;Z:*47.:T-:*T"]@D41#8-R_`?M#[_MUK+R/%>%^G_F6XM^2N3(7
MR-\EA*``(\*+&'W_`/+GA3K^CH&MUNXEU#W_`$6RU>YSJ';7_P!*Z8FI:G(T
M1&B(T1&B(T1&B+F3?FI%JO\`];9:FLS"-I:25XVX(_#14D"-#I#[EYZ&(KW$
M$GN=>[;H&X:^<>\V97\R&:SN'0V;0?4`:7<MMB!NODW^P(\V,C;3X^Z=;V+0
M?4'`NY;;$"M:=/!:U<G4;J5TK&1K(Y'S9DM*LS,5_P`559L3)"NZ)[Z)#IIM
MT"D$QC[`!2@.^P:X5KF,))&+B5U;9SPPAP+*FM!O2IKV]56+3/\`MQT3+N[D
M!M9'ACN33&"XFC?*:$DG;K7:JM3,\C)QAFMG</UU"-UD4U2KI%;)B3]DZ;9`
M$_?4)TV+U$WIN&MUQ';V=WRQ;8FCD"1K4_$UHI5U':V-\),*R%HY@D%IY$=Y
M=]OB?DD.[CQ!JL#%V]?HL3F`YP049/41*80,FN@<ZZ9TC?T3$.80'H(>FK%#
M,V20>NUC)'BHU#FFO8137Q%%:HYXW70_(9'%)(*@%S7-(/4.']7:"%ZKVUB5
M_"'+X(HJIMFCUX4ZI/='8!25*0#*AWE#]HI1V'H&M60+L;&;J&/UNUK:`T[1
M6@_4+5E2[#L_/BB,X:/,QE`:'J*Z?JG*91K&/,G!/)5PF1`.PKQ@FF9-Z<#@
MJMV*.3H]IA,78F_PVW#IJKW-Q--6^AA!Y;L<=6]->(/B?YJEW-S<W8.1M8&N
M+]V/-"SH*AH=TU5)+J(RT@5PQ3.1)D@FT.*CHJC@R0&(4RCQ,#"(@H8![A`.
MW4BQY6=N8IW#E(ZH\I#1OH#]-U)L`^QMC%<.JZ1W(>4AH[FGZ)-SC]:,018D
M1.S!1T#IBHW;B9V@J42E$?J53[F(N!`.!-OE`?7KKKV<$=QSF!:]A;Q<TN\I
M'AT.NZ[>+MH+N5]P7![>'%X<[R$;[#8ZTK7N5KE)^9DFAQW3.V%0%72!#N@%
M5R(C^]63446^G,`[")43%3W_`)-;[3'65L\%@/,"@<0-!V5%*]Q<"5-M<=C;
M2X'I`B4_::,T`Z`@"HIMRJ:*[0EBE6QP;RK!$&!B`!/W9$5$""(F%1LN<>X_
M<)AW'<P[Z@WV-M)@9;20_D#OJ">PCHN;E,59W`]:QD/Y0)V)(<>P@:#Y!+%A
M'X^E9(LJNZEFP$53^I_"MCO`5#J<")."`W,!R@(?*<GS=?NUQ;BZ]QVUM^%'
M'`YQ::<ZAI':2#O\%7+J]]V65K^!'%;O<6GB):AE.TEI!J.\%2;82!:R*ZM8
M;33QKV)&%&29-Q='V(F!G"Z/;V[&*<_8(`8P!MMON`AOQ+LE-`UN4=!'-L"T
MFG<`I."=E;BV9#F701770L<[C7HT$Z_1*2N2U/-&*F3ETVQ738&KM!1NHU<L
MR@<AA3%N.Z:Y0'<HG)L8=^H:Y&1L\XVY#G0N/!U6N#@X.[Z[CP_5<3+V7N%E
M\P&W<9(W\F.Y!S3W\M_@=!T*;%2;G6K\T0W)^*P+198K).18M5O80,H)RF:.
MW"/O-@'?H0I]AVZAU'5Q%C92VPNG$Q7SP.7!SAJ.UH-/C2JOC<=C;BU%[.3!
MDW@<RQ[@*CM8#2O?1/AC>NR]J1E%?8,]^F*W.NJY%LR!@R32546(DFV#W%TP
M23#M$PD*3X!UU\]]T9.PQ3X82\QAQ-`*N#GDC4UV-=Z5)7ROWEF,9@I((P[@
MYY<&M:'.]1Y(U).@-3WD_!,A:6A9JRR->8_2LVR$BL0'XK^P#MNH8O[TQ#FZ
MF+Z]Q3"`_'7T#&2''XR.^O.3YW1@T`Y`&FU>SX!?3\//_C</#EKKF^X=&T\`
M.0::;?P%DOX^:=$-/(%PE3.\0(LSY@\:52J/#.EC+J(YII(I%;@V3*B4ZYR_
M*)A$I?CN&NQ!F;J4PNC8[@^0`\>(H"=2:ZT`[-58+7W#?7$L+VQO,,DC1Q8&
MCB"=2[D=@-PW7N7;"U=%]$1HB-$6GE^=*$`\<W'#?_3/JW^1C-&H]R*L'C]"
MHEX"8QX_0KF=+&,!@`!$`VWV^W_N:B-;044.%K2RI&J@`]A@'O*;]8;=>GP'
M7A'2B\=YQ0-(5:D[*5(Z([`10Q3#U]!+^C[1UI?'5P>!Y@%&=`\O#Q6H[E-(
MKVC\@DW,':4W<40VZ=0`P>O]S6!8>H*UNC)^ZM.J4;&Q.(]N1)14KD2&$4^Y
M00$A=@`"B<-A';U``'IKG7.,CN'\J%OP7)O,1;W<_J1M+&TV[^U4C^PJNRB4
M2IB/K[AC")@-_A`(#MU#6VTQT=N:ZT[-ENL\5%;:ZGN7WE\-L+P8GZ9RUL^8
M>)R6=\F\?.$_*_DO><CYNM"4KAFB-Z;!,*IA2H8NPM%,4&=CO%OO=OCQD)NS
MO'Q6HE%*,8(*$%Z/=A:P,\N]/X_GV_KJK/;AHBHVM:;=]/\`KV[=*ZK7I,42
MI`<YC;D2`3[;"(B4NYO7U$1UJ!!?1H%"=%I:X%Y:T:%VGQ6R%?'^#O%1<N(O
M#*-X2\6N57([(&.\#94YQ77E5C9]EB90MO(U"&ME?XVX:BW4[&1.+(FAXRLL
M<5W-LFIYJ1FGPK`NFB@1(\NK6T;_`!H*J=Y6T;_&U4X^.N(GCMQ1YS^8_$?+
M)Z"?CFRSK'8+P[B^V1^2Y:]M']_N]<E2/,2Y1C+E4J1BU_@%5HH$I8KU(23$
M:XDX;!'R;MQV@HUI\=_G3^/JA#6GQ_>G\?5?/3S4\A>+')'E4KDSB6RIBU,O
M*]XR=<K2E7,E0F;I#(^0KK(N;+5<]/KC-RE"EY.EJ0I"UPM%20J[.NO6Z:8G
M<"L5/!Y#N\+6\APIH6KX^>\J0=@4$P?S?R>FM7!KAJ%H]-AW`7H%U#%V,([;
M^H;%`/CMN(;>NO"QHV7GIL&P"F)`*INT!`1_0/3^?KK!_D%>B2.$;>71>EFW
MMCN.X]>HE`=MQ^_80'1DO+:B1R>H*CHII!(F4/Z0@`=.G00^_P".^O#J=>JT
M/8]SR-A5;AGY+!3O\D')<-A`/[$UC';]&<\(_P"OJ5;M`U'?]%-M8^`[]?HN
MF-J2IB-$1HB-$1HB-$1HBY</YLU)^Y\Q,PVAR%5E#<9L$'12!LHJN?9W=B![
M*@*"F0X"?IW$'].J_FWV\;`^\_\`\VHK44V'3_JJM[DEM8(Q+?D-M!74N``T
M!U!'U7P.;JK12X0LJ_EHZ6`$6W8FK[,DZ;RC<2JD(I\Q7A#"H;O*(=I$QZ]!
MU\HFB9<,-_:,C?:5Y5(JT<34>7^D]FNI7Q*6.*[C.4M(H)<>X\B:`QM+#4&F
MA8=-"-2=DH9VHM(BKLC.!D&KE5PF19R9DT<"U3[`!(R+A)<B@G<E-W&#VQV$
M?M#7.QV:FOLJ\1MA?%PT;R<*D;Z4.VVZX^*]PS9',R^B(9&ANC>;Q4]20130
MZ#S;)*)0T<1TJ[CIA4S%)IVN_J4TP77.`D3%$[<#IF.F8W7N#N#I^O74??W+
MHQ!=0@7'/R\:TITU^B[;\A=R0"WOX`VZ+ZMXDD#L\W;W*,0:O0B<NM%FCRSC
M]EM'++F`YV1E%!^J*@8Q-D%%-A$#@("4@AL/J.LKK_)W_I170D_`8^K@*CE3
M:O:.Y9WW^5R<EO'>-E.)C=YVBOFH/+6GW`'HF3D^Z.7>)JR!E$3I'$4?J"/1
M%VH(F[DNP_:`$.`#W_*8`'XZO=JYEW$SA&T2`4KQX"@_Z?-?2K5S;R.-PC#9
MF@"O'AY1H!MV:'?54M=:VRPK*GBU??-'$*"IU%BIJE1-N'[LQA*=78`^`B/W
M:SR4V&QK!^2"TRZ[5%?X\%GEY<#BHP,AY#-J`!R!/?V%;'7BLX13MCXGY^YE
M1O$V!YM9@JF9*-QWP5B'))/Q3"5#L4W57^1,EYYS9'/[%3JY.5ZFUI.-BXAG
M,RS.(/+RI!7]TWM$#FV=+FWDO\?&)7!P8QM"&5H22^G2E`*Z`NU!V7(L&,NK
M>7)XR%LT@<(V-XEK-BYSI*4TI0>;RU<*AU`%@EY!ZSENL<AH9AR@XD8AX8Y%
M;46#56I>$\3-<38_R'`K2\T[C<HM(*!L]IH-A<3":QF!Y2OKDC7)(\A1**Z:
MIS<[,SYQ\?I-MQ')PH`WZ';X@4T7+ST_N&1GHMM6PS".@#33H=CH/_QH-.VJ
M<SCWS/PUA&J3<-`<+N,7(G)]@F6SAA>.2..I;,4;&5LK%FP0H58QF-BA:O&*
MR4F595>3*DM)+?5`DD8@)D,-)PG_`,@P6MQ%;R/DFJYTG-S@W2C6MY!H/*I+
MB"[H*+YU[>/N?VT[G=16DLDUQ5SI?4>\,H*,:WD&`UJ2\@N(H!QHLP.5O'+B
M-Q^\NM?K+VAX<Q!QS5Q-C;(/(O`F0H7+.0,58CRCD3!7\096Q#"PF)[%#93&
M?@9J82_AU!"3;$A;"Y;`N9%HW,0EZRN:Q5ED6QWU&SD#GRYN]/E&'%OE/+<D
M#70TJ0`5])SGN#"X[+QQY&C;EP;ZG+U'"'E"'EHX'GN2T4U#B*D`&BF\[,YP
MMFG^/DN+:L##9>2KW'0+DM>&-LL&>G%'9\4J&TQ<UCLBUVU2_'\,7PM.*PC9
MV(39-[6G>&[APNLNU$IPE9&[Q4L;/3;ZMO2,N!J7<3&WB06DMH!0$"CN5>BE
M9B^PUQ%&(F":UI&7M=4OX&)I:YI:2S04#AH_D#6H6N;(,V<XFFUM*1&;P$B=
MCY%`I%DUR=H"NX5;=HJ-E`^;J42C]O37*M[BXQY,N*/J0$D\"XG3L'+8_'X+
MD6-U<8M[IL(3-:..K'.)HWL8';$=E?@D6F22:6EI%-GD6Z:O%T46:ZX@WCMR
ME`HG]]R<A0,!1$/F$`$>GV:[T@M)L2;F1DK96`EX;J_Y`55EF%E-@GWTL<T<
MT;2Y[6BLG:!Q`KJ>Y9#-I1S!13R+67%G]>=5LNZ9N4TQ,!=@[S*F%,B;1P&Y
M=@'<2^G3;7S22TCO;UMU&/4#-FN;7Y#_`)#M7R"6QBR=]'?1`2E@!:QS22*Z
M[?\`(=IIX)`.*Y)+.73@7T.XC5O<.V7;)"X,V1$OR"58B154B&$0`1-OUZ]-
M689.U8QL4<<S9FT#@2!4]=]#\%;H<S90QLMVPSLNFTY-=H"X;U!-#\%F%P2Q
MA*)<VN#$O]:Q=()\O>-CPJP.E??(DCF>DKG05+L4HG,`;E*(F]/T:8;W;8OR
MHLN$C9S(QM.(IJX"OA\EG@_?=E+GFX]T<K)G2L93B*5+@*U[._1=FS7V5?H!
M&B(T1:?GYT!BJ_\`'1QU31,0#I<R:NKL<P%[P##69B]I1$0^;YM0;Z=D$;7/
MK0NIIX%<[)7,=M$UTE:%]-/`KF:+-'!#;*$V$@B41W`2@/QV$!]!^&H[9F$5
M:="H\4\!;H[3P4L$B@/:8=Q_^"(;?K'[=9EP`63IJMJT&JB='8.XH]/3K\1^
M[0.!%=5BR;H[=0#T]?V=@]?3]7K\->:[KPZFO:II@3*4H^X"@F+N(!W%[!W]
M!$VW</Z.FO!KN%A1W310)V=IA$!,8H"(%*/4VW78-Q`-Q]-8.Y5H-D/*M*T"
MV4>)N+N%N%N!'/;$TCY5.$D1GOFYC_C71ZZX/"\J5XK&&-Z9D1/+.9*C;G['
MCLN[6ME@<QT9%I)QJ;QBJ+5;O6`HIF&9"'-90UKOL?\`^/AVJ;"US(Z&O(T.
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M$*4```U&E-3RV'\?)0KEY^\:435.4S@?8Q#%Z[B`@(=-O4!'7C"!X)"06"A!
M3J5>0P,V@VB5TJ&8I6QE.X^M?U7)%(K\&L0RQQ:@TB9C$UGD6QTVW:503O50
M.H`F*!`$"ALJ"=A7XK=4=WZ_NLBE,S<)%H08L>&5M)(A!L89.R(\@)1&3(X:
M(OTW%B.R2J00J]ADE7::BQSMA:%%JF5-N0IE>_,/C`\QJ?BO2X=3_-,C*FP.
M\C'2%)IN9(NRJ`B$=(6G)=&GH)N/OI"N+Z'B,1UJ1>%,V`Y2>V^1[3B!A[@`
M2FY]U<QLB+J"@\5SKR[B9`YQ`H/%6<:0NJT]Q%TA[Y@`2^X)1(&^XCW#_1,'
M7X#JMLST+9N$C'<>X;JG1^Y8F7/IO8[A7O"2;NM"AN*SUF"W])-(X".P>O<4
MO4H_?KKQY5LI_MQO]/O"L$&<;-I%$\,Z&A_FMNO\EH@5#R0<ERE,!]N$]C`1
M*(B'_+IA/IU#[M=JUD]05U&^_P`%W[*1TC>3N_\`]*Z8.IBGHT1&B(T1&B(T
M1&B+F)?FK[,_BO+Q.Q;!FV3^NXXX&.\DRMBF?&:@M>"F9E=@7WD4O4=B&+U'
MK\-4'W?C(+J5EU</>>#3QC+O)R_Y<=B?$'9?,??>'MKV>.]N9'EL<;@V(N\@
M=I1_"M"?$'9:V=E?Q:#LKDCYY'2Q7*#A!(!,Y[SDV'O,HL<?8`NP;_X?QV`-
M5G%PWDT#H7LCDLW-(<:4WZ4`_P#!5#"6]W-:FVGC9+C^#@:>7<;``4->VE0K
MJ6<L5S>L&\[)O'[1=P7W3@U!(I'"8"9O[`MP^E!0B93#L`%[@W$=QZZCNL<?
MA+5YQL+&3-::"M33K6OFW4`X[%8"SE?B;=D=PT&@K4\3O6OFI57NY2L14FRB
M$6Q2>R`MA3:*/&[?]\980,J9=`#F,?VBG$"G'I^L-0<#:7F9G$EY*8H`_7B7
M:4["?Y*![:L<AG;ALM[*Z*U#ZGB7:`=A^B:&84_%4TC)1B,8*J"#@I$C'_=K
MF2^<B:HB!S)*''N$HCL`C\=7"S__`*E6OF,K0XCS=G;38=E0K_8\+$ECY73,
M#R*NUT'6GU"1)DU6)%4'R3Q!81)[A2]OM]V_>D4Q#;]Y.T0';XAKM->)W!UN
M6&,^/Q5C8?R"'VCF.A/C7O\`UJG(HEPB(&ORB1U&3"<=O"F1=N0=MW`,1*`*
M'C7;<3-2K"8!*9-<@E$O4-AU7,]@KG(Y"-U))+*-A!8WB1RZ<P?-\6E5#W/[
M>O<KE(90V67&LC-6MXN;RZ<P[S?%ATZK[+\3,X<?L^^////CFRWR9H/&>^ON
M36..6>$LEYG97Q;"-U?P]"E\79"Q??[)C^M6R3JCM2$=M96*<.(ERS5<H"GW
M$.!>[IXW%.BQS[.1IM_[HD;2N_$MV'(TV\::D576Q.'+<5)82`VH]<2-I4:\
M2W6@<0`*'O(H2*A*'DKD+A7GRS^,3@$/,ZI16'.(.$\HXYS#S\?XMOD]CTUR
MR%;;1EI2!H=#EDZ]D&TXRHTBW85F$>/$HTJIG9EBHIMDP$_5EM!<^E9N?)Z3
M0:N%>1J2>P'2M`:`[KMSV`O/1L'/F]%@/)X!J:ESMZ`Z5H#0'<T"4_B4-PVQ
MO3LN<G,@\S>+U(Y@T:VN*EQ,HG(:EY05Q117J"#-<G*BSP%"QE=W.0K%"$=J
M?PA7G)6[!A+MA>R'NBDW1UQH\;C8+KU;ECQ<L</2]02/;L"7UXO:"TFC0[^H
M<B"*+AQX?#VMZ;BZBD;=1O'H^J)9&UHTF2H:]@+2:-#A]S>1!%`OGIR@JS:`
MR[*NZ_S+QYR]M.1$GV2;OG3%SC+?T#Z[V2P3*L]%VXV8Z=3)M_;WBR0/UW"#
M95L*3Q,`4`Y3)DXF?@MK2Y$]X&73'C4%NH)KK7BT]_[FJK7N6TL[.[;<9`1W
ML+QJTL\P)KKR+6N[^IUKJ:IA&EA;1\<ZB)J.CYF9.K^XDP*!%&I@`=^X@`9N
MH142AN8P==]^GKJLOQC[F[9=V,DD-B!JSH[X[_!4^7#S7=]'>XN66WQX'FCW
M#NS4D'X*7`R*;(OX\RB4)4[=55%9D[;(N6:2B93%3V%4Y``JP#L`!^R;;IMK
M._MG7#S833.@8X`AS20XU[M:D+;E+-]VW_%W4[X&N`(>QQ:\@]P!.E-^J0\Z
M@E;+,V>%K<-71<+IBO&,$5DFZ!$Q*)C@"BBBO<L`"8P@!2@/ITU8;.9^'Q3[
M<W4]SQ::/?3D3WTH-.FZLV/N),#A'6[[RYNWL80)'T+G5%`"=`:?-.+8:_\`
M5JH(P:JSLR8%[XQ-03&1*0I2"D1,0(`F'?;81Z[_`':JV,R9@C,M^UL8)-'G
MKWE5#"9@VH=/DV-BW(D(I4]II^R0LM6)V`66;)@Y2;>T!C,3N"E5;KG3$Q4"
M`85"&1*;H(;[_#5@MLKC<B`YQ:7\OOH:$=O:K1CLYB<PQKYBSU.7W@&CF]3V
M\OT67WCY4>CS6X2!(J2)!5Y?<;!%J/>`![68Z6"`F$A#`!1W^;T*(:W6HA&8
MC_&$1'JL\VE?N%:+.T%L/<4(LVPEHFC\VE35PK_TZU79OU]D7Z!1HB-$6H)^
M<VB)J9\=W'-M!PTQ-N4^95875;0L:]DW*2!<-9F(991%BBNH1$#G*7N$`+W&
M`-]Q#4>X87L`%*U^BC7,9D8`*;]?`KFP!C[(9NO\`7OKU,'\'60=]O\`"_Q:
M(#J"87CL^8_=<TP2-_X_,?NO!\<Y#W$Q<?7H`^S^#K(&WZ/\6;:V<'$]/F/W
M638Y-C2OB/W0&/,B"3M'']ZZ=0_\3K)O^C_YLU[P=MI\Q^Z&%X=44_\`R'[J
ME''.1-QWQ]>@'XA_!]B_WMUEZ;N[YA2@PT&WS'[J']7.1/\`\O[S_P`$+%_O
M;KWTW=WS"]X.[OF%Z#'>10#;^K^\_P#`^Q?[VZ\])W=\PL3%4U-*^(_=0''6
M11ZC0+T(_?4+$/\`]6Z]]-W=\PLN#N[YA>?ZNLB"(;4&\;?9_!]AZ_K_``[7
MOINIM^H3@>[YA0'&^11ZC0;UMN/3^#[$'3[_`/%W70-<-@*^(7H8ZO3YA5;?
M'&1$/WH8^O)3!T((4ZR"/Z_\5[#OO]^L7-<06FE#WA1IFND_MBE.NK?W7E>@
MY(7.)E*!>?N#^#[$&WZ@C>FO&PEK0UM*#O"S@MQ`VC*5\1^ZEIXWR$([&H%[
MVV_^Q]C,/K_]&CKUS']WS"RD;(!Y:5\1^ZJ@QY?$P$`Q]?##\!&GV(`^_H,8
M!NNM1AE=K5OS"T&"9^II\PJY*DW]`/<3H=\%80V#VZ?8P]L-^H'$8P`$=@^&
M^M+K-[QQ<&\?$**_'S2>1X;P[R/W4\]4R:HF*84G(!2F``,!*?9`'?;J(F"-
MZ[_'[=:ACHVN#BUG(=X6MN)B8X/<R,N&VH^JM!J#D$#B;^`;Z8V_J-2L8"(_
M>(Q^^I@@DI2C:?!=`02<:`,`^"V]/R8E8M4+Y&>2CJ=K%CA&BW"RQH).)F$D
MXQ!1P.<<**%135?-D$SJF3(8P%`>X0(8?0!U+@9P[*Z_3]E,MH_3%#2NOT_9
M=*G4A2D:(C1$:(C1$:(C1%S-OS3.,[E:/+=8["QA[`O7&/&S!Y#.XF!F)8'3
MU!6['4:I#'L7!!$@'*!@$W3NVVU0?=U\R&>*UBB,MX\:#8`&@!))H.J^9>^L
MG';W$-A;P&?(RC2NC6`T%22:=NBUDK16+LDB4Z>'KN(*@=-&8>42TIN%C@;N
M_<IKL.PX%]!'L+TU'Q>.NI#1\^V\;7-H/$C^55$PF)O72^:[\[""Z)KVD#Q(
M_=6=N\S&RK2M90I=_-'N'Z4F=`:5/II)/4"&335]PD1[YQ]LXE$`[2]?CUU+
MD]I6,^3&4D8W\D,+.7+7B34BE:;Z]JGR^QL7<YH9N1C1>MC,8<'5/$FI%"ZF
M_6E5>Z31YV34G)ZXT+(X-8YHBBTBV-4LH+RDDY[Q(`+*Q:GTZ"8D$Q]O0H_'
MT&'G;7)VPM\?A61^I(XN<]U*,8W<D=3V=%SO<ECF+)MKB?;PB,DTA<^62E&1
MMI70:%VM!7=7]GC2_6:.;C%8PR&@C%N5UURDJMD<*?3!V&3*`*1Q.T@&'J(>
MOQUSI#)B;DMO9&.=*T`>4#S=>I^BY,QFPMV69!\<CYV@#0#7K2A/3P3>V2E9
M`0(JQ7QO>S+AL)52U*QJ%4/UV5!4(SN_=CN`;=>FK%B;1\@$['`,/30?56S!
MV$CZ74+^+#TT'PHD"?&^35$RB&.[X9,!$O<-,LOJ.P[CW1FV_P!@AJP-8UKO
MN;6G:%:&1Q,>0YS:TZ.'[I90F&LDNR%9%Q]>@<.C)B=12I6`B!``1[4Q4-'?
M)U'<P_JUQ;^_9!_><:L:.FI^755W)Y-MM68T,;1L-7?+JKP;#E\0<N(YM0KM
M,K)=_NJ)4JU`@04R_,4IOPU(1(01V$WQ$-06WLCHVW,H$,1V!(J:[==*_HN>
MS(SNB;=3M_'B=L'.;R-=C2II7>FZM">/LAQKT6K7'M]!50H(N?\`Q(L:ADEM
M]Q%`I(TX&,F([`(CJ<8C/!ZSR"S<>8"OZKH20/N[83R$%@U;Y@`1WU(HE`O4
ML@0:I2.Z%D(JWM%)NC3;(!%0'<0,9`8M,4A+O\VP]1U`;CSD&5C#.'2I'\^J
MY,6(=E&5A$?`:ZD?H>OBKM#52\R+AP[&D7IBF5`YE1-3+*D"B*)?F!(2QG^V
M"7X=.OQ#7/O,;<VC&Q-`<[D*4-:$]O<H.0Q5U9QLB:P/>7@"C@:$]3W*VQD)
M>S/':32CY`;(.E1]TCNHV0&JZ9.B0BB6+-V'.7H/J&^VI5YA9O2CDF8UTC!N
M"*@]=:[*9?>WKAL4<URQKW,:*%I`>#UUK2G8GBQCC[,CZP./PC&5N(]8-5EB
MR3VCV,[1JEVB!F;XYHPIA*Z*/83L'?N$-^FX:IGN:*PM<>S\R23T)'@%C'>8
MFOW-&OVG4U&WP7S[WG!B+7%Q-R4LGX<L@'IM=YW&M0YH%?M(JZO15C63R#7[
M"LB_QI>`FBK+-W*)J-8&J@+&,(&(+I-B``W$X@)#E,!A]=PUHF]E29#'-DMW
MDV3@'-\U:]]#K7M%%$N/]>R93$,EM)*XXM#@>?+2FFA&I[0?DK\K&W>Y/OI2
MT&X@Z$HF(L--GS";8H&(!ECQP;JDW_:$1$VN6/;]S@X!.2YT50"*TIVZ=G@N
M0/;%[[=M_P`E_,V]0"*T^0%=$]/"3%N1R\^>&1)&!O3-K$<L>-LHNNZK-B;1
MITVF:*4LX[S?0$12(1(H@(JF`H%W,/IJYX.Y9"^"2*!KO4E:T[<FU.YKK0=R
M^@>V[QD,EM-%;-<)9V,TIR;4CS&NM!OHNR1K[`OO*-$1HB-$1HB-$1HB-$1H
MB-$1HB-$1HB-$6'/)7GSQ4XBW'%M"S]E6&H5HS!,A$TZ.DC`11=(8JSR?XNJ
M"ITCN(WZBJJL>UF5V\%^Z:I`@(+E.!%F*40,`&*.X&`!`?M`0W`?Y-$4=$7S
MJRWY+L1XNSID/CO#86Y<YVR+B6(H<ODPO'+CG<\P5ZCCDN(>S],B;%/UX091
M\[+P3$SPK4W[PK8Y#CT.&B+)/C/R<Q/RUQE_6KB!_85(5G;+=C^T5ZZU&Q8_
MO]!R)0)MS7+QC^_T6VQ\59*E;ZM--#HNF;I`AMA(HF)T5$U#$5WS/G_'6!3X
MC1R`ZED76<,UTG`&/&D-$.9AU*9%OK>;?Q#5PDVZL8EG$5M^^>NS_NFK-HHH
M;<"["1/7HBQMKG*O%%YA*#:,;EN^3JKD3-MSP)$VB@T"UV"O1-PQW)9`@;O.
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M).7I$:8C]$"O"((J-RJ`W<N4EB+'/R#X%R/G_'5%KV-<6UK*LG!W@TW(1-FY
MG\G.%+6,CQK\LP"2;W?B[7K%:K@X%R[(E^$22:<<!3BY[O?13`2*B\>G'[)?
M'ZEY&ALEXIK&*7]BML=+1D=6.;/*3FRWEV3>#08JOW5JY25RN6"C+HN$Q3"-
MBB*L5RA[YS`L8P:(OCMC?$?D`RW4/*#STX6\M[+B2[97Y@<@G>,<*EPG@N[U
M_--4X=I1G&.HQJ-VR70+;;ZO,Y$CL(/V<.Y0.O$1SQT@[.Q<%,Y*N18FY%7Q
M*4>$4=5\DX?C>`>9.+N8.><W/^2O)=_@*;RMYFY<R3#2N3C9^G\<I5:N9%SQ
MB>N2*RZ-)=M$XHB\DN>/B3&AVX-")[J'8\D8MJ'CV7M#:^YOA>)V`_)]Y4J]
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M(3*K:?8FG')U@:D2(E]-X?S1RO\`+KR]OF).4&1^+3?B+QCXU<5FMDQ]CG"^
M0%;C.YAD[AR9R5%KDS9CW(43')140[I`J'C46KA0XD(LH<J92%(L8?)%8,NX
MIN5_^OR1?<]Y$X`^';F/EEMF63JU5KEH=9QYGWV,PIBNY34)BBJUBFPA\>4'
M%MG64-'QS?Z>*1.X4+W'55.1(ODYGN6=IPM0\?N1YS,[?QG>(3,%LK66,1/9
M')%6G<OY6+B_CIC^X5J<BE):#S%;<48FQY?K(5-F>6`)42(*][KWD"D2!S%?
M.,?'=Y:LI>*>[KY"KN(?'!RSF>7&9,=Y$M.5ZMEO*>2:O2JKPJA,R7M6=G8B
M\<J[1G&3>S)%G*XVJ+ARORNO9:.VZ0D5NY)<1*[PJO7"'CO9KE@ZNX3G>+\W
M=N3.5N>.8LRQV&>8')[`D1CFBT*E9AND3/BQF5,<4BS6*=JU(>KMJ^_2$YDF
M+I2(;E0(K?8(MB'$+B+BK*7)##%#BIK*G(WEWQRQGS=J6=,9^.[+V`B2\G5*
MEQ'R'=<KV>MY6AW%!C[X%NQHE-)2:J,&@R>$A7C5HBW0(EACS(_$^68<3X7G
M/'W/"/`J,\>ERY.89XR\E,I7&XUZ_9^R#G^[,+=CFO24\I!2W(M3!.,&,*GB
MBJ.6KN33KER9NF4:5PFB=L1(;D6E%U+*V+\29LMU"K_#;"WC]Q7DSCEA7RN7
M_-+:W7ZS9:N&2Y+(A/P/%;LQ\S\E>/=695NDQ];7/-V.LMW34\>FJ]>*/52+
M)C`N&7^0LBX9QYS:O%[S'B?@%XGD\G9A@K:MDNG15VL'*;*5JLU*JN=*=;9C
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?9P<RQCF$BRIT1&B(T1&B(T1&B(T1&B(T1&B(T1?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>pg118c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg118c.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!4P&B`P$1``(1`0,1`?_$`.0````&`P$!`0``````
M``````0%!@<("0`#"@(+`0$!``,!`0$!`0$```````````$#!`(%!@<("1``
M`0,#`P($`P,'!`L$$1$)`0(#!!$%!@`2!R$Q02(3"%$4"6$R%7&!0E(C,Q:1
MH20TL<'18E-4-387&`IR0[0FX8*28W-$="551E:V-U>7.!GPHK)D165U9G;&
MUD=WQU@Y&O&#DZ.4E:8GUQ$``@$"!`0$!`,&!`8"`P````$"$0,A,1($47$R
M$T%A,P6!(A0&D:$CL<'A0E('T:(T%?!B<K+20X(()$07_]H`#`,!``(1`Q$`
M/P!&CZB?O<NTFX2K%[O^=Y$:/,F>M`5GDT3(#*)+K8);;*FI41I*>CK1H.R@
M@]P!T;ZA'OG-2KW:\[+`H059U</-WZ>--`'T7Z@OO?6!N]UG.)J&_O9S//<@
MD_=\0/Y]`*:+[^O>HOO[JN;%]0DDYM/IX&H-::`4</WW^]$T]3W0\U*KT`5F
ML^IZA514=>@I^?6:YW>Y\M=(%9`]\OO'5YG/<QS,H&GE7F4XTW>/5/AK2!<6
M_P!['NY=V>I[D>73Y1][,)AW=2*]A7MH!<P/>3[K72G?[A^5R*T).63""`>_
M;[-$FW19@-E>^+W&Q'A'_P!/W+%SEIW5B6_)Y#Z@JGE1(D+6W#B5(_WUQ*OL
M.I<91S5`&L;W:>[S(VRVOGCDRT1G-O["W91-3,H0#LD7EU#:FE$#J(Z&U`]E
MJK76FWVM"U::@=ZP>Y#W*T;7/Y]Y.?Z)JVK)I>WMU\Z_.NOVZYN]O3\E*U\`
M.M;O<CSVZ!NYAY`=%!52[_*[DG^Q^76<"ZMWN"YO4$ESE?.'*@=%7V0:GH#W
MKVT`NK?SKS$[M]3DW,?$$KO3YJ:@#N!UZ:`7<#F?E16T.<AY4YT'55W=/4CK
M]GE[ZZ4)-52=`+6%RSR0M24KSK)%5%=QNCI!\*?;WU.B?!_@!90>3L]5Z:G,
MQORJ;04KN*R%$GN:CKK3:MQT?.L0(W^,>3+[:,YXBE\IYI8;]<[-<9N#9]#O
M$F/?(ULN+ZU6^:W-0H/2+AAU[4W%F]"78+K"B*NFEG;AP1(R/L^]SG,&3VK*
MN(^6,QR1?,O"U[DXMEPGW!QRX7JUJDO(L^5*]2JYWK!Q3*W`DAUQ$90(]?5U
MJU9>#BG(SW==5HK2A/VVYQE#GI!>0W%6X;0IV8XIJE14`UWJ"2W3>:E3;;BA
M]\:M=BRL'!5Y%&N:P;=1;P,JO:Z!VZW%T;0*!]7JK`"$@IJ"G>H%()H:..'K
MY>D.Q9ITQ+;4W5ZG^(JXN07-T`JN,A2P#5(7M2/*NJ_#H4[EI\``V.M=9KD+
M494HB]3AQ0HHUVF+5L,AX4!`*EK4225!7WZFB77`*T[-DCIKAVHK&B_`Z;2Q
M>"&\S3W$\4<=$-Y5GEI8GUVM6&#*-YO\AP-^J&46BUB7-]4H"0-Z4@K6!6I%
M>'85Q_+@$U)5B\!@\^FH]SL*TVM7M*QCDG'[3/\`Q*PY'[EL.QB5CEHG+0TD
M7FQ8]D]NNEP1*_95WL)2M02D'H:)Y=BW#&4URK5@>K'N)>3):XTK->7KK;XT
M>,Q%C8EQE&1B>/0(D<%,>%'D>FJ1Z$=HAM/IM-*"$)`504U5<NVX):(5_,DD
M-:H*;9;X5O$R;-3"C-QDRKG+<G7"0EH;4O39CQ]65)6!YW%>91ZG5:EJ^:E*
M^!`85'Q'\HT!^Z`S0&:`3.6X7AV?6C^'\ZQ/&<TL/S]LNOX)EEBM>1VC\4LD
M^/=;-<OPV\19D/Y^T72*U)BO;/48?;2X@I6D$`*;0&:`S0&:`S0&:`S0&:`S
M0&:`S0&:`2V:8/A?)&-73"^0\1QG.\/O;2&+UBF8V*V9+C=X8;=;?;8NMCO,
M6;;+@PA]I*PAYI:=R0:5`T`88[CF/XC8[5C&*6.T8UC=BA,6VR8_8;=$M%EL
M]NBH#<:WVNUP&F(4"#&;`2VTTA#:$BB0!H`YT!F@,T!F@,T!F@,T!\M6ZVEV
M-?I]QL<MRUW1NZ3G0MG<W'=6F2\4A8:.YM2C^FD5`[U&@%18\JA762(60I18
M+\$I")!2ENTW50%"\]L'IQ'2>[K8#)KYT-JJH@+]#4B(Z&9"2VNJ"4$)/DKY
M5)6*I<0M)Z*22".QT`HX3HZ)`--W4^.[OT_O:?SZ`6$!^M%J-0%`)3TKV(H/
MCH!<1)*$)*E*2$I05+65)2E"$^*U$@)":=SH`>UF$1M*46U!NKP.WU6E>E#0
MH&FTS%)*'"">S273\::`7=H8OU]2S^(/+CQW4A2H47=&AJ36@#BPH3)(-:D+
M6$']374)*,E)^!U%:I4'CLEB@0FFT*0DE*O*E"`AH&@H$-(\B0/&G<:[N7%<
MI3"AU.#AF.O;J!+:$#8!3_<UIW`[=M5$JTW'547MN=KZ?0@`A-"!UJ.X^SIH
M5#B6IPDMJ!*04@?$"G7J#TJ=`.%:GDD)`J#N!J37N:'OH!Q;9(W403UJ:'R]
M_`T\170#@VR2*4.XE-:BE*>7\U:ZTPOJ,5&CP`N;=-`*$J404D$$@=B*@?90
MG77U$>#`OH,DK*>IZ!!(\O<=3I]1'@P?N4P9L^#%N]D"1E.-R3=L?+KB6FI3
MJ6E-3K%*<VDH@9#!*HSI[(4I#OWFDD7DD'?<[*<X[RWC/WU\<Q9<BW0$0,/Y
MSLD9M+,B[8/<9"+2S<9T=`'IWK'Y*3;WRKJS+C12?N*.N[<M%Q3>2!93A^76
MC([):<ALUQ9N=DO-LAW>V75@A;$BV3X\>5#EI%2A#+C#C94D]4@(:/FWZV.2
MG+5DGQ,,EJN->8FLN]U7"'&SQM^1\@VMV^J"_1Q?&E/93DTMUK>#&:M5@1,D
M(EJ>4I`*_3'JK<56B:CK3#^M%G8?%!5;/<#S]R,&F^'O;[<+#:I!_9YQSI<4
MX;:@A0_82XF)P5OY+-;6K:MM-$@H0E)I55*9O;ITDFY<50*P\ZH6T#@+E7D%
M2'><>?,JO$5PH6Y@_%41OCW$]H0IOT9%UV2,@NB$I4JI/HE14HU!H!FO78J-
M:&I*%?U%6))'CSA;B?C0(.&8-CUGEHZ+O#L55WO[Z@#5R1?;LJ=<UN%1ZD.I
MK\-9>_'*C#T+"VJ1'W9E-J]/<XI2BE()45*)(33NHG69NK;61`/3)Z42NM/`
M`&@_+34`WHD@BA!)Z]>E#U^S0'OUT=OTOU>E=`#&SN0D_'^Z=`>]`9H#-`9H
M#-`9H#-`9H#-`9H#-`9H#-`9H#-`9H#-`9H#-`9H#-`9H#-`9H#Y=T]=+M<E
M*J:7*?VI_C+OY/CH#]?@0;HR&'VD.))"@KJE;2Z5"VUI\S:_M&@!EJO=YQ)*
M(=W2[D.,)-62?\HVE"CYG6']J_10"-Q`"FE==R!]\`.;%N5M?@BZ0)[3UL.P
MN/N[&'8JG/W2)K!4HL%?9*P5-.?HJ/70'K^,&DD,6Z,J8_6H>4%H9*J=%-MA
M)=="?M"`?CH`_M\&XW@M.75]U;!4%?+*/IQVP:>5$)NC0-?%S>KQT`\^/0K;
M#*?30DN(V@..>97QHE--J0#V`'30#XV106&R">E*]J$D;JC4&N-N"I)9CFVY
M)*4*Z42:'X^8"E/Y-#J4(SS%_;PH!NI&T]0!W'E/?II442C194%I;^B$*/8*
MW'\@Z`?EZZDQ"YM[]`A*:BNSN!W2H5KUU#-%NW&4:O,6UMD[5)`W=E$]$]TJ
MK\?LU)0\Q>6V;NZGR'J`?'H.A(\/S:$"[MTX[4K]5=%';6O<D;:`5T`N[?-"
M5`UZ)`"O%?4@@D'L!^70"ZM]T2G;YT`J()(ZU"NP`('PT`KHUR\I*E(*:!0J
MNA!J$]U$#^?6FU<G*:C+(#=RK%"EW7,<2N=OC7KC?DZPW1S);6\M`BVV]SD1
M[5>F4I<\J6,PA2TNH])*G&KC%6\**=W:U$C%<4^QD63&+;AN8<W\LYGQ[97I
MS>-X;;;TK",>C6QZY3)L>#<'[7(E7:[EAV4HJ"7F6PXHA*4IVA/6N6G3X%?;
MAJU>-2=G%G"_%7$[+:,#P;%,4>`0AV=:[2RJ]2-M"DRK_,$B\2EGI4K>-=5Z
M5Y_B=DAX,IA'G71;O4DN54OH:`E1)\-9[ER<):8O`"DB7<'H'$I`J`1WI0=.
MWVZB$I77HGTDAZU=$52G?4'J:$IZT^`[]M7=FWP`<1KH$@>9*DJ-`-Q*O+X=
M?RZQR5)-+*I`9?BX``\HIX5'\^HHP9^+@J^\!4C]+IK1&U!V]36-`;/Q9"%;
M5E)%.X4:_9UZ'68"ZM#OKVZ*[6N]"C7OV<6/[6@#+0&:`S0&:`S0&:`S0&:`
MS0&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`^6W<)-;M<U]*?B$])Z'_
M`!IT_'XZ`W"XQHJ?6D/MM^4)155%+/B$I\RE*^P`G0&K^)G9(]&V1E..'RAQ
MU)*E>"MC(*>WQ6H#[-`"8=HN\)EQR(B(B0\\)"H[CBDH>*PD.M>1*F(X="1Y
M=BD!77;7KH!R\5OMBE.MVQ^&WC^1,H0A<.6H-PIYH$@1I3KA##QH.ZELN*[*
M23MT`KI66V^R*>%R?;BNQ@HR&=W[=D`"OK(&XL(IW4O:D#N==1BYNBS`RF8>
M\#$,9==AXLU)R^\M52ABTJ:>M[3I2`1(O*J6\%"R`KTB^I`[I)Z:XN-6I:9Y
ML[A;E-5CD2O]J'.5PS'&$W7D:!%A1[U>KNW#F0GG'W+&Y!?9B,QWUO);,B`\
MAL*6?(E+I-$H!ZUJ["3HJU9T[4XK4\BQ.'`2EEJ0R6W6)*0_'D,K"V9""3YV
MECH0#T([I/0ZB["4Z:?`FS.,&]0=1@6]M>X.X^/V?V#K+).+H\S6FI*JR%/`
MDI2"D#H023]H/P_/JRSU_`,5D.4`HU4@5(Z]:=.IZ@GKK6<BL@30A(55*MRJ
M]*TI2AZUZ:DR2MR59/(5\"8@E#@H`>@5N!IV`Z4[Z%8L8]V:9VN.R&VTTIO>
M<2D4`ZD5IM^ROCH`\BY<PVM'HEV4L>4"."I!ZT^^0$C0"SBW:]2@CTFVH2:A
M(+Q]5U(/0*HD4!Z]*:TVKL(PH\P+JV,EU2%3)KTE?1>U:RAH^!(0"FE*'MJS
MOV_,D/;Q8[-E%@N%AFH4U%FI0$RXJBB=!FQG$2;==(3X\[,ZV3VFY#"NP=;2
M345UGO3C-IQX$`[B?/;B_P#.XAE"VAD]FD*BRRWM:9E3VFDK;N,-FI#<#)K>
M43&$CHVLEK[R3K1_Z/\`X@?R/>&W.I6JI2GNH#[.OCJBS.,&W("F8NH24IWF
MGI@TWCXC[-<W)*4]2R`=,7HJ-$D!/7H%4Z]/M.M/?M^?X`-V;TFH45=NE2>H
MZ>'3MUUW&:FJQR)#1%]\H\PI04H16E/'78!K5\.T55Y:#;1?7^SH#;^.#]8_
M\V/[N@,_'!^L?^;']W0#_P"(/?,8W:GJUWLN&O?M(>']K6"]ZC(%+JL&:`S0
M&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`^4A=,BG
M3+O=8]K;*`NYW`*?51702W*=35"!\#UKH`?;;075?,72:J2Z>GIAP]">@"G*
M`E!'=(IJF[<<&DJ`<>W*B0DI;::::2"BGII`K3N5$5)U7&_*4E&B!JO>?8YC
M$5R9=[M#A,MCJMV0TA*ECJ&V]ZAO=)_13N5]FM0(QYG[CV;N/E,9LOXAZ3X+
M%QN##D..VZA?E>:)2BX/`;?#T4K3T.X5!SW+TH3TI*@&3O>8Y;EDE9R^[S;E
M#<4%)@Q%?*6YDF@"EQ&-J'PVD;072LA(H"-52O3DJ9<CNW%3EI8+A1V(C"7&
M"V&2"&0V`$>4;MO2I!ZUI\-5MMYNK-D(*"HBVGVMV]#_``MCKX0DA^[9,X%[
M%UZWAY/3Q%%(I^;4Q>EZN!,HZHN/$FGAV>W7"JPY0=N&/KH7;>HJW15$G>]#
M<*DEI02>U:'MTJ:ZK5R4ZUI@4NQ%>+),6F_6N[PF+C;Y:)<:0KTTK11*VU@`
MEJ4WT+#Z00""!4_R:3LIUDZU.5<=M]M9(4[#E/+4`4)!KWJ1JFQU_`NNR<(U
M7$,/Q6)";'SDIF,@;AM<6`HT%=Q1U77\WAK70S]^7!`J/E_K%+-IAR9M*46E
M"VVCVHHJ4!Y*>.IH1*[*2HZ8BK@R\BF=7I#%O9J0I+"=[S=220%&IK^30J%Q
M:X,)I6^4IV<XH(H9"RL5W>+8Z`'0#G6V4RREI#2$M]0/)M2!6I"1NZT(.@%U
M"N`"6ZKH4]2$%-*CKXU)T`K(-TV!(WJK0@[BBHI55/SZ`5<*[$FOJ4"DUK5.
MVH^P?:=`([-FWH<B%G=G<6W<[*TEF[(8!*[A8VG?7+J6FZJ=FV*03):)!/HE
M]`^_J^-UR2MM*CP`]^.Y6Q?;9#NS"T),E*$RMJDJ;:D)0%.A.U:OV;P*7&SV
MV+^PZB[:5M)JN(%:S>P:#U%=:@*J.I^'V=M4@.&;ZD*`]4@A`^'<UW5_)H`X
M1?$^17JFM#5-12I'VZU[?I?,!DW>B$;PI124A1415``K4[NP`/<]M:"0&[FM
MK84IMVZ1RZD?N(JOGY%:@4#$,O+J/'M35-V<K=*+,@+G^0F&4U2R\FO5+EQD
M1[6RI->_I.*>FFH[4;&J_J[,5^HZ269&F^W\D4X"<F\J+37TY*%`=-ELAK?)
M!KT^<N:PE*@/%+)%=9;GNVU4:VG67F:K>UO3E2A8+PK<G+OQ=B%R>]8.2H,E
M:OF'$.O>6Y36QZCC;;2%&B/!(`'341NJ_'NK)E-R#MS<)9H7=_R"PXK9KAD6
M47NT8WC]HCJF7:^W^Y0K/9K9$00E<JX7.XO1X4*.@J`*W%I2">^I;257D<9C
M.GW4>V$&A]QW`P/P/+_'P/\`)_$.N>Y;_JC^*.M,N#-9]UOM<36ON3X"%.]>
M8N.Q3\M<BZ:G5'BAHGP?X`<^[CVI!UI@^YSV]A]XJ#+)YHXW#KI2*J#;?\2;
MUE([T!IIJCQ0T2X,-4^YOVVK0ZXCW"<'K;8:6^\M/+&!*0RPV*N/.J%_*6VF
MQU4HT`\=-<>*&B7!B</O+]GX?$8^ZSVV"261)$<\Y\8!\QU.ED2`T<H]0LEY
M)0%TV[A2M=-<>*&F7!BGB^Y;VXSL=E9?"Y_X3F8G!4^B;E$7E7!9&.PUQB@2
M4RKVU?EVV.J.7$[PMT;*BM*ZZ.0KP[W9>UCD26Y;^/\`W+<`YS.:9?D.P\/Y
MCX[R:4VQ%<9:DOJ8LN1374LQW9#:7%4VH4M()!(J`Y2.2^.'#1'(&$K([A&5
MV)1_D$\Z`:K*/>#[2L'<D-9K[H_;KB#L-Y<:6UE'-G&E@<BR6J!R/(;NN31%
MLOMD^9"@%#Q&NE&3R3`(MWNU]JEWN4*RVGW->WVZ7BY0G;E;K3;N9N.)MSGV
MZ.D+?GPH$;)')4J$RA0*W4(4A(-21J&FLP*M_GO@N-$E7"3S1Q/'@00RJ;-?
MY%P]J)#3(>^785*DN7A+,</O^1!6H;E]!4]-<N45FT@$'^M+[9/_`,1?!/\`
MY7>/_'H/^V'Q.B:>0/T^Z3VR@E)]Q7!04D`J!Y<P`$!0J"0<@J*CKHVEFTB4
MF\D>/]:CVP__`(CN!O\`RO\`'W_TAU&N'%?B3IEP9^'W4^V`=3[D.!0/MY@X
M]'_SBTUPXK\1IEP9Y_UK/:Z._N1X#_\`+#QY_P#2+37#BOQ(<9+%I@=SW;^U
M-IP-.^YOV]MNE'J!MSF?CA"RW7;O"%9(%%&X4KVKJ5*+=$U4@V_ZV'M9H#_K
M*\`44`I)_P!,G'5%)/8@_P`1]0=2#\/NR]K`Z'W+^W\'X'F7CH?_`#CT!Y5[
MM/:JA)6OW,^WU"!2JU\S<<I0*]O,<D"=`%<SWH>SNW);7</=A[:8*'>C2YG.
MO%T5+AVE5$*?REL+.U)/3P&@`C'O?]ELFHC^[SVOO[02KT>?>*7=H3W*MF6*
MV@?;H=:9<&#O]<SV?_\`XK/;;_5_F_\`PY\8?U7_`!C_`#H_<?WWW?MU&J/%
M#1+@SYBUQGM-W6Z)31FESGD(VH_QIWS"A``U3=N1T-1>)R)^X9M'M:2KU$.N
M!*BE`5N*U#H-P!-*GO761MO,@9',^;LN<<8M..EJV."&_)N$U>R0X6FW0*P4
MK0&H^Y"O]\#BB1TIK3JMJWA370L5N;54L!FW)$FZO_/W25+NLTJ*B_/D.27$
M@FI*/5*@VG=X)`'V:HU3XO\`$NLP:;UH.8KZ$I&TE7<;4^"JU!I\::AMO%YE
M^B'!?@&["7G5%*CZ3=.H[J5X&AZ4Z'4$J,5DD@ZC15MM%+?1`J2E2CM4:$@J
MH>HH=2279>TFV^KP'@KQ:2CUW\E<HDDI!&1W)L[2:U`+>@'_`+K!"$J"R"%I
M"0"I5?&NT4ZG1-K("8M>0WK#YZI=H*BPZJDR*Z%KCRVP:%+C8(&Y/0!0H0/'
MPUTI2KBW0YE%-/!5)(XOE;.81V$P[N_$<"$KN%H44IEQZ*%7(3H'J2HI_6J5
MIZ`CX;(NVW\E*^1BDKB7SUH.M;+';V@'@U\VXKS*<D+]<K2>U34)K]M-)3C%
MT;Q++;MZ?FI45T=?R]`VVA`2*H`H$I\-H`%*4.LS5VN%:%VJS_RAS$FT_34E
M54DBM$`GO^E3;75UE32>JI1><'310/&;XW'_`&S\AMIE/1Q]QU#;*0.ZEO+6
M$)2GXJ--:>W-K53`S=R%=-?F%Q:+Q'N,9N=;I;$^$M3K29<%UN7'4\P[Z*T)
M?;44J6%)-*$]`=';G&*FT]#\3L6\2XJ\NU*^QK4`FOC4G7`%-$NA`%:CQZ54
M*D4(J:4H!H!31+QM":'PZ#:`2*4-/$"N@#UJ[^HA*2FH4`"D@!*@H4(56HH=
M/V@;7&<C<X]RQ_%I3RTXW>`9-G>53T8;"G$@P_4-4H_!9;_IGK7Y5]L_HJIV
ME.>"JP/.KD&Q0E>DY=6)$H*($2`';G(-/%"(*'QNJ*=2!J79NQCKDJ1XX'48
M3FZ056#4Y])4E)B62:K<D.!R[/Q[6TI*A5)"$*ERRD_`I2K[!K++=[:RM=UZ
MH\$6K;;ANB@ZFIS,;Q*-'KHQ";"2%1K1$#Q4%D`I7,N/J+[^*6T]-43][A##
M:0;AXUXFBW[?>G&LDXOS/U-UN$Y1#B)MQ()`-RD29;1'4!2(Z2S$2``.R*:\
M^Y[OO6F]4-/!9\N9=#VR6I:G@'$2+?76]H68<9P;?28"8K>T5IY&4M`=^M:U
M&L4]_N+U-4I*GFS5'91M>"E7X@Y%FAL@&=+:V]22%;E%5>OEW=2*TU4[LY9R
MDZ^;+%:HJ*.!Z=G8W;A53GKE*0C::`@CL-O4BNN7'2JM4.TKBRJ6D\`R69G#
M^#R8Z0AEVW2RVD5H`+M<$]*]>I3KZ;8?Z2'+][/"W=?J9ZLZ_N&5^H8RV_[)
M_<BR\@+:<XUNB5H4`0H&3#Z$&H(U;N/0ER*;?6N9PV9%CH:*W4-,MMJ4=JTM
MI-!WHH`5"0=>/#K7,W#=R6&B%,J892Y0T7L11T4^\.@Z].VMI(36FR6^=D5D
M9D1VSMNL1]M7I-AUM;)6Z%-G;5)JFBO`CH=`/MGDE&-X/D[\5N/\U<+:Y:HY
MHD"LYQ`<ZI`-"VD].U#H"L>\PX\3.,4N+L1(1=;;?L7D^0"DQ"&+]:F4I`'E
M6Y`E!L_K=#WTH^`JN*+H.4?;9CDKA3V&<1Y7!$NQ-<RX!?N0<:4[)AV[*&\_
M%Q>N=LO,:(]'3,;!GM[-X-2W0$`$:]"/2N1YTNI\R8'(&/X%[>N8O9@C"\6Q
M["<4R'DK/.%I<6P6F!:8*CR!QQ+E6)J0(D=I3J59'BT1M!420X=PZDG4D$W\
M)N&1S+]R'&O-B%JL5DOMJMV$SB0ER]6?^'&)=VNSH6FJU?C<M4<)W$!#*5#J
M3IY>(.,3ZG>4QLJSVZ16@%G(,^OLE/EHI29N0N,,A*A17E90`"#6FMUGTT",
MGN5Y)R/`.4.)LDP>\/XUDV#XG9+C9;K!Z2(;CDIYU!6WN2F7'E,-!M]ERJ'F
M5%)Z'6>_ZGP!?%P3[R<2]T7L_P`XO26H%AY(M>3\;XAR1AK92A%ON#OXW>VK
MU9FUI0[(QR_+M2W&B$UCO;F5I"@"?.W";DJ<!09Z[YM,Q&0PBV&-`DSF%[+M
M\G&D.1]JBA:(IDMNHBON!0HX!O`J`1776WHDZX!)\&%S7(-^R?=$NLHWQ44I
M<1<)$:,9[*7%`+C*FMM(<>84>H0X5E![&FE^C2-.WK5AF"W]Y335#UVE"*))
MZT[>&LYI`[CK%2E3#-`>Z6TD_P`E-`!G512A02RWNZ4!:0/$'X5[:@IO-=L1
M>66QN9";FL1V1+M_J/(VH0"N.!62APA.Y0*!T'Q%1UUW:]1&(*[9=8ZH39>H
M$A+:6'?2"@M"P%)_9H271MW4/2M=;R1"9GR[AV+K,1V2Q)GMJ`5&B-)N$T$I
M*DI,2/O;B&HJ%/*K3PIH!D;KR+F>8!;=AM"+'$>)2F?=`F5-(30*=;9*$18:
MOAM2HCXZBJXHFCX,3\;CUN6X9N0R9%\DJ))5.42D`E(2I3:AO`7442"D!*JG
MJ-*KB*/@Q90[1;("`VU!BANHJA+#24*"0"H%26R05"E2*;NM03UU%57,W+(4
M?RD#_$8_^;-?ZHG][_A/N_<_O?N_9K+7_O.B.62W^2Y=[N`YT_$K@-H)34&8
M^`*5ZT/75!YHWDR4MZH4:&IJ0:;B/$_$ZDMMVNXFZT&_NB5&XREM@*].SK30
MH*P=[X`/3L4]?Y=#9%:8I<$:H;.[9ZBB:#JE("14G_FNGP.I.A1164()%`?T
M@:=CT'Q.@#]DIK2GFZ^;[-`'C:Z-E%#4BM?^5']S0%]GM#LZG/;CQFXGJEUC
M)':5%"%99>TTKU\4:`?:Z6=%?N54D)J":4K7J">^@&^N-M0-U6E!(22D@@BN
MZO3R_$:`2R6'H;[4N"^]#FPY`>9D,J])UM1J>B@/T>W4$$$@BFN[<]$JYE=R
M&M4K0?"T^XS$L7LTA7(\]5CDQ(RA'NK4!Z5`NLQM*4QX+[4-+CT*=./E0H(4
MA2^XZDCMZ+KU.6EF2Y!P=/(;Z_>]C'6?+C&.7*]/44D*DA-KCA0KU)D!R0I*
M/'^C@_;JVY>MVX:DZM%O8;QJ,K??==RU?*HMC]JQAERJ0B!"$Z8@'IYI=Q+K
M(Z?JL)IK-]<OZ7^/\!V'Q&>N.0YEF$IM.39+?;TE;O1N=<Y;D7:H*JVB('1$
M0DFG1*!VUP][=G6,6U%X9Y'?8M4R6OC^\L&X7Y/N?$%JQUHM*G8E<K):'+]:
MD5=7&=<ALA5WMS8.Y,]N@+J1^^2.HW`$[;-Z<H*U-UIB4W+7;2=:ED&.999\
MEM46]VB?&FV^:R'V)D98+*VR`?-4`-N)33>#3:JNK2H'JS:Q1EEL7%AYY*BD
MQ(27+E(*^U"FWHD!LD=@HI_-H`9&S&X/K_H6/S_3`(3(NKS%J:`(Z*]`"7*4
MDD]BE)T`+_%,BEH'S-\BVQ%04M6>$E3X">P,R>N0I)IWVH!)&@"C([6;I9Y7
MREPN+]Y:*)5ODW&?(DM+D-+"A%=05(:;AS$`MN!"1M2:@@@$66KG;;=*U`48
M-F35R:;9#AM\UI3C,A"PIA;3[*E)D190338^R6E5^*@:=*:\KW52N1<XJ?P>
M!MV.-\D+;)6.):2[<;R%K("E);<6X#7KT4J@I3KUKKY>%Z_-Z;B:B>[&WIE6
MHI6,FQB(H"!$=F.]"'5I)"NP%-J*$?;7KJ91E)X3T_"O[RT,F\NO#U1`M:64
M5/[5QM+*`.HH"L5UP[UN.%:R7Y@T/7:[NK/SMTB1:#S)2XI:OR4%4COU'2FN
M%?E+IBW\2`L>N-M:),BXS)A*31#)#::E0*O@2*_S:Z[MUX*#KS&&;R"I[)+<
MP%I898W5(K(/K*IXJ\Q[Z[MVMU7'YL"FYN;,(ZJUQ+E?;!.%RX&XYG)*%"1:
MIR@6P`@[;W=&_*!T'W-?7;!2CM(*:I*F7Q9\_NIJYN)3CDW^X:[ZACB6?9/[
MD75D)2CC6YE14:`#YF%W/AJW<>A+D56^M<SB.O5U9<2L(23MWD%73<JA/0>*
M?[.O'AUKF;AHKHD/+]124A25E20D4%:=`?#H=;23\Q%IR-<;_F=QAW&5CW&6
M/S<TR86N$NX7!5KC.,VYF/`AI*!)GS;A/;;;1N%!51Z#0$B>:N+)F8LXMC7'
M,&[WES)[)CF03['-0S&N6)2;G!-PDVC)9+0;CQIEK2&W'!N!;4HH(.T@@&_'
MWT^\7O5_PB+R+DEYN=YMF4VG(7(E@<8AP5.V::S<8K#LIZ,](<1N;<$K8I*)
M#;BD@('?T5D>:\Q9<^W[DBZ>[KA:8G*;?_H5'N&XCQ:R8](M2T7"%EUE<N:I
M9LDYI6YZ!.@-I7,0X"$.);V4Z[@)-_4`_@*9B_![62YVO&+[A/N'X^Y8MEMQ
MUF)>\^NT#C5YZ]WZ/B^+.3H4B>$P%M(G2%J1%@PI*GW5A*"D@+_"OJ"^WCE*
M_P#)>'8ADB6I>.6*^7/&+S/7&@VC/!;K9)D7-S&5ES<M<%^."VE80J0@*6A-
M!355C_5@X_\`W6767D7-F"6WI+<<O]I<4D+-'5JE"8^KJ"4U*"2#V).O89)&
M[W:W/YOFF]PT@>E9+;8K.R`?N(A6J.A3?;IM<)UBO^I\"!RO9)S#=\!R7-,/
M0W$.-9K!M5YN[GH;KJS=<45+8LPBR4*]1,)YJ]2$/-[:%2DJJ"GK2S38Z7S+
M3[7D=NS-CTU!#RDJ)6EPH<4C;^\!`/EZ_P`NLM_-&A"NMK<*"T6(Z&VTUW**
M$[2M7;<O]95/'5!(+>DT2/VU!NZ"G84-!W/;0`(3$[E!"O.D*)4>B:#N3\`?
MMZ:@HW'1\0BN&3VV$7/5EAYY`\T=FCB0:"FZ2/V([CH"5?9J#&)I627JY_Y.
MM[C#)`J[O4TA:2.M7U!+CH^(0D$?;JVUZB)$S/LYN;=QL=]D.(;OD-]AB5;E
M.Q7HS1;6'4(6@AWYR,XI+C:ZC<D*!&MP(?8M8V\=RF[V&^L(7<8DIUA4AX%:
M7D-;'`ZA+HHIB9'2'FS2JDJ6FOCKF72^1,>I<Q^(R&4M@ED;MJ:]**(":A('
M6H;4LE0_1-?U>OGGHF\T`!K7>4*%%>;S'IN53SGXD_>H:]M2`,XO>?2`"$E5
M:#M45-*=*+24C</T:C0!Q\TY^O\`]JWQ'_,ZG_`8?F0ZR!X_C%VZDJ-SGT(`
MI3YU_7)@M*+G260G'%;CXUJ:_ET-D5"'2)Z2T52;BX.WX<VCQK4R6Q4^%*JU
M)V`XJ2#V)[=@?UM`*1E(VA0'F(-3U[5^';PT`:,)J2JH\O2GB:Z`.*A":JZ`
M)^'Q%/[.@.DCV76MI[VK\1/-A+CRK/>'70A22ML2,NR%;8>0"5-J6BA%1U!%
M-`/5?X+;;+SJDT2$$J"@:IIT[@=ZG0#%7Y[8ASY=&[H0BO1(ZUKU-3UT`TTL
M7%^:A"WE(0X5-D-'T_O?D\33XZ`37)5@#G%^5J<0E=)E@*2XA"J.-R)*TN=0
M1ZB`#0]Q7\NN'",G5G$K<).LD15CH6S/E-N)J3(?4ATD[R"M9VG]$@#MK&UB
M2*2,PXI2"EOO155?=505^/CH2*NTPWG':N>4!56P@]0>M`#T-==1ZES!+U^!
M(5C^.MB0IIK^&+'5(0%/C=;V>I=7O!\OV:W1E*+K$B48RPED!L'Y'N/$]Z1\
MVT]?<#GR@N]6=Y2GUV^0I5/QB"T*=4E1+J*%*AUIW!UVY5A63Q,EV%)TBL"S
M3&<OLEZM,&Y6!^&_;9D9M^*[$2VTTMM:!T]-D`(6D&A!%=6E09.7\I53>%=3
M2G84/AJ&TLP:_P"(OMTU1XH'O^)%CR^H:5*>G;X&GV:53R`T.83'<;R"-ED`
MD0+@MJ->T)4KTX\M92S&N6P&I5(&U#GAO0@_I'4R;E#0^D[MW)VI:H.C'LP[
M,;3\NA?R3$IQPUI(=<(25`.)4$U&Y"DJ"DC]4C7R.ZVF\C<TQ;T<OX'T6WW]
MB=FLTM0X4SE>':F@7YELM2=G9/R\8TK]VBSO7^;54/;KUU5N5;7P(N;^Q&5(
MK`0MQYUM;I]-FXSKHY6J&[?%E2TJ)[-[TMI:2/B=U-:[7L-IR4FL>;_Q,#]S
M=7185"5?+>22]R;=B\G:.C;]WG,PFP:?>+""X^13XZ];;^S;:%=<M'YU*KGN
MLXTI7\`IEYIR!-2-]XLUG:6-O]!C.2Y+9\:+EK*/S@`?RZT_0;6'RI:J>/$J
M>_W-S%2:B_"B_P`!*R_6E"MXR:_W2OWFA.^2C'<?,/2BA-4GPJ335T(0MO5!
M),RMMJCR.E'V-ML,^U'AIN,G8PFPW0-I*E+(!R>^DDJ42I1*B3UUVW7%D"<^
MHLTZ_P"Q_P!R[+&WU7.,KHEO>K:G<9,*FY1!H-0X=SY.)*GVWKX'#7<(S[:W
M1-VBE0D)43574BBJ"HJ>FJ;VR=NU*=51*I9#>JY-0H\6&&$8!?N2\KLF#8HU
M$>O^12'XUMC3)8BH?7%AOSY1#B@20Q"C+6H)JHT``W*2#X\>I<S830Q_A!/`
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M`\$>]K!,8]T'#N3\+SI2KO>K)^-S['><.OZ(-O<6XO&<WQR;-QG(4Q3)2KT&
MGD2VOO+92BJM>C9]-'!65SO=VKYRWR'=65!QI_)KDVRL*2I*V67E-,*2M-4J
M3Z212FJ+_J?`#@>U""U(R[));U`B)8HK142E-/G+DCIN6I*4E0C$"I`J=>??
MZER-6WZ7S+".'83\C*,W95*<#,#&\SN%NCJJ4R)]HAO72.L%"T44P(BE"M13
M5!H'4QO.6KG;F9*GTAAQ(6'%J2E**^*E="?S#4,S;CP#&3F<1*@AK?+=6*-+
M;*VVUCK0)0$^J^@4`/W4_;J#,%LEN]WY+29+[EOB(<#Z$('IJ'7=M]!*C5*J
M_=654\="`V@V>W1=I5'^9>34EY\E:B23520>C=1X)Z:DML^H@_+J"C:-J#MV
MA":]AV_FU)N"*[1ER6/V9VR65)>B.`E*T2$&M"L4(;=1Y33XZZM]:YE=SH?(
MC7S%9_6-ISVTA;#\<-VZ];*;VDLK4W$DD4ZIAS'@PX3U#*P>R3K=+I?(QQZE
MS!5BO29T",\-M76PVH(J5!T"CK*QU*-Z_NU[)[Z\X]`.UJ"Z#JG])9214K/E
M70]MBVR0?RZD&KX=MU*+`_0I]Q'Y0"=`'U#\&?\`-C_U>'[S0C\<R!<FZ79^
M[7CYVWN1PF[7%*%2UMMNNI^=>\R$@^JFE>J7&Q]A.N3S0KAWQFZO3(\-#[#L
M.0[%<5-C/,!QQHC>N,'`D2&?[Y/0ZDLA;E-55`<VR5HO"G%!2T08P40-@H9D
M852*FM2?'0VQ6F*3S2`T5E7>FUN@\RB``*T)JHC4G0>QFFZ("5+>W$IHA)\2
M3Y54H:$>%=`'K,)])2"TS'*JE(DJVN'XT0JJU$?8FF@/UN1\PTAY!=6H%Q`0
M^CT$A;#JVR*$..^F5H[%*:CKXZ`Z:?999W6?:7P3+9AJ#SF*W"2J7;5E%R+K
MV59`"76W?V5PCI2E(](D_='D4>P#W7J7'DPY#,Y+:%)W(^>C-J$?<E50+C"6
M%2+4_5)J:*:/>B!30#,7>RH+0V@.(])*FUM[%MK20**0XE12M/V@Z`;*79CZ
MI7LZE?EHE.X*2JH(![&HT!XY,LS:^&LED-I'[2XV1*^@)2NMP%*5IT*=5RN1
M@Z,$+;E8PQ,=%%%9<5M(;%`351[=:4UFC%W)4CFSFL5C)I1XL4%MQ5_YJSQK
MID^*8K%OD)B?:+U?[JRNSS?FH-TG1;1&EV]<QMS)I3=I<"+9_7`:;VT@IW9E
MNMM*<H0N1E.#HTLT:/IKJBI-4@\GQY"GB1XL.YJCLNAUMMP-@.K;$@J2VA:B
M?*&ZA1Z[?#MJ^V]337$I:<6T\T2RF-I19,=IXXQ8#W/8VB*?'[3K>!IKTC:5
MI4$JJ5`@BJ2"%"A!'70!EQ1RA.XWO:+5)DK.)W.0A*F5J.RT2W5$!UM?4M1'
MB:*K1*#U^Z33;&[&3TJM3%.U**U.E">\?)XSS/J^L&@G<%^LX&B@I)!2M*U`
MH*:=0>VN+MN4VG&A4`7,VMP*DMSFWE"HVPTN3'3\#LCH<*B3VU5]/<\B#S_%
M5T>;0J%99SQ4.BYST>VH!/;>DK?D`?D;UU!=EUGX\#N$'/!`>8N_7R#(@7!Z
MRP8<QE<>2TTB7<9.Q8HHH<><A,H<2>H.PT-".VK._#S(E%QEI>8BL<FJAW>9
MC-YGW%,BW-I=MAA37(L2X0%*4M+RDH._U0.XW*`4E8[4U<0.*/P)E?K?(1G7
MU`'UI(,ISO6N^07*&OPZ==5SNQ@Z.M0"U7Y+*0E@)0@UJEM*4I';P`%.^N/J
M(>8`[N2+2!1P=3XG3ZB'F`K>R!?2KB=HZ#KU\WF(/3XUU=&2DM2R`7+OIIU4
M.X^Z>M?S:D'4E["72_[1.$G5&I7CUU)/?_MJOX_M:`U_4`8F2?9A[C&+?'5+
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M,":V]Z2'?0VH<:3&"O3INZ`:`A%S=[I?<_R[(Q_(>=<_@X5CB[TIIGC*(TQ:
M2Q9'V[C$7=OPIA2YLAB%+8:<2IXJ4MHBG>FK]XW&.!QI7!$<8[F'WB\OV6;%
M795?*"X?Q;D"3+5&6EUMU)D6GU?0M+\AB5O:;F.*!00HM)24ZSQE+2JMY'6F
M/!%R?MLL%HQSV#>Z+$Y4G",PXB8O?%L_++-FO'.,Y)<<LFY#>KLS^+')Y#?X
MC:'["Y`:<M+$0)CI07@ZE7JFDDG2?]$KV]XIP5PQBEAPVS"RV-RTKR&);]KB
ME1DWEB&]M+KW[5P5>.TJZ[`!X:VVO31@N^HRQ$\9<;\U\VY<SR=Q]A/)%CQR
MVRE6^TYYBUCR^UV^=<)L*(Y*AP+_``;A$B3518I3ZK:4K**BM-6U:R;.#YZ'
MU@O8_&=YNYL]P_MXQ.%$Q61GF83LVXKQ*ULPXECA1+O+C)R[!;/;D-Q&K0AE
MD&X6V.RGT*^O'3^\28;;S!6_[+E3XJ,YO5GNLJ&L2K'`#T)](9>2(TN:0XV4
MNQY%$2$+2%!0IUZ'IK)N.I<C5M^E\RRKAJ)"S#(+C>6K;$MM^MLCD''LI3;(
MR(D2_P!OO6#Y#&M.1?AS(3$MUQ8NC`C30PE+4LN-N[$+4M.J300[XG;F3;C*
MM-PES"B+':DQTI=HT&$.)CF*I!31/ID^4CJ1WU!FW/@2GM[4>`C:VUM!4%%8
M.YQ0IT"BJE1H<6$G)UX!\A\.$;=XJ*BO@.].A.AKTQX(WH64J!)505['["/C
MH*(W>NGOYJ_'I_=U))^^N@T"@LC\W\W73(XN>F^0W^3Q&MDEJ4T'K3=VWXL]
MK:-K:I*/1H``2@2F@05#J%I!^W4QD]2Q>9@(XVIJ;AU_F6">XKT@]^P=6`CU
MXRTDPIM!N]02&=J7*=2Z#V'?<XQIDB=4N+'0;6%I!`(%!W`'\P)U@/1/7Q^W
MJ!^K]@/=5?B>HT`>;%_J#_-K=]Y/W?U_N_S=]!C^9"N\AM%ZNQ"4@_BEQH0#
M7K+>&H:Q*.Q#S"1YEI\GU$)4*@^(K3MXUT+(04%1'N!%5Z5T#DAR+!4F,T[+
M<;=DT1ZR%B.TK8Z0M3J$@=J?$==9Y79*32IF=5!S$*W,G>PR_/6:?TB:Z4MG
M^^$=IQQZE.G5U/Y-1WI^0J'K;RTH2EI2&4=]D5M,9-?[Y382\Y3^_4JOCJ^$
MG*-7F2;64DJ*_`@@FO4]N_QTG)QC5`$K;W@MJKYA3H16GV>&J.]+R(J=3GLO
M;8A>T+@)3I0P$X(7B](5Z;9^8R&^N#SF@Z5UI6*J2.Q?A9+TIU1>BJGQF"KY
MVVO,B:TA%:)=<'J"3&)%"AT+1\`#UT!&[))$7%7@AB=$C)D*JIES:[:I*GJK
M<=G6X+$NW.K!_K#%4`BJS3IJF5R2GI5*5(J5]>X7E_/LHX:S>^<<Q;-A=ON0
MFV;$[W=LP79;[>HT54MJXY"Q+-B<M=HQFY)MTI$12)(NCZ"RX$-!T)-D[D+:
MU3=(G<83N/3#J.Q7@'BWV5^YGVN\(8_>;)PIR+<7>%^)HF4,XY>+1%RN-D=O
MP*QQ;FQ=',:N$#)&KU#GEU#PE#UTNA06-U=6VK-G<Q[B;SH9=Q'=VIZ4HY>)
M'SG;Z%OMOY-@2(V`\A\K<0NRY+;DR&W)@9=9YT-"5J<M#B;HW;<@AVV8YM#R
MF9_K+:!0%`*)UW](H+59;[GA4K[Z_P#<HN'BO^/,>WWA>P3'>7/9.OV]X;QW
MA^599QYBF"L<,.2F[9CO\.YGA'X1;8V6VF:\8L:R7=-GCRZ.>JE2P\6RL[JZ
M\B7V_;=Q[R"<+JSTX*7_`%+&M/#(V6_<H7)QM3?Z:R7#D<Y7)OL8]TG#,23G
M_*?'*<7A25WE2V6[U9;A)=,*UR[B_(AVZVW":MZ(Q#AE3JFG'5LI\ZTANJA9
M"SN:IM)+D=W=+N-PZ:@U]<G^'L5#<:@7B&-+]5;J0CK:(HZ4!*BD]"!V/0ZW
M'`T][ASGMU7F&MRZ$H2M2@!U%"5`=0=`-E>[)("SZ[REI/<BJ!L((%>Y.IC)
MQ>I9G,HJ:TO(6>%<L.8NY!M^3/-W*P1&O0;F3`N1)MS32=K:%J7ZAD,M(2$(
MW>9"`$UV@;==J<IIM\3)=A&#27`EU;,XLDN)'?M\F*8\EM+S7R[C*6U(6.CB
M=@"2@CQU5*_-2:5*)E()A\@VF6MV-'DR3*94M)95;IWI@MDA1,PM)CC<.J0:
M!0\=5RN2GG0T[?-\@8K*4*ZEX5/@*U_+3=JOS+9VHR;DZU$'EEQ<"860VYRE
MVL#HD-B@I+@5W3(+I[*0M/5(H>M0.^M5J[*<J.E#$&3F>V=B,Q<53X\:')CM
M2V5R)338;:?3N2VHK6"5MDE!\217QU9.W&;JZ@)O]*-G>4H0WI-T<4-S:+7#
ME3R=Q.T%49MQ/77'T\/,B@)3D^13Z_(XM=R%)!#D[Y>`BBJ)KLDO-/!(KWVG
M3Z>WYDF]MO-Y@*5,VBW)5W]64[-=0`?U&66T5['HO\^KH12I%9`3-_.36EV*
M9MS#K$@M)_H[2XJ1^V]%]!!<</\`OS2@JHIU'6HUINVHPC55S!V`_3S8^6]F
M?!+/[2B,=O-"ZHK<(5F&1J!4H]55!K^36<#A>[JSVG(?;1S18[]'3+LMWP>Y
M6^Z1EN.,AZ#*4RS(;#S1#C*E-J.U:>J30CMKBYT/D#G!XYSR%Q?'>M"YUK2H
M66,FY&1!CFXN/VZ;<;<$/2Q]XL>CM4/,"L5-5$G6)3FG5-IDPC%S2:5*E,OO
M\R;)>2^5;UE."W^%88V4XW9L6SRYP+U?8=TO-NL3\B3;X#T*+,;M<JV)<>!V
M>EZA4@;E@``I2E/&3;?F;M,80>A)8>!RB^X1/,?#W)F9X"[GF7R,5RBX.Y#:
M@;A,>@7N#*0J(VZB*I9:C2X3)5&<],(6A*:$TIKM:7"M,48>Y/BQTO9G>[#B
M6?+_`-($'/OX(GVI^)>&^/+-`O&2W5]IAV?"9M"KS)BVJ-+@W*,A;KQ$@LQE
M+.RO:HG7/BR5G)=K:S.9=<^QY-SMZ).]]S'\IOS^3WZW1F`EIF(YD*_3;NDE
M]M'J.!*$-H4K:A.U-=3)N:I)U1O60A,??-V@3+4^]-B27X$QJ%L0_*:7,>:*
M4J2-JE^HA2MPV`T(KX:C+`DZ-_I_<<3<\^GERQC[\Y^Y-YUS5QSCD><MLMF1
M;,-B7E4AI;2AZY6U)E[E[J460=2#LU]F6.M8UBA2TTEIBT8M:K>@)'E"(D?:
MFGP_9M"@^'36VUZ:,-WU'S%?Q#.$(<YYT\I*DPDOO!]9!*&[7`N]T>!)Z@)"
MD$]::L*SDYFW!VX7.=<GJJ5/N<RX.)J%)7\[*<EK'FJ%;B^0:_'0%$T+CZ9A
M?,GNBM<RQP;*P/<1FGX1'M,+Y&S.6?TH+\5=HBHCQVF8C7SRV5AI/I&0VZ4U
MJ=>;O925Q4;R-5CI?,?SVO%$?D6YI4@"/<,A%F=`"-CC]XR2,Q$W"H25E+*T
MC=U`-*==566VG4O(<<?&)9\VN,26X&W74S;4P5_NU3&KB:(17HNH95M\3X:M
M,^XR1)!32P.P/4#RTIX]12H`T.=OU/D"452E/<$)`Z=#VU)K%3@UE3EV61<8
M0JZ/RWVV77&;4S$6Y$B/O>BW(ER+A,9A1TNN5],%)6X4F@H-`#\DQJ18YU[$
M-FYS+19KFFT3+E-BH:^5FN)WLQI*F''8R9#R>J=AHM/6@[:`2?K(^W^30-)X
M/("RT-2F76E)!]1&P%20K;4U)%:]4FA'VC4QZES*Y0@HNB60Q^?8X_<K:BZ,
M-.*ON,%:'UHJHR+3U<+I'<K8H'4_[E0UO>1A683V.[&Y0FE5VO(`0\!TJLBJ
M7"02`AQ/5(J>FO./2%2A"E=!W`%>NI`H/EU?J-_YL?X57?\`6[_>^SMH/\2"
M=ZEI_&;O]WI=+C\?\<>U$I*.+R_']A%52KR"I3X610T\*"O]BFIBI258QDU_
MTNGXT.>Y#2Y5JEPQ_)#QX-9(5WQX>LR9R9<MQ8:9=(`<AS6`WZI;).Q92K[=
M>%OMS<MJ2FJ0E)Q3\_ABCTK$=6G#%Q4LO#CC^S,=%W$8+C*693$&&PA-&V6T
M-A=.A-5('J*74&E=>7;W%RU5JKKYFMV;5S"=$(^?A(WDVGU7>]6WVTMB@\&U
M@#H?M`_+KV=M[A)64FL<?VF"]MIJXU:58"5?MLN"M3<AA;2TU"DD"@IW^[4'
M\VKU<C)T3JS+*$XJLE@:"A0&XCITZU'CVZ5KKHY.JOVSVIR?['>!+7"AIDW"
M1Q7;IA6NB?0C?BEP?+B#0E2W=^T#M0$ZMVLM,91GFW@;&JV\%\U`GL<%5KF7
M@3Y"(DAVW2$QF]Y"7EJ%0AP$)VIHI*DU-=::F?M7.!'_`-SF"7:;AC=]M4A"
M;G$3(;)]4M;&UQ%J:4VH&@=2XYN;6KHA20!]XZR35;GAGXNB^+>"7%O!9E]N
M+FG;BG*XEDE5\DEBWP2Q>69`_A[(+?D.$XO8,FQMN5!L46W66:Q.L*[G;(]]
MQEH6F0B7;WFBB-<8$J*NCS:FWT;M]5`]?G-_]U_;/MWR^X;_`&MO.FJY''3@
MVG5II/Q5?(^M]J_MY]]>XVY;C8>U;ZY:A%.3C;E@I8JJP:KP:J&TI62IR_D>
MW6O`)V-8]8X7&DOC&XX1*N\2`VAR%D7\928ROG'7I&3WNXQ8BKB]1HH0U&`"
M>B=>:OO;[+OR6CW7:+4L$KE/CX+\3Z&W_:K^Z2M*=O[?]SNVVJZHV)3^%8IX
M^6:))X?[Z_?CP$BS-\<\C\P91;$-)3-QJ]WIR7#MSP;0XPW';Y.AR,<N$7:5
M!U")<=Q!H4!8)`^A]I^X?:?<YRE[5N[&Y[4M,M%Q2HZ<$\<.%3X[[@^TON#[
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M8EQTM/>B9#4IM8=B3(Y(2F5#?05-/-K/ZI.T]#UJ-`-A<5(D%V$Y*;8<538?
MV;BE*H:)JI*R-PZ=*'4J+DZ+,#)Y-;W78<^(R'%.EF4TIU*"!^Z750*AW0D_
MRZEJ4,'@11,2/&.)S(EL?EF[Y"E5ONMWBQD_BCJF(+5OF[$*BQ0DLH)8-5!0
M6E12*C56N-:5^8XG%.+22K0F4N^9!$O.0VYER-\G;;W<[;&D+0M:RB+)<0R5
M-!*3N2T4_I4IXZZ,O:NK),W)GW)Y*?F;O(2KKO$5IF-4D^!5ZI%/#K72@[=W
MS_$V%<1TI]94J4M(!"WY3KA-#6I`4E!KX]-,5D1VKG`;#(&G[%D%LR1B/\]&
ML\@S%0GD"0VNP/E#=[C)9<2I*WX7D>:-`0E)`.M=BNEUXG+C*+H\R8=F4S,A
M1Y4)2#%>CLR8ZVJ!E;+[84VI`30%)!';5QLBEI7(5,6&Y4$A8(Z'Q0"KO5-*
MFG?0ZHN"#^-:%+V!9)'<FA[$]#6G6NA%%P"W*\4]>VR"IL_U.>-W3[R(CDIK
M=7L!(B-_G&IJWF57DM'Q.I;Z>DA4KV8<`OJ-5*Q"6E2NGG4UD=\:*^G<.%%:
M^-=#,$WU+\\O'&'L-]T&?V!N,Y=\4XRGW:&F84"-N9N-M2ZI[U'&D*0VPM:M
MI4G=2E175=U-VVHJKH2J5Q=$?/Y]POO9O43$+SGH?B2,G@WR[L.8O:9K-KBF
MWW+Y5ZSH8NDZ1\K+@3=R9:9U0@MN*W`.':<<8-RTRP8RE6#K0K9QOWD(Y7$>
M5#]9BYRU[)MN=DI><MSW7U&U+!H^AMTD)6*!:>HZ:M>W>EX^'`[5R;:3>`<Y
MIAEBY?MEOL]YM,J\WB*\)=IF6R*EZY6F0JA<6TI27/4COA`#K3U67!U/6AUD
MT7>)J[5KR"7!?;[E&$9!D5T=F7N^WI./3K+C\)=E5;;9C\:[V]R',EN/-S)3
M$B8ZB2M(#7I(0DGH2:ZLH4_3OB.-BO"DRP,L.Y-/<EK94AR/;U%`CLJ%%C>T
MV:NE/@I2JCM34FK+`<F!9K':9:IT2V08DA8*52FX[:74>)<0:4:60.I3M)\=
M`=07L<P5BP>U'BB"8R&7+_E4_*)"4M):1(<7:<9?3)*4`;W'%WK<5&IK^70'
M2'P4RFQ\.9#=5@I_H*D@GHJD>%1/F/AN7K;:]-&&[ZCYC92KLG%?9S[A<P2=
MCLZR<B.)<)H"Z[:46*(FOQ,ATCP[ZL*SF`L4-4ZXVBW%5/7G0(E4B@3ZLEEB
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MB$IHIU#`15)7YDDFF@[MSBP?R=#<<X.S*[MH2J5.YE)C.D?MGV[?&"_EP\:J
M#;VQP4^[4=M"8WIIU;JB'R94=U#;S:@$.MI<2*'H%BM"#4@I/3\VA8]Q542:
M8GK]/GJML]FRO-1[JN,ZBVOO)+C3<PH6&UN-IH5MH4H$@=>FE7F5.Y-X-X"7
MQ.)ET&Q(?R^3#NU^"WFYTVWQ3!A.0'7BXRQ\FXI:W51&BJJS3<#VUWW;G%G"
M&[DVO^$LE5'25-V:Z%<B$I75ML/.`K933RA4)?1/Q;6-<5-/U*X"_90E0W)(
M`VD`@?>W`C?]E"`4ZDTBB],_KM_YKT^X?O?#[OWOM[?;H1_B,?@7"G&667&X
M7#,.9HS2'KK/*;!A-F-RNHW3GO*_<KJN+$C*(32H9=H?#7Y_[U]W^\;"X[/M
MFT;N?UMO#CAII^9[6W]L]OW<%KO-QJOEI^^O@3^X^]N?`M@C1KG9^+HN0;6T
MNMY)RWD7XDT5)/[YNR-+@6,`=PDQ7/@:Z_+_`'3[P^Y-RW:WFYW$(2_EM/2O
MC18L^SVWM/L=BW&5FVN\EU-U_(C3RM,M2.6,^1$DV*##A2+1'97B\&+;;(AO
M\(MQ;C6^)%8C1&&T!*MVQ(W*J377Z3]OV=UN/8;-R[*<TW%IRQEEXOQ?%GR?
MN-RS8]VG'4FG!^0W;^16.-YF2);B1^\45/$JKUZ!(;K7[2->W]))=6!AN[JW
M!+1\S$U.RIZ14,-E*25`^IY0.HVD(;-/Y];K.U_37S?EYE7UK_I_/^`FY$R1
M*/[9>X5)H!3O3O\`'MK3"TH2U5,T[NN.F@5OI2*#:*4-104Z'QU<4G6![8W'
MK9[-."G$`^H]Q%B;#;B'$M*:#S<I;8Z]DH4ZI73Q.D7253T+:U41'GF"_.8Q
M!G7QT_--6]+<F24RE.%+,9-5.H6^!N0E`"=J22`/@-7]WR-'9\R'UZ]R&/YI
M81`9O,QEMQ*9DR!)2P_$DPXZMSC*"22VMQA*@H@I(Z$:\_W!1O;._;FJQE9F
MFO)P:9?[1*6T]YL7X/YH[FTT^#4XT?PH08A>Y2W6>\,7C!G["[/OL:(G*L*N
MLF0F#=IEMBIB-Y!;)3*9;ULR*)":3'><+3C$QD-AY(<0AP?P-9^Q?=ON.SN/
M9/N#9WKUC;WIK:;BU;U3MPE*O;G#5%2MK/5JU)^#39_J#=_NK[/]KPV_NOL?
MN%BS>W-B'U6WNS2C=G%9PGI;C-^$--,\<![\4]YV"Q1?F,Z?Q'$)YQ&1=<<@
MW2_JE+G9`"ZF!;7HEJQZ^2EQGW6Z;]L9)50!T4.OH_8?[$[+V^U*[[[O(;BU
M;@G&%NPZU_HDW<34EXJCI4^8]X_^SON%^Y:C[-[1;MRG<TSW&ZOW86H17\T7
M:HI1X5BGY@_BSG:9S#)RJV9OD^)DQ[G99=FM>&8Y*B,X8XS;YT*X0+C=)#JY
M=]3.<D-.2$N*+C"DH+*:*4@?K?\`:'V/_9/<KMOVWV:[L?:K.S<)7;F/=G*Y
M57E5_(Z?+15JGX'XE_\`83[NN?=GVOMY>[>\;;W'?V_=-5FU;>CZ:#M4=M43
M=Z+K5.6EK/%COS>,"TH7!4>(_$E[/2N]N]*5$E@4I_24`.(=!`_9NA#B?U=?
MO]N>NN%#^1&J",8XBQ%K(9$I-G8;E*MEVN;LEIM*)#D^%!DR8\EQU("RIN0@
M*(KYCJQ.CKP.9=+Y%D%H,EW%,3J^Z[7#<505+4E;CB19HP&YYY#JU*4!W-30
M:]+3^FKG$Q!&XW96D/6+)(,AZRSGR\ZP9*@F(^[T7/@/);,JS3T]#ZK0<C/=
MGV'!0IY`B<QXHD6R`<BLCK>1X>)+4891$CAJ38ILC<8=IS2"R7?PN;("2(\H
M*5"G;2675[5[>H2TRU`9._W/%F)<.TY7<[?:KQ=9L?&;8EQ]I+UXOUX06[+:
MVV&O5><NMU<HF.W1*GNE`>^K)_J0=S*G@1D68^Q'VE>WOEO)[OQ3G5EY%MV8
MP[0_(ODF[W9ZQV.X9I>YLJ[(LF%P(UJMLZ=!;QMCY.5+7,>;8O"O33OI1&*,
M*R4ZYXE'>I/33Q&>]W?`%S]N7.^9X<\I4O$[S..585>W@AD3;#>VV5V]N4IU
MP*^9]-*$+54^F_O2OH"1>7IU1&5V*M2:JBNBCA2>J4$%(-04@FA%>NA($$6X
M"GH,LLU4!N==4X*GH?*VD&E/MT!X_`;](GM2E7-E4-AA8_#$P&=LF5T"7%35
MK5)0P6]S;C8!2M*R2>FK;=W0J4J57+6MUK0?+AF%\LM_$7`M<9+#EUQLK4I3
M@MJW=EQM)50GYFR3%E-._I*0=:EBJE<;OS*%/(E9:\->="`EM12$]BE2E$`4
M!7XE1_GU)<+%G$8\=`<G.1X2:IJY*>:C(2D#N5/J0D`T^.@-%U.!M1767LIL
M#DE3C26X42XQY[[JPXDEM3,`R71ZB04FJ>@-3TUU'17YW1%5[H^)T.>P:";9
M[0.#[>13Y/&[G'!`(2M+>47Y*7$5H2AU("DGQ!!T>FORNL3*,_\`5];]7Z9O
MO-07`U7A>]GU#2B-LZVJW'=Y:"GCTUK]OA"YO;<+G0Y8F/?J;V=Q6W2YIP/F
M%\CO6C.;%,BX_%BY/<<=AFW7S$6'TM2LKQ52'7WG<9&U1>R7#U(?EH0A)5)A
M*?:H=C8-WN7MTOJ5*RXZ4_,Q>W;SMP5F_&3N/"JI3_$@:OVV9M&Y@PR+@64R
MAB7(DUI5KSF#'=:_"$"`_-GP;U"CAQF//9CPE*9H"V^DH(()('E6KVWGN?II
MW(PN)TQ\7P1[M^U*Q8[[HXM>&9=SAEB>Q>/C5MM4QIQN&S'CY#=YD%@SL@:C
MP5-.O58V-QIDR>$O*54I0"I(';7H7XV[-5)8\C!8=V[1J5,4.=)DH2T=Y(!%
M"#2A[?;U&O!/=&VODL;%I:'J$U\PH4BM:`=1U&@&HR"=+AVVXRVH[\QV);IL
MEJ%#0A<J6\S%=6W'8;<2IIQYTC:$J202:?;H"1/T4_J`^Y?DSW;\->VNZ1,E
MR[#Y"\]C\C.Y#>[W=G++:[;8UW*U9!'Q^<ZJVX'_``H]8XT1:(4>*U,8<0V^
M''$H6#5"AWXIM4>!]%6T.G'_`&T/2RO]K/A+55=`752'"H43]T?``=`!36VU
MZ:,TY:I.2\2-ON:N1Q/Z<UZ006G\NBV>`D%6U:E9)EJ)S@7U&XF(P3TJ:#5A
MR<]F"MLM9GCJWBVEJ/>8\QU:TJ4TVQ!#DYYQQ*$.+4AKY?<JB5':#0$]-0_E
MCJ>1,4Y2TK,XS/J$<.<PXAS/;KE<K'+ON-\OWF^,<095%M,V/;,W9DYA<+67
MH5SD1(+M]E3KD\5(>*$J<96D*"2%#5$-Q";:2:IR-$]K."3;6*\P=B[\S'.9
MI^4V%J3<<(]I.$P^$\`MEK:<ECD3W`WBP7W&H]BL,9H$W.7?^1,@O=^EE`(;
MMD(K71"D!7?=6'F<=EU:36`]7$?%MPXMQ?\`A:_H4SD'XA(DWR"IQ+K5INGI
M(0NVMJ02@&*E"4O$=%O5(Z:HNW%<2H3]/+BBL9NY6:[^Y.=.Y6=B(LK6<7,W
M6->R_'MXCV^0\W!C3O2:<6S%=;8:%=BTD4W)4DD'N$9.-(8/B53MN&;1:W[(
M[K;LU]R]RDVK+K'=K=CF'9/.MMGM#*9#D.!(,&VP?G+EY0IN*F<4-LL-M,)`
M[>&JYVG".IM'!T+>V"V%_+,XNVT*:M\><TIPA)"4VZR+<VJZD@@R:DZI`D>3
M[2XS[:,0E!`"K[RGE\]:=M=S<1RYL-.4Z`I5LJ-2=1BY245FROE%J6]O,UXN
M*2Z[M::;2PTD;B4`>G15`#0Z4+OIY<4#T6^(A*0EI*:?9NJ>U:JZ@TT'T\N*
M!*&FT`IIN2H4*3VVD4*:5(`(/72A'T\N*&\R;&A<[>_:U[4S6%*N..O.;C5Q
M"#_0U$`G:XR"U0]=I!/4#4%`E,6GIF1"PNOS,4^@^A:=JVUHHDI77])*@4GP
MJDZD])9(<[T?^=?]JM>Y[_X3[_W?L_FU)-/VD,,GXMMR[W=YUO4_:YR;K/<1
M)M[ZX;P5\ZZ14L*;2HU^(.O&O;Y7T[=Z"E!^#1I4%9C_`/CK3+R-$++N8,(4
MRJ'D9R")&-40<C2N2/3!!2A,I"RYM!'0$:\2_P"P>R;ZW+3:C8O-YQ6?GB:[
M7N7N=I:5\Z_YL*"CG9+><R9N>5WV%'@7*^72!(EQ(:0B&TXQ!D0P(Z4I2@(*
M6$GI^D3UU[FRV\=EM+>TM.L(12KQ:6?-GF7Y._>=^\OUGGY>7("(2H"I42#0
M=J`&E:5^--:9+7U8G"261M"5'J$J(^(!.H225%D2?NQ?ZJO^9/\`<U(/ST=Y
M`4D]32I2?'P\.^@.I[A)+S/M"X'C%*U!KB7!RREI-5(4[;`LJ4G<#NW.5_(=
M:XVX46"-D-Y""7R8I<"/G+F-3,JL4V'/3/<M3JD-7(M,`/M0WEEI6UU::@E)
M*00335=RV\-"_`G_`'!?T_D,T[[,L`MCK;]K@S$6U^.VMA"9@?:^6?;("2MP
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M&L:R?/(V`VMNVX=,&&Y9C\`,^BN+;\JL1?:=+9<>+;DUF`VXXC<H(=*MIH=>
M`]O8A<E*"QRK5XJOBJT/6N;B]N7W+[U7)-2=:9TI7X+#D2UQ!%VLC`2PM3;:
MDT>CJHY'>1XM2X[@4T\GP(4/R:[45')4*P?<8'XY>"BU0V(,[\$NA?CL.K4T
MO9'6I;K33A)A-!BH(*UI->E!K/*<NY1/"IJALI78J6JD9$SN.[6JYV['K"(T
MK\0M>&XC\ZTY%?#"$KM,5IN4B3Z987'=?44!07U6".XU]`HM[>-%XGE[APLW
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M10(QJX*`*;<-^\)`DR4MJ'2M:,)D=$_EIH0I1>350]@XC>'"D"/!92"#N7Z\
MA0J>O0.1QX_D(T)%_C>!+1=;<].G7"WMBYM/Q[E9BQ;IUNGN,F&[\J\XU+'H
MW>*YZ+WJ;T;TMF@-3JR$YZDJX&"2G&3E1YEB.*>W/BRY-LR;I?>3,@]9M#GI
MW7D"ZPV'`M(51;-LEVMB@K0C8->;?N[V-QJ+FH\OX'JV.S*TG+2Y^(^5C]NG
MM_MY8=''V)2I+9'[:_.KO3RA]ZJG+D_/4I7Q-:'5ENYO'!-N=>7\#M]A/^7\
M1];!A_'5D2E-IL&'6I*0GTQ;K1`;*21T"/18;(-/MUTWN982UM<BB]V'#^7/
MB65\2AM/'6+ADI4V(;^PI;+22/GY9J&S]T5UZ>WKV8ZLZ'G7$E-J.1!CZQMK
MG7KZ7_O7M=LEH@W&9PC?40I3J5+::E)FVUUGU4IZJ;6X@)5]AU:[DK2[D.I9
M%4XJ<7%Y,^9!B>06FSS7,?RK`F,&R&3E%GOLW.K9:VUW5-QL"FODF++D[Y5*
MQK';@\R';A&C$&:319*`4G98]UM*-;VIW.7C^)F^E@G59AWQ'A-RM.8WFZY+
MD&&8Z_>+M/N%UMMAOD"Z8]FMRE+;7:LKQ-N+.<3@SUS:3NN$!]H-?-=8ZTI6
MMH>#])L;_N"WNZ<TXR36E+P=57CC^1Z>YN1O[56(5[GGD/\`2\Q?C7=F&B'+
MA-16S'4)3+D42G0LU<9;?"/520/*I((4.Q.O5W6\LWVW'5CY&?;;2[95)4KY
M"P9O/XDC>MX)Z%00I92"`/-0&B:_`=SX:\P]()KK)9BM*><JVA50E`0?46H@
MJ\K0&[[HK4@#0&<)PH7(O.W$F#AMY:LGY+PRS-MG:I"D2,CMY?*FP"HE;"%$
MU!V`'OH#M.LG%W'>&91FN9XEQS@^,Y5?;3=5WV_X_B5ALM^R!V4]'C,(O-VM
MMOCSKDE7J'JZXJJAJ#)*S-R;5,667<I..8U[;L-MJU'UG[?;F7DE1*M_RF]5
M*D*.U9[_`!UNM>FBF47%Z7F1@^H],&.^T/B##Z@.77(<.;6THFJV;)BLZ8^5
M)/=2)4ANO0]]6$%#$=2+8SDMXJ&EV7",WNK*T)'D?;QJXLQ5=0`%"4\G55VY
M%1[;S+K,).2G_+4B;QM)P?D3B_'^(>=,;@YG@^.9+;LUX\NT^*7\CXGS],AQ
M#5_P*7\Q&<C.W,J4F3%<=^5=5^V*-[:3KS4U:;U>+\#T+DU+2EX(9+VZ\'</
M8E,E-8GQI9K.Y@.=9U9<77->DWR7:Y;]V3$ON3*GSUR')F3Y$N,D.SU)]=$5
M+;+90VC:;(W.YB5*G@5]<I-J3R1G2`TI!1EE]04[=M/Z>Z12GZ*DJ!'Q!UT2
M,%*]BF.>ZC*[G.9N<3CVZ6JS2<@R_D"7,9MV.6ZP6Q+;;UUR5N0S(;E/LI&Q
M*F_3<<H`:TKJVU<4,)9%5VVYTTTJ6=^Q7Z>G"WMDOEUN\7+^1L^O'(]N@8;;
M^2+MBK>,\8,SI,C\0MEJMT62F/>+@]<KJPTTT_5<60H)05-*4`>KMR,XZ5F4
M=BYY%B'N@YALGM&XJN&88IB]DO+MLM=T@9%C<&4W:ES5WZ';(")+DQIB4^S.
M+:C(:4Z%)4GHJ@).J(Q<GI69S*U*"JZ4(^M<Z\7<[>T7@"X\?9/9I]W2K*KI
MF&'BYPWLJPZX/3);*X&1VMI]R5'`D**6WBGT7@04&AIJR5F<5J=*(BUZB(?+
M\SS@'^%6D?\`-'^;59O-@854=4]QXG^YH`5Z(_51_(/[FH(>*H!;G;G),8NH
M21*B*$J,KXK;Z*:)ZD>J@TK]FE#)V)^0S-WMR;'?(E^C`)M5]HB8GLB-=&@3
M(0O=M2A+J0%`'H%[_CUN[$WP+5?@E3$7/X_C/_9FT_YKT_>C[WZO[SO_`'_W
M/LUQI?YT+-:_*OP&#O+A5=;LDK%/Q.?^KX2W=?+MXGIVY*+JPHE663-B.OM1
MGGD(;+BW&FE.I;:!"2XYM2KTT!1`J>E2-<RO=O#3)\CN<U)U5<!0XY;$#'&4
MN-@I7)82=R!UJF<:@4'8*\=>K:=;<7Q2/-GUOF>Y>-P7`=C6Q2NRF!LV=.^P
M`H54ZL.0G<QI]I)+3FY*?T7$[3U[^9(I6N@"ER!*:W;VB0@FI0?4%!W/EKVT
M!I90%N)"B`*]020?*"K[#W&A!U:\"P$R/;MP-#=D",POB?`E*?V[@DLXJS*0
M@I)%?56D)'Y:ZVQZ5R.AKN7+=<&\83*VRFH4Q]Q+#A4A/K+C$(DH1L5O+;3C
MG0D>/<TU=;FH5J0U4!\'15R>.[S%EN*>=A7*8J.MU6]33:F([H0@FI2G<HFG
M:NLE^V[DI33P?^!HA<48J.(F?<-$CW3VN>X"W/QVW@KBG+9(#@J%+@VY4UM5
M*]FW&`JO@!767:VI1N-MX4(W<7<M**XG%1.]-GB*.ZRZT/6Y8S%*'4J;](IC
MXQBS:=C@VAP(3U[KH%?HU\WJPMZE6J6)@BW96EIMYX%_7$&<SYC4.XLK#\>Z
M<5\*.^JPM*T%$>R7N*V4K1Y5IHST4.AKTUYDNI\SUEDN1,QN_)9L?S#K*O4^
M64L$BJC0$>)ZT'CWU!(B\6OMX9R"^Y+`FVQR(QBF3LQFX\U@R6)+]@G)AEZ*
MZL27?VZ156TIJ.U-4.TW/554J>A;W=N-M6Z.J5/`L$Q/WE9EPIC>"W5BR8IE
M$"1B&+6G*\9OT8RE7V*JSL3WG5._NH;B52B8[A0I2':$&FX:^AM34+";XGSV
MZ_6OM1PH7!81C/LJYQP'#,@B\Y1<1R#D;&H-]@85<A;(UZCRIZ7FW[5'L8E.
MRY[UNFQGFUJC;TK2R70`@ZMC+7'4C%*.B6EG-+]5/Z*-Q]P/*SG*_M[Y4PRY
M7]BQP,<N5BS-4RV63*F;&M]=DO-ER.U-7>);[BAB06'6Y#98<"$+2XE04#3W
MXUR9NN6JPHI1;P*D;Q[!.8_9?PIF/('(,BVW'->+^4^,<VR'C_'))R7%<@X_
ML5[M\R[*OJU1TP[]"^8D1)'H%@LM,17%N;E4V579J;31F^GGQ19+[9LOQ[AW
MWB<@KY`SV+8L&]T>&8KCV!6.KR+'D&>/Y*EW"XL&T1T2UF\,6"]?)(>9;2TF
M*E2Y!0VG=JI1=V$M/A4NDJ6G'R.GKZ;W+D*QIY,]MO(TN*JU6ANXY)C[=X>;
MCPG<>?AOQ[]:7I$M:([<>?92ZS4J"4NL)/0ZO@NY!06<3-;GHJ5F\NX9A".?
M\YP+!,PP;/\``FXDY.*99B64V?)PN[7-'XS9[<^;1*E1(`58270M:E*>>;<0
MD#83JJ47!Z7F;(RUQU+Q$]C%LE151[9>'8S;+\CY:W7*87%*B(55#46X*20#
M4C:A9(]-22A1[40@Y.BS,\8.R]<J->0_]KXOFE2?7F)HH5*8UO0CH%4!"GY$
MCH:?JZF<'!T9?":FJH=>T<46]Q(3-D/J;6@!U#LB/&"D4J?W++2V_C4'X'PU
M=;M24E*JH4W+T7%PHZCXV#$[3M0F;=VVG8ST:!^WN"@P^7D..POE6R]M]1]E
MLA;:*G>E1([ZLNP<Z4\"NU<4*U\20^*83C3GI@J+IW`51%F/5(%#YVV%"E1\
M==VXN,5'Q.)M2DY(DUBF"X^$-%$*0YV44B*6PDD`J)]=QNE=:OIY\4<T)E8K
M$8@X]:XD9M33#+"DMMKV[D@O.J-=BE)ZE1/0ZIE%QDXO-`@]]52*)GT[?=Q%
M)*0]Q#>$5'<?TRWD?SC5-WTWR)2;=%F?.#SQM]FWRH966G4+4?33M6EU)31*
ME)(4BBP*=NFL#P56=]FYP_,C_#MA2?5++;1\Q5Z:$)J02`*(`%*&GPIJONP)
M5F::?F+&U9!>;>R(S4Z0J(B@1$?4F3'0/#TFI2'D-`>&T"GAKKNPXFT<VU93
M,>92TMQEAP`?M8\.&S2O2J2U&;6"!XUK\-1W8`3.4W6YQG24NK;"XQJ^H!Y3
MK;A)WA2R=KAI3XTU/=AQ!*7Z6&)*S[W_`'`-O6VIV/CMXON;S54!(9Q3&KK<
MVEK)\J5*E);I_?$:[SQ!VQ1+0IZX/MJZ_-3\=M"$)ZU#UPES7$`=?T$IKJ8?
M.],<RMW8)T>9+?W0J4;'QSB#-:S)-HC!M/0J7(?C1=M#VW!?QUOA%QBHO-&2
M;4IMK(AG]6N[--Q^#\10`$1D99>2@5HDL(M-E8\H[)*0NA^S71P4@Y2PXU@/
M)<WU/2"<0%O!J**-ZO\`9[8&3]CK;RP1^K76'<SC&Y1YT-=CH^)$?'8T>)9K
M.TA*02^)C#R!N,H-^I&C/M(`4K:M:WMI^VOB-9)IW'6&2+LQ(<(SKY;\AY$D
M1+8B]6I[EC)W9CWXI#M@L=E:5/GW*\23*5ZTMIIZ&&D,L)6ZM]U`IMJ1W:C*
M*=0B*]_X6S?DOEO-W,2LJ)EHD7L2&;I+FQH,3;,AQ7'/4<<="P^Q(#C91L*B
M6S0:M)'@RKB3(.`>"LEQ.7:%9CD_,KTF/DJL=8DS8>/X)8;>\Q&1//IMONL7
M7)9J&U);;475E(2#H"0_MNY^MMB]I]MQ'G<72V9S@H3@%JM[T*6]E]SMUHC^
MIAN1KAW$?.VU=H9A[79UR;C1R88<05)*:@0L^HW[JL&Y>X-RG%;*R[8\BLSV
M)VJ>Y<W+>S=\HGA,29=IS$6UI^74RPAFJ-JW`IIRH"$@)%EGU$57O392C[=>
M39/#O)&(Y:R5FU.L/6C+HX4MO\1QR\3W8TFI1T*X"EID("@1N:[5.M-WTV9K
M7J(NH3Z+I#[("FG5>LTL=0MIU7JLK_(II23^36(W`T,`E*E';2A\4IIW\QZ)
M'YSH#PY,@(7Z7J(<=I4-L@O+(^(2V37^70`I+]SD`-0X@VG[S\T@>;P*(S04
M2BO@7!30!9+Q=J;ZMNOD9J=;KK*:<#*6U,1VIB"IT(`0ZI]GU5@FH40M1VTZ
MZV*];IF8^S<X+\19_P"AOC[_`+GX/^9/H_N&OWG^+?\`4?\`_-_OM5:'^=?@
M=5C_`):?$K]ODKTKO<]U3NNDY(VIW=Y;W4T\!XZ^6<54]E+`35^RG(V;9,ME
MHFK:AW"W2;3<HR@%,3($TM+?CNHHI*P'H[3S94"IIYI#B"%)!UHL6X.+JO$I
MNSE!I1\4.M8+J\UA5GDSFU*F3'HGJML!3@]9<1]%17S>F:?>41]NM222HLC*
MW5U>88&<O;41Z4H5>HY0@&GZ*4JZ]?CJ0%[TN4\M;:PEII.Q;3C52I2O/O0O
M<>FT$$4[Z`*9K#SS7EE/-5`VE*R-NZH)VIVBIT!IM5N0TAYIY:I+@<0L.NDE
M02ZV2I())(&\'0'57Q(PTW[8^+WZ!+EOXFXE:B@#[TF18[0"D4I4J80Y^6IU
MMCTKD2(2ZXC/S%NZ188:@EA#;JVY;CWFZI2M:$E*R"MVM4T2-2!28CQZ]@EB
MN-N=F-S'YBG)#A;0I#;56T-AIO<`I7E'<C6>=R2DX^`6:YB,OJ,)8P_.F>4F
MH@XW.(Y*QGJ;JM]FW*P]=IEC(&YCL9QJ4EIRV[TCTE)=*B-A"J:BQU_`TWNG
MXE)/)7M*P2]\61<GXH^GAQ7B7#BI%BR_#H'*/-&>0^6,KM^57.Y6F!E$7&O6
MN]@QS^+H-A:;1#NDQ+T>,TRX0@NK5J]QJZU:^)0IN*I1?@*CVM7;%.2,DY&M
MULP^?QX[@EJX]PVY\=7:"W$FX1/L2<HA&P+:CK>CO08L9+*HTAHJ9D-+"TJ/
M754[48Q<EF60N2E))Y$KN5L5>A8E)=COEL)2T"6E+"@D@U2-NTT4@4/V5UG.
MKLY1:H1FXI$KYJ^A:5.(-IG,`*/W/6CNM%0'7]$GII2I6KTUP+/,<X\X.R;$
MK">5KMR/%EM8OB;MNL>`6FQ2'+E%9Q^*9ZYMWOLV-'MH*&TH2M*'2VDJ60:`
M:UV[LY1[;II1DO-P?<74V.78^&N,K-)7S=9L]>L.3V[&[%;N.L(MUZF)N<S$
M8UBNLYC`8E[L\>XSK#"R5M@0YT]7HLO[G&PXIQW8OTMM<L+;W'<KK@JKXGG7
MKUSN>&01Y%[;.5LXSG&N:QR?-XWGSF+?'N6!\0W9EC$4PRZI;[RK#DCT^$+9
M!B^FT8;#22X1N2/44HC":K'J(<Z^XO=FLBXXOEU$.Y7$"#C64NQ(43Y&\LRY
M`8:N#UGN]V=3^"HMTM:9C7S$EPL&J6W!5(DW$%N?_99[2N5;UQYD?,_N!R3C
MD6"]R9.-6C'<KP_!<YQ^9D4=JR6VWP+DF3.NUK-EG%IY-$.NK]%#1<"`0>K7
MRO0LI/'XF*=V;;CX5)\6KGS'.(+&WREDEOBN\/8ADMUX@YHRN0E=US_A&^8_
M<8F.L9%S@J&P(V18/*?C-.7.X1F$IM#4YJX*]:$Y(=C[(6XPZ2HJSY&Q29[3
M_>!*M=B"+7QARY$MV;\<RTS&)5GC6G(KW^)XP&;A!<>AOV[%<ZE&,7&EK0JT
MW<J35"@-1*W"3U/,LC=G%:5D3H]P.89WC'&4'.^&^&IG.%QRZ1#>8Q.VY!_#
M+=F>F-/Q[N_=IDB#)<:MMNO;)3**6M[`DH5L4FM,49.,JH[A.5V6B?2/O[9,
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MK0W+D1R0'4(<`WLGN!K)*<9O7"2E%^*\01`^J"CU/I^^ZU%-V[B>[]*TK_3(
M!^(^&J[GIOD66O47,^>?E]GB72&^A;:`[4CU*%*]Z:]*BAZ?;TUYT^A\C<1Z
M<L1AO*8=04)&\BI/FJ30]">^L9`GY<#8Y1)Z=1T!\*?9WT`8VU+JY3+*$FBE
M=3V"4I!*B2:=-HT`>O,6W(;BU:Y3Y@,NM*BQ)S2`N.)*$*+33JU@*W+`-`2*
MGMH"V'Z&/'39]YO(U]96N:S@/#.3!J>IH(;5-R:_66S)JTHJ+;B(ZE[#^JA7
MCK;'I7(DZUL2A/3<UQ"*E-4R\N=EK15)*T6Z!&0GIU-$N+)'Q\*ZMV]N<9N;
M7RLP7.M\Q\^:'7+WSYQ)CZ?.B-D5E>6BH"3\H#<74D*VGJF-2@^&M[I7`X*X
M/JAWDW;F[&K."5?@/'T!7I5_=OWVZ7&>\.M**+;37C_;U6[D(NC>(*?N<+@[
M8^#\S6E"ER;_`)?QYC$)I(W+6MV?<KL^E-`0=R;>BH-.@UYVZ3N7=4,50T6I
MQC"DGC4B994R8^77%-]4MO$;?:V;?&N#<GY/'X*(B6W53;C,FKC1TRGE(4TM
M:'5>F.H23UUS:3BG4M[MOB,W*]T_#?'N<3K)"S3&+=%N%W>N607QBWS<A@65
MB(VQ-^;^7A1TQ[F94MHE:0OKMH-X62.W*,<V=QG&72ZT`EG]VG$./VR]KXCX
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MUWG`K[C=^C7F/D%EA7.*'WKG%:;9?Q^]F/=F)#L)WU'$H51)4`3J^Y<A*#2>
M)5&$H24Y*D46867YJZVZW&V.M&((D..GTP79#1;CH;5'D*?\K:D["!0'IVKK
M(:.];XBZL_'UTOUSB6@*8<G3/4^6:NEQBP6"IEAV2XE,FY2(MO8"665*`44U
MIT/AH.];XB@FX7)QFYPK-?(L"WWB78HN1M6D7&TW"2S9IBFFF9#B[7+FPU%;
MS@&U"RH!0J*UT'=M\0^AV924IWM>:OD&T5^/8?#[=26!NO%Q<(CK#R5-%P>1
MY``4TM*@4.(ZC]HVL!0^T:`%_AUY_P`17_FQ\C]W_P!T?^R7_4/_`*J:T:X<
M?Y:?P,O;GP_FK\"HJ^N*3>+J.A'XE//6I_Z<?^W[-?+^)ZT;L).BS$K*<W!S
M=0??``!IXC[?CH6^(^-F2HXK:.PJVP`?L3'30]Z_>7K=#H7(\^?6^;-J&MRR
MA1W$`'IV/;O6O@==G)N+8*0DDT!J.U?@!V[`:`TK:3L45#:2"*(I2I'3N#H`
M%;U)2Y+0>BDKCDBGZT8'OVZ'0'4/@#CD'@3@5M25F-(Q?BQV4Z$DMIBIQ6TQ
MT-K4"4)4IUU5*CKMUMCTKD2+VTIF1H\]^=&<CJEN2%1U/(VN.QU25J9<1U.Y
MHI`VJI0ZJO\`@0S9,G-N.J;7N)<)*C4%6[<!3H*`:S@8GW1<6W?DSVZ\QXIA
MT(3,IO>%S#:;4E7I_C4VV2H5Y_`TDA1+E\:MJHJ4]0I3U#T.K;/7\`A*(SGC
MCW$</)R3#,BMS=L:QOBM5ZM,AZ-'NN&7N#>LO7><4R*UN%F1:+I9);:FEM.^
M5"2E0`"TUB^WKP4GAX)LOMSC%4EG48/A'B2-<?>G<<CQ^=8\HX8Y(X^O_'=N
MR&RQ(?R&8<F<21+!EV17NVW^&VE^^P,:@Y*;,7_6>85+9D(03Z)([W%]1V,(
M6_5B\1;MR5Q2_E)W\I^VZT7:W/0@P_\`)+;3O;8<4'FE)ZI6FNX*%.X(.O/M
M;B4WINX2>1W>A*35"&]UX/L&`V>YO6R*KUA'?4])DC<^XCTW%!*EI0VD)2E)
MH!^?6EJCH<ZHQAH?502?((Y)>A8UBN)*0;7?L,QM3-[N2),2QVIV\VF%#"9E
M_"%1H$0.1D!25G:GU#T\VK;.;Y&*["4XI1XE;]DY\S_A;W`S<5R9Z5<86/Y.
MQ%D'&X4:7=F)4*)(M\ZU0I-Q;C/7C&9<&>;@((3Z<LQT.A/J(;4+/I;>XN.K
M^?A^PY3C9MUNX+\26.-9_E/*_+N=O7+D?)>-N.\$PK#,^XFN*[2B_7O.,O??
MD.72+&A_BEA9Q)BUM11<6&GTR)/H/H`0L5*;Y6XJ7;O8(B5R%VTY6\AW^(,5
MRMGD7C*Y7GF_*_XKQW),NNMGNO/?+%TM3>;P5V%R>C%)F)RI\?"\?M\7\6*H
M"UQOG)@3Y5+*.G2L1_\`3EX^!FJSQE_MNXOXOS"V\_7GVJVZX9I<YLG)[7;#
MS3#NF/W/+LU"H[U_EX7,QQR`XA$B0MV")\E80XE*4I44"G#5'I>:-*G"5O0N
MNE!P\@]R.'6%B5BG%W&EJ//GNKLK,'EK'<SRW"I5AN^0VS"A89*$V,7VX0LE
MG72WQW0ZT8[9FH=<]1ITJ#0C%$6UV76YA4GM],7V=<%YM>,LOON=PJ!S5R,]
M9+1;<1M6:S[]=L9XFQC&K-,M]SX:Q+%9<QG'TMPK%->FQ+HF)ZDY894GTO32
MTSTGQ+JJ4=4<A$?5"XUNG#6`9E8<8RVWXS?N-YS7,O#-PB3I-INEX@X_,MZ7
ML)N<6W->A=\:S#&;FY#0\Z%!XJ].0E2F0\KJVU&5994.LU@,-[)_<#;,\S.1
M>($MMR#F/'&'\A18X>2Z8LW#LHM$^7"6L$!Y^#:;[,8<(2.B#TH"-+LE*58\
M#+?PDN0ALFYJDX#F&;8BER4E_&LURRS-M29[S,<(A9!/:8`:2\741_EMNVGZ
M-".E-<69QE.J>$<SAVIQ:4EU9!Q"]T[R-O1D[*!0=N)<*5$#=W;*ET[CH#K9
MWK?'\B)0E#J`./\`NB5CE[N>Q<;Y*=2X04J!=1$<*R)D-+H0ET-!9"VTF@2D
MT';7G;W;VMQC&3J\\S1M-W.Q)IKY/`7Y][LYIL!J2ANM0K8B2I0![4JZ!0Z\
M_P#V7:_UO\S5_N4SJC^G[F3O(/LZX-S%]PO.WW';O)6X1M*BSEF0Q`:5-*"/
M37N[2S';[>-F#K&*_>>?>N.[<=QYL3WU,D*<]A/NF0GJI7%5V`%*]?FX/AJZ
MYZ;Y$6O47,^?KD=M?;4M26R3ZA4`$]U=J4IUKKSYJL6EG0WC-7NW+=<6E;*V
MW$@N%*FE(7M3YPX`4@ELCJ#]TCMTUDT3I6C($!(C`N*]1(5U-*`=/CV%-<@$
M.V\0;49)361.JS'#?WPRJG[392H6Z30?D^W0"KM6.Q),/^&)8;3+G1XSZWBH
M-J8F2_VD>2A92I:%06/VJEI!*$@FAZ#0%M7LWRAWZ7\7/.0>6'\+S;&><X?'
M=JQOD7&LO@P)J8/S][<BVS#\$RN#;<ES_(KS<I:4[&?DVV&F_6<WI"0=L>E<
MB2`G+'U;O?#E?N[RJVX3S]F''N)XQD][A8C8,'_"[!%MEJ@WF1&0998@.R;A
M-EL04^NM]U86JOE`Z:]"WT+D8+G6^8_'`?UUO?/:/=%[=,=S2_XKS9)S?EH8
MA%?Y!Q",Q=%X_<VY&/N*BY-BCMC=^<M>YR2V'H[ZE%`JK83KLX+Q_<)R[*YY
MY(N'(\RSMX^_<+?9K>FU,S')S$86>"(*G6GW8\97I2GM[H04D)"@-RJ5UBO>
MHP,+E5PLMHP6QVF\HCKN69\EL6^QIF%?RS4FU6R,%35I;"W4)BL71W<MM)6D
M*Z=0-4D''%]1/_2MAURP:39>4\JR;&,FEY);KE8K#^(1K+9;LU-3<H,"TQQ*
MEROE'X$U82I2TN++:N@I37<4FGQ`S'#EY9:Q!D7FS.1<B2_):E.NP%/W>Y,!
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M2Y>\:SYU]=AR:0\[$OUWQRU1[K:6F49&J<XC`KV\HQ9+#:/6?4RO>X$D)$'!
MT+7FU8IE_'?MLY+_`(<L:+/.M%^X1RZU-VZ''A-1[M&1EV/QEL,--L1VXLQZ
M?'0D!*@6`D?=`$$K,@KG?&C.(YW?L=A1U(APYRW[<PHNO+:M\UM$R,T7'2IU
M[TTO;=ZBI1([ZZ/2,CXK&CH29[\>(E5"`^I+*S7J`$KHXHD?`:@X[D.*%=_#
MEF_PQ_S;V_U2;^[_`,8_J_[C_GOW/MU([EO^I'.+?E#\5NX).[\3GTZ]:?.O
M:\CZ=<3N$G!ZA,OGR+/P"M4W8*#21=]0^!("TC_BS9TI/1,>+4CI0_+H4?SE
M(ULAT+D4MZG7B"B0A8*J))I_)T^'AKH@URYL=JB"16H(I3J*'^WH#4\M!0GT
MT+"5=2HGRCX=S7K70&F(VG?(6V`OU'6%'H.R&DA8KT^Z/CVT!T[\=2[;=>'>
M+L?E7=,,'C7`7X[,9AN;-0U;;%;6O7=B&5%4Q'7*0ZA*R3N7T'W=:(76VHT!
M83A?LZS#-^-L9RW&LXM-P-YM*I+-JR*/+M3\1'K+:9CLS(OXG%+6UJHJ$D5U
MW.&O,D9_+O:ISUBL]V1*P&YW>WH;4KY_&'HN0LT2H^935N?>F(!I6BFDFG<#
M5;V]S./00-^Y:[S9DKC7&!<;7-;6D*8N,21!DMJI3S,2VVG`0HTZCOJJ$M#J
M@1$YJ]I/`6;9AF^6YCQS9+AD5PQGC6?*E6YRXX_&NUTO-RS-JZS<@@V";:K=
MD4RXL0HC4ER8V^ZZ&T[U>!Z=^^G\DM*Y%L+:G&K9(S(;SCN&\G>S:PV7&;38
MK3ALSG7&[?9,=8AV6R0[4WQ%&3&BV^WP66XT-@40HMH0$A:2>YKK-=Q@ZYFI
M$J[O/A72&F6TP`'V@I/F"BD;:4)J34'H?M&L2PFI^*.B#W-MN;3B5^6A.W?!
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MR=EBP\B6W(K2S(D8KG$BRL39=G1'D2)4F[EBS7)`3+2GY-*T+3'5LI5%-M)X
MLTV[*HIUQS&+XL]LG&\NYXFJW\J9+:6+6\Y<)-P@&PXE?+;)QNZ1678F&7)^
M6XF\90RHE4=%&UK="30[CJ-H_J82E+"DJ%6]E<48NVDW7Q.KGVN>Z^P0,=Q7
MW#8+ESEYM>"34V'E.>]^&INBG,$:0]=[OD4&T2KA#9O$6#6>ZRVL^I'DR&4A
M/J`)[G'1/2<V;]Q6TIQ299I[H\0]O?U`/;QPY[W>&<A=SNR\30KYE.&Y-B4J
MY0G+WQ1E#TK'<X@EA]B/)5<>,,BMTEQ@O,A<8V_:`$R"#;<M*$:U-%JXY2H_
M$IAYIQ2![3O<1QCGD.&PNQ<C6_,>/<9M6*XU+AV7)[I=N/;A>+'/OK]@MR[+
MB3V06UYA]^:XA+$V;'?6$AT.D4'<[2N.K;J0&S+E&X>\V$[F-LAX_P`:S<KM
ML:]7>%BU[?9SS'I-U4]#EIG7]J#'>E>O=+-(6Q*^7'93:2"A2=8K.T=BXYJ<
MG63=.?@=WM]KBK?;BM"HG5UPPJ3T]OWLYQ8^WWD?*<YRK*;[<L3XPE7Z!=)L
MF.[=X^2R+U*D63T[HW'8,L&+(:CNMO1W4*C-42E*AZ@V9F=?KYX4(JY9P?F>
M&7%JSYI-N=DN*XL2Y,Q7K<=LZ!,;WQKA;)1D"/,MD]JI:D-*6VL&J2="7MXI
M5JQ*1^-EJ:5\[?9[ZPXHI,=KT!L*B4#TWG9'5*:`UK4]0!J#*=PGTLK<W:?8
M#[:[<TXZZW%Q.^H2X\4EU05G.5.$K*4H235?@!TUOL^FB0_^I3_YB'N@_P#L
MMNO_``N#J;G0^1W;]1<SA&<LZ;G<&8R6M_S+\>/M3XE]Y+73HH[SOZ4!UA-D
MVU!M9T(:_50LGOV8]]<KC>R^WKD#)+!=<'X@P?VT7'`\7S&Z6AO%X]JQV3"O
M>.3,:9:Q]Z\RI[DB+>6[AZJ6E+<2XAM(*P44XMLQJY<<DJO,M>O7TMLPQRUQ
M9MT5R3;;FBU6QZ[LY5PQ?+O98-S,-G\50+WP[>>0DO1VI_J;%+BQPILIK3KK
MAPAP1O(RY1[/.3V\DBR;:YQCE,&V,(0BV63.K'C>1R)"?4#:CB/(B\.R1+BE
ME(]-,=:C3I6FL9`P?)O$'N&XNN=MN3O%G)-IN?XW;[I`O[F#763!AW"&\PY:
MXT.Z18%PL\NC[:=K9<4VZ$T/30#<\]\Z<X^ZS-?;7C/+LVWOX_A'+%MO$:5;
M;##L620LAP.TLY'DMXR"0RM,Q]#5AMCJU.;&6D^HXD#KMUNCTKD25GXIRS@C
MG*V59!=LJM41VY?B3\66X^"AUZ:I;R4)=0%)6DNO*/?K7[=>A#H7(P7.M\QT
M^$N7>+L+]Z?M5SC/\I8M7&?'.3W2XY'DPCOS+7:)LZR9"W8KG.DPFY+K4.3=
M9[`><V;8B$;ET3U&:<YJ<HIOR*V=DUDNMERFR6S)\=N=KR'';Q$8F6N]V*X1
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M5V;4<TBK>6K<()PBDV_`N\XVP.WXCQ1Q5A]NA)AP;1CF`62#%1'3'#+(%K3Z
M88])I3145*)3M!J37KK2><6'>X82[-P+[>;?'M3CS&1<JOB;-0*AEN5=K/92
MXXVFM6RV`2HU`(U)9:2E-)XH?'ZE-OC2^/.8$R<CB8W#A<22X"LIN$"3>;?8
M6SCDEL7>;;887*FQ8"WDK6VV"HI!Z&E-#T$W%:8X1.4OVQY/9N9++=Y.3M<8
MS\YM!=B7Z9A;T*Y,Y`U&8=?@9"E(MK)B3&GVD+6TEY[Y53R=NP.!(DY:35'D
M6P>R.YR<<S/)<33*=1;,AL[=PB,*;V,LW.U/^?TPY1"?G(4I:5!/?8-05RMV
MU%T2R)P8%#5-X]]S7"Z?ZUA]X9YDP5LGJQ^!S$9PDQD'IZ:K+<+S'&SJ`P/!
M)&H,(D>6L4@9:G#,\COS!'O%A1%F",^[';>>C-HFPBZIBCZEJB2%)(+E%[-2
M=]VY_4Q'V/#;5$6AR)"89>K4O)8!>J1U/JN%;E3_`+K0V*W;IBD.9^!G_"._
MY!V?><[_`!^]VU-!VX<$<AV0?Y:NO_PE/_X:_K`=+(3,E7E4@=-X-%`]NO>G
MCKEQC+-)@?Z`\M-BM<:.TM]\-6T%M"DMC:[""BHN+\H"1][\NI2I@LB05)BS
MW5_<994$$!*Y)6>H%%5::4CH?MU("S\`670[,N._[I#33%0CIU353_F%?&F@
M!SL!PH#3TYY8/4>DS'9&T*/D`*'3T2!UK7QT!H8=@VU28GS1*WG'%`OO(4X5
MN@@)W41T!Z`>&@.CWB1UIG%^.E/3?30KAW#@F._*:1$;K(E(^9;:<"=K[P2&
MRK=YDI2*5%=87<N*>#>9!TE>VI?I\%\:=*[L<85WI2K\@T['XZ]N%7;BWF=#
MWK=*@*#:000:]01VIT%.NK-<TM*;H!+Y7:;5?[>8=[@0+FRZ\RDMW")&F';Z
MB?N&0VM22#UJ-5:(<$0W&.+P(8W#VP\/<B<M\I6"]8_*MT)K!^)IK#F-W639
M7HTQ=YY(<+S;;9>B'>IA'E4RM'3H!UT4(2>E)-DQFZ?*\"I/W;7W`>"/?3[<
MN`;2WDE^%H8S6_.W*^+@/ON.<F<>LVZ,A^0R(WS!A/J*EDLHJ@#:*C6#<+3%
MJ6#_`(EMJ4G-)MT)5W*W/6:*IEN."E5=JHZPM*4GJ3UVK&W=T%/SZP&PCAR[
M"7<<>F1A&?\`21;YREDMJ2E32(4DN^?;M)*2?RG5D9R36+H<3Z'R&KX4Y*Y;
MP?/,4F\?W9%F8X_:LUS9G7%GUX+,6?9++&GQT,/L2&9*G8T#:AG;L20:TW5/
MTNW[4;2G\JDSR+_2N8>>XGZF/O(SK(LMXVPV^2;Q:+D]+AVRRVS#,?>DO6YT
MJ^27+<9M2BW(0@IWN#8@.`D$"FK7N[5IZ6E)\2A1D\DZ$5^:/IU?4<GX2C+^
M/.6;OR!;[_#_`(D<Q*ZY%*LE^$67;8UR><;<9GS\?)?=><0U'6MAX>F`:J4-
M4_[A=\%(V=N-,BI.+Q_S6K+;!@O+G&N88D<OOL*$]EN78S=8UOE-3[:(K;YO
M8B*0]##K*7%,+*E>H"0D*-#YN^]PN:XU3R+;>VM7%63C&G)$@^2/8!C7%W$>
M<\OQ+QCMVE\?8CEG(5S3!8N_JSY&-PFEQHMM<D0&&)-RDM/D);)Z>FH'JE-:
M9[^4+#N*#U*+>7D3"VNXK55IK2O@5Y\9<`7+F>U7[/>,;M/NN98'`@7*UX%C
M6,Y$Y=<KD7JY2KY=9-I3Z2WP]9(#(D3I"DM-*8=%%('E/B?:?N&^W-F];W<;
MD)JXVM2:;3?A7P-GO>VLVI6WM7&4:8Z>(8?2C]QXXR]V?*O`V4W%0P7W#Y-D
M]I@MS9)7"M_)5BNEZ5BY0AT!EK^);:J1:E]*..JCCK0:^WMI2AJDJR/`::>.
M9W6?3OYCP?%..LLX@RIW&,5Q/CF/=KPB)-_"L>Q=''N0A$//+:XE\PK9$BQ7
M7&+N$_LPI:'P`5*.LVJ<_EJV0G1U68QG-7"J.1>!LXL7%M[MF6OX"L7?@W-[
M%=!?<2S[`H5UG7KBZX,7*TON1+_9$*3/QF<IIXEQR8$;TJVJ$:)\&==RYQ9S
M'<\^ROFSVV<83;AP-F36<<K9!;VWS>56>SXA\HG%>1LCR"?C&),WN9?6;0PK
M^+`M3<B8E$J(ZIAXJ*4;HIX,T4A.V]%'.GAQ+X_;_EEDC\5X9Q--RJUS^1>0
M<AX]Q@V-VXVU.2WAFR0;<QD%Z3:HZH[ST)NZS*ONLLAAM:J$)%!JZQ%2K58&
M?YX<54;/WUY0CD#W0<D2+<EMRRX>_:>-["444@6K`[7%L-&R```N?'?4:>*M
M<7$E-I9&RW5VU7$B@U:%K_12A-#]Y(5X_F[ZK97>C&,*I).IV+_3<8,;V0^W
MY@TJWC%Y'04'7,LD5T'6G?6ZSZ:,IN^I`R9'L7]S;([N\871`_*9<'47VU9D
MUG0[M]:YG'3P]Q(]E&46D+9"8S=VMOJK6%GU'#+9V,-D*"5^L#0_#[->3&Y-
MR2;P-=SH?(ZUH<%RVV.-";5^Y9A0RI.U(48<$0E`#LE(HKIT'7[!K08<L0E<
MA);V[%%%:U4DG>:4I59._H.G?L*>&A9WKG$;?D*P6J[X_>6;M;K;=VEP7FPQ
M=K=$N;)#FU!`9G,R&D^4D`@"E>E-<=N'`CNW.)0M[@_99`3=9^8^W[-\GX'S
MY;IF-M8_>KRWQS<K@`K<Y<<1A3&HD1QQ(H76`6S6JF5"H.5YFU9%*"_:-[@+
MOSA^$<UXQ=;C;;19<AY"N<^RW&#:VN2;)CQ;E7RPXEGR(IBV?(\GAOJCTFEI
M#3+BRXV4]#WW)I8,DI>]T?MUP'DGGS,'_8U@.>VSB6+B6`7I.(Y5=6,BEX9?
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MX-N-6ZF>[%1E194.96]<HW[),VR[('GY$5[()[\UP(>=<V`K_H[!6X2XZEEM
M"2%*\Q551\VMEN$96G)YU_<76.E\SH#]D_&''_+6*YK>,Q8OE[NUEP"RP<3L
MUNN#<,S<NO=I<C0GY#KI2'!!=_I*@ZXAH(;45G:#KRK]Z-F,KUW&W$VV81G7
M4JA9#O6+2/<5@6;Q[4]?KDU:+9;,>]:YPK;;%W?',2<M<1%RN6U]N+;99M[B
M5O`G9Z@6*A/7#?IO+4+]GTW4T1A&.2H2BYSOG`^>N\?V_E2\YC@91<;!=.-8
MN+BWQ;Y(O%Z>^0_$IE]NK091^+2$_*0H:%ASY1`DJ3O6E*;-AMKJN2:JOE,F
M^]./_46!*MZ/Q/"[8VM>QG*;2PTXOSNKCVMI;[+CI&[>L",%+/Z2J_DU[5FQ
M-3_5JXT/++2>2<49NF/>S'$)<9#L>]9+:IC[2A4%F;ES#C@6`H*(VM!5:@BG
M35]VW",*I8DIN+K'!C6_5UOEOP+VX>ZC*I&+W++H=JX\F1?X2L,R9!O&1_-&
MV6C\&@2X34J;&?DNS=J2RVM9"C0'5%M*4TGD=]VYQ.:'V7>UCZAW+EFNV1^V
M7Z7T?@9N1!M+&*YKSCE.0XG8[V+M+2+A.NZ<T3:)-RM=NM,13J_1B.O.OK:0
M@;=VM?:M\!W;G$LMB?3_`/KKP.4./+JK%?:K:^(TW'$!R9CV"Y-C!RUN"MIA
MO.D8_>KHQ%?EQ$N(<=A+2II]2%I;4FJ"I42M6U%T7@.[<>#>9+_%[#R;[?\`
MW*\4S>5L/OUCM&:663QW?)]Z@>G;KZY:&UN2$L3XZI%ME.R<9N=Q_9H74@]0
M0.F$J'(M.'.Q\6Y,XRF#=>.*,FNS4%2@HJ7`LEWDLH44)ZJ^:L<]#R!YOV8%
M/#0"-AVR-&"5/%J,DU(+[B&4E/Q!=4G<`3X5U.)9W;G$5&^T?X]&_P`C5_>?
MS]ON_;V^W6G1'A_+4GNW.)QA7U9-XNP))/XG/Z_9\X]KR#8LA-25]%D="A*Q
M7[16A_ET))"8VKU([-03Z46U@`]PH1$`G\XT`IY"=H4[6I">@'?M6GYCH`I"
MRX`HUZ_'["1H`$\X5)Z5`%#0FO6O>OY-`(R2G?<&5'NB2V=QJ:`.=A^;0'1U
MC.*8]GG''%EBO5EQRYBR\>X?>X\V[VLW6XPGW2$M18R)#B8C48JM?KH6*K0Z
MHFFO.EUOG^\@Z>O;DI/^@OC$4H3B\-9)/?<MVO\`/KWH>E$E#U;A\1_*-=!X
M*H3W104RA?;:ZU2OQ+J>VH,ERZIQTI>(T&)K/^G?EFA348!Q#Y@14UN7)A2*
M4[`CI_9\-=;?_4?`LL='Q*0_?C[7\JY`^J3PIR'$S+%K<W?>/KS=,>QJ9`RN
M5=ID/B3&[`O-)LR=;;+*L-J92W=XZ(OS$E"GW'0D`&NLV\LN]+4FE0TP>B2E
MX(?2\79U9:W`^8(J%&E`0*@BNO&_F<>!LA-3JTLA/7*6AVW+CN,-.LNMNMJ;
M=0EUM:%M.A:=C@4DI->HT9U/H?(KPS_F>XXAEEXQVULP&H$%3D=,<PT]5(CQ
MZ)J@H*:!R@Z&@&O=L^@CR[D.XJ)C^>WB:SD>,?CIAQ8TJ7<YC,AR.TD.NAAQ
ML)#CQ!=6E)<-`20!JB[UDVX:(Z67_P"%1D)P7"4;`DC$L>H:$4_ZVQC]AZ#6
MHL*`OK#^_#$?9QR_Q=B.:8%G^0VOD?")N4KRK#%VZ<W97<?OS=K3!N=BN+L5
M$Y"BH2$.)?"FU(^[6A'F;]TG'E^\AD9)?N\XA]QGM$S![`'KK>XV83K]A;4*
MY8^_C]QBY*Q:8>17AB8U)*&$.N6B6E276UO,+6X`:@'3;7%-9=/')D.M/ES(
MJ<-L0+#9.5+KQQD$W'X5TNJ_P)=ZC_\`&!N+>+-#8DB1<[*PJT,PFE>LRE*W
M0VIIM)\H)&MBO+^F*Y',>XG\[JBD_#_:1RIPWS8/<+SSP\7.`;?G=XR6VY#.
MY7Q[BN'/N5PO$JY8#<K-E<J]6YU4]NY*8?:CQ%NR"XFA:=*5,JVVKZ[=*,KG
M9<Y:DU0>KWKCWBKMV,\HYWB^?8Y$BYN7L4P:=EPR!W*\4RN^7:XP+;/5:FXM
MHR%FU1YZ%1WYB#*CL2'VQ^R"-G-N2A+4\BJ=IPCJ;J/+R3G7O1P;Z?WM5Q]<
M;,K!BN3\QY+<>)K/Q_G>46MC*,&Y>B7V;$QQK.F[;9\<N`P?D'%'+I)9_$'8
M=K<FLJ811Q2Q?]1&N3H1"VYJJ9/?)KCRWRA[2.*!RM9'L.Y/A97+XSSABZYC
M-BS7,CFI@8I$GQI]ECOKN<O)+MBRU*$B,VXE1>6=M`X<LFG*OF3MOTI.#Q;8
M@LAO'NFXDRVW>YVP8HQ(RFU<$YUBW%L[C^'>\XO.`<A7'+K$D<@9#`D8N+3:
M;4[''S/JO%Z&&DCU`A)*19;N*W6JK4LW'@2N95>;A2;DEQ5=LAG)$[(+ML:0
M;I?)=)%WN10RE+"#.N#KCI2A*4)WT2``!KF<M4G(MM>F@UC0$N"E5^/6GP/V
M#7#.+_1\3KL^G@V&O9AP,V*T3C5W`KW_`,[LB/76ZUZ:,@(^H2CU?95[CFQU
M*^-[DD#XDRH0USN/0ER.[?6N9SK^W/&FG<JXZMR&0A,K)<?0*BJ5N"3&6XA7
M?>M0KU\*:\>'6N9KN=#Y%^\]`])``\BG'5@?`=2*_;N)J=:S`)EQJM-X([T\
M/A70"&S5I`L5SI7<IM#8Z]][@J`/B::D%#GOO]YV%^TWDKAO%<WQS(KQ;N7E
MY&PJYXZ8LI>,MV%^W-"=+LDHL2+E%D+N)2X8[R'F4,E0;=*J'#N[UBRGHP9Z
M*R#&S<I<6\VXK)8PG(K%E]E?9<B7^!;YK;CT:/.C^BY`O<%+C-SMIE,+(4'T
M-E2217H:5QOV=*;SH"O/-?8?'XSY#Q3F;VGXOC#-\LDV5^-<891D%XL6)7-B
MY6T6B/,LTFRF/*#]G8DN.>A)DA#C#9:;)*Z&]794^7I)'L]#W-7GAGD3VSY)
M[2>$XW%>1W&XW%KD;$[]E;S>,7:ZWVW72ZR+7$OL24\N)=$1M@987"#7S*TI
MI4UTP;<4WF99W9QFTJ4*3KG[9^;>:97-_&3^<06[=C/(5\AX1F]UL3USGV%-
MIR!,JTL8Y<$K3/AR[:U$6Q(>;DH<+!"%)6`!K-=NVHW*2S-^WA&[:4YYU975
MD7$G)V+Y!F]K?Y)G9:U<[\F-?W9-G4H9`_:GW8AOJ@99>BW1B.XM#-%("D*-
M:@Z1O)QI;R*K]FWK\<A`7+@#,+6]#N3<-=PL\U_TH]UAL/)CAHT5OFM.)]>$
M\U6BT.`!)'0J!KK59NS=MQ\*G,81BJ1R+;/:G&RNQ<,>Z618LEB8AEN$VJ1<
M\3N%WO43'8\^;CT*3;T1;=/O#C$,37&)=&@HE+G44-=>9[O:MOVZX[KI8KCX
M<L35M;D8WU:G%RA+AY"3]JUA5=N0^(L>GQ6,O::O<F;EB'B+A:HUDB-/IN\6
MLD,,RVD1U*]9XH1T)V)'<Q[9"%OVA3LR3M+I\:<^)9*ZGOEMX1<;?G_B2K]S
M&'VKE_G3VY6"VLQA!LO,O$LM##;+;<>+:\5RT7244$U*([$0%-:T#?2M!KTM
MG<EV.[AK;H9?=/EN]J/0L25'O?\`>5;/;)AW&_(.`N83R-E63<@7W&K79$9(
MQ<H-DGVBV//7.5E+5CD+ELJ@"8VA,;U&EO*4%%24&IVVKLYRI*E*<#S`_P"!
M?K9<Q<C>Y'VO8%RYPIAV4M6B]8!9L85QS*EX?/5(N^1V^TQ6)[5WDWJT+1ZM
MT4^IY2V-J62%'J#JVY.S;@Y7_3_XH=0M7+TNW:ZV=J4''K"Y<)5]7:8$RY7"
M8F0N3)CM2W&=KOJ-*C&0'$L)J@*0I'4&A"CKBW"S/]2S72O,3A*V]$^H<=3\
M=IER7()HI(;0EQ6]U:=H"MRB=[A5MJJIZD5.KCDTJ5%4E*T4"%)!4F@21NKT
M(2>M0-&JJCR`D<CQZRW^$[#NT"WW&WN)</RL^+&E-I2^RY'<4@OMK6TIV.\I
M!4@I44*(K0ZJ[%O@_P`0<H?U:/=-[EOIV>\S"L\LN"<>YA[5O<'$QFPW*3<K
M;<X=UL-^LX9QK.\>DWFW7-HP[C,QUYB?;GG&G4E"'#52FB-1V+?F"7V"PL<R
M&QV;(;7#9<A7B%&N,=<C^FNH#[25>DY)>*RMUAPJ1N&W=L)H-8WF0.[\@CX'
M_)'H=_\`>_Y/NZL[D^/A0T:(_P"6OQ.&6_*";Q=E&M!<Y_;[9KPUYII60E)2
MZ;SUVE*U$4%?$C0DDSCS81`C&@JMN$H$=]HAQ@`3]AKH!1.[*#<">]*?&GCU
M&@"242@^3R]1V`^!\.WAH`GD+4E/E-.W@#X_:-`$?IJ3*0Z=IV^HX?&I2A:N
MQ&TZ`Z2.(5@XQAA%03Q-@"?"E2+RJM/R$Z\Z76^9!TK>WD4X-XO'PQ2!3\A!
M5_94=>]#THDCR=NOPUT2\50)KL]NC#]4/QP!3K4NI)\?LU%"KLV^`S&&2D/<
M[<NJ;4"I.#\0I[=:";R64A78=ZT/7QZ^&N]O_J/@=1C&"I'(BYS!:DW3WR<4
MWQ3:BJ'[=?=A"B.+#E$&#:^&Y,HMI6!M65W#J0.H2-<7/YN;.GD1*NDP>DRM
M1\NQI)H`?!/7XTU\\_4ES-6WR837"<A-L+@75+3+ZR`!N"=KE>].OY]2\BZ?
M0^3*A.6IT65R-D\U<B4'')3DCTF8K:V$K7#@O!!6N6'%$HH-U`!U-->S&3AM
MHM<3SQY<"]U>&<#8[:;!E&*Y7<XD[YR[F]V)%L<;8$B:IE;#D25)8WK9$>IV
MN5HKL*=:FW)U>9'[2\#VQ?4C]J_/\_`N*L(R++8F?S+/#LT&PY)AERMK<V=9
M;.7)XCW:*Y<+2$)9AN*3ZCS94!T%>FMAS=DXPK',H2_VF:9:K=G7`\F>@N%'
M&.4*<91M4^[#&4,M2/2;42#U<`KVKXZ\3W*4EN8Q73VF_C4XM3<TW+.I63[*
M;W'=]LT,Q/72W)]Q7(KO[=M+;BVU\8XVB.=J%+;*S&VE5/+N)US[9)RLZI=3
MC5EDW2+:S'.QOCZV\E\&7O%+DYD-NM%RR:&[+EXW=96/7AF58TVJZPU19[*%
M+9J\D;P4J2M%13L1Z!5:G*3>H<]WW(\CR^;L0]L.56/#.2.,KWA<.6N'G&/#
M)+Y%G?Z,;LJVR6YLQ<I=S?9O$E+S?S"'5I<0DI(H*9Y[B];EIB_EY%U2>6:<
M!>W#E?`6\@YESN_<=8=Q--LN)V7-,<RN9'L[/+G(%^MT"UP8\!YB\6E4N%;9
M=IMR$-Q6@J1<%H4XDM*(VV[DY;?6^NJ(E%25)9$+O=A[K\2XIX4SSZ:F+8[R
M3R?=K/=L%R?C3DO"FXB<RXLRK)+6+CDN(X]B+$5<R]7V:82U-QV5Q$QXTA)*
MBXFAV;6*N0<KF=2B;E:>FWA$B-[/O=2]R9G?(/MVY2P[*L.R_&<KR'G%B[\@
MY`[<\OF9/8'&H5HQ_*GI;3TF0^<;O[\]V?(F/K<D-A*"EM*$ZNG:A&#DEC0H
M3:EJ\2Z*T7G*L?LW+4:>FVJP^Z6#"<$PE45YEM]<V+`DP^0(ES87(?=EMF.S
M&?CNH;:86EU3=%K!4,I,IRGU#>PXR$-M--H0V$-I0E*:I0E":`(0D"B4I%`!
M3MH;+7IH/&60/*D`&A/<T[_GT9Q?Z/B=:'T^0![-^"P.@&.7;_OMR'6ZUZ:,
M@,]_2=_LX]P:!3SX!+3U_OIT`'^8ZYW'H2Y'=OK7,HI]K%G7+Y9X\BA*2B)/
M-P4DI/W84*3("Z'ML,9-3VUX\.M<S7<Z'R+GYXHVV/@W45[D+.ZOY#X:UF`(
M7$H53<K;2M.H%>U>^@&XSA1%H?2.RWF4J^(2-ZB1\*$:`Y$OK@2+0GG/A*^7
ML_\`6?#>'LWN4E3@"FFY5XRQ)<?[CJF#;BV*>;<::\/W#;P:S?XGHK)',;B_
M-V=8[GL[DWCC-;_AF4OS79,6\8W=7X,IB'O!C0GFT++$F*VPA"5,/H<:53S)
M[Z\%WMU%Z52BYDG03]/3ZF7(O-W+?&7M]YAPIG(;[G5U8M%IY(Q=#5J84[$8
MD3WW\NL"ML%MOY:`LN283C?6I]#OKTO;M]N+UQ6+FG2L,,_V@[#,VAV_'/:^
MR&+;';?GJD2`HL("EH;?53>0`:;(J:=:T^W7U"6E41AN^HRF7)?:>_C^.9%<
MN+73=)-RB7S(EXT['AP[Q<+[<T2KA)-ON3:&HDV6_,D%`+C;;U*!2CKSMSMX
M7+KE)RK1>)MV]V4;2BJ4J/\`\9>RGVXR?9YPE,S'@;$(?+#V#V%W+;O=[(8>
M1HR!]MV5>3?T;T>K=&I+JFW"\A2AM`K2FENW&U'3&M*^)W*3FZO,Y^OJS<]X
M1[0N1.+_`&_63@^TS[5G>.RLL9R41[E`#CDG)GK#&QO%Q:6DD7ICTE.2'EJ?
M0E+K(#)2O>-]B-;3DLTS/.XXS45DR'F4\!^X>]2,_P`58XXB9QQVSR%-S-C(
M\$R2S<JWU^W/H6U;L9?L>&WN\91C,:T,NN*FQY,1APNI2EUL;`-?F/\`<'>>
M[RV4=M[?31*KDTG5-/#QI^1]C[!;V4%*]N%6>%*_GX"M]D>(YED_NIQ;ARQ0
MY5@F/0,UN+$?)[/D-MG18=FB.R[U;2Q+MT28XS=6%J1N2/30\$UIXV_VYN>Z
MR]MN['W+T(QCI?C5MUJZT_(X^X/I%<M;C:I=RKKPR1+GFKFOC#@7*N3N!\WX
MEL6?<MVR`9&+W>]O6EV%:9EWM[-PA75=CF61VYWA=G8^7<$9]YR,\&@E*`DK
MK^E6X*U;[<>FM3YG</ZF?<N9^1SX^Y7*1QIQYQ1Q]ZV/)S,9UROR[DULA,LL
M6>VC-H>#,8REB)9XL6,PJ[Q;)(>$5M"6XP&Q1"M:;%%.KX&&_;[<4[>=?R%/
M[1.>LSS3FV+F4K#[#<[I@5CM=TAVR`)4*%>5VRYQ$Q(JUOOE422I25++P>13
MTR-9?>'">QE!-JLHY/S/6]FM2ANU=DLHR_-'TUOIN^X6/RS[.N(^0+]<8DW(
M)>-_AEX!N:KBS:YV,3)5H>LZ9+[33DN1#,9L...$I*CN2M=1K1[4VMFUP1B]
MU_U=?,FDNY/W1UM]YQQ4NXI)C(45LQK?`H%J+;0]/<N4H`!2A7;7IV.MIA%-
M#EQP$*^9;37Y5E+%2I3CJDK"R$@U)"NE*&E-`![Y+>:;:15*64R4-J-#N*0S
M5NJJTHI0^'6F@.;G_:3[!8<M^GG>;V]*C.W7`N:>+KO99!0RN1#<O$^XX5<6
MVG"KU4)>BWSU"$!2E*0GIH",WT^/<]C>7>VGA?\`'9+;603,+3^P<EH93-GX
M^\Y9L@B-+6%M_-VZ[0G`M(J2E:2"0=>:\R&6*?Z2;+_AH?\`D+YG^N*^Y\/Z
MO][_`-;]NIJ_R-=/^PXD;^H"[WA/B;G/(_\`ZU[^YK`7B6D'<%!/<)4.OQZZ
M`D[82ENWP=P4%;(Z14=#MCM)J/B#NT`H)'1(_.?YJZ`(I*BI()[[A_8.@"J5
MT!'B"`?RU.@".I3ZBAW#;Y'_`/"7H#I!X<=*\6Q`_J<4<>^'Q9N]?YSKSI=3
MY_O(.E?@$I_T(\7)'Z&(6P'\[==>_#THDCOH5MW?:"-22$EX=4F,@)I13[%:
MCX.C0$=..;GM]PO.;+BZHC8?Q&YO4/NM-N<BNJ7M`"E&A[`$^`^&N87(6KVJ
M>5"&-;RED-JE^\?VBOPYJ!#Y4X2]Z47'VIH<MTZZJA<>\>W"2F-;IR8\UY*V
MK3'>2`W79YO#7<HZZT:QJ<1FKDNW&NIE<MURRWNI8CQY25/-K;:D`AT;5M_L
ME#>IM*'-KJ2D[20"*'7SLUHN23IGX&ZU%PK7Q,NDQ/X`]ZJTG>EQH$5-2O<E
M"2KJ`55URY*A:_F3BLV5%\KR&&LUR:,JGJLRI+8)\%-P[<V3\4FAUZT)QEMH
MI<3SJ_,X/J1*/V^6NU9LY`Q+(7X@QIN!<YTI=QL=OOEN@SI`4TP^ZU/86AHR
M!$+8HXV5"O>E->S[9MK=_:W_`.NAY'N%R-N_;N2Z(.K_`./$.^!,>M^$_42]
MK$.V6.RV-<U7(:Y;=AMQM$68(,7)H4":N%Z\A+3DFWM-N#:0-KG;5.\MRA>C
M7@6[:Y&6V>FN+(V_[2]>8K7./MFB36GUHE\,Y8M#CD*2]`W_`,<MH>CR)*65
MQ6U.!(.Q9!4D5[:\/W-UBH*NIHU[?I?,K2]IX7!]K5C;GQ&&DO\`/O*,@MQG
M$QT2F&>-,1=:(,=6YA"D+">A2H#K35/MR<;;3S2+Y-)5>1:A[/+!BV<<(7O(
M[?;%->OFMRA2(TEZ1*1&=AV:SN+0TV^1Z+M9?F(2"X-I5U``]*[9G9DHW*5:
MJ<QG&;HB#O)KT/'/J%*G-N.QHF,8WC3"3!>]*2TB!QA,N4AN(XVM"VYCRY"6
MT;5)4'"D5!UYM[U?P.CHUX6QB5CG&V-PG8T5J;<9MRR/*X:MJFUWZ]W1Z^/-
ME2O60M5EE2A%:74J#;""#4#7H6Y*,JO(DY<\BE>WK@OW49OSYF.=W#*\XS_+
M^2)5CP^_8O*MF+\9Y!R9@TEZX9M)=$J[95?9>*W+)42K0X\4MA*DM,E.PG6J
M,U)51Q.[&#I(JLPO'[MEV<\F2N4_<'C7'F/3_P`9O.)9#&MQEO7BYQ7C!LK4
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M`<3/^T/9'(5RK@^$VV2U\U=.,+2J<DD@,VE5^O$R2*_HKDN%`/QH=>/[E=MP
MW*L)_*_'Q/161RJW&+>8=UC6Z&J7"EN.!"5L*4F.$J)V@J02CS([UU3MH6)N
M6JCBG3S'B7Y?0^A3LL]]G&\*9$:EQL+PCD')52^SB%0L<5;6U+-0D/J?NM$D
M>*M=V/;[6WON]"4FVZXT).Y;WTYA(XY]H-SGPG_EIU@XXOU\BK4E*DLS8E@E
MS(:RA0*'"U.4CH00JG4'7MW_`-+:QW$<9267Q,-WU'S.<+Z47U2.4O<]RG"]
MMW-6*VJ9ET?%,GR"!R9CR3:4W-O#H:'KA!R#%RA4%B7+:=2$R(+K2-P.Z/U*
MM>/#=RO3Q23KYFFSZ:.CA^ZM##U05J4HQGW02I15M4XD*[JW"B=_3IK;)).B
M+!A>3,"PS.+!C<O),6QW(7[&1<+-)O5DMETD6::\LK5,L[\^*^];)/0?M&%-
MJ-.^NHW7&#@E@SB4%*2EXHX<_<'[>\PN?NNY_P`JQ&ZW;%W+7G.:W^->V$3K
M2MUIG)VH*PQ<&5(:6B,F6%!0510%!36:>QL;JW*%[%-_@72WMVRE&"5!;\(>
MYCWC\87;*&,%Y;S+*(F/8WD,=R9S#E,ZX69*V("T/(PNR2'7[A<+N$GTV(_K
MK8H07FE)4D#1M-G9V=OMV5@<K=7-QA.E$*6![_N2/<-=;'A//O"7#?+"K+:9
MC4#)<RP&QV[.K(U8;?)EMQ+)FF'QL5R5AY$9KTF&YBY;3"Z5!03K65W9N"37
M$B5RCD'MU]V7+F)V;C_&LML>`8)A;V<9M>LUFPXN79!%QYF*Q=,5B)A)=C%4
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MHA`888!&W<`0GPKKUCQ#6U)E1RAE=%2(+#RGO(*&6L#TDU%/(DDD'OH#+ZZF
M?C3LL+5O:::=6XE1`0M&]*QUZ[VS0?`UT!3'[R,(XK]Q%Y@^TSFW'(F8V+EX
M9/<<3MBI]VM*&<UPFP.9+B%Y+MGG0'Y"8N2);C%E2RVLO>9)3H"KSF/VH</\
M2^RWCSD[@#';QB$;"N38F-YYC<2^W>]6B&K/X<J&O+`BZ/3;E:[C(S&R^G<5
MB0F*4NI(:2>I\UYL@2?^D$_]E?\`ZB/GOWS7]?\`U?ZU]S^]_GU)L_\``Y\,
MC44WF[J'<7*?W^V<^-8"X2,E1K7Q(4:=A7OH"4MJ43!BK%/*ANE2`/(RS3H2
M"=`*%Y86@?K4Z@`]/+T[Z`('UT.TTIT/C6M#H`CG*4:&O>F[J?B:>/CH`A6X
MHAT]*I8D_'K1EP]>O70'2%PT]7%<2VT_\%?'>[H1U$:[BGAXG6&,5-3F\T_W
MD'2]P*0.%N,T5ZC$;0?S&/\`R=]>Y#TH\B1V%*"14FG@._?\VI)$[?'08S55
M4/KL]!6G[U-/C\=`1/XTG?,>YOGIP+W(3AW$:"2>J:?QZE0V@BFXGN!^?66]
MU_`@JE]X%OY2O?NJP_.L6]PW-6!XWQ!A]FMD+CW#\F<@85*NE]L$4WI^X16Y
M3+]N;O420AE\L`&70I6%`4U_+?WK_?'[F^V_[@7OMGV_VRQ=^W]ON[-J]N+E
M]*["-YQBFK*DI3>N22HL$ZO!']&_:?\`9_V#WK[!L?<GN.YWEG[CW&UO7868
M04[,G:4FD[FAJ*TJKU2J\EB,5>[ZIK(<?5N(*HMTWT5N%%7A!ZD=/TCK^AE;
ME"<G*2<FTZ>*5$U7G4_">S2BG773'\_\!RKS>T-XNT\IQ?IHGQEDBBOV:'RX
MHGIWV@T'CH_$K45W5'PJ5`<Q94Y,Y(RJ3&JAJ7<94AL+4G>&G8ML<3N[#=2E
M137HPFX;:+7$Q.Q'ZJ2J\A8XG[IK)PEZ4*\XO>\G1>;/;Y:A:KE;K>P#%O$Y
M47UW)=)16Q);"MJ2&W`2%A2:C7L^V[VY8L2TJ+UX.OEP/(]RV5R]<<(UT408
MX![W+,GW4<+\RV;`;@N-QA;LJ9<QF[Y3`A&[/W*U7?T4)O[R93,%OU)?=Q+B
MO+M2#5(TW.XE=_4:54B-M9C!*TFZ$X^2?K#Y;<\*?RRX\'</SK6_&MKD:P+S
MNYSLC8B7(MLH8F0I-L<=,R(I](?2(Z$HH2H)`.L$I*>,DFS?""@J*I53S7[V
M?]81K&FXO%^.8`K$9.4W-F#9[@J9!O,B[VEN(XU*0S;[665>G#IO25+-:>`U
M7:MJ,W3*3_#D2UJ5&2$]HGN1XXXGX!NF/O6UU%X5GTVXQ[.Q=4E3MONL2PQ$
MSTS;[<'[A,$5;2U.H;0H-LM`)%336W=S=V2F\TJ?@<QMJ#J@BG\Q<5<A7G&;
M5<.!\&>S?.L@O.4O<K-/QG\F%FQ]B7DEL<,E%J1),.4B/;[9M4_7T4.M;=NZ
MGE;F*@E=6;9V7I6&Z2UX[!:!>:9F-3O6EH-31'K.+:.VA8"E(KO)'V==:B3D
MTYTG\-HM6:HY*XCEYUR)FBI1PSD&!F][QFXX:TMB<TU>9%G1`NE@RN([)4SO
MC26VSM8`0M%5$V6Y2@ZM+L^+\RJ=N,W5UR!W(?M1PCD?VY<:Q;9A\_+\AXTQ
MZT1\1M]IO*['=+O;U7+\6N=@>N,29;X9<GKGN-N..G>A"P-R.BA?:W%C<6?J
M-N]5ES<*O^I9DW+5ZU=^COJD]"EA_2\4_P!@['LZY5]S%JCVOAWE[CB\9-D5
MDO%MA3L@=NL)F9Q]Q_*:<:A.9A*5N@WY=I:898B"WN27U,K2'R%)J>R86U;R
MKB6E1G`F@!!(!J"#VW5KJ2S/`-D.U3Y:$?'K\?S?'4&2[:C"-57,ZT?IZ&OL
MTX)/_P`6[O\`]]N0ZW6O310(_P"J<*_3R]VH"MO_`/J.[^:E:4F6\]M+OIOD
M66O47,^>;/:*'PXE-0K?NZ^*A]ZM?'6(W%SWT3X;/^G[DV]O#_)'$3["%TZ-
MF[Y38FE-DU[NHAGP[#0B6,7PH=,R9B%)2H4Z]P54I\/RZ@QN%OPF-#R;+;1$
MC-I'J;OF'`"0GKY$-FE#U!%=04G#-];6_-W;WN7^WI"G9%FXPXX@/K<*5M)0
MNU2[IZ45I22ECS7$J6H&JC0Z^*]V<O\`<DJL]%9%,%IL%JF71ZYJ;;2I#.P(
M26U!?JJ`WK2I!&[RDUH#]NN+2E:FYUJQ4OD_V?\`X_C.^YKE_+FV$'^'N)8=
MG:4H`)2_E^7Q4%QKJ=CBF+64^-4`]M?3;.7?@D\,$5N4UE%T.E_ZR^6#&?:)
MG\)M:D.'"&;,RV"``;O(MEK2VDU\Q`E&@\::]+?Z+>QA"N2_>9IMN;;5&<JG
MT=;(+5]29AZ/&"(JN%N6+JVH*JG]K;[0PXFM`>BWZD_$?;KYO:-.=5E4TV?3
M7-G6'DMWE1XE^;;><;1ZH+:6UD!`4RV10`4)[FNO8N3C%XNF!=&$Y*J6`!FN
MN/878W79CCJ?PF$M3BG`"15:Z;4I'@1W[ZY4E)5BZH.+CA+`H^_A?CN]<D<N
MX?R1;8DX7?-;XY`GQ7[A;)UM>7D(O5OF0YK2&);*0V^4K6T5MK+92M*T52=%
MG)F3<9HLF]H7TU,4Y1L&1V*\0.#\\XPN5YQN]G,<NM+1YKP.V17FXEYQ[')>
M%3HC4&]WM4=;K\V9%:9E-AI890=P-Z)V^;%Y[X?I4>SCA3@WE/D_B;B!E.2V
M_$):A=G[[=9]WPK*+//:`RZT,IDM1Y<"]6D.1IK,A#H:]4.-A(*@;+<.XZ5H
M=;CI7,^=9A]LS3'.3<BQFR8KETR9)SIZQ0+M9;;/2(J7<@>M*V)A5:9<&?99
M$>7M6TK9THH*U9/;6IK]5_*95.Y;:E;=)5/H(X[<,:X^OSUR1@?&SMYM%DBQ
M<XR!S$+"Q?6Y-KC1K-:[1!DMPW7I4M-KA[RMXJ4BH*2`5`^=?VNW:<;%E2N5
MK6OAXGVWM_N.YC8TSOUB_`GA[3\^Q?-I?)<['[C8;=>+/D$'\3LEQ<5;/4^>
MB.>DI3L(E%OG^BE`;'Q;'ID`]-6PTR7Z64<TO`\;WBW)2UWJJ3R\R?\`$R*<
ME]N9<;B_(80V5-*N"1*D!X;0ADRTA/S22D4WK\P2!4D]=>B>$*Z#(:E,14L2
M&Y,NYNN2'PAY+I2RLJ*4*(J`D)37P(!T`*ELK%LNEM(4&E,J430>2@*CM'F"
MDA(_FT6+H#FS^H1RO?\`B'WM^UR].KBL606J=<<:=C,N-.?QAC64QIKQ=]1:
MED7^S@Q5-U`6MYL4[`5[B4["QC4$J+CBUMOED]VW`[2V58_GN(Y'F&$J/GB+
M9N5J1R;ALF,$)4FC$N.&FW$54"KI7MK`0<RW^MAP3_W3-_YH?Z.?\V;I_GC_
M`(7_`"3]S_GG[O\`O]=Z)\/`N[KX?RT*[,@=(O%W"CT-SGFI)/\`TZ]T_FU1
M=BE#!(V"6>7]\E51YJ5/AX4^S68$G[?06^'M45=&5?[DJ;0"G\G3^;0!Z\\0
M*$[>E`:D$]-`$JG"L>8&M3W->@)`_E&@"F>Z@)5YQ4)IW['S:`3+T@-L2#XJ
MBO@>8@U+2Q4&G<UT!TA\-O).)XBE%.G%7'-5"H)*HMW-2?$@C7G-M2:6%7^\
MCQ.ES@AT#ACC(E="</M`/4UZ1Q0D^/?7OP]*)(ZY>!'5=?L)/?\`/J21,9%)
MVPTJ-$[7F"#6G7U4]/SZIO-J.'$AD0>&WE.^X3W!2$)0^XK&^+$(2%I;4XXR
MGD!2&RI0HA2E414@T'7MTUG59RTK&0*BN?BF=[C^7&[],MUJRBSS.,(+-@_$
MKRJ\VKYS&K5*N$2*MB;%Q^5&FPTA+XF1'%N*0DQB"A2D_P">G]V-CM/_`.M>
MXW;^RVZ]WN^Z>U2LW/FG==NVI=^5MN."CAW/F7AG@?WK_;??7X_VOV5G;[R_
M_M\?9=U;N6Z1A;[S4M,9)25994=&\L1JK]9;DS+A7.X*CL):5(AQXS&Y:_2?
MN/KB2\ZM7WW$@>4`;=?W=:<9?J+.2BZ^+6E49_$%IRBFKS?<3:=<ZIO#X"CR
M5QTX5*#*P-ZF5(0D[EK=:62M*1T`!W4_+35KQ37B6QE:U)NF93)R3,E-YU>H
MSR%(D-OJC.I6/.AY,.U)*#W.[<->K9@_I?F6>1Y%Z:>ZK%X>)-#VKX#AO(]U
M58LRLN,7`PK.9$*XY';Y$PVPHD2Y*T),67`5LD*211QQ7FV[0*&OJ>T;/O;*
M\Y/]15P\5R/-]WW,;>\LR4Z6VL<<&1>]Z&(V3'<QP"WV[';%COSF.9$J='L=
ML<M<:6]#R-V''DNQ7Y4MQ3CL=A*DJ4JI2L?9KC?P=N:5*(IV$_EU2?XD$LD8
MCPX3WH!)\A/E"0>QJ1M`ZC<?Y=85&4LD>FFI9!1C+H<22RKTW'3.*'2$U2?E
ME[33KO&X]1JR$)J2=/$D??$/2_A2Z+W"-(D7!VV%2W$`0I$U,1B0XEQ5-K3+
M3RWPL_HBNM+2>9(['&I0C-L,R*]MKM5EO4N\-V-R,VS)GL8]`PZ^M6F`8DV=
M!81(E%Q4A#&Y(=<E)0I:2D:S;I0E:48I.1!T;6S,[3B7'$.=R3=,;P\^C<A.
M;NU]M4&"W'<D2@QZC\^>(Y4]$"5%*7'-JE4!--1:2<\>`1Q3<J<P9/GF6N0,
M/QRQWNSXV_,MC]R3E]L`=BMS9+49UI"THBL(0A.Y:"^5#=VUJHFM+IIX>!S*
M4(X-JI;W[<.09SW"^.XY=.+YD?)VIZW(=[MUVCV^Q1V7WHHE70AW'E_B4:]P
M6D_,)^=><0\VA3=`FBN86[=N';MQ4;=:T2257XT6%?,LE.5R7=FW*>E*KQ=/
M!5SIY$Q+4_5MM&\[4?=\QH"I/2E:=>O\NNR!2,O$$`G_`):IJ>O;0AY,-VI`
M2*D@=_+4T_+34&&2N)?/6AUP_3P5O]F/`ZOCC=W[?_*[(A_:UNM>FC@2?U3!
M7Z>?NT!\>([Q_P`+M^EWTWR++7J+F?/5F*"EA!(KN`H#UI4>'?6(W-I8O(N]
M^C"PB%=N=[XXW7U(&%6%IRGW0N5=I[J2?U5*0W7\FA7*<-+Q61T!1+BI;*2=
MWV$=C^2IZZY,`U_([]6H*GE*V",ZH[5;227E`T)KUZ:`X)OJ[W\7;W^<],,K
M*6[8G!+*AU:OW2(F!V!UQ`5V*P[(4*=.HIX:^)]UQ]P4UT<?`]%9%;MM9C0D
M)DLN$ONM`.EY)2/3W.*0$@TV[4]36NIT2:P3H#IX_P!G1QI4I[G7*WF@K\4S
M/C'$6%A/53-LC72\3&T$@U24W-M70T!36FOH?;%@JD.<?%HL9^OAF(@<"S[6
MATI<O.8X=9@D+`24)D/7%Q`2"#M"+>*T\1K9[Q.$-JM;2KE4RS3E-M*J*0OH
MYP4S/>X+F$%;]NX,Y40X1YJL2'\8CIJ*$U2MP]=?/^W5E)*.+J:+2:@D\SH.
MY!RY5KN>60DN+6TPMI!`(V$&&TLE)[?<4.NO2W+3N8<#?M^CXA`C/B]@5G2^
ME3`-ECI0%*H5E+8*=IJ.R>O\^NK#6EKQJ5[CJ7(IR]R5UN;7--J>M,0RW;BW
M>4%*9:XDH_+39<D-Q'=JV2_M42`L>;HFO4:]"U&23JC!?C)M43)8>TWG[.N+
M<KQ?((;F=*QBX7&%9[XQ8)JL<NM\AR)+3;-H?GRT2+3+A,/N)6M&[?Z04$%!
M-=652S8L)Q;JJ%H.?^\[&^2>6N8?;)DF$9S&LL&T1[5E&87*WH8X_O[=XQRW
MS+C8F[FB7$N42Z3+==`&`E"PZ&"X%@=-76+D%)U:RXG5]-Q5,<2%G*')?TE?
M:8F58.5D<+XEGQL#M]L5MOLW*<BR-I3L*3(LDF4AB=<XMKG3U1BN()@:6^M&
MYL%/76B\G*W\N.)E<9+--%7>/_4VX8Y\]T1P+A7*)D9O(K+*=EW3-X4C%\?O
M&3VIK>PP)A?+4FV.1FDNL-.*;6ZXM0%::JL;6[N+JM1^5OQ/2MWX6]NW5=Q+
M!5+4?:'S7;\=YJ=P>_V:="=Y`FIQ21E;5A:M%FRSD&U0;A?)CCH4X9<ANX6O
MT4Q'GD!.R&"E"/4)5Z5[[>7M:5^U=C.+QDDT_P`3P5[EO?<-Q3<PG&$'1-II
M'09:K+<[A:(*/EY,B.PE)V-LN*>J:`!"DIZ*2I)_/K.:QR+)B5UM:VUP8[T,
M+"G"V75*4$+ZJ;<-5;TUZ[>A';0"I>@RW(<L*84A\1EI*A5;1J@H2:@;@5`G
MH>HU*S7,'*I_M`EEN=N1[=\DQV.E5QL#>?.1;BTM20G)BY8+G:8TN<E*?DI/
MJ1@M"21Y$*/<&C?_`#TT8\@);Z;'NHYTYLXQX:YQ]P&.8KC^36G*<@X"FMXX
MTJ-^-P..8V/WG';C?;7Z\J+`G2[3D#L)M+;JFI,:.A>U"MR=>8U1TS(/7_HJ
M[+_V"B?_`)BW^FO]_+_\U_\`Q?O_`%+_`-I_U;6S_P`"3F-R%P+N]W[`_B<_
MI6I_KKW7PUY]WH/2$L^L;5`D"@/<CKUUE()06VJH$-:7"$H,8J0-I"QZ1.U1
M-:#IX:`-77@L=:`BIZJKX?D&@"=3YV_J'<KJ5=Q55!U`[C0"<E2"4**O%)&T
MJZJ-#U[=]`):9)5Z#Q)(*67:)W=3Y%?97IH#H8PO)7K+B?&,>Q7-+UZE\;<;
M#(+,]BF1Y"(EJ?\`61;[@F98T1HUI^>;>DMH4^XM&Y@K(`!UYTNI\R#J9X/4
ME/#?&HW#RXA:@`5"O1BE.A-3T[^.O?AZ424.:9'][3[=W_(U)(C\N>4;4KJ5
M'U6"$@]00Z*'H*ZIO=/Q(9#'VZW13ON#]P;#BJE%CXH<`W"I)<Y``43M%`H)
MJ/R:SVWHN]S/`'.Q]42XIC?5XEH6^MA/X-P.7T>LII"T_P`*P""\G<E)V@]U
M`]]8_=]ELMS>6YO;;;3W;I\[MIRPRHSTMI[E[A9L_1K<7UM\:1C-J*KGAXCW
M\L\C8W`$%I=^M:2EY!<2)T8K3YJG>`Z2"#XG6+1>;U2C\SX8+#@CBBBE&/2O
MB\?,;.=SO@S]O_#&LCCS'D(D2#'CDO`%G]HI(((25JVB@K4D].NIT7,W%T%=
M*U<"L'E'(8TKE&^W&.^"S+O3LEE2N@])3%M4A1!/0[>_PU[G_P"M'G^X\YJM
MQW.)(+B[W/X;PZ;RSE#602&K[$L4N.S88R?6D+M$RYJ:2N8Y/AMLL!UTI=;V
MN!Y"B#M%=WH^W;M;2W-..K6J9TH>5[EMOJKD/FTZ/*M:D2?>A[D<7Y0CV>^X
MS'RRPIQRRNV".$S;-(O#CESO3$@S#,N+[D='I-+*`%E>[IYD]*3>OQO7%.4?
ME2RJ7PVWT]FE:_`C+'PJ\9;CA6QS%D#@NKT82,?NN*V:WY#%^5!6AQN\Q\E9
MML>`KU**]*8E$CH5HJF@IDXRZ51&G;]+Y@N^\.<HXQ@TY_"\OC+R/U$MQKCG
M.2<?VRQVL3$NA`8?9DW5V;+D16W"VVJ8L[@3W30\F@3EMQ[/5XQ9L=R?F!AW
M-7!=;G-A6&/<,@AW>&VU'CNL)N*;#C=CAM,>LIE3_J2@I,E(JK8-SD!^<6M_
M)K;MEGWC+XX?+U8C3\6+=%,K7$?45IC.PD0$J])L@$`J!HH&H!U3.UJE6I%!
M4>XWFOEVX8WAV/W;-C>HTFXF')<N>/8Q,D/QFWVE+2J3+M$F4AQ2)2@%!84E
M(`%*:0M:'6H(+<Q6>R1)EBM=@LK%J9-HEB[FTP1'MDB\+EJ=EK^8:9::N$@J
M712TE=#45';5I5<M.XZUI@7J<*4''>%)W=48W:6P">J=L-I&WO4&@IH1&[\R
MMT\B1,!W8A%#2@!I6E2:4'\VI+Q0QY.X`$T(!)JOX*^'30!HU(KYBH*%#TW#
MX_'4,HO]'Q.O?Z="M_LJX#5\<:O'C7_MPR,=];K7IHR";^J7_P#EZ>[/_P"R
M2\?\+@:7?3?(LM>HN9\]&8D)=W]=^X`)/V=NG?K76$UW/3?(O=^D:P87'?*%
MU4BBKEG-OA`_K(MMF9"TUI^@]+"A]AKJ#SR[>$^51FMCBS04->G]COH!"<B*
M4I$9M1)"(*R">]2ZHC^4_P`N@/GA_4LNLK(??G[FY7[1<1GE^X6<+3O^Y:;9
M:K>DJ4/+L08ZDCPZ:^,]P3=:8YGHK+X$3%/;&-J4IHAI20*GL&E`:V6O3C_T
MK]@.QG_9T,43$X)%W<9WO97S#F%W9]/87Y,/';-9K:@MHJ%NHBNQW`2*[0K[
M=>OL(3K6CIR,,^M\Q%_[0!G#,RU<=8O&G)<>?Y3O2I[+3A/HJL&-*6&Y`4``
MM*KJA210]"#75'W3**V]JK537;Z$0A^B/'2_[N,D).YQ/!^<*2LT)2'K]B+5
M#3H$$*-#\=8?8W^O+E^XL+>.<;R(.=\CP-RT(CS&$I2`?+_UH@D@CPZZU7/4
M?,UV.CXB'5DK2\)L*5*H$0(J>Y[+C)2HFI';75CU45[A?-Y4*^>?7$IY@P"4
MT24.7*[N+W="$!I;JZ#IY*$U/@!KW'33%>10I*N#)E\2Y7<W_9Q>K38(CMUO
M%MY;M,^VVR+$7,D2KA$7#FVYAME@>LX7G6PDTIT)J0*ZINVYR2TQD^291<W6
MUM24+MVU&;R4IQ3?)-XE;MFM_/WN)Y"YDM7/F:/>W?DK+LS<;:R?D:U2+-&Q
M8HQ:+#M,7'K.\]:XUZN+<%EMJ`VU)2RXI7G>2$DZH49*2JGGP.XW;4G2$HM^
M33*/O?+QCG?L\Y7N'#7(O*.%\^29C]EST9NQ\[DR95^MD*59'+#DJKWZKBW6
M;7-0V[$1*F0V@IL-.U;IKV[32MTY'%]K33S'%^DO[><UY:]R?'V52,3<9XQX
M_N_\6YM?Y:GV;;,LRC+B6['[?%?>#5PFSWVW8C!92L,MAU2E5135ENZK<M::
MJ93O7]H/L_NF3\V6'F?D*]6][`K)>9>:<1X3;K.U$N-^NPQ?^!IF69A<RI+1
MM5N86ZW!@QFTEYU:GW5D;4"V6[=R+A7,%]QLL*-;OE(\2.QZ;2'4!"*!#JJT
MW@=:;A4@]]4`2Q9*W2)$UST4=T,J6A.Y)ZI1MH-A[?#0`XNL1P65K*'7DDL#
M8XX`W]A0A84L_P!]H"*_NQ]K''GO"X0S_A#+9)L2+XVW)M&3VZWM2)F+YA";
M,JRWUN,ZWM=6V\L-R$-E"Y$=Q;8^]4`4'\>^SSG3VB<0<L\5\HXXT^U@F58E
MR[@7(&.+7<,,RQ#3IQK+)-KN?I(D6^6[;Y,:0_"F);E-H33:0D*UYSC*KP8)
M+?Z:7O\`&Y/_`(*=W]:/^2_U_N?^KX:UX_Y`<05\6HWB[DGK^*7`=AV^<>^S
M6"ZOE=#T1-RJ'O\`JFOY=9*-9D$F;))K$9;W%5$1]P%.B@WW[#P5H2&CKFU2
MBI0*54"4]`4^7K7XU.@"F0Y3[4@I[4Z$]*D_`5T`FYKJ4!(([A5#4=">V@$A
M.6I2'D%055*TT[5\I)'EH>H/\N@+6>&??K9,)1+L'*&,7F!!L6.XAB.*RL4<
M_'F9T'&XUT^:N=SBSDVIZW39QGM[D-K?;\A"2*=:^U;>-`7!6'_:!?:9QMQC
MA./VSC7G#-;Q9,<@6Z:B'9,7L$#YN.V$+0S,N^2*==;K^D&>W;5ZN32TIX`C
MWG?^TMW+<XUQI[2(X;VN*3-SWDY1=2>OIDVS&\>VKJ"*@2!0^)T[D^((/\E?
M[0S[Z\NCNP\=PW@GCQAUQ9:<M>+7W)IS3>ZK.Z1D=]<CK=;\2(X!^&H<Y25&
M\`13B?47]\MUDWC*V>=LCQ3),XN&*P,AG87;[!BHFVV"_<#`B%-NMOK1D14W
M21M4VI"R7#51H-<@K]RGD;E#D7.)6?<DYWE^>9M<G(PN.6Y9?)]ZO\M,!I$6
M`V[<ICSDHL0HK26VD`A#:4@)`&IDW)J4L6B4VG59CKV/+[H^E`DRY#BMB4>H
M\\Z\LT`'WE%1&IU2.N[<XCLV+()'S$0^NH?TR*5*4M20$^L@$G<:4^.H;;5'
MDP[DVJ-X#?<RYZO%;I%O:[=+NC4MY^*MN+*;C+!C6NTR%U+C2DK0^E5-O053
M7KJVVFUHET(X0S:N95\E-V>9:,:G6M;;2K4$WJ6P6_7*W)R%[H+2UF.&Y(22
M:$*!\-7J*BJ+(Y=N$G5K$1\V-FE_]6)DLC'H%L]9*DP;-&ERGW4LOAQE;DZ<
MM&W=L22$H'4?`ZFJXDRBI+3+(/KT[FXQR[RL7,PNV"U/W:4W:X_JRT6N/Z4>
M9<-WI.K0U;TR$O.*JE*6TJ)(`T$8QCTB'X\R\9!D$0K<N%P>@WB5;Y$JZ)?4
MZZ^S"+I>:<E%3CC*T.C:H43WIT[R=$DKA>5VUZ#<H5OD7&YW`BW/I4A3T=FW
MPU%:&@0I'RH<?DU4HJ`6L)!^ZD:`7ENRV_7"]V1B5&B0XZ)C:&XC"'U+0!:Y
MZUNN/NI3N7Z9Z!-4A0ZG0#BWN\0&F6'YWRJ6FTR2VJ2@%LOER&&4`K0KS..`
M)Z"N@(G9O/7D%RQ\2(+<41_Q$*2D.N(6J2\MU2R'0G:4;=H`HG[-`6S\3W2Z
M2..<1D6EA@2#"MP<;D%/IIAMNEF2I!*D`NICH)3_`'WAJ#CMP3U4Q%AF7-L;
M`;Y&LTRP3+H'XK4M#L2;%CN[5N+0E'H2&CO75'@JE"-2=AI;/<!89=ANN1+Q
MZ]QXMGE0(<N.783DU:[D5!I3+86ALMM;:J)4.G;0!QCGN`Q7(+E`M$2W7]B3
M<I3<-A3\>"64.O'R*?6W+6MM%1U.TZAE%_H^)V\_3>45^R/V_J/<XS>?^_+)
M!\!K=:]-&0)?JCFGT^/=@?AQ+=_^&6_4W/3?(LM>HN9\]V4RA;X!'F*]X5\-
MI!`IK`:[GIOD=`WTO[7\EP+)G;-GXMG.02A3]),9FVV]/CX)9IJ#SRWB`C9'
M10DU;;/\V@$;GZ:J17_>XD?_`)8;=_YNO30DX]?>U])3W-9+S)RQS'QI?>/^
M1[-R)F]\R]K&$WE_%,NMS=SE&5^&EJ_LMV*Z/15**`MJ<@.=-HK4#R'L?F?-
MGH)JA3'RMP!S=PV]*B\G\59Y@RBI2$3;QC\U-G<0E)!7'O<1$NTNM@$^8/%)
M`K4:R26F3CP)&"C>XJ[\;7>X6RQW+*;7?X,[$CB-_L6476S-8M"C.7!_*$P8
MUNG1PM_)C(CMNNM@52P=]:HU];M/]+;_`.A&&?6^9(Z-R[R;RA#+^?\`)&3Y
MC:[?=G!9K=EN33KY,MURO,4O/OVN-<9DB2B/)AQ*/O#RH4E"#U4G7S_W3LE=
ML6[BS9JM="+O/H:,H/NESV0154?@J^HK3MORS$D)3^15>NO/]EM]K<2A_P`J
M_8=^-2PGW(WYUGFGE6*AY1;_`(A:96D]!Y;;;@1_RR=:KOJ/F;+'1\1M)EW+
M.)V]H+J!!C;:]-@"=GA6H\E==6/51W>]%D,.<;M?YN4Q[@,9G2K391Z-NO%G
MFM+O:Y,^*#*=19Y[,:#,86TXM"6VI#KY">K9K37L3ZX<CP(UE>5J/J26!%7F
MSZG]NX5XYR#A3CM`Q^YVF+'BWQ%EC76TY/R%?[[95R_Q3/+Y=*W7%;9CA?;0
MY:[3&]>0I``?:CKJ?=L;AV+;IXGP]S[,W.Z]XN;[WJDK-JCM^3;^;\DB77N=
MQ5CWS<#XSR[AW*TK-[_R#@W#LB-Q]-S[&>*N-N!LOLN*8[$SO*,BR#);K$G9
M+D-^N4!]3$>(PI4!I84"LD$^1=W+OW'%^&)]Q;V&QL;2.ZVRI-O2^68TN%<%
M<`8M=#GW/^7>V+E&_6"ULJGSABF9\WW:RB&F3)E08ZOD+!QK:X$0%M3,ER2X
MI>YU3H71&N$VE19$8$M>)[-&YRYAXW1Q3?[IP?E][DXWQICD;'[-:E\?Y1C4
M*]2KU^$W?"&5_AEK>?MMXDOIDQOW;BJE5`*\@[4>.[!#LF30+1;VF(]GQ#`[
M?98#3,=*6V'4REJ(2D!`"_38JJE:J434^-EKU$2.]E]^8Q''T72<I:VI,J(W
M)<25>NEAY13ZS;:0K<&UT!%10'6\!<'4Q0`G9Z,E*'67"MM[H[1;12V7`Z-V
MX5%.]=`%EU:O2DIERY#32&'6W(J4,EEQUQ"2/00@_O/4^!H*Z`((4^YSOG0]
M;W+5\R]\VRAQ]MQ]\QDT<4XAHE+0(H2-QK70&F_RK/?K%-M-_MT&]V6Z19$*
M[VBYQT2H$Z%(0IB5'D,.>1;3[9*5>-#TH0"`*O?_`$47LX_[K_<?_GI_&/\`
MX<\T_P`V?_$M_E#_`,&7]Y_7_P#GV@/G\WU8%XNZNM!<[A^7^NO?;]NO.>9Z
M0F'U]3^JK<2/&A/]FFLU[-$,D/8)B/2;HH;DLL@@TK^Z20*5I6NJ0'KKI=42
M>W2G2A[`:``/K(JD_=-/R_'^UH!*W-VM*5V)52E!7^SJWLR\A02DAU.^J:@T
M=74CQ;:4KXG]4:XE%Q=&!\+SC$J>J.ZEL4=9:=*BGJ0N(TNO:AJ3KD"9?X^=
M,&$HE*4D-D>6I(\I4!TZ:`+I6$1663ZBCN21UZ@UZD=.W;0@)[=C,$S@A\)6
M*DA6VII\#JWLS\B:"RN#,6#ZB6&DI,>?C3C=!5(.V6>J3N'79XTJ/R=79GY`
M8VXQ$M.U1M'GKVH0#UH"!JH!C"E>E0I*DA*17P%2.YH3TZ:`5;-_*&QL6.V[
M[QZJ0"H$GP^[KJ/4N8#/D&`WD%KMY=&\^L7DFFZBE8];JT!(Z>7^76TD9&UL
M0L8M=@2ZVEIENYSWI#Y3O)0U&B-@EO95(V]*5-3\.VH!NF91!NDU;=DA39;*
M$("WDLDC]'S>0>DV!7NXM/YM8U%RE19G(!N5]N<6/<(]M>G0!<;5,M,]3,@?
MMK?,1Z-P@.%A2FW69:4;5IW%-.G?6FW!P5&2(K#VWX\Z-*0EP_*?.+H#LW;8
M[I2`!Y14?GU82+]N;DWS2I[-QD,.+6TII"5;VFFT.[@T&G4J:-'"DU*:E20?
M#0!F_DN=E^(XJ[2S(:+AC+2W&"FU+'I.^GMCI2%.-+*34&HT`7W#*LX=#PNE
MRESF%.!U3$E0:2%LEA:5(^7"-A68Z1T`'<TW&N@/V-?KQ=;NQ(O+ZWDM*6B)
M'Z^E&94VX=C`6I:_,KJI:B5+5U/70$A<8]WG+V'P8UBAXCA-PMMJ08L-;L*\
M,N.QDN.$*4]&NWIN.DFA4$`5%*#0"HE>]"^W):'<DX8PZ\/[4(4X;K=V5H".
MR6A(CS0T/L2:5T`<PO>7CH@2;=+X&B,Q)3C,B5%A9;M8D/Q23'=>2]CQ<W,E
M1I0]M`*/'/=_Q;#N4.ZKX6OUMG0GFY$5ZU9):GREYHU%&I46$%CJ0-U=05W8
M.<:+B?1)^D=GD'D[Z<WM;SRVP9MM@Y'AV02X\&X%A4R.EG/\NA*0^J*XZP5%
MR*2-JB*$>.MUKTT8I1<7I>8HOJE"OT]?=F/CQ)>/^&6_2[C;?(ZM^HN9\]*8
MH@J((!2LBIK04IU-`336$V7.A\CH:]B6><?\7>U#!;WGF8XYB4&:[DUS>D7N
MZQ()*I.27&B@R^ZEY94TR"`E))[4U!YX+Y9^L3[9>.T/VW`/QSE>^QV@VVNQ
MM)MN.^N"4#U;S,4"ZPFAW%MI>A*S(ZXO]:S!LE4N/R9Q!D=A<6X4?BF'W2+?
MF&HJ24M%^V7!-O?0XE%"X&GE)W&H&L1Z(\5G]YOMMY44E./<EVNV37_*FUY8
MV]C,]+JNS*Q<$IB*<(5V0ZNHZ]M`+U,NW7B*8X?M]\LDI&UV.XJ%=[7*CN$$
MJ#)^9BNM*0-PW)4E0[@C0@^?Y]3K`'>*??K[C[`U:HMGM[G(+N4X_$AQF8<!
MJQ91"@WVV?AL=A"([=O:$M2&T-I2@!'0>&O;L>C'D89];YB7XFS=%YB_A\:1
M;[9=D2(JV+]=ITIB#;4LQIB);4IEA#K2X$_U4%QTMK6T4"GCKG<[-W;6OB<G
M8O\`2/\`:%SUP-R9?.4.4,2@6S#^0/;]9W\7R"U7RWW2!*E91<L5R"-:76F'
M/G(%S;MI4MQIYM-%)4D$TJ?EW;[6Z=MYX&RSZ:YL_/=#DK$'GCF%#[P21F:V
M6Z[4U4FV6[R#<0-U$5'7QU=NO47)'H;?T_B+_#?;%[K.4\2LUPP;@7DN\6N3
M;H!BW5RP.VBW20ZRA2%L2[VJVM.-%)!"@:$=M=;?;*_%RX.A7N.M<AJ?<[P?
MSS[>KYA]MY1]O&?1\>RYZ"+AD,*RO7K';&F);8K<N\7&\61NYVJ*&'FR'`^_
M'**U)IKT-OM^Q*G$\??U3M.'J]Q4.>SD+`>),AP7W(W+(N!^6<ZYBMWO&CWV
M7EF'Q[NM47@L2+1)F8H;I',RWK9O6.RU_+T;<<BO(:4DA((/TJA&4:M8_N=#
MY/?;WW>Q_<>*W[?T*VZE&-<-6-73CE\!J/>A.ROCK%\`B\?X7DG&?'<`1;3=
M[JXVQCF27M5UCIR2T8U<V+6XHV&V66T2Q'C1R\ZMW8''75N*('DVU^M(^GVN
M[7N%J[NUEWFOR8SG$'NSD8+QDY@ZL1C7>WW#D1/(>?2;C)F28_(MBM!M34/`
M+R_(<48]I;M[#OJ*8JZZ\I/J52*:U1\>11O;3O65!?U)G:)]%?B8YG[B<3S*
M=`<3;.,>(86>/Q'GA,5:\IRV"+1CL1UQS>$S(5LD20E*O-M:2H@@`CSE_JU\
M?V%]C:.U:UG6GB<AA<VX752T1Q-3+EO.J("$VZW^C%;7X4\X)^%>GY-Y:)#+
M<^@Y8H0(4-<N'!E.*83*95\K)+(*&G'%=-H"5':GJ#6O<#0#R6"1Z-CMTQ^W
M0GE2V66G64166D!>XE0"PA3A*$)4OJ>PI]N@$CR1E$EM=KQ^Q0FY.09`^F#%
MVJ;]&T05(*IMUDE1"O58CU+20!N6>XT`29O,C8O!L#:%EN/(6JVI2E-5N.?)
M5]=T@UI^Q.X@&A(&@&1R3(WX5M0RTLTN4E5J@QG4A!E$A*%J00HNL,Q8BG7U
M$=3MIXZ`:'_2I;_\=7_E/9]]/]4^';][H#YN.0N?]>+NI/6ESGCK_P!6O?W=
M><STA*ON*K3IYJD_G/AUUQ*"GF!Z,?NK+;8.U1#+<<*'91(9)Z`_HGP.LVE:
M]/A4@/GL@0OHVPH4/0J5]GP'P.K^S#S%#5\^Y(:2M03O*NOWB*"H'4D:HFE&
M5$!/3W"?*:4]17QKT`^W5MNY*4J,":DOJ`<J$T]%\'H:T+:Q\>^N+W5\`R:R
ME@8_&<4M2*6-A06D=4J,!D`@4)\=<02<DGD!"17'&X/H*<+@;5_?%"-YJI*:
MF@(^S7=R"A2@"^X*HT5CKV3U[4^]]AK4:K6:YD/(3C-"^%$]>JC3M36TYNS<
M(U6=2/%FY>OF1\N\A<?R+#(8M6*71MD78PI(82F"J(FT>K+55OU[NF5*="%!
ML*;0@M[J+)ZI1)\2+4W.-7G44D])4YZ@[4-?Y?`:P/-\SL+B0.^H)/Q<IQ#:
M]B^B6G#V[`(.NH]2Y@6V5/29EC##3DIE:(<2<AYA)6MU0MMM96REO<CR^F34
MU-*=CK:2-;`Q/*5J-NN\O\2M0C,R[8MZ%&0F/&N#;3JV"M,=I3[B/32DJ4""
M0>I!T`O8U@^3MHB)<]395Q#?5#:'-^^B`@IV=OT:=-5QMQBZJM2*"3GVQINW
MR4^F4>D[Z=>@(!()ITZ]3_/KFY-P:H`-B]M0J,7$)'D5.!W4)5Y5@_#KUU:G
M55)%.U`2I7I-^52F%J()J*)>8[=.G4G4@Q<(M2K>@;E!Q4OJ"":(8W'P%*:`
M_9$$N*0@-54IE_:I:-U#N9H:$4Z*'PZ:`1;[;L2Z6IIVI60I:0$]Z(=22*=Z
M&M?AH"7&$6J-)QZSE^,PI:XR?4W(0:*4Z[N\*]2/CH`7>;"VS."&;/%D,%H*
M4LQVU>8_H?<42/CH#4,8MKULDRG\<A;FGVVBVF,$*6E8K5)&TDC^30&FV85C
M=PEL1EXZVVAU>TKW.)(/;NE0.@/HW?1PM46R?3/]IUJA->A%AX3D3;+52=B5
M<B9DX14]3YEDZVVO31AN^HQ<?5+5L^GI[LU'PXDO!Z?]66_2[Z;Y%=:'SQ+Q
M(0TAQU1%*K5Z:@5`@5-"E(.X$>`ZZ\^72^1W!MS2;PJ#\DX3S6]6VSS)C,UV
M',MD.Z6F)<I%P;CQ[?.0J3'7`:?6F(U&?"BH%%*E1--9*OB;:+@AH+EP]DT!
MU2A"F(2@T08SK<QL"G@/OI`)Z"G72K%%P0GI&+7B%02/4*S4(:D(6PL%/P"T
MC:.OCJ"3:T\_"6F+*;*7%BJ$$)7N2/O*2E*E$TIWIH!=8SR+EV(R$2<6R^^V
M!]"M^ZT765"2-I&Q182KTE&G<+20>Q!T`PWN?XIM_NVR_%^0>3,DN[V;V:V0
M,=EW6S0;:FZY=C]O?4[;K/-0VP'9%QC(=6Q&D-H<=0A5-BZ`:T[3<;V,],85
M@GAR,7N&XV?M]KZCW"6FTU6M?`>CZ2_T(N?O<%[K<35[C.-\ZXF]LD9NYYG>
M;I-7:85[R6Q6*?'EV;%DP[@X+I;F\K*D17);D1"PTI2D)J:CUY;>_?6N;H^'
M\#P_:O?_`+?]]W-W;^W7=5ZT\J^)]*6!Q%Q58[1;H-OX]Q9F)`M\6UL1O1)=
MBP8<5J&PPTZ^XLAN/':2E&XJHE(UQV(V_EDDY<:'KQE)K'P;7X#/O>U7VA8Q
MG$GD>[>W?#U9'<+DB^.\A3K*<GBQKFE*4"9(C3)LV':74I:%'3&`&T$$4U.B
M#S2_`ZU2639+8.QG$1)L22#`DLM!AYEXF(8Z6PEAQ@LJV*82V`FGA2E!J5&*
MR20K+BPK5-AS9LBPW9,>38;G&=C2%S&V7K->BXV4NV>2)`<@'UFB0IMRH=2-
MHTHB,PBX[XJXMXKQEK$>-L!Q'!\1BO2I,:P8QCUNMEJ3)DO.R)<I3;#!2X^Z
MITE:W5J*4`)!V@`=5?%D3C&Y/N7$I7.+57^+Q$IR+8.`\WM\O%^0<)XPS^S2
MD^C.L&2XEC676Z0"@ME+T&Y0)D;<E/EK0*3X'440C&,5IBDHUK18*O$HM]U'
M^SA_34]V,^=>>/;'D_M(N]ZD0G,A'"5LM\3!;JU$<<<'RF%Y0S)QC'9TD.J#
MCMH^5;<!`=9<^\1)=?[?/;OQG[7,(Q_C3BS&K#:<>L-DL]JD7:WQ(POV3+M5
MN8@"^9I<EAR=<\A?])3DAY;RVCO.Q*$T3J**M:8DU=*>`\<QVR^H8=U@-*MM
MQ9<8><6/2CNMJ6"AH/-E%&7%@=J`G4D`5K'K%;_F&8%HBQPC]JME7F94TI/I
MA*5*+@J=P-13IXZ`-TQ'TMVAIA"A;Q%6A#H'[MY:2=PW$`%*:I!504T`U-I:
MBW+DAZ7'<2MN*P[;FDH5ZKB'7!O?4IQ.Y(4I38I0D)[>.@$K<K[:LTY5EV6V
M*8R"S8);I,2_.QUE<&%D,IT(5!$MO<VJ7;8S!$@)/[-Q6PU4%``0GNN>HR'_
M`$E9BTX%V'`49#C>,>DVYLN&87LO-/E*E`;U0&MB-R?+YNF@&E_@:Z_KR?\`
MP>?C/W?_`'=_QOO^Z_OOYM`?/SR!Q/XU=SN\HN=PKW[_`#K_`(4^W7G'HK(2
MLA=`LUZ><@]?RBGPT)',L"U[IK)"=X9MI!K7]Y&<(!ZUKK,K<NY6F%2!0.1P
MV/4?>0V.A-7$)2!VK52N@Z:TDA9)R*U01M7+0L@':EE8=*C4U`].H'7XZSSA
M)SJLB!&S\V9)4(\=Y2E5(4ZH(`\!Y0%DA1'V:OHED2)-_)YRU.N*2E#89?*D
M)"=JB&G"GJ25BIIVII1>(+!X5YB?@UJ:><0OUK+;O4;20M0]6!'4I)36@5U[
M'65VYU;2("&4_%0QZ,9I;:22?,:^9:JFI*E*-/M)US*,H]0$O<GE);(\`GJ:
MGQ(-?S:NA*"BDZ5`5-+`(622DT/0D%0J.GQ%1JU3C+!,8,C9%P_D:R9O!N<C
M\"BXG$D7J-<;Y$N<J7?^0!/EHE8XF_VU^.EN#*QEI0:2\'%**=P2HI40)<X1
M5&_F&3\A<.DE"OR'6)XL!>XA5$FG0U(ZC[/MU``[J2&W.G4MK2/AYDT-:5\-
M3'"2?A4#N.-)(Q]E8"D*LI#E*@$BV6^@/B>IUL4XRP3)-Z8ZM^Y54C;M[@]!
MT`[]NFN@!7VA11J10;>E.Q-*_EZZX4XMT3Q`A;LRHPIE3T1+(J.O0);INKXD
MG75$\P`\/84JV/N4-$R[PD=NJ0\IL?S:D!\BB)#8_4CN)K3J0MY"JG\E-`:Y
M!'XK:%`FB6[FH@=`=K#=*_'OH`:BOKHW5KZ:E@=>H]9E-`.YJKI0=3H!38_Q
ME\[,CW;)XKSKZ4NMPHY>7&7%CNKW)W)84@I>VC[IJ1W5UZ#ASC%T;Q!+7'+3
M%C6V!$8A---QV$(0A2$*.T5\VXDK))ZDDDDDG4=R'$"I-IAN["Y';W4"3M2!
MT^`H3372E&60-HLUO#:F@R-JNI!-:'P(KTZ:Z!LBV&`VZVZ&NB%5'W1U'Y`#
MH#OC^DJA+?TZ_:^A'W4X?D`%37I_'V7'Q_+K;:]-&&[ZC#CZJ)V_3P]VQ^'$
M5X_X9;]+OILX3HZTJ?.POKU%"H`#=%D]ZA)*B"/@>VL.#Y%\;D7))12(TWG+
M^2K4^[+L'(&;6V.V^]Z$!O(KC*MC#8<6I#,>W7!V7`8CM@T2A+02`*#IKG1'
M@C2U54/RT>YOF2T.I1<;C9\F830$7FRL-25CJ/--MJH+@)^--5]E<2KM//4Q
MU;?[N?60&LJXW;DE/5^58KHRH)KT*D1KO'0E73LD.U.LY:)/)N0L7Y`SOCJY
M8]D!P&P6B8[)SJ!>\:ER)=WB`1UHA09=G1<&6M[8<:4=S24*(6JM*:`DE!A\
M4WFLFP9CCL\QU?-MPYTV&RF0Y&_I`9?8N*X;R6W`WM<-"E*2JNHNZXWHVK2U
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M^!*C&.2+U/B-*N:7;C(AR`W*D.V]J'"G1'%K#JBPR@,QT%NNQ(W!*:5J:D]G
M`-O6*7=45R\\1W2'8KDI[YJ?BEX+LW!\A#H!DL+CL?TG'9RFSN3+C+2VE?53
M9!T`6V#DN:T[(QC*,`N&#S+@^68=]NMPMUXP&XW-Q.QF(Q>-H,9V2XDEM$EA
MI"B*!PJHD@>;LQF##H@9#BMIE6UI6]3KF37:/:7&U=`18[#!9]<@]O6=23VT
M`X.+.8Q#B)4+3C]E>`"/78MYA!RJD[2A<HOR7$!5!4J*JZ`),USR$FZ1L9MS
M#%WGAHF>^VB/+AV5E0&TS5(<'K2'@I*FF`">IW`$:`&6&_-20B)<B4SV4@QW
MVBMB(^V#3]HT*?MBCND@Z`-[WCD*]Q''_1<F.1AO6TTLJZ4JCTD*HD*0:$=N
MV@$Q9<BGVQQR'>XSDRWN-_+M2R5!R"E(V^G*6KR%*:5%2!H!!\C\O,2$L8;8
MG)#"&XK[F07AU)0PBW0T!WT(SL=WYA16DG<I/@:#0$,;WS9R0SAF3WRQN6'!
M(5_D/8_BMR4I2;D+<V&_QB^?B,L(4Q%C0_V0#,=3ADNAMM9<ZZ`0R^2E<7<7
MVW!\,N3LK+<IDJ<N\EM"DSY$N^+4EEHJ?W2%I0AXN.JKO2:`D'0"]M6`_)6[
MCOB5E+:C:`O+LZ>2I80[=KD5.PHBUE1*Y;;/[1>[[.N@)+?@@_[$I_R%Z'W1
M_DOX?=[:%>A\7G4^57F?*^"VR\7H&^MSW472XI^7M33TU2E":]4%:$HCIH?'
M?3IKSCUAF+USZSL<;LF/2']U0EZY24,]^E2Q&#R]H/@'!4>.@'=:R6ZJ1$DB
M:^RN='BN.)9<4E)(:0$IW`A6U`70=>@^W0`O\1FR#YWG'5=Z+6M9Z]*U6H]?
MMT!L"'E)^[0DU(6HT[GQ`[Z`W^B3]]=3]AW=/RG0'AYE"67U"I'HO#:JJJE3
M:DCO7L3JJ=S0Z4!/2P6Y#EOM<A?FWVRVFGF.T?(L>*J=1]FN.^^!%03>$-LM
M)]-.VBC553UIM_DT];/"@S$#?)"DQE%MPU(2.Y[;NNJ9+3)H`&-(JA-:GRTV
ME1-!7OU&K+/7\`@!?G%.0X3:03NN;!VA78BG6G;S?VM+W7\`Q#U!H#3S#L>M
M?'50/#B`4U[;`2`/R=OYM``BCU"$UI5*_"M>GPZ:E*K2X@=EQ)1*QMHU)_"I
M`(/=6RVPO#QI36J%M0=:U%`?2O;5A)H>`VD>FFA`)50=#N_)]FJHVM,M52*"
M'NR$IAW`@[DB6K=4=!T;`!&K20%B*`FTO@*J%RKNL"G1(5+72GV:I[OSZ:>)
M%0UV#Y@'I4L'I0=/V@[?EU<2:U!M5UM;.W>\IN8A#2&RZZI<A"&VFTM(!7ZC
MA'04KH"2.)8!'M;[-SN[29-S+!]%E7F9MZ%.(<`VI.U<SI12NR*T37OH!UHU
MCB/H2X$@+Z;0D%`2>M14]:_;JJ=O6ZU(%/"M2F6V]KBDTJD`J430>%?SZKE:
M48MU`<LVU]1!J5"J37>:#KW[BNIL>(09IMS@2/V:5*ZU455!%3^C0@4UH)-J
M(;J#4M@I^`%>I^P#0'=[])U.SZ>/MB33;3$+]T/A7/,L/]O6VUZ:,-WU&"/J
MNK]/Z<WN]76FWA^\FOP_IENTN^F^16?.4NTRJ'7:;]B%'H2*T!Z"H.L*S.K?
M6N8U,B.M:/3`J%)(4KP%:UZ5Z]]2>@-;>K*M#KH2WO2?NJ'0$#[#7IH!-_A)
M_4/\G_(UG[/F*(5^.XZ65JE/AQQQTD!*CT"*=#7KX?9J@@,LKN=HPVR1[_=(
M295KA9#C+%Z:])M]?X+,OL")=O20X"GU#"=6.O2A.O0]OE!;F.YN+4H^'&A\
MO]U]^'VGN;.WQW,]5'^(_O/GO*Y"Y)Y*QSC2!=A:K)<H+L"U2K*@1+5%LUIA
M(3`B0X+K(++ZXD`-H:;VI#@4>M=?=[KWF\K"[*T1I@JY?D?RK_;O^W>R^X/=
M+NX]SO);J4VY1E&M6WBJZB$G&GO=Y+]N?,5BY3_&K/G/(O#?+QBV_BO(;;<I
MMHRC&VR]`=1*>BON7#UWH4M;I<!])!2$^FJNOE;ON=V=Z3O1<GQK18?\4/Z:
M]C^P/9/MS=2W&T@E??EXG8=PU]6J%E;MHN6&XC@=ER-<*+(N'&^2,74-2FTL
M>JF3!=8N$1J:M"75(6ZVR%M[:*1UJ,SW<;OSQAI7"O\``^O[$GU2JR==A^KP
MR\U\EF'MWM&Q#;;<C^&LUD1D-J2H%+D9F\VEX.)6?!3O3XZCZCR)^G\Q\<5^
MJ[P=+A//GC#DZ"\PRLO6V%+QFY;5)Z"K1N$1UV,LG:%A&W=WII]1Y?F4W(=M
MTS#E[ZK/!MP;?MT_B7DF7$DQO2<ARTXHIB2A(\R)#+LQ;:D$'LH$=:CJ!JRW
M<[B>%*$PMZZXTH$<3ZI_%U@V0[;Q9R5.QQ2QZ-MGW7'WW;0JHHFTS5O/R?DD
M`FD9:UA/9!0/+JT3MZ*8U%5;?>?B'+[CUNXADQ[#D]U"F',1SR?#QO)%;J[E
M8@_,COXX[<)#9*`ZN4%@]D!02="L-K#G#^%LRB[@&:QKQ"?<=O-CN=S@FZ,-
MN)"C,#CS,9%Q]9T$"BE@]P170"D:]U.(/J1'GXGG%HE>LGT7#:;7)WJH*%!:
MO"5!07T-0$_;H!UN,/=IQ'D67/8,[E[-HR=RW/S$1+Y$1;W)2([C3?RJ)+KS
MT)^:E;NX,I4I6VG?0"NY3R*P62R7J^W:^2'L;-OE39DAAMV0VRN*@;6#`A(;
M45N*<HE0!*CTZZ`J#R;F>\S)=U>Q5&3KM]Q`^>>GP';3!++:R6FF[@\W*F,)
M6D!*DH0E2Q3H.^H;HJ@;!WE>'?<C8R7D*!-O\>Q1H\*PVBW*9LV,VMB(=ZRY
M&?=7*N#_`,RI2B?2.YP[Z5`.LZW'E^8)!<0V2)?KU-Y_S>*NWX]8V7Y&*V!U
MSR2%,I;##J_42S\VN2ZA#;20@'S`5UI!+3BBXL&"_E&3R4H?R2[R+C<9KRMC
MKDB2Z7GXD1%"Z4):`::0`4I;;`'CH"9WSUM_7C_Y*_6;_P`E?'_H7V]M,"ON
M>7C0^+O=["^Y?[W1M?6]7;H>Q_IT@UKUUYQZQC>+J/F<.T=#M`*E'IVZ4H:Z
M`D[%:"H=N'3]G%C@#KX-H'3K7]'0"C;V`)VTZ4J`1H`Q2K<D*[5K_,::`]`$
M]`"3]G70'A])]!T$$50KN#\-9KW4N1#+!<>I^`V-0%-UGM:C^>"P=4@+\C)2
MT#6@'<=JDT_N:E2<<@-I<U!YE21V32I!J#V/A3L=0W5U>8"E#^Q(`!J!2H.K
M;/5\`C\G/!2+>@D*)N35#4'M0_S4TO=?P`@4N[@VH*J=B:$$=>G4BFJ@;5.E
M0`%1THK[>@T!ZC@%U-17N/Y03_:U,>I<P.RZD?B..J4*[;7._F@Q$]_MIK:F
MGDR0;0#L!J0!'A1M5?L_]D-`(:\I].U7-2C4F8[7P[+0`-``L56E-J2D`57\
M\LT(Z;Y"SU\>^LNE]RM'2I`8J:NDR=%M]GB*DSYR"TRI*`Z6"%H)6&R0E1VB
MM5$)2`2>@UJ)))\=\6QL?3'N<\HFWRKCAD*4'/EW'6RAP1G5!)<=(/F=H*]0
MD!/<!Z1`0=W0"@J*K1YB3]T?'KH`=#8+8H!1(-2"H$@T-``.O0G0"L@H2II*
M?+4FA'<CIUJ.XZZAI-4>0#QEL(33:.PZT[]]0HJ.0-]/`:Z`(:;(\Q^T4(_N
MZ`[H/I3T_P#1\^V>E*?PC?NW;_/O*];;7IHPWO48&^K4OT_IM^\1=0-O#=Z-
M3V_KMNTN^F^16?-XG2TNQ9(*AN4*`@].JDH'YZJUA.H=:YA`I0-#\$@'\PZ_
MRZD]`(ID5<H^2@J3W':NWIT_(=0`$NRQFW$D]5MU*2/NU/0U'B-5=Z/!D5!S
M;9;)ZCMTITI368#<<VV6]Y#Q/F=GQMIZ9>)EJ3\K#B$_-R"S)8?<;82"E3CN
MUNH2.I(UNV[5I5>-2B_MX;B/;N8VGFB,/%L[D?D]C'\9S;CG(HT[%(SC3G(-
MW+]F4VU%:`M[:'I<=#ZIRG6PD>@55'4]"=>O=WUN5F,$G5*A^<W?LV[M/=);
M_P!FN6[.J;DTT_W$ZK;8[>V($J7!B*OC7HO3KM'CL1;A<)C*`@R)<UIH2'_4
M2@$A711ZZ^?O2U79/P;/T3:=_P"FA]5)2W%/F:R;\JC7\K6V7>9<*'&OEWQN
MY1'K=<;9D>/378%YL]Q8G"5&G0)2""EUM?10/1:>^IMW5!)-5-/@6;<5>X&\
M63'K/9N2+U*RR;%A1(TK-5P8T&YW-00V?G;K&MZ40E3`/WBVTI]2FXBI.N^_
M&N3!,S!N1;$9T*^V&6Q=WT+2Z(\IQL,RF'4['XTAHMN5CR(ZU)4%4VFBAVUW
M&6M513<M.XZII$T[+QO+Y*CQ[SAUGGJMTH%PMW!AR/"MRW"-T-FX*9;;E^BZ
M2A*@I2G6PE0'76O;K!G"78PEC47<3VY9:PG;-8;M\=%=[RBZ^T00!OHV$*:"
M5>-03VUH.+EQ3I1`-W@*&)`:N>0N+<:6A8++2GP\4T*&T.,NJ].AH4E:PH;1
M7KJ2H??'<KY+PNR-6)N\Y),QE@K9B9->\D:D)L;X0-UN8L]Q+[DZW.I&X(4Z
M6VR?V6T:XG-056`FDS<MY"ENQI-YL=I9<0E$B=\X^Z#'65(#S<1:F]H*6]VS
MU2!7Q[:XA>4Y:4F!/9#POB5N;8BN96V+K#D+?_$DNJB/AY2$D+9>9WN,NMT!
M`2HTH!4ZN`5CFCDBQQF<-C\A7&_8[`?W.NW=B)+5-^6%6&`),=3C\-E8"@AP
M$*6`36E#$GIBWP`GLMY:SW(XJ(ESO]P=BA(:9@QUQ[>PEM1*7)"H\"/&91(>
M`'6AVCMJCOJ7RI.K!LPO!+2B>S>LXNRW6&U"0U:XZ"IAM.W<A3RR$%;A"^JC
MWZZY6WDGF@258Y-1RE>+3Q]CD>*QBN/(CLK#+RG)TJ1'`0VVQ%;"FD,[E*4I
M1/2E>^M0+(L&P&R6YMIZ8PM\L1G%LM..J=:@>JVCUOE@3L9<>V@JI6A'3QT`
M<_.6+_WT_<_@7]='^3OA^Z_G_GU;VGQ_EJ9*_P#>?(VO;2$WN]@("?\`KQ=#
MT%#_`%Y_K\=>2>Z%2D@`D#^S\=`//"2!!MZJ=2P@$]>P2@C[/'0!NR@@;J_>
M'0?GT`9-`[$BAKU_]D=`#&4&N[\HIX^&N92TJK!HN!*65$=]IIX^/VZRW)*;
MJN!!/_&S7';"?_>6U?\``6-<`+<G6$,)J":D`4\/*K^WH!K9+@2A2"":J-?^
M6W*'\E=$JN@"93GP-/RTUIA;<'5\"0#)>4K\.IT!N*`>@K0I`-#W2:'N.HU7
M>Z_@0Q&1%DLMU54A-!VK_P`G50!84JHZ^(\!H`?"`,IE)[*7U'Q\JOSZ`>)Q
MI!GV'RU_ZVS1W/8QH?P/PUW;DH.K`/+"!W0?Y5?W=:HR4E5$A8\`3M(J#4>/
MZ)KKH"`R.HLMTH0*3G@#X='0#W^)3H`DQ%9>ALI0:GTI._IT!]=5*FG3N?Y=
M5=Q:M-,:@EQQ/98S=C3=FK6Z[<+@](9?GNMK6/E8SY0W&C$@!EA7I[E;:[U#
MJ?`6@?N%$DJ4TDQT-G;Y?(`=U*`IZ'<:]2!UT`/7;"A-%^1:P=AVD@@4J:DD
M#I7PT!I]%#9_9[MH(W%77K6@^.@%7$CJ]-+FP=B0JJ1T5UZBH)J/L.H`:--E
M5*]A2O?J/L.I`*#*>X0?Y5?W=`>Z4[Z`[F/I3@#Z?/MG`[?PC?O^_O*];;7I
MHPWO485_5X5L^FA[S%$TIPO>S7X?TVVZF[Z;Y%9\S_*[_P#P[CMVO7RDBXB"
MVT\8D5;*),FC[568[DEQIE#I"JU4H)`'?6&*;:2S9,'IDGX)C#*]T.&1WS$N
MUBS2Q>9^LB[6=$5(1%0A<IY3CDCT#%;*TI2M*OVA4`D$G5W8GY&KOP\PYMON
M-XLF!.V^3HZW`A24/VN8*@I)IZC(=:JA8*%>;RN#:>NH=B=/`=^'F'HYDX_D
M["UD\(%2D))<8EMD%U.]L.%QBB"4CJ":CQIK!V9>1'?AYA@WR/B#BBG^)[,D
MI%5;Y;:"E-`2I0(JE*:@'X$BO?3M2\AWX<&*BU7>+=%I5;IL&<5J]-'R<AF2
MM3CG1"4)C*<<7ZA.T$`@J.WOK2L$D7IU50U^=6E93(`:#'JAP2"I'H*0$^JE
MQ+G[HI5T-0.J2/#53NT=*,AW=LL)J6KQP0-9E4<!3X(*Z#[@Z$4-.Q![BG37
M#MRF]2\2:QEC#I&KS*6'LD1N/0*C-D=-@H4&G?M74=F?D!^S<6$PA12J!-*"
ME#1L``C=2E!KB491=&J@7ENOS]LA19=ODO1WQ'05+:<6T04M-CR[%"H)23UU
M?9KI=>(0M\,]\7N#X?RZ^VS$\SN*+#%FQ6DVA<I]AGT'8,9YY)+2EL.*<?)5
M13-.P\!K7:N1A6M<2F[;E-JA)EGZG'(5QC_,7^^YK&#+!4]';?A72*VA!&];
M+;9@*4FBJ[=F[IWU=WX>95V)^0X=F][TNY*B34Y]<8B7T-O;FV7H#RFEA*@X
M0N'*C]=P)W`_ET[\/,GZ>?D2.QGW!SN2+5.3;<DG92]:&8KUPEQ[4F[*BE:U
M_*.SXEKBO*CI<0TM*5+0`K81V&N925Y:(9^9Q.U*"JZ&A/)=W6^)4>ZRT*0R
M^EH,1'+<IQT.5"F@\PVI"6`KOV36@/?7,;<K3[DNE<"L-H><7&>PTQ)NTA:5
MT2]ZCZ7`>NY9HE(4ZI-*D)%3X5UW]1#S`Y=NDJ$1<C<'FPM+:5A`6M;X5M=0
MAL;B5(4-JB2!N%">FN9WX.+2K5@+6;W#MT^3(O4^&@>O2*W*?8:2I]:BM#2B
MIV@+;8KM/3X:SQZES(&KY5Y9RA:1&QYUU=J2M`O-R!<0Z\DJ1N9@H04F/`CH
M*5%8&Y=*)Z5KZ)).CV4<K2XMSM*KQ9L?G6I\R8POIB/)GPGD-&3;W751W$HG
MM2?3*2`DKHH=1U!`NCQ?.[/>;=ZD"UF;%<7N)6]+@>KU"2%)<&\MBO3H"H:`
M7WXG:?\`L!:/ZEZ7AV_P'?\`>?\`KM:__`R_^9\@C(6U+OMZ(I_E>Z#J?_;\
MG^[KPCW`B4.Z3X&A_,=2!X[>=T.U@]EL`'_E4MTI_+H`]1Y=H'8$?S'0!HTH
M)54]B*=/RC4/(`[61W)25'D0%]PIZ1^)'3\E%$_V-<`GYC'^;6/?_`=I_F@,
M:`*LK-(R5>`60?S)-?YM`-//=`ZI^&XU'V;0>_QT6#J!-OO&O]_T\.E.NM%N
M<I2H\J`#O.KI;.W6Y(\/]QKB]U_`>(C89(8:6*5.[^X=5`-&U[Z4[C;7X5/_
M`"1H`[M:`J9'*O!Q/;_<+K_8T`]*D!N98"/O"U3R#WZAF)7^<C5EN*D\<@&B
M@%BA[?9K3&*BJ+(D3UQ=CPFG9#[B6(R`5%Q9-!2E4B@*E*/@!4FNN@!L4P*]
M\EK?LULA.+CR)#\N5+>WL1K?&>>6N._*<0%K25)`VMIJMP]!XD`28Q_VM8GC
ML:"%SK]*2SM5/:<=BABYK*@IQO<E@2HD92ZT2A9(3Y:]2=5]N.K5X@?J-98T
M**Q&BPT1XC"4MQV&DE+3+;8VI0A`Z)0D#5@!S</_`'P)(%/(4J*1O!\>AJ._
M30&.PW%U6Z\%D)(&X5Z'NE(/3KX#XZ`*S")"BE&VA51LBF\J[$^'0_R:`-V8
MIV,J)VI\J4I2HA2>E!N3\".U?#0!RF.E"0DU)`';QZ5Z#0&U(V@#:H`>*@:?
M&E?CH#]4P%#U#^3N:_V*:`[C/I5)V_3\]M"3X8E?NW_R[RLZVVO31AN^HP@^
ML$L-_3(]Z*S2B>%;V37M_7K;WTN^F^1PDY.BS9\N'W!9$8/%60QXS,A<BYNV
MR`TN"M")+?J7!AQ:FU+\GW6P"#T(-*'62WUKF=NS-*KR1`/$.7>5;$\F*]BK
MN1VL.[7([T8(5+CAP$-2(U9=L?W;14%FBB/CK>5E@O'&2\"<CX'EUASKVJYY
M#S*^-VB/"ON%8K>;:_"@QKN;Q=)B9V)7BUV[^ER>JTNP]ZB>YZZK=VW3,#K\
MG<6>R5[A?B*Q<3<;>[2V\QVZ1DTCD?(W\>EBP/1+FA+-MM$?\9@3I5Q5;_02
M^RH@);<?6"3VUA+>Q<\B.'^K^ZXK99$<UM,_+LM-_CO&V/7!)V,!HEUUP6]2
M@H*4"GL*]/L#L7/(V3^",IQH6Y5WE918_P`7:$^VSYO%BK>9T)N4XPY*ARK5
MD;;+D=$AA25%`)2M/@=3@;(IJ*3X`=GB)BXS$,S.1DM)?>+#QDX?E;,AYDNE
M32'3^/*84&E+*BM9\U:*Z:OC]/1:NKD99V9N3:2I47EM]L=U@.JE6KGRTQ/4
MW(0W'@WV$@,MPS#80O;D+GI.)75U913>X!7QK5/3J^3I-%M.,$GF'-SXGS&T
MI,Z?RS@M\V2%J;<?M=W:<,9H@M!U4,3'''RA%%5*@5&NN3L9WE?W(/8*Z[B]
MO_"9E^8A)5<;RQ;<@F6>'*D(W-1K7;)$"&_.?0@`J5(?;;!52IZC5]J-MQK/
M,AB/XFY:YLY!D&98>4<.N;5OJY-Q;+GL1PMQ#"?30J-*3=YT%A$9UE86S*CR
M7`%5#E%"FN+JBFM.03J2IR&Y@YE>UMW.Q7)$M%JN"9E@OEMOMK4U(M48I0U<
M;9(D1776BA27$I42A8H=5DAW%DA3-"HJ2H#J"%)4DE0!!23T5MJ*T)'70#FV
MN8A,5AM'I)HVVE(J$FFQ(Z@'L::`M\^DK?Y>*YAS%EJ%AR(]<L(PX-4&Q,B-
M8;W>9B4%?D>6EJ_,$I\-R?'5MCK^!3?Z/B6Z<OS+==^/L@'RL'YI33BHSZX4
M8275--,J`*@WZ@4JI%*]:ZT78N4'%9F,K>^=BFU0I$&WM?.MM%B2Y";2R^P^
MPZI#;CB$@+4X$I!/B#K*[4XJKR(&ZN<R\QI"1\U<$QOV@41)?2ADK)44N`.`
M)W%1/6M23JH'Y\FQ)"C-1\TQ(:]*0`I+JT*<IZ4MK?4&3&5U![D=-=0ZUS)'
M#L%MM\VY,XOD*U-R?D69;$IMUI3-RM4G=$;N00K]LEE(JE21Y6W!M/50KZ()
M&X]P/E^"6QO,^*,CMF;V?'ID><K'D2E-7*VK0D/J>;6M*V'HY<20MM2:I3V*
M=`3'X.]V<I%VAV',L9@0XUPD_A[\R"K\/<MTY:0B.]<XH,I'H..>4.,J)%=U
M.^@)S?Q[;?\`#/\`]2^:_P`HL_=^/;^K_P!_]_\`O=:.Y'_+0HT2_P`U3Y5E
M^;!OEZ'6OXO<^G:G].?(`/<:\8W!$XW2M0?$'KU\/ST^.@'4MW2);J]:,IZG
M_H;1_LZJDZKXET(TQ\A1M'RCJ:U`IW[&OV4US4Z!C=`.GQJ>O<:ZU,BF;X@U
M(J:=_P"Q_;Z:Y)`LT58<'AU%1T`K7^[H"=^)+_XM8\=Q_P`A6O\`-2$P"-5_
M^PZ;=,0LRY?]";->[J@>_2B%>)^TZL.1GYCY&X>'A7L:_P!O2E0)U]VOZ7C3
M[.O\OAIB@!%O4=MH!KMN*>__`"G0]J=]=))NI/B)6"OR-BM0D*[GM57A6E*U
M_DU#S#S%/;X<B8I'HI.VH"EJ%$@>(^W\VH('!A6EJ.J*:%;ADM541U(])TD)
M`Z`5&H>0',+=9UG%.B;;-ITH0D_)@T!'0:E?F2"9LB+!8+KZP*I*6T"@6XH#
MLA)->IIU[?GUVZ)5)#+`^)LAY5N@D/`P<?@N)^8F/-%<2"2E)###1*1<;PZD
M]&ZT:'F64IH#$4WB,RP;%./K-AUF9L]HA%F(T@+4XI>]^6^4E#DJ<\E*3(E.
M&E30)2*)2`D4U82J!W)MK3<7>$A&T)J5>8*K0]$D#I7X?'04"\05*H5M52E2
M@`D$`4%.I`/6OC_+J0;A;@4U"0*IJ*@D"HJ.I%:TJ?LT`7RHB4)2%)`I4JH$
MBH[DU^TGQ'70!&Y;7%$]%)W#=4U"2A0/05("D_`_9H#;#@24[BDEY(!KMW*`
M!`(`)H>E>_QT`8J"O*@MK*DCJKP`!I05I50(T!Y#JD="E0!&Y6Y)H*&AH1\3
M\==0I7$,W>JV0554*U!)%0*4!Z>/7QT47F0VEF=Q'TK#N^GY[:#_`/%&^_S9
MUE0^)ULAT(P3ZWS$G]9,$_2[][0'?_0A?/&G_3UL\=+G0^1-KU%S/DY>[&X.
M-<=1X"'%!,W(;8V4@GJ6D292B?B0(XI\/#62VTIIO(V7?3?(B+@J5K<9)W*2
MD`)JHT^\#U!/FZ_'6AWK;32?[3`L<B>N'..LVV.WO+90VDE*2$TZ5404T^/A
MK&6=FYP_8.>S=F6&%+==#2&FZNNK<*4(0CJ5N.*4$II7N374FX;W)N=\7L3+
MC,!Q^_3FJJ^7M^_Y<+*2`B1/</RU":'R!1IH!IKW[N^3I4.S6Z-;;'#@6"/+
M8MS`,U]Y#4F:],/KO"6VAY27Y"]NU"$@&M*G0#<S_==R<%J?<MUC?5YE+4M4
M])57H2!\VH)I]FBI7'(&]GW3Y\68CCULM*7I,A31]*3<4[/3!Z#SK`.T"M?C
MHZ`4K'N9SC>I1@,(0.B5QKI,04J'<[5H)-/R]=`'MK]XO)UJ4MJ*\ZA("J)7
M-;=`2*424R8<@*'Y?Y-`+>/[ZN5OEO3E,6::A1)5\]9<4G=TE"A69C$A7F0H
M@]14=#V&@%7C?O)YGOCB(EEQ#';BA"]J6Q@^#_((KU6EU4G%41$H(H2.^@'5
M3R!FV7(1+S"UXK:9C&],>)C-FL]L*6W"DK,UVS6VV1Y2ZI%`4J*?`TT`R.=\
ML9;8;A"@V>XLQW';J(KKRH33Q;AI9>)92'$J2ES>A-%$$]#\=`=!WTNIDYCV
M@67/YS_KW;*>7LJRV=.=0@.2&8V42</BLJ0T&T(0+;8$)J4I'0`:ML=?P*+_
M`$?$MQY'GA5JD.0):IL0QWI@>VAI*$O1V@D!!!]4)H?A2FMAD*][,U(<N]S;
M9?4E0E!Y20I02LN$DU`([K/Y]5W?38%+?;$_+B%T>H25!M[L-Q2"H5`IN&T]
M#WUA2;=%F0$N+6U;,A;+Z'%Q2O:"MM5$U_1ZIW&A->M1JV-JXI)M85))7X+@
M=@RKY.V7YHQGHLHOXUD$-*!=;'(6ID./L*_=O1'VDJ0_&<_9/H-#0A)&T$AL
M1X[OEGO,_&X?SEPDW9GU(:[4\4Q;A&D;=LAI*=J-KC*5I4D^(VD@]P$7<<&>
MQ&X7U=UBRK=*0ECT6U-*3(5)HL,EKS42YN%*@_970`K_`$@Y!\9G^;?X?]US
M]]^OW_>?S?;H#@-OJ2+Y>>E"+O<R#X_UY_::B@%`=><7K`(G0H]>HKN!^VOQ
M/7QT)QDZ+,<>UN!<>`GK1+*4FOQ"6P3_`&M5R5/Q+(NK^`J$#RDT\13Q[FA\
M/#7!V"VAT-0?#O\`D'0=B=37&I"5%0&H-#^;K4]1^?J/#1NI/[#7+\T=WKV2
MI7V'IT/Q[:CF"<.'.;L:QP>"K!;.X^$1H&M.QH-<-+6J'3RKX`R[P&)S/I.;
MP$G<"A6U52*=`0H4H>U-=G(WD_#@Z#\M(J37RO)^`KT4BO\`8UTI49*8@+CB
MUVB%2_EE.(14E;)#B:=R:#S?S:ZK%YDUJ)8,/&X6]DH6DKN%$A22DG8ELJ(!
MZ]!WU":BJ^)"HC+1CKS9:<F(*25`ENJJ%)\5*[=:^';7+Q=0.+'0TPE(2D("
M$D%*0`/**DCL/R:Y3J31<0_MS[<G:NE`VLD`BA!2E:0:"A&X*TDU'!D4%-<9
M3T=5L>B,?,/JA2&FVJ]"X[\MLW4H:`I_D^&GA5$#T<1\!WG/Y;61Y2]*B8ZE
M5&WT#TI-U=2JCD*QMJ2I+<=*AM=F$%".H1N4#3J*J\2<:^1858\0@8_;HENM
ML-J#$@M!F'&CBC$=OK7IU4X\Z?,MQ6Y;BNJC75IT&XMCGJ.;@:*2"1X4I2H(
M"2:G\^I!ID6H&*I24FHV]!0DT-.Y%/'[/RZ@[607&WT(111%#0]1O[T!\:5'
MYJ:'-#6N$VH>*>JJI%:BG@3T`34?GU)`7OL`)_=H(3Y:4Z]150'^Z0370``0
M&EN+<`!*U':`5(2@FE4`$*"0"J@'8:`$MP?0"U-`!*Z;O*>M`"$[0?TOR5_/
MH`-\OO<4XL!`J*4%"2*#H!\1X_R_'4J+>0/*H*":;1Y:*`Z$@*%*D=?O#MUU
M;I5,L2`ND04@K"14$UIVKV!Z[.E!KHYDDU1G;O\`2O0&_I_^VM`_1Q._#_\`
MSK*_R:OATHPRS&G^N5D$G%?I'^_;(8;#$F5:N!+]*98D[_0<6+G:$`.^FI"]
MH"Z]"#TTFJQ:XDP>F2EP/D1Y_P`E7[EV#;K9=[5;+4Q;)AN+9MBI:G)+A8<8
M"'2^LT"$N&G3QU@6!Z&>8"Q6S-P%ME25AL`%2E]A2A)H232@U!&F/!#UJS.3
M!8;:@H((0$H><"?25M`!/I@[E_G(U)(F;C<[M>%+-SGO/MJH4QPLICH_O?10
M$-*I\2*Z`('+:E:%(20`:T!)H/"M`GH:'0!,[86W%*\IJE!"C0T)%`=OV'0"
M,N^/.['"VV5)`.VE:T'7L/AH!N4/N0I$6(ZE9*)#S^U0*EE2AMZ$^`'4U/0:
M`6\&'<KF^ABWL/2I#ZZ,,,!2BYN"E)4*>78:`5[>8:`>.R<'7^0V9%_E0[&T
MH+*F%%<V>"!7:66E)8;W4Z`K)^(T!(W&^*./[!$CRA;3=YJ&D$R[TZ)82X45
M4MJ'1$-'7L%)70?;H`_GO-HRIU#"(S+(1`2VVTA#3:`8;(HEMM`2D53X#0"_
MM#J/4-03T/6@/04/Q^!T!&7DRQ7QW*9$V);WY,5=X:>]1@H<]-M:*'<VE16D
MC=UZ4T!TL_3N@+C>P3C%IIP!-VXXS*],M^CM<:GPN3\ND/D;U`N/%20M*J#:
ME03]NKK'7\"B_P!'Q+$+=DK>0X);WON+DVI$1]H'HE3(0T\1\%*=-?Y=:S(1
M@:AF)FD^`V7F43K<\]!)4$...L*2?1;)4$%P[JDDUH#IGF!S\`@3+C>+C:;L
MZXMN3'0I#+S9/IR&Z?M6*T5O"!MZ$I.ZO?4*,5DD!^K?Q6)Z&VX$=:VWE(94
M2$H4TX"5I60JAV$@`D5U('%Q_C//+`J+<(]N8O-MB2E.NKA!:;E&VT\AB+7M
MF-?`-T5T^[H"5%JP.Y<LXHE^SY+=<-OEL?>3B=[@6.08=ERIN,H,1KX^I2'W
M;+<WEI;DL)"D%*E*JE:`0!%N^\T7?*E3N+?<%B,J#F6*S/D'<JL+X8>M<AA8
M;].[L-MDWZS/)4'H[J%;PTM*R5!6I,+E*N;"_P#@?CW_`+JD?Y,^9_K$[_)7
M^%_Z-]GW=0::O_*<-F:<<72/>;TY%86^DW6XJ*4&BA_37ZD>!!&O./5TQX(9
MVY6^3;UJ1)96E8.VBT*&VO<5(H:4_/H315KXBC@.>DU#`)44MJK0D$?N^M/R
M:YFJQ?$47@*]A\.4*3TZ4.[[Q'<4^.LNFYP8H&*%I4.E`>IH/#K3[-0W).CK
M4@WI64FIJH4(I7_]NHU/B#S)>W,.@)IY#0U[4_,--3X@FGA[RAC6.TJD?@-M
M3N"B!41D=>W?2K)#Y]T)34JKX4W=ZT_+VTU2XD!#*N3;&]2UI"13:$D5KV/7
MQZZZ2FU55H2*/!\#R[DV9Z%F8^2M#3OISK],0M$!@?I-MI&U4Z6$@_LFRJA^
M\4CKJRW&6KYDZ"A/S">"^+L;M3,29CD')9SR`)]YOL1B=)DK3U(:;<0MBV,5
M^ZEBB_UE*U?1$A3?O:UPU?O47%MEVQB2KJE=CNCJ&4K6>A1;YZ9L90HJNT!(
M%-`,MD'LMDH"SB6>6N:-Q4F+D=M?@2">@2W\[;E3HZA3N2R@=]*(4&(R7@;E
M;"4ORIV)3)L)E*@[<,=<:O<7:"4AQ3=N+DU*/M6RD"O6FLTXS<FTG0B@_?!W
MM^EY-$A9AFS+L/'AL-ILSZ)$>??'(]`MV4DI2]"M`6:'].010;4]3U:C*OS5
MH*$\H<%J(&66_EFDMH0PREL);9C1VFPEMJ+';0D,--I%`FA%!J\D,%R?0H2I
M#BD$*4MHT#J0"*4(`!2#\3_/H#4B8FA/J)*>B]M/,BHJ.QKOI^;[-`;''`M@
MA`%5I*JU`))!(KT\=W\VI`5%!*:J#?4$`[@1TZ#P\H%370`!U@D+)7N0X$I!
M0H@@BM3X]2.^H`,9MS*4%;F_8L=2>J@=I37;7:=WQ%.GAJ0%2X**4.Y*B:[@
M$I)'P5TJ37[=`:S`;312G#MV@#:HDIH*$T"@`55\:Z`\&(`*(0E::BIW5W)H
M?#;TTJP`5Q=BJUV%P[0E2ZGK]U)16H!-:?DU.I\0!9#8"%4-2DUI3J.Z5$_#
MM_)J*L':_P#2X"4^P;VW!((2,3OE`>X_X\93WK36VUC;1ANX7'09#Z[T%RY_
M1_\`J`P&E!#DGV^Y`VA2A5(/XE:%=0/#IJ9O3%O@1!5DEQ/DEVO!UP=JEN>H
MZ%`54:HITZTIV'P^&L)O%;$Q]];B4*?;2DU`2E%1\22*#PU`#MK#DN@^I,^[
MT3^SKW[_``IJ0#6L+:5NW35JI3[K:!3OWWUT`):PN,$D.2GB:G]!H]*_[G0'
MO^#80K^T>/@3N":_F`H*_#0&(P>VN*VK"UC:112Z#M_>BN@$Q=^-,4CO094Z
MVL/*#KJDDK=2@%+9*4J+:P5^9-:*%-`)C&78S=W2_&CM1V&I3CK#;:$H0D7.
M>\\$"@%4,P&&D!/Z)5]F@'_?G[_55Y=J@X`2>R"5`BAK0:SW924J)^!`:JN(
M:@H2'.A:32II0!'AKJRVXNO$D(+A+].]ETU4HH@*WGJ3_1F^Q\335P'2LTM)
M6@ESH4*J*_8/[FH`U.5WN[Q)67LQK:[(EQVX3MA?V%+$J1?'$V>U1-ZJ(5,_
M%2H[/O%#9(%$G0HORE&*<73$Z:/9%8TV/VH>W;'Y3K:Q#X;O8D.L@CYMW\?N
M4N>ZML^1MN0N2I:CWH!J5)IUC@97*4E1ML=?%<I>MCB[3Z8E,K,ST8Z5D(9V
MNH6@LE:@'`XBM1XD#XZGN7.+.0/F,CY&[8UDJ4@MVZY,JD#T]B6PY0/-O)/4
M+#+A33L>VK+<YNXDVR235SL;5CEV3.H2UF/\Q$>4&TG8N%,:0[5Q*.[:$*Z#
MM7IK8"S/!L$M,V/!N<1*'H\VWPY\-QD-^D\WU4?NA235*P3U/70$GL>P6$Q&
M4F/':6RXI*W$J:V@J4D5&U(Z@$'[=`&MRBIMEV+4?THT>=&B-2T,I2SO2THI
M:=3L2E7JL[J`I\U%&IT!"KW3<$1KO<(G(MLA*CRHS#-CR5Q#*RU+L3JTL6NX
M2'D)\DJT.N%EQ77]DI)/;4F!YD9?]7F\_J'_`"7N[._U?X]NWV=M#K5+\CD"
MO%M"KU=5ELA`N5Q"CT)J9;M*$&E.O\^O-/?"*;A5AO;"FKE;V)*'*BBF@EWK
M4$H>0$NH41XI(.@&MO7`.[8[B]W>AE&[;$NS'S<5233RF:RIF0P$@4!4EWIW
M!T`V-XP?,L8"G+KCTL1VB-]QM*C=K?\`#U"N*@R6$T'7U6FP/CH`DC7%IY`=
M8>0XBFT[%))"@:'<030U'8]1JF=IRE6I%`U3-:(-*;ATVKZ?#KUIJJ=MQ5:B
MAX4^E3:TE0)57](=CX:K!,?$I[9QJPH]0@HM4)('Q`CM]J=P-`#IEPDR76[?
M;V'ILZ0M+,:-':6^^^ZYY4H:8:2IUU9/8)!.NX0<\@2(XU]M\B:6;YR(MQMM
M2DNLXTRZE*ME$+2+W+:6HMC<.K#)J:T4L4VZU1CICI))L6>R1;;&C0H42/!A
MLH#,5B,A+4>.PD#TDM1V]C;8`2:!(JJO770%0Q5M"4;"#MW$=2"230;.@0HT
MZ:`'?*.+!VI"R:[U`?830$]0`D4\-`"$0"HI*E[`:#91*@4FE:^((\/[>@!+
M45MAXN-HWN54D+/<?=.X`]4J*3X==`+1JWJ><BA:DE*F&>E2K=N2%)*`D%*4
MJ3X#X:`&S[`TRSZB4M%9-%%(3^[0-RE530J5N4!T^/70"1D04I-=ZR1UI3<$
MU5]T()*>@Z5T`!=BMI*P!YUE/FK0%2@#15>E0/AH`,HK31/78%#S4">B>E$A
M7@H=.G6F@"UU:FE'H:*)\*IH>I[]Z5T!Y"U%!W`)!KMIV^*54/8E)[>&@#H*
M]5E*0=O1-0:=QU_+H`KD>4@$T"5;"LCHKN?+2M21TT`#<?152=A()Z&M"JA\
MM!V`)[_$:`-QM^2;2VC:L`A:@-WWCU23W!37K\`=`$$A:4E:7`-YHG;TW#;Y
MA17C4?#XZ@`%;6\!(2*KZ5*J41UZ$'IT`_+KN$-;H#M6^E\G;["_;BG:$TQ6
M^>4"@'_'C*>PUMA'3%1,-WU&-/\`6Z07/I-^^]L=U<"W\#_^X6KXZB[Z;Y"U
MZBYGRC"PIHE#@J5+*4DI`K7H!T`IK";@7%CD.@[!4=1U':HW>/PT`>I2D=A2
MI%=0`Q"$I["E>^LG<GQ(J?M!IW)\14WMM=:J3Y2GIU^-*>->VG<GQ%3>$(!J
M$@'3N3X@`9;C]ZE8+.O=GPK),WEB^PK#;H.-R4L.VZ;.AO*%XGI3'DR'8+"U
M(;(2G9O4"LI2.NJW\T55^`K@1=R$73C^>QCEV+#%UM-R7'O"B-X1)B+2TMD$
M$AP!M`0:==P.NB0OE<S3$Y39[%#AH=@/NPF)KTEM2),AV>ZD?T8I\K;#"'`:
MT)5U!IH[2E'6S+>N2C.B>%!^9]Y(0EEE)71L)I]WKT%/-0=1KF,5%8%EB3E%
MZLZAK,D)<D1'2-G]$MJUCO0F#&434`UK4_'71<+NU2*.)"#N.U1I6E!M'7J1
MU)T`\G%^2X);#E47/K;;;BPI-MON.BX0_G?3R.QHGMVYV,'$K#=P;,\EM9.U
M(W>)T.91C+J52\KVGY&S$X&]L\J2CYJ*[B>36*X,;@DJBNW:8P[%5YNI3&=/
M8U[&NH.>U;X"AR-J/C%[6TF0[(B"YN-1)+M1(9CS6_6B[U)`1ZT=Y-">U!H.
MU;X#[PK9%R;'VDNI$M4F`MQ8W[4-K"D);#A5YDK(W>8CH3^35EKU$<7+<(P;
M2Q)C\;81)OG$T/'):S(?;@RH,&4\H!Y"(KCSL-IQ:5$^HT@I2%'J0D=];C(/
M1[5^88F*OM<=Y>VZAA,EUFRS5`N+@34K,>=9I2%K3M;<2`MM2:@+%"`"*@6K
M8K<(<UA;T-?]%2X&76W$!M3;@3N"7`2312%=#V.@#"_8G;[_`!"XQZ<>>GR(
M4LN%LA-"$N;55\I'E(IU[Z`2+MFF7"QW3&KVXU,:EP'XD@.56%1%I4R4-*.W
M]J-^X5%*I'6H&MRM6Z9'';AP1&#^!LW_`,8<_=?P3^Z_]R_^S';O_?=].U;X
M>/$ST7EU4^!PAW:,7+O<O6J@.7*X[4@)3]R6\:J`2._AUUX![BR,B1D[5@HH
M!^M6J@"4@IZD]?S:$AU'@MN)0K:E/Z/8U511`"SWV@:`,4VN.LJ*``I)`HGM
M4I!'7O0Z`0>3\.XAE&]ZYV=A%Q<!I=+<G\/NC95U)$N+Z1>2D]O4"Q\1H!D;
MU[;+TPER3BM^8N#22L"V9"TJ-,*A6@;NL!"F%=?\+''VJ&H:4E1Y`9>\XAE>
M*N+1DN-W2UH`61*+(EVRJ025)ND%3\+8D"OG6D_9KCM0X`ECP_@V6<B1+='Q
MN,&[;%A0T3+_`"BM-J@(4R@;/5%3+EA70,-5</<[4^;3M0X`L7X]XHQ;CYGU
M(48W:^K0%3LAFMH,IPFA4U#:!*;?"J!M0@[CUW*77748QCD!XHC("T@>EYBA
M2@4]2D@[DJ\OZ/3^4:Z`?I1YDA)'0;D$DDIV[34$GRJ2#X>&@#!L-)24@..`
M+WDUW*J!0;E)VE0'Y-`&\9+J74*]2C!2:H2GJIPT(JNFX`)[@$:@`\!3BZ;4
M^6JN@"4CJ*A6VA[ZD'XAH+6D`#S&OG!#9H0:K`!JE/Q[TT`XT5JLL*":H]%E
M**)H%+0E(4%E"MH0HUH*5(ZZ`.;O$=0RDTH"DE(6!O2"`GH4`!1(33L3TT`A
MW6@"X@I"6TKI45]3H#T%:>4JI_/J`$TU!4RA(#:0E6_<*J6M5*`DD&@/V?DU
M(",#U'%-JHM*":=-A"JT!)W>9*305Z:`+)":D)6VH;%#J:>8TZCI4D'0`%:#
M4-I)H$[E;CN34FH"33<4#=T-:$UT`.BI4$_M-CB`HE0`*UGH!Y4`'<G[>V@/
M$C<XZ$)4EE'J%8]524)*$=DU(-"033K6N@-CC#:BDMI2$D&JB!U57<BBDC=4
M].I^&@-X#@0IL!55-D**$I4DD]@=PHDD"A[G0!(Z@*=4@H"2LT"5`"@2*5!'
M0=NM.U>O?0&M#55'R+%*>4#J2H4K4]!T/;OJVSU_`AY':?\`3$24^P_VZ)*M
MU,5O@W&E3_QVRCKY:C^36Q&&YUL:SZUJ=WTIO?0D$"O!-^ZD5_Z?M?AKB[Z;
MY$VO47,^5A<(6T524U^]0)[GK\>Q.L)N"^*CH5$>:I2#]G2O3\N@#%*4)_>T
M2:]*DC^P=`;O6;_PB?Y1JKM0!O84VM(*R"2H@=?MZ=$_8-97F0"@ZV/*">E!
M]U5!U"14TI2OCH#4MQ86H`]`2.P\.GPT`\?$G*EDP2#D\+(5R6DEU-XMCK,=
M;HE*5%;8EPFRR2MN4"PDC=1*T*-*%/79;Z$2B#.9ROXORBYWV=&07;K>I=Q2
M@I20RJ7)6\$]`*E*%`FOC4:[`12K58_Q.)=9%N9<N-M`3"D+"CLI4H/I@AMS
M8M1V[@:'2KI3P.)6X3=99BA7=7%)0L]5E-:[?$=!T'30F,(P5(BU=FEST"3M
M/R%L[@=1\DTBHZ>&S0Z%G9W4E32PY7<VH*(4>J@`:4T`/>=)=\R_+MZ=2*]1
M3JFA(I\=`7\\#RFX/M9X#D1V_25$=BR55.]3B;FLQ7DMJ[-AY^+4BE:JU!5>
MDX0K'.H^W(,)-U@R7HX4`_'BR4`%16W)CJ6VM)76H*A04K3IH56KLY349/`,
MN'LM>0ZB/ZZO42MF"^PZO:C>H;N@`/0%/Y*ZLM>HBZ[Z;+I>)(#BL2MCZ$E=
M8[3U5)3U60I1`4/,003U[ZW&$:?F_C^3A-]AY?&9<7:;^EJ8^["J)%JNP1O,
MIKI4K6L55UZZ`D-P/[JPBX6G'\T:3MN*4VU%[:32,^MI*66'9K"RE34A*2D+
M->I/3QT!9G9)#4I`4P\A]M[TUH4A04E:5-A6]!\4*KT(Z$=NF@`5_;]&2U.8
M3N!"VI`2.C:0"0I?84*A35O>N<0)3YF/^N?O;_\`]Y_@_P#H?\VM&J7^6IE_
M\SYU]U:2N\71925!-RG)[>5/]*>2E1`Z#?7H?'7@GN'IMDBG0;@4TZ]`GH#]
MG;\^@#J/'3YAO(-1TI6A)/2N@#B(P0%!O;4#<L[:J4`>W?H-`&C"55W;54(.
MVH`IU^[YCWZ>'?0!O%M[:V_54VI+@]1(34[EGIM*E#J3N)T`;BV,K0EEUEAQ
MI5$K8<9;6A05T6%I6E054$@@]"-`.%C<9FU18\.VM1[="C-D-0XC;<6(WO\`
MO!J,RE#"5+<430)%3U[UT`Y=MN``2%T)``J:^I1L`)`W)-4@=3UK0Z`5<*4R
MZLK!\H(`K]U7F/2GWC0'Q`ZZ`/0L*0@!:?3W?M":`U)(2E"@"?"IKH`RBC]@
MM*5I3O<-5*[;00I*>]"4CM\3H`R92M03Z:ZDDAT)JD%-`0*)KU-.H_FT`:-#
M[]%.%*?,=Z0DI4I*@L)JD;@?MKJ"VU.,*U-K)]1YL`@AHIWIK0#=3RT'4IV@
M]^@[5T.)-.3:R'*AJV.H4T$E6U)32J4[M@JI%16@!(_+J3D,)9;<2&PI04E)
M4M5?4HL$[E*)2!5->H``Z:`1DQ1#SB`>X/;=YS0]$':#U`[=]`).:Z"W1*U`
M@HH14)H`:=!4FB>GCH`G;<**JJ@E3E-ZE!-0Z`0"WWWU-!TJ:==`!WB5J;^*
ME+J%?=JE7P[[5#\W?0'ZE*DMI31)*54\WF"1NW>1-`"`@]B.^@-ZTE)*=J4K
M4FA".CFT_>I3L4^/V:`!.E1(*@@"@H5$+"S7X*!!*@*CI_:T`*894=Q0I2E[
M%*#92-J4420E%1M02FH/\V@#%55(JG<'20%)4`$A8;\NW9W(!%36I(Z:`*7X
MN].ZB@NH'ZZ^I/D)/=-0:5\0/'0`5N(7*!(Z*6H`D]/@`30$=/R:`[0_IE(V
M>Q3V[(JD[<5O0\M-O^>F3]J$C6VUZ:,-WU&-1]:UQMGZ4OOH==4E#:.";\5K
M6K:E(_$+7U4JAH-3=]-\A:]1<SY55POMJ"5;ID<J37HVLKZ#J*4%*ZPFX2IR
M>$VE260ZZ0HD`)2"0>IJ%*!_.!H#6B]O2`-K)25?NZN`4[5W].O70!_;F'I*
MP)+ZFD?I*"54ZUH*U(!_LZ`4T=N#&/E6$I03O<?_`&*0`3516X4I`)U5V8>9
M%#S>LC@O-P[;;IL.2IU8,QV%(8?;;;:H$QE.LK6GUBH56GNGI73LQ\R0,7O)
MNW)4K[2"3UIX'X:=F'F`EN!+R7PKI^R6/+T[MT\:Z[24519`:!\;9C('^'1W
M^TD'^8:Z`6WCHMS;U`KM\:^/?QZZ`"L*<"`"":!)\P)/4==`.&^HI$0=*_AM
MOJ#W']'3H!46)\H>4T%I.U#2D!1!40M%5&E145\1H!1NK*E&M*)J`1\*T!)T
M!?!PK='?]5/BF/L9]%%BB);?JX%LRHLY]:`H`&M55.[P/E[ZAE%_H^),FQQ&
M[Y9P?6CM^K:XS3RB:H]0/DE0"^OJ&G;N=098R<):EF,5=&KIA&0(F1DA"%/[
M#T/HR*K_`&+E04A)H0._E)U;:]1'<KTY+2Z4+\O;1DEOR/BC%KTV^%1Y,=##
MBDC>6Y;2%,NLJVD@!$@%*B>PZ^.MQ62_R7"[?F&-JL<N,EP/P8S;*U%%&WRW
MO:511%`E74D=!4:`J^RS!)V)W^YXS>(KT9F7+6Y`?*2VN+,&YQF0PM-*B3Z8
M2*=*FN@).>U[W,7K$'4\?\A2I$JV1G$L66[37D*>M9]12$193M03#6*`5*E(
M412B>P%B=QSS'IUN=3\RN.]*050U/(4A`4NJ6G4/I6N*^UZAH5;MN@$;\Q>/
M\,G_`"3\U]QCO_A/O]O_`%GVZUU_[#+5_P"<^?U<"HW:ZC:DC\2GEPD`E7]*
M=V@@]#0CX:\-YGN`B,%+HI:$*0.@%$[B1TZ5^[^44&@#9A(W(404!0.Q-`3M
M"5A14=W2GAW.@#Z-%'D45$``D5H!U!`J2**Z'PT`:LL[DTHI022*A'6I)/W5
M%-!3QT`<16E;%;P4U(_+45KT(Z`=/C70!\Q0H25]#1(;I^EMH/-WZT!/AH!6
M0S5+;90DO*&Y(*B*`T'0A*AX>)T`H8A<2IM*T@)36E4^?K0*Z$FA^&@%-$=#
M7G*E.-DJJ5[RX`G[NXJI44%*?#0"IB3BD`H3N2HUH5!02B@H4I_2H0.A.@#9
MF91I(`4*D>H":!(37HFAK4U\/AH`RCO)2\%!2Z^D3T&TJ!*DUJLI":?"GY]`
M&0G-E392I)`JHHJ7.@30DC:`!0F@57KH`6S);6HJVN*2L(H-JCWZC>:=4BG8
M'^30"\C22=JP^05!!4E05120EJJ$T%0B@%3U`ZZ`'/W#82E3I`\Q;(()4D`@
M!"4@EQL5[]*_9H!*2IFX_M%'MOW=:)":(IT'<GI]IKH`CER$N(*>R?,2@J2@
MK(%`/,*I/4&G2HT`7J+0V4"4E(`<V$'RK`.^GWMM23U%`3H#RKJX"AQ);2`@
M*/F2%DU204CX5_-H#RW5M96D*65GS)H5%H$DDA"0%&O2I-#70&QYU!)<"5E)
M2$E-!Z@WBIW;2H5!/Y>V@`+RPLC9O2H`I!Z$J`V@(IX>953H#<T6VSN*U!9<
M)<"&RI0V`==A4/B-Q`(^.@#=HJ(\B$GHE80=P55!W)V*-`@C[1TT!K6"5>;8
MG>%)6&Z"@57S[0*E77O0?D/?4`V!"E;0A2MAZ@$*(JD!*CL34UIU)(%*'OJR
MW!3E1\"&=DWTT#7V,^WDT`KB][-!V%<UR8ZV16F-$8KOJ,</WM^V.'[SO:?S
MM[69^9S./(?.&!W#!I&;6^RQ\BFXVW/D17S<HUDE3[7'N3C1BT#2Y#0.[[W3
M22U1<3F,M,E+@<IG_P"C6P`FI^H)R#U-:#V^XL!^2G^DTZI^G\_R+OJ'P!#/
M^QN<=-&JO?YGSA^WV_8L/_O+.GTZXCZA\`6[_L=V%);2F![_`+,HZQ3SRO;I
MC4U/YFARK&1U^VNGTZXD?43X(U1O]CJQ5VHO/U'.5I#5>D6Q<!83C<8I(H4+
M4UGL^>I)^R0-.PN(^HEP0,__`$</#HH5>]?,YR@:^I?>#+/D2^G8[;SRG+8W
M#_<4'@`.FH[#_J_+^)/U#X'ZC_8[>.F90?8]^.:QFD*W-Q8OMYQ",PBJ0DA+
M;'(S;:11(IM2D#4_3KB/J'P#D?[(/@8%/]?+._\`R!XQ_P#])T^G\_R'U#X&
MEW_9`<"="P??IG@WI*33@/&.E4[?_&3I].N(^H?`2CG^QL<?./(>_P#2`9^"
ME87M_P!7W%B#0GI7_2;]NGTZXCZA\`+*_P!C/X]E$D_4#S]%13I[>\65_P#>
M<-/IUQ)^H?`_$_[&=QZD?_F!\@'H!_YO>+=@*?\`C.[Z?3KB1]0^`=N_['1@
M#A;/^OYGJ=D=AC_S?L7-?0;"`K_PF"FZG;PT^G7$?4/@#(?^QZ8##D)D)]_&
M>+(:0UM/`&+@$(!`-1R62":Z?3KB3]0^`;'_`&0C`B"/]?+.^M/_`*A,8^(/
M_C(^S3Z=<2/J'P)LX'_LZN)X1QO9..O];++;M$LL-4-J>[Q-8HJGDK"=ZS$;
MS1X-K*P5"CAH2>^GTZXG%R[W%2E![L0^AYC>*PDPG/<CDUU"8C$4K=XXL\<$
MLJJ'O3&4OH"E)Z'O^74?3KB5!1D_T),1R)9<3[C\D@$E54CC2RRD$*'6J',J
M;%?R4UU&PHRU5!)3VU_2ZC>WABX6E?.MSS[&+DV'7,>N_'EKMC$.ZM_LV[I;
M9,;)9:XJG8U&WVBE;;I2E8V*%3>"5/\`JI04N!36<W%#2"?1CFRQ5H901^[0
M1.0=E>N@&[Y-]A.+<F0D,S<XGVR>SM]"Z1L=A/OM%%*>1=Q;W4IXJU.!&(P*
M_I.61U]3[W.-Y=*RE2P<"M@WJ2:[E'^(S4U`_.-02/WC7L9<QR&S`1S%>9L5
M#"&G8TG$X"HSJT`I]5#+EX>]"J#3:"1XZ`47^I=:O^[V=^X]'_-Z/][X_P"5
MOW'_`#K[FK>[Y>%"OMKC_-4^;1<T;+I<A7JNYSQU('7YMX)3W(Z"FO)/3C<A
M)T3Q-["/,$DJ"@1_N2?TQ4`@DT%!V'?0[#QAMM9;ZE:FU[B:*VI"@0$K-.H!
M[Z`/8_1='!NHD4"`@;4CJ2"2-PZ]_'0!RS1:@:;FU5-5%/W>E">A%130!U'`
M)`W%0V`;CUW`]T]>Q(`/Q`T`;12TXI5"*)^/:O8`K1Z@"4D_83X:`5<9I`2R
M5IWIVU2NJD@D@4;VT40$$_I&AT`H&%+0E!3MZBB:56I(2*K!W%1K0CJ.V@#E
MF2DJKL-=HVI338M01V`-?TJC\V@#%M])"-J25I0LN*WD[0:;4]3W2KO7\V@#
M&'+4#M72A4A24J5Y5$A2>E`5&OYOB-`',275*?VQ318;42WY_.JB!ZGE0NI/
M3IJ`&!D4*-I'5%/.*)-#106$$+"3MZ4/6IU(!T62M*:AQ)0A36X!12$]0D)2
M1X5_D%=`*6+<E!2#3S4(IN!W)4>H2*[P%$UZ]*?#0&Z1='0#0%Q6T-^FI3=:
M=QL&XE*TJ%:JK4>&@"*5,4X0%`#>H*V5<7T4D]%"B%>6E`H&@.@"Q<APO*6X
ME!1N*ROR+"F]@%6SY@%$BE#6A[Z`]"42HEI"D#8#NZ(%*T2YT30&E0?#PT!Z
M<>51)*@DA"4$4"BL`&@H`*?>\/#0'A+JP"M>\A/10%-X*QL'IK\`F@/FKUT!
MY+RPJCZP5EPI.TD$([^<H%-R"0.]*>.@/QY2=_IK]0(4M!!;Z)VDT5M-%%06
MH`]">^@/+1<!75Q!])8'JK4BJ5%(*E[01M10BA/WJ:`.([SYHBHZ#8ISN5K4
MXDFFXA52CX=!H`<DE13M\P=_2*0H-J'E;*MHW^G4$JJ?S:UVU%P3HCEADU5P
MU4WL40"4M]*=1U(4!N"J5HGIV_+JQ)+)'+DHJLG@=C?TU_\`S'O;YY_4_P"+
M%Z\YI57_`!SR7KTZ:Z,EQIS;61./0X,T!F@,T!F@,T!F@,T!F@,T!F@,T!F@
M,T!F@,T!F@,T!F@,T!F@,T!F@,T!\I6YJ*+K<QL"U_B4T)VJ"J;I;M5]C^B/
MRT.L<K.B.JIJMVM,M50:P%+!7N*DI;2`GJ1YB**%?@/LU4:`V84H)10D)5L0
ML]ATKY5)`*NI%`:==`&*$^HH)*J)/WJA1J10@)3MW*3TZ=*5T`;I3Z:$J%*A
M.U2TT":=ZBE!2BJ=>M1H`ZC.I0E)7\2@!">E32@%*`]_Y=`'$9?H[$I3M("T
MDIIT)`/2H()J0?RBF@%-&>=#:?*6VB0LH4M0]0I%%+*5;E%-3TH!_)H`W97V
M]-PE2G#1!`Z!6U-`K=1844T\!TT`;,GS.()1Y%G:%#<4]]PJ:4)*J`?SZ`-(
MSB&0-X4`M2FE[4CTZ[=P).ZI(!\!0:`$H=/JI4HA*@4J'592LU*3N6BG50[`
M5(Z=-`#FWDI-%`]DD**E*;/4]]X*?B3TW$`4T`8-OO)J$;0A:E*2.Z14^9>Y
M14K:JOY!H`QCR>A;6M)JD!*$*2D=``O<H4*AM((%1TZ>.@#EF8I&_P#<@;=G
M1225A0!\U:K2%#KWT!I-Q"2HKZ```+24FH54`4*2`$JH2>^@``D)2:U+CWE(
M_:[2`4G=0;2$FJB3\.^@/:"T=Y<*?,=S:4+<*D^5&[<-M"DK)/0$CKX:`_!-
M"DJ"2SM3Y"4CSU%%;#4@)VE9/:M*5ZZ`V?.>LE+BRGU7%`>D"*A9/F/B=P0-
MWV_GT!Z6^D$H25*"MCC>Y?F(0KJI:>OD/@>Q_-H#]4[N4-QJ$IIN`*>A(*MW
M7S]J?"OQ&@/#KOG2-RBH`[PE74I51&P%-4`4H>@':F@!:'60I"?(EPH-*!1J
MUX&NS915:'[1_*`+04E:*[$I*TJ*T@E2B1V(*J*)'8#X:LMPUUQH0W0,&'*+
M2VH520D.*0M8"4J25*6:5HLDGJ$D`?:=:HQTQTD"@MK+DX-%3:@@(6/4#CA6
MVBI\[@*S0T-2*]$T.ND4WNCXG9%].!OT?9)[?VQ6B<7N]"H)!*59?D:DDA)*
M:J2:_;J3*3<T!F@,T!F@,T!F@,T!F@,T!F@,T!F@,T!F@,T!F@,T!F@,T!F@
M,T!F@,T!F@/E,S]GXK<UN#</Q*>"":$),IU/>O0U/?7,E%JDLBQ7+G@P4PD!
M*5>92C7=0=-O0I"4BE::RW8Q36C(T6IMIZWB'3;J-@2T"$O"J20`2$D@K\U=
MI0KXZJ+@R;6A:=J%*W@E**[3M-$J)"DBI!W?;H`TC`NE)%%DJ55:B4)]5*4B
MFQ0`)'4=4T([:@!FR^"E85M"E!0IV6-I!"J?=`'?XG4@,HVY052B@@4!"$I'
M[,5*JBN[RIT`H(SR5>1:P@[$CUG"E*0D`T(*ONUK4"G70!HTXA"@4I4A2BW4
ME223M'E/3ITW?FT`;1I'I@+4NBW5;D@D$N=BI*O&BOLZZ`,R^D+W%0"-O1(3
M4^:FXN*!H%)IY:>'?0`YEY9"A1:VP4%*5G:$&A.X;4@E*5(HFA`IH`29"'"E
M&UQ*04U`'E#B:J!+E1]T=3WJ-`"FY(2AL$MAQ*:']J?VH)VA(!4*."@-36J?
MS#0`V.ZA16ILJ2I03N2I)56AW=`%>0))/Y>F@#(3=BD^I^ZV!3BB-I]0"B*`
M*(4`GJ0D?"O?0'E:TIW**B5+*`@D$`%%224]$)Z'X>:HKH#TV^E.Y8:<.X[P
MMQ"?U:.@;.H0@TI]F@,=?W*W$I<45;*MUVE"D*#2B?NH)I0?'QT`%;<9:\BR
M=Y*06R5UZ*)<2G8E9425?S4_(!^N2?,]L])*"I1V;ED4;5L*'%[4N-E70BG6
MF@!8D`NG>OS)0.K)((]3;Y>M`1TZ#H>F@/)?0R*!ST]A.\A'WU5`)Z4J$A0Z
M]NO34`TAWTE54L'IZ@VD*V44`4[>H2:'K^6M-2`87FGRD[O5.WTT*'EJD=0D
MG<0JA-/R>&@!C+B6^AVI+;E$@'U%A)7L3Y:%*0GH*CJ2>VK['B0PVA2V`I&]
M;B4T2"H>9)*B4J2V`0L`U\2.WY]:3D6MLDLL-/%2*!H@57T;6RM24`IV+4"M
MQ!(K]ZNB*KR;CAQ.R+Z<4AN5[)N`)#0(;<QB\%`(`(`S#(T]0"0.WQU)E)MZ
M`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0'R
MDI_^6KI7TZ_/SZ^KW_KCU/N^7\E/SZJO>FRVSZB!:/O-_O.Z:>EV\.U>G?X]
M-<[?I?,ZW'4N0;,[MC?[W[YK3TZ5_O*?HU[TZ:SSZWS9HM^FN08([)[_`'$=
MZ;>XKZE.GJ?#^;7)V';7Z/[VGK)_+78>WZ5?R]-`&/\`A.WWG-WP_G\?UMOC
MH`S;IZ":>I^[Z4W[:T_0W=?]S7IH`W:[IK\.G^&[==^W]+\OVZ`/6=^YNGK_
M`+IRFST/3^XW6F[^WX]O'0!K$K1%._I]=M/4[>&[R_R>&@!I_JK%:?U=7WZT
M^^BOI[.M/C7Q[:`,45VN_P!;KL1]_;LIZ(I7]'_<^/Q\-`>D5\M?5K5/ZNVE
M4=MODW_#QU`!K?[M%/\`"*IV]']XBN^OZ-?O5_2I3I74@&#]\O=O_?)^Y7=^
M\3V]/IOKV^W[-`#7ZT37?]]W[^VOW?-3;X?'PK]W4`]?[XJE:>F*[_OUVBF_
M=YO]Q3I74@U)IZJMOS%=P_=U^8^YU_>^6OP^SMH#\9KYN]*MUV[?3^\>]?-3
MX4T!ND_NS^_V[33U_P!W7:*?\\_YKI6M=`:H]>M/4IT[4]2NWQW>;TOYJ4T!
MX'[IRNZGS)KZ?QZ_OJ==U/NTZ=_'0'L[O1<K^L/N^E3]&O;Q^'][2F@/!I4_
M<IO<^[OI7R]OTM_\V@!K7Z-/F*5/[C[OWT=Z^;?^M7QT`(9^^JOS7WU_OJ>C
MMW']7KZM>_Z5?S:OL>)##J%^[_WG;Z/7;7TOWJ*;:_M/3^%/TN^M)R'J=U.G
MS-=[_P"]]+;M_1W;_)O_`%?TZTKJ"4=G_P!-"O\`J+^W>O?^%+O^K_W8Y)^K
MY==&*YULG3H<&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`S0&:`
*S0&:`S0&:`__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>logo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo2.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,P$@`P$1``(1`0,1`?_$`.@```("`@,!`0$`````
M``````D*``@'"P$"!08#!`$``@("`P$`````````````!P@`"04&`0(#!!``
M``4"!`(&!`<)#`,1`````0(#!`4&!P`1$@@3"2$Q%!46%T%1(AAA<8$R(QD*
ML<%"4C,D-"5W\)&A0[0UM28V-S@YX=.V\9+"4[/#15659B='2"EY&CH1``$"
M!`,$!0<##P@)`P4```$"`P`1!`4A$@8Q01,'46$B%!5Q@9&A,D((4C,6\+'!
MT6)R@I*RPB-#-'07\5-CLS5U-C>BTG.#)$14)1BC9':D548G./_:``P#`0`"
M$0,1`#\`:#J:VO.>6J.>7I/<7L[94PO+R"M/,Y6WE7+232%4=*&C6S]5.`43
M6>H-!*50Q3"!C@(@.">Q7\J@R@/T-R+H`G)Q$B98RQA>ZRS_`!#]\<707.R]
MR43E"FES`),I]DXRE,SA?2YG/!YD=KK@UY;J:J6TKZ1H"MJMH-_*1UM6Y8>3
MDJ,G7D!*.XM5V9!95JHZ9B8@&*50I#%UE*(Y8/\`:N2O+VZT#-R;%2AIYM+@
M07.T$J$Q.71/&%1NGQ+<V[5<7K=4/4?$8<6THI9!25(44D@DSVC#9ANB_7+7
MYZ\[=6YZ=F]Y+BEX9W6DBU:6ZN9"1C:FX!A++AP4Z8JYOV@R#8DJX$H-'I<B
M%5'AJY`8IL:+S"Y'HM5N-VTF''&V4DN-*)4HI'O(PQD-J?1!4Y0?$_5W>])L
M7,/@I%0H)9J$)"$H6<`EP3]E1D`O<=N$-!D.4Y0.00,0P`8IBB`E,4P`8IB&
M`1`Q3`.8"&%L((,C@KHZ/+#MH4E:<R<4G?N,\9CJCL/^[CK.7DCL<8HANKI'
MF$5#5=.N=GUU[`T#2#>`71J:,NY2T[.2S^HA>B=N[CG<3%2*;>/*PR(8IA`V
MOIR'&YZ:J=#T],Y]*::K?J2KL*:6$@#K!(@5Z[HN:E57-'0-9;Z>@2R0XFH0
MI2BY/`@I!D)0#NZ>\OG8VKW645L_D#V1J&YUQ&J$G1$K3U%,S4?4,$H9X5U/
MIR<@5FX8QT3W<OVOCI)J(\,0$N8AF:;1H_D_=-,O:L4NK:MC'96DK[87A@!C
M,F8E+;"R7WF+\1EDUHQH5\T2[Y4A)9X;22VXE4Y*S'8D959B0)2,X/7M)IK>
MW`156#O-N)9JO)=\I"*T6E:&GY2#1@D2H/._FTTM)L&`2*JRYT."9,HE*!#^
ML,P9J>HTBZ^A.EF:EE@$SXR@HJZ"`)RAI]`T7,FFIG_X@U5%452LI:%.DIR?
M*"E$`'JD.F+65+4].T9!2=3U7-1M/4]#-5'LI,R[M%E'L6R09G5<.%S$(0/0
M`=9A$``!$0#&K$@8F"3`FKH<YO;G1LH[B*%IBMKHJ-3G3&7C21\!3RIR&T_F
M[V66%^Y2,/S3D:B00Z<\=<Z8DHQ9"\\>W2SLI*AL36\<R,8`,YB*F@99PF41
M`!/V5VC$)GT@.>0*`(XF=,2"4;=]Z.W_`'.)&0MK6"85&@AVEY1E0)!#U2V2
M#+B*$CEU#`^13$?:.W.J4`Z1R#IQR%`X1(M;CM$B8D2)B1(F)$B8D2)B1(F)
M$B8D2)B1(F)$C%=ZV-X)&V%6,[!S=%TY=Q9FW"C)FX;"1DZ-9/BOFIW)YUC$
MD4D7#52.*L0H)!J!0Q1Z@'&0M2[:W7MJNZ''+<#VTMD!9$O=)PG.48/4C=^=
MLSR-,N,,WLI'"6\DJ;!F)Y@,2)3@!F_3<+S>-D]EV]XZVO'M2?0;RKHBC$V5
MNK=5&YFTGTX@_7;/,JR8C'"V2!@<#>T)LQ#(HX.&A]/\LM:WDV>CIJ]NI#2G
M)NN)RR20".R9SQ'VX5+F?JSGSRYTZB]W"NM"Z5Q_A?H&E9P5)4H*[8RR[)'H
MC`?**YF>\G=9O1B;97ON:SJ6B'=NZYG%H-E2-,0*!I.&2CCQ[@JL/&M'!."9
M<WLZM)L^D,;#S7Y;Z4TMI#Q.SLE%8'VTYBHF8.:>TGHC5N0/.'7VM.8:;/J&
MN+]N52N*R%*$C,,LB,H!W],-AX5Z'RB8D2)B1(F)$B8D2)B1(F)$B8D2)B1(
MF)$B8D2.,ON_N_?Q#T1QMA9&P>PRV._';COBH>J4FL%7\'O]W/O[9W'28D6E
M*5G`J(HI-7!BBFL^IN24-H>-1.`&*.LN1RE'#%7G6]QT5J.T5C"E+H3:*8.M
M3P*2,2.A0W'S'"$ETERLM',S16H:*H2AJ]HU#6&G?EVDJ!P23A-"MBANVB%:
M;_6%N=MGNO4]GKMT\YIRLJ2D%$50$#BQE&>O5'U!`O@`$WT/)(@55!=,1#IR
M'(Q1`&CL-^MVI[4S<[<L+I7$SZT]*5#<1T&$JU/IB\Z,O;]CO+:F:]A4CT$;
ME)/O`C$'[,X9GY,W-W&8+3&T7=%4H=[D*V@[,W3G'@B:633*=-E0M7/G'05^
MBD0B4:]4/],4"HG]H"&,MO-_E.:?BZKTXB=.25O-)&SI6D#SYA+K$.1\///X
MDL:$UF[A((IJE9V'8EIPG=L"%$_<G<8:=#U"/3EZ,+'A.4/.-DCMCC2`?O?N
M''(`&`$<2EO.R`_7\02/SD-BBADR"H&W;<![8E`3?1).#)](AG[`J&R]6H?7
M@L6,G^$]Y'N]^8P\N6%VU4@?^1.FB,%>$56/D*R/KGTP8+(,";*,)[MD,7OG
M`[N:#9R=O!M.K$M-N9'OB@7#:ODXADNJ5"?CX0J@RT<\;)F`CL4HU51PD!P$
M`41#HS'/'56*22,?JQCHHD)F#C]6$)_Y@(`(`&7HZ,ON].>/(X&4>DP<1LB8
MD2+8[';<5?=#=+:.GJ)DY.`D&51M:EE*@AUE&SR&IRG5T9&;<`LF)=)'#5+@
M"4PZ3BJ`"`YY8DR5I2$F1G,_6C@J"3B)B7HV0Z]JT@.H0RZ1U#D4`#T9CT8^
M@`G#?'0JR@E1&7;/8`.N.G&3$,^*F`9=>LG7_OL=LB]F4S\D>/>J<C-Q$99?
M*'VXY!9(>I5,?B.0?^%B9%C`I/H,<BJIE>RZV3U*'VX[@8!#,IBB`^D!`0'X
M`R''4@C#WH]4K2H!22"GI$=15('08Y2CZC&`H_'D(AB95^Z"8Z&H93@M24JZ
M"0#Z#''&2S`.*F(CZ-9<Q^3/';(OH/HCCO-.3E#B"KHS#[<=\\>>8@3(.V/:
M8.\1C:X-Y+46G:=ON9<>BJ$:9:BJU34D5#:PR$1$B;URDJ<,@]!1ZL9*AM%T
MNB\EOIWG5?<I)G&"O&J-.Z?;+E[K::F2/YQQ(]6WU1@2(YA&R"?DBP\1NGLD
M]DSFT$:IUW#%.8^8%R`57"9!Z1]>,VK0VL$-\9=NJ@WTY#&IL\X>6-2]W=F]
MT!>.[/+ZX$6OAIZ&J*/;RU/RL;.13LH':R<0^;2+!P0P`(&1=,U%D3AD/H-C
M67V7J59:J4J0Z-H4"#Z#&_TE=2US8?HW$.TZA@I"@I)\X)CUNOXL>.,^J/JE
M/;`&?M$H`&PV&Z/_`#TH#^CZEP</A_E].%9L?^#<&/WR(5KXM@!RW8E@/$4?
MU3L`M^S_`&7UA\!T!_=+<W^310_=P;N?@'T#F!*56V/RH6;X51_^U6Y_]$]^
M9#W.$BBS^.N?3]_KQ(ZS,Y2PCXNM[D4!;.)4G;AUI2]$PR8")I*IYN/A6N0=
M8%5?KH`H(>HN8X^RCMU?<70U0-./.="$E7UHQ5VOUFL+!J;Q5,4S'2XL('K,
MS%07/-"Y?;1X=BONSLV"J2ID55"5,FLU25*.DR:CQ)$[0A@'UGQLZ>7>MUHX
M@MU1EZP`3Y`3.-"5SMY5H64JO5'(;2%$IGY0F46<ME?6S5YF(25J+GT/<)D)
M"GXM)U'&3!BD,4#E,H@T<J.$RZ!SS,0,8"XV2[VE?#N=,\PK[M)'KV1N%CU?
MIG4K?%L%=35;9_FUA6Z>S;LZL(RN&,7Y(V3J.V(/5T=>),#;'!G+#;'C3M10
M5,,%9:I9N)I^*;E$R\C-2+2,8I`4NH=;IZJBB7(H#Z<>K--45*PW3)4MSH2D
MJ/JCY*NOI+>UWBO=;9IP,5+4$B?E)$5^-O1VDD?C%FW(68*_*<4Q;#<*F]8'
M`<A*)NWZ`'/X<9WZ(ZH+7&%!4\,B<\A^U.-15S.Y>I>-.J\4`>!D1Q4_7V1G
MRG:JIFKXY*7I2H82I8I<`,E(P,HREF1P,&8:7+%9=(1$/AQA*BEJJ1?"JFUM
MN="@0?6!&V45RH+DR*BW/-/L$3FA04/48]T39"`#ZA'/,/1\&>/GQP(.$X^L
MKDK*<,)[8Y#[^.3'80(+E!9^%-Z_3G_[@6Y?+X/ZSI=6"CS4$JRU!.'_`&BF
MG^*87OX>@?"K[/9](:N7XT90YE'+GH#?K:I9EPV%-7LI!B\<6ON"*)2G0=B4
M%C4Q42B9!6>4Q+JD`JA1U&;'-Q4^D!`WQ\N>8%PT)=`M)4Y9G2`\UM$OEI'R
MD^O9&;YS<H;9S.L9#24,ZF822P]*4R/U2R-J%;)GV3B(0-NU::Y%@;E5+:ZY
MM/R5&W`H>5,QDH];B(J(.6YP5:2D4])H*[CGA-*[5TB.A1,Q3%$!P]EHN=KU
M%:T5]N<2[0/(F-XF=H4/408JROEDN^EKP[:+NTNGN5.X0I*L""-A!W@[01MA
MK_DW\WE"YK6G=J>YZI$T;D,D&\1:JY4PXT)U\T2+PVM+5(^6.!$ZN:I`4C98
MXAV\@9"/%#VU8YN\J%6MQS4^G&YV]1)=;3[AVE21\CI&[=A#R_#SS\3<FVM#
M:T>E<!V::H6?G.AIQ1/M#W%':,"9PS!GA=)B<M\.EN@0=^O\X[8J'JV[;A/^
M15P6+'_E1>?WZG^Q"[ZI_P#Z)TT.BT5?Y\%\SZOAP*!C##DR('3`9R<U^@*F
MYE#;8O'L(A];M>(G:$F:W<B*H2]Y0;%>EI=D`G[*:#19I+QRAC%$5WYA*'L@
M`B6E<K:UKETK6;Q4*K.%!OH9V9E=9P4.J%S1SZM[_.%OE[2A"K3VF5/;S5;0
M$[L@Q02=JH!IO7L,ZVY[CKA6_!LHE3[B14JFBUA#-)>DZ@65>QJ9%`#2<\>H
M*C8X=93)=.`Z04X'8!.<,;/MA.XC;N$51Q-TXYVP>3EQPE.[5=JU_-]URTDF
MC="EYIO2`.0`B[J"ILAU!0:@H4#<:JJL(BU2TC[0)8S>GK/4WZ[T]GI9EVH=
M2G#<)]H^83/FC6=9:DH](Z9K-25ADU24ZUR^4J783YU2'GBTNQG=S1_-DVD7
M"H>O'<I0=R6C7PA=Z,M[./J7F(]I+N5G<#5%&S+97O*.:RC1B*8J$$3(N$E"
M".0AF0-9Z3K>6&I6*MC*[1D9F5+&83`DI*QLF)X=1@.\M-?4'/70U9:KJI5-
M>4#AU`944$(4HEMQL[9$"1Z""-\`-YO>S>Y^Q*IJ!JRSUY+_`$E8VO61H4'=
M1W<K>:DZ=KV-*HX=QLA(EE4,VDU'9+M!,4,C)J$`1R#!UY4ZLM>LV'Z6[4E,
MF\,R/92`%-D@`@&>PX*],*QS]Y?7CEI<*>NLE96N::J4A(*G"2AU/M)41(8C
MM)PV3Z(^&Y2=*6RW?7?JJQFXV]&Y.,K"3@O$-K)"E[[5O3S.5/#]-1TZ[1&3
M<%<278U"NFXAD)DTE2]8``_?S9>KM)V]JZ6&EHUTJ%`.A30)`/LJPEA/`GK$
M8SD-1V;7>H7=.:MKJ]-4XWFIRV]E!4DS4DSGB4XI'48<^VZ6"I7;3:Z*M/1M
M05U4T%%/I61;RUQJJD:SJA566<B[<)NIV4.=VNW24-DD01R3+T!A/[[>G]0W
M)5UJT-M/J`&5"<J<,-D6,:2TM0Z-LR;%;7'W:<+6L*>7Q%349G'##H`P$4[W
MN\NFW6YYY4UUYB]]\;25A%T$I&Q\I15SIRG*&ADJ?0?/T)>6I=JY;QK@I#*&
M%VJ)B'.D7YP"4!QMVC->5^G4-6AJDIJFE4^"H+1-Q68@2"MOD@<\SN4MLUAW
MG4+UQK*2O;I2$E"Y,IX:29E/0?>((],!2Y3'+AN=N.ITFY&_E_[],+?,JM`E
MIZ?IVY]8,#5XG2LT<CRJI5R\DEU/#+I^P!)LB0N3H@*"8VG(!,7-+F#:]/O>
M`6*CI#6*9'&6I`.3./8`^4)XG="Y<AN4MYU@Q]+=17"M:MB'O^'0A9"GB@XK
MF=B`1(2]K'&47+YO_-T?[6WCK;;MT=LUKWNHM%:NZV<)$>M+91<FS*M'M(Q(
M3&0=UH_;*@J'$`2,DS%.8!.8H!J7*;E4C4X3J#4,T64+["!M<(.)/0@'#K\D
M$'G]SY7HU:]&:14#J$H"7GL#P0H"24[BX09D^Y/ICS>67RN8:O:(@=W6^Q.8
MOI>2Z;5&K*9IFY\B^J*(H^FY/2^AGDE$R*AT'502;<X+BD<H-V:2A4RIZM0X
MYYC\QWJ.M7IC1F2CME,HH4ML!)61@0"-P.\8DQX<E^2-+=[:UKOF0%7"Z5J`
MXTT\5*"$JQ2MR9FI2AB$G!(PE!AJ[V0[1;DTP\I"K-N-G'4*];F;G+'T!34&
M_0`2&(11E*0T<QD&BR.K,AB*!D8`'IP)J'6&I[=5BJI:ZI#H,\5J4#U$*)&,
M,+=.6&@;S0&W5UJHN[E$@4-(0M/04J2`H$;C,PI5N2<;C.2-O#:Q-A+AU#*6
M-K9F2MZ,HBKY-[+TK/4P9Z+.=I.;CU5>SI2L$\`4B/FQ4G`IJ(J&$1S`6ITV
MC3_.322G;W3MIO+*LBW4`!252FE0(QDKH/6(0S5Z]8?#AKT4VG:QY=@>2'6D
M.$J0XV204+3L*DD$%0QV&<-M[/=U%OMY-B:.OE;Q0R#.>;*,ZA@7"A32-)U7
M'B5&;IV2`O\`',W/M)G^:L@<B@=!LL*QJW2];I&_/6:NQ+9FA0V+0<0H>;;U
MS$/MR\UQ;.8.F:?4=MD%.)DZB<RVX/:0?/B#O!!@7?VB7_`=#?MTH#^CJEP2
M^0'^.%?NCGY2("GQ;_Y;L?WBC^J=@%GV?W_,0@?V2W-_DL5@W\_/\!']\;_.
MA9OA4_S5;_<GOS(>YPD,6?0%_FR<TZ.V,4W'VXMBA%5)N+KB.._B&<B7M4-0
M-/F/P`JBHFR:A#.';DP&!@S,(`L8ACG^C+[1?Y6<L%ZXJ55EP46K(PK&6UP[
MTI.X#WCZ,86[GQSP1RUITV2QI2YJBI;S3.*6$[`M0WJ5CE3LPF8&WRQ=B56<
MP=1UO8W\U?5MWZ7D)I^RMC;^J)J0[CJ!>*=F0DZAD8DATV;6F6KPAVS-FV(D
MFN9(QSB8I2@._P#,C6='H0_0_1++5-4!`+SJ4C,F>P)/RI8DG$3$!_DKRQK>
M:N;F#S+J'ZVA+RDLM+4?TBD^T5=#8/9"4R!(,,K1VVK;Q%0J=.1UBK0M8%)$
MK<D2G;JD19&1*0$P*JB>(."PZ0Z3'U&'K$<\+P[J&_//&I=K*E503/-Q%S^O
M#C,Z&T<Q2"A:M="*("63@MD>>:2?29P`[FK<M*'LI1<KO:V/=[V.N+:XY:AN
M!35M9![3T5-4WVD@R%2Q,?'JII,Y*#$X+.6Y2BU<M`/J3S(&9RY9\PE7JL3H
M_6016453V6UN`%252P2HG:D[CM!A6>>7)QG2UM7S$Y=J<M]=1D*>;9)2G(58
MN-RQ3E)[2=A3/",E\H#F[OMTKMMMRW%/(]"^+.,4<4163=(C%G="-C6PJOFC
M]`HE;M:R9-TQ5,5,`3>I`8Y0`Y3`./YL\J6M,$WZP!1M!,G$;>&3[P/R#U[/
M)&:Y`<_:C63XT?JV0OJ4?H7L!Q\HQ2L3^<EB"/:QWP9G=#?NG-L&W^Z=^JI0
M.\B;;4J\G`CDS`166DSG180<.D<1#0>5FGC=OJ_!XF?HP(M-6-_4E]IK)3'*
MY4.A)5\E.U2O,)F&+UQJJET7I2MU-5)SHI62I*-F=9P0G\)1`@&G+XL(KS1:
M>G=Z6]^K)JZ,9)U]4-/VPL(TGY*,M/0<;3SA--8[VFXYT@C*/U#+@DGVC,_"
M)Q#"85.@QZ[NZ>6U2G2.D6D,/I:2IVI*07G"KH)V=.'DA9.4NDU\Z:9_F!S&
MJ':VE55K33T?$(8:",#F;&[$!(W@`F##I[`-DR,5W*3:W90(WA\/@#0D*<^G
M+++M)VXNQ'X>)G@4?3;5G%XYN%3Q>G.?Y(/R>4'+)+'=A9*#@]&3[,Y^N*EW
M6Y5M*4R5_</8O<*L=I5YF*:CV(:TE4,LO:2IG21-9(BKZ`?.'D29F],0J9G*
M28*I%Z@$,PQM%LYDU%0L46LF&KE;%]E16D<9`^4A8D9CHWQHFH.1E)1!=YY9
M5E19;\CM(2A9[NLC8A;9G('83CUP-3E?WPW=7/YJ=Z:?W;U).!<&C+15!2\Q
M1"*SB+HJ$7@YB`1:N8*F6JQ84$7Z*G:4WA4Q.X(OK`V1L@)/,BRZ6MO+&BJM
M,-)%(]4(6%X%9!"\%*VSW$;I2@.<DM3:YO/.NNI-;ONJN;5&\VMO%+:2V4`9
M6QV0)8@@8@SWPTZ'W\+,8>80(+E!?V4WK_\`R`[E_P#:=+!3YI_MEK_N>F_)
M,+Y\/1_[5??_`)%5_E07PW5EUY^K^'IP+")X;(8)1W2G`H.:)RS**WV6X4GJ
M<0C:9W$43&.#T%6!TP11GVZ8`L:BJK53#4XBGXD$K=8VH[-8P&#V!,42ARSY
MB5FB;B&7RIRPNJ`<;^3NSHZQO&\=<`;G=R9MW,JT*KJ%*&=5TZ"6W-G%`V-.
M$;9RDE6)23T0A96M$5Y9ZO9NB:WA9JA;@T--G92L4\!6/F(*9C5@.F=%9(P&
M(<BA"JH+I'$IPTG(80$!P\U%7T%^MR:RB6AVW/([)$B"#M!'J,XJ[N-ONFG[
MDN@KVW*>YTZY*2J:5H4/K$;B#T$'9#AO)UYMR&X&,A=LNXV?1;7PAF2;.A*W
MDUDFR-UXQL`)I1CU32FBG7,>@``8.CO!,NLH<4#`92.;?*M=C=5J.PMDV99F
MXA(GPC\H#Y"C^*>J+`?A[Y[HU)3M:-U:]*_-`)8>4<'TC`)6?YQ(V'WQUQ:J
M_.?UQNQ4<O\`T[[A,_@^A4Z_BQJ]C(_A/>0?^NI_L1NVJB/_`")TU+_[35_G
M03:\%8J6]M1<JND2&47H^A*KJ1N0N6H[B&A'K]N4-71TK(!@;6JG1672GHU^
MPX\A)\A4`?5!MU)7KM6GZVY-_.,TSBD_?!)EZ#(QK$HJY-9Q%Q8^[K"7<(U[
M'UFE<%M.`<W:1J@DQX@*^,?5K-KD!]H!$=11$.K%DJ[51OVDV;(#;G&<F7[@
M"4O1%+K-WKJ:]"]MN*%R2^'<^_.%9LWXV)AO[?$,'O5V-V"WT4&V15E82GV3
M>OT&VE1=BQE3H1U11SH29&*-+UF@?+,,P27$>H0Q73J^Q5&G+W56=[8PX<I^
M4@F:3YTD1</R[U:QKC1]#J.G]E]G]*-Z74#*M)_"!\Q$!@M?;V<NS<:BK:TT
M@=::K>HXNGV0$#5P.\')$W#Q0>HJ3%KK6.(]`%(.>-:FD^SLC>-HS;H(ASZ+
MV4_9:R=@N7Y;%V1JQ:1,-5M>M&2@$$E-TRF=C2<;(`41."D].\>15*(YG%N0
MPYZNEG/A\TLMVK?U.XCLM@M-$_*,BM0\@DGSF$?^+O7B6:6ET'0N?I5R?J`-
MR1,-(/E,U]643VQ1K[/W<:8I3?RPH]FY4)!W.MG6T+-,P,()+JTZV1J.(643
MSR,=LX9J`41Z@./KP1>?-M;JM$FJ=2.-3U"5`[Y*.4CUP'OA8NU3;N:#5$T2
M6*MAQ"Q/`R25@G[TIP\IAOK>QM>IS>#MKN18N>(W0=U)%=LI*963UGIRM8DW
M;J;FD3?.3X#]($U<OG-U5"Y"`Y84W1FI:C2>HF+TS,I;5):=RFU8*'HQ'6!#
M_<SM$T^OM%UFFUA(?=0%,J/N.I,T*]/9/43&NQIJ>NEM.O\`1LXW(]I2[%BK
MB`*[134@NTG:6DS(OXYP`@/$82"2*B"G655NMF&8"`XL"J&+9JW3Y:<`<MU9
M3[=N"AV9>3;Y8J3I:B[Z'U2E]`4Q=[?53D9@A;:L4GJ,B#T@GIC9#[9[\TCN
M;L7;:^%%.4EH>O::CY95LF<#J0\P*)4YR"=``B9-U#RA%4#@/2.D#=0ABO'4
MEBJ]-WNHLU<"'F'"`>E/NJ'E$7`Z(U50ZUTO2:CMY!;J&@5`>XX`,Z#T%*IB
M*5\S6O:FJ6F[8[([42"[.[.\>I%*+>2#$PB\HVRT+PI*[E9J@4,T$24Z0[%(
MXB`"HY'+,0RQMG+J@IZ:HJ=87(3MML1Q!/8M\X,H_&QE`TYUW:NJZ.BY:Z>4
M1?[ZYPR1M;I4F;[AZ!E!3/RQ?:FJ6I"P=G(JE*3CD(FB[2T`5A$1Z)-";:'I
M.$,8I1``S,HHFS$ZANLQS"(](XTFIJ*B^7A535**JFI?S*\JU?8GA!4HZ&CT
MGIA%#0)2BCM](0D#`2;03ZR)GRQK7:JN0O>G<E)W5N8\7=IW#O&G5%6KG(L]
M52AY6JD7#ML1%(IUG)&$*(()I$*)C$3`I0$<6*TEN3:=+IM]"`@,TA2WT*6$
M2$^B9Q)Z8IYK[RJ^ZO7>;H2>\5O$<)[1RJ<F1+?(8#J`$/@1?-<V)Q$9'13*
MX-5(LXU@S8-$4K/W5(FBV9MDVZ"29`H_(I$TDP``#H``PD#O+'63SJG2TRI2
ME$D\9K:3,^]%G--SVY:TM,W3-OU(;;;2D`4KX``2``.QL$?W?6U;'!R'S'J[
MXO*&ZW7D/_<_IQXJY7:O/9+#4]OSS7^M'T?Q]Y:G$U-4"/\`VS_^I`%N>1N&
ML=O"I6P+O;ZK5U=590M0U>C4!4K:5[$KLZ;FXR/,AJ<3-.L2*I&DV/00@F$!
MZ1P<N2MCNND:JN1?RRQ1OMH*1Q6S-8)Z%'<=\*Y\2VK].Z_I[8=*BIJ:RG+H
M</`=3E0H)*<5($\0=D9A^S<U#<"GIS<O:>I8.IXFF7471-?PB<U#R<:S0FDG
M4I`3?93/FZ)#+/F:C,3%*/\`$9B'IQA_B&;M]5W"Z4JVEOS6VK*I*CE`24SD
M>F?IC8O@^?NU'67>SUS;S=&MIEU`4E24YP5I41,`3*2D>:+E_:)?\!T-^W2@
M/Z.J7&I\@/\`'"OW1S\I$$3XM_\`+=C^\4?U3L`L^S^_YB$#^R6YO\EBL&_G
MY_@(_OC?YT+-\*G^:K?[D]^9#W`B``(CU``B/Q!A(8L])`!)V"-:GS`+Q3-]
MMXFXFY$VZ6<&<W%J&"ADU#G.2/IZE'2M/0D<U`V8IMVS2.+D4/PC"/6(XL6T
M'9V;+H^BM[(`5W8+40-JE#,9^6<4V\S-15.J=?7&[5*B2Y6+2`3/*E"BA*1T
M`!,;!G9[0<5;':OMZH>';HM64#:*A$@(B700[IY3S%^_7$`ZU'+YTHH8?28V
M$(U;7.W+5%=6/DEYRI<]`40!Y@!%K?+FU4]DT':+<Q(,MT375,J2%$^<J,63
M#J#TXU\3`D=L;P!+"/DJ_IB-K:AJRHV9;$>155TK4%.2390H'378S44ZCG*1
M@'\=)P/Q8^R@J'*2N9JFCE=;=2H$;9@@QB[W0T]SL]7;JM(73/4SB%`B8(4D
M@QK+:&JVH-NNX6`JVDW:K&?L_=E)S&N$CF3/JI:ICM5&QCAF84'C-N=%3/,3
M)G,`XL>K*-C4&G%T3R9TU72R5Y"C`CSQ3-;KA5Z;U6U<:!915TE7F0>M"]_E
ME(]1,/U\RBUM0;G^7K>RE;=-EY*H:EM_"5Q2T8@43.)@\!(0U:IQ2*68<5U(
MQ\>=)(GI6,7"*\OKFSIO7=*_6*"66WU-J5\G--&;R`R\T6E\XK-6ZRY3US%K
M25U;E,V^A`VJR%+A2.LB<NN$H-GG,8W1[%'$Y"VIJ!HI24K*F=5';6M(P9"G
M^^T!!LZ>HMCF;OX27$$027,B<NL"`!RB)0$'*U=R^TSKW([<4GO:&^P^V9'+
MNGT](GYHK@T%S8UIRS=<I[$]EI'%`N,N)S(*DX>R?9,L"1(],X+I3'VEN[;8
MC=.L-M-!2F@A2N'<#5\Y&KKF#+48C=ZT=()9^H#"`8%-5\.-K*CW2Y.I'0I`
M/K@]TGQCZF0$HJ[31+EM(<<23Y@"!%O[5_:0]NU1O&S*[-F+D6T254(DM+Q#
MZ)K:.1U9`*ZC=L6+?E1*(](%*<V7KQJ%U^'K4#"5+M-2Q4RV)(*%?9'K@@V+
MXO\`3-4ZEN^T%13`F14T0XD3WD$)5Z!!$[`4)MIW";H5^8GMYNS$5@6H[1%M
M+5T'`-T@2=2*$@V>L)B?3<@WF8:>91S4K4S==`@J)D*;,0`!P/K[6:BL.G1H
M._4JVBBIXR%JW"1!2DXI*23/`X$P5M)6S1FK=<*YM:3KT/%=$:=YI"934926
ML&2TKDD)Q&,MIE!+0^_@>&#<($'R@O[*[V!]?,"W+_[3(X*?-/\`;+5_<]-^
M287KX>?[*OO_`,BJ_P`J"^X%D,-'4WW.GX,3?/=*.J@3LVP%WFR<K.`WK44X
MN;;!C&4_N4HR,4/$/@*BS:7+B6:!C$I"IG!2!F^`":8YX<1%`X\,P\,WLE_E
M;S,>T;7"W7(J7IYY0"A,GAJ)]H=7RAOVPMW/?DA3\PK>J_6-M#6K6$DB0`[P
MD#V%GY8]Q7F,(QR#"L[8UHXCY)G.T-7M#3W"7;*@[A:CIJHH9R!BJ`/T+MF^
M8ND@.0Y1#J`Q1$!`<.VA5!>*#B-K0]0/HGA(I4DC9T2E%9[K5QLEP+3G$I[E
M3N8SFE:%I/F((.STPR-RX=\=>[U.8%LR-=)DDM<*S5D;WT1.U:W,4J5;-74&
M9[&3SMKF(MIH6Z0D>"&2:JH<0H!J$`77F!HNATAH.["VDFDJJUEP)/ZN1`*1
MU$[.@80W?)_F/=^8?-;3R[RD*K[?;ZEA3F]T%*E!:ON@-O3MAL>XE'M+@T#6
MM"O^AG6%*S],N#"(@!$IN+=1QE,PZ0T=IS^3"M4%2:*O9K!B6G$J_%(/V(?.
M]VX7:SU5L/Z]AQ`\JDD`^DQJ^;B4%.VMKZM+:52T695%0E43E*R[=<ADU"/H
M2078**:#@!@(N"`*%]9#@.++;37T]SH6+A3$*IWF0I)Z,PG+S;#%*MZMM79K
MK46NL3EJJ=U3:Q*6*20?-,8=(AD#D"WU@J\IB_FP6Y;I-Q3EP("6K*@63TX*
M$$T@R-%5[$,4U3:`<%2%M))%*`"!TE3]>%K^(/2V%/J>G3,I_1/$=!Q;)\\Q
MZ(<WX1=<!JHK-"5:Y%T<=B?RDB3J1Y4Y5#I(,7AY=>U,;"WIW'7@O`B6-I[;
M8>IZ4A9B13!-HLJ@S/,2M5-5'`%343;T<"0D.4V13/!#//J5RCI7:NJ11TR"
M7G5I2!TJ)D/23#RW.X4UJH7;C6+#=OIVE.+)Z$@DGT##I,*C;Q]Q,QNLW+79
MOI*J+<&M*H=C33)8YQ"'HV,-W=2L4D!Q$4RMHA!,QP#(!5.<V09XL=T;I]K2
MNFZ:SL?.);&<]*R)J/IG%-W,+5=1K76%=J)^>1]]10#[K8,D)ENDD"8Z9P4K
M[/1:B5K'>]*W(3:JJ0-HK85(YD7G#-V=.7K/A0$,T%40T`Y51*Z4*7/,2I&'
MJ`<#/G_=&Z+2#=K*QWFI?2);\J>TKU@0;?A/L3URYC&[93W6AI5K)W!2QD0"
M>N:L.J'A!#X.D?N@'7A+")R$^R(LP&W'?]B$^OM"^RTU'5]3>\>AXGATW<$S
M"B[L)LD`!&/K1HW7\/5,Y32(4I"5#&MQ;+K&'I<H)YCJ4#-L^0.L35T:]*7!
M<GV9K9F=J#M2)_))F!T$]$5[_%?RY-MN[6N+8W_P57)#\A@EX;%&7RTC$GW@
M!OCO]GJWIM*%JZMMHMP9Q-C3-9%D;B6Q>2;HJ3*+J:)8@K5\$5=PJ5%HC,0[
M0'B9`^<LW4RZ3CGSS\T6Y5T[.J:%!74((;=`Q)23V3+[E1EY#'/PH\R6;/75
M.BKNZEN@J07F5*,@EQ(FM,]P4@3^^'7!G]C#!]N7OW?;F`5.V.I3DZ_>6*VK
M).R&TL+*47)+HSU8LDE`,"*UQ*K246XB8@"C9$H9B&0X#.LG$:>LM'HFF5^E
M`%162WOK'90?]FG"7288?E>PYK35ESYKUR5"F4I5%;@K=3-J(6Z`=A=5O&!$
MX)Y6\"-4495],@.D:BIF>@P-GED,O%.V(&S'JR,XP.Z)X4U8S4'8AU*CYE`_
M8@W7:E-=:ZJB`^=8<3Y2I!`]9C6(,&,A:.]L='U4T%C(6RNLQ;U`T<E$HMW5
M(5<D21(J10I1X918&',0R$@Y]0XLG4XU=;#G8([L_2DH(WE2,/68I<0T[9=1
M!FL3E?IJH!:3N+:Q,'SB4;.JG4:7J&GX*>CXV&=,)N&C)9DY38,CIKM)%D@[
M;+)G!(0,11%8!`0]`XK;J7*NGJ7&%K<2M"U`B9$B"0=\7/6UFV5MN8JV6F5-
M.LH4DA*3,*2",9=<>SW#!_\`4T3_`-G,_P#4X\.\U'\XOTG[<?9X?;_YAG\1
M/VHG<4&'_0T5\D<T_P!3B=XJ?YQ9\Y^W$\/H/YAK\1/VHQ/1%X;:57=VZMG*
M116/6-G(ZBW->N&D.FW@F*M=-)&2A(5*91^B=323".%=RUR`[=)9$QOR@8R-
M9;+C3VVGNE43W6I*^&"<3DD"9'=,R!WXQ@;5J"PUVH*[3MN`\2MR&N-E2`E/
M%F4IS##,`)E.X$=,"'^T2_X#H;]NE`?T=4N"SR`_QPK]T<_*1`$^+?\`RW8_
MO%']4[`+/L_O^8A`_LEN;_)8K!OY^?X"/[XW^="S?"I_FJW^Y/?F0]P(9@(#
MU"`@/R]&$AV8Q9Z1F!2=A$:S+>U;28M'NRW&6]FT%&[R$NI6:B9%`-DLPFI1
MQ-13M,P@`*(.V$BFH0P9E$!Z!Q8[HJY-WC2=%64Y["J5&;R@92/5%,6O[-4:
M=UQ<K55`A]FN<F>D%94#US208V%>RFX$?=':3MSKB/72=(3EH*&XATC%,4C^
M.@FD9(H")1'2=!^R4((#T@)>G"#:RH7+9JJOH7`0XBI<(\A42/48M?Y8W9B^
M<O[1<6R"VY1-`CH4E.4CS$1:(/OXUN-^$]\>'5$TSINFZ@J*173;1\#!RTR_
M<+&`B2#.,8.'KE90QLBE(DBB)A$?0&/:F9745;3#0FXMQ*0.M1`CX;I5-4-M
MJ*U]02PTPM:B=@"4DGU"-8W"4Y,7[W$LJ9HYJH]F;M7?4:0K9$AE1.>JZN5.
MFJ()@)A1;MG0JG,'4F41Q9+4U+-CTP:JI4$M4M),]>5.SSQ3!2T=5J'5*:2B
M25U-7620!CBXO#S8X]0,;'F^5VZ5VC[<*KNO4,7+S=(V8HJ.=2$9"]F&8>14
M5W?#@5F#M1%N9<J:A3B!C%`0`0#IQ7A:+54:HO[=MIUI1553QD5;`3,XQ;_J
M.^T>A-(N7FM0MRBH:=.9*)9B!E3A.0])@<]^>4?L;WWQ<3?JF6DM;*H[GP<7
M6C>M;9+Q[2.J!*H8]"1;2<[3"R"T,]?JD<`98Z(MU3JZM9C#G@A6+FIK/0M0
MNRU!34,TZRV4.SF"@RD%3S2Z`9X;(#6I.0G+;FA2-ZHM6:@J*Y"7PZP!E4'$
M@S+1DC,?>(D9S@:]7?9GY8%UC4+NA8J-0$PMTZJH95)P/7I!96)D5B!Z.HN"
M+2_$<5?VC;Y=;:A^=`CN/P;U*3.T7AM2?Z5L@_Z!E%/+N?9[-ZU`1+R9H:;M
MC=]-F15P:(I^5D(*H%T4BF,)6C*?:(MGCHX!D5,JP"(CD`XVZT<_=)5KZ&:Y
M#].2?:4!E'ERDX>:!WJ#X4^8MGI%5=$::NR^XRHA9'4E03/R3BM_*]OI=O9[
MOSMY1D@A4=+LJSKUC:2[UN95)VQ!R27<'BD3R<,X%,J<S`2:Z:[=82B8"Z@`
M1(<<]@YFV6UZQT2[<*8(=6VT767`1@4C,2#T$`@],:?R8U-?=`<RZ2B<4ZRT
M[4IIZID@S4%*R95)/O)404F4QNVPX+=SFL[#K04[4<Q*;B:!J*9@4I$B5&4I
M)#.5/+2S#B)##,V#)%02.S.R<,QE#$(GTB(Y!A2K5RTUG=ZINF:H7FTJ(FM8
MRI"3C.9ZHL#O_/3EI8:%VJ\48J:E`5E:9FM:E"8D0!@,V!)(E`2.3?S0K`VZ
M4W'T5N*KF*M6ZNM?.K;Y4G/U"*J=.N%:[625FJ=<2+=)=-E(M'B0*)\7210B
M@@!LR])EYN\MKW5B@K[&R:A#%(AA:4D%4T#`@3$^B%N^'GG-IRS*NMLU6^FC
M35UJZM#B@K)-P]M)(!EN()PAFFS^X.RNX".EY>RES:1N;&0#QM'S;RD95&50
MBGKQ`SEJU>G2_(K+MR&.4H](E#"X72S7:R/(I[K3NL.K!("Q(D#HAT-/ZKT]
MJEA=3IVK9K&6U)"BTK-E*A,9NB8QC,8=/7\7P?&'QXQLL9QL(F=NV(.7I_T8
MX)`&.R.8`]S>^5'&;L:<D;\6.B6<7N/I:,45DHMLF5NA=Z"CVYSIPSO(Q$B5
M8S(3)BY-EQ@^A4$0$@E-O*?F<[I>I39KTLKL3BNRH_J23M^\Z1NVB%7^(#D;
M3ZUI%ZHTRV$ZH902MM(_:4@?U@`P/O#`[C`%.1A%2<!S-J$@YN.>1,S#TG=Z
M,E8N0;J-'\=(,Z7?-G;-ZV6`JJ#EJNF8IR&`!*(8/'.RH:J^7#M6RM):<=:4
MDI.!25`@S&V<+!\-#+]'SBI:>H0I+Z&ZA*DD$%)#:@01M$C.8,/FX1N+1X6!
MYV'*GJZZL_);OMN%.+5!5JL:B2\5N8=N!IBH4XIJBU:5O3;4@E[=*-XY`J3]
ML4.*L1(JI-1P.`LIR:YI4MJ83I/4"PFCS'@NG8@G'(H[A/8?-"2?$;R,K[S5
MNZ]TBUQ*A20:EA()6K*`.*A(G/`=M($\)@;861VW7GJ?:SN.M=>%@@^BYNUM
M<QTC,Q;E!=H[4BD5^PU/!2#-<J:Z?;X9=PB=,Y0$!,`Y9@&&1U):J;4VFZFT
M9D.-U#!DH8XG%!!ZC(X0FND+]<-$ZKH[ZP%(JZ.H2HI(()`,EH(ZTE22.N&V
MN=YO6I^E-C]'4I:Z8:J2N\)G%OFKN/42*X-:E6*8S4])J&1R.)I8B[./U".>
ME10H_-RPJ7)G1JZG6KU1<T'AVM2@1+`O3*4CS2*O1#V_$CS,IF>6U)06AQ/&
MOS:5R!F1390M6R7M*(0?PNB%&-ONVZ\^Z*OXVW%DJ&F:SGWKA`CM=BV/W-`-
M%%"$6E*BF3@5A$QS0AA.<RAP,)0'24PY!AKK[J>S::M_?KN^VTEN?9GVE'<$
MC:3NE"&Z5T?J+6=S1:=/TSE15+(G('*D;U*5L2D;23T&4SA#_'+DV)4GL+L(
MRMVQ<-IZX=3+HU%=6M$$C)%J"I12.FBT8$4'BI0<`W4%NT(;I$-:@^TH(`B?
M,#6U5K>^KKU@HH43#*#CE2=I/6J4SZ-T6G\GN5U%ROTT*`%+E[?DJI=$Y*4)
MY4IG[J`9#I,S!`<:)(06XPIN*L91NY.REQ;)5XT3<T[<"FWT*LJ8N:T8_.F*
MD1-LS=!DWL/)D2<)B`AF9/(>@1`<S8+S5Z?O#%WHB0^RL'RCWDGJ(F(UC66E
MK?K/357INXIG3U+1$]Z5[4+!Z4JD?5&OBMQLLO1);YXO9FD23@;C1]RW5(S<
MTR[2U5B:7CE53SE:(.$#$4+%JTGK=)G*8`.18I<_:RP^M?K*T)T0=932NBX`
M(!D9K4.RB73FPBIVV<N+]5<QAH`(<;N8JRRHB8RI"CF<P]T(!5.<B/+&Q.ME
M;VF;2V]HNV-&1Z472E!4S"TI3[!$A2$0C(5@BQ;@)2Y`*BA4=9QZS',(^G%?
MMRKZBZ5[MQJE3J7W%+5/K)/JBW.PV>DT_9Z:QT"0FCI&$-(ET)3*?G.)ZS'W
M6/DC+0IESKN5#7$O7-2[P=N%+O*K95*09*\MNX)J+B8C)5DS*FZKN!CR"9>3
M9R:"&N002*95-8!5*42F,`--R<YIT-/1MZ5U"X&UM?,.*/9(G@VH[!+<3@1A
MM$(5\1G(VYJNCNO=(LK>IGSFJF4":FU@";J4C%2%RFH"9"L92,9`Y1W.(MQ"
MVZI;:INPJ0M!5+0""5+4!<BI!4;PDQ!LSD:Q-+54X53XL'4$,0>S)K.`!)9(
MA0.8ARCGC>;'*FK?KW-4Z4`J:5\YW6T;0HXJ4@;P=LALW1EN0G/^VT%J:T/K
MMSNSM,.'3U"@0C(,`VZ?=*-@6<",#C#+L/<"A*AC23,%6E)S,0HF58DG&5!%
M/6(I&("A5`=-W2B.D2"`YZNK"ZNV^M8=+3[+J7?DE!!]$IPY--?+-7,=YHJN
MF=IOE)<01TXD&44KW%;_`&W5N536OL:#?<7N=J1,[*A[-VX?(3CA!\O]"E/5
MU,1QG$92-)11S<5VX<JD.*9!*0!,/1MUBT55UBA<+W.AT^W)3CS@RS3\EL'%
M2U;`!Y8&NK^;5FMJ39=)J%WU@^2AFGIR%Y5[ENJ3-*&TDS))QE*/3VU6OB=E
M=@*SN'N$N!">/JRG92\NY:[$LN#*#-5]0*MT5TTG"FH&M-4NT%O&,2CT`BD`
M_A8\=17-S5=[;H;(RON#*`Q2M`35D3,[-ZE&:E1].AK$SRYTI47G5=0TF[5+
MAJKA4*,D\1<A*>/91,(3NZ!`<^>5O'VMWYV:15&6=OO;JXM6)7AHN:/3],3B
M4A(A%,F,^F[?F0(0H@V;'<$`QLPR$X8+O)+2VH+-K!55=:1YACN;B<RDR!42
MF0'7ALA?OB8YA:+U1H1FW6"XT]77)KT**&U%1"0VX"HX#`$@>>`]<E2\5KK'
M[Y(6N[N5S3ENZ.0MK7T4I452ORL(LLC(MHXK)F9P8#@5=T9(V@!RSTC@N\Z;
M77WC1@HK4TY457>$**4B9PG/#JG"]_#KJ"T:7YDLW*_5**6W]V>27')A,R`0
M"0-\H=LM)O$VOWZJ5S1UF;YV]N15+.+6FW4#2LVE(R*,2V60;KR!T"%*)6R2
M[DA3&]`F#"7W+3.H;.P*JZ4;S%.59<RTR$^B+*;%S"T7J>L50:>N5-65R4%1
M;;42K*)3.P88B`\<Y_E65'NA!#<KM\BDW]YZ>ADHFMJ(2$B#FY=.QQ0+&NHA
M14Q$?%,$AJ3(F<P`[;Y$`0.0N9BY.\SJ?3"CIW4"B+,ZLE+@_5*/3]R3Z#"[
M?$3R/K-9$ZSTJC->VT`.L[%/)3L4C[M(V@XJ$5CY(?,$@+)QTKL4W//EK6S,
M'4$G)6JDJ](M3Z39Q+NA6F;?RYI0B`13HDF*KIB942)*\50@&S`N>?YR:#J+
MPXG6FFP*IEQ(2X&^T2!L<`$YX8*\@C3/APYL4FEV7>7FLU=S"'5+8<=!2E*S
M+.TLD#+,XH)PF2)"&JF\E'N6))-N_9N(U5'M*<@BY058G;Z=7'([3.9N9'3T
MZ@-IR].%E+3J'."M*N*,)$$&?DAYFZND<IQ5-NMJI5"86%`HE]\#*7G@`7.&
MYD='4[:VH=HFW*<)<Z_UXVBM'S32@#C4:E%TO(G!M--EE(D'7&J6=9B=J@V2
M$QTDSJ**:=)0,<N4^@'WKHWJG4213V6E.=/$[/$4/9P.Q(.))D"<!"I?$%SA
MMJ;&[H/2#HK+]7S:=+/Z0-HG)2)I!!6O9),R!,QCGDQ\I2I+"RC#=/N3@B15
MSC1YT[6VY>`11Y0+22;"B\J.HTRF.BE5#MHL**#;I%FF8QC""A@TY/F]S2IK
MVTK3%@7FMB5?I'!L7+8A/W(.T[XP_P`/'(FML%0C7&L&2BZRG3-*]IN?ZU8W
M+(,DI.*9SVP4'FR"4O+GW9&-D`!:]P/3U=$Q$99Y^C`SY7B>OK9LQJ1]8P<^
M>P!Y3WH$D$TN[IS)D//`>.5)O\KG:S8VVEJ-[%$5M;VP]2M1>[>-Q$_"/S44
MG`R#U8Q*6J>2117[IBTG*@J1SI8"%!!0"B&C0;!8YI:)M^HKS4W/23S#MY:,
MJFF2H9RH>\@3Q5+V@/+MG"[<BN:=ST1I^DL7,"FJ6-,/DFCK%H5PT)4?84J6
M#<YY#N$\)2AF>CK@4-<2);SE!UA358P[M$CAO(TU-1TRT414`IB'!9@X6*4#
M%,'7D/3A=:R@KJ!TLU[+C3B3+*M)!]8ASK7>[/>Z<55GJ6:EA0F%-K2H>HX>
M<1S65?41;N%=U%7U74Y1L&P04<O)6I9AA#L44$2"=0XKOET"FTE*(Y%S'HZ`
MQ*.WUUP>%+0,N/.DR`2DG'S1S<[W:;)2JK;S4LTU.@34IQ82`/.<?,(6,M#8
MEES#^;G4N\ZWU.ND-J-IYRF'K>X;J.7CHN[5<T1`$C&"M+@X(W5DVCF82(LL
MY*&D&S8@B.I0`PQMUOZ]#<JDZ0KG`=1U*3^C!FIE"U$G-+9(&4ND]4)3IW2Z
M>;'/9_7MJ96C1E'4I67RG*FH6TE(2$S`F5+3,D3D$S.V/IZB\-^)ZDU?4$ZN
M_)75WSYK]_Y]X.,^_.%]#WOG^D:/9XVK+HQB:7O'#1+Z92RCV.#+9NZNCJC+
MU/AW?WI_PSS9U>UWW/M/M2PGTRWSCR%?#.@G_P"?GX.)YN:/X/1\>.P[QPC_
M`(R]K^@E_+'C4^'3:G_#+;AF[]ZI?9@LO+=[O\'7/[N]Q31XJA.+[BGBCPSK
M[J7R\>^*/IO$&7Z+P?8[-JSZ<#;7>?O;'$\5]@_M^3/M]S)[O3/&<'CE+P.Y
M7#N_T>^>;GX/QLOLGY[C>]\G+AEGO@EH?+\N6-%&R#"//'4_S1^3[N.1]B.C
MOL&(/H_T9_P^C'D?9ZL/)_)'??YO/"UE*=S?7_179?=][V\OKG=X^3GCWQ/_
M`&1==F\W>]_ZE>87"SX_=?\`$Z>/])EAC*G/_`]6;ON7C-2X^3+[8GP,O:X?
M1GQZ,(2VV\/_`,IT</PZ?`?S=SS[>&J7><^''E[7"[&S-C*&5L+O#IQT-U?O
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M&>'D$O">-U?.<?MRZ)[X(V&!\G9!JCG':)'4_P`T>OY,<C;'5?L'R0)JG_#_
M`-;Q6FCW5?$ONY1O&[!YF^]#W9VE#A]X\?\`\)NZ^)^5[/\`K;N_@:_H\L$U
M[C?PP1_:7`[[OX7=)X_[Z?1/L3G`!HNZ_P`>JF7@O>_#1/+WCQ#+(>U/_AO+
ME_29)3@LOI#]WHP+3\Y]4X8#=';'I$C\5OF'^;^34_*?D_FC\_+\#U_!B#VA
MMVC9]7U&/%V4CL]D[=FSZI]4*;\SGP!YG3OBWZG[C=/"\4>\QYV99+Y>)/)+
M\PXF7_'=.O//IPT?+;O_`(>GNWTIRR]SN?!_!X^,O)"&\WO"?&CWWZ"<3';X
MEWC\/NOZ.?EQGM@==JO(WLQL_=PRUFS[G^L2\L^H/TG1T]G]>71HRQM]?XOW
MD_M^;+[_`(;Q?-NE]F!=9?`>'CX3ED?F_&.!^%+M3^Q*&7>53W#X4J+PY[@'
M=O$^C]S[S(\6_,)_>#YJ?UK[;^-Q?3EA?N8G&XHX_C.?-_S?"X7X'![$-]R.
M[IW57<_HOP\A_L[O/>/]YWKM^7S1?W=9P/=VNQVKR9[/X7/Q?>*[Q\D]';F?
M]X_<_P"L_#^?7P?;XVCT9XT?3.;QNFR][S<7_E\O'V'YK-AF\N$H+6N<GT1K
MN+W')P1/OV?NLLR?G^'V\GWN.:6Z%\2>&O9__/MZ?F>;6O\`@_!P;D]YS?\`
MYGM_H)[/K],*\GP_*G_+64]W?9_5Y8Z.?#'#Z?\`Z^V6H/RWF]IZ_3IZ<\=D
M=YGA]--O]!]F,97^&<+M?POEC[7?Y?Z.,7LY>?<_G5.=W_58<?P'(ZO<H\=>
M:VCO*-S[T\3_`*O\(Y_E]/TG'X671GC3-<<;PA&?Z19>*/VWA<+?[.3'-ZH*
MO*CNGTC=[O\`0[B=U/\`9/>>\RFGVN-V.'ZYR@U73D'7UAUZ<^K][/`G],,=
M[HZ>O;_+ZH7QYMOA3O5MXK^J[[)P3:?>;\Y_.7/H_FGR7_7>K\77T=6#QRN[
MUPCW7Z29I?\`*=WX/_U'9]&,*+SU[AWH=^^A>69EWOOG>M^SNF.;IS?6@3D'
MY']P)_S/HX`?S/\`6&^3?S!_(9_G'<__`#6"2KQ;.J7$_"\-XWGGO\D`:D\#
MR&?`R\,;/%^Z_@R[67UP4[E1^$?%LCX2^JW[+QAU^0/G?Y]]9OYX\[?UQVK\
M;A]&>>!KS%[UW)/>/I#.7Z[N_=__`$,)>6#AR,\.[\ON'T+EG,^[=][YO_ZS
M&?DZ]T,2%^7J]/7\OPX`S6P^7S^>'%^O*,![I>![OUT>T^3G`\-GXGO!=X>3
M.GMC3^\+NK]8]PY_.X7M<31Z,\9NPS\78R]YGG_42XW^[GAF\L:MK7)]&:KB
M=QR9,>^9N[;1\[D[67R8Q\I=#A^[&GJ]VO@^!(K/S([3[N_#[C3_`$;A?G_A
M'3^B:?I>R9?A8^^VS^D1EXAFXQ^:EWGVM\\,W3NG&%U#D^@Z<W@>3@I_:,W<
M92]V7:R?)EVLO7"H+CR9\13':_=([;W@MVCW%O?V\*\35[6GN7]0=?5V7Z+J
MRPR?_=.Z-_VCERB7?O#\_P#K>G&$5K_`N(]+P:>94_"/%^#YYX?B8;(^@C/)
MSOF'[#[I';^\V_`]^OW\/#/$U%R_M#_5KB?B=I^BSZ\?,[XGW8YO$LDC^P]P
MS>:7:CUH?`LU-/P;/G3+Q;QCA^>79\F;">V&Y[%:?*RCM'E7I[G:Z?)/B>66
MG1T>%>-]+W;E\W5[7KPL5]GXF_F[Y[?_`#4N+^%EWP_VC<O@;.7PR7#'[#F[
*O^!FQ]./3'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>10
<FILENAME>v236909_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNDERWRITING AGREEMENT</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">between</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOVELOS THERAPEUTICS INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">RODMAN &amp; RENSHAW, LLC</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">as Underwriter</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOVELOS THERAPEUTICS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNDERWRITING AGREEMENT</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">New York, New York</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">___________, 2011</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Rodman &amp; Renshaw, LLC</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1251 Avenue of the Americas, 20<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Floor</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">New York, New York 10020</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ladies and Gentlemen:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The undersigned, Novelos Therapeutics, Inc., a Delaware corporation (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Company</font>&#8221;), hereby confirms its agreement with Rodman &amp; Renshaw, LLC (hereinafter referred to as &#8220;you&#8221; (including its correlatives) or the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Underwriter</font>&#8221;) as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Purchase and Sale of Securities.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Firm Units</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.1.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Nature and Purchase of Firm Units</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On the basis of the representations and warranties herein contained, but subject to the terms and conditions herein set forth, the Company agrees to issue and sell, to the Underwriter, an aggregate of [_____] units (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Firm Units</font>&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Underwriter agrees to purchase from the Company the Firm Units at a purchase price (net of discounts and commissions) of <font style="DISPLAY: inline; FONT-WEIGHT: bold">[</font>___<font style="DISPLAY: inline; FONT-WEIGHT: bold">]</font> per Share (95% of the per Firm Unit offering price). The Firm Units are to be offered initially to the public (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Offering</font>&#8221;) at the offering price set forth on the cover page of the Prospectus (as defined in Section 2.1.1 hereof).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Firm Unit consists of one share of the Company&#8217;s common stock, par value $0.00001 per share (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Common Stock</font>&#8221;) and one warrant to purchase one share of Common Stock in the form attached hereto as <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit A</font> (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Warrant</font>&#8221; or &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Warrants</font>&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.1.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Shares, Payment and Delivery</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Delivery and payment for the Firm Units shall be made at 10:00 a.m., Eastern time, on the third (3rd) Business Day following the effective date of the Registration Statement (as defined in Section 2.1.2 below) (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Effective Date</font>&#8221;) or at such earlier time as shall be agreed upon by the Underwriter and the Company at the offices of Sichenzia Ross Friedman Ference LLP, counsel to the Underwriter (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">SRFF</font>&#8221;), or at such other place (or remotely by facsimile or other electronic transmission) as shall be agreed upon by the Underwriter and the Company. The hour and date of delivery and payment for the Firm Units is called the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Closing Date</font>.&#8221;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Payment for the Firm Units shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order of the Company upon delivery of the certificates (in form and substance satisfactory to the Underwriter) representing the Firm Units (or through the facilities of the Depository Trust Company (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">DTC</font>&#8221;)) for the account of the Underwriter. The Firm Units shall be registered in such name or names and in such authorized denominations as the Underwriter may request in writing at least two (2) full Business Days prior to the Closing Date. The Company will cause any certificates, if any, or Warrants representing the Firm Units to be made available to the Underwriter for checking and packaging at least one full Business Day prior to the Closing Date at the office of SRFF. The Company shall not be obligated to sell or deliver the Firm Units except upon tender of payment by the Underwriter for all the Firm Units. The term &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Business Day</font>&#8221; means any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions are authorized or obligated by law to close in New York City.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Over-allotment Option</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.2.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Option Units</font>.&#160;&#160;For the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Units, the Underwriter is hereby granted, an option to purchase a number of units equal to <font style="DISPLAY: inline; FONT-WEIGHT: bold">fifteen</font> (15%) percent of the Firm Units sold in the offering from the Company, up to [_______] units (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Over-allotment Option</font>&#8221;). Such additional<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>[_______]<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>units, the net proceeds of which will be deposited with the Company&#8217;s account, shall be identical in all respects to the Firm Units and are hereinafter referred to as &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Option Units</font>.&#8221; The Firm Units and Option Units are hereinafter referred to as &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Units</font>&#8221;, and the Units, the shares of Common Stock and the Warrants included in the Units and the shares of Common Stock issuable upon exercise of the Warrants are hereinafter collectively referred to as the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Public Securities</font>&#8221;. The purchase price to be paid for the Option Units will be the same price per Option Unit as the price per Firm Units set forth in Section 1.1.1 hereof.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.2.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exercise of Option</font>.&#160;&#160;The Over-allotment Option granted pursuant to Section 1.2.1 hereof may be exercised by the Underwriter as to all (at any time) or any part (from time to time) of the Option Units on or before forty five (45) days after the Effective Date. <font style="DISPLAY: inline">If the last day to exercise the option falls on a day that is not a Business Day, the expiration date of the option will be postponed to the next day that is a Business Day.&#160;&#160;</font>The Underwriter will not be under any obligation to purchase any Option Units prior to the exercise of the Over-allotment Option. The Over-allotment Option granted hereby may be exercised by the giving of written notice to the Company from the Underwriter setting forth the number of Option Units to be purchased and the date and time for delivery of and payment for the Option Units (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Option Closing Date</font>&#8221;), which will not be later than five (5) full Business Days after the date of the notice or such other time as shall be agreed upon by the Company and the Underwriter, at the offices of SRFF<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>or at such other place (including remotely by facsimile or other electronic transmission) as shall be agreed upon by the Company and the Underwriter. If such delivery and payment for the Option Units does not occur on the Closing Date, the Option Closing Date will be as set forth in the notice. Upon exercise of the Over-allotment Option, the Company will become obligated to convey to the Underwriter, and, subject to the terms and conditions set forth herein, the Underwriter will become obligated to purchase, the number of Option Units specified in such notice.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.2.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Payment and Delivery</font>.&#160;&#160;Payment for the Option Units will be made on the Option Closing Date by wire transfer in Federal (same day) funds as follows: $<font style="DISPLAY: inline; FONT-WEIGHT: bold">[&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;]</font> per Option Unit, 95% of the per Option Unit offering price, payable to the order of the Company upon delivery of certificates (in form and substance satisfactory to the Underwriter) representing the Option Units (or through the facilities of DTC) for the account of the Underwriter. The Option Units shall be registered in such name or names and in such authorized denominations as the Underwriter may request in writing at least two (2) full Business Days prior to the Option Closing Date. The Company will cause any certificates, if any, or Warrants representing the Option Units to be made available to the Underwriter for checking and packaging at least one full Business Day prior to the Option Closing Date at the office of SRFF. The Company shall not be obligated to sell or deliver the Option Units except upon tender of payment by the Underwriter for applicable Option Units.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As used herein &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Agreement</font>&#8221; or &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Underwriting Agreement</font>&#8221; means this Underwriting Agreement entered into as of the date hereof between the Company and Underwriter.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Representations and Warranties of the Company</font>.&#160;&#160;The Company represents and warrants to the Underwriter as of the Effective Date, as of the Closing Date and as of the Option Closing Date, if any, (except that in case of any representation or warranty relating to a Preliminary Prospectus, as of the filing date of such Preliminary Prospectus)&#160;&#160;as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Filing of Registration Statement</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.1.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Pursuant to the Act</font>.&#160;&#160;The Company has filed with the Securities and Exchange Commission (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Commission</font>&#8221;) a registration statement and an amendment or amendments thereto, on Form S-1 (File No. 333-175284), including any related prospectus or prospectuses, for the registration of the Public Securities under the Securities Act of 1933, as amended (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Act</font>&#8221;).&#160;&#160;Such registration statement was prepared by the Company in all material respects in conformity with the requirements of the Act and the rules and regulations of the Commission under the Act (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Regulations</font>&#8221;). Except as the context may otherwise require, such registration statement on file with the Commission at the time the registration statement becomes effective (including the prospectus, financial statements, schedules, exhibits and all other documents filed as a part thereof or incorporated therein and all information deemed to be a part thereof as of the effective date of such registration statement pursuant to paragraph (b) of Rule 430A of the Regulations), is referred to herein as the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Registration Statement</font>.&#8221; The final prospectus, furnished to the Underwriter for use in the Offering and filed with the Commission, is hereinafter called the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Prospectus</font>.&#8221;&#160;&#160;Each <font style="DISPLAY: inline">preliminary prospectus included in the Registration Statement filed with the Commission which</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>omits Rule 430B information is herein called the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Preliminary Prospectus</font>.&#8221;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.1.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Registration under the Exchange Act and Stock Exchange Listing</font>.&#160;&#160;Upon the Closing Date, the shares of Common Stock of the Company shall be registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Exchange Act</font>&#8221;), and shall be approved for listing on the NASDAQ Capital Market.&#160;&#160;The Company has taken no action designed to, or likely to have the effect of, terminating the registration of its shares of Common Stock under the Exchange Act or causing the delisting of its shares of Common Stock from the NASDAQ Capital Market, nor has the Company received any notification that the Commission or the NASDAQ Capital Market is contemplating terminating such registration or listing.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.1.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Integration</font>. Neither the Company nor any of its affiliates has, prior to the Effective Date, made any offer or sale of any securities which would be &#8220;integrated&#8221; under the Act or the Regulations with the offer and sale of the Pubic Securities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Stop Orders, etc</font>.&#160;&#160;Neither the Commission nor, to the Company&#8217;s knowledge, any state regulatory authority has issued any order or threatened to issue any order preventing or suspending the use of the Preliminary Prospectus, Prospectus or the Registration Statement or has instituted or, to the Company&#8217;s knowledge, threatened to institute any proceedings with respect to such an order.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Disclosures in Registration Statement</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.3.1.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Conformance of Registration Statement; 10b-5 Representation</font>.&#160;&#160;At the respective times the Registration Statement, the Preliminary Prospectus, the Prospectus and any post-effective amendments thereto become effective (and at the Closing Date and the Option Closing Date, if any):</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Registration Statement, the Preliminary Prospectus, Prospectus and any post-effective amendments thereto did and will contain all material statements that are required to be stated therein in accordance with the Act and the Regulations, and will in all material respects conform to the requirements of the Act and the Regulations;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither the Registration Statement nor the Preliminary Prospectus nor the Prospectus, nor any amendment or supplement thereto, on their respective dates, do or will contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The representations and warranties made in this Section 2.3.1 do not apply to statements made or statements omitted in reliance upon and in conformity with written information furnished to the Company by the Underwriter expressly for use in the Registration Statement or Preliminary Prospectus or Prospectus or any amendment thereof or supplement thereto.&#160;&#160;The parties acknowledge and agree that such information provided by or on behalf of the Underwriter consists solely of the following disclosure contained in the &#8220;Underwriting&#8221; section of the Prospectus: the first paragraph under the heading &#8220;Pricing of Securities&#8221; (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Underwriter&#8217;s Information</font>&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.3.2.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Disclosure of Agreements</font>.&#160;&#160;The agreements and other instruments described in the Preliminary Prospectus, Prospectus and the Registration Statement conform to the descriptions thereof contained therein and there are no agreements or other instruments required by the Act and the Regulations to be described in the Preliminary Prospectus, Prospectus or the Registration Statement or to be filed with the Commission as exhibits to the Registration Statement, that have not been so described or filed. Each agreement or other instrument (however characterized or described) to which the Company or the Subsidiary (as defined below) is a party or by which it is or may be bound and that is referred to in the Preliminary Prospectus or Prospectus has been duly authorized and validly executed by the Company or the Subsidiary, is in full force and effect in all material respects and is enforceable against the Company or the Subsidiary and, to the Company&#8217;s knowledge, the other parties thereto, in accordance with its terms, except (x)&#160;as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&#8217; rights generally, (y)&#160;as enforceability of any indemnification or contribution provision may be limited under the federal and state securities laws, and (z)&#160;that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefore may be brought and neither the Company nor any Subsidiary nor, to the Company&#8217;s knowledge, any other party is in breach or default thereunder and, to the Company&#8217;s knowledge, no event has occurred that, with the lapse of time or the giving of notice, or both, would constitute a default thereunder. To the Company&#8217;s knowledge, performance by the Company of the provisions of such agreements or instruments will not result in a violation of any existing applicable law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic or foreign, having jurisdiction over the Company or any of its assets or businesses, including, without limitation, those relating to environmental laws and regulations such as would result in a material adverse effect on the business, prospects, assets, liabilities, financial condition, property or results of operations of the Company and the Subsidiary, individually or taken as a whole (a &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Material Adverse Effect</font>&#8221;).</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.3.3.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Prior Securities Transactions</font>.&#160;&#160;No securities of the Company have been sold by the Company or by or on behalf of, or for the benefit of, any person or persons controlling, controlled by, or under common control with the Company, that are required to be disclosed in the Registration Statement except as disclosed therein.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.3.4.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Regulations</font>.&#160;&#160;The disclosures in the Registration Statement concerning the applicability and effect of certain United States federal, state, local and foreign regulation to the Company&#8217;s business are correct in all material respects and do not omit to state a material fact necessary to make the statements therein, in light of the circumstances in which they were made, not misleading.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Changes After Dates in Registration Statement</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.4.1.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Material Adverse Effect</font>.&#160;&#160;Since the respective dates as of which information is given in the Registration Statement, the Preliminary Prospectus and the Prospectus, except as otherwise specifically stated therein: (i)&#160;no event has occurred that would result in a Material Adverse Effect; (ii)&#160;there have been no material transactions entered into by the Company or the Subsidiary, other than as contemplated pursuant to this Agreement; and (iii)&#160;no executive officer or director of the Company has resigned from any position with the Company or the Subsidiary; and (iv) no event or occurrence has taken place which materially impairs, or would likely materially impair, with the passage of time, the ability of the officers and directors of the Company to act in their capacities with the Company as described in the Registration Statement, the Preliminary Prospectus and the Prospectus.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.4.2.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Recent Securities Transactions, etc</font>.&#160;&#160;Subsequent to the respective dates as of which information is given in the Registration Statement, the Preliminary Prospectus and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed in the Registration Statement, the Preliminary Prospectus and the Prospectus, neither the Company nor the Subsidiary has: (i)&#160;issued any securities; (ii) incurred any liability or obligation, direct or contingent, for borrowed money in excess of $50,000; (iii) entered into any transaction other than in the ordinary course of business, or (iv)&#160;declared or paid any dividend or made any other distribution on or in respect to its capital stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Disclosures in Commission Filings</font>.&#160;&#160;None of the Company&#8217;s annual report on Form 10-K for the fiscal year ended December 31, 2010, its quarterly reports on Form 10-Q for the quarters ended March 31, 2011, June 30, 2011, and September 30, 2011 or any current reports on Form 8-K having event dates on or after January 1, 2011, each as filed with the Commission, contained any untrue statement of a material fact or omitted to state any material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading; and the Company has made all filings with the Commission required under the Exchange Act.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Independent Accountants</font>.&#160;&#160;To the knowledge of the Company, Grant Thornton LLP (&#8220;Grant Thornton&#8221;), whose report is filed with the Commission as part of the Registration Statement, are independent registered public accountants as required by the Act and the Regulations.&#160;&#160;Grant Thornton has not, during the periods covered by the financial statements included in the Registration Statement, the Preliminary Prospectus or Prospectus, provided to the Company and the Subsidiary any non-audit services, as such term is used in Section 10A(g) of the Exchange Act.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Financial Statements; Undisclosed Liabilities.</font> The financial statements, including the notes thereto and supporting schedules included in the Registration Statement, the Preliminary Prospectus and Prospectus, fairly present the financial position, cash flows and the results of operations of the Company at the dates and for the periods to which they apply; and such financial statements have been prepared in conformity with generally accepted accounting principles (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">GAAP</font>&#8221;), consistently applied throughout the periods involved; and the supporting schedules included in the Registration Statement present fairly the information required to be stated therein. No other financial statements or supporting schedules are required to be included or incorporated by reference in the Registration Statement, the Preliminary Prospectus or the Prospectus.&#160;&#160;The Registration Statement discloses all material off-balance sheet transactions, arrangements, obligations (including contingent obligations), and other relationships of the Company with unconsolidated entities or other persons that may have a material current or future effect on the Company&#8217;s financial condition, changes in financial condition, results of operations, liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. <font style="DISPLAY: inline">Except as disclosed in the Registration Statement, the Preliminary Prospectus and the Prospectus, (a) neither the Company nor Cellectar, Inc., its wholly owned subsidiary (the &#8220;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Subsidiary</font><font style="DISPLAY: inline">&#8221;), has incurred any material liabilities or obligations, direct or contingent, </font>(<font style="DISPLAY: inline">other than liabilities and obligations of a type or nature not required under GAAP to be reflected in the Company&#8217;s financial statements, which, individually and in the aggregate, would not reasonably be expected to have a Material Adverse Effect), or entered into any material transactions other than in the ordinary course of business, (b) neither the Company nor the Subsidiary has declared or paid any dividends or made any distribution of any kind with respect to its capital stock; (c) there has not been any change in or amendment to the terms of the capital stock of the Company or the Subsidiary or any grants under any stock compensation plan and, (d) there has not been any material adverse change in the Company&#8217;s or the Subsidiary&#8217;s long-term or short-term debt.</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Authorized Capital; Options, etc</font>.&#160;&#160;The Company and the Subsidiary had, at the date or dates indicated in the Preliminary Prospectus and Prospectus, the duly authorized, issued and outstanding capitalization as set forth in the Registration Statement, the Preliminary Prospectus and the Prospectus. Based on the assumptions stated in the Registration Statement, the Preliminary Prospectus and the Prospectus, the Company will have on the Closing Date the adjusted stock capitalization set forth therein. Except as set forth in, or contemplated by, the Registration Statement, the Preliminary Prospectus and the Prospectus, on the Effective Date and the Closing Date, there will be no options, warrants, or other rights to purchase or otherwise acquire from the Company or the Subsidiary any shares of capital stock of the Company or the Subsidiary or any security convertible or exchangeable into capital stock of the Company or the Subsidiary, or any contracts or commitments of the Company or the Subsidiary to issue or sell shares of capital stock of the Company or the Subsidiary or any such options, warrants, rights or convertible securities.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Valid Issuance of Securities, etc.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.9.1.&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Outstanding Securities</font>.&#160;&#160;All issued and outstanding securities of the Company and the Subsidiary have been duly authorized, and all issued and outstanding shares of capital stock of the Company and the Subsidiary have been validly issued and are fully paid and non-assessable; the holders of such shares of capital stock have no rights of rescission with respect thereto, and are not subject to personal liability by reason of being such holders; and none of such shares of capital stock was issued in violation of any right of first refusal, preemptive right or similar contractual rights granted by the Company or the Subsidiary. The authorized shares of capital stock of the Company and the Subsidiary conform in all material respects to all statements relating thereto contained in the Registration Statement, the Preliminary Prospectus and the Prospectus. The offers and sales of the outstanding shares of capital stock of the Company were at all relevant times either registered under the Act and the applicable state securities or Blue Sky laws or, based in part on the representations and warranties of the purchasers of such shares, exempt from such registration requirements. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&#8217;s or the Subsidiary&#8217;s capital stock to which the Company or the Subsidiary is a party or, to the knowledge of the Company, between or among the Company&#8217;s stockholders.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.9.2.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Securities Sold Pursuant to this Agreement</font>.&#160;&#160;The Public Securities have been duly authorized for issuance and sale.&#160;&#160;The Public Securities when issued and paid for in accordance with this Agreement, will be validly issued, fully paid, non-assessable. The issuance and sale of the Public Securities are not and will not be subject to any right of first refusal, preemptive rights or similar contractual rights granted by the Company or the Subsidiary. The Public Securities conform in all material respects to all statements with respect thereto contained in the Registration Statement, Preliminary Prospectus and Prospectus.&#160;&#160;The shares of Common Stock issuable upon exercise of the Warrants have been reserved for issuance upon the exercise of the Warrants and when paid for and issued in accordance with the Warrants, if and when issued pursuant to the exercise of the Warrants in accordance with the terms thereof, including the payment of the exercise price for the shares of Common issuable upon exercise of the Warrants specified therein, will be validly issued, fully paid and non-assessable. The shares of Common Stock issuable upon exercise of the Warrants are not and will not be subject to any right of first refusal, preemptive rights or similar contractual rights granted by the Company or the Subsidiary.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Registration Rights of Third Parties</font>.&#160;&#160;Except as set forth in the Registration Statement, the Preliminary Prospectus and the Prospectus, no holders of any securities of the Company or any rights exercisable for or convertible, exercisable or exchangeable into securities of the Company have the right to require the Company to register any such securities of the Company under the Act or to include any such securities in a registration statement to be filed by the Company. The Company is not obligated to file a registration statement (the &#8220;Registration Statement&#8221;) under that certain Securities Purchase Agreement dated as of April 8, 2011 between the Company and investors named therein, as amended by that certain Amendment No. 1 dated as of November 3, 2011 (the &#8220;SPA&#8221;), until the 180<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> day following the date of the Prospectus (the &#8220;Filing Deadline). The Registration Statement is not required to be declared effective pursuant to the SPA until the earlier of (i) the 240<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> day immediately following the date of the Prospectus, or (ii) 5 business days following the Company&#8217;s receipt of a letter from the Commission relating to the Registration Statement that it will not review the Registration Statement or that it has no further comments with respect to the Registration Statement (the &#8220;Effectiveness Deadline&#8221;). Liquidated damages under the SPA shall not be payable unless the filing of the Registration Statement does not occur prior to the Filing Deadline or the effectiveness of the Registration Statement does not occur prior to the Effectiveness Deadline.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.11<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Validity of Agreements</font>.&#160;&#160;The Company has all corporate power and authority to enter into this Agreement, the Warrants and all ancillary agreements, to issue the Public Securities and to consummate the transactions contemplated hereby and thereby.&#160;&#160;This Agreement, the Warrants, all ancillary agreements and all transactions contemplated hereby and thereby have been duly and validly authorized by the Company and no further action is required by the Company, its board of directors or its stockholders. This Agreement, the Warrants and all ancillary agreements executed and delivered in accordance with the terms hereof, will constitute the valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, except: (i)&#160;as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&#8217; rights generally; (ii)&#160;as enforceability of any indemnification or contribution provision may be limited under the federal and state securities laws; and (iii)&#160;that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefore may be brought.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.12</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Conflicts, etc</font>.&#160;&#160;The execution, delivery, and performance by the Company of this Agreement, the Warrants and all ancillary agreements, the consummation by the Company of the transactions herein and therein contemplated and the compliance by the Company with the terms hereof and thereof do not and will not, with or without the giving of notice or the lapse of time or both: (i)&#160;result in a breach of, or conflict with any of the terms and provisions of, or constitute a default under, or result in the creation, modification, termination or imposition of any lien, charge or encumbrance upon any property or assets of the Company or the Subsidiary pursuant to the terms of, any agreement or instrument to which the Company or the Subsidiary is a party such as would result in a Material Adverse Effect; (ii)&#160;result in any violation of the provisions of the Company&#8217;s or the Subsidiary&#8217;s Certificate of Incorporation or similar document or Bylaws (as the same may be amended from time to time); or (iii)&#160;violate any existing applicable law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic or foreign, having jurisdiction over the Company or the Subsidiary or any of their properties or assets or business constituted as of the date hereof such as would result in a Material Adverse Effect.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.13</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Defaults; Violations</font>.&#160;&#160;Neither the Company nor the Subsidiary is in default under any license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument evidencing an obligation for borrowed money, or any other agreement or instrument to which the Company or the Subsidiary is a party or by which the Company is bound or to which any of the properties, assets or business of the Company or the Subsidiary is subject, such as would result in a Material Adverse Effect. Neither the Company nor the Subsidiary is in violation of any term or provision of its organizational documents.&#160;&#160;To the Company&#8217;s knowledge, neither the Company nor the Subsidiary is in violation of any franchise, license, permit, applicable law, rule, regulation, judgment or decree of any governmental agency or court, domestic or foreign, having jurisdiction over the Company or the Subsidiary or any of their properties, assets or businesses such as would result in a Material Adverse Effect.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.14</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Corporate Power; Licenses; Consents</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.14.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Conduct of Business</font>.&#160;&#160;Each of the Company and the Subsidiary has all requisite corporate power and authority, and has all necessary authorizations, approvals, orders, licenses, certificates and permits of and from all governmental regulatory officials and bodies that it needs as of the date hereof to conduct its business as currently conducted, as such current conduct is described in the Preliminary Prospectus and Prospectus.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.14.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Transactions Contemplated Herein</font>.&#160;&#160;&#160;All third-party consents, authorizations, approvals and orders required in connection therewith have been obtained. No consent, authorization or order of, and no filing with, any court, government agency or other body is required for the valid issuance, sale and delivery of the Public Securities and the consummation of the transactions and agreements contemplated by this Agreement and as contemplated by the Preliminary Prospectus and Prospectus,.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.15</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Questionnaires</font>.&#160;&#160;To the Company&#8217;s knowledge, all information contained in the questionnaires (the &#8220;Questionnaires&#8221;) completed by each of the Company&#8217;s directors, officers and shareholders prior to the Offering as well as in the Lock Up Agreements provided to the Underwriter is true and correct in all respects. The Company has not become aware of any information which would cause the information disclosed in the Questionnaires completed by each of the Company&#8217;s directors, officers and shareholders to become inaccurate and incorrect. &#160;The Company agrees to promptly inform the Underwriter at any time when it (or any officer or director thereof) should learn of any fact that would cause any such Questionnaire to not be complete and accurate in all material respects or to contain an untrue statement of a material fact or to omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading as of the date hereof and as of the Closing Date or the Option Closing Date, if any.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.16</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Litigation; Governmental Proceedings</font>.&#160;&#160;There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding pending or, to the Company&#8217;s knowledge, threatened against, or involving the Company or the Subsidiary or, to the Company&#8217;s knowledge, any executive officer or director which has not been disclosed in the Registration Statement, the Preliminary Prospectus and the Prospectus.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.17</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Good Standing</font>.&#160;&#160;The Company has been duly incorporated and is validly existing as a corporation and is in good standing under the laws of the State of Delaware as of the date hereof, and is duly qualified to do business and is in good standing in each jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification, except where the failure to qualify would not have a Material Adverse Effect.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.18</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Transactions Affecting Disclosure to FINRA</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.18.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Finder&#8217;s Fees</font>.&#160;&#160;There are no claims, payments, arrangements, agreements or understandings relating to the payment of a finder&#8217;s, consulting or origination fee by the Company, the Subsidiary or any officer or director of the Company with respect to the issuance, sale or delivery of the Public Securities pursuant hereto or any other arrangements, agreements or understandings of the Company or the Subsidiary or, to the Company&#8217;s knowledge, any of its shareholders that may affect the Underwriter&#8217;s compensation, as determined by FINRA.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.18.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Payments Within Twelve Months</font>.&#160;&#160;Neither the Company nor the Subsidiary has made any direct or indirect payments (in cash, securities or otherwise) to: (i)&#160;any person, as a finder&#8217;s fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or the Subsidiary or introducing to the Company or the Subsidiary persons who raised or provided capital to the Company or the Subsidiary; (ii)&#160;to any FINRA member; or (iii)&#160;to any person or entity that has any direct or indirect affiliation or association with any FINRA member, in each case within the twelve months prior to the Effective Date, other than (w) the prior payment of $250,000 to the Underwriter in connection with a merger of the Subsidiary that was completed on April 8, 2011, (x) the prior payment of $200,000 to the financial advisor of the predecessor company that was merged into the Subsidiary in connection with such merger, (y) the prior payment of $200,000 to the Underwriter and the issuance to the Underwriter of warrants to purchase 192,931 shares of Common Stock in connection with a private placement that closed on April 8, 2011, and (z) the prior payment of $50,000 to the Underwriter as provided hereunder in connection with the Offering.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.18.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Conflicts of Interest</font>.&#160;&#160;&#160;To the knowledge of the Company, no&#160;FINRA member participating in the offering has a conflict of interest (as defined by FINRA rules) with the Company.&#160;&#160;&#160;For purposes of this Section 2.18.3, <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8220;</font>no FINRA member participating in the offering&#8221; includes any associated person of a FINRA member that is participating in the offering, any member of such associated person&#8217;s immediate family and any affiliate of a FINRA member that is participating in the offering.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.18.4.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Use of Proceeds</font>.&#160;&#160;None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its affiliates, except as specifically authorized herein.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.18.5.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">FINRA Affiliation</font>.&#160;&#160;No officer, director or any beneficial owner of at least 5% of any class of the Company&#8217;s securities (whether debt or equity, registered or unregistered, regardless of the time acquired or the source from which derived) or any beneficial owner of the Company&#8217;s unregistered equity securities acquired during the 180-day period prior to the initial filing date of the Registration Statement (any such individual or entity, a &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Company Affiliate</font>&#8221;) is a FINRA member or has any direct or indirect affiliation or association with any FINRA member (as determined in accordance with the rules and regulations of FINRA). The Company will advise the Underwriter if it learns that any Company Affiliate becomes a FINRA member or an affiliate or associated person of a FINRA member participating in the Offering.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.19</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Foreign Corrupt Practices Act</font>.&#160;&#160;Neither the Company nor the Subsidiary nor any of their respective directors , employees or officers or, to the Company&#8217;s knowledge, any other person acting on behalf of the Company or the Subsidiary has, directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal price concessions to customers in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or official or employee of any governmental agency or instrumentality of any government (domestic or foreign) or any political party or candidate for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company or the Subsidiary (or assist it in connection with any actual or proposed transaction) that (i)&#160;would subject the Company or the Subsidiary to any damage or penalty in any civil, criminal or governmental litigation or proceeding, (ii)&#160;if not given in the past, would have had a Material Adverse Effect or (iii)&#160;if not continued in the future, would have a Material Adverse Effect. The Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company and the Subsidiary to comply in all material respects with the Foreign Corrupt Practices Act of 1977, as amended.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.20</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Company Lock-Up.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.20.1.&#160;&#160;&#160;&#160; Each of the Company&#8217;s officers and directors holding shares of capital stock of the Company (or securities convertible into such shares) have executed Lock-Up Agreements in the form attached hereto as Exhibit B-1, and each owner of at least 5% of the Company outstanding shares of capital stock (or securities convertible into such shares) (together with the Company&#8217;s executive officers and directors the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Lock-Up Parties</font>&#8221;) have executed Lock-Up Agreements in the form attached hereto as Exhibit B-2.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.20.2. &#160;&#160;&#160; The Company, on behalf of itself and any successor entity, hereby agrees that, without the prior written consent of the Underwriter, it will not, for the period of one hundred and eighty (180) days<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>from the Closing Date (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Lock-Up Period</font>&#8221;), (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (ii) file or cause to be filed any registration statement with the Commission relating to the offering of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company, or (iii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of capital stock of the Company, whether any such transaction described in clause (i), (ii) or (iii) above is to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 81pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The restrictions contained in this paragraph 2.20.2 shall not apply to (x) the Units to be sold hereunder, (y) the issuance by the Company of shares of Common Stock upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof or (z) the grant of options or the issuance by the Company of any shares of Common Stock of the Company pursuant to any equity incentive plan or arrangement of the Company, including without limitation, pursuant to the Company&#8217;s 2006 Stock Incentive Plan.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 81pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The restrictions contained in this paragraph 2.20.2 shall not apply to registrations on Form S-8 promulgated under the Act or pursuant to the registration rights set forth in that certain Securities Purchase Agreement by and among the Company and the investors party thereto dated as of April 8, 2011.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.20.3.&#160; Notwithstanding the foregoing, if (i) the Company issues an earnings release or material news, or a material event relating to the Company occurs, during the last 17 days of the Lock-Up Period, or (ii) prior to the expiration of the Lock-Up Period, the Company announces that it will release earnings results during the 16-day period beginning on the last day of the Lock-Up Period, the restrictions imposed by paragraph 2.20 shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event, unless the Underwriter waives such extension.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.21</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Subsidiary</font>.&#160;&#160;Cellectar, Inc. is the sole subsidiary of the Company and the Company has no other direct or indirect subsidiaries. The Subsidiary is duly organized under the laws of State of Wisconsin and is in good standing under the laws of the State of Wisconsin, and is in good standing in each jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification, except where the failure to qualify would not have a material adverse effect on the assets, business or operations of the Company taken as a whole.&#160;&#160;The Company&#8217;s ownership of the Subsidiary is as described in the Registration Statement, the Preliminary Prospectus and the Prospectus.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.22</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Related Party Transactions</font>.&#160;&#160;Except as disclosed in the Registration Statement, the Preliminary Prospectus and the Prospectus, there are no business relationships or related party transactions involving the Company, the Subsidiary or any other person required to be described in the Registration Statement, Preliminary Prospectus and the Prospectus that have not been described as required.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.23</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Board of Directors</font>.&#160;&#160;The Board of Directors of the Company is comprised of the persons set forth under the heading of the Preliminary Prospectus and the Prospectus captioned &#8220;Management.&#8221; The qualifications of the persons serving as board members and the overall composition of the board comply with the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder applicable to the Company and the rules of NASDAQ. At least one member of the Board of Directors of the Company qualifies as a &#8220;financial expert&#8221; as such term is defined under the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder and the rules of NASDAQ. In addition, a majority of the persons serving on the Board of Directors qualify as &#8220;independent&#8221; as defined under the rules of NASDAQ.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.24</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Sarbanes-Oxley Compliance</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.24.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Disclosure Controls</font>.&#160;&#160;The Company has developed and currently maintains disclosure controls and procedures that comply with Rule 13a-15 or 15d-15 of the Exchange Act, and such controls and procedures are effective to ensure that all material information concerning the Company will be made known on a timely basis to the individuals responsible for the preparation of the Company&#8217;s Exchange Act filings and other public disclosure documents.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.24.2.&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Compliance</font>.&#160;&#160;The Company is in material compliance with the provisions of the Sarbanes-Oxley Act of 2002 applicable to it, and has implemented or will implement such programs and taken reasonable steps to ensure the Company&#8217;s future compliance (not later than the relevant statutory and regulatory deadlines therefore) with all the material provisions of the Sarbanes-Oxley Act of 2002.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.25</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Investment Company Status</font>.&#160;&#160;The Company is not and, after giving effect to the Offering and sale of the Public Securities and the application of the proceeds thereof as described in the Registration Statement, the Preliminary Prospectus and the Prospectus, will not be, an &#8220;investment company&#8221; as defined in the Investment Company Act of 1940, as amended.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.26</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Labor Disputes</font>.&#160;&#160;No labor <font style="DISPLAY: inline">dispute</font> with the employees of the Company or the Subsidiary exists or, to the knowledge of the Company, is imminent.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.27</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Intellectual Property</font>.&#160;&#160;Each of the Company and the Subsidiary owns or possesses or has valid right to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions, trade secrets and similar rights (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Intellectual Property</font>&#8221;) necessary for the conduct of the business of the Company and the Subsidiary as currently conducted as such conduct is described in the Registration Statement, the Preliminary Prospectus and the Prospectus.&#160;&#160;To the knowledge of the Company, no action or use by the Company or the Subsidiary of its Intellectual Property infringes any Intellectual Property of others.&#160;&#160;Neither the Company nor the Subsidiary has received any notice alleging any such infringement. To the Company&#8217;s knowledge, no person or entity is infringing any Intellectual Property of the Company or the Subsidiary.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.28</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Taxes</font>.&#160;&#160;Each of the Company and the Subsidiary has filed all material returns (as hereinafter defined) required to be filed with taxing authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof.&#160;&#160;Each of the Company and the Subsidiary has paid all taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed against the Company or the Subsidiary.&#160;&#160;The provisions for taxes payable, if any, shown on the financial statements filed with or as part of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of such consolidated financial statements.&#160;&#160;Except as disclosed in writing to the Underwriter, (i) no issues have been raised (and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted as due from the Company or the Subsidiary, and (ii) no waivers of statutes of limitation with respect to the returns or collection of taxes have been given by or requested from the Company or the Subsidiary.&#160;&#160;The term &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">taxes</font>&#8221; means all federal, state, local, foreign, and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments, or charges of any kind whatever in the nature of a tax, together with any interest and any penalties, additions to tax, or additional amounts with respect thereto.&#160;&#160;The term &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">returns</font>&#8221; means all returns, declarations, reports, statements, and other documents required to be filed in respect of taxes.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2.29</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Definition of &#8220;Knowledge&#8221;</font>.&#160;&#160;As used in herein, the term &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">knowledge of the Company</font>&#8221; (or similar language) shall mean the knowledge of the executive officers and directors of the Company who are named in the Preliminary Prospectus or the Prospectus<font style="DISPLAY: inline; FONT-SIZE: 10pt">, with the assumption that such officers and directors shall have made reasonable and diligent inquiry of the matters presented.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Covenants of the Company</font>.&#160;&#160;The Company covenants and agrees as follows:</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Amendments to Registration Statement</font>.&#160;&#160;The Company will deliver to the Underwriter, prior to filing, any amendment or supplement to the Registration Statement or Prospectus proposed to be filed after the Effective Date and not file any such amendment or supplement to which the Underwriter shall reasonably object in writing.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Federal Securities Laws</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.2.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Compliance</font>.&#160;&#160;During the time when a Prospectus is required to be delivered under the Act, the Company will use its best efforts to comply with all requirements imposed upon it by the Act, the Regulations and the Exchange Act and by the regulations under the Exchange Act, as from time to time in force, so far as necessary to permit the continuance of sales of or dealings in the Public Securities in accordance with the provisions hereof and the Prospectus. If, at any time when a Prospectus relating to the Public Securities is required to be delivered under the Act, any event shall have occurred as a result of which, in the opinion of counsel for the Company or counsel for the Underwriter, the Prospectus, as then amended or supplemented, includes an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, or if it is necessary at any time to amend the Prospectus to comply with the Act, the Company will notify the Underwriter promptly and prepare and file with the Commission, subject to Section 3.1 hereof, an appropriate amendment or supplement in accordance with Section 10 of the Act.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.2.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Filing of Final Prospectus</font>.&#160;&#160;The Company will file the Prospectus (in form and substance reasonably satisfactory to the Underwriter) with the Commission pursuant to the requirements of Rule 424 of the Regulations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.2.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exchange Act Registration</font>.&#160;&#160;For a period of three years from the Closing Date, the Company will use its best efforts to maintain the registration of its shares of Common Stock under the Exchange Act.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.2.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Free Writing Prospectuses</font>.&#160;&#160;The Company represents and agrees that it has not made and will not make any offer relating to the Public Securities that would constitute an issuer free writing prospectus, as defined in Rule 433 of the 1933 Act, without the prior consent of the Underwriter. Any such free writing prospectus consented to by the Underwriter is hereinafter referred to as a <font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Permitted Free Writing Prospectus</font>.&#8221; The Company represents that it will treat each Permitted Free Writing Prospectus as an &#8220;issuer free writing prospectus&#8221; as defined in Rule 433, and has complied and will comply with the applicable requirements of Rule 433 of the 1933 Act, including timely Commission filing where required, legending and record keeping.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Delivery to the Underwriter of Prospectuses</font>.&#160;&#160;The Company will deliver to the Underwriter, without charge, from time to time during the period when the Prospectus is required to be delivered under the Act or the Exchange Act such number of copies of each Prospectus as the Underwriter may reasonably request and, as soon as the Registration Statement or any amendment or supplement thereto becomes effective, deliver to the Underwriter two copies of the manually executed&#160;&#160;Registration Statement, including exhibits, and all post-effective amendments thereto and copies of all exhibits filed therewith or incorporated therein by reference and all original executed consents of certified experts.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Effectiveness and Events Requiring Notice to the Underwriter</font>.&#160;&#160;The Company will use its best efforts to cause the Registration Statement to remain effective with a current prospectus through the third anniversary of the Closing Date and will notify the Underwriter immediately and confirm the notice in writing: (i)&#160;of the effectiveness of the Registration Statement and any amendment thereto; (ii)&#160;of the issuance by the Commission of any stop order or of the initiation, or the threatening, of any proceeding for that purpose; (iii)&#160;of the issuance by any state securities commission of any proceedings for the suspension of the qualification of the Public Securities for offering or sale in any jurisdiction or of the initiation, or the threatening, of any proceeding for that purpose; (iv)&#160;of the mailing and delivery to the Commission for filing of any amendment or supplement to the Registration Statement or Prospectus; (v)&#160;of the receipt of any comments or request for any additional information from the Commission; and (vi)&#160;of the happening of any event during the period described in this Section 3.4 hereof that, in the judgment of the Company, makes any statement of a material fact made in the Registration Statement or the Prospectus untrue or that requires the making of any changes in the Registration Statement or the Prospectus in order to make the statements therein, in light of the circumstances under which they were made, not misleading. If the Commission or any state securities commission shall enter a stop order or suspend such qualification at any time, the Company will make every reasonable effort to obtain promptly the lifting of such order.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Review of Financial Statements.</font>&#160;&#160;For a period of three (3) years from the Closing Date, the Company, at its expense, shall cause its regularly engaged independent certified public accountants to review (but not audit) the Company&#8217;s financial statements for each of the first three fiscal quarters prior to the announcement of quarterly financial information.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Reserved</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Payment of Expenses</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.7.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company will make all necessary state &#8220;blue sky&#8221; securities law filings, if any, with respect to the Public Securities to be sold in the Offering (including the Option Units). The Company and the Underwriter will cooperate in obtaining the necessary approvals and qualifications in such states as the Underwriter deems necessary and/or desirable. The Company will be responsible for and pay all expenses relating to the Offering, including, without limitation, (a) all filing fees and communication expenses relating to the registration of the Public Securities to be sold in the Offering (including the Option Units) with the Commission; (b) all COBRADesk filing fees associated with the review of the Offering by FINRA; (c) all fees and expenses relating to the listing of such Public Securities on the Nasdaq Capital Market, the Nasdaq National Market or the NYSE Amex and on such other stock exchanges as the Company and the Underwriter together determine; (d) all fees, expenses and disbursements relating to the registration or qualification of such Public Securities under the &#8220;blue sky&#8221; securities laws of such states and other non-foreign jurisdictions as the Underwriter may reasonably designate; (e) all fees, expenses and disbursements relating to the registration, qualification or exemption of such Public Securities under the securities laws of such foreign jurisdictions as the Underwriter and the Company may reasonably designate; (f) the costs of all mailing and printing of the underwriting documents (including, without limitation, this Underwriting Agreement, Warrants, any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters, Selected Dealers&#8217; Agreement, Underwriters&#8217; Questionnaire and Power of Attorney), Registration Statements, Prospectuses and all amendments, supplements and exhibits thereto and as many preliminary and final Prospectuses as the Underwriter may reasonably deem necessary; (g) the costs and expenses of any public relations firm retained by the Company; (h) the costs of preparing, printing and delivering certificates representing the Public Securities; (i) fees and expenses of the transfer agent for the Common Stock; (j) share transfer and/or stamp taxes, if any, payable upon the transfer of securities from the Company to the Underwriter; (k) the fees and expenses of the Company&#8217;s accountants; (l) the fees and expenses of the Company&#8217;s legal counsel and other agents and representatives; (m) the $16,000 cost associated with the use of i-Deal&#8217;s book building, prospectus tracking and compliance software for the Offering; and (n) up to $20,000 of the Underwriter&#8217;s actual accountable &#8220;road show&#8221; expenses for the Offering.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.7.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Non-accountable Expenses</font>.&#160;&#160;The Company further agrees that, in addition to the expenses payable pursuant to Section 3.6.1, on the Closing Date it will pay to the Underwriter a non-accountable expense allowance equal to 1% of the gross proceeds received by the Company from the sale of the Firm Units by deduction from the proceeds of the Offering contemplated herein<font style="DISPLAY: inline; FONT-STYLE: italic"> provided however,</font> that $50,000 in the aggregate was previously paid by the Company to the Underwriter shall be deducted from the non-accountable expense allowance payable to the Underwriter on the Closing Date.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Application of Net Proceeds</font>.&#160;&#160;The Company will apply the net proceeds from the Offering received by it in a manner consistent with the application described under the caption &#8220;Use Of Proceeds&#8221; in the Prospectus.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Delivery of Earnings Statements to Security Holders</font>.&#160;&#160;The Company will make generally available to its security holders as soon as practicable, but not later than the first day of the fifteenth full calendar month following the Effective Date, an earnings statement (which need not be certified by independent public or independent certified public accountants unless required by the Act or the Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Act) covering a period of at least twelve consecutive months beginning after the Effective Date.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Stabilization</font>.&#160;&#160;Neither the Company nor the Subsidiary nor, to its knowledge, any of its employees, directors or shareholders (without the consent of the Underwriter) has taken or will take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to cause or result in, under the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the shares of capital stock of the Company.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Internal Controls</font>.&#160;&#160;The Company will maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i)&#160;transactions are executed in accordance with management&#8217;s general or specific authorization; (ii)&#160;transactions are recorded as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets; (iii)&#160;access to assets is permitted only in accordance with management&#8217;s general or specific authorization; and (iv)&#160;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.12</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">[Reserved]</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.13</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">FINRA</font>.&#160;&#160;The Company shall advise the Underwriter (who shall make an appropriate filing with FINRA) if it is aware that any 5% or greater shareholder of the Company becomes an affiliate or associated person of an FINRA member participating in the distribution of the Company&#8217;s Public Securities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.14</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Fiduciary Duties</font>.&#160;&#160;The Company acknowledges and agrees that the Underwriter&#8217;s responsibility to the Company is solely contractual in nature and that neither the Underwriter nor its affiliates or any selling agent shall be deemed by the Company to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company, the Subsidiary or any of their affiliates in connection with the Offering and the other transactions contemplated by this Agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3.15</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Reverse Stock Split.</font> The Company has taken all necessary corporate action to authorize and approve a reverse stock split of its Common Stock on the basis of one share of Common Stock for each and every _____ shares of Common Stock issued and outstanding prior to the Effective Time and the reverse stock split has become effective under the laws of the State of Delaware.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Conditions of Underwriter&#8217;s Obligations</font>.&#160;&#160;The obligations of the Underwriter to purchase and pay for the Firm Units and Option Units, as provided herein, shall be subject to (i) the continuing accuracy of the representations and warranties of the Company as of the date hereof, the Effective Date and as of each of the Closing Date and the Option Closing Date, if any; (ii) the accuracy of the statements of officers of the Company made pursuant to the provisions hereof; (iii) the performance by the Company of its obligations hereunder and (iv) the following conditions:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Regulatory Matters</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Effectiveness of Registration Statement</font>.&#160;&#160;The Registration Statement shall have become effective not later than 5:00 P.M., Eastern time, on the date of this Agreement or such later date and time as shall be consented to in writing by the Underwriter, and, at each of the Closing Date and the Option Closing Date, no stop order suspending the effectiveness of the Registration Statement shall have been issued and no proceedings for that purpose shall have been instituted or shall be pending or contemplated by the Commission and any request on the part of the Commission for additional information shall have been complied with.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">FINRA Clearance</font>.&#160;&#160;By the Effective Date, the Underwriter shall have received clearance from FINRA as to the amount of compensation allowable or payable to the Underwriter as described in the Registration Statement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">NASDAQ Capital Market Clearance</font>.&#160;&#160;On or before the Closing Date, the Company&#8217;s Shares, including the Public Securities shall have been approved for listing on the NASDAQ Capital Market.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Free Writing Prospectuses</font>.&#160;&#160;The Underwriter covenants with the Company that the Underwriter will not use, authorize the use of, refer to, or participate in the planning for the use of a &#8220;free writing prospectus&#8221; as defined in Rule 405 under the 1933 Act, which term includes use of any written information furnished by the Commission to the Company and not incorporated by reference into the Registration Statement, without the prior written consent of the Company. Any such free writing prospectus consented to by the Company is hereinafter referred to as an &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Underwriter Free Writing Prospectus</font>.&#8221;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">17</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Company Counsel Matters</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.2.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Closing Date Opinion of Corporate Counsel</font>.&#160;&#160;On the Closing Date, the Underwriter shall have received the favorable opinion of Foley Hoag LLP, counsel to the Company, or, as noted below, Wisconsin counsel, dated the Closing Date, addressed to the Underwriter covering the following:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;The Company is a corporation validly existing and in good standing under the laws of the State of Delaware. The Company is duly qualified to transact business and is in good standing in Massachusetts.&#160;&#160;The Subsidiary is a corporation validly existing and in good standing under the laws of the State of Wisconsin.&#160;&#160;The Company has the requisite corporate power and authority to conduct its business, and to own, lease and operate its properties as currently conducted.&#160; <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[The subsidiary has the requisite corporate power and authority to conduct its business, and to own, lease and operate its properties as currently conducted].<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">1</font></font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(ii)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font>The authorized shares of capital stock of the Company is as set forth in the Prospectus.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The shares of Common Stock included in the Units (the <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8220;</font>Shares<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8221;</font>)&#160;have been duly authorized and, when issued and paid for in accordance with the Agreement, will be validly issued, fully paid and non-assessable.&#160; <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The shares issuable upon exercise of the Warrants have been duly authorized and, when issued and paid for upon exercise of the Warrants in accordance with the Warrants and the Certificate of Incorporation, will be validly issued, fully paid and non-assessable.&#160; </font>The issuance and sale of the Public Securities are not and will not be subject to the preemptive rights of any holders of any security of the Company arising under the Delaware General Corporation law (the &#8220;DGCL&#8221;) or under the Certificate of Incorporation or Bylaws of the Company.&#160;&#160;The Over-allotment Option constitutes a valid and binding obligation of the Company to issue and sell, upon exercise thereof and payment of the consideration specified therein, the number of Units issuable upon such exercise, and the Over-allotment Option is enforceable against the Company in accordance with its terms.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Agreement and the Warrants have been duly and validly authorized and executed by the Company.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The execution, delivery and performance of this Agreement, the Warrants, the Lock Up Agreements and the Lock Up Period restrictions on the Company, and compliance by the Company with the terms and provisions thereof and the consummation of the transactions contemplated thereby, and the issuance and sale of the Public Securities do not, with or without the giving of notice or the lapse of time, or both, (a)&#160; conflict with, or result in a breach of, any of the terms or provisions of, or constitute a default under, or result in the creation or modification of any lien, security interest, charge or encumbrance upon any of the properties or assets of the Company or any Subsidiary pursuant to the terms of, any mortgage, deed of trust, note, indenture, loan, contract, commitment or other agreement or instrument filed as an exhibit to the Registration Statement, (b) violate the provisions of the Certificate of Incorporation or Bylaws of the Company, (c)&#160;violate any United States federal or Massachusetts statute or regulation or any provision of the DGCL, or (d) violate any judgment, order or decree applicable to the Company or the Subsidiary of any federal or Massachusetts court or regulatory authority or other governmental body that is applicable to the Company or the Subsidiary.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(vi)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Registration Statement and the Prospectus and any post-effective amendments or supplements thereto (other than the financial statements included therein, <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the notes thereto, and other financial, accounting and statistical data data appearing in the Registration Statement and the Prospectus, </font>as to which no opinion need be rendered) each as of their respective dates complied as to form in all material respects with the requirements of the Act and Regulations. The&#160;Public Securities&#160;offered pursuant to the Prospectus conform as to legal matters in all material respects to the description thereof contained in the Registration Statement and the Prospectus.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">_________________________________</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">1</font> To be provided by Wisconsin counsel.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(vii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline">Based solely upon oral telephonic advice from one or more members of the Commission&#8217;s staff, (a) the Registration Statement has become effective under the Securities Act, and (b) no stop order suspending the effectiveness or use of the Registration Statement or the Prospectus has been issued under the Securities Act and no proceedings for that purpose have been instituted or are pending or threatened by the Commission.&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any required filing of the Prospectus, and any required supplement thereto, pursuant to Rule 424(b) under the Securities Act, has been made in the manner and within the time period required by Rule 424(b).</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(viii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company is not and, after giving effect to the Offering and sale of the Public Securities and the application of the proceeds thereof as described in the Registration Statement and the Prospectus, will not be, an &#8220;investment company&#8221; as defined in the Investment Company Act of 1940, as amended.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font color="black" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font color="black" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font color="black" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ix)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font color="black" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No consent, approval, authorization or filing with or order of the </font>NASDAQ Capital Market<font color="black" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">, any U.S. federal or Massachusetts court or governmental agency or other body having jurisdiction over the Company or under the DGCL is required for the consummation by the Company of the transactions contemplated by the Agreement and Warrants, except (a) such as have been made with or obtained by the </font>NASDAQ Capital Market,<font color="black" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> (b) such as have been made or obtained under the Securities Act and (c) such as may be required under the blue sky laws of any jurisdiction in connection with the purchase and distribution of the Public Securities by you in the manner contemplated in the Agreement, Warrants and in the Prospectus, as to which we express no opinion.</font></font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(x)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Shares have been approved for listing on the NASDAQ Capital Market upon official notice of issuance.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Notwithstanding the foregoing, inasmuch as any of the foregoing opinions relate to intellectual property or regulatory matters, such matters shall be expressly excluded from such opinions, and opinions as to such matters shall be separately delivered by the Company&#8217;s special intellectual property and regulatory counsel.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.2.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Foley Hoag LLP shall further deliver a written statement to the effect that such counsel has participated in conferences with officers and other representatives of the Company, representatives of special counsel to the Company, the Underwriter and its counsel, and the independent registered public accounting firm of the Company, at which conferences the contents of the Registration Statement and the Prospectus contained therein and related matters were discussed and, although such counsel is not passing upon and does not assume any responsibility for the accuracy, completeness or fairness of the statements contained in the Registration Statement and the Prospectus contained therein, solely on the basis of the foregoing without independent check and verification, no facts have come to the attention of such counsel which lead them to believe that the Registration Statement or any amendment thereto, at the time the Registration Statement or amendment became effective, contained an untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein not misleading or the Prospectus or any amendment or supplement thereto, at the time they were filed pursuant to Rule 424(b) or at the date of such counsel&#8217;s opinion, contained an untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statement therein, in light of the circumstances under which they were made, not misleading (except that such counsel need express no view and shall not be deemed to have made any such statement with respect to the financial statements, including the notes and schedules thereto, any other financial information, statistical data or information, and matters regarding any law other than United States federal and Massachusetts laws and regulations or the DGCL included in the Registration Statement or the Prospectus).</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">19</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.2.3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Closing Date Opinion of Intellectual Property Counsel</font> On the Closing Date, the Underwriter shall have received the favorable opinion of Wolf Greenfield &amp; Sacks, P.C. special intellectual property counsel, dated the Closing Date, addressed to the Underwriter and in form and substance satisfactory to SRFF.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.2.4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Option Closing Date Opinions of Counsel</font>. On the Option Closing Date, if any, the Underwriter shall have received an opinion of Foley Hoag LLP, dated the Option Closing Date, addressed to the Underwriter and in form and substance reasonably satisfactory to the Underwriter, confirming as of the Option Closing Date the statements made by such counsel in the opinions delivered on the Closing Date.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.2.5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Reliance</font>. In rendering such opinions, such counsel may rely upon such matters the form and substance of which shall be reasonably satisfactory to the Underwriter.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Cold Comfort Letter</font>.&#160;&#160;At the time this Agreement is executed, and at each of the Closing Date and the Option Closing Date, if any, the Underwriter shall have received a cold comfort letter, addressed to the Underwriter and in form and substance reasonably satisfactory to the Underwriter from Grant Thornton<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>and Stowe &amp; Degon LLC dated, respectively, as of the date of this Agreement and as of the Closing Date and the Option Closing Date, if any.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Officers&#8217; Certificates</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.4.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Officers&#8217; Certificate</font>.&#160;&#160;At each of the Closing Date and the Option Closing Date, if any, the Underwriter shall have received a certificate of the Company signed by the Chief Executive Officer of the Company, dated the Closing Date or the Option Closing Date, as the case may be, respectively, to the effect that the Company has performed all covenants and complied with all conditions required by this Agreement to be performed or complied with by the Company prior to and as of the Closing Date, or the Option Closing Date, as the case may be, and that the conditions set forth in Section 4 hereof have been satisfied as of such date and that, as of the Closing Date and the Option Closing Date, as the case may be, the representations and warranties of the Company set forth in Section 2 hereof are true and correct in all material respects. In addition, the Underwriter will have received such other and further certificates of officers of the Company as the Underwriter may reasonably request.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.4.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Secretary&#8217;s Certificate</font>.&#160;&#160;At each of the Closing Date and the Option Closing Date, if any, the Underwriter shall have received in form and substance satisfactory to it a certificate of the Company signed by the Secretary or Assistant Secretary of the Company, dated the Closing Date or the Option Date, as the case may be, respectively, certifying: (i)&#160;that the Certificate of Incorporation and Bylaws of the Company are true and complete, have not been modified and are in full force and effect; (ii)&#160;that the resolutions of the Company&#8217;s Board of Directors relating to the public offering contemplated by this Agreement and the resolutions of the Company&#8217;s Board of Directors in the form provided to the Underwriter<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8217;</font>s Counsel prior to the execution hereof are in full force and effect and have not been modified (the <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8220;</font>Board Resolutions<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8221;</font>); (iii) as to the accuracy and completeness of all correspondence between the Company or its counsel and the Commission; (iv)&#160;as to the incumbency of the officers of the Company executing agreements or other instruments on behalf of the Company in connection with the Offering, (v) as to the capitalization of the Company&#8217;s securities and the matters covered by Section 2.9.1 of this Agreement, and (vi) as to the matters covered by Section 2.18.5 of this Agreement. The documents referred to in such certificate shall be attached to such certificate.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Material Changes</font>.&#160;&#160;(i) Since the date of this Agreement through to and on each of the Closing Date and the Option Closing Date, if any: (a)&#160;there shall have been no event which would result in a Material Adverse Effect from the latest dates as of which such condition is set forth in the Registration Statement and Prospectus; (b)&#160;no action suit or proceeding, at law or in equity, shall have been threatened or initiated against the Company, the Subsidiary or any of its officers or directors in their capacities as such before or by any court or federal or state commission, board or other administrative agency wherein an unfavorable decision, ruling or finding would result in a Material Adverse Effect, except as set forth in the Registration Statement and Prospectus; (c)&#160;no stop order shall have been issued under the Act and no proceedings therefore shall have been initiated or threatened by the Commission; and (d)&#160;as of the Closing Date or the Option Closing Date, as applicable, the Registration Statement and the Prospectus and any amendments or supplements thereto shall contain all material statements which are required to be stated therein in accordance with the Act and the Regulations and shall conform in all material respects to the requirements of the Act and the Regulations, and neither the Registration Statement nor the Prospectus nor any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Delivery of Agreements</font>. On the Effective Date, the Underwriter shall have received executed copies of this Agreement and the Lock-Up Agreements.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Closing Date Deliveries</font>. At least one Business Day prior to the Closing Date, the Underwriter shall have received at the office of SRFF any certificates, if any, or Warrants representing the Firm Units to be for checking and packaging.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Option Closing Date Deliveries</font>. At least one Business Day prior to the Option Closing Date, the Underwriter shall have received at the office of SRFF any certificates, if any, or Warrants representing the Option Units to be for checking and packaging.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Completion of Reverse Stock Split</font>.&#160;&#160;Prior to the Effective Time, the Company shall have completed all necessary corporate action and filed all necessary certificates or amendments to its Certificate of Incorporation with the Secretary of State of the State of Delaware, to effectuate a reverse stock split on the basis of one share of Common Stock for each ____ shares of Common Stock issued and outstanding prior to the Effective Time.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.10&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="TEXT-DECORATION: underline">Deliv</font><font style="DISPLAY: inline"><font style="TEXT-DECORATION: underline">ery of Board Resolutions</font>. </font><font style="DISPLAY: inline">Prior to the Effective Time, the Company shall have delivered to the Underwriter the Board Resolutions, </font><font style="DISPLAY: inline">duly adopted by the Board of Directors of the Company.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.11&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="TEXT-DECORATION: underline">Further Documents.</font> In addition to the foregoing, the Company shall deliver to the Underwriter at or prior to the Closing Date or Option Closing Date, as applicable, such other instruments or other documents as the Underwriter shall reasonably request.</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">21</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">5.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Indemnification</font>.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">5.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Indemnification of the Underwriter</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">General</font>.&#160;&#160;Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless the Underwriter, and each dealer selected by the Underwriter that participates in the offer and sale of the Securities (each a &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Selected Dealer</font>&#8221;) and each of their respective directors, officers and employees and each person, if any, who controls the Underwriter (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Controlling Person</font>&#8221;) within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, against any and all loss, liability, claim, damage and expense whatsoever (including but not limited to any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action between the Underwriter and the Company or between the Underwriter and any third party or otherwise) to which they or any of them may become subject under the Act, the Exchange Act or any other statute or at common law or otherwise or under the laws of foreign countries, arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained in (i) the Preliminary Prospectus, the Registration Statement or the Prospectus (as from time to time each may be amended and supplemented); (ii) any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Securities, including any &#8220;road show&#8221; or investor presentations made to investors by the Company (whether in person or electronically); or (iii) any application or other document or written communication (in this Section 5, collectively called &#8220;application&#8221;) executed by the Company or based upon written information furnished by the Company in any jurisdiction in order to qualify the Public Securities under the securities laws thereof or filed with the Commission, any state securities commission or agency, NASDAQ Capital Market or any securities exchange; or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, unless such statement or omission was made in reliance upon and in conformity with written information furnished to the Company with respect to the Underwriter by or on behalf of the Underwriter expressly for use in the Preliminary Prospectus, the Registration Statement or Prospectus, or any amendment or supplement thereof, or in any application, as the case may be. With respect to any untrue statement or omission or alleged untrue statement or omission made in the Preliminary Prospectus, the indemnity agreement contained in this Section 5.1.1 shall not inure to the benefit of any Underwriter to the extent that any loss, liability, claim, damage or expense of the Underwriter results from the fact that a copy of the Prospectus was not given or sent to the person asserting any such loss, liability, claim or damage at or prior to the written confirmation of sale of the Securities to such person as required by the Act and the Regulations, and if the untrue statement or omission has been corrected in the Prospectus, unless such failure to deliver the Prospectus was a result of non-compliance by the Company with its obligations under Section 3.3 hereof. The Company agrees promptly to notify the Underwriter of the commencement of any litigation or proceedings against the Company or any of its officers, directors or Controlling Persons in connection with the issue and sale of the Public Securities or in connection with the Registration Statement or Prospectus.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Procedure</font>.&#160;&#160;If any action is brought against the Underwriter, a Selected Dealer or a Controlling Person in respect of which indemnity may be sought against the Company pursuant to Section 5.1.1, the Underwriter, such Selected Dealer or Controlling Person, as the case may be, shall promptly notify the Company in writing of the institution of such action and the Company shall assume the defense of such action, including the employment and fees of counsel (subject to the reasonable approval of the Underwriter or such Selected Dealer or Controlling Person, as the case may be) and payment of actual expenses. Such Underwriter, such Selected Dealer or Controlling Person shall have the right to employ a single counsel in any such case, but the fees and expenses of such counsel shall be at the expense of the Underwriter, such Selected Dealer or Controlling Person unless (i) the employment of such counsel at the expense of the Company shall have been authorized in writing by the Company in connection with the defense of such action, or (ii) the Company shall not have employed counsel to have charge of the defense of such action, or (iii) such indemnified party or parties shall have reasonably concluded that there may be defenses available to it or them which are different from or additional to those available to the Company (in which case the Company shall not have the right to direct the defense of such action on behalf of the indemnified party or parties), in any of which events the reasonable fees and expenses of not more than one additional firm of attorneys selected by the Underwriter (in addition to local counsel), Selected Dealer and/or Controlling Person shall be borne by the Company. Notwithstanding anything to the contrary contained herein, if any Underwriter, Selected Dealer or Controlling Person shall assume the defense of such action as provided above, the Company shall have the right to approve the terms of any settlement of such action which approval shall not be unreasonably withheld.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">22</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">5.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Indemnification of the Company</font>.&#160;&#160;The Underwriter agrees to indemnify and hold harmless the Company, its directors, officers and employees and agents who control the Company within the meaning of Section 15 of the Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity from the Company to the Underwriter, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions made in the Preliminary Prospectus, the Registration Statement or Prospectus or any amendment or supplement thereto or in any application, in reliance upon, and in strict conformity with, written information furnished to the Company with respect to the Underwriter by or on behalf of the Underwriter expressly for use in the Preliminary Prospectus, the Registration Statement or Prospectus or any amendment or supplement thereto or in any such application. In case any action shall be brought against the Company or any other person so indemnified based on the Preliminary Prospectus, the Registration Statement or Prospectus or any amendment or supplement thereto or any application, and in respect of which indemnity may be sought against the Underwriter, the Underwriter shall have the rights and duties given to the Company, and the Company and each other person so indemnified shall have the rights and duties given to the Underwriter by the provisions of Section 5.1.2.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">5.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Contribution</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.3.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Contribution Rights</font>.&#160;&#160;In order to provide for just and equitable contribution under the Act in any case in which (i) any person entitled to indemnification under this Section 5 makes claim for indemnification pursuant hereto but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Section 5 provides for indemnification in such case, or (ii) contribution under the Act, the Exchange Act or otherwise may be required on the part of any such person in circumstances for which indemnification is provided under this Section 5, then, and in each such case, the Company and the Underwriter shall contribute to the aggregate losses, liabilities, claims, damages and expenses of the nature contemplated by said indemnity agreement incurred by the Company and the Underwriter, as incurred, in such proportions that the Underwriter is responsible for that portion represented by the percentage that the underwriting discount appearing on the cover page of the Prospectus bears to the initial offering price appearing thereon and the Company is responsible for the balance; provided, that, no person guilty of a fraudulent misrepresentation (within the meaning of Section 11 (f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. Notwithstanding the provisions of this Section 5.3.1, the Underwriter shall not be required to contribute any amount in excess of the amount by which the total price at which the Public Securities underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages that the Underwriter has otherwise been required to pay in respect of such losses, liabilities, claims, damages and expenses. For purposes of this Section, each director, officer and employee of the Underwriter or the Company, as applicable, and each person, if any, who controls the Underwriter or the Company, as applicable, within the meaning of Section 15 of the Act shall have the same rights to contribution as the Underwriter or the Company, as applicable.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.3.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Contribution Procedure</font>.&#160;&#160;Within fifteen days after receipt by any party to this Agreement (or its representative) of notice of the commencement of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another party (&#8220;contributing party&#8221;), notify the contributing party of the commencement thereof, but the failure to so notify the contributing party will not relieve it from any liability which it may have to any other party other than for contribution hereunder. In case any such action, suit or proceeding is brought against any party, and such party notifies a contributing party or its representative of the commencement thereof within the aforesaid fifteen days, the contributing party will be entitled to participate therein with the notifying party and any other contributing party similarly notified. Any such contributing party shall not be liable to any party seeking contribution on account of any settlement of any claim, action or proceeding affected by such party seeking contribution on account of any settlement of any claim, action or proceeding affected by such party seeking contribution without the written consent of such contributing party. The contribution provisions contained in this Section 5.3.2 are intended to supersede, to the extent permitted by law, any right to contribution under the Act, the Exchange Act or otherwise available.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">23</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">6.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Additional Covenants</font>.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">6.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Board Composition and Board Designations</font>.&#160;&#160;The Company shall ensure that for a period of three years from the Closing Date: (i)&#160;the qualifications of the persons serving as board members and the overall composition of the board comply with the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder and with the listing requirements of, NASDAQ Capital Market or any other national securities exchange or national securities association, as the case may be, in the event the Company seeks to have its Public Securities listed on another exchange or quoted on an automated quotation system, and (ii)&#160;if applicable, at least one member of the board of directors qualifies as a &#8220;financial expert&#8221; as such term is defined under the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">6.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Right of First Refusal</font>.&#160;&#160;The Company agrees that if all of the Firm Units are sold in accordance with the terms of this Underwriting Agreement, the Underwriter shall have an irrevocable right for a period of twelve (12) months from the Closing Date to purchase for its account or to sell for the account of the Company, or any subsidiary of or successor to the Company any securities of the Company or any such subsidiary or successor which the Company or any such subsidiary or successor may seek to sell in public or private equity and public debt offerings of the Company or any subsidiary of or successor to the Company of its subsidiaries, whether with or without or through an underwriter, placement agent or broker-dealer. The Company and any such subsidiary or successor will consult the Underwriter with regard to any such proposed financing and will offer the Underwriter the opportunity to purchase or sell any such securities on terms not more favorable to the Company or any such subsidiary or successor, as the case may be, than it or they can secure elsewhere. If the Underwriter fails to accept such offer within 10 business days after the mailing of a notice containing the material terms of the proposed financing proposal by registered mail or overnight courier service addressed to the Underwriter, then the Underwriter shall have no further claim or right with respect to the financing proposal contained in such notice. If, however, the terms of such financing proposal are subsequently modified in any material respect, the preferential right referred to herein shall apply to such modified proposal as if the original proposal had not been made. The Underwriter&#8217;s failure to exercise its preferential right with respect to any particular proposal shall not affect its preferential rights relative to future proposals during the aforesaid twelve (12) month period. The Company shall have the right, at its option, to designate the Underwriter as lead underwriter or co-manager of any underwriting group or co-placement agent of any proposed financing in satisfaction of its obligations hereunder, and the Underwriter shall be entitled to receive as its compensation 50% of the compensation payable to the underwriting or placement agent group when serving as co-manager or co-placement agent and 33% of the compensation payable to the underwriting or placement agent group when serving as co-manager or co-placement agent with respect to a proposed financing in which there are three co-managing or lead underwriters or co-placement agents.&#160;&#160;For avoidance of doubt, the right of first refusal set forth in this Section 6.1 shall not apply to any resale offerings of the Company&#8217;s securities by its security holders.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">6.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Prohibition on Press Releases and Public Announcements</font>.&#160;&#160;The Company will not issue press releases or engage in any other publicity, without the Underwriter&#8217;s prior written consent, for a period ending at 5:00 p.m. Eastern time on the first business day following the 40th day following the Closing Date, other than normal and customary releases issued in the ordinary course of the Company&#8217;s business or as otherwise required by law (including without limitation the filing of any reports required to be filed under the Exchange Act). The Company covenants to at all times adhere to all &#8220;gun jumping&#8221; and &#8220;quiet period&#8221; rules and regulations of the Commission.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">7.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Effective Date of this Agreement and Termination Thereof</font>.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">7.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Effective Date</font>.&#160;&#160;This Agreement shall become effective when both the Company and the Underwriter have executed the same and delivered counterparts of such signatures to the other party.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">7.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Termination</font>.&#160;&#160;The Underwriter shall have the right to terminate this Agreement at any time prior to the Closing Date or the Option Closing Date, (i)&#160;if any domestic or international event or act or occurrence has materially disrupted, or in your opinion will in the immediate future materially disrupt, general securities markets in the United States; or (ii)&#160;if trading on the NASDAQ Capital Market (or any successor thereto) or any other securities exchange or any over-the-counter market shall have been suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities shall have been required by FINRA or by order of the Commission or any other government authority having jurisdiction, or (iii)&#160;if the United States shall have become involved in a new war or an increase in major hostilities, or (iv)&#160;if a banking moratorium has been declared by a New York State or federal authority, or (v)&#160;if a moratorium on foreign exchange trading has been declared which materially adversely impacts the United States securities markets, or (vi)&#160;if the Company or the Subsidiary shall have sustained a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss shall have been insured, will, in your opinion, make it inadvisable to proceed with the delivery of the Firm Units or Option Units, or (vii)&#160;if the Company is in material breach of any of its representations, warranties or covenants hereunder, or (viii)&#160;if the Underwriter shall have become aware after the date hereof of such a material adverse change in the conditions or prospects of the Company or the Subsidiary, or such adverse material change in general market conditions as in the Underwriter&#8217;s judgment would make it impracticable to proceed with the offering, sale and/or delivery of the securities or to enforce contracts made by the Underwriter for the sale of the securities.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">25</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">7.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Expenses</font>.&#160;&#160;In the event that this Agreement shall not be carried out for any reason whatsoever, within the time specified herein or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Underwriter its actual accountable expenses incurred through the termination date up to a maximum of $100,000 (provided, however, that such expense cap in no way limits or impairs the indemnification and contribution provisions of this Agreement) for all such expenses (which expenses will include, but will not be limited to, all reasonable fees and disbursements of the Underwriter&#8217;s counsel, travel, lodging and other &#8220;road show&#8221; expenses, mailing, printing and reproduction expenses, and any expenses incurred by the Underwriter in conducting its due diligence, including background checks of the Company&#8217;s officers and directors), less amounts, if any, previously paid to the Underwriter in reimbursement for such expenses or as an advance.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">7.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Indemnification</font>.&#160;&#160;Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of Section 5 shall not be in any way effected by, such election or termination or failure to carry out the terms of this Agreement or any part hereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">7.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Survival</font>. Except as set forth herein, all representations, warranties and agreements contained in this Agreement shall be deemed to be representations, warranties and agreements as of the Closing Date or the Option Closing Date, if any, and such representations, warranties and agreements of the Underwriter and the Company, including the indemnity agreements contained in Section 5 hereof, shall remain operative and in full force and effect regardless of any investigation made by or on behalf of the Underwriter, the Company or any controlling person, and shall survive termination of this Agreement or the issuance and delivery of the Public Securities to the Underwriters until the earlier of the expiration of any applicable statute of limitations and the seventh anniversary of the later of the Closing Date or the Option Closing Date, if any, at which time the representations, warranties and agreements shall terminate and be of no further force and effect.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">8.</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Miscellaneous</font>.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">8.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Notices</font>.&#160;&#160;All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed (registered or certified mail, return receipt requested), personally delivered or sent by facsimile transmission and confirmed and shall be deemed given when so delivered or faxed and confirmed or if mailed, two days after such mailing.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If to the Underwriter:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Rodman &amp; Renshaw, LLC</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1251 Avenue of Americas, 20th Floor</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">New York, NY 10020</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attn: General Counsel</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fax No.: 646-841-1640</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Copy to:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Sichenzia Ross Friedman Ference LLP</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">61 Broadway, 32nd. Floor</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">New York, NY 10006</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attn: Harvey Kesner</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fax No.: 212-930-9700</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">26</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If to the Company:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Novelos Therapeutics, Inc.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">One Gateway Center</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Suite 504</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Newton, MA 02458</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attn: Harry S. Palmin</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fax No.: 617-860-1170</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Copy to:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Foley Hoag LLP</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Seaport World Trade Center West</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">155 Seaport Boulevard</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Boston, Massachusetts 02210-2600</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attn: Paul Bork</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fax No.: 617-832-7000</font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">8.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Headings</font>.&#160;&#160;The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">8.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Amendment</font>.&#160;&#160;This Agreement may only be amended by a written instrument executed by each of the parties hereto.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">8.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Entire Agreement</font>.&#160;&#160;This Agreement (together with the other agreements and documents being delivered pursuant to or in connection with this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">8.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Binding Effect</font>.&#160;&#160;This Agreement shall inure solely to the benefit of and shall be binding upon the Underwriter, the Company and the Controlling Persons, directors and officers referred to in Section 5 hereof, and their respective successors, legal representatives and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Agreement or any provisions herein contained. The term &#8220;successors and assigns&#8221; shall not include a purchaser, in its capacity as such, of securities from the Underwriter.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">8.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Governing Law</font>.&#160;&#160;This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 8.1 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company agrees that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys&#8217; fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefore.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">27</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">8.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Execution in Counterparts</font>.&#160;&#160;This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall constitute valid and sufficient delivery thereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">8.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Waiver, etc</font>.&#160;&#160;The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[SIGNATURE PAGE FOLLOWS]</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If the foregoing correctly sets forth the understanding between the Underwriter and the Company, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between us.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="38%">Very truly yours,</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="38%">&#160;</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="38%">NOVELOS THERAPEUTICS, INC.</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="38%">&#160;</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name: Harry Palmin</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title: Chief Executive Officer and President</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accepted on the date first above written.</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">RODMAN &amp; RENSHAW, LLC</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:&#160;</font></td>
<td align="left" valign="top" width="35%" style="BORDER-BOTTOM: #000000 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="32%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name: John Borer</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="32%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="justify" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="justify" valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title: Head of Investment Banking</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="justify" valign="top" width="32%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">29</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT A</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form of Warrant</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(See Exhibit 4.2 to this filing)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">30</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT B-1</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Lock-Up Agreement</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">___________ __, 2011</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Rodman &amp; Renshaw, LLC</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1251 Avenue of Americas, 20th Floor</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">New York, NY 10020</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ladies and Gentlemen:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The undersigned understands that Rodman &amp; Renshaw, LLC (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Underwriter</font>&#8221;) proposes to enter into an Underwriting Agreement (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Underwriting Agreement</font>&#8221;) with Novelos Therapeutics, Inc., a Delaware corporation (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Company</font>&#8221;), providing for the public offering (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Public Offering</font>&#8221;) by the Underwriter of up to $15 million (not including over-allotments) in aggregate offering price of shares of common stock, par value $0.00001 per share, of the Company (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Common Stock</font>&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To induce the Underwriter to continue its efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent of the Underwriter, the undersigned will not, during the period (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Lock-Up Period</font>&#8221;) commencing on the date hereof and ending 180<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>days after the date of the final prospectus relating to the Public Offering (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Prospectus</font>&#8221;), (1) offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Shares</font>&#8221;) or any securities convertible into or exercisable or exchangeable for Shares, (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Shares, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Shares or such other securities, in cash or otherwise, (3) make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any Shares or securities convertible into or exercisable or exchangeable for Shares or other securities of the Company, or (4) publicly disclose the intention to do any of the foregoing.&#160;&#160;Notwithstanding the foregoing, the undersigned may transfer Shares without the prior consent of the Underwriter in connection with (a) transactions relating to Shares or other securities acquired in open market transactions after the completion of the Public Offering,<font style="DISPLAY: inline; FONT-STYLE: italic"> provided</font> that no filing under Section&#160;16(a) of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Exchange Act</font>&#8221;), shall be required or shall be voluntarily made in connection with subsequent sales of Shares or other securities acquired in such open market transactions, (b) transfers of Shares or any security convertible into Shares as a bona fide gift, by will or intestacy or to a family member or trust for the benefit of a family member; <font style="DISPLAY: inline; FONT-STYLE: italic">provided</font> that in the case of any transfer or distribution pursuant to clause&#160;(b), (i) each donee or distributee shall sign and deliver a lock-up letter substantially in the form of this letter agreement and (ii) no filing under Section&#160;16(a) of the Exchange Act, reporting a reduction in beneficial ownership of Shares, shall be required or shall be voluntarily made during the Lock-up Period, (c) transfer of Shares to a charity or educational institution, or (d) if the undersigned is, or directly or indirectly controls, a corporation, partnership, limited liability company or other business entity, any transfers of Shares to any shareholder, partner or member of, or owner of similar equity interests in, the undersigned, as the case may be, if, in any such case, such transfer is not for value. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#8217;s transfer agent and registrar against the transfer of the undersigned&#8217;s Shares except in compliance with this Agreement.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If the undersigned is an officer or director of the Company, (i) the Underwriter agrees that, at least three business days before the effective date of any release or waiver of the foregoing restrictions in connection with any transfer of Shares, the Underwriter will notify the Company of the impending release or waiver, and (ii) the Company will announce, in accordance with the Underwriting Agreement, the impending release or waiver by issuing a press release through a major news service at least two business days before the effective date of the release or waiver.&#160;&#160;Any release or waiver granted by the Underwriter hereunder to any such officer or director shall only be effective two business days after the publication date of such press release.&#160;&#160;The provisions of this paragraph will not apply if both (a) the release or waiver is effected solely to permit a transfer not for consideration, and (b) the transferee has agreed in writing to be bound by the same terms described in this letter that are applicable to the transferor, to the extent and for the duration that such terms remain in effect at the time of the transfer.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If (i) the Company issues an earnings release or material news, during the last 17 days of the Lock-Up Period, or (ii) prior to the expiration of the Lock-Up Period, the Company announces that it will release earnings results during the 16-day period beginning on the last day of the Lock-Up Period, the restrictions imposed by this agreement shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release, unless the Underwriter waives such extension.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No provision in this agreement shall be deemed to restrict or prohibit the exercise or exchange by the undersigned of any option or warrant to acquire Shares, or securities exchangeable or exercisable for or convertible into Shares, <font style="DISPLAY: inline; FONT-STYLE: italic">provided that</font> the undersigned does not transfer the Shares acquired on such exercise or exchange during the Lock-Up Period, unless otherwise permitted pursuant to the terms of this letter agreement.&#160;&#160;In addition, no provision herein shall be deemed to restrict or prohibit the entry into or modification of a so-called &#8220;10b5-1&#8221; plan at any time (other than the entry into or modification of such a plan in such a manner as to cause the sale of any Shares or any securities convertible into or exercisable or exchangeable for Shares within the Lock-Up Period).</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The undersigned understands that the Company and the Underwriter are relying upon this letter agreement in proceeding toward consummation of the Public Offering.&#160;&#160;The undersigned further understands that this agreement is irrevocable and shall be binding upon the undersigned&#8217;s heirs, legal representatives, successors and assigns.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The undersigned understands that, if the Underwriting Agreement is not executed by the Company, or if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Shares to be sold thereunder this agreement shall be void and of no further force or effect.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Whether or not the Public Offering actually occurs depends on a number of factors, including market conditions.&#160;&#160;Any Public Offering will only be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriter.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="35%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Very truly yours,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</td>
</tr><tr>
<td valign="top" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Name):</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</td>
</tr><tr>
<td valign="top" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Address)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">32</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT B-2</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Lock-Up Agreement</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">___________ __, 20__</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The undersigned understands that Rodman &amp; Renshaw, LLC (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Underwriter</font>&#8221;) proposes to enter into an Underwriting Agreement (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Underwriting Agreement</font>&#8221;) with Novelos Therapeutics, Inc., a Delaware corporation (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Company</font>&#8221;), providing for the public offering (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Public Offering</font>&#8221;) by the Underwriter of up to $15 million (not including over-allotments) in aggregate offering price of shares of common stock, par value $0.00001 per share, of the Company (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Common Stock</font>&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To induce the Underwriter to continue its efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent of the Underwriter, the undersigned will not, during the period (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Lock-Up Period</font>&#8221;) commencing on the date hereof and ending 180<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>days after the date of the final prospectus relating to the Public Offering (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Prospectus</font>&#8221;), (1) offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Shares</font>&#8221;) or any securities convertible into or exercisable or exchangeable for Shares, (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Shares, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Shares or such other securities, in cash or otherwise, (3) make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any Shares or securities convertible into or exercisable or exchangeable for Shares or other securities of the Company, or (4) publicly disclose the intention to do any of the foregoing.&#160;&#160;Notwithstanding the foregoing, the undersigned may transfer Shares without the prior consent of the Underwriter in connection with (a) transactions relating to Shares or other securities acquired in open market transactions after the completion of the Public Offering,<font style="DISPLAY: inline; FONT-STYLE: italic"> provided</font> that no filing under Section&#160;16(a) of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Exchange Act</font>&#8221;), shall be required or shall be voluntarily made in connection with subsequent sales of Shares or other securities acquired in such open market transactions, (b) if the undersigned is an individual, transfers of Shares or any security convertible into Shares as a bona fide gift, by will or intestacy or to a family member or trust for the benefit of a family member; <font style="DISPLAY: inline; FONT-STYLE: italic">provided</font> that in the case of any transfer or distribution pursuant to clause&#160;(b), (i) each donee or distributee shall sign and deliver a lock-up letter substantially in the form of this letter agreement and (ii) no filing under Section&#160;16(a) of the Exchange Act, reporting a reduction in beneficial ownership of Shares, shall be required or shall be voluntarily made during the Lock-up Period, (c) transfer of Shares to a charity or educational institution, (d) if the undersigned is, or directly or indirectly controls, a corporation, partnership, limited liability company or other business entity, any transfers of Shares to any shareholder, partner or member of, or owner of similar equity interests in, the undersigned, as the case may be, if, in any such case, such transfer is not for value, or (e) if the undersigned is a corporation, partnership, limited liability company or other business entity, any transfer of Shares made by the undersigned (i) in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned&#8217;s capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially all of the undersigned&#8217;s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by this agreement or (ii) to another corporation, partnership, limited liability company or other business entity so long as the transferee is an affiliate of the undersigned and such transfer is not for value.&#160;&#160;The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#8217;s transfer agent and registrar against the transfer of the undersigned&#8217;s Shares except in compliance with this Agreement.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">33</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If (i) the Company issues an earnings release or material news, during the last 17 days of the Lock-Up Period, or (ii) prior to the expiration of the Lock-Up Period, the Company announces that it will release earnings results during the 16-day period beginning on the last day of the Lock-Up Period, the restrictions imposed by this agreement shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release, unless the Underwriter waives such extension.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No provision in this agreement shall be deemed to restrict or prohibit the exercise or exchange by the undersigned of any option or warrant to acquire Shares, or securities exchangeable or exercisable for or convertible into Shares, <font style="DISPLAY: inline; FONT-STYLE: italic">provided that</font> the undersigned does not transfer the Shares acquired on such exercise or exchange during the Lock-Up Period, unless otherwise permitted pursuant to the terms of this letter agreement.&#160;&#160;In addition, no provision herein shall be deemed to restrict or prohibit the entry into or modification of a so-called &#8220;10b5-1&#8221; plan at any time (other than the entry into or modification of such a plan in such a manner as to cause the sale of any Shares or any securities convertible into or exercisable or exchangeable for Shares within the Lock-Up Period).</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The undersigned understands that the Company and the Underwriter are relying upon this letter agreement in proceeding toward consummation of the Public Offering.&#160;&#160;The undersigned further understands that this agreement is irrevocable and shall be binding upon the undersigned&#8217;s heirs, legal representatives, successors and assigns.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The undersigned understands that, if the Underwriting Agreement is not executed by the Company, or if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Shares to be sold thereunder this agreement shall be void and of no further force or effect.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Whether or not the Public Offering actually occurs depends on a number of factors, including market conditions.&#160;&#160;Any Public Offering will only be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriter.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="35%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Very truly yours,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>
</td>
</tr><tr>
<td valign="top" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Name):</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>
</td>
</tr><tr>
<td valign="top" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Address)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">34</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>11
<FILENAME>v236909_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<!DOCTYPE HTML PUBLIC "ex4-1">


<HTML>
<HEAD>
   <TITLE>ex4-1 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY bgcolor="#ffffff">

<!--$$/page=-->
<A name="page_1"></A>

<IMG src="ex4-1x1x1.jpg" border=0>
<BR>

<HR size="1" width="100%" style="page-break-after: always">

<!--$$/page=-->
<A name="page_2"></A>

<IMG src="ex4-1x2x1.jpg" border=0>
<BR>

<HR size="1" width="100%" style="page-break-after: always">

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>12
<FILENAME>v236909_ex4-2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">COMMON STOCK PURCHASE WARRANT</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOVELOS THERAPEUTICS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%" style="BORDER-TOP: medium none; BORDER-LEFT: medium none; BORDER-BOTTOM: 4px none">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrant Shares: [_______]</font></div>
</td>
<td valign="top" width="50%" style="BORDER-RIGHT: medium none; BORDER-TOP: medium none; BORDER-BOTTOM: 4px none ; TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Initial Exercise Date:_____________, 201_</font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THIS COMMON STOCK PURCHASE WARRANT (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant</font>&#8221;) certifies that, for value received, _____________ or its assigns (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Holder</font>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Initial Exercise Date</font>&#8221;) and on or prior to the close of business on _____________, 201__<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: super">1</font> (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Termination Date</font>&#8221;), but not thereafter, to subscribe for and purchase from Novelos Therapeutics, Inc., a Delaware corporation (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Company</font>&#8221;), up to ______ shares (as subject to adjustment hereunder, the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant Shares</font>&#8221;) of the common stock, par value $0.00001 per share, of the Company (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Common Stock</font>&#8221;). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 1(b).</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 1</font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exercise</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed facsimile copy of the Notice of Exercise Form annexed hereto. Within three (3) Trading Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 1(c) below is required in connection with the applicable Notice of Exercise. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.&#160;&#160;The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within one (1) Trading Day of receipt of such notice.&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.&#160;&#160;</font>&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Trading Day</font>&#8221; means a day on which the principal Trading Market is open for trading.&#160;&#160;&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Trading Market</font>&#8221; means any of markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<hr style="COLOR: #000000" align="left" noshade size="1" width="20%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">1</font> Five years from initial exercise date.</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exercise Price</font>.&#160;&#160;The exercise price per share of the Common Stock under this Warrant shall be <font style="DISPLAY: inline; FONT-WEIGHT: bold">$[</font>_____], subject to adjustment hereunder (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exercise Price</font>&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Cashless Exercise</font>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for, the issuance of the Warrant Shares to the Holder, then this Warrant may be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a certificate for the number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 137px">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td width="838">
<div style="MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(A) =&#160; the VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a &#8220;cashless exercise,&#8221; as set forth in the applicable Notice of Exercise;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 138px">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td width="837">
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(B) =&#160;&#160; the Exercise Price of this Warrant, as adjusted hereunder; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 103.5pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td>
<div style="MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(X) =&#160; the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">VWAP</font>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&#160; if the OTC Bulletin Board is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board, (c) if prices for the Common Stock are then reported in the &#8220;Pink Sheets&#8221; published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&#160;in all other cases, the fair market value of a share of Common Stock as mutually agreed to between the Company and Holder.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Notwithstanding anything herein to the contrary, this Warrant shall not be exercisable by means of a &#8220;cashless exercise&#8221; under any circumstances other than those set forth in this Section 1(c).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Mechanics of Exercise</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">i.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Delivery of Certificates Upon Exercise</font>.&#160;&#160;Certificates for shares purchased hereunder shall be transmitted by the Company&#8217;s transfer agent to the Holder by crediting the account of the Holder&#8217;s prime broker with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">DWAC</font>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise and the Holder is not then an Affiliate of the Company, and otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise by the date that is three (3) Trading Days after the latest of (A) the delivery to the Company of the Notice of Exercise, (B) surrender of this Warrant (if required) and (C) payment of the aggregate Exercise Price as set forth above (including by cashless exercise, if permitted) (such date, the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant Share Delivery Date</font>&#8221;).&#160;&#160;The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 1(d)(v) prior to the issuance of such shares, having been paid.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Affiliate</font>&#8221; means, with respect to any Person, any other Person which directly or indirectly Controls, is Controlled by, or is under common Control with, such Person.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Control</font>&#8221; means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Person</font>&#8221; means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ii.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Delivery of New Warrants Upon Exercise</font>.&#160;&#160;If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">iii.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Rescission Rights</font>.&#160;&#160;If the Company fails to cause the Transfer Agent to transmit to the Holder a certificate or the certificates representing the Warrant Shares pursuant to Section 1(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">iv.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Compensation for Buy-In on Failure to Timely Deliver Certificates Upon Exercise</font>.&#160;&#160;In addition to any other rights available to the Holder, if the Company fails to cause the Company&#8217;s transfer agent to transmit to the Holder a certificate or the certificates representing the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Buy-In</font>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.&#160;&#160;For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.&#160;&#160;Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">v.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Fractional Shares or Scrip</font>.&#160;&#160;No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.&#160;&#160;As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">vi.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Charges, Taxes and Expenses</font>.&#160;&#160;Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <font style="DISPLAY: inline; TEXT-DECORATION: underline">provided</font>, <font style="DISPLAY: inline; TEXT-DECORATION: underline">however</font>, that in the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">vii.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Closing of Books</font>.&#160;&#160;The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; [<font style="DISPLAY: inline; TEXT-DECORATION: underline">Holder&#8217;s Exercise Limitations</font>.&#160;&#160;The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 1 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&#160;&#160;For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other&#160;&#160;Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates.&#160; Except as set forth in the preceding sentence, for purposes of this Section 1(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.&#160;&#160;&#160;To the extent that the limitation contained in this Section 1(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.&#160;&#160;&#160;In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.&#160;&#160;For purposes of this Section 1(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Securities and Exchange Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Company&#8217;s transfer agent setting forth the number of shares of Common Stock outstanding.&#160; Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&#160; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported.&#160;&#160;The &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Beneficial Ownership Limitation</font>&#8221; shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant.&#160;&#160;The Holder, upon not less than 61 days&#8217; prior notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 1(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 1(e) shall continue to apply.&#160;&#160;Any such increase or decrease will not be effective until the 61st day after such notice is delivered to the Company.&#160;&#160;The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 1(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.]&#160;&#160; [NOTE:&#160;&#160;TO BE INCLUDED AT INVESTOR REQUEST.]</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 2</font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Certain Adjustments</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Stock Dividends and Splits</font>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged.&#160;&#160;Any adjustment made pursuant to this Section 2(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Fundamental Transaction</font>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Fundamental Transaction</font>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder [(without regard to any limitation in Section 1(e) on the exercise of this Warrant)], the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Alternate Consideration</font>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction Holder [(without regard to any limitation in Section 1(e) on the exercise of this Warrant)].&#160;&#160;For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.&#160;&#160;If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.&#160;&#160;Notwithstanding anything to the contrary, in the event of a Fundamental Transaction that is (1) an all cash transaction, (2) a &#8220;Rule 13e-3 transaction&#8221; as defined in Rule 13e-3 under the Exchange Act, or (3) a Fundamental Transaction involving a person or entity not traded on a national securities exchange, including, but not limited to, the Nasdaq Global Select Market, the Nasdaq Global Market, or the Nasdaq Capital Market, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within 30 days after the consummation of the Fundamental Transaction, <font style="DISPLAY: inline">purchase this Warrant from the Holder by paying to the Holder</font> an amount of cash equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction.&#160;&#160;&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Black Scholes Value</font>&#8221; means the value of this Warrant based on the Black and Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg, L.P. (&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Bloomberg</font>&#8221;) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date.&#160;&#160;The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Successor Entity</font>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 2(b) pursuant to written agreements prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction). Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Calculations</font>. All calculations under this Section 2 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 2, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Notice to Holder</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">i.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Adjustments</font>. Whenever the Exercise Price or the number or type of securities for which this Warrant is exercisable are adjusted pursuant to any provision of this Section 2, the Company shall promptly mail to the Holder a notice setting forth such adjusted Exercise Price or such number or type securities, as applicable, and setting forth a brief statement of the facts requiring such adjustment.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ii.&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Notice to Allow Exercise by Holder</font>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice.&#160;&#160;To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of its subsidiaries, the Company shall simultaneously file such notice with the Securities and Exchange Commission pursuant to a Current Report on Form 8-K.&#160;&#160;The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 3</font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Transfer of Warrant</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Transferability</font>.&#160;&#160;This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.&#160;&#160;Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.&#160;&#160;The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">New Warrants</font>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney.&#160;&#160;Subject to compliance with Section 3(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant Register</font>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrant Register</font>&#8221;), in the name of the record Holder hereof from time to time.&#160;&#160;The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 4</font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Miscellaneous</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Rights as Stockholder Until Exercise</font>.&#160;&#160;This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 1(d)(i).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Loss, Theft, Destruction or Mutilation of Warrant</font>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Saturdays, Sundays, Holidays, etc</font>.&#160;&#160;If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Authorized Shares</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">i.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.&#160;&#160;The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant.&#160;&#160;The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.&#160;&#160;The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.&#160;&#160;Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (c) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">iii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Governing Law; Jurisdiction</font>. This Warrant shall be governed by, and construed in accordance with, the internal laws of the State of New York, without reference to the choice of law provisions thereof.&#160;&#160;The Company and, by accepting this Warrant, the Holder, each irrevocably submits to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Warrant and the transactions contemplated hereby.&#160;&#160;Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Warrant.&#160;&#160;The Company and, by accepting this Warrant, the Holder, each irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court.&#160;&#160;The Company and, by accepting this Warrant, the Holder, each irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING RELATING TO OR ARISING OUT OF THIS WARRANT AND THE TRANSACTIONS CONTEMPLATED HEREBY.</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Nonwaiver and Expenses</font>.&#160;&#160;No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies.&#160;&#160;Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Notices</font>.&#160;&#160;Unless otherwise provided, any notice required or permitted under this Warrant shall be given in writing and shall be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed given upon such delivery, (ii) if given by telex or facsimile, then such notice shall be deemed given upon receipt of confirmation of complete transmittal, (iii) if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such notice by the recipient or (B) three days after such notice is deposited in first class mail, postage prepaid, and (iv) if given by an internationally recognized overnight air courier, then such notice shall be deemed given one day after delivery to such carrier.&#160;&#160;All notices shall be addressed as follows: if to the Holder, at its address as set forth in the Company&#8217;s books and records and, if to the Company, at Novelos Therapeutics, Inc., One Gateway Center, Suite 504, Newton, MA&#160;&#160;02458, Attention:&#160;&#160;Chief Executive Officer, Fax:&#160;&#160;(617) 964-6331, or at such other address as the Holder or the Company, as applicable, may designate by ten days&#8217; advance written notice to the other.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Remedies</font>.&#160;&#160;The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant.&#160;&#160;The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Successors and Assigns</font>.&#160;&#160;Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.&#160;&#160;The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Amendment</font>.&#160;&#160;This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company <font style="DISPLAY: inline">and the Holder</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Severability</font>.&#160;&#160;Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Headings</font>.&#160;&#160;The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">********************</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Signature Page Follows)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NOVELOS THERAPEUTICS, INC.</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">&#160;</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTICE OF EXERCISE</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TO:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NOVELOS THERAPEUTICS, INC.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)&#160;&#160;&#160;&#160;&#160;&#160;The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)&#160;&#160;&#160;&#160;&#160;&#160;Payment shall take the form of (check applicable box):</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[&#160;&#160;] in lawful money of the United States; or</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[&#160; ] [if permitted] the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 1(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 1(c).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(3)&#160;&#160;&#160;&#160;&#160;&#160;Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is specified below:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 108pt"></font>_______________________________</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 108pt"></font>_______________________________</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 108pt"></font>_______________________________</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 108pt"></font>_______________________________</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[SIGNATURE OF HOLDER]</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: -36pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name of Investing Entity: ________________________________________________________________________</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: -36pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Signature of Authorized Signatory of Investing Entity</font>: _________________________________________________</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: -36pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name of Authorized Signatory: ___________________________________________________________________</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: -36pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Title of Authorized Signatory: ____________________________________________________________________</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: -36pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date: ________________________________________________________________________________________</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ASSIGNMENT FORM</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(To assign the foregoing warrant, execute</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">this form and supply required information.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Do not use this form to exercise the warrant.)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_______________________________________________ whose address is</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_______________________________________________________________.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_______________________________________________________________</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 252pt"></font>Dated:&#160;&#160;______________, _______</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 108pt"></font>Holder&#8217;s Signature:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_____________________________</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 108pt"></font>Holder&#8217;s Address:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_____________________________</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 207pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_____________________________</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Signature Guaranteed:&#160;&#160;___________________________________________</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOTE:&#160;&#160;The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company.&#160;&#160;Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>13
<FILENAME>v236909_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: vintage-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<a name="FIS_EXHIBIT_3"><!--EFPlaceholder--></a>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 23.2</font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="FIS_EXPERTS_CONSENT"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have issued our report dated June 14, 2011, with respect to the financial statements of Novelos Therapeutics, Inc. contained in the Registration Statement and Prospectus.&#160; We consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the caption "Experts."</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/ GRANT THORNTON LLP</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chicago, Illinois</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">November 9, 2011</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>14
<FILENAME>v236909_ex23-3.htm
<DESCRIPTION>EXHIBIT 23.3
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: vintage-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 23.3</font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have issued our report dated April 11, 2011, with respect to the financial statements of Novelos Therapeutics, Inc. (Pre-Acquisition) contained in the Registration Statement and Prospectus.&#160; We consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the caption "Experts."</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/ Stowe &amp; Degon LLC</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Westborough, Massachusetts</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">November 9, 2011</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex4-1x1x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-1x1x1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0`617AI9@``24DJ``@```````````#_
MVP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+#!D2$P\4'1H?'AT:'!P@)"XG("(L
M(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_VP!#`0D)"0P+#!@-#1@R(1PA,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C+_P``1"`)D`Q@#`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"
M`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A
M!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9
MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H
MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+
M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1
MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W
M^/GZ_]H`#`,!``(1`Q$`/P#WOR@.F?\`OHTHC'O^9I]%`#-@]_SIV*6B@!**
M6B@!,9HQBEHH`2BEHH`2BEHH`#24M%``****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***0KD@Y-`"T444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%(:6D-`%>YW;X\$@;N<&BG3C)3_>HH,WN3T49I,B@T%H
MHS1D4`%%&:3(H`6BDR*7(H`**3(I<T`%%&:,B@`HI,BER*`"BDR*,CUH`6BC
M(I,B@!:*3(I<T`%%)D4N:`"BDR*,CUH`6BDR/6C(]:`%HI,CUI<B@`HHS1D4
M`%%&11D4`%%&11D4`%%&11D4`%%&11D4`%%&11D4`%%&11D4`%%&11D4`%%&
M11D4`%%&11D4`%%&11D4`%%&11D4`%%&11D4`%%&11D4`%%&11D4`%%&11D4
M`%%&:*`"BBB@`HHHH`****`"BBC-`!112'KGO0`M%(">]+0`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!2&EI#0!%-U3_>
MHHFZI_O44&;W,?7=5FL)H$CGAA\Q6.9X6,9Q@G,@X3CGGT/IFLBY\4WMNGF[
M)6M\9%Q#`LD)Z_QJQ&1CD9I/&O-W9")C]H*,H"LP8`LJYQ]T_>Z'TS7,6\]Q
M:.7LY6!";@@<(3N4L`Z_=8=!DYSEN@&:=C0VO^$ZFRH$KLQ8KA84)!&[_:_V
M34I\8W>S*Q77(+9\A/?W]C^GK6"VJZM&599RA/(9DMUVC+#JJ`_W>?1C4D>J
MWTJ>8^J3^<XRJ^?(`#MZ8&!PX&>.C#@\"BPKFTOC.[)*A)/,!P4;8K`^X[=#
M3K/Q;>7;2861?GCB1<)DLP9LDG```4UC/J(N(YEU;,WER*$G"+YL:Y(#A@`)
M%P"Q!^;!J"%5T\W$-]N`MK^$.\>"3\L@#+UZY&..AHL,Z2Z\3WT#@)ND*L%=
M%*-G<I*D,`1U0_G4+>,-01XT^S2_-C),D2A>G<C!]/K@=ZQI;NWFN#,J2;-\
M0"N2,'$O<#^?`I+N&*]N`D,8W!04A5BQY`[DC_.#Z8+`;W_"67Y1F\F4X`/R
MLAX/<_+QU_PI[^*+^%/WL<B2?W6,8QV'..YX_EGG&#,EU;QQK>6[0.TI#LRX
MR`Q8'OV`Z9_I27"K_:4B'/W]Q`?&U%7=G..1U&>O%%A7.BC\3WMU*(K=&Y(`
M>62-`?T/\ZAG\5:I:@B:SG5P2"H:-L8)'8=>#QZ"N435U$CS-#'*JJVW:Y!&
M,$L3UX0-@8'W>E7-5F$8?4X6>*WG#R%7`*QOT96]<.P<_7;WQ189N_\`"8W8
MD9&BEC(95Y,9Y8J!T'JV#Z8;^Z:;'XSO)21'!<-]W!Q'@D\<<9."<'CC\JYM
M9[>6Y,$HFCED<1[<[E>1@VY%/&,9D7/`!#>U.;5(I(!):B23>4E$DH`#JS?,
M=O/.,#J?O*>HHL*YV<>LZO(6VV\F54N<F-5`!(ZGW_G5-_%URC!&#C)QG]V1
MUP._0D$`^U8*79T?07GNFNI[J\@\UD\S``5L#/?#L%'`[_6J4&HQ/J,41@1%
MED,23!\L&R5S\QP07#`8'`7.,]2P7.L7Q3?&)I1O\M`"24C`'7ON]OP[XI9?
M%ES$`=TC9X&R.-B?7@-T'KVZGBN3MF!%R&9UB!2%E"]2>!CV"@\]:L2:5?/%
M$Z6DLT7WG<N5V<]AD$CA3U[]*+!<Z@>)KPHC9F4.,@/`JGU[L/\`]?%/C\1W
M3DCY@WO;KSSC@A^<=3CH*YB&2*SMA%)$CA#ACE@>W&WG/(P._P"M6?MA:-F6
M-QNA;RP`,A@2C`YQDC!'/O18+F^/%$R;BSG"E`V+8';NZ9_><?C0?%;B%7WD
MJQVAA:Y!/''$GO7-Z1=S322B3R]K(P*DACD*6YZC'TS5HRVR,D<XF<N`RHF#
MG`!P<GWSMXS18+FROBJ4W"0[9\G&2U@0HSC'S>9C^)>_?V-3OXIVNB*P9W&<
M);%L?7$E<G<P0RRAC`\L>U4"O,S#;MV\D<`;5/(]3S5V*)C>VD]X"K2LH?D_
M+_#R/0E1@XSS18+F^_BD(SJYVN@RR&V)(Y(Z!\]O\\TJ>*2Q`,<A!`(*VS8Q
MZYW=N/S'K7*QF:WN+X2/(RQ.[2!""<(Q!(W=0<=#Z$`5)::A;PW,<\$$H$.S
M<%(8XW?,.0",,`@!SPP/I18+G4V?B@7>=D+!0!P\4BLQ.>B@$]OUJRNNRLI9
M+4L`2#\DXY'&/]7QSZUS=F\D-])$)\0&YA"N"`?)99'*9'^T#SP1G@U9AO)K
M^\,,32PQP?N9+E0!YN"0P4#N1@$D?*<A>>:+!<V3XB*W`@>*`3;=QC\R3>![
MKY61^-.;7_+1GE@CC50<L[2*!CW,8Q6?CR=L<9^RHQ*[T`8DC_:^\S8]367#
MJF^]^QW,6+@.82TG#(X`.'(X(92I!![@9%.R"YTBZ^6*`01EF7(P[G/T^3FD
M&NW`QYEDB]R!(Y./4#R_K7.%9K9I'M[@^7EF<`@^6V"`#Q@%<_>'?&[@[JT[
M74U@FB\K8(WD;=*QRX0,`0V3GKQR2>XXQ2L%S0_X2)=P79:Y/`S<XW'T&5Y/
MM2G7\,5\NV#*H+*UT`P]>-OK^=9$<FGZ;8ZC(LLQD25U1,ENR[8T)X&X$<>K
MU6CCMHXS)?PF6XE"NJM(<PQ29QZ88%6'MCWH"YOCQ)`QV`VIESC8+M<_YQ3Q
MXBM2FX26IR<#_2X^?UK"O+^TTZW@F>3['Y;1VXF5`[L<$[>^.[$]>E<SKWBY
M;BY?^QI`@D)>2=%YQ@#;&",YP#DX!^:BP7/1!XCLB0OGVNXG!47<>1^M'_"2
M6&<-<6BXZYO(O_BJ\ZM/^$EN(X)$:[BA;YM]U<E`P]>3N/Y5LG3M6$'F2:JR
M(S$@H64X^LA4?I18+G7?\)#8C83/;`,<`_:HL?\`H7--_P"$DT[:6:ZM5`[F
M[BQ_Z%7*)<6-G'B;5[V]8$Y_?R8S_P`!VC]::=?AC97$<[LJ>6N]@HQ[\$Y]
M\YHL%SK'\3:9&F][RS5!U8WD0'_H5.C\2:7*<17EK)_N743?R:N,-Y-</BUT
MJ-I"0"6C:<GZ%R1BI]OB,*%5!"/80Q<_A@T6"YV@U:%AE8W?T\O#Y_(U#)KL
M<;8-AJ!]_LQQ^=<;_9^K7#;9M6&[N/-D<_\`CHQ5A?"MY*"QNV/L8Y#_`#HL
M!U2:_:NI)BG3!QAPH_K2G7K$=9%'UEC&/_'JX\^$)^6Q.3VV6ZC^;BGKX3N<
M?=O-V.3LB'_L]%AG6?\`"0V&<>:A/M-&?_9J!X@LB<*=Q]G0_P#LU<G_`,(G
M<<CR;P^^(O\`XNF?\(C.2!Y=X,<Y:.,_R>BP'9#6K<D`17)_W8B?Y4]]7@0D
M&&\_"UDQ^>VN,7PA<L"1*ZM@#YX,8SU^Z31-HM_:(`-1*8).?+E&<_046`ZY
MM?L4X9I`<X"F-@Q_#&:L+J=O(N4$K#U6)C_(5P*0ZZC`P7HF'<?:<@_@^/Y5
M*UQKT4>9;0/$>.+6-A_XYS18#NFU&)1DQW)'M;N?Y"AM0B7_`)9W/X6\G^%>
M:RW=D)=USI.R0$'=!=30\_[N=OYU=@UBP'F":WDVN.'DB1BOOE<']#18#OOM
M\77RY\>H@?\`^)IPO8S_``3_`/?A_P#XFN%VV4Z`6=[`)<`A2@8_7#[?YT2V
M6H6RCBPFW<C$;QDCL,LQ7_QZBP'=B[C(SMF_[\O_`(4T7L1;;MF_[\O_`(5Y
MU=ZE>65M_I5B(MP(!,#8S_O(Q'ZU1@UQ)95M&BQ+.2L$D,S"-21D!PSY!ST(
M-%@/5/MD6<$2#ZQ-_A3A=1$9^?'^XW^%<7>65M;7L/V9;V&(,A:5[N4ECDY4
MHS<`[<;O7./0P36MM+))#;3WB7?F@+_I,GSAF*J@&X?=`))'8=3U)8#NC>0J
M1EB,^JD4&]@'_+05QFCZ&;R.\0:I<B[MF:%F2:7]U+CN&.&ZCL1398;.+1[2
MY8WYGDC$QVW<IR/O%<!Q_#DCV4T6`[7[9!G!EC!QG&ZE^VVYQB:/_OJN#\Z,
MSX@%ZY*`-%]KGPC<'KNW;B#C9Z@Y-)+'<Q(6O;NZ\S86Q]I9<*O.,!@H_$D^
M]%@.\-[;+UN(A]7`H^W6O>XB_P"^Q7!G<1'-'?W:JX"[OM4J]C_"Y[GZ<#@U
M;%O,MU%:2)?;ICN29+^8@J.O!<8(XXY^]P3U!8#KWU&RCY>[MU'3+2@?Y[4T
MZK8#_E^M?^_R_P"-<1J;(NF2?9+N^+3+;H));J1CMDEV!E#'Y22JD'C@_A4-
MSN6Y=+674'C0D!UO)F#`9'3.=W\7I]WUHL!W@U;3S_R_6OX3K_C38M6LG4;K
MNU5^ZB=3BO/[6]EW`/<7,@4#)$[G@Y7=]['49QGN/QLW$TXO9426X95;A%F9
M2XX8#/4^G8G]:+`=T-5L#TO;4_\`;9?\:#JEAG'VVVSZ><O^->=075[<W"AO
MM:1'>,;V&<#UW>PY]SZBKEQ!=K9B5Y+E>/D;SGRP/0G)X'7W%%@.X&K:<6P+
M^U)';SE_QIW]IV!Z7MM_W]7_`!KA9I1;M$#=SJK!7DWRL<9*X7/7D$\CCWIS
M"9)E1=0DEB!#%5^\RL>.2,<#WHL!W']IV/\`S^VW_?U?\:7^TK'./MEO[?O5
M_P`:\]NI[RWLI'::=9>BA4!(7L0,`9Y!P>3S4$=]>&!9)MQ/F!`/D!<')X/0
M9P?P(HL!Z5]OM/\`GY@_[^BE^W6N<?:8<^GF"O-_[1:"PA<R"1YP6&4!4+V/
MS*#W`XQT]Z>MQ?J7=HY)$!8'R88\`#OG;T![\\9ZT6`]&^VVW_/Q#_W\%*+J
M`])H_P#OL5PFI2?998(HKAE$L98-+;Q%5;YLY.T$XV_W?KZ51DU*]C8%0JQ`
MDEWAB^8=E'R<'H3Q_'CC%%@/23=0#_EK'_WV*<)XB,^8G_?0KRYM6O+M8_LP
M4$`$_P"C0@G()&=R'!P4SC@'-7[*[^W7HMGU18SY;-*$M(2(RF0P)*=>">XX
M/2BP'H?G1_WU_.CS%_O+^=>77&LW&]FM6+Q("-SVL1`P"<EA&!D]...,]#4V
MGZI<O>+;W%T)'?<5_P!'A4<'A>$R"<^_OBBP'IF\>H_.EW"O,WUNXDM#<*Z+
MSM`CMXVV<>XZ<$]:CCU34YX"T5W%(_W=HL@'1L<$@\=5(X)Y)';-%@/4,T;J
M\W>[F1(PVH+'N5WDE,"EFRY`^7(`P%[52N-7G@M[25)8YS(UQ&TP+(KJDC!6
M`5^.%YY[T6$CU7/L?RHS[5Y?!J&KW0?['9^>JY&]+F8(F-V<L7QQ@586]UV,
M%5M+><[L;8M5;.?QDSZ?G18#TC=[4;J\[-]XEW`/HT_(RI6YF(/7C(;'85(N
MNWMHF=3*63\_N!=R32\<_=!(`Z\L1THL,]`W"C-><VWBZ4J=TM\>K`331(Q'
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M$JSG`<#&[;,,8'3@1U,[NTF_S5E1"3C!)<E\C'&,8$38'/WN_(I2ZS!,KR?:
M8H$9B/,9)'3)P?OXVCDMS[XK3MY6N-/N)9HA%<Q.PE5>@(4$G*YX(`]>GI@4
M"99(AN;1),C'480G"R#;*N0IP,=#GJN<\8%Z*,QP:?+:R*DC?94W2Y`W1F6,
ML3C(P%`_"LBR?=I.`(T:2W+!2,L3U(Z9ZYQVY&,8K0BEBF:*"Y0B)IOM$?F?
MNUW$C,#D<IE][`CC)(/N`5-;^T-'-NDMCEX66XD)VA0)LME@`#R1R,'@8R:;
MITZI:CR'!*-Y4CI"4;(X`$?4=QCD#G!QBKMY&LYNH)K86HW0Q,L@R%)\\CY3
MG(SMX[]>!S6!I$L4&K1P30B-KA!Y=HC`E(>TRL?OQX`8*W0`M[%".SL]8DAT
M[Y5%S`&V2;L,NP]LYZ=AV-.N[S1;Q+:[FCEM2&"[T4,BX`8Y[Y`8_E6';H\5
M[(I#/;RH(I(0"<X!P0?X1D#J%Z<9!I=N+B\L)&=HB54@_,`YP`RYSN!SW/MB
MF!7?3'M-56X*/>::SX>>,AE\H_=+\AAC@D$G&.E=-8:3(8I(K5DW21;EBX:-
M<#Y77/!C;;MQ[YZ5SFG:I-H=S.\JM%`BFTWE0IRISE54'TZ,1G..];MQ?&:P
M?2T8VC*RF"[M&**C9W`\=0<YP1CD@CB@9S=S$TDD@M+AH7._*YP8F8DM(-W7
MICCD;F.*U]"T^%[]%P6GE=G\LD;8%)!V#JIX`!(R,#@U%<F)]9:W5W6]EC$G
ME%1&W7DCL<'G@D$,,]S4]I>![:[M],OS!+'+Y4UPD??&Y@K'@'(V\9YSQP*!
M$>JZ?%/<27FH*9`FY?+#86+@[53'5QM`[CY/0&J&G:&T,JW6I2)90PH!$`@+
M2<$!MHRP'(/.`"*W[S7@5:XBMXX(;?*JSL/F?T+-PIXY)QWZYKGY;:XUB^\^
M3B+=Y[Q;?EQG.U77]<9&,GVH&C?AO-.TNTC%A:>=(5\SS)^3OV\<#ITQ4&HZ
MDTUZ`9&)5`65!M"@GMT'0D=169&?M=P]RY;&PNI=@<,3A0#G@<'&2/H*C6Z,
M5W-<-`Y8J'PB@R,>%`4'AOF*\%BA`;I0!7U*4O=M$J),]L%7[.P.5)7)(;CR
MQ@\@?.<8'`J>[G:V>VBA*K+;1K#N*^8L84[MK*O[S;DE<`'(_NU0L0HU"#[0
MS2?8&-RDR2%HBHP<9SF1P5?+$<#('.,W1D1O<RP_-`/-@+$#.1\F'X!4'M*>
M``-H!%`B6\G>&*0PF61I965SDR8`QD$DA0<Y^\W\');I3=2\XV]G]FB2:)T^
M?S&#11*IQED4J'Z$Y4%LD[0:8D.ZX$,LFZ29!+&L[,S2.G.4B``;.'!92,_W
M2!2-:I+I=Q%*C2K'.K-B0C+*<!01@(QW```#;GG(YH&C6LKSR],M&L7DEA;Y
M58<+,0QRP(^5MW#''.2<\YK=35K<V%NU];?:6D4DR#!&5^;J.^1@#VSTKB]&
MFW7!6X::1IAYB0HOEB`A2562,-A&(_N\'&6.>*VK97N+>73]WS28D@D&`K.,
M'@8!(QW"X]S0!K:E;:7>7+2-=1H;E6(BE7:Q..JYX)R,@'O7-P:=YFH6UO=^
M?9R.C*A12C*<$@JQ#`9.T\'J%P.*M/$U[:I9S%1<6X\V$*2`,CG.,<#'<#&?
MI3=&O)6:>SN5,\9VHKSJ5C4@_=&X[@3G[V!CZ<T`27,DMC"JVRF68WMO'"4`
M8`LLP0C/7:2/R]*DDGFV+!;W,L,%LI1?+;_6<8W,>IR=Q`Z\^I.;8\Z]198T
M>*2U92Y)&Y2(K@;O;EE&?457=5LK8I&R@Y0G<@'/7C/UP.E`B6Q^UV15[R%O
MLLL+)YD+*7=N-A*YX(4!3D8X&:S_`.S-6NI+Z_ECW33R1;3'@A_+`!8*.F.F
M.N>U3W,,T.KQ7<!>.U:W\A'F?]S<3"1=PY/4JCX)`'%6V-U.WDZ)=1+Y"EIU
M,Y93NP.=H(W=3QZ#Z4#)KB^M/[2MX"Q@NS&YF+G:N0JE,D\'AB,\GCFJOV%K
M9H!&CF9HRL9W[05S@JIR#_</)(.[CI3K73Y91>7]T$D<Q,IE9/\`62-]Y@O8
M#'RCD\XJI>6NH&\MC:72V]M;P;6DO)=Z*6?<%QR6;:5Z#CVH&6;JQ272;^!K
MB:"]9P[0(,MYPV."Q/;*H=Q/3O5@//)!Y<RO)/\`,>I`F/W2P`YQDN2<<9'?
MBJLU[%:@;69Y7&=XC\L$]#P23],G/I2&WO;F%YI&DMEF);S)3MSDYQW8CT`H
M$Q=3TO3+FXMY-2NI)%MT.R)W`21F^\S(H+D\8_AP`!4":K9:=SI=DJ2="$3R
ME('TRY/_``+\*T;/PD[/\XDD&.K#R5/X\N?Q`K>LO#4%KR&5!CI$F&'_``,Y
M;\L4KC.0^TZW-*9HX6M#+CE0(=W_``)L$_G4\7AJZN7+S2R2RG[RQHS$_P#`
MVPOZUWD.G6D`79`I9>CO\S?F>:LA:+@<?;>$50AO).3U%U+N_2,#]2:UH?#E
MM$X=<1,!C]S&J_J<G]:V\48I`4_[.@:+RY`\B=Q)(S`_KBI+>RM;48M[>*(?
M["`?RJQBEH`3%****`"BBB@`HHHH`****`&E0001D'UJH=*L3*9?LD(D/5P@
M!_,5=HH`S[C2H9T*EYU!'029'Y-D?I67/X4MG0[([>1_[TT>UC_P)-N/R-=)
M28H`X.Y\&;?]5#<[NF8Y4D0?@VUOU-4/['U?2BQLKD[>I"%H"?J'P#7I>*:T
M2L"&`((P0>A_"@#S>+5M6TV-VFLCY1Y,GEM&<?[R\'\:A=O#^J1NMU9I`TF=
M\CQD,2>X:,8S[LOXUZ%)I-FY&V,QX[1':#]5'!_$5D7GA2WN"S$1LY/!`\H@
M?51@_B*=P.2TOPV;._,EEJ/VJQN$,,\5R1(Y4<JP=,CY3@\A>]!FE5EN(0#(
M@C290P)0J[9(YP?OD=>-M6;GPS=6!$D5V\#;MH,@*;N>@=.,'WQ39IKNVE<W
MT8_>*"P>-0),'^^!@GW'/)YHN(?#<:WJ&F7UQ+9-'!?1/!;R17&/+4*RHV-Q
MYZDYQT%53<7DH6,95D(<-:,W#+G:H)^ZN#T`S@<$5;M]3\@*T!D^S.^YK>1]
MJ$G(P?KG)YY/)YJC=:[=:=XGBMX]*DMY#`^!<#,6,9+@Y.\@`XR1QFF!I01_
MV5;HS(HWAPJ*"`J@DMCN021GJ:J:F]U+K",T,MU]EO8FD2($R20*#RJYY7S-
MA..ORYZ42P7UAJ4UX]ZNH2R0/;H;@&..*=)"3@9.%)P?<>PJ_'J2_:[18[*Y
MT]WDS</<PC,9"$A5?D$D`KD=NV:!!J$UK81QR^097F+S`D!I6W!2H7&0`QXS
MUQFJ]K=3ZO;M8:K`+<3+^XGA!*PN`<?>)(ZD=1QP>M(3;IJJ6MG=;/-/V;=(
MF_RI%P5"<'/!.#VYYJ&UAN8?ML!9Y9(%#,HP1G+#'7)/R/\`6@"QJVH-9Z7-
M>SQ,LT"6V^,$!@RW#C;GMC'!],=:Y2XN[UVC>>2Z2<C=`K*R!5"E`0#@#GS&
M[#``[FNBNI&OKO5$F8B.5;!VV88H3NW$#O\`='YT_5=,@"P7>HR/<*(A!%;I
M)C)4'(=V)`/S9X'<B@HJVEE)J4>G0PPS,LBKYV&!(0$X^8``G8,<\DD'UKIG
MTM@E[=7TGV59MROY?S2!03MYP>PS67;^(;U4NI7MEM;=8T$<2IAW/?MN.`N/
M3G@\53AN+B.PDNC,["Z.U&)SD)QNW#(`Z@\T!<?-;V]K%++;%UA(.]V3J../
MEYQST]^M4K._N;PS*^YXC`\OS2AT+`'A6#D,V>#C``XSFFW5U/%9QV<<A\]E
M213*X10F0,/@GENP&=V,9'.*L5Q;VFC37AMC:O<%5S(6C6)ESP-N?)!)4A!G
M@8(.>`1<NF.H);7(G+*08]J'<5P0205!&#@<<_0'-6I;F6".86XW26\:1%H\
M,Q?=C`^;D@-P.*RH9WM"1,#YCN'6(1CS(T&5\S*X$@R>`QY"_=/43V?G>8]C
M<GEVDAPQ4_>7`;Y?D50-K#D$XX7G-`@74KG4_,@N")`205=BRKG`/R9+#KT/
M.?45H6V@QSF1[>[3S9$"B/R]H)W9Z@\C/`[<^U<S:W2V%[Y1C$%FSE3$2&E=
M03D[O^6BK_$#\R8P`>:WK6=HM3>&61UVIM<G.5)8@,<_7&21@D=*`+-SX?FL
MM.B\R!U,%U)L*X("D[E8=<8.>OK61>W$J>(&\J1RBR(T.YN%5`&3(.&_B/3*
M_/R.*W+#5M1@M[BW6Y)E5=JK.N0&7I^?`'USFH3/!KTT"7L(M;Z5$B^0*P?)
MZ-&?K\Q!SQZ<T`58WGU'3O[+O(F-R1NM6N$8%AQN0,1SE=ISG[U9OVW4M(81
M2`S7*J6$,OSQSRLQ*J&]RKG@X!=?6NZM+":2!DN%C/D;=\R/\K@8.Y/0C;R/
MYYKG=46UO(Q<PSFYL+AO-M9HLY@8@D,OHW7((_@H'8QSJ=]JKQVL>3;L6C!M
MEV&0,.)/49S(2>@.,XS5QC<^']/*+$J:I='BWB`D9(5)=0-N>&8G\U]#5K2=
M-M_.FL;96BB<;)9)6&Y8\@;0W0#'8=2^?X<5O7%D+KS=1M&\^*8J4D5@JS``
M@8.?E0#-`CSV/4-3MKF-YI[R:965-X(`?:<[LO\`*<NW?)PHP.0:W+/3+V77
MYKFTADEBM3)(@"9)<$JB]@."/^^:E^Q66AZC)>ZBS:E?B3S=@4;58\Y'4D>@
M`'/Z6)/$6H)IMLHV1&5C(%A8+A2X*@DX.<=<_P![&<\4`/B\,&QM$-W=16EP
M!]R-2=XR<=#Z9Q_*L^ZEETX"73Y6.\%?-@.UV``ZCOQCU'&:LW4Y2)(<,TZQ
M"60DD[,Y(!4_,"NYAP.?:L?7I[6WM?)8K):PR,MPBAF9)25V[<\2$`?=X7@[
MN3B@#6MI;N\MK29K5+FY*DDS[,`^=*,$MC)..N!]WZ53EC@+6<EW;/;V=HEY
M<7$"`<#SW"QC;ZM@#![U-826UEIEA'=O=2`Q$X0,2P,]P220IP1Q[>E27DT4
M>BB2-VDADD0>8RY+`27$W(..F$/MF@#/NYFOP(KMH'BBD^6VC&8$6,ABL:],
MD;AEB>M0W&DP8VNXF6,[&_T9,9VE?3(RR.WIQ[BFWTJVND)M6&%R(^'W94M@
MY.?KWP>.O4"N$:81EV<R@@R2#^(AADD<=M_!_O'IDY`)6M9((XH(I[=0^>JN
MG`\OH/4C<V/5A[U8T^U$:H/W8B)#F&)-D><!B3[9W`Y[2!3CBJ<-K?01Q[7$
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MN[D$X'/&>IR>:M6=U=V=[OEBAAGD=4:6*%89$#M@/\IQ(`2I*G]*+`:<6EM:
MW&L"V2W1[JY\^69@=L$8^Z..I)!.!T+'UK(%[8IKUCIR3K>W$$DCB=""L$8@
M?**1_#TP.W-74URWO[F:PMU22ZA(6ZM%4`@@@%AD89<A1TZ<GK61=Z=#9^.;
M%H+1+6%K":7*8Q*?*<$D#A3UX'%`T>H0Y%E:@]0JC]!13D!%K;@C!`7^0HH)
M>YR7Q!AANA96ES;B>VFW*\9)YY&,>X/0UY_!X9TZTW-$LMUY&?WFH,"D04G@
M#@9^4+D_WAP*]!\>ZA%I;6=W--:D+'+BUN)O)\TC!RCX(W#I@]0:\PN[;6O&
MSQPV3V2V[89+&VO48H">3("0Q..I_+C-!9T>IRS?V+>1EV>V6U<2/OR'#`[,
M8X(.5QCO3M*TV23P_,D)1YY7;>W4*0NW<0`#CC/'-:=]I7A^'3;'PO<:K=.T
M,<;&*S3#NL:\,SG@*"-V214,FD.MQ+<WUU)#;,`8(G96FP"!G<`#\W0?UH%<
MI0Q75O$JW-J-J,<%3TX).T^O?'O6G&(+E'-NJ91"[%ON@'H&'U`_+BK#A[TK
M!$BPP(1MWG+'TR0<<9.1[_DAE`:.SMR(B-Q\]]QPJ\-(?103Z\L?>@0R"S34
M?-L)I)?(@N52+=(4`40<J&49VJ6Z8X\PC-3#P98`I(LC[@VX-]LFR#D'@[>.
M0/RHETBYF6W%NVJ6B0A@I%O('<L<L[%2.6/;MB@:-J`!Q?ZR3[I/S_X_0%R=
MO#%LVT&9B%;>N;N8X/J/E]Z?)X=MI9F>28M(X*L3=2]",?W/3C\ZA_LJ^R<W
MFL<G/^KG]/\`>I/[)U#:=NH:RN1CF*4_^S4@N2GPO;?VBM^S(;M5VF?SY5<K
MC`!95!(QZU)%X?@BB6.)TCC0L45)I`!N)8\;.A))^I-5QHVH*.-1U?\`&*7_
M`.+H_LG4`23J&L9]H9O_`(NBX:CKOPCIVH"-;L><D9)13=38&1C^[3H?"]K!
M;QV\=S*D$8Q'&+N3:@SV!3ZY]<U$VD:BS[AJ&K_]^9O_`(NFC2-1W@MJ.L\'
M/RQS\_\`CU,"U+X6L)0BM+)A#\H-Y)A/FS@#;C\:1?"]I$LB)/*!*P,FZ^D^
M<CH#E321V-^``USJ;#&!F.XR#Z]:;)IU\5^6[U1<#`(BN"1Z]^:`)!X9@1)1
M]NN%63A@M\P';'_+/MBHV\)V,B$/?SE&!#(+["G((/\`RS[@D'ZU#_9NI[B5
MU+50/3[/<5(+/5$4C[;J;;N,M#<<?IQ0.P0^#-,LH4A@O[BWCC!$02^`\O)!
M)7]WP20I)]AZ4O\`PBFD)$T3:@VQI!(RO>1[789^9@8\,>3R1WJ,Z?K#`[;^
M^4>\5R3^HIPL-:1,#4;TY_O0W&?_`$&@6HRV\'Z9:!C!K$X1B2P;4(R&R,?\
M\\]JE7PWIP61/[3;:Z["/ML6-O&?^6?.<#K339:T""NH78;&"##/@_FM*MGK
M>"1?.?3,<P`_\<HL!#;>$]-M;[[>-5E:Z;AY9+V$M*,YPY\OYAG!Y]!5B+1+
M:&YCF75KN0J=YS>P?O6]6^7YCC'7TH%GKAZWW;H4E'\UIWV;6D_Y>XMV!P=W
M_P`118=R`>'HO,:2/4+K#R;P/M-L=I]OE_/\:KS>%[:XN9)3=W#%G^4&>V=8
MN.=@/W<^WO5_R-9;_EXLL#U?_%*8T&KYR)M-Z=V7_P"(H$07$,EA%NEGGFF\
MR.,S3%';9L?<"5SD'`R.]5T:6.TN'D5F#RQ1@YVERV2W)]`J_G5Z/3Y9K>6.
M_O+1)#*)$\DJ`R[<'/W>G--EM)<16MJ_VA_.,K;6`X*%>,-R>^/\10`LL5KJ
M]C!9R3!;6-G5I(FQN^3Y).>FTD@Y]1GC-2:@D7V]+O3;I-.G3;&R!=J2J"6"
ML!@YR2/2H;9T$KFS\YI7<Y=PP)Q_"$'W2#QD\CVJ:UT>29POEJ[J1\J@$8]'
M?!"GVY/T/-`$KSNKE_WMS-,0[;%*B1E``$:#.!SC+<C.2:KPZ1->2M</YDDK
M,7<)AG<\+P?NJ.,<GH`,<&NFM=#2,'S3P2,1QY48]&/5_P`>/85K1Q+&@1%"
MJ.`HX`I7*.?L?#4-JV0HBVGAXSF0_5R./^`@?6MR&QM8)'EB@19'^^_\3?4]
M:L`8HI`)M'IUI:**`#%%%%`!1110`4444`%%%&<T`%%%%`!1110`4444`%%%
M%`!1110`4444`%)M&,8XI:*`&E%/:L^?2+9XY(HE,"R'<PBP`Q]U/RG\16E1
M0!QUYX8,8D:VB"*Q`Q;``'W9#_[*?PK&>PNH+5[)WF-HA4D1_<^\#DK]Y>F.
M@Z]:]*/2JUS917*CS$RZC"NIVL/H1R*=P.+B,5W;/!<0JSL4WNO.'Q]X#NN1
MG`/'S=R*GDM#=7"::5GL=,LY"RS^:N]VQE-O4@@[CSS5^_T&95D>+,ZGDCA7
M7Z8X;Z<9K&MQ)8AVD221'&'*@AHR<<MR"AX[\^G%!+)M'TUG?4H[YTF\@#R)
M^T+/DX'`PP&S/_`:SWN[(W-U,<RRQS%98^S*RR%1]<[Q6E]I>2$6]L8[4J=Z
MJ0%20,1SN8$;S_M<^]9#6<CW5W''"Q<-$Y7`W@AI,<#'0G]:8%S=:SX^RQSP
M6T4L1V0*2Q&&RV%!W-A2/;ZU@72ZEJ$Z236U[;JI,<<?V5WCVG.6"JO';EF/
M.>!6U:LFCPM<W]M(L/G1K^\CSO(63H,C./6M&+Q)HC*K+9[<\C%ICG_OJ@HP
M'MWAND@MM.FCM+8L(PEJ^#SUR1R>3Z>]2WL=VFJ+(MK=N\1\OS$@<A%Y.<XS
MZ<AF_P!TUO#Q)HZQAC;<'G_CU/\`\52?\)+H@52(2,GHL+?R!H%8X;5K*ZOK
MI+-;*^"+&&@O'MB19X`'RC;R[8P3C`R",<XLW%O>"VM9X+:^CD,*R32>3()=
M[9+>8<?.3QN48RV><5UP\1Z,7!%O+GG'[B05)_PD&DDH#:7&6Z?Z/+0,XF[M
M+Q7:.WT^\%I\B01P0,(Q\H#-Y9`\M3CDJ=Q[8J5HI?*B>:PF,A3]Z([=O+8+
MD#8"-SG#``2C^#/O78G7-+4&1;>0-GG]W*#^E!U[3`<?9[G/LD_^%!)YYK=O
MJ4TXN+6PNI&RLD5O+`Q0L54M*#CB4,6],G)^NE+%)-9(LR7<[;!ND:!MY*Y&
MXDKC)XZ#)(/M76#Q'I$DGEK'/O/08N`?_0:4Z]I18J5N,Y(ZW0_I0!S5V97\
MF\C@G>8(1Q;R*2RG&>@P2H_B*CV-5M7WATN(+:\$UR0)3%:ME903]Y@`<<=5
M#+QP*Z^/6M*9B5\XE1D_/=?X4AUW265F+RG!P=LMUC\]M`&)#J%Y%&+B.&=+
MI`H=UC?;(",`YV\G^]P,U6GO6L;.*XMM-DEMPWFW<:0L+A0Q)W1G&&VL2<'!
MY(R<UT8UG2]X"F3)X_UUU_\`$TXZKIQVLS.!U'^DW0X_[YH'<Y6UOK>[^TPM
MI\ZV`'E;;J$AI';[Y$9'"C(`W'`RPP:EN]9N1;JC17)$(6.&T,;8<\#.>@P.
M><?6N@_M?2]Q`G<9ZYO+H?\`LM._M73"H/VEQGUOKD?S6@#BK>5=0U&>;4`T
MEN4:26.[B)E&T`[5<`)UXQEN_3K6F)H7O`;F0QQE&E,A!VLW!PO<]#U4^QXS
M72/J5B%+&91CDDZC./\`V6D.HZ>X3_24.>5']I2?_$T".5CU"W<K<S%!%R3$
M9`N2#EB,?+^1R/:L4,MUJB2R7$<,T9%M>RDA1/'PN(`2=JX.2>O&0?7T9M1T
MXX_TNW)/`#:H1_-:<UYI;QE6GM">A']H*<^V2*`.:MYKA(+:Y2[@2T4L&GC0
MEW=99RJQIGD[7!YX''/:L^_DN=4CB,$4D$>&\I"P8@N,.\C="^`/N\`<>N-G
M4Y5;R;BT,5S##]IMB(I-_ER2NLJG*]VP5!ZYX[UF:A,T42O;JBI(1Y3D939S
MS@<9'IF@#,U6V,>F%(Q&`C(8AG:,KZ=_7GWJSJDJV=FCHP$/S2M(,G<$Q\H(
M/?YO3MS4,NBRWMLMS<:F6B8'>P``"]Q@<#OT'?FG:WY#:*HM9Q-+`)G:3RB(
MM@7<H.?O<A<?4T`5H[G6[:*(W%CJ$84*KAF27'#98Q@E@07W<=Q4D'C/2H;=
MY#>Z=;2X`.`596`.?E(R,<#N![U=O+BWATL:S<3&/2V5+B.;)=E+'`''.3N7
M/'8^M5A8:3JB6NIF"PU./[R7FP'=M`(WCNQ!YW<\=J`*<ES?7<(U)-+/V8@%
M&N9"EPZ#^-$Y'0`_-@G&:Z.:6>[ATV[M%>>0L5WJFXEP"`V.^Y<9ZG!.:L62
M1/XBM+.ZU"!;R0K-';^9O>2-`<$=,#&./KQQ4O@S4U.GV-I%&KP(I#3-@&([
M?E`]B%+9X]::`R]7768[."2X(B:0@0Q?*V\C&!(.3SN['BI[ZZ6VFM(I`69(
M59LXP%$B,V/7"CT/05?UJYO-0OH;JU%O,;94*^7,&"G=GJ.H.T9R!TY-9<UR
MCRQB\@56'RJV0`",9P1R/PYXQ3"X_7KH65U'JNEP,R2^8TLZG`E#L>8I%Z-C
M^F16'I@DAULYN7N[<Z;=26]Q)U\KRFP,=F4Y!'8^QK<B@EM(C)9M$;>3_71,
MH:)ER,[T)(R3@;@0V3TXJ*#3[00SW5I`UNHCNXGMF;=Y3R0GA3W4[00?4MZ4
MF-'K#?ZN(>X%%.F^ZN!_'12(>YQ'CFZ2T\3>%_-0,EQ)/;DN,J&:/Y,_\#`K
MG;@:+I\Z7]U!I6G7+%C%,8PK/P,D;1GG/<8YKMO%ZVLL-LDT$4\\3-<P[QRA
M4<LOTR,^U>9WL$=SX@TD2HMP\%F3%&^"/,,@5<YZX)/'M067+[4[:_LI1IMQ
M!?7]N`]KY2D@/G'WB`%&#SD@$>HYKH8?](@FCD#2B(B./J&4$D@`]P/E(],_
MC56:&UA0FXEFD*DQD%SL7.",*`"3M/W??VJ2VO8-R_9+9B9-Q"LNT9P#G!Y(
MZ8Z<8/<4")[*ZM&1X2%66-P&W./F)/09]Q^M2V4L5KKSF3;M,.T[N,-$X8C_
M`+Y+-S_=/H*K:?!.`92,L_RX8X"@,2Q;&".!T/(P1U'+)O-:_19(=T,9EN#@
MG=L6W>-N^.2P'0<M]:`/30.:7%1VZLD$:R'+A0#]<<U+4E";:3:*=10`W8*7
M;2T4`)MHV\TM%`";:3;3J*`&[!3'*QY+,`O0?6I:1E5NH!YS0`F*7;[TN**`
M&[?>EQ[TM%`";?>C;]?SI:*`&X]ZANIS:VLDH4N5'"@XW'L/Q-.FGC@0/+(L
M:Y`RQP,GH/K6#JTL^K[[*R$AA4?/*``C'T!/7\./R-`%'4?%K^45MEVD@AFS
MDKV!]*R;.+5;VY^UPK++.C+(&+<9(Y`SZC`/MC%:=IX7N/MT;3;DB!R2&'&.
MF!US78Q0QPQK'&H5%&`!38C"TW19)))[S4%5);B3S&@CXV_*HP6ZGD$X''S'
MK6Y'!'"@6-%11T"@`#\JEQBC%(8F*6BB@`HHHH`****`"BBB@`HHHH`****`
M$S0.*,4M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`"$9
M/-5KBQAN02R[9,861.&4>Q_ITJU1B@#C=7T,VT+2JI8("V^(`<#GYE]>HR..
M>E8&J7\$NH6@L[:*-(U4F(A7RNWOZ]?>O4"`<9K.U'1[3483')$H;DAP.03_
M`#HN!S=K'H=Y&I?RHF[1-;HP!]OE]SVK3@T#3KN$/%Y3ID@'[,@Z'']VN3U#
M2FL+F2-D)C$FP-QZ9VD\9XP<>C>QKI_"U\BQM;-D;\N@8\DCAATZ<;L^Y]*8
MB[_PC5B>L,&/3[,G^%(?#.GXQY%N,=#]G3/\JVQTI:5QF)_PC5CMP882/>!?
M\*/^$9T[.1;6X/8B!1BMNBBX&(?#5@>D$`SU_<KS0?#&FXQ]EM^>O[D5MT8H
MN%C#7PQIJ`A;6V&?2$4A\+V&01!;#'_3'_Z];N*,47"Q@MX6L2N/(M?^_'_U
MZ9_PB=BQRT%H<]<V_7_QZNAQ1BBX6.?/A:T``2*T4#L;<G_V:F?\(E9X`$-E
MQZVQ_P#BJZ.C%%PL<U_PB%F<$P6.1_T['_XND/A*$@@)9;>P,#__`!==-BC%
M%PL<J_@Z)N3%IQ)/)^SO_P#'*8/"!0G:NGC(P#Y,@(_\B5UM&*+A8Y,^$6_N
MV>,=C,/_`&>HO^$-;./+L]O;YY<_^A5V.*3`]*+A8Y!O"DMK#.UND)#H5DB$
MCD2+S\OU]#U!QBN3O8OLET]O,XEMRBMDK@D-]QR!_%PRL!UQGBO4;Z5H+69X
MQF0+A!ZL>!^N*\WD47&IR;(W%O"WE*[9+,(AL7'8Y;>W>FA,S8RVGAF"0M"6
M*/%U5AQD_D>E26UEI:)+JD-K!&J0K&]M>1B6)RV&`4'ICD'_`"*I7S-?ZLL+
M(HBVC*%6.YR">_8;1CO3_$,<[VRVWS*C1/\`-M;`=L8)XZ]/RIB-*"?1O$NB
MWF@)H@T_3I%:.*\@=?)9PV044X8X;&>,<=:\T4/X%URXM=,UO^T)@3'/9VUF
MS0RO]W#ACR1D<CGCK766VJ&.QMX[JSN@T$:HKV&V=3M``QR".1G&.M;GA[5X
M]<69[+4+X>1.L5PES&$92<[<<GT;\J`.9TW5;-=:U+7H=%U!M4M8AB?4VPQG
ME'[F..(<*,<\YX7\:U[?4+N[TM6U/3+&RO"6\V&&)=JC(P2.<-@'C)[=!P>.
MUW6+^TUV[\1R+,8I-6(B1FQ',D2E",8Y(#!0?K770W45Y;)<Z=.LC3P/)8>:
M1_K-K#:>@R&.,9)R/K0!3NY1;^*8=/LUVL;4O/'_`,\R&.SITW#JHZ^W&=B[
ME6>P=V;9<J@:11R58\XV^N,?GVKD_`X5;":1F,EU-))-/O(+2%6("G@G&#GC
MGD^E;]]--+MLTD=D3YGSPQ(_A^[]W\CTY&:+@6[=S$MJI)B).XAVYP,8/)!7
MD>I_#K4^GQ%;RYM066'[*H8GHA\^,1Y!`P<.XZ#(/?J8TN9+*Q1P@1Y'(5E5
MC@L.6;.<=>^1V[BKNG-'%;Q0*`8[E//BQQB"-L1#'^T6=L=!QQ0V!Z;-]U3_
M`+5%$W1?]ZBIN%CE?'NG2WVGV[6TJQW$+%HR&`DZ8(4GKP2".X)'>N(TVS:6
M]-Y<W$MW.KJK,R*@14<X"C'RDMNR/]D?CW7C83>5IQB3?BY4LI3<&&1Q[=,Y
M[5R[:G%&#YD3K,R1CD@@LRC!SUQN)..O)ZU0Q$02ZHH*,^Q%#J%[Y^8Y]=Q`
M]1D<8(:KL\JP!EBA;S01T.U0#@+G/\.20<\'Y@.M4X=JQS73DJ9AN+IDLRKG
M'"CL.@_V05R,"KFB69U29T8HY$WSB1=RK-@-R.C;%"8XQEQZ'("$6&ZN3YJ-
M_HT@(8%B(RV0<;0"\@R64X&TCZ9KI-)T%XCNFW#N[/CS)B#D9QPJ#LO7NQ)S
M6U9V$-H&9%S*^/,E;EY".Y/].E7`/SJ1AWI:9)((T+L0`!DDG%5?[5M.\A'<
M'8V#^.*`+M5;V\CLX"[\DYP,@9P,GD\``<DGH!4?]KV7_/1O^_;?X5Q7B[4!
M?DZ>CA!,ORRYP$0.N_\`%B-OLH/K0!T%MXKTZZN/(BF1GP'PNX''J-P&_P#X
M"36]',DD8>-@R'H1T->5S6,]Y:^25'EL%P&)51A=H9<XZ`[NW3VJW8:Y?Z=/
M+8WL5PSORK;]I`.,>:Q&"W0;E['N>:+`>@W&I6UNWEN^9/[B\G\>P_$UD3^,
M=+M6(GF52"055C(5(ZYV!L5PKF6\EB>\N%,^]G@5<[$!(&V-3_RTW`X)R>0<
M],O4,`X4L'^ZJL"-AR21]`<]<=SWX87.YA\6Z;+<+$LJDMT#-LX]<.%]#^5;
M-O?6UV,P2J_TZ_E7E4O$1$+^<[,=BA<L3CH`!RQ'0=2.,<U7L+Z?197\J5I%
M5U,EM$W[I`V!^Y;L<ECD97MVI6`]>N;J*VC,DQP!P`!DL?0#N:QH_%5C+<-"
MC*\JMAD23<0.<X(&#TZ`DUYYK'BBX\17C65C#<2PJG[\J!O9<C,>%/[M3P<]
MR!VXI?(E7369VD2>,I'"%0@QN"K*=H'0M_,]*+`>P1NLB*Z-N5AD$=Q3ZYCP
MWK*2VS)<CR51F";V'&#RO^Z-RE3W5ATQ6V=4LE(!NH<G_;%`%RBJT>H6LSJD
M4\3LW0*XR>_3\*LT`%%%%`&?J&F1ZB(Q(SH8F+*R8[C!'/L:MP0B*)8U&%4`
M#\!BI:*`$Q2T44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`%<V=
MNTS2-;Q,[?>8H"3^-0W&FVTH4BWC5T;<C(-I4^H(_P`XJ]10!AZ*NJFXD?4$
ME2,Q)Q)(C9DZMM"]`.G/M6Y28I:`"BBC-`!11FDS0`C$#K2!P3@$5EZ_J,=C
M8S%I?+Q&TCN",QQJ"6?\`./?%><IK^H*T5REM:+/(/,D0ADD"$@*`X).[D=B
M.O&*`/7,@GK1D9KE?#OBZVU2#!$@=1DAE`8#&1N4>O9ERK=CGBJFK>-!'=-;
M6<4C%<B4K@>4<9&]SQ&<9.""W!X'<L!VF1C-&1ZUYG'KFK3.\4WE>6%(`8R.
MW3N2X&>G&._J0"G]MZRD2R0/!MQ\ZC>DA(QDKRP/4<;3QDT6"YZ;D<\]*6N*
MT/QS%>7,EK<PR).C`"/'S-Q_"1P_0G`PW^S6EK7BFTTZU66.5&5R%60$,&8]
M%7GYF/Z=3BBP'1$@=32@BO+E\67\L$=T5/EL<A#(PEP5#8#`XW\D`8QD$5W^
MBWIO=,BD9U=\?,R\!NX;';<,-^-`&G129HS0!5U$-]BE91EDQ(%_O;2&Q^.,
M5YS)%]CU"1I&A\@F1U<,%#QLVY'P>>,D'GJ'XY&?3S^5<]J_AF*]C=8<"-R6
M:($+ACG+(V#M8YYZ@]Q30'$W=@LLD4UM*%G9EP%X!)QZ9P>?7'KV`J_;KR-U
M#6J,K$E9$?;D*/?C&=I]N!]XFM:[TS4+:[.P`-YC2"-4VNRY9BIB^[("VW.W
M)('2J]H\,LK+)&&9\[6+9C=!QCW;D9'7A^F,4Q,BL1:ZBK%;1(I,;48!=Z-@
MM@XYZ=^G\JJZ/#')J.K^4NR>X,%P(U/).UU'U^8`$\XW9J_IT;PZT49V);!`
M\U2QVXR?KM.,YQD8SGY:CO/"<>J71^TV,4D:<PSF1T0J6W`%AU4X(H$7GBT#
MQE;:KI5W!'/%I<8D6]Y0%VR69&Z8&W!Z]*PK3PU;>'K%;"R:>6T\QIHYFF5L
ME@H(!48VC;D#'4]:Z#58VL-!D2QAGN@EI-I[6T<6T%74XV*<9`*`CVW#J>>9
ML_#,^EZ:QTG4)K"'<4*Q7>//=0`S*K`K@G^E`T9]I%)IOBN]223%O<)'=,J<
M[3+D,.AQDKNYQ6K<QSB[C.U`LBX#*.>#D$#=QP%YQWZ5#8:-/;O.LA:=[ME:
M:>:=99"$Z*.P&.!]:GU3+0VYGW,S.'6,1[N,@9VD'C((S@?H:`'W4C16D4D8
MC+PPS$H/WF'VCG(&.XZ-]<@8K1A"-X[N(,C;#'';PQJ/E5!Y>!T[?7OTJE=1
MB2'*^4P/F*3\N>5!ZY`4DX[9SWZ&K]E'$WCI+L*0UU;P3,Q'KY'M[Y.?6AB/
M39.@_P!ZBDD_U:_[PHJ0.>\62&/[`1L`,C<N<8(4X-<TZVTP92'W+`A<J@<#
M:CD#@9[$?@/4UZ#<V9N63,TL:J<XC;:6^I'.*RKKPX)R&WPSNOW'NXM[J/9U
M*M^>:=RCD)!))Y5M%$KL&#*DN06.X'!X.%Y))X('<YKJ_"^EI:6Z2^8TH`98
MY&R#)N.7D([;FZ#LH7WJ6T\-0PY\P0*&.9$MXMJS>@<L2S`>F<5O#BD`N***
MH:K>Q:?9/<2-&,=/,.%SZD^@QD^PH`=J;A=,N02N3"X4$]3M/%><BWNE8'>;
M:%(4)F=0L2]N6;OQV!^E0ZCKMW??9KR.Y>&P>5DDE"$3X&"PSTB4J,@#DCJ2
M:>M@+BZ,LJ^:Y8['D621G!Y^4MDG()/'K3L`DXSN;^W;,-G@Y=B..H4)D^N.
M?K5<7/VUR1'*+;RA'$9@P>0#<Q=@`Q7+/P.2`H[FM5](=K9A)8W<K$$8CMG$
M@R!D[B,9XQ]*6VTR2.1?]`U54RN`+<?+^O`''ZTQ7,Z_\N!(;0NZ,DK/*?+5
MPI;!RQ!W(`I?:W48R:JV@FG\FSN\I;10J^U%WO`YP-RE1R02>/ND8(P>FQ>:
M;>75[),=.>&--K&5[=M^%4<!UY/`88/!#,.XJGIDMA<Q3M<V=S(OVAD%M`Z-
M#)L)W,4;WZEVY)R#0`LNGPS`1S7,8GB<[)8W!503R`#SR2>@[#'6HI6<><MQ
M&Y:VB'F2+%*/+!/`)*!2,`#D$\5>;2;Z\L-.M[JW=A%$Z$I%(5=#(KIN5=JE
M@$3D9'7VJ_<VMU=6]Q!/::E+%.GE,AMU*[,Y"X*'@%B>O:@1D-%<;Y%2":UC
M&&DEEBESC'WL[,*..P`..3R:KG359!:V\ZQG*&21N54@YX&3@9S@9'>MW4K:
M\U73)].N(-2:"XC6-]]L#P.WRJI'KQ45W#=W3I+?P7"P":/S8(X"J31JH`0A
MP1MSDG+9P2!0-')3SR^4T,2M9VUNS1)L<@MB,@M*<YZ[3]3P.":W8IDEL4:/
MS6G@4*V8]@898!@/F(QGCY>0`:@UFXLK>_TZ.V+O/.)7<L>;61(RP"9&000.
M#D8/':K>GVTUC^[;2KA89(@K-#:R%^_!9OO'@#TQMYSF@+E2.ZFB$T$MQ]FW
M.989N2J@KAE?`R!\JL.#SD?2SYMR8P!KUD'Z@K(>.2``649.03SZ&I)K5)Y,
M?9=38N%/R6C)C!'<KV/./]ZIKJS=HLD3K''GK9RKP=^YON^I!Y[&@+EC1DN(
M=<MKFZ25(D5\M)D@??4'=R.1MZ<8KOTD$BAD8,IZ%3D5Y8MC86V^[:*"-8P0
M94&-IX"X*G@Y(]/7IS5_1-3O]-N8!=EVAO'8PO)PSX_A;GDD`;&`]%YXP@N>
MC"EJ*"198PZG(8`@_7FI:0PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"D/2@L!U/6N<UOQ;IVD1LT]Q&@R55W)PS\?
M*H`+-]1Q[T`9&I>,)[#4KRVDFVB.1PA\H$``COW/-54\=7!4'SC@G[S6X`'L
M>:QM0NH)]0:XFTV],AD,J"1HXH2Q&><%FV\\C.3^-0BZG83;[336(8Y!T^,*
M>&P%SS_#MY!X%5H*Y-KVKS:]'9@S'R[D2N&$90,$\M4)Z_+N=_;(_&HV*IIS
M37L2,"1&`#L5B>0/E&`H`/\`B*IK"]U?S23O-<-(J@23*,*N?E"IC&T9X`'7
M/K5K4(9(;1+:%WAA$0+*DX$@[D%#A3E2Q(P"<@9-`S.>W,\@O-$FDANV9E2U
M,FR61%.,A@1\N,_+QC!QG`-2BXFBMVN((LPO/ND1UQ&X8`JSM@GCUZGG.:FA
MTR6.\+RJ5U`*[)`K`X=B2&VG&U`SR$*Y'/M6_!'-?3Z;=6_V&"&[$CK<LIX=
M,[LJI7!.6_B/(/M0*YCQ3,8%EM'>>WD.5<`Y0GG#J>5.>XZ_.W!"@2RR326A
M>65H8"3\YB57``R-HQG<.#C@#!Z9.;=K9PM;3"X&FZ?=HKM:H(XF1<%@@<Y8
MY)YX(X/K5W3[&"]M[:87\,5T\!E:,I%+Y4BXX!7;N/X]A0(Y:0//Y@VF&(H[
M11C@QN"N&5NYSD@Y&,X["H+BTN+YXKK6YY2\VZ&%/F9U!^8`IM&P\?>SN.,G
M-;JQ7$6CV-[J-E`?W;/'`!L"+G!5T8\J<9'SC.<>E936TL1E"!G=F\Z9)059
M6*G'F*X!P2021G.%'K0,T(@DEDDEJ6"3.6$S*GR']WG`5N,%NO(QGM4_AO5I
M=*>[$9)@@ECCB5P>(Y%;&X#T=!CTW$#M4.C0QE;G##[(8?/%N-J@#=E<QXR/
MEQUR?E/%5+A!92_:H2Z3QLR>48PZ2IC)1EQ@CY,_@#0%SND\:Q2*VTVP9<?*
M6;)S^%+8^,A?W<,,44>)"O.X]&91Z?[0KA[74M2V1LFGZ0)"2$4I/G'&,'S/
MJ/PJQI\D5IJ$,]M%?%@_F"-PLB]4.`=P8#Y>,COBE8+GK:\C]*7`%8.C^*+#
M5/E20`[MA;L'_N$$`J?3(&>V:WLTAE>[M8;N`Q3+E"<Y!P5/8@]B/6O.]8MI
M+'4%FVO([3;?W:X^9<$XP!]Y=C8R`2".E>FUS?B72_M43R(N`X4.ZKEHV4_)
M)[@9((]":8'&7T"&[2^M@KQ$_)-$`"W^Z?3G/8=@!4UI/J.J3)'"P6UR"RD^
M7E6(([9Z#T'7UZ5_M$FE7,5OJ$<"8'(N,LO4G=&YX((R>_IA>ANV-U>7FGM'
M967EJ@CP+2(A<KV,C[5..`"#_#WIBL.\J33;I;.Y51;W2EI'5V<1D;03EN0<
MG</7:#SC%4];VC[!:V<CH%`"KN#2%<$]1GDEQSDY"9J>.<JDNFWT4D98*CM,
M@+(2,*<#AE//*Y`(QWIEAI4RS!+M?(2%"?.QQMY&68<%N.W]:!%)H]11E9+G
M<BN&VJHD)Z'A]O7Y3SZX(IJ6+SS"65O,9(^AX&23S\PQGY6&>>@/2K)GEO[[
MS(Q*B$!W56\M;>/D9D8]/0`9;);@U/+HD\J%I)/-B/0+#+,^W#`X+;0,AL`\
M]!3L!0G>[,4=G#_I4S!D7*_>D<!0$.#TPV1N&`A[<5H64\<_C>:.(@QVYBMT
M;'+!)(E)S]1ZU6FM+^&)Q96.I+-,"/M,JCS(_41JO"`\YZL1QFI_#NE2:?JD
M4C6\R#=&C2&$X)\R/J<<=^M#V`]-E^Z/]X44DGW!_O45`$U%%%!0F*6BB@!#
M7*^-8A=:>]L=H$D>W)YP&=%/Z$CZ&NKK&\1:;_:.GR1YDZ;2$`)*GK@'J1@$
M>ZCMF@#S^185N);62,2PSON,A.WID@<=^IR2<@>Y`W+"",6L=RL86>52@<2%
MBJAB-H)YP<9/3T]ZPKVYN-/MS>7,0>2U\O[0B?<EMV?`=._4AAZ?,#C-;VGN
M);"!XR'1U8K(,#>"[D>W3GTY[C=5"+`#1X;>ZO\`>W`YQUQP>.JY[#CT9@'<
ML^X@C'4;V]OTX'/7@^AS2U>].EZ7<7Z(#)"N5WC(W;L8;N>0?^^0#R/FI:;)
MK:7B1:@L<]I+`)%E2,)Y3C&%QGG@#W^48/W<`C78,89HE)&Y"N2Q.,\9_/\`
M#KC[N"V&W@ARD2!<DD;1MP3C.`.A)(SCGD]<#*7INDM_^)?'&TQP(_./RIP`
M2!WZC`Z>N!C&=X=N9KCP]:R32R7$Q0[RW)8Y.!V'0@?\"Z\_*%(U@WRY#/N.
M03D]3QGKSU/'N/48"64Y!91GC+D>X'/TS^`]25YV]U.XE\66-M:RLEFEP+>X
MQC]XQ1I""3Z+Z@#YCGJ:TKZP-P_VG^T[ZQ2)"Q^SLH4`#<2V5)SC=^O4CY@+
M%_C<"&;')^^3C!P/H/P[<CEA32A.?]:&&T8W-^77C@]>H]\#.-X;;49=%FN[
MB>666=VFM4N)`&5,`+N(7@GT`!X_-=$N]1GO]4@U*:/?;/&L:0+M2,,I.U>Y
M_A&>^!C!Q@`NW6F07L+)L3>%949UR(BP()`]>3GUYZ[1FZ=V_(=TZ#.\_=[]
MS_D'KM&71D=5!)P"!R0O3CC!XXZ?AU7#@>A7<21Q\V>.N.!]/Z=5P"9$00>K
MCC'WF/'?OQ_3GT&7*THV%)&^4E@3(0/0<C/M].?[HRX(1]X8`SM('7@8_D!Q
M[8Q\I#2&&"B%B<[<<XP,^HXX`X]>."-H(S+RWM8GW1H$#ML=5`4AMN?H5*N?
ME]<@'%5+\)<64AP83%"H4!`067IC.,;2I'U%7=7N[73-+N+^\5C:Q2,_EH<M
M)^[0!1[DX_4\'@4GMKF]:WL9S^]+)-=JG0=,(/Q&U<GN6X.:!H]`T1=FFH@4
MJL;O&H)S@*[*!^``K1JM8PFWM(XBVXJHW,3G)[G\ZLU(PHHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*.U%%`&5K]XMCI4DKN
M4`R2XZA5!9L>AVJV#ZXKRR2UFU.Q>XN5/VQ%CDB8''E`?\L4X^[M*CUSU[UZ
M-XQT]M2T5[9&VO('C4GIED8#\V*C\:X26:&XMX)&9@6P$SQAFXVG/0G[H/0,
M6SP13`O6%O=-MADQE%`N9`,A1@?<R,LQZ#..F>E:4=ND.8HTE3Y3A@\9))R,
MY*]<_P`Q[X981>5IT`*HTD<DN"JD`#(W<''/`'7_`,=S5M=@X+%2>`03VXSD
MC)XSR?0\?>RR2"*W,465O]4&$V(-\;@C!(P6'TY_VA[U0O=#L)H[J6>>]FDV
M,<N(V(QSQ_=&?3T]B*U6P(V+#;QDGGC@^OISU]#P<-D?)+CY@".><C/3OQQA
MO^^1UVG<`95G)J]O-J,<$T$$;WLMS&\>UB5+'.[(P.C?WC@=!4T6C62*(YFN
MY50DHL^UPA)).-Q(4Y)S@#OZ5=0+L15#(H("HN1M('``&<8QC@]%`YP"R)]X
MX&UP`,]`#V``Y';H2<*,'[N0"-+58R`FH:GY8Z*&4*O3C[P`Z]/8TZ6T$^W.
MI7V.I20!P>A(*LQ'`/Z&I3@;0"R@<*^<GL,9],XX]A_LX50=N%08R,*/;'&1
MQUQ^F,?+@`H'2[7RW2-IAYD>TQJJQ1OD@;64$J>20<KS@XZ55OY+YY;`R013
M212JTEZ7Q*%`.1C!!`.,G.<=NU;7=L$DX(SD<<>@QUPO0XY&,?*1&Z+(#'(H
M*D8V'H0?_P!:^F=W'#?*`9T.A1VT[S0WTS,IRNVT4\^S%LMD$#'3IQR,SK9N
MDF(KYPFW!6.SC!<\A2#DG)R,>NX>HJTR%@<#.0,$X;(R<>W.1V_C[9PHP4H0
M,NC9Y./F!SGK]>I_O'(.6P`51;1O(SSSM(9#\H6T52@SQT;IA1_WT/6L^6VF
MAO,3(H>'!C()V-D?*QX&$]^QX^NP`<'(92Q/3*\Y/;GMGKZD]F%1:@\LZ1Q2
M*"(70QN5P3N#@KDG/50.<=@<X)H`YN2P72K*#4XL1WQ4-+&&5?W0Q^Y;'WB<
M<-@D''<5ZAH=\;_34DWF3!V^81C>."K?BI!_&N`O)9+'39I);AW\B-R8Y!OV
ML5W8P?XL8)[`GK77>"X&MO#\$#\-$(XF![,L2*P_!@1_P&DQHZ2FE<CK3J*0
MR@-)MD!$)E@4DG;!*R+R<]`<4CZ-92JHGB^T8Z&X8RX^FXUH4AH`X'Q"+.QN
MI_M"$6D3+'&8\![<-&[,R^J_*,IT/![5G75A=*DML][:&%"$4/>&./C(^9#R
MN,C@9X4"K?CR,/;ZB#R'D52#C&/L\G^-/\2EHO"NKR`,S++=LJJ<$GSDP,^_
M2FF)F<&CCD*ND=S:,ZROYIBVW+L&W,REOEXV;0!Q@X[U16WM/LL40TNR,R3>
M8K!(=RIM<;6P3D9V\^Q],5S=QJ[+;N4C@6V1E1GLQATFR2D/S$@D%F+-T.20
M1WDL-.U2]:"XND9Y8OWAF4J?M$38S\V>I4X7V#$]LNXCHI[>%A>B'P_%B=2(
M@L4?R-Y:X93GCY@V?;GVK1T%574[;%HEOY?[MY`JKYQ,]N4R!W&UOIFLJTLX
M+6VEM;L)O,0!9$*=/+"XW<J"%;K@GJ:T-#Q_PE-O^\C+F#<51<`9N(,D]LY)
M^E#`]-?_`%8]B**)/N#ZBBI`FHHHH*"BBB@`JAJE]'8VAE:2-"3A3*<+GJ2?
M8`$GV!J_7+>,51K0),`86C(?.?NF2)6_0G\_K0!Q>M7%WJNFW08-&UV!;VL<
M@`949@\DSCJ,K\WHH`K<T6".'1+."$AHH(?+C96SN"NV.GJ`.0>3SV&:TL1V
M[PZRP)A2RLJ@<@XYQMP0">Q(P>,`7M.8?9"C%3)!_K4P1@,S,K8./E.2N0.W
MI@B@9#K=D^HZ!>6L/,LL>%P!R<@@>QPJ\'/##M@BAIMY?7E]$/L=S9VD-F%E
M6X@V,TI_N_[(`/3[Q)Z=:W,Y^8<L%.<X^O?\_3GT+`.VM\Q['D!@3TSSG'M@
M_P"Z<@\[PDK7%Q#8Q>;*DVPLP_=1-(>Y.=H/;()(['/5@,WPI,(M)LK.>*?[
M1%%ND6:!T7&YLC+<9Z@CMDGNU;6#N(!3"`!@3T`(SGN1QWST/7^)<2*X4_*Q
M.#GN?Y^WX=>%R#L<?+I.LV4^EH&MIV6]:7SUCD!$CJ<LYYX.['']T>V=OQ#'
M._A>\CMU_>31I$PC7?D.4!P!VP5'LN!_=-:B!L'Y0,@'@CV]#P<D?F.G&UVX
MY&!QGCG`Z$]^O)';^+T)`!C96BMXGD48BA4D%5WX4#CA>HP.W7M][C`TN[C7
MQ#K/R7$:W4T;1,;>0!@L>"<E>F0>3@'!]370*QP'1@0`2&[?7)Z=_P"O5LO*
MN!R'QD'#$X_7/I^G?^(`854@!@,D\;QGGD<9_'@>XSECAWS;,`D8]<GGGZ>_
ML<'.,G:T94LA`3&1DX&,=/7/`_\`'3U'WGD%@65"O&23STQW]L=?]@]?X@!&
M4!F"E2>>.`0?FZ]^YZ^ASU;!((P-TF-AR?FQP<MP=WMGW^]_MX`RA\``D#[I
M)RO;^GO]T]?XE!)9>@P3R.,#_#('_?/<@;@1@>*;"XU3P]=V]GM%_%<;X%+8
M\R15B;9CJ203\IYJS9:R%N+:^C*&"Y*NNX<Q2,"K!C_XX<XVL/0G%B>0BU0E
M"?,D,D:<+\A5$`)R,;BK`=^G:JUVZ&-A<!(U<&7Y\!F8K]X#&1D[21QV/<Y0
MST."198Q(ARK`,#Z@U)6?HV?[/4$;</(-O\`=P[<?ATK0I`%%%%`"=ZX[Q=X
MLU'PQ=V^VSMI[6?[I,C!Q@C=GC'<8KL:XSQC8+JFNZ-I\F-MQ;WJ<]CL0J?P
M(!H`OZAK6IIJNG6]A:V<]M?C,4LDY4X"[F.`#GY<8]:AU#Q3<#Q&F@:/9QW-
MWM+S232%$A7&><`DGGVKF/!E^]TOARQGSYVG3W5NQ)Y($61^AQ^%2>`W-QX]
M\23R9\S+@G_MJ1_(+0!T&E^+9I]<N-"U.R2UU)!F'RY2T<PP2,'&1D#TJ/1/
M%M_JWB&;1[G28;::W5VG*W1?&T@<?(,_>7\ZY;QF[6_Q2T22-MKF:T7ZYFVL
M/R.*T[P#1OC!:70!":E&%<9[E=OY?NT-`&M+XIU=/[5:/1+>1=,;;*1?$9&-
MW&4Z[<'\15"W\?:I=Z!<:U%X>B-E;LR2D7^&!&,_+Y?OZYJ72\3_``YU?4^2
M^HK<WC$]\Y"_^.JM<_X/OM0MM`L;>*V1;*YUGRIIBX8LK'E"A'0\`F@#I-;\
M;W>CZM:V(T=+A+W9]DF%WCS-VT?,-G')/<],UU`OFMM)-[JD:6AC0R3('\P)
M@=`V!G\J\[^(*X\=>%E0`*LB#`&,`2CBNB^)K-_PAEP@;:KS1*_/4;P?Y@4`
M,C\9:G-IT^K6_A\R:3"3B9[K;(Z`_,X3;C`^O:M*;QAI<?AK^WED9[8G8$5?
MG+YQLQV.?\:A\.VR2?#FPC<`I+IH+AAP=Z9.?S->?^$=%F\3^"]4TY9O)E2[
MBFB>0<%]F.?J.X[\T`=U;^+K\76EC4="-G:ZDXC@G%T),,1E0R[1@GTS737M
MVEAIMS>2Y$<$32OCT4$G^5><^$O%#PW5OX8\26NR\MW"6\DP!P1C8#VSV##K
MD>M>DW$,=Q:R031K)%(A5T89#`CD$4`<=-\01:M9BXT2\C-X`;=2Z9?)P._'
M/K5F7QQ%!8W]S<Z7>PM82K'<Q$H6CW`;6ZX()..*YWQ_`D7BSPU&J@1QF,*H
MZ+B50/TK?^(%G;6_@_7+V*%5N+A85F<#!<+(H`/X$B@"7_A-[8:"NL_V=?&R
M:4QA]J]CC.,]-P(IW_";VJZ.FK-INH"RD;"R>6N,9P#][H3Q7GL^J7*_".'3
MCI5X8L_\?X*>2?WI)_BW>W2MVX;9\"K0D?\`+O!_Z-6@#HU\=63107#:=JJ6
MLS!5N6ML1C)P"6SC&:=>>.+"PUAM,N+'41=;]D:BWSYOH4YY!_I7,>'=2-SI
MWAKP[=:5*;&Y602S7"CRYO+#2)L(.?O*#SBH/&=U#8_%'1KJX(%O`B.Y`)(`
M+]`*`.\T;Q1INLW$MK"\L5Y%]^VN(C%(!QSM/..11J_B;3]'U33M/NC)YVH/
MY<6Q<@'(4;N>.6_GZ5PWA=)?$/Q+O_$UG$T>FQ%H@S@9=O+5<#OS]_Z8]>*/
MQ`$]W>ZAK<;8ATJX@M$'.2RJSL?J"RT`>F:YX@M/#]O'<7RW'DLQ!>&$N%^N
M.E9]GXYT*\FAC%R\)N!^Y:XB:-)#G&`QX//'6L[Q_<1W?P_DN48&.5H)%8'.
M06!XKSN\;^W/#'A?1-+)FU2-9!+Y:9,19AU/\/K0!ZQ<^--)L]3;3I_MB7>X
MJL7V1\OUY7CYAP>1UJ5/%FEM'=N#<C[)M,Z&UD#QALX)7&<?*>?:N'\57267
MQ8T2:>0^7%"C.50L>/,R<#)[UL0WMIKWAWQ5KD-JT<K07%D)"S`R1QH=I*GH
M?F/:@#H[+Q5I>HVMQ<VDEQ)#;KND<6TF/PXY/L.:B'C'1O)MYOM,NVYW>2!;
M29DV\M@8R<9K!^%N_P#X0ZZ9R`QNY#P,`?(@JYX:TBUFT/2-9??]HAT]XHUW
M':%8DGCUZ<T`:0\;>'C$9/[0VQA@I9H9``3T!)&`:FF\6:+;WK64UX5N5.TQ
M>2^[/L-O/X5POP]TJ#6?#>N6%UO\F=U#!&P5R.<'\/UJ;5QM^+NF1G+8:/D\
MYPAY-`'?:AK6G:6L9O+M(VE($<9R7<DXPJCD\GTIMEKFG7ZW!AN0#;C,Z2J8
MWB&,@LK8(&._2N!M)FU3XOGS2&%L9EC!/"A!@<?4YKJ/$F@3W-EK4]G(S7-Y
M9K"(```Q0DCGKDAB/RH`O1>+-#GE1(]1C8.^Q'"MY;MG&`^-IY]ZVQ7F'@V_
MT_7/#]MX:O/-M;NRD#)@!?-*.6^7W'1A7IPXS]:`([BXAM8'FGD6.)!EG8X`
M'O6?'XET*5ML>KV+L06VK.I.`,DXSTP*U&7<,'I7G'PW3=K6O%L$!U"^P+OQ
M^@H`[B#7=)NHYI+?4[29(4\R5HYE8(O/)(/`X-26>JZ=J+.MC?6UT4P7$$JO
MMSTS@\5YEX5E71_$NG22`?9M626W5B>"ZR'C]!_WU4_VN;3?`6JM;$1S7&J2
MP`^@+<_H#CTS0!WH\2:&9?+&L6._.,?:%Z^G6M12",CI7'Z+X<MKKX>6]BBI
M$]W;+*9`O21@&#=><''Y5U\8*QJ&.6`Y/J:`'4444`%!Z44'I0!7NX(KBW:*
M9`T;#!!&?\_XXKS3Q%;62+JL2R>8MW:3O+@''RH767T&2OON*9%=QXGODL=)
M>1\[2"6`;!*@%B,]LD!<]@V:X!=/:ZM[F*XF,TMTX^U2(=ID7G=$@_@R(R..
M@''6F@-#PO>7>H>$].NM1SY\NXR,W?#8!//4C!_+';.JN!P>IZGT/'_V/KU'
MHN2WEC;38-C)M#2E?+4KC#;?NXR`,=/<<=,+M`!.-Q(P`,9/MUP>I^FX<\C:
MP8B`(R%5"N!]T#G''IR,848![J,GY#357GKPHXP`./ESR.W3IP<C_8J1BWED
M#:Q`.`>C=QUX/7Z8;W^5J`$@@J>#CGZY_G^O^]M"0#'!7Y@.V,_TP/3].>F$
MX"$E5V[2<]01].`1],#UVY&%*`93H!G()Y'7DYYQP>O'//\`%A6PN[(P-QRQ
MZ9Y')]1@C)&>&SGYMP`BC#?3@\'GJ,^OKW_A)]=H1R0RC<05;=S\O)(/MDMV
MP<]L_*?>'')SDC'O^78GU^4^X+L!7V@@8Y`]AD#U]#TS]TY']X`1\NI60':2
M0Q)..<Y)SP>ISG'4Y_B(:W*XS\V#P.^<^WU_(^C`.!"-G`7'&[@8Z'![\`=#
MGA3UP-S`IVC"\`D8P?4#M[X'OCN0N0;%.&<ME03G'KR3GUQU;U[CL=QRS*<9
M88(!)!]O4CGCC.">^/F3=^[!",2S@`#J#@<`#C\1Z8S@+3D8.P4Q9SC(`R3G
M'H<]#^JX_A(!$<193\BX(R04'N/3WQZG)'H,XGB/6'T;1;V>TB5IXXXDC90-
ML982!78#L,`XZ=,'&*W=K<<#H=N>_P"?L?\`QX=L;:=_;6E_:7-G>+YUM<HD
M+KR#@JY!7C[V3D#VZ#D`&5HM-:26'3D8>5;!`TDS9:21N2Q_V68Y8]S\HZYK
MT6UMTMK=(4+%5[L<DG.22?4FO-YUNK>S1YIS+=V<0BD=5Q]H4<!L^CXVD`?>
MY`X!KO=%O_[0TZ*8EF)XWL`-XZAL#U4@_C28S2HHHI`%(>E+2$]/K0!Y]XXV
MLMVF?F,HXQ_T[M_B*?XD8)X6U(G>!YMSDH<-_P`?"=/>D\;C=YR,VT&<X(ZY
M\CM^9H\4@GPGJ*]-TMR-Q[?Z0E-`<;;QV=HSK#8P*[1F)]\BCS,G#<?=;D$,
MV#V;HQ%:,`NIIH]J-M5">6Q@#;_#C[N,MDXQTZDU!$+2#]U96027B.$W1+%>
M,*%&>2H\K.?7OTK?TFQD^T-J5UNC%O`6^8X&<;=I[8R.AZX'7FF)E+5X)&U2
M)F5=R(CRN[#'F!=IZX(8%CGU#"F>'+=8/%$05@$6U5%0$G8OVJ$@<@8QD\`"
MH[EE:YDF,TY>1]S8P%)W[@%!R<#[WKC`JUH:0KXDA\@.B_9U'EL!^[Q=0+MR
M.N``,\]!SS2$>GM@J/K10WW5^M%("2BBB@H****`"L3Q)IZW^G.IW93DE5W?
M+@@Y'4CH<#J0*VZ3O0!Y?+<2BWBL5"Q7<XS/L<?(%;"NF?E9-QR0"3CWXJ2V
M/V2X18&:!(798H$P492=N"O^T0H//4UU^J^'[6\CD8Q#'WFCQE6P.W(*GW!'
MO7"2S6OVJ>)+6YAFR`TJW;NR;790P1\ANYQD9]:=P9I2:DQ3,/\`9:L>5CF@
M<'^\,GS<#DGDG')I8YKMP5-KI$8W*R`JS;L'!.5D(!!0#TROM69-'"RQ"2ZE
M*;<';9IE@5P3GS,^^!TZ#I3W%XU\$B6-R8TE#1$@3H^[#+G[N"IRI/8]0:8D
M3/K=[$TBSV>FHD(!VF-QM4-P2PD*C(52!GG&#CBG+K5YY(>&RTP,A9'C??&4
M")G)S)P&`X&.`03TYIZYG<EU),H@F6-(HV4OMD`YPGW2=QC(SD<=^E9/D'4+
MJ&!H#^]@F:=D8LR*LC*6)XW$%$'7)Z<`#(,Z)]<**1]AL6#(=@V/@X5RQQOZ
M9W<=1N'K3K?5;F79<"TTV*-AD2-%)\PY./OY)&3V/6L"Z%NEN&\V:*U@W>:K
M?,\JNI*H"OW<[\CC`.3S4EI%<:E)(B*(S&A`B7"K"JD@*,\`\=1W[')I7`W)
M=<EMYHV%I8R0D$M*B2`;L\`!G!R<+P1SS@U7B\0+&C%[.PC*Q*0WE/CS<+M!
M^?(!.S!^GI69J4,E@Q$\#2Q/'AH2W##)Y!R<,,#!!XSUIC+&;:5A,$LW96M7
M@C!V(J_.'!ZA3AO?D#C%,#:FUV>VMEE&F6J,T@'*D`Q@+E_]9]W&S#=`>*FC
MU:XD*!-,M%`P\C21E0B_WCF3!'"<@]NG2N5`ECU)[6,F.YBG2.,GLV&7.,D'
M(5,@X!"GOUVM)A+V<DMG(+B&6#8(XR<9SP%#8VG85XZ9-`K&C_:UT'5/(TF1
M5`(QYB8P0>C..B@'IV%%QJLX`41:;)%C=EK:4!05;DX<Y&%Z#/&/:J9!@6XB
MF40P)A7=X\N696.U%!&2!SDD8XJ62%Y;8N#.`!@L;>(,<\G&9?<]<CVH`K9^
MT7%SY@E:1P[^>Q`D8`8V`YX4]!A>#CZ582.34Y8(%`\[/E76V,C`&2$4],D,
M%..@&[@8IVF6L.LSV]I+:&&*XC+$-.\A!1G`W`L`WW!VKO=/TN&P"[(U+A0-
M^T#`QT`'`_#]:3&6+"$6]I'"!]Q0,YZGO^N:LT@I:0!1110`8KD-7&JR>+M+
MNX-%N+BUL?-5IDGA&_S`!P"X/RXYR/I77TF,T`<%;>&[NR^)IU""WD.G2[IV
MDXVK(R%2.N>O/XT2:5J'A[QU-K5G92WFG7L;"=80-\1.#G!(W<C/XUWNT48]
MJ`//;'0M1U[QZ?$&IV+VEI:G%K'-C>^`0I(!.#G+=NWI4_Q*T>]O;2PN]-MI
M)KV&5D41KDC<I()]!N4?G7=]Z",T`<YK-LUAX0;3+&SGN?\`1?LL20H/[N`3
MTQ7+:`^M:!X3O+"/P_J#:@9)9;=A$I16(&T\GJ,9KTRB@#ROQ+9:O>:[H4ZZ
M??W9TY8C<3B$?O&#!F(Q@'I6S?6VH^,6UFUEM[VQL3;Q+:I<QA,S!MQ;OZ`'
MVKNZ,9H`\[M]0U&S\$2:)+IE^NJ+$UI$B6[,A!X#!P-H`4]S_#4>FZ7K'A'P
MM92I#*]W+J"37\$*"0^25*[!C/HIR/6O2,4;:`/-M<M)/%?BO2)M-L;A8[;:
M;B]GMVA&S>#@!P&)`#<8_B%>D-]WGO2X'7K2]J`/,_&GGWWBW3);>SO)8K-E
M$TBVTFT8D#'!V_-P,\<<5M>.+I;_`,$SQ6T=U+)=^7Y4:6[[F`=6.05RO`/6
MNQ^M(-IS@_6@#RIT/_"H[;2S;W1O!(4\DV[[L^8S^G3'.>E27DF_X2VFE+!<
M-?*L49@^SOE65P3V[>M>I8'O1B@#S:RUFTT[P9IWD64EQK5E'MMX6MI/W;L=
MIYP`!ACGFJ?B"5)?BEI5Z3(8+4JD\@A?8I`;=DXYY/TYKU7'XT8'I0!Y;X8E
MC\%^+M6TJX5XM-G(FAF*,5&!D=!W4X^JU'+I5CJ/P_U74YKR?SYYIKAE,K*G
MF;\JA0]]H4=._6O5=H/;/UHV+_=%`'C=UJ]I/\(H-,:8+=VTR6WE'[Q".""/
M4!&7FNW^'5W;3^"]/@BF5Y8(]LJ`Y96)8X/X"NJ-O"?^6,9_X"*$ACBSY<:I
MGJ5`%`'E7B#5+$?%_29VO+?R+8!)I2W"%0^03]2*Z(:AI^K'7]&\/B&=9[*6
MYFG@E#!IY05`YXR<$_A78?8K8Y)MH23R3Y8YIT5K;P$M%!'&6ZE%`)_*@#S'
MP/XATW2O!^I6UY>PPW<4LC&!LJQ)50``>3D@CO77Z.R:5X%L/MTB6P2S4/YK
M!0I9<X)_'%;1TRQ:?SVLK8S?\]#"N[\\9J::"*X0I-$DB9SM=0P_6@#S?X37
M%LEKJ-N+F-II90RQAQN88Y(%5]0O[*3XMV=Q]J@:")U5I!(,*1$>I^I`_&O2
MH=.LK>020V5O$X&`R1*#SU'`IATC32VXZ=:%B<D^2N?Y4`><2;?#GQ86ZOG$
M5M=M(T<S\(0ZYZ^S#!_#MS76:AXPMK6.^FMXQ=VMDL7G3PR`@,SX*CU('S?E
M6_<V-I>1B.ZM()XUZ++&&`^@(H33K..U:V2SMUMVZQ"-0I^HQ@T`>9>.XK&3
M5]+O-'EBDU*YE4D6[;C(05V-QW[9]`:]#AUNPDU:32H[E7O8@6DB"GCN><8S
MSTS4MMHNF64OFVNFVD$G]^*%5;\P*K+HN/$+ZJSQC]SY:QI&%.2>69NK'``'
MI0!K.ZHI+$``9)/`KS?X:3I_:>MGS$^8QOZ9!>3],#.?>O1+BVANX&AN(4EB
M889'&0?J*H+X=T:$DQ:39H64H2D*@E3P1T]*`/.A;/<_#*RU"!O](T^Z>X#(
M1E5\P\_H#]!4KQ3ZA\+IKB./YTOGN&&,$J&(8_D:]"@T'2K:WN;>WTZWBAN4
M\N9$0`2+@C!_`G\ZEL-)LM,LOL=G;)%;Y)\L#Y>>O6@#"T+7K2V\!6MX9%<6
MML(V12,EU&-O/<D<>M;:ZQ9B^BL9+A([R1-X@;[P[X],^U4;?PAH5M?F[BTV
M%9=Q8==H/KM)QGWQ5Q]&L9-735'M5:\C0HLIZ@'],^]`&E128I:`"BBB@#FO
M&>GR7NE;H"/-0,J[CQDC(_,JJ_\``JYS[6EW82RNZ>2@!W19R0S#Y2.A(&3G
MK@UW]Y:K>6SP/G8PYP>G<'\\'\*\_P!8\/WEK>1QVY1HB[O#;JWE>9(1SM<$
M;<CJ#W/!QQ3N!)93^5`B3N$7)D0?>"$Y).X8!1MV<$@@G/W35MKM"&&Z+H,E
M;F+DDM\N2WU//]X=]^:&H2WEA"\MUI\MO`5S)*R(<<8VG!)/4\\]*CDNB'DC
MD@@FV[RPV+CHQ'/4?=&,>@IBN:IF!W[7A+9+#9*A.?F(QEC[D?[RYS\PI#(/
M,56DC(/&/-3@C..K<=_7MUP0V*]OIUL;B$:;;E0?LZ^8Q)(4$`D]1G"G(YZ^
MN*HWT=NER?L\6PS*K$"-?E7ALEB/EQO/3D\T".I).X%2`,GCS$`'X9]^W([Y
MP<N19/,#*C9(QNWJ`!QW!R/Z8'7`SPHO(#%`9+0M`TDDMHN\*?EB#;2>>`"F
M,\DAB<G`I7D2Z^S.X@0*HMT*#[[<D#`Z#Y<GZ+SG-`['=>3*4P4D/WB,+T!(
MR,_@/P4X/`)6."4(@$$RC@@.O(^[@-M_IZ''\..9CLH+5<7$$9N3M\Q#@K&<
M''(ZYRW3@9QVI+BT$MC+<VT3!XD9V0<?*R\R`]>XX/3@^Q`L='Y;H@&)D(`*
M[T^[C!`.!Z@'WVG&/EP]D?+9MYGQU`B)''ZGH/?@]MI'&B66)+CSHHDV@1_O
M`#EMQ)'`."I!''3Y<9Z""6[M?-%H'ECD\W#22``+E<H,+UY!.[@C:01CJ".Y
M,5P!L,$Q!ZYB9L^O.`#T';![=?E!!((]H@N,J#_RR))ZY[8YYZ]=WHQ`YC3W
MCN1+YV`.&DC/WP"<`$_=SU&X'GDT^1;62-2]OG:,!HG*;AR6/?'S*.>,9)H`
MZ;R)]K`PS$CIL0_[7J.3U]L$>^<F\NP(W\R0&'D7,J$>6K8QM7)RVW+9(SDD
M8Z'-::^=@TTD4$8";R5B``QPV!C)."/?IWS56#5;2:X,2D"1@4V1Q$EF/15.
M`!AAG(QC';@4#-&]865LC3--(B1EG=R!_"=RJ./]H'!['WQU/A"![71(HI(F
MC==J%2.A6-$(^@*L/PKG++2KW59(;62(0);2B98FP7A+`G+')!!)SM!.3C)`
MR#W]M;QVMO'!$"$C7:NYBQQ[D\D^YI,9-1112`*0]J6D-`'G_CDD>;AB`TC\
M#O\`N4_QJ7Q;`TOA:\B1-[/+-A20,G[2G?M4'C;/VC8%)#/-G'7_`%4(_J:?
MXX(/@^]()&6E!(XQFYC%-`<B-4BV@V$+K!(B.SW+!G:(MDCC&.JY_P"N@XR,
MC32\&BZ(L$F]KR_D\Z>5VX6/I&K8Y.5PW'O4GAFP#:FR11Q&Z\QVFZ;8/FYB
M3CE1P,\<*!@9J;4+2(+=7=RC2N'R"&SO<JP5%[#@GDXZ8IB9GV=['/*ML]G%
M"CH?*93M.U1N4-N.6X7D`8^<<]16CH*JOB.,*F%\A0I]1]I@(_'D=AVXJ`VB
M:7"\NJ2O;G8=L<2@N,D`LV,@CICEB*U=.>-]?LS;VQAC6T0_,^XL6N(CSP!Q
MMQ_A28COCT%%*W`_&BD.P^BBB@84444`%%%%`#)%WQ,N2-PQD=JYD>"[4D,[
MJ\@.=[*<GDGGGU)KJ<44`<FG@:R0J08]RXP=A&,'/K6%JEJFDZA`OD,;:$&,
MY'RJ6?*$\\*2Q'U!]L^DXK)US3$U+398`@8LC(5SC<K#:RY[9!^F<9HN!Q<I
M?[$D+L@9$&]4;`7:$Q@XSG[O8<@#WK"6&:6UDM]-LY(XH6WF),'!*94K(6Y;
M(4[,#(S^/2P^&-3,$,#,3^\):155&C7<K+CDC(*CD;AQTY&.JTS0[6PMA'M4
M_*5(Z``GGCW(R2>2?RHN!YM=Z<DTJERBP6K#S0&.X,,`*5(SMX()(!`P0.:L
M?9W*JC#RHT^18E7@#(4JS=R"`"3D_+G^*NQU#PG;75W#<H-LD1.R0'$BC&-H
M;!RN."K`\=,5EP>&)X]\4L96)6W*=F2>@`^4GH!@<"A`<^B1QK)`JB>,X_<N
M<%CTPI&<'!QD#OSTJN]IY+,Y"RPS;ECDQG)8E"@4="".,`YXZ"NC/A2\`'E@
ML&.9&"8+\8/WBN`<<^M:^G^$+6"\>ZE!+N?XFW,!MV[1@`*@``P!VZFFP.$6
M::TF!U&W:.:(K+'YR['"1L#N)`P0">._)!(J]Y0M;>WMK;RT=1\TA`X8,!C`
M&.0!G@8]A7<:KX<M[Q%,*K$ZMN4*``K8QN7((5N,9P01D$'MS3>%[Q[<6LBA
M]ZA)5\LJ60X#9;[N2,Y(/4\#%`$>A:')J]H5F'DCSGN$VY7Y65`F?_'L?3WK
M7/@K*[3<$!N7Q(XW'U_E72V%M]E@\MB&8DLS#H2?3V'0?2KF*5P.:TOPP=/O
MH;HSAVB!'+,W4-GJ?5B:Z6C%%`!1110`4444`%%%%`!1110`4444`%%%!X!-
M`!1562]MXG(DN(TP-Q#.!@8)S],`G\*8VIV2&0/=P+Y6!)ND4;">F>>^"!]#
M0!=I,U4_M*TW,!=P97J/-7C]?I^=*-0M"P47,.2F_P#UB_=_O=>E`%NBJHOK
M<HK+/$5;.TAP0<=<'/:D&IV1Z7EN<YY$J]NO>@"W2!0I.,#-0+=PNBNLJ%6.
M%*L"&/?!_`_E0;N%06::,*.2Q<`?YZ4`6**KF[B&`TJ!MN[:6&<>M.,Z!0Q=
M0#T.X8/ZT`344P2+CJ/S%.W#UH`6BF[A2A@<X[4`+12$\4F_'6@!U%(&S]*-
MV!F@!:*:'!I<B@!:*3-&10`M%)FC-`"T4"B@`HHHH`****`"BBB@`HHHH`**
M**`"HI88I`?,174=B`:EHQSF@#RB&:_2^D:&2Y:-A@)YQ"ORV1@Y!X[8J$Q/
ML(?1+7)&<"%<<@\=`>N>A[UZNUI;O]^")OJ@-0OI>GL.;*VSGC,2_P"%%PL>
M5>9'$+9$CE@AG@&Z%F,@@;>P;DG.WC/<C(JQ?VHOM*6;R?,"D!M[,H`4$!C@
M9(Y/&2,XZ"MGQ;X:B@6;4;.%3*JL8X`N%<X#%"!CDF,!2",%B>XKFIKR:'-_
M!(L*B'<S)(.&W`$\9YQGOZTT)E&**07B:A>[H(5.Z2)@'DE+@G@$@!2&&<<*
MJX&<\7)M4,T5O<W%H$DCDS#$@V1JS*I3<0!C!Q@XZY'-6]%\+7.LI]JO8YEE
M3YXU1DR&.<G+@[0V3^[SGD[B.*>T-QI-ZK3P*7>4H)T4K''OP2KCDJ3M^^<@
M=1FF-%:WB93Y=]<(H9M[I&@:3.[JPX52>>_!)('%32(T0CNH'F;RQN9FC(9"
M?O-M!Y'.,9XXZ8J:W*S1*P=O)?!#CENG.!W;U]?F(R"#4=S)Y,:W6U;>13^Z
MP<%6P`-I('.25SGCJ3@T`RI$+-(7\JS>8S2M+<KNW!2<+M5^_/?'8]:J3V31
M0&60I+:7,J+%)$=RNK;@V>_=0>X(W"M*SM'OKB1;.U6/>K0L2A,<;$`;8APS
M`XYQ\N>2<8I]WIFHZ'=22IYH21"79F`,8SA0V"5*9)/'([\4"15TZWA>V-PY
M`GN0P6-'$A&65B58$$@EF"C.,9%6(52:>\EF1YX8Y%A6-&93([*SL=PP<`*.
M!C+'V%3W=^RV(G:5S;;C(2';[H4'C!]!QP>6'!KH?#7AYDDDNKURY=F8JK$+
MOPB_+W&W9MR>22QP!B@#">VTQ+52MG(",D(HFQGIT\WGZ5)IL>H2^(K2"_FF
MEMGE*D$F)&XDX"K@#&!Q7H/]DV)`S`#CI\Q_QI$TFPCD21+=0R-N4Y/!P1GK
M[FE=!9EB&WC@7;$BH,]%&!4N*!2TAA1110`4AZ4M(>E`'GGC0YOT4D#,DW4=
M?W<`_K5GQ;&9?"\L8C#%Y6`4OM!S=1<9[55\:*#JD&1G#S?^@6]6_&5A-JGA
M2>QMY?*GN-T<<G]UC=1X-,2,2WG-E'-%I6H!)DE%O<3)$LDJ-U91G@,`,>Y[
M<#%YM;CW"Y2T5((`SJ'^:25B<L%SGYB2.>V:YW2;62'P_:V7V5K::P'D30N!
MAF3;OD1APP8C=_>.?:G7<1N+*TEAM_-ACD"F([3L;+'<`YVI[-D'/%,9+:6\
M-SJ%R]PQ%L@#OO5T;`YVYW;<?B<[2.*V-$F-QXE620-O:VA.XC&[]^O/Z>]9
M6D.@LY0LFYXKA9'992VT8/.6&\X+<!<C)&TG#"KGAF+;XC9N`72!LY'/[X]N
MW0=<&DQ'J#'*C\**4CBBD,J:A>26D*R)`TN3@A6Q@8SSQ[54CU^T9`S;UR,E
M>.!D#/7D$D`8SG/%5?%D32:071V22(EHW60+M;&._!Z]#UQ7+W5P;[38(7`\
MZ.YC\U0I``&W=)N[`CG;G)SCF@#T>.5)(U='#(PR&7D$>U/K"\-^:M@T#R>8
M(GP#TQD`D?GG\#6[0`4444`%%%%`!11FF[^`<=:`%_"E'2F;^<;3F@.2?NT`
M//2DQGJ*3=1O]CB@!<8[4=Z3=STHW\]#0`IH_"C=[&C=[4`%+2;N0/6@'VH`
M6BBB@`HHHH`****`"BBB@`HHHH`****`"D/0\9I:0G`S0!SNM^%8]9-P6N'C
M\Z'RAM097C&??@G@\')J)O"LZ,SV^H!"LS2P!K96";BY8-DY?.\]3Q@<'G/3
MALTM`''P^!8X3`4O9`(I5<@KU`\O@<X4XB'S#UI;KP0CB:&TNOL]LXRJ>5O9
M'\KRL[BW(QU'<\YKKZ*`.3?P?)]MBGCU!E2&4RPHT(<J6;YPQ)RV5PG;BJS^
M!'^Q_9H]01(SIJV#?Z.1G".N\8<<_/WSTKM:*`.;B\.W,,8,=W`)Q?&]!^S8
MB!,9CVA`W`QSG/4DUFOX#=EM5&H(5A$89);;<DA1HB"1N[B+!]<K_=Y[:DQ0
M!QL?@F10%DFLY/EC0L;3!`5]Q"#=A5/(`[`]ZN2>$XI;"QM98[646MX9P9(%
M(\LR,VP#H."!Z<=*Z;%+0!Q,G@RZ:[MYFG@N(XDC0PS9"DJKKD<'CYP1QVZU
MJ:CI&IW#WT5M-#%#>PQQ-(7;?%@$-M7'.03W'-=#BEH`XZ'PMJ<4EL[:CYK(
M8TE.6'F1JS@\9(R4*#_@-/BT'5H](NK<2QH[74<R1K,<.BE=ZE@`0'"GL>O.
M:ZW%&*`.:T?0[ZUO5N;RY<JD6U(%G9T4DL2`6Y^4,%'J%%53H&L)(#;WLL*[
MI2P%RSY4S*R+ST`0$9&".G>NPP*,"@#CK;2=;70KNUF>X^UO(C+-]M+,5R,@
M$C(X'<]^M5I]"\236>U+UX;F2")9)!?2E4<*VXJ,GDL$Y]">O.>ZI-M`'#ZA
MHOB"8+);7-U&[7!DD1+^3`0QK\H^8``/NX':K^IV.MS7DCVAF560")A=E5C'
MEL"I7H26(.[GU[5U.*7%`')76DZU#HEK;074]S<AI&ED6X:,DF-@O+,3@,0<
M9QQTJ*ULO$-M<":>2XN/]+WNOF@*T>UQ@`MC&2AQA>E=E@4F!0!Q9L?%,MY=
MDR-';RSJT.RYP8XP[*5QC`^0JP]UIHM_%K;"P*AK=D<>>#B5G#[@!V490'(/
M-=M@4M`')Z?!KL6OG[5-.]B.$&`5^])R?FR.#'V:NK7('-&!Z4M`!1110`44
M44`%%%%`!1110`4444`%%%%`!2&EJ"]N19V<MPRLPC4L0H))Q]`30`L\"7$3
M12+E6QG!QT_E6)'X2TZ.[:<PQ$E]X`A1<$]\@=?<<TLGB=(H6DDM2/+A,T@\
MP$J`">W7I^O:IY]?CMK&&ZFAV>86^4R#@*"2<_0$XHL!IP0101B..-44=@*B
MNK&"Y8,\?[P#`D4[7`[C(YQ[=/:J/_"1VJN_FCRXU9U#LW#%021[?=/7TH_X
M2&VY(0[?,:,$L!DKNS^6TT6`J2^%H_.,MK)';LPP=L`''IE2I/XTD?A"T:59
M+OR;ED^Z9+=6*_0ON(_"K:>)+.2,N@<KNVKD$%NO8CC[K8]<<5-<:[:6MP\$
MQ(D2-97`!.`Q*K]22I&!0!:M[*&V)**2Y&"[,68CTR>@]AQ1=V<-W&%EB#8Z
M'N/I5-=?LO/\ABRRAQ&RE3E6)P`?KQCV-/?7+5,Y\S;N*!]AVL0VT@''K0!D
MKX,MDE7:ZB%6#>4(SMP",87=L'0?P_K716L*6\"Q(FQ$`51G/%9[^(M/2.5S
M(Q$.[S,(3C`!/;T(ISZ_8113R22E1"VUQL.0=I;&,>@-`&KVHJ"UNXKN+S(6
M#*&*9'3(.#4]`!1110`4444`&:0FL[5-6@TQ8_/(4R$X/)P`,DFL<^)KB:`O
M!;Q9;<49W.V1!_'SC:/K0!B>,R1JML1C_7N#G'=;>K?C&00^%F995B`=079]
MBJ#=1\EN@%9NO3-J0M[U7ADB$X#R0MD(S>6`.">NP_G5KQ[(8_!=RZP>>R[6
M$.,^9_I<?RX]Z;)06NFSW!:&6_:QGMI8Y8RX#(^W."P/WAL7&[TQ_=J;43HU
MM<R2/:FUMQ^[G9,*%!_A93P$/4,,8/N<US?AS6/[,=;*?,Z(Z1K*['<S,"S?
M>SE0CIQZMVS5V^OKNV,UMY2S07$(>VG8Y.P_,$&/^!#=[@4%$`MY])/VJWAC
MN8$0#%I)^Z4DX;Y57]V3],G&*U-+MUMO$_DQD&-!;E/W>W(,DA]2.WZUEZ)=
MSQZG+]F++;^22)D(P-I^4,.PVL6&?[PZUNV>H/J.O0R."&7[.A^7&?WDI!_(
M#\J&([P]111C.**0SGO%MLUUI:+'/''*DRR1B0@*[`'Y23QS[USD"W5PQW64
MRS2D*(S)&R(06`P%)W':>"<+SRV.G3^)E8Z?&P&0DH9@3CC!R>>XZX[XQ5?P
M\N+V1EC"YCV.%A\M`5/WEXY#9;';CCO3%<V-,L_LUL-Z@2R'?(1_>Z?H`!^%
M7J0=*6D,****`"BBB@!C$_PD9[`UYQI$]N+6&19[UO$WE7#7$8+<N%;B0'C`
MRNWWQBO2J:``2<#)ZG%`'FEM=VT<5C_95S=37+V$[Z@CR.P!\K.Z3/1M_`QS
M38KRZ$UI&+ES%:0SQ-EV!9C%,ZGK_<"'GUKTT*HSA0,]>.M&Q<_='Y4`>:V.
MH73#1X6EFS'<0;F,K?.90KC//3ANOK4MG=*3HUQ%J%PVN37>V\MFG8@+SYBL
MG\(4=/PKT,1)G_5)V[>E-$$:R-(L:*[=6"C)_&@#S_PUJ5^;KP_;W$\KPW>^
MYB=WW%AY<F^,GOA@K#V/M4_B>]:TUV:<7\A6W6%C;I<M`\7/5%(*R[NXYQT[
MUW2PHNT*B@)]W"]*;+:Q2R)))#&[I]UF0$C\30!P6J-=6=WXD:RO+Z1[&SBG
MAB,[$;I/,W$@GT'`[8J/4=1DTM[H:/JL]Y$VG^=-*TWG>5^\1=X]#L+MC_9K
MT,0('=PB!G&&8*`3]?6HXK."%66*"*,/]X(@&?KB@#A]0N8M-M)TTO7+R[83
MVNY))=X4LQ`^?`X?'*Y/X5T/A2Z^V6,TLMQ))>F9ENXW;/D2@X,:CLH[>HYR
M:UDL+9(O+2VA5-V[:(P!GUQZU+'!'%))(D2*\G+LJ@%OJ>]`$HHH%%`!1110
M`444C'`SC)H`6BD!R,TM`!1110`4444`%(P!4@C(/!I:*`&HH10JC`'04ZBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBJ=_JVGZ6J-?WMO:JYPIFD";C[
M9H`N56U!(GL9A,NZ,(2RYQD`>M4E\3Z`_37--.?^GI/\:<VNZ)(I4ZMI[`C!
M'VE#Q^=`'.^?IXN4TZ2PG22X7]Z#<X#`[?F.#\Q/F5/#J=A<VD`EM9WB9BH+
M3;RHD4[B<G.`,_2M`2^&05*W&E#9]W$J>H/K["I#?>'VVA[W33L&U,SIP,8]
M?3BG<#`COM.NK)KO^S[N6U<?:&,ER"J%0'.%S_M#IU#$=#5F"_TQ;A;AX+I8
M;IS/"TD@:-E;?EPN?E'S<YQC<.V<7Q=>&([<P+>:2D14IL$\8&"`".O3`%-2
M?PNCEDO-*^;@_OT(Z$8`SP,,W%%Q&?:6^F70G4+J$,<$>\2-/@JJCG:,Y`PQ
M[<U+)J>CSLSRQW+RW%I"&8-\P4&7&TY^\I#9Q]:N1_\`"-1.YAN].42)Y;`7
M*_=]`,X'(%(UMX;F9V,NGG>_F$"=?O889X/^T:06(;*TTN9E9[:X2Z:Y52TY
M#2K(!Y@.X$_PD=.P`JM.-/G,NZ._422%XXQ.F!M;<[*-V`.A.[GGBM+[)X?^
MR+;"YMEC63S05NL-OZ9W!L]..M1'3/#9A:+[3`4//-X3CC!`.[@$$Y'>@91*
M:+&DL4JW(6XD>U>Y+*68LNTY(Y`PO4@`$41'2-BS)'>`R,'5B0#.^<]3QN_>
M=3@=<<`U>CL?#44QE2XMCR3L-WE<D;2=I;'2B*P\-Q?ZNZ@0!0L8%WQ&!C[O
MS<?=7IZ4`:VCVUM:Z<B6F\0N[S*'.2-[%B/S)K0K+M;W2;2VBMH+ZU$<2A0#
M<*3@>IS4_P#:^FDX_M&TSZ>>O^-`%VBJ8U/3R,B^MB/^NR_XU/%/'.H:*19$
M/1D.0?QH`EHHHH`\[\<0?;-6,$\ACB$`V$H67G>#T]\9]OI6?=R7C:=IMK,C
M1V=L86F9L3">1><Y#8(8<X)';@5W&O:3)J-M^Y<QRJPVE3MR,YZ_7L>",CHQ
MQQDMC>M.^FAEB#EEFDM[23<^1Z#*+@X^7=CUIH#2&G60NAJU@XAAD@*7"HA5
M9>%\H^F59,?\"/XR>*9&B\/(^^1&\R-0T7WE/VI,'\P*9]KA%LEFD8BM+81P
MP1LF[>_`#,1QE2#P.-WTI/%T\EMX<66WF6&5)4*NPR!_I"TR3`=[?5]@N'G+
MC<D<ZL$E`*D!R,?,WS(3G')7TK8MM.G?0&BN8K2\DMF#PA%^8Q<<]>#PIP#^
M%9,6JQR2/]MCA=T8AYE7!B`()V@<'#;<_P"[6QHJ"RO,FX5[-\HTAW;PK*S'
M(Z#G;SZT#N9-E+;6P+6L>)?*6-GDD^;8#\O)P0N[/R@9``/`Q5OPVC#6-P&(
M6:S,>.A'[_G\P>>3C%274-ZEU/;N$E:)C^Z<JS[0.J@X8C!QW[>E3Z1),WB-
MTG?<ZS6PP!@#_CY''MD$TF!Z$.E%`HI#.?\`%@/]DHQ.$%S"'P>2K2*A'_?+
M-^5:FENTVF6SLP9C&H8@\;@,']<UG^(H3+#9MND"17`E<QC)PJL?_K?C6EIL
M;0Z;;QR#$@C7>/1L<_KF@"U1110`4444`%(32TAH`7-&:QFU*9)9!E`H)`)'
M0#N?U]>F?7#/[5N1D%8UQURI'(//?T'X<]=OS`&Y16`VK7(5L+&'R<#U';Z$
M]/J3Z<R?VK.&QL0Y/7MZ8QU]/S^FX`V\TF:P_P"UIVV[0C9ST&<^G3ZCTZCU
MX<NKS<`HHSR#T_G['^OJ``;>:3-82ZS+MWN$V]>`1Q[YZ=^?;V-#:U<`?ZI.
MG3!ZYQ_0Y_'T^8`WLT9K!_MF0.V40J"<?Y_`_KZ<N;6)E.-B9!&<],?7\&^G
M/7'S`&Y1FL'^V9\`>4JDC/(/3OV_S[\9=_;$PX6)&/U_PS[?KZ<@&WFC/%8A
MUJ7&51/3YCW_`,[>/?OD4#5YD#91&'\)'`.2<>Q_A'!Z^@(H`V\T9K&&L29.
M8U(SQUZ=?Y?TX'9/[9E&/W2$9&>3G&?_`*S<^W/?`!M9H_"L7^VI0.85X!W\
MGY??ITSG\CW!%*VLR@#$*Y!^8$GCK[>HQ^?L"`;.:,UC?VU)M.8!GGG=Q[?T
M_7&>"4;6W#8\I!G[OS'_`">J_7/N"0#:S1FL8ZS+D;800>!\P)S^'U'UR,=1
M2?VVY`*P*3QD!L]<>G?!'_?2],T`;6:,UC'6VVG]RH(_VN/?],G\5]3APUHD
MC,6!W/4>G\\\^W;G`!KYHS6-_;;[01`.^?FZ'G_`\]L'TIQUK:6_=<`\[CC`
MYY/IC'/H`?2@#7S1FL<:WEB/)('\.[C\,?ACZY]!E?[:7`_=L"20.1^'YG_/
M(R`;&:*QUUHD`^2Q!&?E(/IT]>OX\>HI4UK=UA8]_E(/8?X_JI[\`&MFES62
M-8!7/EL?E).,=NO\O\]C^V5^8%",9&>F/0G/3\?]K^Z:`-:C-91UJ,9&V0'U
M9,#I_GCKP?3-']L1_P!V3(ZC;CTQ_/\`3W&0#4S1FLL:PF>5DR#A@%R1P/\`
M''Y>M`UF(OMPQ_W1D]!_B.?=?7@`U,TM98UF#.#O/'WMN<G_`#C_`+Z'O@&L
MP-C;YC`\A@O!!YZ]NWYCWP`:E%9G]LP$X^<=^5QQ_G^1]#2'6(<<[UR.FT$_
MYZ_D?3D`U**R_P"V8,X)*GG[RX_SW_[Y;TY<VL0J0"L@SZH<?3Z_X4`:5%9G
M]L6X!R[$#/1"<X_G_7\12KJ\&T$LV2<8V]>/\_F/6@#2HK._M>`.R[B<#((0
M_-]/\_Q+ZTO]JPEE4,03@`E>I_SC\QZ\`&A16>-6MV*@.3NQ@@<<].?\\4+J
M]J1N\WCC^$_7_'\CZ&@#0HJC_:EOG!?!]"IS]/Z?4&G?VC;XYE7KCZ'G_`T`
M7**HC5+<\[\#W4C_`#Z?B*<-0@W!3,N[..G4YQ_4?F/6@"Y15(ZG;AB!,K'&
M<+SQQ_B/SI?[2MB<&91CJ._^>10!<HJG_:$!&5F4^G^<?YY]*/[0MQEFF4*%
M+9/'`&<]/3^OI0!<HJI_:%NI(:=,\Y&>F,Y_D?RI1?0%MHGC+=AGG@D?T-`%
MJBJIOX-N[SH\?[W;G^H(H%]`<8GC(SC(;\/YD#\:`+5%51?6Y(`G0YQCGUQ_
M\4/SI%U"W9@JSQ,3R/F[8'_Q2_G0!;KR+XZ,XMM%5"`29R#^"?XUZG]NMP,^
M?'ZY+=O\Y_*O*_C2LMW:Z.UNAD,?VC>8U+[?N9SC_=;_`+YH`\(EFD;.\J<>
MU0LS*OR8`/J!6F^EW6XM)8W*CN?+;L?I49TB\4$-;3YR5;$;=1U_S[T`4XYF
M`+-M(/`P!_A4#LN<D!3ZXJ^='N?NK#,>@^:-AR>E1-I%V5YMIB``,^6W4]!0
M!4,C-U"L!WP*:T@.<A0?H/\`"K2:/>$`K:W)!Z?NF`/Z4X:7>'&VTG.1D8C/
MT_F10!G$G=PJFG$X`4QH1]*M'3;U6S]DF&><&)NGKTIK:=,%#/%)^*,*`(`H
M(^55Q],T\&1%W^7A/N[@H-2+;3D',4@'J$-"6DN]AY+]<GY3TH`;&P"91$&?
M44]IUV[3&FX\?<%6$L'7[T1`/3Y#FHQILS-GRG//=".U`#;=T3+;0K$]2*ED
M<,VX!6XYXI8--G1B`LF<]T/^%3M9MO&5<`^BG^M`!$>BE4#$]P,&OJ+X;#'P
M\T8#C]R>!Q_&U?,0M9$6"9I8@C'<JB12ZX]1U%?3_P`.26^'^CDGDPDG_OHT
M`=31110`UAE2/6N0U;3]0%S>LRF2VGD'EA9B@+L41=X'.T<FNQ/2L'Q1*D%E
M;RRGY(Y6<_A&_%-`<Q-%`94,+!88<*`>FX+#*HX[M^\.?K4WC#>/#T7E*'<R
MKM!8+D^>".3QU%9Q@GLIX)H9Q\TL<$J?,5EBE91&W0C[C;>2/N<&M'Q8&?1+
M18DCF9YEVI*2JM^])Y8=*9)Q]OK!Q;1SVA:XN,>1!;81XW`#*KL<CS,8=?E4
M9.6&>1IV<L4[L+6>&01LLCD-_JP<@#G@8W%3[KCGBJ&[3I8C,MO+;6]PBB9D
M;,EPC9,8;?EMS8?&"#Q@EAT4VERRP-;F&=(9'=(A)M=YA\F]LA>&.-V,@$`K
M0!L:C.]S?2LF9=J"/Y06'"-SC#9SC&??D9!S8\-1RPZUY4XVNKV8P,8YCN">
M.O4GDEL]B:I:':SV=K,KDH[Q^1'+(<$@#[QXSG*CMA@5YS6UHR-_;8#[?.\R
MW:0*``IQ<$C`Z=?4TF-'>#D44"BD,@N+2.Z5%E!**P<J#PQ'(SZ\X/X5.HP*
M6B@`HHHH`****`"D-+36ZCB@#G9F`N&/(!;J.N<^P]A_^L\TW=XX1LB:63.P
M1J0.<\=3C`R.?88ZIBQ,<ROA&8;CN`SGJ?Q[C\Q[5'N*_,K`N.<@@#IGL.F/
M;N>F?E`,-_$48L);QK"Y^S1[\ME3RK%&'!ZYP>/8\<%9[K78[:^O[62UE;['
M"LTIC*D;&R1C!YZ^W3MQBK_8$P\,S:4CP%WD9M[`A0-V['U&"!GOGWPZYT22
M:_U>XB\I4O;=(,$GY"!RYPH],Y`XP<]#0!:76%E)$<$L[B*.9D#+N"N,],_,
M<$DD#@-R,9JU<W,=K<0V[;GN)F81*O#,0,L<]@!SSW/.?FSFW.B27,,`DC2.
MYM3$8+F-BKQ[%4,.@!SM;@].>..;E]9F?4K&_MUC,EH641G(5T<8QD9P1E<'
MZ#^Z2P(7UF+[0L9M+D223F`#:%(<(&X)ZC&#D<\`\XY6;4XHKB*!K:<-*)&C
MY4CY`6P.<="I&/\`9/\`=PV_LKF]-G,T=N_V:5G:(D_,I0KMX!)SNZ\<%0.,
M&J.HZ)-JDEK$\L"VT"S18BE(=0P`7;@`$_*"<]=V.!T8D71KMKY%I/$)I([K
M8L#(F-[,F\#'7.`O'((P,'BFMK]G`)PRW*BW@%P^4P?+R<'KGM^G'\&(Y-/O
MIK?1@Z6[S6$H>8*Q590$9?D&.,Y#`<$;AVQB#4-&O+JXUB6,6[K?62V\1+M\
MI&1N;"X&20./7MS@&:<^IV]G'NG24(6B51L!YDW!>_\`LC..GMQB2&_ANI;F
M!89O,AD\AL1_=?@8!X)QGG'IV&W&==Z5-+IEK;6XAWQ745P0S_*=G)`.,DD`
M>F,_7$MKI\]IJT]^\,"M)=O+&[3-D*Q`8-D<G:./I['`!=M=1M[]%DMP[0RY
MV,5PO8'_`'>IZX^Z3TZ+<:C;6T@+R_,;A+8[.2)7.`IYR,CU]>>X%'3M)%EJ
MYNXX4M@T.VXBCERC29!#*#PN,-SZ;AV.8+_1[NY9TC2':VIP7NXR$,$41Y4C
M:?[AXYZ>V2`;J$OLQL.X`IE@`V<8QD'KDG_@1_VLMCECG+F&17VML)4\JXZ_
MC[]?K@YYNVT74839%(K??"(BSK,V[Y9R^W&T\8..@Y'?"YU](L9+".\@=(@'
MNI95:(_>5CN7@=^1QWX([$H"ZP^52/F0$#&#C&<`@9]><`\\`$G:2X!D4J,A
MATQ\WTX'X#CVQU7`"`=Q(4$_*>F3['H>,>G7MG(7<%Q@#(^[TP>>G^?[WH3M
M8`"-OR``$\8(./R]_P#(XVKG^(C(_BR,'OGK]?QSU`/"#@*%88SGD_=[>@]#
MU[[B>IP;@<C/3G'H,CG\",_@<Y^84K@)MW'#G()VX(/0^_3N?S^N#>VW)4C!
M^8>N?R[$]\=0?XMJ%2/E.TE<DY_N^^?I_P".G/?<$$-D`!1R&Z`]LY[X]?8=
M<'+`3+8`[]=P'(Z'Z^I_$G^\M/4GS!DX/WAG`R<8[Y_SUZ'=&>F,*01\O!QP
M,8P/?'KS_M#YG_-R`,G/0'&>.H_-?S&/X:`$QG@_ANSU'3G)';/J.W4%@'!W
M)G,8R`I)`';&/H.GIQGY259E+`@JW&,_GZ>Q!QCN/]G`00Q'RY(X)&>3GUQD
M]^/4GN,`D&&PP4D`#`Q_+CWQW],<%2$<?-OP.3CH#]/SW>W3/'&'%E(WLOR'
MDYY`/<]LC&?PW=,G:G*KAB"P_''/_P!8]?1B>I%`QIQSE`PZ.".??K]?U/(Y
MPO4YP#M/0<;@.O7@]_QSD`JU*.#G.W!Y'`P<GKU[@]>X.>0PIJD;C@A>`,DY
M../Q'Y9XZ''S`"X&T*<$'&#@CD8['_\`7U[@[C./OY."1PIY`'MDC/'KT'4[
M26EFXR`H;J#TR?0?7'3.<^H7*R#`/R`L,_*H)Z=`!WZXZ\@@=P0`*N`<@`LH
MP-HR3[C'/8<<]L$Y&47'`['IC\?P]!Q[=,KM4;BY52'/\()#9'KVX)8'K@YS
MQGY6D[E4_P`(&3W/'\^G?WSU.T`?_K#P,[^W!Q].F1@XXQGMC^%3AC\RC+'&
M!R.3].<@]>X/.`3M9DKN#9&TDN&/)P.ISV.&SG'(;('S4DJ''S'H>6/XYSN^
MF<GG@Y'W\@"\G&W!)`P?4'O].3STZ]?FPJ*,G^Z3D;CS^O3@9]><GHV0DL><
M<]NG?_ZV/7(Z9!W)'AHU*LK*R@+@]/YG(R,=>@ZD9<`-P4@LP!8\Y&WGC]<#
M/KQW[H2>F/NG&WT/&.!WX'OQQT&]20,`*/[I"CD^@XY[C\Q@_=I.QV<Y`.?;
MMCCIR/KQCJN``XB!0$@18^[GD#@=,^@Z<\#KE20C8"`.G(P.,^P'3\#Z`'E2
M&AB0K(#TXZ[3G..G7OQW!XZ_+)YA##!&1S@$'CMD?@?U]3M!#3EG*@`J>,X)
MZ'GT[X].@QC*[0@2Y!)96R&`Z`'/IQT8_A@]QM8!L(!*8'4'],YZ]/QY]3M>
M1\Y8C@<LQ&2!CKD^F._HV?XL`A0V0N0N>-V<=_\`ZQ/)XZY[X</NCG!SNY[\
M8[Y]^OOG^*D((VJQ9B.#SGCCUYZ@_D?]H4TY8G/&<'*DCKCGCIT'Y#TPP`W:
MH.[.3C[S#`[<DG_=[_4YVMF3''*YQU!'T]1C_P#5W.=[48/@(0'//RG!]L8R
M1V/^.!N0$`J1M`Z<#C'/3J,9(Z>J_P"S0!(N5"CN""",GTQ[GD#N3P.2=I*`
MG"X4'/(((.0/8<D9)/IQQ_":0,A7*C@CY6X.[K[X(Y[?WN/O+A<G&XD$;OEW
M'=D\\^_`/?!RQXR=H-#B,=OJ/0__`%SCIUP!W7##P-PVL&.T\<?3CCG(X.!R
M.Q&UW0<9..3W/ISW]?U]3M0AOFZ;L')8C('<G/;KU'K_`+0`,4D.-KC<"?FX
MXVGK[=_ISD@<[6G=D\\8SD_Q9&2?8=_Q/HU/))8Y!![DGZ=SGI]#T/!P<QH"
M?F)0G.,Y_P`_3J?;)&6`')EL%N&X8$GH3UZ].@Z^O/W6R@Y`8L.@R<$$$XP>
M<XQCTS]<'>H(^49(#9X7@G/\NO3MQUP,IDE=V/F'9!R./0>V,#D9*X/"T`(2
M?*W*@`S]U@.G'\L9_`8R0-ZJ2`$4[=F`IYXXPO`^@Q@YX&.JDH&`^8L..CYZ
MCD^GHWIW^A"\_<+8!P5/\/(Z>F.<]N#QU&`!."2JC"LN1CT[=/KU&.@QU0TI
M(#ECECR,8&>YX!]VQ]?][Y3<3C!'7&.#U)QD#KT/?UZ9^5`2Q;HN`&P6QQSZ
M]>AZ\<'U>@`#?-P,AL`G/+?CQG.[N,?-VRVUVX\AE#+W''/<]>G<<^I]&IN0
M,*I^88`Y`)]OFYXYR2#SG.>=R@XVD$!-QPO/![=<^GOC`Z[3N`'*P7(4C'4@
M_*.HS]._)]3W5J9ALB4\;",C&">G;J/N]QGGN0<NVDL`<$#CY<]?;'3K^&1Z
M?,BMDY4DGT&,G.#QCIU'`SU&#PM`&-J5S=17UIIU@(?M,RO)ON%8HB*`.G4D
MDKQ[=^-R7&HS02W:*D>VUGM8D)S@F4H"3CIC(]>F?0FWJ&F_VB(E$LEO)$QD
MBF@?8Z<$'!P>.1V(Y'JN(;G18+O4#>FYN4\QH9#$LB^5(8^4)&,D`[3\I'7T
M(P"*UK/J+ZU=6LJ6L=I!N$2A&\XQ\&.0$'E>!]WI@8.0N8&O=4M8=4NK@V.V
MU.Q=L3#YMB,&/S$;?G[?W?7;5X:-#_:XU(7=V[@NZ1&0,BA\Y`&W)7IQG&0O
M3(PV/1/W.H)+?WEPM]N,J.Z$!N/G&U`<X`'N!SR3M!#-%O+O4&N8I7M[@Q2)
M'YEK&P0Y7)')()!)Y^@X^6DTZ_\`[2MYBLUL+AI9E2$29(`9E!*GD]B>@YQQ
MQC6'[MV=E'R9=@Q#'Z@G'H3R,9SZG&1:>'K;3-5-['-='R_-/ES,I1"_W\?*
M"1P>I[-ZM0!1?5-0@6_MW-G=&$6Z++"C*BO(Q4JP))8J"3@$$9(XR=LJ7^H3
M#[-Y5B;[[5/`TQ5C&P12V>ORDY/##&23Z@:#Z)"^F36/G3K%+<FX+H_*N9-^
M%SQP00,YZ'/((,,7AQ+8Q*NJ7QNHYVG6X9HS(&8!6!RG3"\\9X/'!R#,V36K
M^72FO(H;$B&R%Y<(ZMALLRD`<C'R$')Z,0>":GDUF]36FLETZ+[,MRD+7"N1
MM+(IP>/O$N&![C=GJU3MX9B^R?9XKR\BC-K]DE^X#*N[^+Y3ALEN0`<'C)'-
MS^QH#+(5>=O,NDN``XRKJ%`VD=CL.>OZ`,`RZL>Y4!0`]C@#!`SG&,]0/U!_
MBSS7]OR0PWDB?8+M+>T,\3P%PJG>`%8MD9^[@>BX^O3KM>!LY`9=K;1@<C&0
M.>[#&#D#:.RYQX_#H_LJ32VU*_FM7A$,<;E,HHX&W"YS@J.N#D#^Z:`1N^$)
M+F:XU*"^^SM);S+'F+(#`HK`X8=?FVYSV^E6_%6J76CI:&RM(W65F$CM:O,$
M`&1\L?//3-0^$K'[)->2-<7,\L\@DEDG.<G&T=``.`.W3GO74S1^9$R;BN1C
M*]14C,CPS=+K7AG3]2N+6!);F$2,J)P"?3-;**(U"JH`'8#`%4]&TV/1]'M-
M-AD>2.VC$:O)C<P'<XJ]0`4444`%8_B6R6]T:0,I)B/F#'4#!#$>^TMCWQ6Q
M377<*`/.;6+4U(B:^A%HC1'R"<N(TD4$`@<#.#C/?!I?%MW]C\.:=<$L5#`O
MLC#'!W$X!XKLAH%@+AI_+8EB25+$J23GIT/4]:Y?Q]!$(=+APR!;E!$L:\[\
M-M`'H2,4[B.)AN&:(O>P(DX5=\ELXA"RL-Q?;C:0@".#Q@Y'>K9MX$<LUR!%
MPH9(OG9%PBA00`,,S$D]@GI5.!K:%O.@A,BE&WRW2^8A220G.#TQ(K$[C]R/
M/KC0LH;V)_M;])&&];@YBD8J%VL#@9.W(QZN!G`-,1+;SV[!DCM!Y+*#N$C;
MPI9@#U.3T&#C[WU%=!H4B-XEN0@*@7,((SN`8I.3@]P.F?:J%FUB6MYS;R[6
M)8D3*RL`5S\P&3]W\TYK4T-Y9_$,KRQF)Q+#F+8%$9"3Y7]<_C28SN1THH'2
MBD,6BBB@`HHHH`****`"D:EIKGI0!S,J;IG#`@<Y`(&.2>Y]_7O]<0OUP`Q!
M/T_G_7\>C"IY@JRMU^0G#$\GGN>AY]NO/7.8P#M'Z9!ZC!QG_)Z>@R`-VG=Q
M@8`Y'8@YP,<]N^?QYR$$ON*=?7U&/Q[?^.]SC<8/0DG/!R.A'M]>P]@`/EI0
M"&XR6V[L9X[]?_'<?ACC;0`TIT7&T_=(P#D=>W^>.,97"E49CQD\\=#^OL<?
MCZ8V@"'.W9\PR""#D8Z=.>O?CD_WCA<D-WQGG/;H>_X]?<_WJ`&MEU)('(P<
M]^I]@.OZ]AN`0N<XSD;NF2`>GK]._KS_`!9<#\P8C!'4XR??KR#G/Y'/W6RG
M*CD8`R<8QT[<]L_^R]<+E@(B[".03GCD#^?'K[<^S4%-S`$`\=?;IW_'VYYZ
M'(""%]<!L(<'\-O0=O3IZ#+L8RQV@9W$G"YZ<_\`U^W'H,L!N`WS`\#@X..A
MR?<?CGKWPVY1\@`^5<'MQC@?7L!_]<@[D)`"@@GT^7(X`(Q^G3_9QT7*L"45
M57=G(9D!.?<$?A_XZ,?=)``9&!@@]P.P[Y_+I_L^I4DVE@J'`^;C]/P__5QU
M7"MDMQ@M_=4YSWY`XQR./R^\N&<;LD@+Z@#U.>?Q`/3OGAOE0`RADQMW<`XQ
MD#MZ^G''X<%=LA&2R=1T//K_`/K'/09YX^ZFX;58E<'/#8('Y\$X_K_M80],
M,6()Z$G\2<_CGZ'/1J0"G<`6VX+9_P"!#DGH/0GJ._.<-D<'(P0<Y'/'/XY]
M^H[^S;C=D@##$>_(/H/3ITYP<=UY<I;Y6Y+'^Z"#VZ8Y';_QT=EIL!H7*L5`
MQ]"!CIWSQQ_^O!)"`003\R].!QCO]/E!P/3K]W*@*I+_`">A95'I[>V,?AC^
M&D()+#D9'!)SG)(_'Z=^G`(P@$)*J1T"_P`6?X?3CT(_\=[_`"TC+M'.5Z_C
M^7T`_#CJN$8,P!`W8&1P6'Z<'MTZY[9P''D`JXY.0<YR/J.Q)Y[=<_>X:`3&
MX#@%7Y(SR.V!V]!^7."I`1DDXY.>,?7_`!_4=.JG<L5.-J\DD;AR>I[<YYXP
M2>A:A-X(//3)+?KR?^!9_$GH^6`'OTZX./?^G)]OF.>Y47`/3/7&/4]N?Z\<
MCIAJ#NR,L6VGJ<\COU[=?_U@Y51\X"\C.?E'0_AGICW[<?*,@#0#N!P0OWNN
M`.1Z\]L],_DVY5&5"_W<9Z^W7\OT[\;E)&5`#;AP>HQC&.!SG&/_`!W&?D-,
M8';NW8`X&.>HQZX[KTZ\8_@P"L.(`X7.5Y!Z\]NGT'3/0<$@90';\HZ=1C_Z
MWN!W],'E0%8`*1C)P=N1G).1T[G&..IR0.",(<,>%ROICC)SCV[]^#R>YP#&
M@XY89W#GL.?I]?;\B-JJ3N5C\S9SG(Y_/@YS[#G.,;@JYW#/!/<#OTZ]_7KT
MY//S`*&PQ)'?)R2/3.XGD'KG//KT.0!JCYB,YQA@23^9S]2?QY!^;*Y!.6;@
M?P\\'UQ^'OWZ\T@.UL$8Z9[$-TQ]<CIUXXZ<K@$`$`9Z`CC\.WIC'JN/X:!7
M%4D;5.5P<<>V.?;IWZ8YR1RW)1`<8`_EU[9/&#^7'\(+G5B%&W.``NT=NG&/
MPZ>P'\.$W$94D9!SQCISP._<#CJ3VR,*XQK`A#\H''3V'!_R/3@\H2B@,NU>
M/EQ@=L_3`Z<<8]L97#GSP23@\Y.?<_T'TW?[7",3C!QMP=P/7WY/'//7CALX
MRV&`O^L`[CG(&.0>GZ-[#GGOA&&-SO\`,#S]<]/?!R>OOZMAQ!W;B>^#N)VG
M'7KP._/;!R.&-,8X1>1Q@X0<>XP/HWZ]<-D`85?H`2"I(&1SGZ^Y/48.[H!N
MJ5F#N#G<IYZG@_4^V>O]&RUDVD!F^;M\V#D=>>H/!YZC\/F,,<;AD'@$+CGT
M'I]![`<A:"1%.'W#@@\C@8Y'/&?\]?=R+AN>,<8S@\=?7T_0]?XFELG"G.W[
MN`6/;&,?0=.>GHE/0$[@K`=AZ`\XZ9XZ<9';'&V@`[D9Z,.,'/\`/GH.G]WU
MVEF??.`#@_D.OT]NG/IU4A[HN21@8!Q@`G'I@=>H]/U7!U8AR"&/4D<Y/7)Z
M]1^O]XT#L,!&,9Y^HSR?;'KV..G3C#@?XN1[]0>H[8]3_P!]=OX6*I=6!!VE
ML8;//!R.>#W_`/'L]6Q)DER-Y'0]>H[\?G_X]_M"@+"X"[0`"",CG@C'OQW/
M7CYNWS"@L3SZ#CMQ[Y_'KS['#9`-VU3NQ_$1D;3QD^N<]<]"HST.1>&!"KD#
M&%7!!XQC'(^[T]AC[HH&*P)&`Q[C'IT]?\_KEJ`Y'7(P?3'(YQU[?7CN?O./
M!+;?E)P,KQ[8[9R!T_V1V6@*2I(/7@8/&<<``<'MC'MC^&E<!G1`%^4@\$\8
M`Z=.<C`Z?W3@\I2C`8D<+GMW_P`^WIQV-*PS\J@$DEE'#?*>P`[<CIP?49&$
MY&0.O/;).`<>_<G\^S'#`-OS$<`'@KUY].,#T]/;`("A#ME"`>#D$^O)].N>
MQ'WN@YVA^\3C.<C<PR<>I)ZCKG_@6>K8"-RX)W*O3=^)/)XSU&>W.?XJ`$;Y
M^7))..<YSD\_S_\`'AG@,`#.-Y`Z[B>@_7IGW!Z\\A@5X`R-H7.Y>RD<=OP;
M\>>JG+D8G:Q!+``G!(YXY]0>#_7IR`,PS,``">AS[]B3Q[^OL<-N#G:I&%YS
M\V3C@8Z?0^O3V^8"N-I)(8_*"`>O'3OU'0<Y`Q]U:4@M]S:2.`2,XXZ#'X?F
M/5:!7$4E4VX(4#CKQC@=,GC';GY>^4R;."-I4'D8Y^@X_IZ?[M'WOFA.Y,<%
M1D'KCIP1C;@#J.AP1A^,KM5ACIV/'/X=QUX.>>&X!B<R-Y@52O3'!XY_J?S]
ML;0D'*G:PVX.<G<.<\\#G/MG/;.0H8`$D@'!P20>W0Y]LG'U/=L(=V1E<@=R
M"3QUSGC/7KZ,3_%0`-D]/F;<,$<]3U.,>OMU'3G#,(QWIDYR5)(&>IZD?[77
M@?,/1A3W0M)R#D\88$\\<<]#U_R#D&2@7)^8Y/)&.F?4]F'/.<YY!I7`:HZ9
M./FR!T'L<G_///1J3:"64?Q8)'/)_'Z'_(;<Y1U!(![E%QCIZ<\\X_#J0,J,
M[MTFT<XZXQ^/X=O;'W1E@1$_>;AL'H>W3KW['\N^#N"#&<]`HZ]_RY/;WZ'K
MP"[@*P3<"N!\H]`,#`X].G^SC^&E"@8"G(`PN.F.V`/7@C'J,?PT"8TCYQ@X
M_'IZCG(XP,^N/7&X*X#1[@`!QNS_`$Z_=['/R\=J4J#E?F55&<<YQSU/IT_0
M?W<+P3E2`A);=U&<'J>GI^>1]X8!#<``L<J0.`"#@],<?3MZ<$?+2LJM]U?E
M.>,=Q_\`J/3\/X<+MXY'7J7.=N<]?TSZ]3U&'-P2"-K$8P?3G&0?<]/KV+``
MQIPQ(+94G#'J,=SD8'?T'7T(VHP'W0O7[P!'^>_Z].?E?@*<@H?5C@YY[EOJ
M>3UY_P!JF]/FRV5YR<D@CZ]Q\QY[YS_%0!JZ",/-SDC`S^I[Y[Y_$=\BMVL/
M1"H>501P1P,8'L/Q_P`.M;E2,****`"BBB@`HHHH`3%>>_%*YCM;"TDE0NGG
M*I4$@G(8=000.>H(KT.O/_B1$LL>FHZ,\9N5!55#$\/Q@\$?6@3.(77/,G(M
MX;=)G8M9S+\T,S[1NR6R50`1@M\O.01Z"6.IZC.LNV1E$3I<0S*<,#@JXYPN
M[;G@G8HX'S"K<%OIT$7DVMH#%QE)(M\:<<%$;I_"2!RV>3D5J6ZW\MW;L1*/
MO,IQ@)DI@Y/(XQSWZTT(;HDBPVL_FLS22*LQ*D*02<D@'(!^9LK@C!7)SFN@
M\,^8VM3B79O22%"$((&(Y2>A/=B!6%J%M"L]W#';I'!AE10J[5&4<[1D<$;Q
MCOD9XK;\(02V^JWB3-N??$A8Y)RL3KR>AZ=@![`8H8SNUZ44#I12&+1110`4
M444`%%%%`!3'ZK3Z:_5?K0!S$PVSMA?GR2,$G_Z_8G_]2FF$'<<;<D8!`S],
M?C^/(Z<;7RK\Y0+PK':#R`>>V?\`//8\-/.223P21G.>./Y]_P"]_O8`$(W$
MC:2/3/M^7Y8ZCIP5,`Y4GOS@=?P].?I],D!QY.6P#G)VGK]/S/7UYS\U`7@%
M>'R/FZ<')R"?H/\`OGIP<@#,/E1M!!;@]^OOUZ]_7D?>R/PHP2#G[N#GJ`.F
M<<C]/7[RA2205')[9XP<COZ\\<\#!X&5V9*MA".,#&<<<'L.,?ICN,`#5&-H
M`/&",\<=.WX=_IG"Y:"0V>IX.`!D'TX_3ZKR.-KT4;<<#'08_+VQS_X\>F?E
M:Q&[&2Q!QGJ>^/Y_3YN<?-@`4#/RCDY`RN>O&3V_#ZK_`+(`21SQSSD<`'\/
M\\K@CC:`-D9&XY)';/)YYZ@_UZYW85M[,2S;LD]!GGG],'Z?-R1\V&`S@Y'.
M.F<<9Q_GIZKZC"N"$)?&!DXZC'Z?X\CIGY78.,X.`#N)[@_TZGG^]S_%32"O
M53G'L,C))'/X_P!?XLJX#MNT[<9P<COGKUZ?YSG^(!N,DG((ZC!R3W]<GMU]
M3GJV55<*H(PH[GJ,?_J_3VY7)P5W%APH'/!S[].0?;CV&0!,L"6!4>K'\#G.
M"?0\^_OE.59BJGCC'0=O?.>GOQWPN54N6+!L$\L>>I[X'/H/7Y<?W33?IUS@
M=.#V!Q^'^/(V@"G<&5<;E!"X]O8>O88]O]G!QA58`@#G&.<^F,=CV/<8[84C
MID#81@$C.?7GOG/H.OUPIZL&`;'&,CGDYZ\<Y/\`WT<_QT`-7<68_>Q_=Y)'
M?H,^O'3IZ_([[KY'\(/7H.N02?KSGWS_`!80E2%#-DC)&X'D=SS^/Y]#AL@!
MSR,'/T`(([?A^G?'S``P&\''RL>.!CZ\_P">O^W3#@GD'EASD]>QY_`_@W'W
MMTAQG);:_!/MTY/'/3M_='IRPJ0&.S8JXXZX.!W'IQ_WR,=J:`3C>2J@D'J3
MC^+KP<]1^8/\0.YR@;B%^]VXP<<8&>OIZGCO@;D`.05'(P,<8[#/IG([>@`X
MVFG)DJ%ZX(PH]>./?KCM[8R,,!/NGW[<]>N>F?\`/T7*'&[=DMEB,#O^6/TZ
M<`9PF%P=O!SEAR6!Y)'L.I_F<_>X=QA\C<&&6!&=WWN.?J.O][GJ<)@-;G)/
M(/7N"#GTXQSQS@@CIU0^96QGY@,[N"1U_7D^W(]6VO(.[DA@H.,_Q9R3UXR?
MFYQWYY#9:JGY0&^Z>QP#Z]?Q^GOALJX"=0V>^3VSWSR>/3K]3_%31]_)('^U
MMX!(]^GTQQSGG<&?D##9V#)SCM@Y/3\3GGIZCYDX5F)PNW&>..,'/'7&.W]T
M8_AHN`FW`QMP.`!R>.G].N?7'^T*`501CY?EV\\CTZ=_Q]/8TFWH6&`"1VY_
MIZ#\!T^6GA&*DA<X)PI/(/<>G0J/3D]B,-`1)PW(R,8P`.X'''T.!TSC!'RX
ME&<'E<G&6&`,\^G^>G3G:T@#"'$O8J>_4?J..N/FYX)PH9B1AAWYS[#\?S]?
M]ZF`U@&8K@<YXSUZ^N./RZ]@?E<V6Y8`JV>IQZY]!CEO0>H&6(:"I?<'`R21
MSUY..3_P(\_CT),@48R2RJ#\S#/7UY[_`.'L<R@(]I)W<]SDC![]>_7K]#G^
M,4X`CYCU)!Y&/3K^&.OO^(HQ]SC/&.,#D`=/I_X[[`DC&&7!`R`#UQGCTZ?_
M`&/!X%-@-1=IRI(;IN(X&.N>O/`[<8]AE""$`V@DDX`.><C(X^@]^..0N5"G
MY&7"NN%4%<@<\`8Y]/Z'D85EW9!(=3P<\DY[9/7.0.F.?0_*K@(JJ%Z\'!X)
MR/3IWZ=.>P_APFW'7GUZ`GMV_P#K=1VVD#+N).P$DD$8SUS^'\0Y[[B>`QQ(
MRD.RGEN=V.XQS^')Z_WL_P!ZJ"Q"V=V2,,.&).01G.,D^IZ<=1G`/RN"_*R]
M<`]NO'H<>_I^`)VGEGG<5R<`G\P![=3U]?9LN53N]<?Q'`/^<^O]#D"PC$YY
M`!/7)XSG/\\GGL,]"PIJC`!`7Z,?_P!?<<Y].?XLR$$\!L*",@CI]#^!/U`[
MC#-5>5)XW8S@?3D8]QV_NC&<+N`&8(9B<@#'WQ^//7V[$\'K_%+W*D_BW7\0
M?P_$'K@9BA;=AU7YE`';CH<8'3\,].#G;4BKL7;D!<#!_3U^G;MZ%<``1D(N
M,XQVY_3Z'H?3&?D-(=LD?!P&7D@@<=3T^O8XZ<CY,/=,H4"<8Z>O7Z#G\N>P
M/RH[$JX<M)N!W#LX[G!XYX_[Z;(^]28#4R&/R\L.>-N0<G/'X\>X[$;3=E?]
MG`VMQC'/T'KQ@#D9QGY5;:<YR_!R2<YZ]NO_`.UD_P`5#'&X'IG)/<>I]1TS
MGG!YYP<@`?F^5E7D=/?GU'N3T[C(Y8!O#-ELD$],#@<D''U/KZ^C$R*I4X!&
M"1GCO@<Y]L$<C(P.N.8T))//S<';^0!].W_COLI*N`K`LZD$9!)Y'ICKD=N/
M4\'(SPR@`$*@(QC!(QMY'&>>^.O(['@91`,(!\N,#;GH`!V[8]O3C/RTJC&U
M4'S+@(0<[3V&!TZ]B/PR,-`(6!7L><@C@=C_`(8X[#H=I)MS][!####)^A(Q
M[G@#VQ_!@W?)D$8V]?4X)X/TQZ=??@VD@Y^8,NUN_!SU)X.<^F.3T#'#`:Q*
MKDCDGD8Y;KP,=?;H.G3Y<*XW]3M?C:W!XR?4>I)_R0JMAD8D[B02><[NN1SQ
MZ]>/F.>K4XY"L"2!S\PR.<Y)'7`P#UY_7(`C*<'G!.<<<`^^[M]1ZY_B`#G@
MG`&>>_TZ_3OVW9_BW`!1G!VA@""1QM[$]^<C\-O?`W.Y5B`,`=N1C)'3'OZ?
MW>.0,@#%#;"%ZXZ'(([#]<=??OD,@`!.T8RHVD]`0>G!SGIZ]#CI\SQE]NP#
M[O'&1C@=OZ>@_P!G*+DJ%R=P'R#KMXP`,=N!T(Z<8RN`!`1M`##IZ#Z8]`.G
MM^F4(SLR<Y[`<GU[^V>.G7GY,NV\`KQTV[3T]/NY/Y8Z\8R`&E0%8$!AC'./
M_P!1_#`Z]C\L@*<E?F.>"#C'N#TZ=<8''ICBAAASR./;^6.?3_ZV5VIC<A#-
MO!!4_P"T,X[\<Y_\>YZG"@[ERYWN<Y8C(SSSC\?U.>K8:$Q"560_+@\#C!QU
M^@QR?09(Z<!0MEO=L\>F/3/'YX[9`RP4V;0IQ\P)P2><_-USS_>'/J<_Q93/
MS@ECLSDD<<CWZCN.>?3H<L`PI"CY@"1@<Y'OC.?\^FX!6VK@D`'&0!S[<9Q]
M.1^'WC1LQ'DHN0?NX`[]3V'(SCU'J/F=T?!)+L<'YL<]_P#]?MWQR#L-7(Q@
M#/&"<_@<GZC.?4YW9:E*\`1A<_[7`]??COSV'U#)'D]5"[L$X&,GUP.F/3VX
M/'S&TE@RMC@;3UQR/_K?]\_[N0`QMP%*@$97).1TZ]3QCZ_C]Y57Y555QP-O
M;:.`/?TZ?AT7<NW@=!G)`P3Z<\>G'Y<=1A'R21MQN!^7`.1T^A&,=P"#V!!4
M`U=$QF4C/)'))YQ^G?T';J,5MUBZ*26D.,`;1GUZXZ\_GZ_@-JI`****`"BB
MB@`HHHH`,UP'Q(CCE33DEGDA0W*9>-<MT?@5WQK@?B--'`+%YY?+A29#(^TM
MM7;)DX_"@3,"WN+7SHQ96[3;F\P3S.5:,DCHH^]]X]?2NCTOS[6"YO;YDC"1
M*B>8."Y1><`#H%[>I]*Y2XU%8I9(K**9&3<LMTZJTB/MR,8X4D[OQ4CI6G?3
MP:7I4&F3.TLJL9IE)X9F^8Y[\*,$YZDYIH0S_16G8-//.Z`+Q%@^A//<]/;B
MMWPF&&I7'[]9HS)&8V";3@Q,>1ZY)S]<=JYRS9KN$N]OY+Q+&Y;)*D\#(4G=
MU.-V,'GIC-=!X/#?VE=_*54W`8@@C!\IMP]^<]/6AE'=BB@44@%HHHH`****
M`"BBB@`IK]O6G4UNHH`Y>4JSL"JA<\@@$#).3SQT)]NOOE.0,A6&&._.1C_]
M0Z]QSZ<R229E>3=@ER6;G)_+GC&/7@#TS&/O$X53GG;[`<?Y]N?NX`']<*-P
MX&PGN,\?CT.>V?893*EQM7T8$CJ>`/Y#WX'HM&S`&%!Y)Y''I_4?7/TPT#*$
M!^2<?/R.>/I@Y^GS'LQV@"`JK@KC'`X`.>W7Z8]L;>Q&'8+#;QO![@DDX(.<
M_CU]_5L&X-)PQ+YR0V1QZGCW_4Y!^;*'##[X`Y''\..HX],$_4#C(^8`!LW`
MD`*W52.!R<@_@3GZ'C[V4(W$EPW!Y'7&?7/?D$]\G/NRD8<KC8V?F`ZY''N>
M,8_`>V69*LK#`XQP!^7^?7W&&@'=6RO(YY!ZC\/\\CVRAP<G.2!C[H'M_7K[
M]^,@Y&>N1D#))Z9/I[_F/4852#QN;(&!M;K_`)R>.^1TR,,!#(0/4#YN<\]?
MUZ8]S[#(JL,^7]\DX/3\]O0'@Y[9[X`*Y/RE4&.?Y?KV].O;/RHV78[&+'J"
M1GGMP<=R/SQQGY0!01G(R0<8'<$@`?T_\=QT6D!.-O;IC'&/3TQC'3';U&%"
MAL\C'0]P,G/XYS].3T^;#6^8\8&3V&<^^.N<'H?4@C[PI,!5",F-VX+_`!%1
M@C&`>>!_@/0G#=A(.Y0`QQEAT'(_+DC\6SU84XGY?O%3G`.<Y/)QW/J<D>O?
M.4WC'`([\<$8SS^&#[\#K\NY6`5\MN8Y#8YQU)[>AZ_CR>O.X7>2<*3C``.>
M?K@$XS@=S]2`&4A\$#`&T?+VQQQ]..H]C_=H&XJH'\)!0,,@''&<>YZ9[^F"
M``R2WR\AF!'N>,>O<#ISZ=!N7Y0&!50"!CI@=,?^R],=%'&%H3;Y>%&1G`.1
MQG&/S/7ZY]-JA\EF!//7CG'/K[MWZ9.?X@``&1G[_P#P'.2.O`&/;\EQC(VM
MQSQ]X<$*.H]?U^G3IV&;?&=IW`J>6/7()'7Z_J?>EE=6)#D%OO`$$C'?/;U_
MKWH`C+%2=RJ,G/?&,<Y]L'OT')P"0LG[MP%8':V<AEXSR".>^,Y_X%G^+"$$
M#;R`2<XZ@YSVZ8^;UZ=R/F4L,!C\H&3DG&..W?MW]!Z#<`(026)#`YSR3GGC
MG/\`G[V01N!,$DLO)0$>F1D]?UR/]X=0<JHP&)!7!PQ^[S_]8C_QWC^`D^;*
MJK*<M@#KGG&/T'3MC'\.`!O(8E1R""-PZG`_'.<?AZX4%QVL0@!(.!@YY(Y'
MX\+[_=Q_#2#IC[JD`8/3D9Y].2#U[Y'7*H!_"%QGIDC)/OZY)'7U.?\`9``$
M!5P&SP.!CGC&,>_I@_=QCY<(<@L,#IV'4`>F,9Z#MT'3.%4G(=-I8L"""<`@
MYX.?][!SZG_:PXJ`X*\D$XSP3R?7WZ\=>#U;)8!KD+)E3QG[H')'.2>_<_ES
M_%@!VJ3)@!00X;E1CJ3GJ,YZ_P"UWW4I`QA>?;G\O8<>O;VY4$*3PPVD'UVX
M//`Y'W2.,GCV4L`-0[,!Q(`#@L<]<\Y/3.-WOU]#E%4OLR2?]K'4>H]OQ[CV
MW+&-A.20#@`J!GC`XQ_N_H,?PTS&2NW[V/O#_//7VSST^7#0#E;#G;D#HI&1
M\W;.._"GO@GH<`E&"G'S')SP"`>PX(YZ!3]=N.=I`?WBL!@=1DGA>X.>,CD=
M,=>W15`(!*YXX()]1QD<?X<G@9.``)9<\<C(`Q@8P!Q^G'^Z.WRBY(`4?3KC
MN/QZ=.,X'3/RHS8!/5MO4=<#D>_O]2?]K"X!P6/RD\MCD=>>>?7J#[]&W#``
M?D*G`#>K9`SD8YX/\7L>>!EJ3(4DA=I(P0?7G].6X_WNN32N2#DD(<^AR#_B
M-N>YX'7'S`;!<XZ8R">@_P`CM_<7'0;E8!-H&3QD'Y@2,#J3D\XY)SQZDC@Y
M4951G/R\D8/;G\.0!QWSCG[QPHQSD<D<]01TZGC'8]-N,X0T!5W8P`%.!CL?
MP]<=1U'I\N``C*H`L9(`ZA><GC/3TXZ>WH,JJM&%.-A<!AD8!Z>GT'3)`(QG
M`RP@LSMC.?4?]]9)/H1^9]1M<,YP>&/4')P3C@8P!U_\>/3^$`,]"0Y(^7A<
MX']3@=/]WG[IH.2>V2?7.2<>O^>GJ-H`1\QX)&,KC!SG'\P>>V>@+;5)&`!P
M#TR<9)Z?3KR/K_M`@#&'"@+GNN.>?8<<<_J.F?E>^`&VECV..QPV"3UY]3Z'
MU;#6)+$D<D9YX_GG]?3G/.7/R2K$8'&.>OX_0^IX'7&&`!C@-D'<.<$].2,\
M]._7T;T>F\A@1QR"I(/S#DX^N/K_`!=<?,X#"*=I0@DX`/3MCZ8QQZ+_`+)I
M$4<8P>,9`'(],#GKCH2...-F``7.W`W`#H3U^G7UQZ\Y[@%E4COG;N[<%>1D
M<=#C&.<],8PI*,=F&)"_[?<Y]QUR<?AGV(,9&T+E"<`8X`X&WL,<J.PP3T!^
M4L`!<E?EPX&"1UZCD8YXXQCVP1\M`W'#=/8'KD<C\!CI_L]`1M1F5DVY9@W7
M<<YR/O<\'KU^N1UPH.2^0<Y/`&#W[>G)X^I_O9+`,)/EG(501P!SU^N/?'3M
MTS@/.'7`R`V1G&1DY.1V/WB??!SP6H/WF)50I)Z^_8CD],]<]?\`>W(2(RSD
M[>=Q;&#GKDGV(/;^$=2`6:`5F4Y8?(""/U/'_CS=^YZ\TT\Y8X\Q3NYZD\X'
M/..6&2.[9'#!G`<;57&!@KZ8X^@^[^B^@W)GA=AY&,#J.HZ>O0=#GA<')4TP
M#+AP1@\X&<\XSQZ]OK][&<#<A4+C;GR\<E?P]/PY_P`$R@SMX4;<>@X'3H.O
M;I^'5,.=0_)+-N./FP3D\=>X.[V^\>Q^4``V"!AB/]D\$#&`,<#^8^3';"8`
M3`8^V!^8`'X?@HZ#!!MWR;]@8-CECG?G/&3ZY`[?>;IS@W94D8=2.,GEL].O
M'0CKZDGC=0`XC<&+@9;&#@>Y)Y[_`-"/4A1P75@?NL#P?NC(.>O;KG/;.>"V
M%++'CYN=OS;>V=WY=^N>_<-E'PC,[Y3JS8'/7DYZ@\?^@D=]P`9<J691O+88
M\Y.=QZ<9YSU]\XY!097<3C<!\W/U'4\^O7_:XZY&RN5(YR=PQCH/RX^;VP%]
M!N?DJQ7G(Y*C\0/Y=.O`&2-N9`:#P<J2P.00#R0>_?J3[_>[YRC'=R,[1T#'
MTQCK_GKUP-ST8K\A8<X'7'/X<CH>G0`8_AI`0&WC/)[<=\#I^'].JX:`:H^7
MH0,`L0.<\=A[?KTY`R$*D@P"#@`;<9.<>G/88`]L=%R("RA5Z=QUQP,>GMZ9
M]N`$;)7;)@MM^[GY2""#QP,88#C`^;G'\+`7))^[\RXX`Z_E[!>W]T<@*0U2
M50A.`,8VC(QG@CL3P.G^SST`79NRA!!8'GZ^H^A_\?)Z%MHZL&W##YYW9Y/4
M@9^IST_B/J=J`1N!G&`AXP<DCV_(8[=,X^7#V`!P?ND]NW`]>O\`@!T!^5%<
MF(E"<D9!;C=GW/3)(_,YSAJ-NU>6*KSGC`QSG/U)S^!_V@1`+D8(;C(PW''3
MG^O]<9:D=OD;=MVD?-GIR&)SGMUZ]LYSEA3]Q3<>01]]2<8]?<=/T!/3EO*X
M8D[@`#UZ9SP?J.@_NC'(&Y@:>BX1YES_`!*>0,]__K_C[YK;K#T4`22'>V#M
M`4GM_+MCCT]`#6Y4@%%%%`!1110`4444`(:\\^(L4DTME'';_:#YT68<@"0?
MO>"3P`:]$KA_&%I-?:S:V\`)<^62-^`5Q-G=[8%`&7H6FHL9A6&'4&BB4S/(
M@*2-M*@`,2%Y)R2,X)].8+VUB$0N94EDO9)<(YX:5P5&`!_#@?\`ZLBKVGW9
M,5G+INHA=-$N9FC4>9<;<[06/3)!X`/!'-3:AK2I#<W"00JTL+11PH!YCCID
ML2`%!)XXS30&?:V=M8QRG4[GR_,942)57S2!SELG<.<9R3SGBNDT9H3JTZ01
MO&B2(FU^N?))Y_.N/TB[$@6_0Q>4HPC[&C;S1R2-VT'`QR<CT.>*Z7PHV^^N
MGP^XW()+J0<^3SQC`Z]LBA@=J.E%`Z44@%HHHH`****`"BBB@`IK\C'KQ3J:
MW2@#F7^61F`/!VE0,GUQ@'TQ^G/3$8!W;58$^O7CJ?3U/MR?7B1S\S@Y`7)Y
MVDXS[^A/TX'^U3`N,`G:W;.>,?7T//KT]#D`4L-A`RI;AFZ=\G/YGK[YQ\V`
M$[R[=QR#T`YR>>G?G'8Y'#90E2A.TX49`Z'CD?3D=N!QZ<N(.X@<D'&5&<_E
MSR.PYZ?[-`!A@"N6)7N0>3G/\_J>..?O)\K,`><=0O([>GU'Z<_=-(-NT`8(
M(&.F,<9Z<8Y^GX8P,2HST(SDGT]3GMR3^![;L4`JD*,HQX`'7)/3'3C//Z^X
MPI4Y.,8[#.<CK^7)S]3TSPP?*!G*Y*L,\$>_/X_U_BI"000,@D<$`X]/YCZ]
M/Q0`%#?>#/NY^;`)/<\\'J1]2>Q.'9+#)R<C(."?K^')_,\C)PS>N<<\$@X_
MAX/I]![<#\59@H))^F/QP<'_`#CV!RP`,,MQ\WKQ\QQG^I//][K]["ENH<G#
M')ST/?))[8R?Q//WL`Q@YR.O3\<8]_3'?'XH"!N8#!4G@+V&3QM_`?E[9!7$
M#-NS)N##CYACCOR>PY[=FXX(9V<N1R0.<]QR3G'_`-<_I\S=H'S`=L<>GX?4
MX_#'\-+Q\I`;D@C'OC)].X]N?]W`,5%9FX/)X/)R#D>G(/`]>@ZD#(<$JPX(
M`#8&,<]./8+C\.1\N``+MX!`[$#';UX'!'3^708]1U.TD9ZD<YZ_C[?FV``W
M`*H^[STS@#I^F,^GX?PA4$;'&5;&!QC\.WK[?-UY.`D\]U`.22>..?IT/7U[
M\Y3E$_B&<[@2<YY],G.<#GN.YX96`1F!W;B<,#NSTY&#U[=3G/'S9SAJ4,01
MY:G<20.><\]?U/MSU.=SE7+%@#G))&.O4].>V.V>F/X<MRO0%AD@X[<_ITP/
MH0!T4T@'8!?`7H0WISGN/7@?Y'S+]T#)/S'=GU/Z_P"<=<#<W@ONQC=QD9Y/
MX?H!_A@#8'4<M@=`/T^OZC&/EV@"!AP-P"GA0,8[?3_8X'H.?N,5&2N%STVY
M')[=/4].`>PP>!2LQ'4$X.#V[X/\SU]"3@9PF">VXA<]<Y'YX]1V!SCNQ#L`
MCN%4DMTX^7DX)'3'7C';\1D;#)V'(.6Y&>>O`]/?TR".G\*G,C$!B!C(SZ<Y
MZ^X;Z]P?FRA8`Y''?OQUS^'RCV]>^4`[)8_-N(();=R#DG_/3\OF%)]\-QD8
M(8GG(.023U_O>O?K\U&5"G((;T`^O(ZGT'U'?Y0P0?,V_P`..&))/T]^@Z?4
M<A<@##D`[00R?Q=/7`/7CKZ]#QD,"\J0X5#M8G*G/(/.#W]C^7H,JJ]-K$L>
M4)Z`\8/'IQP/8=EH7]X5(Z/C&3@=0.W'?'XGOC%`-)`&WG83T(P..G\U_3I\
MI9>50*H^8?=&.3QQW'MW&,CG!!#&;,9?=C./J`>/\_5L\9Q)Q@D8&[D-G.,Y
M[G\3SCN>/FI`1E_F('3@#![=?0?3KC)&<?PI_$Y!P3PV.H([^O//7WZ9.U^0
M>A;+=#R,'G'X_7K@Y'!RT%>P``)'&1C&,?YZ=>O.Y@*#SN9>"!G=@@\9SSP>
MIZXSELXPU)CD"4GRP=KELX`YSG/'][KSR3C@@ARFX`8\OMD\`9QTR3TQW.`.
MN5RH7/"D$KTP`>_Y^WXC!/RT`-/4DD@M\W'U/7D\]>^<ANX.Y5.77'!9@%S]
MX<\''4=5/U[GC<[*D*P^8D\8`_ST_P#0O]RF#<8]H&58$9QGK[#CN/3J,8R-
MH*XJ*,J064G"Y4@G/&._/`7&/;!'RTH)**S`@X&!GIZ8)';`QQ_=]1A2P)'`
M(R.?;.>?P.??/ID!K+M)`QDG/TZ_CZ_E@Y^;`%P.\H`,D<$!,D>W`[8/KCGJ
M,C!D?*(RNTYXSG'0CT]3U]^@)VMW`C?]W/(.!P?_`*W)Y&/7^(4K,2N"=HXR
MP'/`..WM^2_7<#$8HK+O;)R=RLW7ZY'?Y^O^UG'S8F/'#'"D8+/Z8/K^)Z'^
M+(R&S'N8`DY^7.?7C//'T/K[YQ\R`$*4'R\GA1Z9],G^9Y`&>-P`]26;+-R<
M[SWY)]?^!=<]^OS91\D;@3@<\9'3KT'L/<8'!(^8R"P(Y!/`!_SGMP/8@_=H
M?:4WA>&VCK[C_'MSR<?PX`$R!QN`P,9&,@\$=#G/W3W['/3<\[E!90P/;T'/
MX]@,>^W_`&<QJJR*$<M)AQC/&<]@.F?FQZ?3^%^2I&S.XD=^V!_CG\<GN0`-
M.'3RQ@\8&TY&T@`8Q@'CMWR.F1A2&(&WA1@CYACIQ_7N!R.F3L!S$>H7H,MC
M!QG'/3MQVP<]6I6PC;CG.><\9(SQS[#O_=&?XLH!!D\H2,G).><X[]/?/3C.
M>K;4!()8$EE7#$^G/4GUR>2/[Q(&&%*2I^4<*,@[N!C&/P^[_DYR@(7<2IX!
M'![<_CT!Z<G\!E@+N<*.HXZL"!W[G\>H!ZYSSEIV;=@R%X'7&#S[?3KZ8Z@;
MG@.7V@8+'"D`#&3@?3D?RQ_#30Z+B1<X;'RD$$#('U[^G<#(RI``[+9X^5G.
M-O3G/([^JC@\<#GY=S3DE"I^;IN7@@<=._\`=_3'\.!=K(,]">=W\73KV[_S
MQ[(/FQN7H.<^F`>>W?/X\]6P``0Y'4L#TSGTY_+';M[J5<Q4C"GY0?EVMD$8
M&`.W3&!TQCD<80+A%SQQG))^I]__`-3>K`+P2&))7//'(YY]^Q.#[9ZM0`W.
M[!!&?O8'/3`!...A(ZC\`3A6(.[)&`"<$]N>O_CWZ_[64)VQ<YR@)).<CKZY
M]/0\^O(*NK9VX("`E<9YZCC';`![]/H6`'$;2&#<\C+?YS]?Q[@Y1L;&4LQX
MSENWI]#U]>_H<IN^8!3D'Y5QG&<\=/PZ=FXS\M*N"NXC`.,\Y//`Z=\'VZG_
M`&6``OS`X7KG`"Y]<<>G8?4=^,I]P`QL"5&$VCJ.HQCG^[TS_#C/RY>NUN=P
MXP,,,@]/7Z]??Z8;@$A.J8W9))R.!SGKG<<_CGO@`"N#P2N.-PZ_IGT7&.OR
MXZKA/*)SM4;3R@X(7/IVZ8'X#!Y&U<9[[@P/WL[>W7'7W^A[;MJ`D+N/4CIZ
M<9)Z9'<=NG^]0`$,V-I^5N@4\>@]./Q'!YQD$)CG(.&XR1@YQW[?WCZ?@,X<
MPV`,>%ZOGMQWR>W/N.<_Q4UO=.Y4]OY_0^_0>N0!%QC:V<@?-GTZDG//][KZ
M'I\V%()3)9B>`6[Y&<\GJ<YZ@=\C[U.8[&*C+,#Q[GDX_3COT]LH%`)7.57I
M@C..0.>HX'^0!D`0C+!1]UCP`.#DY(YX/.>OOW#95>>K#>W3G![GOS_>]^#Z
M'(2JJ68#)YP!C_/4=N,K_LTB@;@@+?-QD`@'/ICCT''.",'[F0!<91RI/)W$
M].2./7^1_P"!?Q#9SN!=CM(P/FQ^7T'KT'4CE8W.T,`Q)Y.W'4^F/J.A_P"^
M?EP`]<@;O3'!Z8';U'IU./X<`";CV;CU7G].^>.A_P#925`*84#:1D+W&!CC
MCK_#TQG`Z94A%0;,MN+8P2>XP`/;N3QZ]NH?NW9()7<V<XR!_CR>_OZG`!HZ
M-D*X).05]^WK_GC\AM5CZ/@!PJ[5#COQG'/Z_@<>N:V*D`HHHH`****`"BBB
M@`KSCXC6-QJ4DMK:,PN7@C\I0^T.1YQ*D^C*&'XUZ,:X'QDLDOB"UBBD5)6$
M0C8OMPV)\8]3G&*:`RH<WND020VCVT+0C%K*FPPC&#A<<KG@$`YP*H:IIS31
M)=A#<Q292!MH)C`XQN/,6".`N[UX-=/86LMSJ"7)N)K2>U9_M%H5#QSQL0"O
M/0Y/!'7<.M,U&33+=Y$FC\FWE8)&3(602E2P$@.2K`J3QD8ZCBF!B6,JG18_
M*F5KI)Y$E:&1I6+$*>7X:0[<9)'`ZX'-;O@=$0SA(RF+K!!"CD0#^[Q6/;V]
MS8&/[23+!<DXGC;S%Q_"5`7`QCI\H&X&NA\+1B'4+Q,@O]K._`Q\PA4''MZ4
MF([,=**!THI#%HHHH`****`"BBB@`IK=*=36SCCK0!R[@(3M?:.H8-CGYNA/
MTSSZ?[)IL@90!PO/S<8QZ9^G7CGY2!RHJ1D_?-'NY9L?+GY>?_U#\0/]YN.A
MR.V1QC)P.O\`WS^0QU```G(<]P<97'/MG\^H_NG'\.#!#X[=/SQP0.._3_%<
M+ND9ESDD#.<>O!_G[?AD8""3U5<CCGIW_+KZ=^1G``#)+9"L>,DY!]_U!'/3
MY@3PQIN5++\Q4`G!/`(Y/],_CGL:=M(+$[N."2<^O7UZ$_B>I#"F@D,2N=W7
MJ0<<#J/Y\]>^/F8"LI'&<G=U`Q^/Z`^V#_=IF"0,[1V(Z$9Q^6/;^Z?0848W
M#'))`QG^+CMZ].^>G^QEO'&YL8(&5]R/UP5''X=5PP'H,[2[%>.N<8[\8]_P
M^7C[HIC;5'3:,')Z8[Y_#';^Z?2EC8LYV\$=<G=DG!SQ[D?Y*X-A?"KN&UAR
M&SZ=2.O4>YP,#E=H`KD*0[$9P.,=.V?3`QGC^Z1V%`&Y0,DN<<L=WMV_$<>A
M]5I-I*A<$#&>.HZ8Y_`>GM@%2'@<KSC/<_3W]O\`(S\H(C#9/RG(R.&Y(Y''
M'UZ=R>.'%.R"`6ZL>N.I)X^N2WX[_P#:--R<`\Y(SUYSS_A_/IGA<+R/F.XD
M,,\C&1_CU]#GC-`(&)\LMM+MR0!C+<9ZG@G//_`@<=:)"/GCW8V@XVDCUYYR
M!TZXXX]&HSE<G`"^^..>"3D]<]1^H8%S;EP!RN?H0>.^3Z9]>1UP-P,3<I4C
M((P1]"#TQU&#S[;3S\M&1@Y.W^(AA_ATZ$?\!/H,(V&&YSQQWX[`'K]#U],?
MPFG*"Q7&<@]`>O([<#N._;T(*@"C@@C'#;2Q[C`SS^)]SMXZBD#'`89(QC.<
MG/'?N3G\23V84R/"NNULL<$'L<#.>Q_Q]OX9&S\V<Y*D8;Z=QP3GZ=CZG"8"
M@KP1G?\`QA?F()`/T[CZ[A_>IF_8-B@N,X(4]_\`ZXQ[?.,]34HYDR0[DGGD
M8]/IGMZ9SVW5&1D&3JN.2>1WSU]LCKQS_M4@$R0N3P0,ENF1C/4_3//]X'H6
MI1QQM.`3AL8QU[GZ$_B,\*U.&X\`G(;G:#SU![^H;\^A(8%N1CG/KN'4=!C/
M7M^HZX&X`4[!QG*DY/&.>>>?3'7'&!UV&DQDG^$@$MDX`QGTZ=/PV?[-*W`)
MSE3P<<$'H/U8$#Z8Z+E(MV00,D'IUSC&,8_#IG'&,_*2`+(<$@?+U`)[<\\#
MGMT[;3CHN&G#`,0!G'X9QG)Z'@X]P.,Y7"@$!<#)^7\LC'3WP>/PZKAI)`YV
MC(Y)[;>>>F>HS^/K\@`H`W`DE@Q!QC=CI^?!_$DXX<"E^\`<;^FX=>HZ9Z$X
M./<-_M4,IV@E2=V1M/!)/..>O''Y],G:$@`,>%Q\V[OUSUXZ9_7L6HN`%@V=
M_)/<_K]#C&,]-XSU:@$+G((P/O9Q]<$_3/S>@SRK9%W9'9L=,Y(Z_CZC^6<-
MEW)/&0>PS@C.`>GT`[].^!EH!IVX7(VEQ[KMY)SD^@'U&W_9-(#R2W4[?EZ;
M1DCH>F,GC_8/H,N!5Y.P&X<#KG(QT^HQ]1SP-T>,QCYB,X`XXYQC^8_/ME:8
M"A5'"LJ@+P&'"YX'`Z``_H1Z4N,,%`V@?0D>V.O4_P`_[RT@)!`&`P.4)YQQ
M@>G3@\8]L`@A>C`+D=UQSCJ!Z>O_`.KG:`-)+`E^AQ@@GGO_`#XQWS_M"E48
M!))<'J,;MWJ,]\YZ]_,S_$:5LY.5!4<$X(/`_P`^G0],G:S)`RW1.6)/;DG.
M?QSGWSQNH"P-D%5!#$+Q@_>ZY//J3G/N/5LHV]N%ROS'M]<G'^>H_NFG-Y@4
M`EL]<9QZ\$GOP??UX#9`!P5!]<CH?P'_`.OI[;@0S<,.%8A54GS,C&!QD>GU
M/]WG[I%/(*9'R@]"0I&.._IC`X_V3S\N0UL,5!SDD9P>0W'3@G/3U/W<9PNY
M&)R.GJ,#Z=,'ITZ>V"3LH&&X\`#!./O<[<>N.!CV_NGT7$A.&R3@9&,D\=?R
M_GP?]G#2-I"[CSC:6_#IT]OS[?+AZ%@BD;QR&7KCL,\#G\#ZX(R"``*X8!4`
MY!!`'JN/KDG_`#E*/E"$?*X;C``PV<=,]<Y_\?[[A354]$!'&!T.,<C^?MWZ
M`_*X-C)*YV=,G'3.,Y]\\GWS_%A`!D7+L<R$J<1YR7]>N<[LC!_Z:#^\:0@H
M2/O'!Y)SD=>!UY]^.?7=E74*0>J*Q)R#R!G/7ZGKZ\\;LKR7&`0P[\]LG.#]
M,<\^O`.5<!!C:VX@+CA@2/7D'J.@/X#J5:F$!4+$[`K9WXV]`22#TXQCU&SU
M0TY%P3M(`)^8#C=QCCJ<].Y(^7KA=PRDOD-A@1G:/O'C'3G\.>@QT6F@$?`C
M'&&X!7!7'.._`QC&/12!R!2@-&XPY#':`#GY>?08X'/'!PI'4+AJ99`.5R.@
M/;CWZ=.GK[J:50609.U6&[/4#('I@'KVX/K@J0P!&`901M&1\O7'T'<\XX]3
MCEEI$3H6SG`!SSN]!QUZG_OO_:%&2HPW`X)W$8Z8YZ`\?0?0'Y5"L"RY^8`Y
MY))^O?M_Z%GJVU`*2/F90)#R5XSOSVSWSG\=X_O<A.0&7]X`,C/.<=_0YY.?
M]H9_CRC-\C[L@C)!W`$C#`]1]3D^IS_%A6SDA6)0\\\$'G^]QD<_>P?7H01`
M`&6``8X'1AW&><?4`Y]A_=.0G:&W?*,_,0=H`P?F'<=/_'1C.RA2FP,IRO&`
MH[Y'./K^/3N!N7'.2?GS\WO[COW]\<8SA<L",@J['[I7'S?=VC'Z8[>FS_8J
M3:5SP`0?[I..<=?IVZX4]]N&J<N".3@D`'J.#GCG^[T]5Q_!E<8^4G.X#H.G
MTYZ>WMUY4*`-#!EP<`!L,IYY('''7&><?APP`<N"1NC8Y&=OK[^_#8]]_P#M
M"D3E%="=I(..H!Y/L.Y]`<'.,G89`A)W!!@[N0!CG).>.,'KZ-GJV`0!F\UL
M`L3M`(P-WH/S(X]7'][%.W!4^7#,RY78<9QR""?TSTW#/!Y"3G(#`@'CGN#Z
MY]^OO_M4;9#G+9(/4#!'7W/OUYZ_>.[<#$!+LP4%^X"@D]?3OT_4>C4N[.</
MA2,YW8SU.?7GU/8#NIH?!0YY0G.TGC/.#S]?IR,\C!"Q`.<C!PVTD9.>1Z^G
MOR!SP&5P`;1EN%`.=V-OKR3V^[GVQV*F@_*C9'^R1C;@?TQC\-A_NTU0H(C`
MW'ACM&,Y(Y`'X=,D<>BY4`D[=V>BY''^/^S^F/X*8"C*O@94ES\O3'?[O;'/
M';;VQPFT&105)SCZ+G[HP/4$Y`ZX/^S@.65<<*<;0%)QG'8'D8(Z8Z=>5"O+
M;]HP2'!(P00,D?@>O8X]=H(V@#')VKNXW<ELXZ=,_P`N/0CNM`9F7.P$\<$9
M)[XXX)YZ#Z_Q"A2_W2=H)P2<^AXXYZ<_@>QX7D+R<Y&TC';K],<GVZXY/``B
M\Y!5G5AR"^_/3L.N<]NN?]H9=EBXR<MUXYW?AWZ_^/8_B%)]V,[B2J@JQ8\'
M&22<_CG/OGC=A2I+'D@@'OCKG/7\1S[_`.T``-!P2P!8@#:PQUYX!]\\$_WQ
MQRVY.JG:<X&00V">IX)Z?CTR#G[QI<'=@DEF]>""<@Y')SVYS^C9"&9><ACT
MP?Y=<=/?KD9(.X`U-%^]+R.J\`8QUZCMV_EU&:VJQ="P8Y<`#]YT'3'/IQW_
M``X]*VJD`HHHH`****`"BBB@!#7FOQ&<1ZA!G?F9H80R_P`)87"AO7*[B:]*
M->?>,KA;?Q)9.V,%E7#*&'^JGSD$>G3WH0F4]$UN&1VLI[3SH9&:.)E&/E!5
M"&R,YW,0.A^3'K4&I7E](EYI\Z18$@S<QHT;S!=QV\$\E64;B,?>X-5I(+:^
M5VVBQF9?+."/+!W[F#`<DY#@D<YW'G-:UW:M+H-O?3VNZXB9H[AX'^9U&0NX
MCJ,<<^E4PN0:#JMU:6TGV?*(I69+<Q[#R.6.."I&,8_NGTKI]'O&OM3\\J$\
MXARH.0#Y*?XUQD,^G1PO!9'RP9=[3.XY!'\6!CU;IU85T?@\L=0NBR,H:YD*
MAAC`\N/'U^O\J3`[<=**%Z44ABT44C+N!'J,<4`+UHIJ+L4+DG'<G)IU`!11
M10`4U^E.IKG`Z4`<RX)F<`;EW'`4\C('0#'8GH?XAV(VL4NN=V#D$Y7\?Z9Z
M_C_%3GQO.6R,\>IY/<C!YSQCU_V@3&>P(&"./R_7O].O&X`1R.N23^'T_P`>
MOH?]J@C&002W4`GGCOSSUQS['/((93E2,=3C.1P/3_(]/ID0,<`DE@>_(SD=
MAWZ<\>@/(H`0*K'.&`)SGVZ`#\E'KQQT&4PK*HR1@G)`XX`Z?@?U!Z;<"C()
M(ZGH<9_ST[>OJ0BLI!4E2/QV^I_Q_//8X8#0N0[%<KWZX(X_#)YX]_?AIPTB
MAC\H'KU'.>O7HWMZ]6IRG=A@0#R`<8..3]?7MZ\<'<Q0OSJ%4`^G4?YQQCVZ
M_+E@*&$8R054'DMSGUSG\<CKU_VL*&'1B1ZGUY/K_P`"_7/\=(""S;@<?[!/
M'.,<?3Z<#'0;EZ\`'C^YV)XQ^@_3&?EW``HVLQW#<<@D]L9ZD?5NON3U:ER%
M^8Y0+G);MC_)Z^_^UE`X.0H((['ICM_D>@QGY<N!R^3N*K@@9S^6._3\OID`
M0K@,""''S-G&!C///3IU]0?0Y0A2Q)SL'3/;GCV].GH,=!E%Y)"CIU'7ICTQ
M[?R!Y7:NUAVP"1G`YZ_Y]./0'*@"H!D;0W(P.#D=/3GT_,#KM-)D$;PV2".`
M,DC@YXZC'\QC'&%/N`$/!Z>GO@'CZ=^@R`AR=K$L,=/?\^_^//.Z@0@`.``2
MV!@COQ_/[WIG=SC)PC`%07QQR&R.F#Z\>IZ8()Z`L*=DA2NT\Y&#^O\`4=^@
MZL#N0C=GKCN4SQGOQD_Y'7C<`"9*\A@!QEB>#SZ_0G\#GD-D!"DC&T=`".AR
M?RQC)SG[IXX;+@#M^Z%YP2!WXZ<]N/R&,_*298LH15*9P/;``'3@_P`/`';C
MJII,8CR+N(4X(!."0",9X[G/'Z'K@;GX0`,>".!NX!]/U`_+CH,H&!X0':,!
M>XZ#`XX].GOC!(VJH);"YR.<C!QT...?3/\`3/RH!#MVM@;ER1V/?'';N!QS
MT']PTBKR2,X#?P^O'(Q]>![C';"\E>F<YR?P[?IP1TSGC(5A7:,':PQM`/X]
M<_CU].<?-@`3'S')!'&<8QVR!P/7_P`>ZC(VOY.P<?,0.>_&0.>_+'M]X'CL
M$$N2V3QQ^OK^/\NH;(3QC`X))'3GN._0[N3D<CK_`!``=IPSMP1]_/0<^OT;
M/X\#YZ,X5FY`[\XQ@MU[CD?^._[P+F;:Q)SDGG&<_P"/8>^0.IVECCJ0I^G3
MMT'3CY>GH,?PF@")CM4E<+D'.3M(SD^_<8.<XV'KA@7G/F?*"">,XZGG'J<\
M#ITVXY(&Y5!4KM."#E<C('Y8R!Q@#MG'\-,V\$88`X(YR!TP..,?C@^N2-H`
MK8&TX;'&,G/_`-;D8'X#T6G??'W&9."`!].F.!D<#GC(QU&T!<YVC\,_U_\`
MK>I/4[6X4_,HW9/`X&>N!R,9Z]1UZ]#30"*`'8,P?"Y*@CD'&2/P)'/!W8XR
M-J]#PQWC.<<Y/?\`K^O^UA<@`#[W<+SSU]>_7WY[_-D&,D98@]>3U[8_+@<]
M.,XY8#=Q!^;&1G<<CWSUZCKUP,YZ?.*4D@DX*D]<Y^4C///'&.<\\'/1LK(>
M&&"`!MX)!P">F.G<#'/`[XRI+')&,Y[?TQSZ?D,?PT`1Y.3M+;>.._<=_P`/
MR.><[D#9DX!!S\O;O^./X?4\=\#*G<0I&5R/EYZ=/_K=/P.,$!Z8VE?7T'`X
M]",$9QCV./N@!G`&T-P1]T=/;.?Q[]1@YVU'@@!6!=B1DH>#R/8>I[`_,,8^
M7:X!@^2.`,GIZ#V`[#\SP`6*AZ\J>I'7C'X\^O7U.?XZ!,%Y0\[UZDX)R,#H
M!QSGI[C'4;4#;GP67/5LMD_Y)W>G?J"0!L+@E20.",=>O'/?KR?7G^.C<26!
M(YSNSG'?_P"OZ]L]]P,:PVDY0IMR2Q.,8ZCGKT;TZ]N:>KJ3O^<$<YP#QCWX
MXYY/<'/5J1L\,@(]L<D#.,8^O;TXZ?-)D"/IG<>W![_4^O3TX/3(`GR!1N^7
M')&<!0!UY'J#U]#Z,"H4AMRY9@=P7.WGG`..G*CGG[OUWN&<@J1QR-O''7].
M.G;'3Y20=,*`%/3VZ?3_`&?3V[;98"`K@;&4$-@9&,=>O4CD#CJ,>H&1B1$=
MJN5R<\<_CZ]CQZ]L*:4;F52"S$#L>!QCV[`=".IX&?E0LQDR``<9`..`/IT_
M3J1QDE0!<Y'R\@GM@AQQC';O^.1@\@JA;.&;YE*YSU##C/!XZYXZ'VSPI8C;
MC)4#(/?ZDG\<YX]0,/2-E,R8^[G.3R,>I/T/49QZ\[F`TM[L6`.?\]>N3SCO
MG^(!OR#<QSD*223TXY//;KVQR<C[P#V;EL#&..#CN2>OMGU[>F2W+*Q5LE^,
M8SSU^O?H<D\<9ZLP&NB$_,Q0@DELG/\`%SSGD<^_#=<-N>?F;YAQR1@YP1GC
M\,#OV/<985ES%L;H,X7G/3@`')XQT]!CJM!Y3KA>`6SDYX]/JO3]`5(``94_
M("N6X&<'/.!@<C'R].1^"EA6V2$`%2#C;T('IQR#T`'N,?PT[&.<#/&X9R0?
MTR3^&2&Z9PJ=&&`.#D#D9]?8>G'J>,9`!,11D*1R>N5[CCI^?Y$=!@@5CC)^
M?(P"IR&''X=^G&<C&,_*K!@/F(R>F1CMR/;C\B3U&X`8D[A@$%CU//IR3^/7
M)ZY&<A@:&)C`QEB1R,`]AVZ<Y/X$YZMA\F.1@;1AN3Z]^?7W]#_M4ULG((<#
M!!&#D<'UY]>QYQUYWC,3(?F!;;GG..<C((]\\<G`'48R`(5.[)^7/)!^K#OS
MV&<YS@Y'#!GYV+PK9)^7KUYX_0?]\^W*8.=@7:#TX_F!T[<#G'`_@(53T['C
M!QG'3&<'Z?R&,I@``I;.!NP2?E!(!/T]./R'H,J.&V;B1NX4<'VQCG\CZ8Q\
MIIH^88"Y`'!.TXZ<\C&.GI^1`4#!0V[>P*GY6.<C\>/3.<=3NP,[0!V]3(!@
MYX/&!P.I'L,CMQE?]FFY&%Y!.`,`<-TQCMW[?WEP<;<2!2S#;R5/S=>?Y<\=
M#CJ>G($8[`'@C&=WM]/KSQU/`&X4`"D;4)&X$`]N<X/TYR>>`?QRJI]X?,2,
M$G&,^_'XGTZG(Z[5>0A7#+RI.>W/.>3[YSG^C4F"I);.1R<_CZ]^"?\`'#;@
M!I*;")`5P"V3SCU//49[G_XJGL^S)PX/)8L#T'7KZ?T.?XJ!Q*5.2P(4A<@`
MY/3KSG/OC';&Y<@,>2-O/R]3TVXQR..P]L?PY0`RL#\K<]B1WY./0>OKP3US
M3<#>`N1N`VCH3][CUS@=^P.<_-DZKP0H.5R/KC'\NV/QP2+N?+<!NH7J,]>W
M^/IS]W#``I#-MW!L8!S@')./7VZYQ@]<'<N1LW#)."`0.G3ICIV^A'J!E0!P
MB_*1GJ<X[#I]1T]NF5P`CS`0..",CMQCZ=OZ=5P`-7YL^6,H.,*<=?3''IT]
MN?NY/D:15P3W..,\CI]<\8(ZC&/EPH/S,3TP,9[YXQ_^L8Y_!!,X')?D\$\'
MGGKP#GN?4YS\V`1JZ-P'S]\L,GVQQ[^O4?IQ6Q61HXPLC!NK@8QP./YGZ^E:
M]2,***#TH`**R]5U633MA6V,J,#N;/"G(XXSSSG\*T8G+Q*Q&TD`D>E`#Z*0
MG`JM>W@M+22X";_+&2N<<?7M0!9->>^-)IK?7K26#:6$BY5AG</+DX'ODK^`
M-=OIUX;^U,S1^6?,=,!MP.UBN0>X.,_C7`?$&X:UO4N(X&GD1\)"K`%SY3$X
MSWP2>.>*:$RBTUO<JRW4)@_A\^-,J<*W53TX#G'H:Z3P_;7<=I=02RQ1P3)^
M[D5R3N)^3&X$#CG%<1;:M%).+:>%9)2I=VLR42)`?G))9@&7@-@],;<UN64U
MJX2>&:-[>.="[J=N,*<L-_!)!SP#UXZ'#$.:&[\TRFS@ENHV'F.T`)SD`,0#
M_>QV'`K3\%S2SWCM*Q+&1V)Z[OW4."3ZX/;KS6+>F>ZU2XEMXI/,9@"B=!F0
MKSGDXW$]1QC!K9\'/))K%P\B;"9KGY/[N%M\=A^H%(9W:]**!THI#%HHHH`*
M***`"BBB@`IDGW:?3).!GTH`YAP3*^TMO;(R,@@GC!QSV'XX]C5;4+L6EDTA
M<+F6.,X4-]Y@,8X!SGMTR,=@+*B,\%2V#SG'UZ=.A''3MTZ0W5NEX!%<(=BN
M'`5B/N\YSUR,9Q[<_P`=`#;*_BO5D,2.IA8HZ.0&!#$%<=C\IZCNO7MC6_B.
M=XK"XFMT%M-9S7,BQ?-M".HS@]`,L,>Y]:W(;.WM+B66&(J\@&XY)SM!..N?
M[WX_B*IIH&G0JB?9G5%ADA5#*Y`1B"RCG('`Z=/K]X`(]8M[C4$LXQ,Q;@N<
MD#Y`XSG!`P1SZ@^ARZ;5[:.[%L!,SK<>0`HZN8]X4<@D\#Z$@=1DRVVFVUM.
M\T$#)(0JD"1L,%7:I(SC(4`=S[YVTU]/M&N_M'E`3>:LI97.UG";=V#@9P1Z
M=O8J`4X->M+RY@MK6.5GGC\Q`"OR_,5P2#P1M''7!'H*CMO$=G<6WFE)4!17
M0.JY;<_EK@`\<@_0`'Z:$6GVL,HEAA5'C+XD`.1YGS,>>.H'7C@=/FQ430['
M[*ML("(8XEC5/,8X56+C!/0[BQ]NAXW`.X#[;6HKB[@MD@NI3)&DC,D>5C#D
MX+<Y'((/7G'/3#I]7M;666*1]SQ?*3G"L^QI`H;ID@$>V1[8FCT^""\EN$#+
M-*@C9WDSE025^]D9Z_7O_%22:597%R]PT)\R;YF()^8[&3<1G[P4L,_GD@D,
M!NE7,][86]S<HBM.B2!0NT#<JG'4YP3U]"O3(Q?&XL,\D=\_3U[\_J.QXKVU
MO':6T4$6?*@3RT7=G`5<8R?3'?T.?XLS$$R,6!X;'H/R]^1S_/=2N`O/4@@`
M`@]O?K@#DGOP,_[5#-A6.!P2".NWZ_S/7@-UY!,?(W.6&=V,?F>_3_/JCC?G
MU&,<'IG`('IQT'J,<@9+@!SCJ,XR<M_^OW_(]P=S3NZ[<$<C;\O//H>O&/48
MX/"YD(4MC!(/0@X(],8_+CU'^S3#G)SQTSP,<D?_`%_;GJ.-I<`88!4C(Z`$
M\8[#^6,>HQCY<&22P9<XSP1U_ER<_J.Q&US#*@9&1@DGTQUQU]3SQZ\$X1BQ
M)/S`X&,G.>W\7?K^*\_Q47`0-@<MN8`9Z9QU/;_ZW/;.``%LB0X#8R2,CGD@
MY[<G.>Q.?XJ7.#C)!YQR>V?7H?\`Z^<G=E,D/P.^0.Q[CU]O7J.#W0`BJ,!U
M//?TSC)Y^IZ]><_Q9>[%L`XQCE3SU]CZ<GGT.>^6-MCP!R1\N/;KSU[C_P#7
MQN5T()W'E#US^>?S'/OQT7<`(2=S$%B>N!U__7U_(]P=SPJ@`@8../?G\^OZ
M`]2!D^]A<$<\`<$<]/KGC`_3Y<-0[MO/RG`'`]`>W'3/3U&,?+M`$PO)(`YX
M(X!/8G'T&._RC&,+3@"6`P2H^4%><8/;&..%Z<],?PX3>6+*GS`G!`]3CV'7
M_)'\*@%1SC!^8`\Y!QP-W]<?@,A0`4<\8(Z!0>WMCZC\QC`QA2`0206Y.1@<
M]R/;K^.??@(<$$G'<8]<$]_<$].>X&6%'(;"_*HSCV`SC]1^@[[L@"`*P`8@
M]"I89`/'8_4\=QQZT%N"S$*N"3DYQZY[=CDXQ][(^]E=H(XPW4$_0G/8]_8C
MIUR<H?W;=R5/?))&,^Y)_7Z\!@!IW,S8!5NH'0X[9SWZG\#W!RK9VD`;&_AZ
MY!]^XQ@>I!SU.,GEJ@`(&,#!!]^?Y@>^<<82@#<,OT((89Z\#TX[]CWZD8*@
M"':N[86+9R,?C@<=S\H_+!Z;D7.`4'[L@E>>,]L=L=/S'^SARDG=G:QZ.#Q[
MD^W7MZ]LX!GY,`#/<D8R._O^?3OWQ0#`N&`P"%/R`')/88Z`<$#C'5>@QM<!
MNV@L"I&XD=OITP.3STZ@@9.U`?F4D?,1GG'4Y[G\#SCIS_$*5"#@K\N>_/!S
M[\=N_IS_`!4`(<'YOF)Q\Q],=<]_7/U/^T*#E<DX#$[B7Z$]3G...O8_Q9_B
MRG&W[@X&/3!&>?PQ]?E]>JR,4C;'.SD`=,#\SC(QW/UXR`)DIU9NG)8<?C[]
M_7AO3D;&\@#)Y(`QQTSP.XXZ>GJ!N4*22`<8;"`>WT.?3CG';D+2D9'3&2>O
M?D<]!US_`./>A&`5B,@A#\V!S@@<@X[8].#QTXQT%-;`X(V\<?GTXZCIT[E?
M]C#@OR`C^[R<=>Y]B/F__5QA,G>OS@Y.[)(S[G(`S^..GN0H,7!"\DGG&`<@
M_3]/K\OMAPYPH^ZQY"DX*GZ8'.?U4C&1AI5\X&!GH.!CMW[#W[`Y_B`>F%VL
M0",Y*YQGVR<?F?3)QEJ`!,A5`)8G'3'//8CZ]^/F'3/#VQL&XC8%^8GZ#KGZ
MD<^_^U3.3D$J,G&#Z_EZY_7C[P9?F&<*V5R.ISWQTSZ'U]\\;I8#C\QRP(R<
M-NX4Y'.<\>H/T.>^6#)(^4\<8/?OSG\?R?N#E7'E_+@':2`.-IP<8[G\.>>F
M3C*L"!@'/7GZ?_K'ZC^Y0`AW\J`1G.UN<J>^>_8>^?4@90$$MM'S],#!(YX_
M'(7'X8_AH4!EXR`.""!S@C/ZGMW/'8JOWE7++]6Y&.Y88]_IR.!GY0!.@.T`
MD<<'_/;'3_9_V<&PLN%.5S@!!D,.V!T/J!QGY>>5PK`GKG`()!ZX'T_'T&0>
MN6`3:,')[9.<?B.?3Z?4=0*`/FR"K#:3V)X/X\8^_G\<]6P,-SL,D8'/KWZ_
M^/#D]SU^;*JV!N+*FT$'<QXP3US_`+HY/TYYRA&<$!@<G`P.G3^F/_KC+`"D
M#8%=LLF0=^,XXSG/)R0<Y'\)R/O9,$*<;@P/#$X!;&>ISR,>G8]?XD#C.1@\
M\;1W[=.G7C'J,?PT$!2%/`)SC@8YXZ<@]>G][C@+0*PF5((8C:"!Q]?\=H^J
M^N"3#<!3P>5`&=I]!CV(Z<CC'\-*.,'!R"![=0.W^>>P(*JJA54KCJN<'.>1
MT[8^;VZ]N@!D84;,)N!QCY"02.G!7KC"CC_9Q_#B1CYO'0GD#';V_0?EZ_+&
M0K$%NF.!@<$#GV/?K[YZMB3@=<XQ\V#WYZ'K^?H/]J@!-A(!QG/!*C`]>G<8
M)QGL3T^84*H*G@'*\].0<>OU/7OG/5J<QP"3M!7);';'7KSC@XZ\=1P0PR,J
MD$_,`03SUYZ#GTZ#/0]2/F`$&=NYB0^!G<?UP<GCYCSZ-G^+(%SQMP^._`XX
MP>_'/7H`WOE%RV.#S@`'.1UR./;'3\.@+.VEQ@'&[`P,9R1P!CZ]CW."/ERK
M@#+D<D\9QN'`QG@Y_P`_*?3EN.&."01C'0Y'K[YQ[@@^@)4D#/*@D8(/'IC&
M/PZ8')]%IR!D;KN/'(`Y&0![=<]..<#C&"X"$$`C'S9(^7@CVR.1GC&/;'\-
M)C.X`MCU4<\XZ8Z=L`?[./X<.R.BD<XPQ_4\\?Q+]<\^S6QS@-M'8D]!C/3G
M'(^O?[QI`"@)A5RR@8!'0CG`XX],=OF&#G`"KDR*5^Z#QCGZ$#N>/Y=">#.2
M!QSQT!R>>?;/Y<?[]`Y`8?*".6QT./?OQGGI@9[T`)M8A#@`LV1P<]N/7&#]
M,'T.`B'*H'8\\EAT]_\`)X^;ZX>Q.?F&/;TZ\X/!]>??ON!:V(P2J@%<[DSG
M.!GDGD]O?CGJ<NX"@%@N3\I'.[..>I]QR0?09SQFD`.>2,D\[L=\=<Y]2>??
MU:A@`KG!R@(SWXX^O8>_;G'+BC,<#YB/1?7(.,?4=/Y@9+@-;ACDA7P,<XSV
M]R._7GAL]#D/)"C*GHH(QCL!_P#6]B!T&Y%())0$HW/RDD?IQ^1[YS]S(6Z<
M!@Q"D#'?UQ^G('S?PG;1<#9T<(L+B(Y7S/PZ=JU:R-$),#Y`_P!8>0<YX'?O
MU_PXK7I`%%%%`%2ZTZSO547,"2%/N,1\R>ZGJ#QUJRBA$"@D@<9)R:=10!D^
M))'B\/WKQCY_+('+#!/&?E^;\N:Y_2[L3^%[U4O[B_\`)*J&GA9=I&.[9+@=
M3G/'%;WB0R'0KA(H_-=V2,+_`+S@9/#<<YZ&N?T2.XB\/ZG%>6[0[V7"-,[*
M`Z@8&$&WGC"J10!TF@*%TM"'1]SNQ,8(7.XY`!`Q^5<=X[EC@NXIIHB\2RL6
M97*NH$:Y*8YW8)QBNM\,RO-HRLXC!$TR`1_=`61E'8=AZ5R/CVYFLF^T0,1,
M+@K$=FX"1DB"DC^[GK^--`<REKIS_P"BEI;"1IBTB6SCY9E(+ON/\*@KEN1@
MYQP2'MI%W\GD".6((L<45MG_`$=7!+.P(!!QN*'!/S,"<5%YBR3&!HC"[2>4
MLT:*N`#T,1^4EG+)P`2I]CB2.%K8"2:9U'<1H097;[IW-\H`10">H.\=Z8F=
M!:F<6C-=#R+JYE\PQ`;F12-PR/7=N&T]#]*O^$8]NNSG.09+MA[9%MD?3.:Y
M[3]76YND\JR&QPI9G=E(X9LDYSU\OCZCJ#6[X(>%]5E-OGR0]V(]W7:/LP&?
M?`%(#OA10.E%(8M%%%`!1110`4444`%-8;ABG44`9)T92S9E)0]MH/\`//8G
MMW]SD&CLHXF/'3Y1_GU_3TYUJ,4`91T?*X,Q/3^'T(Z>AX_0>E(-'('^NY_W
M`!TQ_GOTYX%:U%`&1_8N&SYQZ`9*#/?O_3W/KP?V,3D-.2,YP$'X]<^I_,]B
M16O10!C_`-B?.&\W)!SR@.?K^9_3_:W-_L,G'[T9'3*9`_7C_P"L/2MJB@#'
M&AD'B<C_`'5`QP!_G\/2C^Q`#D2*.<\1CV_P'Y#TK8HH`QAHT@4#SAD'/W>G
MICT_^L/04IT9QDI*`2<GY<?R/L/T]!6Q10!CG1B=Q,H);G[O?_\`4%]^.O`P
M@T>7<1YRA<\87Z]1],`XQQQQQB/4-7O(/$5EIEM"CI-"TSMMW,`&5>FY<#YN
MO/TK$M_'$\JVG[FWS)Y`FPY_=%[@PG/IP,\_RH`Z$Z1)@+YJD#U0?Y__`%GL
M::=&D)),V2<=1QVS_7\SZFJ[:_/(^KQ6\=O)+9,GD+YF#,#&KG\>2./2H)O$
MEW'H-EJ0MXP;VYC2&,AF(B<G:Q"Y)8K@X'K0!>;1I<#$B9[G;CG`Z?CGK['K
MG+3H]P%&V2-3WVY';_\`5^G<5BQ>-;I+^.SO+*."8P%F4R<B3;(RKCL"J(<9
MR"X%3VGBR[GU2"&2"U6WEO/LF$D/F@^4)`^".5[&@#4&CRC/SQXSG`&#TZ_7
MA?R'I2_V1,1C>F.>WUQ^N/R`["LJZ\9&*\U6U@CMY);48MU:;;YS#8'!]`"X
M'?OZ5'+XOOV9Q:6-L1&9R_VBX*$+$L9;HI^;,A&/]F@#7.DSCRPK1X'!&2,#
M_/\`GIA#I$_WB\9.1DG\.GM[=\GUXS]>\8-HR>8+7S$-@UVNYBI+Y`5#@'&<
MXSUR1QC.&7'B^[A,DBV,)MF-RENYN"&9X0Q.]=ORJ=I&06ZCUH`U#I%QCJA^
MIZC@?RS]<GLV`@TFX90'$)R.1UR?\EOS/]YLPV7BJVN/M`N"MLT3,J1N?F;;
M&KOQV(R0?]VJ;^-,:4MXEF&,<KQW(WMM@VX/+*K=0RG)`'J10!H#3+L,<^40
M<YY.#UYQZ\]?I[Y'TFZY*F,MCLV/R_'/7(Z9SSFA>>,'LYKN/["S&$!H1O;=
M,-ZH2,+S]X'Y=WOBIO\`A*)Q<V,,FGF,7)`,CLX52SE0!E`<Y&<-MZ\&@"S_
M`&5=*"%$1;DJV<8."?KU"G\NNT&G'2KH*P3RL$<`L>,9Q_3_`"!5&+Q@'CN?
M/LVMYXMFR%Y,,Y=MJ@Y``.<<@LO7GB@>-+9[RTAA@EDBN4MV69<D#SFVC.`0
M,'KDCVH`MC2KH-G$73D,V1V]/PZ?W?9<.73+KY3M0$#'W^W!Q^I_[Y^E0WGB
MF*STK3;]H'*7P^1=WW?D+C)`/88X%3ZKX@BTF&WEFB8I,"VXN%5<`'!)XR<\
M`XS@T`,.F71^4I$,DG.[G/'MWYSZXYZC:ITR[/S%(VW`%U+Y/TY&#U;\SV)J
M%?%UBUZUIMD$J&?S!CA!%U.>ASQC!IEUXRLK6SCNF5]K"<LOF*"AB/S#D\GG
M@#K0!.-*O./,6-AMPWS]?7\2,\_[1SG)R#2KS<<K$`.X;C\NW_UQ[YC/BZS$
MM[&8Y<VF=ZY7><;<D+G.!O&3C`Q5EO$$$>E1W[([+),L,:1E7,CLP10"I(Y)
MSG/2BX$!TN]"OA$)`)4JP!)[8_(8]..XR7'2;@9PB]>"IQZ`'VP,8]-H]!35
M\5VSW:6BV\PN2[1-&S(I1@P7')P?O`C!.:EU#Q$NGW;V\EC=N8X&N&:,*5\M
M<9(R0>"<8P*+@0_V;=!B1`!QQAAQZ8]QQ^0]%PT65TO_`"Q"JIQM5OX0!_\`
M7Z>V,<867Q?IJ/LC$D[EU3]WM(W%-^-Q('`]^M6]2UZTTB..2YBF`>)YCM`/
MEHI7<6Y[;QTS1<"DUA=JI'DL!P.H/"C.,#MD'V.<<;L@.GW#$_N,'[I)/)QG
MOW_B_P"^N^35F;Q+IT27#8E?[/)'$0B9W,[;5V\\C=D'TP:D3Q!8/91WF9%A
M>Z%H<I]R0MMY_P"!8&>E%P,]K2Z<D-:ECN(;(##\SQSD\D?Q'/\`$"OV"[#X
M,+MDCGJ,YY)!^N?SZX.ZW'XETJ50X=US;&[&Z/&8QN.?QVL0.X&:GEUNP@6'
M=(P$MJ]TGRG_`%:!2Q_)UHN!E?8IV"G[/*AX(Y`P>O.._(S]/;F1+*X8',+C
M<,AL8()&!].@'MM`_AYT+#7;+4;CR;99VZC>8R%&`#C/K@BJ[>)]*C$KM+((
MD5V\XQML?8=K;6Z,0?2BX%7[/*6)$$F,'.%.,=L?_6],=0#2_9;I3N^SR$C!
MSMW8P?3(Z;>WH`/X=NE/K=A;:>M].\L4+/L7S(GW%L]EQGL:=)K&G0-:))/M
M^U`&'Y&((.,9('RCY@.<=:`,AK6Y7_EA(`K8"J"2,?A_O=,`Y'KQ)Y$X;F!M
MN0?E''Y]^,_@??BU#XIT.<QB/4!F63RERCJ=WR^HX'SKR>/F'-2QZ_HTL1F2
M_B9//6WR&/,A/RJ/7.>O0T`4!:W!928'8]"?7UY/U[]<DD#Y@42VGR/W+L#@
M\C`.>N[/U/7G&>OS9U;C6=.M+^.PEG87,FTK$L3M]XX!)`(&3W-,EUK2H8KF
M>2\14MY/*E.3\K]-O')/7I[T`9HMYR0#"Y/7)'?/Z=OQ!]/F06TKJQ:&15QE
ML*0WOZD8]CUSCH-VE'KVD3PM(E]$T:B,L<GY?,;8F?JV1]:DN=7TNUOHK">[
MBBNI<!(B>>>!GTSCB@#(,$RQ[OL[JN""R#!7&>F.>,8'NH`[&CR9L$B%LXZ8
M['(_Q&/]WMC;JV^MZ3>1SO!>1R)`N92I/RCO_+MZ4VU\0:1>@M!J,$FU&D)#
M]%&,GGL,C\Z+@9;1R<CR964Y(Q'G=_+/MTZ]L_*K1.,#8PW*<!5X/I@<`]>_
M49Z;CC9BU33)[I[6*]@DN5R&C60%AC\?>@ZMIK23P_;K8-`I:53*,H.A)YX`
MZ&BX&(4=E),;CG;RI_ST//L23W%'EM]UDW.OW@R=0?7/;ELY_P!K.?FW;<.H
MZ=+'&T=Y;NCJQC*RC#A?O$>N._6E34M,D^9+ZV;.S[LR\[ON]^_:BX&$5D4,
MSK)L4`Y8$8P.<GG'?Z;3UQ\SBC$["K+CKA3Q[<=.1CC.,9Z`;MX:A9;I?]+M
MQY7^L!E7Y.WS>GIS3S/;+&[M*BI&=KL6&$/H?0]./<47`Y]@=Q4*V!G/!'(/
M/`Z8^7IT^7'\.UIC(7`5F8#'W>H]L?1?3MT^4KOB]LGV*MU;DO\`<`D'S<XX
MYYYXIPO+)HW=;F`QH<.WF#"^QYXHN!SP4XV%"Q)P"RYSG`]O0<<=5Z`X4VES
M@J2'YV]<YZGGJ#GGIG(SUPO1?:;5@#YT1#88'>._`(Y[]J5FMHY%A9X][]$9
MAEA[#]*`.<&-X?OGYMH)SSU(XS_^OLQI2Q`S(1E0,[C][CD_3KSW^;IS72)+
M!*Y$<B.1UVL"14GDQG^$?E_GUH`YES@9D'`&#O'4<YSG_@6<^K=>06;N>C$@
M%@6!XQUSGW^O1NI!#=5Y29)VC)]J0PH01MZT`<N1\[)D`L>3T()SD]_0].F.
M^T90D-SPI)RQ`Y!_GVX^G'0;NI\F/^X/R_S[?D*/(BSGRUSZX'^>P_*@#F"5
M#@,1QSQC&<C_`#TZX[A26+LP-@)((RHZ$#V'OZ'L/1<]5]GBW;M@SC'3MZ4@
MMX1C$:\8[#MC'\A^0]*`.84_,&4*S+C!0\GIT^O'U^7ID4T`%0IPQ`RI'/7&
M<<C_`"1[8ZG[-#@?NDX&!\HXH^S0GK&I^J@T`<MN1<DD;>F1@CGC_#MCG'<[
M4#*P.\AA@[N_KUS[9'/KSWQU7V:'D^4F2,$[1SU_Q/YFAK:)@04'/M_GU/YF
M@"AHQ+6[$D_?(Y]L<C\?U]\BM2HXX4B&(QM&<X'2I*`"BBB@`HHHH`R=?<QZ
M+=/Y*S[`#Y9&0>1VW+_,5RGAEHCX1O'A,C1>9&D<A*KN("*'!1W&<X8G/X5T
MGBU4/AJ[,A`5-LG+*/NN&_BX/3H>O2LFQN[:ZT;5]1LQ)Y<UT&<31+$NU0@(
M5NC+M!^;GF@#<\-)LT6,9D;,DIS(H!.9&/\`D]^M<AXZ,(U"&29F5XY9VC(R
M,#R(P_8_P,^/]K%=GH!D.CP-)]YMS#@#`+$@<=<#`SWQGO7"_$*_73KRWD:)
M6C^TN6>0D)'B.$AB!R>0,>]-`8&_RP]M;P&`JJ1IALR(54K$0QZ':1'P,AC(
M<\<WK>S>S@1+XQ16SF1WANF&UL_,S`-CYA\X/LP[J*Q&UN]EE:SC86,LV)(-
MFUA)$?N,#T#R$G`^Z,DG!)JS!I.HF<WKQ%(F$<KPY`,$L9P,9P2H&<<#<3N.
M0`2Q,Z"T3[-B6"TC:0(/F9]_[P@X[#.>F>^YN]:?@P.-9E#1E`KW:;2N-N#;
M`#\AU[X-8]B8X=(M;7>HG1RI4R8XP"!N/5=V[YCR2W'6MGP([3WMU.S*S-+<
M'<F<$%H\8_(\42`[RB@45(PHHHH`***0G`)-`"T4BL&&:6@`HHHH`****`"B
MBB@`I"<4IZ5FZEJL-E$RDDS8.U0#U_R:`-#=GUHW9XYK@1/,L@'GS#/38Q.?
MI^5#3SI)AY)T)RH#9&>,'K]:+`=]G%&[V-<UHNKQQVT=I<B1Y22$.W.1[_K5
M;7;*736%U!<2"&23'EES\IP3Q['!H`Z[=['\J7.>QKSA;F>1`JRS,1\Q"N<\
M<_TH^UW6,M+.,X7<S,/H/:G9`>A,D?F^:8P9`I4/MY`[BJS:7IS)*C6%LRS-
MYDBF($.WJ>.36)H,;ZC:7<,TTP967#^9\RG!Y'Z5EWLE[IET\#WCL5^8-O8\
M$=>OO2`ZU=$TI95E73+-9%&%80*"!C&.G3%6#9VS111&",QPD-&I480CH1]*
MX/\`M2\Z_;)L$8RI/&/_`-=":C>.V&N9=K?]-#UQ@?K18#NI;&UFC>.6VB=7
M?>RL@(+>I]_>HXM)T^&\-Y%86R71&#*L0#XQC&<9JMI>L07EI&C28N0GS+@\
MD#J/YURS:M>)NW7DPYX^;\J+`=DVDZ>R(C65N50L4'EC"[CDX^IYJ*?0=)NF
M#7&F6DK;S(#)$&^9B"3^)`S7)QZS?"0'[9,W<*3_`#_2I$U?42"#=3;<G!XS
M]#18#K;K2["]#_:K*"?S(C`_F1AMR$@[3[9`X]A43:'I3W$TYTZV,TX997\H
M98-C=GZ]_6L6*[OWT22\%U('BE^<D_P`<U6CU;47D\I;DLV[:`3@9[<_6BP'
M5#3K/RKB(6L/EW)+3*%`$A/4GU-5IO#^DS[_`#=.MF\P_/\`(!NR`.<=1A5&
M/84V6TOUT]<7TC7:G?G@*?5?I^M8"ZYJ'\4S9;C![9_I32`Z&7P]I,K.9-/M
MSY@PW&,Y8,?IRJG\*!H&EK,LPLH_,0@ALG/#;AGGG#<\US;^(;HL42[96!QT
MSGOZ>E7]-U&]OKB>`W)W&(E#_=(-#0&E'X9TB,H?[/@.P@H&&X+C=@#/;YCQ
MTR:;'X8T:W=&BL8XRA4J`3M^5BR\=.&)(]#6&=9U%V/^E,,YZ*,"I]1OM1MO
M!NIZHUVR.MLS0E5&Y"/XOY4@-/\`X1?2\(HBF58VW1A;F0>61D?+AOE'S-T]
M:LWVB6&HPQQ7,;NJ(8S^]8%D.,JQ!^8'`R#P<5Y[>^,-6A$T:W+"XL=-(F0!
M=K3B14\P9Z@AE85/-J^MV]W';QZU([7D4H0S(A*.JY##`&%S]:+!<[27P[ID
MT`B:%EC#2':LC#/F'+CW!..*C/A31RD\<=J8DF29&2-BJ@2JJO@#@9"KTKA4
M\7ZS=VK317;1FTT\F=3&"6G(;O[!<CZU<GUC6;3P_K%ZNJ:HS0QQ",W=E'&J
MDR8;:5)RV`00>F:`.O/A>R66XD2XU!!/DO&EVZH&X^8`'AAM'-.7PS8#26T]
MC<.C2^>9FF)E\W.X/OZ[@>]<]X@U?7]+O[6PCN$$EV[E9M@(6-%R<#CG_`UG
M-XJUR*UO;&.=KFZMWB;[0ML&D\IP26V`X+#;C'O0!V6G>&[#3;I+F/SI)@C*
MTD\A<L68,7;/5L@<]L5-?Z);:@\CRM,#):O:L$;:-C$$_0Y'6L3PYJFJ:OIM
MWNO89&MRZ+.8=KEMH*EX^-I&>1WKGO\`A+?$$4>JN=1MI6L5(4&RQO/E[AG#
M<<D<4`=?<>$K&XF$JS7$+`A@8]G79Y?0J1R/;K5VYT*SOKFUFO8EN7M8V2/S
M45ERQ4EL8Z_(*XF?QYJBS%(5@`33)+EQ+;N#Y@!(`R>1277CC6[33[RX$MA*
M\,2OL:RFBQEO]IN>,_E0!TS>#-/$6PR7#JY5I1))N$A$@D!8'C[P[8^\:N#P
M[:?V++I/[S[*[LRC/^K);<`N.@4@8_W17-:?XTO6-XT_V*ZMK2,/+/:JP49+
M<'+'GY:K-\0]0AT>\GN+:U2^@\LB([\;9-N"?P;K0!T-QX,L+F661I[N-G3R
M\)-A53RC%M"XQC:2?7)/-27'A9+F*)'U"Y)BMWM48!`1$R@,O3'.T<]17,-\
M0]25Y(Q%IDH62%%NH6D>'+YX..<C'-7K/QEJ,[:?O2PE6YU!+0F#>,*5+'[W
M?A<?6@#=TSPS::5J+7D#DLQ9L/$A8`@#&_&['R],U5D\&PR69LC>S"U595AB
MPO[KS&#-SC)[J/8U3U#Q1J\-AJUY9VM@\6FWK6\@F=P64!,$8[Y<U4U'QMJF
MBW#Q:C96+NMJ;EO(F;@;PH4Y[_,.*`.EU+P_#=Z2-/M1%:Q*_F*JQ`J#SV[?
M>)R"#D"JD_A9KE[8S7TD@BCCA?<N6D1&#KECT;<H)/?)K$F\;ZS9VUQ)=:/:
MLT:;E\F=L;LXVGC([\].*M:5XXFO&)GMK9HPP!EM9RXYZC:0#D9%`$B>!R;O
M[4^H.\CHL,O[L8>-3'M`YX;]TN6YZGBK%MX.\BU$3WAD*S6[JQCQB.$Y1<9/
M/7)S4GB/Q'/H\]O';VL=SYEK/<$O*4P(UW<'!ZUC6_Q$D:&UFNM-2)'CDDN%
M\XEHMB[NA'((P1SWH`W]0T"YGU]=5MKJ!"L21F.6W+G"L6^4AA@\GM5"/P==
MP1)Y.IYGC:.9&EA#+YRLY+$#!VMO;(SGIS4$'C34&$4D^D1+%*`5\NX9VCR`
M0'&W`SG'&1FK_P#PEG+8M>0"?OG_`#_GVH`AF\(W%W+-<7-]')=R"WQ)Y&U5
M,<F]B%!QST'7%6]3\.W5[?W#Q7R1V=VT)N8S#F3]V>-CY&,@#J#CDCK701/O
MC5\8W`'Z9J&]O([*U>>4C"C@9^\>P%`%#0=%_L:R$)N'FD+%G8NVWEF/RJ20
MHY[5DW'A">YMK>&2\C'E6EQ#E`R9>1@P/!^[QR.]6!XOC'#VCJWLW%(?%\>T
M_P"BON]-W:BP#]'\/WVEZM=W+W<<EO/+)(L:M*NW=C^'<4[==N?>J2^$M06R
M%H;NS:*!FDMF-N3(6,WF@.<\KQ@@=>IZ5TNG7Z:A9+,@(R2"I/0@UEW/B:*U
MNYH#;NYB8J2#UH`RW\'ZB\K7'VZV2>2:>5]L1"CS`JD+S_<5N3U)J"V\"WD,
M4"M>0ED^S^854KN$0B'_`+++C_>%;/\`PEEMR#;S`CTP:4^*[3`'E2Y)V]J+
M!<RAX*NFBMX9Y;-XK>)X1A6S.CS)(=_X*1WY.<CI5N'PO=1:'?V,EPDKW%Z+
MA7+,IV@H1EAT?Y.HXR>AK7TK6(M3DE1(Y$>,`MNZ<^E&H:]::=-Y,HD9PNX[
M!P*`,J+PS<FTMX[B6#S8TN%+H@R/,^[@X&2IYS@9ZXJG_P`(EJ!2-R+!'A^S
M@11[@D_EEB=_'4[O0X([UK-XML58CRIS[@#_`!J:V\2V5U<)"D<P+L%#,`!G
M\Z=@,@>%[U=8@U()9`PI$HM8P1$<-)NXQU`DR#CJ#ZU-K/A^YO\`5&ECAMF6
M5X&6Z=OWMH(WW'8,'D]L8YSG-=3FL_4-9M--ECCGWEG4L`@!X'7O[T@*7AK0
MSH]I^\6,7$A8R;%7`^8D#=C<>#_$36]6)_PE.GC@K,.,_='^-*OBC3V=5Q,N
M3C)48_G0!MYHS44DHCA:7:S!1G"#)/TK*_X2?3R"1YQ`Z_)_]>@#:S1FLB'Q
M%83SQPQ&5FD;:N$.,^]))XCL89FBE6='4X8&(\?_`*^U`&QFBL?_`(2731UE
M8<@#*'D^@K5CD$J!@&`/]X8-`#Z***`"BBB@`HHHH`****`"BBB@#)\007%S
MHMQ%:0O+<$J8U2;RCD,#G?@XQUK$M+2_B\-W,.K)>-*TZ9\^Z63(W+DJP^ZG
MU/'-:_B<;M"FS+'%MDC<-(&VDK(IP=O.#C'%9W@N&W2PO;>&Z-VJ3`/(P;YG
M\M-Q.XGD_>/`&6H`T_#$1AT&WC/F85I,>8<G&]L?7C'-<AXVB@DU:%;B%IHM
M\K,IP5(\N$<@]1D#@=SGM7HH&T8]*\\\9):?VU;R78G98YI76.$$ESY,><D=
M!MS^.*:`P+,0PVXBLK8NBN9(R%+L"P/&6.5R`5''\(SQ6UIVERR:BC3P_N]H
M4N6&"'PQ&,=R"?SSU-4K*5#+MBAVPQ-F295S*P'MG#9VL2:WK2,:;X7EDN',
M%S<%@0X9S\HV9`!YR.?3G-,1S,MJ\DKAR"[;5#*ZCYL[ASC)`)7'ISTZGI?`
M,2)+=^7MV"6=DVC`VLZD?H`?QK!MOL:W)4WM^X5BQ#1JH.X[<GTZ%1[JM=)X
M$C"&]_>B4^8WS@8!&X]!V'8>P'H*);($=I1114C"BBB@`HHHH`****`"BBB@
M`HHK`UMKZ*0R6K7*M]ED"M"F_$FY-O!!'.&ZB@#?I"0`2>U<K?W&J0S7$5JU
MZ5%O((Y/)#$OM380<8ZENPZ'/05)%<ZE]O@_X^WA$\JRJ8@/DWML;..1LQD=
M\CN#0!T:2QR[@LB,5.U@I!P?0^]8OBB,-:V[<`B7&XCH"#Q^@K.TF.[M8-/B
MV7-N&@B>4I!N+R`D2!SVXVX/UQ5.^FU`V>F_;3>.DBQO<>="@4,P8,/E`Y'T
M[CWH0,?HBJ-7M68+_%]XC`.#@#]/SK4\6#%G;$=?-(_\=.17)Z5'.+_3D4/)
M$DD#!&`&PA6W=.<<#KZUOBVOM2TB62>2X:YBC61898!&!+L.4!P"1NQV^E,2
M*WA_G7(=R@D(Q!/KCWK<\4\:7%SC]^O)&<<-7-77]I64#G3C*LXAFDAS;*9'
M80J0#E2<;\CMGFM'QR+E["%(&E$+I(&VCC.!M!]#@MCZ4AE'0_EU^SX'.[MV
MV-Q78WWV:2-+.;!%R?+"CKTS_(&O.6O+FSO`]O-(K*Q*3+&K$Y*C!&,#Y<C-
M7;>YOKSQ';SK-*[E(E5E"D'$C;AD@\A2>>.W/%-@=5H%A)IT][#(&*97RY#_
M`!KSS]:PO$X)UF7KQ&IYZ'BK=O?:VTMKYOG+#*J_:G$*AK=\OPHQR,A1SNX.
M:P+I[Z756>^WK*T:#/E@@A0V"5QP2,$@<9&.F*$!TOA!04NR0,`J..AZU1\3
M(J:T-BXS$K-@=3R,^G0"L_3M3O-)TZX1(V:X9@&D*@D`8!*C'.!SCZ"J=W+?
MW^KAKJ0RE!(B87:&`*[<]LY+?D::W`Z?PK@M?'.66-`H]`=W3\A6=HMG_:&J
MQJ3OBC_>2\?DOX\?E5;3WN1=3)%)+'^^5E*1;A&%B<<YZ@DUI>&FOUO`A400
M2$%HFC8O(#$K!PW0?,6'7MC%(#/OT,FI70<#;YK;N.,9]JU39_:?"T$T?+PR
M,P*C&03@Y_G^%8DX:34=1\T2!S=N/8+D;2OMCKBM"PU#4HK*VA&Q(Y3'O+0[
MA$6D8.OO\O.338%NQ`?PI??/P9.#GI]W_&LNU+&[MSG=F1#P.O(ILMU>VNG7
M5O%$DML+B2.3"%1'LF5`Q(/<;N!_=JI:7$R&*9XS&8\,"8_O_.5##GN,'^=!
M)Z9-@0.<?PGI]*\W1QY)"Y&$R!Z5HW&NWA6Z>9QL,%L$A9"%+&=T=@1CH-I]
M/7C-8RW96WBD>-,N0'CP?W9WJ-K<]2I8@_[/H10AGHT-E;7&G11R0H4>)<X7
M';UZUB:1:266N3V[<A("5;;C>,C!%8DWB>ZE\.+O$2$,D>49E.!*!D?4#/\`
M/BMC0M6%]?10.+9F6S8HZGY@!(5P>>>%#'W-(##P&8KN`;JW8?3]:["WL+;5
M/"\5E>0B2VF@"21DD;A7`B_7$6Z*-HF+*[(_^JQ)C+;C@C:._?\`"MZP\0W4
M&GG<MI$EK%!OCW$O\_)QN/.!DCN2,4QHR[ZRLQJMVPAC!`>V/!.Y`3\IYY'`
M_*NA\->&])@L%O%LU:=T>/=(S.`@<_*H).!P#Q7):CK)62\N4M5EVRS.1EAN
M4('!QU`8_P`ZZK1M;^S>&-4G,2G^S)9(]JYPP`5\^O\`%C\*"3FY=.LK6>_M
M([9%AEED\P#^(D[>?P&/QKH=)\):;=Z"R7'VMENT*2J;J0@`.",9/!RHY^M4
MHH&N-=2VDCM96FFEWXE<(RJL;$H1R3B3'/=36JMQ<Z?J<UG9I"UKOCC1))6R
MKLA(V]<@GKSGGVI#1AZSI%G!>O:K)<S"(*ZO/=R.Z28/W"3D<$<=ZS_[/@\L
MB5GDF=UE^TL29/,!/S9/Y>E6KG4/MGVF^9&7";I53)(95^91GKC;C/K4?F2)
M&#.H<LS%2K_*J>0DH!![_,?ID4`SJ?#%M#;:/=R*7,\LKO<RRMN9WQU/T``_
M"N?TGP_!JTU_%(7$%RH-PR<$DJ``O''`Y^E2Z?K!LUU6!@\UKO`#$;6CWQ9&
M!C)RWR\]"16W;7`\.:7:K+`7FF4RRJKC(QC.!U(&X47&<==:7;O=R$>8N+62
MS)WY'E'O]>>M:%]X<CD\+QS37]Y+',%64.4P@)ZC`[$?K45[>11K)((_O&01
MHQ`W$2"/''3J#6]9ZDMO8_8+I'GCD:6*!AA=V)A$(SP,<NG)Z\T,#+O-(M[O
M0+B[FEG62?9;2*C_`'D60N!GKU)SSSC%95MX=LKJ^-JL1A@NGC618CGH^[/.
M2#Q@^U;=W>)!X9EM'AN(GA,DLTJ;3Y15V]_F.0..F#6;8:M':W0GEB<K;LO(
M5?F9SMC&.`"2>G;K0A7.JOO!^FSVZ)!YEJT<JS(T3\[EQC[V1V%8VF>'3J,L
MT5S>W27%K-'/%*"A:.09]%`(P>A%69/%$M_>:6L%O-;;[N-)DE`XR&RO!Z]/
M:M:^U&UTW4)Y#;S/,8<LZ8PP5'<#D]<(_-%QC&\)VLFAW^ERW-Q(+^7SKB<D
M!V<E3D`#`^Z*XO5=.AFO9U=9'7RWM"2^,IOSD<<$%17:VOB!I<"2SE61MBQH
M'4EV:(2,.O8'Z5R,EY:W%R]PBRF&9PT;B/[^\[E'KT//TH0F:FF>$K?4=.-W
M<:G>L\R;8V5Q%Y.">0%X)..2>O-<ZUA+::E=3M,3<;U21@@7]VKDX]R>>:[;
M0M7@&DV\4*7$X0$%XHB0&V[]O/?!'U)%<J98[R266%V82/N5BI&"<L,X[X(S
M^-,:-BU\+#5M/M[J2_DC9[:Y@"A=P`D#(",GL.?>L76/#\4.O[R\C)#;+;NH
M``D'E*F[/\/%=7I.MV-KI-M;OYK2(CC"1%L[9`AQQ_>9?SK"UBZ@NM7N)%DV
M[2`Z.A!3^#YAC@;@WX4K@,T+PY=W]O,7U4@6Z>1;@P#!?;P\F3\_4>E6M8TB
M32K:)C,TJN@220_*"^#D@=L^GUJ;PWK>GV2S6[RR>;*PD`$9Z9*>GJI_"K-O
MK=EJ=E>_;I6:"1G`5$(\L(FYATX88-`'46PS:1?[B_R%<MXMB:.>W9I9)%DW
M$1GHI&.GYUL1:U91A8@TS8980PA;#-MW8SCKMY-<[XCU>QU%[3[+<!@H8<*<
MG<`PQQT(4_E2`KZ-81:I?O;O+(J)$7R,#G(&/ISFI-=TV+2KF%8'=ED4D*PR
M>#EN1[=JHZ=JXTJ]2=&@<OB.7<2,*8S(#D<9PBG'H:VXO&EG.P)LV9@S(.AP
M00".G'4?G5"1!X9#G4S&LDJ!4W2`9`?&!SGT_K5+55,FM721!GE><JJXXW'@
M?R%=%:^)=,NG<D+'<*&VH0"Q`4,0#ZD=O:LG3)XSJDVKWR!8WG2.!44L2\A&
MW/&1CI^M`RAJ%F+"^-L'5MBJ-QX)RHJ6WT[[5I%U>JI+PR!0O0%,<\?0U7U*
M]^UZ@\Q14D^0.A).,GRQ^;`@?2MSPY/:0^'+ZYF<O9INE=\9!C"`EA^`H%8;
MX34//=C)7]V@!'&.3TK#DD9I7,SEY,_,Q8Y:M3PW<G3M5FCGA\FWD@5_,9QE
M#E1&A'JP8GCTK$::/RS+YR%,`''S8W$8/X\4`=+:>'$O=+BN/M,BSR1;AW7/
M;(KGWRKN,?*"<LIZ5U5CJI@TVSMXX5DF`,>`_`"`;B3C@^U<G(R@;CM1FR1G
ML!@\D=>".:!G>Z,UPVEQR7,Y=Y!D$CE1C@>]<=>R2O>7"7,IEF5S'NSC."?T
MKJ],U.T%C:PO.N_[.KD\D8SMZ^N<BN0O+BWDOIY1)'Y4D[LDF[A@6.,?6DM`
M-73=`.HV/VDW/E[V(C"KNZ94G\ZRWA2&:6/<3Y;%2%!&>2.M=)X>U.P31H+;
M[9"TP5WV*V3M+MSCTS6`\/VS5G5)[>(RS,4:63&\%R`5'?)XH%8ZOP]]I?2X
MI9K@RAA\F[DJ`<=>_2L/Q)&B:R/+C`+1AG*\9//)_(5LV6HZ9IFFP03:C:`)
M\F[S``6ZX'O[5S>L:C;ZG=)=1ED3R<$2#&/G=03^(-"&:/A1$-U=3%<NBJH9
ML<>M4]9OX[N_>5%R(P(T(YWX/K[GBJ=O>-:Q7<$;B-IB!R0"`-V<9J.TO+>T
MN([V:5&M[?+OAL_=!.![^U,1V6CZ/!8PI*Z!KEE&YR,D>P]*UQ52'4;27`6X
MCWB-9&0N`RJ0""1VZC\Z>+^U*EA<PD!/,)#CA?[WTX/-2,LT50N=4M+::UCD
ME&^Y<)$%YW9!.>.W!YZ5>!X%`"T444`%%%%`!1110`444F1G&10!D>(YIX-&
MFFMY&B9'CWNLB(P3>N[:S_*"03C/>JWA.1IH+V=G#I)<$QL[H\I4`#YRG<$'
M@\@8!IWBV41:&TNT,Z31-&N\+E@X(`R""21TQS4?A&3S[>^NGMGMIY[II)HG
ME#,K$#@@`;2!@8QGCDDT`=$:\^\5W%M#K40N1*WF3/'&(V`W,4BPI)Z#(#9_
MV:]!/6O-O&%D^HZM%$H(B\R82/N`*9$8W#)R3P1@=F/I30&''?W6J&.VM!)"
M+@#RXU(!#-G&_CG@*<#NA!K4U358%\FV@MO-MK6,0J9')0_="\#KR"<>BGIS
M6K86K"PN3;*L8$V//F7849B?,D(ZAN<8'`+\5DWVGK#$MK'#BYR7"[V)V[>-
MW(4'GOCJ>M,D8)8[S3YV>"-9XV#8R%^\1U7)(R!W/5CGD5T?@%)(X+Y905D6
M5@RMU!$L@/ZBL[3X=.M(X[>\D-S-+*S2_9_]6IZ@9X&,`\#U)K:\(L&FU-QN
M!DN))-K=1F>;C]*3&E8ZJBBBD,****`"BBB@`HHHH`****`"BBB@!,<T8/K2
MT4`5[IIT@+6T222[E`5FVC!(!.?89/OC%<GJ^H7=YIUN\\$,<4EV\(978G*&
M1<D8_P!G(^M=A*Z1H2[A`!RQ.`*YF\T'%H([74SY4,KSB.1@?G9BW)'N3UH0
M,R-&O;6WU""Z>4^6L>XE48DAD8CZDA3P.<\=2!6YXCU6:TEL[>V=TDF$DA93
MC"*!ZCU8?G7*?8PMN482^6$6(ER,X`8#G'WAN)SU!`]*N7ES/J<D#32*[6^=
MA3@C/!!ZY^[S]*8D2Z9J-O9:H+F\GV?NY&8X9N-I.>!D<+G\JO\`B#6K6\LX
MHXA)DSQ8,L,B!M^X``$`YX/6JNF^'GOUG,]W/%!,K1/&),&52"I].QZ^U/U^
M.R,D:V]Q++,C1L_S!D'E@@$^_P`^#189F:!<VXU"WN925CQ(V'0\C.T<;>23
MC@=R*Z*ZNM)BU"UOA*T+(&)'V=QO4!N#\N`WRMQP>#7'BVCC,2`R$Q_<Q)RI
MWJX8>^5!'TJW>NU^O^E32ML)VL6&>C`X],[CG&.U,#J-%UVVOM0G/V@%IPK0
M1[6X7;G'UP0<>_%8?B*YB;791O`8;4`&23A0>>/0YXR,`U?\*64"O<W19DV,
MI."`AQ'MR?P_45CZVMM?:M<2Q.TB2''S8QG;C(]..,TA,LZ5%I,SR0W\CI,S
MAD0%@=I(4$D#&-Q`_&LJ>5+42QR3$X?RR4&[<<X!'KSQ6WH%K:W-U(9;EX+E
ME41J"`&`</T]=R_E69?V=E#?2V]KDV\+CR\G/EX;>0/;=36XSI=!U"QL],$4
MDGERXDE?()+!3\QZ8XS_`"K3?6+=61(")B)TB=0<;-Q*@\CD9!Z>A]*YK16L
MI;JW@N@P,=QYL!#8&[&"&]LA3]0*VUT""S<W+:A/D%"[R;3D([,,G'JQY[\4
MF!Q]_=('DN-P<3SA4$4FX?-($SGT!_D:[#1M2M8=+M[>6X2.3"C:QY^=B%_/
M!`KC3;)EDC\QHE<$$K@D+(77]2>/2NCT[3;;4HH9ENY8IXEA66,*.?)D9T/(
MZ98Y]>*&`:E?:9;Z((+!TDBN+E%+(Y(4R$MN.>Q(-8]B4&H6KF5%Q(HR'R0<
M`X_(_2K^J:%!IMA!&=0E?RUB1(\#D1[N2>H&&.?PK(MK2.*XM07V&&5%\_8%
M?:,=6'/3C-"$ST%IXKBVG$<JG8K`D'..#7GV_P`R%7$J%3Q][//7UZ].OK77
MI9166D7WFWAEBN`=I3A4!7`"#)QZX''/`KB3:YLG62224R1&%F`VJ58#)`SP
M<J.:<=1G5S:1IDFFAHIEMI]@8GS.%/`(()]?EK4M+VVCMH+=IXA<BV#L`>P^
M4G(_VN/K61'H7]HVS/!J:-!)]Q3#NVGS%D(/S#)RN/QHN-"EM1-=MJ4<9VMD
M?9\C/GM*O&[_`&B,=^/2EU$SG4ARGE+@9&?DD!WY/4=>#SZUVNGSVQT]!)Y:
MH(H]TDC*0V5!YY_#GWKBC9JCNJO'$65(SY47EXQGD8;*]<8[8K4BTJ>72(Y+
M699WE\G<4CR4V1%,$%ANSG'MG--C15U'9+J-V%:-@\C'AP25)SCW'&?SKI-.
MN[73_#45Q.0RC<6"[2SDDC\>"*XV]TJ52R2I]DFR,JD>WRP(RAPV>0"<Y_#O
M3_+F:-H@UN5E5U(6'`#,ZMD+N.6^0CKW'I02:E]JLJWC6PE2'!=8TBCP``V/
MO?E^M;6G>1'X<CE&Q9A`Y5AC>#ST[@\CZ5RMPC7DK%CDRAP1MSN=RI&,'J"/
MUK1CM!8:==O*DT32'$$$@Y3)!=N,X#;5Z^GO0-&6RJH,>_\`>[2Q)YS@X+="
M,Y.,?6M/4KJTN(8XXK)+;9G)**P/R]P`3TK,&EB_O#$K11^:[D,PP$R^_/3@
M]OJOO6O)X8:S@N[BXNF.,LA:4_-ELA2",<#Y>,YX/'2@97T:2SEUB&$3R$N^
M&C$##>54,H8E/H>HYQ7:W%C:WNS[1!%*4SMWJ&QGJ/H?3Z5YVL;)>NX"O&9H
MI65\@[5V`@\=PA_,]:Z.XTS41=W$D26ZV[,N")2@V+(K@XQUVY7K^72E8#!E
MB"//&((@-S_=`^8'!.?;@'\#72Z%I^E76DQ&.!'.PQN2CKR<%L;O4[3D=Q7)
M,)T9LON.R1.&)&T^9@=,@_,.>XS6W!I]_<V*?9&/EK9>7&8[PH(I?+*%2`.3
MD[LG'0<4,"]XAT>QATDM':Q[@HA^8G&P\D'GD9%<SI^F6MSJ%M"5W17+G<RG
M&X;200?RKH/$"RQ:!96^T)(75I4$@=N`<@9^]DX_.N35)+26)V\U!'))'%Y;
M8780=I[#<`1CG^'I0A,ZUO"=A8ZCITT"NZQRJA#\D`9*D8QW[G/6M%M/TS5-
M;N'DM0\T2H&EWD;CAACCT#$?\"KFI-6ED:5B]Y&WG,4?[60/+,RN,H.A"?*/
M8&I_"HOXII9O(>[D5!&6:49'[QCDD_[+#_OF@9TR>'M.10$@`P%48=N`J[1C
MG@XXSZ5PMQ;PK>3A(PH68R*0>A'`QZ8Q7I4LQBA>0([[<_*@R3[8KSF59!<2
MK-')&[,25=?N@GG\.:$)G2Z#HEHFF6MW`H2Y\K:&R2O!."5S@D9(!_PKD'B\
MN=_F!V,^2!MR2V3Q]1^5=7I7B&UL]*AMY%?S8UQM4=3DUSDOER.[-A=Q)(/;
MOUIA<Z"T\.6]SHL-Q;XBNY4#&1V9A@R+(V!GJ2@-9&NP1Q:S=QK&#N`!SR2#
M\Q&?]XG\ZZWP_(6T:"-H9(C&-F'3;GW'J*YG72KZS<L'4DE0/0G`XI+<!NB>
M'AJ%L]Q'+]G*MY6W!;@9;U]6K2T;P_!-#>6]XCETD,3$,1E3'L//?()Y_&K/
MA*0&PG3>N_S-V`>@(`_F*Z,*`Q/<T,9FKH=NC(4>4>7/YZ?.3M;9L[]1M)&/
M>J$_A&Q:VA@A>:+[.H2$[RVR,`J$`]`&('X5T9KD?$E^_P!N189)4"1D.`2N
M<GK[T@(?^$%3RWB^WMY<A_>*8\;_`)"F3SUV\5E:MHDFEWD+/-).I5MK,>2/
MEX/Y#IZ5HZ'JRVMW,UY/*R,H52Q+X(/(_6F^(=2@U*>(VS,R1*06QCD^U4)Z
M$&@Z9#J.I3"0%"(F<,N,JY&S<,@\[374G0(#IL-B)90L,J3+*,;RZL"">,=L
M5@^%YDBU3;(=KR1;5'KR/RKM,\4F-'F>K:9'#JD\'VJ5_+\I<MC)V-Y@'`]6
M/Z5T/A:Q@N=$OX)LR1W+F.4-QO78%[8'3VK,UQ<:]<$D?>XXYZ"MSPA@:?<*
M&&[SBV#UQ@8_E1T`<?#*,'1[ZX9<1>4Q"YC:-B5/3#8X'(/2N(DMUD9V,DFY
MUC4MP#E&+!N<]R>/I7I]W=Q65LT\K81>GO[5YTPRF&...21T_P`\T)W$=1H^
MBL+"UN3=R!F1Y"-BX_>@$]N@Q^M<A]C=5?,TC)M*D;5!SM"[AQQ\J_K79Z=K
M5C!H\,3SJ)(XMA3DG(&,"N6VG8_0$G'YTT%SH-.\-9TRU=;Z17\I<$QJ<8D$
MJ\>S?F*YS58BMYY:L',5X"^>,@,<D#IU[5W>DWD$FD1N&8)"H1RZXQC^=<7<
MGS;J6<#AY2W`SU)-)!<UM"\/1SZ.DHG=/,,3+\HRC12LP/ODGIBLR[>&*]N(
MX5\ZU:,;RR[6\P3M(1CLO3&.G..:Z'0M5M(-&BCFGCCDCW%E8^Y;^1%<U)@O
M++M;:Q)&3SC/_P!<4QG1Z)I+R:?IMS]IC;ROF_U`&\!60`X/7#?IP!7.:SI3
M:??VL+,S1PP/^\P`)2SE\$>BDD_6NR\/W$4FD0Q1NI:(;'4=5.>F*PO$PSK`
MQ@XA7Z]6_3BEU$S$LM/?4=81`O+X#`IG9A6&>O3YA5>;3C;M-;O*H=0\.=N0
M,H%SC/L.?K76^$47S;TX`($8_G_@*I^([=(=4=^BS`.>.IZ'\.E-;@2V&@"\
MTN$+=*R-YKKOCRP:0$.I.>0#NQ^`["KMWX;EN)WE2>&(-(DOE*AV.PQ][G..
M.Q&?3U3PK<,R36K,,1D.H'<'K^H_6NDJ1G.Q^'7@GLS'+`D5O*DH18SQM5EV
MCGI\W>MZ(2"-!*07P-Q48&>^*EQ10`4444`%%%%`!1110`&LW6+YK"S\Y75?
MF"_,N<D]!6D:Q?$R@Z2S&W:<JX(0*S=B,D*#QSWP/4B@!TU_+%HT=VT,#2_*
M3').L:@G_;.1Q[4SPYJ-QJ<-W-<0PPE;AHT6)PX*@+R6'#')/-9GB"2"U\#!
MY?):VP@ER8\*K'!QN)7C/'/XU:\%0V<6CN]E([QS3-(6>W$.X\#*@<%>!@C(
M/J:`.C/6N"UVYM;:\FNKR=([:$SM(Q/)^9%POJV>W>N^KROQ=9W%QJUE?VT"
M73:=<7,[VQX,B^8J_+P>5SN'TIH#1CU9[&\CN$N'D@,?RVH7RX@SG.3D9..0
M-WU(R:HZCJTL%M-8^6KW+MYDL<>P-`I;<N%P6D)!7(&[&<'%27?F6MTDSQSS
M1JX:56!\P#CACSR<<-R#SS6#J44T%U))YL>V<*\4SOF*3/.U5!#D@Y!PS<CI
M3$S2M,V2+-O8R3JL>PKM/E\Y#88A3_WS]T<&NM\$#_19VXY9SQT(\^>N1O!)
M)%;HC29DA2-7DRK1L!RI7Y2>@.,IU!.:ZWP.`+*3;DJ0V-W7_7S^Y]N])@F=
M:****0PHHHH`****`"BD9=PQ2C@8H`****`"BBB@`HHHH`KWEK#>VDUO.N^*
M5"C+Z@BN4TK1=1ANX1>1QM;R*%N`5[P-B-_<R##'Z8KLL44`<.VEL="5SIDQ
MNQJ62##ES%]I+YQZ;?\`"K.I:-+#/>3:59C]W"$>W9<).&+,V#_>7.1CUQ78
M4F*`.,AM)[>ZU23['/L^VN\<45L"TB>2`-CG[HW9/;FB'3YQ$L)\Q3!+'Y=Y
M]E!,HV-D2Q]",$@E>I(QS79X/K1CO0!S*VKII6CR"R-H^^(W$<:!S&NPY4Y!
M.`=H]?YUE0Q:C#9P0^1(!MB#2M:(S6X*/G``&[#*N<Y^]W[=WBC'O0!SU[;R
M0V5ND%N46=U^TQK&`7&!GLP!]N,X//2L<P7#6\DC6)68N=J?8\")@7RN[G<I
MP.QZ]>:[C;GN>O:@K0)G)Z;9D-K-VFGJURKK);(ZE58BWC&!Z#>&'3CFJ:V7
MGW=DCQ,;=YD\QS;!3\T4NY&^7H&V#/J_M7<[>.>:3;^M`SA==TX1ZG+;P0;+
M<QV;1)'#D;C<_O3G&?N!?PS5R&XNM2>SM[V/*<,P>!@)CN9#C'0@`''3D&NN
M*FC:<]:`..FTG3EU2^M=1A,=JT48LBA;H0=_(_CW#OVQBJ^X:<TT]O9A9(/-
M4@JVZ,JVV,GGYMX.3GUKNL4A7/>@#B[V?[1J-ZLL$%W)9R"%AL8'R_)20O@'
MG!?&.^:A#VQN9(C;PF$+*\<P5SYZ1JA^4;N.2Z^^TUVD5G#!+-+%&JO,V^1A
MU9L`9_(`5+Y>,8/2@#S\7]M<PJ9O(%M'#=X3>Y5F3RRG4Y!(8\"EOI;&WM+M
MA91;[;S,0-*X("H"CD[LE6R!_P`"'O7?>7QVI0F.AQ]*`.8M+BRL[#5+RV,2
M_9Y71V61BAVX()&[K@@9_IFJ4VMVNJ726\WV9X00,"8@DM<-#V.,X`;C/)]*
M[38>YS]:/+&",T`<+H:Z;K.J*G[MHOL,<IMXY6/E/O((/.<\`?C4>F:HME+'
M-"T)+;4EB\QL#=="('&3R%/I7?;#CKWS2>2O/RC\J`.8MI+7Q());B*V<Q1*
M5"7#;HV8<K)C&,'MDGKQQ6'%<V,=MIS74:7$MU$LDA6=E?YMPR`3MS\O`'<G
MBO0Q"`Q(ZG.<4UK>-L91<CH<=/I0!QMK-9Q&TO((K>5796#1S,XC#*I!9>O5
MB/08%,N)1<W"&6U69I`=[27#?+FX\D`8'3G/X5VGV2$KM,4>`<@;1@&H_P"S
M;(C!M+?!ZCREY[^GKS0!QAL[9H)66,QNB\@2;U_U_EL/F&>=A.?>M.U$>KJ;
M:1;B*R@WI$S3KN<JQ1@PY/&`1VYYK>;2;%LYL[8D]<Q+SW]/4`_6I([*&&1W
MBCC1I#ER$`W?7'7IWH`XCR8"EN9+>Z5GDD5XED#."L32;3E>2<'E2`>#DYJ6
MXU&6#29+>2WN3"(Y903<`;DC17.UBN3]_'U4BNIN=#L+FU>`VT2!E90R(`R[
MEVDJ>QQQ45OX=TZ%'4V\<H;(Q(BX`(P0````10!RE[!#;AA$DDN)`D8,HPVZ
M9(FS@'!'F9Q^=7+":/3+H%#<L7)C9"Z;6*S^2<\#^)@<^E=+_86EY8_V?:_-
MU_=#GD'^8!_"G-HNG.[2&R@WL<E@G).<Y_,`_6@#`EM%UO4V2;[7'M5@K@*8
MU*MM91[@\_05F7-M;163S0RW,A9)&B+;=KE9`ASZ?,PXKMHM-M(;J2YCMXDF
MD)+NJX+9]33&TBRD#A[:,[^7XX)W;O\`T(`T`<IJVDQ:/9--)=7$Q6*64`(H
M4F-"^/;[M:F@K#9WLUCF3[4T:R.'*\#`/&.2,L1D>AK;GL;>Y`$\22`*R@.,
M\,,'\P2*9#IEK!*LD<$:NJE58#D*<<?3Y1^5`&8^NXU"`%'%M("@&`27\Z.+
M(.>F7YK$U&ZMM2U`W+I-#`+=79D5=RGSC'N8DXP-N>*ZO^Q;#<6^S+DL6)R>
MI;>3[?,`WUJO<Z#;R6KPVJQVWF1F!V";CY3$EE&>F22?QH`P!H=L]@+H3WC0
MR.(]OEID_-M!ZXQT.:ALX-/#6]PKW<R?NW5#&BJVZ,RJ#@\#`Y]Z[*6PMY[9
M+>2)6BC*,B_W2I!7\B!5=-#T^)D*6RC8`J\G@`$#\@2![&F!C76N-/"4E>:Q
MADCC83*BML#1LY#<\8"GD<5DI;61N%@6>_>21D_<I$I;#*65L[NA4-_WR:Z\
M:#IX*?N20FW`,C'[H*COR,$C\:$T&RC>)U60/$P9'\QLY`*C)SR`"0/K2`Y.
MS%M:FSNHKVYC-RA9)?(`3"@ELC=G`VDGTS6O>^+H(-'O+FVCDEN(())!&8B`
MP0`EO]WD<CUK03PWI\;1[$D"QIY:KYK%=I.XJ1GD$XSZX%,E\+Z;/;>1(+@K
MY;P[O/;=Y;8RN<].!Q[4V!;O-2AL6"S;V;87(C7=M48RQ]`,USNI7S:S.UF+
M7:5NY+:.1D)P57.[(_A/MSTKH[O2+:\,9EWAHU*!E<@E#C*GU!P*@30;>.<3
M)-<*XN'N,"3C<R[3VZ8[4@.273[:6!)AJ`6*2+S&D,3;$&W/S$],A7.3Z"G0
MV-E=2+''J/FO*[1J([<D@@C.<'`'SH?QKI8O"UA%$L(,[0^08&C:9BKIS]X?
MQ$;B!FI(_#MO&T3"ZO6>.-XE9IR3M8`'G';`Q]*8$FD:1%IMN0,M,YR\A&"?
M0>WI5RX6=X2L#*CD8#-SC\JG4;5`HQ2`Y&3PK>NY<WR,S?>8H<GW_P`^E/M/
M#VIV$YFM[FW5NA!5L./0^WOUYKJ\48H`9MW1`2`$XYXXKG-0\-/+=>9:.D<3
M#YD8G@Y[5TV*,4`<>WA6_P#X;BW/N=P-/A\*7`DC$[6[1!@7"%LX]N*ZW%&*
M=[@1I$D<8C10J`8``X`K#U;09KFX6:R,,1(^</GKV(XKH,48I`<8?"VH$YWV
MI(X'SMQ_X[4L7A>\,L8G:#RMP+[')./RKKL48IW`J-"]M;%;*&/<.`K':/J2
M`<USUSH6K7EPTTK6[,W!!<X`]OEKK,48I`<YI.EZGIUYO/D>1*!YJAB2",\C
MCWIFJ:9J=_<O(8H<+@1`2=N>O'TKIL48H`Y"UT;6;*Y%Q`(1)T(\SAAW'3V_
M6NK@+M&IE0(^.5!SC\:DQ10`M%%%`!1110`4444`%%%%``:R=>GF@L08)A;R
M.X43,0%3@G+$@X'&,X[UK&L?7SOLTA2,2S.X\N(XR^.2!GITH`HZO-)+X6MI
M?+7SI3$56:8IAC_M'D^O;IVJUX5N3=Z.LIO);O+O^]D9&/7I\O&/0=<51\06
M7F>#XXDEC1D0,IG8QECL/RC!&"PRO7H35OPF6:QN3+#"DOVN;<T.=KG=]X9S
M[#KQ@4`;QZUY[>-$-=6-G47#M=F-&8C?B89Z?0=:]#KR/Q8EPVN6YBM7GA1K
MF60H.5*3[@#[-@K]2#VIH#>T8@B74(MTSNHMY['`*R,@R'3(RI`8C`XXS574
M)M.):VFVP&X<-!.F6C8@X/7[IR<'&>A.*S]%O_M-FME>ODN8D:Z!*-OP3&?4
ML5`))S]X9JO?WMS.4BE6)7MI7#!`0X;H>G)Y1N1D9`X(-,3-*TTRYMR]I-;S
M%9$:59U9FCD88(.[/`QG.U1[UTG@M=EG(HQ@;P-N<?\`'Q<=,\_G7+:+J<]A
MI44T$[F.*;R@OF*5905(Y7@_>(['D<"NN\)MYL5Q,I)CD>1TSZ&YG(_0BDP1
MTM%%%(84444`%%%%`!1110`4444`%1/<1(P5Y8U8C(!8`XJ6L2[MG;6[>X^Q
MF>!;22-L!3EBR$#!]@>:`-D.I`((P?2EW#UKC8=.UR"VM[8"X`5'5\3#:%99
M"JCGJI*+NZY4'@=9UAUU&G*"[VH@2",NI!3:N226SO!#=><GKB@#J5D5\[64
MX.#@YP?2G"L32[.6VN&)6[16FE<!WR&5MN"W4Y],\\&MR@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BDS69J.OZ;IB2/<W2J(HVE<#DA%(#'CTR,^E`&I17,/X@U"?,>GZ9*\@9U
M_>=-T<JJXSP.4;<ISSBF%_%C^8HCMUP6"L-N&(GX(Y.`8?7H?>@#JJ*Y@GQ4
M%SLMV.YN"5X!N!@]1TAR?<^])+KNJ6))O-,=@T@5/*_VY]B`GD<(0['H.*`.
MHHQ6-I_B33-0,0BN"IEB$R^8-N5+E%YZ98@X'>M?<,XS0`ZBD'(S2T`&*3%+
M10`4444`&*,444`%&***`#%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%)D4`+11FB@`-9NJO=I`OV)4\XMCS)#@
M(N#ENA_I6E6;J=C->JB)Y#1C.Y)D+!N..A%`&%XODMW\)175T+:XC7$A$LJH
MLF8F7*D@@GYL@`=JM>"#"VC3M;PQ0Q&[E(2&0.@.[G:0`".*7Q!=W&D:+;&&
MV6[F$J1D-"SCA2<[0<C)7&>V<UJ:1)-+9J\]C]BD.<PA@<#/!X]:`+_>O+M?
MDN8M=86S/GRIBX'W<&Y;&?H?F_X#7J5>4>())XO$P:(R$-#*&"GM]I?]3]W'
MHQ/:F@*;&UN)A(TOV6X_UBS(@VME<`LI],YQ[$>U=)K5J94MKP00W+LB1.P'
MS!A\QR!\Q&0#^%<[#.MU$D5\OSLJ$3VQ"#<WRY8'[V27(/HI/>M_2S;SZ/-9
MR7BO-([R6R;=NP+P#Q]T\XYIB9DQ3BYD2UAA"IM"".(9(YY+GOT`R3DGKTKK
M_!*E=,^8\A2".P/G3?XUR%I+<31&/[5G*!.)-NX]<9;H,#([\CTKKO`\AET:
M*1L[GCW\^\LII,$=2**6BD,****`"BBB@`HHHH`****`"D(S2T4`)@>E&*6B
M@!-H]!2T44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!3'D6,9<@#U)Q3F.*Y'5KN;7-373;!MUM#)MNR"&
MCE7E7C?',;#AE/?M0`ZYU:?7));33R\=D1MFN@Q0JO*R+N_Y9R)D,,]16=9R
M::S:A)IT0U>_AA>:6Y$>+9IM@1U&.`7"\@9KH)+C1;(KHLKI^\B(D23+%DP0
M6D8^H!&6/-49M-GTGQ9I][I=K_H%S']ENX8``%QDI(1Z#!''K0!17QO(+(RG
M29(%DL9;BRD9@4F:)<LF!R/4#N!61-XSUE;0K]JM?,>6U:*9HT#>7+)M8&,.
MWR],'(-:@B\/^'8E@U2]2ZDBN[B^L8(@Q:(<ED4`\XR?E/Y5):ZSMF$>E^#+
MK[/++%F8Q+"K(R[M^".2IXQVH`S]5\3:AIFIQZ?#JHFFMIK>VE$L,:&5W().
MTG<>#_","M"'QI=?;%DGL(#IDVIMI\-PDQW\':&*$'(SG)R,#G%17/B+5'LA
M+<^#+U9WMC*'C59FCDW[5&W`R<8;KQ6;I.F>%[NQ-E%<;=<C@FLDEN`\>9A&
M5>01EBN>3R.>*`.F">'?$<I_L^YM_ML+"59(%`<,JLJ.01\P7<<'IG%0"ZU'
MPN4BN3+=Z>HV1L,O(,`*B#^*25V)8Y.`*YF?3KO1%C/D+HMU>`:;%*EX98HU
M)#O*,X$?"'`]ZZN#Q5I;VY%QO-DT@MK>X?+&[(P&*@#.`3C/?F@#I+:[AN8O
M,@=70L5RISA@2"/J"#FK%<5:Q/X8UM(&'F6EY)LC9>!&@&(X8XQDL1@LS>AR
M379(^X`@Y![CF@!]%%%`!1110`4444`%%%%`!1103B@`S16;_;-F^HFQ24F8
M,4^Z=I<#.S=TW8YQ6B#0`M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`#6.%..M9FE:M_:+S(8'1HNK9RC<D?+G![>GI6FQPIS7.>&
MY4-W-:P(Z6\$,:JK,K;6&X%<@9/`'4F@#<BO8)KJXMD;,T&WS%QC&X9!_G^5
M6:PI"MAXLWLK;-0MP@;G'F19./J58X_W36WG`&3CZF@!U%(#DTM`&/K^IMI-
MBER)[&',@0M>SF*/!S_$`>>!^M,\+ZA<:GI;W-S+!(YGE4-`08]H<@;2.H]S
MR:I^,7!TV*U=Y,7,WEA$9$W_`"L2"SG`X!]^E7O#,;1Z/#N4JY:1GS(KEF+D
MDY3Y>2:`-FO(?%5U=6_B:)[/:`L+/,S9RB>?+EE[;A^.>G0FO7:\D\374D/B
M@PQQQ.'LB0DB`_.;B7:3D?*N>I]Q30&,NM130F6>"-K$$D76,-+&1C>L:@#`
M!PRX^3UZUMV%[9Q?O"6C<1,_E2+L;;\JG>,$`'(.3DX;(ZUD23Z1>S1S+;-'
M<)(TL<C993SM!V#E0Q##RQ\IP3V%5FTV\$+NC07+,TC2.D@!&T,L0YP<J[$>
MF..0M,DW(H+PSF9!'%LE9I"Y&5DV8/'&&W!!C(QOZ]<]=\/%*^'+89!7R$Y#
M;LG<_.>_4>]<\"C7(B64[,NW[I_]6VXDX/<8`X]\5TO@+`T"'&?]4G7ZM28T
M=91112&%%&:*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!#5._U2STU
M$:YF"LYVI&H+.Y]%4<DU<(R*YRR*)XNU07@'VQPKVA8?\NX500OT<MD=>1VH
M`N6OB&TN;A(9(;NT=VVQ_:H&C$A]`3P36L&'K6!K=[:W44VDQV;:A<E`SVZ<
M"//(9W/">H[G'%<I8^);BRU&V76-8F5+`21W@2!C&77*JA(!+-A3(3GIC`H`
M],ZT'I6=IFMZ?J\;M8W(F\MMDBX*LC>C*0"/QJ>WU"VN[=+BWF22%SA)`>&Y
MQP>_-`":A>0:?937ERY2"!&D<CK@"JVC-J4]FMQJ)2.68!Q;H.(01]TGJQ]?
M>HO$6#IJLZLT*3PO,%4L?+#J6.!R0*5?$^@^0)!J]@$;A2+A#D^@YZ^U`&J9
M`H))``&23V%*K!AD'(/((K@+Z2_\:7@6SS%X=C)#7;M@3$'#G;D$@8(&<`'Y
MN>E=J+BVL[:-G98XB5C3N.>%`_'B@"V2,TF[D9[US-_?2:O/-%;WAM-)M=PO
M+U6V%F7JB,>%`_B;ZCK4?ANS@_M2YU6Q@6#3Y(5AAV];G!+&8\Y.<X!.3P?4
M4`=63@9ID$\5S;I/"ZR12#<CKT8>HK*U=S>/'I4<FPS_`#7&TD%8!P>>Q8X4
M?4^E:L&SR$\L*$VC:%Z`>WM0!)11FB@`HHHH`****`"BBB@`H)`&3136/RG%
M`&/XDOS9:<0`1YQ\OS&B=XTS_?*<J#TW#H<5G.Y\)>%9+N5#/=9127DW?,S!
M54O@$JN[&3S@4_R!J?BPS;8S!9(5SL4G=QTD5LCG@HP[9KG_`!#=P#6KU+9[
MR#=G[3+(HEM6*!0RM&><?.@)'K[4`0WVBW/B#7-3L]0%K:WHMT>61':2"2$A
MU5PN1AUR>3P.M:TUY?ZQ.V@:&[6]I:[8;J^D/[P+MRK1'HV<$'TS52]L?L%E
M:^']-@MK35M5`%W):`,(D`Y)#<E,94>E6]7FLM!MX-#,]KIVDFTD,A<$><#D
M,D;%@%;G/.>HP.M`%..]TG0HXTT**SOYYYI#-=M(7_TC9R"!D[I.P'&<TVTU
MG7=8U6YN=)NA+;16JW`M6V;!NB8"/&W<6\U2"=P`P1BM70O#LEVMIJ.IM;2`
M6<"PQQ1%&^4AU9SGEAQCICGUQ76)"B`A%5<G)VC&3WH`\\CU?5+6VCBL;J_N
MY[E8(R;F(;HYRQ,@4,`,[`<CH..>:L-J&D:]I-I%XBMD\^_E\F!8EQ*(6DVH
MS;2=F3C//<^]=Z02.V:YW4?"UMOBO-+MK:WOH':2/Y`$=BI4;P.H7=N`]10!
M@7US-X<@:WUV4:MX<N@4$Y3<Z%OE6)57J,9^;K3-7TJ72]5,R6\,D(0+:W$P
MQ!IL2[>PX+Y(*]S3M(N8;>[;1K>TO[K3KAFBN)YW)W/EDD9$Q\F'(#=.&!`Q
MS4EII2Q7%WX,O_..GR()["5(BHB"L&V^8V=S@D'\#ZXH`NZ$=*UW1KW3EDNY
MI9/WES]J5X7D+X.\+G(1B.W;(K0\,W5PK2Z;=QLC6Y(A9D6)9$'!\N/);8IP
M`S=<US5CXC^S^)X(3"L\S!;2YNI6_>RJ+AX5PJ\#!PQZ<&MO798-"URTU5Y(
M8([F013,\R0JQQ@%B1N?C&%'I0!UU%,0Y)'<4^@`HHHH`****`"BBB@!#TZ9
MK"TG5)G\/W=[=L7DM9;E6)&-RQNP'Z`5NMT..M<?:#;X7\26_.8KJ\X/H3O_
M`)-0`KV;V6@Z$9SOO#?P2S.!@M+(V9#]/F/X"NN7H*P]207=[H=NI!`N/M)&
M?X40_P#LS+6X.,4`.HII?`SBC?Z#/M0`ZBD#9I<T`%%%9JZ[IS:E_9_G_P"D
M[MF-IV[L;MN[&W=MYVYSC-`&E110>*`$R*6N8O\`7+U=>^S:9'#=QP1,T]N,
MK(Q!7=L;I\H=>.^<9K9T[5+;4XWDMF8A&V.K*5:-NZL#R#T/XCUH`O4F12,<
M*36#X3UN;7=-EGG5%ECG>-@HQ@8#+_XZPH`Z"BBB@`HJL;Z`7RV18^>T9E"[
M3]T$#.?J:L`@CB@!:***`"BBB@!K9VMCKCBN7\-W$\DE_&AS,`KR+(?NS'<#
MCU7Y1R<'@UTL[;()6]%)_2N0\-WP6YNA]G>:;R(&E>%<EF8R9/.#C*^IY)H$
M0ZAI'B/4MS:C=S(T#>;"E@Z+$[`<`DCS`#D@X/0UJZ;X9T`B&_AM9'=L2(\U
MQ(Y!Z]V-%SK6HOILM_;P6MM9)'YHN9W:7*8ZA$Y_#-9VE1:W>0&33_$=B;>4
MF1'BL,KN+'>.7R,'MVH&=D\B1+N=E5>F2<"D@N(;F%9H9%>-LX93D'G%<=KE
MKXEMK(/-K]F8RZJ"MEL<,>`1\_)]L5L^'8=2MM+MX;DP2(HP'V/$^/=&&0<Y
MH`K^+4NWL84M+BUBWRD.+EU5<$$`@L#G!.<=ZN>&!MT:-3(CE7D7*8P,2,,9
M``)&,9`YQ4>OWL5NEM!_9B:C<W$A6&"0JJD@9.688!P#]:G\.R6TFC0R6D'D
M0NTA\K(.QM[;@".#\V[D4`:O>O'/%MT]MXI2.-&*S69$F$W*8Q-,SK[,0#@_
MXU['WKQ[Q2EI)XE=;J.2539)N1."P^TRD8X)^^$)QV!IH#*$BW#P;L0S2L9=
M]N"1.^!MS&>1M5HWX.`V14\4,&G72*Y:9E*IM3*;,#!!SR03N;@#!"U!(LT[
MF"")%9I69RH.YR2?,5AR6W`F3&/[@QDU?LXE@9(;JYC>0A-D,S`[!R,J.2,X
MCX&/NDGO3$2V-YYH(FL$5'4LTL39()Y(&#C@[!]6KM_`'/ANV/!S$AR/<9KD
M=/C^S6H2WAV%XTRBMEBN!SSWY)SWVCN*Z[P!SX8LR223;0\GO\@IO8$=9111
M4#$[TM)WI:`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!#S7-^(U74+F
MUTNW`&HN_G1RY(-LB_>E&._(`'0D@'@&MZ\FCM[:2>5ML4:EW;T4`D_I61X?
MMI9(Y=6NT(N[\^9@G/EQ#B-!]%Y/^TS4`9<\6I>%M._T+[)?QO+S]H+)/+,[
MX!W`$,23W`KD[+4`UK<VE]$ACTZYN=2N7=LK<S"1ECC#8Y&X\GTVCUKT3Q);
MV\NBS3W+2JEH#<CRF*DE5/''J"0?K4>C:%:IX>TRVO;*WEE@@4-O0-M<@%L9
M_P!K-`'!Z7(^EZ(MB6VZIK4L7V^Z&`MG%(/E!;^_LR0.N6)Z8K2N->L)+N.2
M%0-`T5`;5%S_`*7<!/D5!W5%YSTY!KO$TRQCMVMULK<0L<F/RAM)]2,5"-%T
M\7$\YLXC).@CD8KG<N,8]AC@T`<<_B2\TR)[9]0MI[V-F69YF&QKJ0_+`O(P
ML8.6/8`>M7I]8L[K0I7TY5^W.\=I'=BWV!Y),*)$8CD?,2"#VKHX="TN"21X
MM.M4:1=CXB'S#T(_`?E4U[IUK?VHMKF(/$"K`#*[2#D$$=,4`<Q>M;W3Q>%;
M&?R;*V@_T^92!Y42A0(\]BP//H-W>JTVL?VMY^H:=$)+73'6'3U?(2XNG4*K
M'_84.`/J3V%=)_PC>D9B/]G0$QC"_+[YYY^;DD\YH'AO35U%;Y+?9.)A.2K$
M!W"E02/8'@=J`..GT%=#TV&SU;4'U9R7:ULGQ#;AAEVEEP<L`<L221D\#-.\
M.:O+;V^JPZ9;PS0Q8NA<NQAC;>2"54?\LU\M_3@*,=37>7&GVMV4:ZMHIC&V
MY/,0':?\@?E6<?#5BMM]GMH$MH7F269(E_UH4Y"D\_+G''ID=#0!PNI6OVJ"
M]GU,W%W<QQK)>.I*+&Q`\JWB0<;R"N2<XR<<FMVV\0MX<L[/3K]X6>W@:XOB
MG"VL9)\N-1U+9*J`>3C)J[=>!X+N9Y3J6H1,;DW*!'4"-RVYBOR_>).`3G``
M`Z58D\%Z--)F2U+)Y8CV%SMX8MO/<OD_>STH`JGQDTDNZVLFEAM;<3ZBN[Y[
M;=_#G[K,N'W#/1>*ZQ<]\?A7/GPC8/<NX:YCMI"IDLTD"PR;1@9`&<>HS@^E
M="!0`M%%%`!1110`4444`%,D.(V/M3ZCEXA?G''6@#G/#(.+^[G$FZ63)DE2
M`94`G[T7WA[MSQ7(V+Z)KOBY8+G9?7$[[FGTZ618WV?,/.0X`^XO(X)Q74>&
M6E_L*]\B-#<;WVQ/-`X9M@V@F'Y0#QP><9]JQ/"EW?2:M81QW>I3;X6.IV]U
M;F.*V8`X\L[0#\PV\$\<T`;.D6YU#QUJVI7"2G[(JVMN)K=5"?WRCCD@D=_6
MNIFABF`62-)!U`90<?G7(^!9(VN-?C4P[TU*0,(Q)@<#'+]_I78L,X]*`.0/
MCU$<W']B:@=*$_D&_4*4#;MN<9SMSQG%3S>,W74+VTL]!U._-G)Y4KVPC(!Q
MGNP[5RUSX>UO>\FGZ)/I^J?:MWVBSOD2V="X)8Q%R>1GCKG\J9J6DO%K.M7=
M_I$US#+=;DFAU6*V"C:,!@9!SD9&:`.SUSQA:>'K>QEO[>XS=`L415S$H`+%
MLGH,]LU>N=:M[;5M-TYEE:74!(8G4`JH1=Q+<]^V*XS6-*U37]?GD6;3[&"W
MT\0".[83G9(`9&PK_*1@KD\'\:=;P:Q$GA&_.FO=-ID$\,ZQ7$9+?*$1@=V#
MD#/6@#O(M/M8;B:XCA59)V#2L/XC@#^0`]\5S/CQ;>PM]-UMQ`DFGW<;>;(C
M,51B`P55ZD^]='IUY+>VPFFLY;1]Q'E2LK'`[Y4D?K6)\0G1?!E]NW'.P`+-
MY1SO'\7\_6@"QIFCO;ZS?:G+#I\8N%41O;QD28&3ER?;'Y4>*2Z:.\L=R+8Q
MR*3(9TB`[8+,I`[=!FL'Q):&6:QD:TLIVCM$#Q76IM$^<Y(X(#?[W>IK3[#'
MX#.I6EF;7[9&KNEO*Q.=V%(<AOSQWH`ZO2;E;O3+:XCECE62)6WQR%U;U(.!
MGZU>K*\.L9-`LG8OEH@?GE\QOQ;`S^0K5'2@`HHHH`****`"DI36%J6I7\>K
MII]M%!$9HM\-Q<,2KL/O*%7G('/)&>W0T`;AY&,U@6L<<MQXBMF*KYDXW$G`
M&^WC'\P:D?2;Z[C7[;K=TK#DK9!8%/Z,W_CU<SJ%I::+XANH8[47%U?VT"6/
MGL9&,P+H[$MGHI4GV%`$7AO5;G5'TW[)<1BX2U6TQ*-WE!$1II,`\DN47T^6
MM-_%-P/#6E:I,\<'GZ@(96"DAHP[@D#J,A,UGV>F:K'%#'I$2E5-YISW+LH^
MSC[2,2;<Y8[5(P.A45JZ/X:O-/UM5>57TBQ20Z>C'+AI<%BWKM^8#V<^E`$,
MNKWLW@J^U"=I"^H2M'90JN'C5V$<:_[W5CZ9]J1?$5_#>ZE/?0O:V]A91O#8
MDJTLS2,0F['&[*```D9;K5^T\-7,&L02S7WFZ;:R2SVUNRG>LC_WFS@A<MMX
MS\U:EUHNGW][:WES;(]Q:OOB?N#UY]>>1GH:`.8_X2+5()K#4+Z"ZMM.M5\K
M46>+:K2,O+@<G8K<$^_<5V\9)&<@@]"*;)%')"T4B*\;+M9&&01Z$>E<_H1E
MT?4[C0)Y&DA53<6,C')$).#&?]PG@]PP]#0!TASVQFN$TK=?RZ9I;JRW5G=2
M7VH,<9202-M!]W+;A_LCT-=Q(&9&V$!L':2,C/;-<T/#C[6O;34FCUG<6EO`
M-RRG^Y(G0H````00%&#F@#J:0UD^']5.JVTY=%2>VF,$P23>F\`'*MGD$$$=
M^<'G-:QZ4`<=9-L\:1H<E\WZ'`[%K=Q^A_6I=0U&STKQ?'<[PA>T*W87):1M
MP\E0.[$[P!C.,]@*HG2SJWCC687N;JT2W1'22UFV.3*D8;UX_=#@BF6&C:K!
M?73)I1BN9962"^GFCDCMX@?E8*&WL[#)R1U(S@<4`=M9S-<V<4\D$D#.H)BE
MQN7V."1G\:Y?P18O87/B"-A^[6_*(?7`!S^3*/PIUOK\?AR#^S==EG\V#/DS
MB-I/M40.%8E0</T!!P<\]*RXKC7[1[JV:UD6YUN59X&4#%L3\KACG`*QJA'J
M<T`=^K[CP<C.,T^N*T[3M?TN.XT:PMDBM6N9'BU&:82>7&QR/D^\7Y/7CC-6
MK'_A+8;86$D5J98LK_:-Q+Y@E&3@^6N#G&.XZ4`:FKZ2U^]I/;RB&[M)Q-')
MZCHR'OM8$C\JU5SFN?AU/7([!1/H,LU^I*N(YXDC;!X8$N2`>N,$BHV\3S:<
MF==TN>Q#'$;VV;M6_!%W#\5_&@#IJ*S=,UBVU97:W6=0H4YFA:/<#T(R!Z5I
M4`%%%%`$<P!@D!;:"I!;T]ZYSPU"J/<L+NSG;RX8\6[!MNW<=QPHQDL?RKH;
MG_CUFRF_Y&^7CGCISQ^=<_X55!)=NKI(2$RZ[`?XCM(7GC.<GKN^M`#9_#%^
M_G16?B*\L[&0MBUC@B8(&ZJK,I(')^E3+ICZ-J!OM/$CQ3Y^V6Z@?O7P<2`=
M-_`!Q@&NBI,#.<"@#`\5N?[*4!-V9!G@9``)XST)QM![$UHZ*H&BV@$0B'E+
M\@8MCCU/)JGXG5VTET1H5C8,)3*NY=NTXX_WL?AFK'AXJWAZQ9-I0Q`J5&`1
MZ@4`8OC._P#[-ALI)+AX;8RMYWD-&L[<8787XX)Y[XK2\+2/+X?LG>592T7#
M*5/&XX!V?+N`P#CC(K(\>VUQ/IL#Q1,R1R_.X*_)N(`)W,HQD]\BMCPK*9?#
MMBSD%_+(/RJN<,1G"DKCCL:!&R*\6\9:E%8>)]]P(E0V`5)9%R`WGS#;Z<@G
MZ=Z]I[UXWXDBMW\7![B)I"MFFU2V%!\R?)],XZ$]QQUIH&<VFLZIJ4GV0*8[
MGS"C6"J!&Y/1`2,[0!N;.>@`XJS;:'/IR-*0PB\\;5;EHE?APP[`D#GLN`.3
M6E`[2;;2U@6.-5VQ^1'QM/`Y;HOW2,GGG-;%G9.([R>Z4E%MU^4,2&)4$@X'
M7)')]3Z4Q$.];>&WC,R)+$BQ,)#M+%`.R@\;2#@<]?2NP^'YSX7LL]?LL!/X
MQBN!@B$Q3SV;<LA=M[<G*!2#M&.<'KZ]^W>_#V,1^%K$+DC[+;]?^N0YIO8$
MSK11114%"#FEI%Z4M`!1110`4444`%%%%`!1110`4444`%%%%`!1110!C^)X
MQ<:(]HV=EU-%`^#C*-(H8?\`?)-:RXV@``#L!6?KMO/<Z4ZV@5KJ-EFA5S@,
MZ,&`)]#C'XU2'BBU:W'DP74MWC_CS2$^:&_NG(POU)`H`-=8:A=V.BKDB>07
M$^T_=AB8-S[,VU?<%O2MU0=HSUQS65H]A-#+/?WPC_M"ZP)-F<1H,[8QGL,L
M?J36O0`4444`%%%%`!1110`A/-&ZL/6#JB7I:RFE$8MW;RQ&I4N"H4$D$\Y/
MY5FV]]KR7TZWB2^5`#M$<.?.(+]#LP3@)SE>M`'7;A1FN1.I:ZD:`P2/*B,C
MQK!G>P+?-G[N"`IX/\70U)J&I:T@FN;.%WB4@(C0D%@7VYQC/`YH`ZK-+7'I
MJFMM%$Z1O*`L1<>01AFD"L#D`\#)P.1WKKQ0`M%%%`!1110`4444`%-DP8VS
MTQSFG4C?=-`'%66^#3M6LX-3CTV>!A*\QAA8Q)R"?+3`7A3][)KF]"U*";Q#
M:W[:SK5\J'9!;?/(TA8;2[A0%1><A>>.37974HT_Q(J32@VE]\IB?:%W$=D5
M"S'())8X&370P6\4,>R*-(U_NQJ%'Z4`<II<ATGQ_J=C<3R^7J4:W5N)9UV[
MEX=43\<D]\5U^X<>]<YXITR8K;ZSIT;-J-BVY5C0%YDSS'D]`<FJE_J\VMZ5
M;3::9I;%Y#'?"SP\\9QDQ@=.N`3UYXH`Z\'(X_*N/U#PK+)/?3VL=JIFO8[J
M)`WEC(B\LEOE()//!!ZU'HOB\1`6=]%(!"K;[@L&\M02?GYR0HPI<9&X$<5V
M(<$*=Z_-R.>M`'G\O@2^$X\JX3RTB0',A)G8"#(.5^4$0XZD<YQ79:':3:=H
MMM:3[!+$I!$>,`9.!T&<#`S@9ZU<DECB5F>54"YR2>G?^5<YKWBR.QB2.S7S
M7G@:6.5&!4J#M.S`.]QG.W';DB@#I@^2/K7*>-"^H-I^BP`M)=7"/*!"DH6)
M3R61B./?VJIX?U&ZL+266^:-=.7,K7C2AHIMW0QL3N+,<LV[&#P!5SP_I[ZI
MK,OB:^@DCE93#9Q3)MD@CZ-DC@@]1G-`&#XN>1]0U"YEM-,,.FQPB**ZT\3&
M[WD_(LG\/S`C:,X/-='XAFAL/#,:AOL40"!?*F>W$0`SC<BL0!Z8QVK;LM*L
MM.BDBMHBB23-.P9RV78Y)Y)K&OF>_P#$EK:Q']W;Y>0[I$)]<,ORMV!1OPH`
MWK*-HK2)&9F(0`EGW'IW/?ZX%6::HP.M.H`****`"BBB@`JEJ.G0:E;^5./N
MG=&ZG:\;#HRMV/N*NT$9H`P;/4[BSNXM+U=E::3B"\4;4N/]DCHKX_A[CD>E
M:TD4,DJ2R1(7CSM=E&4SUP>V1Z4R^T^TU*U>VO(5FA?JC?SX[^_:LV71;]X9
M+9-;G%L_R%9(E=U3&"H?KT[G)]Z`'^%F6;0EN4!"W-Q/<+N'.UYG9?T(K9Q4
M=M!';6T4$*!(HE"(@_A4#`'Y5+0`UNE8%MJ5_=ZY=63O;6GV9]WDM&SR3PGH
MX;<``3QP#@]:Z`C.*S]1TF&_\M]\D-S$28+B)L/$2,<=B/52"#Z4`7\C'MBN
M=5UU+QJ#"28],M7CE<<J9)2OR9]0J9/IN%2?V?KTD?V9]9A2,#_7Q6P$Y_,E
M1]<5J:;IUKI=J+:TBV1@ECSDEB<DDGJ2:`+0K(D\,:+)<37#:?"9)B&<XP&/
MK@5L-]T_2LXSRK<`;FP>W!%-*XF[%FSL[>P@$%K!#!`H^6.)`H'X#\*L'D52
M^TLA.26/IFH;B]E3.U2/]W!HY6',B/3],EM=>U?4'>-DO6A\L#JJH@4Y_')K
M7_"L>*^N#(5;TR..E3B\<[>3UP<4<K#F1?9=Q'(QUH'U^M8,GB.UAN)(7EE+
M(Q7`0<D8S_,=<5*FOVI#LLKLJ[22$SP0I''7^-?SH:8<R-NCZUDC6K;9&QE.
MUN=P4X`^7&?Q=?SI4UNT=U3S2"0&RR]<D#`]^:0S5_&DQZ<#ZU2M]1AN%WH6
M"C()*G@BIOM(R`!G'6G9@3XR<YIU003^<3@$#L?6IZ0!1110!',"89`"02IP
M1U%<]X55X?M-O+O,R;':1W8E]P."0PR#QSR?PK?N.;:7YMOR'YLXQQUK!\*,
MK+=@1QAE=59T9CO('7Y@/K^-`'244E%`&!XJD,>FJ%@BGE>50B3(C(>><AN.
MF:U-*E6?2K65%1%>)6"QKM49'8=A67XI"_88W<M\LF5"*I8M@[<;L#.?4BM3
M2V8Z5:EWWL8E);CGCKQQ^5`'->.MQLK8A)TB65FFGCW81,=&4?>!..#Q6WX=
MW?V'9%G=SY"_,T`@S_VS'W>,<5G>*],GOX(7MM.AO9(&9P)+J2$KD?P[,;C[
M$CZBM/0D>/1[1)%F#"%=PG&'!]",GG\30(T\UX_KKP+XME^T12.HLX\!&Q_R
MV<]><D<-C'137KQ.#7CWB"ZAA\43QRVC7,KV:"-%.!D22''/KG:/<TT#&6T\
MMR%CBBM[:V55.4.Q0F>,]-^,J.?3IR<;%_Y.FZ):::LA\URLDRA0Y"MD@9)X
M'4Y[`U@Z<L^L7$;SS-]D4>8TD1.R-!@EP".>5.,_W^>PJ/4-8%[J<ACA0;=@
M"$[P5P">2>R[002`"_M5"+D$MHRNQ:=!@DL7SNY7!8`<?PG\"!7<^`"?^$7L
M=W46EO\`^BEKA,R7%@C*BAV!4A"3N("G.,#[Q/;`//%=[X%#+X:LE;.X6EMG
M/_7%:'L);G4YHHHJ"Q/7THR/6JVHLJ:7<.X&U8RQR">G/8$_D*X%9-(>,Q[8
M&V(QQN<E-RA22#'E>H(SCFBUPN>CY'K1D>M>?O/IUQ/*XFC0JP9U$C93`4?Q
M1YQP/PW#N:A#:.$DE^V=F+/YYP`PVYXBQ@9&#TR!1R@>CTF17G*3:/YK1KJC
ML^!($6<G"C)!SY?3YCGU[]*W;S6K#4;<KY\:K;NLK>7+T`.,$E<;3D9[<T6`
MZJBN!4Z1*2/[3E=HXL-^^)958,-Q^3W/)]!4J7.E^3%;KJLD@DN))%_?\L?F
MW*"%Y`R?TH`[C(]:,CUK@H[O1O-9?^$@>1L;E5[D`HH8$@>V5]^I[5/)?Z:(
MX%7Q#)`4>2//VA3O8L,K@]2,8'UH`[;(]:,CUKAWN=/2\E)\02AU7!C^U!3D
M'.?KGCTY^E,%UIWG26O_``DDCW*_.RFZ!D4`KD$`@X.TY_WS0!W>1ZT;E'>N
M1FU:RFDDE35P@.X`I.IP<;>/FQ\I]OKFJ=QJ>GV\2RR^)&16ROF27,:J>.WS
M``\GIZ]*`.[!!'6F[E]:Y6PU_3K-9"VI"Y#;2#)<1_*`H'!W=R"WXU1;6-DI
MD;7$$83:%,T0'W2N[.[KNR?PH`[D8/3FEKF[7Q78+;0J9UF;8!YGGQ_.0.OW
MO:G_`/"8:;M+!T*@X)%Q%C\]U.S`Z'BEKG6\8:<HSUYV\31'G_OJE7Q=8,Q4
M*Q(.T[98CS_WU2L%SH<T9K`'BVP*A@KE"<;A)&1GTX;K3AXJL"2-DF1Z-&?Y
M-0!NYHS6(/$UGSF.88&>2G3Z;J</$MB5R!*1C(X'(_.@#9HK('B&R+;1YN>N
M-O)_6G+K]BRA@[@$X!*\?G0!J8YSBC%9RZU9MP'?)Z#8:?\`VO9\?O3ST^0\
M_I0!>P/2CKVJD=6LPNXRD=N5(_I2'5K3J'<CU"-_A0!>QSTI>!6=_;-GT$C%
MCT&QN>,^E*-9LRV/,/M\C#^E.S`T*,UGG6+,9_>GC_9//N*=_:MI_P`]&Z?\
M\V_PI6`O49K(37X'`80S['#&)MN?,VG!`'7/UQ5FSU*.\>2,1RQRQJK.KKT#
M$@<]#]T]/;UH`O9HI!2T`%%%%`&7KNFG4M/:%=Y;J%$S1A_]EBOS;>>0.N!5
M?P_JC7EM]FNF_P!.A!\Q63RV9<D*^PDD*<<9]*VV&17.:KIUU9W;:II1Q*3N
MGB(Q&W]Z1@!N=@HPJYP":`.A8;UKEM1\/W6F7[:MH#;7;_CXLF_U<B#D[%X`
M<D#DX^M;.E:U;:I$=@:*9,"6WD(\R)B,[6&>&QSCJ.]:.0_3_P#70!YK]KT?
M5H[K3(KA](OY)H#-8W@)C#E]Q1.1RQ`SM_+FM;5=*UG5M5TR_P!MN\%I(A\J
M*8D.K$"5@>.Q(`//%=+J.B:=JR(E_9PW`1MZ[UR0V,`Y]:YJ_P#`NB0QJ\5W
M>Z?'L2W7R+D@`;\@`'/+,0*8&=8>$]9CO7-ZZ26R2L1)++RVR`QQ/CW+L3GD
M$56MTTCPTEI9WNJ_;;T21M!9VW5+Q5Y",.5#CY<'KD^M=#'X`T]I";F_U*\4
M^<&CGN,JPDP"#@=L<5M:7X=TS1@_V"UCA:14$C@?,^T84D^N">?>D!SMEHVI
M>(+J&[UJ%;338R'MM-3NK#E9UZ$@XZ>]=I&JQJ$484#`'H*<>!DG@52U#4K3
M3K=IKJ98U52YSR=H(R<#G`R,GM0!'K.I)IM@\Y>,,2$C\Q]BEST!;!"Y]3[5
MG>%M-FMHYKZZ0K=7;;GS&(WP.GF!259^OS#&1BJFG6=QKNI'4KZ(K:@,L,;C
M!(/!0X^62%@%8$C.:ZT#``%`"T444`%%%%`!FC-1R2I$"SL%48Y8X'/O4+7]
MJJ*S7$05C@'>,&@"UFC-0BXA/_+6/_OH4OVB+_GJG_?0H`DXHXIGFQ_\]%_,
M4>;'_P`]$_[Z%`$F11FH_-C_`+Z_G2[U_O#\Z`'Y%)Q2;E`SN&/K2;U_O#\Z
M`'<4N:9O7U'YT!@>X_.@!QJD;60_W!R3QUJWO'J/SHW#^\/SIIV"UR@UG,0!
M\C#/4DYIIL)CD'8.>,'_`.M6CN']X?G2[AZBGS,5D9RV,N,$KC'S`-U_2D-G
M,H8(D>.V#S_*M+(HS[4<S%RHP)=&:3<6MU)\PS<-U?CD^M,3PZ8VD"-*L;8!
M43NHP``",'@_**Z/K11S,+(YO_A'T@2,B"5A'_RSAF/S'"C)!(!QM4]>U._X
M1JW\G8$E<@JRF63)4J=P(].:Z&EI78T94.E&($!B%W;MN[/)Y/6K+Q&,EQ"T
MF>`JD<>YR15RD_"E=C(XX]N"1@CBIN*3\*/PH`7-&:;FE_"@".>)9X)(7SMD
M4J<>A&*J:?I-IIK3&U0H)2"P[9&?\:OYQ3=P]<4`.HIN\>M-#<]:`([JT2ZC
M".TB@'.8W*G]*6RMDLK*&UCW>7"@C7<<D@#%2[J-XH`=BDI-U!/'%#0A&ZUX
M]KMO%<>+I3/,Z1);Q-A&PS$/*1C/`[Y)]!CM7L#'IFO']5U&&Q\77"EGDGEM
MX(XH(UWM(V^1L[?11AOJH'>J0C9_L^?_`(1Q/-A*6\TOSPP#:2HSA5SQM/7/
MTK&OH6F5`8E@MD+'S0-@,F.QZDCO@Y.35QM3DLM0EDLVD:XN"8Q+,Q:2-!T7
MT`YW'`/?\,W4=4G\I463S$)'F2.Q21WP0-C<+C[V,,>O3FF(UK&^T^VEFDM[
M1YY((-_GROE?O$#*XSU)()/&[FNL\$'/AVR.`/\`1+7H>/\`4)7!R0FVA-DT
MDLV,^87Z\=`>.WT!!^M=YX)POA^T4<@6MM@_]L$I,#J**0=:*DHJ:HGFZ/=(
M02&A8849/3TKRG,FBZC&DDP,B`QRLL6,+QC)9LGMD9/3@<UZQ>HLFG7"/(8T
M:-@7_NC'7\*\PM-1@OV^S:D@GMQ&T<=RXPXDQ]T.`0?N]^>0:I;"W8Z-)([N
M"%5)C*L@=2?E8\AQCM_M8!JO"LF_R>5EVY#.2V)/X6<,3_L_>)R`5QS6RFDI
M-I]NNGW_`)FP!?)G*A^^.G'4C'3BJ&H13172+,-LRJ-ZYPH(Y`_/'/X]J!G.
M:2TNGWSI'Y*V]O/NE!(`FD;/S1L21T)+)U49ZGKK)"WVIK6-F#LIB:.,GA23
MC9M.R,!@IRG/^SUJEKEF2RW$,4ERH;S%A`Q'D\F23C/4@[EY'\6>UMH9+BQ@
MG0^=-<E<F,"0^8,Y(V\,WR]3G.<C`YH&B.WBC^U(]P(F=9&G96?S'&SC_6\!
MB2<?/@`\8)J2VO)`]U=B-F<1L9@&$;<KL&\'J!NX=<*,=32W;OJ"RQ&3SVD=
M6E("2!BB_P`:<]\J2,D\<XQB*^AD6TM[6&W2224EG1G8JRLI*J`?F;E3A.2"
M!GB@"MIUO/)JBR7;HTL"Y6\V@)+!P"L8)P!A@/,_X"1DUL6^Y]1C9IBH0,)'
M0,'"KG"X.&7G.%.]1VQ4>G0[-/W@L2[D1O+CSE4$##$'`VG(VJ-N<8&1FK-I
M;W%Y;,+>WFN`9,.1@A`1P`.P!SGCO0(@6X:65[F:0;%<OLSV)(`)]>0,87.1
M@U';02WLSF9I?DF.]/))?`Z;2A^;TR2WTK8ETN!+2WLK^8(`Y9X(4WDKP`<\
MJ,!23[&J5M?*^HO:Q_\`$O@,9D5E9H_-0#."6P>?FZ=,>U`BU/9+:P">[@G2
M+/E0PQL7>1N@`5>2<Y)Z#CDUG7=M9RWYDFMOM+^6$$=SAEA['`_A9N/<<#/6
MM[3K^417,UNJ7$D2F(M'RB$G:%3'N"Q)[?C7/3SQVER\"[+NY)`EE<$H6=BB
M[=IR5W;MQ/93CI0`^QCL;*QBM1<SFW:;RHO,<LL)<_(N?X0.1@\8*].E7;O2
M;R&1+>XBN4EW;4GAF.-I_AW#E5)]00#G@U%X;D_TY+JW&8+A"CV]P,X).$+#
M'*;@1N[%<=JM3:A(K7+6]PZ7%KN^5V!:,YY1AD;@3TYY/2@#)L"\43VKPQJ&
MD9T6!"J1LN?F)&!DC/.%!I\,2"PEMP,[GWO&`O7H=N1SP<Y(SQ5R,V.I+Y<Q
M:SNXMK-+"=RC)ZE2=RD=SCOBKMWI.H1SI>V4B7"%U*&!L*W3[P[=^GKBBX&%
M*LMSILR>8K.[!E+L<C)"ELG+<`G:S'L<*`36=HLX(EC,;2VRI]GC>16\R9P0
MQ$B`Y+83`(.>BC-;$T<<$[6\;+P2&0(QSU/(P<C&?K6-)'_9FHBXB2:XD4[8
MX(AQ$@Y*EAPPV8.T\KDD$\46`M_:II+*6W59C-$R.K#RY)`H;D-QL&!CY6"M
MP>:@@"6<EW.N$B@W?*KEU$C@KN>(_,",Y\QS@[3CCFK4EKF_"6B12/(0B+)N
M,;KC[Q5<D@J>I)&!T[U3N$=$B5&E$1#&$_ZM]P;;RX^4@#@`DL!Z9S0`]&FM
M[":2&,S2SD1QB1_,P5(DPTV/FCPOH`,[1G<#4>E)%+'<7J,C1L=DGGJ0I;&,
MH"ORQ\M@L,Y"\8'+M4$<YCM&26.'(;[0Z`)'-C)RJ_>?!7Y>VT$UHPV[6]H9
M+J0273I^^+R`DM@`$L,`G;@_+QF@=QUG%%:W$ET(8/W2F,X`4!7!``!Z=_NL
M0>PJ&"**TCDG,46Q)#C$?S%L<97;]/X<G!]ZM?9+BX:."&VEE"GS&C51@L>#
MZ=.N>_&:EU#38[0$W5S!!!;H,P1-^];Y1D''`^;/)XZ4",:VTN,Q,(K6%8F.
M&$`#)=,<<,#D]\Y+#`Y"]JU$TVUM3;G4DBM!-(?+A<`-M`Y..I'X8]ZDL+N?
M!:SA/V:-1DIEF;C@E\=,$9QWXK4NKE+K33*H2>]D<HET5!90,,0A/.T''/0_
MA0,Y&71K6[1[B6?_`(FF_P#=2H=L439^6/RQP1T!SR>HK7GL/M)9;14DFB19
MY$1=I;'\6TC(PWRD#/3M5-[G3[5_L9NY'?DM<Q`<G.TD+CG$C!<=<D8X%;>E
MR"TMY7N"L=Q;MB"ZC`)6)B023UVEORXSS0(YRXM(V5)P-J.Q\_8OERPG&6'F
M<,J\XQR.E3Q+#<VD22+!$\*E2<CY3DE6)Z\@CD;<^IK6NKF2.&2[N(1-;3AL
MQR8!!X(*-C)!Z\G@`<T^PTB)WAFLIK<V\J$>3+E94ZG@#"YST^N>].X&%+;Q
M/;V<\EK'O2,JZR@8)RWWL_*?8D.3V&>:JZI:PB*WF58[6,H8YI70!0H`^1@2
M,,2^`WKCVSO/8S6SS65Q!)&YC?$CGN!N!SR#G!7WYK'F`^Q7,!\V=$!=(Q\O
MS*N=IZ`J2H!')P<4`;.AM''X5M4^SSVUL)Y2D4DI=]A;'EY.`2Q1FW=`,G(!
M-;]OJ)TX-(7^R+.P_=1VTDJ*0,<2-M!)^F#@8]3CVDKZ;IUG'!M%P\0BMT08
M54^\[A?X=S@CCLJU*E[/=65Q87?F.)XA(%V-EE.0&!W<8/\`>/I18#97Q/<1
MS)B2.>-TWKF/9D<<YZ8R>HSCTK9TK78-37:`8IUX>)S]T_7O_GBN`N6>PTYY
M9V19(Y!-'MD!56VMO`(R,L0%VGKQGJ*@@NY[>Z=G/EK!+M\QBRGRSM(;/HH?
M_P`<I:#N>M@Y%+6%H.LB]B-M<'9>1$HZ-P6(QD_7D=/6MP$'O4C%I"H-+10!
MSVH>'(IKE;RT=K:X5R<QC'#.&D*],.X`4L<\57MO$=W9B*WUBU,5PS*AECYC
M+%6<[<]510`S9ZFNHP/2HYK>*>-DEC61&!#!AG(/44`5K/5+._BCDMKJ*02*
MK*`>>5#CCK]T@UA^*O#MQKIMQ:R1QNH=F>7+)G&$^0$?,&.0W;;WJY=>%-,N
M$;9$T#-YK;H6QAY(Q&6'N%``],57N?#5P\=U]FU6ZA:;S6!)SY9>,(H&#_#C
M/U-`&IHMJUCI4$$AD,BH/,,DIE8MW)8]:LSWUM;*6GN(XP.NY@,<@?S(_.L"
M?PM=W,EWYFLW:I.)E4(Q&Q71$&.>JE"P]V-6(_"M@7EDN1+</(TI_>-]U9`N
M]1CL2H./6@"&?Q0TTBPZ?9S3L<[FQC;LE$<@Q_?7<&VG&14>G^'KN>YBOM:N
M1-<(5<1Q$A8Y%#*63T5U(W)R,UTL5M#;AA#$D8=BS;5QN8]2?4^]2"@!J1JJ
M!5`"@8``P`/2GT49H`**0D9ZUGZIJ<6G0@NZ"1^(P[8!QUS[#O\`7%`$]W?0
M64)EGE6-0">>^.N!UK..O[Y_)@@5CMR?,F5"/^`\D#W(%<)KVL.9+N:XD0O#
MNC3SN$$F5`S_`+(+8/NK5<63[9;SBS:5XWD0V_DY+21?-N=<=RR@$_EP13L*
MYT&I7UQ>I$B00"0.'!2=79<?[!"EOI7,:G?N-(U:X6Y1&>-8WF"?,,L59F0\
M@@,JL#G!"GD5:MQ8:5IBQ^1;M>3GS6601!T)QA/F&[@8R3WI-5N(-2T6\N[<
M/'*+<I<Q1,`^SM(#R"RLH`;T)]!AC,?3]7O9%N!=I;Q3Q;08!;1OMS\P^8+@
ML5W84<\#KFM!-3FDM;R8K;MY840[+>,[6R,Y..<>C!#6/8VLL%@EMNW+&`S"
M%N#N)(^9N"=I&<X)[<5>G+1+:P2.ZM%F609)PQ&,#(/R@=LB@5R==4D33FN)
M!$S+'C,5G&Q+D]<`'(`Z@5%9ZM=7,.3'I[QH-TETL40R`>1Y6,J3T`9@?8U#
M<6%U?74EI8PR>5`REY!)L*/T8,V=O?OFM_3K6RCB@5\S(GSR-_RR8YSE,`%F
M;'T&*!%&&YE<32[8S%$&8[+6,EA@D8^48/'.>*JK>:]$]O<W5GI[VDKA9+6"
M"-KB!3P"V?E)SC('2M368(H8Q>QSRM/*%MH;`$>7&R\D,HR6.2"0363+O$LD
M<!>25&*M`'#R;>2X*YX`S@CDY(H'<NRWT\.Q)(K<`Y!;[)'\N",DKCCC@@X(
MZU1NM5U*WN9D,5D@3E5^S(RN/52HR1@CG&*Z#3(+4VLVH22M=VUV`S6\P#F!
MU4ABIZE<!>#Z9%95VEC<".R6>.VO(R#;[V7R^G2%B,@$[<;N^:`N0/JT_P"Z
M:&6RDCD4$2"SC;T[=#CGG(^E2W>J7`E00+9?O%!B4VT9WY`R0V.0.>@.>U4U
MM[RWD^R7]G<;%'G12$[@".3ENG/;;4_F1RPF/YI)+?<\>0><\')XZ8]:`N5-
M7\27EBZI:PV4OFIG*VR$P@'#2,,<KZC@CO2PZ[>2:9;W'^A3-)G#Q6D?S88`
ME<\8PPZD$=/6H-4AGFTI5C+H8`'1T8QR!0/F"..,DE,*<@\YYJIHL37MA<6I
M@0,3F*)HSAEP=Q:/'W@6'!&"23[T!<TM0UR]C(:!+.-?+5M[6*R1Y)QRP`(8
MD'Y<'_>IK>([J.W5YX;!)3)Y:QA("KD#G]Y]U<DK@')X(QFJ*SB=;:6%%^VQ
M$A$)WS&/I(B[3A1GG;DKU'<FHG@S=QV5D$6%$+"6%`#(P)R9(L`#J.4R1ZT"
M-"Z\47MFUI$?L(N)U.Q9+`1F5]Q^3:>5^4?>/&0/[PJ>S\1:A+;">2*Q5T.V
M:/[&,!ER'&X=E/4@''0^M<[J2?:-0FM%BWVC;8`59O,1P%4;B?N1GYO=@P(K
M>2WE80)'(9RG[MS&O$A`P6P?]K)!!SCKTH'<LRZSJRZ<TZ/IY8R@(?L:;2O<
M_?P?S_"DO_$&I6]D)(WT\,\NQ'^PF12!U)53N_$`_A44@B>[\D2MY"`Q@DDE
M^^XD]3[Y`^M49K*:^E^UPNT=AN"B21@D3J!_$&&"25[#Z4"+\?B#59(S(\=@
ML:G"LENL@F/8*5?`]P22.E6VUG5HM-:Z^S0.Q4"&*.TR7<G`!)(VC)Z^QZXJ
MWI8TF=S#'"]Q&ORV\,IV@GIA`.<9'+'KD8J/6;-HR4@O)+Z:]8RF)-JJBD,%
MV8XX&1DGOGM0!1AUSQ"MS':WEMIV^5"8YK6`RH'`R4<=5Z_>Z'!/05<_M;5&
ME:%([7SCGR@UM@/CJ203C@Y'!Z50M9I8)P[-(\/R&7R6#;"1QR,]F'U!/K70
MMHMM!I(MKHK=.&+VTY/EEHR5.QB.-V.!QCI0!@Q>)-36=(;DV,4;2>6T\D/E
ME2>F$W$-GK][\*O1:[=+?/%.EKY9E\J-O*"Y)]\XSZ@D54N+*WU%W>P9Y;E`
MT=S;MM$P8="Z]R`<9!_`U0CS.J^>7:XMCY<X?(4#D@Y.#G[V?0K0,TG\0:D)
M5BV6OW]A/D,-_./ER>O7[NX#H2,UGS>,]12_EM7BLH1"<M/+#\C#G"#YN).@
MP3USVHN5C?R;JW"2^9\DP0_Q`8'?!)'3/J:RM8M86=+F[DCCM-@:5)%#1S2`
M;29AC(``'SJ?:@+G3_V_,+N-9X++:2"QV`!5(!&YCQ&1G&#G=ZBLY_$UXDKJ
M;:TDR247[*L;,`.B;QAQ_M<"JP^TSV%K/-#+'*,1NH)=E<[B0`.,[2#GTP-O
M%5KEHYH[AVD5H0?],WL)6W*0?G'^K!.!C`&"6RO`H"YIR^)IE9$6TM=[+N;-
MM&3'D$C`QF3`P3MJI?\`BG4$O&AM%TSS4^9HI((_ECQDR;AP`.GZU3MUFNKY
M[Z>%$$1^X#O5E^\`CC#`@`#!VJ<<532VDNM307`CCD5BX>,965`3D2-QO?'W
M5'RC'/;((Z(:[?M;QS":Q,<B`[WLE4`$`AN3CD'[I*_7TM'6;N&&)I?L+2,N
MXI]D4-U/;D]NVZJ3I)+(0Z_*R[F.-N/0CH>@'!!QP!1YD3[YYI`L`P6W_=`!
M[#W/M30%N;Q!<V]Q!"WV`RR!I&C-NN5CSQC'?@Y)Q^%.B\07CVJ2R0VR;CM"
M>0NY\#DC!*[>F""<Y[5G6-FUYMNM7)33GE+N7.(W/H`PY(&>@SQUKIM*M].E
M2::U@W2,N89)P`$&.'90>$'&!U(S18#+U'5-5MK)1!;P2WT[>7#&+<%%..2[
M9PJCC.>?I7-PIJ+^(SJ>J?98KV%%B=8E_P!&EM&PH9)!G#ALY!R<=JZJZMI+
M&9;$7LEZ\8(DFE(&PG!)P,``G_T$#UJ".V2:V^PW-V\)DD9/-0AB&/')Z'D`
MD?[!]:`(5MGRMU$/.MT.USG/EG!RNX`CH>IQ]!6/?Z>UF8A%OD,KAH3Y9DW(
M``3\Q*IQW!4@UV-K&WA.U9)H8W>Y5!=31Y"R.`PW!3TW=V]<5BW=U%)YFFW%
MN\8E)FCN+:-1Y@^89=3UQD9(QR*`$O8XKB0S(S26\VZ126WX;'WN00V2I&[&
M?>NY\&JJ:';A<<6UL./^N$?:N+AT6^BM[X0QQ7=J(C-&\.TH#@]%&#D^_3FN
MW\'H4T2!?[L%N"/3]PGO0Q'1"BE'M14%)E34@S:1=A7,;>2V'`R5..N,'^5>
M71Z9"L]K<R-'MB=#N0DME<,H`SG[Q((.>@^[W]6NMWV.78I9MIPH`.3]"1_.
MN&DT"_:0/%%>1<@D"VB;W/64]?3MS5+8#(MYY`)&.Q0H\T$'[NU\9&>K'.,]
M<?2I/[5N$4PP,&`8`"0\%PP&<MWPRXY[?A5QO#=ZJR*$O?WAVLWV6/=MQ@@D
M2="">1R,T/X8O74@13KD\9M5.!Z8W\CZ]#@]J-`,[^SX=0.^6>&,$K("P67!
MQG<#R%]>W49SD4Z.T:"&-``^`R@A`#\P_NCIZX'?%7H_#.H1I&C/.RH.C6*@
M-TSG:_?GCIDG`%66T35.L4DL>,8S;'KG.?O<^G-%T!C6RR&Y*%8WBDW*X9B4
MVYX')QTYSC&?3I4$M@E]!#N*MA1&"V%#`G!^;!(!/)&>?I70KHVI"0N1)@EO
ME^SM\H)Y`.[./TJ,^'=1,10D9Q@$VS<<^Q]_THN@,J+S;*9@R1GR\2".4C:P
MQ@=2!CKP,`;?:KDVHW5U;QP*4@8_*4BCR-F2"3@_-QSW]>,4^7PSJ\EQ&PEA
M\M#T-DV<<=_J#^8_NU(GAW4P1Y<D4:I]QD@D]3Q@Y7&..AH$5-_VN^N$EF6-
M')1'5&7`;Y1T_#([!CTS6:NFW$4*'9;QQ.WSQ"0;7SPWR@D_W5.<YYY&X@;\
M_A_5YY693;Q!NH$<N#[8QTZCCKGGM5FST34+.59O(M)9`VY2_G+C\A_/CB@#
M!OXY-/FCTJQDE>2#<TS19_>2,1NW#)PO!'L,FJS:-`-XN+]AA95Q'"6"JZ[#
MDY_A&[';<^>_/47&D:U/)<3$VB22G(VQR<$*<<A<GD@^^*I'POJ;O\\ML!DC
M"++@K@@#E?39_P!\"@#"%E/9WKW=I.[\XS$A#1*%W%0"<G)YQZR>M798%O[2
M&\BDC6>();S#?C<,94@GJ"..>I!YXJ_#X>UR(QEKBT+!MPSYPQQ_N=<EC^/L
M,78M-U*.UEBFM-,F,R@2N'F3+!F((Q&1QGCZT`<[#:20O*TC((R`I3S!_$Q&
M3G(&<%L@J,%>!@U9BOKJVTO=%Y@*2^2C+DG#`'(X['<<XSSC-6H_#>I(C`?8
MAG`',Q/4>B`<<=NU2MHNH^3'&5LEV'>75I2?K@Q[>IZ$8H`JW>J-)$T<ELC-
MT5Q$7!&.Y`/)Z^W%4+BR_M*$"<JPF0`B0G@<$'RP0`<].^0>2.*TKCP[?31C
M<MI)+C@OY^TCMG:H([CC^>")(M&OD,#2Q6:B(#(C:4Y(&/XDXQTHN!G3*19O
M"T4J21Q+`,D,2#@<\8].W?I3;.TS8AF+.8@LX+/\P;`4EL`%L],'/W1C%:L=
MA?QEU=;0[LJ`6E^5<87_`)9\D=>:ABL;^.!TF-H96Q\X+X&#D#_5Y'X<>U`(
MS7L;A[NXOHD0Q3NVZ1026YSA_FQU&,`#=U/H9O-ALRJWED9RJDME&'&.0V`?
M0CVY]*LRQ70\I4CM%"8P@FD`Z'Y1E/I5)]/OI;@O/;V)1R6=ENIE//'`(VD9
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M6SE3$+\R;?G60LK,_P#];G[J@\YJPEHS2JTKV:!@-Y%T1U.#C`/\!QGZ^M."
M21P[;@V<P8`M']H!^;')7ICT]L<<4[`5;FPGLY%BQ*80`\$BMDF+Y0",?=^7
M''^R<YJ2WCN(]/17B>"2>8NNT`D*<!CA<#((QP!TZ"M%YK*XAM8T46LD$7E(
MXN8RFWH!NW;LC\:HH9IN#=6S2+EM[7:';D]1@]>2<^YH%<T+C6;AYH_/5I(;
MN)3M`)`Y.<8[95L<X/'7-9\DD4T<\MK#]G*9`S+GUV]>N,=QQCFII@%O(8[6
M.W584"PN;I#MY.1G=G.,XX/!J*6&4W$+1K*Z1NN$6ZC1<#'(&[GC`P>VWTY8
M7*<:)<"U@N(99+>*VA\M50DNJQ8V\#INW?\`?1K2CCM=/T2YFBTS>TUR%>".
M1HF=P(PD>XGY<E_PRW>I;:1"RR!9/M,4I5(8IP)-O#$$`A<'.<`Y_7$]HES!
M]H5]/FN8;HXE4LF77'WB0W![\=^](9D7UK=V,,4UQ`\EM)$-RHK.2-R_NR<$
M@J!C)YX!/-4];::71[J-8\7=Y&;>V@&=Q:08&>^=S],?PDUT\UM*TK2>3>`2
M98[`J.>>C$-@CG[W6BQCN[2\:YCTU)&56VI)R4;L^[<3D^IY^;TI`5M3FFCU
MRX:"X(FP)T"KA21E&8D'IA`2?3-;>F^*[B:\@MKI([?#LDHF!5EVY!R<XS]W
M&,YS5&/3KF2TMI#9S'44C6(RL0R?(Q8M@'YMV]A@BF-87GDBW-C>2R(I43K&
MHR,G:"">!R>>#18=SK5\0Z>P_P!9)N\T0E/*;<K$`C(QQP1S[UJ*V1G!KS_[
M/JX@\N2&Y=B^]V2+:`HYP.Y;=M.<<[>35Z:[UTS3+##?"(9*;@&8D`84]@#S
M_2E8+G9YQ1FN);5?$"`_\2^YRH.[:S=<D8'R^V?QIQU?71DBQO-H&3SS_P"@
M4<K#F1VF:3-<8=9U=<_Z/?[<#!"KC/?K'3&US5T.3;ZELV;P5$9S[?ZKBCE8
M7.WS0#Q7$MX@O%4$MJ7.,X2+CDC_`)Y^V?QH;Q'=IG<;\@8PP2/D'/;9[46&
M=MFC-<*OB>[+#<VH+D`X,<6`3V^Y3T\3W;3%/]-50N2Y1,=5&!A.OS9[=#1R
ML5T=ON'O^55)-3LHBRO=0JZG:5+C.?3'K[5QX\2WOG()+R<1,,N5@7Y",Y4'
M;SVY]C67)//,\LC3*'60S$S*1N))Z`=",<<`\\T6!NQT^I^+H[&ZN8%B!,:!
MU8DG*E5(8#'(Y(ZYR#7,IJEQJ6M6=Q>#8'F)"E3E%0H22".""R<?[)%12S)N
M65(K;[3E5\V.&3`*G(()^;(QCC&.V:FBEMHHGN3L-[&L@BB"L8SDJT8SC)"E
M3NSR<G-%@N<L;NXAM;FZDMS<"SN9XKVVV98*92V[&#T.TY(_B%:6CW<-K%)8
MZ8CSP;IIY'4!#,0V0&`Z!1R`,`UKW%Q87ER;JS06L\_-SO;#2OC&X*,KTZYQ
MGO44%U;V$JLMW;QMN`W+"L8=>ZN5'3V'6F(OF]MM3T>6]M[R:>:U8*'^SB-]
MC,59"A''*G(QQMS68+F,7>V:1I4DAD1I&Z^400^1ZY88^AIVHW<:6OV>&2(I
M).9[FX?"B4EBPR/[N6/`!Z]*<\]K)#?7]L(YHHE5<VR`&W1OX7.0,]2>2.#G
M!`%`Q-'M#>6\,C3PVX.W"2#Y<]UQV&,>E=#%+HEG-<3QVIEEBC\YW=MQ)&`.
M/4[B/PYKA+'5[`W#!+FRG&1\L+R;@`>"-YY/&>/]H<8K4@O[*X6[C6]C5F50
M55L[F!.,9/?M].1CF@1/KFM75W:>6P;#7&-B$*&P`HP""3]X=.?PJO87EV8U
ML;!TCEEE/DR%,DY^4L/<JK$YYZ<BFKJ^GJX#3VD^<.Z2/ABPSUVCN#VZ_+P#
MTV+"XLK;2[UA=V-K.(MD+AE&"1M!7JW3`R:`,;5-:BAA6"Q@EE2V3RC*2=TJ
MDX;9W#R$!>,D<>M8@%W9.DD\<ZI;9=Y@<>8L3$\$=/,+%N^2H.:UQ>6-H\$E
MG<PW,Q/[MWE`5"2I"@=`,[1GKSGM2OKJJ)%>_D4-A"V[(;</E(!XX4],8)'X
MT`6+35([R)K/<J7\F&69``HF*X!"]MQ&PC/;VJC=Z@U[%&6B%N8=P<(65ES@
MMURN<*W&"/E.,4K2Z?<(9(KR"SN6<R1@MD.1@YR!G"@>F>/]HUK:E]E=[344
MN=-NF9%>5U<J5<#)(VX(^;)P>.30!!I&M7.EZ3;SO.[0JQB,.0R%%8'(P2",
M$C.>HK:GGTN>YN=]JEO.C%#(K'&WAL<<8.?2N1FN[-X5MD>VCMPK*(E;"JW.
M"2<'.23R3DXJU<WD-QJ2QP7ULYC14GD60[6PN3C`)(XQG:*=@+-Q'%$DODW/
MVI0I^41%>&#C+`YSVQQC('UK(L+0+KS.JLT[%M\CJS,R$8*#.!MSC(;)&.#B
MIK;4K*:_@W7%K'#(Z*6FN')Y/`V@XYR..G)SC%7(-2L;N)V>XMU52NYE(7/3
M&=I''/KV.:0$-W"UM8,RN[&8QL$8@*JAP5P``-Q9<DG/0<@=71Q-'>M<I-*S
MRJTT:JAD$$JC_EF&R>O(^;H*DNKC27M%G>^2,*X1PS!2`1E3P3Q^?6E>>P$4
M"-?6C`YW!)6`SG`R0.OX4`<_IR)!JQG`$4;G=)&F6B8YY958`YX'S<]\8KK;
M6W1G@DGO(4"KG9G+X7L/0Y!XY[UF/?Z0T\D<C6$4OEDEQ($P1TSM/?IT/X51
MM[ZU+AH[RQ'5C+%<,02`!C#'@G<>PP,>I``.DDU;2-.AN+C3M/47(^19)3G:
M[9.%'?H3GW%8FL:E=7,EMY]SOPK,!N0XW;B<J!N`XP>5'YT1K9S61\J[@81S
MLP17&5Z`D?3:/7K3A>V4S"$V]G=`#:&,I7J0P'RGV'![JWX@"V=T;RX2S"QV
ML4$3&ZE7.]8UY=-V>H+@9[D'.<T[6M76_N'AM&EM5E4QK)_&H`!"(!_#M#'W
M;`]JTC8QV?A[9]MM+5[B7,B[E4M$,GD<GDDMC/4CGBLE9;2UVQ64\3L&4-<2
MR!B_15P#T&,DGC'/7(P`9EE<S:<R_*54[4$;I\LAFR^PC@X0;HO8E#QC%=4V
MII/8_:;56(M(P+A9CN$L62%)92/ND=>^?P&0^J,5`GOK6:(;2WF$$Y.W)&>@
M)*`D$<AO2KFAQ65OJL$T%W!'`%2*XM)B!MC(("D\@_>Z>J&@"CJ%^UU>K>K%
MY:DK(/+.[801]WH225;Y5.3C@5U-OK3W=\^GZA#'-"Z%QN4D9*D@9[$J6XR2
M*RM5L+:RNI$EL8#$\I*RK(55F+!@<!CQRW'UXYJ*VDBEU&.XRC!9-\BH0NQ`
M`1T^Z,$<#@@=>U.P%TP:5>6/FVLK6?W3)%<JW#''`)&0>V<9K.OHF2!EA=3*
MA)CDB`RAY!*DCY3COT'<'-0QPPW%M(RODR$/"(3MW'.TJ#C`)!X)SVY%&GSH
MMW(DD\#1PH0L4DJOR2HW8`R?O`\GH5[YP6$4=(M-FFWMOY&0-K;CE\NQPP*C
M`'?@97OSFK,K>1<QVDDC`(A1I%RI1L88JR@!>@`_W.V:TY+JT80/%]F20`<H
M0689&..O8'MVJMJ%E8M>B2.[A4-M9%.-RC=T!S][TQGIR:+!<S/LDL.E3>82
M\DD@MY,J%#(0=P9E7C.#R`"?4YY;I<4MJC;]P5,B)68;X\X/RE<8!!Y&,\9)
MK:9[%;YUCN;:1W(5%CD&",<`;L'L#U)P!52]FL)(A);"TAF5AE6G+!@<97G=
MDY&#T!R.])C-*+3;9?,GU"XMTB8%6%LZLV.^<9]NN,5,=1TZQM4CTVS'FS[X
MQ<S`.Y53@D@#`SV/'2L&WD#6C7$)@C,A7):;=O7!S@X88)8=QTI9%@:*SG,H
M:-85\LJX`Y.2,>YX'7O30AFH7ES>:S/)/ODE4B(,HX"J<`8!R`7Z'(!YZUJV
M6J_;KJ2\FAMX+&-D=T126F9F(13D].0<<=*H,MK?W3(MG#-<,Q&8KEU5L#'W
M48`G!)#=?FSVK5U72UMK6TLEE@M%\H321IM!+YR"/[S!4P#ZL>>>"XS"U[73
M<SR+`'2(!9&`^=K@-C)8>H9DXY`^;TJKI-^;5_)E4RVKDQ/CAU\H8,JX[LX!
M'KO/-:J3V]L$%@B*""&EDP2S$L>^>>9#GL0V,9J-KB&[61=21'RFPF+:&0<;
M1QCMTSGD].!A@:=YJR^=%=B-I+6<[9%(V[9<*2>IQNR?Q%<[J5[=.XDN-\T6
M0H5D^ZH).T`;3@8P6&/NC).<5T>A6@>>XMQ<6=S:78=U1VSY<@`9,J>X'''8
MGGBJSPV]A?#S[9$DC'RHTOR=`.!USD9QG![T"($O9(;$S(UP)#$<,"^['S?-
M\WS<KD?@*]!\)@II"*<$A(AQ_P!<8Z\Y==]O,C3^;!M8"620'R@5R.">>`%&
M..0,=37H?A)MVD\8R/*_]$QU+&=$O-%"\44@!:=CVIJTZD4&***,4`&/:BEH
MH`3'M1CVI:*`$Q[48]J6B@!,>U&*6B@!,>U&/:EHH`3'M12T4`)1CVI:*`$Q
M[44M%`"8HI:*`$Q1MI:*`&[1Z4N.<XI:*`&X'<4;!UP*7%+0`T*N,``4TH#G
M(!SZT_%&*`&%`1C:/RI##&PPT:G_`("*DQ1B@1"UM`0?W4?/7*#FD^QVV[<;
M>')[^6/\*GQ1B@9#]CM?^?>'_O@4GV&TQ_QZP?\`?L58HH`K_8+3.3:P9X/^
MK'^%'V&T_P"?6#_OV/\`"K%%`%?[%:Y)^RP9/4^6/\*/L5KC'V6'_OV*L44`
M5O[/M,@_98./2,4G]G6><_9(<]/]6*M44`5/[,L?^?2+_OFFMI5BV,VL?X#%
M7:*`,XZ)II.39QY_&@:+IX.1:J#_`+S?XUHT4`9PT6P'2V`^CL/ZTTZ#IS'F
MW/'3$CC^M:=%`&9_8.G#GR&_[^O_`(TC:!IS`@P-@]?WK_\`Q5:E%`&9_86G
MGK`Q/KYK_P#Q5+_86GXP(7'_`&V?_&M*B@#-&AV(SB.09&#B9_\`&C^P['.2
MDQ(X_P!>_P#C6E10!FC1+(,6`FR>O[Y_\:?_`&5;@8!G&.?]>W^-7Z*`,\:3
M;@DAIQGMY[X'ZTCZ/:OC<)3@8R9FZ?G["M&B@"@-*MQGF3G_`&Z7^S81T:3Z
M[^:NXHQ0!1_LN`'(,@/KOI&TN$MNS)G.<[^]7\48H%8H_P!F1<_/,,_[=+_9
MD//SR\]?GZU=Q1B@91?3(9/OO*WU?-,_L>W!R#(,=,,/\*T<48HNP,\Z3"RX
M:29OJP/]*:=&MB<YD!QCJ/\`"M+%&*`,\:1`"S;Y=S9R=PYSZ\5$VDK]H3;G
MRL'>Q89SV`XK5Q1BBX&<=&MB<DN3ZDK]/3TI/[&MN<&3GKRO/Z5I8HP:`L9W
M]CVX4*&D`'0`KQ^E-.B6Q7;NDP.@^7_"M/%&*+L#+.AVY/\`K)1_WS_A2'0H
M.3YLN3U/R?\`Q-:N*,47`R1H-N.DLG_?*?\`Q--_X1^#!!ED.>#\B<C_`+YK
M8Q1B@5C(&@P@<7$P[\+'_P#$TT^'("V3<RD_]<X>/_'*V<48H&8?_",V^"/M
M,N#V,4/_`,12?\(O;<?Z3+QT_<P?_&_85NXHQ0!A-X7MV`!NY>/^F,'_`,;I
MI\*VW:X;KGFW@Z_]^ZW\48H`Q/\`A&X^";R4%<X(@AXSU_Y9TW_A&82,->3-
MQQF&'_XW6[BC%`&(?#5N>3=3$^\</_Q%,?PO`Z!3<R[1V\J'_P"(K>P:,&@+
M(Y\^%;8C!N)<=<>3#U]?N4@\)6HR3=2DGOY$'_QNNAQ1B@#GE\)6R8(NY1WP
M+>#_`.-^](?"-KS_`*2^3_T[P?\`QNNBQ1B@#FSX/MF!#7+$'_IVM_\`XBC_
M`(1"V&<74G/7_1X.?_(==)BDQ1=B9S:^$+8$'[5)D#`_T>#C_P`AT?\`")V^
M0?M4NX<`^1!_\;KI#2`<4U(1S?\`PB-N$*_:Y"N,;?(@_P#C=:VEZ>NG0R1K
M+++YC[RTFW/0``!0`!@#M5_'O0!1<8#I12T4@&K3J0$8I:!A2TE%`"T4@I:`
M"BBC-`!1110`4444`%%%%`!111F@`HHR/6C(H`**,CUI,CU%`"T49'K1D>M`
M!11D>M&1ZT`%%&129'J*`%HHS1D>M`!11D>M&1ZT`%%&1ZT9'K0`449'K1D>
MM`!11D>M&1ZT`%%&1ZTF1ZB@!:***`"BBB@`HI**`%HI**`%HI/QHH`6BDX]
M:./6@!:*3CUHX]:`%HI./6B@!:*2CCUH`6BDX]:./6@!:*3(]:.*`%H-)10`
MM%)1QZT`%+2<>M&1ZT`+12?C10`M%)QZT4`+1244`+124?C0`M%)QZT4`+12
M44`+1244`+1244`+1244`+12<>M%`"T4E%`"T4E%`"T4E%`"T8I**`"BBB@0
M44E+0,****`*SR%`<`4P3L>H%%%`"BX?'1?RI1</@=/RHHH`D65BH/&32-,P
M8<"BB@!3*V.U"R,<]***`)%8FG'I110`FXTTN<]!110`QI6"D\5%]H?T7\J*
M*`%\]O1:A>\D4<*OZ_XT44`1G4)1_"GZ_P"-']HS?W4_7_&BB@!G]IS?W4_7
M_&E.I3#'RIS]?\:**`%&I3$?=3\C_C0=2F`^ZGY'_&BB@!O]J38SLC_7_&F'
M5Y\_<B_(_P"-%%`$?]M7.?N1?D?\:236KA2<)%^1_P`:**`$;6[D'&R+_P`>
M_P`:6/6KENJ1?D?\:**`)/[7G_N1_D?\:4:M/_<C_(_XT44`!U:?^Y'^1_QI
M/[7G_N1_D?\`&BB@!1JT_P#<C_(_XTG]KS_W(_R/^-%%`"-K%P/X(OR/^--.
MM7`_@B_(_P"-%%`"'6[D`G9%^1_QIG]NW7_/.'\C_C110`HURZ(^Y%_WR?\`
M&D_MNZ_NQ?\`?)_QHHH`8^NW8/"Q?]\__7IIUV\!P/+'_`:**`(O^$@OMQYC
M_P"^:5=?O2?^6?\`WS1109H>==O/^F?_`'S3O[=O/^F?_?-%%`V1C7KTD\Q_
M]\TO]O7H[Q_]\T44"$_MV]]4_P"^:/[=O?5/^^:**`#^W;WU3_OFF_V_?9ZQ
M_P#?-%%`"C7[[UC_`.^:4Z]>XZQ_]\T44`-_MV^_OI_WS2#7+XG[ZC_@(HHH
M`4ZS?'_EMCZ**0ZO?$_Z\CZ****`#^U;[_GY;\A_A2'5KX'_`(^&_P"^1_A1
M10`G]K7W_/P?^^1_A1_:M]_S\-_WR/\`"BB@0?VK?'C[0W_?(_PH.J7X'_'T
M_P"0_P`***!@NJWY/-T_Y#_"G?VG??\`/T_Y#_"BB@0'4;X#/VJ3\A_A3#JM
M\/\`EY;_`+Y7_"BB@8JZI?$?\?+_`)#_``I?[4OO^?EO^^1_A110(/[4OO\`
MGY;_`+Y'^%-.K7P/_'P?^^1_A110,7^U;['_`!\M_P!\C_"A-4OB3_I+?D/\
M***`'G4[[_GZ?\A_A3?[2OO^?I_R'^%%%``-1O?^?F3\Z4WUX#_Q]2_G110*
MXT7MX6_X^YO^^J5KV\Q_Q]2_]]444#&_;KS_`)^I?^^J?]MN\9^U3?\`?5%%
M`"?;KS_GZE_[ZH^WWG_/U+^=%%`""^O&ZW4O_?5*+V[/_+U+_P!]444`!O;L
M'_CZE_[ZH^V71_Y>IO\`OJBB@!K7%QCFXF/_``,TGG3%>9Y?^^S110`P3S$9
M,TG_`'V:<"[<F20_5C110`$'/WW_`#HV?[;_`/?5%%`"B/\`VW_[ZH\H'^)_
G^^J**``QCGYF_P"^J!&,?>?_`+ZHHH`L6<8%PARQ^8=31110!__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex4-1x2x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-1x2x1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#`!`+#`X,"A`.#0X2$1`3&"@:&!86
M&#$C)1TH.C,]/#DS.#=`2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!#`1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P``1"`0@`RX#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#MLO\`WF_.
ME^;/WF_.K&!Z"C`]*";%?Y_[S?G1\W]YOSJQ@48'I0%B#YO[S?G1AO[S?G4^
M!Z48H"Q!\_\`>;\Z,/\`WF_.I\48H'8@P_\`>;\Z7#_WF_.IJ*`L08?^\WYT
MN'/=OSJ;%%`6(</ZM^=&&]6_.IJ*`L18;U:@!_5JEHH"Q%M?U-&U_5OSJ6B@
M+$6U_4_G1A_4_G4M%`6(]K>I_.C:WJ?SJ2C%`6(\-ZG\Z-K>I_.I**`L,VMZ
MG\Z-K>I_.GT4!89M;U/YT;6]3^=/HH"PS:W]XTNUO4_G3J*`L,VMZ_K1M;U_
M6GT4!8;M;U_6C:?4_G3Z2@+#=I]3^=&T^IIU+0%AFT^IHVGU-/I*`L-VGU-+
MM/J:6B@+";?<T;?<TM%`6$V^YHV^YIU)0%A-ON:,>Y_.EI:`L-Q[G\Z,>Y_.
MG4E`Q,>Y_.C'N?SI:*`#'N?SHQ[FBB@`Q[G\Z,>YHHH`,?6C%%%`!BBBB@`Q
M1BBB@`Q1110`44M%`"44M%`"4M%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!2'H:6D/2@#
M,6>0Y^=OSJS:NS2$,Q/'<U17J?K5RR_UA_W:"47:***"@HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`***2@!:*2EH`***2@!:**2@!:*2B@!:**2
M@!:*2EH`**2B@!:*2B@!:*0$'H:*`%HI**`%HI**`%HICR*KHI<!GR%!/7O3
MCTH`6BF1NLB!E.0:=0`M%12S+%U))R!@#)Y..@J2@!:*3(]>M!8+]X@?4T`+
M13&D1<[G48Y.34+7D8G\K(.%W,VX84=J`+-%0FXA!P9H\XSC<.GK1]IAW*OG
M1[F^Z-PYH`FHJN;RV4$FXC`!P?F'!IR74,DK1I(K,!D@&@":BJAU&U5-YE&,
M[1P>N,^GM3)-03SK>.([_-(R<'`!!(.>F>!Q0!>HJC-JMK`S*[R`J<']TQY]
M.E-.I)&KRR-F$!61E4YP03S^5`&A15$7^^0`*X7<5`*Y+X7=QZ?C33J]N$5A
MO8$`C`Z\9H`T**9&X=`PZ$9&:?0`4444`%%%%`!1110`4444`%%%%`!1110`
M4AI:0]*`,@?>/UJW9?ZT_P"[50??;ZU;L_\`6G_=H)1=HHHH*"BBB@`HHHH`
M****`"BBB@`HHHH`****`$HS[53U1";22197C,:,1M<KSCOBL^[N38R1S139
M4PLY61RP."O3GZT`;E&>:R[2^GN9)XSY0=0<(,[E/;/UZU5M6A2U1U02:K&I
M)5O]86P<Y]O_`*U`&]2UB_:[QYECCFS$3@2^5R>"2/3@@?G3;6XO)K9':>5E
M<*6=8P"GL!CG]:`-RF/(J#+,`,@9)QUZ5CH;]C(\DUS\B_*HC`#<D9/'I@U(
MHN,(Q$V_"C.#V?G]*=@-8'CIBC-97EW9W9,P;YM_S<'GY=O^?K4_EW#6DZ+Y
M@=')BRV,@<@9].W-("XTBH,MQD@?B:8ES%)((T8%B"0/8'!_6L^*"]"EI"^[
M<NU1(3@%@3G)[=/PJ6W@F6[5VB95`E!)(_B<$=_2@"VEQ')(R(22IP>.,^F:
ME)Q6*VG2B&8)``7ED.,@95@<?J13UTW=O::W5G:12=Q!RN`"/S%`&H)E+%3D
M$#))!Q^?2FQ7,<KR*I.8VVL"".<`_CUK+;3YF#CRU^:-$ZC@J3ZC!J>.SD6[
M$YCB#^;NWC[VW9C'3U[4`7C/$#@R)G_>J";48((B[YR`Q"#&Y@IY(Y_&H)M/
M9[LR*ZK%D-M`QR>&S]0*9-83R[_]4I/F`#D\-CV]J`-#[3`$W&:,+G&=PQFD
M>[@C!,DJ+C.<L,\#)JN]I,TAD#(&SP",C!`!J(Z5_"9OW6#P5^;E-O)S^-`%
MYKF%%5FD10WW<G&:C6^A.X2.L;*6!5F&>#C/\OSILEO(S0OYJJ\8()V<$'VS
M["HYK"24@K.48%R"J\C=^/M0!8^VV_'[U>02.?3K2?;[8$`R@$G:`<CFJ_V)
MH;=EB(;Y'`7;C[QS4<=N4EC>:80ODJN<!G!['D\^XH`NO=Q1R^6^X$+N)VG'
M7%!O(!$TA?"J<'@Y!],=<TRXM!<2*QD=,*00N.><@].Q&::]G&('5I&5F;S&
ME&`P8=^F.U`#S?VXVY?&Y=P.TX/&?3V-0S7^R5#L80X;?NC8$8&<_2F_V?!<
ME)O.E=2JG.X8;KSP.X)Z4^2TBV(DLLQW90%FR3D8_E0!+/>I"T:['=I`2NT?
MXU'%J(:.)V@D4.JLQX(3/3//\JE>UAD*%PS>7C&6/;H:%LX$*E5(V@`#<>@Z
M4`5YKXJ(G*-&I?&&`^<%21CTZ4CW[6TCF:-S'P>,$KP3CWZ4^:VLX$4/&Q#-
MA1EF).#Q],9XZ5)Y%K#'O<;409RQ.``/?VH`@:_)N(EP4`.YP.0RE&([>HI#
M>2QRDLH;<J%$#<#.[OCVJU'!:@CRT3(^88Z]/\*KM'IB+M,%OY+Y#':NP8YP
M:`)X)Y)2W[M5"@?Q9.<9]*K0WS768WC,3,O&&.1C.[G`Z''YU;+VEMB0F&+S
M,#<<+N]/K2K+:R.ZK)$S)]X`@E<^M`%"*_DVQPGRPQ5?WA8D#*D\_E3YK^06
MEO,%2(R'Y@X)VCV`QFK(FLU4,&C56PH.,?Y[4P7\#2($D1E);+;ONX_GTH`C
MM;J66?#A0&W\8(,>TX&?KU[5`;R\'E$/;X<MSL8`;3TX)Y/]*T%N8&*@-DDX
MQ@\'W].HID]VL3,FURR[,_*<88XH`I/>7!*E6`8[B8]G*@,!_(YJ7[1,9D56
M`7<<DH3N&[V'I4K7=F9HY&D_>$,J9SZ\C'U'Z4HU*T+1CS<&3[FY",Y_"@"N
MD\S3'+.%4]0H*G(/H,]1T_G2K+/)9L7\T,LBY(7JN1G''(QGM4ESJ"QPAH5+
M.VW;E2`02!G]:E:Y$(B6<X=R!E0<9)Q_6@"A#]HA2?R?,`:60X:/I\P.1QUQ
MGZU8:6=+)2TC[_-5=_E!25+`=#['TJ0ZA#NVX<')`RN-QSC`_&FF;S+(O/#O
M*R[=H'3#X!Y/XT`5P;[=\[28_P"69"=?F/WN./EQZ4^..]%[EB_E9*9W<8SN
M#8_\=I\&HG$OG(V5D=%V#KAL`=>O(JQ]J`A$IBD4D[0C#!SG%`&:L5TQC#/=
M@-*/,&2,<'.#G..G3BK5H9('=765E>3`9B3CKUR?IR/:E74XR<"*48)!R`,8
M8*>_O0U[YDOE1EHV1QDX!##=M(H`@NH+AKS=%%+O!)67?\H!0@<9ZY/I2I%.
M%B"PS*!)NQ(ZD@=^AX]>,T+/-,B['E4*9"S#;N)4XQC&,5,U^51V6-2D8&YF
MD`.2N1_,4`4'$B""*:.4E2S%05+8W9&#GN.._%3"SG5<)#UW;MS`Y^<$?IFG
MM?3RVTC"((520D"3#`KZ'']*FEOIE=_+BC95)4DO@@[<\C'2F!2CTRZ5,E(R
M^U5SNY&U\CG'IBGS:5-+'MS&2-V6)/[S+`C=QVQ4[:A,B9>-%*L`Q!)`!`/I
MGO4FJ3@:7)-%+C#+\R-_M#(R/Q%(0Q;.6)XV41J(W=@!TP3G&,?3Z4Z<23BR
M:6W4R!R63&X+\I'7%1R7SQEE1X@P,A.XD]!GUJ,WS37'EYA,B.54@GG*$CC/
M//%`Q5TET4A3$<;,%@3G`P0:F;3Y'CV?N5"A<`*=N0<XQZ=JA7497RD;JX\O
M(=4/7:3Z^HI\<[!Y-CJ-VW=((R3T/)&?4#\Z`%DTMI%8;XU)5<83@%23T].:
M>VG2MLS-&,;=P6+`R&SQSQ^M,6ZO/-&Y<+M7@1'J0?\``?G2P3W;:>YD\SS@
M<;BF#CN0,<\9[>U`#O[-D,:J;A#Y9PF8@<+C&#ZGWIUOIQAN6F\XG*[<!=OX
MG'!/'I44'VQ[E5>>81*20QB`W@;<`\>[>G2FS"\,MP4N;A5W@*!&,*I'4<9/
M-,"5=+52"9Y"00>@&2,C)XZ\TL=A%;F(><X`*X4D89@N`>G7`_2H9$NW)5C*
MZ^4`2/D)/'8<<\]Z:L=]N>023Y\_"*V,!,<'IZT`6YK1"6D:9T^<29!`VD#'
MIZ>M,>PAN8P3+(RL!@AASP><X]S42Q3D1L8[C()R"XX.TC(Y]:2&&]\N(2B7
M>$3)$G''W@1GD_\`UJ!%I+&-)%</)E#D#/&<8_E22:;;LBJ`R;7+@HQ4@GKR
M*I-;7W\(F*@*0K29!.#G/S9';I5N_MYI?]7O)\M@I5MNQNS4ADMN(TGE59'8
MY'!R0N!V-6JI6%L;?S=R$,SY+9^]P.>*NT`%%%%`!1110`4444`%%%%`!111
M0`4444`%)2TE`&1_&WUJW9_ZT_[M5/\`EHWUJW9?ZT_[M,E%VBBBD4%%%%`!
M1110`4444`%%%%`!1110`R21(EW2,JKZL<"HUNX'V;98VW_=PV<U'?+*UNX1
M<_=('4D@BH38R%@PE4?-O(V'&=V>.?YYH`DFOK8QG;)%)@%L;ACCWZ4EQ=V\
M"L`8BR#A2=HZC//XU&]DWD+"TZ@E&CR4Z@^@S2RV#RPR0_:,129PH3IDY/-`
M$QO;97*F4!N<CZ=?QJ.;48E0F,CINW,IVCG'/%0_8))V<RNR!9&,9`'<8S_/
MCWIDMA!\MHUX4,@8!`J@L"=W''L:`+C7ML-\;.01G(VD=.N#BELA"MNJ6ZNL
M:$KAP<C\^:KW6G,ZN\<I,GS%0<`<@`]O:EL;2YA\LS3MM3.(P0>#ZD`4`/?4
MX$)RLA`)"L%R'(Z@>XY_*H)]7X=(X9594<N2%RA4#MGGKZU-/IZF.4Q<NV2B
MLQ"JQZD<<=33O[/@=<R1Y=@0Y#GG(P>>,]*`(Y-6CB5F\F1D7*[QC!;&=O7_
M`.M0-5!C9FMW0H1D$CIC.>/:IS8VYR"A(/&"QQTQGZX[U'-:V<2#?%D2,J]2
M<D\"@!+>Y=;>ZDE/F>5*X4<#@=!3H[V5[D0&W`()#-OX'`/''/6E@^RF.2,*
M%1W92K'[YZ'&>M.1+.)2Z>4HBZMD?+ZY-`$=S?O$9`D(8(P4DM@Y/MCD57@O
M9@T<K@/YD,;.H8\$YS@8^E6&>QEF>5_*)C4'SMR\#)[]13(I=--PL<:6X)4&
M-U"X/)X'XB@")-2G=H4\J,-(^T$N#@8SV^E.U"_FMIV6,1X$1?YAG)&>.#QT
M]/7FK,,]F3&$"`L<J-N.?\BI;B!;B%XSD!UVY'!`H`SFOKK"@26H).1(00C<
M`[1R>:<;IW0N[H/WBYB92&C^<#G\.:THHQ&BIDD*`,FGX'I0!C17<L\C+*4*
M*RE3MQ@A\']*FOY)0TR!U*"$L$*`Y/IS^'%:>!Z48XH`R)IG>::$-B()]W`P
MV4R`.^<T&2Y-WC=+Y<;'!"9R"F1G`YYS6B+:,2F39\Q.>IQGUQ4U`%#S+G[`
M[!6\X'TSD9&2.!VSVJ"))7U&)Y0Y1-^TLAZ<8SQUZ_E6M10!E2_:?M<Y#3[`
M,*B)P1MZY^OXT1><&A61+E@N<,I('7^+)R01ZYK5P/2B@#,LXYHF9%\U5,"X
MWY(#\@XS^%-ACG\F+=;S"177?N<'<<')'/`_+Z5JT4`8\<-WY2K]G<$.K_,5
M8=!G/.?QZU82VF>&[C!,1DR$;C(Z\\=OUK0P/2CMB@#+2RD,L3^7&BHRDH3D
M9`(+#CJ<C\J=?6#W,K%2@#1;,MSZ^W'7KFM+`]*,#TH`S7L7D7:VQ3UW`Y(^
M7;CITI9+2>2-#B!)%??\H."<8Y]?_K5HT4`5;B"27:5**P4JP89&#C_"E@MS
M"DJY'S-E3CD<8YJS1B@#-BTR1`H,R84]"A8`<=,DXZ4Y],,L4<4DP**7)PF"
M=V??WK0I:`*7V#)C+2G<ASE5"_ECI[U)+9K))O\`,=2=N0,8.TY'459HH`I)
MIR(25EE!;.[!'.23SQ[FE33TC6-5ED"HFS&1\P]^/Y8JY10!3;3HFB6,N^U,
M!.GR@$'`XZ<#\J?/91SRI(Y8,G0J<>A_H*LT4`4SIT!SDN>I'/0EMV1[YIRV
M$*V[P_.5<[B2YSG.<Y^M6J*`*@TZW",N'(8L3ESU/6GBSA%OY&TF/W8YSZYS
MG/O5BB@#/M--CBC*S!9,.S+UX!.<<]>E3BQMPY?REW$Y)_'/\ZL8I:`*ZV=N
MO2)._;UZ_G2_8[?.?(B)QMR4'3T^E3T4`0BU@`P(8\>FT4I@CW;MB9QC.T=*
MEHH`B^SQ9SL3/^Z*%@C5-H4;<DX//).:EHH`8(U'10/H*7;3J*`&[:-M.HH`
M;MI<4M%`#=M+BEHH`2BEHH`2BEHH`2EHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"DI:0]*`,@#YV^IJW9?ZP_[M5#_K&]B:MV7^L/\`NT$HNT44
M4%!1110`4444`%%%%`#%?<S+W4T^D``)..32T`%%%%`%>^9TM)&C.&`X/^0:
MSXKFZ\Q0_FG<%*@Q<=P<D#CL:V**`,"=YYI+>0"Y)20Y)@Y0[3G''(SCM^-7
M)YI?L]K(7FCWG]XJ1Y8_*>Q![BM.HY(4D92ZABIRN>QH`R`-2=)@[S"10GW4
M7'.-V.F3QZTCVUT?-;-P9FC0;P0,X)S@`XS@^M;8I:`,0V=V=^9+HX10N90"
M>3NZ'KBG_8YP\93[1\FW!>?.,'G/.#Q6Q10!C&QN#&`5(;(\W][_`*SKR...
MN:FM+2>&^,K;=A7!RVXYXZ'CCCO6G10!B+IDYF9I%B*%@<9ZX?=_=]/6IOL,
MP";4APK`C)/RX?=QQ_A6K10!F'3Y/,5B8VS&%?/!#`Y+#\S3WLC)IT]MMC1I
M-W0<<GO6A10!DW-E,I,D2J6V(NU1T*MG/:GP6<Q9)&*1D*JE<9Z,3G.?>M.B
M@#+33IA-'(;E<Q@A=L94XYP#SR/K^E:2`A`"<D=33J*`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***2@!:*2DX&:`'44
ME+0`44E&:`%HI**`%HHI*`%HI*,B@!:*2B@!:*3(HS0`M%)FC(H`6BFE@!DD
M`>]+D4`+129IID0.$+J&(R`3R:`'T4F>:,@4`+13$ECD!*.K!25.#G!'44-*
MB,JLP!8[0#W/6@!]%)D>M&:`%HI,T9%`"T4F0:6@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`I#T-+2'H:`,@_ZU_J:MV7^L/^[55O\`6O\`4U:LO]:?]VF2
MB[1112*"BBB@`HHHH`****`"BBB@`HHHH`****`"BHY2X3,:AF]"<"L^'49F
MACFD@`B=ROR$N>"1TQ[4`:E%5%U*U>X2%9,NXRO'MG^513WDL=X5"?ND`+';
MDMG(`'/'..HH`T**S)KV9GS"51=CDK(AW*RD>_H:FFU!(`Q>.3:N[Y@!@XZ]
M_K^5`%VBJ#WZL)%17#)G+#:<``'/7WI'U)%DD4Q2`1EANXP2!GUH`T**J07?
MFV\LOELHC+#DC!QW!]*HG5'DD62-3MC#;XP1AL*#D''_`-:@#8HK)@OY4CDD
M9#(C2,4)/(XW`$8Z8J9KRX8R*D"%D^4YD_BQG`XS0!H45F/?%HHI]FU<M@EB
M,$(2<@#GD$57>_GG@<$Q`*'#+S\V%!'(.1U_2@#<HK'FOYXTW1&+&,;&!R/E
MSNZ]/\YI_P!LG0D/)&Y$H&47JI`/`S0!JTTL!UJ!Y#-:R&UD4N`0K=0&%9ES
M/-<VDK898QM==Z#D$C;^6#^E`&V*6LDW,ZL$,C$!V`8)G=R,#@?X5-932LX\
MQW;<&/S*!C#8'0>E`&A2&LJ>>X6=T0S87=DB,D<@$<X^O2DB>]:>/_6JNWY5
M9"V3SG+<8_$4`:23QO(\:NI>/&]0<E<],TY'6094@CU%4--1EGN'*3*KJG,N
M221G/6H=ERTT+`7("<D;B,_..HSS\M`&K)(L:EF(``S2J0PR*H:C;232P/&A
M8('#8.,97`]*KK97*[T_?"(D<"0%L[<9!)..:`-9G"LH(/S'`P,T[-4KZ&:5
M+<1J25?+8;MM(]NY%5ULIA:+&(\-L3.2""P!SGU_G0!JYIJR!MW!&#CD8K,-
MA(PP\$1?S=Q<-G<-P.,8].*9+9`,T1BA/FRL4!Z*-N/3CI0!IK<([%48,5;:
MV#T.,TUKRW6,NTT04'!)<8!],U4_L^4*5!3!<MN!P<%-OIU[T"PES$S>6'0*
M"`3@X##/3WH`O//'''YDCJJ<?,>E,^VV_F)'YT>]QE5#9)%,:W<Q0;=N^$@X
M/0\8/\Z@BTUX90Z.G09&.^_=Q[4`3WMZMI&S;2S*N[;T&,@'G\:>UY"BAF?:
M"2.0>#G'-1WMI)<KB.14RI4[ESP<>X]*8U@[3^:94^\21Y8/!QZ]^.M`$MU<
MO$8ECC#M(Q')(``&>H!H^WP%20Y..P4YZ9Z8STYITUNTDL+APOEDG&.N1C^M
M5XM+$3[UF<-Z@#TQZ>PH`GCO8)9VA216D49*CMZTV6^1`P"L6&0.."0,XS3H
M+40$[7?;DD(<8&>3V]::;%26^=\,2VW(P"1@XX]S0`CW<D-K')*FYW95PO&,
MGZTPWNT['RLA)YVY!`;![U/+:K-`L3,P"D$,#SD=*C>PC=PY9]PSCD=SD]O4
M4`20W23221H#F([6SCK].M,:^4+N$,K*3A2H!W'/;_Z^*?%;+'(TFYF8\9)Z
M<YJ(Z;`=_P#K!N;<,2,-I_V>>/PH`26_*CY8')RF<D#&X@>O7_"H_/ED+)&T
M@Q,5)(4;<#.!ZBK!L82K*0Q#``_.>W(/7K[TB:?`C%E$@);<?WK=<8]:`&Q7
M;&-"(V=1&"[$J""5SR*@&J.4$K0!44G?\W.-H8$<<]15H6%N-O[H':GEC<2?
ME].>M*EG`B!%A3&<],\XQ_*@!;6:29"981$V>`'W9'K56_NY5$L<8VE0"K9(
MR?3.,?UJVEK%&5\N-4"G("C'M2M;Q,26B1BW7*@YH`IR7TL46YXD!$FQE5R1
MC(&>GO3K;=YD6Z1V^:4?,QY`;BK36T+#!AC(ZXVBG+#&A!6-`1G!`Z9H`I2W
M$UO/*0N^,-]W)S]S/'Y5):W;30RN=CE/N^6<[N,^I_G5KRTW[]B[L8SCFE5%
M0810H]`,4`9B:EO166XMF1C_`*T`[0<9P>>OXU&-2F+L'\J,@X*,#E3Y>[DY
M]?:M?8N,;1CKC%+@>E`&/)?RB&.3SD0LI`#`$$[AZ'T]Z&NKM)WC#&5T8[5\
MO`<;"0<@>HK8P/044`8LIFFM?+F>21&#'<L&<GC`.1]>PJYJDDZ6NZV5_,.2
M`%SS@]L'OC_ZU7J*`*%H]P]U)YGF&,C*[E*XZ<8(_J?PJG<13;MT(G\Q/-*N
M%)Y/W>O:MO%%`&4!=LDC,9!+\^!SC;_#CWZ>_6H)99U<JSRH&D=P"3D)QSQS
MQSQ6Y3'ACD96>-&*]"PSB@#.T^%X[B1]KJKR2-R3@@D$''YTDMK*;N0^7(4:
M8/D/CC9CUSUK5HH`Q_)E7=)<O/''Y>&8R*$4;<$^N<U9TZ$_83YS"3S`.1T*
MXP/S`S^-7R`1@@$44`8D.FW2^8S,JML*+CV!"G/N":>FG'RP@MS&H5MA9@=C
M''.!QV[5L48'I0!1TRW:VA*M%Y63DC=G)[FK])2T`%%%%`!1110`4444`%%%
M-8'C&.O>@!U%%%`!1110`4AZ4M)0!DM_K7_WC5JR_P!:?]VJLG^O?ZU:LO\`
M6'_=ID]2[1112*"BBB@`HHHH`****`"BBB@`HHHH`2CH*;*I>-E#%21C(ZBL
M81ZBT4CR&124R`K<A@,<?4\T`:XE1I6B#KYB@$KW`/2JT%D888XQ*"(Y"X.W
MU)./UJD+>X,F2+ATVQMR^#N!R1U'Y46UI<Q&!66<;,D;91C.XDYYY!%`%NUT
M[[,ZE+B3:``4P,$@8';([?E4DUD)I9'::1=R@`+CY2#D$<=<U5TNVN(-_F>;
MEDZR2[QN!/N>V*9#:7B*A8,SK_K?G!\P[@<C/3C/IUH`LMIR,0#<2[]K!C\N
M6W=2>/8?E4L=I%N+9D(.?E;IGH3C'>J^GVDL#JTL:[MA4MG)'S$C]"*AEL9Y
M)0RQ@;=^W+="2"*8$[VUE9`1+&P,P$8"9R0,G_&B[M840[0_F2,1NW$\D<]_
M04^]M'N9K9@J$1EMQ;ME2./QQ^50VMA<0I&I$(*%,E6/.W(]*0$]L(S8EI6S
M%(N2'8\*1T))/\Z06U@&"_NPSC=@ORPQ@GW&*5K68V$</[O>FW.3D8'H<?TJ
MO'I<R6Q@W189-NXY)4X(X_SZT`3YT]@9/,A*R$KD.,$]#^-,:>PC>2:-H'GC
M79]X;AC^'(Y[&AK"9U)8PAW1HW"@A<$#GZ\4BZ=,D12.9`?,+`LI;@C&#R.:
M`#[19R0QR3I"H&TJ&PQ!89QTZU,LMI^[50A60`IA.#D<=O0&H?[-F`C`N(_D
M$?\`RS/\/X^]-2RN(KJ##`QQ(J$[>#C/.,]>?0T"+/VJ%)WAVE6C5>0O!!Z`
M4\7430":,ET/`V#G.<=*CDL%>Y:<2,I;:<`#@CH?UIXLD6W\E6(&[<3QR<Y]
M,4#(DO;9'\N,/R`V0AQ\W0YI8KU)]IB!"G:3O4C*G."/RJ.'3VBN6(=C%L4#
M+#)()//'O4EE9/%;1+,Y,JA02#QQT`XZ4`-MK\3*FV-W9OO%5`V\XY!/M[TP
M:F92A@A9L/L=.-WW21@YQ4L>EPQE"AD&WC[Y^8=<'UHBTR&$'8T@/'.\DC`P
M,?@<4`0IJ?[Q_D9PVWRE5?F.5R0?R-6IG</;[#M5W(8$<D;2?Y@4QM,MF+$J
MP+;?NN1C`P,8Z=ZF>UB<("I`C.5`8C';M0!4_M(A"_E<*<,=W3*Y';N<"G+J
M&_RF6(>7*VT-GC^7KQ^%3QV-O$K*L8PV,@\].G7TIYMHB4)C7*'*GTH`AGNG
MCD9$BW;$WMEL9'MQSTH-S*MK-.T2CRPQ"A\YQGKQQT]ZG>%)&#/&C%>A(SB@
M0H$9-B;6ZKMX-`%(ZA."/W"8"@L?,`QD<=?\]:!?RB`RNB(IY7.1GY<_S&*M
MR6L+C_5JIV[`P`RH]J9;V44"%5`;IU5>WT`H`I/J/DPF8,N9`C89L@94GCGV
MIJ:BT@+;HY"91LC!P<&/(^O-:OE(#D(N?I3@H'84`9;:E,60(T.QBH,F"0"0
MQ*XSU&!^=*E_))M9I$53"')5<[3QGCKBM2EH`:IIU%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%)1F@!:*2B@!:*2B
M@!:***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`I*6DH`RI1BX?ZU9LO\`6G_=JM-Q<2?6K-E_K#_NTR5N7:***104444`%%%%
M`!1110`4444`%%%%`"48%)(^Q&<@G`S@=35!]61%G9K:?$'^L^[QQGU]*`-#
M`%&!5!]46)/,EMY53Y<ME3@'UP:FCO%=I\J52''SY!!&,Y_*@"SBC`]*SSJ,
MJQK,]HRP,-P;>"0,9&1VSTZ]Z9=:I-:C;):CS64M&HDR&QU!..#@^_UH`T\#
MTHQ6>^I!GLQ!&'%PV"2<;!@^WMBM`G`H`,#THI"P"DGMR:JQZE!*N4WGY@N-
MISSST^E`%NEJK->K#.(VC8C87+#&!@@8_6H_[3A+H@23+=\#`Y`Y/XCI0!=H
MJBVJ1;VC$4K,&"X`'<D#OZBFOJ6S+>21'L5MQ(&"21@^G2@#0HXJG<77EI;N
M`V)'`PN#G()Q^G:EM;TS1%WB,>$$@!.?E/\`^HT`7*2J!OYL(!;IOD/[L&7@
MC&>3C@^V/QIG]H7$A4PV\>QR`I=R",C/(V^U`&EQ16:;ZX>;8D404!#DL<_-
M^'M26NHR7*AO+50-@(/));T]A_C0!J450L;R6=RLBH/W:2#;[YX_2KU`"T44
M4`%%%%`!1110`4444`%%%%`!1110`4444`%5[NX-M#YGEL_S*N%QGD@#K[FK
M%0W4'VB`Q[MAR&!QG!!!'\J`*\^H>1,ZF%V5-I++SP<]O;%.-XWF$)&K)N4!
MM_7=WZ4OV1S*93*N\XZ)@8&??WIBZ<L1?R9-J,ZN$*Y"XYP/;-`"VUZUPP&Q
M%^9EP'R?E)&<8]J:]]+MF=(1LB;;EW"[B.N./YU-;6:VZD9#$LS;MN",G)J*
M735DCGB\UA%.Q9E(!P3UQ_\`7S0`V343%)(KK$BI*(][R8'*[L]*!>SLJ,D4
M161BJ,)<@\$YZ>U2_8OWS2>:V6D$F`!CA=N/RJ62`.\;;ROEMNP`.>W]:`(+
MJ\:U\@NGRNVU\'.S/\ZCDO9A+(J(H56159N=VYL9JS/:I/C>S8`(P,<Y&*B_
MLV/;M6615`4`#'&TY';UH`B^WS"62)E52#^[D(RK8ZC&>M3W]W]CMO-.TX(R
M"<<=3^.,TK6,3QLDF9`7$F6`X88Z8^E/>V5YDE).Y`0!VY]J`(!>/-=K#`5"
MF$2[V!.03@`#BDEEO(WA4R0`R/LSY;'^$GU]JD73XD5`C2*4!`8'G![?2GFS
MB+1$ER8CE?F/7&,GUZT`-@OK>5Q$MQ$\O0JK=^]6:3%57TV"1V9WN"6.<"X<
M#\@:`+E)5/\`LNU_Z;?]_P"3_&E&F6B_P.?]Z1C_`#-`%NBLQ19,2L=H9#@M
MC`S@''<^M*G]F-@+#&22`/W74\^WL:`-*C('4UGVZ6-P<+9QKE0XW1`9![]*
MLBQM!TMH?^^!0!*9$'5U'XUG-,K:A.EW+Y<053#^\V!ASN(P>>U7?L=L.EO%
M_P!\"I/+7`&T8'08Z4`9QU`QRM#YL19`<!N"1M!!/ZTPZC(2C%U7>HX(R!\V
M"W!Y`'/6M7:.M+B@##N[J6X@59%&WS0495)\T!AR/3CFIFNYDEC2$?+YA#A(
MB1]['X<'-:N/>EQ0!G6=S<&5Q,S.@CW9$1&""1CISQCBK/VR/^Y-_P!^'_PJ
MP!BEH`K?;$/2.<_]L6']*0WJCI#<$_\`7(U:K-O;N6"5BH!564;,9+`Y)Q^5
M`$WVYNUG='_@`_QI/MTG:PNC^"__`!50+>S;7<["<DJA;;@8!&>":&U&8`;8
MHMV<8+_AGITXH`F%]<'IIEU_WU'_`/%4GVVZ[:9<?B\?_P`55BV9R'#D$JV,
MCZ`_UJ>@"K#<7$D@62S>)3U9G4X_(U:HHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`*2EI*`,J?_CYD^M6++_6'_=J"X_X^7^M3V7^M/^[3)ZEZBBBD4%%%
M%`!1110`4444`%%%%`!1110`AK,DTZ1UU`%U'VO&./N_*%_I6DQ(4D#)QP*R
MS?W@>Z5EA!ME#-P2#E2?Z4`20Z<T(14\B-%(+*L>-V._6I+73X[9)H@<PR'A
M#_",8QG\ZKKJ$[Q%H3%*P56*!"OWNV<U8L[O[8TCQLABV@H=O(SG.>?:@!JV
M<IMA;RSJ\87;Q'@D=LG-)<:>]SM::9"Z*0A$>`,]21GDXJM:ZC=7-KYB^6'V
ML2IA8#(.."3S4\5Y/<3+$A2&15/FQLNXH1COGH0>*`)%TY8Y0\3!?WF\C;QG
MT'IR2?QJ[(BR(R.H96&"#T(JEI4T]U:I/,R$..`JXP02*O,<*2`3CL.]`%>.
MPM8-Q@MXHF*[=R*`<?6JL>D1I&(S/*P!4_,%ZCIV_7K5Q9W.=UO(@`SN8J1^
MA)K-74Y&A9]\1Q@\#G'.>,^W3B@"]/:).ZN7=2%*_*<<''M[#\J8=/C9T=Y)
MF=1C);D\@^GL.E-OKB2'8Z,`#&Y`8<%@`0/YU4.H7.%(DC(PS$HAP<8(&3C]
M!0!>_L^W$A?YRV0>7/8Y'ZTX6-N,85A@!<AV''/O[FJ(O;AKJ2,,5C!P&V=/
MG`/;'0__`*J:]S<"5F#2Y\LJOR':2'/)X.#C%`&E);P,D2.H"QD;.2,$#`IT
M5O%#_JEVX4*!DG@=*H7RR26EE,4<.LB.Q5-S+P<G&/?TJ2-KK[1`K291TRP(
M`9<'TQWXH`F-I8Q@*T<2[F^7/!)]!4IM;<MN\I<Y!_(8%9\\<O\`:,S,LQ1A
M'M*C(&"<_C1:B]:2`R^>`!@]`#R?O#Z8[4`7Q96H.1;QYX_A';I2BWMHPF(8
ME"`A,*!MSU`JE<07#WCN&N`@7Y/+D"K[Y'7_`#VJ**TN//0RK,41@1F7+<I@
M\Y]:`-.&.!`&AC1`0,;5`XI[R*B\^W`!/7CH*QUL;ER9)!*76)%`,Q`+#[W&
M<<CU%/:RG6+$<9+%5`9I/F7#DXSWX/Z4`:^:*R?L5R%E&%+,?O%OO#=D9&.,
M?YQ6G$"L:AL;@.<=*`)****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBJDMX8[SR/+S\JMNW>K8Z4`6B<=:#S
M6;'J4LQ*K;J&)PF9>N&P<\<=/>FVE[<$11M&)).?,<N``-Q`QQSTH`L)9*@&
M'=2">5."03G:?:E^PP9.`WW@2-QQP2?YDU#//<OI$TX`AE"%DV-NQZ=1_2DO
MKB2T*R1GS`L9)#-@'E1DG'N:`+4-LL,A8$D!0J@]A5C-9LT\QA<Y5'"2#()Q
MD=\413O"TD$;*PB8*-Y+,VX9SDGH,_I0!I49K*FOKB."*3=`2Z!R-IQR0/7W
MI]W<3'3)VB/[V-MI,8Y`##.!SSC-`&ED49'K6)<M%$W^C-&R;`22Y/1EZ\]:
M<',4D\PEPWG,N2,C&W('YT`;.1ZT9%9GGW$FER2999E/WE`/Y>M/AN'>Y";F
M/S$%2F!MQP0<?2@#0S1N!.`:QO+(O+EH-VR5O+E`!`7Y0=X]^HX[XJ&W:2!+
M>.&.5$6$+D0'(PX]1Z9H`W\TSRT\WS,?-C&?:LM9KUBP/F@#<L9\OJP;C=QP
M",<_6G!KO;&P,S,92&5DQP"<<X],<F@#5P*,"@4M`#(XTB7;&H49S@#O3Z**
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`I*6DH`RY_^/F3ZU/9?ZT_
M[M07'%R_UJ>R_P!8?]VF3U+U%%%(H****`"BBB@`HHHH`****`"BBB@!#TJH
MUDA>X?>X-P`'Z8P./2K9K&N;F[2+472X(^S'Y1L4_P`(/I[F@"\EF%51YTI"
MX"@D<8_"GQ6L4,LTL:[7F(+D=R!C--1)7ME/GMN.&W;1G&.G3%9\$]U);V$W
MGR.;CEE"H/X2?3U%`%U-.@BB6(/*$4G"[SQG.?YFIQ;Q>=YVW][MV[NAQ6<\
MUW&ID\QF14S*A"[EZY(P.HJ]IQ9K&!G<R,R`ECWH`DMK>.U@$40(0<@$D_SJ
M6EI&^Z<<4`'%'%0)',IR\P<>FP"LUK&Y=)(VC0!^20_4Y/M].]`&LTBJRC!.
MXX!`SBDEDV!<1L^3CY1T]ZS[Q&?[-;)_K5.254@*-K#.?K35M&QLVVZ.<$HK
M]0`06Z>]`&D\T490.ZJ7;:N>Y]*1KB!9#&TBJRJ'()Q@=,UG1:=,A@PL"B(H
M2`2<D`@GIZ$?E4UY8&>9I%=54JH((/8D]C[T`7//@RH,B9;H,CGZ57-QIZ,U
MUYUNI/R-)N`Z<XS53[$C+'-')'L_=A2(R>A/^..?2I4TQ@@4S*><G*?[)7UX
MZT`6C>VH9E,T8*D*<GOC-.FNK>#B614."0#Z"JLNGM(H7S0-I!!"\@@8R#FI
M-0AAG2-9BP4N!\O?/&#[<T`.EO(H@S$@A`20`=W&.@Q1#>(\S0MPX8@#!YP,
M^G7!J-[%/*6'S2`%*Y/4Y[TAABCG$\DX^23<<X&"1MP:`)GNDW[(S\RN%;*-
MCGMG'6HY+^,H&A)?#+GY&Y!;'''-/EB3)W3;?,<,`<#D8X'Y"J=E;R;7$DD:
M*"&?8X;!!R.W`Z]:`+L%Y'/)MC5RNW.[;@=2,?7BJUWJBQ6\C0JS/M;RSCAR
M.N/I^%.M3:QB-X[H8<,P#,OS`DMZ=N:8T>GM"S?:$\O)`"L"%W<G'U_E0!?M
MO,\A?.;<_<XQ^F34M56O((MRM,I9!D@'+<#)X'M3HKN&:4QHQW`9(*D8H`L4
M4E+0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!4$EM%),)70%P,!L]LYJ>J>I7$EO;YA4-(QPH()'<]OI^M`#Q90;=OE#'
M/&??/\^:%L;561EMXPR9VG:,C/6HDO\`S'C6%%8%0[DMC:#QQQS^E2:?<2W-
ME%-,BJ[C)"DX'YT`3QQ)'&(U4!!T':H4L;1(VC6VB".`&78,''3(JQD#N*:9
M%7JRC\:`(S96I&#;0D>GEBG^3$,?NT^48'RC@>E'GQ?\]$_[Z%--U;CK/$/^
M!B@"0(@QA5&.!QTI<#TJ#[;:_P#/S#_W\%)]OM`,FZ@`_P"N@H`L8'I1@>E5
M_P"T+/\`Y^H/^_@I/[0M,9^T1GZ'-`%G`]*,54_M.TQ_K<_16/\`2FG5;7UE
M/T@?_"@"[@>E&!C&*I?VK;_W;@GVMY#_`.RTG]JQ'I!>'_MUD_PH`O8HQ5>W
MNUN&(6*=,=Y(F3^8JQ0`4M%%`!1110`4444`%%%%`!1110`444E`"T444`%%
M%%`!1110`4AZ4M)0!F7/_'T_UJ>R_P!8?]VH+H8NW_"IK+_6'_=ID]2]1112
M*"BBB@`HHHH`****`"BBB@`HHHH`0C(JLMA;K;-;B,>4W5<DY_'\*M44`1B)
M1&(\?+C&,]JA^P6IC2,P(40Y52,A:M44`5X[.WA.8H(T.-N0HZ>E3(BQJ%10
MJC@`#I3J*`"BBB@!#TK*#705R5E/S\;000"#V^N.E:IK&FO)D)6*2-5!D)(7
M/0_6@":-;EHGSYWFK&I4$X!;'(_.FF.\DD4$NI:)B2K':KYR*ENY98WAC$C(
MK+S(L>[<PQA?QY_*JIEO%8C[3)\I(;,:_+SP>G>@"7R;P.C-YC"1.0K_`.K<
MG)SSR.V/;WI5BN<QG9*")F)+R;AMR<<9Z8/;TJ*.6Z`FW7,[$>8J?NAQ@C!^
M[]:16N\R[9;ISO94S&!\N`<_='/44`21V]RD@*QR!<<CS.,[\^OIFGZ?'YD\
MDR'Y5>1&_>%MWS<<=N*BE:X$;,CW97YC'^[.[.T8!&,XSTK60[D!P1GG!&*`
M,J+2I1)*TBPL)&!(WG!^;/IZ4^#398Q"&6!O+"@')RN&SQQZ<?A6K10!0NK#
MS[D3!(MP0`,?O`Y!]*B_LR1578R;X_NLW\?S!OFX]JU**`*5[:2W)C*.B[>N
MX$^GICTIUG:O;[][J=W91@#K_CTJW10!E)I#@AGG1F\L(28N>!@$<\<?Y%.&
ME,0ZO<<.%!")C.%Q[UIT4`4/[.W2AVF8X)/``_@V_P`JEBLA'<F?S79R,'H`
M?J`.:M44`)2T44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`5$T*M*)2/F4$`Y/`/_`.H5+10!62QMT*%8E!0DJ?0FG?9(
M/LYM_*7RFSE".#4]%`%'^Q]-_P"?"V_[]C_"G#2M.`XL+4?]L5_PJY10!5&G
M62_=L[<?2)?\*D6U@7[L$0^B"IJ*`(9%$,#LB*"JDC`K,FOYK><H9XY"HYZ`
M#IG=W'7/<5L$`C!&0::L4:`!44`#&`*`,DZSEFV1JP0D$;^OH>G'?\JOVLCR
M$ESPRJP4'.W.>,XYZ59P/2D5$4DJH!;DD#K0`M+110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!24M)0!F7?_`!]-^%36
M7^M/^[4-W_Q]-]!4UE_K#_NTR>I>HHHI%!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!4;@[1M(!R/RSS4E-==P`YX(/%`"@<<TC,%&32C
M@`44`%+24M`!1110`4TM@@>IQ3J3%`"T4E%`"T4E%`"T44E`"T4E%`"T4E%`
M"T4F:*`%HI**`%HI,T4`+14;RHCHI8!G.%&>O?\`H:>#0`M%1O*BRI&3\S@E
M>.N/_P!=/SQUH`6BDR/44F]>,,.>G/6@!U%5H[M)))D!/[K!9CC'(S1!>PS,
M`C@AE#*Q(PP.>GY4`6:*C\^'_GK'P<?>'6FFXAPO[Z/Y_N_,/F^E`$U%5[:Z
M2X0$,H<C)3<"5^M!O;;+`3H2O4!LD=NE`%BBJL=[#+.L,;%F*%\@'`P<$$^O
MM47]HQQM/YS`"-]GR*S'IGD8H`OT56FN@BPE0S><<*5!(Z$\^W%00ZG&;1))
M<H^U2RA3U/IGJ.#^5`%Y@2IVD`XX)&:4=*KRW:10+*VXH1D$#VS_`$JLFIJO
MFO/Q"&&R0+Q@J&Y]^M`&E15-;^,R^65=6XR&QP,$@GZX-*EZKS>5LE#=#\O"
MG&<'TXH`MT52\^07)1F)'F;1M7MLS@TV+4#-/`L<?R2*Q))'&,?XT`7Z*04M
M`!1110`4444`%%%%`"4M)CG/>EH`****`"BBB@`HHHH`***0D#J<4`+13<YP
M0>*=0`4444`%%%%`!1110`4444`%%%%`!24M)0!F78_TIOH*FL?]8?\`=J&[
M_P"/IOH*FLA^\)_V:8NI>HHHI#"BBB@`HHHH`****`"BBB@`HHHH`***2@!:
M*2EH`****`"BBB@`HHHH`:%Y)SG)SCTH==RD9(]Q3J9(N]&7)&01D'!%`#AP
M*6D'2EH`****`"HKB7R('D*EMHS@#)/M4M,DC60`,,@$''N*`*%K>2&W*3[3
M<JX0K]WKT/(X_P#K5%:7DDMM$'?+J5\Q\CG+$=,>WM6@UI;NS.\$;,XVN2H.
MX>AH%G;#9BVA'E_<^0?+]/2@#-6^D,1RN$$6[!D^?(;'7'M4MSJ;P*SK$C`;
MP%+X(V^O'`./Y5>%I;!0HMX@H[!!BG&&(EB8T);&X[1SCUH`SY]0>':#Y6X-
MAADG(XZ?@?\`/95F%KI<LB2;O+9\%R6Q\QQ[UHA5`P`!]!2XH`R$N)6"3>9$
MLA#JP()#8;@`9X)'UI#-<P$10R1;"^.4),?SXYY]#^E;&!Z48'H.*`,T2W?F
MNGF+N4$8V')..#TQS]>]1M-,3'.JL"Z.5#199!@8%:V!Z48H`QTDN6=WD$O$
M;JJ^62"0W!QCN,5)-+=^7-L,H=2^T"/(Q@[2#CKG'^%:F!Z44`98>Z9U!,K*
MLW]W;E?E]NG6GW*3/?`AYUC$:\(2!G=S^E:-&!Z4`8FV]#0@K<%4?YG+\%=W
M?D=N]7-.#;7.\NB?)&^[=N4<@^YYQ^%7\#THP!T`H`Q[>*Z693);R;`V[[R\
M':P/?/I0EI<F`AXRW)"H2%;D`!B03R,'I6Q@48'I0!1N;1I5A!5)`BE2'/J,
M9Z4VVLGBN_-?:Q&1YF\Y88[CIV]36ABC%`&=+8NSR86/8Q8\L0>0/0<=*8FG
M2[MSR`DKC()!7KT`X/6M3`]**`*5M:RH\[2LG[Q57"`\8!&:BBT^9($C,D?R
MHB@[3_"V:TJ*`,PZ;(8D43H&A_U9,?;(////0>E1O:W$=Q;JGSK&!N.SY3\V
M?[PQCZ&M>C`]*`*L%H\<D;M*&"*RXVXZD'U]JC.F[Y5D>8DJ2RX7&"3G^8%7
MJ6@"I#8I#,9E=BYW;NF#G'^`H-@A>5_,DS(VX]/[NWT]*MT4`5S:J8H8Q(Z^
M3C:1C/`QZ>AJ,:=$`F'D!1552#R,9Q_,U<HH`K364<\21N6"H<C:<'H1_6FI
MI\"@+@LH`&UCD'`QG\JMT4`5?L%OY31LN\,5SN.3\IR/RIPLH1<FX`;S&Z_,
M<'C&<=,^]6**`*QL8&E,A#[B=V?,;KC'3/I2+86Z@#9G&>6))Y&#R3FK5%`"
M*`H`'04M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4E+10`@&*6B
MB@`HHHH`****`"BBB@`HHHH`****`"DI:2@#,N_^/IOH*FLO]:?]VHKL?Z4W
MT%2V7^L/^[3)ZEZBBBD4%%%%`!1110`4444`%%%%`!1110`4C#(QDCW%+10`
M@I:**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M2@!:*04M`!24M%`!1110`4444`%%%%`!1110`4444`%%%%`!2&EI*`,V[_X^
MF^@J6R_UI_W:BO/^/H_05+8_ZP_[M,GJ7J***104444`%%%%`!1110`4444`
M%%%%`!1129YH`6BJK:C9*Q4W465Z_../K3X[RVF7,4\3CU5P:`)Z*9'(DJAH
MV5E/0J<BGT`%%%%`!124`YH`6BBB@`HHHH`****`"BBB@`HI**`%HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBDH`*6JD\[-<K;P,!)PSD\[%
M^GOT_7M5N@`HHI&(498@`=2:`"EJE:R2W4QN,E+;&(E(P6_VC_2KM`!1249%
M`!145S<1V\)DD)`'YD]@/>L_S+A1EWQ=7/$,)Z1+ZD=\=3^5`&K2U#;0F"%4
M:1I&`Y9CDD^O_P!:I<XH`6BF/(J(7<@*HR2>PIOGQ;(WWC;*0$.?O9Y&*`):
M*BF9U0&)-[9'&['&>34F:`%HI,BB@!:*B-Q")/+,B!_[NX9I'NK>/?OFC79@
M-E@-N>F:`):"0.IJ">\M[<9FE5,@D;CUJO;QR7<_VJ92D:']PAR#Z;B/7T]*
M`+]+5*^NS`4AAC\VXDSL7(&/<^U%G.J(L4DI>;."2.IYZ=NU`%VBJO\`:-KY
MGEB3<V[9\JD_-Z9`ZTV;5+.!G627!09("D\4`6Z"0H))P`,FJTUX%DCCB3S'
M8@L,XV+W8_X51N[E;W=#&V+96VS2XSD]D`[YXH`O17BS3^7&K,-N=^.#]._X
M]*LCI6?%=VMK;LRA@`3NXY..I-6X+F.X3<F<'ID8R/7'I0!-156XOHH)%B(9
MY6Z(@R<>I]!4)U6W$3RA79!]T@#]Y[KSR/>@#0ICR)'M#NJEC@9.,FJ2:M`?
M,9DDC2,<LR\9_N\=ZH1O,9TN;EY6E`+16Y"#RU]7../\^]`&\*6JMC>)=PAE
MVAOXE5MP'XU:H`****`"BBB@`HHHH`****`"DI:2@`!R<>E+24M`!24M)0!F
MWO\`Q\GZ"I;'_6'_`':CO?\`CY_"I++_`%A_W:9/4O4444B@HHHH`****`"B
MBB@`HHHH`****`"J%^%>YACG8"W(9F!'RL1C`)_/CO5UV"(6.<`9XJI)=PM9
M">;?%&_0$D-[8V_TH`@DU!(E(A"@8V1H!RS?[N,X%26<5O/`)'AWY.=\JJ2W
MO5--UL#=20K&6^2VM^``3SDGL3W]`*G6ZFABEGE<&+"D2,H6-?7'\6.GU]J`
M-,!5&%``]!2UF6;WN]?/$FWD@87G)_B],`=/?O5G4;DVMC),I`VXY(SCF@"U
MD>M%82RWT%NL\KM(%&<XX)8X`/0D#(Y]J=;/=R7+N99B(N,%2JN?4CL!Z=30
M!HWMT8`L<?S3RG;&OOZGV'6GVD)MX%1Y&D?JSL>I[UC1F[,;7.V3[1.=F=A_
M<KGL,>G)IQ^W"-FC$^^(&./S2><\%V]?8#-`&]D49%4-/CE5B9"Q!49+DY+>
MN#^//'T%&IPRW"K!&7"R95L#``]2?;L.YH`OY`ZFC<..1STK$%G=H!;,Q>`L
MS,P^9I#V!Z`#';IQ2P6<AXFMLR1G;""?D11CG@\D]^/RH`V2R@@%@">@S3'D
MP?D*$`X?+8VC_/TK)%E=$-(V6N""=[`?*3V7GWXY`_&E;394M%ABC*HTF7"D
M;F]7)Z9/ISC-`&N)$8X#J3C.`>WK3?M$)C+B:,H#@MN&`:S+C39Q&!%(=K,/
M,10/N_W1G\*26RNG;<#MP!M"L#M/0MSU;'3H!0!/+(=0<V\)S`I_>R#HW^RI
M'?UK14`*`.`*H(DUM;`11J3T6('Y1SR2<=>IJ69KWS?W$=NR8ZR2,#GZ`&@"
MU2U2#:CW2U'T9C_2G#[;CDVX/T8T`6J6JH2\(YF@_P"_1/\`[-3O+N_^>\'_
M`'Y/_P`50!/14!CNO^>\(^D)_P#BJ0PW7_/R@^D7_P!>@"Q154VUR?\`E]8?
M2-:;]CN>^HS_`()'_P#$T`7**I?8)L\ZC=?@(Q_[+2BP?/S7UTWU*C^2T`7*
M*JK8@=;FY;ZR8_E3S9QG^.?_`+_/_C0!8I*@^QQ9SNF_[_/_`(T?8X_[\_\`
MW_?_`!H`L4E5FL+=OO*S?[TC'^M,_LFP)R;6,GU(H`N9JI?W;VZ*L$8EGD.U
M%+``GWIT.G6=O()(+6&.3IN5`#^=2M`C2"1E!<`J"1GCN*`,:UNI;>-GV^>9
MF&S"D.['N?1?P[58DN[U8'56C:9CM3"]_0#.#W[\"KPLK<0F(0Q^6?X=HQ3Q
M!&&1MBY084X''T]*`,Y[ZZ&(V3RI"6+,1PB@XXSU)J*XFENB+>8@Q*H:5,?-
M*?X0!C.,CGVK8:-68,R@E>A(Z4%1G=@9]<4`9=Q=W4$$:.1#(V26?'`'TR.!
M4UG=RW3B1=WE$#:N!T]6..OL/QJ-8FU%T:Y5A$"'V'@9[`>OJ<^V*U`,4`4K
M^\-NFU>&920<9Z=L=S5"/[0BQP@-&'7?(_1W<GM_D=NE;F/>C%`&,1/)=DR@
MR+;+^[0KG#8^^3W/./KFELY&@ADOKD2R.PW,2N"H[(H_SS6OB@H"<G!^HH`%
M;<`><$=Q65J)O))W6-9!&@`4!>&8_P`1(Z@>GYUK4M`&$8;D1BV2"9E#`MO;
M)<<9)8\8/3;4OEWCSB80D>7&0BL1A6..@]AD9QWK8IDI<1-Y8!?'RYZ9H`P)
M(WLX!YGFL\S?O2)`97]%7G@9].U6(["=8F9(5CFEX8@X51Z`#H.!GN?Y6K6R
M_>^?,!Y@Z9Y.?4G_`#BK]`&/:Z7)#<[E`54/R,1Z_>./?L.@K0OTGDM'2V<I
M*V`&'4#//XXS5FB@#'CL)HI7<1J-G$04_=!QDY(R6/J::ND.)%+"-P>9,]"1
M]T8/8?J>M;5%`&+'IUR75IQ%(S$M(Q)^9A]WMT'I6K`C(F'<NW4G_"I:*`,W
M[`_VVXFRH$H`!!.<`=.G`)IG]E$V[$L%NG'+IP%XQ@>@Q6K10!E0Z9-&Y)E7
M:(]B!5QL'H/ZGJ::=)DW1.LRAAS)F/.YNQ`SQCL*UZ*`,&:QN(V6)+K=,Z[5
M`7`5>-SMDG)Z?H*LC2OW$2-(&:-MPW)\I/<[<\GGO5];:-;AKC&964*6]`.P
MJ6@"E_9Z&5&8[E4[MI'5NQ_#L*LQP11;C&@4MR34M%`%"YTV*YF>21Y?WD?E
MD*V`!3ETZ%61CO;9T!/&<8'0<8[=A5VB@"@-*MQ`8OG(/?/3G/'^>:>FG6Z3
M-)ARSX+98G<1TSZU<HH`0`#H*6BB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`I*6B@#-O?^/G\*DL?]:?\`=J.^_P"/G\*DL?\`6G_=ID]2]1112*"BBB@`
MHHHH`****`"BBB@`HHHH`2HUMX%;<L,8;U"C-2T4`-:-'&'16'N,T%5(P5!'
MH13J*`$Q1@>E+10`F!Z48'I2T4`)@>E&!Z4M%`"8'I1BEHH`2C`]*6B@!,#T
MHP/2EHH`3%&!Z4M%`"8HP/2EHH`2BEHH`2EHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`I.M+10`F!Z4M%%`!1110`4444`%%%%`!24M%`"
M4M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4E+24`9U]_P`?/X"I++_6G_=IE]_Q
M\#_=I]C_`*T_[M,GJ7J***104444`%%%%`!1110`4444`%%%%`!44\\=M"TL
MS;47J<$_RJ6JU[;_`&FUDA#;2V.?H0:`'0W4,XS&Q/7@J01CV/UJ&/5+62!Y
MU:3RD&XNT3*"/8D<_A3C;-&ZM`X7`(;>"Y/3OGVJ"#2_*M_(>4,F1G`*G@Y'
M?C\*`++WT*,J_.V0&RJ$@`]":+:\CNAF-)0O9F0@'\ZS!!;J5Q,Q\LD!C$2R
M`,>C#I^-/MS!IJR/Y?[M`0SK`1W]<\T`6X]4MY,E=_RA3RO4,<"D&I1F,.(Y
M"&("_=Y_'.!^.*H/#;QKM5)YBACP\87Y>F._?.*1H4\[`2=I6(RZK&",$_>R
M<$T`:#:DB\&&3.`QP4X!./7GIVI\5Z9))E,$B"'AB2O7&<``^E4%-N86W"25
MPH5\J@:,EL`8`X.3^E.BO(6W,D4C/=<E"0"#PN/:@"9-3\Q!L@+.Y`51(#V)
MY],8IYOYG;;#;!F3/FAI`NWZ<<G\JK)%"UI).?.>2([00X++CH%(Z]>_KS2*
M;:XE,8B9EVME]Y'F#&<,.^<]Z`+']IC?$IC&6F:,Y;H`<9_/''O5@W#BQ:<1
M@R!2=F>X[9K-BN+558BV"N^W"[R<AOF)'IC)Z>E.%PH9HC;$JX^ZSNP(W8Z$
M>_:@"3^TI?*3Y1N9]I_=.2.,\KC/7\*E2[GD$CKY:I$VPAU*DG`.>>G4<54E
MD5'\LVY;9%YN27SW&,D9''KQS5F546^2.&*+S$BWAG)[<`?_`%Z`%FO94*!5
M'S(K<*6.2?0&J[:G=&&1D\H%$9OF0Y)#8Z9&*EL5C,I,=ND2D@X$1/8'[W3O
M4*WB2R7(CMH^?]6VW/F#(!ZX!Y]Z`+OFW2W$<+)&P?YO,'&`.HQ^51S7<J2S
M$.A\IU41`<G.._X_I47VZ4%3LC&P'S"$Y09[@G(X],]*9)>,-US(D0:W!))3
M)QN(."2,`8_6@"S8SSR^69<@.A/(`Y!'3!_G44=U/*L1^T!99-V^(`9CP"?Y
M@=?7M4$VHW$:X"HIWN(VVC!`!X^O`HEO+A&B_?A`S$,<Q^F1ST%`%DW%TN0G
M[T>4KEF(&TG/MS4)NKDQR8E_>!MJJ&3.-^.FWCCZUK1X9%.X-P.1WI^!0!5L
MI)6,L<V=Z,!V/!`/7`SWJW28I:`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"DI:2@#/O_P#CX7_=I]C_`*T_[M,U#_7K_NT^Q_UI_P!VF3U+U%%%
M(H****`"BBB@`HHHH`****`"BBB@!"<49H-9VGVD4UE')+YC.<Y)D;U^M`&C
MF@]*JG3;1OO0[OJQ/]::=)T\];.$_P#`:`$-F%W;9@H;=NR.Q.>/2HY+"$AP
M98U5CUVC=USUJ7^R--_Y\+;\8A3QIM@,8LK88_Z9+_A0!`D%I")%$ZJ'=7V[
MQA<$'`_*A3IZR^8UQ"6Y^\Z\9.:MI:6R?<MXE^B`5($1?NJH^@H`SW;3V$N;
MN+]XZLV)%ZC&/Y"HA!IBNK)=QJR(%!$B]CD'ZUK8Q10!G126,,;H+E6WMO8[
M@<GCT^E1,=-W.1(X9VW$H&],'D"M:B@#)\[3D(Q'*<#`VP2''`'8>PIH:P.[
M%O?-GUBFXYSQQQT[5L8%%`&7&]J`0MI=G<I0[HWY![<U+(T<X4O8ROMZ;D''
MYFK^**`*HF900ME,/IL']:;UB$9T]]BC`4B/`'_?57*,4`4MJA1C3F^7E1B/
MC]:&+/C.G$XZ;BG'ZU=HH`IEY\8%B/H77K4>;H<+IT&/>;'_`++6ABB@"B)-
M2'"VEL!_U\'_`.(IV_4B?^/>T`_Z[M_\15S`]**`*F=1_P">=J/^VC'^E26D
MCRJYD"AD<J0O3BIZJ6'^LN_^NY_D*`+E%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%)2TE`%#4/]:OTIUC_K3_`+M-U#_6)]*=8_ZT_P"[3)ZEZBBB
MD4%%%%`!1110`4444`%%%%`!1110`E5=+XL(QZ%O_0C5H]*K:<,6@'H[C_Q\
MT`6J***`"BBB@`HHI*`%HI*6@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`*HZ?G[1>@]IO_`&45=S5*P_X_+\?]-1_Z"*`+U%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%)2TE`%'4?\`6)]*6Q_UI_W:34?O)]#2V/\`K#_N
MTR>I>HHHI%!1110`4444`%%%%`!1110`4444`(:KV9"VYS@?O'_]#-6#5633
M+&61GDLH'=CDLT8)-`%@R(.K*/QIIN(AUD3_`+Z%0#2M/'2PM?\`ORO^%2+8
MVBC"VL`'M&*`'&ZMQUGB'U<4TWUJ!_Q\P_\`?P4];>%?NPQCZ**D"@#``'TH
M`K_;[3_GZ@_[^"C[?:?\_,)^C@U8HH`K'4;0#/G*?IDTPZI:]0TA'M$Y_I5R
MB@"E_:MOCA;D_2VD_P#B:/[3B.<079Q_T[./YBKM%`%47X.,6UR?K$1_.G"Z
M9NEK/^(4?S-6*6@"N;B0?\N<WYI_\51]HE_Y\YO^^D_^*J>B@"O]HF[6<OXL
MO^--,]WVLQ^,HJU10!4,U]_#9Q?C/C_V6F^=J1_Y=+4?6X;_`.(J[2T`4O,U
M+/\`Q[VH'KY[?_$4H;4">8[4?\#8_P!*MT4`5A]N)Y^SCZ;C_A2A;L_\M(1_
MVS)_]FJQ10!!LNO^>T/_`'Y/_P`51;0&&25V<,TK!CA<`<8]34]+0`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4E+24`4M1^]&:+'_6G_=HU'_EG
M]318_P"M/^[3$7J***0PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HI**`%HI**`%HI,T4`+129HS0`M%)FC-`"T4F:*`%HI,T9H`
M6BF-+&GWY%7ZG%,^U6__`#WB_P"^Q0!-158ZA9#K=P#_`+:"F'5=/'6^MO\`
MOZO^-`%RBJ)UC31_R_6_X2"E&K6!Z749^AS0!=HJI_:5IVE)^B-_A3OM\';S
M3](7/]*`+-%5A>Q'^&?_`+\/_A0+V(]%G_[\/_A0!9HJJ;Y!TAN#](FIIOCV
MM+IC_N`?S-`%RBJ)OY!_S#[O_P`<_P#BJ3[;<'&-,N?Q:,?^S4`7Z*H"[NS_
M`,PV4?61/\:>MQ=D?\>6W_>E']*`+E%50]V?^7:+\9C_`/$TNZ\_YX0?]_C_
M`/$4`6:*K;KWM#;C_MJ?_B::?MYZ+;#TR6/]*`+=%4MNI?W[0?\``6_QIIBU
M,XQ<6B_]L6/_`+-0!?HJ@(=3[WEL/I;G_P"+I1;ZAWOHOPM__LJ`+U%4Q;77
M>]/X1"G"VG[WLOX*G_Q-`%JBJWV:7_G]G_[Y3_XFI(8GC)W3/+G^\%X_("@"
M6BBB@`HHHH`****`"BBB@`HHHH`****`"DI:2@"GJ/2/ZFDL?]:?]VEU'I']
M326/^M/^[0+J7J***!A1110`4444`%%%%`!1110`4444`%)2U6FLH)Y?,E3<
MV,?>-`%BEJH--M!_RP0_[W/\Z<+"T'_+K#_WP*`+-)5?[!:?\^L'_?M?\*46
M-J.EM#_W[%`$QD0=77\Z89X1UE0?\"%(+2W'2WB_[X%*((ATC3\%%`#6N[9>
M3<1#ZN*;]NM/^?J#_OX*F$:KT4#\*=B@"O\`;[3_`)^H/^_@H.H6@/\`Q\1G
MZ-FK&.*,4`56U&U'_+7/T4G^0IAU2V&?]<<>D$A_]EJ[2T`4/[5@[1W1^EK)
M_P#$THU.,GB"[_\``9Q_,5=/2LQ);J6=`A8*45S]W"Y9L@\9Z#''I0!8%]GI
M;7/_`'[(IPNW/2UG_$*/YFJ-Q>-)';".<`EL2X8+C@]3@XYI\D\XNPT0F:$)
MY98`,H8C.<=2>G;N:`+GVB7/_'G-_P!])_\`%4?:9?\`GSG_`#3_`.*K(<RX
MCCW3E`X+$3/@Y!_B`R.W':KEW#),;-8_,V<[L2.O\/&2.?SH`MFXF[6<N?=D
M_P#BJ3[1<8XM&S[R+5-K659@YWLRE%+B1N1@9^7I3;>.X!RRR%)&C#*Q/RX5
M>1^N:`+AGO/X;('ZR@?TIOGZB2/]"@'_`&\'_P")IL=L(;:X$*,KL6QD\GTJ
M+[.)"WV>+R5.W(DC^7/^[D=!_DT`3^;J9./LMJ/K<-_\11OU//,5H/\`MJQ_
M]EIB6C'3&AF1'=2V/EP.IQ@'I3+NR+.5AB`B:)LHH`&['R_S-`%C=?8R?LH'
MU8TX?:R?];;CZ(3_`%J@VGO'#$ZQEY/EWJBH,``]CP3SWISV=PWS01^4=F_#
M$9\P<#IQT]*`+>^?.W[3;;O3RS_\53?/D!(-[:`CK\G_`-E5>73Y#$RHW`=<
M*<8("@9Z9_\`U5,UI*8<+M#>0(^O\7Y4`/\`,E>,NM[;[`<%ECR`?^^J:XGZ
M?;PI!"G$8Z^GUIWV=Y+1XI<,6;/S.6!''L*@.FRNDD;383?NC*CD84``Y'U_
M2@!26`RVK/C?Y9(2/[W]WIUYI(8S.3Y>JW3=^%CQ^>RA-,EW[GE7EQ(0!_$#
MU_+(_*GV]C-"DBK(BEE*JV6.#V."<?E0`R,1OLQJ=R^]F1?NC)'4<*/0TD;V
M[,BBYNW#@$-\V.>F2!@=*D73"&`>8O$!]UAR#C&0?R_*EAT^:-8XS<JT:JJL
M/*P6P2>N>.OI0`YTMTE$32S[RI;'G/T'XU$A@?A5N]W&%:5P2#W&6QVJ:33H
MY+DW!9A+T!!.`,8QCIW/-.%FP49G8N``&VKP!Z<4`53+;;2P%T0H);]ZV5QP
M<@M2N]LBNQ2?"$Y)F]\=VS^=6/[.A*L'W.6#`LV,\]3TZTOV%?FQ-(H)S\NT
M<YSUQGK0!6)M<1[H9"7)P#)Z?\"YZ]JL36UM$@8PYRRK^9`_K2_8$P09'YSN
MZ8;..V,=ATJ5H-\>QV)&X-Z=#D4`9JS6<D<;)9AGDSM1@,@@CK^><U-%';/+
MY<EA$CA-QR@/?Z5,VG0/MR""JA0P)!P.GXT#3H0Z.&D#K_$'(+<]_6@"C.]O
M'#;O'I]NS3J&`90`"2O7Y?\`:_2FO/`CB+^SH/,4X<*!P<KTXYX;VJ^=,MSD
M$.0>@\QOEYSQSQVZ>E/6PMTV80Y3D$L2<Y!R3WZ#KZ4`43-"0_D6EM\OS99<
M#&!Z#KDU-*4%E'/#;P%G"D*5SDD<`8JPUA;M_P`L\`N7.TD9)ZYQZT][2!XT
MC:)2D?W5QP.W%`&:UTZ_+]GC\Q2056(MD@+QQTZGFK,LT@G\F-84(B\QC)TZ
MXQ_]>K<<$<1RB*O&.!]/\!^5$MO%,P,D:/MZ;E!Q0!G?VA.(?/"Q;/-\K9@D
M^F<_KCTI/M]UB``1,98U?*KC;DC(P3[^O:M'[/$9/,\I-^,;MHSCZT"UA"E1
M%&%/5=HP:`(Q*ZVS.1ND"D[<`?RS51YYUVJETLOFC(*(N5Y'3MCGO5]+>*-R
MT<:J2,<#'%.6)%R515R<G`ZT`4;B2YBLT19)/M#MA6**2._0<=!C\:ACO3+>
M>8L[>1\NV-<9Y'<$9_(]JUMHSG`HVB@#$M[JYW*/.,K$9P&#J3M;O@$<XXQV
MJ:*61G>*WNFD/RLLC,&'7G.`,9]*U<4`4`8_VB5GB8@J&+9621TQAO0#FF_:
M)$64[V\U"2,LYS\W3!^7GI6W2,H;K0`HHQ12T`)12T4`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4E+10!2U'[J?6DL?]
M:?\`=I=1^ZGUI+'_`%A_W:!=2]1110,****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`2FI&J`A1C))_$T^B@!,#THP/2
MEHH`3`]*,"EHH`3%&!2T4`)@48'I2T4`)BC%+10`F!1BEHH`3`HQ2T4`)12T
M4`)12T4`%%)1F@!:*3-&<#F@`I:;O7N1^=-,\8ZR*/\`@0H`DHJ'[3`.LT8_
MX$*0WEL.MQ"/^!B@">BJ_P!MM?\`GYA_[^"@7MJ?^7F'_OX*`+%%0?;+;_GX
MB_[[%)]MMLX\Y3]#F@"Q15?[;!_>)^BG_"C[9%V\P_2-O\*`+%%5_MD?]V;_
M`+\O_A1]LC_NS?\`?A_\*`+%%5_MD?\`=F_[\/\`X4AO4[13GZ0M_A0!9HJJ
M;WC(MK@^PCIGV]^UA=G_`("H_FU`%VBJ7VV7/&GW7_CG_P`52?;;D]--N/Q>
M/_XJ@"]15,75R?\`EPD'UD3_`!IXFN3_`,NJCZR__6H`LT57\RZ[01?C*?\`
MXFC?=]X(?^_Q_P#B:`+%)5<O=?\`/&'_`+^G_P")I";T]$@'U8G^E`%FBJ9&
MH=FM1_P%C_44FS4B?^/BT7_M@Q_]FH`NT52\C43_`,OEN/I;'_XNE%O>][U/
MP@`_K0!<HJL+>Y_BO&_"-12BVE[WLW_?*?\`Q-`%BBJ_V63_`)_9_P#OE/\`
MXFC[+)_S^3_^.?\`Q-`%BBJQLB>MU<?]]`?TIHT]>]Q<G_ML1_*@"V2!UHJF
M=-B/6:Z/_;P_^-26]E%;,6C:4DC'SRL_\R:`+%+24M`!1110`4444`%%%%`!
M1110`4444`%%%%`%/4?NI]:;8_ZP_P"[2ZC]U/K26/\`K3_NT"ZEZBBB@844
M44`%%%%`!1110`4444`%%%%`!3&D1/ONJ_4XI]1/;PR/O>)&;IDJ":`$:ZMU
M&6GB`]W%1G4;%>MY;CZRK_C4HMH!TAC'_`12B&)>D:#_`("*`*QU;3EZWUM_
MW]%`U?3B<"]@/T<5;"@=`!]*7`H`JC4;0GY9MWT4G^E.^VP'IYA^D3'^E6,"
MC%`$'VR+^[/_`-^'_P`*/MD7]V?_`+\/_A4^!1B@"`W:=DF/_;)O\*/M0)XB
MG_[]FI\48H`K_:CG`MYC^`'\S2_:)/\`GUF/XI_C4^**`*_GR_\`/I/^:?\`
MQ5+]HE_Y\Y_S3_XJIZ6@"J9Y_P"&SD_%U']:3S[OM9_G**MT4`4S+?Y^6TB_
MX%/_`/8TGFZEVM+7_P`"6_\`B*NT4`4@^I$\V]J!_P!=V/\`[)3LW_\`=MQ_
MP(_X5;HH`K`7AZO`/HI/]:79=_\`/:'_`+]'_P"*JQ10!7V7?_/:'_OT?_BJ
M-EWC_71?]^C_`/%58HH`K>7=G_EXC'TB_P#KTTV]V3_Q_,/I&O\`A5NB@"G]
MEN?^@A+^")_A2?8YSUU&Y_!8_P#XFKM%`%,6<O\`S_7)^I3_`.)IPM"/O7%P
MWU?'\JM44`5_LB]Y)C_VU;_&C[)'_>F_[_O_`(U8HH`@^RI_>F_[_/\`XTPV
M,#?>5C]9&/\`6K5%`%3^S;0]8%/UYI/[+L"0396Y/O&#5RB@"H-,L!TL;;_O
MTO\`A3ULK1?NVL(^D8JQ10!&(8ATC0?113P`!@``>U+10`E%+10`E%+10`E+
M110`E%+10`E%+10`E%+10`F*``!@``4M%`"44M%`"44M%`"44M%`"44M%`"4
MM%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4E
M+24`4]1^ZGUIMA_K#_NT[4?NI]:;8?ZP_P"[0+J7Z***!A1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%)10`M%)2T`%%%%`!1110`44E%`"T4E+0`444F1ZT`+
M13#(@ZNH_&D,\(ZRH/JPH`DHJ`W=N.MQ$/\`@8I/MMKG_CYA_P"_@H`L457^
MVVO_`#\P_P#?P4&]M1_R\P_]]B@"Q154W]J/^6RGZ<TAU&V`_P!8Q_W48_R%
M`%NBJ7]IV_87!^EO(?\`V6C^TX>T5T?^W:3_`.)H`NT52&HH3Q!=?]^&']*=
M]M).!;7!_P"V>/YT`6Z*K"Y<]+6?_P`=']:4W$@_Y<Y_P*?_`!5`%BBJ_P!H
ME_Y])OS3_P"*H$\O_/K,/J4_^*H`L457\^;_`)]9/^^E_P`:!-.?^74@>[B@
M"Q158RW/:V'XR?\`UJ!)=G_EA$/K*?\`XF@"S15;?>?\\(?^_I_^)HWW?_/"
M'_O\?_B:`+-%5BUYVB@'_;0G_P!EII^WGI]F'U#4`6Z*I%=3/26T7_MDQ_\`
M9J3RM2_Y^[8?2W;_`.+H`O4E4O)U#(S>Q8]K?_[*GB"Z_BO#^$8H`M9HJL+>
M;O>2_@J?_$TOV:7_`)_)_P`D_P#B:`+&:,U7^S2'@W<_Y)_\31]E;&#=3_FH
M_I0!8HS54V(;&;FY_"3'\J;_`&;'WGNS_P!O#_XT`7*,U2.E6Y/+W1_[>9/\
M:D@T^"WD$D?G;A_>F=A^1-`%FEI*6@`HHHH`****`"BBB@`HHHH`****`"DI
M:2@"GJ/W$^M-L?\`6'_=I^H_ZM/]ZF6'^M/^[_A0+J7Z***!A1110`4444`%
M%%%`!1110`4444`%,>1$QO95SZG%/J.2&*7'F1H^.FY0<4`--U`OWIHQ]6%,
M.H68&3=0#ZR"G_9;?_GA%_WP*<(8EZ1(/HHH`K'5].'6^MA_VU7_`!I!J^G'
MI>P'Z.#5P*HZ*!^%+@>E`%0:G9L<+.&^@)IPOX&^Z7;_`'8V/]*LXHH`@^V1
M?W9_^_#_`.%'VR+^[/\`]^'_`,*GQ1B@"N;Q.T<Y^D+?X4GVP=K>X/\`VS-6
M<48%`%0WSYPME=-]`H_F:3[=-C*Z=='ZF,?^S5<Q1@4`4_MEUG_D&S_]_(__
M`(JE%U='_EP<?61?\:MXHH`K"6[/6V0?67_`4HDNS_RPA_&8_P#Q-6**`*X>
M[_YX0?\`?T__`!-*'N^\$(_[:D_^RU/10!!FZ_YYPC_@9_PH_P!*QQY(_.IZ
M6@"N%NO[\(_X`3_6@I=?\]H?^_1_^*JQ10!6\N[_`.>T/_?D_P#Q5+Y=T?\`
MEO#CVA/_`,55BB@"J8;H_P#+TH_W8A_4TGV>Z)_X_F_"-:MT4`4C9W)_YB,X
M^B1\?^.T?8I_^@E=?]\Q_P#Q%7:*`*8L9.]_=-^*?T6G?8O^GFX_[[_^M5JB
M@"M]C3&/,F/_`&V;_&@640.=TW_?]_\`&K-%`%?['$>K3'ZS.?ZTALH",$,1
MZ%V/]:LT4`4SI=DQ^:V1OJ,T@TG3^,V5N<>L8_PJ[10!573K)?NV=N/I$H_I
M3UL[9?NV\(^B"IZ*`&+&BG*JJGV%.I:*`$HQZ4M%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!112'IUQ0`M%0VU
MPERC/'DJ&*Y(QG'I[5-0`44E%`"T444`%%%%`!1110`4444`%%%%`!1110`4
M444`4]1_U2G_`&J98?ZT_P"[4FH?ZI?]ZH[#_6G_`'?\*!=2_1110,****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HI**`%HI**`%HI*,T`+1244`+129HS0`M%)
M1F@!:*3-%`"T4E(74=6`^IH`=149FB'61!_P(4W[3;_\]X_^^Q0!-14!O;4=
M;F$?\#%)]NM/^?J#_OX*`+%%5_MUI_S]0_\`?P4W^T;/M<(?H<T`6J*J'4K0
M?\M2?HC'^0IG]K6G8S'Z6\G_`,30!>HJC_:D':.Z/TM9#_[+2#5(CT@O/_`9
M_P#"@"_15(:@#TMKK_OR1_.G"[9AD6MQ^*@?UH`MT56^TR]K.<_BG_Q5'VB7
M'_'G/^:?_%4`6:*K?:)O^?.;_OI/_BJ0W%Q_#9/^+K_C0!:HJF;B][6(_P"_
MP_PIIGU'^&RB_P"!7&/_`&6@"]15`2ZH?^72U'UN"?\`V2EWZH?^6%H/^VS'
M_P!EH`O452!U+NEH/^!L?Z4[%^>K6R_\!8_U%`%NBJVR][SP#_MB?_BJ`E[W
MG@_[\G_XJ@"S15;R[S_GXA_"$_\`Q5)Y5W_S])_WZ_\`KT`6J0G`JL8;K_GZ
M_*,5.`PC`)W-CD],T`0W%V(9(XU3S))&`"`\@=V^E4;W489YC9(YP>)G3)VC
M.-O'<_XU(NFSABS7>XE2,^6,Y/<G/\L4D&CK`\927A<LPV<ES_%^7`':@":2
M_M+,>46(\O"E44G;G@#CUI+K5[6SV^>67/!P,[#C.#4<6D^4T9$['86/('4_
MQ?7ZY_"I/[,B9V,H\Q-NU4/1?4YZY/K0`Z348T945)))"%)10,J#TSG_`#Q2
MVUZ+FXE2,?NX\#>?XB><#\*@.CQ#S-CLN]@V3RW'8L>2..E6;:R6!B[,TLA8
MMN?'!/I@<4`61R*6DI:`"BBB@`HHHH`****`"BBB@`HHHH`****`*FH_ZD?[
MU1:?_K#_`+O^%2ZA_J!_O5'8?ZP_[M`B_1110,****`"BBB@`HHHH`****`"
MBBB@`I,G/2EJ*6"*<`31)(H.0'4&@"3--+J.I`_&H?[/L_\`GTM_^_:_X4?8
M;0<BUA_[]C_"@![74"_>FC'U<4PZA9CK=0#ZR"E^R6H/%O$#_N#_``IXMX1T
MAC'_``$4`5VU;3UZWUL/^VHI/[8T[_G]@/T<5;V(.B#\J<`!T%`%,:M8GI<H
M?IDTO]I6O'SL<^D;'^E6Z*`*WV^'^[,3[0/_`(4?;HN?DG_[\/\`X59HH`K&
M^3M#<'_MBP_F*3[=QQ:W)]O+Q_.K5+0!2^WO_P!`^[_[Y7_XJD-]/_#IET?^
M!1C_`-FJ[2,ZJ0&(!/`]Z`*0O;L_\PN<?62/_P"*IRW5VQ_Y![J/5I5_H35R
MB@"KY]YG`LU^IF_^M2B2\QS;P#_ML?\`XFK/6B@"MYE[_P`^\'_?YO\`XBC?
M>G_EE`/^VC'_`-EJ:::."/?(<*/8G]*?0!5)U`]!;#\6--8:B1Q):C_MFQ_K
M5REH`H;-3)YN;4?2!C_[/1Y.HGK>VX^EN?\`XJKU%`%,07W>]C_"#']:<+>Y
M/6\;/M&O^%6J*`*XMYN]Y-^"I_\`$T?9Y<_\?L_Y)_\`$U8HH`K_`&:3_G\G
M_)/_`(FE-LQZW,_Y@?TJ;>N_9N&[&<9YQ2YH`K_9/6><_P#`Z7[&G>2<_P#;
M5O\`&E@N4GDD2+++&<%\?+GT_"ILXH`K_8HO[\^?^N[_`.-'V*+NTY_[;O\`
MXTRUN7NIY&C5?LR_*K]V8=?PJW0!7^PP=Q(?K*Q_K3#I=DPPT"M_O$FKE1SS
MQV\+2RMM1>IQF@"L=)T\];.$_5`:!I.G#_EPMO\`ORO^%.NKAPJ)`O[Z7[H;
MHOJ3_GK5A`0H!8L1W]:`(5T^R3[EI`OTC4?TIXM8!TAC'T05+1D4`($51A5`
M'L*7%&144ES'$Q$IV*%SO;A?SH`EQ1BL]=3#P/.$^0G;$`<L_IQVJ:SADB1G
MF8M-(=S@,=H/H,]J`+5&,TR-RR*SHR$_PG!(_*G,ZJI9B%4<DGH*`%Z=Z@EN
ME23RD4R2XSL7L/4GM52\U$O(EK8_O)WY)QPB=VR>"?:G6]D?*,<NT(3EP#EI
M#ZL?Z"@"W;R^?$LF"H/8U+BFJ54<<`#\J;-/'!"\KMA4Y8CM0!)B@\"J-I<R
MW!:1D,4;?ZI7&"WOU_2HY[N;Y;6/8]V1F78?EC'KDC\J`+WGIYIB#`R`9*CT
MJ6LZW6"V42F:+RR""V[C/MV]<]ZNR3Q18\R1$STW'&:`)**IW=\D$"21J9S(
M=L:QD?,?:DLIW_U5S*IN3DLBD87V'_UZ`+M%)02%Y/`H`6BJB:E:R2B-)"Q.
M<$(<$#J0<8Q[TW^U;,R>6)"S;Q'PI/)Z?A[T`7:B>:-)4C9@&?.T>N*JW.J0
M0[D7=+(I"E4&<,>@-.M+9]S7%Q@W#C'J$']T>U`%VHYI4@B:65@J(,L3V%1W
M-U';[0V6=S\JKU/O[#W-9[7/VEEGE1A:AP(HP`6F;L?IZ?3-`&K&XD177[K#
M(R,?SI]5K:Y2?=QM9205)&>/I^523S)!"TLA(51DD#-`#;NY6UA,C<GHJ]V;
ML![FGPL[1J9%"O@;E!R`?2L:WU`W5XLTT9CB1695<@;%'\9]SV]LU8AU7SVW
MI#^X9<H^[ECV^G'/7ZT`:M(:Q8==8JYGM_+*X"J&Y<DG&,XXP,YI\FHW)"0Q
M1J;B1MJD@X08Y)&,_P`J`+C73/?BV@P=@W3$@G:.P^M6ZPK6]6RM)\*&VN?F
M)R6)."3]>PJQ!J,S[5E5%=/]<%!.">BJ.Y]?2@#6HI!TI:`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`*FH?Z@?[PJ+3_`/6'_=_PJ;4/^/?_`($*AT__`%A_
MW:!&A1110,****`"BBB@`HHHH`****`"BBB@`HHJ*YGCMK>2:4D)&NXX&30!
M+5:]NTM(2[X))PJYQDUFB\N3BY>3$:_,Z*5V(N.['J?7!XIVFL;NY%U,OFNW
MW!CY8%QV]S0!;LXYV;S9I&'!^7H#[X[>W?UJ2\O4M8R?OR$X6,$98_YYJ:4[
M(V8=0":YU9)9D:X2-9;VYX3<N!$,=!D>G)_R*`->>9Y[@6L#8*X:9P>8QV'U
M/Z5>KG;1KB"WG>$RS.N0&?(R<X+M_0=<#\M/3!/@F1V<$#+,3\Q]O_U#Z4`:
M%%5=0DDCLY&A#&3``VJ6(R>N!UQU_"LZ59T"I;)=,DAR\C,0QP.@S]W/J<4`
M;1Z5'',CRO&K99,!L=C6&BSJBHOF17%U]<QCO@'H!_>ZDT^&RN;?SC"DC2(&
M"%F^]ZMGNQ_(4`;,KNB@QH'Y&[G&!W/O56"\>ZN<P@BV4$;V0C>W3CV'\ZI_
M8KE;78J.3(P\XEQO<'KSG@>@S3)+*ZG&R2W41`A%1'P$0#L/7MGMVH`VII5@
MA>60X5!N)JG9PO--]MN@1(01$AX\M3V(_O>OY57?3Y3)`/+3RH_F5`<*K=LC
MOZY[GTK5B4K&%9MS`<G&,T`-GF6"(N^<9`X&2?PJIJ%]+$ZVUM"9+B525Y&%
MQU)&0<5"UG>S7,;RF,"-RP8$GCL`/ZTP:;=9F(,>Z1\%S(=Q3^[NQD?KUH`O
MVMS'(FP2AY$'S\@D'WQQ2+J%J\4DB7$92/[[`\+4$NFL8-L94-P#'DJA7^[W
MXHDTUIYE,QC,).Z2-5P&(&!]?Q]!0!'9S1ZE=><Y^5/FAC(Z=BQ_SQ6KVJC9
M:>]O%&DDQ8IG[HQG_P"M[=*O$97%`%5[^WCD$;R@,3C&#R>F![\BG&\B\XQ;
M_F!PW'"G&>3TZ5$FFQ@NTF&9C\I7Y0@[!<=/?UJDUD$,=C$[,6!9G"\JN>K$
MYY)X'Y]J`+$.JQW%V$B;,1)0-M/SMWQ[#FI6U.`726XWF1\;<+PW/;Z4)IL:
M3%U.$P`J#HHQT'MW.,9[TZ/3XE1@_P`[-U8\?@,=!]*``ZA&)O+`8KR&E&-H
M(Z_7\/6H_P"T"BL\H4*S$1*.&('4G/2HUT9$C1([B2-4!`V!1^?')]ZD_LF!
M6A9&D#1+M#9!./Q''3MB@!)]52$1GRG;=][&/DXSS_GO39=29[2,QQL)Y^(D
MX)Y/#?3O]*E.EP%7!+$N>6)Y`SG'T]JD:QA+JV""N?XCS]:`,^VN8[>:4^89
MY%_X^)F(`4CKCCH/3I^-227[W&(U4P1LN]I2V"B>N,<$]OQJT--M0C((_D+;
MMN3@'.<C\:?%8P1.S(G+-N;+$Y/KSWH`D@CCBB5(E`0#@"L_4KIVE>U165%3
MS)I,X^7G@>Y]?K6K4,D,7F&9E&0!DGV_R:`,Q=0E2QB6VBC\U_EC'\('_P!8
M=>?\*MVU]]IF4Q_ZAAA25.7/]X?[/O\`Y-66/^TYT5^(4^9@.,@]`3[\<>U:
M<,$<*XC0*.G`[4`/8XK"DG:<O>3J6C'$$"LW)S@EL<9SP*WB,U$EM#'CRXD7
M!R,*!@^M`&);W$UM++<W95V5/G\M<Y(YV+].Y_4]M&QGN))<3\/CYT7&$]/?
M]?RJVL$:EB(T!?[V`.?K3HT6-<(JJ/11B@!L\GE0/)Q\BD_D*Q(KVY80QRW#
M"2[)(*J,1*.PZ[F.<=_TK?I`H&,#@4`8TDMZBX=C"\S[59B#M49/`YYI9WD,
MR12[C`B>8R-]Y^>-WMQD_P"16S2T`<\RWLMQ'+-)(GF9\I5'W%XST[G(QGI5
M@2W<MQ-))'.BQ'"1@'!XZG'WOI6S10!A%+UIE\PW*^8`Y"$X`'1<]`W.3VQ6
MS$&*`R8W=]O2I**`,R:,K=23%)-S*%W(N25&?E!['/.?>H'M9U3?$GD^:X#I
M&,G8`>IR/F)/)S6U10!BG3C($MA'Y<1;S&P`0!Z#_:/KVI7L)4$4(7S8MY9@
M.`>X+\Y///X=*V:0\B@#!F2Y@F:9H3)=,_EP_,.5_P!D=N.3GL*D73)EM!"-
MNUV!F&<-)ZY/:M);8_:VG=RW&$7L@[_B:L4`9(TZ4LRND+Q!`L:GA(QW^7O^
M=1-I5S(^Z?R9?,)\[>3EQ_".G`''`ZXZUN44`936$YO3,95+>7M1\<J>^!T'
M:B&TDLH-T2;GC4[55MVYCW)./K6K10!';^8($\[;YF/FVCC-1:A;_:[1H<@!
MB,YZ$`@D59HH`RQILR^<?M`+2$?-LYVCMUZ#M^N:4:6%N%DCF90JGMEBQZMG
MU[=/IBM.B@#+M]+,+18N"/+!&`F,DXRWU]SG\*T8D6-`B@@#U.?UI]%`%"ZT
MV*ZG:5WD4M&(SMQ]W.<=.^:/[,A,T<I>4LB&,#(P![8''X8J_10!%%;Q0C]W
M&J=N!BDN+>.YC,<H)0GYE_O>Q]JFHH`IMIMLWF!U++(<LI/'3'\J<VGV[H4D
M4N"-IW'MZ?2K5%`$+VT3A05QL.5*G!';C'U-,:R@9%4H=HSQN/.>N?7\:LTE
M`&1?L]T%M;3:N&`5Q_"1W'H!_/BKMG86]FBI"A&T=223SR>OK4Z1(C%E15+<
MD@8)J2@!*6BB@`HHHH`****`"BBB@`HHHH`****`"BBB@"K?_P#'O^(J&P_U
MI_W?\*FO_P#CW/U%0Z?_`*T_[O\`A0(T****!A1110`4444`%%%%`!1110`4
M444`%(0#UI:2@"C*DES>+"49+>+#,<<2'L/H,9J]@>E-D=E1F5"Y`SM!QFES
MQTP?2@!<48'I1FDS0`N!Z48'I2;O7BC>"2`02.V:`%I"/0<TT2J<X(..N#T^
MM()XB"1(G`R?FZ"@"M!#Y!ENKQT\P]6Z!$[+_P#7]:MDJ%W,0%ZDFLV.1=2O
M-Y8?9XCF-#UD8'[_`+KZ?G1<SK>S/;A@+:$_Z0Y.`3_<]QZ_E0!HQLDD:R1D
M,K`$,.XI^!4*3PA8@CIM<?)M/!&.WM4K,%!)(`'4DX%`"X'I15:._MI(Y'64
M%(_O,<@#\>]"ZA;M"TNY@BG!RC`YQG@$<]:`+.!Z456BU"WE<JCY(3>3@@`?
M6H#J0-I+<;-D>[;$3R9.WW?K0!H45E6\[17:_:G+W$PXBC4XB7WYX^M02SAH
MY46?_0+<?O)7#,SGKM!!Y'K^5`&Y1TZU1BU&(E%\J1"R[BK`#8OJW/`JBUT;
MQ_M#OBSWXAB*<S'N2">@_IF@#<ZU#%;QQ222*OSR'+,>I]/RI;6;SX=^S8<D
M;2<X]/TP?QJI=:HL#2+'"TQB(#[3T)Z`>I]A^.*`-"BLZ;5#"(U>#]Z3AE#\
M+W/..<#DTU-5+0*SQ*DKY9%+\;!_$3@8'X4`7YYD@B>1SA5'^12PR&2,.R-&
M2,[6QD5G6I:]F2>YVJ@)\F(=\?QD?R]*L7UZEKM0;3(P)`)P%4=6)]!0!<HR
M/6LG^TYUMC(T2&20XMT'\6>C'T!]/\B.UO9((99)L2'V!R[]]O/W1TX%`&U1
MFL.UO9XY))[S9D9#!1G:>-L8YY;UX_'TG:_GA#33I\H4DQHN0A[`GU_SZ4`:
M4LR1;-[A=[;5SW/I3^HYK%^V72P$R.KSR'"1QKE4ST&?7USP*9#?74:O-/()
M%BB*L@7&YP>6Z9QP1[^E`&J\D5MY<44?+G"H@'XFK`Z5F:5;I\TTBI).WS-(
M%``/]T?2M.@!:***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBDH`K7_\`Q['ZBH=/_P!:?]W_``J;4/\`
MCV/U%0Z?_K3_`+M`NIH4444#"BBB@`HHHH`****`"BBB@`HHHH`*2EHH`PX%
MN7EFNIA.7&0HP<1J#_"N.6-.M["YA(N6<JY#,4W%O+)QT'<X'>MG`HH`PUTZ
MZ0&[C^68AB(F8D*<8!_VCC/YTAL[J.T8PAV<X7<Z_,V2.>N<?4\].!6[2T`8
M(TVXMH0;92,X79@%U!/S$-D#)_2IIM/E2'Y(\H<!X(L`E/3<2,^];%%`&+<6
M%R[J88(XXV!+Q@\%@!MW>H]AZ4'2YFM#&RJ3(RF5<X,G/.2/;/`Z5M44`9DF
MG2-'*RR;)6CV(B\(HQP.F?3-4KNV%I91PM\Q4@+"A.6!///<D\9XK?/2JD5E
MB<RR.&(.0`N.?4^I]*`*UA8W"$2SLJNV-P3L!T0<<*/UJY>P-<0;%V\,"0W1
ML'H:L4M`&;+83S312/*A"$L$V?*IXP1ZD>]!TJ,R@Y)B/+AB6+GWSQCUP/TK
M2HH`R%TJ=4PER%8N6)\O.?3OV[=O:IQIBJD"H^TPD8;`/&",#\\UH44`4(]-
M1)9&SE7()&.OL3WI(]+C6!(F=GV'*L0..<^GK6A10!0BTR*-9%#RL');YFR0
M3WS_`(]*7^S8B\<A+>9&,*W'`Z8`Q@?@*O44`1Q1K%&$08`JJ=,MS('(?(8L
M,.1C/7'YU>HH`IG3[?;(OEG]YC)R>W0#TI&TVV<8>-CQM/SGGZ\\GWJ[10!%
M#!'"FU%^I)))^I/)J.>VMY3YD\:-A2"6Z`=ZLTUE##!&0:`,^QC6>0W(0+"O
MRPKV(_O_`%/\OK20(EQ>'R45+>W8K@(!O?\`P'\_I6B%`7`&`.`*4`#I0!']
MGARQ\F/+?>^4<_6G>7'LV;%V8QMQQ3Z*`&A$&,*HP,#CH*`B`$!5P>O'6G44
M`(`!T`%+110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!2$@=:6L^XACGU+;/AXTB#+&W*DY.3@\'H
M*`+S'`SG&*SI+V:XF2*T*J&.=[#)*_W@/3MGO^M5I+B*&*;[WV96'EQ\CS6/
M1!ZKD?Y%1AKF!A;Q&+[?<J7D9C_Q[KZ#C[HZ?6@#>4G')I:YY+F29`#*JV<#
M@&59&9IG'\([G\/I6L-1A^S--AP%.W:RX;.,]*`+E%45U6V:V,ZDE`<<=^.U
M)'JUM(7Y95C0.S,,``]*`+U%4&U>!86E=)%48QD#G]?YU+#?1S2!%5@VT%PV
M!Y>>@/O[4`6Z*0'(I:`"BBB@`HHHH`****`"BBB@`HHHH`*2EHH`JW__`!['
MZBH=/_UI_P!W_"I[_P#X]F^HJ#3_`/6G_=_J*!&A1110,****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBDH`6BFE@.I`_&D,J#JZ_G0`^BHOM$(ZRQCZ
ML*;]KM^\\0_X&*`)Z2JYO[0=;J`?]M!1]OM/^?J#'_704`6:*J_VA9_\_4)^
MC@TC:E:+UF4_0$T`6Z*I'5;0?Q2'Z0N?Z4G]K6WI<?A;2?\`Q-`%ZBJ/]J0]
MH;L_2UD_PIPU!3TMKK_ORP_G0!<HJJMX6Z6MQ^*@?S-.^TR?\^<_YI_\50!8
MHJM]HFS_`,>4W_?2?_%4OVB7_GSF_-/_`(J@"Q150W-S_#9-^,BBD^T7O_/D
MOXS#_"@"Y15'S]1/2RA'UN#_`/$T>;J?_/K:CZW#?_$4`7J*HA]3/6&T'_;5
MC_[+3@=0/5;8?0L?Z4`7**J@7IZR6X_[9L?ZTNV[_P">T'_?D_\`Q5`%BBJ^
MV[_Y[0_]^3_\52>5=G_EY0?2+_Z]`%FBJ9MKLG_C_<?2)?ZB@VER1C^T9Q]$
MC_\`B:`+F:,U2^PS'KJ5V?PC'_LM.%B_>^NC_P`"7_"@"WFC-5A9`8W7%PWU
ME(_E3OL<?=Y_^_[_`.-`$]%0"SB'\4W_`'_?_&D-E$>IF/UF?_&@"Q1FJW]G
MVQZQD_5R?ZTS^RK$];:,_49H`M[AZTAD0=74?4U5_LC3?^?&W/UC%*-*T\=+
M&V'TB7_"@"<W$(ZRH/\`@0I#=VXZSQ#ZN*8MA9I]RU@7Z1@5(+>$=(D'_`10
M`S[;:?\`/S#_`-]BC[=:8_X^H/\`OX*G``Z48H`@%]:'I<P_]]BC[=:]KB,_
M1JGQ10!!]NMO^>RGZ<TGVZW[,Q^B-_A5C%&/>@"#[;#V\T_2%S_2D^VQ?W9_
M^_#_`.%6,"C&*`(/MD7]V?\`[\/_`(4GVV/M'.?^V+_X58Q1B@"HU[C[MO<M
M](C_`%I/MS\8LKL_\!'^-7*,4`4C?3?PZ==G_O@?^S4?;+H]-,N/Q>/_`.*J
MX>%))X'K5:._@DG$2,26SM;:=IQZ'&#0`S[5=]M.E_[^I_C3UFNR/^/,+_O2
MC^@JU10!6WWA/_'O$/K,?_B:7=>9_P!1!]?./_Q-6*6@"I+%<7-K+%(%A9EP
M&CD)_H,5!_9\LB(DDBJL2@(%&X_B3U'M6E10!EIIL[7;7%Q<AN"J+&FW:/7)
M)YI%TEE^T+YP"2G*X7D<8&3GG%:E%`&;'I3J\+&X.(XRFT)@#W'H>.O)^E2R
M:;"X10BJH(+@*,O[$_7!]\5=I:`*3Z;`\XD*8`.[8/NL?<=ZB71X5@$3/(X#
M;@7P><YR>.?QK2I",C%`&%=IYCQQ60+3;\B5\$`]#QCH/P&<8K1LM-ALT55+
MR%,X9SDY/4_4^M30VD,#%HUP3U)))^G-3'B@`'2EJ&"YCN-YB)94;:6QP3['
MO4U`!1110`4444`%%%%`!1110`4444`%%%%`%:__`./9_P`/YU!8?ZT_[M3W
MW_'J_P"'\Z@T_P#UI_W:!&A1110,****`"BBB@`HHHH`****`"BBB@`IKJ'1
MD;HPP:=10!272[0?\LB>W+L?ZTX:;9C_`)=T/UYJU0"#T(-`%;^S[/O:0?C&
M/\*/[/L_^?2#_OV/\*LTUI8UD5&D4.^=JD\G'7%`$(L;0?\`+K#^$8IPM+8=
M+>(?\`%344`1BWA'2)!_P$4X1J.BJ/H*=F@F@``QV%+6=/?/)*UO9E3(,AFQ
MG!],?U/`^O%7HM_ECS""V.2.F:`'T4E0M<QBY6WW$RLN[:!G`]:`)Z*I0S2W
M-T3&VVVBR"<??;T'L/7O5R@!:*3-%`"T5')($9%VL2QQP,@?7TJ"[NFA*PQ;
M6N9<^4C=\=2?84`6Z*BCW10CSI=Y4<NP"YJ.\O8+--TSA2?NKU+?0=Z`+-%0
M6DKS6Z22*J,W\(;<!^-39H`"0.M`.:SIG-_<_9X_^/:,_OW_`+Q[*/Z_E6@`
M``!@"@!U%)FC(H`6BHYI5AA>5SA44L3Z`5G_`-H3;7N6C9(F`$$;8!D)Z$]Q
M_09S0!H":,RF(.OF`;MN><>N*DJA;>5:0>?<3Q[YFW/(6&"3T`/H.U701ZB@
M`=E12S$!1R2>U)%(DT:R1MN1AD'U%9L]S'?RK`DI%LK[974\.W3R_P#'\JNK
M<PB7R5?YAP549V\9Q[=.E`%BFLP12S$`#DDFH8[N&20JD@;!()`.,CJ,],UG
M3WT.HSK;1G?;!OWK[3ACV3\3WZ<4`:EO.EQ&)(\E#T)!&?SJ6JD=U&UT;>'Y
MMBY<CHOH*EGN8X`#(V"QVJ`"2Q]`.]`$U5[FZ2W3+<L?NJ"`3^?;WJ.74(HH
M/,8/N+%%0#+,WH,5'9VLA9KB]93,^,HI^5,=![XH`MV\ADA5V0H3_">U*TJ*
MK,S`*OWB3P/K5&^NW,GV6SD42XS(Q4D1KW/U]*HI<12&*R2-W@5\/E<><WMD
M\@=2?:@#9M9C<1"7RV12?EW<$CUQ4]45U*!Y_+C.Y5.UGSP#Z>_/%37ETMK#
MYC*S9.T*HR6)Z"@"Q166VK%$.^-%=!NF7S,B+T!..I]*$U8R",1HKLPW.P;Y
M$7USCGZ4`:)E149RP"KG)SP,=:@N+M4MQ+&/,9P!&H_C)Z5DS/!*\C%&BL8B
M2RK\OFR`Y/`[>OO1:WC/=^?<Q@+&N!N;)B4CC/JS<>]`&U&QCA1KAD5\`,0<
M#/MFI:R/[39XY))8D$?!B1CEF&>&/H">@Y/I3[749YIE1HU55)5^.<]A]>F1
MVH`U:2JU]="TM_,."20J@^IZ?7Z#FLZ/5[GS"98T"1DAPBDL3V4<]>1GL/6@
M#:HK'AU&ZEF&XQJ@R6"KGWV@GJ?4]!5674[^5Y#!+&B-'E/ESMP>6Z=!SR>O
M84`=%1FL)-1NUA+F17:9]J$JNV,`9))XYXZ9XIKZA.B-$TK?N\;W;`9B?N@'
M``'J2/I0!J7MQ(I6&VVFXDZ;N0H[L?;^N*F::.%1YLB+@<EB!533(-@,C@RS
M2`&2<KC=Z`>PIVJ6D,UK)N3!?:KNB_-LR,\CGIF@"HD[ZG+YHA+6RM^Z1@5#
M$?QL3V]`*OV]N8W,LK;YB,9QPH]%':J,DDLT>ZV#G'W50E410>3D?>)]*6`W
MTK"<!RS'=L=C&L8]!Q\Q]2:`-;<`*;)*D94.<;C@<=36/*EY)(UR7D2*(\@L
M4WCOQV`Q]3S5=[6[N[A9I_.Q)D*$!'EIW'L3[_\`Z@#HLT;@#6.L%W>LQN$*
MX)$<;CY8P.Y_O,?7H*+FPN;V9@[,`@ZG@,<?=7VQU/7F@#8W@#)J*YNXK:`R
MRD[>@V@DD]@,5ARV%Y=L!<VYV!RH52-J(.@4'N>[=1VJ<V%S]KA(C`BA0&)!
MC9&W\R0/Y]J`+EI<7$L$C.$6=LM'$X*E!VSZ^Y%7$EC8':ZL5^]@YQ6%'IUX
M$+LC^=,W[^3<N\K_`'`>R^_6K,NG7'E+'$50/A2JJ-L:_P!?ZGVH`TQ<PL5"
MRHQ;H`PYJ3I6+9:5+;W+,!Y:CY5(.>/4?[1]3T["M>4,T+!/O%>.<<T`1M>V
MR&0//&IC&7!8?+]:#>VZH[M,JK&,N2<!?QK*M=*N(4@0I$$5B[J22"W9CQS]
M..U/ET9@T(C<R()-\HE/!_(<T`3W=\8=DT3"=)1B*$##,?4'N*HO<O'&;6>Z
M3SY#FXECD)$0[`#L3T&/K5IM.N1>-.DB$^5M5R,,#Z#C@=!^=-MM&:W,)#KN
M7+.V.K^N.^.V>E`&M%&D42QQJ%11@`=J?3(D$<:H"QQW8Y)I]`!1110`4444
M`%%%%`!1110`4444`%%%%`%>]_X]7_#^8JOI_P#K3_N_X58O?^/5_P`/YBJ^
MG_ZT_P"[0(T****!A1110`4444`%%%%`!1110`4444`%)2TAZ4`9>H7K/*;:
MUE$;("TTA'$:=S]:-/NHH4@@$;1HRY0OA2>>X]ZFGTU+B25GDD`EQD#'!'3M
MS]#Q5B"W2$<9+$Y+MRS'&,DT`1W]VEI!O8.S-\JA!DDGI_DUFQR/:2&><O<W
M;$(ZK@A>?NKQUQR<>G.*U[B!+A55\X5@PP<8(J-;.!)4D"?-&I5,_P`.>I^I
M]:`*AUA#%N6++A0SC>,)GH"?4^@I7U1D10\`$A(RGF#"COD^PY/I5E["VDD:
M1HR68ALACU'0C\A2FQMF5@T((9"A!S]T]1^-`%.+5B\<CF$*NW=&-W+#NQR!
M@=.>]1->S&%+8R?OF&9IL86,=\>_I[U;N[:TA@9Y(MW0;<D[ST4'UYQ2:?ID
M4'[Z6&,7#G>VT<*>P'TH`IV-SY:I]E@*6V2!YJG?)_M9/;OG_P#54MM?W<ET
MH>%3;NQV21JQ!'3'Y]SC@5HBSMP''DIAP5;CJ#U'T]JE5%10JJ`HX``Z4`5M
M0N&M[1BB!G;"+N.!D\#/MFL*0^3&T%NNZ0KNN+D`DD'C"?4\#\?K72R11RKM
MEC5UZX89%-,$)#@Q)ASEAM'S'WH`R(KN>&&*W4)OY)?@)&@QQ[MR/:KZ77DV
M0EF#L>G;+>_;^E6MB`#Y5P.G'2G<4`8/VY_.>96+R,WE1$*?+3N3[_UQ2QWM
MRT3SK)(R[/EC=5'.<;F(''^[6[@>E&!Z4`8+7=S"FUI)7.-\DA3&X?W4';ZG
MZU:TJ%XR9'!DD?[\K$X]@H/.!Z_SK4XHP.M`&//=2W4ZP?9Y?+WX>-H^H!ZD
MXQ@^E1RF[-Q+<.K/)"=L*[&V1YX+=,M^&>/2MS`]*3`'8<4`9+174,3S1"1G
M90I9B2YR1EMH&.!G`%,>VGP(;3SHQ/\`>ED))4#O[9K:Q1@>E`&1IMG)#&@6
M'RBC,,L0?E+9Q@<$X`_^O5B]CN)YHXP@-OC+_-C)[`]\>OK5_BC`H`R9+*Z9
M/(W(8F)+;$V`#TQDY/Y8Z\T[3+*6%O,D01N1ALMN('8`_P!3S6I@44`4=1MG
MN3"H!,:/N=<X!QTSZC-4Y-+GGF,\Y5WW;5`.-J'K]"?TK:XHP/2@#*&G2_:-
MY8;0@2-0V%0?3'/Z9J[<P-+9R0H?F*X!;U]\58XJ.>9((FDD.%49/&:`**Z>
MZVP1'6)XT(C"=`Q'WB2/Z4?V6WV;8LIC8?=V,1]23W8\\UH1MO16((R,X/44
MZ@#.DTPO;%%E\M\;5*Y"JN>>,\GW--.DF-G^RR+;H8PBA5Y'.>N>_P"=:>12
MT`4+/3V@=I)IA(Y.<(FU1Q@#&3FGSV7FWBW!DQM4J!CE<]<'MGC\JN5'/"EQ
M"\,H)1Q@@$C(_"@#+LK9;N;[7%F&!1MA4(H)]6Z=^U:D<2Q($084=*<HVC`X
M`Z"ES0!3ETZ.66:1I)`90`P!'&.F./<T+IENI7:"JJ@0(O``]NX]^>:N9HS0
M!5M]/AML",$*I)5>P).:EGMDN%59-V%.X8.,&IJ*`*D.GP02M)&N"QW$9XSZ
MXIWV*$W)G*DN>N6./RZ59HH`IC3;;(/EY(?S.6)YSG\L\XZ4Y+"W1Y7$8W2D
ME\DD$GV-6J*`($M($556)`$(*_+T-.2WACD:1(T5F.6(7DGOS4M%`#'C5RI9
M02IR,CI3/LT.6/E)E_O?*.?K4U%`$0@C&<(HR,'CJ*<(E7HJCC'3M3Z*`(_+
M4KMP,>F.*=L'H*=10`@HI:*`$Q0*6B@"G=V[7<L4;C]PIW/S]XCH/I_]:K8&
M*,<YI:`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@""]_X]7_`,]ZK:?_`*T_[O\`A5F[_P"/>3Z56T__`%I_
MW?ZT"-"BBB@84444`%%%%`!1110`4444`%%%%`!1124`!.*S7O9;J41V3*!D
M_O"N<_X#Z]>WK2WUZ3*UG`2LFW+R]!$OKSU-5[.ZA@A5+2W)W?+$78!I<=3[
M`>OZ4`:TDBPQM(Y`51DGT%9ZW\P1IY(SME(%O!C$A]<Y_/V%0W5Z+MGA`*V\
M>#._=AU"KZY_E]:?9$7MW%<S#8JJ3;P\Y4="S>Y[>U`&C:K,L"BX=7E_B*K@
M?@*E!S5'4KYK142%-\LH.S)P!CDD^P%5+34'2%5?:\CY:,,V"R]2S9Z#\*`-
MD@$YHK)_M.=(GW1^9)N"QD1LJ'/3D]1[CL.U1_VE=NG[LQN8\J[(A.]O]@9Y
M`[GVH`VJ6LA-1N)2`J%1&0CLPP7?N`#_`)^G6@7E[)<L8U4P(X5MJ$G/<`]_
M3/09H`UZ*AFF\FU>9E/RIN*]_I6<;ZXACDN;A@8TR6"XV+Z#/5C[CCM0!:OK
MX6^V)`7GE.$4#./<^U):6K1R&XG;,A!&3U]^?PZ#@?K5;35:><W5P!)*PPK`
M?+$O4*/?U-.U.\<*UM#N1CA<[<DY_NCK^/\`6@#2219%#(0RGH0<@T/($1G8
MA549))X%8LL]Q`XCA22.&!1A%'+GMN/8>M$D=PT$<4TD[QSMF4[2&;V4?PCI
MQUZT`6X%-],MW*N(4_U",.<]W/\`2II-1MX[`W>XM#_>4$YYQT^M9SR7<"RP
MB.57?'E[%+`#H`.,+CO3Y8)#-;VJP%+5!N$(7AB.@9L8'//^-`%RVN+B1'>2
M$1L?]7$YP?Q//\N*8]])+<&"WC(\LCSI3C"=\#US^E4X?MSK+=R1S&900B$$
M*H'HO<F@V=TL,5LBR[)"3/*&`D;OR>WI]/RH`V%E3Y0&7+#(&[J*HB_:6;>!
MY-I&2))9"N&/3`.?7O\`A4"6]ZT#RF(QS,NQ4#`^6OHOOW)I&TZ4F"W\L_8T
M!)C+\L?]HY]>>]`&EYPCE832Q`,1Y:YP<?\`ZZ=+>00L5EFC0A2Q!8#@=ZS8
M[*ZE'FSJJSD@DL-P4`\*@SQ[GO4<VES7+>;,I+L=I&[D*>N>WY=*`-J.1)8U
MDC8,C#((/!J*:ZABD2-W`D<X51R3^'I[]*+6)H(%CX``PJJ.%'I[U0>PN)+Z
M6Z(4L!B$EONC'.!V)/Y>]`$ZZC;P$Q37(>5/O%4(ZY[#\OPJ^#D5BC2)3-&[
M>6W&7)Z[@>!TY4<GW/6MB-2J`,Q8]R>]`&=>WKR3/9VKHKA-TLA8CRUSCTZ^
ME5[6ZCN;FWB3=]GBR%R"=[#^+)ZJ/U)J0Z7-_I`4QJ9I"6?)+;<].GIV]:0:
M1(@D2*01+L,<3)G<JX_GGJ>M`%ZVO8KB0I$'(`)W$8!Y[=Z=>WD=E;M+*&*C
M@!1DD^@%16-B+7&<#:,``D_J?Y=*;)B_N_+"JT$#9<GG+CHOX=30`RUU$OYA
MFC==I&`!D<]%]SZTB:Y;,TV]'1802SG!7&<<$=<FECTZ6.W91.!+DD.$R`<]
M<$\G^5.DTBU,`C2,*5``ZD'G/S#^+GUH`5M45(6E>(JO!7YNO^>/SJ(ZPQ;8
MEJ3)P-A<?>/;\!R?3OBIFTU)`OF,QV\[0`%SVXZ8'7_]5(NF0J8V5I0R!OFS
MRQ;&23C.?>@!3JD9N#'&NY$^_(3@#T`]3[57CO!;%PL:QPJ1'#;H`"6ZD^V/
MZ'O5C^S8MQ(+J"VX`8P#^7/XTJ:9"BKR[.K;@[G<<G.>O'>@"":^D=`D96.0
MMM9^H0=3^.`?ZUH0RK*`5ST!P1@CZBJR:9`KJW[QMI)"EN,GJ3Z_C5B.!4F>
M1=V7`!!/`QZ#MUH`FHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`(+K_CWD^E5M/_`-:?]W_"K5U_Q[R?2JFG?ZUO]V@1
MHT444#"BBB@`HHHH`****`"BBB@`HHHH`*@N[C[/`6"%W/"H.K$]!4],:)'=
M79%+)RI(Z4`4;33$1"UPSR2R'<^YB1GT^@J1-+M$*D1Y(79RQ.1Z'UJY10!7
M-E`7=BN2V<Y)XR,<>G'I2[+>QA>3B-`,LS'^9-3T,H888`CT-`%"TMVN&DNK
ME2/-&U8F_@3_`!/4U.+"V!!$*Y!SG&3GW]:L=*6@"*6WBF"B5%<*<C<,X-(E
MM%'(SQQHCN<LP49/U-344`1"VA$K2B)!(PPS[1DCT)IT<:1($10JCH`,"GT4
M`(PRI!Z529);B\4$%+>$[AD???M^`_G]*NT4``%(5R<YI:6@!N,GK1BG44`)
MBBEHH`****`"BBB@`HHHH`****`"BBB@`HHHH`9(N]"H8KD8R.HIMO`EO"L4
M>=JCJ>2?<GN:EHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBDH`6BBB@"*Y_X]Y/I533_P#6G_=J
MW<_\>\G^[5/3O]:?]V@1HT444#"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBDSB@!:*2EH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*0#%+10`4444`13_`.ID
M_P!TU4T__6G_`'?\*N3?ZI_]TU2T[_6G_=_PH$:-%%%`PHHHH`****`"BBB@
M`HHHH`****`"BBDH`BNIQ;6[S,"0@S@=35*19Q"UQ>2-G`VP0MM`)Z#(Y)SB
MKTZ":,J#@YR#CN*S[^26#R]KK-=L2((L;5SW)Z\`<T`.$\D-\MO"[.A(#^82
M?+.,X!ZG(]3Q^E:58R/'9>3'O>5HV)R?O2R,#_(9)]!3X]7Q#)-/$J0ID*R/
MN\P_[(P,_6@#3DFCC=$=U5G.%!/)/M3ZY^*66.X22=C)?,I/EDJ5A3/`.!U/
M^>!5E]2FE(2V6,%SM5G.=WJP_P!D<\]Z`+TEX!>I:QKYCD9?!_U:^I^M6JIZ
M=#%%`3%(92Y)>4]7-6Z`%HI**`%HII91U(IIFC'611^-`$E%0FZMQUFC_P"^
MA2&]M1UN81]9!0!/15;[?9_\_4'_`'\%'V^S_P"?J#_OX*`+-%5OM]I_S\P_
M]]BD;4+1>LP/T!/\J`+5%4_[3M.SN?I&W^%(=3MA_P`]S_NV\A_D*`+M%4O[
M4A[179_[=I/\*/[2C/2"[_\``=Q_,4`7:*J"^!/%M<_]^\4[[6QZ6MP?P`_F
M:`+-%5A<R?\`/G/^:?\`Q5+]HD_Y\Y_S3_XJ@"Q15;[1*?\`ETF_%D_^*I#/
M<=K-_P`76@"U15(SWW:RC_&?']*/-U'M9V_XW!_^(H`NT57MFN6W?:8HH_[H
MCD+?S`JQ0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%)S10`M%%%`#)>8V^AJCIW^M/^[_`%J])_JV
M^E4=._US?[O]:!&C1110,****`"BBB@`HHHH`****`"BBB@`I*6B@"I-9B64
MR>?<(3V1\"FQZ?&DC2"24N_WF+<G\>OZU=HH`IRZ=;2+&ICPL88*%.``W6E3
M3[9(1$L9"C&/F.1@@C![=*MT4`5?L%MS^[^\,-\Q^;Z\\]3UI$TVTC*E8?NC
M:,L3QZ=>E6Z*`(Y(DDC,;9VG^ZQ'\JA_L^V[JY^LK'^M6J*`*9TRS/WH0WU8
MG^M)_9.G\9M(CCU7-7:*`*7]DZ<>MA;'_MD*<NF:>OW;&V'TB7_"K=%`$`L[
M5?NVT(^B"I%BC7[L:CZ"GT4`)@>E&*6B@!*,`]:6B@!,48I:*`$HQ2T4`)BB
MEHH`2C%+10`F!1BEHH`2C%+10`E+110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%)2TUE#8SG@YH`=1110`4444`%%%%`!
M1110`U_N-]*H:=_K3_N_UJ^_W&^E4-._UI_W?ZT"-&BBB@84444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`-;[I^E4--_UI_P!W_"M!ONGZ5GZ;_K6_W?\`"@1HT444#"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBDH`6BDHH`6BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`***0D"@!:*;N&>H_.D,L8ZNH_&@!]%,2
M5'8A74X]#FGT`%%%%`!1110`4444`%%%%`!1110`4444`(>AK.TW_6G_`'?Z
MUHUGZ=_K6_W?ZT"-&BBB@84444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44E%`"T4E%`"T4E%`!
M1F@]*I73VT4JF:296?IM9\?^.\"@"[1FL^1K2-E!:=BX!`5I&R#TZ?0T3&S@
M<+()<[=W\9`'N>U`&AFBLSS+##-Y;;%ZN4;'7'7\:5WL`V/LZ.QW``1@].O6
M@#2R,T9K,=["*W\R2S51D#'E+GD9^E(KZ>TBHMG%N)P/E3V[Y]Z`-)I8U^\Z
MK]3437MJGW[F%?JX%593;Q7`A6P!8C*D(H!IWF)Y/F16:;@^QE.T%3G'^%`$
MIU.P'6]MA_VU7_&F_P!KZ=_S_6__`'\%0QZA$RC;!\V2&7&,8..N.:5=1;[#
M).84$B'`3<1R<8SD`CKW%`$XU.R/W;E#]#FE&HVIX$A)]E)_I5:349`^(XE=
M&0,C$D;CC.,XQ^&<TG]HR,%4(`Y!_A;C&>V,]J`+?VV'TF/TA?\`PI?MD7]V
M;_OP_P#A6>^K2",LL2X.-F?XN`3^/-*NIRR711?*$1)VMU)''/)'O0!?%Y$?
MX9_^_#_X4AO$'2*<_2%O\*H?VC<&`':B29R<H2"-P`(Y]ZFOKRXMI-JHK*8\
MAL=&_P`,`_E0!.;[!XM+H_2/_$TAOG[6-T?P7_XJJL]_,R((7C5LL),_PX(`
M^G?K4MJ]P\ZEIF9#'G844#/3J/\`&@!_VV?.!IMU^)C'_LU+]KN>VFSCZO'_
M`/%54%Q,54/=2)NP7*Q`^6>?ESCU]?ZU%)+J)$DBN^T)A1@#G:<'&WKG'?\`
M"@#0%S='_EP=?K(O]#3A-=$?\>RK]9>GZ5GF2]BE193)C?SMRPQA>X3_`'NN
M![TY/MLWR(TBX;EWW+@X/.,>N..E`%_?=]H(?QF/_P`31ONA_P`L(?\`O\?_
M`(FJ06Z*[`TXG!P[$?+C/4=O\G-+`MV;AC.)0Q88VL2@&XYXSTQ0!<WW>.(8
M/^_I_P#B:-UX?X(`?]\G^E5;B*]DN2L998<@[M^,@]?RQ^M)#:W(*,SRAO+4
M'=(6`;=SQGTH`L-_:!/RFU'U#&FA=2[S6@QZ1-_\53#;2O:,C,7D$VX$-CC<
M,_IGBJTUK<.RA9MZJSY3</ERP(^O`/6@"X8]2/\`R]6P^ENQ_P#9Z!#J/5KV
M$#VMC_\`%5%)!*]O$8I!&T.XDDC'3OCBH6MYC,P%Q$LLF-R;SE=OW2/7ID].
MM`%T07F>;P8_V81_C2F&91E[UU`ZG8@_I6=%`(YXI?/MY%W9+-*!R>3C@^I]
M*?<6RK++,UQ"5G)W+(V`=IX`(YXP:`+YC9<9O9A^"?\`Q-,9E1BK:DX8#."8
MP1_X[5-X+=[2".2YCS%G)7T/0?F!^5(+2":SD=K@':OSRE2!GG)P>O>@"=[F
MT0X?5P#Z&2,?TH62TED,::FS.#C"RKG]*@<V;)(1,?WA0X6%B1MYR1C.#CO5
MB:W164S3#9)+\H&[(8].<X'UP*`%:T@P':\N<%2W^O8<#J>*A\O3V./M=RQS
MC'VB3)YQQ@\_A1)-;&WAB%R5PAC,A0G(Z'/H>*<8(([2*6$2;V;=&P3+<\XP
M>U`""VTTN%\^<L<<?:9<\]/XO:G+!I_F^5B;>#M^9I,9^IXJ*-+(E'\QUE23
M<V0%8D+N.1Z?UI\EQ9SRH9`^)%63#*,<$C!]^3^5`$L5OI\K[4B9O<AMOYGB
MD4::<`VJKE]@+0\$\]\>U58Y+:TNE=?.4D`!&\L`@C@YZCITR*FNXK2&W2=H
M7._)`3&=QRV<^O8'WH`5GTY0O_$OR&/R_N``??)I\XT^WD"M8QG`W.RQ+A!Z
MG_ZU4Y'LV<*RRDC;LS*3C/&!],T][V.[N0([82?,8V/G%>!SR`.1]:`)(;BS
MEAEEATT,(^RK'D_KQ^.*:=0L(@PDM%BE7_EDP3=C;NSP?040WX2W(-JB(PVJ
MJLQR3VY4>_3-1&\W*<V:?O'V=9#T!'9>>!VS0!IV$L-Q#YL,<:`G!VE3^HJY
M5>R*M:QNH(WJ&P7+8S[FK%`!1110`4444`%%%%`!1110`4444`%(#D9%+24`
M%9^G?ZYO]W^M:%9^G?ZYO]W^M`C1HHHH&%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`(>HKGEU
M"Y2-EDD.6GVQL%!Z2893QZ?UKH:@^Q6WEF,PKL+[R,?Q9SF@#&-Q</;S7IO'
M29)=BVX("@!L8(QG)'/XU*MLZ:G,AO+MECB$BJ93C)SUXZ<"M(Z?9M=?:3;1
M&?KYFT9J;R8_-,FQ=Y&TMCDCTH`YJVE-TJK>WTUL(K='C82E2Q.<L?[V,#BE
MD??J3>=<.R[(R&-T8!]=OO70M96K)&C6T)6+[@*`A?IZ4LEK;ROOD@B=O[S(
M":`([>1VGG4R1.JE=H0Y901_%_GI3;R:,-'&PD+MD@1C)`Q@G]?K5E8T4EE1
M03U(')ID]M%.1YBDX!'!(X/:@#%:2S1@4@F4(1'QY6"1D9P3QWY.*LS2I<;9
M'@N!'M4AOD.0>G?-7ELX58,%;Y3N`+D@'V&<4_[/'M"[!@8_3I0!E1/#B)EA
MERQ^12RGN.XZ=<XHD-M;.0+<&7:7P6'RG)R!^OY5JM;0NJ*T8(087VZ=/R%'
MV:$IL,8*YS@T`4EBCN+C;)$P"J%(#,0>/ICO]:@NYH$NFW0R[H^-R2LO0+UQ
MVY'Y5J"V@$WFB)1)C&X#G%.:")B2T:$G@Y'6@"I?>6'C5XP=XQN)88`(]!^M
M56O#%$D<4,<:JP1PQ)V/R<>_0'\16K)!%+M\R)'V\KN4''TI3&AZHIYST[T`
M90F?<RB"%E4D@!",]">>F34S[X-.$D4$:2LR_(J`XRP'3(R<'UK1P,=**`,-
MY9T63=;0B3:%7;%G+$C//3H>F>QIQ-R(U&Q5&V3,9A'!7[O0D5M8%&!0!EK<
M.&4L-HW'?'Y>=@S@'-(+B;RYP82T@QY*^7US6K@>E&!Z4`923W@*-+&Z*H42
M+MSW.3P#GH#P>*LWC3-#&UJ6RYQD+G`(ZX([5<P/2C%`&4ZWLEN"[R*Y.=J8
M&!N`QT],TLPO1P"QC$A^[]\K6IBC`SG%`&0BW.]P1<&)_DCRW*C/4]QQWZ\5
M9M8'M8)R@E=]S%1)(S9],9/%7L48H`QO(O%A$<\<LQ8,,QR="<$$Y(/!S3);
M*X""..*0Y@"[MX^5^<\EL^G:MS%&!0!DM97.Q44KA'$N2,9P`-N`>_/7UIW]
MGLK*8XT"Y<LF<!OF!`/X#]*U*,"@#*M].GCN#)N506'R@D@+DG`X[<5+>64D
M\Q=2GS1[,L3E.<Y'^16ABB@"C96)MCDL"2""0`.^1V%1PZ:P5XW.$+EPRMR.
M21CCCK^E:5%`&7'IMP(&@>:/RW(WE5P>W3MVI5TCA@\[MD!1R>@XY['BM2DH
M`RFTJX>0RM=+O)!P%;:,#M\V?UQ[4Z31EDWDS'+9/W>`3G)`]^/RK3HH`SUT
MM=R.[Y9&!!1=O0DX_6K1MU:W:%B2K9R>_-34M`%(Z;$\ADE=Y7(QE\=,>P]S
M3YK))_+\QG/ECY<''/K]:M4E`%4:?!O9L$EH_+.3U'K]:EGMUG0*S,N#D%3@
M@_6I:6@"I_9\'E^65)7=N.3U.,<_A2+IMLI8K$!N(..P(]!VJW10!2_LFU))
M*R;LY!\Y^/ISQ^%61`GE+&1E4QC<23QTY-244`0+96ZJ5$*!3U&/?/\`/FG"
MVA4J1$@*C"D*.!Z5+2T`0K:PI]R*-><\*!SZT+;0HVY(HU;.<A0#4U%`#$C2
M,8154>@&*?110`4444`%%%%`!1110`4444`%%%%`!1110`E9^G?Z]_\`=_K6
MA6?IW^O;Z'^=`C1HHHH&%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`"5GZ?Q.X]C_`#%:%4+$
M?Z3)]#_.@1H4444#"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`JA9?\`'U)]#_.K]4++_C[D
M^A_F*`+]%%%`!112'IQ0`M%,0,%PV,^U/H`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@!H)[C%.HHH`****`"BBB@!*HVG_`!^2
M_0_SJ]5&T_X_)?H?YT`7Z***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`JC:?\?LOT/\ZO
M51M1B]F^A_G0!>HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**0G%5DU&
MT<.5N86"?>Q(#CZT`6J*0'-%`"T4P2+O*9&X#)'<4Z@!:*CEF6)-S=,@<<\D
MX'ZFB298@I<X!8+^)Z4`245!<7<5LJM(2"S;54#)8^@'X&B"ZCGW;<JRG#*P
M(*GW%`$]%1&>-652Z@M]T%AS]*:]Y;H<//$N#CEP.?2@">BJTE];12>6]Q$K
M_P!TN,],]*9#J=I-'"ZSQ@3`;`6&30!<HJM]NMM[IY\>Y`2PW=,=:+>\BN9)
M%B(8)C)^M`%FBBB@`HHHH`****`"DI:0#%`"T444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%4;;_C_`)OQ_F*O52M_^/\`F'L?Z4"+M%%%`PHH
MHH`****`"BBB@`HHHH`****`"BBB@".<$Q.`,DJ1CI7/L)G@"VT,QV1$$O`8
MW3D<`@`'..U=&1FC:,8Q0!SLAD:[2,277GNT@<JY\LC:V,=LCCIWJ::UGBEF
MAC6X>V9U.2[,1\IS_$"><=\5K):6\<SS)"BR/]YPHR:FP*`,*"UN$`G>&8S;
M(PQ+`D[7Y'7TI\]E<W#LVV1?DDVKOQR3QT/I6UBC`H`QHH);<F22,QPB1#L.
M/IG`)QR0>O:F?9)X8Y`4";UV;B<DN6^4C'7UR1FMS`-!`/6@"G>Q3-Y$L"J[
MQ-DJQQN&"#@^M58;6]CW2%=Y\Q61'FR0,$')Q[UK44`8YT^\W0X2$[$7/S`<
MALX^Z3^HHNM+N)86CC$`\PR;ST/S'@YQD_3CZULT4`9JZ=)Y"JWE^9OC<GK]
MT+D=/;]:B;297,>Z10`@C;!(^4$D'ZUKT4`8XT0Y93,3'EBO+<%O;.*T((94
ME>25T9G`&%3:!C\3ZU8HH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@!*IP?\A";Z?X5<JG`/\`B8R_3_"@"[11
M10`4444`%%%%`!1110`4444`%%%%`!1124`+1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!112'-`"T4E+0`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`(3[4M)2T`%
M%%%`!1110`4444`%%%%`!1110`4444`%4X1_Q,9O]W_"KE4X?^0A+_N_X4`7
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`$I:2B@!:***`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**0]*101G))R
M>_:@!U%%)0`M%)10`M%)1F@!:*2B@!:*3-%`"T4F11F@!:*2B@!:*2B@!:*2
MB@!:***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`JG#_R$9?\`
M=_PJY5.+_D)3?[O^%`%RBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!#6#
M97=UYZ%YIY`TKJ5:$+'P6`PP'7@5O&LV"WL/M!DAG+N&)$8G+*&.3PN<9Z]J
M`+%K?+=2,$3Y516W9[G/'Z5:S6?8I;K`\#20N\I+.(SP<\\?A2O::;$RI)#`
M"W0,H_K0!?HS]*SQ'I/016IXSQ&#[^E*(M,V!A#;%20!B,<D].U`%[>HZL/S
MIIFC'61!]6%4E_LTG:+>,=>L&.@R>HH6;3`,B-,>HA.#^E`%LW4`ZS1C_@8I
MOVVU'6YA_P"^Q4#7.GQ+DHJC`/\`JB.IQZ5/`]O-GRD'RXSE-O49[B@!IU"S
M'6Z@'_;04O\`:%GC/VJ#_OX*@?4[:(.<-\LAC("\Y`R?PXZU)+?QQ,%9'))"
M\`<9'N?Y<T`..H6@_P"7F'_OL4AU&S'_`"\)1;W33R2(;>6,1G!9RN">O8FH
M9=42.:6,PN?+.W.5&3C/K0!(=5LP<>8Q_P!V-C_(4G]K6GK,?I!)_A4\$IFB
M#[=G/3(/\JJP:CYK(#$4\P!DRPY&<9Q0`XZM;]H[H_2VD_\`B:3^UHNUM>GU
M_P!%D_PJ/^V(\LOED.$9@">I';\<9IQU-$=4E78QDV'DX`P#GD`]QVH`D&IJ
M>EK>?C`P_G3A?D]+.Z_[X`_F:KKJ;O"SK`JNH+%&?MG`(P.])/J4L+3@QIF(
M@?Q'/3OCW_2@"V+N0_\`+E<?^.#_`-FI?M,O_/G/^:?_`!55!J$I*\1=!D9(
M)RQ'`_"IM3N);:*-H=@8M@EAGL?<>GK0!(;FX[64G_?:?XTAN+O^&R_.4"H[
M2XGFF9'50J*&)`X;=R,>F.<U%=7DZW#QP`;50C+(3A\9'-`$QN+_`+6,?XS_
M`/V-(9M3[6=M^-P?_B*?:2R2F1I49'4A=O;H/_K\U`MU*LAWR$@28(QT&3[?
M2@"7S=3Q_P`>MJ/^V[?_`!%('U0_\L+-?^VS'_V6JXN;KS7W;P@8[,)]\;NG
M3TQ2W$]XIDV!^`VT!/K@]/IW_`T`60VI'JEJ/HS'^E*!?GJULOT5C_45#Y\S
MWZ;?-$&Q>#&1\V3G^'Z=Q4U\THC3RBZC/)1<GH<=CQT[4`."WI',UN#[0M_\
M50$O.\\'X0'_`.*JL\ET5VJK^83N&1P`4QUQV:H4BO3,C.9,0*%(WGY\-U[`
M\>HH`OF&[/\`R]1CZ1?_`%Z8;6[/_,08?2)?\*IB+4%;`#%@3("7X.1]TT^2
MS=9!*L<CC"EE$I^8\Y')QZ'\*`+'V.Z_Z"4P^D<?_P`32?8;C/.IW7X+&/\`
MV6J]M9W:72RR,2!MX)Y`YXSGL"/KBI]3M9+I8@@R%)W8;'&*``6$O?4KP_\`
M?`_]EIPL&'6]NF^KC^@J%[.Y8KN*,X?(8],<=1CKQVIYL4W*?+A"!F)&T<@C
MCM0!*+)!UN+@_P#;4T?98>IEG./^F[_XU`+()(@'E*GR;E]"N>@QSG-,DLXQ
MY?EM;J(]V5/1LL"`?RH`M_98-N=\P'K]H?\`QI6MH5&6>4#U,[C^M4I+(.1B
M6&.4-G:#D`$@X`]\?G5F_P!CPA2Z#YA]Y@/4?Y^E`"K#:L,K*S#..)V(SZ=:
M#!:#&YL$G',IZ_G5)=+\E#YTX5#MY)W<@<'+9J5].2>3/G*1UD5!][)SGKQQ
M0!/Y-BS!!Y98]`7R35R-%1`JC``X%9?V<"572\B_<Y08'((!X)SSCN,?E6E"
M28E)(;(!R.AXH`DHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*2EHH`3/.*6DP,]*6@`H
MHHH`****`"J<7_(2E_W?\*MU5C_Y",O^[_A0!;HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`0UGRK;>8[2W2!1+O(W[2/EVXSG\:T*R&M%0W2M=Q+DC(Y
MPA)R,@G`_#&:`)+5(K=RPO(G50"WS'@``9/S8[>E/N5@GECF%U&H3N"..>QS
M[&JK0VY(!OH0L;%H0`,@DYY.?F^G%.:"V9O.FO%,K+@N!@8Y!X_'OZ4`((+=
M51!?#83P/<`#^6*<8;/>X%X0,YVAL;2!U&/_`-5(+6S5RCS;Y"N0J+T!QS@?
M04OV6QECS)*SPQ*2JD8"K^63TZTP$FEM)5XN)E:,EBR1$]1R/NXZ4T6^F2,J
M1ATEDS\XA.X>S$KQTZ&I/(M?OO+*^X8(:,;CCC^[GTI1#9F1O*F9'!#!=H^0
M]L`CCI0`LMI';0DR7$WE[0G"C.<\8`&.Y&,4ZUGM[5HX@S`2*HC4H1M`XY_&
ME>YMKB%83)(V5W;U0\XZ]L?A59QIR3-:LKER=I;'(XQU].>U(![#3C,TKJ^Y
M]Q)).#W./KFE+6(4AHI<=?F8_,,@=STZ=?2G1M9W$,SB%RBIM(XY''0`]>!4
M*M9$N_EW*NJDE?,.4Y&0,-@'D=*`-(2QQVSW(5@I7S".I/'_`-:J4D]DQ+O'
M+F1!+CD9)X]<;ABD>]MDM"GD.Z)(8RI8#..<\GD<?C0+G3MSQB'/W7(QGJ?3
MVSS]:`+EI(C;HU5T*X.';)P>^<FJ:?9G@C:*S!:56.S.,*#SSTZXXIT-VL,)
M>"V`CP3G?U`./2B,0-,(?L<0!`<\$@9)Z?+[>U`##>VA#1+;JR(5)``.`>^/
M:I_.M_[/>]>%/F7YAUW=L9_`56?4X8AMCM$+)(R;>!MQ_%T[XJP;H1QA6MD2
M)`I(R1C+8X!4=,9[4`5SJ*DH(K6,QLGWL]#W7@$=1WQ2&Z#^9+]CMC(@)D#Y
M5C[<KUQZ^U3P74$ZF1K>)9`&(!QD],=NX-++/&ABCBB@&1N5VQM0T`11WH2)
M9O*@1,G:HX91NP>*:-4N'B,FV)2%=F0J<KC&.X[$=J?:WYFG96MT3<R@,.=Q
M[\_J*1[J],C[(X]F\J&\HG'./[PW=/:F`HU*8JC*L3LYY1<Y3Y@,'WQ].14E
MO?O/.JG:$;.%V\]^N3G]*@2_N'C$H:$$8!BV'<>.O7L?Y'FHY-0O`76+]Z$R
M=ZHN&&,_WCQ^OM0!<O;N6&=4B7*!29#MSM)^[^M5FO;S[0R$A-@(";.&;`P`
M?0DT\WUR7D*H3'E3'\AY`^^*M6D\K,%N,!F&0N,8Y/'Y4@"_DECBB*,8]S@.
MX7<5&#V^N!5#S[\B2023%,X7Y`O\(YQM)SU]:G\V]C9)'W&(N0PVY('.#P.G
M2HXI=1,9>3?RP'W/;KC;GKGGGZ4`1K-=EEV2W!;:-J^7E3R0<G8.V*OV$<V=
M\TTSY13MD`&">O0"JIN+P(3LF8AEP/+Z@,<\X'48]*8)-3;:)$<%00X`'.2.
M1CN,_H:`)YFNV>2*(RA_,W!]O`3`[]/PIBK>F9C.LOE[N1&V/7ISTZ4\VTQL
M[H&6Y,FYC&=Y!X'&,46D4T<ZAC<;@Y#%W+*4QQU/7./?K0`QX=0*CYWY/W5<
M`KQQS5N&*62SDAFW1EMP!W9('8]3CZ9K,,-Y]GN8UCG.\@JV3ZY/!;^1%61'
M*;6)'M9G"OEE!"D]?5S_`#H`6"UO"0+IMZX!/S=SP1],"FG3YUMMD3;6Q\W.
M=QW9ZGVJS/#)/'"NS9L?D/AAC:1^/.*IFSO&M5C*#<"KY+_[.,4`7+^">1X9
M+;:'B)(#'CD8_K68-#E42+LCVLNT$XX&,==N?R-:44,AOVN)(-N0`"2IQQCT
MS^M+_9X+,'5'0R[P6)8C@>ON/RH`H2:5<23F:0Q%FQN(;'3`'53V`]*?!I<R
MDK(8T0/N#(RDXP>Q3CKW)I?[)N\!7G1EWB3@LN&R"?7/3O5R:Q+B3&',@0,6
M."2#GL/Z4`5#I<SO&&9$5=I)5CDD8'IQT['\*M?V>K,=[9C8G<,G)!SP3^-6
MXE=4`D(+#N.]24`5+JU%Q;K$,*`0>?2EM;7[-Y@1_E8_(N/N#TJU10!EC25V
MNIE8ALMRH^5S_$*T(4$<*(#G:H&?PJ2B@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"JD?_(2E_P!W_"K=5(_^0C+_`+G^%`%NBBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@!#5!-.83O*T[GS&W.`,=.F".>E:%%`&>
MVEP$.!N&6#+@GY<8Z?EU]Z#IJX=`Y"2']X",D\D]?QK0HH`S?[)C&S#D[6)^
M9<^F!^&!3DTY5C9&<M^[,:G:/E!_G_\`6K0HH`SDTM$BV"1P1G!55`&<=!C'
M;T[FD&CVPB\L;_3=P#C\!TK2HH`II80QAP@958$8!Z`XSC\J2/3H%)9E9Y".
M78\GI_@*NT4`0):QI&T8W[",8+GCZ<\4PZ?;'.48DG))=B3TZ\\]!^56J*`*
MZ65M&P9(E4A=N1W']>M$=G;QA0D2C:<CVJQ10!`+2W$7EB)0F",#WY-(EE;(
MZNL0W+T)))%6**`*YLK5MVZWB.[[V4'--73[)"I6T@4KG;B,#&:M44`0O;02
M$%X8V(Z$J#BE6W@5"BPQA3U`48-2T4`-VKV4?E2X%+10`F!Z48'I2T4`)@>E
M($4'(4`GO3J*`$P*,#.<4M%`"8'I1@>E+10`F!1@4M%`"8`H(!ZBEHH`3`]*
M,#TI:*`$P,YI:**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"JJ?\A&3_<_PJU59?^0@_P#US_K0!9HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHI#0`M%(K!AD$$>U+0`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`57'_'^?^N?]:L57`_T[_MG_6@"Q111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`"49%+47E%0^V1QNY&>=I]J`'8^<'
MGCWXI7[<D?C42K+O4L5"]P.OY_TJ5E#=<_@:`!<XYY-.I*6@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"H/\`E]_[9_UJ>H/^7P?]<_ZT`3T444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1244`+1244`+1244`+1244`+124
M4`+124M`!1129H`6BDHR/6@!:*;N7^\/SH+*I`9@"?4T`.HIN],J-RY;[O/7
MZ4DDB1J6=@JCJ2<4`/HI,\5#%=V\LACCGB=QU57!(H`GHJ$7$)>1%E0M$,NH
M893Z^E5UU?3W.%O8&PNX[7!X_"@"]152UU&TO'9+:X25E&2%[5'=ZM9V4WE7
M$Q1]N[[C'`]20*`+]%00W44TKQQON*`$X'&",CFF/?VZ7Z63.1.Z[E&.,<]_
MP-`%JBLR/7+*6X$2._+^6'*$(7_NYQUIUOK$%S<>3'%<$[RA?RCM!'7G\*`-
M&BF2R"*)Y&SA5)./:L\ZS'OB6.VN96DB$H"(#A3Z\T`:=%4[V^6RLS<R1N5!
M4%1C/)`_K4)U.87RVOV";+#=NWIC;GKUH`TJ*JW5X+:>VC*%O/<ID?P_*3_2
MJ=AK#WLD12T802D[9!(&(QG[P'3.*`-:BJLURT=Y;P!`1+NR<XVX&:J7&HW3
M7DMM86JSM`!YADDV#)Z`<'-`&K16$^O/*EL]I'"!,A<_:9-G0XVCU.<U+<7V
MJ*\'E6UL%FP%#R$D'&<''T[4`;%%1[G6WWNH+A<D+ZX[5B6&L7MXX4&R5V5O
MW3,P>,\XR#U]\4`;]%<\-6U%5D+K:LPN1:@*K#YSCGKTYI][JE]8-+#-]GDD
M^SO-&Z*54%>H().>OK0!O45E:G?SVVEQ7$142.R`Y3=P>O%5GU.\%B)8'$TA
MG5`'@,>0>W)_6@#>I*SM/OS=WDRAAY0C1E&.03G(/Y4:W/<6]FKVKA)#(J@E
M<]:`-'-&X5S]UJ=U^_>&7"BWW*-@P&`4YY'N:MW$UP]_9P1SM&DT+,Q55)R`
M,'D&@#5)`ZT9KFI;F]CTFYN1?2EXIQ$!M3&-X&>%SG!K6TZ5Y)[U9'+!)RJ@
M]A@<4`7\BC(KF%U#[7JTB?;94@F<PJJ,5*8`PP/09((_&H[B*2'2M0G%[>%X
MI/*7=.2,;AS]:`.KS[&@$&N2GBECL)!)+-&6FB&1>F0XR<\\8K3TG]SJES;6
M]Q)<6P16)>3?L;T!^E`&UD49%<[?"&?5KQ-0N'ACBB5H!YA0'CDCU.<5GO%<
MWHL6=!<2&T9L22%,X/!..<XH`[+(I-P/2LW2FWZ#"=Q8^40<^N.E8&DI8F+3
MA:#%\&_?;`?N<YW=NE`'7B:-CA74GV--^U6^'/G1X3[YW#Y?KZ5RFDBT53&6
MM_-9)%`C@/G9(/\`%G&:=I$=NVH6L,<4$\8B*N3`R.HQT?\`A)H`Z3^TK'#'
M[9;X7DGS5X_6GQ7MK,K-%<1.J_>*N"!]:YK[$@TG4"ENJR+>,%(CYV[A@?2B
M[TZ=;JZC\F-V:T7`@B\M6`?)7&3D\>M`'0)JVGNI*7L#`$`X<'!/2GW&HV=L
MSK/.D90`L&[`]*Q4BM=3O5$%E)%$L#I*S1;.N,#GJ>_X5$MG-'H<CNLSSM<*
M6.S+[5(`XQZ"@#9_MO3?*,OVN,Q@[2PSP:LVMW;WD9DMI5D4'!([&L"2>1H8
M7%K>RF*=6;?;!25P>@`J:PD>VOKB[>TEBCO941$*@,N!C<PH`U;[4;33U5KN
M7RPW3Y2?Y4EOJEG<NB0REFD!*@HPSC&>H]Q46N02W.CW,4*EI67"@=<Y%0:A
MI\MW?V3!IHHXXW#/$^T@G;@9_"@"PVM62Q1R!Y&61F5=L3$DJ<'C%6[>=+F%
M98]VUNFY2I_(USPTZ]CLK6,0S$QR2D^5,J/@G@Y]ZW-.61+.-94D1QD$22!V
MZGJ1UH`M4444`%%%%`!1110`4444`%%%%`!1110`5!_R^#_KF?YBIZA_Y?!_
MUS/\Q0!-1110`4444`%%%%`!1110`4444`%%%%`!1110`5E:SJG]F26Q*!XY
M"^X8^8X&1CTK5JK<6D<]S;S.3N@)91Q@Y&.:`,RYU*]@@LW9H`;ACDI$T@48
MR!P<DTR[U&]C%DL<HS,9-S+:,3QC'R$Y_P`YJS_8<"QHD=S<QK$Y>/:P&S/4
M`XZ4Z71XI$3?>79:,DK)Y@##(P><=.*`*-YJ-U!'9[KP0F17+,]J020>!MSD
M5J6K7-WI:/(WV>YD3EMF=I]<&DAT^&%H)6GFD:#?M:23<3NZY-72Z;=VY=HZ
MG/`H`YWSM12UOIVOVD-LQ0*(E&>G/3WIM[JMTTKE4FM`MN6$<@7).1\W?Z5K
M_9K(VUQ^\7RIVW2-O&,_6DELK'4'WLXE(C,1*2=`?I]*`,J:ZOEO3,9IQ;HZ
MC,*H\:CC(<?>S6KK$[PV#-$XC9F5/,QG8&(!-026>C&7[4\D2X8*3YV%9AZC
M.":NM/87J&`SV\RR`@H)`<^M`&5=++9P74*:I--(81(J-C>O.-P8=NV*A=;V
M*P=G^W*[.@`-RK,PST!'3KWJ_:0Z*%FM;=K=MP/F()-S$#\<XIUO!I"(DEO'
M!ME<(&7G+#D#/X4`9]LL\GVR&6:\A\E!(J/-EP<'G<.Q]/:GV^];33)UN+AV
MN)%W[Y6(^XQ_*MBX%M;J]S,J+E0CN5SD9X!]N:@:\TZ$/&2BBTVDJ(S\F>!@
M8]^WK0!BQ02?V1-<LKE/*<B0W<A/_?/0?G4E[+9M=W!U*Z>%HXE>WQ(5(7^\
MH[MFM6*^L'5(4`V22&(*(R`6')&,5*\EH;^*UDC5I_+,BYCR``<=?QH`P]4N
M9)+B'R8IYOLD:RAU7G<<'YO3@?K4MCING'6"]O$A0P+)&<YP2>M="8T&XA%R
MW7CK]:RK76+*=XQ%%.@<[%=H"J_3-`&1X>%BLMON-DMQDXPI\W/\JT->VG4+
M/..8IQGT^2K-MJEM-.(X;2XQNV^8(/E!SZTL6M6L[HRQS^4[[%N&CQ&3TZ^_
M2@#+M8Y(;W2$<YBRTD3=QN0Y4_B:NZ^TL\MM916YG$FYY$!`X`P.3[G]*N-J
M<*VTMQL?9%+Y1&!G.0/RYJ.35T63RXK6:5_-:+:H7JHR3R>E`"Z9<276D?OT
M83*K1NO?(X_6L;3,VCP%+9W$*-E6M2CQ#!XW#ALUK-K2[$V6LQE>4Q>6VU2K
M`9Y.<?K5ZUE:>+?)"8CD_*7#?J*`.?LH+Z!TN);4C[4'$I4DM\V2N1CC'2G6
M^GWR^'SOFE+F`J(#$H*GZXS6IJ&IBRO+:`Q;UE/SL&QY8R`"?Q-7W.U"P&2!
MF@#'T5[GS3'.+[`C',\:JH(/08YI;[3[B[U*0++)!!)!L=D`.[GD<].*BM-=
MEFEA\VWA$<I*YCGWLO?)7'`XJ1=5N_W=RUK&+*6145MYWX)P&(QB@`475AJ$
MHM[&2>!HT565U&,#'>H7L]1DN9;TQ('6<,D9(W%1P,-G`ZFE77I#YR&)!+'<
M;%X.&3>%)^H_PIYU2^1KB8QVYM;>X,+<D/C(&?3N*`%L8M1MEALS:1&-)-QG
M9P1MSG@==WZ5%I]K>6MSAK27;YK-O^U80`Y_@S[UM7,P@M))R,K&A<CUP,UF
M17^H*+.:X2W\FY8*%C#;DR,CGH?R%`&CB6>R82QB.1D(*[MP'XUDP:(99K8W
ML:LD=J(B%<@[P<]NU.T?59KZ<))/#D%LQI`X/'^T3BM"^N'M_LVS'[R=8VR.
MQS0`W5;)[S3GMH2JL=N"W3A@?Z4]K9VU6.Z!78L1C([Y)S61!K5RX5)!AS.`
MKA,!DW8(^HIXOKQ+-KXSAT6?88?+`R-^WKUSS0!JWEJUQ-:NK`>3)O.>_!']
M:S[;1)([R&>1K<O$Q)ECBV/)P1SCCO3+"\O9[UTEDN"BS,H*0KY8`[%NM4DU
MB^.FS%YB)=V8W"KG:-V>,8_A_6@#=O;:>6:":VECC>$M_K%)!!&.Q%5UTZ\C
MN)+B&ZA26<#S1Y)*DCH0-W!YJG<ZC=0W%X/-(C"*%.!\C%`1CZ\]?:D$US<#
M4,7<\9@1'79@=5)]*`+;Z,5M(K:"X41HI#)+$'#$G.[&1@]:FBTQ8;2SMXY2
M!:G(.W[W!'X=:HS?:K+2XK^*YFN'4*SI*XVD$#/;L>:U-,BECM%^T2&29OF<
MEB0">P]!0`^V286BI<.6D(Y88!%4X=*D2>)Y[Z6X2%MT:R*,@XQRW4UGZIJD
MD>KCR7(2V(##G:^3\V>PP.F?PJ*^>1=2N+@W+2PQ,K8BN"C1#`.`F,-F@#7;
M1X6AN4>1CYTQG##@QM@8(^F*C&BB193<W4UQ*\1B$K@`HIZXP*TGE5+<S-PJ
MKN.>PQ7.:-=2?VEYK^<$O"Q_>*0H/50I/7B@#1.BDP>5)?W4B#&T$K\I!R".
M*EBTP*1YMY<SA760"5@0"/PIOB%W33@066,RH)BIP1'GYJS;@6$<-REA+*8=
MB&;RGW(%W<X/9L?I0!HOH\0F>:WDDA>1T=MIP.#G]?ZU=N8HI@BRL!L8.HSW
M%<[*+'S+H::0T/V&3S1&<I[>V[K[U#*KQQV]M+EU-L[1/C^`I]WZ@C\C0!OP
MV-E'$0,.@#9W-D8;DY_*HH(-*L9A(LL2NJ[5\R<L57T&3Q63"+.5(?[/B562
MV?[04C*@_+WXY.:N?9(&ATEFM8F9V42$QC)&P]?TH`NO'IGV.=7>(6[/OE)D
M^7=D'DYX[5'):Z-*PU%A"V7&)O,XSG'7/K6?-%Y-Y-++;M):Q7(9T5,\;,`X
M[@'%1O;K>"^EBMG2TGDA"J4*[B#AB!VZT`;B06!7^SU6/$6'\H'E><@_G4=]
M)IEI$\5ZT44<YW,K]'/&3_*JNEP31:S<"<,S)"J"4K@.,\<^N#^E6?$4!GT>
M58XB\F4P%7)^^,T`5A)X?@A&/LJQR]@.#@]_QK5M(;>&/_18XT1^?W8`!_*L
MJ>.6SU&\D%C)<)=*H0QJ"%(&"#Z#O5_1[9[32[>"48>-`"/2@"M+JFD7$XBF
M*2.C<!H6;:<_3CZU9%Y:,D-R"")&\M'V'.2>G3(Z4R6"4ZRDP0F+[.R$CUR,
M"LVUT:XAM[1\SF5)U9XFERBKN/('3I0!HV^J6\L@A@AN"-Q7<(2%!'7GI5B\
MN8[*W,TB,4!`P@YY./ZUC6-E>VU\7^QRD&4G=]JP@!/796KJML]U8211*"Y*
MD`\=&!H`@.MV_P!I,0AF,8D\HS!/D#^F:$UJ.2Z,2VT_E>;Y/G[1LW],=<_I
M5";2;\ZCYL,440,P?SHYF7*YR04Z$_SIW]DWO]I^:D<42F;S#-%*RDKG."G0
MDT`7/[;A^S0S&%\2W0M@.,@YQGZ<4^#689]2GLD1@\*D[CT8C&0/S%9S:3J&
M1`/)^SQ7)N8WR=V<Y"XQ[]:F@T:Y@:"<3YF#EY$Z+\V=V"!GN.M`$T.O1300
M2K$P,LXA*%AE<YP3[<4Z#5IKB<;;"7[*TA19]P.??;UQ[U47P\X^Q2*R"6&0
M&7DX=03[=>:M6MC?VSI`EQ$+-&+#"'S",GY3VQ[T`-T[69;Z<)]D6-"S+DW"
MEN,_PXSVJ[J=RMG:&X:+S60C8@ZECP,5GZ9I5S97`8BS*[F.X1'S,'MNK3U"
MT6]M6A9F3)!#+U4CD&@#.GU>ZM5D%S9(C^49(P)=P;&,@\<'FK.E:@U]O.ZT
M(4`X@F,A&?7@8J&32KBY5_METLC&)HX]D6T+NZD\\FM"VMHK:,+'&BG`!*J!
MF@"KK%_)8PQ^1")I9&PJ$XX`))_(5;M9DN+=)HCE'4%:K7VF1W\\;SNWEQ@@
M(I*\GOD5+IUF+"T6W1RZ*3MR,$`G.*`+5%%%`!1110`4444`%%%%`!1110`4
M444`%0G_`(^U_P"N9_F*FJ$_\?:_[A_F*`)J***`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"L;7BIFLH[F398O(PGRVT'CY03Z9K9JGJ-W:6D`:]YC=MH'E
ME\GZ`&@##G:R$:1P3.VF>?BX)<F-1C@!O3/7FJ\L<#P:A#9E7L@T/EJ3NC#$
M\@>WK6W_`&KI:6)=2/(#;"BPG@GL5QG]*:-6TY;4,L<@BW[0@MV'/7IB@#%^
MR>0-5M6AAC)$!\N//EG+>_-69-,^P6CM<QPI;/,C2Q0`[%4=2<]NF:U8=3L;
MEH3%EFG8QC]V005YPV>G2K%_>P642-/D*[A!@=S_`$H`YJX6SECU!M,1!:&%
M`^U<(S[N./YU*R/I4]U\L(N&MOW1@38I).`,>N<5LW>K6]I+Y(BFF<+O80Q[
MMB^IICZW#O18+>YN-Z"0&&,$8/XT`8L-M)!;W-I<V)0&U:5`P#XD"X)!'0G^
ME33V;R1V"VT.QI+:0$JF,,4P,FM7^V(1/+"T,R-%#YQW`=,`XZ]:B77`ZV_E
M64\C3AB%RH*[>N<F@"@$:Z33+>"QGAEM75I&:+:J@#!`/?/M3K.QN838L(V$
M+2[I4*\JPR`Q]!CC\JOG61'?6]K/;/$TZ[@2P.TYP`<?YYJ)M8O"D;PZ:KI(
MYC!,X7YLD8Z>W6@#4OH/M-C/!_STC*CVR*YVSTR[\RUGF1RTKD7`/8#!!_\`
M'?UK<N;V2UT[[1-#B7``B#9^<\`9^O>J,NJW\%M.;FP6.5$#J0Y,9YQ@MC@T
M`5?LMW`T<JVLDACO7EV+C)4CKS4\DUZVHPWR:9*=L31F,NH/)!SG..U*-7N_
ML<\QCLV9-H413[^2<?-QQ1'JNH2M-"D-HTT:"3<LI9-O3&0.#Q0!LQ.TD*N\
M9C8C)4G./:L.RTNXBL[1G$OF)-N:(R`H%W'H.G3!I\.J:@4M)9([81W#[1L+
M$@8-5(M?O'M'G\W3]RQE_*&[>,>HS0!-86%U!/B2R8CS2?,^UD*`3UV#@\4P
MZ9J8L8=/*QM;1,-SJV#(H8$=N"*MO>ZC<7,B6*6^V*-6/F9R[$9QP>*-4U::
MSN;=4C7R]N^X!Y902`,?B3^5`#7T^]Q-;((?L\LPE,C,=RC(.,8]O6G-H[RW
M):8QM$;AY"`2#M(P.1WS2)<:E_:+VS7%OM2,2Y$)RP)Z?>J/1]4GO)H5FGRS
M9RBVS!>,_P`><4`)-H<S6BP1_9V5)VD5)"Q4J>Q[DUI:9:26T`6>.V1E)">0
MI``/UJ\.E%`&1=Z0]U=74SW#+YB*L:KT7`[^O/-:2+(8%20@N5PS#UQ4M%`&
M#:^'W1H!-/"T<#[U$<(5B?=JG31YE9(GO2]E&X=(3$,C!R!N]`:U\44`91T1
M#$4,QW?:6G#!!P"<E?\`Z_M2C1LR2[[N1H)9O-:$*`"?<]>P[UJ4M`$<L230
MO$ZY1U*L/4'C%4H-)6)H0UU-)#`08HFQA<#`Y`R<>YK1HH`KV=HEG`(8V9E!
M)RW7DYI;BU2X\OS"?W<@D7'J*GHH`SQHUH(8HBK%8I3*O/(8G-":/;++YF96
M^?S`K2$J&]=O2M"B@"@NDVRRF16G!+[]HF8+GZ9Q0=&L655,.0H91\QZ-R>]
M7Z2@"H^F6D@F#PAA,%#Y)YVC`_R*='I]K$)0D0'FJ%?D_,`,"K-+0!`UK"]M
M]G=`T.-NT^E2JH48`P!P!3J*`(%L[=5E58E`F),@Q]XGKFHVTVR:2-VMHBT0
M`0E!E0*MT4`-D19(V1U#*PP01D$4P01!$3RUVQXVC`PN.F*EHH`1E#*00"#U
M!ID<*1+MC547KA1@5)10`Q451A0%'H!BG`8I:*`$Q28]Z=10`W;1CWIU%`#<
M4M+10`E+110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`"5&?\`CY7_`'#_`#%2U$?^/A?]P_S%`$M%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!6?JD$DYMA$75EF#%TQE1@\\@
MUH4E`'-W-C=AKK"3S$3Q.L@(#NH'.,8''T%3+!<W2VZ^3>0&.;/F22*S@%3R
M.OTK>HH`P[JPFLY;66RADNG65I)"SJ"Q*XY)P/R%,OK*_P!6FB\Q!:1B)@RL
M1)R>,<$=N];]&!Z4`<]:VNK6F9!#%+)*@C;=)C;MX5O?C^5.N]+NYKJ*:6**
MZ/E!')E:(;L_[(K?HH`PI])N9KKS5\I-VQ64.3\NTAAT]ZBN-!N)4A!6VE6-
MG)64M@ACQT%=%10!BQZ/*TD;3B!%2W,*K#G"G<"",^F*EM]-FCLH(9)4,D<_
MFE@#@\DUJT4`5M0M!>6C1;BC<,C`?=8<@_G6?+IE]=6TZWE^K,Z!5"QX1>0<
MD=S6S10!BQZ--]GEAEN("K[?]7;!,8.>>>:LQ:7';WLLT&R**6(1F)$P,Y/S
M?K6CBB@#,&D@6]E%YI_T5]P(7[W7M^-.72H_[';3VD;8RE2X`!P:T:6@#+DT
M=6??'<W$)9`D@C(^<`8[C@^XI9-"LII7DF5I"RA5W-]P`8XK2I:`*<.G10R"
M3?([B(198CD#\.M1VVE1VJJL5Q<"-<X3?\HS[8]ZT**`(X8Q#$L89F"C&7.2
M?J:DHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"HB/](7
M_</\Q4M1G_7K_NM_,4`24444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`"4P_ZY?]T_TJ2F
M'_6K_NG^E`#Z***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`$I:0C-%`
M"T444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4P_ZU?H?Z4^F?Q@^Q_I
M0`^BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHI*`%HID<BR
M`E&#`'&13Z`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`2D_B_"G4E`"T444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%-==Z%<D9&,@X-.I*`&Q\`
MJ!C'%/I*6@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`2D!RQ&#P.M+10`M%%%`!1110`4444`%%%%`!1110`4444`%)2T4`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`44E(6`ZF@!U%1F:,=7%)]HB'611^-`$M%0?:X/^>R?]]4GVRV[SQ_]]4`
M6**K&_M!UN(Q_P`"IIU&S'6ZB_[ZH`MT53.J6(ZW<(_X&*0ZOIXZWL'_`'V*
M`+M%4#K.F_\`/];_`/?8IIUS3!_R_0?]]BBX&C166?$&F#_E[B/_``(?XTT^
M(],'_+PO_?0_QI7`UJ*QCXFTT?\`+;/XC_&D/BC31_&Q_+_&F!M45AGQ5IV,
MYD_\=_QII\6Z<.TWX!?\:+@;U%<^?%^G#_EG<?@J_P"--/C'3Q_RQNC_`,!7
M_P"*H`Z*BN;/C.P[6]U_WRO^--/C2S[6MS^2_P"-%P.FHKECXTM^UE.?J0*:
M?&J=K"0_5\?TI7`ZNBN2/C4]M-;_`+^__8TT^-)>VF_G+_\`8T7`Z^BN//C.
M?MIP_P"_A_PH_P"$QNNU@O\`WV?\*+A8["BN/_X2^\/2QC_%C2KXMO2?^/.(
C?B:+@=?25S4/B2[D/S6T:_0FM;3K^2[D*NBJ`N>/PI@?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>17
<FILENAME>nvlt-20110930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- EDGAR Online I-Metrix Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.12.8 -->
<!-- Round: 46fe4b0a-935c-45f1-95b0-e159dfba7207 -->
<!-- Creation date: 2011-11-08T18:13:49Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nvlt="http://www.novelos.com/20110930" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="nvlt-20110930.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE638436--11S-1-0011_STD_0_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">5611732</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE638436--11S-1-0011_STD_0_20100930_0" unitRef="iso4217_USD" decimals="0">387967</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">446101</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">33333</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">162760</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-74986768</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">28042</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:Assets contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">1109349</us-gaap:Assets>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">358333</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">30</us-gaap:CommonStockValue>
  <us-gaap:DeferredOfferingCosts contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">28500</us-gaap:DeferredOfferingCosts>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="shares" decimals="INF">2959871</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:AssetsCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">1087484</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">1030942</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD_per_shares" decimals="5">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">75291653</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">250008</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">1109349</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">304915</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="shares" decimals="INF">2959871</us-gaap:CommonStockSharesIssued>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">6515</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:DepositsAssetsNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">15350</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">27222</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">4665</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">2197</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">521817</us-gaap:LiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">77967</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">303633</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">55000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:Assets contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">6994975</us-gaap:Assets>
  <us-gaap:CommonStockValue contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">268</us-gaap:CommonStockValue>
  <us-gaap:DeferredOfferingCosts contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">159300</us-gaap:DeferredOfferingCosts>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">576059</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">121394</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="shares" decimals="INF">26826157</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="shares" decimals="INF">7000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:AssetsCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">2108688</us-gaap:AssetsCurrent>
  <us-gaap:Goodwill contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">1675462</us-gaap:Goodwill>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">29514506</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">1590755</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD_per_shares" decimals="5">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">35411337</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">441653</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">6994975</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">5897099</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="shares" decimals="INF">26826157</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD_per_shares" decimals="5">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">3183603</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:LongTermNotesPayable contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0" unitRef="iso4217_USD" decimals="0">450000</us-gaap:LongTermNotesPayable>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0_452905x444581" unitRef="shares" decimals="INF">26826157</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0_452905x444581" unitRef="iso4217_USD" decimals="0">268</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0_452905x453698" unitRef="iso4217_USD" decimals="0">35411337</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20110930_0_452905x478726" unitRef="iso4217_USD" decimals="0">-29514506</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20021231_0" unitRef="iso4217_USD" decimals="0">599377</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20021231_0_452905x444581" unitRef="shares" decimals="INF">6541343</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20021231_0_452905x444581" unitRef="iso4217_USD" decimals="0">65</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20021231_0_452905x453698" unitRef="iso4217_USD" decimals="0">599312</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20031231_0" unitRef="iso4217_USD" decimals="0">388936</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20031231_0_452905x444581" unitRef="shares" decimals="INF">6782784</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20031231_0_452905x444581" unitRef="iso4217_USD" decimals="0">67</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20031231_0_452905x453698" unitRef="iso4217_USD" decimals="0">684659</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20031231_0_452905x478726" unitRef="iso4217_USD" decimals="0">-295790</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20041231_0" unitRef="iso4217_USD" decimals="0">46175</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20041231_0_452905x444581" unitRef="shares" decimals="INF">6782784</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20041231_0_452905x444581" unitRef="iso4217_USD" decimals="0">67</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20041231_0_452905x453698" unitRef="iso4217_USD" decimals="0">684659</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20041231_0_452905x478726" unitRef="iso4217_USD" decimals="0">-638551</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20051231_0" unitRef="iso4217_USD" decimals="0">400206</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20051231_0_452905x444581" unitRef="shares" decimals="INF">7393448</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20051231_0_452905x444581" unitRef="iso4217_USD" decimals="0">73</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20051231_0_452905x453698" unitRef="iso4217_USD" decimals="0">1520521</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20051231_0_452905x478726" unitRef="iso4217_USD" decimals="0">-1120388</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20061231_0" unitRef="iso4217_USD" decimals="0">6546165</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20061231_0_452905x444581" unitRef="shares" decimals="INF">9551808</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20061231_0_452905x444581" unitRef="iso4217_USD" decimals="0">95</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20061231_0_452905x453698" unitRef="iso4217_USD" decimals="0">8629898</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20061231_0_452905x478726" unitRef="iso4217_USD" decimals="0">-2083828</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20071231_0" unitRef="iso4217_USD" decimals="0">2526232</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20071231_0_452905x444581" unitRef="shares" decimals="INF">9687103</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20071231_0_452905x444581" unitRef="iso4217_USD" decimals="0">97</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20071231_0_452905x453698" unitRef="iso4217_USD" decimals="0">9700288</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20071231_0_452905x478726" unitRef="iso4217_USD" decimals="0">-7174153</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE638436--11S-1-0011_STD_0_20081231_0" unitRef="iso4217_USD" decimals="0">6176609</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20081231_0" unitRef="iso4217_USD" decimals="0">9844567</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE638436--11S-1-0011_STD_0_20081231_0_452537x486814" unitRef="iso4217_USD" decimals="0">1262452</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20081231_0_452537x486814" unitRef="iso4217_USD" decimals="INF">-19488601</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20081231_0_452537x486814_452905x440920" unitRef="iso4217_USD" decimals="INF">-59693153</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20081231_0_452537x486814_452905x444581" unitRef="shares" decimals="INF">287423</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20081231_0_452537x486814_452905x444581" unitRef="iso4217_USD" decimals="1">3.0</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20081231_0_452537x486814_452905x449416" unitRef="shares" decimals="INF">272</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20081231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="INF">40204549</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20081231_0_452537x486814_452905x469151" unitRef="shares" decimals="0">413.5</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20081231_0_452537x486814_452905x469151" unitRef="iso4217_USD" decimals="INF">13904100</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20081231_0_452905x444581" unitRef="shares" decimals="INF">12820102</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20081231_0_452905x444581" unitRef="iso4217_USD" decimals="0">128</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20081231_0_452905x453698" unitRef="iso4217_USD" decimals="0">23109307</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20081231_0_452905x478726" unitRef="iso4217_USD" decimals="0">-13264868</us-gaap:StockholdersEquity>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">11872</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">8411</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">1944</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">908321</us-gaap:LiabilitiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">69626</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">555000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:Assets contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">5824706</us-gaap:Assets>
  <us-gaap:CommonStockValue contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">128</us-gaap:CommonStockValue>
  <us-gaap:DeferredOfferingCosts contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">99461</us-gaap:DeferredOfferingCosts>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">789492</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">105338</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="shares" decimals="INF">12820102</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="shares" decimals="INF">7000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:AssetsCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">1704212</us-gaap:AssetsCurrent>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">19484741</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">980125</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD_per_shares" decimals="5">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">23611506</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">715588</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">5824706</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">4126893</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="shares" decimals="INF">12820102</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD_per_shares" decimals="5">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">4088951</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:NotesPayableCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">190789</us-gaap:NotesPayableCurrent>
  <us-gaap:LongTermNotesPayable contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">675743</us-gaap:LongTermNotesPayable>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">19671</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">16967818</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">33333</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">10486594</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-76072088</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">102923</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:Assets contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">8931899</us-gaap:Assets>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">400000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD_per_shares" decimals="5">0.00001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:CommonStockValue contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">5</us-gaap:CommonStockValue>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="shares" decimals="INF">548.26078125</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="shares" decimals="INF">455281</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="shares" decimals="INF">7000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:AssetsCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">8872452</us-gaap:AssetsCurrent>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="shares" decimals="INF">548.26078125</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="shares" decimals="INF">204</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">8769529</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD_per_shares" decimals="5">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">49176545</us-gaap:AdditionalPaidInCapital>
  <us-gaap:DividendsPayableCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">2902963</us-gaap:DividendsPayableCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">3299217</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">8931899</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="shares" decimals="INF">204</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="INF">-26895538</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="shares" decimals="INF">455281</us-gaap:CommonStockSharesIssued>
  <us-gaap:TemporaryEquityCarryingAmount contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">18459619</us-gaap:TemporaryEquityCarryingAmount>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD_per_shares" decimals="5">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">44097</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:DepositsAssetsNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">15350</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">245711</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <nvlt:PreferredStockSharesDesignated contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="shares" decimals="INF">272</nvlt:PreferredStockSharesDesignated>
  <nvlt:TemporaryEquitySharesDesignated contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814" unitRef="shares" decimals="INF">735</nvlt:TemporaryEquitySharesDesignated>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814_452905x440920" unitRef="iso4217_USD" decimals="8">-76072088.00000000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814_452905x444581" unitRef="shares" decimals="INF">455281</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814_452905x444581" unitRef="iso4217_USD" decimals="INF">5</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814_452905x449416" unitRef="shares" decimals="INF">204</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="8">49176545.00000000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814_452905x469151" unitRef="shares" decimals="0">548.26078125</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814_452905x469151" unitRef="iso4217_USD" decimals="8">18459619.00000000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452905x444581" unitRef="shares" decimals="INF">12820102</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452905x444581" unitRef="iso4217_USD" decimals="0">128</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452905x453698" unitRef="iso4217_USD" decimals="0">23611506</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20091231_0_452905x478726" unitRef="iso4217_USD" decimals="0">-19484741</us-gaap:StockholdersEquity>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">11872</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">6326</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">2085</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">904817</us-gaap:LiabilitiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">51042</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">305049</us-gaap:InterestPayableCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">555000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:Assets contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">4802142</us-gaap:Assets>
  <us-gaap:CommonStockValue contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">128</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">3763563</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">115311</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="shares" decimals="INF">12820102</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="shares" decimals="INF">7000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:AssetsCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">1279781</us-gaap:AssetsCurrent>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">24045004</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">2720985</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">673739</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD_per_shares" decimals="5">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">24178638</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">392881</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">4802142</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">133762</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="shares" decimals="INF">12820102</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD_per_shares" decimals="5">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">3510489</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:NotesPayableCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">204802</us-gaap:NotesPayableCurrent>
  <us-gaap:LongTermNotesPayable contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">920941</us-gaap:LongTermNotesPayable>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">887306</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">33333</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">288250</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-73976696</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">63526</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:Assets contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">2460582</us-gaap:Assets>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">366667</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD_per_shares" decimals="5">0.00001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:CommonStockValue contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">30</us-gaap:CommonStockValue>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="shares" decimals="INF">0.00000000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="shares" decimals="INF">2959914</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="shares" decimals="INF">7000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:AssetsCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">2436477</us-gaap:AssetsCurrent>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="shares" decimals="INF">0.00000000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">2372951</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD_per_shares" decimals="5">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">75183275</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">565723</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">2460582</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="INF">1206609</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="shares" decimals="INF">2959914</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD_per_shares" decimals="5">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">8755</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:DepositsAssetsNoncurrent contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">15350</us-gaap:DepositsAssetsNoncurrent>
  <nvlt:PreferredStockSharesDesignated contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="shares" decimals="INF">272</nvlt:PreferredStockSharesDesignated>
  <nvlt:TemporaryEquitySharesDesignated contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814" unitRef="shares" decimals="INF">735</nvlt:TemporaryEquitySharesDesignated>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814_452905x440920" unitRef="iso4217_USD" decimals="INF">-73976696</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814_452905x444581" unitRef="shares" decimals="INF">2959914</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814_452905x444581" unitRef="iso4217_USD" decimals="INF">30</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="INF">75183275</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452905x444581" unitRef="shares" decimals="INF">12820102</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452905x444581" unitRef="iso4217_USD" decimals="0">128</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="0">24178638</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE638436--11S-1-0011_STD_0_20101231_0_452905x478726" unitRef="iso4217_USD" decimals="0">-24045004</us-gaap:StockholdersEquity>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">99461</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <us-gaap:CostsAndExpenses contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">3630928</us-gaap:CostsAndExpenses>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">1446</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-3269364</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">4765</us-gaap:IncreaseDecreaseInDeferredLiabilities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">331186</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-419634</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-213792</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">141794</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">19671</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-4098423</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-467495</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">2616834</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">435917</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="INF">-467495</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-3630928</us-gaap:OperatingIncomeLoss>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">2720985</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-592158</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">-20614</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestPaid contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">42888</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">222748</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">1014094</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD" decimals="0">2677206</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
  <nvlt:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_273_20100930_0" unitRef="shares" decimals="0">12820102</nvlt:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <dei:TradingSymbol contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">NVLT</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">NOVELOS THERAPEUTICS, INC.</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:DocumentType contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">S-1</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">2011-09-30</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">0001279704</dei:EntityCentralIndexKey>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">655656</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-130800</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <us-gaap:CashAcquiredFromAcquisition contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">905649</us-gaap:CashAcquiredFromAcquisition>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
10. STOCKHOLDERS&amp;#x2019; EQUITY&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
January 1, 2008, Cellectar converted from a Wisconsin limited
liability company to a Wisconsin corporation (the
&amp;#x201C;Conversion&amp;#x201D;). Each issued and outstanding unit of
equity in the limited liability company immediately prior to the
Conversion was converted into one issued and outstanding share of
Cellectar common stock and each unexercised unit option outstanding
immediately prior to the Conversion was converted into an option to
acquire the same number of shares of the corporation&amp;#x2019;s common
stock.&amp;#xA0; For the purpose of presentation in these financial
statements, all amounts and disclosures related to equity issuances
prior to the Acquisition have been retroactively restated by
applying the Exchange Ratio in order to reflect the capital
structure of Novelos and therefore the issuance of Novelos common
stock, rather than member units in the limited liability company or
common stock of Cellectar, as applicable.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;From
inception until December 31, 2010, Cellectar issued 12,559,218
shares of common stock for net proceeds of approximately
$21,710,000.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
April 2011 Private Placement&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Concurrently
with and conditioned upon the execution of the Merger Agreement,
the Company entered into a Securities Purchase Agreement with
certain accredited investors under which the Company sold an
aggregate of 6,846,537 units, each unit consisting of one share of
its common stock and a warrant to purchase one share of its common
stock, at a price of $0.75 per unit, for gross proceeds of
approximately $5,135,000 (the &amp;#x201C;April Private
Placement&amp;#x201D;).&amp;#xA0; The warrants have an exercise price of
$0.75 and expire on March 31, 2016.&amp;#xA0; The warrant exercise
price and/or the common stock issuable pursuant to such warrant
will be subject to adjustment only for stock dividends, stock
splits or similar capital reorganizations so that the rights of the
warrant holders after such event will be equivalent to the rights
of warrant holders prior to such event.&amp;#xA0; The relative fair
value of the warrants issued to the investors was $2,124,286 at
issuance and has been included as a component of
stockholders&amp;#x2019; equity.&amp;#xA0; The Company uses the
Black-Scholes option pricing model to value warrants and applies
assumptions that consider, among other variables, the fair value of
the underlying stock, risk-free interest rate, volatility, expected
life and dividend rates in estimating fair value for the warrants.
Assumptions used are generally consistent with those disclosed for
stock-based compensation (see Note 11).&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
Securities Purchase Agreement included a requirement that the
Company file with the SEC no later than October 5, 2011 (the
"Filing Deadline"), a registration statement covering the resale of
the shares of common stock, and the shares of common stock
underlying the warrants, issued pursuant to the Securities Purchase
Agreement that are not otherwise saleable under an available
exemption from registration requirements.&amp;#xA0; The Company is also
required to use commercially reasonable efforts to have the
registration statement declared effective by December 4, 2011 (the
"Effectiveness Deadline"), and to keep the registration statement
continuously effective under the Securities Act of 1933, as amended
(the &amp;#x201C;Securities Act&amp;#x201D;), until the earlier of the date
when all the registrable securities covered by the registration
statement have been sold or the second anniversary of the
closing.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;In
the event the Company fails to file the registration statement
within the timeframe specified by the Securities Purchase
Agreement, or if it fails to obtain effectiveness of this
registration on or prior to the December 4, 2011 (if there is no
review by the SEC) or by January 3, 2012 (if there is review by the
SEC) with respect to the maximum number of shares permitted to be
registered by the SEC, the Company will be required to pay to the
purchasers liquidated damages equal to 1.5% per month (pro-rated on
a daily basis for any period of less than a full month) of the
aggregate purchase price of the units purchased until the
registration statement is filed or declared effective, as
applicable, not to exceed 5% of the aggregate purchase price.&amp;#xA0;
The Company will be allowed to suspend the use of the registration
statement for not more than 30 consecutive days, on not more than
two occasions, in any 12-month period.&amp;#xA0; The Company has also
granted piggy-back registration rights with respect to any shares
of common stock that it is required to exclude from the
registration statement as a condition of its effectiveness, and has
also agreed to file further registration statements with respect to
any such shares six months after the effective date of the initial
registration statement.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
November 3, 2011, a majority of purchasers in the April Private
Placement, which majority constituted the requisite holders, as
defined by the applicable securities purchase agreement, consented
to extend the Filing Deadline to the 180&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;th&lt;/font&gt;
day following the final prospectus of a public offering of
securities contemplated by the Company and to extend the
Effectiveness Deadline to the 240&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;th&lt;/font&gt;
day following the final prospectus of the public
offering.&amp;#xA0;&amp;#xA0;As of September 30, 2011, and through the date
of this filing, the Company has not concluded that it is probable
that damages will become due; therefore, no accrual for damages has
been recorded.&amp;#xA0;&amp;#xA0;The Company will use its reasonable best
efforts to register the shares as may be permitted by the SEC until
such time as all of these shares either have been registered or may
be sold without restriction in reliance on Rule 144 under the
Securities Act.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company paid to Rodman, the placement agent for the financing, a
cash fee equal to $200,000 and issued warrants to purchase 192,931
shares of its common stock (having an exercise price of $0.75 and
which expire March 31, 2016) in consideration for their advisory
services with respect to the financing pursuant to the placement
agency agreement between Rodman and the Company.&amp;#xA0; Rodman is
entitled to registration rights with respect to the shares of
common stock issuable upon exercise of these warrants.&amp;#xA0; The
cash fee was recorded as a reduction of gross proceeds
received.&amp;#xA0; The estimated fair value of the warrants issued to
the placement agent was $112,096 and was recorded as a component of
stockholders&amp;#x2019; equity.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Common Stock Warrants&lt;/font&gt; &amp;#xA0;&amp;#x2014; The following table
summarizes information with regard to outstanding warrants to
purchase common stock as of September 30, 2011.&amp;#xA0; There were no
outstanding common stock purchase warrants as of December 31, 2010
and 2009.&amp;#xA0; The Company issued warrants to purchase 7,039,468
shares of common stock in connection with the April Private
Placement.&amp;#xA0; In addition, outstanding warrants to purchase
315,164 shares of common stock, originally issued in connection
with Novelos equity and debt financings from 2007 through 2010,
remained outstanding subsequent to the Acquisition (Note
4).&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="MARGIN-LEFT: 36pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Offering&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Number&amp;#xA0;of&amp;#xA0;Shares&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Issuable&amp;#xA0;Upon&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Exercise&amp;#xA0;of&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Outstanding&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Warrants&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Exercise&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Price&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="20%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Expiration&amp;#xA0;Date&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="20%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;April
8, 2011 Private Placement&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;7,039,468&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0.75&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="20%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;March
31, 2016&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Series
B Preferred Stock &amp;#x2013; placement agents&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;5,392&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;191.25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="20%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;May
2, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Series
C Exchange&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8,169&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;191.25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="20%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;May
2, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Series
E Preferred Stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;60,330&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;99.45&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="20%" nowrap="nowrap" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;December
31, 2015&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;August
2009 Private Placement&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;31,194&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;100.98&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="20%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;December
31, 2015&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;July
2010 Direct Offering (1)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;77,729&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0.75&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="20%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;July
27, 2015&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Preferred
Incentive Warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;105,040&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;16.065&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="20%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;July
27, 2015&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="20%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
7,327,322&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="12%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="20%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&amp;#xA0;
The exercise price of these warrants was adjusted to $0.75 per
share in connection with the private placement completed on April
8, 2011.&amp;#xA0; This warrant has been accounted for as a derivative
instrument as described in Note 2.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
May 4, 2011, 18,153 shares of common stock were issued in
connection with the cashless exercise of warrants to purchase
27,310 shares of common stock at $0.75 per share.&amp;#xA0; The Company
reclassified $48,339 from the derivative liability to additional
paid-in capital upon the exercise of the warrants.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
following shares were reserved for future issuance upon exercise of
stock options and warrants or conversion of debt:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;!--EFPlaceholder--&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; MARGIN-LEFT: 36pt"&gt;
&lt;table style="TEXT-ALIGN: left; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr style="TEXT-ALIGN: left"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="64%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
September 30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;December&amp;#xA0;31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="64%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;(unaudited)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;7,327,322&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Stock
options&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,632,638&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;769,189&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;991,736&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Convertible
notes&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
&amp;#x2014;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
3,646,370&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
&amp;#x2014;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
number of shares reserved for future issuance&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
10,959,960&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
4,415,559&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
991,736&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;


&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:CommitmentsDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
14.&amp;#xA0; COMMITMENTS&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Property Lease&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
September 5, 2007, Cellectar entered into a 36-month lease for
office and manufacturing space, commencing September 15,
2007.&amp;#xA0; The lease provides for the option to extend the lease
under its current terms for seven additional two-year terms.&amp;#xA0;
Rent is $8,050 per month for the first year and then escalates by
3% per year for the duration of the term including any lease
extension terms.&amp;#xA0; The lease also requires the payment of
monthly rent of $1,140 for approximately 3,400 square feet of
expansion space.&amp;#xA0; The monthly rent for the expansion space is
fixed until such time as the expansion space is occupied at which
time the rent would increase to the current per square foot rate in
effect under the original lease terms.&amp;#xA0; The Company is
responsible for certain building-related costs such as property
taxes, insurance, and repairs and maintenance.&amp;#xA0; Rent expense
is recognized on a straight-line basis and accordingly the
difference between the recorded rent expense and the actual cash
payments has been recorded as deferred rent as of each balance
sheet dates.&amp;#xA0; Due to the significant value of leasehold
improvements purchased during the initial 3-year lease term and the
economic penalty for not extending the building lease,
straight-line rent expense and the associated deferred rent has
been calculated over 17 years, which represents the full term of
the lease, including all extensions.&lt;/font&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company is required to remove certain alterations, additions and
improvements upon termination of the lease that altered a portion
of the rentable space.&amp;#xA0; In no event shall the cost of such
removal, at commercially reasonable rates, paid by the Company
exceed $55,000 (&amp;#x201C;Capped Amount&amp;#x201D;) and any amount in
excess of the Capped Amount shall be the obligation of the
landlord.&amp;#xA0; The Company is required to maintain a certificate
of deposit equal to the Capped Amount during the term of the lease,
which amount is shown as restricted cash in the accompanying
balance sheets.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Effective
June 1, 2010, Cellectar entered into a seven-month extension of its
office space and effective December 13, 2010 amended the extension
to increase the lease extension an additional five-months, expiring
May 31, 2011.&amp;#xA0; In connection with the extension, the monthly
rent was adjusted to fifty percent of the rent due immediately
prior to the extension and the Company could terminate the lease at
the end of a month with 10-day written notice.&amp;#xA0; The option was
retained, prior to May 31, 2011, to further extend the lease
through September 14, 2012, in accordance with the original lease
terms provided that it pay the unpaid rent for June 1, 2010 through
March 31, 2011, based on the original terms of the lease, plus
interest at 10% per annum.&amp;#xA0; As of December 31, 2010, $45,000
was accrued in the accompanying balance sheet for the unpaid rent
and accrued interest.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
April 15, 2011, the Company extended its building lease for the
Madison, WI headquarters through September 14, 2012 according to
the terms in the original lease and paid all unpaid rent and
related accrued interest.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Future
minimum lease payments under this non-cancelable lease are
approximately $196,000 and $124,000 during 2011 and
2012.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As
a result of the Acquisition, the Company assumed the lease
agreement for Novelos&amp;#x2019; office space in Newton, MA, which has
a term that is month-to-month and requires monthly rental payments
of $5,300.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Rent
expense was $143,000 and $117,000 for the nine months ended
September 30, 2011 and 2010, respectively, $159,000 and $180,000
for the years ended December 31, 2010 and 2009, respectively and
$945,000 from inception to December 31, 2010.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Capital Lease&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Certain
equipment is leased under a capital lease.&amp;#xA0; The lease
agreement requires monthly principal and interest payments of $217
and expires on September 3, 2014.&amp;#xA0; The outstanding obligation
is being amortized using a 7% interest rate based on comparable
borrowing rates.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
following table provides the estimated future minimum rental
payments under all capital leases together with the present value
of the net minimum lease payments as of December 31,
2010:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="85%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="55%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Minimum&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;lease&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;payments&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Less&amp;#xA0;interest&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Present&amp;#xA0;value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;of&amp;#xA0;net&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;minimum&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;lease&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;payments&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="55%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,608&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;523&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,085&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="55%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,608&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;373&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,235&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="55%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,608&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;211&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;2,397&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="55%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2014&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
1,739&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
45&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
1,694&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="55%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
9,563&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
1,152&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
8,411&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
equipment recorded under capitalized leases is included in fixed
assets as of December 31:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;!--EFPlaceholder--&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="70%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Office
equipment&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;10,973&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;10,973&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Less
accumulated amortization&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
(2,928&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
(732&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
8,045&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
10,241&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Retention Agreements&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Following
the Acquisition, the Company has retention agreements with each of
its four vice presidents, three of such agreements were executed by
Novelos during 2010.&amp;#xA0; The agreements provide for the lump-sum
payment of six months&amp;#x2019; base salary and benefits to each such
officer following a termination without cause or a resignation with
good reason occurring on or before November 14, 2011.&amp;#xA0; Certain
of the agreements provide that if the executives were employed with
Novelos as of October 1, 2010, they would receive a payment of two
months&amp;#x2019; base salary as a retention bonus on that date. The
retention bonus of $68,000 was paid in October 2010 and will be
deducted from the severance amounts that may become payable upon a
subsequent involuntary termination.&amp;#xA0; The total remaining
amount that may become payable to the Company&amp;#x2019;s executive
officers pursuant to the retention agreements is approximately
$350,000.&lt;/font&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
May 18, 2011, the Company&amp;#x2019;s board of directors approved the
entry into a retention agreement with each of 5 individuals that
were employees of Cellectar at the time of the Acquisition.&amp;#xA0;
The agreements provide for the lump-sum payment of six
months&amp;#x2019; base salary and benefits following a termination
without cause or a resignation with good reason occurring on or
before November 18, 2011.&amp;#xA0; The agreements expire November 18,
2011.&lt;/font&gt;&lt;/div&gt;


&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">1293454</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
16.&amp;#xA0; EMPLOYEE RETIREMENT PLAN&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;On
January 1, 2009, Cellectar adopted a Safe Harbor defined
contribution plan under Section 401(k) of the Internal Revenue Code
which covered eligible employees who meet minimum age requirements
and allowed participants to contribute a portion of their annual
compensation on a pre-tax basis.&amp;#xA0; Cellectar contributed 3% of
each participant&amp;#x2019;s compensation.&amp;#xA0; Contributions made for
the years ended December 31, 2010 and 2009 were $23,000 and
$56,000, respectively.&amp;#xA0; Cellectar paid administrative expenses
for the plan of $3,300 and $2,800 for the years ended December 31,
2010 and 2009, respectively.&amp;#xA0; The plan was canceled effective
August 30, 2010.&lt;/font&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Following
the Acquisition, the Company has a defined contribution plan under
Section 401(k) of the Internal Revenue Code which allows eligible
employees who meet minimum age requirements to contribute a portion
of their annual compensation on a pre-tax basis.&amp;#xA0; The Company
has not made any matching contributions under this
plan.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
  <us-gaap:CostsAndExpenses contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">5019146</us-gaap:CostsAndExpenses>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">1549</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
8.&amp;#xA0; LONG-TERM NOTES PAYABLE&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
January 11, 2008, Cellectar entered into a loan agreement with a
bank to borrow up to $1,200,000.&amp;#xA0; The borrowing, evidenced by
a note (the &amp;#x201C;Bank Note&amp;#x201D;), bore interest at a rate of
7.01% per annum, could be prepaid without penalty and was payable
in 48 monthly principal and interest payments of $20,520 with a
balloon payment of any remaining unpaid principal and interest on
March 28, 2012.&amp;#xA0; In the event of default of payment, Cellectar
would be required to pay a late charge equal to 5% of the
delinquent payment and the interest rate on the unpaid principal
would be increased by 3%.&amp;#xA0; The Bank Note was collateralized by
substantially all assets of Cellectar and a deposit account in the
amount of $500,000.&amp;#xA0; The cash collateral is classified as
restricted cash in the accompanying balance sheet.&amp;#xA0; As of
December 31, 2010 and 2009, $470,941 and $675,743 are classified as
a long-term note payable in the accompanying balance sheet,
respectively.&amp;#xA0; On April 8, 2011, immediately prior to the
Acquisition, Cellectar paid approximately $627,000 in full
settlement of the Bank Note. The payment was made in order to avoid
an event of default that would have occurred as a result of the
change of control that occurred at the time of the
Acquisition.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
September 15, 2010, Cellectar entered into certain loan agreements
with the Wisconsin Department of Commerce (&amp;#x201C;WDOC
Notes&amp;#x201D;) to borrow a total of $450,000.&amp;#xA0; The WDOC Notes
bear interest at 2% per annum beginning on the date of disbursement
and allow for the deferral of interest and principal payments until
April 30, 2015.&amp;#xA0; In the event of default of payment, interest
on the delinquent payment is payable at a rate equal to 12% per
annum.&amp;#xA0; Monthly payments of $20,665 for principal and interest
shall commence on May 1, 2015 and continue for 23 equal
installments with the final installment of any remaining unpaid
principal and interest due on April 1, 2017.&amp;#xA0; As of December
31, 2010, $450,000 is classified as a long-term note payable in the
accompanying balance sheet.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Long-term
notes payable consists of the following as of December
31:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;!--EFPlaceholder--&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Bank
Note, 7.01% interest&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;675,743&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;866,532&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Wisconsin
Department of Commerce,&amp;#xA0; 2% interest&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
450,000&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
&amp;#x2014;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,125,743&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;866,532&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Less
current portion&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
(204,802&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
(190,789&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Long-term
note payable, net of current portion&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
920,941&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
675,743&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As
of December 31, 2010, long-term notes payable matures as
follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="70%"&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="85%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Years
ended December 31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="85%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&lt;!--efplaceholder--&gt;2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;204,802&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="85%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;470,941&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="85%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2013&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="85%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2014&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="85%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2015&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;119,957&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="85%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
330,043&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="85%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
1,125,743&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;During
the nine-months ended September 30, 2011, payments of $675,743 were
made in connection with the Bank Note including a payment of
approximately $627,000 in full settlement of the Bank Note made
immediately prior to the Acquisition in order to avoid an event of
default that would have occurred as a result of the change in
control that occurred at the time of the Acquisition.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;As
of September 30, 2011, the outstanding principal on the WDOC Notes
of $450,000 is classified as long-term debt outstanding in the
accompanying balance sheet.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-4434607</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">145</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
13. &amp;#xA0; NET LOSS PER SHARE&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Basic
net loss per share is computed by dividing net loss by the weighted
average number of shares of common stock outstanding during the
period. Diluted net loss per share is computed by dividing net
loss, as adjusted, by the sum of the weighted average number of
shares of common stock and the dilutive potential common stock
equivalents then outstanding.&amp;#xA0; Potential common stock
equivalents consist of stock options and convertible debt.&amp;#xA0;
Since there is a net loss attributable to common stockholders for
the nine months ended September 30, 2011 and 2010 and the years
ended December 31, 2010 and 2009, the inclusion of common stock
equivalents in the computation for those periods would be
antidilutive. Accordingly, basic and diluted net loss per share is
the same for all periods presented.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
following potentially dilutive securities have been excluded from
the computation of diluted net loss per share since their inclusion
would be antidilutive:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Nine
Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;(unaudited)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Twelve&amp;#xA0;Months&amp;#xA0;Ended&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;December&amp;#xA0;31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Cumulative&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Development-&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Stage&amp;#xA0;Period&amp;#xA0;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;from&amp;#xA0;&lt;/font&gt;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline"&gt;November&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;7,&amp;#xA0;2002&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;(inception)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;through&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;December&amp;#xA0;31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Consolidated&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Convertible
debt&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
&amp;#x2014;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
3,547,198&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
3,646,370&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
&amp;#x2014;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
3,646,370&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
7,327,322&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
&amp;#x2014;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
&amp;#x2014;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
&amp;#x2014;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
&amp;#x2014;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Stock
options&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
3,632,638&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
775,853&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
769,189&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
991,736&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
769,189&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;


&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:LiabilitiesAssumed1 contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="INF">439615</us-gaap:LiabilitiesAssumed1>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">6083</us-gaap:IncreaseDecreaseInDeferredLiabilities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">655656</us-gaap:ShareBasedCompensation>
  <us-gaap:StockholdersEquityOther contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">145</us-gaap:StockholdersEquityOther>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-331357</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-6009</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-500000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-257973</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">675743</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-5469502</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-450356</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 27pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
15.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
LITIGATION&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Following
the Acquisition, the Company is party to certain legal matters that
existed with Novelos prior to the Acquisition. The following
summarizes the status of those matters.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
Class Action&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;A
putative federal securities class action complaint was filed on
March 5, 2010 in the United States District Court for the District
of Massachusetts by an alleged shareholder of Novelos, on behalf of
himself and all others who purchased or otherwise acquired Novelos
common stock in the period between December 14, 2009 and February
24, 2010, against Novelos and its President and Chief Executive
Officer, Harry S. Palmin.&amp;#xA0; On October 1, 2010, the court
appointed lead plaintiffs (Boris Urman and Ramona McDonald) and
appointed lead plaintiffs&amp;#x2019; counsel.&amp;#xA0; On October 22,
2010, an amended complaint was filed.&amp;#xA0; The amended complaint
claims, among other things, that Novelos violated Section 10(b) of
the Securities Exchange Act of 1934, as amended, and Rule 10b-5
promulgated thereunder in connection with alleged misleading
disclosures related to the progress of the Phase 3 clinical trial
of NOV-002 for non-small cell lung cancer.&amp;#xA0; On December 6,
2010, the defendants filed a motion to dismiss the complaint with
prejudice.&amp;#xA0; On January 20, 2011, the plaintiffs filed their
opposition to our motion and on March 3, 2011, the defendants filed
their response to the opposition. On June 23, 2011, the motion to
dismiss was granted and the case was dismissed without
prejudice.&amp;#xA0; Because the dismissal was without prejudice, the
plaintiffs could&amp;#xA0;reinstitute the&amp;#xA0;proceeding by
filing&amp;#xA0;an amended complaint.&amp;#xA0; On August 5, 2011, the
plaintiffs filed a second amended complaint realleging that the
defendants violated Section 10(b) of the Exchange Act and Rule
10b-5 in connection with alleged misleading disclosures related to
the Phase 3 clinical trial for NOV-002 in non-small cell lung
cancer.&lt;/font&gt; &lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
On September 9, 2011, the defendants filed a motion to dismiss the
second amended complaint. The plaintiff&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#x2019;&lt;/font&gt;s
opposition to the motion&amp;#xA0;was filed on&amp;#xA0;October 14, 2011
and the defendants filed a reply brief on November 4,
2011.&lt;/font&gt;&lt;/font&gt; &lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
Company and Mr. Palmin believe the allegations are without merit
and intend to vigorously defend against them.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
BAM Dispute&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
June 28, 2010, Novelos received a letter from counsel to ZAO BAM
and ZAO BAM Research Laboratories (Russian companies, collectively
referred to as &amp;#x201C;BAM&amp;#x201D;) alleging that it modified the
chemical composition of NOV-002 without prior notice to or approval
from BAM, constituting a material breach of a technology and
assignment agreement Novelos had entered into with BAM on June 20,
2000 (the &amp;#x201C;June 2000 Agreement&amp;#x201D;).&amp;#xA0; The letter
references the amendment, submitted to the FDA on August 30, 2005,
to Novelos&amp;#x2019; investigational new drug application dated August
1999 as the basis for BAM&amp;#x2019;s claims and demands the transfer
of all intellectual property rights concerning NOV-002 to
BAM.&amp;#xA0; Mark Balazovsky, a director of Novelos from June 1996
until November 2006 and a shareholder of Novelos through at least
June 25, 2010, is, to our knowledge, still the general director and
principal shareholder of ZAO BAM.&amp;#xA0; On September 24, 2010,
Novelos filed a complaint in Suffolk Superior Court seeking a
declaratory judgment by the court that the June 2000 Agreement has
been replaced by a subsequent agreement between the parties dated
April 1, 2005 (the &amp;#x201C;April 2005 Agreement&amp;#x201D;), that
Novelos&amp;#x2019; obligations to BAM are governed solely by the April
2005 Agreement and that the obligations of the June 2000 agreement
have been performed and fully satisfied.&amp;#xA0; On November 29,
2010, BAM answered the complaint, denying the material allegations,
and stating its affirmative defenses and certain counterclaims. On
January 14, 2011, Novelos responded to the counterclaims, denying
BAM&amp;#x2019;s material allegations and stating its affirmative
defenses.&amp;#xA0; On June 9, 2011, BAM filed an amended counterclaim
alleging additional claims related to Novelos&amp;#x2019; acquisition of
Cellectar.&amp;#xA0; In that amended counterclaim, BAM alleges that the
acquisition evidences Novelos&amp;#x2019; abandonment of the technology
assigned to it by BAM constituting a breach of the June 2000
Agreement or, if that agreement is determined to no longer be in
effect, a breach of the April 2005 Agreement and/or a breach of the
implied duty of good faith and fair dealing with respect to the
April 2005 Agreement.&amp;#xA0; On June 15, 2011 the Company filed its
response to their amended counterclaim.&amp;#xA0; On August 5, 2011,
the Company filed a motion for judgment on the pleadings as to its
declaratory judgment count and all counts of BAM&amp;#x2019;s amended
counterclaim.&amp;#xA0; The motion&amp;#xA0;was opposed by BAM and a
hearing on the motion&amp;#xA0;was held&amp;#xA0;on September 27, 2011.
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
October 17, 2011, the court ruled on the Company&amp;#x2019;s
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;behalf for each of
its declaratory judgment claims and dismissed all counts of
BAM&amp;#x2019;s counterclaim. Judgment in favor of the Company was
entered on October 20, 2011 and BAM has until November 21, 2011 to
appeal or otherwise seek post-judgment
relief.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;We
do not anticipate that these litigation contingencies will have a
material impact on the Company&amp;#x2019;s future financial position,
results of operations or cash flows.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">2445429</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
accompanying financial statements reflect the application of
certain accounting policies, as described in this note and
elsewhere in the accompanying notes to the financial
statements.&amp;#xA0; The unaudited financial statements as of and for
the nine months ended September 30, 2011 are presented on a
consolidated basis to reflect the Acquisition described in Note
4.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
accompanying consolidated unaudited September 30, 2011 balance
sheet, the statements of operations and cash flows for the nine
months ended September 30, 2011 and 2010, and the statements of
stockholders&amp;#x2019; equity for the nine months ended September 30,
2011 and the related interim information contained within the notes
to the financial statements have been prepared in accordance with
the rules and regulations of the Securities and Exchange Commission
(&amp;#x201C;SEC&amp;#x201D;) for interim financial information. Accordingly,
they do not include all of the information and the notes required
by U.S. generally accepted accounting principles for complete
financial statements. In the opinion of management, the unaudited
interim financial statements reflect all adjustments, consisting of
normal and recurring adjustments, necessary for the fair
presentation of the Company&amp;#x2019;s financial position at September
30, 2011 and results of its operations and its cash flows for the
nine months ended September 30, 2011 and 2010 and the period from
November 7, 2002 (inception) to September 30, 2011. The results for
the nine months ended September 30, 2011 are not necessarily
indicative of future results.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Development Stage Company&lt;/font&gt; &amp;#x2014; Cellectar has been in the
development stage since its inception.&amp;#xA0; The primary activities
since inception have been organizational activities, research and
development and raising capital.&amp;#xA0; No significant revenues have
been generated from planned principal operations.&amp;#xA0; As of
September 30, 2011 and December 31, 2010 and 2009 the Company
continues to be in the development stage.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
summary unaudited condensed statement of operations for the
cumulative development-stage period from November 7, 2002 (date of
inception) through September 30, 2011 is as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%"&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;COSTS
AND EXPENSES:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Research
and development&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;19,651,388&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;General
and administrative&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8,797,688&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Merger
costs&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;799,133&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
costs and expenses&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;29,248,209&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;LOSS
FROM OPERATIONS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(29,248,209&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;OTHER
EXPENSE, NET&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(266,297&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;NET
LOSS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(29,514,506&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;BASIC
AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON
SHARE&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(2.80&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;SHARES
USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON
STOCKHOLDERS PER COMMON SHARE&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;10,549,244&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
summary unaudited condensed statement of cash flow for the
cumulative development-stage period from November 7, 2002 (date of
inception) through September 30, 2011 is as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%"&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Net
loss&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(29,514,506&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Adjustments
to reconcile net loss to cash used in operating
activities&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;5,558,106&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Changes
in working capital&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;359,177&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Cash
used in operating activities&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(23,597,223&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;CASH
FLOWS FROM INVESTING ACTIVITIES:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Cash
acquired in a business combination&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;905,649&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Purchases
of fixed assets, net of $7,000 proceeds from sale of fixed
assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(5,473,376&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Change
in restricted cash&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(55,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Payment
for intangible assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(19,671&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Cash
used in investing activities&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(4,642,398&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;CASH
FLOWS FROM FINANCING ACTIVITIES:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Proceeds
from issuance of common stock and warrants, net of issuance costs,
repurchase of common stock, and cash paid in lieu of fractional
shares in a business combination&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;26,794,302&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Change
in deferred issuance costs&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(130,800&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Proceeds
from issuance of long-term obligations&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4,398,930&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Payments
on long-term obligations&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(1,232,056&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Cash
provided by financing activities&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;29,830,376&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;INCREASE
IN CASH AND EQUIVALENTS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,590,755&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;CASH
AND EQUIVALENTS AT BEGINNING OF PERIOD&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;CASH
AND EQUIVALENTS AT END OF PERIOD&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,590,755&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;SUPPLEMENTAL
DISCLOSURE OF CASH FLOW INFORMATION&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Interest
paid&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;208,689&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Fair
value of derivative warrants reclassified to additional paid-in
capital upon cashless exercise&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;48,339&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Issuance
of common stock upon the conversion of notes payable and accrued
interest&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,184,707&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Fair
value of assets acquired in exchange for securities in a business
combination&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;78,407&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Fair
value of liabilities assumed in exchange for securities in a
business combination&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(439,615&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Excess
of purchase price over net assets acquired in a business
combination&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,675,462&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="center"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
&lt;!--EFPlaceholder--&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;Use of
Estimates&lt;/font&gt; &amp;#x2014; The preparation of financial statements in
conformity with accounting principles generally accepted in the
United States requires management to make estimates and judgments
that may affect the reported amounts of assets, liabilities,
revenue and expenses and disclosure of contingent assets and
liabilities. On an on-going basis, management evaluates its
estimates including those related to unbilled vendor amounts and
share-based compensation. Management bases its estimates on
historical experience and on various other assumptions that are
believed to be reasonable, the results of which form the basis for
making judgments about the carrying values of assets and
liabilities. Actual results may differ from those estimates under
different assumptions or conditions. Changes in estimates are
reflected in reported results in the period in which they become
known.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Cash and Cash Equivalents&lt;/font&gt; &amp;#x2014; All short-term investments
purchased with original maturities of three months or less are
considered to be cash equivalents.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Restricted Cash&lt;/font&gt; &amp;#x2014; Restricted cash at September 30,
2011 consists of a certificate of deposit required under the
Company&amp;#x2019;s lease agreement (see Note 14).&amp;#xA0; Restricted
cash at December 31, 2010 and December 31, 2009 consists of a
certificate of deposit required for collateral for a promissory
note with a bank (see Note 8) and a certificate of deposit required
under the Company&amp;#x2019;s lease agreement (see Note
14).&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Fixed Assets&lt;/font&gt; &amp;#x2014; Property and equipment are stated at
cost. Depreciation on property and equipment is provided using the
straight-line method over the estimated useful lives of the assets
(5 years).&amp;#xA0; Due to the significant value of leasehold
improvements purchased during the initial 3-year lease term and the
economic penalty for not extending the building lease, leasehold
improvements are depreciated over 17 years (their estimated useful
life) which represents the full term of the lease, including all
extensions (Note 14).&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Intangible Assets&lt;/font&gt; &amp;#x2014; Intangible assets at September 30,
2011 consist of the excess of purchase price over net assets
acquired in connection with the Acquisition and will be allocated
to intangibles, which could potentially include the fair value of
the compounds developed prior to the Acquisition by Novelos, with
the remainder allocated to goodwill once the Company completes the
final allocation of purchase price (Note 4).&amp;#xA0; Intangible
assets at December 31, 2009 consisted of costs incurred to obtain
trademarks.&amp;#xA0; These costs were capitalized when the expense was
incurred and at which time the assets were deemed to have an
indefinite life.&amp;#xA0; During 2010, following a reduction in staff
and suspension of research and manufacturing activities in order to
reduce operating costs, it was determined that the trademarks had
been impaired and the carrying value was reduced to
zero.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Impairment of Long&lt;/font&gt; - &lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;Lived
Assets&lt;/font&gt; &amp;#x2014; Whenever events or circumstances change, an
assessment is made as to whether there has been an impairment in
the value of long-lived assets by determining whether projected
undiscounted cash flows generated by the applicable asset exceed
its net book value as of the assessment date.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Stock-Based Compensation&lt;/font&gt; &amp;#x2014; Employee stock-based
compensation is accounted for in accordance with the guidance of
Financial Accounting Standards Board Accounting Standards
Codification (&amp;#x201C;FASB ASC&amp;#x201D;) Topic 718, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Compensation &amp;#x2013; Stock
Compensation&lt;/font&gt; which requires all share-based payments to
employees, including grants of employee stock options, to be
recognized in the financial statements based on their fair
values.&amp;#xA0; Non-employee stock-based compensation is accounted
for in accordance with the guidance of FASB ASC Topic 505,
&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Equity.&amp;#xA0;&lt;/font&gt; As such,
the Company recognizes expense based on the estimated fair value of
options granted to non-employees over their vesting period, which
is generally the period during which services are rendered and
deemed completed by such non-employees.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Research and Development&lt;/font&gt; &amp;#x2014; Research and development
costs are expensed as incurred.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Income Taxes&lt;/font&gt; &amp;#x2014; Income taxes are accounted for using
the liability method of accounting.&amp;#xA0; Under this method,
deferred tax assets and liabilities are determined based on
temporary differences between the financial statement and tax basis
of assets and liabilities and net operating loss and credit
carryforwards using enacted tax rates in effect for the year in
which the differences are expected to reverse.&amp;#xA0; The effect on
deferred tax assets and liabilities of a change in tax rates is
recognized in income in the period that includes the enactment
date.&amp;#xA0; Valuation allowances are established when it is more
likely than not that some portion of the deferred tax assets will
not be realized.&amp;#xA0; Management has provided a full valuation
allowance against the Company&amp;#x2019;s gross deferred tax
asset.&amp;#xA0; Tax positions taken or expected to be taken in the
course of preparing tax returns are required to be evaluated to
determine whether the tax positions are &amp;#x201C;more likely than
not&amp;#x201D; of being sustained by the applicable tax
authority.&amp;#xA0; Tax positions deemed not to meet a
more-likely-than-not threshold would be recorded as tax expense in
the current year.&amp;#xA0; There were no uncertain tax positions that
require accrual or disclosure to the financial statements as of
September 30, 2011, December 31, 2010 and 2009.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Comprehensive Loss&lt;/font&gt; &amp;#x2014; There were no components of
comprehensive loss other than net loss in all of the periods
presented.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Grant Income&lt;/font&gt; &amp;#x2014; Cellectar received a cash grant of
$44,000 and $200,000 for the nine-month period ended September 30,
2011 and the year ended December 31, 2010, respectively, from the
U.S. Internal Revenue Service as a qualifying therapeutic discovery
project credit pursuant to the Patient Protection and Affordable
Care Act.&amp;#xA0; This grant has been recorded as a component of
other income.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Fair Value of Financial Instruments&lt;/font&gt; &amp;#x2014; The guidance
under FASB ASC Topic 825, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Financial Instruments&lt;/font&gt;
, requires disclosure of the fair value of certain financial
instruments. Financial instruments in the accompanying financial
statements consist of cash equivalents, accounts payable,
convertible debt and long-term obligations.&amp;#xA0; The carrying
amount of cash equivalents, investments and accounts
payable&amp;#xA0;approximate&amp;#xA0;their&amp;#xA0;fair value due to their
short-term nature.&amp;#xA0; The estimated fair value of the
convertible debt, determined on an as-converted basis including
conversion of accumulated unpaid interest, was approximately $0 and
$3,264,000 at September 30, 2011 and December 31, 2010,
respectively.&amp;#xA0; The carrying value of long-term obligations,
including the current portion, approximates fair value because the
fixed interest rate approximates current market rate of interest
available in the market.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Derivative Instruments&lt;/font&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#xA0;&lt;/font&gt;&amp;#x2013; The
Company generally does not use derivative instruments to hedge
exposures to cash flow or market risks.&amp;#xA0; However, certain
warrants to purchase common stock that do not meet the requirements
for classification as equity, in accordance with the Derivatives
and Hedging Topic of the Financial Accounting Standards Board
Accounting Standards Codification (&amp;#x201C;FASB
ASC&amp;#x201D;),&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#xA0;&lt;/font&gt;are classified
as liabilities.&amp;#xA0; In such instances, net-cash settlement is
assumed for financial reporting purposes, even when the terms of
the underlying contracts do not provide for a net-cash settlement.
These warrants are considered derivative instruments because the
agreements contain &amp;#x201C;down-round&amp;#x201D; provisions whereby the
number of shares for which the warrants are exercisable and/or the
exercise price of the warrants are subject to change in the event
of certain issuances of stock at prices below the then-effective
exercise price of the warrants. The number of shares issuable under
such warrants was 77,729 at September 30, 2011. The primary
underlying risk exposure pertaining to the warrants is the change
in fair value of the underlying common stock.&amp;#xA0; Such financial
instruments are initially recorded at fair value with subsequent
changes in fair value recorded as a component of gain or loss on
derivatives in each reporting period. If these instruments
subsequently meet the requirements for equity classification, the
Company reclassifies the fair value to equity. At September 30,
2011, these warrants represented the only outstanding derivative
instruments issued or held by the Company.&amp;#xA0; There were no
outstanding derivative instruments at December 31, 2010 or
2009.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Concentration of Credit Risk&lt;/font&gt; &amp;#x2014; Financial instruments
that subject the Company to credit risk consist of cash and
equivalents on deposit with financial institutions, which may
exceed federally insured limits.&amp;#xA0; Excess cash is invested on
an overnight basis in an investment account that is fully
collateralized principally by government-backed obligations.&amp;#xA0;
Cash and equivalent balances are maintained with a stable and
well-capitalized financial institution.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
New Accounting Pronouncements&lt;/font&gt; &amp;#x2014;&amp;#xA0;In January 2010,
the FASB issued ASU No.&amp;#xA0;2010-06, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Improving Disclosures about
Fair Value Measurements&lt;/font&gt; , which requires additional
disclosures about the amounts of and reasons for significant
transfers in and out of Level&amp;#xA0;1 and Level&amp;#xA0;2 fair value
measurements. This standard also clarifies existing disclosure
requirements related to the level of disaggregation of fair value
measurements for each class of assets and liabilities and
disclosures about inputs and valuation techniques used to measure
fair value for both recurring and non-recurring Level&amp;#xA0;2 and
Level&amp;#xA0;3 measurements. Since this new accounting standard only
required additional disclosure, the adoption of the standard in the
first quarter of 2010 did not impact the accompanying financial
statements. Additionally, effective for interim and annual periods
beginning after December&amp;#xA0;15, 2010, this standard will require
additional disclosure and require an entity to present
disaggregated information about activity in Level&amp;#xA0;3 fair value
measurements on a gross basis, rather than one net amount.&amp;#xA0;
The adoption of this accounting standard did not impact the
accompanying financial statements.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
December 2010, the FASB issued ASU No. 2010-29, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Disclosures of Supplementary
Pro Forma Information for Business Combinations&lt;/font&gt;, which, if
comparative financial statements are presented, requires the
supplemental pro forma disclosure of revenue and earnings to be
presented as if the business combination had occurred at the
beginning of the comparable prior annual reporting period
only.&amp;#xA0; This standard also expands the supplemental pro forma
disclosures required under FASB ASC Topic 850, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Business Combinations&lt;/font&gt;
, to include a description of the nature and amount of material
nonrecurring pro forma adjustments directly attributable to the
business combination in the reported pro forma revenue and
earnings.&amp;#xA0; This standard is effective for the Company for any
business combinations completed after January 1, 2011.&amp;#xA0; The
Company adopted the provisions of this standard during the first
quarter of 2011.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
May 2011, the FASB issued ASU No. 2011-04, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Amendments to Achieve Common
Fair Value Measurement and Disclosure Requirements in U.S.
Generally Accepted Accounting Principles (&amp;#x201C;GAAP&amp;#x201D;) and
International Financial Reporting Standards
(&amp;#x201C;IFRSs&amp;#x201D;).&lt;/font&gt; &amp;#xA0;This standard updates
accounting guidance to clarify the measurement of fair value to
align the guidance and improve the comparability surrounding fair
value measurement within GAAP and IFRSs.&amp;#xA0; The standard also
updates requirements for measuring fair value and expands the
required disclosures.&amp;#xA0; The standard does not require
additional fair value measurements and was not intended to
establish valuation standards or affect valuation practices outside
of financial reporting.&amp;#xA0; This standard will become effective
for the Company on January 1, 2012.&amp;#xA0; The Company does not
expect that the adoption of this standard will have a material
impact when applied prospectively on the Company&amp;#x2019;s financial
statements or required disclosures.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
June 2011, the FASB issued ASU No. 2011-05, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Presentation of Comprehensive
Income.&lt;/font&gt;&amp;#xA0;This standard eliminates the current option to
report other comprehensive income and its components in the
statement of changes in equity. The standard is intended to enhance
comparability between entities that report under US&amp;#xA0;GAAP and
those that report under IFRS, and to provide a more consistent
method of presenting non-owner transactions that affect an entity&apos;s
equity. Under the ASU, an entity can elect to present items of net
income and other comprehensive income in one continuous statement,
referred to as the statement of comprehensive income, or in two
separate, but consecutive, statements. Each component of net income
and each component of other comprehensive income, together with
totals for comprehensive income and its two parts, net income and
other comprehensive income, would need to be displayed under either
alternative. The statement(s) would need to be presented with equal
prominence as the other primary financial statements. The ASU does
not change items that constitute net income and other comprehensive
income, when an item of other comprehensive income must be
reclassified to net income or the earnings-per-share computation
(which will continue to be based on net income). The new
US&amp;#xA0;GAAP requirements are effective for public entities as of
the beginning of a fiscal year that begins after December&amp;#xA0;15,
2011 and interim and annual periods thereafter. Early adoption is
permitted, but full retrospective application is required under the
accounting standard. The Company does not expect that the adoption
of this standard will have a material impact on our results of
operations, cash flows, and financial position.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;In
September 2011, the FASB issued ASU No. 2011-08, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Intangibles &amp;#x2013; Goodwill
and Other (Topic 350) Testing Goodwill for
Impairment.&lt;/font&gt;&amp;#xA0;&amp;#xA0;This standard simplifies how an
entity tests goodwill for impairment and allows an entity to first
assess qualitative factors in determining whether it is more likely
than not that the fair value of a reporting unit is less than its
carrying amount as a basis for determining whether it is necessary
to perform the two-step goodwill impairment test.&amp;#xA0;&amp;#xA0;This
standard is effective for entities as of the beginning of a fiscal
year that begins after December 15, 2011 and interim and annual
periods thereafter.&amp;#xA0;&amp;#xA0;Early adoption is
permitted.&amp;#xA0;&amp;#xA0;The Company does not expect the adoption of
this standard will have a material impact on our results of
operations, cash flows, and financial position.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Reclassifications&lt;/font&gt; &amp;#x2014; Certain prior-period amounts have
been reclassified to conform to the current-period
presentation.&lt;/font&gt;&lt;/div&gt;


&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">257973</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-66820</us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments>
  <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 27pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
4.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
ACQUISITION&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Merger Agreement&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
April 8, 2011, Novelos acquired Cellectar through a merger with and
into the Merger Subsidiary, pursuant to the merger Agreement
entered into on that date.&amp;#xA0; As a result of the Acquisition,
the Merger Subsidiary, which has been renamed Cellectar, Inc., owns
all assets of and operates the business previously owned and
operated by Cellectar.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
the Acquisition, the former stockholders of Cellectar received an
aggregate number of shares of Novelos common stock constituting
approximately 85% of the outstanding shares of Novelos common
stock, after giving effect to the Acquisition but before giving
effect to the concurrent private placement of Novelos securities
described below.&amp;#xA0; Prior to the Acquisition, Novelos amended
and restated its certificate of incorporation and in connection
therewith, among other things, effected a 1-for-153 reverse split
of its common stock (the &amp;#x201C;Reverse Split&amp;#x201D;) resulting
in&amp;#xA0;2,959,871 shares of Novelos common stock outstanding.
Novelos then issued 17,001,596 shares of Novelos common stock to
the stockholders of Cellectar upon the effective date of the
Acquisition.&amp;#xA0; Warrants and options to purchase Novelos common
stock that were outstanding prior to the Acquisition remained
outstanding following the Acquisition. These consist of warrants to
purchase a total of 315,164 shares of Novelos common stock with
prices ranging from $16.07 to $191.25 and options to purchase a
total of 49,159 shares of Novelos common stock with prices ranging
from $1.53 to $1,072.53.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;XMS
Capital Partners, the financial advisor to Cellectar in connection
with the Acquisition, received a cash fee of $200,000 upon the
completion of the Acquisition in consideration of their
services.&amp;#xA0; Rodman &amp;amp; Renshaw, LLC (&amp;#x201C;Rodman&amp;#x201D;),
financial advisor to Novelos in connection with the Acquisition,
received a cash fee of $250,000 upon the completion of the
Acquisition in consideration of their services.&amp;#xA0; These amounts
were recorded as merger costs and expensed as incurred on the date
of the Acquisition.&amp;#xA0; In addition to the investment banking
fees, the Company also incurred an additional $296,207 of
merger-related legal and other costs during the nine months ended
September 30, 2011 which were included as a component of expense in
the respective period.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Acquisition was completed principally to leverage synergies between
Novelos&amp;#x2019; strategic focus and experience in developing and
funding the development of cancer drugs and Cellectar&amp;#x2019;s
portfolio of cancer-targeted compounds.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Purchase Accounting&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Acquisition was accounted for using the purchase method of
accounting as a reverse acquisition.&amp;#xA0; In a reverse
acquisition, the post-acquisition net assets of the surviving
combined company includes the historical cost basis of the net
assets of the accounting acquirer (Cellectar) plus the fair value
of the net assets of the accounting acquiree (Novelos).&amp;#xA0;
Further, under the purchase method, the purchase price is allocated
to the assets acquired and liabilities assumed based on their
estimated fair values and the excess of the purchase price over the
estimated fair value of the identifiable net assets is presented as
excess purchase price over net assets acquired.&amp;#xA0; The cost of
acquisition and related purchase-price allocation is based on
preliminary evaluation of the fair value of assets and liabilities
assumed from Novelos and may change when the final valuation of
certain intangible assets is determined.&amp;#xA0; The evaluation is
preliminary principally due to the pending evaluation of the
Company&amp;#x2019;s intangible assets.&amp;#xA0; The excess of purchase
price over net assets acquired will be allocated to intangibles and
goodwill once the Company completes the final allocation of
purchase price.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
fair value of the consideration transferred in the Acquisition was
$2,219,903 and was calculated as the number of shares of common
stock that Cellectar would have had to issue (adjusted for the
Exchange Ratio) in order for Novelos shareholders to obtain a 15%
equity interest in the combined Company post-acquisition,
multiplied by the estimated fair value of the Company&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#x2019;&lt;/font&gt;s
common stock on the acquisition date.&amp;#xA0; The estimated fair
value of the Company&amp;#x2019;s common stock was based on the offering
price of the common stock sold in the private placement which was
both completed concurrently with and conditioned upon the closing
of the Acquisition.&amp;#xA0;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;This
price was determined to be the best indication of fair value on
that date since the price was based on an arm&amp;#x2019;s length
negotiation with a group consisting of both new and existing
investors that had been advised of the pending Acquisition and
assumed similar liquidity risk as those investors holding the
majority of shares being valued as purchase
consideration.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
following table summarizes the Company&amp;#x2019;s preliminary
estimated fair values of the assets acquired and the liabilities
assumed at the date of acquisition.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="85%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Consideration
issuance of securities&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
2,219,903&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="85%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="85%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Prepaid
expenses and other assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;71,892&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="85%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Fixed
assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;6,515&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="85%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Accrued
liabilities&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(380,130&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="85%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Derivative
liability&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(59,485&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="85%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Excess
of purchase price over net assets acquired&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
1,675,462&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="85%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="85%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
purchase price &amp;#x2013; net of cash acquired of
$905,649&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
1,314,254&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;br /&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
excess of purchase price over net assets acquired will be allocated
to intangibles, which could potentially include the fair value of
the compounds developed prior to the Acquisition by Novelos, with
the remainder allocated to goodwill once the Company completes the
final allocation of purchase price.&amp;#xA0; The estimated fair values
of assets acquired and liabilities assumed are provisional and are
based on the information that was available as of the acquisition
date to estimate the fair value of assets acquired and liabilities
assumed.&amp;#xA0; The Company believes that the information provides a
reasonable basis for estimating the fair values of assets acquired
and liabilities assumed, but the Company is waiting for additional
information necessary to finalize those fair values.&amp;#xA0;
Therefore, the provisional measurements of fair value reflected are
subject to change and such changes may be significant.&amp;#xA0; The
Company expects to finalize the valuation and complete the purchase
price allocation as soon as practicable but no later than one year
from the acquisition date.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">439587</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="INF">-428015</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">112195</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">2219903</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">-5019146</us-gaap:OperatingIncomeLoss>
  <us-gaap:RevenueFromGrants contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">44479</us-gaap:RevenueFromGrants>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">4866406</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
5.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
FIXED ASSETS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Fixed
assets consisted of the following at December 31:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2010&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2009&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Office
and laboratory equipment&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,984,375&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,982,723&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Leasehold
improvements&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
2,317,597&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
2,317,597&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
fixed assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;5,301,972&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;5,300,320&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Less
accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
(1,791,483&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
(1,211,369&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Fixed
assets, net&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
3,510,489&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
4,088,951&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;During
the nine months ended&amp;#xA0;September 30, 2011, the change to net
fixed assets consisted of an increase of approximately $440,000
related to accumulated depreciation and amortization, purchases of
equipment totaling approximately $112,000, equipment disposals of
approximately $6,000, and approximately $7,000 related to the fair
value of fixed assets acquired as a result of the Acquisition (see
Note 4).&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">917016</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">224548</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:FairValueOfAssetsAcquired contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">78407</us-gaap:FairValueOfAssetsAcquired>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Novelos
Therapeutics, Inc. (&amp;#x201C;Novelos&amp;#x201D; or the
&amp;#x201C;Company&amp;#x201D;) is a pharmaceutical company developing
compounds for the treatment of cancer. On April 8, 2011, Novelos
completed a business combination with Cellectar, Inc.
(&amp;#x201C;Cellectar&amp;#x201D;), a privately held Wisconsin corporation
that designed and developed products to detect, treat and monitor a
wide variety of human cancers, and Cell Acquisition Corp. (the
&amp;#x201C;Merger Subsidiary&amp;#x201D;), a Wisconsin corporation and a
wholly owned subsidiary of Novelos. Pursuant to the transaction
Cellectar was merged into the Merger Subsidiary (the
&amp;#x201C;Acquisition&amp;#x201D;, see Note 4). References in these
financial statements and notes to &amp;#x201C;Cellectar&amp;#x201D; relate to
the activities and financial information of Cellectar prior to the
Acquisition, references to &amp;#x201C;Novelos&amp;#x201D; relate to the
activities and financial information of Novelos prior to the
Acquisition and references to &amp;#x201C;the Company&amp;#x201D; or
&amp;#x201C;we&amp;#x201D; or &amp;#x201C;us&amp;#x201D; or &amp;#x201C;our&amp;#x201D; relate to
the activities and obligations of the combined Company following
the Acquisition.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Immediately
prior to the Acquisition, Novelos completed a 1-for-153 reverse
split of its common stock (the &amp;#x201C;Reverse Split&amp;#x201D;).&amp;#xA0;
Novelos then issued to the shareholders of Cellectar at that date
17,001,596 shares of its common stock as consideration for the
Acquisition, representing a ratio of 0.8435 shares of Novelos
common stock in exchange for one share of Cellectar common stock
(the &amp;#x201C;Exchange Ratio&amp;#x201D;) as set forth in the Agreement
and Plan of Merger (the &amp;#x201C;Merger Agreement&amp;#x201D;) dated April
8, 2011.&amp;#xA0; The shares issued to Cellectar shareholders in the
Acquisition constituted approximately 85% of Novelos&amp;#x2019;
outstanding common stock after giving effect to the
Acquisition.&amp;#xA0; Upon the closing of the Acquisition, the Company
completed the private placement of 6,846,537 shares of its common
stock and warrants to purchase an additional 6,846,537 shares of
its common stock for gross proceeds of approximately
$5,135,000.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
Accounting principles generally accepted in the United States
require that a company whose security holders retain the majority
voting interest in the combined business be treated as the acquirer
for financial reporting purposes.&amp;#xA0; Accordingly, the
Acquisition will be accounted for as a reverse acquisition whereby
Cellectar, Inc. will be treated as the acquirer for accounting and
financial reporting purposes. The financial statements presented
herein as of and for the twelve months ended December 31, 2010 and
2009 represent the historical financial information of Cellectar,
except for the capital structure which represents the historical
amounts of Cellectar, retroactively adjusted to reflect the legal
capital structure of Novelos by applying the Exchange Ratio. On
April, 8, 2011, Cellectar was merged into the Merger Subsidiary a
wholly owned subsidiary of Novelos; as such, the financial
statements presented herein as of and for the nine months ended
September 30, 2011 include the historical results of Cellectar from
January 1, 2011 through April 8, 2011, except for the capital
structure which represents the historical amounts of Cellectar,
retroactively adjusted to reflect the legal capital structure of
Novelos by applying the Exchange Ratio, and include the
consolidated results of the combined company from April 9, 2011
through September 30, 2011.&amp;#xA0; All per-share amounts and
outstanding shares, including all common stock equivalents, and
stock options, have been retroactively restated in these financial
statements and notes for all periods presented to reflect the
capital structure of Novelos by applying the Exchange
Ratio.&amp;#xA0;&amp;#xA0;The cumulative capital activity from the date of
inception (November 7, 2002) up to the closing of the Acquisition,
as presented in the accompanying statement of stockholders&amp;#x2019;
equity, equals 17,001,596 shares of common stock, which represents
the equity interests the legal parent (Novelos) issued to effect
the Acquisition. The number of authorized shares of common stock
disclosed on the balance sheet (150,000,000) represents the number
of authorized shares of Novelos common stock following the
Acquisition.&amp;#xA0; Additionally, on the accompanying balance sheets
as of December 31, 2010 and 2009 and statements of
stockholders&amp;#x2019; equity for the period from inception (November
7, 2002) to December 31, 2010 the aggregate par value of the issued
common stock was reduced to reflect the $0.00001 par value of
Novelos common stock associated with the shares of Cellectar common
stock adjusted for the Exchange Ratio and the difference was
reclassified to additional paid-in capital.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As
a result of the Acquisition, the Company has implemented a revised
business plan focused on the development of the Cellectar
compounds.&amp;#xA0; Development of Novelos&amp;#x2019; other compounds
(NOV-002 and NOV-205) has been suspended.&amp;#xA0; The Company is
conducting its operations from Cellectar&amp;#x2019;s headquarters in
Madison, WI and the Company&amp;#x2019;s executive offices are in
Newton, MA.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company is subject to a number of risks similar to those of other
small pharmaceutical companies. Principal among these risks are
dependence on key individuals, competition from substitute products
and larger companies, the successful development and marketing of
its products in a highly regulated environment and the need to
obtain additional financing necessary to fund future
operations.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
accompanying financial statements have been prepared on a basis
that assumes that the Company will continue as a going concern and
that contemplates the continuity of operations, realization of
assets and the satisfaction of liabilities and commitments in the
normal course of business. Cellectar has incurred losses since
inception in devoting substantially all of its efforts toward
research and development and has an accumulated deficit of
$24,045,004 at December 31, 2010. During the year ended December
31, 2010, Cellectar generated a net loss of $4,560,263 and the
Company expects that it will continue to generate operating losses
for the foreseeable future.&amp;#xA0; The Company believes that its
cash on hand following the Acquisition, plus the proceeds from the
private placement completed in connection with the Acquisition, is
adequate to fund operations until the end of 2011.&amp;#xA0; The
Company&amp;#x2019;s ability to execute its operating plan beyond that
time depends on its ability to obtain additional funding via the
sale of equity and/or debt securities, a strategic transaction or
otherwise.&amp;#xA0; The Company plans to continue to actively pursue
financing alternatives, but there can be no assurance that it will
obtain the necessary funding.&amp;#xA0; The accompanying financial
statements do not include any adjustments that might result from
the outcome of this uncertainty.&lt;/font&gt;&lt;/div&gt;


&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div&gt;
&lt;table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 27pt"&gt;
&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
&lt;!--EFPlaceholder--&gt;3.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
FAIR VALUES OF ASSETS AND LIABILITIES&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;In
accordance with Fair Value Measurements and Disclosures Topic of
the FASB ASC, the Company groups its financial assets and financial
liabilities generally measured at fair value in three levels, based
on the markets in which the assets and liabilities are traded and
the reliability of the assumptions used to determine fair
value.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 27pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="font-family:Symbol, serif"&gt;&amp;#xB7;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Level
1: Input prices quoted in an active market for identical financial
assets or liabilities.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 27pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="font-family:Symbol, serif"&gt;&amp;#xB7;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Level
2: Inputs other than prices quoted in Level 1, such as prices
quoted for similar financial assets and liabilities in active
markets, prices for identical assets and liabilities in markets
that are not active or other inputs that are observable or can be
corroborated by observable market data.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 27pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="font-family:Symbol, serif"&gt;&amp;#xB7;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Level
3: Input prices quoted that are significant to the fair value of
the financial assets or liabilities which are not observable or
supported by an active market.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Assets
and liabilities measured at fair value on a recurring basis are
summarized below:&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" width="58%" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;font style="DISPLAY: inline"&gt;September 30,
2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;font style="DISPLAY: inline"&gt;Level 1&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;font style="DISPLAY: inline"&gt;Level 2&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;font style="DISPLAY: inline"&gt;Level 3&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;font style="DISPLAY: inline"&gt;Fair Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="40%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="40%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
Liabilities:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 4px; MARGIN-LEFT: 9pt"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;
-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;
77,967&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;
-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;
77,967&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" width="58%" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;font style="DISPLAY: inline"&gt;December 31, 2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;font style="DISPLAY: inline"&gt;Level 1&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;font style="DISPLAY: inline"&gt;Level 2&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;font style="DISPLAY: inline"&gt;Level 3&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;font style="DISPLAY: inline"&gt;Fair Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="40%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="40%"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
Liabilities:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="13%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 4px; MARGIN-LEFT: 9pt"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;
-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;
-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;
-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;
-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
Company uses the Black-Scholes option pricing model and assumptions
that consider, among other variables, the fair value of the
underlying stock, risk-free interest rate, volatility, expected
life and dividend rates in estimating fair value for the warrants
considered to be derivative instruments. Assumptions used are
generally consistent with those disclosed for stock-based
compensation (see Note 11).&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
12. &amp;#xA0;INCOME TAXES&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Deferred
tax assets consisted of the following at December 31:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Deferred
tax assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Federal
net operating loss&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;6,116,804&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4,754,001&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Federal
research and development tax credit carryforwards&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;390,600&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;273,788&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Wisconsin
net operating loss credit carryforwards&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;814,492&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;589,548&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Wisconsin
research and development tax credit carryforwards&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;220,738&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;171,552&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Stock-based
compensation expense&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;552,859&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;415,060&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Charitable
contribution carryforwards&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;49,725&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;49,725&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Accrued
liabilities&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
25,327&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
75,711&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
deferred tax assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8,170,545&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;6,329,385&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Deferred
tax liabilities&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Depreciable
and intangible assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
(434,056&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
(475,524&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
deferred tax liabilities&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(434,056&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(475,524&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Net
deferred tax assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;7,736,489&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;5,853,861&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Less
valuation allowance&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
(7,736,489&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
(5,853,861&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
deferred tax assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
&amp;#x2014;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
&amp;#x2014;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;br /&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As
of December 31, 2010, Cellectar had federal and state net operating
loss carryforwards (&amp;#x201C;NOLs&amp;#x201D;) of approximately
$15,684,000 and $15,633,000 respectively, which expire beginning in
2030 and 2025, respectively.&amp;#xA0; In addition, Cellectar has
federal and state research and development and investment tax
credits of approximately $391,000 and $335,000, respectively.&amp;#xA0;
The amount of NOLs which may be utilized annually in future periods
will be limited pursuant to Section 382 of the Internal Revenue
Code as a result of substantial changes in the Company&amp;#x2019;s
ownership that have occurred or that may occur in the future.&amp;#xA0;
The Company has not quantified the amount of such
limitations.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Because
of the limited operating history, continuing losses and uncertainty
associated with the utilization of the NOLs in the future,
management has provided a full allowance against the gross deferred
tax asset.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Cellectar
did not have unrecognized tax benefits or accrued interest and
penalties at any time during the years ended December 31, 2010 and
2009, and does not anticipate having unrecognized tax benefits over
the next twelve months.&amp;#xA0; The Company is subject to audit by
the IRS for tax periods commencing January 1, 2007.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;For
the nine-month period ended September 30, 2011, the federal and
state NOLs increased by approximately $5,470,000 as a result of the
loss recorded.&lt;/font&gt;&lt;/div&gt;


&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:InterestPaid contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">13716</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">158672</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
11.&amp;#xA0; STOCK-BASED COMPENSATION&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Cellectar&amp;#x2019;s
stock-based compensation plans prior to the Acquisition are
summarized below:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
2006 Unit Option Plan.&amp;#xA0;&lt;/font&gt; The 2006 Unit Option Plan (the
&amp;#x201C;2006 Cellectar Plan&amp;#x201D;), as amended and restated,
provided Cellectar the ability to grant to employees, directors,
consultants, and other non-employees units of interest in
Cellectar.&amp;#xA0; The maximum aggregate number of shares that were
subject to grant under the 2006 Cellectar Plan was
1,012,200.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Cellectar
granted 631,360 unit options under the 2006 Cellectar Plan and no
additional grants will be made thereunder.&amp;#xA0; In connection with
the Conversion described in Note 10, each issued and outstanding
unexercised unit option outstanding immediately prior to the
Conversion was converted into an option to acquire the same number
of shares of Cellectar&amp;#x2019;s common stock.&amp;#xA0; A total of
606,889 and 691,248 options to purchase shares of Cellectar&amp;#x2019;s
common stock were outstanding under the 2006 Cellectar Plan as of
December 31, 2010 and 2009, respectively.&amp;#xA0; These options
generally vested annually over four years and expire on the eighth
anniversary of the grant date.&amp;#xA0; No options were granted under
the 2006 Cellectar Plan during 2010 or 2009.&amp;#xA0; There have been
no exercises of options issued under the 2006 Cellectar Plan.&amp;#xA0;
On March 17, 2011, in contemplation of the Acquisition, Cellectar
terminated the remaining options outstanding under the 2006
Cellectar Plan as of that date.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
2008 Stock Incentive Plan&lt;/font&gt;.&amp;#xA0; The 2008 Stock Incentive
Plan (the &amp;#x201C;2008 Plan&amp;#x201D;) provided Cellectar the ability
to grant to employees, directors, consultants and other
non-employees of Cellectar options to purchase common stock.&amp;#xA0;
The maximum aggregate number of shares that were subject to grant
under the 2008 Plan was 823,930.&amp;#xA0; Cellectar granted a total of
382,223 options under the 2008 Plan.&amp;#xA0; A total of 162,300 and
300,488 options to purchase shares of Cellectar&amp;#x2019;s common
stock were outstanding as of December 31, 2010 and 2009,
respectively.&amp;#xA0; These options generally vested annually over
four years and expire on the tenth anniversary of the grant
date.&amp;#xA0; &amp;#xA0;During 2009, 90,929 options were granted under
the 2008 Plan.&amp;#xA0; During 2010, no options were granted under the
2008 Plan. No options have been exercised.&amp;#xA0; On March 17, 2011,
in contemplation of the Acquisition, Cellectar terminated the
remaining options outstanding under the 2008 Plan as of that
date.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As
of December 31, 2010, an aggregate of 1,066,941 shares were
available for grant under the 2006 Cellectar Plan and 2008
Plan.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Cellectar&amp;#x2019;s
Board of Directors determined exercise prices and vesting periods
on the date of grant, subject to the provisions of the 2006
Cellectar Plan and 2008 Plan.&amp;#xA0; Options have been granted at or
above the estimated fair-market value of the common stock at the
grant date. Options granted pursuant to the 2006 Cellectar Plan and
2008 Plan generally would have become fully vested in the event of
a business combination whereby the options are not assumed or
replaced by the surviving company, as defined.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
connection with the Acquisition, the Company assumed options to
purchase 49,159 shares of common stock at exercise prices ranging
from $1.53 to $1,072.53.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
2006 Novelos Stock Option Plan.&lt;/font&gt;&amp;#xA0; Following the
Acquisition, option grants to directors and employees will be made
under the Novelos Therapeutics 2006 Stock Incentive Plan (the
&amp;#x201C;Plan&amp;#x201D;).&amp;#xA0; On May 18, 2011, the Board of Directors
of the Company approved certain amendments to the Plan to, among
other things, increase the aggregate number of shares of the
Company&amp;#x2019;s common stock reserved for issuance under the Plan
(including any shares that have already been issued thereunder), to
7,000,000 and remove the 750,000 share annual individual limitation
on grants under the Plan.&amp;#xA0; On June 30, 2011, the
Company&amp;#x2019;s stockholders ratified those
amendments.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;A
total of 7,000,000 shares of common stock are reserved for issuance
under the Plan for grants of incentive or nonqualified stock
options, rights to purchase restricted and unrestricted shares of
common stock, stock appreciation rights and performance share
grants.&amp;#xA0; A committee of the board of directors determines
exercise prices, vesting periods and any performance requirements
on the date of grant, subject to the provisions of the Plan.&amp;#xA0;
Options are granted at or above the fair market value of the common
stock at the grant date and expire on the tenth anniversary of the
grant date.&amp;#xA0; Vesting periods are generally between one and
four years.&amp;#xA0; Options granted pursuant to the Plan generally
will become fully vested upon a termination event occurring within
one year following a change in control, as defined.&amp;#xA0; A
termination event is defined as either termination of employment or
services other than for cause or constructive termination of
employees or consultants resulting from a significant reduction in
either the nature or scope of duties and responsibilities, a
reduction in compensation or a required relocation.&amp;#xA0; As of
September 30, 2011, there are an aggregate of 3,476,112 shares
available for grant under the Plan.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Accounting for Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Employee
stock-based compensation is accounted for in accordance with the
guidance of FASB ASC Topic 718, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Compensation &amp;#x2013; Stock
Compensation&lt;/font&gt; which requires all share-based payments to
employees, including grants of employee stock options, to be
recognized in the financial statements based on their fair
values.&amp;#xA0; Non-employee stock-based compensation is accounted
for in accordance with the guidance of FASB ASC Topic 505,
&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Equity&lt;/font&gt;. As
such, the Company recognizes expense based on the estimated fair
value of options granted to non-employees over their vesting
period, which is generally the period during which services are
rendered and deemed completed by such non-employees.&lt;/font&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
following table summarizes amounts charged to expense for
stock-based compensation related to employee and director stock
option grants and stock-based compensation recorded in connection
with stock options granted to non-employee
consultants:&lt;/font&gt;&lt;/div&gt;
&lt;div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.6pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Nine Months Ended&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.6pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
September 30,&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.6pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
(unaudited)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.6pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Year Ended&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.6pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
December 31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Cumulative Development- Stage Period from November 7, 2002 through
December 31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Consolidated&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2009&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Employee
and director stock option grants:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Research
and development&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;121,393&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;52,492&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;61,791&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;87,598&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;298,386&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;General
and administrative&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;349,781&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;278,694&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;291,549&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;414,401&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,577,303&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;471,174&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;331,186&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;353,340&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;501,999&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,875,689&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Non-employee
consultant stock option grants:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Research
and development&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;46,851&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;200&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;71,724&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;General
and administrative&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;137,631&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;184,482&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;200&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;71,724&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="40%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
stock-based compensation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;655,656&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;331,186&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;353,340&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;502,199&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,947,413&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
July 14, 2010, the expiration date of vested options held by a
former employee was extended until July 8, 2015.&amp;#xA0; The
extension constituted a modification to the terms of the award and
additional stock-based compensation was measured as the excess of
the fair value of the modified award over the fair value of the
original award immediately before the modification.&amp;#xA0;
Accordingly, incremental stock-based compensation expense of
approximately&amp;#xA0;$20,000 was recorded in connection with the
modification.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
Company granted 3,496,400 stock options to employees and
non-employees during the nine months ended September 30, 2011 under
the Plan.&amp;#xA0; The Company issued options to purchase a total of
200,000 shares of common stock to non-employees outside of any
formalized plan, but 100,000 were forfeited as a result of the
cancellation and replacement as described below.&amp;#xA0; Exercise
prices for all grants made in the during the nine months ended
September 30, 2011 were equal to the market value of the
Company&amp;#x2019;s common stock on the date of grant.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
May 18, 2011, the Company cancelled 100,000 options originally
granted on April 25, 2011 with an exercise price of $3.00 per share
and issued 100,000 replacement stock option awards with an exercise
price of $1.40.&amp;#xA0; The cancellation and replacement constituted
a modification to the terms of the award and additional stock-based
compensation was measured as the excess of the fair value of the
modified award over the fair value of the original award
immediately before the modification.&amp;#xA0; Accordingly, incremental
stock-based compensation expense of $4,494 was recorded in
connection with the modification.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;!--EFPlaceholder--&gt;Assumptions Used In Determining Fair
Value&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Valuation and amortization method&lt;/font&gt;. The fair value of each
stock award is estimated on the grant date using the Black-Scholes
option-pricing model.&amp;#xA0; The estimated fair value of employee
stock options is amortized to expense using the straight-line
method over the vesting period.&lt;/font&gt; &lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
estimated fair value of the non-employee options is amortized to
expense over the period during which a non-employee is required to
provide services for the award (usually the vesting
period).&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Volatility.&lt;/font&gt; Cellectar estimated volatility based on a review
of volatility estimates of publicly held drug development companies
in a similar stage of development. Subsequent to the Acquisition,
the Company estimates volatility based on an average of (1) the
Company&amp;#x2019;s historical volatility since its common stock has
been publicly traded and (2) review of volatility estimates of
publicly held drug development companies with similar market
capitalizations.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Risk-free interest rate&lt;/font&gt;. The risk-free interest rate is
based on the U.S. Treasury yield curve in effect at the time of
grant commensurate with the expected term assumption.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Expected term&lt;/font&gt; . The expected term of stock options granted
is based on an estimate of when options will be exercised in the
future. The Company applied the simplified method of estimating the
expected term of the options, as described in the SEC&amp;#x2019;s Staff
Accounting Bulletins 107 and 110, as the Company has had a
significant change in its business operations as result of the
Acquisition and the historical experience is not indicative of the
expected behavior in the future. The expected term, calculated
under the simplified method, is applied to groups of stock options
that have similar contractual terms. Using this method, the
expected term is determined using the average of the vesting period
and the contractual life of the stock options granted. The Company
applied the simplified method to non-employees who have a
truncation of term based on termination of service and utilizes the
contractual life of the stock options granted for those
non-employee grants which do not have a truncation of
service.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Forfeitures.&lt;/font&gt; &amp;#xA0; Stock-based compensation expense is
recorded only for those awards that are expected to vest.&amp;#xA0;
FASB ASC Topic 718 requires forfeitures to be estimated at the time
of grant and revised, if necessary, in subsequent periods if actual
forfeitures differ from those estimates.&amp;#xA0; The term
&amp;#x201C;forfeitures&amp;#x201D; is distinct from
&amp;#x201C;cancellations&amp;#x201D; or &amp;#x201C;expirations&amp;#x201D; and
represents only the unvested portion of the surrendered
option.&amp;#xA0; An annual forfeiture rate of 0% was applied to all
unvested options as of December 31, 2010 as Cellectar had
experienced very few forfeitures through 2009 and there was
insufficient history to develop an accurate estimate of future
forfeitures.&amp;#xA0; An annual forfeiture rate of 0% was applied to
all unvested options as of September 30, 2011 as the historical
experience of forfeitures is not representative of expected future
forfeiture rates as a result of the significant changes in the
business operations as a result of the Acquisition.&amp;#xA0; This
analysis will be re-evaluated semi-annually and the forfeiture rate
will be adjusted as necessary.&amp;#xA0; Ultimately, the actual expense
recognized over the vesting period will be for only those shares
that vest.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
following table summarizes weighted-average values and assumptions
used for options granted to employees, directors and consultants in
the periods indicated:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: center" align="center"&gt;
&lt;table style="TEXT-ALIGN: center; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr style="TEXT-ALIGN: center"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Nine Months&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Ended&amp;#xA0;September&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;30,&amp;#xA0;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;(unaudited)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Year&amp;#xA0;Ended&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;December&amp;#xA0;31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Volatility&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;110&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;85&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Risk-free
interest rate&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1.84%
&amp;#x2013; 3.17&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1.72%-1.91&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Expected
life (years)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;5.5
&amp;#x2013; 6.25&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;6.25&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Dividend&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Weighted-average
exercise price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1.45&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0.76&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Weighted-average
grant-date fair value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1.22&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0.55&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;There
were no stock options granted in the nine months ended September
30, 2010 or the year ended December 31, 2010.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;Stock
Option Activity&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;A
summary of stock option activity under stock option plans is as
follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;!--EFPlaceholder--&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="95%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Number&amp;#xA0;of&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Shares&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Issuable&amp;#xA0;Upon&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Exercise&amp;#xA0;of&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Outstanding&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Options&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Weighted&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Average&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Exercise&amp;#xA0;Price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Weighted&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Average&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Remaining&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Contracted&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Term&amp;#xA0;in&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Aggregate&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Intrinsic&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Outstanding
at November 7, 2002&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Granted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;922,654&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.52&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(12,653&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3.04&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Outstanding
at January 1, 2009&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;910,001&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.86&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Granted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;90,929&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0.76&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;
&amp;#xA0; Forfeited&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(9,194&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.72&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Outstanding
at December 31, 2009&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;991,736&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.68&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Canceled&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(222,547&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.63&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Outstanding
at December 31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;769,189&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.69&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;
&amp;#xA0; Canceled&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(769,189&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.69&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt; MARGIN-RIGHT: 0pt" valign="bottom" width="52%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Options
acquired in connection with a business combination&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;49,159&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;100.52&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt; MARGIN-RIGHT: 0pt" valign="bottom" width="52%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Granted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,696,400&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1.45&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt; MARGIN-RIGHT: 0pt" valign="bottom" width="52%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Canceled&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(12,921&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;112.21&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt; MARGIN-RIGHT: 0pt" valign="bottom" width="52%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(100,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3.00&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Outstanding
at September 30, 2011 (unaudited)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,632,638&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.35&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Vested,
December 31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;743,450&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.69&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4.07&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Unvested,
December 31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;25,739&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.62&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;5.08&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#x2014;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Exercisable
at December 31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;743,450&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.69&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4.07&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Vested,
September 30, 2011 (unaudited)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;332,685&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;10.47&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;9.25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Unvested,
September 30, 2011 (unaudited)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,299,953&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1.53&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;9.63&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#x2014;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Exercisable
at September 30, 2011 (unaudited)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;332,685&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
10.47&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
9.25&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#x2014;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
aggregate intrinsic value of options outstanding is calculated
based on the positive difference between the estimated per share
fair value of Cellectar&amp;#x2019;s common stock at the end of the
respective period and the exercise price of the underlying
options.&amp;#xA0;As of December 31, 2010, the estimated fair-market
value of Cellectar&amp;#x2019;s common stock at the end of the periods
shown was less than the exercise price of the underlying options,
as such, the aggregate intrinsic value is $0.&amp;#xA0; As of September
30, 2011, the fair value of the Company&amp;#x2019;s common stock was
less than the exercise price of the underlying options, as such,
the aggregate intrinsic value was $0.&amp;#xA0; There have been no
option exercises to date. Shares of common stock issued upon the
exercise of options are from authorized but unissued
shares.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
weighted-average grant-date fair value of options granted during
the year ended December 31, 2009 and for the period November 2,
2002 to December 31, 2009 was $0.55 and $1.90, respectively.&amp;#xA0;
There were no options granted during the year ended December 31,
2010.&amp;#xA0; The total fair value of shares vested during December
31, 2010 and 2009 and for the period November 2, 2007 (date of
inception) to December 31, 2010 was $199,600, $185,600 and
$2,050,000, respectively.&amp;#xA0; &amp;#xA0;The weighted-average
grant-date fair value of vested and unvested options outstanding at
December 31, 2010 and 2009 was $2.01 and $1.91 and $1.85 and $1.88,
respectively.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;As
of December 31, 2010, there was approximately $58,000 and $0 of
total unrecognized compensation cost related to unvested
stock-based compensation arrangements related to employees and
non-employees, respectively.&amp;#xA0; Of the total unrecognized amount
as of December 31, 2010, all was recognized in the nine months
ended September 30, 2011.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
March 4, 2011, in contemplation of the Acquisition and in
accordance with terms of the applicable option agreements,
Cellectar accelerated the vesting on all outstanding and unvested
options at that date and notified all option holders that any
unexercised options as of March 17, 2011 would then be
terminated.&amp;#xA0; On March 17, 2011, Cellectar terminated all
outstanding options.&amp;#xA0; The remaining unamortized compensation
expense of $58,000 was recorded related to the acceleration of
outstanding options in the quarter ended March 31, 2011.&amp;#xA0; No
additional compensation expense was recorded related to the
acceleration of unvested shares as the acceleration did not
represent a modification to the original terms of the
options.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;As
of September 30, 2011, there was $2,728,294 of total unrecognized
compensation cost related to unvested stock-based compensation
arrangements.&amp;#xA0; Of this total amount, the Company expects to
recognize $281,357, $1,125,400, $858,452, $387,397 and $75,688
during 2011, 2012, 2013, 2014 and 2015, respectively.&amp;#xA0; The
Company expects 3,299,953 in unvested options to vest in the
future.&amp;#xA0; The weighted-average grant-date fair value of vested
and unvested options outstanding at September 30, 2011 was $1.44
and $1.17, respectively.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
October 6, 2011, the Company granted 70,000 options with an
exercise price of $1.05, which was equal to the closing price of
the Company&amp;#x2019;s common stock on the date of grant, to a
non-employee in exchange for certain consulting
services.&amp;#xA0;&amp;#xA0;The grant-date fair value using the
Black-Scholes option pricing model was $0.85 per share, or
$59,500.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;


&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">746207</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;
17.&amp;#xA0; RELATED PARTY TRANSACTIONS&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;Jamey
Weichert, the Company&amp;#x2019;s Chief Scientific Officer, director,
shareholder and principal founder is a faculty member at the
University of Wisconsin-Madison (&amp;#x201C;UW&amp;#x201D;).&amp;#xA0; Cellectar
paid $16,082 to the UW during 2009 for research related
activities.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Cellectar
made contributions of $25,000 to the UW Foundation, a
not-for-profit, tax-exempt Wisconsin corporation, which serves as
the official fundraising and gift-receiving organization for the UW
and other donor-designated units of the UW System during the year
ended December 31, 2009.&amp;#xA0; During the nine months ended
September 30, 2011, the Company made contributions totaling
$125,000 to the UW Foundation for use towards research activities
associated with the development of the Company&amp;#x2019;s
compounds.&amp;#xA0; No payments were made to UW during the nine months
ended September 30, 2010 or the year ended December 31,
2010.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">1827510</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">4058169</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
  <nvlt:IssuanceOfCommonStockInExchangeForConvertibleNotes contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">3184707</nvlt:IssuanceOfCommonStockInExchangeForConvertibleNotes>
  <nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">48339</nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <nvlt:IssuanceOfCommonStockAndWarrantsValue contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">4866406</nvlt:IssuanceOfCommonStockAndWarrantsValue>
  <nvlt:ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="iso4217_USD" decimals="0">48339</nvlt:ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital>
  <nvlt:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0" unitRef="shares" decimals="0">21847984</nvlt:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <nvlt:SupplementalFinancialInformationDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
18.&amp;#xA0; (UNAUDITED) SUPPLEMENTAL PRO FORMA
INFORMATION&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
table below summarizes&amp;#xA0;net loss for the periods shown as
though the Acquisition occurred as of January 1, 2010:&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div align="center"&gt;
&lt;table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr&gt;
&lt;td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;font style="DISPLAY: inline"&gt;For&amp;#xA0;the&amp;#xA0;Nine&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
For&amp;#xA0;the&amp;#xA0;Twelve&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
Months&amp;#xA0;Ended&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
December&amp;#xA0;31,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td align="left" valign="bottom" width="64%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="right" valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Net
loss&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;
(5,290,519&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;
(783,007&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="DISPLAY: inline"&gt;
(1,704,966&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;The
pro forma&amp;#xA0;net loss&amp;#xA0;has been adjusted for the
following:&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr valign="top"&gt;
&lt;td align="right" style="WIDTH: 9pt"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="LETTER-SPACING: 9pt"&gt;
&amp;#xA0;&amp;#xA0;&lt;/font&gt;1)&lt;font style="LETTER-SPACING: 9pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Elimination
of $165,000, $266,000, and $361,000 of interest expense for the
nine months ended September 30, 2011 and 2010 and the twelve months
ended December 31, 2010, respectively; such amounts relate to
interest accrued on the Convertible Notes which were converted
immediately prior to the Acquisition (see Note 7) and the Bank Note
which was paid in full settlement of the note immediately prior to
the Acquisition (see Note 8).&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr valign="top"&gt;
&lt;td align="right" style="WIDTH: 9pt"&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="LETTER-SPACING: 9pt"&gt;
&amp;#xA0;&amp;#xA0;&lt;/font&gt;2)&lt;font style="LETTER-SPACING: 9pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Recognition
of a additional BCF of $463,000 in the nine months ended September
30, 2010 and the year ended December 31, 2010 and the elimination
of BCF of $258,000 in the nine months ended September 30, 2011 in
connection with the conversion of the Convertible Notes, which is
assumed to have occurred on January 1, 2010 for the purpose of pro
forma presentation (see Note 7).&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr valign="top"&gt;
&lt;td align="right" style="WIDTH: 9pt"&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="LETTER-SPACING: 9pt"&gt;
&amp;#xA0;&amp;#xA0;&lt;/font&gt;3)&lt;font style="LETTER-SPACING: 9pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Elimination
of Acquisition costs incurred during the nine months ended
September 30, 2011 and the twelve months ended December 31, 2010,
which are assumed to have been incurred prior to January 1, 2010
for the purpose of presentation in the pro forma statements of
operations.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr valign="top"&gt;
&lt;td align="right" style="WIDTH: 9pt"&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;&lt;font style="LETTER-SPACING: 9pt"&gt;
&amp;#xA0;&amp;#xA0;&lt;/font&gt;4)&lt;font style="LETTER-SPACING: 9pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Elimination
of $450,000 of investment banking fees incurred upon the
consummation of the Acquisition on April 8, 2011 from the nine
months ended September 30, 2011.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr valign="top"&gt;
&lt;td align="right" style="WIDTH: 9pt"&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="LETTER-SPACING: 9pt"&gt;
&amp;#xA0;&amp;#xA0;&lt;/font&gt;5)&lt;font style="LETTER-SPACING: 9pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Elimination
of dividends and deemed dividends on Novelos&amp;#x2019; preferred
convertible stock, which is assumed to have been exchanged for
common stock at January 1, 2010 in order to reflect the
post-acquisition capital structure for the purpose of pro forma
presentation.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr valign="top"&gt;
&lt;td align="right" style="WIDTH: 9pt"&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="LETTER-SPACING: 9pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;6)&lt;font style="LETTER-SPACING: 9pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
Elimination of Novelos historical revenue related to the
amortization of deferred revenue that was determined to have no
fair value in purchase accounting.&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr valign="top"&gt;
&lt;td align="right" style="WIDTH: 9pt"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;font style="LETTER-SPACING: 9pt"&gt;
&amp;#xA0;&amp;#xA0;&lt;/font&gt;7)&lt;font style="LETTER-SPACING: 9pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Elimination
of liquidated damages accrued in 2010 related to
Novelos&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;&amp;#x2019;&lt;/font&gt;
convertible preferred stock. The liquidated damages are assumed not
to have accrued as the preferred stock&amp;#xA0;is assumed to&amp;#xA0;have
been exchanged for common stock at January 1, 2010 in order to
reflect the post-acquisition capital structure for the purpose of
pro forma presentation.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</nvlt:SupplementalFinancialInformationDisclosureTextBlock>
  <nvlt:CollaborativeAndLicenseArrangementDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div&gt;
&lt;table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
6.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
LICENSE AGREEMENTS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;
2003 License Agreement with the University of Michigan&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;In
September 2003, Cellectar entered into an exclusive license
agreement (the &amp;#x201C;U. Mich. Agreement&amp;#x201D;) with the Regents
of the University of Michigan, (&amp;#x201C;U. Mich.&amp;#x201D;) for the
development, manufacture and marketing of products under several
composition of matter patents in North America which expire at
varying dates in 2016.&amp;#xA0; The U. Mich. Agreement expires upon
the expiration of the last covered patent.&amp;#xA0; The Company is
responsible for an annual license fee of $10,000 and is required to
pay costs associated with the maintenance of the patents covered by
the U. Mich. Agreement.&amp;#xA0; Additionally, the Company is required
to make milestone payments of $50,000 upon the filing of a New Drug
Application (&amp;#x201C;NDA&amp;#x201D;) for a licensed product intended for
use in a therapeutic or diagnostic application (such milestone fees
may be deferred and paid within 12 months of the first commercial
sale of such products) and make certain milestone payments within a
year following the first commercial sale of any licensed
products.&amp;#xA0; The sales milestones range from $100,000 to
$200,000, dependent upon whether the drug is for use in a
therapeutic or diagnostic application, provided that if sales in
the first 12 months are less than the amount of the milestone, then
we are required to pay 50% of all sales until the milestone is
satisfied.&amp;#xA0;The milestone payments may&amp;#xA0;total up to
$400,000. The U. Mich. Agreement provides that the Company pay a
royalty equal to 3% of net sales of any licensed products sold by
the Company or its sublicensees for such licensed products,
provided however if the sublicense fee payable to the Company is
between 4%-5% of net sales, then the royalties payable to U. Mich.
shall be equal to 50% of the sublicense fee.&amp;#xA0; Furthermore, the
U. Mich. Agreement provides for a reduction in the royalties owed
by up to 50% if the Company is required to pay royalties to any
third parties related to the sale of the licensed products.&amp;#xA0;
If we receive any revenue in consideration for rights to the
licensed technology that is not based on net sales, excluding any
funded research and development, we are required to pay U. Mich.
10% of amounts received.&amp;#xA0; U. Mich. may terminate the agreement
if the Company ceases operations, if the Company fails to make any
required payment under the agreement, or if the Company otherwise
materially breaches the agreement, subject to the applicable notice
and cure periods.&amp;#xA0; To date, the Company has made all payments
as they have become due, there have been no defaults under the U.
Mich. Agreement, nor has the Company been notified of a default by
U. Mich. The Company may terminate the agreement with six months
notice to U. Mich. and the return of licensed product and related
data.&amp;#xA0; The U. Mich. Agreement contained milestones that
required certain development activities to be completed by
specified dates. All such development milestones have either been
completed or have been removed by subsequent amendment to the
agreement.&amp;#xA0; U. Mich. has provided no warranties as to validity
or otherwise with respect to the licensed technology.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;Cellectar
paid approximately $600,&amp;#xA0;$300 and $5,000 to U. Michigan for
the reimbursement of patent maintenance fees during the nine months
ended September 30, 2011 and the years ended December 31, 2010 and
2009, respectively.&amp;#xA0; As of September 30, 2011 and December 31,
2010, all annual license fees have been paid in a timely
manner.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;In
connection with the Michigan Agreement, during 2003 Cellectar paid
approximately $54,000 of back patent costs and issued 203,483
shares of common stock to U. Michigan as partial consideration for
the rights described above.&amp;#xA0; The estimated fair-market value
of the issuance was $80,412 and was recorded as a license cost and
is included as a component of stockholders equity in the
accompanying balance sheets.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"&gt;
License Agreement with Wisconsin Alumni Research
Foundation&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"&gt;In
January 2006, Cellectar entered into a license agreement (the
&amp;#x201C;WARF Agreement&amp;#x201D;) with the Wisconsin Alumni Research
Foundation (&amp;#x201C;WARF&amp;#x201D;) under which Cellectar received a
license, with a right to grant sublicenses, to develop,
manufacture, and market products with respect to certain
patents.&amp;#xA0; The WARF Agreement required an initial license fee
of $8,800 and provided that Cellectar pay royalties equal to 0.3%
of sales of any licensed products.&amp;#xA0; Cellectar was also
required to reimburse WARF for patent filing fees and related
costs.&amp;#xA0; During the years ended December 31, 2010 and 2009,
there were no costs related to the patents under the WARF
Agreement.&amp;#xA0;&amp;#xA0;During 2010, the WARF Agreement was
terminated.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"&gt;
Novelos License Agreements&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;During
2007, Novelos entered into a Collaboration Agreement with
Lee&amp;#x2019;s Pharmaceutical (HK) Ltd. (&amp;#x201C;Lee&amp;#x2019;s
Pharm&amp;#x201D;) whereby Lee&amp;#x2019;s Pharm obtained an exclusive
license to develop, manufacture and commercialize NOV-002 and
NOV-205 in China, Hong Kong, Taiwan and Macau (the &amp;#x201C;Chinese
Territory&amp;#x201D;). Under the terms of the agreement the Company is
entitled to receive up to $1,700,000 in future milestone payments
upon the completion of development and marketing milestones by
Lee&amp;#x2019;s Pharm and to receive royalty payments of between 12-25%
of net sales of NOV-205 and NOV-002, as applicable, in the Chinese
Territory and receive royalty payments of 12-15% of net sales of
NOV-205 in the Chinese Territory. The agreement expires upon the
expiration of the last patent covering any of the licensed
products, or twelve years from the date of the first commercial
sale in China, whichever occurs later.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;During
2009, Novelos entered into a collaboration agreement (the
&amp;#x201C;Collaboration Agreement&amp;#x201D;) with Mundipharma
International Corporation Limited (&amp;#x201C;Mundipharma&amp;#x201D;) to
develop, manufacture and commercialize, on an exclusive basis,
Licensed Products (as defined in the Collaboration Agreement),
including NOV-002, in Europe (other than the Russian Territory),
Asia (other than the Chinese Territory) and Australia (collectively
referred to as the &amp;#x201C;Mundipharma Territory&amp;#x201D;).&amp;#xA0;
Mundipharma is an independent associated company of Purdue Pharma,
L.P. (&amp;#x201C;Purdue&amp;#x201D;).&amp;#xA0; The Collaboration Agreement
provides for Mundipharma to pay the Company royalties and fixed
milestone payments based on sales and commercial launches in the
licensed territories.&amp;#xA0; For countries in which patents are
held, the Collaboration Agreement expires on a country-by-country
basis within the Mundipharma Territory on the earlier of (1)
expiration of the last applicable Novelos patent within the country
or (2) the determination that any patents within the country are
invalid, obvious or otherwise unenforceable.&amp;#xA0; For countries in
which no patents are held, the Collaboration Agreement expires the
earlier of 15 years from its effective date or upon generic product
competition in the country resulting in a 20% drop in
Mundipharma&amp;#x2019;s market share.&amp;#xA0; The Company may terminate
the Collaboration Agreement upon breach or default by
Mundipharma.&amp;#xA0; Mundipharma may terminate the Collaboration
Agreement upon breach or default, filing of voluntary or
involuntary bankruptcy by Novelos, the termination of certain
agreements with companies associated with the originators of the
licensed technology, or 30-day notice for no reason.&lt;/font&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;The
Company has suspended development of the products covered by the
collaboration agreements described above. The Company does not
anticipate that the collaboration agreements will have a material
effect on its results of operations, cash flows, and financial
position following the Acquisition.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</nvlt:CollaborativeAndLicenseArrangementDisclosureTextBlock>
  <nvlt:LineOfCreditFacilitiesTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
9.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
LINE OF CREDIT&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
2009, Cellectar had a $100,000 line of credit with a bank.&amp;#xA0;
Borrowings under the line of credit bore interest at LIBOR plus
3.25% with a 4.5% minimum rate.&amp;#xA0; The line of credit expired on
January 10, 2010 and was not renewed.&amp;#xA0; There were no amounts
outstanding under the line as of December 31, 2009.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</nvlt:LineOfCreditFacilitiesTextBlock>
  <nvlt:ReverseStockSplitTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
19.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
PROPOSED REVERSE STOCK SPLIT&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
June 30, 2011, the Company held a special meeting of
stockholders.&amp;#xA0; At the meeting, the stockholders approved,
among other things, separate amendments to the certificate of
incorporation that would effect a reverse split of the
Company&amp;#x2019;s common stock within a range of 1:2 to 1:10, and
authorized the Company&amp;#x2019;s board of directors to determine the
ratio at which the reverse split will be effected by filing the
appropriate amendment to the certificate of incorporation.&amp;#xA0;
The purpose of the proposed reverse split is to increase the price
per share of the Company&amp;#x2019;s common stock in order to exceed
the minimum price per share required to secure a listing on a
national securities exchange. &lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
July 1, 2011, the Company filed with the SEC&amp;#xA0;a Registration
Statement on Form S-1 for an underwritten public offering of its
common stock with proceeds of up to $15,000,000, excluding the
underwriters over-allotment. The Company has applied for listing on
the NASDAQ Capital Market under the symbol "NVLT" in connection
with the proposed underwritten offering.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</nvlt:ReverseStockSplitTextBlock>
  <nvlt:ConvertibleDebtDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0">&lt;div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
7.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
CONVERTIBLE DEBT&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
January 25, 2010, Cellectar issued nine convertible promissory
notes (&amp;#x201C;Convertible Notes&amp;#x201D;) in an aggregate principal
amount of $2,720,985.&amp;#xA0; The Convertible Notes provided for
interest of 12% compounded annually with a maturity date of the
earlier of (i) the date on which Cellectar&amp;#x2019;s cash reserves
fall below $250,000 or (ii) January 20, 2011.&amp;#xA0; Upon an event
of default, as defined, the interest rate increased by 10% to
22%.&amp;#xA0; The outstanding principal balance, together with any
unpaid interest, was convertible immediately, by the lender, into
common stock of the Company at $0.82987 per share (giving effect to
the Exchange Ratio).&amp;#xA0; Furthermore, the Convertible Notes were
subject to an automatic conversion feature equal to 70% of the per
share price of a qualified financing, should the Company complete a
qualified financing transaction which raises at least $20,000,000
in proceeds to the Company.&amp;#xA0; Since the Convertible Notes were
convertible into common stock at date of issuance at a per share
price which was less than the estimated fair value of the
Company&amp;#x2019;s common stock at that date, the Convertible Notes
contained a beneficial conversion feature
(&amp;#x201C;BCF&amp;#x201D;).&amp;#xA0; The estimated intrinsic value of the BCF
of $213,792 was determined as the difference between the conversion
price and the estimated fair value of Cellectar common stock on the
date of issuance, multiplied by the 3,278,786 shares of common
stock into which the Convertible Notes were convertible at
issuance. This amount was recorded as a component of interest
expense on the date of issuance.&amp;#xA0; The estimated per-share fair
value of Cellectar common stock was determined by management based
on a number of factors including an independent valuation, which
was determined to be the best indication of the fair value as of
the issuance date of the Convertible Notes.&amp;#xA0; Since the
conversion price was subject to adjustment in the event of a
qualified transaction, as defined, the Convertible Notes also
contain a contingent beneficial conversion feature
(&amp;#x201C;CBCF&amp;#x201D;).&amp;#xA0; This contingency did not materialize;
therefore no intrinsic value was allocated to the CBCF.&amp;#xA0; As of
December 31, 2010 and 2009, principal of $2,720,985 and $0 was
outstanding, respectively, on the Convertible Notes.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As
of December 31, 2010, the Convertible Notes are classified as a
long-term obligation on the accompanying balance sheets as a result
of the conversion of the short-term obligation through the issuance
of equity securities in connection with the
Acquisition.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
January 20, 2011, the Convertible Notes matured but remained
unpaid.&amp;#xA0; Following the maturity and default of the Convertible
Notes, the holders of the Convertible Notes agreed that all of the
outstanding notes would be automatically converted simultaneous
with the completion of an acquisition and financing (the
&amp;#x201C;Conversion Time&amp;#x201D;), if completed.&amp;#xA0; The amount of
shares issued upon such conversion would be dependent on the amount
of investment made by the note holders at the Conversion Time and
were negotiated based on outstanding principal and projected
accrued interest based on an assumed closing date for the
acquisition and financing.&amp;#xA0; Since the number of shares to be
issued upon conversion could not be determined until the Conversion
Time the Convertible Notes contained a CBCF.&amp;#xA0; On April 1,
2011, Cellectar&amp;#x2019;s Board of Directors voted to accept the note
holders consent to convert the Convertible Notes into 4,181,535
shares of common stock immediately prior to the Acquisition.&amp;#xA0;
On April 8, 2011, immediately prior to the Acquisition, the
principal and unpaid interest on the Convertible Notes was
converted into the agreed total of 4,181,535 shares of common
stock.&amp;#xA0; Upon conversion of the Convertible Notes, the Company
reclassified the aggregate outstanding principal and interest
totaling $3,184,706 to a component of additional paid-in
capital.&amp;#xA0; The revised conversion terms resulted in the
issuance of an additional 343,963 shares of common stock over the
3,837,572 shares of common stock that would have been issued if the
unpaid principal and accrued interest on the Convertible Notes had
been converted on that date in accordance with their original terms
at the stated conversion price.&amp;#xA0; On the date of conversion,
the Company determined that the value of these additional shares
was $257,973, based on the $0.75 per share offering price of the
common stock sold in the private placement completed concurrently
with the Acquisition, which is the best indication of fair value on
the date of conversion.&amp;#xA0; Since the conversion was not
completed until April 8, 2011, the value of the additional shares
of $257,973 was recorded as a component of interest expense during
the second quarter of 2011.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</nvlt:ConvertibleDebtDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x444581" unitRef="shares" decimals="INF">2959871</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x444581" unitRef="iso4217_USD" decimals="0">30</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockholdersEquityOtherShares contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x444581" unitRef="shares" decimals="INF">41</us-gaap:StockholdersEquityOtherShares>
  <nvlt:IssuanceOfCommonStockAndWarrantsValue contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x444581" unitRef="iso4217_USD" decimals="0">68</nvlt:IssuanceOfCommonStockAndWarrantsValue>
  <nvlt:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x444581" unitRef="shares" decimals="INF">18153</nvlt:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <nvlt:IssuanceOfCommonStockAndWarrantsShares contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x444581" unitRef="shares" decimals="INF">6846537</nvlt:IssuanceOfCommonStockAndWarrantsShares>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x444581_455296x449620" unitRef="iso4217_USD" decimals="0">42</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x444581_455296x449620" unitRef="shares" decimals="INF">4181535</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x453698" unitRef="iso4217_USD" decimals="0">655656</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockholdersEquityOther contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x453698" unitRef="iso4217_USD" decimals="0">145</us-gaap:StockholdersEquityOther>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x453698" unitRef="iso4217_USD" decimals="0">257973</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x453698" unitRef="iso4217_USD" decimals="0">2219873</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x453698" unitRef="iso4217_USD" decimals="0">48339</nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <nvlt:IssuanceOfCommonStockAndWarrantsValue contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x453698" unitRef="iso4217_USD" decimals="0">4866338</nvlt:IssuanceOfCommonStockAndWarrantsValue>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x453698_455296x449620" unitRef="iso4217_USD" decimals="0">3184665</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x478726" unitRef="iso4217_USD" decimals="0">-5469502</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_273_20110930_0_455296x449620" unitRef="iso4217_USD" decimals="0">3184707</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">31667</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
6. STOCKHOLDERS&amp;#x2019; DEFICIENCY&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Exchange of Outstanding Preferred Stock for Common
Stock&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
November 30, 2010, the Company entered into an Exchange Agreement
with each of the holders of its Series E convertible preferred
stock (the &amp;#x201C;Series E Preferred Stock&amp;#x201D;) and Series C
convertible preferred stock (the &amp;#x201C;Series C Preferred
Stock&amp;#x201D;) pursuant to which each such holder exchanged all of
the holder&amp;#x2019;s shares of Series E Preferred Stock or Series C
Preferred Stock, as applicable, and all rights, preferences and
privileges associated therewith (including but not limited to any
accrued but unpaid dividends thereon) and any rights of the holder
to liquidated damages under agreements to register the
Company&amp;#x2019;s capital stock, for an aggregate of 2,228,338 shares
of common stock, representing 75.3% of the Company&amp;#x2019;s common
stock outstanding effective immediately following the
exchange.&amp;#xA0; As a result of the exchange, all of the liquidation
preference applicable to the preferred stock, approximately
$27,337,000 as of November 30, 2010, was eliminated.&amp;#xA0;
Furthermore, future dividends totaling $2,327,000 annually were
eliminated, special voting rights applicable to the preferred stock
are no longer applicable, and the former holders of Series E
Preferred Stock have released any rights to require the
registration of shares of the Company&amp;#x2019;s common stock for
resale under the Securities Act.&amp;#xA0; The effective price per
share at which the common stock was issued in connection with the
exchange (based on the aggregate liquidation preference of all of
the preferred stock divided by the total number of shares of common
stock issued in exchange for such preferred stock) was
approximately $12.27.&amp;#xA0; The market price of the Company&amp;#x2019;s
common stock as of the last trading day immediately preceding the
exchange was $6.12.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
exchange was accounted for as a recapitalization and the carrying
value of the Series E Preferred Stock of $13,770,000, accumulated
dividends totaling $4,476,000 and estimated liquidated damages of
$819,000 for failure to timely file a resale registration statement
(see &amp;#x201C;Registration Rights&amp;#x201D; below) were reclassified to
additional paid-in-capital as of the date of the exchange.&amp;#xA0; If
the preferred stock had been converted according to its terms, the
holders would have received a total of 274,882 shares of common
stock.&amp;#xA0; At the date of issuance the fair market value totaling
$11,955,151 of the additional 1,953,456 shares issued in the
exchange has been recorded as a deemed dividend to preferred
stockholders in the year ended December 31, 2010.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Issuance of&lt;/font&gt; &lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;Series C
Preferred&lt;/font&gt; &lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;Stock&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;During
2007, the Company issued 272 shares of Series C Preferred Stock in
exchange for all 3,264 shares of Series A preferred stock,
originally issued in 2005.&amp;#xA0;The Series C Preferred Stock was
initially convertible at $153.00 per share into 21,333 shares of
common stock.&amp;#xA0; In connection with the sale of Series D
preferred stock in 2008, the conversion price of the Series C
Preferred Stock was reduced to $99.45 per share, according to its
terms.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
Terms of the Series C Preferred Stock&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Series C Preferred Stock had an annual dividend rate of 8% until
October 1, 2008 and 20% thereafter.&amp;#xA0; The dividends were
payable quarterly.&amp;#xA0; Such dividends were to be paid only after
all outstanding dividends on the Series D Preferred Stock (with
respect to the current fiscal year and all prior fiscal years) had
been paid to the holders of the Series D Preferred Stock.&amp;#xA0; No
dividends were paid on Series C Preferred Stock during 2009 and
2010.&amp;#xA0; The conversion price was subject to adjustment for
stock dividends, stock splits or similar capital reorganizations
and upon the occurrence of certain dilutive issuances of
securities.&amp;#xA0; The Series C Preferred Stock did not have voting
rights and was redeemable only at the option of the Company upon 30
days&amp;#x2019; notice at a 20% premium plus any accrued but unpaid
dividends.&amp;#xA0; In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Company&amp;#x2019;s
affairs, the Series C Preferred Stock would have been treated as
senior to Novelos common stock.&amp;#xA0; After all required payments
were made to holders of Series E Preferred Stock, the holders of
Series C Preferred Stock would have been entitled to receive first,
$12,000 per share and all accrued and unpaid dividends.&amp;#xA0; If,
upon any winding up of the Company&amp;#x2019;s affairs, the
Company&amp;#x2019;s remaining assets available to pay the holders of
Series C Preferred Stock were not sufficient to permit the payment
in full, then all of the Company&amp;#x2019;s assets would have been
distributed to the holders of Series C Preferred Stock (and any
remaining holders of Series E Preferred Stock as may be required)
on a pro rata basis.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
Conversions of Series C Preferred Stock&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;During
the year ended December 31, 2009, 68 shares of the Company&amp;#x2019;s
Series C Preferred Stock, having an aggregate stated value of
$816,000, and accumulated dividends thereon of $184,000 were
converted into shares of the Company&amp;#x2019;s common stock, leaving
204 shares of Series C Preferred Stock outstanding which were
convertible into 24,615 shares of common stock as of December 31,
2009.&amp;#xA0; During 2010, all shares of Series C Preferred Stock
were exchanged for shares of common stock (see &amp;#x201C;Exchange of
Outstanding Preferred Stock for Common Stock&amp;#x201D;
above).&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Series E Preferred Stock Private Placement&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
Sale of Series E Preferred Stock to Purdue&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Concurrently
with the execution of the Collaboration Agreement on February 11,
2009, Novelos sold to Purdue 200 shares of a newly created series
of the Company&amp;#x2019;s preferred stock, designated &amp;#x201C;Series E
Convertible Preferred Stock,&amp;#x201D; par value $0.00001 per share
(the &amp;#x201C;Series E Preferred Stock&amp;#x201D;), and a warrant (the
&amp;#x201C;Series E Warrant&amp;#x201D;) to purchase 60,330 shares of
Novelos common stock for an aggregate purchase price of $10,000,000
(the &amp;#x201C;Series E Financing&amp;#x201D;).&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Series E Warrant is exercisable for an aggregate of 60,330 shares
of Novelos common stock at an exercise price of $99.45 per share.
The warrant expires on December 31, 2015. The warrant exercise
price and/or the common stock issuable pursuant to such warrant are
subject to adjustment for stock dividends, stock splits or similar
capital reorganizations so that the rights of the warrant holder
after such event will be equivalent to the rights of the warrant
holder prior to such event.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
Exchange of Series D Preferred Stock for Series E Preferred
Stock&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company also entered into an exchange agreement with the holders
(the &amp;#x201C;Series D Investors&amp;#x201D;) of the Company&amp;#x2019;s
Series D preferred stock, issued during 2008, under which all 413.5
outstanding shares of Series D preferred stock and accumulated but
unpaid dividends thereon totaling $1,597,144 were exchanged for
445.442875 shares of Series E Preferred Stock. The rights and
preferences of the Series E Preferred Stock were substantially the
same as the Series D preferred stock. In addition, the Series D
Investors waived liquidated damages through the date of the
exchange as a result of the Company&amp;#x2019;s failure to file a
registration statement covering the shares of common stock
underlying the Series D preferred stock and warrants not otherwise
registered. In connection with the execution of this exchange
agreement, warrants held by the Series D Investors to purchase a
total of 77,551 shares of the Company&amp;#x2019;s common stock were
amended to extend the expiration of the warrants to December 31,
2015 (from April 11, 2013) and to remove a forced exercise
provision.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
Terms of Series E Preferred Stock&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
shares of Series E Preferred Stock had a stated value of $50,000
per share and were convertible into shares of common stock at any
time after issuance at the option of the holder at $99.45 per share
of common. If there was an effective registration statement
covering the shares of common stock underlying the Series E
Preferred Stock and the VWAP, as defined in the Series E
Certificate of Designations, of Novelos common stock exceeded
$306.00 for 20 consecutive trading days, then the outstanding
shares of Series E Preferred Stock would automatically convert into
common stock at the conversion price then in effect. The conversion
price was subject to adjustment for stock dividends, stock splits
or similar capital reorganizations.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Series E Preferred Stock has an annual dividend rate of 9%, payable
semi-annually on June 30 and December 31. Such dividends were
payable in cash, in shares of Series E Preferred Stock or in
registered shares of Novelos common stock at the Company&amp;#x2019;s
option, subject to certain conditions. The Company has not paid any
cash dividends on Series E Preferred Stock.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
terms of the Series E Preferred Stock provided that for as long as
any shares of Series E Preferred Stock remained outstanding,
Novelos was prohibited without the prior consent of holders of a
majority of the outstanding shares of Series E preferred stock
(including in such majority the Xmark Funds and Purdue) from (i)
paying dividends to its common stockholders, (ii) amending its
certificate of incorporation or by-laws, (iii) issuing any equity
security or any security convertible into or exercisable for any
equity security at a price of $99.45 or less or with rights senior
to the Series E Preferred Stock (except for certain exempted
issuances), (iv) increasing the number of shares of Series E
Preferred Stock or issuing any additional shares of Series E
Preferred Stock, (v) selling or otherwise granting rights with
respect to all or substantially all of its assets (or in the case
of licensing, any material intellectual property) or the Company&apos;s
business and/or entering into a merger or consolidation with
another company unless Novelos would be the surviving corporation,
the Series E Preferred Stock would remain outstanding, there would
be no changes to the rights and preferences of the Series E
Preferred Stock and there would not be created any new class of
capital stock senior to the Series E Preferred Stock, (vi)
redeeming or repurchasing any capital stock other than the Series E
Preferred Stock, (vii) incurring any new debt for borrowed money in
excess of $500,000 and (viii) changing the number of the
Company&amp;#x2019;s directors. As of December 31, 2010, no shares of
Series E preferred stock remained outstanding, and accordingly,
none of these restrictions applied. See &amp;#x201C;Exchange of
Outstanding Preferred Stock for Common Stock&amp;#x201D;
above.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
Advisor Fees&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Ferghana
Partners, Inc. (&amp;#x201C;Ferghana&amp;#x201D;), a New York consulting
firm, received a cash fee for their services in connection with the
negotiation and execution of the Collaboration Agreement equal to
$700,000 (or seven percent (7%) of the gross proceeds to the
Company resulting from the sale of Series E Preferred Stock and
common stock purchase warrants to Purdue in connection with the
Collaboration Agreement).&amp;#xA0; Novelos is also obligated to pay
Ferghana six percent (6%) of all payments to Novelos by Mundipharma
under the Collaboration Agreement other than royalties on net
sales.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
Accounting Treatment of Series E Financing&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
terms of the Series E Preferred Stock contained provisions that
required redemption in circumstances that were beyond the
Company&amp;#x2019;s control, such as the acquisition of more than 50%
of our outstanding stock by any person or entity. Therefore, the
shares were recorded as redeemable preferred stock outside of
permanent equity in the balance sheet as of December 31, 2009. The
gross proceeds of $10,000,000 received in conjunction with the
Series E Financing were allocated on a relative fair value basis
between the Series E Preferred Stock and the warrants. The relative
fair value of the warrants issued to investors of $2,907,000
(determined using the Black-Scholes option pricing model, estimated
volatility of 80%, a risk-free interest rate of 2.17% and a term
equal to the term of the warrant) was recorded as additional
paid-in capital while the relative fair value of the Series E
Preferred Stock of $7,093,000 was recorded as temporary equity. The
carrying value of the Series E Preferred Stock was immediately
adjusted to its fair value of $7,385,000 based on the fair value of
the as-converted common stock. The difference of $292,000
represents a beneficial conversion feature and was recorded as a
deemed dividend to preferred stockholders. Issuance costs related
to the Series E Financing of $795,000 were netted against temporary
equity. The Series E Preferred Stock that was issued in payment of
dividends was initially recorded in temporary equity at the value
of the dividends that had accrued totaling $1,597,000. This amount
was then adjusted to the fair value of $1,179,000 based on the fair
value of the as-converted common stock. The difference of $418,000
was recorded as an offset to the deemed dividends recorded. The
Series E Preferred Stock that was issued in exchange for
outstanding shares of Series D preferred stock was recorded at
$13,904,000, the carrying value of the shares of Series D preferred
stock as of the date of the exchange.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As
a result of the modification to the warrants to extend their
expiration by approximately 32 months that occurred in connection
with the exchange of all outstanding shares of Series D preferred
stock for shares of Series E Preferred Stock, in the year ended
December 31, 2009, a deemed dividend of $840,000 was
recorded.&amp;#xA0; This amount represented the incremental fair value
of the warrants immediately before and after modification using the
Black-Scholes option pricing model, volatility of 80%, discount
rates of 1.54% and 2.17% and the remaining warrant
term.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
Conversions of Series E Preferred Stock&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;During
the year ended December 31, 2009, 97.18209375 shares of the
Company&amp;#x2019;s Series E Preferred Stock, having an aggregate
stated value of $4,859,000 and accumulated dividends thereon of
$301,000, were converted into 51,889 shares of common stock.&amp;#xA0;
The associated carrying value of the converted shares totaling
approximately $3,213,000 was reclassified to permanent equity from
temporary equity.&amp;#xA0; During the year ended December 31, 2010,
140 shares of the Company&amp;#x2019;s Series E Preferred Stock, having
an aggregate stated value of $7,000,000, and accumulated dividends
thereon totaling $635,000, were converted into 76,770 shares of
common stock.&amp;#xA0; The associated carrying value of the converted
shares totaling approximately $4,690,000 was reclassified to
permanent equity from temporary equity.&amp;#xA0; In November 2010, all
outstanding shares of Series E Preferred Stock were exchanged for
shares of common stock. See &amp;#x201C;Exchange of Preferred
Stock&amp;#x201D; below.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
August 2009 Common Stock Private Placement&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
Securities Purchase Agreement&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
August 25, 2009, the Company entered into the August 2009 Purchase
Agreement with Purdue to sell 89,126 shares of its common stock,
$0.00001 par value and warrants to purchase 31,194 shares of its
common stock at an exercise price of $100.98 per share, expiring
December 31, 2015, for an aggregate purchase price of $9,000,000
(the &amp;#x201C;August 2009 Private Placement&amp;#x201D;). Concurrent with
the execution and delivery of the August 2009 Purchase Agreement,
the Company sold Purdue 34,660 shares of its common stock and a
warrant to purchase 12,131 shares of its common stock at $100.98
per share for approximately $3,500,000 (the &amp;#x201C;Initial
Closing&amp;#x201D;). On November 10, 2009, the Company completed the
final closing under the August 2009 Purchase Agreement and sold
Purdue 54,466 shares of Novelos common stock and warrants to
purchase 19,063 shares of Novelos common stock for gross proceeds
of $5,500,000. Issuance costs associated with the transactions
totaled $61,000 and such amount was recorded as a reduction of
additional paid-in capital.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Pursuant
to the August 2009 Purchase Agreement,&amp;#xA0;Purdue acquired a right
of first refusal (the &amp;#x201C;Right of First Refusal&amp;#x201D;) with
respect to bona fide offers for the license or other acquisition of
NOV-002 Rights (as defined in the August 2009 Purchase Agreement)
in the U.S. (the &amp;#x201C;U.S. License&amp;#x201D;) received from third
parties and approved by the Company&amp;#x2019;s board of
directors.&amp;#xA0; Under the Right of First Refusal, Novelos will be
required to communicate to Purdue the terms of any such third-party
offers received and Purdue will have 30 days to enter into a
definitive agreement with Novelos on substantially similar terms
that provide no lesser economic benefit to Novelos as provided in
the third-party offer.&amp;#xA0; The Right of First Refusal terminates
upon business combinations, as defined in the August 2009 Purchase
Agreement. Novelos has separately entered into letter agreements
with Mundipharma and its independent associated company providing
for a conditional exclusive right to negotiate for, and a
conditional right of first refusal with respect to, NOV-002 Rights
for Latin America, Mexico and Canada.&lt;/font&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Pursuant
to the August 2009 Purchase Agreement, Purdue has the right to
either designate one member to Novelos&amp;#x2019; Board or designate an
observer to attend all meetings of the Board and committees thereof
and to have access to all information made available to members of
the Board.&amp;#xA0; This right lasts until the later of such time as
Purdue or its independent associated companies no longer hold at
least one-half of the common stock purchased pursuant to the August
2009 Purchase Agreement and no longer hold at least one-half of the
Series E Preferred Stock issued to them on February 11, 2009.&amp;#xA0;
The right to designate a Board observer had previously been granted
in connection with the financing that occurred on February 11, 2009
and Purdue appointed such an observer in February 2009.&amp;#xA0;
Purdue also has the right to participate in future equity
financings in proportion to their pro rata ownership of common
stock.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
Common Stock Purchase Warrant&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
common stock purchase warrants have an exercise price of $100.98
per share and expire on December 31, 2015.&amp;#xA0; The warrant
exercise price and/or the number of shares of common stock issuable
pursuant to such warrant will be subject to adjustment for stock
dividends, stock splits or similar capital reorganizations so that
the rights of the warrant holders after such event will be
equivalent to the rights of warrant holders prior to such
event.&amp;#xA0; The relative fair value of the warrants issued to
Purdue totaled $1,929,000 and was recorded as a component of
additional paid-in capital.&amp;#xA0; The fair value of the warrants
was determined based on the market value of the Company&amp;#x2019;s
common stock on the dates of issuance using the Black-Scholes
method of valuation, estimated volatility of 90%, risk-free
interest rates ranging from 2.02% to 2.7% and a term equal to the
term of the warrant.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
Registration Rights&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As
part of the August 2009 Private Placement, the Company entered into
a registration rights agreement with Purdue (the &amp;#x201C;Purdue
Registration Agreement&amp;#x201D;).&amp;#xA0; The Purdue Registration
Agreement required the Company to have filed with the SEC no later
than May 17, 2010, a registration statement covering the resale of
all the shares of common stock issued pursuant to the August 2009
purchase agreement and all shares of common stock issuable upon
exercise of the warrants issued pursuant to the August 2009
purchase agreement.&amp;#xA0; The registration rights agreement
provided for liquidated damages equal to 1.5% per month (pro-rated
on a daily basis for any period of less than a full month) of the
aggregate purchase price of the common stock until the delinquent
registration statement is filed.&amp;#xA0; The Company did not file the
registration statement and accrued $819,000 as a component of other
income (expense) during the year ended December 31, 2010,
representing management&amp;#x2019;s best estimate of the probable total
liquidated damages that may be settled. In connection with the
exchange of their shares of Series E Preferred Stock for common
stock on November 30, 2010, Purdue released the Company from any
requirement to register shares of its common stock for resale and
forfeited any rights to receive liquidated damages pursuant to any
registration agreements. The accrued liquidated damages were
settled in connection with the exchange and, accordingly, the
amount that had been accrued was reclassified to additional paid-in
capital.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
July 2010 Registered Offering&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
July 27, 2010, pursuant to securities purchase agreements entered
into with institutional investors on July 21, 2010, the Company
completed the sale, in an offering registered under the Securities
Act of 1933, as amended, of an aggregate of 140,056 shares of its
common stock and five-year warrants to purchase up to an aggregate
of 150,040 shares of its common stock at an exercise price of
$10.71 per share, for gross proceeds of $1,500,000 and net proceeds
of $1,249,000 after deducting transaction costs.&amp;#xA0; The warrant
exercise price is subject to adjustment in certain circumstances
and therefore, the relative fair value of the warrants at the date
of issuance, $504,000, has been bifurcated from the proceeds and
recorded as a derivative liability.&amp;#xA0; The Company uses
valuation methods and assumptions that consider among others the
fair value of the underlying stock, risk-free interest rate,
volatility, expected life and dividend rates in estimating fair
value for the warrants considered to be derivative instruments. The
assumptions used to value these warrants at the time of issuance
are generally consistent with those disclosed for stock-based
compensation (see Note 7).&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Since
the securities in this financing were issued at a price less than
$100.98 per share, the Company obtained the consent of its
preferred stockholders pursuant to a consent and waiver dated July
6, 2010, as amended on July 21, 2010. In connection with obtaining
this consent, the Company issued five-year warrants (the
&amp;#x201C;Incentive Warrants&amp;#x201D;) to its preferred stockholders for
the purchase of up to an aggregate of 150,039 shares of common
stock at an exercise price of $16.065 per share. No adjustments to
the conversion price of the preferred stock or warrants held by
preferred stockholders were made in connection with the financing.
The fair value of the Incentive Warrants at date of issuance,
$586,000, is reflected as a deemed dividend to the preferred
stockholders on the statement of operations. The Company used
valuation methods and assumptions that consider among others the
fair value of the underlying stock, risk-free interest rate,
volatility, expected life and dividend rates in estimating fair
value of the Incentive Warrants. The assumptions used to value
these warrants are generally consistent with those disclosed for
stock-based compensation (see Note 7).&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
financing resulted in adjustments to certain warrants pursuant to
their terms.&amp;#xA0; Warrants issued in 2005 that were exercisable
for 1,591 shares at an exercise price of $99.45 per share as of
immediately prior to the transaction became exercisable for 14,776
shares at an exercise price of $10.71 per share, and warrants
issued in 2006 that were exercisable for 29,787 shares at an
exercise price of $263.16 per share as of immediately prior to the
transaction became exercisable for 33,569 shares at an exercise
price of $234.09 per share.&amp;#xA0; The 2005 warrants expired
unexercised on August 9, 2010, and the 2006 warrants will expire in
March 2011.&lt;/font&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Common Stock Warrants&lt;/font&gt; &amp;#xA0; &amp;#x2014; The following table
summarizes information with regard to outstanding warrants as of
December 31, 2010, issued in connection with equity and debt
financings since 2005.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%"&gt;
&lt;tr&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Offering&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Outstanding&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;(as&amp;#xA0;adjusted)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Exercise&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Price&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;(as&amp;#xA0;adjusted)&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="20%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Expiration&amp;#xA0;Date&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="20%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2006
Issuance of Common Stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;33,569&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;234.09&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="20%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;March
7, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Series
B Preferred Stock &amp;#x2013; placement agents&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;5,392&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;191.25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="20%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;May
2, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Series
C Exchange&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8,169&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
191.25&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="20%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;May
2, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Series
E Preferred Stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;60,330&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;99.45&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="20%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;December
31, 2015&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;August
2009 Private Placement&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;31,194&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;100.98&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="20%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;December
31, 2015&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;July
2010 Direct Offering (1)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;105,039&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;10.71&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="20%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;July
27, 2015&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Preferred
Incentive Warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;105,040&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;16.065&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="20%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;July
27, 2015&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="50%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="12%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="12%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="20%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="50%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
348,733&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="12%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="20%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)&amp;#xA0;
The exercise price of these warrants was adjusted in connection
with the private placement completed on April 8, 2011.&amp;#xA0; See
Note 12.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;During
the year ended December 31, 2010, warrants to purchase 14,776
shares of common stock at $10.71 and 5,941 shares of common stock
at $99.45 expired unexercised.&amp;#xA0; On March 7, 2011, warrants to
purchase 33,569 shares of common stock at $234.09 expired
unexercised.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;During
the year ended December 31, 2010, 53,478 shares of the
Company&amp;#x2019;s common stock were issued upon the cashless exercise
of warrants to purchase 89,752 shares of the Company&amp;#x2019;s common
stock.&amp;#xA0; The Company reclassified $2,584,000 from derivative
liability to additional paid-in capital upon the exercise of
warrants.&amp;#xA0; The following is a summary of the
exercises:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="MARGIN-LEFT: 27pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Original&amp;#xA0;private&amp;#xA0;placement&amp;#xA0;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Shares&amp;#xA0;of&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Common&amp;#xA0;Stock&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Issued&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Warrants&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Exercised&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Exercise&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Price&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2005
Bridge Financing&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,059&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,614&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;95.625&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2005
Issuance of Common Stock &amp;#x2013; placement agents&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,481&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,074&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;99.45&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2006
Issuance of Common Stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,395&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;6,480&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;263.16&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Series
B Preferred Stock &amp;#x2013; purchasers&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;29,709&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;49,019&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;99.45&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Series
B Preferred Stock &amp;#x2013; placement agents&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;229&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;490&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;191.25&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Series
D Preferred Stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;17,292&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;28,531&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;99.45&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Series
C Exchange&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
313&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
544&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;191.25&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
53,478&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
89,752&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;During
the year ended December 31, 2009, a total of 3,162 shares of the
Company&amp;#x2019;s common stock were issued upon the cashless exercise
of warrants to purchase 6,975 shares of common stock. The Company
reclassified a total of $1,001,000 from derivative liability to
additional paid-in capital upon the exercise of warrants.&amp;#xA0; The
following is a summary of the exercises:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="MARGIN-LEFT: 27pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Original&amp;#xA0;private&amp;#xA0;placement&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Shares&amp;#xA0;of&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Common&amp;#xA0;Stock&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Issued&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Warrants&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Exercised&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Exercise&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Price&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2005
Bridge Financing&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,429&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,091&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;95.625&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2005
Common Stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,310&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,172&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;99.45&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Series
A Preferred Stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;250&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;396&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;99.45&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2006
Issuance of Common Stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
173&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
1,316&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;263.16&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
3,162&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
6,975&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="9%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;br /&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
August 21, 2009, the Company entered into exchange agreements with
certain accredited investors who held warrants, issued in the 2006
private placement, to purchase 45,409 shares of its common stock.
Pursuant to the exchange agreements, an aggregate of 13,623 shares
of the Company&amp;#x2019;s common stock with a fair value of $1,626,000
were issued in exchange for these warrants. The holders agreed not
to transfer or dispose of the shares of common stock before
February 18, 2010. The warrants had been recorded as a derivative
liability on the Company&amp;#x2019;s balance sheet at their estimated
fair value of $1,109,000 at the date of exchange. The difference of
$517,000 between the estimated fair value of the warrants at the
date of exchange and the common stock issued to settle the
derivative liability has been included as a component of the loss
on derivative warrants for the year ended December 31, 2009.
Following the exchange, warrants expiring on March 7, 2011 to
purchase a total of 35,504 shares of common stock at $278.46 per
share remained outstanding. Following the final closing of the
August 2009 Private Placement, described above, the number of these
outstanding warrants was increased to 37,584 and the exercise price
was reduced to $263.16, as a result of anti-dilution provisions in
the warrants.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Authorized and Reserved Shares&lt;/font&gt; &amp;#x2014; On October 18, 2010
the Company&amp;#x2019;s stockholders approved an amendment to the
certificate of incorporation to increase the total number of
authorized shares of the Company&amp;#x2019;s common stock from
225,000,000 to 750,000,000. On April 8, 2011, the Company completed
the Reverse Split described in Note 12, and amended the certificate
of incorporation to decrease the total number of authorized shares
to 150,000,000 from 750,000,000.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
following shares were reserved for future issuance upon exercise of
stock options or warrants or conversion of preferred stock as of
the dates indicated:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="MARGIN-LEFT: 27pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="28%" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;December 31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2000
Stock Option Plan&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;291&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;366&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2006
Stock Incentive Plan&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;38,366&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;43,856&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Options
issued outside of formalized plans&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;10,569&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;16,037&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;348,733&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;232,164&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Preferred
stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
&amp;#x2014;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
329,451&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
shares reserved for future issuance&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
397,959&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
621,874&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:CommitmentsDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
10. COMMITMENTS&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Property Lease&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Effective
September 1, 2010, the Company entered into a six-month extension
to its lease for office space, at a rate of $5,275 per month,
expiring February 28, 2011. Rent expense was $65,000 and $87,000
for the years ended December 31, 2010 and 2009, respectively.
Future minimum lease payments under this non-cancelable lease are
approximately $10,600 during 2011.&amp;#xA0;&amp;#xA0;After February 28,
2011, the lease may be canceled with 30-day notice by either
party.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Royalty Arrangements&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company is obligated to a Russian company, ZAO BAM, under a royalty
and technology transfer agreement. Mark Balazovsky, a director of
the Company until November 2006, is the majority shareholder of ZAO
BAM. Pursuant to the royalty and technology transfer agreement
between the Company and ZAO BAM, the Company is required to make
royalty payments of 1.2% of net sales of oxidized glutathione-based
products. The Company is also required to pay ZAO BAM $2 million
for each new oxidized glutathione-based drug within eighteen months
following FDA approval of such drug.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;If
a royalty is not being paid to ZAO BAM on net sales of oxidized
glutathione products, then the Company is required to pay ZAO BAM
3% of all license revenues. If license revenues exceed the
Company&amp;#x2019;s cumulative expenditures including, but not limited
to, preclinical and clinical studies, testing, FDA and other
regulatory agency submission and approval costs, general and
administrative costs, and patent expenses, then the Company would
be required to pay ZAO BAM an additional 9% of the amount by which
license revenues exceed the Company&amp;#x2019;s cumulative
expenditures.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As
a result of the assignment to Novelos of the exclusive worldwide
intellectual property and marketing rights of oxidized glutathione
(excluding the Russian Territory), Novelos is obligated to the
Oxford Group, Ltd., or its assignees, for future
royalties.&amp;#xA0;&amp;#xA0;Simyon Palmin, a founder of Novelos, a
director until August 12, 2008 and the father of the
Company&amp;#x2019;s president and chief executive officer, is president
of Oxford Group, Ltd.&amp;#xA0;&amp;#xA0;Mr. Palmin was also an employee of
the Company until September 2008 and performed consulting services
through December 2009.&amp;#xA0;&amp;#xA0;Pursuant to the agreement, as
revised May 26, 2005, Novelos is required to pay Oxford Group,
Ltd., or its assignees, a royalty in the amount of 0.8% of the
Company&amp;#x2019;s net sales of oxidized glutathione-based
products.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Employment Agreements&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company entered into an employment agreement with Harry Palmin
effective January 1, 2006, whereby he agreed to serve as the
Company&amp;#x2019;s president and chief executive officer for an
initial term of two years.&amp;#xA0;&amp;#xA0;The agreement is
automatically renewed for successive one-year terms unless notice
of termination is provided by either party at least 90 days prior
to the end of such term.&amp;#xA0;&amp;#xA0;The agreement was renewed most
recently for an additional one-year term on January 1, 2011 in
accordance with its terms.&amp;#xA0;&amp;#xA0;The agreement provides for an
initial salary of $225,000 in 2006, participation in standard
benefit programs and an annual cash bonus at the discretion of the
compensation committee.&amp;#xA0;&amp;#xA0;The agreement further provides
that upon resignation for good reason or termination without cause,
both as defined in the agreement, Mr.&amp;#xA0;Palmin will receive his
pro rata share of the average of his annual bonus paid during the
two fiscal years preceding his termination, his base salary and
benefits for 11 months after the date of termination and fifty
percent of his unvested stock options will vest.&amp;#xA0;&amp;#xA0;The
agreement also contains a non-compete provision, which prohibits
Mr.&amp;#xA0;Palmin from competing with the Company for one year after
termination of his employment with the Company.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Retention Agreements&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
May 14, 2010, the Company entered into retention agreements with
each of its four vice-presidents.&amp;#xA0;&amp;#xA0;The agreements provide
for the lump-sum payment of six months&amp;#x2019; base salary and
benefits to each such officer following a termination without cause
or a resignation with good reason occurring on or before November
14, 2011.&amp;#xA0;&amp;#xA0;The agreements further provide that if the
executives remain employed with the Company as of October 1, 2010,
they will receive a payment of two months&amp;#x2019; base salary as a
retention bonus on that date. The retention bonus, an aggregate of
$140,000, was paid in October 2010 and will be deducted from the
severance amounts that may become payable upon a subsequent
involuntary termination.&amp;#xA0;&amp;#xA0;Elias Nyberg&amp;#x2019;s employment
was terminated on March 10, 2011, without cause, and he received a
payment of approximately $83,000 pursuant to the executive
retention agreement. The agreements expire November 14,
2011.&amp;#xA0;&amp;#xA0;The total remaining amount that may become payable
to the Company&amp;#x2019;s Named Executive Officers pursuant to the
retention agreements is approximately $86,000 to Christopher
Pazoles. Concurrently with the execution of the retention
agreements, the employment agreement between the Company and
Christopher Pazoles dated July 15, 2005 was
terminated.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
May 14, 2010, the Company also entered into retention agreements
with each of its three non-executive employees. The agreements
provide for the lump-sum payment of six months&amp;#x2019; base salary
and benefits to each employee following a termination without cause
or a resignation with good reason occurring on or before November
14, 2011.&amp;#xA0;&amp;#xA0;The agreements expire November 14,
2011.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">7000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">-5935852</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">1161</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:CostsAndExpenses contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">24229063</us-gaap:CostsAndExpenses>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="INF">250000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">2563</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">-19162616</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">89520</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
9. &amp;#xA0;&amp;#xA0;NET INCOME (LOSS) PER SHARE&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Basic
net loss per share is computed by dividing net loss attributable to
common stockholders by the weighted average number of shares of
common stock outstanding during the period. Diluted net income per
share is computed by dividing net loss attributable to common
stockholders, as adjusted, by the sum of the weighted average
number of shares of common stock and the dilutive potential common
stock equivalents then outstanding. Potential common stock
equivalents consist of stock options, warrants and convertible
preferred stock and accumulated dividends.&amp;#xA0;&amp;#xA0;Since the
Company has a net loss attributable to common stockholders for the
years ended December 31, 2010 and 2009, the inclusion of common
stock equivalents in the computation for those periods would be
antidilutive. Accordingly, basic and diluted net loss per share is
the same for the periods presented.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
following potentially dilutive securities have been excluded from
the computation of diluted net income (loss) per share since their
inclusion would be antidilutive:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div align="center"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Year Ended&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;December 31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Stock
options&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
50,074&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
60,260&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
356,925&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
232,164&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Conversion
of preferred stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
2,042,108&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
329,451&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;(1)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;(1)
Includes shares of common stock that may become issuable upon
conversion of preferred stock dividends accumulated at the
respective date.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0">&lt;div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;5.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;COLLABORATION
AGREEMENTS&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2007 Collaboration Agreement with Lee&amp;#x2019;s Pharmaceutical (HK)
Ltd.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
December 2007 the Company entered into a Collaboration Agreement
with Lee&amp;#x2019;s Pharmaceutical (HK) Ltd. (&amp;#x201C;Lee&amp;#x2019;s
Pharm&amp;#x201D;). Pursuant to this agreement, Lee&amp;#x2019;s Pharm
obtained an exclusive license to develop, manufacture and
commercialize NOV-002 and NOV-205 in China, Hong Kong, Taiwan and
Macau (the &amp;#x201C;Chinese Territory&amp;#x201D;). The Company has
suspended further development of NOV-205; however, this suspension
may not impact the development strategy of Lee&amp;#x2019;s Pharm.&amp;#xA0;
Under the terms of the agreement the Company received a license fee
of $500,000 in March 2008 and is entitled to receive up to
$1,700,000 in future milestone payments upon the completion of
development and marketing milestones by Lee&amp;#x2019;s Pharm. This
initial $500,000 payment received is being amortized over the
estimated term of this agreement, 15 years. Accordingly, $33,000 of
license revenue was recognized in each of the years ended December
31, 2010 and 2009.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Lee&amp;#x2019;s Pharm agreement provides that the Company receive
royalty payments of 20-25% of net sales of NOV-002 in the Chinese
Territory and receive royalty payments of 12-15% of net sales of
NOV-205 in the Chinese Territory. Lee&amp;#x2019;s Pharm is obligated to
reimburse the Company for the manufacturing cost of pharmaceutical
products provided to Lee&amp;#x2019;s Pharm in connection with the
agreement. Lee&amp;#x2019;s Pharm has committed to spend a minimum
amount on development in the first four years of the agreement. The
agreement expires upon the expiration of the last patent covering
any of the licensed products, or twelve years from the date of the
first commercial sale in China, whichever occurs
later.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2009 Collaboration Agreement with Mundipharma&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
February 11, 2009, Novelos entered into a collaboration agreement
(the &amp;#x201C;Collaboration Agreement&amp;#x201D;) with Mundipharma
International Corporation Limited (&amp;#x201C;Mundipharma&amp;#x201D;) to
develop, manufacture and commercialize, on an exclusive basis,
Licensed Products (as defined in the Collaboration Agreement),
which includes the Company&amp;#x2019;s lead compound, NOV-002, in
Europe (other than the Russian Territory), Asia (other than the
Chinese Territory) and Australia (collectively referred to as the
&amp;#x201C;Mundipharma Territory&amp;#x201D;).&amp;#xA0; Mundipharma is an
independent associated company of Purdue Pharma, L.P.
(&amp;#x201C;Purdue&amp;#x201D;).&amp;#xA0; The Collaboration Agreement provides
for Mundipharma to pay the Company royalties and fixed milestone
payments based on sales and commercial launches in the licensed
territories.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;For
countries in which patents are held, the Collaboration Agreement
expires on a country-by-country basis within the Mundipharma
Territory on the earlier of (1) expiration of the last applicable
Novelos patent within the country or (2) the determination that any
patents within the country are invalid, obvious or otherwise
unenforceable.&amp;#xA0; For countries in which no patents are held,
the Collaboration Agreement expires the earlier of 15 years from
its effective date or upon generic product competition in the
country resulting in a 20% drop in Mundipharma&amp;#x2019;s market
share.&amp;#xA0; Novelos may terminate the Collaboration Agreement upon
breach or default by Mundipharma.&amp;#xA0; Mundipharma may terminate
the Collaboration Agreement upon breach or default, filing of
voluntary or involuntary bankruptcy by Novelos, the termination of
certain agreements with companies associated with the originators
of the licensed technology, or 30-day notice for no reason.&amp;#xA0;
If any regulatory approval within the Mundipharma Territory is
suspended as a result of issues related to the safety of the
Licensed Products, then Mundipharma&amp;#x2019;s obligations under the
Collaboration Agreement will be suspended until the regulatory
approval is reinstated.&amp;#xA0; If that reinstatement does not occur
within 12 months of the suspension, then Mundipharma may terminate
the Collaboration Agreement.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Concurrently
with the execution of the Collaboration Agreement, Novelos
completed a private placement of Series E preferred stock and
common stock purchase warrants to Purdue.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company expects that the negative results of its Phase 3 Trial will
adversely affect development and commercialization of NOV-002 under
the collaboration agreements with Lee&amp;#x2019;s Pharm and
Mundipharma.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">115311</us-gaap:IncreaseDecreaseInDeferredLiabilities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">1947413</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">392881</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">-30468</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">555000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0">&lt;div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 27pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
12.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
SUBSEQUENT EVENTS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Merger Agreement&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
April 8, 2011, the Company entered into an Agreement and Plan of
Merger (the &amp;#x201C;Merger Agreement&amp;#x201D;) with Cellectar, Inc.
(&amp;#x201C;Cellectar&amp;#x201D;) and Cell Acquisition Corp. (the
&amp;#x201C;Merger Subsidiary&amp;#x201D;), a wholly owned subsidiary of
Novelos, pursuant to which Cellectar was merged into the Merger
Subsidiary (the &amp;#x201C;Acquisition&amp;#x201D;).&amp;#xA0;&amp;#xA0;As a result
of the Acquisition, the Merger Subsidiary, which has been renamed
Cellectar, Inc., owns all assets and operates the business
previously owned and operated by Cellectar. Prior to the
Acquisition, Cellectar was in the business of developing drugs for
the treatment and diagnosis of cancer.&amp;#xA0;&amp;#xA0;The Company will
continue to develop Cellectar&amp;#x2019;s compounds following the
Acquisition.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As
consideration for the Acquisition, the former stockholders of
Cellectar&amp;#xA0;&amp;#xA0;received aggregate consideration consisting of
a number of shares of Novelos common stock constituting, after
giving effect to the Acquisition but before giving effect to the
concurrent private placement of our securities described below,
approximately 85% of the outstanding shares of Novelos common
stock.&amp;#xA0;&amp;#xA0;Prior to the Acquisition, the Company amended and
restated its certificate of incorporation and in connection
therewith, among other things, effected a 1-for-153 reverse split
of its common stock (the &amp;#x201C;Reverse
Split&amp;#x201D;).&amp;#xA0;&amp;#xA0;Immediately following the effectiveness
of the Reverse Split, there were approximately 2,959,871 shares of
our common stock outstanding, and the Company issued 17,001,596
shares of our common stock to the former stockholders of Cellectar
upon the effectiveness of the Acquisition.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Rodman
&amp;amp; Renshaw, LLC (&amp;#x201C;Rodman&amp;#x201D;), financial advisor to
Novelos in connection with the Acquisition, received a cash fee of
$250,000 upon the completion of the Acquisition in consideration of
their services.&amp;#xA0;&amp;#xA0;XMS Capital Partners, the financial
advisor to Cellectar in connection with the Acquisition, received a
cash fee of $200,000 upon the completion of the Acquisition in
consideration of their services.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Securities Purchase Agreement&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Concurrently
with the execution of the Merger Agreement, the Company entered
into a Securities Purchase Agreement with certain accredited
investors under which the Company sold an aggregate of 6,846,537
units, each unit consisting of one share of its common stock and a
warrant to purchase one share of its common stock, at a price of
$0.75 per unit, for gross proceeds of approximately
$5,135,000.&amp;#xA0;&amp;#xA0;The warrants have an exercise price of $0.75
and expire on March 31, 2016.&amp;#xA0;&amp;#xA0;The warrant exercise price
and/or the common stock issuable pursuant to such warrant will be
subject to adjustment for stock dividends, stock splits or similar
capital reorganizations so that the rights of the warrant holders
after such event will be equivalent to the rights of warrant
holders prior to such event.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Securities Purchase Agreement includes a requirement that the
Company file with the Securities and Exchange Commission
(&amp;#x201C;SEC&amp;#x201D;) no later than October 5, 2011, a registration
statement covering the resale of the shares of common stock, and
the shares of common stock underlying the warrants, issued pursuant
to the Securities Purchase Agreement.&amp;#xA0;&amp;#xA0;The Company is
also required to use our commercially reasonable efforts to have
the registration statement declared effective by December 4, 2011,
and to keep the registration statement continuously effective under
the Securities Act of 1933, as amended (the &amp;#x201C;Securities
Act&amp;#x201D;) until the earlier of the date when all the registrable
securities covered by the registration statement have been sold or
the second anniversary of the closing.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
the event the Company fails to file the registration statement
within the timeframe specified by the Securities Purchase
Agreement, or if it fails to obtain effectiveness of this
registration on or prior to the December 4, 2011 (if there is no
review by the SEC) or by January 3, 2012 (if there is review by the
SEC) with respect to the maximum number of shares permitted to be
registered by the SEC, the Company will be required to pay to the
purchasers liquidated damages equal to 1.5% per month (pro-rated on
a daily basis for any period of less than a full month) of the
aggregate purchase price of the units purchased until the
registration statement is filed or declared effective, as
applicable.&amp;#xA0;&amp;#xA0;The Company will be allowed to suspend the
use of the registration statement for not more than 30 consecutive
days, on not more than two occasions, in any 12 month
period.&amp;#xA0;&amp;#xA0;The Company has also granted piggy-back
registration rights with respect to any shares of common stock that
it is required to exclude from the registration statement as a
condition of its effectiveness, and has also agreed to file further
registration statements with respect to any such shares six months
after the effective date of the initial registration
statement.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company paid to Rodman, the placement agent for the financing, a
cash fee equal to $200,000 and warrants to purchase 192,931 shares
of its common stock in consideration for their advisory services
with respect to the financing pursuant to the placement agency
agreement between Rodman and the Company.&amp;#xA0;&amp;#xA0;Rodman is
entitled to registration rights with respect to the shares of
common stock issuable upon exercise of these
warrants.&amp;#xA0;&amp;#xA0;The warrants have the same terms as those
issued to the investors in the private placement.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Changes in Directors and Executive Officers&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Effective
April 8, 2011, prior to the completion of the Acquisition, Michael
J. Doyle, Sim Fass and David B. McWilliams resigned from the
Company&amp;#x2019;s board of directors and their respective committee
appointments.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Effective
April 8, 2011, as a condition to the completion of the Acquisition,
Jamey P. Weichert, Thomas Rockwell Mackie, John Neis, John E.
Niederhuber and Michael F. Tweedle were appointed to the
Company&amp;#x2019;s board of directors.&amp;#xA0;&amp;#xA0;Committee
assignments have not yet been determined.&amp;#xA0;&amp;#xA0;Jamey P.
Weichert, Thomas Rockwell Mackie and John Neis, previously served
on the board of directors of Cellectar.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
Amendment of Certificate of Incorporation&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Effective
April 7, 2011 the Company&amp;#x2019;s certificate of incorporation was
amended to eliminate the Certificate to Set Forth Designations,
Voting Powers, Preferences, Restrictions and Relative Rights of
Series C 8% Cumulative Convertible Preferred
Stock.&amp;#xA0;&amp;#xA0;There had not been any shares of Series C
preferred stock outstanding since December 2010.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Effective
April 7, 2011 the Company&amp;#x2019;s certificate of incorporation was
amended to eliminate the Certificate of Designations, Preferences
and Rights of Series E Convertible Preferred
Stock.&amp;#xA0;&amp;#xA0;There had not been any shares of Series E
preferred stock outstanding since December 2010.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Prior
to the closing of the Acquisition on April 8, 2011, the Company
amended and restated its certificate of incorporation in order (a)
to effect the reverse split; (b) to reduce the number of shares of
our authorized common stock from 750,000,000 to 150,000,000; (c) to
eliminate the right of the stockholders to act by written consent;
and (d) to classify the board of directors into three
classes.&amp;#xA0;&amp;#xA0;Class I directors will stand for re-election at
the Company&amp;#x2019;s next annual meeting of stockholders, Class II
directors will stand for re-election at the 2012 annual meeting of
stockholders, and Class III directors will stand for re-election at
the 2013 annual meeting of stockholders.&amp;#xA0;&amp;#xA0;Thomas Rockwell
Mackie, James S. Manuso and John Niederhuber serve as Class I
directors, Stephen A. Hill, Michael F. Tweedle and John Neis serve
as Class II directors, and Harry S. Palmin, Jamey P. Weichert and
Howard M. Schneider serve as Class III directors.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">-213792</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">552201</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">19671</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">-24045004</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">184059</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;
11.&amp;#xA0;&amp;#xA0;LITIGATION&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;A
purported class action complaint was filed on March 5, 2010 in the
United States District Court for the District of Massachusetts by
an alleged shareholder of the Company, on behalf of himself and all
others who purchased or otherwise acquired the Company&amp;#x2019;s
common stock in the period between December 14, 2009 and February
24, 2010, against the Company and its President and Chief Executive
Officer, Harry S. Palmin.&amp;#xA0;&amp;#xA0;On October 1, 2010, the court
appointed lead plaintiffs (Boris Urman and Ramona McDonald) and
appointed lead plaintiffs&amp;#x2019; counsel.&amp;#xA0;&amp;#xA0;On October 22,
an amended complaint was filed.&amp;#xA0;&amp;#xA0;The amended complaint
claims that the Company violated Section 10(b) of the Securities
Exchange Act of 1934, as amended, and Rule 10b-5 promulgated
thereunder in connection with alleged disclosures related to the
Phase 3 clinical trial of NOV-002 for non-small cell lung
cancer.&amp;#xA0;&amp;#xA0;On December 6, 2010, the Company filed a motion
to dismiss the complaint with prejudice.&amp;#xA0;&amp;#xA0;On January 20,
2011, the plaintiffs filed their opposition to our motion and on
March 3, 2011, we filed our response to their opposition. Our
motion to dismiss remains pending. The Company believes the
allegations are without merit and intends to defend vigorously
against the allegations.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
June 28, 2010, the Company received a letter from counsel to ZAO
BAM and ZAO BAM Research Laboratories (collectively,
&amp;#x201C;BAM&amp;#x201D;) alleging that the Company modified the chemical
composition of NOV-002 without prior notice to or approval from
BAM, constituting a material breach of a technology and assignment
agreement the Company had entered into with BAM on June 20, 2000
(the &amp;#x201C;June 2000 Agreement&amp;#x201D;).&amp;#xA0;&amp;#xA0;The letter
references the Company&amp;#x2019;s amendment, submitted to the FDA on
August 30, 2005, to its investigational new drug application dated
August 1999 as the basis for BAM&amp;#x2019;s claims and demands the
transfer of all intellectual property rights concerning NOV-002 to
BAM.&amp;#xA0;&amp;#xA0;Mark Balazovsky, a director of Novelos from June
1996 until November 2006 and a shareholder of Novelos through at
least June 25, 2010, is, to the Company&amp;#x2019;s knowledge, still
the general director and principal shareholder of ZAO
BAM.&amp;#xA0;&amp;#xA0;The Company believes the allegations are without
merit and intends to defend vigorously against any proceedings that
BAM may initiate as to these allegations. On September 24, 2010,
the Company filed a complaint in Suffolk Superior Court seeking a
declaratory judgment by the court that the June 2000 Agreement has
been replaced by a subsequent agreement between the parties dated
April 1, 2005 (the &amp;#x201C;April 2005 Agreement&amp;#x201D;), that
Novelos&amp;#x2019; obligations to BAM are governed solely by the April
2005 Agreement and that the obligations of the June 2000 agreement
have been performed and fully satisfied.&amp;#xA0;&amp;#xA0;On November 29,
2010, BAM answered the complaint, denying the material allegations,
and stating its affirmative defenses and certain counterclaims. On
January 14, 2011, the Company responded to the counterclaims,
denying BAM&amp;#x2019;s material allegations and stating our
affirmative defenses.&amp;#xA0;&amp;#xA0;The Company believes the
counterclaims are without merit and intends to vigorously defend
against them.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">17205959</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
accompanying financial statements reflect the application of
certain accounting policies, as described in this note and
elsewhere in the accompanying notes to the financial
statements.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Use of Estimates&lt;/font&gt; &amp;#x2014; The preparation of financial
statements in conformity with accounting principles generally
accepted in the United States requires the Company&amp;#x2019;s
management to make estimates and judgments that may affect the
reported amounts of assets, liabilities, revenue and expenses and
disclosure of contingent assets and liabilities. On an on-going
basis, the Company&amp;#x2019;s management evaluates its estimates
including those related to unbilled research and development costs,
valuation of derivatives and share-based compensation. The Company
bases its estimates on historical experience and on various other
assumptions that are believed to be reasonable, the results of
which form the basis for making judgments about the carrying values
of assets and liabilities. Actual results may differ from those
estimates under different assumptions or conditions. Changes in
estimates are reflected in reported results in the period in which
they become known.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Cash Equivalents&lt;/font&gt; &amp;#x2014; The Company considers all
short-term investments purchased with original maturities of three
months or less to be cash equivalents.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Fixed Assets&lt;/font&gt; &amp;#x2014; Property and equipment are stated at
cost. Depreciation on property and equipment is provided using the
straight-line method over the estimated useful lives of the assets,
which range from three to five years. Leasehold improvements are
depreciated over the lesser of the estimated useful lives of the
assets or the remaining lease term.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Impairment of Long&lt;/font&gt;-&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;Lived
Assets&lt;/font&gt; &amp;#x2014; Whenever events or circumstances change, the
Company assesses whether there has been an impairment in the value
of long-lived assets by determining whether projected undiscounted
cash flows generated by the applicable asset exceed its net book
value as of the assessment date.&amp;#xA0; There were no impairments of
the Company&amp;#x2019;s assets at the end of each period
presented.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Stock-Based Compensation&lt;/font&gt; &amp;#x2014; The Company accounts for
employee stock-based compensation in accordance with the guidance
of FASB ASC Topic 718, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Compensation &amp;#x2013; Stock
Compensation&lt;/font&gt; which requires all share-based payments to
employees, including grants of employee stock options, to be
recognized in the financial statements based on their fair
values.&amp;#xA0; The Company accounts for non-employee stock-based
compensation in accordance with the guidance of FASB ASC Topic 505,
&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Equity&lt;/font&gt;
which requires that companies recognize compensation expense based
on the estimated fair value of options granted to non-employees
over their vesting period, which is generally the period during
which services are rendered by such non-employees.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Revenue Recognition&lt;/font&gt; &amp;#x2014; Revenue is recognized when
persuasive evidence of an arrangement exists, the price is fixed
and determinable, delivery has occurred, and there is reasonable
assurance of collection.&amp;#xA0; Upfront payments received in
connection with technology license or collaboration agreements are
recognized over the estimated term of the related agreement.&amp;#xA0;
The Company has not yet received milestone or royalty payments in
connection with license or collaboration agreements.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Research and Development&lt;/font&gt; &amp;#x2014; Research and development
costs are expensed as incurred.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Income Taxes&lt;/font&gt; &amp;#x2014; The Company uses the liability method
of accounting for income taxes.&amp;#xA0; Under this method, deferred
tax assets and liabilities are determined based on temporary
differences between the financial statement and tax basis of assets
and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the
differences are expected to reverse.&amp;#xA0; The effect on deferred
tax assets and liabilities of a change in tax rates is recognized
in income in the period that includes the enactment date.&amp;#xA0;
Valuation allowances are established when it is more likely than
not that some portion of the deferred tax assets will not be
realized.&amp;#xA0; Tax positions taken or expected to be taken in the
course of preparing the Company&amp;#x2019;s tax returns are required to
be evaluated to determine whether the tax positions are &amp;#x201C;more
likely than not&amp;#x201D; of being sustained by the applicable tax
authority.&amp;#xA0; Tax positions deemed not to meet a
more-likely-than-not threshold would be recorded as tax expense in
the current year.&amp;#xA0; There were no uncertain tax positions that
require accrual or disclosure to the financial statements as of
December 31, 2010 and 2009.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Comprehensive Income (Loss)&lt;/font&gt; &amp;#x2014; The Company had no
components of comprehensive income other than net income (loss) in
all of the periods presented.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Fair Value of Financial Instruments&lt;/font&gt; &amp;#x2014; The guidance
under FASB ASC Topic 825, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Financial Instruments&lt;/font&gt;
, requires disclosure of the fair value of certain financial
instruments. The Company&amp;#x2019;s financial instruments consist of
cash equivalents, accounts payable, accrued expenses and redeemable
preferred stock. The estimated fair value of the redeemable
preferred stock, determined on an as-converted basis including
conversion of accumulated unpaid dividends, was $114,780,000 at
December 31, 2009. The estimated fair value of the remaining
financial instruments approximates their carrying value due to
their short-term nature.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Concentration of Credit Risk&lt;/font&gt; &amp;#x2014; Financial instruments
that subject the Company to credit risk consist of cash and
equivalents on deposit with financial institutions. The
Company&amp;#x2019;s excess cash is on deposit in an overnight
investment account that is fully collateralized by
government-backed obligations.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Derivative Instruments&lt;/font&gt; &amp;#x2014; The Company generally does
not use derivative instruments to hedge exposures to cash flow or
market risks; however, starting January 1, 2009, certain warrants
to purchase common stock that do not meet the requirements for
classification as equity, in accordance with the Derivatives and
Hedging Topic of the FASB ASC, are classified as liabilities. In
such instances, net-cash settlement is assumed for financial
reporting purposes, even when the terms of the underlying contracts
do not provide for a net-cash settlement. These warrants are
considered derivative instruments as the agreements contain
&amp;#x201C;down-round&amp;#x201D; provisions whereby the number of shares
for which the warrants are exercisable and/or the exercise price of
the warrants is subject to change in the event of certain issuances
of stock at prices below the then-effective exercise price of the
warrants. The number of such warrants was 91,524 at January 1,
2009, 48,489 at December 31, 2009 and 138,611 at December 31, 2010.
The primary underlying risk exposure pertaining to the warrants is
the change in fair value of the underlying common stock. Such
financial instruments are initially recorded at fair value, or
relative fair value when issued with other instruments, with
subsequent changes in fair value recorded as a component of gain or
loss on derivatives in each reporting period. If these instruments
subsequently meet the requirements for equity classification, the
Company reclassifies the fair value to equity. At December 31, 2010
and 2009, these warrants represent the only outstanding derivative
instruments issued or held by the Company. As a result of the
significant decline in the Company&amp;#x2019;s stock price following
the announcement of the results of the Phase 3 Trial, the Company
recorded a gain of approximately $8,118,000 during the year ended
December 31, 2010 in connection with the revaluation of the
derivative liability balance at December 31, 2010.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
New Accounting Pronouncements&lt;/font&gt; &amp;#x2014;&amp;#xA0; In September
2009, the Financial Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;)
amended the accounting standards related to revenue recognition for
arrangements with multiple deliverables and arrangements that
include software elements (&amp;#x201C;new accounting
principles&amp;#x201D;). The new accounting principles permit
prospective or retrospective adoption, and the Company elected
prospective adoption at the beginning of the first quarter of 2010.
The adoption of the standard in 2010 had no impact on the
Company&amp;#x2019;s financial statements.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
January 2010, the FASB issued ASU No.&amp;#xA0;2010-06, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Improving Disclosures about
Fair Value Measurements&lt;/font&gt;, which requires additional
disclosures about the amounts of and reasons for significant
transfers in and out of Level&amp;#xA0;1 and Level&amp;#xA0;2 fair value
measurements. This standard also clarifies existing disclosure
requirements related to the level of disaggregation of fair value
measurements for each class of assets and liabilities and
disclosures about inputs and valuation techniques used to measure
fair value for both recurring and non-recurring Level&amp;#xA0;2 and
Level&amp;#xA0;3 measurements. Since this new accounting standard only
required additional disclosure, the adoption of the standard in the
first quarter of 2010 did not impact the Company&amp;#x2019;s financial
statements. Additionally, effective for interim and annual periods
beginning after December&amp;#xA0;15, 2010, this standard will require
additional disclosure and require an entity to present
disaggregated information about activity in Level&amp;#xA0;3 fair value
measurements on a gross basis, rather than one net
amount.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Adoption of New Accounting Principle&lt;/font&gt; &amp;#x2014; Effective
January 1, 2009, the Company adopted the guidance of FASB ASC
815-40-15, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Derivatives and
Hedging&lt;/font&gt; , which establishes a framework for determining
whether certain freestanding and embedded instruments are indexed
to a company&amp;#x2019;s own stock for purposes of evaluation of the
accounting for such instruments under existing accounting
literature. As a result of this adoption, certain warrants that
were previously determined to be indexed to the Company&amp;#x2019;s
common stock upon issuance were determined not to be indexed to the
Company&amp;#x2019;s common stock because they include
&amp;#x201C;down-round&amp;#x201D; anti-dilution provisions whereby the
number of shares for which the warrants are exercisable and/or the
exercise price of the warrants is subject to change in the event of
certain issuances of stock at prices below the then-effective
exercise price of the warrants. The fair value of the warrants at
the dates of issuance totaling $6,893,000 was initially recorded as
a component of additional paid-in capital. Upon adoption of this
guidance on January 1, 2009, the Company recorded a derivative
liability of $999,000, a decrease to the opening balance of
additional paid-in capital of approximately $6,893,000 and recorded
a decrease to accumulated deficit totaling approximately
$5,894,000, representing the decrease in the fair value of the
warrants from the date of issuance to December 31, 2008. The
increase in fair value of the warrants of approximately $12,114,000
during the year ended December 31, 2009 and the decrease in fair
value of the warrants of $8,118,000 during the year ended December
31, 2010 have been included as a component of other income
(expense) in the accompanying statement of operations. Certain of
the warrants that had been recorded as a derivative liability were
exchanged or exercised for shares of the Company&amp;#x2019;s common
stock during the years ended December 31, 2010 and 2009. See Note 6
for a description of those transactions. The fair value of the
warrants of $288,000 and $10,487,000 at December 31, 2010 and 2009
is included as a current liability in the accompanying balance
sheet as of that date.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Reclassifications&lt;/font&gt; &amp;#x2014; Certain prior year amounts have
been reclassified to conform to the current year
presentation.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">1831197</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="INF">-17102</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">5368181</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">19671</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">-24229063</us-gaap:OperatingIncomeLoss>
  <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">5500730</us-gaap:PaymentsToAcquireShortTermInvestments>
  <us-gaap:RevenueFromGrants contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">200000</us-gaap:RevenueFromGrants>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">21709708</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
3.&amp;#xA0; FIXED ASSETS&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Fixed
assets consisted of the following at December 31:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="MARGIN-LEFT: 36pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2009&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Office
and computer equipment&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;61,907&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;73,261&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Computer
software&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;43,896&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;43,896&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Leasehold
improvements&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4,095&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4,095&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
fixed assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;109,898&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;121,252&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Less
accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(101,143&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(77,155&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Fixed
assets, net&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8,755&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;44,097&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">2720985</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">673739</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">62914</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Novelos
Therapeutics, Inc. (&amp;#x201C;Novelos&amp;#x201D; or the
&amp;#x201C;Company&amp;#x201D;) is a biopharmaceutical company developing
compounds for the treatment of cancer.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
April 8, 2011, the Company entered into a business combination with
Cellectar, Inc. (&amp;#x201C;Cellectar&amp;#x201D;), a privately held
Wisconsin corporation that designed and developed products to
detect, treat and monitor a wide variety of human cancers (the
&amp;#x201C;Acquisition&amp;#x201D;, see Note 12). Immediately prior to the
Acquisition, the Company completed a 1-for-153 reverse split of its
common stock (the &amp;#x201C;Reverse Split&amp;#x201D;). The Company then
issued 17,001,596 shares of its common stock to the former
shareholders of Cellectar as consideration for the Acquisition,
constituting approximately 85% of Novelos&amp;#x2019; outstanding common
stock after giving effect to the Acquisition. Upon the closing of
the Acquisition, the Company completed the private placement of
6,846,537 shares of its common stock and warrants to purchase an
additional 6,846,537 shares of its common stock (in each case after
giving effect to the Reverse Split) for gross proceeds of
approximately $5,135,000. As a result of the Acquisition, the
Company is implementing a revised business plan focused on the
development of the Cellectar compounds. Development of
Novelos&amp;#x2019; other compounds (NOV-002 and NOV-205) has been
suspended. The Company will conduct its operations from
Cellectar&amp;#x2019;s headquarters in Madison, WI and the
Company&amp;#x2019;s executive offices will remain in Newton,
MA.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Reverse Split reduced the number of outstanding shares of Common
Stock from 452,866,983 shares to 2,959,914 (2,959,871 after the
cash settlement of fractional shares). On the accompanying balance
sheet, the aggregate par value of the issued common stock was
reduced by reclassifying the par value amount of the eliminated
shares of common stock to additional paid-in capital. All per share
amounts and outstanding shares, including all common stock
equivalents, stock options and warrants, have been retroactively
restated in these financial statements and notes for all periods
presented to reflect the Reverse Split. Additionally, the number of
authorized shares of common stock disclosed on the balance sheet
has been reduced to 150,000,000 from 750,000,000 to reflect the
reduction in authorized shares of common stock that became
effective concurrent with the Reverse Split.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Accounting
principles generally accepted in the United States require that a
company whose security holders retain the majority voting interest
in the combined business be treated as the acquirer for financial
reporting purposes.&amp;#xA0; Accordingly, the Acquisition will be
accounted for as a reverse acquisition whereby Cellectar, Inc. will
be treated as the acquirer for accounting and financial reporting
purposes. The financial statements presented herein represent the
historical financial information of Novelos, prior to the
acquisition.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company is subject to a number of risks similar to those of other
small biopharmaceutical companies. Principal among these risks are
dependence on key individuals, competition from substitute products
and larger companies, the successful development and marketing of
its products in a highly regulated environment and the need to
obtain additional financing necessary to fund future
operations.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
February 24, 2010, the Company announced that its Phase 3 clinical
trial for NOV-002 in non-small cell lung cancer (the &amp;#x201C;Phase 3
Trial&amp;#x201D;) did not meet its primary endpoint of a statistically
significant increase in median overall survival. Following
evaluation of the detailed trial data, on March 18, 2010, the
Company announced that the secondary endpoints had also not been
met in the Phase 3 Trial and that it had discontinued development
of NOV-002 for NSCLC in combination with first-line paclitaxel and
carboplatin chemotherapy.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;These
financial statements have been prepared on the basis that the
Company will continue as a going concern. The Company has generated
insignificant revenues and has incurred operating losses since
inception in devoting substantially all of its efforts toward
research and development. The Company expects that it will continue
to generate operating losses for the foreseeable future. The
Company believes that its cash on hand at December 31, 2010, plus
the proceeds from the private placement completed in connection
with the Acquisition, is adequate to fund operations into the
fourth quarter of 2011. The Company&amp;#x2019;s ability to execute its
operating plan beyond the fourth quarter of 2011 depends on its
ability to obtain additional funding via the sale of equity and/or
debt securities, a strategic transaction or otherwise. The Company
plans to continue to actively pursue financing alternatives, but
there can be no assurance that it will obtain the necessary
funding.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
4.&amp;#xA0; FAIR VALUES OF ASSETS AND LIABILITIES&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
accordance with Fair Value Measurements and Disclosures Topic of
the FASB ASC, the Company groups its financial assets and financial
liabilities generally measured at fair value in three levels, based
on the markets in which the assets and liabilities are traded and
the reliability of the assumptions used to determine fair
value.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="font-family:Symbol, serif"&gt;&amp;#xB7;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Level 1: Input prices quoted in an active market for identical
financial assets or liabilities.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="font-family:Symbol, serif"&gt;&amp;#xB7;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Level 2: Inputs other than prices quoted in Level 1, such as prices
quoted for similar financial assets and liabilities in active
markets, prices for identical assets and liabilities in markets
that are not active or other inputs that are observable or can be
corroborated by observable market data.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;br /&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="font-family:Symbol, serif"&gt;&amp;#xB7;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Level 3: Input prices that are significant to the fair value of the
financial assets or liabilities which are not observable or
supported by an active market.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Assets
and liabilities measured at fair value on a recurring basis are
summarized below:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="MARGIN-LEFT: 18pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="46%" colspan="14"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;December&amp;#xA0;31,&amp;#xA0;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Level&amp;#xA0;1&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Level&amp;#xA0;2&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Level&amp;#xA0;3&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Fair&amp;#xA0;Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Liabilities:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
-&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
288,250&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
-&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
288,250&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="MARGIN-LEFT: 18pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="46%" colspan="14"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;December&amp;#xA0;31,&amp;#xA0;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Level&amp;#xA0;1&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Level&amp;#xA0;2&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Level&amp;#xA0;3&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Fair&amp;#xA0;Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Liabilities:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
-&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
10,487,000&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
-&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
10,487,000&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company uses valuation methods and assumptions that consider among
others the fair value of the underlying stock, risk-free interest
rate, volatility, expected life and dividend rates in estimating
fair value for the warrants considered to be derivative
instruments. Assumptions used are generally consistent with those
disclosed for stock-based compensation (see Note 7).&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
8. &amp;#xA0;INCOME TAXES&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company&amp;#x2019;s deferred tax assets consisted of the following at
December 31:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="MARGIN-LEFT: 18pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="76%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Net
operating loss carryforwards&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;12,872,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;9,543,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Research
and development
expenses&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;14,180,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;14,906,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Tax
credits&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,711,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,563,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Capital
loss carryforward&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;340,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;340,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Stock-based
compensation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
365,000&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
650,000&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Gross
deferred tax asset&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;29,468,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;27,002,000&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Valuation
allowance&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
(29,468,000&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
(27,002,000&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Net
deferred tax asset&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
&amp;#x2014;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
&amp;#x2014;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As
of December 31, 2010, the Company had federal and state net
operating loss carryforwards of approximately $33,180,000 and
$25,812,000 respectively, which expire through 2030.&amp;#xA0;&amp;#xA0;In
addition, the Company has federal and state research and
development and investment tax credits of approximately $1,382,000
and $449,000, respectively, which expire through
2030.&amp;#xA0;&amp;#xA0;The amount of net operating loss carryforwards
which may be utilized annually in future periods may be limited
pursuant to Section 382 of the Internal Revenue Code as a result of
substantial changes in the Company&amp;#x2019;s ownership that have
occurred or that may occur in the future.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
capital loss carryforward relates to the loss recorded in prior
years for Novelos&amp;#x2019; investment in an unrelated
company.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Because
of the Company&amp;#x2019;s limited operating history, continuing losses
and uncertainty associated with the utilization of the net
operating loss carryforwards in the future, management has provided
a 100% allowance against the Company&amp;#x2019;s gross deferred tax
asset.&amp;#xA0;&amp;#xA0;In 2010, the difference between the
Company&amp;#x2019;s total statutory tax rate of approximately 40% and
its effective tax rate of 0% is due to the nontaxable gain of
$8,118,000 on derivative warrants, an increase in the valuation
allowance of $2,466,000 and nondeductible liquidated damages
accrued of $819,000.&amp;#xA0;&amp;#xA0;In 2009, the difference between the
Company&amp;#x2019;s total statutory tax rate of approximately 40% and
its effective tax rate of 0% is due equally to the increase in
valuation allowance and the reduction in tax loss resulting from
the nondeductible loss on derivative warrants.&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company did not have any unrecognized tax benefits or accrued
interest and penalties at any time during the years ended December
31, 2010 and 2009, and does not anticipate having any unrecognized
tax benefits over the next twelve months.&amp;#xA0;&amp;#xA0;The Company is
subject to audit by the IRS for tax periods commencing January 1,
2007.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:InterestPaid contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">194973</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">305049</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="INF">5500730</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
7.&amp;#xA0; STOCK-BASED COMPENSATION&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company&amp;#x2019;s stock-based compensation plans are summarized
below:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
2000 Stock Option Plan.&amp;#xA0;&lt;/font&gt; As of December 31, 2010, there
are options to purchase 291 shares of the Company&amp;#x2019;s common
stock outstanding under a stock option plan established in August
2000 (the &amp;#x201C;2000 Plan&amp;#x201D;).&amp;#xA0; There will be no further
grants made under the 2000 Plan. Options generally vested annually
over three years and expire on the tenth anniversary of the grant
date.&amp;#xA0; No options were granted or exercised under the 2000
Plan during 2009.&amp;#xA0; During 2010, options to purchase 65 shares
of common stock under the 2000 Plan were exercised and options to
purchase 9 shares of common stock were canceled.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
2006 Stock Incentive Plan&lt;/font&gt;. On May 1, 2006, the
Company&amp;#x2019;s board of directors adopted, and on July 21, 2006
the Company&amp;#x2019;s stockholders approved, the 2006 Stock Incentive
Plan (the &amp;#x201C;2006 Plan&amp;#x201D;). A total of 65,359 shares of
common stock are reserved for issuance under the 2006 Plan for
grants of incentive or nonqualified stock options, rights to
purchase restricted and unrestricted shares of common stock, stock
appreciation rights and performance share grants. A committee of
the board of directors determines exercise prices, vesting periods
and any performance requirements on the date of grant, subject to
the provisions of the 2006 Plan. Options are granted at or above
the fair market value of the common stock at the grant date and
expire on the tenth anniversary of the grant date. Vesting periods
are generally two to three years. In the year ended December 31,
2009, stock options for the purchase of 12,679 shares of common
stock were granted under the 2006 Plan. During the year ended
December 31, 2010, options to purchase 1,438 shares of common stock
were exercised and options to purchase 3,921 shares of common stock
were canceled. As of December 31, 2010 and December 31, 2009,
25,555 and 21,503 shares remain available for grant under the 2006
Plan. Options granted pursuant to the 2006 Plan generally will
become fully vested upon a termination event occurring within one
year following a change in control, as defined. A termination event
is defined as either termination of employment or services other
than for cause or constructive termination of employees or
consultants resulting from a significant reduction in either the
nature or scope of duties and responsibilities, a reduction in
compensation or a required relocation.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Other Stock Option Activity.&lt;/font&gt; &amp;#xA0; During 2005 and 2004,
the Company issued options to purchase a total of 17,345 shares of
common stock to employees, directors and consultants outside of any
formalized plan.&amp;#xA0; These options are exercisable within a
ten-year period from the date of grant, and vest at various
intervals with all options being fully vested within two to three
years of the grant date.&amp;#xA0; The options are not transferable
except by will or domestic relations order.&amp;#xA0; The option price
per share is not less than the fair market value of the shares on
the date of the grant.&amp;#xA0; During the year ended December 31,
2010, options to purchase 4,488 shares of common stock were
exercised and options to purchase 980 shares of common stock were
canceled.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Accounting for Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company accounts for employee stock-based compensation in
accordance with the guidance of FASB ASC Topic 718, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Compensation &amp;#x2013; Stock
Compensation&lt;/font&gt; which requires all share-based payments to
employees, including grants of employee stock options, to be
recognized in the financial statements based on their fair
values.&amp;#xA0; The Company accounts for non-employee stock-based
compensation in accordance with the guidance of FASB ASC Topic 505,
&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Equity&lt;/font&gt;
which requires that companies recognize compensation expense based
on the estimated fair value of options granted to non-employees
over their vesting period, which is generally the period during
which services are rendered by such non-employees.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
following table summarizes amounts charged to expense for
stock-based compensation related to employee and director stock
option grants and stock-based compensation recorded in connection
with stock options and restricted stock awards granted to
non-employee consultants:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="MARGIN-LEFT: 45pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="28%" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Year&amp;#xA0;Ended&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;December&amp;#xA0;31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Employee
and director stock option grants:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%" colspan="2" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Research
and development&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;230,101&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;148,030&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;General
and administrative&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
356,220&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
289,036&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
586,321&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
437,066&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Non-employee
consultant stock option grants and restricted stock
awards:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Research
and development&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(220,969&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;328,614&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;General
and administrative&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
(28,054&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
98,657&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
(249,023&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
427,271&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="70%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="12%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
stock-based compensation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
337,298&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
864,337&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
December 31, 2009, the expiration of options held by a former
employee was extended until January 31, 2010 and incremental
stock-based compensation expense for non-employees of $15,000 was
recorded in connection with the one-month extension.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
January 2009, the Company modified the terms of options to purchase
261 shares of common stock held by two employees to vest all
unvested options and to extend the expiration dates of the
options.&amp;#xA0; The modification was made in connection with the
termination of the two employees to reduce costs.&amp;#xA0; During the
year ended December 31, 2009, incremental stock-based compensation
expense of $8,000 was recorded in connection with the modification
of the option terms.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Determining Fair Value&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Valuation and amortization method&lt;/font&gt;. The fair value of each
stock award is estimated on the grant date using the Black-Scholes
option-pricing model.&amp;#xA0; The estimated fair value of employee
stock options is amortized to expense using the straight-line
method over the vesting period.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Volatility.&lt;/font&gt; The Company estimates volatility based on an
average of (1) the Company&amp;#x2019;s historical volatility since its
common stock has been publicly traded and (2) review of volatility
estimates of publicly held drug development companies with similar
market capitalizations.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Risk-free interest rate&lt;/font&gt;. The risk-free interest rate is
based on the U.S. Treasury yield curve in effect at the time of
grant commensurate with the expected term assumption.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Expected term&lt;/font&gt;. The expected term of stock options granted is
based on the Company&amp;#x2019;s estimate of when options will be
exercised in the future as there have been limited stock option
exercises to date.&amp;#xA0; The expected term is generally applied to
one group as a whole as the Company does not expect substantially
different exercise or post-vesting termination behavior within its
population of option holders.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Forfeitures.&lt;/font&gt; &amp;#xA0; The Company records stock-based
compensation expense only for those awards that are expected to
vest.&amp;#xA0; FASB ASC Topic 718 requires forfeitures to be estimated
at the time of grant and revised, if necessary, in subsequent
periods if actual forfeitures differ from those estimates.&amp;#xA0;
The term &amp;#x201C;forfeitures&amp;#x201D; is distinct from
&amp;#x201C;cancellations&amp;#x201D; or &amp;#x201C;expirations&amp;#x201D; and
represents only the unvested portion of the surrendered
option.&amp;#xA0; The Company has applied an annual forfeiture rate of
0% to all unvested options as of December 31, 2010 as the Company
has experienced very few forfeitures to date and believes that
there is insufficient history to develop an accurate estimate of
future forfeitures.&amp;#xA0;&amp;#xA0;This analysis will be re-evaluated
semi-annually and the forfeiture rate will be adjusted as
necessary.&amp;#xA0;&amp;#xA0;Ultimately, the actual expense recognized
over the vesting period will be for only those shares that
vest.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
following table summarizes weighted average values and assumptions
used for options granted to employees, directors and consultants in
the periods indicated:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="MARGIN-LEFT: 18pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Year&amp;#xA0;Ended&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;December&amp;#xA0;31,&amp;#xA0;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2009&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Volatility&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;90&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Weighted-average
volatility&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;90&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Risk-free
interest rate&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.12&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Expected
life (years)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;5&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Dividend&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;%&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Weighted-average
exercise price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0.75&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Weighted-average
grant-date fair value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0.53&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;There
were no stock option grants during the year ended December 31,
2010.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Stock Option Activity&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;A
summary of stock option activity under the 2000 Plan, the 2006 Plan
and outside of any formalized plan is as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; MARGIN-LEFT: 18pt"&gt;
&lt;table style="TEXT-ALIGN: left; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%"&gt;
&lt;tr style="TEXT-ALIGN: left"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Options&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Outstanding&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Weighted&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Average&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Exercise&amp;#xA0;Price&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Weighted&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Average&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Remaining&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Contracted&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Term&amp;#xA0;in&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Years&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Aggregate&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Intrinsic&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Outstanding
at January 1, 2009&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;47,580&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;91.80&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;7.9&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;989,718&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Options
granted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
12,679&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;114.75&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="9%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="9%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Outstanding
at December 31, 2009&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;60,259&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;96.39&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;7.5&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;17,650,255&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Options
exercised&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(5,991&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;26.01&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;663,600&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Options
canceled&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
(5,042&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;139.23&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="9%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Outstanding
at December 31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
49,226&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
100.98&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
6.9&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
24,842&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Exercisable
at December 31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
39,270&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
100.98&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
6.4&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
$&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
24,842&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
aggregate intrinsic value of options outstanding is calculated
based on the positive difference between the closing market price
of the Company&amp;#x2019;s common stock at the end of the respective
period and the exercise price of the underlying
options.&amp;#xA0;&amp;#xA0;During the year ended December 31, 2010, the
total intrinsic value of options exercised was $663,000 and the
total amount of cash received from exercise of these options was
$158,600.&amp;#xA0;&amp;#xA0;Shares of common stock issued upon the
exercise of options are from authorized but unissued
shares.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;As
of December 31, 2010, there was approximately $647,000 of total
unrecognized compensation cost related to unvested stock-based
compensation arrangements.&amp;#xA0;&amp;#xA0;Of this total amount, 70% and
30% are expected to be recognized during 2011 and 2012,
respectively.&amp;#xA0;&amp;#xA0;The Company expects 9,956 in unvested
options to vest in the future.&amp;#xA0;&amp;#xA0;The weighted-average
grant-date fair value of vested and unvested options outstanding at
December 31, 2010 was $62.73 and $68.85, respectively.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">52925</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">6970179</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">25772207</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD" decimals="0">1677945</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="iso4217_USD_per_shares" decimals="2">-2.53</us-gaap:EarningsPerShareBasicAndDiluted>
  <nvlt:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_2977_20101231_0" unitRef="shares" decimals="0">9513115</nvlt:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20031231_0" unitRef="iso4217_USD" decimals="0">-295790</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20031231_0_452905x444581_455296x452748" unitRef="shares" decimals="INF">37958</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20031231_0_452905x444581_455296x479658" unitRef="iso4217_USD" decimals="0">2</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20031231_0_452905x444581_455296x479658" unitRef="shares" decimals="INF">203483</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20031231_0_452905x453698_455296x452748" unitRef="iso4217_USD" decimals="0">4937</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20031231_0_452905x453698_455296x479658" unitRef="iso4217_USD" decimals="0">80410</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20031231_0_452905x478726" unitRef="iso4217_USD" decimals="0">-295790</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20031231_0_455296x452748" unitRef="iso4217_USD" decimals="0">4937</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20031231_0_455296x479658" unitRef="iso4217_USD" decimals="0">80412</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20051231_0" unitRef="iso4217_USD" decimals="0">-481837</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20051231_0_452905x444581_455296x452748" unitRef="iso4217_USD" decimals="0">6</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20051231_0_452905x444581_455296x452748" unitRef="shares" decimals="INF">610664</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20051231_0_452905x453698_455296x452748" unitRef="iso4217_USD" decimals="0">835862</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20051231_0_452905x478726" unitRef="iso4217_USD" decimals="0">-481837</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20051231_0_455296x452748" unitRef="iso4217_USD" decimals="0">835868</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE638436--11S-1-0011_STD_365_20061231_0" unitRef="iso4217_USD" decimals="0">43994</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20061231_0" unitRef="iso4217_USD" decimals="0">-963440</us-gaap:NetIncomeLoss>
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="eol_PE638436--11S-1-0011_STD_365_20061231_0" unitRef="iso4217_USD" decimals="0">31667</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:StockRepurchasedDuringPeriodShares contextRef="eol_PE638436--11S-1-0011_STD_365_20061231_0_452905x444581" unitRef="shares" decimals="INF">43819</us-gaap:StockRepurchasedDuringPeriodShares>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20061231_0_452905x444581_455296x452748" unitRef="iso4217_USD" decimals="0">22</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20061231_0_452905x444581_455296x452748" unitRef="shares" decimals="INF">2202179</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE638436--11S-1-0011_STD_365_20061231_0_452905x453698" unitRef="iso4217_USD" decimals="0">43994</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockRepurchasedDuringPeriodValue contextRef="eol_PE638436--11S-1-0011_STD_365_20061231_0_452905x453698" unitRef="iso4217_USD" decimals="0">31667</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20061231_0_452905x453698_455296x452748" unitRef="iso4217_USD" decimals="0">7097050</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20061231_0_452905x478726" unitRef="iso4217_USD" decimals="0">-963440</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20061231_0_455296x452748" unitRef="iso4217_USD" decimals="0">7097072</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE638436--11S-1-0011_STD_365_20071231_0" unitRef="iso4217_USD" decimals="0">570392</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20071231_0" unitRef="iso4217_USD" decimals="0">-5090325</us-gaap:NetIncomeLoss>
  <nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE638436--11S-1-0011_STD_365_20071231_0" unitRef="iso4217_USD" decimals="0">250000</nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE638436--11S-1-0011_STD_365_20071231_0_452905x444581" unitRef="iso4217_USD" decimals="0">1</nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <nvlt:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE638436--11S-1-0011_STD_365_20071231_0_452905x444581" unitRef="shares" decimals="INF">75045</nvlt:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20071231_0_452905x444581_455296x452748" unitRef="iso4217_USD" decimals="0">1</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20071231_0_452905x444581_455296x452748" unitRef="shares" decimals="INF">60250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE638436--11S-1-0011_STD_365_20071231_0_452905x453698" unitRef="iso4217_USD" decimals="0">570392</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE638436--11S-1-0011_STD_365_20071231_0_452905x453698" unitRef="iso4217_USD" decimals="0">249999</nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20071231_0_452905x453698_455296x452748" unitRef="iso4217_USD" decimals="0">249999</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20071231_0_452905x478726" unitRef="iso4217_USD" decimals="0">-5090325</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_365_20071231_0_455296x452748" unitRef="iso4217_USD" decimals="0">250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">502199</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">-99461</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">-143347</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:CostsAndExpenses contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">6176285</us-gaap:CostsAndExpenses>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">619</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">-4775250</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">62789</us-gaap:IncreaseDecreaseInDeferredLiabilities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">502199</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">278131</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">-1607</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">177807</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">-6219873</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">-43588</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">4351983</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">576745</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="INF">-43588</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">143347</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">-6176285</us-gaap:OperatingIncomeLoss>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">-5196484</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">-23152</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestPaid contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">68436</us-gaap:InterestPaid>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">1824302</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD" decimals="0">-277887</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.49</us-gaap:EarningsPerShareBasicAndDiluted>
  <nvlt:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0" unitRef="shares" decimals="0">12820102</nvlt:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <us-gaap:StockIssued1 contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">1625760</us-gaap:StockIssued1>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="INF">839923</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="INF">427271</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-18000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">1013</us-gaap:InvestmentIncomeInterest>
  <us-gaap:CostsAndExpenses contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">10262495</us-gaap:CostsAndExpenses>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-10618338</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="INF">3296289</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">864337</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-1354695</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-22273306</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-12044145</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">8080242</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-12114371</us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">32354</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-26283626</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">1625760</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">18000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:SalesRevenueNet contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">33334</us-gaap:SalesRevenueNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-10229161</us-gaap:OperatingIncomeLoss>
  <us-gaap:RevenueFromGrants contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">62980</us-gaap:RevenueFromGrants>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">6233</us-gaap:OtherNonoperatingIncome>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="INF">437066</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">8938884</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">7507077</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-26862</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">5072</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-33333</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">2182253</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">18143415</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:DividendsPreferredStock contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">3296289</us-gaap:DividendsPreferredStock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD_per_shares" decimals="2">-80.57</us-gaap:EarningsPerShareBasicAndDiluted>
  <nvlt:ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">9204531</nvlt:ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants>
  <nvlt:ExchangeOfConvertiblePreferredStock contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">13904100</nvlt:ExchangeOfConvertiblePreferredStock>
  <nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">1000962</nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <nvlt:StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">2907208</nvlt:StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants>
  <nvlt:DeemedDividendsOnPreferredStock contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">714031</nvlt:DeemedDividendsOnPreferredStock>
  <nvlt:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="shares" decimals="0">326209</nvlt:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <nvlt:SupplementalIssuanceOfStockAndWarrants contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">4835727</nvlt:SupplementalIssuanceOfStockAndWarrants>
  <nvlt:ReclassificationOfWarrantsToDerivativeLiability contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-998945</nvlt:ReclassificationOfWarrantsToDerivativeLiability>
  <nvlt:AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">839923</nvlt:AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants>
  <nvlt:AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-125892</nvlt:AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x440920" unitRef="iso4217_USD" decimals="0">-22273306</us-gaap:NetIncomeLoss>
  <nvlt:ReclassificationOfWarrantsToDerivativeLiability contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x440920" unitRef="iso4217_USD" decimals="0">5894371</nvlt:ReclassificationOfWarrantsToDerivativeLiability>
  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x444581" unitRef="shares" decimals="0">13623</us-gaap:StockIssuedDuringPeriodSharesOther>
  <nvlt:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x444581" unitRef="shares" decimals="INF">3162</nvlt:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <nvlt:IssuanceOfCommonStockAndWarrantsValue contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x444581_455296x452841" unitRef="iso4217_USD" decimals="0">1</nvlt:IssuanceOfCommonStockAndWarrantsValue>
  <nvlt:IssuanceOfCommonStockAndWarrantsShares contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x444581_455296x452841" unitRef="shares" decimals="INF">89126</nvlt:IssuanceOfCommonStockAndWarrantsShares>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x444581_455296x486823" unitRef="shares" decimals="INF">10058</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x444581_455296x486824" unitRef="iso4217_USD" decimals="INF">1</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x444581_455296x486824" unitRef="shares" decimals="INF">51889</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x449416_455296x486823" unitRef="shares" decimals="INF">-68</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="INF">839923</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="INF">427271</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="0">1625760</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="INF">437066</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:DividendsPreferredStock contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="0">3296289</us-gaap:DividendsPreferredStock>
  <nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="0">1000962</nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <nvlt:StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="0">2907208</nvlt:StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants>
  <nvlt:ReclassificationOfWarrantsToDerivativeLiability contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="0">-6893316</nvlt:ReclassificationOfWarrantsToDerivativeLiability>
  <nvlt:AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="0">839923</nvlt:AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants>
  <nvlt:AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="0">-125892</nvlt:AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue>
  <nvlt:IssuanceOfCommonStockAndWarrantsValue contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698_455296x452841" unitRef="iso4217_USD" decimals="0">8938883</nvlt:IssuanceOfCommonStockAndWarrantsValue>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698_455296x486823" unitRef="iso4217_USD" decimals="0">184246</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698_455296x486824" unitRef="iso4217_USD" decimals="INF">3514313</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:PreferredStockDividendsShares contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x469151" unitRef="shares" decimals="0">31.942875</us-gaap:PreferredStockDividendsShares>
  <us-gaap:StockIssuedDuringPeriodValueStockDividend contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x469151" unitRef="iso4217_USD" decimals="0">1597144</us-gaap:StockIssuedDuringPeriodValueStockDividend>
  <nvlt:StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x469151" unitRef="iso4217_USD" decimals="0">6297323</nvlt:StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants>
  <nvlt:StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x469151" unitRef="shares" decimals="0">200</nvlt:StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants>
  <nvlt:AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x469151" unitRef="iso4217_USD" decimals="0">125892</nvlt:AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x469151_455296x486824" unitRef="iso4217_USD" decimals="INF">-32130560</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x469151_455296x486824" unitRef="shares" decimals="0">-97.18209375</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <nvlt:DividendsPayableOnConvertiblePreferredStock contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_455296x449416" unitRef="iso4217_USD" decimals="0">184246</nvlt:DividendsPayableOnConvertiblePreferredStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_455296x452484" unitRef="iso4217_USD" decimals="0">795469</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <nvlt:DividendsPayableOnConvertiblePreferredStock contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_455296x452484" unitRef="iso4217_USD" decimals="0">1898402</nvlt:DividendsPayableOnConvertiblePreferredStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_455296x452841" unitRef="iso4217_USD" decimals="0">61116</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <nvlt:IssuanceOfCommonStockAndWarrantsValue contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_455296x452841" unitRef="iso4217_USD" decimals="0">8938884</nvlt:IssuanceOfCommonStockAndWarrantsValue>
  <nvlt:FairValueOfDerivativeInstrument contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_455296x453171" unitRef="iso4217_USD" decimals="0">998945</nvlt:FairValueOfDerivativeInstrument>
  <nvlt:FairValueOfDerivativeInstrument contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_455296x471365" unitRef="iso4217_USD" decimals="0">1000962</nvlt:FairValueOfDerivativeInstrument>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_455296x486823" unitRef="iso4217_USD" decimals="0">184246</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_455296x486824" unitRef="iso4217_USD" decimals="INF">3514314</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452905x453698" unitRef="iso4217_USD" decimals="0">502199</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20091231_0_452905x478726" unitRef="iso4217_USD" decimals="0">-6219873</us-gaap:NetIncomeLoss>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">353340</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">99461</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-1652</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-426</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:CostsAndExpenses contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">4193681</us-gaap:CostsAndExpenses>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">1944</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-3382447</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">9973</us-gaap:IncreaseDecreaseInDeferredLiabilities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">353340</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-322707</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-213792</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">190789</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">19671</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-4560263</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-366582</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">2984207</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">213792</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">580114</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="INF">-566156</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">1652</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-4193681</us-gaap:OperatingIncomeLoss>
  <us-gaap:RevenueFromGrants contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">200000</us-gaap:RevenueFromGrants>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">2720985</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-306386</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">-18584</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestPaid contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">55454</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">305049</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">52925</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">1156549</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">3077713</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD" decimals="0">450000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.36</us-gaap:EarningsPerShareBasicAndDiluted>
  <nvlt:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0" unitRef="shares" decimals="0">12820102</nvlt:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">158567</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="INF">819000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="INF">-249023</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">2421</us-gaap:InvestmentIncomeInterest>
  <us-gaap:CostsAndExpenses contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">5484016</us-gaap:CostsAndExpenses>
  <us-gaap:RegistrationPaymentArrangementGainsAndLosses contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-819000</us-gaap:RegistrationPaymentArrangementGainsAndLosses>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-7804283</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="INF">2207827</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">337298</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-2733494</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">158567</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">2095392</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">7546074</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">2997984</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">586050</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">8118174</us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">35342</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-12653636</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:SalesRevenueNet contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">33334</us-gaap:SalesRevenueNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-5450682</us-gaap:OperatingIncomeLoss>
  <us-gaap:RevenueFromGrants contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">244479</us-gaap:RevenueFromGrants>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="INF">586321</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">1249138</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-6396578</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-39397</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-245711</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">-33333</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">2486032</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">1407705</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:DividendsPreferredStock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">2207827</us-gaap:DividendsPreferredStock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD_per_shares" decimals="2">-15.36</us-gaap:EarningsPerShareBasicAndDiluted>
  <nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">2584397</nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <nvlt:DeemedDividendsOnPreferredStock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">12541201</nvlt:DeemedDividendsOnPreferredStock>
  <nvlt:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="shares" decimals="0">823933</nvlt:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <nvlt:SupplementalIssuanceOfStockAndWarrants contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="0">504227</nvlt:SupplementalIssuanceOfStockAndWarrants>
  <nvlt:AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="INF">586050</nvlt:AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders>
  <nvlt:AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="INF">11955151</nvlt:AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred>
  <nvlt:AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814" unitRef="iso4217_USD" decimals="INF">11955151</nvlt:AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x440920" unitRef="iso4217_USD" decimals="0">2095392</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x444581" unitRef="shares" decimals="INF">5991</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x444581" unitRef="iso4217_USD" decimals="0">1</nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <nvlt:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x444581" unitRef="shares" decimals="INF">53478</nvlt:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x444581_455296x444874" unitRef="iso4217_USD" decimals="INF">22</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x444581_455296x444874" unitRef="shares" decimals="INF">2228338</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <nvlt:IssuanceOfCommonStockAndWarrantsValue contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x444581_455296x479440" unitRef="iso4217_USD" decimals="0">1</nvlt:IssuanceOfCommonStockAndWarrantsValue>
  <nvlt:IssuanceOfCommonStockAndWarrantsShares contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x444581_455296x479440" unitRef="shares" decimals="INF">140056</nvlt:IssuanceOfCommonStockAndWarrantsShares>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x444581_455296x486824" unitRef="iso4217_USD" decimals="INF">1</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x444581_455296x486824" unitRef="shares" decimals="INF">76770</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x449416_455296x444874" unitRef="shares" decimals="INF">-204</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="INF">-249023</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="0">158567</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="0">586050</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="INF">586321</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:DividendsPreferredStock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="0">2207827</us-gaap:DividendsPreferredStock>
  <nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="0">2584396</nvlt:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <nvlt:AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="INF">586050</nvlt:AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders>
  <nvlt:AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="INF">11955151</nvlt:AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred>
  <nvlt:AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x453698" unitRef="iso4217_USD" decimals="INF">11955151</nvlt:AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x453698_455296x444874" unitRef="iso4217_USD" decimals="6">19064869.000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <nvlt:IssuanceOfCommonStockAndWarrantsValue contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x453698_455296x479440" unitRef="iso4217_USD" decimals="0">744910</nvlt:IssuanceOfCommonStockAndWarrantsValue>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x453698_455296x486824" unitRef="iso4217_USD" decimals="INF">5324517</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x469151_455296x444874" unitRef="iso4217_USD" decimals="6">-13770026.000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x469151_455296x444874" unitRef="shares" decimals="0">-408.264045</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x469151_455296x486824" unitRef="iso4217_USD" decimals="INF">-4689593</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x469151_455296x486824" unitRef="shares" decimals="0">-139.99673625</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_455296x444874" unitRef="iso4217_USD" decimals="6">19064891.000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <nvlt:DividendsPayableOnConvertiblePreferredStock contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_455296x452484" unitRef="iso4217_USD" decimals="0">5110790</nvlt:DividendsPayableOnConvertiblePreferredStock>
  <nvlt:FairValueOfDerivativeInstrument contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_455296x471365" unitRef="iso4217_USD" decimals="0">2584397</nvlt:FairValueOfDerivativeInstrument>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_455296x479440" unitRef="iso4217_USD" decimals="0">250862</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <nvlt:IssuanceOfCommonStockAndWarrantsValue contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_455296x479440" unitRef="iso4217_USD" decimals="0">744911</nvlt:IssuanceOfCommonStockAndWarrantsValue>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_455296x486824" unitRef="iso4217_USD" decimals="INF">5324518</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="0">353340</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="0">213792</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_365_20101231_0_452905x478726" unitRef="iso4217_USD" decimals="0">-4560263</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_366_20041231_0" unitRef="iso4217_USD" decimals="0">-342761</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_366_20041231_0_452905x478726" unitRef="iso4217_USD" decimals="0">-342761</us-gaap:NetIncomeLoss>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE638436--11S-1-0011_STD_366_20081231_0" unitRef="iso4217_USD" decimals="0">477488</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_366_20081231_0" unitRef="iso4217_USD" decimals="0">-6090715</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_366_20081231_0_452905x444581_455296x452748" unitRef="iso4217_USD" decimals="0">31</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE638436--11S-1-0011_STD_366_20081231_0_452905x444581_455296x452748" unitRef="shares" decimals="INF">3132999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE638436--11S-1-0011_STD_366_20081231_0_452905x453698" unitRef="iso4217_USD" decimals="0">477488</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_366_20081231_0_452905x453698_455296x452748" unitRef="iso4217_USD" decimals="0">12931531</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_366_20081231_0_452905x478726" unitRef="iso4217_USD" decimals="0">-6090715</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_366_20081231_0_455296x452748" unitRef="iso4217_USD" decimals="0">12931562</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_55_20021231_0_452905x444581_455296x452748" unitRef="iso4217_USD" decimals="0">64</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE638436--11S-1-0011_STD_55_20021231_0_452905x444581_455296x452748" unitRef="shares" decimals="INF">6440123</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_55_20021231_0_452905x444581_455296x455803" unitRef="iso4217_USD" decimals="0">1</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE638436--11S-1-0011_STD_55_20021231_0_452905x444581_455296x455803" unitRef="shares" decimals="INF">101220</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_55_20021231_0_452905x453698_455296x452748" unitRef="iso4217_USD" decimals="0">590205</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_55_20021231_0_452905x453698_455296x455803" unitRef="iso4217_USD" decimals="0">9107</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_55_20021231_0_455296x452748" unitRef="iso4217_USD" decimals="0">590269</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE638436--11S-1-0011_STD_55_20021231_0_455296x455803" unitRef="iso4217_USD" decimals="0">9108</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">157400</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:CostsAndExpenses contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">2555652</us-gaap:CostsAndExpenses>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-3315197</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="INF">656635</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="INF">4689593</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-97479</us-gaap:ShareBasedCompensation>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD_per_shares" decimals="2">3.41</us-gaap:EarningsPerShareDiluted>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-403760</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">5350122</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">7897441</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">1910889</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">7897441</us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">27290</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">4693487</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD_per_shares" decimals="2">8.99</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueNet contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">8333</us-gaap:SalesRevenueNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-2547319</us-gaap:OperatingIncomeLoss>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-3157797</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="shares" decimals="0">522350</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">47574</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-238022</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-8333</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">644763</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="shares" decimals="0">881861</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">157400</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <nvlt:ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814" unitRef="iso4217_USD" decimals="0">2584397</nvlt:ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital>
  <nvlt:DividendsPayableOnConvertiblePreferredStock contextRef="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814_455296x452484" unitRef="iso4217_USD" decimals="0">634925</nvlt:DividendsPayableOnConvertiblePreferredStock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
4.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
STOCKHOLDERS&amp;#x2019; EQUITY&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;
Common Stock Warrants&lt;/font&gt; &amp;#xA0;&amp;#xA0;&amp;#x2014; The following
table summarizes information with regard to outstanding warrants as
of March 31, 2011, issued in connection with equity and debt
financings since 2005.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="96%"&gt;
&lt;tr&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="58%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Offering&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Number&amp;#xA0;of&amp;#xA0;Shares&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Issuable&amp;#xA0;Upon&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Exercise&amp;#xA0;of&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Outstanding&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Warrants&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Exercise&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Price&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="18%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Expiration&amp;#xA0;Date&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="58%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="18%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="58%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Series
B Preferred Stock &amp;#x2013; placement agents&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="top" width="9%"&gt;
&lt;div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;5,392&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="top" width="1%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="top" width="9%"&gt;
&lt;div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;191.25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="18%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;May
2, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="58%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Series
C Exchange&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="top" width="9%"&gt;
&lt;div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8,169&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="top" width="1%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="top" width="9%"&gt;
&lt;div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;191.25&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="18%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;May
2, 2012&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="58%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Series
E Preferred Stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="top" width="9%"&gt;
&lt;div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;60,331&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="top" width="1%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="top" width="9%"&gt;
&lt;div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;99.45&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="18%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;December
31, 2015&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="58%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;August
2009 Private Placement&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="top" width="9%"&gt;
&lt;div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;31,194&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="top" width="1%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="top" width="9%"&gt;
&lt;div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;100.98&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="18%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;December
31, 2015&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="58%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;July
2010 Direct Offering (1)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="top" width="9%"&gt;
&lt;div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;105,042&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="top" width="1%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="top" width="9%"&gt;
&lt;div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;10.71&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="18%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;July
27, 2015&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="58%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Preferred
Incentive Warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="top" width="9%"&gt;
&lt;div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;105,042&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="top" width="1%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="top" width="9%"&gt;
&lt;div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;16.065&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="18%" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;July
27, 2015&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="58%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="18%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="58%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="top" width="9%"&gt;
&lt;div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
315,170&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="18%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(1)&amp;#xA0;&amp;#xA0;The
exercise price of these warrants was adjusted to $0.75 per share in
connection with the private placement completed on April 8,
2011.&amp;#xA0;&amp;#xA0;See Note 10.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
March 7, 2011, warrants to purchase 33,569 shares of common stock
at $234.09 per share expired unexercised.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
May 3, 2011, 18,153 shares of common stock were issued in
connection with the cashless exercise of warrants to purchase
27,311 shares of common stock at $0.75 per share.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:CommitmentsDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0">&lt;div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
9.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
COMMITMENTS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Retention Agreements&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
Company has entered into retention agreements with each of its
three vice presidents.&amp;#xA0;&amp;#xA0;The agreements provide for the
lump-sum payment of six months&amp;#x2019; base salary and benefits to
each such officer following a termination without cause or a
resignation with good reason occurring on or before November 14,
2011.&amp;#xA0;&amp;#xA0;Certain of the agreements provide that if the
executives were employed with the Company as of October 1, 2010,
they would receive a payment of two months&amp;#x2019; base salary as a
retention bonus on that date. The retention bonus was paid in
October 2010 and will be deducted from the severance amounts that
may become payable upon a subsequent involuntary
termination.&amp;#xA0;&amp;#xA0;The total remaining amount that may become
payable to the Company&amp;#x2019;s Named Executive Officers pursuant to
the retention agreements is approximately $86,000 to Christopher
Pazoles.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;During
the three months ended March 31, 2011, pursuant to retention
agreements, the Company paid a total of approximately $218,000 in
severance payments to employees terminated during that period,
including $83,000 to Elias Nyberg, the Company&amp;#x2019;s former vice
president of regulatory, quality and compliance.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
6.&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
NET INCOME (LOSS) PER SHARE&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Basic
net income (loss) per share is computed by dividing net income
(loss) attributable to common stockholders by the weighted average
number of shares of common stock outstanding during the period.
Diluted net income per share is computed by dividing net income
attributable to common stockholders by the sum of weighted average
number of shares of common stock and the dilutive potential common
stock equivalents then outstanding. Potential common stock
equivalents consist of stock options, warrants and convertible
preferred stock and accumulated dividends.&amp;#xA0;&amp;#xA0;Since the
Company has a net loss for the three months ended March 31, 2011,
the inclusion of common stock equivalents in the computation would
be antidilutive. Accordingly, basic and diluted net loss per share
are the same for the three months ended March 31,
20011.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
following table sets forth the shares and net income used in the
diluted earnings per share computation for the three months ended
March 31, 2010:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Net
income available to common stockholders used in basic earnings per
share calculation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4,693,487&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Derivative
gain recorded on dilutive warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(2,340,515&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Dividends
on convertible preferred stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
656,635&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Net
income available to common stockholders used in diluted earnings
per share calculation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
3,009,607&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Weighted
average shares of common stock used in the computation of basic
earnings per share&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;522,350&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Dilutive
effect of stock options&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;26,430&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Dilutive
effect of warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;79,646&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Dilutive
effect of convertible preferred stock&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
253,435&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="88%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Shares
used in computation of diluted earnings per share&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
881,861&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
following potentially dilutive securities have been excluded from
the computation of diluted net income (loss) per share since their
inclusion would be antidilutive:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;March&amp;#xA0;31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="76%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Stock
options&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
49,227&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
3,970&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
315,170&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
43,349&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
3.&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
COLLABORATION AGREEMENTS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;In
December 2007 the Company entered into a Collaboration Agreement
with Lee&amp;#x2019;s Pharmaceutical (HK) Ltd. (&amp;#x201C;Lee&amp;#x2019;s
Pharm&amp;#x201D;). Pursuant to this agreement, Lee&amp;#x2019;s Pharm
obtained an exclusive license to develop, manufacture and
commercialize NOV-002 and NOV-205 in China, Hong Kong, Taiwan and
Macau (the &amp;#x201C;Chinese Territory&amp;#x201D;). The Company has
suspended further development of NOV-205; however, this suspension
may not impact the development strategy of Lee&amp;#x2019;s
Pharm.&amp;#xA0;&amp;#xA0;Under the terms of the agreement the Company
received a license fee of $500,000 in March 2008 and is entitled to
receive up to $1,700,000 in future milestone payments upon the
completion of development and marketing milestones by Lee&amp;#x2019;s
Pharm. This initial $500,000 payment received is being amortized
over the estimated term of this agreement, 15 years. Accordingly,
$8,333 of license revenue was recognized in each of the three-month
periods ended March 31, 2011 and 2010.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
Lee&amp;#x2019;s Pharm agreement provides that the Company receive
royalty payments of 20-25% of net sales of NOV-002 in the Chinese
Territory and receive royalty payments of 12-15% of net sales of
NOV-205 in the Chinese Territory. Lee&amp;#x2019;s Pharm is obligated to
reimburse the Company for the manufacturing cost of pharmaceutical
products provided to Lee&amp;#x2019;s Pharm in connection with the
agreement. Lee&amp;#x2019;s Pharm has committed to spend a minimum
amount on development in the first four years of the agreement. The
agreement expires upon the expiration of the last patent covering
any of the licensed products, or twelve years from the date of the
first commercial sale in China, whichever occurs
later.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
February 11, 2009, Novelos entered into a collaboration agreement
(the &amp;#x201C;Collaboration Agreement&amp;#x201D;) with Mundipharma
International Corporation Limited (&amp;#x201C;Mundipharma&amp;#x201D;) to
develop, manufacture and commercialize, on an exclusive basis,
Licensed Products (as defined in the Collaboration Agreement),
which includes the Company&amp;#x2019;s compound, NOV-002, in Europe
(other than the Russian Territory), Asia (other than the Chinese
Territory) and Australia (collectively referred to as the
&amp;#x201C;Mundipharma Territory&amp;#x201D;).&amp;#xA0; Mundipharma is an
independent associated company of Purdue Pharma, L.P.
(&amp;#x201C;Purdue&amp;#x201D;).&amp;#xA0;&amp;#xA0;The Collaboration Agreement
provides for Mundipharma to pay the Company royalties and fixed
milestone payments based on sales and commercial launches in the
licensed territories.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;For
countries in which patents are held, the Collaboration Agreement
expires on a country-by-country basis within the Mundipharma
Territory on the earlier of (1) expiration of the last applicable
Novelos patent within the country or (2) the determination that any
patents within the country are invalid, obvious or otherwise
unenforceable.&amp;#xA0;&amp;#xA0;For countries in which no patents are
held, the Collaboration Agreement expires the earlier of 15 years
from its effective date or upon generic product competition in the
country resulting in a 20% drop in Mundipharma&amp;#x2019;s market
share.&amp;#xA0;&amp;#xA0;Novelos may terminate the Collaboration Agreement
upon breach or default by Mundipharma.&amp;#xA0; Mundipharma may
terminate the Collaboration Agreement upon breach or default,
filing of voluntary or involuntary bankruptcy by Novelos, the
termination of certain agreements with companies associated with
the originators of the licensed technology, or 30-day notice for no
reason.&amp;#xA0;&amp;#xA0;If any regulatory approval within the
Mundipharma Territory is suspended as a result of issues related to
the safety of the Licensed Products, then Mundipharma&amp;#x2019;s
obligations under the Collaboration Agreement will be suspended
until the regulatory approval is reinstated.&amp;#xA0;&amp;#xA0;If that
reinstatement does not occur within 12 months of the suspension,
then Mundipharma may terminate the Collaboration
Agreement.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Concurrently
with the execution of the Collaboration Agreement, Novelos
completed a private placement of Series E preferred stock and
common stock purchase warrants to Purdue.&lt;/font&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
Company expects that the negative results of its Phase 3 Trial will
adversely affect development and commercialization of NOV-002 under
the collaboration agreements with Lee&amp;#x2019;s Pharm and
Mundipharma.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0">&lt;div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
10.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
SUBSEQUENT EVENTS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Merger Agreement&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
April 8, 2011, the Company entered into an Agreement and Plan of
Merger (the &amp;#x201C;Merger Agreement&amp;#x201D;) with Cellectar, Inc.
(&amp;#x201C;Cellectar&amp;#x201D;) and Cell Acquisition Corp. (the
&amp;#x201C;Merger Subsidiary&amp;#x201D;), a wholly-owned subsidiary of
Novelos, pursuant to which Cellectar was merged into the Merger
Subsidiary (the &amp;#x201C;Acquisition&amp;#x201D;).&amp;#xA0;&amp;#xA0;As a result
of the Acquisition, the Merger Subsidiary, which has been renamed
Cellectar, Inc., owns all assets of and operates the business
previously owned and operated by Cellectar. Prior to the
Acquisition, Cellectar was in the business of developing drugs for
the treatment and diagnosis of cancer.&amp;#xA0;&amp;#xA0;The Company will
continue to develop Cellectar&amp;#x2019;s compounds following the
Acquisition.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;As
consideration for the Acquisition, the former stockholders of
Cellectar received aggregate consideration consisting of a number
of shares of Novelos common stock constituting, after giving effect
to the Acquisition but before giving effect to the concurrent
private placement of the Company&amp;#x2019;s securities described
below, approximately 85% of the outstanding shares of Novelos
common stock.&amp;#xA0;&amp;#xA0;Prior to the Acquisition, the Company
amended and restated its certificate of incorporation and in
connection therewith, among other things, effected a 1-for-153
reverse split of its common stock (the &amp;#x201C;Reverse
Split&amp;#x201D;).&amp;#xA0;&amp;#xA0;Immediately following the effectiveness
of the Reverse Split, there were 2,959,871 shares of common stock
outstanding, and the Company issued 17,001,596 shares of its common
stock to the former stockholders of Cellectar upon the
effectiveness of the Acquisition.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Rodman
&amp;amp; Renshaw, LLC (&amp;#x201C;Rodman&amp;#x201D;), financial advisor to
Novelos in connection with the Acquisition, received a cash fee of
$250,000 upon the completion of the Acquisition in consideration
for their services.&amp;#xA0;&amp;#xA0;XMS Capital Partners, the financial
advisor to Cellectar in connection with the Acquisition, received a
cash fee of $200,000 upon the completion of the Acquisition in
consideration for their services.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Accounting
principles generally accepted in the United States require that a
company whose security holders retain the majority voting interest
in the combined business be treated as the acquirer for financial
reporting purposes.&amp;#xA0; Accordingly, the Acquisition will be
accounted for as a reverse acquisition whereby Cellectar, Inc. will
be treated as the accounting acquirer.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Securities Purchase Agreement&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Concurrently
with the execution of the Merger Agreement, the Company entered
into a Securities Purchase Agreement with certain accredited
investors under which the Company sold an aggregate of 6,846,537
units, each unit consisting of one share of its common stock and a
warrant to purchase one share of its common stock, at a price of
$0.75 per unit, for gross proceeds of approximately
$5,135,000.&amp;#xA0;&amp;#xA0;The warrants have an exercise price of $0.75
and expire on March 31, 2016.&amp;#xA0;&amp;#xA0;The warrant exercise price
and/or the common stock issuable pursuant to such warrant will be
subject to adjustment for stock dividends, stock splits or similar
capital reorganizations so that the rights of the warrant holders
after such event will be equivalent to the rights of warrant
holders prior to such event.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
Securities Purchase Agreement includes a requirement that the
Company file with the SEC no later than October 5, 2011, a
registration statement covering the resale of the shares of common
stock, and the shares of common stock underlying the warrants,
issued pursuant to the Securities Purchase
Agreement.&amp;#xA0;&amp;#xA0;The Company is also required to use
commercially reasonable efforts to have the registration statement
declared effective by December 4, 2011, and to keep the
registration statement continuously effective under the Securities
Act of 1933, as amended (the &amp;#x201C;Securities Act&amp;#x201D;), until
the earlier of the date when all the registrable securities covered
by the registration statement have been sold or the second
anniversary of the closing.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;In
the event the Company fails to file the registration statement
within the timeframe specified by the Securities Purchase
Agreement, or if it fails to obtain effectiveness of this
registration on or prior to the December 4, 2011 (if there is no
review by the SEC) or by January 3, 2012 (if there is review by the
SEC) with respect to the maximum number of shares permitted to be
registered by the SEC, the Company will be required to pay to the
purchasers liquidated damages equal to 1.5% per month (pro-rated on
a daily basis for any period of less than a full month) of the
aggregate purchase price of the units purchased until the
registration statement is filed or declared effective, as
applicable.&amp;#xA0;&amp;#xA0;The Company will be allowed to suspend the
use of the registration statement for not more than 30 consecutive
days, on not more than two occasions, in any 12 month
period.&amp;#xA0;&amp;#xA0;The Company has also granted piggy-back
registration rights with respect to any shares of common stock that
it is required to exclude from the registration statement as a
condition of its effectiveness, and has also agreed to file further
registration statements with respect to any such shares six months
after the effective date of the initial registration
statement.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
Company paid to Rodman, the placement agent for the financing, a
cash fee equal to $200,000 and warrants to purchase 192,931 shares
of its common stock in consideration for their advisory services
with respect to the financing pursuant to the placement agency
agreement between Rodman and the Company.&amp;#xA0;&amp;#xA0;Rodman is
entitled to registration rights with respect to the shares of
common stock issuable upon exercise of these
warrants.&amp;#xA0;&amp;#xA0;The warrants have the same terms as those
issued to the investors in the private placement.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;As
a result of the financing, warrants to purchase 105,042 shares of
common stock at $10.71 per share, giving effect to the Reverse
Split, became exercisable for $0.75 per share according to their
terms. On May 3, 2011, 18,153 shares of common stock were issued in
connection with the cashless exercise 27,311 of these
warrants.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Changes in Directors and Executive Officers&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Effective
April 8, 2011, prior to the completion of the Acquisition, Michael
J. Doyle, Sim Fass and David B. McWilliams resigned from the
Company&amp;#x2019;s board of directors and their respective committee
appointments.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Effective
April 8, 2011, as a condition to the completion of the Acquisition,
Jamey P. Weichert, Thomas Rockwell Mackie, John Neis, John E.
Niederhuber and Michael F. Tweedle were appointed to the
Company&amp;#x2019;s board of directors.&amp;#xA0;&amp;#xA0;Jamey P. Weichert,
Thomas Rockwell Mackie and John Neis previously served on the board
of directors of Cellectar.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
April 25, 2011, the Company&amp;#x2019;s board of directors appointed
the following individuals to serve on the following committees of
the board of directors.&lt;/font&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Howard
M. Schneider, John Neis and John E. Niederhuber were appointed to
the audit committee of the board of directors.&amp;#xA0;&amp;#xA0;Mr.
Schneider was appointed as the chairman of that committee, a
position that he held prior to the Acquisition.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Thomas
Rockwell Mackie, James S. Manuso, John Neis and Michael F. Tweedle
were appointed to the compensation committee of the board of
directors. Dr. Mackie was appointed as the chairman of that
committee.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Stephen
A. Hill, John E. Niederhuber and James S. Manuso were appointed to
the nominating and corporate governance committee of the board of
directors.&amp;#xA0;&amp;#xA0;Dr. Hill was appointed as the chairman of
that committee.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
Amendment of Certificate of Incorporation&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Effective
April 7, 2011 the Company&amp;#x2019;s certificate of incorporation was
amended to eliminate the Certificate to Set Forth Designations,
Voting Powers, Preferences, Restrictions and Relative Rights of
Series C 8% Cumulative Convertible Preferred
Stock.&amp;#xA0;&amp;#xA0;There had not been any shares of Series C
preferred stock outstanding since December 2010.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Effective
April 7, 2011 the Company&amp;#x2019;s certificate of incorporation was
amended to eliminate the Certificate of Designations, Preferences
and Rights of Series E Convertible Preferred
Stock.&amp;#xA0;&amp;#xA0;There had not been any shares of Series E
preferred stock outstanding since December 2010.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;
Prior to the closing of the Acquisition on April 8, 2011, the
Company amended and restated its certificate of incorporation in
order to (a) effect the reverse split; (b) reduce the number of
shares of authorized common stock from 750,000,000 to 150,000,000;
(c) eliminate the right of the stockholders to act by written
consent; and (d) classify the board of directors into three
classes.&amp;#xA0;&amp;#xA0;Class I directors will stand for re-election at
the Company&amp;#x2019;s next annual meeting of stockholders, Class II
directors will stand for re-election at the 2012 annual meeting of
stockholders, and Class III directors will stand for re-election at
the 2013 annual meeting of stockholders.&amp;#xA0;&amp;#xA0;Thomas Rockwell
Mackie, James S. Manuso and John Niederhuber serve as Class I
directors, Stephen A. Hill, Michael F. Tweedle and John Neis serve
as Class II directors, and Harry S. Palmin, Jamey P. Weichert and
Howard M. Schneider serve as Class III
directors.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
8.&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
LITIGATION&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;A
purported class action complaint was filed on March 5, 2010 in the
United States District Court for the District of Massachusetts by
an alleged shareholder of the Company, on behalf of himself and all
others who purchased or otherwise acquired the Company&amp;#x2019;s
common stock in the period between December 14, 2009 and February
24, 2010, against the Company and its President and Chief Executive
Officer, Harry S. Palmin.&amp;#xA0;&amp;#xA0;On October 1, 2010, the court
appointed lead plaintiffs (Boris Urman and Ramona McDonald) and
appointed lead plaintiffs&amp;#x2019; counsel.&amp;#xA0;&amp;#xA0;On October 22,
2010, an amended complaint was filed.&amp;#xA0;&amp;#xA0;The amended
complaint claims that the Company violated Section 10(b) of the
Securities Exchange Act of 1934, as amended, and Rule 10b-5
promulgated thereunder in connection with alleged disclosures
related to the Phase 3 clinical trial of NOV-002 for non-small cell
lung cancer.&amp;#xA0;&amp;#xA0;On December 6, 2010, the Company filed a
motion to dismiss the complaint with prejudice.&amp;#xA0;&amp;#xA0;On
January 20, 2011, the plaintiffs filed their opposition to our
motion and on March 3, 2011, the Company filed its response to
their opposition. The motion to dismiss remains pending. The
Company believes the allegations are without merit and intends to
defend vigorously against the allegations.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
June 28, 2010, the Company received a letter from counsel to ZAO
BAM and ZAO BAM Research Laboratories (Russian companies,
collectively referred to as &amp;#x201C;BAM&amp;#x201D;) alleging that the
Company modified the chemical composition of NOV-002 without prior
notice to or approval from BAM, constituting a material breach of a
technology and assignment agreement the Company had entered into
with BAM on June 20, 2000 (the &amp;#x201C;June 2000
Agreement&amp;#x201D;).&amp;#xA0;&amp;#xA0;The letter references the
Company&amp;#x2019;s amendment, submitted to the FDA on August 30, 2005,
to its investigational new drug application dated August 1999 as
the basis for BAM&amp;#x2019;s claims and demands the transfer of all
intellectual property rights concerning NOV-002 to
BAM.&amp;#xA0;&amp;#xA0;Mark Balazovsky, a director of Novelos from June
1996 until November 2006 and a shareholder of Novelos through at
least June 25, 2010, is, to the Company&amp;#x2019;s knowledge, still
the general director and principal shareholder of ZAO
BAM.&amp;#xA0;&amp;#xA0;The Company believes the allegations are without
merit and intends to defend vigorously against any proceedings that
BAM may initiate as to these allegations. On September 24, 2010,
the Company filed a complaint in Suffolk Superior Court seeking a
declaratory judgment by the court that the June 2000 Agreement has
been replaced by a subsequent agreement between the parties dated
April 1, 2005 (the &amp;#x201C;April 2005 Agreement&amp;#x201D;), that
Novelos&amp;#x2019; obligations to BAM are governed solely by the April
2005 Agreement and that the obligations of the June 2000 agreement
have been performed and fully satisfied.&amp;#xA0;&amp;#xA0;On November 29,
2010, BAM answered the complaint, denying the material allegations,
and stating its affirmative defenses and certain counterclaims. On
January 14, 2011, the Company responded to the counterclaims,
denying BAM&amp;#x2019;s material allegations and stating its
affirmative defenses.&amp;#xA0;&amp;#xA0;The Company believes the
counterclaims are without merit and intends to vigorously defend
against them.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
1.&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
NATURE OF BUSINESS, BASIS OF PRESENTATION&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Novelos
Therapeutics, Inc. (&amp;#x201C;Novelos&amp;#x201D; or the
&amp;#x201C;Company&amp;#x201D;) is a biopharmaceutical company developing
compounds for the treatment of cancer.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
April 8, 2011, the Company entered into a business combination with
Cellectar, Inc. (&amp;#x201C;Cellectar&amp;#x201D;), a privately held
Wisconsin corporation that designed and developed products to
detect, treat and monitor a wide variety of human cancers (the
&amp;#x201C;Acquisition&amp;#x201D;, see Note 10).&amp;#xA0;&amp;#xA0;Immediately
prior to the Acquisition, the Company completed a 1-for-153 reverse
split of its common stock (the &amp;#x201C;Reverse Split&amp;#x201D;). The
Company then issued to the former shareholders of Cellectar
17,001,596 shares of its common stock as consideration for the
Acquisition, which shares constituted approximately 85% of
Novelos&amp;#x2019; outstanding common stock after giving effect to the
Acquisition.&amp;#xA0;&amp;#xA0;Upon the closing of the Acquisition, the
Company completed the private placement of 6,846,537 shares of its
common stock and warrants to purchase an additional 6,846,537
shares of its common stock (in each case after giving effect to the
Reverse Split) for gross proceeds of approximately
$5,135,000.&amp;#xA0;&amp;#xA0;As a result of the Acquisition, the Company
is implementing a revised business plan focused on the development
of the Cellectar compounds.&amp;#xA0;&amp;#xA0;Development of
Novelos&amp;#x2019; other compounds (NOV-002 and NOV-205) has been
suspended&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
Reverse Split reduced the number of outstanding shares of Common
Stock from 452,866,983 shares to&amp;#xA0;2,959,871 shares. On the
Company&apos;s balance sheet, the aggregate par value of the issued
common stock was reduced by reclassifying the par value amount of
the eliminated shares of common stock to additional paid-in
capital. All per share amounts and outstanding shares, including
all common stock equivalents, stock options and warrants, have been
retroactively restated in these financial statements and notes for
all periods presented to reflect the Reverse Split. Additionally,
the number of authorized shares of common stock disclosed on the
balance sheet has been reduced to 150,000,000 from 750,000,000 to
reflect the reduction in authorized shares of common stock that
became effective concurrent with the Reverse Split.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Accounting
principles generally accepted in the United States require that a
company whose security holders retain the majority voting interest
in the combined business be treated as the acquirer for financial
reporting purposes.&amp;#xA0; Accordingly, the Acquisition will be
accounted for as a reverse acquisition whereby Cellectar, Inc. will
be treated as the acquirer for accounting and financial reporting
purposes. The financial statements presented herein represent the
historical financial information of Novelos, prior to the
Acquisition.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
Company is subject to a number of risks similar to those of other
small biopharmaceutical companies. Principal among these risks are
dependence on key individuals, competition from substitute products
and larger companies, the successful development and marketing of
its products in a highly regulated environment and the need to
obtain additional financing necessary to fund future
operations.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;On
February 24, 2010, the Company announced that its Phase 3 clinical
trial for NOV-002 in non-small cell lung cancer
(&amp;#x201C;NSCLC&amp;#x201D;) (the &amp;#x201C;Phase 3 Trial&amp;#x201D;) did not
meet its primary endpoint of a statistically significant increase
in median overall survival. Following evaluation of the detailed
trial data, on March 18, 2010, the Company announced that the
secondary endpoints had also not been met in the Phase 3 Trial and
that it had discontinued development of NOV-002 for NSCLC in
combination with first-line paclitaxel and carboplatin
chemotherapy.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;These
financial statements have been prepared on the basis that the
Company will continue as a going concern. The Company has generated
insignificant revenues and has incurred operating losses since
inception in devoting substantially all of its efforts toward
research and development. The Company expects that it will continue
to generate operating losses for the foreseeable
future.&amp;#xA0;&amp;#xA0;The Company believes that its cash on hand at
March 31, 2011, plus the proceeds from the private placement
completed in connection with the Acquisition, is adequate to fund
operations into the fourth quarter of 2011.&amp;#xA0;&amp;#xA0;The
Company&amp;#x2019;s ability to execute its operating plan beyond that
time depends on its ability to obtain additional funding via the
sale of equity and/or debt securities, a strategic transaction or
otherwise.&amp;#xA0;&amp;#xA0;The Company plans to continue to actively
pursue financing alternatives, but there can be no assurance that
it will obtain the necessary funding.&lt;/font&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
accompanying unaudited financial statements of the Company have
been prepared in accordance with accounting principles generally
accepted in the United States (&amp;#x201C;GAAP&amp;#x201D;) for interim
financial information and with the instructions to Form
10-Q.&amp;#xA0;&amp;#xA0;Accordingly, they do not include all of the
information and footnotes required by GAAP for complete financial
statements. In the opinion of management, all adjustments
(consisting of normal recurring accruals) considered necessary for
the fair presentation of these financial statements have been
included. The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions
that affect the amounts reported in the financial statements and
accompanying notes. Interim results are not necessarily indicative
of results to be expected for other quarterly periods or for the
entire year ending December 31, 2011. These unaudited financial
statements should be read in conjunction with the audited financial
statements and related notes thereto included in the
Company&amp;#x2019;s latest annual report for the year ended December
31, 2010 on Form 10-K, which was filed with the Securities and
Exchange Commission (&amp;#x201C;SEC&amp;#x201D;) on April 14, 2011.&amp;#xA0;The
report from the Company&amp;#x2019;s independent registered public
accounting firm dated April 11, 2011 and included with its annual
report on Form 10-K indicated that factors exist that raised
substantial doubt about the Company&amp;#x2019;s ability to continue as
a going concern.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Comprehensive Income (Loss)&lt;/font&gt; &amp;#x2013; The Company had no
components of comprehensive income (loss) other than the net income
(loss) in all periods presented.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Derivative Instruments&lt;/font&gt; &amp;#x2013; The Company generally does
not use derivative instruments to hedge exposures to cash flow or
market risks.&amp;#xA0;&amp;#xA0;However, certain warrants to purchase
common stock that do not meet the requirements for classification
as equity, in accordance with the Derivatives and Hedging Topic of
the Financial Accounting Standards Board Accounting Standards
Codification (&amp;#x201C;FASB ASC&amp;#x201D;),&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#xA0;&lt;/font&gt;are classified
as liabilities.&amp;#xA0;&amp;#xA0;In such instances, net-cash settlement
is assumed for financial reporting purposes, even when the terms of
the underlying contracts do not provide for a net-cash settlement.
These warrants are considered derivative instruments because the
agreements contain &amp;#x201C;down-round&amp;#x201D; provisions whereby the
number of shares for which the warrants are exercisable and/or the
exercise price of the warrants are subject to change in the event
of certain issuances of stock at prices below the then-effective
exercise price of the warrants.&amp;#xA0;&amp;#xA0;The number of shares
issuable under such warrants was 105,042 at March 31,
2011.&amp;#xA0;&amp;#xA0;The primary underlying risk exposure pertaining to
the warrants is the change in fair value of the underlying common
stock.&amp;#xA0;&amp;#xA0;Such financial instruments are initially recorded
at fair value with subsequent changes in fair value recorded as a
component of gain or loss on derivatives in each reporting period.
If these instruments subsequently meet the requirements for equity
classification, the Company reclassifies the fair value to
equity.&amp;#xA0;&amp;#xA0;At March 31, 2011, these warrants represented
the only outstanding derivative instruments issued or held by the
Company.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman"&gt;2.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
FAIR VALUES OF ASSETS AND LIABILITIES&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;In
accordance with Fair Value Measurements and Disclosures Topic of
the FASB ASC, the Company groups its financial assets and financial
liabilities generally measured at fair value in three levels, based
on the markets in which the assets and liabilities are traded and
the reliability of the assumptions used to determine fair
value.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: symbol, serif"&gt;
&amp;#xB7;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Level
1: Input prices quoted in an active market for identical financial
assets or liabilities.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: symbol, serif"&gt;
&amp;#xB7;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Level
2: Inputs other than prices quoted in Level 1, such as prices
quoted for similar financial assets and liabilities in active
markets, prices for identical assets and liabilities in markets
that are not active or other inputs that are observable or can be
corroborated by observable market data.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: symbol, serif"&gt;
&amp;#xB7;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Level
3: Input prices quoted that are significant to the fair value of
the financial assets or liabilities which are not observable or
supported by an active market.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Assets
and liabilities measured at fair value on a recurring basis are
summarized below:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="96%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="46%" colspan="14" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;March&amp;#xA0;31,&amp;#xA0;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Level&amp;#xA0;1&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Level&amp;#xA0;2&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Level&amp;#xA0;3&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Fair&amp;#xA0;Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="52%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Liabilities:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Warrants&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
162,760&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
162,760&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
Company uses valuation methods and assumptions that consider among
others the fair value of the underlying stock, risk-free interest
rate, volatility, expected life and dividend rates in estimating
fair value for the warrants considered to be derivative
instruments. Assumptions used are generally consistent with those
disclosed for stock-based compensation (see Note 5).&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
7.&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
INCOME TAXES&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
Company accounts for income taxes in accordance with the Income
Taxes Topic of the FASB ASC. Under this guidance, deferred tax
assets or liabilities are computed based on the difference between
the financial statement and income tax basis of assets and
liabilities, and net operating loss carryforwards, using the
enacted tax rates. Deferred income tax expense or benefit is based
on changes in the asset or liability from period to period. The
Company did not record a provision or benefit for federal, state or
foreign income taxes for the three months ended March 31, 2011 or
2010 because the Company has experienced losses on a tax basis
since inception. The net income reported for the three months ended
March 31, 2010 was a result of the gain recorded on the revaluation
of derivative warrant liability during that period, which is a
nontaxable item. The Company has not recorded deferred tax assets
as their realization is uncertain.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
5.&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
STOCK-BASED COMPENSATION&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
following table summarizes amounts charged (credited) to expense
for stock-based compensation related to employee and director stock
option grants and stock-based compensation recorded in connection
with stock options granted to non-employee
consultants:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;March&amp;#xA0;31,&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="76%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Employee
and director stock option grants:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Research
and development&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;49,298&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;57,113&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;General
and administrative&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
59,682&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
82,928&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
108,980&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
140,041&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Non-employee
consultant stock option grants:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Research
and development&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(545&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(210,825&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;General
and administrative&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(57&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(26,695&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(602&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(237,520&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="76%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="76%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
stock-based compensation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
108,378&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(97,479&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;There
were no stock option grants during the three months ended March 31,
2011 or 2010.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Number&amp;#xA0;of&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Shares&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Issuable&amp;#xA0;Upon&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Exercise&amp;#xA0;of&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Outstanding&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Options&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Weighted&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Average&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Exercise&amp;#xA0;Price&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Weighted&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Average&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Remaining&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Contracted&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Term&amp;#xA0;in&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Years&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Aggregate&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Intrinsic&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline"&gt;Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Outstanding
at December 31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
49,227&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
100.61&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
6.9&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
24,842&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Outstanding
at March 31, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
49,227&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
100.61&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
6.6&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
12,421&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Exercisable
at March 31, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
40,348&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
101.03&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
6.2&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
12,421&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;The
aggregate intrinsic value of options outstanding is calculated
based on the positive difference between the closing market price
of the Company&amp;#x2019;s common stock at the end of the respective
period and the exercise price of the underlying
options.&amp;#xA0;&amp;#xA0;There were no options exercised during the
three months ended March 31, 2011. Shares of common stock issued
upon the exercise of options are from authorized but unissued
shares.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;As
of March 31, 2011, there was approximately $538,000 of total
unrecognized compensation cost related to unvested stock-based
compensation arrangements.&amp;#xA0;&amp;#xA0;Of this total amount, 64% and
36% are expected to be recognized during 2011 and 2012,
respectively.&amp;#xA0;&amp;#xA0;The Company expects 8,879 in unvested
options to vest in the future.&amp;#xA0;&amp;#xA0;The weighted-average
grant-date fair value of vested and unvested options outstanding at
March 31, 2011 was $62.75 and $68.07, respectively.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-28500</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">668</us-gaap:InvestmentIncomeInterest>
  <us-gaap:CostsAndExpenses contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">1144563</us-gaap:CostsAndExpenses>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-1313509</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">108378</us-gaap:ShareBasedCompensation>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD_per_shares" decimals="2">-0.34</us-gaap:EarningsPerShareDiluted>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-315715</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-1010072</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">126158</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">532686</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">125490</us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">2240</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-1010072</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD_per_shares" decimals="2">-0.34</us-gaap:EarningsPerShareBasic>
  <us-gaap:SalesRevenueNet contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">8333</us-gaap:SalesRevenueNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-1136230</us-gaap:OperatingIncomeLoss>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-1342009</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="shares" decimals="0">2959871</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-35483</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-8333</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">611877</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="shares" decimals="0">2959871</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814" unitRef="iso4217_USD" decimals="0">-28500</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <context id="eol_PE638436--11S-1-0011_STD_90_20110331_0_452537x486814">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_90_20110331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814_455296x452484">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_90_20100331_0_452537x486814">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_55_20021231_0_455296x455803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:GoodsAndServicesExchangedForEquityInstrumentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2002-11-07</startDate>
      <endDate>2002-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_55_20021231_0_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2002-11-07</startDate>
      <endDate>2002-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_55_20021231_0_452905x453698_455296x455803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:GoodsAndServicesExchangedForEquityInstrumentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2002-11-07</startDate>
      <endDate>2002-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_55_20021231_0_452905x453698_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2002-11-07</startDate>
      <endDate>2002-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_55_20021231_0_452905x444581_455296x455803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:GoodsAndServicesExchangedForEquityInstrumentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2002-11-07</startDate>
      <endDate>2002-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_55_20021231_0_452905x444581_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2002-11-07</startDate>
      <endDate>2002-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_366_20081231_0_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_366_20081231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_366_20081231_0_452905x453698_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_366_20081231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_366_20081231_0_452905x444581_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_366_20081231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_366_20041231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_366_20041231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_455296x486824">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_455296x479440">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:PublicOfferingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_455296x471365">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:NonCashItemsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_455296x452484">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_455296x444874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x469151_455296x486824">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:SeriesDAndSeriesEPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x469151_455296x444874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:SeriesDAndSeriesEPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x453698_455296x486824">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x453698_455296x479440">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:PublicOfferingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x453698_455296x444874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x449416_455296x444874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x444581_455296x486824">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x444581_455296x479440">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:PublicOfferingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x444581_455296x444874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0_452537x486814">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_455296x486824">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_455296x486823">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_455296x471365">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:NonCashItemsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_455296x453171">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:NewAccountingPronouncementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_455296x452841">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_455296x452484">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_455296x449416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x469151_455296x486824">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:SeriesDAndSeriesEPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x469151">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:SeriesDAndSeriesEPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698_455296x486824">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698_455296x486823">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698_455296x452841">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x449416_455296x486823">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x444581_455296x486824">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x444581_455296x486823">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x444581_455296x452841">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0_452537x486814">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20091231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20071231_0_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20071231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20071231_0_452905x453698_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20071231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20071231_0_452905x444581_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20071231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20071231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20061231_0_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20061231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20061231_0_452905x453698_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20061231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20061231_0_452905x444581_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20061231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20061231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20051231_0_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20051231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20051231_0_452905x453698_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20051231_0_452905x444581_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20051231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20031231_0_455296x479658">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:LicenseRightsAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2003-01-01</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20031231_0_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2003-01-01</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20031231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2003-01-01</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20031231_0_452905x453698_455296x479658">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:LicenseRightsAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2003-01-01</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20031231_0_452905x453698_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2003-01-01</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20031231_0_452905x444581_455296x479658">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">nvlt:LicenseRightsAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2003-01-01</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20031231_0_452905x444581_455296x452748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2003-01-01</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_365_20031231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <startDate>2003-01-01</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_2977_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <startDate>2002-11-07</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_273_20110930_0_455296x449620">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x453698_455296x449620">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x444581_455296x449620">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_273_20110930_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_273_20110930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_273_20100930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20101231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20101231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20101231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20101231_0_452537x486814">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20091231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20091231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20091231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814_452905x469151">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:SeriesDAndSeriesEPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814_452905x449416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20091231_0_452537x486814">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20091231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20081231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20081231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20081231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20081231_0_452537x486814_452905x469151">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:SeriesDAndSeriesEPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20081231_0_452537x486814_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20081231_0_452537x486814_452905x449416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20081231_0_452537x486814_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20081231_0_452537x486814_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20081231_0_452537x486814">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20081231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20071231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20071231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20071231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20071231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20061231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20061231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20061231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20061231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20051231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20051231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20051231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20051231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20041231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20041231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20041231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20041231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20031231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20031231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20031231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20031231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20021231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2002-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20021231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2002-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20021231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <instant>2002-12-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20110930_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nvlt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-09-30</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20110930_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-09-30</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20110930_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-09-30</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20110930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <instant>2011-09-30</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20110331_0_452537x486814">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-03-31</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20100930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
    </entity>
    <period>
      <instant>2010-09-30</instant>
    </period>
  </context>
  <context id="eol_PE638436--11S-1-0011_STD_0_20100331_0_452537x486814">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001279704</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nvlt:PreAcquisitionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-03-31</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>nvlt-20110930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.12.8 -->
<!-- Round: 46fe4b0a-935c-45f1-95b0-e159dfba7207 -->
<!-- Creation date: 2011-11-08T18:13:49Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31"
  xmlns:us-types="http://fasb.org/us-types/2011-01-31"
  xmlns:nvlt="http://www.novelos.com/20110930"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2011-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31"
  targetNamespace="http://www.novelos.com/20110930"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/DocumentDocumentandEntityInformation" id="DocumentDocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/StatementOfIncomeAlternative" id="Role_StatementOfIncomeAlternative">
        <link:definition>105 - Statement - STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>106 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>108 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical" id="Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen">
        <link:definition>107 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <link:definition>109 - Disclosure - NATURE OF BUSINESS, BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>110 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock" id="Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock">
        <link:definition>111 - Disclosure - FAIR VALUES OF ASSETS AND LIABILITIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsMergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="Role_NotesToFinancialStatementsMergersAcquisitionsAndDispositionsDisclosuresTextBlock">
        <link:definition>112 - Disclosure - ACQUISITION</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
        <link:definition>113 - Disclosure - FIXED ASSETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock">
        <link:definition>114 - Disclosure - LICENSE AGREEMENTS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock" id="Role_NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock">
        <link:definition>115 - Disclosure - CONVERTIBLE DEBT</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlock">
        <link:definition>116 - Disclosure - LONG-TERM NOTES PAYABLE</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock" id="Role_NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock">
        <link:definition>117 - Disclosure - LINE OF CREDIT</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>118 - Disclosure - STOCKHOLDERS' DEFICIENCY</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>119 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>120 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlock">
        <link:definition>121 - Disclosure - NET INCOME (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlock">
        <link:definition>122 - Disclosure - COMMITMENTS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock" id="Role_NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock">
        <link:definition>123 - Disclosure - LITIGATION</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock" id="Role_NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock">
        <link:definition>124 - Disclosure - EMPLOYEE RETIREMENT PLAN</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
        <link:definition>125 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSupplementalFinancialInformationDisclosureTextBlock" id="Role_NotesToFinancialStatementsSupplementalFinancialInformationDisclosureTextBlock">
        <link:definition>126 - Disclosure - (UNAUDITED) SUPPLEMENTAL PRO FORMA INFORMATION</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsReverseStockSplitTextBlock" id="Role_NotesToFinancialStatementsReverseStockSplitTextBlock">
        <link:definition>127 - Disclosure - PROPOSED REVERSE STOCK SPLIT</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
        <link:definition>128 - Disclosure - COLLABORATION AGREEMENTS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>129 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="nvlt-20110930_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="nvlt-20110930_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="nvlt-20110930_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="nvlt-20110930_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-types/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-types-2011-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2011-01-31" schemaLocation="http://xbrl.sec.gov/country/2011/country-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2011-01-31" schemaLocation="http://xbrl.sec.gov/invest/2011/invest-2011-01-31.xsd"/>
  <element name="AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred" id="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders" id="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants" id="nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock" id="nvlt_AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue" id="nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborativeAndLicenseArrangementDisclosureTextBlock" id="nvlt_CollaborativeAndLicenseArrangementDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertibleDebtDisclosureTextBlock" id="nvlt_ConvertibleDebtDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeemedDividendsOnPreferredStock" id="nvlt_DeemedDividendsOnPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember" id="nvlt_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DividendsPayableOnConvertiblePreferredStock" id="nvlt_DividendsPayableOnConvertiblePreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentDocumentandEntityInformationAbstract" id="nvlt_DocumentDocumentandEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExchangeOfConvertiblePreferredStock" id="nvlt_ExchangeOfConvertiblePreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueOfDerivativeInstrument" id="nvlt_FairValueOfDerivativeInstrument" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IssuanceOfCommonStockAndWarrantsShares" id="nvlt_IssuanceOfCommonStockAndWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IssuanceOfCommonStockAndWarrantsValue" id="nvlt_IssuanceOfCommonStockAndWarrantsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IssuanceOfCommonStockInExchangeForConvertibleNotes" id="nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseRightsAndEquipmentMember" id="nvlt_LicenseRightsAndEquipmentMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LineOfCreditFacilitiesTextBlock" id="nvlt_LineOfCreditFacilitiesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonCashItemsMember" id="nvlt_NonCashItemsMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NotesToFinancialStatementsAbstract" id="nvlt_NotesToFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreAcquisitionMember" id="nvlt_PreAcquisitionMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreferredStockSharesDesignated" id="nvlt_PreferredStockSharesDesignated" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants" id="nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PublicOfferingMember" id="nvlt_PublicOfferingMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" id="nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReclassificationOfWarrantsToDerivativeLiability" id="nvlt_ReclassificationOfWarrantsToDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReverseStockSplitTextBlock" id="nvlt_ReverseStockSplitTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember" id="nvlt_SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesDAndSeriesEPreferredStockMember" id="nvlt_SeriesDAndSeriesEPreferredStockMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember" id="nvlt_SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants" id="nvlt_StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesStockWarrantsExercised" id="nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants" id="nvlt_StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodValueStockWarrantsExercised" id="nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SupplementalFinancialInformationDisclosureTextBlock" id="nvlt_SupplementalFinancialInformationDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SupplementalIssuanceOfStockAndWarrants" id="nvlt_SupplementalIssuanceOfStockAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TemporaryEquitySharesDesignated" id="nvlt_TemporaryEquitySharesDesignated" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageNumberBasicDilutedSharesOutstanding" id="nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>nvlt-20110930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.12.8 -->
<!-- Round: 46fe4b0a-935c-45f1-95b0-e159dfba7207 -->
<!-- Creation date: 2011-11-08T18:13:49Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.novelos.com/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.novelos.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.novelos.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.novelos.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.novelos.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsMergersAcquisitionsAndDispositionsDisclosuresTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsMergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsSupplementalFinancialInformationDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSupplementalFinancialInformationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsReverseStockSplitTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsReverseStockSplitTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/DocumentDocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:label="us-gaap_DividendsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityCarryingAmount" xlink:label="us-gaap_TemporaryEquityCarryingAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredOfferingCosts" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmount" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.2700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.3300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DividendsPayableCurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermNotesPayable" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.2800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.2900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.3000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" order="1.3100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.3100" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_DeemedDividendsOnPreferredStock" xlink:label="nvlt_DeemedDividendsOnPreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:label="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RegistrationPaymentArrangementGainsAndLosses" xlink:label="us-gaap_RegistrationPaymentArrangementGainsAndLosses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="1.1600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="nvlt_DeemedDividendsOnPreferredStock" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_RevenueFromGrants" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_RegistrationPaymentArrangementGainsAndLosses" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SalesRevenueNet" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="1.0500" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:label="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants" xlink:label="nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.3600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="1.2700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.2800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.3000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants" order="1.3100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="1.3200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" order="1.3300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.3400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="1.3500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="1.2000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.2200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1.2300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsMergersAcquisitionsAndDispositionsDisclosuresTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSupplementalFinancialInformationDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsReverseStockSplitTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>nvlt-20110930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.12.8 -->
<!-- Round: 46fe4b0a-935c-45f1-95b0-e159dfba7207 -->
<!-- Creation date: 2011-11-08T18:13:49Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.novelos.com/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.novelos.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.novelos.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.novelos.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.novelos.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsMergersAcquisitionsAndDispositionsDisclosuresTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsMergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsSupplementalFinancialInformationDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSupplementalFinancialInformationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsReverseStockSplitTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsReverseStockSplitTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/DocumentDocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_EntitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:label="us-gaap_DividendsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PreAcquisitionMember" xlink:label="nvlt_PreAcquisitionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityCarryingAmount" xlink:label="us-gaap_TemporaryEquityCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nvlt_PreAcquisitionMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DividendsPayableCurrent" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmount" order="1.2600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PreAcquisitionMember" xlink:label="nvlt_PreAcquisitionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PreferredStockSharesDesignated" xlink:label="nvlt_PreferredStockSharesDesignated"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_TemporaryEquitySharesDesignated" xlink:label="nvlt_TemporaryEquitySharesDesignated"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nvlt_PreAcquisitionMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_TemporaryEquitySharesDesignated" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_PreferredStockSharesDesignated" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_DeemedDividendsOnPreferredStock" xlink:label="nvlt_DeemedDividendsOnPreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:label="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PreAcquisitionMember" xlink:label="nvlt_PreAcquisitionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RegistrationPaymentArrangementGainsAndLosses" xlink:label="us-gaap_RegistrationPaymentArrangementGainsAndLosses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nvlt_PreAcquisitionMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_RevenueFromGrants" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_RegistrationPaymentArrangementGainsAndLosses" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueNet" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_DeemedDividendsOnPreferredStock" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue" xlink:label="nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember" xlink:label="nvlt_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember" xlink:label="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_IssuanceOfCommonStockAndWarrantsShares" xlink:label="nvlt_IssuanceOfCommonStockAndWarrantsShares"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_IssuanceOfCommonStockAndWarrantsValue" xlink:label="nvlt_IssuanceOfCommonStockAndWarrantsValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_LicenseRightsAndEquipmentMember" xlink:label="nvlt_LicenseRightsAndEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PreAcquisitionMember" xlink:label="nvlt_PreAcquisitionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="us-gaap_PreferredStockDividendsShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PublicOfferingMember" xlink:label="nvlt_PublicOfferingMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ReclassificationOfWarrantsToDerivativeLiability" xlink:label="nvlt_ReclassificationOfWarrantsToDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember" xlink:label="nvlt_SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_SeriesDAndSeriesEPreferredStockMember" xlink:label="nvlt_SeriesDAndSeriesEPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember" xlink:label="nvlt_SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="us-gaap_StockholdersEquityOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityOtherShares" xlink:label="us-gaap_StockholdersEquityOtherShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants" xlink:label="nvlt_StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants" xlink:label="nvlt_StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nvlt_PreAcquisitionMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.5200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.5300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nvlt_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember" order="1.5400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nvlt_SeriesDAndSeriesEPreferredStockMember" order="1.5500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.5600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.5700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_CashMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="nvlt_LicenseRightsAndEquipmentMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="nvlt_SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="nvlt_SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="nvlt_PublicOfferingMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_PreferredStockMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_ReclassificationOfWarrantsToDerivativeLiability" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityOtherShares" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityOther" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_IssuanceOfCommonStockAndWarrantsShares" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_IssuanceOfCommonStockAndWarrantsValue" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsShares" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPreferredStock" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.4700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.4800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.4900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="1.5000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders" order="1.5100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_DividendsPayableOnConvertiblePreferredStock" xlink:label="nvlt_DividendsPayableOnConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ExchangeOfConvertiblePreferredStock" xlink:label="nvlt_ExchangeOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_FairValueOfDerivativeInstrument" xlink:label="nvlt_FairValueOfDerivativeInstrument"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:label="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes" xlink:label="nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:label="us-gaap_NewAccountingPronouncementMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NonCashItemsMember" xlink:label="nvlt_NonCashItemsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PreAcquisitionMember" xlink:label="nvlt_PreAcquisitionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants" xlink:label="nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" xlink:label="nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_SupplementalIssuanceOfStockAndWarrants" xlink:label="nvlt_SupplementalIssuanceOfStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.4700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.4800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" order="1.4900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.5000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="1.5100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.5200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" order="1.5300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="1.5400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.5500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nvlt_PreAcquisitionMember" order="1.5600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_NewAccountingPronouncementMember" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="nvlt_NonCashItemsMember" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.5700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.5800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.5900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.6000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.6100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.6300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_LiabilitiesAssumed1" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_Goodwill" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nvlt_DividendsPayableOnConvertiblePreferredStock" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nvlt_FairValueOfDerivativeInstrument" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_StockIssued1" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nvlt_ExchangeOfConvertiblePreferredStock" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nvlt_SupplementalIssuanceOfStockAndWarrants" order="1.1300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PreAcquisitionMember" xlink:label="nvlt_PreAcquisitionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PublicOfferingMember" xlink:label="nvlt_PublicOfferingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nvlt_PreAcquisitionMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="nvlt_PublicOfferingMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="3.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsMergersAcquisitionsAndDispositionsDisclosuresTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:label="nvlt_CollaborativeAndLicenseArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_CollaborativeAndLicenseArrangementDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ConvertibleDebtDisclosureTextBlock" xlink:label="nvlt_ConvertibleDebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_ConvertibleDebtDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_LineOfCreditFacilitiesTextBlock" xlink:label="nvlt_LineOfCreditFacilitiesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_LineOfCreditFacilitiesTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSupplementalFinancialInformationDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_SupplementalFinancialInformationDisclosureTextBlock" xlink:label="nvlt_SupplementalFinancialInformationDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_SupplementalFinancialInformationDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsReverseStockSplitTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ReverseStockSplitTextBlock" xlink:label="nvlt_ReverseStockSplitTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_ReverseStockSplitTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>nvlt-20110930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.12.8 -->
<!-- Round: 46fe4b0a-935c-45f1-95b0-e159dfba7207 -->
<!-- Creation date: 2011-11-08T18:13:49Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred_lbl" xml:lang="en-US">Adjustments To Additional Paid In Capital Accretion Of Deemed Dividend Associated With The Incremental Shares Of Common Stock Issued In Exchange Of Preferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred_lbl" xml:lang="en-US">Accretion of deemed dividend associated with the incremental shares of common stock issued in connection with the exchange of preferred stock</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred_lbl" xml:lang="en-US">Accretion of deemed dividend associated with the incremental shares of common stock issued in connection with the exchange of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred" xlink:to="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Accretion of Deemed Dividend Associated with the Issuance of Warrants to Preferred Stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders_lbl" xml:lang="en-US">Accretion of deemed dividend associated with the issuance of warrants to preferred stockholders</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders_lbl" xml:lang="en-US">Accretion of deemed dividend associated with the issuance of warrants to preferred stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders" xlink:to="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants_lbl" xml:lang="en-US">Adjustments To Additional Paid In Capital Associated With Extension Of Expiration Date Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants_lbl" xml:lang="en-US">Accretion of deemed dividend associated with the extension of expiration date of warrants</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants_lbl" xml:lang="en-US">Accretion of deemed dividend associated with the extension of expiration date of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants" xlink:to="nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xml:lang="en-US">Intrinsic value of beneficial conversion feature associated with the conversion of convertible debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock_lbl" xml:lang="en-US">Adjustments to additional paid in capital, fair value of incremental shares issued to preferred stockholders in connection with the exchange of preferred stock for common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock_lbl" xml:lang="en-US">Fair value of incremental shares issued to preferred stockholders in connection with exchange of preferred stock for common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock" xlink:to="nvlt_AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Fair value of the extension of expiration date of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xml:lang="en-US">Compensation expense (benefit) associated with options issued to non-employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Compensation expense associated with options issued to employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Fair value of warrants issued to preferred shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net income (loss) to cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue" xlink:label="nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue_lbl" xml:lang="en-US">The adjustment to additional paid in capital for the decrease in carrying amount of redeemable preferred stock that is classified as temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue_lbl" xml:lang="en-US">Adjustment to record the carrying value of Series E redeemable convertible preferred stock at fair value on the date of sale</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue_lbl" xml:lang="en-US">Adjustment to record the carrying value of Series E redeemable convertible preferred stock at fair value on the date of sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue" xlink:to="nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_lbl" xml:lang="en-US">Merger costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Capital lease obligations, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Capital lease obligations, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US">Cash acquired in a business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">CASH AND EQUIVALENTS AT END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">CASH AND EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">INCREASE (DECREASE) IN CASH AND EQUIVALENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">INCREASE (DECREASE) IN CASH AND EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashMember_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:label="nvlt_CollaborativeAndLicenseArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_CollaborativeAndLicenseArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaborative and License Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_CollaborativeAndLicenseArrangementDisclosureTextBlock_lbl" xml:lang="en-US">LICENSE AGREEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:to="nvlt_CollaborativeAndLicenseArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">COLLABORATION AGREEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">EMPLOYEE RETIREMENT PLAN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Carrying value of redeemable preferred stock converted into common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ConvertibleDebtDisclosureTextBlock" xlink:label="nvlt_ConvertibleDebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_ConvertibleDebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_ConvertibleDebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nvlt_ConvertibleDebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE DEBT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_ConvertibleDebtDisclosureTextBlock" xlink:to="nvlt_ConvertibleDebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible debt (Note 7)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total costs and expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">COSTS AND EXPENSES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">LONG-TERM NOTES PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">Intrinsic value of beneficial conversion feature associated with convertible debt</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">Intrinsic value of beneficial conversion feature associated with convertible debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_DeemedDividendsOnPreferredStock" xlink:label="nvlt_DeemedDividendsOnPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_DeemedDividendsOnPreferredStock_lbl" xml:lang="en-US">Deemed Dividends On Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_DeemedDividendsOnPreferredStock_lbl" xml:lang="en-US">PREFERRED STOCK DEEMED DIVIDENDS</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="nvlt_DeemedDividendsOnPreferredStock_lbl" xml:lang="en-US">PREFERRED STOCK DEEMED DIVIDENDS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_DeemedDividendsOnPreferredStock" xlink:to="nvlt_DeemedDividendsOnPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred Rent Credit, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue - current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">DEFERRED REVENUE - NONCURRENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">DEPOSITS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_lbl" xml:lang="en-US">Development Stage Enterprise, Deficit Accumulated During Development Stage</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_lbl" xml:lang="en-US">Deficit accumulated during the development stage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember" xlink:label="nvlt_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember_lbl" xml:lang="en-US">Development Stage Enterprise, Deficit Accumulated During Development Stage [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember_lbl" xml:lang="en-US">Deficit Accumulated During the Development Stage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember" xlink:to="nvlt_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:label="us-gaap_DividendsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableCurrent_lbl" xml:lang="en-US">Accrued dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrent" xlink:to="us-gaap_DividendsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_DividendsPayableOnConvertiblePreferredStock" xlink:label="nvlt_DividendsPayableOnConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_DividendsPayableOnConvertiblePreferredStock_lbl" xml:lang="en-US">Dividends Payable on convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_DividendsPayableOnConvertiblePreferredStock_lbl" xml:lang="en-US">Dividends accumulated on shares of preferred stock converted into shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_DividendsPayableOnConvertiblePreferredStock" xlink:to="nvlt_DividendsPayableOnConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Dividends accrued on preferred stock</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Dividends accrued on preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_DocumentDocumentandEntityInformationAbstract" xlink:label="nvlt_DocumentDocumentandEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_DocumentDocumentandEntityInformationAbstract_lbl" xml:lang="en-US">Document - Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_DocumentDocumentandEntityInformationAbstract_lbl" xml:lang="en-US">Document - Document and Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_DocumentDocumentandEntityInformationAbstract" xlink:to="nvlt_DocumentDocumentandEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">BASIC NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">DILUTED NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">NET INCOME (LOSS) PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitiesTable_lbl" xml:lang="en-US">Entities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitiesTable" xlink:to="dei_EntitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ExchangeOfConvertiblePreferredStock" xlink:label="nvlt_ExchangeOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_ExchangeOfConvertiblePreferredStock_lbl" xml:lang="en-US">The fair value of stock issued in noncash financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_ExchangeOfConvertiblePreferredStock_lbl" xml:lang="en-US">Exchange of Series D for Series E preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_ExchangeOfConvertiblePreferredStock" xlink:to="nvlt_ExchangeOfConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUES OF ASSETS AND LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Fair value of assets acquired in exchange for securities in a business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_FairValueOfDerivativeInstrument" xlink:label="nvlt_FairValueOfDerivativeInstrument"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_FairValueOfDerivativeInstrument_lbl" xml:lang="en-US">Fair Value Of Derivative Instrument</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_FairValueOfDerivativeInstrument_lbl" xml:lang="en-US">Fair value of derivative warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_FairValueOfDerivativeInstrument" xlink:to="nvlt_FairValueOfDerivativeInstrument_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of fixed assets</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember" xlink:label="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember_lbl" xml:lang="en-US">Professional Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember" xlink:to="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Excess of purchase price over net assets acquired in a business combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">EXCESS PURCHASE PRICE OVER NET ASSETS ACQUIRED</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xml:lang="en-US">Impairment of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:label="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments_lbl" xml:lang="en-US">(Gain) loss on derivative warrants</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments_lbl" xml:lang="en-US">(Gain) loss on derivative warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:to="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Change in restricted cash</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Change in restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">INTANGIBLE ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_IssuanceOfCommonStockAndWarrantsShares" xlink:label="nvlt_IssuanceOfCommonStockAndWarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_IssuanceOfCommonStockAndWarrantsShares_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_IssuanceOfCommonStockAndWarrantsShares_lbl" xml:lang="en-US">Issuance of common stock and warrants (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_IssuanceOfCommonStockAndWarrantsShares" xlink:to="nvlt_IssuanceOfCommonStockAndWarrantsShares_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_IssuanceOfCommonStockAndWarrantsValue" xlink:label="nvlt_IssuanceOfCommonStockAndWarrantsValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_IssuanceOfCommonStockAndWarrantsValue_lbl" xml:lang="en-US">Value of issuance of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_IssuanceOfCommonStockAndWarrantsValue_lbl" xml:lang="en-US">Issuance of common stock and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_IssuanceOfCommonStockAndWarrantsValue" xlink:to="nvlt_IssuanceOfCommonStockAndWarrantsValue_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes" xlink:label="nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes_lbl" xml:lang="en-US">Issuance of common stock in exchange for convertible notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes_lbl" xml:lang="en-US">Issuance of common stock upon conversion of notes payable and accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes" xlink:to="nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of stock for technology and services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US">LITIGATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIENCY)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIENCY)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIENCY)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xml:lang="en-US">Fair value of liabilities assumed in exchange for securities in a business combination</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xml:lang="en-US">Fair value of liabilities assumed in exchange for securities in a business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAssumed1" xlink:to="us-gaap_LiabilitiesAssumed1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long-term liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG-TERM LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_LicenseRightsAndEquipmentMember" xlink:label="nvlt_LicenseRightsAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_LicenseRightsAndEquipmentMember_lbl" xml:lang="en-US">License Rights and Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_LicenseRightsAndEquipmentMember_lbl" xml:lang="en-US">licensed technology</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_LicenseRightsAndEquipmentMember" xlink:to="nvlt_LicenseRightsAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_LineOfCreditFacilitiesTextBlock" xlink:label="nvlt_LineOfCreditFacilitiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_LineOfCreditFacilitiesTextBlock_lbl" xml:lang="en-US">Line of Credit Facilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_LineOfCreditFacilitiesTextBlock_lbl" xml:lang="en-US">LINE OF CREDIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_LineOfCreditFacilitiesTextBlock" xlink:to="nvlt_LineOfCreditFacilitiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes payable, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xml:lang="en-US">ACQUISITION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Cash provided by (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Cash provided by (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET INCOME (LOSS)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:label="us-gaap_NewAccountingPronouncementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementMember_lbl" xml:lang="en-US">Adjustments for New Accounting Pronouncement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementMember" xlink:to="us-gaap_NewAccountingPronouncementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NonCashItemsMember" xlink:label="nvlt_NonCashItemsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_NonCashItemsMember_lbl" xml:lang="en-US">Non Cash Items [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_NonCashItemsMember_lbl" xml:lang="en-US">Cashless Exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_NonCashItemsMember" xlink:to="nvlt_NonCashItemsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSE):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="nvlt_NotesToFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">NATURE OF BUSINESS, BASIS OF PRESENTATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">OTHER ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Miscellaneous</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xml:lang="en-US">Non-cash settlement of liquidated damages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Repurchase of common stock</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Repurchase of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl" xml:lang="en-US">Cash paid in lieu of fractional shares in a business combination</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl" xml:lang="en-US">Cash paid in lieu of fractional shares in a business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Payment for intangible assets</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Payment for intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of fixed assets</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Purchases of short-term certificates of deposit</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Purchases of short-term certificates of deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PreAcquisitionMember" xlink:label="nvlt_PreAcquisitionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_PreAcquisitionMember_lbl" xml:lang="en-US">Pre Acquisition [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_PreAcquisitionMember_lbl" xml:lang="en-US">Pre Acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_PreAcquisitionMember" xlink:to="nvlt_PreAcquisitionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">PREFERRED STOCK DIVIDENDS</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">PREFERRED STOCK DIVIDENDS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="us-gaap_PreferredStockDividendsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsShares_lbl" xml:lang="en-US">Issuance of Series E redeemable convertible preferred stock in payment of accumulated dividends(in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsShares" xlink:to="us-gaap_PreferredStockDividendsShares_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock and Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PreferredStockSharesDesignated" xlink:label="nvlt_PreferredStockSharesDesignated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_PreferredStockSharesDesignated_lbl" xml:lang="en-US">Preferred Stock, Shares Designated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_PreferredStockSharesDesignated_lbl" xml:lang="en-US">Preferred Stock, shares designated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_PreferredStockSharesDesignated" xlink:to="nvlt_PreferredStockSharesDesignated_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Proceeds from long-term obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants" xlink:label="nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants_lbl" xml:lang="en-US">Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation and the cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants_lbl" xml:lang="en-US">Proceeds from issuance of Series E convertible preferred stock and warrants, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants" xlink:to="nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US">Change in deferred issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xml:lang="en-US">Proceeds from short-term certificates of deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">FIXED ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">FIXED ASSETS, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PublicOfferingMember" xlink:label="nvlt_PublicOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_PublicOfferingMember_lbl" xml:lang="en-US">Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_PublicOfferingMember_lbl" xml:lang="en-US">Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_PublicOfferingMember" xlink:to="nvlt_PublicOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" xlink:label="nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital_lbl" xml:lang="en-US">Reclassification Of Derivative Liabilities To Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital_lbl" xml:lang="en-US">Fair value of derivative warrants reclassified to additional paid-in capital upon cashless exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" xlink:to="nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ReclassificationOfWarrantsToDerivativeLiability" xlink:label="nvlt_ReclassificationOfWarrantsToDerivativeLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_ReclassificationOfWarrantsToDerivativeLiability_lbl" xml:lang="en-US">Reclassification Of Warrants To Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_ReclassificationOfWarrantsToDerivativeLiability_lbl" xml:lang="en-US">Reclassification of warrants to derivative liability (see Note 2)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_ReclassificationOfWarrantsToDerivativeLiability" xlink:to="nvlt_ReclassificationOfWarrantsToDerivativeLiability_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RegistrationPaymentArrangementGainsAndLosses" xlink:label="us-gaap_RegistrationPaymentArrangementGainsAndLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RegistrationPaymentArrangementGainsAndLosses_lbl" xml:lang="en-US">Liquidated damages (see Note 6)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegistrationPaymentArrangementGainsAndLosses" xlink:to="us-gaap_RegistrationPaymentArrangementGainsAndLosses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Payments on capital lease obligations</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Payments on capital lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Payments on long-term obligations</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Payments on long-term obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US">Grant income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ReverseStockSplitTextBlock" xlink:label="nvlt_ReverseStockSplitTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_ReverseStockSplitTextBlock_lbl" xml:lang="en-US">Reverse Stock Split [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_ReverseStockSplitTextBlock_lbl" xml:lang="en-US">PROPOSED REVERSE STOCK SPLIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_ReverseStockSplitTextBlock" xlink:to="nvlt_ReverseStockSplitTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US">REVENUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember" xlink:label="nvlt_SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember_lbl" xml:lang="en-US">Series C Convertible Preferred Stock and Accumulated Dividends [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember_lbl" xml:lang="en-US">Series C Convertible Preferred Stock and Accumulated Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember" xlink:to="nvlt_SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Cumulative Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_SeriesDAndSeriesEPreferredStockMember" xlink:label="nvlt_SeriesDAndSeriesEPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_SeriesDAndSeriesEPreferredStockMember_lbl" xml:lang="en-US">Series D and Series E Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_SeriesDAndSeriesEPreferredStockMember_lbl" xml:lang="en-US">Redeemable Preferred Stock Series D and E Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_SeriesDAndSeriesEPreferredStockMember" xlink:to="nvlt_SeriesDAndSeriesEPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember" xlink:label="nvlt_SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember_lbl" xml:lang="en-US">Series E Convertible Preferred Stock and Accumulated Dividends [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember_lbl" xml:lang="en-US">Series E Convertible Preferred Stock and Accumulated Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember" xlink:to="nvlt_SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xml:lang="en-US">Series E redeemable convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesEPreferredStockMember" xlink:to="us-gaap_SeriesEPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning Balance (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Statement, Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US">Statement, Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity (deficiency)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity (deficiency)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY (DEFICIENCY):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' DEFICIENCY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="us-gaap_StockholdersEquityOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityOther_lbl" xml:lang="en-US">Stockholders' Equity, Other</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_StockholdersEquityOther_lbl" xml:lang="en-US">Cash paid in lieu of fractional shares in a business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityOther" xlink:to="us-gaap_StockholdersEquityOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityOtherShares" xlink:label="us-gaap_StockholdersEquityOtherShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityOtherShares_lbl" xml:lang="en-US">Cash paid in lieu of fractional shares in a business combination, (in shares)</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_StockholdersEquityOtherShares_lbl" xml:lang="en-US">Cash paid in lieu of fractional shares in a business combination, (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityOtherShares" xlink:to="us-gaap_StockholdersEquityOtherShares_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Fair value of common stock issued in exchange for tender of derivative warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Issuance of common stock in a business combination (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of Convertible Securities (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock in exchange for warrants (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants" xlink:label="nvlt_StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants_lbl" xml:lang="en-US">Stock Issued During Period Shares Preferred Stock And Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants_lbl" xml:lang="en-US">Issuance of Series E redeemable convertible preferred stock and warrants, net of issuance costs of $795,469 (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants" xlink:to="nvlt_StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xml:lang="en-US">Number of shares issued during the period as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xml:lang="en-US">Exercise of warrant to purchase common stock (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Issuance of common stock in a business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock in exchange for warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants" xlink:label="nvlt_StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants_lbl" xml:lang="en-US">Stock issued during period value preferred stock and common stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants_lbl" xml:lang="en-US">Issuance of Series E redeemable convertible preferred stock and warrants, net of issuance costs of $795,469</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants" xlink:to="nvlt_StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl" xml:lang="en-US">Issuance of Series E redeemable convertible preferred stock in payment of accumulated dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xml:lang="en-US">Value stock issued during the period as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xml:lang="en-US">Exercise of warrant to purchase common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Common stock repurchased (in shares)</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Common stock repurchased (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Common stock repurchased</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Common stock repurchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_SupplementalFinancialInformationDisclosureTextBlock" xlink:label="nvlt_SupplementalFinancialInformationDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_SupplementalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">Supplemental Financial Information Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_SupplementalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">(UNAUDITED) SUPPLEMENTAL PRO FORMA INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_SupplementalFinancialInformationDisclosureTextBlock" xlink:to="nvlt_SupplementalFinancialInformationDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_SupplementalIssuanceOfStockAndWarrants" xlink:label="nvlt_SupplementalIssuanceOfStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_SupplementalIssuanceOfStockAndWarrants_lbl" xml:lang="en-US">Supplemental Issuance of Stock and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_SupplementalIssuanceOfStockAndWarrants_lbl" xml:lang="en-US">Relative fair value of warrants issued to stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_SupplementalIssuanceOfStockAndWarrants" xlink:to="nvlt_SupplementalIssuanceOfStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US">REDEEMABLE PREFERRED STOCK:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityCarryingAmount" xlink:label="us-gaap_TemporaryEquityCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmount_lbl" xml:lang="en-US">Series E convertible preferred stock, $0.00001 par value; 735 shares designated, 0 and 548.26078125 shares issued and outstanding at December 31, 2010 and 2009, respectively (see Note 6)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmount" xlink:to="us-gaap_TemporaryEquityCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Series E convertible preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_TemporaryEquitySharesDesignated" xlink:label="nvlt_TemporaryEquitySharesDesignated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_TemporaryEquitySharesDesignated_lbl" xml:lang="en-US">Temporary Equity, Shares Designated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_TemporaryEquitySharesDesignated_lbl" xml:lang="en-US">Series E convertible preferred stock, shares designated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_TemporaryEquitySharesDesignated" xlink:to="nvlt_TemporaryEquitySharesDesignated_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Series E convertible preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Series E convertible preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xml:lang="en-US">SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:to="nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">SHARES USED IN COMPUTING DILUTED NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">SHARES USED IN COMPUTING BASIC NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>nvlt-20110930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.12.8 -->
<!-- Round: 46fe4b0a-935c-45f1-95b0-e159dfba7207 -->
<!-- Creation date: 2011-11-08T18:13:49Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.novelos.com/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.novelos.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.novelos.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.novelos.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.novelos.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsMergersAcquisitionsAndDispositionsDisclosuresTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsMergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsSupplementalFinancialInformationDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSupplementalFinancialInformationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsReverseStockSplitTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsReverseStockSplitTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nvlt-20110930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/DocumentDocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_DocumentDocumentandEntityInformationAbstract" xlink:label="nvlt_DocumentDocumentandEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_DocumentDocumentandEntityInformationAbstract" xlink:to="dei_EntitiesTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.0700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_DocumentInformationLineItems" order="100.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:label="us-gaap_DividendsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PreAcquisitionMember" xlink:label="nvlt_PreAcquisitionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityCarryingAmount" xlink:label="us-gaap_TemporaryEquityCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.3300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.3400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.3500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="1.3600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.3800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.4000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.4100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.4200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="1.4300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nvlt_PreAcquisitionMember" order="1.1800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.0400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" order="1.0600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.0700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DividendsPayableCurrent" order="1.1200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="1.1300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="1.1400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="1.1600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" order="1.2100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="1.2200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="1.2400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.1900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.2000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.2700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" order="1.3000" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmount" order="1.2600" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PreAcquisitionMember" xlink:label="nvlt_PreAcquisitionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PreferredStockSharesDesignated" xlink:label="nvlt_PreferredStockSharesDesignated"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_TemporaryEquitySharesDesignated" xlink:label="nvlt_TemporaryEquitySharesDesignated"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nvlt_PreAcquisitionMember" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="1.0300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_TemporaryEquitySharesDesignated" order="1.0400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1.0500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1.0600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_PreferredStockSharesDesignated" order="1.0900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.1000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.1100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.1200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.1300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.1400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.1500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_DeemedDividendsOnPreferredStock" xlink:label="nvlt_DeemedDividendsOnPreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:label="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PreAcquisitionMember" xlink:label="nvlt_PreAcquisitionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RegistrationPaymentArrangementGainsAndLosses" xlink:label="us-gaap_RegistrationPaymentArrangementGainsAndLosses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nvlt_PreAcquisitionMember" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.1800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" order="1.1900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.2100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_RevenueFromGrants" order="1.2200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" order="1.2300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_RegistrationPaymentArrangementGainsAndLosses" order="1.2400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1.2500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="1.2600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.2700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueNet" order="1.0300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1.0400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="1.0800" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_DeemedDividendsOnPreferredStock" order="1.0900" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="1.1200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding" order="1.1300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.1400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.1500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.1600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock" xlink:label="nvlt_AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue" xlink:label="nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember" xlink:label="nvlt_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember" xlink:label="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_IssuanceOfCommonStockAndWarrantsShares" xlink:label="nvlt_IssuanceOfCommonStockAndWarrantsShares"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_IssuanceOfCommonStockAndWarrantsValue" xlink:label="nvlt_IssuanceOfCommonStockAndWarrantsValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_LicenseRightsAndEquipmentMember" xlink:label="nvlt_LicenseRightsAndEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PreAcquisitionMember" xlink:label="nvlt_PreAcquisitionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="us-gaap_PreferredStockDividendsShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PublicOfferingMember" xlink:label="nvlt_PublicOfferingMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ReclassificationOfWarrantsToDerivativeLiability" xlink:label="nvlt_ReclassificationOfWarrantsToDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember" xlink:label="nvlt_SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_SeriesDAndSeriesEPreferredStockMember" xlink:label="nvlt_SeriesDAndSeriesEPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember" xlink:label="nvlt_SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="us-gaap_StockholdersEquityOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityOtherShares" xlink:label="us-gaap_StockholdersEquityOtherShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants" xlink:label="nvlt_StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants" xlink:label="nvlt_StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nvlt_PreAcquisitionMember" order="1.1100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.5200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.5300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nvlt_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember" order="1.5400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nvlt_SeriesDAndSeriesEPreferredStockMember" order="1.5500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.5600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.5700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_CashMember" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember" order="1.0300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="nvlt_LicenseRightsAndEquipmentMember" order="1.0400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="1.0500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="nvlt_SeriesCConvertiblePreferredStockAndAccumulatedDividendsMember" order="1.0600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="nvlt_SeriesEConvertiblePreferredStockAndAccumulatedDividendsMember" order="1.0700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1.0800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="nvlt_PublicOfferingMember" order="1.0900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_PreferredStockMember" order="1.1000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="1.1300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="1.1400" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.1250" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="1.1301" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="1.1700" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_ReclassificationOfWarrantsToDerivativeLiability" order="1.1800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityOtherShares" order="1.1900" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityOther" order="1.2000" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_IssuanceOfCommonStockAndWarrantsShares" order="1.2100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_IssuanceOfCommonStockAndWarrantsValue" order="1.2200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" order="1.2300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised" order="1.2400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised" order="1.2500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1.2600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="1.2700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="1.2800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" order="1.3000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants" order="1.3100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock" order="1.3200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants" order="1.3300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred" order="1.3400" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend" order="1.3600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsShares" order="1.3500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue" order="1.3700" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="1.3800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants" order="1.3900" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPreferredStock" order="1.4000" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.4100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_2" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.4400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.4500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.4600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.4700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1720" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.1710" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="1.3250" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders" order="1.3260" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="11.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="12.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_DividendsPayableOnConvertiblePreferredStock" xlink:label="nvlt_DividendsPayableOnConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ExchangeOfConvertiblePreferredStock" xlink:label="nvlt_ExchangeOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_FairValueOfDerivativeInstrument" xlink:label="nvlt_FairValueOfDerivativeInstrument"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" xlink:label="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes" xlink:label="nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:label="us-gaap_NewAccountingPronouncementMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NonCashItemsMember" xlink:label="nvlt_NonCashItemsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PreAcquisitionMember" xlink:label="nvlt_PreAcquisitionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants" xlink:label="nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" xlink:label="nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_SupplementalIssuanceOfStockAndWarrants" xlink:label="nvlt_SupplementalIssuanceOfStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.4700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.4800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" order="1.4900" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.5000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="1.5100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.5200" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments" order="1.5300" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="1.5400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.5500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nvlt_PreAcquisitionMember" order="1.5600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.2200" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.2700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.2800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="1.2900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="1.3000" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.3100" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.3200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.3300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants" order="1.3400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="1.3500" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" order="1.3600" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="1.3700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.3800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="1.1400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1500" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.1600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="1.1700" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="1.1800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.1900" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1.2000" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.4400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.4500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.4600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="1.4000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.4100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_NewAccountingPronouncementMember" order="1.4200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="nvlt_NonCashItemsMember" order="1.4300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.5700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.5800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.5900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.6000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.6100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.6200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.6300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="11.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital" order="1.0300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes" order="1.0400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="1.0500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="1.0600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_LiabilitiesAssumed1" order="1.0700" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_Goodwill" order="1.0800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nvlt_DividendsPayableOnConvertiblePreferredStock" order="1.0900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nvlt_FairValueOfDerivativeInstrument" order="1.1000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_StockIssued1" order="1.1100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nvlt_ExchangeOfConvertiblePreferredStock" order="1.1200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nvlt_SupplementalIssuanceOfStockAndWarrants" order="1.1300" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PreAcquisitionMember" xlink:label="nvlt_PreAcquisitionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_PublicOfferingMember" xlink:label="nvlt_PublicOfferingMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nvlt_PreAcquisitionMember" order="1.0500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="1.0300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="nvlt_PublicOfferingMember" order="1.0400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1.0600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="4.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsMergersAcquisitionsAndDispositionsDisclosuresTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:label="nvlt_CollaborativeAndLicenseArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_CollaborativeAndLicenseArrangementDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ConvertibleDebtDisclosureTextBlock" xlink:label="nvlt_ConvertibleDebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_ConvertibleDebtDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_LineOfCreditFacilitiesTextBlock" xlink:label="nvlt_LineOfCreditFacilitiesTextBlock"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_LineOfCreditFacilitiesTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSupplementalFinancialInformationDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_SupplementalFinancialInformationDisclosureTextBlock" xlink:label="nvlt_SupplementalFinancialInformationDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_SupplementalFinancialInformationDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsReverseStockSplitTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_ReverseStockSplitTextBlock" xlink:label="nvlt_ReverseStockSplitTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="nvlt_ReverseStockSplitTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nvlt-20110930.xsd#nvlt_NotesToFinancialStatementsAbstract" xlink:label="nvlt_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nvlt_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1023
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E5VAG"><tr><th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) (USD $)<br /></strong></div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th><th class="th"><div>Dec. 31, 2009</div></th><th class="th"><div>Mar. 31, 2011

</div><div>Pre Acquisition</div></th><th class="th"><div>Dec. 31, 2010

</div><div>Pre Acquisition</div></th><th class="th"><div>Dec. 31, 2009

</div><div>Pre Acquisition</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Series E convertible preferred stock, par value</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">$ 0.00001<span /></td><td class="nump">$ 0.00001<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_TemporaryEquitySharesDesignated', window );">Series E convertible preferred stock, shares designated</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">735<span /></td><td class="nump">735<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Series E convertible preferred stock, shares issued</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">0.00000000<span /></td><td class="nump">548.26078125<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series E convertible preferred stock, shares outstanding</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">0.00000000<span /></td><td class="nump">548.26078125<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td><td class="nump">$ 0.00001<span /></td><td class="nump">$ 0.00001<span /></td><td class="nump">$ 0.00001<span /></td><td class="text">&#xA0;<span /></td><td class="nump">$ 0.00001<span /></td><td class="nump">$ 0.00001<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td><td class="nump">7,000<span /></td><td class="nump">7,000<span /></td><td class="nump">7,000<span /></td><td class="text">&#xA0;<span /></td><td class="nump">7,000<span /></td><td class="nump">7,000<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_PreferredStockSharesDesignated', window );">Preferred Stock, shares designated</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">272<span /></td><td class="nump">272<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, issued</a></td><td class="nump">0<span /></td><td class="nump">0<span /></td><td class="nump">0<span /></td><td class="text">&#xA0;<span /></td><td class="nump">0<span /></td><td class="nump">204<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td><td class="nump">0<span /></td><td class="nump">0<span /></td><td class="nump">0<span /></td><td class="text">&#xA0;<span /></td><td class="nump">0<span /></td><td class="nump">204<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td><td class="nump">$ 0.00001<span /></td><td class="nump">$ 0.00001<span /></td><td class="nump">$ 0.00001<span /></td><td class="nump">$ 0.00001<span /></td><td class="nump">$ 0.00001<span /></td><td class="nump">$ 0.00001<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td><td class="nump">150,000,000<span /></td><td class="nump">150,000,000<span /></td><td class="nump">150,000,000<span /></td><td class="nump">150,000,000<span /></td><td class="nump">150,000,000<span /></td><td class="nump">150,000,000<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td><td class="nump">26,826,157<span /></td><td class="nump">12,820,102<span /></td><td class="nump">12,820,102<span /></td><td class="nump">2,959,871<span /></td><td class="nump">2,959,914<span /></td><td class="nump">455,281<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td><td class="nump">26,826,157<span /></td><td class="nump">12,820,102<span /></td><td class="nump">12,820,102<span /></td><td class="nump">2,959,871<span /></td><td class="nump">2,959,914<span /></td><td class="nump">455,281<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_PreferredStockSharesDesignated"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Shares Designated</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_PreferredStockSharesDesignated</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_TemporaryEquitySharesDesignated"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares Designated</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_TemporaryEquitySharesDesignated</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 4<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockSharesIssued</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.28)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 29<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 2, 3, 4, 5, 6, 7, 8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 29<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 2, 3, 4, 5, 6, 7, 8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.28)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 29<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.28)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 29<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.28)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of stock classified as temporary equity; generally not indicative of the fair market value per share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 28<br /><br /> -Article 5<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquityParOrStatedValuePerShare</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 28<br /><br /> -Subparagraph b<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.27(b))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquitySharesIssued</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 28<br /><br /> -Subparagraph b<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.27(b))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquitySharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1024
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E51BI"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS (USD $)<br /></strong></div></th><th class="th" colspan="2">9 Months Ended</th><th class="th" colspan="2">12 Months Ended</th><th class="th" colspan="1">99 Months Ended</th><th class="th" colspan="2">3 Months Ended</th><th class="th" colspan="2">12 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Sep. 30, 2010</div></th><th class="th"><div>Dec. 31, 2010</div></th><th class="th"><div>Dec. 31, 2009</div></th><th class="th"><div>Dec. 31, 2010</div></th><th class="th"><div>Mar. 31, 2011

</div><div>Pre Acquisition</div></th><th class="th"><div>Mar. 31, 2010

</div><div>Pre Acquisition</div></th><th class="th"><div>Dec. 31, 2010

</div><div>Pre Acquisition</div></th><th class="th"><div>Dec. 31, 2009

</div><div>Pre Acquisition</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">REVENUE</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">$ 8,333<span /></td><td class="nump">$ 8,333<span /></td><td class="nump">$ 33,334<span /></td><td class="nump">$ 33,334<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>COSTS AND EXPENSES:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td><td class="nump">2,445,429<span /></td><td class="nump">2,616,834<span /></td><td class="nump">2,984,207<span /></td><td class="nump">4,351,983<span /></td><td class="nump">17,205,959<span /></td><td class="nump">532,686<span /></td><td class="nump">1,910,889<span /></td><td class="nump">2,997,984<span /></td><td class="nump">8,080,242<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td><td class="nump">1,827,510<span /></td><td class="nump">1,014,094<span /></td><td class="nump">1,156,549<span /></td><td class="nump">1,824,302<span /></td><td class="nump">6,970,179<span /></td><td class="nump">611,877<span /></td><td class="nump">644,763<span /></td><td class="nump">2,486,032<span /></td><td class="nump">2,182,253<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed', window );">Merger costs</a></td><td class="nump">746,207<span /></td><td class="text">&#xA0;<span /></td><td class="nump">52,925<span /></td><td class="text">&#xA0;<span /></td><td class="nump">52,925<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td><td class="nump">5,019,146<span /></td><td class="nump">3,630,928<span /></td><td class="nump">4,193,681<span /></td><td class="nump">6,176,285<span /></td><td class="nump">24,229,063<span /></td><td class="nump">1,144,563<span /></td><td class="nump">2,555,652<span /></td><td class="nump">5,484,016<span /></td><td class="nump">10,262,495<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td><td class="num">(5,019,146)<span /></td><td class="num">(3,630,928)<span /></td><td class="num">(4,193,681)<span /></td><td class="num">(6,176,285)<span /></td><td class="num">(24,229,063)<span /></td><td class="num">(1,136,230)<span /></td><td class="num">(2,547,319)<span /></td><td class="num">(5,450,682)<span /></td><td class="num">(10,229,161)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">668<span /></td><td class="text">&#xA0;<span /></td><td class="nump">2,421<span /></td><td class="nump">1,013<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant income</a></td><td class="nump">44,479<span /></td><td class="text">&#xA0;<span /></td><td class="nump">200,000<span /></td><td class="text">&#xA0;<span /></td><td class="nump">200,000<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">244,479<span /></td><td class="nump">62,980<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments', window );">(Gain) loss on derivative warrants</a></td><td class="num">(66,820)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">125,490<span /></td><td class="nump">7,897,441<span /></td><td class="nump">8,118,174<span /></td><td class="num">(12,114,371)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementGainsAndLosses', window );">Liquidated damages (see Note 6)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(819,000)<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td><td class="num">(428,015)<span /></td><td class="num">(467,495)<span /></td><td class="num">(566,156)<span /></td><td class="num">(43,588)<span /></td><td class="num">(17,102)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Miscellaneous</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">6,233<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(426)<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1,161<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td><td class="num">(450,356)<span /></td><td class="num">(467,495)<span /></td><td class="num">(366,582)<span /></td><td class="num">(43,588)<span /></td><td class="nump">184,059<span /></td><td class="nump">126,158<span /></td><td class="nump">7,897,441<span /></td><td class="nump">7,546,074<span /></td><td class="num">(12,044,145)<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td><td class="num">(5,469,502)<span /></td><td class="num">(4,098,423)<span /></td><td class="num">(4,560,263)<span /></td><td class="num">(6,219,873)<span /></td><td class="num">(24,045,004)<span /></td><td class="num">(1,010,072)<span /></td><td class="nump">5,350,122<span /></td><td class="nump">2,095,392<span /></td><td class="num">(22,273,306)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">PREFERRED STOCK DIVIDENDS</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(656,635)<span /></td><td class="num">(2,207,827)<span /></td><td class="num">(3,296,289)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_DeemedDividendsOnPreferredStock', window );">PREFERRED STOCK DEEMED DIVIDENDS</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(12,541,201)<span /></td><td class="num">(714,031)<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">$ (1,010,072)<span /></td><td class="nump">$ 4,693,487<span /></td><td class="num">$ (12,653,636)<span /></td><td class="num">$ (26,283,626)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</a></td><td class="num">$ (0.25)<span /></td><td class="num">$ (0.32)<span /></td><td class="num">$ (0.36)<span /></td><td class="num">$ (0.49)<span /></td><td class="num">$ (2.53)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">$ (15.36)<span /></td><td class="num">$ (80.57)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">$ (0.34)<span /></td><td class="nump">$ 8.99<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding', window );">SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</a></td><td class="nump">21,847,984<span /></td><td class="nump">12,820,102<span /></td><td class="nump">12,820,102<span /></td><td class="nump">12,820,102<span /></td><td class="nump">9,513,115<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">823,933<span /></td><td class="nump">326,209<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">SHARES USED IN COMPUTING BASIC NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">2,959,871<span /></td><td class="nump">522,350<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">$ (0.34)<span /></td><td class="nump">$ 3.41<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">SHARES USED IN COMPUTING DILUTED NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">2,959,871<span /></td><td class="nump">881,861<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_DeemedDividendsOnPreferredStock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividends On Preferred Stock</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_DeemedDividendsOnPreferredStock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 141R<br /><br /><br /><br /> -Paragraph 57<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 141R<br /><br /><br /><br /> -Paragraph 68<br /><br /><br /><br /> -Subparagraph n<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 805<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (f)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1392-128463<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 225<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (SX 210.5-03)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CostsAndExpenses</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CostsAndExpensesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 260<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 55<br /><br /><br /><br /> -Paragraph 52<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6945512&amp;loc=d3e4984-109258<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /><br /><br /> -Number 07-4<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 20<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 944<br /><br /><br /><br /> -SubTopic 225<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.7-04.19)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 04<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Paragraph 18<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 942<br /><br /><br /><br /> -SubTopic 225<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.9-04.23)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 128<br /><br /><br /><br /> -Paragraph 36, 37, 38<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 260<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br /><br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 225<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (SX 210.5-03.21)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /><br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 04<br /><br /><br /><br /> -Paragraph 21<br /><br /><br /><br /> -Article 9<br /><br /><br /><br /><br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 260<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EarningsPerShareBasic</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 128<br /><br /><br /><br /> -Paragraph 11, 12, 36<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 225<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (SX 210.5-03.21)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 20<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 260<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 04<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Paragraph 18<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 04<br /><br /><br /><br /> -Paragraph 21<br /><br /><br /><br /> -Article 9<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /><br /><br /> -Number 07-4<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EarningsPerShareDiluted</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 225<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (SX 210.5-03.4)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period, which was recognized in earnings, in the unrealized gains or losses on derivative instruments that are not or are no longer designated as hedging instruments.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 133<br /><br /><br /><br /> -Paragraph 18<br /><br /><br /><br /> -Subparagraph a, b<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 815<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 4C<br /><br /><br /><br /> -Subparagraph (e)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6935481&amp;loc=SL5624171-113959<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 815<br /><br /><br /><br /> -SubTopic 20<br /><br /><br /><br /> -Section 35<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (a)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6439004&amp;loc=d3e65527-113976<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_InterestIncomeExpenseNonoperatingNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 7<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 115<br /><br /><br /><br /> -Paragraph 14<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 225<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (SX 210.5-03.7(b))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 944<br /><br /><br /><br /> -SubTopic 225<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.7-04.22)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 230<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 28<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 225<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (SX 210.5-03.18)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 51<br /><br /><br /><br /> -Paragraph 38<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 260<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 220<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 6<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 51<br /><br /><br /><br /> -Paragraph A7<br /><br /><br /><br /> -Appendix A<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 130<br /><br /><br /><br /> -Paragraph 10, 15<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Other Comprehensive Income<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br /><br /><br /><br /><br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 51<br /><br /><br /><br /> -Paragraph 38<br /><br /><br /><br /> -Subparagraph d<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /><br /><br /> -Number 87-21<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Net Income<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br /><br /><br /><br /><br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 944<br /><br /><br /><br /> -SubTopic 225<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.7-04.19)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br /><br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /><br /><br /><br /><br />Reference 15: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 95<br /><br /><br /><br /> -Paragraph 28, 29, 30<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 16: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 04<br /><br /><br /><br /> -Paragraph 20<br /><br /><br /><br /> -Article 9<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetIncomeLoss</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 128<br /><br /><br /><br /> -Paragraph 9<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 260<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 11<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1377-109256<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 7<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 225<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (SX 210.5-03.7)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OperatingIncomeLoss</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 7<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Audit and Accounting Guide (AAG)<br /><br /><br /><br /> -Number AAG-BRD<br /><br /><br /><br /> -Chapter 4<br /><br /><br /><br /> -Paragraph 80<br /><br /><br /><br /> -Subparagraph Exhibit 4-4<br /><br /><br /><br /> -IssueDate 2006-05-01<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 225<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (SX 210.5-03.7)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OtherNonoperatingIncome</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 9<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 225<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (SX 210.5-03.9)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockDividendsIncomeStatementImpact</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementGainsAndLosses"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (gain) or increase (loss) in the carrying amount of the registration payment obligation that was recognized in earnings during the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name FASB Staff Position (FSP)<br /><br /><br /><br /> -Number EITF00-19-2<br /><br /><br /><br /> -Paragraph 12<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 825<br /><br /><br /><br /> -SubTopic 20<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (f)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RegistrationPaymentArrangementGainsAndLosses</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 985<br /><br /><br /><br /> -SubTopic 20<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 730<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 141<br /><br /><br /><br /> -Paragraph 51<br /><br /><br /><br /> -Subparagraph g<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 2<br /><br /><br /><br /> -Paragraph 12, 13<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 86<br /><br /><br /><br /> -Paragraph 11, 12<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 225<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (SX 210.5-03.1(e))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RevenueFromGrants</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 225<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (SX 210.5-03.1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_SalesRevenueNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 260<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 16<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1505-109256<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /><br /><br /> -Number 07-4<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 128<br /><br /><br /><br /> -Paragraph 40<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 128<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 260<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (a)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 260<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (a)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 260<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1448-109256<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 128<br /><br /><br /><br /> -Paragraph 171<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Weighted-Average Number of Common Shares Outstanding<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 128<br /><br /><br /><br /> -Paragraph 40<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 128<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /><br /><br /> -Number 07-4<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1025
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE RETIREMENT PLAN<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE RETIREMENT PLAN</a></td><td class="text"><div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
16.&#xA0; EMPLOYEE RETIREMENT PLAN</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
January 1, 2009, Cellectar adopted a Safe Harbor defined
contribution plan under Section 401(k) of the Internal Revenue Code
which covered eligible employees who meet minimum age requirements
and allowed participants to contribute a portion of their annual
compensation on a pre-tax basis.&#xA0; Cellectar contributed 3% of
each participant&#x2019;s compensation.&#xA0; Contributions made for
the years ended December 31, 2010 and 2009 were $23,000 and
$56,000, respectively.&#xA0; Cellectar paid administrative expenses
for the plan of $3,300 and $2,800 for the years ended December 31,
2010 and 2009, respectively.&#xA0; The plan was canceled effective
August 30, 2010.</font></div>
<br />
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Following
the Acquisition, the Company has a defined contribution plan under
Section 401(k) of the Internal Revenue Code which allows eligible
employees who meet minimum age requirements to contribute a portion
of their annual compensation on a pre-tax basis.&#xA0; The Company
has not made any matching contributions under this
plan.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1026
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ECJAC"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td><td class="text">S-1<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td><td class="text">false<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td><td class="text">Sep. 30,         2011<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td><td class="text">NVLT<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td><td class="text">NOVELOS THERAPEUTICS, INC.<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td><td class="text">0001279704<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td><td class="text">Smaller Reporting Company<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_AmendmentFlag</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:booleanItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentInformationLineItems</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentPeriodEndDate</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:dateItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, and Other.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentType</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:submissionTypeItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation 12B<br /><br /> -Number 240<br /><br /> -Section 12b<br /><br /> -Subsection 1<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityCentralIndexKey</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:centralIndexKeyItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityFilerCategory</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:filerCategoryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation 12B<br /><br /> -Number 240<br /><br /> -Section 12b<br /><br /> -Subsection 1<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityRegistrantName</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:normalizedStringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_TradingSymbol</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:normalizedStringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1027
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPOSED REVERSE STOCK SPLIT<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_ReverseStockSplitTextBlock', window );">PROPOSED REVERSE STOCK SPLIT</a></td><td class="text"><div>
<div>
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
19.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
PROPOSED REVERSE STOCK SPLIT</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
June 30, 2011, the Company held a special meeting of
stockholders.&#xA0; At the meeting, the stockholders approved,
among other things, separate amendments to the certificate of
incorporation that would effect a reverse split of the
Company&#x2019;s common stock within a range of 1:2 to 1:10, and
authorized the Company&#x2019;s board of directors to determine the
ratio at which the reverse split will be effected by filing the
appropriate amendment to the certificate of incorporation.&#xA0;
The purpose of the proposed reverse split is to increase the price
per share of the Company&#x2019;s common stock in order to exceed
the minimum price per share required to secure a listing on a
national securities exchange. <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
July 1, 2011, the Company filed with the SEC&#xA0;a Registration
Statement on Form S-1 for an underwritten public offering of its
common stock with proceeds of up to $15,000,000, excluding the
underwriters over-allotment. The Company has applied for listing on
the NASDAQ Capital Market under the symbol "NVLT" in connection
with the proposed underwritten offering.</font></font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_ReverseStockSplitTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse Stock Split [Text Block]</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_ReverseStockSplitTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1028
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1029
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EGDAC"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th><th class="th" colspan="1">12 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">FIXED ASSETS</a></td><td class="text"><div>
<div>
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
5.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
FIXED ASSETS</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fixed
assets consisted of the following at December 31:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
2010</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
2009</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Office
and laboratory equipment</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,984,375</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,982,723</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Leasehold
improvements</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
2,317,597</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
2,317,597</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
fixed assets</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,301,972</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,300,320</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less
accumulated depreciation and amortization</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
(1,791,483</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
(1,211,369</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fixed
assets, net</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
3,510,489</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
4,088,951</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During
the nine months ended&#xA0;September 30, 2011, the change to net
fixed assets consisted of an increase of approximately $440,000
related to accumulated depreciation and amortization, purchases of
equipment totaling approximately $112,000, equipment disposals of
approximately $6,000, and approximately $7,000 related to the fair
value of fixed assets acquired as a result of the Acquisition (see
Note 4).</font></div>
</div><span /></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
3.&#xA0; FIXED ASSETS</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fixed
assets consisted of the following at December 31:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="MARGIN-LEFT: 36pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
2010</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
2009</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Office
and computer equipment</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">61,907</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">73,261</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Computer
software</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,896</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,896</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Leasehold
improvements</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,095</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,095</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
fixed assets</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">109,898</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">121,252</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less
accumulated depreciation and amortization</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(101,143</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(77,155</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fixed
assets, net</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
$</font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,755</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
$</font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">44,097</font></div>
</td>
</tr>
</table>
</div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 205<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.13-14)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 5<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 360<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 360<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1030
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E3H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AGREEMENTS<br /></strong></div></th><th class="th" colspan="1">3 Months Ended</th><th class="th" colspan="1">12 Months Ended</th></tr><tr><th class="th"><div>Mar. 31, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS</a></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr valign="top">
<td style="WIDTH: 36pt" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
3.&#xA0;</font></div>
</td>
<td align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
COLLABORATION AGREEMENTS</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In
December 2007 the Company entered into a Collaboration Agreement
with Lee&#x2019;s Pharmaceutical (HK) Ltd. (&#x201C;Lee&#x2019;s
Pharm&#x201D;). Pursuant to this agreement, Lee&#x2019;s Pharm
obtained an exclusive license to develop, manufacture and
commercialize NOV-002 and NOV-205 in China, Hong Kong, Taiwan and
Macau (the &#x201C;Chinese Territory&#x201D;). The Company has
suspended further development of NOV-205; however, this suspension
may not impact the development strategy of Lee&#x2019;s
Pharm.&#xA0;&#xA0;Under the terms of the agreement the Company
received a license fee of $500,000 in March 2008 and is entitled to
receive up to $1,700,000 in future milestone payments upon the
completion of development and marketing milestones by Lee&#x2019;s
Pharm. This initial $500,000 payment received is being amortized
over the estimated term of this agreement, 15 years. Accordingly,
$8,333 of license revenue was recognized in each of the three-month
periods ended March 31, 2011 and 2010.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
Lee&#x2019;s Pharm agreement provides that the Company receive
royalty payments of 20-25% of net sales of NOV-002 in the Chinese
Territory and receive royalty payments of 12-15% of net sales of
NOV-205 in the Chinese Territory. Lee&#x2019;s Pharm is obligated to
reimburse the Company for the manufacturing cost of pharmaceutical
products provided to Lee&#x2019;s Pharm in connection with the
agreement. Lee&#x2019;s Pharm has committed to spend a minimum
amount on development in the first four years of the agreement. The
agreement expires upon the expiration of the last patent covering
any of the licensed products, or twelve years from the date of the
first commercial sale in China, whichever occurs
later.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
February 11, 2009, Novelos entered into a collaboration agreement
(the &#x201C;Collaboration Agreement&#x201D;) with Mundipharma
International Corporation Limited (&#x201C;Mundipharma&#x201D;) to
develop, manufacture and commercialize, on an exclusive basis,
Licensed Products (as defined in the Collaboration Agreement),
which includes the Company&#x2019;s compound, NOV-002, in Europe
(other than the Russian Territory), Asia (other than the Chinese
Territory) and Australia (collectively referred to as the
&#x201C;Mundipharma Territory&#x201D;).&#xA0; Mundipharma is an
independent associated company of Purdue Pharma, L.P.
(&#x201C;Purdue&#x201D;).&#xA0;&#xA0;The Collaboration Agreement
provides for Mundipharma to pay the Company royalties and fixed
milestone payments based on sales and commercial launches in the
licensed territories.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For
countries in which patents are held, the Collaboration Agreement
expires on a country-by-country basis within the Mundipharma
Territory on the earlier of (1) expiration of the last applicable
Novelos patent within the country or (2) the determination that any
patents within the country are invalid, obvious or otherwise
unenforceable.&#xA0;&#xA0;For countries in which no patents are
held, the Collaboration Agreement expires the earlier of 15 years
from its effective date or upon generic product competition in the
country resulting in a 20% drop in Mundipharma&#x2019;s market
share.&#xA0;&#xA0;Novelos may terminate the Collaboration Agreement
upon breach or default by Mundipharma.&#xA0; Mundipharma may
terminate the Collaboration Agreement upon breach or default,
filing of voluntary or involuntary bankruptcy by Novelos, the
termination of certain agreements with companies associated with
the originators of the licensed technology, or 30-day notice for no
reason.&#xA0;&#xA0;If any regulatory approval within the
Mundipharma Territory is suspended as a result of issues related to
the safety of the Licensed Products, then Mundipharma&#x2019;s
obligations under the Collaboration Agreement will be suspended
until the regulatory approval is reinstated.&#xA0;&#xA0;If that
reinstatement does not occur within 12 months of the suspension,
then Mundipharma may terminate the Collaboration
Agreement.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Concurrently
with the execution of the Collaboration Agreement, Novelos
completed a private placement of Series E preferred stock and
common stock purchase warrants to Purdue.</font></div>
<br />
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
Company expects that the negative results of its Phase 3 Trial will
adversely affect development and commercialization of NOV-002 under
the collaboration agreements with Lee&#x2019;s Pharm and
Mundipharma.</font></div>
</div><span /></td><td class="text"><div>
<div>
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-SIZE: 10pt">5.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-SIZE: 10pt">COLLABORATION
AGREEMENTS</font></font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
2007 Collaboration Agreement with Lee&#x2019;s Pharmaceutical (HK)
Ltd.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
December 2007 the Company entered into a Collaboration Agreement
with Lee&#x2019;s Pharmaceutical (HK) Ltd. (&#x201C;Lee&#x2019;s
Pharm&#x201D;). Pursuant to this agreement, Lee&#x2019;s Pharm
obtained an exclusive license to develop, manufacture and
commercialize NOV-002 and NOV-205 in China, Hong Kong, Taiwan and
Macau (the &#x201C;Chinese Territory&#x201D;). The Company has
suspended further development of NOV-205; however, this suspension
may not impact the development strategy of Lee&#x2019;s Pharm.&#xA0;
Under the terms of the agreement the Company received a license fee
of $500,000 in March 2008 and is entitled to receive up to
$1,700,000 in future milestone payments upon the completion of
development and marketing milestones by Lee&#x2019;s Pharm. This
initial $500,000 payment received is being amortized over the
estimated term of this agreement, 15 years. Accordingly, $33,000 of
license revenue was recognized in each of the years ended December
31, 2010 and 2009.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Lee&#x2019;s Pharm agreement provides that the Company receive
royalty payments of 20-25% of net sales of NOV-002 in the Chinese
Territory and receive royalty payments of 12-15% of net sales of
NOV-205 in the Chinese Territory. Lee&#x2019;s Pharm is obligated to
reimburse the Company for the manufacturing cost of pharmaceutical
products provided to Lee&#x2019;s Pharm in connection with the
agreement. Lee&#x2019;s Pharm has committed to spend a minimum
amount on development in the first four years of the agreement. The
agreement expires upon the expiration of the last patent covering
any of the licensed products, or twelve years from the date of the
first commercial sale in China, whichever occurs
later.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
2009 Collaboration Agreement with Mundipharma</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
February 11, 2009, Novelos entered into a collaboration agreement
(the &#x201C;Collaboration Agreement&#x201D;) with Mundipharma
International Corporation Limited (&#x201C;Mundipharma&#x201D;) to
develop, manufacture and commercialize, on an exclusive basis,
Licensed Products (as defined in the Collaboration Agreement),
which includes the Company&#x2019;s lead compound, NOV-002, in
Europe (other than the Russian Territory), Asia (other than the
Chinese Territory) and Australia (collectively referred to as the
&#x201C;Mundipharma Territory&#x201D;).&#xA0; Mundipharma is an
independent associated company of Purdue Pharma, L.P.
(&#x201C;Purdue&#x201D;).&#xA0; The Collaboration Agreement provides
for Mundipharma to pay the Company royalties and fixed milestone
payments based on sales and commercial launches in the licensed
territories.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For
countries in which patents are held, the Collaboration Agreement
expires on a country-by-country basis within the Mundipharma
Territory on the earlier of (1) expiration of the last applicable
Novelos patent within the country or (2) the determination that any
patents within the country are invalid, obvious or otherwise
unenforceable.&#xA0; For countries in which no patents are held,
the Collaboration Agreement expires the earlier of 15 years from
its effective date or upon generic product competition in the
country resulting in a 20% drop in Mundipharma&#x2019;s market
share.&#xA0; Novelos may terminate the Collaboration Agreement upon
breach or default by Mundipharma.&#xA0; Mundipharma may terminate
the Collaboration Agreement upon breach or default, filing of
voluntary or involuntary bankruptcy by Novelos, the termination of
certain agreements with companies associated with the originators
of the licensed technology, or 30-day notice for no reason.&#xA0;
If any regulatory approval within the Mundipharma Territory is
suspended as a result of issues related to the safety of the
Licensed Products, then Mundipharma&#x2019;s obligations under the
Collaboration Agreement will be suspended until the regulatory
approval is reinstated.&#xA0; If that reinstatement does not occur
within 12 months of the suspension, then Mundipharma may terminate
the Collaboration Agreement.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Concurrently
with the execution of the Collaboration Agreement, Novelos
completed a private placement of Series E preferred stock and
common stock purchase warrants to Purdue.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company expects that the negative results of its Phase 3 Trial will
adversely affect development and commercialization of NOV-002 under
the collaboration agreements with Lee&#x2019;s Pharm and
Mundipharma.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 07-1<br /><br /> -Paragraph 21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 808<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CollaborativeArrangementDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1031
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(UNAUDITED) SUPPLEMENTAL PRO FORMA INFORMATION<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_SupplementalFinancialInformationDisclosureTextBlock', window );">(UNAUDITED) SUPPLEMENTAL PRO FORMA INFORMATION</a></td><td class="text"><div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
18.&#xA0; (UNAUDITED) SUPPLEMENTAL PRO FORMA
INFORMATION</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
table below summarizes&#xA0;net loss for the periods shown as
though the Acquisition occurred as of January 1, 2010:</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<font style="DISPLAY: inline">For&#xA0;the&#xA0;Nine&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
For&#xA0;the&#xA0;Twelve</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
Months&#xA0;Ended</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
December&#xA0;31,</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr>
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<font style="DISPLAY: inline">2011</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr>
<td align="left" valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net
loss</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">
(5,290,519</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">
(783,007</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#xA0;</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">
(1,704,966</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr>
</table>
</div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The
pro forma&#xA0;net loss&#xA0;has been adjusted for the
following:</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="LETTER-SPACING: 9pt">
&#xA0;&#xA0;</font>1)<font style="LETTER-SPACING: 9pt">&#xA0;&#xA0;</font></font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Elimination
of $165,000, $266,000, and $361,000 of interest expense for the
nine months ended September 30, 2011 and 2010 and the twelve months
ended December 31, 2010, respectively; such amounts relate to
interest accrued on the Convertible Notes which were converted
immediately prior to the Acquisition (see Note 7) and the Bank Note
which was paid in full settlement of the note immediately prior to
the Acquisition (see Note 8).</font></div>
</td>
</tr>
</table>
</div>
</div>
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 9pt">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="LETTER-SPACING: 9pt">
&#xA0;&#xA0;</font>2)<font style="LETTER-SPACING: 9pt">&#xA0;&#xA0;</font></font></div>
</div>
</td>
<td align="left">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Recognition
of a additional BCF of $463,000 in the nine months ended September
30, 2010 and the year ended December 31, 2010 and the elimination
of BCF of $258,000 in the nine months ended September 30, 2011 in
connection with the conversion of the Convertible Notes, which is
assumed to have occurred on January 1, 2010 for the purpose of pro
forma presentation (see Note 7).</font></div>
</div>
</td>
</tr>
</table>
</div>
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 9pt">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="LETTER-SPACING: 9pt">
&#xA0;&#xA0;</font>3)<font style="LETTER-SPACING: 9pt">&#xA0;&#xA0;</font></font></div>
</div>
</td>
<td align="left">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Elimination
of Acquisition costs incurred during the nine months ended
September 30, 2011 and the twelve months ended December 31, 2010,
which are assumed to have been incurred prior to January 1, 2010
for the purpose of presentation in the pro forma statements of
operations.</font></div>
</div>
</td>
</tr>
</table>
</div>
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 9pt">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="LETTER-SPACING: 9pt">
&#xA0;&#xA0;</font>4)<font style="LETTER-SPACING: 9pt">&#xA0;&#xA0;</font></font></div>
</div>
</td>
<td align="left">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Elimination
of $450,000 of investment banking fees incurred upon the
consummation of the Acquisition on April 8, 2011 from the nine
months ended September 30, 2011.</font></div>
</div>
</td>
</tr>
</table>
</div>
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 9pt">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="LETTER-SPACING: 9pt">
&#xA0;&#xA0;</font>5)<font style="LETTER-SPACING: 9pt">&#xA0;&#xA0;</font></font></div>
</div>
</td>
<td align="left">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Elimination
of dividends and deemed dividends on Novelos&#x2019; preferred
convertible stock, which is assumed to have been exchanged for
common stock at January 1, 2010 in order to reflect the
post-acquisition capital structure for the purpose of pro forma
presentation.</font></div>
</div>
</td>
</tr>
</table>
</div>
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 9pt">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="LETTER-SPACING: 9pt">&#xA0;&#xA0;</font>6)<font style="LETTER-SPACING: 9pt">&#xA0;&#xA0;</font></div>
</div>
</td>
<td align="left">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
Elimination of Novelos historical revenue related to the
amortization of deferred revenue that was determined to have no
fair value in purchase accounting.</div>
</div>
</td>
</tr>
</table>
</div>
<div>
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="LETTER-SPACING: 9pt">
&#xA0;&#xA0;</font>7)<font style="LETTER-SPACING: 9pt">&#xA0;&#xA0;</font></font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Elimination
of liquidated damages accrued in 2010 related to
Novelos<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#x2019;</font>
convertible preferred stock. The liquidated damages are assumed not
to have accrued as the preferred stock&#xA0;is assumed to&#xA0;have
been exchanged for common stock at January 1, 2010 in order to
reflect the post-acquisition capital structure for the purpose of
pro forma presentation.</font></div>
</td>
</tr>
</table>
</div>
</div>
</div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_SupplementalFinancialInformationDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Financial Information Disclosure</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_SupplementalFinancialInformationDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1032
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EXEAC"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' DEFICIENCY<br /></strong></div></th><th class="th" colspan="1">3 Months Ended</th><th class="th" colspan="1">9 Months Ended</th><th class="th" colspan="1">12 Months Ended</th></tr><tr><th class="th"><div>Mar. 31, 2011</div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' DEFICIENCY</a></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr valign="top">
<td style="WIDTH: 36pt" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
4.</font></div>
</td>
<td align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
STOCKHOLDERS&#x2019; EQUITY</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">
Common Stock Warrants</font> &#xA0;&#xA0;&#x2014; The following
table summarizes information with regard to outstanding warrants as
of March 31, 2011, issued in connection with equity and debt
financings since 2005.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="96%">
<tr>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="58%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Offering</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Number&#xA0;of&#xA0;Shares</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Issuable&#xA0;Upon</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Exercise&#xA0;of</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Outstanding</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Warrants</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Exercise</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Price</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="18%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Expiration&#xA0;Date</font></font></div>
</td>
</tr>
<tr>
<td valign="bottom" width="58%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="18%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="58%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series
B Preferred Stock &#x2013; placement agents</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="top" width="9%">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,392</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="top" width="1%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="top" width="9%">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">191.25</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="18%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May
2, 2012</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="58%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series
C Exchange</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="top" width="9%">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,169</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="top" width="1%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="top" width="9%">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">191.25</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="18%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May
2, 2012</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="58%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series
E Preferred Stock</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="top" width="9%">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,331</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="top" width="1%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="top" width="9%">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.45</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="18%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December
31, 2015</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="58%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">August
2009 Private Placement</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="top" width="9%">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,194</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="top" width="1%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="top" width="9%">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100.98</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="18%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December
31, 2015</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="58%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">July
2010 Direct Offering (1)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="top" width="9%">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">105,042</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="top" width="1%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="top" width="9%">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.71</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="18%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">July
27, 2015</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="58%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preferred
Incentive Warrants</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="top" width="9%">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">105,042</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="top" width="1%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="top" width="9%">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16.065</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="18%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">July
27, 2015</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="58%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="18%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="58%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="top" width="9%">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
315,170</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="18%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)&#xA0;&#xA0;The
exercise price of these warrants was adjusted to $0.75 per share in
connection with the private placement completed on April 8,
2011.&#xA0;&#xA0;See Note 10.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
March 7, 2011, warrants to purchase 33,569 shares of common stock
at $234.09 per share expired unexercised.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
May 3, 2011, 18,153 shares of common stock were issued in
connection with the cashless exercise of warrants to purchase
27,311 shares of common stock at $0.75 per share.</font></div>
</div><span /></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
10. STOCKHOLDERS&#x2019; EQUITY</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
January 1, 2008, Cellectar converted from a Wisconsin limited
liability company to a Wisconsin corporation (the
&#x201C;Conversion&#x201D;). Each issued and outstanding unit of
equity in the limited liability company immediately prior to the
Conversion was converted into one issued and outstanding share of
Cellectar common stock and each unexercised unit option outstanding
immediately prior to the Conversion was converted into an option to
acquire the same number of shares of the corporation&#x2019;s common
stock.&#xA0; For the purpose of presentation in these financial
statements, all amounts and disclosures related to equity issuances
prior to the Acquisition have been retroactively restated by
applying the Exchange Ratio in order to reflect the capital
structure of Novelos and therefore the issuance of Novelos common
stock, rather than member units in the limited liability company or
common stock of Cellectar, as applicable.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">From
inception until December 31, 2010, Cellectar issued 12,559,218
shares of common stock for net proceeds of approximately
$21,710,000.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
April 2011 Private Placement</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Concurrently
with and conditioned upon the execution of the Merger Agreement,
the Company entered into a Securities Purchase Agreement with
certain accredited investors under which the Company sold an
aggregate of 6,846,537 units, each unit consisting of one share of
its common stock and a warrant to purchase one share of its common
stock, at a price of $0.75 per unit, for gross proceeds of
approximately $5,135,000 (the &#x201C;April Private
Placement&#x201D;).&#xA0; The warrants have an exercise price of
$0.75 and expire on March 31, 2016.&#xA0; The warrant exercise
price and/or the common stock issuable pursuant to such warrant
will be subject to adjustment only for stock dividends, stock
splits or similar capital reorganizations so that the rights of the
warrant holders after such event will be equivalent to the rights
of warrant holders prior to such event.&#xA0; The relative fair
value of the warrants issued to the investors was $2,124,286 at
issuance and has been included as a component of
stockholders&#x2019; equity.&#xA0; The Company uses the
Black-Scholes option pricing model to value warrants and applies
assumptions that consider, among other variables, the fair value of
the underlying stock, risk-free interest rate, volatility, expected
life and dividend rates in estimating fair value for the warrants.
Assumptions used are generally consistent with those disclosed for
stock-based compensation (see Note 11).</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
Securities Purchase Agreement included a requirement that the
Company file with the SEC no later than October 5, 2011 (the
"Filing Deadline"), a registration statement covering the resale of
the shares of common stock, and the shares of common stock
underlying the warrants, issued pursuant to the Securities Purchase
Agreement that are not otherwise saleable under an available
exemption from registration requirements.&#xA0; The Company is also
required to use commercially reasonable efforts to have the
registration statement declared effective by December 4, 2011 (the
"Effectiveness Deadline"), and to keep the registration statement
continuously effective under the Securities Act of 1933, as amended
(the &#x201C;Securities Act&#x201D;), until the earlier of the date
when all the registrable securities covered by the registration
statement have been sold or the second anniversary of the
closing.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In
the event the Company fails to file the registration statement
within the timeframe specified by the Securities Purchase
Agreement, or if it fails to obtain effectiveness of this
registration on or prior to the December 4, 2011 (if there is no
review by the SEC) or by January 3, 2012 (if there is review by the
SEC) with respect to the maximum number of shares permitted to be
registered by the SEC, the Company will be required to pay to the
purchasers liquidated damages equal to 1.5% per month (pro-rated on
a daily basis for any period of less than a full month) of the
aggregate purchase price of the units purchased until the
registration statement is filed or declared effective, as
applicable, not to exceed 5% of the aggregate purchase price.&#xA0;
The Company will be allowed to suspend the use of the registration
statement for not more than 30 consecutive days, on not more than
two occasions, in any 12-month period.&#xA0; The Company has also
granted piggy-back registration rights with respect to any shares
of common stock that it is required to exclude from the
registration statement as a condition of its effectiveness, and has
also agreed to file further registration statements with respect to
any such shares six months after the effective date of the initial
registration statement.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
November 3, 2011, a majority of purchasers in the April Private
Placement, which majority constituted the requisite holders, as
defined by the applicable securities purchase agreement, consented
to extend the Filing Deadline to the 180<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font>
day following the final prospectus of a public offering of
securities contemplated by the Company and to extend the
Effectiveness Deadline to the 240<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font>
day following the final prospectus of the public
offering.&#xA0;&#xA0;As of September 30, 2011, and through the date
of this filing, the Company has not concluded that it is probable
that damages will become due; therefore, no accrual for damages has
been recorded.&#xA0;&#xA0;The Company will use its reasonable best
efforts to register the shares as may be permitted by the SEC until
such time as all of these shares either have been registered or may
be sold without restriction in reliance on Rule 144 under the
Securities Act.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company paid to Rodman, the placement agent for the financing, a
cash fee equal to $200,000 and issued warrants to purchase 192,931
shares of its common stock (having an exercise price of $0.75 and
which expire March 31, 2016) in consideration for their advisory
services with respect to the financing pursuant to the placement
agency agreement between Rodman and the Company.&#xA0; Rodman is
entitled to registration rights with respect to the shares of
common stock issuable upon exercise of these warrants.&#xA0; The
cash fee was recorded as a reduction of gross proceeds
received.&#xA0; The estimated fair value of the warrants issued to
the placement agent was $112,096 and was recorded as a component of
stockholders&#x2019; equity.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">
Common Stock Warrants</font> &#xA0;&#x2014; The following table
summarizes information with regard to outstanding warrants to
purchase common stock as of September 30, 2011.&#xA0; There were no
outstanding common stock purchase warrants as of December 31, 2010
and 2009.&#xA0; The Company issued warrants to purchase 7,039,468
shares of common stock in connection with the April Private
Placement.&#xA0; In addition, outstanding warrants to purchase
315,164 shares of common stock, originally issued in connection
with Novelos equity and debt financings from 2007 through 2010,
remained outstanding subsequent to the Acquisition (Note
4).</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="MARGIN-LEFT: 36pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Offering</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Number&#xA0;of&#xA0;Shares</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Issuable&#xA0;Upon</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Exercise&#xA0;of</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Outstanding</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Warrants</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Exercise</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Price</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="20%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Expiration&#xA0;Date</font></font></div>
</td>
</tr>
<tr>
<td valign="bottom" width="50%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="20%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">April
8, 2011 Private Placement</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,039,468</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.75</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="20%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March
31, 2016</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series
B Preferred Stock &#x2013; placement agents</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,392</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">191.25</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="20%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May
2, 2012</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series
C Exchange</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,169</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">191.25</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="20%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May
2, 2012</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series
E Preferred Stock</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,330</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.45</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="20%" nowrap="nowrap" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December
31, 2015</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">August
2009 Private Placement</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,194</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100.98</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="20%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December
31, 2015</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">July
2010 Direct Offering (1)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">77,729</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.75</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="20%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">July
27, 2015</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preferred
Incentive Warrants</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">105,040</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16.065</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="20%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">July
27, 2015</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="50%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="20%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
7,327,322</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="12%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="20%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)&#xA0;
The exercise price of these warrants was adjusted to $0.75 per
share in connection with the private placement completed on April
8, 2011.&#xA0; This warrant has been accounted for as a derivative
instrument as described in Note 2.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
May 4, 2011, 18,153 shares of common stock were issued in
connection with the cashless exercise of warrants to purchase
27,310 shares of common stock at $0.75 per share.&#xA0; The Company
reclassified $48,339 from the derivative liability to additional
paid-in capital upon the exercise of the warrants.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
following shares were reserved for future issuance upon exercise of
stock options and warrants or conversion of debt:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br /></div>
<div style="TEXT-ALIGN: left; MARGIN-LEFT: 36pt">
<table style="TEXT-ALIGN: left; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr style="TEXT-ALIGN: left">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="64%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
September 30,</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">December&#xA0;31,</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="64%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2011</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">(unaudited)</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2010</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2009</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="64%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,327,322</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock
options</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,632,638</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">769,189</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">991,736</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible
notes</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
&#x2014;</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
3,646,370</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
&#x2014;</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="64%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
number of shares reserved for future issuance</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
10,959,960</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
4,415,559</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
991,736</font></font></td>
</tr>
</table>
</div>


</div><span /></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
6. STOCKHOLDERS&#x2019; DEFICIENCY</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Exchange of Outstanding Preferred Stock for Common
Stock</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
November 30, 2010, the Company entered into an Exchange Agreement
with each of the holders of its Series E convertible preferred
stock (the &#x201C;Series E Preferred Stock&#x201D;) and Series C
convertible preferred stock (the &#x201C;Series C Preferred
Stock&#x201D;) pursuant to which each such holder exchanged all of
the holder&#x2019;s shares of Series E Preferred Stock or Series C
Preferred Stock, as applicable, and all rights, preferences and
privileges associated therewith (including but not limited to any
accrued but unpaid dividends thereon) and any rights of the holder
to liquidated damages under agreements to register the
Company&#x2019;s capital stock, for an aggregate of 2,228,338 shares
of common stock, representing 75.3% of the Company&#x2019;s common
stock outstanding effective immediately following the
exchange.&#xA0; As a result of the exchange, all of the liquidation
preference applicable to the preferred stock, approximately
$27,337,000 as of November 30, 2010, was eliminated.&#xA0;
Furthermore, future dividends totaling $2,327,000 annually were
eliminated, special voting rights applicable to the preferred stock
are no longer applicable, and the former holders of Series E
Preferred Stock have released any rights to require the
registration of shares of the Company&#x2019;s common stock for
resale under the Securities Act.&#xA0; The effective price per
share at which the common stock was issued in connection with the
exchange (based on the aggregate liquidation preference of all of
the preferred stock divided by the total number of shares of common
stock issued in exchange for such preferred stock) was
approximately $12.27.&#xA0; The market price of the Company&#x2019;s
common stock as of the last trading day immediately preceding the
exchange was $6.12.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
exchange was accounted for as a recapitalization and the carrying
value of the Series E Preferred Stock of $13,770,000, accumulated
dividends totaling $4,476,000 and estimated liquidated damages of
$819,000 for failure to timely file a resale registration statement
(see &#x201C;Registration Rights&#x201D; below) were reclassified to
additional paid-in-capital as of the date of the exchange.&#xA0; If
the preferred stock had been converted according to its terms, the
holders would have received a total of 274,882 shares of common
stock.&#xA0; At the date of issuance the fair market value totaling
$11,955,151 of the additional 1,953,456 shares issued in the
exchange has been recorded as a deemed dividend to preferred
stockholders in the year ended December 31, 2010.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Issuance of</font> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Series C
Preferred</font> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Stock</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During
2007, the Company issued 272 shares of Series C Preferred Stock in
exchange for all 3,264 shares of Series A preferred stock,
originally issued in 2005.&#xA0;The Series C Preferred Stock was
initially convertible at $153.00 per share into 21,333 shares of
common stock.&#xA0; In connection with the sale of Series D
preferred stock in 2008, the conversion price of the Series C
Preferred Stock was reduced to $99.45 per share, according to its
terms.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
Terms of the Series C Preferred Stock</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Series C Preferred Stock had an annual dividend rate of 8% until
October 1, 2008 and 20% thereafter.&#xA0; The dividends were
payable quarterly.&#xA0; Such dividends were to be paid only after
all outstanding dividends on the Series D Preferred Stock (with
respect to the current fiscal year and all prior fiscal years) had
been paid to the holders of the Series D Preferred Stock.&#xA0; No
dividends were paid on Series C Preferred Stock during 2009 and
2010.&#xA0; The conversion price was subject to adjustment for
stock dividends, stock splits or similar capital reorganizations
and upon the occurrence of certain dilutive issuances of
securities.&#xA0; The Series C Preferred Stock did not have voting
rights and was redeemable only at the option of the Company upon 30
days&#x2019; notice at a 20% premium plus any accrued but unpaid
dividends.&#xA0; In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Company&#x2019;s
affairs, the Series C Preferred Stock would have been treated as
senior to Novelos common stock.&#xA0; After all required payments
were made to holders of Series E Preferred Stock, the holders of
Series C Preferred Stock would have been entitled to receive first,
$12,000 per share and all accrued and unpaid dividends.&#xA0; If,
upon any winding up of the Company&#x2019;s affairs, the
Company&#x2019;s remaining assets available to pay the holders of
Series C Preferred Stock were not sufficient to permit the payment
in full, then all of the Company&#x2019;s assets would have been
distributed to the holders of Series C Preferred Stock (and any
remaining holders of Series E Preferred Stock as may be required)
on a pro rata basis.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
Conversions of Series C Preferred Stock</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During
the year ended December 31, 2009, 68 shares of the Company&#x2019;s
Series C Preferred Stock, having an aggregate stated value of
$816,000, and accumulated dividends thereon of $184,000 were
converted into shares of the Company&#x2019;s common stock, leaving
204 shares of Series C Preferred Stock outstanding which were
convertible into 24,615 shares of common stock as of December 31,
2009.&#xA0; During 2010, all shares of Series C Preferred Stock
were exchanged for shares of common stock (see &#x201C;Exchange of
Outstanding Preferred Stock for Common Stock&#x201D;
above).</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Series E Preferred Stock Private Placement</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
Sale of Series E Preferred Stock to Purdue</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Concurrently
with the execution of the Collaboration Agreement on February 11,
2009, Novelos sold to Purdue 200 shares of a newly created series
of the Company&#x2019;s preferred stock, designated &#x201C;Series E
Convertible Preferred Stock,&#x201D; par value $0.00001 per share
(the &#x201C;Series E Preferred Stock&#x201D;), and a warrant (the
&#x201C;Series E Warrant&#x201D;) to purchase 60,330 shares of
Novelos common stock for an aggregate purchase price of $10,000,000
(the &#x201C;Series E Financing&#x201D;).</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Series E Warrant is exercisable for an aggregate of 60,330 shares
of Novelos common stock at an exercise price of $99.45 per share.
The warrant expires on December 31, 2015. The warrant exercise
price and/or the common stock issuable pursuant to such warrant are
subject to adjustment for stock dividends, stock splits or similar
capital reorganizations so that the rights of the warrant holder
after such event will be equivalent to the rights of the warrant
holder prior to such event.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
Exchange of Series D Preferred Stock for Series E Preferred
Stock</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company also entered into an exchange agreement with the holders
(the &#x201C;Series D Investors&#x201D;) of the Company&#x2019;s
Series D preferred stock, issued during 2008, under which all 413.5
outstanding shares of Series D preferred stock and accumulated but
unpaid dividends thereon totaling $1,597,144 were exchanged for
445.442875 shares of Series E Preferred Stock. The rights and
preferences of the Series E Preferred Stock were substantially the
same as the Series D preferred stock. In addition, the Series D
Investors waived liquidated damages through the date of the
exchange as a result of the Company&#x2019;s failure to file a
registration statement covering the shares of common stock
underlying the Series D preferred stock and warrants not otherwise
registered. In connection with the execution of this exchange
agreement, warrants held by the Series D Investors to purchase a
total of 77,551 shares of the Company&#x2019;s common stock were
amended to extend the expiration of the warrants to December 31,
2015 (from April 11, 2013) and to remove a forced exercise
provision.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
Terms of Series E Preferred Stock</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
shares of Series E Preferred Stock had a stated value of $50,000
per share and were convertible into shares of common stock at any
time after issuance at the option of the holder at $99.45 per share
of common. If there was an effective registration statement
covering the shares of common stock underlying the Series E
Preferred Stock and the VWAP, as defined in the Series E
Certificate of Designations, of Novelos common stock exceeded
$306.00 for 20 consecutive trading days, then the outstanding
shares of Series E Preferred Stock would automatically convert into
common stock at the conversion price then in effect. The conversion
price was subject to adjustment for stock dividends, stock splits
or similar capital reorganizations.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Series E Preferred Stock has an annual dividend rate of 9%, payable
semi-annually on June 30 and December 31. Such dividends were
payable in cash, in shares of Series E Preferred Stock or in
registered shares of Novelos common stock at the Company&#x2019;s
option, subject to certain conditions. The Company has not paid any
cash dividends on Series E Preferred Stock.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
terms of the Series E Preferred Stock provided that for as long as
any shares of Series E Preferred Stock remained outstanding,
Novelos was prohibited without the prior consent of holders of a
majority of the outstanding shares of Series E preferred stock
(including in such majority the Xmark Funds and Purdue) from (i)
paying dividends to its common stockholders, (ii) amending its
certificate of incorporation or by-laws, (iii) issuing any equity
security or any security convertible into or exercisable for any
equity security at a price of $99.45 or less or with rights senior
to the Series E Preferred Stock (except for certain exempted
issuances), (iv) increasing the number of shares of Series E
Preferred Stock or issuing any additional shares of Series E
Preferred Stock, (v) selling or otherwise granting rights with
respect to all or substantially all of its assets (or in the case
of licensing, any material intellectual property) or the Company's
business and/or entering into a merger or consolidation with
another company unless Novelos would be the surviving corporation,
the Series E Preferred Stock would remain outstanding, there would
be no changes to the rights and preferences of the Series E
Preferred Stock and there would not be created any new class of
capital stock senior to the Series E Preferred Stock, (vi)
redeeming or repurchasing any capital stock other than the Series E
Preferred Stock, (vii) incurring any new debt for borrowed money in
excess of $500,000 and (viii) changing the number of the
Company&#x2019;s directors. As of December 31, 2010, no shares of
Series E preferred stock remained outstanding, and accordingly,
none of these restrictions applied. See &#x201C;Exchange of
Outstanding Preferred Stock for Common Stock&#x201D;
above.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
Advisor Fees</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Ferghana
Partners, Inc. (&#x201C;Ferghana&#x201D;), a New York consulting
firm, received a cash fee for their services in connection with the
negotiation and execution of the Collaboration Agreement equal to
$700,000 (or seven percent (7%) of the gross proceeds to the
Company resulting from the sale of Series E Preferred Stock and
common stock purchase warrants to Purdue in connection with the
Collaboration Agreement).&#xA0; Novelos is also obligated to pay
Ferghana six percent (6%) of all payments to Novelos by Mundipharma
under the Collaboration Agreement other than royalties on net
sales.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
Accounting Treatment of Series E Financing</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
terms of the Series E Preferred Stock contained provisions that
required redemption in circumstances that were beyond the
Company&#x2019;s control, such as the acquisition of more than 50%
of our outstanding stock by any person or entity. Therefore, the
shares were recorded as redeemable preferred stock outside of
permanent equity in the balance sheet as of December 31, 2009. The
gross proceeds of $10,000,000 received in conjunction with the
Series E Financing were allocated on a relative fair value basis
between the Series E Preferred Stock and the warrants. The relative
fair value of the warrants issued to investors of $2,907,000
(determined using the Black-Scholes option pricing model, estimated
volatility of 80%, a risk-free interest rate of 2.17% and a term
equal to the term of the warrant) was recorded as additional
paid-in capital while the relative fair value of the Series E
Preferred Stock of $7,093,000 was recorded as temporary equity. The
carrying value of the Series E Preferred Stock was immediately
adjusted to its fair value of $7,385,000 based on the fair value of
the as-converted common stock. The difference of $292,000
represents a beneficial conversion feature and was recorded as a
deemed dividend to preferred stockholders. Issuance costs related
to the Series E Financing of $795,000 were netted against temporary
equity. The Series E Preferred Stock that was issued in payment of
dividends was initially recorded in temporary equity at the value
of the dividends that had accrued totaling $1,597,000. This amount
was then adjusted to the fair value of $1,179,000 based on the fair
value of the as-converted common stock. The difference of $418,000
was recorded as an offset to the deemed dividends recorded. The
Series E Preferred Stock that was issued in exchange for
outstanding shares of Series D preferred stock was recorded at
$13,904,000, the carrying value of the shares of Series D preferred
stock as of the date of the exchange.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As
a result of the modification to the warrants to extend their
expiration by approximately 32 months that occurred in connection
with the exchange of all outstanding shares of Series D preferred
stock for shares of Series E Preferred Stock, in the year ended
December 31, 2009, a deemed dividend of $840,000 was
recorded.&#xA0; This amount represented the incremental fair value
of the warrants immediately before and after modification using the
Black-Scholes option pricing model, volatility of 80%, discount
rates of 1.54% and 2.17% and the remaining warrant
term.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
Conversions of Series E Preferred Stock</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During
the year ended December 31, 2009, 97.18209375 shares of the
Company&#x2019;s Series E Preferred Stock, having an aggregate
stated value of $4,859,000 and accumulated dividends thereon of
$301,000, were converted into 51,889 shares of common stock.&#xA0;
The associated carrying value of the converted shares totaling
approximately $3,213,000 was reclassified to permanent equity from
temporary equity.&#xA0; During the year ended December 31, 2010,
140 shares of the Company&#x2019;s Series E Preferred Stock, having
an aggregate stated value of $7,000,000, and accumulated dividends
thereon totaling $635,000, were converted into 76,770 shares of
common stock.&#xA0; The associated carrying value of the converted
shares totaling approximately $4,690,000 was reclassified to
permanent equity from temporary equity.&#xA0; In November 2010, all
outstanding shares of Series E Preferred Stock were exchanged for
shares of common stock. See &#x201C;Exchange of Preferred
Stock&#x201D; below.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
August 2009 Common Stock Private Placement</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
Securities Purchase Agreement</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
August 25, 2009, the Company entered into the August 2009 Purchase
Agreement with Purdue to sell 89,126 shares of its common stock,
$0.00001 par value and warrants to purchase 31,194 shares of its
common stock at an exercise price of $100.98 per share, expiring
December 31, 2015, for an aggregate purchase price of $9,000,000
(the &#x201C;August 2009 Private Placement&#x201D;). Concurrent with
the execution and delivery of the August 2009 Purchase Agreement,
the Company sold Purdue 34,660 shares of its common stock and a
warrant to purchase 12,131 shares of its common stock at $100.98
per share for approximately $3,500,000 (the &#x201C;Initial
Closing&#x201D;). On November 10, 2009, the Company completed the
final closing under the August 2009 Purchase Agreement and sold
Purdue 54,466 shares of Novelos common stock and warrants to
purchase 19,063 shares of Novelos common stock for gross proceeds
of $5,500,000. Issuance costs associated with the transactions
totaled $61,000 and such amount was recorded as a reduction of
additional paid-in capital.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant
to the August 2009 Purchase Agreement,&#xA0;Purdue acquired a right
of first refusal (the &#x201C;Right of First Refusal&#x201D;) with
respect to bona fide offers for the license or other acquisition of
NOV-002 Rights (as defined in the August 2009 Purchase Agreement)
in the U.S. (the &#x201C;U.S. License&#x201D;) received from third
parties and approved by the Company&#x2019;s board of
directors.&#xA0; Under the Right of First Refusal, Novelos will be
required to communicate to Purdue the terms of any such third-party
offers received and Purdue will have 30 days to enter into a
definitive agreement with Novelos on substantially similar terms
that provide no lesser economic benefit to Novelos as provided in
the third-party offer.&#xA0; The Right of First Refusal terminates
upon business combinations, as defined in the August 2009 Purchase
Agreement. Novelos has separately entered into letter agreements
with Mundipharma and its independent associated company providing
for a conditional exclusive right to negotiate for, and a
conditional right of first refusal with respect to, NOV-002 Rights
for Latin America, Mexico and Canada.</font></div>
<br />
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant
to the August 2009 Purchase Agreement, Purdue has the right to
either designate one member to Novelos&#x2019; Board or designate an
observer to attend all meetings of the Board and committees thereof
and to have access to all information made available to members of
the Board.&#xA0; This right lasts until the later of such time as
Purdue or its independent associated companies no longer hold at
least one-half of the common stock purchased pursuant to the August
2009 Purchase Agreement and no longer hold at least one-half of the
Series E Preferred Stock issued to them on February 11, 2009.&#xA0;
The right to designate a Board observer had previously been granted
in connection with the financing that occurred on February 11, 2009
and Purdue appointed such an observer in February 2009.&#xA0;
Purdue also has the right to participate in future equity
financings in proportion to their pro rata ownership of common
stock.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
Common Stock Purchase Warrant</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
common stock purchase warrants have an exercise price of $100.98
per share and expire on December 31, 2015.&#xA0; The warrant
exercise price and/or the number of shares of common stock issuable
pursuant to such warrant will be subject to adjustment for stock
dividends, stock splits or similar capital reorganizations so that
the rights of the warrant holders after such event will be
equivalent to the rights of warrant holders prior to such
event.&#xA0; The relative fair value of the warrants issued to
Purdue totaled $1,929,000 and was recorded as a component of
additional paid-in capital.&#xA0; The fair value of the warrants
was determined based on the market value of the Company&#x2019;s
common stock on the dates of issuance using the Black-Scholes
method of valuation, estimated volatility of 90%, risk-free
interest rates ranging from 2.02% to 2.7% and a term equal to the
term of the warrant.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
Registration Rights</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As
part of the August 2009 Private Placement, the Company entered into
a registration rights agreement with Purdue (the &#x201C;Purdue
Registration Agreement&#x201D;).&#xA0; The Purdue Registration
Agreement required the Company to have filed with the SEC no later
than May 17, 2010, a registration statement covering the resale of
all the shares of common stock issued pursuant to the August 2009
purchase agreement and all shares of common stock issuable upon
exercise of the warrants issued pursuant to the August 2009
purchase agreement.&#xA0; The registration rights agreement
provided for liquidated damages equal to 1.5% per month (pro-rated
on a daily basis for any period of less than a full month) of the
aggregate purchase price of the common stock until the delinquent
registration statement is filed.&#xA0; The Company did not file the
registration statement and accrued $819,000 as a component of other
income (expense) during the year ended December 31, 2010,
representing management&#x2019;s best estimate of the probable total
liquidated damages that may be settled. In connection with the
exchange of their shares of Series E Preferred Stock for common
stock on November 30, 2010, Purdue released the Company from any
requirement to register shares of its common stock for resale and
forfeited any rights to receive liquidated damages pursuant to any
registration agreements. The accrued liquidated damages were
settled in connection with the exchange and, accordingly, the
amount that had been accrued was reclassified to additional paid-in
capital.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
July 2010 Registered Offering</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
July 27, 2010, pursuant to securities purchase agreements entered
into with institutional investors on July 21, 2010, the Company
completed the sale, in an offering registered under the Securities
Act of 1933, as amended, of an aggregate of 140,056 shares of its
common stock and five-year warrants to purchase up to an aggregate
of 150,040 shares of its common stock at an exercise price of
$10.71 per share, for gross proceeds of $1,500,000 and net proceeds
of $1,249,000 after deducting transaction costs.&#xA0; The warrant
exercise price is subject to adjustment in certain circumstances
and therefore, the relative fair value of the warrants at the date
of issuance, $504,000, has been bifurcated from the proceeds and
recorded as a derivative liability.&#xA0; The Company uses
valuation methods and assumptions that consider among others the
fair value of the underlying stock, risk-free interest rate,
volatility, expected life and dividend rates in estimating fair
value for the warrants considered to be derivative instruments. The
assumptions used to value these warrants at the time of issuance
are generally consistent with those disclosed for stock-based
compensation (see Note 7).</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Since
the securities in this financing were issued at a price less than
$100.98 per share, the Company obtained the consent of its
preferred stockholders pursuant to a consent and waiver dated July
6, 2010, as amended on July 21, 2010. In connection with obtaining
this consent, the Company issued five-year warrants (the
&#x201C;Incentive Warrants&#x201D;) to its preferred stockholders for
the purchase of up to an aggregate of 150,039 shares of common
stock at an exercise price of $16.065 per share. No adjustments to
the conversion price of the preferred stock or warrants held by
preferred stockholders were made in connection with the financing.
The fair value of the Incentive Warrants at date of issuance,
$586,000, is reflected as a deemed dividend to the preferred
stockholders on the statement of operations. The Company used
valuation methods and assumptions that consider among others the
fair value of the underlying stock, risk-free interest rate,
volatility, expected life and dividend rates in estimating fair
value of the Incentive Warrants. The assumptions used to value
these warrants are generally consistent with those disclosed for
stock-based compensation (see Note 7).</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
financing resulted in adjustments to certain warrants pursuant to
their terms.&#xA0; Warrants issued in 2005 that were exercisable
for 1,591 shares at an exercise price of $99.45 per share as of
immediately prior to the transaction became exercisable for 14,776
shares at an exercise price of $10.71 per share, and warrants
issued in 2006 that were exercisable for 29,787 shares at an
exercise price of $263.16 per share as of immediately prior to the
transaction became exercisable for 33,569 shares at an exercise
price of $234.09 per share.&#xA0; The 2005 warrants expired
unexercised on August 9, 2010, and the 2006 warrants will expire in
March 2011.</font></div>
<br />
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">
Common Stock Warrants</font> &#xA0; &#x2014; The following table
summarizes information with regard to outstanding warrants as of
December 31, 2010, issued in connection with equity and debt
financings since 2005.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%">
<tr>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Offering</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Outstanding</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">(as&#xA0;adjusted)</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Exercise</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Price</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">(as&#xA0;adjusted)</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="20%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Expiration&#xA0;Date</font></font></div>
</td>
</tr>
<tr>
<td valign="bottom" width="50%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="20%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2006
Issuance of Common Stock</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33,569</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">234.09</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="20%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March
7, 2011</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series
B Preferred Stock &#x2013; placement agents</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,392</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">191.25</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="20%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May
2, 2012</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series
C Exchange</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,169</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
191.25</font></font></div>
</div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="20%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May
2, 2012</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series
E Preferred Stock</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,330</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.45</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="20%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December
31, 2015</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">August
2009 Private Placement</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,194</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100.98</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="20%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December
31, 2015</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">July
2010 Direct Offering (1)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">105,039</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.71</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="20%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">July
27, 2015</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preferred
Incentive Warrants</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">105,040</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16.065</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="20%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">July
27, 2015</font></div>
</td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="50%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="12%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="20%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="50%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
348,733</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="12%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="20%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)&#xA0;
The exercise price of these warrants was adjusted in connection
with the private placement completed on April 8, 2011.&#xA0; See
Note 12.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During
the year ended December 31, 2010, warrants to purchase 14,776
shares of common stock at $10.71 and 5,941 shares of common stock
at $99.45 expired unexercised.&#xA0; On March 7, 2011, warrants to
purchase 33,569 shares of common stock at $234.09 expired
unexercised.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During
the year ended December 31, 2010, 53,478 shares of the
Company&#x2019;s common stock were issued upon the cashless exercise
of warrants to purchase 89,752 shares of the Company&#x2019;s common
stock.&#xA0; The Company reclassified $2,584,000 from derivative
liability to additional paid-in capital upon the exercise of
warrants.&#xA0; The following is a summary of the
exercises:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="MARGIN-LEFT: 27pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Original&#xA0;private&#xA0;placement&#xA0;</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Shares&#xA0;of</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Common&#xA0;Stock</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Issued</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Warrants</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Exercised</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Exercise</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Price</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="64%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2005
Bridge Financing</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,059</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,614</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">95.625</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2005
Issuance of Common Stock &#x2013; placement agents</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,481</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,074</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.45</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2006
Issuance of Common Stock</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,395</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,480</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">263.16</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series
B Preferred Stock &#x2013; purchasers</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">29,709</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">49,019</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.45</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series
B Preferred Stock &#x2013; placement agents</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">229</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">490</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">191.25</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series
D Preferred Stock</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,292</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,531</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.45</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series
C Exchange</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
313</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
544</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">191.25</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="64%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
53,478</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
89,752</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During
the year ended December 31, 2009, a total of 3,162 shares of the
Company&#x2019;s common stock were issued upon the cashless exercise
of warrants to purchase 6,975 shares of common stock. The Company
reclassified a total of $1,001,000 from derivative liability to
additional paid-in capital upon the exercise of warrants.&#xA0; The
following is a summary of the exercises:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="MARGIN-LEFT: 27pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Original&#xA0;private&#xA0;placement</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Shares&#xA0;of</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Common&#xA0;Stock</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Issued</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Warrants</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Exercised</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Exercise</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Price</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="64%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2005
Bridge Financing</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,429</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,091</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">95.625</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2005
Common Stock</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,310</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,172</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.45</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Series
A Preferred Stock</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">250</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">396</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.45</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2006
Issuance of Common Stock</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
173</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
1,316</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">263.16</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="64%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
3,162</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
6,975</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="9%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<br />
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
August 21, 2009, the Company entered into exchange agreements with
certain accredited investors who held warrants, issued in the 2006
private placement, to purchase 45,409 shares of its common stock.
Pursuant to the exchange agreements, an aggregate of 13,623 shares
of the Company&#x2019;s common stock with a fair value of $1,626,000
were issued in exchange for these warrants. The holders agreed not
to transfer or dispose of the shares of common stock before
February 18, 2010. The warrants had been recorded as a derivative
liability on the Company&#x2019;s balance sheet at their estimated
fair value of $1,109,000 at the date of exchange. The difference of
$517,000 between the estimated fair value of the warrants at the
date of exchange and the common stock issued to settle the
derivative liability has been included as a component of the loss
on derivative warrants for the year ended December 31, 2009.
Following the exchange, warrants expiring on March 7, 2011 to
purchase a total of 35,504 shares of common stock at $278.46 per
share remained outstanding. Following the final closing of the
August 2009 Private Placement, described above, the number of these
outstanding warrants was increased to 37,584 and the exercise price
was reduced to $263.16, as a result of anti-dilution provisions in
the warrants.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">
Authorized and Reserved Shares</font> &#x2014; On October 18, 2010
the Company&#x2019;s stockholders approved an amendment to the
certificate of incorporation to increase the total number of
authorized shares of the Company&#x2019;s common stock from
225,000,000 to 750,000,000. On April 8, 2011, the Company completed
the Reverse Split described in Note 12, and amended the certificate
of incorporation to decrease the total number of authorized shares
to 150,000,000 from 750,000,000.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
following shares were reserved for future issuance upon exercise of
stock options or warrants or conversion of preferred stock as of
the dates indicated:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="MARGIN-LEFT: 27pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="28%" colspan="6">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">December 31,</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2010</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2009</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2000
Stock Option Plan</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">291</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">366</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2006
Stock Incentive Plan</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">38,366</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,856</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Options
issued outside of formalized plans</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,569</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,037</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">348,733</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">232,164</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preferred
stock</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
&#x2014;</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
329,451</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
shares reserved for future issuance</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
397,959</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
621,874</font></font></div>
</td>
</tr>
</table>
</div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 29, 30, 31<br /><br /> -Article 5<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 310<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SAB TOPIC 4.E)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 4<br /><br /> -Subparagraph (SAB TOPIC 4.C)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 2, 3, 4, 5, 6, 7, 8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Preferred Stock<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 5<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 08<br /><br /> -Article 4<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /> -Number Topic 4<br /><br /> -Section C<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29-31)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 4<br /><br /> -Section 08<br /><br /> -Paragraph d<br /><br /><br /><br />Reference 15: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /> -Number Topic 4<br /><br /> -Section E<br /><br /><br /><br />Reference 16: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 30<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br /><br /><br /><br />Reference 17: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br /><br /><br /><br />Reference 18: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.4-08.(d),(e))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br /><br /><br /><br />Reference 19: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 43<br /><br /> -Chapter 1<br /><br /> -Section B<br /><br /> -Paragraph 7, 11A<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 20: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 21: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 22: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br /><br /><br /><br />Reference 23: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 11<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1033
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EXEAC"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS, BASIS OF PRESENTATION<br /></strong></div></th><th class="th" colspan="1">3 Months Ended</th><th class="th" colspan="1">9 Months Ended</th><th class="th" colspan="1">12 Months Ended</th></tr><tr><th class="th"><div>Mar. 31, 2011</div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">NATURE OF BUSINESS, BASIS OF PRESENTATION</a></td><td class="text"><div><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr valign="top">
<td style="WIDTH: 36pt" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
1.&#xA0;</font></div>
</td>
<td align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
NATURE OF BUSINESS, BASIS OF PRESENTATION</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Novelos
Therapeutics, Inc. (&#x201C;Novelos&#x201D; or the
&#x201C;Company&#x201D;) is a biopharmaceutical company developing
compounds for the treatment of cancer.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
April 8, 2011, the Company entered into a business combination with
Cellectar, Inc. (&#x201C;Cellectar&#x201D;), a privately held
Wisconsin corporation that designed and developed products to
detect, treat and monitor a wide variety of human cancers (the
&#x201C;Acquisition&#x201D;, see Note 10).&#xA0;&#xA0;Immediately
prior to the Acquisition, the Company completed a 1-for-153 reverse
split of its common stock (the &#x201C;Reverse Split&#x201D;). The
Company then issued to the former shareholders of Cellectar
17,001,596 shares of its common stock as consideration for the
Acquisition, which shares constituted approximately 85% of
Novelos&#x2019; outstanding common stock after giving effect to the
Acquisition.&#xA0;&#xA0;Upon the closing of the Acquisition, the
Company completed the private placement of 6,846,537 shares of its
common stock and warrants to purchase an additional 6,846,537
shares of its common stock (in each case after giving effect to the
Reverse Split) for gross proceeds of approximately
$5,135,000.&#xA0;&#xA0;As a result of the Acquisition, the Company
is implementing a revised business plan focused on the development
of the Cellectar compounds.&#xA0;&#xA0;Development of
Novelos&#x2019; other compounds (NOV-002 and NOV-205) has been
suspended<font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
Reverse Split reduced the number of outstanding shares of Common
Stock from 452,866,983 shares to&#xA0;2,959,871 shares. On the
Company's balance sheet, the aggregate par value of the issued
common stock was reduced by reclassifying the par value amount of
the eliminated shares of common stock to additional paid-in
capital. All per share amounts and outstanding shares, including
all common stock equivalents, stock options and warrants, have been
retroactively restated in these financial statements and notes for
all periods presented to reflect the Reverse Split. Additionally,
the number of authorized shares of common stock disclosed on the
balance sheet has been reduced to 150,000,000 from 750,000,000 to
reflect the reduction in authorized shares of common stock that
became effective concurrent with the Reverse Split.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounting
principles generally accepted in the United States require that a
company whose security holders retain the majority voting interest
in the combined business be treated as the acquirer for financial
reporting purposes.&#xA0; Accordingly, the Acquisition will be
accounted for as a reverse acquisition whereby Cellectar, Inc. will
be treated as the acquirer for accounting and financial reporting
purposes. The financial statements presented herein represent the
historical financial information of Novelos, prior to the
Acquisition.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
Company is subject to a number of risks similar to those of other
small biopharmaceutical companies. Principal among these risks are
dependence on key individuals, competition from substitute products
and larger companies, the successful development and marketing of
its products in a highly regulated environment and the need to
obtain additional financing necessary to fund future
operations.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
February 24, 2010, the Company announced that its Phase 3 clinical
trial for NOV-002 in non-small cell lung cancer
(&#x201C;NSCLC&#x201D;) (the &#x201C;Phase 3 Trial&#x201D;) did not
meet its primary endpoint of a statistically significant increase
in median overall survival. Following evaluation of the detailed
trial data, on March 18, 2010, the Company announced that the
secondary endpoints had also not been met in the Phase 3 Trial and
that it had discontinued development of NOV-002 for NSCLC in
combination with first-line paclitaxel and carboplatin
chemotherapy.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">These
financial statements have been prepared on the basis that the
Company will continue as a going concern. The Company has generated
insignificant revenues and has incurred operating losses since
inception in devoting substantially all of its efforts toward
research and development. The Company expects that it will continue
to generate operating losses for the foreseeable
future.&#xA0;&#xA0;The Company believes that its cash on hand at
March 31, 2011, plus the proceeds from the private placement
completed in connection with the Acquisition, is adequate to fund
operations into the fourth quarter of 2011.&#xA0;&#xA0;The
Company&#x2019;s ability to execute its operating plan beyond that
time depends on its ability to obtain additional funding via the
sale of equity and/or debt securities, a strategic transaction or
otherwise.&#xA0;&#xA0;The Company plans to continue to actively
pursue financing alternatives, but there can be no assurance that
it will obtain the necessary funding.</font></div>
<br />
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
accompanying unaudited financial statements of the Company have
been prepared in accordance with accounting principles generally
accepted in the United States (&#x201C;GAAP&#x201D;) for interim
financial information and with the instructions to Form
10-Q.&#xA0;&#xA0;Accordingly, they do not include all of the
information and footnotes required by GAAP for complete financial
statements. In the opinion of management, all adjustments
(consisting of normal recurring accruals) considered necessary for
the fair presentation of these financial statements have been
included. The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions
that affect the amounts reported in the financial statements and
accompanying notes. Interim results are not necessarily indicative
of results to be expected for other quarterly periods or for the
entire year ending December 31, 2011. These unaudited financial
statements should be read in conjunction with the audited financial
statements and related notes thereto included in the
Company&#x2019;s latest annual report for the year ended December
31, 2010 on Form 10-K, which was filed with the Securities and
Exchange Commission (&#x201C;SEC&#x201D;) on April 14, 2011.&#xA0;The
report from the Company&#x2019;s independent registered public
accounting firm dated April 11, 2011 and included with its annual
report on Form 10-K indicated that factors exist that raised
substantial doubt about the Company&#x2019;s ability to continue as
a going concern.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Comprehensive Income (Loss)</font> &#x2013; The Company had no
components of comprehensive income (loss) other than the net income
(loss) in all periods presented.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Derivative Instruments</font> &#x2013; The Company generally does
not use derivative instruments to hedge exposures to cash flow or
market risks.&#xA0;&#xA0;However, certain warrants to purchase
common stock that do not meet the requirements for classification
as equity, in accordance with the Derivatives and Hedging Topic of
the Financial Accounting Standards Board Accounting Standards
Codification (&#x201C;FASB ASC&#x201D;),<font style="FONT-STYLE: italic; DISPLAY: inline">&#xA0;</font>are classified
as liabilities.&#xA0;&#xA0;In such instances, net-cash settlement
is assumed for financial reporting purposes, even when the terms of
the underlying contracts do not provide for a net-cash settlement.
These warrants are considered derivative instruments because the
agreements contain &#x201C;down-round&#x201D; provisions whereby the
number of shares for which the warrants are exercisable and/or the
exercise price of the warrants are subject to change in the event
of certain issuances of stock at prices below the then-effective
exercise price of the warrants.&#xA0;&#xA0;The number of shares
issuable under such warrants was 105,042 at March 31,
2011.&#xA0;&#xA0;The primary underlying risk exposure pertaining to
the warrants is the change in fair value of the underlying common
stock.&#xA0;&#xA0;Such financial instruments are initially recorded
at fair value with subsequent changes in fair value recorded as a
component of gain or loss on derivatives in each reporting period.
If these instruments subsequently meet the requirements for equity
classification, the Company reclassifies the fair value to
equity.&#xA0;&#xA0;At March 31, 2011, these warrants represented
the only outstanding derivative instruments issued or held by the
Company.</font></div>
</div><span /></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Novelos
Therapeutics, Inc. (&#x201C;Novelos&#x201D; or the
&#x201C;Company&#x201D;) is a pharmaceutical company developing
compounds for the treatment of cancer. On April 8, 2011, Novelos
completed a business combination with Cellectar, Inc.
(&#x201C;Cellectar&#x201D;), a privately held Wisconsin corporation
that designed and developed products to detect, treat and monitor a
wide variety of human cancers, and Cell Acquisition Corp. (the
&#x201C;Merger Subsidiary&#x201D;), a Wisconsin corporation and a
wholly owned subsidiary of Novelos. Pursuant to the transaction
Cellectar was merged into the Merger Subsidiary (the
&#x201C;Acquisition&#x201D;, see Note 4). References in these
financial statements and notes to &#x201C;Cellectar&#x201D; relate to
the activities and financial information of Cellectar prior to the
Acquisition, references to &#x201C;Novelos&#x201D; relate to the
activities and financial information of Novelos prior to the
Acquisition and references to &#x201C;the Company&#x201D; or
&#x201C;we&#x201D; or &#x201C;us&#x201D; or &#x201C;our&#x201D; relate to
the activities and obligations of the combined Company following
the Acquisition.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Immediately
prior to the Acquisition, Novelos completed a 1-for-153 reverse
split of its common stock (the &#x201C;Reverse Split&#x201D;).&#xA0;
Novelos then issued to the shareholders of Cellectar at that date
17,001,596 shares of its common stock as consideration for the
Acquisition, representing a ratio of 0.8435 shares of Novelos
common stock in exchange for one share of Cellectar common stock
(the &#x201C;Exchange Ratio&#x201D;) as set forth in the Agreement
and Plan of Merger (the &#x201C;Merger Agreement&#x201D;) dated April
8, 2011.&#xA0; The shares issued to Cellectar shareholders in the
Acquisition constituted approximately 85% of Novelos&#x2019;
outstanding common stock after giving effect to the
Acquisition.&#xA0; Upon the closing of the Acquisition, the Company
completed the private placement of 6,846,537 shares of its common
stock and warrants to purchase an additional 6,846,537 shares of
its common stock for gross proceeds of approximately
$5,135,000.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
Accounting principles generally accepted in the United States
require that a company whose security holders retain the majority
voting interest in the combined business be treated as the acquirer
for financial reporting purposes.&#xA0; Accordingly, the
Acquisition will be accounted for as a reverse acquisition whereby
Cellectar, Inc. will be treated as the acquirer for accounting and
financial reporting purposes. The financial statements presented
herein as of and for the twelve months ended December 31, 2010 and
2009 represent the historical financial information of Cellectar,
except for the capital structure which represents the historical
amounts of Cellectar, retroactively adjusted to reflect the legal
capital structure of Novelos by applying the Exchange Ratio. On
April, 8, 2011, Cellectar was merged into the Merger Subsidiary a
wholly owned subsidiary of Novelos; as such, the financial
statements presented herein as of and for the nine months ended
September 30, 2011 include the historical results of Cellectar from
January 1, 2011 through April 8, 2011, except for the capital
structure which represents the historical amounts of Cellectar,
retroactively adjusted to reflect the legal capital structure of
Novelos by applying the Exchange Ratio, and include the
consolidated results of the combined company from April 9, 2011
through September 30, 2011.&#xA0; All per-share amounts and
outstanding shares, including all common stock equivalents, and
stock options, have been retroactively restated in these financial
statements and notes for all periods presented to reflect the
capital structure of Novelos by applying the Exchange
Ratio.&#xA0;&#xA0;The cumulative capital activity from the date of
inception (November 7, 2002) up to the closing of the Acquisition,
as presented in the accompanying statement of stockholders&#x2019;
equity, equals 17,001,596 shares of common stock, which represents
the equity interests the legal parent (Novelos) issued to effect
the Acquisition. The number of authorized shares of common stock
disclosed on the balance sheet (150,000,000) represents the number
of authorized shares of Novelos common stock following the
Acquisition.&#xA0; Additionally, on the accompanying balance sheets
as of December 31, 2010 and 2009 and statements of
stockholders&#x2019; equity for the period from inception (November
7, 2002) to December 31, 2010 the aggregate par value of the issued
common stock was reduced to reflect the $0.00001 par value of
Novelos common stock associated with the shares of Cellectar common
stock adjusted for the Exchange Ratio and the difference was
reclassified to additional paid-in capital.</font></font></div>
</div>
<div>&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As
a result of the Acquisition, the Company has implemented a revised
business plan focused on the development of the Cellectar
compounds.&#xA0; Development of Novelos&#x2019; other compounds
(NOV-002 and NOV-205) has been suspended.&#xA0; The Company is
conducting its operations from Cellectar&#x2019;s headquarters in
Madison, WI and the Company&#x2019;s executive offices are in
Newton, MA.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company is subject to a number of risks similar to those of other
small pharmaceutical companies. Principal among these risks are
dependence on key individuals, competition from substitute products
and larger companies, the successful development and marketing of
its products in a highly regulated environment and the need to
obtain additional financing necessary to fund future
operations.</font></div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
accompanying financial statements have been prepared on a basis
that assumes that the Company will continue as a going concern and
that contemplates the continuity of operations, realization of
assets and the satisfaction of liabilities and commitments in the
normal course of business. Cellectar has incurred losses since
inception in devoting substantially all of its efforts toward
research and development and has an accumulated deficit of
$24,045,004 at December 31, 2010. During the year ended December
31, 2010, Cellectar generated a net loss of $4,560,263 and the
Company expects that it will continue to generate operating losses
for the foreseeable future.&#xA0; The Company believes that its
cash on hand following the Acquisition, plus the proceeds from the
private placement completed in connection with the Acquisition, is
adequate to fund operations until the end of 2011.&#xA0; The
Company&#x2019;s ability to execute its operating plan beyond that
time depends on its ability to obtain additional funding via the
sale of equity and/or debt securities, a strategic transaction or
otherwise.&#xA0; The Company plans to continue to actively pursue
financing alternatives, but there can be no assurance that it will
obtain the necessary funding.&#xA0; The accompanying financial
statements do not include any adjustments that might result from
the outcome of this uncertainty.</font></div>


</div><span /></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Novelos
Therapeutics, Inc. (&#x201C;Novelos&#x201D; or the
&#x201C;Company&#x201D;) is a biopharmaceutical company developing
compounds for the treatment of cancer.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
April 8, 2011, the Company entered into a business combination with
Cellectar, Inc. (&#x201C;Cellectar&#x201D;), a privately held
Wisconsin corporation that designed and developed products to
detect, treat and monitor a wide variety of human cancers (the
&#x201C;Acquisition&#x201D;, see Note 12). Immediately prior to the
Acquisition, the Company completed a 1-for-153 reverse split of its
common stock (the &#x201C;Reverse Split&#x201D;). The Company then
issued 17,001,596 shares of its common stock to the former
shareholders of Cellectar as consideration for the Acquisition,
constituting approximately 85% of Novelos&#x2019; outstanding common
stock after giving effect to the Acquisition. Upon the closing of
the Acquisition, the Company completed the private placement of
6,846,537 shares of its common stock and warrants to purchase an
additional 6,846,537 shares of its common stock (in each case after
giving effect to the Reverse Split) for gross proceeds of
approximately $5,135,000. As a result of the Acquisition, the
Company is implementing a revised business plan focused on the
development of the Cellectar compounds. Development of
Novelos&#x2019; other compounds (NOV-002 and NOV-205) has been
suspended. The Company will conduct its operations from
Cellectar&#x2019;s headquarters in Madison, WI and the
Company&#x2019;s executive offices will remain in Newton,
MA.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Reverse Split reduced the number of outstanding shares of Common
Stock from 452,866,983 shares to 2,959,914 (2,959,871 after the
cash settlement of fractional shares). On the accompanying balance
sheet, the aggregate par value of the issued common stock was
reduced by reclassifying the par value amount of the eliminated
shares of common stock to additional paid-in capital. All per share
amounts and outstanding shares, including all common stock
equivalents, stock options and warrants, have been retroactively
restated in these financial statements and notes for all periods
presented to reflect the Reverse Split. Additionally, the number of
authorized shares of common stock disclosed on the balance sheet
has been reduced to 150,000,000 from 750,000,000 to reflect the
reduction in authorized shares of common stock that became
effective concurrent with the Reverse Split.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Accounting
principles generally accepted in the United States require that a
company whose security holders retain the majority voting interest
in the combined business be treated as the acquirer for financial
reporting purposes.&#xA0; Accordingly, the Acquisition will be
accounted for as a reverse acquisition whereby Cellectar, Inc. will
be treated as the acquirer for accounting and financial reporting
purposes. The financial statements presented herein represent the
historical financial information of Novelos, prior to the
acquisition.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company is subject to a number of risks similar to those of other
small biopharmaceutical companies. Principal among these risks are
dependence on key individuals, competition from substitute products
and larger companies, the successful development and marketing of
its products in a highly regulated environment and the need to
obtain additional financing necessary to fund future
operations.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
February 24, 2010, the Company announced that its Phase 3 clinical
trial for NOV-002 in non-small cell lung cancer (the &#x201C;Phase 3
Trial&#x201D;) did not meet its primary endpoint of a statistically
significant increase in median overall survival. Following
evaluation of the detailed trial data, on March 18, 2010, the
Company announced that the secondary endpoints had also not been
met in the Phase 3 Trial and that it had discontinued development
of NOV-002 for NSCLC in combination with first-line paclitaxel and
carboplatin chemotherapy.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These
financial statements have been prepared on the basis that the
Company will continue as a going concern. The Company has generated
insignificant revenues and has incurred operating losses since
inception in devoting substantially all of its efforts toward
research and development. The Company expects that it will continue
to generate operating losses for the foreseeable future. The
Company believes that its cash on hand at December 31, 2010, plus
the proceeds from the private placement completed in connection
with the Acquisition, is adequate to fund operations into the
fourth quarter of 2011. The Company&#x2019;s ability to execute its
operating plan beyond the fourth quarter of 2011 depends on its
ability to obtain additional funding via the sale of equity and/or
debt securities, a strategic transaction or otherwise. The Company
plans to continue to actively pursue financing alternatives, but
there can be no assurance that it will obtain the necessary
funding.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 22<br /><br /> -Paragraph 8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Name Statement of Position (SOP)<br /><br /> -Publisher AICPA<br /><br /> -Number 94-6<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Name FASB Interpretation (FIN)<br /><br /> -Publisher FASB<br /><br /> -Number 46R<br /><br /> -Paragraph 4, 14, 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1034
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE DEBT<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_ConvertibleDebtDisclosureTextBlock', window );">CONVERTIBLE DEBT</a></td><td class="text"><div>
<div>
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
7.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
CONVERTIBLE DEBT</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
January 25, 2010, Cellectar issued nine convertible promissory
notes (&#x201C;Convertible Notes&#x201D;) in an aggregate principal
amount of $2,720,985.&#xA0; The Convertible Notes provided for
interest of 12% compounded annually with a maturity date of the
earlier of (i) the date on which Cellectar&#x2019;s cash reserves
fall below $250,000 or (ii) January 20, 2011.&#xA0; Upon an event
of default, as defined, the interest rate increased by 10% to
22%.&#xA0; The outstanding principal balance, together with any
unpaid interest, was convertible immediately, by the lender, into
common stock of the Company at $0.82987 per share (giving effect to
the Exchange Ratio).&#xA0; Furthermore, the Convertible Notes were
subject to an automatic conversion feature equal to 70% of the per
share price of a qualified financing, should the Company complete a
qualified financing transaction which raises at least $20,000,000
in proceeds to the Company.&#xA0; Since the Convertible Notes were
convertible into common stock at date of issuance at a per share
price which was less than the estimated fair value of the
Company&#x2019;s common stock at that date, the Convertible Notes
contained a beneficial conversion feature
(&#x201C;BCF&#x201D;).&#xA0; The estimated intrinsic value of the BCF
of $213,792 was determined as the difference between the conversion
price and the estimated fair value of Cellectar common stock on the
date of issuance, multiplied by the 3,278,786 shares of common
stock into which the Convertible Notes were convertible at
issuance. This amount was recorded as a component of interest
expense on the date of issuance.&#xA0; The estimated per-share fair
value of Cellectar common stock was determined by management based
on a number of factors including an independent valuation, which
was determined to be the best indication of the fair value as of
the issuance date of the Convertible Notes.&#xA0; Since the
conversion price was subject to adjustment in the event of a
qualified transaction, as defined, the Convertible Notes also
contain a contingent beneficial conversion feature
(&#x201C;CBCF&#x201D;).&#xA0; This contingency did not materialize;
therefore no intrinsic value was allocated to the CBCF.&#xA0; As of
December 31, 2010 and 2009, principal of $2,720,985 and $0 was
outstanding, respectively, on the Convertible Notes.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As
of December 31, 2010, the Convertible Notes are classified as a
long-term obligation on the accompanying balance sheets as a result
of the conversion of the short-term obligation through the issuance
of equity securities in connection with the
Acquisition.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
January 20, 2011, the Convertible Notes matured but remained
unpaid.&#xA0; Following the maturity and default of the Convertible
Notes, the holders of the Convertible Notes agreed that all of the
outstanding notes would be automatically converted simultaneous
with the completion of an acquisition and financing (the
&#x201C;Conversion Time&#x201D;), if completed.&#xA0; The amount of
shares issued upon such conversion would be dependent on the amount
of investment made by the note holders at the Conversion Time and
were negotiated based on outstanding principal and projected
accrued interest based on an assumed closing date for the
acquisition and financing.&#xA0; Since the number of shares to be
issued upon conversion could not be determined until the Conversion
Time the Convertible Notes contained a CBCF.&#xA0; On April 1,
2011, Cellectar&#x2019;s Board of Directors voted to accept the note
holders consent to convert the Convertible Notes into 4,181,535
shares of common stock immediately prior to the Acquisition.&#xA0;
On April 8, 2011, immediately prior to the Acquisition, the
principal and unpaid interest on the Convertible Notes was
converted into the agreed total of 4,181,535 shares of common
stock.&#xA0; Upon conversion of the Convertible Notes, the Company
reclassified the aggregate outstanding principal and interest
totaling $3,184,706 to a component of additional paid-in
capital.&#xA0; The revised conversion terms resulted in the
issuance of an additional 343,963 shares of common stock over the
3,837,572 shares of common stock that would have been issued if the
unpaid principal and accrued interest on the Convertible Notes had
been converted on that date in accordance with their original terms
at the stated conversion price.&#xA0; On the date of conversion,
the Company determined that the value of these additional shares
was $257,973, based on the $0.75 per share offering price of the
common stock sold in the private placement completed concurrently
with the Acquisition, which is the best indication of fair value on
the date of conversion.&#xA0; Since the conversion was not
completed until April 8, 2011, the value of the additional shares
of $257,973 was recorded as a component of interest expense during
the second quarter of 2011.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_ConvertibleDebtDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Debt Disclosure [Text Block]</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_ConvertibleDebtDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1035
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EXEAC"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br /></strong></div></th><th class="th" colspan="1">3 Months Ended</th><th class="th" colspan="1">9 Months Ended</th><th class="th" colspan="1">12 Months Ended</th></tr><tr><th class="th"><div>Mar. 31, 2011</div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr valign="top">
<td style="WIDTH: 36pt" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
7.&#xA0;</font></div>
</td>
<td align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
INCOME TAXES</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
Company accounts for income taxes in accordance with the Income
Taxes Topic of the FASB ASC. Under this guidance, deferred tax
assets or liabilities are computed based on the difference between
the financial statement and income tax basis of assets and
liabilities, and net operating loss carryforwards, using the
enacted tax rates. Deferred income tax expense or benefit is based
on changes in the asset or liability from period to period. The
Company did not record a provision or benefit for federal, state or
foreign income taxes for the three months ended March 31, 2011 or
2010 because the Company has experienced losses on a tax basis
since inception. The net income reported for the three months ended
March 31, 2010 was a result of the gain recorded on the revaluation
of derivative warrant liability during that period, which is a
nontaxable item. The Company has not recorded deferred tax assets
as their realization is uncertain.</font></div>
</div><span /></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
12. &#xA0;INCOME TAXES</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Deferred
tax assets consisted of the following at December 31:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2010</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2009</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred
tax assets</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Federal
net operating loss</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,116,804</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,754,001</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Federal
research and development tax credit carryforwards</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">390,600</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">273,788</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Wisconsin
net operating loss credit carryforwards</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">814,492</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">589,548</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Wisconsin
research and development tax credit carryforwards</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">220,738</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">171,552</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based
compensation expense</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">552,859</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">415,060</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Charitable
contribution carryforwards</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">49,725</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">49,725</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued
liabilities</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
25,327</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
75,711</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
deferred tax assets</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,170,545</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,329,385</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred
tax liabilities</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciable
and intangible assets</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
(434,056</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
(475,524</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
deferred tax liabilities</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(434,056</font></div>
</td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(475,524</font></div>
</td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net
deferred tax assets</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,736,489</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,853,861</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less
valuation allowance</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
(7,736,489</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
(5,853,861</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
deferred tax assets</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
&#x2014;</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
&#x2014;</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<br />
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As
of December 31, 2010, Cellectar had federal and state net operating
loss carryforwards (&#x201C;NOLs&#x201D;) of approximately
$15,684,000 and $15,633,000 respectively, which expire beginning in
2030 and 2025, respectively.&#xA0; In addition, Cellectar has
federal and state research and development and investment tax
credits of approximately $391,000 and $335,000, respectively.&#xA0;
The amount of NOLs which may be utilized annually in future periods
will be limited pursuant to Section 382 of the Internal Revenue
Code as a result of substantial changes in the Company&#x2019;s
ownership that have occurred or that may occur in the future.&#xA0;
The Company has not quantified the amount of such
limitations.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Because
of the limited operating history, continuing losses and uncertainty
associated with the utilization of the NOLs in the future,
management has provided a full allowance against the gross deferred
tax asset.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cellectar
did not have unrecognized tax benefits or accrued interest and
penalties at any time during the years ended December 31, 2010 and
2009, and does not anticipate having unrecognized tax benefits over
the next twelve months.&#xA0; The Company is subject to audit by
the IRS for tax periods commencing January 1, 2007.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For
the nine-month period ended September 30, 2011, the federal and
state NOLs increased by approximately $5,470,000 as a result of the
loss recorded.</font></div>


</div><span /></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
8. &#xA0;INCOME TAXES</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company&#x2019;s deferred tax assets consisted of the following at
December 31:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="MARGIN-LEFT: 18pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2010</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2009</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="76%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net
operating loss carryforwards</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,872,000</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,543,000</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research
and development
expenses&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,180,000</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,906,000</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tax
credits</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,711,000</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,563,000</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Capital
loss carryforward</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">340,000</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">340,000</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based
compensation</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
365,000</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
650,000</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gross
deferred tax asset</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">29,468,000</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,002,000</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Valuation
allowance</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
(29,468,000</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
(27,002,000</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net
deferred tax asset</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
&#x2014;</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
&#x2014;</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As
of December 31, 2010, the Company had federal and state net
operating loss carryforwards of approximately $33,180,000 and
$25,812,000 respectively, which expire through 2030.&#xA0;&#xA0;In
addition, the Company has federal and state research and
development and investment tax credits of approximately $1,382,000
and $449,000, respectively, which expire through
2030.&#xA0;&#xA0;The amount of net operating loss carryforwards
which may be utilized annually in future periods may be limited
pursuant to Section 382 of the Internal Revenue Code as a result of
substantial changes in the Company&#x2019;s ownership that have
occurred or that may occur in the future.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
capital loss carryforward relates to the loss recorded in prior
years for Novelos&#x2019; investment in an unrelated
company.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Because
of the Company&#x2019;s limited operating history, continuing losses
and uncertainty associated with the utilization of the net
operating loss carryforwards in the future, management has provided
a 100% allowance against the Company&#x2019;s gross deferred tax
asset.&#xA0;&#xA0;In 2010, the difference between the
Company&#x2019;s total statutory tax rate of approximately 40% and
its effective tax rate of 0% is due to the nontaxable gain of
$8,118,000 on derivative warrants, an increase in the valuation
allowance of $2,466,000 and nondeductible liquidated damages
accrued of $819,000.&#xA0;&#xA0;In 2009, the difference between the
Company&#x2019;s total statutory tax rate of approximately 40% and
its effective tax rate of 0% is due equally to the increase in
valuation allowance and the reduction in tax loss resulting from
the nondeductible loss on derivative warrants.&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company did not have any unrecognized tax benefits or accrued
interest and penalties at any time during the years ended December
31, 2010 and 2009, and does not anticipate having any unrecognized
tax benefits over the next twelve months.&#xA0;&#xA0;The Company is
subject to audit by the IRS for tax periods commencing January 1,
2007.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 109<br /><br /> -Paragraph 136, 172<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 109<br /><br /> -Paragraph 43, 44, 45, 46, 47, 48, 49<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 08<br /><br /> -Paragraph h<br /><br /> -Article 4<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 9<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 15<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.4-08.(h))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1036
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM NOTES PAYABLE<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LONG-TERM NOTES PAYABLE</a></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
8.&#xA0; LONG-TERM NOTES PAYABLE</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
January 11, 2008, Cellectar entered into a loan agreement with a
bank to borrow up to $1,200,000.&#xA0; The borrowing, evidenced by
a note (the &#x201C;Bank Note&#x201D;), bore interest at a rate of
7.01% per annum, could be prepaid without penalty and was payable
in 48 monthly principal and interest payments of $20,520 with a
balloon payment of any remaining unpaid principal and interest on
March 28, 2012.&#xA0; In the event of default of payment, Cellectar
would be required to pay a late charge equal to 5% of the
delinquent payment and the interest rate on the unpaid principal
would be increased by 3%.&#xA0; The Bank Note was collateralized by
substantially all assets of Cellectar and a deposit account in the
amount of $500,000.&#xA0; The cash collateral is classified as
restricted cash in the accompanying balance sheet.&#xA0; As of
December 31, 2010 and 2009, $470,941 and $675,743 are classified as
a long-term note payable in the accompanying balance sheet,
respectively.&#xA0; On April 8, 2011, immediately prior to the
Acquisition, Cellectar paid approximately $627,000 in full
settlement of the Bank Note. The payment was made in order to avoid
an event of default that would have occurred as a result of the
change of control that occurred at the time of the
Acquisition.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
September 15, 2010, Cellectar entered into certain loan agreements
with the Wisconsin Department of Commerce (&#x201C;WDOC
Notes&#x201D;) to borrow a total of $450,000.&#xA0; The WDOC Notes
bear interest at 2% per annum beginning on the date of disbursement
and allow for the deferral of interest and principal payments until
April 30, 2015.&#xA0; In the event of default of payment, interest
on the delinquent payment is payable at a rate equal to 12% per
annum.&#xA0; Monthly payments of $20,665 for principal and interest
shall commence on May 1, 2015 and continue for 23 equal
installments with the final installment of any remaining unpaid
principal and interest due on April 1, 2017.&#xA0; As of December
31, 2010, $450,000 is classified as a long-term note payable in the
accompanying balance sheet.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Long-term
notes payable consists of the following as of December
31:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br /></div>
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2010</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2009</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Bank
Note, 7.01% interest</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">675,743</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">866,532</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Wisconsin
Department of Commerce,&#xA0; 2% interest</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
450,000</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
&#x2014;</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,125,743</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">866,532</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less
current portion</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
(204,802</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
(190,789</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Long-term
note payable, net of current portion</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
920,941</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
675,743</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As
of December 31, 2010, long-term notes payable matures as
follows:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="70%">
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="85%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Years
ended December 31,</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="85%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
<!--efplaceholder-->2011</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">204,802</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="85%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">470,941</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="85%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="85%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2014</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="85%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2015</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">119,957</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="85%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Thereafter</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
330,043</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="85%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
1,125,743</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During
the nine-months ended September 30, 2011, payments of $675,743 were
made in connection with the Bank Note including a payment of
approximately $627,000 in full settlement of the Bank Note made
immediately prior to the Acquisition in order to avoid an event of
default that would have occurred as a result of the change in
control that occurred at the time of the Acquisition.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As
of September 30, 2011, the outstanding principal on the WDOC Notes
of $450,000 is classified as long-term debt outstanding in the
accompanying balance sheet.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.19,20,22)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 2, 4<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 19, 20, 22<br /><br /> -Article 5<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1037
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_CollaborativeAndLicenseArrangementDisclosureTextBlock', window );">LICENSE AGREEMENTS</a></td><td class="text"><div>
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
6.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
LICENSE AGREEMENTS</font></div>
</td>
</tr>
</table>
</div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">
2003 License Agreement with the University of Michigan</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In
September 2003, Cellectar entered into an exclusive license
agreement (the &#x201C;U. Mich. Agreement&#x201D;) with the Regents
of the University of Michigan, (&#x201C;U. Mich.&#x201D;) for the
development, manufacture and marketing of products under several
composition of matter patents in North America which expire at
varying dates in 2016.&#xA0; The U. Mich. Agreement expires upon
the expiration of the last covered patent.&#xA0; The Company is
responsible for an annual license fee of $10,000 and is required to
pay costs associated with the maintenance of the patents covered by
the U. Mich. Agreement.&#xA0; Additionally, the Company is required
to make milestone payments of $50,000 upon the filing of a New Drug
Application (&#x201C;NDA&#x201D;) for a licensed product intended for
use in a therapeutic or diagnostic application (such milestone fees
may be deferred and paid within 12 months of the first commercial
sale of such products) and make certain milestone payments within a
year following the first commercial sale of any licensed
products.&#xA0; The sales milestones range from $100,000 to
$200,000, dependent upon whether the drug is for use in a
therapeutic or diagnostic application, provided that if sales in
the first 12 months are less than the amount of the milestone, then
we are required to pay 50% of all sales until the milestone is
satisfied.&#xA0;The milestone payments may&#xA0;total up to
$400,000. The U. Mich. Agreement provides that the Company pay a
royalty equal to 3% of net sales of any licensed products sold by
the Company or its sublicensees for such licensed products,
provided however if the sublicense fee payable to the Company is
between 4%-5% of net sales, then the royalties payable to U. Mich.
shall be equal to 50% of the sublicense fee.&#xA0; Furthermore, the
U. Mich. Agreement provides for a reduction in the royalties owed
by up to 50% if the Company is required to pay royalties to any
third parties related to the sale of the licensed products.&#xA0;
If we receive any revenue in consideration for rights to the
licensed technology that is not based on net sales, excluding any
funded research and development, we are required to pay U. Mich.
10% of amounts received.&#xA0; U. Mich. may terminate the agreement
if the Company ceases operations, if the Company fails to make any
required payment under the agreement, or if the Company otherwise
materially breaches the agreement, subject to the applicable notice
and cure periods.&#xA0; To date, the Company has made all payments
as they have become due, there have been no defaults under the U.
Mich. Agreement, nor has the Company been notified of a default by
U. Mich. The Company may terminate the agreement with six months
notice to U. Mich. and the return of licensed product and related
data.&#xA0; The U. Mich. Agreement contained milestones that
required certain development activities to be completed by
specified dates. All such development milestones have either been
completed or have been removed by subsequent amendment to the
agreement.&#xA0; U. Mich. has provided no warranties as to validity
or otherwise with respect to the licensed technology.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cellectar
paid approximately $600,&#xA0;$300 and $5,000 to U. Michigan for
the reimbursement of patent maintenance fees during the nine months
ended September 30, 2011 and the years ended December 31, 2010 and
2009, respectively.&#xA0; As of September 30, 2011 and December 31,
2010, all annual license fees have been paid in a timely
manner.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In
connection with the Michigan Agreement, during 2003 Cellectar paid
approximately $54,000 of back patent costs and issued 203,483
shares of common stock to U. Michigan as partial consideration for
the rights described above.&#xA0; The estimated fair-market value
of the issuance was $80,412 and was recorded as a license cost and
is included as a component of stockholders equity in the
accompanying balance sheets.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">
License Agreement with Wisconsin Alumni Research
Foundation</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In
January 2006, Cellectar entered into a license agreement (the
&#x201C;WARF Agreement&#x201D;) with the Wisconsin Alumni Research
Foundation (&#x201C;WARF&#x201D;) under which Cellectar received a
license, with a right to grant sublicenses, to develop,
manufacture, and market products with respect to certain
patents.&#xA0; The WARF Agreement required an initial license fee
of $8,800 and provided that Cellectar pay royalties equal to 0.3%
of sales of any licensed products.&#xA0; Cellectar was also
required to reimburse WARF for patent filing fees and related
costs.&#xA0; During the years ended December 31, 2010 and 2009,
there were no costs related to the patents under the WARF
Agreement.&#xA0;&#xA0;During 2010, the WARF Agreement was
terminated.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">
Novelos License Agreements</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
2007, Novelos entered into a Collaboration Agreement with
Lee&#x2019;s Pharmaceutical (HK) Ltd. (&#x201C;Lee&#x2019;s
Pharm&#x201D;) whereby Lee&#x2019;s Pharm obtained an exclusive
license to develop, manufacture and commercialize NOV-002 and
NOV-205 in China, Hong Kong, Taiwan and Macau (the &#x201C;Chinese
Territory&#x201D;). Under the terms of the agreement the Company is
entitled to receive up to $1,700,000 in future milestone payments
upon the completion of development and marketing milestones by
Lee&#x2019;s Pharm and to receive royalty payments of between 12-25%
of net sales of NOV-205 and NOV-002, as applicable, in the Chinese
Territory and receive royalty payments of 12-15% of net sales of
NOV-205 in the Chinese Territory. The agreement expires upon the
expiration of the last patent covering any of the licensed
products, or twelve years from the date of the first commercial
sale in China, whichever occurs later.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During
2009, Novelos entered into a collaboration agreement (the
&#x201C;Collaboration Agreement&#x201D;) with Mundipharma
International Corporation Limited (&#x201C;Mundipharma&#x201D;) to
develop, manufacture and commercialize, on an exclusive basis,
Licensed Products (as defined in the Collaboration Agreement),
including NOV-002, in Europe (other than the Russian Territory),
Asia (other than the Chinese Territory) and Australia (collectively
referred to as the &#x201C;Mundipharma Territory&#x201D;).&#xA0;
Mundipharma is an independent associated company of Purdue Pharma,
L.P. (&#x201C;Purdue&#x201D;).&#xA0; The Collaboration Agreement
provides for Mundipharma to pay the Company royalties and fixed
milestone payments based on sales and commercial launches in the
licensed territories.&#xA0; For countries in which patents are
held, the Collaboration Agreement expires on a country-by-country
basis within the Mundipharma Territory on the earlier of (1)
expiration of the last applicable Novelos patent within the country
or (2) the determination that any patents within the country are
invalid, obvious or otherwise unenforceable.&#xA0; For countries in
which no patents are held, the Collaboration Agreement expires the
earlier of 15 years from its effective date or upon generic product
competition in the country resulting in a 20% drop in
Mundipharma&#x2019;s market share.&#xA0; The Company may terminate
the Collaboration Agreement upon breach or default by
Mundipharma.&#xA0; Mundipharma may terminate the Collaboration
Agreement upon breach or default, filing of voluntary or
involuntary bankruptcy by Novelos, the termination of certain
agreements with companies associated with the originators of the
licensed technology, or 30-day notice for no reason.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company has suspended development of the products covered by the
collaboration agreements described above. The Company does not
anticipate that the collaboration agreements will have a material
effect on its results of operations, cash flows, and financial
position following the Acquisition.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_CollaborativeAndLicenseArrangementDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and License Arrangement Disclosure [Text Block]</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_CollaborativeAndLicenseArrangementDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1038
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EFEAC"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) (Pre Acquisition, USD $)<br /></strong></div></th><th class="th" colspan="3">12 Months Ended</th></tr><tr><th class="th"><div>Dec. 31, 2009

</div><div>Series E redeemable convertible preferred stock</div></th><th class="th"><div>Dec. 31, 2009

</div><div>Private Placement</div></th><th class="th"><div>Dec. 31, 2010

</div><div>Public Offering</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td><td class="nump">$ 795,469<span /></td><td class="nump">$ 61,116<span /></td><td class="nump">$ 250,862<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Direct costs (e.g., legal and accounting fees) associated with issuing stock that is deducted from additional paid in capital. Also includes any direct costs associated with stock issues under a shelf registration.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Technical Practice Aid (TPA)<br /><br /> -Number 4110<br /><br /> -Paragraph 1, 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1039
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EGDAC"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th><th class="th" colspan="1">12 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
accompanying financial statements reflect the application of
certain accounting policies, as described in this note and
elsewhere in the accompanying notes to the financial
statements.&#xA0; The unaudited financial statements as of and for
the nine months ended September 30, 2011 are presented on a
consolidated basis to reflect the Acquisition described in Note
4.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
accompanying consolidated unaudited September 30, 2011 balance
sheet, the statements of operations and cash flows for the nine
months ended September 30, 2011 and 2010, and the statements of
stockholders&#x2019; equity for the nine months ended September 30,
2011 and the related interim information contained within the notes
to the financial statements have been prepared in accordance with
the rules and regulations of the Securities and Exchange Commission
(&#x201C;SEC&#x201D;) for interim financial information. Accordingly,
they do not include all of the information and the notes required
by U.S. generally accepted accounting principles for complete
financial statements. In the opinion of management, the unaudited
interim financial statements reflect all adjustments, consisting of
normal and recurring adjustments, necessary for the fair
presentation of the Company&#x2019;s financial position at September
30, 2011 and results of its operations and its cash flows for the
nine months ended September 30, 2011 and 2010 and the period from
November 7, 2002 (inception) to September 30, 2011. The results for
the nine months ended September 30, 2011 are not necessarily
indicative of future results.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Development Stage Company</font> &#x2014; Cellectar has been in the
development stage since its inception.&#xA0; The primary activities
since inception have been organizational activities, research and
development and raising capital.&#xA0; No significant revenues have
been generated from planned principal operations.&#xA0; As of
September 30, 2011 and December 31, 2010 and 2009 the Company
continues to be in the development stage.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
summary unaudited condensed statement of operations for the
cumulative development-stage period from November 7, 2002 (date of
inception) through September 30, 2011 is as follows:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%">
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">COSTS
AND EXPENSES:</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="top" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research
and development</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,651,388</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General
and administrative</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,797,688</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Merger
costs</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">799,133</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
costs and expenses</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">29,248,209</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">LOSS
FROM OPERATIONS</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(29,248,209</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">OTHER
EXPENSE, NET</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(266,297</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#xA0;</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">NET
LOSS</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(29,514,506</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BASIC
AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON
SHARE</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2.80</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">SHARES
USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON
STOCKHOLDERS PER COMMON SHARE</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,549,244</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
</table>
</div>
&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
summary unaudited condensed statement of cash flow for the
cumulative development-stage period from November 7, 2002 (date of
inception) through September 30, 2011 is as follows:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
<div>
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%">
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net
loss</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(29,514,506</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjustments
to reconcile net loss to cash used in operating
activities</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,558,106</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Changes
in working capital</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">359,177</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash
used in operating activities</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(23,597,223</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CASH
FLOWS FROM INVESTING ACTIVITIES:</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash
acquired in a business combination</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">905,649</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Purchases
of fixed assets, net of $7,000 proceeds from sale of fixed
assets</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,473,376</font></div>
</td>
<td valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change
in restricted cash</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(55,000</font></div>
</td>
<td valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;&#xA0;&#xA0;&#xA0;Payment
for intangible assets</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(19,671</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash
used in investing activities</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,642,398</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CASH
FLOWS FROM FINANCING ACTIVITIES:</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds
from issuance of common stock and warrants, net of issuance costs,
repurchase of common stock, and cash paid in lieu of fractional
shares in a business combination</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,794,302</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change
in deferred issuance costs</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(130,800</font></div>
</td>
<td valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds
from issuance of long-term obligations</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,398,930</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payments
on long-term obligations</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,232,056</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash
provided by financing activities</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">29,830,376</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">INCREASE
IN CASH AND EQUIVALENTS</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,590,755</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CASH
AND EQUIVALENTS AT BEGINNING OF PERIOD</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CASH
AND EQUIVALENTS AT END OF PERIOD</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,590,755</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">SUPPLEMENTAL
DISCLOSURE OF CASH FLOW INFORMATION</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest
paid</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">208,689</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair
value of derivative warrants reclassified to additional paid-in
capital upon cashless exercise</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48,339</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance
of common stock upon the conversion of notes payable and accrued
interest</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,184,707</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair
value of assets acquired in exchange for securities in a business
combination</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">78,407</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair
value of liabilities assumed in exchange for securities in a
business combination</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(439,615</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Excess
of purchase price over net assets acquired in a business
combination</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,675,462</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div align="center">&#xA0;</div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<!--EFPlaceholder--><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Use of
Estimates</font> &#x2014; The preparation of financial statements in
conformity with accounting principles generally accepted in the
United States requires management to make estimates and judgments
that may affect the reported amounts of assets, liabilities,
revenue and expenses and disclosure of contingent assets and
liabilities. On an on-going basis, management evaluates its
estimates including those related to unbilled vendor amounts and
share-based compensation. Management bases its estimates on
historical experience and on various other assumptions that are
believed to be reasonable, the results of which form the basis for
making judgments about the carrying values of assets and
liabilities. Actual results may differ from those estimates under
different assumptions or conditions. Changes in estimates are
reflected in reported results in the period in which they become
known.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Cash and Cash Equivalents</font> &#x2014; All short-term investments
purchased with original maturities of three months or less are
considered to be cash equivalents.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Restricted Cash</font> &#x2014; Restricted cash at September 30,
2011 consists of a certificate of deposit required under the
Company&#x2019;s lease agreement (see Note 14).&#xA0; Restricted
cash at December 31, 2010 and December 31, 2009 consists of a
certificate of deposit required for collateral for a promissory
note with a bank (see Note 8) and a certificate of deposit required
under the Company&#x2019;s lease agreement (see Note
14).</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Fixed Assets</font> &#x2014; Property and equipment are stated at
cost. Depreciation on property and equipment is provided using the
straight-line method over the estimated useful lives of the assets
(5 years).&#xA0; Due to the significant value of leasehold
improvements purchased during the initial 3-year lease term and the
economic penalty for not extending the building lease, leasehold
improvements are depreciated over 17 years (their estimated useful
life) which represents the full term of the lease, including all
extensions (Note 14).</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Intangible Assets</font> &#x2014; Intangible assets at September 30,
2011 consist of the excess of purchase price over net assets
acquired in connection with the Acquisition and will be allocated
to intangibles, which could potentially include the fair value of
the compounds developed prior to the Acquisition by Novelos, with
the remainder allocated to goodwill once the Company completes the
final allocation of purchase price (Note 4).&#xA0; Intangible
assets at December 31, 2009 consisted of costs incurred to obtain
trademarks.&#xA0; These costs were capitalized when the expense was
incurred and at which time the assets were deemed to have an
indefinite life.&#xA0; During 2010, following a reduction in staff
and suspension of research and manufacturing activities in order to
reduce operating costs, it was determined that the trademarks had
been impaired and the carrying value was reduced to
zero.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Impairment of Long</font> - <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Lived
Assets</font> &#x2014; Whenever events or circumstances change, an
assessment is made as to whether there has been an impairment in
the value of long-lived assets by determining whether projected
undiscounted cash flows generated by the applicable asset exceed
its net book value as of the assessment date.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Stock-Based Compensation</font> &#x2014; Employee stock-based
compensation is accounted for in accordance with the guidance of
Financial Accounting Standards Board Accounting Standards
Codification (&#x201C;FASB ASC&#x201D;) Topic 718, <font style="FONT-STYLE: italic; DISPLAY: inline">Compensation &#x2013; Stock
Compensation</font> which requires all share-based payments to
employees, including grants of employee stock options, to be
recognized in the financial statements based on their fair
values.&#xA0; Non-employee stock-based compensation is accounted
for in accordance with the guidance of FASB ASC Topic 505,
<font style="FONT-STYLE: italic; DISPLAY: inline">Equity.&#xA0;</font> As such,
the Company recognizes expense based on the estimated fair value of
options granted to non-employees over their vesting period, which
is generally the period during which services are rendered and
deemed completed by such non-employees.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Research and Development</font> &#x2014; Research and development
costs are expensed as incurred.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Income Taxes</font> &#x2014; Income taxes are accounted for using
the liability method of accounting.&#xA0; Under this method,
deferred tax assets and liabilities are determined based on
temporary differences between the financial statement and tax basis
of assets and liabilities and net operating loss and credit
carryforwards using enacted tax rates in effect for the year in
which the differences are expected to reverse.&#xA0; The effect on
deferred tax assets and liabilities of a change in tax rates is
recognized in income in the period that includes the enactment
date.&#xA0; Valuation allowances are established when it is more
likely than not that some portion of the deferred tax assets will
not be realized.&#xA0; Management has provided a full valuation
allowance against the Company&#x2019;s gross deferred tax
asset.&#xA0; Tax positions taken or expected to be taken in the
course of preparing tax returns are required to be evaluated to
determine whether the tax positions are &#x201C;more likely than
not&#x201D; of being sustained by the applicable tax
authority.&#xA0; Tax positions deemed not to meet a
more-likely-than-not threshold would be recorded as tax expense in
the current year.&#xA0; There were no uncertain tax positions that
require accrual or disclosure to the financial statements as of
September 30, 2011, December 31, 2010 and 2009.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Comprehensive Loss</font> &#x2014; There were no components of
comprehensive loss other than net loss in all of the periods
presented.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Grant Income</font> &#x2014; Cellectar received a cash grant of
$44,000 and $200,000 for the nine-month period ended September 30,
2011 and the year ended December 31, 2010, respectively, from the
U.S. Internal Revenue Service as a qualifying therapeutic discovery
project credit pursuant to the Patient Protection and Affordable
Care Act.&#xA0; This grant has been recorded as a component of
other income.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Fair Value of Financial Instruments</font> &#x2014; The guidance
under FASB ASC Topic 825, <font style="FONT-STYLE: italic; DISPLAY: inline">Financial Instruments</font>
, requires disclosure of the fair value of certain financial
instruments. Financial instruments in the accompanying financial
statements consist of cash equivalents, accounts payable,
convertible debt and long-term obligations.&#xA0; The carrying
amount of cash equivalents, investments and accounts
payable&#xA0;approximate&#xA0;their&#xA0;fair value due to their
short-term nature.&#xA0; The estimated fair value of the
convertible debt, determined on an as-converted basis including
conversion of accumulated unpaid interest, was approximately $0 and
$3,264,000 at September 30, 2011 and December 31, 2010,
respectively.&#xA0; The carrying value of long-term obligations,
including the current portion, approximates fair value because the
fixed interest rate approximates current market rate of interest
available in the market.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Derivative Instruments</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#xA0;</font>&#x2013; The
Company generally does not use derivative instruments to hedge
exposures to cash flow or market risks.&#xA0; However, certain
warrants to purchase common stock that do not meet the requirements
for classification as equity, in accordance with the Derivatives
and Hedging Topic of the Financial Accounting Standards Board
Accounting Standards Codification (&#x201C;FASB
ASC&#x201D;),<font style="FONT-STYLE: italic; DISPLAY: inline">&#xA0;</font>are classified
as liabilities.&#xA0; In such instances, net-cash settlement is
assumed for financial reporting purposes, even when the terms of
the underlying contracts do not provide for a net-cash settlement.
These warrants are considered derivative instruments because the
agreements contain &#x201C;down-round&#x201D; provisions whereby the
number of shares for which the warrants are exercisable and/or the
exercise price of the warrants are subject to change in the event
of certain issuances of stock at prices below the then-effective
exercise price of the warrants. The number of shares issuable under
such warrants was 77,729 at September 30, 2011. The primary
underlying risk exposure pertaining to the warrants is the change
in fair value of the underlying common stock.&#xA0; Such financial
instruments are initially recorded at fair value with subsequent
changes in fair value recorded as a component of gain or loss on
derivatives in each reporting period. If these instruments
subsequently meet the requirements for equity classification, the
Company reclassifies the fair value to equity. At September 30,
2011, these warrants represented the only outstanding derivative
instruments issued or held by the Company.&#xA0; There were no
outstanding derivative instruments at December 31, 2010 or
2009.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Concentration of Credit Risk</font> &#x2014; Financial instruments
that subject the Company to credit risk consist of cash and
equivalents on deposit with financial institutions, which may
exceed federally insured limits.&#xA0; Excess cash is invested on
an overnight basis in an investment account that is fully
collateralized principally by government-backed obligations.&#xA0;
Cash and equivalent balances are maintained with a stable and
well-capitalized financial institution.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
New Accounting Pronouncements</font> &#x2014;&#xA0;In January 2010,
the FASB issued ASU No.&#xA0;2010-06, <font style="FONT-STYLE: italic; DISPLAY: inline">Improving Disclosures about
Fair Value Measurements</font> , which requires additional
disclosures about the amounts of and reasons for significant
transfers in and out of Level&#xA0;1 and Level&#xA0;2 fair value
measurements. This standard also clarifies existing disclosure
requirements related to the level of disaggregation of fair value
measurements for each class of assets and liabilities and
disclosures about inputs and valuation techniques used to measure
fair value for both recurring and non-recurring Level&#xA0;2 and
Level&#xA0;3 measurements. Since this new accounting standard only
required additional disclosure, the adoption of the standard in the
first quarter of 2010 did not impact the accompanying financial
statements. Additionally, effective for interim and annual periods
beginning after December&#xA0;15, 2010, this standard will require
additional disclosure and require an entity to present
disaggregated information about activity in Level&#xA0;3 fair value
measurements on a gross basis, rather than one net amount.&#xA0;
The adoption of this accounting standard did not impact the
accompanying financial statements.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
December 2010, the FASB issued ASU No. 2010-29, <font style="FONT-STYLE: italic; DISPLAY: inline">Disclosures of Supplementary
Pro Forma Information for Business Combinations</font>, which, if
comparative financial statements are presented, requires the
supplemental pro forma disclosure of revenue and earnings to be
presented as if the business combination had occurred at the
beginning of the comparable prior annual reporting period
only.&#xA0; This standard also expands the supplemental pro forma
disclosures required under FASB ASC Topic 850, <font style="FONT-STYLE: italic; DISPLAY: inline">Business Combinations</font>
, to include a description of the nature and amount of material
nonrecurring pro forma adjustments directly attributable to the
business combination in the reported pro forma revenue and
earnings.&#xA0; This standard is effective for the Company for any
business combinations completed after January 1, 2011.&#xA0; The
Company adopted the provisions of this standard during the first
quarter of 2011.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
May 2011, the FASB issued ASU No. 2011-04, <font style="FONT-STYLE: italic; DISPLAY: inline">Amendments to Achieve Common
Fair Value Measurement and Disclosure Requirements in U.S.
Generally Accepted Accounting Principles (&#x201C;GAAP&#x201D;) and
International Financial Reporting Standards
(&#x201C;IFRSs&#x201D;).</font> &#xA0;This standard updates
accounting guidance to clarify the measurement of fair value to
align the guidance and improve the comparability surrounding fair
value measurement within GAAP and IFRSs.&#xA0; The standard also
updates requirements for measuring fair value and expands the
required disclosures.&#xA0; The standard does not require
additional fair value measurements and was not intended to
establish valuation standards or affect valuation practices outside
of financial reporting.&#xA0; This standard will become effective
for the Company on January 1, 2012.&#xA0; The Company does not
expect that the adoption of this standard will have a material
impact when applied prospectively on the Company&#x2019;s financial
statements or required disclosures.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
June 2011, the FASB issued ASU No. 2011-05, <font style="FONT-STYLE: italic; DISPLAY: inline">Presentation of Comprehensive
Income.</font>&#xA0;This standard eliminates the current option to
report other comprehensive income and its components in the
statement of changes in equity. The standard is intended to enhance
comparability between entities that report under US&#xA0;GAAP and
those that report under IFRS, and to provide a more consistent
method of presenting non-owner transactions that affect an entity's
equity. Under the ASU, an entity can elect to present items of net
income and other comprehensive income in one continuous statement,
referred to as the statement of comprehensive income, or in two
separate, but consecutive, statements. Each component of net income
and each component of other comprehensive income, together with
totals for comprehensive income and its two parts, net income and
other comprehensive income, would need to be displayed under either
alternative. The statement(s) would need to be presented with equal
prominence as the other primary financial statements. The ASU does
not change items that constitute net income and other comprehensive
income, when an item of other comprehensive income must be
reclassified to net income or the earnings-per-share computation
(which will continue to be based on net income). The new
US&#xA0;GAAP requirements are effective for public entities as of
the beginning of a fiscal year that begins after December&#xA0;15,
2011 and interim and annual periods thereafter. Early adoption is
permitted, but full retrospective application is required under the
accounting standard. The Company does not expect that the adoption
of this standard will have a material impact on our results of
operations, cash flows, and financial position.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In
September 2011, the FASB issued ASU No. 2011-08, <font style="FONT-STYLE: italic; DISPLAY: inline">Intangibles &#x2013; Goodwill
and Other (Topic 350) Testing Goodwill for
Impairment.</font>&#xA0;&#xA0;This standard simplifies how an
entity tests goodwill for impairment and allows an entity to first
assess qualitative factors in determining whether it is more likely
than not that the fair value of a reporting unit is less than its
carrying amount as a basis for determining whether it is necessary
to perform the two-step goodwill impairment test.&#xA0;&#xA0;This
standard is effective for entities as of the beginning of a fiscal
year that begins after December 15, 2011 and interim and annual
periods thereafter.&#xA0;&#xA0;Early adoption is
permitted.&#xA0;&#xA0;The Company does not expect the adoption of
this standard will have a material impact on our results of
operations, cash flows, and financial position.</font></div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Reclassifications</font> &#x2014; Certain prior-period amounts have
been reclassified to conform to the current-period
presentation.</font></div>


</div><span /></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
accompanying financial statements reflect the application of
certain accounting policies, as described in this note and
elsewhere in the accompanying notes to the financial
statements.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Use of Estimates</font> &#x2014; The preparation of financial
statements in conformity with accounting principles generally
accepted in the United States requires the Company&#x2019;s
management to make estimates and judgments that may affect the
reported amounts of assets, liabilities, revenue and expenses and
disclosure of contingent assets and liabilities. On an on-going
basis, the Company&#x2019;s management evaluates its estimates
including those related to unbilled research and development costs,
valuation of derivatives and share-based compensation. The Company
bases its estimates on historical experience and on various other
assumptions that are believed to be reasonable, the results of
which form the basis for making judgments about the carrying values
of assets and liabilities. Actual results may differ from those
estimates under different assumptions or conditions. Changes in
estimates are reflected in reported results in the period in which
they become known.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Cash Equivalents</font> &#x2014; The Company considers all
short-term investments purchased with original maturities of three
months or less to be cash equivalents.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Fixed Assets</font> &#x2014; Property and equipment are stated at
cost. Depreciation on property and equipment is provided using the
straight-line method over the estimated useful lives of the assets,
which range from three to five years. Leasehold improvements are
depreciated over the lesser of the estimated useful lives of the
assets or the remaining lease term.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Impairment of Long</font>-<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Lived
Assets</font> &#x2014; Whenever events or circumstances change, the
Company assesses whether there has been an impairment in the value
of long-lived assets by determining whether projected undiscounted
cash flows generated by the applicable asset exceed its net book
value as of the assessment date.&#xA0; There were no impairments of
the Company&#x2019;s assets at the end of each period
presented.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Stock-Based Compensation</font> &#x2014; The Company accounts for
employee stock-based compensation in accordance with the guidance
of FASB ASC Topic 718, <font style="FONT-STYLE: italic; DISPLAY: inline">Compensation &#x2013; Stock
Compensation</font> which requires all share-based payments to
employees, including grants of employee stock options, to be
recognized in the financial statements based on their fair
values.&#xA0; The Company accounts for non-employee stock-based
compensation in accordance with the guidance of FASB ASC Topic 505,
<font style="FONT-STYLE: italic; DISPLAY: inline">Equity</font>
which requires that companies recognize compensation expense based
on the estimated fair value of options granted to non-employees
over their vesting period, which is generally the period during
which services are rendered by such non-employees.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Revenue Recognition</font> &#x2014; Revenue is recognized when
persuasive evidence of an arrangement exists, the price is fixed
and determinable, delivery has occurred, and there is reasonable
assurance of collection.&#xA0; Upfront payments received in
connection with technology license or collaboration agreements are
recognized over the estimated term of the related agreement.&#xA0;
The Company has not yet received milestone or royalty payments in
connection with license or collaboration agreements.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Research and Development</font> &#x2014; Research and development
costs are expensed as incurred.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Income Taxes</font> &#x2014; The Company uses the liability method
of accounting for income taxes.&#xA0; Under this method, deferred
tax assets and liabilities are determined based on temporary
differences between the financial statement and tax basis of assets
and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the
differences are expected to reverse.&#xA0; The effect on deferred
tax assets and liabilities of a change in tax rates is recognized
in income in the period that includes the enactment date.&#xA0;
Valuation allowances are established when it is more likely than
not that some portion of the deferred tax assets will not be
realized.&#xA0; Tax positions taken or expected to be taken in the
course of preparing the Company&#x2019;s tax returns are required to
be evaluated to determine whether the tax positions are &#x201C;more
likely than not&#x201D; of being sustained by the applicable tax
authority.&#xA0; Tax positions deemed not to meet a
more-likely-than-not threshold would be recorded as tax expense in
the current year.&#xA0; There were no uncertain tax positions that
require accrual or disclosure to the financial statements as of
December 31, 2010 and 2009.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Comprehensive Income (Loss)</font> &#x2014; The Company had no
components of comprehensive income other than net income (loss) in
all of the periods presented.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Fair Value of Financial Instruments</font> &#x2014; The guidance
under FASB ASC Topic 825, <font style="FONT-STYLE: italic; DISPLAY: inline">Financial Instruments</font>
, requires disclosure of the fair value of certain financial
instruments. The Company&#x2019;s financial instruments consist of
cash equivalents, accounts payable, accrued expenses and redeemable
preferred stock. The estimated fair value of the redeemable
preferred stock, determined on an as-converted basis including
conversion of accumulated unpaid dividends, was $114,780,000 at
December 31, 2009. The estimated fair value of the remaining
financial instruments approximates their carrying value due to
their short-term nature.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Concentration of Credit Risk</font> &#x2014; Financial instruments
that subject the Company to credit risk consist of cash and
equivalents on deposit with financial institutions. The
Company&#x2019;s excess cash is on deposit in an overnight
investment account that is fully collateralized by
government-backed obligations.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Derivative Instruments</font> &#x2014; The Company generally does
not use derivative instruments to hedge exposures to cash flow or
market risks; however, starting January 1, 2009, certain warrants
to purchase common stock that do not meet the requirements for
classification as equity, in accordance with the Derivatives and
Hedging Topic of the FASB ASC, are classified as liabilities. In
such instances, net-cash settlement is assumed for financial
reporting purposes, even when the terms of the underlying contracts
do not provide for a net-cash settlement. These warrants are
considered derivative instruments as the agreements contain
&#x201C;down-round&#x201D; provisions whereby the number of shares
for which the warrants are exercisable and/or the exercise price of
the warrants is subject to change in the event of certain issuances
of stock at prices below the then-effective exercise price of the
warrants. The number of such warrants was 91,524 at January 1,
2009, 48,489 at December 31, 2009 and 138,611 at December 31, 2010.
The primary underlying risk exposure pertaining to the warrants is
the change in fair value of the underlying common stock. Such
financial instruments are initially recorded at fair value, or
relative fair value when issued with other instruments, with
subsequent changes in fair value recorded as a component of gain or
loss on derivatives in each reporting period. If these instruments
subsequently meet the requirements for equity classification, the
Company reclassifies the fair value to equity. At December 31, 2010
and 2009, these warrants represent the only outstanding derivative
instruments issued or held by the Company. As a result of the
significant decline in the Company&#x2019;s stock price following
the announcement of the results of the Phase 3 Trial, the Company
recorded a gain of approximately $8,118,000 during the year ended
December 31, 2010 in connection with the revaluation of the
derivative liability balance at December 31, 2010.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
New Accounting Pronouncements</font> &#x2014;&#xA0; In September
2009, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;)
amended the accounting standards related to revenue recognition for
arrangements with multiple deliverables and arrangements that
include software elements (&#x201C;new accounting
principles&#x201D;). The new accounting principles permit
prospective or retrospective adoption, and the Company elected
prospective adoption at the beginning of the first quarter of 2010.
The adoption of the standard in 2010 had no impact on the
Company&#x2019;s financial statements.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
January 2010, the FASB issued ASU No.&#xA0;2010-06, <font style="FONT-STYLE: italic; DISPLAY: inline">Improving Disclosures about
Fair Value Measurements</font>, which requires additional
disclosures about the amounts of and reasons for significant
transfers in and out of Level&#xA0;1 and Level&#xA0;2 fair value
measurements. This standard also clarifies existing disclosure
requirements related to the level of disaggregation of fair value
measurements for each class of assets and liabilities and
disclosures about inputs and valuation techniques used to measure
fair value for both recurring and non-recurring Level&#xA0;2 and
Level&#xA0;3 measurements. Since this new accounting standard only
required additional disclosure, the adoption of the standard in the
first quarter of 2010 did not impact the Company&#x2019;s financial
statements. Additionally, effective for interim and annual periods
beginning after December&#xA0;15, 2010, this standard will require
additional disclosure and require an entity to present
disaggregated information about activity in Level&#xA0;3 fair value
measurements on a gross basis, rather than one net
amount.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Adoption of New Accounting Principle</font> &#x2014; Effective
January 1, 2009, the Company adopted the guidance of FASB ASC
815-40-15, <font style="FONT-STYLE: italic; DISPLAY: inline">Derivatives and
Hedging</font> , which establishes a framework for determining
whether certain freestanding and embedded instruments are indexed
to a company&#x2019;s own stock for purposes of evaluation of the
accounting for such instruments under existing accounting
literature. As a result of this adoption, certain warrants that
were previously determined to be indexed to the Company&#x2019;s
common stock upon issuance were determined not to be indexed to the
Company&#x2019;s common stock because they include
&#x201C;down-round&#x201D; anti-dilution provisions whereby the
number of shares for which the warrants are exercisable and/or the
exercise price of the warrants is subject to change in the event of
certain issuances of stock at prices below the then-effective
exercise price of the warrants. The fair value of the warrants at
the dates of issuance totaling $6,893,000 was initially recorded as
a component of additional paid-in capital. Upon adoption of this
guidance on January 1, 2009, the Company recorded a derivative
liability of $999,000, a decrease to the opening balance of
additional paid-in capital of approximately $6,893,000 and recorded
a decrease to accumulated deficit totaling approximately
$5,894,000, representing the decrease in the fair value of the
warrants from the date of issuance to December 31, 2008. The
increase in fair value of the warrants of approximately $12,114,000
during the year ended December 31, 2009 and the decrease in fair
value of the warrants of $8,118,000 during the year ended December
31, 2010 have been included as a component of other income
(expense) in the accompanying statement of operations. Certain of
the warrants that had been recorded as a derivative liability were
exchanged or exercised for shares of the Company&#x2019;s common
stock during the years ended December 31, 2010 and 2009. See Note 6
for a description of those transactions. The fair value of the
warrants of $288,000 and $10,487,000 at December 31, 2010 and 2009
is included as a current liability in the accompanying balance
sheet as of that date.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">
Reclassifications</font> &#x2014; Certain prior year amounts have
been reclassified to conform to the current year
presentation.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 22<br /><br /> -Paragraph 8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1040
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EXEAC"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUES OF ASSETS AND LIABILITIES<br /></strong></div></th><th class="th" colspan="1">3 Months Ended</th><th class="th" colspan="1">9 Months Ended</th><th class="th" colspan="1">12 Months Ended</th></tr><tr><th class="th"><div>Mar. 31, 2011</div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUES OF ASSETS AND LIABILITIES</a></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr valign="top">
<td style="WIDTH: 36pt" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman">2.</font></font></div>
</td>
<td align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
FAIR VALUES OF ASSETS AND LIABILITIES</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In
accordance with Fair Value Measurements and Disclosures Topic of
the FASB ASC, the Company groups its financial assets and financial
liabilities generally measured at fair value in three levels, based
on the markets in which the assets and liabilities are traded and
the reliability of the assumptions used to determine fair
value.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div>
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif">
&#xB7;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level
1: Input prices quoted in an active market for identical financial
assets or liabilities.</font></div>
</td>
</tr>
</table>
</div>
<div>
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif">
&#xB7;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level
2: Inputs other than prices quoted in Level 1, such as prices
quoted for similar financial assets and liabilities in active
markets, prices for identical assets and liabilities in markets
that are not active or other inputs that are observable or can be
corroborated by observable market data.</font></div>
</td>
</tr>
</table>
</div>
<div>
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif">
&#xB7;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level
3: Input prices quoted that are significant to the fair value of
the financial assets or liabilities which are not observable or
supported by an active market.</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Assets
and liabilities measured at fair value on a recurring basis are
summarized below:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="96%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="46%" colspan="14" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">March&#xA0;31,&#xA0;2011</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Level&#xA0;1</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Level&#xA0;2</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Level&#xA0;3</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Fair&#xA0;Value</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
-</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
162,760</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
-</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
162,760</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
Company uses valuation methods and assumptions that consider among
others the fair value of the underlying stock, risk-free interest
rate, volatility, expected life and dividend rates in estimating
fair value for the warrants considered to be derivative
instruments. Assumptions used are generally consistent with those
disclosed for stock-based compensation (see Note 5).</font></div>
</div><span /></td><td class="text"><div>
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<!--EFPlaceholder-->3.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
FAIR VALUES OF ASSETS AND LIABILITIES</font></div>
</td>
</tr>
</table>
</div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
accordance with Fair Value Measurements and Disclosures Topic of
the FASB ASC, the Company groups its financial assets and financial
liabilities generally measured at fair value in three levels, based
on the markets in which the assets and liabilities are traded and
the reliability of the assumptions used to determine fair
value.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#xA0;</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="font-family:Symbol, serif">&#xB7;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
1: Input prices quoted in an active market for identical financial
assets or liabilities.</font></div>
</td>
</tr>
</table>
</div>
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#xA0;</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="font-family:Symbol, serif">&#xB7;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
2: Inputs other than prices quoted in Level 1, such as prices
quoted for similar financial assets and liabilities in active
markets, prices for identical assets and liabilities in markets
that are not active or other inputs that are observable or can be
corroborated by observable market data.</font></div>
</td>
</tr>
</table>
</div>
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#xA0;</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="font-family:Symbol, serif">&#xB7;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
3: Input prices quoted that are significant to the fair value of
the financial assets or liabilities which are not observable or
supported by an active market.</font></div>
</td>
</tr>
</table>
</div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Assets
and liabilities measured at fair value on a recurring basis are
summarized below:</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="14" valign="bottom" width="58%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<font style="DISPLAY: inline">September 30,
2011</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<font style="DISPLAY: inline">Level 1</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<font style="DISPLAY: inline">Level 2</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<font style="DISPLAY: inline">Level 3</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<font style="DISPLAY: inline">Fair Value</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
Liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 4px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">
-</font></font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">
77,967</font></font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">
-</font></font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">
77,967</font></font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
&#xA0;</div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="14" valign="bottom" width="58%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<font style="DISPLAY: inline">December 31, 2010</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<font style="DISPLAY: inline">Level 1</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<font style="DISPLAY: inline">Level 2</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<font style="DISPLAY: inline">Level 3</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<font style="DISPLAY: inline">Fair Value</font></font></div>
</td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
Liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 4px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">
-</font></font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">
-</font></font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">
-</font></font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">
-</font></font></td>
<td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company uses the Black-Scholes option pricing model and assumptions
that consider, among other variables, the fair value of the
underlying stock, risk-free interest rate, volatility, expected
life and dividend rates in estimating fair value for the warrants
considered to be derivative instruments. Assumptions used are
generally consistent with those disclosed for stock-based
compensation (see Note 11).</font></div>
</div><span /></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
4.&#xA0; FAIR VALUES OF ASSETS AND LIABILITIES</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
accordance with Fair Value Measurements and Disclosures Topic of
the FASB ASC, the Company groups its financial assets and financial
liabilities generally measured at fair value in three levels, based
on the markets in which the assets and liabilities are traded and
the reliability of the assumptions used to determine fair
value.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div>
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="font-family:Symbol, serif">&#xB7;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Level 1: Input prices quoted in an active market for identical
financial assets or liabilities.</font></font></div>
</td>
</tr>
</table>
</div>
<div>
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="font-family:Symbol, serif">&#xB7;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Level 2: Inputs other than prices quoted in Level 1, such as prices
quoted for similar financial assets and liabilities in active
markets, prices for identical assets and liabilities in markets
that are not active or other inputs that are observable or can be
corroborated by observable market data.</font></font></div>
</td>
</tr>
</table>
</div>
<br />
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div>
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="font-family:Symbol, serif">&#xB7;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Level 3: Input prices that are significant to the fair value of the
financial assets or liabilities which are not observable or
supported by an active market.</font></font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Assets
and liabilities measured at fair value on a recurring basis are
summarized below:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="MARGIN-LEFT: 18pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="46%" colspan="14">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">December&#xA0;31,&#xA0;2010</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Level&#xA0;1</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Level&#xA0;2</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Level&#xA0;3</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Fair&#xA0;Value</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="52%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Liabilities:</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
-</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
288,250</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
-</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
288,250</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="MARGIN-LEFT: 18pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="46%" colspan="14">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">December&#xA0;31,&#xA0;2009</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Level&#xA0;1</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Level&#xA0;2</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Level&#xA0;3</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Fair&#xA0;Value</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="52%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Liabilities:</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
-</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
10,487,000</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
-</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
10,487,000</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company uses valuation methods and assumptions that consider among
others the fair value of the underlying stock, risk-free interest
rate, volatility, expected life and dividend rates in estimating
fair value for the warrants considered to be derivative
instruments. Assumptions used are generally consistent with those
disclosed for stock-based compensation (see Note 7).</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 820<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19296-110258<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 159<br /><br /> -Paragraph 17-22, 27, 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 825<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 10<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 107<br /><br /> -Paragraph 15C, 15D<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 825<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 825<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 16<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13504-108611<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 107<br /><br /> -Paragraph 15A<br /><br /> -Subparagraph a-d<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 825<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 21<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13537-108611<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 133<br /><br /> -Paragraph 44A, 44B<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 820<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19207-110258<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 825<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 30<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 107<br /><br /> -Paragraph 3, 10, 14, 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 107<br /><br /> -Paragraph 15B<br /><br /> -Subparagraph a, b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 157<br /><br /> -Paragraph 32, 33, 34<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1041
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1042
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E3H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br /></strong></div></th><th class="th" colspan="1">3 Months Ended</th><th class="th" colspan="1">12 Months Ended</th></tr><tr><th class="th"><div>Mar. 31, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td><td class="text"><div>
<div>
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
10.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
SUBSEQUENT EVENTS</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Merger Agreement</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
April 8, 2011, the Company entered into an Agreement and Plan of
Merger (the &#x201C;Merger Agreement&#x201D;) with Cellectar, Inc.
(&#x201C;Cellectar&#x201D;) and Cell Acquisition Corp. (the
&#x201C;Merger Subsidiary&#x201D;), a wholly-owned subsidiary of
Novelos, pursuant to which Cellectar was merged into the Merger
Subsidiary (the &#x201C;Acquisition&#x201D;).&#xA0;&#xA0;As a result
of the Acquisition, the Merger Subsidiary, which has been renamed
Cellectar, Inc., owns all assets of and operates the business
previously owned and operated by Cellectar. Prior to the
Acquisition, Cellectar was in the business of developing drugs for
the treatment and diagnosis of cancer.&#xA0;&#xA0;The Company will
continue to develop Cellectar&#x2019;s compounds following the
Acquisition.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As
consideration for the Acquisition, the former stockholders of
Cellectar received aggregate consideration consisting of a number
of shares of Novelos common stock constituting, after giving effect
to the Acquisition but before giving effect to the concurrent
private placement of the Company&#x2019;s securities described
below, approximately 85% of the outstanding shares of Novelos
common stock.&#xA0;&#xA0;Prior to the Acquisition, the Company
amended and restated its certificate of incorporation and in
connection therewith, among other things, effected a 1-for-153
reverse split of its common stock (the &#x201C;Reverse
Split&#x201D;).&#xA0;&#xA0;Immediately following the effectiveness
of the Reverse Split, there were 2,959,871 shares of common stock
outstanding, and the Company issued 17,001,596 shares of its common
stock to the former stockholders of Cellectar upon the
effectiveness of the Acquisition.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Rodman
&amp; Renshaw, LLC (&#x201C;Rodman&#x201D;), financial advisor to
Novelos in connection with the Acquisition, received a cash fee of
$250,000 upon the completion of the Acquisition in consideration
for their services.&#xA0;&#xA0;XMS Capital Partners, the financial
advisor to Cellectar in connection with the Acquisition, received a
cash fee of $200,000 upon the completion of the Acquisition in
consideration for their services.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounting
principles generally accepted in the United States require that a
company whose security holders retain the majority voting interest
in the combined business be treated as the acquirer for financial
reporting purposes.&#xA0; Accordingly, the Acquisition will be
accounted for as a reverse acquisition whereby Cellectar, Inc. will
be treated as the accounting acquirer.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Securities Purchase Agreement</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Concurrently
with the execution of the Merger Agreement, the Company entered
into a Securities Purchase Agreement with certain accredited
investors under which the Company sold an aggregate of 6,846,537
units, each unit consisting of one share of its common stock and a
warrant to purchase one share of its common stock, at a price of
$0.75 per unit, for gross proceeds of approximately
$5,135,000.&#xA0;&#xA0;The warrants have an exercise price of $0.75
and expire on March 31, 2016.&#xA0;&#xA0;The warrant exercise price
and/or the common stock issuable pursuant to such warrant will be
subject to adjustment for stock dividends, stock splits or similar
capital reorganizations so that the rights of the warrant holders
after such event will be equivalent to the rights of warrant
holders prior to such event.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
Securities Purchase Agreement includes a requirement that the
Company file with the SEC no later than October 5, 2011, a
registration statement covering the resale of the shares of common
stock, and the shares of common stock underlying the warrants,
issued pursuant to the Securities Purchase
Agreement.&#xA0;&#xA0;The Company is also required to use
commercially reasonable efforts to have the registration statement
declared effective by December 4, 2011, and to keep the
registration statement continuously effective under the Securities
Act of 1933, as amended (the &#x201C;Securities Act&#x201D;), until
the earlier of the date when all the registrable securities covered
by the registration statement have been sold or the second
anniversary of the closing.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In
the event the Company fails to file the registration statement
within the timeframe specified by the Securities Purchase
Agreement, or if it fails to obtain effectiveness of this
registration on or prior to the December 4, 2011 (if there is no
review by the SEC) or by January 3, 2012 (if there is review by the
SEC) with respect to the maximum number of shares permitted to be
registered by the SEC, the Company will be required to pay to the
purchasers liquidated damages equal to 1.5% per month (pro-rated on
a daily basis for any period of less than a full month) of the
aggregate purchase price of the units purchased until the
registration statement is filed or declared effective, as
applicable.&#xA0;&#xA0;The Company will be allowed to suspend the
use of the registration statement for not more than 30 consecutive
days, on not more than two occasions, in any 12 month
period.&#xA0;&#xA0;The Company has also granted piggy-back
registration rights with respect to any shares of common stock that
it is required to exclude from the registration statement as a
condition of its effectiveness, and has also agreed to file further
registration statements with respect to any such shares six months
after the effective date of the initial registration
statement.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
Company paid to Rodman, the placement agent for the financing, a
cash fee equal to $200,000 and warrants to purchase 192,931 shares
of its common stock in consideration for their advisory services
with respect to the financing pursuant to the placement agency
agreement between Rodman and the Company.&#xA0;&#xA0;Rodman is
entitled to registration rights with respect to the shares of
common stock issuable upon exercise of these
warrants.&#xA0;&#xA0;The warrants have the same terms as those
issued to the investors in the private placement.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As
a result of the financing, warrants to purchase 105,042 shares of
common stock at $10.71 per share, giving effect to the Reverse
Split, became exercisable for $0.75 per share according to their
terms. On May 3, 2011, 18,153 shares of common stock were issued in
connection with the cashless exercise 27,311 of these
warrants.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Changes in Directors and Executive Officers</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Effective
April 8, 2011, prior to the completion of the Acquisition, Michael
J. Doyle, Sim Fass and David B. McWilliams resigned from the
Company&#x2019;s board of directors and their respective committee
appointments.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Effective
April 8, 2011, as a condition to the completion of the Acquisition,
Jamey P. Weichert, Thomas Rockwell Mackie, John Neis, John E.
Niederhuber and Michael F. Tweedle were appointed to the
Company&#x2019;s board of directors.&#xA0;&#xA0;Jamey P. Weichert,
Thomas Rockwell Mackie and John Neis previously served on the board
of directors of Cellectar.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
April 25, 2011, the Company&#x2019;s board of directors appointed
the following individuals to serve on the following committees of
the board of directors.</font></div>
<br />
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Howard
M. Schneider, John Neis and John E. Niederhuber were appointed to
the audit committee of the board of directors.&#xA0;&#xA0;Mr.
Schneider was appointed as the chairman of that committee, a
position that he held prior to the Acquisition.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Thomas
Rockwell Mackie, James S. Manuso, John Neis and Michael F. Tweedle
were appointed to the compensation committee of the board of
directors. Dr. Mackie was appointed as the chairman of that
committee.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stephen
A. Hill, John E. Niederhuber and James S. Manuso were appointed to
the nominating and corporate governance committee of the board of
directors.&#xA0;&#xA0;Dr. Hill was appointed as the chairman of
that committee.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
Amendment of Certificate of Incorporation</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Effective
April 7, 2011 the Company&#x2019;s certificate of incorporation was
amended to eliminate the Certificate to Set Forth Designations,
Voting Powers, Preferences, Restrictions and Relative Rights of
Series C 8% Cumulative Convertible Preferred
Stock.&#xA0;&#xA0;There had not been any shares of Series C
preferred stock outstanding since December 2010.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Effective
April 7, 2011 the Company&#x2019;s certificate of incorporation was
amended to eliminate the Certificate of Designations, Preferences
and Rights of Series E Convertible Preferred
Stock.&#xA0;&#xA0;There had not been any shares of Series E
preferred stock outstanding since December 2010.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">
Prior to the closing of the Acquisition on April 8, 2011, the
Company amended and restated its certificate of incorporation in
order to (a) effect the reverse split; (b) reduce the number of
shares of authorized common stock from 750,000,000 to 150,000,000;
(c) eliminate the right of the stockholders to act by written
consent; and (d) classify the board of directors into three
classes.&#xA0;&#xA0;Class I directors will stand for re-election at
the Company&#x2019;s next annual meeting of stockholders, Class II
directors will stand for re-election at the 2012 annual meeting of
stockholders, and Class III directors will stand for re-election at
the 2013 annual meeting of stockholders.&#xA0;&#xA0;Thomas Rockwell
Mackie, James S. Manuso and John Niederhuber serve as Class I
directors, Stephen A. Hill, Michael F. Tweedle and John Neis serve
as Class II directors, and Harry S. Palmin, Jamey P. Weichert and
Howard M. Schneider serve as Class III
directors.</font></font></div>
</div><span /></td><td class="text"><div>
<div>
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
12.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
SUBSEQUENT EVENTS</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Merger Agreement</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
April 8, 2011, the Company entered into an Agreement and Plan of
Merger (the &#x201C;Merger Agreement&#x201D;) with Cellectar, Inc.
(&#x201C;Cellectar&#x201D;) and Cell Acquisition Corp. (the
&#x201C;Merger Subsidiary&#x201D;), a wholly owned subsidiary of
Novelos, pursuant to which Cellectar was merged into the Merger
Subsidiary (the &#x201C;Acquisition&#x201D;).&#xA0;&#xA0;As a result
of the Acquisition, the Merger Subsidiary, which has been renamed
Cellectar, Inc., owns all assets and operates the business
previously owned and operated by Cellectar. Prior to the
Acquisition, Cellectar was in the business of developing drugs for
the treatment and diagnosis of cancer.&#xA0;&#xA0;The Company will
continue to develop Cellectar&#x2019;s compounds following the
Acquisition.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As
consideration for the Acquisition, the former stockholders of
Cellectar&#xA0;&#xA0;received aggregate consideration consisting of
a number of shares of Novelos common stock constituting, after
giving effect to the Acquisition but before giving effect to the
concurrent private placement of our securities described below,
approximately 85% of the outstanding shares of Novelos common
stock.&#xA0;&#xA0;Prior to the Acquisition, the Company amended and
restated its certificate of incorporation and in connection
therewith, among other things, effected a 1-for-153 reverse split
of its common stock (the &#x201C;Reverse
Split&#x201D;).&#xA0;&#xA0;Immediately following the effectiveness
of the Reverse Split, there were approximately 2,959,871 shares of
our common stock outstanding, and the Company issued 17,001,596
shares of our common stock to the former stockholders of Cellectar
upon the effectiveness of the Acquisition.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Rodman
&amp; Renshaw, LLC (&#x201C;Rodman&#x201D;), financial advisor to
Novelos in connection with the Acquisition, received a cash fee of
$250,000 upon the completion of the Acquisition in consideration of
their services.&#xA0;&#xA0;XMS Capital Partners, the financial
advisor to Cellectar in connection with the Acquisition, received a
cash fee of $200,000 upon the completion of the Acquisition in
consideration of their services.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Securities Purchase Agreement</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Concurrently
with the execution of the Merger Agreement, the Company entered
into a Securities Purchase Agreement with certain accredited
investors under which the Company sold an aggregate of 6,846,537
units, each unit consisting of one share of its common stock and a
warrant to purchase one share of its common stock, at a price of
$0.75 per unit, for gross proceeds of approximately
$5,135,000.&#xA0;&#xA0;The warrants have an exercise price of $0.75
and expire on March 31, 2016.&#xA0;&#xA0;The warrant exercise price
and/or the common stock issuable pursuant to such warrant will be
subject to adjustment for stock dividends, stock splits or similar
capital reorganizations so that the rights of the warrant holders
after such event will be equivalent to the rights of warrant
holders prior to such event.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Securities Purchase Agreement includes a requirement that the
Company file with the Securities and Exchange Commission
(&#x201C;SEC&#x201D;) no later than October 5, 2011, a registration
statement covering the resale of the shares of common stock, and
the shares of common stock underlying the warrants, issued pursuant
to the Securities Purchase Agreement.&#xA0;&#xA0;The Company is
also required to use our commercially reasonable efforts to have
the registration statement declared effective by December 4, 2011,
and to keep the registration statement continuously effective under
the Securities Act of 1933, as amended (the &#x201C;Securities
Act&#x201D;) until the earlier of the date when all the registrable
securities covered by the registration statement have been sold or
the second anniversary of the closing.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
the event the Company fails to file the registration statement
within the timeframe specified by the Securities Purchase
Agreement, or if it fails to obtain effectiveness of this
registration on or prior to the December 4, 2011 (if there is no
review by the SEC) or by January 3, 2012 (if there is review by the
SEC) with respect to the maximum number of shares permitted to be
registered by the SEC, the Company will be required to pay to the
purchasers liquidated damages equal to 1.5% per month (pro-rated on
a daily basis for any period of less than a full month) of the
aggregate purchase price of the units purchased until the
registration statement is filed or declared effective, as
applicable.&#xA0;&#xA0;The Company will be allowed to suspend the
use of the registration statement for not more than 30 consecutive
days, on not more than two occasions, in any 12 month
period.&#xA0;&#xA0;The Company has also granted piggy-back
registration rights with respect to any shares of common stock that
it is required to exclude from the registration statement as a
condition of its effectiveness, and has also agreed to file further
registration statements with respect to any such shares six months
after the effective date of the initial registration
statement.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company paid to Rodman, the placement agent for the financing, a
cash fee equal to $200,000 and warrants to purchase 192,931 shares
of its common stock in consideration for their advisory services
with respect to the financing pursuant to the placement agency
agreement between Rodman and the Company.&#xA0;&#xA0;Rodman is
entitled to registration rights with respect to the shares of
common stock issuable upon exercise of these
warrants.&#xA0;&#xA0;The warrants have the same terms as those
issued to the investors in the private placement.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Changes in Directors and Executive Officers</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective
April 8, 2011, prior to the completion of the Acquisition, Michael
J. Doyle, Sim Fass and David B. McWilliams resigned from the
Company&#x2019;s board of directors and their respective committee
appointments.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective
April 8, 2011, as a condition to the completion of the Acquisition,
Jamey P. Weichert, Thomas Rockwell Mackie, John Neis, John E.
Niederhuber and Michael F. Tweedle were appointed to the
Company&#x2019;s board of directors.&#xA0;&#xA0;Committee
assignments have not yet been determined.&#xA0;&#xA0;Jamey P.
Weichert, Thomas Rockwell Mackie and John Neis, previously served
on the board of directors of Cellectar.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
Amendment of Certificate of Incorporation</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective
April 7, 2011 the Company&#x2019;s certificate of incorporation was
amended to eliminate the Certificate to Set Forth Designations,
Voting Powers, Preferences, Restrictions and Relative Rights of
Series C 8% Cumulative Convertible Preferred
Stock.&#xA0;&#xA0;There had not been any shares of Series C
preferred stock outstanding since December 2010.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective
April 7, 2011 the Company&#x2019;s certificate of incorporation was
amended to eliminate the Certificate of Designations, Preferences
and Rights of Series E Convertible Preferred
Stock.&#xA0;&#xA0;There had not been any shares of Series E
preferred stock outstanding since December 2010.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Prior
to the closing of the Acquisition on April 8, 2011, the Company
amended and restated its certificate of incorporation in order (a)
to effect the reverse split; (b) to reduce the number of shares of
our authorized common stock from 750,000,000 to 150,000,000; (c) to
eliminate the right of the stockholders to act by written consent;
and (d) to classify the board of directors into three
classes.&#xA0;&#xA0;Class I directors will stand for re-election at
the Company&#x2019;s next annual meeting of stockholders, Class II
directors will stand for re-election at the 2012 annual meeting of
stockholders, and Class III directors will stand for re-election at
the 2013 annual meeting of stockholders.&#xA0;&#xA0;Thomas Rockwell
Mackie, James S. Manuso and John Niederhuber serve as Class I
directors, Stephen A. Hill, Michael F. Tweedle and John Neis serve
as Class II directors, and Harry S. Palmin, Jamey P. Weichert and
Howard M. Schneider serve as Class III directors.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1043
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EXEAC"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br /></strong></div></th><th class="th" colspan="1">3 Months Ended</th><th class="th" colspan="1">9 Months Ended</th><th class="th" colspan="1">12 Months Ended</th></tr><tr><th class="th"><div>Mar. 31, 2011</div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td><td class="text"><div><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr valign="top">
<td style="WIDTH: 36pt" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
5.&#xA0;</font></div>
</td>
<td align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
STOCK-BASED COMPENSATION</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
following table summarizes amounts charged (credited) to expense
for stock-based compensation related to employee and director stock
option grants and stock-based compensation recorded in connection
with stock options granted to non-employee
consultants:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Three&#xA0;Months&#xA0;Ended</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">March&#xA0;31,</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2011</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2010</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Employee
and director stock option grants:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research
and development</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">49,298</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57,113</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General
and administrative</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
59,682</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
82,928</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
108,980</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
140,041</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-employee
consultant stock option grants:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research
and development</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(545</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(210,825</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General
and administrative</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(57</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(26,695</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(602</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(237,520</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
stock-based compensation</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
108,378</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(97,479</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">There
were no stock option grants during the three months ended March 31,
2011 or 2010.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br /></div>
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Number&#xA0;of</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Shares</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Issuable&#xA0;Upon</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Exercise&#xA0;of</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Outstanding</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Options</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Weighted</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Average</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Exercise&#xA0;Price</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Weighted</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Average</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Remaining</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Contracted</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Term&#xA0;in</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Years</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Aggregate</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Intrinsic</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Value</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding
at December 31, 2010</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
49,227</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
100.61</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
6.9</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
24,842</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding
at March 31, 2011</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
49,227</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
100.61</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
6.6</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
12,421</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercisable
at March 31, 2011</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
40,348</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
101.03</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
6.2</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
12,421</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
aggregate intrinsic value of options outstanding is calculated
based on the positive difference between the closing market price
of the Company&#x2019;s common stock at the end of the respective
period and the exercise price of the underlying
options.&#xA0;&#xA0;There were no options exercised during the
three months ended March 31, 2011. Shares of common stock issued
upon the exercise of options are from authorized but unissued
shares.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As
of March 31, 2011, there was approximately $538,000 of total
unrecognized compensation cost related to unvested stock-based
compensation arrangements.&#xA0;&#xA0;Of this total amount, 64% and
36% are expected to be recognized during 2011 and 2012,
respectively.&#xA0;&#xA0;The Company expects 8,879 in unvested
options to vest in the future.&#xA0;&#xA0;The weighted-average
grant-date fair value of vested and unvested options outstanding at
March 31, 2011 was $62.75 and $68.07, respectively.</font></div>
</div><span /></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
11.&#xA0; STOCK-BASED COMPENSATION</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cellectar&#x2019;s
stock-based compensation plans prior to the Acquisition are
summarized below:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
2006 Unit Option Plan.&#xA0;</font> The 2006 Unit Option Plan (the
&#x201C;2006 Cellectar Plan&#x201D;), as amended and restated,
provided Cellectar the ability to grant to employees, directors,
consultants, and other non-employees units of interest in
Cellectar.&#xA0; The maximum aggregate number of shares that were
subject to grant under the 2006 Cellectar Plan was
1,012,200.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cellectar
granted 631,360 unit options under the 2006 Cellectar Plan and no
additional grants will be made thereunder.&#xA0; In connection with
the Conversion described in Note 10, each issued and outstanding
unexercised unit option outstanding immediately prior to the
Conversion was converted into an option to acquire the same number
of shares of Cellectar&#x2019;s common stock.&#xA0; A total of
606,889 and 691,248 options to purchase shares of Cellectar&#x2019;s
common stock were outstanding under the 2006 Cellectar Plan as of
December 31, 2010 and 2009, respectively.&#xA0; These options
generally vested annually over four years and expire on the eighth
anniversary of the grant date.&#xA0; No options were granted under
the 2006 Cellectar Plan during 2010 or 2009.&#xA0; There have been
no exercises of options issued under the 2006 Cellectar Plan.&#xA0;
On March 17, 2011, in contemplation of the Acquisition, Cellectar
terminated the remaining options outstanding under the 2006
Cellectar Plan as of that date.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
2008 Stock Incentive Plan</font>.&#xA0; The 2008 Stock Incentive
Plan (the &#x201C;2008 Plan&#x201D;) provided Cellectar the ability
to grant to employees, directors, consultants and other
non-employees of Cellectar options to purchase common stock.&#xA0;
The maximum aggregate number of shares that were subject to grant
under the 2008 Plan was 823,930.&#xA0; Cellectar granted a total of
382,223 options under the 2008 Plan.&#xA0; A total of 162,300 and
300,488 options to purchase shares of Cellectar&#x2019;s common
stock were outstanding as of December 31, 2010 and 2009,
respectively.&#xA0; These options generally vested annually over
four years and expire on the tenth anniversary of the grant
date.&#xA0; &#xA0;During 2009, 90,929 options were granted under
the 2008 Plan.&#xA0; During 2010, no options were granted under the
2008 Plan. No options have been exercised.&#xA0; On March 17, 2011,
in contemplation of the Acquisition, Cellectar terminated the
remaining options outstanding under the 2008 Plan as of that
date.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As
of December 31, 2010, an aggregate of 1,066,941 shares were
available for grant under the 2006 Cellectar Plan and 2008
Plan.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cellectar&#x2019;s
Board of Directors determined exercise prices and vesting periods
on the date of grant, subject to the provisions of the 2006
Cellectar Plan and 2008 Plan.&#xA0; Options have been granted at or
above the estimated fair-market value of the common stock at the
grant date. Options granted pursuant to the 2006 Cellectar Plan and
2008 Plan generally would have become fully vested in the event of
a business combination whereby the options are not assumed or
replaced by the surviving company, as defined.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
connection with the Acquisition, the Company assumed options to
purchase 49,159 shares of common stock at exercise prices ranging
from $1.53 to $1,072.53.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
2006 Novelos Stock Option Plan.</font>&#xA0; Following the
Acquisition, option grants to directors and employees will be made
under the Novelos Therapeutics 2006 Stock Incentive Plan (the
&#x201C;Plan&#x201D;).&#xA0; On May 18, 2011, the Board of Directors
of the Company approved certain amendments to the Plan to, among
other things, increase the aggregate number of shares of the
Company&#x2019;s common stock reserved for issuance under the Plan
(including any shares that have already been issued thereunder), to
7,000,000 and remove the 750,000 share annual individual limitation
on grants under the Plan.&#xA0; On June 30, 2011, the
Company&#x2019;s stockholders ratified those
amendments.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A
total of 7,000,000 shares of common stock are reserved for issuance
under the Plan for grants of incentive or nonqualified stock
options, rights to purchase restricted and unrestricted shares of
common stock, stock appreciation rights and performance share
grants.&#xA0; A committee of the board of directors determines
exercise prices, vesting periods and any performance requirements
on the date of grant, subject to the provisions of the Plan.&#xA0;
Options are granted at or above the fair market value of the common
stock at the grant date and expire on the tenth anniversary of the
grant date.&#xA0; Vesting periods are generally between one and
four years.&#xA0; Options granted pursuant to the Plan generally
will become fully vested upon a termination event occurring within
one year following a change in control, as defined.&#xA0; A
termination event is defined as either termination of employment or
services other than for cause or constructive termination of
employees or consultants resulting from a significant reduction in
either the nature or scope of duties and responsibilities, a
reduction in compensation or a required relocation.&#xA0; As of
September 30, 2011, there are an aggregate of 3,476,112 shares
available for grant under the Plan.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Accounting for Stock-Based Compensation</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Employee
stock-based compensation is accounted for in accordance with the
guidance of FASB ASC Topic 718, <font style="FONT-STYLE: italic; DISPLAY: inline">Compensation &#x2013; Stock
Compensation</font> which requires all share-based payments to
employees, including grants of employee stock options, to be
recognized in the financial statements based on their fair
values.&#xA0; Non-employee stock-based compensation is accounted
for in accordance with the guidance of FASB ASC Topic 505,
<font style="FONT-STYLE: italic; DISPLAY: inline">Equity</font>. As
such, the Company recognizes expense based on the estimated fair
value of options granted to non-employees over their vesting
period, which is generally the period during which services are
rendered and deemed completed by such non-employees.</font></div>
<br />
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
following table summarizes amounts charged to expense for
stock-based compensation related to employee and director stock
option grants and stock-based compensation recorded in connection
with stock options granted to non-employee
consultants:</font></div>
<div>
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Nine Months Ended</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
September 30,</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
(unaudited)</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Year Ended</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
December 31,</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Cumulative Development- Stage Period from November 7, 2002 through
December 31,</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Consolidated</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
2011</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
2010</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
2010</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
2009</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
2010</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Employee
and director stock option grants:</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research
and development</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">121,393</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52,492</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">61,791</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">87,598</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">298,386</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General
and administrative</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">349,781</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">278,694</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">291,549</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">414,401</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,577,303</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="40%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">471,174</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">331,186</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">353,340</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">501,999</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,875,689</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-employee
consultant stock option grants:</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research
and development</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">46,851</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">200</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">71,724</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General
and administrative</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">137,631</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">184,482</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">200</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">71,724</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="40%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
stock-based compensation</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">655,656</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">331,186</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">353,340</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">502,199</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,947,413</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
July 14, 2010, the expiration date of vested options held by a
former employee was extended until July 8, 2015.&#xA0; The
extension constituted a modification to the terms of the award and
additional stock-based compensation was measured as the excess of
the fair value of the modified award over the fair value of the
original award immediately before the modification.&#xA0;
Accordingly, incremental stock-based compensation expense of
approximately&#xA0;$20,000 was recorded in connection with the
modification.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
Company granted 3,496,400 stock options to employees and
non-employees during the nine months ended September 30, 2011 under
the Plan.&#xA0; The Company issued options to purchase a total of
200,000 shares of common stock to non-employees outside of any
formalized plan, but 100,000 were forfeited as a result of the
cancellation and replacement as described below.&#xA0; Exercise
prices for all grants made in the during the nine months ended
September 30, 2011 were equal to the market value of the
Company&#x2019;s common stock on the date of grant.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
May 18, 2011, the Company cancelled 100,000 options originally
granted on April 25, 2011 with an exercise price of $3.00 per share
and issued 100,000 replacement stock option awards with an exercise
price of $1.40.&#xA0; The cancellation and replacement constituted
a modification to the terms of the award and additional stock-based
compensation was measured as the excess of the fair value of the
modified award over the fair value of the original award
immediately before the modification.&#xA0; Accordingly, incremental
stock-based compensation expense of $4,494 was recorded in
connection with the modification.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<!--EFPlaceholder-->Assumptions Used In Determining Fair
Value</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Valuation and amortization method</font>. The fair value of each
stock award is estimated on the grant date using the Black-Scholes
option-pricing model.&#xA0; The estimated fair value of employee
stock options is amortized to expense using the straight-line
method over the vesting period.</font> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
estimated fair value of the non-employee options is amortized to
expense over the period during which a non-employee is required to
provide services for the award (usually the vesting
period).</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Volatility.</font> Cellectar estimated volatility based on a review
of volatility estimates of publicly held drug development companies
in a similar stage of development. Subsequent to the Acquisition,
the Company estimates volatility based on an average of (1) the
Company&#x2019;s historical volatility since its common stock has
been publicly traded and (2) review of volatility estimates of
publicly held drug development companies with similar market
capitalizations.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Risk-free interest rate</font>. The risk-free interest rate is
based on the U.S. Treasury yield curve in effect at the time of
grant commensurate with the expected term assumption.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Expected term</font> . The expected term of stock options granted
is based on an estimate of when options will be exercised in the
future. The Company applied the simplified method of estimating the
expected term of the options, as described in the SEC&#x2019;s Staff
Accounting Bulletins 107 and 110, as the Company has had a
significant change in its business operations as result of the
Acquisition and the historical experience is not indicative of the
expected behavior in the future. The expected term, calculated
under the simplified method, is applied to groups of stock options
that have similar contractual terms. Using this method, the
expected term is determined using the average of the vesting period
and the contractual life of the stock options granted. The Company
applied the simplified method to non-employees who have a
truncation of term based on termination of service and utilizes the
contractual life of the stock options granted for those
non-employee grants which do not have a truncation of
service.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Forfeitures.</font> &#xA0; Stock-based compensation expense is
recorded only for those awards that are expected to vest.&#xA0;
FASB ASC Topic 718 requires forfeitures to be estimated at the time
of grant and revised, if necessary, in subsequent periods if actual
forfeitures differ from those estimates.&#xA0; The term
&#x201C;forfeitures&#x201D; is distinct from
&#x201C;cancellations&#x201D; or &#x201C;expirations&#x201D; and
represents only the unvested portion of the surrendered
option.&#xA0; An annual forfeiture rate of 0% was applied to all
unvested options as of December 31, 2010 as Cellectar had
experienced very few forfeitures through 2009 and there was
insufficient history to develop an accurate estimate of future
forfeitures.&#xA0; An annual forfeiture rate of 0% was applied to
all unvested options as of September 30, 2011 as the historical
experience of forfeitures is not representative of expected future
forfeiture rates as a result of the significant changes in the
business operations as a result of the Acquisition.&#xA0; This
analysis will be re-evaluated semi-annually and the forfeiture rate
will be adjusted as necessary.&#xA0; Ultimately, the actual expense
recognized over the vesting period will be for only those shares
that vest.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
following table summarizes weighted-average values and assumptions
used for options granted to employees, directors and consultants in
the periods indicated:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-ALIGN: center" align="center">
<table style="TEXT-ALIGN: center; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr style="TEXT-ALIGN: center">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Nine Months</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Ended&#xA0;September</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">30,&#xA0;2011</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">(unaudited)</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Year&#xA0;Ended</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">December&#xA0;31,</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2009</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Volatility</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">110</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">85</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk-free
interest rate</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.84%
&#x2013; 3.17</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.72%-1.91</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected
life (years)</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.5
&#x2013; 6.25</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.25</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dividend</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted-average
exercise price</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.45</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.76</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted-average
grant-date fair value</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.22</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.55</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">There
were no stock options granted in the nine months ended September
30, 2010 or the year ended December 31, 2010.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Stock
Option Activity</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A
summary of stock option activity under stock option plans is as
follows:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br /></div>
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="95%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Number&#xA0;of</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Shares</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Issuable&#xA0;Upon</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Exercise&#xA0;of</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Outstanding</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Options</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Weighted</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Average</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Exercise&#xA0;Price</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Weighted</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Average</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Remaining</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Contracted</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Term&#xA0;in</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Years</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Aggregate</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Intrinsic</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Value</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding
at November 7, 2002</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">922,654</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.52</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Forfeited</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12,653</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.04</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding
at January 1, 2009</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">910,001</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.86</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">90,929</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.76</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;
&#xA0; Forfeited</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(9,194</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.72</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding
at December 31, 2009</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">991,736</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.68</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Canceled</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(222,547</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.63</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding
at December 31, 2010</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">769,189</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.69</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;
&#xA0; Canceled</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(769,189</font></div>
</td>
<td valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.69</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt; MARGIN-RIGHT: 0pt" valign="bottom" width="52%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Options
acquired in connection with a business combination</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">49,159</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100.52</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt; MARGIN-RIGHT: 0pt" valign="bottom" width="52%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,696,400</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.45</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt; MARGIN-RIGHT: 0pt" valign="bottom" width="52%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Canceled</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12,921</font></div>
</td>
<td valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">112.21</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt; MARGIN-RIGHT: 0pt" valign="bottom" width="52%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Forfeited</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(100,000</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.00</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding
at September 30, 2011 (unaudited)</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,632,638</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.35</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="52%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vested,
December 31, 2010</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">743,450</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.69</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.07</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unvested,
December 31, 2010</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,739</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.62</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.08</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#x2014;</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercisable
at December 31, 2010</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">743,450</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.69</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.07</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vested,
September 30, 2011 (unaudited)</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">332,685</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.47</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9.25</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unvested,
September 30, 2011 (unaudited)</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,299,953</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.53</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9.63</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#x2014;</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercisable
at September 30, 2011 (unaudited)</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">332,685</font></font></font></div>
</div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;$</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
10.47</font></font></div>
</div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
9.25</font></font></div>
</div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#x2014;</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
aggregate intrinsic value of options outstanding is calculated
based on the positive difference between the estimated per share
fair value of Cellectar&#x2019;s common stock at the end of the
respective period and the exercise price of the underlying
options.&#xA0;As of December 31, 2010, the estimated fair-market
value of Cellectar&#x2019;s common stock at the end of the periods
shown was less than the exercise price of the underlying options,
as such, the aggregate intrinsic value is $0.&#xA0; As of September
30, 2011, the fair value of the Company&#x2019;s common stock was
less than the exercise price of the underlying options, as such,
the aggregate intrinsic value was $0.&#xA0; There have been no
option exercises to date. Shares of common stock issued upon the
exercise of options are from authorized but unissued
shares.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
weighted-average grant-date fair value of options granted during
the year ended December 31, 2009 and for the period November 2,
2002 to December 31, 2009 was $0.55 and $1.90, respectively.&#xA0;
There were no options granted during the year ended December 31,
2010.&#xA0; The total fair value of shares vested during December
31, 2010 and 2009 and for the period November 2, 2007 (date of
inception) to December 31, 2010 was $199,600, $185,600 and
$2,050,000, respectively.&#xA0; &#xA0;The weighted-average
grant-date fair value of vested and unvested options outstanding at
December 31, 2010 and 2009 was $2.01 and $1.91 and $1.85 and $1.88,
respectively.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As
of December 31, 2010, there was approximately $58,000 and $0 of
total unrecognized compensation cost related to unvested
stock-based compensation arrangements related to employees and
non-employees, respectively.&#xA0; Of the total unrecognized amount
as of December 31, 2010, all was recognized in the nine months
ended September 30, 2011.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
March 4, 2011, in contemplation of the Acquisition and in
accordance with terms of the applicable option agreements,
Cellectar accelerated the vesting on all outstanding and unvested
options at that date and notified all option holders that any
unexercised options as of March 17, 2011 would then be
terminated.&#xA0; On March 17, 2011, Cellectar terminated all
outstanding options.&#xA0; The remaining unamortized compensation
expense of $58,000 was recorded related to the acceleration of
outstanding options in the quarter ended March 31, 2011.&#xA0; No
additional compensation expense was recorded related to the
acceleration of unvested shares as the acceleration did not
represent a modification to the original terms of the
options.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As
of September 30, 2011, there was $2,728,294 of total unrecognized
compensation cost related to unvested stock-based compensation
arrangements.&#xA0; Of this total amount, the Company expects to
recognize $281,357, $1,125,400, $858,452, $387,397 and $75,688
during 2011, 2012, 2013, 2014 and 2015, respectively.&#xA0; The
Company expects 3,299,953 in unvested options to vest in the
future.&#xA0; The weighted-average grant-date fair value of vested
and unvested options outstanding at September 30, 2011 was $1.44
and $1.17, respectively.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
October 6, 2011, the Company granted 70,000 options with an
exercise price of $1.05, which was equal to the closing price of
the Company&#x2019;s common stock on the date of grant, to a
non-employee in exchange for certain consulting
services.&#xA0;&#xA0;The grant-date fair value using the
Black-Scholes option pricing model was $0.85 per share, or
$59,500.</font></div>
</div>


</div><span /></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
7.&#xA0; STOCK-BASED COMPENSATION</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company&#x2019;s stock-based compensation plans are summarized
below:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
2000 Stock Option Plan.&#xA0;</font> As of December 31, 2010, there
are options to purchase 291 shares of the Company&#x2019;s common
stock outstanding under a stock option plan established in August
2000 (the &#x201C;2000 Plan&#x201D;).&#xA0; There will be no further
grants made under the 2000 Plan. Options generally vested annually
over three years and expire on the tenth anniversary of the grant
date.&#xA0; No options were granted or exercised under the 2000
Plan during 2009.&#xA0; During 2010, options to purchase 65 shares
of common stock under the 2000 Plan were exercised and options to
purchase 9 shares of common stock were canceled.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
2006 Stock Incentive Plan</font>. On May 1, 2006, the
Company&#x2019;s board of directors adopted, and on July 21, 2006
the Company&#x2019;s stockholders approved, the 2006 Stock Incentive
Plan (the &#x201C;2006 Plan&#x201D;). A total of 65,359 shares of
common stock are reserved for issuance under the 2006 Plan for
grants of incentive or nonqualified stock options, rights to
purchase restricted and unrestricted shares of common stock, stock
appreciation rights and performance share grants. A committee of
the board of directors determines exercise prices, vesting periods
and any performance requirements on the date of grant, subject to
the provisions of the 2006 Plan. Options are granted at or above
the fair market value of the common stock at the grant date and
expire on the tenth anniversary of the grant date. Vesting periods
are generally two to three years. In the year ended December 31,
2009, stock options for the purchase of 12,679 shares of common
stock were granted under the 2006 Plan. During the year ended
December 31, 2010, options to purchase 1,438 shares of common stock
were exercised and options to purchase 3,921 shares of common stock
were canceled. As of December 31, 2010 and December 31, 2009,
25,555 and 21,503 shares remain available for grant under the 2006
Plan. Options granted pursuant to the 2006 Plan generally will
become fully vested upon a termination event occurring within one
year following a change in control, as defined. A termination event
is defined as either termination of employment or services other
than for cause or constructive termination of employees or
consultants resulting from a significant reduction in either the
nature or scope of duties and responsibilities, a reduction in
compensation or a required relocation.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Other Stock Option Activity.</font> &#xA0; During 2005 and 2004,
the Company issued options to purchase a total of 17,345 shares of
common stock to employees, directors and consultants outside of any
formalized plan.&#xA0; These options are exercisable within a
ten-year period from the date of grant, and vest at various
intervals with all options being fully vested within two to three
years of the grant date.&#xA0; The options are not transferable
except by will or domestic relations order.&#xA0; The option price
per share is not less than the fair market value of the shares on
the date of the grant.&#xA0; During the year ended December 31,
2010, options to purchase 4,488 shares of common stock were
exercised and options to purchase 980 shares of common stock were
canceled.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Accounting for Stock-Based Compensation</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company accounts for employee stock-based compensation in
accordance with the guidance of FASB ASC Topic 718, <font style="FONT-STYLE: italic; DISPLAY: inline">Compensation &#x2013; Stock
Compensation</font> which requires all share-based payments to
employees, including grants of employee stock options, to be
recognized in the financial statements based on their fair
values.&#xA0; The Company accounts for non-employee stock-based
compensation in accordance with the guidance of FASB ASC Topic 505,
<font style="FONT-STYLE: italic; DISPLAY: inline">Equity</font>
which requires that companies recognize compensation expense based
on the estimated fair value of options granted to non-employees
over their vesting period, which is generally the period during
which services are rendered by such non-employees.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
following table summarizes amounts charged to expense for
stock-based compensation related to employee and director stock
option grants and stock-based compensation recorded in connection
with stock options and restricted stock awards granted to
non-employee consultants:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="MARGIN-LEFT: 45pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="28%" colspan="6">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Year&#xA0;Ended</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">December&#xA0;31,</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2010</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2009</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Employee
and director stock option grants:</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research
and development</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">230,101</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">148,030</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General
and administrative</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
356,220</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
289,036</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
586,321</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
437,066</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-employee
consultant stock option grants and restricted stock
awards:</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research
and development</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(220,969</font></div>
</td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#xA0;</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">328,614</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General
and administrative</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
(28,054</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#xA0;</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
98,657</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
(249,023</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#xA0;</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
427,271</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
stock-based compensation</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
337,298</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
864,337</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
December 31, 2009, the expiration of options held by a former
employee was extended until January 31, 2010 and incremental
stock-based compensation expense for non-employees of $15,000 was
recorded in connection with the one-month extension.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
January 2009, the Company modified the terms of options to purchase
261 shares of common stock held by two employees to vest all
unvested options and to extend the expiration dates of the
options.&#xA0; The modification was made in connection with the
termination of the two employees to reduce costs.&#xA0; During the
year ended December 31, 2009, incremental stock-based compensation
expense of $8,000 was recorded in connection with the modification
of the option terms.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Determining Fair Value</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Valuation and amortization method</font>. The fair value of each
stock award is estimated on the grant date using the Black-Scholes
option-pricing model.&#xA0; The estimated fair value of employee
stock options is amortized to expense using the straight-line
method over the vesting period.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Volatility.</font> The Company estimates volatility based on an
average of (1) the Company&#x2019;s historical volatility since its
common stock has been publicly traded and (2) review of volatility
estimates of publicly held drug development companies with similar
market capitalizations.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Risk-free interest rate</font>. The risk-free interest rate is
based on the U.S. Treasury yield curve in effect at the time of
grant commensurate with the expected term assumption.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Expected term</font>. The expected term of stock options granted is
based on the Company&#x2019;s estimate of when options will be
exercised in the future as there have been limited stock option
exercises to date.&#xA0; The expected term is generally applied to
one group as a whole as the Company does not expect substantially
different exercise or post-vesting termination behavior within its
population of option holders.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Forfeitures.</font> &#xA0; The Company records stock-based
compensation expense only for those awards that are expected to
vest.&#xA0; FASB ASC Topic 718 requires forfeitures to be estimated
at the time of grant and revised, if necessary, in subsequent
periods if actual forfeitures differ from those estimates.&#xA0;
The term &#x201C;forfeitures&#x201D; is distinct from
&#x201C;cancellations&#x201D; or &#x201C;expirations&#x201D; and
represents only the unvested portion of the surrendered
option.&#xA0; The Company has applied an annual forfeiture rate of
0% to all unvested options as of December 31, 2010 as the Company
has experienced very few forfeitures to date and believes that
there is insufficient history to develop an accurate estimate of
future forfeitures.&#xA0;&#xA0;This analysis will be re-evaluated
semi-annually and the forfeiture rate will be adjusted as
necessary.&#xA0;&#xA0;Ultimately, the actual expense recognized
over the vesting period will be for only those shares that
vest.</font></div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
following table summarizes weighted average values and assumptions
used for options granted to employees, directors and consultants in
the periods indicated:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="MARGIN-LEFT: 18pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Year&#xA0;Ended</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">December&#xA0;31,&#xA0;</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2009</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="88%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Volatility</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">90</font></div>
</td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted-average
volatility</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">90</font></div>
</td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk-free
interest rate</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.12</font></div>
</td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected
life (years)</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dividend</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></div>
</td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted-average
exercise price</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.75</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted-average
grant-date fair value</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.53</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There
were no stock option grants during the year ended December 31,
2010.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Stock Option Activity</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A
summary of stock option activity under the 2000 Plan, the 2006 Plan
and outside of any formalized plan is as follows:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-ALIGN: left; MARGIN-LEFT: 18pt">
<table style="TEXT-ALIGN: left; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%">
<tr style="TEXT-ALIGN: left">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Options</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Outstanding</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Weighted</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Average</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Exercise&#xA0;Price</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Weighted</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Average</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Remaining</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Contracted</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Term&#xA0;in</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Years</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Aggregate</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Intrinsic</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Value</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding
at January 1, 2009</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">47,580</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">91.80</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.9</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">989,718</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Options
granted</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
12,679</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$&#xA0;</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">114.75</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="9%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="9%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding
at December 31, 2009</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,259</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">96.39</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.5</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,650,255</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Options
exercised</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,991</font></div>
</td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26.01</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;663,600</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Options
canceled</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
(5,042</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">139.23</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="9%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0&#xA0;</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding
at December 31, 2010</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
49,226</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
100.98</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
6.9</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
24,842</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercisable
at December 31, 2010</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
39,270</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
100.98</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
6.4</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
24,842</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
aggregate intrinsic value of options outstanding is calculated
based on the positive difference between the closing market price
of the Company&#x2019;s common stock at the end of the respective
period and the exercise price of the underlying
options.&#xA0;&#xA0;During the year ended December 31, 2010, the
total intrinsic value of options exercised was $663,000 and the
total amount of cash received from exercise of these options was
$158,600.&#xA0;&#xA0;Shares of common stock issued upon the
exercise of options are from authorized but unissued
shares.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As
of December 31, 2010, there was approximately $647,000 of total
unrecognized compensation cost related to unvested stock-based
compensation arrangements.&#xA0;&#xA0;Of this total amount, 70% and
30% are expected to be recognized during 2011 and 2012,
respectively.&#xA0;&#xA0;The Company expects 9,956 in unvested
options to vest in the future.&#xA0;&#xA0;The weighted-average
grant-date fair value of vested and unvested options outstanding at
December 31, 2010 was $62.73 and $68.85, respectively.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Statement of Position (SOP)<br /><br /> -Number 93-6<br /><br /> -Paragraph 53<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /> -Number Topic 14<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 123R<br /><br /> -Paragraph 64, 65, A240<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 40<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 50<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1044
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">ACQUISITION</a></td><td class="text"><div>
<div>
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
4.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
ACQUISITION</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Merger Agreement</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
April 8, 2011, Novelos acquired Cellectar through a merger with and
into the Merger Subsidiary, pursuant to the merger Agreement
entered into on that date.&#xA0; As a result of the Acquisition,
the Merger Subsidiary, which has been renamed Cellectar, Inc., owns
all assets of and operates the business previously owned and
operated by Cellectar.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
the Acquisition, the former stockholders of Cellectar received an
aggregate number of shares of Novelos common stock constituting
approximately 85% of the outstanding shares of Novelos common
stock, after giving effect to the Acquisition but before giving
effect to the concurrent private placement of Novelos securities
described below.&#xA0; Prior to the Acquisition, Novelos amended
and restated its certificate of incorporation and in connection
therewith, among other things, effected a 1-for-153 reverse split
of its common stock (the &#x201C;Reverse Split&#x201D;) resulting
in&#xA0;2,959,871 shares of Novelos common stock outstanding.
Novelos then issued 17,001,596 shares of Novelos common stock to
the stockholders of Cellectar upon the effective date of the
Acquisition.&#xA0; Warrants and options to purchase Novelos common
stock that were outstanding prior to the Acquisition remained
outstanding following the Acquisition. These consist of warrants to
purchase a total of 315,164 shares of Novelos common stock with
prices ranging from $16.07 to $191.25 and options to purchase a
total of 49,159 shares of Novelos common stock with prices ranging
from $1.53 to $1,072.53.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XMS
Capital Partners, the financial advisor to Cellectar in connection
with the Acquisition, received a cash fee of $200,000 upon the
completion of the Acquisition in consideration of their
services.&#xA0; Rodman &amp; Renshaw, LLC (&#x201C;Rodman&#x201D;),
financial advisor to Novelos in connection with the Acquisition,
received a cash fee of $250,000 upon the completion of the
Acquisition in consideration of their services.&#xA0; These amounts
were recorded as merger costs and expensed as incurred on the date
of the Acquisition.&#xA0; In addition to the investment banking
fees, the Company also incurred an additional $296,207 of
merger-related legal and other costs during the nine months ended
September 30, 2011 which were included as a component of expense in
the respective period.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Acquisition was completed principally to leverage synergies between
Novelos&#x2019; strategic focus and experience in developing and
funding the development of cancer drugs and Cellectar&#x2019;s
portfolio of cancer-targeted compounds.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Purchase Accounting</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Acquisition was accounted for using the purchase method of
accounting as a reverse acquisition.&#xA0; In a reverse
acquisition, the post-acquisition net assets of the surviving
combined company includes the historical cost basis of the net
assets of the accounting acquirer (Cellectar) plus the fair value
of the net assets of the accounting acquiree (Novelos).&#xA0;
Further, under the purchase method, the purchase price is allocated
to the assets acquired and liabilities assumed based on their
estimated fair values and the excess of the purchase price over the
estimated fair value of the identifiable net assets is presented as
excess purchase price over net assets acquired.&#xA0; The cost of
acquisition and related purchase-price allocation is based on
preliminary evaluation of the fair value of assets and liabilities
assumed from Novelos and may change when the final valuation of
certain intangible assets is determined.&#xA0; The evaluation is
preliminary principally due to the pending evaluation of the
Company&#x2019;s intangible assets.&#xA0; The excess of purchase
price over net assets acquired will be allocated to intangibles and
goodwill once the Company completes the final allocation of
purchase price.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
fair value of the consideration transferred in the Acquisition was
$2,219,903 and was calculated as the number of shares of common
stock that Cellectar would have had to issue (adjusted for the
Exchange Ratio) in order for Novelos shareholders to obtain a 15%
equity interest in the combined Company post-acquisition,
multiplied by the estimated fair value of the Company<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#x2019;</font>s
common stock on the acquisition date.&#xA0; The estimated fair
value of the Company&#x2019;s common stock was based on the offering
price of the common stock sold in the private placement which was
both completed concurrently with and conditioned upon the closing
of the Acquisition.&#xA0;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This
price was determined to be the best indication of fair value on
that date since the price was based on an arm&#x2019;s length
negotiation with a group consisting of both new and existing
investors that had been advised of the pending Acquisition and
assumed similar liquidity risk as those investors holding the
majority of shares being valued as purchase
consideration.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
following table summarizes the Company&#x2019;s preliminary
estimated fair values of the assets acquired and the liabilities
assumed at the date of acquisition.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="85%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consideration
issuance of securities</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
2,219,903</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="85%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="85%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid
expenses and other assets</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">71,892</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="85%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fixed
assets</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,515</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="85%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued
liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(380,130</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="85%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative
liability</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(59,485</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="85%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Excess
of purchase price over net assets acquired</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
1,675,462</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="85%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="12%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="85%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
purchase price &#x2013; net of cash acquired of
$905,649</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
1,314,254</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<br />
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
excess of purchase price over net assets acquired will be allocated
to intangibles, which could potentially include the fair value of
the compounds developed prior to the Acquisition by Novelos, with
the remainder allocated to goodwill once the Company completes the
final allocation of purchase price.&#xA0; The estimated fair values
of assets acquired and liabilities assumed are provisional and are
based on the information that was available as of the acquisition
date to estimate the fair value of assets acquired and liabilities
assumed.&#xA0; The Company believes that the information provides a
reasonable basis for estimating the fair values of assets acquired
and liabilities assumed, but the Company is waiting for additional
information necessary to finalize those fair values.&#xA0;
Therefore, the provisional measurements of fair value reflected are
subject to change and such changes may be significant.&#xA0; The
Company expects to finalize the valuation and complete the purchase
price allocation as soon as practicable but no later than one year
from the acquisition date.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1045
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EXEAC"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS<br /></strong></div></th><th class="th" colspan="1">3 Months Ended</th><th class="th" colspan="1">9 Months Ended</th><th class="th" colspan="1">12 Months Ended</th></tr><tr><th class="th"><div>Mar. 31, 2011</div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">COMMITMENTS</a></td><td class="text"><div>
<div>
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
9.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
COMMITMENTS</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Retention Agreements</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
Company has entered into retention agreements with each of its
three vice presidents.&#xA0;&#xA0;The agreements provide for the
lump-sum payment of six months&#x2019; base salary and benefits to
each such officer following a termination without cause or a
resignation with good reason occurring on or before November 14,
2011.&#xA0;&#xA0;Certain of the agreements provide that if the
executives were employed with the Company as of October 1, 2010,
they would receive a payment of two months&#x2019; base salary as a
retention bonus on that date. The retention bonus was paid in
October 2010 and will be deducted from the severance amounts that
may become payable upon a subsequent involuntary
termination.&#xA0;&#xA0;The total remaining amount that may become
payable to the Company&#x2019;s Named Executive Officers pursuant to
the retention agreements is approximately $86,000 to Christopher
Pazoles.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During
the three months ended March 31, 2011, pursuant to retention
agreements, the Company paid a total of approximately $218,000 in
severance payments to employees terminated during that period,
including $83,000 to Elias Nyberg, the Company&#x2019;s former vice
president of regulatory, quality and compliance.</font></div>
</div><span /></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
14.&#xA0; COMMITMENTS</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Property Lease</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
September 5, 2007, Cellectar entered into a 36-month lease for
office and manufacturing space, commencing September 15,
2007.&#xA0; The lease provides for the option to extend the lease
under its current terms for seven additional two-year terms.&#xA0;
Rent is $8,050 per month for the first year and then escalates by
3% per year for the duration of the term including any lease
extension terms.&#xA0; The lease also requires the payment of
monthly rent of $1,140 for approximately 3,400 square feet of
expansion space.&#xA0; The monthly rent for the expansion space is
fixed until such time as the expansion space is occupied at which
time the rent would increase to the current per square foot rate in
effect under the original lease terms.&#xA0; The Company is
responsible for certain building-related costs such as property
taxes, insurance, and repairs and maintenance.&#xA0; Rent expense
is recognized on a straight-line basis and accordingly the
difference between the recorded rent expense and the actual cash
payments has been recorded as deferred rent as of each balance
sheet dates.&#xA0; Due to the significant value of leasehold
improvements purchased during the initial 3-year lease term and the
economic penalty for not extending the building lease,
straight-line rent expense and the associated deferred rent has
been calculated over 17 years, which represents the full term of
the lease, including all extensions.</font></div>
<br />
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company is required to remove certain alterations, additions and
improvements upon termination of the lease that altered a portion
of the rentable space.&#xA0; In no event shall the cost of such
removal, at commercially reasonable rates, paid by the Company
exceed $55,000 (&#x201C;Capped Amount&#x201D;) and any amount in
excess of the Capped Amount shall be the obligation of the
landlord.&#xA0; The Company is required to maintain a certificate
of deposit equal to the Capped Amount during the term of the lease,
which amount is shown as restricted cash in the accompanying
balance sheets.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective
June 1, 2010, Cellectar entered into a seven-month extension of its
office space and effective December 13, 2010 amended the extension
to increase the lease extension an additional five-months, expiring
May 31, 2011.&#xA0; In connection with the extension, the monthly
rent was adjusted to fifty percent of the rent due immediately
prior to the extension and the Company could terminate the lease at
the end of a month with 10-day written notice.&#xA0; The option was
retained, prior to May 31, 2011, to further extend the lease
through September 14, 2012, in accordance with the original lease
terms provided that it pay the unpaid rent for June 1, 2010 through
March 31, 2011, based on the original terms of the lease, plus
interest at 10% per annum.&#xA0; As of December 31, 2010, $45,000
was accrued in the accompanying balance sheet for the unpaid rent
and accrued interest.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
April 15, 2011, the Company extended its building lease for the
Madison, WI headquarters through September 14, 2012 according to
the terms in the original lease and paid all unpaid rent and
related accrued interest.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Future
minimum lease payments under this non-cancelable lease are
approximately $196,000 and $124,000 during 2011 and
2012.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As
a result of the Acquisition, the Company assumed the lease
agreement for Novelos&#x2019; office space in Newton, MA, which has
a term that is month-to-month and requires monthly rental payments
of $5,300.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Rent
expense was $143,000 and $117,000 for the nine months ended
September 30, 2011 and 2010, respectively, $159,000 and $180,000
for the years ended December 31, 2010 and 2009, respectively and
$945,000 from inception to December 31, 2010.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Capital Lease</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certain
equipment is leased under a capital lease.&#xA0; The lease
agreement requires monthly principal and interest payments of $217
and expires on September 3, 2014.&#xA0; The outstanding obligation
is being amortized using a 7% interest rate based on comparable
borrowing rates.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
following table provides the estimated future minimum rental
payments under all capital leases together with the present value
of the net minimum lease payments as of December 31,
2010:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="85%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="55%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Minimum</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">lease</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">payments</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Less&#xA0;interest</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Present&#xA0;value</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">of&#xA0;net</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">minimum</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">lease</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">payments</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="55%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,608</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">523</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,085</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="55%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,608</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">373</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,235</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="55%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,608</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">211</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;2,397</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="55%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2014</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
1,739</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
45</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
1,694</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="55%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
9,563</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
1,152</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
8,411</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
equipment recorded under capitalized leases is included in fixed
assets as of December 31:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br /></div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="70%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2010</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2009</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="13%" colspan="2" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Office
equipment</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,973</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,973</font></div>
</td>
<td valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less
accumulated amortization</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
(2,928</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
(732</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
8,045</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">$</font></font></div>
</td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="12%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
10,241</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Retention Agreements</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Following
the Acquisition, the Company has retention agreements with each of
its four vice presidents, three of such agreements were executed by
Novelos during 2010.&#xA0; The agreements provide for the lump-sum
payment of six months&#x2019; base salary and benefits to each such
officer following a termination without cause or a resignation with
good reason occurring on or before November 14, 2011.&#xA0; Certain
of the agreements provide that if the executives were employed with
Novelos as of October 1, 2010, they would receive a payment of two
months&#x2019; base salary as a retention bonus on that date. The
retention bonus of $68,000 was paid in October 2010 and will be
deducted from the severance amounts that may become payable upon a
subsequent involuntary termination.&#xA0; The total remaining
amount that may become payable to the Company&#x2019;s executive
officers pursuant to the retention agreements is approximately
$350,000.</font></div>
<br />
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
May 18, 2011, the Company&#x2019;s board of directors approved the
entry into a retention agreement with each of 5 individuals that
were employees of Cellectar at the time of the Acquisition.&#xA0;
The agreements provide for the lump-sum payment of six
months&#x2019; base salary and benefits following a termination
without cause or a resignation with good reason occurring on or
before November 18, 2011.&#xA0; The agreements expire November 18,
2011.</font></div>


</div><span /></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
10. COMMITMENTS</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Property Lease</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective
September 1, 2010, the Company entered into a six-month extension
to its lease for office space, at a rate of $5,275 per month,
expiring February 28, 2011. Rent expense was $65,000 and $87,000
for the years ended December 31, 2010 and 2009, respectively.
Future minimum lease payments under this non-cancelable lease are
approximately $10,600 during 2011.&#xA0;&#xA0;After February 28,
2011, the lease may be canceled with 30-day notice by either
party.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Royalty Arrangements</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company is obligated to a Russian company, ZAO BAM, under a royalty
and technology transfer agreement. Mark Balazovsky, a director of
the Company until November 2006, is the majority shareholder of ZAO
BAM. Pursuant to the royalty and technology transfer agreement
between the Company and ZAO BAM, the Company is required to make
royalty payments of 1.2% of net sales of oxidized glutathione-based
products. The Company is also required to pay ZAO BAM $2 million
for each new oxidized glutathione-based drug within eighteen months
following FDA approval of such drug.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If
a royalty is not being paid to ZAO BAM on net sales of oxidized
glutathione products, then the Company is required to pay ZAO BAM
3% of all license revenues. If license revenues exceed the
Company&#x2019;s cumulative expenditures including, but not limited
to, preclinical and clinical studies, testing, FDA and other
regulatory agency submission and approval costs, general and
administrative costs, and patent expenses, then the Company would
be required to pay ZAO BAM an additional 9% of the amount by which
license revenues exceed the Company&#x2019;s cumulative
expenditures.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As
a result of the assignment to Novelos of the exclusive worldwide
intellectual property and marketing rights of oxidized glutathione
(excluding the Russian Territory), Novelos is obligated to the
Oxford Group, Ltd., or its assignees, for future
royalties.&#xA0;&#xA0;Simyon Palmin, a founder of Novelos, a
director until August 12, 2008 and the father of the
Company&#x2019;s president and chief executive officer, is president
of Oxford Group, Ltd.&#xA0;&#xA0;Mr. Palmin was also an employee of
the Company until September 2008 and performed consulting services
through December 2009.&#xA0;&#xA0;Pursuant to the agreement, as
revised May 26, 2005, Novelos is required to pay Oxford Group,
Ltd., or its assignees, a royalty in the amount of 0.8% of the
Company&#x2019;s net sales of oxidized glutathione-based
products.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Employment Agreements</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company entered into an employment agreement with Harry Palmin
effective January 1, 2006, whereby he agreed to serve as the
Company&#x2019;s president and chief executive officer for an
initial term of two years.&#xA0;&#xA0;The agreement is
automatically renewed for successive one-year terms unless notice
of termination is provided by either party at least 90 days prior
to the end of such term.&#xA0;&#xA0;The agreement was renewed most
recently for an additional one-year term on January 1, 2011 in
accordance with its terms.&#xA0;&#xA0;The agreement provides for an
initial salary of $225,000 in 2006, participation in standard
benefit programs and an annual cash bonus at the discretion of the
compensation committee.&#xA0;&#xA0;The agreement further provides
that upon resignation for good reason or termination without cause,
both as defined in the agreement, Mr.&#xA0;Palmin will receive his
pro rata share of the average of his annual bonus paid during the
two fiscal years preceding his termination, his base salary and
benefits for 11 months after the date of termination and fifty
percent of his unvested stock options will vest.&#xA0;&#xA0;The
agreement also contains a non-compete provision, which prohibits
Mr.&#xA0;Palmin from competing with the Company for one year after
termination of his employment with the Company.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Retention Agreements</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
May 14, 2010, the Company entered into retention agreements with
each of its four vice-presidents.&#xA0;&#xA0;The agreements provide
for the lump-sum payment of six months&#x2019; base salary and
benefits to each such officer following a termination without cause
or a resignation with good reason occurring on or before November
14, 2011.&#xA0;&#xA0;The agreements further provide that if the
executives remain employed with the Company as of October 1, 2010,
they will receive a payment of two months&#x2019; base salary as a
retention bonus on that date. The retention bonus, an aggregate of
$140,000, was paid in October 2010 and will be deducted from the
severance amounts that may become payable upon a subsequent
involuntary termination.&#xA0;&#xA0;Elias Nyberg&#x2019;s employment
was terminated on March 10, 2011, without cause, and he received a
payment of approximately $83,000 pursuant to the executive
retention agreement. The agreements expire November 14,
2011.&#xA0;&#xA0;The total remaining amount that may become payable
to the Company&#x2019;s Named Executive Officers pursuant to the
retention agreements is approximately $86,000 to Christopher
Pazoles. Concurrently with the execution of the retention
agreements, the employment agreement between the Company and
Christopher Pazoles dated July 15, 2005 was
terminated.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
May 14, 2010, the Company also entered into retention agreements
with each of its three non-executive employees. The agreements
provide for the lump-sum payment of six months&#x2019; base salary
and benefits to each employee following a termination without cause
or a resignation with good reason occurring on or before November
14, 2011.&#xA0;&#xA0;The agreements expire November 14,
2011.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.25)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 942<br /><br /> -SubTopic 210<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.9-03.17)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 25<br /><br /> -Article 5<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 210<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-03.(a)(19))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 03<br /><br /> -Paragraph 17<br /><br /> -Article 9<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 7<br /><br /> -Section 03<br /><br /> -Paragraph 19<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommitmentsDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1046
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E1RUQ"><tr><th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)<br /></strong></div></th><th class="th"><div>Total

</div><div>USD ($)</div></th><th class="th"><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Cash

</div><div>USD ($)</div></th><th class="th"><div>Professional Services

</div><div>USD ($)</div></th><th class="th"><div>licensed technology

</div><div>USD ($)</div></th><th class="th"><div>Convertible Debt

</div><div>USD ($)</div></th><th class="th"><div>Series C Convertible Preferred Stock and Accumulated Dividends

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Series E Convertible Preferred Stock and Accumulated Dividends

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Private Placement

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Public Offering

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Preferred Stock and Dividend

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Common Stock

</div><div>USD ($)</div></th><th class="th"><div>Common Stock

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Common Stock

</div><div>Cash

</div><div>USD ($)</div></th><th class="th"><div>Common Stock

</div><div>Professional Services

</div><div>USD ($)</div></th><th class="th"><div>Common Stock

</div><div>licensed technology

</div><div>USD ($)</div></th><th class="th"><div>Common Stock

</div><div>Convertible Debt

</div><div>USD ($)</div></th><th class="th"><div>Common Stock

</div><div>Series C Convertible Preferred Stock and Accumulated Dividends

</div><div>Pre Acquisition</div></th><th class="th"><div>Common Stock

</div><div>Series E Convertible Preferred Stock and Accumulated Dividends

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Common Stock

</div><div>Private Placement

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Common Stock

</div><div>Public Offering

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Common Stock

</div><div>Preferred Stock and Dividend

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Additional Paid-in Capital

</div><div>USD ($)</div></th><th class="th"><div>Additional Paid-in Capital

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Additional Paid-in Capital

</div><div>Cash

</div><div>USD ($)</div></th><th class="th"><div>Additional Paid-in Capital

</div><div>Professional Services

</div><div>USD ($)</div></th><th class="th"><div>Additional Paid-in Capital

</div><div>licensed technology

</div><div>USD ($)</div></th><th class="th"><div>Additional Paid-in Capital

</div><div>Convertible Debt

</div><div>USD ($)</div></th><th class="th"><div>Additional Paid-in Capital

</div><div>Series C Convertible Preferred Stock and Accumulated Dividends

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Additional Paid-in Capital

</div><div>Series E Convertible Preferred Stock and Accumulated Dividends

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Additional Paid-in Capital

</div><div>Private Placement

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Additional Paid-in Capital

</div><div>Public Offering

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Additional Paid-in Capital

</div><div>Preferred Stock and Dividend

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Deficit Accumulated During the Development Stage

</div><div>USD ($)</div></th><th class="th"><div>Redeemable Preferred Stock Series D and E Convertible Preferred Stock

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Redeemable Preferred Stock Series D and E Convertible Preferred Stock

</div><div>Series E Convertible Preferred Stock and Accumulated Dividends

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Redeemable Preferred Stock Series D and E Convertible Preferred Stock

</div><div>Preferred Stock and Dividend

</div><div>Pre Acquisition

</div><div>USD ($)</div></th><th class="th"><div>Series C Cumulative Convertible Preferred Stock

</div><div>Pre Acquisition</div></th><th class="th"><div>Series C Cumulative Convertible Preferred Stock

</div><div>Series C Convertible Preferred Stock and Accumulated Dividends

</div><div>Pre Acquisition</div></th><th class="th"><div>Series C Cumulative Convertible Preferred Stock

</div><div>Preferred Stock and Dividend

</div><div>Pre Acquisition</div></th><th class="th"><div>Accumulated Deficit

</div><div>Pre Acquisition

</div><div>USD ($)</div></th></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Nov. 06, 2002</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">6,440,123<span /></td><td class="nump">101,220<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">$ 590,269<span /></td><td class="nump">$ 9,108<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">$ 64<span /></td><td class="nump">$ 1<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">$ 590,205<span /></td><td class="nump">$ 9,107<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2002</a></td><td class="nump">599,377<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">65<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">599,312<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2002</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">6,541,343<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td><td class="num">(295,790)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(295,790)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">37,958<span /></td><td class="text">&#xA0;<span /></td><td class="nump">203,483<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">4,937<span /></td><td class="text">&#xA0;<span /></td><td class="nump">80,412<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">2<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">4,937<span /></td><td class="text">&#xA0;<span /></td><td class="nump">80,410<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2003</a></td><td class="nump">388,936<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">67<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">684,659<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(295,790)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2003</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">6,782,784<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td><td class="num">(342,761)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(342,761)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2004</a></td><td class="nump">46,175<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">67<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">684,659<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(638,551)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2004</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">6,782,784<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td><td class="num">(481,837)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(481,837)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">610,664<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">835,868<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">6<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">835,862<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2005</a></td><td class="nump">400,206<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">73<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1,520,521<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(1,120,388)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2005</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">7,393,448<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Common stock repurchased (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(43,819)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Common stock repurchased</a></td><td class="num">(31,667)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(31,667)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td><td class="nump">43,994<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">43,994<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td><td class="num">(963,440)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(963,440)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">2,202,179<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">7,097,072<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">22<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">7,097,050<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2006</a></td><td class="nump">6,546,165<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">95<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">8,629,898<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(2,083,828)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2006</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">9,551,808<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Exercise of warrant to purchase common stock (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">75,045<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Exercise of warrant to purchase common stock</a></td><td class="nump">250,000<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">249,999<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td><td class="nump">570,392<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">570,392<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td><td class="num">(5,090,325)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(5,090,325)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">60,250<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">250,000<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">249,999<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2007</a></td><td class="nump">2,526,232<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">97<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">9,700,288<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(7,174,153)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2007</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">9,687,103<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td><td class="nump">477,488<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">477,488<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td><td class="num">(6,090,715)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(6,090,715)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">3,132,999<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">12,931,562<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">31<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">12,931,531<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2008</a></td><td class="nump">9,844,567<span /></td><td class="num">(19,488,601)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">128<span /></td><td class="nump">3.0<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">23,109,307<span /></td><td class="nump">40,204,549<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(13,264,868)<span /></td><td class="nump">13,904,100<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(59,693,153)<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2008</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">12,820,102<span /></td><td class="nump">287,423<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">413.5<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">272<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_ReclassificationOfWarrantsToDerivativeLiability', window );">Reclassification of warrants to derivative liability (see Note 2)</a></td><td class="text">&#xA0;<span /></td><td class="num">(998,945)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(6,893,316)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">5,894,371<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_IssuanceOfCommonStockAndWarrantsShares', window );">Issuance of common stock and warrants (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">89,126<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_IssuanceOfCommonStockAndWarrantsValue', window );">Issuance of common stock and warrants</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">8,938,884<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">8,938,883<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Exercise of warrant to purchase common stock (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">3,162<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Exercise of warrant to purchase common stock</a></td><td class="text">&#xA0;<span /></td><td class="nump">1,000,962<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1,000,962<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock in exchange for warrants (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">13,623<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock in exchange for warrants</a></td><td class="text">&#xA0;<span /></td><td class="nump">1,625,760<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1,625,760<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense associated with options issued to employees</a></td><td class="text">&#xA0;<span /></td><td class="nump">437,066<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">437,066<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td><td class="nump">502,199<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">502,199<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Compensation expense (benefit) associated with options issued to non-employees</a></td><td class="text">&#xA0;<span /></td><td class="nump">427,271<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">427,271<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants', window );">Issuance of Series E redeemable convertible preferred stock and warrants, net of issuance costs of $795,469 (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">200<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants', window );">Issuance of Series E redeemable convertible preferred stock and warrants, net of issuance costs of $795,469</a></td><td class="text">&#xA0;<span /></td><td class="nump">2,907,208<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">2,907,208<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">6,297,323<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsShares', window );">Issuance of Series E redeemable convertible preferred stock in payment of accumulated dividends(in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">31.942875<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockDividend', window );">Issuance of Series E redeemable convertible preferred stock in payment of accumulated dividends</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1,597,144<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue', window );">Adjustment to record the carrying value of Series E redeemable convertible preferred stock at fair value on the date of sale</a></td><td class="text">&#xA0;<span /></td><td class="nump">125,892<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">125,892<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(125,892)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Fair value of the extension of expiration date of warrants</a></td><td class="text">&#xA0;<span /></td><td class="nump">839,923<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">839,923<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants', window );">Accretion of deemed dividend associated with the extension of expiration date of warrants</a></td><td class="text">&#xA0;<span /></td><td class="num">(839,923)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(839,923)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends accrued on preferred stock</a></td><td class="text">&#xA0;<span /></td><td class="num">(3,296,289)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(3,296,289)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td><td class="num">(6,219,873)<span /></td><td class="num">(22,273,306)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(6,219,873)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(22,273,306)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Convertible Securities (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">10,058<span /></td><td class="nump">51,889<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(97.18209375)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(68)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Convertible Securities</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">184,246<span /></td><td class="nump">3,514,314<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">184,246<span /></td><td class="nump">3,514,313<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(32,130,560)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2009</a></td><td class="nump">4,126,893<span /></td><td class="num">(26,895,538)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">128<span /></td><td class="nump">5<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">23,611,506<span /></td><td class="nump">49,176,545.00000000<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(19,484,741)<span /></td><td class="nump">18,459,619.00000000<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(76,072,088.00000000)<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2009</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">12,820,102<span /></td><td class="nump">455,281<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">548.26078125<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">204<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td><td class="text">&#xA0;<span /></td><td class="nump">5,350,122<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2010</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2009</a></td><td class="nump">4,126,893<span /></td><td class="num">(26,895,538)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">128<span /></td><td class="nump">5<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">23,611,506<span /></td><td class="nump">49,176,545.00000000<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(19,484,741)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(76,072,088.00000000)<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2009</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">12,820,102<span /></td><td class="nump">455,281<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">204<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td><td class="text">&#xA0;<span /></td><td class="nump">158,567<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">158,567<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">5,991<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_IssuanceOfCommonStockAndWarrantsShares', window );">Issuance of common stock and warrants (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">140,056<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_IssuanceOfCommonStockAndWarrantsValue', window );">Issuance of common stock and warrants</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">744,911<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">744,910<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Intrinsic value of beneficial conversion feature associated with the conversion of convertible debt</a></td><td class="nump">213,792<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">213,792<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Exercise of warrant to purchase common stock (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">53,478<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Exercise of warrant to purchase common stock</a></td><td class="text">&#xA0;<span /></td><td class="nump">2,584,397<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">2,584,396<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense associated with options issued to employees</a></td><td class="text">&#xA0;<span /></td><td class="nump">586,321<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">586,321<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td><td class="nump">353,340<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">353,340<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Compensation expense (benefit) associated with options issued to non-employees</a></td><td class="text">&#xA0;<span /></td><td class="num">(249,023)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(249,023)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock', window );">Fair value of incremental shares issued to preferred stockholders in connection with exchange of preferred stock for common stock</a></td><td class="text">&#xA0;<span /></td><td class="nump">11,955,151<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">11,955,151<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrants issued to preferred shareholders</a></td><td class="text">&#xA0;<span /></td><td class="nump">586,050<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">586,050<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders', window );">Accretion of deemed dividend associated with the issuance of warrants to preferred stockholders</a></td><td class="text">&#xA0;<span /></td><td class="num">(586,050)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(586,050)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred', window );">Accretion of deemed dividend associated with the incremental shares of common stock issued in connection with the exchange of preferred stock</a></td><td class="text">&#xA0;<span /></td><td class="num">(11,955,151)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(11,955,151)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends accrued on preferred stock</a></td><td class="text">&#xA0;<span /></td><td class="num">(2,207,827)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(2,207,827)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td><td class="num">(4,560,263)<span /></td><td class="nump">2,095,392<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(4,560,263)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">2,095,392<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Convertible Securities (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">76,770<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">2,228,338<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(139.99673625)<span /></td><td class="num">(408.264045)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(204)<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Convertible Securities</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">5,324,518<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">19,064,891.000000<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">22<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">5,324,517<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">19,064,869.000000<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(4,689,593)<span /></td><td class="num">(13,770,026.000000)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2010</a></td><td class="nump">133,762<span /></td><td class="nump">1,206,609<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">30<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">24,178,638<span /></td><td class="nump">75,183,275<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(24,045,004)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(73,976,696)<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2010</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">2,959,914<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td><td class="text">&#xA0;<span /></td><td class="num">(1,010,072)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2011</a></td><td class="text">&#xA0;<span /></td><td class="nump">304,915<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2010</a></td><td class="nump">133,762<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">128<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">24,178,638<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(24,045,004)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2010</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">12,820,102<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in a business combination (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">2,959,871<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in a business combination</a></td><td class="nump">2,219,903<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">30<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">2,219,873<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Cash paid in lieu of fractional shares in a business combination, (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(41)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Cash paid in lieu of fractional shares in a business combination</a></td><td class="num">(145)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(145)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_IssuanceOfCommonStockAndWarrantsShares', window );">Issuance of common stock and warrants (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">6,846,537<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_IssuanceOfCommonStockAndWarrantsValue', window );">Issuance of common stock and warrants</a></td><td class="nump">4,866,406<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">68<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">4,866,338<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Intrinsic value of beneficial conversion feature associated with the conversion of convertible debt</a></td><td class="nump">257,973<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">257,973<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Exercise of warrant to purchase common stock (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">18,153<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Exercise of warrant to purchase common stock</a></td><td class="nump">48,339<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">48,339<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td><td class="nump">655,656<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">655,656<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td><td class="num">(5,469,502)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(5,469,502)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Convertible Securities (in shares)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">4,181,535<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Convertible Securities</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">3,184,707<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">42<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">3,184,665<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2011</a></td><td class="nump">$ 5,897,099<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">$ 268<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">$ 35,411,337<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">$ (29,514,506)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rc"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2011</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">26,826,157<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital Accretion Of Deemed Dividend Associated With The Incremental Shares Of Common Stock Issued In Exchange Of Preferred</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIncrementalSharesOfCommonStockIssuedInExchangeOfPreferred</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Accretion of Deemed Dividend Associated with the Issuance of Warrants to Preferred Stockholders</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_AdjustmentsToAdditionalPaidInCapitalAccretionOfDeemedDividendAssociatedWithTheIssuanceOfWarrantsToPreferredStockholders</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital Associated With Extension Of Expiration Date Of Warrants</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_AdjustmentsToAdditionalPaidInCapitalAssociatedWithExtensionOfExpirationDateOfWarrants</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital, fair value of incremental shares issued to preferred stockholders in connection with the exchange of preferred stock for common stock.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_AdjustmentsToAdditionalPaidInCapitalFairValueOfIncrementalSharesIssuedToPreferredStockholdersInExchangeForCommonStock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The adjustment to additional paid in capital for the decrease in carrying amount of redeemable preferred stock that is classified as temporary equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_AdjustmentToRecordCarryingValueOfRedeemableConvertiblePreferredStockAtFairValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_IssuanceOfCommonStockAndWarrantsShares"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock And Warrants, Shares</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_IssuanceOfCommonStockAndWarrantsShares</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_IssuanceOfCommonStockAndWarrantsValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of issuance of common stock and warrants.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_IssuanceOfCommonStockAndWarrantsValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_ReclassificationOfWarrantsToDerivativeLiability"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification Of Warrants To Derivative Liability</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_ReclassificationOfWarrantsToDerivativeLiability</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Preferred Stock And Common Stock Warrants</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_StockIssuedDuringPeriodSharesPreferredStockAndCommonStockWarrants</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the exercise of warrants.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_StockIssuedDuringPeriodSharesStockWarrantsExercised</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value preferred stock and common stock warrants.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value stock issued during the period as a result of the exercise of warrants.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_StockIssuedDuringPeriodValueStockWarrantsExercised</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to Additional Paid in Capital resulting from the recognition of deferred taxes for the temporary difference of the convertible debt with a beneficial conversion feature. A beneficial conversion feature is a nondetachable conversion feature that is in-the-money.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 55<br /><br /> -Paragraph 51<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6909077&amp;loc=d3e34017-109320<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Beneficial Conversion Feature<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 05-8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents increases or decreases in additional paid in capital not separately disclosed.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in additional paid in capital related to exercise of share-based payments awards (such as stock options) and the amount of recognized equity-based compensation during the period (such as nonvested shares).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 10<br /><br /> -Section 35<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 20<br /><br /> -Section 55<br /><br /> -Paragraph 12<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11149-113907<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 123R<br /><br /> -Paragraph 64<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 123R<br /><br /> -Paragraph A91<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 20<br /><br /> -Section 55<br /><br /> -Paragraph 13<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11178-113907<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 123R<br /><br /> -Paragraph 39<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in additional paid in capital due to warrants issued during the period. Includes also the proceeds of debt securities issued with detachable stock purchase warrants that are allocable to the warrants. These warrants qualify for equity classification and provide the holder with a right to purchase stock from the entity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Warrant<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 31<br /><br /> -Article 5<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 470<br /><br /> -SubTopic 20<br /><br /> -Section 25<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6923874&amp;loc=d3e4724-112606<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 14<br /><br /> -Paragraph 16<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of aggregate cash, stock, and paid-in-kind dividends declared for preferred shareholders during the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 942<br /><br /> -SubTopic 405<br /><br /> -Section 45<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Statement of Position (SOP)<br /><br /> -Number 01-6<br /><br /> -Paragraph 14<br /><br /> -Subparagraph l<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DividendsPreferredStock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.22)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.18)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 220<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph A7<br /><br /> -Appendix A<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 130<br /><br /> -Paragraph 10, 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Other Comprehensive Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph d<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 87-21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Net Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.19)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 19<br /><br /><br /><br />Reference 15: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28, 29, 30<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 16: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Paragraph 20<br /><br /> -Article 9<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetIncomeLoss</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsShares"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockDividendsShares</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued and outstanding as of the balance sheet date.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_SharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29-31)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph A3<br /><br /> -Appendix A<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 29, 30, 31<br /><br /> -Article 5<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /> -Number Topic 4<br /><br /> -Section E<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 310<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SAB TOPIC 4.E)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquity</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquityOther</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements in the number of shares included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquityOtherShares</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 141<br /><br /> -Paragraph 53<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 141<br /><br /> -Paragraph 51<br /><br /> -Subparagraph d<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.28,29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 29, 30<br /><br /> -Article 5<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockIssuedDuringPeriodSharesAcquisitions</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 4, 5<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29-30)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 29, 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 29, 30<br /><br /> -Article 5<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockIssuedDuringPeriodSharesOther</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.28,29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (c)(1)(iv)(2)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 29, 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29-31)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 29, 30, 31<br /><br /> -Article 5<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockIssuedDuringPeriodValueAcquisitions</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 29, 30, 31<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 4, 5<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29-31)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 29, 30, 31<br /><br /> -Article 5<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockIssuedDuringPeriodValueOther</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockDividend"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued to shareholders as a dividend during the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29-31)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 29, 30, 31<br /><br /> -Article 5<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockIssuedDuringPeriodValueStockDividend</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value stock issued during the period as a result of the exercise of stock options.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29-31)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 29, 30, 31<br /><br /> -Article 5<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 29, 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 43<br /><br /> -Chapter 1<br /><br /> -Section B<br /><br /> -Paragraph 11A<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockRepurchasedDuringPeriodShares</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 29, 30, 31<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 43<br /><br /> -Chapter 1<br /><br /> -Section B<br /><br /> -Paragraph 11A<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockRepurchasedDuringPeriodValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1047
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EXEAC"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LITIGATION<br /></strong></div></th><th class="th" colspan="1">3 Months Ended</th><th class="th" colspan="1">9 Months Ended</th><th class="th" colspan="1">12 Months Ended</th></tr><tr><th class="th"><div>Mar. 31, 2011</div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">LITIGATION</a></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr valign="top">
<td style="WIDTH: 36pt" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
8.&#xA0;</font></div>
</td>
<td align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
LITIGATION</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A
purported class action complaint was filed on March 5, 2010 in the
United States District Court for the District of Massachusetts by
an alleged shareholder of the Company, on behalf of himself and all
others who purchased or otherwise acquired the Company&#x2019;s
common stock in the period between December 14, 2009 and February
24, 2010, against the Company and its President and Chief Executive
Officer, Harry S. Palmin.&#xA0;&#xA0;On October 1, 2010, the court
appointed lead plaintiffs (Boris Urman and Ramona McDonald) and
appointed lead plaintiffs&#x2019; counsel.&#xA0;&#xA0;On October 22,
2010, an amended complaint was filed.&#xA0;&#xA0;The amended
complaint claims that the Company violated Section 10(b) of the
Securities Exchange Act of 1934, as amended, and Rule 10b-5
promulgated thereunder in connection with alleged disclosures
related to the Phase 3 clinical trial of NOV-002 for non-small cell
lung cancer.&#xA0;&#xA0;On December 6, 2010, the Company filed a
motion to dismiss the complaint with prejudice.&#xA0;&#xA0;On
January 20, 2011, the plaintiffs filed their opposition to our
motion and on March 3, 2011, the Company filed its response to
their opposition. The motion to dismiss remains pending. The
Company believes the allegations are without merit and intends to
defend vigorously against the allegations.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
June 28, 2010, the Company received a letter from counsel to ZAO
BAM and ZAO BAM Research Laboratories (Russian companies,
collectively referred to as &#x201C;BAM&#x201D;) alleging that the
Company modified the chemical composition of NOV-002 without prior
notice to or approval from BAM, constituting a material breach of a
technology and assignment agreement the Company had entered into
with BAM on June 20, 2000 (the &#x201C;June 2000
Agreement&#x201D;).&#xA0;&#xA0;The letter references the
Company&#x2019;s amendment, submitted to the FDA on August 30, 2005,
to its investigational new drug application dated August 1999 as
the basis for BAM&#x2019;s claims and demands the transfer of all
intellectual property rights concerning NOV-002 to
BAM.&#xA0;&#xA0;Mark Balazovsky, a director of Novelos from June
1996 until November 2006 and a shareholder of Novelos through at
least June 25, 2010, is, to the Company&#x2019;s knowledge, still
the general director and principal shareholder of ZAO
BAM.&#xA0;&#xA0;The Company believes the allegations are without
merit and intends to defend vigorously against any proceedings that
BAM may initiate as to these allegations. On September 24, 2010,
the Company filed a complaint in Suffolk Superior Court seeking a
declaratory judgment by the court that the June 2000 Agreement has
been replaced by a subsequent agreement between the parties dated
April 1, 2005 (the &#x201C;April 2005 Agreement&#x201D;), that
Novelos&#x2019; obligations to BAM are governed solely by the April
2005 Agreement and that the obligations of the June 2000 agreement
have been performed and fully satisfied.&#xA0;&#xA0;On November 29,
2010, BAM answered the complaint, denying the material allegations,
and stating its affirmative defenses and certain counterclaims. On
January 14, 2011, the Company responded to the counterclaims,
denying BAM&#x2019;s material allegations and stating its
affirmative defenses.&#xA0;&#xA0;The Company believes the
counterclaims are without merit and intends to vigorously defend
against them.</font></div>
</div><span /></td><td class="text"><div>
<div>
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
15.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
LITIGATION</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Following
the Acquisition, the Company is party to certain legal matters that
existed with Novelos prior to the Acquisition. The following
summarizes the status of those matters.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
Class Action</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A
putative federal securities class action complaint was filed on
March 5, 2010 in the United States District Court for the District
of Massachusetts by an alleged shareholder of Novelos, on behalf of
himself and all others who purchased or otherwise acquired Novelos
common stock in the period between December 14, 2009 and February
24, 2010, against Novelos and its President and Chief Executive
Officer, Harry S. Palmin.&#xA0; On October 1, 2010, the court
appointed lead plaintiffs (Boris Urman and Ramona McDonald) and
appointed lead plaintiffs&#x2019; counsel.&#xA0; On October 22,
2010, an amended complaint was filed.&#xA0; The amended complaint
claims, among other things, that Novelos violated Section 10(b) of
the Securities Exchange Act of 1934, as amended, and Rule 10b-5
promulgated thereunder in connection with alleged misleading
disclosures related to the progress of the Phase 3 clinical trial
of NOV-002 for non-small cell lung cancer.&#xA0; On December 6,
2010, the defendants filed a motion to dismiss the complaint with
prejudice.&#xA0; On January 20, 2011, the plaintiffs filed their
opposition to our motion and on March 3, 2011, the defendants filed
their response to the opposition. On June 23, 2011, the motion to
dismiss was granted and the case was dismissed without
prejudice.&#xA0; Because the dismissal was without prejudice, the
plaintiffs could&#xA0;reinstitute the&#xA0;proceeding by
filing&#xA0;an amended complaint.&#xA0; On August 5, 2011, the
plaintiffs filed a second amended complaint realleging that the
defendants violated Section 10(b) of the Exchange Act and Rule
10b-5 in connection with alleged misleading disclosures related to
the Phase 3 clinical trial for NOV-002 in non-small cell lung
cancer.</font> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
On September 9, 2011, the defendants filed a motion to dismiss the
second amended complaint. The plaintiff<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#x2019;</font>s
opposition to the motion&#xA0;was filed on&#xA0;October 14, 2011
and the defendants filed a reply brief on November 4,
2011.</font></font> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
Company and Mr. Palmin believe the allegations are without merit
and intend to vigorously defend against them.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
BAM Dispute</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
June 28, 2010, Novelos received a letter from counsel to ZAO BAM
and ZAO BAM Research Laboratories (Russian companies, collectively
referred to as &#x201C;BAM&#x201D;) alleging that it modified the
chemical composition of NOV-002 without prior notice to or approval
from BAM, constituting a material breach of a technology and
assignment agreement Novelos had entered into with BAM on June 20,
2000 (the &#x201C;June 2000 Agreement&#x201D;).&#xA0; The letter
references the amendment, submitted to the FDA on August 30, 2005,
to Novelos&#x2019; investigational new drug application dated August
1999 as the basis for BAM&#x2019;s claims and demands the transfer
of all intellectual property rights concerning NOV-002 to
BAM.&#xA0; Mark Balazovsky, a director of Novelos from June 1996
until November 2006 and a shareholder of Novelos through at least
June 25, 2010, is, to our knowledge, still the general director and
principal shareholder of ZAO BAM.&#xA0; On September 24, 2010,
Novelos filed a complaint in Suffolk Superior Court seeking a
declaratory judgment by the court that the June 2000 Agreement has
been replaced by a subsequent agreement between the parties dated
April 1, 2005 (the &#x201C;April 2005 Agreement&#x201D;), that
Novelos&#x2019; obligations to BAM are governed solely by the April
2005 Agreement and that the obligations of the June 2000 agreement
have been performed and fully satisfied.&#xA0; On November 29,
2010, BAM answered the complaint, denying the material allegations,
and stating its affirmative defenses and certain counterclaims. On
January 14, 2011, Novelos responded to the counterclaims, denying
BAM&#x2019;s material allegations and stating its affirmative
defenses.&#xA0; On June 9, 2011, BAM filed an amended counterclaim
alleging additional claims related to Novelos&#x2019; acquisition of
Cellectar.&#xA0; In that amended counterclaim, BAM alleges that the
acquisition evidences Novelos&#x2019; abandonment of the technology
assigned to it by BAM constituting a breach of the June 2000
Agreement or, if that agreement is determined to no longer be in
effect, a breach of the April 2005 Agreement and/or a breach of the
implied duty of good faith and fair dealing with respect to the
April 2005 Agreement.&#xA0; On June 15, 2011 the Company filed its
response to their amended counterclaim.&#xA0; On August 5, 2011,
the Company filed a motion for judgment on the pleadings as to its
declaratory judgment count and all counts of BAM&#x2019;s amended
counterclaim.&#xA0; The motion&#xA0;was opposed by BAM and a
hearing on the motion&#xA0;was held&#xA0;on September 27, 2011.
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On
October 17, 2011, the court ruled on the Company&#x2019;s
<font style="DISPLAY: inline; FONT-SIZE: 10pt">behalf for each of
its declaratory judgment claims and dismissed all counts of
BAM&#x2019;s counterclaim. Judgment in favor of the Company was
entered on October 20, 2011 and BAM has until November 21, 2011 to
appeal or otherwise seek post-judgment
relief.</font></font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We
do not anticipate that these litigation contingencies will have a
material impact on the Company&#x2019;s future financial position,
results of operations or cash flows.</font></div>
</div><span /></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">
11.&#xA0;&#xA0;LITIGATION</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A
purported class action complaint was filed on March 5, 2010 in the
United States District Court for the District of Massachusetts by
an alleged shareholder of the Company, on behalf of himself and all
others who purchased or otherwise acquired the Company&#x2019;s
common stock in the period between December 14, 2009 and February
24, 2010, against the Company and its President and Chief Executive
Officer, Harry S. Palmin.&#xA0;&#xA0;On October 1, 2010, the court
appointed lead plaintiffs (Boris Urman and Ramona McDonald) and
appointed lead plaintiffs&#x2019; counsel.&#xA0;&#xA0;On October 22,
an amended complaint was filed.&#xA0;&#xA0;The amended complaint
claims that the Company violated Section 10(b) of the Securities
Exchange Act of 1934, as amended, and Rule 10b-5 promulgated
thereunder in connection with alleged disclosures related to the
Phase 3 clinical trial of NOV-002 for non-small cell lung
cancer.&#xA0;&#xA0;On December 6, 2010, the Company filed a motion
to dismiss the complaint with prejudice.&#xA0;&#xA0;On January 20,
2011, the plaintiffs filed their opposition to our motion and on
March 3, 2011, we filed our response to their opposition. Our
motion to dismiss remains pending. The Company believes the
allegations are without merit and intends to defend vigorously
against the allegations.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
June 28, 2010, the Company received a letter from counsel to ZAO
BAM and ZAO BAM Research Laboratories (collectively,
&#x201C;BAM&#x201D;) alleging that the Company modified the chemical
composition of NOV-002 without prior notice to or approval from
BAM, constituting a material breach of a technology and assignment
agreement the Company had entered into with BAM on June 20, 2000
(the &#x201C;June 2000 Agreement&#x201D;).&#xA0;&#xA0;The letter
references the Company&#x2019;s amendment, submitted to the FDA on
August 30, 2005, to its investigational new drug application dated
August 1999 as the basis for BAM&#x2019;s claims and demands the
transfer of all intellectual property rights concerning NOV-002 to
BAM.&#xA0;&#xA0;Mark Balazovsky, a director of Novelos from June
1996 until November 2006 and a shareholder of Novelos through at
least June 25, 2010, is, to the Company&#x2019;s knowledge, still
the general director and principal shareholder of ZAO
BAM.&#xA0;&#xA0;The Company believes the allegations are without
merit and intends to defend vigorously against any proceedings that
BAM may initiate as to these allegations. On September 24, 2010,
the Company filed a complaint in Suffolk Superior Court seeking a
declaratory judgment by the court that the June 2000 Agreement has
been replaced by a subsequent agreement between the parties dated
April 1, 2005 (the &#x201C;April 2005 Agreement&#x201D;), that
Novelos&#x2019; obligations to BAM are governed solely by the April
2005 Agreement and that the obligations of the June 2000 agreement
have been performed and fully satisfied.&#xA0;&#xA0;On November 29,
2010, BAM answered the complaint, denying the material allegations,
and stating its affirmative defenses and certain counterclaims. On
January 14, 2011, the Company responded to the counterclaims,
denying BAM&#x2019;s material allegations and stating our
affirmative defenses.&#xA0;&#xA0;The Company believes the
counterclaims are without merit and intends to vigorously defend
against them.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LegalMattersAndContingenciesTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1048
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td><td class="text"><div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">
17.&#xA0; RELATED PARTY TRANSACTIONS</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Jamey
Weichert, the Company&#x2019;s Chief Scientific Officer, director,
shareholder and principal founder is a faculty member at the
University of Wisconsin-Madison (&#x201C;UW&#x201D;).&#xA0; Cellectar
paid $16,082 to the UW during 2009 for research related
activities.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cellectar
made contributions of $25,000 to the UW Foundation, a
not-for-profit, tax-exempt Wisconsin corporation, which serves as
the official fundraising and gift-receiving organization for the UW
and other donor-designated units of the UW System during the year
ended December 31, 2009.&#xA0; During the nine months ended
September 30, 2011, the Company made contributions totaling
$125,000 to the UW Foundation for use towards research activities
associated with the development of the Company&#x2019;s
compounds.&#xA0; No payments were made to UW during the nine months
ended September 30, 2010 or the year ended December 31,
2010.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.4-08.(k))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 3A<br /><br /> -Section 04<br /><br /> -Paragraph b<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 57<br /><br /> -Paragraph 1-4<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 850<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 4<br /><br /> -Section 08<br /><br /> -Paragraph k<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 850<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 850<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 850<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 850<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1049
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EAUCK"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS (USD $)<br /></strong></div></th><th class="th" colspan="2">9 Months Ended</th><th class="th" colspan="2">12 Months Ended</th><th class="th" colspan="1">99 Months Ended</th><th class="th" colspan="2">3 Months Ended</th><th class="th" colspan="2">12 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Sep. 30, 2010</div></th><th class="th"><div>Dec. 31, 2010</div></th><th class="th"><div>Dec. 31, 2009</div></th><th class="th"><div>Dec. 31, 2010</div></th><th class="th"><div>Mar. 31, 2011

</div><div>Pre Acquisition</div></th><th class="th"><div>Mar. 31, 2010

</div><div>Pre Acquisition</div></th><th class="th"><div>Dec. 31, 2010

</div><div>Pre Acquisition</div></th><th class="th"><div>Dec. 31, 2009

</div><div>Pre Acquisition</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td><td class="num">$ (5,469,502)<span /></td><td class="num">$ (4,098,423)<span /></td><td class="num">$ (4,560,263)<span /></td><td class="num">$ (6,219,873)<span /></td><td class="num">$ (24,045,004)<span /></td><td class="num">$ (1,010,072)<span /></td><td class="nump">$ 5,350,122<span /></td><td class="nump">$ 2,095,392<span /></td><td class="num">$ (22,273,306)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to cash used in operating activities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td><td class="nump">439,587<span /></td><td class="nump">435,917<span /></td><td class="nump">580,114<span /></td><td class="nump">576,745<span /></td><td class="nump">1,831,197<span /></td><td class="nump">2,240<span /></td><td class="nump">27,290<span /></td><td class="nump">35,342<span /></td><td class="nump">32,354<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td><td class="nump">655,656<span /></td><td class="nump">331,186<span /></td><td class="nump">353,340<span /></td><td class="nump">502,199<span /></td><td class="nump">1,947,413<span /></td><td class="nump">108,378<span /></td><td class="num">(97,479)<span /></td><td class="nump">337,298<span /></td><td class="nump">864,337<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Intrinsic value of beneficial conversion feature associated with convertible debt</a></td><td class="nump">257,973<span /></td><td class="nump">213,792<span /></td><td class="nump">213,792<span /></td><td class="text">&#xA0;<span /></td><td class="nump">213,792<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of stock for technology and services</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">89,520<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td><td class="text">&#xA0;<span /></td><td class="nump">19,671<span /></td><td class="nump">19,671<span /></td><td class="text">&#xA0;<span /></td><td class="nump">19,671<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td><td class="nump">6,009<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1,607<span /></td><td class="nump">30,468<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments', window );">(Gain) loss on derivative warrants</a></td><td class="nump">66,820<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(125,490)<span /></td><td class="num">(7,897,441)<span /></td><td class="num">(8,118,174)<span /></td><td class="nump">12,114,371<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Non-cash settlement of liquidated damages</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">819,000<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td><td class="num">(224,548)<span /></td><td class="nump">20,614<span /></td><td class="nump">18,584<span /></td><td class="nump">23,152<span /></td><td class="num">(62,914)<span /></td><td class="nump">35,483<span /></td><td class="num">(47,574)<span /></td><td class="nump">39,397<span /></td><td class="nump">26,862<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td><td class="num">(331,357)<span /></td><td class="num">(419,634)<span /></td><td class="num">(322,707)<span /></td><td class="nump">278,131<span /></td><td class="nump">392,881<span /></td><td class="num">(315,715)<span /></td><td class="num">(403,760)<span /></td><td class="num">(2,733,494)<span /></td><td class="num">(1,354,695)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest</a></td><td class="nump">158,672<span /></td><td class="nump">222,748<span /></td><td class="nump">305,049<span /></td><td class="text">&#xA0;<span /></td><td class="nump">305,049<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(238,022)<span /></td><td class="num">(245,711)<span /></td><td class="nump">5,072<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred rent</a></td><td class="nump">6,083<span /></td><td class="nump">4,765<span /></td><td class="nump">9,973<span /></td><td class="nump">62,789<span /></td><td class="nump">115,311<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(8,333)<span /></td><td class="num">(8,333)<span /></td><td class="num">(33,333)<span /></td><td class="num">(33,333)<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td><td class="num">(4,434,607)<span /></td><td class="num">(3,269,364)<span /></td><td class="num">(3,382,447)<span /></td><td class="num">(4,775,250)<span /></td><td class="num">(19,162,616)<span /></td><td class="num">(1,313,509)<span /></td><td class="num">(3,315,197)<span /></td><td class="num">(7,804,283)<span /></td><td class="num">(10,618,338)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired in a business combination</a></td><td class="nump">905,649<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td><td class="num">(112,195)<span /></td><td class="text">&#xA0;<span /></td><td class="num">(1,652)<span /></td><td class="num">(143,347)<span /></td><td class="num">(5,368,181)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(18,000)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of fixed assets</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">7,000<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term certificates of deposit</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(5,500,730)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from short-term certificates of deposit</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">5,500,730<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted cash</a></td><td class="nump">500,000<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(555,000)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payment for intangible assets</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(19,671)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash provided by (used in) investing activities</a></td><td class="nump">1,293,454<span /></td><td class="text">&#xA0;<span /></td><td class="num">(1,652)<span /></td><td class="num">(143,347)<span /></td><td class="num">(5,935,852)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(18,000)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td><td class="text">&#xA0;<span /></td><td class="nump">2,720,985<span /></td><td class="nump">2,720,985<span /></td><td class="text">&#xA0;<span /></td><td class="nump">2,720,985<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term obligations</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">450,000<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1,677,945<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on long-term obligations</a></td><td class="num">(675,743)<span /></td><td class="num">(141,794)<span /></td><td class="num">(190,789)<span /></td><td class="num">(177,807)<span /></td><td class="num">(552,201)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payments on capital lease obligations</a></td><td class="num">(1,549)<span /></td><td class="num">(1,446)<span /></td><td class="num">(1,944)<span /></td><td class="num">(619)<span /></td><td class="num">(2,563)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td><td class="nump">4,866,406<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">21,709,708<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1,249,138<span /></td><td class="nump">8,938,884<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrant</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">250,000<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants', window );">Proceeds from issuance of Series E convertible preferred stock and warrants, net</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">9,204,531<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(31,667)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities', window );">Cash paid in lieu of fractional shares in a business combination</a></td><td class="num">(145)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Change in deferred issuance costs</a></td><td class="num">(130,800)<span /></td><td class="nump">99,461<span /></td><td class="nump">99,461<span /></td><td class="num">(99,461)<span /></td><td class="text">&#xA0;<span /></td><td class="num">(28,500)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">157,400<span /></td><td class="nump">158,567<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by (used in) financing activities</a></td><td class="nump">4,058,169<span /></td><td class="nump">2,677,206<span /></td><td class="nump">3,077,713<span /></td><td class="num">(277,887)<span /></td><td class="nump">25,772,207<span /></td><td class="num">(28,500)<span /></td><td class="nump">157,400<span /></td><td class="nump">1,407,705<span /></td><td class="nump">18,143,415<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">INCREASE (DECREASE) IN CASH AND EQUIVALENTS</a></td><td class="nump">917,016<span /></td><td class="num">(592,158)<span /></td><td class="num">(306,386)<span /></td><td class="num">(5,196,484)<span /></td><td class="nump">673,739<span /></td><td class="num">(1,342,009)<span /></td><td class="num">(3,157,797)<span /></td><td class="num">(6,396,578)<span /></td><td class="nump">7,507,077<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND EQUIVALENTS AT BEGINNING OF PERIOD</a></td><td class="nump">673,739<span /></td><td class="nump">980,125<span /></td><td class="nump">980,125<span /></td><td class="nump">6,176,609<span /></td><td class="text">&#xA0;<span /></td><td class="nump">2,372,951<span /></td><td class="nump">8,769,529<span /></td><td class="nump">8,769,529<span /></td><td class="nump">1,262,452<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND EQUIVALENTS AT END OF PERIOD</a></td><td class="nump">1,590,755<span /></td><td class="nump">387,967<span /></td><td class="nump">673,739<span /></td><td class="nump">980,125<span /></td><td class="nump">673,739<span /></td><td class="nump">1,030,942<span /></td><td class="nump">5,611,732<span /></td><td class="nump">2,372,951<span /></td><td class="nump">8,769,529<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td><td class="nump">13,716<span /></td><td class="nump">42,888<span /></td><td class="nump">55,454<span /></td><td class="nump">68,436<span /></td><td class="nump">194,973<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital', window );">Fair value of derivative warrants reclassified to additional paid-in capital upon cashless exercise</a></td><td class="nump">48,339<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">2,584,397<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes', window );">Issuance of common stock upon conversion of notes payable and accrued interest</a></td><td class="nump">3,184,707<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Carrying value of redeemable preferred stock converted into common stock</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">4,689,593<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired in exchange for securities in a business combination</a></td><td class="nump">78,407<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Fair value of liabilities assumed in exchange for securities in a business combination</a></td><td class="num">(439,615)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Excess of purchase price over net assets acquired in a business combination</a></td><td class="nump">1,675,462<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Fair value of common stock issued in exchange for tender of derivative warrants</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1,625,760<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_ExchangeOfConvertiblePreferredStock', window );">Exchange of Series D for Series E preferred stock</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">13,904,100<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_SupplementalIssuanceOfStockAndWarrants', window );">Relative fair value of warrants issued to stockholders</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">$ 504,227<span /></td><td class="nump">$ 4,835,727<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_ExchangeOfConvertiblePreferredStock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_ExchangeOfConvertiblePreferredStock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in exchange for convertible notes</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation and the cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrants</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification Of Derivative Liabilities To Additional Paid In Capital</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_SupplementalIssuanceOfStockAndWarrants"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Issuance of Stock and Warrants</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_SupplementalIssuanceOfStockAndWarrants</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15, 16, 17<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 12<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAcquiredFromAcquisition</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.1)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 1<br /><br /> -Article 5<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 7<br /><br /> -Footnote 1<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 8, 9<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Cash<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 7, 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Cash Equivalents<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 32<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ConversionOfStockAmountConverted1</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Beneficial Conversion Feature<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 8<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 4<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 98-5<br /><br /> -Paragraph 7<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 00-27<br /><br /> -Paragraph 56<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 32<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_FairValueOfAssetsAcquired</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 142<br /><br /> -Paragraph 45<br /><br /> -Subparagraph e<br /><br /> -Clause 1<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 142<br /><br /> -Paragraph 43<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 141R<br /><br /> -Paragraph 68<br /><br /> -Subparagraph l<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 142<br /><br /> -Paragraph 45<br /><br /> -Subparagraph e<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 141R<br /><br /> -Paragraph 34<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 350<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13816-109267<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 350<br /><br /> -SubTopic 20<br /><br /> -Section 45<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 141R<br /><br /> -Paragraph 72<br /><br /> -Subparagraph d<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_Goodwill</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an indefinite-lived intangible asset, other than goodwill, to fair value.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 142<br /><br /> -Paragraph 46<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 350<br /><br /> -SubTopic 30<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16373-109275<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInDeferredLiabilities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period, which was recognized in earnings, in the unrealized gains or losses on derivative instruments that are not or are no longer designated as hedging instruments.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 133<br /><br /> -Paragraph 18<br /><br /> -Subparagraph a, b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 815<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4C<br /><br /> -Subparagraph (e)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6935481&amp;loc=SL5624171-113959<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 815<br /><br /> -SubTopic 20<br /><br /> -Section 35<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6439004&amp;loc=d3e65527-113976<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInInterestPayableNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 13<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15, 16, 17<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 12<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInRestrictedCash</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 29<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 25<br /><br /> -Subparagraph (e)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_InterestPaid</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of restricted stock or stock options granted to nonemployees as payment for services rendered or acknowledged claims.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 32<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesAssumed1</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from financing activity for the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 26<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from investing activity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 26<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 25<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.22)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.18)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 220<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph A7<br /><br /> -Appendix A<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 130<br /><br /> -Paragraph 10, 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Other Comprehensive Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph d<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 87-21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Net Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.19)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 19<br /><br /><br /><br />Reference 15: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28, 29, 30<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 16: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Paragraph 20<br /><br /> -Article 9<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetIncomeLoss</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OtherOperatingActivitiesCashFlowStatement</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 15<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 20<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsForRepurchaseOfCommonStock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for financing costs associated with business combinations.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18, 19, 20<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 15<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 13<br /><br /> -Subparagraph (c)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 17<br /><br /> -Subparagraph c<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsToAcquireIntangibleAssets</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 13<br /><br /> -Subparagraph (c)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 17<br /><br /> -Subparagraph c<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 13<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15, 17<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 159<br /><br /> -Section Appendix C<br /><br /> -Paragraph 5<br /><br /> -Subparagraph c<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsToAcquireShortTermInvestments</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 14<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 19<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 14<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 19<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 14<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 19<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromIssuanceOfLongTermDebt</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from other financing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 8<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3095-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18, 19, 20<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 9<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3098-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15, 16<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 159<br /><br /> -Section Appendix C<br /><br /> -Paragraph 5<br /><br /> -Subparagraph c<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 12<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 12<br /><br /> -Subparagraph (c)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 16<br /><br /> -Subparagraph c<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (j)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 123R<br /><br /> -Paragraph A240<br /><br /> -Subparagraph i<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 14<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 19<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromWarrantExercises</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26, 31<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 15<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 15<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 20<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RepaymentsOfLongTermDebt</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ShareBasedCompensation</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 32<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockIssued1</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1050
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ELG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LINE OF CREDIT<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvlt_LineOfCreditFacilitiesTextBlock', window );">LINE OF CREDIT</a></td><td class="text"><div>
<div>
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
9.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
LINE OF CREDIT</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
2009, Cellectar had a $100,000 line of credit with a bank.&#xA0;
Borrowings under the line of credit bore interest at LIBOR plus
3.25% with a 4.5% minimum rate.&#xA0; The line of credit expired on
January 10, 2010 and was not renewed.&#xA0; There were no amounts
outstanding under the line as of December 31, 2009.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvlt_LineOfCreditFacilitiesTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facilities [Text Block]</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>nvlt_LineOfCreditFacilitiesTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>nvlt</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>1051
<FILENAME>0001144204-11-062631-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-11-062631-xbrl.zip
M4$L#!!0````(`%R+:3_"PQ@R*L,!`$@`%0`1`!P`;G9L="TR,#$Q,#DS,"YX
M;6Q55`D``R_^NDXO_KI.=7@+``$$)0X```0Y`0``W%U9<^.VEGYWE?\#1Y-*
M)5623)`$%W<ZM]RVG'BNV_;8RG9?NF@2DGE#D1J2<MOWU\\!J(6D*)'@)B5=
MJ>J.B.7#P=EP@`/\\(^WF2N\DB!T?.]C#PW%GD`\R[<=;_JQMP@'9F@Y3D\(
M(].S3=?WR,?>.PE[__CQ].2'_QH,A-'53Q>/PKWG.AX1;@:?210X;\+O%G%)
M8$;PDT>K6D2X\JW%C'A17W@V0V(+OB?\_NGQ5I"&2!!>HFA^?G;V]>O7(;&G
M9C#P68-#RY^="8/!JK-?8YSG@J`.D334$Y\>_85GGPN*.B'*LV@.#!E;`P5/
MT,#`S^*`(&S8DV=3DT0M4>LR(&8$+0HV8#T7)!&A`?PGZF.DGR/Y7#'^E2SM
MS]\#9_H2"=]9WT-A$0]HC10-^C!B:RA<N*[P2(N&PB,)2?!*[.&RI;?GP!6`
MZE[XL9<8-_UYZ`?3,VA7/G.69.O%)<_I5W=/>>CZ3TK7=7GZ0ZK\5YF51H9A
MG+&OJZ).Z"L2TO:!B4NLVPZ=O):A*#K[_?/MD_5"9N8@.P(+)B@*WM<U61<A
ML893__5L^?&,38"(!C):5;.)DU\%/N04=[Q7$D;Y->)O.94\W_,6LWP"V%%P
M%KW/R1D4&D`I$CC6NEYQI4R%5S=*U?#\5^+Z(>-SBDLT9'%5&(1O:IKS=?F)
M&3ZSUI<?<@8"7VBW86X=]B6G$D5M9XB\G$_U+/Z8*AKE%L5QT:@'+"X(C,G=
M\Y"QPB.9"(SCSBF$C[W0F<U=RA?L-S.P`M\EY7B;U7@)R.1CC])RL*+9\"VT
M*[!^>:DZBX>U)/WYI1F^7'@V_6OT?POGU71!LX47T:49!.^@.G\UW041+-^+
MR%OT2.$2W_WR,%)E79'5`>B8IP%,`Z#_\C2^^B)^@8%`AS*"?RI8PK+VINBJ
MCI2>L/"<N(6E%'[YY>FJ)]C$<F:F"S,M]G[$*D*:+/UPQ@6OBQ'!U'P12XU!
MUC5#U6H-X=8QGQW7B1P27BZ"`,ISXD659T!15"2B#?IM*&FH5V1"X&?[D;P2
M;T&ZABO3/QNT^6BRB`.8A,AY)0<D,U(E3163P'>#2L-_))$)UMD>F8$'W!->
M6."-+%RP^C:,WK&<[@8QT!1#5S55WXRC&%UZ-`\!F9N./7J;$R\D(";WT0L)
M+L*01)W/B:2+2D+UE("6'DO\J3L6HO9",3:`X_[WBN>=[UE=2RC6]XGH!E%&
MB_NSF>\]1;[U9Q6%70-O0BJS(/)I>S^!OX'9+_VPP^F7="R*VV1-@=DFJ1/-
MF/4!>P0XH1PLD4#3M(D:G.QSSP'G)`H6.?['AL1/+V9`POM%Q)9H@*UA5"%K
M/TG&F[MK(*2!#5U#N;.^!2E/XCNW':*N*;J2%?Q<G=2&,U0'N2P:2DWW;C,[
M#V9P'SQ%U+BP@@\D8!/6WGB^S$GP99N/<.]'<2C"GWPNVH4SPTRV[=`5O.D^
M@-FY\2[-N1.9;F>3HV')0"I.J.H=B#*P+;;D#1_,=_/9I782?@%)MP_H74F@
M&L6$5\*!<:<C#I789+[XKDV"D+)K]'XX8U^$+#V.`R*71<5`>`.\".J6]KT)
M0YBI8[$%,9JL$^N#7HC>'US3BV`VZ+#FU,[>D>YX7L5)*N^#5$#OBT7TX@?.
M?[JB.:+"2O_LH?H&4]8%F_NA`Q:#6<`#>+<(RSCEA>7C2:-.+"1J0"X?D9`T
M24H8W=SNLVX#T_2WQ`S)_;/K3%ELN1NTBJKBI(=0@*04\*H&B(/&R-`*41?9
MF/9A8@GI2.,)[S08+"D/4TN'T,I'1]J()W"$_D193:YUN4,(CR2,`L<"1[$=
MQYV#47!*(W,":R0P4AZL:AB*H>']H9#:$04.99`,B7411"@/#6$H>[BXP5Z@
M^R,%"='OQ`YA315QOL>]R_IL8EM>=`E_.U$G2)&$9$/)"[%MPV@Q^I(%O,O'
M5G5)15BK$G`!A1H/K1E_M21B+:4*]V-H,D#$XWV(X+/JI4)"/_F^_=5Q^0,+
M'`RI:EA1$R[GJL^LN-`]8[8L>8K,*1D!GF`>."%9[A4D=P\65#ME:[1)4@,C
M!8MJ4JSJPBUFY@[DKX"5=\K>H3T2L%RBAO'1!0_WC."O$"[D\&ZQ@I`L:T<4
M(.1852J9V.;1A`1KN+E\0<`\::\87&M&U>3'TI+E6M`I^YW,3N<3ZX8F&D;W
ML='F/+7B*3PR/5L.7(OQ70Y]BW19%>5#!W5+,DN=,.ZM[TW'))C=^1%9:>0V
M;0%.X\SK/J,6FG'.:(#9$/&;HBA81U4$L,!':TI][01:,N;1P7Y4&B>654.O
MZ,5T#E;3-4DM=\)J>Q72-EI10A+=#"EGP0Q#UGA(64^.5MAXY4B%.9<5N3,Q
M*L2Y;QNO^ZFN($5TXI'4(529@RME73=D'I&IR95R1:[4=$E+GN-IFRN+<.[A
MR@[5Y1;,\ERIZHJ*.?SIQJ'R:7;-$#O$JG!(D*(BC4<1U10@Y2\B0$4XCT2`
MLC"/6("R4#D$")K%&'6(%?,($!A7+J^MI@3A:A*DR8:L*'IW$E2$<\^1`+G[
MJ:X@00A+(I8.P)951`@A293U#M=MHLHA0^"UJXC+'ZXI1&HU(3)`#>EBAT)4
MA',W28TN5Q=9F.6%2%<E0S<.P)>5'#E1EW6I2[`:AQ!)6%(EF6>E5E.(M(I"
MI.H:$CM<HA?AW"-$7?IR69CEA<C0P`?I5+EGL7((D88T!6$.$]_";K2H\Q@G
MI*FJF'"5*^Q&UR8X#V!#!P[G68:T2.$J!ZU!C4&MHZ`W+WRFX`;(4'1=%;MT
M#7/Q;C2>:$@E>"=&CPW5D+DDM*XA*0!?<@=%UQ2I0ZO"!WH'Q5'O1WG($QIJ
ME]*&@M02E-:D8R%S21O)8"NP3E>PPA/S:)7:JH'P?KZFT04D#_&Q4#N+>!^U
MD6R("A(/P]L\>@-).KWVXS`LS>F/HDX7'UF<Y1U2J$<W0KOTGK-@>6(CLJ12
M3B^/MH&T+M'@\.@0TK6#IG5QH=45E#SN>+BT+CX:&XI2B+J5M"XNF(:HRQ+'
MK3V-ITEQH54-54K$QH\K2XIK)/C0:5)\:'5)T9*[$LVG2?$)E]1EFA2?0!F*
MFI"G+K.DBG"VGB7%12A--Q1#RM4\[6=)\7&;B&59WY[3+K.D<@"7=D`/DR55
M'O%!LJ3X.$`3X8N4U7\[$I^[S4WB]4IT15-2"NJ(<Y/*\]`1Y2;QF0M=1-*1
MI2;M'\#1IR9QT5^25812QV0/FYK$9T(1QOKQW594S[4\3&I28YJFE=2D>IY=
MI_.I($G5#9[]N"92DQIUC[I*36I,SQXV-8F//41=-W`*>^>I21S,4B,U*9D3
MU$6X280%U09F3N]-9T[Q16XTK"7S*(HSIVX\<-BF#K5C<6B21*,WRUU0'Z[:
M302<!%63U[F50=-.&*_2'=$`7D=Z^;!>$Y=QUP!\T,NXZQ!:A,(X?8/*H:[C
MKC&,@::*FB3JQW0==ZU9D0RISF5:=>*I%?""NX1THYO[N&O`5#*6L.1]W&,R
MF_N!&;S'SE^SKE/#5^^6Q-I&W+O*FQ=E8^"98=5WLWEOZL2*/I1`Q^BI6,<>
M6"U'R(_K_O&J5%4PEO1*UX^W$>?E17_0J&\5+:UKZ7.$>PQ(+F=WSA\<4L?%
M*9T/1!*5XPOO5F$A336P5._H;VO1WK_%+?9UW!L#:2I6,&<D^,IY=6SBV8TL
M]:O<6&^`MZLF%T_Y@#J.7U=9!$J&(26O&#ZR<'83GOUA@]N-Z]U6@]U-.&F'
MFOOXZ#N-A&,L<YP$;#08WK@_F3?=&7=B9;DN9E1TNUORZPHV5&3L='/2N+J+
M[3=L58\CTE_I=4`QF?UVP*C_7^^5B3IR4>65B=%L[OKOA#P2%N\[H$L`"RXM
M>?BW$%D\$/HN:JZ]NB*A,_5HU8X,*#UF70)-`G;N\JQKW)J,E[@+X'1A;7G3
MSO1$0'LH;@EOVWDC!6,HET62-<5MYY#P@=[G]'1XZT(!Z)+99V*'UP#M1UPR
M(4;?K%6/CKU+):'EQZ4.2_N2N6CZQM4\+.V/.R6M".BQI*1E<?*DI&7/#78.
MEB<E;>O8;P<I:4CD.6YQZ)0T+K2JG$Q#.N1+8SRHP2$J?A^MG9?&>&`:HL+U
MTECS+W?QH,6HWMO?-_2\/0FC.N%C+L"RB,5DUGH^@`[SYOC(?>B\.2ZTBBY*
M2-G:,VSR_`"?EBV?-]?<VUT%`-M_NXM+.C15QLGME&X?[^(SF5A&.:F&G3[>
MM0WXR-/2RB,^S.-=?.*L&5HR3'!$:6E\GHDBTJ<54N<HCS@MK3P/54Y+\[U7
M$D3TO/$5>>Y&GTB:)!HI#W$7B-;/6/`YXYJLR4=VJ&+_`([^&`6G\")-5Y.[
MG`=^W8O+WAN2GM*@QW'FH)Z7>:#7O9K2BNV\[E7+#>UT/NDC,RK'Q:O-/.[5
MI"?7V>->3:G9`S_NQ:6Q:,0AF>IUB,>]RC/+(3/H.*-C5(]VFD''%Q8#[RP9
MP2W.H&O*D%8[+"WO2.IN+?^L!MR#YI_5P`V^BY0^WW&H[+,:@QB`]ZZIJJ$F
MHWH'SCZK,1Q5QK7N**L3E*QTQ$85L5X0HFPH^:R.A*KP1]LIHITFG_$,X[B3
MS^I,2+Y%;S/[K!#MKN5&SE9]][EG?+3N*O>L*DTE`QL&4HXEFON72#ZKI:5E
M54F^E]E9\EGK0M=-ZEGE81Q/XED=]I$U*77KRC'%2/\6B6<U)D?#2)<EC3?Q
MK/7X:96,=!5KR9L7CBR:VH1[?-C8:L/JJ]5(ZS'D;U6=^66@4TR_U--I(+9Y
MCZSKJ.S?*O>I3C!,P_@HPK5_O=2G&E3G2GUJ/&.HLA0?.&.H\H+J,!E#^7"K
M/52U'89L^3Q_$?B2#U5E]7[+A_LY4>\CN=SA*^8%L'E>?MIVV#MDE*-._"@$
M>B2)'ULX.1(_MDZ[=`Z6YXG9K8-UQ2L6WR+$#J\#?P;+-A;XO/8#MFMQ[7BF
M9]$L>BMR7MD:J/Q0)$UF@Z$O.55[2X,36M:9"ED$=[D1TRYP697!\J3.6J=[
MSV[&S9?#N9^LMG5WI&>T"ALI2FH3KC2JS+X]B6A@"::+WD1C?WK_)23VC7</
M;J\9=<<]`UE2#5E-\'YY8-D<#2N@([XB\=\WWFK[*1$-:'4LBI9\SKP4GAP+
M]`G*VN#!4QYD$]>N$,@(Z6K&]FQ!**)TF1!2NVRD($.5E7W4+X,QNSIZCFZ\
M,`H65,`2!VT_$8]M<)MN_&,()+HF9K3@6817&:6$9"WY'$\5A,5:C;;:L@I#
M6O(^WET@,FPWFYM.0(O=3[(W/=]X-HP7>B:N\TKL&G=05QE.YA;J&CBW=#3P
ML3\CMW[8MOR(AIYZ2C?5=_;(E^>OM'%<9FDQ6X:H:HJ14+`[86REQ1$SL.A.
M2B+[H`O$DHI474[Q^1XH6Y&9`-IBVA?^[1+Z#ZJS9CY(^'_:-PR*C`V4.LM1
M#"@_:3(U-\E)XPKO\0XA#A=D>:8,IDR.=9K%VI?$+;<T!\'NU4`F':1=_L[F
MHNP!4F;C]8$$CF]G+7>[U,:&A'!R#<"!K,@K6IXJ6[E]N:?+6O871!7M=8K*
M0-R5"NUP1"VK*"!)3]YUG^RWB/"9;.E6]0R5`TG2%'T?F;<!I8?P$[AK@>E2
M=6K/P#T`CXX=$.W"2B$1@?%/<$D!F%++R*Z#$)*J@3)2"U>1A1&(U6'6U4X5
M+(4<B]IKQUUPQ>G+#&+'OIH$DBL.Y82?7X`JL<_P&W&F+_#3!2A?<TKN%K-G
M$K#BR[(UHIP[AY1[@=`FKED16#PJFSCGX\"D/SR]SYY]?E<>+?'^>/?K[?B'
MLZT&-_V,O,B)WA_)E/&\%]V9,W[9VW1W_^OH]OY)&/\\>KQX&/TROKE\Z@LW
M=Y?#&$1>;QLL%^`:VM0]O'9-_CE:@YC`=)"XOU2+V4%?.RX)+LV(3/V`(_29
M[>X)IA\:$F!%1]U"X"X:1C"]]^204WUM@%SY%EO&CM_G-:@.'^.^DLUM=Q);
M]!&($."HWAO]]T`T!G239&?S65I?0@%0L'0M^/9/4H/:=.N=9I?3T/'.YK/G
MJ/Z]"..3LF-_QQ$F)HG/V1C0(P%_*(25ZQ,)7AV+Q$-\))8_]5@KG*=0,H,I
M=6H?8Q6G7H%L=S#=!MUY*#%`LJBG3\?6";M3I]<"BH`+2!M@_PZ=2FM,GE$8
M(E:5;%)X/HZBW1J:8'7EA);KAXN`C`'Q)Q?*5)>M;]WH@^V\?CN-/IR>+/]'
M"*-WEWSLC4>_CP<W=U>CN_&Y(,ZC#\+5S=/#[<4?Y\(S[?6#\/GB\:>;N\'M
MZ'I58OG+X\U//\<_]033=:;>QYY+)E&/]D-[F0#>53?K1AW/=3SR0;B^OQL/
MKB\^W]S"CV-G!DQV1[X*C_[,])9?GV[^-3H7$.N2_?#;*.X1#)W=BT>#Q*'P
M-+Z__.?/][=7H\>G;\W9_,-_O\'HC0_"Z']_N1G_0:&<42PK7&=5:;$>V7,@
MG-5NK1/*1HRR'E`VR*4L:_+>.SWY']-;F&`N45^01%'O"Y<$K)\5F0'E.[K\
M!8]Q`HT(IO`;,*?OA8XGN,X,%(]]>N(N`\_4`C`C*41^JJ3E!_24!I/#[T"2
M@5SKJ;K\L(GL;GZ]^O#]4!B9UHO@Q*?:P)42_(2S1Z52\">G)R3>Y(1>H.$5
M)F$;DC.;$=L!*^:^"W-0D@$%R;!L^A>^FF%BQ(X'17R/[,+`W$4&(DDO>F0)
MYH<*+:U`Z"`6'GDC@>6`]EXBGS-B)%H[/=F%4-@/T/16K47^Z8D9JQU6+Z1N
MG\<<5$`9PPWIO^C'Q)PDY29<CN#TA`UAN/QV(0+W4$10<[Z`FB$=.,`D(6CH
M>&;C*8`/DUA/FRYM!,;#E'@?F-D53'8C>L@H8Z_57"@$\1W+=,2K"06:0RLD
M/#U)$2.ITU_,5R(\$^)!_2CP36H6*/7H$I4U]_P.%)G/77K*G-4>O5DOIC<E
MPB/%3"'[`2A?VGA`)G0.8^+$-I?B#Q86VP^!T=[Y--89@Z?VB$S\):578).E
M4G3L"T#J%]H1="_,")L3R@EA,>?ZP>E)BJV@DS7#`5D!$`S1L>B*?-B<PJNJ
MHM8,<_P*LLCTL":I`0?AA-F-I0SXUW&%*V+%DR@SI8G$I-)<Z@LD]3$V^A+2
M@0O6PI>:2N`@4-`1"%+L]M`",)N!_P;>!=4$IR??2*BO0?O@)#<XNT=ISF+R
MC_^X!?I3^7.L1$<-.P\7H%5<.G-(>&!YS$1X<$V+*:N_.9D;\!HNUT=:*8M^
M=:(7IA7!-,6+%VKGYGZLV<#T68O8W,6FYS,)IB`Y%].`,'+W3T]B,Q?K.\*"
MC"OK)CQ![2!>B3PL`E#?8&'6507:-:A'L(<F*%+3LMA==*SV*U@!/PA!8*F&
M__KB@"%.]A,",P!JL!!3:&Y*.0``JGU=4?M8UF+UW%\9\#A'/71"%@V`@M0Q
MV'@`3A1NVWX3['5`0R+4OLQ7X),5A4V]M:4P(Z@(W!F;DV_$H8:%^=)<])G&
MF`9T]R:A,YB5VR@-X1O<1S*F*H/Y6T+2W8H9?\GSIR<;ID\Y7PF[/X8&EN,(
M8Y,+)FSESZR!@J)B2)G/\S:G/@C0XC/=)ESI2'5'J^O&F*FW:/OVV=+92-&4
MF5EZ\070DAI<1M=P`3TL6Z*L"%[&,Q!X\?QO9LV!A=:K:T`$Q*$4C-NS5Z]7
M]>,?8`K`D,(H:0FPQRYUZ)8)6@'Q@ZGI+7<(0^`>:LMC=R&@(<&59P48EL-:
M+NP$<P(,'>.D">24:6.09+TSL_)NXI9.3Z"I;"MK+VC34):>S(L"%TB8F`XX
M#:\LD+$4NO4,+HW3LL.-F%#7\ANICR2E+^DJ<"$P]<JMH9,*O!O[6F`*W85-
M_6$8&O-2@*.]V!L/$PO:U'(L]NJR@%>BN*!GY!CM/@$[_CEXLJ`-:BYCDTNY
M@DK=S+>)2Y''(UL/B<D:]8&HMV@"Z-D\GB0V0TQL`5"?>I]4=IDC]FH&#N4E
MF'M*!THQ846P6!\QO1&[CBL?S@G_'$Q`]5#=Q#9"J%M'^L*K3PE/O;8^97YB
M+==%$[+T=&,^8Z69QP=5J:S2MA,]3Y9,OQK8$,Q48C0+NGR@>F,:[VRX[RN5
MM-*$4)MZYDO/FB[:J//(T`]8[(A-U_I`UG<A#(5&'`2$OO^[.Q<-6+TQY=#]
M]F@C'""-;"G&?EZI"KK:C%E^XH`>6\X9$9Y&EX+G"W01M%PCW%N13_U+W(^=
ME'C=W+L&+@.FN2*F34?1^[[__^S]:7/CR+$H#']G!/\#SCP];W1'0#+W9>;8
M$6I)/99OM]1/2^VY?KY,@&11@@<$:"Q2R[_^S:4**(#@)HD2E[KGVFY)0"$K
M*_?,RJ0OW<KL%HE*Z7+!68.?J#P?H%:0-"EQE]NCMO)MYOR]6M&80J=46XD5
M73+3QF:Q!42=HHOP@B3M!S$SY@,J%025!#WK;D"'<^^`.(9?@<?_0S!'<$@B
MMWD-Y]$\8>."P/`B\)7EPR0+DXAU#2HBXBS,>`8^`2'&P$8@9N`Q4G]T$G-P
M/A)#T!JP)KPDR!\%)S3S%EKYTSQ7#_D"%'KN4'T"ZT\AIO+XRCZ'CB'VB$B"
M)`*8LV\RW@H'<#)$(6W5^\TFNXV82$%!-6,CY%_*60:V=(#(LG-"D+FA4C$C
M,B@>[D!'H*^O@XUHC+)%B3+)/Y_9G!8ST/Q[LM6D=(1U`A3XON]B6`0#5TKS
MHM0#TC2B;*DHN_!9#K!!HIO%H(\\HG624(MH#Z67C%[@-\<AQILBT'[NV,T.
M=[$$L/%47;2#LP\'`S+F18XYZ(C=J,!X^/_#?+1LEM?<,8=KD/-]XOM[%["C
MX#L__8"+P(\J#MJD-QOY-W-O@1K`UTA^@YR<2E,3UYLX8(8GD]G`&]CP$S>6
M4:Y!*D)T1H!%[=QA*$M1%U53YS&-72JG`NPWSX5'1A3V&CD3YQ:^""\Y9"_5
MC]L_DP\!DAP@?@^^PE%(CR+#.?"""^(#+`38)QHA^.DII9(0?@_Q3TK)L<8)
M`$2K?$BY+O.?4A\G=5_8D$*;6OUME`F0N5(4P0#J(Y:?E:@HO#BNQT$OF[0'
MA@Y_H$-DP5[EE^=!IJF&:N6F!-\@OX('1G>4P/%*K9A$Z:;FR2R*Z``X$XX-
M`M*:-3+3R`F^1RGY".H2MIM["KCQ`2A_.'0PSHOZU*=3J#>.^,SX..;I-#3.
M6:G=HCY&1>S>WCZ"T0=N3EY#LJ]2I%QRB(E.R?G(N5VDI-V8F2"C0T%%OX*U
M\*+3E'Z"#`THKS?'WK9R,>!<81MP<*'@KY`4&B<A&>WE'YC9#2R"VT$_2?)>
MY/Y@JE7>&,F^5%V.I///'A&`B;'?\H\=>H1UAW4>IKHP.L]Q6]8.:#Y/G'\'
M(4;<,:.1"52IVN;%2VP94DK?1B:/W9C*JUA"R-R\<N%9;E'A?";R,S&F&TBI
MN'(R14E"Q"?/DK@O5E*IX!,H153OU59#(J.I6_OY5^N?Y]]N+DY//A^=?+[X
M[1+P"I\YBH,IX2^^R]$^;,7!:`J*2N4/8.K'P\@4L6+"\6S8S0#V"/\>LS]"
MD0+=&H1=3::>3-GD%*"T@[/=5BOE1K/:=:.U';OF3!GN&P4J;UR3WMF_3NCQ
M:S&-)6'64LJD'8=!<GNGV=?2$$+!"$OFS054`ZA6`*/2#=5D-\`W8`^*?JF,
M!*GRL"3;&B6`G32UA7J50JIH1:!>4Z^0G)9YMR$FT$:E.YM1K*@^4?1KOM5`
M1&!):AZ6,HIT+Q1V-0&D@U[.;*C,8F)[`B@*Y3T*`E(X\#D^A2A=1KBD1/2L
M86J`P>[@$[@K]C50HP1)3*E$'/DC$YRA\%Q.]/G6MP3@K[=:F;.5"PZ`X[3=
MNF*[O9B5<G,W>D0%"\"1@KX%(WB!&6.JI#4(4F6=*8ZE4B+@,G`;G>C.&@N1
M&<SO&C7*N!$/RM!&&F[4@_GU?L/N-^MZ@F\F%?`>*`Y%15G8W$JCYN@YHSZ1
MP?-\Y/R#1644',ADBT1NQ05K?73O1D'XB$*5JL!FS;O<GF>"-"F6T)87_O`Q
M4SO`*/$#\@IC-8T/2:3K]JA\`GTT@05\'AMPJUB?N8A3(=N=!OTIH90B,&7N
M-%B:-XVU4\7(MA)4;(P"QR=#98SFLREH]PT%7FHKVMHR9HM153U8/">ZSNYU
MD?XHR%ZO-^Q:OT.XG(5MS8"ZB70LL?I66[(D0\S=ARRJT;-^EP><P[<UH_7@
M;%I,+9J%P$HW2B83!WL7H64)S#MACI"L<.N$Q"UZ?9$F<#)/OY!EG&,\%&@7
MY,F#H"@KV`^YDGEMK?0+65Z%5I\I=4#W:H258OWY(=;Y$K-KUYI]N]697Q3!
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M"?HWH2#R-G)N2^6;>"(]U9NPH6&`5.WC[:A7(*<A%=-L'4'QK:D,\<$X^S??
MGUJ'U`X->Q?2(LYP]ATL1H.Q^1@[EUY#CN(,ON8+_,P8,6B:CZ92I^"`]>)>
M;,(H]Y<2MD9RS,715PS_&;'Q+(YKY#R_M9W=E\FBOEU&=DLI^QS#U_JU,L`*
M7AY_,K'_)>?3Y_W[=1SWMR5U!2EF%;>7(5?4;7."(F\/]VY@=S>@-#3PBMAM
M;)G$*@A=:W`+1Q^$?_WI_SD]_?3I]/2G53:U1_%36I(2$-5*SW[:M<$5"79[
M:'0W`&MD1$;9Y=>@LNQ#&T!(FB`S]+0E*F.'9=:[ER"BO6,QK+G9-^Y:8%'L
MQZ%1113F[+DDZAD^9&;./-RYL3A(8^9:A'1=]J.5SGZ2I2Y9*4OSUV(!4TFH
M^RE<LTVF[FY#N7>BN6TW^XU#I+*-8M481<8H6H:5>K]^W'@ALVA+6>\`;*3'
M:J7!UU=?Q$`ZY'B/,I%.T[9Q+\L<NR;QMQ#*O1/"/;O>Z>^U#-X39MAAN6;,
M'V/^&//'Q(=6,G[.B_$A8P-M&91[)XD[-;O9K.VU)-X3;MAA^6:,H#*L]/O'
MK<.S@?S@(72F?_V)_W?/CE1=WTTS9VN=KPD,E14");<)MBW!*]";*@/:596P
MA5#NG90&1J[W6WLMIO>$&W98R!D#J31*5*L=]U^H,F]+66_OHT0;LH@.-U;T
MCP2G@&!'$^O,#;&GD^H88;VO?W@99MD>_M@-P/9.\G:[=K?Q0JFQ+3VS+09L
MG\25L6Q,3?2>')K4O-U-!W:><-U\WXR<-`U6K5SX>/D:&X?/[P#R[-O[)4S%
M[[_POJJ5-1AKS1O[K[6'5]K!WLG\>JUMUUKKIMIVG7H/`O!]$KWK&FQKHVO_
M&+MS7.NL:\[M-7L84_#5(UK;X0/L1M!U!Z%L;).GMX/X,U!N.-JYA7!N+3;W
MJA_-''N@=4#1BIL@=KR7L?]:*W@9V\)TB[Q[V(<U"I*!)U9WFG9X-WOGTRQ9
M4NZO:S<;^)^2^O]7X83M(IT=WL%N0+DVGK?04ME]6GF"PM]J"^<O-#A%^_F`
MACJM-/@-RTH*(WQG1ZOEYX/1J"UG].\DDB.8>?+:%.N`:/[/O+E#4UG@F[7"
MP1%=GN#QR5:^*V!^(I(;J<_3:$8:.N@,AT%"(WIITC*._!H)^H1[+ZH5UX_B
M,%%S<T<B&H;N@`</708`1>.P1WZM1!TXZ/6+\Z@F@-M6O6?7V\TY8YYX-%8Z
MWPG'S\T2`0Z3HSG8^@"Z\J%2:'[4:_,^YL09X?$S<X9HT2`ZSXDBGJ;^KM6S
MF\U^.FU9(QK+<YV!Z^'L*9SD+.=?X0AC'(EXA&3M3%WP!WB$7JPS2V%^G2&N
MU69.9M/=Y#$3#<$_1'@O.7N<Q(FD*YH86AQ?*&?[6<$43RN2TP`E0<'[0(7W
M(HSDD$(<*/;+RQW.,]#Y/T='YY_HL@./)3PZ6O^@Y9Q=7+<`"4T3TW2[/D!L
M]M7UU/%31XK-^_ZS2R0ZK>VR09X\5R!;XN4@E[\H:T._V>W4#F&01VYDY-.\
MXUEV7'<:1>'>W6ON_^!9XJE#-QHZ=W3VE#M6"36I6P09ZIOU$DXR;+5"/-\H
MTOV6&H>A4U>1&NB/KB,D#@T_[Q/?2<"!%:.2>T-&EAIA8X3-6L*FI+;7<)'A
M(L-%ZW!1K>3:H>&B=>WZW;'==V:`YHJ\NW6SVN8%5-^4^@V5&"HQ5&*H9,N+
M6]=1H]N99ET)>4^\6;N<W;:LZFH=NMT8NSW%K]`!9YS.@[R_0<@7E'ONG9PP
MY'UPY)W-8FL=@B8T%&XH?+\I_`7NVNZ;I4=3!:H560=G[#TC+A:UOK4[S0;\
MIZ0%Y][)"D/>!T?>W4[?KO=*T@V&N`UQ[SIQ]_MUN]LL&=R]=\2]\>9Z^V8#
MGM)EA]@=>*):\8-8;**CWL[(F<4I^U^M=>70SFUJ)1FUB5TM7C(O?^>XK$^0
M;%M8"O`ZY:Z&_[9S4]O-?^`#MCIVL[NLMLTPGV&^'=S4=C.?47ZO%-'==M]\
M2P`UKOGV(WS+.-:0MR%O0]Z&O`UY[R)Y;[P5Z+[%5JD5:+7B)]3N(1BKEC6+
MNM6\3/1U$99WS`'-VFWNDP<Z;U?;[8+6:W:_W;?[G4T%@);1[78)1,-_AO]>
ME?]:=JO>MMOM9;<B#?L9]MO)76TW^\TMHUC-9)[?6Q;_3__-__XEB8YN'6?Z
M"Y5H<KN_Z/P_B1L_7@:Q.'.CH1=$8#?>B!_Q1[1Z_U:M6-;_JM=.@\G$C;&7
M:53R+'8XC.&';V+\UY]$X/WQ];S3[+6:G:.C>OWZJ'Y4J]7K?US?G/W1Z#;_
MP,8IM7ZS]D?MI[])4WQ[[?)EC23E+THN6M=;>CO0TZLO7RYNOL!>KI=8Y+O>
MF),1=/.OSX`A;%7J#K4/O3".OX;!5(3QH_59.-$R5V?7$?M"[72S?H%M;*I;
MZ]K6J?`\,8R=T**^#=0\%_O/6L#!$X#@#K0#X!?=RVHE&(^Q*S,V.87O)&-G
M"/XF]4^=.D-A4X]<X6-G3BO[%%@9.%:\UBVVR.6%IV%P[XX`?G1@L8LMEY!C
M$UP0*P(^%:MGJY7$!^$%I!59PR0,L;TRP#SA=R-QCXV9T\:Y5OP0'#T*V!D]
MHWV]6OF&K[J1]:YGU]HUZN++FU5`C-TPBBUZVV$0?$M$0\=S8@!U\%BM-'^F
MU^@1]=8H"9U8]GK%G_'#@,^AEV!W4ECI46V$MD9M88O`::AQO"@`!Q]$-7KZ
MU,7:>:2FTMAXE@#V'JV0?V&]J]OU5HW[44\!JS_<"0`+#S3M5JUF1?])L#WV
M6`A^7?R8.@P!'5X1@MSJ:G^%=P"#U<K8_0%$D_BQZUE1,KPC)8E=K\M?L(+A
M,)EB+V0GMA[NW.%=M4)OX./TL8<@\9`*AR$A`>B`6C?+\Z:&RW(K01!;(3;U
MQG[/8CS&F?5,(41'8`"X2`>,S%(\RR[-M!'`\30`8+%7+6YX"-+%<7UKD+@>
M'M]1*/#T1T#E$1`@[16V.95R"+;A_!"1#<"`@L3PBTVD$XJI`\0DF0:82_CX
M1QT2HD9`%5`$]@['H,XPN/7=_W)O<@>D0.B@-7.$S&\-G,CE];`+>8BPP4'%
MV-%XY`(6`$^`ZH&('[!3.>,5GQ,C1K#\DB)L"[D8T(3-L;'9-%%8E+4Z3U^F
M3N8\/9<7<J@QMG``$0/@#/@J-F%'`ALAF^A;/$O2DXQ`U+D@1["?.AAG";6O
MIC-"VP3V/T&1(!@*U9![A+R%/(0KN#ZP.$#<9/;.SE=M":@!S))@X@Z!7H`$
M0$O@B?I!+&6*6DF=+:]A8S=G'=/EZ(JB8.@2)>31`7!6*X0RD!/#A(D%=@(B
ML$MR`HB#*!YI`N-VU'0<A4WB>0P_,F8J[FQ==,`3J<Q8VN!;J2ZC_/1VWQFS
M*Z%*$P1",8%#2MD=J$6P%(?C4MJ$V*U`FMR&'4X-A(PN]"4YWH%\H[60<ZQI
M$.(SJ$)32<==L8O"]\('.K50E\48XT7*0/$',H>BO@D*3`+9\6R4H:1S0R!(
MCZ2U$X'NPX51,,(.L'D\Z"M:).U)+WX,!7:C;[?M&JB&]UDYR.FOIZ`\X&\G
M$YQOD/WA[-</+'(`@0[]C:4NK!1%:NNY=R7T`Q;MP0!.6<=3M0(28^2!:)DO
ME'/G1,*33HC.BD1(+`BC(S$-(A=8]3\HR*2<R0.CB0_):=EA`=\S7ZJ-@72_
M"QY\%'#`IW'H#DGN@X#$"0XL,X<,)2P*3,_2SR+A9]KO+^?'<U+6-"KC'PD(
MVCK->*@M,$?)NI,6:68\P2F",9@:IFQD()D*]0%+=?BUZDW^")PR:``QD@:*
M7`KD;J`9'2D?9]]R<L;E&-9F<(#)0$6X(5$"#JQHUF>GB%R43R5)5[?I1VET
M(8.C(508=3)VQZ#(P-@82HLO-9E&H$1=$`,CERP^T.*ABR9;D/](JL(4APW)
MU%(R3-^V$[,B0OL;ON1(\Y@`K]>.1K#-A]"-86'4JNZL_2BM^`>'+"OD6S&R
MK10N'4\V;2X)X7MAB<T?WX5!<GNG>Q0\$J2!"E+:0,1^*5KSIA\L04Z"]#1&
M+)M!7("M0X\G/DG)U-352=*2G\>C!5-$`WI`9HD<Q9%^D3^5DR[6U$LBG`F#
M!`UB'#Y>K['WX/A^,M%1=T+OIC3;3!GC78MD-4@JI(KA,.0Y)S/"R,K)HM1R
MU[98K4C342[!4!FAM9('37."T*55E*MQ$Y,NXA2L@[QEJ<X!J6CD1LCOOU]8
M=\(9H2L#)Q!9\\D\,_.!49@MF<I<OX3:B<GIL%'[ZJ1-)HQR8LSYKWW^GRB[
M#HXW^!^39*+B%\IA4IXG6`]^X!\-D0L],L7DN>"[><_\7;W?(0L,S^Q=O=&B
M'Z2I@@3&9X9$8,YGZ?F<@)!UT&!+O%0]G@S!@(Q(:>>9%;RX9")RBL:Y#06/
M!D-NO01#WPNBS`+N_VKES`R<Y24>8ESXRXGR[,@'=-C$9#43L>H\B@-IO7!0
M0`9U]#`+<+`B)K)JW[7M9JUVV`>_4L;E&VDUY:>C@GQ7;S4UQJIWZ0>E#'WT
M[=EVLTAB%R:II*PG=2]&AMB:]!Y!$]?;?6WM7HWULEJ<''U>=E:/RT5K_?RB
MS.;O^JSC>3H8V*(BC83.++3O5/&:F813.5?-)!)6$K.G'"@!A@,9-IW(2#K)
MT)%4@DXZJXY^71K=UN7MC#@$*\L?NE-8`!DFM9Q378O2L5'OLBE+WA<.Z?,U
MXXF=O=:,6Y+$4>QP`#`+25#0=2`HT#;!2`U&7I.(?K:Z/V<`4+0Y-?S)Z@X=
MNNX\",*09\F%'/LT=+3>"#X.AZ79('(^HY@LI9$J;%26%VM++5@MR<[S\H2'
M,QUO!?F5VB!0BKQRZ#F-Q_G@*\VQZYP9EXPLLMH+#O)[PA'G:F]FU\\=<J.[
MXBG+>@M]7-]ZVGCEX7SM_'"^50IQ%ETH:[>WM2C^B=<YMVL33YT^T#33![C>
MYPN+EB75/@<],\@KM[X,@A2"E$):!T?[+)3V8A-&LCZ3*SZ+*,K0K@QUPR-[
MM`G#(\_DD:_L\F28)]_'Z-KY&`O&&;+`-32HFH^JB3%MC6EK3-MMF2#3SD56
M=H^0:,GR^;HKM1"/@^FVGN\:4&YG6'<E;+Q[B8-KE%VLVS!2-GJ#KV%W:B7=
MS@^(I'<#2L-X>\9X[4;3L-W60VG8;L_8KF'7>NW]8[P7:!.Y+P9ZR:R^YYSN
MMO1/V`$B/"`A<J!&LV$&PPPS,[.Z!VG(&E8PK#"K%QK-0S(N#S'^>Y#";INA
MW$,I<J#6I8'2\$*1%PX\WV:@-)Q01$C#;O:[^\<5ZX0PGW@38Q_LS]::)[\*
MJK:8*M:OMMS?S>R?3%N\I-P?]J-=U@SZ,%A@]W=@F/A`F;A5$A<S'+R#.S`<
M?*`<7+<[_1+C\V"8>..3H7;GKGAKA2/;EOS8(D[/)C2L3H$[7!&V&I^7U(VM
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MHL[)"(P2=&V\*GX+8^,[7J!BJLA>),UE"LM>O;"LMI%;A+O'M[N_`R-YC.39
M'<E3K]F-EJEI?5)-ZY*ZQ:=01CFG\/Y>9S+[(KP=T(#Z;R(6/D8EK1,U,KUD
M5)(I><XSW2<U6KQ:P0G?)\/_)&[D(AIM&OE]BM/;_4?KSHFL,,5P.I0^XI'A
MPAG>6<&X6G'A-^,@":U[=\A3Q-T1/H:+P2M8$!TE\*R^@`B%)7Z(88+AY<%C
MM7(9W`LOB*Q1$N+,<RQG+$ZHU]Z7P]#ALR%!["63Z5&43-+!Y_11]X<U`<S=
MJ3&8L&C_5QI2;T6.YX2/EN/#UX4OQKB'..`](;`X_ARS[*&5S6%WK%B$$]>G
M,#CA($AB:^@DL![`X5BX\UOMS]7*;1",X-=.!+\)AL,DI,WA#^"H"H!>6+AQ
MJA6OMVS<=EW?]JD(8\?UTV'L)2B([YS8<OG/C%'W7B@,3Z9>\`@89F@4CKE(
M_6H8!_1=^FR-CO[1>@@2#T$>"E@&]J3A,WX(JI5E"(T(#XIF!H&?1+A?@G+D
MQ.+8HH+[F4?&UKL.V->UFO4`:TP=EXKK%8P((!W6@^MY@+EJ921&R1")9PS:
MA38?B7L1.CZ0H#,)$D01?73B/,(+PV!"@^NIZCR9(CE7*U$RB,1_$MR>Z]\'
M'KR$>]!.N4B"<0`"#?8W@4,A_N%/S?T2D)3&4#K6HNRP4EJ#?2=AE#BX(+]8
MRGTNX'@*Q__#G0!"/6">=\UV#7%WO$3V*3EF)*$JI0'6^@+'5N\Q[]GSCVL0
M..$(Z73D`G?$02A/X1YH,*8[)'X,Q./Z<'1.V<'EI*;5AB<!9>XH<3RFU&I%
MYUE!/'$J/`\^YH!TB0DT-*HL*0PTN:W1:;6RHJRT\J)R.6OKLG*.5(0]+!>+
MU@*I6*W,B,7>K%@L[%#\F+J%5ZH5?F<^/^#_Z;_YW[\DT=&MXTQ_@>.?N#$M
M?>9&0Y"822ANQ(_X(Q+OWZH5R_I?]>REB$^=Z.XKXWCT\?%[)$87_H4/,CB&
M79T,@</AB.`XAP`&+/)-C/_ZDPB\/[Z>=YJ]5K-S=%2O7Q_5CVH`\!_7-V=_
M-+K-/Q#Z6K]9^Z/VDY7X+K_E1D&K4>_^\?WZ["=K)(;`_UZ$-U[^5F_TFZUV
M*]O#ZG#E]X.D+_R(#NO$'YU+8OS(Y_[5<_PHQ<23=_0W*2]*A<=R43'W[M'S
MA8=N8LXS0^<(&.6I=71"/?_R]?/5O\[/K6_G-Q??SK\`R!9\]G)U&[6(CN+F
MUY/,;XK<M3")DOD?CI^@Y"$+I=:W=7$X"J94F6!=.V-A_=T)!R!K1D"D/M[&
M0\H,W4%",F<*5"NO\UW#V_BK5JW^_L\/2I!>X"T&'Q3[-S`A_`05P`@$^L.=
M"[)Z"%(EA"\)V+.+.CT3T`]W@341`C0_3_H%F80J&Z1RR)()[`,0F@Z*2EAA
MZH2Q.W1!M;"QF0))=A966*`())!<V*$/F_=P*QE'HHQTT,(^BIT?*)S=*&\M
M*O1D2X^LYL]DI9/BT4#(:S?]*[DE-41&8.&P'F&_X5$XH`2%CQ<AM1N/=F:M
MX:FQ)?JNT23C#GX+YDJ[@S_8J!FF>")@ECZ6;X0,06>$"([BT,%'4=P#J`*P
MJU0:G3":D$V[R1^!#]H]^*=Z8AZLI"<R8.>#=*,^@^;I$,U,#XEB/.:'JY63
MY#:)8JM9LZ7S\D13[%`9?AVGU%&<;LUA]&IE#4ZWF-&)3:.4SX%C5F?T>>RL
M'+>4GZTUV/DFVW6U@MOV@YA9$/$`MO_P#NVF88Y%6<[%=RZP!^)C&1V6FC\K
MFP!%XR&*(WQ%,NA&39XV"*YZJZ/#G?]Z'K9O0HW2OAI_#OS;&S!:3_ER]V>\
MUWTU@'-W&(<;M=3:K7X&\QI0Y;=S)@9QB7&Z&9-L)_RY^4'"GLY4GZ\N?SNZ
M.?_VQ;J\NCF_MKZ>_.ODX^?S@PX:KG;K1#?(V"+KZ189706EE@CD`'N!,^/[
M.N#=.?Z?*"S!6@N#!RN9X@_OZC:LQ@&,O/CCQT#*V99`1P;4+H<+'12&PGJ/
M0CVS9$Y__8CK7\*?LE^>_?K!QH4$@@8@@I(&9QK<4B<69!EUCVOUGZVI8!D]
ML8&),`8VH%@F&2#*J07!XG@QN\(<IJ(P3[7B@J+I<;#1>X377!^-+(\>3+^J
M6)TLE4;-;C=J&EY`^Z`*RWQR%/)II`E$"T$R9^F`XA@A:+$&N\L-'9,7/D<'
M[^7*H#R=Q*-_RN]I!PEVK]J^U'`C/"-X$$\5<3:\<T+0?_!'``/^U/Y9JE>,
MR@%Y<41-[03AQ*^GL#+>&:3BKK2/PV\P1$#G#39LD3+2@V:##(P'6#:4G3J0
M0C"X%X.=ZP)F'U&Y6[)%1SZL@O8Y(&0:@*UA.<,AA?-<G[<CHWMX7NUR`AV"
MDZU]'6-S0P\^Y(Y=]$XBC'2"X>I2J)(>YK7I4Z3:\7#A]"EP&=V!D:%_XB0B
M"IUO7=O6NU:W9O=;=;9Z.]VVW6TU+0?(O0`(\J1_>X31&F8>%:1<"I%-NR@U
MBZ]\ZP1.S[/2`)H[F8B12X%)/%>TOP/&9LZD*YKX>D`3MM'HDKN`_542#\@"
M3B[V1!J)U@G@F&US26Y(#60CN1A.(EL(Q-%]X&*/%G^6!RARRT1WYX!SP?$H
M0AF'KB2CT`Z`\OU;BK^1T15X_'KVSDR0+K?K9;;8?FN9E0.RUP)<>P[DM55N
M8HZ>&7)^I*!M(@Y#TEG\#D826$_PS)E`[U>1$`;Y1`@4_EY7'[^?79UBGB06
M44Z!:"K+D4D`%`JM=JE0P%6(-",,9P+,NN)I:*H&Y-RMZ_LR^HG@CE@I62,W
M&B1A1-O1H@BI/POD*\*0P<A6]W4%D:H;$&$NL!#SJ?1/V^OJ!_41\&@DI+.B
MWDTUHJ9A4S51YYWC;F#K^O>_*+U94)"=3ILV7*[T0"C<H5@?XDFBK`+`*);/
M&Z1GD4U=]/-PF4:3@4%U#:K!\[1D)NX(/$J4X-G?YFEA\*S*U?`H(2@8TPQ'
M=T:<I_&':J69YMX4*<TH$&N)V*:+.G,UB9$W2^3-9X7;:@61FQ$P"8V(:9&(
M(TMXS!SB;O?XFNWE\FH=NOJF0]>6UUV9KD2F0Y?A!<,+ID.7Z="U@S?_37<F
M`Z6A`=.AZY5S)1B;Y#"2;7%V084(UM1S.T``IF'0RBC9N\M+,MMPT$2]&U`:
MUMLSUNMU.G:[K,O$KK.>:=:U%EK3_!9FB<L27+:6?V@\V1#9<8?;].398U&X
M2L`)YS]3@NV`HT[[M`/#Q@?*QEE91JL$OP?#RYL+N^R&/V.@?"*4>R<VZG:]
M8:(0!DK##R8P8`(#Q2[>5)B,)9I\'^VPC"3C+NRQG%O-77C?J+7L7LUTXS7M
MNXW0,$)C1:%1[]?L;N_-*]0.16B\30OO'<9NX=:"NK1@PWN4^]F(U;<KK4)-
MCU_3XW<7M4Z_0?=X-Z!T=H]S=W\'1O88V;,[LF=N(=_!R)YG-!@_P&NS)Q%U
MMIKI2V$7+BMG]VDG3IR$(J).%'R7-GK!:[-/P/.2MO`Y3#>ZR_K`O\)EV6[A
MLNS3<KZ]]M[H&%KR7]C8#YOO%CO[K2F^=D!$F8LLVY)>>CG>.NHO9:[^VS$7
MP_X_1T=B/"TV%L!N/R_+8YNU@TQ-O:FI7X*5N;FB7=<<+U(MMG?2#=OD';8$
MVT(H]TZHR/9\!R14#MA@`I'RPG6(1J08D3('(7-JX/=6KARZL=(RDF7+H#22
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M.F=>Y4K#U*^F`B?_OMHP]:-6J]GJU+I+IZF7`);?T-=TN.<7$=Z*\)O`.7$C
MFE3ZR?4!H:\X(K[5SC:T)F#Y79T[(0Y#BKZ*\/K.,=-'%]]WJ#>/K4R;6Y?G
M-];GJ^MKZ^OY-^OZ[R??S.C1%=II1^ZP6L'+C2`_(IJ?%B'ED5@#&45SS@>/
M%NS.)1&6/@J_1+'X(-!<Q<GPH-Y"G-[L)R1:04;22A$/]9N`00"`(RWK$G%$
M=@-+1?BX&XR.K3/7H\^N!U6U@L_:I%A'_TXB>,160$;)1"E,!:\U`RY-/2N#
M5\W9'"%<."9]"EJ`QE_FGJM6<*@G6+8\MOI.^/I.]6%E7U=X7T[)(C0RUJ8\
M0ED.7P/H8QRF34I&6[Q:N791F\08#$1\.1D>G9C'65-%/<W5SK[.!:A1-H,>
MK3AKB14GAV7*J9GI-/BRHG&K,%R3!Y>"!1?1N.[Q`E3(*9I\\#S>FX?U!9&P
MF&@B2TTWQ2%XL:N.ZA@,I"'8:7``WJ--@\"'!,1H$8TQ`B)GPM/M<!2>^LP4
M"`0'OXP.V]I:Z2K+#3)U-MTMY1KO,6.E2(!MRRJ:[..!`+81/]"RA],9@^CB
MP]`/GX8XSCV^2)&_&V8$IDV_U<GCS<;+H7QRQX^;POPB'W>?I]2UMJ_MXA-V
ML66!D&</YVHT]#LTG=>(H6WI<*Y+^$>U0D-9HPS]YZ@LLQ]3-9O]"O3M.I&X
M0T/K^\1WDI$+"J&D.<K+)H!VA57W8A-&WCR3,6X>A'<O,L272QXC6>8B4'DP
MFB@NN_]J9,S.;N*I`T=K9N`HL\AI,DD\![TI(T@6"9)[X053#`T?&3S-Q]-U
M[-QJ"NLKA5T6<;5!G4(=!DM6Q=3F85[)'0KN6;N:4YV+HZXV9:I16Z_=[J'A
MZCV&_BA,OI8?>&AHBN_"(+F],R@R=O\:)O.BR>HF5+MMFS!NS7/=FL`G5&'Q
MAI&4\_%4WJSHD`3CGFW"2([G<\3&9V'N"C'MQ28,1QB.,!QA..)%.:*V\1DH
MNT),>[$)PQ%&1VQ#PX-%5WA+0R[;65^Z$F)/LRIHO'`UB%^&9`[Y*O'N[J9_
MF#=U-SRT?5<NZQINWMH#,=R\.C<W[7:K:]?[/</*AI6W[T`,*Z_#RIU6QVYV
M-^'4&%;>%>+?V@,QK&QL;,/-AIL/CYN-8EX0:GR97H'[%FC\W0E#QX^CS1/)
M2O'RIVPAU6*O(".-6-Q!L=BUFPW\SUH%YOM&\3L+N&'5`V+5-_1'MHKH=Q9P
MPZV&6PVW[@K@AEL-MQINW17`#;<:;CT0;C4%@VNB]II[B\I.JJ\7\C6YCVW;
MS8'*RZ;=:3;@/Z:^R+#R%AZ(8>4UXO7=MMUK'_*`'L/(6WL@AI'78.1.WZ[W
M-G$;T##RKI#^UAZ(8>35&;G?K]O=9L<PLF'D[3L0P\BOIY%7G!R)_Z?_)ILA
M-G<,6'Y:V&?7&;@>#4\YB:)D(D;US<TYN[C\]-/?6LU^IZX-.RN!(`_BA3\,
MA1.),\'_>^&?B;'`88;:JQL=SM:I]9H9P"O!D]\"G<!'>'9T&DRFPH]X",U&
M86ZW.^U.!G4Y"`4PM2%.Y_])W/CQ"D=`O=[@NSD`+*,'G,^4^''TU7E$1CGQ
M1_";,'D]`CEJ-NO-=G<1C:P"8WZ?OSFN_SF(HBO_VO'$U?AK&$Q%&#]^]1P_
M1NQ0)^C-[JM3J_6S7:T&T;+3^B:B.'2'.-#0B>XV"W^[AO]OT;GDH<G#CF,Q
M+WSX>X+[TEH%?!2^&+M#U_'XES@>ZI-PXB04F]U/H]WM=YOYP9WK0IC?XS<Q
M3:=-?@[\VQL13G#5S0JG;KO;TK8Q#XB9`:1P?L%$(`UNF&Y:G7Z[ULC-&,V^
M70`K\`,U:I2?.?^!`G;#I-!JUYJZ@)\+1D'ABUO'^^+$,=`$""&@#GQ!^$.0
M/QL:%:K9DL\8!S:@4<GI)+`5)H/5:UKN<78T69BS5\L,WM\OSF[^_HO5Z$Y7
M-EM7,5.?DO9]QH33]M)YP'ES/[_3YWDB3P?[\\7-Q6\G-Q=7EQLPF]?T/M*-
M[]EPQ4]JKB+/1]3F@/-LS5,>,(T30*<.Z'F:]PD*!LP`RT,Y8DU8D-",\6I%
M_'!Q9"H/6L?&_%X0S9U^?FS=W.%LS!0$L/TG3NC^5T0\;S4&;17QR%4<TBD_
MM>\S,_F<;O[U&0[*C>'IH?:AIQ]UM7**`\8MG!H=^'N.PQ?P\D^J%9X5>@\T
M*D#Q`+%K<T9I6KOE#*4;-YEZP!.Q]>!$UMCU@`5P7.@7)QS>66TYME9.H/WN
MXXPYZQK6AG7.7+8^@=62,)8C:47Z:YH2_P4^Y0SODDC$,8U,=GP<)RMN81D:
M5\H.$W**Y#D;Y\T/Q)WCC6DF\9T[B03\&X?6XB#:`)VJR'JX"ZQI`C"B5VC!
MI^GW#RXPFX-\"AZM6K%:R4TSEGOA@;;PI?@!1ZZFHWKK+=QSK4\?_"0&8>*$
MC]5*H\6HL"WG%M`5Q:F,P.=<V-S74$3N"+T:_,WIG2O&UOD/0#N>0[5R-0:3
M5H2V]7<G#!^MZV/KJ^--7%^?BWSE6U?#."`PU.=X^"L@N%IQIM/`Q=F[(,"<
MD<7GYH['D?7^8Q""H/L>3A"_\/EO#FS8L;X,S^!_O-$'_.6"!;(ZLOZO^#6P
MO+PY@#4:-F"#,0'?FO"DXQ(RTM]':3GS*)P+_.\$1U8#L+=\@K!?C/S8))53
M'-^[`4V1MZX%DVV]]G[P@>@#\7.=$??Y#R`)L`E16"!5U?O-%L_$YL_;C)X$
M3+EZ;7#4!E8!3DJ\6UJ>AD8G/E*D2R$.7WZ/M((BW(D;(?Y(\(_<:`@0)C@W
M.^11]TI?P,*W\.M(3=[^BK1J-8'_7-\=`D\"FS@>L<GEU3_!+&T0#_F!?Q1-
MD-31-+2\!%`S='R@G<*)I"3;24^$IG2+,>P4KVM*=G:L24";`+@`7(`^2N=)
MRS.#W2$BQ+^3$1!IX3O_<'SD`:!''GK-G]&HCS]#$X>QN&P:L)+$[P'AJJ\C
MWN%_6+`T]:6*$-.ANB'@,YH&Z(M(A&9+'Q-<B2^L1FZE=*-T,+13I,=;O+V*
MF)!#NH=X$/@'^9!4^T$2S\'"1S%TDDC(*>CT#IP?KB#?L]+7;#G+/4//$"<O
M9XN%`L6'&R<QK9?]`>AE*`2-<Q^`Q`%4P#^S/Y=Q6^&D3I+;!"136T-)#A)%
M#Z`,`A2G,\P;"J)QGD@/_$<+:,<SEP\),SG>4VP&1CSRV6K\9)6S$W-Y.?\0
MSRC^@8^4L`\(&LD_NNE@O7Y\_6GEL'"PV>3Y_B+&F<?J8)_..7$V9%,2>1;\
M>F:&-$D.W5%1-&3\FA&Q;H-DOTUU(NO@.HZX'\U#0"BFWJ,U"%']PH?4B"VK
MQ4*R7F*#;Y(B:`:\\D40["^ATOQ@>WBNN&>I0KQ`86U05:%(Y<H$S)28-XR:
MVR?M<N_>!F&01#A(GC"0&B6PU,1X&4_T,CZ>?$'K%6SGDE&.>X7"%R#L*W`2
M6`/WE*FJK+40#!.P>9$;/8&.KX6C^91=B03\_YU<68!MIFOY@_5-1(*,@\_.
M(`B=&$Q:`./]MR2*7(<]%<>'7]G8,-I#10*?`T49R@P6+@SR(Y-`I[_"LMF/
M9[]^L/+JS07^"D;NV&7S!?0$L`^I%OR8DE6:?99I>Y<LM1@4/IDYH06V=1C<
MHSU'FX4O(YQ2T^,7'8P""%)9`]"SL$]8V+%B,;SS`R^X?90V.NSVUJ?LB`/F
MHZ!_*<S>@=5.L4!!XB!@/8K("Y0]5",Y5ZM9[U&LZ,B0?X<_G:B%<\@I&NQ\
M=A*_`A0HFXVD0_!EVXJ2P<2--9/WT]D)0B+MD"89C+4V0`1_EWO(N1JN?R\`
M0RSX`#%(<Z,PN45L`E]SII%&$,DUP9KH]_MXS/BY@1.!UX,&0.Z@^[^2DPNN
M!4G<D0`B'O$;,5B"T1AWA<@'^P"%*A%3`I^?RIR014EX"M.#V8"IZ)0"T!B!
MC^FX`HOV3^NCXSG_#>ZC/Q_!PP#="SP0![I?RSQ`9P!;Z%0K"6A<+]-/@*@.
M.[ES'&-+CJVS@'#!7$)<\(FV%?^YZ#:QS?VG'SR`/KP%<Q3P"_O$S=\*GV(!
M*71$<$#+_M"=8HP@_UW)EP4;,S-%4I>X6DGW*)5P9E&"FKM.QN/`^Q/^EWSN
M4,8+(B'^)+Y`"Q..BSC^T0(K^I9H?O"8^;ZI-6J5$#%P!1@7`_3B4?D[0P`!
M(PU(GI'X3Y)G)>7PDP_CA.0T$H55*R>`"H\][UI[EG_XS_2W<@:R92BQC-*#
M@><J_0YGA"R+:OX6'@U]#(8$GD"[A3=-GR(^UKXEW1>)"'U!:7]GN$FW6ZW<
M.6!A$'(`^\`J$^D'C1,/OH>9]`CE7^&4,[+LI\XEP>Q'#R1]<@ZD#3SF/[)8
M%9F8TVP:FT4]QD7Q,8R7...Q&TXX2D563"287U64EG+.(F1.1H\/"%ZZHLH2
MU'4.^HJC3!3EWDX!).;-2XHR<*T%P$J'"*`M^LF(_M0^1VQ)=M`=MPPHP(A2
M1IC^D1)0RBTME%!&34X6BJ8@R"G+,"<7(KCPF5K*/BY/DQRP2//U](7%/8:S
M4.R7@C``'`6LJ"3]9:I,J3'>@4O,C!\L*,1,#^;(%S@QI?D@!+DVEAM)?PM2
M?R1@+V!%\R?\P/("<#U#('60.=6*&(\!(?;,1\J8&$_[+R@.\\]6*R[0-]H&
MHP1T`OSR-@B`<1SR77WZ5PAP..BGLR9&*H3/2AI4$B7_M3*JJ4N7/9>Y8.H!
MZD,5G(N$P&?+#G5Q-("=Z/SBJ;^(.C25O(&4CM(ICTC=!@Q)J:@F(-((+=>*
M(+YF>$U"C1'9<K!OYCB%Y#JR7&<Q-$*]<0?V(N)>`ESVXIW08R]!3G]U&3/'
M&[G&BN(J=5R[NM?.&BU,V,W5CSR'K%6A*GQ7AL[Q0"4M`QW'R"]E!Z=926DH
M+'>&)0(S=W9`OW(MD-ACYYYM'IW2'E`[*Z,UT`+),IQ(7\=#!35N%8VBNN*+
M@*+7P&OY6#\:$1:01GRD]H3,`DP[7N#G'[1SMY(O_#MJ.92JR-7@Y(!Y2-%*
M5A.`=ZSYNLT*`=,J#!"#0#UD<P!_IJH5!*DSC!=1.]@C5($T=GW'Q](?2_E?
M-HF_Q&.1(LM$R.H),9![9XV]X&%I:G6VR'2E8I)BO1%[J/#XF4"52#5CKU$Q
MTVBUVJU&7Z\Z6@!*H3(2R`5\W"&<I"SD@WU^#<"_VES9S$Z1_/Q"CL:Q=?W]
M"P#T+^OJDW5]\=OEQ:>+TY/+&^OD]/3J^^7-Q>5OUM>KSQ>G%^?7!RU65@^&
M.D..Y)"_D+$[6MMD'Z'Q._;(BL)H@Q8(0&VDG`,GI600%$S*E.8;B6@8N@.*
MCV`N,4(A)MC3%5XD'C##IW+`.5#PN4AY#RE<U4H&6-%027PG&5%&O'0;#@DL
M,A2#D*TO'Q`'9HH?WT46VV^9.=),]6&(N4/@;\I98>8,[:5L&K,,>P"D.J*T
MZI0\$BYA7]5*:]^CPALASQS:L^,N.;2!XV&."<CE3HC83JN`)"WD-1=YN:GJ
M2BLGD#I`:2XC#WA9Y=]'L]]!@LT*T7,NFZ"J]-SG%A`CITO2CRB/%`-FH3N!
M_\5@0F8"..2*H1<DF8OXB2)_.8;2H=5B$Z&8.AS5)*X,1XA-F9BFSX.YS(@+
MQ6WBY0,?6OX?GTCSD&!HH$WK8D'+>SV4<WU^FH\+(T[4SC)0M3T>6R<$%E"%
M]\B^U*,E3237'WK)2'!Y"D.D8T=AD`5,*+@ZI5H!7^;[\?6Q"LMYC[AS/(%1
M3KIQ>`YWCT!2S$4@1Y=A])B=?DR5N[Z,70.Y.[>"`[:Q+K7`+YC9<8D4QETY
MHW^#*TF_YZBV&Q%P2&X^;M231P/G$')$0WO!%T,111BW4:2'GC.EVE'(*>&^
MP#:<,0HQ")I2:[628P[-6D3'I\!W^*M9WH-MK"2:)>^E9RJKB#"VRW$_>I[<
MO5K#>@]')ZC9S@<4U[,+<OI5`;R^FD#J4]AU,1?B^B/2EL!7L'UI4\OU#UL#
MK.3W/#W56&(\:G8YELS=9L2=3SIK/;RL-)!'WC")1A:G&'G)EHMHN0C)BP@Z
MI;.BB0+28X*,A]5^]R0A03_P:^H530H'X:WCN_]5V9CL)1MIB)-S9$GIL!#+
M.6!Z4)W2%-&D0W$96%'F@,`Z]\)/!,M^&;5G`4AV%.9(IJ!)49=DB8F,A?65
M3UC=S6'3M#JJ*4OI)//6^KJ<(<L*1%G"IM\@-0UGL&VX9RGWD/W$E="/FK6$
ME2?HE8XR[5*PAU(A/$PFI-OO<P=PQ.2NR5IK5M2BC<;!+DWFRHQ9"8FX9)]S
M!7?TR\N=[?:<QJ([TJ^\NYD;&;,76IYQN6;%&S7]FMZT<&F[P#DM`7N]M5L"
M'O67(K(_B\CZ<>>UQ@A?7=]<5RLGEV?6^?_]>GYY?7Z]C"&*E^S?9,!T;_UF
M`*_?LN"%@.SO`I#;A<EU9OR\*K/7>V_)[2IPS`EY3<N^.,MOHI/%,RAU!=FT
M`7WX>@?[[F4.\+5ZGN01L]&N)_6^W6G7[6:OI.WG[JNU];H@'Y"D^XWC:BSH
MG-'$]?%F&GD7+T8'6RS=MA6T/10P/;O;[]J=%Y0O6RI25A^/V%C05GT?A<T7
M$=YB)'H81"\U)W$1"K?/S%K49PUV8E$>;97];(%*??9V]E#&=?M]N]XLZ;>\
M0=+>`E)XD1D3KR\,FYVW%(8W08QV%\E""KL+KDLR@M$(QKT3C(V^W6CU[$:M
MI&'F@<K&9T;8MM%KV2[,[SZ<6QO0WFI\[J@U\J;IK<]7U]?5RJ=O5U^LJZ_G
MWZ@MV[):76.(;#DC&$-DEM#?O[4ELM/IDP_KX,Q8/@9.8_D8RV>[+9^KF[^?
M?ZM69%&/;5V>WQR:BVK,G@,P>SH=N]'O[HW-4SONO9K-LVJ-J+%^#)S&^MEM
MZV?1I/,]M'[`VJE6,/CS,HIA$?9V*]93-O5LW[W[=8LCGXF_O32S^G:[WK+;
MM9()CQMDJ/V@OXU%EXRLQR4_GEQ?G/(5EK.+S]]OSL_0V;50^ELG-S??+CY^
MOSGY^/G<NKFR3J^^?+FZM*YOKD[_S]^O/@-_7UM?S[_)WU<KUW\_^79N=(;1
M&49G/%]G'/=J1EN\D;8POL%<!).,OZY6OE^#IKBX1-G_]3LU<R)-8JVA2$!A
ME&L2RRB2EU,DN[R?/13L]9K=;F&VN?4VTGU+(C$+AO3EE]OJ;@*K]\9:N;=#
MVF#'M'8H4M;\`:.[U1]A:U*L;WOOYU+$U8H71(=<VG[0.;0G>HGKX.RU#(@\
MTG8KFGA0-+<5M6H[+KA/L@Z%U*0RQ`EI0Q>TK"]B"R4Z30Q&0R:)N#%E.J(<
MNX2JUFAKDN_.R/:=L,;?_I;Y*\K,MMUN]^SZVA)S)TYR1^O[WE:&G5*;VP@=
M(^LA"/_46C`>L#EJ*OWV5``VVWV[WGVC0K\M%(W;W(VCU7Y3P0AF6[4R8[=9
M3S;;C'S<,J8P\K',J6[:[7[7;C3>J$V'<:JWH.G:V_:2/;G^>[7RZ?/5[]<6
M7;F]N/SG^35E5D].;R[^>7%SL?_=97<4SE*)N(V`;A="37QM@0E&\T357!=K
MD$2P6H0C!"<#UZ?N[R\F"[:86K<5M#VT@?JUMMUIK7L!?EN/;HO-C+>5+E^3
M<'CG1!C[PCDW[@\<FA1%@L<-40W"NZZ-H["G83`48B3GKT>.QY-Q\`V:4BS6
M;M>X,_[>3JC/@Y).[]MVJ]NTF]T-QO"-$W;HEA=E!2@I$(HH#MTA56J!/68$
MW5;"N9>"KHW:UTBY+:GO?^$$P);?G]!8<N&_OCJ//#)>CO\$N>EBG>63S$*3
M(M@^@6M2!$6YC+-0NO57)6TCLTW*=MV4K>O?B\BD;(T\WG=YW+([K8;=[*\[
M.L:(9).QW4S&]M/%Y<GEJ<G8[@"<)F-K,K8OF%.1F1)PAS%5XD91XN"D>+S/
M&4PF@0_?`IAIH,N#$X:.KV5;TJ=IZ(M=K81B*G,TQ05L6H%N5DP=E\P]SQ4)
MI65"-/=P^'RU$MTYH8A>(7%L6,@$,Q=/>.G8W7[+;M8:^Z@&M]@PVIH\RDB,
M14AE+#DQ]V+DL*W,O,6@[:&<>5]OUNR>R9J8W/!;V'A>X-\>Q2*<6,$``"$;
MRY3&;"><>RC\6A@$L_O-#4J_7;&QMB8C\,:RBK.S6.+GOXAT,AF!+6,+DQ$H
M,P+M1K-AU]JF,<H6F8A;(Y*W(4D[#8-[=P3>\.#1&KL^&)`F46O$\GZ+Y4;?
M[H%WOG[E]OZV'WC[^.";)DXO+D^_G9]<GU<KV$#XY/KOU#7X_/_]?O'/D\^P
M@W7GCNR,J-L)JCTHW[ENM_LUN]MN'Y3OO,UFVA:4=!2DD75R8WT\!W@NL;3C
MZA-V*K^X.C.VFK'5]DT<2MPU:O56"?:,M;9TNP<V#6*NO#R'7[VPI#SX20X[
M'5_:TY%`.V"J/H^=MEDPOW5"^FT'\7S_^O7S^1>`]>1SM0(+GGZ^NO[^[1S%
M+OG46)AL75Q^NOKVY>3FXNIR'SV<W8?3%"(?DK'VMFGA"QR-(J*X6L'J86.5
M&:O,6&7/SF[4>G:GMV[7K(.RR8STI24_.6Y8K<"&$RH:'(G0O>>I7NI*"$[2
M\)PH<L>N&.$,#1PUQ9<ZZ+['D>M7*[)+O95,`Y^N@GAXNT/\$.'0C<2KT&&V
MA!'D1I#OB2!O]>QF\W7D^%OSCS&>GV(\RX)O:IN8N]5'DCB^PYLM_KT((Q#8
M*.#]((95I\XC#2#$BWO.<!@FV#S1E8;X05";D=9&6K_\0!.[WFO9W=H+C339
M<A8RUO9SK6WN2V;I3;7%CR%=4Z1!NY$8)B&58.:O38.]_>1[T[M):T9<&W']
MXACL]NS6H<MJ8URO+*T]UQFX'HMCD-S)9+G$KE9>H-/%;E*<D=A&8F^@O5JS
M;W?J;U1LL-/$]]I7J0Y-69S_&))E#HHB;90T#5V\BW\O0FJK5&+N&YO>:`BC
M(5ZT'JW3;=NMSKJMG7:3A7)R^B\QQG2UGW,;Q@.5^Q@*C/26?2B/HIGW7XX@
MGL]/-X3&2T#CM_G4P*#_S]'1^:>OP!3B+O!&(CPZ*OL<OW_SK\^P`.8RW:&V
MKQP(OY_S+@:P&GWF.S7%JU;.(SA<)R[<F+7T^G7KY@[U@I@Z(4EZ'EY$=VX=
M#T"!MZE)@D59U<`'IV+BQH]`<_$=ANJ#Q*<VRJ!:X)6I!SBX%;X('<][Q+^+
M:<R:);X3U<IWW\4?KW%93.22XHDLP)=S2]_!?.[$^5-80H%..8%_)Z-;V:LA
MOG-B>`06'X_%,*:4`H`?A+BP,T%XHBR69>M>$G4-O!=^PHD&\6,J_$A^8>1&
M0R^(DE"V$Z1=(4!*2?JC:D5;Z]BZ`FT)Z/*/;@-$P,")7/B<MA6!GAIMP47`
MLQT!IKQDA"_%=T&$X'M.S+GLQ(</>/!O`',$_IO:$'V>.A8>P8=PW$HP0>CI
MS(ZM+]E7\<_T10V%`9S=G1O%`>A_.%7<>.@*[,N#6X=#OW="-TC@0<!FR,[D
ME#I@6(1N^"QXCL)S`7L$Y@"!=J+`1PZWY1E$B<>H!Z-L>(?NYX3^0IC!'ZL5
M.%K<=GJ<EC,($C[#H1.&C_A'\F\C/1PY@_J389S`/M0GD1I&+I!#R$.X&*O9
M]A,?F*Q:X4?DF:8;!"3#:7,%`2PM1]Z3(YV1(.X_%&-/#"4UIQ2G8&`*MQ"Q
M`3W!2(#?/0*VX+1@A3_]X,$_7J((UI!KJ90:A-9?GKW:]DC)%Y2$U0JV%"`R
MIW^<@\0!`D/:6R`33SP0?7=PP-P1AIO%2_FCC.D1BT!@J5L72T^`4E2D!4@W
MO@N%L":P^AV1&)6?$!D!L44NT&/*2-2H5&1P'3:!K'8!ZR4)Y%LVP^JT.,,J
M3Q;?\M.N+)",UZC?)@.0/,T:J!=XKF[1"4=2"UE#$<;N&.1N+`N:ID'DQDKW
MC5@XL78\!9GN^(_9-_N_1D`YZ+DYMT!/)-_?1T!8EP&L5F]].,[L)0TZ+']B
M\,[$4$)7MRU8L$:<4/AMK9\'&5Y?`O.8A*:'6@L4/?WHX"#$B1M%0?A8K6!6
M7YH((/[]/S6H>Q\XR[\,,=5*BAEK/<14*X290^:BUQ>SGVA$YLGL8*,\"WT-
M`U"18#^2`08G/:6S`\G(MB801HPR,HJ/@4S!+@4SE,U2'PFL[%VP+=*&,1B[
MN&5F`F9PT+$[0KBMB0"C8,2A#Z0HI=OQ%3%./#`3[Y7D5O.9JI7W;>M1.&&4
MX[,S,!]!<N-S$9P1D3"`D87ED2[1L*]6W`E")@WH3'&,0%$PF(!64!G`0LTC
M_)"D:5(ZN$G:"!@//G#6$&P+T#.P?60W8#`PXV(P$M5*@\3UZ`=:PYX+!J)Z
MI#`K)$KJ7=ZH]1Z6<L,9]*#]-18?I%$3XNL1K89?AK][#+-$GX0@,W/!&8!]
M(+@1V5SO,_EUR%SZ^KKN(IM!MI15+XKSRI;H.W7Z@@*/UM*X8WYX-RSB"^K-
MSGH#5SK!OT=DF7-3>'"-T&("<@I0;0!I`R-F<]7`_6("!:_4&UE3(#(?N0L\
M4:9%P?3J`(4K=D6'4I`W!8[6*`+6N!<>R)D1`@V,)CE=!V7P"&H&G\+O`:R\
M1"@FCDL:*P4/7[X-@A'!':"[I2DS^J8GT+T@-A^3%2G?E8YX`8',-GFMGYV2
MFC9<HO<S#8\,/^;FTHB3))1V:#"('?3P06B.8"/AGY'^D9L[8'?YU@.8KI8L
MKW;_BV;PG?#EP9,_;3TX$1;OR<5)V<?*'0**UR0L+S9"!4Y0W#GWZ)+BVR,Q
M1MD(P@0$3U[\DO!$8\8&40CX>B`1`P<P2IB`7*PY=,9PMOCQ*(FF+'APZRBX
M',`JP05,EXR=8<Q+9@W&<(4@).LC0,</%@9:`>7C4*R#1Q``]^%6`7R4?<!V
M(W:6<7L9&F%/(_2=`4<@AAU7H636Y:7%^%LC^NY_11@<MH!\?3/F@LZ([`H@
MEL^!?YN7D$?6"W[N,]@<0!Q+)?'OP&$"A2<&KV(.6;CA,)D`E8-4B2Q.^-O$
M.LA94:0LHPG0(3`;,A?P*45W\+\$D&5D$54ZBC#Y%9^E66;-8%]4-([4_',4
M?XKDD7;5LF!B_%NP]P&"U(TH,J@\I3%PJ0H,QMS8CZ3`=`KX<E(50[J#2G_C
MB#3%(`C^E+`X.>M,[G`$JQD6>5T6N<9R[J./9,F>:E'(!01\#IHN>!2"2\$Y
M@DGYQ?1EI%4939;^)28CX1?AB/J'IS;!;>*.9$=Q=#I4H/HDBT1?`U.,G!!T
M^<<`_J?T3^AKC]CYQ(^_SZ`]_?73R?5'Z^3Z-/O=V:\?K)M@"B9XM]ZSGR(!
M"'4ZLC3\-'^U"*7L_Y=C4]G=,E[N4'PJ"P9/92=C4AM"(CO2+?!;OCH%'"1R
M9P%:C0*?-@>C4-D-`W!J_IL&[<NS`?Q=KN@':VJ<52;E#(?+P#\2)8=OS3U[
M-2MWV>%;ZICDR;1K;7LV\[7JT6!8,'X\GI/F`EL9K(CAG<VR41EP*:JBU/31
MT:(Y406+4^*<#X4M'U]#5)2ZJ?B6'%/)@65IX(*`U-,L6N!9NI9,+Y$([]TA
MQZ\!6I^CCA1.ES:7LD%)(N,6\X"\H&A]JC!<D`_<V-?_G0#.QX\[(8V_Z?;L
M&3LOR**+PYC9*Z/L%8Z[,+5(@D:EG_H)AZUHW\)9Q[21=>/\6)C`E8_%^!B=
M75Z/4DB,!9?*H3VFX;"QEL+5Y?9W&7I%"Y(>M5%DR!E%\"4M-9<O0R5W+O6'
ME#B$SX-,"4(G5(DZ07;K0,0/0LQ5,^PHP=<H@TBE3/.^"S_3H+C41P/OG'\]
M!)!=I&UTM@`A#V0:<*!0^`Y%\_$;H4S-6H+SRH@[A(OB<F@6IPF]W!84LPRE
M(,<$<QB)@O>L%D54K()'SAQP&2^JX0R^J*BB73[^?/Z1'%$9\^`@'6V5N9R-
MY@R^?U*:FH(LZ$T[V;XBK.!PHSOEY;OL4P28Q_+</P7I'G`@,!I)GXP0%,R,
M2F^;L%6R7XR(4)9`9I(IDJ##I"6TT5-)`[P.1QOO%<C@[RB8+>?6<?THGI\Q
MN`V1*'1X9,PD=UH`)64B./WM_"DP%I`[XX&0OU=E#<!"(<\AY$H*BLGBF8DX
M"7VE?V6PBQ=0Q0'LZJ<\HWMIM$0&"BZBVZEX#)9V"H1/W6A%>`8"88E`H3G,
MD3..%V,A`28/\R90`1/28J"C#D`J8!RO6D$@CAB((P3BB$D!C%0,/5L/%(BC
M,T9KCO4);DL93,K?)`T#AXW<5N`=V"6%B7RLCL"DD2,Y0CNE.\P:2`SS!5*0
M(W!J6E6'#.256K/D6X)GHP<W,<)4M^=DT#"D=MCJ\`T2^<#2H;C#4-Z]L#X#
M*R^N:M+HAL*[/L=.QNQX9BN1I@@DTZ$P`\JFW[DD$)488\F*!0"<^S#VT&O;
M0[^ANR3-G05'?RH\K-,!K0U"1W#DBJ-0Y&\1!;QKM>Q:C7GY'3`S_:`TO@]0
M'%'IAE*GZ#J-2G,?*I1+5@(_-B,Q;`PZH_8`6+Q'6]4H83G<\?6Q1?VF,/;_
M3=:F7;/;AE+)L?X#D@Q\$9GE"YVI2&)P=RG`!I;&(TW+P,";-'0P9X!7\&,E
M\+Z"GD3)^C4,8IE@0:!/QF-TKREO<(JJY6285X-H^S'"TE"A+L2=C*G8IR4&
M8F/$,,;K,@;>"R,KC@,CJ8:[`&LH3"9+BIUNM,"**KHH!%=ZC?;3PU[+X:E6
M["RVE2_$G,G76<H"2!4Y9HO2=8^U[6N_5N8Q>CMD&"(_:2MHMH"6S2Q69MG*
M6TH;5MA4SW6/E2QH2XW$@)V6TFEB19]`I7_`_*(JS_)/:L5GJCT&@8#MZ0B&
M;%6PZL+@!\6<LE]2&"G[44/F*"UDP."=5N_F8RG;K`M3'LY2%G`>"[;N!I+(
M`:%Q))]BS]#5"F'5`BI+!YM,)@E7Q2:^G.+-W4!LRI-I6P7S]UV-HUKOFG:C
M(R5[(5=MI>)Z5CZCZ9@)Z'G'5,B)%$_7IIQG6M>;F;32';)UF",=AP,Q=))(
MJ#3P#Y%MEKR^_(MJ6<PN"OD`SD=/NQ8Z]X[KD6DOB9Z?/&RA_/KFZEG6N6R>
MW'NJ1)UW&T-/*=QH!85:J'@4H&X"'PT)3FNNILM*3,2+$4ZF!B^-)#']+DWD
MH6.EJ,^-\I4"?P\>,`!B*S%=K:1MVV")M)XAUQF((@>C@,`BOY++*4@?R*);
M*CB43=]DS@:$@*"HO3TO6Y"=0,25`'^'72%WLE*3VF65'%*U4OJWQ3DD>*F0
M1+)?^,#1;,M:X6$L0P\BY:M$.+J/QTSQ'1O=G",ZTDC$L2=DPI@"(G23'%&>
M.<M<[TZ)B"0$HL`5T%S-JC]0'D9I00V9$=XC5TOX<>@,@0+D&<M@CBP;+8'C
MN%KABI.4=FBG6>'T',+-"=*T,)14.ID,^@F-@@?_*,2:GUS(A&#C(K4'="$Y
M7E*M^`FI#*`9RKO1=8:LQ#\/J.PRJ!I:_260Y;VJ^Z`JAQK/OAHE`[+ED=VR
MZ!\JWWL*W6GVCQJM3,%"9B0GYJ41$\BG="QP/D<<?01T+0/BF#3>S&;I6[@=
M>9.":"D%'/5QMVMW&_URK7LL[QB!`D-_12,-%!^6$C+H;.'.2'\&>=RX',1D
MG*"BG;5!\B27B1>=#:X1[G+#D=`OJS&]1\W5B?5/D6R!0XI`]'#&)+LNHCTV
MWU&R,$9)%P(HZD#AX%1*4?39X0)+Q6WD@(*32'N,<O2.YZ`@\1[+12?1*<O)
M@@"U<S7G>E/-J&AUPVGP$L?626D)H"V!TUITIE$26BSP`<`@B5'ZD(&4[3I_
M"DAI:#&&H(*\-%PI@9P;&`3&*%T[)QU*R^'Q4I()YKU%,,_'6Y_9G<-3CEY\
M`XFPP%<M=>[DG<!4=FHI>I2CO#")FJ)O1TZ#YFVAIZ+N(1"KCW/?<^-$%DNP
MY)\XCRA0L63)&HN1-+'@R025E.=.W#BGA?E*/G^:O!_T[&2"#*\2@N'D8\EZ
MZAU1<5;J_RG73V9W(DJ%/*+KI&YB4$Y(WL0D6(!_;FE9?/]HX`S_Q,^5NJ3:
M3:D,(P")E^6#L,!5YA'DW0Y*$`G&XX/PO".],+04>8;17I?1\%N:\?HU#/P`
MTRA+HD(978#I^`_'3S!U*YUELIHQ0"2%]<GU=^LRT$@)GSNJ=9X>,KJ@"PL(
M[UD:#9)W17/1KB_"P3^5[,6>*9E*FT3C1=#"HAP;TNX.^R-YOY45J';/@TJD
M_6@L0LF@(]1K5"R*E109$CC84/AE0U.KU<I$`_^8(ZZ1="Z`SJ(`-7;(&EG\
M<+D.*(,]37BQ>M,N$?,=#/@PW:L"2_06;.';['KW'!#85D#[@TP!:V&ZO0R+
MKC]-Y--I@A;\@N&=[_X'K_0F$<,G/PIN769CX+<'08PGAA$.JL?&I'X`5GKZ
MFQEL$B"%WS:M/%ZO7:Z\=SDHJ]U93Y&-YDF*SI'>4#S;)-]R=D9<O*6,SG0)
ME0H>NR$HF/\`O\1L0I.9,7(Y<XJ5ME)%+0]%@K65`H)Y@]2*E_61\`&7[PDY
MOH\)SS1%-1#@YY(A[8P1#&7W:-395KF).$=V=%5!(@*44ADB)'?(7"M8K(#,
MF%2MM/F(-!3-43`+KX)+KYT(15;:HZXLGFES/GGBZS*'+R_;@_F0INW`PN;+
M)<3&.<5V,W-P6<5AC@YFCPDOJ92=DY8]-AIMJ4:[\#$>)FUO17:E2H3^>M3H
M/UUWZ!H#SOHZF4XYJD#.)^@_ZQ-2HW6A427RTT?5&.\T:WN45RI2I]B6*W/(
MU#+C?EY-02BLU`G2\AM\.3&#RL.8`S5+<`JYCURO"B=$?HY4F6[F7F&!WEC>
M`)QM[8?73ZQ@J.[B2)K.Y(,48W(W:,OQM2<I48J.*#A:?C%"/J.UP*%W\"H5
MR<?2C>:51^$J=#'WU*X]G1B6'RKFGN@2&=\/@S,0T3!T<T*>\R$L:=-,#4;C
M0Y+8H*,R%94=IC/".E(FAA'L;XA.NA/'H3M(V&QF55W>DU$%?M)&$]G"&EV`
M^R$)8_Z9P+_SFD-WD"@&YS^6PQ!I]<&L2)0E6)>1G;Q#GD432-I*WU\+J2G9
MFPG<["8L*<YJ):\YZP=:@;QI8?S%>;32P,T\.5P_JK6>SGHG0/FC-*%P,KS#
MYC%(=Q-T=\N->,[/94+PFV[@`D-@O42U\EN:S3A1_85R'D[:B"@7DO_MY.1K
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M#L`@KM:L2R8H<J*"@J@ILX.G>L=%3GFAJ&XAD"/+Z0\GEFPL;=+OU]EVE6#$
M0%A`V<;BTR@Q;2X-#-)LIT-U\^D]?'23LUL8TIQ'.8D1C^#!1[<6`TW.4._#
MQK(H=;K_?\XTB'Z-.(:-N_^>MLP!TK`U[WR(__1D:E%^#5`L*&6+?C-5KRC<
M+S@:ESUM;I"78,^X]$2HCD;5U@=4Z7TGK/R!E2QI6WSA+WX`VHBX$2'\$HQD
M0A98UBAX;-WCMLXI2J7GU=#UY_4XUR]FGIB_*?0`;KGL7O9S"(!7(MGF:`%]
M`L@6P!MS.EW[JZJ'+/\:5\7[(KT,`$)QZCF/J0LD7'P;];LT3NY%2MF,@_?1
MA]EE,J>0PO,":T>I/A3+L'RN**5LG+RP30G9\I@&?0W%"VH6OJFA$M)$-$2.
M>#P4UQ>%[9?A6A&8+76+3RLM/AAK`AZ4NI::F_FG?4\J3>4('8&G>D1Y:UHR
MB>4]D?<<$":M)ZE72+REMS:S53_(3+AXJ%9FF#]GY5#&/^=?31,P*(:9.'&R
MLHB<X^T`ZB/LQTC%PX11^GNT*&JGU1W/CP#R'7]:!7DE]!XS.P!K/*98F1=3
M7`+9C*[4A"+.U+RZ(**NYY9U*RL)H!V7&B76/)N$#*?E1HD*QZ%J2D*MT23>
MI!6A++_3&@VP[,WH6ET4.71G<CL-H16',NO7<U:QAIYQ43_KJ1/E[^G_)IOY
ML(JY(KGUGL-4S7;M@W4C+VNKY[CI:=939)X%-<^6BH#R/4X`W04/U-Y#1=L%
MWM2]U;ZC=_$@B>!1SXU<@%[&6+B!!E\MB&4($Q@LX)1667./[.*?O'%&.7?M
MXM]LG;:C!0\3GQ>@+ICT(G7$32MK952-JF72;K$+`/$%)M(IH(OFC`C37K.@
MD8_`NIIFJ-'0@D@[GH=U,BWG1,SRHMR:*\FKE26BW))YEWD"G$1S48*70;Q(
MJ,_9XB+!G/,3\6RW1B;OI$NX6PT$\G5ABZZ*G,K:0\H1',G+42IOCA0B.UT5
MK379-USEIJ5/>*1R"E/-^UQ$#_A_^F_^]R])='3K.--?KK,$?18*_!H`)H!K
M;\2/^",>XM^J%<OZ7_7.21:?OPFR3.M7QQU=^*=<QW*:76LX$X/X=S"K3].+
M"I\$YP70FH1/?!/CO_XD`N^/K^>=9J_5[!P=U>O71Z"*@-__N+XY^Z/1;?Z!
MS%_K-VM_U'XBL4AON5'0:M2[?WR_/OL)Q-X0#',O^NM/M9_^UFAW^]UFMM&7
M`CJ/"O#OL=P!'N?_O?`Q/DOAV:OQ=Y^JP4=9.;56S[[1S1]U.KU&+=O\T\',
M;_>+"&\!&UI/O^C$'YV!$Z9N%&M)Q)1ZGKS5OTE9DQ,\V0^<"])9>67+"/@8
MN]0ALJRA\+P(9#(0?OKS%".C\F<U)*)6RX9L:(,7TM$Z:KA$'$Q+Y^K\?G%V
M\_=?K$9WNK)1N8KHS)9Z.6$Y7^BUEJJ=_#B._$8W&_B;#_7)Z?_[_>+ZXN;B
MZG(=\-<<RK%YC;A5&;75E>?S#Y`%CW6BKB:8`/@R4^<*7)X3,#<\JZ<Z,LC>
MJ]G8JNS"=WP7!LDM%J9.&--<INKS,'$V/N097">#R!VYX$/8,U>F)X5C(J]+
M<*-:[)7JRRM+A3XJ)Q$Y/6@)*R]!4S&R<++D\QR8TFY9^\Y$WY:-=]Z/;2MX
M\"/J=Z+*\F2E(AO<,MZ>YO'!J+K'F1Z8L7GP5=\O^2Q5UJ<?,(F8E1(QQ0-E
MIQ?L6CA/NFK"TWSH7,J:$&"5MZJ*F[UC`_]2E)V['9<&6?FF<.[>:Z_]LZ(T
M_0+$O!71Q84E;>F4WKI48BM;$Y4U.D[0C1VCU\_/`B/D'@;8TENN9'4):XIC
MC52X7WT^FT**]UVPOF:`)(B7E'0&^CJGX[+&\Q-*YG#\!:^[<H$AVJ'Y:0(8
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M,@.%'VGU[7J[O\I7K?Q'JQ7YU6.@7/JH7>LVX(?#EO8K19O_[Y=KO`Y#WK3U
MU0EC']C!+O2/<D;WX+H2.69<4I`R9:WL[9F^-&-!;)0VHE&LQHEJ3^BUB#K5
M\\?H4JRC/4/='&3KS]R`F&`$.V;IA/^QO@D?Z.K!MCY_/LT72_&C^<O+W*)^
M9N^*'I?W\*?\\)R=M_,[MV8VGA,P\W=NE6V<F5W&J?"B4IB_HBGM/=G],IL,
ME^M^J>I>4.C)Q%5>IN2O6ZN:)"6MM&M<.!"'&92:].H5/U0_J[7.UZ\BO&OT
M.W8#)`@&61GD(W7IPP.CPLME7G$K6G6E3T-0>!R55*$E[3%DBE3055@JB"V[
MPEKLW98USU#750]:PJQD3]X4*1J+T[)J6_T.'Q`07N8)G5M0SX\@B6[=K'5F
MJO?U.BP+9]_$XM8=@@H<)AE-RZ%_E.2AMJ_RF@V08I)-DM%:PO)-2>RZ9XW"
MY)972J5=KO8+E%X0QJ!RW2![ZPB>NJ4=I1,V]ITX7C.>\%59#%G0>\^QNRG6
M*^F9R\7K"L-IK5:N\,%AEY]-?&>^,E#/R)DWN@,Y!5%]I/U6G\RM+IDEH-/N
M99LDK,Z7_(0:(]?D59OQB1I`YE+5+081IR-BU"0%;2<<30FM]RE[?P!G+BDV
M`TA5WRR8LZO1R!H23Q]R%[(^)2&J*3LK)RDBVL[_DIM5N%%A]`]]M3#$?.:N
MHNQGDN]8GXUCU=M916D_OVR(40D<JCU[^2+J)3!.?'1)*;RO88OFE66W=_@&
M>12M.J5]ICU5$,62+//3DI1MH-8]XG6U"4-NI'5H!IBX<C-\5,UI-;.SD-LO
MO1:J]8Y!SR/UV6G0SJ.J'TL;QO#`(_U+/'B0FIO,S)YR]4$[,ZW)LE7<*+\5
M79-F#<]PEAKINYF=SIG".`/0#`@S4Z^D%SCW(&?'65GY:5:LF5<<(&65S(_2
M'%D"Y6U5[\GGB]\N?[%0M`/*7D1=/"5IM)(#2#IBEJ7S/H>Z"!YFLS(*:J5:
M>=>P&_6^W:\UTRL(()V'LK6=K,<LBP66A$,R+Y,K/ZDD`^_W(=E@P,=ZSW?.
MI!8C:C[_(?GN&P+]P4HG6^$3:7P./ZNB/NDT,(Q]M7]6Q<593SHW==%8%2EZ
M+&HR\/<F&.#B2P2RE<LBB:DX[SGGJ6>8B'=S-!^1!M5":*HM9'9LQ:C^S0S0
MZM),`>J<O,A'9YS\P!1X$\B&]'FN"U/NI0C[9ZNN[C/!5>FI(8G1K?G,=<AB
MLMYCFO_(1EQC#6?J9,/9$Q0+O=F-F&`LIG'OQ1%JW%Z=*JR(UD9N-@]/)QE?
MMGVA(&3D*N&8+9IB'-WH<%(<'NO?8J#.%[=!+$>,RIXFMV&03%5H4!9X$8ZI
M>P!Y4OP'#-NB4X]U<P0*\B+/U,+PB!AEK:-9V13F&6;Z,@)MY>'X3Q<>&"&S
M4;L:$@]!I(('^!UDTG3$Z<3Y-S5MUR0']WLG%)%XR9113G:5:`+C,RSS&;1P
M,I=L)).)$]+\G[ER0#-%YIF<N9FS>3L6?U]J8,F*2Q6`SWD>KWV8Y57&SZEJ
M6;&4I5?[.5^Z,K@=!EX0_O6G_^?T]-.GT]/2^I6O)V=G%Y>_'7V\NKFY^O*+
MU9K^^"DM>@$^CX-)]H7VSWM517VJRX!JY2AM(D@2)$W2K5<;\Q3$UG_>G.TV
MKSOJ?,@_7GT[._^6`CX`+?LG@F^-@@2H6%JKFOVZ;%\;V-6[C6PFQ'9C\W?3
MV-AVEBPIJ2,UGI>HJW),S'H=:Y*HY0</H3/]ZT_\OQO#Q8H$FZOCTL4=&(.Q
MR`N[!0+MC7<Q'[C-,<_Z(F%=CM^()(-%GP7X:MR])4)X'8SO"F.6VB$'8FM\
MQ4E8[H@[$OB1C*UR>M*9G7B\W,PP4F-5J;&RK;`EPJ);MWO]QB$+BO4T^#Z)
MB4\X[T+EI8Q$,'9$'O2.W:ZW#UDR'+()<8*#'%$Z:#$P(R*,B,B#_K[9J]GU
M9FV'I<0'8S:LB;$S;7Y$.M;:R`8C&PJRH=VW6[U=-B">*AK628$T#B@%PC,X
M*.6]8L'5FE+E"3C>@6P(@(\5">YH*Y(AF]W4EB=%ZG:GV[9;G9*`R8LD1990
MZJXX3B8I8JR1+;-&3%+$%&<LJ#'"*Y_%DMU\_SFT3M+99:I0B.;9]VMMN]/J
MOXRM8BHW3.7&LXV49KUE-]JM#1DI.URYL;@#CZJU,Z67>NGE[.V*)4[;[.4*
MNC"DW:Y0?5>&5$L_#;`EMRL'./(LF)E[+WS=-;W)J"Y*\GW-\L8$@T=59&^K
MWM)T8Q;;%6`5?N[NQXI7/?@B=N&NAU6\ZK&H@EV6GI(7O.K]*9YG)$>YR,O&
M#DY?R%6VZ[.^N(<#7I%+)]([VF6Q%$G5"M6Q8H-V">6"*T=SP$Q+8^=-2!@(
M#P>01%F[4AU4V:0]PM8+//B/P,UZD4K(TF$U^?K=`G#<GJ0$B=QN63]8%\<G
MNS%WJPAS4PIU^-*&I]S%U:<)F[(X7(.E./4LI.8M\BZ==G;YL6KC_.CBL2<[
MGX0TJ*HXD!JW1O.?5?-]O-LU$/J,Q+EC@;C?:%38A-`N@?%=!2;VW-4[=5U`
M(WH@IBC@_Y4S.?C0`,5^8-%(5"L=#8>-665+C/(;'TLLIYF6DT]K(IAO1'B&
M8Y*'?/T`_LT-#V"5DPDVSOTO;W.3'19;S7Z[U\TVM0I`Q=:1?"N(1T2<<ZW/
M9>#++K#^[:6(-[>%B\M//_WMJ-7HU>IMO4_D<ICRN_CJ/*J>FLS#7T-\.'[\
MZF%+47]T#K_E&_&;/(YZO5'O:QM9':S\=J[Q!M$%]0`ZHQX07ZDO`W7*U`EV
MLZU+82_]FM:[=%6H\GNY4H?&I_DYB#;<=+1=J_?KK4X&=PD$>1"_\4"V3R!<
M?N,F0AOEV5:KV\^@F_EX@;+#`.=31_CW"UGM?S7F,5S7JL'8YF#M=3JMFH;+
MI>#,0%].[YEL-?U9\[Z3[,]:[^UR?];V3O9G_73Q?\_/K)/KZ_.;ZW7@WTR#
MUGUU"',5@^D\I?2R979+#^S\M.]^L_[+DA/9V6;P"V(0VW-7KU^XJ_?<E&FW
M5A+\W8J0Y,)=H-#6PU1;N8/%N=*]VDP^IBK5;?D&-Q)1G:]+<`[V#I)<84,^
M1C"\)^?MUMG8)K(2+[N;[>2KU]SC-K-;K21YMO7L]IR,["K5!UNH9G<`T;L-
M92,#DY.,6PKG;F!S&\IW=AA]AAC?[#91J>S?SKC!2LB[&H_=H9P.[#D#G`T0
M8*]#%5)<+^*T"V2P!I0[?*XE]37K'URIG-DP4C8JT!IVO]>RF]V2NP_[2]9;
M"YCAMT/@MX;=;92T*MIU?ENGQ/ZE0KD[S!^?<30E]FFL5MP)5MUPG<V:=+'C
ML89MCWJ]YF;V3M8M65*%U.QFO6NW^]U9Y!X@&[QU*'O/HM:&?PW_FD#*FUY4
M&F,=QO-:N6WQR>\VE'LGLMIVLU:W^]V22\_[2VE;"]@NH&\O6:!F-QLE92&[
MS@(FPK!FA`$[F#C#83*1@V1&VKT-OIFE7=@X+)/->"Y[+`-7\US>U^UNOVZW
M>LOZQF^<#W98R)0TGGII=)DXAY$66R$M&O6ZW>R4%``::;$):;'QUC#[9O#E
MKKS8V._@9:BSM1\V7=8C9=]Y;7X!\RJRKB1SOS8)/>T`#E2U-.UVO09VZ"8T
MR^[Q[CH[V'[3T`@=(W2V4NBT[%JO9_?;]0,6.OMWH_KIMXA7ZZ>>\#QB&D<-
M:U@36/\NLH0_$J,,Z]=B&LL+U37;PAX*W%Q(]@:*`[1-\ZG!_`UM!V>[#['%
M$G=UFD[#X`?U?/(>K7>M5LVNU6K8@\E33;%6#G/:::^@B'IUI87=L$H,6,0;
MX?G/U>L-_)R=U8!;(^K?XWB\1.'Y#C]-'\[_I8M_L32H59,H;59T#BE9'ROX
M-[P8)5YLS8YAMMY'0E0KET$LK-:']9L4K=,_(]]YX]2)[N`%_!]\"7:!16S<
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MIB*)W6%D6\#BQ];[K*WOJ7HP^]79KQ9VD\3.>?IS,P/&SW[]@`T$'6MZYX03
M9TB?<#QJH(?M]F1_2E+L6=?*,:]MQ2!A8E)ZU%+8'XKPV+KRK9-IZ'I63ZGW
M=!NJ+1_H+&N01(`5ZL0U&0!GDJ["_I;6J?"P?Z`3\DZKE=Q6T[_F-F'C%FB>
M"RK3.^&-K-^!M]%NP/9WX310$ZNI>>-(8*]!V0-2[\$9C!+977`$<`YCF_=(
MSX$]X\;88;%:`9,56PZ&KH@?<>]W"9RAQ$#$ZAWAS.GA4X`"CFWF3+@+H'6=
M#")WY#KAX\S&2G?"-@2`<A=@Q]'@`;<3I8L@5!+OQ];7),0^6;$R*^+0\2-L
M=X@(21%*C38G",T(NYSRHS/0E>Q`VZ4.NVV!Y6$IP\/ZAOI'`(8B6!W7CF0;
M4I+)P#5**-/._(!:E0;6TK.7-A,\R[8G[NM>]LR$A;(OZ-TP`3O9OO76J]6*
MMAL;>UDJH`NPE+%<"@FOM"HD<JGY<-#K\T'1NH$6)$#^G!Y$44#H?TUFQ(?^
MUR!9!^G!`(2CPPT"I4G*;`ZDI3IYIEV6>`5MN\N,5*,9?KV83`2P(TH[:FM:
MVCHXE;R6+GCK1T!\1_5V$\[P'L05MFB=>B[)<)>,5>RD!["BL8/,GJ.#;_R.
M=8VOY"15KG.L^C"\#NX:-6Q4`$:@:>AR"ZR3YT/JJHO2&?8%-@5Z1'6[W>_P
M*U$I@([T#D="BL6QTGL%/IZR+4@^G$7/XGJU8S#=VMH'=%V5?04$EO@A/53\
M`+:#I7?R&]#?`;55Q-VY6N(;?CZOA+$3K8AQ<="`+!^MD]M0D$CD&\?H@>'W
MI$B>65[^/GTK_X$1^96DF:L5J9J+G8XE&K+SRK:6.S6&+R^B\!1B-TZ(R'*N
M;:_]LX;9#*H^T$F0Q"#X?>SU53C7,?;>O06A`G\1X['L(%S\K+Z#[U/901I-
M>GQMUAFV]<[)NCW"[8W)?K"F'MA!RJKIV+U6QVXWNZ5$"*S#T,+Q/#@A=^X$
M,--.VG!B64/FLL6JE1F21@*[#;%)Z52VNIR)<U0K[]IVO=G&F,&+2\M\@&Q^
M5\MM$YPO$0!]6CX@<Q>1B$#'`U5%UJWP02BA<>8,AQCU&BG&_@Z&)/Q$?FB$
MH2IR;%GX.:GM_4"]N2,Q3$(7S$S%?*&(';G.Q/EW@'^K5NX#^KHKVQ:K#Z5*
M-[6V!])JY[A1VL<Z%-C:&@@O,U)`9&)D#/>4@-49Y7J#6[CE$-G6>[1GA4':
M.I\1@SWCT7#F0!4K$+U]]@/V&1\\:K:H='+4.G-`YE4SY`,;ZB9ER0Y(S)4:
MG5(_8)(<H7%]V6F>+#?E[SP([SX?V-3[0Y)0K3$4V`TJTSKT]IT+_!V2>[7<
M*+5Y8L$T3C\^=*9N3#"'X*,D0"\\?2#]2%3X"FB-"6(FKV51%\9A0`8;2F=G
MA'%A%O>R<SNMXXE;7&+VJYK!.GA$L>0]JI[V>06'KB"0!6H<.W,&UW4W5G)Q
M?B7]F0SO6,"GZ$7Y/'O"UMP#GHE;5RNS\>K<=`?M4#D$6[!IL%U\M?(/QT\0
MXKI<(;X+@^3VKN@HEY\X;F+%([=*3QPES,I'7D)GJ*56.W)V?37\H(Y5,3DQ
MTE&4$T]*Y%%S?49*GY&"S@'C:O8@<O((!,54A$=LE2DT$"OJ-@;K75N"2#+#
M\_+J5V0A89L7X-\'4_)G;.O.`1DP$&#8YM&*@M?)I'PTCPXS]Y;$%P/N!B.=
M0O,G\T0VK%:8#S6-GOX+Y:#,B@#TZ:%+/TZ>!"Y&@S7(3O&1."FC@!^FD^CB
M0=0:'ZQDJLS[!<87EA]I>Y0Z"N4WG3Z=CT(3OD]XEVHO;S;B&<6/E'7!1$NI
MJZ`?JCW#..QT\CJIVHPT-IC".@#&>XGD#YI5S.;HK-M*RL5/"#,H6)+X#MCR
MORBT2J&J5D8<?\Z&GPP<#X-(\((`;^!]O4W9+/S/AR+7\X=X`$O9ES3?3[<M
M56OC19;T26JRHG8/2LXI!R>-3L%/ENI"BU0AS?S(>``):M[QJE-18I"Y@RFR
MA`BKE90*X6QF02#8;\$INB7CWM$FPM`,%SK6@K^'JBD4HV0X*R3?U8[A-&KU
MW$J9?"PXIU&`N48:)@1^7>K^1F5^8^I,*/&L$)"7L81*XDQW+"-"""\*^:$'
M7W3'KDQ[9HX'YG^.,'[(;%[B,BQ/">8\@"5.PE;Y!2L%5$Z0B.=G47..(V@`
M\('1=9RP)".KUHV0C%)#>XK>^C@8)AIWRTBSDF^TI"("+;ZNL^)9_I42)]H*
M,(V7S92J5MY?7OWS"!B"*`7_W:BU/Q#0I+6B))J2<3-OT)%+X0\?0^'D5""_
M3F5\)6(^+(G$]G^-P+!R1B"2PYBC!-7*%P=$'*+O]XN4;F="E?BF^`%^#JFB
M@)JL130M"I>`@XMQA2\G)BZXVJ@S;3*4-GS)T513Z$9_PA_=B>LY,G(8<#D%
M$1-(H@G9)65)(1?=J*_LYK+%R=H$WN=E:>K32!"-H7`"XO]3H)(%C+HC5-@V
M+25B]OZ(H-"LY_!1FH51??;((TB_S9P(MCZ.LQHG7HZI*$WCA'^*F$T0CJZD
M:1VT^<%:OKTC:^U6EH0(_]X-`S]=@)2K(!D*VG5`WK8F2Z51!^OG1VHEZ$<D
M:)O!6RF[K$NSN9&%+T-WI36+6TWJJ_40X!2+9I24^O69M3[%.HB0I;'#@]ED
M.I!GJVF#W10'4?P!$_ZNGPB.7]P&'*O$5)_/_@&]1F4!H!,<.6)/O>9RAC"C
M"'3``3W_53Y_.H="T5X$?XG&G)[#5W-3X'BXV<2->7<J$LL]MW$28<A\K/30
ML69FD-KRAPE6@5B@1;#,*4*+2C?N847@*`XG$5,Z:J@A2@09_00+.`@IU/G@
MA",T/2+AA&!@:_G4E)_PLQ@'S55A@8RGE$.U\J[1LFLM#&6V"O,VV(`[MKBR
MC'"#,]@*@9=J13VI!Q<X^,;*&8<[XG81^G<MN]VIV8U.4^&[9+8<GB=`ES]]
MG*XH%[72,6`2C1P[X]DAB`M!XS!8&JPV3M!%>4=3>>$,[C@FH9GJ>5MDZB61
MFLC'`6+EKE$RJ!#%SJ+<E$'V06QER?:9M9$IG!$Z5IS))+FFJ7\,M7GTFO"I
M'J\DD9"B-*_CF8Q)6K*Z%[IM@6$ZM)D&XC&@DW'0Q0))8+$NB1`S^+RV3(ET
M3MC1OW<=QD<$KCR"*9T*P.Q?X*A&8A"KT"HI%0==:]CRK3O4T^.40R6=^`#V
MW;RC1+@I[J\32QH7F&+V/<MU4\P!#"2?/.\H'>@8HA>.V\?1@RB10H=G>&;$
MF*HC5E%*^\@]%Z$KEXVY4,0HP$A$&K#!O;#W,9%N)GQ[@O7(RC+F<!9^/DAB
M'&7&=JR+=`$"$8&+'Q?I//R_\D+#UR[DFE/R5C9R<;-SP:2N5+,,"@._]$DX
MQ4DYN8%?4K.6UVRM6:@_YW']5MW*8\0:W7ECQ&8MB;F#Q9XX1DPO55NVUX)]
MK7WG?XZ.SC]]17G*T8JC(_Q;\PT&C#U_/Y].+KY9_SSY_/W\&FOU>-(8U>9]
MOCCY>/'YXN;B_!4FCQ6-RN+!K^>?+3=15R&L)Y[)6@=PX;/-&HY(N),*1M%C
MD>RQONA3==$(T*21=1-,03FI&=*?3JX_PO&=YB,3MV&03"-2DYDUK-F7FAK0
MS<HL52GG^H[0%--F^I+."04&1T&GH=)R*-P1J$0D^EQDCG*@E8)NV6=S)FQ(
M!6@CKKY3TZS5$X_I=&>TR:?2YH@XHH4U>>$$<S1:8?P:'M;+4-W!R^\-\<;*
M8^CFW#1:.K9R\_IFO?T6EL1_'XV=B>L]_G+].`$9CQ64H3O6L?.Q6X*=5]5!
M:^WQ,XJ+:J7^BW7A3\'.I0G<D?6?))#^"#F&%/=C&4)!;W>$E5JY1'GJ)<.?
M-6FRE@Y>3U49-C=L;MA\+39O2#:/9$X"_$=_EN7I82R%P((-BU+"^$2U(A]!
M":!"TZ5&C&Y-N$I^5"O2"+'5%_.29/[[\CT5"PP%^<12*F&Q)^W%Y8VESP0#
M.+1[D@SP#'ONF#8)PX`&PV#1U:/^E)1OX-,Z1FH9J66DUK9(K6:Y<9)R>I2%
MD_1[N5KR/U=S9I4:*M(O4M(E)SVJE2B98JDBRXRB2;1!:7'H[CA?+)6)1NVP
MYGC!E#@*,6H<<A%,Y,IT)_BJ<%A4@3,07O"PQJCP%\)]>:,05@(KBOK>6TCZ
MG+"<TXRKI0%6UA[M1:1@&9!/Z"!<`+W^<I"O$_R;@_'5MS,,D$)@/_76W!YI
M[5ZVN27M`E]!3D@39S/!U/D4O*R;2JYLE89R/ZNKBA\\A,[TKS_Q_\X]FL5D
MEQ^B_%("]CD,](3!PD8HO)U0:,PGO*:1"4ME@O2`=UL.O"KE&48RC#27D4HF
M>AA&,HQD&&E=1GI6LWO#2(:1#"-EQ1R&ES;J^KVQP[I0`FPCFE?G\2V%?GV>
MV`GR-X1D",D0DB&DK=J9(21#2"]NV2T9TJ,G,)<9?MN5<GX^1C]GN>=EF>--
ML.JF+.07Y\I-`?JJ#+C-_HBA!$,)AA(,)1A*V"M*6&<Z]JIV6#'RJ-E:)3-_
M"B99?UX9[$)#KO]6M8-EN/]=]GM],7MM7BBWM3/%+$N&;+U>V5')Q+`5-]-X
MXF[6G=JUWB$M7E)2Q]'LIE]6JI6R];:).L-BAL4VQF+=KMWO=`V?&3XS?&94
MV580JF$QPV)&E;V<=_SD.W-/2CG,0<9,CL5<]S(W.\QUKQVH_YMI7[E$PFYY
M&:"Y[&5$@JD(?H'2>G/9RS"28:078"1SV<LPDF&D%V`D<]G+,))AI&<QDKGL
M92Y[;26:347\=I*_(21#2(:0#"%MU<X,(1E",I>]7@^CYK+7VP*Z^^7\AA(,
M)1A*,)1@*,%0PAJ6F+GL92Y[F?+=_2C?-17RAL4,BQD6VPY"-2QF6,RPF&$Q
MPV*&Q;:2Q=[PBE?JG_X[B6)W_%@&]^Y/4KNY$]6*FD*>1"*B.7D?D3N.KH=W
M@0>_"6B<-XW9P_%IDV`D/!K(J<WZEE,XA_!/=R1"VW(F`3S+,SCOG=#%HXOL
MV2E\^)MJ)?'A)>\1EX]B0)D-+!C]>33&T>4NUI")*+9P.J=MW0>>$]/(<=L2
M/Z9B&.-`<\\="X()3@&'AX[H:9H3"J^Z$W@%UM:^C%-&$9@'&2'`&:`,.\\L
M'P@+_NW>.S31S_6C.$QHOONQ=5(<<4ZCY+)9[+10%,/#/"@^O@LB6(U'PJM!
MJ;C+(SF-?0CX%W[D$)K?1[#GRR`65KW^8>D,0?G3__XEB8YN'6?Z"]:V46F;
M-H+^1OR(/R(E_JU:L:S_58]>^/!A<>/\R!Y-G\1-Q/##-S'^ZT\B\/[X>MYI
M]EK-SM%1O7Y]5#^JU>KU/ZYOSOYH=)M_X'2L6K]9^Z/VT]\D*Y3RQ2S5+^>4
M%^.+.6PPCVOTA*&4R?7&L95)@(O+TZLOY];-R?\]OUYR3&N@(-W02B,;=P*A
MM.29&(LP1&J/G1]JUJ;BE)$4!,`:GA<\(*N",-'NY*TQE_%E49(3_B^/E97'
MTVIWA[6BVJIV>U@"M4CUSL(P<\>X>`=9V@W]7$Z_4`"ZH)1ZGAW2Q=CT\ZAN
MZ=[6-(A7V05.-=9-J:W<P9*R[X65XUJZYQ68:^WR\#4OMI>(\%6,[^=>_]T;
M2MK]'1A>>#8OU/H'S`M/N/>PA:IM!Q"]((A3X,4Y+53>'N[=P.YN0&EH8-.B
M;$FA[SK";3N]TI605^:5KJGA=N#H=QO*QFZ`::`\-"@-8;ZD&BJI<GQ-)=1_
M.R7T28PP<U"M^"*V@BG\FY(57A`=MB[:8;NB)&6]_L%I\B5+2&\8*>MFOM?"
M2L>NUSMVK]8Z:++>#2@-\^T9\[7L;KMEUVHE'>UVG?FVU[7=!JLB%)%PPN$=
MET=@#ZE@BI4,%KJ\0W!^W=@:.F'X.`["!R<<';;1L850[ITH:O9K=J=6DF,S
M=&:@/#AN:'2;=K?7VS]N,*[^#.I^=R.J>?++G'VCC'<`RKT3/[UZRV[U2]KS
M&CHS4!X<-[1[?;O=.B1E?,@^LJ:.C9>\XU#NG2AJ-&IVM[F'HLA`:;AA;834
MNW6[W=Y#,]5XR3.HNYY[.0XO_/E12=OV7:>"W89R[Z0-2!J[URZI?#=T9J`\
M.&YHU=MVK;.'^1KC%)<@[_3."5VZ4TIWXN/0'22D?(W[N\50[I_0Z=O=1MN0
MF8'2,,/>,L,ZSN]+M1G88=5\,AR&";>[26<1K$D4.WXA=_VKW?N[F;V3<DN6
ME/MKM.UFHSN+V0/D@=W?@>'B`^7B;MONUI\U77W'>6![8P]O>'7C)HBQ9'TD
MKV5;YE;VMD*Y=V*K9]>[-;O=VD,ORT!I^&%MA'3`RN[;S=X>\L.F4NY;2)8&
M2M/OP4"YYU`:PC3^UR;Z83T]RKP#Y[_;4!J6-U!N)92&,$T:=/-::AJ*H<LE
M2GA?Q_5CQ[]UL0W^DZ*%.QY*-NF4/8[#+%E2[N]]J]FR:^W.+&Y?EPMVV/;]
M8(2&$1H')C2Z;;O=*&G'9X3&)H2&"3FLF/(U@8>MA7+O1.5\R^E%"&V'.7-=
M@VB'J7HWH-Q#WIMG@!C>>PF[PN2S#90F5&N@W#$H#6&:?/;+(.]2Q*::>`>@
MW#O+MFMWFQV[U3,M1`R4AA_B7]MVK]VT>YU#FCYADO=E:/TLHJA:@<TFW-++
M\;S@P?&'ZS;U,NFWO=G,WDF[)4NJ]-L"(\$DX$S6WH@-(S;*Q,8"6\J(C=W*
MVV^AZV&@-(%,`^6>0VD(\VT<_=9K._I;5MCUDM7YK?TPV6$;UBA(!I[8=\-+
M_N+W<_[B(/!&VFZ6&;XE4WW7)J&G'<"!^AF2OANU>JL$W0?(OKN_`R.`C``R
M`FC'V#=G=OZ%&K-K/^=V/@BMOSR)-M(]JA5FU]XV9K\A'%\"CK\M:)@;52O!
MV#H30S$9B-!JUFT+Z*EF6Z?"\\0P=D+KSAE98QZ63L/?HMB)A94;SUJM\'Q6
MO0&^]3ZCS]-?+Z\^1]G/9[]^L."SSG0:!C_<":SG/58K[^IMN]-KV;5:C3Y$
M/S>;]',HHBF`X][#D[8%#L7P#H?=N*&P!N+6]7T<$HMSZAJU)K_=J#7:=NZ]
MXXRBK`O?<D8C%S-L^;T"0F8W.W?X'5^NO1=1K&;A52L\#"^:V:#UKMFO9YMK
M-MOXPUP0JY6;.V$YDR"!A6$MQ*#<^,1YA%U;2>QZ[G_!<W!\/W$\^(+K6^,D
M3@`I<#)N,(+-/+B>AP][[@2<L)$U3<(H<1#6P+K&SP:^U>PU\`LQ?._"CT7H
MP^:_P2[]1%0KI\$(;PU;#@*:>`1+E`P`,7[LPH/#.\>_!4J#;^,"I\%DZOB/
MV5GW?T4:>_!%&-VY4WC&B0'-]\(*AL.$')\@Y-_BMNB7:BW>RPQ.Y"?PL"P_
MB*W_X'[<L8L^5`YE43*\PU[0L'/*I4;'2R2CD0B_?A1#)XD$B07$IJ*;;!3S
MG1O%00A<B,,O7#]1XYEA;23LQ!^*,'9</P:6!G\V&+H.+O#@QG>T(I,M)[?E
M1XBV<X=N5RL`HG,KB*_PI(&3[MT14CL\`C2=YL4MYQ:^%L7T]FV(@FB4:]-"
M3K4Y^J5'GXK!:F7DCHBUB%$3/Q3#X-8G68,('0A?C$G$A9;#+=>QQ8```4$B
ML5J9"I`A>#W-<O`WCZ3QK5$2(K'@.3V"/(TLX>.!SF@?7J-1J_5MEKB!8$Y'
M/A^Z4Q3)`!FNM0"V>P$;P6_YX@<0QX/P8"\30-E=I&L"7:*X$8JV?P,24#PZ
M"0XU'3SR*A??KJTQBBKXB)2NP`$3H,\A`O(/!V1P^&C1%FK=PR:WE>R[3X$Z
M'UC@B`Y&(E;2Q;68QI(P:D08@%N2$)E^KE9804L!`JH7A^+!F155;]MN=6NL
M?/.J#!:4U@L24@C?771T^'_Z;_[W+TET=.LXTU\N?"`&<>/\.'.C(:P',NP&
MZ.XCXOQOU8IE_6_V)'/*5P>8#&4H//9-C/_ZDPB\/[Z>=YJ]5K-S=%2O7Q_5
MCVJPZS^N;\[^:'2;?R`*:OUF[8_:3T#X+K_E1D&K4>_^\?WZ["<0?$/8LA?]
M]:?:3W^K-[OUC@YA]MTB1(PX8$3ZWPL_>_81[>E+,/8V"FF[U^DV<LA<"E!^
M"QG6K\:GVD3$;\)#[7,:1'%T?>>$XB,2"*R">B5*3^C)N_N;9+_MY<5EHG^^
MTU^OZW+R^N;J]/\<?3RY/C^S3J^^?#V_O#ZYN;BZ/&A!MYY>+1C%43;&T\I-
M\9QZCH\&CXOJ)B"9=S+\3^)&+E<$AB"RHF0R<4)2>P-P1QY^,>>P[!R*2_(S
M-__Z#`^!A^"Y0PWV_$B-6JUC?0<Y9EU-Z0B^P@D=SPE0D$51^H;UGK2-[A?3
M<YG_B4_EW&2;]-6$%2+:0B@$4:*!@9Q:Q-G[Y/]0:X!'I)S;4'IZ8C+U@D<A
M(ML:@<\\!`,^LFE\'>I!>"AB2RN`!4(PM?RC]`V2W^3-IB8>^MGI-XNVU,0!
MK9M,P"J_#<4MA0H24N+HD*$$CMC;>Q!,QJFYQ<`FL%/>1PEJK`?TS\&)KC=L
M^/-A&UGKVO2$7Z"6#IC9S4Z-SA7<.G*,EZ`=2<,/P)V3(1,POFBUR%+AA8DS
M$OAZ*&BE0J@%Z,R7L09T`]GL.PU\,-$C_.5(1,/0'9`;85T&0#,8@A+.\`Y,
M\BB1I!\D,48=1A1P2L"J%^'01>&I[41_R'+!.A^Y;`'JTA2#&NFW@:00/O@Q
M9C<&#']?K88_H.0-:7-6!)PHR9D<9$G/\*]R&4\.`BQ#DE['R0FL#!('WJQ6
M.K6.W>OU:8N=?MUNM'KIL<#WITDX!/]7+/T8C8).OT;\E</&DB..")A27\QB
M5VQ>+`VX'L"3(`.=@0<64C@*XV)Z>`I=,O"ADE"Z?[BT#.(%[/P+C*K?8=,Z
MW\4#0H]*Q@A8/(S@-/5O7P8IKFC#BLAILTQG9;N5GBAM$,@"]U?842C8^1T(
M`=+.!Q$JR8U.0'U34N="U.;B5U>^]84BB?6N<FE<GZU/$+BYH(BF\K40)>Q)
MA!/7IY@*/A:*B>-2^%,!-?_0-;&MG3K+8\:L$:B;-")Z%HUN!Y$X!/<#*)P5
MOH[THCHM>ZM:2:T)JV!,]&9-"&NQG0`$M<Q0L#0[(3,3D"MT.T$73*4";(XP
MY*#N.F:#5;0:4!UH=-Y+C06KUVC:X*GI6,V`5,+"T:1QLP>F1:-9KAA[18;6
M!+E5[S3L9DT&K^`?=JOW-$$N$24=A%E!SDR[0%)7*RN):FNQI*Y6%HKJ6&#`
M9IZ@KE:*DCK[YYD2OJA4^C6[W^BO(L1GD7^627$;[),%B[#6SQ;1]48JYE,1
M/](_,BNQJY7U1+:5E]AX.BN+[%Y13BO$&D']Y-0FXC.5,LBX=JW3L?NMNN),
M=DV<>\?U,-A$8=]5O!/)@#V6S^:,GAP9^1@XX8B$G-)!X"(P%XE1RJ9HTP]E
MU@D%&#)/FO>44FHDSYB.S]85!_Z5-&/$'#A>8"7)<YT10%<S(B15*>"0@.AR
M!B!)V;(%^"8D`L:.&QY-G/!/$6-Y12+4MW/FNQ.SK-#,WO1SZB-Z+G<!36J"
M3Q/Y#T'BC13D&+NFM%JJ"F0V#K/`,2E&QQHD$>`_(OTT0'E&[A.:RH-'>EA)
M,V`B3M>`=3RA!"_*/)"50X[-DRN5A/<NI7"&G'RA2,=(C/&(#>LL99T+G\(W
MNEL]JX*TA'QV&*E%4JVD)DFK;]?;?<TR*=)BD>="[">.?O@X#";6N_IQNXE4
M^`YD:;<!/Y@3W'0X\C+`,I1(^@:YN&0.]9FT^A1@REQF8*N5'*7(>(>,ZL!)
MIM8_FWZIE:\'?'2S6X&#KK,S%4GL#B,62&4N3TDD=,9OF3'"'JUZ3\\#SFJ)
MM&HA)7K,`MYC?)UK$CB42KD?)30)G#BPL6X$"9I#H/$=X"FRTYPB>TSS?1.5
M22PK?\DS$]82A0@26A48/Z`:A@R1"$^U\AX^["5L[L,^=`^(1+;C`5BC1U8Z
M,@J1A=\^V,3>72HP4A5'8'4J9=1M\Z]I66GUPU:!C=P1_C,KF2%%*JDB#V/A
M>/Z1^"*?IYV##,+"7>#!6BA&TL*=`(M.LN,Y;`&RVK1[=-VE\YD=]3P9'HIR
MTM.9F'@AM79ET%_Q;4")@?\`??"1T;I`'ZQ/;(LJ8O.>+F8+0%_$,H"+Q1KI
M+U(X\W%+6\$[Y1D6));DTK@&&'@`X(28AI:0)E*4]\IQ23>.16I<#92P&,V:
ME"`W"OK-+AJ4]&WD1/W[H:#0,-'KDRW.V1"A9D7ES$DKLR;1AK3FVY`J=."H
MHBAE0Z[AQ^=,3PVW_RPB!L%,K<J!B!]0)`6^8-,SBR&4&<[S+-F\K9I6,<Z:
MJ<D4$Z*IAXW$(DU6JBY$0-$T<DF0<=D1$+C2@XZL7E0QV##P\F:H1E)9X#7[
MB)L^BF\)EU6']AB@DE4GE;&A'8P<2!:4TC.2XZCJ#@\98VUQF%#PIK`6D&D6
M;0MS43DN:,$]D4'F6!&('^#3(2(U%*.$S43$@P(3*V\<*A:%M:)A,"4B&B5<
MML6I1L!NY*I6XX`:M..SM?)9:R10Q1+X,@A+^D,.B\SP<RI[4!>1/LK[YTV[
MU>W8]7I#RHQEKKEQOI]>\W$R'&+U+!$2H)9LMR.JF;'TLAJ#W676_;GDU`5E
M'B`]'$:W4LD^_2(<D791+AT(XL3E7P$S?#JY_FB=7)]:-\'4'5I=-(F?ZDGH
M)ZHE$IJ_\KFS`5=ZY+(077)[A,6XS)QRGU-98$5FJ)93R*S:S,)0?Y:*/[4G
M0!4,*%B:UG>J"F&0B/X0:\^I%((_Q-]EG0:Z$14D=]$243Y?F*4LK)5.!E78
MO*.Q%IQ,N]:V9R].K7HTYX#8^#&?&;(PI(DU[7G'/D50A)H=]B!RR"A$GB12
M]"2F4L*`\$)&YYXE*N!3FD-8V8MJ7UW!</4D`MDW7,`I\ZO\4*KRR%H+L98E
ME!;A2(B)1+XG8HX.X0[S@"P3YN9:3_%J.4J-S,RA.U%66C$6R2L2$5H_X2V?
MO"*=,1DI\Q@CY')*/5/(YRB-ZKQ3H)B<+]+,79++;J4-)@-::/(!C^5$PCQ"
MS=4QK5`'ES]<>1SHY8A0;U+`2-/8=F7GS!H*SXNF#A:&8WTK_3S%XAGYL[Q(
MUZ_]K']0[Y[PI%:(K<VVT.F]V,W@19NHZSAYE;NM&^O&5=A9`^^I#@.D#/AC
M9U.W5%O''4W,:'3]6@B]A,6L+W31PCK'PL67LQ9W8/<YW^:@=OX^\>G*C!@]
ML>D@X>#D\\5OE[]8*+]^M=84'*`6'D)G^M>?^']?]XJ\D8I&*BY`Z+\P]'1X
MXE"OOS!2X?"DPEK;J>FBH+$I45!_:YXX328)%H[="^LL:R9P9%W'SJVPOK(+
M37%<S*H2]U#M6:T!/G88)+=WAJ^>UI/.>%B[(36>:$L<C``)?$($QF)>TYIX
M\XUCJLA(.R,/C#PHLD7-L(5A"\,6ABT,6QBV6,86M77'[AFV,&RQ_VQAM,6F
MY^>6QD\V3DR;+,+.ZKQFZR#RMRJ652;,F_A00BY;%8%:46S,.?:W#IP5>??M
MV/0%46](Q)"((1%#(H9$#(D8$C$DLO$]K#/ZZS5=@Y(YWJ_G&GR34P.D:Y!E
M^E_<$=CL,)*-TO$F@B9RT9*!-,OA953.`[B_08#KC;K=[#=W3U@\9YRAH>F]
MINEVPV[U&X:D#4GO#4EWZG:W7U*$8DC:D/2.DG2O:[?[/4/2AJ3WAJ0;_9[=
M['4.@*;7R\N]5,WS3COFO_&5=?;+G='$]=TH#JD@?TW7_&F%`ELJ:1;7!_QJ
MK2N)=FY3*XFK#>RJV>K;W=Z3;<HM+#=XG5L,AH^V<U-OQ4>-;L_N]%N&CPP?
M&3YZEO%<M]NMDAI1PT>&CW9P4V_%1ZUZRV[5C%UG^,CPT;,RHW:[V[6;M2?G
M1G>=DS957O%R6]I(3=&6\?^61&*?!_C;A61;W;I=[S[9.]LA=C7$?7#$W6P"
M<1]$OL$0]^$1=[MI-ULEE^,,<1OBWG7B;M?J=K__Y&"7(6Y#W-M+W'6[UVW;
MG=XAD+>YH%R*OLLYG=*M`[JBO`7"I+>KLN00KS,9TC:D;4C[K>$TI+WMZ#:D
M;4C;D+8A;4/:NX3N[2)MTSJ@Q&DWK0-,O.]).?:.W6N;RZF&MO>0MK,!M:T=
M5(N&P@V%&PHW%'[8%-ZHF2H20]A[2-C=NMUM'$)MJVDWL#9J3;L!<YUFJZ[3
M-+MVIVFNI1D^,GSTUNZ:82;#3%NU*<-,VW!BAID,,QEF,LQDF,DPTS8PTSI%
M&D^,^;QT:.[IM31&7AAY\9SP2J]EMWI/;GJ_ZZ+"\)'A(Z-W#3,99C+,9)AI
M6^C.,--V5+$8'C(\M%6;>BL>>E[!S*ZST>9Z5;QI`,7<45L;ZITK>3O$.VJ&
MM`UI&])^:S@-:6\[N@UI&](VI&U(VY#V+J%[NTC[!4H-6J]]O>1-&SS>!#%>
M+J%VCD<#)Q(C:QA,IL*/'&SM.(OMIUPQ6832'8ONP5:L49`,/+$5X;V5!^NN
MM9FW"NMUVFV[TWYR'_S9N-XRPMNNN)YA(,-`S^RU_[Q!$H:!#`,=.`,];UB%
M82##0(?-0.U:PZX_?2"&82##0(?-0'6[W^K:K?H+CJO<+1;*A7#^$CMP,MK/
M^?!#[J<7C<#42N,O^2V\]M=?_DRN_&KE'XGW:-5;MM6HU6NV%=\)2_R8NB'%
M?ZR1$PLK&%OW(HK%2`[\B*P[X8VLP:/E5"OC()R(T%)30JP')X(%8N&/X/G$
MCUW/HD_TZ`OMXPR)ULV=J%;HV0B_A>-%8C=.\$..-0E&[M@=,AAQ0(#%(IQ$
M"`[^X#PX(3SHCZH59S1R\3G'L^9%L@BNB7"B),3E([G1H8APP6H%?QP[;HB,
MD@CU#08"7Z"/!?>PT](GJY4`)(:+$/"C[F0B1BY@#[8^$(`DH2W(N])04:V<
M#(=!.'+]6^_1AA,=A@([MB[:$)P2_%L0],YT&@8_W`E]+UOV7:-FUVHUVGLH
M\`.PB$N8]L60T>+&=[R!/&B+`W]K4'M*NX/0^LNS5]L>WB'B/84#<?Q'GH`#
MN&W:K7[';@'*]0$Y$=*O8I"(2=;7)NM$UB@)X>B)0GR`!\C$C^^`CXB)KL4T
M%I,!D%ZS1DQ4![X:B9")]JOG^`6FLA18;A0E&M<"%-,D'-X!+0&#Q1CZ)>II
MU)A,HCLG%,1?0&@`@MP$O):'-DCBR!T1Z<-76`0`QO\+GYH"-+8U2&)`E*0]
M`:0/3XR%&S/G.4"+.$<H99VAXP^%YS%98Y^C4,`Z0^(`?&$DHF'H#N#M@?""
M!WVWYS]$.'0C6&0:NL#,^"4X?4_.)+(F#L`)%(^86H3D:J4$RP2Z^$\":)("
M:.*$?XJXP/D2VUF5?/_7*(_!0`(@A2G!9EAL)?7TQ0'MQ+JCSMI)$;>D&J`*
M16J*SI4H]H`V%6?"$9P`B7A6HZU.%R6?@W*42<@B"L+S>=<\AM6F0`K$$=Q[
M2_*2^I9.HKEA6"3^HYG5)8'2\O7C5JW(L@MY0-.,`,P:JM$JUXPXRFM5U3A/
MWZVL&JV\9JQ6UE.-UCS-.#]KI:E&ZUT+1'*KJ`%IEEE1!5I&`RKVO"'VO`3V
M_%;*GO(7OY_S%P>!-])RH?]S='3^Z2M2[QW\081'1_BW$V"@B>30[WAD%[YU
M)I!N71_E\B<@G&KEGT@Y!XW[U;RIPI+\S,V_/L-#+C"'.]1@Y\_(`T($9U+&
MF01A[/Z7?S$1\5TPRB'_F(13GJ>%@[,%6.A)8Q>T*`@H-#]'2MF1X&65ET1*
M[WY$G_OH>@AT(2*PF8D<CE`RXA/`?\(K"L9LX0(4Z5C"O*D%L,A-P2MH=TE9
MD`&!_1/1NS]"K(`@HUUG`@Q='7P4Y+\;C/)RP-J4(3EOEV2L:,;7O&VB'R5E
MGMH'PZ^LGH<[=P@**;^8BT+Q/XD;RC7`B;A'PRX2X7UJ364*Y7T2):A5=33!
M2_2=#T9@+A*8SV7:`"T#SXT?"_1XBA;0,'9"C4_NTX<MUHW(ZW#0]ZYX`)X;
MZP^HMTC33Y,!P`#G2^[]*$QN]>DAI&(=WT7&=7'%R)VX'GPYBIU;(E;MX6/K
M.AE$0%OXHC113H9`:A&9(S;[+LJ4RZ`HA1W^/Q"U_,C[^H<%9O>="](`Q`E8
M&]I2P/I@>KEQP2P'1ZA:&0CA9SL'T8`6`HK&]XT/$FG6?)P!^:^(-#8S%,[8
MD4#79THGSQ(X,DRT02;ZYD9_'HU#E'O@$H`/&ELA'&.)O@O+GP1Y"?2BR!()
M^/OQ-;P1DNW\:#VZ2`+#)+PGGU.,Q\":EA.S@0Z;(X)AQ8B$"/(ZH753"Q2%
M^!!Y&,TB,,65Q63H8H-T<:XC/2]>F1SRIP+"(&]Q2!<3I&*4$UI*3N`;#W<@
M9=0+#Z[G@>>3^H8C&:&H5L9)#$[8<2Z(XTRG'OI99+JXH+K9[5)FRUA]1YHW
M;`GDP"4GC+]MY^,I,C)R?7Z:%Z/7L3,><U`20[BP\L<$%`W\*P*,=TD^UC%<
M++U%!2M(5/C/"./"$9PX>5-(['>.?TL\@3)X@*88.9=@.K#<L\@]RP6%-&U!
MG\//:-(=-QFZ@N0ZF%A!#*N/R'>[SWS4%!,#<>?<NV#,R`WK>,ZARP9'W!LF
MGD,'2F&V<L3;9(&IHPF`"()D&LT0!^HY$`#P=9'*?G`]0<T,8XHKH=M^#/X0
MGYX;I<N7'*6+1\<.$\;64X-6TXZS!BQ'+_#W^G=A+^GSI=2<HT$*,"\@PID(
MX<-=P'L&0HC#Q)>Q"OP@;B23H;29](_2[J3S3E#;_E=$,D2X#NS2;`TPZI*S
M=V50D&WA44!DPV!:.2B!>AF2%Y2[)N?T7#G]B8/(P+A1T2O+7,;K93$AU.%I
M)"CPP7!+J47%[HAEG5`7#0%Q52YC\^GD^J-U<GUJW013=VAUZSWE3$4JWHV@
MXKL#W8W5[`&RQMD>X)#?/6H#$"UCP"+&WYR08EY6E!G3S-41/L/\0/'W]&LC
M%ZR.T!K#"<A-I>9JT;-&YDMO-8#@/_U56RC[]=FO)'A<%"I@SN#*^;?TT&7^
M/4"L_F"65\P_1@F14$SALP+YDTX%<93X,N\X14]7"A#D^B0,,6P?HI`.IC,1
M0]08/HJ*;$-LP,'[M9\I&*B);G!I4=074IP."?,S.`9."M0Y0XJ_SYPNT'4L
MI%D5@>\EP`X<`P?D*.`.E,/M';Q?ZRM=%E*F%#VI*!F#FG3Q;%F_/2)0TH<@
MYV<X9#-1-RA8@^7._NDH`/D.%LD<%)0D1J36S]2QC@2"3MN]5,_I^:8J.N6N
MV;T0J%%)LLB:-2NBU'J:8U@4E]`LBSQ+H&AP?,=[C-S,2`O%D;BGF!E`&HF)
M>\2(!1)5BK4`=[6BWG5&_TXBF?5*&5K_YG<OEDE;SFU(#2=E%0LJV"_&>.;$
MIU(X48I)QD&NYUR>-#]8=AD78HD+09&X<>!YP0.95EA[`K)F`LXZ62(/`L.&
M8G2D#"X*TT4<2,VBVR!,(FF$%`T3/0]L@TR%\P4.XA4PR0-42A8*9BBR&%ZD
M;%LQ^N7M#9(-N&X+2H,6[DZ6/0T%>NDIJ/)'K5B*#W+>B^M:,19JNVCJ8,SZ
MKS_5^.<I9MKDS[*VJI=K3!N'"T!?I8)P49.:[F:[N;Q>IZ=LB9>#?$&RZH6[
M(\W?61/.9Q@@U<`?&YNZ-Z@SK$99KX;.Q=^AIRZQ\N(+55[,XOP-Y-J6HND<
MBU(R\DQM,(.S^3@#\S3#&-JI!EGSD?4^\9UDA"59']9!T^ZV6'M)+6"4FE%J
M.C/]2SAAAG:6W4;VS$67"JID*&O6;8.P^0C#P)&1TJ_8';/4G]I.#WLEORVK
M'UF3<G;NQMH!C**N-S8(>KV^RT/6?UX*NR'H`R/H7GM_Z7F==E<'HNG2(B],
MK<VK\C)Z;U?%Q"OQ7?VXU_I9SW(W?[6:Q_7N_HH20_.&YKN-GX_JQ_V2N.F^
M4+EQ#DMPINI?JQ6JK'O_*)PP*HD*&X6Y@\)C8Z"WC]L%!=DY;NRRK?VB[9,-
ML>\5L1\(:1M_<@9U9R[>B/1+\CE&'1H)D8%NHJ:&G`TY[P(Y&Q^P!&>_%TJ;
ML:!?;XMCU-^KR(N5>UENB9BH'[<.P2XV%'TP%%T[[CZY?_X.4;3Q]%90@71K
MYXA:&&5=>8PF-'*C5!,V&@<@-PQ%'PQ%UX[;AV#;K=%O?+^OR*[:K`YO:E-G
M7#^PRMMOR"8K"SH95ROR+GG-DAWF,.DHGYJY<V^N+J]YA7;YXC,%UM0WHUJY
MXB:V)\/8O2^M%C:GL.`43JH5OB[^6&P$A#?[":/<NCO_-VR:S1T=(W7_/-J.
MB][EG5R7G]Q*-['7DSZKWKKNM_.WKLO4U3K7'MJ-G;Q:'0?35QKK^]+C95:X
M>%8[A(MGETG^CE0P?BN1\`:;OZ;V)0>TX8LH2LCV3,_[^W3I_-U]0H":Y'"@
M!'^5Q%'L^*C-#FG7[#FL&5/;&_VW^SLP&GP!=:N(\@$Q]`G'S@]HQ[-ZZ^L3
M$N9[(Q!V?P=&I!F1=M@B[9N8.#23YX#V?!IP@^F#(NT;;'B?"DCWD-Q-;-EC
M_(Z=W8%1THLTUNUM*&Z77WK?ISU?@/AV_<@='M">5YF5MV<2X$6*MTM3.HO)
MXZB_E#[Z;Y>5UX*'U8H36Y?!/6?0NYA`KY44)CVS9FT;2&$/`.V7U4QM6$Z]
M1G%6HU9O+2L7V+>S-(!ND#NV&]"=P:@!U-"H`?30`#4T^F9W9)[@:2PW\-[0
MT?B-*WR-:;>=@.Z=/]%O-.Q.NV7H;>L!W0]Z*[FC\Q1*VSL^;!RW31#)`&KL
M4`/H?@-J:/0U\C(O=0UGASTI.<QZ;5_J":C;,E)Y?A)_S_:S=];B^SIZ;<VW
MH>SMO#ZZ$M[6[;F\%[+`N)8O=KA[)TB:Q[5U8S][P1-[L8F=`?1YG+:[F]B+
MD]B^3>P,H(;NMV(3;Y-FW*V"QG\X?H)=5:@A4-DLU#WIP;<;%'M`B8]^O6;7
M:B43D4SN8\L`W0]Z,PG(>0G(7DE;7L.$!M"G<<5V`[HS&#6`&AK=#D#?ZF+8
M5B<9-U6N:=PEXRZ5NTLUN]]X>?=\NT]Q%P'=#W(SWE(Y7LJ'F!@F-(`:2]0`
MND>`&AK=?,[I=8HUMSL?E>&UJLWTM$P1IRGBW%<;\GW?KO??J/K*U'#NEB@P
M_J:IX9R?N>NN>W5P+WAB+S:Q,X":6C:S"4/WANZWS9\V;2FU*L["8$=3Q[FU
M@.Z=%=KOU^UNTR1%MA_0_:`WDYF<YPUV>H8)#:`FZV,`W6M`#8T>4&:RWGL[
M)^O4\8?",RE(DX+<.V/Q?:/1L-NM[MN0MDE"[I8P,*ZE24(N<#O?J!W55BB4
MW=[$S@!JDC%F$X;N#=UOF^MLDI#SDY#UF@E';R>@>V>$=CM]N]XSMR.W']#]
MH#>3@YSK#!HF-(":_(X!=+\!-31J.G)N^`;D$[./NT$'>P#HWAEO[S?N11U0
MWF_7J=NX;`?"]<9E,X`:<]@`NO>`&AI]C=R7K@!//E_\=OF+A9OXU9I5B2H?
M.*L#^3>M5F>.7ES@&<Y7QTN@>8IWF'WLI3-KT]@-_*A:<8;_2=Q0C&`M:QCX
MOACB'V##\9WE6(,D@@]$$?QI,G!]!__V8KI\F_EC:V';._.P!2YA^^4,Q*T]
MN"V';;^(:JM\L4UMLEZKO>1H]VVF3@/;TU3%UL*VS7@SL!EZVXK+<<;'>=;)
MO/0$!4/<QE^)?VW:G7[';M5>KO9T:\]NRV';+[K:*I=EB_!2/VZU#:L9V(S-
M:6![>]@,O9E,SG9Y.2]>Q6?HV[@Y\:_OZPV[W]C@\&Q3JK?-]&S<JP/A\WJ]
M<?R";+[-!&U@,P:O@6W+83/TMO$D4DF;#.-SK75<KSL[;F/;>,UNC6_/U,_;
MPMX9?N_KM9I=6SN-]4*M=@[(^]M=IC>^X8N=Z-Z)C^;Q*XF.;6"$W85\!Q3R
MFFRT#5C=77K87<@-)6\)Y-M`#T]*-!8WV3JD*>C%5HK78AK+7HHUZJ58M]XG
MOI.,T*U](1-W$8*W@8J6.(4`OC4*DH$G=M>Q76$/^V>:VIUF`_ZS[K"JG:?B
M@X%\O^CUA=S/13C;.QYO'#?7K0H]-"8QD+\RY-MMTN\GS@WDALYW"^>;:E"Y
MK=$9`ZAI,F0`/2A`#8T:0+<=4$.C!M!M!]30J,D.O4YVZ)\BBL7(KE:>.V'K
M>?'<;2">%TD*[=>&]BYZW&TU[5;[D&G[D#>Q'S1LLD9/R1JMW8K>\(O9Q)N'
MV_>+"UO'M:[APMW>Q`O8QOM!S$]4P\84SY,>N)JM$N+;<Z'PA.N<!QVF^.[?
MOVV@(EMBER7PSFN1O9."C;;=;;Z.:[)%)'PPD.\7L9K(PY,B#^M.:C@T)C&0
MF\#"\]#5/JZ9.Q\[`_DS#=A=)M0-+%FME*CEUPQ+F#,I.9/%T8V]%U.F$&-=
MS)[_$.'0C1Q@-KJF:^HQ3#W&_AMNIA[CD#>Q'S1LHB*F'L,P_0%L8N^XT-1C
M[/XF3#V&J<<P]1BF'N.-KHV8;F*F-&-/!6(3>XGU3+.A?85\OZC51"'6QUF]
M=MQZ'0=H=[G$0&ZB#,]#5_^X893HSD!NX@DFGK";\80W9R)3]/",:QTFD&`"
M"7LJ"9MVH]^W^^WFH5'QP4"^7_1J0@E/""4<&_8VD&\7Y'O'9/WCCF&RG8'<
M7/,PUSSV_4S,-8_RB(<IFUCIDL<6!#U>,Q9HKGSL6C1DCP7^YJ3GW,*1597#
MGA?;F4WL$9.EZ-K[J-%.'],FC-\YY3-O(]BVS'XQN]C-71@1LU4BIKQVR)A.
M>[()4VQDBHUVL]AHF_@I%X7[2XS1I7D2<6.G^^\DBMWQ8QG<KP/`)@_BY@[#
M=;>WH;AU8@$+Q:'K1^X0Z2,15C"V@FGL!GYD!4D<Q8X_<OU;RXVLH>,-$P_>
M&54K`R<2(ROPK?A.6-,@<F/W7E@C=SP6H?"'PAJ(^$$(_KL`;$[P/6LJ0BNZ
M<T*`8.RX8?;)4^%Y8A@[84;[_5_AD\%D`A^)8L"@Y<2\FC_"-V+<1BBB*;R&
MWX:EW6!D`;C\%`<GX?>A.Q3R!2OQ1R+T'F%#U8K<Y7%VP"<1/C?3J\8N;`(A
M/YHXX9\BKE:>MP,)=52M1'?!@V\].)'EB2B"OSG^2OM0AV7#F496E`SO&-SY
M!PPG^:ZF[=KB;:?1VVI%A6]YI?Q!X6].@\G4\1\7;!3V4:T\<2.6VD>ULG@C
MB*S\3H"T0V'=.?=(?T!\?J"..?T\0!18(UCNV+I&0J2]YV!WHRB!4TZF3-W5
M2@JYQAKPIC4&)K.<)+X+0O>_\,8@B6$__#H>**Y^O$1^&Q%6$&$W),(N081]
M6R+"'@3J8#$Z@N,.G5MAW8:.'Q_AV19H5AT:/0`'-4I"D@!(7H_""9$AX=<%
MQJ_U29B,@U#C5.LRN.>'&D"?\%`#Z6GV34F;[3:M\:Y^W`>>RJ25]ZB1;;7"
M=/N`_^4'<\"U%D"+D-2+G`"`Q8Y70`53I<6%JFIEM11POA1Y!/4**,!GNM9[
MPGDPKE9<$/T$_8<2M,"RA)9ZOV]W:H"/=_5>&_^%'ZE6WC7L6KMFUVKS,65E
M_\0-%BF@6IE+`G+#N)M$ENF6JCDG+NG)GF&#X&\<U^KIL:;_ZJ5'W>O9NF;"
M';R8$$@Y:A!:?WEED;))H^0$],5<W1NRK'>FTS#X04K8>[3>M7M(*XST&E$?
M$WSBAV(8W/HDDT&R3X4?.:0#AD$4`VF1"8/TJ2@!A#5*_B,V:G*O."%0U*V8
M"#^.]%?%9.H%CP(V1K3K!_Y1^JOYY'O%2J\$3F<2)'Y,.KP<#8[G$1*T=UQ6
MK#Z@W`+U%=\!#EDVS&9B#YL$5U(J5WZU\L4)AW=62YD_+M(,R&`X628':;6<
M#/^3N&CS(H7X>!)P<L-A$(X<M'T?W/C.BD4XB=0+0+J>.T1?1DH=,&M"P60%
MPB*U'2U817@@S(C,X$4D4#*.?**`G*C29%EJS;*)"?]%,A`?\0.P`UPD,7R?
M/WX7>&!V1?PD6'+52N(K*R>3BTR+C))Z5V;T'X+$(]!\,+&`Y6"7KH_@YNC<
M+[QF9^:QE;V"(`'DVIYF;7+29*&8.*Z/#R0^<$H8S_`V6FGX`PE[)1H4OX3(
M$QKSTHDH1/.QEH*A..P_B1,"U%+Q\LXD9]9U4"_!W'1&(Z(+8/"<(%'@+8")
M:$@'*E-54FT[T2SL(Y?.&#7.%)X!BK(<$`?@B@'!T1-RQV"EWKH(ETZ9FAMT
MR`)B'1TU*UQU)0563+?1LQO]%F%X1M)7*RNI)&N>1@(BT532C')Q(_E-5BBV
M[J\1#0YC?`*I14($$/?J=K/=17O,KC?:=HMLLQXP4:L-)MZ[9J]K-_M=UK1=
ML-AZO6I%FHZ\??AOL@7K3?KOEC28ZNWYJI!,^")@Z=T2Y+P9.PW0@[^17%FM
MC),X"4515JSN%BC1N8)16%;;Q+;L<:O%*\`_4=IMR.Y[*A>\J>>WP[R.QL#5
M,`[PQ#MZ-$21K'+.NN2QI&1#JM_QM:!!&NX``JD!0SS<N:`^D'@$Z!5/2>>A
M%T1(:^IQ]DZ71UID"$YZ8`R6C8LZ>:L4N4;\&-ZAZ""';BC"V&$#)TJ\F!SB
M2(3W\'E=K.0]KG)>2B+IGU8K'S%H?W0]!`L#0RML;N">\`G02L)3KC'X2VDT
MT`;E!`Y@NV^W:[5E7)/]A/^G_^9__Y)$1[>.,_WES(T0H2`>KL:GFO3\QI+V
M%*1N1.&?CRA@OSJ/)$UOQ(_X(]+AWZH5R_I?M=A'W)^((EAH@(8+K`/BP`G)
M#_F62O8;P$WD#(D.3E(K((,DTJQ&!."<+8(1FY@_XF]B_->?1.#]\?6\T^RU
MFIVCHWK]^JA^5`/B^^/ZYNR/1K?Y!U)BK=^L_5'["8--_)8;!:U&O?O']^NS
MGZR1&(*/Y$5__:GVT]^ZK4ZCULT0L^&]Y!$GL?T5K*='?<5LG13C3T;"WZ2(
M*94WRZ7+K$1Z,7F3293%WL@:2_Y^SE`-P'Y792M=70%^._]\<G-^9GT]^7;S
M+^OFV\GE]<GIS<75Y?4Z>><%&"SB:SU;;W?.XQ_.1(!;]+L`80V"TIX?]SZ]
M<P48A4,7)`C:W&"'P7^+T`;+'(RL.`AM&0QFKXML(Y"(_M"=8G@NH!`X1N4=
MD*E#$,6/UH1-#4X75"O??3`G0N"V1Q3QOP/W`!.Y_M$79P2<[UOO,XA.?_W^
M>_;3V:\?=.I(?;!J9>JX:+)T[%JOH530]]^MU*JK]4E)H$-![HXT4=%%`=L&
M^'ZMT/8A4%'!K*`E-81/G)$@(1>Z@T2:F&`3@+F-YD-V`I^0'D@NVZS"XR,X
MB*-I&(Q=)$/GQQ&8%I-IG-$!+!M.@U"^Q/8%:G)R&-F.")`F720W6#UTW$@%
M$&[=<7P$9"K@4-'Q#6\=4`#LFZBP[_??V<(-T,NQ1H$/\(Q$!-@CKP6U4!KH
M@!U</X(A/2E&K55H:B94KA/H6?:.%M5BO[NLJ4+>)"M!,?E"9-J\JR]`-6TU
MB3`R]^"$HRBC^XS<,387!8!$W#-'>-#N$F#H!U,T'Q9EQ]CKP^]%^8"!-96V
M!T?_:0L`8<:*JT;XP`0-5TD1K&9;90;#&CH\K_Q_$S[X7]Z)/SH935S?C6*D
MT'LA386-6CWU7J/;KM>R72P!)@_YI8A/G>CN:QC<NX#&CX_?P;*Y\#^!O>2C
M'7N2TL1&-]&JM7OU3C_;Q.IPY?=S[H08.XN^BE#9O.X04''F>DG\TO;G'V#4
M_\'A*GT_C9_^=E0[;K2SW2R!BK?@WWOQ+Q=1E&!<E4QY8(-K='PN_'/IS7P*
MPM,`W/<P=@>>N`SB#9]+L]YK==&F?B)PVL[X84H8L^C[2AFV?Z)717_[G8(]
M<72>!F<W2G&]9K,O][4^:,M.#,Y6O4.K;'@KG4ZKUEET2$5X-/C!$?)`VJ<A
MU*OQ&>S^GD3&9]<9N!ZQV4V0^49?P:"Z\$^=J1M3Z/=U3NFY@&I[_EW&S4XX
M;':9H.8@II0<R>425UI<[/F[G!44L,$&,EB_UY)[7!\PG<.2Z=2C6*GC24'I
M>!<^Z/L)(>PP7%'=;WR*-P1N9D^W6]Y_OSSY?G8!GN8'Z_K[UZ^?S[\`U">?
MK:_?KF"U;U].JI6+2_H'.I_&45B&8(J&4ZVC-0![\L&*DLG$P;*B*$.[+V(+
M:#4JU&-$%M>.L:T?)+=W,SG*8#A,PA`3;F2H_\/Q$R=\M&1R^9=7/Q^)T2&P
MI0CUB]6$@2%X35/,H_FW*`_HYVCJ#-7/JNRW]O-/"JZU7+.G>'+J4GBNV%8G
MC'G5M9U6!F6Q*K<Q_;$ISW.-ZO727<3!-%<@O-4[&`9('P!U9^XQ-!K9)DKK
MS&$G5A1X[J@\<_&RHD0C_)<7X//)=]G]83!6,ZR##,E^N(1'LI^^D"N:_7R.
MWF;V8^J;9K\")W6MBR][1Z*[OX.4R1KS;Q+4EF]B_SAK/M?</`CO7CQ=N^X<
M*LH%P^'L7P7<-,%7+Q%\^RSK"DUTC+VTA3M84Y0;>VF.O82^OS%K=GL'AA=>
MC!=*!E\;7MBE'1A>,+RP)2;@VS/#*H=@H%P+2FZ:4`IF?XO`W`UD&B@-86XE
M,@V4AC"W")GKS;%Z;HBJ]3IA[DT6K5YB6Q/,,S_-:EU`L@O,UM;;FZUK&M[+
MNE7M.!6LXN<\LXO_2C)NB]"];L^O#>#[?=MN]&MVN]Y_*_]R#P3<NJWHC6`S
M@LT(M@T+MFZO:==JZS5@-F(M+]86R`,CX+:*XXR`.S@!5[>[M9;=[W2,B'L=
MR^UIC60/H0*]#+54@3X-`XNN1LP6G6>_N7,B[J[IC+#)I$C[`U8KX\#S@@?7
MOWWUDO+-85\^=/+YXK?+7ZQ";Q-9LH_=G,*T5GV%VO5Z[2V*UW,28X%`EW#]
M?G%V\W>:,+9!N;$0O1N6U)_/;VY`,UU_/3D%09G;:4G_DQQ)US^LNMC2I9ZA
M`O;C6,X]=R)[D5"#K7?U3IO;@+YK=#K\+^JPU.S4N=G.&'L!BQ";0:F^:JD,
MFKDX7M:[2?:GJJ7MHF,JU2U<LBYIPZBW=_J5VA3+3ENJ.R0UUTJA<X;#,,D:
M96M702V^J"J[`>'=[R'_$6^ZNY.)&+G<YW(:NKBU8.92S_M(\"I6]T.ZCX^.
M_R?]LEK)&@U1LP?7M\:)YUF1B&.^$:<NK/NX1MDGN7=`^3=['Y;>)7^B,EX@
MVP]2W.X'D[^@[&V\GNQ]FB3>CQ.3W:!2L>Q86F_+CZ>?J'])J],DD3S;B[8H
M?-.V\IG0G=][6WM(%+2#^G)#-OE<_N5,[&.?5A"SOJ`>%ED7#Q:]D=;A=492
MJ\8J+C<"22;<KY%ZS:?7*^']PMW*[*YF$DX#;D\*5C::RF!F6[)CIS,CT%=O
M@O9,O\<(USU@U1<4KDTC7-_"YM6-+.P)B[V'I5`I;P0TORE2N4T[3\[:RE#$
MB19%P49N?@I(:HD69!P)LUDAITDV*:/3\`(@$BQ-[GM$O9>GLIOQTJ9B1NX9
MN;<1N=<R<N]-?/U6NY;Y]-B#F3S3`;BQ*/3&.&$A%4#92!YJ6CN9S&W*#___
M!,259_6D3*19/4J$5BM+#$4CA8P4>GKOUF=(H;:10F\AA6`O[@B$`4USL48X
MF&.D_1*D"<X\\@*5!:&FCFCBC`4*)I)'J;M(?;DS=['<J%*MN"EY0MTA<U/B
MBEXD&%`D&7`1^"HV%65!".96?.3HQJ/L0!;%83+$_OAS/%`VQ##ED]EI1NP=
MC-A[LECIO+"$VE&AI$D09"@I'JP[%U@X=(?`@*&X%WXB9F>\\/R:]-61%"+I
M"S24!\/V(\&C<C39@0,-M<;[(!:`JT&21#04!O,0P"?'K\*Y)NEJDJZO;!UU
M3=)U8R:0YX(-,2))-7(FSBTV#Y?)2Y`R9(1DDJQ:4?;02H"M4.-'%E7N4/)&
M56IKL8UT3*-^RF#6HE@^3L52DE-M1H[0*JR744G.8-.+7NY!=L^:;C/S?1=8
M;CAT*37=K"=9;EJ)CK66Y?8BN=AYO<*?VFE5Z]-Z&GB>,PBX*_>)/_KL#C&M
M?Y+-NMIXI]:B@LGW&-@#?9/7,/7>/!7SM"*U=235\_O1=M:B>/W?6O_15^^B
M^_GB]/SR^MPZ^>W;.;7,+1G+8@H:GW4`US?_^@R_04GJ#E<ZE$:MUK2DO+%.
MU%C.+#F<G[[R!;QZ]];QEQS<?A[`6@+IPM>S4XAE?0HH254R+G!6&6E5+XD`
MTZ#5Z2C`4TK/XCV>0V[(S3$=Q'%V7KFA-]GA?1.WF&4B$V?^8=J%$3IR]?R:
M:869-O/#MF"WR=AA?8W!HXD3_BEX9"O%648)#C;D&3^1P!;FGAP&HD+58W@G
MQO&B4[!D?,K\@3\9P@9.)@)]21E*$C^F+GX$C)I[L##P$VC[1-(^ZQ0'(<[B
M2"X142"=B[OH-[DPNN=$,2C6>SH=!JFXLAJX@K406!"'4VA08R*&')R(Z^-@
M.WF.&,/G\7>U=%ZSB]5R8/F$TIJ<.H\RZUDV8P5GOP(8-%I7`JE0I>`<//)V
M9O>LPYXUP?<>\Z-C-(#(9)PX?\)W74^`7>>+;$@+#9?E?:ADA#5V/7G<#LF6
MLS"YK59.>.(O%W;HQ'5Y=C)+5X["UDC1#%4X4GJ"`H0XG`;.V:%)H\Y4)+$[
MQ(DO(]>Y]0%S\).C?Y$J$[,-8!X%9Q`]6@.111QH$A76!B*J8?5Z0R6+)9K'
M;DC$,)G@C`>DW,CQ>(X\KJ_(^X.D_#]%.E6P!'?R(TZU0G4_::UXZ9<L]2$\
M'84;LG[IBT6*Q*>C[*-PFCSG$+,^0'@U.?D'A\S7Y(CYD9@B?H$KZ"0?[@2-
M-Z*A/G""2!)J*A!#O1+F;40*C6?A.(X[EK"YDN%XHQFFT6&!O],L9J8GKB=5
M1Y#NB0@6%GD0]([&/XABJUW[F=#E>?*#&`OR\DL0P^(@Q`@'0FLXO+DKI7:@
M%ZVS+8^RG3(:6XS&XWF21F)!CIC660V!!6R&P:.#H\[2(9A-@A^O&S#\A;//
M9&D$VC]E>+4J'`A.H8J2@7Q!\/$1G<ZL81,E\3'=!0\HEO&D<,%L!1)<`"TY
M`[+^5I=\`Q$_H#_8^OFHG8>=CXI>X&WBJ"!M)84OF@L'!P8\F:)!GN,L*#K)
M?TI"I,9)$#)95"N+CH`%#-!*,M2K,3+0``/`6X-'/ET"P1W/DX^*X++728'3
M>;@A"I20?EN8MZWXF51,\3RTO54K%V/K`>D;9Y()H@$5&9732F%383:VB\)G
M41I>3=>.Q?#.#[S@]E%R8H0!`8LG*L.[VFF1[2%GJC_B7&&?AW.K&6"4$])T
M_AP6S(ZU+IDQK0RGO>1&I*<'AD(Y'8G.`D`=8;52.(:A`.AQK*HJE[&+!S5V
M7(^00=*8MI."*?E:&B.Y+]G$0/FE:-S;@XN6&!@H8(F@VK0&H7"&=R(JO@_$
M^F\*;03%@?>`=3@3'B$W1#-)CJW(R?"`;)F\4L:+1C00#7E$"26LOL2G'E4R
M#70&2.Q$J"'<68[-#U#5.8F7&F!L(E0K!5:QX=&0/J=_7JZ!0QV18E"]R^5(
M^J0'J%M$"PZ3[9G(_9%>,F#$Z`(A+=T*!1B49)+-V`7X2#J-$9#FK&#W89S$
MH42"IB*1*S3J4)I;GVB73;]#*`>")I%[(I86%UZ%8.R0(0I?1.V#$E=?1/LD
MG8UP2=$B>MD2Y@7I!-31A6("EAU^!0DK`A@)'%AO1&NFR90R,R]%`)YH*N>!
M&AYXW)-+@Q%IG#BX06`2PE;@ZRF]\TG)FQZ*H$ODBAF`N=0'+$X<!;$0!C_<
M"=\S>=<!*R([N'=-Z1Z\2R<URJ-$'XWM8&8.=S)(PBB]Q,+>0,Y/H,*A-4<H
MUG.%Z7,K)O$IBAKTYT^W/R'[9<X79L<RVB3B9OVF2&,)=8G'(41[CRB5?5^$
MA@I7BD24E?VGI*5I@FP";E.+5B#R0=KDJ;?=4I5K`[S2+JE0^K'DY>+T/%BJ
M:;=Z33D$F`@CES0HD#G=UP(3BJ?(Y8T=2?]L\8!I-PS=`?IQ`Q"6134`,I<@
M'=&D]B..2W#>.(V&N'(N'L]D[]7L%C@F"#K^#%8+AKPI99+ZI[0]Y@"7*O/`
M<%*/4%3#ESQ)>^.)QS3I'B,NKJS>PU0UZ4O$],#Q"(3H3HAX7X8*X\5H=_SX
MBK'-\I3`G+!F-CKXQ$LFOFM]D[8N3C-10W'WXR0V+5=4O@\$1F=^?#-EGWQ,
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MM=."O8*8ULH0`K^@-4&;"I')T?ZOD?45++J),Z28,`B0]W__/Q^LS_'H."]_
MBZ]5*_1>0<`CNX*[6_X-*QA(!UY/E:5B6A?!,QFI+*CN_E=8EU?_/*K5&FS"
MX0^-6AL-L],[8%?;^GL`K/U_X+]LZ\9Q'RB;,[*^.$,GF<W"X3L"XT,W(@S=
M.`@?<WLZMKZG@@7E09I6R)1@,:8*OW-C3PE.C@!R4/(=]D^JJ1N_XX2V-QNS
MKE;2O(P,+:1EEEI8(Y>GT^(3&-28<P#D&F9`J?"UGAE2`>%ZXZC19C62"V<K
M;.-2\AALLIS36)FM8K.SF)4:8O[7X:OU]DP,/7?&VLI6NC`'L)S2'"&;ZW-R
MA*F_<R]"&3LM!GBSA`T%&.6%1%9AZ8T<C!TM23AE]$DV"\7KZ=)U9*%",S[P
M6N*O/U?\#7/B;Y&M.D=0EABM7\"Z<*<D**N5"_P>5QV"O#P-PJE:XK,[<=$T
MR4E.[=W\RIB#6DW@V1CKS]47#)S(Q0S09V75?56FZ7LJNAZ3G%7L4K[/#S8V
M>5%9@Y29X:7S)`RFPGH?R&RB3.I]2Z+(A7^G;(<KG,"O9IZ<85#.KIZ`1QG"
MCN`%/"45=**:0L[FX@ER!'L."JTY8EI/ONB/8RDD&ME9IE3+S@]5EF!L?4W"
M42*D,D3$'G\M:$!^8MY7902]%-%IHH[36#IX,NNBJY#,HD>4C=T?*()*$IMI
M$HC%9)YH0*0D/J4X5+Q"B_TR`N$+N70<U8$F?HQ_P+?8LU+FM1/"&G?"&]F+
M2"H5O$BO<KG'H\'CD?QGM4*$J]+H%+\J.UO5:PB$K.>BG!Q;[^L?YDIQ+5&C
MA((4[-J'4A!@H^\;'UAL"V7CN_1%)[8XO1OKV7[M;<:#ZU/0'=AR<.\&263E
M(N^)+[!B="@0H$4H5K?6_4!'L[4ZEEFS93BJMW6]A+ED,1XSETD-%;)*O!4^
M5N4H7Y!3&&!)Z*E5M6/X4.*1D4&!VT;M9VL$XH'@+Y5M:&](AYFBA?,J;W)Y
M)I4)+]\P`<U9.RI;T%)8&@CZAW2RFDUHY;ZC^8IS/F1K]3'W@0=XP6@)AC*!
M$M*?\;YOF$SCX2.F?"0AVJGEJ-VT2<,%J7:2(0462)S;F:TA`IZ]Q56"4%FA
MI:EB,E.:M:,1;%NFYU#L^&CX.='R.FMC:'`C23V%&R71E.,5N@VN"KF4[LTJ
MN=0-[U)39#;LG>.+42`BKOO'/-_0G3+5RA*4N6L^N)XGKPE8*M<-TH$$`,I3
MEV(G$662`7`]_SYTHCMK[`4/D2V5CBQ]I[N9KHS<ZZ5.VCWU52]<RA+[)Q7)
M:T7VG^%(K\:G@&8W_N0,@2]15[Y2.;U>![]JV?M,U;U>95^LPL]5W<\."'RY
M^OBYG*9QX_/JX^?PUSQVU(--\CO]-ZB/?S[4GR\NSZVK3];IM_.SBYO-U\;/
MGF1>SJXGHY>MMAJ=;!CY:>*"'<$L>GWG@$3-BB5Q:=*W)"U4&@#U=,Y?^!B$
M(8DV/8I<>!=X6&0-.T$6?[[X>/7-FH(_5JTTCQOMG]7RK6/X-VA[=Y),+!!S
M,_9/864VYM"2SQ(Q=;W+'(;DL>HK!*/M(5^`=9.+C\M2+;!PDSB*X564UH4=
M.23\"T'WVG).RPOQ)4)8$]??,,X1B6O,I%Z#E1X;2;V'DKJ^FZ+ZZ[>KKU?7
MYV?6M_-_GG^[/K>N;ZY._X\%'S."^TE'L93#<,DK%'3@)*<%186*27!_08Q2
M79[C61.A;J)4*WH]1JY2B4UC^2@OEZO=H**7>S&RJ74!KB;C52CT;2L24P<E
M=5:<IVIQR55SQU@8SU=777^H!?RXS4&0`,32T':HT!<SI1%*N]1/D[O+>\FY
M$AIUM4"6_:,[_TL#P:C_4N?FT0!\$M^!%_A?,=)1EE]T$#@AE7J.0*T,R5FD
MS(KLP\#@$/RHQC@"P15I.MSD36!--VV+?1KI!'/Y"V)T&KHYK)4CS<KA+*=Y
M;_(M7:0SA3^."O"XM`M8"7U8(9^DDMPI7DK".$/6]G09JO5.-.+'4-"%&;H^
MP%J;5K:RA?54>"2H_A>K(2(F3+I8D<:#Z>]<;JHN61];&^,B3UW2+C`1')4>
M.;@^/\W0[N"%,A<CL1S]N%9]#'$KGX)P8H'V5?>@R'QX@`W%6+Y'%1.`YS%G
M2_!LT=Z8H6,\140K&1LJ]\7]T.G>2E:L3L24?@1Y%7WH(P><3>JBEG>-[U2F
M25Y<S\Z`#_#RY/KLY/^U3N4M]"\<A<I,H.AQ`N+?^NGRGY]O?I*E^+*BKEI)
ML9628&[S:M<EFFYENVF^-92[1IZV##@3@]>_,VY,I]<TG;H[:3F=7EV"Q71S
M\?'SN75V_M%82YNUEE1]7EN-<,A<7EF@2[7A^68CP03^%F#&PZ<Q#>_SN<]"
M;_!\;M*E?*-S>QN*6]3BH!%]C$1Z9$#)JWWO&G:W4;/[O?9LB+\X(R*M81MS
MV%PZTI3S_YFK;OG&$A>0@UZ3[O3$B5&?/NHI]ES2X[W[04O!^\6*P((9@)%.
MO!05WN-ETC'?7/."!^S%+IMXAK`DK)D51:I^FMKMC*E,R-Y3>H\[8'&F($N_
MLD9.MTH&IC)@R)["&U:8!&XT?BXB4/?@4]RK,F.L5KSEFYZ,)+PAE?BRN)X_
M9U/80"<(;3B&+2/4EH<Q[="FU'E!C>>-*305W]6.>XU^KZL91N]OW7L$41J_
M:MK&N31\K&]H8GQ8=.NO;)R(P!R;=A<+*3&)`VS!,M3;W(^%0_GRM/*QF]T[
MG&*S?@:2K3FZ^X0/\F4?&>)&;R&Z(P,^=T=-WNA!RZ[D'0ML)S]R9"4^T5OH
MN'BK#=#D"4Q)OFO4E+F#Y)X91/E+F#IJKETL(5^$D]QQ8K5#L7&/XI&T)AX3
MFMEY82(:<9%-5<G?VLV7V\O^;*M[,)2AD%#,.5S:@ZH"`\[S@56&\II`X5BK
ME9S`^GCZ:6'N/8/=Q02K'P&MZ!O`F0M<6-NH-^UNOU%L3R?K#D8NVGD"D:=J
MH3CMHN!32$QG.\Q!6B:B\WPE\_'%H[*M":99V;:5[-FT&]V>W>UUK.*U"^D+
M,Q5D/EPYX>3$`-Z74]]$XQH+)%BBS]Z7R%V&4)*%LO!4L">3],6=S#\9(,0C
MYDE$%;:`6(RKP@D-,&?L.YPEXOH'.%%TF?V$HIFP$M;0H,N;%;84RC_PF_*6
M.^$-[/Z9-H4#9L,!BFUX5S4D4/5=V3$[7)Z6NX:BEX+-G$<IORO&)NJ7'$HY
MQTP"TI0ZVK;,SI/F(:&F2RA-+LUJHEGBX$)OR9%TWM1[D;"[!FN>+N9--\H6
M'H(>=ZFK69JC=/\K?I65WN.``]E%#N:B=+#+],)O_.K,=;5J94$]N:9)<]8+
MW]>K<=&WIGGS5^/LN0.PUDBH[Z$5NU*RYH2[UY0,(YM#F2BU/">*F*[Q_*L5
M+_!OCY!/K6``(#NJ2SJ5X\Z_CL6RC%/?Z:VQV6DY8`:$\<SR\5T8)+=WN9MF
MM(B\#J:%>W+AA#3V4JVLD2O?;TI9W]\I!(B+5$*^`2J&!+-C$S(KE"6<+[S2
M:Q=2CX)[(G`IT:S`QIL*L>R#8:E`\CRYSH48\H8..A7*:M(->7;#.%P,*B:U
M:<G=22?G69&+EH#CBP!SB]I\)[T4'&UBK>^B5K4!'RHK=4W)'?DU)ZVI_T)Z
MA[VHO5-W+[W[*3U.*I6BB_(:+Z6;RQ1NH'>$(=;19B10:P1I[2!Z4D2G#5=R
M<',4G/.=XC:(N4`JK80L]YKD%:I_4QR;+F[*CJ#2,4M?IXNKW#83(VZJ.576
M-&LNQLO-^,PJD9@CTX+-+X5`#7=#PAWU]Q"Z09(UP3G5C%!"1SDMZB9V44M>
MJ:$2\MIVW9[G*G]4>82S-(]P'TC]"S@4TS@]M6I%'1M>ZY.)`$G0<V`DP[5E
MUWMUN]ULS[U7O,H0R5Q&X:HP-,->:0G9@"9/,P6/>L'\2R=*?3-5AQZK^PB(
MKY@MCG2[\\SYF1##2C/=-'<2*ZDUM<E`J!C.?.[(3'N"%1]XUP1@6W:WUK%D
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MC7ZM_:/5:K5[]9\`S2ZOP>C["2AXZ$[`;?WK3Q>7GW[Z6Z/?[O>Z]?_]R]H0
MKK2Q?^)A;G1?;A2T&O7N']^OS_3-U7[Z6[.V=%<SX)5L2BKF<_)6KM#+9ER\
MU@FUBH<S#R`M`7HA-<'5^)0$![UWXH]^Y]9'$>W[%8^BTY/\LA)@VD864B/]
M4;UY_@/O[4A%^1KG`I9(NZFZGJ\/YAJG];KTUNFU.NUF=\4#TTEO%6;+#'!<
M,16>UUD0X$6V"3_!CQWXJ=]IU%:BT59C-7&Q=`=K2/RWQL9<D8.TW5Y1*:R)
MD),T$AO=!%DOWJ]@,E[XLNZ$%B8["0TO4-UDCWP3+*AAZ?`>K",&0AM0_3)B
MK=WL]'NKB;5VN]/N9&C:]-96TDZON/]ZJT@CL^"L?_@%F^IWL%LS$OLD,Y:O
MMTFP-<'47.^05]G"&]E/:VR\40?3L/E4(VJ18J17-J2^5]]@J]=L]A=K\`6`
MOKJYM<[&.IUF\PDVUW9H<-KH$S1XLPZF2V>YVGJ*&K\4\86/368_!]'S=]CM
M=1N=E?9TU&YU^NV:9IOD(-F.8WO*075KW8T<U%=YN_]3$'X3:BQ>CO37V&B_
MV\6=UNJ-9OV/5??6Z6@[6P[.,J6.0;%G5;`V.VU]$Z45K%N5Y7IZ467GF"^@
M_/WJ\]GYM^O<G-:S\T\7IQ?GEZ?_VO,48EE7L4TA/*U3"\;6E18=_YKV(V&6
MPP30J0S4TV_V_`Q>(.&/:5QL@:!W#J[E[R@4I^>DIZ$U3J&P+W=C&!<3L7BA
M'1P.%/[GA=+7=*8QAYQGFGZEKQ5..E\$BX%_^>3IPDE^<S]PFGU`44[N"R!2
MT;JA?)D<D(-[I:PJ[U2;U,=I90[_\A_S";LLYS%O>UC;FFVH\,>9-EZ4]X!O
M<JM>6VX:*^,BSL-B]-[UQ&V^7055\M"YO<^*L#!#CYE-3W9(4N,65%X%_RX3
M+]G(:EHI\/D@J#4.-PW.D0*-NBD9HLB7/K3^"-3X#.^]J&Q1>4%C.L"04**F
M`65)M+'5L!N-G@T6JA[4UU,<6#<D!QOBWKOMX^;/6?YN;A6EHE8]3Y?U;]'3
MF+E>#%B/)^\9Y:NA5,V+^K1ZS-8*%%+,R<)&=<)Z2QW5:#-/\W:^#SI.I>D"
M4KH\'RE2`X4+_(\I#R&G=N9J#:J57&6P[(VGT4*:F&S8S8;\2EHJ3M6QV;IV
M>GOP/J`CD(2S=%-`D%R!AJ5&2#X%=J#ROR"<P)\T0:38;8:E.,D8"H]+OC42
M)F*D2V7R/IYV(TLK&%CY1AM5U<,;V&@NN^ZDF<<GPYD)6!EMI??=5,ET[F+@
M3$FF2IC.J7=2=&:]S^4*,Q[2:$X3*FKRCQ)Q11G+M)#6QG)6?:;$8K9"-@4V
MA2N=J5/XQ`?.Y!<ZI-<;QXUN$7=I0^`LS5EZ2H7<IY,>*?6M@@,?<97)8Z%,
M00S%:(:_N<-YYQ@@,@;(,@/D9@9S<KBXO#HHBP*EO%>SS!63#YV0IM-I-<K,
M4/,4*\Z&:]K=KKS@"-]*)HD:<%(BQ5IVJ]M)9\EE)=(EF@P9XEVOWJ>G$72<
MCX/2$648C5&@ZYXL[U$`Y(1)I&YW5BOO(Y&W4O1[H-8WDDRZ?<(W8SYP#7F^
ML"0`-IDI`CE2RC,C<[T8NDQ-7<QA=FSD42BBX*()8HJ`;#\JDY"5.TH::[4=
M62?PK`*GT6W9O=YL>4A)_8V\4SYSHR*M`->'$:0'"R=5K]O]=MNNM^LE90#X
MMZ;=:J<5_9EXRK,ZWG254V3T`H$16C.9C43]`PO6KD*%++&@.75S6FT;,;)4
MC#S=/2WQ-R^R$J<<YF?NAS_C*R7V_>:^5>X+&X):0%#Y%MZZ/ZQ&K>3*UV8=
M2:EQL.8N9]&@[=2T&YW6[-LG,\8[=L'D:C/O49-!`)1^E_,F4WFS`)"M)*<7
M9/7+\HX17O=O'H.^RFK#R,UOU,%'T"KY\O913C.46I?I"#X)UIER6C+5P=OH
MV<4JKIRM-M<+ED59HV3(7NJ[?O^XI96XV3-ZB.<$[/TED)>/RTFA>*-W59]'
M;7N.W)>R=^<R*S5&2Z<:I^9#**V;WL]<T5BM7`WC`$T$[@O6DY>G?N98C#.F
M/N5Y5RBS;MD-5S-"96EB?J;8-0W6R[TA+]Q1["?P09+05\"^1%]0"X5D;TF'
M4HF`F<V^YTD'A>%WLI@4;.4(YQR07:1"7%P7KOTE^J`5\A)H<I7"19!Y,.A[
MO@QT%X"V+#<[7[AF$[SZ:E0;FFMYS*]Q:Y#B`[H?#:#8JB`7&Y%0#^/(G;@>
M7L*4=GPH@O#6\:5S%/'XRW0V`36O3UWW=/0B^"8<L)+&#HOY[)Y4<1?S<2`O
M"I(USX$<.%09R4GG>Z%%3/3&M,-6>S#5+VPJ!4N0-VMX]_8QRF579)M<NBV-
MU`XZ9>)B(R`OB2AL,QNGU,ZTH+;RUS/A9;UEL*5U#,;NO6DDQ(;]1E&`R$/(
M\6J_;.`W71Q@<,;HCLA[`/.U=:'H/09N)J\*IRD+7UZ+4-VSYRGE$V1-#@H7
M!K)&\EH.7>B!E4K"8T68BC>K%HBO(O1E(S9H[(*-#EB#/.7,\E!<K@Y1N]Q1
M?H9C6X[@P--;[1PL_1CFQ);YBAK=28XBNIAX#YZ\"D>J/O"K(81;/N(0JS%>
MTY5W;J98WL\L(,^%F@^,$\^3\YRUT&_Y-ABR`L*1V*,X=('\19DHG`OG>QFZ
M1VFL-K\":5@T-9<&O2M"^R"O>D_#`-66PR,0C-7U1*LKJTM8>(![CMX7].<6
MQUKP]GFGMT)8?S[/V\B.LJ%!%DN7MX-4E)(BA1T9@^1[2RH..9M8XZAECR>`
MYCJ,J*SLFFD(&YN?W$OWML0/G94/NH$GNY*4=SIIM.Q.??;B7"ZN7IQ)BVUM
M9^;/9:-JEX,G=5J6@J7,03D(,\%5K;@`S.J5J@MFD]"@WK%!_(<7EW/93+PM
M8,/7K/F8JW*^RKMH7]5=M#V7?1M3+=?Y$,TLIH&=Y3"=_<;P"V#SM/P2I/@!
M[E3>Q2D?G((=/<4@Y*;B2BIFH[/H+F9Z'*BG-/'F8*L&C.Q)5R&B\TP[:)1J
M@YDB@9&(`$GT?ED!CC)$6-(7-5XN&35UU%7.=[5CT%BUNM[8ZFDE/E))@BM)
MQ<0EC1/2962]<7&$EZ6J(JU.S6XV:WIHL\R;FJTH21=(`Y3OZEKOL/D;^Z2Z
M#Q1Z[QBF6B-4EAXLWB(67!U/'EE9Y4_NB(D12H^8IDBIQ?1S+<22C[D!LB(^
M;796,5/7YC:XV9.\M-:*["_<HZ+0/0%#,%2OIM694>6#6LDIMMK+A8RL52-&
MZ?7_8L@()$QVU3Q?OJ5`4&5<%/9CZ#AZDK:@!@<0&%_K+UVZD$H"9TT>LK7V
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M@2:'-6A2`D=0Q8]8J`ZB,U,M4R#AP6)4H]ZVWM-\1]G'B2V$YH=LNO,DH"%P
M-(-RE#,6@GLW.H`V=)O/5<_U+O8;L2^E[5:XJL"CO`KA3>M=6[I%^>S.3)?;
M0O1RUCP';SJFAG)D=>K]DF?SA]*NQ*J6@@6OE?Z#7!JS;N)B4U^KKYY7D+F"
M^+3*I6=)K;DJ7?WG[R=?]>:OJA!0<[GSXUG.I(O.LR#G.34\)P7-NG?-6N=8
MEJ(V:MSR;<@Y7ZV@.9())T)G9@>L=/:<?2KMCUC6JCR=C%E(A]/W7740QX6<
M>=H,>U'2?+$'1+.$ER3-]UW6OK@_/BL(HD6E*_V?;4N6G&`F>^(>I=="@!#D
MG"EB#DV1'I<5HF2E*WBSP8GN:!;Z:K>JL!HOLU&TE^8%".9;WBQ[;)TF56T%
MMOSB)@6S8W'08")+F60;S3G(5<S,M7@-?:Y$GW%)F=HL*:1C+BCH(>\9X&4B
M*K3`LUJ!GE0K6UUNVEDX$046?.?.';AJ/#0\J/KIT8QQ;L()W]!R[6#$3IQ_
M!]3Y5FYCH7]V/GLY2KO0Y\K>K^F2N-[_Q9IXZU.")(<<QV'E#SR._+W[@3@L
M7\LE:_EU]I`PVSR&@TQF^B)-FEHP60SY</!XY#D/_"Z\C'J=4Z:/LF%S6HE$
MQ3AT(.KG&?LA"$LB@K!"OO7SHQRR4(CRX70J'*X0R"$=TJ?D6ANZM+B0D-ZC
MOITR"2GV!V`F4[I1DM96?<"=WG]0<T64E5!V+6J^Y1"$.43-="U<^#8``-^/
MA,<#TL/,:[-NT8?1KM_-E.51,4I8\)AEA8H;I\4H[TG`RGLY$1M=//><FK3S
M+'EN)D]-$ZF=+2H+'.0%N'O\8,GH:"IQIT&$LG:0P!)X2C*"2H$7)F_J>CH1
M(5X#E#P5>.K6&N_$\7F,X%#5E_ETXBF?JE[(9-TEX3W/2M$H5K;G7&('L3C(
M"0-E:.+?L4@1KRRRKQL58J3<_'AN"&.N&:E65_V(51((]XD=O.DR$!=PZS=F
MK:R6;-'.D&A0''#YGB2<4'684(287UF-;'2*YFS9VBZQ1!*&:BV$>20&S%`#
M&O@++X#,$8^JE)ZXE5R,6GHQ"Y>"M0BWL\PUO]0KG;UXS',)RCK?^X&>+)HG
M=<NU@8J5<26Z]VCCD"=?Z^.*C4-!(G$07H[,`ZMG@S4*^VY(;"RH<#*Z=R/`
M[R<AHCW'X0O@ZQ.(9*!9L&:^.F'LDZ%PX0^/\^/-U%/%;"^M_J\@I`8T&`@E
MEW3LAA-;OS!(YO-8I*W?W1"SW]C:;OZ8!]607ETC73E'K\97@6?=E:('-5Z$
MF2L,->!H1.M]]^<T8G\;8A>GPD2I+(7`$5[D8K*[2F[-E-1;8J@[YZ.DP4\]
M%BGK!.:A8,X./^2KX5D[NCQ^1LW:X*`HF(?5BCH[\*Q_9/OO\/ZI6E^6'.L5
MRX-'ZPO8G>X4).K$D4'GQ:41F3X)@T?'HVOR\(0O8HS8>QN8Z[+G15=*GO$]
M:R3`&[0:)M(7*2E<,-+NY5S/;.I#&N>GT6XQFEFR6!_MK0G'-I&'W7"83%#G
M#P4_RH'4@7@,V`J<._7-C\/`L]D%E(DM?3@&P(I]/)B[VK6?R60/DC#O<1+8
M@T>RSX#/(W;AJ+;_D0(</!%*EM1+6TE=1D\O16M70(JF$WX-_$RR;K`TWO&E
MO$6O37H4N5E!)86D5+Q+T%0K!<&;+]7)]`>+QW\G?E$^SG(`;R>;;44E[J'P
M'`JG:NWKJ=H=3?UL)-TB89[+(LFDIEP5IUX6AOME,EXF=VG4MLJ$4<MZNU_K
MRH(D?31)ZG%^])SAGT?70W#>48Q.8Q6&Q0<FP4@`M:1=#JJ5^P"!\60LHE?[
M&75SZ$9_'HU!/A>&9N+%_>-Z]V=9K(5?)R><AS[BUWEJ4VXO'V;;ZZ=^+<8A
MJ&-!ZF(\W&&B,];0-#L"<9$'#2@"]/2;7$I=^'`,/`?Z)U0Q"$E-JL=$^4?*
M[MOJ34*P`0-&JN5IQ5$!8("GV:.1V_F1#;FGV/]THJ.L[CMW]4=>\$LG(A(I
M]!M,"&F3HVC9*$?MNI9V'-7*HFX&N5C0L95>G1\&41SQ*='8]H*CF7$6X:#?
M3HO;4;&3!WL+4A*;KZA340&=8_TZ6DG5*LG'7/L;:8@0(K58,CZ3WHM.MXSR
MID`(ECZ#(RVLU$L=G)@38?+F4K'F`?:6F^'(PSKXHH]&'3/GCN_7N_URZBCT
M/%F/.EKU'E/'S''3!/5(I$5<A<//GI;LL<Y!Z!?AURX[R4,:XPVR)HB[%M^B
MB+5N,'E.7;2TNFRYK!.*,8!6&!Q8+%H!=<(Q8)HF%,Q43&2E%4C,6G4%VAJY
MYD[-!H:`XCO):O)&:Z&U5:[N.BN'*]Y/7H4<\O='YD?'9GJWS,RUQ"KNV78P
MR(&]5DUI(1H'Q3Q5G,@IQ[JE,ERPR4!Q9)1I(,<SB9&*ILQ.T+I5#7AN)REG
MRJ;GSB<U$:J556R$$L-@Y$9#%FYH#1#FZL?M%IL#F6'`REM=,DR+0M$TV'<^
M>^5;@J;J98.W!/O=XWJO`:9DKEYQOB\V7XB47!=$.50HJ&G9O78_C7<ONR](
MU1]UUHQZT8TJ5FW7[5ZO/Z>6)=?N\89,B[1K:+F*U89BJ@F*JL]6H4M?T\:Q
MWIKUK3<KLV:</XR,H6PH&.:SUP47'QAX?]5*O55;I1QPV4%A/FG^Q4[R+VJU
M)3<[Y1SE7'5LI]F>?U[=#O:L6Z4?SWKGE;KK*1R%\VK9G7YMWGF5>.L<REQP
M7A=^UF\TO>.YQ!:<4\%;*"">0\R+DBD+V_YR6SVCDU[N3N=)<@N^#G=+T;-4
MYD[GB]WIS#K)?E6)@324ON=(?:%NZ(I(VTK3:YHB?^,#_Z"3M,(XK)&__R'3
M,5CJ*L`;Z?7M>J.CB;EB90UV1TGO3J;7*7-U]WK9.^BX>K^57V^V]++\JEN]
M5CON]_2^:>2'D9Z;N=U6TF>[Y%9D?\&ER!RZ9I@^=S_2RN[4RCJ._.T!G@KN
MN:#(TD*ILM/(Z+\P994NU<JC:8*>Z]06'`GK<@R7\&TX'?_UAEUOUA>^'"M,
MZQ71A,RB>:2J&F90=\&A*C`O>>9U`5M7FEZMU\IH-YN*2E;JF&;8J@':61YN
M,0X)#XBY:D6BKMVR6YW.TE+*//$"&E+L`;WDA@;/O8Z;#^OSC-:V0MA,Z%$S
M@M*X0`S?CYRA[))%-@_\^5VGGAK6G"EAIWMV[BLU')29D[+.NE8Z7=F(VB6B
M]JN\ZIJ&AI?P;F9"2KJC/%9(90!40T7T0,VEX)C&202G,L-#U#L9:>P3/?>-
MG\M?MYNI?AO`"</"(SDV.5+%!K*V3:3%=(746K5R>?7/HUJM(5LV6^]GB_T7
M;_H#=87"Y[X?7Q_/;H=^^YFAR&\BS7')T@(WQ"MR3DB6`8DRE#OX@+Q95>H*
M#>1H>8R:JSHI??1Y*C/*\9KU+Y!7A+4,)PV>GTP2GVM$LYH%E2;B6E@4TPGU
MMX<='.$&'O&<Z1BR.I"TA)4_1.VPFC6ZW4!Q1I_NCE"I("8SQA3UOY^YIJF@
M1:&3*W545P?DP&^*0<H*8AI"(*(()X"`5Q5,W*',L<1ZV0.7`G/)L2LG7&M[
M8LHJNG'E6+4XJX<A-MG]+*V.!(P.W/2&R&K4IADKQRFX6*@>"0"-U5+.ZO$P
M/:-/[)!Q5ZVL@X?58_@1*&2*'CDJ#LTIE1J)4<*E/:@+L\)YV"9X=QYL[%Z6
M2"(V5>D.J4Y;J63]I5"A+"\(N+(W96D@S!QG\N<_`^)\ZV0"/N?0L:TOXH<[
M#.@CIX[OC)QE0ET):"/BGRCB%1/?R4H%=>[5BG!)OJ9-2BRLH9RPL9-Q6:Y5
MY$>67?I+#C!>,,`",7[-B2G_@`F"B1!8")-&AOAM/'N44BX\*%1X;<SM-;%W
M(LH99T@%J;)*VO5Q[`A'U*G%8JYU($,<I0E=^LI,R)^WC8,G(CF_GI2-(^?'
MLSRD.W%1:H1AY?4R?D/1GXU,P8PM9=%PZ`DVH!%'=XXWSB)$)35FHUR#BNQ$
MN5W-/&MQYIM6Z2<79!*S:@=X;E)LEF,5.HAQS#(5&MKY*Z)0-(`IVVDH[MT@
MB2A!(GPNAJ?:_?+KR^,T<9U/194!Q92B[)7I-'`I@<,VII_!X6KOSFQ&O8Y%
M>$7.L$BE#]TI;H\:2%(:7UVA2&&E:DBLL@]"+1GGAEF7QN`!2S3OW&D6/TN'
M+>RW+;O!I(P>X5*\H?H3[3=27ZJD;DFI*TO@!8&-X@5D[MU3WKJG8'VEF<G"
MXEH3G_E3C0J-?<C=+>_LH[KG++G:JA6NK-T/6C7W8:6SJ+M/9,WK[L/%-_/:
M^Q17R;7V@5>YMT\>OPL*N&;+W%(QF/KL=;O?R/)ALZXZZKS`5U4_BUSU/%CS
MH>%:&:VJ+E>1DQLSL[!E2XY"Y-LCE3%/;[C/*=FK5B8BO@NHA`"_)7M29X.)
M\HGY/B;FTWH]5&I:P1Z@3%Z7(2^Q<5QK_(R'UCC.U?!9>@D?)^H+J#$JXHDJ
MHFRPTWZC\H5*C=#N*0WZ%F/*\\/W7*^DX5_=Q"N-W<_$7OCWA2/,4BWY5G]Y
M$2.7U-_44P99C$2#7+D;V.A'"VA>GY^2?>W0*`8JX_[B@`':59?7"GN<TQ)(
M#B0C2>EYA:JY&8TVUP^01F_6CR?G!^1[^98WP,-XAJ9QY^B#-;\^JWD6G+IL
MOS/BK')9`Z=4'-:/VS]3YH1JTZSW\.)1R.6N5!\^`M?OD2O"U:5D?-QEZ4UW
M4.G$'&K\SJM\2+VA13F6&0\M\Q,Q)>+_)Z&=S#EZ!`?)J(@716MJH,-8UEK/
M74C6-U#):SKY;D;[<G`4=0_.D\<;TU,,6'Y0K<E6*-W(S6D%P0#GD.<RBE:B
M7E.*4&$)SF0@W>\8DR>E#;G`CY-=[",1X[R"><VKM"9=O+Z[2IT@7P[/SX[U
MRZ:N2L&0#B+5!0"I:-FAG^3#1%IBZ;#<!?FG,5W;)1ZG&V3P\UBXZIZP/NN4
M9S248$GG.0F&1A-9-)"KC155E"S$+3PDHN=<4=,ZZ?DC.W>!5C('9VC2PFMR
MW=5'RRJ+9@W`]$:TL5Y>KL+C'XGW2,0LM1MIVRL,;IMK9"O6'S`*4P6><QRS
MZHY9+1<IZX:L_(!Y"6]0N'$B*5^[*X0M=_`[]9*)[^2B9*EBNI5*M<Y\-X#-
M!JV+3MD@8[Q>2,*_WF\V>60Y]]2S.:^3;]A;QUKH=F=Q"0,HFS$(IR/2%:6%
M$,F4I9->2(FK8S.RUN+L?GE]!-XQJ!UWZWI]Q&PF6E[4T/L1^#1T6$]4U^U&
M2RI(<K%'G$I&_9<EI3EUO6HDPIW7$`N%JFI%I-\=E)'KW(6]E?QP)QNR2KM1
M7JJ-71CD!8QT$NK`'<.!D,Q/+S:GJ"+U4YR52D8[ZQUG0+[K/-,DB7`7J>-K
ML3,L4YH`%%^:E#H=KXZ[U!%N@IU]R`R)9/'#S%ZU_FVR@>J<:VZV?BN.RF7@
M`$C5C3G&E&M]19%7:920IZU=W%%YY!3-"F!660.AHP8Y.4PR%0MGJ>TWB?@=
M.>666DL43X]R!MKA\1#U6^&+4'5NBY"ELZZU022HJM\+(FD.$VJ.*/#!4@(L
M.3X)FJMQ&0`_=TUO\^62_MJE$R#QFDEURM.2>9Z[=RK='JU_4>H\D(0JEG#I
M=F,PD+>-9=VOZCA%`K;\%E_>UDM?XC@;UEM9;-&A!JE6.JFKF<KX&?52:D\S
M9++<WHW4=TJ'K98(_MD9`!<^MB!`9I%!]D(C97G_<LZFJ8:89)52)X"E68UB
M*872G"V?3V^3S:VVZQS7.GIG>>`837!S9516H#T[#W7FYK2&$-DH=^ZI9G/?
MEJ6V9,/[62$YBV'<:W'V-I8OMGMRNA$F-,788QDY;S9V;FN%^=@R0IIYG>A1
M`@:=D@9["<FE/5$/<W%^K(K\R\4_45!._J\KYN4)L)RWC)A_9A(KD^9\/Y+=
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M'<^G?\XY`$A0(G6S)%,RMG:W8YL$@8-SQ\'O@)G#-RQ=V+2B5"\W9$%Z)%<2
MD#HI*O4-A0,R[Z4ESB8#SPN>*&84.+K)>.R$[G_(CF251Z+<[1Z+71`?4VW>
MEQH%+M$%>'>9A$T["1(-@2KO[^)<@4F$#JW!&]/OVBR(+1]0`N1=]C>B4BX-
M)K<YIFU&L,&P>)M!'WM>-'%P<;^^:_"?)YA%%#\_N</XX==W_<9/Z@=#Y=]#
M^>7/5]_/SK\??;ZZO;WZABMS8/?MR0^#D"K?H=6F^=\%<1R,TZ';,/0,-[\J
MHE4%T;'F2_.B;2Z7U`7?X=FZTKQF.?/_'`^+6.3ZY.SLXO*WE$>`.S*^B(-)
MRA16`4]LEB9%FYQ;3_$*UF1RJPD+&@0H:O!'>ST>7XV7%#51*6[*M/0J#/76
MR/3!B3+FE.`Y'[4('L0*M!)YH72<B[A`:Y!R&EUC^*4)I%7L[A24G8L2WISW
M7E$^/T\1QS*JG#GQ2KHAQR<_Y^*_?"RX2I#WNJR^'P*YI"M0$D"__KSW@[K[
M,4O-`SNDKETQC36E=(V[>]CZ(/SUW7^=GG[Y<GKZ;IE%;2;75HF<%@V)J?]Z
M+47$"$;YKB"K>6\+V)7*1U^;"_9.JG*SM(NHN67VV^JV\0.PS?)9E3=P?Z5A
MCY7<^TWPU\&)'C]3/FC1F^.1',8>TME\O<:+P*T7A*"9-_3TX,;L3?I"_%I.
MO?9YYEY.=L#>_&1,Y)5!P[EGT\?RAR9!>SC+@U/4;;/9M]\BEVD72;M(KRIY
M5M\ZMML'+7IOP$5ZKM=L<I!64J(Z733'13HU)#BZ3A%5;)8'IX1[IJ4S1!6>
MYB'HM0-P?_99Q+<P9+U6YKS-V>4#TBG:K].)KU6]NE7[@!VX/:O@+`_.N>LT
MS&:SH;V[RD[S$/3;`7AW6Z`*7=T]:,D[>!](7LJLUR0XL<YPO9"D>:#Z%=O-
M';@)J.`L#TXK\QYM!ZV6#T0:]EC):8>H\+2/\+$.6O2T1Z1S0ZL1E&.W$5+K
M&?5V2U%:C0]6P5V_=82E.O*Q'Q,[0,W;1IP\S4W:M=&NS78$[+B[4GGP/G#Q
MP3LSPO9VMYW:6>;6_8&[.=<9J&@!.NQJ@K,&B$'V_L:/P;>'7;"K->QH!0>H
M]-L(9__&N/=-3/R05.^J'MO*Y#H\P29T<"W7<V%T#FO+M^`*%N2T-N4(5L()
MV&,0J?V8Y3J*N$).XA[SAU[!'JZ@T`W9LS7LY2X<%"Y1R8);;RA7<XL=.C?C
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MF/-9T1^RK$ESR`:>$T7NR(7YO+?-=H]:1/-NT%E+XWHM;??,^U</7=&G?.*X
MPR-4>,X$&]9G:TI5)K8NDTN9GD;6)<W%=J.\1]IS2DXY1O3+:[%NCC'M;A$;
M"D=A^_W+>MOK7]9I'4Q^0OQBW<Y.X#>[P-<9GPJCK?PBO8DTQ_O:[*'@-&CZ
M=I+X<RBWL^Y`#=T=B#/B#2GXC/#!:!4F>VO4XHCI&;5*H!,TP23!+L@#V8#>
M(FJ=?+WX[?(7`S7Z)V-%36;XP5/H3'Y]Q_^[6TIM]91#J^G#EZ/R^E2M:Z8;
MW6EUH]6-5C<;$26M;LIIM'+/R+>L:M9H@U>8*WC=(YKY&K&:<RO0:94XYYIF
M^]?E\,UQPIZP[!1;E"3E-)=H+M%<4IV2P,-/J].0=J/1KM<^A^[PGAE?7-_Q
M\<QB1?=JL?!5K'9E%2[>FO"M$VZI$^<T+9MY?XLSM\U&NP!7XN`TAF;M-\C:
M':L`*$ZSMF9MR=H%5VNKS-']]G&G"+'_X%AZ`SACA^G=E36BWDH'1JU-WH:A
MM,Q6KP#\Z."TBF;M-\?:$-YTM0^H6?N`?,#BK@0'Q]$ZQ5?L!';*G4#MYFE;
M.-<6-OMO07-HUGYSK-V!"*8`QT^SMF;M/77S[$[SV.J\`9;6J;[2=I.?I]M-
M3F7YQ*W#4.?WM'6<JTOZ9K>A#WDU;Q\@;[?Z9L/2O*UY^W!</YWA>\,9OF5]
M/WW"JZWD"AZ@K4VD9NP#9.Q67Z?]-&,?CN]G]:UC7>'WMM-^9].NGW;NM`V<
MIS.ZIMVWWX#.T+S]YGC;[IGMIJY-U;Q]."Z>3N]MJ,7JH?I_I\;YC\&#X]\7
MX*1L`:RRHLIE/AK1)V-5Y;-WBUI*0VUC5?.'%%+6M!:UV=A;W)XU]U:+G1:[
MK8M=NU5PFT6+W=Z+W=Z[TJLQU/;$Z&4)U'T7BVUE5:L:&+_^W*HEO_N:YGE3
MX%6:HS5'OR&.UAZ7YN\]Y^^M=R`^M%3FMCH0[XUV6="V]Y#R*&6KJG@BA3K$
M;2F7LHAGJZ7=M.QIV=NI[/$NB5KV#E#V#L>K7HVSMBA2+]Z#?9<1W1];4/66
MJ'K)-M`DM]$W#<>(T4U'%*&F:77LW;?+[9C];KND7_*QV@FW7LNUPE5F_MXR
M&PVKJ"NNH3;%K==6[(IKE#3%K=?F=L4UMM$4MSK,-4]D=9/>0PGAQ2]VT:1W
MO@_XXFJG.)A4N'_(RQA.]UUS=3=>W8UW^P3;6#?>_5=5^[\"K6QU3]VMTVB3
M/77W7^3V?P5::>C.N%NGT:8ZX^ZKN!U6L]L*$WI.M4[5.U?N%W7W8Y::!_0L
M-0]H=+N]:U%;LOE5.1'?`QXMF66_B)A;YKJM[IIEMHH`\%["917>/BT+6A;F
M=8%I]`L`5;0L5&2:AV#F"ZZ1KLQ?!R=X9<U[]UWR-))?B9N[@=9L!Z+*JC?+
M@],NEMFT"J!P]UVY:%G0LK`R/9JFU2VX7J!EH2+3/`03KUW<(A>W&-IPWP5/
MIW(+B"?1"D\VA%9]("JM>K,\."UCM[6C6]UI5IB8!R<)S7Y!AU@M"169YB%8
M>>WF:C>W*)&[3*WA@3O`=J/1J=?P<HCC#^C*Z`L2OB^HW:R*-ERQ5KK"@O"R
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M41R$\,A#8#PP;YBB?)L2QMSE2."\N$,`%QLI7K&9@R]OM<U6HZ_@E[MQ'B#]
MN%Z[3D(L$(GQ18X//C-ATW!@FO?P\SU^#,:QFF;';HJ!"3Y=(<`\/'98N>$8
M(\<-44P2)A#2.W8'$=+K-16P'5::3F84A/@)6%,*>T[PZP^!-V1`+YKLT/"#
MN%[#A<`CT8B%!KPV=*-)P"'3<9+%8.[&'8-/L'KM"[L+$X1+MWJXMU:#?R=%
MAW]PAO`L\XV0#8(0@>L=!%G/4-WKM0S67:"V%]+ESO&H+"=Z8"PVG!B?!*K`
M_KMCH/*P7INAD@6<ACCR_&%C*#9#$HG/=.B.8.&,5_S4:^_;5I=>NF/Q$\Z;
M]EA^9&HG8G6E_"OUVO1G@!F&'$=?I9_8,Z!]Q.+88^+=(K![8$U.0M<?>$E*
M0AAN$OC`;W(F7A`A;_DJ9'XZ.\$0<SL(`'=_2;'P5=XVLW'8CXF+_0APK[XY
M(#=&E_;=(DS^5)+45@1ML]UHE?$14.V]W>T=MSK&A(7U&CT&S#(&48<Y!DD<
MQ4!`^.*QD9_<"#')C0&LFJ8C>AQ(30/+,:Z%M%]GTCYDT2!T[Y"&=\$CXXK(
M3X@,?`AJ;Y!]-5OY$U`==B!DL#[:N&;7;/=:Z?:FO08FB/L'H@G/@Z)*!OSI
M]_S(SN2;!Z1(/-HY&-L]&KI>@KT,X-W@T8W@7_@MWO,AZULPW[_4IF;)(0O@
M'$^2^"$(W?\@7\!V?@<N"!_Q_@L'(E<);V1JJ?7)N/*-JT$<(/M(!<AWK5"'
M$<NG*GB"FTU?-!S@SB%RJ+`JW-JY(W<@E`DP7A!.@M`A+H&')"<2ZW%92]FX
M7G.R]>1Z@"QA<K#I1KUFVVW4@J0)X6O==D/^>(QK/@$>]PR^8"MOS5$M>8P4
M,O[Z.WN$Q3+C9@*Z3!$_,%:7`:S-LDTB.5&`"469K9ULY<SBAZQ\\<;,VLG"
M6=D*>%\1=4E:LA9)UE2C%,%4Y'V$4EC0Q(R2.!$>"5EKZL2B=&$!!4]<%DQB
M4G+P2JI@X=^#P$=VP6V&G9RD]]"$K8AH!&G+444.B4N&NC>+^.R^]699I=Z\
MVZA64+C_%34O!L2V>RJN9&<7J;^*@CVKSO06LH+[PE'S,)^UR%=J!>MBX#<U
M!CX3]X6*`'K>C*@?T@JT++Q8%AH%>*QO1A;6:'500=.V!X2>`W$^)8L:XOP-
MS%+S0#5O610JMVJF8I:]&MZHU^@>N'%%J2L\5/!7-')[4MJT!TQ:-DO[T&J1
M;`WM7>%I5IF8!R<*S<X!8B-M`&O[`&UM1]K:"Q_C72QDT.:V@K,\/!W3,P]2
MS6AIT-*P.D%:3;/7/D!IT"%N49DNK\BHUT1E(M;`N4,J/AH%X1AF@!4U$S##
M!9W"M1W6FF>CS2\:9KNC&[Q5=YI5)N;A24/';#2[AR<-.OB=(=T_13&D-K$5
MF^7!*95FJV=VFP40G_NN5;0X:'%8(^O8M$VKTSH\<5@MV-U4C>8>F^"T^XVX
MJ[`B2[R@DJDJ>FG%HK@*,_\+%W-P6F[!D')]R@VW6?J^F:(^+<Q5W0\MS,L+
M<]/NFZUV017)FY'C;:49*NB6ZUEN-,2IZ,SV@WYZEEL.MRLXSVI1<R.A[SQ(
MUD,+?0F256"P1',O]F_&@]"`CWNYFK?J2?>[9K^]C6MN^P*#IR6YLANB)7D%
M2>[8EMGK%B3[EY3D%>`@Y4]_^3F)CNX=9_++C0("=?[OQ(V?+X.8G;D10IF!
MC;UE/^+/2-:_UFN&\1?Y&O:B=&/"%RQX%I%S8OCA.QO]^HX%WA_7YYUFK]7L
M'!U9ULV1==1H6-8?-[=G?S0[[3_PYKIE-ZT_&N_^*O:ZNI[+(JP<\8N"B\L(
M1GAZ]>W;Q>TW6,'-@AW>=Y0G3I;;__T*=''!CW,'RH<V3-GK,)BP,'XVOB(,
MU^8(6PF&6JB!]W]UYZ,1&W#TS1LVB3ERC<7QZ^:`LSI&Y/XX&L-<'@Q0-LQ'
MI"Z"5T.@5(\@V3!8"$8C%Z$Z)\Z`F0CQZ!BA`+)[WS;M;ANQ'@T:QZS74DC)
M%$O4%LARQ\9WQ,2#!^!3C!`8WW?:'-/3'QKO>UV.@JJ"6T;%Z)86?X6CST)D
M,^'K]YX1])+'-F/7=\?)6*QCXCQS]-D$AL/A73`^@7\TP/#'(_0L_J"#,*@$
MYO>#0$*]9^,]4+$#DQPFM"Y:BL)0Z;].1D#<W++KM0Q1CP\_=IZ-.V;PS\*Z
M"!*VV3@:PN_]($8ZW\$VP6\1/G/B@%1N$,^N.BQ;88'<I>;]'CP['BC>$ZP3
MN^=XPY4CR&%O]Z;@%*6*!<42W,$W"6"8M.SW)(I<QR<L37C"-/[OY,KX?/+-
M%,H(U"EG`U`\B#[+!@]^X`7WSQF0<XI&?8PPO7\:GQW/^4_P&/T)HSG&T`U!
M_P5ABJ<HYY+XL>L9E\$CUYUX%P^1M$D?C9U_!2$"$E-^B'NPJ-)A<O4:S.[8
MF,;&%K,T%DZR7E/AEN5D\+5TY>H?7$Q.@>L<<H*-G3^!G/)CJ>)&W.UC^R?\
MK\]@]QR/XZ""GA[2989[+XD=4.R!SX[N$-47`<*#83*0:-G*]QPO"G(?A<_(
MR1GO;3`>GD?&$&T1<P8/%*F4?\H8ALD]*7.$[<:0"%=/)C%2D3:_G)T(I%B.
MIAPE,#2^6P$EGQ?1_9?*"T3.39F6['T,MA>W8>*XM.MRQP._F*?J-66G#<E-
MQ+W^/!96N*E>:Q+/.IYG@"DASR=DC\Q/&+#EQ6CFEPC3S3AT;JI4I@!^DW'B
M<4!P\J6&+CH\D0`4A_69QET2TW(]=^QR\-[`1`#6`1#3'0#OH3"F/T0QO,9P
M70B-CN\3G\(C`?=#0G:/7PS`JW'NF3\`I9'<C=V(H%T)[U?R]""(D$#P$`OY
M9V`3ANB+17'(YRP>P=<FH"0SC["(L$]!X@U1GY1**^(M#X$$,!7X8/\GB8WL
MC`-0?^A-/3VX@P<$IB\E=`F0<DIG\FI30E=`5K6%7FUU)Q'I@A2FG1@$V/?>
MES#=:"2]($76!M[PDH@P]X/0&SZY0V`"B)J8YX&I38#3)C)H1D8>@U%F*#H&
MY<-*#5.]]H%&'DK8>^D;W+(0C#$(V$<SG<JT)T$:X>H'F*2A\5L8)!/3^!H/
MCTV$6L:(C2^(H1QE9SS2DKK(MP5!RXT[?D;\&\<#(45G8A1PKP16("8"OZW7
M4A^#^Q0"F!_QOL&KZ*6P^2,'-4:*WU\H5Z"'\"XBT)VTT(/+L+T"&R2D'GBT
M&9*?DCY)P.&S2R]:T+?P6*R&(DRR]$!@-IYXP3-C)3Y2%C>GRX'=Q:N20/M!
MX"/C$%0V"Q]A>HA"_@#SN'_((E/JN5`THVD_*O63L'L`*M='%UV(;Z#4[`[1
MLYUC@FG-EZ-#O5;&`XKM\U6-")1L'/=^FK]'J[M8.A^WL:CPG'B5---)VH;F
MP.F[Z3`LG^F2\D\T3>6/9U_^YH3@UW"5`89>YM*,OSL^;X5CBL#I"30;`W]"
MBK#H]Q(^HBUYJ;XCE>WX:&3`EP'[`M,?DXP^!3P35JA;;E5]`LJ"FD4`B6)T
M[+QGT!T0N(A#?P@V0'.144,!IMXQ^!5,BH&D1R(!Q1L:P>]=G[=H($4</+J8
MATN34P;EIC`;B(FMV.@WC*'SC$^Z0<B[$*$911]2A#DXY!)KX(U6^*S'X"JB
M@D38&%@,)Y'J[N76@6Y\;M,LB]JN.`/L540-#&C#44_2NI>8C5AX-+,]H!SQ
M.Y@#%=TU4,UR1D'2N`-W(LB'O3A@YYV0'%F?C5P:]SYT@/3D/:,3[:-3,7"B
M!]`$?A*E;8[<:!"R6/10X,U$@,G`D^6C#^@@"<+-)18S2D*^=6)1:,3@,]35
M`7GT7FPXKO4^"(8&MN7`#X<Y?D`B!A!@#)PD8F"`[@)L:Q490UB9G_7H4LP<
MV&3%'`KC#"$VMI%BR(\/R+DP+4PL.SPCD;IICQ!)W-./F+05A.(THCA.I&6)
M-"@L(Z`8/,&SQQCS,/*V\&5E%2;]`HV8W$J*5<3^\/T&_N$AO.%0:E=M.Z42
M!/=PY(XP@0-.PT`T<<+Q$VIIEK:\D'TR:.WXE[)-`Z9-=XT\&#P0=%P?FPU1
MVAI9(&99@R&31SGXBP?W#A90KQ41G7JE\)>I&Q**@^H,4;K?%WVE:-%`4V6E
M8EF*,IT>0OL!&\P.,PR/D>[:#5BM0R'ZTE9KX0E8F!)XIC\A)?U$ST`(B4(#
MW?ZCU)0O83M2JYF=:'G)>'(4)6.9U23;Z/X06D;U&N9H)FRKB),CHYIY#S+%
MZ)3K:K#L(>]6EJIZ$M^<KA\,DE"VA(/'>6?`-(=<KPFR%A^!31%@RN`89&Y<
M8<92%R@2#>)DC#:<U4O4*RCKS24VE@*YY[PE<53:HCE81-L(H]N,$;AAH=:%
M,%?4]CQY//7$3%/(>NV]U>(]J,B%(=/D9OW$TC-+FNT=&!)L)D=-"%$G$T4B
M[*Y%?@H/U2(^"7YF"%J;CC'IK)),MH-9N`B"0PJ07?\Q\.`E7)3"`87;=.ZY
M,,7+9YC8?=Y7S30[;WDG1T(((=DB$$6*GVOF/0%:'I&*MF*(A%4V8^I0M=<D
MIVDRTX!3<(6Z*<KQQQ2'T6ESQIXH]/S0M90]>8,QSG$D+SPJ+J%TZLD6>O:7
M#J8'SE-?_HI+8S2]JL*U4&P_392.[-%V^A"ZX#1,*/]Z[?PG\#!??!KX*)[<
M'4ZE1-`L=1$S9E7\")Y=+8Z#2HYK()[)9F&(29!,#(V_)S`#J\W3%<CQF:/`
MAH?N!&S=2I'/M]!4@8@B"ZBF*GZ`/Y*+F$68,O4534L/N=RDF%]FH/BYY8R!
M2E-NU31.<U3'@N+!F2+`^=5\^<J_ZS#`8X?H"ZC]&\=C5R-9?H6@J/&)/\0R
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MII9?TH6XPG0UHDIL8$`)NO4E"&_$:<U5>.HY[GC+J^KUV[;"9BO-++^H<R=$
MWS2Z9B'U+-:%X?/2)/UCH\C<7Y[?&A>7IU??SHT/7Z]N;CX:U^??C9N_G7P_
M?ZTC[G\E8'A&S_H,?YW5?78B=U"OX<DD.%@1%1WS3+%+3:\G2<P/*&!U+J5\
MTT>=.`[=NX1WR<7.]FJ/;-G!&]ZD!NV\?&N8)IZS7M1I\^W\`&I;>R4;C1-T
M@^&Q<8;MX&%`G([K\^@2G=7U)B_Z>PLX(S%YWH=^B/S%AJ9<"CKR(B*<7A70
M<799^=;A\DB?=[.'.&(24`A"53[*%`P\GGX$EY$G+"",5.AQ;%Q/O<5'K]?4
MM_"`'>),FHR:*#>S=M)T=$;]I&.7XO*9=M)XD#(0-3M8D8>$9/ZPK.P!TRSJ
MF9WQX%!V?3[9\RPCPJ9Z;=E2=:0GE6G)IMCEE!2G*)PWLG,9B)@BR5H1+X^"
M,`@CL-B5.W5LG-"1%]#?>S8Q4G,'-(FAPHDS,L3+(B)GG(6#\C.8]L1H=).!
M_0LTYZ%5*DZU8T_ES'O.A"^":#[DKMD#R##L.?-YE=)0Y!#Y_JG\`OPUG-4]
M'W#G/RI;'TE9<$-,(TKNE+QEJ*SU:JW9JV0ZQ924YIWB_N8>=F'O5/4*["JK
MV*][O$LT8K?SC=@-/W@*G<FO[_A_=W&OMZ*=:?\7#Z;/T<[.;L$K:*6*4FF7
M[>NK+8J;[F"OU64%U:75F&H4J]7E#IO:[PMS'<0BM(1L7$*VW^J^VLRU?5RU
M(J-9S7!]*<+>\`26R%%MAE_FT>\`0)>J+0$O7U#_;2(OM1MFXP7`2R\6AVHQ
MCY;I2FZ+ENG5T-0:IMW91M"P1S*]"L:X=HC6;7.FU6;U.%^KS77A9-L=LV^W
MW[;>U$)=\6W10KV24)>VD7M+0JWS0RL2]I3*E#B89C`RI@J5M).D]>F;U:=F
MHP4:M=';O4;-AGAUIM&RK&5Y_V5Y>YWH5O6-]MA5R+CT@_5Q%>JMT+-`7[9%
MXM9K%P2/"0^7U+M/WP"GYDCRLCU6_$NOSIAUZK)J\UP-.L?PP=O?$J&<(PHL
MVNF9"Z:E%X*F[P!ZGG,7<*!-!5-ZZRTF%+%^00TLS'S(PK3\=8ER6*NA].R:
MK<<-<WU2BG3//R_.;O\&W^]-EM8ERS#U.M[&^A>@EOO.E$RT"[AP:=6=)]5K
M7?Q::]VG5U^_GH"M/[F]N+JLUTY^^WY^7M)01.OB:0KO$OW(;C2ZAJ+15!@D
M#@WPE;$\'L<UZ,:Q,V`)P=\9'_[VWQ\Y/N:"[=SW;=D$6C:8.!7*M#NO;TC)
MK@@\BF6VA>!;C0_9<Z>?IE^KU^B]['=GGSY.@](C@DH&,U?\X7HMN$/L-$9`
M>QFPK\2#AH&&#,%6)R:8?S\9.0-J($(`*.@AX-5PV('_,./RZA]@%VVZ2X7_
MMAMMO*=U^N#ZCFG\+?#OC?\.$#_[UG&?"-5OB"@?`R<Q/B`YU>7B2PP^GR+_
M3BU41:Q_0'B5*(DF_(:9A%42TY9`'6)&GXR'X`F1A$Q.(/X>3T>->9L1PX5Q
M!P)@4!F$,+K9/<$:%A-3N4Q7K_TN>JDP`2,I$?M2*559*$,%2BD_8AQL\GV[
MT9`(BAQB*`7A1;`Y/W9CCZ-M2I2G9$+7.-];9C=[=20;OW@,G#)?;?HR";+;
M=)Y$4ZS7U+7G89S30>A>:`DM8(_PVIR$A$R7(<%3TB4CTB`38$-A3%"ZP2,3
M=P<1C&+,,9XEY.<47UMM@0":O]?WOLDAE'`E4^#F`D5S$-S[]#4$UQ(H,66=
M=2"BF[ZOJ-7F<E?WBMFC"$648HP"J2CN=V$WCNSV;,<+J87$#5&A2.JU5)/0
M!DI1*6RD81]9LP/7:XI.4T;.5-1QB21,0Y5CQ...[T!5LQEX2=Y[1*I9%`IL
M"$`Q5<Y,9-#2&?HL:("R"2`2JN]CD"6!@^(<C&;IU/':KP11Y8B^J&5!2XD&
M4C"&P,WV<[I2T&CDAC![0@CD4C6M!$F3JWB>''=(44KT"T?%[_(045<T1QB@
MI@`RX17?Y_0!+NY#I2<%DO:)>8]2NB6L7(982K=,:;J95:/-5VP8H8BB\>!8
M2Z#=,)(-#UT3[-BO[<_W:[\E_M#ETG#@=-\0D%K:<\WB8-W]##]_RG,=Y.BN
M="R:]<^*=RCGI<UL%V:9X'L<OPRDZS0()W*(K[P72][I5;<Z-S(JT3*WU,AY
MI:9!$,2*9XL7_B/L#""UQ+74I!]F89I+UOD1WN>0PJ[,FY7"('K,H3E-L'6$
M*>V32>#;YPG"B!D?J),,VC^_M._%"?QF^D&$()PR0A^)!"<).JL>OH%[*OO_
M&6E>#K=;H+*7$+S,]<Y<7'5K":V1`,"'C/QP]!FC*(!=B-E0-O="10LARA!<
M,![U0%1R?'T,_*5.@C]1^M7;\FU1L+O1F*KS$]TA<MZ%;/TA(*I_(*:Z]&Q3
M<$X.@TT`G]P5R+,86*/$!Z.00E)(XT.(CT1`=Z--<0Y54WU!8/P!^A)(,*2F
MP.PF0Q]AZTGC@7E#<YY<B@:;C#!J49_A<,]'=\]'XI]<^F4O,APIIY\R)U%Z
M'T[HN1P(YH/UL<P9<283V':.B"I5JW!0E"_)*0!G?K`_BO!217PD_Q<X$WDO
M3M&6I]XF.!(?,[=`BN#NT0T0D3?DS:B>7'1U$Y_YP/\#AC-210=H;!20V`]F
MJ2S;P!3+F:3R%(ED*"80-Q#N,NL8P3VMD'MVU`++'4@/3:*NRY8``LF?KY@W
M)D)?V,5-M1L_&4-0FQ0/%QD(5+H\5A4H0BH)Y/9@K)]"LLYC*7'`<1?R$!'S
M"B,'&R5!Y*M\ODPOYKXSGZA$F)GOF*"9/`+UA!`D`S'&CC8*IO&=X_\9)I-X
M\(SS2EL3R>Q#AE`/9&4A)GRF0;V%CB9UF"GN%$47U-@]CA*@USOM9V?]#LG3
MSG=L14WL!P*D-)<AN1@9/,K+^J?)3FG%`IK9)$+DR7(^!$Z4-;#"PRD"SO:4
M[E"@OD<L?DZ=_1G[+QJLE?)4H.`9RD:YA)!4YJQR*.MLEKR9$H<@EDL6[71Q
MS=3,R/6CF(,$9_QT,>*J(?TKC3\,&._:1[$(SRX"R2Q;MF40NY1EN&87N`)[
M;MR$'1I.D8H^+7*]A?#3)?1-G7+>PL1C=$2*'6,>44--/(C]92[SAI$"/Y\Y
M:$VSLNFY[20)!P\.-9066&$@#=S#TD[)BDV3?N`QM9*F\A'>GK)(I'DB"3-]
M301O&K>A2ZK,\[#-(YZ/HP_ND$4TIK.K:M22>A@RF47J1D)8%<9HT;Q#'Y%J
M5ZW5JF?L*QR>3T&0^@-4_>R,\?]>^&>"9[^ZSAV8MNT#JEI6NVDIP,%+32F_
M"JHK^(R!P&F^O]`VI]UO=5N6@FQ;/(E%Y,:L.+9+N.:8_2?^$'X3)CND?[-O
M]WISZ;_,'//K_`U<F*]!%%WY!7C<.\((/VHV6IU>MJ[EYK1HO[Y#``JN,:A_
MA/S=[@K:[78._'G1;*:$(FVP<?Z(*DB7SQ26S]C=?2Z?L>R%QJ**U2\WOW^^
M.?]_OP-EC?-_%!>PZ)J5'>?VO['P'J*F+%NL_<\ETO<G$`)X1D]V%2HO/%&#
M3_0HT>Q0Q"_H/I/$G]F/V>S]*6_I[(2F`;9A.E.;_C7_)GX<_V2<#,#H13RK
M@\G^8YK#5,J93P)MB3MTG:ET,S;J?7H($.PU>,*\?)0^Q\]D9:9#[2G$LUKI
MY.BX?XR?$92BK`)]%O1$-MX,?93IEV6CLW^=9"F(-$&B#&`J7U46*SL3XCDK
M@=9"_(AMDR#JR%/>Q/5CPV8/TS-,8#[SUA<B$7>71'@80(UK&.4%4ZHISQ*.
M=CKXL7&-+4G33DRY&><I*-(Q\BN$G\MC&$+V#I-[@GSF44H,[D.<<B(L]=X/
M,/&*9<4(^Q^6]J!)>]M3V(2.A(LE&UD=DE'`==207ARQ1$I'G>DUZ9!WJ6;P
MA#@^9*$*K%W`S=0`/#1RH-\HE-,;E-OCK-(I[0^7_YR`.Y<I3Z<(8CY-X^9R
M'?AF[,8)OFO*!IWW[B,.Q?/0,A6H*J:[)):MDHJ>)6J(Q$YQ-@:K&Q0`ZB&+
M!J%[AX(&4WPR188O;6/6:\ONXCEH_+*U"?3SXM[IBNS.;D_:+FLLDJ28!(!O
M4'Z1$A68"G9'[D#40"`$=G8B2P5F:N$(27;(T"Z86*N%&R2.(['ZWA1TH[25
M=00$/8*XFVJNL-(EFD`81YJ1OJSNVXSB_<[?`>V,+RW6O1=C4)DN)V].^+/C
M!ZX8!=W%^`8-3\0*L0D`GA_GMLHV^^V^V>M::G,#W.ZR!@=FVA=`$I]2T4/#
MZIH0\YCM?D><2422<_*W+((Y@I4IOGHM*X]1%VC,VAVM\19JO._!<(QGU\1/
M^'_`'SYLTI-I?/UZFJ](X,].N2@CUP>;AKD^9_@(P79(]0E2C(N+K_+BJI1_
M4I/K$1-=,^TV+YHLKM&<T66N/Z5,<1#"KJ=6[-A3IU"`_N?;C2%Z)!G73AC[
MU#6#5W")M5$*4RQ.\0Q66QTHTVQYQGN[L>+JIDT3?RBWNL-F]UV&:S>93;N6
MIP@Z=MOX>=!T%%88XF%E#95HS=T4<9`K#W@'`W@3JZJH_RW6M83RY))''>J'
M(MCXZ;:]1L?LM3IFN]G%H@(7CTCI=!K_G??3J"]ZVIE^QL)3^QGLF4MG4%2,
M(R<_]T43+PG2(=A`*,3&<;=-W3EP#B;YIO<A-6L1?>MFFNG"2VW3:K91TY1&
M'>GI&+4/H7HQWO,N_;9!G^;-/$5SS+3GKZ@-[RP:?FI4&NQGX5WGZ)7>KE3#
M6FII+4<2I\MX"'[W+^&M\A9'Q`A(EZF[EZ;X!3EB5#(2N6/70V]B(%1_R(+P
MWO'%`50$/)$==M&EZM3#D-,0W@FL!+UM/D4LLL^.O[.N/=*[R482H]1KTLF9
M2(<V&^C5FNIL4S<<=B\R.C6=KZC2LDG,F0"'A/)*C+P4G!;%NR`%J?)4!D4Y
M//\!X_KWI,3&(#,4I.3\M9OSTWQNR@\,JMGF-92R_WA;9M=P.O<NW?1Q>>PE
MRRUDI;FHWZ#*<%EA47AEVN0!5_D#7!5[SW)0J8-,&31(X4_;;,^EZ<*,"I;,
M4.MD07$JC$E0!8LPA!\_4YDHUNJ0`H+X(@AYU0"J1KX>E4:&4I'"!J!.8-RL
MZ.ON.>OX);H/FUR'PH!_,C8QYHPGDC\\D96-J1R&*P0Y&5`P;O6;3=[O342]
M,\%E]@ZFAJ:2GEF)CE+6EMX3>,+R&4S!J9.FJC\E_B=&X6FV.6O+VE21X95Y
M,Q@G0%OI^RZ&J#S-R>T#Q!+8,DX[7LM<UJ0=?)R^93=R7(]8F;1*^>ZDQ524
MRH1OCD)L_(8P!>[(S?:V0!Z!IS)'#HOTT*G)/LPO6Q9%[2B=N=GP)MX3-<4S
M+4K&!W<DLA<NUH+A"(\N4$?.[_ST(W4"?S;^[OAT!Z!);]KY-W-O@>K&UTCG
M"F@&^?VQ\P,O_<QFY"980B:O"-TQN1)5#F#0O&<K'015&U&)MDB[20\1W`+/
MA4>&O'&A,W;NX8OP$C@L\*QUW/Z)'$*J>C,^@.=WQ//<J+\=>,'U9-DO>D7X
M:=ZY#^?O(?W)%#C&*($)T2@?TR+!S!M.'=;4(<3%D%><_DTI\9O:S$SP<1HN
M7MBD$L]IA8FJBQ*&HIYXJ30YM:'#K)>XHL4+#ODL2+^/YFDB7I\9P\I#QDG1
M;)!S3W$*JORA\QS1/8K\8_%3@+6'3L2;46+$`1.2]8>P@;S#YZ(54&=)-$OW
M:/W0[+GW]\]'=PZV$<C-63B.TYQ)T4LY:@G6(7,FS_A,M`;,KH&5T`:G1CF'
MH2M#MEQ1,XHOS_FEJZ"*K&&J9,1MY#)V*%D->K]B29'[0Q1T2B<[E_93+[`9
M\JYMB0^C2SA7*?>;."YM(T_Y<=V5Y?U!"0G94;)DE`!6<ERIDDHS7<@J:B5F
MJE6LOFWVFS+17)PGG\GNB<^[H4P\/J>),)%QF%+@Z3QS@>7LR@;/ZIW,.Q8_
MH:?"*3&=XBX4</$H&K7\#?7%XIQSF*>J67.H0UDTS=D?C:^D[9*!/B\+'\LK
M^G0E*L!QA`<NII-E3X1/,',.=.ANV2[SCJ<4TQ&MST!A#XCP/-P3)LFX&HV`
MR<-%F.K[3O4-J+1S:2AF"DERGN7<Q+MI?'-!2S&O7OO[L7$6P-Q,X\8=&U^<
MB._,F?,(RO+SL?%M\$]P2%QGC/8V@M6)]KNYH#Y_;G\7..&0=^-5-YOK-04;
M3%Y#9^0?!:Y/F:Z#S_AOE0?HWDSFWBS%#,`$H#&?C>MCXY\,[\.'$.G</L#G
M(YC$X,\GK/SY!MZ;"USR]^#!A^FYD?CG^7&]=@D1%`L?$@PA<*<%<QE?CHU;
ML#-#+SN+Q5U.U?#2_%.H_$\5]HF0,[G[168`_=IG%O-X7-[)8\6NJUQ\O;9H
M];0XA0!*50Y::4S+BV.O`A%0CWL/G<4W;UR$)3G!')`LTSC-%SM<J,4.!T[@
M;>B0KDA!*)[@5#W6O.*2)PIS18H.`S+/5:]B*J_"'V]`-+\$$$<99V13^.D$
M**)_!'3\=`V1+YY77]-M*/!>&?P@"]?I(`,E\3O>!D1#\EV>/V"2FBY2G1J]
MGXQ3#DR)3W",\MA%3_-:7K&"ITL+<6XID_+@#$F5D!K)1Z7R0U2;E[NRE:L!
MHE[S"M"8U3ATV=]GUH17<PRI,B!/<J>LEEW9VQIOG6O>VCQO485=>OXB<O!%
MM2EXE;.T4#OC)XX]M6P)GHLI8#RN_^!\I$G(RL0'EJ^K^V1\N/O(`^QA,N"<
M6E`VR8O7G`2"W)"0SW+!-?GI75YP1,D*S*YF/\(W!AQY)2\1%,:G1V%JR1IF
MLP9T4?XI1->+IR_`''_BTO%A2',>>.B0C9[+7"%1LQVBZT;/EA0QG>+?C`OE
M34J.D@10JB1D1\P3E4J8%RS5#S[[@87+/F9OQHS)&@=U<:8A/G=1KRWY05H?
M)=]GAA9%GNG85$$OQE]Q0?"!YH*YEZB9G`]+R(S<A7=03FX@MG/\!!.<J5>K
M^/'DT&(X(6:M$`5"Q9A-\.3LY-CX&RS`+/+X<[XR'PX=]90*AC(>/OLW)PR?
M<5;7C@?,R*>9"TKX\>O?@B=DJ&_'QLW@P6>8.YN9K#KZZC=C2V_!Y2_+G;&[
M^,('GR1!AU2Q`I^9ST`!N(Z7M4;YPAR",]KN]47;:G;[=K:2=::87^1W)E%S
MKD9?`__^%B(I''7;MQAM>"-;1]DLIFY>@N"[(3YV-;KP0:;N<:DG=+GBPB<<
M*#<&50>!VCD=%X`D_18$0Y+!+5_\[735Z[(OF&A^R9<LQK!GS/"6ZK:9J]5H
MM1N-5K:.W->G)A;X_'H*3)T_<_YC0I"=VR5TK]5H]Y49EDTC/]NO[-[QOCE@
MT<+HQ!^>4ID"9LW!#=O2'=C]\YR6&[+HPJE5:)^^7MQ>_$:PY+,:^E7KIP[M
M$.R$CM[!!R7@-K*0SD#<S!E//,?%XCXG/<66-9!M`8\KT9M^]PG/[R:F^VEG
M+H_&P=]*PNS<+/TU>"C?X$O.X"$!M8:@:^@T4[$-PWM[Y,)R]R7#42'/C0ZF
M[]B#XXWP+P_N.&+>B%><HAM#5U0BO$2H'-.K>%FP.GDP7.(/3A]"B3,@7D0@
M#\?2R,IJ<91%FH+$7JS7;%ZST0#WY=Y!')_\'1V?AP/7F#4?RGMSIP\N&V7'
M'O6:./<PI]V?0HFYRNK;+/EMGMZ%+4B3Z+!N0BCD.^N.1I'QX3.$!Y'Q>RA/
M^[[C;1_'^#8X0]S&X4?N6I4.H!*/\,9@1Q;-T+9-ON$B4"K@M=(SO9EW*$X`
M1C!F$(4?W8!C0MT(M]EJ8.0D6$HM#4MK"[/"LI9:6,;=T.\)^*Y6X^ZHC07(
MX\0CD%]Q4XJ76A?<D)!</4S!4Z;!J@C>G4!D!B#'!`P?$YJ,`@K#"S?\HVB,
M)6D(8F!X"4+ASKEA>:4P:D=E"K7>DO!]`W'E*\!98G%E=C3`MP47,@G9O\#?
M&!37J<#'9-F1W3`1VU7&Q0JS\0_RTYX`."I*CR(P5N73X/=7?8Q)J-Q:AMA/
M3&JAA!\5!0*R?GJX8^,*(;+$:,J:0C9&832P8`:KZW+`\G?@5$&4+7`R:=-$
M8326JR,!@B3&F\5N+&[+Q=3DANZJCK`$Y]&]#T)*^>-Y>B;VREBZ*&.)._!_
M3WR(;'M%#*LBYS-TR7@>0Z@=W(O_.[FJUSZ??*,]@A\,_/=W%C%BIJ\<U8A@
M.O-HJ6;^HCJ\-77-'3>1%^].:9EQ,.1U@B0R#VS,(;OIAG*45A)).9:,Q`]D
M!6H>\G^8X>%Q0$68@IF[Y8J"BM7,J!DD<B#8/@60CQO"],!++>M09XSIQ1R:
M`(DW$@KFRJG?(+/6*``#%G]O-$J@!$H5-]\PK(V2:=/RG*TCSW),Q`#(J@WQ
MA2]G)Z0>3I+[!"2LR:<*'@G\':TJK]\0X'U`*L2)P0OK$KB3=F3(-;<8P^KW
M^P(B5RD>S/$`99*YG:%+[J!*2/I16<2AXT<C[JR@=D;50)R%:9F)P`62%3!X
MP9A1"ZN4)S#-!A\KI!PHP3^-SX[G_"=XC/Y\QJ)UF;Y0KP^3&.#6@$O=[W=$
M:2+^578QZ7#FF':NY`#Q`ZBN^P?*+(&%!Z+PC6Y+,<1#3;$#A5OVIQ\\@7:^
M9WCUA*[SXZ,$_0E42.>,DP#>A_!I@I#K^<E(X5U81J@J:Z-$5X,%6$I9IRX:
MU8'QBT5XQ5G4$Z)8('`B+[>+*97$Z1#E5;L!%O"&36)!<>D!YC*/J<7-3"MX
M##?):!1X?\)_R<T,A=\<,?8GB3W"7V/M*(?-!!M\SRNUGC,/+U-+!?+)FZ8(
MQ`FJ8J)"78?P-7@VRY@M`"/3[83\FKL0%TIZ<V#Q=@&$!OV9_E:L&TQ!4\%T
M.==1!=P$^I(*QUOZ6&!/6""!A[>TQ:+I4P0@WYX"0DD)H0XH7+Z,-@K<>5:<
M#]2GR]@\<X\5PL\&PJY%J-[+G)Y,QOK<ZP%9X?8G>F(RT$BWVP3^\]-+(*DZ
M5_A(W)C`4P-"P47P#P@$P#WG%:#(OI%$IA:7_PA/C85</R$C8MD&]\6L5A&6
M#'>?AIE2S8U@(L/Q6<[HP*(I&^J$`_2]BF:\DE`+0&`YH\4^F"+/7,)S/MAX
M]4SO4GF?Z80H=S/@\;,,\'$WR:VNW6CWU?36W,E,0;N!OT#'4GXLL/E@I=<!
M&$N=XUK4P>+8N/G]&TSH?XVK+\;-Q6^7%U\N3D\N;XV3T].KWR]O+RY_,ZZO
MOEZ<7IPO0B73)["\)ML9B`X"J$XRN`6EC!Y<2$\>C:I>70[Q.N5D8R)8F2+Z
M#+&%4CMTE286+<Z8%[$G?D^&V[_<5/"Y:*JX&CW];&+ZC'WE3/'RY6`%TO<[
M+P<_%VW#\A7"BFO2XHTD)N#].!F81.$6B@P.^@%N_"PR.`HK<=<56T,(UY:B
M_<$`';^TD4@^'2KNHI2'.]B,SG?N1:`6@(W]DQFR%QJWKM+I$UDN=$B=M#P`
M8RJ1PN4-FOB]>#HS,@TO0U4UTZ9HXF)[ZDK@$:Y,3_&+-<+<Q2H"F3(4N;L(
M.><?W0?4DXFW6BD/$)0U,HAR$UH;7;"1*T7D`G&DQ4OSU3Q9XL.GT7D.93#/
MX[`,6!F;9Z'OP@<7FPR1!5;ONX^"D!1Q'/$N'P,%6#>7#*+%3,\.@V-0%Y@\
MP`P=4B]T,8X5"2OCT0EY?P9^!PCHEHPGPJ&E9@\ADSZ.N#JGW+TUY55C@2TM
M6\X@(T[%I<`>2*&,)9P[=(O(C<-,,?X1:2!NEI3MWPF/3^4GD:6&[F@D<RKB
M;D2V?)[@Y(\(ODC71ZTF1&$Q#)T5]:L#X/J%YN:BDG*MG$,^V2Y;5E`$E?:B
MQCAS\T!'AY9'VZB:)6CB\Q3:89&:E?Z\O+X4\;.9Z`$V^X@:._(4#6?>[)R&
M=*UH/>%AH"&OVU+T1A5!LME!*.YRDA#1#:P,>4);X1VSQQ=JIL1+%.:PA@3(
MYK8G!>U&K2!*Y#`U@$K\V#AC8*NQ*XFHMIL4O^LJ#1&3*,6`Q$MGF&P[PGE#
MN`BJ+.LR:F1-1I.(09!O>&0<9+-";C6E^B7H>ZD0@07Y54_961`[*0+K8@(+
M^\B&F`J0G74PAA:+4'J<$M]FQYISYT(FA''T%FX<\/@"5XD).GZ-3?/Z;GD]
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M1Z`*?\!%XLO)S6?CY.;4N`TF[L#H6CW36&/-`DY.^7BVBN8G@Q;.Q;AXS<)N
MR9@3SZ/4F"=M=$BUW6+A!.@@(Z][?F4:63U'%R.8B)L/*>R'VE0[EQ11DS5I
M1T5^3C\"V1/"&TW):.'V4-5#T0[Q(]9EM\B8W:%VHVW.ME98=HO0'XZ?<[1/
MG88LX'=BI=5:2K`\<XDXW!"KDEBOJ6N`%..JE[#W1,@E`31@,U0*8<PG?`U\
MBW',/JZO)/ZXJR0OU(!KF/#NROPI"2X@XC:,_KB*)L"*W#>U]MNM]OLNLCC?
M.4,M4'SR:5?AP"'!6Q%L2Y0XU"J7$70@EQ2LS<K:/@&'NI%HF2<0<0C8Y@>R
M*\_"B+9RE,@84GERR,%>J%]=*"NHX@R$2"8^>*(DE#(J:S)RW0.-WR?@@B,D
MM]1>:2&(@(G-8])F!1&B:R%/4)3TTB)G7:%,0:1`46N*K,-S4DX!%EN]IJHQ
M7+^\;9Q..&TZBW.:Z4A?M)PEUJ`%<-<"J.0@E>.UN5)8G+;D(2_7LL(24(M+
MEP/*:L]RUQ$>704P;IT?"\\3I)PGD4CNR_SJLT@Z\/QK=GHPHD:N-'Z,X^=4
MG&@RZD;B99,.LOF%47BZ)(]+?).A&"C>%EAG4!18C2QSMFC,U>J.`G>-:VGX
M&D\WI^ECKN=SWX6?,1A+[U!`3"@`0C@2,4]&PY+Q3E:$X&34;L%W*!K$;_!N
M)BE"7EHHCKF5K&$QA:WJ$J2D#&*),T27(Z>=23$H%GLM0T<JI1-5P.C.9O-3
MS28>4<@MS&>KR=?+-8BGI1;%H_7:/](C"H)R<[)U1=B`RHT>A(4V.)P9X;!Y
M[I^,'#;$KT>[0I^,<"J81U<0/(9IY_=LO723B5\J1FN'G2?SC6>!XPU9L0@+
M</YDA$FH4OJ.B=\K79M#?@;'S]9D84MA.$TD97$2^M*G3#':L#HI/14:\C(M
MP=)J@H*&R.:(@ZCU1TBE>DTA$ZY7+4#"B=XQNB"=1'A*7)AS@(\`N_-[L_%S
M.8F&:'SY16T\M&,@#`ZFJ"'6XG,XPCD<\9V"<(#2A$]!X@WYT0\&*US7X[)D
M%.`*0$O9A02%H3R7D?CRO#M/&EYG)2A,X.!XUH,HA-DQW_1)MAJT.3PUDI:/
M"]!KCFF&%QZT6=KQ&0Q(5,@>L+<S^.K"2'W`RW4?E[12'%1`%";[(OM%D6@V
MKM!LLM,+2A"+Y6\_H(+_2`R*606A:[CZPT2\3H6]SO$+I@?^(=,#7U)ISB[W
M+O)CLC06/^.=RI/TL`AXW33)XOG4:V:6,<E7(9!ZRF4_I+93:C?<;-S<(7[>
M^&1:3GE>MC7@A4-3QXAFEH::\$ZU)E>D+%\Z@3`,8`EX+#L%RL$G5);*X=%D
MZ<NFZM?1O1A0RT<#?E.;NWINE"7N*'`4][4-[G=RD!O*O1/`I=(>`"]:O;>L
MEMGM";#*>$;=@Y9?8O[B4*I>*R:QTIXA$EFI?)6",:2.;VGKFNR8V*=+YUJ?
M[-K2^-C_-JN3.N7N_'<W^G..(OE2M/NXJ>BCRK85BCE"+!`^<`@#*Y+(S_-Y
M/5XFC=R/)P>'9T7RW$979*CVY+84.PY/D?`F/`[OY@9T>2D35IKCN;'LH,(#
M(JX$A'\?B;)P2L3$F$*EE!%>8.65ZO@.P1FCS&85Z)J)=\O$9VG9UPIV4+)F
MEAP?!IA01P\>H;6S6K*<AL-N"7CQ!:V"N-^)S"T/.`GN?^R$?S+.ZM$GXR%X
MPI@5;\K@!0O0A&FY/M>[9FKH)(0M7<Y,`81G<*]AIARP&Z,0KI?31AOBE$L@
M[\A:68=@U2'`,<N.3L[RI7/UVM]@E3A9[A8(`R"=!9/",?D1'M?DZLT0J9^.
M#I!V#L=M`^_RB`B%]\"]%#.=2LL8A[U1+#VO%Q.`QD!J'`%SVSQ2IOB0D'U3
MN/:TXP:6,X80C0,9!:%$W0A'B2^:!VF22,$0IC2QK&G"^[S%W""ND2GY9?RX
MX_KY"X;#X,D_"K&%:2Y`I6D1QKI!A<@B.IV&=P)C&ZA]G=1)2J1D?GZ>]1R:
M:7+$X\ST543BR=H+*9F0!]E=0?&_")N90Y])O"$\)Z>A(]X+DV\([,Q1AE\^
MVVB)T@@ID#.)H;)8I0E21"Y+WS+;=@L_E4D,70,"D6GUS%:OCW^;\6/(3[.:
M/;-C604/6(UCGKF':8UQ4(5UR#I)R<9H)Q9%.")\5N@G`O>4<K/>4HXE,Q$^
M-FX2K',L\:#"%.R=VK7(O$&L?,`D+1-*U$/ERSR+Q!&N>84=!7?*!TSZ/367
MDK?!!ADJLS*4FK+@5]@HCL3%X54;F@(E`<FT9LH#,WP.G8NF\LN[!1@7`LL[
M[S-D$_&>RS6:4%]&7J]-E;F$+-5(T70X@1!K-,2Q<5+`$CSER5DKSJN"D(EH
MEU\T\['ULH*^EZT]%YW(78"I/S`OS3Q)9'5#:2J=2D:47<VA!A*8$!,R6>CC
M<$GDTI4V1^5\Z?A^@.DB6;R4KS>F'R4,P2W>\)H"M<LV7VSV5.<UXWW/M*P>
MQ1+\(#G+Y1*&0E$VJ:2A9,AR-=P\`YRIVRS-?N=X9+,*17IS+M=J3A+V97-'
MS[JP>*&7AM_*;IQAA6C&HG.<-24;>J'<N95V@+R25),JX]^@@.)AA/&9@`=S
MS</0C\E=5E5P0<5-(#%,E`ZC7$^0%RO"[$B>NUW*.;IH?P!!>8Q72.1!.1IJ
MGDG(/2O:F?`3!2,*1O$367=/_#TW>[SDGDT14PGRGDK^<CXWL+F'U3LMO+4/
MOAZD4.P$/1@KOW"&O`9EMO\QX[7]^??EX[*.[@YQ%'P%67/DAA#X_1NL><S-
MOF*0TY=3R$E.>]0<I$%X5I-J^OAA3UP:_Q4ENG5<ME2'K0S912)RD-LO#-K)
MS>_&9:`<4N!C1XW.^EG#"RJF1AXY4U!SZ)Y++N'YC3GXIUE]8<[4P0WY[12,
M(X;38W()5ZY.458/*U2XIZ%8X0SM(>)I`\2CX<7`>*:?T<"BOTW]TE;\#\0G
MR&:/DHD>N.1O:B^$E_ZYZT(5..1;I'-/CW=D18P**61X^&$.K1K)OE;RWEO)
M%+A3A8X:!P(KO3LT?6%,4M'U)XEX.K/?5(SC@C<780P]Y$=E#E^`XHSAM^\"
M:@Z#)U^$>X`GS`%$2>EO9JA)$YGZ;=/(T_6&L)#Y3<^\XDN)C1Y<2LZAPBL*
MN3G;S]-'I'D*E1D,P\\)A9HJ==^*;Y4:)^F$/`C7LW"*UQ/@A?PQMQ\<"58<
MR>"AJE2UO)F4])$4+FUG,#LJ^]%IL2`(-@,O((B0$G'"Z!O4^H?R>L(Y)A9)
M>ZHAB?`RF\@^$,,@U-PCO@34F]G%4C;%UT4?8''G,'2R`RNLK()P'JTW[K-6
M\+MUZ4X4`9EQ[X2?,2<-I\"[SZ3$5$^#Y%"X9D4EOO5:SVH?M1I'U@O.KLH2
M8/GY2U.3E6Y@'$=-))^"\$\24N5F!);7\H*&]"PK9"R-'>F"$\CH<$@2,YT%
M&#(JNJ3NX(,B#1(\I0C?V%!2Y,FHFGLVIIHJ34JS<_*;_#@PM3VJ@PF6`.M^
M\'QF-G#%%%[J)$YG,H5C2Q4,2I<4Y:R+5YJ(Q<X#'9K":J0^83(SQ4LDE%%%
MG<;,R"7>8F[D.S9P,`-,%U&%2[Y4/@\6[!X-78\W@2_.[M5K,^CM*V?WZK7"
MU-IJV;T,/"%-[QDK9/<6S8$''[-)L6QY`M5\R*];C[*]C`,44V#!]QVSUV]2
MDN&)BB1GTV)8JY9/3BGF"X]!CS#KP)N@'QN_(\_DK3HF\C*=XL_FYE5%I*1%
MU+1/EJ+`9O+]?I^`]>FA0<AO[W&V#B:,#+3,9.`NE,^W(.N2$83;8SX=:H:J
M?$H]#!X2O'><$34W8KWVO@U#MOB$TTR7S.>D@\HK']/;F65SLX:;LFVELI\S
M.=J>.+H#Z4H_,(=79@EAV2:>9Q-J76$"JB0M/+TJY8)*T5<7I;G2K]1K:9HK
M@Y@2NJ,HA2KSLEAK4Z]]$"4&'PNA2+)Z3;H1(EI$XLU[(<`SV7TZ),)@6<"`
MJ9G<PM0:JD^4:*XJAKP4D(LW/YC)>I*4NK-<AXI^!]/DBHIW1:TQ,VX8@\@2
MF*?#3SP<`=^B2"O"1%!(QG&+R[2,PI:XB7:OE\K,>W!_6[VNJ(*8,Q_L%#F]
M@Z)*+Z-;T78)X<8[\%0E**CFR,K0@W!1<VG/BGNIWUG^U&#>R;`4*8[828(N
M4P4HURFPGG+TB1:68\BD^&I*-6=Z;90#CRS8_8(>%$O!=4TWI,@NU,._><._
M$W]X,L83F?\X`O)[J_#[3<OJ=]4&%(NG--7$@3!+HSB'UJ_"^%^R;3:?N+C\
M\NZO1U;7:BAM-):94WX5U^*NSVUPPK'()3#"M8<[Z@_/4WR#[3;2:'9Z5D]I
M/;'\Q!8L:+IOQ4X;:"R<37[R5_D6$#OIE6';_4:GF4VY8`X+*'R#17+8Z>1"
M05+9<MN51J/;;,RA<]&<IO$1Z8SD"[B%OW%3O-4I(]!GHZ$B(DY]?HK('/HU
MPK]?"$?U:G1*+@S=NM[R;*UNH]]M]!0*+YK0S/R+I35+H6LLQWE8CDWUFL67
MB_\Y/S-.;F[.;S5NXT+G[(NX"YRJ>ZSE9,/TA$]6(DSYU[]4XHA^"[YJ_M1_
MJ07FIM_L%&T<?R>FU(_J!<NYQ30W/.0(B^=&?2.BB3.`K4"E0S]/,-T@?GYR
MA_'#K^]ZC9_4#X;*OX?RR]<G9V<7E[\=?;ZZO;WZ]HMA3WZ\PXB+IGP7Q'$P
M3L?KPG@O9,.%:UM$]WBX\BKB8)(NP:KJ"CY??3\[_YXNX,YS0+W#,A`PVQV6
M;HG5A`4-`N0&^*/];@="-Z">`UN@W!QX7K!<B^*K0V6,_5^!9NVYK-WHORW6
M_CEGB/)&:7\,SQX0NIR>TZ)5XJ*\_KSW@[K[,4O-`]M69<;=/1`T"']]]U^G
MIU^^G)Z^6UNY53.(7(IXO-\A+[O'PY,$2Y92L-<5;=T>,,$*L]SC77V_B8VS
M,YI0&ZU=$"7[T!:HTK',?J/[IGEZ/V:I)>_`)*_;-.V.=7B25^I2/#VX,7N3
M#L6I<"+J-7E[YO"V?;]G>7#:I=4T>_V.9C,]2RT,!RL,JT7OFSHOVV-#G'9)
MJ=?4-BDK<L:>IZ]7/]<XW,4<GJHS&_WV6^7G_5^!ED@MD?O/SSH%,-M0&.\X
MX:WL'VFGJL/S1_=[E@>G>:Q&'^*>GN8S/4LM#9\LVS+MMGUXTJ"S`"MG`:*(
M,`>4F\A*FU<",%'N?KTMWTW'(@>L`S]8#<NT6LU78.D]UA<?M0;0&N!0-$"W
M:UKMU\A'O!4%L$KRHX2NK3?DC.5N[!$0^V9XLW48VA:680R#Y,YCARYIY3=,
M5JT?>Q$]#T[C]\SNIO3]_LG4_J]`:P6M%;;`B"T\EEJI[COGU_Q,E[^5GQ=`
M!:V""5&.AG'*6XXAA,H9N]LR+(W=M1O]7KL8!F-J)ODIGSK1`ZP1_W.>-8ZZ
M)C#<"X$J=R:!WK:ZADZWV6WVLR6L,K-IR*/\7R_\:VRTZ@[/1*LX@3@$HU\A
M?MPN`'<Z=M]JJ0A(ZTQQ"H4GO'=\D?>#/:;0T!%X4-<*6-;5*`7VOTGQD3->
MAJ>7`\?2^"<%FMTZ-BY/;G__?FY<?3$^_WYS<7E^<V,:5]]_.[F\^+^3VXNK
M2^/D\LSX[0I,NW%Z=7EZ_OUR@2K3V"B?+@/L]1Y1/X/0F;`D=@<0<8'8'.=[
M.(@'\PV+!;JK^MP,U.+9IX_4-<NX<X/)@Q..G0%]Q?$D1K!L."_:1(XG"%0;
MI0VW8Q#<6,))#A!G*#P04,)M;NR57Z^=3$+7,WH$%&GED6$)$H!`G`FM^0[[
MGU/_P6!\!THL[7A3KYTR#QMG.&$15Z1_S.TW0LE."+43L4^QG5"]]D_0@XB\
M@T!^(?9^Y_C[!#/)L(4!ED#X0\D+\-,D#(;)@%K888.=&+YC<F:@!\<!&`-"
MW7S"5FF/3N@RCFC[D`!5!*=$QH<9%B5(,-Z+6IVV:402T-.R/QX;%^,Q&[I\
M#1Q>44(R*P/DJ8K,Z[&8`'>M(V#@(ZO=E"W@C6CBN<3$;CP-#HV3S'4+_R[>
MN<%W"KJDI(TJ'YB/R)_4ZL)"F%#+;/<["OZI&T_!1<O.VD$XIMLG^"26OR*Q
ML*&FW%)$`I4=Y1S9,H9>5=?/N\[Q%I?3:+U&K_T30:U/ZX[^IUQ+JCP2*^\&
M<.]2APV.WRSGK'Q8@",3?"6,S3NV<%C9);8GYNW4D$.-"7C[$JZV7NN8O5;'
M;#>[\TB(_)>!URJM#QT_!Y"\U&`?9`>R`8TPHCM!A<O/,<5'V@[>:6`BO%`.
MT)Q''FZ;5K.-\+%%/;QF:)4U)T,T62376.`KXYN/A*^;*@N@'#+%@%IGR.XV
M0H#51EX92Z7:_=@XRSU7KQ4R"8>B3TW"A\NK?X#W0ZTU#/RWW6A_-(#R!!R,
MO=FB">'VYH6$^D4`FZ(Z(?IGH,0$`ZTHN3Q$\`-SAJ);!C54^>8,P?,$2OWS
M0J(SE[9S98.$=RBBB^.1;%HQ)@1S']5W3.+S[41;LX76C,"W<^R/O:F3@1#E
M#*)>52N9S)T*!<.1$@GYN]6VS5ZG8_9[3?D@2)EM]MM]$R((XP/_9Z]K"85$
M>SW=#A0;UH0<VQD[-]$XH*&O%L(LBX8MLO^(,7&FL,2%2L]IBB>$CY?KOE/Z
M!SY+Z.IL&(X"+$=CGCM&LXY9]8PLTV9A'A3]B4>M6_@:9?^22+88FJ*Y::2-
MOX$[O-R'<HV33?%QCG`?Y12KJ2"34X\O:LC">#,<PAB7C6TB5M@^2_3HB47+
M`L=3FL\(D&/9'FWDR0[0.2:;;FZ3XS4@0A(_!"'U6"XAJFA(DZK'%$F?F*!>
MDZHKX^;`L-K4\YP0OXE5N\HO\K,5W$#&&?L]+9P/^5O8+P)1W+-6/:`;)09T
MVN8P3PBMHA:IJ)/"!G=*NV;0!FR2,:WQ._BO\!.E"J*T5Q'MD,/C(+)=A"$?
M89<I!'"7CAH(A"/&&3O_"NAOCP$9:E>`/F.W`NX?D4^O&NX[$55QH'BNJNCS
MX>*NQBH.Z0DU9H:_2N%0W`EN\.ZR1BX"F=_A3@AG+D=]7C0=F0XX<!S$,9\[
M9:59#$I]I@[2!<"NR!5P$/XBC9&I!9R,Z^>;J8*\NB!'(06O:CO<K'54YNV:
M4T&#LE0M3<L9?,455=K#.(JYIY;E1@3&S7,$J5%<9,,*,'9C5/MEJ0=J_2TZ
M/\$OP:AQ.PI#\)')U@T9.96BX<J?U&0'B.H.$\>#;<:A6"R::J*^Q@[!%!"Q
M-(;EN$$PQWOAS]*WN<Q$"2B&*!HEGJ'ZSA3C4F-V&=NXQ*`B*$9U;SRX]P_4
M7N9>U"PR_]$-`S\=@`P6([M2KP5WI#,4*R]X&,;W&<X!&\D`$4<)BE`24QL\
MI8&'9MMELBY?V%W(^U&VLO9U2G,PT>EXR%4];JKL;(P=E)$[L8TC*A94;#+B
M@8W#=H.<GQ$9U_`2#)TIRS&;/Q!#UFO4+3F?C9/]_JAY-6<JWE@<N'P2N*(M
M$:E%[*TU0.N5;_:LML&A)`DHOD<R<\#-X2-Z=\?&EZS#\TQW+VQ]Y;@>$H%6
M.G1BQT3I^N9`)&U8/85RF1Z8(AT)#\.X3IU\1(UDJ$,E+I('AF-<J3_;1EH(
M">T#O3>D-!6(7,*&JCA2)WFY%[0O-Z=?3WF+Z'S&C'>,/:)FV!,'MC1V?C"/
MMV@;..%=,,$VZ/#>`QN3DG(FSUJREC$($5.;T"M6.XL3)GBX$ZKN=N1&*;=D
MG"0S`K31W"6Y#W@J"N7)S^</T$OG?AP%4*ZORH+HK<RCC0=J^T6^]-!(NVP8
MV'>>H9VB`!#__T3Z[,!CW&TCJX$=V;BSZ'DR601N.G@P&)Y"9#2DX(>1E"CI
M4J1#?L[8H6D@6RNY<7[%U*-/KFAVGC+/!_^%;S&"].;F0+3!DA^Y@[B2/;(H
M4V44(,/*'JA@OJ!?$;A%7A+Q1%V:MDI[<<WFY+*<7:X=>[V6!BJY%!8U]P-7
M&@>1EDS)]E"ZF[="#9(0!LCW0K5R-,QG=&0+)1B`)W<8S^-FU*-TV!U[#H3A
M+?Z$P=T)ZA1*`R@#%UCHA,?5CZ[#]1W$S=0O$=8</XL>>^BBW,4R2"#'`M4W
M;NZ].U`;4.&1#2F=)S=BN<6">PS3CT1W("X7U)J-Q]SH_D<)4SP&QX-%^;P!
MI0FA!6^/!Q',@*B`?:^="*P!;ZFF<J%8)?=-A-L!&\)7NGK'H5T?S^8/A['?
M,[5[5GI!ZY/<>2>YK5PGBY.+[\8_3K[^?GZ#![N\I04=Y'Z]./E\\?7B]N)<
MM[A8J@VZ0\$X[RZ*NK&D$SF9#;5Q^6TP`24A#T]DC]J\TWH?!LDD(@V?66"E
M_[:2,5!;<6?)#]$CF6R"TOZ.U$#(1$=PU"/@G(&-"V1J`^,?"G:RAJ-E;;]#
M:K4WY.>(?#$AR[6Z%&\G8Y%ME"V_TSZL:GO%G?MD2F':"YIHW&'KQ##MG[%$
M/PVKH52/*UCQ:;&Z6OQ65#WWSXNSV[^)MB`S*]H"LR_=P*2DVD_,U^I-S[=\
M/Y>1\VRH3:]W:DC\]]'(&;O>\R\WSV-0K7AT';HCE3J?NP7469I4>;+L0($M
M-^342_4:]64WK%^,"W^2I#V`_YT$PF$$5X1[,$*5\*;T0SS2''#HA2EE!G]6
ME$J!#MA\8:06?2WZ6O37%'U;B'XD:@4@T/!GU8!0$R9O(N]$XHEZ33Q"'8-%
M$KG0OU$=#5?JE'I-^">F_&).N\QY7[R'3@J>]H2,4E5"4\D0#1ZDA:7/!'>P
MU8^D(.`9'F;A05$8!G<!Y2;P4%AY2N@\3*[M1)-)]T8[2%I+:BU9(2W9G'*0
M4I6B)C)E7>!L<_(%7I*(S:0:RZDIK,F:X`DL5T[3_MBN'*RWGA_@UQK$*:2R
M<R5A.0*>8'51$H:\=`FSZ'06"L$S[!R5F-PQ+WC:8)/,U6B?HRQIJL/I2-FV
MJWKQ\.W`5TQM2:NC]I6R6KNXZ_<*??L6?(>>DD<Z&>V;EIG]4-S5\LT`I<SK
M`ZA50:56L&X'S\9;Z."YC"8@YS*C>T'?FC<C]H>T`BT7FY6+`GA)+1=[N`(M
M%YN5BP+$02T7>[@"+1<OE`NLU,C(3B4;;U@TUNBD7L$H:0\(/:>+]I1HZB[:
M;V"6F@?T+#4/Z%EJ'GCE;@RK.#G5/)-<WUW^FAU.+CI:W$,^T%*F9ZEY0,]2
M\X">I>:!5_&X-M-P82N^6/_U&B[\4V`N;2;3J`'5]\P?7V9(L;P"A/65^64M
M:O</#6U].7H?;8#>^R^?^[\"K6&TAJFFAK%[/=-N;Z-F<_^D=/]7H/6,UC/5
MU#/:DSF,%6@-HS5,-37,ZW@R6\O(U6MK9;M>Z3*DOI!7!7.R+T5^^D+>#B_D
M-?I;4(G[PFGZ0E[%-T@7DNL+>5HNM%SH"WE:+K1<Z`MYK\U5^[\"+1?Z0IZ^
MD+=_16NZ)%#/4O.`GJ7F`3U+S0/Z0IZ^D*>E;)^E;.]FJ7E`SU+S@)ZEY@%]
M(4]?R*M<"EL7F>HBTU<O,M5E[(>Q`JUAM(:IIH:Q&F:KUS4;#7TG[S!6H%6-
M5C755#7:F3F,%6@-HS5,-36,=F:FDU^Z6>&"9H6WV'/R-!A/'/_92")X`;L2
M.K$;^,:8Q0_!D#?5=:(H&4_PUZ*CY0#^Y0Y9:#CCP+^OUZB-;E3<U=)(?'C2
M>\;^AE$,ZS>-T(W^/!J%C,'<8Q:R**[7L*VN:3P&'GS><^-GTV`_)FR`[2P]
M=\1H'D!D;/H[-/!AZN\+K[IC>`,GH7P9VP/CIY]$<B^=,(P6!\8=,^#?[J/#
MFPN[?A2'R9C!@\?&B;)6(,F0NFW>,Y^%CN<]\X&B&)X%"8@?X"M!!$,,W6C@
M!9'L<(S+/+IS\.<!D)?Y$2?JAPC6?!G$S.A^+.C(F9=,\=-??DZBHWO'F?R"
MQ9)4(GG&OY8`Y6[9C_@S<M5?ZS7#^(M\],*'[[);YT?V:/HDKB&&'[ZST:_O
M6.#]<7W>:?9:S<[1D67='%E'C89E_7%S>_9'L]/^`[O,67;3^J/Q[J^"T?>7
MZ\M/WWO'1J9C+BY/K[Z=&[<G_W-^LV"7MD:!?R7`VJ/G;8G^TIV+]VV+9Q2;
M6"GP<?]3!'(_8B&I`>>';+(K97HH-=8H\+S@"166`YI)WOHTFM8&F[#N/3=4
MZ1IZ?\/7T+N=:KDU^U_:OO$[$X8?/(7.Y-=W_+^[</(K>H?BC?>!/:05:-G8
MN&QH2(;5+A15T/3M`:%7*&F:DLV*KF(_:+T?L]0<L0^7#`H5WWRK>=2O<F7;
M)8/@-9BPD/)CAA=$$.HZ8?@\"L(G)QRN6O*V@!&VFP+?/+]6,[VQ%#4*CE96
MWKF#.R6Q;+/7M8O//P[H]HR6/BU]%92^OMEN-0]3^%8IJ'\KOL5W%C$G'#S4
M:W0NA^@VP01/T.HU/+;S(Q8IY*W2O]ZTSU.]61Z<(K1:IM5K'*8FU`*A!6(=
M@>@W.H<I$#KQ4'CZ[ORHUP8A&[HK7ZO3ZD6KEQ75B]FUK,/4+EH>M#RL(0_M
MC@[$WXRM/74F;NQX]=I,>E];WFK-\N`T3;.EP]QJ3[/"Q-32L"\;N%J,NZEB
MVWVVR3?9]0^(@Y7['RLRQPN*SZJBH%:L:ZRP&+QL,0>G[A8,*=;7[+2W="%Q
M7RHPM1A7=3^T&"\MQIUVB6_S9L18IQYF:?=;&$11O39[HTYG'JHURX/36G;?
M;'5ZAQEN:8'0`K&Z0"#NQX'6ONK\PZJ4_8<$\:C7'+S([OB#@JY:.O6@8Y:]
M5';+Q2P?YCD)NXU;]KC6_:/6&UIOO#&],<>7TGIC&WICRQT+#LZ_HXN=+TZ[
M+$/)/5;5&I.S0+EI3,[=TCO#'FL54'LGLEHM1T1K&ZUMM+;1VF9G"<.-80"O
M*WSY2>\_M.9)5*\%(T,!Q30-1*`S"3E3@@D_.$-CQ(8(FDO(O5'LQ`PV>`$B
M"0)P.I-)&/Q`5%_F/1OOFTUYGQ('`J5BM\V>1?&9$;(((8+=1WC2-"!:&#P@
M:K`;,IA,&"3W#S"U9N.XZ"+P!69'AT,7\Z33<X\*YAZ*&\]\%LJ-9WK&]1]9
M%-./Z(^+RT\%R[',9H\FSV].OV^U^OB3N<1:ZK72Q=S"])UQD,#GX9-`9F,>
ME>LU/OS8>48HY`0!E_^#2,>^GQ#(L>L;HR1.X-,PBHLHT.)1SQU#1`;KGR1A
ME#BXVL"XP6D'O@$+DP"J%P@&YP/]O@.=_`1I.X091H:#ZTP\G&:]%B5W0%L_
M=N'!P8/CWW-,9V4O\MBMP9//PNC!G7`0Z@<'P9N#P2"A.(@@G^'7.%7ZI1R+
M+V41W/);@F[='VU#0+X#?L=AEI.!F3Q"`@<NQ)VF!T(V",(A0YDT)L"]8;WV
M#)(;$3+W98!R&ZE\I<HNO.+X1N+S<47U)O"A9IY]9)[/;.`DB,XNM%*A4A$J
M35&8#VX4!R$H8<1)=_U$*E$6<9V=^`,6QH[KQ\^8>`D&+O**A(.7^I0#OHLO
M+S9\.5UE@A+SG7M&/(GF"$P((M\#0SJPO,9/1GJN9SCW#N+7ER_P'LMT<KC7
M,`KFBTK,HF+-A^X(WF+XF3L6/S%&DRQ!UHX#E%$TE@F2C^P@XO3/&L$6+@"M
M*)I(!I\@LY=[`9YP8=)@.81H^[`7S@]"DL8%D_UXWS,MBTYX#"!UANB?POZ;
M*,VN#];8B9@D\6/!Z2A^\KUMMCH=Z6C@!X'@"4P-O^FY_T[<(>WST!G#UB`O
M#`9APD'#W_<L,N/E)&WTJT-2]F]NY@5I%0+5:UD#"(7%@!SX8,CI$?A$2AA:
MZ%LTZ,C6(W#>ZS6Q6RKQ\+'B'3I^?0VD5>RF.H@,710;[I@9U%+$1V-\[Y-W
MB0QSQWPV(L<X-(3X8/L-W@.$^&S"P&V,7?BR$],8&!H"UX;(8,A:W)8SY*\T
M"*G79!1"8W!I(V"B`,/*`$>*W8$[05&`V1&R_]3\@'%S$WQDH5#=/T"Y/C$/
MUC0&XCU$I1ZXI(,;D6_[+Q!"E#$G@5C`N'OFGO'W&]Z=!#XFG6MP,D#3(\:]
M\7<'7'"0=,M$;[_17;U)R+S.'],]0CC=KQUWN'Q/$+O?[:I-08"(+G_-C8*6
M;77_^/WF[!W(^@!TDQ<A2O]?K7ZKWVVJ<\R^/-.WA'01["S]]\+/GGU&[7_)
MXNW.M=EH-UK]'#T7SBB_ANLP&#`VC+Z`.KQQ//8-U'?HQL\G_O`T\#P>+5V-
M;AZ",(:1QA>I_QEM<6D7EU_>_;7=!IYJ-K+5O6"N^45GW'8U.E6N/'WGGO1I
M$,71S8,3LL]X+0I(1V/HGC3S`,Z[BJ8Q;FZO3O_[Z//)S?F9<7KU[?K\\N;D
M]N+J<G-6)5W;`7>YROM7I7V:)I[C1]3Y*4K&8R?D!N(.0L>G#;:`.52"3P_)
MG[G]WZ_P$`;R[D"9>RZ#;:/W3=<GC2OJP65<PTZ4.8G&"678BE.1(6PZ;F`@
M^Y8%QB0)!P_HZ-I]RXA0&47&O-`0[3*&"<0F1I#$F*W"UC.\I9GA&.(ODY1I
ML"$9&`4W>N`)B)/D/L'N9K2P#_BE[!.GG^BWN,+LEV>?/JI2?XL+@=#2\S#]
MY@<0((:XN'KMGC<V&SM#T6&-UI&.>"P(&"F]RU!U*VD^B$BYDX.-V+A;A3Z3
M2#H&/%K"3F>8\_3!:P\C=$T$Q>C[]1K&1.J$+X.4XD\X=7J,9^?8#Q8.7)2U
M_'SK-9RP]/'0>5,'/)._QGTMVLQ.6^PEQ?E\S\3&%-"%SRJ;"JXX&Y42FWS8
MOL(AN4%I@`$&1AX;;C`QI+5!@3;H"&T`7A@P(D:.)"XJT8'3?>.;@SXS;G/'
MG!-0WP68-80='0*+#R"F!I8?PO:S(8\78)/_GH"DV&(L'LV6VXX',-;8^)""
M\4<<13#;S+P%DQ>I@$Z!"C!.1/`/<^VTS69;84?*2F;\B$H.#R?"1]%]T(TP
M-3^84@O\*_A`JCM@;#>E*[P(43MF!MR1RX8YU19AR\;[AWA*1-`)#MU!+,0(
MHZGT%\7"8_+_@&8&@C%,G*'B%&/S\"^$&8YI^C0$5R#8EY$&<L$+940#7%;!
M=@X9NJG`0U$JY)@%'C!8`^H_U"4B[N+9/`S8U*^&[-\)C,;=<:$$AR*%0G.!
M-:2Q'9\&9><B4B%".:;TSM2PHRA#"&TQ`+X+D"_2IIG@9_P)T4VN=V9^I^-,
M\_(Y4<IG%85-KQT;_YBA1*[)9?P4\.10:AF.@9/3\'LJ^D:[2\+:-_-<D[;A
M3#D&IF+99J<[JUREE<T9C0(&/I8&(3^97)<^<XZUL,Q6LU?"G?7:7..0#=(T
M^[8U?Y#40)0Y*33XU&^!@D#(MMENMWDBPS+;C:;\$#`E9CZ=1\?U*!&*Y.6[
MFB<4US6*!R#(J1[:Y;5"MO7H:J"GBTD$<#84MR&98%+0X.+%!1</]V)^V$9[
M@BEPS,WZC)^YJ(T4Q0D?.D48ZX6!9^*!X)"-0%B'I/"F1Z[7W/0!?):YZ/KD
MG@/*LO'$"RB<1*%"/8C2;@3<38H?N-(SZ"@`G\!NCW&8B`1IT5@,7P]1S?J8
MVB1=F<]RHNL'AA,TY0#IF4N,REFB$?(=.D7%>0V""?'_,.'9+>QBRZ()MIZ\
MPX:W+FHH)S=4'CR$5(943W3T%0SH#]H'V:(/<D6;F0M)3I!UW'CJ4-`H\ED;
M;9F0;)DY7X*,-"O6+DYF^JVNV6RU2TT_O)5RK*GZ-#XE]%+FQ=#%'?)C`Q_\
M?C)V_,Q_DH^O,."(LJ#)R=0A:1PAX`ZLA?E').+<A'"I*+"5.)5'2NZB98-'
MDTAD?,'.1?S0#!1/^L4[1C*F*A[Q4=4HR2/=6=.67TIN(9@'CN'):`2Z#E:#
MEG/`)I2:I0@+!&P(:@],XX"?+'.3'H)N+1Z7>Q;@$0&+<&_%Y>EFCT74*=LW
MYEIWN:\^YPU)NG1)!7'0`AM<9O9:9JM79O;(YB(Q%IF]?J\Q?XBM144'5$15
MGNX[&0RP@H?X/Q`ZYXC2I<;I\B!26MOG#Z4<3E7NC$IM69[Y0ZN+KX1#B@;2
M0_U[//X5)\5?3FX^&R<WI\9M,`%5T;5ZIK&NA5%W5@D,FY_X_O-U%&Z]J!$3
M#D%$6I2D4RQK(G+L%*8H9@)"/B^A+%86!N;IDD5](/UW0$OE%$_6*8#3Y`]<
M<3HMHB7^71Z'@,9#M<</E%DTK3\+=P?BSZ.B'9KR@]``K;9#[4;;Y/R\SA:=
M`X'CYQSM905=2GRJ/./%0B[C-4A$L#QSB=8HAEB5B-C0X(RIM(`,16HA@BGW
M'39#I5"4YN^0V/G85A80NFKZCR(Q;JUYKDVN(O69>2H!8PGX'%C%*(&_YKZI
M?<WEM$\6^(CNY_(8(1)UFA'&0^$]WU;)%Y2<*55-HBA-]?KX(;?P^V3\*7P3
M(=V\@K5TR*Q6#AQ&GY_W`5^@4.5C>1&PI/D=GI'@Q4L9AT+(HPJQXH2^VKE)
MCB]:[2(N$)7OV^]3W]MTG_I&M4KO]Q_HZ\6]N.V>VMVULXNK)Q7MO?V_$*9D
M9#_'>&656REOC5PRE,M(!C'=*@0[,$F<U[M<J\I*K6!-56DU\XVPWZ[L8^+F
M#8OZ(:U`R\*+9:'1?\.R,,_L[8]IVP-"E]-S6A9+XL77G_=^4'<_9JEYH*+=
M,8N46S73@TL1[USDQD3G[%SNSLBE[A9ES/:0([2\Z5EJ'G@5G;M"HX)M:-Q7
MA,O[+I`[A,;-D#LVJU^K`E/U!N"G"H"E5M\Y^]!`HNQFP[0:UD%[#5KVM.Q5
M4?:L5L]L-'7WA0V=R^RQM_$;K[<1ETN&8]=WHS@DU(O=)3*KH@]7S(E76`Y>
MN)B#4W@+AA3K:[8[IFWKHRTMQ]7;#RW'R\NQW>N#>]-YPW*\@1X%;Z<Z1:NM
MBBWFC:JM=J]C-NV"C,B;45M:CJNZ'UJ.EY?C5K-K-CK:_=!'Z?D^2,I5$_6V
M?M%A>N']E7J-7V`Y[)/V/9RE_5-59[8?]*N>"=]C8A8:W0K.LUK4U(4(NA"A
M\DSZ9LXG/]AVP^QW"@KK-^+H[+$3^7%I@'8MAEH,7TB0IMTS.U;K\,(-72:@
MRP1T?D_G]];MN=XS&^T"M;C;_-Z;]&*T^M#J8\_51Q^<JG;WM;5'%;TO79R@
MM5;E%_-&M=8'&UO_VLW7UEO:Z]'Z8Z\7\T;U1\ONFG;W+1<W;:\HHH*Y4#U+
M75Y0O5E6Q1CN,3%U><$KA;RM71\WO**G?(L=1<JQI3?C-[0.Q'N&=1C#(+GS
MV)N(HI9S-PON?:_,,.M1^XWZ]\TF^/?]WA;\^V7DM`HZ7FL:K6FTIMD^P7N=
ME@G:Y@UKFIPW^3,U@E!^UAU.\E2]\F?:;6+O3^IE@[U(TW:*LG?(`_.HGXR#
M'4[&V)8Q[1#RA'T=?\2\FQEVO_*,OSM^@GU+<YTR77_`F[+.<V/51BKYOC4X
MF_=6V\0VT/!)WM)HMO-)UDTH\-G1.,!6JC2[2/=97(8S+H`SY/9E3"&;/8V#
M(>\MS/O4AN-(91*ETUR]9G?*^JNFS(3]`+/]A;=YFT%L7YKXHG6@VKR&^NP@
MHTTS*K;=DZT$9?><F895?.Z\X28Q+35>+V8>[(Z8:RM*ZYV>+G7ZQ!8Y41P5
M-_H3351G._T)VBHR892)!+4')IE`">A)`2CI_)/QO[I>:JP>9UT/:>NT-*S7
MY>],-*C&/?Z"_;[^@?V^-#&WU\(5"<Q%D6HMQT$8N__AOQBS^"'(=Z4Y)G'/
M=V)C#E[:4%I>86.UK&V;Z..F].5.(MFK\S-ZGD<W@X?`HXYM)$%'V#<4GP`I
M8]ZTJBGK!Y===<QWYG(CN:A\-[%L$EA9BF[F$5*E7N.K-F3WN*G><5JPM\F+
M`;:5]6:[!ZM-$24#1,9C^GC67-'!#I6P=<X]<<4'ZZ-J9+,6DOU/X'BYP"K`
M:V`@E*&`+\#PN'$TU4X83*]QQY@/=O@.UH`M`T-G*!K"?K`_@M%X=($R\-5L
M-#`PZ73A#^FK9*:'87*O7G126B3R%G/NV/4<\`=%=]R!,R'Z<?'4-F:;K/C=
MC?X\&H4,O1@P2>@\@4/$"I1A6/PD*)YZ3>WY:?Q^?`-OA,R)$G``GUUD@4$2
M/I*CQ$8C<#*P#S2Y0[`X:FC-M2;R(2BMA,9-G1#49'1;&TVFX411,I[HCN=;
MYHMSE>@%W)#?%!#YO#62O2!GF*-004G=@>,\/8#JD<-00^Z[7%MJV7HVB9.0
M`3?@3_"/!U"&7&UYH$VRWI1\I&P`<KJ+>H3G%Y1KF>I,)IXK&EM"1`B+"Y()
M?MJ!V8)%%[-(-?<P8+P!.!_3B)*["!$)7!RM7@.7>@13]F/95)UAS_$)1`!'
MT@:KD<,=@[6Y\(3H@$X:>Q),$F\JPC9@+D,6:GVY3;GX$H0CYB+O3='9F.(G
MR0P\Q(J,\D[&:6CF`Z]AS@+\,OA1=%6EGL+8DC=C4&!#9!25@V>;46==B4?9
ME'DKY\RW!!\BIXB%]\I1,AY1WB"^'!D0%[(H@G`>HTUB9Q@;&)AZWH.S&.%#
MSB!.P,-0O\8YW1B%P5@L*O42E,G7:[<B$Z"TOC[]I`R4_?KL$XKFT$4Q`<G"
MD8$-E;=X\WDN&OGW@+#J@UGHGW\,UHYYH0E\EMI9TZX@B=)TP@2]["RD!W,E
MNR5+S[ZLSS6Z5E*9..C#^7F*<8.*]K#Q$VX5-O.>S6*0AS65",#\6$X)U6L/
ME%/##6)`DB'X]V"-1R`74_Q`H0KN^!V#B3TRSG+U&M>K0&T7+/)H!*$*JBSN
M2S[3B]RCHY4,!MQH*YJ\7A,Z>J2*3):*3?]U^X"QB^]XSY&;JGS@OR/V2#$;
MTC5B8_>(TPL5LDC?3%-.ONL,_Y40S3#'ES)OX<=_]_B$O6>>I1)<+&4RZWF>
M]=F>BI32KZ+H"FY!5A>)*TY,+J^KZ>63KQ>_7?YBH!X$-MJ(;A4?R^?#]U^=
M+VJV_<0P[D5^$!$3;T?/,P&I/PF\DJ"'0?LXVW4]3=N9:;\>/H+2WAK60()C
MI'K1'V+ZC`TWV/BZ.G1?NO"ZK!&WU2N:J3A/VGXC[OZ&&W'W>M4ZT%IO%14[
ME7MY4\W&5$,A/W@*G<FO[_A_=W&\6]$FF[HW]P9Z<\]A8TTZ=X?M7*NMQM;H
MZ%I!<[('51QS.LLM,`05746%:;V1NS>%;%Y-KW@IXF6G.RLJN3TI9=P#OBR9
M9?_0*OOZV^HUM<?B]],J)-D`/N6AJ:]_BF3)D4B6U&N/6J%5=)9:H6F%ICVR
MQ9"[LG2A7BNO<M#J[-5G>7#JS#ZV;*W0M(>V6?K)VIQZS7-'S/B`]>'11ZW,
MJC7+@U-F[2UI,IV_JI9Z.7,?W2'S"XZ"M$+1"F6#]-"QGG:-MIZ\2FML\;;-
M&X_X]GAC"^``5MZYPU.@QUWME+U5Q4:EB4=4O9O=$-3Z;4_W5^NW0OW6+@!&
M/BC]IF%&%M=VAZ#MGO`R@A\814U=ARE6@E$"E5"OX16)#5Z,J@Y]UJG!WHO5
ME1<<WA`/7'$>.!G$[N/BHVDM29].ZC5^)^)Y^KXFWGHA(AH)7F0B2;(1(^3:
M<WQ3_MBA'WFOJB")(W=(5\;P8A,"^N"%;;P=!<\0&`%>/,,;&0O[*F]W:W*W
M:&8O'RC&0[UO,/OJ;FX@E'T_[_.N40W;MJME!`^BIE=?3=A:P3C7[M$L_75-
M?4HBT,$Q*&-0*:N0Z9#%\"`6H77)A@5%YDZT,BFGT0E/*VD2E9/H7)PD9!)]
M77RDH'7OWBY"ZUZM>[7NK1Z)OK.Q0VB9FDCE1#J%OX?.0$O;7"K=(J!9:AC<
M@JXGFE8J0,!*,?@A^P8'L0CMX&S:>-_?A^R^\#*)UB.22!=@F%P_<@>:2.5$
M*H$`?TO*=B.E/X5''?-9ZJB_D*?ZKU<;HB1Z";!1]E80+0!6Y)(#J_FIWBP/
MK@RGU37;O6T5:U=O__98&*I9G:`+X-:^#F\=:\&K\#0K3,R#DX7N\88]G0IO
MWAY+@C9!AR5V_5[?[%H%#6CW7?0VT#M\Y8*[ES+":P:A$B-;0&)O(3=1<0VX
M8@:UPJS_LL4<G(I;)CE7KUFVV>EN'<1V+[CFC:]@KUV<9:^+O)1P!Z<E+*NU
M^G5;+3!Z!;M?0:'L[=<2]G\3]`I>?P5:$/0)[6N<T,ZT:=]L^J0JO+P'_/I6
MTG2=AFFW=8*\NM,\C.A1)\AG$^2=XZ86O.I.L\+$/#A9Z!X?(![9X4F"-D&'
M)796U^RTT0$\0.G;`,CIP1[%2FS3#4,U5V';]WJ6!Z=@/K3-?M_:$I?ML37:
M<-.%"K/T@6V<=B,*B&)WCAO;$O+]X&@]RQ<;O`K/<C]HN;^SU/;@L.Q!QB*=
M3M/L-`[P)LIJQYF[*0->XJ@3H4M?/?H<./Z`>;NL!*X"Q^A"X`-6>/.'%.N#
M8+C1*FCKN%L1V&-CNVK4?#`:XZUN^*K>E:XU;O:/[55;7V@QT2MXU1++/5W!
M_N_!8:Y`&[RW8_`:.[N75#%9V<`MY-;.TP_5K;2V5LU1+4/3"K//@@`>EF$,
M@^3.8V]A-0>G%9?+1[3ZIFUWMI"/V#\AV/\5;$R,]]A[6H[M"WRLE3E>JYGE
MZ6TU&L?]`AP8K6;V<`7:6WBK8MPI@E'3,KR'*]"N@G85JJEC[);9V\H)Z;X(
MZ4;*2MY47D<T5\,>O*^=UZG*;2[MJKUQ-=KLFW:W@/'?C!K5<JS=->VNZ<R.
MUC/:7]!RO$1JI[5C(<[>W_""8="MRFZE)JX]`^T95%.CZ$2.FLCY.<;TA/+S
MNNT*TU7=A<;/Q72LFA#?$E4O@:K?RZEZ^X#)&]D0$P8271]QIQ-F!",CX)>'
MC"`KXS'<R!@XWB#QX)UAO7;G1&QH!+X1/S!C$D1N[#XR8^B.1BQD_H`9=RQ^
M8HS_?>#!`S#&V`G_9+$Q"=T!3`$^A'\\#<83QW\6>VTWK/XG^%0P'L/@40R4
M,YR8'F3^T!#OA"R:L`%^LEZ;L-`-A@9,DS\ET#;X5^0+B3]DH?=,]4AB=<<*
M=Z7_.DM"G"B^\LR<$+\)RYQ)<YGX1+T6!['CS2-@"OUA/#F1\1XOZ#4:#3E7
M.8`S#A+887AOX$0/L+@!@Y4-C1&(1K8>OA+\AQ@<A@1=:[5[>.FO<#4W#PY0
MB@96Z>E&40+#)Q.^?1E"B3IU>)-/P$GBAR!T_P-OW"4Q4)*_7J]%-/KQ`E6C
M!>[3243,7LQ%0&;D#6<R"8,?[ABDRWL&3FEUB5-PTY%'ZK7$![X([GW:"-C.
M"?,C![<*?HAB8!H23'@:=NB11?AOVNTCDM1Z+?>*$X:.?\_&S(^+Y>`*F0U$
M7F50T^@V?D+>K=>:^(\0A0W%D'_V#L4RG>&0"Q(LTR)VAW_89KV6":[W7/CA
MVTPCB-$CHV_VVQV@?[JR5(;QN_@K_"/*["B)DY"5#OS$T%BSX9'SR$+GGHDV
M*4=#U(,CQPTS"18DQ*FG]"Q2BTY<K\ULK)!V^[C;I!'>=WK'O;9IY%>_P$2+
MG_[R<Q(=W3O.Y)<S-T)%"@N\&ITJN_F=;_TIL$%$$O\9=_S:>:;MO64_XL\H
M#W^MUPSC+W*PSPEH9!9%,-"=Z],X-VSBA,1_W]-]O`7Z1,Z`UGTR'+KX#\?+
M9A*=#/Z=N!']'B=P_@.G11SJQ_#E[VSTZSL6>']<GW>:O5:S<W1D63='UE$#
M&../F]NS/^Q^M_L'$LVRF]8?C7>H8/AK;A2T;*O[Q^\W9^^,(1N`<'C1K^\:
M[_[:MOMV.R/,EM>2)]QOS`?>\4[\X<EP[((RC.$[L*/BZ>TNO-/O-JQN/UOZ
M@MGDIW[)XE,P,-=A\.B"6?O\_#NL[L+_`C3S!\#,)\B:L'P6;7<5=KO;M>U&
M-UO&\C/+KPA>&#`VC+Z`H;H`LX1WG:]&7P/__I:%XS-V%V]W)5:GV^VW%%9<
M/*'\`LZ=T(?U1=<LE*+K#F`WSUPOB3<N1G^`K_0'-]OJ0NQW?SVRC]O-;!D+
MIL77X#]Z\2__%"KUA&O4RP05(3TNGN4^B%(0OHDUS:X!-J/?MIJ6!9NQYL1F
MA.7"!Z/)O@;1"O+0[+1ARHWF"DQT9/?;W7XC)PW9I_.SND&3?D$.&'=5K\G[
MY6L!-X3^M/9T_VB!9FVT?[1:K7;/@I_@Q\X/^&6WU9M+_8O++^_^VNSVV[UL
M%<M-=:GE4<_U;:VNV^^T>\OIK86+RT^T`ELWO;B2K;,;S5:ON0][UVYV^KU2
MSBS?NU:_V=W&]FUU><NS9J_1LAHO6M]&]%VZCFZO:W=VI?TVM@<'QU3KL-'+
MM-S+V*B]BMEL]:Q>L_N*C-->R6K.\>JK:%=66UR)7>E8C4ZG546[,KV\=>U*
MK]GN=2H@,NMHW@H)T%ID7^QLSB/[R?!?213S'$F0Y0.N'1<BSU-GXL:.1XQ)
M";1\PH7G"=@-"Q_=`>/?$HD&?(`^NS(U.BLHOU:SWU?D:MMKV23#KK+,HWZG
MV6JMX!Q\9Y,D'#S@*F?X8*LS;5J=SK0O,&\RR\]=)/'7G'Q>?R_6V*UFS^HO
MMPX^L5WHB<*UK*$U[$I&<*NMKBR"LQMV+C.XCJFMJDK,6^GJ*\BMJ:(U"+$!
MQ;1U>5[7^>HV^MU&^S7CWNF5K.!]K6K:MK@+:]&]^S)E6CE=TUWE`*K;:/;M
M_?2_5EGG4;O1;S35L[8"+J5T^SP.H+_]D\Z<X^@\+8G8YL3M=@/^1QP%K#ZW
M5UE8J:LVY_QIBRODGL*.EECBU73;C59[_AKG37,76K1P96OH5*N*KNEJBRM+
M`C7L)6ST?CFFTX19WA]['=/Q6JIL>;K8K3[\SPOUV6Y%?5VW52[UU;S6Z86L
MX+4NXQ#L:A=6IKMP"@[):^VOXK4V;$OEN]UZK6IIC"Q.^Q*$5U@#^:(2I#4H
M<=3OMSJ*Q5UQ;DN555U0V>`.UV2UFLW6XJ*J@GGEUT.%A"?^4-20;7?6':O;
ML7N*/IG^>GYNW]E$;$]6524X]2L#+KVZ\]Q[AY=I;G?:BARM,*FE..=JPK"*
M;W><T^IVVSD?;?F)Y1<$EB#$%9\Q_M\+_XR-6!BRX5?7N7.][:^E8W=[RM8L
M-:$IJY66T)[FJZQWIYB+I["(U">#`99I1Z#`\`8,UH0.!F&R.]H#Z:VF-8_X
MRTQQJMS6<7WT+*[\&\=C5R-@26#"^/G:`_?O'*S0!`5ORXJUH]:J+C>CQ6IK
MM>K4->9M=;L]=>)ED]BD9[D273O`];UN<RE?\C+P`ZE]^#,K%UROI1F;[9YR
MS%PZB^GMCI@3#AZP8I8],B\@EMC%A&&^0-.FNNESII*?]1F;A#`6Z1KXM\?P
M'RBBXR",W?_L0`UV.UVUF'J9"4TKQ9B%X-WD]D;=-."P[2V!LAW3++/,E*8<
M97ES(Z`+"2'+:1ATC7:B]J;=R>6GE5_.55Y@=J!6IEW*@AE,>;S@Z\`"\#^X
MB$?0ZVBD**B9-F+;G3M(;Z?54PXN5YG:(@?A.@0+X`ZE!R1X$4:G..<DBEB\
MY:V!1]OV/`=AF2D6BSQ&K=OU+'&@6;G&[V[IAM`Z0MNS6\V&0N)7OR"T%IN`
MY]+;P/6@C=VN6681<R[7-(Y;BG=?C<LUI4LJO%MCV3V\B&-OZ'*-DGFSUITR
M9B_;S>Z/5J_3LUI+7M>RP<<HS@!:JR?Z2"?M:OKD7/2:_;[=7"V#1[/<5!:3
M$C,\Y7XU(NJ)1J,[)4/+[MI=:Q.)S-+U[#K%MP8W'UF]7#I[W7P??P"IQ_TC
M:=EV*9@-JZF:UN();2=-N=9T[8[=ZB^=M=Q^GF\M]FETK%ZSV7MYV@^\-NZO
MD02=N?BV/XSX[MW$3DQ(`Q?CB3/8&5?Q*XEV'T*!OIKH7WZFVTP+KK%?O0X$
M9-TJ)PG78L)FN]51)6D32<.-Y+#668UMV]UFL]%YG9366O2W&ZV6I69=7C/'
MM8Y8-'H-NV6OE?&:Y;4OCAO2V>75Z'?_@0WO&0P20MB-,=.%#]%30F[&;K?(
MLEK-[MS$^K+SWEW&;XV5-FU0!B])_^6$[>31<3U4&+?!*:$?D<I_"+PA"R.*
M57:J&<`.-3MVF698/-GE2RMV&I8LB*J*)[?K?.<ZB\K[UNLF/_&(*/H.:LC'
MDI)=+J`)_Z/>O,Q/9&LIVO4<4=ON6VH]QL*,K5@)UFO\1H5@.YQOQ^[W&JJ]
MF9K*%&V1X6=MZD[GVU2"JY+YK)D@F/$_U1AZ8970;I,&S6ZCTUDC:?"R-2X#
M6*2H_%UZ3OUFKZ>>-2R<W.Y/3=985K?=Z#:ZW?T[0EG/K<C=/M_,@<KT&.?C
MB1<\,R:`YEXG4FSG+ARM,LEE2Y2$(M_E]J&1;LY;U=3<=G+0M,9";*MGVRJ`
M6,6.G=9R`"'H:EGMEY]"I5FF?/)IIX'55!JL9$H[.3U;9OYSSM)ZC>-V=YW#
MM&+KEB<`FHG,W,E+!CO<J;[=:+6;\EK7^E-6UGW^8_"`8*]HR?U'B%E<"#-?
MC16M9A^AJN35O"4FM]L++"\Y%("W._:V[QQ6C&'M/MCE1F^)5:_(MF>,C6$4
MJ:BN_%=CV:[5:J0BN6!:KW)X7[JFPJ/\IMVQ&_T7'N3SW4XF$X\.3!PO4T]R
M>U^!&5N]9KMK=R4S+C4]93T0M7E.%+DC=T!QWM5(/G0;9-E4Z5D^[])1[/=[
M_?0F[(KS5%:X3,P+,4&`65<V_*<;/YS_B,%AHX^`[^:&/!L+?\T^NLN05=0_
M;&\QA<2Z#3"@#R&$#$/L(2`R[=_9$+0!9FU+C==)G&;F=WMDT.[U[1DZ;60=
M6S]JRVX;-\`=VN#!V^L)^1I+@@WDAS[KB_Q2-ZXW>%JPPNU^\@0[]K*0L\JI
MP<X@"UZZ1%Z`8"WR"!?C%]#;A?DXQ8QM4,64WO;OM59#I5AJSBNL<4TDM)<L
MLF1;>S!F9\E5K@"3QA_E2IB;*44AW[`!/+JY+$@)!>!O=G,Q!2#:61KL>^&"
MEC_;?'W:+'O<L"2>QV9H4Q7&F1]\$%W:5J^W+$S=7A.GW[(ZJTK5T1*8IFN1
M9L?ES*OB?[R)XN:UB++S4N<=59:L@1#STCJ3O3K47H]9JG#$O=7CCG4`,%<Z
M_'C5//,Z0G%H6>=UH*.VE8-^W5S!\@0`MZ'?A%#SD/.#:Y!%9PO7X:7MYPY?
M+:$Q#=BV;$*#5THU5T]K5#&DS1-A.C"95Q#1LEM+MBK9XXA_ECQ+7S9J6ZVF
MM3BEN0Z%2NXM;24CUNE;[879VZ9UW&_9O6ZN]^&<.2Z_X;FWM[RT.=S>[G>M
MUN+6-;-3KJY'M?SJ.W:_VTQ-YP8]JKDYC0J0I)#7[45(TLM/?V\<AA4D96=G
MC54R$T2?M<S$4=.VFHWVLHF,?<Z!SB=2H:P=];O'5L]N])NJ:=E$*I27[Z2Q
M/[],>N5ON2@N73WE@U=RM%:=\!K9KHRLTJFEB^P;7GK;;O66++7JXVW@%1-8
M)8NHQ*XOOW2KU^^U4H"5P]CV9>.KCF59JZ8M%^_Z;B/,]6+*UII'Y<I]WZ)[
MOIM>5=/J+K>J7)W:@DF^VG*Z%CRV1G9UJ?54RUG107XI058+ZY>,!+=P+/L:
M</)KY`U?%UQ^8V6(J_9#6`7#MFJ[;36LY4'YFNUF4VU7=E#-`U:BQ'[T#EAI
M24=61\7E7!=)K.1N^9KW$5=;04O%UI@_D<WBB*TTS9;5;X(EJD"[@Y6F;?75
M5&@%^QVLQBO-)IC_)5IEO$Z_@Q6547>I"\1;;G?P(E-2'22S%=G(MKLJP/XF
MH,L0D#\+*107\C/SV<@=N(Z7^9A?F!,GX985JVTUNVK#LG5FN)UN""NJL$:N
M,\ARW1`0"=`-\;&KT84?._X]KI3#)ESX0U@O?)EY$`>"!A]X"=Z0^RT(AD^N
MYVUY.9T<(M@+YKE!3WI%D]WN-.S.COL_K"CBG4Z[IWI&KP".M]*,[3Y$\/FN
M'TO#X2WCTBORCM*"=3*[U4?3ZFA3D]X^,MY*RVSWX.47@>%MHQ?&\DO@1UWM
M3L=J%X#F5Z$9QFKJ-A<?O6(KC!4U['2XL7U@M=6$N9'OR+@`2TT-M:=D>KO3
M[-J-?J]='/-/361W&%DK6K(&#*:(8M51L5;,7_3:*I+9:S<664W5MUOMUJR.
MG&TL,KNJ[%F*+[:JT3%P:[0;K;G=]68GE%_"YR1R?19%$.C=N3Z_:@`;`SJ)
M><\B!?@?-KP%X8^<`:40,IM^YD8#+XC`6$>D=R/Z/690Q'9N>9_LOMKX=LM+
MV2K4UVJV#TQX6]WVBH![K<BZW6[7:BY,^2S,V!9C,NTLC&U-]3!>/)VM@GK-
MG_O<ECAJ,Z4JM<0I6-(N6N*H&ZG>OEK[BI%<QSI05NU>N],M9K+"N14<`Q3D
M3E'>OGC!4]IG85=+XM=+K7Y.<I:>9>6NE[Z(#$=VJ]]8]9KMBVZ4;JJ_S`L8
MVH;?[[J_S`NFVV[U6@VU(FK1*=&]L,&!+T+3$RP;NB?VQ7ZU^"[&>CM=Q=&T
MQ*TRSUT?'*VSOFZOT;)[BWV*5^V?\R)E8=N-;L_.68+7[9_S@NUJ-KMVOU?E
M4Z>U`*"[S6:K/S?T7?T0:N%=EPKY)BO/=0O''>M8I$:_W>S;KW/VL1:J>JO3
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MVCX4W4MVJ`WC]KN;`)_;<+N/%_D8[98%(U2PX<?"514>5/9LL+C-ZC;\>$GV
MH]&RU^_WL10DW`!L&@?1RW-"'BON]H%EG\S0]O*\(L+778<0E!]ZS05OC^3H
M>/`-%VRKNOX"'<#/>DREL]OI%EA6O]VVVM9V-F%=$JRX*4I";>:3_"LEFY]]
M_$L0OD+4N.X6;'S!6S]W6*/)R"JG$(O[5VSG5&C5EAOM?G\Q]OZ<65?`^2I=
M\N*>&]M``-YD6Y4-[7&SU5V`][NXK\HR)X@;!Z989OT99E2KUUW^J/X`\,1>
M1)T27K%MN]=L;KBOPO8`AE8B0;</RGX/>_*\:)%E'6E:C49["TUY*J`'WEK?
MF1<1IX0]NIUN=S'DXA[TG5E$G%S?F25UY)'=6`QPM+7&,Z]2+KM6@XW=%\^^
M4BG6.ITH-EN8]4I%-^L@7VVV!&>O#K+7DJ)*'&MO]7QCG28F*YUV5",\76%U
M=%+0V420NM=9VW7E1>=PMY3#76M#=$9W>QG=76W(EO.[50HF\RU-EDPJ=0@R
MJ0-#]8\;4S`-&P@L7RV!DB?&\@F4+D165F-/6@"M1(-5L@OMIMUJ6TMZ^9L)
MHU^%0OG.!<N+S)'5['8;#;NS#9FI9+YA/J6*>SRT&KUCN]-JM#;<XJ'ZG+12
MHY!6I]=O][?34*K"/+1<GQ"KV3_N]SO=9L<^:"Y:SVCWK:T9[2TVTUA`A.6;
M:;0MJ]'M-]9MIK&-G@0+UK9\3X)\T=U*/0EVV1QDT7J7=KSL=J/761'P[[6Z
M@VQLT>1MKG%F5T7=M;I_N?BP]A":+:AD6[6G]:N"\;\V3N@Z^<>=H(9NK*AK
MU2X4*R'IKCO)#K;*:%FK8`ZV[*[:*F';LUJ'="O,L4H*A);=6V$S6MUNJ]=[
M+97QLNU=99U'G4:_T;7:+ZEII`5<LB?ZR]K3+:E7:-NP$<MI^25K.=*9KA#B
M[6IU)04'3:MI]]5V0<M-=C_D<0W[]+K2N1LQF.Z^OJP86':_:;5?*`P;44#K
MV)<JJ:/U*-]9LK)T-36T[J+:U+'+WI"*[2S9UVU'*G:=Q95HV`Z$FI:].'DX
M5\.^QMZU>XTE>Q7NW]9-K:VLDA4VSEZV5O$U=VY=C=[N-^S&XJSMJVN5J?4M
MS9E]J['D$=GKK&Z=_>HL=M9>?T6K[-"22::2]6P0KK??H.B_T5P;$:_;*H.$
M7J+0<GV<TY=.W&ZWV[F^&O-A3K<!`OK2)1S!BVVKOX%6<MO!`'W1^K@?T>YT
MFKG6%^LB@*KI6I["'B,NI4BSL:&URV7-G*TNG-UFX4Q?S'C];@X=:QDTTVG4
MB94A,5:>=#DB1O.XI?AO)3/;+1CKB[>DU6AV.XHBW@04ZYIQZTO7TFZVT0G=
M%3SI2Z?;[8$XJ`RU6W32%UMP=$?RS0F7!B?=!6+GQK>GFH"=+_9GNG9?$?\*
MX76^=&6M3K_9ZG5+U,&J8)V%Z$>O8H5ZQVH.NG!>&\(9?>D.]'*(:]M#&7VQ
M$;3;K6[34JBZ$&1T.Z",+_?L(:[JJI[]^IB,A:!+X&9.0RUM11`*R^?:MMU4
M[ZRM-,/=`DZ^6'=UV_.QHJL"-_ERT6OV&JK/5@FTR1>OJE<)K,F7+J/3:G75
M`HV5D"9+I//EL'(OT""]GM53ZR96G./VH30WG59;%4B32O>^LX'G1)$[<@>.
MO/TEO5I%^DK/>'>9C%/+2E\Z[VW7"\]9[1KEPIUFBUH[KE<MG,LB"Z\7'83X
M^3*(6=;I\196]ME;8YD67^:[O_Y_7OQIZ#[^?_?QIWI-_&!$\;/'?GUW>_X_
MMT<7EV?GE[>_&(U)_,DXN[BY_GKRO[\8=_C13\:WD^^_75P>?3W_(I\0O_E^
M\=O?^*_>&8[GWON_OO/8*'Z7?2=&0L@O?;FZO#WZ<O+MXBN,';MC$$J?/1EA
M,';\3P;]]>;B_\Y_,2P:\2X(@2)(9V/`/"^:."@MZ<\39SB4/S^YP_CAUW>P
MKS^I'P^-1S&M.)BH?QC**?WSXNSV;[\8S8ZRA!#UT;M=T@J_,H*ME9])!W5]
MS_69H,VRE!._^.<Y_^(=,)983>L8O_0S?DI^]N<<6_P<#W-4*M[4PR'(S>W5
MZ7__[>KKV?GWF__/&4\^_=</$)O^)^/\__U^<?N_JU#KYSA4?T"^5WY>5_A2
M:MR%QL_%L]BWW5AAR((=XWD"@VM]6<>>VR=#;.1)X]/,OV!S6Y^,VP=FC`+/
M"YY`?]1K0D<EX[$3NO^!N;O^*`C'/`?TY,8/1LCNG7!HQ($1*,[2DX2M=:)Z
M+1@9WS#Q9C0MTT#5:QHN1Q=Q*9'DLT$V'B,E;\`X8$[NXGIM)'V!R(A<?\!@
MA$9[D;!NGHTVK\.75-S]3EYO%ZGJSU??04R//E_=WEY]PW4YP`'VY(<1!9X[
M?)>J^KL@CH-Q.G2[]U.9<=HWR2F7B@7?H:>N1N"``-UGN6IY>R"&OSXY.[NX
M_"W="]B%=SE3FQKDGY:;X#HJ!`;-Q'MF&<437Y.'+'`K0(B1DWU,_QE^\!0Z
MDU_?\?_N@J4&#'N-5HZI>+26;40PRO[-0[=5V.VM48_N9Z&CD-+L]TG@:XJ5
M4TR6HN0X3M.K7.EG_HHF4SF9"AW)-V8;]W;BVJAO2\EJC5%*H^O0':Q$H`U(
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M)Z3JM?/IA)2V;]I[VHH*[C3,9M/2[*7=I^KPI':?EJ-3OW_<TM[37GM/9VS`
ML-"X7A/7*U;:3YUXFB'H27*?1#%XI(U&'YPHO*#)C&MY@*?MG':CMJ**07JM
M?DNSEW:CJL.3VHU:,@O5:!SW>]J/TGZ4SD4I)/U[XF%FKV$UC#,W9(/8D!<M
MC0_61VWJM">U)6W<-ALM706E7:D*,:5VI985WN/NP263#]YY$I:^JQ-0&R!F
M>G!7KUWX>$G+?63%>"X'(!J5F]C;5;S::])>4\684GM-2PIOY[C1V=!!WNN+
MB':;-IQO6N9"?<D-Z*VPJT;@F($`V-4:-KT"H1J75K:56-+><I.>>&4GWM_7
MB5?OS&D-<[4WE^4+TAHERVTML,Z'E/*X#6+'6\_7GTNV*FN60KL*LS>&07+G
ML;F+J(1\+EC`JI[!`81A"X84'VY:;=/J-F;)_'9X?_\F7G5A7)JB5?=3YK%"
ME2S\>H:[TGZ*AN9?0%6L6BE`T+]]8/4:$\B0Q@3A#XU@9,0/#'Y,H?"?G,AP
MAO]*(FP/&P?&^\9QMVU,6&A0+R"85KTVC88/0^!X5(*<80@-@C%V/H1AX+D3
M^+MG]$PJM+&.B^9WPYAQ&<`05F/WP/E[M\E7L`^\7T%7MBM(]Q"V;9+`G[!K
M7K-IMCM]OGD1[O>`]U^(\+9=O>;$QGN[V3IN])4]9HAM"/N6^))=AGI'EMR1
M9Z,I]\/JF5:[64)ZXXFA-,D.$\5"-7"B!X]%D9&*+8Q2M,V4GFU:5MG'<)OS
M@KRPD8SX2>D\N6R3H^G>W^.Q&U,'UVTW1%+,WNZ[%A7@E:9Q]2I-C):4@M>*
M(,0O"E!3^ROV)LHO=+L"6C[KTZMOWRYNOP%A;U:9_AOR2#@I;__W*]`2&[RY
M`^5#&]Z-[^`O^*0#3^Y#1G[$HEJ2?2?O)O)2Z-F!GITX_K,!YL`@%41V!6Q$
MF-+426DJNA@YX#Z`J7#CJ%Z+'^"/QB-ZA1,P(=@(+XX*'37LOJ0,->%M$8U1
M$*+1JM>\9#PYBI*Q,7&>R1.$3T3N#P/,4?P0Y;ITW:&+$CF>$_)F2G?,9R.7
M;!OXJCB]**$YCF!>8=;SR7`,6.'8];,>3T$"+J>3H(T,#:=>PS7<*W\W[H-@
M:&#G4/A%,!@D(95XXP\A?!=FC^[G(U77&U9KGJ=ZRL+8<7WA/1?1(GX`B^N.
M.#W`>`\2+(^*N-%GO!7K,+/S<N\<LMQ7@SB@29`CT3!Q;]BS\10D'BY@P+#2
MRE&I&S\%"ZD;<:)(7K@+_"3"U=-4A^"Z'U-;K>DG,![`'KGDH\B94;$\[M>3
MZWE`/&/(ALD`7?T1L"DM*6+8#10[83GC("%W!3Y4KXW!0[ICV`X:%T!F.ID@
M;\).WT7LWPDNR?4?`P]>@HG#XK.-+F7'&#.S,/<Q;`NQ!WV3KRW[8KTF/PEB
MH=!=)5ID7#IC6,BYW#2\#8#,%Z&S%24.#AO0EA1+E@N$G@`?_'#'0%3OV7C?
MZYB-1@._>?H0NN"031[P`L>U\Y\`G#OM62^^])*$O,\;[C2I*<[LH.>`\6;:
MMBG[E&T1A#KI'IDYH2/N=@0+@3!-[9X-;CQN'_)_QM1"^,@)%_(,ZY"L"I,:
MTIPY!TZH43C(L>L/O(1:S[WO-253G'LNR-CE,PC6O5G.EMC1#D0/%33PL=30
M..&0W2>>$P?ALVG\.X']$)WI*`!W<;JK._OSO?:\AW_NA"ATV`^=.D;I;J>Z
MV^E&O,'.\;P$X=RCA\,X=2PGS>7YK7%Q"<'+N?'AZ]7-S4?C^OR[<?.WD^_G
M.HS9EAWZ[$3NH%[S&7HHY,)\`,48?533HQ&I76Q\;MP]&T/L*(WZ/GNG7A,O
M.7$<NG=)+!T2-6$CTBPX!!J$)]%AW7!XBW68`[7M(\^Z...C]CE-;1$3INBX
M7A/=V96)K;B*%::/L0`FKE9?!9HQ'&&(LT5G;!*0/:?VZ/@<V&1Z$!NR@O+D
M)OF!^>KZCXWKJ;=D]E-]"VQ5!,X93893<()^0Z3D5;E133N"DQD6X&79=!T(
M+<9HC]$)D`W%BQ/>U"@VG@[>'"(S\H@,J99P>KAS1/Y%A`[I-"'5E;H^3R[2
M#HL`"6.+>@T\>5BH*ZE];)P,!F#5@(8>^!9WR/Z\YZW"/#31E'6`+T+&-QW<
MZ*460!@F&&EMS`]>36/@68<[>BXZD-I_E46I@2QL%OX-BXFW1/0I9`\W5M$&
M$$D/!:O4:W+#F7#U%%VALE'Y=LO#"L&PC5_V8;<W[R,NZ1CVIOW"M2[J]PZL
M_.HR@0`(XYQ%S+-LI7X5"B/VN&]1R76=\JJ"GPJ7496Z@O6N=?8JU8--<[CF
M\,TCOAR<(6$QY>+0S7$>'=>;%\-(/XA[OZH#!+$']X`<;X`.OUO4^7MO#=,:
MO+\UD:W7"JY8KGRI<FK"VRPQ;)F=?M-L];IO6<5H(WJHTKA1H((=BJ4V_94P
M_?U7/$ID5*?J/K)Z[1[/\$.&&2Y>I)IF&9]>!F.B%<BA*I`/MMEL-<QVT37X
MO5$@!9B&&[X4..\.Y,%I%)GCK]=`A2C'`\;4Z<"*RF2=ZZ65,IVKW,A?1A7M
MW:*64E/;6-7\(>7A>KMC=IH%>FP-I?;)6)%-#]55>GT^W0,9TCY(A0F^+Y*Y
M&80"G=ET?6/Z<+=>4TYWU\YMKG/MM%)2LQ)PP"LY,$NG15^"@E`QQP4+9_MF
MIU&06]V(Z[*`0_=%06K71;LNVG6IHF2N=BYR2.[)&?,#NB!Q6#4\6CE4G^#[
MHARTV=:2J26SBI+Y=LWV/\7%C7I-W-PHNZZAU(SGZL+AN3M^=V:V@%S[`5K;
MY&;>MFVSV2X`'GP[JD8[`5HLJR:6V@FH@!-@]5ZST(%71X$1'XVP3>;T34EM
MR;7*R,W<[IBMIC;DKUEJ636%48A1J<806HEH)9*;>;=O=EJ=MZQ$*EQW637U
MHLLO=?GE?E0QV.TF.$>Z_%+G0;0_LE?^B,Z#Z/++,K(2_&%4K\ESD*DSD'(4
MG<TX)[JV<H]656WWI->SS%['VI)[LL<EEAL&25P!;VR?.F)/P8ZEJ'W><W;)
M-F*#)'1C%T9[<.#G.\9\@_U`A%P!),U![4J4Z#P4QD@BZ[FA`-V-4I0[8PKD
M3B.1K8)$]M(8N=NIE!VJ0'@O?E&`\;J]-LY3*[-M%8JI,P>*:6O"H'1-V1EY
MES"$MPADF.W#MT#!V(>?SQ':<(&-W(TRJ2C]"/0QHU?3,E>AUOZF/UXNU%.1
MUV;U[D&QX;H0X=H$K(7&=U"\LX0*0WAEK;2T8Z6E:L-2M8G6TF]"JN:Y`@O,
MO3X,675N&I56\X;FC:ID6Q<>!J]Q$H*Z\:`.G7@OD_6*</5)4K54S^&=)+7Z
MIFUKK`XM;UK>=@2/T^\N"JW>AKAMN7CET/R(?ZX'>JPUFM9H6]9H5MNTM$[3
M`J<%;D<N>]-LMOHKR-L*%5*SK:9+VT?GNTR?!I[GW`4A@?>?H*FZIV[>!>VI
M==]IW7?Z)8GYINX[74::TZNO7T]`U9W<7EQ=&B>_?3\__P9+N5F%3+KI]"HJ
M^\*OU\[8@%&G9+O1Z!*ZCFP83*=[5&P>!X9C*$HR\(V3^Y"1CJS7GMSXP?B:
MUC*!TNM_BHQKT+=C9\"2V!TXGO'A;__]T?@:#X^-#]ESIY^F7ZO7Z+WL=V>?
M/AX;UTD8)1`_X,W>^,&-#$=^W2SY<+T6W,4.D`7$1E1^1E@8ZKD#YD<$6SQD
MC\P+)J8!Y$E&SB`&-8^-:NLUO#/,PH$+._`?9EQ>_0.4NDT];/'?=J.-]?>G
M#Z[OF,;?`O_>^&_X?Z9QZ[A/\#$:XILS<!+C`Y)372Z^Q.#SMRP,W3@(GZ<6
M>JN0_\$!:D1)-.$]C4=)"*.%<MJX>"Q9%3/Z9#P$3_"7T.0$XN]A96J]-G:>
MP=.,#1?&'<2\Y[4R2!3#EK+[9QRM9#L*6TS_#M,2+7E9.";`)OPAW1J5E^JU
M$-@,-@"V(]V#$6/XTOMVHV$V&@TD*F_D"YS8(W*[V.$W=F,/WHN#=!`CF>`&
MOK?,;O;J**$-'+L>B^+`9\;$>1Y33^ID$HA6PUCNZ[&TVE<A`GYM[(1_PA]A
M/]-!J,UX&5%@MUSL>.U2]^]T&>*[1KIB>.B.X;#..`AC8"G@C^!1T`Z^XXZI
MH3=2D1,QS^!6VWAF3ACE.V;7:^][9K/9Q#<D04-8D)]@BZ&(>@_=^_@Q)`YS
M@*QB@ZB!\A$U4"8T;C<8%C?^)J+@87HUVF>OI/YN2?U=@OK[OIXCOO_*G>KD
MB[6C(J23,,`>,]C9WLF)K.1?D+K@V?'BYTR@@)'LQI'=_@G_A;7RD>-QQ#:I
M*P5.FU!W]5JJ[XBGI!@7#6S91];LP/6:HGF5D3-%>EQB"%#Z@CN@-I<Q4B+N
M^`X,"LNM5K87SXP!2NP@B$C+3G+&#,0F#(;)`&8LR(<CETZ`.O?X;$!ZAXPE
M*:-T#TJG#A:`\"O<F,_=(%L`&G0,2F><@)$#C9*@'?!SRDS0:.2&,/M1D(1<
M@<QH:+(WRD3`3DY<Q-Z3&I/_(KT>@;_Q'!ASXN"="Y@;:#$@$PSA/Z</<&4T
M-"2-3`-)^\0\V'$^#[Q_P<T0C"/>J]?X=#/;2YNO6-JG!W?P@";."`8#V+]Z
MS8/70ZV<]E$Y78%?\H7=A8D#.L$B@]/HF\9E@%P<3;N>@YSKZ62NYZR#5>RD
MYMPL+H/?$G_H<KFNUR[P>SZ]!(QW&H03.<17%\0/9I+S6I5W\R.C?BGS*XV<
M6VFBT.9<4T2QC,"N?Y4"="V5S`?0`T,V(F]6ZK_B=7Z$]TE.#+J9Q/5ZJN3R
M.@:=(=`>0U-J;1,'/T_"8`+2^"$@;Q.L`O_@]R2*7/AWJG`_FL8)_,:8?G!6
MYW^DU9\DZ&AZ^`9N)ZI#H!.:&8&D@3L=<5500NLRMSD3%7574?,[/M[1&C+R
MH='-BZ(`-@`W="`4/Z@?""^&X#;QB`4BBN/K8R"`.@G^1-E7LW_=EF\-&0UN
M:M'6J!-%O"+PT7/&ETPCWE]#VHW<'^@T%OBVP#2\OR2WE'DV`V6=^*`S(\$U
MH#$E;\6"DO"%#2K00XV3OP0A!@]@:I%@2$TN9-P.`ME!PA^8-S3GR6:])LTK
M2K[!AWL^NGL^$O_D&H"TDY#RG([*?"AIG)W0<]$<CHP/UL<R6^U,)K#KF`@!
M)TJH5V&_E2_)*0!G?K`_BA@1(Q*7:T7N'E(D)Q==\#;2P?4QX0>D".X>W2")
M<$A2$4\N:H7$9S[P_X#AC`IE"(AM%-#:#U1RUVL+Z9UZ,U.TDO$4>!SHA[@P
M(`?Y027,/9*0>T#WS`?_9B`]&5(9$"#29]PTI.1+AP\E'@6/+NZNW?C)&((F
MI:"VR%J@!N8!IVCU7D@+N6$8PLO=8/.9C&9^%_*(#],%(P<FAG&L,H\RE0G?
MJ=>6^I!1_!T3_3@/R0"4?@P\(([#V0KX(OWQSO'_#)-)/'C&>8E%FIR@*M,A
MZA(+,8^3&7W.>$)]DX+,=#K^A5_L!<UVSYM!1#..:<P&#W[@!??/Y)HV&T=#
MGB&!!T@W^Q0E.%'@%V[*Q<C@\=$]=J^BH&:"NAT4;B83]5JAX3+2W`P&#6#O
M',$Y.$LWBA*&H;N7!BLX\<@9L3CUKV?<`Z);.9=A)HS"'ZS@,Y(T:5.VKT^N
MY^$]YG26*+.QZ]%+16MV<<:N'\4XZ3*"H?J@T(L_1U\:!JAY@YC[\Y)VEFU0
M;B+=MRR591(]_&F.G2<9]5JZ,FWG%MJYT\"'G0B!6-ZSR.OR*)`-$M6PE/!.
MZK^GF3;*]TVH+38X+1Y$T#)O><-(O9]/0ZEE&=@4^3W%<E0!'KE'MFA/Y?[H
M'5:30FF"_\>$87R1IGY\=D]'H$(GD0BB?;PF\C>-V]`E)>=Y$/(/(12/T(-W
M.$3>=#I5#7=2=2X31*2')`9#87`G]'Q9`HN2[*I!6W!(-',TO,*9;_ZP^":Y
MB]B_$WCT_!'GN9VCX5<]ORVXX+76<>Z2PO):<"+E1Y&+<]Y3A[/YE;[6">K-
M[Y]OSO_?[T!9X_P?^NBTE/Z<H+?_^Q4HZL;P]$#YT(;WY!L+[\'ERE)1V@M9
M(C=X`DZ#9_3X09292XWD<X.JZXI6Y]IS?#HP$'2?R1#.[,=L:O"447[*"4WC
MPA],YX+2O^;?Q(_CGXR3P;\3-^)1(F82CVD.4TDM/@DT)>[0=:826B8X34\/
M8)^>CX(G3/I%Z7/\+$0&3!/E7)Q'R>GDZ!!PC)\1E*)\`GT6]$0VW@Q]E.DO
MSG>=9`$,Q!G<.50&,)6O*HL5N7PZWR!D)O`XG3%&&E.4A_CL"8(6!Z@*41[C
M#@D2.I@P/+3FL?U=$F'*$7L+AXQR#N"4<,(ISPXQU$S'/X;PR<5SB8`':[E)
MYXDH<ASR*\K),8:YPS"YIXP>=V9BB!OCE!EAM?=^@$D=C&0=?X#'%:5I0\[>
MW+M"5\+%L]RL4,$H8#PUCXNSD*!8TVO2L<]"K7-"40O$F4,F7%%Y)#C#T/"'
M,>*!J0VO42XSOLFJ'>Y!S^#9HY$?FWZ*8I$H<0P_P1H<DJ&L_Y7,_N2B(7PS
M=N,$WP5%,0)E:-R[CS@23V,!(P;3\P;NC4'48.(L_[`0`!Q51'XH107Q6NDQ
M@@*U-F31('3O4)#O8.)/)D\2_*`"!Y#)'C_8I?Q,$D<QB`C.9&;!^?BO4&)4
MZ9W=H+3J!+0*3[30J3-/45!$@VDE=^0.Q`$D@KUE9SY4>N(3.\AC6TQ@,C0.
M)E9QX*Z)4P^L+C4%,2G:M8Z`RD=6NXGI#@J1C&CBN;&,I7*;.:-]O_-70$7C
M.XL5\`7$6$.7DS<G_EE.DZM&07<QOD'#FWQ9QA/^/]OLM_MFKVN5-&"#(;(]
M,XE&JE6FW-70L+HF1#EFN]]1ALF67:_Q=8N-*Q8D1?]FI3NYY1BSID9KN(4:
M[GLP'..!&'$/_A]P@P^[!'+Z]>MI_H23/SOEE8Q<'VP8I@`@^'<C$L#L4*&X
MSB$OG$H5V,")'D0)6+WVWF[SXJFT\B!?JC6MSEP_KT\1$#+DH(R@D,)'=X#G
M6@7R\C_?;HQ39X).OW'MA+$/+">4NEP<I3;$ZA167&UYH#RR]1GO[<:*RRNQ
M1;GE:89?9-('=#I#%2I@U&!W)WA(2L<ZA!?J#`9L$F>GZK_[=-9_$Y-O&3+8
MD9")HR^>TR0/[2&(4HC19T,JKI#1004O(OI70'][#,21$(8L48R'T7+[[^@X
M/_4J[X3OR$\%J$QG0)\/:>\5[@S9!,L($?HT`9L5Y3@]5R,XPU<BMP\<SBF#
M9:4PN#B&X);!49]'\Z"ZS=PM%SYJT90EP=/9'SJ;[C*5<).Y6M<R)Z[S"AL_
MW9C.$!2F'U"4J39I[J:(LTIYACD8P)MNS-]^Q%J.4![)\8A8_5`$&X_YC2R$
M@/EUS%ZK8[:;73R5<_'PCPY@\=]3,066B7#$XB+'$]TW4&GB1"77,6ONB^#X
MQ?Q(9R`L=^.XVR9X9)R#2?KD/@PB*HT<,#;D,;L:!\!+;=-JMM$BEH;#Z5D/
MX3=3H10>)D0L_;9!G\;:PZ$XZL?"B%P)<V?1\%.CTF`_B[`O1R]T;RD/KZ9<
MH@0^)4=*=6N4W/U+1%;.$(L$B1&0+GPHD!VPZQ"OF^(7%!Y0G43DCEW/P5H3
MX:*$+`CO'5\<H$"P%62'-71'*G6%Y32$-8*54&1(4\2R\.Q@%ZW:H^,Q/PW^
MLI'$*/6:-&H3&6=E`[U:P>6:ND%76_)3O_F**JT7=*3?(^YP<&[+#@U'+DA!
MJCQOSD^Q,H<J<7D-X-4@#O`Z45OF;AUT6>Y=NF;BDD#)`@!9/RQ*"ZC>5Q[Z
M3\6@(G#,XLZR+N&H3+UG.:C4(B8H7!Z@3G)7B5B1^L[5#"S(UF&-H0=2*6A&
M58Q)Q-0[1%3CB,4DI#\@C@7OC8ZP2;.)JHH"\F`EZ0"T`3;U2.N3P!E++VRU
M4@K[]-T_&9OPO2JE-R45>8(T&S.K"<F(@=E#2EE8_6;3)`]1I%)F4A8*!>&=
MJ9"12D=X:E0IP4IKOY^PG`/3NRH9Z+@S&Y2XA')*SW.HI>#\D^$42AS&"?"H
MV/%]%_U;GD+G^AV"5N"30W=0-W1-D';P<>I:ES%R7(]XF;3"/%Y6J@7QFZ,0
M^`GO,PS<D<MS\XNED<JU7'1*L@_S:WY&07K(C:8$`?\WS"P:?F]:EHP/[D@D
MQ=Q(U($]ND`=.;_STX\X"/SX=\>GXO4FO6GGW\R]!:H77R.="3IKHJ1=Q\X/
MO,@ATK]&EOV=8$F3O/9QEXHT'7QE<\E[IM+`J[J(ZHK%&8?T\,"L>RX\,J30
M;>B,G7OX(KP$#@<\:QVW?R*'CLJPC`_@N1WQ`Q14PPZ\X'JR5I6B1_@TOT9&
M=]&0_F0('&.4P(1HE(_I+8_,FTT=SM2AP\605YO^;6BDM6>E6@VGX>(-0:I"
MG-:8J+O@JVD1[%+G+]3'`Y.IXMH-+X7CLTBB=*XE$^(EA#&LG"</?*/9(.><
MX@R\435TGB.Z`)!_+'X*L!;.P5JWB*KQ<4*R($Y>UENX`CQ6(Z-TC[8/;9Y[
M?_]\=.=@$C<W9^'X37,F11_%]I77\;DQ9_*,ST1OE>QJ3PEM<&J4VQJZ,N3*
M%>"B^'*#EJZ"*H*&J9(1]V#+V*%D->B]BB5%[@]182B=Y%RZ7+V4E%[N5+^%
MKHCXF+8=JQ6<31R7-I)GE[GVRDZ90`T)Z5'RL736H&134S65YE2160I;/UM]
MV^PWY7D&'8',Q,'3B60ET2JRP,]IQE7D#*94>#K/&=<RO[+!LWK3[H[%3^BK
M<$I,GZ84BKAX%,V:<BG:6$:@<P[S5'5E&ME2;CJ-A[D`H/F5M%TR5.<5RV-Y
M*YPR@P&.(QQP,9TL_R&\@IE31RU<2YU9JP7D4W)3+!6-MMEHV:7\`/'>>ZMQ
MW+6RGE=F\9EQ_JS2!)X>X+X+%B*>0FG*,D0\J^3(#+48!_MH$:\<&U>8OY$N
M%00V5L^TVLTR6_3$G2WBJJGCVC0^1;U!+DG*V';7;(*C5\3?A\UON\Q4GSY@
M.2W)]AFX"`,2=%1RYS^$$V1<C4:@5,-%D(#[3O4-2/FY=$UFRN)RL<S<(T73
M^.:"_#.(Q?]^;)P%,#?3N'''QA<GXCMSYCR"<?Y\;'P;_!-<8-<9HX<7P>I$
MQ[Q<&BA?`W(7..&0-]!3-YO;46&'<,_E979&'GG@^I0;/7C)VRH/T.%=YE`O
MQ0S`!*"IGXWK8^.?#&_5AZ"^;Q_@\Q%X)(,_G[".\1O$"RYPR=^#!]^X9&XD
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M-13@@!=9"G[9VH]DN6P)Z]1K&>\89^&QU/]+,0F/?&A<O>5+]`)ADP>&VO[8
M^!MXB&:A!B#-D.>!,JW@!_RB-U8+T7U!7H'+C'L\\<$HEBVW\45*`WD!9[F0
M$W`NJKXX=$[8?!@H8KX3/""4Y>*G^?KJ"[6^^L`)O`UOORN.ITH=J[GU[$]T
M!"+.;S%9[[GJ?7GE5?CC#8N-+T$8/QAG%/WQRA/PM/_!:QFO@R>JF;VF>]L,
MA!1^^,ZB.'0'O$@%A?D[8AA@R/==UI9@`0)=^3XU>C\9I\DX$4^<!OXC3@'S
M1=?R,C@\75K[?TNG;`_.D(Y/Z,@W?V(A/T07@G*7RW/7#JB1NP)_NE&@0\V:
M&V9->#7'D"H#\B*PE-4R<(&M\=:YYJW-\]9R0\X8GMQ=(%'54515CU`5,]=*
ML\.I]>X*8>*9+MGC!#XX'],<^0,S<O=_/AD?[C["KX;)@#-W>N8O`(!XH602
M/P0AP;;F<MV4@.OR2Q)TZH4']=F/0(4/@X]3TD.'06E!E7K'!D]%!X0)]!2B
MTR.N&X#M_D3+_S#\"(1THL@=/9=$:O)2:8C)/'JVY,;%*?[-N%#>I!-V$A4Z
M'PC9$?-$WAY]\E)%XK,?>*W2QP/`,6.RT%5=F6F(SUTH_N'\#]+ZJ()C9FA1
M=):.35=\Q?@K+@@^T%PP]Q)]E$MO$;!T49RE)+P49YSG3.!],6N%**8A_'DC
M=><+DGCY-!H-![HV'4\A`J?.WYPP?,9973L><"*?9BYEQY$[>'[!4-,+,Y/-
M[6&!]EP%[*,4LR,/[?&5W3O>-P<D(HQ._.$IU<OAV2VH?-T!0G>`V,C96$]W
M@"@CS=>+VXO?J/W#*H1Y0\`EFZ@9H$)`O$*&/@:I6F<@DVP3SW'QJH"3UM3)
M&Q4\M]](<0_S5^7.7![_@>%.PJR&)_TUF+IO\"5G\)!$+$;<4JR&H=)?A@@5
MY`!Q.SAUV9S*Y.[8@^.-\"\/[CAB'@>!<-`>TCWL"._D*46#*N2DO(DV+(U0
MI@MB1#T*+VF4A3JI+V^U.%@Q34%"&-=K-J\@;8`=O'<0Y2Y7FDDWRA%("T]4
MAQ(>XO3!9:/L2+Q>$V?BYK0=+70-KK):>TM^FR=.80O2`U98M\<@G.$[ZXY&
MD?'A,WB8D?%[*"N/ON.5=L?X-CA#^./A1VZC2P=0B4=(G;`CBV9HVR;0B-/'
M3UWM`HXKK3(2[PAH.7H)N!?8P9A!KG]T`XZ@>".\,*N!OK<L056*C,]_#*A2
MP<BJW5MJM3OW:KXG'M;-W!VU"<1WG'@"31Z#15X]7W`[6/+V,`44HX)DB>U(
M,Y;`:@.09FJ3$A/"F@*4QHM)_:-HC&7R`_(!O00/OLKA1*X4=NVHK*'>X:#[
M7^-`'AK#+,=N%&6'QWQ;<"$0Z/XK&0)CEGP,3Y-Y+;3=4$\`%9;C'^3U`,$D
M.XT)(&H.TVD06DMZA:L(^X>/@Y*$504![^1"'G9N8-Y(979Q(1NC;!I8S8NE
M_T:N.O$.PB>(V,155MP]<>L*JY:0$A#A(Z2.&PN$B!AO<0G,[Q$6"#^Z]T'(
MSYE5+:",M?$L0-Z5V'_S1.R4^!`Q]8HX5VTCP]!/YY&QT$*XU_]W<E6O?3[Y
M1GL$/QCX[^\L8L157SGD'P%?&Q\DJ'D*)FNB>BD')U>OO<"P4P!0N,O\XM'T
MG:EQ,.37'/C9`QN3K!-P3Y3604N)EYQ&IY/UFL"E15$),]!56C5,P<SAP6!K
M"+R)A3I$0O..4,XSR%MN.2-,I(G2U()V/90`4W&V1.DKDA(FR_>'9+W1F+T0
M)/[<:"A7-Y:#3A=;FB7VYM2,./*XP41XK.RR!,[FR]D)97N2^P1$L,EGVC8)
M&0>5!R\^%:"X0"OD201RDF#9M"7\>H08P^KW^W23@+(AZ=V''!-0LI.;)`)_
M`F5#^@&OO(2.'XVX<T-N"RH/XC-,"$P0<C^,GV7Y+H+Q,&I<F#(%;@%\K/A\
MW`G_-#X[GO.?X#'Z\QG1PV3<K*(($<O@WM1KL)J.N%F!?Y7MOSJ<.::],3E`
M_`"Z[?Z!<AK@$@!5^$ZWI:!BB9#8@<(M^],/GD!_WS.\^4H0`OBH@&/(YHR3
M$'`-V`4D/QDIW@MO02RCS<'R%*ASHUR;4Q$[O]>,P#_B%!G%`G&(^6V!F)(8
MG`Y17OEC@>L-(DYPBDN7,9?SDL99L<+@7-PDHU'@_0G_);\T%(YVQ-B?)/?R
MLB#'9@9S?<_+S)\SES#SDU(!5>Y_4K<Q`<9&)=ATS\@AZ#F>.3%FJ]?)RCLA
M!W]RJ(:'9UAY0X]V`;H<KQ3"OQ7K!E/05#!=SM=4@:R!OJ3D0WE<C%%$X*'2
M%HNF3Z'3J7Y+U"4*0J@#BK`CHXW29B2[6PC4)]`BGB;&"T[/!M8H1*C>RYRQ
M3,;ZJ1?,+53TQ&1DDFZW"?SGIS=84WVN\)')SSLP14V%4@B)#Y$#^//\`@NR
M;R2[00CL`8[W$7+]A(R8>6U6J\C5X@[64"W(4$8PD>'X+&=T8-&4C:D)X]6;
MV1FO)-0">U_.:*&7ILHSEW"\D)%Z:>/5(8272A?F,XQ7RG5^>!XX%J_AP0_P
M/@:'P&[TX]7HBT1\N4FO-F70Q/#T#5AP.I7PXPSGYAK&T\E*G:S<'!"R3E:6
MD>;RY/;W[^?&U1?C\^\W%Y?G-S>HU6\N;O!7U]_/;V!=.I>YU6`QQ8O$8WMG
M0NWY(H%1E8.SF_$FSCX)A(`\+N^,VXJ!'98N&G=ND&\"F#:0RL!@>6Y*8K&*
MWJ@I(*P"`:LK`38)`9V!J'%8-2?-P<T`"AM+(#F;6<L*\!2P4+A>^R=87KPF
MZAOJV3_YD4-Y1X;'?,0+2O=#D1Z"`!QQI)`9>*_9P'<IUD%#Q,#HA*[H\?*0
M8%J6<TI4`!U=@L]L8BP`GF:,F<J%6*&$A[<80%5>(\D#F\JZAGIM=6!3HP#7
M-)^%B_%,.G]75,*$9I%@_I8&F*GYL*/R:F-4?-EW"OZ90W&)<=+T"M*@`,VV
M)%)1:H'R4YC%ZRW"H"YNN)R"1Y;6N$R5M&3;5WC#-@<HEB?<]*70LCO6F,P?
M\JM'H!(5=+(YV_!!-B0>T`AS*))CFH\;P193$,O+Z)?!!V-[9Z0@$HNGU_`B
M4:3B-DX0;WX4#)(HNU6D=$))@7<S(-'41A37+>?:>Y=P%QX\*+C?'PI:E'],
MT=65)N++:>H97V>EX@MMO3CF08YW1=W7,%_X58*"?2H0KVZRRJ]6VS9[G8[9
M[Z6WH>,@8YII[&9*-.53IY,@POM7CD=E]=$#8P+74`%D<2CZ23+T"]+"4ZJ`
M-Q?GJ[FCA+PH%),9BVP8V9U8W,M*J].&I>@B@:I-$"WBB"YV<S2\8^/$\]2+
MY#0\3RW,4M(4D&:\/['GY;^4@>"E,'S!),M4I+AA&:P4GMW%8>!D1P.R1-`7
MF;X,'EE!(\'1_"!FHD>`PU=`/=<G/-Z7,`XC3]8-YE@'5IV2A/J^YUE(*1@L
M(:HX?TS54[V6XP*U"X/@T5QI85'I(=(BFRZ])V&9%\^'Y_<D6$`*NY(AT&>W
M]_.$T(I'`QY7#O!8F;**?DQ->Z4Z2!<@2F]P!71"7:@Q,K6`DW$I(<]_Q:7W
MP47<%`I!L_==;*HZSMJLI1UBRKJ<:&E:#;J(^G9FP*Z*!@[=Z,](0K=R4@<<
M0(?\-'"_J'2C+(&`'9BQ&8TX[N+=);A!X2-3MUO9PGI`5Z#_9,_J]6@SUYF6
M]#4>V_"P)8U$^:$!S/%>.(_\Q)M7AR>@&*)HE'@S;?QXDUI9$$W@;#*TI4ZW
M#^[]@Y=V0T7H-?_1#0-?.6W!QH+BWI^`ZU.L?(:?Y#.<`YY((-970N<KV#P=
MWIJ(B&V3]1,:?'9WN1Q9)Y>=>4Z5Q_F@.;E_#*9';3DI*Z/`[Z$S)52T,MQQ
M_:G2*$.IC)KJVG5Y<_KU-)_7F\E1Y-I<YI\=NN3&X8$QXQ,$S3K&%8%84IT<
M[^-#1UP1R3>>#&9G-.B-(@PL(Y-(B1C0U(]DET'\PD=T1X^-+RFP`4,?.M?.
M>XCVUB.@!"+%T(D=,RN8L@H+9J9(2V:`@Z*JDX^HXH/@]M)[3V,62S<AW_^3
MJ@/%1M%[0\J.4;^J84Y_3-6QT1X(J*9\H@ZT0!C%1\ABX/;#GL?.#^;Q`TPG
MO`LF>%<0WWM@8]*JSN196[!E+!@R7*&;H9QI@X-!H)D2%(7*6V:KF,B92AN3
MD0]U'_`,%]6K<)]&1:'DCJ?`NU>%`7TO/Q%'U`_49(V<?]FM#4<%_R4BN$9_
M0$*#GJL(,H#'N)])9@X&Y##+*$H9H*2`6>9`%J$L`%.RM`0REYMSKB&N&^=7
M3-5#<D6S\TQQ"P/\%K6W!\J3`5OE6%NH/\([A,4^4$5.C/=^%%Q[A'[RDDAD
M]40J+(7>G,GSJ>V8EVEC@P<>0P1:Y#>"T12K-CCK)SC"NI('`YX,8^X,X>3*
MEEM6R'7G>A@Z$(HHED(SHD!&8$JQW;'G0)1NP$8`\QO<)8J02E0!D0U3X&0D
M/#7PZ#I"!0JL<8QX8BJ*^YG@8^]B!7K:)(6.VWWO#G@-ERB5QU`^K3!?N+VX
M`$J;JEW]9"*!8H(H48$D'2]&_`/\.\P!6[=1I3$:-@R;?*Q%!)-!,7P*R$J\
M*E;.72[I38G%:Q"<=?Q_#.IH%W%C$I^0;-BP.'++WUP@#2MJJE(5R[N`0,!*
MF\?KQ+.PL2AFIRG,"=IS7LYO)R?7><<%U1)%X^Y8-01JO$@)+ZD(L!PF3`9I
MD=47>`S[(1_]O^)T^E3T_6P,N0LA^@E(G4Q"-_W141#$/#>60@E#[(UKH&E+
MI:7F`C)J'T-DSHNX)N`A<B\)MM*Y%U#AU#0T[;\1X0797'\4'Z>"L3D:'MZQ
M:!!B-/4Q/22"^2A2)%M\CAPWE$&ZZI^590"5#*(@RI!;'<X4Z1"%+W-UC60#
M-26J<(E`@F*1LF;<KK'S)S.PMG5,S"&*?9,QSVT*M\W)KBC+'"I/460\5I;+
MG!((VCW<"6*PM&T\9F>1"23U$#`<X]6!P^^Y8-0L'B5X<V%X17:&'V\(H^(]
MI_G2(,P.[/!`!C[R#$;=X,7\V94':22)RA$KDEJ5D8SH(4B\(4=.=Z2%_!<X
MS7D3.7\0?FN<1\"<ITEG8\&QV/3TZE2A%<0WH_1Z,]^.U*>0RX1!Y"KK-;',
M!AI`E%)07$?_+4\OLQM<6:N.[-H+;61Z]P7/&]P(0<?SRN3F?"I@2B_0RXK!
MXRG[+J<M/9'"E0(CB&1&;"BH]I/DSG,'::8.=Q0+!&49-O^NV%E1V2?H2BLD
M%X"(ETY#I8MD/QD'C1Q^=9O]<"-1&1LZ>+)'_7ND3PG*+`&/P+D+DKA\08KG
MH7C'B,R;=X]UO+(J`,026$42<!8V)F0/#!0W:%N$&P(/\<-7<,T_YLBNQ/O-
M3U/QRI`:/M"QJB_M^2`WKBO&19?_8]H"UI$.5RP>`%O#GW!Y<Y.9`Q_-"EMD
MA3-&\0_G`W1F2$$OR0794<DPP/MZ:,6PX\,P&]3-!J4N/GBA`0T8O^)'6H#`
MZKW@B>($GD#ER=Q"'^IOP1,>19AIK791I<74*2PO/>*N%J6D^$%<VKB)QZ/B
M:%;<:"'D!A[PF$6.*`Z1$8^;M+_!ZE"'W8*7-4A/<M/:9",[<4)_%)-*P.>?
M"2VDZ$\HJ,-T0GES\^7DYK-Q<I.W.>:Z?%"24T7/1%(%E;V#O5"X`G=+ZL_!
MS:3V$;CO#H>[`E$_HDW&R\R>B+$Q:D972W@Q!<<_Z?F52:UT>/<C*A(DJ'Q)
M7:6'%=J3T,&4A-AKO/Z%!6-TWE0TCV,JAHP45'Y:<N;1EG`RGL<BH\>\28NX
M^D#U3\23ZDX-@R?_*,3:DUQ!)<V->I>DYV@TVDQS&YQ\UN\P-U$5/#[KQ0?^
MWDSWOYE7E>,9X=@(7Y;:%I'3*06,>A[0_3*)P8)`,#0T4@(EE[8%]N>(98!7
M\R=1F@:87C]OA<![+M#E8;6/8$2NFP3IAUFEB1^Z.5*:7$GST0KWH,I)-1-:
M(5P\!][GG)9^TTUA$07=*,C)%8/DN%)IR58XH1M<D1IM9HR&6R7:JM"Q$>H@
MDL18_2@I).7NT2`#E%>>DF^G;66$Z<8YX\T.#!G0$J,K.%0TFRQ`4R23M]:I
MURYD+*?..9L(3+E<W7+=*N"04BTW<X%5JA].<V4YN"U\C.)8.S:FLX!Q7M33
MDV*)IASX,&&U-J9$^D6]):R!@'&EY*;M2%:]&;/K:R[Y2S9?@*3_0(IF(^D;
M,?I&S&:N?;SH.S2&O1J8U1N[5O/EY.*[\8^3K[^?TT6:DYN;\]L;X^3RS/AZ
M<?+Y`B&"SF_TE9IM]GJ<#@Q0GQJD4(UOS$%UFN6\%!4['20(?SYO_^[!;YQ$
ME*[)_`-$#Q3C*=DUQ3%7XK(QGP&>BJFVDWP]\%H-#P_W\-C$H6Q.(`O4,`@C
MRY]YGLIGU6^AAP)>M\""Y(L)F7PB[1^JY%4-JOZFF^/HRN,I-DZM7J.Y[3S:
M?U73(9ET0)=TUK<D,RO:1I)AW;N-^?E:O>GYEN_G,G*^`4/S$H!5.63T/`:]
MC!>+0G<D)\4I]KE;0+&ER9<GU0Z4VE?4"?6:]8MQX4^2--+[=Q*((P^\QL++
MD$6VAH[-,$6=K[/$A`'I#`PLU+S!UNR1EF4MRUJ69V79%K(<J6GX&;FFAQ&-
MA%(L3B2>J-?$(RCFLG*WT!U1_0)7*@F9T^7UU0.1T<K41?G[XCUY#BN.287J
M28\^7;ZP])G@#K%Q2?PQJ4M5()CM",.`T*SXN;GRE%!B6""H59-635HU[50U
M-8O=C%2<U4)(64BGIEM%F<FT.LJ['"*,D2HDIR+P#'LBZCD0Q&G*N=FB2GCK
MT?,);96X::%L5DG0BG502@42+[RE^QX06L)FT34Z.H_X9><GQIO/12ZIWON=
M?/ZQ2"->GYR=75S^=O3YZO;VZMLOACWY\2Y5^W=!'`?C=+RV_=,65=T<U5ZL
MS%>9NK6=F<]);JZ\G,]7W\_.OZ>KN?.<P9^X)H-R_J4K:\$F&X,`^0'^:+7>
M@19["IW)K^_X?W>1VE1<AXHDC^DI.N/)-J)IF<I%[X9EO21YK-+QY.O%;Y>_
M&"C@GXP5N;)HMZK&HSG+I=7(0:H1JZ&J$5MKD52+D"^:[8/6&EK"M(1M4\)L
M+6%:PK2$;5'"FEK"M(1I"=NDA&%E1[8-5.*AA>SEX>6"$/)U`\CYXE_-N2TM
MP*\>ET_S_NNRN>8-S1N:-S1O:-[0O/$JBYCRDHR[>R!Y$/[Z[K].3[]\.3U]
MM\Q6H=]T\'7O7[/CXD6'O5KZM/1IS:QY0_.&Y@W-&YHWJN'1/3VX,7M7M-KI
M[%]K09G%QGV]_NM5!/Y3W,U>+Y.Z"N6VE+]?D\,+4_4P?8)4\F`2JXC`EO;F
M_586PZ\^EZVFOST%.G](P1Q'LVM>0U_-9O07<&;%E)B6,"UAVY(PJV.;W4Y#
MRYF6,RUGVI)I"=,2MJ<2IBU92=B[L7MPJYU)()BU.WHNFO?^7YW+=5M*L*-"
MU@!ES.('!%"=@K/F5RHEMB%OG21P^6>PU691[`B]SB20O*,1(L=D3<OP3K5I
M/`;8=<0CN,P4H-IS1XPWD<#N2PQ1GPEI&R'E..PV]?E2OBQ!G%.4-@6,D:-?
M9Z!LU"=#HK(=&R?3$#-XW3.#PA&`YDK+O`"!0K.&?W2]'9=Y1&@XO$V4'PGP
MS;1A</OCZ@AO<S'6\G!L'(WWUOF1/:K1V#0:VT9.3;O'\Q3XFP92N[@\O?IV
M;MR>_$\5\-)>0*P#NR.>,W0"[5X@B'!X<>Q]%94!-%\(A/%;>D@BKADJX-JQ
M\3O!RL8/;F3<)RZ-8(*5&3%JL03CE^`8":S@\83:G7.;(7M:NR-XG1H0WK'X
MB=I9E#2*D.C\8BWB6CNV1TMQ47+@;B9ODLOBJ:9*V/HK?`;"8`LG>"J)1(MA
M;/_@D#7&X<G^'AMG<GG*E]%J^Q&AIMR!U1RY,2+=9LAP"JILB@>GDN29MS+@
MX+"$QLUA8O,=ZT5O.(%&:S@9$++Z8<*$9MAZ'K$N8NHA%8*C$(0,6"Z_]])E
MX(AVX-;$#Y'H_Y!'@*4AJ`F$@M^<:\&%)`A=1AW@1*<J0AU(-Z9>HPY;1MI@
MBS<GR=#LL]X@Y=.:ZD_5(!#CZ3[KA,B;0O8*O@JS/G<$T:P`U`J'2=F-81)R
M%D"T9MH*V>_")0!@'Z;D_"`#[0(OSC8DR[:)D+`S@1"\28#@,"UPWD(&NH`C
MV.+HV$./\)-7=Y7F^3]Y3RE[X&ITJOAJWWECD=,@BJ,;Q)#^C"Q\[3R3GZB=
M*>U,;<1C:&MGJHPT-[=7I_]]]/GDYOS,`+?J^OSRYN3VXNIRWQRKPT\AC-(.
MJD*Y2"2=*&UV!68_O`>]_V$`VA][.GWDS0?)62"37!XURQY/^,)XX@7/3*8#
MP*[$\DULETB/WXO^!/YPWI#"(.5Z,XIF7[P[02"2`#0<_SIVOI4S0#`X'TTM
M?NP-007UIO3Y,FGQ>5?/NIU*Y<7U[4U<F6VK95T=?7LSS=#?HA^>[<,W<LBS
MG\_1,U^0O-^-TJ\H_0J0EE:@EK[\JO7N(>M=?6N^3&]H%+9UV%!+E9:J!5*U
MJ-1`2]42]G>!C7U="ZNOE>AK)9HW-&]LYLK1*I?(4?\=2)J:ACQ/<W^SZ4<C
MEWW4U\FU'&H=K7FC,M="=ZFA7_'JYW<6,<PP"@V-8);!!$_L#T@?K\&X6Y.W
M>FWI(OV5:_"W,N%6W[3[O3>@'#03'RX3M[NF915`\QX<$Z\6A:QY"G)(]N\W
M?E&!FS]G.'9]-XI#JNU;+[57@0SR)F^XI<GB2EQPV^ZBJGW1K=TW.[U%`/Y[
MFV[>WU-0+6V'*&T]V^S;!6[O&Y2V#8`IZ;J*B@F?UB@[URA6HV?V>]NZJ+Y?
M*D6+FQ:W;8M;JV$V6HM*H-Z&N.FSR0+B79;<33CTT\EJ)1)?-O'7RRB^J7,S
MS=&:HP^+H_5)L#X)UIIBS9E_:+?:>ZPC/FICIUG8MAIFSSY@-M8GP?HD6*>V
M]BRU]:'=/;0<U6)KJ\5%B\NZ5KQC=OIK&_$]%1E]'JO5PEXLZM740J=14"=U
MT#I!RXN6EQ>8T6;7;-L%I0D'+3,;.Q5]?6;;`T'0":L*$[QBIS.:HS5''Q9'
M;[DAZ:'5YMP&,69BR]!(-Y./U;VG=.^IEY?T-KO;NB6P7[VGM)QI.5LC].QW
MS5:W?VA"LTKDN3&0]2*F/PB\])#5:T_P_V'SBHISLXX;\YN14!,2[$9"W3\6
MM<BH0MN@5\,LGVE"L6ZFL;)&:3>3%;]X%2Q/C=]9X+-=)N,[%F;$#T8+G+<W
MC3U.;7PB3:%R"EU$44+F.^6HWR=%\:FFF*38^0\6#MR(:1E<CEY721S%CH\6
M6I-I#IEX\YE52+39TZT]`&36WI#VAG)"\T^&8;_NOS*/1B>/+'3N"TJ`-8G*
M3?IUZ`Y6(IG6Q5H7:UVL=;'6Q2\DT7<V=EQ?!PMSB70*?P^I.;>F4CF5;EDX
MSHR!J[,:<VCUO\P)=?"I'1[M\"QOS._O0W;OQ-J<S\LO@Z%R_<@=:"*5$^D?
MCI?H:'-SI>YKU/&T[94+$(_Z5;X-KJ3=ZS4G-L[8@.'1(182&,5=`'4-XFO7
M1FUY5=4N1L1&'7;!]?$#*JO2M8C5DK?#JD5<3LRL1N.XLRU842UF6LRT6<O)
M6^>XH#I8"YL6-FW3-B9C=LOLM;;56F:_Q&S+%_4./DY.J^TQ2"YPDW20_-H*
M[DU[$SI(UO*F'0H=)&LQ.S0Q>]-FK7/<T<*FA4T+VTZ,FVVV;&W<YD;+^ERY
MA+*B5A[O#.IX6>NZJNNZ5L-LMC3`C98W'2]O-UZVCAM-+69:S+19VTV\K$^[
MM+!IFZ;#Y-V'R1O&>_,6@8AMY2;`EA'?(#26MT-@('$%`O<[848P$O!OD1%D
MA\^&&QD#QQLD'KPSK-<X:&S@$RK<)(A<[.-E#-W1B(7,'S#CCL5/C/&_#SQX
M`,88.^&?+#8F>'N]7H,/X1]/@_'$\9_%7D.4WO\4(1KM&`;G:'00QN.#S!\:
MXIV011,VP$_6:Q,6NL'0P*YB])2X+,^_(E](_"$+O6<Z11>K.U:X*_T7H>$9
M$@Q/TD&..52@\.JU>5AXE&TX-CC`$TXBMR`WBA(D8C(1!$PGK1`?WC1&L(V&
MD\0/0>C^!\:_2V)8BGP]HM$W"+1WJ!Q_$A&WY7?'1,KC9CM`Z\DD#'ZX8^!M
M[]EXWV[VS$:C0<S#D9(3/V2#X-ZG75"ADN&'*`9^)+&`IV%['EF$_U;`E;']
MN?**$X:.?\^P]VLQ%UXATX+`T<<-9QPD?FP:G=9/R.7U6K/S$W$'^X%"P#][
MAT*1SE"P*>$QHF#`/VRS7LO$QGLN8W\ICV+TR.B9O6X?B)^N+)4@_"[^"O^(
M7#Q*XB1DI0,_B1OX1PZ_9EZO$;[DT1"UT,AQPTP!"1+BU%-Z%BDE)Z[7\KM*
MV_F^8Q]WV_3Z^T[ON-$UC?S2%Z0!Q4]_^3F)CNX=9_++F1NA#H/578U.E:W\
MSO?]%'@@(EG_C-M][3S3WMZR'_%GE(2_UFN&\1<YV'48#!@;1E^`8^6C7X+P
M"MGQB^L[/J)'GN!<0:DRU(5^#"-]9Z-?W['`^^/ZO-/LM9J=HR/+NCFRCAJP
M[#]N;L_^Z#?^0!(TFDWKC\8?K;;=;G9_M'J=GM5ZAVJ##^%&`?@-W3]^OSE[
M9PS9`+C>BQ"<\J]'=J_=:&2K7G&B^55>T+[A.Q<^<#^[P*MMR"P[6TZGT\O6
M4C:=_*1I(T_\X?D/W.)=TMZR6JUVIYE->'HJ^8E>LOC4B1Y@AQY=,#R?GW\'
MOKOPK\`8`F.^$OM83:O9;O2S-2P_R_SJ,E$ZS:O:76U&H]?L*LQ3/)_\G,^=
M$&$AHFL6TN-GKI?$9"RV->D_@(Q_<!]`G;\-.]$X;K:RZ9=,;5I>!R&#)9XQ
M_M\+_V0P0,,3@>BC1PV\"+\)P?/XZCIWKK=K[FI:[:[55B5ZG0G/B!%7!U^#
M:*>2TK`:C:Z=DY1L(E-S#/Q`"@Q_1JB$'<J#W;':BCR43BD_<]GQ'C;B+&MW
MO_/9MYMVI]?)9C]W6HN$X@OX*70?^FKTN__`AO<,!@G=1^IC?.%'<9B0G=SE
MYK1;_<8\N5AVSOFUG[$)>)0NJ3KXM\?P'RA3XR",W?_L6"7;=DM9XS)SFR/I
M)X^.ZZ&*N`U.*2Z[05_](?`@2(Q`ST,L7!5=L'BJ\\W0ME>SMA$JF/N-X['H
M.XBDGS`@PN[VH-=L*I[7U#3R<[S*Z[U=VPVKV;&;BB`43&?*HP7_"P0#_W/^
M[P1DWD-)OZ:<R;2FV*FKV+(;JJNXRCSS*Y3`;@*\C".07XUXZD6Y/K$529CE
M?-15_7:_U[6RQ:TTQ446Z#ID$\<%#3YB8<AD?`"TH[CL)(K8+JW/4;/=ZC7G
M69]EYKMHS?)E(94[7%Y>-2R<67XAOS$?-MQ#PS0<N[X+EI9L[LY=H(YE];K=
M;!T+)K:4@(DH8H:)*R5B99-<*IJN5#)F^3GRM8F)&N[P!1.EH6`PT,5N_"Q^
M@I]A!O";D<M"(QH\L#'[]=U#'$]^^?GGIZ>GXX@-CN^#QY]/+_[[W5\;\"&[
MV^\VP!?(7LN&BM@].I]__<N/N]`;NK^P'Q//';CQ-PX',W3AKQ&X<[^^DY3X
MG$2NS\`U&H"AP(,'</U^N-&[O_J/7OP+J!OE#WR4O_Q<./A?__*S_+I8Y\^Y
MA?Z%'RTH<XV=,#YS8O97I-A1`_\7QDA_FS[((+3('FM"[(I##Y6'_O*S,OA?
M?A:[]9*MV_IF[2=U&D6,#3^U[7[G!_RRU3M\-E_ZFS<Q[`'.\V;`?`=V@'\Q
M_3-L"HO.X=O<Z%$LLD41:RS'1(W78:*#9YL]W[IV&[:N85NVV#HA\>U>HUG-
MK5L@?;\%P1!/!$`*']T!R.&/P0.>(PZ_!"'&3/%SELO9WLXV["/4VMT%.XN/
MV3O>6;O;ZNWESJ)C][9VS.XWVK!CS4Z_MU>2R>4,3X$"'Q,4^7T\&0Y)KSK>
M-42\%_ZI,W%CQ]N1==;Z825NVP-M465N>ZLZJ]5J]ZP#TEG*J8+64U7DL+W7
M4[OGL,/73<U.!UFGIUW@Y;:LMU0X"H_M<,NXM'=[7;M3\2TKEF]**"@5%/#X
M/3O'NKI)Z.(9R0B'/QD,DC&O&C^CJM3I-][DKFM?=(_T?<79Z`TRSF'NIG;\
MM")8C74J=>97(?*TM).U,R>KM=RNMW:VZ]42BDJ0ITV'F%HH=B44RQ]_[GS7
MM<MX(+M94,T"/]F'7Y;P4F>1OBA*64X#_Y&%L7OGL7Q5"[\\E.H/%XON_&&D
MF:S5[;=:V[>Q!\%DU\D=O'V%F`A@?C3OM+H6/*9Y9QG>N0Q\C&8OX`&M=72A
MYH$4:KXR%[5:O:[FHF6Y2+-/RCX\=NKTK;:EO>WU8W:NE\YX\<?*&DH[_A7B
M?JU*]XS[M58OX>O\6;S6ZOMS_J\5^@897^=U]HSQ=79I+C]K!V5_^%G[)O-8
M6C.Q/B'<$#^U^BVKHU7DB[B+.YRG.GBK!$/G:B9U\%;M.DT=L&V0V77`M@?,
MKH.TN3RL/9!J\[#V.^:QL6;<K3'NF^"A1M_6!GQ5'OK.8@?F-I2`PF^7D0Z>
M=0YJ[RIU+:4ZY&GT];64G=W5ZB]W&:F_^UVO<**[JDGG:NZFOI9R4+FQO6*R
MBB)Q59/)3C63K<QD^OY*Q>ZO[`WGM)M65^>+EDTW7K(GT<P-_./K,/#AGP-Z
M7K,2_++7TJRT?.8:&YVQ:\_1#*3OTE7_+MW><!&5$FDN6HF+5BL:.FPNTE?J
M#N!2D4Y:O)S[-;_OCM_?`E/I^VS[>@U":],-,[Y.".\=X^NT]$L97^>']H?Q
M=99*7WVK`!N_!7[*7WW3WL&^7'W3OL'+V%Y?D-MAV;J.`"O&[%K'[P6S:\W^
M4F;745^UF5U'>OHNW?[=I=L?'M)WZ2I]EZ[JC'3PK'-0>U>INW05(D]7]P->
M;LNZRVU9=Y=;IJ\_;OOZ8W5W7?<#WF2,]6:51X7/S"I[?E7=W=3]@+4B>`GK
MO!%F.:@=K%9D4QWR='1DL]R6=9;;LLXNMTQ'-MN.;*J[ZSJRV2.'IN)L]`89
MYS!W4T<V6A&\A'7>"+,<U`Y6*[*I#GG:.K)9;LO:RVU9>Y=;IB.;;4<VU=UU
M'=GLD4-373;2OK!FG=58IUJ>5'7(TYSRI+K]3KOJLE10$?_5A=]%[+M[_P"R
MY0]1W"9;+A5N+K>)S=UOXCXHQ%=12U7<,NT.;]L=KNZN3W>3KK[NK:([K"W`
M`L;:!WM01<9Z\U9INGGBONNG'=_3U#I)!^U:#ZW/.M4*VBM`'KO?[5:U/5;#
MAMD>-;JOV1[+[C:1/%:CWVPH\7"KWZGJ1<=%$I]=\3]C=_$-&T#P%+MLFQW\
MK.7:G,$S_:-F8S?[J(/D+0?)%=[U?"RS#[)<Z5A&:Q1=(G>@NSG5)WWO-<4K
M1!A:.^BZN?W?P4H%1A4B3Z.*Y%FZK?+VR-.8ZA>NHXW-1QNN#_L+3ZLI`/F[
M;6^E=O,JOT7:UE9M6S2^N);==9BDPI)<829Y`]I#XPU6#V_PU;GCX/FA^AOR
MZN'@#M>L(EGJ*&^;45Z&W;BKK:RP=UI-3W'W6U1AW[`Z?MI.MT5W6-V$&MYI
MA]7J<$J%-6X%.>4M:/FR)F*:27;0-FQ_6:2Z;D&%6>0-N"(Z953EE-$K<<?!
M\T/U-Z1"*:/MK[FG4T8[2AGU=KV5%0Y@*AI,['R+*NP;5LA/V^6VZ)31/J>,
M7IE3*JQQ*\@I;T'+ZY317J:,7IM%JNL65)A%WH`KHE-&E4X9O0YW'#P_5']#
MJI0RVOJ:=8?*7:6,NKO>R@H',!4-)G:^117V#2ODI^UJ6ZJD^+>^9MW`:U>*
MO[/KK=2*O_);I!5_E;:E2HI_ZVO6_4UVI?C;N]Y*K?@KOT5:\5=I6ZJD^+>^
MYI96_#M2_*U=;Z56_)7?(JWXJ[0M55+\6U^S;N&R*\7?W/56:L5?^2W2BK]*
MVU(EQ;_U-=M:6[R0+>U=;Y'6%E7:EBIIBVVO63<QV!FL:`J@NZNMU(J_\END
M%7^5MJ5"BG\7:V[J0M35-J2Y7;B[ZC%A8]M,V-!,N.J&K,J$B>_RW7"CH&5;
MW3]^OSE+*3QF3I2$[*_B;[_`W_[RL_PE'PS?GQHI>G!"%LT,PG^]Q/O*3/Z`
MB?\Q-=[0?80MR]:/[UTF8Q8Z<9!MX3*SY[0I?I^&/6-^,';]LH&+5I2-.?OR
M7WY6YIXNG?,!_./_!U!+`P04````"`!<BVD_XC,M'5T/``!%T0``%0`<`&YV
M;'0M,C`Q,3`Y,S!?8V%L+GAM;%54"0`#+_ZZ3B_^NDYU>`L``00E#@``!#D!
M``#M75MOXS86?B_0_Z!U7W:!.HZ3F7823%HXF600(&F".-,M]J6@)=HA5J9<
M4LZEOWX/*5D76Y0HRQJ*G@4&D\3FY7Q'1^2Y\?#CKZ]SWWG&C).`GO6&!X<]
M!U,W\`B=G?6^C/NC\<7U=>_77[[_[N,_^GWG\M/GT8-S1WU"L7/=O\4A(Z_.
M'R[V,4,A=A[1:T"#^9MS@7QWZ:,0AG5N"/WO!''\HR/^]QSXZ(_SAQOGZ&#H
M.$]AN#@=#%Y>7@ZP-T.L'\C!#]Q@/G#Z_=7$OT<DGCH_'0R/#CYDOGD(EM0[
M==[]-,7O)H>H?W+\WNV_>S\=]D_>3P[[>/C^Q)M.T,]'AS]G>ETP'!'G`=FG
MSM'A<-B'?X<?'H<?3H?'I^]._I-M'2S>&)D]A<X_W7]!X\/W?=$CQXX?G6OJ
M'C@CWW<>1%/N/&".V3/V#N*1_)@/#O"<\K->!OKKA/D'`9L-8.SCP:IA[_OO
MG*CQZ2LGN0XOQZOFP\$?MS=C]PG/49]0'B+JYCJ*P8JZ#D].3@;RVZ@U)Z=<
MCG(3N)(U&@0ZRA;BK_ZJ65]\U!\>]8^'!Z_<Z_TB)OS(`A\_X*DC:3@-WQ;X
MK,?)?.'C7OS9$\/3LQY]]D/)[L.3XT/1_X=/@;N<8QJN?B+J7=*0A&_7=!JP
MN:2^YXCQOSQ<YV#0X!G[`9?2%<:R.A`-!UIC#II2_@`]_QR'('-BCKOI%:'P
MO`CR[P-.Q!07/N*<3`GVZ@+0'/5K0KA'#-=^$#6&#I]P2%SD[QX4O,K!'(_\
M$#,*C_X9-T"Q.=9NR'5)/S/+^`DX\A3X'BR4EW\M07!'U+L##K&+8+Z`KS#E
M,'=$3`,T]>;9^8.Y0/SIR@]>^#7U",-NV`#*YEC&'TS3-Z;^9#M^AWX+0LP?
M@^3-36CC=VR&*/E;+J07`>6!3SSY!U!XSV"KA#57_)EY[=/.GPAW`?R286@]
M)C,*BX"+:#AR7=C^0]!6[F$\E\#<^#4\]P/WOW6YV"'*VWX47YN!'8%]A0C[
M'?E+G#Z3-M"63],VR%O,9O#RCUQX^Z--DX/@`2F+>`_E[:+?<OZVV7+/@@5F
MX=N]+X00=#L@;R'UO82:%IA1:]:V67`1^#Z:!$SJ($#,#7%A-\`CQA"=X=9Y
ML=WT[3.%@O4;DHF//^%)VQRHG*MMN*UC-`7L!BQPT.@8]DAXA5SBPUK3ROI6
M-5'K>W<(L^0T/-&VU6>J/V7KXIO,"8\`%%I80*3F]8!]:.)=!!RH%2KPN7`T
MW:,WV:L-,6](2-N,BA3\1_3:JF"4SM(VQ$O$**B1_!XSR>D6\*FG:'];FL])
MN"9JK6Q)I?.TOFKC&?)O41@*C9'":R,M`TQ;LD/TIOL*SS99+X1."$,&;QB?
M8XJG)!2J8AO8:\W:-@OB9?(>@6[\"/H?1^Z::=`"!^I,VOHNOES`(-+/["=?
M9SS-[>[G6TS>OD2((!26JL9X`4I5*P*@G./KVEY&+"ZS=M9X.>'XKR7\>OG<
MDDZFGB(&YZ8Q21&2S(&$MIAZ(NH2?2KFVF7D**)@L$9"JW1I!H0D#4`%<"HW
MLR_"@`'+/_=X8AGKFR(^D0&_)>_/$%H,A#P,L!_RU2=20OJ'PSCN]T/\\9^Q
M$Y"#7HS`&(;M"#YA2^S=$#2)+:J+)1/>Z=7T(,C8/^MM,\+`!$+/DWP&CB/B
M7=,+M""PVJK0*%H;H9QS''(5H=&7YNBJD(I<&Q-4QD_N!H/9=S?QR4R^U15D
M5W3J$([?`NIN`R73SPP:_B3T??@A_!?/R!?[PRB\0(R]@04@O?5*1#I]C:`"
MVRV@4ILI!;#>S`RM.==GM1PIVYN@_A.>8IC=NYO"3WCFTKVCH+RXK4FJ'X!M
MD;^RDNVE7<QB`)5NB<O7447C#M!=@_'K[<U0+X-U/-I/-8A7-#=#.X-%6E@\
MVLID:1<S&(1.+P.%H,3/,)@3F"T8X;`83HE+1!1].5]*=\:GI5AEUGLHD38>
MV`@_R#/QP`Q:J?L5CU/1V@3E*S=;['O2%LGJ?B;0?`X"[X7X*C,F^=H$;=?"
M\)X)A2%>AG!X^>KZ2Y')7$&W5E=#F###/-02>T5C$W1GQ%4D/6V$#Q4(*KL9
MQE+._XZ\HQDR*C?NXK9&J`[H[!&SN?3NQ1*L(KJHJ0F:LP24BT912Q,4RT10
M3:6NN*T)JN]9K!Q7FKI%+0U1O$#$NWQ=R`RG.`-7QX.ET],,(D4B&^R52B@E
M74Q@>(#-D1%7I&<T\`?5'<4,TA`1BKU5_D)6JX_T?"6XRHXF\&AK$!W1&1[Q
M?!$PQ-XB&E8",9J+F(6"]/(^"8I,K&C$\H`0<U=CPZ\;@:+\^:RXQ8`OYU&$
MJD]"/%_UG[)@ON'U7TT6J!SN3L"`\?(4X?O#PY[S@L4Y./DW_`5F9L``V5GO
MJ.<L.1`7+**@1U?1E2]Z*=B?]@&LGOV4@OYY'T"K'5TIT`_[`+3H"9[L`S"%
M2IN@'![:AG)-0<R"U=1;TD<\W"/PM=6WE`U'>\0&+=LBA7Z\1]`58;@4[#M[
MP.JZR++XBUQ1Z4)GT7*^#?B2B%K"@R.+%ON&`E",WR*U>QO\%7;5-\.'0H]8
MBMXBU7P;]$6M$O#'%FUXZM!"SL:NDRR9;@<6J7YZ?-`(I:;H+=+X]-"K0H$I
MY+T3?&74/\5LI\)7JN*69:^DP.W<X$J`%P;34KP6N=AT'W1Q8EL*V<Y=O-1[
M49X;G4*WR.56&F[/H5=GP*::FYV;=CGPXM!^BMG.K;H<<WGJ;8K=SCV[0M"K
MCPZD#+!H`]^):6;1RJ:'=_,00@K6(H^4'ECEJ:[4_+3(`Z7K=VN>BYRR)[?!
M]?>!/SJY%@K\FO"[>&HT7SK0+)F;]34-I'R<+SE(`1=E%B:$2KACO$"B*++_
M]H#=8$;)W]C+UAU(5Y-,1;1,W301WHC#/`F'UI)&VI[5S%$Q'@IG8$R$ZIS5
M1K-ZM&X>8!>?P&H'0N4EGH<[FM_/UVC1ZF(D41]3S)`O?(7>G%#"PZ@(0,PL
M!4NK>IE)@7>9T"0_X>CG-4W**]Y-O]`G[,W$0KORFEQ3(%J>PE?)38,!31X!
MB!:Y^$F`+BTRDY"H7J-.P-3J:@;3,Y`E>!J1MB)4B4/1W$C2-XZIN`FX2L3R
M;8Q3.7I&Q!=6]V.0T=9CQ>8<<>+JX-`8Q4P2?BK/.4%785*V-Y*0GR>E1*:*
M6AH[0K#)1!75BM8=HKQ<7"HZF3\.D>@=$6&)6GP]7R"WY)2!_A!F$MAGL?81
MT+AX8J9^T6<PN(3J)UX"I7Y8:PA#QQ$PF*,BDRUC,9>+8WD?,RAD_.(*+.?/
MP%VEVK79SLA!`N1COLH@4BI.ZZV,>B%4YM!::F29*%F9"*F#N]+,L3(/4@=Y
MZ^X&*Y,J"Y7S7+9XD;YEY4&.2J@EFHZ5^1-;FC0YEN1Y9F4VQ0[84$^!5.1@
M=-QWWX!->GY`19Y&U]E29?[D4\Y4;AHK3X'5PEZ@UEIY(JSF`]_>UVKEL;*:
MW-'QQ%IY\*SFJU''-M]_?B@]8E9F(^\">H&B:1$'2GRRN5,(ZZX$*T]=:H+=
M-$D51_UU]1]CR0+UKJ\T2^OF_92F:N<*+P'HOD(=RG@,5)'YDA[=J?Y[#WI,
MX*VK/&60=(<P4S%R$J;Z6";7.+K?0R3Q1!^*2[2O,`J73%TC<HNA#%4IA9>"
MR#<0?O>Q7#FI-YH'0'!T7:<2HT97(XD;H#Z)1?B.BOWE;IHK09+4'U'E;^AU
M-A+RGR_`E%CE:^4KC<#J!G)%89/R8>7UM*LV-AFR&ZDL.D?[M--8M`;K!NY5
M>OPV,(OZ=@M5K!361K3JUPTTZN.6VL!*AN@&QF\ME6R=W+5#I66I9!I=NX$I
MKH^R>JD*ZZ1HH]0:K!NX\^5QM!&N=3."A?,EHBZ\,]*W#MS]-V+2Z7H5L#%F
MS\3%_(Y=^(C,E8^NUAB&4O($AT$G$S$%[_SM"\=@.\0Y]G0V<F&-*%M?:PS0
M(7Q1$*$!OJ(!.H0O<:!LBZ]H`.,IHYU-;)7K;@'+5JZ2Q'M2EL^GU=](:E]\
M3S"L60]XL63NDSA#.<T$+54)?=4=3>*YF]YB-L,L>SNR_L)7=Q232!^#V/.U
M;I%68%/WZP0:925475CJ`3J!;_P4L%`<4D]CWMI/K+"OH1K=+L8>%S[7M6H#
MRCQ@=0_3"%*-3F/YJ^S7'32K<@B:CT71<2>'W8KGR6>ZR&NR$SZNE.HUPIN.
M9OKI9+9/J2#4V)MJCF(:J7`,WPJ7?13X$C<$8YD>*B)CL(Z%>FM@@Q&[P($U
MU[C.AE9C!.,(Q;MU)^.M_/(5,Y>H#Q!7]S.-)EXD5@3IB.1&%S,'(Q:)WKI:
MNA6E491')O1'Z`K"DEU-V=S(01"1!G`.3!3[D7#JE44+%8W-'A+8(JB]E@NM
M[<ZPL@Q;2PPJ]&=96<^H)085ZDYI`12+)*B^QW;M\A"U-69EI>+=\4-E#:5L
M^6;$1+V)*NHY=_V$P<ZYH52:%%75]II!&AX2*^NO[8XKF_:"E<79MF-(8[=.
MLTIE5O&J3M`E9<O1M[/4U`W>*&KP[S>3JOTN*5LL,@YVQQ4MWVK*(_OUX9*,
MAXV[O%1Y]596`6_&CSHQ1T6E<#M7&EW^U/%A6WDKU([EISBFJ[@KZIL2G5H!
M("N+TS?C5W5RI:)Z_7Y+476*BZ*PO9UL*<GLTRDJ8M,IT&8<T#N'9641JF:,
M4069K*Q*U51&MCF?J"A"M=?K2<UL>"NO7&_(H49G"6VM]M6`8;J'2A5E??;[
M==M)S9L],$,U^54C`=_.DD`[EB:]XVB**CE[+4G;'H>V\HK37;.J['2NE55W
M=LV@HJ.M_V>,ZNR]K15!6^%,<GZ_&5?L*'%D_"(G>2WD8Y#<-94``2-GAFCL
M/P#CD`<^\5#L6X!ME4,;%'DN"SJG-8[%O>)D1@E8F<)/'NTQ(![W,)X+PO$(
MQ)_[(LS;*?0VTIRHSID*TQTE-8II9^M?B_IF0/<BONN,=Q^#,@"4DMY1RD78
M`4V"J%J[J!9)7*D6IW4D+8"0R^GL/+U6$`FSB-0;>6/N%7)C_:2CQ&[>#RG:
M=I['*8$RR2GQ2V?S>U+/=1+UZ2:82(EY1*^=9_OJ?M![S"1W.TJF2'LCX9J@
M=)36&SQ#_BT2,6LN8]E21\*TPQI2]H43.W9LQD=1D%!LY%VE/%X>P%X(W[+7
MBG1>2L;+Q<*7OR(_^?J:3@,669B=!R#L4<:QW&[&"]@2.TIG7JFS2)4;+R<<
M_[445R8]:^YU'P=B^@GLD/#'_P!02P,$%`````@`7(MI/Q.+,XKD(```&8<"
M`!4`'`!N=FQT+3(P,3$P.3,P7V1E9BYX;6Q55`D``R_^NDXO_KI.=7@+``$$
M)0X```0Y`0``[5U;;^,XEGX?8/Z#-_.R`TQN=>GN*G3-P)5+(]A4)4C2TXU]
M*<@2[6A'IMR4G$KZUR])2:9DBQ2IBTDJ;!0ZB4U2YSNDSCDDS^7G?STOH\D3
M0$D8PT\'IT<G!Q,`_3@(X>+3P:_WA]/[LZNK@W_]\Z]_^?F_#@\G%^>_3.\F
M-S`*(9A<'7X!*0J?)[_[(`+(2\'DP7N.8;Q\F9R#>0C#%(\ZN0[A?V9>`OXQ
M(?\/)OBCWS_?74_>')U.)H]INOIX?/S]^_<C$"P\=!C3L8_\>'D\.3PLGOOO
MC,*/DQ^.3M\<_53ZYBY>P^#CY-T/<_!N=N(=?GC[WC]\]WY^>OCA_>SD$)R^
M_Q#,9]Z/;TY^+/4Z0\"CQ`68ZH^3-R>GIX?XW\E/#Z<_?3Q]^_'=A_\MMXY7
M+RA</*:3__;_CAN?O#\D/2K<^,?D"OI'DVD43>Y(TV1R!Q*`GD!PE(\4Y7R8
M8);#Y--!"?KS#$5',5H<X['?'A<-#_[ZETG6^.-S$E8Z?'];-#\]_OW+];W_
M");>80B3U(-^I2,9K*[KZ8</'X[IM^76F(X@W30OD_7^./LR:YV$'Q/ZS.O8
MIXR4@#/AMB!_'1;-#LE'AZ=O#M^>'CTGP<$_R0-_1G$$[L!\0BG^F+ZLP*>#
M)%RN(G"0?_:(P/S3`7R*4CHY)Q_>GI#^?SN/_?42P+3XZ<'@`J9A^G(%YS%:
M4NH/)F3\7^^N*C!@_`2B.*%K,<T7]C%I>"PUYG%7RN]PSV_W*5ZAY!DW\\L0
MXMD-O>@V3NBK=19Y21+.0Q"H`I`<=9\0;CT$E"="8>CT$:2A[T7]@\(O?KP$
MTR@%".*I?P(=4.R.U0^Y?GA8>LK](^;(8QP%6*Q>_+'&"W<*@QO,(706+U?X
M*P`3_.R,F`YHU)[3^\2<><GC911_3ZY@$"+@IQV@[(ZE?6*ZOC'J#^OY'?H:
MIR!YB#=O[H:VY`8M/!C^207I60R3.`H#^@>F\!9AQ8IE+OFS]-JSSN=AXF/P
M:P1PZ_MP`;$0\#V83GT?&PLI-FUN\7A^B)\-GM//4>S_1Y6+!E$^]%3LFX&&
MP+[T0O1O+UH#-B=#H!4_9FB07P!:X)=_ZN.W/U.:"5YXF)15KD.38=&W?/[0
M;+E%\0J@].4V(HL0VW:8O!6U]S;4#,`,I:<.S8*S.(J\68RH#8*)N0Y]K`W`
M%"$/+L#@O&CW^.&9`O%6.0UG$3@'LZ$YT/BLH>$.CE$7L&N\7\<6'0)!F%YZ
M?AAA63.(?&MZT."Z.\5/J5AXI.V@<RK_R,&7[^:9>`JP08L%"+6\[D"$FP1G
M<8*I)2;P9W(L=>N]T%Y#+/..A`S-J,S`?_">!UT8PJ<,#?'"0Q";D<DM0)33
M`^#C/V)XM;1<ANG64AM$)0F?,[C4!@LO^N*E*;$8(7YMZ,X`P('V(7*/V\/<
M;N0%L0GQD/$+`)\!!/,P):;B$-B5GCHT"W(Q>>MAV_@!VW^)YV]M#0;@@,I#
M!]?BZQ4>A)XS1YNO2R?-P^KS%@\??D60&RM`38W[%3:J!ED`W&?L=^^E9<>E
M=Y]UOYXEX(\U_O7B:2";C/^(')R'?%E\G'NMXL:,7&B]I["]*#J8Y`.706QZ
MA3`]#L+E<=[FF'08D![\*'+$&\/#`,R]=92J4;?;?3^TQDLOA*U)S7H/22E]
MPN$2+&<`*9)9Z3H@C8]X".2O9^!PPQDU2NL&R.D--E?_Y.:_0C-^R0`,R'5E
M]BD9JL\K5TH`)@&_R)7G1N26.D:US*(0$^`?+>*GXP"$QT12D5^HR#H\.<TO
MHO^&/_HVQ8\.R.,O(V]1#(?E)H@^'>Q^?SPX/04W2DP@9PY76,HE->0)F^^/
M6KQ%"F,\?<$Y%L<",JOM]D??`QY60!;]>GAJZ/(FFPUO%M614_U^3_2\G&$&
M(&(!!N#Y?\`+CZZ==ONB[SS7#ARRSLOB?WAJ+L,(H#.\>A<QXO.JVFI?M-V!
M19C@.8+I5V_)76#;S8:GCFZ\LV=/G\,Z,;;=8GB:\!:0N,3=ORQG<51#4?7[
M#3U,%4Y1E3*L1XMA<I4J9PWF?>8H7DJ(].*1<9W$F,0H`.C3P>G)R=$)_@^W
MIE;"1V+O@^#308K6@'T8PQ2K[XML+XC-#[`@OQQ,5EA&(SP3GP[>'$S6"<81
MKP@5WF!\V#*PNG"D*O$+AAR=G!)V6(ULRU)AT-Y8#XUC1C"(;ZV'N"5O&+1W
MUD.K5SX,X?N1(-PQE!C$'T8"<<NZ80!_U`.P=E>[#;/6K"YP[=@>#-.)IDG;
M.??8!L2QEZI359C%JGA^/JYNYX?<XDLZ);<V]N9>,J,\7B>'"\];918?B-*D
M^&3;],L__I8[HB6WW@M9-5,8X$^P=11<A]XLO]4_6R-$#:**<=AFA/;F;`>$
M01!F$W_KA<$5//-68>IMF[I-K;50GB0@W=XE;'VICZ[IC&@YG[LLJHWTT=FP
M>BMMM%,IQ=3MMCJH_KQ.L`9-R@Z.]%<$0.TYA7P_4]#L;M";6NN@/)=/U\!+
MP,TL"A?4NFE8]`V=#,+Q-89^&RBE?GK0)(_$LP+_()YB3UY$;N*FZ9F'T`O>
M_5"_:"XBF;Y:4#$OF6VW$1X600]="&)(;[Z%4[#=3`^M%3?9YC>!VUX']>=@
M#O#3@YLY_HDGG;H"<BBO;ZN3ZCO,MLRWM9'MPBYZ,3P!N`9B3<!I;`#="HS?
M;J^'>AK8D606F@3QG.9Z:$=8S1#O&.E-G["+'@QD[TV#2O!F>P$N8`K0"H4)
M(/'Z?D@BKM;+-75].U\3*;/=@XNT\\!:^!$^A0&`0;$M;YA.3FL=E!<NF;F?
MHO22;.XWEHO:]KS])8Z#[V'$._S8?*V#MBOB^;(@YDLN%$%Z\>Q':W);T$"W
M5%=-F``"22KU$G(:C^M:NCTO2R\T"2'>"<;A<+6QFXE8&HZ!I+MKQB9>[X98
M#KMDR'/?A).X$CF-9F=]6V.HEF=\31\M*&*X>`!H2;VQ<[G-([ZNJ0Z:RP2(
M7]"ZECHHIHD[)#=6]6W5J-[UZB>??+M%H'3B^Z5RUYQ3P6^G@V^8D&R+W'C@
M5==2$\4K+PPNGE<T)C[/V2)SCR/34P\B3NH#;*-RH0BZZ,!PAXU2%/HDH+?#
MN;;J*'J0IGAK!H(BXK6\M\]V^UQPC1UUX-GX'5QS7.<%#;726^<9SFFDAT[)
MW8<A^PWE'89A>XH'L%S%R$,O4L3S6AM`>2'BIDOB,R-'_U:?_;O0%735^WT0
M;ZQJBYUMU,8UZZUY_JORX,2JG&$TSY%5'J/<(1S#:IY+JSQ6_I4-PV>>/ZL\
MOKKYTN2^V@L>SC:0@?O)8G"%KQ]#\\%P-)S#LC(HR>W"!O,[79[(/6)6WBPQ
M].:%YBBCE]K`,\3F1>PH(^8XNC",IIL\$ABY\V>NJ2/MGTIP"H[W-EA/=6D7
M892$".Y6Q(0"9UY[:(B.!:MZ)5B>4M$5ELGAD3UCK[M(,CETL@_X`J\YDT,K
M^X`N=$<V.>JR#_#<$S&38S'[`"YJK3U,<W^RCN,"PSA@[F:XV>&B8GNJ!"@R
M^.;NGM7@\SS(F%UJA4DC@53"[Y.!-G>KK`::ZZ;+H%IAMDEME$5>Y@RO%7::
M!-Y:/QL&TPJ;3.'\8SO<A"&UP@"3.LT4AUHRQ%987A*(Q2^J%386W[FPNI7@
MQMIM\+ZQ0N?(X:WW6V10K=`Y<E#%(7T,LA5J1W(U-\=2,]Q6Z"')55WO"<VP
M:M)$.]GMFMVSJCO>JE/4")/;J3%D^S:5J21S=WURR.0/!]BBUK3_:\Q()?;I
M,S<M50_`&F]E<I!O3+Z04#N:JO4U9XO47%M1_<RYFD""833WQ$T-(S=A%H-J
MLIQ5NSWI'C7./';&\B[+>,$SU.9NB[I>+)11FKLC:O"-%EP:;3LCL_=;[@##
MO`R*U5+.AB02&U=:M%[0?'MC#!Y+TKPQNP.O\1M$7X>`FB!%53X."IF>FA%1
M(I+I.GW$\N9/)A[X2'9Z&('@*DG6\M3GK8V@_&:=)J3N#%8&LN27NXPEL<H`
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MM=T^$M_<:8^Y<4ZA>W0*U>1^<P7QUV`:I0!!&L[G_&Q>KU]*00N62[,0TCB3
M>[#R$%XMT<L=\.,%)%KF`7DP\7P:AL+<2\_#A)Q9K(E"8EA(`J4\?Q3O+'SH
MI^KQR4AH'HN<"'Y%O:UF)M#:D(^5V[R7&Z%S@`53L`FDOH%5.[;N1JBIBY:R
M1[FS;6%_?O:2T.<PM+ZM,53CJ3X/H_7N=9QL+Q.0J"'H3KE9GE`=2DP!")`7
MD3P=P1);(N15)U9"_O)S^-G42T_Q)A^1$,ISD/V\@I=>B.@F\6;^*WP$P8(X
MQ!=9#:X@)GI-TQ%Q0'884&?QJLS@RV?B*S8*L2GLD5Q+_!(&4EWU8'K"9!&>
M9J05A')Q<)K;[]/74S$9D'/F.DYXR[[:1CN5TR<OC,CF["$N[:;SP`^1UE4=
M14]Q'_:.55X^'B9N>Z.H;S`PF_MI*5M4)4GPAM2UU%9H:9>9/*HYK0VB7+SX
M&SHY'VG_/YL]4L::S3'0U7+%?QV5AM!3YF>16Y@QO/5>"#53A#RXH(3]@DUG
MLETEKR%W'ZXTA*:B3<!#/LE`7HI9%;\0XCYZ4-"L4I<H7OZ"N<LUK7?;:?'W
M]2*0%)E8N<;Q=BOG26V")S5'?O\&PL4CWME/G[".6("O:R*8J7V7;_F;'%_;
MCJ*#R[5DWLPED;8=Q2"D.\2)]@-J8SB_YNY87V4J_.8);CJ.WRI/(C(+;,CN
MIP*W\312?WV'?@$/?B%G0[(M%8;MWKMI3ZWU"JM?2)_\5'-C\PYS;4C:V0IR
MS7[(AJR=+:>W_?V+#7D]6RX`E:,+&])\MEP;,G=3VC-_#@6?>U"KFL+)=L2[
M=IS!J09;`9?"K,EV=8%M_7KW[IP?VA_`UFR2CR=XK?;";SQ!:Q+B:SQ1:UN.
M#6,-3FNZWQM)J%JCC^AX8M64?5W&$\#6Z(PZG@`VCK>P_2%KK2_=QA/&IG@W
M-9[@-JX+MO:XMJ'G5F99:[*H7$C?^$/ZZ+JK)DJ'`3UQP5;#"G]%V$-.6.DA
MDX;K>DY)@EIW.KD^O3B'3(/_6V<7$,E#S'D>J58*R.?X+:]8H=,DB?V0Q)W_
M%J:/#X^`GG>3P;PH%P3SDM&6Q3)?P8MG_Y$<]][,-S9LG<>)*:29R&=,K@=]
M3.9O'J*7*`]Q=3^0OPI[X*LT*?OC8X7&"R)?$@H%;_;#[-[A''_+*&[-)>4'
MZ7`4DD&R53V0P,D^(G@N@9>NN;DS>QM^;^NC=`>W(Q4R0<!9PDP^7,:H)#W:
MKI_^"3%U?5%-W&$!9?U-14=G;.8E("#&!A8"]-6G1\78/@L3/+]T>FZHJ<3S
M4QWB279Q[`YDQB>X!^@I]$DBFS`.<I<?TB`O6-4S^R0?:S0O/V^#*B^#1H!=
M6=KQZ:9R-E?;PJ3&ZN/TK.<>8L)*%!2ED'*%<@<";+C1RMU,^5:5R33=*""Q
M!NOG$::D)7%)5C2DV_"21^%6M]1`<SD9,9D[[?106S&G[X&_1B&IN-I`N[A7
M3ZE,NI8CY`<8]C:VCCG;W-P)<[LTM7;).?*Z?]C6B"&>5J$4KV]K)=6:RLW]
M$L<!K>.<F6Y)L>T,\+XSHY/YK`J%3XN!>I%'['BJ)+HQ'<6)3+;9KI,VDCWW
M0B771I/K:'^J#P[?KO%2@@FX(S=2U#4+KZ05=RU*==&>W(/S`G5)03+RP/[:
M=UBNCWX40JE9VU0/S21$`=Q&G@\:93VG<3]K=CV+0O]FCMF"[3O!FJUKUPL%
M>"N<%^OUO>R&A%U\L%".Z]";A1&MP+Q+G.H0>M(65"MH"V><TUA+F#T6[QX*
MXU]AL@(^+:DLM+;X[7M9+=C>P3NL,_X!"0S*NY9"//$7=K<!M<Q(1K&"V!/U
MZ'%6SC-[%/]V(4&<0L<>:;SH>^6T'5#+RI%,UV!&0H:--\K6!BX1G-&)^[BT
M*@KT%H)<AMN5MN-,!M,7G>S2.5NB7%IW&II!K^CFF=?:(,J%>QMQ'VTHLGNN
M[`0VN^S+2W:P3:00D51_X]`QAQ9R&+/1L>R8O0WDYD&-X\-7\)U^U0HOZVP<
MKD9!(N[8CTTH>LZ.-5<Z$A1YNG4?U+BY*KL?%)XQO`O\%@,-/Y<5_O(0M![&
MH/FB!]3M%<-N=].P]:P6),<TC0LME<)67]-0M5`)I7Y#2I&L#ER_"D%^3-/F
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MJM[TU&^`29UR]`/WVQL#`+NTQ#VG)1:E)3/8\):<;6FGF_&D&)0Y91]/7L$Z
M/[SQI!24]PW0GDMP+^LWOU6QH9*51"I4Y8`9&PI:M7UM*TZ=-A2BZ@34A$I4
MO:QAV3!B&ZHV]0!W6T`97+=);OWVER//AK)-$BN@E7>B#;6:VF,7>JO84*>I
MA]W$CE0?A1DF=N^SH2Y3?U*NEVQRVLLZ[9]EK9,9,E[9;@0.DBISPYZW5AN0
M/41N,$Y8;5MJRM#+N&>KK=J3OS=CA-4&JBG9X4O\M-7H;>%"ST#;;NXVY!1B
M0&VU=(=)%\OX\AJ,XNV=P%M;S=HA:R@P[MANR')S=6X@OK/5&"U:\8I#OK/5
MME2-36>(QZRV:P';KK*[IF%@G+!5I_<4>,P88;L2;Y,-@*&W59MWB`YEX&U7
MUBT*.;``"5O5N-Z:8HQ_1D<]"E.#5=X?ODNH=D]`5[QRC\4K30;)6<TYQ+>C
M@ECOP)M#?6=X*5(2W749Q=^3*QB$"/BIGG*C)=U`3GR@'T:@LNM[B`FEMR@F
M"B'X_/)K0LXX;_!LXNT]7$S]%*L*8BA.9TF*/'_C9"ZJ@-37HTPIK^.*!>DI
M%I0S,+C$(J1$$X=Z40]M"&!`?A!1]N1%5(JEE4-7$9;&ON:@RO8:]`+%(['V
MV4\E<)PA])56RG;-V:GW,E[#--]`@^"4!ZRQGY:B0V"6LFC;TBG`9P!I4H3"
MJZVYS&NKH?1@7F&E&V9'U&`5@=S!`$\()OA/3R!&I+KV4R9K<\+LO1!KZ`9R
MKUVV:%7N;G/)*`[WV#VL$M=DNNE8L25O![PK!VE2J#+.,N6W[X6[I>&9>SY[
M]>LXV]1%2^DJO-R([7D#[[&6(5?V,;8WTY?;R,LV&*L:-(J==97D^AZR^,":
M0EOT:QVT72U7>"5DVZ`KF.*7C;QBV2+%NZ%LYP4BO#@"_#)&:Q*)UX"GTY!:
M>+!EQESAS8!/;(%"6&<!\6@-@B+FA9\%M.5@9N`^SR5K&YAU?<U"=0>>`.1:
M\<W]S$!SL5Q%\0L`=X"F9V@S58(AS,!8TDZ_PD<0+$!0IZ7D$4L/:`;^*Y()
M#21I+C*^`I[6D^IJ!J;-V5%QSR$^HU(8P`Q\V"S%>B\HA,;%,_&5)M*>NB)E
MZD\:J]1@9N"^PXL-A3Z6(^2,0!KA5C<]6(I7)>09[I4FO=CJM8%Z6T[0FZW.
MUSA5*'4J'D4+AS=D;L<C8@J+=&,WZ"SR0F[5(K4QAM\[#UTXM1_.EW0ZEA98
MN7'/P>I:ZJ`8:ZJZ*X?+$.+9KUPY<(`H#&`VO@;-V&(@@_!>8;&4I!WFLVX`
ML_&UFT_10`;AK;D25,-9-X#9^-K-IVEWIT.7L.Z+RN_Y^0EQDD,QQ+]*%#1N
M[-:++?<UAF2FJ:\7OXIG32L=G*0[AYI%6#@_;/PA."R5[Z\#'=[NT@T\M@E9
MBIZ*=<R!)=%1)YZ;^1>`%@#E1S5G<8))E3:)5$?1B?0ASB]%ML^,&[#Q^QF!
MIG(/44XM+`N+/X`1^.X?8Y0^`+3,[!71L9Q<WUXD<WWMCUW97-M."U]1[`,0
M),079BMM#8^;@AZZ$=0>3TC@J.]G#IKK&"[(>I6<%D['GE9XW7/:%A#K,)KN
MV2DI<&JB*&A'Q5%T(R47VU^(FPXY6"*3$47`SR(%J"1-Y:1PAQ%-X,#6U;Z,
M2E4803M"A=)PS?UTH\F%1$&0S)+<Z=*+M-S-:+F;QQ*_XMR@G#J9V7E,';.#
M]SB;/4&AE')ZKLG%S,TL"A=>GLFG=K)41C`%H4!?<YMK*=S7E.E^NV`?M[T6
MZD5UG.KI%_30AX!3<TN`H+Z'%@2UR>!XQ-<WUE.RDA<\N5.C<J>A5GKK(A5Y
M)%?::J6Z$M#%(S=KI(?.37@T[]JRTD0+C>O5*LHS4!5GH%=P'J-EEB!/?$D@
MV[L7ZZ?\,/YU>IV-(]E37]#UD%%SE00S4C$*-J1GV!?'>)K(AB0.^UM5;:)]
M;,@$L2\.*GH8V9!'8F^LZ^3ZKS^CA#F<E`U<L:%,]=Y67P>G;QM*8.^+CPK7
M^C94R=:W_/C^Z384VY;.A,#J0=9>D>HOMRV5**@A54)3JIDMSFC/K",QP>H!
M%>+E+A>N8$.]F+XY(Q?\9T/5F+XY4Q>69$,%F;[Y(`K!LZ&L3-_\J`T;M:'B
MS%",V$2:ZJ]$(U2G@GB6(@U=-56$#9JR?:!%-<N\P"'+AFHY_;.!YP=E0SV<
M?KC!OUNVH>C-<#S@>A#84`%GR!?%NH(V_3-CUP?(AGHVW?C0V4/3AA(U/2T5
MB<`-&VK7],L-Z;`/&ZK=]"]3I'Q^;2AXTS]KFK+'&UP(IQ]FJ,21VU``IWV<
M<9DKP@RMK*JY==I&D0TJX5F,*]9I'56NJ+C8,[98IW&Z+I;Z6#?&$.OT3,=U
MHA2,PMADG0929%-SCB3&B['K'8GH7G9\9-W1B2(S5%*B,*Y8=W*B>!7/+6QG
MG3&B"'P87P<;JL;UMG"D,])844&N*?JGXEXK"E6QHNJE.EI.:)$5I3!5T#8G
MO6&0S3U*EH+,S:/#$&HZ)/98@NMV%?ZJH38%GI.3_.Z4/#A(/_I1C*76IX,4
MT<S$^8<Q3,%S>I&%7GPZ2,`BVWR9.=&R]6O;Z[+WYFZM.J$7&I`,O;D[ID[H
MA2=[#+VY>R0Y]&I5>#:X?S!8=W?`O5-3B0$V6'W+R7S9D$`&6=<-J"O'R4?K
MRG%NW*E=.4XSQ(]:K''U,+*<Y)PM6H/W#>I@>\KQPKACKF-*6^ZTR3O/^&'N
M45R'5T.B<B#C@+F':1TX(*ACQI`;?&#6'GEM?GR&V>#M9GO,-<&[)P;O+%L*
M.J5"C8P1!F\R6S*BL2H@NX4<I>5332+#P!J\RVPYTU+5-1D#QF?ZR2:X83R0
M,_`TU:.GJ5,>XP@3FY"3$^IA01T=22H5_!79")%WF5P3WN*V$'^78K,WTEZX
MGF-;E][%8GZH3VM!CZA`O>J0.I)!28=?NT+T5I0Q-K$PU'A2G1-;!-Q&GD0A
M#T[C?CBWGD6A?S/':C*$"P'GZMJY]*#:J/_VQB4'=4DVQYEDT_[$,=I.REYE
MXIC7%]ZOY$G%LS6LN`?IWQW0Y'L-:6^Q>K--^UV%\Q?KUYFBV[&"_NL+)IG!
MW%M':0,O;':QV)<W"3;\]8-U_B3.GZ1/?Y)]GC'3>_V'./>[)/(SAY#<H(4'
M\SSF9S%,XB@,LC-W&&"C(B%'ZYE314WG\S`A:FF-2+*\^W`!J0\&3$M.['@\
MGSA?8.(_1^0^PAT.]GHXV%.-V'VO@OK-\=[)<(<Q=AUKC&S7Z[8._6X=]B_&
MM)\GF&*5FF'-.!O$7ANDD^7@]+W3]T[?OS9][[2TE5IZXZ#*3*[Q*>?V`EC,
MGGIY+.[C3`RGBITJ=JIX0%7<(+2<!C9*`V=)ALO7-,D4!GCJ5G'^YYA5\[B4
M6LNYK%<F+0=SRMPI<Z?,1Z/,VXH4I^6-TO+<9,YL]IQN-UJW*\U@O491&L+I
M<:?'G1X?C1Y7$Q].>QNEO4EF?6\6(YJ^`4_>=>C32KTDIGT!>E'CG/C(=D^N
M"L(.`[GX81--$:>FG9IV:KI7-=U%V#IE;9BRKE0*'DXS-SZF5@TW]G(ZU^E<
MIW.=SGTM.K=9C#H%:Y2"[46K]B/EY#1O4VNG<9W&=1K7:=S1:]Q&L>DTK5&:
MEDSBS?P,@2!,+SV_R)[O+HKWFMVQ:19JMOE-79P^=?K4Z5/K]:F<>'!*U2BE
M2A-653)[D[;.#\MM"\U38WNE4_:UX$&0[>^4M%/2.B*4Y1>XT]A&:6PV1[1R
MV@HSA.:.N0,1;A+0=).T7L=G#R_E6^^%]M)[,-V19,X!=L=1W4&WLVC<QMSI
M_%>C\SN+86<)&&4)9.6V'KSG$6_7VPMF(7?JQ;2PBU/03D$[!>T4](`*6BRR
MG/8U2OM>>`B&<)'<`D2-)JT[;#XQ]?*.W][MBIW2=4K7*=U7HW0%HM-I7*,T
M[EF\7(;IUB&X5K7;0%&]V&OHY!2P4\!.`3L%_&H4<),0=5K8*"U,87SQTI0D
M8H/!64R3FP/H*ED8K\3DIJY>5\CU=:K9J6:GFD>CFB4%AM/01FGH\MT^2:ZV
M7$7Q"P"?`<2$I"3GFEYW,"7ZN'MH^2'<CMI$8\2I;:>VG=H>:D>M(&"=]C9*
M>^?>>+<>2E\>$)XJSR</[_?(VRFVX12%R@36:Q&5$9SJ=JK;J>[1J&XEX>$T
MMU&:^WZ]6F5KT8LV7U_!>8R6U!1S&MP2#?ZJ])L4G9QD,&U6?)6ZUL,X_>ST
M\[Z3F[1:[DY)&Z6D[\`30`F@\>_WJRA,G2[>;P(QP034J`9!:V<9N)VOTZSC
MT*PBH>`4J%$*M%H7I,>B3WU=+LN35R\.549P5\MN_^ZTM-/2H]?2K<2KT]Q&
M:>[[]2P!?ZSQKQ=/H)^<8$Z+.2VVOU/HGNCDO@8<DKGMG0YV.EA'[D[^`G8:
MEZ]Q?SXFCYAY"<!__#]02P,$%`````@`7(MI/]TRT.@F,P``(*,"`!4`'`!N
M=FQT+3(P,3$P.3,P7VQA8BYX;6Q55`D``R_^NDXO_KI.=7@+``$$)0X```0Y
M`0``[%WK;^,XDO^^P/X/O-R7;B!..M,S.].-F5DHMM(CK&-E;:>G]QJ'A2S1
MMFYER2O)Z63_^F-1#TNR2%&V3"I[!PPF;IM5K,>O^"H^?O[S\\9#3SB,W,#_
MY>+FZMT%PKX=.*Z_^N7B<3;09D/#N/CSKW_\P\__,1@@??1)FR+3]UP?(V-P
MC^/0?49?;.SAT(HQFEO/@1]L7M#86F`O0F/7_\?"BO`E@O\[*/#1E]OI&'UW
M=8/0.HZW'Z^OOWW[=H6=E14.`LKWR@XVUV@PR.K\G$CW$?WIZN:[JY\*OTR#
MG>]\1-__:8F_7[RS!A_>_V`/OO]A>3/X\,/BW0#?_/#!62ZL'[][]V.!:AAB
M*R8,D4,D_HB^>W=S,R#_O?MI?O/3QYOW'[__\%_%TL'V)717ZQB]L=^2PN]^
M&`!%R1*7R/#M*Z1Y'II"T0A-<83#)^Q<I9R\U`Z(F-N/?KDHJ/Z\"+VK(%Q=
M$][OK[."%W_\`TH*?WR.W!+!M_=9\9OK+_?CF;W&&VO@^E%L^7:)$)C5D=Y\
M^/#AFOZ:E([<CQ'E,@YL:AH!`1&S!/QKD!4;P%>#F^\&[V^NGB/GXE>H\.<P
M\/`4+Q&5X6/\LL6_7$3N9NOAB_2[=8B7]5)X87@-]-<^7A$'.E##3P-225+#
M?Z9?7R`H]#@U<BZ4PRZZWD6#E65M$R8>X#1C=7&=B$>_!.B6!,3/,?8=X)Q\
M"_0<0R7LP<:4*;`-[!)##ZP=A+4J4UY+*UI0AIG(@+QK[,6Y$A2+@W<WF?+I
MUW_7;)O$1AP]6"_6PL.:[Y!OPAUVQJZU<#TW=G$TW(4A]N.L>JKT+Q?'<+C.
M-00>)1U#'`6[T,:MC`9<3A?K[]X"N&P\P@-:,^P/'F<7OV8<4,H"6;Z#4B:H
MP.42I7Q^3@3J5D?2Y"Z""(_EJ+HMJ&JEJGI[+G4::F$9K%9H9W*2CPTJIB6N
M[8"T2-MX4/+H,@PVQ^$L$R@XWDC7*H+1<5QH52WOP7(=PQ]:6S>VF&YGE)89
M9/4BL%"6ET90'+D^2@F41<ZQ\F])<=*3(ILMO[2XX(.F%`,<=7N$]WN\6>"P
MG<M2&O783P01BX`!/P(4(ZCL!@$<%51OAR;_R8LI1MY]>/\N&9N1;T@U_[.+
MX@UID:-YP*@3&G$,WYO+$<8;[(S<)]<APR\MB@+;A<':[VZ\GJ\Q&7F'&)A9
MWFQM$328RV&PV03^+`[L?QA11/H"P]>?[37Q&#:7#T0T3/H#I^+_7HG6,=Z=
MP-Y1.4#L'NO-#*]<.C0/4+6_,?)H0[F,R%RB1$J4B8GV<B(0%!%)44%4E,@*
ME(FTB(J+$GFAEDQB*)++?)8^KJZ!>@V.RLT?+)&3F-_)S&_MS?\-S!\3\[L%
M\T>)^0FEG9@_HN9W$_-#IQSX/K8I^YP!SEQ"R+:9=`GE:8X1F"S^OWNZ=L^Y
M>\8^^:C8`?=)KM[V\T1D6-\RE[];86A1IKG05*EUX#DXC"3$I;`HK[P?%]53
MH-^.#_OM_2CY$I6:)D['G;<LF6Q0/I,.*LGE0T4!7W4G?:H76K?Z!=-^*YBV
MTH!W8MI>=+.OS\"OL:-LVWZ?JV-LY6UY'6%)3AU2#1%51W_>NB%M\$?DU[W4
M1\=%ZXIZV8FUU>+TJ65E]IC7";/!?:T(JH6OLHI[V/5T9;NV[1[.348(\-YD
MD(<MMH6][5)>H^'ZTU4<V\*UZPB.\I&:5?)F;8:!_X3#V%UX>(07,:B4?`4Z
MW6$KWH6X@N;.V4M=>^]&9D;<&7X<N@0.-GJRO!V-G`7V\=(E@/%@_2+E@I8)
MF]I8+!2C:R&Y-"22%[6Y8GGK_=T"JIP:Z-`ST@95=Y8;?@97F\N#]9!D"80Q
M]MNOC-P%86'=Y-B>HWM!^C@HZUQ+L74%JYR_1?O\[25:$I'VT5ZSGIFN7S)G
M7T>L;*)E$)862:_Z-P:4Y:J[<]B_C>U[/20Z6_O4:LAT'BST=4AEDNAE;T(0
MI>_9H(@*)12"?9].'.W*MJ.5O<GZBE0:@73;-(FM+?$8]9+F._HS#FTW(O%*
MP\W<PO?5!:%SUM0S]+<4GQ$G15J("O(9HS?)!"%^>S`7"!)FA0[,#_P!WFR]
MX`4KWE)Y/G"UC;)C7/.ZXG&*_[ES(S?&,QP^N39^P*$;.%-L!RN?<J%=:^?H
M%JSV542JF"ZG)QEI[8/D($JQ_DN42X!2$5`B`RH(H6XSJQ*[TK!,C647F+[.
MAJU=E';3RK4P?Z^;O-NJ8L46NU')4U%]8NU];`!/4ZG-\*5YT/*Z!BS=0/&H
M\.[`:;V-\L*6L#0[/@RB@Q1S)RS[%H\,.5D9A&SGA@V%>A\R#7YM'0<\8_45
MW&F>+Q'[!*24^?0,QB7AA-:!\GU'M0NPT.`IW'YTLG_;(OO0?LKA#)V';[L>
MGN#8\,D('(^#B'P_M*+U0QC`;@'G]N4Q@FV\YA9.W[O^2K-C]XF>>=0641Q:
M-O-T[SFJ4A44'<DO-L$,L\J0CV/(:)#JT!N/5/@6?K9)G6@7)5OB@ZPR9.6U
M?>Q-0'6,,&;,=>F>CE/'B7"A,R3Q_T)J3=,@4PR[<N`\<2&G74Z!:'&>-N'G
MX+JI0EVZMQ/Y&:$%)["LO"9^+I=F]B![X6`[Q'`!!?TM$0I9&S@%#AU;F`MV
MD!N,UQ:)V`C9'ID7N4L7PVXK%),I4!!:X0N"07S\HBQ;>TY+:R4KA[2>9#M+
M9L%\9$"F,"3JD%ZT9'&;2]6JQ*;%++N?."E-)466A]5NY_N_9%7)B>U.6\^:
ME'5WKCM^-!=A^VH5/%T[V$T&<N1#=?Q&OOJ[1@1V0.@[SUI5$'GXNX21TD&E
M+`QG91`44H$JIOD`$O5J*!F=1Q%FKXDD/\H<`=,:61VK.=?&2)O-]/GL+-U9
M')`NF9NU.$4\:</ADDM+`]B]^.JPUC2'*Q>2CKVF>5-/W,N=IQPJHL[=#?=Q
ME<I(=S;_HJDY-`?(3LI`U@&?Z>"+8+O3C;1R<<J[Y.I`*>4H%6J;JF55H;:A
MI1H^3J?Z9)YV2&H7:'@V9D)">0-VNXM<'T>19B=Y,-CC`Q]#C$?!QG)96>!F
M.HF0:12&`9^,#A4(+U%&BKXFQ/^M$E;"_BE"3,P>?8';L\L:F[-**X86$:$%
MH-!7(.@=B`I6;X).IJ]*P`R#S<+UD_0]WEIP9;'WDJ;I_X6=>6CYD45/&D3[
M3-'(C6POB'8$%`5](/.I)]LL6&G%<]>J`,!G4H41"/<X7.%0?;)=$GSJ(NB<
M!E<1B6G"=0PK^.;"<U=4M8:Y3P.1Q#C@2\(:7Z89#(^F+8(]V64^"=D&H>K-
ME6*>*6)4P!@]@MB$F.`8E!7HU`-M+TQ[K$&^&HXL]QYRAYX20%W%,FJ`%ZW3
M$;)S1Q0MM+U,+[,II(*-*0839M$:62D)9&(MM,A&K?:^RU(+KD9OE&'%MX$R
M0/D._-&)-$^6!SLJM+B4$./YM)%6-LB:!.+"S7>2[35X3WZ61<8MW;VK^PYO
MH?$D=;39;TB;C)#^UT?CLS;6)_,9TN9()U^9=^A!GQKFZ(RJS6(KC&4K=ZM_
M,B838_*)KZ+4YD$TM@X:"B';]*?)2/:CT]/=I-<<I3MH6CF?P4)Y`U(O%VO_
M]F0XU;69CMZ,].336V1,4!UDU:0OU.NH-O[X0&T.0XZE5$4C]]F#0@')D<1]
MT``*J`8'^YV"BOB=[`D=!AZ1)X#-IT_PBLS8M6&A1(-]X2MZ)<9^466.G^-;
MCW$=T'&,9._O/$I*YLFS`B\Z2DNYH0([M.>'O@)'1%G6+FB?!?N=JSTVAOJ$
M-+/:IZFNWZMJ3D\';[[Q[GCC*&E:2]*V"=-C.,ALG,7%8@6D.1YKM^94FQOF
M1#$^3W!7J<EO:10UB-QLW.30`PQ,`A_.,6#?=C$K,\FCD(HXIAA,A-W?&_/[
M9&I'QI1#<S(G,SM],C1TQ3!K]$$95GS-%<.H35O&)5(#IC8M5HZGGJ!'N%UJ
MU%85AM(3ZOSIQT$YR4@I5<Z^V2!_C4DU.FJ-6@7$H5**,?!@A68XB^&P#%V=
M(K-D>J=!LV.8E&IPPA*'CQQZHN82;:WT.$U/0-3D%0:LN#90#+3DTDAM%Z^#
M$+8G-'OT@$(-L*IB"`$JO<+4RJEZ`BR6%QB`JM6]%T#B7MK`*JT20-P+&&K!
MDUR_T"O@L*]2X.G;"\"8NSB*+=\AHWA1EQ5)5$*G($<;_`1[LEZ!J,837"15
MU5<,)VYFO5I,#6RX.=C"D/D2T9*7Z4.FJJXQ;">YLKN[F[#``+'BI&_E;M7T
M3K?;Y.[:!V+@2&`!09R%7,`+R\6`E'[_,#;_INMHJL^-*5T*10]C;:(87JT]
M5H%>.[.H@67V^D=ZRZ]&;^E(3^UCYX;I\R8ZJ0!L$(:90JU>`<&YF<3.N"'7
MATN$>M,("CJP#$T1@W64M"V].".<H6VDDI^.;1*)V5WNKQ`!RKZD65^C.IQ!
MS(E:F9//^G1NW(YU--)OYPKSQ*+Q4D@*"RFMKGO)16O>W\\L+[T[J1%"("+@
M@3'T9A+$&/WX5GV_P+'\87_`TK@'P)EA(A"]:JXA5\*G4@>BJBB"C6N/$,1R
M`0='M4JK05-$L\?IT3IVKK]23"I>RG7S[\6`PG0;5WJ+N**;/,X@M#QTUT.B
M#.<:]?J`WX:;/9C%%>*YZ7X/<Y;N4]&_/,">/;5W?#09G(<2Y3=]B,VSFDI+
MQ$J[H?K8G'P:S/7I/9J8<WV&'K2_:638KA(N`B-U$5U5@<7P"6+I[+?0@=_F
MS^Z*/F=\%"O),&LKW[F>*19YE%C<&*TO8'VM)I$9T,=&137:C[)O)VMO(_IN
M_2A]MCXR_?(-K'4+*$TDLE?=&N1A8#&A0CD9,GV4$[)WJ9UOM>TX-1ZF^IT^
MG>HC-)N;P[^@$6P2'Z&1\=D8Z9/1B>??CKNU69XF4I;;!$,D7VL345]--YY(
M82[)7]=?\1X'JB\KM2.N$8`9RFG4NKUYUX=KZW+KS])3)42FT!.1OV[S<BR7
M1`%@ZN1HP@W0H(3H$NW)5.VQ.$45EMRR@<]#4!W^F;JJ#8,G[.\P_U8K1F$E
MT"]*T(P46AH-$`?N\F%39_%ZP!PHVP.HM&@NJ^75`::Y=<E&9E/]LSYYU`EF
M)N8DO6^W1[`1;6KJM%8#GFT0N7&4W`(L@!U&<:G0J9>!B9P'<V:H/0[69.4R
M1CCJ*8)(B&$)A$Q^R6</IUO%M`W<^_:ONDEQ*U*YT&F4A]EI[4EI>L@JT"C&
MEK![*C@3LX4:S(7N$SVB/7:MA>O1]&S3((A#(A5C;#F8V,I(D)?2O*B%5+/U
MRU!J4%D-A)ZP%VQAW6X66RNL^S$.MZ$+E_G`FF:LV?9NL_-@"6FT@XEOE8+I
MX),92X7CJ=(R09L70[0<VK.^1"ES5.".$O;H@%!95N%LEDETMPJZ.XGNR;.#
M>_TCEO[R0KVK*"DW")V8MJ/TPJFRU&[FZI:W_(1%-X*?O6U`7Y.*).\[/KM]
MF!:`%D*HA924>.@V>`H9B@X-K&1XD>^.,)?%,S133&6FB^CT0.*M%6'GP7I)
MWC!NVN9R(E>9`XO31&5%QGZ;?K!$1;XH98PHYTM$>0\6P!QEW)5N[3^O86A&
M<G"KS72X).D>=I_16[F4#AZZB8'2R*$#XZEI#M)<*Q&)/BC+GZLR2DL-WUH1
M6$\PVG:X@V%L1J46=EQ;E^'$UK*;T66E`M-G/B5<.\YH02Y]C"@N&[,QSW:V
MI"S@^6G.6]62'TSO4L'B7`\.7*9W*BR;#FCN"ZH^JGDLG/=#NI;F5-M,\T*S
MJ;229KHU'FF#31!50:"JU18IBLCO@I@Q(:)X-UU0VI!G?RW?(;,I-WXQ_&40
M;I*3_?5',=K32^^$6@C'PE)*B@8H_P@)G(0/*C!"7S-6LI<;>J2EG'[F",SN
M.YJVUCJ^IXFP?;4*GJX=[":=#/E0[5O(5[E(!0G&KH^-&&^J^QL;BTOH79ID
M:,)8"4U`A2B9$CR)FA_@(Z2W/+0\9,\#C4C'R7%1N9QD?)0J;P)&4I@T.@Z"
MXJKQ4&O@*A`.%92'@#EAR[$]_5FROZ'.)C=#&=6^+9JNZM)<!Q5S#-T*?==?
M1=EUJK=6Y-H5@_/+2IQ?U`K`>DU:FQE#--'GR)@,S7L=O1F;L]E;I,WG4^/V
M<0[G&]'<A.7)>W.2G*'XS1R/].D,GNG*O_]-FRH]!\EU4''HSC9.;W"ED6;+
M]7;L>5<3E6JL[47AH@[.7(^,\>-<'U$$`O+^/8!WZ,%&"%9LU@<PM@-A#\#'
M!UT1:O]>C5T+K/4-8TW)4W9YA3AKRNL=(@S0TSO8<)-V?)V50">]QC)-&PIO
M(FVFDPFE)F%8UY2F=(,PS9@7*"_14.W)LF.5RC*0=B$IK#1`1!%6"A0AY<\_
M_:3+9:36.>1I:N:"Y=\E34!+E;*@G99!7VDI90M.M0;,9J&'BDCRZ,N00"BT
M/,-W\/-?\`O+R`?E9'JX6CG/TR\H+8QH:42**_4XR\`ES]<J*`L!HV!CN=5,
MRL'/4OV=U,EW\]>DD-IXKABO[-2"%K)\>>=Z.!R2CF(5A.Q8+I>2ZME2U7P'
MTZ(H*ZO6S;5V+7O[4#-93I_BE0NI*S^>6!MFWUPM)M7MY;KY?M^715!8K>/K
M;5OV?(UR2B8P_]Q!3T(&NX%/4YTUS3J_K,R)2IT`+%S0LB@OK+3I%[)V:0#/
MU+23K1SZL[V&!VEA[VN+780B9+(W;@C(Q+J'=8W1TG+#_0UMR<ZYY($KY/K(
M)QZUHC5:NK[EVW!JPK)C]XD.NB7O(3Q>S8P2%)SA$"8U([0,PNP?>A_V.[5%
M9;Y'0]0N*MK6.P(N^LS.?K-YX\$,/HW$MI8K"`-J=YHQ19^U\:,^0^8=TF8S
M/;W&=FQHM\;8F"M^;%G((\5VN-D*2H%E+I/;&S2;]!<A,RW"+J\"4%4A6&`J
M-<T6)2'M;T(#K3/.&C9HS*+\<G7XR4*+7>3Z.(I@'6]!FF_5RWB-+JM%7:VI
M.AD!%*K8GZK?W\U9UP4UD<CN^1ODX<&*DB%SB0HW(NPIY?;L)ZB11X>S5^.;
M%<*D0LG!F3;(RGMP$?U5-+*?R(A['$21Z<\LCPCW$`9;,KYX@:?*8AB?;VL"
MI26QQ.973"+6)>.$$';&.VZT#2++`\PMW6?2#B?MLJ*]_M)UDM5;M,->L>MH
M81(E085]'%H>7/_C;%R?KH!`O*>O!;#\W$`E,XSXHC"PEE(E]SF5Z)2B3,P9
M)7@)J*\$5T'@P*L39$[[Y-HXRJ:%SET0)FLI^QZ%^V;2$8QDHJ^U=*P;J,-@
M24;'9&1%4)EQ4XK%HQU8@N=Q]E&%V&^NQ_,T_5DRNJ!.]D(23*C@K"FI=6U%
M<*Z66!D%3SA$/H[K)FGB,[&358MQR-\2TJ3?EZ$^FZ&'Q^GP-VVFHX>I,=21
M^5F?TNUYV6K&\*^/QE0?J0Z6(G:J(9`KJ0+8QF9+1O008>;2@$-3*UB22^:Q
MD*I>DFXCQA[I-!R"*&\'#Z@W!,-)+"4&T"ERLMX1R5E"X+DYTQX,4KMP=!&Y
M)UM/"=I]TJSA64QF*2!YPU-DK-(R,5HO`O,9&RB-\N**SW0*6KV$*HZ^Z@`S
MMY[%WR3CDDB'3KT<+/PD.X[GVA>U"_\B5C]$#4=51=`)L04WER5_#5^S;7BI
M/+L)`Z9ER?;5PHY/MC./8287;D=(R&[(*!/T)F/W%H:G&<?\XAB8H6=;@`M<
M5>UB[M0&N;+;@K+9O1<>7UF)@7H"QBLA?*SI^A'<V27^Q\1R':W2T*T1J%VD
MYH]Y]#(JQ=7KS?,UK0#'#RR6]OV*H_0QC-8^S>AZ$3^I,((OWO037Q5'B&&K
MJ'@_<,4^9"/L50X+I6ACR]6NT<[XY'>J]K+Q;JUMW\Z('8--?M0UF*0?`5C8
M.?#HK[&SPD[=#@+Q<!1FJ#0X1:5D@/<-I(C?(B]+?XMM'9&0S>^)INJ"MBV>
M^2'<RGC]"&@#+F?'49Q.T":8LX[:3*HT2`_E:==S9O39PL0E(BSZTV4*JY=U
ME6Y*T*^(8P..'UL,]?L11>86PZ8,?S6TMFYL><TY"5$&2B.*)14#>$.:^(?=
MP!_[A;DF]_"1Q[5"/_#W$.*MY3K9Q"W=&J3YCAFO<9CD\X2]+L1,*2Y%)&S7
M]J<<4<J*+M-29DA3N=NR4]4S'7%"$U$E`ZID^@YE'S+<)V&;'\C"MNM'4$])
M;Q>Z-CR-845K8814R)0&:ED6;K<!41CFQ1$<`NQ-T'6OAKIPJD<5/W!J]%<3
M(N4=*F0,*+R=2814:J@TR\/,[\^UR2<#[JA+]L>IQ9>X2\H8$]1?$<[H5"/9
MD9!V$Y/`#[*!(&^6+$`J%V>-\C!'2NET.!TO7,)^4\58$W9+!6MB-E")M0<R
M,&GP(2VB`#M0;Q-&8%S5!VP4S5B'@5P7M;X6>$>,45B)_P5>$3M</%-\&6$K
MZ?NU9,9#23VH3WP`K2MX/Q%ADO<7H*7-Q&,ZB%%<*L3K96@"N4M+JT4)W]AE
MG'"T[.1HNQ%%.XO(3!]VW`0^O02$3*Q_3Y,^].K8Z@I4&TK9!]W%Q&+!)"6&
MT^X).:+TB#!`&8?TE=/SY.3K,-^A7I4G[>A"4I;?0V_<[(V\M\H.Q+?#8WXN
MOH5UI(0-S24>X\:$L&]!0Z5B8.MS=J^"*P(RR3=!G:*84-#T-E!*"!2.D[T]
MSA<FAI^=-+T+PL)%5),@;M'3\+GT(H"X(K8%7?4.G^*+K3XP[$%@=:KP;IN_
M2PM'K^%WJF?MAGR5P_\3D<Z/S6:3*IDPY*)6&Q`B97:>W`R'GN4>/+5W'`^9
M4XLV@@F@.H$SQ&R,[;4?>,'JA8(WZL%5`D=YLC1%:6VM\U_:.\8KRTMNCM6>
MW;JW'JLE)%W56ZF6==D.E,K>"/T*!95=P<VP9'8[;YT^*MHC*L>]%<.M!@2!
MI)V$U6'LVV[S)9)BM!+;'R&!6-`QYL8G;6Z8$Y6-2BMW%!L3<=65H&R_L1NN
M38'F;AUX#I$UN2Z%Y<\F,IG8:I"%=?NO.=?^M[QK:V[<1M9_!0];M9XJSYPD
MNTDV9Y]DB9ZPRJ84D9KLU#QLT1)L\QR:U)*4)]Y?O[CP*A$74A0:<TY>,K;1
M8*/Q=:/1`+KOVGE)K]':63C./2NXM5H[M\Z:_((7W&(Y3-NEM_Z,G-\V;O`9
M72V<6W?N.M[\<V^$X>RA%VD1QK+8LMWC-Z:?FD#NJ*:.Y&S42L6-3FURB[14
M<9OS_PU.9;=!!\D0&K?$AW[!N^\UX%"U!$)C^7FM/*NM1_+T>B(EG"P3L?Z`
M1U\FLW'8$(IWA$V1CK5%!*Q.\N-YV/*!VJ7U`NK*U-=[%0DGC#I.$_(-@&?)
MJ?SDE?^F1+.^&W-,`(INU<.3#?%'O*#M6H.^0%'+70X8F[P*CPQ7UQ*VVL+`
MI6%`:E?B-'EZ7^#LQ2J+.#7S`&@_!8L`Z$=CM0;C^O:QAP8:\ZH-W=+[^#YP
MUO<VVDGQ%"@1=(:U%!PXWT5;>D=X'3T]%W3?5R=Q[\UCK45B^BA9P8\((IP*
M<3)VO%03HB^<M/<4X7)'Q.,&$G.J7>NP#.Q05Q--]0FNSH@G@GE"CXDSO(N*
MVW!;*I;HI$.+Q#S,I?P(89ZP33:G0PTA^D))$:,UCO-1(W$]A];]FJ^=A1L`
M0EP+22V(JP<+XA,0WRH@KA6[%U%>JQ:MP'U-37H`/=\7@,1K7WAASWC8-9ER
M<[U/,_!`D43LG>5?-&8(K-SC[(D>,-+,^WE$14B-]8*5MN$_#JA!.+(S@W@;
MQZ'HO07-Z.^[T"?,YTUA&YEG2`<"NQXNZ$O>59:^1CN\NWG;$%_)36ZKHJNS
MNN:J``T#.C"(47VN1($D6GIV7Y*CAS=T=<A9X/U=;T%:F)"!#:,TI:'#@=K6
MRH&2LEL3%:&)$1U9J9FJ4._,_Q7=WBU_]]'M>GF/;EUOYLU=[R.:S0/W$WQ,
M8_R$CD,N>*Q8P"I_=';&6M+7`3QB>[@:;F6CJA-;UQ*CHP363`E0-312)"F[
M-7'<6B+KR$K-'+B6N-XGQP_L7TLT)G0<<FU=2^H,?&/7DKX.X!';PY7,RI:&
M%=5Y2VQ=/2X\+F#MDX!10^M$LK%;V\:M%[*.K-2^@>O%<N6L9]_`>J$QH>.0
M:\-ZP5-:T/K;XNEOM3&+N^;#HM`\KI*)H"N:-!WH08,6JTZ`RMIR5W=+WP>]
MT]T[\4<@/AH1.#YGKV$4TR.+(&T]S2VOD]^$>;35F1V-7J`PKF9-%UIH%@1K
M]V83L!<'P1*1O]TOO<X[`PLT!7[`(/JF#V2A1FI*#D9GOY95Z\A:1Q;!A/QS
MBY55[)5D1K52SHOH5&[W/P>>)RIG[PM(-ZCI!W4ZDMX&,H=*O:GJPE!#-I-<
MK_'2A/I1;H%?<O'%L9Y6IB_1G+(@O$B0(+9E8TV!+H1I<TM;Q?0YC/,'SK91
M#I*O38&$^D:,8%0@!K"5&K63,U5D;83M39H\$1/2N]0\^WWE@)>);J%\\`N/
MP)A15L&G8XVE@[8*_:H8B)+.!FU01#B6P:_.NO9,G7^L',]WWL'&-'3G0PM6
M\!&+UM4U^0O#OI9&(73R>;WKA1;=*Y0(NXN6_J%.Y`62SH.T/+D/8Y_X8<S=
M%`55=:G,>XDJEJ3X*%)4DZ*&%GVIJ(V[D0##,>1MZB*NY7UJ"0/"8"Z[=EP2
MZ.UK:=!@]GQ>^!#+[YX@+#V@:-;T/)LR[1)8M$V[:(`@2,Z>PB3Z-S.P\S3)
MTSC:L1]FR6Y%IK<ROLO''CULK@_3/"314Q(]1MLP*5JQ#-*?3J8RXVR8U$'#
M8Q,M$;-@LV;O<FXVONLYOG^-;F:^Z]-?K=:.[W@!>'HU*#AVU!-BOD!TOZDP
MIWQ0W]_6I!;U,2#=,<(7HI(*N`,YX>#`<'&Z6Y5-3$]KT]@X94&`CGNBHC@F
MO\+I`?0NCT+.)P`1C-`BB,ACL@HB>,#(8YO+5E330MA(`IH:PP4#4<\-'GKF
M<!NG7^M553:+6O2FH:7#E/@XZSTMT(G(8E#$_%B3I5[[UX&Z(7B'=N%+^`1[
M"W'PS)V@45M"$,!<A6_,F;M-LS7>$W0\AWDW=[U@\C4(#4)1S8T`@TWKX](%
M0`D+#8W$E/KHXZNM-YI"@%28Y2-_<[S&,9W->9H3=K7?[P[M!4"5-%F3ODNB
MY<ZCA%AT?*"@?*213+*=#..R0I5UZ4+M';QIA1V([S[M'2)$2%4.4I8W(,/'
M59$5(!'3`:BKD!D!1DLZ=M$LJDEHKEO<7P_+H/9=?"RFE4F)L#[UD4O!"H59
M972?5;RM8AKW:Z7*TIU@<0>0*B3D2H2_TD/)F9V/_B`[%[OTZ*(#`E,F)?JD
M6B67B17JY3^G64$3+C459+77I%Y:2*7J8T@'?CFEXPE7M[1L&CUD*/B?=IBE
M][%%R\R.$$SM9*B4:IQ0/I-<]%EEN)7^27SAN[>=Z<L\?4R(H))AU&H+=.M[
M/,-@]W!D@*AOW@C'!;(`D+YPEF%>Z&01T?>?R2[G(>PZ5NB^[,778`=U87(Y
M&,"7"%='A6\6[B=WX7B+,^_NC+?_AH=DS."/0&''[@^5BT6JUBU,KC?A)0V\
M,FD7C_=Q1I/M.HAT@?$+J\/;KD2\K_IOJA;ORRTVH0ZW9'$[Q/R`IOHV<-7Y
M0=.J`=;1E>8O@4[IN\?>IF!85#D&):S\N@)[)7%[0"-^NB@<*CQ$5F&VS)AM
MW;'B[RN<,0AK39J0&`Q&(HZ4P&+VZII8J[*4ESVP4LV0&&A28<!#CYO*V:$@
MN[OHWYK>T@D1&-2..=&S7=?5&4Y8$]H#-=&,B"'6*X2I=N4GWUG@/'I*>CQK
M'0J`G;J$'5VT<#K4$!K?O4\PB!+R.^D@3&WM-5#5WN2KAF^+':5N^B`;6A(`
MVT_.A2Z0(M;:-H/9%;W*6+9&;`MVEH<B+XA3'25/`Z:N306,HA8KNIY>VI#8
MAJ>>Z5"!ZE@`\,AB'J?6%/*68`ABG]=#C3U`Z4A7#(YF;$"`H'>9JA?\R:[U
MA$/^A%Z'TBQ@5.R(`<2N<Y7Y/7AE-I[ZHWIN;\'YN/X\'4%-2RHPT(M>B8NV
MBD.-#&""QD8!UL>!$%.L,:I;PV)')N@N7(1CA$%(NL5XE]^2X<R;$/8"/XB-
MDIC"*%:$;`@!PRD0G3KF0U?Q_';L/J&I!&"AI)R1+I[D<H`&575NHO4F0DD'
M!+!>9D;`K'E34)>QJQMLZ?5>6X`GG341_,12L@>$50D^30,G(`2'89L;+1PV
M5;?3ASAZ8N$Z"]'6-SUJN)U(8Z+0:]^WNCL+XNZUL/Y[F&7AZ1W#<WLS'[(=
MR^IPDQCN(YH&D)^3?WV.MG4U'I[#-43Y'F_IE;[ZK!P5SV%!>N$O1(J4_(QY
M;+7,OXL>,"'%9)/QUARPTX9M`URUI3L1_MTB_%^:!RS#6TPH*'^O='_20Q,E
M[)OX]>C%);U>%C(&B3FG;UBBY#%.OYX..^/UJ0E+]9NSZCOEL4A!&=EAJK%1
M0C;>^RPBI%<'TD<<OY410-+!$V:[J*]1\4RZR/9I1GWB'5&$=Q],Q\B-H::^
M?R&[=,$FMOP"6VT!H^WG&I)6)/XL(4.OPZUWB6R7/.#!W\!>@%9H#=9$;]Z>
MR4^8FI9=A6,[7<,!<RA:N76E!`U7/XSQ?5@<LJAX8UH5QWC+\_FPN]B%WM."
M,WH$@O%`-K4,N.6W],^?=A':QPC3!N33=67@\[0!/0`B6\*6'I))'U8][!H^
M<3*LJL0#CDWJUBSW;`=;I<87G_BKZ*!PV,>,%OIPV9J]?&*>;KJW:C<OG1\A
M\(3R@(9;Z4!73.FL\B<D0"`[YF,POLK]DRW($DV%"%2]XP?"4[]!;7)`JM*>
M#NK"+-ZT^1+@[];]A[.P(`?CF%DZ@MXP45@%10]+W#HQB0U0(WQH0.L:>4Y@
M);Y:HM?"4S7>:<+<AX<XVBX?'W%&=N"2=[]][8R'IGN8$#X1ITU1U1;JW>]H
MAN'"E1)`-(%(T;@FP>0:;V.RK^(Q`K937F!V;R)ZQ7=1^!#%+$@4I+/=+N))
MH59AM'.3.3]/Z)N)L_LTC?5S&1;FN>MV2P"'FHY1JV<4I*CI&]'.D4LKJ+'N
MS>K1A81Q&T;E2R<>AZK%4)T<H*S^,#MO06$C$'K^]#Y*ZD.LPSY-V+D/J]J&
MH:NV3:5$M<Y/,@<7L@_5,4>0GO+TI@<H>1?PVB_E;X"R5_U0]>Y1_#=HQ9YD
MG,WFE1VSMC0[KKI"5SG&B):.03^`/+H^!\H2I53+#V+?L<9/$2W%0WDLSW]F
ME,\G=@OR8Q@E.7%Q:8$388AE4!<&]R5#^!*5ISG)V=Q"YT^@*0'&3%Q[%S-8
M.C#H9/D85B'9;@6$N9SG&LWUXS-#>C"*36VV1*;5N9L%9!.]FJV#SRA8SSQ_
M-@>OGS1BPKJ@'"86&$SNZT2PU0VWTI.ZPS2?<W.13SCY^CT8Q:0V6_*$I3E*
M&^\[QBQUM_QVH_ZX1J<U`AR=.>4;C,RN\@V3D"W*)[DS+&P.K%:R^\$ME&G?
M#@;2GZF'`:DHHJO-TG'#J$".R5B?B7>VP*\X3EGL65ZW1TYC5!DDC`@WD9R&
M71W=-52P"-*8A"Z,5`,'PE*115N:Q3[,*6_T?_0\XS6,*>1GQ9SL6M^BY$GV
M8'IH+V;Q-H0U,0++7E@<$1AX8V;L"(J#90(#SB*DE^R=,$L(,_FL2="WP(_1
M-A*O^DI"HQ!4<2-$'2=$%26Z:M&BDK@W"''V@%YQ]I#F^.X2XVH/8L=;PFJ4
M+LRZ2J0U>AOT1OJZ7-`84#^DA[$]"F`3=L3ORR6CA,'(*TX.F-[&^MCW-D[<
MSB@RCCXN``7[HP5E'85"[0*A;U`3';\1LYUCGGAG'T>%*#BJ:FW^4$W$BG!I
M9`1EPE5&@KY0(L2H#%\F&<S^:KU<+7UG@=;.)V?M.V6:;']UYX+<A-)$3^MP
M2SI@"(-&;\CGI6Z)K\P=MS)HS(X^+8SJ?W*\C0-IQ022;-NPOK&`3/H6)V$6
MI9ND?(U,G*_TA:RSHCD0MC<)!!$3`DA4[:]1BP)]X32]ELX84E3B[V!&.NQ)
MUC_^_GC>2K=R\@*W[:973]#%=RO/Z]#T*GH6MR+P\2?=<]3J%?4E/.\XYO7C
M?IC+G?8)`FQ1GT0EZG7_?,&"K!*<ZP'%!V04)E<*,1M*E/))H!>K)(`%73S4
ML])9/A2RF'`!61`8\W\Y&I@90`BS("BXDB-IP6Q:G=CCV.!!VO=QXUHWI6&.
M!],9LF.;W@P'Z)'9UI'7A%KD3.V&C>T01NM&<BO71BDH+77#;!($L-Z>J1)'
M^GR.8.'<,)TE58?"N!LV8O'4+40&[X8IUQ%=68``B^9FNPES3/-KT?L4?:99
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M%TH(>QZF,Q\=?"EE``JKNRC!+OFG$DM-0P@`U5]7H09]H4T1:VL'4$XDW(N.
M[@!!(;%\I)>%;^/T:SY[H,]'M\*K%C(2")CT\*$$3/J(*!%B5,3"E'1V@$<R
M%[TP$@D`&%!EEN$P7M%DLV2+I0\L,2D,P(3\Z`"M)D85M7V`4\Z5`'ARP0`#
MT&_5$.`+L3X");0P$!0SI(/!-O6?*Q_+.A2J)TP`0X5P0'%8W8_2\=T[;2%P
MUF9`[:M7K6URT?O$W8N:DZ&"HB2@9PFJV>&-('#!OJQVPUDS.W#0$6@O`)HQ
MP<S\L<D2SL%)0Z,(./ZZ``5!6M<5JM<9S->9*_X8#"?;MTM&5%718-V1=,/!
MH"%@799/8L`7X;J@4SP)OV>`Q9PA$>EGUYCTCM@.@Z+T=NUP<8?ZM?1)S:_+
MNX6S]HDK^]O&#3ZCJX5S2^/1WOSSN_^V"S9R%]9"O_68)9H333\OESX]*,@$
M3&EAKL&:74A33)0<>#*!V(%#5KI*>X)Y:U",,19D5RB.-N37B%$`Y0$:QC^+
MGK*"D%&"X@@?6(&>C*=UHVL[KZM(_ABBAT,>)31%[S9]>8@2^*LB<FC)]:01
MBD5:P4_1ATUL20.O(9R1"^'L>KKK'%-K%NRX@96MBU@-E6M)"TSQ7%8%]GO9
M-%=-3*M5^5VMM.OM$KM595L"%OS'EM?$I'6`"YR0"1`D:0?'T]%$G,"G+0U@
MM"P.M&##BF_X&89G6X)J?EHB-=E:]#`XDS,E`*';KD/=@:#(B%EEPX9,IP"0
M&F*S#JW\,4+.,IVW'B;X>$L+;(H+")_9J2VX5G(J6K]K.G;7H/5&H"'])N"M
M/?_:F-<3J76*X.&O[$^C`-\0VP+LFJ.AUOI;`.W)7&F#LRL6ZT"HC('("6T!
MGRRR(',3.BYJ76_D6T"D/,*@EM,T#WAEWSIY:CAGPF<_525.CN9ZHDZ-/^0]
MEV-93`_QCA'O&?&N$>_[Y$$KZ1[Q_LM?_"[985U$72\JD+8J#WPZR=[Z5AI^
MC1+,KC%%58?;-"]8*?L__?S+C]=__>D7:",PK7XU+X(GF1GKEC'V1\V2XB,Z
MLF69Z^5.=.M`5&8<&MGG3ZCV<B>6U^67OX[6B#`YNANKEKA^'@6X]`[T#3A#
M91ERYNO;CJ]OQ$%!_#8+"G,4$NN>'V)FJ^E?>FJ;YQ\L6ML&2<(Y'0PM=;<G
MK#[38C$V[9+.Q;O>`B01GT5+#DMV/S[H>DH.O[R<\#19R-7"%48X?QKK2K^@
M;`/GQ#%6S3XM@?$E(ZRVHGG*H.H`(=J&^Y$AU2-:2W`\-J!J*T;'Q%![!&$;
MYD9$4%MTEF!MTOBIK0`<&C(]DLPEMXSL4Q,'3/7[M&0SJ<VP-%S:W4Z66TE^
M5:4O)-A!M%U;RG/E83!::MN6=+`^J?:GP^;"MC6*_:U*[SAB>>C26[)F=9BZ
M@`J0Y:TLZ$FIPW8M,L@TH:/G6W?%.Y6KE7`^+]HOZ<<F>)\;Z[<:H&>$]Q42
MNKBK=G9P7]:+3>[8H(`VH^A>`_[&H_K#93`DJ&^EUW1>'%\E,+"E9(VK*>@Y
M=Y"99SFAZ<5"RHTPL-G:XF1-![:\9#$Y)J.+GQ;F3E8[M3AL4R)9R6\UG24J
M)"OK+4*;A5HSU3!L4!1A87(]`8"HR>$AQ_\ZT$R=KS0_I_)UN["]2;40,2',
MYGOC.[]M'"]`M`IE`)NT5R7Q#G"D(X4!S'X?L_1!85QE7723QS1["752'&I2
M&P63%DM":*U6=\X]`=7L#BU<?WZW]#=KQZ>9H[VE]WX^\W]%MZXW\^8T:_1L
M'KB?W``Z;_2P.>P"4E]:T^QJ6Q^LDRVVOJA.S#&Z&^/[VN$\BE#9ZJF5?K/5
M%VHZ,[QQG6R05QMOMEFX@;-XASIJN%HOT>UR?3]#KL?^'[A+#V[O.A[`S>9U
MI-`FU\`J/EUFG)PE.^E!GQXEI)Z)V=)1K4ZXOCZ'`GK#<,ZHUKBLJ?G8>2A?
MOS`JHV-%VLE99H5.J2'9JT8*$4&X5@%^V:=9F+UI92\3M3;H.@E8$%:`7SC.
M_>SFSB$6VKEUUN07B"66`DU8II!ZV_F1C=<"P,P)@-_(OG+V0@MZZ,W9$0T<
M>+J,J,K/2<Y!K]&?OOOP'?GO>[0/2UOV=_3S7WZL[N_O<!X])31<<8V^8P;[
MQ[_^[<,//WWW\]^^_^''HUO^],]I4YP'A05:X"TK"X?^\OTU(C/#^R"#_N6:
MGA/L\99:TO@-7>48(YI6#/T$&MO3@HD$YSU38P':5V&VS%@NV_*R0YDB1P]N
M0FHX#1"Q=)8NU"I@$0!5,R>!HE1&DWB[1Q_D4>Q%;3+Z/"\5B6G_5L&/*"5M
M154GXRO?[#:49AW:<</04XN3I0#,E=7$6^W#ZDC%`NO,^>+GK7KFKT,!9X7;
M;$P!,>Y'6&1]^V9&8G%/Y&$-N-050Y5DT##3J"<Z!&NIO.@H*.`493"UQ#,>
M>CG>?GA*7_]KAR...O*/8["17_TSR$+Z-?_MY2$]GLG3OQN`S\E'1:LW;X-X
M(XC9%XJ/3G/_,"9QV'['T=,S6?EF1#W")\R?:]^$>;1=1/&!_$%E+<;V8MJM
M&\ZB`"M51ZCL"35/W$N7K]4'^OJ,,XS8=]A&M_P8(@W99;@\?,'L#QDF&LS^
M0F_,Y826F"HR"L,'#).)R?]U1@_R-KZS0*Z'YLO[U8:5?KV9^>X<S;P%6KAW
MFX#\V7,"=+?T?30+@K5[LPE8E"M84J+[I8?:Z=/1REG7OZ>?`',]QVM.[8V.
M%#:$#]'+ZO)1TTB,[<6@AS&0M:&H;V/=]<CO'71%,?_NFP']F4AHNRMC9&T1
MZ$\89"H[#%>"/N`!W\_8."/_?Q;L<@1H0%TB90Z!<M!WI#_R,_F)_.,AS#'Y
MX3]02P,$%`````@`7(MI/_#CRDT&(@``EKD"`!4`'`!N=FQT+3(P,3$P.3,P
M7W!R92YX;6Q55`D``R_^NDXO_KI.=7@+``$$)0X```0Y`0``[5U;;]PXEGX?
M8/Y#K>=E!QC'ER3=G:`S@XHO#6.=V+#=TX-]"502JZQM%54MJ1R[?_V2E%34
MC12I2Y&4N1ALW#9)G>_P]I$\EY__];P.9D\@BOT0?CHX>7-\,`/0#3T?KCX=
M_'I_.+\_N[HZ^-<___J7G__K\'!V<?[+_&YV`P,?@MG5X1>01/[S[#\N"$#D
M)&#VX#R',%R_S&XC$`.8.`EJ=W;MP]\73@S^,</_WYNA7_WG\]WU[/3-R6SV
MF"2;CT='W[]_?P.\E1,=AJ3U-VZX/IH='N9?_G<JX\?9#V].3M_\5/C+7;B%
MWL?9NQ^6X-WBV#G\\/:]>_CN_?+D\,/[Q?$A.'G_P5LNG!]/CW\LU#J+0"J<
MA^3^.#L]/CDY1/\[_NGAY*>/)V\_OOOPO\72X>8E\E>/R>R_W;^CPL?O#W&-
MDC[^,;N"[IO9/`AF=[AH/+M#.HB>@/<F:RG(]#!#2H?QIX,"].=%%+P)H]41
M:OOM45[PX*]_F:6%/S['?JG"][=Y\9.C_WRYOG<?P=HY]&&<.-`M5<2--54]
M^?#APQ'Y:UHZ]C_&I)7KT"6J$1!PQBR!_^LP+W:(?W5X<GKX]N3-<^P=_!-_
M\.<H#,`=6,Z(#!^3EPWX=!#[ZTT`#K+?/49@^>D`/@4)4??QA[?'N/[?SD-W
MNT;#*__7@=X%3/SDY0HNPVA-I#^8X?9_O;LJP8#A$PC"F(RN)!NL1[C@D5";
M1WTEOT,UO]VC>0'P-VZ6ESY$_>4[P6T8^_@39X$3Q_[2!YXL`,%6]PGAUHF`
M=$=(-)T\@L1WG6!X4&@JAVLP#Q(00=3U3Z`'BGI;PXCK^H>%K]P_(HT\AH&'
M%LJ+/[9HX,ZA=X,T%)V%ZPWZ$X`Q^G8J3`\T<M\9O&/.G/CQ,@B_QU?0\R/@
M)CV@U-M2WC%]9XS\QP:>0U_#!,0/X6[F[F2+;Z*5`_T_R4)Z%L(X#'R/_`>2
ML$@7"M.>5C[W8Q>!WT8`E;[W5Q`M`JX#D[GKHNT_073E%K7G^NC;X#GY'(3N
M[[):U$CRL;MBWPK4!/:EXT?_=H(MH'TR!EK^9\8&^05$*S3YYRZ:_>FF&:.!
MAT399'MH/"[ZCM\?6RVW4;@!4?)R&^!!B+@=$F]#^-Y.FA&4(?75L55P%@:!
MLP@CPD&0,->^BW8#,(\B!Z[`Z+KH]OGQE0+1\3?Q%P$X!XNQ-=#ZK;'ACHY1
M%;!K=`)'C"X"GI]<.JX?H+5FE/6M[4.C[]T)^DJ)X>&RH_:I^"=''[Z[;Z(N
M0(06+2"$>=V!`!7QSL(828LI\&=\T73KO)!:8PSSGH*,K:B4X#\XSZ,.#.Y7
MQH9XX400T<CX%D1$TR/@8W]B_&UIO?:3RE`;94OB?F?T51NLG."+DR28,4(T
M;<C)`,"1SB%BG]M#W^[6"\P)49/A"P"?`01+/\%4<0SL4E\=6P79,GGK(&[\
M@/A?[+B5H\$(&I#YZ.B[^':#&B'WS,'NSX6;YG'W\PX?'W]$X%<H0*C&_0:1
MJE$&`/,;^SU[*3EQJ3UGW6\7,?ACBWZ\>!J)D[$_D8';%.[J\)MD"24J#*"'
MGUW2W^*/#?ET1$1`0B"!2M\-\&M;&)75FWV6/*G%P'VS"I^./.`?88WC'XCJ
M#X]/L@>UOZ%??9NC3WOX\Y>!L\J;0_T/@D\'];\?2<E3[V[\FV\BP.>+.(D<
M?$]?DDB^OIS$7328BU'X.C[M7:'Q%3<HE%M\?](B<NJ'2&_>.9H('#'+Y?8G
MWP-JEB,6^?/XTI!QA6F>LPB:Q"G_?4_RO)PA!41X[_7`\_^`%Y9<M7+[DN\\
M7#L^9(J5_7E?TESZ`8C.T.A=A1%;5^52^Y+M#JQ\O%#!Y*NS9@ZP:K'QI2-'
MGO3;\V>_:1FKEAA?)D2^L8'1_<MZ$08-$I7_OI.GN'W/H[)L3N3F#:$?:WMW
MV38E*W&T(>^?A^ZC'^RV_644KKOL3KDT8=-R,@LC#T3$O@K]W\%L@U;B"#7T
MZ>#T8+:-D:SA!K?FJ$$KNO?EX,HK.\5V,@%L%19%P9U.`!R#,E"0;R<`LK*Z
M4'#O)@"N>;.A&-]/!F.-&E&0/TP&9(714(@_:@JQD4;GF&I<0_]MCXN'WY\Y
MN.-C?>$QV%]Y$.8D7[:W?CZJ7JB,>\TB:.#:F;XNG7A!%+R-#U>.LTDY+`B2
M./]-E<QFO_Z6&37%M\X+'D=SZ*'?1%O@7?O.(GLA/MM&N*<J=+=+"]T)>@^$
MGN>GG7_K^-X5/',V?N)4R7M;:262QS%(JN>>RA_5R<6X'6,44B=GR^@ME5$N
MI9!2JV552/UY&Z/])"X:RY$?(P`:;U[$Z^F"IG[ET%9:A>39^G0-G!C<+`)_
M1?:NED'?4DDC'%]#Z':!4JBG!DW\B%_IT3_8ZNC)"?"KSCPY<Z+H!9WPB(TM
M$Y%(726HJ,5%U02!A8530Q6"$))75&X75(NID;5D<MD^$YCE54A_#I8`?=V[
M6:)_4:<3LS*&Y,UE54I]A]26VDFVJIU;12V&)P"W@+\3,`IK(+>$XJOEU4A/
MG`3BE*$)",\HKD;V"&TSV-)"^-#'K:(&`SY[$P<%=-A>@0N8@&@3^3%:#)>^
MZV/OG>UZ2\RHSK=XE:G68"+MW;`2??A/O@>@EQ_+6[J345J%Y+EY7V;S)CPD
MV^M-Y>FYNVY_"4/ONQ^P+C]V?U8AVQ5^IEQA^I(MBB"Y>':#+7X1:9%;J*HB
M3"`"<2(T"1F%I_70WEV7A0F-W5%KCAT,K;96TQ%+RS60<'7%V/CC71/F4!=#
M7/LZW,05Q&FEG<UEM9%:7/$-=92@".'J`41K8MF;K=LLX9N*JI"Y*`!_@C:5
M5"$Q"0(A>+!J+CN(R?!M!`HWOE_`>@&BBA3L<BKTA@1)C\BM%UY-)15)O'%\
M[^)Y0_RKL_@?(N\X(C75(&*XT2..RH3"J:("PQTBI9'O8N?0'O?:LJVH09J@
MHQGP<N_)XMD^/>TSP;565(%G9W=PS7`&X!14*F^#G40+.1"JJA13D_T^HY`:
M.05/5)J<H:1/39J=DQ[`>A-&3O0B)#RKM`:2Y\OV?(WM@,3DK]1186262]9L
MS8+MS,HE:H?#G='96QUMC\7A\2D*1:FC$;(X2K'K18I61W-D<;3LYRB*4$=;
M9'&$37V6F1YG9YGK=`5B2D-$P?$4`"EIL"X8!V2JF)^,[NK<#I+B^="AHT-L
M)F1`1S,N(8L*$3R&[?3U3D<C;VG4TL=0BE]']RYI_$*7(Q2SCEY?TI@99D04
MI?[42P`ELP_?37*=$[8=QCKB7+WN]'2B\_[68EM<'`<"BM'?+VE4QQTU72C[
M7%OL4][SHMXNN@.C;WKFT]M]=P@%<*P:]7;O'0(\UV!<;\_?(>`S;_CT]@<>
M`CJOM-ZNP@.O>@Q3):J#GR9)\=J-:DK\5\8)E:JNPRW`$X@6H>X7/G+*8]D8
M4G9\;/4D9E=,579B5<8S(J>*,H2X"ETU\+P@*&)#F*H`XD9+,`K4$%8J<8M4
M=8FB6`VAH$)WPWR'8(K9$.XI@)D_8;N\"AG%L-@&M.7#&-.?=*>K4YTORJ41
M-UOG4K"&[%UB8/FNJQ3TV^DS&\'YT!YQ@&K-D+U0<%XT>PQ0M.\GN6*RC2'K
M;S$-MQ4G'S0>`V+8Q.\TZ%C0^5Y>QERT?#M5-LDTXQ6BV9#4T`AV[:!:W\]V
M4>Q,1]@T>74/T2=NA5LQ8:A[I-"U1N?[8/F7CW*@&8JRPXVO$0Q,3D/,L'Q4
M45.]WY5]0>P?V8):SO'N@@F>[<[\.]4HL>,^@FAW27#HRTFH5,3-AZILJG?!
M?5_TBCHZG>2)H<5%@_/66_6)H(N:V*V;G@%JRUG7-8G3:*-.*HVCA\;$342&
MCT>83IYPDH%"I*9B1$2(>+Y-'M$<_9-.)S:26@TM$%S%\59<^JRT%I+?;),8
MYRQ!"ZBH^,4J4XGSI$O\GFG&0Y!<N`0KJ\<EN'RU5!IJA-2^<0YB?P73PT3C
M6.'5T$6[W*654T$7^=L7V+9:-IJ!C6:@<S2#RGE,<K$7K3W(*EGYF,@RV59%
M`XT++)2\&MH@:%\J6ZOIYGW4R]=*:U<5ZVM5>A.\,-#72NPE6WAY-\/#B`]:
M;)<PPYVH4_>6]Q(S'(=Z`"UM.6;X"HFA%3V`F^$AU`5S_7!>\P0R$*O08;_F
MMV,@4)$[@9K?S<1P-J].)SI;#HN!%7K4,,/S11HP9UW2VN&E(]#Z7#6?,_%?
M4<QP=;$&G=:@\^#4=(##V',J-`&Y@NC/8!XD((+$(]+:>KQ>6X]<%K2_+'Q(
MAMT]0-,$C9;@Y0ZXX0IBQO`0.3!&RS/VH:&VG>=^[*+AML7D@F+!4;RR,&:L
MN^&QOZK&SB$F@5`R(=A),RO%=)"UY;V*67R0%Y)S@!8F;^>-?@/+YY*F%Y*V
M*DHRFV7FIOEIXK,3^RY#H<UEM9$:=?6Y'VSKSU.BM71`(H>@O^1Z61?UR"('
M((B<`(=I\=8^]/%4QRPAF_P,?;;54I.?#1.='?-I6>18I15)'F'/U7.0_GL%
M+QT_(I<5-\M?X2/P5MB8/0]I<061K%L2B8L-KFN#*C/KI7V2C:&OB,YN`!Y6
M<,7.KR)450VF)R06UFDJ6BXH$P>CN/D6A\/H$_5CJIGK,&8-^W(9Y5+.GQP_
MP.?*A[!PGY.Y7?#X@FPK:C*/T3E6FGPL3,SR6DG?LFNTUU.24ZTL$F>&-)54
ME@6NKDR6U(S2&DG.'_PME:P%M_O[[G17(697ZPU[.DHUH28'V2KCQB&\=5X(
MTXPB!ZZ(8+\@TH\/VG@:,F\0I)I0E%$..)&+@_@7G%7Y$X)?1PT*$D[L,@K7
MOR#M,JEUO9P2RUTG`'$>AIA)CJNEK)VW#C;1C/7[-^"O'A/@S9_0'K$"7[=X
M82;\+KNL:#-A[=J*"BTWBGFS%$3:M16-D-:$XYT'Y-K0S6;76BA/P4)9]"VA
MDN2'QPQJ41V-!]QZF6I&EA,9R*._*)H1LTU&9?6GPUJ$MHG%WFBYFC?7^F>B
M?AO"UV/EV/6L&V\S0M)V`MUP;#0C)FW'+N[^4%6+6CL=M<C=\I@1B+;C^!!Y
MR*O%IIV.`ICWVK(QH\S'7.>\6H>$[`1="/4TDP*)V;'7[BFGX,+9SOFGY+[9
M^+A8<]M\E:-;8,V8DL=GQ02CYMCY*L>`W"NF6*HXHV.WMOJ6MAH`BR6%FZR2
M.ML2]4H2-YD)V6KB/"4W5X85^A0<6SL_BD[)V57R]7!*+K!,`W_#O%^[]*_(
MX#:"3UIG6)O=I(Y.H3<LF5+E./G0(S=8B%:A[S^BXQNYN2;7=@KL11BI-!KM
M.<7J#&*=-/?^;YL^[L0/(>-[.,\SP+]'"UB)X\_C.'1]3,E_\Y/'AT=`WA%P
M8TZ0K7'+`JM-`SI<P8MG]Q%?HM\L=R>$)I,G74334<](7`>Z2,S?G(@\3SV$
MY=-6-A7VH%=A4?:GQY*,%WA]B0F4B^>-G[[FG*._4HD[:TGZ0RHLU4205/*.
M8CCIKS">2^`D6V88UL&:W]OX*+QMUE:%="%@#&&Z/ER&46'UZ#I^AA=$U_%%
M=N(>`RBMKRLZTF,+)P8>)AMH$4C)'7Y!`)'KQZA_2??<$+K$,I0>XTMF:>P.
MI/P:W(/HR7=Q1"\_]#)C,UP@2],VL/H$/ZNU+C]7016'02O`OBKM^75=-9MM
MV]SXV/+M#+S//818E9&79[/*-I0[X"'BAL][A<VWO)G,D]T&Q-_!AOF$+A%]
M;'PB!9%JG/B1>]0M%%"<W8@O9JV<&FE+=/H>N-N()(QND9U?:Z`H0'T38;(]
M7`=K6T6?[=Y%N6&1VDK;N#99ZD;$-4*(NI6[BC>751*-)PP]DLX]I4!Q?GSS
MT/DME9+:U'(G<8>&!IG7])JGL`0B.?*;C?30VC1K!6ON14HFUQ&K:'[,%H;>
MKM%0@C&XPX]6Q/(-C:0-<RP*55$>I84Q@?K$DIEXA(;&.2Q61ST*[JK96%2-
MS-B%`MP&C@M:UWI&X6'&['81^.[-$JD%\23.F&TJ-X@$Z$B9Y2QVG?2E@3X@
M4%>3:]]9^`%)9%T73K8)-?$GRFG,N3W.**PD7@):WIW(#W^%\0:X)+,TEVNQ
MRP\R6A#?02>5,_9%`_2*[#]?GM@#NU^#2GHDE5ABV>/5&+!7SE,^BGZZ$!!.
MHN*`,EX,/7*Z-JADY`C&W=`CLD9G:;^=JHTL4SENQIR[.7X=&\]'*F]K\64T
ML_T13MS*J:L45;Z=BHRA4MEIQE8:2LYJ9S-EK14T3%YE:V%5$-[+/ZNT1I)S
MS\3\.LI0I.^,Z0UX^MB:98ZBEP]<1$+UM4-'#8KP)=Z.F]%GCBZ0VQO53@]?
MP7?RITYX:67M<+4N)/R*PYPE>-^IG0(*5\D\2\/^C6K75T7SC]PRB65`T:&A
M\?NRI%\6@L[-:-1?Y&&C^\90KZX;MH&W!<$V==-"QTVA4E<W5!VVA$*],5>1
M-"'IL!N">)NZ]5/IR:A#?Y7K:XFNWV;':6?T4=I[J^.UHJRO[L!F&[F/V"ZU
MOBWS.H=?43<\/(/H]GJZQ=CM%5%8:Z__UQA1F&NIQ4B*7.O5]SH'.A!&V.+\
M2='J'-F@%>W`!J!4*SH'/1#3BN!#*86L<P@$X6'/?;&F6'6.>"",E67G06'J
M&"5QHG&.6XU72MM/P3?!C/P$4O"ZF!X;$LU11`UB]JV&!':4&M9M3B*U6(_F
M8A["1,R0B(Z2ZNAL]U2+`FFN.O+"+./;6O!&<Z%R;'MKT1?-14D[E$LL3[2F
M*")68Z6X:<U,U!!")A95FA<7[50^]N4FO;I+G"B90@1,">..*<5*%+G/K05(
M?)VA99L,Q@HSZ+V=0:*/X,4)=#(%U/P'A%K*MM<U?[HY))F1]*WKRE$R?ZPE
M:WM=XZ/5O%4LT=MD]2/E(FY&UK`!`%?75JWSAHE-@.%B"9J1-DQ@%'2R(S0C
M5UAW]%S+$C/RA`UP)JMM#EK?+/9FT#6X6M\<#K;>#1)_KY96[#4HK7,`2*HM
M'AUEG&G13K0(8S"%\^PHP4EWRGUK[HWB4-X:5!>&<U5%<9&I_LSEO@/9>5-5
M&$YX=8G+7]"HO?05L[RG&C.?B;8$L:)0S3UDC!/IEVKF5=[URG"GZHGFK;GD
M?,SL&50_K_IVF!GB=:>?=Z_R=C@OQ<HS^\Y<;LVT7/AV6@38V7;A`GI3.*<V
MQB<IZ.>MU8]00`>J,7.OC27=E2ED<WF<4#<+.*I379A/WWOZ[%-5F'_)W"64
M1L%@XW2B^'G.U07X)Z;#[Y")IG"M]MY4^&K3(A8T^,.T*;E(?,3&5+!9,#_#
M#(R;`B>6X+$-S`U#:G,P3S0'<WD(Y_B,[\$6CX<<Y^ED<!:V/:-R:6.'V,L@
M_!Y?0<^/`-HF5.?GP_?>T/4#4+I">@BQI+=1B.F`]_GEUQ@_%=UL`+ZEA*NY
MFR"B@(\++>&`1_F4+OGA;+8[-=GN,@5ZEVCU*,C$D)Y70QD"Z.%_\&K]Y`1D
MH4Y*3T\\+*UU)XE*4=3E9MG24S1Y7W=P])7T7REXC";4Y3Q,[X32-\UUN(5)
M=CT$O!,6L-9Z2K(!@D5"PRX4[K@^`TC"Y.1FU.WYUSLUI08SXB[XO(Y?$,$F
M`)D=&NH0)/"?#F=Y%*HZ3/[*W1N>\X()W@UD/JI79)6N;G(N1X;VJ)F.E-9$
MJJD8L06#N'D<@R3.MVC&,&67'T2[A>:I/QJ=^DV:;:NB)!<F&FZ84]_`>[3+
M8(NN$/'HY.4V<-*SX:8!C61E53D^O_M!P)(\_[,*V:[6&S02TN/=%3H]PA6>
M8ND@1:<\M$]`/P$!&AP>FHS!%C]AM^#IU:02'51HS!4ZY+B8"^2+=1H1)=H"
M+W?R9(>'[MB8'KC/\\ON#C";ZNJ%Z@X\`<CD\>WU]$!SL=X$X0L`=X#$Y^G2
M59PF],!8V)U^A8_`6P&O:9<21RS<H![XKW!L3!`GV9+Q%;!V/:&J>F#:W8GE
MKW?\NS>)!O3`AV@IVO>\?-&X>,8N-7BU)[:BZ?8GC%6H,3UPWZ'!%ODN6D?P
M'8$PPDHU-5CRJ>*SB'NIR"!<O=$WO.(GLSOJ?`T3B=SI_%:4:'@G9M4%'DF8
MQYV\B<X"QV>F%91K8_RS\]B9V(?1?&%/1ZL%VMR8]V!-)55(C':JIJ>42Q^B
MWB\]I3"`2#2@-[Z6G;%#0QKAO4++4ISTZ,^F!O3&UZT_>0UIA+?AJ5,.9U,#
M>N/KUI^ZO0E7G"Y84`IEU$CY/;L_P>:?40C1C^4@K0S!6ZH-PN6^AA#W-#'E
M8*<%;RBE0I/DY-`P"'.CCIV=!T.EXO55H$/'77*`1YR0!K0KL6,&+(&**O'<
M++^`:`6B[*KF+(R1J,*42+85E4@?PNQ1I'IGW(*-74\+-*5WB&*$>5%8[`:T
MP'?_&$;)`XC6*5_A7<N)U1UD96Y."55?FQO+*=%K%+H`>#&V\:G$26-IDU-#
M-8+&ZPD!',WU]$%S'<(5'J^"W<*H.-`(;_I.U\R2/5I3W3N%#9Q0%(G=4;(5
MU4CQP_87;*:#+Y9P9P0!<%/_%[*2)F*K<(\6==!`Y6E?9$N5:$$Y0HF<H>WU
M5*/)%HE<()$A6:LRR&I9#^%<#]R,ICC3U:QIS>S=IHK>06><W9D@WY0R>:[Q
MP\S-(O!73A;PK;&S9%K0!2%GOV865Y+1M2W)2363*[.\$NEY6?V:Y>?44(>`
MD8.1@Z"YAA($C3%'6<(W%U8B-],EN):\N%90J;P%KZB6>V%N%:48FEQC6<*7
MRBJ5NN1GQQ(W+:1&SEWP`M;3:ZF($AFWFTV0!5G,Q^057(;1.O6<;!G0@K4'
M87#%C[%-`IIXFF!-E;ZC8_HTE@*1"7E:F!%"95\Z8^VH5$L_3334]/Y&91>?
M)ZK_B<86W)?Z)8VT:-YJG;WQ]Z:\7OX35)<Z1SK<ERY%_7^HUGCA$^W,;Q^\
M/0SO:2?P8C3:3FCM!`F[#*ISG:,\JAN];!<#JCF=@T4*A^F@&9T;W[DI6IW#
M0;:$\6B+\511C!GAK.3=8O@C7LSII)9H;FIK]=!J%?/_K&6JF]P)<&B]-OFU
MU3+>62VV:)'G`5I+H6>UV:+-1I_G6F8^JT9!->Z<K/7.]L?QY,HC9I:#I)C!
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MS&S+!E(X2>CCF":9D8EVL,$C'`6LEI5V8M.QU5NSY$;`<RVLY8&?"EZ&,Z@A
M&=YE\+8'*JME?3<7-#/Z62USNYX8A=+O=EDPJ>6ESC>/O?!S^1O%K_-AJ1=^
M[H4DQ:^S,8`8?KGD83OD/_".,P9O]CUT5DLD1Y75X:"R29/`)TZ4O!J5?3LM
M*HUGQ<Q5V@7TIJ`R8;=MJC(CMF-.+`6;B-P<(T2;B-PF(C<;WW6?!-V*T,F%
M\BC?^A?SH-#IJ/4Q51[N0('@J'ZTWE,[ZJ=+>AJJ$9UOD'M,$($4PU0'.M\!
M]]`!)^4IQ:[SPWP/[(W)="CJB;Z]]U!80X2+8ZTOA#JNEE))H:DJM+X;ZJB*
MUAS$U')@HC2J'/"-PM7ZB:-C;POE\Z8JF"*3%`U(1[4@QA=_/BHJ`9U$?D]_
M7?UM23?@.4'+$(T47=,.#)]`$,9OW'!]E#C/(0S7+^EF5+A](:'.'L,`"1SC
MNSAB(47,K''H,_0G`&,RJ_%C^2W1["-($),.#A0$+RP]YC/H>F%.YGU$S/%S
M>2H1#7LUJ2*`HW#$D`K0]GJZH&&')&65'C\%Y$7),[@D7.W/YB>DG$Z*%<Q*
MP&W@""008Q0>1G/;1>"[-TNT6?IPQ=%<4SD;EEQ:>O.#>IL;')NHKDPIA*-D
M<^K:<-E["9>M252P7C'0M+Z0>TTQT"8:<D7*2I#%00QY=!G>X%7O1Q1A6\AF
M2F?(PXB0S4F_T[8A3P0RO,5:I!BT1EN+E":+E%/3`?(-4MY-!MYU'WN4?5\H
M$ZN`AS"SD\:[0H8BOHE6#LS2C)R%,`X#WTLU#KW;@C0WRX;*YW[LH@]N(QR.
M]=Y?06+#`9."UP5JS\7&&TCXSP%^@K`W@?NX"61W...L+UI+Q7EY[V.T^42^
M=S'LO=9T[E(F=M*67&0F1,RY)[+]KU2&W%*\3K(_-;)H*9ZE>"-MXWV(F:53
MEDY9.C5!.F5)D#D=^6I(T,ZJFO+UZ7&?[CL(7SW-&PJ_CF5P1C`XRW0LT[%,
MIR/3:5DU+<'1$-14"4Z:*:'X0AW/H8<&YB;,_G/*S$<7SC#,+M>Q+YMWPXZ-
M6:YDN9+E2I8K#<65NJYIED1I"&JJ)(J9-(..34N=['5+#\])B?'5O&%+-6%I
MDJ5)FFXREB8UTB2Y%<*2(PU!394<X0Q/SB*,2$`B-#2O?1?`&,QQ?)85&(0E
M,3A`MR\WT()N#=DX&);I619D69!E06.SH#ZKO>5"&H*:+A?:!>L[!XL1B4_K
M9QI93FLM2VDLI;&4QE(:2VGV1&G:U_$:?Y')RH-:7X0Q,"0GC^4^)G.?00C/
M,$N\&"EJ*VW)D"5#E@Q9,F3)T+Y>N<1)D-X@+9$QF<A@&#?+,\2Q_>32<?.,
M5=;`9Z^TH*T7&CA!6Q5+5RQ=L73%TI5![FY:UR?+630$-57.4@^GB\M:\V1[
MJ6%9@AQ+V*N<HI.6!4&TON5`E@.-%-5'?`Q;0J0AJ*D2(CH"2:;M#8`Q^?H=
M"%`1CZ1-(.D8/SLQ\&Z=%U)+[:M53Y$9KUL]6[6O8)8P6L)HKY4LI=K;*UC?
M?<":#%F29@1)2Q-=/SC/$[ZHZKXK<;73O$=QJUCN9+F3Y4Z6.TV9._'73'L#
MI2&HJ9*;"R>"/ES%MR`B;%WIW1);F.8%FUW>W@=93F,YC>4TEM/LB]-PUFY+
M:#0$-55"<Q:NUWY2>5U3RFI:)&I>MULJ67YC^8WE-Y;?6'ZS+W[3MHI;DJ,A
MJ*F2'-)17YPDP4')H7<6DC1U`-JDJ"-RA&%V-;&N:][LQ.I:YF.9CV4^EOD,
MQ7P$5RQ+@#0$-54"5+0XPX'&UYL@?`'@,X!@Z2<X_KA:*VDI^9@W0.)-V/L@
M>Q]D69%E1985[?$^2&*%M^1(0U!3)4>9"?ZM$R4O#Q$:B&AZ^J4<=?:.R/*&
MSONPS/!JWJ1E6K#,R#(C37<8RXP:F9'4^F")D8:@IDJ,[K>;34!^=(+=GZ_@
M,HS61`I+D"Q!LO1!CC[TZ?4N\[%A&'1IQM(?2W]&B+?8:41;#J0AJ*ERH#OP
M!*(8D(A8]YO`3RS5>954AR$=9W@T2,4I;8F7O;?1=/&WQ*5.7'CSWO(3#4%-
ME9^4$^@.F)Y]*,,><?&:UW.9%JQ9SVNB9)8$61)D29!JLQZ)]=T2(PU!3948
MW6\7,?ACBWZ\>`+#1(&V),&2A%=`$O8I)W.2,D1FEK<4QU*<D9)AL,>H)30:
M@MH#H?GY"']MX<0`_<?_`U!+`P04````"`!<BVD_"R(!_B$,``#%:@``$0`<
M`&YV;'0M,C`Q,3`Y,S`N>'-D550)``,O_KI.+_ZZ3G5X"P`!!"4.```$.0$`
M`.U=_W.;N!+__6;N?]#S+Z^=J>,X:=HFD]P-L4G*G&,X(/WR?KF107;T#@M7
MB#1Y?_U;"6QC8V/`Z3O[GF<Z+8;=U>Y^5M)JD>CEKT_C`#T2'M&0737:1\<-
M1)@7^I2-KAKW3E-S.H;1^/67GW^Z_$>SB?3NK68CDP64$60T[XC@]`E]\4A`
M.!8$N?@I9.'X&3G>`QGC-VB`(^*CD*$OUW8/G1RU$7H08G+1:GW__OV(^"/,
MFZ$2=^2%XQ9J-J=-?4J4ND#OCMHG1Q\R3^PP9OX%>OMN2-X.CG'S_/3,:[X]
M&[:;YV>#XR9IGYW[PP%^?W+\/L/5X00+$(A\4/0"G1RWVTWX<_S!;7^X:)]>
MO#W_5Y8ZG#QS.GH0Z)7W&HB/SYJ28\$!;Y#!O".D!0&R)6F$;!(1_DC\HU12
MI+R`P,<LNFID#/]^>A3R40ODMEM?[GJ)MQH__X02VHNG`0_H`H>\,^4Y;5$6
M"<P\DF$!C?XLX)"/)1C91G(LJ5KM\_/SEGJ:H8ZCY@CCR8Q^B*.!HDX?M)1'
MC]O-T_8BEWB>D&@EFWJRFH\]!F)!-18^DB",5)1(CN/ST^,L?<A8/%YMOR]X
M2S;5`J(F4!%.O2SK9KX<CZ3QYPIF77W62AYFJ#T(6,&?%\DCXAV-PL=6^G"U
M&WQ"5W/!@]4<E#V22*QF2IXM\PG,1T3T\9A$$^R1<EZ'#C\F3-R$?-PE0QQ+
MM+[%.*!#2OP&P@(&AD$LR`)!S.8DOT@IEYBQ4*ANJ7[+.Y,)9<,P_0DW9!A>
M\#`@+D"!Y,6];:Q54J0#4$L2MKJA%TLUI_]BYNM,4/%L0!-\K!IN(.I?-4I1
MSI2:JN63(654J=\^;J,FFK)G+T$42F2AC+#+UK*$9>$QC)PF^T5=>SCPXD`Q
M]N!WRIQ2%#%..`Q)3-3@G&NVGB^].T7G94!S0%L57.;PAC(8Y2@.K#!2JG0"
M'$5IC$G8;&#XHR1#,7JG`-E,$%Q?:SVMW]&1\U'77>>`UG9H69@#R0,1%'Q3
M&3K%O0&_MX7XH5<+&KP^X%D"3\ANPC'1`D$X`Q,>R6K@\F3%2)TM(>6XFJO?
MZ7U`R;Q!IJ7;FFN8_4.?*X.1\P!Q_1`&/F3+^K<8)AF-^2;$.>^$8S#M@;`(
M($DPRN#GT69M*<7POBN$UW'-SF\?S5Y7MYU_(OWW>\/]>@"Z!-`='#W<!.'W
MR&`^Y<03JSMCGJP8K0^%:'4TYR.ZZ9F?#YWQQ3OCNBEQBYY99IY\7[E['N;.
MLJ'0#P6)W'"6R<S\')E\A!G]CS*F$[(H#*BO?@":5L;03!HT9^[2R(,&8TZ`
MVJ$C!DF1AYG0/+5VI&QD@3R/0MOD25P'H?=G)IYV2*GBR#R7BZ:95/C1U]Q[
M6Y=A>7WO&'W=<=Y`6N<8*E(M6W<@:E6J<(C(ZA'Y@G'T$NBWCY?1=^[O[C3[
MJQJ5C-N^<6-TM+Z+M$['O.^[1O\666;/Z!CZ86ZJ`?\-IOP3#F(R]WE%U(LE
M%(/=7@;[1C-L]$GKW>NJ<VN.(Q=M6K^+>H9V;?0,]X!S+9SO"!]!ZJ!YD#LD
MR^H(QFOP_21=94>U`Z"FZ.+(.%F.#*T#28AC'(;Y>OA;/)P0+IZM0([.S)<Y
MY$05.F=.KH9Z)8'%6)_F1@'CB]Y-._\![.I@=\(@P(.0JRH,8-.C'BP/B,8Y
M9B.R#>KU)!?#_W89?IC-];ZC(^W6UI,ER2$(Z@0!>X0.2@<!Z9+!%HAO%%,,
M[]DRO!VS_TFW7>.ZIZ.N?NT>P*T.[C:(UH/Q7:Z7FOW;IJO;=ZAONI"N6=I7
M#2`]H%D=35"$F,,.)SX5-]BC`:A7-0O;)*,8W??Y,;BO5MP=6^\:ARY:9V$M
MP.T+%3M)6[?3EI=6#/2'W/)ZH=+7U6_D4KK?.13CZXS*,\="3PS'$TB-E&$V
M`=<0OQ-&`*0LY%[+W5`6?E9<%4?O+=LH#H]<[4V%1_-:<R`A[YAW%B1FAU);
MS?!(BO,N?JH["!0**`3V)%=6,_H`IXY<[<NAH%('3!US1MDHL@A7W:T:DNNY
MBV',%<SZNCN%\E7/=)S7R-)MY'S4[$,F5FO1-!Y3L3305ETP%8HHQC=7]@)D
M[PSWL`BNFUF3$0[NL!"R0,E@=E3O)`BK_G*CG*1B='.%+EG/OCW,I_4[ZRS]
MD17(\20(GPFY)@QT%;(P61'C2@*+H<X5M?0[JV=^U75DZZYAJ[(6LGK:`?@:
MP*>YKH6Y>'8YH(*]I?<,U7"O(J\8]ERQR]9[F@NYLZ79[E?DVAKDSYW#MK:Z
M:^IX,DDVG.-@]CBSF;KVZKJ&W.)`R)7+7MWWM?NN`;'P&CGWEM530X#60Y9M
MHAO3OM,@CU/_'J:#NJ."/+]$5*7$F0145!T$UK(70YVKG0&BEBD7S+;^2;<=
M/5E$(\?J'2IIV[_.>NF76%N\NCK)5=,Z9J^G79O)SN7#"ZPM!_M!1+[%<*D_
M5J^3K><NAC1?`;N_=O3?[V6^!MWY_P-+^9<\)&B3(5+G_R[D^;>K1D0A)2:-
M]![FGN0O/CG8FB0;!6"9U)J*G0K(<2\>553QL>2_5*NIA`=.AE<->4BP.3V6
M]@=P'#V-@RF)H$*VTIG+05)0]`;A(&BT=M?R11A+&`X,*PSOSL3LB=TP-I.@
MI,E`N\+DGI2P)]8N=_,21@/+"J.S.W57V7[9RAZIA%^+1RXOP?20"\16GO]<
M<^H8)0>;>Z&G!!6PR%_-*5]3WFJV3YJG[:.GR$]5K*+!W-/5-)CR5=5@Y<'>
MLFU/&62C9Z6:*SP<O:Y9U>3*T]@M$HAH)JLYEU7=^[FST*6<L,PE/7$NW=]^
MMXT*F6/<%=4(6;^>)D6GW;<`1MZIBLNFT^.%ZJSBF_[82I&E`^FEE)CRR(NM
M&L\?;"_5?H8MO5ZC17K:7:EQU=#\?\=14NEW0\WWU22+`PM3WV`=/*$"!YKG
M<2+OF\,N`6:_2Q^I3YBO15$(&:L@_F<J'MP'>72'IR4(]4HH4N]WQR%3*U(C
MBF("8O4G[T&N5\PAC/=#POGT!+2<(O[8&8V2Z51]O>("&(C`_-F`S%SFF@V$
M!Y'@V!-7C2$.U'2I"&$:I:'O*E8_YNFI_.39``=RYH`'9$!AZ&54KN'DO"=X
M+*<!2/=A(HPESRT/X\FT=0JM_D_@`W=(#<WA9RR7E%+HS"'9W1L_#J[R&OQM
MX%GP@?XDY"DXZ2K]:4(3#;OP=.Z1JLZO+O_OXMK9L0YUL'MQ'$BZ_IKHFH\(
M-R'/C!<57?\#VO]QT'AJV]T+8^.&-O%"[G<@MIXI&Z7>L(D/XX!L);,U=]$3
MFIAY;Z777TCR/H3Z%EOAE=-J\B>N23Y&="&F]VLZYT7<4&XS>&KS9N)=,W!Q
M;HQ,MABW&>LV4NY#6'>)K*>J\S:.P".B,T'XA-.(R'*/1^4!S'@<J]>:W9A#
M'U_FN"/C`>$+?GDID0NQX8=C3-E?&!A3H"W\+$69;.W@EG5&%:Z]")@2W[72
M4DVS?JC$EG4$W(,06>6&Q(8?#/M\55(&[E+4^P!S)FOJ0LN/:MHR&*BFX,N8
MO)%R'\R=+WDRB1[,TM-T/$D7,U:795B(Y"3G_,M&L$TZ+^=Y)>GW(AM>:<M2
MAC_KL.IEX"9';&#>"Z^D26CRL='LV=O<I+Z1<J?FZEZ9<U"I71LH=RT_[8=,
M?I))*A#E4%KU<*>`6?^:?47.4(9XAS(%F.8SGR[(8;/Z\4ZALYBH)%-8ET1T
MQ&2NOFA+(>&6LU[R>N]EACB+AQXA?G3#P_%\'%\J1LAMV+.!?46);QLA^Y#^
M6/$@H)XY!'.@!^5#=^7CG0I=FWCIUST]/"UR3Y/1'L6#Z<"^KDJ8L79[4?L`
M>=[*>;$_;^]SH7\V<.Y%*K1ITV=J^GJB74L4'!!,HL[Z"BSSLX68:9TBU_FW
ME+-3HT1B2U=^8$Y=Z8NFK+%](_T.VJB_$.ZUY>R63^;OF9.*HZ5:2A*7BKG`
M"\C:I:)`H3D+>NM/A'LT6D@$:W'O@?FJM/$R@5%!U%Y,E$5FUHV70N;]\$K=
M`T6)6^IP[US"D3%BODA:+AJNL;J(81_2:9?(?66@6/)-E8*U\T;*'5H\?R:R
MWD=\#5(`/"+]6,[MUSBB7I<&,3Q(MW/%0K8I_X^GC*%UF/_"J>&RE>SP@\O_
M`E!+`0(>`Q0````(`%R+:3_"PQ@R*L,!`$@`%0`1`!@```````$```"D@0``
M``!N=FQT+3(P,3$P.3,P+GAM;%54!0`#+_ZZ3G5X"P`!!"4.```$.0$``%!+
M`0(>`Q0````(`%R+:3_B,RT=70\``$71```5`!@```````$```"D@77#`0!N
M=FQT+3(P,3$P.3,P7V-A;"YX;6Q55`4``R_^NDYU>`L``00E#@``!#D!``!0
M2P$"'@,4````"`!<BVD_$XLSBN0@```9AP(`%0`8```````!````I($ATP$`
M;G9L="TR,#$Q,#DS,%]D968N>&UL550%``,O_KI.=7@+``$$)0X```0Y`0``
M4$L!`AX#%`````@`7(MI/]TRT.@F,P``(*,"`!4`&````````0```*2!5/0!
M`&YV;'0M,C`Q,3`Y,S!?;&%B+GAM;%54!0`#+_ZZ3G5X"P`!!"4.```$.0$`
M`%!+`0(>`Q0````(`%R+:3_PX\I-!B(``):Y`@`5`!@```````$```"D@<DG
M`@!N=FQT+3(P,3$P.3,P7W!R92YX;6Q55`4``R_^NDYU>`L``00E#@``!#D!
M``!02P$"'@,4````"`!<BVD_"R(!_B$,``#%:@``$0`8```````!````I($>
M2@(`;G9L="TR,#$Q,#DS,"YX<V155`4``R_^NDYU>`L``00E#@``!#D!``!0
52P4&``````8`!@`:`@``BE8"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1052
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EXEAC"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER SHARE<br /></strong></div></th><th class="th" colspan="1">3 Months Ended</th><th class="th" colspan="1">9 Months Ended</th><th class="th" colspan="1">12 Months Ended</th></tr><tr><th class="th"><div>Mar. 31, 2011</div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME (LOSS) PER SHARE</a></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr valign="top">
<td style="WIDTH: 36pt" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
6.&#xA0;</font></div>
</td>
<td align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
NET INCOME (LOSS) PER SHARE</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic
net income (loss) per share is computed by dividing net income
(loss) attributable to common stockholders by the weighted average
number of shares of common stock outstanding during the period.
Diluted net income per share is computed by dividing net income
attributable to common stockholders by the sum of weighted average
number of shares of common stock and the dilutive potential common
stock equivalents then outstanding. Potential common stock
equivalents consist of stock options, warrants and convertible
preferred stock and accumulated dividends.&#xA0;&#xA0;Since the
Company has a net loss for the three months ended March 31, 2011,
the inclusion of common stock equivalents in the computation would
be antidilutive. Accordingly, basic and diluted net loss per share
are the same for the three months ended March 31,
20011.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
following table sets forth the shares and net income used in the
diluted earnings per share computation for the three months ended
March 31, 2010:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Numerator:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net
income available to common stockholders used in basic earnings per
share calculation</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,693,487</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative
gain recorded on dilutive warrants</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,340,515</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dividends
on convertible preferred stock</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
656,635</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net
income available to common stockholders used in diluted earnings
per share calculation</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
3,009,607</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Denominator:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted
average shares of common stock used in the computation of basic
earnings per share</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">522,350</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dilutive
effect of stock options</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,430</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dilutive
effect of warrants to purchase common stock</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">79,646</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dilutive
effect of convertible preferred stock</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
253,435</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="88%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares
used in computation of diluted earnings per share</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
881,861</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The
following potentially dilutive securities have been excluded from
the computation of diluted net income (loss) per share since their
inclusion would be antidilutive:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Three&#xA0;Months&#xA0;Ended</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">March&#xA0;31,</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2011</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2010</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock
options</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
49,227</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
3,970</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
315,170</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
43,349</font></font></td>
</tr>
</table>
</div>
</div><span /></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
13. &#xA0; NET LOSS PER SHARE</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted
average number of shares of common stock outstanding during the
period. Diluted net loss per share is computed by dividing net
loss, as adjusted, by the sum of the weighted average number of
shares of common stock and the dilutive potential common stock
equivalents then outstanding.&#xA0; Potential common stock
equivalents consist of stock options and convertible debt.&#xA0;
Since there is a net loss attributable to common stockholders for
the nine months ended September 30, 2011 and 2010 and the years
ended December 31, 2010 and 2009, the inclusion of common stock
equivalents in the computation for those periods would be
antidilutive. Accordingly, basic and diluted net loss per share is
the same for all periods presented.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
following potentially dilutive securities have been excluded from
the computation of diluted net loss per share since their inclusion
would be antidilutive:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Nine
Months&#xA0;Ended&#xA0;September&#xA0;30,</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">(unaudited)</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Twelve&#xA0;Months&#xA0;Ended</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">December&#xA0;31,</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Cumulative</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Development-</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Stage&#xA0;Period&#xA0;</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">from&#xA0;</font></font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">November</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">7,&#xA0;2002</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">(inception)</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">through</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">December&#xA0;31,</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="40%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Consolidated</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2011</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2010</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2010</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2009</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2010</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible
debt</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
&#x2014;</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
3,547,198</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
3,646,370</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
&#x2014;</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
3,646,370</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
7,327,322</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
&#x2014;</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
&#x2014;</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
&#x2014;</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
&#x2014;</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="40%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock
options</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
3,632,638</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
775,853</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
769,189</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
991,736</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="top" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
769,189</font></font></div>
</td>
</tr>
</table>
</div>


</div><span /></td><td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
9. &#xA0;&#xA0;NET INCOME (LOSS) PER SHARE</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Basic
net loss per share is computed by dividing net loss attributable to
common stockholders by the weighted average number of shares of
common stock outstanding during the period. Diluted net income per
share is computed by dividing net loss attributable to common
stockholders, as adjusted, by the sum of the weighted average
number of shares of common stock and the dilutive potential common
stock equivalents then outstanding. Potential common stock
equivalents consist of stock options, warrants and convertible
preferred stock and accumulated dividends.&#xA0;&#xA0;Since the
Company has a net loss attributable to common stockholders for the
years ended December 31, 2010 and 2009, the inclusion of common
stock equivalents in the computation for those periods would be
antidilutive. Accordingly, basic and diluted net loss per share is
the same for the periods presented.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
following potentially dilutive securities have been excluded from
the computation of diluted net income (loss) per share since their
inclusion would be antidilutive:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div align="center">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="80%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="22%" colspan="6" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">Year Ended</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">December 31,</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2010</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline">2009</font></font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock
options</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
50,074</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
60,260</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
356,925</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
232,164</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="76%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conversion
of preferred stock</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
2,042,108</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double" valign="bottom" width="9%" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
329,451</font></font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;(1)</font></div>
</td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)
Includes shares of common stock that may become issuable upon
conversion of preferred stock dividends accumulated at the
respective date.</font></div>
</div><span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 55<br /><br /> -Paragraph 52<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6945512&amp;loc=d3e4984-109258<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 128<br /><br /> -Paragraph 40<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1278-109256<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.21)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1053
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EO5BI"><tr><th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (USD $)<br /></strong></div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th><th class="th"><div>Dec. 31, 2009</div></th><th class="th"><div>Mar. 31, 2011

</div><div>Pre Acquisition</div></th><th class="th"><div>Dec. 31, 2010

</div><div>Pre Acquisition</div></th><th class="th"><div>Dec. 31, 2009

</div><div>Pre Acquisition</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td><td class="nump">$ 1,590,755<span /></td><td class="nump">$ 673,739<span /></td><td class="nump">$ 980,125<span /></td><td class="nump">$ 1,030,942<span /></td><td class="nump">$ 2,372,951<span /></td><td class="nump">$ 8,769,529<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td><td class="nump">55,000<span /></td><td class="nump">555,000<span /></td><td class="nump">555,000<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td><td class="nump">303,633<span /></td><td class="nump">51,042<span /></td><td class="nump">69,626<span /></td><td class="nump">28,042<span /></td><td class="nump">63,526<span /></td><td class="nump">102,923<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred issuance costs</a></td><td class="nump">159,300<span /></td><td class="text">&#xA0;<span /></td><td class="nump">99,461<span /></td><td class="nump">28,500<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td><td class="nump">2,108,688<span /></td><td class="nump">1,279,781<span /></td><td class="nump">1,704,212<span /></td><td class="nump">1,087,484<span /></td><td class="nump">2,436,477<span /></td><td class="nump">8,872,452<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">FIXED ASSETS, NET</a></td><td class="nump">3,183,603<span /></td><td class="nump">3,510,489<span /></td><td class="nump">4,088,951<span /></td><td class="nump">6,515<span /></td><td class="nump">8,755<span /></td><td class="nump">44,097<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">INTANGIBLE ASSETS</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">19,671<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">DEPOSITS</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">15,350<span /></td><td class="nump">15,350<span /></td><td class="nump">15,350<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">EXCESS PURCHASE PRICE OVER NET ASSETS ACQUIRED</a></td><td class="nump">1,675,462<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">OTHER ASSETS</a></td><td class="nump">27,222<span /></td><td class="nump">11,872<span /></td><td class="nump">11,872<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td><td class="nump">6,994,975<span /></td><td class="nump">4,802,142<span /></td><td class="nump">5,824,706<span /></td><td class="nump">1,109,349<span /></td><td class="nump">2,460,582<span /></td><td class="nump">8,931,899<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td><td class="nump">441,653<span /></td><td class="nump">392,881<span /></td><td class="nump">715,588<span /></td><td class="nump">250,008<span /></td><td class="nump">565,723<span /></td><td class="nump">3,299,217<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td><td class="text">&#xA0;<span /></td><td class="nump">305,049<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">245,711<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Accrued dividends</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">2,902,963<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td><td class="nump">77,967<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">162,760<span /></td><td class="nump">288,250<span /></td><td class="nump">10,486,594<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable, current portion</a></td><td class="text">&#xA0;<span /></td><td class="nump">204,802<span /></td><td class="nump">190,789<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue - current</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">33,333<span /></td><td class="nump">33,333<span /></td><td class="nump">33,333<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligations, current portion</a></td><td class="nump">2,197<span /></td><td class="nump">2,085<span /></td><td class="nump">1,944<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td><td class="nump">521,817<span /></td><td class="nump">904,817<span /></td><td class="nump">908,321<span /></td><td class="nump">446,101<span /></td><td class="nump">887,306<span /></td><td class="nump">16,967,818<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debt (Note 7)</a></td><td class="text">&#xA0;<span /></td><td class="nump">2,720,985<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, net of current portion</a></td><td class="nump">450,000<span /></td><td class="nump">920,941<span /></td><td class="nump">675,743<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td><td class="nump">121,394<span /></td><td class="nump">115,311<span /></td><td class="nump">105,338<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease obligations, net of current portion</a></td><td class="nump">4,665<span /></td><td class="nump">6,326<span /></td><td class="nump">8,411<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td><td class="nump">576,059<span /></td><td class="nump">3,763,563<span /></td><td class="nump">789,492<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">DEFERRED REVENUE - NONCURRENT</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">358,333<span /></td><td class="nump">366,667<span /></td><td class="nump">400,000<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>REDEEMABLE PREFERRED STOCK:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmount', window );">Series E convertible preferred stock, $0.00001 par value; 735 shares designated, 0 and 548.26078125 shares issued and outstanding at December 31, 2010 and 2009, respectively (see Note 6)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">18,459,619<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY (DEFICIENCY):</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td><td class="nump">268<span /></td><td class="nump">128<span /></td><td class="nump">128<span /></td><td class="nump">30<span /></td><td class="nump">30<span /></td><td class="nump">5<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td><td class="nump">35,411,337<span /></td><td class="nump">24,178,638<span /></td><td class="nump">23,611,506<span /></td><td class="nump">75,291,653<span /></td><td class="nump">75,183,275<span /></td><td class="nump">49,176,545<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage', window );">Deficit accumulated during the development stage</a></td><td class="num">(29,514,506)<span /></td><td class="num">(24,045,004)<span /></td><td class="num">(19,484,741)<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(74,986,768)<span /></td><td class="num">(73,976,696)<span /></td><td class="num">(76,072,088)<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficiency)</a></td><td class="nump">5,897,099<span /></td><td class="nump">133,762<span /></td><td class="nump">4,126,893<span /></td><td class="nump">304,915<span /></td><td class="nump">1,206,609<span /></td><td class="num">(26,895,538)<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIENCY)</a></td><td class="nump">$ 6,994,975<span /></td><td class="nump">$ 4,802,142<span /></td><td class="nump">$ 5,824,706<span /></td><td class="nump">$ 1,109,349<span /></td><td class="nump">$ 2,460,582<span /></td><td class="nump">$ 8,931,899<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 20<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.19,20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.30(a)(1))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 12<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Concepts (CON)<br /><br /><br /><br /> -Number 6<br /><br /><br /><br /> -Paragraph 25<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 18<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.18)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_Assets</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 3<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 9<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.9)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AssetsCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid within one year (or one operating cycle, if longer) of the balance sheet date.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 840<br /><br /><br /><br /> -SubTopic 30<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (b)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 840<br /><br /><br /><br /> -SubTopic 30<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 13<br /><br /><br /><br /> -Paragraph 7, 10, 13<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CapitalLeaseObligationsCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 840<br /><br /><br /><br /> -SubTopic 30<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.22)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 13<br /><br /><br /><br /> -Paragraph 7, 10, 13<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 22<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 840<br /><br /><br /><br /> -SubTopic 30<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (b)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CapitalLeaseObligationsNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 95<br /><br /><br /><br /> -Paragraph 7<br /><br /><br /><br /> -Footnote 1<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 230<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 95<br /><br /><br /><br /> -Paragraph 8, 9<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (a)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Cash<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 95<br /><br /><br /><br /> -Paragraph 7, 26<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Cash Equivalents<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 942<br /><br /><br /><br /> -SubTopic 210<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.9-03.17)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 17<br /><br /><br /><br /> -Article 9<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 25<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 944<br /><br /><br /><br /> -SubTopic 210<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.7-03.(a),19)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 450<br /><br /><br /><br /> -SubTopic 20<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 5<br /><br /><br /><br /> -Paragraph 8, 9<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.25)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 30<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 22<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.22)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ConvertibleDebtNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /><br /><br /> -Number Topic 5<br /><br /><br /><br /> -Section A<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.8)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 340<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6955238&amp;loc=d3e105025-122735<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredOfferingCosts</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.26(c))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name FASB Technical Bulletin (FTB)<br /><br /><br /><br /> -Number 85-3<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 13<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /> -Subparagraph b<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 840<br /><br /><br /><br /> -SubTopic 20<br /><br /><br /><br /> -Section 25<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (a)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6453417&amp;loc=d3e39927-112707<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredRentCreditNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -Subparagraph (b)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 7, 8<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /><br /><br /> -Number Topic 13<br /><br /><br /><br /> -Section A<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 605<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 605<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -Subparagraph (b)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 7, 8<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /><br /><br /> -Number Topic 13<br /><br /><br /><br /> -Section A<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 48<br /><br /><br /><br /> -Paragraph 6<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 17<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.17)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DepositsAssetsNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 815<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 6<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name FASB Staff Position (FSP)<br /><br /><br /><br /> -Number FIN39-1<br /><br /><br /><br /> -Paragraph 10A, 10B<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 133<br /><br /><br /><br /> -Paragraph 4, 17<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 7<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 815<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 5<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 825<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -Subparagraph (a)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Current Liabilities<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 825<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 15<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13495-108611<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DerivativeLiabilitiesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative net losses reported during the development stage.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 7<br /><br /><br /><br /> -Paragraph 11<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 915<br /><br /><br /><br /> -SubTopic 210<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6472335&amp;loc=d3e37729-110921<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 7<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 20<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Current Liabilities<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DividendsPayableCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 20<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EmployeeRelatedLiabilitiesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 142<br /><br /><br /><br /> -Paragraph 45<br /><br /><br /><br /> -Subparagraph e<br /><br /><br /><br /> -Clause 1<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 142<br /><br /><br /><br /> -Paragraph 43<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 141R<br /><br /><br /><br /> -Paragraph 68<br /><br /><br /><br /> -Subparagraph l<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 142<br /><br /><br /><br /> -Paragraph 45<br /><br /><br /><br /> -Subparagraph e<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 141R<br /><br /><br /><br /> -Paragraph 34<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 350<br /><br /><br /><br /> -SubTopic 20<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13816-109267<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 350<br /><br /><br /><br /> -SubTopic 20<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 141R<br /><br /><br /><br /> -Paragraph 72<br /><br /><br /><br /> -Subparagraph d<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_Goodwill</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 142<br /><br /><br /><br /> -Paragraph 42, 45<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 350<br /><br /><br /><br /> -SubTopic 30<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph ((a)(1),(b))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 350<br /><br /><br /><br /> -SubTopic 30<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IntangibleAssetsNetExcludingGoodwill</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 7<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 9<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e7018-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 20<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Current Liabilities<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_InterestPayableCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 32<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.32)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 25<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 21<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.21)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 22, 23, 24, 25, 26, 27<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.22-26)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 22<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.22)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LongTermNotesPayable</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 19, 20<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.19,20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NotesPayableCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 17<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.17)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 129<br /><br /><br /><br /> -Paragraph 2, 3, 4, 5, 6, 7, 8<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 505<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.3-04)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /><br /><br /> -Number 12<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.28)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 04<br /><br /><br /><br /> -Article 3<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 29<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PreferredStockValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.13)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 13<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 12<br /><br /><br /><br /> -Paragraph 5<br /><br /><br /><br /> -Subparagraph b, c<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 360<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Audit and Accounting Guide (AAG)<br /><br /><br /><br /> -Number AAG-BRD<br /><br /><br /><br /> -Chapter 4<br /><br /><br /><br /> -Paragraph 80<br /><br /><br /><br /> -Subparagraph Exhibit 4-8, 3<br /><br /><br /><br /> -IssueDate 2006-05-01<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.31(a)(3))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /><br /><br /> -Number 12<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 04<br /><br /><br /><br /> -Article 3<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.29-31)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 51<br /><br /><br /><br /> -Paragraph A3<br /><br /><br /><br /> -Appendix A<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 29, 30, 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /><br /><br /> -Number Topic 4<br /><br /><br /><br /> -Section E<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 310<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (SAB TOPIC 4.E)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquity</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquityAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmount"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value (book value) of an entity's issued and outstanding stock which is not included within permanent equity in Stockholders Equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.27(b))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /><br /><br /> -Number D-98<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 4<br /><br /><br /><br /> -Section 08<br /><br /><br /><br /> -Paragraph i<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 28<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquityCarryingAmount</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>1054
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.3.0.15</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ReportType />
  <ContextCount>156</ContextCount>
  <ElementCount>183</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>20</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>true</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/DocumentDocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/StatementOfIncomeAlternative</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - NATURE OF BUSINESS, BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>NATURE OF BUSINESS, BASIS OF PRESENTATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - FAIR VALUES OF ASSETS AND LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock</Role>
      <ShortName>FAIR VALUES OF ASSETS AND LIABILITIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - ACQUISITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsMergersAcquisitionsAndDispositionsDisclosuresTextBlock</Role>
      <ShortName>ACQUISITION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - FIXED ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock</Role>
      <ShortName>FIXED ASSETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - LICENSE AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock</Role>
      <ShortName>LICENSE AGREEMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - CONVERTIBLE DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock</Role>
      <ShortName>CONVERTIBLE DEBT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - LONG-TERM NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock</Role>
      <ShortName>LONG-TERM NOTES PAYABLE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - LINE OF CREDIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock</Role>
      <ShortName>LINE OF CREDIT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - STOCKHOLDERS' DEFICIENCY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>STOCKHOLDERS' DEFICIENCY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>INCOME TAXES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - NET INCOME (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock</Role>
      <ShortName>NET INCOME (LOSS) PER SHARE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock</Role>
      <ShortName>COMMITMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - LITIGATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock</Role>
      <ShortName>LITIGATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - EMPLOYEE RETIREMENT PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock</Role>
      <ShortName>EMPLOYEE RETIREMENT PLAN</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - (UNAUDITED) SUPPLEMENTAL PRO FORMA INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSupplementalFinancialInformationDisclosureTextBlock</Role>
      <ShortName>(UNAUDITED) SUPPLEMENTAL PRO FORMA INFORMATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - PROPOSED REVERSE STOCK SPLIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsReverseStockSplitTextBlock</Role>
      <ShortName>PROPOSED REVERSE STOCK SPLIT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - COLLABORATION AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock</Role>
      <ShortName>COLLABORATION AGREEMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_StockholdersEquity had a mix of decimals attribute values: 8 1 0.</Log>
    <Log type="Info">Element us-gaap_StockholdersEquity had a mix of decimals attribute values: 8 1 0.</Log>
    <Log type="Info">Element us-gaap_StockholdersEquity had a mix of decimals attribute values: 8 1 0.</Log>
    <Log type="Info">Element us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities had a mix of decimals attribute values: 6 0.</Log>
    <Log type="Info">Process Flow-Through: 103 - Statement - BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2008'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2007'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2006'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2005'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2004'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2003'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2002'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2010
Pre Acquisition'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2008
Pre Acquisition'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - BALANCE SHEETS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2008'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2007'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2006'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2005'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2004'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2003'</Log>
    <Log type="Info">Process Flow-Through: 107 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 108 - Statement - STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>nvlt-20110930.xml</File>
    <File>nvlt-20110930.xsd</File>
    <File>nvlt-20110930_cal.xml</File>
    <File>nvlt-20110930_def.xml</File>
    <File>nvlt-20110930_lab.xml</File>
    <File>nvlt-20110930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>1055
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0D%,04Y#15]32$5%
M5%,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"04Q!
M3D-%7U-(14544U]087)E;G1H971I8V%L/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`S+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4U1!5$5-14Y44U]/1E]/4$52051)3TY3/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U1!5$5-14Y4
M4U]/1E]35$]#2TA/3$1%4E-?15%5/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`U+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4U1!5$5-14Y44U]/1E]35$]#2TA/3$1%4E-?15%5
M,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-4051%
M345.5%-?3T9?0T%32%]&3$]74SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/DY!5%5215]/1E]"55-)3D534U]"05-)4U]/1E]04CPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-534U!4EE?
M3T9?4TE'3DE&24-!3E1?04-#3U5.5#PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P.2YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D9!25)?5D%,54537T]&7T%34T544U]!3D1?3$E!
M0CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%#455)
M4TE424]./"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#$Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M1DE8141?05-31513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^3$E#14Y315]!1U)%14U%3E13/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$S+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^0T].5D525$E"3$5?1$5"5#PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DQ/3D=415)-7TY/5$537U!!
M64%"3$4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,
M24Y%7T]&7T-2141)5#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-BYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-43T-+2$],1$524U]$149)0TE%3D-9/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$W
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U1/0TM"05-%1%]#3TU014Y3051)
M3TX\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y)3D-/
M345?5$%815,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y.151?24Y#3TU%7TQ/4U-?4$527U-(05)%/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0T]-34E4345.5%,\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,C$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,251)1T%424]./"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#(R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^14U03$]9145?4D5425)%
M345.5%]03$%./"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#(S+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4D5,051%1%]005)465]44D%.4T%#5$E/3E,\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C0N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y53D%51$E4141?4U504$Q%345.5$%,
M7U!23U]&3U(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,C4N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y04D]03U-%1%]2159%4E-%7U-43T-+7U-03$E4/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(V
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T],3$%"3U)!5$E/3E]!1U)%14U%
M3E13/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#(W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U5"
M4T51545.5%]%5D5.5%,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C@N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z17AC96Q7;W)K<VAE971S/@T*("`\
M>#I3='EL97-H965T($A2968],T0B5V]R:W-H965T<R]R97!O<G0N8W-S(B\^
M#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z06-T:79E4VAE970^#0H@(#QX.E!R
M;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R93X-"B`@
M/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O=W,^#0H@
M/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-"CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E(&]P96YE
M9"!W:71H($UI8W)O<V]F="!%>&-E;"!84"!O<B!N97=E<BX\+W`^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14-*04,^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET>2!);F9O
M<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D1O8W5M96YT($EN9F]R;6%T:6]N(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U
M;65N="!4>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y3+3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#YF86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$871E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#Y397`@,S`L#0H)"3(P,3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R861I;F<@
M4WEM8F]L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y.5DQ4/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;G1I='D@4F5G:7-T<F%N="!.86UE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#Y.3U9%3$]3(%1(15)!4$555$E#4RP@24Y#+CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-E
M;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XP,#`Q,C<Y-S`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/E-M86QL97(@4F5P;W)T:6YG($-O;7!A
M;GD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0R
M9#%A,V8X7S!C-3=?-#$V.%]B961C7S@V-S=D8V1B,S5E8PT*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]D,F0Q83-F.%\P8S4W7S0Q-CA?8F5D8U\X
M-C<W9&-D8C,U96,O5V]R:W-H965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M3S5"23X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY"04Q!3D-%(%-(14544R`H
M55-$("9N8G-P.R0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#`Y/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3$\8G(^4')E($%C<75I<VET
M:6]N/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3`\8G(^4')E($%C<75I<VET:6]N/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#D\8G(^4')E($%C<75I<VET:6]N
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-54E)%3E0@05-31513.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#$L-3DP+#<U-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N
M8G-P.R0@-C<S+#<S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B9N8G-P.R0@.3@P+#$R-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,2PP,S`L.30R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)FYB<W`[)"`R+#,W,BPY-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#@L-S8Y+#4R.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I8W1E
M9"!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M-34L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-34U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R
M<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P
M,RPV,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,2PP-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV.2PV,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR."PP-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,RPU,C8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#(L.3(S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E
M9"!I<W-U86YC92!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,34Y+#,P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDY+#0V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(X+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@87-S971S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$P."PV.#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(W
M.2PW.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#<P-"PR,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#`X-RPT.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0S-BPT-S<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#@W,BPT-3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9)
M6$5$($%34T544RP@3D54/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#$X,RPV,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#4Q,"PT.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT+#`X."PY-3$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#4Q-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-S4U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L,#DW
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y)3E1!3D=)0DQ%($%34T544SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3DL-C<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$15!/4TE44SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,34L,S4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,34L,S4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,34L,S4P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%6$-%4U,@4%520TA!4T4@
M4%))0T4@3U9%4B!.150@05-31513($%#455)4D5$/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#8W-2PT-C(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]42$52($%34T544SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L,C(R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L.#<R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L.#<R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5$]404P@05-31513/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV+#DY-"PY-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT+#@P,BPQ-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU+#@R-"PW,#8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$P.2PS-#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0V,"PU
M.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX+#DS,2PX.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0U524D5.5"!,24%"24Q)5$E%4SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N
M=',@<&%Y86)L92!A;F0@86-C<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#0Q+#8U,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y,BPX.#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,34L-3@X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P
M+#`P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4V-2PW,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#(Y.2PR,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@:6YT97)E<W0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P-2PP-#D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@8V]M
M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#4L
M-S$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!8V-R=65D(&1I=FED96YD<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPY,#(L.38S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E(&QI86)I;&ET>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S<L.38W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38R+#<V,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X."PR
M-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,"PT.#8L-3DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.;W1E<R!P87EA8FQE+"!C=7)R96YT('!O<G1I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P-"PX,#(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.3`L-S@Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$969E<G)E9"!R979E;G5E("T@8W5R<F5N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S,L,S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S,L,S,S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,L,S,S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87!I=&%L(&QE
M87-E(&]B;&EG871I;VYS+"!C=7)R96YT('!O<G1I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L,3DW/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP.#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DT-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U
M<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4R,2PX,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY,#0L.#$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.3`X+#,R,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T-BPQ,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.#<L,S`V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L.38W
M+#@Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY,3TY'+51%4DT@3$E!0DE,251)15,Z/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE
M(&1E8G0@*$YO=&4@-RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L-S(P+#DX-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F]T97,@<&%Y86)L92P@;F5T(&]F(&-U<G)E;G0@<&]R
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDR
M,"PY-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV-S4L-S0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R96YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,C$L,SDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3$U+#,Q,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P-2PS,S@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<&ET86P@
M;&5A<V4@;V)L:6=A=&EO;G,L(&YE="!O9B!C=7)R96YT('!O<G1I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-C8U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPS,C8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#0Q,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&QO;F<M=&5R;2!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-3<V+#`U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-S8S+#4V,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<X.2PT.3(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1%1D52
M4D5$(%)%5D5.544@+2!.3TY#55)214Y4/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS-3@L,S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S8V+#8V-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-/34U)5$U%3E13
M($%.1"!#3TY424Y'14Y#2453/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4D5$145-04),12!04D5&15)2140@4U1/0TLZ/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!%(&-O;G9E
M<G1I8FQE('!R969E<G)E9"!S=&]C:RP@)FYB<W`[)#`N,#`P,#$@<&%R('9A
M;'5E.R`W,S4@<VAA<F5S(&1E<VEG;F%T960L(#`@86YD(#4T."XR-C`W.#$R
M-2!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!A="!$96-E;6)E<B`S
M,2P@,C`Q,"!A;F0@,C`P.2P@<F5S<&5C=&EV96QY("AS964@3F]T92`V*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L-#4Y+#8Q.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY35$]#2TA/3$1%4E,G($5154E462`H1$5&24-)14Y#62DZ/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E
M9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I
M=&EO;F%L('!A:60M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S4L-#$Q+#,S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(T+#$W."PV,S@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPV,3$L-3`V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4L,CDQ
M+#8U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<U+#$X,RPR-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT.2PQ-S8L-30U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969I8VET(&%C8W5M=6QA=&5D
M(&1U<FEN9R!T:&4@9&5V96QO<&UE;G0@<W1A9V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(Y+#4Q-"PU,#8I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C0L,#0U+#`P-"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.2PT.#0L
M-S0Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C=6UU;&%T960@9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-S0L.3@V+#<V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@W,RPY-S8L-CDV*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<V+#`W,BPP.#@I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@<W1O8VMH;VQD97)S)R!E<75I='D@*&1E9FEC:65N8WDI/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#@Y-RPP.3D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S,L-S8R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-"PQ,C8L.#DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S`T+#DQ-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,C`V+#8P.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(V+#@Y-2PU,S@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5$]404P@
M3$E!0DE,251)15,L(%)%1$5%34%"3$4@4%)%1D524D5$(%-43T-+($%.1"!3
M5$]#2TA/3$1%4E,G($5154E462`H1$5&24-)14Y#62D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@-BPY.30L.3<U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`T
M+#@P,BPQ-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XF;F)S<#LD(#4L.#(T+#<P-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,2PQ,#DL,S0Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB
M<W`[)"`R+#0V,"PU.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XF;F)S<#LD(#@L.3,Q+#@Y.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#)D,6$S9CA?,&,U-U\T,38X
M7V)E9&-?.#8W-V1C9&(S-65C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V0R9#%A,V8X7S!C-3=?-#$V.%]B961C7S@V-S=D8V1B,S5E8R]7;W)K
M<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4U5D%'/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/D)!3$%.0T4@4TA%1513("A087)E;G1H971I8V%L*2`H
M55-$("9N8G-P.R0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#`Y/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3$\8G(^4')E($%C<75I<VET
M:6]N/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3`\8G(^4')E($%C<75I<VET:6]N/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#D\8G(^4')E($%C<75I<VET:6]N
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@
M12!C;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL('!A<B!V86QU93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`P+C`P,#`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB
M<W`[)"`P+C`P,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y397)I97,@12!C;VYV97)T:6)L92!P<F5F97)R960@
M<W1O8VLL('-H87)E<R!D97-I9VYA=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!%(&-O;G9E<G1I8FQE('!R969E
M<G)E9"!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4T."XR-C`W.#$R-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S($4@8V]N=F5R=&EB
M;&4@<')E9F5R<F5D('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-#@N,C8P-S@Q,C4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E
M<G)E9"!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XF;F)S<#LD(#`N,#`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#`N,#`P,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD
M(#`N,#`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XF;F)S<#LD(#`N,#`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#`N,#`P,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E
M<G)E9"!3=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M969E<G)E9"!3=&]C:RP@<VAA<F5S(&1E<VEG;F%T960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(W,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D(%-T;V-K+"!I
M<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R969E<G)E9"!S=&]C:RP@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A
M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#`N
M,#`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XF;F)S<#LD(#`N,#`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#`N,#`P,#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#`N
M,#`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XF;F)S<#LD(#`N,#`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#`N,#`P,#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S
M=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$U,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U
M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,34P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-BPX,C8L,34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3(L.#(P+#$P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#@R,"PQ,#(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DU.2PX-S$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DU
M.2PY,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-34L,C@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!O=71S=&%N9&EN
M9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L.#(V+#$U-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R
M+#@R,"PQ,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,BPX,C`L,3`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPY-3DL.#<Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY-3DL.3$T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4U+#(X,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#)D,6$S
M9CA?,&,U-U\T,38X7V)E9&-?.#8W-V1C9&(S-65C#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V0R9#%A,V8X7S!C-3=?-#$V.%]B961C7S@V-S=D
M8V1B,S5E8R]7;W)K<VAE971S+U-H965T,#0N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4U,4))
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-4051%345.5%,@3T8@3U!%4D%4
M24].4R`H55-$("9N8G-P.R0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^.3D@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$P/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`P.3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3$\8G(^4')E($%C<75I
M<VET:6]N/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,3`\8G(^4')E($%C<75I<VET:6]N/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^4')E($%C<75I<VET
M:6]N/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,#D\8G(^4')E($%C<75I<VET:6]N/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y2159%3E5%/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XF;F)S<#LD(#@L,S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`X+#,S,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@
M,S,L,S,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)FYB<W`[)"`S,RPS,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T]35%,@04Y$($584$5.
M4T53.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L-#0U+#0R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C$V+#@S-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.3@T+#(P-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,S4Q
M+#DX,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$W+#(P-2PY-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,S(L-C@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY,3`L.#@Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY.3<L.3@T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PP.#`L
M,C0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PX,C<L-3$P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,30L,#DT/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-38L-30Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PX,C0L,S`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-BPY-S`L,3<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C$Q+#@W-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8T-"PW-C,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0X-BPP,S(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$X
M,BPR-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DUE<F=E<B!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S0V+#(P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4R+#DR-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4R+#DR-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-O<W1S(&%N9"!E
M>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,3DL
M,30V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,RPV,S`L.3(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-"PQ.3,L-C@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BPQ-S8L,C@U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0L,C(Y+#`V,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,30T
M+#4V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L-34U+#8U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L-#@T+#`Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#(V,BPT.34\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,3U-3($923TT@
M3U!%4D%424].4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PP
M,3DL,30V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#,L-C,P+#DR."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@T+#$Y,RPV.#$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPQ-S8L,C@U*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(T+#(R.2PP
M-C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,2PQ,S8L,C,P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(L-30W+#,Q.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#0U,"PV.#(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`L,C(Y+#$V,2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^3U1(15(@24Y#3TU%("A%6%!%3E-%*3H\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@:6YC;VUE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-C@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0R,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#$S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y'<F%N="!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0T+#0W.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C0T+#0W.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R+#DX,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^*$=A:6XI(&QO
M<W,@;VX@9&5R:79A=&EV92!W87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-C8L.#(P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$R-2PT.3`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#@Y-RPT-#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#$Q."PQ-S0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M,BPQ,30L,S<Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3&EQ=6ED871E9"!D86UA9V5S("AS964@3F]T92`V*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#$Y+#`P,"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R
M97-T(&5X<&5N<V4L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-#(X+#`Q-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@T-C<L-#DU*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#4V-BPQ-38I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#,L-3@X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$W+#$P,BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI
M<V-E;&QA;F5O=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L
M,C,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/=&AE<B!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#0R-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#$V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&]T:&5R(&EN8V]M92`H97AP96YS92D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0U,"PS-38I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#8W+#0Y
M-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S-C8L-3@R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#0S+#4X."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ.#0L,#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(V+#$U.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L.#DW+#0T,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L-30V
M+#`W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$R+#`T-"PQ-#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3D54($E.0T]-12`H3$]34RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#4L-#8Y+#4P,BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#`Y."PT,C,I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PU
M-C`L,C8S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#8L,C$Y+#@W,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R-"PP-#4L,#`T*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,#$P+#`W,BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#,U,"PQ
M,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#`Y-2PS.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R,BPR-S,L,S`V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4%)%1D524D5$(%-43T-+($1)5DE$
M14Y$4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C4V+#8S-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M+#(P-RPX,C<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,RPR.38L,C@Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4%)%1D524D5$(%-43T-+($1%14U%1"!$
M259)1$5.1%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$R+#4T
M,2PR,#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-S$T+#`S,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.150@24Y#3TU%("A,3U-3*2!!5%1224)55$%"
M3$4@5$\@0T]-34].(%-43T-+2$],1$524SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XF;F)S<#LD("@Q+#`Q,"PP-S(I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`T+#8Y,RPT
M.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B9N8G-P.R0@*#$R+#8U,RPV,S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD("@R-BPR.#,L-C(V*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0D%3
M24,@04Y$($1)3%54140@3D54($Q/4U,@05144DE"551!0DQ%(%1/($-/34U/
M3B!35$]#2TA/3$1%4E,@4$52($-/34U/3B!32$%213PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD("@P+C(U*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[)"`H,"XS,BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N
M8G-P.R0@*#`N,S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XF;F)S<#LD("@P+C0Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[)"`H,BXU,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@
M*#$U+C,V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)FYB<W`[)"`H.#`N-3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"05-)0R!.150@24Y#3TU%("A,3U-3
M*2!!5%1224)55$%"3$4@5$\@0T]-34].(%-43T-+2$],1$524R!015(@0T]-
M34].(%-(05)%/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P
M.R0@*#`N,S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)FYB<W`[)"`X+CDY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y32$%215,@55-%1"!)3B!#3TU0551)
M3D<@0D%324,@04Y$($1)3%54140@3D54($Q/4U,@05144DE"551!0DQ%(%1/
M($-/34U/3B!35$]#2TA/3$1%4E,@4$52($-/34U/3B!32$%213PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L.#0W+#DX-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#@R,"PQ,#(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,BPX,C`L,3`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3(L.#(P+#$P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDL-3$S+#$Q-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@R,RPY,S,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,C8L,C`Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M2$%215,@55-%1"!)3B!#3TU0551)3D<@0D%324,@3D54($E.0T]-12`H3$]3
M4RD@05144DE"551!0DQ%(%1/($-/34U/3B!35$]#2TA/3$1%4E,@4$52($-/
M34U/3B!32$%213PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY
M-3DL.#<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3(R+#,U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1$E,551%1"!.150@24Y#3TU%("A,3U-3*2!!5%12
M24)55$%"3$4@5$\@0T]-34].(%-43T-+2$],1$524R!015(@0T]-34].(%-(
M05)%/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#`N
M,S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)FYB<W`[)"`S+C0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y32$%215,@55-%1"!)3B!#3TU0551)3D<@1$E,
M551%1"!.150@24Y#3TU%("A,3U-3*2!!5%1224)55$%"3$4@5$\@0T]-34].
M(%-43T-+2$],1$524R!015(@0T]-34].(%-(05)%/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#DU.2PX-S$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.#$L.#8Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D,F0Q83-F.%\P8S4W7S0Q
M-CA?8F5D8U\X-C<W9&-D8C,U96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO9#)D,6$S9CA?,&,U-U\T,38X7V)E9&-?.#8W-V1C9&(S-65C+U=O
M<FMS:&5E=',O4VAE970P-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13%255$^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0Q/CQS=')O;F<^4U1!5$5-14Y44R!/1B!35$]#2TA/3$1%4E,G($51
M54E462`H55-$("9N8G-P.R0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E1O=&%L/&)R/E531"`H)FYB<W`[)"D\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4')E($%C<75I<VET:6]N/&)R
M/E531"`H)FYB<W`[)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^0V%S:#QB<CY54T0@*"9N8G-P.R0I/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E!R;V9E<W-I;VYA;"!397)V:6-E<SQB<CY54T0@*"9N
M8G-P.R0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/FQI8V5N
M<V5D('1E8VAN;VQO9WD\8G(^55-$("@F;F)S<#LD*3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y#;VYV97)T:6)L92!$96)T/&)R/E531"`H
M)FYB<W`[)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5R
M:65S($,@0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K(&%N9"!!8V-U;75L
M871E9"!$:79I9&5N9',\8G(^4')E($%C<75I<VET:6]N/&)R/E531"`H)FYB
M<W`[)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5R:65S
M($4@0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K(&%N9"!!8V-U;75L871E
M9"!$:79I9&5N9',\8G(^4')E($%C<75I<VET:6]N/&)R/E531"`H)FYB<W`[
M)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4')I=F%T92!0
M;&%C96UE;G0\8G(^4')E($%C<75I<VET:6]N/&)R/E531"`H)FYB<W`[)"D\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4'5B;&EC($]F9F5R
M:6YG/&)R/E!R92!!8W%U:7-I=&EO;CQB<CY54T0@*"9N8G-P.R0I/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E!R969E<G)E9"!3=&]C:R!A
M;F0@1&EV:61E;F0\8G(^4')E($%C<75I<VET:6]N/&)R/E531"`H)FYB<W`[
M)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N(%-T
M;V-K/&)R/E531"`H)FYB<W`[)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^0V]M;6]N(%-T;V-K/&)R/E!R92!!8W%U:7-I=&EO;CQB<CY5
M4T0@*"9N8G-P.R0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D-O;6UO;B!3=&]C:SQB<CY#87-H/&)R/E531"`H)FYB<W`[)"D\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N(%-T;V-K/&)R/E!R
M;V9E<W-I;VYA;"!397)V:6-E<SQB<CY54T0@*"9N8G-P.R0I/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D-O;6UO;B!3=&]C:SQB<CYL:6-E
M;G-E9"!T96-H;F]L;V=Y/&)R/E531"`H)FYB<W`[)"D\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N(%-T;V-K/&)R/D-O;G9E<G1I
M8FQE($1E8G0\8G(^55-$("@F;F)S<#LD*3QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y#;VUM;VX@4W1O8VL\8G(^4V5R:65S($,@0V]N=F5R
M=&EB;&4@4')E9F5R<F5D(%-T;V-K(&%N9"!!8V-U;75L871E9"!$:79I9&5N
M9',\8G(^4')E($%C<75I<VET:6]N/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D-O;6UO;B!3=&]C:SQB<CY397)I97,@12!#;VYV97)T:6)L
M92!0<F5F97)R960@4W1O8VL@86YD($%C8W5M=6QA=&5D($1I=FED96YD<SQB
M<CY0<F4@06-Q=6ES:71I;VX\8G(^55-$("@F;F)S<#LD*3QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y#;VUM;VX@4W1O8VL\8G(^4')I=F%T
M92!0;&%C96UE;G0\8G(^4')E($%C<75I<VET:6]N/&)R/E531"`H)FYB<W`[
M)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N(%-T
M;V-K/&)R/E!U8FQI8R!/9F9E<FEN9SQB<CY0<F4@06-Q=6ES:71I;VX\8G(^
M55-$("@F;F)S<#LD*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y#;VUM;VX@4W1O8VL\8G(^4')E9F5R<F5D(%-T;V-K(&%N9"!$:79I9&5N
M9#QB<CY0<F4@06-Q=6ES:71I;VX\8G(^55-$("@F;F)S<#LD*3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!9&1I=&EO;F%L(%!A:60M:6X@
M0V%P:71A;#QB<CY54T0@*"9N8G-P.R0I/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D%D9&ET:6]N86P@4&%I9"UI;B!#87!I=&%L/&)R/E!R
M92!!8W%U:7-I=&EO;CQB<CY54T0@*"9N8G-P.R0I/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D%D9&ET:6]N86P@4&%I9"UI;B!#87!I=&%L
M/&)R/D-A<V@\8G(^55-$("@F;F)S<#LD*3QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y!9&1I=&EO;F%L(%!A:60M:6X@0V%P:71A;#QB<CY0
M<F]F97-S:6]N86P@4V5R=FEC97,\8G(^55-$("@F;F)S<#LD*3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!9&1I=&EO;F%L(%!A:60M:6X@
M0V%P:71A;#QB<CYL:6-E;G-E9"!T96-H;F]L;V=Y/&)R/E531"`H)FYB<W`[
M)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^061D:71I;VYA
M;"!086ED+6EN($-A<&ET86P\8G(^0V]N=F5R=&EB;&4@1&5B=#QB<CY54T0@
M*"9N8G-P.R0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%D
M9&ET:6]N86P@4&%I9"UI;B!#87!I=&%L/&)R/E-E<FEE<R!#($-O;G9E<G1I
M8FQE(%!R969E<G)E9"!3=&]C:R!A;F0@06-C=6UU;&%T960@1&EV:61E;F1S
M/&)R/E!R92!!8W%U:7-I=&EO;CQB<CY54T0@*"9N8G-P.R0I/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%D9&ET:6]N86P@4&%I9"UI;B!#
M87!I=&%L/&)R/E-E<FEE<R!%($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C
M:R!A;F0@06-C=6UU;&%T960@1&EV:61E;F1S/&)R/E!R92!!8W%U:7-I=&EO
M;CQB<CY54T0@*"9N8G-P.R0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D%D9&ET:6]N86P@4&%I9"UI;B!#87!I=&%L/&)R/E!R:79A=&4@
M4&QA8V5M96YT/&)R/E!R92!!8W%U:7-I=&EO;CQB<CY54T0@*"9N8G-P.R0I
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%D9&ET:6]N86P@
M4&%I9"UI;B!#87!I=&%L/&)R/E!U8FQI8R!/9F9E<FEN9SQB<CY0<F4@06-Q
M=6ES:71I;VX\8G(^55-$("@F;F)S<#LD*3QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y!9&1I=&EO;F%L(%!A:60M:6X@0V%P:71A;#QB<CY0
M<F5F97)R960@4W1O8VL@86YD($1I=FED96YD/&)R/E!R92!!8W%U:7-I=&EO
M;CQB<CY54T0@*"9N8G-P.R0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E9FEC:70@06-C=6UU;&%T960@1'5R:6YG('1H92!$979E;&]P
M;65N="!3=&%G93QB<CY54T0@*"9N8G-P.R0I/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E)E9&5E;6%B;&4@4')E9F5R<F5D(%-T;V-K(%-E
M<FEE<R!$(&%N9"!%($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:SQB<CY0
M<F4@06-Q=6ES:71I;VX\8G(^55-$("@F;F)S<#LD*3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y2961E96UA8FQE(%!R969E<G)E9"!3=&]C
M:R!397)I97,@1"!A;F0@12!#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL\
M8G(^4V5R:65S($4@0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K(&%N9"!!
M8V-U;75L871E9"!$:79I9&5N9',\8G(^4')E($%C<75I<VET:6]N/&)R/E53
M1"`H)FYB<W`[)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4F5D965M86)L92!0<F5F97)R960@4W1O8VL@4V5R:65S($0@86YD($4@0V]N
M=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K/&)R/E!R969E<G)E9"!3=&]C:R!A
M;F0@1&EV:61E;F0\8G(^4')E($%C<75I<VET:6]N/&)R/E531"`H)FYB<W`[
M)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5R:65S($,@
M0W5M=6QA=&EV92!#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL\8G(^4')E
M($%C<75I<VET:6]N/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<FEE<R!#($-U;75L871I=F4@0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T
M;V-K/&)R/E-E<FEE<R!#($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!A
M;F0@06-C=6UU;&%T960@1&EV:61E;F1S/&)R/E!R92!!8W%U:7-I=&EO;CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397)I97,@0R!#=6UU
M;&%T:79E($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:SQB<CY0<F5F97)R
M960@4W1O8VL@86YD($1I=FED96YD/&)R/E!R92!!8W%U:7-I=&EO;CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!8V-U;75L871E9"!$969I
M8VET/&)R/E!R92!!8W%U:7-I=&EO;CQB<CY54T0@*"9N8G-P.R0I/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@0F%L
M86YC92!A="!.;W8N(#`V+"`R,#`R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R`H:6X@<VAA<F5S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPT-#`L,3(S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`Q
M+#(R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#4Y,"PR-CD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#DL,3`X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)FYB<W`[)"`V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B9N8G-P.R0@,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@-3DP+#(P-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@.2PQ
M,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N9&EN9R!"86QA;F-E(&%T($1E8RX@,S$L(#(P,#(\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4Y.2PS-S<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Y.2PS,3(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN
M9R!"86QA;F-E("AI;B!S:&%R97,I(&%T($1E8RX@,S$L(#(P,#(\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-30Q+#,T,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&EN8V]M
M92`H;&]S<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Y-2PW
M.3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,CDU+#<Y,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R`H:6X@<VAA
M<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<L.34X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`S
M+#0X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT+#DS-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@P+#0Q,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#DS-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P+#0Q,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD
M:6YG($)A;&%N8V4@870@1&5C+B`S,2P@,C`P,SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S@X+#DS-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C@T+#8U.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Y-2PW.3`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I
M;F<@0F%L86YC92`H:6X@<VAA<F5S*2!A="!$96,N(#,Q+"`R,#`S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#<X,BPW.#0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-O
M;64@*&QO<W,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-#(L
M-S8Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#,T,BPW-C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L86YC92!A="!$96,N(#,Q+"`R,#`T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-BPQ-S4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8X-"PV
M-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@V,S@L-34Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4@*&EN('-H87)E<RD@870@1&5C
M+B`S,2P@,C`P-#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPW
M.#(L-S@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@:6YC;VUE("AL;W-S*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-#@Q+#@S-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@T.#$L.#,W*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M
M;6]N('-T;V-K("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV,3`L-C8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@S-2PX-C@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#,U+#@V,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YD:6YG($)A;&%N8V4@870@1&5C+B`S,2P@,C`P-3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#`P+#(P-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,C`L-3(Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PQ,C`L,S@X
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0F5G:6YN:6YG($)A;&%N8V4@*&EN('-H87)E<RD@870@1&5C+B`S,2P@
M,C`P-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPS.3,L-#0X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM;VX@<W1O8VL@<F5P=7)C:&%S960@*&EN('-H87)E<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0S+#@Q.2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C
M:R!R97!U<F-H87-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,S$L-C8W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#,Q+#8V-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,L.3DT/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,L.3DT/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M:6YC;VUE("AL;W-S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M.38S+#0T,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Y-C,L-#0P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K("AI
M;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(P
M,BPQ-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-RPP.3<L,#<R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#`Y-RPP-3`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN
M9R!"86QA;F-E(&%T($1E8RX@,S$L(#(P,#8\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8L-30V+#$V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDU/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PV,CDL.#DX/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPP.#,L.#(X*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YD:6YG($)A;&%N8V4@*&EN('-H87)E<RD@870@1&5C+B`S,2P@,C`P-CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PU-3$L.#`X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R
M8VES92!O9B!W87)R86YT('1O('!U<F-H87-E(&-O;6UO;B!S=&]C:R`H:6X@
M<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4L,#0U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>&5R8VES92!O9B!W87)R86YT('1O('!U<F-H87-E(&-O;6UO;B!S=&]C
M:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#DL
M.3DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4W,"PS.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-S`L,SDR/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@:6YC;VUE("AL
M;W-S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PP.3`L,S(U
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#4L,#DP+#,R-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R`H:6X@<VAA
M<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`L,C4P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M<W-U86YC92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C0Y+#DY.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4@870@
M1&5C+B`S,2P@,C`P-SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPU,C8L,C,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY+#<P,"PR.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@W+#$W-"PQ-3,I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L86YC
M92`H:6X@<VAA<F5S*2!A="!$96,N(#,Q+"`R,#`W/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY+#8X-RPQ,#,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E
M;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<W+#0X
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0W-RPT.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!I;F-O;64@*&QO<W,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@V+#`Y,"PW,34I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPP.3`L-S$U*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@
M;V8@8V]M;6]N('-T;V-K("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#$S,BPY.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L.3,Q+#4V
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3(L.3,Q+#4S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4@870@1&5C+B`S,2P@,C`P
M.#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PX-#0L-38W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3DL
M-#@X+#8P,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C,L,3`Y+#,P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+#(P-"PU-#D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,RPR-C0L.#8X*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S
M+#DP-"PQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@U.2PV.3,L,34S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4@*&EN('-H87)E
M<RD@870@1&5C+B`S,2P@,C`P.#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3(L.#(P+#$P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(X-RPT,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,3,N-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;&%S<VEF:6-A
M=&EO;B!O9B!W87)R86YT<R!T;R!D97)I=F%T:79E(&QI86)I;&ET>2`H<V5E
M($YO=&4@,BD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DY."PY
M-#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-BPX.3,L,S$V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L.#DT+#,W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T
M;V-K(&%N9"!W87)R86YT<R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#DL,3(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O
M8VL@86YD('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX+#DS."PX.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^."PY,S@L.#@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!O9B!W87)R86YT('1O
M('!U<F-H87-E(&-O;6UO;B!S=&]C:R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ-C(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F('=A<G)A
M;G0@=&\@<'5R8VAA<V4@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#`P,"PY-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,"PY-C(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F
M(&-O;6UO;B!S=&]C:R!I;B!E>&-H86YG92!F;W(@=V%R<F%N=',@*&EN('-H
M87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#8R,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&EN(&5X8VAA;F=E(&9O<B!W87)R
M86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV,C4L-S8P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PV,C4L-S8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VUP96YS871I;VX@97AP96YS92!A<W-O8VEA=&5D('=I
M=&@@;W!T:6]N<R!I<W-U960@=&\@96UP;&]Y965S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT,S<L,#8V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,W+#`V-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@
M8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,#(L,3DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3`R+#$Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M<&5N<V%T:6]N(&5X<&5N<V4@*&)E;F5F:70I
M(&%S<V]C:6%T960@=VET:"!O<'1I;VYS(&ES<W5E9"!T;R!N;VXM96UP;&]Y
M965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,C<L,C<Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(W
M+#(W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^27-S=6%N8V4@;V8@4V5R:65S($4@<F5D965M86)L92!C;VYV97)T
M:6)L92!P<F5F97)R960@<W1O8VL@86YD('=A<G)A;G1S+"!N970@;V8@:7-S
M=6%N8V4@8V]S=',@;V8@)FYB<W`[)#<Y-2PT-CD@*&EN('-H87)E<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@
M4V5R:65S($4@<F5D965M86)L92!C;VYV97)T:6)L92!P<F5F97)R960@<W1O
M8VL@86YD('=A<G)A;G1S+"!N970@;V8@:7-S=6%N8V4@8V]S=',@;V8@)FYB
M<W`[)#<Y-2PT-CD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M.3`W+#(P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L.3`W+#(P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8L,CDW+#,R,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@4V5R:65S
M($4@<F5D965M86)L92!C;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL@:6X@
M<&%Y;65N="!O9B!A8V-U;75L871E9"!D:79I9&5N9',H:6X@<VAA<F5S*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$N.30R.#<U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U
M86YC92!O9B!397)I97,@12!R961E96UA8FQE(&-O;G9E<G1I8FQE('!R969E
M<G)E9"!S=&]C:R!I;B!P87EM96YT(&]F(&%C8W5M=6QA=&5D(&1I=FED96YD
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU.3<L,30T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M9&IU<W1M96YT('1O(')E8V]R9"!T:&4@8V%R<GEI;F<@=F%L=64@;V8@4V5R
M:65S($4@<F5D965M86)L92!C;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL@
M870@9F%I<B!V86QU92!O;B!T:&4@9&%T92!O9B!S86QE/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4L.#DR/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(U+#@Y,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$R-2PX.3(I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M86ER('9A;'5E(&]F('1H92!E>'1E;G-I;VX@;V8@97AP:7)A=&EO;B!D871E
M(&]F('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M,SDL.3(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#,Y+#DR,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06-C<F5T:6]N(&]F(&1E96UE9"!D:79I9&5N9"!A
M<W-O8VEA=&5D('=I=&@@=&AE(&5X=&5N<VEO;B!O9B!E>'!I<F%T:6]N(&1A
M=&4@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#@S.2PY,C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH.#,Y+#DR,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1I=FED96YD<R!A8V-R=65D(&]N('!R969E
M<G)E9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPR
M.38L,C@Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#,L,CDV+#(X.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-O;64@*&QO<W,I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#(Q.2PX-S,I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C(L,C<S+#,P-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V
M+#(Q.2PX-S,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,C(L,C<S+#,P-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@;V8@0V]N=F5R=&EB
M;&4@4V5C=7)I=&EE<R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3`L,#4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3$L.#@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.3<N,3@R,#DS-S4I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C@I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV
M97)S:6]N(&]F($-O;G9E<G1I8FQE(%-E8W5R:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$X-"PR-#8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#4Q-"PS,30\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@T+#(T-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M-3$T+#,Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#,R+#$S,"PU-C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L86YC92!A="!$96,N(#,Q
M+"`R,#`Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#$R-BPX
M.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@R-BPX.34L-3,X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,RPV,3$L-3`V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#DL,3<V+#4T-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Y+#0X-"PW
M-#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3@L-#4Y+#8Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#<V+#`W,BPP.#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L86YC92`H:6X@
M<VAA<F5S*2!A="!$96,N(#,Q+"`R,#`Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,BPX,C`L,3`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#4U+#(X,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4T."XR-C`W.#$R-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F5T(&EN8V]M92`H;&]S<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4L,S4P+#$R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4@870@36%R+B`S,2P@,C`Q
M,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@
M0F%L86YC92!A="!$96,N(#,Q+"`R,#`Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT+#$R-BPX.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@R-BPX.34L-3,X*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPV,3$L-3`V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#DL,3<V+#4T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$Y+#0X-"PW-#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-S8L,#<R+#`X."D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!"
M86QA;F-E("AI;B!S:&%R97,I(&%T($1E8RX@,S$L(#(P,#D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#@R,"PQ,#(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-34L,C@Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M>&5R8VES92!O9B!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-3@L-38W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,34X+#4V-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@;V8@<W1O8VL@
M;W!T:6]N<R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2PY.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!A;F0@=V%R
M<F%N=',@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$T,"PP-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!A;F0@=V%R
M<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<T-"PY,3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S0T+#DQ,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YT<FEN<VEC('9A;'5E(&]F(&)E;F5F:6-I86P@8V]N=F5R
M<VEO;B!F96%T=7)E(&%S<V]C:6%T960@=VET:"!T:&4@8V]N=F5R<VEO;B!O
M9B!C;VYV97)T:6)L92!D96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,3,L-SDR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C$S+#<Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@;V8@=V%R<F%N="!T;R!P
M=7)C:&%S92!C;VUM;VX@<W1O8VL@*&EN('-H87)E<RD\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4S+#0W.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@;V8@=V%R<F%N
M="!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L-3@T+#,Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4X-"PS.38\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!E;G-A=&EO
M;B!E>'!E;G-E(&%S<V]C:6%T960@=VET:"!O<'1I;VYS(&ES<W5E9"!T;R!E
M;7!L;WEE97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X-BPS
M,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU.#8L,S(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,U,RPS-#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-3,L,S0P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUP96YS
M871I;VX@97AP96YS92`H8F5N969I="D@87-S;V-I871E9"!W:71H(&]P=&EO
M;G,@:7-S=65D('1O(&YO;BUE;7!L;WEE97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(T.2PP,C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,C0Y+#`R,RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@
M:6YC<F5M96YT86P@<VAA<F5S(&ES<W5E9"!T;R!P<F5F97)R960@<W1O8VMH
M;VQD97)S(&EN(&-O;FYE8W1I;VX@=VET:"!E>&-H86YG92!O9B!P<F5F97)R
M960@<W1O8VL@9F]R(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3$L.34U+#$U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#DU-2PQ-3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@
M;V8@=V%R<F%N=',@:7-S=65D('1O('!R969E<G)E9"!S:&%R96AO;&1E<G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X-BPP-3`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.#8L,#4P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!8V-R971I;VX@;V8@9&5E;65D(&1I=FED96YD(&%S<V]C:6%T960@=VET
M:"!T:&4@:7-S=6%N8V4@;V8@=V%R<F%N=',@=&\@<')E9F5R<F5D('-T;V-K
M:&]L9&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3@V+#`U
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@U.#8L,#4P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-C<F5T:6]N(&]F(&1E96UE9"!D:79I9&5N9"!A<W-O
M8VEA=&5D('=I=&@@=&AE(&EN8W)E;65N=&%L('-H87)E<R!O9B!C;VUM;VX@
M<W1O8VL@:7-S=65D(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@97AC:&%N9V4@
M;V8@<')E9F5R<F5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q,2PY-34L,34Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$Q+#DU-2PQ-3$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:79I9&5N9',@86-C<G5E
M9"!O;B!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(L,C`W+#@R-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R+#(P-RPX,C<I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@:6YC;VUE("AL;W-S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PU-C`L,C8S*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M,#DU+#,Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#0L-38P+#(V,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#`Y-2PS.3(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@;V8@0V]N
M=F5R=&EB;&4@4V5C=7)I=&EE<R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-S8L-S<P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR,C@L,S,X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3,Y+CDY-C<S-C(U
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#0P."XR-C0P-#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!O9B!#;VYV97)T:6)L92!3
M96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#,R
M-"PU,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ.2PP-C0L.#DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-2PS,C0L-3$W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL,#8T+#@V.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L-C@Y+#4Y
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q,RPW-S`L,#(V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4@870@1&5C+B`S,2P@,C`Q
M,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,S+#<V,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C`V
M+#8P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C0L,3<X+#8S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<U+#$X,RPR-S4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-"PP-#4L,#`T*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<S+#DW-BPV
M.38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;F1I;F<@0F%L86YC92`H:6X@<VAA<F5S*2!A="!$96,N(#,Q+"`R
M,#$P/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DU.2PY,30\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!I;F-O;64@*&QO<W,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q+#`Q,"PP-S(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L86YC92!A="!-87(N(#,Q+"`R
M,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#0L.3$U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"
M96=I;FYI;F<@0F%L86YC92!A="!$96,N(#,Q+"`R,#$P/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,S,L-S8R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0L,3<X+#8S.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(T+#`T
M-2PP,#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y"96=I;FYI;F<@0F%L86YC92`H:6X@<VAA<F5S*2!A="!$96,N
M(#,Q+"`R,#$P/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPX
M,C`L,3`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@:6X@82!B=7-I;F5S
M<R!C;VUB:6YA=&EO;B`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPY-3DL.#<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O
M8VL@:6X@82!B=7-I;F5S<R!C;VUB:6YA=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPR,3DL.3`S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(Q.2PX-S,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%I
M9"!I;B!L:65U(&]F(&9R86-T:6]N86P@<VAA<F5S(&EN(&$@8G5S:6YE<W,@
M8V]M8FEN871I;VXL("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@T,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%I9"!I;B!L:65U(&]F(&9R86-T:6]N
M86P@<VAA<F5S(&EN(&$@8G5S:6YE<W,@8V]M8FEN871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$T-2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-#4I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C
M;VUM;VX@<W1O8VL@86YD('=A<G)A;G1S("AI;B!S:&%R97,I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#@T-BPU,S<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F
M(&-O;6UO;B!S=&]C:R!A;F0@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0L.#8V+#0P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PX-C8L,S,X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1R:6YS:6,@
M=F%L=64@;V8@8F5N969I8VEA;"!C;VYV97)S:6]N(&9E871U<F4@87-S;V-I
M871E9"!W:71H('1H92!C;VYV97)S:6]N(&]F(&-O;G9E<G1I8FQE(&1E8G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U-RPY-S,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3<L.3<S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>&5R8VES92!O9B!W87)R86YT('1O('!U<F-H87-E(&-O;6UO;B!S=&]C
M:R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3@L,34S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%>&5R8VES92!O9B!W87)R86YT('1O('!U<F-H87-E(&-O;6UO
M;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#@L,S,Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#@L,S,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8U-2PV-38\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-34L-C4V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@:6YC;VUE
M("AL;W-S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PT-CDL
M-3`R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#4L-#8Y+#4P,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@;V8@0V]N=F5R=&EB;&4@4V5C
M=7)I=&EE<R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-"PQ.#$L-3,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)S:6]N(&]F($-O;G9E<G1I8FQE(%-E
M8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,3@T
M+#<P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPQ.#0L-C8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L86YC92!A="!397`N(#,P+"`R
M,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#4L
M.#DW+#`Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B9N8G-P.R0@,C8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`S-2PT,3$L,S,W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD("@R
M.2PU,30L-3`V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4@*&EN('-H87)E<RD@870@4V5P
M+B`S,"P@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L
M.#(V+#$U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?9#)D,6$S9CA?,&,U-U\T,38X7V)E9&-?.#8W-V1C9&(S-65C#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0R9#%A,V8X7S!C-3=?-#$V.%]B
M961C7S@V-S=D8V1B,S5E8R]7;W)K<VAE971S+U-H965T,#8N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5&14%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-4051%345.5%,@
M3T8@4U1/0TM(3TQ$15)3)R!%455)5%D@*%!A<F5N=&AE=&EC86PI("A0<F4@
M06-Q=6ES:71I;VXL(%531"`F;F)S<#LD*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`P.3QB<CY397)I97,@12!R961E
M96UA8FQE(&-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#`Y/&)R/E!R:79A
M=&4@4&QA8V5M96YT/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3`\8G(^4'5B;&EC($]F9F5R:6YG/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!C;W-T<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`W.34L-#8Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB
M<W`[)"`V,2PQ,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XF;F)S<#LD(#(U,"PX-C(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V0R9#%A,V8X7S!C-3=?-#$V.%]B961C
M7S@V-S=D8V1B,S5E8PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D
M,F0Q83-F.%\P8S4W7S0Q-CA?8F5D8U\X-C<W9&-D8C,U96,O5V]R:W-H965T
M<R]3:&5E=#`W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%055#2SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY35$%414U%3E13($]&($-!4T@@1DQ/5U,@*%531"`F;F)S<#LD
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CDY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,#D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$Q/&)R/E!R92!!8W%U:7-I=&EO;CQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$P/&)R/E!R92!!
M8W%U:7-I=&EO;CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$P/&)R/E!R92!!8W%U:7-I=&EO;CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#`Y/&)R/E!R92!!8W%U
M:7-I=&EO;CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY#05-(($9,3U=3($923TT@3U!%4D%424Y'($%#5$E6251)15,Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!I;F-O;64@*&QO<W,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B9N8G-P.R0@*#4L-#8Y+#4P,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#0L,#DX+#0R,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@
M*#0L-38P+#(V,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B9N8G-P.R0@*#8L,C$Y+#@W,RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#(T+#`T-2PP
M,#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XF;F)S<#LD("@Q+#`Q,"PP-S(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`U+#,U,"PQ,C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD
M(#(L,#DU+#,Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)FYB<W`[)"`H,C(L,C<S+#,P-BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T
M;65N=',@=&\@<F5C;VYC:6QE(&YE="!I;F-O;64@*&QO<W,I('1O(&-A<V@@
M=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N9"!A
M;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0S
M.2PU.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT,S4L.3$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3@P+#$Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4W-BPW-#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@S,2PQ.3<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(T,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W+#(Y
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,U+#,T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,R+#,U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-34L-C4V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,Q+#$X-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U,RPS
M-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU,#(L,3DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PY-#<L-#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3`X+#,W.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DW+#0W.2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,S<L,CDX/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#8T+#,S
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YT<FEN<VEC('9A;'5E(&]F(&)E;F5F:6-I86P@8V]N=F5R<VEO;B!F
M96%T=7)E(&%S<V]C:6%T960@=VET:"!C;VYV97)T:6)L92!D96)T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3<L.3<S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$S+#<Y,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q,RPW
M.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR,3,L-SDR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!S=&]C:R!F;W(@=&5C:&YO;&]G>2!A
M;F0@<V5R=FEC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Y
M+#4R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26UP86ER;65N="!O9B!I;G1A;F=I8FQE(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL-C<Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL-C<Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL-C<Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M;W-S(&]N(&1I<W!O<V%L(&]F(&9I>&5D(&%S<V5T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-BPP,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8P-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#0V.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^*$=A:6XI(&QO
M<W,@;VX@9&5R:79A=&EV92!W87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C8L.#(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,3(U+#0Y,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#@Y-RPT-#$I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PQ,3@L,3<T
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$R+#$Q-"PS-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYO;BUC87-H('-E='1L96UE;G0@;V8@;&EQ=6ED871E
M9"!D86UA9V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,3DL
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-H86YG97,@:6XZ/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T
M:&5R(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@R,C0L-30X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(P+#8Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$X+#4X-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#$U,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8R+#DQ-"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-2PT.#,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T
M-RPU-S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,SDL,SDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C8L.#8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R
M=65D(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S,S$L,S4W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#0Q.2PV,S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,S(R+#<P-RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-S@L,3,Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDR+#@X,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,Q-2PW
M,34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-#`S+#<V,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R+#<S,RPT.30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,2PS-30L-CDU*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!I;G1E
M<F5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34X+#8W,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R
M,BPW-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS,#4L,#0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S`U+#`T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!C;VUP96YS871I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(S."PP,C(I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C0U+#<Q,2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M+#`W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5F97)R960@<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-BPP.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT+#<V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDL.3<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-C(L-S@Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$U+#,Q,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@
M<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PS,S,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M."PS,S,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,S,L,S,S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#,S+#,S,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('5S960@:6X@;W!E<F%T:6YG
M(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L
M-#,T+#8P-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@S+#(V.2PS-C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,RPS.#(L-#0W*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L-S<U+#(U,"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.2PQ-C(L
M-C$V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$L,S$S+#4P.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@S+#,Q-2PQ.3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RPX,#0L,C@S*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P+#8Q."PS,S@I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-!4T@@1DQ/5U,@1E)/32!)3E9%4U1)3D<@04-4259)5$E%
M4SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V%S:"!A8W%U:7)E9"!I;B!A(&)U<VEN97-S(&-O;6)I;F%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,#4L-C0Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S97,@
M;V8@9FEX960@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q,3(L,3DU*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$L-C4R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$T,RPS-#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PS-C@L,3@Q*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$X+#`P,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;V-E961S(&9R;VT@<V%L92!O9B!F:7AE9"!A<W-E=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S97,@;V8@<VAO<G0M
M=&5R;2!C97)T:69I8V%T97,@;V8@9&5P;W-I=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-2PU,#`L-S,P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!S:&]R
M="UT97)M(&-E<G1I9FEC871E<R!O9B!D97!O<VET/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#4P,"PW,S`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!R97-T<FEC
M=&5D(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@U-34L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4&%Y;65N="!F;W(@:6YT86YG:6)L92!A<W-E=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Y+#8W,2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!R
M;W9I9&5D(&)Y("AU<V5D(&EN*2!I;G9E<W1I;F<@86-T:79I=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR.3,L-#4T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PV-3(I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,30S
M+#,T-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@U+#DS-2PX-3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3@L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#05-(($9,3U=3($92
M3TT@1DE.04Y#24Y'($%#5$E6251)15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@
M;V8@8V]N=F5R=&EB;&4@;F]T97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L-S(P+#DX-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L-S(P+#DX-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S(P+#DX-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@
M9G)O;2!L;VYG+71E<FT@;V)L:6=A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8W-RPY-#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A>6UE;G1S(&]N(&QO
M;F<M=&5R;2!O8FQI9V%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-C<U+#<T,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q-#$L-SDT*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$Y,"PW.#DI/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<W+#@P-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U-3(L,C`Q
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4&%Y;65N=',@;VX@8V%P:71A;"!L96%S92!O8FQI9V%T:6]N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PU-#DI/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PT-#8I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PY-#0I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-C$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(L-38S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@
M<W1O8VLL(&YE="!O9B!I<W-U86YC92!C;W-T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PX-C8L-#`V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L-S`Y+#<P.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C0Y+#$S.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L
M.3,X+#@X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O8V5E9',@9G)O;2!E>&5R8VES92!O9B!W87)R86YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D
M<R!F<F]M(&ES<W5A;F-E(&]F(%-E<FEE<R!%(&-O;G9E<G1I8FQE('!R969E
M<G)E9"!S=&]C:R!A;F0@=V%R<F%N=',L(&YE=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.2PR,#0L-3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297!U<F-H87-E(&]F(&-O;6UO
M;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S$L-C8W
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V%S:"!P86ED(&EN(&QI974@;V8@9G)A8W1I;VYA;"!S:&%R97,@:6X@
M82!B=7-I;F5S<R!C;VUB:6YA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,30U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN(&1E9F5R<F5D(&ES<W5A;F-E(&-O
M<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,S`L.#`P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDY
M+#0V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDY+#0V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#DY+#0V,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R."PU,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&5X97)C
M:7-E(&]F('-T;V-K(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$U-RPT,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-3@L-38W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!P<F]V:61E9"!B>2`H=7-E
M9"!I;BD@9FEN86YC:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0L,#4X+#$V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C<W+#(P-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#<W+#<Q,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(W-RPX
M.#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C4L-S<R+#(P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(X+#4P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-3<L-#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,#<L-S`U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L,30S+#0Q
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DE.0U)%05-%("A$14-214%312D@24X@0T%32"!!3D0@15%5259!3$5.
M5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDQ-RPP,38\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U.3(L
M,34X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#,P-BPS.#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-2PQ.38L-#@T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8W,RPW,SD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#,T,BPP,#DI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPQ-3<L
M-SDW*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#8L,SDV+#4W."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW+#4P-RPP-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-!4T@@04Y$($5154E604Q%3E13
M($%4($)%1TE.3DE.1R!/1B!015))3T0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8W,RPW,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY.#`L,3(U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3@P+#$R-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,3<V+#8P.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S<R
M+#DU,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@L-S8Y+#4R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@L-S8Y+#4R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C8R+#0U,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T%32"!!3D0@15%5
M259!3$5.5%,@050@14Y$($]&(%!%4DE/1#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PU.3`L-S4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S@W+#DV-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W,RPW,SD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.#`L,3(U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C<S
M+#<S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,#,P+#DT,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L-C$Q+#<S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S<R+#DU,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-S8Y+#4R.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY355!03$5-14Y404P@1$E30TQ/4U5215,@3T8@3D].+4-!4T@@1DE.
M04Y#24Y'($%#5$E6251)15,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^26YT97)E<W0@<&%I9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3,L-S$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#(L.#@X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-34L-#4T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C@L-#,V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DT+#DW
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1F%I<B!V86QU92!O9B!D97)I=F%T:79E('=A<G)A;G1S(')E8VQA<W-I
M9FEE9"!T;R!A9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;"!U<&]N(&-A<VAL
M97-S(&5X97)C:7-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M."PS,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#4X-"PS.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!U<&]N
M(&-O;G9E<G-I;VX@;V8@;F]T97,@<&%Y86)L92!A;F0@86-C<G5E9"!I;G1E
M<F5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ.#0L-S`W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#87)R>6EN9R!V86QU92!O9B!R961E96UA8FQE('!R969E<G)E9"!S=&]C
M:R!C;VYV97)T960@:6YT;R!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0L-C@Y+#4Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!A<W-E
M=',@86-Q=6ER960@:6X@97AC:&%N9V4@9F]R('-E8W5R:71I97,@:6X@82!B
M=7-I;F5S<R!C;VUB:6YA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S@L-#`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&QI86)I;&ET:65S(&%S<W5M
M960@:6X@97AC:&%N9V4@9F]R('-E8W5R:71I97,@:6X@82!B=7-I;F5S<R!C
M;VUB:6YA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#,Y
M+#8Q-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X8V5S<R!O9B!P=7)C:&%S92!P<FEC92!O=F5R(&YE="!A<W-E
M=',@86-Q=6ER960@:6X@82!B=7-I;F5S<R!C;VUB:6YA=&EO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV-S4L-#8R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E
M(&]F(&-O;6UO;B!S=&]C:R!I<W-U960@:6X@97AC:&%N9V4@9F]R('1E;F1E
M<B!O9B!D97)I=F%T:79E('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#8R-2PW-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X8VAA;F=E(&]F(%-E<FEE<R!$(&9O
M<B!397)I97,@12!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$S+#DP-"PQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;&%T:79E(&9A:7(@=F%L=64@
M;V8@=V%R<F%N=',@:7-S=65D('1O('-T;V-K:&]L9&5R<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`U,#0L,C(W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`T
M+#@S-2PW,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V0R9#%A,V8X7S!C-3=?-#$V.%]B961C7S@V-S=D8V1B,S5E8PT*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D,F0Q83-F.%\P8S4W7S0Q-CA?
M8F5D8U\X-C<W9&-D8C,U96,O5V]R:W-H965T<R]3:&5E=#`X+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%6$5!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.05154D4@3T8@
M0E5324Y%4U,L($)!4TE3($]&(%!215-%3E1!5$E/3CQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.05154D4@3T8@0E5324Y%4U,L($)!4TE3($]&(%!215-%3E1!
M5$E/3CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R('9A
M;&EG;CTS1'1O<#X-"CQT9"!S='EL93TS1"=724142#H@,S9P="<@86QI9VX]
M,T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"C$N)B-X03`[/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^#0I.05154D4@3T8@0E5324Y%4U,L($)!4TE3($]&(%!215-%3E1!5$E/
M3CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY.;W9E;&]S#0I4:&5R87!E=71I8W,L($EN8RX@
M*"8C>#(P,4,[3F]V96QO<R8C>#(P,40[(&]R('1H90T*)B-X,C`Q0SM#;VUP
M86YY)B-X,C`Q1#LI(&ES(&$@8FEO<&AA<FUA8V5U=&EC86P@8V]M<&%N>2!D
M979E;&]P:6YG#0IC;VUP;W5N9',@9F]R('1H92!T<F5A=&UE;G0@;V8@8V%N
M8V5R+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^3VX-"D%P<FEL(#@L
M(#(P,3$L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(&)U<VEN97-S(&-O
M;6)I;F%T:6]N('=I=&@-"D-E;&QE8W1A<BP@26YC+B`H)B-X,C`Q0SM#96QL
M96-T87(F(W@R,#%$.RDL(&$@<')I=F%T96QY(&AE;&0-"E=I<V-O;G-I;B!C
M;W)P;W)A=&EO;B!T:&%T(&1E<VEG;F5D(&%N9"!D979E;&]P960@<')O9'5C
M=',@=&\-"F1E=&5C="P@=')E870@86YD(&UO;FET;W(@82!W:61E('9A<FEE
M='D@;V8@:'5M86X@8V%N8V5R<R`H=&AE#0HF(W@R,#%#.T%C<75I<VET:6]N
M)B-X,C`Q1#LL('-E92!.;W1E(#$P*2XF(WA!,#LF(WA!,#M);6UE9&EA=&5L
M>0T*<')I;W(@=&\@=&AE($%C<75I<VET:6]N+"!T:&4@0V]M<&%N>2!C;VUP
M;&5T960@82`Q+69O<BTQ-3,@<F5V97)S90T*<W!L:70@;V8@:71S(&-O;6UO
M;B!S=&]C:R`H=&AE("8C>#(P,4,[4F5V97)S92!3<&QI="8C>#(P,40[*2X@
M5&AE#0I#;VUP86YY('1H96X@:7-S=65D('1O('1H92!F;W)M97(@<VAA<F5H
M;VQD97)S(&]F($-E;&QE8W1A<@T*,3<L,#`Q+#4Y-B!S:&%R97,@;V8@:71S
M(&-O;6UO;B!S=&]C:R!A<R!C;VYS:61E<F%T:6]N(&9O<B!T:&4-"D%C<75I
M<VET:6]N+"!W:&EC:"!S:&%R97,@8V]N<W1I='5T960@87!P<F]X:6UA=&5L
M>2`X-24@;V8-"DYO=F5L;W,F(W@R,#$Y.R!O=71S=&%N9&EN9R!C;VUM;VX@
M<W1O8VL@869T97(@9VEV:6YG(&5F9F5C="!T;R!T:&4-"D%C<75I<VET:6]N
M+B8C>$$P.R8C>$$P.U5P;VX@=&AE(&-L;W-I;F<@;V8@=&AE($%C<75I<VET
M:6]N+"!T:&4-"D-O;7!A;GD@8V]M<&QE=&5D('1H92!P<FEV871E('!L86-E
M;65N="!O9B`V+#@T-BPU,S<@<VAA<F5S(&]F(&ET<PT*8V]M;6]N('-T;V-K
M(&%N9"!W87)R86YT<R!T;R!P=7)C:&%S92!A;B!A9&1I=&EO;F%L(#8L.#0V
M+#4S-PT*<VAA<F5S(&]F(&ET<R!C;VUM;VX@<W1O8VL@*&EN(&5A8V@@8V%S
M92!A9G1E<B!G:79I;F<@969F96-T('1O('1H90T*4F5V97)S92!3<&QI="D@
M9F]R(&=R;W-S('!R;V-E961S(&]F(&%P<')O>&EM871E;'D-"B9N8G-P.R0U
M+#$S-2PP,#`N)B-X03`[)B-X03`[07,@82!R97-U;'0@;V8@=&AE($%C<75I
M<VET:6]N+"!T:&4@0V]M<&%N>0T*:7,@:6UP;&5M96YT:6YG(&$@<F5V:7-E
M9"!B=7-I;F5S<R!P;&%N(&9O8W5S960@;VX@=&AE(&1E=F5L;W!M96YT#0IO
M9B!T:&4@0V5L;&5C=&%R(&-O;7!O=6YD<RXF(WA!,#LF(WA!,#M$979E;&]P
M;65N="!O9@T*3F]V96QO<R8C>#(P,3D[(&]T:&5R(&-O;7!O=6YD<R`H3D]6
M+3`P,B!A;F0@3D]6+3(P-2D@:&%S(&)E96X-"G-U<W!E;F1E9#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0G/BX\
M+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"E)E=F5R
M<V4@4W!L:70@<F5D=6-E9"!T:&4@;G5M8F5R(&]F(&]U='-T86YD:6YG('-H
M87)E<R!O9B!#;VUM;VX-"E-T;V-K(&9R;VT@-#4R+#@V-BPY.#,@<VAA<F5S
M('1O)B-X03`[,BPY-3DL.#<Q('-H87)E<RX@3VX@=&AE#0I#;VUP86YY)W,@
M8F%L86YC92!S:&5E="P@=&AE(&%G9W)E9V%T92!P87(@=F%L=64@;V8@=&AE
M(&ES<W5E9`T*8V]M;6]N('-T;V-K('=A<R!R961U8V5D(&)Y(')E8VQA<W-I
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M(')E9'5C960@=&\@,34P+#`P,"PP,#`@9G)O;2`W-3`L,#`P+#`P,"!T;PT*
M<F5F;&5C="!T:&4@<F5D=6-T:6]N(&EN(&%U=&AO<FEZ960@<VAA<F5S(&]F
M(&-O;6UO;B!S=&]C:R!T:&%T#0IB96-A;64@969F96-T:79E(&-O;F-U<G)E
M;G0@=VET:"!T:&4@4F5V97)S92!3<&QI="X\+V9O;G0^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\
M8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
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M97!O<G1I;F<@<'5R<&]S97,N)B-X03`[($%C8V]R9&EN9VQY+"!T:&4@06-Q
M=6ES:71I;VX@=VEL;"!B90T*86-C;W5N=&5D(&9O<B!A<R!A(')E=F5R<V4@
M86-Q=6ES:71I;VX@=VAE<F5B>2!#96QL96-T87(L($EN8RX@=VEL;`T*8F4@
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M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
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M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^3VX-"D9E8G)U
M87)Y(#(T+"`R,#$P+"!T:&4@0V]M<&%N>2!A;FYO=6YC960@=&AA="!I=',@
M4&AA<V4@,R!C;&EN:6-A;`T*=')I86P@9F]R($Y/5BTP,#(@:6X@;F]N+7-M
M86QL(&-E;&P@;'5N9R!C86YC97(-"B@F(W@R,#%#.TY30TQ#)B-X,C`Q1#LI
M("AT:&4@)B-X,C`Q0SM0:&%S92`S(%1R:6%L)B-X,C`Q1#LI(&1I9"!N;W0-
M"FUE970@:71S('!R:6UA<GD@96YD<&]I;G0@;V8@82!S=&%T:7-T:6-A;&QY
M('-I9VYI9FEC86YT(&EN8W)E87-E#0II;B!M961I86X@;W9E<F%L;"!S=7)V
M:79A;"X@1F]L;&]W:6YG(&5V86QU871I;VX@;V8@=&AE(&1E=&%I;&5D#0IT
M<FEA;"!D871A+"!O;B!-87)C:"`Q."P@,C`Q,"P@=&AE($-O;7!A;GD@86YN
M;W5N8V5D('1H870@=&AE#0IS96-O;F1A<GD@96YD<&]I;G1S(&AA9"!A;'-O
M(&YO="!B965N(&UE="!I;B!T:&4@4&AA<V4@,R!4<FEA;"!A;F0-"G1H870@
M:70@:&%D(&1I<V-O;G1I;G5E9"!D979E;&]P;65N="!O9B!.3U8M,#`R(&9O
M<B!.4T-,0R!I;@T*8V]M8FEN871I;VX@=VET:"!F:7)S="UL:6YE('!A8VQI
M=&%X96P@86YD(&-A<F)O<&QA=&EN#0IC:&5M;W1H97)A<'DN/"]F;VYT/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY4:&5S90T*9FEN86YC:6%L('-T871E;65N
M=',@:&%V92!B965N('!R97!A<F5D(&]N('1H92!B87-I<R!T:&%T('1H90T*
M0V]M<&%N>2!W:6QL(&-O;G1I;G5E(&%S(&$@9V]I;F<@8V]N8V5R;BX@5&AE
M($-O;7!A;GD@:&%S(&=E;F5R871E9`T*:6YS:6=N:69I8V%N="!R979E;G5E
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M:71S(&-A<V@@;VX@:&%N9"!A=`T*36%R8V@@,S$L(#(P,3$L('!L=7,@=&AE
M('!R;V-E961S(&9R;VT@=&AE('!R:79A=&4@<&QA8V5M96YT#0IC;VUP;&5T
M960@:6X@8V]N;F5C=&EO;B!W:71H('1H92!!8W%U:7-I=&EO;BP@:7,@861E
M<75A=&4@=&\@9G5N9`T*;W!E<F%T:6]N<R!I;G1O('1H92!F;W5R=&@@<75A
M<G1E<B!O9B`R,#$Q+B8C>$$P.R8C>$$P.U1H90T*0V]M<&%N>28C>#(P,3D[
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M=`T*:70@=VEL;"!O8G1A:6X@=&AE(&YE8V5S<V%R>2!F=6YD:6YG+CPO9F]N
M=#X\+V1I=CX-"CQB<B`O/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"F%C8V]M<&%N
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M;G-T<G5C=&EO;G,@=&\@1F]R;0T*,3`M42XF(WA!,#LF(WA!,#M!8V-O<F1I
M;F=L>2P@=&AE>2!D;R!N;W0@:6YC;'5D92!A;&P@;V8@=&AE#0II;F9O<FUA
M=&EO;B!A;F0@9F]O=&YO=&5S(')E<75I<F5D(&)Y($=!05`@9F]R(&-O;7!L
M971E(&9I;F%N8VEA;`T*<W1A=&5M96YT<RX@26X@=&AE(&]P:6YI;VX@;V8@
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M92!Y96%R(&5N9&EN9R!$96-E;6)E<B`S,2P@,C`Q,2X@5&AE<V4@=6YA=61I
M=&5D(&9I;F%N8VEA;`T*<W1A=&5M96YT<R!S:&]U;&0@8F4@<F5A9"!I;B!C
M;VYJ=6YC=&EO;B!W:71H('1H92!A=61I=&5D(&9I;F%N8VEA;`T*<W1A=&5M
M96YT<R!A;F0@<F5L871E9"!N;W1E<R!T:&5R971O(&EN8VQU9&5D(&EN('1H
M90T*0V]M<&%N>28C>#(P,3D[<R!L871E<W0@86YN=6%L(')E<&]R="!F;W(@
M=&AE('EE87(@96YD960@1&5C96UB97(-"C,Q+"`R,#$P(&]N($9O<FT@,3`M
M2RP@=VAI8V@@=V%S(&9I;&5D('=I=&@@=&AE(%-E8W5R:71I97,@86YD#0I%
M>&-H86YG92!#;VUM:7-S:6]N("@F(W@R,#%#.U-%0R8C>#(P,40[*2!O;B!!
M<')I;"`Q-"P@,C`Q,2XF(WA!,#M4:&4-"G)E<&]R="!F<F]M('1H92!#;VUP
M86YY)B-X,C`Q.3MS(&EN9&5P96YD96YT(')E9VES=&5R960@<'5B;&EC#0IA
M8V-O=6YT:6YG(&9I<FT@9&%T960@07!R:6P@,3$L(#(P,3$@86YD(&EN8VQU
M9&5D('=I=&@@:71S(&%N;G5A;`T*<F5P;W)T(&]N($9O<FT@,3`M2R!I;F1I
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M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I
M=&%L:6,[($1)4U!,05DZ(&EN;&EN92<^#0I#;VUP<F5H96YS:79E($EN8V]M
M92`H3&]S<RD\+V9O;G0^("8C>#(P,3,[(%1H92!#;VUP86YY(&AA9"!N;PT*
M8V]M<&]N96YT<R!O9B!C;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RD@;W1H
M97(@=&AA;B!T:&4@;F5T(&EN8V]M90T**&QO<W,I(&EN(&%L;"!P97)I;V1S
M('!R97-E;G1E9"X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M:6-A=&EO;B`H)B-X,C`Q0SM&05-"($%30R8C>#(P,40[*2P\9F]N="!S='EL
M93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN92<^)B-X
M03`[/"]F;VYT/F%R92!C;&%S<VEF:65D#0IA<R!L:6%B:6QI=&EE<RXF(WA!
M,#LF(WA!,#M);B!S=6-H(&EN<W1A;F-E<RP@;F5T+6-A<V@@<V5T=&QE;65N
M=`T*:7,@87-S=6UE9"!F;W(@9FEN86YC:6%L(')E<&]R=&EN9R!P=7)P;W-E
M<RP@979E;B!W:&5N('1H92!T97)M<R!O9@T*=&AE('5N9&5R;'EI;F<@8V]N
M=')A8W1S(&1O(&YO="!P<F]V:61E(&9O<B!A(&YE="UC87-H('-E='1L96UE
M;G0N#0I4:&5S92!W87)R86YT<R!A<F4@8V]N<VED97)E9"!D97)I=F%T:79E
M(&EN<W1R=6UE;G1S(&)E8V%U<V4@=&AE#0IA9W)E96UE;G1S(&-O;G1A:6X@
M)B-X,C`Q0SMD;W=N+7)O=6YD)B-X,C`Q1#L@<')O=FES:6]N<R!W:&5R96)Y
M('1H90T*;G5M8F5R(&]F('-H87)E<R!F;W(@=VAI8V@@=&AE('=A<G)A;G1S
M(&%R92!E>&5R8VES86)L92!A;F0O;W(@=&AE#0IE>&5R8VES92!P<FEC92!O
M9B!T:&4@=V%R<F%N=',@87)E('-U8FIE8W0@=&\@8VAA;F=E(&EN('1H92!E
M=F5N=`T*;V8@8V5R=&%I;B!I<W-U86YC97,@;V8@<W1O8VL@870@<')I8V5S
M(&)E;&]W('1H92!T:&5N+65F9F5C=&EV90T*97AE<F-I<V4@<')I8V4@;V8@
M=&AE('=A<G)A;G1S+B8C>$$P.R8C>$$P.U1H92!N=6UB97(@;V8@<VAA<F5S
M#0II<W-U86)L92!U;F1E<B!S=6-H('=A<G)A;G1S('=A<R`Q,#4L,#0R(&%T
M($UA<F-H(#,Q+`T*,C`Q,2XF(WA!,#LF(WA!,#M4:&4@<')I;6%R>2!U;F1E
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M>$$P.T%T($UA<F-H(#,Q+"`R,#$Q+"!T:&5S92!W87)R86YT<R!R97!R97-E
M;G1E9`T*=&AE(&]N;'D@;W5T<W1A;F1I;F<@9&5R:79A=&EV92!I;G-T<G5M
M96YT<R!I<W-U960@;W(@:&5L9"!B>2!T:&4-"D-O;7!A;GDN/"]F;VYT/CPO
M9&EV/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/&1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
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M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY.;W9E;&]S#0I4:&5R87!E
M=71I8W,L($EN8RX@*"8C>#(P,4,[3F]V96QO<R8C>#(P,40[(&]R('1H90T*
M)B-X,C`Q0SM#;VUP86YY)B-X,C`Q1#LI(&ES(&$@<&AA<FUA8V5U=&EC86P@
M8V]M<&%N>2!D979E;&]P:6YG#0IC;VUP;W5N9',@9F]R('1H92!T<F5A=&UE
M;G0@;V8@8V%N8V5R+B!/;B!!<')I;"`X+"`R,#$Q+"!.;W9E;&]S#0IC;VUP
M;&5T960@82!B=7-I;F5S<R!C;VUB:6YA=&EO;B!W:71H($-E;&QE8W1A<BP@
M26YC+@T**"8C>#(P,4,[0V5L;&5C=&%R)B-X,C`Q1#LI+"!A('!R:79A=&5L
M>2!H96QD(%=I<V-O;G-I;B!C;W)P;W)A=&EO;@T*=&AA="!D97-I9VYE9"!A
M;F0@9&5V96QO<&5D('!R;V1U8W1S('1O(&1E=&5C="P@=')E870@86YD(&UO
M;FET;W(@80T*=VED92!V87)I971Y(&]F(&AU;6%N(&-A;F-E<G,L(&%N9"!#
M96QL($%C<75I<VET:6]N($-O<G`N("AT:&4-"B8C>#(P,4,[365R9V5R(%-U
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M=&AE<V4-"F9I;F%N8VEA;"!S=&%T96UE;G1S(&%N9"!N;W1E<R!T;R`F(W@R
M,#%#.T-E;&QE8W1A<B8C>#(P,40[(')E;&%T92!T;PT*=&AE(&%C=&EV:71I
M97,@86YD(&9I;F%N8VEA;"!I;F9O<FUA=&EO;B!O9B!#96QL96-T87(@<')I
M;W(@=&\@=&AE#0I!8W%U:7-I=&EO;BP@<F5F97)E;F-E<R!T;R`F(W@R,#%#
M.TYO=F5L;W,F(W@R,#%$.R!R96QA=&4@=&\@=&AE#0IA8W1I=FET:65S(&%N
M9"!F:6YA;F-I86P@:6YF;W)M871I;VX@;V8@3F]V96QO<R!P<FEO<B!T;R!T
M:&4-"D%C<75I<VET:6]N(&%N9"!R969E<F5N8V5S('1O("8C>#(P,4,[=&AE
M($-O;7!A;GDF(W@R,#%$.R!O<@T*)B-X,C`Q0SMW928C>#(P,40[(&]R("8C
M>#(P,4,[=7,F(W@R,#%$.R!O<B`F(W@R,#%#.V]U<B8C>#(P,40[(')E;&%T
M92!T;PT*=&AE(&%C=&EV:71I97,@86YD(&]B;&EG871I;VYS(&]F('1H92!C
M;VUB:6YE9"!#;VUP86YY(&9O;&QO=VEN9PT*=&AE($%C<75I<VET:6]N+CPO
M9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^26UM961I871E;'D-"G!R:6]R
M('1O('1H92!!8W%U:7-I=&EO;BP@3F]V96QO<R!C;VUP;&5T960@82`Q+69O
M<BTQ-3,@<F5V97)S90T*<W!L:70@;V8@:71S(&-O;6UO;B!S=&]C:R`H=&AE
M("8C>#(P,4,[4F5V97)S92!3<&QI="8C>#(P,40[*2XF(WA!,#L-"DYO=F5L
M;W,@=&AE;B!I<W-U960@=&\@=&AE('-H87)E:&]L9&5R<R!O9B!#96QL96-T
M87(@870@=&AA="!D871E#0HQ-RPP,#$L-3DV('-H87)E<R!O9B!I=',@8V]M
M;6]N('-T;V-K(&%S(&-O;G-I9&5R871I;VX@9F]R('1H90T*06-Q=6ES:71I
M;VXL(')E<')E<V5N=&EN9R!A(')A=&EO(&]F(#`N.#0S-2!S:&%R97,@;V8@
M3F]V96QO<PT*8V]M;6]N('-T;V-K(&EN(&5X8VAA;F=E(&9O<B!O;F4@<VAA
M<F4@;V8@0V5L;&5C=&%R(&-O;6UO;B!S=&]C:PT**'1H92`F(W@R,#%#.T5X
M8VAA;F=E(%)A=&EO)B-X,C`Q1#LI(&%S('-E="!F;W)T:"!I;B!T:&4@06=R
M965M96YT#0IA;F0@4&QA;B!O9B!-97)G97(@*'1H92`F(W@R,#%#.TUE<F=E
M<B!!9W)E96UE;G0F(W@R,#%$.RD@9&%T960@07!R:6P-"C@L(#(P,3$N)B-X
M03`[(%1H92!S:&%R97,@:7-S=65D('1O($-E;&QE8W1A<B!S:&%R96AO;&1E
M<G,@:6X@=&AE#0I!8W%U:7-I=&EO;B!C;VYS=&ET=71E9"!A<'!R;WAI;6%T
M96QY(#@U)2!O9B!.;W9E;&]S)B-X,C`Q.3L-"F]U='-T86YD:6YG(&-O;6UO
M;B!S=&]C:R!A9G1E<B!G:79I;F<@969F96-T('1O('1H90T*06-Q=6ES:71I
M;VXN)B-X03`[(%5P;VX@=&AE(&-L;W-I;F<@;V8@=&AE($%C<75I<VET:6]N
M+"!T:&4@0V]M<&%N>0T*8V]M<&QE=&5D('1H92!P<FEV871E('!L86-E;65N
M="!O9B`V+#@T-BPU,S<@<VAA<F5S(&]F(&ET<R!C;VUM;VX-"G-T;V-K(&%N
M9"!W87)R86YT<R!T;R!P=7)C:&%S92!A;B!A9&1I=&EO;F%L(#8L.#0V+#4S
M-R!S:&%R97,@;V8-"FET<R!C;VUM;VX@<W1O8VL@9F]R(&=R;W-S('!R;V-E
M961S(&]F(&%P<')O>&EM871E;'D-"B9N8G-P.R0U+#$S-2PP,#`N/"]F;VYT
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:R<^)B-X03`[/"]D:78^#0H\9&EV/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
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M:6YG(&%N9`T*9FEN86YC:6%L(')E<&]R=&EN9R!P=7)P;W-E<RX@5&AE(&9I
M;F%N8VEA;"!S=&%T96UE;G1S('!R97-E;G1E9`T*:&5R96EN(&%S(&]F(&%N
M9"!F;W(@=&AE('1W96QV92!M;VYT:',@96YD960@1&5C96UB97(@,S$L(#(P
M,3`@86YD#0HR,#`Y(')E<')E<V5N="!T:&4@:&ES=&]R:6-A;"!F:6YA;F-I
M86P@:6YF;W)M871I;VX@;V8@0V5L;&5C=&%R+`T*97AC97!T(&9O<B!T:&4@
M8V%P:71A;"!S=')U8W1U<F4@=VAI8V@@<F5P<F5S96YT<R!T:&4@:&ES=&]R
M:6-A;`T*86UO=6YT<R!O9B!#96QL96-T87(L(')E=')O86-T:79E;'D@861J
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M(&UO;G1H<R!E;F1E9`T*4V5P=&5M8F5R(#,P+"`R,#$Q(&EN8VQU9&4@=&AE
M(&AI<W1O<FEC86P@<F5S=6QT<R!O9B!#96QL96-T87(@9G)O;0T*2F%N=6%R
M>2`Q+"`R,#$Q('1H<F]U9V@@07!R:6P@."P@,C`Q,2P@97AC97!T(&9O<B!T
M:&4@8V%P:71A;`T*<W1R=6-T=7)E('=H:6-H(')E<')E<V5N=',@=&AE(&AI
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M9V@@4V5P=&5M8F5R(#,P+"`R,#$Q+B8C>$$P.R!!;&P@<&5R+7-H87)E(&%M
M;W5N=',@86YD#0IO=71S=&%N9&EN9R!S:&%R97,L(&EN8VQU9&EN9R!A;&P@
M8V]M;6]N('-T;V-K(&5Q=6EV86QE;G1S+"!A;F0-"G-T;V-K(&]P=&EO;G,L
M(&AA=F4@8F5E;B!R971R;V%C=&EV96QY(')E<W1A=&5D(&EN('1H97-E(&9I
M;F%N8VEA;`T*<W1A=&5M96YT<R!A;F0@;F]T97,@9F]R(&%L;"!P97)I;V1S
M('!R97-E;G1E9"!T;R!R969L96-T('1H90T*8V%P:71A;"!S=')U8W1U<F4@
M;V8@3F]V96QO<R!B>2!A<'!L>6EN9R!T:&4@17AC:&%N9V4-"E)A=&EO+B8C
M>$$P.R8C>$$P.U1H92!C=6UU;&%T:79E(&-A<&ET86P@86-T:79I='D@9G)O
M;2!T:&4@9&%T92!O9@T*:6YC97!T:6]N("A.;W9E;6)E<B`W+"`R,#`R*2!U
M<"!T;R!T:&4@8VQO<VEN9R!O9B!T:&4@06-Q=6ES:71I;VXL#0IA<R!P<F5S
M96YT960@:6X@=&AE(&%C8V]M<&%N>6EN9R!S=&%T96UE;G0@;V8@<W1O8VMH
M;VQD97)S)B-X,C`Q.3L-"F5Q=6ET>2P@97%U86QS(#$W+#`P,2PU.38@<VAA
M<F5S(&]F(&-O;6UO;B!S=&]C:RP@=VAI8V@@<F5P<F5S96YT<PT*=&AE(&5Q
M=6ET>2!I;G1E<F5S=',@=&AE(&QE9V%L('!A<F5N="`H3F]V96QO<RD@:7-S
M=65D('1O(&5F9F5C=`T*=&AE($%C<75I<VET:6]N+B!4:&4@;G5M8F5R(&]F
M(&%U=&AO<FEZ960@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:PT*9&ES8VQO<V5D
M(&]N('1H92!B86QA;F-E('-H965T("@Q-3`L,#`P+#`P,"D@<F5P<F5S96YT
M<R!T:&4@;G5M8F5R#0IO9B!A=71H;W)I>F5D('-H87)E<R!O9B!.;W9E;&]S
M(&-O;6UO;B!S=&]C:R!F;VQL;W=I;F<@=&AE#0I!8W%U:7-I=&EO;BXF(WA!
M,#L@061D:71I;VYA;&QY+"!O;B!T:&4@86-C;VUP86YY:6YG(&)A;&%N8V4@
M<VAE971S#0IA<R!O9B!$96-E;6)E<B`S,2P@,C`Q,"!A;F0@,C`P.2!A;F0@
M<W1A=&5M96YT<R!O9@T*<W1O8VMH;VQD97)S)B-X,C`Q.3L@97%U:71Y(&9O
M<B!T:&4@<&5R:6]D(&9R;VT@:6YC97!T:6]N("A.;W9E;6)E<@T*-RP@,C`P
M,BD@=&\@1&5C96UB97(@,S$L(#(P,3`@=&AE(&%G9W)E9V%T92!P87(@=F%L
M=64@;V8@=&AE(&ES<W5E9`T*8V]M;6]N('-T;V-K('=A<R!R961U8V5D('1O
M(')E9FQE8W0@=&AE("9N8G-P.R0P+C`P,#`Q('!A<B!V86QU92!O9@T*3F]V
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M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
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M>$$P.R!$979E;&]P;65N="!O9B!.;W9E;&]S)B-X,C`Q.3L@;W1H97(@8V]M
M<&]U;F1S#0HH3D]6+3`P,B!A;F0@3D]6+3(P-2D@:&%S(&)E96X@<W5S<&5N
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M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY4:&4-"D-O;7!A;GD@:7,@<W5B:F5C="!T;R!A
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M6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0HF
M(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
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M=&5D(&1E9FEC:70@;V8-"B9N8G-P.R0R-"PP-#4L,#`T(&%T($1E8V5M8F5R
M(#,Q+"`R,#$P+B!$=7)I;F<@=&AE('EE87(@96YD960@1&5C96UB97(-"C,Q
M+"`R,#$P+"!#96QL96-T87(@9V5N97)A=&5D(&$@;F5T(&QO<W,@;V8@)FYB
M<W`[)#0L-38P+#(V,R!A;F0@=&AE#0I#;VUP86YY(&5X<&5C=',@=&AA="!I
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M:6]N<R!U;G1I;"!T:&4@96YD(&]F(#(P,3$N)B-X03`[(%1H90T*0V]M<&%N
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M('1H870@:70@=VEL;`T*;V)T86EN('1H92!N96-E<W-A<GD@9G5N9&EN9RXF
M(WA!,#L@5&AE(&%C8V]M<&%N>6EN9R!F:6YA;F-I86P-"G-T871E;65N=',@
M9&\@;F]T(&EN8VQU9&4@86YY(&%D:G5S=&UE;G1S('1H870@;6EG:'0@<F5S
M=6QT(&9R;VT-"G1H92!O=71C;VUE(&]F('1H:7,@=6YC97)T86EN='DN/"]F
M;VYT/CPO9&EV/@T*#0H-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M#0HQ+B!.05154D4@3T8@0E5324Y%4U,L($]21T%.25I!5$E/3B!!3D0@1T])
M3D<@0T].0T523CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
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M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\
M8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/D]N#0I!<')I;"`X+"`R,#$Q+"!T:&4@0V]M<&%N>2!E;G1E
M<F5D(&EN=&\@82!B=7-I;F5S<R!C;VUB:6YA=&EO;B!W:71H#0I#96QL96-T
M87(L($EN8RX@*"8C>#(P,4,[0V5L;&5C=&%R)B-X,C`Q1#LI+"!A('!R:79A
M=&5L>2!H96QD#0I7:7-C;VYS:6X@8V]R<&]R871I;VX@=&AA="!D97-I9VYE
M9"!A;F0@9&5V96QO<&5D('!R;V1U8W1S('1O#0ID971E8W0L('1R96%T(&%N
M9"!M;VYI=&]R(&$@=VED92!V87)I971Y(&]F(&AU;6%N(&-A;F-E<G,@*'1H
M90T*)B-X,C`Q0SM!8W%U:7-I=&EO;B8C>#(P,40[+"!S964@3F]T92`Q,BDN
M($EM;65D:6%T96QY('!R:6]R('1O('1H90T*06-Q=6ES:71I;VXL('1H92!#
M;VUP86YY(&-O;7!L971E9"!A(#$M9F]R+3$U,R!R979E<G-E('-P;&ET(&]F
M(&ET<PT*8V]M;6]N('-T;V-K("AT:&4@)B-X,C`Q0SM2979E<G-E(%-P;&ET
M)B-X,C`Q1#LI+B!4:&4@0V]M<&%N>2!T:&5N#0II<W-U960@,3<L,#`Q+#4Y
M-B!S:&%R97,@;V8@:71S(&-O;6UO;B!S=&]C:R!T;R!T:&4@9F]R;65R#0IS
M:&%R96AO;&1E<G,@;V8@0V5L;&5C=&%R(&%S(&-O;G-I9&5R871I;VX@9F]R
M('1H92!!8W%U:7-I=&EO;BP-"F-O;G-T:71U=&EN9R!A<'!R;WAI;6%T96QY
M(#@U)2!O9B!.;W9E;&]S)B-X,C`Q.3L@;W5T<W1A;F1I;F<@8V]M;6]N#0IS
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M;V8@:71S(&-O;6UO;B!S=&]C:R`H:6X@96%C:"!C87-E(&%F=&5R#0IG:79I
M;F<@969F96-T('1O('1H92!2979E<G-E(%-P;&ET*2!F;W(@9W)O<W,@<')O
M8V5E9',@;V8-"F%P<')O>&EM871E;'D@)FYB<W`[)#4L,3,U+#`P,"X@07,@
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M9FEC97,@=VEL;"!R96UA:6X@:6X@3F5W=&]N+`T*34$N/"]F;VYT/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY4:&4-"E)E=F5R<V4@4W!L:70@<F5D=6-E9"!T
M:&4@;G5M8F5R(&]F(&]U='-T86YD:6YG('-H87)E<R!O9B!#;VUM;VX-"E-T
M;V-K(&9R;VT@-#4R+#@V-BPY.#,@<VAA<F5S('1O(#(L.34Y+#DQ-"`H,BPY
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M,34P+#`P,"PP,#`@9G)O;2`W-3`L,#`P+#`P,"!T;R!R969L96-T('1H90T*
M<F5D=6-T:6]N(&EN(&%U=&AO<FEZ960@<VAA<F5S(&]F(&-O;6UO;B!S=&]C
M:R!T:&%T(&)E8V%M90T*969F96-T:79E(&-O;F-U<G)E;G0@=VET:"!T:&4@
M4F5V97)S92!3<&QI="X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
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M<&]S97,N)B-X03`[($%C8V]R9&EN9VQY+"!T:&4@06-Q=6ES:71I;VX@=VEL
M;"!B90T*86-C;W5N=&5D(&9O<B!A<R!A(')E=F5R<V4@86-Q=6ES:71I;VX@
M=VAE<F5B>2!#96QL96-T87(L($EN8RX@=VEL;`T*8F4@=')E871E9"!A<R!T
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M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
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M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/;@T*1F5B<G5A<GD@,C0L(#(P,3`L
M('1H92!#;VUP86YY(&%N;F]U;F-E9"!T:&%T(&ET<R!0:&%S92`S(&-L:6YI
M8V%L#0IT<FEA;"!F;W(@3D]6+3`P,B!I;B!N;VXM<VUA;&P@8V5L;"!L=6YG
M(&-A;F-E<B`H=&AE("8C>#(P,4,[4&AA<V4@,PT*5')I86PF(W@R,#%$.RD@
M9&ED(&YO="!M965T(&ET<R!P<FEM87)Y(&5N9'!O:6YT(&]F(&$@<W1A=&ES
M=&EC86QL>0T*<VEG;FEF:6-A;G0@:6YC<F5A<V4@:6X@;65D:6%N(&]V97)A
M;&P@<W5R=FEV86PN($9O;&QO=VEN9PT*979A;'5A=&EO;B!O9B!T:&4@9&5T
M86EL960@=')I86P@9&%T82P@;VX@36%R8V@@,3@L(#(P,3`L('1H90T*0V]M
M<&%N>2!A;FYO=6YC960@=&AA="!T:&4@<V5C;VYD87)Y(&5N9'!O:6YT<R!H
M860@86QS;R!N;W0@8F5E;@T*;65T(&EN('1H92!0:&%S92`S(%1R:6%L(&%N
M9"!T:&%T(&ET(&AA9"!D:7-C;VYT:6YU960@9&5V96QO<&UE;G0-"F]F($Y/
M5BTP,#(@9F]R($Y30TQ#(&EN(&-O;6)I;F%T:6]N('=I=&@@9FER<W0M;&EN
M92!P86-L:71A>&5L(&%N9`T*8V%R8F]P;&%T:6X@8VAE;6]T:&5R87!Y+CPO
M9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
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M8V%S:"!O;B!H86YD(&%T($1E8V5M8F5R(#,Q+"`R,#$P+"!P;'5S#0IT:&4@
M<')O8V5E9',@9G)O;2!T:&4@<')I=F%T92!P;&%C96UE;G0@8V]M<&QE=&5D
M(&EN(&-O;FYE8W1I;VX-"G=I=&@@=&AE($%C<75I<VET:6]N+"!I<R!A9&5Q
M=6%T92!T;R!F=6YD(&]P97)A=&EO;G,@:6YT;R!T:&4-"F9O=7)T:"!Q=6%R
M=&5R(&]F(#(P,3$N(%1H92!#;VUP86YY)B-X,C`Q.3MS(&%B:6QI='D@=&\@
M97AE8W5T92!I=',-"F]P97)A=&EN9R!P;&%N(&)E>6]N9"!T:&4@9F]U<G1H
M('%U87)T97(@;V8@,C`Q,2!D97!E;F1S(&]N(&ET<PT*86)I;&ET>2!T;R!O
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M=CX-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?9#)D,6$S9CA?,&,U-U\T,38X7V)E9&-?.#8W-V1C9&(S-65C#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0R9#%A,V8X7S!C-3=?-#$V
M.%]B961C7S@V-S=D8V1B,S5E8R]7;W)K<VAE971S+U-H965T,#DN:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5'1$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-534U!4ED@
M3T8@4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4SQB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-5
M34U!4ED@3T8@4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SX-"C(N(%-534U!4ED@3T8@4TE'3DE&24-!3E0@04-#3U5.5$E.1R!0
M3TQ)0TE%4SPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
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M=',N)B-X03`[(%1H92!U;F%U9&ET960@9FEN86YC:6%L('-T871E;65N=',@
M87,@;V8@86YD(&9O<@T*=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E
M<B`S,"P@,C`Q,2!A<F4@<')E<V5N=&5D(&]N(&$-"F-O;G-O;&ED871E9"!B
M87-I<R!T;R!R969L96-T('1H92!!8W%U:7-I=&EO;B!D97-C<FEB960@:6X@
M3F]T90T*-"X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1H90T*86-C
M;VUP86YY:6YG(&-O;G-O;&ED871E9"!U;F%U9&ET960@4V5P=&5M8F5R(#,P
M+"`R,#$Q(&)A;&%N8V4-"G-H965T+"!T:&4@<W1A=&5M96YT<R!O9B!O<&5R
M871I;VYS(&%N9"!C87-H(&9L;W=S(&9O<B!T:&4@;FEN90T*;6]N=&AS(&5N
M9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,2!A;F0@,C`Q,"P@86YD('1H92!S=&%T
M96UE;G1S(&]F#0IS=&]C:VAO;&1E<G,F(W@R,#$Y.R!E<75I='D@9F]R('1H
M92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L#0HR,#$Q(&%N9"!T
M:&4@<F5L871E9"!I;G1E<FEM(&EN9F]R;6%T:6]N(&-O;G1A:6YE9"!W:71H
M:6X@=&AE(&YO=&5S#0IT;R!T:&4@9FEN86YC:6%L('-T871E;65N=',@:&%V
M92!B965N('!R97!A<F5D(&EN(&%C8V]R9&%N8V4@=VET:`T*=&AE(')U;&5S
M(&%N9"!R96=U;&%T:6]N<R!O9B!T:&4@4V5C=7)I=&EE<R!A;F0@17AC:&%N
M9V4@0V]M;6ES<VEO;@T**"8C>#(P,4,[4T5#)B-X,C`Q1#LI(&9O<B!I;G1E
M<FEM(&9I;F%N8VEA;"!I;F9O<FUA=&EO;BX@06-C;W)D:6YG;'DL#0IT:&5Y
M(&1O(&YO="!I;F-L=61E(&%L;"!O9B!T:&4@:6YF;W)M871I;VX@86YD('1H
M92!N;W1E<R!R97%U:7)E9`T*8GD@52Y3+B!G96YE<F%L;'D@86-C97!T960@
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M86YC:6%L('!O<VET:6]N(&%T(%-E<'1E;6)E<@T*,S`L(#(P,3$@86YD(')E
M<W5L=',@;V8@:71S(&]P97)A=&EO;G,@86YD(&ET<R!C87-H(&9L;W=S(&9O
M<B!T:&4-"FYI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,2!A
M;F0@,C`Q,"!A;F0@=&AE('!E<FEO9"!F<F]M#0I.;W9E;6)E<B`W+"`R,#`R
M("AI;F-E<'1I;VXI('1O(%-E<'1E;6)E<B`S,"P@,C`Q,2X@5&AE(')E<W5L
M=',@9F]R#0IT:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R
M,#$Q(&%R92!N;W0@;F5C97-S87)I;'D-"FEN9&EC871I=F4@;V8@9G5T=7)E
M(')E<W5L=',N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@
M1D].5"U714E'2%0Z(&)O;&0G/@T*1&5V96QO<&UE;G0@4W1A9V4@0V]M<&%N
M>3PO9F]N=#X@)B-X,C`Q-#L@0V5L;&5C=&%R(&AA<R!B965N(&EN('1H90T*
M9&5V96QO<&UE;G0@<W1A9V4@<VEN8V4@:71S(&EN8V5P=&EO;BXF(WA!,#L@
M5&AE('!R:6UA<GD@86-T:79I=&EE<PT*<VEN8V4@:6YC97!T:6]N(&AA=F4@
M8F5E;B!O<F=A;FEZ871I;VYA;"!A8W1I=FET:65S+"!R97-E87)C:"!A;F0-
M"F1E=F5L;W!M96YT(&%N9"!R86ES:6YG(&-A<&ET86PN)B-X03`[($YO('-I
M9VYI9FEC86YT(')E=F5N=65S(&AA=F4-"F)E96X@9V5N97)A=&5D(&9R;VT@
M<&QA;FYE9"!P<FEN8VEP86P@;W!E<F%T:6]N<RXF(WA!,#L@07,@;V8-"E-E
M<'1E;6)E<B`S,"P@,C`Q,2!A;F0@1&5C96UB97(@,S$L(#(P,3`@86YD(#(P
M,#D@=&AE($-O;7!A;GD-"F-O;G1I;G5E<R!T;R!B92!I;B!T:&4@9&5V96QO
M<&UE;G0@<W1A9V4N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-
M"G-U;6UA<GD@=6YA=61I=&5D(&-O;F1E;G-E9"!S=&%T96UE;G0@;V8@;W!E
M<F%T:6]N<R!F;W(@=&AE#0IC=6UU;&%T:79E(&1E=F5L;W!M96YT+7-T86=E
M('!E<FEO9"!F<F]M($YO=F5M8F5R(#<L(#(P,#(@*&1A=&4@;V8-"FEN8V5P
M=&EO;BD@=&AR;W5G:"!397!T96UB97(@,S`L(#(P,3$@:7,@87,@9F]L;&]W
M<SH\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*
M/&1I=B!A;&EG;CTS1&-E;G1E<CX-"CQT86)L92!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,"4^#0H\='(@
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M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#DE(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0X."4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3EP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T
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M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+C9P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`Q+C9P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^,3DL-C4Q+#,X.#PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(T-#1D9#0SX-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X."4@86QI9VX],T1L969T
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3EP=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#$N-G!T
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M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XV<'0G(&%L:6=N
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W
M:&ET93X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0X."4@86QI9VX],T1L969T/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3EP=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#$N-G!T)R!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DUE<F=E
M<@T*8V]S=',\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`Q+C9P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
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M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/"]T<CX-"CQT<B!B9V-O;&]R/3-$(T-#1D9#0SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X
M."4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3EP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`S-G!T.R!-05)'
M24XM4DE'2%0Z(#$N-G!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/E1O=&%L#0IC;W-T<R!A;F0@97AP96YS97,\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A
M;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`Q+C9P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-0
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M;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-
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M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
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M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#@X)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M.7!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#EP=#L@34%21TE.+5))1TA4.B`Q+C9P="<@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY,3U-3#0I&4D]-($]0
M15)!5$E/3E,\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`Q+C9P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^*#(Y+#(T."PR,#D\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XV<'0G(&%L:6=N
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
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M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$.24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
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M#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N-G!T)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXH,C8V+#(Y-SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXI)B-X03`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#@X)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
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M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(T-#
M1D9#0SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0X."4@86QI9VX],T1L969T/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3EP=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`Y<'0[($U!4D=)3BU224=(5#H@,2XV<'0G(&%L:6=N/3-$
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#1P>"!D;W5B;&4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,2XV<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XV<'0G(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@R
M.2PU,30L-3`V/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
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M;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A
M;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
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M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N-G!T)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,BXX
M,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX]
M,T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q
M+C9P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXI/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\='(@8F=C
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M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N-G!T)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,"PU-#DL
M,C0T/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*)B-X
M03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY4:&4-"G-U;6UA<GD@=6YA=61I=&5D(&-O;F1E;G-E9"!S=&%T
M96UE;G0@;V8@8V%S:"!F;&]W(&9O<B!T:&4-"F-U;75L871I=F4@9&5V96QO
M<&UE;G0M<W1A9V4@<&5R:6]D(&9R;VT@3F]V96UB97(@-RP@,C`P,B`H9&%T
M92!O9@T*:6YC97!T:6]N*2!T:')O=6=H(%-E<'1E;6)E<B`S,"P@,C`Q,2!I
M<R!A<R!F;VQL;W=S.CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^)B-X03`[/"]D
M:78^#0H\9&EV/@T*/&1I=B!A;&EG;CTS1&-E;G1E<CX-"CQT86)L92!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0Y,"4^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M.#@E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TY<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%2
M1TE.+5))1TA4.B`Q+C9P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY.970-"FQO<W,\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M*#(Y+#4Q-"PU,#8\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
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M+4E.1$5.5#H@+3EP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q
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M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H
M=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
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M;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T
M<CX-"CQT<B!B9V-O;&]R/3-$(T-#1D9#0SX-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X."4@
M86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3EP
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM
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M:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE(&%L
M:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXS-3DL,3<W/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
M(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X."4@86QI9VX],T1L
M969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3EP=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`T-7!T.R!-05)'24XM4DE'2%0Z(#$N
M-G!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/D-A<V@-"G5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG
M;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^*#(S+#4Y-RPR,C,\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*3PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#@X)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M.7!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#EP=#L@34%21TE.+5))1TA4.B`Q+C9P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#05-(
M#0I&3$]74R!&4D]-($E.5D535$E.1R!!0U1)5DE42453.CPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C
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M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
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M24Y$14Y4.B`M.7!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X
M<'0[($U!4D=)3BU224=(5#H@,2XV<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^0V%S:`T*86-Q=6ER960@:6X@
M82!B=7-I;F5S<R!C;VUB:6YA=&EO;CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CDP-2PV-#D\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(T-#1D9#0SX-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X."4@86QI9VX],T1L969T/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3EP=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#$N-G!T)R!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/E!U<F-H87-E<PT*;V8@9FEX960@87-S971S+"!N970@;V8@)FYB<W`[)#<L
M,#`P('!R;V-E961S(&9R;VT@<V%L92!O9B!F:7AE9`T*87-S971S/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
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M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X\
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M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#@X)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M.7!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
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M;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE(&%L:6=N/3-$<FEG
M:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXH-34L,#`P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
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M(#!P=#L@34%21TE.+5))1TA4.B`Q+C9P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#LF(WA!,#LF(WA!
M,#LF(WA!,#M087EM96YT#0IF;W(@:6YT86YG:6)L92!A<W-E=',\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS
M1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
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M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@X
M)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M.7!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#0U<'0[($U!4D=)
M3BU224=(5#H@,2XV<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^0V%S:`T*=7-E9"!I;B!I;G9E<W1I;F<@86-T
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M5$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH-"PV-#(L,SDX/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
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M63H@8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[($U!4D=)3BU224=(5#H@,2XV
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^0T%32`T*1DQ/5U,@1E)/32!&24Y!3D-)3D<@04-4259)5$E%4SH\
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M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
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M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0X."4@86QI9VX],T1L969T/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3EP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#$N-G!T)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E!R;V-E961S
M#0IF<F]M(&ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!A;F0@=V%R<F%N=',L
M(&YE="!O9B!I<W-U86YC92!C;W-T<RP-"G)E<'5R8VAA<V4@;V8@8V]M;6]N
M('-T;V-K+"!A;F0@8V%S:"!P86ED(&EN(&QI974@;V8@9G)A8W1I;VYA;`T*
M<VAA<F5S(&EN(&$@8G5S:6YE<W,@8V]M8FEN871I;VX\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR-BPW.30L,S`R/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&
M1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@X)2!A;&EG;CTS
M1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M.7!T.R!$25-0
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M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX]
M,T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B@Q,S`L.#`P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
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M(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`Q+C9P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY0<F]C965D<PT*9G)O;2!I<W-U86YC92!O9B!L;VYG+71E<FT@;V)L
M:6=A=&EO;G,\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXT+#,Y."PY,S`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS
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M1TA4.B`Q+C9P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SY087EM96YT<PT*;VX@;&]N9RUT97)M(&]B;&EG871I
M;VYS/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B@Q+#(S,BPP-38\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*3PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0X."4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3EP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`T-7!T.R!-05)'24XM4DE'2%0Z(#$N-G!T)R!A;&EG;CTS1&QE9G0^/&9O
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M;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(Y+#@S
M,"PS-S8\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L
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M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^
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M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI
M9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
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M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
M(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@X)2!A;&EG;CTS
M1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M.7!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@34%21TE.+5))1TA4.B`Q
M+C9P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY#05-(#0I!3D0@15%5259!3$5.5%,@050@14Y$($]&(%!%4DE/
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M;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A
M;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+#4Y
M,"PW-34\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@X)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M.7!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@34%21TE.+5))1TA4.B`Q+C9P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY355!03$5-14Y404P-"D1)4T-,3U-54D4@3T8@0T%32"!&3$]7($E.
M1D]234%424]./"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(T-#1D9#0SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0X."4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3EP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#$N-G!T)R!A;&EG;CTS1&QE9G0^
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#1P>"!D;W5B;&4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(P
M."PV.#D\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#@X)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M.7!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
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M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O
M=6)L92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF;F)S<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X\9F]N
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M;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-
M"CQT<B!B9V-O;&]R/3-$(T-#1D9#0SX-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X."4@86QI
M9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3EP=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'
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M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T
M<'@@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS
M1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
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M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS+#$X-"PW,#<\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X
M."4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3EP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'
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M;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A
M;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXW."PT
M,#<\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#@X)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M.7!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[
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M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D
M;W5B;&4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE(&%L:6=N/3-$<FEG
M:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXH-#,Y+#8Q-3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@X)2!A
M;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M.7!T
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M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O
M=6)L92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF;F)S<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X\9F]N
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M;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T
M<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@86QI9VX],T1C96YT97(^)B-X
M03`[/"]D:78^#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*/"$M+45&4&QA8V5H;VQD97(M+3X\9F]N="!S
M='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@
M1D].5"U714E'2%0Z(&)O;&0G/E5S92!O9@T*17-T:6UA=&5S/"]F;VYT/B`F
M(W@R,#$T.R!4:&4@<')E<&%R871I;VX@;V8@9FEN86YC:6%L('-T871E;65N
M=',@:6X-"F-O;F9O<FUI='D@=VET:"!A8V-O=6YT:6YG('!R:6YC:7!L97,@
M9V5N97)A;&QY(&%C8V5P=&5D(&EN('1H90T*56YI=&5D(%-T871E<R!R97%U
M:7)E<R!M86YA9V5M96YT('1O(&UA:V4@97-T:6UA=&5S(&%N9"!J=61G;65N
M=',-"G1H870@;6%Y(&%F9F5C="!T:&4@<F5P;W)T960@86UO=6YT<R!O9B!A
M<W-E=',L(&QI86)I;&ET:65S+`T*<F5V96YU92!A;F0@97AP96YS97,@86YD
M(&1I<V-L;W-U<F4@;V8@8V]N=&EN9V5N="!A<W-E=',@86YD#0IL:6%B:6QI
M=&EE<RX@3VX@86X@;VXM9V]I;F<@8F%S:7,L(&UA;F%G96UE;G0@979A;'5A
M=&5S(&ET<PT*97-T:6UA=&5S(&EN8VQU9&EN9R!T:&]S92!R96QA=&5D('1O
M('5N8FEL;&5D('9E;F1O<B!A;6]U;G1S(&%N9`T*<VAA<F4M8F%S960@8V]M
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M87-S971S(&%N9`T*;&EA8FEL:71I97,N($%C='5A;"!R97-U;'1S(&UA>2!D
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M8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
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M8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@
M:71A;&EC.R!$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD)SX-
M"E)E<W1R:6-T960@0V%S:#PO9F]N=#X@)B-X,C`Q-#L@4F5S=')I8W1E9"!C
M87-H(&%T(%-E<'1E;6)E<B`S,"P-"C(P,3$@8V]N<VES=',@;V8@82!C97)T
M:69I8V%T92!O9B!D97!O<VET(')E<75I<F5D('5N9&5R('1H90T*0V]M<&%N
M>28C>#(P,3D[<R!L96%S92!A9W)E96UE;G0@*'-E92!.;W1E(#$T*2XF(WA!
M,#L@4F5S=')I8W1E9`T*8V%S:"!A="!$96-E;6)E<B`S,2P@,C`Q,"!A;F0@
M1&5C96UB97(@,S$L(#(P,#D@8V]N<VES=',@;V8@80T*8V5R=&EF:6-A=&4@
M;V8@9&5P;W-I="!R97%U:7)E9"!F;W(@8V]L;&%T97)A;"!F;W(@82!P<F]M
M:7-S;W)Y#0IN;W1E('=I=&@@82!B86YK("AS964@3F]T92`X*2!A;F0@82!C
M97)T:69I8V%T92!O9B!D97!O<VET(')E<75I<F5D#0IU;F1E<B!T:&4@0V]M
M<&%N>28C>#(P,3D[<R!L96%S92!A9W)E96UE;G0@*'-E92!.;W1E#0HQ-"DN
M/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&
M3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'
M2%0Z(&)O;&0G/@T*1FEX960@07-S971S/"]F;VYT/B`F(W@R,#$T.R!0<F]P
M97)T>2!A;F0@97%U:7!M96YT(&%R92!S=&%T960@870-"F-O<W0N($1E<')E
M8VEA=&EO;B!O;B!P<F]P97)T>2!A;F0@97%U:7!M96YT(&ES('!R;W9I9&5D
M('5S:6YG('1H90T*<W1R86EG:'0M;&EN92!M971H;V0@;W9E<B!T:&4@97-T
M:6UA=&5D('5S969U;"!L:79E<R!O9B!T:&4@87-S971S#0HH-2!Y96%R<RDN
M)B-X03`[($1U92!T;R!T:&4@<VEG;FEF:6-A;G0@=F%L=64@;V8@;&5A<V5H
M;VQD#0II;7!R;W9E;65N=',@<'5R8VAA<V5D(&1U<FEN9R!T:&4@:6YI=&EA
M;"`S+7EE87(@;&5A<V4@=&5R;2!A;F0@=&AE#0IE8V]N;VUI8R!P96YA;'1Y
M(&9O<B!N;W0@97AT96YD:6YG('1H92!B=6EL9&EN9R!L96%S92P@;&5A<V5H
M;VQD#0II;7!R;W9E;65N=',@87)E(&1E<')E8VEA=&5D(&]V97(@,3<@>65A
M<G,@*'1H96ER(&5S=&EM871E9"!U<V5F=6P-"FQI9F4I('=H:6-H(')E<')E
M<V5N=',@=&AE(&9U;&P@=&5R;2!O9B!T:&4@;&5A<V4L(&EN8VQU9&EN9R!A
M;&P-"F5X=&5N<VEO;G,@*$YO=&4@,30I+CPO9F]N=#X\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB
M<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$
M25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD)SX-"DEN=&%N9VEB
M;&4@07-S971S/"]F;VYT/B`F(W@R,#$T.R!);G1A;F=I8FQE(&%S<V5T<R!A
M="!397!T96UB97(@,S`L#0HR,#$Q(&-O;G-I<W0@;V8@=&AE(&5X8V5S<R!O
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M=&EO;B!O9B!P=7)C:&%S92!P<FEC92`H3F]T92`T*2XF(WA!,#L@26YT86YG
M:6)L90T*87-S971S(&%T($1E8V5M8F5R(#,Q+"`R,#`Y(&-O;G-I<W1E9"!O
M9B!C;W-T<R!I;F-U<G)E9"!T;R!O8G1A:6X-"G1R861E;6%R:W,N)B-X03`[
M(%1H97-E(&-O<W1S('=E<F4@8V%P:71A;&EZ960@=VAE;B!T:&4@97AP96YS
M92!W87,-"FEN8W5R<F5D(&%N9"!A="!W:&EC:"!T:6UE('1H92!A<W-E=',@
M=V5R92!D965M960@=&\@:&%V92!A;@T*:6YD969I;FET92!L:69E+B8C>$$P
M.R!$=7)I;F<@,C`Q,"P@9F]L;&]W:6YG(&$@<F5D=6-T:6]N(&EN('-T869F
M#0IA;F0@<W5S<&5N<VEO;B!O9B!R97-E87)C:"!A;F0@;6%N=69A8W1U<FEN
M9R!A8W1I=FET:65S(&EN(&]R9&5R('1O#0IR961U8V4@;W!E<F%T:6YG(&-O
M<W1S+"!I="!W87,@9&5T97)M:6YE9"!T:&%T('1H92!T<F%D96UA<FMS(&AA
M9`T*8F5E;B!I;7!A:7)E9"!A;F0@=&AE(&-A<G)Y:6YG('9A;'5E('=A<R!R
M961U8V5D('1O#0IZ97)O+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I
M;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD)SX-"DEM<&%I<FUE;G0@;V8@3&]N
M9SPO9F]N=#X@+2`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[
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M:&5T:&5R('!R;VIE8W1E9`T*=6YD:7-C;W5N=&5D(&-A<V@@9FQO=W,@9V5N
M97)A=&5D(&)Y('1H92!A<'!L:6-A8FQE(&%S<V5T(&5X8V5E9`T*:71S(&YE
M="!B;V]K('9A;'5E(&%S(&]F('1H92!A<W-E<W-M96YT(&1A=&4N/"]F;VYT
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-4
M64Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O
M;&0G/@T*4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N/"]F;VYT/B`F(W@R,#$T
M.R!%;7!L;WEE92!S=&]C:RUB87-E9`T*8V]M<&5N<V%T:6]N(&ES(&%C8V]U
M;G1E9"!F;W(@:6X@86-C;W)D86YC92!W:71H('1H92!G=6ED86YC92!O9@T*
M1FEN86YC:6%L($%C8V]U;G1I;F<@4W1A;F1A<F1S($)O87)D($%C8V]U;G1I
M;F<@4W1A;F1A<F1S#0I#;V1I9FEC871I;VX@*"8C>#(P,4,[1D%30B!!4T,F
M(W@R,#%$.RD@5&]P:6,@-S$X+"`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%
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M9"!O;B!T:&5I<B!F86ER#0IV86QU97,N)B-X03`[($YO;BUE;7!L;WEE92!S
M=&]C:RUB87-E9"!C;VUP96YS871I;VX@:7,@86-C;W5N=&5D#0IF;W(@:6X@
M86-C;W)D86YC92!W:71H('1H92!G=6ED86YC92!O9B!&05-"($%30R!4;W!I
M8R`U,#4L#0H\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)
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M97,@87)E(')E;F1E<F5D(&%N9`T*9&5E;65D(&-O;7!L971E9"!B>2!S=6-H
M(&YO;BUE;7!L;WEE97,N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#XF(WA!,#L\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
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M979E;&]P;65N=`T*8V]S=',@87)E(&5X<&5N<V5D(&%S(&EN8W5R<F5D+CPO
M9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4
M.B!B;VQD)SX-"DEN8V]M92!487AE<SPO9F]N=#X@)B-X,C`Q-#L@26YC;VUE
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M<W,@86YD(&-R961I=`T*8V%R<GEF;W)W87)D<R!U<VEN9R!E;F%C=&5D('1A
M>"!R871E<R!I;B!E9F9E8W0@9F]R('1H92!Y96%R(&EN#0IW:&EC:"!T:&4@
M9&EF9F5R96YC97,@87)E(&5X<&5C=&5D('1O(')E=F5R<V4N)B-X03`[(%1H
M92!E9F9E8W0@;VX-"F1E9F5R<F5D('1A>"!A<W-E=',@86YD(&QI86)I;&ET
M:65S(&]F(&$@8VAA;F=E(&EN('1A>"!R871E<R!I<PT*<F5C;V=N:7IE9"!I
M;B!I;F-O;64@:6X@=&AE('!E<FEO9"!T:&%T(&EN8VQU9&5S('1H92!E;F%C
M=&UE;G0-"F1A=&4N)B-X03`[(%9A;'5A=&EO;B!A;&QO=V%N8V5S(&%R92!E
M<W1A8FQI<VAE9"!W:&5N(&ET(&ES(&UO<F4-"FQI:V5L>2!T:&%N(&YO="!T
M:&%T('-O;64@<&]R=&EO;B!O9B!T:&4@9&5F97)R960@=&%X(&%S<V5T<R!W
M:6QL#0IN;W0@8F4@<F5A;&EZ960N)B-X03`[($UA;F%G96UE;G0@:&%S('!R
M;W9I9&5D(&$@9G5L;"!V86QU871I;VX-"F%L;&]W86YC92!A9V%I;G-T('1H
M92!#;VUP86YY)B-X,C`Q.3MS(&=R;W-S(&1E9F5R<F5D('1A>`T*87-S970N
M)B-X03`[(%1A>"!P;W-I=&EO;G,@=&%K96X@;W(@97AP96-T960@=&\@8F4@
M=&%K96X@:6X@=&AE#0IC;W5R<V4@;V8@<')E<&%R:6YG('1A>"!R971U<FYS
M(&%R92!R97%U:7)E9"!T;R!B92!E=F%L=6%T960@=&\-"F1E=&5R;6EN92!W
M:&5T:&5R('1H92!T87@@<&]S:71I;VYS(&%R92`F(W@R,#%#.VUO<F4@;&EK
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M9@T*4V5P=&5M8F5R(#,P+"`R,#$Q+"!$96-E;6)E<B`S,2P@,C`Q,"!A;F0@
M,C`P.2X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
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M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ
M(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0G/@T*1W)A;G0@26YC;VUE/"]F
M;VYT/B`F(W@R,#$T.R!#96QL96-T87(@<F5C96EV960@82!C87-H(&=R86YT
M(&]F#0HF;F)S<#LD-#0L,#`P(&%N9"`F;F)S<#LD,C`P+#`P,"!F;W(@=&AE
M(&YI;F4M;6]N=&@@<&5R:6]D(&5N9&5D(%-E<'1E;6)E<B`S,"P-"C(P,3$@
M86YD('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$P+"!R97-P96-T
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M(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[($9/3E0M
M5T5)1TA4.B!B;VQD)SX-"D9A:7(@5F%L=64@;V8@1FEN86YC:6%L($EN<W1R
M=6UE;G1S/"]F;VYT/B`F(W@R,#$T.R!4:&4@9W5I9&%N8V4-"G5N9&5R($9!
M4T(@05-#(%1O<&EC(#@R-2P@/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@
M:71A;&EC.R!$25-03$%9.B!I;FQI;F4G/D9I;F%N8VEA;"!);G-T<G5M96YT
M<SPO9F]N=#X-"BP@<F5Q=6ER97,@9&ES8VQO<W5R92!O9B!T:&4@9F%I<B!V
M86QU92!O9B!C97)T86EN(&9I;F%N8VEA;`T*:6YS=')U;65N=',N($9I;F%N
M8VEA;"!I;G-T<G5M96YT<R!I;B!T:&4@86-C;VUP86YY:6YG(&9I;F%N8VEA
M;`T*<W1A=&5M96YT<R!C;VYS:7-T(&]F(&-A<V@@97%U:79A;&5N=',L(&%C
M8V]U;G1S('!A>6%B;&4L#0IC;VYV97)T:6)L92!D96)T(&%N9"!L;VYG+71E
M<FT@;V)L:6=A=&EO;G,N)B-X03`[(%1H92!C87)R>6EN9PT*86UO=6YT(&]F
M(&-A<V@@97%U:79A;&5N=',L(&EN=F5S=&UE;G1S(&%N9"!A8V-O=6YT<PT*
M<&%Y86)L928C>$$P.V%P<')O>&EM871E)B-X03`[=&AE:7(F(WA!,#MF86ER
M('9A;'5E(&1U92!T;R!T:&5I<@T*<VAO<G0M=&5R;2!N871U<F4N)B-X03`[
M(%1H92!E<W1I;6%T960@9F%I<B!V86QU92!O9B!T:&4-"F-O;G9E<G1I8FQE
M(&1E8G0L(&1E=&5R;6EN960@;VX@86X@87,M8V]N=F5R=&5D(&)A<VES(&EN
M8VQU9&EN9PT*8V]N=F5R<VEO;B!O9B!A8V-U;75L871E9"!U;G!A:60@:6YT
M97)E<W0L('=A<R!A<'!R;WAI;6%T96QY("9N8G-P.R0P(&%N9`T*)FYB<W`[
M)#,L,C8T+#`P,"!A="!397!T96UB97(@,S`L(#(P,3$@86YD($1E8V5M8F5R
M(#,Q+"`R,#$P+`T*<F5S<&5C=&EV96QY+B8C>$$P.R!4:&4@8V%R<GEI;F<@
M=F%L=64@;V8@;&]N9RUT97)M(&]B;&EG871I;VYS+`T*:6YC;'5D:6YG('1H
M92!C=7)R96YT('!O<G1I;VXL(&%P<')O>&EM871E<R!F86ER('9A;'5E(&)E
M8V%U<V4@=&AE#0IF:7AE9"!I;G1E<F5S="!R871E(&%P<')O>&EM871E<R!C
M=7)R96YT(&UA<FME="!R871E(&]F(&EN=&5R97-T#0IA=F%I;&%B;&4@:6X@
M=&AE(&UA<FME="X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M4$Q!63H@:6YL:6YE)SXF(WA!,#L\+V9O;G0^)B-X,C`Q,SL@5&AE#0I#;VUP
M86YY(&=E;F5R86QL>2!D;V5S(&YO="!U<V4@9&5R:79A=&EV92!I;G-T<G5M
M96YT<R!T;R!H961G90T*97AP;W-U<F5S('1O(&-A<V@@9FQO=R!O<B!M87)K
M970@<FES:W,N)B-X03`[($AO=V5V97(L(&-E<G1A:6X-"G=A<G)A;G1S('1O
M('!U<F-H87-E(&-O;6UO;B!S=&]C:R!T:&%T(&1O(&YO="!M965T('1H92!R
M97%U:7)E;65N=',-"F9O<B!C;&%S<VEF:6-A=&EO;B!A<R!E<75I='DL(&EN
M(&%C8V]R9&%N8V4@=VET:"!T:&4@1&5R:79A=&EV97,-"F%N9"!(961G:6YG
M(%1O<&EC(&]F('1H92!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@
M0F]A<F0-"D%C8V]U;G1I;F<@4W1A;F1A<F1S($-O9&EF:6-A=&EO;B`H)B-X
M,C`Q0SM&05-"#0I!4T,F(W@R,#%$.RDL/&9O;G0@<W1Y;&4],T0G1D].5"U3
M5%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4G/B8C>$$P.SPO9F]N=#YA
M<F4@8VQA<W-I9FEE9`T*87,@;&EA8FEL:71I97,N)B-X03`[($EN('-U8V@@
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M875S92!T:&4-"F%G<F5E;65N=',@8V]N=&%I;B`F(W@R,#%#.V1O=VXM<F]U
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M;G1S('=A<R`W-RPW,CD@870@4V5P=&5M8F5R(#,P+"`R,#$Q+B!4:&4@<')I
M;6%R>0T*=6YD97)L>6EN9R!R:7-K(&5X<&]S=7)E('!E<G1A:6YI;F<@=&\@
M=&AE('=A<G)A;G1S(&ES('1H92!C:&%N9V4-"FEN(&9A:7(@=F%L=64@;V8@
M=&AE('5N9&5R;'EI;F<@8V]M;6]N('-T;V-K+B8C>$$P.R!3=6-H(&9I;F%N
M8VEA;`T*:6YS=')U;65N=',@87)E(&EN:71I86QL>2!R96-O<F1E9"!A="!F
M86ER('9A;'5E('=I=&@@<W5B<V5Q=65N=`T*8VAA;F=E<R!I;B!F86ER('9A
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M4V5P=&5M8F5R(#,P+`T*,C`Q,2P@=&AE<V4@=V%R<F%N=',@<F5P<F5S96YT
M960@=&AE(&]N;'D@;W5T<W1A;F1I;F<@9&5R:79A=&EV90T*:6YS=')U;65N
M=',@:7-S=65D(&]R(&AE;&0@8GD@=&AE($-O;7!A;GDN)B-X03`[(%1H97)E
M('=E<F4@;F\-"F]U='-T86YD:6YG(&1E<FEV871I=F4@:6YS=')U;65N=',@
M870@1&5C96UB97(@,S$L(#(P,3`@;W(-"C(P,#DN/"]F;VYT/CPO9&EV/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L
M:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0G/@T*0V]N
M8V5N=')A=&EO;B!O9B!#<F5D:70@4FES:SPO9F]N=#X@)B-X,C`Q-#L@1FEN
M86YC:6%L(&EN<W1R=6UE;G1S#0IT:&%T('-U8FIE8W0@=&AE($-O;7!A;GD@
M=&\@8W)E9&ET(')I<VL@8V]N<VES="!O9B!C87-H(&%N9`T*97%U:79A;&5N
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M960@;V)L:6=A=&EO;G,N)B-X03`[#0I#87-H(&%N9"!E<75I=F%L96YT(&)A
M;&%N8V5S(&%R92!M86EN=&%I;F5D('=I=&@@82!S=&%B;&4@86YD#0IW96QL
M+6-A<&ET86QI>F5D(&9I;F%N8VEA;"!I;G-T:71U=&EO;BX\+V9O;G0^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z
M(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9"<^
M#0I.97<@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<SPO9F]N=#X@)B-X,C`Q
M-#LF(WA!,#M);B!*86YU87)Y(#(P,3`L#0IT:&4@1D%30B!I<W-U960@05-5
M($YO+B8C>$$P.S(P,3`M,#8L(#QF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z
M(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE)SY);7!R;W9I;F<@1&ES8VQO<W5R
M97,@86)O=70-"D9A:7(@5F%L=64@365A<W5R96UE;G1S/"]F;VYT/B`L('=H
M:6-H(')E<75I<F5S(&%D9&ET:6]N86P-"F1I<V-L;W-U<F5S(&%B;W5T('1H
M92!A;6]U;G1S(&]F(&%N9"!R96%S;VYS(&9O<B!S:6=N:69I8V%N=`T*=')A
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M,C`Q,"!D:60@;F]T(&EM<&%C="!T:&4@86-C;VUP86YY:6YG(&9I;F%N8VEA
M;`T*<W1A=&5M96YT<RX@061D:71I;VYA;&QY+"!E9F9E8W1I=F4@9F]R(&EN
M=&5R:6T@86YD(&%N;G5A;"!P97)I;V1S#0IB96=I;FYI;F<@869T97(@1&5C
M96UB97(F(WA!,#LQ-2P@,C`Q,"P@=&AI<R!S=&%N9&%R9"!W:6QL(')E<75I
M<F4-"F%D9&ET:6]N86P@9&ES8VQO<W5R92!A;F0@<F5Q=6ER92!A;B!E;G1I
M='D@=&\@<')E<V5N=`T*9&ES86=G<F5G871E9"!I;F9O<FUA=&EO;B!A8F]U
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M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/DEN#0I$96-E;6)E<B`R,#$P+"!T:&4@1D%30B!I<W-U960@05-5($YO
M+B`R,#$P+3(Y+"`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[
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M9`T*;VYL>2XF(WA!,#L@5&AI<R!S=&%N9&%R9"!A;'-O(&5X<&%N9',@=&AE
M('-U<'!L96UE;G1A;"!P<F\@9F]R;6$-"F1I<V-L;W-U<F5S(')E<75I<F5D
M('5N9&5R($9!4T(@05-#(%1O<&EC(#@U,"P@/&9O;G0@<W1Y;&4],T0G1D].
M5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4G/D)U<VEN97-S($-O
M;6)I;F%T:6]N<SPO9F]N=#X-"BP@=&\@:6YC;'5D92!A(&1E<V-R:7!T:6]N
M(&]F('1H92!N871U<F4@86YD(&%M;W5N="!O9B!M871E<FEA;`T*;F]N<F5C
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M2F%N=6%R>2`Q+"`R,#$Q+B8C>$$P.R!4:&4-"D-O;7!A;GD@861O<'1E9"!T
M:&4@<')O=FES:6]N<R!O9B!T:&ES('-T86YD87)D(&1U<FEN9R!T:&4@9FER
M<W0-"G%U87)T97(@;V8@,C`Q,2X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B8C
M>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<^26X-"DUA>2`R,#$Q+"!T:&4@1D%30B!I<W-U960@05-5($YO
M+B`R,#$Q+3`T+"`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[
M($1)4U!,05DZ(&EN;&EN92<^06UE;F1M96YT<R!T;R!!8VAI979E($-O;6UO
M;@T*1F%I<B!686QU92!-96%S=7)E;65N="!A;F0@1&ES8VQO<W5R92!297%U
M:7)E;65N=',@:6X@52Y3+@T*1V5N97)A;&QY($%C8V5P=&5D($%C8V]U;G1I
M;F<@4')I;F-I<&QE<R`H)B-X,C`Q0SM'04%0)B-X,C`Q1#LI(&%N9`T*26YT
M97)N871I;VYA;"!&:6YA;F-I86P@4F5P;W)T:6YG(%-T86YD87)D<PT**"8C
M>#(P,4,[24924W,F(W@R,#%$.RDN/"]F;VYT/B`F(WA!,#M4:&ES('-T86YD
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M<&%N>2!O;B!*86YU87)Y(#$L(#(P,3(N)B-X03`[(%1H92!#;VUP86YY(&1O
M97,@;F]T#0IE>'!E8W0@=&AA="!T:&4@861O<'1I;VX@;V8@=&AI<R!S=&%N
M9&%R9"!W:6QL(&AA=F4@82!M871E<FEA;`T*:6UP86-T('=H96X@87!P;&EE
M9"!P<F]S<&5C=&EV96QY(&]N('1H92!#;VUP86YY)B-X,C`Q.3MS(&9I;F%N
M8VEA;`T*<W1A=&5M96YT<R!O<B!R97%U:7)E9"!D:7-C;&]S=7)E<RX\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
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M)B-X03`[1T%!4"!A;F0-"G1H;W-E('1H870@<F5P;W)T('5N9&5R($E&4E,L
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M=7,@<W1A=&5M96YT+`T*<F5F97)R960@=&\@87,@=&AE('-T871E;65N="!O
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M="!I;F-O;64I+B!4:&4@;F5W#0I54R8C>$$P.T=!05`@<F5Q=6ER96UE;G1S
M(&%R92!E9F9E8W1I=F4@9F]R('!U8FQI8R!E;G1I=&EE<R!A<R!O9@T*=&AE
M(&)E9VEN;FEN9R!O9B!A(&9I<V-A;"!Y96%R('1H870@8F5G:6YS(&%F=&5R
M($1E8V5M8F5R)B-X03`[,34L#0HR,#$Q(&%N9"!I;G1E<FEM(&%N9"!A;FYU
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M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B8C
M>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/DEN#0I397!T96UB97(@,C`Q,2P@=&AE($9!
M4T(@:7-S=65D($%352!.;RX@,C`Q,2TP."P@/&9O;G0@<W1Y;&4],T0G1D].
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M=&ET>2!T;R!F:7)S=`T*87-S97-S('%U86QI=&%T:79E(&9A8W1O<G,@:6X@
M9&5T97)M:6YI;F<@=VAE=&AE<B!I="!I<R!M;W)E(&QI:V5L>0T*=&AA;B!N
M;W0@=&AA="!T:&4@9F%I<B!V86QU92!O9B!A(')E<&]R=&EN9R!U;FET(&ES
M(&QE<W,@=&AA;B!I=',-"F-A<G)Y:6YG(&%M;W5N="!A<R!A(&)A<VES(&9O
M<B!D971E<FUI;FEN9R!W:&5T:&5R(&ET(&ES(&YE8V5S<V%R>0T*=&\@<&5R
M9F]R;2!T:&4@='=O+7-T97`@9V]O9'=I;&P@:6UP86ER;65N="!T97-T+B8C
M>$$P.R8C>$$P.U1H:7,-"G-T86YD87)D(&ES(&5F9F5C=&EV92!F;W(@96YT
M:71I97,@87,@;V8@=&AE(&)E9VEN;FEN9R!O9B!A(&9I<V-A;`T*>65A<B!T
M:&%T(&)E9VEN<R!A9G1E<B!$96-E;6)E<B`Q-2P@,C`Q,2!A;F0@:6YT97)I
M;2!A;F0@86YN=6%L#0IP97)I;V1S('1H97)E869T97(N)B-X03`[)B-X03`[
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M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$
M25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD)SX-"E)E8VQA<W-I
M9FEC871I;VYS/"]F;VYT/B`F(W@R,#$T.R!#97)T86EN('!R:6]R+7!E<FEO
M9"!A;6]U;G1S(&AA=F4-"F)E96X@<F5C;&%S<VEF:65D('1O(&-O;F9O<FT@
M=&\@=&AE(&-U<G)E;G0M<&5R:6]D#0IP<F5S96YT871I;VXN/"]F;VYT/CPO
M9&EV/@T*#0H-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HR+B!3
M54U-05)9($]&(%-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
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M63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
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M)B-X,C`Q.3MS#0IM86YA9V5M96YT('1O(&UA:V4@97-T:6UA=&5S(&%N9"!J
M=61G;65N=',@=&AA="!M87D@869F96-T('1H90T*<F5P;W)T960@86UO=6YT
M<R!O9B!A<W-E=',L(&QI86)I;&ET:65S+"!R979E;G5E(&%N9"!E>'!E;G-E
M<R!A;F0-"F1I<V-L;W-U<F4@;V8@8V]N=&EN9V5N="!A<W-E=',@86YD(&QI
M86)I;&ET:65S+B!/;B!A;B!O;BUG;VEN9PT*8F%S:7,L('1H92!#;VUP86YY
M)B-X,C`Q.3MS(&UA;F%G96UE;G0@979A;'5A=&5S(&ET<R!E<W1I;6%T97,-
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M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SXF(WA!,#L\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I#87-H($5Q=6EV86QE;G1S/"]F
M;VYT/B`F(W@R,#$T.R!4:&4@0V]M<&%N>2!C;VYS:61E<G,@86QL#0IS:&]R
M="UT97)M(&EN=F5S=&UE;G1S('!U<F-H87-E9"!W:71H(&]R:6=I;F%L(&UA
M='5R:71I97,@;V8@=&AR964-"FUO;G1H<R!O<B!L97-S('1O(&)E(&-A<V@@
M97%U:79A;&5N=',N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN
M93L@1D].5"U714E'2%0Z(&)O;&0G/@T*1FEX960@07-S971S/"]F;VYT/B`F
M(W@R,#$T.R!0<F]P97)T>2!A;F0@97%U:7!M96YT(&%R92!S=&%T960@870-
M"F-O<W0N($1E<')E8VEA=&EO;B!O;B!P<F]P97)T>2!A;F0@97%U:7!M96YT
M(&ES('!R;W9I9&5D('5S:6YG('1H90T*<W1R86EG:'0M;&EN92!M971H;V0@
M;W9E<B!T:&4@97-T:6UA=&5D('5S969U;"!L:79E<R!O9B!T:&4@87-S971S
M+`T*=VAI8V@@<F%N9V4@9G)O;2!T:')E92!T;R!F:79E('EE87)S+B!,96%S
M96AO;&0@:6UP<F]V96UE;G1S(&%R90T*9&5P<F5C:6%T960@;W9E<B!T:&4@
M;&5S<V5R(&]F('1H92!E<W1I;6%T960@=7-E9G5L(&QI=F5S(&]F('1H90T*
M87-S971S(&]R('1H92!R96UA:6YI;F<@;&5A<V4@=&5R;2X\+V9O;G0^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
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M5#H@8F]L9"<^3&EV960-"D%S<V5T<SPO9F]N=#X@)B-X,C`Q-#L@5VAE;F5V
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M<FEO9`T*<')E<V5N=&5D+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I
M;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD)SX-"E-T;V-K+4)A<V5D($-O;7!E
M;G-A=&EO;CPO9F]N=#X@)B-X,C`Q-#L@5&AE($-O;7!A;GD@86-C;W5N=',@
M9F]R#0IE;7!L;WEE92!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@:6X@86-C
M;W)D86YC92!W:71H('1H92!G=6ED86YC90T*;V8@1D%30B!!4T,@5&]P:6,@
M-S$X+"`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,
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M#0IV86QU97,N)B-X03`[(%1H92!#;VUP86YY(&%C8V]U;G1S(&9O<B!N;VXM
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M=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
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M:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L
M:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0G/@T*4F5S
M96%R8V@@86YD($1E=F5L;W!M96YT/"]F;VYT/B`F(W@R,#$T.R!297-E87)C
M:"!A;F0@9&5V96QO<&UE;G0-"F-O<W1S(&%R92!E>'!E;G-E9"!A<R!I;F-U
M<G)E9"X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5=%24=(5#H@8F]L9"<^#0I);F-O;64@5&%X97,\+V9O;G0^("8C>#(P,30[
M(%1H92!#;VUP86YY('5S97,@=&AE(&QI86)I;&ET>2!M971H;V0-"F]F(&%C
M8V]U;G1I;F<@9F]R(&EN8V]M92!T87AE<RXF(WA!,#L@56YD97(@=&AI<R!M
M971H;V0L(&1E9F5R<F5D#0IT87@@87-S971S(&%N9"!L:6%B:6QI=&EE<R!A
M<F4@9&5T97)M:6YE9"!B87-E9"!O;B!T96UP;W)A<GD-"F1I9F9E<F5N8V5S
M(&)E='=E96X@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G0@86YD('1A>"!B87-I
M<R!O9B!A<W-E=',-"F%N9"!L:6%B:6QI=&EE<R!A;F0@;F5T(&]P97)A=&EN
M9R!L;W-S(&%N9"!C<F5D:70@8V%R<GEF;W)W87)D<PT*=7-I;F<@96YA8W1E
M9"!T87@@<F%T97,@:6X@969F96-T(&9O<B!T:&4@>65A<B!I;B!W:&EC:"!T
M:&4-"F1I9F9E<F5N8V5S(&%R92!E>'!E8W1E9"!T;R!R979E<G-E+B8C>$$P
M.R!4:&4@969F96-T(&]N(&1E9F5R<F5D#0IT87@@87-S971S(&%N9"!L:6%B
M:6QI=&EE<R!O9B!A(&-H86YG92!I;B!T87@@<F%T97,@:7,@<F5C;V=N:7IE
M9`T*:6X@:6YC;VUE(&EN('1H92!P97)I;V0@=&AA="!I;F-L=61E<R!T:&4@
M96YA8W1M96YT(&1A=&4N)B-X03`[#0I686QU871I;VX@86QL;W=A;F-E<R!A
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M=VAE=&AE<B!T:&4@=&%X('!O<VET:6]N<R!A<F4@)B-X,C`Q0SMM;W)E#0IL
M:6ME;'D@=&AA;B!N;W0F(W@R,#%$.R!O9B!B96EN9R!S=7-T86EN960@8GD@
M=&AE(&%P<&QI8V%B;&4@=&%X#0IA=71H;W)I='DN)B-X03`[(%1A>"!P;W-I
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M;V8-"D1E8V5M8F5R(#,Q+"`R,#$P(&%N9"`R,#`Y+CPO9F]N=#X\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A
M;&EC.R!$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD)SX-"D-O
M;7!R96AE;G-I=F4@26YC;VUE("A,;W-S*3PO9F]N=#X@)B-X,C`Q-#L@5&AE
M($-O;7!A;GD@:&%D(&YO#0IC;VUP;VYE;G1S(&]F(&-O;7!R96AE;G-I=F4@
M:6YC;VUE(&]T:&5R('1H86X@;F5T(&EN8V]M92`H;&]S<RD@:6X-"F%L;"!O
M9B!T:&4@<&5R:6]D<R!P<F5S96YT960N/"]F;VYT/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R
M("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)
M4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0G/@T*1F%I<B!686QU
M92!O9B!&:6YA;F-I86P@26YS=')U;65N=',\+V9O;G0^("8C>#(P,30[(%1H
M92!G=6ED86YC90T*=6YD97(@1D%30B!!4T,@5&]P:6,@.#(U+"`\9F]N="!S
M='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN92<^
M1FEN86YC:6%L($EN<W1R=6UE;G1S/"]F;VYT/@T*+"!R97%U:7)E<R!D:7-C
M;&]S=7)E(&]F('1H92!F86ER('9A;'5E(&]F(&-E<G1A:6X@9FEN86YC:6%L
M#0II;G-T<G5M96YT<RX@5&AE($-O;7!A;GDF(W@R,#$Y.W,@9FEN86YC:6%L
M(&EN<W1R=6UE;G1S(&-O;G-I<W0@;V8-"F-A<V@@97%U:79A;&5N=',L(&%C
M8V]U;G1S('!A>6%B;&4L(&%C8W)U960@97AP96YS97,@86YD(')E9&5E;6%B
M;&4-"G!R969E<G)E9"!S=&]C:RX@5&AE(&5S=&EM871E9"!F86ER('9A;'5E
M(&]F('1H92!R961E96UA8FQE#0IP<F5F97)R960@<W1O8VLL(&1E=&5R;6EN
M960@;VX@86X@87,M8V]N=F5R=&5D(&)A<VES(&EN8VQU9&EN9PT*8V]N=F5R
M<VEO;B!O9B!A8V-U;75L871E9"!U;G!A:60@9&EV:61E;F1S+"!W87,@)FYB
M<W`[)#$Q-"PW.#`L,#`P(&%T#0I$96-E;6)E<B`S,2P@,C`P.2X@5&AE(&5S
M=&EM871E9"!F86ER('9A;'5E(&]F('1H92!R96UA:6YI;F<-"F9I;F%N8VEA
M;"!I;G-T<G5M96YT<R!A<'!R;WAI;6%T97,@=&AE:7(@8V%R<GEI;F<@=F%L
M=64@9'5E('1O#0IT:&5I<B!S:&]R="UT97)M(&YA='5R92X\+V9O;G0^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z
M(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9"<^
M#0I#;VYC96YT<F%T:6]N(&]F($-R961I="!2:7-K/"]F;VYT/B`F(W@R,#$T
M.R!&:6YA;F-I86P@:6YS=')U;65N=',-"G1H870@<W5B:F5C="!T:&4@0V]M
M<&%N>2!T;R!C<F5D:70@<FES:R!C;VYS:7-T(&]F(&-A<V@@86YD#0IE<75I
M=F%L96YT<R!O;B!D97!O<VET('=I=&@@9FEN86YC:6%L(&EN<W1I='5T:6]N
M<RX@5&AE#0I#;VUP86YY)B-X,C`Q.3MS(&5X8V5S<R!C87-H(&ES(&]N(&1E
M<&]S:70@:6X@86X@;W9E<FYI9VAT#0II;G9E<W1M96YT(&%C8V]U;G0@=&AA
M="!I<R!F=6QL>2!C;VQL871E<F%L:7IE9"!B>0T*9V]V97)N;65N="UB86-K
M960@;V)L:6=A=&EO;G,N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN
M;&EN93L@1D].5"U714E'2%0Z(&)O;&0G/@T*1&5R:79A=&EV92!);G-T<G5M
M96YT<SPO9F]N=#X@)B-X,C`Q-#L@5&AE($-O;7!A;GD@9V5N97)A;&QY(&1O
M97,-"FYO="!U<V4@9&5R:79A=&EV92!I;G-T<G5M96YT<R!T;R!H961G92!E
M>'!O<W5R97,@=&\@8V%S:"!F;&]W(&]R#0IM87)K970@<FES:W,[(&AO=V5V
M97(L('-T87)T:6YG($IA;G5A<GD@,2P@,C`P.2P@8V5R=&%I;B!W87)R86YT
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M971T;&5M96YT(&ES(&%S<W5M960@9F]R(&9I;F%N8VEA;`T*<F5P;W)T:6YG
M('!U<G!O<V5S+"!E=F5N('=H96X@=&AE('1E<FUS(&]F('1H92!U;F1E<FQY
M:6YG(&-O;G1R86-T<PT*9&\@;F]T('!R;W9I9&4@9F]R(&$@;F5T+6-A<V@@
M<V5T=&QE;65N="X@5&AE<V4@=V%R<F%N=',@87)E#0IC;VYS:61E<F5D(&1E
M<FEV871I=F4@:6YS=')U;65N=',@87,@=&AE(&%G<F5E;65N=',@8V]N=&%I
M;@T*)B-X,C`Q0SMD;W=N+7)O=6YD)B-X,C`Q1#L@<')O=FES:6]N<R!W:&5R
M96)Y('1H92!N=6UB97(@;V8@<VAA<F5S#0IF;W(@=VAI8V@@=&AE('=A<G)A
M;G1S(&%R92!E>&5R8VES86)L92!A;F0O;W(@=&AE(&5X97)C:7-E('!R:6-E
M(&]F#0IT:&4@=V%R<F%N=',@:7,@<W5B:F5C="!T;R!C:&%N9V4@:6X@=&AE
M(&5V96YT(&]F(&-E<G1A:6X@:7-S=6%N8V5S#0IO9B!S=&]C:R!A="!P<FEC
M97,@8F5L;W<@=&AE('1H96XM969F96-T:79E(&5X97)C:7-E('!R:6-E(&]F
M('1H90T*=V%R<F%N=',N(%1H92!N=6UB97(@;V8@<W5C:"!W87)R86YT<R!W
M87,@.3$L-3(T(&%T($IA;G5A<GD@,2P-"C(P,#DL(#0X+#0X.2!A="!$96-E
M;6)E<B`S,2P@,C`P.2!A;F0@,3,X+#8Q,2!A="!$96-E;6)E<B`S,2P@,C`Q
M,"X-"E1H92!P<FEM87)Y('5N9&5R;'EI;F<@<FES:R!E>'!O<W5R92!P97)T
M86EN:6YG('1O('1H92!W87)R86YT<R!I<PT*=&AE(&-H86YG92!I;B!F86ER
M('9A;'5E(&]F('1H92!U;F1E<FQY:6YG(&-O;6UO;B!S=&]C:RX@4W5C:`T*
M9FEN86YC:6%L(&EN<W1R=6UE;G1S(&%R92!I;FET:6%L;'D@<F5C;W)D960@
M870@9F%I<B!V86QU92P@;W(-"G)E;&%T:79E(&9A:7(@=F%L=64@=VAE;B!I
M<W-U960@=VET:"!O=&AE<B!I;G-T<G5M96YT<RP@=VET:`T*<W5B<V5Q=65N
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M=F%L=64@=&\@97%U:71Y+B!!="!$96-E;6)E<B`S,2P@,C`Q,`T*86YD(#(P
M,#DL('1H97-E('=A<G)A;G1S(')E<')E<V5N="!T:&4@;VYL>2!O=71S=&%N
M9&EN9R!D97)I=F%T:79E#0II;G-T<G5M96YT<R!I<W-U960@;W(@:&5L9"!B
M>2!T:&4@0V]M<&%N>2X@07,@82!R97-U;'0@;V8@=&AE#0IS:6=N:69I8V%N
M="!D96-L:6YE(&EN('1H92!#;VUP86YY)B-X,C`Q.3MS('-T;V-K('!R:6-E
M(&9O;&QO=VEN9PT*=&AE(&%N;F]U;F-E;65N="!O9B!T:&4@<F5S=6QT<R!O
M9B!T:&4@4&AA<V4@,R!4<FEA;"P@=&AE($-O;7!A;GD-"G)E8V]R9&5D(&$@
M9V%I;B!O9B!A<'!R;WAI;6%T96QY("9N8G-P.R0X+#$Q."PP,#`@9'5R:6YG
M('1H92!Y96%R(&5N9&5D#0I$96-E;6)E<B`S,2P@,C`Q,"!I;B!C;VYN96-T
M:6]N('=I=&@@=&AE(')E=F%L=6%T:6]N(&]F('1H90T*9&5R:79A=&EV92!L
M:6%B:6QI='D@8F%L86YC92!A="!$96-E;6)E<B`S,2P@,C`Q,"X\+V9O;G0^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1J=7-T:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)
M1TA4.B!B;VQD)SX-"DYE=R!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]F
M;VYT/B`F(W@R,#$T.R8C>$$P.R!);B!397!T96UB97(-"C(P,#DL('1H92!&
M:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A<F0@*"8C>#(P,4,[
M1D%30B8C>#(P,40[*0T*86UE;F1E9"!T:&4@86-C;W5N=&EN9R!S=&%N9&%R
M9',@<F5L871E9"!T;R!R979E;G5E(')E8V]G;FET:6]N(&9O<@T*87)R86YG
M96UE;G1S('=I=&@@;75L=&EP;&4@9&5L:79E<F%B;&5S(&%N9"!A<G)A;F=E
M;65N=',@=&AA=`T*:6YC;'5D92!S;V9T=V%R92!E;&5M96YT<R`H)B-X,C`Q
M0SMN97<@86-C;W5N=&EN9PT*<')I;F-I<&QE<R8C>#(P,40[*2X@5&AE(&YE
M=R!A8V-O=6YT:6YG('!R:6YC:7!L97,@<&5R;6ET#0IP<F]S<&5C=&EV92!O
M<B!R971R;W-P96-T:79E(&%D;W!T:6]N+"!A;F0@=&AE($-O;7!A;GD@96QE
M8W1E9`T*<')O<W!E8W1I=F4@861O<'1I;VX@870@=&AE(&)E9VEN;FEN9R!O
M9B!T:&4@9FER<W0@<75A<G1E<B!O9B`R,#$P+@T*5&AE(&%D;W!T:6]N(&]F
M('1H92!S=&%N9&%R9"!I;B`R,#$P(&AA9"!N;R!I;7!A8W0@;VX@=&AE#0I#
M;VUP86YY)B-X,C`Q.3MS(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO9F]N=#X\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^26X-"DIA;G5A<GD@,C`Q,"P@=&AE($9!
M4T(@:7-S=65D($%352!.;RXF(WA!,#LR,#$P+3`V+"`\9F]N="!S='EL93TS
M1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN92<^26UP<F]V
M:6YG($1I<V-L;W-U<F5S(&%B;W5T#0I&86ER(%9A;'5E($UE87-U<F5M96YT
M<SPO9F]N=#XL('=H:6-H(')E<75I<F5S(&%D9&ET:6]N86P-"F1I<V-L;W-U
M<F5S(&%B;W5T('1H92!A;6]U;G1S(&]F(&%N9"!R96%S;VYS(&9O<B!S:6=N
M:69I8V%N=`T*=')A;G-F97)S(&EN(&%N9"!O=70@;V8@3&5V96PF(WA!,#LQ
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M('%U87)T97(@;V8@,C`Q,"!D:60@;F]T(&EM<&%C="!T:&4@0V]M<&%N>28C
M>#(P,3D[<R!F:6YA;F-I86P-"G-T871E;65N=',N($%D9&ET:6]N86QL>2P@
M969F96-T:79E(&9O<B!I;G1E<FEM(&%N9"!A;FYU86P@<&5R:6]D<PT*8F5G
M:6YN:6YG(&%F=&5R($1E8V5M8F5R)B-X03`[,34L(#(P,3`L('1H:7,@<W1A
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M("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)
M4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0G/@T*061O<'1I;VX@
M;V8@3F5W($%C8V]U;G1I;F<@4')I;F-I<&QE/"]F;VYT/B`F(W@R,#$T.R!%
M9F9E8W1I=F4-"DIA;G5A<GD@,2P@,C`P.2P@=&AE($-O;7!A;GD@861O<'1E
M9"!T:&4@9W5I9&%N8V4@;V8@1D%30B!!4T,-"C@Q-2TT,"TQ-2P@/&9O;G0@
M<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4G
M/D1E<FEV871I=F5S(&%N9`T*2&5D9VEN9SPO9F]N=#X@+"!W:&EC:"!E<W1A
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M870-"G1H92!D871E<R!O9B!I<W-U86YC92!T;W1A;&EN9R`F;F)S<#LD-BPX
M.3,L,#`P('=A<R!I;FET:6%L;'D@<F5C;W)D960@87,-"F$@8V]M<&]N96YT
M(&]F(&%D9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L+B!5<&]N(&%D;W!T:6]N
M(&]F('1H:7,-"F=U:61A;F-E(&]N($IA;G5A<GD@,2P@,C`P.2P@=&AE($-O
M;7!A;GD@<F5C;W)D960@82!D97)I=F%T:79E#0IL:6%B:6QI='D@;V8@)FYB
M<W`[)#DY.2PP,#`L(&$@9&5C<F5A<V4@=&\@=&AE(&]P96YI;F<@8F%L86YC
M92!O9@T*861D:71I;VYA;"!P86ED+6EN(&-A<&ET86P@;V8@87!P<F]X:6UA
M=&5L>2`F;F)S<#LD-BPX.3,L,#`P(&%N9"!R96-O<F1E9`T*82!D96-R96%S
M92!T;R!A8V-U;75L871E9"!D969I8VET('1O=&%L:6YG(&%P<')O>&EM871E
M;'D-"B9N8G-P.R0U+#@Y-"PP,#`L(')E<')E<V5N=&EN9R!T:&4@9&5C<F5A
M<V4@:6X@=&AE(&9A:7(@=F%L=64@;V8@=&AE#0IW87)R86YT<R!F<F]M('1H
M92!D871E(&]F(&ES<W5A;F-E('1O($1E8V5M8F5R(#,Q+"`R,#`X+B!4:&4-
M"FEN8W)E87-E(&EN(&9A:7(@=F%L=64@;V8@=&AE('=A<G)A;G1S(&]F(&%P
M<')O>&EM871E;'D@)FYB<W`[)#$R+#$Q-"PP,#`-"F1U<FEN9R!T:&4@>65A
M<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`P.2!A;F0@=&AE(&1E8W)E87-E(&EN
M(&9A:7(-"G9A;'5E(&]F('1H92!W87)R86YT<R!O9B`F;F)S<#LD."PQ,3@L
M,#`P(&1U<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<@T*,S$L(#(P,3`@
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M92!#;VUP86YY)B-X,C`Q.3MS(&-O;6UO;@T*<W1O8VL@9'5R:6YG('1H92!Y
M96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,"!A;F0@,C`P.2X@4V5E($YO
M=&4@-@T*9F]R(&$@9&5S8W)I<'1I;VX@;V8@=&AO<V4@=')A;G-A8W1I;VYS
M+B!4:&4@9F%I<B!V86QU92!O9B!T:&4-"G=A<G)A;G1S(&]F("9N8G-P.R0R
M.#@L,#`P(&%N9"`F;F)S<#LD,3`L-#@W+#`P,"!A="!$96-E;6)E<B`S,2P@
M,C`Q,"!A;F0@,C`P.0T*:7,@:6YC;'5D960@87,@82!C=7)R96YT(&QI86)I
M;&ET>2!I;B!T:&4@86-C;VUP86YY:6YG(&)A;&%N8V4-"G-H965T(&%S(&]F
M('1H870@9&%T92X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I296-L87-S:69I8V%T:6]N<SPO
M9F]N=#X@)B-X,C`Q-#L@0V5R=&%I;B!P<FEO<B!Y96%R(&%M;W5N=',@:&%V
M90T*8F5E;B!R96-L87-S:69I960@=&\@8V]N9F]R;2!T;R!T:&4@8W5R<F5N
M="!Y96%R#0IP<F5S96YT871I;VXN/"]F;VYT/CPO9&EV/@T*/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15A%04,^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^1D%)4B!604Q515,@3T8@05-31513
M($%.1"!,24%"24Q)5$E%4SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&04E2(%9!
M3%5%4R!/1B!!4U-%5%,@04Y$($Q)04))3$E42453/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#$P,"4^#0H\='(@=F%L:6=N/3-$=&]P/@T*/'1D('-T
M>6QE/3-$)U=)1%1(.B`S-G!T)R!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
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M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
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M/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
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M63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=CX-"CQT86)L92!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!W:61T:#TS1#$P,"4@86QI9VX],T1C96YT97(^#0H\='(@=F%L:6=N/3-$
M=&]P/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`S-G!T)SX-"CQD:78^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#$X<'0G/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@<WEM8F]L+"!S97)I9B<^#0HF(WA"-SL\+V9O;G0^/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9#X-"CQD:78@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY,979E;`T*,3H@26YP=70@
M<')I8V5S('%U;W1E9"!I;B!A;B!A8W1I=F4@;6%R:V5T(&9O<B!I9&5N=&EC
M86P@9FEN86YC:6%L#0IA<W-E=',@;W(@;&EA8FEL:71I97,N/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV/@T*
M/'1A8FQE('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E;G1E<CX-
M"CQT<B!V86QI9VX],T1T;W`^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#,V<'0G
M/@T*/&1I=CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@
M,3AP="<^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9
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M5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N=&5R/@T*/'1R
M('9A;&EG;CTS1'1O<#X-"CQT9"!S='EL93TS1"=724142#H@,S9P="<^#0H\
M9&EV/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q.'!T
M)SX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G
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M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
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M1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&QE
M9G0^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$.38E/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0V)2!C
M;VQS<&%N/3-$,30@;F]W<F%P/3-$;F]W<F%P/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/DUA<F-H)B-X
M03`[,S$L)B-X03`[,C`Q,3PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
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M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
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M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
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M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO
M=W)A<#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$P)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A
M<#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
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M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/E=A<G)A;G1S/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SX-"C$V,BPW-C`\+V9O;G0^
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T
M<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE)SX-"C$V,BPW-C`\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/B8C
M>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
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M"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQD:78^#0H\9&EV/@T*/'1A8FQE(&%L:6=N/3-$8V5N=&5R(&)O
M<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T
M:#TS1#$P,"4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*/'1R('9A;&EG;CTS1'1O<#X-"CQT
M9"!S='EL93TS1"=724142#H@,C=P="<^#0H\9&EV('-T>6QE/3-$)TU!4D=)
M3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@
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M($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU2
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M<R!A<F4@=')A9&5D(&%N9`T*=&AE(')E;&EA8FEL:71Y(&]F('1H92!A<W-U
M;7!T:6]N<R!U<V5D('1O(&1E=&5R;6EN92!F86ER#0IV86QU92X\+V9O;G0^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.
M1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX-"CQD:78^#0H\=&%B;&4@86QI9VX]
M,T1C96YT97(@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0H\='(@=F%L:6=N
M/3-$=&]P/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`R-W!T)SX-"CQD:78^/&9O
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M86X@86-T:79E(&UA<FME="!F;W(@:61E;G1I8V%L(&9I;F%N8VEA;`T*87-S
M971S(&]R(&QI86)I;&ET:65S+CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R
M/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=CX-"CQT86)L92!A;&EG;CTS1&-E
M;G1E<B!B;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS
M1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"CQT<B!V86QI9VX],T1T
M;W`^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#(W<'0G/@T*/&1I=CX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^)B-X03`[/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,3AP="<^#0H\9&EV('-T
M>6QE/3-$)TU!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I3>6UB;VPL('-E
M<FEF)SXF(WA"-SL\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9#X-
M"CQD:78@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SY,979E;`T*,CH@26YP=71S(&]T:&5R('1H86X@<')I8V5S('%U
M;W1E9"!I;B!,979E;"`Q+"!S=6-H(&%S('!R:6-E<PT*<75O=&5D(&9O<B!S
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M9&EV/@T*/'1A8FQE(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`@8V5L;'!A
M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86XG/@T*/'1R('9A;&EG;CTS1'1O<#X-"CQT9"!S='EL93TS1"=72414
M2#H@,C=P="<^#0H\9&EV/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SXF(WA!,#L\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)U=)1%1(.B`Q.'!T)SX-"CQD:78@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#!P
M=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O
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M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
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M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0X
M,"4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#0P)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
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M:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN92<^4V5P=&5M8F5R(#,P+`T*,C`Q,3PO9F]N=#X\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,G!X.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,G!X)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
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M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SY,979E;"`Q/"]F
M;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
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M($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE)SY,979E;"`R/"]F;VYT/CPO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[
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M.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE)SY,979E;"`S/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U7
M14E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;B<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)SX-"CQD:78@<W1Y
M;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M
M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E
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M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O
M;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3,E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U7
M14E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;B<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&
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M:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%
M24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P
M86X],T0R('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
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M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3,E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'
M2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;B<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(T-#1D9#0SX-"CQT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E/@T*/&1I=B!S='EL
M93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)
M3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
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M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
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M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
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M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
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M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY787)R86YT<SPO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^#0H\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*+3PO9F]N=#X\
M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>#L@
M5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/@T*
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M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF
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M"C<W+#DV-SPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#1P>#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`T<'@G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
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M/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@-'!X)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HW-RPY-C<\+V9O;G0^/"]F;VYT
M/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@[(%1%6%0M
M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^
M#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$58
M5"U!3$E'3CH@;&5F="<^#0HF(WA!,#L\+V1I=CX-"CQD:78@86QI9VX],T1L
M969T/@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@
M=VED=&@],T0X,"4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#0P)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,G!X)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0HF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,30@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-3@E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9"<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^1&5C96UB97(@,S$L(#(P,3`\+V9O
M;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
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M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L
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M8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
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M/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L
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M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"CQF
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M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[
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M:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&
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M24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^
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M+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN92<^1F%I<B!686QU93PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!L
M969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)
M1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$S)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0HF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L
M9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
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M9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$S)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%
M24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
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M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
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M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
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M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M8F=C;VQO<CTS1'=H:71E/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0T,"4@<W1Y;&4],T0G4$%$1$E.1RU,1494.B`P<'0[
M(%!!1$1)3D<M0D]45$]-.B`T<'@[($U!4D=)3BU,1494.B`Y<'0G/@T*/&1I
M=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@
M5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^5V%R<F%N
M=',\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/@T*/&9O
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M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF;F)S
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M.B`T<'@[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M-'!X)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#1P>"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4G/@T*+3PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>#L@5$585"U!3$E'3CH@;&5F="<^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/@T*/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
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M:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@[(%1%6%0M04Q)
M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF
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M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
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M#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*-"XF(WA!,#L@1D%)
M4B!604Q515,@3T8@05-31513($%.1"!,24%"24Q)5$E%4SPO9F]N=#X\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
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M1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=CX-"CQT86)L92!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4@86QI9VX],T1C96YT97(^#0H\='(@=F%L
M:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`S-G!T)SX-"CQD:78^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#$X<'0G/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ4WEM
M8F]L+"!S97)I9B<^)B-X0C<[/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0^#0H\9&EV(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*3&5V96P@,3H@26YP=70@<')I8V5S('%U
M;W1E9"!I;B!A;B!A8W1I=F4@;6%R:V5T(&9O<B!I9&5N=&EC86P-"F9I;F%N
M8VEA;"!A<W-E=',@;W(@;&EA8FEL:71I97,N/"]F;VYT/CPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=CX-"CQT
M86)L92!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@86QI9VX],T1C96YT97(^#0H\
M='(@=F%L:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`S-G!T)SX-
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M:&5R('1H86X@<')I8V5S('%U;W1E9"!I;B!,979E;"`Q+"!S=6-H(&%S('!R
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M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I
M=CX-"CQD:78^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N
M/3-$8V5N=&5R/@T*/'1R('9A;&EG;CTS1'1O<#X-"CQT9"!S='EL93TS1"=7
M24142#H@,S9P="<^#0H\9&EV/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE
M/3-$)U=)1%1(.B`Q.'!T)SX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*
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M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T)SX-"DQE=F5L
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M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
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M1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=-
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
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M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M)SY$96-E;6)E<B8C>$$P.S,Q+"8C>$$P.S(P,3`\+V9O;G0^/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,B4@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4G/DQE=F5L)B-X03`[,3PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
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M+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN92<^3&5V96PF(WA!,#LS/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/D9A:7(F(WA!,#M6
M86QU93PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X]
M,T0R(&%L:6=N/3-$;&5F=#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&%L:6=N/3-$
M;&5F=#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&%L:6=N/3-$;&5F=#X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E
M(&-O;'-P86X],T0R(&%L:6=N/3-$;&5F=#X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
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M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/@T*3&EA8FEL:71I97,Z/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&QE9G0^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED
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M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$P)2!C;VQS<&%N/3-$,B!A;&EG;CTS1&QE9G0^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@.7!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY787)R86YT<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G
M/@T*)FYB<W`[)#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE)SX-"B9N8G-P.R0\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U
M8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X
M)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
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M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G
M/@T*+3PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
M1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*)FYB<W`[
M)#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE)SX-"C(X."PR-3`\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^
M#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=-05)'
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
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M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E
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M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G
M/DQE=F5L)B-X03`[,3PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$P)2!C;VQS<&%N/3-$,CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
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M5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/D9A:7(F(WA!,#M686QU
M93PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R
M(&%L:6=N/3-$;&5F=#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&%L:6=N/3-$;&5F
M=#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3`E(&-O;'-P86X],T0R(&%L:6=N/3-$;&5F=#X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O
M;'-P86X],T0R(&%L:6=N/3-$;&5F=#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-
M"CQT<B!B9V-O;&]R/3-$(T-#1D9#0SX-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0U,B4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*
M3&EA8FEL:71I97,Z/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@]
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C
M;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)2!A;&EG;CTS1&QE9G0^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@.7!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY7
M87)R86YT<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
M;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*
M)FYB<W`[)#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
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M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE)SX-"B9N8G-P.R0\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE
M)R!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HQ,"PT.#<L,#`P/"]F;VYT
M/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X
M)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
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M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G
M/@T*+3PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
M1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*)FYB<W`[
M)#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE)SX-"C$P+#0X-RPP,#`\+V9O;G0^/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T
M<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
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M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#)D,6$S9CA?,&,U-U\T
M,38X7V)E9&-?.#8W-V1C9&(S-65C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V0R9#%A,V8X7S!C-3=?-#$V.%]B961C7S@V-S=D8V1B,S5E8R]7
M;W)K<VAE971S+U-H965T,3$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,1SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY!0U%525-)5$E/3CQB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!0U%525-)5$E/3CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQD:78^#0H\=&%B;&4@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N=&5R/@T*/'1R('9A;&EG;CTS
M1'1O<#X-"CQT9"!S='EL93TS1"=724142#H@,C=P="<^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
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M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"DUE<F=E<B!!9W)E96UE;G0\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]N#0I!<')I;"`X+"`R,#$Q+"!.
M;W9E;&]S(&%C<75I<F5D($-E;&QE8W1A<B!T:')O=6=H(&$@;65R9V5R('=I
M=&@@86YD#0II;G1O('1H92!-97)G97(@4W5B<VED:6%R>2P@<'5R<W5A;G0@
M=&\@=&AE(&UE<F=E<B!!9W)E96UE;G0-"F5N=&5R960@:6YT;R!O;B!T:&%T
M(&1A=&4N)B-X03`[($%S(&$@<F5S=6QT(&]F('1H92!!8W%U:7-I=&EO;BP-
M"G1H92!-97)G97(@4W5B<VED:6%R>2P@=VAI8V@@:&%S(&)E96X@<F5N86UE
M9"!#96QL96-T87(L($EN8RXL(&]W;G,-"F%L;"!A<W-E=',@;V8@86YD(&]P
M97)A=&5S('1H92!B=7-I;F5S<R!P<F5V:6]U<VQY(&]W;F5D(&%N9`T*;W!E
M<F%T960@8GD@0V5L;&5C=&%R+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
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M<B!T;R!T:&4@06-Q=6ES:71I;VXL($YO=F5L;W,@86UE;F1E9`T*86YD(')E
M<W1A=&5D(&ET<R!C97)T:69I8V%T92!O9B!I;F-O<G!O<F%T:6]N(&%N9"!I
M;B!C;VYN96-T:6]N#0IT:&5R97=I=&@L(&%M;VYG(&]T:&5R('1H:6YG<RP@
M969F96-T960@82`Q+69O<BTQ-3,@<F5V97)S92!S<&QI=`T*;V8@:71S(&-O
M;6UO;B!S=&]C:R`H=&AE("8C>#(P,4,[4F5V97)S92!3<&QI="8C>#(P,40[
M*2!R97-U;'1I;F<-"FEN)B-X03`[,BPY-3DL.#<Q('-H87)E<R!O9B!.;W9E
M;&]S(&-O;6UO;B!S=&]C:R!O=71S=&%N9&EN9RX-"DYO=F5L;W,@=&AE;B!I
M<W-U960@,3<L,#`Q+#4Y-B!S:&%R97,@;V8@3F]V96QO<R!C;VUM;VX@<W1O
M8VL@=&\-"G1H92!S=&]C:VAO;&1E<G,@;V8@0V5L;&5C=&%R('5P;VX@=&AE
M(&5F9F5C=&EV92!D871E(&]F('1H90T*06-Q=6ES:71I;VXN)B-X03`[(%=A
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M8V]M;6]N('-T;V-K('=I=&@-"G!R:6-E<R!R86YG:6YG(&9R;VT@)FYB<W`[
M)#$V+C`W('1O("9N8G-P.R0Q.3$N,C4@86YD(&]P=&EO;G,@=&\@<'5R8VAA
M<V4@80T*=&]T86P@;V8@-#DL,34Y('-H87)E<R!O9B!.;W9E;&]S(&-O;6UO
M;B!S=&]C:R!W:71H('!R:6-E<R!R86YG:6YG#0IF<F]M("9N8G-P.R0Q+C4S
M('1O("9N8G-P.R0Q+#`W,BXU,RX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/EA-4PT*0V%P:71A;"!087)T;F5R<RP@=&AE(&9I;F%N8VEA;"!A9'9I
M<V]R('1O($-E;&QE8W1A<B!I;B!C;VYN96-T:6]N#0IW:71H('1H92!!8W%U
M:7-I=&EO;BP@<F5C96EV960@82!C87-H(&9E92!O9B`F;F)S<#LD,C`P+#`P
M,"!U<&]N('1H90T*8V]M<&QE=&EO;B!O9B!T:&4@06-Q=6ES:71I;VX@:6X@
M8V]N<VED97)A=&EO;B!O9B!T:&5I<@T*<V5R=FEC97,N)B-X03`[(%)O9&UA
M;B`F86UP.R!296YS:&%W+"!,3$,@*"8C>#(P,4,[4F]D;6%N)B-X,C`Q1#LI
M+`T*9FEN86YC:6%L(&%D=FES;W(@=&\@3F]V96QO<R!I;B!C;VYN96-T:6]N
M('=I=&@@=&AE($%C<75I<VET:6]N+`T*<F5C96EV960@82!C87-H(&9E92!O
M9B`F;F)S<#LD,C4P+#`P,"!U<&]N('1H92!C;VUP;&5T:6]N(&]F('1H90T*
M06-Q=6ES:71I;VX@:6X@8V]N<VED97)A=&EO;B!O9B!T:&5I<B!S97)V:6-E
M<RXF(WA!,#L@5&AE<V4@86UO=6YT<PT*=V5R92!R96-O<F1E9"!A<R!M97)G
M97(@8V]S=',@86YD(&5X<&5N<V5D(&%S(&EN8W5R<F5D(&]N('1H92!D871E
M#0IO9B!T:&4@06-Q=6ES:71I;VXN)B-X03`[($EN(&%D9&ET:6]N('1O('1H
M92!I;G9E<W1M96YT(&)A;FMI;F<-"F9E97,L('1H92!#;VUP86YY(&%L<V\@
M:6YC=7)R960@86X@861D:71I;VYA;"`F;F)S<#LD,CDV+#(P-R!O9@T*;65R
M9V5R+7)E;&%T960@;&5G86P@86YD(&]T:&5R(&-O<W1S(&1U<FEN9R!T:&4@
M;FEN92!M;VYT:',@96YD960-"E-E<'1E;6)E<B`S,"P@,C`Q,2!W:&EC:"!W
M97)E(&EN8VQU9&5D(&%S(&$@8V]M<&]N96YT(&]F(&5X<&5N<V4@:6X-"G1H
M92!R97-P96-T:79E('!E<FEO9"X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
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M:6YG(&%N9`T*9G5N9&EN9R!T:&4@9&5V96QO<&UE;G0@;V8@8V%N8V5R(&1R
M=6=S(&%N9"!#96QL96-T87(F(W@R,#$Y.W,-"G!O<G1F;VQI;R!O9B!C86YC
M97(M=&%R9V5T960@8V]M<&]U;F1S+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I
M=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M#0I0=7)C:&%S92!!8V-O=6YT:6YG/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
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M9`T*=&\@=&AE(&%S<V5T<R!A8W%U:7)E9"!A;F0@;&EA8FEL:71I97,@87-S
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M(&1E=&5R;6EN960N)B-X03`[(%1H92!E=F%L=6%T:6]N(&ES#0IP<F5L:6UI
M;F%R>2!P<FEN8VEP86QL>2!D=64@=&\@=&AE('!E;F1I;F<@979A;'5A=&EO
M;B!O9B!T:&4-"D-O;7!A;GDF(W@R,#$Y.W,@:6YT86YG:6)L92!A<W-E=',N
M)B-X03`[(%1H92!E>&-E<W,@;V8@<'5R8VAA<V4-"G!R:6-E(&]V97(@;F5T
M(&%S<V5T<R!A8W%U:7)E9"!W:6QL(&)E(&%L;&]C871E9"!T;R!I;G1A;F=I
M8FQE<R!A;F0-"F=O;V1W:6QL(&]N8V4@=&AE($-O;7!A;GD@8V]M<&QE=&5S
M('1H92!F:6YA;"!A;&QO8V%T:6]N(&]F#0IP=7)C:&%S92!P<FEC92X\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"F9A:7(@=F%L
M=64@;V8@=&AE(&-O;G-I9&5R871I;VX@=')A;G-F97)R960@:6X@=&AE($%C
M<75I<VET:6]N('=A<PT*)FYB<W`[)#(L,C$Y+#DP,R!A;F0@=V%S(&-A;&-U
M;&%T960@87,@=&AE(&YU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N#0IS=&]C
M:R!T:&%T($-E;&QE8W1A<B!W;W5L9"!H879E(&AA9"!T;R!I<W-U92`H861J
M=7-T960@9F]R('1H90T*17AC:&%N9V4@4F%T:6\I(&EN(&]R9&5R(&9O<B!.
M;W9E;&]S('-H87)E:&]L9&5R<R!T;R!O8G1A:6X@82`Q-24-"F5Q=6ET>2!I
M;G1E<F5S="!I;B!T:&4@8V]M8FEN960@0V]M<&%N>2!P;W-T+6%C<75I<VET
M:6]N+`T*;75L=&EP;&EE9"!B>2!T:&4@97-T:6UA=&5D(&9A:7(@=F%L=64@
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M#0IO9B!T:&4@06-Q=6ES:71I;VXN)B-X03`[/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/E1H:7,-"G!R:6-E('=A<R!D971E<FUI;F5D('1O
M(&)E('1H92!B97-T(&EN9&EC871I;VX@;V8@9F%I<B!V86QU92!O;@T*=&AA
M="!D871E('-I;F-E('1H92!P<FEC92!W87,@8F%S960@;VX@86X@87)M)B-X
M,C`Q.3MS(&QE;F=T:`T*;F5G;W1I871I;VX@=VET:"!A(&=R;W5P(&-O;G-I
M<W1I;F<@;V8@8F]T:"!N97<@86YD(&5X:7-T:6YG#0II;G9E<W1O<G,@=&AA
M="!H860@8F5E;B!A9'9I<V5D(&]F('1H92!P96YD:6YG($%C<75I<VET:6]N
M(&%N9`T*87-S=6UE9"!S:6UI;&%R(&QI<75I9&ET>2!R:7-K(&%S('1H;W-E
M(&EN=F5S=&]R<R!H;VQD:6YG('1H90T*;6%J;W)I='D@;V8@<VAA<F5S(&)E
M:6YG('9A;'5E9"!A<R!P=7)C:&%S90T*8V]N<VED97)A=&EO;BX\+V9O;G0^
M/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"F9O;&QO=VEN9R!T
M86)L92!S=6UM87)I>F5S('1H92!#;VUP86YY)B-X,C`Q.3MS('!R96QI;6EN
M87)Y#0IE<W1I;6%T960@9F%I<B!V86QU97,@;V8@=&AE(&%S<V5T<R!A8W%U
M:7)E9"!A;F0@=&AE(&QI86)I;&ET:65S#0IA<W-U;65D(&%T('1H92!D871E
M(&]F(&%C<75I<VET:6]N+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV
M/@T*/&1I=B!A;&EG;CTS1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#`E/@T*/'1R
M(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@U)2!A;&EG;CTS
M1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY#;VYS:61E<F%T:6]N#0HM(&ES<W5A;F-E(&]F('-E8W5R:71I97,\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$R)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SX-"C(L,C$Y
M+#DP,SPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-
M"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.#4E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
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M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@U)2!A;&EG;CTS1&QE9G0^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY0
M<F5P86ED#0IE>'!E;G-E<R!A;F0@;W1H97(@87-S971S/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXW,2PX.3(\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.#4E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D9I>&5D#0IA<W-E
M=',\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^-BPU,34\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(T-#1D9#
M0SX-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X-24@86QI9VX],T1L
M969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^06-C<G5E9`T*;&EA8FEL:71I97,\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
M"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*#,X,"PQ,S`\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BD\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#@U)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY$97)I=F%T:79E#0IL:6%B:6QI='D\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
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M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^17AC97-S#0IO9B!P=7)C:&%S92!P
M<FEC92!O=F5R(&YE="!A<W-E=',@86-Q=6ER960\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
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M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI
M=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.#4E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@U)2!A
M;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY4;W1A;`T*<'5R8VAA<V4@<')I8V4@)B-X,C`Q,SL@;F5T
M(&]F(&-A<V@@86-Q=6ER960@;V8-"B9N8G-P.R0Y,#4L-C0Y/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HQ+#,Q-"PR-30\+V9O
M;G0^/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE
M/@T*/"]D:78^#0H\8G(@+SX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
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M=&EN9R!F;W(@861D:71I;VYA;`T*:6YF;W)M871I;VX@;F5C97-S87)Y('1O
M(&9I;F%L:7IE('1H;W-E(&9A:7(@=F%L=65S+B8C>$$P.PT*5&AE<F5F;W)E
M+"!T:&4@<')O=FES:6]N86P@;65A<W5R96UE;G1S(&]F(&9A:7(@=F%L=64@
M<F5F;&5C=&5D(&%R90T*<W5B:F5C="!T;R!C:&%N9V4@86YD('-U8V@@8VAA
M;F=E<R!M87D@8F4@<VEG;FEF:6-A;G0N)B-X03`[(%1H90T*0V]M<&%N>2!E
M>'!E8W1S('1O(&9I;F%L:7IE('1H92!V86QU871I;VX@86YD(&-O;7!L971E
M('1H92!P=7)C:&%S90T*<')I8V4@86QL;V-A=&EO;B!A<R!S;V]N(&%S('!R
M86-T:6-A8FQE(&)U="!N;R!L871E<B!T:&%N(&]N92!Y96%R#0IF<F]M('1H
M92!A8W%U:7-I=&EO;B!D871E+CPO9F]N=#X\+V1I=CX-"CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#)D,6$S9CA?
M,&,U-U\T,38X7V)E9&-?.#8W-V1C9&(S-65C#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V0R9#%A,V8X7S!C-3=?-#$V.%]B961C7S@V-S=D8V1B
M,S5E8R]7;W)K<VAE971S+U-H965T,3(N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5'1$%#/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D9)6$5$($%34T544SQB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9)
M6$5$($%34T544SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I
M=CX-"CQD:78^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N
M/3-$8V5N=&5R/@T*/'1R('9A;&EG;CTS1'1O<#X-"CQT9"!S='EL93TS1"=7
M24142#H@,3AP="<^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
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M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
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M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO9&EV
M/@T*/&1I=B!A;&EG;CTS1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3`E/@T*/'1R
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#<P)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@
M8V5N=&5R)R!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"C(P
M,3`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!N
M;W)M86PG/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&YO<FUA;"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&YO<FUA;"<^#0HF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^#0HR,#`Y/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
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M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
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M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L
M:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^,BPY.#0L,S<U/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXR+#DX,BPW,C,\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0W,"4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^3&5A<V5H;VQD#0II;7!R;W9E;65N=',\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,G!X('-O;&ED)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#)P>"!S;VQI9"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$
M<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L
M:60G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O
M;&ED)R!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*,BPS,3<L-3DW/"]F
M;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$;&5F
M=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R
M:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXU+#,P,2PY-S(\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-2PS,#`L,S(P
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R
M/3-$=VAI=&4^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$;&5F=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DQE<W,-
M"F%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M<'@@<V]L:60G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I
M9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
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M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI
M9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*
M*#$L,C$Q+#,V.3PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
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M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^1FEX960-"F%S<V5T<RP@;F5T/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4
M.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^)FYB
M<W`[)#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN92<^#0HS+#4Q,"PT.#D\+V9O;G0^/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
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M:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SX-
M"C0L,#@X+#DU,3PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-
M"CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$=7)I;F<-"G1H92!N:6YE(&UO
M;G1H<R!E;F1E9"8C>$$P.U-E<'1E;6)E<B`S,"P@,C`Q,2P@=&AE(&-H86YG
M92!T;R!N970-"F9I>&5D(&%S<V5T<R!C;VYS:7-T960@;V8@86X@:6YC<F5A
M<V4@;V8@87!P<F]X:6UA=&5L>2`F;F)S<#LD-#0P+#`P,`T*<F5L871E9"!T
M;R!A8V-U;75L871E9"!D97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;BP@
M<'5R8VAA<V5S(&]F#0IE<75I<&UE;G0@=&]T86QI;F<@87!P<F]X:6UA=&5L
M>2`F;F)S<#LD,3$R+#`P,"P@97%U:7!M96YT(&1I<W!O<V%L<R!O9@T*87!P
M<F]X:6UA=&5L>2`F;F)S<#LD-BPP,#`L(&%N9"!A<'!R;WAI;6%T96QY("9N
M8G-P.R0W+#`P,"!R96QA=&5D('1O('1H92!F86ER#0IV86QU92!O9B!F:7AE
M9"!A<W-E=',@86-Q=6ER960@87,@82!R97-U;'0@;V8@=&AE($%C<75I<VET
M:6]N("AS964-"DYO=&4@-"DN/"]F;VYT/CPO9&EV/@T*/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M5T5)1TA4.B!B;VQD)SX-"C,N)B-X03`[($9)6$5$($%34T544SPO9F]N
M=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^1FEX960-"F%S<V5T<R!C;VYS:7-T
M960@;V8@=&AE(&9O;&QO=VEN9R!A="!$96-E;6)E<B`S,3H\+V9O;G0^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)TU!4D=)
M3BU,1494.B`S-G!T)R!A;&EG;CTS1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#`E
M/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)2!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4
M.B!B;VQD)SX-"C(P,3`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C
M;VQS<&%N/3-$,CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*,C`P.3PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P
M>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-S`E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
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M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#<P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/9F9I8V4-"F%N9"!C
M;VUP=71E<B!E<75I<&UE;G0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[
M)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^-C$L.3`W/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI
M9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-S,L,C8Q/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$
M=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L:6=N
M/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
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M.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/C0S+#@Y-CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$
M<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^-#,L.#DV/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
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M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^3&5A<V5H;VQD#0II;7!R;W9E;65N=',\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-"PP.34\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M)R!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT+#`Y
M-3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)2!A;&EG;CTS1&QE9G0^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4;W1A
M;`T*9FEX960@87-S971S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M,3`Y+#@Y.#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
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M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C
M;VQO<CTS1"-#0T9&0T,^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$;&5F
M=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/DQE<W,-"F%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T
M:6]N/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG
M;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B@Q,#$L,30S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@W-RPQ-34\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BD\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D9I>&5D#0IA<W-E=',L(&YE
M=#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
M1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF;F)S<#LD/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T
M<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R
M:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXX+#<U-3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
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M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
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M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/C0T+#`Y-SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L
M93X-"CPO9&EV/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]D,F0Q83-F.%\P8S4W7S0Q-CA?8F5D8U\X-C<W9&-D
M8C,U96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#)D,6$S9CA?
M,&,U-U\T,38X7V)E9&-?.#8W-V1C9&(S-65C+U=O<FMS:&5E=',O4VAE970Q
M,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14Q'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQ)
M0T5.4T4@04=2145-14Y44SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,24-%3E-%($%'4D5%345.5%,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78^#0H\9&EV/@T*/'1A8FQE(&%L:6=N/3-$
M8V5N=&5R(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG
M/3-$,"!W:61T:#TS1#$P,"4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*/'1R('9A;&EG;CTS
M1'1O<#X-"CQT9"!S='EL93TS1"=724142#H@,3AP="<^#0H\9&EV('-T>6QE
M/3-$)TU!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)
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M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*,C`P,R!,:6-E;G-E($%G<F5E;65N
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M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SY);@T*4V5P=&5M8F5R(#(P,#,L($-E;&QE8W1A
M<B!E;G1E<F5D(&EN=&\@86X@97AC;'5S:79E(&QI8V5N<V4-"F%G<F5E;65N
M="`H=&AE("8C>#(P,4,[52X@36EC:"X@06=R965M96YT)B-X,C`Q1#LI('=I
M=&@@=&AE(%)E9V5N=',-"F]F('1H92!5;FEV97)S:71Y(&]F($UI8VAI9V%N
M+"`H)B-X,C`Q0SM5+B!-:6-H+B8C>#(P,40[*2!F;W(@=&AE#0ID979E;&]P
M;65N="P@;6%N=69A8W1U<F4@86YD(&UA<FME=&EN9R!O9B!P<F]D=6-T<R!U
M;F1E<B!S979E<F%L#0IC;VUP;W-I=&EO;B!O9B!M871T97(@<&%T96YT<R!I
M;B!.;W)T:"!!;65R:6-A('=H:6-H(&5X<&ER92!A=`T*=F%R>6EN9R!D871E
M<R!I;B`R,#$V+B8C>$$P.R!4:&4@52X@36EC:"X@06=R965M96YT(&5X<&ER
M97,@=7!O;@T*=&AE(&5X<&ER871I;VX@;V8@=&AE(&QA<W0@8V]V97)E9"!P
M871E;G0N)B-X03`[(%1H92!#;VUP86YY(&ES#0IR97-P;VYS:6)L92!F;W(@
M86X@86YN=6%L(&QI8V5N<V4@9F5E(&]F("9N8G-P.R0Q,"PP,#`@86YD(&ES
M(')E<75I<F5D('1O#0IP87D@8V]S=',@87-S;V-I871E9"!W:71H('1H92!M
M86EN=&5N86YC92!O9B!T:&4@<&%T96YT<R!C;W9E<F5D(&)Y#0IT:&4@52X@
M36EC:"X@06=R965M96YT+B8C>$$P.R!!9&1I=&EO;F%L;'DL('1H92!#;VUP
M86YY(&ES(')E<75I<F5D#0IT;R!M86ME(&UI;&5S=&]N92!P87EM96YT<R!O
M9B`F;F)S<#LD-3`L,#`P('5P;VX@=&AE(&9I;&EN9R!O9B!A($YE=R!$<G5G
M#0I!<'!L:6-A=&EO;B`H)B-X,C`Q0SM.1$$F(W@R,#%$.RD@9F]R(&$@;&EC
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M86QE(&]F(&%N>2!L:6-E;G-E9`T*<')O9'5C=',N)B-X03`[(%1H92!S86QE
M<R!M:6QE<W1O;F5S(')A;F=E(&9R;VT@)FYB<W`[)#$P,"PP,#`@=&\-"B9N
M8G-P.R0R,#`L,#`P+"!D97!E;F1E;G0@=7!O;B!W:&5T:&5R('1H92!D<G5G
M(&ES(&9O<B!U<V4@:6X@80T*=&AE<F%P975T:6,@;W(@9&EA9VYO<W1I8R!A
M<'!L:6-A=&EO;BP@<')O=FED960@=&AA="!I9B!S86QE<R!I;@T*=&AE(&9I
M<G-T(#$R(&UO;G1H<R!A<F4@;&5S<R!T:&%N('1H92!A;6]U;G0@;V8@=&AE
M(&UI;&5S=&]N92P@=&AE;@T*=V4@87)E(')E<75I<F5D('1O('!A>2`U,"4@
M;V8@86QL('-A;&5S('5N=&EL('1H92!M:6QE<W1O;F4@:7,-"G-A=&ES9FEE
M9"XF(WA!,#M4:&4@;6EL97-T;VYE('!A>6UE;G1S(&UA>28C>$$P.W1O=&%L
M('5P('1O#0HF;F)S<#LD-#`P+#`P,"X@5&AE(%4N($UI8V@N($%G<F5E;65N
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M-3`E(&]F('1H92!S=6)L:6-E;G-E(&9E92XF(WA!,#L@1G5R=&AE<FUO<F4L
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M9"!C=7)E('!E<FEO9',N)B-X03`[(%1O(&1A=&4L('1H92!#;VUP86YY(&AA
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M;V1U8W0@86YD(')E;&%T960-"F1A=&$N)B-X03`[(%1H92!5+B!-:6-H+B!!
M9W)E96UE;G0@8V]N=&%I;F5D(&UI;&5S=&]N97,@=&AA=`T*<F5Q=6ER960@
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M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SY#96QL96-T87(-"G!A:60@87!P<F]X:6UA=&5L
M>2`F;F)S<#LD-C`P+"8C>$$P.R9N8G-P.R0S,#`@86YD("9N8G-P.R0U+#`P
M,"!T;R!5+B!-:6-H:6=A;B!F;W(-"G1H92!R96EM8G5R<V5M96YT(&]F('!A
M=&5N="!M86EN=&5N86YC92!F965S(&1U<FEN9R!T:&4@;FEN92!M;VYT:',-
M"F5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,2!A;F0@=&AE('EE87)S(&5N9&5D
M($1E8V5M8F5R(#,Q+"`R,#$P(&%N9`T*,C`P.2P@<F5S<&5C=&EV96QY+B8C
M>$$P.R!!<R!O9B!397!T96UB97(@,S`L(#(P,3$@86YD($1E8V5M8F5R(#,Q
M+`T*,C`Q,"P@86QL(&%N;G5A;"!L:6-E;G-E(&9E97,@:&%V92!B965N('!A
M:60@:6X@82!T:6UE;'D-"FUA;FYE<BX\+V9O;G0^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@
M+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86XG/DEN#0IC;VYN96-T:6]N('=I=&@@=&AE($UI8VAI9V%N($%G<F5E
M;65N="P@9'5R:6YG(#(P,#,@0V5L;&5C=&%R('!A:60-"F%P<')O>&EM871E
M;'D@)FYB<W`[)#4T+#`P,"!O9B!B86-K('!A=&5N="!C;W-T<R!A;F0@:7-S
M=65D(#(P,RPT.#,-"G-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=&\@52X@36EC
M:&EG86X@87,@<&%R=&EA;"!C;VYS:61E<F%T:6]N(&9O<@T*=&AE(')I9VAT
M<R!D97-C<FEB960@86)O=F4N)B-X03`[(%1H92!E<W1I;6%T960@9F%I<BUM
M87)K970@=F%L=64-"F]F('1H92!I<W-U86YC92!W87,@)FYB<W`[)#@P+#0Q
M,B!A;F0@=V%S(')E8V]R9&5D(&%S(&$@;&EC96YS92!C;W-T(&%N9`T*:7,@
M:6YC;'5D960@87,@82!C;VUP;VYE;G0@;V8@<W1O8VMH;VQD97)S(&5Q=6ET
M>2!I;B!T:&4-"F%C8V]M<&%N>6EN9R!B86QA;F-E('-H965T<RX\+V9O;G0^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.
M1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M1D%-24Q9
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M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SY);@T*2F%N=6%R>2`R,#`V+"!#96QL96-T
M87(@96YT97)E9"!I;G1O(&$@;&EC96YS92!A9W)E96UE;G0@*'1H90T*)B-X
M,C`Q0SM705)&($%G<F5E;65N="8C>#(P,40[*2!W:71H('1H92!7:7-C;VYS
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M;V8@)FYB<W`[)#@L.#`P(&%N9"!P<F]V:61E9"!T:&%T($-E;&QE8W1A<B!P
M87D@<F]Y86QT:65S(&5Q=6%L('1O(#`N,R4-"F]F('-A;&5S(&]F(&%N>2!L
M:6-E;G-E9"!P<F]D=6-T<RXF(WA!,#L@0V5L;&5C=&%R('=A<R!A;'-O#0IR
M97%U:7)E9"!T;R!R96EM8G5R<V4@5T%21B!F;W(@<&%T96YT(&9I;&EN9R!F
M965S(&%N9"!R96QA=&5D#0IC;W-T<RXF(WA!,#L@1'5R:6YG('1H92!Y96%R
M<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,"!A;F0@,C`P.2P-"G1H97)E('=E
M<F4@;F\@8V]S=',@<F5L871E9"!T;R!T:&4@<&%T96YT<R!U;F1E<B!T:&4@
M5T%21@T*06=R965M96YT+B8C>$$P.R8C>$$P.T1U<FEN9R`R,#$P+"!T:&4@
M5T%21B!!9W)E96UE;G0@=V%S#0IT97)M:6YA=&5D+CPO9F]N=#X\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P
M<'0G/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M4U193$4Z(&ET86QI8SL@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0I.;W9E;&]S($QI8V5N<V4@06=R965M96YT<SPO9F]N=#X\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$
M14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^1'5R:6YG#0HR,#`W+"!.;W9E;&]S(&5N
M=&5R960@:6YT;R!A($-O;&QA8F]R871I;VX@06=R965M96YT('=I=&@-"DQE
M928C>#(P,3D[<R!0:&%R;6%C975T:6-A;"`H2$LI($QT9"X@*"8C>#(P,4,[
M3&5E)B-X,C`Q.3MS#0I0:&%R;28C>#(P,40[*2!W:&5R96)Y($QE928C>#(P
M,3D[<R!0:&%R;2!O8G1A:6YE9"!A;B!E>&-L=7-I=F4-"FQI8V5N<V4@=&\@
M9&5V96QO<"P@;6%N=69A8W1U<F4@86YD(&-O;6UE<F-I86QI>F4@3D]6+3`P
M,B!A;F0-"DY/5BTR,#4@:6X@0VAI;F$L($AO;F<@2V]N9RP@5&%I=V%N(&%N
M9"!-86-A=2`H=&AE("8C>#(P,4,[0VAI;F5S90T*5&5R<FET;W)Y)B-X,C`Q
M1#LI+B!5;F1E<B!T:&4@=&5R;7,@;V8@=&AE(&%G<F5E;65N="!T:&4@0V]M
M<&%N>2!I<PT*96YT:71L960@=&\@<F5C96EV92!U<"!T;R`F;F)S<#LD,2PW
M,#`L,#`P(&EN(&9U='5R92!M:6QE<W1O;F4@<&%Y;65N=',-"G5P;VX@=&AE
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M87EM96YT<R!O9B`Q,BTQ-24@;V8@;F5T('-A;&5S(&]F#0I.3U8M,C`U(&EN
M('1H92!#:&EN97-E(%1E<G)I=&]R>2X@5&AE(&%G<F5E;65N="!E>'!I<F5S
M('5P;VX@=&AE#0IE>'!I<F%T:6]N(&]F('1H92!L87-T('!A=&5N="!C;W9E
M<FEN9R!A;GD@;V8@=&AE(&QI8V5N<V5D#0IP<F]D=6-T<RP@;W(@='=E;'9E
M('EE87)S(&9R;VT@=&AE(&1A=&4@;V8@=&AE(&9I<G-T(&-O;6UE<F-I86P-
M"G-A;&4@:6X@0VAI;F$L('=H:6-H979E<B!O8V-U<G,@;&%T97(N/"]F;VYT
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@5$585"U)
M3D1%3E0Z(#!P="<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SY$=7)I;F<-"C(P,#DL($YO=F5L;W,@
M96YT97)E9"!I;G1O(&$@8V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@*'1H90T*
M)B-X,C`Q0SM#;VQL86)O<F%T:6]N($%G<F5E;65N="8C>#(P,40[*2!W:71H
M($UU;F1I<&AA<FUA#0I);G1E<FYA=&EO;F%L($-O<G!O<F%T:6]N($QI;6ET
M960@*"8C>#(P,4,[375N9&EP:&%R;6$F(W@R,#%$.RD@=&\-"F1E=F5L;W`L
M(&UA;G5F86-T=7)E(&%N9"!C;VUM97)C:6%L:7IE+"!O;B!A;B!E>&-L=7-I
M=F4@8F%S:7,L#0I,:6-E;G-E9"!0<F]D=6-T<R`H87,@9&5F:6YE9"!I;B!T
M:&4@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0I+`T*:6YC;'5D:6YG($Y/5BTP
M,#(L(&EN($5U<F]P92`H;W1H97(@=&AA;B!T:&4@4G5S<VEA;B!497)R:71O
M<GDI+`T*07-I82`H;W1H97(@=&AA;B!T:&4@0VAI;F5S92!497)R:71O<GDI
M(&%N9"!!=7-T<F%L:6$@*&-O;&QE8W1I=F5L>0T*<F5F97)R960@=&\@87,@
M=&AE("8C>#(P,4,[375N9&EP:&%R;6$@5&5R<FET;W)Y)B-X,C`Q1#LI+B8C
M>$$P.PT*375N9&EP:&%R;6$@:7,@86X@:6YD97!E;F1E;G0@87-S;V-I871E
M9"!C;VUP86YY(&]F(%!U<F1U92!0:&%R;6$L#0I,+E`N("@F(W@R,#%#.U!U
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M;&4@3F]V96QO<R!P871E;G0@=VET:&EN('1H92!C;W5N=')Y#0IO<B`H,BD@
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M(&EN#0I-=6YD:7!H87)M828C>#(P,3D[<R!M87)K970@<VAA<F4N)B-X03`[
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M4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(
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M8VEA;`T*<&]S:71I;VX@9F]L;&]W:6YG('1H92!!8W%U:7-I=&EO;BX\+V9O
M;G0^/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V0R9#%A,V8X7S!C-3=?-#$V.%]B961C7S@V-S=D8V1B
M,S5E8PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D,F0Q83-F.%\P
M8S4W7S0Q-CA?8F5D8U\X-C<W9&-D8C,U96,O5V]R:W-H965T<R]3:&5E=#$T
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%3$<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T].
M5D525$E"3$4@1$5"5#QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#3TY615)424),12!$14)4/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\9&EV/@T*/&1I=CX-"CQT86)L92!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O
M<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#$P,"4@86QI9VX],T1C96YT97(^#0H\='(@=F%L:6=N/3-$=&]P/@T*
M/'1D('-T>6QE/3-$)U=)1%1(.B`Q.'!T)SX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M5T5)1TA4.B!B;VQD)SX-"C<N/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9#X-"CQD:78@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I#3TY615)424),12!$
M14)4/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/D]N#0I*86YU87)Y(#(U+"`R,#$P+"!#96QL
M96-T87(@:7-S=65D(&YI;F4@8V]N=F5R=&EB;&4@<')O;6ES<V]R>0T*;F]T
M97,@*"8C>#(P,4,[0V]N=F5R=&EB;&4@3F]T97,F(W@R,#%$.RD@:6X@86X@
M86=G<F5G871E('!R:6YC:7!A;`T*86UO=6YT(&]F("9N8G-P.R0R+#<R,"PY
M.#4N)B-X03`[(%1H92!#;VYV97)T:6)L92!.;W1E<R!P<F]V:61E9"!F;W(-
M"FEN=&5R97-T(&]F(#$R)2!C;VUP;W5N9&5D(&%N;G5A;&QY('=I=&@@82!M
M871U<FET>2!D871E(&]F('1H90T*96%R;&EE<B!O9B`H:2D@=&AE(&1A=&4@
M;VX@=VAI8V@@0V5L;&5C=&%R)B-X,C`Q.3MS(&-A<V@@<F5S97)V97,-"F9A
M;&P@8F5L;W<@)FYB<W`[)#(U,"PP,#`@;W(@*&EI*2!*86YU87)Y(#(P+"`R
M,#$Q+B8C>$$P.R!5<&]N(&%N(&5V96YT#0IO9B!D969A=6QT+"!A<R!D969I
M;F5D+"!T:&4@:6YT97)E<W0@<F%T92!I;F-R96%S960@8GD@,3`E('1O#0HR
M,B4N)B-X03`[(%1H92!O=71S=&%N9&EN9R!P<FEN8VEP86P@8F%L86YC92P@
M=&]G971H97(@=VET:"!A;GD-"G5N<&%I9"!I;G1E<F5S="P@=V%S(&-O;G9E
M<G1I8FQE(&EM;65D:6%T96QY+"!B>2!T:&4@;&5N9&5R+"!I;G1O#0IC;VUM
M;VX@<W1O8VL@;V8@=&AE($-O;7!A;GD@870@)FYB<W`[)#`N.#(Y.#<@<&5R
M('-H87)E("AG:79I;F<@969F96-T('1O#0IT:&4@17AC:&%N9V4@4F%T:6\I
M+B8C>$$P.R!&=7)T:&5R;6]R92P@=&AE($-O;G9E<G1I8FQE($YO=&5S('=E
M<F4-"G-U8FIE8W0@=&\@86X@875T;VUA=&EC(&-O;G9E<G-I;VX@9F5A='5R
M92!E<75A;"!T;R`W,"4@;V8@=&AE('!E<@T*<VAA<F4@<')I8V4@;V8@82!Q
M=6%L:69I960@9FEN86YC:6YG+"!S:&]U;&0@=&AE($-O;7!A;GD@8V]M<&QE
M=&4@80T*<75A;&EF:65D(&9I;F%N8VEN9R!T<F%N<V%C=&EO;B!W:&EC:"!R
M86ES97,@870@;&5A<W0@)FYB<W`[)#(P+#`P,"PP,#`-"FEN('!R;V-E961S
M('1O('1H92!#;VUP86YY+B8C>$$P.R!3:6YC92!T:&4@0V]N=F5R=&EB;&4@
M3F]T97,@=V5R90T*8V]N=F5R=&EB;&4@:6YT;R!C;VUM;VX@<W1O8VL@870@
M9&%T92!O9B!I<W-U86YC92!A="!A('!E<B!S:&%R90T*<')I8V4@=VAI8V@@
M=V%S(&QE<W,@=&AA;B!T:&4@97-T:6UA=&5D(&9A:7(@=F%L=64@;V8@=&AE
M#0I#;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:R!A="!T:&%T(&1A=&4L
M('1H92!#;VYV97)T:6)L92!.;W1E<PT*8V]N=&%I;F5D(&$@8F5N969I8VEA
M;"!C;VYV97)S:6]N(&9E871U<F4-"B@F(W@R,#%#.T)#1B8C>#(P,40[*2XF
M(WA!,#L@5&AE(&5S=&EM871E9"!I;G1R:6YS:6,@=F%L=64@;V8@=&AE($)#
M1@T*;V8@)FYB<W`[)#(Q,RPW.3(@=V%S(&1E=&5R;6EN960@87,@=&AE(&1I
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M=6%N8V4N)B-X03`[(%1H92!E<W1I;6%T960@<&5R+7-H87)E(&9A:7(-"G9A
M;'5E(&]F($-E;&QE8W1A<B!C;VUM;VX@<W1O8VL@=V%S(&1E=&5R;6EN960@
M8GD@;6%N86=E;65N="!B87-E9`T*;VX@82!N=6UB97(@;V8@9F%C=&]R<R!I
M;F-L=61I;F<@86X@:6YD97!E;F1E;G0@=F%L=6%T:6]N+"!W:&EC:`T*=V%S
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M(W@R,#%$.RDN)B-X03`[(%1H:7,@8V]N=&EN9V5N8WD@9&ED(&YO="!M871E
M<FEA;&EZ93L-"G1H97)E9F]R92!N;R!I;G1R:6YS:6,@=F%L=64@=V%S(&%L
M;&]C871E9"!T;R!T:&4@0T)#1BXF(WA!,#L@07,@;V8-"D1E8V5M8F5R(#,Q
M+"`R,#$P(&%N9"`R,#`Y+"!P<FEN8VEP86P@;V8@)FYB<W`[)#(L-S(P+#DX
M-2!A;F0@)FYB<W`[)#`@=V%S#0IO=71S=&%N9&EN9RP@<F5S<&5C=&EV96QY
M+"!O;B!T:&4@0V]N=F5R=&EB;&4@3F]T97,N/"]F;VYT/CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^
M/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY!<PT*;V8@1&5C96UB97(@,S$L(#(P,3`L('1H92!#;VYV
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M.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]N#0I*86YU87)Y
M(#(P+"`R,#$Q+"!T:&4@0V]N=F5R=&EB;&4@3F]T97,@;6%T=7)E9"!B=70@
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M)B-X,C`Q0SM#;VYV97)S:6]N(%1I;64F(W@R,#%$.RDL(&EF(&-O;7!L971E
M9"XF(WA!,#L@5&AE(&%M;W5N="!O9@T*<VAA<F5S(&ES<W5E9"!U<&]N('-U
M8V@@8V]N=F5R<VEO;B!W;W5L9"!B92!D97!E;F1E;G0@;VX@=&AE(&%M;W5N
M=`T*;V8@:6YV97-T;65N="!M861E(&)Y('1H92!N;W1E(&AO;&1E<G,@870@
M=&AE($-O;G9E<G-I;VX@5&EM92!A;F0-"G=E<F4@;F5G;W1I871E9"!B87-E
M9"!O;B!O=71S=&%N9&EN9R!P<FEN8VEP86P@86YD('!R;VIE8W1E9`T*86-C
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M=F5R=&EB;&4@3F]T97,@:6YT;R`T+#$X,2PU,S4-"G-H87)E<R!O9B!C;VUM
M;VX@<W1O8VL@:6UM961I871E;'D@<')I;W(@=&\@=&AE($%C<75I<VET:6]N
M+B8C>$$P.PT*3VX@07!R:6P@."P@,C`Q,2P@:6UM961I871E;'D@<')I;W(@
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M;G1E<F5S=`T*=&]T86QI;F<@)FYB<W`[)#,L,3@T+#<P-B!T;R!A(&-O;7!O
M;F5N="!O9B!A9&1I=&EO;F%L('!A:60M:6X-"F-A<&ET86PN)B-X03`[(%1H
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M#0IA="!T:&4@<W1A=&5D(&-O;G9E<G-I;VX@<')I8V4N)B-X03`[($]N('1H
M92!D871E(&]F(&-O;G9E<G-I;VXL#0IT:&4@0V]M<&%N>2!D971E<FUI;F5D
M('1H870@=&AE('9A;'5E(&]F('1H97-E(&%D9&ET:6]N86P@<VAA<F5S#0IW
M87,@)FYB<W`[)#(U-RPY-S,L(&)A<V5D(&]N('1H92`F;F)S<#LD,"XW-2!P
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M=`T*8V]M<&QE=&5D('5N=&EL($%P<FEL(#@L(#(P,3$L('1H92!V86QU92!O
M9B!T:&4@861D:71I;VYA;"!S:&%R97,-"F]F("9N8G-P.R0R-3<L.3<S('=A
M<R!R96-O<F1E9"!A<R!A(&-O;7!O;F5N="!O9B!I;G1E<F5S="!E>'!E;G-E
M(&1U<FEN9PT*=&AE('-E8V]N9"!Q=6%R=&5R(&]F(#(P,3$N/"]F;VYT/CPO
M9&EV/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14Q'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQ/3D<M5$52
M32!.3U1%4R!005E!0DQ%/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQ/3D<M5$5232!.3U1%4R!005E!0DQ%/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*
M."XF(WA!,#L@3$].1RU415)-($Y/5$53(%!!64%"3$4\+V9O;G0^/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/D]N#0I*86YU87)Y(#$Q+"`R,#`X+"!#96QL96-T
M87(@96YT97)E9"!I;G1O(&$@;&]A;B!A9W)E96UE;G0@=VET:"!A#0IB86YK
M('1O(&)O<G)O=R!U<"!T;R`F;F)S<#LD,2PR,#`L,#`P+B8C>$$P.R!4:&4@
M8F]R<F]W:6YG+"!E=FED96YC960@8GD-"F$@;F]T92`H=&AE("8C>#(P,4,[
M0F%N:R!.;W1E)B-X,C`Q1#LI+"!B;W)E(&EN=&5R97-T(&%T(&$@<F%T92!O
M9@T*-RXP,24@<&5R(&%N;G5M+"!C;W5L9"!B92!P<F5P86ED('=I=&AO=70@
M<&5N86QT>2!A;F0@=V%S('!A>6%B;&4-"FEN(#0X(&UO;G1H;'D@<')I;F-I
M<&%L(&%N9"!I;G1E<F5S="!P87EM96YT<R!O9B`F;F)S<#LD,C`L-3(P('=I
M=&@@80T*8F%L;&]O;B!P87EM96YT(&]F(&%N>2!R96UA:6YI;F<@=6YP86ED
M('!R:6YC:7!A;"!A;F0@:6YT97)E<W0@;VX-"DUA<F-H(#(X+"`R,#$R+B8C
M>$$P.R!);B!T:&4@979E;G0@;V8@9&5F875L="!O9B!P87EM96YT+"!#96QL
M96-T87(-"G=O=6QD(&)E(')E<75I<F5D('1O('!A>2!A(&QA=&4@8VAA<F=E
M(&5Q=6%L('1O(#4E(&]F('1H90T*9&5L:6YQ=65N="!P87EM96YT(&%N9"!T
M:&4@:6YT97)E<W0@<F%T92!O;B!T:&4@=6YP86ED('!R:6YC:7!A;`T*=V]U
M;&0@8F4@:6YC<F5A<V5D(&)Y(#,E+B8C>$$P.R!4:&4@0F%N:R!.;W1E('=A
M<R!C;VQL871E<F%L:7IE9"!B>0T*<W5B<W1A;G1I86QL>2!A;&P@87-S971S
M(&]F($-E;&QE8W1A<B!A;F0@82!D97!O<VET(&%C8V]U;G0@:6X@=&AE#0IA
M;6]U;G0@;V8@)FYB<W`[)#4P,"PP,#`N)B-X03`[(%1H92!C87-H(&-O;&QA
M=&5R86P@:7,@8VQA<W-I9FEE9"!A<PT*<F5S=')I8W1E9"!C87-H(&EN('1H
M92!A8V-O;7!A;GEI;F<@8F%L86YC92!S:&5E="XF(WA!,#L@07,@;V8-"D1E
M8V5M8F5R(#,Q+"`R,#$P(&%N9"`R,#`Y+"`F;F)S<#LD-#<P+#DT,2!A;F0@
M)FYB<W`[)#8W-2PW-#,@87)E(&-L87-S:69I960@87,-"F$@;&]N9RUT97)M
M(&YO=&4@<&%Y86)L92!I;B!T:&4@86-C;VUP86YY:6YG(&)A;&%N8V4@<VAE
M970L#0IR97-P96-T:79E;'DN)B-X03`[($]N($%P<FEL(#@L(#(P,3$L(&EM
M;65D:6%T96QY('!R:6]R('1O('1H90T*06-Q=6ES:71I;VXL($-E;&QE8W1A
M<B!P86ED(&%P<')O>&EM871E;'D@)FYB<W`[)#8R-RPP,#`@:6X@9G5L;`T*
M<V5T=&QE;65N="!O9B!T:&4@0F%N:R!.;W1E+B!4:&4@<&%Y;65N="!W87,@
M;6%D92!I;B!O<F1E<B!T;R!A=F]I9`T*86X@979E;G0@;V8@9&5F875L="!T
M:&%T('=O=6QD(&AA=F4@;V-C=7)R960@87,@82!R97-U;'0@;V8@=&AE#0IC
M:&%N9V4@;V8@8V]N=')O;"!T:&%T(&]C8W5R<F5D(&%T('1H92!T:6UE(&]F
M('1H90T*06-Q=6ES:71I;VXN/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY/;@T*4V5P=&5M8F5R(#$U+"`R,#$P+"!#96QL96-T87(@96YT97)E9"!I
M;G1O(&-E<G1A:6X@;&]A;B!A9W)E96UE;G1S#0IW:71H('1H92!7:7-C;VYS
M:6X@1&5P87)T;65N="!O9B!#;VUM97)C92`H)B-X,C`Q0SM71$]##0I.;W1E
M<R8C>#(P,40[*2!T;R!B;W)R;W<@82!T;W1A;"!O9B`F;F)S<#LD-#4P+#`P
M,"XF(WA!,#L@5&AE(%=$3T,@3F]T97,-"F)E87(@:6YT97)E<W0@870@,B4@
M<&5R(&%N;G5M(&)E9VEN;FEN9R!O;B!T:&4@9&%T92!O9B!D:7-B=7)S96UE
M;G0-"F%N9"!A;&QO=R!F;W(@=&AE(&1E9F5R<F%L(&]F(&EN=&5R97-T(&%N
M9"!P<FEN8VEP86P@<&%Y;65N=',@=6YT:6P-"D%P<FEL(#,P+"`R,#$U+B8C
M>$$P.R!);B!T:&4@979E;G0@;V8@9&5F875L="!O9B!P87EM96YT+"!I;G1E
M<F5S=`T*;VX@=&AE(&1E;&EN<75E;G0@<&%Y;65N="!I<R!P87EA8FQE(&%T
M(&$@<F%T92!E<75A;"!T;R`Q,B4@<&5R#0IA;FYU;2XF(WA!,#L@36]N=&AL
M>2!P87EM96YT<R!O9B`F;F)S<#LD,C`L-C8U(&9O<B!P<FEN8VEP86P@86YD
M(&EN=&5R97-T#0IS:&%L;"!C;VUM96YC92!O;B!-87D@,2P@,C`Q-2!A;F0@
M8V]N=&EN=64@9F]R(#(S(&5Q=6%L#0II;G-T86QL;65N=',@=VET:"!T:&4@
M9FEN86P@:6YS=&%L;&UE;G0@;V8@86YY(')E;6%I;FEN9R!U;G!A:60-"G!R
M:6YC:7!A;"!A;F0@:6YT97)E<W0@9'5E(&]N($%P<FEL(#$L(#(P,3<N)B-X
M03`[($%S(&]F($1E8V5M8F5R#0HS,2P@,C`Q,"P@)FYB<W`[)#0U,"PP,#`@
M:7,@8VQA<W-I9FEE9"!A<R!A(&QO;F<M=&5R;2!N;W1E('!A>6%B;&4@:6X@
M=&AE#0IA8V-O;7!A;GEI;F<@8F%L86YC92!S:&5E="X\+V9O;G0^/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/DQO;F<M=&5R;0T*;F]T97,@<&%Y86)L92!C;VYS
M:7-T<R!O9B!T:&4@9F]L;&]W:6YG(&%S(&]F($1E8V5M8F5R#0HS,3H\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/C(P
M,3`\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A
M;CTS1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN92<^,C`P.3PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)2!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3,E(&-O;'-P86X],T0R(&%L:6=N/3-$;&5F=#X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P
M86X],T0R(&%L:6=N/3-$;&5F=#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT
M<B!B9V-O;&]R/3-$(T-#1D9#0SX-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0W,"4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$
M<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C@V-BPU,S(\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0W,"4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^5VES8V]N<VEN#0I$97!A<G1M96YT
M(&]F($-O;6UE<F-E+"8C>$$P.R`R)2!I;G1E<F5S=#PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V
M86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*-#4P+#`P,#PO9F]N=#X\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V
M86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*)B-X,C`Q-#L\+V9O;G0^/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L
M:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^,2PQ,C4L-S0S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI
M9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXX-C8L-3,R/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E
M(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/DQE<W,-"F-U<G)E;G0@<&]R=&EO;CPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M)R!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T**#(P-"PX,#(\+V9O;G0^
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXI/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG
M;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HH
M,3DP+#<X.3PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
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M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^3&]N9RUT97)M#0IN;W1E('!A>6%B;&4L(&YE="!O9B!C=7)R
M96YT('!O<G1I;VX\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
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M/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
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M1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX]
M,T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
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M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
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M+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB
M<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<^07,-"F]F($1E8V5M8F5R(#,Q+"`R,#$P+"!L;VYG+71E<FT@
M;F]T97,@<&%Y86)L92!M871U<F5S(&%S#0IF;VQL;W=S.CPO9F]N=#X\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM3$5&5#H@,C=P=#L@
M34%21TE.+5))1TA4.B`P<'0G/@T*/'1A8FQE('-T>6QE/3-$)T9/3E0M1D%-
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M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^665A<G,-"F5N9&5D($1E8V5M8F5R(#,Q+#PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
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M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0X-24@86QI9VX],T1L969T/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3EP=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`Y<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*/"$M+65F
M<&QA8V5H;VQD97(M+3XR,#$Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S
M<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR,#0L.#`R/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
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M8VL[($U!4D=)3BU,1494.B`Y<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H
M:71E/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@U)2!A;&EG;CTS
M1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M.7!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^,C`Q,SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(W@R
M,#$T.SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C
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M1D].5"U325I%.B`Q,'!T)SXR,#$T/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS
M1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>#(P,30[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR,#$U/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
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M+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C$Q.2PY-3<\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#@U)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M.7!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
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M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
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M33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
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M5$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$<FEG
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M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
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M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE)SX-"C$L,3(U+#<T,SPO9F]N=#X\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$=7)I;F<-"G1H
M92!N:6YE+6UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3$L('!A>6UE
M;G1S(&]F("9N8G-P.R0V-S4L-S0S('=E<F4-"FUA9&4@:6X@8V]N;F5C=&EO
M;B!W:71H('1H92!"86YK($YO=&4@:6YC;'5D:6YG(&$@<&%Y;65N="!O9@T*
M87!P<F]X:6UA=&5L>2`F;F)S<#LD-C(W+#`P,"!I;B!F=6QL('-E='1L96UE
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M:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SY!<PT*;V8@4V5P=&5M8F5R(#,P+"`R,#$Q+"!T:&4@
M;W5T<W1A;F1I;F<@<')I;F-I<&%L(&]N('1H92!71$]#($YO=&5S#0IO9B`F
M;F)S<#LD-#4P+#`P,"!I<R!C;&%S<VEF:65D(&%S(&QO;F<M=&5R;2!D96)T
M(&]U='-T86YD:6YG(&EN('1H90T*86-C;VUP86YY:6YG(&)A;&%N8V4@<VAE
M970N/"]F;VYT/CPO9&EV/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14Q'/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/DQ)3D4@3T8@0U)%1$E4/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQ)3D4@3T8@0U)%1$E4/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV/@T*/&1I=CX-"CQT86)L92!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#$P,"4@86QI9VX],T1C96YT97(^#0H\='(@=F%L:6=N/3-$=&]P
M/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q.'!T)SX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)SX-"CDN/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9#X-"CQD:78@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I,24Y%($]&($-2
M141)5#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY);@T*,C`P.2P@0V5L;&5C=&%R(&AA9"!A
M("9N8G-P.R0Q,#`L,#`P(&QI;F4@;V8@8W)E9&ET('=I=&@@82!B86YK+B8C
M>$$P.PT*0F]R<F]W:6YG<R!U;F1E<B!T:&4@;&EN92!O9B!C<F5D:70@8F]R
M92!I;G1E<F5S="!A="!,24)/4B!P;'5S#0HS+C(U)2!W:71H(&$@-"XU)2!M
M:6YI;75M(')A=&4N)B-X03`[(%1H92!L:6YE(&]F(&-R961I="!E>'!I<F5D
M(&]N#0I*86YU87)Y(#$P+"`R,#$P(&%N9"!W87,@;F]T(')E;F5W960N)B-X
M03`[(%1H97)E('=E<F4@;F\@86UO=6YT<PT*;W5T<W1A;F1I;F<@=6YD97(@
M=&AE(&QI;F4@87,@;V8@1&5C96UB97(@,S$L(#(P,#DN/"]F;VYT/CPO9&EV
M/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P15A%04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U1/0TM(3TQ$
M15)3)R!$149)0TE%3D-9/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3`\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-43T-+2$],
M1$524R<@1$5&24-)14Y#63PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/&1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q
M,#`E/@T*/'1R('9A;&EG;CTS1'1O<#X-"CQT9"!S='EL93TS1"=724142#H@
M,S9P="<@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"C0N/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^#0I35$]#2TA/3$1%4E,F(W@R,#$Y.R!%455)5%D\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB
M<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
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M;F<@=V%R<F%N=',@87,-"F]F($UA<F-H(#,Q+"`R,#$Q+"!I<W-U960@:6X@
M8V]N;F5C=&EO;B!W:71H(&5Q=6ET>2!A;F0@9&5B=`T*9FEN86YC:6YG<R!S
M:6YC92`R,#`U+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I
M=B!A;&EG;CTS1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.38E/@T*/'1R/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-3@E(&%L:6=N/3-$;&5F=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^
M3V9F97)I;F<\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SY.=6UB97(F
M(WA!,#MO9B8C>$$P.U-H87)E<SPO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
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M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE)SY/=71S=&%N9&EN9SPO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT
M97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^
M5V%R<F%N=',\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4G/D5X97)C:7-E/"]F;VYT/CPO9F]N=#X\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE)SY0<FEC93PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q."4^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
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M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A
M<#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q."4@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-3@E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E-E<FEE<PT*0B!0<F5F97)R960@4W1O
M8VL@)B-X,C`Q,SL@<&QA8V5M96YT(&%G96YT<SPO9F]N=#X\+V1I=CX-"CPO
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C4L,SDR/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"CQD:78@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M;F)S<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/C$Y,2XR-3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q."4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY-87D-"C(L(#(P
M,3(\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$
M=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3@E(&%L:6=N
M/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
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M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/C@L,38Y/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"CQD:78@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S
M<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$Y
M,2XR-3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q."4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY-87D-"C(L(#(P,3(\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(T-#
M1D9#0SX-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U."4@86QI9VX]
M,T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^4V5R:65S#0I%(%!R969E<G)E9"!3=&]C:SPO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M.24^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)FYB<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE/@T*
M/&1I=B!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXY.2XT-3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q."4@86QI9VX],T1R:6=H=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$96-E;6)E
M<@T*,S$L(#(P,34\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CQT<B!B
M9V-O;&]R/3-$=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-3@E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/D%U9W5S=`T*,C`P.2!0<FEV871E(%!L86-E;65N
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$.24^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#DE/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXQ,#`N.3@\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3@E(&%L:6=N
M/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^1&5C96UB97(-"C,Q+"`R,#$U/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-3@E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DIU;'D-"C(P,3`@
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$P
M-2PP-#(\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$58
M5"U)3D1%3E0Z(#!P=#L@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/@T*/&1I=B!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.R0\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)R!V86QI9VX],T1T;W`@=VED=&@],T0Y)3X-"CQD:78@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,3`N-S$\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q."4@
M86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SY*=6QY#0HR-RP@,C`Q-3PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0U."4@86QI9VX],T1L969T/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
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M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0G('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE/@T*/&1I=B!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,#4L
M,#0R/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M
M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"CQD:78@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$V+C`V-3PO
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M1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/DIU;'D-"C(W+"`R,#$U/"]F;VYT/CPO9&EV/@T*/"]T
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M.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(')I9VAT)R!V86QI9VX],T1T;W`@=VED=&@],T0Y)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
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M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/E1O=&%L/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#1P>"!D;W5B;&4G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U
M8FQE.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M.24^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
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M-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Y
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T
M<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3@E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,2DF(WA!
M,#LF(WA!,#M4:&4-"F5X97)C:7-E('!R:6-E(&]F('1H97-E('=A<G)A;G1S
M('=A<R!A9&IU<W1E9"!T;R`F;F)S<#LD,"XW-2!P97(@<VAA<F4@:6X-"F-O
M;FYE8W1I;VX@=VET:"!T:&4@<')I=F%T92!P;&%C96UE;G0@8V]M<&QE=&5D
M(&]N($%P<FEL(#@L#0HR,#$Q+B8C>$$P.R8C>$$P.U-E92!.;W1E(#$P+CPO
M9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^3VX-"DUA<F-H(#<L(#(P,3$L
M('=A<G)A;G1S('1O('!U<F-H87-E(#,S+#4V.2!S:&%R97,@;V8@8V]M;6]N
M('-T;V-K#0IA="`F;F)S<#LD,C,T+C`Y('!E<B!S:&%R92!E>'!I<F5D('5N
M97AE<F-I<V5D+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^3VX-"DUA
M>2`S+"`R,#$Q+"`Q."PQ-3,@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!W97)E
M(&ES<W5E9"!I;@T*8V]N;F5C=&EO;B!W:71H('1H92!C87-H;&5S<R!E>&5R
M8VES92!O9B!W87)R86YT<R!T;R!P=7)C:&%S90T*,C<L,S$Q('-H87)E<R!O
M9B!C;VUM;VX@<W1O8VL@870@)FYB<W`[)#`N-S4@<&5R('-H87)E+CPO9F]N
M=#X\+V1I=CX-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HQ,"X@
M4U1/0TM(3TQ$15)3)B-X,C`Q.3L@15%52519/"]F;VYT/CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^
M/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY/;@T*2F%N=6%R>2`Q+"`R,#`X+"!#96QL96-T87(@8V]N
M=F5R=&5D(&9R;VT@82!7:7-C;VYS:6X@;&EM:71E9`T*;&EA8FEL:71Y(&-O
M;7!A;GD@=&\@82!7:7-C;VYS:6X@8V]R<&]R871I;VX@*'1H90T*)B-X,C`Q
M0SM#;VYV97)S:6]N)B-X,C`Q1#LI+B!%86-H(&ES<W5E9"!A;F0@;W5T<W1A
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M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SY&<F]M#0II;F-E<'1I;VX@=6YT:6P@1&5C96UB97(@
M,S$L(#(P,3`L($-E;&QE8W1A<B!I<W-U960@,3(L-34Y+#(Q.`T*<VAA<F5S
M(&]F(&-O;6UO;B!S=&]C:R!F;W(@;F5T('!R;V-E961S(&]F(&%P<')O>&EM
M871E;'D-"B9N8G-P.R0R,2PW,3`L,#`P+CPO9F]N=#X\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB
M<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%
M.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^#0I!<')I;"`R,#$Q(%!R:79A=&4@4&QA8V5M96YT/"]F;VYT/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY#;VYC=7)R96YT;'D-"G=I=&@@86YD(&-O;F1I
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M9W)O<W,@<')O8V5E9',@;V8-"F%P<')O>&EM871E;'D@)FYB<W`[)#4L,3,U
M+#`P,"`H=&AE("8C>#(P,4,[07!R:6P@4')I=F%T90T*4&QA8V5M96YT)B-X
M,C`Q1#LI+B8C>$$P.R!4:&4@=V%R<F%N=',@:&%V92!A;B!E>&5R8VES92!P
M<FEC92!O9@T*)FYB<W`[)#`N-S4@86YD(&5X<&ER92!O;B!-87)C:"`S,2P@
M,C`Q-BXF(WA!,#L@5&AE('=A<G)A;G0@97AE<F-I<V4-"G!R:6-E(&%N9"]O
M<B!T:&4@8V]M;6]N('-T;V-K(&ES<W5A8FQE('!U<G-U86YT('1O('-U8V@@
M=V%R<F%N=`T*=VEL;"!B92!S=6)J96-T('1O(&%D:G5S=&UE;G0@;VYL>2!F
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M;W)S('=A<R`F;F)S<#LD,BPQ,C0L,C@V(&%T#0II<W-U86YC92!A;F0@:&%S
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M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/E1H90T*4V5C=7)I=&EE<R!0=7)C:&%S92!!9W)E96UE;G0@:6YC;'5D
M960@82!R97%U:7)E;65N="!T:&%T('1H90T*0V]M<&%N>2!F:6QE('=I=&@@
M=&AE(%-%0R!N;R!L871E<B!T:&%N($]C=&]B97(@-2P@,C`Q,2`H=&AE#0HB
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M<F]M(')E9VES=')A=&EO;B!R97%U:7)E;65N=',N)B-X03`[(%1H92!#;VUP
M86YY(&ES(&%L<V\-"G)E<75I<F5D('1O('5S92!C;VUM97)C:6%L;'D@<F5A
M<V]N86)L92!E9F9O<G1S('1O(&AA=F4@=&AE#0IR96=I<W1R871I;VX@<W1A
M=&5M96YT(&1E8VQA<F5D(&5F9F5C=&EV92!B>2!$96-E;6)E<B`T+"`R,#$Q
M("AT:&4-"B)%9F9E8W1I=F5N97-S($1E861L:6YE(BDL(&%N9"!T;R!K965P
M('1H92!R96=I<W1R871I;VX@<W1A=&5M96YT#0IC;VYT:6YU;W5S;'D@969F
M96-T:79E('5N9&5R('1H92!396-U<FET:65S($%C="!O9B`Q.3,S+"!A<R!A
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M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/DEN#0IT:&4@979E;G0@=&AE($-O;7!A;GD@9F%I;',@
M=&\@9FEL92!T:&4@<F5G:7-T<F%T:6]N('-T871E;65N=`T*=VET:&EN('1H
M92!T:6UE9G)A;64@<W!E8VEF:65D(&)Y('1H92!396-U<FET:65S(%!U<F-H
M87-E#0I!9W)E96UE;G0L(&]R(&EF(&ET(&9A:6QS('1O(&]B=&%I;B!E9F9E
M8W1I=F5N97-S(&]F('1H:7,-"G)E9VES=')A=&EO;B!O;B!O<B!P<FEO<B!T
M;R!T:&4@1&5C96UB97(@-"P@,C`Q,2`H:68@=&AE<F4@:7,@;F\-"G)E=FEE
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M<'5R8VAA<V4@<')I8V4N)B-X03`[#0I4:&4@0V]M<&%N>2!W:6QL(&)E(&%L
M;&]W960@=&\@<W5S<&5N9"!T:&4@=7-E(&]F('1H92!R96=I<W1R871I;VX-
M"G-T871E;65N="!F;W(@;F]T(&UO<F4@=&AA;B`S,"!C;VYS96-U=&EV92!D
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M9B!T:&4@:6YI=&EA;`T*<F5G:7-T<F%T:6]N('-T871E;65N="X\+V9O;G0^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]N#0I.;W9E
M;6)E<B`S+"`R,#$Q+"!A(&UA:F]R:71Y(&]F('!U<F-H87-E<G,@:6X@=&AE
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M($1E861L:6YE('1O('1H92`R-#`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@-S`E.R!615)424-!3"U!3$E'3CH@=&5X="UT
M;W`G/G1H/"]F;VYT/@T*9&%Y(&9O;&QO=VEN9R!T:&4@9FEN86P@<')O<W!E
M8W1U<R!O9B!T:&4@<'5B;&EC#0IO9F9E<FEN9RXF(WA!,#LF(WA!,#M!<R!O
M9B!397!T96UB97(@,S`L(#(P,3$L(&%N9"!T:')O=6=H('1H92!D871E#0IO
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M=')I8W1I;VX@:6X@<F5L:6%N8V4@;VX@4G5L92`Q-#0@=6YD97(@=&AE#0I3
M96-U<FET:65S($%C="X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B8C>$$P.SPO
M9&EV/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY4:&4-"D-O;7!A;GD@<&%I9"!T;R!2;V1M86XL('1H92!P
M;&%C96UE;G0@86=E;G0@9F]R('1H92!F:6YA;F-I;F<L(&$-"F-A<V@@9F5E
M(&5Q=6%L('1O("9N8G-P.R0R,#`L,#`P(&%N9"!I<W-U960@=V%R<F%N=',@
M=&\@<'5R8VAA<V4@,3DR+#DS,0T*<VAA<F5S(&]F(&ET<R!C;VUM;VX@<W1O
M8VL@*&AA=FEN9R!A;B!E>&5R8VES92!P<FEC92!O9B`F;F)S<#LD,"XW-2!A
M;F0-"G=H:6-H(&5X<&ER92!-87)C:"`S,2P@,C`Q-BD@:6X@8V]N<VED97)A
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M9'5C=&EO;B!O9B!G<F]S<R!P<F]C965D<PT*<F5C96EV960N)B-X03`[(%1H
M92!E<W1I;6%T960@9F%I<B!V86QU92!O9B!T:&4@=V%R<F%N=',@:7-S=65D
M('1O#0IT:&4@<&QA8V5M96YT(&%G96YT('=A<R`F;F)S<#LD,3$R+#`Y-B!A
M;F0@=V%S(')E8V]R9&5D(&%S(&$@8V]M<&]N96YT(&]F#0IS=&]C:VAO;&1E
M<G,F(W@R,#$Y.R!E<75I='DN/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4
M.B!B;VQD)SX-"D-O;6UO;B!3=&]C:R!787)R86YT<SPO9F]N=#X@)B-X03`[
M)B-X,C`Q-#L@5&AE(&9O;&QO=VEN9R!T86)L90T*<W5M;6%R:7IE<R!I;F9O
M<FUA=&EO;B!W:71H(')E9V%R9"!T;R!O=71S=&%N9&EN9R!W87)R86YT<R!T
M;PT*<'5R8VAA<V4@8V]M;6]N('-T;V-K(&%S(&]F(%-E<'1E;6)E<B`S,"P@
M,C`Q,2XF(WA!,#L@5&AE<F4@=V5R92!N;PT*;W5T<W1A;F1I;F<@8V]M;6]N
M('-T;V-K('!U<F-H87-E('=A<G)A;G1S(&%S(&]F($1E8V5M8F5R(#,Q+"`R
M,#$P#0IA;F0@,C`P.2XF(WA!,#L@5&AE($-O;7!A;GD@:7-S=65D('=A<G)A
M;G1S('1O('!U<F-H87-E(#<L,#,Y+#0V.`T*<VAA<F5S(&]F(&-O;6UO;B!S
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M;W5G:"`R,#$P+`T*<F5M86EN960@;W5T<W1A;F1I;F<@<W5B<V5Q=65N="!T
M;R!T:&4@06-Q=6ES:71I;VX@*$YO=&4-"C0I+CPO9F]N=#X\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG
M/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=-05)'24XM3$5&5#H@,S9P
M="<@86QI9VX],T1L969T/@T*/'1A8FQE('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@P)3X-"CQT<CX-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#4P)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
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M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SY.=6UB97(F(WA!
M,#MO9B8C>$$P.U-H87)E<SPO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
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M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M)SY%>&5R8VES928C>$$P.V]F/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M)SY/=71S=&%N9&EN9SPO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,R4@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
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M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4G/E!R:6-E/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(P)3X-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/B8C>$$P.SPO9&EV/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:R<^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
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M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3`E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L
M<W!A;CTS1#(@86QI9VX],T1L969T/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,C`E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
M(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#4P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY!<')I;`T*."P@,C`Q,2!0<FEV871E(%!L
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI
M9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXW+#`S.2PT-C@\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG
M:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
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M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DUA<F-H#0HS,2P@,C`Q-CPO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,"4@86QI9VX],T1L969T/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^4V5R
M:65S#0I"(%!R969E<G)E9"!3=&]C:R`F(W@R,#$S.R!P;&%C96UE;G0@86=E
M;G1S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG
M:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^,3DQ+C(U/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(P)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DUA>0T*,BP@
M,C`Q,CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(]
M,T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4P)2!A
M;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY397)I97,-"D,@17AC:&%N9V4\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E
M(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L
M969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)FYB<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,3DQ+C(U/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
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M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/DUA>0T*,BP@,C`Q,CPO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0U,"4@86QI9VX],T1L969T/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^4V5R:65S#0I%
M(%!R969E<G)E9"!3=&]C:SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H
M=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXV,"PS,S`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C`E(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D1E8V5M8F5R#0HS,2P@,C`Q-3PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4P)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^,S$L,3DT/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O
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M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
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M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$P,"XY.#PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R,"4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$96-E;6)E<@T*,S$L(#(P,34\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3`E(&%L:6=N/3-$;&5F
M=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/DIU;'D-"C(P,3`@1&ER96-T($]F9F5R:6YG("@Q*3PO9F]N=#X\+V1I=CX-
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXW-RPW,CD\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB
M<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
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M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DIU
M;'D-"C(W+"`R,#$U/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\='(@
M8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3`E(&%L:6=N/3-$
M;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/E!R969E<G)E9`T*26YC96YT:79E(%=A<G)A;G1S/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXQ,#4L,#0P/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/@T*
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG
M:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^,38N,#8U/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(P)2!A;&EG;CTS1')I9VAT/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DIU
M;'D-"C(W+"`R,#$U/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\='(@
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q,B4^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
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M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^5&]T86P\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^
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M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$
M<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(P)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-
M"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^*#$I)B-X03`[#0I4
M:&4@97AE<F-I<V4@<')I8V4@;V8@=&AE<V4@=V%R<F%N=',@=V%S(&%D:G5S
M=&5D('1O("9N8G-P.R0P+C<U('!E<@T*<VAA<F4@:6X@8V]N;F5C=&EO;B!W
M:71H('1H92!P<FEV871E('!L86-E;65N="!C;VUP;&5T960@;VX@07!R:6P-
M"C@L(#(P,3$N)B-X03`[(%1H:7,@=V%R<F%N="!H87,@8F5E;B!A8V-O=6YT
M960@9F]R(&%S(&$@9&5R:79A=&EV90T*:6YS=')U;65N="!A<R!D97-C<FEB
M960@:6X@3F]T92`R+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^3VX-
M"DUA>2`T+"`R,#$Q+"`Q."PQ-3,@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!W
M97)E(&ES<W5E9"!I;@T*8V]N;F5C=&EO;B!W:71H('1H92!C87-H;&5S<R!E
M>&5R8VES92!O9B!W87)R86YT<R!T;R!P=7)C:&%S90T*,C<L,S$P('-H87)E
M<R!O9B!C;VUM;VX@<W1O8VL@870@)FYB<W`[)#`N-S4@<&5R('-H87)E+B8C
M>$$P.R!4:&4@0V]M<&%N>0T*<F5C;&%S<VEF:65D("9N8G-P.R0T."PS,SD@
M9G)O;2!T:&4@9&5R:79A=&EV92!L:6%B:6QI='D@=&\@861D:71I;VYA;`T*
M<&%I9"UI;B!C87!I=&%L('5P;VX@=&AE(&5X97)C:7-E(&]F('1H92!W87)R
M86YT<RX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
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M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS
M1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"E-E<'1E;6)E<B`S,"P\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,B4@8V]L<W!A;CTS
M1#8^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
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M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS
M<&%N/3-$,CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
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M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4
M.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^,C`Q
M,#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,"4@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^,C`P.3PO9F]N=#X\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&%L:6=N/3-$;&5F
M=#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E
M(&-O;'-P86X],T0R(&%L:6=N/3-$;&5F=#X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&%L:6=N/3-$
M;&5F=#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
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M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
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M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X,C`Q-#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
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M+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY3=&]C:PT*
M;W!T:6]N<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXW-CDL,3@Y/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXY
M.3$L-S,V/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-C0E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
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M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*,RPV-#8L,S<P/"]F;VYT
M/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
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M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C
M0T-&1D-#/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4;W1A;`T*
M;G5M8F5R(&]F('-H87)E<R!R97-E<G9E9"!F;W(@9G5T=7)E(&ES<W5A;F-E
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4G/@T*,3`L.34Y+#DV,#PO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!
M3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4G/@T*.3DQ+#<S-CPO9F]N=#X\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H-"@T*/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)SX-"C8N(%-43T-+2$],1$524R8C>#(P,3D[($1%1DE#
M245.0UD\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
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M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/;@T*3F]V96UB97(@,S`L(#(P
M,3`L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A;B!%>&-H86YG92!!9W)E
M96UE;G0-"G=I=&@@96%C:"!O9B!T:&4@:&]L9&5R<R!O9B!I=',@4V5R:65S
M($4@8V]N=F5R=&EB;&4@<')E9F5R<F5D#0IS=&]C:R`H=&AE("8C>#(P,4,[
M4V5R:65S($4@4')E9F5R<F5D(%-T;V-K)B-X,C`Q1#LI(&%N9"!397)I97,@
M0PT*8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K("AT:&4@)B-X,C`Q0SM3
M97)I97,@0R!0<F5F97)R960-"E-T;V-K)B-X,C`Q1#LI('!U<G-U86YT('1O
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M:RP@<F5P<F5S96YT:6YG(#<U+C,E(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS
M(&-O;6UO;@T*<W1O8VL@;W5T<W1A;F1I;F<@969F96-T:79E(&EM;65D:6%T
M96QY(&9O;&QO=VEN9R!T:&4-"F5X8VAA;F=E+B8C>$$P.R!!<R!A(')E<W5L
M="!O9B!T:&4@97AC:&%N9V4L(&%L;"!O9B!T:&4@;&EQ=6ED871I;VX-"G!R
M969E<F5N8V4@87!P;&EC86)L92!T;R!T:&4@<')E9F5R<F5D('-T;V-K+"!A
M<'!R;WAI;6%T96QY#0HF;F)S<#LD,C<L,S,W+#`P,"!A<R!O9B!.;W9E;6)E
M<B`S,"P@,C`Q,"P@=V%S(&5L:6UI;F%T960N)B-X03`[#0I&=7)T:&5R;6]R
M92P@9G5T=7)E(&1I=FED96YD<R!T;W1A;&EN9R`F;F)S<#LD,BPS,C<L,#`P
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M*2!W87,-"F%P<')O>&EM871E;'D@)FYB<W`[)#$R+C(W+B8C>$$P.R!4:&4@
M;6%R:V5T('!R:6-E(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS#0IC;VUM;VX@
M<W1O8VL@87,@;V8@=&AE(&QA<W0@=')A9&EN9R!D87D@:6UM961I871E;'D@
M<')E8V5D:6YG('1H90T*97AC:&%N9V4@=V%S("9N8G-P.R0V+C$R+CPO9F]N
M=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^5&AE#0IE>&-H86YG92!W87,@86-C
M;W5N=&5D(&9O<B!A<R!A(')E8V%P:71A;&EZ871I;VX@86YD('1H92!C87)R
M>6EN9PT*=F%L=64@;V8@=&AE(%-E<FEE<R!%(%!R969E<G)E9"!3=&]C:R!O
M9B`F;F)S<#LD,3,L-S<P+#`P,"P@86-C=6UU;&%T960-"F1I=FED96YD<R!T
M;W1A;&EN9R`F;F)S<#LD-"PT-S8L,#`P(&%N9"!E<W1I;6%T960@;&EQ=6ED
M871E9"!D86UA9V5S(&]F#0HF;F)S<#LD.#$Y+#`P,"!F;W(@9F%I;'5R92!T
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M=F4@<F5C96EV960@82!T;W1A;"!O9B`R-S0L.#@R('-H87)E<R!O9B!C;VUM
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M87(@96YD960@1&5C96UB97(@,S$L(#(P,3`N/"]F;VYT/CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^
M/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[
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M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D1U
M<FEN9PT*,C`P-RP@=&AE($-O;7!A;GD@:7-S=65D(#(W,B!S:&%R97,@;V8@
M4V5R:65S($,@4')E9F5R<F5D(%-T;V-K(&EN#0IE>&-H86YG92!F;W(@86QL
M(#,L,C8T('-H87)E<R!O9B!397)I97,@02!P<F5F97)R960@<W1O8VLL#0IO
M<FEG:6YA;&QY(&ES<W5E9"!I;B`R,#`U+B8C>$$P.U1H92!397)I97,@0R!0
M<F5F97)R960@4W1O8VL@=V%S#0II;FET:6%L;'D@8V]N=F5R=&EB;&4@870@
M)FYB<W`[)#$U,RXP,"!P97(@<VAA<F4@:6YT;R`R,2PS,S,@<VAA<F5S(&]F
M#0IC;VUM;VX@<W1O8VLN)B-X03`[($EN(&-O;FYE8W1I;VX@=VET:"!T:&4@
M<V%L92!O9B!397)I97,@1`T*<')E9F5R<F5D('-T;V-K(&EN(#(P,#@L('1H
M92!C;VYV97)S:6]N('!R:6-E(&]F('1H92!397)I97,@0PT*4')E9F5R<F5D
M(%-T;V-K('=A<R!R961U8V5D('1O("9N8G-P.R0Y.2XT-2!P97(@<VAA<F4L
M(&%C8V]R9&EN9R!T;R!I=',-"G1E<FUS+CPO9F]N=#X\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB
M<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%
M.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"E1E<FUS(&]F('1H92!3
M97)I97,@0R!0<F5F97)R960@4W1O8VL\+V9O;G0^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@
M+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/E1H90T*4V5R:65S($,@4')E9F5R<F5D(%-T;V-K(&AA9"!A;B!A
M;FYU86P@9&EV:61E;F0@<F%T92!O9B`X)2!U;G1I;`T*3V-T;V)E<B`Q+"`R
M,#`X(&%N9"`R,"4@=&AE<F5A9G1E<BXF(WA!,#L@5&AE(&1I=FED96YD<R!W
M97)E#0IP87EA8FQE('%U87)T97)L>2XF(WA!,#L@4W5C:"!D:79I9&5N9',@
M=V5R92!T;R!B92!P86ED(&]N;'D@869T97(-"F%L;"!O=71S=&%N9&EN9R!D
M:79I9&5N9',@;VX@=&AE(%-E<FEE<R!$(%!R969E<G)E9"!3=&]C:R`H=VET
M:`T*<F5S<&5C="!T;R!T:&4@8W5R<F5N="!F:7-C86P@>65A<B!A;F0@86QL
M('!R:6]R(&9I<V-A;"!Y96%R<RD@:&%D#0IB965N('!A:60@=&\@=&AE(&AO
M;&1E<G,@;V8@=&AE(%-E<FEE<R!$(%!R969E<G)E9"!3=&]C:RXF(WA!,#L@
M3F\-"F1I=FED96YD<R!W97)E('!A:60@;VX@4V5R:65S($,@4')E9F5R<F5D
M(%-T;V-K(&1U<FEN9R`R,#`Y(&%N9`T*,C`Q,"XF(WA!,#L@5&AE(&-O;G9E
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M:&4@;W!T:6]N(&]F('1H92!#;VUP86YY('5P;VX@,S`-"F1A>7,F(W@R,#$Y
M.R!N;W1I8V4@870@82`R,"4@<')E;6EU;2!P;'5S(&%N>2!A8V-R=65D(&)U
M="!U;G!A:60-"F1I=FED96YD<RXF(WA!,#L@26X@=&AE(&5V96YT(&]F(&%N
M>2!V;VQU;G1A<GD@;W(@:6YV;VQU;G1A<GD-"FQI<75I9&%T:6]N+"!D:7-S
M;VQU=&EO;B!O<B!W:6YD:6YG('5P(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS
M#0IA9F9A:7)S+"!T:&4@4V5R:65S($,@4')E9F5R<F5D(%-T;V-K('=O=6QD
M(&AA=F4@8F5E;B!T<F5A=&5D(&%S#0IS96YI;W(@=&\@3F]V96QO<R!C;VUM
M;VX@<W1O8VLN)B-X03`[($%F=&5R(&%L;"!R97%U:7)E9"!P87EM96YT<PT*
M=V5R92!M861E('1O(&AO;&1E<G,@;V8@4V5R:65S($4@4')E9F5R<F5D(%-T
M;V-K+"!T:&4@:&]L9&5R<R!O9@T*4V5R:65S($,@4')E9F5R<F5D(%-T;V-K
M('=O=6QD(&AA=F4@8F5E;B!E;G1I=&QE9"!T;R!R96-E:79E(&9I<G-T+`T*
M)FYB<W`[)#$R+#`P,"!P97(@<VAA<F4@86YD(&%L;"!A8V-R=65D(&%N9"!U
M;G!A:60@9&EV:61E;F1S+B8C>$$P.R!)9BP-"G5P;VX@86YY('=I;F1I;F<@
M=7`@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@869F86ER<RP@=&AE#0I#;VUP
M86YY)B-X,C`Q.3MS(')E;6%I;FEN9R!A<W-E=',@879A:6QA8FQE('1O('!A
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M8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&
M3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"D-O;G9E
M<G-I;VYS(&]F(%-E<FEE<R!#(%!R969E<G)E9"!3=&]C:SPO9F]N=#X\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P="<^1'5R:6YG#0IT:&4@>65A<B!E;F1E9"!$96-E
M;6)E<B`S,2P@,C`P.2P@-C@@<VAA<F5S(&]F('1H92!#;VUP86YY)B-X,C`Q
M.3MS#0I397)I97,@0R!0<F5F97)R960@4W1O8VLL(&AA=FEN9R!A;B!A9V=R
M96=A=&4@<W1A=&5D('9A;'5E(&]F#0HF;F)S<#LD.#$V+#`P,"P@86YD(&%C
M8W5M=6QA=&5D(&1I=FED96YD<R!T:&5R96]N(&]F("9N8G-P.R0Q.#0L,#`P
M('=E<F4-"F-O;G9E<G1E9"!I;G1O('-H87)E<R!O9B!T:&4@0V]M<&%N>28C
M>#(P,3D[<R!C;VUM;VX@<W1O8VLL(&QE879I;F<-"C(P-"!S:&%R97,@;V8@
M4V5R:65S($,@4')E9F5R<F5D(%-T;V-K(&]U='-T86YD:6YG('=H:6-H('=E
M<F4-"F-O;G9E<G1I8FQE(&EN=&\@,C0L-C$U('-H87)E<R!O9B!C;VUM;VX@
M<W1O8VL@87,@;V8@1&5C96UB97(@,S$L#0HR,#`Y+B8C>$$P.R!$=7)I;F<@
M,C`Q,"P@86QL('-H87)E<R!O9B!397)I97,@0R!0<F5F97)R960@4W1O8VL-
M"G=E<F4@97AC:&%N9V5D(&9O<B!S:&%R97,@;V8@8V]M;6]N('-T;V-K("AS
M964@)B-X,C`Q0SM%>&-H86YG92!O9@T*3W5T<W1A;F1I;F<@4')E9F5R<F5D
M(%-T;V-K(&9O<B!#;VUM;VX@4W1O8VLF(W@R,#%$.PT*86)O=F4I+CPO9F]N
M=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VLG/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^#0I397)I97,@12!0<F5F97)R960@4W1O8VL@
M4')I=F%T92!0;&%C96UE;G0\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC
M.R!$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^#0I386QE(&]F(%-E<FEE<R!%(%!R969E
M<G)E9"!3=&]C:R!T;R!0=7)D=64\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/D-O;F-U<G)E;G1L>0T*=VET:"!T:&4@97AE8W5T:6]N(&]F('1H92!#
M;VQL86)O<F%T:6]N($%G<F5E;65N="!O;B!&96)R=6%R>2`Q,2P-"C(P,#DL
M($YO=F5L;W,@<V]L9"!T;R!0=7)D=64@,C`P('-H87)E<R!O9B!A(&YE=VQY
M(&-R96%T960@<V5R:65S#0IO9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!P<F5F
M97)R960@<W1O8VLL(&1E<VEG;F%T960@)B-X,C`Q0SM397)I97,@10T*0V]N
M=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K+"8C>#(P,40[('!A<B!V86QU92`F
M;F)S<#LD,"XP,#`P,2!P97(@<VAA<F4-"BAT:&4@)B-X,C`Q0SM397)I97,@
M12!0<F5F97)R960@4W1O8VLF(W@R,#%$.RDL(&%N9"!A('=A<G)A;G0@*'1H
M90T*)B-X,C`Q0SM397)I97,@12!787)R86YT)B-X,C`Q1#LI('1O('!U<F-H
M87-E(#8P+#,S,"!S:&%R97,@;V8-"DYO=F5L;W,@8V]M;6]N('-T;V-K(&9O
M<B!A;B!A9V=R96=A=&4@<'5R8VAA<V4@<')I8V4@;V8@)FYB<W`[)#$P+#`P
M,"PP,#`-"BAT:&4@)B-X,C`Q0SM397)I97,@12!&:6YA;F-I;F<F(W@R,#%$
M.RDN/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"E-E<FEE<R!%
M(%=A<G)A;G0@:7,@97AE<F-I<V%B;&4@9F]R(&%N(&%G9W)E9V%T92!O9B`V
M,"PS,S`@<VAA<F5S#0IO9B!.;W9E;&]S(&-O;6UO;B!S=&]C:R!A="!A;B!E
M>&5R8VES92!P<FEC92!O9B`F;F)S<#LD.3DN-#4@<&5R('-H87)E+@T*5&AE
M('=A<G)A;G0@97AP:7)E<R!O;B!$96-E;6)E<B`S,2P@,C`Q-2X@5&AE('=A
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M9B!T:&4@=V%R<F%N=`T*:&]L9&5R('!R:6]R('1O('-U8V@@979E;G0N/"]F
M;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
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M("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY4:&4-"D-O;7!A;GD@86QS;R!E;G1E<F5D(&EN=&\@86X@97AC
M:&%N9V4@86=R965M96YT('=I=&@@=&AE(&AO;&1E<G,-"BAT:&4@)B-X,C`Q
M0SM397)I97,@1"!);G9E<W1O<G,F(W@R,#%$.RD@;V8@=&AE($-O;7!A;GDF
M(W@R,#$Y.W,-"E-E<FEE<R!$('!R969E<G)E9"!S=&]C:RP@:7-S=65D(&1U
M<FEN9R`R,#`X+"!U;F1E<B!W:&EC:"!A;&P@-#$S+C4-"F]U='-T86YD:6YG
M('-H87)E<R!O9B!397)I97,@1"!P<F5F97)R960@<W1O8VL@86YD(&%C8W5M
M=6QA=&5D(&)U=`T*=6YP86ED(&1I=FED96YD<R!T:&5R96]N('1O=&%L:6YG
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M97)I97,@1`T*26YV97-T;W)S('=A:79E9"!L:7%U:61A=&5D(&1A;6%G97,@
M=&AR;W5G:"!T:&4@9&%T92!O9B!T:&4-"F5X8VAA;F=E(&%S(&$@<F5S=6QT
M(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&9A:6QU<F4@=&\@9FEL92!A#0IR
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M92!W87)R86YT<R!T;R!$96-E;6)E<B`S,2P-"C(P,34@*&9R;VT@07!R:6P@
M,3$L(#(P,3,I(&%N9"!T;R!R96UO=F4@82!F;W)C960@97AE<F-I<V4-"G!R
M;W9I<VEO;BX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<^#0I497)M<R!O9B!397)I97,@12!0<F5F97)R960@4W1O
M8VL\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1H90T*<VAA<F5S(&]F
M(%-E<FEE<R!%(%!R969E<G)E9"!3=&]C:R!H860@82!S=&%T960@=F%L=64@
M;V8@)FYB<W`[)#4P+#`P,`T*<&5R('-H87)E(&%N9"!W97)E(&-O;G9E<G1I
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M8G-P.R0S,#8N,#`@9F]R(#(P(&-O;G-E8W5T:79E('1R861I;F<@9&%Y<RP@
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M63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^5&AE#0I397)I97,@12!0<F5F97)R960@
M4W1O8VL@:&%S(&%N(&%N;G5A;"!D:79I9&5N9"!R871E(&]F(#DE+"!P87EA
M8FQE#0IS96UI+6%N;G5A;&QY(&]N($IU;F4@,S`@86YD($1E8V5M8F5R(#,Q
M+B!3=6-H(&1I=FED96YD<R!W97)E#0IP87EA8FQE(&EN(&-A<V@L(&EN('-H
M87)E<R!O9B!397)I97,@12!0<F5F97)R960@4W1O8VL@;W(@:6X-"G)E9VES
M=&5R960@<VAA<F5S(&]F($YO=F5L;W,@8V]M;6]N('-T;V-K(&%T('1H92!#
M;VUP86YY)B-X,C`Q.3MS#0IO<'1I;VXL('-U8FIE8W0@=&\@8V5R=&%I;B!C
M;VYD:71I;VYS+B!4:&4@0V]M<&%N>2!H87,@;F]T('!A:60@86YY#0IC87-H
M(&1I=FED96YD<R!O;B!397)I97,@12!0<F5F97)R960@4W1O8VLN/"]F;VYT
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"G1E<FUS(&]F('1H92!397)I
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M92!F;W(@86YY#0IE<75I='D@<V5C=7)I='D@870@82!P<FEC92!O9B`F;F)S
M<#LD.3DN-#4@;W(@;&5S<R!O<B!W:71H(')I9VAT<R!S96YI;W(-"G1O('1H
M92!397)I97,@12!0<F5F97)R960@4W1O8VL@*&5X8V5P="!F;W(@8V5R=&%I
M;B!E>&5M<'1E9`T*:7-S=6%N8V5S*2P@*&EV*2!I;F-R96%S:6YG('1H92!N
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M(&-O<G!O<F%T:6]N+`T*=&AE(%-E<FEE<R!%(%!R969E<G)E9"!3=&]C:R!W
M;W5L9"!R96UA:6X@;W5T<W1A;F1I;F<L('1H97)E('=O=6QD#0IB92!N;R!C
M:&%N9V5S('1O('1H92!R:6=H=',@86YD('!R969E<F5N8V5S(&]F('1H92!3
M97)I97,@10T*4')E9F5R<F5D(%-T;V-K(&%N9"!T:&5R92!W;W5L9"!N;W0@
M8F4@8W)E871E9"!A;GD@;F5W(&-L87-S(&]F#0IC87!I=&%L('-T;V-K('-E
M;FEO<B!T;R!T:&4@4V5R:65S($4@4')E9F5R<F5D(%-T;V-K+"`H=FDI#0IR
M961E96UI;F<@;W(@<F5P=7)C:&%S:6YG(&%N>2!C87!I=&%L('-T;V-K(&]T
M:&5R('1H86X@=&AE(%-E<FEE<R!%#0I0<F5F97)R960@4W1O8VLL("AV:6DI
M(&EN8W5R<FEN9R!A;GD@;F5W(&1E8G0@9F]R(&)O<G)O=V5D(&UO;F5Y(&EN
M#0IE>&-E<W,@;V8@)FYB<W`[)#4P,"PP,#`@86YD("AV:6EI*2!C:&%N9VEN
M9R!T:&4@;G5M8F5R(&]F('1H90T*0V]M<&%N>28C>#(P,3D[<R!D:7)E8W1O
M<G,N($%S(&]F($1E8V5M8F5R(#,Q+"`R,#$P+"!N;R!S:&%R97,@;V8-"E-E
M<FEE<R!%('!R969E<G)E9"!S=&]C:R!R96UA:6YE9"!O=71S=&%N9&EN9RP@
M86YD(&%C8V]R9&EN9VQY+`T*;F]N92!O9B!T:&5S92!R97-T<FEC=&EO;G,@
M87!P;&EE9"X@4V5E("8C>#(P,4,[17AC:&%N9V4@;V8-"D]U='-T86YD:6YG
M(%!R969E<G)E9"!3=&]C:R!F;W(@0V]M;6]N(%-T;V-K)B-X,C`Q1#L-"F%B
M;W9E+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"D%D=FES;W(@1F5E<SPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<^1F5R9VAA;F$-"E!A<G1N97)S+"!);F,N("@F(W@R,#%#.T9E<F=H
M86YA)B-X,C`Q1#LI+"!A($YE=R!9;W)K(&-O;G-U;'1I;F<-"F9I<FTL(')E
M8V5I=F5D(&$@8V%S:"!F964@9F]R('1H96ER('-E<G9I8V5S(&EN(&-O;FYE
M8W1I;VX@=VET:"!T:&4-"FYE9V]T:6%T:6]N(&%N9"!E>&5C=71I;VX@;V8@
M=&AE($-O;&QA8F]R871I;VX@06=R965M96YT(&5Q=6%L('1O#0HF;F)S<#LD
M-S`P+#`P,"`H;W(@<V5V96X@<&5R8V5N="`H-R4I(&]F('1H92!G<F]S<R!P
M<F]C965D<R!T;R!T:&4-"D-O;7!A;GD@<F5S=6QT:6YG(&9R;VT@=&AE('-A
M;&4@;V8@4V5R:65S($4@4')E9F5R<F5D(%-T;V-K(&%N9`T*8V]M;6]N('-T
M;V-K('!U<F-H87-E('=A<G)A;G1S('1O(%!U<F1U92!I;B!C;VYN96-T:6]N
M('=I=&@@=&AE#0I#;VQL86)O<F%T:6]N($%G<F5E;65N="DN)B-X03`[($YO
M=F5L;W,@:7,@86QS;R!O8FQI9V%T960@=&\@<&%Y#0I&97)G:&%N82!S:7@@
M<&5R8V5N="`H-B4I(&]F(&%L;"!P87EM96YT<R!T;R!.;W9E;&]S(&)Y($UU
M;F1I<&AA<FUA#0IU;F1E<B!T:&4@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0@
M;W1H97(@=&AA;B!R;WEA;'1I97,@;VX@;F5T#0IS86QE<RX\+V9O;G0^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K)SXF(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0I!8V-O
M=6YT:6YG(%1R96%T;65N="!O9B!397)I97,@12!&:6YA;F-I;F<\+V9O;G0^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
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M=6ET>2!I;B!T:&4@8F%L86YC92!S:&5E="!A<R!O9B!$96-E;6)E<B`S,2P@
M,C`P.2X@5&AE#0IG<F]S<R!P<F]C965D<R!O9B`F;F)S<#LD,3`L,#`P+#`P
M,"!R96-E:79E9"!I;B!C;VYJ=6YC=&EO;B!W:71H('1H90T*4V5R:65S($4@
M1FEN86YC:6YG('=E<F4@86QL;V-A=&5D(&]N(&$@<F5L871I=F4@9F%I<B!V
M86QU92!B87-I<PT*8F5T=V5E;B!T:&4@4V5R:65S($4@4')E9F5R<F5D(%-T
M;V-K(&%N9"!T:&4@=V%R<F%N=',N(%1H92!R96QA=&EV90T*9F%I<B!V86QU
M92!O9B!T:&4@=V%R<F%N=',@:7-S=65D('1O(&EN=F5S=&]R<R!O9B`F;F)S
M<#LD,BPY,#<L,#`P#0HH9&5T97)M:6YE9"!U<VEN9R!T:&4@0FQA8VLM4V-H
M;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E;"P@97-T:6UA=&5D#0IV;VQA=&EL
M:71Y(&]F(#@P)2P@82!R:7-K+69R964@:6YT97)E<W0@<F%T92!O9B`R+C$W
M)2!A;F0@82!T97)M#0IE<75A;"!T;R!T:&4@=&5R;2!O9B!T:&4@=V%R<F%N
M="D@=V%S(')E8V]R9&5D(&%S(&%D9&ET:6]N86P-"G!A:60M:6X@8V%P:71A
M;"!W:&EL92!T:&4@<F5L871I=F4@9F%I<B!V86QU92!O9B!T:&4@4V5R:65S
M($4-"E!R969E<G)E9"!3=&]C:R!O9B`F;F)S<#LD-RPP.3,L,#`P('=A<R!R
M96-O<F1E9"!A<R!T96UP;W)A<GD@97%U:71Y+B!4:&4-"F-A<G)Y:6YG('9A
M;'5E(&]F('1H92!397)I97,@12!0<F5F97)R960@4W1O8VL@=V%S(&EM;65D
M:6%T96QY#0IA9&IU<W1E9"!T;R!I=',@9F%I<B!V86QU92!O9B`F;F)S<#LD
M-RPS.#4L,#`P(&)A<V5D(&]N('1H92!F86ER('9A;'5E(&]F#0IT:&4@87,M
M8V]N=F5R=&5D(&-O;6UO;B!S=&]C:RX@5&AE(&1I9F9E<F5N8V4@;V8@)FYB
M<W`[)#(Y,BPP,#`-"G)E<')E<V5N=',@82!B96YE9FEC:6%L(&-O;G9E<G-I
M;VX@9F5A='5R92!A;F0@=V%S(')E8V]R9&5D(&%S(&$-"F1E96UE9"!D:79I
M9&5N9"!T;R!P<F5F97)R960@<W1O8VMH;VQD97)S+B!)<W-U86YC92!C;W-T
M<R!R96QA=&5D#0IT;R!T:&4@4V5R:65S($4@1FEN86YC:6YG(&]F("9N8G-P
M.R0W.34L,#`P('=E<F4@;F5T=&5D(&%G86EN<W0@=&5M<&]R87)Y#0IE<75I
M='DN(%1H92!397)I97,@12!0<F5F97)R960@4W1O8VL@=&AA="!W87,@:7-S
M=65D(&EN('!A>6UE;G0@;V8-"F1I=FED96YD<R!W87,@:6YI=&EA;&QY(')E
M8V]R9&5D(&EN('1E;7!O<F%R>2!E<75I='D@870@=&AE('9A;'5E#0IO9B!T
M:&4@9&EV:61E;F1S('1H870@:&%D(&%C8W)U960@=&]T86QI;F<@)FYB<W`[
M)#$L-3DW+#`P,"X@5&AI<R!A;6]U;G0-"G=A<R!T:&5N(&%D:G5S=&5D('1O
M('1H92!F86ER('9A;'5E(&]F("9N8G-P.R0Q+#$W.2PP,#`@8F%S960@;VX@
M=&AE(&9A:7(-"G9A;'5E(&]F('1H92!A<RUC;VYV97)T960@8V]M;6]N('-T
M;V-K+B!4:&4@9&EF9F5R96YC92!O9B`F;F)S<#LD-#$X+#`P,`T*=V%S(')E
M8V]R9&5D(&%S(&%N(&]F9G-E="!T;R!T:&4@9&5E;65D(&1I=FED96YD<R!R
M96-O<F1E9"X@5&AE#0I397)I97,@12!0<F5F97)R960@4W1O8VL@=&AA="!W
M87,@:7-S=65D(&EN(&5X8VAA;F=E(&9O<@T*;W5T<W1A;F1I;F<@<VAA<F5S
M(&]F(%-E<FEE<R!$('!R969E<G)E9"!S=&]C:R!W87,@<F5C;W)D960@870-
M"B9N8G-P.R0Q,RPY,#0L,#`P+"!T:&4@8V%R<GEI;F<@=F%L=64@;V8@=&AE
M('-H87)E<R!O9B!397)I97,@1"!P<F5F97)R960-"G-T;V-K(&%S(&]F('1H
M92!D871E(&]F('1H92!E>&-H86YG92X\+V9O;G0^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@
M+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/D%S#0IA(')E<W5L="!O9B!T:&4@;6]D:69I8V%T:6]N('1O('1H
M92!W87)R86YT<R!T;R!E>'1E;F0@=&AE:7(-"F5X<&ER871I;VX@8GD@87!P
M<F]X:6UA=&5L>2`S,B!M;VYT:',@=&AA="!O8V-U<G)E9"!I;B!C;VYN96-T
M:6]N#0IW:71H('1H92!E>&-H86YG92!O9B!A;&P@;W5T<W1A;F1I;F<@<VAA
M<F5S(&]F(%-E<FEE<R!$('!R969E<G)E9`T*<W1O8VL@9F]R('-H87)E<R!O
M9B!397)I97,@12!0<F5F97)R960@4W1O8VLL(&EN('1H92!Y96%R(&5N9&5D
M#0I$96-E;6)E<B`S,2P@,C`P.2P@82!D965M960@9&EV:61E;F0@;V8@)FYB
M<W`[)#@T,"PP,#`@=V%S#0IR96-O<F1E9"XF(WA!,#L@5&AI<R!A;6]U;G0@
M<F5P<F5S96YT960@=&AE(&EN8W)E;65N=&%L(&9A:7(@=F%L=64-"F]F('1H
M92!W87)R86YT<R!I;6UE9&EA=&5L>2!B969O<F4@86YD(&%F=&5R(&UO9&EF
M:6-A=&EO;B!U<VEN9R!T:&4-"D)L86-K+5-C:&]L97,@;W!T:6]N('!R:6-I
M;F<@;6]D96PL('9O;&%T:6QI='D@;V8@.#`E+"!D:7-C;W5N=`T*<F%T97,@
M;V8@,2XU-"4@86YD(#(N,3<E(&%N9"!T:&4@<F5M86EN:6YG('=A<G)A;G0-
M"G1E<FTN/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*0V]N=F5R<VEO;G,@;V8@4V5R:65S($4@4')E9F5R<F5D
M(%-T;V-K/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$=7)I;F<-"G1H
M92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#`Y+"`Y-RXQ.#(P.3,W-2!S
M:&%R97,@;V8@=&AE#0I#;VUP86YY)B-X,C`Q.3MS(%-E<FEE<R!%(%!R969E
M<G)E9"!3=&]C:RP@:&%V:6YG(&%N(&%G9W)E9V%T90T*<W1A=&5D('9A;'5E
M(&]F("9N8G-P.R0T+#@U.2PP,#`@86YD(&%C8W5M=6QA=&5D(&1I=FED96YD
M<R!T:&5R96]N(&]F#0HF;F)S<#LD,S`Q+#`P,"P@=V5R92!C;VYV97)T960@
M:6YT;R`U,2PX.#D@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RXF(WA!,#L-"E1H
M92!A<W-O8VEA=&5D(&-A<G)Y:6YG('9A;'5E(&]F('1H92!C;VYV97)T960@
M<VAA<F5S('1O=&%L:6YG#0IA<'!R;WAI;6%T96QY("9N8G-P.R0S+#(Q,RPP
M,#`@=V%S(')E8VQA<W-I9FEE9"!T;R!P97)M86YE;G0@97%U:71Y(&9R;VT-
M"G1E;7!O<F%R>2!E<75I='DN)B-X03`[($1U<FEN9R!T:&4@>65A<B!E;F1E
M9"!$96-E;6)E<B`S,2P@,C`Q,"P-"C$T,"!S:&%R97,@;V8@=&AE($-O;7!A
M;GDF(W@R,#$Y.W,@4V5R:65S($4@4')E9F5R<F5D(%-T;V-K+"!H879I;F<-
M"F%N(&%G9W)E9V%T92!S=&%T960@=F%L=64@;V8@)FYB<W`[)#<L,#`P+#`P
M,"P@86YD(&%C8W5M=6QA=&5D(&1I=FED96YD<PT*=&AE<F5O;B!T;W1A;&EN
M9R`F;F)S<#LD-C,U+#`P,"P@=V5R92!C;VYV97)T960@:6YT;R`W-BPW-S`@
M<VAA<F5S(&]F#0IC;VUM;VX@<W1O8VLN)B-X03`[(%1H92!A<W-O8VEA=&5D
M(&-A<G)Y:6YG('9A;'5E(&]F('1H92!C;VYV97)T960-"G-H87)E<R!T;W1A
M;&EN9R!A<'!R;WAI;6%T96QY("9N8G-P.R0T+#8Y,"PP,#`@=V%S(')E8VQA
M<W-I9FEE9"!T;PT*<&5R;6%N96YT(&5Q=6ET>2!F<F]M('1E;7!O<F%R>2!E
M<75I='DN)B-X03`[($EN($YO=F5M8F5R(#(P,3`L(&%L;`T*;W5T<W1A;F1I
M;F<@<VAA<F5S(&]F(%-E<FEE<R!%(%!R969E<G)E9"!3=&]C:R!W97)E(&5X
M8VAA;F=E9"!F;W(-"G-H87)E<R!O9B!C;VUM;VX@<W1O8VLN(%-E92`F(W@R
M,#%#.T5X8VAA;F=E(&]F(%!R969E<G)E9`T*4W1O8VLF(W@R,#%$.R!B96QO
M=RX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O
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M("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
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M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]N
M#0I!=6=U<W0@,C4L(#(P,#DL('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!T
M:&4@075G=7-T(#(P,#D@4'5R8VAA<V4-"D%G<F5E;65N="!W:71H(%!U<F1U
M92!T;R!S96QL(#@Y+#$R-B!S:&%R97,@;V8@:71S(&-O;6UO;B!S=&]C:RP-
M"B9N8G-P.R0P+C`P,#`Q('!A<B!V86QU92!A;F0@=V%R<F%N=',@=&\@<'5R
M8VAA<V4@,S$L,3DT('-H87)E<R!O9B!I=',-"F-O;6UO;B!S=&]C:R!A="!A
M;B!E>&5R8VES92!P<FEC92!O9B`F;F)S<#LD,3`P+CDX('!E<B!S:&%R92P@
M97AP:7)I;F<-"D1E8V5M8F5R(#,Q+"`R,#$U+"!F;W(@86X@86=G<F5G871E
M('!U<F-H87-E('!R:6-E(&]F("9N8G-P.R0Y+#`P,"PP,#`-"BAT:&4@)B-X
M,C`Q0SM!=6=U<W0@,C`P.2!0<FEV871E(%!L86-E;65N="8C>#(P,40[*2X@
M0V]N8W5R<F5N="!W:71H#0IT:&4@97AE8W5T:6]N(&%N9"!D96QI=F5R>2!O
M9B!T:&4@075G=7-T(#(P,#D@4'5R8VAA<V4@06=R965M96YT+`T*=&AE($-O
M;7!A;GD@<V]L9"!0=7)D=64@,S0L-C8P('-H87)E<R!O9B!I=',@8V]M;6]N
M('-T;V-K(&%N9"!A#0IW87)R86YT('1O('!U<F-H87-E(#$R+#$S,2!S:&%R
M97,@;V8@:71S(&-O;6UO;B!S=&]C:R!A="`F;F)S<#LD,3`P+CDX#0IP97(@
M<VAA<F4@9F]R(&%P<')O>&EM871E;'D@)FYB<W`[)#,L-3`P+#`P,"`H=&AE
M("8C>#(P,4,[26YI=&EA;`T*0VQO<VEN9R8C>#(P,40[*2X@3VX@3F]V96UB
M97(@,3`L(#(P,#DL('1H92!#;VUP86YY(&-O;7!L971E9"!T:&4-"F9I;F%L
M(&-L;W-I;F<@=6YD97(@=&AE($%U9W5S="`R,#`Y(%!U<F-H87-E($%G<F5E
M;65N="!A;F0@<V]L9`T*4'5R9'5E(#4T+#0V-B!S:&%R97,@;V8@3F]V96QO
M<R!C;VUM;VX@<W1O8VL@86YD('=A<G)A;G1S('1O#0IP=7)C:&%S92`Q.2PP
M-C,@<VAA<F5S(&]F($YO=F5L;W,@8V]M;6]N('-T;V-K(&9O<B!G<F]S<R!P
M<F]C965D<PT*;V8@)FYB<W`[)#4L-3`P+#`P,"X@27-S=6%N8V4@8V]S=',@
M87-S;V-I871E9"!W:71H('1H92!T<F%N<V%C=&EO;G,-"G1O=&%L960@)FYB
M<W`[)#8Q+#`P,"!A;F0@<W5C:"!A;6]U;G0@=V%S(')E8V]R9&5D(&%S(&$@
M<F5D=6-T:6]N(&]F#0IA9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;"X\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E!U<G-U86YT#0IT;R!T:&4@075G
M=7-T(#(P,#D@4'5R8VAA<V4@06=R965M96YT+"8C>$$P.U!U<F1U92!A8W%U
M:7)E9"!A(')I9VAT#0IO9B!F:7)S="!R969U<V%L("AT:&4@)B-X,C`Q0SM2
M:6=H="!O9B!&:7)S="!2969U<V%L)B-X,C`Q1#LI('=I=&@-"G)E<W!E8W0@
M=&\@8F]N82!F:61E(&]F9F5R<R!F;W(@=&AE(&QI8V5N<V4@;W(@;W1H97(@
M86-Q=6ES:71I;VX@;V8-"DY/5BTP,#(@4FEG:'1S("AA<R!D969I;F5D(&EN
M('1H92!!=6=U<W0@,C`P.2!0=7)C:&%S92!!9W)E96UE;G0I#0II;B!T:&4@
M52Y3+B`H=&AE("8C>#(P,4,[52Y3+B!,:6-E;G-E)B-X,C`Q1#LI(')E8V5I
M=F5D(&9R;VT@=&AI<F0-"G!A<G1I97,@86YD(&%P<')O=F5D(&)Y('1H92!#
M;VUP86YY)B-X,C`Q.3MS(&)O87)D(&]F#0ID:7)E8W1O<G,N)B-X03`[(%5N
M9&5R('1H92!2:6=H="!O9B!&:7)S="!2969U<V%L+"!.;W9E;&]S('=I;&P@
M8F4-"G)E<75I<F5D('1O(&-O;6UU;FEC871E('1O(%!U<F1U92!T:&4@=&5R
M;7,@;V8@86YY('-U8V@@=&AI<F0M<&%R='D-"F]F9F5R<R!R96-E:79E9"!A
M;F0@4'5R9'5E('=I;&P@:&%V92`S,"!D87ES('1O(&5N=&5R(&EN=&\@80T*
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M;G,L(&%S(&1E9FEN960@:6X@=&AE($%U9W5S="`R,#`Y(%!U<F-H87-E#0I!
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M('=I=&@@<F5S<&5C="!T;RP@3D]6+3`P,B!2:6=H=',-"F9O<B!,871I;B!!
M;65R:6-A+"!-97AI8V\@86YD($-A;F%D82X\+V9O;G0^/"]D:78^#0H\8G(@
M+SX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P="<^4'5R<W5A;G0-"G1O('1H92!!=6=U<W0@,C`P
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M861E(&%V86EL86)L92!T;R!M96UB97)S(&]F#0IT:&4@0F]A<F0N)B-X03`[
M(%1H:7,@<FEG:'0@;&%S=',@=6YT:6P@=&AE(&QA=&5R(&]F('-U8V@@=&EM
M92!A<PT*4'5R9'5E(&]R(&ET<R!I;F1E<&5N9&5N="!A<W-O8VEA=&5D(&-O
M;7!A;FEE<R!N;R!L;VYG97(@:&]L9"!A=`T*;&5A<W0@;VYE+6AA;&8@;V8@
M=&AE(&-O;6UO;B!S=&]C:R!P=7)C:&%S960@<'5R<W5A;G0@=&\@=&AE($%U
M9W5S=`T*,C`P.2!0=7)C:&%S92!!9W)E96UE;G0@86YD(&YO(&QO;F=E<B!H
M;VQD(&%T(&QE87-T(&]N92UH86QF(&]F('1H90T*4V5R:65S($4@4')E9F5R
M<F5D(%-T;V-K(&ES<W5E9"!T;R!T:&5M(&]N($9E8G)U87)Y(#$Q+"`R,#`Y
M+B8C>$$P.PT*5&AE(')I9VAT('1O(&1E<VEG;F%T92!A($)O87)D(&]B<V5R
M=F5R(&AA9"!P<F5V:6]U<VQY(&)E96X@9W)A;G1E9`T*:6X@8V]N;F5C=&EO
M;B!W:71H('1H92!F:6YA;F-I;F<@=&AA="!O8V-U<G)E9"!O;B!&96)R=6%R
M>2`Q,2P@,C`P.0T*86YD(%!U<F1U92!A<'!O:6YT960@<W5C:"!A;B!O8G-E
M<G9E<B!I;B!&96)R=6%R>2`R,#`Y+B8C>$$P.PT*4'5R9'5E(&%L<V\@:&%S
M('1H92!R:6=H="!T;R!P87)T:6-I<&%T92!I;B!F=71U<F4@97%U:71Y#0IF
M:6YA;F-I;F=S(&EN('!R;W!O<G1I;VX@=&\@=&AE:7(@<')O(')A=&$@;W=N
M97)S:&EP(&]F(&-O;6UO;@T*<W1O8VLN/"]F;VYT/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R
M("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z
M(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*0V]M;6]N(%-T;V-K(%!U
M<F-H87-E(%=A<G)A;G0\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1H
M90T*8V]M;6]N('-T;V-K('!U<F-H87-E('=A<G)A;G1S(&AA=F4@86X@97AE
M<F-I<V4@<')I8V4@;V8@)FYB<W`[)#$P,"XY.`T*<&5R('-H87)E(&%N9"!E
M>'!I<F4@;VX@1&5C96UB97(@,S$L(#(P,34N)B-X03`[(%1H92!W87)R86YT
M#0IE>&5R8VES92!P<FEC92!A;F0O;W(@=&AE(&YU;6)E<B!O9B!S:&%R97,@
M;V8@8V]M;6]N('-T;V-K(&ES<W5A8FQE#0IP=7)S=6%N="!T;R!S=6-H('=A
M<G)A;G0@=VEL;"!B92!S=6)J96-T('1O(&%D:G5S=&UE;G0@9F]R('-T;V-K
M#0ID:79I9&5N9',L('-T;V-K('-P;&ET<R!O<B!S:6UI;&%R(&-A<&ET86P@
M<F5O<F=A;FEZ871I;VYS('-O('1H870-"G1H92!R:6=H=',@;V8@=&AE('=A
M<G)A;G0@:&]L9&5R<R!A9G1E<B!S=6-H(&5V96YT('=I;&P@8F4-"F5Q=6EV
M86QE;G0@=&\@=&AE(')I9VAT<R!O9B!W87)R86YT(&AO;&1E<G,@<')I;W(@
M=&\@<W5C:`T*979E;G0N)B-X03`[(%1H92!R96QA=&EV92!F86ER('9A;'5E
M(&]F('1H92!W87)R86YT<R!I<W-U960@=&\-"E!U<F1U92!T;W1A;&5D("9N
M8G-P.R0Q+#DR.2PP,#`@86YD('=A<R!R96-O<F1E9"!A<R!A(&-O;7!O;F5N
M="!O9@T*861D:71I;VYA;"!P86ED+6EN(&-A<&ET86PN)B-X03`[(%1H92!F
M86ER('9A;'5E(&]F('1H92!W87)R86YT<PT*=V%S(&1E=&5R;6EN960@8F%S
M960@;VX@=&AE(&UA<FME="!V86QU92!O9B!T:&4@0V]M<&%N>28C>#(P,3D[
M<PT*8V]M;6]N('-T;V-K(&]N('1H92!D871E<R!O9B!I<W-U86YC92!U<VEN
M9R!T:&4@0FQA8VLM4V-H;VQE<PT*;65T:&]D(&]F('9A;'5A=&EO;BP@97-T
M:6UA=&5D('9O;&%T:6QI='D@;V8@.3`E+"!R:7-K+69R964-"FEN=&5R97-T
M(')A=&5S(')A;F=I;F<@9G)O;2`R+C`R)2!T;R`R+C<E(&%N9"!A('1E<FT@
M97%U86P@=&\@=&AE#0IT97)M(&]F('1H92!W87)R86YT+CPO9F]N=#X\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&
M3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"E)E9VES
M=')A=&EO;B!2:6=H=',\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D%S
M#0IP87)T(&]F('1H92!!=6=U<W0@,C`P.2!0<FEV871E(%!L86-E;65N="P@
M=&AE($-O;7!A;GD@96YT97)E9"!I;G1O#0IA(')E9VES=')A=&EO;B!R:6=H
M=',@86=R965M96YT('=I=&@@4'5R9'5E("AT:&4@)B-X,C`Q0SM0=7)D=64-
M"E)E9VES=')A=&EO;B!!9W)E96UE;G0F(W@R,#%$.RDN)B-X03`[(%1H92!0
M=7)D=64@4F5G:7-T<F%T:6]N#0I!9W)E96UE;G0@<F5Q=6ER960@=&AE($-O
M;7!A;GD@=&\@:&%V92!F:6QE9"!W:71H('1H92!314,@;F\@;&%T97(-"G1H
M86X@36%Y(#$W+"`R,#$P+"!A(')E9VES=')A=&EO;B!S=&%T96UE;G0@8V]V
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M=&]C:R!U;G1I;"!T:&4@9&5L:6YQ=65N=`T*<F5G:7-T<F%T:6]N('-T871E
M;65N="!I<R!F:6QE9"XF(WA!,#L@5&AE($-O;7!A;GD@9&ED(&YO="!F:6QE
M('1H90T*<F5G:7-T<F%T:6]N('-T871E;65N="!A;F0@86-C<G5E9"`F;F)S
M<#LD.#$Y+#`P,"!A<R!A(&-O;7!O;F5N="!O9B!O=&AE<@T*:6YC;VUE("AE
M>'!E;G-E*2!D=7)I;F<@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P
M,3`L#0IR97!R97-E;G1I;F<@;6%N86=E;65N="8C>#(P,3D[<R!B97-T(&5S
M=&EM871E(&]F('1H92!P<F]B86)L92!T;W1A;`T*;&EQ=6ED871E9"!D86UA
M9V5S('1H870@;6%Y(&)E('-E='1L960N($EN(&-O;FYE8W1I;VX@=VET:"!T
M:&4-"F5X8VAA;F=E(&]F('1H96ER('-H87)E<R!O9B!397)I97,@12!0<F5F
M97)R960@4W1O8VL@9F]R(&-O;6UO;@T*<W1O8VL@;VX@3F]V96UB97(@,S`L
M(#(P,3`L(%!U<F1U92!R96QE87-E9"!T:&4@0V]M<&%N>2!F<F]M(&%N>0T*
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M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I
M=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M#0I*=6QY(#(P,3`@4F5G:7-T97)E9"!/9F9E<FEN9SPO9F]N=#X\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^3VX-"DIU;'D@,C<L(#(P,3`L('!U<G-U86YT('1O
M('-E8W5R:71I97,@<'5R8VAA<V4@86=R965M96YT<R!E;G1E<F5D#0II;G1O
M('=I=&@@:6YS=&ET=71I;VYA;"!I;G9E<W1O<G,@;VX@2G5L>2`R,2P@,C`Q
M,"P@=&AE($-O;7!A;GD-"F-O;7!L971E9"!T:&4@<V%L92P@:6X@86X@;V9F
M97)I;F<@<F5G:7-T97)E9"!U;F1E<B!T:&4@4V5C=7)I=&EE<PT*06-T(&]F
M(#$Y,S,L(&%S(&%M96YD960L(&]F(&%N(&%G9W)E9V%T92!O9B`Q-#`L,#4V
M('-H87)E<R!O9B!I=',-"F-O;6UO;B!S=&]C:R!A;F0@9FEV92UY96%R('=A
M<G)A;G1S('1O('!U<F-H87-E('5P('1O(&%N(&%G9W)E9V%T90T*;V8@,34P
M+#`T,"!S:&%R97,@;V8@:71S(&-O;6UO;B!S=&]C:R!A="!A;B!E>&5R8VES
M92!P<FEC92!O9@T*)FYB<W`[)#$P+C<Q('!E<B!S:&%R92P@9F]R(&=R;W-S
M('!R;V-E961S(&]F("9N8G-P.R0Q+#4P,"PP,#`@86YD(&YE="!P<F]C965D
M<PT*;V8@)FYB<W`[)#$L,C0Y+#`P,"!A9G1E<B!D961U8W1I;F<@=')A;G-A
M8W1I;VX@8V]S=',N)B-X03`[(%1H92!W87)R86YT#0IE>&5R8VES92!P<FEC
M92!I<R!S=6)J96-T('1O(&%D:G5S=&UE;G0@:6X@8V5R=&%I;B!C:7)C=6US
M=&%N8V5S#0IA;F0@=&AE<F5F;W)E+"!T:&4@<F5L871I=F4@9F%I<B!V86QU
M92!O9B!T:&4@=V%R<F%N=',@870@=&AE(&1A=&4-"F]F(&ES<W5A;F-E+"`F
M;F)S<#LD-3`T+#`P,"P@:&%S(&)E96X@8FEF=7)C871E9"!F<F]M('1H92!P
M<F]C965D<R!A;F0-"G)E8V]R9&5D(&%S(&$@9&5R:79A=&EV92!L:6%B:6QI
M='DN)B-X03`[(%1H92!#;VUP86YY('5S97,-"G9A;'5A=&EO;B!M971H;V1S
M(&%N9"!A<W-U;7!T:6]N<R!T:&%T(&-O;G-I9&5R(&%M;VYG(&]T:&5R<R!T
M:&4-"F9A:7(@=F%L=64@;V8@=&AE('5N9&5R;'EI;F<@<W1O8VLL(')I<VLM
M9G)E92!I;G1E<F5S="!R871E+`T*=F]L871I;&ET>2P@97AP96-T960@;&EF
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M4$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^4VEN8V4-"G1H92!S96-U<FET:65S
M(&EN('1H:7,@9FEN86YC:6YG('=E<F4@:7-S=65D(&%T(&$@<')I8V4@;&5S
M<R!T:&%N#0HF;F)S<#LD,3`P+CDX('!E<B!S:&%R92P@=&AE($-O;7!A;GD@
M;V)T86EN960@=&AE(&-O;G-E;G0@;V8@:71S#0IP<F5F97)R960@<W1O8VMH
M;VQD97)S('!U<G-U86YT('1O(&$@8V]N<V5N="!A;F0@=V%I=F5R(&1A=&5D
M($IU;'D-"C8L(#(P,3`L(&%S(&%M96YD960@;VX@2G5L>2`R,2P@,C`Q,"X@
M26X@8V]N;F5C=&EO;B!W:71H(&]B=&%I;FEN9PT*=&AI<R!C;VYS96YT+"!T
M:&4@0V]M<&%N>2!I<W-U960@9FEV92UY96%R('=A<G)A;G1S("AT:&4-"B8C
M>#(P,4,[26YC96YT:79E(%=A<G)A;G1S)B-X,C`Q1#LI('1O(&ET<R!P<F5F
M97)R960@<W1O8VMH;VQD97)S(&9O<@T*=&AE('!U<F-H87-E(&]F('5P('1O
M(&%N(&%G9W)E9V%T92!O9B`Q-3`L,#,Y('-H87)E<R!O9B!C;VUM;VX-"G-T
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M8G-P.R0U.#8L,#`P+"!I<R!R969L96-T960@87,@82!D965M960@9&EV:61E
M;F0@=&\@=&AE('!R969E<G)E9`T*<W1O8VMH;VQD97)S(&]N('1H92!S=&%T
M96UE;G0@;V8@;W!E<F%T:6]N<RX@5&AE($-O;7!A;GD@=7-E9`T*=F%L=6%T
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M4$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^5&AE#0IF:6YA;F-I;F<@<F5S=6QT
M960@:6X@861J=7-T;65N=',@=&\@8V5R=&%I;B!W87)R86YT<R!P=7)S=6%N
M="!T;PT*=&AE:7(@=&5R;7,N)B-X03`[(%=A<G)A;G1S(&ES<W5E9"!I;B`R
M,#`U('1H870@=V5R92!E>&5R8VES86)L90T*9F]R(#$L-3DQ('-H87)E<R!A
M="!A;B!E>&5R8VES92!P<FEC92!O9B`F;F)S<#LD.3DN-#4@<&5R('-H87)E
M(&%S(&]F#0II;6UE9&EA=&5L>2!P<FEO<B!T;R!T:&4@=')A;G-A8W1I;VX@
M8F5C86UE(&5X97)C:7-A8FQE(&9O<B`Q-"PW-S8-"G-H87)E<R!A="!A;B!E
M>&5R8VES92!P<FEC92!O9B`F;F)S<#LD,3`N-S$@<&5R('-H87)E+"!A;F0@
M=V%R<F%N=',-"FES<W5E9"!I;B`R,#`V('1H870@=V5R92!E>&5R8VES86)L
M92!F;W(@,CDL-S@W('-H87)E<R!A="!A;@T*97AE<F-I<V4@<')I8V4@;V8@
M)FYB<W`[)#(V,RXQ-B!P97(@<VAA<F4@87,@;V8@:6UM961I871E;'D@<')I
M;W(@=&\@=&AE#0IT<F%N<V%C=&EO;B!B96-A;64@97AE<F-I<V%B;&4@9F]R
M(#,S+#4V.2!S:&%R97,@870@86X@97AE<F-I<V4-"G!R:6-E(&]F("9N8G-P
M.R0R,S0N,#D@<&5R('-H87)E+B8C>$$P.R!4:&4@,C`P-2!W87)R86YT<R!E
M>'!I<F5D#0IU;F5X97)C:7-E9"!O;B!!=6=U<W0@.2P@,C`Q,"P@86YD('1H
M92`R,#`V('=A<G)A;G1S('=I;&P@97AP:7)E(&EN#0I-87)C:"`R,#$Q+CPO
M9F]N=#X\+V1I=CX-"CQB<B`O/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD)SX-"D-O
M;6UO;B!3=&]C:R!787)R86YT<SPO9F]N=#X@)B-X03`[("8C>#(P,30[(%1H
M92!F;VQL;W=I;F<@=&%B;&4-"G-U;6UA<FEZ97,@:6YF;W)M871I;VX@=VET
M:"!R96=A<F0@=&\@;W5T<W1A;F1I;F<@=V%R<F%N=',@87,@;V8-"D1E8V5M
M8F5R(#,Q+"`R,#$P+"!I<W-U960@:6X@8V]N;F5C=&EO;B!W:71H(&5Q=6ET
M>2!A;F0@9&5B=`T*9FEN86YC:6YG<R!S:6YC92`R,#`U+CPO9F]N=#X\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!A;&EG;CTS1&-E;G1E<CX-"CQT
M86)L92!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0Y,"4^#0H\='(^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0U,"4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^)B-X03`[/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SXF(WA!
M,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
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M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
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M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G
M/D]U='-T86YD:6YG/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SXH87,F
M(WA!,#MA9&IU<W1E9"D\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,R4@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
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M.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4G/E!R:6-E/"]F;VYT/CPO9F]N=#X\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
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M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C`E/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^)B-X03`[/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K)SXF(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SY%>'!I<F%T:6]N)B-X03`[1&%T
M93PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CQT<CX-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,"4@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R,"4@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-3`E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS,RPU-CD\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N
M/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^,C,T+C`Y/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(P)2!A;&EG;CTS1')I9VAT/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DUA
M<F-H#0HW+"`R,#$Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\='(@
M8F=C;VQO<CTS1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#4P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY397)I97,-"D(@4')E9F5R<F5D(%-T;V-K("8C
M>#(P,3,[('!L86-E;65N="!A9V5N=',\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX]
M,T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXU+#,Y,CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S
M<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ.3$N,C4\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C`E(&%L
M:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^36%Y#0HR+"`R,#$R/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-3`E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXX+#$V.3PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R
M:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX-"C$Y,2XR-3PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+V1I=CX-"CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,"4@86QI
M9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY-87D-"C(L(#(P,3(\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-3`E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-C`L,S,P
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@]
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M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
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M.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/CDY+C0U/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(P)2!A;&EG;CTS1')I9VAT/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D1E
M8V5M8F5R#0HS,2P@,C`Q-3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*
M/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#4P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!=6=U<W0-"C(P,#D@4')I=F%T92!0
M;&%C96UE;G0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,S$L,3DT
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@]
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M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
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M.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/C$P,"XY.#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,"4@86QI9VX],T1R:6=H=#X-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$
M96-E;6)E<@T*,S$L(#(P,34\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-
M"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-3`E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DIU;'D-"C(P,3`@1&ER96-T($]F9F5R
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI
M9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXQ,#4L,#,Y/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
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M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/C$P+C<Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,C`E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
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M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^4')E9F5R<F5D#0I);F-E;G1I
M=F4@5V%R<F%N=',\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L
M:60G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I9VAT/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$P
M-2PP-#`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/@T*/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@
M=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ-BXP-C4\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,C`E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
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M('=I9'1H/3-$-3`E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R,"4@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-3`E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/E1O=&%L/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
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M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C`E(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^
M/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXH,2DF(WA!,#L-"E1H92!E>&5R8VES92!P<FEC92!O9B!T
M:&5S92!W87)R86YT<R!W87,@861J=7-T960@:6X@8V]N;F5C=&EO;@T*=VET
M:"!T:&4@<')I=F%T92!P;&%C96UE;G0@8V]M<&QE=&5D(&]N($%P<FEL(#@L
M(#(P,3$N)B-X03`[(%-E90T*3F]T92`Q,BX\+V9O;G0^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\
M8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/D1U<FEN9PT*=&AE('EE87(@96YD960@1&5C96UB97(@,S$L
M(#(P,3`L('=A<G)A;G1S('1O('!U<F-H87-E(#$T+#<W-@T*<VAA<F5S(&]F
M(&-O;6UO;B!S=&]C:R!A="`F;F)S<#LD,3`N-S$@86YD(#4L.30Q('-H87)E
M<R!O9B!C;VUM;VX@<W1O8VL-"F%T("9N8G-P.R0Y.2XT-2!E>'!I<F5D('5N
M97AE<F-I<V5D+B8C>$$P.R!/;B!-87)C:"`W+"`R,#$Q+"!W87)R86YT<R!T
M;PT*<'5R8VAA<V4@,S,L-38Y('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@870@
M)FYB<W`[)#(S-"XP.2!E>'!I<F5D#0IU;F5X97)C:7-E9"X\+V9O;G0^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/D1U<FEN9PT*=&AE('EE87(@96YD960@1&5C
M96UB97(@,S$L(#(P,3`L(#4S+#0W."!S:&%R97,@;V8@=&AE#0I#;VUP86YY
M)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:R!W97)E(&ES<W5E9"!U<&]N('1H92!C
M87-H;&5S<R!E>&5R8VES90T*;V8@=V%R<F%N=',@=&\@<'5R8VAA<V4@.#DL
M-S4R('-H87)E<R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!C;VUM;VX-"G-T
M;V-K+B8C>$$P.R!4:&4@0V]M<&%N>2!R96-L87-S:69I960@)FYB<W`[)#(L
M-3@T+#`P,"!F<F]M(&1E<FEV871I=F4-"FQI86)I;&ET>2!T;R!A9&1I=&EO
M;F%L('!A:60M:6X@8V%P:71A;"!U<&]N('1H92!E>&5R8VES92!O9@T*=V%R
M<F%N=',N)B-X03`[(%1H92!F;VQL;W=I;F<@:7,@82!S=6UM87)Y(&]F('1H
M90T*97AE<F-I<V5S.CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*
M/&1I=B!S='EL93TS1"=-05)'24XM3$5&5#H@,C=P="<@86QI9VX],T1L969T
M/@T*/'1A8FQE('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#@P)3X-"CQT<CX-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#8T)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/D]R:6=I;F%L)B-X03`[
M<')I=F%T928C>$$P.W!L86-E;65N="8C>$$P.SPO9F]N=#X\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O
M;'-P86X],T0R/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4G/E-H87)E<R8C>$$P.V]F/"]F;VYT/CPO9F]N
M=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE)SY#;VUM;VXF(WA!,#M3=&]C:SPO9F]N=#X\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE)SY787)R86YT<SPO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SY%>&5R8VES93PO9F]N
M=#X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
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M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V
M-"4@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3`E(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&%L:6=N/3-$;&5F=#X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P
M86X],T0R(&%L:6=N/3-$;&5F=#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
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M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^,C`P-0T*0G)I9&=E($9I;F%N8VEN9SPO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
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M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
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M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\
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M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C
M;VQO<CTS1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T
M)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXR,#`U#0I)<W-U86YC92!O9B!#;VUM;VX@4W1O8VL@
M)B-X,C`Q,SL@<&QA8V5M96YT(&%G96YT<SPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
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M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
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M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O;G0^
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M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
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M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^,C`P-@T*27-S=6%N8V4@;V8@0V]M;6]N(%-T;V-K/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXR+#,Y-3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M($9/3E0M4TE:13H@,3!P="<^-BPT.#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
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M)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR-C,N,38\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-
M"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-C0E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E-E<FEE<PT*0B!0<F5F97)R960@4W1O
M8VL@)B-X,C`Q,SL@<'5R8VAA<V5R<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,CDL-S`Y
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXT.2PP,3D\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
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M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXY.2XT-3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C
M0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T)2!A;&EG
M;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY397)I97,-"D(@4')E9F5R<F5D(%-T;V-K("8C>#(P,3,[('!L
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M<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!S='EL
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY397)I97,-
M"D0@4')E9F5R<F5D(%-T;V-K/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ-RPR.3(\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
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M3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#DE/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(X
M+#4S,3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&
M0T,^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-C0E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SX-"C4T-#PO9F]N=#X\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N
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M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T)2!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
M"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
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M(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#8T)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY4;W1A;#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O
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M8VLN(%1H92!#;VUP86YY#0IR96-L87-S:69I960@82!T;W1A;"!O9B`F;F)S
M<#LD,2PP,#$L,#`P(&9R;VT@9&5R:79A=&EV92!L:6%B:6QI='D@=&\-"F%D
M9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L('5P;VX@=&AE(&5X97)C:7-E(&]F
M('=A<G)A;G1S+B8C>$$P.R!4:&4-"F9O;&QO=VEN9R!I<R!A('-U;6UA<GD@
M;V8@=&AE(&5X97)C:7-E<SH\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)TU!4D=)3BU,1494.B`R-W!T)R!A;&EG;CTS
M1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$.#`E/@T*/'1R/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-C0E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^3W)I9VEN86PF
M(WA!,#MP<FEV871E)B-X03`[<&QA8V5M96YT/"]F;VYT/CPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE)SY3:&%R97,F(WA!,#MO9CPO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C
M96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M92<^0V]M;6]N)B-X03`[4W1O8VL\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4G/DES<W5E9#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P
M)2!C;VQS<&%N/3-$,CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE)SY787)R86YT<SPO9F]N=#X\+V9O;G0^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/D5X97)C:7-E
M/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
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M.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&%L:6=N/3-$;&5F
M=#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3`E(&-O;'-P86X],T0R(&%L:6=N/3-$;&5F=#X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O
M;'-P86X],T0R(&%L:6=N/3-$;&5F=#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
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M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C`P-0T*0G)I9&=E($9I;F%N8VEN
M9SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$L-#(Y/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR+#`Y,3PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CDU+C8R
M-3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO
M<CTS1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T)2!A
M;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXR,#`U#0I#;VUM;VX@4W1O8VL\+V9O;G0^/"]D:78^#0H\
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@
M86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXQ+#,Q,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE(&%L:6=N
M/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB
M<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXY.2XT-3PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C0E(&%L:6=N/3-$;&5F=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@86QI9VX],T1R
M:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXR-3`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A;&EG
M;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/CDY+C0U/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
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M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
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M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
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M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*,3<S/"]F;VYT
M/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L
M:60G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O
M;&ED)R!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HQ+#,Q-CPO9F]N=#X\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB
M<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@86QI9VX]
M,T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXR-C,N,38\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(]
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
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M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/E1O=&%L/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@]
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M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@]
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M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\8G(@+SX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG
M/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<^3VX-"D%U9W5S="`R,2P@,C`P.2P@=&AE($-O;7!A;GD@
M96YT97)E9"!I;G1O(&5X8VAA;F=E(&%G<F5E;65N=',@=VET:`T*8V5R=&%I
M;B!A8V-R961I=&5D(&EN=F5S=&]R<R!W:&\@:&5L9"!W87)R86YT<RP@:7-S
M=65D(&EN('1H92`R,#`V#0IP<FEV871E('!L86-E;65N="P@=&\@<'5R8VAA
M<V4@-#4L-#`Y('-H87)E<R!O9B!I=',@8V]M;6]N('-T;V-K+@T*4'5R<W5A
M;G0@=&\@=&AE(&5X8VAA;F=E(&%G<F5E;65N=',L(&%N(&%G9W)E9V%T92!O
M9B`Q,RPV,C,@<VAA<F5S#0IO9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!C;VUM
M;VX@<W1O8VL@=VET:"!A(&9A:7(@=F%L=64@;V8@)FYB<W`[)#$L-C(V+#`P
M,`T*=V5R92!I<W-U960@:6X@97AC:&%N9V4@9F]R('1H97-E('=A<G)A;G1S
M+B!4:&4@:&]L9&5R<R!A9W)E960@;F]T#0IT;R!T<F%N<V9E<B!O<B!D:7-P
M;W-E(&]F('1H92!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&)E9F]R90T*1F5B
M<G5A<GD@,3@L(#(P,3`N(%1H92!W87)R86YT<R!H860@8F5E;B!R96-O<F1E
M9"!A<R!A(&1E<FEV871I=F4-"FQI86)I;&ET>2!O;B!T:&4@0V]M<&%N>28C
M>#(P,3D[<R!B86QA;F-E('-H965T(&%T('1H96ER(&5S=&EM871E9`T*9F%I
M<B!V86QU92!O9B`F;F)S<#LD,2PQ,#DL,#`P(&%T('1H92!D871E(&]F(&5X
M8VAA;F=E+B!4:&4@9&EF9F5R96YC92!O9@T*)FYB<W`[)#4Q-RPP,#`@8F5T
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M8V5M8F5R(#,Q+"`R,#`Y+@T*1F]L;&]W:6YG('1H92!E>&-H86YG92P@=V%R
M<F%N=',@97AP:7)I;F<@;VX@36%R8V@@-RP@,C`Q,2!T;PT*<'5R8VAA<V4@
M82!T;W1A;"!O9B`S-2PU,#0@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A="`F
M;F)S<#LD,C<X+C0V('!E<@T*<VAA<F4@<F5M86EN960@;W5T<W1A;F1I;F<N
M($9O;&QO=VEN9R!T:&4@9FEN86P@8VQO<VEN9R!O9B!T:&4-"D%U9W5S="`R
M,#`Y(%!R:79A=&4@4&QA8V5M96YT+"!D97-C<FEB960@86)O=F4L('1H92!N
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M63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I!=71H;W)I>F5D(&%N9"!2
M97-E<G9E9"!3:&%R97,\+V9O;G0^("8C>#(P,30[($]N($]C=&]B97(@,3@L
M(#(P,3`-"G1H92!#;VUP86YY)B-X,C`Q.3MS('-T;V-K:&]L9&5R<R!A<'!R
M;W9E9"!A;B!A;65N9&UE;G0@=&\@=&AE#0IC97)T:69I8V%T92!O9B!I;F-O
M<G!O<F%T:6]N('1O(&EN8W)E87-E('1H92!T;W1A;"!N=6UB97(@;V8-"F%U
M=&AO<FEZ960@<VAA<F5S(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O;6UO
M;B!S=&]C:R!F<F]M#0HR,C4L,#`P+#`P,"!T;R`W-3`L,#`P+#`P,"X@3VX@
M07!R:6P@."P@,C`Q,2P@=&AE($-O;7!A;GD@8V]M<&QE=&5D#0IT:&4@4F5V
M97)S92!3<&QI="!D97-C<FEB960@:6X@3F]T92`Q,BP@86YD(&%M96YD960@
M=&AE(&-E<G1I9FEC871E#0IO9B!I;F-O<G!O<F%T:6]N('1O(&1E8W)E87-E
M('1H92!T;W1A;"!N=6UB97(@;V8@875T:&]R:7IE9"!S:&%R97,-"G1O(#$U
M,"PP,#`L,#`P(&9R;VT@-S4P+#`P,"PP,#`N/"]F;VYT/CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^
M/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY4:&4-"F9O;&QO=VEN9R!S:&%R97,@=V5R92!R97-E<G9E
M9"!F;W(@9G5T=7)E(&ES<W5A;F-E('5P;VX@97AE<F-I<V4@;V8-"G-T;V-K
M(&]P=&EO;G,@;W(@=V%R<F%N=',@;W(@8V]N=F5R<VEO;B!O9B!P<F5F97)R
M960@<W1O8VL@87,@;V8-"G1H92!D871E<R!I;F1I8V%T960Z/"]F;VYT/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=-05)'24XM
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
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M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/D1E8V5M
M8F5R(#,Q+#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#<P)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,R4@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^,C`Q,#PO9F]N=#X\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E
M<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SXR
M,#`Y/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&
M1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)2!A;&EG;CTS
M1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXR,#`P#0I3=&]C:R!/<'1I;VX@4&QA;CPO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@
M86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXR.3$\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX]
M,T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXS-C8\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0W,"4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^,C`P-@T*4W1O8VL@26YC96YT:79E(%!L
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,S@L,S8V/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-#,L.#4V/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
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M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,"PU-CD\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ-BPP,S<\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4@86QI9VX],T1L969T
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(]
M,T0C0T-&1D-#/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)2!A;&EG;CTS1&QE9G0^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY0<F5F
M97)R960-"G-T;V-K/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4G/@T*)B-X,C`Q-#L\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$R)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q,B4^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
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M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^5&]T86P-"G-H87)E<R!R
M97-E<G9E9"!F;W(@9G5T=7)E(&ES<W5A;F-E/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
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M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I9VAT/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HV,C$L.#<T/"]F;VYT/CPO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P15A%04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U1/0TLM0D%3140@
M0T]-4$5.4T%424]./&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-43T-++4)!4T5$
M($-/35!%3E-!5$E/3CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E
M/@T*/'1R('9A;&EG;CTS1'1O<#X-"CQT9"!S='EL93TS1"=724142#H@,S9P
M="<@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"C4N)B-X03`[
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^#0I35$]#2RU"05-%1"!#3TU014Y3051)3TX\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU
M<W1I9GD^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY4:&4-"F9O;&QO=VEN9R!T86)L92!S=6UM87)I
M>F5S(&%M;W5N=',@8VAA<F=E9"`H8W)E9&ET960I('1O(&5X<&5N<V4-"F9O
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M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I
M=B!A;&EG;CTS1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#`E/@T*/'1R/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#<V)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(R)2!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
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M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
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M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4G/C(P,3$\+V9O;G0^/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S8E
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#<V)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%;7!L;WEE90T*86YD(&1I<F5C=&]R
M('-T;V-K(&]P=&EO;B!G<F%N=',Z/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO=W)A<#TS
M1&YO=W)A<#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(]
M,T1W:&ET93X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W-B4@86QI
M9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
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M6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT.2PR.3@\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-S8E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[($U!4D=)
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
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M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI
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M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
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M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4G/@T*,3`X+#DX,#PO9F]N=#X\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*,30P+#`T,3PO
M9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
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M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO
M<CTS1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<V)2!A
M;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@.7!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY297-E87)C:`T*86YD(&1E=F5L;W!M96YT/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
M"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,C$P+#@R-3PO9F]N=#X\+W1D
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M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^1V5N97)A;`T*86YD(&%D;6EN:7-T<F%T:79E/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXI/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/BD\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO
M<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<V)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^*#8P,CPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*3PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,C,W+#4R,#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
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M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1O
M=&%L#0IS=&]C:RUB87-E9"!C;VUP96YS871I;VX\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@
M5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4G/@T*,3`X+#,W.#PO9F]N=#X\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#DE/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXH.3<L-#<Y/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T
M86)L93X-"CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:R<^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&5R90T*=V5R92!N;R!S
M=&]C:R!O<'1I;VX@9W)A;G1S(&1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N
M9&5D($UA<F-H(#,Q+`T*,C`Q,2!O<B`R,#$P+CPO9F]N=#X\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^/&)R("\^/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L
M92!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0Q,#`E/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^3G5M8F5R)B-X03`[
M;V8\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/E-H87)E<SPO9F]N=#X\
M+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
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M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
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M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE)SY/=71S=&%N9&EN9SPO9F]N=#X\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
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M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@;F]W<F%P/3-$;F]W<F%P/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/E=E:6=H=&5D/"]F;VYT
M/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
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M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
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M1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^5V5I9VAT
M960\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/D%V97)A9V4\+V9O;G0^
M/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4G/E)E;6%I;FEN9SPO9F]N=#X\+V9O;G0^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
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M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE)SY996%R<SPO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4G/D%G9W)E9V%T93PO9F]N=#X\+V9O;G0^/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
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M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M)SY686QU93PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
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M1494.B`Y<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]U='-T86YD:6YG#0IA
M="!$96-E;6)E<B`S,2P@,C`Q,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE)SX-"C0Y+#(R-SPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#DE/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*,3`P+C8Q/"]F;VYT/CPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
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M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4G/@T*,C0L.#0R/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U
M,B4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3EP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/D]U='-T86YD:6YG#0IA="!-87)C:"`S,2P@,C`Q
M,3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
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M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
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M.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG
M:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4G/@T*,3`P+C8Q/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%
M>&5R8VES86)L90T*870@36%R8V@@,S$L(#(P,3$\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!4
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE
M.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SX-"C$P,2XP,SPO
M9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<@
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
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M-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^5&AE#0IA9V=R96=A=&4@:6YT<FEN<VEC('9A;'5E(&]F(&]P=&EO
M;G,@;W5T<W1A;F1I;F<@:7,@8V%L8W5L871E9`T*8F%S960@;VX@=&AE('!O
M<VET:79E(&1I9F9E<F5N8V4@8F5T=V5E;B!T:&4@8VQO<VEN9R!M87)K970@
M<')I8V4-"F]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:R!A
M="!T:&4@96YD(&]F('1H92!R97-P96-T:79E#0IP97)I;V0@86YD('1H92!E
M>&5R8VES92!P<FEC92!O9B!T:&4@=6YD97)L>6EN9PT*;W!T:6]N<RXF(WA!
M,#LF(WA!,#M4:&5R92!W97)E(&YO(&]P=&EO;G,@97AE<F-I<V5D(&1U<FEN
M9R!T:&4-"G1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,2X@4VAA
M<F5S(&]F(&-O;6UO;B!S=&]C:R!I<W-U960-"G5P;VX@=&AE(&5X97)C:7-E
M(&]F(&]P=&EO;G,@87)E(&9R;VT@875T:&]R:7IE9"!B=70@=6YI<W-U960-
M"G-H87)E<RX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D%S#0IO9B!-
M87)C:"`S,2P@,C`Q,2P@=&AE<F4@=V%S(&%P<')O>&EM871E;'D@)FYB<W`[
M)#4S."PP,#`@;V8@=&]T86P-"G5N<F5C;V=N:7IE9"!C;VUP96YS871I;VX@
M8V]S="!R96QA=&5D('1O('5N=F5S=&5D('-T;V-K+6)A<V5D#0IC;VUP96YS
M871I;VX@87)R86YG96UE;G1S+B8C>$$P.R8C>$$P.T]F('1H:7,@=&]T86P@
M86UO=6YT+"`V-"4@86YD#0HS-B4@87)E(&5X<&5C=&5D('1O(&)E(')E8V]G
M;FEZ960@9'5R:6YG(#(P,3$@86YD(#(P,3(L#0IR97-P96-T:79E;'DN)B-X
M03`[)B-X03`[5&AE($-O;7!A;GD@97AP96-T<R`X+#@W.2!I;B!U;G9E<W1E
M9`T*;W!T:6]N<R!T;R!V97-T(&EN('1H92!F=71U<F4N)B-X03`[)B-X03`[
M5&AE('=E:6=H=&5D+6%V97)A9V4-"F=R86YT+61A=&4@9F%I<B!V86QU92!O
M9B!V97-T960@86YD('5N=F5S=&5D(&]P=&EO;G,@;W5T<W1A;F1I;F<@870-
M"DUA<F-H(#,Q+"`R,#$Q('=A<R`F;F)S<#LD-C(N-S4@86YD("9N8G-P.R0V
M."XP-RP@<F5S<&5C=&EV96QY+CPO9F]N=#X\+V1I=CX-"CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^#0HQ,2XF(WA!,#L@4U1/0TLM0D%3140@0T]-
M4$5.4T%424]./"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#96QL96-T
M87(F(W@R,#$Y.W,-"G-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!P;&%N<R!P
M<FEO<B!T;R!T:&4@06-Q=6ES:71I;VX@87)E#0IS=6UM87)I>F5D(&)E;&]W
M.CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4G/@T*,C`P-B!5
M;FET($]P=&EO;B!0;&%N+B8C>$$P.SPO9F]N=#X@5&AE(#(P,#8@56YI="!/
M<'1I;VX@4&QA;B`H=&AE#0HF(W@R,#%#.S(P,#8@0V5L;&5C=&%R(%!L86XF
M(W@R,#%$.RDL(&%S(&%M96YD960@86YD(')E<W1A=&5D+`T*<')O=FED960@
M0V5L;&5C=&%R('1H92!A8FEL:71Y('1O(&=R86YT('1O(&5M<&QO>65E<RP@
M9&ER96-T;W)S+`T*8V]N<W5L=&%N=',L(&%N9"!O=&AE<B!N;VXM96UP;&]Y
M965S('5N:71S(&]F(&EN=&5R97-T(&EN#0I#96QL96-T87(N)B-X03`[(%1H
M92!M87AI;75M(&%G9W)E9V%T92!N=6UB97(@;V8@<VAA<F5S('1H870@=V5R
M90T*<W5B:F5C="!T;R!G<F%N="!U;F1E<B!T:&4@,C`P-B!#96QL96-T87(@
M4&QA;B!W87,-"C$L,#$R+#(P,"X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/D-E;&QE8W1A<@T*9W)A;G1E9"`V,S$L,S8P('5N:70@;W!T:6]N<R!U
M;F1E<B!T:&4@,C`P-B!#96QL96-T87(@4&QA;B!A;F0@;F\-"F%D9&ET:6]N
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M0V5L;&5C=&%R)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:RXF(WA!,#L@02!T;W1A
M;"!O9@T*-C`V+#@X.2!A;F0@-CDQ+#(T."!O<'1I;VYS('1O('!U<F-H87-E
M('-H87)E<R!O9B!#96QL96-T87(F(W@R,#$Y.W,-"F-O;6UO;B!S=&]C:R!W
M97)E(&]U='-T86YD:6YG('5N9&5R('1H92`R,#`V($-E;&QE8W1A<B!0;&%N
M(&%S(&]F#0I$96-E;6)E<B`S,2P@,C`Q,"!A;F0@,C`P.2P@<F5S<&5C=&EV
M96QY+B8C>$$P.R!4:&5S92!O<'1I;VYS#0IG96YE<F%L;'D@=F5S=&5D(&%N
M;G5A;&QY(&]V97(@9F]U<B!Y96%R<R!A;F0@97AP:7)E(&]N('1H92!E:6=H
M=&@-"F%N;FEV97)S87)Y(&]F('1H92!G<F%N="!D871E+B8C>$$P.R!.;R!O
M<'1I;VYS('=E<F4@9W)A;G1E9"!U;F1E<@T*=&AE(#(P,#8@0V5L;&5C=&%R
M(%!L86X@9'5R:6YG(#(P,3`@;W(@,C`P.2XF(WA!,#L@5&AE<F4@:&%V92!B
M965N#0IN;R!E>&5R8VES97,@;V8@;W!T:6]N<R!I<W-U960@=6YD97(@=&AE
M(#(P,#8@0V5L;&5C=&%R(%!L86XN)B-X03`[#0I/;B!-87)C:"`Q-RP@,C`Q
M,2P@:6X@8V]N=&5M<&QA=&EO;B!O9B!T:&4@06-Q=6ES:71I;VXL($-E;&QE
M8W1A<@T*=&5R;6EN871E9"!T:&4@<F5M86EN:6YG(&]P=&EO;G,@;W5T<W1A
M;F1I;F<@=6YD97(@=&AE(#(P,#8-"D-E;&QE8W1A<B!0;&%N(&%S(&]F('1H
M870@9&%T92X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE)SX-
M"C(P,#@@4W1O8VL@26YC96YT:79E(%!L86X\+V9O;G0^+B8C>$$P.R!4:&4@
M,C`P."!3=&]C:R!);F-E;G1I=F4-"E!L86X@*'1H92`F(W@R,#%#.S(P,#@@
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M8W0@=&\@9W)A;G0-"G5N9&5R('1H92`R,#`X(%!L86X@=V%S(#@R,RPY,S`N
M)B-X03`[($-E;&QE8W1A<B!G<F%N=&5D(&$@=&]T86P@;V8-"C,X,BPR,C,@
M;W!T:6]N<R!U;F1E<B!T:&4@,C`P."!0;&%N+B8C>$$P.R!!('1O=&%L(&]F
M(#$V,BPS,#`@86YD#0HS,#`L-#@X(&]P=&EO;G,@=&\@<'5R8VAA<V4@<VAA
M<F5S(&]F($-E;&QE8W1A<B8C>#(P,3D[<R!C;VUM;VX-"G-T;V-K('=E<F4@
M;W5T<W1A;F1I;F<@87,@;V8@1&5C96UB97(@,S$L(#(P,3`@86YD(#(P,#DL
M#0IR97-P96-T:79E;'DN)B-X03`[(%1H97-E(&]P=&EO;G,@9V5N97)A;&QY
M('9E<W1E9"!A;FYU86QL>2!O=F5R#0IF;W5R('EE87)S(&%N9"!E>'!I<F4@
M;VX@=&AE('1E;G1H(&%N;FEV97)S87)Y(&]F('1H92!G<F%N=`T*9&%T92XF
M(WA!,#L@)B-X03`[1'5R:6YG(#(P,#DL(#DP+#DR.2!O<'1I;VYS('=E<F4@
M9W)A;G1E9"!U;F1E<@T*=&AE(#(P,#@@4&QA;BXF(WA!,#L@1'5R:6YG(#(P
M,3`L(&YO(&]P=&EO;G,@=V5R92!G<F%N=&5D('5N9&5R('1H90T*,C`P."!0
M;&%N+B!.;R!O<'1I;VYS(&AA=F4@8F5E;B!E>&5R8VES960N)B-X03`[($]N
M($UA<F-H(#$W+"`R,#$Q+`T*:6X@8V]N=&5M<&QA=&EO;B!O9B!T:&4@06-Q
M=6ES:71I;VXL($-E;&QE8W1A<B!T97)M:6YA=&5D('1H90T*<F5M86EN:6YG
M(&]P=&EO;G,@;W5T<W1A;F1I;F<@=6YD97(@=&AE(#(P,#@@4&QA;B!A<R!O
M9B!T:&%T#0ID871E+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^07,-
M"F]F($1E8V5M8F5R(#,Q+"`R,#$P+"!A;B!A9V=R96=A=&4@;V8@,2PP-C8L
M.30Q('-H87)E<R!W97)E#0IA=F%I;&%B;&4@9F]R(&=R86YT('5N9&5R('1H
M92`R,#`V($-E;&QE8W1A<B!0;&%N(&%N9"`R,#`X#0I0;&%N+CPO9F]N=#X\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^0V5L;&5C=&%R)B-X,C`Q.3MS#0I";V%R
M9"!O9B!$:7)E8W1O<G,@9&5T97)M:6YE9"!E>&5R8VES92!P<FEC97,@86YD
M('9E<W1I;F<@<&5R:6]D<PT*;VX@=&AE(&1A=&4@;V8@9W)A;G0L('-U8FIE
M8W0@=&\@=&AE('!R;W9I<VEO;G,@;V8@=&AE(#(P,#8-"D-E;&QE8W1A<B!0
M;&%N(&%N9"`R,#`X(%!L86XN)B-X03`[($]P=&EO;G,@:&%V92!B965N(&=R
M86YT960@870@;W(-"F%B;W9E('1H92!E<W1I;6%T960@9F%I<BUM87)K970@
M=F%L=64@;V8@=&AE(&-O;6UO;B!S=&]C:R!A="!T:&4-"F=R86YT(&1A=&4N
M($]P=&EO;G,@9W)A;G1E9"!P=7)S=6%N="!T;R!T:&4@,C`P-B!#96QL96-T
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M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^26X-"F-O
M;FYE8W1I;VX@=VET:"!T:&4@06-Q=6ES:71I;VXL('1H92!#;VUP86YY(&%S
M<W5M960@;W!T:6]N<R!T;PT*<'5R8VAA<V4@-#DL,34Y('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL@870@97AE<F-I<V4@<')I8V5S(')A;F=I;F<-"F9R;VT@
M)FYB<W`[)#$N-3,@=&\@)FYB<W`[)#$L,#<R+C4S+CPO9F]N=#X\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A
M;&EC.R!$25-03$%9.B!I;FQI;F4G/@T*,C`P-B!.;W9E;&]S(%-T;V-K($]P
M=&EO;B!0;&%N+CPO9F]N=#XF(WA!,#L@1F]L;&]W:6YG('1H90T*06-Q=6ES
M:71I;VXL(&]P=&EO;B!G<F%N=',@=&\@9&ER96-T;W)S(&%N9"!E;7!L;WEE
M97,@=VEL;"!B92!M861E#0IU;F1E<B!T:&4@3F]V96QO<R!4:&5R87!E=71I
M8W,@,C`P-B!3=&]C:R!);F-E;G1I=F4@4&QA;B`H=&AE#0HF(W@R,#%#.U!L
M86XF(W@R,#%$.RDN)B-X03`[($]N($UA>2`Q."P@,C`Q,2P@=&AE($)O87)D
M(&]F($1I<F5C=&]R<PT*;V8@=&AE($-O;7!A;GD@87!P<F]V960@8V5R=&%I
M;B!A;65N9&UE;G1S('1O('1H92!0;&%N('1O+"!A;6]N9PT*;W1H97(@=&AI
M;F=S+"!I;F-R96%S92!T:&4@86=G<F5G871E(&YU;6)E<B!O9B!S:&%R97,@
M;V8@=&AE#0I#;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:R!R97-E<G9E
M9"!F;W(@:7-S=6%N8V4@=6YD97(@=&AE(%!L86X-"BAI;F-L=61I;F<@86YY
M('-H87)E<R!T:&%T(&AA=F4@86QR96%D>2!B965N(&ES<W5E9"!T:&5R975N
M9&5R*2P@=&\-"C<L,#`P+#`P,"!A;F0@<F5M;W9E('1H92`W-3`L,#`P('-H
M87)E(&%N;G5A;"!I;F1I=FED=6%L(&QI;6ET871I;VX-"F]N(&=R86YT<R!U
M;F1E<B!T:&4@4&QA;BXF(WA!,#L@3VX@2G5N92`S,"P@,C`Q,2P@=&AE#0I#
M;VUP86YY)B-X,C`Q.3MS('-T;V-K:&]L9&5R<R!R871I9FEE9"!T:&]S90T*
M86UE;F1M96YT<RX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D$-"G1O
M=&%L(&]F(#<L,#`P+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%R92!R
M97-E<G9E9"!F;W(@:7-S=6%N8V4-"G5N9&5R('1H92!0;&%N(&9O<B!G<F%N
M=',@;V8@:6YC96YT:79E(&]R(&YO;G%U86QI9FEE9"!S=&]C:PT*;W!T:6]N
M<RP@<FEG:'1S('1O('!U<F-H87-E(')E<W1R:6-T960@86YD('5N<F5S=')I
M8W1E9"!S:&%R97,@;V8-"F-O;6UO;B!S=&]C:RP@<W1O8VL@87!P<F5C:6%T
M:6]N(')I9VAT<R!A;F0@<&5R9F]R;6%N8V4@<VAA<F4-"F=R86YT<RXF(WA!
M,#L@02!C;VUM:71T964@;V8@=&AE(&)O87)D(&]F(&1I<F5C=&]R<R!D971E
M<FUI;F5S#0IE>&5R8VES92!P<FEC97,L('9E<W1I;F<@<&5R:6]D<R!A;F0@
M86YY('!E<F9O<FUA;F-E(')E<75I<F5M96YT<PT*;VX@=&AE(&1A=&4@;V8@
M9W)A;G0L('-U8FIE8W0@=&\@=&AE('!R;W9I<VEO;G,@;V8@=&AE(%!L86XN
M)B-X03`[#0I/<'1I;VYS(&%R92!G<F%N=&5D(&%T(&]R(&%B;W9E('1H92!F
M86ER(&UA<FME="!V86QU92!O9B!T:&4@8V]M;6]N#0IS=&]C:R!A="!T:&4@
M9W)A;G0@9&%T92!A;F0@97AP:7)E(&]N('1H92!T96YT:"!A;FYI=F5R<V%R
M>2!O9B!T:&4-"F=R86YT(&1A=&4N)B-X03`[(%9E<W1I;F<@<&5R:6]D<R!A
M<F4@9V5N97)A;&QY(&)E='=E96X@;VYE(&%N9`T*9F]U<B!Y96%R<RXF(WA!
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M03`[($%S(&]F#0I397!T96UB97(@,S`L(#(P,3$L('1H97)E(&%R92!A;B!A
M9V=R96=A=&4@;V8@,RPT-S8L,3$R('-H87)E<PT*879A:6QA8FQE(&9O<B!G
M<F%N="!U;F1E<B!T:&4@4&QA;BX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"D%C8V]U;G1I;F<@9F]R(%-T;V-K
M+4)A<V5D($-O;7!E;G-A=&EO;CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^16UP;&]Y964-"G-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!I<R!A8V-O
M=6YT960@9F]R(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4-"F=U:61A;F-E(&]F
M($9!4T(@05-#(%1O<&EC(#<Q."P@/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,
M13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4G/D-O;7!E;G-A=&EO;B`F(W@R
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M<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&ES(&%C8V]U;G1E9`T*9F]R(&EN
M(&%C8V]R9&%N8V4@=VET:"!T:&4@9W5I9&%N8V4@;V8@1D%30B!!4T,@5&]P
M:6,@-3`U+`T*/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$
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M96UP;&]Y965S+CPO9F]N=#X\+V1I=CX-"CQB<B`O/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
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M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,"4^
M#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E(&%L:6=N/3-$;&5F=#X\9F]N="!S
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M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(R)2!C;VQS<&%N/3-$-CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@-"XV<'0G(&%L
M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I.:6YE($UO;G1H<R!%;F1E9#PO9F]N
M=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M-"XV<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I397!T96UB97(@,S`L
M/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`T+C9P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"BAU;F%U9&ET
M960I/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
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M1TA4.B`T+C9P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"EEE87(@16YD
M960\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
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M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-
M"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N
M/3-$,CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XV
M<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I#=6UU;&%T:79E($1E=F5L
M;W!M96YT+2!3=&%G92!097)I;V0@9G)O;2!.;W9E;6)E<B`W+"`R,#`R('1H
M<F]U9V@-"D1E8V5M8F5R(#,Q+#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P
M>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-#`E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XV<'0G(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^#0I#;VYS;VQI9&%T960\+V9O;G0^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N-G!T)R!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/@T*,C`Q,3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XV<'0G(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^#0HR,#$P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4
M.B!B;VQD)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`Q+C9P="<@86QI9VX],T1C96YT97(^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SX-"C(P,3`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,"4@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#$N-G!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*,C`P
M.3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C
M;VQS<&%N/3-$,CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,2XV<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HR,#$P/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
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M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+C9P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%;7!L;WEE
M90T*86YD(&1I<F5C=&]R('-T;V-K(&]P=&EO;B!G<F%N=',Z/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3`E(&-O;'-P86X],T0R(&%L:6=N/3-$;&5F=#X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
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M;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&%L:6=N
M/3-$;&5F=#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3`E(&-O;'-P86X],T0R(&%L:6=N/3-$;&5F=#X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
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M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&%L:6=N/3-$
M;&5F=#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P
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M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E
M(&-O;'-P86X],T0R(&%L:6=N/3-$;&5F=#X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
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M;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
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M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXQ,C$L,SDS/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT
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M03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#0P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$
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M5"U325I%.B`Q,'!T)SXR-S@L-CDT/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,CDQ
M+#4T.3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
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M.B`Q,'!T)SXQ+#4W-RPS,#,\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-#`E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT-S$L,3<T/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS,S$L
M,3@V/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXS-3,L,S0P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXU,#$L.3DY/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+#@W-2PV.#D\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
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M=#L@34%21TE.+5))1TA4.B`Q+C9P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY.;VXM96UP;&]Y964-"F-O;G-U
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M5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#DE/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
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M1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#DE/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
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M;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#DE/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
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M;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#DE/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P
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M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#DE/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E(&%L:6=N/3-$;&5F
M=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[($U!4D=)3BU224=(5#H@,2XV<'0G
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^4F5S96%R8V@-"F%N9"!D979E;&]P;65N=#PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M($9/3E0M4TE:13H@,3!P="<^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-#`E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[($U!4D=)
M3BU224=(5#H@,2XV<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^1V5N97)A;`T*86YD(&%D;6EN:7-T<F%T:79E
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^,3,W+#8S,3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X,C`Q-#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG
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M25I%.B`Q,'!T)SXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
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M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C
M;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ.#0L-#@R/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X,C`Q-#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(W@R,#$T.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/C<Q+#<R-#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#0P)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP
M="<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D
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M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
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M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
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M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
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M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0T,"4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`Q+C9P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4;W1A;`T*<W1O8VLM8F%S960@8V]M
M<&5N<V%T:6]N/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
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M5$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
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M5$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/C,S,2PQ.#8\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#DE/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS
M-3,L,S0P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-3`R+#$Y.3PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
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M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C$L.30W+#0Q,SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^3VX-"DIU;'D@,30L(#(P,3`L('1H92!E>'!I<F%T
M:6]N(&1A=&4@;V8@=F5S=&5D(&]P=&EO;G,@:&5L9"!B>2!A#0IF;W)M97(@
M96UP;&]Y964@=V%S(&5X=&5N9&5D('5N=&EL($IU;'D@."P@,C`Q-2XF(WA!
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M;B!E>'!E;G-E(&]F#0IA<'!R;WAI;6%T96QY)B-X03`[)FYB<W`[)#(P+#`P
M,"!W87,@<F5C;W)D960@:6X@8V]N;F5C=&EO;B!W:71H('1H90T*;6]D:69I
M8V%T:6]N+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^5&AE#0I#;VUP
M86YY(&=R86YT960@,RPT.38L-#`P('-T;V-K(&]P=&EO;G,@=&\@96UP;&]Y
M965S(&%N9`T*;F]N+65M<&QO>65E<R!D=7)I;F<@=&AE(&YI;F4@;6]N=&AS
M(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,2!U;F1E<@T*=&AE(%!L86XN)B-X
M03`[(%1H92!#;VUP86YY(&ES<W5E9"!O<'1I;VYS('1O('!U<F-H87-E(&$@
M=&]T86P@;V8-"C(P,"PP,#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!T;R!N
M;VXM96UP;&]Y965S(&]U='-I9&4@;V8@86YY#0IF;W)M86QI>F5D('!L86XL
M(&)U="`Q,#`L,#`P('=E<F4@9F]R9F5I=&5D(&%S(&$@<F5S=6QT(&]F('1H
M90T*8V%N8V5L;&%T:6]N(&%N9"!R97!L86-E;65N="!A<R!D97-C<FEB960@
M8F5L;W<N)B-X03`[($5X97)C:7-E#0IP<FEC97,@9F]R(&%L;"!G<F%N=',@
M;6%D92!I;B!T:&4@9'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E9`T*4V5P
M=&5M8F5R(#,P+"`R,#$Q('=E<F4@97%U86P@=&\@=&AE(&UA<FME="!V86QU
M92!O9B!T:&4-"D-O;7!A;GDF(W@R,#$Y.W,@8V]M;6]N('-T;V-K(&]N('1H
M92!D871E(&]F(&=R86YT+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M3VX-"DUA>2`Q."P@,C`Q,2P@=&AE($-O;7!A;GD@8V%N8V5L;&5D(#$P,"PP
M,#`@;W!T:6]N<R!O<FEG:6YA;&QY#0IG<F%N=&5D(&]N($%P<FEL(#(U+"`R
M,#$Q('=I=&@@86X@97AE<F-I<V4@<')I8V4@;V8@)FYB<W`[)#,N,#`@<&5R
M('-H87)E#0IA;F0@:7-S=65D(#$P,"PP,#`@<F5P;&%C96UE;G0@<W1O8VL@
M;W!T:6]N(&%W87)D<R!W:71H(&%N(&5X97)C:7-E#0IP<FEC92!O9B`F;F)S
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M;65N=&%L#0IS=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS92!O9B`F
M;F)S<#LD-"PT.30@=V%S(')E8V]R9&5D(&EN#0IC;VYN96-T:6]N('=I=&@@
M=&AE(&UO9&EF:6-A=&EO;BX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
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M4$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M5%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4G/@T*5F%L=6%T:6]N(&%N
M9"!A;6]R=&EZ871I;VX@;65T:&]D/"]F;VYT/BX@5&AE(&9A:7(@=F%L=64@
M;V8@96%C:`T*<W1O8VL@87=A<F0@:7,@97-T:6UA=&5D(&]N('1H92!G<F%N
M="!D871E('5S:6YG('1H92!";&%C:RU38VAO;&5S#0IO<'1I;VXM<')I8VEN
M9R!M;V1E;"XF(WA!,#L@5&AE(&5S=&EM871E9"!F86ER('9A;'5E(&]F(&5M
M<&QO>65E#0IS=&]C:R!O<'1I;VYS(&ES(&%M;W)T:7IE9"!T;R!E>'!E;G-E
M('5S:6YG('1H92!S=')A:6=H="UL:6YE#0IM971H;V0@;W9E<B!T:&4@=F5S
M=&EN9R!P97)I;V0N/"]F;VYT/B`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^5&AE#0IE<W1I;6%T960@9F%I<B!V86QU92!O9B!T:&4@;F]N
M+65M<&QO>65E(&]P=&EO;G,@:7,@86UO<G1I>F5D('1O#0IE>'!E;G-E(&]V
M97(@=&AE('!E<FEO9"!D=7)I;F<@=VAI8V@@82!N;VXM96UP;&]Y964@:7,@
M<F5Q=6ER960@=&\-"G!R;W9I9&4@<V5R=FEC97,@9F]R('1H92!A=V%R9"`H
M=7-U86QL>2!T:&4@=F5S=&EN9PT*<&5R:6]D*2X\+V9O;G0^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
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M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL
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M=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
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M(&%S(&1E<V-R:6)E9"!I;B!T:&4@4T5#)B-X,C`Q.3MS(%-T869F#0I!8V-O
M=6YT:6YG($)U;&QE=&EN<R`Q,#<@86YD(#$Q,"P@87,@=&AE($-O;7!A;GD@
M:&%S(&AA9"!A#0IS:6=N:69I8V%N="!C:&%N9V4@:6X@:71S(&)U<VEN97-S
M(&]P97)A=&EO;G,@87,@<F5S=6QT(&]F('1H90T*06-Q=6ES:71I;VX@86YD
M('1H92!H:7-T;W)I8V%L(&5X<&5R:65N8V4@:7,@;F]T(&EN9&EC871I=F4@
M;V8@=&AE#0IE>'!E8W1E9"!B96AA=FEO<B!I;B!T:&4@9G5T=7)E+B!4:&4@
M97AP96-T960@=&5R;2P@8V%L8W5L871E9`T*=6YD97(@=&AE('-I;7!L:69I
M960@;65T:&]D+"!I<R!A<'!L:65D('1O(&=R;W5P<R!O9B!S=&]C:R!O<'1I
M;VYS#0IT:&%T(&AA=F4@<VEM:6QA<B!C;VYT<F%C='5A;"!T97)M<RX@57-I
M;F<@=&AI<R!M971H;V0L('1H90T*97AP96-T960@=&5R;2!I<R!D971E<FUI
M;F5D('5S:6YG('1H92!A=F5R86=E(&]F('1H92!V97-T:6YG('!E<FEO9`T*
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M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^)B-X03`[/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN92<^#0I&
M;W)F96ET=7)E<RX\+V9O;G0^("8C>$$P.R!3=&]C:RUB87-E9"!C;VUP96YS
M871I;VX@97AP96YS92!I<PT*<F5C;W)D960@;VYL>2!F;W(@=&AO<V4@87=A
M<F1S('1H870@87)E(&5X<&5C=&5D('1O('9E<W0N)B-X03`[#0I&05-"($%3
M0R!4;W!I8R`W,3@@<F5Q=6ER97,@9F]R9F5I='5R97,@=&\@8F4@97-T:6UA
M=&5D(&%T('1H92!T:6UE#0IO9B!G<F%N="!A;F0@<F5V:7-E9"P@:68@;F5C
M97-S87)Y+"!I;B!S=6)S97%U96YT('!E<FEO9',@:68@86-T=6%L#0IF;W)F
M96ET=7)E<R!D:69F97(@9G)O;2!T:&]S92!E<W1I;6%T97,N)B-X03`[(%1H
M92!T97)M#0HF(W@R,#%#.V9O<F9E:71U<F5S)B-X,C`Q1#L@:7,@9&ES=&EN
M8W0@9G)O;0T*)B-X,C`Q0SMC86YC96QL871I;VYS)B-X,C`Q1#L@;W(@)B-X
M,C`Q0SME>'!I<F%T:6]N<R8C>#(P,40[(&%N9`T*<F5P<F5S96YT<R!O;FQY
M('1H92!U;G9E<W1E9"!P;W)T:6]N(&]F('1H92!S=7)R96YD97)E9`T*;W!T
M:6]N+B8C>$$P.R!!;B!A;FYU86P@9F]R9F5I='5R92!R871E(&]F(#`E('=A
M<R!A<'!L:65D('1O(&%L;`T*=6YV97-T960@;W!T:6]N<R!A<R!O9B!$96-E
M;6)E<B`S,2P@,C`Q,"!A<R!#96QL96-T87(@:&%D#0IE>'!E<FEE;F-E9"!V
M97)Y(&9E=R!F;W)F96ET=7)E<R!T:')O=6=H(#(P,#D@86YD('1H97)E('=A
M<PT*:6YS=69F:6-I96YT(&AI<W1O<GD@=&\@9&5V96QO<"!A;B!A8V-U<F%T
M92!E<W1I;6%T92!O9B!F=71U<F4-"F9O<F9E:71U<F5S+B8C>$$P.R!!;B!A
M;FYU86P@9F]R9F5I='5R92!R871E(&]F(#`E('=A<R!A<'!L:65D('1O#0IA
M;&P@=6YV97-T960@;W!T:6]N<R!A<R!O9B!397!T96UB97(@,S`L(#(P,3$@
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M("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY4:&4-"F9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S('=E:6=H
M=&5D+6%V97)A9V4@=F%L=65S(&%N9"!A<W-U;7!T:6]N<PT*=7-E9"!F;W(@
M;W!T:6]N<R!G<F%N=&5D('1O(&5M<&QO>65E<RP@9&ER96-T;W)S(&%N9"!C
M;VYS=6QT86YT<R!I;@T*=&AE('!E<FEO9',@:6YD:6-A=&5D.CPO9F]N=#X\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
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M24=..B!C96YT97(G/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)2!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
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M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4G/DYI;F4@36]N=&AS/"]F;VYT/CPO9F]N=#X\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE)SY%;F1E9"8C>$$P.U-E<'1E;6)E<CPO9F]N=#X\+V9O;G0^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN92<^,S`L)B-X03`[,C`Q,3PO9F]N=#X\+V9O;G0^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN92<^*'5N875D:71E9"D\+V9O;G0^/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
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M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4G/EEE87(F(WA!,#M%;F1E9#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
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M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4G/C(P,#D\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
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M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^5F]L871I;&ET>3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXX-3PO
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M=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E)I<VLM9G)E90T*:6YT97)E
M<W0@<F%T93PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B4\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,B4@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+C<R)2TQ+CDQ/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXE/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#<P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%>'!E8W1E9`T*;&EF92`H>65A<G,I
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^-2XU#0HF(W@R,#$S.R`V+C(U/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0W,"4@86QI9VX],T1L969T/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
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M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXP/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXE/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M+5-)6D4Z(#$P<'0G/C`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B4\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$;&5F
M=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C$N-#4\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(]
M,T1W:&ET93X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4@86QI
M9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P
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M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
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M/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&5R90T*=V5R
M92!N;R!S=&]C:R!O<'1I;VYS(&=R86YT960@:6X@=&AE(&YI;F4@;6]N=&AS
M(&5N9&5D(%-E<'1E;6)E<@T*,S`L(#(P,3`@;W(@=&AE('EE87(@96YD960@
M1&5C96UB97(@,S$L(#(P,3`N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M5T5)1TA4.B!B;VQD)SY3=&]C:PT*3W!T:6]N($%C=&EV:71Y/"]F;VYT/CPO
M9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^00T*<W5M;6%R>2!O9B!S=&]C
M:R!O<'1I;VX@86-T:79I='D@=6YD97(@<W1O8VL@;W!T:6]N('!L86YS(&ES
M(&%S#0IF;VQL;W=S.CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/"$M+45&4&QA
M8V5H;VQD97(M+3X\8G(@+SX\+V1I=CX-"CQD:78@86QI9VX],T1C96YT97(^
M#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$.34E/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)2!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A
M;CTS1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I3:&%R97,\+V9O;G0^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"DES<W5A8FQE)B-X03`[57!O
M;CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*17AE<F-I<V4F
M(WA!,#MO9CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*3W5T
M<W1A;F1I;F<\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"D]P
M=&EO;G,\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$
M,CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*5V5I9VAT960\+V9O;G0^/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)SX-"D%V97)A9V4\+V9O;G0^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M5T5)1TA4.B!B;VQD)SX-"D5X97)C:7-E)B-X03`[4')I8V4\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E
M<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/@T*5V5I9VAT960\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4
M.B!B;VQD)SX-"D%V97)A9V4\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
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M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/@T*0V]N=')A8W1E9#PO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/@T*5&5R;28C>$$P.VEN/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^#0I996%R<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O
M;'-P86X],T0R/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I!9V=R96=A=&4\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"DEN=')I;G-I8SPO9F]N
M=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*5F%L=64\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4R)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M.7!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#EP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A
M;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
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M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3(E(&%L:6=N/3-$;&5F=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`Y<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P
M.R0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^,BXU,CPO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$.24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
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M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G
M8V]L;W(],T0C0T-&1D-#/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@.7!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY&;W)F96ET960\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
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M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,3(L-C4S/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT
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M/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS+C`T/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)2!A;&EG;CTS1&QE9G0^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M.7!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M3W5T<W1A;F1I;F<-"F%T($IA;G5A<GD@,2P@,C`P.3PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE(&%L:6=N
M/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
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M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
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M03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@.7!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY'<F%N=&5D/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE(&%L:6=N/3-$<FEG
M:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^.3`L.3(Y/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H
M=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF;F)S<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C`N-S8\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
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M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
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M.B`Q,'!T)SXF(WA!,#L-"B8C>$$P.R!&;W)F96ET960\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H
M=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXH.2PQ.30\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/BD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(N
M-S(\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
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M1$5.5#H@+3EP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]U='-T86YD:6YG#0IA="!$96-E;6)E
M<B`S,2P@,C`P.3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS1')I
M9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I
M9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B9N8G-P.R0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,B4@86QI
M9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3EP=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY#86YC96QE9#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@R,C(L-30W/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXI/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR+C8S/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#DE(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
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M25I%.B`Q,'!T)SY/=71S=&%N9&EN9PT*870@1&5C96UB97(@,S$L(#(P,3`\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.R0\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$.24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L
M;W(],T1W:&ET93X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,B4@
M86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3EP
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.PT*)B-X03`[($-A;F-E;&5D/"]F;VYT/CPO
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH-S8Y+#$X.3PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B9N
M8G-P.R0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
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M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
M(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%1%6%0M24Y$14Y4.B`P<'0[(%!!1$1)3D<M3$5&5#H@,'!T.R!-
M05)'24XM3$5&5#H@-#0V<'0[($U!4D=)3BU224=(5#H@,'!T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0U,B4^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@.7!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^3W!T:6]N<PT*86-Q=6ER960@
M:6X@8V]N;F5C=&EO;B!W:71H(&$@8G5S:6YE<W,@8V]M8FEN871I;VX\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX]
M,T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXT.2PQ-3D\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO9&EV
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M.24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G
M8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!415A4+4E.1$5.5#H@,'!T.R!0041$24Y'+4Q%1E0Z(#!P=#L@34%21TE.
M+4Q%1E0Z(#0T-G!T.R!-05)'24XM4DE'2%0Z(#!P="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-3(E/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#EP=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D=R86YT960\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS+#8Y
M-BPT,#`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/C$N-#4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M1E0Z(#EP=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/D-A;F-E;&5D/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*#$R+#DR
M,3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
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M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[
M)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,3(N,C$\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
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M5"U)3D1%3E0Z(#!P=#L@4$%$1$E.1RU,1494.B`P<'0[($U!4D=)3BU,1494
M.B`T-#9P=#L@34%21TE.+5))1TA4.B`P<'0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#4R)3X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`Y<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY&;W)F96ET960\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
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M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXH,3`P+#`P,#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS1')I
M9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/C,N,#`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L
M;W(],T0C0T-&1D-#/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)2!A;&EG;CTS1&QE9G0^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M.7!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M3W5T<W1A;F1I;F<-"F%T(%-E<'1E;6)E<B`S,"P@,C`Q,2`H=6YA=61I=&5D
M*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
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M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,BXS-3PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P
M>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P
M>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G
M8V]L;W(],T1W:&ET93X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U
M,B4@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
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M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
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M3BU,1494.B`Y<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E9E<W1E9"P-"D1E
M8V5M8F5R(#,Q+"`R,#$P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXW-#,L-#4P/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/C(N-CD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
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M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)FYB<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(W@R,#$T.SPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#4R)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M.7!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^56YV97-T960L#0I$96-E;6)E<B`S,2P@,C`Q
M,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
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M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU+C`X/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^#0HF;F)S
M<#LD/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$.24^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
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M<'0G/@T*)B-X,C`Q-#L\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS
M1"-#0T9&0T,^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3(E(&%L:6=N/3-$;&5F=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TY<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@.7!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%>&5R
M8VES86)L90T*870@1&5C96UB97(@,S$L(#(P,3`\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U
M8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/C<T,RPT-3`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B9N8G-P.R0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE
M(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R
M:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXT+C`W/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY697-T960L#0I397!T
M96UB97(@,S`L(#(P,3$@*'5N875D:71E9"D\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/C,S,BPV.#4\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB
M<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI
M9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXQ,"XT-SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@
M86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXY+C(U/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U
M8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
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M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X,C`Q-#L\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G
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M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/E5N=F5S=&5D+`T*4V5P=&5M8F5R(#,P+"`R,#$Q("AU;F%U
M9&ET960I/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T
M<'@@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L
M92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS
M+#(Y.2PY-3,\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+C4S/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CDN-C,\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS
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M1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX-"B9N8G-P.R0\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^#0HF(W@R,#$T.SPO9F]N=#X\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY%>&5R8VES86)L90T*870@4V5P=&5M8F5R(#,P+"`R,#$Q("AU;F%U9&ET
M960I/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
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M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/C,S,BPV.#4\+V9O;G0^/"]F;VYT/CPO9F]N=#X\+V1I=CX-
M"CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#LF;F)S<#LD
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS
M1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*,3`N-#<\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]D:78^#0H\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^#0HY+C(U/"]F;VYT/CPO9F]N=#X\+V1I=CX-
M"CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L
M92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M;F)S<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
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M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
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M;G,N)B-X03`[07,@;V8@1&5C96UB97(@,S$L(#(P,3`L('1H92!E<W1I;6%T
M960@9F%I<BUM87)K970-"G9A;'5E(&]F($-E;&QE8W1A<B8C>#(P,3D[<R!C
M;VUM;VX@<W1O8VL@870@=&AE(&5N9"!O9B!T:&4@<&5R:6]D<PT*<VAO=VX@
M=V%S(&QE<W,@=&AA;B!T:&4@97AE<F-I<V4@<')I8V4@;V8@=&AE('5N9&5R
M;'EI;F<@;W!T:6]N<RP-"F%S('-U8V@L('1H92!A9V=R96=A=&4@:6YT<FEN
M<VEC('9A;'5E(&ES("9N8G-P.R0P+B8C>$$P.R!!<R!O9B!397!T96UB97(-
M"C,P+"`R,#$Q+"!T:&4@9F%I<B!V86QU92!O9B!T:&4@0V]M<&%N>28C>#(P
M,3D[<R!C;VUM;VX@<W1O8VL@=V%S#0IL97-S('1H86X@=&AE(&5X97)C:7-E
M('!R:6-E(&]F('1H92!U;F1E<FQY:6YG(&]P=&EO;G,L(&%S('-U8V@L#0IT
M:&4@86=G<F5G871E(&EN=')I;G-I8R!V86QU92!W87,@)FYB<W`[)#`N)B-X
M03`[(%1H97)E(&AA=F4@8F5E;B!N;PT*;W!T:6]N(&5X97)C:7-E<R!T;R!D
M871E+B!3:&%R97,@;V8@8V]M;6]N('-T;V-K(&ES<W5E9"!U<&]N('1H90T*
M97AE<F-I<V4@;V8@;W!T:6]N<R!A<F4@9G)O;2!A=71H;W)I>F5D(&)U="!U
M;FES<W5E9`T*<VAA<F5S+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^)B-X
M03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY4:&4-"G=E:6=H=&5D+6%V97)A9V4@9W)A;G0M9&%T92!F86ER
M('9A;'5E(&]F(&]P=&EO;G,@9W)A;G1E9"!D=7)I;F<-"G1H92!Y96%R(&5N
M9&5D($1E8V5M8F5R(#,Q+"`R,#`Y(&%N9"!F;W(@=&AE('!E<FEO9"!.;W9E
M;6)E<B`R+`T*,C`P,B!T;R!$96-E;6)E<B`S,2P@,C`P.2!W87,@)FYB<W`[
M)#`N-34@86YD("9N8G-P.R0Q+CDP+"!R97-P96-T:79E;'DN)B-X03`[#0I4
M:&5R92!W97)E(&YO(&]P=&EO;G,@9W)A;G1E9"!D=7)I;F<@=&AE('EE87(@
M96YD960@1&5C96UB97(@,S$L#0HR,#$P+B8C>$$P.R!4:&4@=&]T86P@9F%I
M<B!V86QU92!O9B!S:&%R97,@=F5S=&5D(&1U<FEN9R!$96-E;6)E<@T*,S$L
M(#(P,3`@86YD(#(P,#D@86YD(&9O<B!T:&4@<&5R:6]D($YO=F5M8F5R(#(L
M(#(P,#<@*&1A=&4@;V8-"FEN8V5P=&EO;BD@=&\@1&5C96UB97(@,S$L(#(P
M,3`@=V%S("9N8G-P.R0Q.3DL-C`P+"`F;F)S<#LD,3@U+#8P,"!A;F0-"B9N
M8G-P.R0R+#`U,"PP,#`L(')E<W!E8W1I=F5L>2XF(WA!,#L@)B-X03`[5&AE
M('=E:6=H=&5D+6%V97)A9V4-"F=R86YT+61A=&4@9F%I<B!V86QU92!O9B!V
M97-T960@86YD('5N=F5S=&5D(&]P=&EO;G,@;W5T<W1A;F1I;F<@870-"D1E
M8V5M8F5R(#,Q+"`R,#$P(&%N9"`R,#`Y('=A<R`F;F)S<#LD,BXP,2!A;F0@
M)FYB<W`[)#$N.3$@86YD("9N8G-P.R0Q+C@U(&%N9"`F;F)S<#LD,2XX."P-
M"G)E<W!E8W1I=F5L>2X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D%S
M#0IO9B!$96-E;6)E<B`S,2P@,C`Q,"P@=&AE<F4@=V%S(&%P<')O>&EM871E
M;'D@)FYB<W`[)#4X+#`P,"!A;F0@)FYB<W`[)#`@;V8-"G1O=&%L('5N<F5C
M;V=N:7IE9"!C;VUP96YS871I;VX@8V]S="!R96QA=&5D('1O('5N=F5S=&5D
M#0IS=&]C:RUB87-E9"!C;VUP96YS871I;VX@87)R86YG96UE;G1S(')E;&%T
M960@=&\@96UP;&]Y965S(&%N9`T*;F]N+65M<&QO>65E<RP@<F5S<&5C=&EV
M96QY+B8C>$$P.R!/9B!T:&4@=&]T86P@=6YR96-O9VYI>F5D(&%M;W5N=`T*
M87,@;V8@1&5C96UB97(@,S$L(#(P,3`L(&%L;"!W87,@<F5C;V=N:7IE9"!I
M;B!T:&4@;FEN92!M;VYT:',-"F5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,2X\
M+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]N#0I-87)C:"`T+"`R,#$Q
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M+"`R,#$Q('=O=6QD('1H96X@8F4-"G1E<FUI;F%T960N)B-X03`[($]N($UA
M<F-H(#$W+"`R,#$Q+"!#96QL96-T87(@=&5R;6EN871E9"!A;&P-"F]U='-T
M86YD:6YG(&]P=&EO;G,N)B-X03`[(%1H92!R96UA:6YI;F<@=6YA;6]R=&EZ
M960@8V]M<&5N<V%T:6]N#0IE>'!E;G-E(&]F("9N8G-P.R0U."PP,#`@=V%S
M(')E8V]R9&5D(')E;&%T960@=&\@=&AE(&%C8V5L97)A=&EO;B!O9@T*;W5T
M<W1A;F1I;F<@;W!T:6]N<R!I;B!T:&4@<75A<G1E<B!E;F1E9"!-87)C:"`S
M,2P@,C`Q,2XF(WA!,#L@3F\-"F%D9&ET:6]N86P@8V]M<&5N<V%T:6]N(&5X
M<&5N<V4@=V%S(')E8V]R9&5D(')E;&%T960@=&\@=&AE#0IA8V-E;&5R871I
M;VX@;V8@=6YV97-T960@<VAA<F5S(&%S('1H92!A8V-E;&5R871I;VX@9&ED
M(&YO=`T*<F5P<F5S96YT(&$@;6]D:69I8V%T:6]N('1O('1H92!O<FEG:6YA
M;"!T97)M<R!O9B!T:&4-"F]P=&EO;G,N/"]F;VYT/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R
M("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY!<PT*;V8@4V5P=&5M8F5R(#,P+"`R,#$Q+"!T:&5R92!W87,@
M)FYB<W`[)#(L-S(X+#(Y-"!O9B!T;W1A;"!U;G)E8V]G;FEZ960-"F-O;7!E
M;G-A=&EO;B!C;W-T(')E;&%T960@=&\@=6YV97-T960@<W1O8VLM8F%S960@
M8V]M<&5N<V%T:6]N#0IA<G)A;F=E;65N=',N)B-X03`[($]F('1H:7,@=&]T
M86P@86UO=6YT+"!T:&4@0V]M<&%N>2!E>'!E8W1S('1O#0IR96-O9VYI>F4@
M)FYB<W`[)#(X,2PS-3<L("9N8G-P.R0Q+#$R-2PT,#`L("9N8G-P.R0X-3@L
M-#4R+"`F;F)S<#LD,S@W+#,Y-R!A;F0@)FYB<W`[)#<U+#8X.`T*9'5R:6YG
M(#(P,3$L(#(P,3(L(#(P,3,L(#(P,30@86YD(#(P,34L(')E<W!E8W1I=F5L
M>2XF(WA!,#L@5&AE#0I#;VUP86YY(&5X<&5C=',@,RPR.3DL.34S(&EN('5N
M=F5S=&5D(&]P=&EO;G,@=&\@=F5S="!I;B!T:&4-"F9U='5R92XF(WA!,#L@
M5&AE('=E:6=H=&5D+6%V97)A9V4@9W)A;G0M9&%T92!F86ER('9A;'5E(&]F
M('9E<W1E9`T*86YD('5N=F5S=&5D(&]P=&EO;G,@;W5T<W1A;F1I;F<@870@
M4V5P=&5M8F5R(#,P+"`R,#$Q('=A<R`F;F)S<#LD,2XT-`T*86YD("9N8G-P
M.R0Q+C$W+"!R97-P96-T:79E;'DN/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#XF
M(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY/;@T*3V-T;V)E<B`V+"`R,#$Q+"!T:&4@
M0V]M<&%N>2!G<F%N=&5D(#<P+#`P,"!O<'1I;VYS('=I=&@@86X-"F5X97)C
M:7-E('!R:6-E(&]F("9N8G-P.R0Q+C`U+"!W:&EC:"!W87,@97%U86P@=&\@
M=&AE(&-L;W-I;F<@<')I8V4@;V8-"G1H92!#;VUP86YY)B-X,C`Q.3MS(&-O
M;6UO;B!S=&]C:R!O;B!T:&4@9&%T92!O9B!G<F%N="P@=&\@80T*;F]N+65M
M<&QO>65E(&EN(&5X8VAA;F=E(&9O<B!C97)T86EN(&-O;G-U;'1I;F<-"G-E
M<G9I8V5S+B8C>$$P.R8C>$$P.U1H92!G<F%N="UD871E(&9A:7(@=F%L=64@
M=7-I;F<@=&AE#0I";&%C:RU38VAO;&5S(&]P=&EO;B!P<FEC:6YG(&UO9&5L
M('=A<R`F;F)S<#LD,"XX-2!P97(@<VAA<F4L(&]R#0HF;F)S<#LD-3DL-3`P
M+CPO9F]N=#X\+V1I=CX-"CPO9&EV/@T*#0H-"CPO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^#0HW+B8C>$$P.R!35$]#2RU"05-%1"!#3TU014Y3051)
M3TX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1H90T*0V]M<&%N>28C
M>#(P,3D[<R!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@<&QA;G,@87)E('-U
M;6UA<FEZ960-"F)E;&]W.CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I
M;FQI;F4G/@T*,C`P,"!3=&]C:R!/<'1I;VX@4&QA;BXF(WA!,#L\+V9O;G0^
M($%S(&]F($1E8V5M8F5R(#,Q+"`R,#$P+"!T:&5R90T*87)E(&]P=&EO;G,@
M=&\@<'5R8VAA<V4@,CDQ('-H87)E<R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[
M<R!C;VUM;VX-"G-T;V-K(&]U='-T86YD:6YG('5N9&5R(&$@<W1O8VL@;W!T
M:6]N('!L86X@97-T86)L:7-H960@:6X@075G=7-T#0HR,#`P("AT:&4@)B-X
M,C`Q0SLR,#`P(%!L86XF(W@R,#%$.RDN)B-X03`[(%1H97)E('=I;&P@8F4@
M;F\@9G5R=&AE<@T*9W)A;G1S(&UA9&4@=6YD97(@=&AE(#(P,#`@4&QA;BX@
M3W!T:6]N<R!G96YE<F%L;'D@=F5S=&5D(&%N;G5A;&QY#0IO=F5R('1H<F5E
M('EE87)S(&%N9"!E>'!I<F4@;VX@=&AE('1E;G1H(&%N;FEV97)S87)Y(&]F
M('1H92!G<F%N=`T*9&%T92XF(WA!,#L@3F\@;W!T:6]N<R!W97)E(&=R86YT
M960@;W(@97AE<F-I<V5D('5N9&5R('1H92`R,#`P#0I0;&%N(&1U<FEN9R`R
M,#`Y+B8C>$$P.R!$=7)I;F<@,C`Q,"P@;W!T:6]N<R!T;R!P=7)C:&%S92`V
M-2!S:&%R97,-"F]F(&-O;6UO;B!S=&]C:R!U;F1E<B!T:&4@,C`P,"!0;&%N
M('=E<F4@97AE<F-I<V5D(&%N9"!O<'1I;VYS('1O#0IP=7)C:&%S92`Y('-H
M87)E<R!O9B!C;VUM;VX@<W1O8VL@=V5R92!C86YC96QE9"X\+V9O;G0^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z
M(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE)SX-"C(P,#8@4W1O8VL@26YC96YT
M:79E(%!L86X\+V9O;G0^+B!/;B!-87D@,2P@,C`P-BP@=&AE#0I#;VUP86YY
M)B-X,C`Q.3MS(&)O87)D(&]F(&1I<F5C=&]R<R!A9&]P=&5D+"!A;F0@;VX@
M2G5L>2`R,2P@,C`P-@T*=&AE($-O;7!A;GDF(W@R,#$Y.W,@<W1O8VMH;VQD
M97)S(&%P<')O=F5D+"!T:&4@,C`P-B!3=&]C:R!);F-E;G1I=F4-"E!L86X@
M*'1H92`F(W@R,#%#.S(P,#8@4&QA;B8C>#(P,40[*2X@02!T;W1A;"!O9B`V
M-2PS-3D@<VAA<F5S(&]F#0IC;VUM;VX@<W1O8VL@87)E(')E<V5R=F5D(&9O
M<B!I<W-U86YC92!U;F1E<B!T:&4@,C`P-B!0;&%N(&9O<@T*9W)A;G1S(&]F
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M8W0@=&\-"G1H92!P<F]V:7-I;VYS(&]F('1H92`R,#`V(%!L86XN($]P=&EO
M;G,@87)E(&=R86YT960@870@;W(@86)O=F4-"G1H92!F86ER(&UA<FME="!V
M86QU92!O9B!T:&4@8V]M;6]N('-T;V-K(&%T('1H92!G<F%N="!D871E(&%N
M9`T*97AP:7)E(&]N('1H92!T96YT:"!A;FYI=F5R<V%R>2!O9B!T:&4@9W)A
M;G0@9&%T92X@5F5S=&EN9R!P97)I;V1S#0IA<F4@9V5N97)A;&QY('1W;R!T
M;R!T:')E92!Y96%R<RX@26X@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L
M#0HR,#`Y+"!S=&]C:R!O<'1I;VYS(&9O<B!T:&4@<'5R8VAA<V4@;V8@,3(L
M-C<Y('-H87)E<R!O9B!C;VUM;VX-"G-T;V-K('=E<F4@9W)A;G1E9"!U;F1E
M<B!T:&4@,C`P-B!0;&%N+B!$=7)I;F<@=&AE('EE87(@96YD960-"D1E8V5M
M8F5R(#,Q+"`R,#$P+"!O<'1I;VYS('1O('!U<F-H87-E(#$L-#,X('-H87)E
M<R!O9B!C;VUM;VX@<W1O8VL-"G=E<F4@97AE<F-I<V5D(&%N9"!O<'1I;VYS
M('1O('!U<F-H87-E(#,L.3(Q('-H87)E<R!O9B!C;VUM;VX@<W1O8VL-"G=E
M<F4@8V%N8V5L960N($%S(&]F($1E8V5M8F5R(#,Q+"`R,#$P(&%N9"!$96-E
M;6)E<B`S,2P@,C`P.2P-"C(U+#4U-2!A;F0@,C$L-3`S('-H87)E<R!R96UA
M:6X@879A:6QA8FQE(&9O<B!G<F%N="!U;F1E<B!T:&4@,C`P-@T*4&QA;BX@
M3W!T:6]N<R!G<F%N=&5D('!U<G-U86YT('1O('1H92`R,#`V(%!L86X@9V5N
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M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4U19
M3$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE)SX-"D]T:&5R(%-T;V-K($]P
M=&EO;B!!8W1I=FET>2X\+V9O;G0^("8C>$$P.R!$=7)I;F<@,C`P-2!A;F0@
M,C`P-"P-"G1H92!#;VUP86YY(&ES<W5E9"!O<'1I;VYS('1O('!U<F-H87-E
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M($1E8V5M8F5R(#,Q+`T*,C`Q,"P@;W!T:6]N<R!T;R!P=7)C:&%S92`T+#0X
M."!S:&%R97,@;V8@8V]M;6]N('-T;V-K('=E<F4-"F5X97)C:7-E9"!A;F0@
M;W!T:6]N<R!T;R!P=7)C:&%S92`Y.#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C
M:R!W97)E#0IC86YC96QE9"X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SXF(WA!,#L\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)SX-"D%C8V]U;G1I;F<@9F]R(%-T;V-K+4)A
M<V5D($-O;7!E;G-A=&EO;CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M5&AE#0I#;VUP86YY(&%C8V]U;G1S(&9O<B!E;7!L;WEE92!S=&]C:RUB87-E
M9"!C;VUP96YS871I;VX@:6X-"F%C8V]R9&%N8V4@=VET:"!T:&4@9W5I9&%N
M8V4@;V8@1D%30B!!4T,@5&]P:6,@-S$X+"`\9F]N="!S='EL93TS1"=&3TY4
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M<R!B87-E9"!O;B!T:&5I<B!F86ER#0IV86QU97,N)B-X03`[(%1H92!#;VUP
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M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
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M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C@E(&-O
M;'-P86X],T0V/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4G/EEE87(F(WA!,#M%;F1E9#PO9F]N=#X\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
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M33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O
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M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4G/C(P,3`\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,R4@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^,C`P.3PO9F]N=#X\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R(&%L:6=N/3-$;&5F=#X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3,E(&-O;'-P86X],T0R(&%L:6=N/3-$;&5F=#X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
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M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L
M;W(],T1W:&ET93X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4@
M86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
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M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@
M86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXQ-#@L,#,P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
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M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^1V5N97)A;`T*86YD(&%D;6EN:7-T<F%T:79E
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX]
M,T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*,S4V
M+#(R,#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N
M/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SX-"C(X
M.2PP,S8\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$
M=VAI=&4^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
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M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DYO;BUE;7!L;WEE
M90T*8V]N<W5L=&%N="!S=&]C:R!O<'1I;VX@9W)A;G1S(&%N9"!R97-T<FEC
M=&5D('-T;V-K#0IA=V%R9',Z/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
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M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(]
M,T1W:&ET93X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4@86QI
M9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXH,C(P+#DV.3PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS,C@L-C$T
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@]
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M:SL@34%21TE.+4Q%1E0Z(#EP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^1V5N
M97)A;`T*86YD(&%D;6EN:7-T<F%T:79E/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4G/@T**#(X+#`U-#PO9F]N=#X\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BDF(WA!,#L\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$<FEG
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS
M1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HY."PV
M-3<\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI
M=&4^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
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M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
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M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,G!X('-O;&ED)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#)P>"!S;VQI9"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$
M<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,3(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W
M,"4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
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M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX]
M,T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SX-"B9N8G-P
M.R0\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@
M=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4G/@T*,S,W+#(Y.#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE)SX-"B9N8G-P.R0\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U
M8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*.#8T+#,S-SPO9F]N
M=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R
M("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY/;@T*1&5C96UB97(@,S$L(#(P,#DL('1H92!E>'!I<F%T:6]N
M(&]F(&]P=&EO;G,@:&5L9"!B>2!A(&9O<FUE<@T*96UP;&]Y964@=V%S(&5X
M=&5N9&5D('5N=&EL($IA;G5A<GD@,S$L(#(P,3`@86YD(&EN8W)E;65N=&%L
M#0IS=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS92!F;W(@;F]N+65M
M<&QO>65E<R!O9B`F;F)S<#LD,34L,#`P('=A<PT*<F5C;W)D960@:6X@8V]N
M;F5C=&EO;B!W:71H('1H92!O;F4M;6]N=&@@97AT96YS:6]N+CPO9F]N=#X\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^26X-"DIA;G5A<GD@,C`P.2P@=&AE($-O
M;7!A;GD@;6]D:69I960@=&AE('1E<FUS(&]F(&]P=&EO;G,@=&\@<'5R8VAA
M<V4-"C(V,2!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&AE;&0@8GD@='=O(&5M
M<&QO>65E<R!T;R!V97-T(&%L;`T*=6YV97-T960@;W!T:6]N<R!A;F0@=&\@
M97AT96YD('1H92!E>'!I<F%T:6]N(&1A=&5S(&]F('1H90T*;W!T:6]N<RXF
M(WA!,#L@5&AE(&UO9&EF:6-A=&EO;B!W87,@;6%D92!I;B!C;VYN96-T:6]N
M('=I=&@@=&AE#0IT97)M:6YA=&EO;B!O9B!T:&4@='=O(&5M<&QO>65E<R!T
M;R!R961U8V4@8V]S=',N)B-X03`[($1U<FEN9R!T:&4-"GEE87(@96YD960@
M1&5C96UB97(@,S$L(#(P,#DL(&EN8W)E;65N=&%L('-T;V-K+6)A<V5D(&-O
M;7!E;G-A=&EO;@T*97AP96YS92!O9B`F;F)S<#LD."PP,#`@=V%S(')E8V]R
M9&5D(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@;6]D:69I8V%T:6]N#0IO9B!T
M:&4@;W!T:6]N('1E<FUS+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U714E'2%0Z(&)O;&0G/@T*1&5T97)M:6YI;F<@1F%I<B!686QU93PO
M9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4G/@T*5F%L=6%T:6]N
M(&%N9"!A;6]R=&EZ871I;VX@;65T:&]D/"]F;VYT/BX@5&AE(&9A:7(@=F%L
M=64@;V8@96%C:`T*<W1O8VL@87=A<F0@:7,@97-T:6UA=&5D(&]N('1H92!G
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M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN
M;&EN92<^#0I6;VQA=&EL:71Y+CPO9F]N=#X@5&AE($-O;7!A;GD@97-T:6UA
M=&5S('9O;&%T:6QI='D@8F%S960@;VX@86X-"F%V97)A9V4@;V8@*#$I('1H
M92!#;VUP86YY)B-X,C`Q.3MS(&AI<W1O<FEC86P@=F]L871I;&ET>2!S:6YC
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M8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A
M;&EC.R!$25-03$%9.B!I;FQI;F4G/@T*4FES:RUF<F5E(&EN=&5R97-T(')A
M=&4\+V9O;G0^+B!4:&4@<FES:RUF<F5E(&EN=&5R97-T(')A=&4@:7,-"F)A
M<V5D(&]N('1H92!5+E,N(%1R96%S=7)Y('EI96QD(&-U<G9E(&EN(&5F9F5C
M="!A="!T:&4@=&EM92!O9@T*9W)A;G0@8V]M;65N<W5R871E('=I=&@@=&AE
M(&5X<&5C=&5D('1E<FT@87-S=6UP=&EO;BX\+V9O;G0^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\
M8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
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M<V5D(&]N('1H92!#;VUP86YY)B-X,C`Q.3MS(&5S=&EM871E(&]F('=H96X@
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M+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE)SX-"D9O<F9E:71U
M<F5S+CPO9F]N=#X@)B-X03`[(%1H92!#;VUP86YY(')E8V]R9',@<W1O8VLM
M8F%S960-"F-O;7!E;G-A=&EO;B!E>'!E;G-E(&]N;'D@9F]R('1H;W-E(&%W
M87)D<R!T:&%T(&%R92!E>'!E8W1E9"!T;PT*=F5S="XF(WA!,#L@1D%30B!!
M4T,@5&]P:6,@-S$X(')E<75I<F5S(&9O<F9E:71U<F5S('1O(&)E(&5S=&EM
M871E9`T*870@=&AE('1I;64@;V8@9W)A;G0@86YD(')E=FES960L(&EF(&YE
M8V5S<V%R>2P@:6X@<W5B<V5Q=65N=`T*<&5R:6]D<R!I9B!A8W1U86P@9F]R
M9F5I='5R97,@9&EF9F5R(&9R;VT@=&AO<V4@97-T:6UA=&5S+B8C>$$P.PT*
M5&AE('1E<FT@)B-X,C`Q0SMF;W)F96ET=7)E<R8C>#(P,40[(&ES(&1I<W1I
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M;G,@87,@;V8@1&5C96UB97(@,S$L(#(P,3`@87,@=&AE($-O;7!A;GD-"FAA
M<R!E>'!E<FEE;F-E9"!V97)Y(&9E=R!F;W)F96ET=7)E<R!T;R!D871E(&%N
M9"!B96QI979E<R!T:&%T#0IT:&5R92!I<R!I;G-U9F9I8VEE;G0@:&ES=&]R
M>2!T;R!D979E;&]P(&%N(&%C8W5R871E(&5S=&EM871E(&]F#0IF=71U<F4@
M9F]R9F5I='5R97,N)B-X03`[)B-X03`[5&AI<R!A;F%L>7-I<R!W:6QL(&)E
M(')E+65V86QU871E9`T*<V5M:2UA;FYU86QL>2!A;F0@=&AE(&9O<F9E:71U
M<F4@<F%T92!W:6QL(&)E(&%D:G5S=&5D(&%S#0IN96-E<W-A<GDN)B-X03`[
M)B-X03`[56QT:6UA=&5L>2P@=&AE(&%C='5A;"!E>'!E;G-E(')E8V]G;FEZ
M960-"F]V97(@=&AE('9E<W1I;F<@<&5R:6]D('=I;&P@8F4@9F]R(&]N;'D@
M=&AO<V4@<VAA<F5S('1H870-"G9E<W0N/"]F;VYT/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G/@T*)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"F9O;&QO=VEN9R!T86)L92!S=6UM
M87)I>F5S('=E:6=H=&5D(&%V97)A9V4@=F%L=65S(&%N9"!A<W-U;7!T:6]N
M<PT*=7-E9"!F;W(@;W!T:6]N<R!G<F%N=&5D('1O(&5M<&QO>65E<RP@9&ER
M96-T;W)S(&%N9"!C;VYS=6QT86YT<R!I;@T*=&AE('!E<FEO9',@:6YD:6-A
M=&5D.CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
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M+5-)6D4Z(#$P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0Y,"4^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.#@E(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P
M>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
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M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
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M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^,C`P.3PO9F]N=#X\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#@X)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY6;VQA=&EL:71Y/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^.3`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
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M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
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M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@86QI
M9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXY,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)3PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#@X)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY2:7-K+69R
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@86QI9VX],T1R:6=H
M=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXR+C$R/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXE/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#@X)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%>'!E8W1E9`T*;&EF92`H
M>65A<G,I/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&
M0T,^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.#@E(&%L:6=N/3-$
M;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/D1I=FED96YD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,#PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
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M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
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M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE(&%L
M:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$.#@E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)FYB<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXP+C4S/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
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M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"E-T
M;V-K($]P=&EO;B!!8W1I=FET>3PO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^00T*<W5M;6%R>2!O9B!S=&]C:R!O<'1I;VX@86-T:79I='D@=6YD97(@
M=&AE(#(P,#`@4&QA;BP@=&AE(#(P,#8@4&QA;@T*86YD(&]U='-I9&4@;V8@
M86YY(&9O<FUA;&EZ960@<&QA;B!I<R!A<R!F;VQL;W=S.CPO9F]N=#X\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!-05)'24XM3$5&5#H@,3AP="<^#0H\=&%B;&4@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$.3`E/@T*/'1R('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)2!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4G/D]P=&EO;G,\+V9O;G0^/"]F;VYT/CPO9&EV/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4G/D]U='-T86YD:6YG/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
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M=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U714E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE)SY796EG:'1E9#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
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M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
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M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$P)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
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M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/D%V97)A9V4\
M+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/E)E;6%I;FEN9SPO9F]N=#X\
M+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
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M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE)SY996%R<SPO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
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M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E
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M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/E9A;'5E/"]F
M;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY/=71S=&%N9&EN9PT*870@2F%N=6%R>2`Q+"`R,#`Y/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^-#<L-3@P/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
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M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^.3$N.#`\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C<N.3PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G
M8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,B4@86QI9VX],T1L969T
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@=VED
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M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4G/@T*,3(L-C<Y/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N
M/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B9N8G-P.R0F(WA!,#L\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^,3$T+C<U/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
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M($U!4D=)3BU,1494.B`Y<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]U='-T
M86YD:6YG#0IA="!$96-E;6)E<B`S,2P@,C`P.3PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A
M;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/C8P+#(U.3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF;F)S<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CDV+C,Y/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXW+C4\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI
M9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ-RPV-3`L,C4U
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@]
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M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[($U!4D=)3BU224=(
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE(&%L
M:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^*#4L.3DQ/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#DE(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F
M=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B9N8G-P.R0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[-C8S+#8P,#PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#
M0T9&0T,^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-3(E(&%L:6=N/3-$;&5F=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TY<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^3W!T:6]N
M<PT*8V%N8V5L960\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
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M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4G/@T**#4L,#0R/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@
M=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXP)B-X03`[/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
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M1D].5"U325I%.B`Q,'!T)SY/=71S=&%N9&EN9PT*870@1&5C96UB97(@,S$L
M(#(P,3`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A
M;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^
M#0HT.2PR,C8\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI
M9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SX-"B9N
M8G-P.R0\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T
M;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN92<^#0HQ,#`N.3@\+V9O;G0^/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T
M;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN92<^#0HV+CD\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE)SX-"B9N8G-P.R0\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE
M)R!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HR-"PX-#(\+V9O;G0^/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
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M+4E.1$5.5#H@+3EP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D5X97)C:7-A8FQE#0IA="!$96-E
M;6)E<B`S,2P@,C`Q,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED
M=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN92<^#0HS.2PR-S`\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS
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M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
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M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*,3`P+CDX/"]F;VYT/CPO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#1P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SX-"C8N-#PO9F]N=#X\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T
M<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G
M/@T*)FYB<W`[)#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE)SX-"C(T+#@T,CPO9F]N=#X\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-
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M<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,"P@=&AE#0IT
M;W1A;"!I;G1R:6YS:6,@=F%L=64@;V8@;W!T:6]N<R!E>&5R8VES960@=V%S
M("9N8G-P.R0V-C,L,#`P(&%N9"!T:&4-"G1O=&%L(&%M;W5N="!O9B!C87-H
M(')E8V5I=F5D(&9R;VT@97AE<F-I<V4@;V8@=&AE<V4@;W!T:6]N<R!W87,-
M"B9N8G-P.R0Q-3@L-C`P+B8C>$$P.R8C>$$P.U-H87)E<R!O9B!C;VUM;VX@
M<W1O8VL@:7-S=65D('5P;VX@=&AE#0IE>&5R8VES92!O9B!O<'1I;VYS(&%R
M92!F<F]M(&%U=&AO<FEZ960@8G5T('5N:7-S=65D#0IS:&%R97,N/"]F;VYT
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!<PT*;V8@1&5C96UB97(@,S$L(#(P
M,3`L('1H97)E('=A<R!A<'!R;WAI;6%T96QY("9N8G-P.R0V-#<L,#`P(&]F
M('1O=&%L#0IU;G)E8V]G;FEZ960@8V]M<&5N<V%T:6]N(&-O<W0@<F5L871E
M9"!T;R!U;G9E<W1E9"!S=&]C:RUB87-E9`T*8V]M<&5N<V%T:6]N(&%R<F%N
M9V5M96YT<RXF(WA!,#LF(WA!,#M/9B!T:&ES('1O=&%L(&%M;W5N="P@-S`E
M(&%N9`T*,S`E(&%R92!E>'!E8W1E9"!T;R!B92!R96-O9VYI>F5D(&1U<FEN
M9R`R,#$Q(&%N9"`R,#$R+`T*<F5S<&5C=&EV96QY+B8C>$$P.R8C>$$P.U1H
M92!#;VUP86YY(&5X<&5C=',@.2PY-38@:6X@=6YV97-T960-"F]P=&EO;G,@
M=&\@=F5S="!I;B!T:&4@9G5T=7)E+B8C>$$P.R8C>$$P.U1H92!W96EG:'1E
M9"UA=F5R86=E#0IG<F%N="UD871E(&9A:7(@=F%L=64@;V8@=F5S=&5D(&%N
M9"!U;G9E<W1E9"!O<'1I;VYS(&]U='-T86YD:6YG(&%T#0I$96-E;6)E<B`S
M,2P@,C`Q,"!W87,@)FYB<W`[)#8R+C<S(&%N9"`F;F)S<#LD-C@N.#4L(')E
M<W!E8W1I=F5L>2X\+V9O;G0^/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%6$5!0SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY)3D-/344@5$%815,\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^24Y#3TU%(%1!6$53/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS
M1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P
M,"4^#0H\='(@=F%L:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`S
M-G!T)R!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*-RXF(WA!
M,#L\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\8G(@+SX\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/E1H90T*0V]M<&%N>2!A8V-O=6YT<R!F;W(@:6YC;VUE('1A>&5S(&EN
M(&%C8V]R9&%N8V4@=VET:"!T:&4@26YC;VUE#0I487AE<R!4;W!I8R!O9B!T
M:&4@1D%30B!!4T,N(%5N9&5R('1H:7,@9W5I9&%N8V4L(&1E9F5R<F5D('1A
M>`T*87-S971S(&]R(&QI86)I;&ET:65S(&%R92!C;VUP=71E9"!B87-E9"!O
M;B!T:&4@9&EF9F5R96YC92!B971W965N#0IT:&4@9FEN86YC:6%L('-T871E
M;65N="!A;F0@:6YC;VUE('1A>"!B87-I<R!O9B!A<W-E=',@86YD#0IL:6%B
M:6QI=&EE<RP@86YD(&YE="!O<&5R871I;F<@;&]S<R!C87)R>69O<G=A<F1S
M+"!U<VEN9R!T:&4-"F5N86-T960@=&%X(')A=&5S+B!$969E<G)E9"!I;F-O
M;64@=&%X(&5X<&5N<V4@;W(@8F5N969I="!I<R!B87-E9`T*;VX@8VAA;F=E
M<R!I;B!T:&4@87-S970@;W(@;&EA8FEL:71Y(&9R;VT@<&5R:6]D('1O('!E
M<FEO9"X@5&AE#0I#;VUP86YY(&1I9"!N;W0@<F5C;W)D(&$@<')O=FES:6]N
M(&]R(&)E;F5F:70@9F]R(&9E9&5R86PL('-T871E(&]R#0IF;W)E:6=N(&EN
M8V]M92!T87AE<R!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S
M,2P@,C`Q,2!O<@T*,C`Q,"!B96-A=7-E('1H92!#;VUP86YY(&AA<R!E>'!E
M<FEE;F-E9"!L;W-S97,@;VX@82!T87@@8F%S:7,-"G-I;F-E(&EN8V5P=&EO
M;BX@5&AE(&YE="!I;F-O;64@<F5P;W)T960@9F]R('1H92!T:')E92!M;VYT
M:',@96YD960-"DUA<F-H(#,Q+"`R,#$P('=A<R!A(')E<W5L="!O9B!T:&4@
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M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^#0HQ,BX@)B-X03`[24Y#3TU%(%1!6$53/"]F
M;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$969E<G)E9`T*=&%X(&%S<V5T
M<R!C;VYS:7-T960@;V8@=&AE(&9O;&QO=VEN9R!A="!$96-E;6)E<B`S,3H\
M+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N
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M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
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M+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4G/C(P,3`\+V9O;G0^/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4
M.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^,C`P
M.3PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R
M(&%L:6=N/3-$;&5F=#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R(&%L:6=N/3-$;&5F
M=#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
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M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q,B4@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T
M<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-S`E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI
M9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXV+#$Q-BPX,#0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF;F)S<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT+#<U-"PP,#$\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&
M1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)2!A;&EG;CTS
M1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@.7!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY&961E<F%L#0IR97-E87)C:"!A;F0@9&5V96QO<&UE;G0@=&%X(&-R
M961I="!C87)R>69O<G=A<F1S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG
M:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M8F=C;VQO<CTS1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#<P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@.7!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY7:7-C;VYS:6X-"FYE="!O<&5R871I;F<@;&]S
M<R!C<F5D:70@8V%R<GEF;W)W87)D<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS
M1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I
M9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#<P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@.7!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY7:7-C;VYS:6X-"G)E<V5A<F-H(&%N
M9"!D979E;&]P;65N="!T87@@8W)E9&ET(&-A<G)Y9F]R=V%R9',\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR,C`L-S,X/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXQ-S$L-34R/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$;&5F=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`Y<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
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M.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/C4U,BPX-3D\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS
M1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C0Q-2PP-C`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#<P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M.7!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#:&%R:71A8FQE#0IC;VYT<FEB
M=71I;VX@8V%R<GEF;W)W87)D<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I
M9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M-#DL-S(U/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B
M9V-O;&]R/3-$=VAI=&4^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$;&5F
M=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/D%C8W)U960-"FQI86)I;&ET:65S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN92<^#0HR-2PS,C<\+V9O;G0^/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@
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M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE)SX-"C<U+#<Q,3PO9F]N=#X\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#<P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4;W1A;`T*9&5F97)R960@=&%X
M(&%S<V5T<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-BPS,CDL,S@U
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R
M/3-$=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O
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M03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY$969E<G)E9`T*=&%X(&QI86)I;&ET:65S/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P
M)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@.7!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SY$97!R96-I86)L90T*86YD(&EN=&%N9VEB;&4@87-S
M971S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG
M;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HH
M-#,T+#`U-CPO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/BD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@=VED
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M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE)SX-"B@T-S4L-3(T/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*3PO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4;W1A;`T*
M9&5F97)R960@=&%X(&QI86)I;&ET:65S/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N
M/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
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M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXH-#<U+#4R-#PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,3(E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$;&5F=#X-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DYE
M=`T*9&5F97)R960@=&%X(&%S<V5T<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS
M1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$
M<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^-2PX-3,L.#8Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T
M<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L
M:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/DQE<W,-"G9A;'5A=&EO;B!A;&QO=V%N8V4\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI
M9"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
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M+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
M1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXI/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A
M;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
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M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
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M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q,B4@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT
M<B!B9V-O;&]R/3-$=VAI=&4^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$
M;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/E1O=&%L#0ID969E<G)E9"!T87@@87-S971S/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
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M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4
M.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^)FYB
M<W`[)#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN92<^#0HF(W@R,#$T.SPO9F]N=#X\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/B9N8G-P.R0\+V9O
M;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4G/@T*)B-X,C`Q-#L\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CPO
M=&%B;&4^#0H\+V1I=CX-"CQB<B`O/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!<PT*;V8@
M1&5C96UB97(@,S$L(#(P,3`L($-E;&QE8W1A<B!H860@9F5D97)A;"!A;F0@
M<W1A=&4@;F5T(&]P97)A=&EN9PT*;&]S<R!C87)R>69O<G=A<F1S("@F(W@R
M,#%#.TY/3',F(W@R,#%$.RD@;V8@87!P<F]X:6UA=&5L>0T*)FYB<W`[)#$U
M+#8X-"PP,#`@86YD("9N8G-P.R0Q-2PV,S,L,#`P(')E<W!E8W1I=F5L>2P@
M=VAI8V@@97AP:7)E(&)E9VEN;FEN9R!I;@T*,C`S,"!A;F0@,C`R-2P@<F5S
M<&5C=&EV96QY+B8C>$$P.R!);B!A9&1I=&EO;BP@0V5L;&5C=&%R(&AA<PT*
M9F5D97)A;"!A;F0@<W1A=&4@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&%N
M9"!I;G9E<W1M96YT('1A>`T*8W)E9&ET<R!O9B!A<'!R;WAI;6%T96QY("9N
M8G-P.R0S.3$L,#`P(&%N9"`F;F)S<#LD,S,U+#`P,"P@<F5S<&5C=&EV96QY
M+B8C>$$P.PT*5&AE(&%M;W5N="!O9B!.3TQS('=H:6-H(&UA>2!B92!U=&EL
M:7IE9"!A;FYU86QL>2!I;B!F=71U<F4@<&5R:6]D<PT*=VEL;"!B92!L:6UI
M=&5D('!U<G-U86YT('1O(%-E8W1I;VX@,S@R(&]F('1H92!);G1E<FYA;"!2
M979E;G5E#0I#;V1E(&%S(&$@<F5S=6QT(&]F('-U8G-T86YT:6%L(&-H86YG
M97,@:6X@=&AE($-O;7!A;GDF(W@R,#$Y.W,-"F]W;F5R<VAI<"!T:&%T(&AA
M=F4@;V-C=7)R960@;W(@=&AA="!M87D@;V-C=7(@:6X@=&AE(&9U='5R92XF
M(WA!,#L-"E1H92!#;VUP86YY(&AA<R!N;W0@<75A;G1I9FEE9"!T:&4@86UO
M=6YT(&]F('-U8V@-"FQI;6ET871I;VYS+CPO9F]N=#X\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB
M<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<^0F5C875S90T*;V8@=&AE(&QI;6ET960@;W!E<F%T:6YG(&AI
M<W1O<GDL(&-O;G1I;G5I;F<@;&]S<V5S(&%N9"!U;F-E<G1A:6YT>0T*87-S
M;V-I871E9"!W:71H('1H92!U=&EL:7IA=&EO;B!O9B!T:&4@3D],<R!I;B!T
M:&4@9G5T=7)E+`T*;6%N86=E;65N="!H87,@<')O=FED960@82!F=6QL(&%L
M;&]W86YC92!A9V%I;G-T('1H92!G<F]S<R!D969E<G)E9`T*=&%X(&%S<V5T
M+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^0V5L;&5C=&%R#0ID:60@
M;F]T(&AA=F4@=6YR96-O9VYI>F5D('1A>"!B96YE9FET<R!O<B!A8V-R=65D
M(&EN=&5R97-T(&%N9`T*<&5N86QT:65S(&%T(&%N>2!T:6UE(&1U<FEN9R!T
M:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,3`@86YD#0HR,#`Y+"!A
M;F0@9&]E<R!N;W0@86YT:6-I<&%T92!H879I;F<@=6YR96-O9VYI>F5D('1A
M>"!B96YE9FET<R!O=F5R#0IT:&4@;F5X="!T=V5L=F4@;6]N=&AS+B8C>$$P
M.R!4:&4@0V]M<&%N>2!I<R!S=6)J96-T('1O(&%U9&ET(&)Y#0IT:&4@25)3
M(&9O<B!T87@@<&5R:6]D<R!C;VUM96YC:6YG($IA;G5A<GD@,2P@,C`P-RX\
M+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D9O<@T*=&AE(&YI;F4M;6]N
M=&@@<&5R:6]D(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,2P@=&AE(&9E9&5R
M86P@86YD#0IS=&%T92!.3TQS(&EN8W)E87-E9"!B>2!A<'!R;WAI;6%T96QY
M("9N8G-P.R0U+#0W,"PP,#`@87,@82!R97-U;'0@;V8@=&AE#0IL;W-S(')E
M8V]R9&5D+CPO9F]N=#X\+V1I=CX-"@T*#0H\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/@T*."X@)B-X03`[24Y#3TU%(%1!6$53/"]F;VYT/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^5&AE#0I#;VUP86YY)B-X,C`Q.3MS(&1E
M9F5R<F5D('1A>"!A<W-E=',@8V]N<VES=&5D(&]F('1H92!F;VQL;W=I;F<@
M870-"D1E8V5M8F5R(#,Q.CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O
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M96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,"4^#0H\='(^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-S8E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P
M)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^,C`Q,#PO
M9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^,C`P.3PO9F]N=#X\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#<V)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C
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M1D].5"U325I%.B`Q,'!T)SY.970-"F]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R
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M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE(&%L:6=N
M/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^,3(L.#<R+#`P,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF;F)S<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CDL-30S+#`P,#PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<V)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M.7!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^4F5S96%R8V@-"F%N9"!D979E;&]P;65N=`T*97AP96YS97,F(WA!,#LF
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ-"PQ.#`L,#`P/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ-"PY,#8L,#`P/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
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M8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/E1A>`T*8W)E9&ET<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$L
M-S$Q+#`P,#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,2PU
M-C,L,#`P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
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M1D].5"U325I%.B`Q,'!T)SY#87!I=&%L#0IL;W-S(&-A<G)Y9F]R=V%R9#PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C,T,"PP,#`\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C,T,"PP,#`\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#<V)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M.7!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#EP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
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M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4G/@T*,S8U+#`P,#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
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M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4G/@T*-C4P+#`P,#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G
M8V]L;W(],T1W:&ET93X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W
M-B4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3EP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[($U!4D=)
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR.2PT-C@L,#`P/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR-RPP,#(L,#`P/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
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M3BU,1494.B`Y<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E9A;'5A=&EO;@T*
M86QL;W=A;F-E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@=VED=&@],T0Y
M)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M92<^#0HH,CDL-#8X+#`P,#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BD\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
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M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE)SX-"B@R-RPP,#(L,#`P/"]F;VYT/CPO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
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M3BU,1494.B`Y<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DYE=`T*9&5F97)R
M960@=&%X(&%S<V5T/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4G/@T*)FYB<W`[)#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4G/@T*)FYB<W`[)#PO9F]N=#X\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#1P>"!D;W5B;&4G('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE(&%L:6=N
M/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^07,-"F]F($1E8V5M8F5R(#,Q+"`R
M,#$P+"!T:&4@0V]M<&%N>2!H860@9F5D97)A;"!A;F0@<W1A=&4@;F5T#0IO
M<&5R871I;F<@;&]S<R!C87)R>69O<G=A<F1S(&]F(&%P<')O>&EM871E;'D@
M)FYB<W`[)#,S+#$X,"PP,#`@86YD#0HF;F)S<#LD,C4L.#$R+#`P,"!R97-P
M96-T:79E;'DL('=H:6-H(&5X<&ER92!T:')O=6=H(#(P,S`N)B-X03`[)B-X
M03`[26X-"F%D9&ET:6]N+"!T:&4@0V]M<&%N>2!H87,@9F5D97)A;"!A;F0@
M<W1A=&4@<F5S96%R8V@@86YD#0ID979E;&]P;65N="!A;F0@:6YV97-T;65N
M="!T87@@8W)E9&ET<R!O9B!A<'!R;WAI;6%T96QY("9N8G-P.R0Q+#,X,BPP
M,#`-"F%N9"`F;F)S<#LD-#0Y+#`P,"P@<F5S<&5C=&EV96QY+"!W:&EC:"!E
M>'!I<F4@=&AR;W5G:`T*,C`S,"XF(WA!,#LF(WA!,#M4:&4@86UO=6YT(&]F
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M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"F-A
M<&ET86P@;&]S<R!C87)R>69O<G=A<F0@<F5L871E<R!T;R!T:&4@;&]S<R!R
M96-O<F1E9"!I;B!P<FEO<@T*>65A<G,@9F]R($YO=F5L;W,F(W@R,#$Y.R!I
M;G9E<W1M96YT(&EN(&%N('5N<F5L871E9`T*8V]M<&%N>2X\+V9O;G0^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY"96-A=7-E#0IO9B!T:&4@0V]M<&%N
M>28C>#(P,3D[<R!L:6UI=&5D(&]P97)A=&EN9R!H:7-T;W)Y+"!C;VYT:6YU
M:6YG(&QO<W-E<PT*86YD('5N8V5R=&%I;G1Y(&%S<V]C:6%T960@=VET:"!T
M:&4@=71I;&EZ871I;VX@;V8@=&AE(&YE=`T*;W!E<F%T:6YG(&QO<W,@8V%R
M<GEF;W)W87)D<R!I;B!T:&4@9G5T=7)E+"!M86YA9V5M96YT(&AA<R!P<F]V
M:61E9`T*82`Q,#`E(&%L;&]W86YC92!A9V%I;G-T('1H92!#;VUP86YY)B-X
M,C`Q.3MS(&=R;W-S(&1E9F5R<F5D('1A>`T*87-S970N)B-X03`[)B-X03`[
M26X@,C`Q,"P@=&AE(&1I9F9E<F5N8V4@8F5T=V5E;B!T:&4-"D-O;7!A;GDF
M(W@R,#$Y.W,@=&]T86P@<W1A='5T;W)Y('1A>"!R871E(&]F(&%P<')O>&EM
M871E;'D@-#`E(&%N9`T*:71S(&5F9F5C=&EV92!T87@@<F%T92!O9B`P)2!I
M<R!D=64@=&\@=&AE(&YO;G1A>&%B;&4@9V%I;B!O9@T*)FYB<W`[)#@L,3$X
M+#`P,"!O;B!D97)I=F%T:79E('=A<G)A;G1S+"!A;B!I;F-R96%S92!I;B!T
M:&4@=F%L=6%T:6]N#0IA;&QO=V%N8V4@;V8@)FYB<W`[)#(L-#8V+#`P,"!A
M;F0@;F]N9&5D=6-T:6)L92!L:7%U:61A=&5D(&1A;6%G97,-"F%C8W)U960@
M;V8@)FYB<W`[)#@Q.2PP,#`N)B-X03`[)B-X03`[26X@,C`P.2P@=&AE(&1I
M9F9E<F5N8V4@8F5T=V5E;B!T:&4-"D-O;7!A;GDF(W@R,#$Y.W,@=&]T86P@
M<W1A='5T;W)Y('1A>"!R871E(&]F(&%P<')O>&EM871E;'D@-#`E(&%N9`T*
M:71S(&5F9F5C=&EV92!T87@@<F%T92!O9B`P)2!I<R!D=64@97%U86QL>2!T
M;R!T:&4@:6YC<F5A<V4@:6X-"G9A;'5A=&EO;B!A;&QO=V%N8V4@86YD('1H
M92!R961U8W1I;VX@:6X@=&%X(&QO<W,@<F5S=6QT:6YG(&9R;VT-"G1H92!N
M;VYD961U8W1I8FQE(&QO<W,@;VX@9&5R:79A=&EV92!W87)R86YT<RXF(WA!
M,#L\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"D-O;7!A
M;GD@9&ED(&YO="!H879E(&%N>2!U;G)E8V]G;FEZ960@=&%X(&)E;F5F:71S
M(&]R(&%C8W)U960-"FEN=&5R97-T(&%N9"!P96YA;'1I97,@870@86YY('1I
M;64@9'5R:6YG('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<@T*,S$L(#(P,3`@
M86YD(#(P,#DL(&%N9"!D;V5S(&YO="!A;G1I8VEP871E(&AA=FEN9R!A;GD@
M=6YR96-O9VYI>F5D#0IT87@@8F5N969I=',@;W9E<B!T:&4@;F5X="!T=V5L
M=F4@;6]N=&AS+B8C>$$P.R8C>$$P.U1H92!#;VUP86YY(&ES#0IS=6)J96-T
M('1O(&%U9&ET(&)Y('1H92!)4E,@9F]R('1A>"!P97)I;V1S(&-O;6UE;F-I
M;F<@2F%N=6%R>2`Q+`T*,C`P-RX\+V9O;G0^/"]D:78^#0H\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V0R9#%A,V8X
M7S!C-3=?-#$V.%]B961C7S@V-S=D8V1B,S5E8PT*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]D,F0Q83-F.%\P8S4W7S0Q-CA?8F5D8U\X-C<W9&-D
M8C,U96,O5V]R:W-H965T<R]3:&5E=#(P+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%6$5!0SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.150@24Y#3TU%("A,3U-3*2!015(@
M4TA!4D4\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3D54($E.0T]-12`H3$]34RD@
M4$52(%-(05)%/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H\
M='(@=F%L:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`S-G!T)R!A
M;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*-BXF(WA!,#L\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4
M.B!B;VQD)SX-"DY%5"!)3D-/344@*$Q/4U,I(%!%4B!32$%213PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R
M("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY"87-I8PT*;F5T(&EN8V]M92`H;&]S<RD@<&5R('-H87)E(&ES
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M9F5R<F5D('-T;V-K(&%N9"!A8V-U;75L871E9"!D:79I9&5N9',N)B-X03`[
M)B-X03`[4VEN8V4@=&AE#0I#;VUP86YY(&AA<R!A(&YE="!L;W-S(&9O<B!T
M:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$Q+`T*=&AE(&EN
M8VQU<VEO;B!O9B!C;VUM;VX@<W1O8VL@97%U:79A;&5N=',@:6X@=&AE(&-O
M;7!U=&%T:6]N('=O=6QD#0IB92!A;G1I9&EL=71I=F4N($%C8V]R9&EN9VQY
M+"!B87-I8R!A;F0@9&EL=71E9"!N970@;&]S<R!P97(@<VAA<F4-"F%R92!T
M:&4@<V%M92!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P-
M"C(P,#$Q+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4
M:&4-"F9O;&QO=VEN9R!T86)L92!S971S(&9O<G1H('1H92!S:&%R97,@86YD
M(&YE="!I;F-O;64@=7-E9"!I;B!T:&4-"F1I;'5T960@96%R;FEN9W,@<&5R
M('-H87)E(&-O;7!U=&%T:6]N(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M#0I-87)C:"`S,2P@,C`Q,#H\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/B8C
M>$$P.SPO9&EV/@T*/&1I=B!A;&EG;CTS1&QE9G0^#0H\=&%B;&4@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M.#`E/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#@X)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY.=6UE<F%T;W(Z/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O
M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O
M;&]R/3-$=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.#@E
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
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M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
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M+4Q%1E0Z(#EP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
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M6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@R+#,T,"PU
M,34\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BD\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#@X)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@.7!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY$:79I9&5N9',-"F]N(&-O;G9E<G1I8FQE('!R
M969E<G)E9"!S=&]C:SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
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M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#@X)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
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M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W
M:&ET93X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0X."4@86QI9VX],T1L969T/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^3F5T#0II;F-O
M;64@879A:6QA8FQE('1O(&-O;6UO;B!S=&]C:VAO;&1E<G,@=7-E9"!I;B!D
M:6QU=&5D(&5A<FYI;F=S#0IP97(@<VAA<F4@8V%L8W5L871I;VX\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#DE/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*,RPP,#DL-C`W/"]F
M;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G
M8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#@X)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
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M+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0X."4@86QI9VX],T1L969T/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$.24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&
M0T,^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.#@E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#@X)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY796EG:'1E9`T*879E<F%G92!S:&%R
M97,@;V8@8V]M;6]N('-T;V-K('5S960@:6X@=&AE(&-O;7!U=&%T:6]N(&]F
M(&)A<VEC#0IE87)N:6YG<R!P97(@<VAA<F4\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU,C(L,S4P/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$.#@E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@X)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G
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M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$.#@E(&%L:6=N/3-$;&5F=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$:6QU=&EV
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M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#
M0T9&0T,^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.#@E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@X)2!A
M;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY3:&%R97,-"G5S960@:6X@8V]M<'5T871I;VX@;V8@9&EL
M=71E9"!E87)N:6YG<R!P97(@<VAA<F4\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,
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M.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^)B-X
M03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^5&AE#0IF;VQL;W=I;F<@<&]T96YT:6%L;'D@9&EL
M=71I=F4@<V5C=7)I=&EE<R!H879E(&)E96X@97AC;'5D960@9G)O;0T*=&AE
M(&-O;7!U=&%T:6]N(&]F(&1I;'5T960@;F5T(&EN8V]M92`H;&]S<RD@<&5R
M('-H87)E('-I;F-E('1H96ER#0II;F-L=7-I;VX@=V]U;&0@8F4@86YT:61I
M;'5T:79E.CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[/"]D:78^
M#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X,"4^#0H\='(^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-S8E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
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M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
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M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
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M9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<V)3X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN92<^,C`Q,3PO9F]N=#X\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4G/C(P,3`\+V9O;G0^/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$P)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S8E(&%L:6=N
M/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/E-T;V-K#0IO<'1I;VYS/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'
M3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4G/@T*-#DL,C(W/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W
M:&ET93X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0W-B4@86QI9VX],T1L969T/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^5V%R<F%N=',\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$.24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HS,34L,3<P
M/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
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M8FQE/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*
M,3,N("8C>$$P.R!.150@3$]34R!015(@4TA!4D4\+V9O;G0^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
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M;G9E<G1I8FQE(&1E8G0N)B-X03`[#0I3:6YC92!T:&5R92!I<R!A(&YE="!L
M;W-S(&%T=')I8G5T86)L92!T;R!C;VUM;VX@<W1O8VMH;VQD97)S(&9O<@T*
M=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,2!A;F0@
M,C`Q,"!A;F0@=&AE('EE87)S#0IE;F1E9"!$96-E;6)E<B`S,2P@,C`Q,"!A
M;F0@,C`P.2P@=&AE(&EN8VQU<VEO;B!O9B!C;VUM;VX@<W1O8VL-"F5Q=6EV
M86QE;G1S(&EN('1H92!C;VUP=71A=&EO;B!F;W(@=&AO<V4@<&5R:6]D<R!W
M;W5L9"!B90T*86YT:61I;'5T:79E+B!!8V-O<F1I;F=L>2P@8F%S:6,@86YD
M(&1I;'5T960@;F5T(&QO<W,@<&5R('-H87)E(&ES#0IT:&4@<V%M92!F;W(@
M86QL('!E<FEO9',@<')E<V5N=&5D+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
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M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+V1I=CX-"CQD:78@86QI9VX],T1C96YT97(^
M#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$.3`E/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)2!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,B4@8V]L
M<W!A;CTS1#8^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN92<^3FEN90T*36]N=&AS)B-X03`[16YD960F(WA!
M,#M397!T96UB97(F(WA!,#LS,"P\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
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M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/E1W96QV928C>$$P
M.TUO;G1H<R8C>$$P.T5N9&5D/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M)SY$96-E;6)E<B8C>$$P.S,Q+#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SY#=6UU;&%T
M:79E/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SY$979E;&]P;65N="T\
M+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/E-T86=E)B-X03`[4&5R:6]D
M)B-X03`[/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SYF<F]M)B-X03`[
M/"]F;VYT/CPO9F]N=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN92<^3F]V96UB97(\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G
M/C<L)B-X03`[,C`P,CPO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/G1H<F]U9V@\
M+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/D1E8V5M8F5R)B-X03`[,S$L
M/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-#`E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$P)2!C;VQS<&%N/3-$,CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
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M1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL
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M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT
M97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^
M,C`Q,#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P
M)2!C;VQS<&%N/3-$,CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
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M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
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M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,"4@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^,C`Q,#PO9F]N=#X\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#0P)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY#;VYV97)T:6)L90T*9&5B=#PO9F]N=#X\
M+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P
M>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O
M=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@
M9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HF(W@R,#$T.SPO
M9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#1P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X
M(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T
M<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I
M9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HS+#4T-RPQ
M.3@\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$<FEG
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M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@86QI9VX]
M,T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*,RPV
M-#8L,S<P/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#1P>"!D;W5B;&4G('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE(&%L
M:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#1P>"!D;W5B;&4G('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE
M(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
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M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G
M8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,"4@86QI9VX],T1L969T
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M5V%R<F%N=',\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/@T*
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F
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M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
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M5$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@86QI
M9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*
M)B-X,C`Q-#L\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
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M1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#1P>"!D;W5B;&4G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U
M8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HF(W@R,#$T.SPO9F]N
M=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/@T*/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@
M86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G
M/@T*)B-X,C`Q-#L\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
M"B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(T-#
M1D9#0SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0T,"4@86QI9VX],T1L969T/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^4W1O8VL-"F]P
M=&EO;G,\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@
M86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G
M/@T*,RPV,S(L-C,X/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
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M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE)SX-"C<W-2PX-3,\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4G/@T*-S8Y+#$X.3PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED
M=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED
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M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
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M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
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M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
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M('-T;V-K(&%N9"!A8V-U;75L871E9"!D:79I9&5N9',N)B-X03`[)B-X03`[
M4VEN8V4@=&AE#0I#;VUP86YY(&AA<R!A(&YE="!L;W-S(&%T=')I8G5T86)L
M92!T;R!C;VUM;VX@<W1O8VMH;VQD97)S(&9O<B!T:&4-"GEE87)S(&5N9&5D
M($1E8V5M8F5R(#,Q+"`R,#$P(&%N9"`R,#`Y+"!T:&4@:6YC;'5S:6]N(&]F
M(&-O;6UO;@T*<W1O8VL@97%U:79A;&5N=',@:6X@=&AE(&-O;7!U=&%T:6]N
M(&9O<B!T:&]S92!P97)I;V1S('=O=6QD(&)E#0IA;G1I9&EL=71I=F4N($%C
M8V]R9&EN9VQY+"!B87-I8R!A;F0@9&EL=71E9"!N970@;&]S<R!P97(@<VAA
M<F4@:7,-"G1H92!S86UE(&9O<B!T:&4@<&5R:6]D<R!P<F5S96YT960N/"]F
M;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3XF(WA!,#L\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
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M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J
M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
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M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
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M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE)SY$96-E;6)E<B`S,2P\+V9O;G0^/"]F;VYT
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
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M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
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M9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE)SXR,#`Y/"]F;VYT/CPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-S8E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U
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M<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SX-"C4P+#`W
M-#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN92<^#0HV,"PR-C`\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
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M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#DE(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
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M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L
M92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*,C,R+#$V-#PO9F]N
M=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#<V)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#;VYV97)S:6]N#0IO
M9B!P<F5F97)R960@<W1O8VL\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4G/@T*,BPP-#(L,3`X/"]F;VYT/CPO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS1')I9VAT/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HS,CDL-#4Q/"]F;VYT/CPO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L
M969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[*#$I/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\+W1A
M8FQE/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
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M+V1I=CX-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?9#)D,6$S9CA?,&,U-U\T,38X7V)E9&-?.#8W-V1C9&(S-65C
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0R9#%A,V8X7S!C-3=?
M-#$V.%]B961C7S@V-S=D8V1B,S5E8R]7;W)K<VAE971S+U-H965T,C$N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5814%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/34U)
M5$U%3E13/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-/34U)5$U%3E13/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/&1I=CX-"CQT86)L
M92!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#$P,"4@86QI9VX],T1C96YT97(^#0H\='(@
M=F%L:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`S-G!T)SX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"CDN/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9#X-"CQD:78@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M#0I#3TU-251-14Y44SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T
M86)L93X-"CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
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M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"D-O;7!A;GD@:&%S
M(&5N=&5R960@:6YT;R!R971E;G1I;VX@86=R965M96YT<R!W:71H(&5A8V@@
M;V8@:71S#0IT:')E92!V:6-E('!R97-I9&5N=',N)B-X03`[)B-X03`[5&AE
M(&%G<F5E;65N=',@<')O=FED92!F;W(@=&AE#0IL=6UP+7-U;2!P87EM96YT
M(&]F('-I>"!M;VYT:',F(W@R,#$Y.R!B87-E('-A;&%R>2!A;F0@8F5N969I
M=',@=&\-"F5A8V@@<W5C:"!O9F9I8V5R(&9O;&QO=VEN9R!A('1E<FUI;F%T
M:6]N('=I=&AO=70@8V%U<V4@;W(@80T*<F5S:6=N871I;VX@=VET:"!G;V]D
M(')E87-O;B!O8V-U<G)I;F<@;VX@;W(@8F5F;W)E($YO=F5M8F5R(#$T+`T*
M,C`Q,2XF(WA!,#LF(WA!,#M#97)T86EN(&]F('1H92!A9W)E96UE;G1S('!R
M;W9I9&4@=&AA="!I9B!T:&4-"F5X96-U=&EV97,@=V5R92!E;7!L;WEE9"!W
M:71H('1H92!#;VUP86YY(&%S(&]F($]C=&]B97(@,2P@,C`Q,"P-"G1H97D@
M=V]U;&0@<F5C96EV92!A('!A>6UE;G0@;V8@='=O(&UO;G1H<R8C>#(P,3D[
M(&)A<V4@<V%L87)Y(&%S(&$-"G)E=&5N=&EO;B!B;VYU<R!O;B!T:&%T(&1A
M=&4N(%1H92!R971E;G1I;VX@8F]N=7,@=V%S('!A:60@:6X-"D]C=&]B97(@
M,C`Q,"!A;F0@=VEL;"!B92!D961U8W1E9"!F<F]M('1H92!S979E<F%N8V4@
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M<R!I<R!A<'!R;WAI;6%T96QY("9N8G-P.R0X-BPP,#`@=&\@0VAR:7-T;W!H
M97(-"E!A>F]L97,N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$=7)I
M;F<-"G1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L(#(P,3$L('!U
M<G-U86YT('1O(')E=&5N=&EO;@T*86=R965M96YT<RP@=&AE($-O;7!A;GD@
M<&%I9"!A('1O=&%L(&]F(&%P<')O>&EM871E;'D@)FYB<W`[)#(Q."PP,#`@
M:6X-"G-E=F5R86YC92!P87EM96YT<R!T;R!E;7!L;WEE97,@=&5R;6EN871E
M9"!D=7)I;F<@=&AA="!P97)I;V0L#0II;F-L=61I;F<@)FYB<W`[)#@S+#`P
M,"!T;R!%;&EA<R!.>6)E<F<L('1H92!#;VUP86YY)B-X,C`Q.3MS(&9O<FUE
M<B!V:6-E#0IP<F5S:61E;G0@;V8@<F5G=6QA=&]R>2P@<75A;&ET>2!A;F0@
M8V]M<&QI86YC92X\+V9O;G0^/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/@T*,30N)B-X03`[($-/34U)5$U%3E13/"]F;VYT/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
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M/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY/;@T*4V5P=&5M8F5R(#4L(#(P,#<L($-E;&QE8W1A<B!E
M;G1E<F5D(&EN=&\@82`S-BUM;VYT:"!L96%S92!F;W(-"F]F9FEC92!A;F0@
M;6%N=69A8W1U<FEN9R!S<&%C92P@8V]M;65N8VEN9R!397!T96UB97(@,34L
M#0HR,#`W+B8C>$$P.R!4:&4@;&5A<V4@<')O=FED97,@9F]R('1H92!O<'1I
M;VX@=&\@97AT96YD('1H92!L96%S90T*=6YD97(@:71S(&-U<G)E;G0@=&5R
M;7,@9F]R('-E=F5N(&%D9&ET:6]N86P@='=O+7EE87(@=&5R;7,N)B-X03`[
M#0I296YT(&ES("9N8G-P.R0X+#`U,"!P97(@;6]N=&@@9F]R('1H92!F:7)S
M="!Y96%R(&%N9"!T:&5N(&5S8V%L871E<R!B>0T*,R4@<&5R('EE87(@9F]R
M('1H92!D=7)A=&EO;B!O9B!T:&4@=&5R;2!I;F-L=61I;F<@86YY(&QE87-E
M#0IE>'1E;G-I;VX@=&5R;7,N)B-X03`[(%1H92!L96%S92!A;'-O(')E<75I
M<F5S('1H92!P87EM96YT(&]F#0IM;VYT:&QY(')E;G0@;V8@)FYB<W`[)#$L
M,30P(&9O<B!A<'!R;WAI;6%T96QY(#,L-#`P('-Q=6%R92!F965T(&]F#0IE
M>'!A;G-I;VX@<W!A8V4N)B-X03`[(%1H92!M;VYT:&QY(')E;G0@9F]R('1H
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M;F0@;6%I;G1E;F%N8V4N)B-X03`[(%)E;G0@97AP96YS90T*:7,@<F5C;V=N
M:7IE9"!O;B!A('-T<F%I9VAT+6QI;F4@8F%S:7,@86YD(&%C8V]R9&EN9VQY
M('1H90T*9&EF9F5R96YC92!B971W965N('1H92!R96-O<F1E9"!R96YT(&5X
M<&5N<V4@86YD('1H92!A8W1U86P@8V%S:`T*<&%Y;65N=',@:&%S(&)E96X@
M<F5C;W)D960@87,@9&5F97)R960@<F5N="!A<R!O9B!E86-H(&)A;&%N8V4-
M"G-H965T(&1A=&5S+B8C>$$P.R!$=64@=&\@=&AE('-I9VYI9FEC86YT('9A
M;'5E(&]F(&QE87-E:&]L9`T*:6UP<F]V96UE;G1S('!U<F-H87-E9"!D=7)I
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M=#X\+V1I=CX-"CQB<B`O/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"D-O;7!A;GD@
M:7,@<F5Q=6ER960@=&\@<F5M;W9E(&-E<G1A:6X@86QT97)A=&EO;G,L(&%D
M9&ET:6]N<R!A;F0-"FEM<')O=F5M96YT<R!U<&]N('1E<FUI;F%T:6]N(&]F
M('1H92!L96%S92!T:&%T(&%L=&5R960@82!P;W)T:6]N#0IO9B!T:&4@<F5N
M=&%B;&4@<W!A8V4N)B-X03`[($EN(&YO(&5V96YT('-H86QL('1H92!C;W-T
M(&]F('-U8V@-"G)E;6]V86PL(&%T(&-O;6UE<F-I86QL>2!R96%S;VYA8FQE
M(')A=&5S+"!P86ED(&)Y('1H92!#;VUP86YY#0IE>&-E960@)FYB<W`[)#4U
M+#`P,"`H)B-X,C`Q0SM#87!P960@06UO=6YT)B-X,C`Q1#LI(&%N9"!A;GD@
M86UO=6YT(&EN#0IE>&-E<W,@;V8@=&AE($-A<'!E9"!!;6]U;G0@<VAA;&P@
M8F4@=&AE(&]B;&EG871I;VX@;V8@=&AE#0IL86YD;&]R9"XF(WA!,#L@5&AE
M($-O;7!A;GD@:7,@<F5Q=6ER960@=&\@;6%I;G1A:6X@82!C97)T:69I8V%T
M90T*;V8@9&5P;W-I="!E<75A;"!T;R!T:&4@0V%P<&5D($%M;W5N="!D=7)I
M;F<@=&AE('1E<FT@;V8@=&AE(&QE87-E+`T*=VAI8V@@86UO=6YT(&ES('-H
M;W=N(&%S(')E<W1R:6-T960@8V%S:"!I;B!T:&4@86-C;VUP86YY:6YG#0IB
M86QA;F-E('-H965T<RX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D5F
M9F5C=&EV90T*2G5N92`Q+"`R,#$P+"!#96QL96-T87(@96YT97)E9"!I;G1O
M(&$@<V5V96XM;6]N=&@@97AT96YS:6]N(&]F(&ET<PT*;V9F:6-E('-P86-E
M(&%N9"!E9F9E8W1I=F4@1&5C96UB97(@,3,L(#(P,3`@86UE;F1E9"!T:&4@
M97AT96YS:6]N#0IT;R!I;F-R96%S92!T:&4@;&5A<V4@97AT96YS:6]N(&%N
M(&%D9&ET:6]N86P@9FEV92UM;VYT:',L(&5X<&ER:6YG#0I-87D@,S$L(#(P
M,3$N)B-X03`[($EN(&-O;FYE8W1I;VX@=VET:"!T:&4@97AT96YS:6]N+"!T
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M870@:70@<&%Y('1H92!U;G!A:60@<F5N="!F;W(@2G5N92`Q+"`R,#$P('1H
M<F]U9V@-"DUA<F-H(#,Q+"`R,#$Q+"!B87-E9"!O;B!T:&4@;W)I9VEN86P@
M=&5R;7,@;V8@=&AE(&QE87-E+"!P;'5S#0II;G1E<F5S="!A="`Q,"4@<&5R
M(&%N;G5M+B8C>$$P.R!!<R!O9B!$96-E;6)E<B`S,2P@,C`Q,"P@)FYB<W`[
M)#0U+#`P,`T*=V%S(&%C8W)U960@:6X@=&AE(&%C8V]M<&%N>6EN9R!B86QA
M;F-E('-H965T(&9O<B!T:&4@=6YP86ED(')E;G0-"F%N9"!A8V-R=65D(&EN
M=&5R97-T+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^3VX-"D%P<FEL
M(#$U+"`R,#$Q+"!T:&4@0V]M<&%N>2!E>'1E;F1E9"!I=',@8G5I;&1I;F<@
M;&5A<V4@9F]R('1H90T*36%D:7-O;BP@5TD@:&5A9'%U87)T97)S('1H<F]U
M9V@@4V5P=&5M8F5R(#$T+"`R,#$R(&%C8V]R9&EN9R!T;PT*=&AE('1E<FUS
M(&EN('1H92!O<FEG:6YA;"!L96%S92!A;F0@<&%I9"!A;&P@=6YP86ED(')E
M;G0@86YD#0IR96QA=&5D(&%C8W)U960@:6YT97)E<W0N/"]F;VYT/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY&=71U<F4-"FUI;FEM=6T@;&5A<V4@<&%Y;65N
M=',@=6YD97(@=&AI<R!N;VXM8V%N8V5L86)L92!L96%S92!A<F4-"F%P<')O
M>&EM871E;'D@)FYB<W`[)#$Y-BPP,#`@86YD("9N8G-P.R0Q,C0L,#`P(&1U
M<FEN9R`R,#$Q(&%N9`T*,C`Q,BX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
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M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E)E;G0-"F5X<&5N<V4@=V%S("9N
M8G-P.R0Q-#,L,#`P(&%N9"`F;F)S<#LD,3$W+#`P,"!F;W(@=&AE(&YI;F4@
M;6]N=&AS(&5N9&5D#0I397!T96UB97(@,S`L(#(P,3$@86YD(#(P,3`L(')E
M<W!E8W1I=F5L>2P@)FYB<W`[)#$U.2PP,#`@86YD("9N8G-P.R0Q.#`L,#`P
M#0IF;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$P(&%N9"`R
M,#`Y+"!R97-P96-T:79E;'D@86YD#0HF;F)S<#LD.30U+#`P,"!F<F]M(&EN
M8V5P=&EO;B!T;R!$96-E;6)E<B`S,2P@,C`Q,"X\+V9O;G0^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M5%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0G/@T*0V%P:71A;"!,96%S93PO9F]N=#X\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<^0V5R=&%I;@T*97%U:7!M96YT(&ES(&QE87-E9"!U;F1E<B!A(&-A
M<&ET86P@;&5A<V4N)B-X03`[(%1H92!L96%S90T*86=R965M96YT(')E<75I
M<F5S(&UO;G1H;'D@<')I;F-I<&%L(&%N9"!I;G1E<F5S="!P87EM96YT<R!O
M9B`F;F)S<#LD,C$W#0IA;F0@97AP:7)E<R!O;B!397!T96UB97(@,RP@,C`Q
M-"XF(WA!,#L@5&AE(&]U='-T86YD:6YG(&]B;&EG871I;VX-"FES(&)E:6YG
M(&%M;W)T:7IE9"!U<VEN9R!A(#<E(&EN=&5R97-T(')A=&4@8F%S960@;VX@
M8V]M<&%R86)L90T*8F]R<F]W:6YG(')A=&5S+CPO9F]N=#X\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG
M/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
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M<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!L969T.R!4
M15A4+4E.1$5.5#H@,'!T.R!-05)'24XM3$5&5#H@,C=P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-24^#0H\
M='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-34E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SY-:6YI
M;75M/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SYL96%S93PO9F]N=#X\
M+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
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M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
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M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/E!R97-E
M;G0F(WA!,#MV86QU93PO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/FUI;FEM=6T\
M+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/FQE87-E/"]F;VYT/CPO9F]N
M=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE)SYP87EM96YT<SPO9F]N=#X\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4U)3X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^,C`Q,3PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF;F)S<#LD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR+#8P.#PO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
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M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
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M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
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M.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/C(L,#@U/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
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M1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXR,#$R/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I
M9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/C(L-C`X/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M,S<S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG:'0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,BPR,S4\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(]
M,T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4U)3X-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M,C`Q,SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(L-C`X/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR,3$\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$R)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.S(L,SDW/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS
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M+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXR,#$T/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$R)2!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN92<^#0HQ+#<S.3PO9F]N=#X\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@
M=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4G/@T*-#4\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@=VED=&@]
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M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-34E(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P
M>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O
M=6)L92<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SX-"B9N8G-P.R0\+V9O;G0^
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`T<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Q
M,B4@86QI9VX],T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4G/@T*.2PU-C,\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L
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M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
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M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
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M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
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M:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\
M8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/E1H90T*97%U:7!M96YT(')E8V]R9&5D('5N9&5R(&-A<&ET
M86QI>F5D(&QE87-E<R!I<R!I;F-L=61E9"!I;B!F:7AE9`T*87-S971S(&%S
M(&]F($1E8V5M8F5R(#,Q.CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/"$M+45&
M4&QA8V5H;VQD97(M+3X\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+4Q%1E0Z
M(#(W<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQT86)L92!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W,"4^
M#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SXR,#$P
M/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
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M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4G/C(P,#D\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT
M<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&QE9G0^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-S`E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/D]F9FEC90T*97%U:7!M96YT/"]F;VYT/CPO
M9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
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M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
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M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R)2!A;&EG
M;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/C$P+#DW,SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)2!A
M;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY,97-S#0IA8V-U;75L871E9"!A;6]R=&EZ871I;VX\+V9O
M;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P
M>"!S;VQI9"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E(&%L:6=N/3-$<FEG
M:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
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M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N
M/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/BD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(E
M(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
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M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^
M#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#1P>"<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T
M<'@@9&]U8FQE)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4G/B9N8G-P.R0\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE
M)R!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@86QI9VX],T1R:6=H=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*."PP-#4\+V9O;G0^/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@-'!X)R!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L92<@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@86QI9VX],T1L969T/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
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M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE)SX-"C$P+#(T,3PO9F]N=#X\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@
M<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO9&EV/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I2971E;G1I
M;VX@06=R965M96YT<SPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
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M8W5T960@8GD-"DYO=F5L;W,@9'5R:6YG(#(P,3`N)B-X03`[(%1H92!A9W)E
M96UE;G1S('!R;W9I9&4@9F]R('1H92!L=6UP+7-U;0T*<&%Y;65N="!O9B!S
M:7@@;6]N=&AS)B-X,C`Q.3L@8F%S92!S86QA<GD@86YD(&)E;F5F:71S('1O
M(&5A8V@@<W5C:`T*;V9F:6-E<B!F;VQL;W=I;F<@82!T97)M:6YA=&EO;B!W
M:71H;W5T(&-A=7-E(&]R(&$@<F5S:6=N871I;VX@=VET:`T*9V]O9"!R96%S
M;VX@;V-C=7)R:6YG(&]N(&]R(&)E9F]R92!.;W9E;6)E<B`Q-"P@,C`Q,2XF
M(WA!,#L@0V5R=&%I;@T*;V8@=&AE(&%G<F5E;65N=',@<')O=FED92!T:&%T
M(&EF('1H92!E>&5C=71I=F5S('=E<F4@96UP;&]Y960@=VET:`T*3F]V96QO
M<R!A<R!O9B!/8W1O8F5R(#$L(#(P,3`L('1H97D@=V]U;&0@<F5C96EV92!A
M('!A>6UE;G0@;V8@='=O#0IM;VYT:',F(W@R,#$Y.R!B87-E('-A;&%R>2!A
M<R!A(')E=&5N=&EO;B!B;VYU<R!O;B!T:&%T(&1A=&4N(%1H90T*<F5T96YT
M:6]N(&)O;G5S(&]F("9N8G-P.R0V."PP,#`@=V%S('!A:60@:6X@3V-T;V)E
M<B`R,#$P(&%N9"!W:6QL(&)E#0ID961U8W1E9"!F<F]M('1H92!S979E<F%N
M8V4@86UO=6YT<R!T:&%T(&UA>2!B96-O;64@<&%Y86)L92!U<&]N(&$-"G-U
M8G-E<75E;G0@:6YV;VQU;G1A<GD@=&5R;6EN871I;VXN)B-X03`[(%1H92!T
M;W1A;"!R96UA:6YI;F<-"F%M;W5N="!T:&%T(&UA>2!B96-O;64@<&%Y86)L
M92!T;R!T:&4@0V]M<&%N>28C>#(P,3D[<R!E>&5C=71I=F4-"F]F9FEC97)S
M('!U<G-U86YT('1O('1H92!R971E;G1I;VX@86=R965M96YT<R!I<R!A<'!R
M;WAI;6%T96QY#0HF;F)S<#LD,S4P+#`P,"X\+V9O;G0^/"]D:78^#0H\8G(@
M+SX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P="<^3VX-"DUA>2`Q."P@,C`Q,2P@=&AE($-O;7!A
M;GDF(W@R,#$Y.W,@8F]A<F0@;V8@9&ER96-T;W)S(&%P<')O=F5D('1H90T*
M96YT<GD@:6YT;R!A(')E=&5N=&EO;B!A9W)E96UE;G0@=VET:"!E86-H(&]F
M(#4@:6YD:79I9'5A;',@=&AA=`T*=V5R92!E;7!L;WEE97,@;V8@0V5L;&5C
M=&%R(&%T('1H92!T:6UE(&]F('1H92!!8W%U:7-I=&EO;BXF(WA!,#L-"E1H
M92!A9W)E96UE;G1S('!R;W9I9&4@9F]R('1H92!L=6UP+7-U;2!P87EM96YT
M(&]F('-I>`T*;6]N=&AS)B-X,C`Q.3L@8F%S92!S86QA<GD@86YD(&)E;F5F
M:71S(&9O;&QO=VEN9R!A('1E<FUI;F%T:6]N#0IW:71H;W5T(&-A=7-E(&]R
M(&$@<F5S:6=N871I;VX@=VET:"!G;V]D(')E87-O;B!O8V-U<G)I;F<@;VX@
M;W(-"F)E9F]R92!.;W9E;6)E<B`Q."P@,C`Q,2XF(WA!,#L@5&AE(&%G<F5E
M;65N=',@97AP:7)E($YO=F5M8F5R(#$X+`T*,C`Q,2X\+V9O;G0^/"]D:78^
M#0H-"@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/&1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"C$P+B!#3TU-
M251-14Y44SPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I0<F]P97)T>2!,96%S
M93PO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D5F9F5C=&EV90T*4V5P
M=&5M8F5R(#$L(#(P,3`L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A('-I
M>"UM;VYT:"!E>'1E;G-I;VX-"G1O(&ET<R!L96%S92!F;W(@;V9F:6-E('-P
M86-E+"!A="!A(')A=&4@;V8@)FYB<W`[)#4L,C<U('!E<B!M;VYT:"P-"F5X
M<&ER:6YG($9E8G)U87)Y(#(X+"`R,#$Q+B!296YT(&5X<&5N<V4@=V%S("9N
M8G-P.R0V-2PP,#`@86YD("9N8G-P.R0X-RPP,#`-"F9O<B!T:&4@>65A<G,@
M96YD960@1&5C96UB97(@,S$L(#(P,3`@86YD(#(P,#DL(')E<W!E8W1I=F5L
M>2X-"D9U='5R92!M:6YI;75M(&QE87-E('!A>6UE;G1S('5N9&5R('1H:7,@
M;F]N+6-A;F-E;&%B;&4@;&5A<V4@87)E#0IA<'!R;WAI;6%T96QY("9N8G-P
M.R0Q,"PV,#`@9'5R:6YG(#(P,3$N)B-X03`[)B-X03`[069T97(@1F5B<G5A
M<GD@,C@L#0HR,#$Q+"!T:&4@;&5A<V4@;6%Y(&)E(&-A;F-E;&5D('=I=&@@
M,S`M9&%Y(&YO=&EC92!B>2!E:71H97(-"G!A<G1Y+CPO9F]N=#X\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/@T*4F]Y86QT>2!!<G)A;F=E;65N=',\+V9O;G0^/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY4:&4-"D-O;7!A;GD@:7,@;V)L:6=A=&5D('1O
M(&$@4G5S<VEA;B!C;VUP86YY+"!:04\@0D%-+"!U;F1E<B!A(')O>6%L='D-
M"F%N9"!T96-H;F]L;V=Y('1R86YS9F5R(&%G<F5E;65N="X@36%R:R!"86QA
M>F]V<VMY+"!A(&1I<F5C=&]R(&]F#0IT:&4@0V]M<&%N>2!U;G1I;"!.;W9E
M;6)E<B`R,#`V+"!I<R!T:&4@;6%J;W)I='D@<VAA<F5H;VQD97(@;V8@6D%/
M#0I"04TN(%!U<G-U86YT('1O('1H92!R;WEA;'1Y(&%N9"!T96-H;F]L;V=Y
M('1R86YS9F5R(&%G<F5E;65N=`T*8F5T=V5E;B!T:&4@0V]M<&%N>2!A;F0@
M6D%/($)!32P@=&AE($-O;7!A;GD@:7,@<F5Q=6ER960@=&\@;6%K90T*<F]Y
M86QT>2!P87EM96YT<R!O9B`Q+C(E(&]F(&YE="!S86QE<R!O9B!O>&ED:7IE
M9"!G;'5T871H:6]N92UB87-E9`T*<')O9'5C=',N(%1H92!#;VUP86YY(&ES
M(&%L<V\@<F5Q=6ER960@=&\@<&%Y(%I!3R!"04T@)FYB<W`[)#(@;6EL;&EO
M;@T*9F]R(&5A8V@@;F5W(&]X:61I>F5D(&=L=71A=&AI;VYE+6)A<V5D(&1R
M=6<@=VET:&EN(&5I9VAT965N(&UO;G1H<PT*9F]L;&]W:6YG($9$02!A<'!R
M;W9A;"!O9B!S=6-H(&1R=6<N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#XF(WA!
M,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
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M92!R979E;G5E<R!E>&-E960@=&AE#0I#;VUP86YY)B-X,C`Q.3MS(&-U;75L
M871I=F4@97AP96YD:71U<F5S(&EN8VQU9&EN9RP@8G5T(&YO="!L:6UI=&5D
M#0IT;RP@<')E8VQI;FEC86P@86YD(&-L:6YI8V%L('-T=61I97,L('1E<W1I
M;F<L($9$02!A;F0@;W1H97(-"G)E9W5L871O<GD@86=E;F-Y('-U8FUI<W-I
M;VX@86YD(&%P<')O=F%L(&-O<W1S+"!G96YE<F%L(&%N9`T*861M:6YI<W1R
M871I=F4@8V]S=',L(&%N9"!P871E;G0@97AP96YS97,L('1H96X@=&AE($-O
M;7!A;GD@=V]U;&0-"F)E(')E<75I<F5D('1O('!A>2!:04\@0D%-(&%N(&%D
M9&ET:6]N86P@.24@;V8@=&AE(&%M;W5N="!B>2!W:&EC:`T*;&EC96YS92!R
M979E;G5E<R!E>&-E960@=&AE($-O;7!A;GDF(W@R,#$Y.W,@8W5M=6QA=&EV
M90T*97AP96YD:71U<F5S+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
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M<R!I<R!O8FQI9V%T960@=&\@=&AE#0I/>&9O<F0@1W)O=7`L($QT9"XL(&]R
M(&ET<R!A<W-I9VYE97,L(&9O<B!F=71U<F4-"G)O>6%L=&EE<RXF(WA!,#LF
M(WA!,#M3:6UY;VX@4&%L;6EN+"!A(&9O=6YD97(@;V8@3F]V96QO<RP@80T*
M9&ER96-T;W(@=6YT:6P@075G=7-T(#$R+"`R,#`X(&%N9"!T:&4@9F%T:&5R
M(&]F('1H90T*0V]M<&%N>28C>#(P,3D[<R!P<F5S:61E;G0@86YD(&-H:65F
M(&5X96-U=&EV92!O9F9I8V5R+"!I<R!P<F5S:61E;G0-"F]F($]X9F]R9"!'
M<F]U<"P@3'1D+B8C>$$P.R8C>$$P.TUR+B!086QM:6X@=V%S(&%L<V\@86X@
M96UP;&]Y964@;V8-"G1H92!#;VUP86YY('5N=&EL(%-E<'1E;6)E<B`R,#`X
M(&%N9"!P97)F;W)M960@8V]N<W5L=&EN9R!S97)V:6-E<PT*=&AR;W5G:"!$
M96-E;6)E<B`R,#`Y+B8C>$$P.R8C>$$P.U!U<G-U86YT('1O('1H92!A9W)E
M96UE;G0L(&%S#0IR979I<V5D($UA>2`R-BP@,C`P-2P@3F]V96QO<R!I<R!R
M97%U:7)E9"!T;R!P87D@3WAF;W)D($=R;W5P+`T*3'1D+BP@;W(@:71S(&%S
M<VEG;F5E<RP@82!R;WEA;'1Y(&EN('1H92!A;6]U;G0@;V8@,"XX)2!O9B!T
M:&4-"D-O;7!A;GDF(W@R,#$Y.W,@;F5T('-A;&5S(&]F(&]X:61I>F5D(&=L
M=71A=&AI;VYE+6)A<V5D#0IP<F]D=6-T<RX\+V9O;G0^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\
M8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
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M/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY4:&4-"D-O;7!A;GD@96YT97)E9"!I;G1O(&%N(&5M<&QO
M>6UE;G0@86=R965M96YT('=I=&@@2&%R<GD@4&%L;6EN#0IE9F9E8W1I=F4@
M2F%N=6%R>2`Q+"`R,#`V+"!W:&5R96)Y(&AE(&%G<F5E9"!T;R!S97)V92!A
M<R!T:&4-"D-O;7!A;GDF(W@R,#$Y.W,@<')E<VED96YT(&%N9"!C:&EE9B!E
M>&5C=71I=F4@;V9F:6-E<B!F;W(@86X-"FEN:71I86P@=&5R;2!O9B!T=V\@
M>65A<G,N)B-X03`[)B-X03`[5&AE(&%G<F5E;65N="!I<PT*875T;VUA=&EC
M86QL>2!R96YE=V5D(&9O<B!S=6-C97-S:79E(&]N92UY96%R('1E<FUS('5N
M;&5S<R!N;W1I8V4-"F]F('1E<FUI;F%T:6]N(&ES('!R;W9I9&5D(&)Y(&5I
M=&AE<B!P87)T>2!A="!L96%S="`Y,"!D87ES('!R:6]R#0IT;R!T:&4@96YD
M(&]F('-U8V@@=&5R;2XF(WA!,#LF(WA!,#M4:&4@86=R965M96YT('=A<R!R
M96YE=V5D(&UO<W0-"G)E8V5N=&QY(&9O<B!A;B!A9&1I=&EO;F%L(&]N92UY
M96%R('1E<FT@;VX@2F%N=6%R>2`Q+"`R,#$Q(&EN#0IA8V-O<F1A;F-E('=I
M=&@@:71S('1E<FUS+B8C>$$P.R8C>$$P.U1H92!A9W)E96UE;G0@<')O=FED
M97,@9F]R(&%N#0II;FET:6%L('-A;&%R>2!O9B`F;F)S<#LD,C(U+#`P,"!I
M;B`R,#`V+"!P87)T:6-I<&%T:6]N(&EN('-T86YD87)D#0IB96YE9FET('!R
M;V=R86US(&%N9"!A;B!A;FYU86P@8V%S:"!B;VYU<R!A="!T:&4@9&ES8W)E
M=&EO;B!O9B!T:&4-"F-O;7!E;G-A=&EO;B!C;VUM:71T964N)B-X03`[)B-X
M03`[5&AE(&%G<F5E;65N="!F=7)T:&5R('!R;W9I9&5S#0IT:&%T('5P;VX@
M<F5S:6=N871I;VX@9F]R(&=O;V0@<F5A<V]N(&]R('1E<FUI;F%T:6]N('=I
M=&AO=70@8V%U<V4L#0IB;W1H(&%S(&1E9FEN960@:6X@=&AE(&%G<F5E;65N
M="P@37(N)B-X03`[4&%L;6EN('=I;&P@<F5C96EV92!H:7,-"G!R;R!R871A
M('-H87)E(&]F('1H92!A=F5R86=E(&]F(&AI<R!A;FYU86P@8F]N=7,@<&%I
M9"!D=7)I;F<@=&AE#0IT=V\@9FES8V%L('EE87)S('!R96-E9&EN9R!H:7,@
M=&5R;6EN871I;VXL(&AI<R!B87-E('-A;&%R>2!A;F0-"F)E;F5F:71S(&9O
M<B`Q,2!M;VYT:',@869T97(@=&AE(&1A=&4@;V8@=&5R;6EN871I;VX@86YD
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M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M5%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0G/@T*4F5T96YT:6]N($%G<F5E;65N=',\+V9O;G0^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/D]N#0I-87D@,30L(#(P,3`L('1H92!#;VUP86YY(&5N
M=&5R960@:6YT;R!R971E;G1I;VX@86=R965M96YT<R!W:71H#0IE86-H(&]F
M(&ET<R!F;W5R('9I8V4M<')E<VED96YT<RXF(WA!,#LF(WA!,#M4:&4@86=R
M965M96YT<R!P<F]V:61E#0IF;W(@=&AE(&QU;7`M<W5M('!A>6UE;G0@;V8@
M<VEX(&UO;G1H<R8C>#(P,3D[(&)A<V4@<V%L87)Y(&%N9`T*8F5N969I=',@
M=&\@96%C:"!S=6-H(&]F9FEC97(@9F]L;&]W:6YG(&$@=&5R;6EN871I;VX@
M=VET:&]U="!C875S90T*;W(@82!R97-I9VYA=&EO;B!W:71H(&=O;V0@<F5A
M<V]N(&]C8W5R<FEN9R!O;B!O<B!B969O<F4@3F]V96UB97(-"C$T+"`R,#$Q
M+B8C>$$P.R8C>$$P.U1H92!A9W)E96UE;G1S(&9U<G1H97(@<')O=FED92!T
M:&%T(&EF('1H90T*97AE8W5T:79E<R!R96UA:6X@96UP;&]Y960@=VET:"!T
M:&4@0V]M<&%N>2!A<R!O9B!/8W1O8F5R(#$L(#(P,3`L#0IT:&5Y('=I;&P@
M<F5C96EV92!A('!A>6UE;G0@;V8@='=O(&UO;G1H<R8C>#(P,3D[(&)A<V4@
M<V%L87)Y(&%S(&$-"G)E=&5N=&EO;B!B;VYU<R!O;B!T:&%T(&1A=&4N(%1H
M92!R971E;G1I;VX@8F]N=7,L(&%N(&%G9W)E9V%T92!O9@T*)FYB<W`[)#$T
M,"PP,#`L('=A<R!P86ED(&EN($]C=&]B97(@,C`Q,"!A;F0@=VEL;"!B92!D
M961U8W1E9"!F<F]M('1H90T*<V5V97)A;F-E(&%M;W5N=',@=&AA="!M87D@
M8F5C;VUE('!A>6%B;&4@=7!O;B!A('-U8G-E<75E;G0-"FEN=F]L=6YT87)Y
M('1E<FUI;F%T:6]N+B8C>$$P.R8C>$$P.T5L:6%S($YY8F5R9R8C>#(P,3D[
M<R!E;7!L;WEM96YT#0IW87,@=&5R;6EN871E9"!O;B!-87)C:"`Q,"P@,C`Q
M,2P@=VET:&]U="!C875S92P@86YD(&AE(')E8V5I=F5D(&$-"G!A>6UE;G0@
M;V8@87!P<F]X:6UA=&5L>2`F;F)S<#LD.#,L,#`P('!U<G-U86YT('1O('1H
M92!E>&5C=71I=F4-"G)E=&5N=&EO;B!A9W)E96UE;G0N(%1H92!A9W)E96UE
M;G1S(&5X<&ER92!.;W9E;6)E<B`Q-"P-"C(P,3$N)B-X03`[)B-X03`[5&AE
M('1O=&%L(')E;6%I;FEN9R!A;6]U;G0@=&AA="!M87D@8F5C;VUE('!A>6%B
M;&4-"G1O('1H92!#;VUP86YY)B-X,C`Q.3MS($YA;65D($5X96-U=&EV92!/
M9F9I8V5R<R!P=7)S=6%N="!T;R!T:&4-"G)E=&5N=&EO;B!A9W)E96UE;G1S
M(&ES(&%P<')O>&EM871E;'D@)FYB<W`[)#@V+#`P,"!T;R!#:')I<W1O<&AE
M<@T*4&%Z;VQE<RX@0V]N8W5R<F5N=&QY('=I=&@@=&AE(&5X96-U=&EO;B!O
M9B!T:&4@<F5T96YT:6]N#0IA9W)E96UE;G1S+"!T:&4@96UP;&]Y;65N="!A
M9W)E96UE;G0@8F5T=V5E;B!T:&4@0V]M<&%N>2!A;F0-"D-H<FES=&]P:&5R
M(%!A>F]L97,@9&%T960@2G5L>2`Q-2P@,C`P-2!W87,-"G1E<FUI;F%T960N
M/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/;@T*36%Y(#$T+"`R,#$P
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M96UB97(-"C$T+"`R,#$Q+B8C>$$P.R8C>$$P.U1H92!A9W)E96UE;G1S(&5X
M<&ER92!.;W9E;6)E<B`Q-"P-"C(P,3$N/"]F;VYT/CPO9&EV/@T*/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15A%
M04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3$E424=!5$E/3CQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y,251)1T%424]./"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#$P,"4^#0H\='(@=F%L:6=N/3-$=&]P/@T*/'1D('-T>6QE/3-$
M)U=)1%1(.B`S-G!T)R!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/@T*."XF(WA!,#L\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"DQ)5$E'051)3TX\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^00T*<'5R<&]R=&5D(&-L87-S(&%C=&EO;B!C;VUP;&%I;G0@=V%S
M(&9I;&5D(&]N($UA<F-H(#4L(#(P,3`@:6X@=&AE#0I5;FET960@4W1A=&5S
M($1I<W1R:6-T($-O=7)T(&9O<B!T:&4@1&ES=')I8W0@;V8@36%S<V%C:'5S
M971T<R!B>0T*86X@86QL96=E9"!S:&%R96AO;&1E<B!O9B!T:&4@0V]M<&%N
M>2P@;VX@8F5H86QF(&]F(&AI;7-E;&8@86YD(&%L;`T*;W1H97)S('=H;R!P
M=7)C:&%S960@;W(@;W1H97)W:7-E(&%C<75I<F5D('1H92!#;VUP86YY)B-X
M,C`Q.3MS#0IC;VUM;VX@<W1O8VL@:6X@=&AE('!E<FEO9"!B971W965N($1E
M8V5M8F5R(#$T+"`R,#`Y(&%N9"!&96)R=6%R>0T*,C0L(#(P,3`L(&%G86EN
M<W0@=&AE($-O;7!A;GD@86YD(&ET<R!0<F5S:61E;G0@86YD($-H:65F($5X
M96-U=&EV90T*3V9F:6-E<BP@2&%R<GD@4RX@4&%L;6EN+B8C>$$P.R8C>$$P
M.T]N($]C=&]B97(@,2P@,C`Q,"P@=&AE(&-O=7)T#0IA<'!O:6YT960@;&5A
M9"!P;&%I;G1I9F9S("A";W)I<R!5<FUA;B!A;F0@4F%M;VYA($UC1&]N86QD
M*2!A;F0-"F%P<&]I;G1E9"!L96%D('!L86EN=&EF9G,F(W@R,#$Y.R!C;W5N
M<V5L+B8C>$$P.R8C>$$P.T]N($]C=&]B97(@,C(L#0HR,#$P+"!A;B!A;65N
M9&5D(&-O;7!L86EN="!W87,@9FEL960N)B-X03`[)B-X03`[5&AE(&%M96YD
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M=')I86P@;V8@3D]6+3`P,B!F;W(@;F]N+7-M86QL(&-E;&P-"FQU;F<@8V%N
M8V5R+B8C>$$P.R8C>$$P.T]N($1E8V5M8F5R(#8L(#(P,3`L('1H92!#;VUP
M86YY(&9I;&5D(&$-"FUO=&EO;B!T;R!D:7-M:7-S('1H92!C;VUP;&%I;G0@
M=VET:"!P<F5J=61I8V4N)B-X03`[)B-X03`[3VX-"DIA;G5A<GD@,C`L(#(P
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M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^)B-X03`[/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/
M;@T*2G5N92`R."P@,C`Q,"P@=&AE($-O;7!A;GD@<F5C96EV960@82!L971T
M97(@9G)O;2!C;W5N<V5L('1O(%I!3PT*0D%-(&%N9"!:04\@0D%-(%)E<V5A
M<F-H($QA8F]R871O<FEE<R`H4G5S<VEA;B!C;VUP86YI97,L#0IC;VQL96-T
M:79E;'D@<F5F97)R960@=&\@87,@)B-X,C`Q0SM"04TF(W@R,#%$.RD@86QL
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M04T@;VX@2G5N92`R,"P@,C`P,"`H=&AE("8C>#(P,4,[2G5N92`R,#`P#0I!
M9W)E96UE;G0F(W@R,#%$.RDN)B-X03`[)B-X03`[5&AE(&QE='1E<B!R969E
M<F5N8V5S('1H90T*0V]M<&%N>28C>#(P,3D[<R!A;65N9&UE;G0L('-U8FUI
M='1E9"!T;R!T:&4@1D1!(&]N($%U9W5S="`S,"P@,C`P-2P-"G1O(&ET<R!I
M;G9E<W1I9V%T:6]N86P@;F5W(&1R=6<@87!P;&EC871I;VX@9&%T960@075G
M=7-T(#$Y.3D@87,-"G1H92!B87-I<R!F;W(@0D%-)B-X,C`Q.3MS(&-L86EM
M<R!A;F0@9&5M86YD<R!T:&4@=')A;G-F97(@;V8@86QL#0II;G1E;&QE8W1U
M86P@<')O<&5R='D@<FEG:'1S(&-O;F-E<FYI;F<@3D]6+3`P,B!T;PT*0D%-
M+B8C>$$P.R8C>$$P.TUA<FL@0F%L87IO=G-K>2P@82!D:7)E8W1O<B!O9B!.
M;W9E;&]S(&9R;VT@2G5N90T*,3DY-B!U;G1I;"!.;W9E;6)E<B`R,#`V(&%N
M9"!A('-H87)E:&]L9&5R(&]F($YO=F5L;W,@=&AR;W5G:"!A=`T*;&5A<W0@
M2G5N92`R-2P@,C`Q,"P@:7,L('1O('1H92!#;VUP86YY)B-X,C`Q.3MS(&MN
M;W=L961G92P@<W1I;&P-"G1H92!G96YE<F%L(&1I<F5C=&]R(&%N9"!P<FEN
M8VEP86P@<VAA<F5H;VQD97(@;V8@6D%/#0I"04TN)B-X03`[)B-X03`[5&AE
M($-O;7!A;GD@8F5L:65V97,@=&AE(&%L;&5G871I;VYS(&%R92!W:71H;W5T
M#0IM97)I="!A;F0@:6YT96YD<R!T;R!D969E;F0@=FEG;W)O=7-L>2!A9V%I
M;G-T(&%N>2!P<F]C965D:6YG<R!T:&%T#0I"04T@;6%Y(&EN:71I871E(&%S
M('1O('1H97-E(&%L;&5G871I;VYS+B!/;B!397!T96UB97(@,C0L(#(P,3`L
M#0IT:&4@0V]M<&%N>2!F:6QE9"!A(&-O;7!L86EN="!I;B!3=69F;VQK(%-U
M<&5R:6]R($-O=7)T('-E96MI;F<@80T*9&5C;&%R871O<GD@:G5D9VUE;G0@
M8GD@=&AE(&-O=7)T('1H870@=&AE($IU;F4@,C`P,"!!9W)E96UE;G0@:&%S
M#0IB965N(')E<&QA8V5D(&)Y(&$@<W5B<V5Q=65N="!A9W)E96UE;G0@8F5T
M=V5E;B!T:&4@<&%R=&EE<R!D871E9`T*07!R:6P@,2P@,C`P-2`H=&AE("8C
M>#(P,4,[07!R:6P@,C`P-2!!9W)E96UE;G0F(W@R,#%$.RDL('1H870-"DYO
M=F5L;W,F(W@R,#$Y.R!O8FQI9V%T:6]N<R!T;R!"04T@87)E(&=O=F5R;F5D
M('-O;&5L>2!B>2!T:&4@07!R:6P-"C(P,#4@06=R965M96YT(&%N9"!T:&%T
M('1H92!O8FQI9V%T:6]N<R!O9B!T:&4@2G5N92`R,#`P(&%G<F5E;65N=`T*
M:&%V92!B965N('!E<F9O<FUE9"!A;F0@9G5L;'D@<V%T:7-F:65D+B8C>$$P
M.R8C>$$P.T]N($YO=F5M8F5R(#(Y+`T*,C`Q,"P@0D%-(&%N<W=E<F5D('1H
M92!C;VUP;&%I;G0L(&1E;GEI;F<@=&AE(&UA=&5R:6%L(&%L;&5G871I;VYS
M+`T*86YD('-T871I;F<@:71S(&%F9FER;6%T:79E(&1E9F5N<V5S(&%N9"!C
M97)T86EN(&-O=6YT97)C;&%I;7,N($]N#0I*86YU87)Y(#$T+"`R,#$Q+"!T
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M9`T*86=A:6YS="!T:&5M+CPO9F]N=#X\+V1I=CX-"CPO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\
M9&EV/@T*/'1A8FQE('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E
M;G1E<CX-"CQT<B!V86QI9VX],T1T;W`^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z
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M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^#0I,251)1T%424]./"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D9O;&QO
M=VEN9PT*=&AE($%C<75I<VET:6]N+"!T:&4@0V]M<&%N>2!I<R!P87)T>2!T
M;R!C97)T86EN(&QE9V%L(&UA='1E<G,@=&AA=`T*97AI<W1E9"!W:71H($YO
M=F5L;W,@<')I;W(@=&\@=&AE($%C<75I<VET:6]N+B!4:&4@9F]L;&]W:6YG
M#0IS=6UM87)I>F5S('1H92!S=&%T=7,@;V8@=&AO<V4@;6%T=&5R<RX\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M#0I#;&%S<R!!8W1I;VX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D$-
M"G!U=&%T:79E(&9E9&5R86P@<V5C=7)I=&EE<R!C;&%S<R!A8W1I;VX@8V]M
M<&QA:6YT('=A<R!F:6QE9"!O;@T*36%R8V@@-2P@,C`Q,"!I;B!T:&4@56YI
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M,30L(#(P,#D@86YD($9E8G)U87)Y#0HR-"P@,C`Q,"P@86=A:6YS="!.;W9E
M;&]S(&%N9"!I=',@4')E<VED96YT(&%N9"!#:&EE9B!%>&5C=71I=F4-"D]F
M9FEC97(L($AA<G)Y(%,N(%!A;&UI;BXF(WA!,#L@3VX@3V-T;V)E<B`Q+"`R
M,#$P+"!T:&4@8V]U<G0-"F%P<&]I;G1E9"!L96%D('!L86EN=&EF9G,@*$)O
M<FES(%5R;6%N(&%N9"!286UO;F$@36-$;VYA;&0I(&%N9`T*87!P;VEN=&5D
M(&QE860@<&QA:6YT:69F<R8C>#(P,3D[(&-O=6YS96PN)B-X03`[($]N($]C
M=&]B97(@,C(L#0HR,#$P+"!A;B!A;65N9&5D(&-O;7!L86EN="!W87,@9FEL
M960N)B-X03`[(%1H92!A;65N9&5D(&-O;7!L86EN=`T*8VQA:6US+"!A;6]N
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M;6%L;"!C96QL(&QU;F<@8V%N8V5R+B8C>$$P.R!/;B!$96-E;6)E<B`V+`T*
M,C`Q,"P@=&AE(&1E9F5N9&%N=',@9FEL960@82!M;W1I;VX@=&\@9&ES;6ES
M<R!T:&4@8V]M<&QA:6YT('=I=&@-"G!R96IU9&EC92XF(WA!,#L@3VX@2F%N
M=6%R>2`R,"P@,C`Q,2P@=&AE('!L86EN=&EF9G,@9FEL960@=&AE:7(-"F]P
M<&]S:71I;VX@=&\@;W5R(&UO=&EO;B!A;F0@;VX@36%R8V@@,RP@,C`Q,2P@
M=&AE(&1E9F5N9&%N=',@9FEL960-"G1H96ER(')E<W!O;G-E('1O('1H92!O
M<'!O<VET:6]N+B!/;B!*=6YE(#(S+"`R,#$Q+"!T:&4@;6]T:6]N('1O#0ID
M:7-M:7-S('=A<R!G<F%N=&5D(&%N9"!T:&4@8V%S92!W87,@9&ES;6ES<V5D
M('=I=&AO=70-"G!R96IU9&EC92XF(WA!,#L@0F5C875S92!T:&4@9&ES;6ES
M<V%L('=A<R!W:71H;W5T('!R96IU9&EC92P@=&AE#0IP;&%I;G1I9F9S(&-O
M=6QD)B-X03`[<F5I;G-T:71U=&4@=&AE)B-X03`[<')O8V5E9&EN9R!B>0T*
M9FEL:6YG)B-X03`[86X@86UE;F1E9"!C;VUP;&%I;G0N)B-X03`[($]N($%U
M9W5S="`U+"`R,#$Q+"!T:&4-"G!L86EN=&EF9G,@9FEL960@82!S96-O;F0@
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX-"D]N(%-E<'1E;6)E<B`Y+"`R,#$Q+"!T:&4@9&5F96YD86YT<R!F:6QE
M9"!A(&UO=&EO;B!T;R!D:7-M:7-S('1H90T*<V5C;VYD(&%M96YD960@8V]M
M<&QA:6YT+B!4:&4@<&QA:6YT:69F/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(W@R,#$Y
M.SPO9F]N=#YS#0IO<'!O<VET:6]N('1O('1H92!M;W1I;VXF(WA!,#MW87,@
M9FEL960@;VXF(WA!,#M/8W1O8F5R(#$T+"`R,#$Q#0IA;F0@=&AE(&1E9F5N
M9&%N=',@9FEL960@82!R97!L>2!B<FEE9B!O;B!.;W9E;6)E<B`T+`T*,C`Q
M,2X\+V9O;G0^/"]F;VYT/B`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^5&AE#0I#;VUP86YY(&%N9"!-<BX@4&%L;6EN(&)E;&EE=F4@=&AE
M(&%L;&5G871I;VYS(&%R92!W:71H;W5T(&UE<FET#0IA;F0@:6YT96YD('1O
M('9I9V]R;W5S;'D@9&5F96YD(&%G86EN<W0@=&AE;2X\+V9O;G0^/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0I"04T@1&ES
M<'5T93PO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^3VX-"DIU;F4@,C@L
M(#(P,3`L($YO=F5L;W,@<F5C96EV960@82!L971T97(@9G)O;2!C;W5N<V5L
M('1O(%I!3R!"04T-"F%N9"!:04\@0D%-(%)E<V5A<F-H($QA8F]R871O<FEE
M<R`H4G5S<VEA;B!C;VUP86YI97,L(&-O;&QE8W1I=F5L>0T*<F5F97)R960@
M=&\@87,@)B-X,C`Q0SM"04TF(W@R,#%$.RD@86QL96=I;F<@=&AA="!I="!M
M;V1I9FEE9"!T:&4-"F-H96UI8V%L(&-O;7!O<VET:6]N(&]F($Y/5BTP,#(@
M=VET:&]U="!P<FEO<B!N;W1I8V4@=&\@;W(@87!P<F]V86P-"F9R;VT@0D%-
M+"!C;VYS=&ET=71I;F<@82!M871E<FEA;"!B<F5A8V@@;V8@82!T96-H;F]L
M;V=Y(&%N9`T*87-S:6=N;65N="!A9W)E96UE;G0@3F]V96QO<R!H860@96YT
M97)E9"!I;G1O('=I=&@@0D%-(&]N($IU;F4@,C`L#0HR,#`P("AT:&4@)B-X
M,C`Q0SM*=6YE(#(P,#`@06=R965M96YT)B-X,C`Q1#LI+B8C>$$P.R!4:&4@
M;&5T=&5R#0IR969E<F5N8V5S('1H92!A;65N9&UE;G0L('-U8FUI='1E9"!T
M;R!T:&4@1D1!(&]N($%U9W5S="`S,"P@,C`P-2P-"G1O($YO=F5L;W,F(W@R
M,#$Y.R!I;G9E<W1I9V%T:6]N86P@;F5W(&1R=6<@87!P;&EC871I;VX@9&%T
M960@075G=7-T#0HQ.3DY(&%S('1H92!B87-I<R!F;W(@0D%-)B-X,C`Q.3MS
M(&-L86EM<R!A;F0@9&5M86YD<R!T:&4@=')A;G-F97(-"F]F(&%L;"!I;G1E
M;&QE8W1U86P@<')O<&5R='D@<FEG:'1S(&-O;F-E<FYI;F<@3D]6+3`P,B!T
M;PT*0D%-+B8C>$$P.R!-87)K($)A;&%Z;W9S:WDL(&$@9&ER96-T;W(@;V8@
M3F]V96QO<R!F<F]M($IU;F4@,3DY-@T*=6YT:6P@3F]V96UB97(@,C`P-B!A
M;F0@82!S:&%R96AO;&1E<B!O9B!.;W9E;&]S('1H<F]U9V@@870@;&5A<W0-
M"DIU;F4@,C4L(#(P,3`L(&ES+"!T;R!O=7(@:VYO=VQE9&=E+"!S=&EL;"!T
M:&4@9V5N97)A;"!D:7)E8W1O<B!A;F0-"G!R:6YC:7!A;"!S:&%R96AO;&1E
M<B!O9B!:04\@0D%-+B8C>$$P.R!/;B!397!T96UB97(@,C0L(#(P,3`L#0I.
M;W9E;&]S(&9I;&5D(&$@8V]M<&QA:6YT(&EN(%-U9F9O;&L@4W5P97)I;W(@
M0V]U<G0@<V5E:VEN9R!A#0ID96-L87)A=&]R>2!J=61G;65N="!B>2!T:&4@
M8V]U<G0@=&AA="!T:&4@2G5N92`R,#`P($%G<F5E;65N="!H87,-"F)E96X@
M<F5P;&%C960@8GD@82!S=6)S97%U96YT(&%G<F5E;65N="!B971W965N('1H
M92!P87)T:65S(&1A=&5D#0I!<')I;"`Q+"`R,#`U("AT:&4@)B-X,C`Q0SM!
M<')I;"`R,#`U($%G<F5E;65N="8C>#(P,40[*2P@=&AA=`T*3F]V96QO<R8C
M>#(P,3D[(&]B;&EG871I;VYS('1O($)!32!A<F4@9V]V97)N960@<V]L96QY
M(&)Y('1H92!!<')I;`T*,C`P-2!!9W)E96UE;G0@86YD('1H870@=&AE(&]B
M;&EG871I;VYS(&]F('1H92!*=6YE(#(P,#`@86=R965M96YT#0IH879E(&)E
M96X@<&5R9F]R;65D(&%N9"!F=6QL>2!S871I<V9I960N)B-X03`[($]N($YO
M=F5M8F5R(#(Y+`T*,C`Q,"P@0D%-(&%N<W=E<F5D('1H92!C;VUP;&%I;G0L
M(&1E;GEI;F<@=&AE(&UA=&5R:6%L(&%L;&5G871I;VYS+`T*86YD('-T871I
M;F<@:71S(&%F9FER;6%T:79E(&1E9F5N<V5S(&%N9"!C97)T86EN(&-O=6YT
M97)C;&%I;7,N($]N#0I*86YU87)Y(#$T+"`R,#$Q+"!.;W9E;&]S(')E<W!O
M;F1E9"!T;R!T:&4@8V]U;G1E<F-L86EM<RP@9&5N>6EN9PT*0D%-)B-X,C`Q
M.3MS(&UA=&5R:6%L(&%L;&5G871I;VYS(&%N9"!S=&%T:6YG(&ET<R!A9F9I
M<FUA=&EV90T*9&5F96YS97,N)B-X03`[($]N($IU;F4@.2P@,C`Q,2P@0D%-
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M=&EN9R!A(&)R96%C:"!O9B!T:&4@2G5N92`R,#`P#0I!9W)E96UE;G0@;W(L
M(&EF('1H870@86=R965M96YT(&ES(&1E=&5R;6EN960@=&\@;F\@;&]N9V5R
M(&)E(&EN#0IE9F9E8W0L(&$@8G)E86-H(&]F('1H92!!<')I;"`R,#`U($%G
M<F5E;65N="!A;F0O;W(@82!B<F5A8V@@;V8@=&AE#0II;7!L:65D(&1U='D@
M;V8@9V]O9"!F86ET:"!A;F0@9F%I<B!D96%L:6YG('=I=&@@<F5S<&5C="!T
M;R!T:&4-"D%P<FEL(#(P,#4@06=R965M96YT+B8C>$$P.R!/;B!*=6YE(#$U
M+"`R,#$Q('1H92!#;VUP86YY(&9I;&5D(&ET<PT*<F5S<&]N<V4@=&\@=&AE
M:7(@86UE;F1E9"!C;W5N=&5R8VQA:6TN)B-X03`[($]N($%U9W5S="`U+"`R
M,#$Q+`T*=&AE($-O;7!A;GD@9FEL960@82!M;W1I;VX@9F]R(&IU9&=M96YT
M(&]N('1H92!P;&5A9&EN9W,@87,@=&\@:71S#0ID96-L87)A=&]R>2!J=61G
M;65N="!C;W5N="!A;F0@86QL(&-O=6YT<R!O9B!"04TF(W@R,#$Y.W,@86UE
M;F1E9`T*8V]U;G1E<F-L86EM+B8C>$$P.R!4:&4@;6]T:6]N)B-X03`[=V%S
M(&]P<&]S960@8GD@0D%-(&%N9"!A#0IH96%R:6YG(&]N('1H92!M;W1I;VXF
M(WA!,#MW87,@:&5L9"8C>$$P.V]N(%-E<'1E;6)E<B`R-RP@,C`Q,2X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/;@T*3V-T;V)E<B`Q
M-RP@,C`Q,2P@=&AE(&-O=7)T(')U;&5D(&]N('1H92!#;VUP86YY)B-X,C`Q
M.3MS#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:
M13H@,3!P="<^8F5H86QF(&9O<B!E86-H(&]F#0II=',@9&5C;&%R871O<GD@
M:G5D9VUE;G0@8VQA:6US(&%N9"!D:7-M:7-S960@86QL(&-O=6YT<R!O9@T*
M0D%-)B-X,C`Q.3MS(&-O=6YT97)C;&%I;2X@2G5D9VUE;G0@:6X@9F%V;W(@
M;V8@=&AE($-O;7!A;GD@=V%S#0IE;G1E<F5D(&]N($]C=&]B97(@,C`L(#(P
M,3$@86YD($)!32!H87,@=6YT:6P@3F]V96UB97(@,C$L(#(P,3$@=&\-"F%P
M<&5A;"!O<B!O=&AE<G=I<V4@<V5E:R!P;W-T+6IU9&=M96YT#0IR96QI968N
M/"]F;VYT/CPO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E=E
M#0ID;R!N;W0@86YT:6-I<&%T92!T:&%T('1H97-E(&QI=&EG871I;VX@8V]N
M=&EN9V5N8VEE<R!W:6QL(&AA=F4@80T*;6%T97)I86P@:6UP86-T(&]N('1H
M92!#;VUP86YY)B-X,C`Q.3MS(&9U='5R92!F:6YA;F-I86P@<&]S:71I;VXL
M#0IR97-U;'1S(&]F(&]P97)A=&EO;G,@;W(@8V%S:"!F;&]W<RX\+V9O;G0^
M/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HQ,2XF(WA!,#LF(WA!,#M,251)
M1T%424]./"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^)B-X03`[/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY!#0IP=7)P;W)T960@8VQA<W,@86-T:6]N(&-O;7!L86EN="!W87,@9FEL
M960@;VX@36%R8V@@-2P@,C`Q,"!I;B!T:&4-"E5N:71E9"!3=&%T97,@1&ES
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M97(@,30L(#(P,#D@86YD($9E8G)U87)Y#0HR-"P@,C`Q,"P@86=A:6YS="!T
M:&4@0V]M<&%N>2!A;F0@:71S(%!R97-I9&5N="!A;F0@0VAI968@17AE8W5T
M:79E#0I/9F9I8V5R+"!(87)R>2!3+B!086QM:6XN)B-X03`[)B-X03`[3VX@
M3V-T;V)E<B`Q+"`R,#$P+"!T:&4@8V]U<G0-"F%P<&]I;G1E9"!L96%D('!L
M86EN=&EF9G,@*$)O<FES(%5R;6%N(&%N9"!286UO;F$@36-$;VYA;&0I(&%N
M9`T*87!P;VEN=&5D(&QE860@<&QA:6YT:69F<R8C>#(P,3D[(&-O=6YS96PN
M)B-X03`[)B-X03`[3VX@3V-T;V)E<B`R,BP-"F%N(&%M96YD960@8V]M<&QA
M:6YT('=A<R!F:6QE9"XF(WA!,#LF(WA!,#M4:&4@86UE;F1E9"!C;VUP;&%I
M;G0-"F-L86EM<R!T:&%T('1H92!#;VUP86YY('9I;VQA=&5D(%-E8W1I;VX@
M,3`H8BD@;V8@=&AE(%-E8W5R:71I97,-"D5X8VAA;F=E($%C="!O9B`Q.3,T
M+"!A<R!A;65N9&5D+"!A;F0@4G5L92`Q,&(M-2!P<F]M=6QG871E9`T*=&AE
M<F5U;F1E<B!I;B!C;VYN96-T:6]N('=I=&@@86QL96=E9"!D:7-C;&]S=7)E
M<R!R96QA=&5D('1O('1H90T*4&AA<V4@,R!C;&EN:6-A;"!T<FEA;"!O9B!.
M3U8M,#`R(&9O<B!N;VXM<VUA;&P@8V5L;"!L=6YG#0IC86YC97(N)B-X03`[
M)B-X03`[3VX@1&5C96UB97(@-BP@,C`Q,"P@=&AE($-O;7!A;GD@9FEL960@
M82!M;W1I;VX-"G1O(&1I<VUI<W,@=&AE(&-O;7!L86EN="!W:71H('!R96IU
M9&EC92XF(WA!,#LF(WA!,#M/;B!*86YU87)Y(#(P+`T*,C`Q,2P@=&AE('!L
M86EN=&EF9G,@9FEL960@=&AE:7(@;W!P;W-I=&EO;B!T;R!O=7(@;6]T:6]N
M(&%N9"!O;@T*36%R8V@@,RP@,C`Q,2P@=V4@9FEL960@;W5R(')E<W!O;G-E
M('1O('1H96ER(&]P<&]S:71I;VXN($]U<@T*;6]T:6]N('1O(&1I<VUI<W,@
M<F5M86EN<R!P96YD:6YG+B!4:&4@0V]M<&%N>2!B96QI979E<R!T:&4-"F%L
M;&5G871I;VYS(&%R92!W:71H;W5T(&UE<FET(&%N9"!I;G1E;F1S('1O(&1E
M9F5N9"!V:6=O<F]U<VQY#0IA9V%I;G-T('1H92!A;&QE9V%T:6]N<RX\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K)SXF(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]N#0I*=6YE(#(X+"`R,#$P+"!T
M:&4@0V]M<&%N>2!R96-E:79E9"!A(&QE='1E<B!F<F]M(&-O=6YS96P@=&\@
M6D%/#0I"04T@86YD(%I!3R!"04T@4F5S96%R8V@@3&%B;W)A=&]R:65S("AC
M;VQL96-T:79E;'DL#0HF(W@R,#%#.T)!328C>#(P,40[*2!A;&QE9VEN9R!T
M:&%T('1H92!#;VUP86YY(&UO9&EF:65D('1H92!C:&5M:6-A;`T*8V]M<&]S
M:71I;VX@;V8@3D]6+3`P,B!W:71H;W5T('!R:6]R(&YO=&EC92!T;R!O<B!A
M<'!R;W9A;"!F<F]M#0I"04TL(&-O;G-T:71U=&EN9R!A(&UA=&5R:6%L(&)R
M96%C:"!O9B!A('1E8VAN;VQO9WD@86YD(&%S<VEG;FUE;G0-"F%G<F5E;65N
M="!T:&4@0V]M<&%N>2!H860@96YT97)E9"!I;G1O('=I=&@@0D%-(&]N($IU
M;F4@,C`L(#(P,#`-"BAT:&4@)B-X,C`Q0SM*=6YE(#(P,#`@06=R965M96YT
M)B-X,C`Q1#LI+B8C>$$P.R8C>$$P.U1H92!L971T97(-"G)E9F5R96YC97,@
M=&AE($-O;7!A;GDF(W@R,#$Y.W,@86UE;F1M96YT+"!S=6)M:71T960@=&\@
M=&AE($9$02!O;@T*075G=7-T(#,P+"`R,#`U+"!T;R!I=',@:6YV97-T:6=A
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M<F]M($IU;F4-"C$Y.38@=6YT:6P@3F]V96UB97(@,C`P-B!A;F0@82!S:&%R
M96AO;&1E<B!O9B!.;W9E;&]S('1H<F]U9V@@870-"FQE87-T($IU;F4@,C4L
M(#(P,3`L(&ES+"!T;R!T:&4@0V]M<&%N>28C>#(P,3D[<R!K;F]W;&5D9V4L
M('-T:6QL#0IT:&4@9V5N97)A;"!D:7)E8W1O<B!A;F0@<')I;F-I<&%L('-H
M87)E:&]L9&5R(&]F(%I!3PT*0D%-+B8C>$$P.R8C>$$P.U1H92!#;VUP86YY
M(&)E;&EE=F5S('1H92!A;&QE9V%T:6]N<R!A<F4@=VET:&]U=`T*;65R:70@
M86YD(&EN=&5N9',@=&\@9&5F96YD('9I9V]R;W5S;'D@86=A:6YS="!A;GD@
M<')O8V5E9&EN9W,@=&AA=`T*0D%-(&UA>2!I;FET:6%T92!A<R!T;R!T:&5S
M92!A;&QE9V%T:6]N<RX@3VX@4V5P=&5M8F5R(#(T+"`R,#$P+`T*=&AE($-O
M;7!A;GD@9FEL960@82!C;VUP;&%I;G0@:6X@4W5F9F]L:R!3=7!E<FEO<B!#
M;W5R="!S965K:6YG(&$-"F1E8VQA<F%T;W)Y(&IU9&=M96YT(&)Y('1H92!C
M;W5R="!T:&%T('1H92!*=6YE(#(P,#`@06=R965M96YT(&AA<PT*8F5E;B!R
M97!L86-E9"!B>2!A('-U8G-E<75E;G0@86=R965M96YT(&)E='=E96X@=&AE
M('!A<G1I97,@9&%T960-"D%P<FEL(#$L(#(P,#4@*'1H92`F(W@R,#%#.T%P
M<FEL(#(P,#4@06=R965M96YT)B-X,C`Q1#LI+"!T:&%T#0I.;W9E;&]S)B-X
M,C`Q.3L@;V)L:6=A=&EO;G,@=&\@0D%-(&%R92!G;W9E<FYE9"!S;VQE;'D@
M8GD@=&AE($%P<FEL#0HR,#`U($%G<F5E;65N="!A;F0@=&AA="!T:&4@;V)L
M:6=A=&EO;G,@;V8@=&AE($IU;F4@,C`P,"!A9W)E96UE;G0-"FAA=F4@8F5E
M;B!P97)F;W)M960@86YD(&9U;&QY('-A=&ES9FEE9"XF(WA!,#LF(WA!,#M/
M;B!.;W9E;6)E<B`R.2P-"C(P,3`L($)!32!A;G-W97)E9"!T:&4@8V]M<&QA
M:6YT+"!D96YY:6YG('1H92!M871E<FEA;"!A;&QE9V%T:6]N<RP-"F%N9"!S
M=&%T:6YG(&ET<R!A9F9I<FUA=&EV92!D969E;G-E<R!A;F0@8V5R=&%I;B!C
M;W5N=&5R8VQA:6US+B!/;@T*2F%N=6%R>2`Q-"P@,C`Q,2P@=&AE($-O;7!A
M;GD@<F5S<&]N9&5D('1O('1H92!C;W5N=&5R8VQA:6US+`T*9&5N>6EN9R!"
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M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$<^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^14U03$]9144@4D5425)%345.5"!03$%./&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5-4$Q/645%(%)%5$E214U%
M3E0@4$Q!3CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-
M"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"C$V+B8C>$$P.R!%35!,3UE%12!2151)4D5-
M14Y4(%!,04X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ
M(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%
M6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/D]N#0I*86YU
M87)Y(#$L(#(P,#DL($-E;&QE8W1A<B!A9&]P=&5D(&$@4V%F92!(87)B;W(@
M9&5F:6YE9`T*8V]N=')I8G5T:6]N('!L86X@=6YD97(@4V5C=&EO;B`T,#$H
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M96YD960@1&5C96UB97(@,S$L(#(P,3`@86YD(#(P,#D@=V5R92`F;F)S<#LD
M,C,L,#`P(&%N9`T*)FYB<W`[)#4V+#`P,"P@<F5S<&5C=&EV96QY+B8C>$$P
M.R!#96QL96-T87(@<&%I9"!A9&UI;FES=')A=&EV92!E>'!E;G-E<PT*9F]R
M('1H92!P;&%N(&]F("9N8G-P.R0S+#,P,"!A;F0@)FYB<W`[)#(L.#`P(&9O
M<B!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L#0HR,#$P(&%N9"`R,#`Y
M+"!R97-P96-T:79E;'DN)B-X03`[(%1H92!P;&%N('=A<R!C86YC96QE9"!E
M9F9E8W1I=F4-"D%U9W5S="`S,"P@,C`Q,"X\+V9O;G0^/"]D:78^#0H\8G(@
M+SX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4
M.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^1F]L;&]W:6YG#0IT:&4@06-Q=6ES:71I;VXL
M('1H92!#;VUP86YY(&AA<R!A(&1E9FEN960@8V]N=')I8G5T:6]N('!L86X@
M=6YD97(-"E-E8W1I;VX@-#`Q*&LI(&]F('1H92!);G1E<FYA;"!2979E;G5E
M($-O9&4@=VAI8V@@86QL;W=S(&5L:6=I8FQE#0IE;7!L;WEE97,@=VAO(&UE
M970@;6EN:6UU;2!A9V4@<F5Q=6ER96UE;G1S('1O(&-O;G1R:6)U=&4@82!P
M;W)T:6]N#0IO9B!T:&5I<B!A;FYU86P@8V]M<&5N<V%T:6]N(&]N(&$@<')E
M+71A>"!B87-I<RXF(WA!,#L@5&AE($-O;7!A;GD-"FAA<R!N;W0@;6%D92!A
M;GD@;6%T8VAI;F<@8V]N=')I8G5T:6]N<R!U;F1E<B!T:&ES#0IP;&%N+CPO
M9F]N=#X\+V1I=CX-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?9#)D,6$S9CA?,&,U-U\T,38X7V)E9&-?.#8W-V1C
M9&(S-65C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V0R9#%A,V8X
M7S!C-3=?-#$V.%]B961C7S@V-S=D8V1B,S5E8R]7;W)K<VAE971S+U-H965T
M,C0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5,1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY2
M14Q!5$5$(%!!4E19(%1204Y304-424].4SQB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y214Q!5$5$(%!!4E19(%1204Y304-424].
M4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQD:78@
M<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%
M6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0G/@T*
M,3<N)B-X03`[(%)%3$%4140@4$%25%D@5%)!3E-!0U1)3TY3/"]F;VYT/CPO
M9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[(%1%
M6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^2F%M97D-"E=E:6-H97)T+"!T
M:&4@0V]M<&%N>28C>#(P,3D[<R!#:&EE9B!38VEE;G1I9FEC($]F9FEC97(L
M(&1I<F5C=&]R+`T*<VAA<F5H;VQD97(@86YD('!R:6YC:7!A;"!F;W5N9&5R
M(&ES(&$@9F%C=6QT>2!M96UB97(@870@=&AE#0I5;FEV97)S:71Y(&]F(%=I
M<V-O;G-I;BU-861I<V]N("@F(W@R,#%#.U57)B-X,C`Q1#LI+B8C>$$P.R!#
M96QL96-T87(-"G!A:60@)FYB<W`[)#$V+#`X,B!T;R!T:&4@55<@9'5R:6YG
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M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N)SY#96QL96-T87(-"FUA9&4@8V]N=')I
M8G5T:6]N<R!O9B`F;F)S<#LD,C4L,#`P('1O('1H92!55R!&;W5N9&%T:6]N
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M+"`R,#`Y+B8C>$$P.R!$=7)I;F<@=&AE(&YI;F4@;6]N=&AS(&5N9&5D#0I3
M97!T96UB97(@,S`L(#(P,3$L('1H92!#;VUP86YY(&UA9&4@8V]N=')I8G5T
M:6]N<R!T;W1A;&EN9PT*)FYB<W`[)#$R-2PP,#`@=&\@=&AE(%57($9O=6YD
M871I;VX@9F]R('5S92!T;W=A<F1S(')E<V5A<F-H(&%C=&EV:71I97,-"F%S
M<V]C:6%T960@=VET:"!T:&4@9&5V96QO<&UE;G0@;V8@=&AE($-O;7!A;GDF
M(W@R,#$Y.W,-"F-O;7!O=6YD<RXF(WA!,#L@3F\@<&%Y;65N=',@=V5R92!M
M861E('1O(%57(&1U<FEN9R!T:&4@;FEN92!M;VYT:',-"F5N9&5D(%-E<'1E
M;6)E<B`S,"P@,C`Q,"!O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P-
M"C(P,3`N/"]F;VYT/CPO9&EV/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D,F0Q83-F.%\P8S4W7S0Q-CA?8F5D
M8U\X-C<W9&-D8C,U96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M9#)D,6$S9CA?,&,U-U\T,38X7V)E9&-?.#8W-V1C9&(S-65C+U=O<FMS:&5E
M=',O4VAE970R-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q'/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/BA53D%51$E4140I(%-54%!,14U%3E1!3"!04D\@1D]234$@24Y&
M3U)-051)3TX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^*%5.055$251%1"D@4U504$Q%345.5$%,(%!23R!&3U)-02!)3D9/4DU!
M5$E/3CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQD
M:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%
M24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"C$X+B8C>$$P.R`H54Y!541)5$5$*2!355!03$5-
M14Y404P@4%)/($9/4DU!#0I)3D9/4DU!5$E/3CPO9F]N=#X\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G
M/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^5&AE#0IT86)L92!B96QO=R!S=6UM87)I>F5S)B-X03`[
M;F5T(&QO<W,@9F]R('1H92!P97)I;V1S('-H;W=N(&%S#0IT:&]U9V@@=&AE
M($%C<75I<VET:6]N(&]C8W5R<F5D(&%S(&]F($IA;G5A<GD@,2P@,C`Q,#H\
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M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED)SX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE)SY&;W(F(WA!,#MT:&4F(WA!,#M.:6YE
M)B-X03`[36]N=&AS)B-X03`[16YD960F(WA!,#M397!T96UB97(F(WA!,#LS
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M,T1T;W`@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3`E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*/&1I
M=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
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M:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"DUO;G1H<R8C>$$P.T5N
M9&5D/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0I$96-E;6)E
M<B8C>$$P.S,Q+#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T)2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,"4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED)SX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU2
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M:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
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M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G/@T*/&1I=B!S='EL93TS
M1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%
M3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z(&)O
M;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/C(P,3`\
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M;W`@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3`E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI
M9"<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN92<^,C`Q,#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
M/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V
M-"4^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#DE/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#DE/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
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M=&]M('=I9'1H/3-$-C0E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G
M/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M3F5T#0IL;W-S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I
M9VAT('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`T<'@G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
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M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G
M/@T*)FYB<W`[)#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L
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M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXI/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
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M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*)FYB<W`[)#PO
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M:6YL:6YE)SX-"B@W.#,L,#`W/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/@T*/&1I=B!S='EL93TS1"=$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*28C>$$P.SPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4G/@T*/&1I
M=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
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M1TA4.B`P<'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^
M#0HH,2PW,#0L.38V/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`T<'@G/@T*/&1I=B!S='EL93TS1"=$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
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M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY4:&4-"G!R
M;R!F;W)M828C>$$P.VYE="!L;W-S)B-X03`[:&%S(&)E96X@861J=7-T960@
M9F]R('1H90T*9F]L;&]W:6YG.CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G1$E34$Q!63H@8FQO8VL[(%1%6%0M24Y$14Y4.B`P<'0G/CQB<B`O/CPO
M9&EV/@T*/&1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T.R!415A4+4%,24=..B!L969T)SX-"CQT86)L92!B;W)D97(],T0P
M(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SX-"CQT<B!V86QI9VX],T1T;W`^#0H\=&0@86QI9VX]
M,T1R:6=H="!S='EL93TS1"=724142#H@.7!T)SX-"CQD:78@<W1Y;&4],T0G
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!L969T)SX-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL
M93TS1"=,151415(M4U!!0TE.1SH@.7!T)SX-"B8C>$$P.R8C>$$P.SPO9F]N
M=#XQ*3QF;VYT('-T>6QE/3-$)TQ%5%1%4BU34$%#24Y'.B`Y<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T.R!415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SY%;&EM:6YA=&EO;@T*;V8@)FYB<W`[)#$V-2PP,#`L
M("9N8G-P.R0R-C8L,#`P+"!A;F0@)FYB<W`[)#,V,2PP,#`@;V8@:6YT97)E
M<W0@97AP96YS92!F;W(@=&AE#0IN:6YE(&UO;G1H<R!E;F1E9"!397!T96UB
M97(@,S`L(#(P,3$@86YD(#(P,3`@86YD('1H92!T=V5L=F4@;6]N=&AS#0IE
M;F1E9"!$96-E;6)E<B`S,2P@,C`Q,"P@<F5S<&5C=&EV96QY.R!S=6-H(&%M
M;W5N=',@<F5L871E('1O#0II;G1E<F5S="!A8V-R=65D(&]N('1H92!#;VYV
M97)T:6)L92!.;W1E<R!W:&EC:"!W97)E(&-O;G9E<G1E9`T*:6UM961I871E
M;'D@<')I;W(@=&\@=&AE($%C<75I<VET:6]N("AS964@3F]T92`W*2!A;F0@
M=&AE($)A;FL@3F]T90T*=VAI8V@@=V%S('!A:60@:6X@9G5L;"!S971T;&5M
M96YT(&]F('1H92!N;W1E(&EM;65D:6%T96QY('!R:6]R('1O#0IT:&4@06-Q
M=6ES:71I;VX@*'-E92!.;W1E(#@I+CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/"]D:78^#0H\9&EV/@T*/'1A8FQE
M(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W
M:61T:#TS1#$P,"4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*/'1R('9A;&EG;CTS1'1O<#X-
M"CQT9"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)U=)1%1(.B`Y<'0G/@T*/&1I
M=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!4
M15A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SX\9F]N="!S='EL93TS1"=,151415(M4U!!0TE.1SH@.7!T)SX-
M"B8C>$$P.R8C>$$P.SPO9F]N=#XR*3QF;VYT('-T>6QE/3-$)TQ%5%1%4BU3
M4$%#24Y'.B`Y<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+V9O;G0^/"]D:78^
M#0H\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T/@T*/&1I=CX-"CQD
M:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,
M24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SY296-O9VYI=&EO;@T*;V8@82!A9&1I=&EO;F%L($)#1B!O9B`F;F)S<#LD
M-#8S+#`P,"!I;B!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R#0HS
M,"P@,C`Q,"!A;F0@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3`@
M86YD('1H92!E;&EM:6YA=&EO;@T*;V8@0D-&(&]F("9N8G-P.R0R-3@L,#`P
M(&EN('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3$@
M:6X-"F-O;FYE8W1I;VX@=VET:"!T:&4@8V]N=F5R<VEO;B!O9B!T:&4@0V]N
M=F5R=&EB;&4@3F]T97,L('=H:6-H(&ES#0IA<W-U;65D('1O(&AA=F4@;V-C
M=7)R960@;VX@2F%N=6%R>2`Q+"`R,#$P(&9O<B!T:&4@<'5R<&]S92!O9B!P
M<F\-"F9O<FUA('!R97-E;G1A=&EO;B`H<V5E($YO=&4@-RDN/"]F;VYT/CPO
M9&EV/@T*/"]D:78^#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-
M"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L
M;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=&3TY4+5-)6D4Z
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M+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86XG/CQF;VYT('-T>6QE/3-$)TQ%5%1%4BU3
M4$%#24Y'.B`Y<'0G/@T*)B-X03`[)B-X03`[/"]F;VYT/C,I/&9O;G0@<W1Y
M;&4],T0G3$545$52+5-004-)3D<Z(#EP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO9F]N=#X\+V1I=CX-"CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE
M9G0^#0H\9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/D5L:6UI;F%T:6]N#0IO9B!!8W%U:7-I=&EO;B!C
M;W-T<R!I;F-U<G)E9"!D=7)I;F<@=&AE(&YI;F4@;6]N=&AS(&5N9&5D#0I3
M97!T96UB97(@,S`L(#(P,3$@86YD('1H92!T=V5L=F4@;6]N=&AS(&5N9&5D
M($1E8V5M8F5R(#,Q+"`R,#$P+`T*=VAI8V@@87)E(&%S<W5M960@=&\@:&%V
M92!B965N(&EN8W5R<F5D('!R:6]R('1O($IA;G5A<GD@,2P@,C`Q,`T*9F]R
M('1H92!P=7)P;W-E(&]F('!R97-E;G1A=&EO;B!I;B!T:&4@<')O(&9O<FUA
M('-T871E;65N=',@;V8-"F]P97)A=&EO;G,N/"]F;VYT/CPO9&EV/@T*/"]D
M:78^#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-"CQD:78^#0H\
M=&%B;&4@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<]
M,T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0H\='(@=F%L:6=N/3-$
M=&]P/@T*/'1D(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G5TE$5$@Z(#EP="<^
M#0H\9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/CQF;VYT('-T>6QE/3-$)TQ%5%1%4BU34$%#24Y'.B`Y
M<'0G/@T*)B-X03`[)B-X03`[/"]F;VYT/C0I/&9O;G0@<W1Y;&4],T0G3$54
M5$52+5-004-)3D<Z(#EP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO9F]N=#X\
M+V1I=CX-"CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0^#0H\9&EV
M/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%
M6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86XG/D5L:6UI;F%T:6]N#0IO9B`F;F)S<#LD-#4P+#`P,"!O9B!I;G9E
M<W1M96YT(&)A;FMI;F<@9F5E<R!I;F-U<G)E9"!U<&]N('1H90T*8V]N<W5M
M;6%T:6]N(&]F('1H92!!8W%U:7-I=&EO;B!O;B!!<')I;"`X+"`R,#$Q(&9R
M;VT@=&AE(&YI;F4-"FUO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3$N
M/"]F;VYT/CPO9&EV/@T*/"]D:78^#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^
M#0H\+V1I=CX-"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<&%D9&EN
M9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=&
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M=#L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/CQF;VYT('-T>6QE/3-$
M)TQ%5%1%4BU34$%#24Y'.B`Y<'0G/@T*)B-X03`[)B-X03`[/"]F;VYT/C4I
M/&9O;G0@<W1Y;&4],T0G3$545$52+5-004-)3D<Z(#EP="<^)B-X03`[)B-X
M03`[/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO9&EV/@T*/"]T9#X-"CQT9"!A
M;&EG;CTS1&QE9G0^#0H\9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/D5L:6UI;F%T:6]N#0IO9B!D:79I
M9&5N9',@86YD(&1E96UE9"!D:79I9&5N9',@;VX@3F]V96QO<R8C>#(P,3D[
M('!R969E<G)E9`T*8V]N=F5R=&EB;&4@<W1O8VLL('=H:6-H(&ES(&%S<W5M
M960@=&\@:&%V92!B965N(&5X8VAA;F=E9"!F;W(-"F-O;6UO;B!S=&]C:R!A
M="!*86YU87)Y(#$L(#(P,3`@:6X@;W)D97(@=&\@<F5F;&5C="!T:&4-"G!O
M<W0M86-Q=6ES:71I;VX@8V%P:71A;"!S=')U8W1U<F4@9F]R('1H92!P=7)P
M;W-E(&]F('!R;R!F;W)M80T*<')E<V5N=&%T:6]N+CPO9F]N=#X\+V1I=CX-
M"CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV
M/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C
M:6YG/3-$,"!W:61T:#TS1#$P,"4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*/'1R('9A;&EG
M;CTS1'1O<#X-"CQT9"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)U=)1%1(.B`Y
M<'0G/@T*/&1I=CX-"CQD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T.R!415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)TQ%
M5%1%4BU34$%#24Y'.B`Y<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#XV*3QF;VYT
M('-T>6QE/3-$)TQ%5%1%4BU34$%#24Y'.B`Y<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+V1I=CX-"CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0^
M#0H\9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
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M+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*/'1A8FQE(&)O<F1E
M<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS
M1#$P,"4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/@T*/'1R('9A;&EG;CTS1'1O<#X-"CQT9"!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)U=)1%1(.B`Y<'0G/@T*/&1I=B!S='EL
M93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)
M3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&QE
M9G0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/CQF;VYT
M('-T>6QE/3-$)TQ%5%1%4BU34$%#24Y'.B`Y<'0G/@T*)B-X03`[)B-X03`[
M/"]F;VYT/C<I/&9O;G0@<W1Y;&4],T0G3$545$52+5-004-)3D<Z(#EP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/D5L:6UI;F%T:6]N#0IO9B!L:7%U:61A=&5D
M(&1A;6%G97,@86-C<G5E9"!I;B`R,#$P(')E;&%T960@=&\-"DYO=F5L;W,\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/B8C>#(P,3D[/"]F;VYT/@T*8V]N=F5R=&EB;&4@
M<')E9F5R<F5D('-T;V-K+B!4:&4@;&EQ=6ED871E9"!D86UA9V5S(&%R92!A
M<W-U;65D(&YO=`T*=&\@:&%V92!A8V-R=65D(&%S('1H92!P<F5F97)R960@
M<W1O8VLF(WA!,#MI<R!A<W-U;65D('1O)B-X03`[:&%V90T*8F5E;B!E>&-H
M86YG960@9F]R(&-O;6UO;B!S=&]C:R!A="!*86YU87)Y(#$L(#(P,3`@:6X@
M;W)D97(@=&\-"G)E9FQE8W0@=&AE('!O<W0M86-Q=6ES:71I;VX@8V%P:71A
M;"!S=')U8W1U<F4@9F]R('1H92!P=7)P;W-E(&]F#0IP<F\@9F]R;6$@<')E
M<V5N=&%T:6]N+CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L
M93X-"CPO9&EV/@T*/"]D:78^#0H\+V1I=CX-"CPO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9#)D,6$S9CA?,&,U-U\T
M,38X7V)E9&-?.#8W-V1C9&(S-65C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V0R9#%A,V8X7S!C-3=?-#$V.%]B961C7S@V-S=D8V1B,S5E8R]7
M;W)K<VAE971S+U-H965T,C8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,1SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY04D]03U-%1"!2159%4E-%(%-43T-+(%-03$E4/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!23U!/4T5$
M(%)%5D524T4@4U1/0TL@4U!,250\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQD:78^#0H\9&EV/@T*/'1A8FQE('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R
M/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M,3`P)2!A;&EG;CTS1&-E;G1E<CX-"CQT<B!V86QI9VX],T1T;W`^#0H\=&0@
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M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I04D]03U-%1"!2159%4E-%
M(%-43T-+(%-03$E4/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\+W1A
M8FQE/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]N#0I*=6YE(#,P+"`R,#$Q
M+"!T:&4@0V]M<&%N>2!H96QD(&$@<W!E8VEA;"!M965T:6YG(&]F#0IS=&]C
M:VAO;&1E<G,N)B-X03`[($%T('1H92!M965T:6YG+"!T:&4@<W1O8VMH;VQD
M97)S(&%P<')O=F5D+`T*86UO;F<@;W1H97(@=&AI;F=S+"!S97!A<F%T92!A
M;65N9&UE;G1S('1O('1H92!C97)T:69I8V%T92!O9@T*:6YC;W)P;W)A=&EO
M;B!T:&%T('=O=6QD(&5F9F5C="!A(')E=F5R<V4@<W!L:70@;V8@=&AE#0I#
M;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:R!W:71H:6X@82!R86YG92!O
M9B`Q.C(@=&\@,3HQ,"P@86YD#0IA=71H;W)I>F5D('1H92!#;VUP86YY)B-X
M,C`Q.3MS(&)O87)D(&]F(&1I<F5C=&]R<R!T;R!D971E<FUI;F4@=&AE#0IR
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M,C`Q.3MS(&-O;6UO;B!S=&]C:R!I;B!O<F1E<B!T;R!E>&-E960-"G1H92!M
M:6YI;75M('!R:6-E('!E<B!S:&%R92!R97%U:7)E9"!T;R!S96-U<F4@82!L
M:7-T:6YG(&]N(&$-"FYA=&EO;F%L('-E8W5R:71I97,@97AC:&%N9V4N(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/;@T*2G5L>2`Q+"`R
M,#$Q+"!T:&4@0V]M<&%N>2!F:6QE9"!W:71H('1H92!314,F(WA!,#MA(%)E
M9VES=')A=&EO;@T*4W1A=&5M96YT(&]N($9O<FT@4RTQ(&9O<B!A;B!U;F1E
M<G=R:71T96X@<'5B;&EC(&]F9F5R:6YG(&]F(&ET<PT*8V]M;6]N('-T;V-K
M('=I=&@@<')O8V5E9',@;V8@=7`@=&\@)FYB<W`[)#$U+#`P,"PP,#`L(&5X
M8VQU9&EN9R!T:&4-"G5N9&5R=W)I=&5R<R!O=F5R+6%L;&]T;65N="X@5&AE
M($-O;7!A;GD@:&%S(&%P<&QI960@9F]R(&QI<W1I;F<@;VX-"G1H92!.05-$
M05$@0V%P:71A;"!-87)K970@=6YD97(@=&AE('-Y;6)O;"`B3E9,5"(@:6X@
M8V]N;F5C=&EO;@T*=VET:"!T:&4@<')O<&]S960@=6YD97)W<FET=&5N(&]F
M9F5R:6YG+CPO9F]N=#X\+V9O;G0^/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,T@^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^0T],3$%"3U)!5$E/3B!!1U)%14U%3E13/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0T],3$%"3U)!5$E/3B!!1U)%14U%3E13/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!W:61T:#TS1#$P,"4^#0H\='(@=F%L:6=N/3-$=&]P/@T*/'1D('-T>6QE
M/3-$)U=)1%1(.B`S-G!T)R!A;&EG;CTS1')I9VAT/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/@T*,RXF(WA!,#L\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N
M/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
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M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);@T*1&5C96UB97(@,C`P-R!T:&4@
M0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!#;VQL86)O<F%T:6]N($%G<F5E;65N
M=`T*=VET:"!,964F(W@R,#$Y.W,@4&AA<FUA8V5U=&EC86P@*$A+*2!,=&0N
M("@F(W@R,#%#.TQE928C>#(P,3D[<PT*4&AA<FTF(W@R,#%$.RDN(%!U<G-U
M86YT('1O('1H:7,@86=R965M96YT+"!,964F(W@R,#$Y.W,@4&AA<FT-"F]B
M=&%I;F5D(&%N(&5X8VQU<VEV92!L:6-E;G-E('1O(&1E=F5L;W`L(&UA;G5F
M86-T=7)E(&%N9`T*8V]M;65R8VEA;&EZ92!.3U8M,#`R(&%N9"!.3U8M,C`U
M(&EN($-H:6YA+"!(;VYG($MO;F<L(%1A:7=A;B!A;F0-"DUA8V%U("AT:&4@
M)B-X,C`Q0SM#:&EN97-E(%1E<G)I=&]R>28C>#(P,40[*2X@5&AE($-O;7!A
M;GD@:&%S#0IS=7-P96YD960@9G5R=&AE<B!D979E;&]P;65N="!O9B!.3U8M
M,C`U.R!H;W=E=F5R+"!T:&ES('-U<W!E;G-I;VX-"FUA>2!N;W0@:6UP86-T
M('1H92!D979E;&]P;65N="!S=')A=&5G>2!O9B!,964F(W@R,#$Y.W,-"E!H
M87)M+B8C>$$P.R8C>$$P.U5N9&5R('1H92!T97)M<R!O9B!T:&4@86=R965M
M96YT('1H92!#;VUP86YY#0IR96-E:79E9"!A(&QI8V5N<V4@9F5E(&]F("9N
M8G-P.R0U,#`L,#`P(&EN($UA<F-H(#(P,#@@86YD(&ES(&5N=&ET;&5D('1O
M#0IR96-E:79E('5P('1O("9N8G-P.R0Q+#<P,"PP,#`@:6X@9G5T=7)E(&UI
M;&5S=&]N92!P87EM96YT<R!U<&]N('1H90T*8V]M<&QE=&EO;B!O9B!D979E
M;&]P;65N="!A;F0@;6%R:V5T:6YG(&UI;&5S=&]N97,@8GD@3&5E)B-X,C`Q
M.3MS#0I0:&%R;2X@5&AI<R!I;FET:6%L("9N8G-P.R0U,#`L,#`P('!A>6UE
M;G0@<F5C96EV960@:7,@8F5I;F<@86UO<G1I>F5D#0IO=F5R('1H92!E<W1I
M;6%T960@=&5R;2!O9B!T:&ES(&%G<F5E;65N="P@,34@>65A<G,N($%C8V]R
M9&EN9VQY+`T*)FYB<W`[)#@L,S,S(&]F(&QI8V5N<V4@<F5V96YU92!W87,@
M<F5C;V=N:7IE9"!I;B!E86-H(&]F('1H92!T:')E92UM;VYT:`T*<&5R:6]D
M<R!E;F1E9"!-87)C:"`S,2P@,C`Q,2!A;F0@,C`Q,"X\+V9O;G0^/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"DQE928C>#(P,3D[<R!0:&%R;2!A
M9W)E96UE;G0@<')O=FED97,@=&AA="!T:&4@0V]M<&%N>2!R96-E:79E#0IR
M;WEA;'1Y('!A>6UE;G1S(&]F(#(P+3(U)2!O9B!N970@<V%L97,@;V8@3D]6
M+3`P,B!I;B!T:&4@0VAI;F5S90T*5&5R<FET;W)Y(&%N9"!R96-E:79E(')O
M>6%L='D@<&%Y;65N=',@;V8@,3(M,34E(&]F(&YE="!S86QE<R!O9@T*3D]6
M+3(P-2!I;B!T:&4@0VAI;F5S92!497)R:71O<GDN($QE928C>#(P,3D[<R!0
M:&%R;2!I<R!O8FQI9V%T960@=&\-"G)E:6UB=7)S92!T:&4@0V]M<&%N>2!F
M;W(@=&AE(&UA;G5F86-T=7)I;F<@8V]S="!O9B!P:&%R;6%C975T:6-A;`T*
M<')O9'5C=',@<')O=FED960@=&\@3&5E)B-X,C`Q.3MS(%!H87)M(&EN(&-O
M;FYE8W1I;VX@=VET:"!T:&4-"F%G<F5E;65N="X@3&5E)B-X,C`Q.3MS(%!H
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M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/D]N#0I&96)R=6%R>2`Q,2P@,C`P.2P@3F]V96QO
M<R!E;G1E<F5D(&EN=&\@82!C;VQL86)O<F%T:6]N(&%G<F5E;65N=`T**'1H
M92`F(W@R,#%#.T-O;&QA8F]R871I;VX@06=R965M96YT)B-X,C`Q1#LI('=I
M=&@@375N9&EP:&%R;6$-"DEN=&5R;F%T:6]N86P@0V]R<&]R871I;VX@3&EM
M:71E9"`H)B-X,C`Q0SM-=6YD:7!H87)M828C>#(P,40[*2!T;PT*9&5V96QO
M<"P@;6%N=69A8W1U<F4@86YD(&-O;6UE<F-I86QI>F4L(&]N(&%N(&5X8VQU
M<VEV92!B87-I<RP-"DQI8V5N<V5D(%!R;V1U8W1S("AA<R!D969I;F5D(&EN
M('1H92!#;VQL86)O<F%T:6]N($%G<F5E;65N="DL#0IW:&EC:"!I;F-L=61E
M<R!T:&4@0V]M<&%N>28C>#(P,3D[<R!C;VUP;W5N9"P@3D]6+3`P,BP@:6X@
M175R;W!E#0HH;W1H97(@=&AA;B!T:&4@4G5S<VEA;B!497)R:71O<GDI+"!!
M<VEA("AO=&AE<B!T:&%N('1H92!#:&EN97-E#0I497)R:71O<GDI(&%N9"!!
M=7-T<F%L:6$@*&-O;&QE8W1I=F5L>2!R969E<G)E9"!T;R!A<R!T:&4-"B8C
M>#(P,4,[375N9&EP:&%R;6$@5&5R<FET;W)Y)B-X,C`Q1#LI+B8C>$$P.R!-
M=6YD:7!H87)M82!I<R!A;@T*:6YD97!E;F1E;G0@87-S;V-I871E9"!C;VUP
M86YY(&]F(%!U<F1U92!0:&%R;6$L($PN4"X-"B@F(W@R,#%#.U!U<F1U928C
M>#(P,40[*2XF(WA!,#LF(WA!,#M4:&4@0V]L;&%B;W)A=&EO;B!!9W)E96UE
M;G0-"G!R;W9I9&5S(&9O<B!-=6YD:7!H87)M82!T;R!P87D@=&AE($-O;7!A
M;GD@<F]Y86QT:65S(&%N9"!F:7AE9`T*;6EL97-T;VYE('!A>6UE;G1S(&)A
M<V5D(&]N('-A;&5S(&%N9"!C;VUM97)C:6%L(&QA=6YC:&5S(&EN('1H90T*
M;&EC96YS960@=&5R<FET;W)I97,N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
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M;B!T:&4@8V]U;G1R>2!O<B`H,BD@=&AE(&1E=&5R;6EN871I;VX@=&AA="!A
M;GD-"G!A=&5N=',@=VET:&EN('1H92!C;W5N=')Y(&%R92!I;G9A;&ED+"!O
M8G9I;W5S(&]R(&]T:&5R=VES90T*=6YE;F9O<F-E86)L92XF(WA!,#LF(WA!
M,#M&;W(@8V]U;G1R:65S(&EN('=H:6-H(&YO('!A=&5N=',@87)E#0IH96QD
M+"!T:&4@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0@97AP:7)E<R!T:&4@96%R
M;&EE<B!O9B`Q-2!Y96%R<PT*9G)O;2!I=',@969F96-T:79E(&1A=&4@;W(@
M=7!O;B!G96YE<FEC('!R;V1U8W0@8V]M<&5T:71I;VX@:6X@=&AE#0IC;W5N
M=')Y(')E<W5L=&EN9R!I;B!A(#(P)2!D<F]P(&EN($UU;F1I<&AA<FUA)B-X
M,C`Q.3MS(&UA<FME=`T*<VAA<F4N)B-X03`[)B-X03`[3F]V96QO<R!M87D@
M=&5R;6EN871E('1H92!#;VQL86)O<F%T:6]N($%G<F5E;65N=`T*=7!O;B!B
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M#0IR96%S;VXN)B-X03`[)B-X03`[268@86YY(')E9W5L871O<GD@87!P<F]V
M86P@=VET:&EN('1H90T*375N9&EP:&%R;6$@5&5R<FET;W)Y(&ES('-U<W!E
M;F1E9"!A<R!A(')E<W5L="!O9B!I<W-U97,@<F5L871E9"!T;PT*=&AE('-A
M9F5T>2!O9B!T:&4@3&EC96YS960@4')O9'5C=',L('1H96X@375N9&EP:&%R
M;6$F(W@R,#$Y.W,-"F]B;&EG871I;VYS('5N9&5R('1H92!#;VQL86)O<F%T
M:6]N($%G<F5E;65N="!W:6QL(&)E('-U<W!E;F1E9`T*=6YT:6P@=&AE(')E
M9W5L871O<GD@87!P<F]V86P@:7,@<F5I;G-T871E9"XF(WA!,#LF(WA!,#M)
M9B!T:&%T#0IR96EN<W1A=&5M96YT(&1O97,@;F]T(&]C8W5R('=I=&AI;B`Q
M,B!M;VYT:',@;V8@=&AE('-U<W!E;G-I;VXL#0IT:&5N($UU;F1I<&AA<FUA
M(&UA>2!T97)M:6YA=&4@=&AE($-O;&QA8F]R871I;VX-"D%G<F5E;65N="X\
M+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D-O;F-U<G)E;G1L>0T*=VET
M:"!T:&4@97AE8W5T:6]N(&]F('1H92!#;VQL86)O<F%T:6]N($%G<F5E;65N
M="P@3F]V96QO<PT*8V]M<&QE=&5D(&$@<')I=F%T92!P;&%C96UE;G0@;V8@
M4V5R:65S($4@<')E9F5R<F5D('-T;V-K(&%N9`T*8V]M;6]N('-T;V-K('!U
M<F-H87-E('=A<G)A;G1S('1O(%!U<F1U92X\+V9O;G0^/"]D:78^#0H\8G(@
M+SX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^5&AE#0I#;VUP86YY(&5X<&5C=',@=&AA="!T
M:&4@;F5G871I=F4@<F5S=6QT<R!O9B!I=',@4&AA<V4@,R!4<FEA;"!W:6QL
M#0IA9'9E<G-E;'D@869F96-T(&1E=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L
M:7IA=&EO;B!O9B!.3U8M,#`R('5N9&5R#0IT:&4@8V]L;&%B;W)A=&EO;B!A
M9W)E96UE;G1S('=I=&@@3&5E)B-X,C`Q.3MS(%!H87)M(&%N9`T*375N9&EP
M:&%R;6$N/"]F;VYT/CPO9&EV/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQD:78^#0H\=&%B
M;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N=&5R/@T*/'1R
M('9A;&EG;CTS1'1O<#X-"CQT9"!S='EL93TS1"=724142#H@,3AP="<^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P="<^-2X\+V9O
M;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9#X-"CQD:78@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M4TE:13H@,3!P="<^0T],3$%"3U)!5$E/3@T*04=2145-14Y44SPO
M9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^#0HR,#`W($-O;&QA8F]R871I;VX@06=R965M96YT
M('=I=&@@3&5E)B-X,C`Q.3MS(%!H87)M86-E=71I8V%L("A(2RD-"DQT9"X\
M+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DEN#0I$96-E;6)E<B`R,#`W
M('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A($-O;&QA8F]R871I;VX@06=R
M965M96YT#0IW:71H($QE928C>#(P,3D[<R!0:&%R;6%C975T:6-A;"`H2$LI
M($QT9"X@*"8C>#(P,4,[3&5E)B-X,C`Q.3MS#0I0:&%R;28C>#(P,40[*2X@
M4'5R<W5A;G0@=&\@=&AI<R!A9W)E96UE;G0L($QE928C>#(P,3D[<R!0:&%R
M;0T*;V)T86EN960@86X@97AC;'5S:79E(&QI8V5N<V4@=&\@9&5V96QO<"P@
M;6%N=69A8W1U<F4@86YD#0IC;VUM97)C:6%L:7IE($Y/5BTP,#(@86YD($Y/
M5BTR,#4@:6X@0VAI;F$L($AO;F<@2V]N9RP@5&%I=V%N(&%N9`T*36%C874@
M*'1H92`F(W@R,#%#.T-H:6YE<V4@5&5R<FET;W)Y)B-X,C`Q1#LI+B!4:&4@
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M8G-P.R0U,#`L,#`P(&EN($UA<F-H(#(P,#@@86YD(&ES(&5N=&ET;&5D('1O
M(')E8V5I=F4@=7`@=&\-"B9N8G-P.R0Q+#<P,"PP,#`@:6X@9G5T=7)E(&UI
M;&5S=&]N92!P87EM96YT<R!U<&]N('1H92!C;VUP;&5T:6]N(&]F#0ID979E
M;&]P;65N="!A;F0@;6%R:V5T:6YG(&UI;&5S=&]N97,@8GD@3&5E)B-X,C`Q
M.3MS(%!H87)M+B!4:&ES#0II;FET:6%L("9N8G-P.R0U,#`L,#`P('!A>6UE
M;G0@<F5C96EV960@:7,@8F5I;F<@86UO<G1I>F5D(&]V97(@=&AE#0IE<W1I
M;6%T960@=&5R;2!O9B!T:&ES(&%G<F5E;65N="P@,34@>65A<G,N($%C8V]R
M9&EN9VQY+"`F;F)S<#LD,S,L,#`P(&]F#0IL:6-E;G-E(')E=F5N=64@=V%S
M(')E8V]G;FEZ960@:6X@96%C:"!O9B!T:&4@>65A<G,@96YD960@1&5C96UB
M97(-"C,Q+"`R,#$P(&%N9"`R,#`Y+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<^5&AE#0I,964F(W@R,#$Y.W,@4&AA<FT@86=R965M96YT('!R;W9I
M9&5S('1H870@=&AE($-O;7!A;GD@<F5C96EV90T*<F]Y86QT>2!P87EM96YT
M<R!O9B`R,"TR-24@;V8@;F5T('-A;&5S(&]F($Y/5BTP,#(@:6X@=&AE($-H
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M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*,C`P.2!#
M;VQL86)O<F%T:6]N($%G<F5E;65N="!W:71H($UU;F1I<&AA<FUA/"]F;VYT
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/;@T*1F5B<G5A<GD@,3$L(#(P,#DL
M($YO=F5L;W,@96YT97)E9"!I;G1O(&$@8V]L;&%B;W)A=&EO;B!A9W)E96UE
M;G0-"BAT:&4@)B-X,C`Q0SM#;VQL86)O<F%T:6]N($%G<F5E;65N="8C>#(P
M,40[*2!W:71H($UU;F1I<&AA<FUA#0I);G1E<FYA=&EO;F%L($-O<G!O<F%T
M:6]N($QI;6ET960@*"8C>#(P,4,[375N9&EP:&%R;6$F(W@R,#%$.RD@=&\-
M"F1E=F5L;W`L(&UA;G5F86-T=7)E(&%N9"!C;VUM97)C:6%L:7IE+"!O;B!A
M;B!E>&-L=7-I=F4@8F%S:7,L#0I,:6-E;G-E9"!0<F]D=6-T<R`H87,@9&5F
M:6YE9"!I;B!T:&4@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0I+`T*=VAI8V@@
M:6YC;'5D97,@=&AE($-O;7!A;GDF(W@R,#$Y.W,@;&5A9"!C;VUP;W5N9"P@
M3D]6+3`P,BP@:6X-"D5U<F]P92`H;W1H97(@=&AA;B!T:&4@4G5S<VEA;B!4
M97)R:71O<GDI+"!!<VEA("AO=&AE<B!T:&%N('1H90T*0VAI;F5S92!497)R
M:71O<GDI(&%N9"!!=7-T<F%L:6$@*&-O;&QE8W1I=F5L>2!R969E<G)E9"!T
M;R!A<R!T:&4-"B8C>#(P,4,[375N9&EP:&%R;6$@5&5R<FET;W)Y)B-X,C`Q
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M/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<^1F]R#0IC;W5N=')I97,@:6X@=VAI8V@@<&%T96YT<R!A
M<F4@:&5L9"P@=&AE($-O;&QA8F]R871I;VX@06=R965M96YT#0IE>'!I<F5S
M(&]N(&$@8V]U;G1R>2UB>2UC;W5N=')Y(&)A<VES('=I=&AI;B!T:&4@375N
M9&EP:&%R;6$-"E1E<G)I=&]R>2!O;B!T:&4@96%R;&EE<B!O9B`H,2D@97AP
M:7)A=&EO;B!O9B!T:&4@;&%S="!A<'!L:6-A8FQE#0I.;W9E;&]S('!A=&5N
M="!W:71H:6X@=&AE(&-O=6YT<GD@;W(@*#(I('1H92!D971E<FUI;F%T:6]N
M('1H870@86YY#0IP871E;G1S('=I=&AI;B!T:&4@8V]U;G1R>2!A<F4@:6YV
M86QI9"P@;V)V:6]U<R!O<B!O=&AE<G=I<V4-"G5N96YF;W)C96%B;&4N)B-X
M03`[($9O<B!C;W5N=')I97,@:6X@=VAI8V@@;F\@<&%T96YT<R!A<F4@:&5L
M9"P-"G1H92!#;VQL86)O<F%T:6]N($%G<F5E;65N="!E>'!I<F5S('1H92!E
M87)L:65R(&]F(#$U('EE87)S(&9R;VT-"FET<R!E9F9E8W1I=F4@9&%T92!O
M<B!U<&]N(&=E;F5R:6,@<')O9'5C="!C;VUP971I=&EO;B!I;B!T:&4-"F-O
M=6YT<GD@<F5S=6QT:6YG(&EN(&$@,C`E(&1R;W`@:6X@375N9&EP:&%R;6$F
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M:&4-"DQI8V5N<V5D(%!R;V1U8W1S+"!T:&5N($UU;F1I<&AA<FUA)B-X,C`Q
M.3MS(&]B;&EG871I;VYS('5N9&5R('1H90T*0V]L;&%B;W)A=&EO;B!!9W)E
M96UE;G0@=VEL;"!B92!S=7-P96YD960@=6YT:6P@=&AE(')E9W5L871O<GD-
M"F%P<')O=F%L(&ES(')E:6YS=&%T960N)B-X03`[($EF('1H870@<F5I;G-T
M871E;65N="!D;V5S(&YO="!O8V-U<@T*=VET:&EN(#$R(&UO;G1H<R!O9B!T
M:&4@<W5S<&5N<VEO;BP@=&AE;B!-=6YD:7!H87)M82!M87D@=&5R;6EN871E
M#0IT:&4@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0N/"]F;VYT/CPO9&EV/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:R<^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SY#;VYC=7)R96YT;'D-"G=I=&@@=&AE(&5X96-U=&EO
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M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-
M"D-O;7!A;GD@97AP96-T<R!T:&%T('1H92!N96=A=&EV92!R97-U;'1S(&]F
M(&ET<R!0:&%S92`S(%1R:6%L('=I;&P-"F%D=F5R<V5L>2!A9F9E8W0@9&5V
M96QO<&UE;G0@86YD(&-O;6UE<F-I86QI>F%T:6]N(&]F($Y/5BTP,#(@=6YD
M97(-"G1H92!C;VQL86)O<F%T:6]N(&%G<F5E;65N=',@=VET:"!,964F(W@R
M,#$Y.W,@4&AA<FT@86YD#0I-=6YD:7!H87)M82X\+V9O;G0^/"]D:78^#0H\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
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M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%,T@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U5"4T51545.5"!%5D5.
M5%,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y354)315%514Y4($5614Y44SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQD:78^#0H\=&%B;&4@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N=&5R/@T*/'1R('9A;&EG;CTS1'1O
M<#X-"CQT9"!S='EL93TS1"=724142#H@,S9P="<^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
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M/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
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M63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^3VX-"D%P<FEL(#@L(#(P,3$L('1H92!#
M;VUP86YY(&5N=&5R960@:6YT;R!A;B!!9W)E96UE;G0@86YD(%!L86X@;V8-
M"DUE<F=E<B`H=&AE("8C>#(P,4,[365R9V5R($%G<F5E;65N="8C>#(P,40[
M*2!W:71H($-E;&QE8W1A<BP@26YC+@T**"8C>#(P,4,[0V5L;&5C=&%R)B-X
M,C`Q1#LI(&%N9"!#96QL($%C<75I<VET:6]N($-O<G`N("AT:&4-"B8C>#(P
M,4,[365R9V5R(%-U8G-I9&EA<GDF(W@R,#%$.RDL(&$@=VAO;&QY+6]W;F5D
M('-U8G-I9&EA<GD@;V8-"DYO=F5L;W,L('!U<G-U86YT('1O('=H:6-H($-E
M;&QE8W1A<B!W87,@;65R9V5D(&EN=&\@=&AE($UE<F=E<@T*4W5B<VED:6%R
M>2`H=&AE("8C>#(P,4,[06-Q=6ES:71I;VXF(W@R,#%$.RDN)B-X03`[)B-X
M03`[07,@82!R97-U;'0-"F]F('1H92!!8W%U:7-I=&EO;BP@=&AE($UE<F=E
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M.R8C>$$P.U1H92!#;VUP86YY('=I;&P-"F-O;G1I;G5E('1O(&1E=F5L;W`@
M0V5L;&5C=&%R)B-X,C`Q.3MS(&-O;7!O=6YD<R!F;VQL;W=I;F<@=&AE#0I!
M8W%U:7-I=&EO;BX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M97(@9VEV:6YG(&5F9F5C=`T*=&\@=&AE($%C<75I<VET:6]N(&)U="!B969O
M<F4@9VEV:6YG(&5F9F5C="!T;R!T:&4@8V]N8W5R<F5N=`T*<')I=F%T92!P
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M('-P;&ET(&]F(&ET<R!C;VUM;VX@<W1O8VL@*'1H92`F(W@R,#%#.U)E=F5R
M<V4-"E-P;&ET)B-X,C`Q1#LI+B8C>$$P.R8C>$$P.TEM;65D:6%T96QY(&9O
M;&QO=VEN9R!T:&4@969F96-T:79E;F5S<PT*;V8@=&AE(%)E=F5R<V4@4W!L
M:70L('1H97)E('=E<F4@,BPY-3DL.#<Q('-H87)E<R!O9B!C;VUM;VX@<W1O
M8VL-"F]U='-T86YD:6YG+"!A;F0@=&AE($-O;7!A;GD@:7-S=65D(#$W+#`P
M,2PU.38@<VAA<F5S(&]F(&ET<R!C;VUM;VX-"G-T;V-K('1O('1H92!F;W)M
M97(@<W1O8VMH;VQD97)S(&]F($-E;&QE8W1A<B!U<&]N('1H90T*969F96-T
M:79E;F5S<R!O9B!T:&4@06-Q=6ES:71I;VXN/"]F;VYT/CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^
M/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY2;V1M86X-"B9A;7`[(%)E;G-H87<L($Q,0R`H)B-X,C`Q
M0SM2;V1M86XF(W@R,#%$.RDL(&9I;F%N8VEA;"!A9'9I<V]R('1O#0I.;W9E
M;&]S(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@06-Q=6ES:71I;VXL(')E8V5I
M=F5D(&$@8V%S:"!F964@;V8-"B9N8G-P.R0R-3`L,#`P('5P;VX@=&AE(&-O
M;7!L971I;VX@;V8@=&AE($%C<75I<VET:6]N(&EN(&-O;G-I9&5R871I;VX-
M"F9O<B!T:&5I<B!S97)V:6-E<RXF(WA!,#LF(WA!,#M835,@0V%P:71A;"!0
M87)T;F5R<RP@=&AE(&9I;F%N8VEA;`T*861V:7-O<B!T;R!#96QL96-T87(@
M:6X@8V]N;F5C=&EO;B!W:71H('1H92!!8W%U:7-I=&EO;BP@<F5C96EV960@
M80T*8V%S:"!F964@;V8@)FYB<W`[)#(P,"PP,#`@=7!O;B!T:&4@8V]M<&QE
M=&EO;B!O9B!T:&4@06-Q=6ES:71I;VX@:6X-"F-O;G-I9&5R871I;VX@9F]R
M('1H96ER('-E<G9I8V5S+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
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M9R!I;G1E<F5S=`T*:6X@=&AE(&-O;6)I;F5D(&)U<VEN97-S(&)E('1R96%T
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M<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%
M.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^#0I396-U<FET:65S(%!U<F-H87-E($%G<F5E;65N=#PO9F]N=#X\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^0V]N8W5R<F5N=&QY#0IW:71H('1H92!E>&5C
M=71I;VX@;V8@=&AE($UE<F=E<B!!9W)E96UE;G0L('1H92!#;VUP86YY(&5N
M=&5R960-"FEN=&\@82!396-U<FET:65S(%!U<F-H87-E($%G<F5E;65N="!W
M:71H(&-E<G1A:6X@86-C<F5D:71E9`T*:6YV97-T;W)S('5N9&5R('=H:6-H
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M<')O>&EM871E;'D-"B9N8G-P.R0U+#$S-2PP,#`N)B-X03`[)B-X03`[5&AE
M('=A<G)A;G1S(&AA=F4@86X@97AE<F-I<V4@<')I8V4@;V8@)FYB<W`[)#`N
M-S4-"F%N9"!E>'!I<F4@;VX@36%R8V@@,S$L(#(P,38N)B-X03`[)B-X03`[
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M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"E-E8W5R
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M<B`T+"`R,#$Q+"!A;F0@=&\@:V5E<"!T:&4-"G)E9VES=')A=&EO;B!S=&%T
M96UE;G0@8V]N=&EN=6]U<VQY(&5F9F5C=&EV92!U;F1E<B!T:&4@4V5C=7)I
M=&EE<PT*06-T(&]F(#$Y,S,L(&%S(&%M96YD960@*'1H92`F(W@R,#%#.U-E
M8W5R:71I97,@06-T)B-X,C`Q1#LI+"!U;G1I;`T*=&AE(&5A<FQI97(@;V8@
M=&AE(&1A=&4@=VAE;B!A;&P@=&AE(')E9VES=')A8FQE('-E8W5R:71I97,@
M8V]V97)E9`T*8GD@=&AE(')E9VES=')A=&EO;B!S=&%T96UE;G0@:&%V92!B
M965N('-O;&0@;W(@=&AE('-E8V]N9`T*86YN:79E<G-A<GD@;V8@=&AE(&-L
M;W-I;F<N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);@T*=&AE(&5V
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M=6%R>2`S+"`R,#$R("AI9B!T:&5R92!I<R!R979I97<@8GD@=&AE#0I314,I
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M=&AA;B`S,"!C;VYS96-U=&EV90T*9&%Y<RP@;VX@;F]T(&UO<F4@=&AA;B!T
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M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/E1H90T*0V]M<&%N>2!P86ED('1O(%)O9&UA;BP@=&AE('!L86-E;65N
M="!A9V5N="!F;W(@=&AE(&9I;F%N8VEN9RP@80T*8V%S:"!F964@97%U86P@
M=&\@)FYB<W`[)#(P,"PP,#`@86YD('=A<G)A;G1S('1O('!U<F-H87-E(#$Y
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M<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^07,-"F$@<F5S=6QT(&]F('1H92!F:6YA;F-I;F<L('=A<G)A
M;G1S('1O('!U<F-H87-E(#$P-2PP-#(@<VAA<F5S(&]F#0IC;VUM;VX@<W1O
M8VL@870@)FYB<W`[)#$P+C<Q('!E<B!S:&%R92P@9VEV:6YG(&5F9F5C="!T
M;R!T:&4@4F5V97)S90T*4W!L:70L(&)E8V%M92!E>&5R8VES86)L92!F;W(@
M)FYB<W`[)#`N-S4@<&5R('-H87)E(&%C8V]R9&EN9R!T;R!T:&5I<@T*=&5R
M;7,N($]N($UA>2`S+"`R,#$Q+"`Q."PQ-3,@<VAA<F5S(&]F(&-O;6UO;B!S
M=&]C:R!W97)E(&ES<W5E9"!I;@T*8V]N;F5C=&EO;B!W:71H('1H92!C87-H
M;&5S<R!E>&5R8VES92`R-RPS,3$@;V8@=&AE<V4-"G=A<G)A;G1S+CPO9F]N
M=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^#0I#:&%N9V5S(&EN($1I<F5C=&]R<R!A;F0@
M17AE8W5T:79E($]F9FEC97)S/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY%9F9E8W1I=F4-"D%P<FEL(#@L(#(P,3$L('!R:6]R('1O('1H92!C;VUP
M;&5T:6]N(&]F('1H92!!8W%U:7-I=&EO;BP@36EC:&%E;`T*2BX@1&]Y;&4L
M(%-I;2!&87-S(&%N9"!$879I9"!"+B!-8U=I;&QI86US(')E<VEG;F5D(&9R
M;VT@=&AE#0I#;VUP86YY)B-X,C`Q.3MS(&)O87)D(&]F(&1I<F5C=&]R<R!A
M;F0@=&AE:7(@<F5S<&5C=&EV92!C;VUM:71T964-"F%P<&]I;G1M96YT<RX\
M+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D5F9F5C=&EV90T*07!R:6P@
M."P@,C`Q,2P@87,@82!C;VYD:71I;VX@=&\@=&AE(&-O;7!L971I;VX@;V8@
M=&AE($%C<75I<VET:6]N+`T*2F%M97D@4"X@5V5I8VAE<G0L(%1H;VUA<R!2
M;V-K=V5L;"!-86-K:64L($IO:&X@3F5I<RP@2F]H;B!%+@T*3FEE9&5R:'5B
M97(@86YD($UI8VAA96P@1BX@5'=E961L92!W97)E(&%P<&]I;G1E9"!T;R!T
M:&4-"D-O;7!A;GDF(W@R,#$Y.W,@8F]A<F0@;V8@9&ER96-T;W)S+B8C>$$P
M.R8C>$$P.TIA;65Y(%`N(%=E:6-H97)T+`T*5&AO;6%S(%)O8VMW96QL($UA
M8VMI92!A;F0@2F]H;B!.96ES('!R979I;W5S;'D@<V5R=F5D(&]N('1H92!B
M;V%R9`T*;V8@9&ER96-T;W)S(&]F($-E;&QE8W1A<BX\+V9O;G0^/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/D]N#0I!<')I;"`R-2P@,C`Q,2P@=&AE($-O;7!A
M;GDF(W@R,#$Y.W,@8F]A<F0@;V8@9&ER96-T;W)S(&%P<&]I;G1E9`T*=&AE
M(&9O;&QO=VEN9R!I;F1I=FED=6%L<R!T;R!S97)V92!O;B!T:&4@9F]L;&]W
M:6YG(&-O;6UI='1E97,@;V8-"G1H92!B;V%R9"!O9B!D:7)E8W1O<G,N/"]F
M;VYT/CPO9&EV/@T*/&)R("\^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DAO=V%R9`T*32X@
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M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY3=&5P:&5N#0I!+B!(:6QL+"!*;VAN($4N($YI961E<FAU8F5R
M(&%N9"!*86UE<R!3+B!-86YU<V\@=V5R92!A<'!O:6YT960@=&\-"G1H92!N
M;VUI;F%T:6YG(&%N9"!C;W)P;W)A=&4@9V]V97)N86YC92!C;VUM:71T964@
M;V8@=&AE(&)O87)D(&]F#0ID:7)E8W1O<G,N)B-X03`[)B-X03`[1'(N($AI
M;&P@=V%S(&%P<&]I;G1E9"!A<R!T:&4@8VAA:7)M86X@;V8-"G1H870@8V]M
M;6ET=&5E+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX-"D%M96YD;65N="!O9B!#97)T:69I8V%T92!O9B!);F-O
M<G!O<F%T:6]N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%9F9E8W1I
M=F4-"D%P<FEL(#<L(#(P,3$@=&AE($-O;7!A;GDF(W@R,#$Y.W,@8V5R=&EF
M:6-A=&4@;V8@:6YC;W)P;W)A=&EO;B!W87,-"F%M96YD960@=&\@96QI;6EN
M871E('1H92!#97)T:69I8V%T92!T;R!3970@1F]R=&@@1&5S:6=N871I;VYS
M+`T*5F]T:6YG(%!O=V5R<RP@4')E9F5R96YC97,L(%)E<W1R:6-T:6]N<R!A
M;F0@4F5L871I=F4@4FEG:'1S(&]F#0I397)I97,@0R`X)2!#=6UU;&%T:79E
M($-O;G9E<G1I8FQE(%!R969E<G)E9`T*4W1O8VLN)B-X03`[)B-X03`[5&AE
M<F4@:&%D(&YO="!B965N(&%N>2!S:&%R97,@;V8@4V5R:65S($,-"G!R969E
M<G)E9"!S=&]C:R!O=71S=&%N9&EN9R!S:6YC92!$96-E;6)E<B`R,#$P+CPO
M9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^169F96-T:79E#0I!<')I;"`W
M+"`R,#$Q('1H92!#;VUP86YY)B-X,C`Q.3MS(&-E<G1I9FEC871E(&]F(&EN
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M1&5C96UB97(@,C`Q,"X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M)SX-"E!R:6]R('1O('1H92!C;&]S:6YG(&]F('1H92!!8W%U:7-I=&EO;B!O
M;B!!<')I;"`X+"`R,#$Q+"!T:&4-"D-O;7!A;GD@86UE;F1E9"!A;F0@<F5S
M=&%T960@:71S(&-E<G1I9FEC871E(&]F(&EN8V]R<&]R871I;VX@:6X-"F]R
M9&5R('1O("AA*2!E9F9E8W0@=&AE(')E=F5R<V4@<W!L:70[("AB*2!R961U
M8V4@=&AE(&YU;6)E<B!O9@T*<VAA<F5S(&]F(&%U=&AO<FEZ960@8V]M;6]N
M('-T;V-K(&9R;VT@-S4P+#`P,"PP,#`@=&\@,34P+#`P,"PP,#`[#0HH8RD@
M96QI;6EN871E('1H92!R:6=H="!O9B!T:&4@<W1O8VMH;VQD97)S('1O(&%C
M="!B>2!W<FET=&5N#0IC;VYS96YT.R!A;F0@*&0I(&-L87-S:69Y('1H92!B
M;V%R9"!O9B!D:7)E8W1O<G,@:6YT;R!T:')E90T*8VQA<W-E<RXF(WA!,#LF
M(WA!,#M#;&%S<R!)(&1I<F5C=&]R<R!W:6QL('-T86YD(&9O<B!R92UE;&5C
M=&EO;B!A=`T*=&AE($-O;7!A;GDF(W@R,#$Y.W,@;F5X="!A;FYU86P@;65E
M=&EN9R!O9B!S=&]C:VAO;&1E<G,L($-L87-S($E)#0ID:7)E8W1O<G,@=VEL
M;"!S=&%N9"!F;W(@<F4M96QE8W1I;VX@870@=&AE(#(P,3(@86YN=6%L(&UE
M971I;F<@;V8-"G-T;V-K:&]L9&5R<RP@86YD($-L87-S($E)22!D:7)E8W1O
M<G,@=VEL;"!S=&%N9"!F;W(@<F4M96QE8W1I;VX@870-"G1H92`R,#$S(&%N
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M9F]N=#X\+V1I=CX-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\9&EV/@T*/'1A8FQE('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E;G1E<CX-"CQT<B!V86QI9VX]
M,T1T;W`^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#(W<'0G/@T*/&1I=B!S='EL
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M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I354)3
M15%514Y4($5614Y44SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T
M86)L93X-"CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"DUE<F=E<B!!9W)E96UE;G0\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]N#0I!<')I;"`X+"`R,#$Q+"!T
M:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@86X@06=R965M96YT(&%N9"!0;&%N
M(&]F#0I-97)G97(@*'1H92`F(W@R,#%#.TUE<F=E<B!!9W)E96UE;G0F(W@R
M,#%$.RD@=VET:"!#96QL96-T87(L($EN8RX-"B@F(W@R,#%#.T-E;&QE8W1A
M<B8C>#(P,40[*2!A;F0@0V5L;"!!8W%U:7-I=&EO;B!#;W)P+B`H=&AE#0HF
M(W@R,#%#.TUE<F=E<B!3=6)S:61I87)Y)B-X,C`Q1#LI+"!A('=H;VQL>2!O
M=VYE9"!S=6)S:61I87)Y(&]F#0I.;W9E;&]S+"!P=7)S=6%N="!T;R!W:&EC
M:"!#96QL96-T87(@=V%S(&UE<F=E9"!I;G1O('1H92!-97)G97(-"E-U8G-I
M9&EA<GD@*'1H92`F(W@R,#%#.T%C<75I<VET:6]N)B-X,C`Q1#LI+B8C>$$P
M.R8C>$$P.T%S(&$@<F5S=6QT#0IO9B!T:&4@06-Q=6ES:71I;VXL('1H92!-
M97)G97(@4W5B<VED:6%R>2P@=VAI8V@@:&%S(&)E96X@<F5N86UE9`T*0V5L
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M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!<PT*
M8V]N<VED97)A=&EO;B!F;W(@=&AE($%C<75I<VET:6]N+"!T:&4@9F]R;65R
M('-T;V-K:&]L9&5R<R!O9@T*0V5L;&5C=&%R)B-X03`[)B-X03`[<F5C96EV
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M8F5D(&)E;&]W+`T*87!P<F]X:6UA=&5L>2`X-24@;V8@=&AE(&]U='-T86YD
M:6YG('-H87)E<R!O9B!.;W9E;&]S(&-O;6UO;@T*<W1O8VLN)B-X03`[)B-X
M03`[4')I;W(@=&\@=&AE($%C<75I<VET:6]N+"!T:&4@0V]M<&%N>2!A;65N
M9&5D(&%N9`T*<F5S=&%T960@:71S(&-E<G1I9FEC871E(&]F(&EN8V]R<&]R
M871I;VX@86YD(&EN(&-O;FYE8W1I;VX-"G1H97)E=VET:"P@86UO;F<@;W1H
M97(@=&AI;F=S+"!E9F9E8W1E9"!A(#$M9F]R+3$U,R!R979E<G-E('-P;&ET
M#0IO9B!I=',@8V]M;6]N('-T;V-K("AT:&4@)B-X,C`Q0SM2979E<G-E#0I3
M<&QI="8C>#(P,40[*2XF(WA!,#LF(WA!,#M);6UE9&EA=&5L>2!F;VQL;W=I
M;F<@=&AE(&5F9F5C=&EV96YE<W,-"F]F('1H92!2979E<G-E(%-P;&ET+"!T
M:&5R92!W97)E(&%P<')O>&EM871E;'D@,BPY-3DL.#<Q('-H87)E<R!O9@T*
M;W5R(&-O;6UO;B!S=&]C:R!O=71S=&%N9&EN9RP@86YD('1H92!#;VUP86YY
M(&ES<W5E9"`Q-RPP,#$L-3DV#0IS:&%R97,@;V8@;W5R(&-O;6UO;B!S=&]C
M:R!T;R!T:&4@9F]R;65R('-T;V-K:&]L9&5R<R!O9B!#96QL96-T87(-"G5P
M;VX@=&AE(&5F9F5C=&EV96YE<W,@;V8@=&AE($%C<75I<VET:6]N+CPO9F]N
M=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^4F]D;6%N#0HF86UP.R!296YS:&%W
M+"!,3$,@*"8C>#(P,4,[4F]D;6%N)B-X,C`Q1#LI+"!F:6YA;F-I86P@861V
M:7-O<B!T;PT*3F]V96QO<R!I;B!C;VYN96-T:6]N('=I=&@@=&AE($%C<75I
M<VET:6]N+"!R96-E:79E9"!A(&-A<V@@9F5E(&]F#0HF;F)S<#LD,C4P+#`P
M,"!U<&]N('1H92!C;VUP;&5T:6]N(&]F('1H92!!8W%U:7-I=&EO;B!I;B!C
M;VYS:61E<F%T:6]N(&]F#0IT:&5I<B!S97)V:6-E<RXF(WA!,#LF(WA!,#M8
M35,@0V%P:71A;"!087)T;F5R<RP@=&AE(&9I;F%N8VEA;`T*861V:7-O<B!T
M;R!#96QL96-T87(@:6X@8V]N;F5C=&EO;B!W:71H('1H92!!8W%U:7-I=&EO
M;BP@<F5C96EV960@80T*8V%S:"!F964@;V8@)FYB<W`[)#(P,"PP,#`@=7!O
M;B!T:&4@8V]M<&QE=&EO;B!O9B!T:&4@06-Q=6ES:71I;VX@:6X-"F-O;G-I
M9&5R871I;VX@;V8@=&AE:7(@<V5R=FEC97,N/"]F;VYT/CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^
M/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
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M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY#;VYC=7)R96YT;'D-"G=I=&@@=&AE(&5X
M96-U=&EO;B!O9B!T:&4@365R9V5R($%G<F5E;65N="P@=&AE($-O;7!A;GD@
M96YT97)E9`T*:6YT;R!A(%-E8W5R:71I97,@4'5R8VAA<V4@06=R965M96YT
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M87!P<F]X:6UA=&5L>0T*)FYB<W`[)#4L,3,U+#`P,"XF(WA!,#LF(WA!,#M4
M:&4@=V%R<F%N=',@:&%V92!A;B!E>&5R8VES92!P<FEC92!O9B`F;F)S<#LD
M,"XW-0T*86YD(&5X<&ER92!O;B!-87)C:"`S,2P@,C`Q-BXF(WA!,#LF(WA!
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M('1H92!R:6=H=',@;V8@=V%R<F%N=`T*:&]L9&5R<R!P<FEO<B!T;R!S=6-H
M(&5V96YT+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
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M,40[*2!N;R!L871E<B!T:&%N($]C=&]B97(@-2P@,C`Q,2P@82!R96=I<W1R
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M9&5R#0IT:&4@4V5C=7)I=&EE<R!!8W0@;V8@,3DS,RP@87,@86UE;F1E9"`H
M=&AE("8C>#(P,4,[4V5C=7)I=&EE<PT*06-T)B-X,C`Q1#LI('5N=&EL('1H
M92!E87)L:65R(&]F('1H92!D871E('=H96X@86QL('1H92!R96=I<W1R86)L
M90T*<V5C=7)I=&EE<R!C;W9E<F5D(&)Y('1H92!R96=I<W1R871I;VX@<W1A
M=&5M96YT(&AA=F4@8F5E;B!S;VQD(&]R#0IT:&4@<V5C;VYD(&%N;FEV97)S
M87)Y(&]F('1H92!C;&]S:6YG+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
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M;6)E<B`T+"`R,#$Q("AI9B!T:&5R92!I<R!N;PT*<F5V:65W(&)Y('1H92!3
M14,I(&]R(&)Y($IA;G5A<GD@,RP@,C`Q,B`H:68@=&AE<F4@:7,@<F5V:65W
M(&)Y('1H90T*4T5#*2!W:71H(')E<W!E8W0@=&\@=&AE(&UA>&EM=6T@;G5M
M8F5R(&]F('-H87)E<R!P97)M:71T960@=&\@8F4-"G)E9VES=&5R960@8GD@
M=&AE(%-%0RP@=&AE($-O;7!A;GD@=VEL;"!B92!R97%U:7)E9"!T;R!P87D@
M=&\@=&AE#0IP=7)C:&%S97)S(&QI<75I9&%T960@9&%M86=E<R!E<75A;"!T
M;R`Q+C4E('!E<B!M;VYT:"`H<')O+7)A=&5D(&]N#0IA(&1A:6QY(&)A<VES
M(&9O<B!A;GD@<&5R:6]D(&]F(&QE<W,@=&AA;B!A(&9U;&P@;6]N=&@I(&]F
M('1H90T*86=G<F5G871E('!U<F-H87-E('!R:6-E(&]F('1H92!U;FET<R!P
M=7)C:&%S960@=6YT:6P@=&AE#0IR96=I<W1R871I;VX@<W1A=&5M96YT(&ES
M(&9I;&5D(&]R(&1E8VQA<F5D(&5F9F5C=&EV92P@87,-"F%P<&QI8V%B;&4N
M)B-X03`[)B-X03`[5&AE($-O;7!A;GD@=VEL;"!B92!A;&QO=V5D('1O('-U
M<W!E;F0@=&AE#0IU<V4@;V8@=&AE(')E9VES=')A=&EO;B!S=&%T96UE;G0@
M9F]R(&YO="!M;W)E('1H86X@,S`@8V]N<V5C=71I=F4-"F1A>7,L(&]N(&YO
M="!M;W)E('1H86X@='=O(&]C8V%S:6]N<RP@:6X@86YY(#$R(&UO;G1H#0IP
M97)I;V0N)B-X03`[)B-X03`[5&AE($-O;7!A;GD@:&%S(&%L<V\@9W)A;G1E
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M;&]C:R<^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY4:&4-"D-O;7!A;GD@<&%I9"!T;R!2;V1M86XL
M('1H92!P;&%C96UE;G0@86=E;G0@9F]R('1H92!F:6YA;F-I;F<L(&$-"F-A
M<V@@9F5E(&5Q=6%L('1O("9N8G-P.R0R,#`L,#`P(&%N9"!W87)R86YT<R!T
M;R!P=7)C:&%S92`Q.3(L.3,Q('-H87)E<PT*;V8@:71S(&-O;6UO;B!S=&]C
M:R!I;B!C;VYS:61E<F%T:6]N(&9O<B!T:&5I<B!A9'9I<V]R>2!S97)V:6-E
M<PT*=VET:"!R97-P96-T('1O('1H92!F:6YA;F-I;F<@<'5R<W5A;G0@=&\@
M=&AE('!L86-E;65N="!A9V5N8WD-"F%G<F5E;65N="!B971W965N(%)O9&UA
M;B!A;F0@=&AE($-O;7!A;GDN)B-X03`[)B-X03`[4F]D;6%N(&ES#0IE;G1I
M=&QE9"!T;R!R96=I<W1R871I;VX@<FEG:'1S('=I=&@@<F5S<&5C="!T;R!T
M:&4@<VAA<F5S(&]F#0IC;VUM;VX@<W1O8VL@:7-S=6%B;&4@=7!O;B!E>&5R
M8VES92!O9B!T:&5S90T*=V%R<F%N=',N)B-X03`[)B-X03`[5&AE('=A<G)A
M;G1S(&AA=F4@=&AE('-A;64@=&5R;7,@87,@=&AO<V4-"FES<W5E9"!T;R!T
M:&4@:6YV97-T;W)S(&EN('1H92!P<FEV871E('!L86-E;65N="X\+V9O;G0^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
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M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M169F96-T:79E#0I!<')I;"`X+"`R,#$Q+"!P<FEO<B!T;R!T:&4@8V]M<&QE
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M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%9F9E8W1I=F4-"D%P<FEL(#@L
M(#(P,3$L(&%S(&$@8V]N9&ET:6]N('1O('1H92!C;VUP;&5T:6]N(&]F('1H
M92!!8W%U:7-I=&EO;BP-"DIA;65Y(%`N(%=E:6-H97)T+"!4:&]M87,@4F]C
M:W=E;&P@36%C:VEE+"!*;VAN($YE:7,L($IO:&X@12X-"DYI961E<FAU8F5R
M(&%N9"!-:6-H865L($8N(%1W965D;&4@=V5R92!A<'!O:6YT960@=&\@=&AE
M#0I#;VUP86YY)B-X,C`Q.3MS(&)O87)D(&]F(&1I<F5C=&]R<RXF(WA!,#LF
M(WA!,#M#;VUM:71T964-"F%S<VEG;FUE;G1S(&AA=F4@;F]T('EE="!B965N
M(&1E=&5R;6EN960N)B-X03`[)B-X03`[2F%M97D@4"X-"E=E:6-H97)T+"!4
M:&]M87,@4F]C:W=E;&P@36%C:VEE(&%N9"!*;VAN($YE:7,L('!R979I;W5S
M;'D@<V5R=F5D#0IO;B!T:&4@8F]A<F0@;V8@9&ER96-T;W)S(&]F($-E;&QE
M8W1A<BX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<^#0I!;65N9&UE;G0@;V8@0V5R=&EF:6-A=&4@;V8@26YC;W)P
M;W)A=&EO;CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^169F96-T:79E
M#0I!<')I;"`W+"`R,#$Q('1H92!#;VUP86YY)B-X,C`Q.3MS(&-E<G1I9FEC
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M960@<W1O8VL@;W5T<W1A;F1I;F<@<VEN8V4@1&5C96UB97(@,C`Q,"X\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D5F9F5C=&EV90T*07!R:6P@-RP@
M,C`Q,2!T:&4@0V]M<&%N>28C>#(P,3D[<R!C97)T:69I8V%T92!O9B!I;F-O
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M8V5M8F5R(#(P,3`N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY0<FEO
M<@T*=&\@=&AE(&-L;W-I;F<@;V8@=&AE($%C<75I<VET:6]N(&]N($%P<FEL
M(#@L(#(P,3$L('1H92!#;VUP86YY#0IA;65N9&5D(&%N9"!R97-T871E9"!I
M=',@8V5R=&EF:6-A=&4@;V8@:6YC;W)P;W)A=&EO;B!I;B!O<F1E<B`H82D-
M"G1O(&5F9F5C="!T:&4@<F5V97)S92!S<&QI=#L@*&(I('1O(')E9'5C92!T
M:&4@;G5M8F5R(&]F('-H87)E<R!O9@T*;W5R(&%U=&AO<FEZ960@8V]M;6]N
M('-T;V-K(&9R;VT@-S4P+#`P,"PP,#`@=&\@,34P+#`P,"PP,#`[("AC*2!T
M;PT*96QI;6EN871E('1H92!R:6=H="!O9B!T:&4@<W1O8VMH;VQD97)S('1O
M(&%C="!B>2!W<FET=&5N(&-O;G-E;G0[#0IA;F0@*&0I('1O(&-L87-S:69Y
M('1H92!B;V%R9"!O9B!D:7)E8W1O<G,@:6YT;R!T:')E90T*8VQA<W-E<RXF
M(WA!,#LF(WA!,#M#;&%S<R!)(&1I<F5C=&]R<R!W:6QL('-T86YD(&9O<B!R
M92UE;&5C=&EO;B!A=`T*=&AE($-O;7!A;GDF(W@R,#$Y.W,@;F5X="!A;FYU
M86P@;65E=&EN9R!O9B!S=&]C:VAO;&1E<G,L($-L87-S($E)#0ID:7)E8W1O
M<G,@=VEL;"!S=&%N9"!F;W(@<F4M96QE8W1I;VX@870@=&AE(#(P,3(@86YN
M=6%L(&UE971I;F<@;V8-"G-T;V-K:&]L9&5R<RP@86YD($-L87-S($E)22!D
M:7)E8W1O<G,@=VEL;"!S=&%N9"!F;W(@<F4M96QE8W1I;VX@870-"G1H92`R
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M;G0^/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
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M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-BYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q-2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,38N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q."YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3DN:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#(P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970R,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C(N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(S+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970R-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,C4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(V+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-RYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,C@N:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE
M>'1087)T7V0R9#%A,V8X7S!C-3=?-#$V.%]B961C7S@V-S=D8V1B,S5E8RTM
"#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>23
<FILENAME>filename23.htm
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Via EDGAR</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">November 9, 2011</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr. Jeffrey P. Riedler</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Assistant Director</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Division of Corporation Finance - Mail Stop 4720</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">United States Securities and Exchange Commission</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington, D.C. 20549</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td align="right" style="WIDTH: 36pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Re:&#160;</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Novelos Therapeutics, Inc.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 72pt"></font>Registration Statement on Form S-1</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Initially Filed on July 1, 2011, as amended</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 72pt"></font>File Number 333-175284</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dear Mr. Riedler:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This letter constitutes supplemental correspondence on behalf of Novelos Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), related to the above-referenced filing (the &#8220;Registration Statement&#8221;), and filed together herewith the Company&#8217;s Amendment No. 3 to the Registration Statement (&#8220;Amendment No. 3&#8221;).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Amendment No. 3 is in response to the comments of the Staff on Amendment No. 2 to the Registration Statement, contained in your letter of September 28, 2011 (the &#8220;Comment Letter&#8221;) and, in addition, (i) includes in the Registration Statement and the included prospectus the unaudited financial information of the Company for the reporting period ended September 30, 2011, which information was contained in the Company&#8217;s Form 10-Q filed with the SEC on November 7, 2011, (ii) updates the disclosure to reflect business developments since the date of the above-referenced Amendment No. 2 (iii) includes an estimated price range of the units offered and related disclosures and (iv) includes as an exhibit to the Registration Statement the form of underwriting agreement for the offering.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with the completion of the offering, the Company anticipates that it will effect a reverse split of its common stock within a range of 1:2 to 1:10 (the &#8220;Offering Reverse Split&#8221;) in order to satisfy requirements for the listing of the Company&#8217;s common stock on the NASDAQ Capital Market. The ratio of the Offering Reverse Split will be set within the established range in the discretion of the Company&#8217;s Board of Directors, with the board of directors having the ultimate discretion as to whether or not to proceed with the Offering Reverse Split.&#160;&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the purposes of calculating an estimated price range of units offered in the Registration Statement and related disclosures, the Company has estimated that the Offering Reverse Split will be completed on a 1-for-10 basis.&#160;&#160;As noted throughout, in order to provide disclosures comparable with the estimated offering price of the units, share and per share amounts included in the prospectus have been adjusted to give effect to an estimated Offering Reverse Split at such ratio, with the exception of the financial statements and related management&#8217;s discussion and analysis included in the prospectus.&#160;&#160;These disclosures will not be retroactively adjusted until such time as an Offering Reverse Split has been </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">completed, in accordance with <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">Staff Accounting Bulletin No. 103 Topic 4C</font>.&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As a courtesy, we are separately providing by Federal Express a blackline document comparing Amendment No. 3 to Amendment No. 2.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Set forth below are the Company&#8217;s responses to the Comment Letter. For your convenience, we have repeated the Staff&#8217;s comment below in bold face type. Except as otherwise indicated, all statements contained herein concerning factual matters relating to the Company are based on information provided to us by the Company.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: -36pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Critical Accounting Policies</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Stock-based Compensation, page 26</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">1.&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We may have additional comments on your accounting for stock compensation and related disclosure once you have disclosed an estimated offering price. At that time, please provide quantitative and qualitative disclosures explaining the difference between the estimated offering price and the fair value of each equity issuance.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company anticipates that it will effect an Offering Reverse Split in connection with the completion of the offering.&#160;&#160;If effected, the Offering Reverse Split will be at a ratio of between 1:2 and 1:10.&#160;&#160;For the purposes of calculating an estimated range of offering price and related disclosures in Amendment No. 3, the Company has estimated that the Offering Reverse Split will be at a ratio of 1-for-10. Giving effect to the estimated Offering Reverse Split, the offering price for the units is anticipated to be between $5.00 and $7.00.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All of the equity issuances since the Acquisition, shown in the table on page 26 of the prospectus included with Amendment No. 3, were granted at the closing price of Novelos common stock, as quoted on the OTCBB, on the date of grant. The mid-point of the estimated price range, or $6.00, is substantially less than the exercise prices, as adjusted for an estimated Offering Reverse Split, and the equivalent fair market value of the equity issuances since the Acquisition.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has included quantitative and qualitative disclosure explaining the difference between the estimated offering price of the units and the fair value of the aforementioned equity issuances, as adjusted for the estimated Offering Reverse Split.&#160;&#160;There were no option issuances by Novelos or Cellectar during 2010 or in 2011 prior to the Acquisition.&#160;&#160;Furthermore, all outstanding Cellectar options were canceled prior to the Acquisition (the lowest exercise price of which was $8.95, after adjustment for the exchange ratio established in the Acquisition and the estimated Offering Reverse Split).&#160;&#160;All Novelos options outstanding at the time of the Acquisition (options to purchase 4,915 shares at prices ranging from $15.30 to $10,725.30, after adjustment for the estimated Offering Reverse Split) are also significantly out-of-the-money.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Business</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Business of Novelos, page 27</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">2.&#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Your disclosure on page 28 indicates that the IND for LIGHT is held by Dr.&#160;&#160;&#160;Anne Traynor at the University of Wisconsin, who both initiates and conducts the investigation and under whose immediate direction the investigational drug is administered. Please provide us supplemental documentation supporting:</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic;" face="Symbol, serif">&#183;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">The filing of the IND by Dr. Traynor, and</font></div>

<div style="MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic;" face="Symbol, serif">&#183;&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Anything received from the FDA regarding the initial filing of the IND and its current status.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We may have additional comments after we review the documentation you provide us.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A response to this comment was provided to the Staff in our letter dated October 11, 2011, and the requested documentation was provided supplementally at that time.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company intends to request acceleration of the effectiveness of the Registration Statement as soon as practicable following the resolution of the foregoing comments of the Staff.&#160;&#160;The Company is aware of, and will furnish, the acknowledgements required by the Staff in connection with any such request.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Should the Staff have any additional comments or questions, please direct such to me at (617) 832-1113 or in my absence to Matthew Eckert at (617) 832-3057.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%">

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Very truly yours,</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%">&#160;</td>
<td valign="top" width="3%">&#160;</td>
<td align="left" nowrap valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;Paul Bork</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%">&#160;</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%">

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Paul Bork</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cc:&#160;&#160;&#160;Mr. Harry Palmin (Novelos)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
